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Welcome to the EANM Congress 2015 in Hamburg
With great pleasure the EuropeanAssociation of NuclearMed-
icine welcomes you to its 28th Annual Congress in Hamburg,
Germany.
During the EANM Congress you will be able to discuss the
state-of-the-art that clinical, translational and fundamental nu-
clear medicine has to offer in the usual multidisciplinary set-
ting that is so typical for our profession. From all over the
world physicians, scientists and technologists will travel to
Hamburg for EANM’15 to attend plenary lectures, scientific
sessions and the state of the art in nuclear medicine and mo-
lecular imaging presented in Continuing Medical Education
(CME).
This year’s plenary sessions will focus on Clinical Molecular
Imaging on Sunday, October 11 (including the Marie Curie
Lecture by Prof. Stefano Fanti from Bologna, Italy on the role
of nuclear medicine in prostate cancer), and on Therapeutic
Nuclear Medicine on Monday, October 12. As part of the
M2M - Molecule to Man track, which this year is featured
over three days of the Congress, the plenary session on Tues-
day, October 13 will focus on Targets and Probes. We are very
pleased that Prof. Paul Workman, President and CEO of The
Institute of Cancer Research, London, UK will address target
discovery and probe identification in oncology, to be followed
by lectures of Dr. Matthias Friebe and Prof. Guus van Dongen
on probe selection and development for molecular imaging
and therapy from the perspective of industry and academia,
respectively. Of course the traditional Highlights Lecture on
Wednesday, October 14 is scheduled, this year presented by
Prof. Andreas Buck and Prof. Clemens Decristoforo.
This year we again feature special tracks. Last year’s very
successful Biology track has been renamed to the M2M -
Molecule to Man track. Thanks to the efforts of the EANM
Translational Molecular Imaging, Drug Development and
Radiopharmacy Committees, you will find a wealth of events
on basic and translational research in molecular imaging and
therapy onMonday, Tuesday andWednesday, including Tues-
day’s plenary session. As a sequel to “ISTARD”, the collabo-
rative efforts of the EANMDosimetry and Radionuclide Ther-
apy Committees resulted in an annual track now named Do-
simetry and Molecular Radiotherapy (Do.MoRe) which will
run throughout the Congress.
The Scientific ProgrammeCommittee, representing all EANM
Committees, received a total of 1.916 abstracts, of which
1.710 were accepted for oral sessions (500 presentations) or
poster sessions (1.210 presentations). In the pre-congress and
joint symposia, a large number of experts from disciplines
outside nuclear medicine together with experts from the
EANM Committees will provide new data and will share with
you how nuclear medicine contributes to better science and
enhanced patient care throughout the areas in which nuclear
medicine is utilised.
In collaboration with the European School of Nuclear Medi-
cine, the EANM Committees organised a full track of CME
sessions, including the highly appreciated interactive sessions.
Education in cross-sectional imaging has been expanded to
meet the needs of nuclear medicine physicians for performing
state-of-the-art hybrid imaging. The Young EANM organised
activities focussed on the career perspective of young profes-
sionals in nuclear medicine. Serving the nuclear medicine
technologists, the EANM Technologist Committee again de-
signed a full parallel programme of oral and poster sessions as
well as Continuing Technologist Education (CTE) sessions
and courses.
Organisation of the EANM’15 Congress has been the work of
many members of the EANMCommittees, strongly supported
by the staff of the EANM Executive Office. During the meet-
ing the speakers and presenters will share their data with you. I
thank all those who contributed their time and effort into pre-
senting a five-day meeting for you to learn, discuss and enjoy.
On behalf of the EANM Board, the EANM Scientific Pro-
gramme Committee, the Local Organising Committee and
the staff of the EANM Executive Office in Vienna, I welcome
you to the EANM Congress 2015 and I hope you will experi-
ence a scientific, educational and successful meeting that
meets your expectations and offers you a pleasant stay in Ham-
burg.
Prof. Dr. Wim J.G. Oyen
EANM Congress Chair 2014-2016
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101 - Sunday, October 11, 2015, 8:00 AM - 9:30 AM, Hall 1
CME 1 - Bone & Joint (Interactive): Bone Planar & Hy-
brid Scintigraphy: Patterns, Pearls, and Pitfalls
OP001
Patterns
G. Gnanasegaran, UK
OP002
Pearls
F. Paycha, FRANCE
OP003
Pitfalls
K. Strobel, SWITZERLAND
102 - Sunday, October 11, 2015, 8:00 AM - 9:30 AM, Hall 2
Joint Symposium 1: EANM/EACVI: Cost-effectiveness in
Cardiac Imaging: From Theory to Practice
OP004
What is Cost-effectiveness: Theory
and Implications/Implementation
S. S. Tan, NETHERLANDS
OP005
Cost-effectiveness of the Different Myocardial (Perfusion)
Imaging Techniques
S. E. Petersen, UK
103 - Sunday, October 11, 2015, 8:15 AM - 9:45 AM, Hall 4
CTE 1: Brain Imaging (Tech Guide Book Launch)
OP006
Imaging in Oncological Brain Diseases (PET/CT)
G. Testanera, ITALY
OP007
Tracers for Brain Imaging
A. Socan, SLOVENIA
OP008
Principles of Functional Brain Imaging with Radiotracers
A. Signore, ITALY
105 - Sunday, October 11, 2015, 8:00 AM - 9:30 AM, Hall G2
Do.MoRe: PRRT Treatment Planning
OP009
Investigation on the number of PETmeasurements needed
for accurate prediction of therapeutic biodistribution
in PRRT
D. Hardiansyah1,2, W. Guo1, P. Kletting3, B. Müller4, F.
Mottaghy4, G. Glatting1; 1Medical Radiation Physics/
Radiation Protection, Universitätsmedizin Mannheim, Medi-
cal Faculty Mannheim, Heidelberg University, Mannheim,
GERMANY, 2Department of Radiation Oncology,
Universitätsmedizin Mannheim, Medical Faculty Mannheim,
Heidelberg University, Mannheim, GERMANY, 3Klinik für
Nuklearmedizin, Universität Ulm, Ulm, GERMANY, 4Klinik
für Nuklearmedizin, University Hospital, RWTHAachen Uni-
versity, Aachen, GERMANY.
Aim: Aim of this study was to investigate the variability of
individual time-integrated activity coefficient (TIAC) predic-
tion for different positron emission tomography (PET) mea-
surement protocols in peptide-receptor radionuclide therapy
(PRRT).Material and Methods: Assumed true model parame-
ters were derived using “Simulation, Analysis and Modeling
II” software by fitting the physiology based pharmacokinetic
(PBPK) model parameters to the data of 15 patients (111In-
DTPAOC, serum and organ activity data). Predicted model
parameters based on the simulation of PET measurements
were derived as follows: first, a PET measurement after bolus
injection of 150 MBq of 68Ga-DOTATATE was simulated
using the assumed true model parameters; second, different
PET sampling protocols (PSPs) were implemented to take or-
gan activity data from the simulated time activity curve of
68Ga-DOTATATE. Six PET sampling protocols were investi-
gated: 30min (PSP1), 60min (PSP2), 240 min (PSP3), 30min
plus 60 min (PSP4), 30 min and 240 min (PSP5), 60 min and
240 min (PSP6); third step, random noise was added to the
simulated organ activity data with fractional standard devia-
tion (FSD) of 10-3 using the “PopKinetics” software; fourth,
the PBPK model was fitted to these noisy data to derive pre-
dicted model parameters. The therapeutic biodistribution was
simulated for the model with true parameters and the model
with predicted parameters assuming an infusion over 30 min
of 3.3 GBq 90Y-DOTATATE. Time integrated-activity coeffi-
cients (TIACs) of tumour and kidneys were calculated for both
models. The variability between predicted TIACs and true
TIACs were compared for tumor and kidneys. Results: Proto-
cols with simulated PET measurement (PSP 1 to 3) showed
high values for both kidneys and tumour variabilities. In these
3 protocols PSP 3 sampling at 240 min showed the lowest
variability for kidneys (10±7) % and tumour (28±24) %. Var-
iabilities obtained using two time-point PET data (PSP 3 to 6)
were much smaller than those of one time-point PET data. The
best results were found at PSP6 which were (2±) % for kid-
neys and (7±1) % for tumour. Conclusion: The PET
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measurement protocol at 240 min post injection is important
for predicting the therapeutic biodistribution. Protocols with
two time-point PET measurements showed higher accuracy
than those with one PET measurement. The protocol with
PET measurements at 60 min and 240 min post injection is
recommended for further investigations.
OP010
The prediction accuracy of therapeutic biodistribution
in PET-based treatment planning of PRRTwith different
Bayesian parameter estimation methods
W. Guo1, D. Hardiansyah1,2, A. A. Attarwala1,2, C. Maaß1, G.
Glatting1; 1Medical Radiation Physics/Radiation Protection,
Universitätsmedizin Mannheim, Medical Faculty Mannheim,
Heidelberg University, Mannheim, GERMANY, 2Department
of Radiation Oncology, Universitätsmedizin Mannheim, Med-
ical Faculty Mannheim, Heidelberg University, Mannheim,
GERMANY.
Aim: The aim of this study was to compare the prediction
accuracy of therapeutic biodistributions in PET-based treat-
ment planning of peptide-receptor radionuclide therapy
(PRRT) with two Bayesian parameter estimation methods.
Materials and Methods: A recently developed physiologically
based pharmacokinetic (PBPK) model was fitted to the
biokinetic data of patients (SAAM II, The Epsilon Group,
Charlottesville, USA) using two different methods: Standard
Two-Stage (STS) and Iterative Two-Stage (ITS). The two
methods yield assumed true parameters (TPs) and Bayesian
parameters. Biokinetic data of 14 patients were obtained after
the bolus injection of 152±15 MBq of 111In-DTPAOC from
the serum activity and the organ activity taken by a
Gammacamera. Based on assumed true parameters PET mea-
surements were simulated after bolus injection of 68Ga-
DOTATATE of 150 MBq. Organ activity data from simulated
time activity curves were taken at 30 min, 60 min and 240 min
post injection. A PET noise model with related coefficient c of
3 and 30 which simulates typical error in PET measurements
was included to simulate the organ activity data for used time
points. The PBPKmodel was fitted to the simulated noisy PET
data with Bayesian parameters obtained by STS and ITS to
derive predicted parameters (PPs). Therapy was simulated for
TPs and PPs assuming an infusion of 3.3 GBq of 90Y-
DOTATATE over 30 min. Area under the curves (AUCs) of
simulated time activity curves in kidneys and tumour were
calculated for therapeutic biodistribution using TP (AUCTP)
and PP (AUCPP). Variability between AUCTP and AUCPP
was calculated and analysed. Result: For noise level of c = 3
using Bayesian parameter from ITS the variabilities were (9
±7) % for tumour and (2±1) % for kidney, while they were (14
±9) % for tumour and (2±3) % for kidneys using the Bayesian
parameters from STS. The highest variabilities were (18±11)
% for tumour and (3±2) % for kidneys for c=30 using Bayes-
ian parameters from STS and it was (12±9) % for tumour and
(2±1) % for kidneys using ITS. Within the same coefficient of
noise level the variability of AUCs with the ITS method
showed lower values for both tumour and kidneys than using
the STS method. However, no significant (p<0.05, Student’s t
test) difference was found. Conclusion: The ITS fitting method
seems better suited for deriving the Bayesian parameters and
predicting the therapy. Further investigation based on a larger
population size and with improved sampling schedule is how-
ever needed.
OP011
Fractional contribution of extrapolations after 96 h
in absorbed dose calculation to kidneys in 450 patients
with neuroendocrine tumours receiving
177Lu-DOTATATE therapy
M. Sandstrom, U. Garske-Román, D. Granberg, A. Sundin,
M. Lubberink; Nuclear medicine & PET, Uppsala University,
SWEDEN.
Aim: As in all therapies using ionizing radiation, a
patient-specific optimization of the delivered radiation
should be performed in therapy with 177Lu-DOTA-D-
Phe1-Tyr3-octreotate (177Lu-DOTATATE). To determine
the total time-integrated activity concentration in an or-
gan, extrapolation from the first measurement to time of
injection and extrapolations from the last measurement
to infinity are needed. It is stated in EANM guidelines
that the fractional contribution from the extrapolations
should be less than 20% for bone marrow and whole-
body dosimetry [1]. The main aim of the present work
was to study the fractional contribution after 96 h to the
time-integrated activity in kidney in therapy with 177Lu-
DOTATATE. Secondary aim was to investigate the influ-
ence on the absorbed dose calculation. Materials and
Methods: Four hundred fifty patients (219 female and
231 male) with neuroendocrine tumors with high so-
matostatin receptor expression were included. SPECT/
CT over the abdomen were acquired at 24, 96 and
168 h after start of infusion of 177Lu-DOTATATE. In
two patients one kidney was excluded due to adjacent
tumours. For the kidneys the fractional contribution was
calculated for a single therapy cycle of 7.4 GBy from
96 h to infinity. Ratios between absorbed dose calcula-
tions performed using only 24 and 96 h measurements
AD(24-96) versus absorbed dose calculations performed
using 24, 96 and 168 h measurements AD(24-96-168)
was performed. Results and discussion: In the right kid-
ney the extrapolated fractional contribution after 96 h
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was 29% (Median; Min - Max 12-60) while the
absorbed dose ratio was 0.97 (0.67-1.64). The fractional
contribution after 96 h was higher than the recommend-
ed 20%, not including the time before the first measure-
ment. For the majority of the patients the AD(24-96)
estimation gave a value close to the AD(24-96-168)
but overestimations of up to 60% and underestimations
of up to 30% of the absorbed dose were also seen. No
significant differences between left and right kidneys
were found. Conclusions: To meet the EANM dosimetry
committee recommendation of at most 20% extrapolated
fractional contribution in the determination of kidney
doses and to get a reliable absorbed dose estimation, it
is not sufficient to have the last measurement point at
96 h p.i., and later measurements are needed. 1. Hindorf
C, Glatting G, Chiesa C, Linden O, Flux G. EANM
Dosimetry Committee guidelines for bone marrow and
whole-body dosimetry. Eur J Nucl Med Mol Imaging.
2010;37:1238-50. doi:10.1007/s00259-010-1422-4.
OP012
Preliminary results of a Dosimetry-Based peptide receptor
radionuclide therapy in patients with advanced
neuroendocrine tumors
A. Filice1, F. Fioroni2, E. Grassi2, V. Ferri2, M. Casali1, M.
Roncali1, M. Sollini3, A. Frasoldati4, A. Versari1; 1Department
of Nuclear Medicine IRCCS-Arcispedale Santa Maria Nuova,
Reggio Emilia, ITALY, 2Medical Physics Unit, IRCCS-
Arcispedale Santa Maria Nuova, Reggio Emilia, ITALY,
3IRCCS MultiMedica, Sesto San Giovanni, Reggio Emilia,
ITALY, 4Endocrinology Unit IRCCS-Arcispedale Santa Maria
Nuova, Reggio Emilia, ITALY.
Purpose: Peptide Receptor Radionuclide Therapy (PRRT)
has an important role in the treatment of advanced neu-
roendocrine tumors (NETs). Dosimetry allows to person-
alize this therapy. The aim of this study is to create a
strategy of treatment balancing renal protection and tu-
mor treatment, using both 177Lu-DOTATOC and 90Y-
DOTATOC to obtain the best ratio. Methods: The PRRT
protocol that we are using in our center is a monocenter,
rospective, non-randomized, phase II study. It is a
dosimetry-based study in which the dosimetric evalua-
tion (kidney, bone marrow, tumor) is performed at the
first cycle of 177Lu-DOTATOC. According to these data
we calculate the projected adsorbed dose for kidneys,
bone marrow and tumor tissues (max 5 lesions). A co-
hort of 12 patients who underwent more than 2 PRRT
administrations and 2 68Ga-DOTATOC PET-CT scans
(PET1: baseline and PET2: after the second cycle) were
selected. Up to 5 target lesions/patient (volume range
2.3-243 ml) were analysed. Lesions analysed were
grouped based on the localisation: liver (28), lymph
node (7), and bone (8). The dose to the lesions was
calculated at organ level through multiple SPECT-CT
scans with the OLINDA/EXM sphere model. Maximum
SUV value was evaluated for each lesion and the per-
centage difference (PD%) between PET1 and PET2
values was calculated. Results: Mean, standard deviation
(SD), and range values for PD% were: liver (2.2, 31, -
49-75); lymph node (25, 62, -45-117); bone (8, 16, -6-
45). Absorbed doses were: liver 41±26 Gy, lymph node
19±29 Gy, bone 13±13 Gy. We found higher correlation
between absorbed doses and SUV max at PET1 for all
lesions (liver, lymph node, bone), than between absorbed
doses and lesions volume. We didn’t find a good corre-
lation between absorbed doses and PD%. Conclusions:
These preliminary results suggest that a dosimetric eval-
uation at the first cycle of PRRT allows to obtain a
good personalization of the treatment approach. The
range of lesion adsorbed doses and PD% values is very
broad but probably the second cycle is not adequate to
investigate the correlation between tumor response and
site of disease because is too early in this clinical
setting.
OP013
Pre-treatment intensity of DOTATOC uptake
for prediction of response to selective intravascular
radionuclide therapy
T. D. Poeppel1, H. V. Ngo1, I. Binse1, H. Lahner1, N. Unger1,
A. Bellendorf1, S. Ezziddin2, A. Bockisch1, A. Sabet1;
1Universitaetsklinikum Essen, Essen, GERMANY,
2Universitaetsklinikum des Saarlandes, Homburg,
GERMANY.
Aim: DOTATOC PET/CT is known to depict somatostat-
in receptor expression of neuroendocrine tumour (NET)
lesions. Yet, DOTATOC uptake is also related to the
perfusion of a lesion. There is a strong connection be-
tween the perfusion of a lesion and treatment response
in selective intravascular radionuclide therapy (SIRT).
Yet, it is unclear if DOTATOC uptake may serve as a
parameter to predict treatment response in SIRT. This
study assesses the value of baseline line DOTATOC
PET in predicting the response to SIRT with Y-90-mi-
crospheres in patients with hepatic metastatic NET.
Methods : 25 pa t i en t s wi th hepa t i c metas ta t i c
gastroenteropancreatic (GEP) NET who were treated
with SIRT were retrospectively analysed. Ga-68-
DOTATOC-PET/CT was performed at baseline and three
months after the treatment. The maximum standardised
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uptake value (SUVmax) was determined as a measure of
DOTATOC uptake. In each patient a maximum of three
clearly delineated tumour lesions was selected as target.
SUVmax and tumour-to-spleen ratios (SUVmaxT/s) of
target tumour lesions were calculated. Response of each
tumour lesion was evaluated according to the relative
change in SUVmaxT/s (%Δ SUVmaxT/s). The associa-
tion of baseline SUV parameters and functional response
was tested using Spearman’s rank correlation analysis.
Results: 69 lesions were included into the analysis.
Mean tumour and splenic SUVmax at baseline were
19.9 ±1.7 and 23.4 ±1.7, respectively. 50 lesions showed
a reduction in SUVmax three months after SIRT. Mean
post-SIRT SUVmax was 10.8±1.7. Relative change in
SUVmaxT/s was 26.7±12.8 %. Baseline SUVmax
showed a moderate (r=0.132) and SUVmaxT/s a slightly
better correlation with lesion-based response (r=0.441).
Conclusions: Pre-treatment intensity of DOTATOC up-
take in terms of SUV parameters is only moderately
related to lesion-based functional response to SIRT in
GEP NET patients.
OP014
An image based method for bone marrow dosimetry
in 177Lu-DOTATATE therapy
J. Svensson1, J. Söderström2, T. Magnander2, E. Wikberg2, B.
Wängberg3, P. Bernhardt2; 1Department of Oncology, The
Sahlgrenska Academy, Sahlgrenska University Hospital,
Göteborg, SWEDEN, 2Department of Radiation Physics,
The Sahlgrenska Academy, Sahlgrenska University Hospital,
Göteborg, SWEDEN, 3Department of Surgery, The
Sahlgrenska Academy, Sahlgrenska University Hospital,
Göteborg, SWEDEN.
Aim: Treatment with 177Lu-DOTATATE for advanced neu-
roendocrine tumours expressing somatostatin receptors has
proven efficient and safe. Organs at risk are mainly the kidneys
and the bone marrow. Though well tolerated in general, bone
marrow toxicity might become dose limiting. The aim of this
study was to evaluate an image based method to estimate the
absorbed dose to the bone marrow during 177Lu-
DOTATATE treatment. Materials and methods: 51 patients
with advanced neuroendocrine tumours were treated with
177Lu-DOTATATE on 1-6 occasions. The patients were
evaluated according to the mean absorbed dose to the
bone marrow using the 4 planar images collected at 2,
24, 48 and 168 hour after injection. By using a segmenta-
tion tool in the in-house made software RONSO, the high
uptake area in the images was separated from the low
uptake area. The high uptake area consisted of the tissue
related activity in tumours and organs, and the low uptake
area contained the blood related activity in the images.
Absorbed dose to the bone marrow was calculated as
sum of; the self-dose from charges particles in the bone
marrow, the cross-dose from the tissue related area (solely
γ-radiation contribution) and the cross-dose from the
blood related area. Results: The median of the mean
absorbed dose to the bone marrow was 0.17 Gy (range
0.08 - 0.49 Gy) for the first therapy cycle; where an aver-
age amount of 7.5 GBq (range 4.2 - 8.3 GBq) 177Lu-
DOTATATE was administered to the patients. For all the
treatment cycles (in average 3 occasions) the median of
the mean absorbed dose was 0.51 Gy (range 0.16 - 1.35
Gy). The self-dose made the largest contribution to the
mean absorbed dose to the bone marrow. Conclusion:
The image based method developed in this work might
be useful for bone marrow dosimetry. The mean absorbed
doses varied considerably between patients which illus-
trates the need for individual dosimetry, especially when
the total amount of 177Lu-DOTATATE in on-going stud-
ies tend to increase, and also when other treatment options
make it necessary to preserve bone marrow function. The
method requires to be validated for a more patient specific
purpose, which can be done by blood dosimetry from
blood sampling.
OP015
Prediction accuracy of therapeutic biodistribution
in peptide receptor radionuclide therapy: Role
of patient-based treatment planning
D.Hardiansyah1,2, C.Maaß1, A. Attarwala1,2, P. Kletting3, B.
Müller4, F. Mottaghy4, G. Glatting1; 1Medical Radiation
Physics/Radiation Protection, UniversitätsmedizinMannheim,
Medical Faculty Mannheim, Heidelberg University, Mann-
heim, GERMANY, 2Department of Radiation Oncology,
Universitätsmedizin Mannheim, Medical Faculty Mannheim,
Heidelberg University, Mannheim, GERMANY, 3Klinik für
Nuklearmedizin, Universität Ulm, Ulm, GERMANY, 4Klinik
für Nuklearmedizin, University Hospital, RWTHAachen Uni-
versity, Aachen, GERMANY.
Aim: An accurate treatment planning is needed in peptide-
receptor radionuclide therapy (PRRT) for ensuring the op-
timal tumor irradiation while diminishing the toxicity for
the kidneys. The aim of this study was therefore to show
the prediction accuracy of the therapeutic biodistribution in
peptide receptor radionuclide therapy (PRRT) for different
degrees of individualization when using physiologivally
based pharmacokinetic modelling (PBPK).Material and
Methods: The parameter of a recent PBPK model of
PRRT were fitted to the biokinetic data of 15 patients with
metastasized neuroendocrine tumors (NETs): serum and
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planar gamma camera data after the injection of 111In-
DTPAOC to derive the assumed true model parameters.
Four mathematical phantom patients (MPP) were defined
with increasing amount of patient-specific information:
MPPtrue is the PBPK model with 15 sets of all assumed
true model parameters; MPPmean is the PBPK model with
all model parameters fixed to the mean values of the 15
patients; MPPspecific uses additional individual patient data:
physical parameters (body weight, body surface area, age,
gender), hematocrit, volume of the tumor, glomerular fil-
tration rate and flow to the tumor; MPPPET is MPPspecific
with one simulated positron emission tomography (PET)
data set at t=60 min after injection of 68GA-DOTATATE
to fit the model parameters. Therapy was simulated as an
infusion of 3.3 GBq of 90Y-DOTATATE over 30 min for
all MPPs. Area under the curve (AUC) of time activity
curve in tumor and kidneys were calculated for total sim-
ulation duration of 14 d. The relative differences (RD) of
AUCs of MPPmean, MPPspecific and MPPPET to MPPtrue
were analyzed. Results: RDs of MPPmean were RDtumor =
(625±1266) % and RDkidneys = (11±38) %, demonstrating
that patient individual data are needed for treatment plan-
ning. Inclusion of patient individual data in MPPspecific
lead to significantly lower RD in the tumor: RDtumor =
(-2±27) % and RDkidneys = (16±43) %. RD in MPPPET
showed a major improvement for the kidneys due to the
inclusion of simulated PET data: RDtumor = (-2±22) % and
RDkidneys = (-0.1±0.5) %. Summary: Individual biokinetics
are needed to predict the biodistribution in PRRT using
theses somatostation analogs. Additional use of a single
PET measurement together with the PBPK model signifi-
cantly improved the prediction.
OP016
The variability of predicted area under the curves
for different degrees of noise in PET measurements
for treatment planning in peptide-receptor radionuclide
therapy
D. Hardiansyah1,2, W. Guo1, P. Kletting3, B. Müller4, F.
Mottaghy4, G. Glatting1; 1Medical Radiation Physics/
Radiation Protection, Universitätsmedizin Mannheim, Medi-
cal Faculty Mannheim, Heidelberg University, Mannheim,
GERMANY, 2Department of Radiation Oncology,
Universitätsmedizin Mannheim, Medical Faculty Mannheim,
Heidelberg University, Mannheim, GERMANY, 3Klinik für
Nuklearmedizin, Universität Ulm, Ulm, GERMANY, 4Klinik
für Nuklearmedizin, University Hospital, RWTHAachen Uni-
versity, Aachen, GERMANY.
Aim: Accuracy of treatment planning in peptide-receptor
radionuclide therapy (PRRT) depends on the variability
of the individually predicted biodistribution. The aim of
this study was to investigate the variability of the area
under the curves (AUCs) for different degrees of noise
in simulated positron emission tomography (PET) mea-
surements for PRRT.Material and Methods: A physiolog-
ically based pharmacokinetic (PBPK) model of PRRT
was used in this study. Assumed true model parameters
for 15 patients were derived using “Simulation, Analysis
and Modeling II” software by fitting the PBPK model
parameters to their biokinetic data (111In-DTPAOC, se-
rum and organ activity data). Predicted model parame-
ters based on the PET simulation were derived as fol-
lows: first, a PET measurement after bolus injection of
150 MBq of 68Ga-DOTATATE was simulated using the
assumed true model parameters; second, the organ activ-
ity data of kidneys, tumour, spleen and liver at 60 min
and 240 min post injection were taken; third, random
noise was added to the simulated organ activity data
with fractional standard deviations (FSD) of 10-1, 10-2,
10-3, and 10-4 using the “PopKinetics” software; fourth,
the PBPK model was fitted to these noisy data to derive
predicted model parameters for the patients. Two math-
ematical patient phantoms (MPPs) were built: true MPP
(PBPK model with assumed true model parameters) and
predicted MPP (PBPK model with predicted model pa-
rameters). Therapeutic biodistribution was simulated for
true and predicted MPPs assuming an infusion over
30 min of 3.3 GBq 90Y-DOTATATE. AUCs of tumour
and kidneys were calculated for both MPPs. The vari-
ability V between predicted AUCs and true AUCs were
calculated for tumour and kidneys. Results: The variabil-
ities for FSD = 10-1 and 10-2 showed low accuracy for
the prediction of the therapeutic biodistribution: FSD =
10-1 yielded Vtumor = (27±23) % and Vkidney = (13±5)
%; FSD = 10-2 yielded Vtumor = (23±10) %, Vkidney = (7
±3) %. FSD 10-3 and FSD 10-4 showed acceptable var-
iabilities for the prediction (Vtumor = (8±2) %, Vkidney =
(2±1) % and Vtumor = (1±1) %, Vkidney = (0.3±0.3) %
for FSD = 10-3 and 10-4, respectively. Conclusion: Or-
gan activity measured from two time points by PET
could possibly be used to reliably predict the individual
therapeutic biodistribution. Typical PET measurements
have noise equal or lower than FSD=10-3 and thus could
possibly lead to an acceptable prediction of therapeutic
biodistribution.
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108 - Sunday, October 11, 2015, 8:00 AM - 9:30 AM, Hall E
Pitfalls & Artefacts & Physiology - Interactive: Clinical
Consequences of Neuroimaging
OP017
Value and Pitfalls of Neuroimaging in a Memory Clinic
B. N. M. van Berckel, NETHERLANDS
OP018
Value and Pitfalls of Neuroimaging in a Primary Care
SettingA. Fellgiebel, GERMANY
OP019
Value and Pitfalls of Neuroimaging in Preclinical Stages
of Dementia
F. Jessen, GERMANY
201/203 - Sunday, October 11, 2015, 10:00 AM - 11:15 AM,
Hall 1
Plenary 1: Clinical Molecular Imaging (incl. Marie Curie
Lecture)
OP020
Marie Curie Lecture: Prostate Cancer
S. Fanti, ITALY
OP021
Imaging of Atherosclerosis: Translation from Research
to Practice
J. H. F. Rudd, UK
OP022
Neuroimaging - Mandatory Biomarker in Dementia
Assessment?
P. Scheltens, NETHERLANDS
301 - Sunday, October 11, 2015, 11:30AM – 01:00 PM,Hall 1
CME 2 - Oncology & Paediatrics & Bone and Joint:
Sarcomas
OP023
Molecular Imaging in Bone Sarcomas: Implementing the Role
of PET/CT
E. Lopci, ITALY
OP024
Enchondroma, Osteochondroma, Chondrosarcoma: A
Multimodality Imaging Challenge
F. Paycha, FRANCE
OP025
Soft Tissue Sarcomas, Role of PET/MR
F. Giammarile, FRANCE
302 - Sunday, October 11, 2015, 11:30 AM – 01:00 PM, Hall 2
Joint Symposium 2: EANM/ETA-CRN: What the Doctor
Tells and the Patient Understands - Update on Thyroid
Cancer Communication
OP026
The New American Thyroid Association Guidelines
on the Diagnosis and Management of Thyroid Nodules
and Differentiated Thyroid Cancer: a Summary
of the European Perspective and Commentaries
M. Hoffmann, AUSTRIA
OP027
Patient Information in Thyroid Cancer
J. Taylor, UK
OP028
Patient Information in General Oncology
W. T. van der Graaf, NETHERLANDS
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303 - Sunday, October 11, 2015, 11:30AM – 01:00 PM,Hall 4
CTE 2 - Interactive: Multi-Professional Discussion on Ex-
tended Competencies for Nuclear Medicine Technologists
OP029
How It All Began: 1999 Competencies
J. A. Jorge, SWITZERLAND
OP030
How It All Developed: Advance Practice and Interaction
with External Societies
G. Testanera, ITALY
OP031
Adapting to the Future: EANM-TC Document
on Competencies
P. Fragoso Costa, GERMANY
304 - Sunday, October 11, 2015, 11:30AM – 01:00 PM,Hall G1
Special Symposium: Evidence-based Medicine - Implica-
tions for Imaging Communication
OP032
Evidence-based Imaging - The Editor’s View
D. Delbeke, USA
OP033
Evidence for Advanced Imaging in Radiotherapy Practice -
The Clinician’s View
U. Nestle, GERMANY
OP034
Beyond RECIST: Progressing Advanced MRI Applications
into Clinical Practice
D. M. Koh, UK
305 - Sunday, October 11, 2015, 11:30 AM - 12:45 PM, Hall G2
Do.MoRe: Novel Therapies
OP035
First-in-man experience of CXCR4-directed
endoradiotherapy with 177Lu- and 90Y-labelled
pentixather in heavily pretreated multiple myeloma
with extensive intra- and extramedullary disease
K. Herrmann1, M. Schottelius2, C. Lapa1, A. Poschenrieder2,
H. Hänscheid1, U. Keller2, A. Schirbel1, S. Kropf3, A. K.
B u c k 1 , S . K n o p 1 , H . E i n s e l e 1 , H . We s t e r 2 ;
1Universitätsklinikum Würzburg, Würzburg, GERMANY,
2Technische Universität München, München, GERMANY,
3Scintomics GmbH, Fürstenfeldbruck, GERMANY.
Aim: The chemokine receptor CXCR4 is a key factor for tumor
growth and metastasis in several types of human cancer. Based
on our promising experiences with a radio-labelled CXCR4
ligand ([68Ga]pentixafor) for diagnostic receptor targeting,
[177Lu]- and [90Y]pentixather were recently developed as
endoradiotherapeutic vectors. Here, we summarize the first-in-
man experience with CXCR4-directed therapy with these
radiolabelled receptor ligands. Materials and Methods: Three
patients with intra- and extensive extramedullary manifestations
of multiple myelomawere included. All had exhausted all avail-
able treatment options including stem cell transplant (SCT).
CXCR4-target expression was demonstrated by baseline
[68Ga]pentixafor-PET. Each treatment was approved by the
clinical ethics committee. Pre-therapeutic [177Lu]pentixather
dosimetry was performed prior to treatment with 15.2 and
23.5 GBq [177Lu]pentixather, and 6.3 GBq [90Y]pentixather,
respectively. Subsequently, patients underwent additional che-
motherapy and autologous SCT for bone marrow rescue. Early
treatment response was monitored by conventional criteria and
[18F]FDG-PET/CT. Results: Pentixather-radionuclide therapy
was well tolerated in all 3 patients. Two patients underwent
response assessment with [18F]FDG-PET/CT showing signifi-
cant therapeutic effect with one partial and one complete meta-
bolic response. Conclusion: In combination with cytotoxic che-
motherapy and autologous SCT, CXCR4-targeted radiotherapy
with pentixather appears to be a promising novel treatment op-
tion for patients with advanced multiple myeloma, especially in
patients with extramedullary manifestations.
OP036
Radionuclide treatment with 64Cu-Cl2 in patients
with progressive malignant gliomass
E. Capasso, Jr.1, M. C. Valentini2, S. Mirzaei3, P. Knoll3, C.
Meleddu1; 1U.O.C. Nuclear Medicine, Cagliari, ITALY, 2S.C.
Neuroradiology, C.T.O., Turin, ITALY, 3Department of Nucle-
ar Medicine with PET-Center, Wilhelminenspital, Vienna,
AUSTRIA.
Background: Gliomas are the most common type of brain tu-
mor, of which malignant astrocytomas (MA), also defined as
glioblastoma multiforme (GBM) and anaplastic astrocytoma
(AA) have a poor survival rate. The standard care is based on
cyto-reductive surgery followed by radiotherapy and adjuvant
chemotherapy (CHT). Several trials have been performed with
i.e. combination of temozolomide, thalidomide with
antiangiogenetic drugs, but the impact on survival remains lim-
ited. Further, many types of cancers typically show high levels of
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copper, including gliomas. Beaucase of its ß- emission the cop-
per isotope 64Cu has been discussed for therapeutic applications.
AIM: The aim of this case study was to evaluate the possible
impact of treatment with 64Cu-Cl2 in patients with progressive
GBM and AA despite previous standard treatment. MATE-
RIALS AND METHODS: A 51y female patient affected by
GBMwith primary localization in left thalamus with progressive
disease (PD) after surgery and radiochemetherapy was enrolled.
She received twice intravenously a dose of 3300 and 2590MBq
of 64CuCl2 in alternating days. The treatment was well tolerat-
ed, without clinical side effects. The patient underwent to a PET/
CT scan, from vertex to thorax, 1 hour after the tracer adminis-
tration. RESULTS: The 64CuCl2 PET scan showed a high up-
take in left thalamic and frontal lesions, in correlation to the
known morphologic target lesions. One month later the patient
underwent to a control MRI which showed remarkable volume
reduction of the lesions with disappearance of the previously
peritumoral edema and readjustement of the brain midline struc-
ture. CONCLUSIONS: Radinuclide treatment with 64CuCl2 is
very well tolerated and could be of potential benefit in malignant
glioma patients with PD despite standard treatment.
OP037
Clinical Feasibility and Effectiveness of Intraperitoneal
Radionuclide Therapy with Lu-177 3BP-227 in Metastatic
Adenocarcinoma of Pancreas
A. Singh1, H. Kulkarni1, C. Schuchardt1, S. Wiessalla1, M.
Sayeg1, I. Klette1, F. Osterkamp2, U. Reineke2, C. Smerling2,
R. P. Baum1; 1Zentralklinik Bad Berka, THERANOSTICS
Center for Molecular Radiotherapy and Molecular Imaging
(PET/CT), Bad Berka, GERMANY, 23B Pharmaceuticals
GmbH, Berlin, GERMANY.
Aim: Metastatic pancreatic adenocarcinoma (mPaCa) has a
very poor prognosis. Following our experience on dosimetry
and intravenous (i.v.) radiopeptide therapy with Lu-177 3BP-
227 (a neurotensin antagonist targeting NTR-1), we report the
feasibility and effectiveness of serial intraperitoneal administra-
tions of Lu-177 3BP-227 for the treatment of mPaCa.Materials
and Methods:A 59-year old female with inoperable mPaCa
(vascular infiltration, lymph node, liver, peritoneal metastases)
and massive ascites was referred with progressive disease after
7 cycles of chemotherapy for radiopeptide therapy. Following
initial feasibility and dosimetry using 1400 MBq of i.v. Lu-177
3BP-227, the patient received 6400, 7500, and 5300 MBq Lu-
177 3BP-227 over a period of six months. Dosimetry (MIRD)
was performed using OLINDA/EXM software. Feasibility was
assessed by dosimetry, patient tolerance, side-effects, and tox-
icity profile (hematological, renal, liver) based on serial deter-
mination of laboratory tests and renal scintigraphy. Effective-
ness was assessed by monitoring clinical outcome, tumor
markers, and by imaging (PET/CT) pre- and post-
therapy.Results:Clinical feasibility was confirmed by tolerance
of therapy without any significant side effects. Liver parameters
remained within normal limits during therapy. Serial whole-
body scintigraphy and SPECT/CT demonstrated excellent trac-
er uptake in the primary tumor and in the widespread metasta-
ses. On dosimetry, whole-body uptake showed a bi-exponential
decline, the tumor uptake followed an exponential decline, and
the kidneys showed an exponential clearance with more
prolonged kinetics compared to i.v. application. Mild and re-
versible hematotoxicity (Hb 5.9 mmol/L) was observed after
the second dose (anemia existed before therapy). No renal tox-
icity was observed (despite there was only a single functioning
kidney).Therapeutic effectiveness was confirmed by clinical as-
sessment (significant improvement in quality of life and func-
tional status), and severe reduction in ascites formation (drain-
age from twice daily to once every 3 days). Partial Remission
(PR) was achieved according to RECIST (regression in size of
the primary tumor and the hepatic metastases on MRI and CT)
and by PERCIST (reduction of uptake in primary tumor and
metastatic lesions on F-18 FDG PET/CT). Finally, a persistent
fall of the tumor marker CA 19-9 (from 1423 to 192 U/ml)
occurred. The patient is still alive 8 months after start of PRLT.
Conclusion: Intraperitoneal peptide radioligand therapy using
Lu-177 3BP-227 was clinically feasible and effective for the
management of metastatic pancreatic adenocarcinoma. The ex-
cellent results obtained in this patient warrant the need of further
studies and possibly earlier application of Lu-177 3BP-227 for
the therapy of peritoneal carcinomatosis and associated ascites.
OP038
Nanovectorized radiotherapy by convection-enhanced
delivery (CED), a promising strategy that demonstrates
high efficacy in a murine model of human endometrial
adenocarcinoma.
A. Genin1,2,3, C. Lefebvre-Lacoeuille1,3,2, J. Rousseau4,5, N.
Chouin4,5, P. Fosse6, D. Dabli6, F. Bouchet6, N. Lepareur7, P.
Descamps1,3, F. Hindré1,8,2, O. F. Couturier1,6,2, F.
Lacoeuille1,2,6; 1LUNAM Université, Angers, FRANCE,
2InsermUMRS_1066MINT, Angers, FRANCE, 3Department
of Obstetrics and Gynaecology, CHU Angers, Angers,
FRANCE, 4LUNAM Université, Nantes, FRANCE,
5AMaROC, ONIRIS, Nantes, FRANCE, 6Nuclear Medicine
Department, CHUAngers, Angers, FRANCE, 7Department of
Nuclear Medicine, Centre Eugène Marquis, Rennes,
FRANCE, 8PRIMEX Plateforme de Radiobiologie et
d’Imagerie Expérimentale, Angers, FRANCE.
Aim: To evaluate the biodistribution, the toxicity, the dosimetry
and the antitumor efficacy of intra-tumoral injection of
rhenium-188 loaded nanoparticles (LNC-188Re-SSS) by
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CED. Materials and methods: Ishikawa endometrial carcinoma
cell lines were implanted subcutaneously in nude mice (n=70).
For biodistribution and efficacy studies CED procedure was
realized at D28 after tumour implantation. CED was performed
using an osmotic pump (0.5μL/min for 20 minutes) after im-
mobilisation of anaesthetized mice on a stereotactic frame. For
biodistribution studies, animals (n=30) were injected by CED
either with 3MBq of 188ReO4- (n=15) or LNC-188Re-SSS
(n=15) and sacrificed at 1h (n=10), 24h (n=10) or 72h (n=10).
For efficacy studies, control group mice were injected by CED
with saline (n=8) or blank LNC (n=8) and treated group mice
were injected with escalating dose of LNC-188Re-SSS: 3MBq
(n=8), 6 MBq (n=8) or 12 MBq (n=8). Efficacy on tumour
growth was assessed by clinical palpation and μMRI. The time
for the tumour volume doubling was chosen as endpoint, lead-
ing to the euthanasia of the animal. The physical dose deposited
in the tumour for each treated animal was estimated by Monte
Carlo simulation (Geant4) using measured biodistribution and
μMRI tumour volumes,. Haematological toxicity in mice was
evaluated using blood sampling of 50μL (retro-orbital sinus) at
D2, D7, D14 and D21 after treatment with saline (n=4) and
after treatment with LNC-188Re-SSS, 3MBq (n=4), 6MBq
(n=4) or 12 MBq (n=4). Results: Nanovectorization of 188Re
combined with CED allowed the confinement of more than 30
% of ID in the tumour limiting therefore urinary excretion of
188Re since 0,1% versus 81,9% of ID were excreted in urine
24h after CED of LNC-188Re-SSS and 188ReO4- respectively
(p=0.016). Nanovectorized radiotherapy has drastically in-
creased the median survival time compared with control
group. Animals whose tumor received a dose higher
than 69 Gy (69-340 Gy) showed an ISTmedian of +
933%, whereas animals whose tumor received a dose
lower than 69 Gy (21-67Gy) showed an ISTmedian of
+ 391%. Complete response with eradication of the tu-
mor was observed in 4/12 (33.3%) animals of the for-
mer group. Depletion of platelets was observed follow-
ing LNC-188Re-SSS injection with a time to nadir be-
tween D14-D21 whereas transient lymphocyte depletion
was only observed at D7 for the highest administered
activities (12MBq). Conclusion: CED of LNC-188Re-
SSS demonstrates interesting biodistribution properties
and high efficacy in a model of human endometrial
carcinoma.
OP039
Tumour-Absorbed Dose for Patients in a Phase I study
undergoing antibody-radionuclide-conjugate (ARC)
therapy with 177Lu-DOTA-HH1
C. Stokke1, A. Løndalen2, J. Blakkisrud1, J. Dahle3, T. Bach-
Gansmo2, J. Holtedahl1, A. Martinsen1, B. Bolstad3, H.
Holte4, A. Kolstad4; 1The Intervention Centre, OsloUniversity
Hospital, Oslo, NORWAY, 2Department of Radiology and Nu-
clear Medicine, Oslo University Hospital, Oslo, NORWAY,
3Nordic Nanovector ASA, Oslo, NORWAY, 4Department of
Oncology, Radiumhospitalet, Oslo University Hospital, Oslo,
NORWAY.
Aim: 177Lu-DOTA-HH1 (Betalutin™) is a novel anti-CD37
antibody-radionuclide-conjugate (ARC) currently under
investigation. Betalutin™ is developed by Nordic
Nanovector ASA and consists of lutetium-177 which is
chelated to the DOTA-conjugated antibody HH1. Oslo
University Hospital is participating in a phase I/II study
where Non-Hodgkin Lymphoma patients are treated with
177Lu-DOTA-HH1. In the current work, we estimate
tumour-absorbed doses and aim to investigate dose-
response relationships at the lesion level. Material and
methods: Patients with relapsed CD37+ indolent B-cell
NHL were eligible for inclusion in the 3x3 dose escala-
tion study. Three dose levels have been tested (10 MBq/
kg, 15 MBq/kg, 20 MBq/kg). Eleven patients were
assessed for distribution of radioactivity by SPECT/CT
at the time-points 96 and 168 hours post administration,
of whom 4 also underwent planar whole-body (WB)
imaging at additional time points. Clinical response as-
sessment included 18F-FDG PET/CT. PET/CT scans
were performed at baseline and at 3 months and 6
months follow-up. In this work, response was assessed
by the change in SUVmax value for each individual le-
sion. For 2 patients at each dose level, i.e. a total of 6
patients, we have calculated mean tumour-absorbed dose
for 2 or 3 separate lesions. The SPECT/CT images were
analyzed, and tumour uptake and volume at the different
time points determined. Cumulative activities were cal-
culated from mono-exponential fits, as verified by co-
registered conjugate view WB images when available.
Results: The mean overall tumour-absorbed dose was
2,13 mGy/MBq (range 0,42 - 4,77 mGy/MBq). For pa-
tients in the 10 MBq/kg group, the 15 MBq/kg group
(MTD) and the 20 MBq/kg group the median dose was
138 cGy, 297 cGy and 310 cGy, respectively.
Interpatient and, to some degree, also intrapatient vari-
ances were observed. Dose-rate maps at the voxel level
and dose-volume histograms for each tumour were also
investigated. Only 3 of the 14 tumours studied showed a
less than complete SUVmax response at 3 months, thus
establishing meaningful correlations between tumour-
absorbed dose and response was difficult. However, all
3 lesions with an incomplete response received a dose
below the overall mean dose of 286 cGy. This suggested
dose-response trend requires investigation of more pa-
tients. Conclusion: Tumour-absorbed doses for patients
undergoing antibody-radionuclide-conjugate (ARC)
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therapy with 177Lu-DOTA-HH1 were determined. Al-
though preliminary results are too limited to establish
valid correlations, lesions with an incomplete response
received a dose below the overall mean dose. Further
evaluation of dose-response relationships will require a
larger data material.
OP040
Preliminary Dosimetry Results from a Phase II Study
Evaluating the Efficacy and Safety of Ultratrace®
Iobenguane I 131 in Patients with Relapsed/Refractory
Malignant Pheochromocytoma/Paraganglioma
D. A. Pryma1, C. Jimenez2, B. Chin3, J. R. Olsen4, M. H.
Pampaloni5, L. B. Solnes6, J. Stubbs7, T. Armor8, J. D.
Jensen8, V. Wong8; 1Hospital of the University of Pennsylva-
nia, Philadelphia, PA, UNITED STATES, 2University of Texas
M.D. Anderson Cancer Center, Houston, TX, UNITED
STATES, 3Duke University Medical Center, Durham, NC,
UNITED STATES, 4Washington University School of Medi-
cine, St. Louis, MO, UNITED STATES, 5University of Cali-
fornia, San Francisco, San Francisco, CA, UNITED STATES,
6Johns Hopkins University, Baltimore, MD, UNITED
STATES, 7Radiation Dosimetry Systems, Inc., Milton, GA,
UNITED STATES, 8Progenics Pharmaceuticals, Inc,
Tarrytown, NY, UNITED STATES.
Aim: Radioiodinated meta-iodobenzylguanidine (MIBG)
is used for diagnosis and treatment of neuroendocrine
tumors, such as pheochromocytomas and paragangliomas
(pheo/para). Azedra™ (Ultratrace®iobenguane I131) is a
high specific activity form of MIBG developed from a
solid phase radiolabeling technology that dramatically
reduces cold iobenguane carrier in the final product.
Clinical studies with Azedra suggest this may result in
reduced toxicity, increased tumor uptake, and anti-tumor
activity. The aim of this study is to evaluate the efficacy
and safety of two therapeutic doses of Azedra up to
18.5 GBq each (≤296 MBq/kg) given 3 months apart
in patients with iobenguane-avid metastatic and/or recur-
rent pheo/para. Patient-specific dosimetry was employed
for treatment planning to confirm the protocol-specified
administered activity did not exceed pre-specified
absorbed dose levels. Methods: The absorbed radiation
dose was estimated after a single IV administration of
111-222 MBq of Azedra. Serial anterior/posterior scinti-
graphic images were obtained over 3-6 days. Count data
was extracted from the whole body scans and CT-based
volumes were used to estimate radiation absorbed dose
to normal organs and tissues per the MIRD schema.
Radiation dose estimates for a planned cumulative ther-
apeutic administration of 37 GBq were performed using
OLINDA/EXM software (version 1.1) and reduced when
necessary to limit radiation dose under pre-specified
limits for the kidneys (<23 Gy), liver (<30 Gy) and
lungs (<17.5 Gy). Results: Results are available for 44
patients who underwent dosimetric evaluation. Of these,
41 (93.2 %) demonstrated tumor avidity and 38 (86.4%)
were eligible to receive up to 37 GBq based on dosim-
etry while 6 (13.6%) were eligible with dose reduction.
34 (77.3%) patients received two therapeutic administra-
tions ranging from 32-38 GBq. Mean radiation doses
(±SD) were: kidneys, 12±5.1 Gy; liver, 14±4.2 Gy;
lungs, 10±3.4 Gy. Mean dose to non-source organs
ranged from 2-6 Gy. Mean total body radiation dose
was 3.7±0.9 Gy (range 2.4-7.3 Gy). Azedra was gener-
ally well tolerated with gastrointestinal and hematologic
toxicity most frequently reported. Conclusion: This pro-
spective treatment planning paradigm for high dose ther-
apy is an important safety check-point to estimate po-
tential risks to tissue distribution in critical organs such
as kidneys, liver and lungs. Patient-specific treatment
planning provides a means of optimizing each patient’s
therapeutic administration (in this case, activity reduc-
tion), regardless of the uniqueness of an individual’s
specific biodistribution or biokinetics/clearance patterns.
OP041
Lu-177-Trastuzumab as a potential radiopharmaceutical
for targeted radionuclide therapy of HER2/neu expressing
metastatic breast cancer patients: feasibility study
J. Shukla, P. Bhusari, R. Vatsa, M. Parmar, G. Singh, B. R.
Mittal; Post Graduate Institute of Medical Education & Re-
search, Chandigarh, INDIA.
Introduction:Her2/neu expressing breast cancers are the
most aggressive type of breast cancers. Trastuzumab is a
humanized monoclonal antibody approved by FDA for
the treatment of Her2 breast cancer. Radiolabeled anti-
bodies have emerged as promising vehicles for targeted
radio-immuno therapy of recurrent and metastatic dis-
ease. The aim of the study is to evaluate the feasibility
of Lu-177-Trastuzumab for the treatment of Her2/neu
expressing metastatic breast cancer. Methods:DOTA-
Trastuzumab conjugates were developed using different
molar excess of DOTA (5 to 40). The conjugates were
purified using gel filtration chromatography. Characteri-
zation of the conjugates was done using SDS-PAGE and
MALDI/TOF mass spectrometry. Radiolabeling of the
conjugated Trastuzumab (0.5-3 mg) (dissolved in acetate
buffer;pH=5) was done using Lu-177 chloride(750-
850MBq) at 42oC for 2 hours. Post labeling purification
of Lu-177-Trastuzumab from free Lu-177 was done
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using gel filtration chromatography. The quality control
of the purified Lu-177-Trastuzumab was done by radio-
ITLC. Sterility and Endotoxin testing was performed.
In vitro stability of the Lu-177-Trastuzumab was
assessed up to 20 hours post labelling.The ethical clear-
ance was obtained from the Institute’s ethics committee.
The patients were selected on the basis of [F-18] FDG
scan. Immunohistochemistry (IHC) proven Her2 positive
(n=3) and Her2 negative (n=3) were enrolled after get-
ting informed written consent. Thewhole-body and
SPECT/CT images were acquired at day 1 and day 7/8
post intravenous injection of 185-370MBq of Lu-177-
Trastuzumab. The uptake of the radiopharmaceutical in
the lesions was correlated with IHC and [F-18]FDG re-
ports. Results:Conjugated trastuzumab with 2.5-8 mole-
cules of DOTA per molecule of antibody was used for
clinical grade preparation of Lu-177-Trastuzumab. The
conjugated antibody showed two distinct bands of heavy
and light chains on SDS-PAGE gel electrophoresis. No
peak except corresponding to conjugated antibody was
observed in MALDI mass spectra indicated the presence
of intact antibody. Radiolabeling yield obtained was 70-
91%. The product was stability upto 12 hours post prep-
aration in vitro. The preparations were sterile and endo-
toxin content was <100 EU/V. The physiological tracer
uptake was visible in heart, liver,spleen and nasophar-
ynx. The blood pool activity was very high at 2 hr and
was decreased af ter 7 days.Uptake of Lu-177-
Trastuzumab was observed in all Her2 positive breast
cancer and its metastatic lesions. No uptake of Lu-177-
Trastuzumab was noted in any of the Her2 negative
patients on IHC. Conclusion: Lu-177-Trastuzumab
SPECT/CT imaging indicated that the radiopharmaceuti-
cal may hold great potential for radioimmunotherapy of
Her2 overexpressing metastatic breast cancer.
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OP042
Multiparametric characterization of early tumour
response using PET/MR in patients with lung cancer using
a voxelwise analysis.
A. M. E. Engberg, A. E. Hansen, S. W. Langer, H. H.
Johannesen, N. H. Langer, M. Nørgaard, J. Löfgren, S. H.
Keller, L. Højgaard, A. Kjær, B. M. Fischer; Rigshospitalet,
Copenhagen, DENMARK.
Aim: In this study we explore if multiparametric im-
aging with simultaneous FDG-PET and Diffusion
Weighted (DW) MRI can improve our understanding of
tumour response and flare during chemotherapy and re-
veal patterns enabling us to early and accurately predict
therapy response. Material: Eight patients were recruited
from an ongoing, prospective study including patients
with histologically or cytologically confirmed lung can-
cer referred for standard chemotherapy with carboplatin
and vinorelbine. The patients underwent simultaneous
FDG-PET/MRI (Siemens mMR) prior to (day 0), during
(day 2, 7 and/or 12), and after (day 21) the first or
second cycle of chemotherapy. Four patients completed
5 PET/MR scans and 4 patients 4 PET/MR scans.
Methods: PET/MR was performed one hour after injec-
tion of 18F-FDG over 2 bed positions covering thorax.
MRI included VIBE-DIXON (for attenuation correction),
T1, T2, and DWI (b-values 0, 150, and 1,000). An
experienced radiologist and nuclear medicine physician
defined tumour volumes on all scans and the following
parameters were extracted: SUVmax and SUVmean
(maximum and mean standardized uptake value), and
ADCmin and ADCmean (minimum and mean apparent
diffusion coefficients). A spatial analysis was performed
identifying the centre of mass (CM) for the PET and
ADC tumour volumes. A multivariate Gaussian Mixture
Model (GMM) was applied on the joint ADC and PET
data using the Expectation-Maximization algorithm and
limiting the number of clusters to 5. Results: All scans
were of an acceptable image quality and the CM analy-
sis suggests no significant offset between PET and ADC
tumour volumes. Regarding primary tumour two patterns
of FDG-uptake were identified: A) Responding pattern,
where SUV drops immediately after the first administra-
tion of chemotherapy (day 2) and remains largely un-
changed on the following scans. B) Non-responding pat-
tern: SUV is unchanged during and after chemotherapy.
Regarding ADC values the results are less clear. How-
ever, both responding and non-responding patients
showed a trend towards an initial decrease after the first
dose of chemotherapy followed by an increase. The
voxelwise analysis of the joint ADC and PET data in-
dicated a pattern of decreased tumour heterogeneity and
identified clusters with apparent anatomical features.
Conclusion: Multiparametric imaging with simultaneous
FDG-PET and DW-MRI in lung cancer patients is fea-
sible. These preliminary data indicates that it is possible
to identify a responding pattern by voxelwise GMM
analysis already 24 hours after chemotherapy; potentially
enabling a rapid shift to a more efficient therapy in non-
responding patients.
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OP043
Yttrium-90 PET/MRI is superior
to Bremsstrahlungs-SPECT/CT in treatment verification
after selective internal radiotherapy - initial results
A. P. Bellendorf1, B. Gomez1, J. Schelhorn2, A. Sabet1, S. P.
Müller1, H. V. Ngo1, A. Bockisch1, T. D. Poeppel1; 1Univer-
sity Hospital Essen, Department of Nuclear Medicine, Essen,
GERMANY, 2University Hospital Essen, Germany, Institute
for Diagnostic and Interventional Radiology and Neuroradiol-
ogy, Essen, GERMANY.
Aim: Bremsstrahlung-(BS) SPECT/CT is currently the pre-
ferred imaging modality for assessment of microsphere distri-
bution after selective internal radiotherapy (SIRT). Yet, brems-
strahlung imaging is limited in spatial resolution. With a low
decay probability of approx. 1:30 million, positron emission is
observed in Y-90 decay which allows assessment of treatment
microsphere distribution by positron emission tomography
(PET). This study aims to evaluate Y-90 PET/MR for treat-
ment verification after SIRT in comparison with BS-SPECT/
CTand pre-treatment Tc-99m HSA-Microspheres SPECT/CT.
METHODS: 16 patients with primary and secondary hepatic
malignancies underwent pre-treatment Tc-99m HSA-
Microspheres SPECT/CT (within 6 weeks before SIRT) and
post-SIRT BS-SPECT/CT (both Siemens Symbia T2, acquisi-
tion time[AT] 35 min.) as well as Y-90 PET/MRI (Siemens
mMR, AT 20min) within 48 hours after SIRT. 3 readers with
experience in hybrid imaging and MRI reviewed all datasets.
A total of 247 lesions was analysed with regard to the follow-
ing criteria: 1) number and lesion-to-liver contrast (3-point
ordinal scale (OS):1=low-3=good) of focal intrahepatic nu-
clide depositions including morphological correlation(4-p.
OS: 1=no corr.- 4=excellent corr.). 2) Delineation of extrahe-
patic depositions and quality of anatomical localisation (1=no
local.-3=good corr.). 3) Overall image quality (1=non-diagn.-
4=good). 4) Correlation with pre-SIRT Tc-99m HSA-SPECT/
CT. RESULTS: 1)Y-90 PET/MRI showed more focal deposi-
tion than BS-SPECT (82 vs. 74, mean lesions per patient 5,3
vs. 4,6) with higher lesion-to-liver contrast (median contrast 3
vs. 2, p=0.003). 2) More extrahepatic depositions were found
in Y-90 PET/MRI with better mean localisation quality (6 vs. 1
lesions, mean quality 1 vs. 3). 3) Overall image quality (IQ)
and quality of co-registration (CR) showed no signifi-
cant difference between PET/MRI and BS-SPECT/CT
(mean IQ: 3 vs. 3, CR: 3,5 vs. 4). 4) pre-SIRT HSA-
SPECT/CT (5.9 lesions per pt., 91 total) showed a
higher congruence with Y-90 PET/MR (5.2 lesions per
pt., 82 total) than with BS-SPECT/CT (4.6 lesions per
patient, 74 tot.) CONCLUSION: Y-90 PET/MRI showed
a higher detection rate and superior image quality of
intra- and extrahepatic nuclide depositions after SIRT
compared to BS-SPECT. Moreover, there was a higher
congruence between pre-treatment Tc-99m HSA-SPECT/
CT and Y-90 PET/MR in comparison with BS-SPECT/
CT.
OP044
Lean body mass estimation from standard, Dixon-based
attenuation correction in combined PET/MRI
I. Rausch1, P. Rust2, M. D. DiFranco1, M. Lassen1, A.
Stadlbauer3, M. E. Mayerhöfer3, M. Hartenbach4, T. Beyer1;
1Center for Medical Physics and Biomedical Engineering,
Medical University of Vienna,, Vienna, AUSTRIA, 2Depart-
ment of Nutritional Sciences, University of Vienna,, Vienna,
AUSTRIA, 3Department of Biomedical Imaging and Image-
guided Therapy, Medical University of Vienna, Vienna, AUS-
TRIA, 4Division of Nuclear Medicine, Department of Bio-
medical Imaging and Image-guided Therapy, Medical Univer-
sity of Vienna, Vienna, AUSTRIA.
Aim: Standardized Uptake Values (SUV) normalized to lean
body mass (LBM) may correlate better with the metabolic
activity as SUVs normalized to body weight (BW). However,
patient-specific LBM calculations are based on general as-
sumptions. Here, we evaluate if the information obtained in
PET/MR imaging from standard, MR-based attenuation cor-
rection (MR-AC) can be used to predict LBM for each patient
more accurately. Method: 10 volunteers (5m, 5f) who
underwent a body composition measurement using a
BODPOD system (Life Measurement) were included in this
study. Subjects were scanned within ±3 days in a PET/MR
system (mMR, Siemens Healthcare) from head to toe using
MR head and surface coils. Three consecutive multi-bed ac-
quisitions of the MR-AC image data were acquired in free
breathing, except for the thorax (full-inspiration breath-hold)
using the standard DIXONMR-AC protocol. For each subject
and MR-ACmap, the following compartmental volumes were
calculated usingMatlab (MathWorks): whole-body (WB), soft
tissue (ST), fat (F), and intermediate tissue (IM), with the latter
comprising voxels interpolated between (F) and (ST). We re-
port intra-subject differences in WB and sub-compartmental
volumes (ST, F and IM) relative to the WB volume by means
of coefficients of variation (CV). The LBM was calculated
from the MR-AC by the formula: LBM-AC=(ST*ρST+IM*
ρIM *1/2)/(ST* ρST+ F* ρF +IM* ρIM)*BW , were ρ is the
tissue-dependent density (ρST=1.1 kg/L, ρF=0.9 kg/L, ρIM=1
kg/L). Pearson’s correlation was calculated between LBM-
BODPOD, LBM-AC and LBM estimated by an estimation
formula (Sugawara 1999) (LBM-Formula ). Linear regression
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(avoiding intercept) was used to scale LBM-AC to LBM-
BODPOD. Results: Mean CV for all 30 scans was 2.1±1.9%
(WB). When excluding the AC-maps with missing tissue arti-
facts (MT) the CV was reduced to 0.3±0.2% (WB). Mean CV
for sub-compartments (all maps, maps without (MT) and tis-
sue swap artifacts (TS)) were: ST (0.9±1.1, 0.7±0.7%), F (2.9
±4.1, 1.3±1.0%), and IM (3.6±3.7, 1.3±0.7%). Correlation
analysis showed better correlation between LBM-AC and
LBM-BODPOD (r=0.99, p<0.001 / excluding MT&TS:
r=0.99, p<0.001) than between LBM-BODPOD and LBM-
Formula (r=0.89, p<0.001 / excluding MT&TS: r=0.91,
p<0.001). Linear regression of data excluding MT&TS results
in a scaling factor of 1.08 for LBM-AC . Conclusion: LBM
estimation from DIXON MR-AC maps correlates well with
standard LBM measurements and, thus, offers routine SUV-
LBM-based quantification in PET/MR.
OP045
Semi-quantitative assessment of 18F FDG uptake
in the normal skeleton using simultaneous PET/MRI:
initial comparison to PET/CT in 50 patients
G. Xu, R. Minamimoto, A. Quon, E. Mittra, A. Iagaru;
Stanford University School of Medicine, STANFORD, CA,
UNITED STATES.
Introduction: Differences in the attenuation correction
methods between clinical PET/CT scanners and newly intro-
duced whole-body simultaneous PET/MRI systems could af-
fect the estimated specific uptake values in normal and patho-
logic structures. Here we evaluated the semi-quantitative 18F-
FDG measurements on PET/MRI vs. PET/CT. Materials and
methods: Fifty consecutive cancer patients were enrolled in a
PET/MRI vs. PET/CT comparison research protocol. First, a
PET/CT scan (GE Discovery 600 or 690) was acquired at
mean±SD: 73±16 min after FDG injection, followed by
PET/MRI scan at 161±31 min after FDG injection. Ten re-
gions of interest (ROIs) in representative areas of the axial
and proximal appendicular skeleton were measured from
PET in PET/MRI and PET/CT for every patient. In addition,
another dataset from 30 patients who had dual time PET/CT
was used for comparison. The latter had similar delays be-
tween scans as from PET/CT to PET/MRI. SUVmax and
SUVmean from the selected ROIs were used for an analysis
using Pearson correlation coefficients (CCs). Results:
SUVmax values for the normal skeleton obtained from PET/
MRI and PET/CTshowed good agreement (CC=0.84), similar
to the values from the dual time point PET/CT study
(CC=0.85). However, the SUVmean values were significantly
more variable by PET/MRI compared with PET/CT (CC 0.88
vs. 0.94, P = 0.006). No significant differences were noted in
either the SUVmax or SUVmean values across all ROIs
between PET/MRI and PET/CT exams. Conclusion: Our data
demonstrate reliable quantification in the normal skeleton for
the simultaneous PET/MRI studies in comparison with PET/
CT. The SUVmax is less variable than SUVmean in this co-
hort. Evaluation of semi-quantitative measurements in malig-
nant bone lesions should also be done.
OP046
Evaluation of the influence of truncation artifacts using
in-vivo based quantification accuracy methods
in combined PET/MRI
J. Maus1, G. Schramm2,1, F. Hofheinz1, L. Oehme3, A.
Lougovski1, J. Petr1, I. Platzek4, B. Beuthien-Baumann3, J.
Steinbach1, J. Kotzerke3, J. van den Hoff1,3; 1PET Center,
Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMA-
NY, 2Medical Imaging Research Center, KU Leuven, Leuven,
BELGIUM, 3Department of Nuclear Medicine, University
Hospital Carl Gustav Carus, Technische Universität Dresden,
Dresden, GERMANY, 4Department of Radiology, University
Hospital Carl Gustav Carus, Technische Universität Dresden,
Dresden, GERMANY.
Aim: Quantitative accuracy of standardized uptake values
(SUV) and tracer kinetic uptake parameters in patient
investigations requires determination of regional activity
concentrations in PET data. This determination rests on
the assumption that the scanner calibration is valid in-
vivo. In a recent study we introduced a method to test
this assumption. For 3 different PET and PET/CT sys-
tems the activity concentration of urine samples mea-
sured in a well-counter were compared to those derived
from PET images of the bladder. The study demonstrat-
ed a low but systematic underestimation of 7-12% of
PET relative to a cross-calibrated well-counter for 56
subjects. In the present study we have applied this meth-
od to the Philips Ingenuity-TF PET/MR to evalute the
impact of MR-based truncation artifcats on the overall
quantitative accuracy of this system. Methods: 21 clini-
cal whole-body F18-FDG scans were included in this
study. The bladder region was imaged as the last bed
position and urine samples were collected afterwards.
PET images were reconstructed including MR-based at-
tenuation correction with and without truncation com-
pensation and 3D region-of-interests (ROI) of the blad-
der were delineated by 3 observers. Activity concentra-
tions were determined in the PET images for the bladder
as well as for the urine by measuring the samples in a
well-counter. Results: The in-vivo activity concentrations
of the bladder were significantly lower in PET/MR than
in the well-counter with a ratio of the former to the
latter of 0.756±0.060 (mean±std.dev.) and a range of
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[0.604-0.858]. Linearity scans revealed a systematic er-
ror of 8-11 % (avg. 9 %). After correcting for this sys-
tematic bias caused by shortcomings of the manufac-
turer’s calibration procedure the PET to well-counter ra-
tio increased to 0.832±0.064 [0.668-0.941]. After apply-
ing compensation for truncation of the upper extremities
in the MR-based attenuation maps the ratio further in-
creased to 0.871±0.069 [0.693-0.992]. Conclusions: Our
results show, that the Ingenuity-TF PET/MR underesti-
mates activity concentrations in the bladder by 17%
which is 7 percentage points larger than in the previous-
ly investigated PET/CT systems. This difference in be-
havior can be attributed to remaining limitations of MR-
based attenuation correction as our results on truncation
compensation related influences suggest - leaving only a
2 pp. larger underestimation of activity concentrations if
corrected. Thus, quantif icat ion accuracy of the
Ingenuity-TF PET/MR can be considered acceptable for
clinical purposes. The comparison of PET images from
the bladder region with urine samples has proven a use-
ful method to evaluate quantification accuracy of differ-
ent PET systems in-vivo.
OP047
Improvements in PET Image quality from TOF PET/MRI
R. Minamimoto, M. Jamali, A. Barkhodari, D. Holley, G.
Zaharchuk, C. Levin, A. Iagaru; Stanford University,
STANFORD, CA, UNITED STATES.
Purpose: A completely novel integrated PET/MRI scanner
with TOF technology has been recently introduced. Here we
evaluated the potential of TOF PET/MRI to reduce various
PET image artifacts, by comparing the images to non-TOF
PET/MRI, TOF PET/CT and non-TOF PET/CT. Materials
and methods: All patients underwent a single-injection of
FDG, followed first by PET-CT and subsequently by PET-
MRI scan. The standard of care PET/CT exams were per-
formed using a GE Discovery 690 PET/CT scanner. The re-
search PET/MRI images were acquired on a GE Signa PET/
MRI scanner. All PET images were reconstructed with and
without the TOF data, resulting in 4 series of PET images
(TOF PET/MRI, non-TOF PE/MRI, TOF PET/CT and non-
TOF PET/CT). Visual analysis of these series was performed
for 1) dental metal artifacts, 2) breathing artifacts, and 3) scat-
ter artifacts caused by high excretion of FDG in the bladder.
PET image quality was evaluated using a 3-point scale (1 -
clinically significant artifact; 2 - non clinically-significant ar-
tifact; and 3 - no artifact). Results: Data from 25 oncologic
patients (mean ± SD age: 56 ± 13 years; female 10, male 15)
were used. The average scores of TOF PET/MRI, non-TOF
PET/MRI, TOF PET/CT and non-TOF PET/CT for dental
artifacts were 2.8, 2.5, 2.4 and 2.3, respectively; for breathing
artifacts were 2.8, 2.5, 2.2 and 1.9, respectively; and for pelvic
artifacts were 2.7, 1.7, 2.0 and 1.3, respectively. TOF PET/
MRI images had the highest image quality scores among the
4 series of PET data analyzed for these types of artifacts. Con-
clusion: TOF PET/MRI showed promising results in reduction
of various PET artifacts in this cohort, when compared to non-
TOF PET/MRI, TOF PET/CT and non-TOF PET/CT.
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OP048
In vivo evaluation of [11C]preladenant for imaging
of adenosine A2A receptors in the conscious monkey
X. Zhou1, E. de Vries1, K. Ishiwata2, R. Dierckx1, S.
Nishiyama3, H. Tsukada3, P. Elsinga1; 1University Medical
Center Groningen, Groningen, NETHERLANDS, 2Research
Team for Neuroimaging, Tokyo Metropolitan Institute of Ger-
ontology, Tokyo, JAPAN, 3Central Research Laboratory, Ha-
mamatsu Photonics K.K., Hamamatsu, JAPAN.
Aims: The adenosine A2A receptor (A2AR) is studied as a
therapeutic target in several neurologic and psychiatric disor-
ders. Recently, we have synthesized [11C]preladenant, a PET
ligand with high affinity and selectivity for the A2AR. The
present study aims to evaluate [11C]preladenant in conscious
monkey brain. Materials and methods: Conscious monkeys
(n=6) were i.v. injected with [11C]preladenant and a 90 min
dynamic scan was started. Arterial blood samples with metab-
olite analysis were obtained during the scan to provide the
input function for kinetic modelling. Distribution volume
(VT) was obtained by modelling with the Logan graphical
analysis with t* set to 22 min post injection. Simplified refer-
ence tissue model (SRTM) and multilinear reference tissue
model (MRTM) were used to estimate binding potential
(BPND) in striatum. Cerebellum, cingulate, parental cortex
and occipital cortex were tested as reference regions. The
values of BPND obtained from reference tissue-based models
were compared with the BPND calculated from Logan analysis
using the formula VT, target/VT, reference-1. The best reference
tissue was selected based on high BPND in striatum with low
intra-individual variance. Results: Regional uptake of
[11C]preladenant was consistent with the distribution of
A2ARs in the monkey brain, with the highest uptake in puta-
men, followed by caudate, and the lowest uptake in cerebel-
lum. The tracer kinetics was well fitted with the Logan plot. VT
estimates ranged from 0.89±0.31 in cerebellum to 5.86±2.10
in putamen. BPND values estimated from SRTM and MRTM
were comparable, with slightly higher (1-3%) values predicted
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by MRTM. Striatal BPND predictions with SRTM (5.05±1.01
and 4.02±1.06, for putamen and caudate, respectively) and
MRTM (5.11±1.00 and 4.10±1.05, for putamen and caudate,
respectively) were in agreement with BPND calculated from
Logan analysis (5.64±1.54 and 4.12±1.26, for putamen and
caudate, respectively), but with a small negative and signifi-
cant (p<0.05) bias of <10%, when cerebellum was used as the
reference region. As a trade-off between bias and noise, coef-
ficient of variance (COV) of BPND predicted by SRTM and
MRTM (~20%) was smaller compared with BPND estimate
from Logan analysis (~28%). Other reference regions showed
an increased (7-20%) negative bias of BPND prediction, com-
pared with cerebellum prediction. Compared to VT, BPND
seemed to be a more stable parameter with smaller COV in
striatum (~20% BPND COV vs. ~35% VT COV in striatum).
Conclusions: [11C]Preladenant PET is suitable to non-
invasively quantify A2ARs in monkey brain. MRTM and
SRTM using cerebellum as the reference tissue are applicable
models for A2AR quantification.
OP049
Sigma-1 and dopamine D2 receptor occupancy
of the dopamine stabilizer pridopidine in the brain of living
rats
K. Sahlholm1, J. W. A. Sijbesma2, B. Maas2, C. Kwizera2, N.
K. Ramakrishnan2, R. A. J. O. Dierckx2, P. H. Elsinga2, A. Van
Waarde2; 1Department of Neuroscience, Karolinska Institute,
Stockholm, SWEDEN, 2University of Groningen, University
Medical Center Groningen, Department of Nuclear Medicine
and Molecular Imaging, Groningen, NETHERLANDS.
Objectives: Dopamine stabilizers have stimulatory actions un-
der low dopamine tone and inhibitory actions under high do-
pamine tone without eliciting catalepsy. Pro-mnemonic and
neuroprotective effects have also been attributed to these com-
pounds, which are either neutral antagonists or partial agonists
at the dopamine D2 receptor. The mechanism underlying their
stimulatory and neuroprotective actions is unknown but could
involve sigma-1 agonism, since these drugs have shown
nanomolar in vitro affinity to sigma-1 receptors. In order to
test this hypothesis, we examined the dose-dependent D2R
and sigma1R occupancy of the dopamine stabilizer
pridopidine (ACR16) in living rats. Methods: Male Wistar rats
were treated with various doses of pridopidine (0, 3, or 15 mg/
kg, s.c.), one hour before injection of the sigma1R ligand
[11C]SA4503 or the dopamine D2R ligand [11C]raclopride.
Some animals received 60 mg/kg pridopidine and were only
scanned with [11C]raclopride. Dynamic microPET scans were
made with a Siemens/Concorde Focus220 camera. Cerebral
[11C]SA4503 binding was quantified using plasma input data
acquired by arterial sampling and distribution volume (VT)
calculated by Logan graphical analysis . Str ia ta l
[11C]raclopride binding was quantified using target-to-
cerebellum ratios and binding potentials calculated with a sim-
plified reference tissue model. RESULTS: Pridopidine dose-
dependently reduced the VT of [11C]SA4503 in all examined
areas of the rat brain. Particularly at the 15 mg/kg dose,
pridopidine reduced the clearance of radioactivity from plasma
and increased the metabolic degradation of [11C]SA4503
(parent fraction at 60 min 33% vs 55% at baseline).
Cunningham-Lassen plots based on regional VT and
metabolite-corrected plasma input data indicated sigma-1 re-
ceptor occupancies of 57 ± 2% and 85 ± 2% after pretreatment
of animals with 3 and 15 mg/kg pridopidine. These drug doses
did not reduce [11C]raclopride binding in the striatum, but at
60 mg/kg, pridopidine caused a significant reduction of the
target-to-nontarget ratio of the D2 ligand (from 3.85 ± 0.48
to 1.96 ± 0.10), reflecting 66% D2R occupancy. Conclusions:
At therapeutically effective doses, pridopidine occupied a high
fraction of the sigma1R population and a negligible fraction of
the dopamine D2R population in rat brain. Significant occu-
pancy of dopamine D2 receptors was only observed at a dose
of pridopidine 20-fold higher than was required for occupancy
of sigma-1 receptors. The characteristic actions of dopamine
stabilizers may result from the combination of high sigma-1
affinity (possibly sigma-1 agonism) with low-affinity dopa-
mine D2 antagonism.
OP050
PET/MR hybrid scanner imaging of cerebral blood flow
using 15O-water positron emission tomography
and arterial spin labeling magnetic resonance imaging
in newborn piglets
J. B. Andersen1, W. Henning1, U. Lindberg2, C. N.
Ladefoged1, L. Højgaard1, G. Greisen3, I. Law1; 1Department
of Clinical Physiology, Nuclear Medicine and PET,
Rigshospitalet, University of Copenhagen, Denmark,
København Ø, DENMARK, 2Functional Imaging Unit,
Rigshospitalet, Glostrup Hospital, University of Copenhagen,
Denmark, København Ø, DENMARK, 3Department of Neo-
natology, Rigshospitalet, University of Copenhagen, Den-
mark, København Ø, DENMARK.
Aim: Abnormality in cerebral blood flow (CBF) distribution
can lead to hypoxic-ischemic damage in newborn infants and
is a major cause of later neurocognitive impairment. Thus, a
clinically useful, robust and accurate method for measuring
CBF in newborn infants is needed. The aim of the study was
to investigate minimally invasive approaches to measure CBF
by comparing simultaneous 15O-water positron emission to-
mography (PET) and single-TI pulsed arterial spin labeling
(ASL) magnetic resonance imaging (MR) on a hybrid PET/
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MR system in seven newborn piglets. Materials and methods:
The experimental protocol for the study was approved by the
Danish Animal Experiments Inspectorate and conducted in
accordance with the Animal Ethics Policy at the University
of Copenhagen. On each piglet, four scans at baseline and four
scans after acetazolamide stimulus were performed. Positron
emission tomography was performed with repeated IV injec-
tions of 20 and 100 MBq 15O-water to test CBF reliability at
low activity injections. Cerebral blood flow was quantified
using a 1-tissue-compartment model employing two different
input functions: either an arterial input function (AIF) or an
alternative image derived input function (IDIF) generated from
the dynamic PET scan using a VOI in the left ventricle of the
heart. Results: The mean global CBF(95%CI) PET-AIF, PET-
IDIF and ASL at baseline were 27(23;32), 34(31;37) and
27(22;32) mL/100g/min, respectively. At acetazolamide stim-
ulus PET-AIF, PET-IDIF and ASL were 64(55;74), 76(70;83)
and 79(67;92) mL/100g/min, respectively. At baseline the dif-
ferences between PET-AIF, PET-IDIF and ASL were
22%(p<0.0001) and -0.7%(p=0.9). At acetazolamide the dif-
ferences between PET-AIF, PET-IDIF and ASL were
19%(p=0.001) and 24%(p=0.0003). ASL CBF showed the
largest variance when accounting for dose and acetazolamide
effect (p=0.01). There was no significant difference in varia-
tion between the 20 MBq PET CBF scans compared to the
100MBq PET CBF scans (p=0.06). On visual presentation the
distribution of regional CBF showed that the variation across
voxels was greater in ASL CBF images with both very high
and negative value voxels. Conclusion: In conclusion, PET-
IDIF overestimated global CBF. An injected activity of
20 MBq 15O-water had acceptable concordance with 100
MBq, and may be used clinically without compromising im-
age quality. Global ASL CBF and PET CBF were congruent
during baseline but not during hyperperfusion. Single-TI ASL
was questionable for regional CBF measurements. Further
evaluation of the regional accuracy of ASL CBF and PET
CBF is needed in newborn infants with low absolute rates of
flow.
OP051
PET Imaging of Tau Pathology in two Transgenic Mouse
Models using [18F]-THK-5117
M. Brendel1, A. Jaworska2, F. Probst1, F. Overhoff1, J.
Carlsen1, S. Lindner1, J. Herms2, P. Bartenstein1, N.
Okamura3, A. Rominger1; 1University of Munich, Munich,
GERMANY, 2DZNE,Munich, GERMANY, 3Tohoku Univer-
sity, Sendai, JAPAN.
Aims: Abnormal accumulation of tau aggregates in brain is
one of the hallmarks of Alzheimer’s disease (AD). To visualize
the tau deposition in vivo, a previously developed 2-
arylquinoline derivative [18F]-THK-5117 was evaluated in
two transgenic tau mouse models using μPET in combination
with autoradiography and histopathology. Methods: μPET
scans were performed in P301S (N=11) and BiGT animals
(N=16) of different age groups. For control groups age- and
background-matched wild-type (WT) littermates were used.
After i.v. application of 16 ± 2 MBq [18F]-THK-5117 a dy-
namic 90 min (20-50 min for BiGT) emission recording was
initiated followed by a 15 min transmission scan using the
Siemens Inveon DPET. After coregistration to an MRI atlas
and cerebellar scaling, volume-of-interest based analysis
(SUVR) and statistical parametric mapping (SPM) were per-
formed. PET results were compared with ex vivo and in vitro
autoradiography and validated with AT8 staining for neurofi-
brillary tangles. Results: Emission time from 20-50 min
showed suitability for static economized PET recordings and
test-retest analyses revealed robust SUVR values (r=0.9).
SUVR increases were detected in the brainstem of P301Smice
(+11%; p < 0.001) compared to WTanimals. In BiGT animals
significant increases in SUVR were found in entorhinal/
amygdaloidal areas (+15%; p < 0.001) when compared to
WT. Histologically assessed tau loads correlated well with
PET-SUVR for P301S (r=0.8; p<0.001) and BiGT (r=0.7;
p<0.001) mice while distribution patterns of AT8 positive tau
were reflected by SPM analyses. In vivo PET findings could
be verified by autoradiography where blocking with cold trac-
er proved the specificity to tau depostitions. Conclusions:
[18F]-THK-5117 is a promising PET tracer and suitable for
preclinical tau imaging in the mouse brain. Pathology-related
effects could be successfully imaged in vivo in two transgenic
tau models, where in vivo assessment of the given inter-animal
heterogeneity can potentially improve subsequent treatment
studies in the future.
OP052
Altered brain serotoninergic neurotransmission
and glucose metabolism in an original mouse model
of synucleinopathy
E. LEVIGOUREUX1, C. BOUILLOT2, T. BARON3, L.
ZIMMER1, S. LANCELOT1; 1Université Claude Bernard
Lyon 1, Lyon, FRANCE, 2CERMEP-Imaging Platform, Lyon,
FRANCE, 3ANSES, Lyon, FRANCE.
Aim: Alpha-synuclein (α-syn) aggregation is a neuropatho-
logical hallmark of neurodegenerative diseases called
synucleinopathies, including Parkinson’s disease, dementia
with Lewy bodies and multiple system atrophy. The purpose
of this study was to evaluate serotoninergic and metabolic
disorders in an original mouse model of synucleinopathy. Ma-
terials and methods: This study used a model of transgenic
mouse (TgM83) expressing in an accelerated manner the
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human A53T mutated α-syn. Control animals were C57Bl/6S
mice presenting a deletion of the α-syn locus (KO α-syn) and
C57Bl/6S mice (wild type). MicroPET acquisitions were per-
formed with [18F]MPPF, a serotonin 5HT1A receptor radio-
pharmaceutical, [11C]DASB, a serotonin transporter radio-
pharmaceutical and [18F]FDG. Regions of interest were
drawn manually according to the stereotaxic atlas and anatom-
ical MRI acquisitions. Regional standardized uptake value ra-
tio (SUVR)s were calculated and normalized to cerebellar cor-
tices for [11C]DASB and to temporal cortices for [18F]FDG.
For [18F]MPPF, images were analyzed with Logan BP and
normalized to cerebellar cortices. Results: MicroPET images
showed an increased uptake of [18F]MPPF in this mouse
model of synucleinopathy. In TgM83 mice BP were 0.96,
0.76 and 0.96 in the hippocampus, cingulate cortex and
frontal cortex, respectively, versus 0.54 (p<0.0001), 0.45
(p=0.0001) and 0.65 (p=0.0002) in WT mice and 0.44
(p<0.0001), 0.39 (p=0.0001) and 0.73 (p=0.0133) in KO
α-syn mice. Conversely, a hypometabolism of glucose was
observed in TgM83 mice in the same regions: SUVR were
1.26, 1.26, 1.22 in hippocampus, cingulate cortices and
frontal cortices, respectively, versus 1.35 (p=0.0001), 1.46
(p<0.0001) and 1.33 (p=0.0136) in WT mice and 1.39
(p=0.04), 1.52 (p=0.0003) and 1.34 (p=0.05) in KO α-
syn mice. No significant differences were observed be-
tween the three groups for [11C]DASB uptake. Conclu-
sion: Our results demonstrated in a mouse model of
synucleinopathy a regional overexpression of 5HT1A re-
ceptors, without serotonin transporter modifications and
with a carbohydrate hypometabolism. This study revealed
for the first time that an overexpression of α-syn modifies
the serotonin neurotransmission. Brain serotonin concentra-
tions will be determined to propose a pathophysiological
mechanism.
OP053
Longitudinal Imaging of Acute Neuroinflammation
with [11C]PBR28 in an Ischemic Stroke Rat Model
M. Tóth1, P. Little1,2, F. Arnberg1,2,3, J. Häggkvist1, J.
Mulder4, A. Varrone1, C. Halldin1,5, B. Gulyás1,5, S.
Holmin1,2; 1Karolinska Institutet, Department of Clinical Neu-
roscience, Stockholm, SWEDEN, 2Karolinska University
Hospital, Department of Neuroradiology, Stockholm, SWE-
DEN, 3Karolinska University Hospital, Department of Radi-
ology, Stockholm, SWEDEN, 4Karolinska Institutet, Depart-
ment of Neuroscience, Stockholm, SWEDEN, 5Imperial Col-
lege-NTU, Lee Kong Chian School of Medicine, Singapore,
SINGAPORE.
Aim: Adequate estimation of neuroinflammatory processes fol-
lowing ischemic stroke is essential for better understanding of
disease mechanisms, and for the development of treatment strat-
egies. With [11C]PBR28, we have monitored the inflammatory
response after transient cerebral ischemia in rats longitudinally,
using a recently developed rat stroke model with isolated focal
cortical infarcts. Our aimwas to compare the suitability of BPND
as an outcome measure compared to %SUV, in this novel animal
model. Matherials and Methods: Six Sprague-Dawley rats (300-
400g) were anaesthetized with isoflurane in 100%O2. Occlusion
of the M2 segment of the middle cerebral artery (M2CAO) was
maintained for 90min, and animals were imaged at 1, 4, 7 and 14
days after reperfusion (one animal missing day 14) with a bolus
injection of [11C]PBR28 through tail vein cannulation in
nanoScan PET/MRI and PET/CT systems (Mediso Ltd, Buda-
pest Hungary). PET scans were co-registered to individual T1-
weighted MRI images in PMOD 3.3 (Zurich, Switzerland). As a
primary outcome BPND was estimated with SRTM, using the
contralateral cortex as reference region. Results: [11C]PBR28
showed high uptake in the Infarct region from day 4 with gradual
decrease at later time points. The following average %SUV
values were obtained from the Infarct region on day 1: 67.21 ±
3.68 (n = 6), day 4: 151.16 ± 41.59 (n = 6), day 7: 141.02 ± 51.56
(n = 6) and day 14: 124.59 ± 33.29 (n = 5). At day 4, 7 and 14
there was a significantly increased uptake of [11C]PBR28 com-
pared to day 1, while have found no significant change in the
uptake of Contralateral Cortex during the 14 days of imaging.
BPND in the Infarct region was 0.22 ± 0.19 (n = 6) on day 1 and
similarly to %SUV there was a significant increase in BPND on
day 4: 1.73 ± 0.78 (n = 6), day 7: 1.59 ± 0.96 (n = 6) and day 14:
0.86 ± 0.64 (n = 5) compared to day 1. Conclusion: The longi-
tudinal follow up of inflammatory response with the TSPO
radioligand [11C]PBR28 in rats after cerebral ischemia showed
significantly up-regulated TSPO binding in the Infarct region
from day 4, with both %SUVand BPND. This activation gradu-
ally decreased between day 4 and day 14. The present model
(M2CAO) appears to be well suited for studies on neuroinflam-
mation with a more rapid response compared to the MCAO
model.
OP054
Evaluation of the effect of radiotherapy on neuronal
integrity in rats using [11C]flumazenil PET
A. Parente, D. Vallez Garcia, P. van Luijk, J. A. Langendijk,
R. A. J. O. Dierckx, J. Doorduin, E. F. J. de Vries; RUG,
Groningen, NETHERLANDS.
Aim: Whole brain radiotherapy is frequently used in the treat-
ment of primary and metastatic brain tumors. Unfortunately,
radiotherapy also damages normal brain tissue, which can lead
to serious and debilitating cognitive dysfunction. The exact
mechanisms behind the radiotherapy-induced cognitive dys-
function remain elusive, but it may, in part, be explained by
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neuronal damage and neuronal loss. The aim of this study was
therefore to evaluate if whole brain radiotherapy induced neu-
ronal loss in healthy rats, using PETwith the GABAA receptor
antagonist [11C]flumazenil as a marker for neuronal loss. Ma-
terial and methods: Male Wistar rats (n=24, age 8-9 weeks)
were divided in 3 groups of 8 rats: control, sham irradiated,
and whole brain irradiated. Whole brain irradiation was per-
formed by the delivery of 25 Gy of X-rays in a single dose,
under anesthesia, using an in-house developed rat brain colli-
mator so that only the brain was exposed. Sham irradiated rats
underwent the same procedure, but were not irradiated.
[11C]Flumazenil PET scans were performed 3 months after
(sham-)irradiation. Control rats were scanned at an age of 8-
9 weeks to assess the effect of aging on [11C]flumazenil PET.
[11C]Flumazenil was injected intravenously at a constant flow
of 1 ml/min (62±26MBq) and a dynamic PET scan of 60
minutes was acquired. The PET scan was accompanied by
arterial blood sampling and metabolite analysis. One-tissue
compartment modeling was used to calculate the volume of
distribution (VT) in different brain regions, using blood and
metabolite corrected plasma as input. Results: In control rats,
the highest VTwas found in the frontal cortex (12.0±2.0) and
hippocampus (11.0±1.8) and the lowest in the pons (4.9±0.8)
and medulla (4.2±0.7). No statistical significant differences in
the VT were found between control and sham irradiated rats,
showing that aging did not affect [11C]flumazenil binding.
However, the VT in rats irradiated with 25 Gy was statistically
significantly lower in all brain regions (p<0.05), including
frontal cortex (33%), hippocampus (32%), pons (33%), and
medulla (35%), when compared to sham irradiated rats. Con-
clusion: Whole brain irradiation resulted in statistically signif-
icantly decreased binding of [11C]flumazenil to GABAA re-
ceptor. This finding suggests that radiotherapy-induced cogni-
tive dysfunction could be related to neuronal loss.
OP055
Inverse translation of PET auditory system activation
studies to rats using F-18-FDG PET
M. Mamach1,2, G. Berding1,2, J. P. Bankstahl1, F. Wilke1, L.
Geworski1, F. M. Bengel1, S. Kurt1,2; 1Medical School, Han-
nover, GERMANY, 2Cluster of Excellence “Hearing4All”,
Oldenburg, GERMANY.
Aim:Functionality assessments of the auditory system using
statistical parametric mapping (SPM) with multiple PET acti-
vation studies of a patient with moderate auditory stimuli are
standard in humans. We performed an adapted inverse trans-
lation of this method to healthy, auditory unimpaired rats and
assessed its functionality and magnitude.Methods:Scans were
performed in 12 female Sprague Dawley rats using F-18-
fluorodeoxyglucose (FDG, 16-20 MBq) PET (Inveon,
Siemens). The tracer was always injected via tail vein in awake
animals placed into a motion restricting tube within a sound
attenuated box. Three sets of separate scans were acquired for
each animal, each under the following conditions: (i) 55 dB
background noise (BG55), (ii) 65 dB continuous white noise
(WN65) and (iii) 95 dB pulsed rippled noise (RN95). All
sound conditions started 1 min before tracer injection and
lasted for 41 min. Scanning was performed across 30 min
starting 1 h after injection. Data were reconstructed iteratively
including 57Co-transmission-source-based attenuation correc-
tion. Spatial normalization and brain activity normalization
were performed using a FDG template and mask provided
by PMOD3.6 software. Mean normalized counts were extract-
ed for auditory regions (inferior colliculus (IC), mediate genic-
ulate body (MGB) and auditory cortex (AC)) using Schwarz’s
VOI atlas. Pairwise comparisons across conditions assessed
differences of relative activities in VOIs and SPM8 based
voxel-wise extent and T-value.Results:RN95-vs-BG55 and
WN65-vs-BG55 comparisons revealed significant increased
uptake by 15.5% and 12.5% in the IC based on VOI analysis
(p<0.001). Correspondingly, SPM analysis showed supra-
threshold voxels in 97% and 77% of this VOI (p<0.001), with
T-max value of 9.9 and 8.3, respectively. RN95-vs-WN65 and
RN95-vs-BG55 showed increased uptake (p<0.001) of 6.5%
and 5.6% in the MGB - encompassing 35% and 21% of this
VOI (p<0.001) with a T-max value of 5.0 and 4.3. Comparing
RN95-vs-WN65 resulted in an increased uptake (p<0.05) in
the auditory cortex by 2.8%, corresponding to 1% of this VOI
(T-max=3.9, p<0.001). Finally, WN65-vs-BG55 revealed de-
creased uptake (p<0.001) in the AC (-2.8%) corresponding to
5% of this VOI (T-max=5.3, p<0.001).Conclusions:In contrast
to humans, activation in the AC of rats was lower compared to
peripheral structures (e.g. IC). A deactivation of the AC was
observed with louder continuous stimulus compared to back-
ground. Our data demonstrate the ability of FDG PET to detect
activations in all observed auditory areas and to differentiate
between auditory conditions. This technique may be used to
characterize animal models for hearing disorders.
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OP056
18F-FDG PET/CTas Predictive of Response
after Chemoradiation in Esophageal Cancer Patients
E. Elimova, X. Wang, E. C. Etchebehere, Y. Shimodaira, H.
Shiozaki, R. Wadhwa, V. Planjery, N. Charalampakis, M. A.
Blum, W. Hofstetter, J. Lee, B. R. Weston, M. S. Bhutani, H.
A. Macapinlac, J. A. Ajani; The University of Texas MD An-
derson Cancer Center, Houston, TX, UNITED STATES.
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Introduction: The purpose of this study was to evaluate if a
baseline, an interim or a post-chemoradiation (CTRT) 18F-
FDGPET/CT studies could provide information on pathologic
response to CTRT and overall survival (OS). Materials and
Methods: Thirty-one patients with histologically proven ade-
nocarcinoma or squamous cell carcinoma of the esophagus, fit
for trimodality therapywere prospectively enrolled.Most were
men (93.5%), and had a stage III cancer (74.2%). Chemother-
apy consisted of oxaliplatin/5-fluorouracil (45.2%) and
taxane/5-fluorouracil (54.8%). All patients underwent a base-
line, an interim (performed 12+/-2 days after onset of CTRT)
and a post-CTRT 18F-FDGPET/CTstudy. The 18F-FDGPET/
CT variables evaluated were at baseline, interim and post-
CTRT studies maximum standardized uptake value
(SUVmax) and total lesion glycolysis (TLG). Clinical and
18F-FDGPET/CT parameters were correlated with pathologic
complete response (pathCR) and OS. Results: Among the 31
patients studied, 61.3% achieved a clinical complete response
(cCR) and 87.1% had surgery. The median OS was 35.1
months (95% CI: 19.9 - NA). PathCR rate was 22.2%. There
was only a marginal association between cCR and pathCR
(p=0.06). None of the other variables was predictive of pCR.
There was association between OS and baseline TLG (p=0.03)
at the optimal cutoff TLG value of 75.15. Additionally, TLG
and αTLG post-CTRTwere also associated with OS (p = 0.01
and 0.03, respectively). Conclusion: None of the PET param-
eters are predictive of pCR but TLG at baseline and post-
CTRT are prognostic of OS.
OP057
Diagnostic performance of 18F-fluorothymidine PET/CT
for primary gastric cancer and its lymph node metastasis:
Comparison with 18F-fluorodeoxyglucose PET/CT
M. Nakajo1, Y. Kajiya2, A. Tani2, M. Jinguji1, Y.
Nakabeppu1, M. Nakajo2, S. Shimaoka3, T. Nihara3, S. Tana-
ka4, T. Yoshiura1; 1Department of Radiology, Kagoshima Uni-
versity, Graduate School of Medical and Dental Sciences, Ka-
goshima, JAPAN, 2Department of Radiology, Nanpuh Hospi-
tal, Kagoshima, JAPAN, 3Department of Gastroentenology,
Nanpuh Hospital, Kagoshima, JAPAN, 4Department of Pa-
thology, Nanpuh Hospital, Kagoshima, JAPAN.
Aim: To examine the diagnostic performance of 18F-
fluorothymidine (FLT) PET/CT for primary and metasta-
tic lymph node gastric cancer foci by comparing with
18F-fluorodeoxyglucose (FDG) PET/CT. Materials and
Methods: The enrolled study population comprised 17
patients with 17 newly diagnosed gastric cancers who
underwent surgical resection of primary cancers and re-
gional lymph nodes after both FLT and FDG PET/CT.
The SUVmax of primary gastric cancer was compared
between FLT PET/CT and FDG PET/CT studies using
Wilcoxon signed-rank test. Associations of SUVmax
levels with pathological factors were examined using
the Mann-Whitney U or the Spearman rank correlation
test. Diagnostic indices for detecting nodal metastasis
were compared between the two tracers using the
McNemar exact. Results: Fourteen of 17 primary cancers
were visualized by both FLT and FDG PET/CT studies,
and the residual 3 pathologically T1b cancers were not
visualized by either method. FLT SUVmax was signifi-
cantly lower than FDG SUVmax in all of the 14 visible
primary cancers (7.1 ± 4.0 vs. 10.2 ± 5.0, p=0.003). The
SUVmax was significantly correlated with tumor size for
both FLT and FDG (FLT: ρ=0.56, p=0.036, FDG:
ρ=0.59, p=0.025), but were not associated with the depth
of invasion, nodal metastasis and differentiation. The sen-
sitivity, specificity and accuracy for detecting nodal me-
tastasis were 31.0% (9/29), 100% (166/166) and 89.7%
(175/195) for FLT PET/CT, and 44.8% (13/29), 98.7%
(164/166) and 90.8% (177/195) for FDG PET/CT, re-
spectively. The sensitivity (p=0.13), specificity (p=0.48)
and accuracy (p=1.00) were not significantly different
between the two modalities. SUVmax was not signifi-
cantly different between FLT (4.6 ± 3.1) and FDG (4.2
± 1.0) (p=0.91) in the 9 concordant true positive nodes.
Conclusions: FLT PET/CT has a comparable potential
with FDG PET/CT in diagnosing primary and nodal foci
of gastric cancer despite significantly lower FLT uptake
in the primary foci.
OP058
Role of 18F-FDG PET/CT in predicting pathologic
response to neoadjuvant chemo-radiotherapy and survival
in patients of non-metastatic esophageal
and gastro-esophageal junction carcinoma
A. Pruthi1, S. Taywade2, P. S. Choudhury2; 1Sir Ganga Ram
Hospital and Research Centre, New Delhi, INDIA, 2Rajiv
Gandhi Cancer Institute & Research Centre, New Delhi,
INDIA.
Objective: To assess the role of 18F-FDG PET/CT in
predicting the pathologic response and survival of patients
with non-metastatic esophageal carcinoma treated with neoad-
juvant chemo-radiation (CRT) and esophagectomy. Methods:
32 patients (18 males, 14 females; mean age 56.7 years, me-
dian age 58 years) with locally advanced (stage II/ III) esoph-
ageal carcinoma who underwent neoadjuvant chemo-radiation
(CRT) followed by total esophagectomy at our institute during
2010-13 were analysed. Their pre-treatment staging and post
neoadjuvant chemo-radiation 18F-FDG PET/CT studies were
re-evaluated by an experienced nuclear medicine physician.
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Response to neoadjuvant chemo-radiation on PET/CT images
was compared to pathologic response. Follow-up information
was obtained after careful evaluation of patient’s electronic
medical records. Disease free survival was calculated from
the day of surgery till the first evidence of recurrence. Various
PET/CT findings like SUV max, presence of lymph nodal
abnormalities were correlated with pathologic response, inci-
dence of recurrence and disease free survival using appropriate
statistical tests. Results: Most tumours were squamous cell
carcinomas (29 out of 32; 90.6%) and involved mid-thoracic
esophagus (17 out of 32; 53.1%). Post-CRT 18F-FDG PET/
CT study identified pathologic response with 76.2% sensi-
tivity, 70% specificity and 74.2% accuracy. However, neg-
ative predictive value was only 41.7%. Patients were
followed up for median duration of 10.8 months (inter-
quartile range 6.3- 17.7 months). PET/CT parameters like
SUVmax and presence of lymph nodal abnormalities in
pre-treatment scan didn’t show significant correlation with
disease free survival. Pathologic response was found to
correlate with the post-CRT FDG PET/CT maximal stan-
dardized uptake value (SUVmax) (p<0.05) and a post-CRT
FDG PET SUVmax of >= 4 was found to be the only
factor which correlated with reduced disease free survival
(1 year survival rate of 25% vs. 68.1%; p value = 0.026).
Conclusion: Post chemo-radiation PET/CT was found to be
predictive of pathologic response and disease free survival.
In view of low negative predictive value, surgery should
still be considered even if the post-CRT FDG-PET/CT
scan is normal because microscopic residual disease cannot
be ruled out.
OP059
Recurrence Detection in Pancreatic Cancer: The Value
of Quantitative FDG-PET/CT
J. T. Friis1, O. S. Bjerring2, M. G. Hildebrandt1, S. Hess1, O.
Gerke1, P. F. Høilund-Carlsen1; 1Dept. of Nuclear Medicine,
Odense University Hospital, Odense C, DENMARK, 2Dept.
of Surgery, Odense University Hospital, Odense C,
DENMARK.
Aim: FDG-PET/CT is relatively unexplored in pancreatic can-
cer. The aim of this project was to investigate whether SUV-
based semi-quantitative measures obtained by FDG-PET/CT
could help differentiate cancer recurrence from non-specific
lesions in patients with suspected recurrence of pancreatic
cancer.Materials and Methods: As part of an ongoing prospec-
tive clinical trial, 25 patients with resectable pancreatic cancer
were recruited postoperatively. FDG-PET/CT was performed,
as part of protocolled follow-up, 3, 6, 9, 12, 18, and 24months
after surgery; if recurrence occurred, the patients dropped out
of the study. The reference standard was a composite decision
at a multidisciplinary team conference based on all available
data, including follow-up scans and biopsies, when available.
FDG-PET/CT scans were as-sessed visually by experienced
nuclear medicine physicians and dichotomized into ‘recur-
rence’ or ‘no recurrence’. In patients with recurrence, only
the last scan leading to the diagnosis was included in the anal-
ysis. In patients without recurrence, any scan with a positive
lesion was registered, and the one with the most FDG-avid
lesion was included in the analysis. The FDG-uptake in suspi-
cious lesions was characterized by the SUVmax value and the
partial volume corrected SUVmean (cSUVmean) value. If a
scan had no lesions suspicious of malignancy (true or false
negatives), a value of ‘0’ was imputed. Outcome measures
were sensitivity and specificity and receiver operating charac-
teristic (ROC) analysis of SUV measures with values of area
under the curve (AUC).Results: Of the 25 patients, 16 were
diagnosed with recurrence during the study period, while 9
remained disease free. Sensitivity and specificity were 0.88
(95% CI: 0.62-0.98) and 0.33 (0.07-0.70), respectively. Medi-
an SUVmax values in false positive and true positive lesions
were 4.1 (3.3-16.8) and 7.0 (4.7-20.5), respectively (p<0.04).
Median cSUVmean values in false positive and true positive
lesions were 3.8 (range 3.6-10.7) and 6.6 (3.5-20.4), respec-
tively (p<0.04). ROC analysis of cSUVmean values had an
AUC of 0.75 (0.53-0.97) and a sensitivity and specificity of
0.81 and 0.78 with an optimal cSUVmean cut-off set at
4.4.Conclusion: Visual assessment of FDG-PET/CT imaging
for recurrent pancreatic cancer had a high sensitivity, but a low
specificity and, therefore, seems not suited for the detection of
recurrent pancreatic cancer. Mean SUVmax and cSUVmean
were significantly higher in malignant than benign lesions,
albeit with wide ranges. Quantification seemed to increase
specificity and may, thus, be considered helpful for differenti-
ating malignant from benign lesions.
OP060
Contribution of 18F-FDG PET/CT in patients suspected
for colorectal cancer recurrence, with normal or increased
CEA.
H. Balink1, E. van der Zee1, J. P. E. N. Pierie1, R. J. Bennink2,
H. J. Verberne1; 1Medical Center Leeuwarden, Leeuwarden,
NETHERLANDS, 2Academic Medical Center, University of
Amsterdam, Amsterdam, NETHERLANDS.
Objective: Colorectal cancer (CRC) is an increasing health
problem, in particular in developed countries. Patients with a
history of primary CRC surgically treated with the intention of
curation benefit from an optimal postoperative follow-up. The
current Dutch guidelines recommend computed tomography
(CT) as the imaging modality of choice, whether or not indi-
cated by an elevated carcinoembryonic antigen (CEA) level.
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However, 18F-fluorodeoxyglucose (18F-FDG) positron emis-
sion tomography (PET)/CT, seems to have a better diagnostic
precision than CT in detecting CRC recurrence. The objective
of this retrospective study was to evaluate the diagnostic pre-
cision of 18F-FDG PET/CT in detecting CRC recurrence dur-
ing follow-up, after the primary CRC was surgically treated
with curative intention. Patients were included with either a
normal CEA level (and with equivocal radiology findings), or
elevated CEA levels. Methods: In total 124 were included. All
patients with suspected recurrence of CRC during follow-up
were subjected to 18F-FDG PET/CT imaging. A total of 124
18F-FDG PET/CT scans were assessed and the 18F-FDG PET/
CT outcome was subsequently verified based on the findings
during the follow-up period after 18F-FDG PET/CT. Results:
In the overall population, with a proven CRC recurrence prev-
alence of 68,6% (n = 85), 18F-FDG PET/CT had an overall
sensitivity, specificity, and accuracy of 94,1% , 82,1% and 90,
3% respectively. As expected patients with a normal CEA
level (n = 25) had a lower CRC recurrence prevalence com-
pared to those with an elevated CEA level (n = 94) (48% vs.
72%, p = 0.021). 18F-FDG PET/CT in CEA normal patients
had a sensitivity, specificity, and accuracy of 91.7%, 84.6%
and 88%, and for those patients with an elevated CEA level
t h e s e v a l u e s we r e 94 , 1% , 80 , 8% and 90 , 4% ,
respectively.Conclusions: 18F-FDG PET/CTshowed, irrespec-
tive of CEA levels, a high diagnostic accuracy in detecting or
excluding CRC recurrence during postoperative follow-up.
However these retrospective data should be regarded as pre-
liminary and the role of 18F-FDG PET/CT as the imaging
modality of choice in patients suspected for CRC recurrence
needs to be confirmed in prospective trials.
OP061
Evaluating QuantitativeMeasures in Incidental Colorectal
PET Findings
T. Nguyen, S. Hess, H. Petersen, P. F. Hoeilund-Carlsen; Dept.
of Nuclear Medicine, Odense University Hospital, Odense,
DENMARK.
Aim: In oncologic PET, SUVmax and SUV cutoff values to
distinguish malignant from benign lesions are often reported.
However, studies have repeatedly questioned their validity as
their reliability and comparability are influenced by many fac-
tors. We investigated such measures of common quantitative
analysis in incidental colorectal (ICR) findings using dedicat-
ed software.Materials and Methods: FDG-PET studies in 24
patients with ICR uptake and 28 lesions (8 colorectal cancers,
12 polyps, and 8 with only benign findings) were retrospec-
tively analyzed. To test analysis method variability, two lesion
delineation techniques were applied with dedicated software
(ROVER, ABX, Radeberg, Germany) using background
corrected lesion-based threshold (LT) and voxel-based thresh-
old (VT). A built-in partial-volume correction (PVC) was also
employed and lesion measures of SUVmax, SUVmean,
SUVmean, PVC, metabolically active volume (MAV), and mean
metabolic volumetric product (MVPmean = SUVmean MAV)
were extracted.Results: In all lesions, SUVmax > 5 and
SUVmean ≧ 3. Measured SUVmax values were reproducible
and malignant measures (16.5 ± 6.1) were higher than benign
(10.2 ± 3.7) levels (p = 0.04), but none of them deviated (p =
0.3-0.7) from those of polyps (15.1 ± 7.5). SUVmean values in
malignant (LT: 10.2 ± 3.4, VT: 8.8 ± 2.8) compared to benign
(LT: 6.5 ± 2.3, VT: 6.2 ±2.2) findings were also higher (p =
0.03-0.07) and both were indistinctive (p = 0.3-1) from those
of polyps (LT: 10 ± 5.2, VT: 9.5 ± 5). The differences between
VT and LT methods (p = 0.4-1) did not alter overall relations.
Some malignant MAV and MVPmean peaks were well above
those of polyps and benign findings, both of which were at
similar levels. PVC generally increased values by a factor of
1.3-2.7 (p < 0.01) at preserved relative levels. Inter-group re-
lations for all measures, however, were insignificant (p = 0.1-
0.3) due to value fluctuations.Conclusion: Quantitative anal-
ysis of ICR findings with common approaches showed that
lesion etiology (i.e., malignant, polyp, or benign) cannot be
differentiated by SUVmax or SUVmean alone, nor can any use-
ful cutoff value be set. MVPmean might indicate distinctions
better by incorporating lesion extent (MAV), but also lacks
generally distinctive levels. Variations with different segmen-
tations and PVC contribute to estimate variability, but affected
overall relations less. It remains to be assessed whether more
optimal data analysis methods and corrections can yield mea-
sures, e.g. MVPmean, PVC, that better reflect the disease severity
and extent than SUVmax values.
OP062
18F-FDG PET/CT versus CT evaluation of treatment
response in patients with metastatic colorectal cancer
receiving chemotherapy with a monoclonal antibody
(bevacizumab or cetuximab)
Z. Nemeth1, Z. Lengyel2, K. Boér1, E. Hitre3, K. Borbély3;
1Szent Margit Hospital, Budapest, HUNGARY, 2Pozitron-
Diagnosztika Kft, Budapest, HUNGARY, 3National Institute
of Oncology, Budapest, HUNGARY.
The study aim was to compare the effectiveness of evaluation
of tumour response by positron emission tomography with
18F-fluorodeoxyglucose (18F-FDG PET/CT) and computed
tomography (CT scan) in patients with metastatic colorectal
cancer receiving combination treatment with chemotherapy
and cetuximab or bevacizumab. A total of eleven patients
who were candidate first line systemic treatment for metastatic
colorectal cancer were enrolled in our study from April to
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November 2014. All patients (pts) were evaluated by both
18F-FDGPET/CTand CTscan before and after systemic treat-
ment. 18F-FDG PET/CT evaluation was performed after the
second treatment, while the CT scan after the third therapy in
every case. Systemic treatment consisted of chemotherapy
with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) in com-
bination with a monoclonal antibody bevacizumab or
cetuximab (FOLFIRI+cetuximab: 3 pts and FOLFIRI+
bevacizumab: 8 pts). The primary tumours were histologically
proven and all patients had at least one > 2 cm liver metastasis
on axial imaging (CT). The maximum standardized uptake
value (SUVmax) was measured at baseline and after chemo-
therapy. The relative FDG uptake changes in liver metastases
were calculated (dSUV) as well. Our results were evaluated by
European Organisation for Research and Treatment of Cancer
(EORTC) FDG response criteria. A total of eleven patients
were eligible for response evaluation. Regarding PET/CTwith
EORTC criteria 8 pts. (72.7%) had partial metabolic response
(PMR), 3 pts. (27.3%) had progressive (27.3%) disease
(PMD). Patient were classified in two by two tables according
to RECIST responders (CR, PR, SD), non responders (PD)
based onCTscans, ad classified based on SUVmax responders
(> 25% decrease from baseline) and non-responders (< 25%
decrease from baseline). Results showed an almost 100%
match between the two classification methods (RECIST,
EORCT criteria). SUVmax predicted all eight RECIST-
responders correctly the only mismatch occured to the fact that
progressive disease was not recognised by CT scan, but was
reported by PET/CT scan. As regards CT scans there were no
significant changes in those 8 pts. who had PMR at PET/CT
assessment and in these cases CT showed stable disease. In
one case a new lesion was detected only by PET/CT. Based on
our preliminary results morphological and metabolic imaging
indicates in some cases a differential therapeutic decisions in
metastatic colorectal cancer. Moreover the change of SUVmax
appears to be a usefull tool for evaluating tumour response.
The patient recruitement is open, more data is being collected.
OP063
Comparison of 18F-FDG PET-CT to conventional CT
imaging in providing optimal pre-treatment staging
in patients with incidentally diagnosed gall bladder cancer.
N. Jain, J. Bal, C. Nagpal, B. Rajashekharrao, A. Velumani;
Nueclear Healthcare Limited, Delhi, INDIA.
Introduction: After a cholecystectomy, incidental gallbladder
cancer (IGC) requires accurate imaging studies to determine
the actual extent of the disease to properly tailor subsequent
treatment. Aim: To compare 18F-fluorodeoxyglucose positron
emission tomography-computed tomography (18FDG PET-
CT) to conventional imaging (CT Abdomen and Chest) to
provide optimal pre-treatment staging in patients with IGC.
Patients and Methods: Between January 2014 and April
2015, all patients with IGC and at least T1b stage on histopa-
thology underwent 18F-FDG whole body PET-CT. The PET/
CT findings were grouped as locoregional disease (operable)
and disseminated disease (inoperable). Results of PET/CT
were compared with conventional CT imaging. Results: The
series included 41 patients, 32 women and 9 men, with a
median age of 50 years (range 35-72 years). The Whole body
PET CT imaging was performed at a median time of 6 weeks
after cholecystectomy (range 4-24 weeks). 18FDG PET-CT
findings were negative in 10 patients and positive in 31 pa-
tients. Of these 31 patients 7 were with localized potentially
resectable disease (PRD) and 24 with disseminated disease
(inoperable). Conventional CT imaging observations were
negative in 21 patients and positive in 20 patients. Amongst
these 20 patients, 3 with localized potentially resectable dis-
ease (PRD) and 17 were with disseminated disease. In com-
parison to CT, PET CT changed management in additional
31.7% cases and thus was superior to conventional imaging
(p=0.02, p<0.05). PET CT also identified more number of
lesions in cases with disseminated disease. Conclusions: For
patients presenting with stage T1b or greater IGC, the use of
18FDG PET-CT imaging will help reduce the number of pa-
tients undergoing non-therapeutic re-exploration and avoid
radical surgeries thus tailoring subsequent disease
management.
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OP064
Variation in haplotypes of the norepinephrine transporter
is not associated with sympathetic activity as measured
by cardiac 123I-mIBG scintigraphy
D. O. Verschure1,2, F. Baas1, B. L. F. van Eck - Smit1, G. A.
Somsen3, H. J. Verberne1; 1Academic Medical Center, Am-
sterdam, NETHERLANDS, 2Medisch Centrum Alkmaar,
Alkmaar, NETHERLANDS, 3Cardiology Centers of the Neth-
erlands, Amsterdam, Amsterdam, NETHERLANDS.
Aim123I-meta-iodobenzylguanidine (123I-mIBG) scintigraphy
has been extensively validated and clinically used to evaluate
cardiac sympathetic function in cardiac diseases. The semi-
quantitative outcome (i.e. heart mediastinal ratio (H/M)) is an
independent prognostic parameter in patients with chronic heart
failure (CHF). 123I-mIBG is a radiolabelled norepinephrine (NE)
analog that has the same presynaptic uptake, storage and release
mechanism as NE. The norepinephrine transporter (NET),
encoded by the solute carrier family 6 (SLC6A2), is responsible
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for reuptake of NE into presynaptic nerve terminals and is a
regulator of norepinephrine homeostasis. It has been demonstrate
that polymorphism of SLC6A2 correlates with blood pressure,
but it is unknown if polymorphism of SLC6A2 influence the
H/M. Therefore we investigated if SLC6A2 polymorphism influ-
ences 123I-mIBG results. Materials and Methods: Forty-nine
adults with CHF (age 66.5±8.1 years, LVEF 22,3±6.4 and func-
tional class NYHA 2,3±0.4) referred for 123I-mIBG scintigraphy
were enrolled. 15 minutes (early H/M) and 4 hours (late H/M)
after administration of 185 MBq 123I-mIBG anterior planar tho-
racic images were acquired with medium energy collimators.
H/M was calculated based on the mean count densities from
the manually drawn regions of interest (ROI) over the left ventri-
cle and a predefined fixed ROI placed in the upper mediastinum.
DNA of the subjects was extracted from whole-blood samples.
Twelve exons of the SLC6A2 gene were analysed.Results The
mean early H/M was 2.10±0.39, late H/M 1.81±0.39 and WO
13.7±11.2. Genotyping of the SLC6A2 gene resulted in 6 differ-
ent genotypes. Between the 2 largest haplotype groups C-T-C-A-
T (n=22) vs. C-T-C-A/G-C-G/T (n=18) there was only a signif-
icant difference in early H/M (respectively 2.07±0.30 and 2.11
±0.50, p = 0.027). However, multivariate regression analyse
using haplotype, LVEF and NYHA class possible explanatory
factors, showed only LVEF as an independent predictor of early
H/M (adjusted R2 = 0.063, p = 0.05). Increased H/M was asso-
ciated with increased LVEF. For late H/M similar results were
obtained where only the LVEF was an independent predictor
(adjusted R2 = 0.116, p = 0.01). For WO the LVEF and NHYA
were independent predictors (adjusted R2 = 0.105, p = 0.03).
Conclusion: This is the first study that investigated the association
between NET polymorphism and cardiac 123I-mIBG
scintigraphically derived parameters. Despite a small difference
in early H/M between the two most common haplotypes, varia-
tion in NET haplotype could not explain a significant part of the
variation in the 123I-mIBG scintigraphically derived parameters.
OP065
Effect of standardization of I-123 MIBG
heart-to-mediastinum ratio on the prognostic threshold:
application to multicenter database of chronic heart
failure
K. Nakajima1, K. Okuda2, S. Matsuo1, T. Nakata3, S.
Kinuya1; 1Kanazawa University Hospital, Kanazawa, JAPAN,
2Kanazawa Medical University, Uchinada, JAPAN, 3Hakoda-
te Gryoukaku Hospital, Hakodate, JAPAN.
Purpose. As I-123 metaiodobenzulguanidine (MIBG) has been
used for the assessment of prognosis in patientswith chronic heart
failure (CHF), we have proposed to unify the MIBG heart-to-
mediastinum ratio (HMR) to overcome differences in camera-
collimator systems. The aim of this study was to evaluate the
effect of the standardization on prognostic variables and thresh-
olds for mortality risks. Methods. A total of 225 phantom exper-
iments were performed in 84 hospitals to determine conversion
coefficients (K) to themathematically calculated reference values.
For example, the K value of low-energy high-resolution (LEHR)
collimator was 0.55, LE general purpose (GP) 0.65, andmedium-
energy (ME) GP 0.88. Using the collimator-specific K values, all
HMRs could be standardized to those of the commonest ME
types (ME88). Japanese pooled databases (n=933) from 6 cohort
studies, in which at least 5-year prognosis was known, was used
for validation. Mean age was 61±13 years, time of follow-up 7.7
±4.3 years (range 0.08-14.6 years), and ejection fraction 36±13%.
Late HMR in the anterior image was used for the analysis in this
study. Cardiac death due to pump-failure, acute myocardial in-
farction and sudden cardiac death was used as a single endpoint.
Since 4 hospitals used LEGP and 2 used LEHR collimators, they
were unified to HMRs comparable to the ME88 condition. Mul-
tivariate analysis and receiver operating curve analysis were ap-
plied to compare the original and standardized HMRs. The opti-
mal thresholds for predicting cardiac death were also determined.
Results. The original mean HMR of 1.71±0.33 (95% range 1.18-
2.41) increased to 2.00±0.44 (95% range 1.25-3.01) as the stan-
dardized HMR. The best cutoff values for predicting cardiac
death was HMR=1.66 (ROC AUC=0.694) and 1.89 (ROC
AUC=0.698) for the original and standardized HMRs, respec-
tively. Multivariate proportional hazard analysis for all the
follow-up period selected the same 5 variables of age, male sex,
left ventricular ejection fraction, NYHA functional class and
MIBG late HMR. Chi-square values of the logistic analysis for
the 5-year survival and death using the same variables were 164.9
(ROCAUC0.780) and 167.2 (ROCAUC0.781) for original and
standardized HMR groups, respectively (p<0.0001 for both).
Conclusion. Using the calibration phantom method to unify
HMRs, all HMRs were successfully converted to the ME88 con-
dition. An optimal threshold for stratifying prognosis became
increased (HMR=1.9) with keeping the statistical power to pre-
cisely predict cardiac death. The standardization method could
further effectively functionwhen both LE andME collimators are
used in a multicenter study.
OP066
Proposal for a standardized method to evaluate
123I-MIBG SPECT inHF patients: importance in decision
making of ICD implantation.
V. Frantellizzi, A. Farcomeni, P. Scarpato, G. A. Follacchio,
S. Sollaku, N. Salvi, P. Scarparo, M. Liberatore, F.
Monteleone, F. Fedele, G. De Vincentis; Sapienza University
of Rome, Rome, ITALY.
Patients (pts) with Heart Failure (HF) have high risk of fatal
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malignant ventricular arrhythmias. Implantable cardioverter-
defibrillator (ICD) is the therapy of choice but ICD implant
should be reserved to high risk pts, considering also inappro-
priate shocks and costs. Aim of the study was to assess if
123I-MIBG scan is useful in decision making for ICD im-
plantation. 170 pts were prospectively evaluated in term of
occurrence of arrhythmic events (AE) with mean 19,7 month
follow up. The average value of left ventricular ejection frac-
tion (LVEF) was 31,1% +/- 9,4% and among these 69 had
idiopathic disease and 101 had post-ischemic disease. At 20
and 240 minutes after MIBG administration, planar and
SPECT cardiac images were obtained. Planar images were
analyzed as Early and Late Heart-to-Mediastinum (HM) ratio
and Washout Rate (WR). SPECT studies were processed with
Myovation software (GE Healthcare) and row data for each
of 17 segments of a standard polar map were obtained.
Using a 5-point visual scoring model , data were semi-
quantified and Late Summed Scores (LSS) was obtained.
We evaluated area under the ROC curve (AUC) for each
diagnostic test and thresholds by means of sensitivity and
specificity. Optimal thresholds were chosen by Youden’s in-
dex. Optimal weights for separate segments were estimated
by means of logistic regression, with zero weights fixed by
minimization of the Akaike information criterion through for-
ward selection. The HM ratio value of 1.6 showed a 0.64
sensitivity (SE) and 0.415 specificity (SP), whereas a 1,4 cut-
off value showed 0.588 SE and 0.809 SP. When examining
the WR we obtained for a cut-off value of 20% , 91% SE
and 28% SP. More accurate results were obtained with a
reference cut-off of 30% , with 73% SE and 53% SP. Taking
into account LSS, using a cut off value of 26 we obtained
0.795 SE and 0.274 SP, whereas a cut off value of 43 had a
SE of 0.625 and a SP of 0.804. Has, in our opinion, to be
underlined how studies conducted with SPECT technique
generally have provided very interesting results in the clinical
setting, but did not provide technical details on how to
achieve and interpret the parameters obtained. In our patients
series, the best result in terms of accuracy in predicting AE
was achieved by LSS scoring, in spite of a number of crit-
icisms and doubts about the real usefulness and reproducibil-
ity of SPECT data by several authors.
OP067
Role of Myocardial Perfusion, Sympathetic Denervation,
and Scar Size in Predicting Inducibility of Ventricular
Arrhythmia in Ischemic Cardiomyopathy
M. T. Rijnierse, C. P. Allaart, S. De Haan, H. J. Harms, M. C.
Huisman, A.M. Beek, A. A. Lammertsma, A. C. Van Rossum,
P. Knaapen; VU University Medical Center, Amsterdam,
NETHERLANDS.
Introduction: Myocardial perfusion, scar size, sympathetic de-
nervation and innervation-perfusion mismatch, obtained from
positron emission tomography (PET) and late gadolinium en-
hanced cardiovascular magnetic resonance imaging (LGE-
CMR), may all contribute to enhanced risk prediction of ven-
tricular arrhythmias (VA). There may, however, be overlap
between some of these risk markers, as they are based on
similar pathophysiology. The aim of this study was to assess
the role of PET and LGE-CMR derived risk markers in
pred ic t ing VA induc ib i l i ty in the same pa t i en t
population.Methods: 52 patients (66 ± 9 years, 90% male,
LVEF 29 ± 6%) with ischemic cardiomyopathy and left ventric-
ular ejection fraction (LVEF) ≤35%whowere referred for prima-
ry prevention implantable cardioverter-defibrillator (ICD) im-
plantation were included. LGE-CMR was performed to assess
LV volumes, function, and scar size. [15O]H2O PET and
[11C]hydroxyephedrine PETwere performed to assess both rest-
ing and hyperemic myocardial blood flow (MBF), and sympa-
thetic innervation. Innervation and perfusion defect size, and
innervation-perfusion mismatch size were calculated. After ICD
implantation, an electrophysiological study (EPS) was performed
and was considered positive in case of sustained VA.Results:
Patients with positive EPS (n=25) showed more severely im-
paired hyperemic MBF (1.36 ± 0.39 vs. 1.71 ± 0.39 mLmin-
1 g-1, P=0.003), larger sympathetic denervation size (28 ± 12 vs.
21 ± 13%, P=0.048), and tended to have larger scar size (24 ± 13
vs. 18 ± 9 g, P=0.07) and perfusion defect size (22 ± 13 vs. 15 ±
11%, P=0.06) compared with EPS negative patients (n=27). No
differences were observed in LV volumes, LVEF, and
innervation-perfusion mismatch size. Multivariable analysis re-
vealed that impaired hyperemic MBF was the single best inde-
pendent predictor for VA inducibility (OR 0.78, 95% CI 0.65-
0.94, P=0.007). A combination of risk markers did not yield
incremental predictive value over hyperemic MBF
alone.Conclusion: Of all previously validated approaches
to evaluate the arrhythmic substrate, impaired hyperemic
MBF was the only independent predictor of VA induc-
ibility. Moreover, a combined approach of different im-
aging variables did not have incremental value. These
results suggest that quantitative PET perfusion imaging
may be promising in risk prediction of VA.
OP068
Prognostic value of myocardial I-123
metaiodobenzylguanidine imaging in patients with atrial
fibrillation
Y. Saushkina1, Y. Lishmanov1,2, I. Kisteneva1, S. Popov1; 1RI
Cardiology, Tomsk, RUSSIAN FEDERATION, 2National Re-
search Tomsk Polytechnic University, Tomsk, RUSSIAN
FEDERATION.
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Purpose. The problem of diagnostic and treatment of car-
diac arrhythmias is one of the most actual in modern
medicine. To date, the mechanisms underlying the ma-
jority of cardiac arrhythmias are unclear. The distur-
bance of sympathetic innervation of the heart may be
the cause of atrial fibrillation and reason of myocardial
dysfunction of the left ventricle. In the 1950s the rela-
tionship between the occurrence of AF and the auto-
nomic nervous system has been described. Cardiac auto-
nomic nervous system have been shown to play an im-
portant role in the initiation, persistence and termination
of AF. In addition, there is actual a question evaluate
the effectiveness of the treatment of this arrhythmia.
Thus, the purpose of this study was to detect the corre-
lations between the cardiac autonomic innervation and
the clinical course of AF after radiofrequency catheter
ablation (RFCA). Methods. In this study were enrolled
15 patients with essential hypertension (EH) (the dura-
tion of EH was 5-20 years) and persistent AF. All pa-
tients underwent single-photon emission computer to-
mography (SPECT) with I-123 metaiodobenzylguanidine
(123I-MIBG) to evaluate cardiac sympathetic nervous
system activity before and 12 months after RFCA.
SPECT with 123I-MIBG was performed at 20 min (ear-
ly phase) and 4 h (delayed phase) after intravenous in-
jection. The early and delayed heart-to-mediastinum ratio
(HMR) and the washout rate (WR) were performed. Lo-
cal denervation was evaluated on polar map images
using the 17-segment model of left ventricle (LV). Re-
sults. A year later after RFCA in 7 patients arrhythmia
paroxysms were not observed without antiarrhythmic
therapy (AAT). Atrial fibrillation with frequency up to
1 times per month was observed in four patients with
AAT. One patient had a repeat RFCA. In all patients the
early HMR and delayed HMR was significantly higher
vs baseline (1,58±0,15 vs 1,91±0,20; p<0,05 and 1,69
±0,22 vs 1,96±0,42; p<0,05). There was no correlation
between 123I-MIBG parameters and the duration of EH,
the duration of AF and the frequency of AF episodes.
However, the delayed HMR before RFCA was strongly
correlated with the presence of arrhythmia recurrence a
year later after RFCA (r=-0,878, p=0.001). Also we con-
ducted ROC-analysis and identified the main scinti-
graphic predictors of the effectiveness of interventional
treatment of atrial fibrillation. The most significant indi-
cator in predicting the efficacy of RFCA was delayed
HMR=1,7 (AUC=0,99; p=0,0001; sensitivity - 100%;
specificity - 71%). Conclusions. Thus, delayed heart-to-
mediastinum ratio may be an independent scintigraphic
predictor of the effectiveness of interventional treatment
of atrial fibrillation.
OP069
Cardiac sympathetic activity in 22q11 deletion syndrome
D. O. Verschure1,2, E. Boot1,3, T. A. van Amelsvoort4, J.
Booij1, B. L. F. van Eck - Smit1, G. A. Somsen5, H. J.
Verberne1; 1Academic Medical Center, Amsterdam, NETH-
ERLANDS, 2Medisch Centrum Alkmaar, Alkmaar, NETH-
ERLANDS, 3The Dalglish Family Hearts and Minds Clinic
for Adults with 22q11.2 Deletion Syndrome, Toronto, ON,
CANADA, 4University of Maastricht, Maastricht, NETHER-
LANDS, 5CardiologyCenters of the Netherlands, Amsterdam,
NETHERLANDS.
Aim: 22q11 Deletion syndrome (22q11DS) is a relatively
common genetic condition caused by a microdeletion on the
long arm of chromosome 22. The deleted region spans more
than 40 genes, one of which is the gene that encodes for the
enzyme catechol-O-methyl-transferase (COMT). COMT en-
zyme is involved in the degradation of catecholamines, includ-
ing norepinephrine (NE). Indeed, reduced COMT enzyme ac-
tivity and impaired catecholamine turnover have been reported
in 22q11DS.Clinically, adults with 22q11DS are at increased
risk for sudden unexpected death. Although the causes are
likely multifactorial, increased cardiac sympathetic activity
with subsequent fatal arrhythmia, due to increased levels of
NE, should be considered as a possible mechanism predispos-
ing to premature death in 22q11DS. The purpose of this study
was, therefore, to determine whether cardiac sympathetic ac-
tivity is increased in adults with 22q11DS compared to healthy
controls. Materials and Methods: All study participants
underwent 123I-mIBG scintigraphy. Planar 123I-mIBG im-
ages were analysed by one experienced observer blinded to
patient data. Heart-to-mediastinum ratios (H/M) were calculat-
ed from the 123I-mIBG images using a region-of-interest over
the heart and the upper part of the mediastinum fifteen minutes
(early images) and 4 hours (late images) after administration of
123I-mIBG intravenously. Washout (WO), as an indicator or
adrenergic drive, was calculated as a ratio of early and late
H/M.ResultsFive adults with 22q11DS (mean age 28.6
±4.8 years) without any congenital heart disease and
five age- and sex-matched healthy controls (mean age
28.0±7.9 years) were enrolled. There were 3 males and
2 females in both groups. There were no significant
differences in early and late H/M between the
22q11DS and the control group. However, there was a
significant difference in WO between the 22q11DS and
the control group (-4.92±2.8 and -10.44±7.2, respective-
ly; p=0.027). Conclusion: This preliminary study for the
first time suggests increased adrenergic drive in adults
with 22q11DS using 123I-mIBG scintigraphy. This
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increased adrenergic drive might explain one possible
mechanism predisposing to premature death in 22q11DS.
OP070
Assessment of right ventricular sympathetic dysfunction
in patients with Arrhythmogenic Right Ventricular
Cardiomyopathy using 123I-Metaiodbenzylguanidin
A. Todica1, J. Siebermair2, J. Schiller1, M. Zacherl1, W.
Fendler1, P. Bartenstein1, R. Wakili2, M. Hacker3, S. Lehner1;
1Department of Nuclear Medicine - University of Munich,
Munich, GERMANY, 2Medical Department I - University of
Munich,Munich, GERMANY, 3Division of NuclearMedicine
- Medical University Vienna, Vienna, AUSTRIA.
Aim: Arrhythmogenic right ventricular cardiomyopathy
(ARVC) is a mainly inherited heart-muscle disease, which is
characterized by a progressive replacement of contractile heart
muscle by fibrotic and fat tissue primarily in the right ventricle,
ultimately resulting in heart failure. The regional reduction of
left ventricular myocardial 123I-MIBG-uptake is associated
with higher risk of future recurrent life-threatening events in
patients with ARVC. Therefore, we prospectively evaluated
the sympathetic function using 123I-MIBG SPECT/CT in pa-
tients diagnosed with ARVC and in patients with idiopathic
ventricular fibrillation (IVF). The objective of this study was
to institute a novel approach by using the additional morpho-
logical information from the low-dose CT. Methods: Sympa-
thetic innervation of the heart was assessed using 123I-MIBG
SPECT/low-dose CT in 13 patients diagnosed with ARVC
according to the modified task force criterions, and 10 patients
diagnosed with IVF. Late planar H/M ratio was calculated for
both groups. The 123I-MIBG uptake in the left (LV/M) and
right ventricle (RV/M) was evaluated separately based on the
morphological information available from the CT scan and set
in relation to the uptake in the mediastinum. Results: Themean
planar H/M ratio in the ARVC group was slightly lower as
compared to the IVF group but did not reach statistical signif-
icance (1.5±03 vs. 1.7±0.2, p=0.068). The optimal cut-off val-
ue to discriminate between ARVC and IVF was 1.66 with a
sensitivity of 75%, a specificity of 60% and an AUC of 0.73.
There was a significant difference between the ARVC and the
IVF group for the LV/M ratio (3.2±0.5 vs. 3.9±0.8, p=0.014).
The ideal cut-off value was 3.41 (sensitivity 77%, specificity
80%, AUC 0.78). The RV/M ratio was able to distinguish best
between ARVC and IVF resulting in a higher significance (1.6
±0.3 vs. 2.0±0.2, p=0.001). Hereby the best cut-off value was
1.88 (sensitivity 88%, specificity 90%, AUC 0.93). Conclu-
sion: The separate assessment of the left and right ventricle
could be reliably performed with the help of the low-dose
CT. The RV/M ratio was significantly lower in patients with
diagnosed ARVC and the RV/M ratio could distinguish with
the highest sensitivity and specificity between ARVC patients
and our reference collective.
OP071
Sleep-disordered breathing is associated with impaired
cardiac sympathetic innervation and predict prognosis
in patients with heart failure
T. Pellegrino1, S. Paolillo2, V. Piscopo2, A. Boemio2, R.
Carotenuto2, B. Russo2, S. Pellegrino2, G. De Matteis2, P.
Perrone Filardi2, A. Cuocolo2; 1Institute of Biostructures and
Bioimages, Naples, ITALY, 2University of Naples - Federico
II, Naples, ITALY.
Background: Unfavorable effects of sleep-disordered breath-
ing (SDB) in heart failure (HF) are mainly mediated by im-
paired sympathetic activity. However, few data are available
on SDB and cardiac adrenergic impairment evaluated at myo-
cardial level. The aim of the present study was to assess
the relationship between SDB, cardiac sympathetic in-
nervation and prognosis in HF patients. Methods:
Ninety-four patients (66.1±9.8 years) with systolic HF
(median left ventricular ejection fraction 32±7%)
underwent nocturnal cardiorespiratory monitoring to as-
sess presence and type of SDB by Apnea/Hypopnea In-
dex (AHI), and 123I-MIBG myocardial scintigraphy to
calculate heart-to-mediastinum (H/M) ratios and 123I-
MIBG washout rate. Patients were prospectively follow-
ed for 29±18 months for the combined endpoint of car-
diovascular death and HF hospitalization. Results: Of 94
patients, 72 (77%) showed SDB and, compared to non-
SDB, had significantly reduced early (1.67±0.22 vs. 1.77
±0.13; p<0.02) and late (1.50±0.22 vs. 1.61±0.23;
p<0.04) H/M ratios. At multiple linear regression analy-
sis, early and late H/M ratios remained independent pre-
dictors of AHI (β=-0.749; p<0.001; β=-0.830; p=0.001,
respectively). Similarly, AHI was the only predictor of
early (β=-0.643; p<0.001) and late (β=-0.453; p<0.002)
H/M ratios. Patients with AHI above the median showed
significantly higher event rates and worse survival com-
pared to patients with AHI below the median (35% vs.
9%, respectively; p<0.01). Similarly, patients with mod-
erate to severe disorder showed significantly increased
incidence of the combined endpoint and worse survival
compared to patients with mild or no disorder (35% vs.
11.7%; p<0.01). Adding SDB variables to the already
known prognostic role of 123I-MIBG imaging, we ob-
served an incremental prognostic discrimination with the
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worst survival in patients with both SDB and H/M im-
pairment. Conclusions: Patients with systolic HF and
SDB show more impaired cardiac adrenergic innervation
and more adverse prognosis compared to HF patients
without SDB.
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OP083
Upgrading and downgrading of prostate biopsy results
in a phase 2 study of MIP-1404 SPECT/CT in men
undergoing radical prostatectomy
K. Goffin1, S. Joniau1, P. Tenke2, G. Dabasi3, K. Slawin4, W.
Ellis5, B. Alekseev6, I. Buzogány7, S. Mishugin8, E. Klein9, J.
Stolz10, V. Student11, P. Koranda12, V. Matveev13, T. Armor14;
1University Hospitals Leuven, Leuven, BELGIUM, 2Jahn
Ferenc South Pest Hospital, Budapest, HUNGARY,
3Semmelweis University, Budapest, HUNGARY, 4Vanguard
Urologic Institute, Houston, TX, UNITED STATES, 5Univer-
sity of Washington, Seattle, WA, UNITED STATES, 6Moscow
Research Oncological Institute, Moscow, RUSSIAN FEDER-
ATION, 7Peterfy Sandor Street Hospital, Budapest, HUNGA-
RY, 8City Clinical Hospital # 57, Moscow, RUSSIAN FEDER-
ATION, 9Cleveland Clinic, Cleveland, OH, UNITED STATES,
10University Hospital Motol, Prague, CZECH REPUBLIC,
1111University Hospital Olomouc, Olomouc, CZECHREPUB-
LIC, 12University Hospital Olomouc, Olomouc, Olomouc,
CZECH REPUBLIC, 13Russian Oncology Research Center,
Moscow, RUSSIAN FEDERATION, 14Progenics Pharmaceu-
ticals, Inc., Tarrytown, NY, UNITED STATES.
Aim: MIP-1404 is a technetium-99m labeled small molecule to
image PSMA expression in prostate cancer. The objective of
this analysis was to explore the relationship between MIP-1404
uptake in the prostate gland and the incidence of upgrading and
downgrading of prostate needle biopsies following radical pros-
tatectomy (RP) in the phase 2 clinical trial MIP-1404-201
(NCT01667536). Materials / Methods: Prostate needle biopsy
Gleason scores recorded in case report forms of 104 patients
prior to surgery were compared to the final histopathologic
Gleason score of the RP specimen, assessed by the site pathol-
ogist, to determine the rate of upgrading and downgrading in
evaluable patients with pre-surgical biopsy and post-surgery
pathology results. 99mTc-MIP-1404 SPECT/CT of the pelvis
was acquired prior to surgery. Quantitative results of MIP-
1404 uptake were obtained by calculating the maximal tumor
to background ratio (TBR) for the prostate gland of each patient.
A one-sided Student’s t-test was performed to test for significant
increase in TBR between patients with upgraded or downgraded
final histopathologic Gleason score ≤7 and >7. Results: 31%
(25/81) of evaluable patients had their biopsy Gleason score
upgraded to >7 or downgraded to ≤7 by histopathologic assess-
ment of the prostatectomy specimen. 79% (11/14) of patients
upgraded to a Gleason score > 7 including one downgraded
(Gleason 9 to 8) demonstrated high MIP-1404 lesion uptake
(TBR >30:1) with a mean TBR of 47:1 [95% CI (30-63:1)].
91% (10/11) of patients downgraded to Gleason score ≤7 had
significantly (P<0.001) lower lesion uptake (TBR <30:1) with a
mean TBR of 16:1 [95% CI (10-22:1)]. Conclusion: MIP-1404
uptake in the prostate gland is significantly higher in prostate
cancer patients upgraded at RP from those who are downgraded
at RP.MIP-1404may be useful to indicate if a needle biopsy has
under- or overestimated the severity of disease.
OP084
Differences in biodistribution
of Lu-177-DKFZ-PSMA-617 and Ga-68-DKFZ-PSMA-11
in the same patient group
O. E. SAHIN1, J. NEMATYAZAR1, B. RAZAVI1, N.
YEYIN1, A. AYGUN1, M. OCAK2, E. DEMIRCI3, L.
KABASAKAL1; 1Istanbul University,Cerrahpasa Medical
Faculty,Department of Nuclear Medicine, İstanbul, TURKEY,
2Istanbul University,Pharmacy Faculty,Department of Phar-
maceutical Technology, İstanbul, TURKEY, 3Sisli Etfal Train-
ing and Research Hospital,Department of Nuclear Medicine,
İstanbul, TURKEY.
Aim: PSMA is an excellent target for prostate cancer imaging
and therapy using Ga-68 and Lu-177 labeled ligands. Human
biodistribution studies of Ga-68-PSMA ligand have demon-
strated that highest uptake of radiotracer is observed on kid-
neys and salivary glands and moderate uptake in lacrimal
glands, liver and spleen. However, Lu-177-PSMA-ligand is a
different compound and there is no information about its
biodistribution. Therefore the aim of the study was to evaluate
the biodistribution of these two compounds. Material and
Method: For this purpose, 17 patients (mean age 68.8±6.7
years) who had PSMA PET/CT imaging and who underwent
Lu-177-PSMA therapy were included. PSMA PET imaging
was not longer then 1 month at the time of therapy. SUVmax
values of parotid glands, kidneys, liver, spleen and primary
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tumour (n=6), metastatic lymph nodes (n=8) and bone metas-
tases (n=9) were obtained from PET images. From the SPECT/
CT images obtained 24 h after Lu-177-PSMA administration
ROIs were drawn over the same areas and background
corrected maximum counts are calculated. Results: Highest
uptake is observed in kidneys (45.0±18.9) followed by lymph
nodes (23.2±24.8), bone metastases (15.9±6.0), primary tumor
(12.8±15.9), parotid gland (12.2±3.1) and lowest in lacrimal
glands (7.5±4.3) in PSMA PET images. The biodistribution of
Lu-177-PSMA was completely different giving the highest
uptake in parotid glands (678.7±352.2) followed by bone me-
tastases (651.7±498.8) lymph nodes (561.3±322.8), lacrimal
glands (342.4±231.0) kidneys (249.0±146.8) and primary tu-
mor (102.5±78.2). Conclusion: It seems that biodistribution of
Lu-177-PSMA is different then Ga-68-PSMA and highest ra-
diation absorbed doses are given to parotid gland and to the
metastatic tissues during the therapy of Lu-177-PSMA. Kid-
neys are getting significantly lower radiation doses as com-
pared to that of Ga-68-PSMA due to lower uptake.
OP085
(68)Ga-labelled PSMA in prostate cancer: its diagnostic
value in patients with biochemical recurrence of prostate
cancer
S. Vöö, A. van Kroonenburgh, F. M. Mottaghy; Maastricht
University Medical Center, Maastricht, NETHERLANDS.
Background: There is an ongoing need for an accurate imaging
modality which can be used for staging, metastatic evaluation,
predicting biologic aggressiveness, and investigating recurrent
disease in prostate cancer. Prostate specific membrane antigen
(PSMA) displays an increased expression in prostate tumor
cells and is regarded as an ideal target for prostate cancer. Its
biodistribution is favourable in comparison to choline or ace-
tate. Recently, a new anti-PSMA-HBED ligand [(68)Ga-
PSMA] has been introduced for PET imaging of prostate can-
cer. Goal. The aim of this evaluation was to analyse the diag-
nostic value of (68)Ga-PSMA PET/CT in patients with
suspected recurrent prostate cancer and a possible association
between different clinical variables and the imaging results.
Methodology. We performed a retrospective analysis on 30
consecutive patients (median age 68 years) with suspected
biochemical recurrence of prostate cancer who underwent
(68)Ga-PSMA PET/CT between January 2013-December
2014. Other clinical factors such as prostate-specific antigen
(PSA) level, PSA doubling time (PSA-DT), Gleason score
(GSC), age, and amount of injected tracer were evaluated in
correlation with the imaging results. Furthermore, multifocal
prostate biopsies or clinical follow-up were performed in all
patients following the (68)Ga-PSMA PET/CT. Results. In
83.3% of the patients at least one lesion indicative of prostate
cancer recurrence was detected. A total of 45 focal prostatic
lesions were considered positive on (68)Ga-PSMA PET with
an average maximum standardized uptake value (SUVmax) of
12 ± 8 (1.1-25), compared to a low background SUV (median
SUV 0.7). All PET-positive lesions were confirmed as true-
positive on histology and/or clinical follow-up. However, of
all prostate biopsy samples taken for verification, 3 samples
proved to be positive on histology but false-negative on PET
(Gleason 4). Tumor detection was positively associated with
the PSA levels (>2.5 ng/ml). Other clinical parameters, such as
GSC, PSA-DT, age, and dose of injected tracer, showed no
association with the PSMAPET findings. A lesion-based anal-
ysis revealed a sensitivity, specificity, negative predictive val-
ue (NPV), and positive predictive value (PPV) of 93%, 100%,
92%, and 100%, respectively. A patient-based analysis re-
vealed a sensitivity of 96%. Conclusion. (68)Ga-PSMA
PET/CTshows a high sensitivity and, importantly, a high spec-
ificity in detecting prostate cancer, even in patients with low
PSA levels. Therefore, PSMA(-HBED) PET/CT is a promis-
ing imaging approach that could guide the therapy manage-
ment in patients with suspected recurrence of the disease.
OP086
Pelvic Dynamic Imaging with Pixel-Based Analysis
of Ga-68 PSMA PET/CT
E. Hsiao, G. P. Schembri, D. L. Bailey, E. A. Bailey, P. J.
Roach; Royal North Shore Hospital, St Leonards,
AUSTRALIA.
Aims:Ga-68 PSMA is a relatively new PET tracer for
prostate carcinoma. Little in vivo data are available in
humans on its uptake kinetics in normal and pathologic
sites. The study aims to assess the uptake rates in nor-
mal tissues and to investigate the timing of tracer uptake
in pathologic sites compared to physiologic bladder or
ureteric activity.Materials and Methods:Ten patients re-
ferred for PSMA PET/CT (3 for staging and 7 for bio-
chemical recurrence) underwent a 30-minute dynamic
scan of the pelvis on a Siemens Biograph mCT follow-
ing administration of 127-158MBq of Ga-68 PSMA
(HBED) as well as a 1-hr post-injection whole body
scan. Time-activity data were obtained and Patlak-
Rutland analysis was performed using in- house soft-
ware. Ki (influx rate constant) and Vd (volume of dis-
tribution) maps were generated from the regression
curves fitted pixel-by-pixel. Uptake rate of PSMA avid
lesions and normal sites were assessed.Results:Five pa-
tients had local PSMA-avid disease, while 7 pathologic
nodes were evident in 2 patients and 4 bone sites of
uptake were evident in 3 patients. Two patients had no
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PSMA-avid disease in the field of view. Normal sites
for correlation were defined as the sites without focal
PSMA uptake on conventional 1-hr delay imaging.
There were 9 bone sites, 4 prostate sites and 7 pelvic
nodes. Time-activity curves were so far obtained in 3
patients comparing the pathological sites to ureters and
bladders. Conclusion: Both primary and metastatic pros-
tate carcinomas show rapid and early uptake of Ga-68
PSMA within minutes of injection and markedly higher
uptake rates compared to normal tissues. The bladder
and ureteric activities begin to rise after 15 minutes.
Early imaging of PSMA may offer improved depiction
of disease burden with less confounding bladder or ure-
teric activity..
OP087
Cervical lymph node metastases is not an uncommon
finding in Ga-68-DKFZ-PSMA-11 PET/CT imaging
in patients with prostate cancer
J. Nematyazar1, O. E. SAHIN1, B. RAZAVI1, E. DEMIRCI2,
A. AYGUN1, M. OCAK3, C. OBEK4, A. R. KURAL5, L.
KABASAKAL1; 1Department of Nuclear Medicine,
Cerrahpasa Medical Faculty, Istanbul University, Istanbul,
TURKEY, 2Department of Nuclear Medicine, Sisli Etfal
Training and Research Hospital, Istanbul, TURKEY, 3Depart-
ment of Pharmaceutical Technology, Pharmacy Faculty, Istan-
bul University, Istanbul, TURKEY, 4Department of Urology,
Cerrahpasa Medical Faculty, Istanbul University, Istanbul,
TURKEY, 5Department of Urology, Acibadem University
Medical Faculty, Istanbul, TURKEY.
Aim: Prostate cancer is the most common solid cancer in
men and it is the second most common cause of death.
The type of therapy in prostate cancer is mainly influenced
by the presence of metastases. Recently, it has been shown
that PSMA PET imaging with Ga-68 labeled small mole-
cule inhibitors are highly sensitive and specific for detec-
tion of prostate cancer and its metastases. Whole body
imaging feature of PET imaging makes it possible to de-
tect metastases at unexpected sites of the body. The aim of
the present study was to evaluate the distribution of met-
astatic sites in prostate cancer patients who underwent
PSMA PET imaging. Material and method: We retrospec-
tively evaluated the files of patients who underwent Ga-
68-PSMA PET imaging in our institution between October
2013 and February 2015. There were 391 PSMA PET
imaging studies performed for the indication of staging,
restaging and therapy monitoring. Mean age was 66.7
±8.1 years and mean PSA level was 22.1±69.0 ranging
from 0.01 to 700. Results: In PSMA PET imaging there
was a positive lesion in 315 (80%) patients. Among these
patients, primary tumor was detected in 215 (68%) pa-
tients. Bone, lymph node and organ metastases were de-
tected in 117 (37%), 130 (41%) and 15 (5%) patients,
respectively. Bone or lymph node metastases were detected
in 186 (60%) patients. Among them 54 (30%) patients had
only bone and 68 (37 %) patients had only lymph node
metastases. In patients who had lymph node metastases
108 (82%) had pelvic, 46 (%35) had abdominal and 22
(17%) had cervical lymph node metastases. Conclusion:
The distribution of metastatic sites in PSMA PET imaging
suggested that cervical lymph node metastases is not an
uncommon finding even with low PSA levels. Also these
findings suggested that prostate cancer may have different
biological features, some of them may have osteophilic
and some of them may have lymphophilic behavior
OP088
Prospective Comparison of the detection rate
of 18F-Fluoromethylcholine and 68Ga-PSMA-HBED
PET/CT in men with prostate cancer with rising PSA post
curative intent therapy, being considered for targeted
therapy
J. Morigi1,2, P. Stricker3,4, P. van Leeuwen3,4, R. Tang2,5, B.
Ho2, Q. Nguyen3,4, A. Hickey2, D. Stark2, A. Young2, S.
Fanti1, L. Tarlinton2, L. Emmett2,5; 1Nuclear Medicine OU,
Policlinico S.Orsola-Malpighi / University of Bologna, Bolo-
gna, ITALY, 2Department of Diagnostic Imaging, St Vincent’s
Public Hospital, Sydney, NSW, AUSTRALIA, 3St Vincent’s
Prostate Cancer Centre, St Vincent’s Clinic, Sydney, NSW,
AUSTRALIA, 4Australian Prostate Cancer Research Centre
– New South Wales, The Garvan Institute of Medical
Research/The Kinghorn Cancer Centre, Sydney, NSW, AUS-
TRALIA, 5University of New South Wales (UNSW), Sydney,
NSW, AUSTRALIA.
Aim: In men with prostate cancer (PCa) and biochemi-
cal failure following therapy, current imaging techniques
have a low detection rate at PSA levels at which
targeted salvage therapy is effective. 11C-Choline or
18F-Fluoromethylcholine (FMC), though widely used,
have poor sensitivity at low PSA levels. 68Ga-PSMA-
HBED (PSMA) has shown promising results in retro-
spective trials. The aim of this study is to prospectively
compare detection rates of PSMA versus FMC PET/CT
in men initially managed with either radical prostatecto-
my (RP) or radiation treatment (RT), being considered
for targeted therapy.Methods: A referred sample of men
with rising PSA following treatment, eligible for
targeted treatment, was prospectively included. Patients
on hormonal or chemotherapy treatment were excluded.
PSMA, FMC PET/CT and diagnost ic CT were
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undertaken in all patients sequentially, and assessed by
blinded experienced readers. Scan results and manage-
ment impact change was documented. Results: 38 pa-
tients (pts) were enrolled. 34/38 (89%) pts were post-
RP, 4/38 (11%) pts were post-RT. 12/38 (32%) pts
underwent initial RP and subsequent salvage RT. Mean
PSA at imaging was 1.74 ± 2.54 ng/ml. Overall, 68%
(26/38) of pts had a positive scan indicating at least one
lesion suspicious for PCa recurrence. Of these, 14/26
(54%) were positive on PSMA alone, 42% (11/26) were
positive on both FMC and PSMA, 1/26 on FMC alone
(false positive on biopsy). Histopathology was available
at time of submission for 6 PSMA lesions, all true pos-
itive (6/6). Diagnostic CT was inconclusive in all men.
With PSA 2.0, 86% PSMA vs. 57% FMC. On lesion-
based analysis, PSMA detected more lesions than FMC
(59 vs. 29, p <0.001). There was a 63% (24/38) overall
management impact, 54% (13/24) due to PSMA imaging
alone. The primary limitation is absence of histopathol-
o g y i n s om e l e s i o n s d u e t o sm a l l l e s i o n
size/accessibility. Conclusion: In patients with rising
PSA evaluated for targeted treatment , PSMA demon-
strated a significantly higher detection rate at low PSA
levels, resulting in a significant overall management
impact.
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OP089
Ac-225-DOTATOC - dose finding for alpha particle
emitter based radionuclide therapy of neuroendocrine
tumors
C. Kratochwil1, F. Bruchertseifert2, F. L. Giesel1, C.
Apostolidis2, U. Haberkorn1, A. Morgenstern2; 1University
Hospital Heidelberg, Heidelberg, GERMANY, 2European
Commission - Joint Research Centre, Institute for Transurani-
um Elements, Karlsruhe, GERMANY.
Objectives: There are no established dosimetry tools to predict
toxicity of “targeted alpha-therapy” (TAT), yet. We conducted
an dose escalation to find the maximum tolerable dose (MDT)
of single cycle and fractionation concepts for Ac-225-
DOTATOC radionuclide therapy. Methods: According to Dec-
laration of Helsinki’s “Unproven interventions in Clinical
Practice”we performed 48 treatment cycles in 36 patients with
progressive neuroendocrine tumors (NET). After each cycle
acute hematotoxicity was documented according to CTCAE
criteria. First observations are also available for chronic kidney
toxicity as the follow up for the first 17 patients has now
reached 2 years. Results: The MTD of a single cycle Ac-
225-DOTATOC was considered to be 40 MBq. Multiple frac-
tions were tolerated with 25MBq every 4 months or 18.5MBq
every 2 months. Cumulative activities of 75 MBq were found
tolerable in regard to delayed toxicity. The radiologic treat-
ment response that was observed in some patients is without
clear preference of a particular fractionation concept until now.
Conclusions: We present a well tolerable treatment protocol
for TAT with Ac-225-DOTATOC in NET patients that also
demonstrated promising Treatment efficacy in various pa-
tients. If TAT provides general advantages in comparison to
beta emitter based radionuclide therapy cannot be derived
from the available data, yet. Comparative trials are needed in
the future.
OP090
Optimal sampling schedule: accurate estimation
of time-integrated activity coefficients in peptide receptor
radionuclide therapy (PRRT)
C. Maaß1, J. Sachs1, D. Hardiansyah1, P. Kletting2, F. M.
Mottaghy3, G. Glatting1; 1Medical Radiation Physics/
Radiation Protection, Medical Faculty Mannheim, Heidelberg
University, Mannheim, GERMANY, 2Department of Nuclear
Medicine, Ulm, GERMANY, 3Department of Nuclear Medi-
cine, Aachen, GERMANY.
Aim: The aim of this study was (1) to determine population
parameter values and using these parameter values (2) to quan-
tify the effect of sampling schedules with differing sizes on the
estimation of time-integrated activity coefficients in PRRT
with 111In DTPAOC in 15 patients.Materials and Methods:
Fifteen patients with proven neuroendocrine tumours (NETs)
were investigated. Planar whole-body scans using a double-
head γ-camera (ECAM, Siemens, Erlangen, Germany) were
performed at 45 min, 4 h, 1, 2 and 3 or 5 d and serum mea-
surements were taken at 5 min, 0.5, 1, 2, 4 h and 1, 2, 3 or 5 d
after injection of 111In-DTPAOC [1].A physiologically based
pharmacokinetic (PBPK) model [1] was implemented using
SAAMII software (version 2.2, The Epsilon Group, Char-
lottesville, USA). Population parameter values were deter-
mined using an iterative two stage (ITS) algorithm.Using both
individual and population based parameter values and sam-
pling schedules with different sizes in the model, the relative
difference (RD) between actual and estimated time-integrated
activity coefficients for tumour, kidneys, liver, spleen, serum
and whole body was quantified.Sampling schedules were
modified as follows: (1) one and (2) two measurement points
(5 and 10 cases/patient) omitted once for each organ and the
serum measurements. Mean and standard deviation of the RD
were calculated and averaged over all cases and all
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patients.Results: Using the individual parameter values the
mean RDs were for tumour, kidneys, liver, spleen, serum
and whole body (1) (0±4)%, (0±2)%, (3±11)%, (3±9)%, (5
±14)%, (1±3)% and (2) (13±35)%, (0±2)%, (4±11)%, (3
±8)%, (4±15)%, (1±3)%.Using the population based parame-
ter values the mean RDs were for tumour, kidney, liver, spleen,
serum and whole body (1) (0±1)%, (0±0)%, (0±3)%, (0±1)%,
(-1±4)%, (0±1)% and (2) (13±37)%, (0±1)%, (1±2)%, (0
±1)%, (-1±6)%, (0±2)%.Conclusion: The application of Bayes
parameters in physiologically based pharmacokinetic model-
ling allowed for an accurate estimation of time-integrated ac-
tivity coefficients even in case less information (measurement
data) is available. In this patient group, omitting one measure-
ment point leads only to a small error.Literature1.Kletting P,
Müller B, Erentok B, Schmaljohann Jr, Behrendt FF, Reske
SN, et al. Differences in predicted and actually absorbed doses
in peptide receptor radionuclide therapy. Med Phys.
2012;39(9):5708.
OP091
The intensity of 18FDG uptake is not a surrogate marker
of morphological tumor progression in patients
with metastatic differentiated thyroid cancer.
M. Terroir, I. Borget, F. Bidault, D. Deandreis, A. Al
Ghuzlan, D. Hartl, M. Ricard, A. Berdelou, L. Dercle, J.
Lumbroso, E. Baudin, M. Schlumberger, S. Leboulleux;
Gustave Roussy, Villejuif, FRANCE.
Aim: In patients with metastatic differentiated thyroid carcino-
ma (DTC), thyroglobulin doubling time (TgDT) and
fluorodeoxyglucose (FDG) uptake as well as age, tumor size
and iodine uptake are prognostic factors for survival. High
FDG uptake is a poor prognostic factor. Consequently, lesions
with high FDG uptake are often considered aggressive and
may be monitored and treated with local modalities.The aims
of this retrospective single center study were to determine
whether the intensity of FDG uptake was correlated to tumor
progression or tumor growth rate (TGR) expressed as the per-
centage of increase in tumor size during a one year-period
(TGR) and to TgDT.Materials and methods: Fifty five patients
with DTC were included between July 2012 and May 2014
with the following criteria: (i) at least one distant metastasis
measuring ≥ 1 cm in diameter (ii) evaluation by FDG-positron
emission tomography/computed tomography (PET/CT) per-
formed at our center (iii) at least one CT or another FDG-
PET/CT performed more than 3 months after the reference
FDG-PET/CT (iv) absence of systemic or local treatment be-
tween the two imaging procedures.Results: At the patient lev-
el, DTC were papillary (33), follicular (8) or poorly differen-
tiated (14). Forty-seven patients were refractory to radioactive
iodine (RAI). Their mean TgDTwhen available was 101 days
with TgDT <1 year in 20 patients and >1 year in 12 patients.
The median higher SUV max of each patient was 13.2 (range
3.6-66.2). The two-year survival was 100% for patients with
SUV max <5 and 68% for patients with SUV max >5. The
TgDT was 258 days for patients with SUV max <5 and 101
days for patients with SUV max >5. At the lesion level, one
hundred fifty six metastatic lesions located in the lung (63),
neck lymph nodes (28), chest lymph nodes (42), bone (11),
liver (2) and other sites (10) were studied. Themedian size was
16 mm, median SUVmax: 8.7; median metabolic volume: 3.7
cm3. The median one-year TGR by lesion was 16% (range
0->100%). SUV max and metabolic volume of each lesion
were not correlated to their one-year TGR (p=0.28 and
p=0.77 respectively). SUV max of each lesion was not corre-
lated to tumor size.Conclusion: The intensity of FDG uptake is
not correlated to morphological tumor progression assessed by
one-year TGR and cannot be used as a surrogate marker of
morphological progression.
OP092
Assessment of lesion response in differentiated thyroid
cancer patients undergoing radioiodine treatment using
124I PET/CT
R. Wierts1, B. Brans1, B. Havekes1, S. G. E. A. Halders1, F.
M. Mottaghy1,2, W. Jentzen3; 1Maastricht University Medical
Center, Maastricht, NETHERLANDS, 2University Hospital
RWTH Aachen University, Aachen, GERMANY, 3Klinik für
Nuklearmedizin, Universität Duisburg-Essen,, Essen,
GERMANY.
Aim: This study assesses the lesion response in patients with
differentiated thyroid cancer (DTC) undergoing radioiodine
therapy by means of 124I PET/CT, 18F-FDG PET/CT, and/
or 131I SPECT(/CT) imaging. Materials and methods:
Pretherapeutic 124I PET/CT images of 41 DTC patients un-
dergoing radioiodine therapy were retrospectively analyzed.
124I PET/CT images were acquired 24 and ≥96 hours after
oral administration of approximately 28 MBq. Using an auto-
mated iterative thresholding algorithm, each lesion was seg-
mented on the PET images to determine the volume and resi-
dence time used to predict the therapy-delivered absorbed ra-
diation dose (TAD). The lower volume limit of determinability
was 0.15 mL; following a previous study, the minimum TAD
was determined for smaller lesions. Lesions were identified as
thyroid remnants or metastatic tissue (lymph node, pulmonary,
mediastinal, bone). Lesion response was determined based on
124I PET/CT, 18F-FDG PET/CT and/or 131I SPECT(/CT)
follow-up images performed in the first year after treatment.
A lesion not evident on any of the follow-up images was
considered a completely responding lesion; otherwise
assigned as an incompletely responding lesion. Significant
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differences in TADs and lesion volumes were evaluated by
Mann-Whitney U test. Results: Of 161 lesions included, 113
(70.2%) were identified as thyroid remnants and 48 as metas-
tases (29.8%). 69 (61.1%) thyroid remnants and 26 metastases
(54.1%) were smaller than 0.15 mL. Complete response was
observed for 96 thyroid remnants (85.0%) and 30 metastases
(62.5%). For thyroid remnants and metastases, the median
TAD of the completely responding group was significantly
higher (remnants: 200 Gy, metastases: 62 Gy) than the median
TAD of the incompletely responding group (remnants: 54 Gy,
metastases: 15 Gy); the significance levels (P) were 0.046 for
the thyroid remnants and 0.018 for the metastases. For metas-
tases, the lesion volumes were significantly smaller for the
completely responding lesions than that of the incompletely
responding lesions (P=0.001) but not for the thyroid remnants
(P=0.168). Conclusion: 124I PET/CT-based lesion dosimetry
in combination with 18F-FDG PET/CT and/or 131I SPECT(/
CT) follow-up images can be used for the assessment of lesion
response in DTC patients undergoing RAIT.
OP093
Bone marrow dosimetry assessed with quantitative
SPECT/CT is predictive of subacute thrombocytopenia
following 177Lu-octreotate PRRT
M. E. Marcotte, M. Del Prete, E. O. Gaudin, F. A. Buteau, P.
Després, J. M. Beauregard; Université Laval, Quebec City,
QC, CANADA.
Aim: Along with the kidney, the bone marrow (BM) is a crit-
ical organ in 177Lu-octreotate peptide receptor radionuclide
therapy (PRRT). Traditionally, BM dosimetry has been
assessed using serial blood sampling, which is cumbersome
and also inaccurate when a large tumor burden results in a
significant cross-dose to the BM. Quantitative SPECT
(QSPECT) can overcome these limitations. Our aim was to
correlate QSPECT-derived BM dose estimates with the
short-term platelet (PLT) count variation following 177Lu
PRRT. Materials and Methods: 29 177Lu-octreotate cycles
(median: 7.4, range: 5.6 to 8.3 GBq) in 8 patients suffering
from neuroendocrine tumour were studied. Patients underwent
serial QSPECT/CT at 4, 24 and 72 h. Self-dose to the BM was
derived from activity concentration sampling using a volume
of interest over L4 vertebral body, while the cross-dose to the
BMwas estimated from total activity retention in the QSPECT
field of view. For each individual cycle, the total BM dose was
correlated to absolute and relative PLT count variation from
baseline (lowest count between 2 and 4 weeks post-PRRT).
Results: Median BM dose per cycle was 148 (62 to 370) mGy,
and the cross-dose accounted for a median of 7.7 (2.8 to 47.7)
% of the total BM dose. Median absolute and relative PLT
count variations were -17 (-100 to 64) x109/L and -7.5 (-32
to 59) %, respectively. There was a significant, moderate in-
verse correlation between the absolute or relative PLT varia-
tion and BM dose, with Spearman r values of -0.47 (P=0.01)
and -0.39 (P=0.04), respectively. Thrombocytopenia occurred
following every cycles where >150 mGy were delivered to the
BM, and was more pronounced than where <150 mGy were
delivered (median of -8 vs. -43 x109/L, respectively;
P=0.005). Conclusion: Our results provide an initial clinical
validation of the accuracy of QSPECT-based BM dosimetry,
which appears to be predictive of subacute BM toxicity, i.e.
transient thrombocytopenia. QPSECT has the potential to be-
come a non-invasive and practical approach for simulta-
neous tumour, kidney and BM dosimetry in 177Lu radio-
nuclide therapy, hence facilitating the implementation of
personalized PRRT.
OP094
Comparison of quantitative 177Lu measurements
in European hospitals
A. Fenwick1, J. Merrett2,1,3, L. Johansson1; 1National Physi-
cal Laboratory, Teddington, UNITED KINGDOM, 2Universi-
ty of Surrey, Guildford, UNITED KINGDOM, 3Royal Surrey
County Hospital, Guildford, UNITED KINGDOM.
The accuracy of quantitative imaging in SPECT is critical
when determining doses delivered during PRRT therapies with
177Lu. In order to determine the measurement capability of a
representative subset of hospitals within Europe, a comparison
exercise was developed to test both the inter-clinic variability
and to assess which methods for activity determination were
most effective. An elliptical Jaszczak phantom containing an
anthropomorphic insert with lung and bone-equivalent mate-
rials and an exterior set of body contour rings was used to
compare the ability of leading clinics in the UK, Netherlands,
Germany, Sweden, Italy and the Czech Republic. The phan-
tom was used in conjunction with a set of well-characterised,
traceable 177Lu sources consisting of an inner hot spherical
core surrounded by an outer warm background at an activity
concentration ratio of approximately 1:15. The total activity in
the spheres ranged from 60-100 MBq at the time of measure-
ment. The sources were designed to mimic a relatively large
tumour with homogeneous uptake of 177Lu labelled peptides
within a liver which also had partial homogeneous uptake.
Although this setup could only be described as partly repre-
sentative of a real patient, the principles regarding the ability of
the camera to recover the activity (although simplified) are
largely the same. SPECT/CT Images were taken with both a
standard set of acquisition parameters and those used clinically
at each site (if different). A total of 6 sources were used in the
exercise, all of which were made at NPL and produced in a
manner traceable to national standards. The results show that
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large deviations were observed at some sites, however, the
majority of clinical centres were able to determine the activity
to within ±20%. In conclusion, improved calibration protocols
should be developed and harmonised in order to improve ac-
curacy and guidance on methods for making standard calibra-
tion phantoms should be given at a European level.
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Anatomy Refresher and Cross-sectional Imaging: Thorax
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Enabling Research on Epilepsy through a New
and Efficient Synthesis of [18F]UCB-H, a PET Tracer
for the Imaging of SV2A
C. Warnier1,2, C. Lemaire1,2, J. Aerts1,2, J. Mercier3, A.
Plenevaux1,2, A. Luxen1,2; 1University of Liege, Liege, BEL-
GIUM, 2Cyclotron Research Centre, Liege, BELGIUM,
3UCB Pharma, Braine-L’Alleud, BELGIUM.
IntroductionEpilepsy is a neurological condition that affects an
estimated 50 million people throughout the world. Although a
number of treatments are available for that disease, the cellular
mechanisms at the origin of epilepsy remain largely unknown.
From that perspective, considerable effort was put into the
development of [18F]UCB-H, which recently proved to be a
very promising PET tracer for the exploration of neurotrans-
mission processes, and the diseases related to their malfunc-
tion, such as epilepsy[1-4]. [18F]UCB-H binds specifically,
and with nanomolar affinity to the Synaptic Vesicle Protein
2A (SV2A), which is also the binding site of the anti-
epileptic drug Levetiracetam (Keppra®, UCB Pharma). Until
now, [18F]UCB-H was only available through a long, multi-
step radiosynthesis that is technically complex to implement
and affords a limited yield of radiotracer.[5]MethodsIn this
work, we present a new short, simple and efficient single-
step radiosynthesis of [18F]UCB-H. We successfully synthe-
sized a N-heteroaryliodonium precursor of the radiotracer. The
direct labelling of the iodonium using the classical Kryptofix/
K18F fluorination method afforded good RCY’s of
nca[18F]UCB-H (RCY’s > 50%). An automation sequence
for this straightforward radiosynthesis was therefore
developed.ResultsThe fully automated radiosynthesis, from
[18F]fluoride trapping on QMA to the end of the automated
distribution of the injectable [18F]UCB-H, lasts 60 min and
affords 32±2% RCY (n=6, 50<A(StartOfSynthesis)<240
GBq), non-corrected for decay. High specific activities of
500-1000GBq/μmol at the end of the synthesis were obtained,
as determined by radio-UPLC analysis. Moreover, data
concerning the stability of the precursor, radiochemical &
chemical purity of [18F]UCB-H, as well as solvent trace anal-
ysis and stability of the tracer in the final formulation, confirm
that this production method shall fulfill the standard GMP
requirements.ConclusionWe designed a new production meth-
od for [18F]UCB-H that is short and easy to implement on any
automation system. To the best of our knowledge, this is the
first diaryliodonium 18F-labelling that has been adapted for
the production of high activites (up to 95GBq) of a radiotracer
fit for clinical trials.AcknowledgementsWe gratefully ac-
knowledge the FRS-FNRS (FRIA) for funding this work and
UCB Pharma SA Belgium for collaborationReferences[1]
Warnock, G. I. et al., J NuclMed 2014, 55(8), 1336; [2] Bretin,
F. et al., EJNMMI research 2013, 3(1), 35; [3] Lynch, B. A.
et al. Proc Natl Acad Sci USA 2004, 101(26), 9861; [4]
Mercier, J. et al. ChemMedChem 2014; [5] Aerts, J. et al.,
EJNMMI, EANM abstracts 2013, 40(2), 89
OP097
Radiolabeling of proteins using radiofluorinated nitrile
oxides
P. Krapf1,2, B. D. Zlatopolskiy1,2, R. Kandler2, B. Neumaier3,
2,1; 1University Clinic of Cologne, Cologne, GERMANY,
2Max-Planck-Institute for metabolism research, Cologne,
GERMANY, 3Forschungzentrum Jülich GmbH, Jülich,
GERMANY.
Objectives: 18F-Labeling using azide alkyne “click” cycload-
dition became a popular method of PET chemistry. Recently,
several novel 18F-labeled 1,3-dipoles (other than azides) were
applied for the preparation of 18F-labeled small molecules via
1,3-dipolar cycloadditions. Especially, reactions of highly re-
active radiofluorinated nitrile oxides could be an attractive
alternative to azide “click” labeling. The aim of this work
was the development of a novel procedure for protein labeling
using nitrile oxide chemistry. Methods: The reaction of o- and
p-[18F]fluorobenzaldehydes ([18F]1a,b) with hydroxylamine
afforded o-, p- [18F]fuorobenzaldoximes ([18F]2a,b). o- and
p-[18F]fluorobenzimidoyl chlorides ([18F]3a,b) - more stable
precursors for the generation of nitrile oxides in situ - were
obtained via chlorination of [18F]2a,b using IODO-GEN pre-
coated reaction vials. The solutions of the labeling synthons
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were added to the corresponding derivatized and native pro-
teins to yield 18F-labeled conjugates. The conjugations were
optimized with respect to protein amount. Purification of la-
beled biopolymers was performed using PD10-column. Re-
sults: [18F]3a,b were obtained in RCY of up to 90% under
optimized reaction conditions (1 M HCl, 15 min, 50 °C).
[18F]3a,b were highly stable under strongly acidic conditions
(> 5h). Application of water insoluble oxidant allowed to
avoid undesirable oxidation and/or denaturation of the pro-
teins. The reaction of [18F]3a,b with BCN-derivatized BSA
as well as with native BSA and Annexin V led to the corre-
sponding radiolabeled isoxazole as well as amidoxime conju-
gates, respectively, in RCCs of 30-90% within 10 min
(pH=7.5-9.0; RT-37°C). Reasonable RCCs (60%) were ob-
tained already with 0.5-5 nmol of proteins. Labeled proteins
were isolated in RCPs > 95 after simple gel filtration.
Conclusion:The novel radiolabeling procedure allows a fast
and efficient radiofluorination of proteins and, consequently,
represents an attractive alternative to conventional methods for
protein 18F-labeling.
OP098
Synthesis of PET tracers via SN2 radiofluorination
under “minimalist” conditions
M. A. Omrane, B. D. Zlatopolskiy, E. A. Urusova, R.
Richarz, P. Krapf, B. Neumaier; Institute of Radiochemistry
and Experimental Molecular Imaging, Cologne, GERMANY.
Objective: Recently we developed a novel procedure for the
preparation of 18F-labeled arenes under “minimalist” condi-
tions using only onium salts as radiolabeling precursors and
[18F]fluoride. Neither azeotropic drying, nor base or any other
additives were necessary. The aim of this work was to extend
this method to the preparation of radiofluorinated aliphatic
compounds via SN2 radiofluorination. Methodology:
[18F]Fluoride was eluted from a QMA cartridge with appro-
priately protected precursors of 5-[18F]FDR, 6-[18F]FDGal
and [18F]FET in MeOH. MeOH was evaporated at 65-70 C
within 2-3 min, MeCN was added and the resulting solutions
were heated to give the corresponding 18F-labeled intermedi-
ates. The latter were purified by SPE and thereafter
deprotected under acidic conditions. If necessary radiolabeled
products were purified by SPE or HPLC. Conjugation of
5-[18F]FDR with the model aminnoxy-substituted compound,
methyl 6-aminooxyhexanoate, was optimized with re-
spect to reaction conditions and precursor amount. Re-
sults: [18F]F- was eluted from an anion exchange resin
almost quantitatively. Under optimized conditions the
appropriately protected 5-[18F]FDR, 6-[18F]FDGal and
[18F]FET were prepared from the corresponding 3-N,N,
N-trimethylammoniumalkyl(aryl)sulfonyl precursors in
RCCs up to >92%, 6% and 71%, respectively. After
SPE purification of the radiolabeled intermediate follow-
ed by the deprotection step with 1 M HCl (110 °C, 10
min) 5-[18F]FDR was prepared in 48% RCY (EOB) and
excellent RCP. No additional purification was needed.
The content of D-Ribose (60-80 μg/batch) was suffi-
ciently low to allow an efficient conjugation with methyl
6-aminooxyhexanoate. The corresponding oxime was
prepared in RCCs up to 93% and RCPs >96%. N-
Boc-[18F]FET-OtBu was quantitatively deprotected with
DCE/TFA (10 min; 80°C) to give radiofluorinated amino
acid in 70% RCC over two steps. Conclusion: The SN2
aliphatic radiofluorination under “minimalist” conditions
is suitable for fast and simple preparation of 18F-labeled
compounds. An important additional advantage of this
methode is the cationic trimethylammonium tag, which
in many cases allows an efficient SPE separation of the
radiolabeled compound from the labeling precursor.
OP099
Carbonylation via Conversion of [11C]CO2 into [11C]CO
Mediated by [11C]Silane Derivatives
C. Taddei, S. Bongarzone, A. Haji Dheere, A. D. Gee; The
Rayne Institute, London, UNITED KINGDOM.
Introduction and AimCarbon monoxide (CO) can be used
to synthesise biologically active molecules, such as am-
ides, esters and ketones.[1] [11C]CO is traditionally pro-
duced by the gas phase reduction of [11C]CO2 at elevat-
ed temperatures[2] or by chemical conversion of CO2 to
CO. The chemical conversion of CO2 to CO can be ob-
tained using silane derivatives in two steps: i) CO2 in-
sertion in a silane derivative leading to a silane interme-
diate followed by ii) CO release triggered by an activa-
tor.[3] The produced CO can be transferred in a second
vial and coupled with an amine and an organic halide
yielding the desired carbonylation product. Herein, this
CO2 to CO methodology is applied to carbon-11 label-
ling by converting [11C]CO2 to [11C]CO and subse-
quently used to yield [11C]amide-containing molecules.
This represents the first carbonylation methodology me-
diated by a silane derivative reported to date. Moreover,
the fully automated synthesis was performed utilising an
Eckert & Ziegler Modular-Lab.Method and ResultsThe
carbonylation reaction was developed using a simple
two-vial reaction setup. In the first vial, [11C]CO2 to
[11C]CO conversion was achieved by coupling
[11C]CO2 and a silane derivative at room temperature.
Following the addition of a decarbonylating agent
(activator) with heating, [11C]CO was produced. The re-
lease of [11C]CO from the first vial and transfer of
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[11C]CO into a second vial was time-monitored. The
transfer of [11C]CO to a second vial containing an amine
and an organic halide led to the production of the relative
[11C]amide derivative. As model reaction, [11C]N-
benzylbenzamide was obtained in a high radiochemical
purity (>98%) and short synthesis time (~15 min from
EOB).ConclusionA novel carbonylation method mediated
by a [11C]silane derivative has been successfully devel-
oped. This method is an attractive route to produce
[11C]carbonyl-containing molecules, obviating the need
of gas phase reduction infrastructure. Furthermore, the
deigned automated synthesis will be applied to generate
new carbon-11 PET tracers.Research SupportThis work
was supported by European Commission, FP7-PEOPLE-
2012-ITN (316882, RADIOMI), Medical Research Coun-
cil (MRC, MR/K022733/1) and Biomedical Research
Centre award to Guy’s & St Thomas’ NHS Foundation
Trust.References[1] C. F. J. Barnard (2008) Organometal-
lics, 27, 5402; A. Brennfuhrer, et al (2009) Angew.
Chem. Int. Ed. Engl., 48, 4114. [2] S. K. Zeisler, et al
(1997) Appl. Radiat. Isot., 48, 1091. [3] S. D. Friis, et al
(2011) J. Am. Chem. Soc., 133, 18114; C. Lescot, et al
(2014) J. Am. Chem. Soc., 136, 6142.
OP100
Synthesis and in vivo evaluation of a novel peptide-based
N3S1 chelator for 99mTc-labeled radiotracer
with enhanced renal clearance
D. Lee, K. Choi; Korea Atomic Energy Research Institute,
Jeongeup, KOREA, REPUBLIC OF.
Objectives: Peptide-based N3S1 chelator PXC, which are com-
prised of amino acids (Pro-X-Cys backbone, X are designated for
some amino acids) for radiolabeling with 99mTc has been de-
signed and evaluated for development of radiopharmaceuticals.
However, the lipophilicity of the first core structure, Pro-Gly-Cys
(PGC) in its RGD complex (PGC-RGD) has resulted in substan-
tial hepatobiliary excretion when administered in tumor-bearing
mice. In this study, to improve biological behavior in the
biodistribution with the intention of enhancing renal clearance,
a novel tripeptide chelating sequence, PKC and its RGD
conjugate(PKC-RGD) were synthesized and evaluated in normal
mice to explore the effect of chelator on the pharmacokinetic
properties. Methods: we have synthesized Pro-Lys-Cys (PKC)
by substitution of L-glycine by L-lysine for the preparation of
PKC-c(RGDyK) (thus N3S1 chelator-RGD conjugate with L-
lysine on the PXC backbone). After preparation of the synthe-
sized chelators-RGD conjugates, the properties of the
radiolabeling and a comparison of biodistribution for 99mTc-
PGC-c(RGDyK) and 99mTc-PKC-c(RGDyK) were evaluated
in vitro and in normal mice, respectively. Results: The target
specificity of the resulting PKC-RGD was similar to that of
PGC-RGD as determined by a cell binding assay and a compe-
tition binding assay. The 99mTc radiolabeling of PKC-RGD re-
sulted in radiochemical yields of 98% under mild conditions at
high specific activities. Biodistribution data in normal mice clear-
ly showed a significant decrease in intestinal uptake at 2h postin-
jection for the 99mTc-PKC-c(RGDyK) compared to the 99mTc-
PGC-c(RGDyK) (from 24.35% ID/g to 8.49% ID/g for the GI
tract). The 99mTc-PKC-c(RGDyK) biodistribution was also
showed by a higher retention of radioactivity in the whole body,
but with kidney accumulation over 8-fold higher than observed
with 99mTc-PGC-c(RGDyK) at 2h (12.62%ID/g for PKC-RGD
and 1.54%ID/g for PGC-RGD, respectively). Conclusions:
These results show that the biodistribution may be altered espe-
cially concerning lipophilicity resulting in renal rather
hepatobiliary excretion. This comparative study make it possible
to explore the effects of lipophilicity on the biodistribution of
99mTc-labeled c(RGDyK) through the using different tripeptide
N3S1 chelators. Therefore, 99mTc-PKC-RGD may be an attrac-
tive alternative for the in vivo imaging of integrin receptors.
OP101
Influence of a novel, versatile bifunctional chelator
on radiolabelling, pharmacological and targeting
properties of a minigastrin analogue for molecular
imaging and therapy applications
J. Pfister1, D. Summer1, C. Rangger1, M. Petrik2, E. von
Guggenberg1, P. Minazzi3, G. B. Giovenzana4, C.
Decristoforo1; 1Medical University Innsbruck, Innsbruck,
AUSTRIA, 2Institute of molecular and translational medicine,
Faculty of medicine and dentistry, Palacky University, Olo-
mouc, CZECH REPUBLIC, 3CAGE Chemicals srl, Novara,
ITALY, 4DSF, Università del Piemonte Orientale “A. Avoga-
dro”, Novara, ITALY.
Aim: AAZTA (6-[bis(carboxymethyl)amino]-1,4-
bis(carboxymethyl)-6-methyl-1,4-diazepane) is a promising che-
lator with potential advantages over DOTA for radiopharmaceu-
tical applications. Its mesocyclic structure enables fast
radiolabelling under mild conditions with trivalent metals includ-
ing 68Ga for PET, but also 177Lu for radionuclide therapy. Here
we describe the conjugation of a bifunctional AAZTA derivative
on amodel minigastrin derivative as a potential theranostic agent.
Materials and Methods: An AAZTA derivative with an aliphatic
C9 chain as linker was coupled to a minigastrin [AAZTA0, D-
Glu1, desGlu2-6]-minigastrin (AAZTA-MG) and labelled for the
experiments with 68Ga and 177Lu using standard labelling pro-
tocols. The characterization in vitro included stability studies in
different media as well as the determination of the partition coef-
ficient in octanol/PBS (log D). Affinity determination (IC50) and
cell uptake studies were performed in A431-CCK2R cells
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expressing the human cholecystokinin-2 receptor. Using the same
cell lines μPET/CT and ex vivo biodistribution studies were per-
formed in tumour xenograft bearing nude mice for 68Ga labelled
compound and normal biodistribution for [177Lu]-AAZTA-MG.
Results andConclusion: AAZTA-MG showed a high radiochem-
ical yields for labelling with 68Ga (>95%),177Lu (>98%) and
111In (>98%) at high SA. The log D value of -3.7 for [68Ga]-
AAZTA-MG and [177Lu]-AAZTA-MG indicates a highly hy-
drophilic character of the complexes. Stability test showed overall
high stability in solution with some decomposition in human
plasma for 68Ga labelled compound and transchelation towards
DTPA for 177Lu. IC50 value of 10.0 nM was determined for
AAZTA-MG, which indicates a high affinity binding for the
CCK2 receptor with no significant differens for the correspond-
ing natGa and natLucomplexes. Specific cell uptake after 60 min
incubation resulted to be >7.5% for [68Ga]-AAZTA-MG in
A431-CCK2R cells and >9.5% for the 177Lu labelled counter-
part, comparable to other DOTA-MG-analogs. μPET studies in
nude mice xenografts revealed high selective accumulation in
A431-CCK2R positive tumours of 68Ga-labelled AAZTA-MG
(2.5 % ID/g in 1 h post injection), but also comparably higher
blood levels as corresponding DOTA-analogs. Biodistribution in
normal nude mice for 177Lu labelled compound showed a con-
siderable intestinal (7.3% ID/g) and liver (1.5 % ID/g) uptake.
Overall, AAZTA showed interesting properties as bifunctional
chelator for peptides providing mild radiolabelling conditions
for both 68Ga and trivalentmetals having advantages of currently
used DOTA. Studies are ongoing to further investigate in vivo
targeting properties and stability issues and influence of spacer
length on biodistribution.
OP102
Evaluation of configurationally restricted copper-64
labelled bis tetraazamacrocyclic as potential PET agents
for CXCR4 expression in oncology imaging
G. S. Clemente, B. P. Burke, S. Nigam, C. Cawthorne, S. J.
Archibald; University of Hull, Hull, UNITED KINGDOM.
Introduction: Chemokines are signalling proteins responsible for
inducing cell migration. One of their receptors, CXCR4, is com-
monly over-expressed in several lines of cancer.(1) CXCR4 pos-
itive tumours generally have a higher degree of metastatic poten-
tial, triggering interest in this receptor as target for drug develop-
ment and molecular imaging.(2) Following on from previous
results published by our group showing the synthesis of novel
configurationally restricted bis tetraazamacrocycles that act as
CXCR4 antagonists, in whichmetal complexation enhances both
binding affinity and receptor residence time, the radiolabelling
with a positron-emitting isotope was attempted to evaluate pro-
spective applications in PET.(3,4) Aim: The main goal of this
work is to optimise the radiolabelling of the previously
synthesised bis tetraazamacrocyclic with copper-64 (t1/
2=12.7h) without the need of structural changes and achieving
a radiotracer chemically identical to its characterised cold ana-
logue. Full evaluation of the in vivo characteristics in wild type
and CXCR4 over-expressing tumour-bearing mice is currently
ongoing. Methods: Mono- and bis-copper versions of the bis
tetraazamacrocyclic complex were synthesised by converting
64CuCl2, obtained in cyclotron through 64Ni(p,n)64Cu
nuclear reaction, into 64Cu(OAc)2, pH 5.5, followed by
complexation of the ligand using a range of tempera-
tures, solvents and reaction times. Formation of the
radiolabelled mono-copper complex was attempted by
two different approaches: direct chelation of the
macrocycle and transchelation with previously coordinat-
ed zinc, using stoichiometrically controlled reactions. Bis
copper radiotracer was achieved via direct chelation of
the non-radioactive mono-copper species. Reactions were
followed by radioTLC/HPLC, reformulated and intrave-
nously injected in both normal and CXCR4 over-
expressing tumour bearing mice. In vivo competitive
blocking studies are being carried out using the clinical-
ly licensed CXCR4 antagonist plerixafor (AMD3100).
Results: After optimisation of the several radiolabelling
approaches, yields above 95% and specific activities up
to 9.5 GBq/μmol were achieved. In vivo μPET showed
t h e e x p e c t e d a f f i n i t y f o r t h e C X C R 4
receptor.Conclusion: 64Cu radiolabell ing of bis
tetraazamacrocyclic was successfully achieved to per-
form in vivo biodistribution studies in CXCR4 over-
expressing tumour-bearing mice. The long half-life of
64Cu and receptor residence time could offer improved
tumour/background ratios, making it a potential candi-
date for CXCR4 mapping through PET imaging. Further
studies are currently ongoing to fully validate and opti-
mise in vivo properties. M. Palacios-Arreola et al., J
Immunol Res, 2014, 2014, 1-8. 2. E. Roussos et al.,
Nat Rev Cancer, 2011, 11, 573-587. 3. A. Khan et al.,
J Am Chem Soc, 2009, 131, 3416-3417. 4. R. Smith
et al., Dalton Trans, 2012, 41, 11369-11377.
OP103
Efficient production of PET tracers on a preparative scale
via copper-mediated radiofluorination under “minimalist”
conditions
J. Zischler1,2,3, B. D. Zlatopolskiy1,3, P. Krapf1,3, F. Zarrad1,2,
3, E. A. Urusova1,3, E. Kordys1,3, H. Endepols1,3, B.
Neumaier1,2,3; 1University Clinic Cologne, Cologne, GER-
MANY, 2Forschungszentrum Jülich GmbH, Jülich, GERMA-
NY, 3Max-Planck Institute forMetabolismResearch, Cologne,
GERMANY.
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Objectives: Recently two novel methods for the copper-
mediated aromatic nucleophilic radiofluorination of
(mesityl)(aryl)iodonium salts (MAI) and aryl pinacol
boronates (ArBPin) were published. Evaluation of these
methods revealed that although both showed high efficacy in
small scale experiments, they were inoperative for PET tracer
production on a clinical scale. The aim of this work was the
development of a versatile and practical procedure for the
preparation of PET tracers in a practical scale via Cu-
mediated radiofluorination. Methods: Cu catalysts were unsta-
ble under conventional strongly basic radiofluorination condi-
tions. Therefore, 18F- was eluted from an anion exchange resin
with only 0.06-0.1 mg K2CO3 in MeOH (“low base” condi-
tions). After removal of MeOH the residual [18F]KF/K222 or
18-crown-6 complex was redissolved in a solution of the
appropriate Cu-salt and the corresponding ArBPin or
iodonium salt precursor. The reaction mixture was heat-
ed for 20 min. Furthermore, the radiofluorination of
iodonium salts under “minimalist” conditions (no addi-
tion of base and cryptand, no azeotropic drying) was
examined. [18F]Fluoride was eluted from the anion ex-
c h a n g e r e s i n w i t h t h e c o r r e s p o n d i n g
(mesityl)(aryl)iodonium salt precursor in MeOH. The
solvent was evaporated, the residue taken up in a solu-
tion of (MeCN)4CuOTf in DMF and heated. Results:
[ 1 8F ]F luo robenzene , 4 - [ 1 8F ] f l uo roan i so l e and
3-[18F]fluorobenzaldehyde were obtained under “low ba-
se” conditions in RCCs of 26-56% (from MAI) and 41-
64% (from ArBPin), respectively. Under “minimalist”
conditions, the model compounds were prepared from
M A I i n R C C s o f 7 8 - 9 0 % . P r o t e c t e d
6-[18F]fluorodopamine and 4-[18F]fluorophenylalanine
were obtained in 71-94% RCCs. Subsequent hydrolysis
of the protected intermediates and HPLC isolation
afforded the clinically relevant PET tracers in RCYs of
46 and 66%, respectively. Additionally, [18F]DAA1106,
a promising tracer for visualization of neuroinflamma-
tion, was efficiently prepared in 60% RCY. The specific
activity of 4-[18F]FPhe and [18F]DAA1106 amounted to
109 GBq/μmol and 66 GBq/μmol starting from 49.5
and 2.4 GBq, respectively. Conclusion: A robust “low
base” protocol for the efficient copper-mediated prepara-
tion of [18F]arenes from diaryliodonium salts and aryl
pinacol boronates was established. Furthermore, we de-
veloped a novel radiofluorination method that combines
the advantages of “minimalist” approach to radiolabeling
with the exceptional capabilities of copper mediated ar-
omatic nucleophilic radiofluorination.
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[18F]DPA-714 as a biomarker for an early detection
with PET imaging of synovium inflammation
in osteoarthritis model
S. Pesnel1, F. Gimié1, V. Meneyrol1, G. Pottier2, S. Bénard1,
R. Boisgard2, F. Dollé2, E. Jestin1,3,4; 1GIP CYROI - RIPA,
Sainte Clotilde, RÉUNION, 2CEA, I2BM,SHFJ, IMIV UMR
1023 Inserm/CEA/Université Paris Sud /CNRS, Orsay,
FRANCE, 3INSERM, UMR1188 DéTROI, Sainte Clotilde,
RÉUNION, 4Université de la Réunion, Sainte Clotilde,
RÉUNION.
Aim: The purpose of this study was to assess the
[18F]DPA-714 as novel candidate PET tracer in osteo-
arthritis model. DPA-714 is a translocator protein
(TSPO) ligand. TSPO has been recognized as a bio-
marker for inflammatory diseases. It has been already
shown that TSPO ligands were promising radioligands
for targeting arthritis in an mBSA-induced arthritis
model in rats. Materials & Methods: Female Wistar rats
r ece ived a s ing l e in t r a - a r t i cu l a r in j ec t ion o f
monoiodoacetate (MIA) in the right knee to induce os-
teoarthritis (OA) lesions and sterile saline in the left
knee joint. The animals were scanned in vivo by
microPET/CT at 7, 14, 21 and 28 days post-injection
to assess the uptake of the tracer in the different stages
of the disease. For PET imaging, animals were injected
with 38 ± 5 MBq of [18F]DPA-714 and imaging started
45 minutes post-injection. In order to compare this trac-
er to the current tracers used in clinic: [18F]FDG and
[99mTc]oxidronate, the same study was repeated with
these 2 tracers. Histology study was performed to cor-
relate the uptake of [18F]DPA-714 to the presence of
TSPO and to assess the inflammatory process. Results:
The OA lesions were clearly visible on the CT images
from day 7 post-injection of MIA. For the 3 tracers the
uptake was more important in the right knee compared
to the left knee (control). An average increase in activ-
ity of 40% for the [18F]DPA-714, 8% for the
[99mTc]oxidronate and 7% for the [18F]FDG at day 7
was observed. This uptake increased with the severity
of the disease. The increase in activity was higher with
the [18F]DPA-714 than with the [99mTc]oxidronate and
[18F]FDG from day 7 to day 21. Conclusion: These
preliminary results demonstrate that [18F]DPA-714 can
be used to follow-up the inflammation in our OA mod-
el. Compared to the tracers used in clinic, this tracer
allows a better visualization of the disease in the early
stages of the disease. Currently a similar study is per-
formed on another model of arthritis (rupture of anterior
cruciate ligament in rats).
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Liposomal corticosteroid treatment of experimental
arthritis can be monitored non-invasively
with radiolabeled anti-FAP antibodies
T. van derGeest1, D. Gerrits1, J. M.Metselaar2,3, G. Storm2,4,
T. K. Nayak5, A. Freimoser-Grundschober6, C. Klein6, B.
Walgreen7, M. M. Helsen7, M. I. Koenders7, P. Laverman1,
O. C. Boerman1; 1Department of Radiology and NuclearMed-
icine, Radboud university medical center, Nijmegen, NETH-
ERLANDS, 2Department of Targeted Therapeutics, MIRA In-
stitute, University of Twente, Enschede, NETHERLANDS,
3Department of Experimental Molecular Imaging, University
Clinic and Helmholtz Institute for Biomedical Engineering,
RWTH-Aachen University, Aachen, GERMANY, 4Depart-
ment of Pharmaceutics, Utrecht Institute for Pharmaceutical
Sciences, Utrecht University, Utrecht, NETHERLANDS,
5Roche Pharmaceutical Research and Early development, In-
novation Center Basel, Basel, SWITZERLAND, 6Roche
Pharmaceutical Research and Early development, Innovation
Center Zurich, Schlieren, SWITZERLAND, 7Department of
Experimental Rheumatology, Radboud university medical
center, Nijmegen, NETHERLANDS.
Aim: Rheumatoid arthritis is a chronic autoimmune disorder
involving joint inflammation eventually leading to cartilage
destruction. Fibroblast activation protein (FAP) is highly
expressed by fibroblast-like synoviocytes in arthritic joints.
Therefore radioimmunoimaging with anti-FAP antibodies
might be an attractive non-invasive imaging tool to monitor
therapeutic interventions. Since treatment of arthritis often in-
cludes systemic or intra-articular administration of corticoste-
roids, we treated mice with collagen-induced arthritis (CIA)
with prednisolone containing long-circulating liposomes
(PLP-LCL) and investigated whether the efficacy of this treat-
ment could be monitored with radiolabeled anti-FAP antibod-
ies. Methods: CIA was induced in male DBA/1J mice. Mice
were treated with a single injection of 10 mg/kg PLP-LCL,
while the control group received empty LCL. To monitor the
therapeutic effect, SPECT/CT images were acquired 24 h after
injection of 99mTc-labeled HYNIC-conjugated anti-FAP anti-
body, 28H1, at 1, 4 and 9 days after treatment. After image
acquisition, mice were dissected to determine radioactivity
uptake in joints and uptake was correlated with themacroscop-
ic arthritis score. Results. Treatment of CIA with PLP-LCL
suppressed joint swelling. Already at one day after treatment
the macroscopic arthritis scores were decreased with 50%.
Scores further decreased to only 10% of the initial scores at
4 and 8 days post treatment. In contrast, macroscopic scores
increased up to 600% in untreated mice at 8 days. 99mTc-
HYNIC-28H1 showed strongly increased uptake in inflamed
joints as compared to non-inflamed joints. Uptake of 99mTc-
HYNIC-28H1 ranged from 1.5 %ID/g in non-inflamed joints
to 22.6 %ID/g in severely inflamed joints. Most importantly,
uptake of radiolabeled 28H1 in inflamed joints correlated with
arthritis score (Spearman’s ρ 0.67, p<0.0001) and increased
with severity of arthritis. Conclusions. SPECT/CT imaging
with the anti-FAP antibody specifically visualized arthritic
joints and tracer accumulation correlated with the severity of
the inflammation. We conclude that SPECT/CT with 99mTc-
HYNIC-28H1 can be used to accurately and noninvasively,
monitor the course of CIA in mice.
OP106
Tc-99m-CXCL8 SPECT to image disease activity
in inflammatory bowel disease
E. Aarntzen, D. De Jong, R. Hermsen, J. Drenth, O.
Bo e rman , W. Oyen ; Radboudumc , N i jmegen ,
NETHERLANDS.
Aim: Inflammatory bowel diseases (IBD) are defined as
chronic relapsing immune-mediated disorders of the gastroin-
testinal tract. IBD exacerbations are characterized by an exten-
sive recruitment of immune cells into the intestinal wall, which
may lead to severe tissue damage. The majority of activated
neutrophils are CXCL8-receptor positive. Considering the
chronic relapsing character of IBD, accurate and timely diag-
nosis of an exacerbation is pivotal for early adaptation of the
treatment and reduction of the disease burden. The gold stan-
dard is endoscopic evaluation, but is invasive and associated
with complications. We previously developed a Tc-99m-
labeled CXCL8 preparation with good imaging characteristics
of inflammation in preclinical models including colitis
[Rennen et al. JNM, 2003] and a clinical study [Bleeker-
Rovers et al. JNM, 2007]. Materials and methods: In this
study, we investigate the accuracy of Tc-99m-CXCL8 SPECT
to detect and localize disease activity in a prospective series of
patients with IBD. A total of 30 patients (17 Crohn’s disease,
14 Ulcerative colitis); disease episodes participated. Ninety-
two matched segmental Tc-99m-CXCL8/histology pairs and
72 matched segmental endoscopy/histology pairs were stud-
ied. Imaging was performed after injection of 400 MBq Tc-
99m-CXCL8 (protein dose: 5 μg/patient). Planar and SPECT
acquisitions of the abdomen were performed at 30 min and 4 h
after the injection. Results: Uptake of Tc-99m-CXCL8 in in-
testinal lesions was significantly increased during exacerba-
tions, as compared to scans performed during follow-up,
whereas uptake in bone marrow, spleen or liver remained con-
stant. On a per patient basis, sensitivity was 95% (95%CI 77-
99%) and 44% (95%CI 14-79. The positive predictive value
(PPV) and negative predictive value (NPV) was 81% (95%CI
61-93%) and 80% (95%CI 28-99%). The sensitivity and spec-
ificity on a per segment basis for the detection of colitis in-
flammation was 82% (95%CI 68-92%) and 72% (95%CI 57-
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84%), using histology as gold standard. The PPV and NPV
was 74% (95%CI 60-85%) and 81% (95%CI 66-91%). False
positive segments included ‘faint uptake’ in the ascending co-
lon (4 patients), pseudopolyps in the transverse colon (1 pa-
tient) and terminal ileum that could not be confirmed by his-
tology or endoscopy (1 patient). Conclusion: Tc-99m-CXCL8
SPECT provides a novel imaging technique to target neutro-
phil recruitment to the intestinal wall, which may be helpful to
assess moderate to severe exacerbations of IBD. Further vali-
dation studies are warranted to potentiate Tc-99m-CXCL8
SPECTas a biomarker to scale up or step down treatment with
immune modulating drugs in a personalized fashion.
OP107
Role of 18F-FDG PET/CT in the evaluation of response
to antibiotic therapy in patients affected by infectious
spondilodiscitis
F. Simone, A. Niccoli Asabella, D. Rubini, A. Notaristefano,
F. Iuele, G. Rubini; Nuclear Medicine Unit, D.I.M., University
of Bari “Aldo Moro”, Bari, Italy, Bari, ITALY.
Aim: to evaluate the usefulness of 18F-FDG PET/CT to detect
the early response to antibiotic therapy in patients affected by
infectious spondilodiscitis and to compare the role of 18F-
FDG PET/CT and MRI in post-treatment evaluation.Materials
and Methods: 15 patients (12 M, 3 F), with mean age 65±13
years old, with typical clinical symptoms of Infectious
Spondilodiscitis (pain, fever and increase of inflammatory in-
dexes) and confirmed by blood culture or vertebral biopsy
underwent within three day-interval a 18F-FDG PET/CT and
Magnetic Resonance (MR) at “baseline” and after antibiotic
therapy with Teicoplanine, Levofloxacine and Rifampicine.
Semiquantitative parameters at 18F-FDG PET/CT “baseline”
SUV max1, MTV1 and TLG1 and after therapy SUV max2,
MTV2 and TLG2 of involved vertebrae were calculated.
Follow-up period of at least three months was available for
all patients.T-student test for paired groups was performed to
compare baseline and after therapy 18F-FDG PET/CT semi-
quantitative parameters.Results: According to 18F-FDG PET/
CT parameters all patients showed a response to antibiotic
therapy. All patients were positive at “baseline” MR of the
spine, while at follow-up, 7/15 patients showed MR signs of
infection and were considered “positive”, and 8/15 showed
resolution of infectious condition and, therefore they were
considered “negative”. A statistical significant difference be-
tween 18F-FDG PET/CT “baseline” and after antibiotic ther-
apy was found for all semiquantitative parameters: SUV max
(t=5.8, p=0); MTV (t=2.66, p=0.02); TLG (t=4.53, p=0). The
comparison between the “baseline” and “after treatment” 18F-
FDG semiquantitative parameters showed a significative re-
duction of all parameters. This reduction was relevant also in
patients with positive post-treatmentMR. This bias is probably
due to the tissue remodelling in the very immediate phase post-
treatment, resulted positive at MR and negative at 18F-FDG
PET/CT. Clinical follow-up of at least three months confirmed
these results.Conclusions: 18F-FDG PET/CT is useful to de-
tect the early response to antibiotic therapy in patients affected
by infectious spondilodiscitis. 18F-FDG PET/CT semiquanti-
tative parameters provide critical diagnostic information of the
infectious process. 18F-FDG PET/CT should be considered as
first-line exam in the diagnosis of spondilodiscitis while MR
should be preferred for delayed evaluation.
OP108
The role of 18FDG-PET/CT for interim evaluation
of therapy response in spondylodiscitis
P. Ghedini1, C. Nanni1, I. Petri1, L. Zanoni1, I. Grassi1, S.
Cambioli1, D. Fiorenzo2, S. Fanti1; 1Nuclear Medicine, Uni-
versity Hospital S. Orsola-Malpighi, Bologna, ITALY, 2De-
partment of Diagnostic Imaging, University Hospital S.
Orsola-Malpighi, Bologna, ITALY.
Aim: The aim of this study is to examine the role of the 18F-
FDG-PET/CT in patients affected by spondylodiscitis and an-
alyzing new possible parameters to early evaluate therapy re-
sponse. Materials and Methods: We retrospectively enrolled
61 patients (21 female, mean-age 61) with diagnosis of
spondylodiscitis. Among the 61 patients, 11 had tubercular, 1
fungal and 49 pyogenic spondylodiscitis. All patients
underwent 18F-FDG-PET/CT baseline scan with determina-
tion of C-reactive protein (CRP) value and a second scan after
2-4 weeks of therapy. We analyzed SUVof both scans, delta-
SUV (SUV1-SUV2/SUV1) in comparison with CRP levels
during therapy. Furthermore we evaluated the volume of the
infection, that we named “metabolic infection volume” (MIV)
in the first and second scan. We selected a threshold of 50% of
Lesion SUV1-2 forMIV definition. Delta-MIV (MIV1-MIV2/
MIV1) were calculated and compared with SUV changes.
Lesion-to-liver (LLR) ratio, lesion-to-mediastinal ratio
(LBR), delta-LLR and delta- LBR after therapy were evaluat-
ed in every patients. Relationship between these different SUV
and MIV parameters with therapy response and clinical out-
come were investigated. Results: The mean SUVat diagnosis
was 9,7+/-3,3. The mean CRP level at diagnosis was 2,9+/-2,8
mg/dl. SUV1 was not correlated with the CRP1 level at diag-
nosis (p=0.6) and SUV2 was not correlated with CRP2
(p=0.71). In responders patients, SUV2 and CRP2 were sig-
nificantly lower than SUV1 and CRP1 (p<0.001 and p<0.0001
respectively). MIV2, LLR2 and LBR2 were also significantly
lower than MIV1, LLR1 and LBR1 (p<0.003). ROC curves
for delta-SUV showed a sensitivity of 87% and a specificity of
82% with a cut-off of 33%. ROC curves for SUV2 showed a
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sensitivity of 83% and a specificity of 46% with a cut-off of
5.0. ROC curves for CRP2 showed a sensitivity of 47% and a
specificity of 82% with a cut-off of 0.71 mg/dl. ROC curves
for delta-CRP showed a sensitivity of 82% and a specificity of
55%with a cut-off of 70%. OC curves for delta-LLR showed a
sensitivity of 88% and a specificity of 87% with a cut-off of
30%. Delta-MIV correlate with delta-SUV. Conclusions:
Delta-SUV provided a higher sensitivity and specificity in
responders patients. SUV2 provided significantly lower spec-
ificity. SUVparameters performed better than CRP level. MIV,
despite difficuties in its delineation, represented a possible
useful parameter in infection with high metabolism grade. Fi-
nally, LLR provided a significantly higher specificity, with
comparable sensitivity.
OP109
A Direct Comparison of 18F-FDG and 68Ga-DOTANOC
PET/CT for Detection of Cardiac Sarcoidosis: Diagnostic
Accuracy and Inter-observer Variability
L. C. Gormsen, A. Haraldsen, S. Kramer, W. Kim, P.
Borghammer; Aarhus University Hospital, AARHUS C,
DENMARK.
Aim: Cardiac sarcoidosis (CS) is a potentially fatal condition
resulting in increased risk of sudden cardiac death. Overall
survival in CS patients is substantially increased by corticoste-
roid therapy and correct diagnosis is therefore important. Un-
fortunately, no single test or imaging modality has acceptable
diagnostic accuracy and the CS diagnosis is still based on
insufficient clinical criteria. 18F-FDG PET/CT has previously
shown some diagnostic promise, but is hampered by physio-
logical glucose uptake in the myocardium. 68Ga-DOTANOC
binds to somatostatin receptors on inflammatory cells in sar-
coid granulomas. We compared the diagnostic accuracy of
68Ga-DOTANOC and 18F-FDG for diagnosing CS, and
assessed inter-rater agreement among three readers. Materials
and methods: 19 patients (7 female) with suspected CS were
prospectively recruited in the trial. 18F-FDG (5 MBq/kg) and
68-Ga-DOTANOC (3 MBq/kg) scans were performed 60 and
90minutes post injection, respectively, on a Siemens Biograph
64 scanner with <7 days between scans. Prior to 18F-FDG
PET, participants were instructed to fast for >12 hours. PET/
CT images were reviewed by three experienced nuclear med-
icine physicians. Studies were categorized as positive, nega-
tive, or inconclusive. In case of reviewer disagreement, final
PET diagnosis was based on majority decision. To assess di-
agnostic accuracy of both PET tracers, we used the established
reference standard based on CS criteria laid out by the Japa-
nese ministry of Health and Welfare combined with clinical
follow up. Inter-observer variability for both tracers was cal-
culated using Fleiss kappa for multiple observers and
trichotomous outcome. Results: Based on the reference stan-
dard, 3/19 patients suffered from CS, which was in line with
the expected proportion. 10/19 18F-FDG scans were rated as
inconclusive by consensus diagnosis rendering calculations of
diagnostic accuracy impossible. In contrast, accuracy was 100
% for 68Ga-DOTANOC based on the consensus diagnosis
among readers. Interestingly, Fleiss kappa was extremely poor
for 18F-FDG PET (combined kappa 0.11, NS) showing that
reviewers disagreed greatly in interpreting the images. Fleiss
kappa was somewhat better for 68Ga-DOTANOC (0.36,
p=0.001), which is fair agreement - but still demonstrates sig-
nificant inter-rater disagreement. Conclusion: Despite relevant
and recommended patient preparations, 18F-FDG PET/CT
images of the heart were extremely hard to interpret for signs
of CS resulting in disappointingly low concordance rates
among reviewers and correspondingly poor diagnostic accura-
cy. By contrast, 68Ga-DOTANOC PET/CT had excellent di-
agnostic accuracy with the caveat, that inter-observer variabil-
ity was significant. 68Ga-DOTANOC PET/CT looks promis-
ing as an alternative CS PET tracer with images preferably
reviewed by multiple readers.
OP110
Comparison between 18F-FDG PET/CT
and 99mTc-HMPAO-labelled leukocyte SPECT/CT in 50
patients with suspected osteomyelitis
P. Ferro1, G. Cusato1, S. Fiorino1, M. Spallino1, C. E.
Popescu2, R. Sara2, L. Conversano2, M.Milella2, C. Rossetti2;
1Università Milano-Bicocca, Milano, ITALY, 2Ospedale
Niguarda, Milano, ITALY.
Aim:Early diagnosis is crucial for the management of bone
infections and surrounding tissue involvement in suspected os-
teomyelitis. Several diagnostic tools are currently available ,
such as x-ray, CT, microbiological cultures, and serological
tests. Nuclear Medicine could be useful, with 99mTc-HMPAO
labelled leukocyte SPECT/CT (HMPAO-SPECT/CT) and 18F-
FDG PET/CT (FDG-PET/CT) scan.The aim of our preliminary
study was to evaluate and compare the clinical value of
HMPAO-SPECT/CT and FDG-PET/CT in the diagnosis of
bone infections.Methods:We retrospectively analysed 50 pa-
tients (29 males, 21 females, age range 24-84 years) with
suspected osteomyelitis who underwent both FDG-PET/CT
and HMPAO-SPECT/CT.Clinical symptoms, serological tests
(PCR values), CT scans and ongoing antibiotic therapy at the
time of the studies were analysed.FDG-PET/CT and HMPAO-
SPECT/CTwere considered “positive” or “negative” on agree-
ment of 3 independent observers on qualitative analysis of the
images; SUV max was measured in each detected lesion and
correlated to PCR levels.Final diagnosis of infection was based
on microbiological culture, serological tests (PCR) and clinical
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follow-up. HMPAO-SPECT/CT and FDG-PET/CT were com-
pared with each other considering separately bone and soft
tissue.Results:FDG-PET/CT showed higher values of sensibili-
ty (90 vs 44% in bone and 94 vs 59% in soft tissue), negative
predictive values (NPV) (83 vs 53% in bone, and 85 vs 52% in
soft tissue) and accuracy (88 vs 64% in bone and 88 vs 70% in
soft tissue) than HMPAO-SPECT/CT. On the contrary
HMPAO-SPECT/CT exams demonstrated better specificity
(95 vs 83% in bone and 94% vs 73% in soft tissue) and positive
predictive value (PPV) (93 vs 90% in bone tissue and 95 vs 89%
in soft tissue) (p<0,006).In 14/50 patients (28%) FDG-PET/CT
was positive whereas HMPAO-SPECT/CT was negative. All
these 14 patients were under antibiotic therapy during investi-
gations and their clinical history suggested a chronic process.We
observed a correlation between SUV max and PCR values:
SUV max was higher in patients with positive PCR levels
(SUV max 2,45-12,72 corresponding to PCR 2,3-17,6 mg/
dl).Conclusion:18F-FDG-PET/CT and 99mTc-HMPAO-
SPECT/CT scans are a reliable support tool for clinical and
serological data in the evaluation of patients with suspected
osteomyelitis, providing additional information on anatomic lo-
calization and extent of the infection processes. Either in bone
and soft tissue, FDG-PET/CT has proven to have higher sensi-
bility, accuracy and NPV while HMPAO-SPECT/CT shows
relatively higher specificity. 99mTC-HMPAO-SPECT/CT
could be less effective in patients with chronic disease and suf-
fered from the ongoing antibiotic therapy.
OP111
The added value of 18F-FDG PET for the staging
of patients with invasive fungal infections
A. O. Ankrah1,2, A. W. J. M. Glaudemans1, E. F. J. de Vries1,
R. H. J. A. Slart1,3, R. A. J. O. Dierrckx1, M.M. Sathekge2, H.
C. Klein4; 1Department of Nuclear Medicine and Molecular
Imaging, University Medical Center Groningen, Groningen,
NETHERLANDS, 2Department of NuclearMedicine, Univer-
sity of Pretoria, Pretoria, SOUTHAFRICA, 3Biomedical Pho-
tonic Imaging Group, University of Twente, Enschede,
NETHERLANDS, 4Department of Psychiatry, University
Medical Center Groningen, Groningen, NETHERLANDS.
18F-FDG PET has proven added value in many malignant dis-
eases, but its role in infectious diseases still has to be defined. It is
important to correctly stage invasive fungal infections at an early
time point to make proper clinical decisions, since fungal infec-
tions often occur in immunosuppressed patients, to whom the
infectionmay be life-threatening.The aim of this studywas there-
fore to determine the added value of 18F-FDG PET compared
with conventional imaging for the staging of patients with fungal
infections.Materials and methods- All patients with a proven
fungal infection who underwent a 18F-FDG-PET/CT between
October 2009 andDecember 2014were retrospectively included.
Fungal infection was proven by histology or cultures. All patient
dossiers were checked for infection parameters, clinical history,
and imaging procedures. All 18F-FDG-PET/CT scans were per-
formed on a Biograph mCT TOF system (Siemens) according to
the EARL guidelines. All PET findings were compared to the
findings based on all other imagingmodalities combined in order
to determine if 18F-FDG -PET/CT could provide more informa-
tion. The 18F-FDG-PET findings were also correlated to the in-
fection markers in the blood.Results- 9 males (32%) and 19
females (68%) between the ages of 6 months up to 75 years were
included. All the patients were immunocompromised, mainly
due to treatment of an underlying haematological malignancy
(64%) or organ transplantation (21%). Indications for the scans
included unexplained fever, determining the absence of fungal
infections before proceeding with stem cell transplant and in
some cases to determine other sites of fungal infections.In total,
18F-FDG-PET revealed 107 fungal infection lesions, compared
to 60 lesions detected by conventional imaging. The SUVmax of
all lesions was heterogeneous, varying from 1.14 To 17.86 (mean
5.36) 18F-FDG PET detected more lesions than conventional
imaging in 19 (68%) patients. The majority of these patients
had extra-thoracic disease. In 4 (14.2%) cases, 18F-FDG-PET/
CT noted disease activity where findings on other modalities
were equivocal. In total, 18F-FDG-PET/CT added diagnostic in-
formation in 23 patients (82%) which potentially could influence
clinical decisions. No correlation was found between the infec-
tion parameters and 18F-FDG-PET/CT findings.Conclusion- 18F-
FDG-PET/CT has significant added-value over conventional im-
aging in the initial evaluation of patients with invasive fungal
infections. The main added value is in finding lesions outside
the thoracic region. To our opinion, whole body 18F-FDG-PET/
CT accompanied by high-resolution CT scan of the chest should
be the imaging modality of choice in (suspected) fungal
infections.
409 - Sunday, October 11, 2015, 2:30 PM - 4:00 PM, Hall 8
Physics & Instrumentation & Data Analysis: Data Analy-
sis & Management I
OP112
Pixel-based Source Depth Measurement for Cerenkov
Luminescence Imaging
L. Altabella1, C. R. Gigliotti1, F. Boschi2, A. E. Spinelli1;
1San Raffaele Scientific Institute, Milano, ITALY, 2University
of Verona, Verona, ITALY.
Aim: Optical tomography represents a challenging problem in
optical imaging because of the intrinsically ill-posed inverse
problem due to photon diffusion. Cerenkov luminescence
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tomography (CLT) for optical photons produced in tissues by
several radionuclides (i.e.: 32P, 18F, 90Y), has been investigat-
ed using both 3D multispectral approach and multiviews
methods. Difficult in convergence of 3D algorithms can dis-
courage to use this technique to have information of depth
and intensity of source. For these reasons, we developed a faster
2D corrected approach based on multispectral acquisitions, to
reconstruct source depth and its intensity. Methods: Monte
Carlo simulations were developed using GAMOS plug-in for
GEANT4, validated for Cerenkov optical photon production as
well as optical photon transport. Experimental data were ac-
quired using IVIS SpectrumCT (Perkin Elmert, USA). We
scanned a capillary (1.0 mm diameter) filled with 0.5 MBq of
32P-ATP. Capillary was placed inside slices of chicken breast to
simulate tissue scattering. We considered three thickness of
chicken breast: 6, 9 and 11 mm. According to Beer Lambert
law we can derive the unknown source depth, using a pixel-
wise fit of several images acquired using different spectral filters
from 560 nm to 660 nm with a pass of 20 nm. More precisely
we fit radiance (p/sec/cm2/sr) in each location for all the images
as function of different μeff that depends on the filter wave-
length. Considering a two parameters linear fit of the intensity
logarithm, corrected both for theoretical Cerenkov emission
spectrum and for diffusive optical transport as implemented
by Coquoz, we derived a pixel-based depth source map and a
2D depth corrected intensity source map. Results and conclu-
sion: We obtained a pixel-based source depth reconstruction
with a maximum error in source region of 10% for 6 mm
source, and less than 3% for the deeper sources. Combining
depth information and source intensity, we can recognize and
discriminate source characteristics in terms of intensity. This is
particularly interesting in animal model with several tumor
masses. In these cases image acquired from animal sur-
face can mislead for example in presence of deeper but
more intense tumor. This work demonstrates that it is
possible to obtain reliable information concerning the
Cerenkov optical source using a 2D multispectral imag-
ing approach. Further developments of this work consist
of applying this method on in vivo studies.
OP113
Correcting for Patient Motion on a Solid State Multiple
Pinhole Dedicated Cardiac Camera
S. Redgate1, D. C. Barber2, J. W. Fenner2, A. Al-
Mohammad3, J. C. Taylor1, M. B. Hanney1, W. B. Tindale1;
1Nuclear Medicine, Sheffield Teaching Hospitals NHS Foun-
dation Trust, Sheffield, UNITEDKINGDOM, 2Medical Phys-
ics Group (Cardiovascular Science), University of Sheffield,
Sheffield, UNITED KINGDOM, 3Cardiothoracic Directorate,
Sheffield Teaching Hospitals NHS Foundation Trust, Shef-
field, UNITED KINGDOM.
Aim: Patient motion ≥13mm introduces artefacts into
myocardial perfusion images1. Procedure guidelines
recommend correction, which involves alignment of
the projections prior to reconstruction. Multiple pin-
hole cardiac cameras acquire data at all angles simul-
taneously, presenting the potential for 3D motion cor-
rection. The aim of this study was twofold: a) to per-
form simulations to determine the magnitude and du-
ration of motion that introduces significant motion
artefacts on this system and b) to develop a technique
for 3D motion correction and test this on patient stud-
ies. Materials and Methods: Phantom images were ac-
quired in the centre of the field of view and offset in
the X, Y and Z directions. These were used to simu-
late 5-20mm creep and step motion, with step dura-
tions of 30, 60, 90 and 180s. Qualitative assessment,
through blinded reporting and quantitative assessment
through calculation of the total perfusion defect
(TPD) was performed to identify motion artefacts
(TPD ≥5.5%). Motion correction was performed by
reframing the list mode data into a series of 30s im-
ages, reconstructing each frame and then registering
and summing these to produce a corrected image.
This was validated on images with simulated motion
and applied to images with no motion. Additionally,
forty patient studies were assessed for motion and the
motion correction algorithm was applied to studies
with significant motion. Results: Qualitative analysis
identified motion artefacts for ≥10mm motion. Quan-
titative analysis identified artefacts for ≥11mm 180s
step motion and >15mm creep motion. No artefacts
were identified for step motion with a 30s duration,
confirming that this is a suitable reframing duration
for motion correction. Motion correction visually re-
moved 9/10 motion artefacts on the phantom simula-
tions and reduced all the TPD values to ≤4%. When
applied to images with no motion there was no dif-
ference between the original and motion corrected im-
ages or TPD values. Two patients (5%) were identi-
fied as having significant superior-inferior patient mo-
tion and motion correction improved the appearance
of the anterior and inferior walls on these studies.
This is a retrospective analysis, but arguably it might
have changed patient management in a couple of
cases. Conclusion: Patient motion ≥10mm magnitude
and >30s in duration introduces significant motion
artefacts into myocardial perfusion images acquired
on a multiple pinhole cardiac camera. Motion correc-
tion, as described, successfully corrects for patient
motion artefacts in this study. Correction of patient
motion on this system has been shown to be techni-
cally feasible and accurate. 1. J Nucl Med,42(5)
4687-694
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OP114
Partial volume correction of Image Derived Input
Functions using a novel Single Target Correction
Technique
J. C. Dickson1, K. Erlandsson2, H. Sari2, S. Wan1, A.
Groves2; 1University College London Hospital NHS Founda-
tion Trust, London, UNITED KINGDOM, 2University
College London, London, UNITED KINGDOM.
Introduction: The move to non-invasive image derived input
functions (IDIF) in PET has been hampered by difficulties
correcting for partial volume effects (PVE) in the volumes of
interest used to produce the input functions. We have previ-
ously attempted to use Rubidium-82 PET to quantify perfu-
sion in colorectal cancer tumours [1]. In this paper we intro-
duce a novel single target correction (STC) technique [2], and
apply it to IDIF derived from dynamic Rubidium-82 PET im-
ages of the femoral arteries. Methods: Six patients with
suspected colorectal cancer were involved in this study. Each
had a dynamic Rubidium-82 PET scan and CT perfusion to
assess tumour perfusion. To define a volume of interest for the
IDIF and for partial volume correction, the femoral artery was
segmented from the CT perfusion scan. The dynamic PET data
was then registered to this VOI using a registration between
the CT perfusion scan and the CT scan for attenuation correc-
tion that was acquired for PET. With segmented vessel and
PET data in the same space, the STC partial volume correction
(PVC) technique was applied to the PET data. In essence, the
technique is an evolution of theMüller-Gartner method, which
uses true volume extent and an estimate of the Point Spread
Function (PSF) to correct the PET data. In this study we
used an experimentally derived PSF of 11.4mm
(FWHM). Changes to IDIF pre and post correction were
assessed by measuring the change at peak, where spill-
out factors are greatest; and in final PET frame where
spill-in factors play a larger role. The effect on values
of tumour K1 was also assessed. Results: The peak IDIF
uptake went up on average by a multiple of 2.80
[Range: 2.12-3.43] when partial volume correction was
applied. This is not unexpected given the PSF of Rubid-
ium PET and the typical diameter of femoral arteries. In
comparison, in the last frame where spill-in factors to
the IDIF become more of an issue the uptake increased
on average by a multiple of 1.40 (Range: 1.22-1.62]
with corrections applied. As a consequence, K1 is re-
duced on average by 65.43% [Range: 34.37-79.67] after
correction. Conclusions: PVC using a single target tech-
nique make substantial changes to the IDIF and estimat-
ed kinetic parameters. References: 1. Dickson J et al J
Nucl Med. 2014; 55 (Supplement 1):507 2.Erlandsson
K, Hutton B, J Nucl Med. 2014; 55 (Supplement
1):2123
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Voxel-level dosimetry with a grid-based Boltzmann solver
for patient-specific nuclear medicine dosimetry
J. Mikell1,2, F. Mourtada3, T. Wareing4, S. C. Kappadath1,2;
1UT MD Anderson Cancer Center, Houston, TX, UNITED
STATES, 2UT Graduate School of Biomedical Sciences,
Houston, TX, UNITED STATES, 3Christiana Care Health
System, Newark, DE, UNITED STATES, 4Varian Medical
Systems, Pala Alto, CA, UNITED STATES.
Aim: MIRD assumes uniform uptake at the organ level and
patient geometry based on anthropomorphic phantom geome-
try. Voxel-level dosimetry models are able to overcome these
shortcomings and provide patient-specific dosimetry. Full ra-
diation transport solutions that solve the linear Boltzmann
transport equation (LBTE) under patient-specific conditions
are considered to be more accurate. Deterministic grid-based
Boltzmann solvers (GBBS) are full transport solutions to the
LBTE in addition to Monte Carlo (MC) approaches. We have
validated GBBS Attila v8.0.0 with MC DOSXYZnrc for beta
and gamma sources in both homogeneous and heterogeneous
medium with clinically acceptable uncertainties. The aim of
this work is to implement GBBS for patient-specific voxel-
level nuclear medicine dosimetry and compare its performance
against MC. Materials and Methods: We investigated GBBS
using single time-point quantitative SPECT/CT for 90Y-glass-
microsphere HCC patient and 131I-NaI thyroid cancer patient
with lung metastases. The gold standard for voxel-level do-
simetry was MC. Tissue material and density were obtained
from CTwhile activity distribution was from SPECT. For 90Y
we calculated absorbed doses from only the 90Y beta spectra.
For 131I we simulated the auger+conversion electrons, beta
particle spectra, and gamma+x-ray spectra. To perform
patient-specific GBBS, the required tetrahedral mesh geome-
try was generated adaptively using tetgen v1.5.0. To control
the adaptation, a mesh-sizing function was generated based on
the activity, material, and gradient of the material distribution.
Mapping of material, density, and activity to tetrahedrons was
done using the nearest voxel centroid to the tetrahedron cen-
troid. The electron energy cutoff was 100 keV for 131I
(200 keV for 90Y) while the photon energy cutoff was 1
keV. Quantitatively, we compared mean, minimum, maximum
absorbed dose to tumors and normal tissues. Qualitatively, we
compared dose-volume histograms (DVH) and line profiles
through tumors. Results: GBBS for 90Y took 38s, while the
I131 took 606s (208s for auger+conversion electrons, 94s for
beta, and 304s for gamma+x-ray component). For 90Y the
GBBS mean and maximum absorbed dose to tumor and nor-
mal liver were within 2.3% ofMC. For total I131 the mean and
maximum absorbed dose to tumors were within 4.3%; mean
and maximum doses to left and right lung were within 3% and
7.6%, respectively. Line profiles of voxel-doses through
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tumors and DVHs visually agreed well between GBBS and
MC. Conclusion: GBBS with adaptive meshing provides
patient-specific nuclear medicine dosimetry with accuracy
comparable to MC and computation speeds suitable for rou-
tine clinical practice. Grant support NIH/NCI R01 CA138986.
OP116
FDG-PET/CT of Bronchial Carcinoma
Under Neoadjuvant Chemotherapy: Background Based
Adaptive Volume Metrics Outperform TLG and MTV
in Predicting Therapy Response
I. A. Burger1, R. Casanova1, S. Steiger1, P. Stolzmann1, M.
W. Huellner1, P. Veit-Haibach1, A. Soltermann1, C. R.
Schmidtlein2; 1University of Zurich, Zurich, SWITZER-
LAND, 2Memorial Sloan Kettering Cancer Center, New York,
NY, UNITED STATES.
Purpose: Tumor response assessment to chemotherapy using
FDG PET metrics is gaining acceptance. The most common
PET metric is maximum standardized uptake value (SUVmax).
However, several studies have suggested that the metabolically
active tumor volume (MTV) or the total lesion glycolysis (TLG)
are superior for assessing tumor burden and probably also re-
sponse to therapy. The optimal method for defining MTV and
TLG is still controversial; initially all voxels with FDG activity
above 42% of SUVmax were used. Recently we have suggested a
method that adapts to the local background to determine the
background subtracted lesion activity (BSL) and the background
subtracted volume (BSV). It was the aim of our study to investi-
gate the correlation between PETmetrics and therapy response in
non-small cell lung carcinoma (NSCLC). Patients and Methods:
Forty-six NSCLC patients were retrospectively identified, the
PET/CT data before and after neo-adjuvant chemotherapy were
analyzed regarding SUVmax, MTV, TLG, BSL and BSVon both
scans and the relative changes were calculated. The tumor regres-
sion grade (TRG) as an indicator of tumor response was assessed
onH&E stained sections of the corresponding surgical specimens
using a 4-tiered scale. TRG was correlated with the relative
change of all PET metrics using Spearman rank test. Results:
Both the change in tumor size and SUVmax did correlated
with the TRG with p = 0.038 and p < 0.001, respec-
tively. The PET volume metrics based on a fixed thresh-
old of SUVmax did not correlate with TRG (TLG: p =
0.389 and MTV: p = 0.420). However, both background
activity based PET volume metrics BSL and BSV sig-
nificantly correlated with TRG (p = 0.001 for both).
Conclusion: Volume based PET metrics using a fixed
threshold (42% SUVmax) for delineation did not corre-
late with TRG. However tumor regression correlated
well with SUVmax and both background based PET vol-
ume metrics BSL and BSV.
OP117
Automated organ segmentation in pre-clinical 4D PET/CT
images
C. Maaß1, J. Avelar Rivas1, A. A. Attarwala1, B. Abualhaj1,
S. Niedermoser2, C. Wängler3, G. Glatting1; 1Medical Radia-
tion Physics/Radiation Protection, Medical Faculty Mann-
heim, Heidelberg University, Mannheim, GERMANY, 2Mo-
lecular Imaging and Radiochemistry, Department of Clinical
Radiology and Nuclear Medicine, Medical Faculty Mann-
heim, Heidelberg University, Mannheim, GERMANY, 3Bio-
medical Chemistry, Department of Clinical Radiology and Nu-
clear Medicine, Medical Faculty Mannheim, Heidelberg Uni-
versity, Mannheim, GERMANY.
Aim: Treatment planning in molecular radiotherapy relies on
the estimation of time-activity curves [1]. To provide an opti-
mal therapy, this estimation needs to be accurate and reproduc-
ible (observer independent).The aim of this work was (1) to
implement an algorithm for the automated segmentation of
relevant structures (tumour, organs at risk) in pre-clinical 4D
PET/CT images and (2) to determine the optimal number of
clusters.Materials and Methods: Biodistribution of 18F-
SiFalin-PEG1-TATE [2] in six AR42J tumour bearing mice
was obtained from a preclinical PET/CT (Bruker BioSpin
MRI GmbH, Ettlingen, Germany). This tracer binds specifi-
cally to the somatostatin receptor subtype 2, which is
overexpressed in neuroendocrine tumours.An in-house soft-
ware for automated organ segmentation of 4D PET/CT images
was implemented in MATLAB (R2014b, MathWorks, Natick,
Massachusetts, USA). This algorithm clusters time-activity
curves voxelwise using k-means. The optimal number of clus-
ters depends on the region and was determined by minimising
(1) the Calinski-Harabasz-criterion (ratio of within to outer
cluster variances) and (2) the relative deviation (RD) between
clustered and actual organ volumes. Clustered organ volumes
were calculated by summing up all clusters within an
organ.Reproducibility of the algorithm was tested by deter-
mining both the optimal number of clusters and the time-
activity curves five times for tumour and kidneys (averaged
over six mice).Accuracy of the algorithm was evaluated by
comparing clustered organ volumes and manually drawn vol-
umes to actual organ weights.Results: The mean numbers of
optimal clusters were (1) 10±2 and 4±1 and (2) 7±3 and 9±2
for tumour and kidneys, respectively.RDs of the manually
drawn and actual tumour and kidney volumes were (-1
±54)% and (-17±14)%. RD of the clustered and actual vol-
umes was for tumour and kidney (1) (-37±38)% and (-10
±19)%, (2) (0±6)% and (3±4)%.Conclusion:Automated organ
segmentation of 4D pre-clinical images is reproducible and
observer independent. The optimal number of clusters is cru-
cial and can be determined using the presented method (2).
Thus, an accurate and automated determination of time-
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activity curves is possible.Literatur:1.Glatting G, Bardies M,
LassmannM. Treatment planning inmolecular radiotherapy. Z
Med Phys. 2013;23(4):262-9.2.Wängler C, Niedermoser S,
Chin J, Orchowski K, Schirrmacher E, Jurkschat K, et al.
One-step 18F-labeling of peptides for positron emission to-
mography imaging using the SiFA methodology Nature Pro-
tocols. 2012;7:1946-55.
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Does Reducing Reconstruction Voxel Volume / Increasing
Matrix Size Improve Lesion Detectability? A phantom
and clinical feasibility demonstration using next
generation digital PET/CT
J. Zhang1, K. Binzel1, C. Wright1, V. Nagar1, P. Bardos1, P.
Maniawski2, M. V. Knopp1; 1The Ohio State University, Co-
lumbus, OH, UNITED STATES, 2Philips Healthcare, Cleve-
land, OH, UNITED STATES.
Aim: The replacement of the photomultiplier with a solid state,
digital photon counting detector is a technological leap that
leads to higher photon counting rates, less dead time and im-
proved dose response linearity. PET has traditionally used
comparatively to CT and MRI smaller reconstruction matrix
and thus larger voxel volumes. This study investigates if lesion
detectability can be improved by larger matrix reconstruction
of phantoms and in clinical oncologic PET/CT.Materials and
methods: A Philips Vereos TF 64 digital PET/CT (Cleveland,
OH) was used for NEMA and Jaszczak phantom acquisitions
as well as in 20 clinical patients referred with suspected ma-
lignancies. Clinical whole body PET scans were acquired after
average injection of 480 MBq 18F-FDG with 90s per bed
position, 40% overlap and a 576mm FOV. Images were recon-
structed in 144x144 matrix with voxel volume of 4 x 4 x 4 (64)
mm3, 288x288matrix with voxel volume of 2 x 2 x 2 (8) mm3
voxel volume, and 576x576 matrix with voxel volume of 1 x 1
x 1 (1) mm3. All three reconstructed image data sets were
assessed by comparative analysis using two independent
readers. Lesion detectability as well as confidence of diagnos-
tic relevance was assessed, however only lesions of >2cm in
unidimensional diameter on CT included. The phantoms were
evaluated against the known parameters and the recovery co-
efficients calculated.Results: Image quality of all data sets and
reconstruction volumes was classified as satisfactory. 48 le-
sions are included in this evaluation, all of them visualized
on the largest reconstruction matrix. 11 lesions were only con-
fidently detected on the 1 mm3 voxel reconstructed images. 13
lesions were first visualized on the 2 mm3 voxel and also seen
on the 1 mm3 but not on the 4 mm3 voxel reconstructed
images. Overall, readers consistently rated the 288 matrix im-
ages to be preferable over the 144 matrix images. The 576
matrix images were rated on average 38% more preferable
than the 288 matrix images and equivalent to the 288 matrix
in all remaining cases. The 1 mm3 voxel reconstructed phan-
tom data presented consistently the best recovery
coefficient.Conclusion: Larger matrix size / reduced voxel vol-
ume reconstruction substantially improved clinical lesion de-
tectability and on phantom scans calculated recovery coeffi-
cients. The improved counting capabilities of the digital detec-
tor system appears to enable a consistent utilization of larger
reconstruction matrix that was shown to improve lesion detec-
tion by substantially reducing partial volume effects.
OP119
A New Statistical Model For Quantifying Tumor
Heterogeneity in Emission Tomography
J. Varga1, A. Forgács2,1; 1University of Debrecen, Debrecen,
HUNGARY, 2ScanoMed Ltd., Debrecen, HUNGARY.
Beside biological heterogeneity, the scatter of voxel values in a
tumor volume is also influenced by partial volume effect
(PVE) and noise. The smaller the object, the contribution of
PVE is more significant. We propose a procedure to separately
access the significance of biological heterogeneity. Methods:
We estimate a homogeneous tumor volume that - after convo-
lution with the PSF - would best approximate the observed
distribution in a neighborhood of the tumor. We alternatingly
estimate the tumor mask, and the tumor and background
levels. We statistically test the null hypothesis that the variance
inside the tumor volume in the difference image (observed -
homogeneous distribution blurred) is fully explained by noise.
An F-test is applied to the ratio of observed and expected
variances (based on a reference area), with corrected degrees
of freedom taking into account that neighboring pixels are
correlated. First we tested the algorithm on 2-dimensional
slices of simulated and phantom data. Our simulation data
consisted of rings with 2 to 16 pixels external radius (4 mm/
pixel), and internal radius half of that. Ring to background
activity ratio was 4. Poissonian random noise with variation
coefficient of 0.3, 1, 3, 10, and 30% was added to each,
resulting in 40 simulated images. For the phantom PETstudies
we used (a) the IEC body phantom containing 6 fillable
spheres (diameters: 10, 13, 17, 22, 28 and 37 mm). The
sphere-to-neighborhood activity ratio was 10. (b) A special
heterogeneous phantom consisted of seven 2 mL syringes, 2-
3-2 of them filled with different concentrations of C-11, im-
mersed in F-18-labeled water. 12 images were acquired
through 60 min, resulting in “tumor” max / background ratios
from 16 to 8. Results: The method failed to identify heteroge-
neity at 30% error level in case of the 4 smallest simulated
rings (r=2⋯8 pixels), and at 10% error level just the smallest
one; the rest showed significant departure from homogeneity.
All but the smallest sphere resulted in p>0.05 (keeping the
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hypothesis of homogeneity). The tumor-to-background ratio
from the model showed degraded contrast recovery only for
the 2 smallest spheres. The heterogeneous phantom showed
strongly significant heterogeneity at all contrast levels. Discus-
sion: Our model tests object heterogeneity separately from
partial volume effect and noise; thus it should be applicable
to smaller objects than direct measures of region variance. An
additional benefit is a robust estimation of tumor activity level,
offering an objective parameter for follow-up studies.
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Relationship Between Coronary Artery Calcium Score
and Coronary Flow Reserve in Patients Evaluated
for Coronary Artery Disease: a Hybrid Rb-82 PET/CT
Imaging Study
E. Zampella1, P. Arumugam2, R. Assante1, D. Tout2, V.
Gaudieri1, C. Nappi1, T. Mannarino1, M. Panico3, S. Daniele3,
W. Acampa3, M. Petretta4, C. Tonge2, A. Cuocolo1; 1Depart-
ment of Advanced Biomedical Sciences, University of Naples
Federico II, Naples, ITALY, 2Nuclear Medicine Centre, Cen-
tral Manchester University Teaching Hospitals, Manchester,
UNITED KINGDOM, 3Institute of Biostructure and
Bioimaging, National Council of Research, Naples, ITALY,
4Department of Translational Medical Sciences, University
of Naples ‘Federico II’, Naples, ITALY.
Aim: Limited data are available on the value of coro-
nary artery calcium (CAC) to predict myocardial blood
flow (MBF) impairment and coronary vasodilator dys-
function. We assessed the relationship between CAC
score, hyperemic MBF and coronary flow reserve
(CFR) in patients without known coronary artery disease
(CAD) undergoing hybrid Rb-82 PET/CT imaging. Ma-
terials and Methods: We evaluated 637 (age 58±13
years) consecutive patients without a documented history
of CAD referred to myocardial perfusion imaging due to
presence of multiple cardiac risk factors or risk assess-
ment before general surgery. All patients were studied
by vasodilator stress Rb-82 PET/CT and CAC scoring.
The CAC score was measured according to the Agatston
method. Resting and hyperemic MBF and CFR were
automatically quantified. Patients were stratified into
four groups based on their CAC score (0, 0.01-99.9,
100-399.9 and ≥400). Perfusion measurements were
compared across levels of CAC score using one-way
analysis of variance (ANOVA). The Spearman correla-
tion coefficient was assessed between continuous CAC
score and MBF or CFR. Univariable and multivariable
logistic regression analyses were used to determine the
variables associated with reduced (<2) CFR. Results:
Patients had a global resting MBF of 1.18±0.39 ml/
min/g. During hyperemia, MBF increased to 2.74±0.80
ml/min/g (p<0.001 vs. resting). CFR averaged 2.46
±0.73. CAC score was 0 in 305 (46%) patients. Of
those with CAC >0, the score was 0.01-99.9, 100-
399.9 and ≥400 in 21%, 15% and 18% of patients,
respectively. Global CAC score showed significant in-
verse correlation with hyperemic MBF and CFR (both
p<0.001). No correlation was found between CAC score
and baseline MBF (p=0.611). At ANOVA, among the
four CAC groups, hyperemic MBF (2.97, 2.69, 2.74
and 2.23 ml/min/g) and CFR (2.67, 2.44, 2.38 and
2.00) significantly decreased (both p<0.001) with in-
creasing CAC levels. Differently, a comparable global
resting MBF among the four CAC groups was observed
(p=0.287). At univariable analysis age (p<0.001), diabe-
tes (p<0.001), family history of CAD (p<0.05), hyper-
tension (p<0.05) and CAC score (p<0.001) displayed an
inverse relationship with CFR. At multivariable analysis
only age (p<0.001), diabetes (p<0.001) and CAC score
(p<0.05) were independently associated with reduced
CFR. Conclusions: In patients without known CAD
there is a significant relationship between hyperemic
MBF and CFR, and the extent of CAC. Noteworthy,
diabetes and CAC score independently predict a CFR
reduction. These results suggest that CAC score pro-
vides incremental information about CFR over
established CAD risk factors in patients with suspected
CAD.
OP121
Low-dose relative and quantitative myocardial blood flow
imaging using 82Rb-PET
C. M. Hoff, E. Dul, L. P. Tolbod, H. J. Harms, K.
Bouchelouche, J. Frøkiær, J. Sørensen; Aarhus University
Hospital, Department of Nuclear Medicine & PET-Centre,
Aarhus, DENMARK.
Aim: Relative and absolute measures of myocardial
blood flow (MBF) are derived from a single 82Rb
PET/CT scan using list mode data to extract static, gated
and dynamic PET series. However, due to the short half-
life of 82Rb (76s), high doses of 82Rb (>1100 MBq)
are used in order to maximize image quality of the static
images. Such high doses challenge scanner dead time
performance and require a large eluate volume (20-40
mL) to be infused into the patient. The aim of the cur-
rent study was to examine MBF with a low dose (LD)
82Rb protocol compared to the institution’s standard
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higher dose (HD) protocol.Methods: Nineteen patients
referred to 82Rb PET were included in the study. Pa-
tients were examined during rest and stress with repeat-
ed LD and HD dose Rb-PET. We excluded four patients
due to motion artifacts. Mean HD dose was 1137 MBq
(range 1065-1187 MBq) and mean LD dose 347 MBq
(range 269-449 MBq). Regional and global rest and
stress MBF values, total perfusion deficit (TPD), ejec-
tion fraction (EF) and %-perfusion using the 5-segment
model were calculated using commercially available
software QPET (Cedars Sinai).Results: Mean segmental
MBF (±SD) at rest was 1.09±0.32 and 1.18±0.30 mL/g/
min, p=0.001 at LD and HD, respectively. At stress
MBF was 2.30±1.00 and 2.48±1.17 mL/g/min,
p=0.0007 at LD and HD, respectively. There was good
correlation between LD and HD segmental MBF
(LD=0.85xHD+0.14, R2=0.9, p<0.001). Mean global
MBF at rest was 1.09±0.29 and 1.18±0.28 mL/g/min,
p=0.14 at LD and HD, and at stress 2.26±0.96 and
2.43±1.14 mL/g/min, p=0.08 at LD and HD, respective-
ly. Again good correlation between LD and HD global
MBF. (LD=0.86xHD+ 0.13, R2=0.9, p=0.02).Mean TPD
with HD patients was 1.86±2.57% and 2.44±2.71% with
LD patients. Correlation between LD and HD TPD was
LD=0.92xHD+0.73, R2=0.77, p=<0.0001. Mean percent-
age perfusion with HD was 75.4±7% and 71.7±7.6%
with LD patients. Correlation between LD and HD %-
perfusion was LD=0.90xHD+3.79, R2=0.69, p<0.0001.
Mean EF with HD patients was 65±10% and 61±11%
in LD patients with a good correlation. (LD=0.93xHD+
0.85, R2=0,76, p=0,001).Conclusion: Excellent correla-
tion between reduced dose and standard dose was found
for absolute MBF. Correlation was still good for EF,
TPD and %perfusion with LD being roughly 1/3 of
the institutions standard dose. However, due to the in-
creased image noise at LD, relative measures exhibited
more scatter, potentially decreasing sensitivity.
OP122
Attenuated Coronary Flow Reserve Early
after Implantation of a Bioresorbable Vascular Scaffold:
one-month results of the VANISH-trial
W. Stuijfzand, R. Driessen, P. Raijmakers, A. Lammertsma,
A. van Rossum, Y. Appelman, J. Lemkes,M. van Leeuwen, N.
van Royen, P. Knaapen; VU University Medical Center, Am-
sterdam, NETHERLANDS.
Background: The bioresorbable vascular scaffold (BVS) may
facilitate restoration of normal coronary physiology after re-
sorption of the scaffold. Conversely, early after BVS implan-
tation the mean luminal area is decreased in comparison with
conventional metal stents due to bigger strut thickness which
may impact coronary flow reserve (CFR). Therefore, a
randomised clinical trial of BVS vs. metal drug eluting stent
(DES) was initiated, utilizing positron emission tomography
(PET) perfusion imaging to assess (hyperemic) myocardial
blood flow (MBF) and CFR over a three year period (VAN-
ISH-trial). These are the one-month results of the ongoing
VANISH-trial to investigate MBF and CFR early after BVS
vs. DES implantation. Methods: Sixty patients (45 men (75%),
55 ± 7 years) with a documented single vessel type A or B1
lesion, either stable or unstable angina without biochemical
signs of myocardial infarction, were included in this single
blind randomized clinical trial. Patients were randomized to
implantation of a DES or BVS (Xience Prime or ABSORB,
respectively) in a one-to-one fashion. Approximately 1 month
after percutaneous coronary intervention patients underwent
H2
15O PET to assess (hyperemic) MBF and CFR. Results:
Lesions were predominantly located in the LAD (n=36,
60%) and less frequently in the RCA (n=14, 23%) or Cx
(n=10, 17%). One patient refused PET perfusion at 1
month follow-up (DES arm). Mean rest and hyperemic
MBF of the treated vascular territory were 0.99 ± 0.26
and 3.18 ± 0.79 mL·min-1·g-1, respectively. MBF of the
treated myocardial territory during rest and hyperemia of
DES was comparable with the BVS arm (0.96 ± 0.24
vs. 1.02 ± 0.28 mL·min-1·g-1, p=0.38, and 3.33 ± 0.77
vs. 3.04 ± 0.80 mL·min-1·g-1, p=0.16, respectively). CFR
of the treated territory was significantly lower in the
BVS arm compared to DES (3.09 ± 0.94 vs. 3.57 ±
0.85, p<0.05). No differences in (hyperemic) MBF and
CFR were documented in remote areas between treat-
ment arms. Conclusions: CFR is slightly attenuated one
month after implantation of a BVS compared with a
DES, which may be related to the increased dimensions
of bioresorbable scaffold material as compared with
metal.
OP123
Measurement of left ventricular volumes and function
using oxygen-15 labelled water gated positron emission
tomography: comparison with cardiovascular magnetic
resonance imaging
R. S. Driessen, J. Van Timmeren, W. J. Stuijfzand, M. T.
Rijnierse, I. Danad, P. G. Raijmakers, A. M. Beek, A. C. Van
Rossum, A. A. Lammertsma, H. J. Harms, M. C. Huisman, P.
Knaapen; VU University Medical Center, Amsterdam,
NETHERLANDS.
Measurement of left ventricular volumes and function using
oxygen-15 labelled water gated positron emission tomogra-
phy: comparison with cardiovascular magnetic resonance
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imagingBackground: Positron emission tomography (PET)
myocardial perfusion imaging is used for the diagnosis of cor-
onary artery disease (CAD). Diagnostic and prognostic infor-
mation, however, benefits from an assessment of left ventric-
ular (LV) volumes and function. Recent developments in PET
technology have fulfilled the prerequisites for [15O]H2O PET-
derived LV function and dimensions. The aim of this study
was to explore the feasibility of evaluating LV function by
[15O]H2O PET using cardiovascular magnetic resonance im-
aging (CMR) as the reference technique.Materials and
methods: Fifty-seven subjects with a varying degree of LV
volumes and function were studied. LV end-diastolic volume
(LVEDV), LVend-systolic volume (LVESV), and LVejection
fraction (LVEF) were assessed using both ECG-gated first-
pass dynamic [15O]H2O PET and CMR. Intraclass correlation
coefficients (ICC) were determined for intraobserver and in-
terobserver variabilities.Results: PET derived LVEDV was
comparable with CMR (206 ± 71 vs. 212 ± 68 mL, respective-
ly; P = 0.13). However, LVESV was lower for PET (113 ± 67
vs. 127 ± 70 mL; P < 0.01), resulting in a higher LVEF (49 ±
14 vs. 44 ± 14%; P < 0.01). Correlations between PET and
CMR for LVEDV, LVESV, and LVEF were 0.93, 0.91, and
0.87, respectively (P < 0.01 for all). Interobserver ICC for
LVEDV, LVESV and LVEF was 0.97, 0.97 and 0.91, respec-
tively. Intraobserver ICC was 0.99, 0.98 and 0.85 for LVEDV,
LVESV and LVEF, respectively.Conclusion: It is feasible to
assess cardiac functional data using gated dynamic [15O]H2O
PET within the context of a routine quantitative myocardial
perfusion study, without increasing radiation exposure or
study duration. Good correlations with CMR and excellent
reproducibility were found across a widerange of LV volumes
and functions. However, PET slightly underestimated LVESV,
yielding an augmented LVEF as compared with CMR.
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Gated PET-measured cardiac synchrony correlates
with QRS duration.
L. Juárez-Orozco1, R. H. J. A. Slart1, R. A. Tio1, H.
Boersma1, R. A. Dierckx1, A. Gonzalez-Monroy1, F. Iñarra-
Talboy2, E. Alexanderson2; 1University Medical Center Gro-
ningen, Groningen, NETHERLANDS, 2Instituto Nacional de
Cardiología “Ignacio Chávez”, Mexico City, MEXICO.
BACKGROUND: Gated PET myocardial perfusion repre-
sents a modern technique with state-of-the-art software for
assessment of stress myocardial blood flow (sMBF) and per-
fusion reserve (MPR). Additionally, it offers the possibility to
evaluate ventricular mechanical synchrony of contraction
through the Entropy (E) measurement. Interestingly, synchro-
ny has been previously studied although no current gold stan-
dard technique is available. The standard 12-derivation EKG
is considered useful to assess ventricular electrical synchrony
through the evaluation of the QRS complex. Its prolongation
(>120ms) has been considered in as criteria for guiding
resynchronization therapy. The present study aims to evaluate
the relationship between PET-derived ventricular E and the
EKG-measured QRS duration when sMBF and traditional car-
diovascular risk factors are taken into account. METHODS:
We retrospectively included 70 patients (54% males) who
underwent a rest and adenosine stress dynamic and 8-frame
gated 13N-ammonia PET scan without prior history of myo-
cardial infarction. A standard 12-lead resting EKG was ac-
quired for every patient at the time of the scan. Demographic
variables included gender, age, hypertension, type 2 diabetes
mellitus, dyslipidemia and smoking. MPR was calculated as
the ratio between sMBF and rest myocardial blood flow. En-
tropy was expressed as a percentage inversely proportional to
the uniformity of the ventricular contraction. The QRS com-
plex duration as the dependent variable was dichotomized as
normal or prolonged (cutoff 120 ms) and analyzed with a
multiple stepwise binary logistic regression model. Statistical
analysis was performed using SPSSv.20. RESULTS: Our pop-
ulation had a mean age of 63±10 years. There were 68% of
patients with hypertension, 60% with dyslipidemia, 14% with
diabetes mellitus and 54% with family history of cardiovascu-
lar disease. We documented a mean sMBF=2.09±0.64, mean
MPR=2.65±0.83 and mean E=43.8±8.9%. The logistic regres-
sion showed Entropy as a significant predictor for an enlarged
QRS complex (b=0.116 SE=0.050, OR=1.123 95% [1.018,
1.239], p=0.020). CONCLUSION: Gated PET derived phase
Entropy, as a measure for ventricular synchrony, is related to
the finding of a prolonged QRS complex in the standard EKG
when sMBF and coronary risk factors are taken into account.
This suggests that PET derived mechanical synchrony assess-
ment may be useful in further risk stratification. Further re-
search into its role for therapeutic is selection needed.
OP125
Stress-induced Systolic Dysfunction and Subendocardial
Ischemia in Left Ventricular Hypertrophy Patients With
Preserved Maximal Blood Flow in Ammonia PET
R. Sciagra, H. Castagnoli, F. Cipollini, R. Calabretta, S.
Passantino, I. Olivotto; University of Florence, FLORENCE,
ITALY.
Aim: Left ventricular (LV) ejection fraction (EF) decrease in
stress gated PET reveals ischemia. Patients with hypertrophic
cardiomyopathy (HCM) have abnormalities in myocardial
blood flow (MBF) due to microvascular dysfunction, but
whether these cause ischemia is uncertain. Owing to increased
wall thickness, subendocardial ischemia has been suspected,
but this could remain undetected if epicardial MBF is
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maintained. We assessed whether there is a relationship be-
tween LVEF decrease and abnormalities in subendocardial
MBF despite preserved maximal MBF in LV hypertrophy
patients.Materials and Methods: We studied 15 LV hypertro-
phy (maximumwall thickness 17 ± 5mm) patients undergoing
rest and stress (dipyridamole) 13NH3 gated PET because of
suspected HCM. Gated PET images were analyzed using
QGS,MBFwas assessed using the PCARDmodule of PMOD
software and a 17 segments scheme. Segmental endocardial
and epicardial MBF were evaluated using 13NH3 parametric
mapping. Transmural perfusion gradient (TPG) was defined as
endocardial MBF/epicardialMBF.Results: In all patients stress
MBFwas > 1.85mL/min/g tissue and myocardial flow reserve
> 2.5. There were 10 patients with unchanged or increased
LVEF after stress (G 1), and 5 with LVEF decrease (G 2).
Entire wall resting and stress MBF were not different between
the two groups (rest G 1: 0.85 ± 0.22 vs. rest G 2: 0.89 ± 0.11;
stress G 1: 2.72 ± 0.46 vs. stress G 2: 2.65 ± 0.54; all NS), so
resting endocardial (G 1: 0.83 ± 0.23 vs. G 2: 0.80 ± 0.11; NS)
and epicardial MBF (G 1: 0.67 ± 0.24 vs. G 2: 0.64 ± 0.17;
NS), and resting TPG (G 1: 1.31 ± 0.26 vs. G 2: 1.32 ± 0.28;
NS). Under stress, epicardial MBF remained comparable (G 1:
1.79 ± 0.56 vs. G 2: 1.82 ± 0.59, NS), but endocardial MBF
was lower in G 2 (G 1: 2.26 ± 0.66 vs. G 2: 2.03 ± 0.40, p <
0.0001) and TPG became significantly different: G1: 1.36 ±
0.36 vs. G 2: 1.22 ± 0.42, p < 0.02. The proportion of segments
with lower endocardial than epicardial MBF under stress was
significantly higher within G 2 than within G 1 patients (36%
vs. 16%, p< 0.001).Conclusion: In patients with LV hypertro-
phy suspected of HCM, but with apparently preserved stress
MBF, an abnormal LVEF response in stress gated PET was
accompanied by decreased stress endocardial MBF, a finding
that supports the notion of isolated subendocardial ischemia.
OP126
AQUA-5: Four Software Tools for 15O-Water PET
Myocardial Perfusion Quantification Exhibit Good
Intraobserver Reproducibility
S. V. Nesterov1,2, K. Yoshinaga3, Y. Tomiyama3, C. Han1, R.
Sciagrà4, V. Berti4, P. Knappen5, I. Danad5, J. M. Knuuti1;
1Turku PET Centre, Turku, FINLAND, 2Institute of Evolu-
tionary Biochemistry and Physiology, RAS, St. Petersburg,
RUSSIAN FEDERATION, 3Hokkaido University Graduate
School of Medicine, Sapporo, JAPAN, 4Nuclear Medicine
Unit of the University of Florence, Florence, ITALY, 5Depart-
ments of Nuclear Medicine and PET Research, of VU Univer-
sity Medical Center, Amsterdam, NETHERLANDS.
AIM. 15O-labelled water is considered the gold standard
for myocardial blood flow (MBF) quantification with
PET. Severa l sof tware too ls (SW) enable the
quantification; however, there are still no exhaustive
cross-comparison studies for these SW, needed to stan-
dardize the approach. In the AQUA-5 project, we aimed
to investigate several clinically important issues, and as
an initial step, we aimed to evaluate the intraobserver
reproducibility of MBF and myocardial flow reserve
(MFR) using existing SW. METHODS. Five tools-
Carimas, CardiacVUer, HOQUTO, PMOD, and Siemens
In-House Software-were studied using dynamic PET
scans (a hybrid 64-row Discovery VCT PET/CT scan-
ner) from 91 clinical patients. 15O-labelled water (900-
1100 MBq) was injected at rest; a stress scan was per-
formed using adenosine (140μg/kg/min). Experts used
one of the tools each to analyze global and regional
(LAD, LCx and RCA) MBF and MFR twice with at
least one week interval. We applied a custom linear
mixed model for the repeated measures to produce the
two agreement metrics-intraclass correlation coefficient
(ICC) and difference between the values from the
models-calculated pairwise. Differences below 20% of
median values with corresponding ICCs above 0.75
witnessed to good reproducibility. RESULTS. MBF-rest
and stress-was measured in mL/min/g, MFR and ICC
were unitless. CARIMAS. Global rest MBF (rMBF) -
0.00±0.07, ICC=0.95; stress MBF (sMBF) - 0.04±0.37,
ICC=0.94; MFR - 0.05±0.38, ICC=0.91. Regional rMBF
values ranged from 0.01±0.06 to 0.01±0.12, ICC: 0.90-
0.97; regional sMBF: 0.01±0.45-0.13±0.41, ICC: 0.92-
0.94. Regional MFR: 0.01±0.47-0.10±0.39, ICC: 0.85-
0.93. CARDIAC VUER. Global rMBF - 0.00±0.05,
ICC=0.97; sMBF - 0.01±0.15, ICC=0.98; MFR - 0.00
±0.21, ICC=0.96. Regional rMBF: 0.00±0.06-0.01±0.05,
all ICC values were 0.97; regional sMBF: 0.00±0.19-
0.02±0.17, ICC: 0.97-0.98. Regional MFR: 0.00±0.21-
0.01±0.24, ICC: 0.95-0.96. HOQUTO: Global rMBF -
0.05±0.31, ICC=0.66; sMBF - 0.18±0.97, ICC=0.58;
MFR - 0.01±0.95, ICC=0.96. Regional rMBF: 0.05
±0.34-0.96±8.56, ICC: 0.00-0.69; regional sMBF: 0.04
±1.33-0.18±1.27, ICC: 0.56-0.67. Regional MFR: 0.02
±1.10-0.15± 1.38, ICC: 0.46-0.54. PMOD: Global rMBF
- 0.00±0.07, ICC=0.97; sMBF - 0.09±0.46, ICC=0.83;
MFR - 0.04±0.38, ICC=0.90. Regional rMBF: 0.00
±0.08-0.01±0.09, ICC: 0.94-0.98; regional sMBF: 0.06
±0.43-0.11±0.55, ICC: 0.81-0.89. Regional MFR: 0.00
±0.40-0.06± 0.45, ICC: 0.88-0.90. SIEMENS IN-
HOUSE SW: Global rMBF - 0.09±0.15, ICC=0.85;
sMBF - 0.02±0.29, ICC=0.94; MFR - 0.15±0.36,
ICC=0.93. Regional rMBF: 0.04±0.08-0.11±0.18, ICC:
0.81-0.95; regional sMBF: 0.01±0.32-0.03±0.32, ICC:
0.93-0.96. Regional MFR: 0.10±0.36-0.17± 0.40, ICC:
0.93-0.94. CONCLUSION. The intraobserver reproduc-
ibility was good in four out of the five studied tools
for measuring MBF with 15O-water PET.
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OP127
Spill-over effect of radioactivity from right ventricular
cavity on septum in cardiac PET 15O-water study
C. Han; Turku University Central Hospital and University of
Turku, TURKU, FINLAND.
Purpose: In heart, ventricular septum separates the left and
right ventricles(LV and RV), implying that the spill-over ef-
fects from both sides should be considered in PET studies.
However, in cardiac PET perfusion analysis, the effect from
right ventricular radioactivity is not always corrected, leading
the loss of accuracy of modelling results in septum. This study
investigates the bias in perfusion estimation without RV spill-
over correction, based on human 15O-water studies and sim-
ulated data.Methods: Two 1-tissue compartment models for
15O-water study(Iida et al. 1989), with and without RV spill-
over correction (LV Model and LV_RV Model), have been
implemented in Carimas (a PET data analysis package devel-
oped in Turku PET Centre , Finland ht tp: / /www.
turkupetcentre.fi/carimas). In simulation study, time-active
curves (TAC) from left (LV) and right ventricular cavities were
taken from typical 15O-labelled water clinical studies. In LV_
RV Model, the myocardial ROI TAC was expressed as:
ROI(t)=Va_lv*LV(t)+Va_rv*RV(t)+alpha*C(t), where Va_lv
and Va_rv are spill-over fractions from LV and RV, re-
spectively, and alpha is perfusable tissue fraction. 100
15O-water PET perfusion patient data were analyzed
using two models.Results: In patient data, septal perfu-
sion was found to be reduced 17.3% without RV spill-
over correction, meanwhile, lateral segments had very
slight effect by RV radioactivity (0.9%). In simulation
study, RV was found to affect significantly the perfusion
estimation and this effect becomes bigger for higher
perfusion values and larger Va_rv. When ground values
of Va_rv=0.1, 0.15, 0.2, 0.25ml/ml, for ground flow val-
ue of 0.98 ml/g/min (as rest condition), estimated flow
values with LVModel were 0.94(-13%), 0.85(-20%), 0.
78(-27%) and 0.72(-33%) ml/g/min, respectively; for
ground flow value of 3.2 ml/g/min (as stress condition)
, estimated values with LVModel were 2.66(-17%), 2.
34(-27%), 2.07(-36%) and 1.84(-43%) ml/g/min, respec-
tively. Meanwhile, estimated flow values from LV_
RVModel were very close to ground values (er-
ror<2%).Conclusions: Based on patient data and simula-
tion, this study confirms that spill-over effect from RV
leads to severe underestimation of perfusion in septum,
unless correction is applied in the analysis tool.
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Imaging Infection in the HIV Positive
M. M. Sathegke, SOUTH AFRICA
OP129
Imaging Infection in the Immunosuppressed Patient
C. Bleeker-Rovers, NETHERLANDS
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Imaging Infection in the Post-Transplant Patient
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Hypoxia as Target for Cancer Therapy
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Imaging Hypoxia: Facts and Pitfalls
M. R. Horsman, DENMARK
OP133
Experience using Hypoxia Imaging in Clinical Trials
P. Lambin, NETHERLANDS
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OP134
Optimization of imaging following 223Ra administration
in targeted alpha-emitting radionuclide therapy of bone
metastases.
N. Benabdallah1, M. Bernardini2, C. de Labriolle Vaylet3, D.
Franck1, A. Desbrée1; 1IRSN, Fontenay aux Roses, FRANCE,
2Hôpital Européen George Pompidou, Paris, FRANCE,
3Hôpital Trousseau, Paris, FRANCE.
Purpose: With a growing demand of alpha-emitting ra-
diopharmaceuticals, especially Xofigo® (223RaCl2)
which is used in the treatment of metastatic bone dis-
ease, the optimization of dosimetry becomes necessary.
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Indeed, in Europe, as stated on the council directive
2013/59/euratom, exposures of target volumes for
radiotherapeutic purposes shall be individually planned
taking into account that doses to non-target volumes
and tissues shall be as low as reasonably achievable.
To personalize the dosimetry, patient images shall be
used. Nevertheless, less than 2% of the 223Ra emissions
are from photons. Therefore, the purpose of this study
was then to investigate the possibility of imaging 223Ra.
Methods: The experiments were conducted at the
Hopital Européen Georges Pompidou with an Infinia
Hawkeye 4 gamma camera, equipped with a medium-
energy collimator. Imaging parameters, such as sensibil-
ity, spatial resolution and energy spectrum, were deter-
mined using several physical phantoms with a source of
6 MBq of 223Ra. Bone metastases were modeled with a
NEMA Body Phantom to investigate image degradation
based on the concentration of 223Ra. Results: The ac-
quired energy spectrum allowed to visualize several pho-
ton peaks: at 85, 154 and 270 keV. Camera sensitivity
measured from the phantom study was 102.3 cps/MBq
for the 85 keV ± 20 %, 89.9 cps/MBq for the 154 ± 20
% window and 65.4 cps/MBq for the 270 ± 10 % win-
dow. The spatial resolution (full-width at half-maximum)
was respectively 1.7, 1.9 and 1.8 cm for the three ener-
gy windows. SPECT/CT images of NEMA Body Phan-
tom without and with attenuation have permitted to de-
termine the best reconstruction parameters. Conclusion:
This study has demonstrated that it is possible to obtain
clinically relevant information from images of 223Ra.
Al l these resu l t s wi l l be va luable to ana lyze
biodistribution imaging of the radiopharmaceutical in
the patient body and go further in the reconstruction of
patient images in order to personalize the dosimetry.
OP135
Progress of blood capacity under Radium-223 treatment
C. Körber, N. Körber-Hafner; Nuclear Medicine Fulda, Ful-
da, GERMANY.
AIM OF STUDY: Since some months Radium-223 (Xofigo,
Bayer Pharma AG, Berlin, Germany) is a rationale for the
treatment of castration-resistent metastatic prostate cancer (1)
The relevance of the irradiation on blood building is not yet
well investigated and could be a reason for the decline of blood
cells. We therefore investigated this effect on the blood levels
under therapy. METHOD: We have treated 10 patients so far
and investigated the blood levels of erythyrocytes, leucocytes
and thrombocytes under therapy, at the beginning and the end
of Radium-223 infusion as well as in all cycles of injection.
We compared the blood levels according to the level at the start
point. Furthermore other possible side effects we evaluated.
Statistical analyses were conducted with Statistica 10.0
(StatSoft). Two-tailed P values of less than 0,05 were consid-
ered to indicate statistical significance. RESULTS: The time
interval of investigation was between February 2014 and Feb-
ruary 2015. No severe side effects as nausea or vomiting could
be ruled out. The levels of leucocytes reduced between injec-
tion 1 and 2 (mean ± SD) 5,6 to 4,6 (p<0,08), between injec-
tion 1 and 3 p<0,1, between injection 1 and 4 p<0,01, between
injection 1 and 5 p<0,13, between injection 1 and 6 p<0,3.
Similar results were found for the parameters of erythrocytes
and thrombocytes, revealing a significant decline of blood
cells between injection 1 and 4, but no significant reduction
of the blood building capacity regarding injection 1 and 6.
DISCUSSION: The treatment of castration-resistent metasta-
tic prostate cancer is a save treatment option without severe
side effects as shown. The reduction of the blood building
regarding erythrocytes, leucocytes and thrombocytes are only
significant between the injection 1 and 4, but the blood levels
from start and end point after 6 injections show no significant
reduction. No participant of the treatment group had to be
excluded. Literature: Parker C. et al., Alpha Emitter Radium-
223 and survival in metastatic prostate caner, N Engl J Med
2013;369:213-223.
OP136
Feasibility and efficacy of 223Ra-dichloride in treatment
of bone metastases in patients with castration-refractory
prostate cancer (mCRPC)
s. mazzarri1, G. Boni1, E. Borsò2, L. Galli3, A. Farnesi4, F.
Betti1, L. Antonacci1, A. Traino5, S. Ricci4, D. Volterrani1;
1Regional Center Of Nuclear Medicine, University Hospital
Of Pisa, pisa, ITALY, 2Division of Nuclear Medicine,
Sant’Andrea Hospital of La Spezia, La Spezia, ITALY, 3On-
cology Division, University Hospital of Pisa, pisa, ITALY,
4Oncology Division,University Hospital of Pisa, pisa, ITALY,
5Health Physics Unit, Section of Medical Physics, University
Hospital, Pisa, Italy, pisa, ITALY.
Aim: To present the Tuscany single-centre experience about
the employing of the novel therapeutic radiopharmaceutical
223Ra-dichloride in the treatment planning of patients with
mCRPC. Method:Thirteen patients were treated from August
2013 to date. Five patients have been enrolled in the Bayer
Clinical Study 16216 and 8 have been treated as routine ap-
plication. Patients (age 67±8.4 yrs, median PSA 149.5 ng/mL,
excluding one case of neuroendocrine differentiation) received
223Ra-dichloride 50 kBq/kg i.v. on day 1 every 28 days for a
maximum of 6 cycles. Pre-treatment evaluations were made
using CT in order to exclude visceral metastases, and bone
scan. Patients have been evaluated at every cycle with
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complete blood chemistry (including serum ALP, PSA and
LDH), pain VAS score, quality of life questionnaire (FACT-
p), and analgesic consumption. The last group of patients
started the cure in March 2015. Results: At the current time-
point 13 patients received 72 cycles of 223Ra-dichloride. No
problems in vial manipulation, dose preparation and adminis-
tration occurred. A multidisciplinary team has followed pa-
tients during both screening and treatment period. Only 3 cy-
cles have been delayed (2 due to blood toxicity, 1 due to drug’s
manufacturing hitches) and 3 patients discontinued the treat-
ment (2 because of non reversible blood toxicity and anorexia,
and 1 because of hepatic disease progression). Regarding valu-
able clinical data, bone marrow toxicity resulted in G3 anemia
in 2 patients, G2 neutropenia in 2 patients, and G1 thrombo-
cytopenia in 1 patient. Anorexia G3 occurred in 3 patients,
while no case of diarrhoea was observed. Biomarkers response
showed median ALP decline of -50% and median LDH de-
cline of -5%. We observed mean PSA decline of -15%. One
patient who presented with superscan at baseline received
223Ra-dichloride 5 cycles before hepatic progression, show-
ing ALP levels decline of -89%, LDH -44% and PSA -48%.
According to VAS score and FACT-p, most of patients had
bone pain relief and reduced pain drugs intake. Conclusion:
Single-centre experience shows the feasibility and efficacy of
radiometabolic therapy with 223Radium-dichloride in patients
with mCRPC. Multidisciplinary careful evaluation of bone
marrow toxicity and gastrointestinal adverse events must be
carried out to optimize individual compliance. Palliative effect
allows decreasing pain drugs consume. The mild toxicity
could permit the use of 223Ra- dichloride in combination with
other treatments.
OP137
Metastatic control probability in patients with prostate
cancer metastatic to bone treated 186Re-HEDP
A. M. Denis-Bacelar1, A. Divoli2, S. Chittenden2, Y. Du2, G.
D. Flux2; 1Institute of Cancer Research, London, UNITED
KINGDOM, 2Royal Marsden Hospital, London, UNITED
KINGDOM.
Aim: The metastatic control probability model can be used to
estimate the impact of relevant factors on response to treat-
ment. Disease burden is of particular interest in patients with
castration-resistant prostate cancer (CRPC) metastatic to bone,
where the number and volume of bone lesions varies for each
patient. The aim of this study was to determine the metastatic
absorbed dose necessary to obtain a metastatic control proba-
bility of 0.9 in patients treated with molecular radiotherapy.
Materials and Methods: A cohort of 22 patients treated with
5 GBq of 186Re-HEDP from a phase II clinical trial was con-
sidered. Absorbed dose distributions were obtained using the
QriusTM dosimetry toolkit from quantified co-registered se-
quential SPECT scans of the thorax and pelvis. Bone lesions
were outlined using volume-dependent thresholds obtained
from phantom studies. Tumour control probabilities (TCP)
and biological effective doses (BED) were calculated for each
lesion using the linear-quadratic model. Radiobiological pa-
rameters for prostate cancer cells of α=0.12, α/β=1.5,
clonogenic cell density of 107 cm-3 and a repair half-time of
1.5 h were assumed for all patients. The metastatic control
probability (MCP) was determined as the product of the TCP
to each lesion. The metastatic absorbed dose (the mean of the
absorbed doses delivered to all lesions) necessary to achieve
an MCP of 0.9 was then determined from the delivered
absorbed dose distribution. Results: A total of 379 metastatic
bone lesions were outlined, with a median of 11 per patient.
The mean total volume of lesions was 228 ml (range 17 - 913
ml). The mean lesion volume per patient ranged from 6 ml to
57 ml. The range of metastatic absorbed doses delivered was 8
- 32 Gy. The metastatic absorbed dose to obtain anMCP of 0.9
ranged from 93 Gy to 589 Gy (mean 219 Gy). Conclusion:
Preliminary results show that the metastatic absorbed doses
required to achieve a high metastatic cure probability changes
significantly within the patient cohort studied. This indicates
the effect of the heterogeneous distribution of absorbed doses
delivered to multiple lesions, whereby the MCP is heavily
influenced by lesions with the lowest uptake.
OP138
A DOTA conjugated Zoledronic acid derivative: A novel
bone targeting theranostic compound
M. Meckel1, R. Bergmann2, W. Mohnike3, M. Miederer4, F.
Roesch1; 1University of Mainz, Mainz, GERMANY, 2Helm-
holtz Zentrum, Dresden-Rossendorf, GERMANY,
3Diagnostisch Therapeutisches Zentrum, Berlin, GERMANY,
4University Hospital, Mainz, GERMANY.
Aim of the study: Zoledronic acid proofed to have a high
affinity to calcified tissues and is commonly used in the treat-
ment of osteoporosis and bone metastases. A conjugate of
zoledronic acid with a macrocyclic chelator, labeled with
68Ga and 177Lu, opens new possibilities in bone targeted ra-
dionuclide imaging and therapy. Endoradiotheraphy with
177Lu-labelled macrocyclic bisphosphonates could have great
potential subsequent to PET examinations utilized with 68Ga-
labelled analogous in the treatment of painful skeletal metas-
tases, following the theranostics concept. Methods: We syn-
thesized a DOTA zoledronic acid conjugate (DOTAMZOL) and
labelled it with the PET-nuclide 68Ga, and the therapy nuclide
177Lu. The new bone targeting compound was evaluated in
in vivo small animal PET and SPECT and in ex vivo organ
distribution studies against [18F]NaF, 223RaCl2 and other
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DOTA bisphosphonates in healthy Wistar rats, followed by
first human applications in metastatic patients. Results: The
new ligands reached a RCY of 80 to 90% in 15 min with
68Ga. Af ter res in pur i f ica t ion the pur i ty of the
[68Ga]DOTAMZOL was higher than 98%. The tracers showed
low uptake in soft tissue, a fast renal clearance and a high
accumulation in bone (SUVFemur = 5.4±0.6). Labelling with
177Lu resulted in quantitative yields. [177Lu]DOTAMZOL
showed a superior target to background ratio compared to
223RaCl2. First applications in bone metastatic patients re-
vealed high accumulation in metastatic lesions. Conclusions:
The novel bone targeting compound DOTAMZOL showed a
promising uptake profile and a high target to background ratio.
The theranostic approach seems to be a promising concept for
the management of bone metastases in future.
OP139
Dosimetry Results of Lu-177-DKFZ-PSMA-617
Treatment in Castration Resistant Prostate Cancer
Patients
N. Yeyin1, A. Mohammad1, L. Kabasakal1, E. Demirci2, A.
Aygun1, M. Ocak3, T. Toklu4, H. Tanyildizi1, N. Selcuk4; 1De-
partment of Nuclear Medicine, Cerrahpasa Medical Faculty,
Istanbul University, istanbul, TURKEY, 2Department of Nu-
clear Medicine, Sisli Etfal Training and Research Hospital,
istanbul, TURKEY, 3Department of Pharmaceutical Technol-
ogy, Pharmacy Faculty, Istanbul University, istanbul, TUR-
KEY, 4Department of Nuclear Medicine, Yeditepe University
Medical School, istanbul, TURKEY.
Aim: The unique expression of PSMA provides an excellent
target for prostate cancer imaging and therapy using Ga-68 and
Lu-177 labeled PSMA ligands. Lu-177-DKFZ-617 PSMA li-
gand seems to be a promising tracer for radionuclide therapy in
patients with progressive prostate cancer. However, there are
no published data regarding the radiation dose given to the
normal tissues for the systemic therapy of Lu-177-DKFZ-
617 PSMA ligand. The aim of the present study was to esti-
mate the radiation doses in patients who underwent
radiomethabolic therapy. Methods and materials : The study
composed of 9 patients with progressive disease who
underwent Lu-177 PSMA therapy with a mean age of 62
±5.7 years. All patients had prior PSMA PET imaging and
had intense tracer uptake at the lesions. Patients received a
mean of 5.4±1.5 GBq, ranged from 3.3 GBq to 7.4 GBq Lu-
177-PSMA. To evaluate bone marrow absorbed dose 2 cc
blood samples were withdrawn in short variable times (3, 15,
30, 60, 180. minutes and 24, 48, 120. hours) after injection.
Further more whole body images were obtained at 4, 24, 48
and 120 hour after injection and in order to quantify the activ-
ity taken up in the body, kidneys, liver, right parotid and left
parotid, and over lesions. The geometric mean of anterior and
posterior counts were determined through ROI analysis, after
that background subtraction and attenuation correction were
applied using patients Ga-68-PSMA PET/CT images taking
into account. Organ thickness, body thickness and Hounsfield
unites from Computed Tomography scan. OLINDA/EXM do-
simetry program was used for curve fitting, residence time
calculation and absorbed dose calculations. Results: Calculat-
ed absorbed dose of bonemarrow, left kidney, right kidney, left
parotid, right parotid and total body were 0.08±0.0.03, 2.12
±0.66, 1.95±0.78, 2.88±1.83, 2.79±1.32, (Gy/3.7GBq) respec-
tively. For the liver, left and right lacrimal glands and whole
body radiation doses were 0.6±0.2, 6.2±3.9, 6.4±3.4 and 0.1
±0.04 (Gy/3.7 GBq) respectively. The estimated lesion doses
were ranged from 3.05 to 47.7 GY/3.7 GBq with a mean of
12.6±12.8 Gy/3.7GBq. Conclusions : Our first results sug-
gested that Lu-177 DKFZ-PSMA-617 therapy is a safe meth-
od, which can be given in 3 to 4 cycles of 7.4 GBq. The target
organ seems to be the parotid glands rather than kidneys and
bone marrow. The lesion radiation doses are within acceptable
ranges however there is a substantial individual variance so
patient dosimetry seems to be mandatory.
OP140
Peptide Radioligand Therapy (PRLT) Using Lu-177
Labeled DOTAGA-PSMA Inhibitor Yields Objective
Responses in Metastatic Castrate-resistant Prostate
Cancer
H. R. Kulkarni1, A. Singh1, C. Schuchardt1, I. Klette1, H. J.
Wester2, R. P. Baum1; 1THERANOSTICS Center for Molec-
ular Radiotherapy and Molecular Imaging, Bad Berka, GER-
MANY, 2Pharmaceutical Radiochemistry, Technical Universi-
ty Munich, Munich, GERMANY.
Aim: We present the first clinical results assessing objective
response after therapy with Lu-177 DOTAGA-PSMA inhibi-
tor (Lu-177 PSMA) in patients with metastatic castrate-
resistant prostate cancer (mCRPC).Methods: Peptide
radioligand therapy (PRLT) with Lu-177 PSMA was per-
formed in 56 patients, administering a total of 131 cycles.
Ga-68 PSMA PET/CT (contrast-enhanced CT scan) was used
for patient selection as well as follow-up after 2 and 4 therapy
cycles. The mean administered activity of Lu-177 PSMA per
cycle was 5.7±0.8 GBq, median 5.8 GBq. Post-therapy re-
sponse after 2 or 4 cycles could be assessed until now in 31
patients. The results were analyzed using a prospective patient
database (338 items/patient).Results: According to molecular
imaging criteria, partial remission was observed in 14 (44 %)
patients, correlating with the fall in PSA after therapy. The
disease remained stable in 7 (22 %) patients. Progressive dis-
ease after initial response was noted in 3 (9.6 %) patients.
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S59
Median time to progression after the first PRLT in initial re-
sponders was 13 months (range 4 - 11). Thus, the number of
responders was 24/31 patients (78 %). 7 patients (22 %) with
extensive metastastes did not respond to therapy and died with
a median time of 10 months after the first therapy cycle. Mor-
phological response (partial remission according to RECIST)
was observed in 6 patients, and stable disease in 15 patients.
All symptomatic patients reported significant improvement in
pain and quality of life after therapy. The treatment was well
tolerated by all patients without any significant adverse effects
(especially no dry-eye-dry-mouth syndrome) or alterations in
any of the laboratory parameters or of renal function (as deter-
mined by Tc-99m MAG3/TER and serial creatine and GFR
measurements).Conclusion: Peptide radioligand therapy
(PRLT) utilizing the small molecule Lu-177 DOTAGA-PSMA
inhibitor is efficacious, not only in terms of symptomatic im-
provement, but also for reducing the tumor burden. PRLTwas
well tolerated in all patients, i.e., without hematological, sali-
vary or renal toxicity.
OP141
Quantifying the Effect of Peptide Amount
on the Biologically Effective Dose for Therapy using
Lu-177 Labeled PSMA Ligands
P. Kletting1, C. Schuchardt2, H. Kulkarni2, M. Sayeg2, S.
Wiesalla2, G. Winter1, A. Singh2, R. Baum2, A. Beer1; 1Ulm
University, Deparment of Nuclear Medicine, Ulm, GERMA-
NY, 2Zentralklinik Bad Berka, THERANOSTICS Center for
Molecular Radiotherapy and Molecular Imaging (PET/CT),
ENETS Center of Excellence, Bad Berka, GERMANY.
Peptide radioligand therapy (PRLT) using Lu-177 labeled
PSMA ligands is a promising therapy option for patients with
prostate cancer. The effect of peptide amount on the
biodistribution and absorbed dose has been observed in animal
studies and in patients [1-2] for PRLT, but was never system-
atically investigated and quantified for PSMA ligands. The
aim of this work is to quantify the impact of PSMA peptide
amount on the biologically effective dose (BED) for critical
organs and the tumor using a physiologically based pharma-
cokinetic model. Methods: Included were 5 patients suffering
from metastasized prostate cancer. The administered activity
was 5.7±1.3 GBq (labelled with 160±16 μg) Lu-177 PSMA
ligand. Based on 4-6 [0.5, 3, 24, 48, (72), 120 h] conjugated
planar whole-body scans, time-dependent whole-body, organ
and tumor activities were determined. A physiologically based
pharmacokinetic (PBPK) model was developed using SAAM
2. Relevant biological mechanisms such as blood flow, trans-
port in the interstitial space, specific binding, internalization,
release of activity from cell and renal clearance were included
in the model. The model parameters were fitted to the time
activity data of the patients or were taken from the literature.
For the simulation study the model was implemented in
Matlab/Simulink. The degree of binding sites saturation and
the BED of the tumor and critical organs were calculated using
the estimated model parameters for different amounts of pep-
tide. Results: The model describes the data well. Standard
deviations and correlation matrixes are adequate. The estimat-
ed values for tumor perfusions (0.01-8 ml/g/min) and receptor
concentrations (18-2200 nmol/L) showed high variation.
However, kidney receptor concentrations (21±12 nmol/L)
were in the same order of magnitude for all patiens. The sim-
ulation study using these parameters showed that for moder-
ately or poorly perfused tumors small amounts of peptide led
to considerably lower saturation of binding sites compared to
kidney and salivary glands. Therefore, the BED for a moder-
ately perfused tumor for a limiting kidney dose of 10 Gy was
2.3 -fold higher when increasing the amount from 16 nmol to
256 nmol. Conclusions: Saturation of binding sites in kidney
and salivary glands is reached with considerably lower
amounts of peptide than in many tumors. Therefore, optimiz-
ing the amount of peptide (or preloading) with PSMA ligands
might considerably improve the ratio of tumor-to-salivary and
tumor-to-kidney BED. [1] Kletting et al. 2012 Med. Phys. [2]
Sabet et al. 2013 EJNMMI Res#
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18F-fluorodeoxyglucose PET/CT and Dynamic
Contrast-Enhanced MRI as prognostic indicators
in Malignant Pleural Mesothelioma (the SWAMP trial)
D. O. Hall1, I. D. Lyburn1, J. Searle1, C. E. Hooper2, N. A.
Maskell3; 1Cobalt Health, Cheltenham, UNITEDKINGDOM,
2Worcester Royal Hospital, Worcester, UNITED KINGDOM,
3University of Bristol, Bristol, UNITED KINGDOM.
Aims: The South West Area Mesothelioma and Pemetrexed
(SWAMP) trial was carried out to assess the role of various
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biomarkers in monitoring treatment in Malignant Pleural Me-
sothelioma (MPM). This included 18F-fluorodeoxyglucose
positron emission tomography with computed tomography
(FDG PET/CT) and dynamic contrast-enhanced magnetic res-
onance imaging (DCE-MRI). This paper assesses the prognos-
tic ability of baseline volumetric PET/CT and DCE-MRI. Ma-
terials and Methods: 73 patients were recruited, 58 received
chemotherapy, 15 were included in the comparator arm. Pa-
tients had FDG PET/CT and DCE-MRI on the same day at a
single institution. PET/CTstudies were carried out on a Philips
Gemini system, and DCE-MRI was carried out on a Philips
Open MRI scanner. Follow up was for at least 12 months. The
PETstudies were assessed using volumetric analysis including
all areas with SUV > 2.5. Metabolic Tumour Volume (MTV)
was calculated. The DCE-MRI enhancement images were
assessed, and an ROI was drawn at over a central tumour slice.
The integrated area under the enhancement-time curve in the
first 90s was calculated (IAUC90). Kaplan-Meier analysis was
carried out for PETMTVand DCE-MRI IAUC90. Results and
conclusions: Overall Survival (OS) was significantly longer
for MTV below median than above (p<0.001), 481 days
(IQR 266-709 days), compared with 266 days (IQR 177-456
days). OS was generally longer for IAUC90 below median
than above, 458 days (IQR 233-689 days) compared with
274 days (IQR 204-498 days) though the difference wasn’t
significant at the 5% level (p=0.08). Adding IAUC90 to
MTV gave no significant change in prognosis. Baseline
FDG PET/CT was predictive of OS. Baseline DCE-MRI
(iAUC90) was not predictive of OS. However, DCE-MRI re-
sults were promising, and would be worth further study.
OP144
Respiratory-gated FMISO-PET/CT detects tumor
hypoxia with higher sensitivity in non-small cell lung
cancer
S. Watanabe1, S. Okamoto1, T. Shiga1, T. Inoue2, K. Hirata1,
K.Magota1, K. Nishijima3, Y. Kuge3, H. Shirato2, N. Tamaki1;
1Department of Nuclear Medicine, Hokkaido University
Graduate School of Medicine, Sapporo, JAPAN, 2Department
of Radiation Medicine, Hokkaido University Graduate School
of Medicine, Sapporo, JAPAN, 3Central Institute of Isotope
Science, Hokkaido University, Sapporo, JAPAN.
Objective:More appropriate therapeutic strategies are required
for the tumor hypoxia evaluated by PET. However, respiratory
motion during PET imaging introduces quantitative inaccura-
cies in non-small cell lung cancer (NSCLC). For the exact
targeting to hypoxic area in NSCLC in radiation therapy, re-
spiratory gating (RG) on the hypoxic PET may be a good tool.
The aim of this study was to investigate the usefulness of RG
on 18F-f luoromisonidazole (FMISO) PET image
quantification for hypoxia. Methods: FMISO-PET/CT was
performed in 13 patients with pretreatment NSCLC. PET im-
ages were scanned by integrated PET/CT scanner at 4 hours
after FMISO injection. The respiratory signal was obtained
using a pressure sensor integrated in an elastic belt placed
around the patient’s abdomen. The respiratory cycle was di-
vided into 5 phases, corresponding to about 6 minute/phase
accumulation in our protocol. We used the 3rd phase for anal-
ysis which is equivalent to expiration phase. Non-gating im-
ages (NG) were reconstructed with median 6 minutes of ac-
quired PET data, adapting to RG images. Differences in
SUVmax, tumor to muscle ratio (TMR), tumor to blood ratio
(TBR) and hypoxic volume (HV) between RG and NG images
were analyzed. We defined hypoxia as the area with TBR ≥
1.50. Results: In RG images, SUVmax, TMR and TBR in-
creased in 10 patients comparing to those in NG images. RG
images analysis demonstrated significant increase comparing
to NG images for SUVmax (RG: Median 1.90, Range 0.72 -
4.89), (NG: 1.71, 0.64 - 4.92), (p = 0.008), TMR (RG: 1.58,
0.53 - 3.54) (NG: 1.43, 0.46 - 3.65) (p = 0.011), and TBR (RG:
1.39, 0.50 - 3.90) (NG: 1.31, 0.45 - 3.92) (p = 0.006). Mea-
surements in RG images showed increase of up to 22.0% in
SUVmax, 23.7% in TMR and 22.0% in TBR from NG im-
ages. The hypoxia was observed in 3 patients with NG images,
and increased to 5 patients with RG images. HV in RG was
also significantly larger than that in NG (RG: 9.9 mL, 0.1 -
53.1 mL) (NG: 9.2 mL, 0.0 - 52.5 mL) (p = 0.022). HV in-
creased in all 5 patients from NG images to RG images. Con-
clusions: FMISO-PETwith RG demonstrated higher sensitiv-
ity of hypoxic evaluation. RG might be useful tool for the
exact targeting to hypoxic area in NSCLC for the radiation
therapy.
OP145
Predictive value of intratumoral metabolic heterogeneity
features for early treatment failure of tyrosine kinase
inhibitor in patients with EGFR mutated NSCLC
S. Ha, S. Park, S. Lee, J. Paeng, B. Keam, T. Kim, D. Kim, D.
Heo; Seoul National University Hospital, Seoul, KOREA, RE-
PUBLIC OF.
Aim: Intratumoral heterogeneity has been associated to treat-
ment failure and patient prognosis. We hypothesized that
intratumoral metabolic heterogenetiy measured by textural
analysis on pretreatment [F-18] fluoro-deoxyglucose positron
emission tomography/computed tomography has predictive
value in targeted therapy in patients with non-small cell lung
cancer (NSCLC)Materials and methods: NSCLC cases with
activating EGFRmutation treated with tyrosin kinase inhibitor
(TKI) were retrospectively reviewed. Eight selected textural
features (TFs) were explored for predictive value in test set
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(n=161) and applied in validation set (n=21) for survival anal-
ysis. Recursive partitioning method was used to find the opti-
mal cutoff value and Harrell’s C index was used to calculated
predictive value.Results; All the 8 TFs had significantly in-
creased harzard ratio (HR) for progression free survival
(PFS) in univariate analysis (e.g. local entropy: HR 6.41,
95% confidential interval [CI] 2.80-14.68). Multivariate anal-
ysis with initial stage, performance status (PS), and metabolic
volume showed independent predictive value of TFs (HR
4.86, 95% CI 1.97-11.98 by local entropy). TFs had incremen-
tal predictive value of early TKI failure compared to stage and
PS (C-index 0.596 vs. 0.662, P=0.024, by local
entropy).Conclusion: TFs for intratumoral metabolic heteroge-
neity are significant predictive factors for TKI treatment in
EGFR mutant NSCLC patients. These TFs could be used for
companion diagnostic markers for identification of a risky
population of early EGFR TKI failure. Correlation study to
genomic alteration should be needed in future.
OP146
Correlation of metabolic information on PET/CT
and tissue expression of HIF-1α and CD68+ macrophages
in surgically treated NSCLC
E. Lopci1,2, F. Grizzi1, L. Toschi1, D. Rahal1, L. Olivari3, F.
Marchesi1, D. Qehajaj1, N. Cortese1, G. Finocchiaro1, S.
Mattioli2, M. Roncalli1, S. Fanti4, A. Santoro1, A. Chiti1;
1Humanitas Clinical and Research Hospital, Rozzano (Mila-
no), ITALY, 2Alma Mater Studiorum University, Bologna, IT-
ALY, 3University of Milan, Milano, ITALY, 4University Hos-
pital S. Orsola-Malpighi, Bologna, ITALY.
Purpose: It is largely recognized that tumour hypoxia hampers
the efficacy of chemo- and radio-therapy, and negatively af-
fects the outcome of different cancers. Herein we investigate
the role of FDG-PET parameters in surgical treated Non-Small
Cell Lung Cancer (NSCLC), by comparing the imaging find-
ings with the tissue expression of hypoxia inducible factor
(HIF-1α) and the amount of CD68+ macrophages. Materials
and Methods: A series of 29 patients with up-front resectable
NSCLC (stage IA-IIIA; M:F=22:7), who underwent FDG-
PET examination prior to surgery, was enrolled consecutively
in the study. PET images were visualized on a GE Advanced
4.6 workstation and used to define semi-quantitative and quan-
titative parameters: SUVmax, SUVmean, metabolic tumour vol-
u m e ( M T V ) a n d t o t a l l e s i o n g l y c o l y s i s
(TLG=MTV*SUVmean). Surgical histological specimens
were analyzed and for each patient two consecutive 2μm-
thick sections were treated with antibodies raised against
HIF-1α (R&D Systems, Milan, Italy) and CD68 (Dako, Mi-
lan, Italy) following a standardized immunohistochemical pro-
tocol. The immunoreactivity was semi-quantitatively
evaluated and the obtained scores compared with imaging
findings. Results: Immunohistochemical staining on NSCLC
demonstrated an up-regulated expression of HIF-1α in 17 out
of 29 (60%) specimens. The intensity of immunoreactivity
was categorized as follows: weak (score 1) in 8 cases, moder-
ate (score 2) in 5 cases, and high (score 3) in 4 cases. When
compared to PET data, SUVmax, SUVmean and TLG resulted
significantly correlated to the intensity of HIF-1α expression
(p<0.05). More specifically, score 2 demonstrated the highest
semi-quantitative and quantitative values compared to score 1,
consistent with low hypoxia level, but also to score 3: this
latter result appears more likely related to the increased pres-
ence of tumour necrosis and expression pattern heterogeneity
associated to higher levels of hypoxia. CD68+ macrophages
were consistently present in all of the investigated specimens,
confirming their functional role in tumour hypoxia. Conclu-
sions: Although our findings need to be extended in a larger
series of NSCLCs, the present study shows a direct association
between FDG-PET parameters and the tumor expression of
HIF-1α . Moreover, macrophages are found as the most rep-
resentative immune cell population, being present at high den-
sities in all the investigated specimens.
OP147
Correlation between circulating tumor biomarkers
and positron-emission tomography in advanced non-small
cell lung cancer
G. Ferrarazzo1, F. Bongioanni1, C. Genova2, M. Massollo3, G.
Karalis4, E. Rijavec2, F. Biello2, G. Barletta2, S. Coco2, A.
Alama2, A. Truini2, I. Vanni2, G. Sambuceti1, F. Grossi2, S.
Morbelli1; 1Nuclear Medicine Unit, IRCCS San Martino -
IST, University of Genoa, Genoa, ITALY, 2Lung Cancer Unit,
IRCCS San Martino - IST, Genoa, ITALY, 3Nuclear Medicine
Unit, Galliera Hospital, Genoa, ITALY, 4PET/CT Alliance
Medical, Istituto Salus, Genoa, ITALY.
Background: Circulating tumor cells (CTCs) and plasma
circulating-free DNA (cfDNA) are promising candidates as
non-invasive prognostic markers in malignant diseases. 18-
fluorodeoxyglucose positron emission tomography/computed
tomography (18FDG-PET/TC) has a well-recognized diag-
nostic and prognostic value in non-small cell lung cancer
(NSCLC). Very little is known about the mutual relationship
between circulating biomarkers (CTCs and cfDNA) and
18FDG-PET/CT indicators in NSCLC. Methods: Peripheral
blood samples from 28 patients affected by advanced/
metastatic NSCLC were collected before starting first-line
chemotherapy. CTCs were isolated by size using a filtration-
based device (ScreenCell) and then identified and enumerated;
cfDNAwas isolated from plasma (QIAamp DNA Blood Mini
Kit, Qiagen) and quantified by qPCR method using human
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telomerase reverse transcriptase (hTERT). All patients
underwent 18FDG-PET/TC (Biograph 16 Siemens) at base-
line. Maximum diameter (dmax) of the primary lesion (T),
dmax of the greater lymph nodal (N), and metastatic (M) le-
sions were measured. Similarly, maximum andmean standard-
ized uptake value (SUVmax, SUVmean) and size-
incorporated SUVmax (SIMaxSUV) were computed for T, N
and M, respectively; SIMaxSUV was calculated with the fol-
l owing fo rmula fo r T, N , and M: SIMaxSUV=
SUVMax*dmax. Presence (B+) and absence (B-) of metabol-
ically active bone lesions (bone mets) were recorded. The as-
sociation among CTCs, cfDNA and 18FDG-PET/CT-derived
parameters was evaluated through multivariate analysis. T-test
was performed to evaluate the difference in CTCs and cfDNA
in B+ and B- groups, respectively. Results: Twenty-eight pa-
tients were evaluated; median age was 66 years (range: 51-80);
male/female ratio was 18/10; 15 patients were current
smokers, while 11 were former-smokers and 2 were never-
smokers. Histo-types were grouped as it follows: adenocarci-
noma= 22; squamous cell carcinoma= 5; not otherwise speci-
fied NSCLC= 1. Nine patients out of 28 had metabolically
active bone lesions. Median CTC count was 7 CTCs/3ml
(range: 0-47 CTCs/3ml), while median HTERT copy number
was 109.0 (range: 16.7-1405-5). At multivariate analysis,
SUVmax of Twas the only variable independently associated
with cfDNA (p=0.036). No correlations were highlighted be-
tween CTCs and all the other PET-derived parameters. A trend
towards significance between high HTERT and the presence
of metabolically active bone lesions was observed (p=0.058).
Conclusions: Our data demonstrate that the expression of
cfDNA is correlated with the metabolic activity of the primary
tumor lesion. Since SIMaxSUV was not correlated with
HTERT, it appears that the expression of cfDNA depends from
tumor metabolism rather than its burden. Further analyses on
18FDG-PET/TC-derived metabolic tumor volume are
ongoing.
OP148
Density cut off value for metastatic mediastinal and hilar
lymph nodes in lung cancer patients
P. Flechsig, P. Frank, D. Rath, C. Kratochwil, H. Kauczor, U.
Haberkorn, F. Giesel; University Hospital Heidelberg, Heidel-
berg, GERMANY.
Purpose:Lung cancer often co-exits with chronic lung diseases
such as COPD, and mediastinal lymph nodes may be positive
with FDG-PET due to inflammatory disease alone. Neverthe-
less, FDG-PET is the primary imaging modality used for stag-
ing patients with lung cancer, including nodal status. The pur-
pose of this study is to evaluate if density measurements by
means of Volumetric CT histogram analysis can improve the
characterization of lymph nodes in staging of patients with
lung cancer.Materials and Methods:248 lymph nodes of 159
patients aged 41-78 years (87 male, median age 57) diagnosed
with lung cancer were investigated. Native FDG-PET/CT
(Biograph 6 PET/CT) was performed prior to surgery/biopsy
as part of clinical staging. Analysis of lymph nodes was done
on the basis of FDG-uptake (SUVmax) and Volumetric CT
histogram analysis. These findings were correlated to the gold
standard of histopathology.Results:130 positive and 118 neg-
ative histological proven lymph nodes were successfully ana-
lyzed by Volumetric CT histogram. Histological positive
lymph nodes presented a significantly higher median CT HU
value (p < 0.05, Fig. 1). The incidence of malignancywas 82%
above a cut off value of 20HU, the incidence of benign find-
ings was 91% below a cut off value of 20HU. In subgroup
analyses, density analyses failed to differentiate between dif-
ferent malignant tumour entities (Adeno CA, Adenosquamous
CA, NET, SCLC, other).Conclusion:As an additive value for
the preoperative N-staging in lung cancer patients a possible
cut off value of 20HU might divide mediastinal lymph nodes
of FDG-equivocal patients into affected and not-affected ones.
Nevertheless, density analyses cannot differentiate between
different tumour entities.
OP149
Comparison of predicted FEV1 and observed FEV1 post
lung surgery Using lung Perfusion scintigraphy
V. Rangarajan, N. Purandare, A. Agrawal, S. Shah, S. Nag, P.
Ranganathan, C. S. Pramesh; Tata Memorial centre, Mumbai,
INDIA.
Aim: To study the correlation between predicted
FEV1evaluated by lung perfusion and actual post -operative
values of FEV1 in patients undergoing surgery for lung cancer.
Materials & Method: This was IRB approved prospective
study of patients undergoing lung surgery( lobectomy/pneu-
monectomy) who were referred for pre-operative prediction of
post-operative pulmonary function by lung perfusion scintig-
raphy using 99mTc MAA. All patients underwent surgery
within 2 weeks of the 99m Tc MAA study. Post-operative
spirometry study was conducted 4-6 months after surgery. A
sample size of 50 was estimated and data collected over 18
months. The estimation of post-operative FEV1 was calculat-
ed using actual preoperative FEV1 and percentage perfused
lung using a software that divides both lungs into 3 equal
zones - anterior and posterior and counting using geometric
mean. On the basis of type of planned surgery popFEV1 was
calculated as percentage and absolute value. Pearson’s corre-
lation coefficient was used to evaluated the relationship be-
tween the popFEV1 by lung perfusion scintigraphy and post-
operative actual FEV1 measured by spirometry. Agreement
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between the 2 methods was analyzed by Bland -Altman meth-
od. Results - 50 patients were included in the study. The age
range was 32-77 years, males were 39 and 11 were fe-
males.50% had upper lobe, 26% had lower lobe, 6% had mid-
dle lobe, 12% had main bronchus involvement and 4% others.
Histologically 42% were adenocarcinoma, 16% NET, 36%
squamous carcinoma and others 6%. The correlation between
PPOFEV1 lung perfusion scintigraphy and measured actual
post-operative FEV1 by spirometry showed a statistically sig-
nificant correlation, R=0.847. The correlation coefficient was
higher at 0.930 for pneumonectomy patients against 0.792 for
lobectomy. The Pearson’s correlation coefficient is significant
at the 0.01 level (2-tailed). The agreement analysis using
Bland-Altman method showed a mean difference between
the 2 methods of evaluation of pulmonary function
was 0.0558 (mean) with standard deviation 0.284. Con-
clusion - The current method of quantification using
geometric mean and planar method is exceptionally
good for predicting lung function after pneumonectomy,
however post - lobectomy the planar method is just op-
timal for prediction. SPECT and CT based segmentation
improves the prediction post lobectomy as well. Preop-
erative FEV1 estimation using lung perfusion is a rea-
sonably good predictor of actual post operative FEV1 in
patients undergoing surgery for lung cancer.
OP150
The Relationship between Staging and SUVmax
in Non-Small Cell Lung Cancer
H. KAYA1, T. Balci2, H. KOMEK3, M. CENGIZ4;
1DicleUniversity Medical Faculty, DIYARBAKIR, TURKEY,
2Firat University Medical Faculty, ELAZIG, TURKEY, 3Di-
yarbakir State Hospital, DIYARBAKIR, TURKEY, 4Dicle
University Medical Faculty, DIYARBAKIR, TURKEY.
Introduction: In this study, we aimed to determine the relation-
ship between the stage of the disease and the maximum stan-
dard uptake value (SUVmax), one of the most important quan-
titative parameters of PET imaging for tumors, in non-small
cell lung cancer (NSCLC).Materials and Methods: Seventy
three patients with histopathological diagnosis of NSCLC
(27 adenocarcinomas, 29 squamous cell lung carcinoma, 17
unclassified subtypes) to whom PET/CT scan was performed
between July 2009 to July 2011, were evaluated
retrospectively.F-18 fluoro-2-deoxy-D-glucose (FDG) of
370-555 MBq (10-15 mCi) was injected via a peripheral vein
of the patients at least 4 hours fasting period and blood glucose
levels under the 150 mg/dl and 45-60 minutes following injec-
tion PET/CT imaging was performed of the body areas be-
tween the vertex and the third upper part of the thigh.In addi-
tion to the visual evaluation of the PET/CT images, SUVmax
in the tumor tissue and mediastinal lymph nodes was deter-
mined. FDG uptake of the lymph nodes, distant metastasis and
tumor were assessed by the PET / Ct and they were recorded to
make staging according to tumor, node, metastasis (TNM)
staging system (Phase I, II, III, IV). The cut-off value for
SUVmax was considered as 2.5.The relationship between the
NSCLC subtypes and SUVmax were determined by
Spearman’s correlation test.Results: The patients with an av-
erage age of 61.36 ± 9.6 years (32 to 83 years old), 10 women
(13.7%) of them, included in the study.Distribution of patients
according to the stage was as follows; stage I: 14 patients
(19.2%), stage II: 12 patients (16.4%), stage III: 20 patients
(27.4%), Stage IV: 27 patients (37%).SUVmax values accord-
ing to the stage was determined as; Stage I: 11.6 ± 4.6, Stage II:
13.5 ± 6.4, Stage III: 12.6 ± 4.8, Phase IV: 17.5 ± 8.6.In
NSCLC subtypes, a significant correlation between SUVmax
and the stage was revealed (r = 0.319, p = 0.006).Conclusion:
Due to positive relationship between the increase in SUVmax
and tumor stage, we believe that it could help clinicians in
order to make a prediction about the patient’s prognosis.
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Size doesn’t matter: predictive value of new quantitative
analysis for differential diagnosis of primary
hyperparathyroidism lesions vs. thyroid nodular disease
in parathyroid scintigraphy
A. V. Koljevic Markovic1,2, M. Jankovic, G. Pupić1, R.
Džodić1; 1National Cancer Research Center Serbia, Belgrade,
SERBIA, 2Faculty of Electrical Engineering, University of
Belgrade, Belgrade, SERBIA.
Aim: The problem of segmentation and recognition of para-
thyroid lesions in the presence of concomitant thyroid nodular
disease is present in conventional SPECT/CT investigations as
well as in gamma camera imaging. Aiming to improve speci-
ficity of parathyroid scintigraphy in concomitant thyroid nod-
ular disease, we developed a new processing method in ROI
time/activity data analysis. MM: Total of 53 patients, median
age of 57(19-80) years, with clinical diagnosis hyperparathy-
roidism (PHPT) and ultrasound positive report of nodular or
multinodular goiter, underwent preoperative, dual- tracer: 99m
Tc-pertecnetat and 99mTc-MIBI, double- phase scintigraphy
by EANM guidelines (2009). Specially designed software we
developed examined ROI time/activity changes in the form of
grid with different, optional sizes, up to maximal resolution (1,
5mm). We correlated our findings with PTH levels, histology
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results and conventional scintigraphic findings: subtraction
and visual interpretation of planar images of neck and medi-
astinum in oblique sections, according to ultrasound PTA lo-
calization and delayed scans in one hour interval. Results:
Parathormone (PTH) was increased in the group: median
120,2 pg/ml (range 70- 658pg/ml).Following histopathology:
a) thyroid - benign: adenoma folliculare, colloides and cystica:
45(83%)pts ; malignancy: 8 (10%)pts- papillary 7 pts and one
for medullary; b) parathyroid - autonomy (PTA) 53(70,2%):
solitary: 44 patients, hyperplasia: 8 pts- 7/8 patients with two
lesion and 1/7 had all four lesions and one PT carcinoma;.c.)
median PTA volume was 760(55-6125)mm3. Standard find-
ings (subtraction, oblique planar scans and delayed phase) in
total of 63 lesion (in 53 pts) had 10 FN (mostly in hypeplasia
PTA), and PPV was 81%. Using specially designed software,
thyroid TACs represented, as expected, exponentially declin-
ing curves but parathyroid lesions had typical uptake pattern in
the form of late phase peak, independent to PTA volume and/
or PTH levels. The thyroid gland washout was up to 28% in
normal, adenoma or thyroid carcinoma tissue. A new process-
ing method for a PTA had PPV 97%. Conclusion: Application
of new imaging data quantification, we developed, was effec-
tive in small parathyroid lesions concomitant to thyroid nodu-
lar disease, complementary used with standard protocols. This
novelty could be implemented in various nuclear medicine
hybrid imaging investigations, following pathological metab-
olism, in ROI sizes up to maximal resolution.
OP152
A prospective comparative study of parathyroid
dual-phase scintigraphy, dual-isotope subtraction
scintigraphy, 4D CT, and ultrasonography in primary
hyperparathyroidism
M. Krakauer1, B. Wieslander1, P. S. Myschetzky1, A.
Lundstrøm1, T. Backer1, C. H. Sørensen2, W. Trolle2, B.
Nygaard3, F. N. Bennedbæk3; 1Gentofte Hospital, Helleup,
DENMARK, 2Rigshospitalet, Copenhagen, DENMARK,
3Herlev Hospital, Herlev, DENMARK.
Purpose: Preoperative localization of the diseased parathyroid
gland(s) in primary hyperparathyroidism (PHP) allows for
minimally invasive surgery. This study was designed to estab-
lish the optimal first-line preoperative imaging modality.
Methods: 91 patients were studied consecutively in a prospec-
tive head-to-head comparison of dual isotope (Tc-99m
Sestamibi vs. I-123) subtraction parathyroid scintigraphy
(PS), dual-phase PS, 4D CT, and ultrasonography (US). Sur-
gery, histological confirmation, and postoperative normaliza-
tion of Ca++ and PTH was the reference standard. Results:
Ninety-seven hyperfunctioning parathyroid glands (HPG)
were identified by the reference standard. Sensitivity and
specificity for subtraction PS, dual-phase PS, 4D CT, and US
was 93%, 65%, 58%, 57% and 99%, 99.6%, 86%, 95%, re-
spectively. Inter-rater agreement was excellent for subtraction
PS (κ=0.96) while only fair for 4D CT (κ=0.34). Pinhole im-
aging and subtraction of late images (the latter especially in
case of a nodular thyroid gland) increased the sensitivity of
subtraction PS. SPECT/low-dose CT did not increase sensitiv-
ity but aided in the exact localization of the HPGs. Of 7 neg-
ative subtraction PS studies 4DCTand USwas able to locate 3
and 1 additional HPGs, respectively. Conclusions: Dual iso-
tope pinhole subtraction PS has higher diagnostic accuracy
compared to dual-phase PS, 4D CT, and US as a first-line
imaging study in PHP. In case of a negative scintigraphy or
suspicion of multiglandular disease 4D CT and/or US is rec-
ommended as a second-line modality. However, diagnostic
algorithms should be adapted in accordance with local avail-
ability and expertise.
OP153
Comparison of 99mTc-sestamibi/123I subtraction
SPECT/CTand combined 99mTc-sestamibi/123I
sub-traction SPECT/CTwith planar pinhole image
in hyperparathyroidism
V. Tunninen1, P. Varjo1, M. Seppänen2; 1Satakunta Central
Hospital, PORI, FINLAND, 2Turku University Hospital, Tur-
ku, FINLAND.
Introduction. 99mTc-sestamibi/123I subtraction SPECT/CT is a
valuable tool for localization of parathyroid adenomas. The
aim of this study was to evaluate whether the review of addi-
tional planar pinhole image improves the outcome of
123I/99mTc -sestamibi subtraction SPECT/CT in parathyroid
scintigraphy. Subjects and Methods: Parathyroid scintigraphy
with 99mTc (750MBq) and 123I (20MBq) was performed for 59
patients with hyperparathyroidism (55 pHPT, 4 sHPT). Two
simultaneous 99mTc /123I acquisitions were performed
(SPECT/CT and anterior planar pinhole imaging). Two
anonymized image sets were generated to compare SPECT/
CT and combined SPECT/CT+Pinhole planar images (99mTc-
sestamibi,123I, and subtraction images). Each quadrant in rela-
tion to the thyroid gland (and other, referring to ectopic local-
ization) was classified as negative or positive with the confir-
mation of histologic analysis as the reference standard. A
McNemar test was performed to compare the sensitivities
and specificities between the image sets. Results. There were
68 adenomas confirmed by histology in 59 patients. Fifty-two
patients had solitary adenomas, six patients had double adeno-
ma, and one patient had four hyperplastic glands. Sixty-two
and sixty-six adenomas were correctly visualized by SPECT/
CT (six false positive) and SPECT/CT+Pinhole (four false
positive), respectively. The sensitivity and specificity were
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slightly higher with SPECT/CT+Pinhole than with SPECT/
CT (97,06% vs. 91,18% and 98,24% vs. 97,36%, respectively.
p = 0,7237). False-positive rate was 8,82% with SPECT/CT,
a n d d e c r e a s e d t o 5 , 7 1% w i t h S P EC T / C T +
Pinhole.Conclusion. This study indicates that the use of addi-
tional pinhole image with 99mTc-sestamibi/123I subtraction
SPECT/CT increases both sensitivity and specificity of para-
thyroid scintigraphy. Although the difference was not statisti-
cally significant, the use of additional pinhole imaging is use-
ful especially in cases where SPECT/CT remains negative.
The use of additional planar pinhole image with 99mTc-
sestamibi/123I subtraction SPECT/CT is thus recommended
in selected cases.
OP154
Value of 18F-Choline PET-CT in the assessment
of primary hyperparathyroidism comparing
with 99mTC-Sestamibi SPECT-CT
M. Beheshti1, L. Imamovic1, G. Spaun2, M. Steinmair1, K.
Emmanuel2, V. Alibegovic3, C. Pirich4, W. Langsteger1;
1PET-CT Center Linz, St. Vincent’s Hospital, Linz, AUS-
TRIA, 2Department of Surgery, St. Vincent’s Hospital, Linz,
AUSTRIA, 3Department of Clinical Pathology, St. Vincent’s
Hospital, Linz, AUSTRIA, 4Nuclear Medicine & Endocrinol-
ogy, Parcelsus Medical University, Salzburg, AUSTRIA.
Aim: In this prospective study we compared the accura-
cy of 18F-Choline (FCH) PET-CT with 99mTC-
Sestamibi SPECT-CT for preoperative detection of para-
thyroid adenoma in patients with primary hyperparathy-
roidism. METHODS: Both 99mTC-Sestamibi SPECT-CT
and FCH PET-CT were performed in 25 consecutive
patients with biochemical evidence of primary hyper-
parathyroidism. At least one abnormal 99mTc-Sestamibi
and FCH focus corresponding to a parathyroid gland or
ectopic parathyroid tissue in each imaging modality was
considered as positive finding. Twenty patients with pos-
itive findings in at least one imaging modality
underwent surgical exploration and the results of imag-
ing modalities were verified with histopathologic find-
ings as the standard of truth. RESULTS: All patients
showed biochemical evidence of primary hyperparathy-
roidism with a mean serum calcium level of 2.7 ± 0.4
mmol/l and parathormone (PTH) level of 178.5 ± 165.8
pg/ml. Intraoperative PTH monitoring showed significant
drop in PTH level in all patients. In patient-based anal-
ysis, FCH PET-CT was able to detect parathyroid ade-
noma in 84% of patients (21/25) while 99mTC-
Sestamibi SPECT-CT was positive in 52% of patients
(13/25). The mean serum calcium and PTH levels of
patients with negative imaging modalities were 2.66 ±
0.05 mmol/l and 123.05 ± 18.0 pg/ml. In a lesion-based
analysis in 20 patients who underwent surgical explora-
tion, the detection rate of FCH PET-CT was 87% (21/
24) comparing with 50% (12/24) detected by 99mTC-
Sestamibi SPECT-CT. CONCLUSION: In this prospec-
tive study, FCH PET-CT showed promising results to be
a potential functional imaging modality - clearly superi-
or to 99mTC-Sestamibi SPECT-CT - in the detection
and localization of parathyroid adenoma in patients with
primary hyperparathyroidism.
OP155
Tc-99m MIBI-scintigraphy for malignancy risk
assessment of hypofunctionning thyroid nodules
K. Rösel, C. Schneider, C. Kobe, M. Dietlein, A. Drzezga,M.
C. Schmidt; University Hospital of Cologne, Department of
Nuclear Medicine, GERMANY.
Aim: In Germany with its borderline iodine supply pa-
tients with hypofunctionning thyroid nodules (HTN) as
assessed by pertechnetate scintigraphy have a malignan-
cy risk of about 1.7 - 3 %. Fine needle aspiration cy-
tology is used for futher evaluation being inconclusive
in about 20%. Tc-99m-MIBI scintigraphy can be used
for malignancy risk assessement of HTN. We wanted
to test its clinical usefulness.Methods: Between 2007
and 2010 108 patients with one HTN were retrospec-
tively identified from our institutional database who
had undergone Tc-99m-MIBI-scintigraphy and subse-
quent surgery. Histopathology served as golden standard.
Tc-99m-MIBI images were grades as following: Match =
HTN and MIBI with a concordant lower uptake as the
surrounding thyroid tissue; Isointense Uptake = MIBI
uptake in the HTN equal to surrounding thyroid tissue;
Mismatch = MIBI uptake higher than surrounding thy-
roid tissue. Results: 98 patients had a benign and 10 a
malignant histology. Patients with benign nodules had
34 Match, 11 isointense and 51 Mismatch findings. Pa-
tients with malignant nodules had 8 Mismatch and 2
isointense findings the latter being explained by papil-
lary microcarcinomas. The negative predictive value of
Tc-99m-MIBI scintigraphy was 96% and the positive
predictive value 14%. Fine needle aspiration biopsy be-
ing performed in 77 patients missed 6 malignant nod-
ules. Conclusions: Tc-99m-MIBI scintigraphy can serve
as an additional technique for malignancy risk assess-
ment of hypofunctionning thyroid nodules. Though the
majority of Mismatch findigs represent benign thyroid
nodules the likelihood of malignancy increases in this
group. A negative Tc-99m-MIBI scintigraphy has a high
likelihood of a benign finding justifying a conservative
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management. Though small in number, Tc-99m-MIBI
may miss papillary microcarcinomas.
OP156
Role of real time ultrasound elastography in diagnosing
hyper functional thyroid nodules and predicting treatment
response
V. Stebner1, M. Ruhlmann1, R. Görges1, J. Farahati1, D. Si-
mon2, A. Bockisch1, S. Rosenbaum-Krumme1, J. Nagarajah3;
1Department of Nuclear Medicine, Medical Faculty, Universi-
ty Duisburg-Essen, Essen, GERMANY, 2Department of Gen-
eral and Visceral Surgery, Bethesda Hospital, Duisburg, GER-
MANY, 3Department of Radiology, Memorial Sloan Kettering
Cancer Center, New York, NY, UNITED STATES.
Background/AimUltrasound based real-time elastography
(USE) is increasingly studied in clinical setting primarily for
detection of suspicious thyroid nodules with controversy re-
sults. However, the role of USE for diagnosis of
scintigraphically hyper functional thyroid nodules is still un-
clear. In this study we investigated the detection capability of
USE for benign thyroid nodules and analyzed additionally, if
USE is able to predict radio-iodine treatment (RIT) response in
those patients.The first part of the study included 134 hyper
functional thyroid nodules of 101 consecutive patients. The
following attributes of the nodules were analyzed: stiffness
with the USE using scores of Rago (3 item score) or Asteria
(5 item score) and ultrasound criteria using TIRADS. The
second part of the study included 73 hyper functional thyroid
nodules (51 unifocal, 7 bifocal, 15 multifocal) of 73 consecu-
tive patients prior to RIT. The following attributes of the nod-
ules were analyzed before RIT: stiffness with the USE using
scores of Rago (1 = soft, 2 = medium, 3 = hard), classical
ultrasound criteria like echogenicity and perfusion, thyroid
scintigraphy and TSH level in blood. Approximately four
months after RIT the therapy response was evaluated by thy-
roid scintigraphy and TSH level in blood. Therapy response
was defined as normalized TSH level and thyroid scintigraphy
without hyper functional nodules.94 of the exmined thyroid
nodules (70%) were rated as hard (suspicious for malignancy)
and 41 nodules (30%) as soft (not suspicious) with a specific-
ity of 30%. The scoring systems of Rago and Asteria showed
no significant difference. Applying the TIRADS criteria 44
nodules (33%) had a higher risk for malignancy (33 nodules
TIRADS 4a, 11 nodules TIRADS 4b). Combining USE and
TIRADS 32 nodules (24%) were categorized as suspicious
(intersection of hard nodules that are categorized as TIRADS
4a or 4b).RITwas successful in 66 nodules (responder) and not
successful in 7 nodules (non-responder). In the group of re-
sponders 21 nodules were rated as “soft”, 12 nodules as “me-
dium” and 33 nodules as “hard”. Regarding the non-responder
4 nodules were rated soft and 3 nodules hard. There was no
statistic significant correlation between USE score and therapy
response.ConclusionUSE cannot reliably identify
scintigraphically hyperfunctional thyroid nodules as benign
nodules. Its accuracy in the assessment of at least “hot” thyroid
nodules is to be questioned. USE cannot predict therapy (non-)
response of RIT of hyper functional thyroid nodules and has
therefore no influence on therapy planning.
OP157
Cancer Risk After Medical Exposure to 131I in Benign
Thyroid Diseases
I . CILLERO ETXEBESTE , A. MENDIOLA, P.
SANTESTEBAN, M. MITXELENA, I. ARIAS-CAMISON,
G . R I O S , F . R O D R I G U E Z ; F U N DAC I Ó N
ONKOLOGIKOA, SAN SEBASTIAN, SPAIN.
OBJECTIVE: The objective of this study was to evaluate the
incidence of cancer in patients treated with 131I for benign
thyroid disease. MATERIAL AND METHODS: This is a ret-
rospective study in which a total of 1511 patients , residents in
Guipúzcoa (Spain), were included from 1995 to 2011. All of
them had received a radioiodine treatment (RAI) for Grave’s
disease, autonomously functioning nodules (AFN),
multinodular goiter (MNG) or treatment refractory hyperthy-
roidism. The administered 131I dose was calculated on the
basis of the thyroid’s volume, 24h uptake of 131I and clinical
examination. The dose range was 185-740 MBq. The ob-
served variables were: reason for 131I treatment, administered
activity of 131I, thyroid absorbed dose, other organ groups that
concentrate 131I, time since exposure and pathological anato-
my examination. We reviewed the most sensitive organs for
radiation-induced oncogenesis including salivary glands,
breast, kidney, bladder, pancreas, stomach and thyroid. Lym-
phoma and leukemia’s incidence in these patients was also
studied. Incident cancer cases were identified from
Guipúzcoa’s Cancer Registry. Standardized incidence rate
(SIR) was estimated as an approach to cancer risk. RESULTS:
This study included 1217 women and 294 men. The median
age was 58.37. The follow-up period of these patients ranged
from 1 to 16 years. Thyroid cancer was diagnosed in 10 pa-
tients during the follow-up period. .All patients who developed
a thyroid cancer were men. Among these 10 patients, the av-
erage 131I was 573.5Mbq. Five of these patients were treated
for AFN whereas the other five patients suffered from MNG.
None of these patients were treated for Grave’s disease. Path-
ological examination revealed a prevalence of papillary tu-
mour (6/10) two patients presented follicular tumour, one pres-
ent medullary thyroid carcinoma and one leiomyosarcoma.
Three patients died of thyroid cancer. Among these 3 tumours
one was a papillary tumour, one was leiomyosarcoma and one
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was medullary carcinoma. SIR was 4.3 (CI: 0.86-0.71) which
is similar to Gipúuzcoa’s general population. CONCLUSION:
The incidence of thyroid cancer in these series was not signif-
icantly different from its incidence in the general population.
There is no demonstrable increase of risk overall after 131I
administration in our study.
OP158
Contribution of SPECT/CT in extrathyroid radioiodine
uptake in patients with differenciated thyroid cancer.
J. Villanueva Curto, A. Sainz-Esteban, A. Cobo Rodríguez,
C. Gamazo Laherrán, M. Ruíz Gómez, M. Gónzalez Selma,
M. Alonso Rodríguez, R. Olmos García; HOSPITAL
CLÍNICO UNIVERSITARIO DE VALLADOLID, Vallado-
lid, SPAIN.
Aim:To asses the contribution of SPECT/CT performed after
treatment with 131I in patients with differentiated thyroid can-
cer (DTC) in the localization and characterization of extra-
thyroid uptakes detected in the whole body scintigraphy
(WBS).Methods:We include 40 patients (31 women, mean
age: 57±18 years) with DTC (35 papillary, 2 follicular and 3
indiferentiated). After an hipoiodine diet, a WBS and a SPECT/
CT were performed 6-9 days after the administration of a ther-
apeutic dose of 131I (mean dose: 4.2 ± 0.8 GBq) and 4 weeks
after withdrawal of hormonal replacement treatment (21) or
stimulation with recombinant TSH (19). Scintigraphy findings
were correlated with radiology, histology or follow-
up.Results:In 11 patients, WBS and SPECT/CT did not show
any extrathyroidal uptake. In the remaining 29 patients, 44 foci
were detected. Three foci were only detected in SPECT/CT, 2 of
them were metastases in cervical adenopathies and one a bron-
chiectasis. Of the 41 foci detected in both techniques, 12 were
metastases (9 cervical adenopathies and 3 distant metastases),
and 29 were false positives. SPECT/CT improved the localiza-
tion of all of them, dismissing 26 false positives in salivary
glands (3), bowel (7), kidney (1), thymus (5), breast (1), bron-
chiectasis (4), and contamination (5). In 3 patients, in spite of
the improvement of localization, SPECT/CT did not correctly
characterize three foci that were at final diagnosis a bronchiec-
tasis, a renal and an ovaric cysts.Conclusions:SPECT/CT im-
proved the localization and characterization of extra thyroid
uptakes detected in WBS, dismissing false positives. In a small
percentage of patients, new focus were detected in SPECT/CT,
with no changes in the staging of patients.
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18F-FDG PET/CT: Is SUVreliable to evaluate the adrenal
glands normal metabolic behavior?
I. Rodrigues, A. Martins, J. Pereira, R. Domingos, S. Carmo-
na, L. Oliveira; Joaquim Chaves Saúde – Nuclear Medicine
Department, Lisbon, PORTUGAL.
Aim: To compare normal adrenal glands (AG) SUVmax ob-
tained in two different time points, using two reconstruction
methods, in order to evaluate SUV reliability to evaluate AG
normal metabolic pattern.Materials and methods: This retro-
spective study included 56 AG of 28 patients [13M/15F;
mean age: 61,4 ± 12,9 years] with glycemic values below
120mg/mL and without adrenal disease (excluded by clinical
history, recent image and laboratory tests). The technical
procedure consisted of the administration of 18F-FDG
followed by a rest period and hydration. Two PET/CT stud-
ies were performed [Biograph 6 TrueView PET/CT, Sie-
mens]: a whole body study from the base of the skull to
the mid-thigh (WB) (Δinjection-acquisition= 94,4 ± 15,9
minutes) and a delayed abdominal image (DAI)
(Δinjection-acquisition= 180,6 ± 24,1 minutes). The CT
study was acquired with low dose protocol for attenuation
correction and anatomical localization. The processing in-
cluded the visual analysis of the tomographic studies and
the calculation of SUVmax in AG in the WB and in DAI
by two different iterative reconstruction methods: 1)
SUVmax_2D [8 subsets, 4 iterations, matriz 168x168]
SUVmax_3D [21 subsets, 3 iterations, matriz 336x336]. Sta-
tistical analysis was performed using paired t-Student
test.Results: In initial images, the mean SUVmax_2D (2,00
± 0,40) are not statistically different (p=0,168). In DAI
SUVmax_3D (2,20 ± 0,48) is higher than SUVmax_2D (1,
96 ± 0,52) (p=0,001). Comparing the mean SUVmax_2D of
AG in initial and delayed images, the differences found with
both reconstruction methods were not statistically different,
although both reconstruction methods showed a different
tendency: there is a slight mean SUVmax decrease (-2,48
%) for SUVmax_2D and a slight SUVmax increase (5,26
%) for SUVmax_3D.Conclusion: Small differences in recon-
struction methods can happen when hardware and/or soft-
ware is upgraded and this can significantly change the nor-
mal AG SUV calculation. This change can be non-
homogeneous as verified in this work - we have docu-
mented no significant AG SUV change in the initial WB
images and a significant SUV change on the DAI, using
two reconstruction methods. This aspect conducted to an
apparent different metabolic behavior of normal AG dur-
ing time - although the differences were not statistically
significant, a slight increase or slight decrease in AG
SUV was documented during time as different recon-
struction methods were used.
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OP160
Partial Volume Correction of Amyvid and FDG PET data
using the discrete iterative Yang technique
J. C. Dickson1, K. Erlandsson2, M. Lehmann2, M.Modat2, N.
Burgos2, A. Groves2, J. Schott2; 1University College London
Hospital NHS Foundation Trust, London, UNITED KING-
DOM, 2University College London, London, UNITED
KINGDOM.
Introduction: Partial volume effects can severely compromise
both visual and quantitative PET, particularly in the popula-
tions referred for dementia PET imaging. Atrophy and cortical
thinning can lead to apparent reductions in tracer uptake that
are purely an effect of anatomical features, which compro-
mises the ability of the PET study to accurately map underly-
ing physiological processes. To overcome these issues, partial
volume correction (PVC) techniques can be applied. In this
study we introduce the “discrete iterative Yang” (diY) tech-
nique, and look at the improvement in tracer uptake in a cohort
of Amyloid and FDG PETstudies. Methods: A mix of twenty-
two patients and age-matched controls were involved in this
study. All subjects had Amyvid PET, FDG PET, and a recent
T1 weighted MR study. T1 data were co-registered to FDG
PET and 18F-Amyvid data before being segmented and
parcellated into volumes using the Niftyseg algorithm [1].
PET data were then up-sampled to the MR voxel size before
PVCwas applied using the diY technique. In essence the tech-
nique involves the PET image being represented as a piece-
wise constant image, which is convolved with the system point
spread function. The ratio of the original and convolved im-
ages is used as correction factors that are applied to the PET
image. The regional mean values are estimated iteratively. Af-
ter a few iterations of this process, the PET image can be
considered to be partial volume corrected. Once the correction
had been applied, the visual and quantitative changes to
the PET distributions were assessed pre and post cor-
rection. Results: Of the 22 subjects, 13 had a scan
negative for amyloid deposits. After PVC, global
grey-matter SUVr in these subjects decreased by an
average of 12.2% (95%CI: 8.7-15.7) due to a reduction
of spill-in from non-specific white matter uptake. In
Amyloid positive patients, SUVr increased by 26.7%
(95%CI: 22.17-31.26%) by reducing spill-out from cor-
tical grey matter. Similarly in control FDG studies
SUVr in cortical grey matter increased by 26.3%
(95%CI: 25.22-27.41) after the application of the
PVC. Visually there was better contrast between grey
and white matter areas on Amyloid PET, and FDG PET
with abnormalities better differentiated with diY PVC
applied. Conclusions: Partial volume correction using
diY improves quantitative accuracy, and offers better
differentiation between normal and abnormal studies.
Reference: [1] Cardoso MJ et al 2012. Geodesic Infor-
mation Flows in Med. Image Comput. Comput Assist.
Interv. : MICCAI 2012;7511:262-270 2012.
OP161
Prognostic and predictive values of initial 18FDG PET
features using random forest classifier: Application
to patients after chemo-radiotherapy for oesophageal
cancer
P. Desbordes1,2, R. Modzelewski3,1, S. Vauclin2, P. Vera3,1, I.
Gardin3,1; 1QuantIF LITIS - EA4108, University of Rouen,
Rouen, FRANCE, 2Dosisoft, Cachan, FRANCE, 3Henri Bec-
querel Center, Rouen, FRANCE.
Aim: Many features can be extracted from 18FDG PET im-
ages to describe cancer. We propose a machine learning tech-
nique based on a Random Forest (RF) classifier to select fea-
tures having a prognostic or predictive value among a large
amount of different characteristics.Materials and methods: 65
features are extracted frommedical records (age, stage⋯) and
PET images: classical features (SUV, Metabolically Tumor
Volume (MTV) ⋯), 1st order features (skewness, entropy
⋯) and texture parameters from texture matrices: Gray Level
Cooccurrence Matrix (GLCM), Gray Level Zone Length Ma-
trix (GLZLM) and Gray Level Difference Matrix (GLDM).
Patient classification is performed using RF algorithm with
2000 decision trees, firstly without any Feature Selection
(FS), and secondly with a FS. The selection is performed in
2 steps. First, a correlation analysis is done using the Spearman
method to keep uncorrelated features. They are compared two
by two and are considered as correlated if the Spearman coef-
ficient (sp) verified |sp| ≥ 0.8 and p < 0.05. Next, the RF
algorithm is applied on the remaining features to find the most
relevant features using the importance index. The RF classifier
has been applied to a database of 66 patients with an oesoph-
ageal cancer treated by radio-chemotherapy (CRT). The clas-
sification accuracy has been evaluated using the Out-Of-Bag
(OOB) error.Results: When the RF classifier is applied to the
65 initial features, OOB error reaches 33.3% and 25.8% for
prognostic and predictive studies respectively. The FS strategy
improves the classification accuracy, to reach an OOB error of
22.7% and 22.7% respectively. The Spearman analysis re-
vealed that none of the clinical data are correlated with PET
characteristics, neither for correlation (GLCM), Cluster Shade
(CS, GLCM) Busyness (GLDM) and Zone Percentage (ZP,
GLZLM). Twelve groups of correlated features can be created
leading to 31/65 features selected. The best 3 prognostic fea-
tures are MTV, correlation (GLCM) and the Nutritional Risk
Index (NRI), whereas the best 3 predictive features are MTV,
ZP and correlation (GLCM).Conclusion: ML technique, such
as random forest classifier, is an interesting tool to find the
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most relevant among a large amount of features, to classify
patients. A FS is mandatory to improve the classification ac-
curacy. In case of oesophageal cancer, MTV and texture pa-
rameters appear as relevant feature and improve predictions.
OP162
Biomathematical modeling approach to predict clinical
SUVR in amyloid PET imaging towards efficient
radioligand discovery and development
Y. Arakawa1, M. Shidahara1, Y. Nai2, S. Furumoto2, C. Seki3,
N. Okamura1, M. Tashiro2, M. Tashiro2, Y. Kudo1, K. Yanai1,
K. Gonda1, H. Watabe2; 1Tohoku University School of Med-
icine, Sendai, JAPAN, 2CYRIC, Tohoku University, Sendai,
JAPAN, 3National Institute of Radiological Sciences, Chiba,
JAPAN.
Aim: Purpose of the study is to develop a new methodology to
predict clinical SUVR of amyloid PET radioligands by extend-
ing biomathematical modeling, which was previously pro-
posed by Guo et al. [1]. Methods: 6 amyloid radioligands,
[11C]PIB, [11C]BF-227, [11C]AZD2184, [18F]FACT,
[18F]Flobetapir and [18F]AZD4694 were explored in this
study. For each tracers, time-activity curves (TACs) were gen-
erated using one-tissue compartment model with arterial plas-
ma input function and calculated kinetic parameters (K1, k2
and BPND). By biomathematical modeling simulation, K1, k2
and BPND values were derived using lipophilicity (logP), ap-
parent volume (Vx), free fraction in plasma (fP), free fraction
in tissue (fND), dissociation constant (KD) and density of
Amyloid β (Bavail) [1]. Lipophilicity was using ClogP
(chemoffice ver. 2012, Hulinks Inc.), moriguchi logP, MlogP
(dproperties, Affinity Science corp.). Vx was also computed
using dproperties. Both fP and fND were calculated by rela-
tional expressions among logP, fND and fP. Regression lines
of logP vs. fND and fND vs. fP. were derived from three
publications, Guo et al. [1], Summerfield et al. [2] and Wan
et al.[3]. KDwas obteined from publications. Bavail was fixed
at 3nM for healthy control (HC) and 50nM for severe
Alzheimer Disease (AD) patient. Predicted SUVRs of HC
and AD were then obtained by dividing the summed TACs
of the target region over that of the reference region. The
predicted SUVRs of HC and AD for each tracer were then
compared with previously reported in vivo SUVRs of HC
and AD groups respectively. The correlations between predict-
ed and reported SUVRs were compared for 6 combinations of
logP and regression line (ClogP-Guo, ClogP-Summerfield,
ClogP-Wan, MlogP-Guo, MlogP-summerfield and MlogP-
Wan). Results: Good correlations between predicted SUVR(y)
and in vivo SUVR(x) were observed in the case of MlogP-
Summerfield (y = 1.05 x + 0.04, r2 = 0.70) andMlogP-Wan (y
= 2.67 x - 1.42, r2 = 0.70). On the other hand, poor correlation
was observed in case of ClogP-Guo (y=0.59x+0.36, r2=0.38).
Conclusion:Proposed methodologies (MlogP-Summerfield
and MlogP-Wan) were able to predict SUVR with good cor-
relation against in vivo SUVRs for 6 amyloid tracers, showing
potential to be applied to other amyloid radioligands. Refer-
ence: [1] J Nucl Med. 2009, 50(10):1715-23. [2] J Pharmacol
Exp Ther, 2006; 316:1282-90 [3] J. Med. Chem. 2007,
50:4606-15
OP163
Correlation of SUV and tumor to blood standard uptake
ratio (SUR) with the metabolic uptake rate derived
from quantitative dual time point measurements.
F. Hofheinz1, J. van den Hoff1, A. Lougovski1, K. Ego2, H.
Amthauer2, I. Apostolova2; 1Helmholtz-Zentrum Dresden-
Rossendorf, Dresden, GERMANY, 2Clinic of Radiology and
Nuclear Medicine, University Hospital, Magdeburg,
GERMANY.
Aim: Determination of tumor SUV is widely used for quanti-
tative assessment of tumor metabolism in FDG-PET. Howev-
er, the SUV approach has several well known limitations
compromising its ability to act as a surrogate parameter of
glucose consumption. Recently, we have shown that SUR
overcomes most of these limitations as long as FDG kinetics
in the target structure can be considered irreversible [1,2]. Ex-
cellent linear correlation of SUR and Km from Patlak analysis
was found using dynamic imaging of liver metastases. How-
ever, due to the perfectly standardized uptake period used for
SUR determination and the comparatively short uptake period
these results are not directly applicable to clinical whole body
examinations, in which the uptake periods often vary consid-
erably. Therefore, the aim of this work was to investigate the
correlation of SUR and Km in clinical whole body scans,
where Km was approximated by Ks derived from dual time
point (DTP) measurements [3]. Methods: DTP FDG-PET/CT
was performed in 76 consecutive patients with histologically
proven NSCLC. In the PET images the primary tumor was
delineated with an adaptive threshold method. For determina-
tion of the blood SUV the aorta was delineatedmanually in the
attenuation CT. The aorta ROI was transferred to the PET
image. Blood SUV was computed as the mean value of the
aorta ROI. SUR values were computed as ratio of tumor SUV
and blood SUV. SUR values were scan-time-corrected to
60 min p.i. as described in [2]. Metabolic uptake rate Ks was
computed similar to the procedure in [3]. The correlation of
SUV and SUR with Ks was investigated. Results: There was
highly significant correlation of SUR and Ks ( R2=0.9). How-
ever, the correlation coefficient appeared somewhat lower than
previous results obtained from dynamic imaging and standard-
ized uptake times (R2=0.96 [1]). As expected, SUV showed
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markedly lower correlation with Ks than SUR (R2=0.76).
Conclusion: Our results show that in clinical whole body
PET the correlation of uptake values with the metabolic trap-
ping rate can be improved notably by blood normalization and
scan-time-correction. Furthermore, the high correlation of
SUR with Ks indicates that for histologically unambigous tu-
mor lesions DTP do not provide added value in comparison to
the SUR approach. Literature: [1] EJNMMI Res 2013,3:77 [2]
EJNMMI Res 2014,4:18 [3] EJNMMI Res 2012,3:16
OP164
Impact of Use of Fanbeam Collimator in Interpretation
of 99mTc-TRODAT Scans and Comparison of Image
Quality with Low Energy High Resolution Collimator
by Inter-observer Agreement Using Kappa Statistics
H. Rathore1, T. Bharadwaj1, H. Shah1, P. Aland1, B. Jois KS1,
S. Ghosh1, L. Reddy1, P. Chandrak2, M. Prabhu3, P. Kumar1,
P. Chaudhuri1, C. Sekhar1, S. Shraddha1, V. Lele1; 1Jaslok
Hospital and Research centre, Mumbai, INDIA, 2Tata Memo-
rial Hospital, Mumbai, INDIA, 3Narayana Hrudayalaya, Ban-
galore, INDIA.
Introduction: 99mTc Trodat Brain SPECT is a powerful tool in
diagnosis and evaluation of patients with Parkinsonism. How-
ever the unavailability of finite resolution and lack of anatomic
details makes the interpretation of scans difficult. With the
advent of the Fanbeam ultra high resolution collimator
(FBUHR), the resolution and sensitivity has increased multi-
fold. Aim: 1. To prove if use of Fanbeam Collimator improves
inter-observer agreement within Nuclear Medicine Physicians
in regards to interpretation of 99mTc-TRODAT scans. 2. To
compare image quality of FBUHR and Low Energy High
Resolution (LEHR) collimator in 99mTc-TRODAT imaging.
Materials and Methods:-99mTc Trodat scans acquired over a
period from January 2014 to April 2015 were included in the
study. • 40 scans - 20 from each FanBeam and LEHR were
made anonymous, randomised and were given to three nuclear
medicine physicians A, B, C, who interpreted them individu-
ally as normal and abnormal, the scan quality was interpreted
as good and average or poor.• The data was analysed between
3 groups, Group I included A and B, II included B and C, III
included A and C. Using Kappa(k) analysis in terms of agree-
ment, <0 suggesting that less than chance agreement, 0.01-
0.20slight, 0.21-0.40fair, 0.41-0.60moderate, 0.61-0.80sub-
stantial, and 0.81-0.99 almost perfect agreement, 1 is perfect
agreement and 0 is exactly what would be expected by chance.
Result: Our data indicate that the imaging outcome expressed
by the inter-observer agreements and quality of scans has an
excellent test reproducibility and correlates with imaging qual-
ity and disease severity. In overall evaluation, we found Mod-
erate Agreement in all 3 groups I, II, III with kappa 0.46,
0.525, 0.421 respectively for scan quality andModerate agree-
ment in group I and III, and Substantial Agreement in the
group II for diagnosis of Parkinsonism. Individually, the
FBUHR shows kappa value of 0.48, 0.49, 0.56 and LEHR
shows -0.041, 0.062, -0.086 in groups I, II, III respectively
for Scan Quality which shows moderate agreement in all 3
IOA groups for FBUHR, and less than chance agreement or
slight agreement for LEHRCollimator. These findings suggest
that 99mTc-TRODAT BRAIN SPECT imaging using FBUHR
is useful and feasible for imaging Parkinsonism with more
accuracy than LEHR. Conclusion: The image quality was con-
sistently rated better with the use of FBUHR as compared to
the LEHR collimator. This translated in an improved interob-
server agreement across scans with the use of FBUHR,
resulting in better scan interpretation.
OP165
Standardized uptake values of 99mTc-MDP SPECT bone
scans - a novel method for absolute SPECT/CT
quantification
W. He, W. Zhai, W. Yu; Huadong Hospital, Shanghai,
CHINA.
Objectives : To investigate the variation of SUV values in
99mTc-MDP bone scans using SUV SPECT hybrid recon-
struction based quantitative methods. Methods: 535 patients
(mean age 63.07) without bone metastasis which has been
diagnosed by CT and MRI were enrolled in this study ,and
they were divided into four groups : 100 cervical vertebra
cases , 161 thoracic vertebra cases, 172 lumbar vertebra cases
and 102 pelvis cases. To generate SUV-calibrated images, the
raw SPECT data was reconstructed using the software ‘SUV-
SPECT’ (HERMES MEDICAL SOLUTIONS). Corrections
were applied for CTattenuation, Monte Carlo-modeled scatter
correction, resolution recovery, scaling for injected dose and
radioactive decay. The units of counts-per-voxel were scaled
to activity per unit volume (Bq/cc) based on previously per-
formed phantom calibration work to allow for SUV measure-
ments. The reconstructed images were analyzed using a
constrained threshold-based volume of interest approach to
automatically calculate the uptake in the bony structures.
SUVmax by body weight was recorded in the derived volume.
All the values were measured twice to verify consistency.95%
medical reference range SUV was generated .Results : The
mean SUVmax of cervical vertebra group was 9.78±3.07 (
ranging from 5.00 to 17.27 ), thoracic vertebra8.81
±2.17(ranging from 5.11 to 12.82 ),lumbar vertebra 9.64
±2.48 (ranging from 5.81 to 15.58)and pelvis( ranging from
5 . 7 2 t o 1 6 . 9 9 ) . T h e r e p e a t e d r e s u l t s w e r e
consistent.Conclusions : This method is accurate, easy-to-use
and robust, providing absolute quantification in SPECT/CT,
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which promises to be widely used in primary diagnosis and
evaluation of therapy response.
OP166
Development of Motion Correction Methods for Cardiac
PET Imaging
T. Noponen1,2, R. Klén1,3, T. Kokki1,2, J. Teuho1, K.
Thielemans4, J. Koikkalainen5, E. Hoppela1, H. Sipilä1, J.
Lötjönen5, M. Teräs1, J. Knuuti1; 1Turku PET Centre, Turku
University Hospital and University of Turku, FINLAND, 2De-
partment of Nuclear Medicine, Turku University Hospital,
FINLAND, 3Department of Mathematics and Statistics, Uni-
versity of Turku, FINLAND, 4University College London,
London, UNITED KINGDOM, 5Knowledge Intensive Ser-
vices, VTT Technical Research Centre of Finland, FINLAND.
Introduction: In cardiac PET, pulsatile and respiratory motion
may cause severe artifacts. Especially when imaging few mil-
limeter targets such as coronary plaques, cardiac tumors or
focal inflammations without any motion correction, a few cen-
timeter physical movement of the heart can impair an image
quality significantly. In this project, dual gating and motion
correction methods for cardiac PET were developed and their
technical features were studied. Material and methods: Respi-
ratory gating methods based on spirometry and impedance
measurements were developed and tested with cardiac MR
and PET imaging. Additionally, three motion correction
methods were implemented for cardiac PET/CT imaging. In
the first method, dual-gated data from PET images were only
used to compensate respiratory and pulsatile motion. In the
second method, the respiratory motion correction was imple-
mented by using respiratory gated CT images and pulsatile
motion by using solely PET data (CT-PET based method). In
the third method, dual-motion correction was carried out by
using CT based motion models (CTonly method). These tech-
niques were tested using phantom and patient data. Further-
more, the optimal number of dual-gates for cardiac PET was
studied. Results: Spirometry based respiratory gating method
was found to be feasible in both cardiac MRI and PET studies.
The amplitude of spirometry signal correlated well with the
respiratory induced movement of heart. Impedance based re-
spiratory gating method worked well especially in time-based
gating. The motion correction did not succeed, when only PET
data were used for motion modeling. However, CT-PET based
and CT-only methods were able to correct respiratory and
pulsatile motion efficiently in both phantom and patient stud-
ies. The motion was reduced in the patient study from 19 to
9 mm and in the phantom study from 15 to 5 mm. Addition-
ally, the optimal number of dual gates for cardiac PET was
found to be 24. Conclusions: Using our dual-gating approach
and motion-correction methods, both respiratory and pulsatile
motions can be reduced significantly in cardiac PET imaging.
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OP167
Long-term Prognostic Value of Stress Myocardial
Perfusion Imaging and Coronary Computed Tomography
Angiography: a Meta-analysis
V. Cantoni1, R. Green1, W. Acampa2, M. Petretta3, G. De
Matteis1, B. Russo1, T. Mannarino1, M. Salvatore4, A.
Cuocolo1; 1Department of Advanced Biomedical Sciences,
University of Naples Federico II, Naples, ITALY, 2Institute
of Biostructure and Bioimaging, National Council of Re-
search, Naples, ITALY, 3Department of Translational Medical
Sciences, University of Naples ‘Federico II’, Naples, ITALY,
4IRCCS SDN, Naples, ITALY.
Aim: Although stress myocardial perfusion imaging (MPI) by
single photon emission computed tomography and coronary
computed tomography angiography (CCTA) should be con-
sidered complementary, as the anatomical data provided by
CCTA differ from the functional information obtained by
stress MPI, in clinical these two imaging modalities are alter-
natively used. Thus, we performed a meta-analysis of pub-
lished studies, including patients with suspected or known
coronary artery disease (CAD), to compare the long-term pre-
dictive value for adverse cardiac events of stress MPI and
CCTA.Material and methods: An English literature search
was performed using the PubMed, Cochrane, Web of Science,
and Scopus database to identify articles published between
January 2000 and June 2014. To harmonize the predictors of
interest, a study was included if all of the following criteria
were met: 1) reported a prospective or retrospective analysis of
subjects with suspected or known CAD referred for stress MPI
to search inducible ischemia or CCTA to detect significant
stenosis; 2) provided the unadjusted and/or adjusted hazard
ratio (HR) at Cox regression analyses of dichotomous abnor-
mal versus normal perfusion at MPI or coronary stenosis
≥50% luminal narrowing at CCTA; 3) provided primary data
on clinical outcomes for adverse events with a follow-up ≥2.5
years; 4) included ≥100 patients.Results: Total of 20 articles
(10 MPI and 10 CCTA) were finally included, recruiting 22,
280 patients (13,484 in MPI and 8,796 in CCTA studies). The
pooled HR for the occurrence of the primary end point was
lower (P=0.04) for MPI (HR 2.60, 95% confidence interval,
CI, 2.06-3.29) compared to CCTA (HR 5.70, 95% CI 2.68-
12.1). Among the included publications, 4 MPI and 4 CCTA
S72 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
studies reported the HR for the occurrence of hard events
(nonfatal myocardial infarction or cardiac death). The pooled
HRwas comparable (P=0.11) for MPI (HR 2.75, 95%CI 2.11-
3.59) and CCTA (HR 5.34, 95% CI 2.46-11.60) studies. The
HR for the occurrence of a combined end point including
revascularization was reported in 5 MPI and 6 CCTA studies.
The pooled HR was higher (P=0.002) for CCTA (HR 8.27,
95% 3.77-18.14) compared to MPI (HR 2.84, 95% CI 1.68-
4.79).Conclusion: CCTA appears more predictive than MPI
when coronary revascularization is included in the end point.
On the other hand, no differences exist in the prognostic effec-
tiveness of MPI and CCTA for the occurrence of hard events.
OP168
Clinical utilization of submillisievert stress only
myocardial perfusion imaging and concurrent coronary
artery calcium score: A single institutional experience
of a novel cardiac SPECT camera using cadmium zinc
telluride (CZT) semiconductor technology
J. Liu, E. Hasche, J. Kilian, H. Dixson, B. Elison, C. Bui, H.
Tie, R. Dunn, C. Smillie, Q. Chiam, K. Lee; Bankstown-
Lidcombe Hospital, Bankstown, AUSTRALIA.
Aim: To investigate the clinical impact of ultralow dose
stress only myocardial perfusion imaging (ULDSO-MPI)
and concurrent coronary artery calcium score (CACS) on
patients with low pre-test probability for ischaemic heart
disease while achieving submillisievert radiation expo-
sures. Material and methods: 120 consecutive patient
referrals for ULDSO-MPI with concurrent CACS on
the Discovery NM/CT 570c camera (GE Healthcare)
were studied. ULDSO-MPI was performed using
100MBq (0.8mSv) Tc-99m sestamibi and 10 minute cad-
mium zinc telluride (CZT) - SPECT acquisition. CACS
was performed using low dose (0.8mSv) prospective
ECG gated CT acquisition and adaptive statistical itera-
tive reconstruction (ASIR). CACS CT was synergistical-
ly used for SPECT attenuation correction. Outcomes
were obtained in 103/120 patients based on cardiology
outpatient clinic letters. Results: Technically satisfactory
studies were obtained in all patients. Total (ULDSO-
MPI+CACS) radiation dose was 1.61±0.11mSv (mean
±SD). All 47 patients with zero CACS had a normal
MPI result, and 94 %( 44/47) were subsequently
discharged from COPCs (defined as no scheduled COPC
appointment within the next 12 months). 38/103 patients
were started on more aggressive medical therapy. Statis-
tical analysis using Wilcoxon rank sum (Mann-Whitney
U) test demonstrated that the patient group started on
more aggressive medical therapy was associated with
significantly higher CACS (mean CACS = 253) when
compared with the group of no change to medications
(mean CACS = 28, p < 0.0001). Meanwhile, the patient
group with ongoing follow up was associated with sig-
nificantly higher CACS when compared with the dis-
charge from clinic group (p < 0.001). Conclusion: Ul-
tralow dose stress only imaging with calcium score is
clinically useful and is associated with a very low total
radiation dose (1.6 mSv). MPI assesses the short term
while the CACS assesses the long term risk for devel-
oping ischaemic heart disease. Concurrent zero CACS
and normal MPI aid subsequent patient discharge from
the COPCs (94% discharge rate). Abnormal CACS leads
to more aggressive medical therapy, particularly as the
calcium score risk level rises.
OP169
Detection of myocardial ischemia using artificial neural
network: different characteristics from conventional
defect scoring methods
K. Nakajima1, S. Matsuo1, K. Okuda2, K. Yokoyama3, H.
Bunko4, S. Kinuya1, L. Edenbrandt5; 1Kanazawa University
Hospital, Kanazawa, JAPAN, 2Kanazawa Medical University,
Uchinada, JAPAN, 3Matto Ishikawa Central Hospital,
Hakusan, JAPAN, 4Kanazawa Cardiovascular Hospital, Kana-
zawa, JAPAN, 5University of Gothenburg, Gothenburg,
SWEDEN.
Purpose. Although induced ischemia has been evaluated using
stress myocardial perfusion imaging with visual and quantita-
tive scoring methods, a new approach using artificial neural
network (ANN) to detect ischemia was developed and its char-
acteristics to identify abnormality were examined. Methods.
Patients with coronary artery diseases were selected from 3
hospitals. Mean age was 70±10 years (male 61%) and all pa-
tients underwent coronary angiography (0-, 1-, multi-vessel
disease (MVD): 25, 29, 52 cases). Patients with old myocar-
dial infarction (OMI, 27%) and coronary revascularization
(30%) were included. The training database for the ANN sys-
tem included normal and perfusion defects, and was classified
by experienced physicians, in which 1051 patients (M/F=498/
553) were included. Quantification of defects by summed
stress/rest/difference scores (SSS, SRS, SDS) were used as a
reference, and the normal database using Japanese Society of
Nuclear Medicine working group was installed (cardioREPO
software). The gold standards were expert consensus of well-
experienced nuclear physicians and coronary stenosis of ≥75%
or ≥50%. ANN identified abnormal areas and probability
(ANN values) in the stress map (ANN stress defect) and dif-
ference map between rest and stress (ANN ischemia). Diag-
nostic accuracy of ANN was compared to conventional visual
consensus and scoring methods. Results. The ANN stress
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defect value was higher in the consensus defect group than in
the no-defect group (0.92±0.11 vs. 0.25±0.32, P<0.0001), and
the ANN ischemia was higher in the ischemia group than in
the no-ischemia group (0.70±0.40 vs. 0.004±0.032,
P<0.0001). Area under the curve with receiver-operating char-
acteristics curve analysis (AUC-ROC) showed comparable di-
agnostic accuracy between ANN and the scoring methods
(0.97 vs. 0.98 for stress defect, and 0.88 vs. 0.94 for ischemia,
both P=NS). When diagnostic accuracy was examined with
neither OMI nor revascularization they were also comparable
(ROC-AUC: ANN ischemia 0.93, ANN stress defect 0.97).
The relationship between ANN and scores were not linear,
and the ANN increased in the range of SSS and SDS of 0 to
6 rapidly, reaching plateau (nearly 1.00) in the higher score
level. Even when coronary stenosis was used as the gold stan-
dard of abnormality in patients with neither OMI nor revascu-
larization, sensitivity, specificity and accuracy did not differ
significantly among visual consensus, scoring method and
ANN methods. Conclusion. ANN provided comparable diag-
nostic accuracy to the expert interpretation for detection of
ischemia even including patients with MVD, OMI and revas-
cularization. The different characteristics from the scoring
could provide good adjunctive diagnostic suggestions in clin-
ical practice.
OP170
Nuclear Cardiac Imaging Versus Fractional Flow Reserve
in Diagonal Side Branch Ostial Stenosis After Left
Anterior Descending Crossover Stenting
S. Fukuzawa, S. Okino, J. Maekawa, S. Ichikawa, N.
Kuroiwa, K. Yamanaka, T. Igarashi, M. Inagaki; Funabashi
Municipal Medical Center, FUNABASHI, JAPAN.
Background: Although angiographic stenosis of a side
branch ostium is frequently observed after stent implan-
tation in a main vessel, the clinical advantages of
treating these lesions using complex interventional strat-
egies remain unclear, and such interventions may in-
crease the subsequent risk of adverse clinical events. In
addition, these lesions cannot be properly evaluated by
conventional coronary angiograms. Objectives: The aim
of this study was to compare fractional flow reserve
(FFR) and ischemic burden with nuclear cardiac imaging
in jailed ostial diagonal lesions after main left anterior
descending artery (LAD) crossover stenting. Methods:
38 patients with LAD lesions treated by main LAD
crossover single stenting were consecutively enrolled.
After successful stenting, FFR was measured at the
jailed diagonal side branch. Additional interventions
were not performed at the same procedure except TIMI
3 f low of side branch. Int racoronary pressure
measurements to determine FFR of the jailed side
branch are increasingly performed during coronary an-
gioplasty. Furthermore, one-day stress-rest Tc-99m
sestamibi nuclear imaging protocol was used for all pa-
tients after procedure within 2 weeks. Results: Among
18 side branches with > 75% diameter stenosis, 6 (33%)
had FFR ≤ 0.75, and among 20 side branches with ≤
75% diameter stenosis, one (5%) had FFR ≤ 0.75 after
stent implantation in main vessels. Nuclear study dem-
onstrated inducible ischemic burden (>10%) in only one
case of all patients. On the other hand, 26 (68%) pa-
tients showed no ischemic area. Clinical follow-up was
performed in all patients. Mean duration was 28±9
months. During the follow-up period, one patient of
the inducible ischemia underwent side branch stenting
and 2 patients underwent TLR because of main stent
restenosis. No stent thrombosis was observed in these
patients. Conclusion: The finding of the current study
is that there is a discrepancy between angiographic per-
cent diameter stenosis and FFR in jailed side branch
lesions. Furthermore, nuclear imaging demonstrated that
almost of the patients with inadequate FFR of side
branch had mild (<10%) ischemic burden and good
prognosis.
OP171
In vivo validation of gated myocardial SPECT imaging
for quantification of small hearts: comparison
with cardiac MRI
C. Kondo, E. Watanabe, M. Momose, K. Fukushima, K. Abe,
N. Hagiwara, S. Sakai; Tokyo Women’s Medical University,
Tokyo, JAPAN.
Aim:In patients with small hearts, defined as an end-systolic
volume (ESV) of ≤20 ml calculated using the Quantitative
Gated SPECT (QGS) program for gated myocardial perfusion
imaging, underestimation of ESV and overestimation of ejec-
tion fraction (EF) are frequent and have limited reliability. A
newly developed cardiac software, cardioREPO (cREPO, pre-
viously named EXINI heart), using novel active shape model-
ing and volume-dependent edge correction algorithm for left
ventricular (LV) delineation, effectively reduces the effects on
ESV and EF of a small heart documented on digital phantom
experiments (Nakajima K, EJNMMI 2013). The aim of this
study was to validate cREPO in vivo for measuring LV vol-
umes and EFs of both small and normal-sized hearts compared
with cardiac MRI (CMR). Materials and Methods: We per-
formed stress 99mTc-MIBI SPECT and gated CMR within
30 days interval for 33 patients (mean age, 66 yrs; 19 male)
with known or suspected coronary artery disease. Post-
processing of resting SPECT data using both QGS and cREPO
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provided EF, end-diastolic volume (EDV) and ESV. These
results were compared with corresponding data from CMR
measured independently by experts in a totally blinded fash-
ion. The following data are expressed as mean±SD (range).
Results:The study subjects had body surface area of 1.67±0.17
m2 (1.32-1.98 m2) and consisted of 15 small and 18 normal-
sized hearts. CMR gave EFs, EDVs and ESVs of 61%±4%
(52%-70%), 127±27ml (85-191ml) and 52±17ml (27-91ml).
QGS gave these values of 68%±10% (43%-86%, p<0.0001 vs
CMR), 72±20 ml (42-119 ml, p<0.0001 vs CMR) and 25
±14ml (8-66 ml, p<0.0001 vs CMR). cREPO also gave values
of 70%±4% (61%-77%, p<0.0001 vs CMR), 87±21 ml (50-
131 ml, p<0.0001 vs both CMR and QGS) and 26±8 ml (12-
55 ml, p<0.0001 vs CMR). Bland Altman plots showed the
deviations (mean±1.96SD) of QGS from CMR of EF, EDV
and ESV were 7%±16%, -55±28 ml and -27±23 ml, respec-
tively, and the values of cREPO from CMR were 9%±10%, -
41±29 ml and -26±26 ml, respectively. The magnitude of the
overestimation of EF by QGS compared with CMR strongly
correlated with given EF values (r=0.80, p<0.0001), but no
significant correlation was seen with cREPO (r=-0.09,
p=0.62). Thus, cREPO provided relatively constant overesti-
mation of EFs by 9% from CMR within the range of EFs in
both small and normal-sized hearts. Conclusion:The active
shape modeling and volume-dependent edge correction pro-
gram effectively reduced overestimation of EF of a small heart
in vivo.
OP172
Diabetes Mellitus independently determines PET-derived
systolic function
L. Juárez-Orozco1, R. J. J. Knol2, R. A. Tio3, S. Lazarenko2,
R. H. J. A. Slart3, F. M. van der Zant2; 1Rijksuniversiteit Gro-
ningen, Groningen, NETHERLANDS, 2Medical Center Alk-
maar, Alkmaar, NETHERLANDS, 3University Medical Cen-
ter Groningen, Groningen, NETHERLANDS.
Type 2 diabetes mellitus (DM) has an important role in
the development of coronary artery disease (CAD) and
may influence systolic function by disturbance of coro-
nary vasculature dilatory capacity. Myocardial perfusion
PET is the current reference technique for quantitative
evaluation of myocardial blood flow (MBF) and for as-
sessment of the myocardial perfusion reserve (MPR).
Moreover, PET can accurately determine systolic func-
tion through the left ventricle ejection fraction (LVEF).
The present study aimed to evaluate a suspected rela-
tionship between DM and systolic function when ac-
counting for MPR and additional cardiovascular risk fac-
tors. METHODS: We retrospectively included, with a
prospective analysis, 591 patients without previous
myocardial infarction, referred for dynamic and gated
rest and adenosine stress 13NH3 myocardial perfusion
PET between 2012 and 2014. Six patients were exclud-
ed for incomplete quantitative perfusion, expressed by
MPR, or systolic function expressed by resting LVEF.
Clinical records were retrieved for demographic data.
MBF and MPR were obtained from the PET data using
the SyngoMBF software package. DM was operational-
ized as a dichotomous variable for presence or absence
of the disease. After distribution evaluation of the con-
tinuous predictors we performed a bootstrapped multiple line-
ar regression analysis for gender, age, hypercholesterolemia,
hypertension, smoking habit, DM and MPR as independent
variables and LVEF (expressed as a percentage) as the depen-
dent variable for the model. The statistical analysis was per-
formed using SPSSv.21. P-values ≤ 0.05 were considered sta-
tistically significant. RESULTS: Our population (mean age of
66.3±10 years) was composed by 293 males and 297 females.
Of these, 16% (94) were smokers, 57.1% (336) had hyperten-
sion, 37.6% (221) had hypercholesterolemia, 33.8% (199) had
a positive family history for CAD and 15.2% (83) were known
with DM. A mean global MPR of 2.17±0.57 and mean LVEF
65.7%±12.2 was measured. Consecutively, multiple linear re-
gression analysis showed a statistically significant relation for
age B=6.986 S.E.=1.013 95%CI [5.115, 8.929], p=0.001,
MPR B=2.081 S.E.=0.908 95%CI [0.442, 3.713], p=0.021,
and the presence of DM B=-3.108 S.E.=1.288 95%CI [-
5.674, -0-668], p=0.016. CONCLUSION: There is a signifi-
cant relationship between DM and PET-derived systolic func-
tion in patients without a previousmyocardial infarction which
persists when accounting for the significant relationship that
age and global MPR (along with clinically relevant risk fac-
tors) have with LVEF. Our study underlines the importance of
DM as a risk factor for deteriorating systolic function. This
warrants the need for further research into elucidating the in-
tegration of DM and MPR in early clinical decision-making.
OP173
Are myocardial perfusion reserve and LVEF modified
by diabetes mellitus? A cardiac PET study.
L. Juárez-Orozco1, R. H. J. A. Slart1, R. A. Tio1, H. H.
Boersma1, A. Ayala-German2, L. Walls-Laguarda2, R. A.
Dierckx1, E. Alexanderson3; 1University Medical Center Gro-
ningen, Groningen, NETHERLANDS, 2Universidad
Nacional Autónoma de México, Mexico City, MEXICO,
3Instituto Nacional de Cardiología “Ignacio Chávez”, Mexico
City, MEXICO.
Diabetes mellitus (DM) constitutes a chronic degenerative dis-
ease with an elevated risk of cardiovascular events. State-of-the-
art techniques such as PET myocardial perfusion scanning have
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demonstrated that myocardial perfusion reserve (MPR), as well
as the left ventricle ejection fraction (LVEF), offer predictive
value for adverse cardiovascular events in the setting of coronary
artery disease (CAD). Moreover, MPR in spared myocardium
(MPR-sm) has shown to be related to systolic function in CAD
patients. The present study aimed to evaluate whether the rela-
tionship between quantitative perfusion assessed by MPR-sm
and LVEF is modified by the presence of diagnosed DM.
Methods. We retrospectively included, with prospective analy-
sis, 178 patients (124/54 men/women) who were referred to a
PET perfusion scan for known or suspected CAD. There were
60 patients with previously diagnosed DMwhowerematched to
non-diabetic controls (118 patients) according to age, gender,
BMI, and size of previous infarction (when present). Other car-
diovascular risk factors were comparable. All of the patients
underwent a 2-phase (rest and adenosine stress) [13N] Ammonia
gated myocardial PET scan. SyngoMBF and QPS-QGS soft-
ware were utilized for reconstruction and interpretation of the
scans. The areas of previous infarction were excluded manually
to account for the MPR-sm. After the univariate analysis, we
performed a linear regression analysis utilizing the general linear
model for LVEF using MPR-sm, DM, and pairing variables. An
interaction considering MPR-sm and DMwas manually entered
in a second step. A p-value<0.05 was considered significant for
derived coefficients. Results. Mean age for the diabetic and non-
diabetic groups was 66±9 and 65±9 respectively. There
was cumulative frequency of 93 (57.8%) with dyslipid-
emia, 104 (64.6%) with hypertension, 71 (44.1%) of
smokers, and 77 (43%) with a previous MI. The univar-
iate analysis for LVEF as the dependent variable re-
vealed a trend towards significance for DM (p=0.06)
and a high significance for the MPR-sm (p=0.001).
MPR-sm was found to be significant predictor variable
for LVEF (p=0.001) while DM resulted not to be signif-
icant (p=0.49). The interaction for predictors was per-
formed manually without yielding significance. Conclu-
sion. The presence of DM in patients with known or
suspected CAD is not a modifier for the strong relation-
ship between MPR-sm and LVEF. The independent cor-
relation between DM and MPR-sm with LVEF suggest
that a possible direct effect of DM on LVEF is
outweighed by the effect of MPR-sm. Further studies
for gaining insight on the impact of DM in the
perfusion-function relationship are warranted.
OP174
Coronary Artery Calcium and Coronary Flow Reserve
by Hybrid Rb-82 PET/CT Imaging in Non-diabetic
and Diabetic Patients With Normal Myocardial Perfusion
R. Assante1, P. Arumugam2, E. Zampella1, V. Gaudieri1, C.
Nappi1, T. Mannarino1, D. Tout2, M. Larobina3, B. Russo1, W.
Acampa3, M. Petretta4, C. Tonge2, A. Cuocolo1; 1Department
of Advanced Biomedical Sciences, University of Naples
Federico II, Naples, ITALY, 2Nuclear Medicine Centre, Cen-
tral Manchester University Teaching Hospitals, Manchester,
UNITED KINGDOM, 3Institute of Biostructure and
Bioimaging, National Council of Research, Naples, ITALY,
4Department of Translational Medical Sciences, University
of Naples ‘Federico II’, Naples, ITALY.
Aim: We assessed the relationship between coronary artery
calcium (CAC) and coronary flow reserve (CFR) in non-
diabetic and diabetic patients with normal stress myocardial
perfusion imaging.Materials and Methods: We evaluated 541
consecutive patients (441 non-diabetic and 100 diabetic pa-
tients) without a documented history of CAD and normal
myocardial perfusion imaging at vasodilator stress Rb-82
PET/CT imaging. The CAC score was measured according
to the Agatston method. Resting and hyperemic myocar-
dial blood flow (MBF) and CFR were automatically
quantified. Patients were stratified into two groups based
on their CAC score (0-99.9 and ≥100). The Spearman
correlation coefficient was assessed between continuous
CAC score and MBF or CFR values. Univariable and
multivariable logistic regression analyses were used to
determine the variables associated with reduced (<2)
CFR.Results: Among non-diabetic patients, 330 (75%)
had CAC <100 and 111 (25%) ≥100, while in diabetic
patients 65 (65%) had CAC <100 and 35 (35%) ≥100
(p<0.05). CFR was reduced in 54 (16%) non-diabetic
patients and in 19 (29%) diabetic patients with CAC
<100 (p<0.05). In both non-diabetic and diabetic patients,
CAC score was inversely correlated with hyperemic MBF
(r=-0.15 and r=-0.26, respectively, p<0.05) and CFR (r -
0.19 and r=-0.23, respectively, p<0.05). On the contrary,
there was no correlation between CAC and baseline MBF
in both non-diabetic and diabetic patients. In non-diabetic
patients, univariable analysis demonstrated that age
(p<0.001), hypertension (p=0.05) and CAC score
(p<0.001) displayed an inverse relationship with CFR,
while multivariable analysis indicated that age (p<0.05)
and CAC score (p<0.05) were independently correlated
with reduced CFR. In diabetic patients, age (p<0.05)
and CAC score (p<0.05) displayed an inverse relation-
ship with CFR. However, at multivariate analysis only
CAC score (p<0.05) resulted as independent predictor of
reduced CFR in diabetic patients.Conclusions: In diabet-
ic and non-diabetic patients with normal stress myocar-
dial perfusion there is an inverse correlation between
CAC score and both hyperemic MBF and CFR that
remain also after adjusting for age and conventional car-
diovascular risk factors. In diabetic patients without
known CAD a reduced CFR could help to identify early
structural alterations of the arterial wall.
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18F-FDG PET-CT and Radiotherapy Planning in Lung
Cancer - Technical aspects and benefits from metabolic
radiotherapy planning
J. Pinto1, L. Vieira1, D. Faria2, J. Vale3, G. Fonseca3; 1Lisbon
School of Health Technology, Lisbon, PORTUGAL, 2Hospital
Lusíadas Porto, Oporto, PORTUGAL, 3Júlio Teixeira S.A –
Radioterapia, Oporto, PORTUGAL.
Introduction:18F-FDG positron emission tomography/
computed tomography (PET-CT) has become an integral
component of lung cancer staging because it improves
the detection of nodal and distant metastases and signif-
icantly alters patient man¬agement. PET is more sensi-
tive than computed tomography (CT) for staging, delin-
eation of the extent of malignancy and for the identifi¬-
cation of distant metastatic disease. The use of Positron
Emission Tomography - Computer Tomography (PET-
CT) for target volume delineation in radiation treatment
planning allows the combination of the anatomical fea-
tures of CT with the metabolic evaluation provided by
PET.The aim of this study is to compare the definition
of planning target volume (PTV) using CT versus 18-
FDG PET-CT, the impact on the radiotherapy planning
and technical implications on daily routine PET-CT pro-
cedures in a Nuclear Medicine Department.Material and
methods: A total of 20 patients diagnosed with lung
cancer of both genders, with ages between 35-85 years
old, underwent three-dimensional conformal radiotherapy
(3D CRT). In all the patients a CT scan and an 18-FDG
Whole Body PET/TC, complemented with additional
segmental late images for radiotherapy planning were
performed. The delineation of the GTVs was performed
by independent observers based on CT only vs PET-CT
images. The PTV was created using the same margins
for both GTV volumes. PTV was chosen because is the
volume used for radiotherapy treatment planning and
that influences the patient treatment. Both volumes were
compared.Results: Our preliminary results show larger
CT-based PTVs, compared with the PET-CT-based
PTVs. The average total PTV from the CT and PET-
CT scans was 129.87 cm3 and 66,39 cm3 respectively
(p < 0.05). An average reduction of 38% in size was
o b s e r v e d w h e n P E T- C T- b a s e d P TV s w e r e
used.Conclusion: The use of 18-FDG PET-CT allows a
better identification of the metabolic disease in Lung
cancer patients. In the CT scan radiooncologist while
delineating planning volumes tend to include tissue
non metabolic active increasing the GTV and as conse-
quence, the PTV. An increase of planning volume may
lead to alterations in the treatment schemes and increase
in patient comorbidities.
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OP184
Influence of attenuation correction methods in the renal
scintigraphy with 99mTc-DMSA
A. I. Santos1, A. Amaro2, E. Carolino2, H. Silva2, L. Vieira3, T.
F. Vaz2; 1Hospital Garcia de Orta, Almada, PORTUGAL,
2Escola Superior de Tecnologia da Saúde de Lisboa, Lisbon,
PORTUGAL, 3Escola Superior de Tecnologia da Saúde de Lis-
boa & Instituto de Biofísica e Engenharia Biomédica, Faculdade
de Ciências, Universidade de Lisboa, Lisbon, PORTUGAL.
Introduction: The estimate of relative renal function (RRF)
through scintigraphywith dimercaptosuccinic acid labelled with
Technetium-99 metastable (99mTc-DMSA) may be influenced
by kidney depth (KD), due to attenuation by surrounding soft
tissue. The KD is rarely determined and considered for RRF
estimate, so other methods are applied to circumvent this prob-
lem, namely through calculation of the geometric mean (GM) or
by application of empirical formulae. Aim: Identify the influ-
ence of different attenuation correction (AC) methods on RRF
estimate determined by scintigraphy with 99mTc-DMSA. Ma-
terials and methods: Thirty-one patients underwent the same
acquisition protocol of 99mTc-DMSA scintigraphy. Two inde-
pendent Technologists performed the image processing, chang-
ing the method applied for RRF determination, namely:
Raynaud method, Taylor method, Tonnesen method, GM and
without any method of AC (WAC). Each exam was processed
three times in the same conditions. To identify the influence of
the different AC methods on RRF estimate was applied the
Friedman test and to evaluate the association and significance
between KD and the variables age, weight and height was used
Pearson correlation test. Results: Statistically significant differ-
ences were found between the different methods (p<0.001),
except the comparisons between WAC/Raynaud, Tonnesen/
GM and Taylor/GM (p=1.000), for both kidneys. A strong pos-
itive correlation was found between weight and all the methods
of KD estimation. Conclusion: Regarding the three methods of
KD calculation (Raynaud, Taylor, Tonnesen), the Taylor meth-
od is the closest to the GM. The choice of the AC method
influences significantly the quantitative parameters of RRF, that
way the method selected should be used wisely and standard-
ized for each department in order to allow comparisons through-
out time.
OP185
The role of the Nuclear Medicine Technologists
in Cyclotron related Research & Development
P. Costa1, L. Cunha2, L. F. Metello2; 1Nuclear Medicine De-
partment, ESTSP.IPP & CADCTR, Vila Nova de Gaia, POR-
TUGAL, 2Nuclear Medicine Department, ESTSP.IPP &
CADCTR & IsoPor SA, Vila Nova de Gaia, PORTUGAL.
Introduction: Nuclear Medicine is a highly dynamic field,
based on synergies between several different scientific fields
such as Physics, Chemistry, Biology and Engineering, among
others. Over the last decade, several areas of NuclearMedicine
have been particularly active in terms of research. Some ex-
amples are developments made in Instrumentation, Image Pro-
cessing, Therapeutic Applications, Radiopharmacy and Ra-
dionuclide Production. It is undeniable that modern research
requires multidisciplinary cooperation and collaboration. In
this context, advanced practice adequately based on proper
education and training of Nuclear Medicine Technologists
(NMT) should involve active participation in R&D applied
projects. Aim: Using as example one of the fields already
mentioned (Radiopharmacy and Radionuclide Production)
this paper aims to describe and exemplify the possible role
of the Nuclear Medicine Technologist in cyclotron-centered
R&D processes. Methods: Examples of research & develop-
ment projects on Radiopharmacy and Radionuclide Produc-
tion will be shown, describing the role of the NMT, but also
analyzing the interactions with other professionals from the
different fields of scientific knowledge needed for the specific
requisites of projects being mentioned. Results/Conclusions:
Based on our own experience and activity in the field of
cyclotron-centered research for Radiopharmacy and Radionu-
clide Production (including activities at distinct levels in dif-
ferent projects regarding, but not limited to, the development
of targetry applied solutions - concerning the targets them-
selves and all that it is related - the practical methods and
solutions to transport the produced activity and/or the recov-
ery, the synthesis and/or purification and distinct processing of
radiopharmaceutical products and sub-products, etc.) we con-
sider that multidisciplinarity is indeed a mandatory aspect in
research & development processes, at the same time that only
highly-educated NMTs might play a “real role” in this specific
field essentially due to its versatility and “natural” capacity to
integrate basic and applied research, always without losing the
focus on the practical questions to be solved/answered and the
final applicability of research results, while permanently com-
plying with all the best practices and measures concerning
radiation protection, so assuring a safe environmental condi-
tions for themselves as for the remaining health professionals,
the members of the public eventually around and the environ-
ment itself.
OP186
Occurrence and Characterisation of Perfusion Defects
on 13NH3 Myocardial PET/CT Due to Side Branch
Occlusion After Ramus Descendens Anterior Stenting
H. Kan, R. J. J. Knol, S. V. Lazarenko, M. Wondergem, N. J.
Hoogvorst , F. M. van der Zant; MCA, Alkmaar,
NETHERLANDS.
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Aim: Coronary stenting is frequently accompanied by occlu-
sion of side branches of the targeted coronary artery. This has
been shown to induce small reversible or persistent perfusion
defects on myocardial perfusion SPECT studies. Data from
13NH3 PET/CT studies concerning such perfusion abnormali-
ties after ramus descendens anterior (RDA) stent placement is
lacking, and thus this study aimed to analyze the effect of RDA
stents on myocardial perfusion as measured by 13NH3 PET/
CT. Patients and methods: From September 10th 2013 till Au-
gust 29th 2014, 581 consecutive patients that underwent 13NH3
myocardial perfusion PET/CTwere prospectively entered in a
database. All patients gave written informed consent for usage
of their anonymous data. Baseline characteristics and cardiac
risk factors were collected. The datasets of patients with a stent
in the RDAwere evaluated by two experienced readers for the
existence of reversible or persisting perfusion defects within
the RDA flow territory and subsequently categorized as nor-
mal, infarction, ischemia, small persisting defect after stent
placement or small amount of ischemia after stent placement.
Results: 581 patients {66±10 years (mean±SD), male:female
311(53.5%):270(46.5%)} were included in the database. Of
these, 195(34%) had family history of heart disease,
93(16%) were smokers, 125(22%) were diabetic patients,
238(41%) had hypercholesterolemia, 333(57%) had hyperten-
sion and 110(19%) had a history of myocardial infarction. A
stent in the RDA was present in 53 patients {65±10 years,
male:female 33(62%):20(38%)}, of which 29 patients had a
stent in the proximal RDA, 18 in the mid-RDA and 6 in both
the proximal and mid-RDA. 13NH3 myocardial perfusion was
scored as normal in 26 (49%), as infarction in 5 (9%), and as
ischemia in 2 patients (4%). 6 patients (11%) showed a small
persisting defect within the RDA flow territory whereas 14
patients (26%) showed a small area of ischemia in the RDA
territory. Conclusion: RDA stents cause small 13NH3 myocar-
dial perfusion defects in 38% of the patients of which 70% are
reversible.
OP187
Usefulness of simultaneous intermediate-level exercise
for dobutamine stress myocardial perfusion imaging.
T. Kasai1, M. Aiga1, Y. Iwasaki2, K. Oshima1, Y. Fujita1, Y.
Sasaki1, N. Tanaka1, A. Yamashina2; 1Tokyo Medical Univer-
sity HachiojiMedical Center, Tokyo, JAPAN, 2TokyoMedical
University, Tokyo, JAPAN.
Aim: Although dobutamine stress testing is selected when a
patient cannot exercise sufficiently, and adenosine is contra
indication, not a few cases cannot achieve their target heart
rate, resulting in insufficient stress testing. We developed a
novel stress method of simultaneous intermediate-level exer-
cise for dobutamine stress myocardial perfusion imaging and
assessed the usefulness of this new stress method. Materials
and methods: We retrospectively extracted consecutive 44 pa-
tients who underwent dobutamine stress myocardial perfusion
imaging between September, 2010 and March, 2015. The pa-
tients were divided into 2 groups, dobutamine only (22 pa-
tients, DOB group) and dobutamine + exercise (22 patients,
DOB+EX group). DOB was continuously administered up to
40μg/kg/min. Exercise was performed on a bicycle ergometer
up to 75watts as adjusted for each patient tolerance. We inves-
tigated the frequency of insufficient stress testing, adverse ef-
fects, image quality, hemodynamic kinetics, cumulative ad-
ministered DOB dose, consumed time for stress testing and
compared them between the 2 groups. Results: There was no
difference in image quality between 2 groups. Adverse events
were occurred 4 cases (18%) in the DOB+EX group during
early recovery phase as vasovagal hyperactivity; however, no
severe events were demonstrated. Insufficient stress testing
were frequent in the DOB group than that in the DOB+EX
group (16 (72.7%) vs. 0 (0%); p<0.001). Although heart rate
was higher in the DOB+EX group (140.5±8.2bpm vs. 117.5
±17.5bpm, p<0.001), there was no difference in peak systolic
blood pressure (193.8±22.6mmHg vs. 177.1±30.8mmHg,
n.s.). Cumulative DOB dose was higher in the DOB group
than that in the DOB+EX group (13.8±6.2mg vs. 6.5
±3.8mg, p<0.001). Heart rate reduction at 2 minutes after ter-
mination of stress testing was greater in the DOB+EX group
(24.2±9.6% vs. 2.7±6.4%, p<0.001). Consumed time for stress
testing was shorter in the DOB+EX group than that in the
DOB group (586.0±164.3sec. vs. 1240.5±297.0sec,
p<0.001). Conclusion: DOB+EX reduces insufficient stress
testing and contributes to improve the sensitivity of the stress
perfusion imaging. In addition, DOB+EX is safe and useful
method to improve laboratory throughput.
OP188
Low-dose hybrid CCTA/SPECT image acquisition based
on BMI : a case report
V. Weichselbaumer, J. Trinckauf, E. Müller, D. Benz; Uni-
versity hospital Zurich, Zurich, SWITZERLAND.
Aim: In recent years there was a growing interest in the reduc-
tion of radiation exposure to patients in diagnostic imaging.
The combination of low-dose SPECT myocardial perfusion
imaging (MPI) with ultra-low-dose coronary CT angiography
(CCTA) allows a comprehensive diagnostic assessment of cor-
onary artery disease (CAD) with low radiation burden. Based
on a BMI (body mass index) scale developed at our institution,
we have adjusted our scanning protocols, in order to decrease
radiation exposure and maintain diagnostic image quality. The
aim of this case report is to demonstrate the feasibility of such
a low-dose protocol using the BMI scale. Materials and
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S79
methods: A 74-year-old female with a BMI of 30.8 presented
with new onset of palpitations and an asymptomatic ST-
depression during exercise test was referred to our institut for
ruling out CAD. The diagnostic work-up started with the ac-
quisition of a CT to measure the calcium score (CT Revolu-
tion, GE Healthcare) for risk stratification. Subsequently, an
ultra-low-dose CCTA with prospective ECG-triggering was
acquired. Technologists at our institution are responsible for
selecting BMI adjusted scanning parameters such as kV, mA,
contrast agent volume and flow rate. Immediately after the
injection of 45ml of Visipaque 320, the CCTA was acquired.
Due to calcifications in the right coronar artery (RCA), a low-
dose 1-day 99mTc-tetrofosmine stress/rest imaging exam was
acquired to exclude a possible hemodynamic relevance of this
lesion. Pharmacological stress was done with adenosine, and
163MBq 99mTc-tetrofosmine was injected at stress midpoint.
The99mTc-tetrofosmine dose was prepared by technologists
and the acquisition time was calculated using the BMI scale.
After a one-hour break stress MPI acquisition (Discovery
NM530c, GE Healthcare) was acquired during 912 seconds.
Rest MPI was acquired immediately after stress MPI, using
523 MBq 99mTc-tetrofosmine (912 seconds). Results: The
total effective radiation dose to the patient was 6.06 mSv,
(calcium score: 0.57mSv, CCTA: 0.89mSv, stress/rest SPECT
MPI: 1.09 mSv / 3.5 mSv). Image quality was rated as excel-
lent with sharp endocardial and epicardial edge definition,
high myocardial count density and uniformity, and without
any extracardial background noise. Conclusions: The low-
dose SPECT and CCTA protocols provides excellent image
quality at low radiation exposure. The BMI scale was devel-
oped to optimize work-flow for technologists concerning the
calculation of scanning parameters for low-dose hybrid
CCTA/SPECT imaging.
OP189
Impact of dynamic acquisition in dual-phase
18flurorocholine PET-CT on radiation exposure of staff
and patients
J. BARBIAUX, C. CHNINA, C. HASBROUCQ, S. PETIT,
M. THELU, A. BAILLIEZ, T. BLAIRE; GIE HumaniTEP -
Hôpital Saint Philibert, LOMME, FRANCE.
Purpose: A dual phase acquisition is usually performed in 18-
fluorocholine (FCHOL) PET-CT to assess the prostatic cancer:
anearly phase (dynamic acquisition on the pelvis) and a whole
body scan (starting 60 minutes after the injection). With recent
technological improvements to PET imaging equipment, this
study assessed the impact of early phase in patient’s irradiation
and in staff’s exposure. Materials and Methods: Fifty consec-
utives patients referred for a prostatic cancer in our department
were retrospectively included.After injection of 3MBq/kg of
FCHOL, the dual-phases acquisitions were performed using a
Siemens Biograph mCT Flow 20: the early phase (an 6 mi-
nutes early dynamic acquisition on the pelvis, to avoid the
bother of the prostatic bed’s study before bladder’s filing)
and the classical whole body acquisition (a study from head
to thighs with increased acquisition time on the pelvis and
reconstruction in a finer matrix 400 * 400). The CT radiation’s
exposures (mGy.cm) ofthe patients on both phases were re-
ported and compared. The expositions of the technologists
(μSv) for carrying the patients on both acquisitions were mea-
sured using an operational dosimetry (APVL, EPD MK2+).
Results: For the patients, 263±47 MBq of FCHOL were
injected. The mean weight was 85±15 kg. The mean age was
69±7 years. The mean size was 175±7 cm. The mean radia-
tion’s exposure was 171±39 mGy.cm and 657±196 mGy.cm
for the early and the classical phases respectively. For the
technologists, the mean operational dosimetry was 1.55
±0.22μSv (0.85±0.12μSv in the early phases and 0.70±0.10
μSv in the classical acquisitions). The radiation’s exposure of
the early phases represented 21% for the patients and 55% for
the technologists.Conclusion: The early phases acquisitions
represented 21% of the total irradiation for the patients and
55% of the technologists’ exposure. It might be interesting to
discuss with the medical staff to reduce the systematic realiza-
tion of the early acquisitions.
OP190
Radiation Dose to the Eye Lens: Does Positioning Really
Matter?
C. Baun1, K. Falch1, K. D. Nielsen2, S. Shanmuganathan1, O.
Gerke1, P. Hoeilund-Carlsen1; 1Odense University Hospital,
Odense, DENMARK, 2University College Lillebaelt, Odense,
DENMARK.
Aim: The scan field in oncology patients undergoing eyes-to-
thighs PET/CT must always include the base of the scull ac-
cording to department guidelines. The eye lens is sensitive to
radiation exposure and if possible it should be avoided to scan
the eye. If the patient’s head is kipped backwards during the
scan one might avoid including the eye in the CT scan without
losing sufficient visualization of the scull base. The aim of this
study was to evaluate the possibility of decreasing the radia-
tion dose to the eye lens, simply by changing the head position,
when doing PET/CT from the base of the scull to the thigh.
Methods and materials: The study was performed using a hu-
man like whole body phantom with electronic dosimetry units
placed upon each eye to detect the exact radiation dose to the
eye lens during each scan. The phantom’s head was placed in
two different positions, (a) elevated with a pillow below the
head (standard), and (b) kipped backwards with the pillow
below the neck (kipped). For each head position, CT scans
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were repeated 5 times with both a low dose and a high dose CT
protocol; in this way, a total of 20 CT scans were performed.
Robust standard errors were used in order to account for
intragroup correlation due to repeated measurements. Results:
Overall, position ‘kipped’ reduced the radiation dose to the
lens, on average by 42.9% or in mean by 1.15 mSv (95%
CI: 0.45-1.85; p=0.001) compared to ‘standard’, i.e., from
2.68 mSv (range 0.67 - 4.68) to 1.53 mSv (range 0.69 -
4.46). With the high dose protocol and position ‘kipped’, the
radiation dose to the lens decreased by 41.5%, on average by
1.52 mSv (95% CI: 0.39-2.64; p=0.008) compared to ‘stan-
dard’, i.e., from 3.66 mSv (range 1.62 - 4.68) to 2.14 mSv
(range 1.12 - 4.46). With the low dose protocol and position
‘kipped’, the decrease was comparable in relative terms: by
45.6% or, in absolute terms on average, 0.78 mSv, (95% CI: -
0.05 to 1.61; p=0.07, i.e., from 1.71 mSv (range 0.67 - 2.97) to
0.93 mSv (range 0.69 - 1.66). Not in a single case had position
‘kip’ the effect that one could not overlook the skull
base.Conclusion: These results indicate that it is possible to
reduce the radiation dose to the eye lens without loss of diag-
nostic information in the scan by optimizing positioning of the
head.
605 - Monday, October 12, 2015, 8:00 AM - 9:30 AM, Hall G2
Do.MoRe: PRRT Dose Response
OP191
PRRT toxicity: DOTATOC versus DOTATATE
M. Sollini1, E. Grassi2, F. Fioroni2, A. Filice2, V. Ferri2, A.
Frasoldati2, A. Versari2; 1IRCCS MultiMedica, Sesto San
Giovanni, ITALY, 2Santa Maria Nuova Hospital IRCCS, Reg-
gio Emilia, Reggio Emilia, ITALY.
Aim:Many radiolabeled somatostatin analogues with different
affinity profiles for somatostatin receptor subtypes and differ-
ent biological half-time (63 hours for DOTATOC and 81 hours
for DOTATATE) have been employed in Peptide Receptor
Radionuclide Therapy (PPRT). We aim to compare PRRT tox-
icity profiles of DOTATOC and DOTATATE radiolabeled
with 90Y or 177Lu in patients with neuroendocrine tumors
(NET). Materials and methods: we retrospectively evaluated
16 NET patients of whom 8 treated with 90Y/177Lu-
DOTATOC (group 1) and 8 treated with 90Y/177Lu-
DOTATATE (group 2) with comparable characteristics (risk
factors, number of cycles, cumulative administered activity).
Patients were blinded selected (independently from acute and
chronic/long term toxicities as well as outcome). Risk factors
for PRRT were recorded. 3D-dosimetry of each patient was
calculated at organ-level with OLINDA/EXM software. Both
BED of kidneys and adsorbed dose of bone marrow were
calculated. Haematological parameters including WBC, Hb,
PLT and creatinine were recorded to assess acute and chronic
toxicity according to CTAE v4.0. Results: Hypertension and/
or diabetes were present in 3 patients of each group. Patients of
both groups received a median of 4 administrations (range 3-
6). The mean cumulative administered activities were 4847
±4366 MBq and 5365±4107 MBq for 90Y-DOTATOC and
90Y-DOTATATE, respectively (p=0.8) and 12506
±8362 MBq and 10545±4551 MBq for 177Lu-DOTATOC
and 177Lu-DOTATATE, respectively (p=0.5). At least one
adverse event (leukopenia, anemia, thrombocytopenia, renal
failure) was observed in 7/8 and 8/8 patients, in group 1 and
2 respectively. Overall, in group 1 25 adverse events (grade 1-
2) occurred and in 12/25 (48%) adverse events were chronic/
long term (G1-2 leukopenia=3, G1 anemia=4, G1 thrombocy-
topenia=2, G1-2 renal failure=3). Overall, in group 2 52 ad-
verse events (grade 1-4) occurred and in 9/52 (17%) adverse
events were chronic/long term (G1 leukopenia=1, G1-G2 ane-
mia=5, G1 thrombocytopenia=1, G1-4 renal failure=2). In
group 2 transient acute toxicity between administrations oc-
curred more frequent compared to group 1 (43 versus 13 ad-
verse events, p=0.0046). BED of kidney resulted 32±20 Gy in
group 1 and 49±23 Gy in group 2 (p=0.14) while bonemarrow
adsorbed dose was 0.177±0.113 Gy in group 1 and 0.411
±0.183 Gy in group 2 (p=0.008). Conclusion: our results sug-
gest a major number of adverse events during PRRT using
DOTATATE than DOTATOC although in case of DOTATOC
we observed a more frequent chronicity/long term mild toxic-
ity (48% versus 17%). No cases of severe haematological dis-
ease (i.e. myelodysplasia) were observed while chronic renal
failure requiring dialysis occurred in one patient of group 2.
OP192
[177Lu-DOTA]-D-Phe1-Tyr3-Octreotide
(177Lu-DOTATOC) for Peptide Receptor Radiotherapy
in Patients with Advanced Neuroendocrine Tumours: A
Retrospective Phase II Study of Efficacy and Safety
H. R. Kulkarni1, R. P. Baum1, A. W. Kluge2, M. Sayeg1, U.
Schorr-Neufing2, K. Niepsch1, N. Biterlich2, C. van Echteld3;
1Zentralklinik Bad Berka, THERANOSTICS Center for Mo-
lecular Radiotherapy and Molecular Imaging (PET/CT), Bad
Berka, GERMANY, 2ABX-CRO GmbH, Dresden, GERMA-
NY, 3ABX-CRO, Dresden, GERMANY.
Background: To evaluate efficacy and safety of 177Lu-
DOTATOC as agent for peptide receptor radiotherapy (PRRT)
of advanced neuroendocrine tumours (NET). Material and
methods: Fifty-six subjects with metastasized and progressive
NET (50% midgut, 26.8% pancreatic, 23.2% other primaries)
were included in prospective database and retrospective analysis
was performed. Subjects received on average 2.1 (range 1 - 4)
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cycles of 177Lu-DOTATOC (median administered activity 7.0
GBq) at three-monthly intervals. Efficacy was analyzed based
on RECIST and by number of treatment cycles and histology.
Results: In the total population, median progression-free and
overall survival was 17.4 and 34.2 months, respectively. Repeat-
edly treated patients had an Overall progression free survival of
30.2 months. Objective response rate (complete or partial) was
33.9%, while disease control rate was 66.1%. A high number of
complete responses (16.1%) was observed, 78% of which were
ongoing at the end of the Observation period. 14% of subjects
required more than one cycle to induce an Initial response. In
32% of responders, it took four to eight months from the first
PRRT cycle, before an initial response could be documented.
After initial response, morphological outcome may improve
for up to 20 months after the last PRRT. In 47% of
subjects it took more than 9 months from start of PRRT
until an objective response occurred. No SAE, and only
a s ingle case (1 .8%) of se l f - l imi t ing grade 3
hematotoxicity was observed. No renal toxicity was
found, although 19.6% of subjects had mild renal insuf-
ficiency at baseline. Conclusions: 177Lu-DOTATOC is a
novel agent for PRRT with unusual potential to induce
objective response in progressive neuroendocrine tu-
mours and long lasting disease control, even when ad-
ministered at moderate activity doses. Efficacy was
highest when the agent was administered in repetitive
cycles, indicating that efficacy should be established on-
ly after Administration of the prescribed dose. With only
6.2% non-responders, the overall disease control rate
(DCR) was 93.8%, compared to 80.3-85.0% reported
for 177Lu-octreotate. This difference in DCR between
the peptides is accounted for by an about ten-fold higher
rate of subjects experiencing a complete response fol-
lowing 177Lu-DOTATOC. In the subgroup of patients
with GEP-NET, the proportion of complete responders
was 25%, which is the highest value ever reported to
date. A particularly high therapeutic index is suggested
by the observed safety profile, also in subjects with a
priori reduced bone marrow or renal function, which
reflects a uniquely low uptake of 177Lu-DOTATOC by
normal organs.
OP193
Long term survival analysis after i.a. 90Y-DOTATATE
PRRT, in patients with non-resectable, advance
progressive liver dominant neuroendocrine neoplasms.
M. L. Nowicki1, S. J. Konsek2, L. Jaskiewicz2, M. Mol3, A.
Sankowski1, J. R. Buscombe4, L. Bodei5, R. Mikolajczak6, J.
B. Cwikla2; 1Department of Radiology and Diagnostic Imag-
ing, Hospital Ministry of Internal Affairs & Administration,
Warsaw, POLAND, 2Department of Radiology, Faculty of
Medical Sciences, University ofWarmia andMazury, Olsztyn,
POLAND, 3Radiology and Diagnostic Imaging, Medical Cen-
ter for Postgraduate Education, Warsaw, POLAND, 4Depart-
ment of Nuclear Medicine, Addenbrooke’s Hospital, Cam-
bridge, UNITEDKINGDOM, 5Division of Nuclear Medicine,
European Institute of Oncology, Milan, ITALY, 6Centre
POLATOM, National Centre for Nuclear Research Radioiso-
tope, Otwock, POLAND.
Purpose: To evaluate long term survival in group of
patients with non-resectable, liver dominant and progres-
s ive neuroendocr ine neoplasms af te r i . a . 90Y
DOTATATE peptide receptor radionuclide therapy
(PRRT) in gastroenteropancreatic neuroendocrine tu-
mours (GEP-NET). Patients and Methods: The study
group: 38 patients, 17 female, mean age 56.2. All with
histological proven extensive non-resectable GEP-NET.
Half of them with secretor tumours. All had documented
DP (RECIST and/or clinical in case or secretor tumours)
with relapse on previous therapy. 22 pts with initial i.a.
PRRT after relapse of chemo and somatostatin analogues
(SST) therapy, others 16 pts had previous i.v. PRRT.
Overall 104 therapy session using i.a. 90Y-DOTATATE
performed. Initial clinical tumour responses assessed,
6W after therapy and then after each of the 3M intervals
of follow-up. The objective tumour response was classi-
fied according to RECIST, initially 6W and then after
each of the 6M. Adverse Events (AE) of therapy were
evaluated using CTCAE NCI (ver. 4.0). Overall survival
(OS) and progression free survival (PFS) were evaluated
using Kaplan Meier methods. Results: The median OS
and PFS for all pts were 39.0M and 24.5M, in group
with initial i.a. PRRT were 50.0 and 28.5M in those
with previous i.v. PRRT were 20.5 and 12.0M. The clin-
ical response including performance status (PS), initial and
6W after PRRT were significant improved consider all pts
and in both groups. (P<0.05). Clinical response at 6W seen
as PR 29, SD 7 and 2 had DP. At 6M after treatment 27 had
PR, 6 SD and 4 DP. After 12M 24 had PR 4 SD and 6 DP.
After 24M 11 had PR, 9 SD and rest 6 developed DP. Radio-
logical response (RECIST) at 6W after PRRT was noted in 3
subjects, 33 pts had SD, after 6 M of follow-up 8 had PR, 28
had SD and rest 4 developed DP. After 12M 8 pts had PR, 23
pts had SD and 4 had DP. After 24M, PR was noted in 4, 16
SD and 3 DP. Conclusion: Intra-arterial PRRT using 90Y-
DOTATATE seems to be effective in patients with extensive,
liver dominant, non-resectable and progressive GEP-NET. Es-
pecially as initial therapy after relapse of other therapy options.
Could be used as alternative therapy approach in those after
i.v. PRRT, who relapse and whom i.v. PRRTcould be cause of
AE (kidney and bone marrow). Objective response of PRRT,
base on RECIST, underestimate benefits of this type of
therapy.
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OP194
Early assessment of renal impairment in patients
undergoing Peptide Receptor Radionuclide Therapy
evaluated by MAG3 renal scintigraphy
R. A. Werner1,2, S. Beykan1, C. Lapa1, C. Bluemel1, U.
Eberlein1, T. Higuchi1,2, H. Wakabayashi1, K. Herrmann1,3,
A. K. Buck1, M. Lassmann1, H. Hänscheid1; 1Department of
Nuclear Medicine, University Hospital Würzburg, Würzburg,
GERMANY, 2Comprehensive Heart Failure Center, Universi-
ty Hospital Würzburg, Würzburg, GERMANY, 3Department
of Molecular and Medical Pharmacology, David Geffen
School of Medicine at UCLA, Los Angeles, CA, UNITED
STATES.
Objectives: Due to the potential nephrotoxicity of Peptide Re-
ceptor Radionuclide Therapy (PRRT), pre-therapeutic assess-
ment of kidney function is mandatory. Radiation damage of
irradiation is the proximal tubuli reabsorbing the radionuclide
and the interstitium retaining the radioactivity. Therefore, kid-
ney function test measuring tubular extraction, like
mercaptoacetyltriglycine (99mTc-MAG3), provides additional
information in early stages of suspicious renal failure. The aim
of this study was an early assessment of renal impairment after
treatment with 177Lu-octreotide to investigate the potential loss
of kidney function as a function of the administered activity.
Materials and Methods: FromMarch 2011 to December 2014,
renal impairment was analyzed prior to 136 treatments (32
patients) using 99mTc-MAG3 clearance (mean follow-up, 366
± 201 days). Subsequently, PRRTwas performed with a mean
cumulative activity of 32.2 GBq 177Lu-octreotide (3-7 cycles,
standard intervals of 3 months). The ratio of theMAG3 tubular
extraction rate (TER) to TER of lower limit (RaTER) was
calculated and analyzed as a function of the cumulative ad-
ministered activity by linear regression analysis. Results: Prior
to PRRT, 12 patients showed impaired renal function and 20
patients demonstrated normal kidney function, as indicated by
99mTc-MAG3 renal scintigraphy (mean TER, 233.5 ± 52.6 ml/
min/1.73 m2). RaTER was 131 ± 0.25 %. Linear regression
analysis revealed a median shift of renal function of -0.03%
per administered GBq (quartile, -0.34%/GBq, +0.14%/GBq).
The following equation was utilized: (relative change in TER
per GBq of 177Lu) = 0.0088 - 0.0106 x (initial TER/TERlower
limit). Furthermore, negative gradients showing a high loss of
TER per administered activity were observed in patients with a
good kidney function whereas in the cohort with initial renal
impairment the TER remained almost constant. To illustrate
this, we found in 13 patients having an initial TER of
<1.3*TER of lower limit that the worst reduction of kidney
function was only 0.21% per administered GBq. Conclusion:
Only patients with an appropriate kidney function prior to the
start of PRRT seem to be at risk of developing renal impair-
ment in the course of therapy. On the other hand, an initially
reduced 99mTc-MAG3- clearance prior to the first treatment
cycle seems not to be an exclusion criteria for PRRT. In this
study investigating the early assessment of renal function by
99mTc-MAG3 renal scintigraphy, a low risk of PRRT related
renal damage was demonstrated even in a long-term follow-up
over one year.
OP195
Super-selective Hepatic Arterial Infusions of n.c.a.
Lu-177-Dotatoc in Inoperable Neuroendocrine Liver
Metastases of Gastro-Entero-Pancreatic (GEP) Tumors;
Preliminary Results
G. S. Limouris1, N. Trompoukis1, V. Poulantzas1, I. Karfis2,
A. Chatz ioannou1 , M. Lyra1 , V. Michalaki3 , N.
Triantaphyllou4, G. Nikou5, M. Paphiti6, V. R. McCready6,
L. Moulopoulou1; 1Nucl Med Div-1st Radiology Dept ,
“Aretaieion” Hospital, Athens University Medical Faculty,
Athens, GREECE, 2Nuclear Medicine Dept, Institute “Bor-
det”, Brussels, BELGIUM, 3Department of Surgical Oncolo-
gy, “Aretaieion”Hospital, Athens University Medical Faculty,
Athens, GREECE, 4Neurology Dept, ‘Aeginiteion” Hosp,
Athens Univ Medical Faculty, Athens, GREECE, 5Gastroin-
testinal Div, I Dept of Propedeutic Internal Medicine “Laikon”
Hospital, Athens, GREECE, 6Nuclear Medicine Dept, Royal
Sussex County Hosp, Brighton, UNITED KINGDOM.
Aim: To evaluate the effectiveness of non carrier added (n.c.a.)
Lu-177 DOTA-TOC in inoperable liver metastases, positive
for sst2 receptor overexpression (verified by Octreoscan and
confirmed by biopsy) due to neuro-endocrine gastro-
enteropancreatic (GEP) tumours. Lu-177 DOTA-TOC has
been infused after selective catheterization of the hepatic artery
(‘ARETAIEION’ PROTOCOL), minimising in parallel the
toxicity of non-target tissues.Materials and Methods: The av-
erage dose per session to each patient (9 pts so far in total) was
7.3±2.3 GBq. Repetitions did not exceed 6-fold with treatment
intervals of 8-11 weeks, to avoid stunning effect. Response
assessment was classified according to the therapeutic benefit.
Absorbed doses delivered to metastases, kidneys and red mar-
row was calculated according to MIRD scheme and
perfoermed using OLINDA 1.1 software. The derived values
were correlated to the Response Evaluating Criteria in Solid
Tumours (RECIST). CT/ MRI scans were performed as base-
line before, during and after the end of treatment and monthly
ultrasound images for follow-up estimation and measure-
ments. Toxicity (World Health Organization criteria) was mea-
sured using blood and urine tests of renal, hepatic and bone
marrow function.Results: None of the patients resulted com-
plete response (0.0%); partial response was assessed in 6
(66.0%) and disease stabilization in 3 (34.0%). An 8-month
median survival time was estimated for all patients, so far. Six
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of 9 (66.0%) showed a mean target diameter shrinkage ranging
from 32% to 46%. The organ average radiation dose estima-
tion was found as follows: (a) Liver Tumor 3.0-9.9mGy/MBq,
(b) Liver 0.03-0.1 mGy/MBq, (c) Kidneys 0.03-0.4 mGy/
MBq, (d) Spleen 0.02-1.2 mGy/MBq and (f) Bone marrow
0.008-0.05 mGy/MBq. The average absorbed dose per session
to a tumor for a spherical mass of 20 gr was estimated to be 9.3
mGy/MBq, depending on the histotype of the tumor. WHO
toxicity grade 2 erythro-, leuko- and thrombo-cytopenia oc-
curred in 2 (22.0%) cases observed about after the 3rd
session.Conclusion: In unresectable metastatic liver lesions
positive for somatostatin receptors repeated, trans-hepatic high
doses of n.c.a. Lu-177 DOTA-TOC resulted in a more than
promising therapeutic outcome with a partial response in
approx 66% of the treated patients. Given the loco-regional
modality character of the administration technique, no neph-
rotoxicity has been so far observed.
OP196
Relationship between baseline GFR, [Lu-177]
-DOTATATE Clearance and Radiation Dose to Kidneys
During Radionuclide Therapy
for Somatostatin-Expressing Tumours
D. L. Bailey1, T. M. Hennessy2, K. P. Willowson2, D. L.
Chan1, G. P. Schembri1, A. Aslani1, N. Pavlakis1; 1Royal
North Shore Hospital, Sydney, AUSTRALIA, 2University of
Sydney, Sydney, AUSTRALIA.
AIM: To examine the relationship between glomerular filtra-
tion rate (GFR) and clearance of therapeutic non-carrier added
[Lu-177]-DOTATATE (nca-LuTATE) for treatment of neuro-
endocrine tumours (NETs) and meningiomas expressing so-
matostatin receptors, and to examine the impact on radiation
dosimetry to the kidneys.MATERIALS AND METHODS:
All data were acquired on SPECT/CT cameras (Siemens
Symbia.T6 and Intevo) using medium-energy collimation
and a single photopeak (208 keV ±10%). The accuracy of
our whole body (WB) planar imaging and quantitative
SPECT/CT (qSPECT) data have previously been validated
to within ±10%. Images were acquired immediately after in-
jection of the nca-LuTATE (ITG/ANSTO and Auspep) and at
4, 24 and 96 or 120 hrs post-injection. Whole body clearance
was assessed with planar imaging and kidney uptake was mea-
sured with qSPECT. The qSPECT data were input to
OLINDA/EXM1.1 for estimation of kidney dosimetry. A total
of 36 treatments in 12 subjects were evaluated with this pro-
tocol. Subjects were administered a mean of 7.8 GBq (range
6.2 - 8.7 GBq) of nca-LuTATE.RESULTS: A bi-exponential
fit to the WB data demonstrated a fast component of clearance
of 2.1±0.6 hrs and a slow component of 58.1±7.2 hrs. Baseline
GFR showed a good correlation with the fast component when
fitted with an exponential curve (R2=0.74) but was unrelated
to the slow component. Radiation dose estimated to the kid-
neys from qSPECT likewise demonstrated a significant depen-
dence on GFR with slower clearance rates corresponding to
higher kidney dosimetry.CONCLUSION: Baseline GFR af-
fects the fast component of clearance of nca-LuTATE and
impacts on the radiation dose received by the kidneys. Radia-
tion dose to the kidneys can almost double when GFR is < 60
ml/min/1.73m2 compared to a GFR of > 100. Individualisation
of patient treatments should consider this when aiming tomax-
imise therapeutic efficacy
OP197
Recurrent glioblastoma multiforme - local alpha emiters
targeted therapy with 213Bi-DOTA-substance P
L. Królicki1, A. Morgenstern2, J. Kunikowska1, H. Koziara3,
B. Królicki3, M. Jakuciński4, D. Pawlak5, C. Apostolidis2, F.
Bruchertseifer2; 1Nuclear Medicine Department, Medical Uni-
versity of Warsaw, Warsaw, POLAND, 2European Commis-
sion, Joint Research Centre, Institute for Transuranium Ele-
ments, Karlsruhe, GERMANY, 3Department of Neurosurgery,
Institute of Psychiatry and Neurology, Warsaw, POLAND,
4Department of Nuclear Medicine, Brodnowski Hospital,
Warsaw, POLAND, 5Radioisotope Centre POLATOM, Na-
tional Centre for Nuclear Research, Otwock, POLAND.
Glioblastoma multiforme (GBM) is the most common and
malignant primary brain tumor. The median survival time is
14.6 months from time of diagnosis, in spite of aggressive
surgery, radiation therapy and chemotherapy. Only 3 to 5%
of patients survive more than three years. Recurrence of
GBM is nearly universal, confers a dismal prognosis with a
6-months progression free survival (6M-PFS) rate of 15% to
21% and a median survival of 6.2 months. Advancements in
the past decades have not significantly increased the overall
survival of patients with this disease. GBM has been demon-
strated NK-1 receptor system and substance P can be used as a
ligand for targeted therapy. Alpha emitter, like 213Bi offers the
new potential for selective irradiation of tumors, withminimiz-
ing damage to adjacent tissue.Material and methods:21 pa-
tients with primary recurrent glia tumor IVafter standard ther-
apy were included in the study during two years. Following
intracavitary or intratumoral insertion of 1-2 catheter systems,
patients were treated with 1-8 doses of 2 GBq 213Bi-DOTA-
Substance P (213Bi-SP) in intervals of 2 months. 68Ga-
DOTA-Substance P (68Ga-SP) was co-injected with the ther-
apeutic doses to assess biodistribution using PET/CT. Thera-
peutic response was monitored withMRI. Study was approved
by the ethical committee of the Medical University of
Warsaw.Results:Treatment with activity up to 13 GBq
213Bi-SP was tolerated well with only mild transient adverse
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reactions: in 1 patient transient increase of focal neurological
symptoms and in 3 patients episodes of epileptic seizures sev-
eral days after treatment. PET/CT imaging showed high reten-
tion of the radiolabeled peptide at the tumor site.Out of 21
evaluable patients, 17 progressed within the follow-up period,
5 of them are alive at the end of follow-up. Four patients were
excluded from evaluation due to lack of data. Median progres-
sion free survival was 3.7 months, with a 6 months progression
free survival rate of 19% . The median overall survival from
the first diagnosis was 25.2 months, and from the start of
213Bi-SP was 6.5 months. Follow up of therapeutic responses
and toxicity is continued and patient recruitment is
ongoing.Conclusions:Treatment of recurrent GBM with
213Bi-SP is safe and well tolerated. Targeted alpha therapy
with 213Bi-SP may evolve as a promising novel option for
treatment of recurrent GBM.
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OP198
Non-invasive determination of the Beta Bell Mass
with 111In-exendin-3 in a Rat Model of spontaneous Type 1
Diabetes
L. Joosten1, M. Brom1, D. Bos1, C. Frielink1, P. Hanneke2, O.
Boerman1, M. Gotthardt1; 1Radboud university medical cen-
ter, Nijmegen, NETHERLANDS, 2GROWmumc,Maastricht,
NETHERLANDS.
Aim Thebeta cell mass (BCM) plays a key role in the devel-
opment and progression ofdiabetes, but the onset of beta cell
loss and the relationship between loss ofbeta cell mass and
beta cell function still needs to be unraveled. Anon-invasive
method to determine the BCM invivo would allow measure-
ment of the BCM during the development andprogression of
type 1 and 2 diabetes. Exendin-3 is a stable glucagon-
likepeptide 1 (GLP-1) analogue with high affinity for the
glucagon-like peptide-1receptor specifically expressed on beta
cells. In this study we investigatedthe potential of 111In-
exendin-3 to determine the BCM in vivo in a rat model that
closelymimics the development of type 1 diabetes in humans:
BioBreeding Diabetes Prone(BBDP) rats. In this model the
potential of SPECT, the relationship between theBCM,
exendin uptake in the pancreas and inflammation of the islets
ofLangerhans (insulitis) were investigated.Materials and
Methods BBDPrats (n = 45) of 4-18 weeks of age were
injected intravenously with 15 MBq 111In-exendin-3.SPECT/
CT images were acquired 1 h p.i. and the animals were eutha-
nized afterSPECT/CT acquisition. The biodistribution of the
tracer was determined and thepancreas was used to determine
the BCM by morphometric analysis and degree of
insulitis.Results WithSPECT the pancreas in rats was visual-
ized. In healthy rats (4 weeks) efficientaccumulation of 111In-
exendin in the pancreas was observed (0.29 ±0.03 %ID/g). In
severely diabetic rats (18 weeks) pancreatic tracer uptake
wassignificantly reduced with more than ninety percent
(p=0.0004). The uptake ofthe tracer correlated with BCM
(mg) (Pearson r = 0.80, p < 0.0001). Ex vivo autoradiography
showed high accumulationof 111In-exendin-3 in the islets of
Langerhans in healthy rats andvery low accumulation in the
exocrine pancreas. The accumulation in theendocrine pancreas
was reduced in rats with beta cell loss and in severelydiabetic
rats, with no insulin-positive cells, tracer uptake in the pancre-
as wasundetectable by autoradiography. Furthermore, insulitis
did not have an influenceon the uptake of exendin in the
pancreas.Conclusion Inconclusion, in a rat model of type 1
diabetes, closely mimicking the humandevelopment of type
1 diabetes, the BCM can be monitored with 111In-exendin-
3SPECT. These results indicate that 111In-exendin-3 is a prom-
ising tracerto determine the BCM during the development of
type 1 diabetes in patients,without interference of severe
insulitis.
OP199
Preclinical imaging of the co-stimulatory ligands
CD80/CD86 with 111In-DOTA-Belatacept in oncology
and atherosclerosis
A. Müller Herde1, R. Meletta1, P. Dennler2, E. Fischer2, R.
Schibli1, S. D. Krämer1; 1ETH Zurich, Zurich, SWITZER-
LAND, 2Pau l Sche r r e r In s t i t u t e , PS I -Vi l l i gen ,
SWITZERLAND.
Aim: The co-stimulatory ligands CD80 and CD86 play a cru-
cial role in the initiation and maintenance of an immune re-
sponse and are found on activated antigen presenting cells
(APCs). The human derived Raji cell cell line, originated from
Burkitt’s lymphoma, is associated with a frequent expression
of CD80 and CD86. In the context of atherosclerosis, we iden-
tified CD80 and CD86 on APCs with significant higher levels
in vulnerable plaques [1]. We propose, CD80 and CD86 as
promising targets for imaging inflammation. In a proof-of-
principle study, the fusion protein Belatacept (Nulojix®), con-
taining the extracellular portion of CTLA-4 as binding motif,
was labeledwith indium-111.We analyzed the in vitro stability
of this radiotracer and evaluated it in mice bearing
CD80/CD86-positive Raji xenografts and in a mouse model
of atherosclerosis (ApoE KO). Material and methods: Com-
mercially available Belatacept was conjugated with p-SCN-
Bn-DOTA, radiolabeled with In-111 and purified by size-
exclusion chromatography (SEC). Stability was investigated
after incubation in human or mouse plasma at 37 °C up to 72 h
by SEC. CD1 nude mice bearing Raji xenografts and ApoE
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KO mice were injected i.v. with 10 MBq 111In-DOTA-
Belatacept (25 μg, baseline). Blockade animals simultaneous-
ly received unlabeled Belatacept (500 μg). In vivo and ex vivo
SPECT/CT scans or biodistribution studies were performed
48 h post injection. Oil red o staining was performed with
excised blood vessels to visualize plaque lipids. Results:
111In-DOTA-Belatacept was successfully produced in 73-
78% radiochemical yield. 82% of labeled fusion protein
remained intact after 72 h of incubation in plasma. In vivo,
111In-DOTA-Belatacept accumulated in Raji xenografts and a
reduced accumulation was determined under blockade condi-
tions. These results were confirmed by biodistribution reveal-
ing a significant reduction in blockade animals. Ex vivo
SPECT scans of the aortic arch and the carotids of ApoE KO
mice showed a high accumulation in atherosclerotic plaques
and a reduced signal under blockade conditions. Tracer accu-
mulation and plaque localization determined by oil red o stain-
ing were consistent. Conclusion: The co-stimulatory ligands
CD80 and CD86 are promising targets for the non-invasive
imaging of activated immune cells.111In-DOTA-Belatacept
accumulates specifically in human derived Raji lymphoma
xenografts in vivo and binds to inflammatory plaques in a
mouse model of atherosclerosis. Reference: [1] Müller A.,
et al. (2014) Int J Cardiol, 174, 503-15.
OP200
Initial experiences with the Mediso nanoSCAN preclinical
SPECT/MR
M. Segbers1, J. C. Haeck1, I. L. Bakker1, J. de Swart1, M.
Kovács2, M. R. Bernsen1, M. de Jong1; 1Erasmus Medical
Center, Rotterdam, NETHERLANDS, 2Mediso Medical Im-
aging Systems, Budapest, HUNGARY.
Aim: SPECT and MR imaging are for the first time combined
in a single hybrid platform: the Mediso nanoScan SPECT/
MRI (Mediso, Budapest Hungary). Combining MRI and
SPECTcould improve localization of the radioactivity in small
animals and aid in organ delineation for biodistribution in vivo
and pharmacokinetic analysis, as MRI is well known for its
superior soft tissue image contrast compared to CT. In this
study the first in vivo images were acquired using different
tracers. Materials and methods: System specifications: A 1
Tesla horizontal bore permanent magnet with 500mT/M gra-
dients has been coupled in line with a multi-pinhole SPECT
subsystem with four rotating 9.5mm NaI detectors. For MR
image acquisition a 35mm-diameter solenoid coil was used.
Collimators with 64 pinholes of 1.7mm diameter were used
and all SPECT acquisitions covered in approximately 7cm the
entire body using spiral scanning with step and shoot (rotation
in steps of 12.9 degrees). Images of C7Bl/6 mice were ac-
quired after injection with 42MB 99mTc-MDP and 23MBq
99mTc-DMSA. MRIs were acquired with a T2-weighted Fast
Spin Echo (FSE) using TR/TE=4377/88.5, 0.27x0.27x0.8mm
voxels in 7 minutes and a T1-weighted Gradient Echo using
TR/TE=15/3, 0.15x0.15x0.6mm voxels in 11 minutes. The
acquired MR images covered the SPECT FOV. PC3 tumor
bearing mice were scanned ex vivo 24hours after injection
with 25MBq 111In-JMV4168; a gastrin-releasing peptide re-
ceptor (GRPR) antagonist that binds to the GRP receptors of
the PC3 tumor. SPECT was combined with a T2-weighted
FSE using TR/TE=4000/25 and 0.27x0.27x1mm voxels ac-
quired in 10 minutes. Basic MR image quality was determined
by signal to noise ratios (SNR) of various tissues. Results: The
99mTc-MDP scan clearly showed the expected tracer uptake
in the bones in excellent detail. 99mTc DMSA showed the
expected high tracer uptake in the kidneys that could be clearly
localized to the renal cortex on the T2-weighted MRI overlay.
The 111In-JMV4168 scan showed expected high tracer uptake
in the tumor and much lower uptake in the kidneys. Overall,
MRI SNR was tissue dependent and varied between 7.2 for
muscle and 28 for tumor. Conclusion: The Mediso nanoScan
SPECT/MRI is capable of generating visually qualitative and
well interpretable SPECT/MR images. The MR images show
detailed anatomy within soft tissues and aid tremendously in
localization of radioactive tracer uptake.
OP201
Noninvasive visualization of microRNA by Tc-99m
radiolabeled anti-microRNA oligonucleotide in tumor
xenografts
L. KANG; PEKING UNIVERSITY FIRST HOSPITAL,
BEIJING, CHINA.
Introduction: MicroRNAs have been considered as important
biomarkers for malignant tumors. Although various optical
imaging methods have been developed for the noninvasive
detection of microRNAs, they were generally limited in pen-
etrated ability, genetic modification, and potential toxicity. In
this study, we firstly used a radionuclide-based imaging meth-
od for the noninvasive visualization of overexpressed miR-21
in tumor bearing mice. Methods: MiR-21 targeted anti-
miRNA oligonucleotide (AMO) with partial 2’-O-methyl
and phosphorothioate modification was designed and synthe-
sized. Technetium-99m (99mTc) labeled AMO was prepared
via the conjugation with NHS-MAG3. 99mTc-AMO was
evaluated for its stability, inhibitory ability and cellular uptake
in vitro, and further in vivo distribution and imaging in multi-
ple kinds of tumor xenografts. Results: 99mTc-AMO was pre-
pared with high labeling efficiency and specific activity.
99mTc-AMO inhibited miR-21 and up-regulated the expres-
sion of PTEN. Fluorescence labeled AMO displayed specific
and durable distribution in tumor cells. Further, in tumor
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bearing mice, 99mTc-AMO showed significant more accumu-
lation in miR-21 overexpressed tumors than control probe,
which suggested the effective delivery of 99mTc-AMO in
miR-21 over-expressed tumors. Conclusions: This study sup-
ports the effectiveness of 99mTc radiolabeled AMO in the
noninvasive visualization of miR-21 in malignant tumors
and suggests a potential candidate for tumor imaging.
OP202
Quantitative and longitudinal SPECT imaging
of intramuscular transplanted islets of Langerhans using
[123I]IBZM
S. M. A. Willekens, I. van der Kroon, D. Bos, L. Joosten, C.
Frielink, O. C. Boerman, M. Brom, M. Gotthardt; Radboud
university medical center, Nijmegen, NETHERLANDS.
Aims: Besides insulin therapy, pancreatic islet transplantation
is considered one of the most promising therapies for type 1
diabetes. Despite improved immunosuppressive therapy, islet
transplantation still results in short term insulin independence.
A non-invasive imaging method to monitor the viable
transplanted islets might provide insight in the faith of the
islets after transplantation. Moreover, it could offer the possi-
bility to evaluate therapeutic interventions that might improve
long term transplantation outcome. Dopamine 2 (D2) recep-
tors are expressed on beta cells and are therefore a suitable
target to monitor islet grafts. Here, we investigated the use of
the D2 receptor antagonist [123I]Iodobenzamide
([123I]IBZM) for quantification of viable graft volume and
longitudinal grafts analysis. Methods: Six weeks after trans-
plantation of 1000, 2000 or 3000 islets intramuscularly, rats
received 50 MBq [123I]IBZM intravenously and one hour
post injection SPECT images were acquired. Afterwards, ani-
mals used for ex vivo autoradiography were injected with
[125I]IBZM, euthanized 1h post-injection, and the graft con-
taining muscles were dissected for ex vivo SPECT, autoradi-
ography and histological analysis. Viable graft volume was
calculated histologically by multiplying insulin-positive area
by interslice distance of the analyzed slides. For longitudinal
graft analysis, rats were transplanted with 1500 islets and mon-
itored for 10 weeks. Results: Six weeks after transplantation, a
clear signal of all grafts was observed by SPECT. Moreover,
SPECT signal correlated linearly with viable graft volume
(Pearson r = 0,73). The SPECT signal in the calf muscle de-
tected ex vivo correlated with the signal in the calf muscle
in vivo. Furthermore, ex vivo autoradiography confirmed spe-
cific tracer accumulation and co-localization with the grafts
location, as determined histologically. Longitudinal graft anal-
ysis showed a gradual increase in SPECT signal with a peak
around five weeks after and signal stabilization afterwards.
Conclusion: In conclusion, [123I]IBZM can successfully be
applied for non-invasive quantitative and longitudinal graft
monitoring in vivo. Especially in combination with other beta
cell specific tracers, such as exendin, it might provide a strong
tool to obtain detailed complementary information by non-
invasive molecular imaging and to predict islet graft metabolic
state and transplantation outcome.
OP203
Radioimmunoimaging of targeting CD133 antigen
for colorectal cancer stem cells, a preliminary study
R. An, X. Jin, J. Lang, D. Weng, X. Lan; Union Hospital,
Tongji Medical College, Huazhong University of Science
and Technology, Wuhan, CHINA.
Objective: Cancer stem cells (CSC) provide a new approach
for the diagnosis of malignant tumors. CD133 is the one of
the most intensively studied biomarkers. The aim of this
study was to target the colorectal CSC marker CD133 with
131I-labeled specific monoclonal antibody (AC133 mAb).
Methods: The expression level of CD133 in three different
colon cancer cells (HT29, HCT116 and DLD-1 cell) were
detected by flow cytometry. 131I-AC133 mAb was prepared
and identified. Cellular uptake studies were performed, and
its relationship with the CD133 expression levels was ana-
lyzed. The tumor xenografts models were prepared for
SPECT imaging and biodistribution experiments at different
time points after 131I-AC133 mAb injected. Autoradiogra-
phy and immunofluorescence studies were preformed to ver-
ify the CD133 expression in vivo. Results: The expression
levels of CD133 molecules in HT29 and HCT116 cells were
91.33%±1.66% and 90.83%±2.47%, respectively, which
were significantly higher than that in DLD-1 cells (3.87
±0.57%). The radiochemical yield and radiochemical purity
of 131I-AC133 mAb were 68.37% ± 2.45% and 91.18% ±
3.41% (n=3), respectively. Cellular uptakes of 131I-AC133
mAb in HT29 and HCT116 cells were 29.63% ± 3.92% and
33.99% ± 6.65% at 4 h, respectively, which showed signif-
icantly higher than that in DLD-1 cells (2.89% ± 0.90%, P
<0.01). After incubation with non-labeled AC133 mAb as a
blocking group, the cellular uptakes were dramatically de-
creased to 3.22% ± 0.18% and 3.67% ± 0.56% in HT29
and HCT116 cells, respectively, which suggested specific
binding. In vivo SPECT images, clear tumor signals were
seen on the tumor sites of HT29 and HCT116 tumor-
bearing mice at 7 d after injected 131I-AC133 mAb, and
the tumor uptakes in biodistribution study were 5.49% ±
0.42% ID/g and 5.04% ± 0.05% ID/g (n=5), respectively,
which were significantly higher than that in the DLD-1 tu-
mor bearing mice (1.20±0.11% ID/g, P <0.05). The ratios of
tumor-to-muscle (T/B) at 7 d were 11.34±0.09 (HT29),
11.31±1.05 (HCT116) and 3.43±0.53(DLD-1), respectively.
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The immunofluorescence and autoradiography studies
showed the radioactivity distribution was consistent with
the expression of the CD133 in vivo. Conclusions: 131I-
AC133 mAb could target CD133 antigen in colorectal can-
cer cells specifically, and the uptakes of the tracers were
correlate with the CD133 expression. These suggested that
131I-AC133 mAb was feasible as a radioimmunoimaging
agent for targeting CD133-positive cancer stem cells. This
work was supported by NSFC 81371599.
OP204
SPECT/CT Imaging of Programmed-Death Ligand 1
Expression of Tumors and Antigen-Presenting Cells
S. Heskamp1, W. Hobo1, J. D. M. Molkenboer-Kuenen1, D.
Olive2, W. J. G. Oyen1, H. Dolstra1, O. C. Boerman1;
1Radboud University Medical Center, Nijmegen, NETHER-
LANDS, 2CRCM, Immunity and Cancer, Inserm, Marseille,
FRANCE.
Introduction: Antibodies that block the interaction between the
inhibitory signaling molecules programmed death-ligand 1
(PD-L1) and PD-1 have shown impressive anti-tumor activity.
Patients with PD-L1 expressing tumors are most likely to re-
spond to this type of treatment. Therefore, imaging of PD-L1
expression may aid in selecting patients for PD-1/PD-L1
targeting therapy. Previously we have shown the feasibility to
image PD-L1 expressing human xenografts in mice. However,
in patients, PD-L1 is also expressed on activated antigen pre-
senting cells (APCs), such as dendritic cells and macrophages.
Thismay hamper tumor visualization. The aim of our study is to
determine what the effect of PD-L1 expressing APCs is on the
tumor uptake of radiolabeled anti-PD-L1 antibodies. Material
and methods: The anti-PD-L1 monoclonal antibody, PD-
L1.3.1, was radiolabeled with Indium-111 (111In). Two groups
of immunodeficient NOD/SCID/IL2Rg(null) mice were irradi-
ated (2.5 Gy whole body), followed by intrafemural transplan-
tation of human CD34+ hematopoietic stem cells (HSCs). A
control group was not irradiated nor transplanted. At day 54,
mice were inoculated s.c. with MDA-MB-231 cells. Three
weeks later, one HSC-transplanted group was injected i.p. with
0.6 mg/kg LPS in order to activate APCs and upregulate PD-L1
expression. One day later, all groups were injected i.v. with
13 MBq 111In-PD-L1.3.1. Three days later, mice underwent
SPECT/CT imaging and tissues were collected for ex vivo
biodistribution. Results:SPECT/CT imaging clearly visualized
MDA-MB-231 xenografts in all groups. In LPS-treated mice,
111In-PD-L1.3.1 clearly visualized the activated cells in spleen
and lymph nodes. Ex vivo biodistribution showed that tumor
uptake was not significantly different between the groups (Con-
trol: 42.7 ± 8.1%ID/g, HSC transplantation: 57.3 ± 12.0%ID/g,
HSC transplantation + LPS stimulation: 34.8 ± 18.2 %ID/g).
Strikingly, spleen uptake was significantly increased in
LPS-treated mice (Control: 16.7 ± 3.9 %ID/g, HSC
transplantation: 25.9 ± 9.1 %ID/g, HSC transplantation
+ LPS stimulation: 85.1 ± 30.9 %ID/g, p = 0.004).
Within the LPS-stimulated group, there was a significant
correlation between spleen uptake and tumor uptake
(r=0.91). Mice with the highest spleen uptake showed
the lowest tumor uptake. Conclusion: This study showed
the feasibility to image tumor PD-L1 expression, even in
the presence of human PD-L1 expressing APCs. Upon
LPS injection, APCs were activated and up-regulated
PD-L1. This resulted in enhanced uptake of 111In-PD-
L1.3.1 in spleen and lymph nodes, as was visualized
by SPECT/CT imaging. This did not hamper the visual-
ization of PD-L1 expressing tumors.
OP205
Radiolabelled superagonist rhTSH analogues TR1401
and TR1402 for in vivo imaging of poorly differentiated
thyroid cancer
F. Galli1,2, I. Manni3, G. Piaggio3, L. Balogh4, B. D.
Weintraub5, M. W. Skudlinski5, R. A. J. O. Dierckx2, A. Si-
gnore1,2; 1Nuclear Medicine Unit, Department of Medical-
Surgical Sciences and of Translational Medicine, Faculty of
Medicine and Psychology, “Sapienza” University of Rome,
Rome, ITALY, 2Department of Nuclear Medicine and Molec-
ular Imaging, University Medical Centre Groningen, Univer-
sity of Groningen, Groningen, NETHERLANDS, 3Molecular
Oncogenesis Laboratory, Experimental Oncology Depart-
ment, Regina Elena National Cancer Institute, Rome,
Italy, Rome, ITALY, 4National “Frederic Joliot Curie”
Research Institute for Radiobiology and Radiohygiene,
Budapest, HUNGARY, 5Trophogen Inc.,, Rockville,
MD, UNITED STATES.
Introduction: Patients affected by poorly differentiated thyroid
cancer (PDTC) may show a negative 131I scintigraphy because
of the loss of the iodine symporter (NIS). However, expression
of TSH receptor (TSHR) is usually preserved. Therefore, the
aim of our study was to compare two new radiolabelled
superagonist rhTSH analogues for imaging PDTC. Methods:
Analogues (namely TR1401 and TR1402), with a TSHR bind-
ing affinity ten times higher than Thyrogen®, were
radiolabelled with 99mTc using an indirect method via HYNIC
conjugation. In vitro quality controls were performed to evalu-
ate the stability of the labelling and the retained affinity for the
receptor. These included SDS-PAGE, cysteine challenge and
cell binding assay on TSHR positive cell lines lacking NIS.
In vitro assays were also performed with radiolabelled human
recombinant TSH (Thyrogen®) to compare affinity for the
TSHR of each radiopharmaceutical. In vivo studies were
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performed in 40 athymic nude CD-1 mice bearing either
TSHR+ or TSHR- xenografts from human thyroid cancer cell
lines. Furthermore, 4 dogs with spontaneous thyroid cancer
were studied by 99mTc-TR1401 SPECT/CT, 99mTc-
TR1402 SPECT/CT, 131I SPECT/CT and 18F-FDG
PET/CT in different days within 2 weeks. Results:
Suepragonist rhTSH TR1401 and TR1402 analogues
were labelled with high labelling efficiency (>95%),
high stability and retention of both biological activity
and structural integrity. Analogues showed high affinity
for the TSHR with dissociation constants (Kd) of 2.7
nM for 99mTc-TR1401, 0.5 nM for 99mTc-TR1402
and 8.4 nM for 99mTc-Thyrogen. In tumor targeting
experiments, a focal uptake of radiolabelled analogues
was observed in TSHR+ cells with a target-to-
background ratio up to 3 at 3 h p.i., whereas no signif-
icant uptake was observed in mice bearing TSHR- cells.
Similar observations were made in dogs with spontane-
ous intra-glandular papillary thyroid cancer, in which
TSHR expression was confirmed by immunohistochem-
istry. Conclusions: We were able to efficiently radiolabel
new superagonist rhTSH analogues with 99mTc with
retention of in-vitro and in-vivo binding affinity with
TSHR. 99mTc-TR1402 proved a high superiority than
99mTc-TR1401 and 99mTc-Thyrogen. This new radio-
pharmaceutical opens new perspectives for pre-surgical
TSHR-based staging of thyroid cancer, for diagnosis of
radioiodine negative cancer remnants, local relapses and/
or distant metastases.
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OP221
Investigation of kidney function with a dynamic FDG-
PET/MR
B. K. Geist, A. Staudenherz; Medical University of Vienna,
Vienna, AUSTRIA.
Aim: To study kidney function with FDG PET would be of
clinical relevance for cancer patients undergoing staging before
nephrotoxic chemotherapy will be applied. But investigation of
kidney function with PET is a little explored field in nuclear
medicine. The MR modality is suited for examine kidney, since
the high-resolutionmorphological information of theMR allows
a detailed discrimination of the FDG behavior in various regions
in the organ. Our aim is to extract kidney function parameters
(e.g. glomerular filtration rate, split kidney function, extraction
function, etc.) from a single dynamic PET/MR scan. Methods:
At the General Hospital in Vienna we started to acquire the time
activity curves of the routine PET tracer F-18-FDG directly after
injection separately for each kidney region, usingMR images for
kidney segmentation. From the temporal behavior of the tracer
concentration in the different kidney regions as well as from the
results from kineticmodeling, conclusions to the kidney function
parameters are drawn. The obtained values are then compared to
the results from MAG 3 renography and GFR-measurement.
Results: So far the time activity curves from the FDG PET stud-
ies revealed a good correlation with the renal split function from
MAG 3 renography. The preliminary results will be presented in
detail. Conclusion: In order to facilitate the examination protocol
for the determination of kidney functions, a PET/MR scan of the
kidney is studied in comparison with routinely used kidney ex-
aminations in nuclear medicine and MR renography.
OP222
Wholebody Blood Pool in Bone Scintigraphy: Usefulness
in the differential diagnosis of inflammatory arthritis -
Preliminary Results
M. Casanova Martins, B. Patel, C. Humphreys, P. Ali;
ABMU HB, Swansea, UNITED KINGDOM.
Introduction: To establish a differential diagnosis of inflamma-
tory arthropathy (IA) it is important to assess the presence of
hyperemia and increased relative tissue vascularity in bone scin-
tigraphy. However, limiting early blood flow (BF) and blood
pool (BP) imaging to a single symptomatic anatomic region
might not entirely reveal the nature/extent of a multifocal sys-
temic pathology. Instead, a global approach to the early imaging
stages could be useful. This approach does not allow the
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acquisition of the quick BF study to assess local hyperaemia
yet allowing performing a wholebody blood pool (WB BP)
study and therefore gathering systemic information on the tissue
vascularity surrounding most joints. Aim: The aim of this work
is to evaluate the usefulness of dual-phase wholebody skeletal
scintigraphy in the assessment of IA. Materials and Methods:
Between January 2014 and April 2015, 46 bone scans were
performed for the assessment of IA. Patients underwent either
triple-phase (n=40) or dual-phase bone scintigraphy (WB BP
and delayed imaging) (n=6). Images and reports were retrospec-
tively analysed. Results: In the triple-phase group, 60%(n=24)
cases presented changes in all stages of the triple-phase scintig-
raphy, with accurate localization of active disease in the targeted
joint. 100%(n=24) of these studies however, also presented in-
creased uptake in other joints on delayed imaging. In
40%(n=16) studies there were no changes in the early imaging
stages. Of these, only 25%(n=4) were completely normal in the
delayed stage. In the remaining 75%(n=12) cases, the early
imaging stages were normal, with marked increased uptake in
other joints in the delayed stage, leading to inconclusive reports.
In the dual-phase group, the report issued was conclusive in all
cases. Of these, 67%(n=4) were positive, with matching chang-
es in several joints in both stages of the study and 33%(n=2) had
normal WB BP and increased multifocal uptake in the delayed
WB scan. Discussion: The dual-phase WB protocol has in-
creased the frequency of conclusive reports to 100% in the
assessment of IA. Acquisition of early WB images increases
the diagnostic accuracy whilst only adding 2-3 minutes to the
study time. Hyperaemia is not assessed in dual-phase scintigra-
phy but this does not seem to affect the interpretation of these
examinations. In addition, early WB imaging provides a sys-
temic joint assessment allowing the evaluation of the extent of
disease. Conclusion: Dual-phase wholebody skeletal scintigra-
phy is a simple but useful technique for the detection and char-
acterization of widespread joint abnormalities and its routine use
is recommended.
OP223
Comparison of Ga-68-DOTATATE PET/CT
and In-111-octreotide SPECT/CT for the detection
of neuroendocrine tumors
M. Kieft, E. A. Aalbersberg, M. P. M. Stokkel; NKI-AVL,
Amsterdam, NETHERLANDS.
AIMIn our hospital, Ga-68-DOTATATE was implemented in
Augustus 2011, and thereafter the number of Ga-68-
DOTATATE PET/CTs is increasing rapidly at the expense of
In-111-octreotide SPECT/CT. The aim of this study is to com-
pare the detectability of neuroendocrine tumors (NET) be-
tween both techniques.MATERIALS & METHODSBetween
August 2011 and February 2015 209 Ga-68-DOTATATE
PET/CT scans were performed in 187 neuroendocrine tumor
patients. In 111 cases the patients underwent an In-111-
octreotide SPECT/CT and PET/CT; in 28 cases the scans took
place within a maximum interval of 12 months.Based on the
PET/CT reports, 12 cases showed one or more lesions, eight
showed none and in eight cases the images were inconclusive.
For the 12 cases with tumor lesions we scored the PET/CT, the
SPECT/CT, and the planar images for total number of lesions
and quantified the images. The lesions were divided in three
categories: liver, skeletal, and other. The quantitative analysis
of the PET/CTwas based on SUVmax. On planar imaging and
SPECT/CT lesions were scored visually (0= no uptake, 1=
equivocal, 2≤ liver, 3> liver, 4= intense). Eight patients re-
ceived somatostatin analogues between the scans. One lesion
was resected and this lesion is removed from the
analysis.RESULTSPET/CT depicted 149 lesions, SPECT/CT
41 lesions, and planar imaging 31 lesions. All lesions visible
on SPECT/CT were found on PET/CT except for one. In the
liver, 64 lesions were found with PET/CT, 19 with SPECT/CT
and 16 with planar imaging. Of the 25 skeletal lesions on PET/
CT, 3 were also seen on SPECT/CT and none on planar imag-
ing. Sixty additional lesions were identified with PET/CT in
other parts of the body, of which only 19 were visible on
SPECT/CT and 15 on planar imaging. The discrepancy be-
tween PET/CT and SPECT/CT can be partially explained by
the fact that whole-body SPECT/CT is not regularly per-
formed, however in most cases Ga-68-DOTATATE PET/CT
is more sensitive for NET then In-111-octreotide SPECT/
CT.No correlation was found between SUVmax on PET/CT
and visibility of the same lesion on SPECT/CT or the planar
image.CONCLUSIONThese preliminary results show that
Ga-68-DOTATE PET/CT has a higher detectability of lesions
in comparison to In-111-octreotide imaging. Due to the ongo-
ing application of Ga-68-DOTATATE more data will become
available in the next months, which will also be analyzed.
Based on these results, it can be concluded that In-111-
octreotide scintigraphy alone is not standard clinical practice
anymore.
OP224
Phase analysis using ECG-gated myocardial FDG PET
in the rat in comparison with speckle tracking
echocardiography
A. Mizutani1, I. Matsunari2, M. Kobayashi3, K. Nishi4, W.
Fujita5, S. G. Nekolla6, K. Kawai7, K. Fukuchi1; 1Osaka Uni-
versity, Osaka, JAPAN, 2Saitama Medical University Hospi-
tal, Saitama, JAPAN, 3Kanazawa University, Kanazawa, JA-
PAN, 4Nagasaki University, Nagasaki, JAPAN, 5Kanazawa
Medical University, Ishikawa, JAPAN, 6Technical University
Munich, Munich, JAPAN, 7Osaka UniversityKanazawa Uni-
versity, Kanazawa, JAPAN.
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Aim: Clinical studies have shown that phase analysis using
ECG-gated myocardial SPECT/PET is useful for assessing left
ventricular dyssynchrony. However, its feasibility has not yet
been validated in small animals such as rats, where small heart
size and high heart rate pose a technical challenge. The aim of
this study was to assess the feasibility of phase analysis using
ECG-gated myocardial FDG PET in rats with myocardial in-
farct in comparison with speckle tracking echocardiography as
a reference standard for dyssynchrony. Methods: Twenty-nine
Wister rats with myocardial infarct underwent ECG-gated
FDG PET in list-mode for 20 minutes using a dedicated small
animal PET scanner (Triumph II/LabPET8, TriFoil Imaging).
Image reconstruction was performed using ordered-subset ex-
pectation maximization (OSEM) in 16 frames per cardiac cy-
cle. All the rats also underwent speckle tracking echocardiog-
raphy using Vivid7 (GE Healthcare) with a small and high-
frequency (~14MHz) linear transducer (i13L, GEHealthcare).
For PET, standard deviation of time to peak thickening
(PET_SD) was calculated as an index of dyssynchrony using
AHA 17 segment model. For speckle tracking echocardiogra-
phy, standard deviation of time to peak radial strain on a mid-
ventricular short-axial image (echo_SD) was obtained as an
echocardiographic index of dyssynchrony. Results: PET_SD
measured by ECG-gated PET showed a significant positive
correlation with echo_SD (R=0. 597, p<0.001). In addition,
PET_SD showed significant correlations with measures of
disease severity such as left ventricular ejection fraction (R=-
0.575, p<0.001) and infract size (R=0.614, p<0.001). Conclu-
sion: Our results indicate that phase analysis using ECG-gated
myocardial FDG PET is feasible in the rat model of myocar-
dial infarct, and thus may provide a measure of left ventricular
dyssynchrony.
OP225
Eye Spy: An Investigation into Tc-99m Pertechnetate
Lacrimal Scitigraphy for Protocol Optimization
E. Souza, V. Janse van Rensburg, P. Sandhu, L. Perry, H.
Tam, Z. Win; Imperial College Healthcare NHS Trust, Lon-
don, UNITED KINGDOM.
Aim: To assess the change in diagnosis between three different
lengths of acquisition (0-15mins, 0-23mins, 0-31mins) and
post-rinse static to determine if a shorter acquisition will yield
the same clinical result for lacrimal scintigraphy studies using
Tc-99m pertechnetate. Our local protocol uses a 31minute dy-
namic (eighteen 10-seconds frames, then 60-second frames),
followed by a 60second, post rinse static view. The aim of this
study was to evaluate the clinical utility of extra data collected
after the initial 15minutes dynamic acquisition. Materials and
Methods: Data was retrospectively collected from 40 patients
referred to our department for lacrimal scintigraphy, over a
period of 6 months. The right side and left side of each patient
were considered as separate systems, thus a total of 80 lacrimal
systems were evaluated. Anonymised printscreens were pro-
duced showing data acquired 0-15mins, 0-23mins, 0-31mins
post administration and the post-rinse static. Two radiologists
reviewed the images recording their diagnosis based on 0-
15mins, 0-23mins and 0-31mins of data post administration.
The diagnosis reached when the post rinse image was
reviewed was also recorded. Diagnosis was categorised as no
obstruction, partial obstruction or total obstruction, pre and
post sac. We calculated the percentage of lacrimal systems
where there was a change in diagnosis between the 0-15mins
vs 0-23mins and 0-23mins vs 0-31mins datasets. We also cal-
culated the change between each separate dataset and the post-
rinse diagnosis eg 0-15mins vs post-rinse. Results: The per-
centage of lacrimal systems where there was a change in diag-
nosis changed was 14.4% between the 0-15mins vs 0-23mins
and 7.5% between the 0-23mins vs 0-31mins. When the diag-
nosis reached from the post-rinse static image was compared
to the diagnosis reached from the other time-frames: 31.3%
was changed vs 0-15mins; 21.9% was changed vs 0-23mins
diagnosis; 16.3% was changed vs 0-31mins diagnosis. Con-
clusion: This study demonstrates that although there is still a
substantial amount of information after a 15minute dynamic
phase, as the duration of the initial dynamic phase of lacrimal
scintigraphy increases the impact on diagnosis is reduced.
However we found there was a significant change in diagnosis
after the post-rinse images. Therefore we would suggest that a
shorter acquisition protocol could be adopted clinically as long
as the post-rinse image is included. We suggest a shorter dy-
namic acquisition of 23minutes followed by a post-rinse image
would increase patient throughput and comfort whilst main-
taining diagnostic accuracy.
OP226
Radionuclide therapy of metastatic melanoma
with benzamide derivate I-131-BA100 after patient
stratification with F-18-DOPA
F. O. Spohn, K. Kunze, F. Giesel, W. Mier, U. Haberkorn, C.
Kratochwil; Heidelberg University Hospital, Heidelberg,
GERMANY.
Aim:Benzamide derivates have been shown to selectively ac-
cumulate in melanotic melanoma. Some patients with meta-
static melanoma show therapeutically promising accumulation
of the benzamide derivate I-131-BA100.L-DOPA is a precur-
sor to the biological pigment melanin.We evaluated if it’s pos-
sible to select which patient could benefit from a radioligand
therapy with I-131-BA100 using F-18-DOPA for
prediagnostic.Methods:15 patients with metastatic melanoma
were examined. In line with the propagation diagnostic and
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staging a F-18-FDG PET/CT was acquired.With regard to a
radionuclide therapy both I-131-BA100 whole body scan and
PET/CTwith the melanin precursor F-18-DOPAwere done at
intervals of few days.48 hours after intravenous injection of
230 +/- 35 MBq I-131-BA100 planar whole body scans and
tomographic images in SPECT technique were acquired.In the
best case the F-18-DOPA examination was done on the very
same day of benzamide imaging. After intravenous injection
of 215 +/- 55 MBq F-18-DOPA 15 minutes p.i. an emission
scan of the trunk and a low-dose CT for attenuation correction
was processed.Results:Benzamide- and DOPA-examination
showed no pathological retention in known multiple metasta-
ses in 4 patients. 10 patients showed congruent findings with
both tracers. On the contrary there was found a discrepant case.
This patient had moderate to intensive DOPA-positive lesions
which showed no retent ion with the benzamide-
derivate.Conclusion:The correlation of F-18-DOPA- and
I-131-BA100-uptake is sufficiently enough to preselect pa-
tients who could benefit from this type of therapy. Because
of the individual case of missing correlation between
benzamide- and DOPA-uptake diagnostic imaging with
I-131-BA100 is still advisable.
OP227
Impact of syringe residual activity in SUV measurement
P. Felício1, J. Hunter2, N. G. Dowell2, T. Vaz1, F. Lucena1;
1Lisbon School of Health Technology, Lisbon, PORTUGAL,
2Clinical Imaging Sciences Centre, Brighton and SussexMed-
ical School, University of Sussex, Brighton, UNITED
KINGDOM.
The use of the semi-quantification standard uptake value
(SUV) in PET/CT image has an important role in the evalua-
tion of individual response to therapy however many factors
may interfere with the calculation of SUV. One factor is the
residual activity in the syringe after injection. The aim of this
research is to assess the influence of the syringe residual ac-
tivity in the SUV, in PET/CT images with 18F-FDG. Forty-
eight patients with clinical indication for performing PET/CT
with 18F-FDGwere included. Inclusion criteria were: avid 18F-
FDG tumour uptake in the PET/CT images and blood glucose
level between 4 and 8 mmol/L. Images were acquired 1 hour
after the radiopharmaceutical injection (400 MBq) according
to departmental procedure. Reconstruction and processing of
the images were performed with ordered subset expectation
maximization (OSEM) algorithm (4 iterations; 8 subsets;
5 mm Gaussian filter), 168x168 image matrix; zoom 1; voxel
size 5 mm3. A dose modulated CT scan was acquired prior to
the PETscan for attenuation correction (120KV; 50mAs (ref);
5 mm slice thickness). Maximum SUV (SUVmax) based on
patient weight was obtained, with (SUVmax-C) and without
correction (SUVmax-NC) for the injected activity, keeping the
same procedure (ROI area, slice and lesion). Descriptive and
inferential statistics (t-test for paired-samples and person-cor-
relation) were applied (IBM SPSS software, version 22). Sig-
nificance was considered for p-value<0.05. After the data
collecting, mean values were obtained: 18F-FDG activity
(393±21 MBq), syringe residual activity (3.38±2.43 MBq),
ROI area (1.69±0.65 pixels), SUVmax-C (12.33±6.37),
SUVmax-NC (11.95±6.18). As it was expected a strong linear
positive correlation (r=0.99, p-value=0.00) was found between
the two SUVmax. However, the comparison of means showed
statistically significant differences (p-value=0.00), associated
with an increase of SUVmax after correction. These results are
in agreement with the SUV empirical formula, which takes
into account the activity concentration in the ROI and the
injected activity. This way, the corrected activity will produce
an increase in the SUVmax obtained. No correlation was shown
between SUVmax-NC and SUVmax-C, with regard to the
injected activity, the syringe residual activity or patient weight.
The correction for syringe residual activity increases the
SUVmax and further research should be performed in order to
identify the clinical impact of this difference. It is recommend-
ed that the same method for SUVmax measurement is applied,
especially in the evaluation of individual response to therapy.
OP228
Protocol Optimisation of [68Ga]-PSMA PET/CT Imaging
on a High Sensitivity Time-of-Flight Pet Scanner
E. A. Bailey, E. Hsiao, G. Schembri; Royal North Shore Hos-
pital, Sydney, AUSTRALIA.
AIM: The use of [68Ga]-PSMA PET/CT in the staging and
response to therapy of patients with prostate cancer is increas-
ing. There are limited guidelines suggesting the ideal parame-
ters to ensure high image quality using a Time of Flight (ToF)
PET/CT system. We used external triggered gating to investi-
gate the optimal scanning parameters (dose injected, time per
bed position) for whole body PSMA PET scanning on a Sie-
mens Biograph mCTwith extended axial field of view (FoV),
t ime-of - f l igh t scanner wi th reso lut ion recovery
(HD).METHODS: Patients referred for a PSMA PET scan
with a rising PSA were injected with 150MBq of [68Ga]-
PSMA (HBED). An externally triggered gated (ETG) WB
PET scans were acquired at 60 minutes on a ToF PET/CT
(Siemens Biograph mCT64x64). Data were reframed into 30
sec time bins (6 gates) using ToF 3D-OSEM with CT-based
AC, SC and PSF recovery and then combined using in-house
software to give different total acquisition times (30 secs,
60secs, etc up to 180 secs). ROIs are defined over areas of
assumed homogeneity (e.g., liver and salivary glands), lesions,
bladder and blood pool across all reformatted studies. Image
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coefficient of variation (CoV%), SUVmax and visual assess-
ment were used to quantify the relationship between dose
injected and time per bed position.RESULTS: A total of 6
studies were included for analysis with an average injected
dose of 141MBq (125-165MBq), weight 81kg (71-88kg)
and PSA range 3 to 56ng/mL. Based on a PSMA injected dose
of 141MBq, the scanning time per bed position appears to
plateau based on CoV% in liver, nodes and salivary glands
at around 120 secs per frame. The SUVmax was reproducible
from 60secs to 180secs acquisition time with a maximum de-
viation in the shortest time frames of <15%.CONCLUSION:
The use of ETG acquired data to assess varying parameters
such as different acquisition times and injected doses allows
the assessment of the impact on image quality between
injected dose and scanning duration. In this analysis, the image
quality and reliability of quantitative measures such as
SUVmax appears to be achieved at 120secs per bed position
with an injected dose administered of 141MBq. This approach
is now being used to assess optimal parameters for PSMAPET
delayed imaging acquired between 120 and 180 minutes post
injection.
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OP229
SPECT/CT for Anatomical Mapping of Lymphatic
Drainage in Vulvar Cancer: Possible Implications
for the Extent of Inguinal Lymph Node Dissection
A. Collarino1,2, M. L. Donswijk2, W. J. van Driel3, M. P.
Stokkel2, R. A. Valdés Olmos2,4; 1Institute of Nuclear Medi-
cine, Università Cattolica del Sacro Cuore, Roma, ITALY,
2Department of Nuclear Medicine, The Netherlands Cancer
Institute – Antoni van Leeuwenhoek Hospital, Amsterdam,
NETHERLANDS, 3Department of Gynaecological Oncology,
The Netherlands Cancer Institute – Antoni van Leeuwenhoek
Hospital, Amsterdam, NETHERLANDS, 4Interventional Mo-
lecular Imaging Laboratory and Nuclear Medicine Section,
Department of Radiology, Leiden University Medical Center,
Leiden, NETHERLANDS.
Aim: to assess the lymphatic drainage pattern using SPECT/
CT in clinically node-negative (cN0) patients with vulvar can-
cer, and to evaluate the possible implications for the extent of
inguinal lymph node dissection.Material and Methods:
Lymphoscintigraphy and SPECT/CT were performed in 83
patients (mean age 67.8, range 25-93y) vulvar cancer patients
scheduled for sentinel node (SN) biopsy after four peri-
tumoral injections of 99mTc-nanocolloid. Using SPECT/CT
SN and higher-echelon nodes were identified and were
anatomically localized in the groin according to Daseler’s five
zones: four zones obtained by drawing two perpendicular lines
over the saphenofemoral junction and one zone directly over-
lying this junction. Lymph nodes into the pelvis were classi-
fied into three zones: external iliac/obturator, the common iliac
and the para-aortic zones.Results: A total of 217 SNs and 202
higher-echelon nodes were localized using SPECT/CT. All
SNs were located in the groin and were classified in one of
the five zones according to Daseler: 149 (69%) in the medial
superior region, 31 (14%) in the medial inferior region, 22
(10%) in the central region, 14 (6.5%) in the lateral superior
region and only 1 (0.5%) in the lateral inferior region. The
higher-echelon nodes were located both in the groin (15%)
and in the pelvic region (85%).Conclusion: In cN0 vulvar
cancer patients scheduled for the SN procedure, lymphatic
drainage occurs predominantly to the medial regions of the
groin. Drainage to the lateral inferior region of the groin is
only incidental, and in SN positive patients this zone might
be spared for subsequent extended lymph node dissection; this
may lead to a decrease of the morbidity associated with this
procedure. SPECT/CT is able to personalize lymphatic map-
ping, providing detailed information about the number and
anatomical location of SNs for adequate surgical planning in
the groin.
OP230
3D freehand-SPECT navigation for intraoperative
radioactive seed localisation using single or multiple 125I
seeds in breast-conserving cancer surgery
B. Pouw, L. J. deWit-van der Veen, F. van Duijnhoven, E. J. T.
Rutgers, R. A. Valdés Olmos, M. P. M. Stokkel, M. T. F. D.
Vrancken Peeters; Netherlands Cancer Institute, Amsterdam,
NETHERLANDS.
Background: The use of mammographic screening has led to
the identification of more women with non-palpable breast
cancer. For subsequent treatment adequate localisation tech-
niques are required for radical excisions. For radioactive seed
localisation (RSL) a radioactive Iodine-125 seed (125I-seed) is
implanted in the centre of the tumour and intraoperatively
localised using a gamma probe. In case of extensive ductal
carcinoma in situ (DCIS) or multifocal carcinoma, multiple
125I-seeds can be used to delineate the borders of the involved
area. For localisation control of the seed, preoperative imaging
is not performed in the surgical position and therefore the exact
125I-seed depth remains unknown during surgery. For this
purpose, we evaluated freehand-SPECT (fh-SPECT), which
facilitates 3D navigation towards the 125I-seed. Methods:
Fourteen female patients (Mean age 56 years) with 21 im-
planted 125I-seeds scheduled for RSL were included. Eleven
patients had 1 125I-seed implanted in the primary lesion, 2
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patients 2, 1 patient 3. In 3 patients, an additional 125I-seed
was implanted as a marker for an up-front systemically treated
tumour-positive axillary lymph node. Fh-SPECT localised
125I-seeds by measuring gamma counts from different direc-
tions all registered by an optical tracking system. A reconstruc-
tion and visualisation algorithm enabled 3D navigation to-
wards the 125I-seeds. Surgeons estimated the depth of 125I-
seeds after excision and compared this with the depth indicated
by fh-SPECT. Results: Fh-SPECT visualised all 125I-seeds in
the primary tumours and provided pre-incision depth informa-
tion. The deviation between the fh-SPECT depth and the sur-
gical depth estimation was 2.7 mm (SD 2.1mm, Range 0-
7mm). 3D fh-SPECTwas especially useful identifying multi-
ple implanted 125I-seeds where the conventional gamma-
probe has more difficulty to discriminate 125I-seeds by trans-
cutaneous measurements. In two patients the excision was
irradical and tumour was detected at the resection border; for
1 patient a DCIS component was detected at the resection
margin and another patient had invasive ductal carcinoma in
the resection border. In one patient a diagnostic excision of
three lesions was performed of which one contained tubular
carcinoma. Conclusion: Fh-SPECTwith 3D navigation is fea-
sible in RSL based on single or multiple implanted 125I-seeds.
Themodality is able to provide real-time 3D information about
the depth and location of the 125I-seeds, contributing to ade-
quate excision of non-palpable breast cancer. 3D navigation
may become important in breast-preserving cancer surgery.
OP231
Intraoperative evaluation of a true hybrid modality
for combined radio- and fluorescence guided sentinel node
biopsy
N. S. van den Berg1,2, H. Simon3, G. H. KleinJan1,2, J.
Chambron3, B. M. Tijink2, S. Horenblas2, F. W. B. van
Leeuwen1,2; 1LUMC, Leiden, NETHERLANDS, 2AVL-
NKI, Amsterdam, NETHERLANDS, 3Eurorad, Strassbourg,
FRANCE.
Introduction:The clinical implementation the hybrid tracer
ICG-99mTc-nanocolloid, that is composed of a near-infrared
fluorescence component (ICG; indocyanine green) and a ra-
dioactive component (99mTc-nanocolloid), has stimulated the
generation of sophisticated imaging modalities that allow con-
secutive detection of the two signatures. In the current study,
we report on the first-in-human use of a true hybrid opto-
nuclear modality for image-guided surgery.Materials and
Methods:Nine patients scheduled for sentinel node biopsy of
penile (n=7) or head and neck cancer (n=2) were included after
obtaining written informed consent. The number and location
of the sentinel node(s) were determined after hybrid tracer
injection and subsequently lymphoscintigraphy (15min and
2hours post-injection) and SPECT-CT imaging (2.5hours
post-injection). Intraoperatively, sentinel nodes were pursued
using the hybrid opto-nuclear modality (prototype; Eurorad,
Strassbourg, France). After initial localization of the gamma
signal, the probe was switched to the fluorescence mode. Fluo-
rescence tracing was performed under ambient light condition.
First in the high sensitivity mode (0.9V) first, and after
confirming the location of the node the settings were switched
to a low sensitivity mode (0.7V). Post-excision, the measure-
ments were repeated on the surgical specimens. 5-Second
count rates were noted for both gamma and fluorescence trac-
ing. Obtained fluorescence tracing results were compared to
the results obtained with the conventional fluorescence camera
(PDE; Hamamatsu Photonics, Hamamatsu, Japan).Results:In
the nine patients included in this trial, intraoperatively 20 sen-
tinel nodes were pursued. All SNs could be gamma traced. In
the high sensitivity mode, all sentinel nodes were detected via
fluorescence tracing (20/20). In the low sensitivity mode, how-
ever, only 7/20 nodes could be traced (35%). Presence of the
fluorescence signal in the node was confirmed in all cases
using the fluorescence camera. Surgeons that were used to
gamma tracing considered fluorescence tracing with the
opto/nuclear-probe technology intuitive and the ability to trace
this signature in ambient light was considered valuable for
surgical logistics.Discussion:The hybrid surgical guidance
modality that allows for combined gamma and fluorescence
tracing proved to be feasible and was considered a valuable
addition during sentinel node biopsy procedures that use the
hybrid tracer ICG-99mTc-nanocolloid.
OP232
Role of Robotic assisted PET-CT guided biopsy
in 18F-FDG/Ga68 DOTANOC avid suspicious lesions
S. Gambhir, A. Prashanth, S. Barai, H. Lal, A. Nath, G.
Sankar, N. Kumar, M. Ravina; Sanjay Gandhi Post Graduate
Institute of Medical Sciences, Lucknow, Uttar Pradesh,
INDIA.
Aim: To evaluate the role Robotic guided PET-CT biopsy in
terms of histopathological yield and complication rate. Intro-
duction: CT guided biopsy of lesions with high necrotic con-
tent is unfruitful in most circumstances. So PET-CT guided
biopsy will alleviate the flaws of both CT guided biopsy and
PET-CT as standalone modalities. Robotic systems can en-
hance surgical and interventional procedures through im-
proved precision, stability, and dexterity. The high precision
of registration, planning, and movement of the robotic arm
enables an effective biopsy in all cases, with a high accuracy
for even relatively small targets. Materials and methods: 20
patients were referred for PET-CT guided biopsy in our center
for the following indications, Unknown primary with likely
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primary detected from PET-CT, suspicious lesions identified
from PET-CT in a known primary disease and FNAC or CT
guided biopsy negative lesions which are high index of suspi-
cion for malignancy. Procedure was done on an outpatient
basis with written informed consent after appropriate investi-
gations. PET CT along with contrast was done in order to
locate the larger vascular structures near the lesion. Biopsy
procedure was done on a separate day planned using the al-
ready acquired PET-CT images. 3 cases which were excluded
due to the following reasons lesion resolved completely on
check scan, severe dyspnoea which prevented stable position-
ing of the patient, procedure abandoned because of needle in
dangerously close proximity to aorta. Results: Tissue was ad-
equate and histo-pathological diagnosis was achieved in all
patients except one in whom a repeat procedure yielded posi-
tive results. The locations of lesionwere thoracic in 88%, spine
in 6% and pelvis in the rest 6% of patients. Out of the 17
lesions biopsied 11% (2 lesions) were benign and 89% (15
lesions) turned out to be malignant. Tissue yield from the
procedure was 100%. The only complication (1 out of 17
patients - 6%) which arose was self limiting pneumo-thorax.
Conclusion: In sharp contrast to the CT guided manual proce-
dure which requires multiple check CT scans robotic proce-
dures inherently need lesser manipulation by user. Robotic
assisted PET-CT procedures have lesser complications better
histo-pathological yield. It also results in lesser radiation dose
to the patient and short learning curve.
OP233
FDG PET/CT Guided Biopsy
C . NANNI 1 , A . CAPPELL I 1 , T. BALB I 1 , F.
MANGIACOTTI1, A. GASBARRINI2, T. GRAZIANI1, I.
SANDLER1, R. GOLFIERI1 , S. FANTI1 ; 1AOU
S.ORSOLA-MALPIGHI, BOLOGNA, ITALY, 2IOR, BOLO-
GNA, ITALY.
Biopsy of suspect tissues is required to reach a definitive di-
agnosis. Open incisional biopsy (OIB) is traditionally the
method of choice, providing an accuracy of approximately
100%. OIB is very expensive and is associated with several
drawbacks (morbidity, surgical complications, tumor contam-
ination of surrounding tissues). The development of imaging-
guided biopsies (ultrasound, computed tomography) has al-
most overcome these disadvantages. However, in recent liter-
ature a variable amount of non-diagnostic procedures is report-
ed, leading to an accuracy ranging between 70%-90%. FDG
PET/CT is a functional imaging technique highlighting areas
of active malignancy/infection with a very high sensitivity in
comparison to conventional imaging. It detects abnormal sig-
nals even before cancer-related morphological changes occur,
and can accurately discriminate between fibrous residual tissue
after therapy and disease persistence or relapse. It can poten-
tially be used to drive the biopsy to the most active lymph node
or to the most active area within a suspect mass. Aim of this
study is to preliminary assess FDG PET/CT guided biopsy
feasibility and accuracy in the diagnosis of malignancy/
infection.So far 7 patients with unclear hypermetabolic find-
ings were enrolled (5F,2M, mean age 50). 5/7 had a suspect
malignancy relapse (3 anorectal, 1 ovarian, 1 NHL) and 2/7
did not have a significant clinical history. 4/7 had a previous
non diagnostic CT-guided biopsy. They underwent a FDG
PET/CT guided biopsy performed by experienced personnel
(interventional radiologist, nuclear medicine doctor, orthope-
dic). 5/7 pts underwent also contrast media injection to depict
vessels surrounding the lesion used to help in drawing the
most appropriate needle route. The needle was tracked by
driving its progression into the area with the highest SUVmax
through repeated PET/CT acquisition (1bed/position; acquisi-
tion time 1 min). On average, the procedure lasted approxi-
mately 1h per patient. The sample was laid down on adhesive
glass slide to obtain cytological extemporaneous exam to test
its adequacy and, in some cases, for an immediate diagnosis.
6/7 pts had a definitive pathological diagnosis after PET/CT
biopsy (1TBC, 1sacral chordoma, 2 rectal ca relapse, 1 serous
papillary ovarian ca, 1 intermediate lymphoma) while in 1 pt
histopathology demonstrated post RT scar tissue. This pt is
currently in follow-up. No pts had complications. These pre-
liminary results prove that FDG PET/CT guided biopsy is
feasible in the clinical practice. Furthermore it positively im-
pacted on the time to treatment onset in those pts who present-
ed with a previous non diagnostic biopsy.
OP234
MRI based identification of lymph nodes and nerves,
the next step in sentinel node procedures for head and neck
cancer?
T. Buckle1, B.M. Verbist1, G. H. KleinJan1, M. de Ruiter1, M.
A. van Buchem1, A. J. Balm2, F. W. B. van Leeuwen1;
1LUMC, Leiden, NETHERLANDS, 2NKI-AvL, Amsterdam,
NETHERLANDS.
Background: Sentinel node (SN) procedures in the head-and-
neck area are challenging due to the many critical anatomical
structures located in the five dissection regions (Level I-V).
Preoperative SN identification, based on SPECT/CT, and
radioguided dissections are limited in their ability to identify
clustered SNs. Nor do these imaging technologies provide
insight in the location of peripheral nerves adjacent to the
SNs. In search of methods that allow more detailed lymph
node (LN) identification and visualization of peripheral
nerves, a new MRI-based imaging technology was evaluated.
The locations of the visualized LNs were compared to the SN
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visualization-rate in a historic cohort of patients. Methods and
Patients: Retrospective analysis of a database containing pre-
operative imaging results (SPECT/CT) and pathology reports
from 100 head-and-neck melanoma and 40 oral cavity cancer
patients was used to evaluate the incidence of SN visualization
and occurrence of metastasis per dissection level. Nerve imag-
ing was performed on a Philips 3T Ingenia MRI scanner in
fifteen healthy volunteers using a D-prep MRN sequence
(scanning-time: 2-5 minutes) and a standard head coil. Ana-
tomical reference images were acquired using a standard T1-
3DTSE sequence. AnOverlay of bothMR images was used to
place the LNs and nerves in their anatomical context. Results:
Retrospective assessment of SPECT/CT-based preoperative
visualization of SNs revealed that 61% of were visualized in
levels I-III (61%), and herein 54% contained micrometastases.
With D-prep MRN LNs could be detected with a significant
improvement in the level of detail as compared to low-dose
CT. The highest density of LNs was seen in dissection level I -
III and discrimination could be made between single nodes
and clusters of 3-5 nodes. Next to allowing the identification
of LNs, this MRI technology also improved the insight in the
location of the facial nerve including its mandibular, zygomat-
ic and cervical branches (diameter: 0.19 ± 0.04, 0.17 ± 0.03
and 0.19 ± 0.03 mm respectively). Variation in the course of
the visualized nerves, in relation to the submandibular salivary
gland, as well as variation in the location, amount (27 ± 10
LNs per subject) and size (range 21-1085 mm3) of the LNs
was seen between volunteers. Conclusion: D-prep MRN en-
abled detailed visualization of single LNs located in clusters
and facial nerve branches, which contributes to improved pre-
operative assessment of sentinel node procedures.
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OP235
The potential of F-18 Fluoride PET as a surrogate
for Radium-223 chloride lesion dosimetry in hormone
refractory prostate cancer patients
I. Murray, S. J. Chittenden, C. C. Parker, G. Flux; Royal
Marsden NHS Foundation Trust, Sutton, UNITED
KINGDOM.
Aim: The aim of this investigation was to assess the response
of castration-refractory prostate cancer bone metastases to
223Ra-chloride treatment using sequential 18F-Fluoride PET
imaging. Additionally we hypothesised that since 18F-
Fluoride and 223Ra share a common biological target, a single
18F-Fluoride scan at baseline could serve as a surrogate for
223Ra-chloride dosimetry. Methods: Five patients received
two intravenous injections of 223Ra chloride, 6 weeks apart,
at 100 kBq per kg whole-body weight. The pharmacokinetics
and biodistribution of 223Ra-chloride as a function of time
were determined. In addition PET/CT imaging using 18F-
Fluoride was carried out immediately prior to treatment, prior
to the second treatment at week 6, and subsequently at 12
weeks after baseline. Changes in both the SUVpeak and the
percentage injected activity per kilogram of each lesion were
measured and plotted against baseline 18F-Fluoride uptake on
a lesion by lesion basis. Results: A total of 33 lesions were
identified. Relatively small changes were observed in the up-
take of lesions between baseline and 6 weeks. More significant
changes were observed between baseline and 12 weeks. There
was a clear correlation between baseline uptake of 18F-
Fluoride and the subsequent decrease in 18F-Fluoride uptake
at 12 weeks (r2 = 0.88). The hypothesis that 18F-Fluoride
uptake could predict the effect of 223Ra-chloride treatment
was further supported by the demonstration of a correlation
(r2 = 0.79) between 223Ra and 18F-Fluoride uptake in meta-
static bone lesions as well as the observation that the effective
half-life of 223Ra-chloride in metastatic lesions was close to
the physical half-life. Conclusion: Analysis of this small group
of patients suggest that uptake of 18F-Fluoride has the poten-
tial to predict subsequent response to 223Ra-cloride therapy
and serve as a surrogate measure of tumour dose.
OP236
Feasibility of 223Ra quantitative imaging for lesion
dosimetry
G. A. Follacchio1, V. Frantellizzi1, R. Pellegrini1, R. Pani1, M.
Pacilio2, B. Cassano2, M. Liberatore1, F. Monteleone1, T.
Garkavaya1, G. Ventroni2, L. Mango2, G. De Vincentis1;
1Policlinico Umberto I - Sapienza University, Rome, ITALY,
2A.O. San Camillo-Forlanini, Rome, ITALY.
223Ra-chloride is a novel bone-targeting radiopharmaceutical
effective on bone pain in patients with metastatic castration-
resistant prostate cancer. In 223Ra complex decay spectrum,α
particles account for nearly 95% of emissions while photons
represent less than 2% of total decay energy. Aim of this study
was to evaluate feasibility of an imaging procedure based on
223Ra γ-emitting component in order to acquire significant
data for personalized dosimetric evaluation. Nine male pa-
tients receiving 223Ra-chloride treatment (50 kBq/kg every
4 weeks for 6 injections) were enrolled. On the basis of
99mTc-MDP bone scan, we selected a single area of interest
(thorax or pelvis) characterized by relevant bone metastasis.
Gamma-camera calibration measurements with a source of
223Ra were carried out including sensitivity test and transmis-
sion curves. For each patient we performed serial planar static
images of the chosen district on the 3rd-7th-14th-21st day after
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first 223Ra injection (double-peak acquisitions with energy
window centred at 82 and 158 keV, each 20% wide, MEGP
collimator, 256x256matrix, acquisition time 40’). In 3 patients
we could perform early acquisitions at 4 and 24 h. For most of
the patients, transmissive images were also acquired. Bone
lesions were manually delineated on 99mTc-MDP bone scan,
then ROIs were superimposed to 223Ra serial images after
spatial co-registration with bone scan performed by a
MATLAB tool. Activity quantification was performed
correcting by attenuation, scatter and partial background sub-
traction. Absorbed dose to lesions was assessed by MIRD
approach deriving S-values from OLINDA/EXM tabulations,
estimating lesion volume by CT contouring. 99mTc percent
uptake was evaluated on bone scan images. Over nine patients,
twenty-four lesions were delineated at bone scan. Twelve le-
sions showed a wash-in phase, so biokinetics was assumed bi-
exponential; mono-exponential biokinetics was assumed for
remaining lesions. 223Ra effective half-life showed a median
value of 7.8 days. Median absorbed dose to lesion for a single
injection resulted 0.6 Gy (range 0.2-1.9 Gy); considering Rel-
ative Biological Effectiveness for α particles (RBE=5), DRBE
/Aadm to lesions ranged from 340 to 2450 mGy/MBq. 99mTc
and 223Ra percent uptake resulted significantly related on
linear regression analysis. Our experience confirmed feasibil-
ity of quantitative imaging in patients treated with 223Ra-chlo-
ride. Collected data were useful to perform biokinetics studies
and bone lesion dosimetry. Optimal timing for serial acquisi-
tions resulted at 4, 24, 48 and 168 h. Absorbed dose to lesions
was remarkable compared to β-emitting bone-seeking radio-
pharmaceuticals. Significant correlation between 99mTc-
MDP and 223Ra percent uptake could allow dosimetry-
based treatment.
OP237
A Monte Carlo study of small-scale dosimetry in capillary
vessels during internal radionuclide therapies with 223Ra,
111In, 131I and 177Lu
S. Leotta1, E. Amato1, A. Italiano2, L. Auditore1, R. Gentile1,
S. Baldari1; 1University of Messina, MESSINA, ITALY,
2Istituto Nazionale di Fisica Nucleare, MESSINA, ITALY.
This study was aimed to evaluate the combined effects of
radiopharmaceutical diffusion and range of the emitted radia-
tion in a model of tumour capillary vessels. We developed a
computational model representing a blood capillary vessel
surrounded by solid tumour tisssue, and we simulated the
transport of radiation emitted by by 223Ra, 111In, 131I and
177Lu nuclides using two different Monte Carlo codes:
Geant4 and MCNPX. In particular, we simulated a cylindrical
vessel having 10 um of inner radius and 10 um of thickness
filled by blood and surrounded by cylindrical layers of soft
tissue, 10 um thick each. For each nuclide, several models of
radiopharmaceutical outflow through the capillary vessel were
considered: in blood only, representative of radio-
embolization procedures, in capillary cells, representative of
an anti-angiogenic radiopharmaceutical accumulating in them,
and several models of extra-vascular dispersion. Radial dose
profiles around the capillary vessel were obtained and com-
pared between codes and between the physics models avail-
able. The results for beta and Auger emitters demonstrate that
the photon dose is at least four orders of magnitude lower with
respect to the one deposited by electrons. For which concerns
223Ra, the beta emissions of the daughters give a contribution
three orders of magnitude lower with respect to the alpha par-
ticles, even if with a much longer range. For each nuclide and
for every diffusion model, the Endothelial Cell Mean Dose
(ECMD) and the Tumour Edge Mean Dose (TEMD) per unit
cumulated activity were computed and represented in tabular
form, together with the initial radioactivity (IR) necessary to
deposit 100 Gy of dose at the edge of the viable tumour. Such
results may help to characterize the dose inhomogeneities in
solid tumour therapies with radiopharmaceuticals, taking into
accunt the interplay between drug diffusion from vasculature
and range of ionizing radiations.
OP238
Factors Affecting RADIUM-223 Therapy
E. Etchebehere, J. Araujo, D. Milton, N. Swanston, H.
Macapinlac, E. Rohren; The University of Texas MD Ander-
son Cancer Center, Houston, TX, UNITED STATES.
AIM: The purpose of this study was to evaluate the factors that
may affect Radium-223 therapy (Ra-223). MATERIALS
ANDMETHODS: We retrospectively reviewed 110 histolog-
ically confirmed hormone-refractory prostate cancer patients
(42-88 y old; mean 69yrs.) with bone metastases, with or with-
out visceral and nodal metastases. End points were overall
survival (OS), progression-free survival (PFS), time to pro-
gression (TTP), bone event-free survival (BeFS), and bone
marrow failure (BMF). The following parameters were evalu-
ated prior to the 1st Ra-223 cycle: hemoglobin (HbInitial) levels
(<10 vs >10g/dl), PSA levels (PSAInitial<10 vs >10ng/ml),
ALP levels (ALPInitial<147 vs >147IU/L), ECOG status
(ECOGInitial), pain score (painInitial), use of chemotherapy
(ChemoPrior) and external beam radiation therapy (EBRTPrior).
Additionally, the total number of radium cycles (RaTot) were
evaluated. During/after Ra-223 the following parameters were
evaluated: PSA doubling time (PSADt), use of chemotherapy
(ChemoDuring/After), EBRTDuring/After, AbriateroneDuring/After
and EnzalutamideDuring/After.RESULTS: The median follow-
up time was 8.3 months (0.4-18.4 months). Fifty-eight (53%)
patients received all 6 Ra-223 cycles. Fifty (45%) patients
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died, 85 (77%) progressed and 24 (22%) had a bone event. The
median OSwas 11.7 months, PFS was 4.3 months, TTPwas 4.4
months, BeFS was 8.6 months and BMF was 8.6 months.A
significant reduction of ALP levels (p<0.001) and pain score
(p=0.041) occurred throughout the Ra-223 cycles. A significant
risk of progression was associated with declining ECOG status
(HR=3.79; p<0.001) and increase in PSADT (HR=15.82;
p<0.001).Univariable analysis demonstrated that RaTot,
ALPInitial, ECOGInitial, painInitial and AbriateroneDuring/After were
significantly associated with OS (p≤0.008), PFS (p≤0.003) and
BeFS (p≤0.020). Additionally, RaTot, HbInitial, ALPInitial,
ECOGInitial , painInitial and EBRTDuring/After were associated with
BMF (p≤0.002).When adjusting for all covariates, however, on-
ly RaTot and AbriateroneDuring/After remained significantly asso-
ciated with OS (HR=0.56; p<0.001; and HR=0.32; p=0.033,
respectively), PFS (HR=0.67; p<0.001; and HR=0.52;
p=0.041, respectively) and BeFS (HR=0.62; p<0.001; and
HR=0.32; p=0.019, respectively). Additionally, only RaTot
(HR=0.73; p=0.025), ALPInitial (HR=3.11; p=0.043) and
EBRTDuring/After (HR=3.62; p=0.053) remained significantly as-
sociated with BMF. CONCLUSIONS: More Ra-223 cycles
were beneficial and reduced the risk of death, progression and
the risk of a bone event. The risk of progression was increased 3
times with a declining ECOG status and 15 times with rise in
PSADT. During Ra-223 cycles, the concomitant use of
Abriaterone seems to have a beneficial effect while the EBRT
increased the risk of BMF.
OP239
Therapy of Metastasized Prostate Cancer Using a Lu-177
Labeled PSMA Inhibitor (I&T): First Dosimetric Results
in Patients
C. Schuchardt1, S. Wiessalla1, A. Özkan2, H. R. Kulkarni1, M.
Shahinfar1, M. Sayeg1, M. Weineisen3, H. J. Wester3, R. P.
Baum1; 1THERANOSTICS Center for Molecular Radiotherapy
and Molecular Imaging, BAD BERKA, GERMANY, 2Yildiz
Technical University, Department of Physics, Istanbul, TURKEY,
3Technical University Munich, Pharmaceutical Radiochemistry,
Faculties of Chemistry and Medicine, Munich, GERMANY.
Aim: The prostate-specific membrane antigen (PSMA) is sig-
nificantly over-expressed in prostate cancer cells compared to
normal prostate tissue. The aim of our study was to determine
the kinetics and dosimetry in patients undergoing peptide
radioligand therapy (PRLT) of metastasized prostate cancer
using the Lu-177 labeled PSMA inhibitor (I&T: imaging and
therapy). Methods: 20 patients with progressive, castrate resis-
tant metastatic prostate cancer (aged 73+/-7 years) were in-
cluded in the analysis. High PSMA expression was verified
before treatment by Ga-68 PSMA PET/CT. The administered
activity ranged from 3.6 to 8.6 GBq Lu-177 PSMA. Based on
five conjugated planar whole-body scans, time-dependent or-
gan and tumor activities were determined and dosimetric cal-
culations were performed according to the MIRD scheme
using OLINDA/EXM software. To analyse the kinetics, we
used the following parameters: effective half-life in hours
(representing the slower beta-phase) and uptake in %IA (frac-
tion of injected activity), which were calculated using the fit of
the time-dependent activity curve to a mono- or bi-exponential
function. Blood samples were drawn to determine the blood
kinetics and to estimate the absorbed dose to red marrow.
Results: Very intense uptake in the tumour lesions as well as
significant uptake in the kidneys and the salivary glands was
observed in all patients. Blood sampling revealed fast clear-
ance from blood with half-lives of 12min (alpha-phase) up to
42hours (beta-phase). There was rapid clearance of tracer from
whole body with a half-life of 12-91hours. The maximum
renal uptake was 12%IA and showed a fast wash-out with
half-lives of 19-82hours. Parotid glands demonstrated high
uptake up to 1.2%IA with half-lives of 32+/-20hours (maxi-
mum 118hours). Concerning malignant lesions we distin-
guished between bone (30) and lymph node (12) metastases.
The maximum uptake was 1.6% IA for bone and 1.8%IA for
lymph node metastases. All tumour lesions followed an expo-
nential decline with a mean half-life of 60hours. The following
organ- and tumour doses were calculated: Whole body 0.03+/-
0.02mGy/MBq (0.01-0.07mGy/MBq); kidneys 0.7+/-
0.4mGy/MBq (0.2-1.5mGy/MBq); parotid glands 1.4+/-
1.3mGy/MBq (0.1-4.8mGy/MBq); bone lesions 0.2-28mGy/
MBq; lymph node lesions 0.1-78mGy/MBq. Clinically, no
adverse effects were observed in any of the patients
concerning renal function (serial follow-up up to 24months)
or salivary glands. Conclusions: Despite high uptake in the
kidneys and salivary glands, the high tumor uptake, fast renal
wash-out and rapid blood clearance confirm the efficacy and
safety of PRLT using the Lu-177 labeled PSMA inhibitor
PSMA I&T in patients with metastasized prostate cancer.
OP240
Radiation Sensitivity of Prostate Cancer Cells for Beta-
or Auger-Electron, Alpha-Particle, or Photon Irradiation.
J. Elgqvist, K. Claesson, E. Larsson, S. Oredsson, O.
Vilhelmsson-Timmermand, T. Tran, S. Strand; Institute for
Clinical Sciences, LUND, SWEDEN.
Aim. Radioimmunotherapy against prostate cancer is an evolv-
ing research area due to the absence of a curative therapy of the
metastatic disease. The purpose of this study is to investigate
radiation sensitivity of prostate cancer cell lines DU145,
LNCaP, and PC3 irradiated with 177-Lu, 111-In, alpha-
particles from 241-Am, or 137-Cs. Materials and Methods.
The three cell lines DU145, LNCaP and PC3 were irradiated
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using an unspecific IgG1 antibody labeled with 177-Lu or 111-
In, by external photon irradiation using 137-Cs, or by using an
external 241-Am alpha-particle irradiator. The cells were sub-
jected to absorbed doses equal to 0, 0.5, 1, 2, 4, 6, 8, or 10 Gy.
For evaluation of cell survival; colony forming and tetrazolium-
based assays were used. Regarding the tetrazolium-based assay;
after irradiation in 96- or 24-well plates tetrazolium solutionwas
added to each well, incubated, and then measured for level of
absorbance at 450 nm, indicating the amount of live/viable
cells. Results. For DU145 the SF at 2.0 Gy (SF2Gy) was 0.58
± 0.06, and 0.40 ± 0.08 (mean ± SEM) after irradiation by 177-
Lu or from photons from the LINAC, respectively. Irradiations
using 111-In are on-going for DU145. For LNCaP the SF2Gy
was 0.62 ± 0.03 for the 177-Lu irradiation. Irradiations using
111-In for the LNCaP cells are on-going. Irradiations of the PC3
cells are also on-going. Irradiations using 241-Am shows a
significantly reduced cell survival already at an absorbed dose
equal to 2 Gy. Compared to 137-Cs photon irradiations, a pre-
liminary RBE equal to 4-5 is observed for the alpha-particle
irradiations of the LNCaP and DU145 cells, at 37% cell surviv-
al. Conclusions. A significantly lower SF2Gy value after irra-
diation with 111-In in DU145 cells, compared to irradiation
with 177-Lu or 137-Cs/LINAC is observed. Irradiation using
241-Am show a high level of cell killing efficacy, indicating a
potential use of alpha-particle emitters labeled to specific anti-
bodies for the treatment of microscopic prostate cancer. The
results indicate that the inherent radiosensitivity of prostate can-
cer cell lines might vary greatly and that it therefore is very
important to consider which type of irradiation to use in targeted
radionuclide therapies.
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Influence of Histidine-Containing Tags on Biodistribution
of Radiolabelled ADAPT-Based Imaging Probes
S. Lindbo1, J. Garousi2, M. Åstrand1, H. Honarvar2, A.
Orlova2, S. Hober1, V. Tolmachev2; 1Royal Institute of Tech-
nology-KTH, Stockholm, SWEDEN, 2Uppsala University,
UPPSALA, SWEDEN.
Aim. ADAPTs are a class of small (∼5 kDa) robust scaffold
proteins suitable as probes for radionuclide molecular imaging
in vivo. The attachment of a histidine-containing tags to the
scaffold proteins allows efficient purification by immobilized
metal ion affinity chromatography (IMAC) and permits label-
ling with 99mTc(CO)3. Earlier, we have demonstrated that re-
placement of the hexahistidine (H6)-tag with the negatively
charged histidine-glutamate-histidine-glutamate-histidine-glu-
tamate (HE3)-tag reduces hepatic uptake of radiolabelled
affibody molecules. The same effect has been confirmed for
other scaffold proteins, DARPins, and short peptides. The aim
of this study was to evaluate effect of histidine-containing tag
composition on biodistribution of ADAPTs. Material and
methods. A series of anti-HER2 ADAPT6 probes having
DEAVDANS lead sequence and H6- or HE3-tags at N-termini
has been prepared. In two variants, maleimido derivative of
DOTA was conjugated to a unique cysteine was incorporated
at N-terminus. DOTA-C-HE3-ADAPT6 and DOTA-C-H6-
ADAPT6 were labelled with 111In. HE3-ADAPT6 and H6-
ADAPT6 were labelled with 99mTc(CO)3 using IsoLink kit.
Binding specificity, affinity, and cellular processing of new con-
jugates was evaluated using HER2-expressing SKOV-3 ovarian
carcinoma cells. Biodistribution at 1,4 and 24 h p.i. was evalu-
ated in normal NMRI mice. Tumour-targeting properties of the
best 99mTc(CO) 3-labelled variant,
99mTc(CO)3-H6-ADAPT6
were evaluated in BALB/C nu/nu mice bearing SKOV-3 xeno-
grafts. Results. All radiolabeled ADAPTs demonstrated specific
binding to SKOV-3 cells with affinities in the range of 1.1-2.8
nM. The internalization by SKOV-3 cells was slow. In vivo, all
conjugates cleared rapidly from blood via kidneys with subse-
quent renal re-absorption. The hepatic uptake of 111In-DOTA-
C-H6-ADAPT6 was slightly but significantly (p<0.05) higher
that the uptake of 111In-DOTA-C-HE3-ADAPT6 at 1 h pi, but
biodistribution was very similar at later time points. Surprising-
ly, the uptake of 99mTc(CO)3-HE3-ADAPT6 was significantly
(p<0.05) higher than uptake of 99mTc(CO)3-H6-ADAPT6 in
liver, blood, and bone at 1h p.i. At 4 h p.i., hepatic uptakes were
equal, but 99mTc(CO)3-H6-ADAPT6 provided lower uptake in
blood and bone. 99mTc(CO)3-H6-ADAPT6 demonstrated high
(19± 3 %ID/g at 4 h p.i.) and specific tumour uptake. Tumour-
to-blood and tumour-to-liver ratios were 102± 29 and 12± 3,
respectively. Conclusion. Influence of histidine-containing tag
on biodistribution of scaffold proteins depends on composition
of a scaffold protein and might differ appreciably. This should
be take into account in molecular design of imaging probes
based on engineered scaffold proteins.
OP243
Preclinical development of a novel combination therapy
against ovarian carcinoma: Combination of anti-L1CAM
Lutetium-177 radioimmunotherapy and clinically relevant
protein kinase inhibitors
D. Lindenblatt1, G. Pellegrini2, S. Cohrs1, P. R. Spycher1, D.
Vukovic1, E. Fischer1, R. Schibli1,3, J. Grünberg1; 1Paul
Scherrer Institut, Villigen PSI, SWITZERLAND, 2Univerity of
Zurich, Institut für Veterinärpathologie, SWITZERLAND, 3De-
partment of Chemistry and Applied Biosciences, ETH Zurich,
SWITZERLAND.
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Aim: Previously we have shown that paclitaxel improved anti-
L1CAM lutetium-177 radioimmunotherapy in an ovarian can-
cer xenograft model (EJNMMI Research 2014, 4:54). Based
on this finding we asked whether the addition of modern and
clinical relevant protein kinase inhibitors (PKIs) offers also a
therapeutic possibility to improve RIT against ovarian carci-
noma. Five PKIs for cytotoxicity screenings were chosen
based on their current clinical relevance (clinical phase II-III,
ovarian cancer) and their influence on cell cycle regulation and
DNA damage repair pathways. We combined selected PKIs
with anti-L1CAM monoclonal antibody chCE7 labelled with
lutetium-177 for our investigations. Material and methods:
PKIs cytotoxicities were determined via cell colony-forming
assays. Biomarker of double-strand-breaks (dsDNA breaks;
pH2A.X) was analysed by Western blot after single or com-
bined treatments. Levels of histone phosphorylation were
quantified by fluorescence microscopy. Flow cytometry anal-
ysis was performed to evaluate levels of apoptosis based on
combination- or monotreatments. For immunohistochemistry,
nude mice (n = 3) were subcutaneously injected with
SKOV3ip human ovarian carcinoma cells and treated with
2 MBq 177Lu-DOTA-chCE7 alone or in combination with 60
mg/kg MK1775 administered 72h post radioimmunotherapy.
PKI dosages were applied daily for 4 consecutive days. Ac-
cordantly, untreated controls received PBS. 6 days post treat-
ment start tumours samples were collected and stained against
pH2A.X. Results: In vitro cytotoxicity studies demonstrated
that the IC50 values of the different PKIs ranging from
nanomolar to micromolar concentrations indicating vary-
ing sensitivities of ovarian cancer cell lines. Western
blot analysis of IGROV1 cell lysates revealed that com-
bination of 177Lu-DOTA-chCE7 (5 MBq/ml) and PKI
MK1775 (300 nM) induced higher levels of histone
phosphoryla t ion (pH2A.X) compared to e i ther
monotreatment. This observation was confirmed and
quantified by florescence microscopy demonstrating a
significant increase in pH2A.X positive cells (177Lu-
DOTA-chCE7 + MK1775: 91.1% vs. 177Lu-DOTA-
chCE7: 71.7% and MK1775: 55.5%; p < 0.05). In-
creased amounts of present dsDNA breaks resulted in a
significant higher number of early apoptotic tumour cells
after combined treatment compared to monotreatments
(177Lu-DOTA-chCE7: 7.9%, MK1775: 28.6%, 177Lu-
DOTA-chCE7 + MK1775: 40.1%; p < 0.05). Pre-
treated tumour xenografts showed positive stainings for
pH2A.X foci indicating present dsDNA breaks in tu-
mour tissue. Ex vivo quantification of pH2A.X foci is
currently under investigation. Conclusion: The combination of
177Lu-DOTA-chCE7 and protein kinase WEE1-inhibiting
MK1775 is a promising treatment strategy against ovarian
carcinoma. The amount of induced dsDNA lesions and apo-
ptosis early post treatment start is significantly increased com-
pared to either monotreatment.
OP244
Feasibility of Affibody molecule-based PNA-mediated
pretargeting.
H. Honarvar1, K. Westerlund2, M. Altai3, M. Sandström4, A.
Orlova5, V. Tolmachev3, A. Eriksson Karlström2; 1Institute for
Immunology, Genetics and Pathology, Uppsala University,
Uppsala, SWEDEN, 2School of Biotechnology, Division of
Protein Technology, KTH Royal Institute of Technology,
Stockholm, SWEDEN, 3Rudbeck Laboratoriet, Uppsala,
SWEDEN, 4Uppsala University Hospital, Uppsala, SWE-
DEN, 5Preclinical PET Platform, Department of Medicinal
Chemistry, Uppsala University, Uppsala, SWEDEN.
Aim. Affibody molecules are small (7 kDa) non-
immunoglobulin scaffold proteins, which enable high contrast
visualization of cancer-associated molecular targets. However,
their renal clearance is followed by high renal re-absorption,
which prevents their use for radionuclide therapy with
residualizing radiometals. To overcome this problem, we test-
ed hypothesis that the use of Affibody-based peptide nucleic
acids (PNA)-mediated pretargeting would enable higher accu-
mulation of radiometals in tumors than in kidneys. The aim of
this study was to provide a proof-of-principle for Affibody
based PNA-mediated pre-targeting. Material and methods.
We designed an anti-HER2 Affibody-PNA chimera
ZHER2:342-SR-HP1containing 15-mer HP1 PNA recogni-
tion tag, and a complementary HP2 hybridization probe. Pres-
ence of a tyrosine residue at N-terminus and DOTA-chelator at
C-terminus of HP2 permitted labeling with both 125I and
111In. DOTA-chelator conjugated to the N-terminus of
ZHER2:342-SR-HP1provided radiolabeling of the chimera
with 111In. In vitro binding specificity, affinity, and cellular
processing properties of constructs were studied using HER2 -
expressing SKOV-3 and BT474 cell-lines. The in vivo
targeting specificity and biodistribution profile of
ZHER2:342-SR-HP1 and 111In/125I-HP2 were studied in
mice bearing SKOV-3 xenografts. Results. 111In-
ZHER2:342-SR-HP1 demonstrated specific-binding to
HER2-expressing BT474 and SKOV-3 cancer cells in vitro
with affinity of 6±2 pM. The binding of radiolabeled comple-
mentary PNA probe 111In/125I-HP2 to ZHER2:342-SR-HP1
pre-treated cells was specific with affinity of 200-400 pM.
111In-ZHER2:342-SR-HP1showed specific accumulation in
SKOV-3 xenografts in BALB/C nu/nu mice and a rapid clear-
ance from blood. Pre-saturation of SKOV-3 with non-labeled
anti-HER2 Affibody or the use of HER2-negative Ramos xe-
nografts resulted in significantly lower tumor uptake of 111In-
ZHER2:342-SR-HP1. The complementary PNA probe 111In/
125I-HP2 accumulated in SKOV-3 xenografts only in pres-
ence of ZHER2:342-SR-HP1, injected 4 h earlier. The tumor
accumulation of 111In/125I-HP2 was very low (at the same
level as in muscles) without ZHER2:342-SR-HP1 pre-
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injection. The uptake of 111In-HP2 in SKOV-3 xenografts
was 19±2 %ID/g at 1 h after injection. The uptake in blood
and kidneys were ca. 50- and 2-fold lower, respectively. Con-
clusion. We have shown that the use of Affibody-based PNA-
mediated pretargeting enables specific delivery of radionu-
clides to tumors and provides higher radiometal concentration
in tumors than in the kidneys. This opens a way for investiga-
tion of such promising therapeutic radionuclides as low energy
beta emitter 177Lu, or alpha emitters 212Bi, 213Bi, and
227Th, for Affibody-mediated therapy.
OP245
An Anti-HER2 Nanobody Labeled with 18F Using
a Residualizing Label for Assessing HER2 Status
G. Vaidyanathan1, D. McDougald1, J. Choi1, E.
Koumarianou1, M. Pruszynski2, T. Osada1, H. Lyerly1, T.
Lahoutte3, M. R. Zalutsky1; 1Duke University Medical Center,
Durham, NC, UNITED STATES, 2Institute of Nuclear Chem-
istry and Technology, Warsaw, POLAND, 3Free University of
Brussels, Brussels, BELGIUM.
Aim. A PET imaging method for determination of HER2 sta-
tus in breast cancer (bc) patients would be highly desirable.
Nanobodies (Nbs) are single domain antibodies derived from
Camelidae. Their small size (~15 kDa), nM-range affinity, low
immunogenicity and other properties are very attractive for
PET imaging. The goal of this study was to develop an anti-
HER2Nb labeled with 18F using a novel residualizing labeling
(RL) strategy as a potential tracer for assessing HER2 status in
b c p a t i e n t s . M e t h o d s . N - s u c c i n i m i d y l
3-((4-(4-[18F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-
5 - ( B o c 2 - g u a n i d i n o m e t h y l ) b e n z o a t e )
(Boc2-[
18F]SFBTMGMB) was synthesized by the click reac-
tion of an azido precursor and [18F]fluorohexyne, and treated
with TFA to generate the RL [18F]SFBTMGMB. The anti-
HER2 Nb 5F7 was conjugated with [18F]SFBTMGMB, and
for comparison, with [18F]SFB (non RL) and the previously
validated RL, [125I]SGMIB. The labeled nanobodies were
evaluated by TCA precipitation, ITLC, and gel electrophore-
sis. Binding affinity was determined using HER2-expressing
BT474M1 bc cells and immunoreactive fraction (IF) by the
Lindmo method. Pa i red- labe l in te rna l iza t ion of
[18F]SFBTMGMB-5F7 versus [125I]SGMIB-5F7, and
[18F]SFB-5F7 versus [125I]SGMIB-5F7, was evaluated using
BT474M1 cells in vitro. Paired-label biodistribution of
[18F]SFBTMGMB-5F7 and [125I]SGMIB-5F7 was deter-
mined in SCID mice bearing BT474M1 xenografts. Results.
Nb 5F7 was labeled with [18F]SFBTMGMB with a conjuga-
tion efficiency of 33.4 ± 5.2% (n = 4). TCA precipitation,
SDS-PAGE, and ITLC indicated >95% of radioactivity was
protein-associated. [18F]SFBTMGMB-5F7 bound specifically
to HER2 with 62-84% IF and a Kd of 4.65 ± 0.88 nM. Com-
parable results were obatined with [18F]SFB-5F7 and
[125I]SGMIB-5F7. Paired-label internalization indicated about
50% of initially bound radioactivity was trapped intracellularly
for [18F]SFBTMGMB-5F7 and [125I]SGMIB-5F7 over 1-4 h.
In contrast, only 39.9 ± 0.3% of [18F]SFB-5F7 was internal-
ized at 1 h and intracellular activity decreased to 24.5 ± 1.1% at
4 h. Tumour uptake of [18F]SFBTMGMB-5F7 in vivo was
29.0 ± 3.9% ID/g and 36.3 ± 14.1% ID/g compared to 26.3
± 3.1% ID/g and 32.5 ± 12.1% ID/g for [125I]SGMIB-5F7 at
1 h and 2 h, respectively, with tumor:blood ratio for the 18F
conjugate increasing from 16.6 ± 5.0 at 1 h to 47.4 ± 13.1 at 4 h
. Conclusions. [18F]SFBTMGMB is perhaps the first 18F agent
specifically designed for RL properties and shows advantages
for this purpose both in tumour cells and xenograft models.
Moreover, the [18F]SFBTMGMB-5F7 Nb conjugate is a
promising agent that warrants further evaluation for PET im-
aging of HER2-expressing malignancies.
OP246
DOTAGA vs DOTA: an extra negative charge reduces
hepatic uptake of Affibody molecules labelled with 111In
and 68Ga
J. Strand1, H. Honarvar1, K. Westerlund2, B. Mitran3, A.
Orlova3, A. Eriksson Karlström4, V. Tolmachev1; 1Department
of Immunology, Genetics and Pathology, Uppsala, SWEDEN,
2Division of protein technology, Stockholm, SWEDEN, 3Pre-
clinical PET Platform, Uppsala, SWEDEN, 4Division of pro-
tein technology, Uppsala, SWEDEN.
Aim: Affibody molecules are small (7kDa) scaffold proteins.
Earlier, we investigated the impact of charge, lipophilicity and
positioning of different amino acid tags on Affibody targeting
properties. We found that the negatively charged variant of
tags at N-terminus provide the lowest hepatic uptake. We hy-
pothesize that the N-terminal placement of a chelator provid-
ing increased negative charge of a complex with a radionuclide
might be used for reduction of liver uptake. To test this hy-
pothesis, we compared targeting properties of anti-HER2
affibody molecules labelled with 111In- and 68Ga using
DOTAGA and DOTA chelators. In complexes with trivalent
metals, DOTAGAprovides an extra negative charge compared
with DOTA. Methods: DOTA and DOTAGAwere conjugated
to N-terminus of synthetic ZHER2:2891 via amide bond. The
conjugates were labelled with 68Ga and 111In. In vitro bind-
ing specificity and internalization assays were performed
using highHER2-expressing SKOV-3 and lowHER2 express-
ing LS174T cells. The tumour targeting and biodistribution
properties of 111In- and 68Ga-labelled conjugates were com-
pared in nudemice bearing SKOV-3 xenografts at 2 hours post
injection. PET imaging of SKOV-3 xenograft bearing mice
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was preformed 2 h after injection of 68Ga-DOTAGA-
ZHER2:2891. Results: DOTAGA-ZHER2:2891 and DOTA-
ZHER2:2891 were stably labelled with 68Ga and 111In. The
radiolabelled conjugates showed preserved binding specificity
to HER2-expressing cells in vitro. All conjugates demonstrat-
ed slow internalization rates after binding to both SKOV-3 and
LS174Tcells. In vivo, the tumour uptakewas similar, 22±2, 19
±2, 25±2, and 23±5 %ID/g for 111In-DOTAGA-
ZHER2:2891, 68Ga-DOTAGA-ZHER2:2891, 111In-DOTA-
ZHER2:2891, and 68Ga-DOTA-ZHER2:2891, respectively.
In vivo blocking assay confirmed specificity of tumour
targeting. A combination of a nuclide and a chelator had clear
influence in biodistribution in normal tissues.111In-labeled
conjugates cleared significantly rapider from blood than
68Ga-labelled variants. The use of DOTAGA provided signif-
icantly lower hepatic uptake and blood radioactivity concen-
tration for both radionuclides. The most pronounced differ-
ence between chelators was in the case of 68Ga. The use of
DOTAGA provided appreciably higher tumour-to-blood (61
±6 vs 23±5, p<0.05) and tumour-to-liver (10.4±0.6 vs 4.5±0.5,
p<0.05) ratios that the use of DOTA. MicroPET/CT imaging
confirmed that 68Ga-DOTAGA-ZHER2:2891 can visualize
HER2-expressing xenografts with high contrast. Conclusion:
This study demonstrated that chelators may be used for mod-
ification of uptake of Affibody molecules in normal tissues
and improvement of imaging contrast. The use of DOTAGA
for labelling with 68Ga resulted in a much better
biodistribution profile for Affibody molecules compared with
DOTA.
OP247
Generalized syntheses of tumor targeted yolk/shell
structured multifunctional nanosystems
F. Chen, H. Hong, S. Shi, H. F. Valdovinos, T. E. Barnhart, W.
Cai; University of Wisconsin-Madison, MADISON, WI,
UNITED STATES.
Aim: To develop a generally applicable protocol for yolk/shell
structured multifunctional nanosystems, to be used for tumor
targeted PET image-guided drug delivery. Materials and
Methods: Upconversion nanoparticle (UCNP, with NIR-in-
NIR-out upconversion luminescence) was used as the initial
example. UCNP was first coated with a dense silica (dSiO2)
shell, forming UCNP@dSiO2, followed by re-growth of a
shell-thickness controllable mesoporous silica nanoshell
(MSN) to form UCNP@dSiO2@MSN. A Na2CO3 etching
protocol was then used to selectively etch away dSiO2, leaving
behind yolk/shell structured nanoparticles denoted as
UCNP@HMSN. A step-by-step surface engineering process
was then adopted to conjugate (or label) NOTA, polyethylene
glycol (PEG) linkers, TRC105 (an anti-CD105 antibody), and
64Cu to form 64Cu-UCNP@HMSN-PEGTRC105. Both hy-
drophobic (i.e. Sunitinib) and hydrophilic (i.e. Doxorubicin)
drugs could be loaded inside UCNP@HMSN. Systematic
in vivo PET imaging and biodistribution studies were per-
formed in 4T1 tumor-bearing mice to evaluate and confirm
tumor targeting capability, validated by in vitro/ex vivo stud-
ies. Results: TEM confirmed successful synthesis of
UCNP@HMSN . B y c h a n g i n g t h e “ y o l k ” t o
superparamagnetic iron oxide nanoparticle (SPION) or quan-
tum dot (QD), we confirmed the general applicability of this
protocol. In vitro CD105 targeting in HUVEC (CD105+) and
MCF-7 (CD105-) cells showed strong/specific binding of
FITC-conjugated UCNP@HMSN-PEG-TRC105 to CD105+
cells with negligible non-specific binding. In vivo tumor
targeting and PET imaging demonstrated CD105-specific
targeting of 64Cu-UCNP@HMSN-PEG-TRC105 in 4T1
tumor-bearing mice, with peak tumor uptake of ~6.5 %ID/g
at 6 h post-injection. CD105 specificity was confirmed by
blocking and ex vivo histology studies. Conclusion: We report
the generalized syntheses of yolk/shell structured nanosystems
for tumor targeted PET imaging and drug delivery. With
UCNP, QD, SPION, or other nanocrystals inside each
yolk/shell structure, this nanoplatform is highly versatile for
future tumor targeted multimodality image-guided drug
delivery.
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OP249
Role of [11C]choline PET/CT in tailored Cyberknife
stereotactic Therapy in patients with prostate recurrent
isolated lymph node.
P. Gandolfo1, F. Ria2, A. Bergantin2, A. S. Martinotti2, I.
Redaelli2, M. Invernizzi2, A. Vai2, I. Bossi Zanetti2, L. C.
Bianchi2, G. Beltramo2; 1Nuclear Medicine Unit - Centro
Diagnostico Italiano, Milan, ITALY, 2Cyberknife Unit -
Centro Diagnostico Italiano, Milan, ITALY.
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Aim: [11C]choline PET/CT has been established as a diagnostic
tool in re-staging patients with biochemical failure after radical
treatment for prostate cancer in particular for its capability to
detect the presence of lymph node and bone metastases. The
knowledge of the anatomical site of recurrence may be useful
to refer patients to the specific tailored therapy, in addition to the
conventional anti-hormonal therapy. We investigated the role of
[11C]choline PET/CT as an image method to select patients for
Cyberknife stereotactic tailored therapy. Methods and Materials:
Between March 2009 and march 2013 a cohort of 30 patients
with up to 3 synchronous lymph node prostate metastases staged
with [11C]choline PET/CT (47 lesions, median volume 12,92
cc, range 0,39 -111,67), following biochemical recurrence after
local curative treatment were treated with Cyberknife Stereotac-
tic Body Radiotherapy (SBRT) in our Center. In all patients
[11C]choline PET/CT images was used to select and delineated
target volumes at lymph node recurrent sites. The mean age of
patients population at the time of the Cyberknife treatment was
68 years (range 55-84). Cyberknife prescription doses were
3000-3600 cGy delivered in 3 consecutive fractions of 1000-
1200 cGy. In 14 lesions (37%) SBRT was performed as re-
irradiation (the recurrent lesion was situated in the previously
irradiated volume). Results: The Cyberknife treatment was well
tolerated without any acute or late toxicity at all. There were no
in field recurrence, resulting in a local control of 100%. Eleven
and 3 patients, respectively required a second and third salvage
treatment for metachronous metastatic disease. The median time
to clinical progression was 14 months (range 3-54). After a me-
dian follow up of 33 months (range 13-73) 16 patients started
with Androgen Deprivation Therapy (ADT) because of
polymetastatic disease resulting in an ADT-FS of 80% at 1 year
and 65% at 2 years. Themedian time ADTwas deferred resulted
of 26 months (range 4-56). Conclusions: The recent evidence of
the potential toxic nature of ADT suggest that effective local
therapy might reduce the burden of systemic therapies usually
given to patients with metastatic prostate cancer. Although there
are not literature data that support the use of [11C]choline PET/
CT to plan target volume at lymph nodal level our preliminary
results are promising, showing that the treatment is well tolerated
with excellent rate of local control and suggest a potential role of
[11C]choline PET/CT to select and refer patients to specific
treatment strategies.
OP250
Comparison of [18F] choline PET/CTwith integrated
[18F] choline PET/MRI in patients with suspected
recurrent prostate cancer.
A.Wetter1, B.M. Schaarschmidt2, M. Schenck3, H. Rübben3,
S. Lütje4, T. Pöppel4, M. Forsting1, T. Lauenstein1; 1Universi-
ty Hospital Essen, Dept. of Radiology and Neuroradiology,
Essen, GERMANY, 2University Hospital Düsseldorf, Dept.
of Radiology, Düsseldorf, GERMANY, 3University Hospital
Essen, Department of Urology, Essen, GERMANY, 4Univer-
sity Hospital Essen, Department of Nuclear Medicine, Essen,
GERMANY.
Purpose: To prospectively compare diagnostic performance of
[18F] choline PET/CTwith [18F] choline PET/MRI in patients
with suspected recurrent prostate cancer. Methods: 68 patients
were assigned for a clinically indicated [18F] choline PET/CT
because of a rising PSA-level after radical prostatectomy. Af-
ter PET/CT was completed, patients were transferred to the
PET/MRI unit and simultaneous [18F] choline PET/MRI ex-
aminations were conducted on an integrated PET/MR scanner.
Sequence protocol consisted of one pelvic PET scan with an
acquisition time of 20 minutes and simultaneous acquisition of
T2 and T1-weighted MR images before and after administra-
tion of a paramagnetic contrast agent. PET/CT and PET/MR
image analysis was prospectively performed by different
groups of nuclear medicine physicians and radiologists with
respect to the detection of lymph node metastases, bone me-
tastases and local recurrence of the tumor. Results: Simulta-
neous PET/MRI examinations were successfully accom-
plished in all patients with diagnostic image quality. [18F]
choline PET/CT diagnosed pelvic tumor lesions in 52 patients
(76.5%), PET/MRI revealed pelvic tumor lesions in 55 pa-
tients (80.9 %). Concordant diagnoses of PET/CT and PET/
MRI were achieved in 60 patients, whereas PET/MRI led to a
discordant diagnosis in 8 patients (11.8 %). In three patients
where no suspicious lesion was detected with PET/CT, PET/
MRI led to the diagnosis of a local recurrence in 1 patient and
suspected bone metastases in two patients. In the remaining
five patients, PET/MRI found additional lymph node metasta-
ses in one patient and additional bone metastases in four pa-
tients. From a clinical point of view, PET/MRI led to a change
of management in 2 patients (2.9 %) Conclusion: Simulta-
neous [18F] choline PET/MRI is a robust method for clinical
use and provides additional information as compared to PET/
CT in patients with suspected recurrent prostate cancer. How-
ever, a significant change of diagnosis with following change
of treatment is observed only in a small percentage of patients.
OP251
Prognostic value of FCH PET/CT in response to radical
radiotherapy in patients with localized prostate cancer
M. Sepulcri, A. Negri, E. Agostini, S. Galuppo, A. Cervino,
G. Saladini, A. Scaggion, M. Paiusco, L. Evangelista; Istituto
Oncologico Veneto I.R.C.C.S., PADOVA, ITALY.
Aim: the aim of this study was to assess the value of FCH PET/
CT in predicting the outcome of patients with localized prostate
cancer treated by radical radiotherapy.Materials and methods:
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from a mono-centric PET/CT database, we retrospectively re-
vised pre-treatment FCH PET/CT scans of 11 patients who
underwent radiotherapy (dosage: 78 Gy/39 fractions) for the
treatment of localized prostate cancer. For each study, SUVmax,
SUVavg and metabolic tumor volume (MTV) were evaluated.
Moreover, the value of PSA before radiotherapy (PSAp) was
recovered. A follow-up period after PET/CT scan, of at least
one-year, was required. In accordance with the observational
period, patients were classified as disease free (DF) if the in-
crease of PSA value after radiotherapy was less than 2 ng/mL
respect to PSA nadir value, conversely with an increase of PSA
higher than 2 ng/ml they were classified as recurrent (not dis-
ease free, NDF). AKolgomorov-Smirnov test was used to com-
pare the distribution of semi-quantitative PET and PSA data of
the two patient groups.Results: mean, minimum and maximum
values of SUVmax, SUVavg, MTV and PSAp were 9.6 (3.2-
22.7), 5.1 (3.0-9.4), 11.1 (0.1-49.1) and 19.5 ng/mL (2.0-73.5
ng/mL), respectively. After one year of follow-up, 7 patients
were considered as DF and 4 patients were considered as
NDF. The values of DF patients were 6.2 (3.2-12.6), 3.6 (3.0-
4.2), 6.0 (0.1-25.8) and 15.6 ng/mL (2.0-54.8 ng/mL) respec-
tively for SUVmax. SUVavg, MTV and PSAp. For NDF pa-
tients the corresponding obtained values were 15.5 (10.4-22.7),
7.9 (5.6-9.4), 22.6 (7.1-49.1) and 26.2 ng/mL (5.0-73.5 ng/mL).
In NDF patients, the mean values of SUVmax and SUVavg
were significantly higher than in DF group (p<0.05 and
p<0.01, respectively) while MTV and PSAp were not statisti-
cally different between the two groups.Conclusion: high values
of FCH SUVs in prostate cancer of patients who are candidates
to radiotherapy result predictive of poor outcome after one year
of follow-up. Therefore, the SUV values could be useful to
identify those patients who could benefit from a boosted radio-
therapy dose to the dominant intraprostatic tumour lesion.
OP252
Predictive role of 11C-Choline PET/CT on the lymph
nodal relapse in prostate cancer patients treated by salvage
radiotherapy
E. Incerti1, A. Fodor2, P. Mapelli1, C. Fiorino3, P. Alongi4, M.
Kirienko4, G. Giovacchini5, E. Busnardo1, G. Berardi2, R.
Calandrino3, L. Gianolli1, N. Di Muzio2, M. Picchio1; 1Nucle-
ar Medicine Department, IRCCS San Raffaele Scientific Insti-
tute, Milan, ITALY, 2Radiotherapy Department, IRCCS San
Raffaele Scientific Institute, Milan, ITALY, 3Medical Physics
Department, IRCCS San Raffaele Scientific Institute, Milan,
ITALY, 4University of Milano-Bicocca, Milan, ITALY, 5De-
partment of Radiology and Nuclear Medicine, Stadtspital
Waid, Zurich, SWITZERLAND.
Aim: The aim was to investigate the possible association be-
tween imaging parameters of 11C-Choline PET/CT (Choline-
PET/CT) with survival outcomes: overall survival (OS), loco
regional relapse free survival (lRFS), clinical relapse free surviv-
al (cRFS) and biochemical relapse free survival (bRFS) in pa-
tients with prostate cancer (PCa) treated with helical
tomotherapy (HTT) on lymph node (LN) recurrence.Materials
and Methods: This retrospective study include 68 patients with
PCa (mean age: 68 yrs; range: 51-81 yrs) with biochemical
recurrence after primary treatment (median PSA: 2.42 ng/ml;
range: 0.61-27.56 ng/ml) who underwent Choline-PET/CT from
January 2005 to January 2013. PCa patients presented Choline-
PET/CT pathological uptake at LN site, were treated with sal-
vage HTT. Positive pelvic and/or abdominal LNs were treated
with amedian dose of 65.8 Gy (range: 50.0-74.2) in 28 fractions.
PET derived parameters such as SUVmax of the most active
lesion, SUVmean of all metabolically active lesions and MTV
with a threshold of 40%-50%-60% were calculated. Best cut-off
values of PET derived parameters discriminating between pa-
tients with/without relapses were assesed by ROC analysis:
OS, LRFS, CRFS and BRFS were considered. Univariate and
multivariate Cox regression analysis including the most predic-
tive PET derived parameters were performed. Results: Choline-
PET/CT showed pathologic LNs in 4 patients at pelvic level, in
5 at abdominal level, in 13 at both pelvic and abdominal, in 46 at
abdominal and/or pelvic and/or other sites. With a median
follow-up of 20 months (range: 3-97 months). The 2-year OS,
LRFS, CRFS, BRFS were 86.7%, 91.4%, 51.5% and 40.0%
respectively. Significant best cut-off values could be found for
both CRFS/BRFS for MTVs threshold. The most discriminative
cut-off, based on the AUC of the ROC curves, was
MTV60>0.64cc that also confirmed its independent predictive
role in multivariate analysis. No significant cut-off values were
found for both SUVmax and SUVmean. A two variable model
including MTV60 and PET positive LNs site (pelvic vs extra-
pelvic disease) well predicts the risk of relapse (2-year CRFS
with 0, 1, 2 risk factors equal to 100 ± 10.0%, 62.1 ± 11.4% and
11.4 ± 9.7% respectively, p<0.0001). Conclusion: PET derived
parameters are predictive of tumor response in PCa patients
treated with moderately hypo-fractionated HTT. In particular,
MTV60 and extra-pelvic disease are predictive of relapse in
PCa patients with LNs recurrent. This informationmay be useful
in assessing the comparative effectiveness of various conven-
tional and emerging treatment strategies, and to determine their
ability to stratify patients in clinical trials.
OP253
Dynamic 11C-Choline PET/CT in biochemical relapse
of prostate cancer: feasibility, clinical role and potential
impact in guiding radiotherapy
P. Alongi1, M. Spallino2, E. Incerti1, L. Gianolli1, M. Picchio1;
1IRCCS San Raffaele Scientific Institute, Milano, ITALY,
2University of Milano-Bicocca, Milano, ITALY.
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Aim : The real utility of Dynamic-11C-Choline-PET/CT (D-
PET) in evaluation of local relapse and pelvic lymph-nodes
has not been demonstrated yet. Despite an unconfirmed role,
association of D-PET with standard PET/CT acquisition is
largely used by several PET centre. The aim of this retrospec-
tive study was to assess the clinical use of D-PET in patients
(pts) with rising PSA after prostatectomy candidates to radio-
therapy (RT). Matherials andMethods : 30 pts with rising PSA
(range 0.94-6.5 ng/ml) after prostatectomy who underwent to
RT on suspicious local or lymph-nodal disease revealed by
11C-Choline PET/CT, were identified retrospectively in our
database. In addition to standard PET/CT acquisition (from
vertex to mid-thigh), a post-injection D-PET study was per-
formed focusing on the pelvis. Asymmetry and abnormal 11C-
Choline uptake at prostate bed and/or lymph-nodes stations
were used to define D-PET positivity. PSA levels and clinical
outcome were available for all pts. Results : D-PET showed
tracer uptake on the prostate bed confirmed by standard PET/
CT acquisition in 7/30 pts; 4/7 showed tracer uptake also on
the pelvic lymph-nodes. All these 7/30 pts received RT at the
site of suspicious local relapse and/or simultaneous integrated
boost on the avid lymph-nodes following reduction of PSA
(range 0-0.68ng/ml) and good control of disease (median
PFS: 30,5 months). In 15/23 pts D-PET revealed 11C-
Choline avid pelvic lymph-nodes that were treated by RT
using PET/CT in the planning treatment obtaining sensible
reduction of PSA levels and good clinical outcome. Only
4/15 pts had biochemical relapse after long time (PFS
>24months). Mimicking a clinical scenario, D-PETwas useful
in the decision making to discriminate lymph-nodes uptake to
urethral urine activity in 3/30 pts and to distinguish inflamma-
tory lymph-nodes in 6/30 pts. These 9/30 pts did not received
any local treatment showing no progression of disease during
the follow-up. Overall, use of D-PET associated to standard
PET/CT did not increase significantly the total time of exam-
ination (Mean 21 minutes), showing any difference in radia-
tion exposure. Conclusion : the additional use of 11C-Choline
D-PET, demonstrated to be a valuable tool allowing an im-
proved evaluation of relapsing prostate cancer and providing
crucial information in guiding radiotherapy.
OP254
11C-choline PET/CT in castrate-resistant prostate cancer
patients treated with Docetaxel
F. Ceci1, P. Castellucci1, T. Graziani1, R. Renzi1, J. J. Morigi1,
G.M. Lima1, F. Lodi1, R. Schiavina2, A. Ardizzoni3, S. Fanti1;
1Nuclear Medicine - S.Orsola-Malpighi Hospital - University
of Bologna, Bologna, ITALY, 2Department of Urology -
S.Orsola-Malpighi Hospital - University of Bologna, Bologna,
ITALY, 3Department of Oncology - S.Orsola-Malpighi Hospi-
tal - University of Bologna, Bologna, ITALY.
Aim: to investigate the role of 11C-choline PET/CT in the eval-
uation of the response to treatment in patients with metastatic
castration-resistant prostate cancer (mCRPC) treated with Doce-
taxel in comparison with PSA response. Material and Methods:
inclusion criteria were a) mCRPC with rising PSA levels b)
Docetaxel as first line of chemotherapy (Docetaxel=75mg/m2
+ prednisone=5mg); c) 11C-choline-PET/CT and PSA values
assessments performed before and after Docetaxel administra-
tion. 60 patients were retrospectively enrolled (age
mean/range=68.9/57-84 years-old). 11C-choline PET/CT
(PET1) was performed as baseline before Docetaxel (mean val-
ue=2.4 months) and after (PET2) the end of treatment (mean
value=3 months). PSA values were measured before (PSA1)
(mean value=2.7 months) and after the end of treatment
(PSA2) (mean value=2.8 months). PET2 was reported as com-
plete (CR) or partial response (PR) or stable disease (SD). The
appearance of a new PET-positive lesion was considered pro-
gression disease (PD). PSA-trend was calculated considering
absolute values variations between PSA1 and PSA2. PSA-
response was considered as a decrease ≥50% between PSA1
and PSA2. Clinical, radiological and laboratory follow-up were:
range from 6- to 53 months (mean 13.5 months). Results: the
65%(39/60) of patients showed PD at PET2; 23.3% (14/60)
showed a SD, while 11.7% (7/60) showed PR or CR. The
48.3% (29/60) of patients showed increasing PSA trend, while
the 51.7% showed decreasing PSA-trend. A PSA-response
≥50% was observed in 41,7% (25/60). Considering the 29 pa-
tients with increasing PSA-trend, the 79.3% (23/29) showed PD,
while the 20.7 (6/29) showed SD. Considering the 31 patients
with decreasing PSA-trend, the 48.4% (15/31) showed PD, the
29% (9/31) showed SD while the 22.6% (7/31) showed CR or
PR. Considering the 25 patients with PSA-response ≥50%, the
44% (11/25) showed PD at PET2. All patients with PD at PET2
were confirmed by clinical or radiological follow-up. Conclu-
sion: Our data suggest that the increase in PSAvalues (increasing
PSA-trend) measured after the end of Docetaxel is predictive of
PD. In case of decreasing PSA values after therapy (decreasing
PSA-trend and PSA-response ≥50%), 11C-choline PET/CT may
be useful to identify those patients with PET progression despite
PSA response. In our patient series, this event occurred in the
44% of the patients showing PSA response.
OP255
Usefulness of 18F-fluorocholine positron emission
tomography - computed tomography in occult biochemical
recurrence of prostate cancer. A prospective multicentre
study
Q. Gillebert1, V. Huchet1, C. Rousseau2, A. Cochet3, P. Oliv-
ier4, F. Courbon5, V. Nataf1, J. Talbot1; 1Department of Nucle-
ar Medicine, Hôpital Tenon, Assistance Publique-Hôpitaux de
Paris, Paris, FRANCE, 2Nuclear Medicine Department,
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Institut de Cancérologie de l’Ouest René Gauducheau, Nantes,
FRANCE, 3Department of Nuclear Medicine, Centre
Georges-François Leclerc, Dijon, FRANCE, 4Department of
NuclearMedicine, Hôpital de Brabois, Nancy, FRANCE, 5De-
partment of Nuclear Medicine, IUCT-Oncopole/Institut Clau-
dius Regaud, Toulouse, FRANCE.
Introduction: The aim of the study was to evaluate the clinical
impact of 18F-fluorocholine (FCH) PET/CT on management
of patients with occult biochemical recurrence of prostate can-
cer (rPCa) after initial radical treatment. Methods: 177 patients
with occult biochemical rPCa (mean PSA serum level: 7.5 ng/
mL, range 0.5-244) after initial radical treatment were included
in this multicentre prospective study, due to negative or incon-
clusive results of MRI of the pelvis and of bone scintigraphy.
All patients underwent FCH PET/CT. To determine its impact
on patient management, the referring physicians prospectively
filled-in a 1st questionnaire before FCH PET/CT concerning
the scheduled patient management and then a 2nd question-
naire about the actual management decided after PET/CT. On
basis of data of 6 month post-PET follow-up, an independent
panel determined the adequacy of the management decision
and, if adequate information was available, site-based and
patient-based standard of truth (SOT). If SOTcould be obtain-
ed, centralised masked reading was performed, to determine
diagnostic performance. Results: The positivity rate was 58%
(103/177 positive FCH PET/CT). A change in patient man-
agement was induced in 98 cases (55%). In 38 patients, phy-
sicians changed a palliative treatment for a curative treatment
with 23 salvage radiotherapies (S-RT), 8 surgical procedures,
7 high intensity focalised ultrasounds (HIFU). In 5 patients,
physicians added a curative treatment (2 S-RT, 2 surgical
procedures, and 1 brachytherapy) to androgen deprivation
therapy (ADT). ADT was begun after FCH PET/CT in 24
patients. In 10 patients, curative treatment was changed for a
palliative treatment. In 12 patients, physicians chose to defer
the scheduled treatment (10 ADT and 2 S-RT). Finally, the
therapeutic protocol has been modified after FCH
PET/CT in 9 patients (6 ADT protocols, 2 S-RT and 1
surgical procedure). After FCH PET/CT, 10 CT scans,
17 MRI and 30 biopsies have been performed. The
agreement between FCH PET/CT and the tests was
77%. Of the 177 FCH PET/CT, the induced manage-
ment decisions were inadequate in 8% (15/177). The
SOT could be determined for 70 patients and 72 sites.
The patient-based detection rate of recurrence was 73%.
The reproducibility between on-site and masked read-
ings of PET was substantial with a Cohen’s kappa co-
efficient of 0.67 (95% CI = 0.50-0.83). Conclusion:
FCH PET/CT was a powerful tool to detect biochemical
recurrence of PCa, even after negative pelvis MRI or
bone scintigraphy. It could increase the effectiveness of
therapeutic strategy.
OP256
Helical tomotherapy and bone metastases in prostate
cancer patients: role of Choline-PET/CT
P. Mapelli1, V. Gangemi2, E. Incerti1, G. Giovaccchini3, C.
Deantoni4, A. Fodor4, S. Baldari2, L. Gianolli1, N. Di Muzio4,
M. Picchio1; 1Nuclear Medicine Unit, IRCCS San Raffaele
Scientific Institute, Milano, ITALY, 2Nuclear Medicine Unit,
Department of Biomedical Sciences and of Morphologic and
Functional Images, University of Messina, Messina, ITALY,
3Department of Nuclear Medicine and Radio-Oncology,
Stadtspital Triemli, Zurich, SWITZERLAND, 4Radiation On-
cology Department, IRCCS San Raffaele Scientific Institute,
Milano, ITALY.
Aim. The number of metastases may reflect the biological
aggressiveness of the tumor and may determining the possi-
bility of curative potential interventions such as surgery or
high-dose targeted radiotherapy (RT). The aim of the present
study is to evaluate the efficacy of Choline-PET/CT based
helical tomotherapy (HTT) as an innovative therapeutic ap-
proach on bone metastases, in a cohort of prostate cancer
(PCa) patients with a limited number of metastases. Materials
and methods. This retrospective study included 20 PCa pa-
tients presenting biochemical relapse of disease (value of the
PSA > 0,2 ng/mL) after primary treatment who underwent
Choline-PET/CT and to HTT treatment, from 2007 to 2014.
Radiotherapy treatment was delivered with a median dose of
71±5 Gy (range: 60-76) and 51 Gy (range: 30-60) on prostatic
bed, LN and bone metastases respectively. All patients
underwent to androgen deprivation therapy (ADT) and this
treatment was not discontinued for the whole duration of the
study. The effectiveness of the treatment was assessed with
biochemical response at 3/6/12 months, biochemical relapse-
free survival (bRFS) and overall survival (OS) at 1-2 years.
Results. The median age at Choline-PET/CT was 67 (range:
51-79). Nine/20 (45%) patients had only bone disease while
11/20 (55%) had disease at bone and lymph nodes (LN).
Nineteen/20 patients underwent HTT on prostatic bed, pelvic
LNs and bone metastases and 1/20 patient was subjected HTT
only on bone. Treatment on the prostatic bed and pelvic lymph
node was performed regardless the Choline-PET/CT findings
in those sites. In addition, 6/20 patients who presented extra-
pelvic LNs detected on Choline- PET/CT, HTTwas performed
on these sites. The mean follow-up from primary treatment
was 56 months (range: 6-179 months) with median of 38
months. At 3 months the biochemical complete or partial re-
sponse was 82%, at 6 months was 82% and at 12 months was
63%; bRFS at 1-2 year was 55-30% respectively; OS at 1-2
year was 100% and 92% respectively. Conclusion. Choline-
PET/CT based HTT is a valid therapeutic approach in PCa
patients with a low volume of metastases after primary treat-
ment and biochemical relapse of disease. Further studies are
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needed to confirm our results and to stratify PCa patients that
may have benefit from this therapeutic approach based on
specific clinical and imaging features.
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OP257
The Clinical Impact of Tc-99m HDP SPECT-CT
in the diagnosis and management of complex foot
and ankle pathology
C. Tang1, K. Alsey2, H. Zaw2, M. Nathan1; 1Royal Free Hos-
pital, London, UNITED KINGDOM, 2Hillingdon Hospital,
London, UNITED KINGDOM.
Aims: Complex foot and ankle pathology can pose a diagnos-
tic challenge to the clinician. SPECT-CT imaging is being
increasingly used as a problem solving tool in these challeng-
ing cases, usually when other imaging modalities have been
inconclusive.The aims of this study were:1.To evaluate the
diagnostic utility of SPECT-CT in identifying potential pain
generating pathology2.To determine the influence of SPECT-
CT in directing subsequent patient management3.To evaluate
patients’ clinical outcomes where management was directed
by SPECT-CT. Materials and Methods: Between June 2012
and December 2014, 61 consecutive patients (39 females and
22 males, age range 17-85) who were assessed by specialist
foot and ankle surgeons and who were subsequently referred
for Tc-99m HDP SPECT-CT were included. In total, 65
SPECT-CT scans were identified. Patients were divided into
subgroups depending on the scan indication:1. Localisation of
probable symptomatic site (43 scans)2. Non-union of fusion
(14 scans)3. Metalwork related problems (5 scans)4. Infection
(3 scans). The diagnostic utility SPECT-CT, impact on subse-
quent management and patient outcomes were assessed
through correlation of SPECT-CT reports with serial post im-
aging clinic letters and discussion of individual cases with the
orthopaedic surgeons. Results: SPECT-CTwas considered di-
agnostically useful in 86% (56/65 ) scans : 79% (34/43) of
localisation of symptomatic site scans and 100% in all other
categories.SPECT-CT influenced subsequent patient manage-
ment in 57/65 scans: 37% (24/65) further surgery, 8% ( 5/65)
planned surgery, 22% (14/65) therapeutic steroid inject0ions
and 22% (14/65) conservative treatment.Of 36 patients who
had active intervention, 11/36 (31%) had successful outcomes
following surgery, 10/36 (28%) following steroid injections.
14 patients who had conservative treatment were all consid-
ered to have had successful outcomes as they were not re-
referred to orthopaedics. Conclusion: SPECT-CT was consid-
ered diagnostically useful in the majority of cases, particularly
for non-union, metalwork problems and infection. SPECT-CT
was also clinically useful in subsequent patient management
by directing patients towards active surgical intervention or
conservative management. Patient outcomes following surgi-
cal intervention were mixed, the reasons for which are multi-
factorial. Nevertheless, this study demonstrates that SPECT-
CT has an important role as problem solving tool in the inves-
tigation of complex foot and ankle pain.
OP258
Altered bone metabolism of the spine in ankylosing
spondylitis demonstrated by 18F-fluoride PET/CT - A
novel evaluation tool in patients with relatively low
modified Stoke Ankylosing Spondylitis Spine Scores
J. Kim, Y. Choi, S. Lee, Y. Joo, T. Kim; Hanyang University
Medical Center, Seoul, KOREA, REPUBLIC OF.
Objectives: The purpose of this study was to identify alter-
ations of bone metabolism of the spine in patients with anky-
losing spondylitis (AS) by 18F-fluoride PET/CTand to consid-
er its potential role in the assessment of AS. Methods: Thirty-
three consecutive AS patients with inflammatory back pain
were included in this prospective study. Clinical disease activ-
ity was assessed using the Bath AS Disease Activity Index
(BASDAI) and the Korean version of the Bath Ankylosing
Spondylitis Functional Index (KBASFI). The presence of al-
tered bone metabolism activity on 18F-fluoride PET/CT was
assessed in posterior structures of the spine [cervical, thoracic
and lumbar facet joints (FJs), costovertebral joints (CVJs),
costotransverse joints (CTJs)] and anterior discovertebral units
(DVUs) of vertebral body. Clinical disease activity parameters
and 18F-fluoride PET/CT findings were compared in patients
with different extents of spinal structural changes on radiogra-
phy as assessed by the modified Stoke AS Spinal Score
(mSASSS) [low change : mSASSS (≤9); high change:
mSASSS (>9)]. Results: Altered bone metabolism in the pos-
terior structures of the spine on 18F-fluoride PET/CT were
found in most of the patients (27/33, 81.8%) and there was
no difference between the two subgroups [low mSASSS, 10/
12, 83.3% vs. high mSASSS, 16/18, 88.9%, respectively].
Altered bone metabolism in the anterior DVUs was frequently
detected in the mid-thoracic spine, especially T4/T5 level, and
differed between the subgroups [low mSASSS, 1/12, 8.3% vs.
high mSASSS, 11/18, 66.1%]. In the low mSASSS subgroup,
the presence of alterations of bone metabolism in posterior
structures, especially FJs, was associated with clinical disease
activity scores on the BASDAI and/or KBASFI. Conclusions:
18F-fluoride PET/CT provides additional information about
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alterations of bone metabolism in the spine compared with
currently used methods of identifying anatomical structural
changes. Altered bone metabolism on 18F-fluoride PET/CT
is frequently seen in posterior structures of the spine even in
the patient with low mSASSS. Moreover, in these patients,
metabolic abnormality of the FJs is associated with daily clin-
ical problems. In a single session, 18F-fluoride PET/CT could
be used to investigate alterations of posterior structures of the
spine, including T-spines, which are underestimated by the
mSASSS system. We suggest that popularization of 18F-fluo-
ride PET/CT might contribute to the early diagnosis and eval-
uation of disease activity, especially in AS patients with low
mSASSS.
OP259
99mTc-labelled D-Glucosamine Uptake Reflects Disease
Activity in Patients with Ankylosing Spondylitis
and Rheumatoid Arthritis
S. Angelides, A. Markewycz, N. Manolios, M. Ali, K. Pavic,
R. de Costa, B. Camden; Westmead Hospital, Westmead,
AUSTRALIA.
Background: Currently, assessment of disease activity in in-
flammatory arthritic conditions such as rheumatoid arthritis
(RA) and ankylosing spondylitis (AS) is suboptimal. Sub-
clinical disease is not infrequently under-estimated. This study
evaluated the clinical utility of a novel radiotracer, 99mTc-
Glucosamine, in the assessment of disease activity for both
RA and AS.Methods: 30 RA patients (11 male, 19 female)
and 12 patients with AS (all male) of various stages of disease
were recruited into the study. 99mTc-Glucosamine was pre-
pared in-house and patients received 600 MBq intravenously.
Whole body and static images were acquired at 15 min and 3
hr later, using a dual-head Siemens Symbia SPECT/CT gam-
ma camera. Images were analysed by a nuclear physician and
each joint given a score (0-5) based on the tracer uptake. A
similar scoring system was used for bone scans. A clinical
score (0-3) was given, based on the number of tender and
swollen joints present, by a rheumatologist. An MRI score of
0-5 was given for each imaged joint that was screened. Glu-
cosamine scans were then compared to other routinely used
tests, including haematological, biochemical and autoimmune
serological parameters, MRI, and bone scans, and correlated
with clinical activity.Results: Optimal images were obtained at
3 hr post-injection in all patients. 99mTc-Glucosamine scans
were more adept at identifying active disease and differentiat-
ing inflammatory manifestations of disease from non-
inflammatory causes. In AS patients, active sacro-iliitis was
observed in three patients on the 99mTc-Glucosamine scans.
In RA, 99mTc-Glucosamine accumulated at all known sites of
disease involvement, and was most pronounced in patients
with active untreated disease. Using Spearman’s correlation
co-efficient, there was a positive correlation between glucos-
amine scan scores, CRP (p=0.048) and clinical assessment
(p=0.003) that was not noted with bone scans.Conclusion.
The radiotracer was well tolerated with no adverse events.
99mTc-Glucosamine imaging can detect spinal inflammation
in AS, while plain X-rays andMRI were useful in the detection
of chronic related changes. Bone scan changes in the SI joints
persist longer than those seen on 99mTc-Glucosamine imag-
ing, and thus were less sensitive in tracking changes in the
clinical course. With respect to RA, 99mTc-Glucosamine
scans correlated well with the clinical evaluation of patients
and were superior to bone scans for imaging inflamed joints.
Unlike MRI, which is excellent for imaging specific joints,
99mTc-Glucosamine imaging gives a good overall clinical
picture of the patient and correlates well with the clinical ac-
tivity warranting further evaluation.
OP260
Bone SPECT-CT in the diagnosis and management
of facial asymmetry due to mandibular condylar
hyperplasia
L. Mohamed Salem, Sr., M. Ibañez Ibañez, V. Godoy Bravo,
L. Álvarez Nieto, R. Reyes Marles, D. Segarra Fenoll, M.
Castellón Sanchez, P. Nicolas Ruiz, L. Frutos Esteban, J.
Navarro Fernandez, M. Murcia Durendez, A. Montellano
Fenoy, M. Claver Valderas, M. Roldan Rubio, A. Abella
Tarazona; Hospital Clínico Universitario Virgen de la
Arrixaca, Murcia, SPAIN.
Aim:To assess the value of Bone SPECT-CT, in the diagnosis
and management of facial asymmetry, due to mandibular con-
dylar hyperplasia.Materials and methods:Together with the
Oral and Maxillofacial Surgery Department of our hospital,
we study retrospectively 99 studies belonging to 73 patients
with mean age 24.2 years, who underwent a Bone SPECT-CT
with Differential Condylar Quantification (DCQ), considering
a DCQ ≥ 55% suggestive of active condylar hyperplasia (CH),
46 patients had a normal study and 27 had abnormal one, 10
patients of 27 with abnormal study had several follow-up stud-
ies with at least a 6 month-interval, and 8 patients of 46 pa-
tients with normal studies.Patients with normal study (inactive
CH) and with abnormal study who had a normal follow-up
study were referred for mandibular osteotomy for the correc-
tion of facial asymmetry.Patients with abnormal study and
signs of progression of the disease were referred for condylar
shave first, then for mandibular osteotomy in a second
time.Results:7 of 10 patients with a first abnormal study had
a normal follow-up study a second, third or forth study, until
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Differential Condylar Quantification drop down to values con-
sidered as normal.3 of 10 patients with a first abnormal study
had progression of the disease.8 patients with a first normal
study had normal follow-up study.3 patients of 10 were re-
ferred for condylar shave (30% of patients with abnormal
study who had follow-up).Conclusion:Bone SPECT-CT with
Differential Condylar Quantification is a sensitive method to
exclude active condylar hyperplasia in patients with facial
asymmetry.Practicing follow-up Bone SPECT-CT can avoid
unnecessary condylar shave in 70% of the patients with active
condylar hyperplasia.
OP261
Optimising Quantitative SPECT in Condylar Hyperplasia
D. O. Hall, A. Demmery, J. Kabala; UH Bristol NHS FT,
Bristol, UNITED KINGDOM.
Aims: The intensity of uptake in the abnormal condyle in bone
SPECTof condylar hyperplasia can be used as a biomarker for
disease progression. In our institution, SPECT/CT is used for
older teenagers and adults, and SPECT only for younger
patients.Studies can be quantified to give additional informa-
tion. Methods suggested have included % uptake on abnormal
side, ratio to clivus, and ratio of abnormal to normal side;
previous studies have used 2D analysis and SPECT only,
whereas in this study we have considered 3D analysis and
SPECT/CT. This study was carried out to determine whether
3D quantification of SPECT bone studies in condylar hyper-
plasia is affected by using CTAttenuation Correction (CTAC)
and by peak or mean count over each condyle.Materials and
methods: 13 clinical studies using Tc-99m HMDP SPECTand
SPECT/CT carried out in a single institution in 2014 for uni-
lateral condylar hyperplasia were analysed. 10 were SPECT/
CTand 3 paediatric studies were SPECTonly. All studies were
acquired on a Siemens Symbia T16 system. Volumes of Inter-
est at 40% of maximum count were drawn over both condyles
and over the Clivus in 3D using Siemens Syngo Volumetric
Analysis, and the peak and mean count were recorded. Results
were expressed as % of uptake on abnormal side compared
with abnormal, ratio to clivus, and ratio of abnormal to unaf-
fected side. Results were compared between CTAC and Non-
AC and peak versus mean count.Results and Conclusions: The
ratio of peak or mean condylar count to clivus was significant-
ly affected (p<0.05) by use of CTAC, so different normal
ranges would be needed in each case; this also suggests that
this method would not be good for SPECT-only, as the ratio
would vary from patient to patient. Measurements of % uptake
on each side and ratio of abnormal to normal were not signif-
icantly affected by CTAC or use of peak or mean count. How-
ever, there were individual differences which might affect
results in a particular case, so methods used should be
standardised.
OP262
Clinical value of SPECT/CT in the ‘unhappy’ total knee
arthroplasty (TKA)- a prospective study in a consecutive
series of 100 painful knees after TKA
M. T. Hirschmann1,2, H. Rasch3; 1Kantonsspital Baselland
(Bruderholz, Liestal, Laufen), Department of Orthopaedic Sur-
gery and Traumatology, Bruderholz, SWITZERLAND, 2Uni-
versity, Basel, SWITZERLAND, 3Kantonsspital Baselland
(Bruderholz, Liestal, Laufen), Institute of Radiology and Nu-
clear Medicine, Bruderholz, SWITZERLAND.
Bone SPECT/CT is considered as beneficial in unhappy pa-
tients with pain, stiffness or swelling after total knee
arthroplasty (TKA). The purpose of this study was to identify
typical pattern of bone tracer uptake (BTU) distribution and
intensity values in patients after TKA. The above findings
were correlated with the type and fixation of TKA, the time
from TKA and intraoperative findings at revision surgery. A
total of 100 knees of 84 consecutive patients (mean age±SD 70
±11 years) after TKAwith persistent knee pain were prospec-
tively included. All patients underwent clinical examination,
standardized radiographs and Tc-99m-HDP-SPECT/CT as
part of a routine diagnostic algorithm. The diagnosis before
and after SPECT/CT and final treatment were recorded. TKA
component position was determined on 3D reconstructed im-
ages. Intensity and anatomical distribution of BTU was deter-
mined. Maximum intensity values were recorded as well as
ratios in relation to the proximal mid-shaft of the femur. Uni-
variate analyses (Chi square test, Pearson correlation, t-test for
independent samples) were performed (p<0.05). SPECT/CT
changed the clinical diagnosis and final treatment in 85/100
(85%) knees. Intraoperative findings confirmed the preopera-
tive SPECT/CT diagnosis in 32/33 knees (97%). TKA loos-
ening as well as progression of patellofemoral OAwas correct-
ly diagnosed in 100% of knees. Typical patterns of BTU for
specific pathologies were identified. Loose femoral TKA com-
ponents significantly correlated with increased BTU at the
lateral femoral regions (p<0.05). Loose tibial TKA compo-
nents significantly correlated with increased BTU at all tibial
regions (p<0.05) and around the tibial peg (p>0.01). In con-
clusion, the diagnostic benefits of SPECT/CT in patients after
TKA have been proven. Typical pathology related BTU pat-
terns were identified, which will improve reporting quality.
Due to the benefits in establishing the correct diagnosis
SPECT/CT it should be part of the routine diagnostic algo-
rithm for patients with pain after TKA.
S110 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
OP263
Multimodality work-up of patients with suspected infected
hip prosthesis: radiography, ESR/CRP testing, joint
aspiration, and 18F-FDG PET/CT
W. Broos, R. Kwee, J. Geurts, S. Vöö, B. Brans, R. Weijers;
Maastricht UMC, Maastricht, NETHERLANDS.
Objective. To investigate the relative contributions of radiog-
raphy, ESR/CRP testing, hip joint aspiration, and 18F-FDG
PET/CT in the work-up of suspected infected hip
prosthesis.Methods. In 45 hips of 45 consecutive patients
(58% males, mean age 67 years, range 35-82), the relative
contributions of radiography, ESR/CRP testing, synovial fluid
culture and white blood cell (WBC) count after joint aspira-
tion, and 18F-FDG PET/CT to the diagnosis of periprosthetic
joint infection (PJI) were assessed using stepwise multiple
regression analysis. Cultures of synovial fluid and peri-
implant tissues after revision surgery or clinical follow-up ≥6
months served as reference standard.Results. Synovial fluid
culture (Β=0.4553, standard error (SE)=0.1241, P=0.0011)
and 18F-FDG PET/CT (Β=0.5340, SE=0.1523, P=0.0017)
were independent tests associated with the diagnosis of PJI.
Radiography, ESR, serum CRP, and WBC count of synovial
fluid were not independent distinguishing tests. When either a
positive synovial fluid culture or positive 18F-FDG PET/CT
result were considered positive for PJI, a sensitivity of 96.2%
(95% confidence interval [CI] 81.1-99.3%) and specificity of
33.3% (95% CI 13.8-60.9%) were yielded. When the combi-
nation of both a positive synovial fluid culture and positive
18F-FDG PET/CT result were considered positive for PJI, a
sensitivity of 69.6% (95% CI 49.1-84.4%) and specificity of
100% (95% CI 70.1-100%) were yielded.Conclusion. Synovi-
al fluid culture and 18F-FDG PET/CT were found to be the
only independent tests associated with the diagnosis of infect-
ed hip prosthesis. PJI is very likely when both tests are positive
and very unlikely when both tests are negative.
OP264
The evolution of radiologically occult bone metastases
detected on FDG-PET/CT
P. Martineau, M. Pelletier-Galarneau, X. Pham, A. Sheikh;
The Ottawa Hospital, Ottawa, ON, CANADA.
Background: FDG-PET/CT is widely used for the staging of
malignancies. Occasionally, focal FDG uptake within bone or
bone marrow is present on the PET component of the exam
without corroborative findings on the co-registered CT. Such
findings often requires biopsy, further characterization with
MRI, or followup imaging to elucidate their true
significance.Methods: We reviewed all FDG-PET/CT reports
from our institution dated between 9/1/2012 and 4/2/2015
(N=4280) and identified all patients with focal bone uptake
without corroborative findings on the co-registered CT
(N=75, 1.8%). For these patients, follow-up imaging was
reviewed in order to determine the nature of the PET
finding.Results: A total of 89 lesions in 75 patients were iden-
tified as ‘suspicious for early osseous metastases’ due to focal
FDG uptake and absence of corroborative findings on the co-
registered CT. The mean SUVof these lesions was 4.6 (range
1.5-22.5). 32 (43%) of these patients had followup imaging
allowing for reassessment of the lesion site at multiple time
points. Of these, 20 (63%) subsequently developed osseous
metastases visible on conventional imaging, with aggressive
lesions visible on CT (n=11), MRI (n=7), PET-CT (n=1), and
plain film (n=1) an average of 160, 88, 39, 812, and 88 days,
respectively, following the initial staging PET-CT. The mean
SUVof these lesions was 5.6 (range 2.2-22.5). Of the remain-
ing 12 patients, no aggressive osseous lesions were visible on
followupMRI (n=1) at 75 days or on CT (n=11) an average of
417 days (range 229-597) following the PET. The mean SUV
of these lesions was 3.6 (range 1.5-6.4).Conclusion:Our re-
sults show that the majority (63%) of our patients with
suspected early osseous metastases developed disease which
eventually became visible on conventional imaging; however,
a significant portion (37%) of patients with suspected osseous
lesions failed to develop radiologically apparent disease.
Whether this was due to false-positive PET, false-negative
CT/MRI findings, response to treatment or a combination of
these factors is unclear. Lesions which became apparent on
followup imaging generally had higher SUVs; however, sig-
nificant overlap in the range of SUVs of those lesions which
become apparent and those that remain occult limits the pre-
dictive power of SUV in this context. Our findings are of
particular significance to those institutions which use PET
for initial staging, but perform follow-up with conventional
imaging. Our results suggest that, in cases of ‘early osseous
metastases’, corroboration with MRI or biopsy is strongly rec-
ommended to ensure proper staging.
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Novel treatment strategy for glioblastomas using
Auger-electron therapy and concomitant chemotherapy -
in vitro studies
A. Therkelsen1, B. B. Olsen1, B. Halle2, P. Høilund-Carlsen1,
H. Thisgaard1; 1Department of Nuclear Medicine, Odense
University Hospital, Odense, DENMARK, 2Department of
Neurosurgery, Odense University Hospital, Odense,
DENMARK.
Introduction: Glioblastomas (GBM) remains non-curable by con-
ventional treatment strategies. Due to their infiltrative growth,
complete resection is not possible and chemo- and radiotherapy
are dose limited. A promising treatment strategy is convection-
enhanced delivery of the Auger-electron-emitting thymidine ana-
log [125I]5-Iodo-2’-deoxyuridine (125I-UdR) into the tumor site
of the brain. By combining this therapeutic approach with con-
comitant thymidylate synthetase-inhibition of the GBM cells, a
further increase of the therapeutic effect can be expected due to
an increased DNA-incorporation of 125I in the tumor cells (1).
Using viability- and radioactivity uptake assays to analyze a
patient-derived GBM cell line in vitro we aimed to elucidate the
individual and combined effects of exposure to the therapeutic
components: Thymidylate synthetase-inhibition using methotrex-
ate (MTX) or 5-fluoro-2’-deoxyuridine (F-UdR), Auger-electron-
therapy using 125I-UdR, and the currently clinically used first-line
chemotherapeutic agent temozolomide (TMZ).Material and
methods: The human derived cell line T87 was used in all assays
and cultured as spheroids in serum free medium. Cellular 125I-
UdR uptake assays were performed after a 4 hour co-incubation
with 18.5 kBq/mL 125I-UdR and various concentrations ofMTX
or F-UdR. CellTiter-Blue assays were used to determine cell via-
bility after incubationwith 125I-UdR,MTX/F-UdR, andTMZ for
7 days.Results: Radioactivity uptake assays showed that F-UdR
wasmore potent thanMTX to increase the uptake of 125I-UdR in
the GBM cells. Cells treated with 1 nM F-UdR incorporated 1.8-
fold more 125I-UdR than cells treated with 1 nMMTX and cells
treated with 125I-UdR alone. A 1000 fold higher MTX concen-
tration, i.e., 1 μM was required to achieve the same increase in
125I-UdR uptake as found using F-UdR. Viability assays showed
no viable GBM cells after exposure to 0.01 μMor more MTX/F-
UdR for 7 days, demonstrating the toxic effects of these com-
pounds. Exposure to TMZ and 125I-UdR alone showed therapeu-
tic effects with IC50 values of 206 μM (198-214 μM) and 109
Bq/mL (99-120 Bq/mL), respectively. By combining TMZ and
125I-UdR a further decrease in GBM cell viability was found, but
no sign of synergy between the two compounds was
observed.Conclusion: Concomitant F-UdR resulted in a high in-
crease of 125I-UdR uptake in the GBM cells and at much lower
doses thanMTX.Exposure to TMZand 125I-UdR showed strong
therapeutic effects, albeit without signs of synergy between the
two compounds.References: (1) Kassis et al: Acta Oncol.
2000;39(6):731-7.
OP276
The effects of dose-rate on radiation induced platelet
toxicity in internal radiotherapy.
J. Rousseau1, S. Becavin1, F. Nguyen1, N. Sas1, M.Magnen1,
M. Bourgeois2,3,4, M. Meckel5, F. Roesch5, N. Chouin6,4;
1LUNAMUniversité, Oniris, “AMaROC”, Nantes, FRANCE,
2CRCNA, INSERM, Université de Nantes, UMR_S 892,
Nantes, FRANCE, 3ARRONAX cyclotron, Saint Herblain,
FRANCE, 4CHU Nantes, Nuclear medicine department,
Nantes, FRANCE, 5Institute of Nuclear Chemistry,
Johannes-Gutenberg-University Mainz, Mainz, GERMANY,
6LUNAM Université, Oniris,, Nantes, FRANCE.
Aim:We investigated the impact of bone marrow (BM) dose-rate
variations on mouse thrombopoïesis in a context of internal radio-
therapy. Material and Methods: Mice were injected with
osteotropic agents: 18F-Na (37-60MBq) or bisphosphonates
(BP) labelled either with 64Cu (15-50MBq) or 90Y (0.8-
4.9MBq). Biodistributions were determined by counter measure-
ments and cumulated activities within bones were calculated. Do-
simetry was performed using a representative mouse CT image
integrated into GATE. Absorbed doses were determined for the
entire BM or the femur one. Hematological toxicity was moni-
tored via platelet counts over time after injection. BM toxicity was
assessed by femur histology and via progenitor colony assays.
Experimental data were compared to simulations of a
thrombopoïesis compartmental model previously published. It is
based on the linear-quadradric model and considers kinetics of
BM c e l l p r o l i f e r a t i o n , d i f f e r e n t i a t i o n a n d
radiosensitivities.Results: For each radiopharmaceutical, dose-
effect relationships on depletion and recovery were demonstrated
for BM cells and platelets. Irradiation dose-rates were different for
the three radionuclides as 98%of the absorbed dosewas deposited
in 0.5, 3 and 15 days for 18F-Na, 64Cu-BP and 90Y-BP. A same
absorbed dose to the BM of 4.3±0.3 Gy lead to depletions of 65%
for 18F-Na and 64Cu-BP versus 40% for 90Y-BP between 7 and
10 days post-injection. Platelet kinetics and depletions were very
similar for mean absorbed doses around 4.5±0.3 Gy of 18F-Na or
64Cu-BP and 14.2±2.7 Gy of 90Y-BP.Same dose-rate effects
were noticed for the BM cells and the hematopoietic progenitor
depletions. Similar progenitor depletions (86-88%)were observed
following absorbed doses delivered to the BM of 1.6±0.3 Gy for
18F-Na or 64Cu-BP and 5.5±0.5 Gy for 90Y-BP. Progenitor ki-
neticswere also different: a faster but incomplete recovery (even at
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day 46) was observed following a 90Y-BP irradiation whereas the
recovery was complete at day 21 for 18F-Na and 64Cu-BP.The
compartmental model predicted platelet kinetics and depletions
for the three radiopharmaceuticals except for higher doses of
90Y-BP. Despite the simulated decrease of progenitors radiosen-
sitivity in the case of the protracted 90Yirradiation, themodel was
still unable to accurately predict platelet kinetics or the fastest
progenitor recovery. These results highlighted the possibility of a
radiobiological process which is not considered in the compart-
mental model in addition to dose-rate effects.ConclusionWe ex-
perimentally demonstrated a significant impact of the dose-rate on
BM cells and platelets. A potential adaptive biological process
during the Y90 long-lasted irradiation could be involved in this
effect.
OP277
Different DNA Damage Repair Rates in Blood
Lymphocytes after Peptide Receptor Radionuclide
Therapy and Radioiodine Therapy of Thyroid Cancer
U. Eberlein1, C. Nowak2, C. Lapa1, C. Bluemel1, M. Peper2,
R. A. Werner1, A. K. Buck1, H. Scherthan2, M. Lassmann1;
1Department of Nuclear Medicine, University of Würzburg,
Würzburg, GERMANY, 2Bundeswehr Institute of Radiobiol-
ogy affil. to the Univ. of Ulm, Munich, GERMANY.
Objectives: Radiation-induced DNA double strand breaks
(DSBs) cause, in their vicinity, the phosphorylation of the
histone H2AX (then called γ-H2AX) and the accumulation
of the 53BP1 protein that binds to and signals damaged chro-
matin at a DSB site. This leads to the formation of microscop-
ically visible nuclear foci containing both markers, which thus
mark radiation-induced DSBs. The aim of the study is to de-
scribe the time course of DNA damage in blood lymphocytes
in molecular radiotherapy after internal irradiation with I-131
and Lu-177. Methods: We investigated blood samples of pa-
tients either after their first peptide receptor radionuclide ther-
apy (PRRT) or their first radioiodine therapy (RIT) of differ-
entiated thyroid cancer (DTC). The average frequencies of
radiation-induced foci (RIF) containing both γ-H2AX and
53BP1 fluorescence were determined in the nuclei of two-
colour immunostained γ-H2AX/53BP1 lymphocytes isolated
from peripheral blood samples of patients before and after
molecular radiotherapy (MRT). The foci containing both
DSB markers were scored manually in a fluorescence micro-
scope equipped with a red/green double-band-pass filter by an
experienced observer. The individual background focus rate
was determined in a sample taken prior to therapy. The EANM
SOP for DTC was followed to determine the absorbed dose to
the blood. The number of RIF as a function of time was de-
scribed by combining a linear dose-dependent increase with a
multi-exponential function characterizing different rates of
DNA repair. Results: 283 blood samples (at least 6 per patient)
of 36 patients (PRRT: 16, RIT: 20) up to 168h after therapy
were evaluated. At late time points (10-12h) after therapy the
decay of the average RIF number per cell is best described by a
mono-exponential decay function with a decay constant of
0.04h-1. When the absorbed dose to the blood exceeded
20mGy in the first hour, only seen in patients with DTC, we
observed the on-set of a fast repair component with a fast
decay rate of 0.33h-1 resulting in a bi-exponential decay func-
tion. Conclusions: This analysis provides a comprehensive
description of the time course of the number of radiation-
induced DNA damage foci after molecular radiotherapy of
beta emitters. It furthermore reveals a threshold dose for the
induction of a fast repair component after in vivo DSB induc-
tion by incorporated I-131.
OP278
Impact of Bi-Exponential Repair Kinetics of Sub-lethal
Damage on the Relative Effectiveness in Molecular
Radiotherapy
A. Malaroda1, A. J. Green2, A. B. Rosenfeld1; 1University of
Wollongong, Wollongong, AUSTRALIA, 2National Physical
Laboratory, Teddington, UNITED KINGDOM.
AIMS: In Molecular Radiotherapy, the rate of production of
sub-lethal lesions competes with the rate of their repair, more-
over each type of lesion is characterised by their specific pro-
duction and repair rates. For example, there is evidence that the
repair kinetics in mouse kidney cells is at least bi-exponential,
with a fast (<1 h) and a slow (>2h) component. The aim of this
study was to compare the impact on the Relative Effective-
ness, and by extension on the Biologically Equivalent Dose
(BED), of bi-exponential repair kinetics with respect to the
widely accepted mono-exponential repair rate. METHODS:
The Linear Quadratic model takes the repair rate of sub-
lethal lesions into account through the Lea-Catcheside time
protraction factor. Thus, Lea-Catcheside factor (G) and
Relative Effectiveness (RE) were calculated for a bi-
exponential repair rate of constants 0.15 h (fast) and
5.03 h (slow), data published in the literature for mouse
kidney cells. Partition coefficients, for the fast and slow
components respectively, of [0.5,0.5], [0.25,0.75], [0.75,
0.25], [0.9,0.1], [0.1,0.9] were considered. Mono-
exponential dose-rate was assumed with effective decay
rates ranging between 0.001 and 5 h-1 (i.e. 0.13< T1/2<
693 h). Effective Lea-Catchised factors (Geff) and Rela-
tive Effectiveness (REeff), explicitly accounting for the
bi-exponential repair rates, were calculated. These were
then compared to Gmean and REmean factors calculated
using a mean repair rate for each pair of partition coef-
ficients; the mean repair rate representing the global
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repair rate used when a mono-exponential repair rate
kinetic is assumed. Comparison was carried out by cal-
culating the percentage difference between Geff and
Gmean and between REeff and REmean. RESULTS: The
mean repair constants ranged between 0.17 and 1.18 h,
depending on the partition coefficients. When the per-
centage differences were considered, these were equiva-
lent for the Lea-Catcheside factors and the Relative Ef-
fectiveness and depended only on the repair rates, their
partition coefficients and the effective half-lives: for all
the partition coefficients, a percentage difference greater
than 50% was observed for effective half-lives greater
than 5 h. As a function of the effective decay rate, the
lowest percentage difference was observed when the fast
repair constant was dominant (partition coefficient [0.9,
0.1]). CONCLUSIONS: Under the assumptions of this
study, the mean value of the individual repair constants
of each sub-lethal lesions repair mechanism led to an
underestimation of the RE, and therefore of the BED,
up to 50% for clinically relevant effective half-lives
(T1/2 > 5 h).
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Terbium-161 a Promising Radionuclide for the Irradiation
of Tumor Cells and Micrometastases: Monte Carlo Dose
Assessment using CELLDOSE
E. Hindie1, M. A. Quinto2, P. Zanotti-Fregonara1, C. Morgat1,
C. Champion2; 1CHU Bordeaux - University of Bordeaux -
UMR 5287, Bordeaux, FRANCE, 2Université de Bordeaux,
CNRS/IN2P3, Centre d’Etudes Nucléaires de Bordeaux
Gradignan (CENBG), Gradignan, FRANCE.
AIM: Radiopharmaceutical therapy, traditionally limited
to the treatment of advanced metastatic disease, is now
being considered in earlier settings to destroy minimal
residual disease or occult micrometastases. The current
study compares the effectiveness of 161Tb, 177Lu and
111In to irradiate micrometastases. 161Tb and 177Lu asso-
ciate a medium-energy β- emission with various conver-
sion and Auger electrons. They also have a small pho-
ton component which allows imaging. By contrast, 111In
is a γ-isotope for imaging that emits conversion and
Auger electrons potentially helpful for therapy.
METHODS: Electron dose was assessed in spheres of
various sizes (from a 10-mm metastasis to a 10-μm sin-
gle cell) with the Monte Carlo code CELLDOSE. The
spheres were uniformly labeled with 161Tb, 177Lu or
111In. Doses were compared for a fixed amount of en-
ergy released per unit volume (1 MeV per μm3). The
dose contribution from photons was neglected.
RESULTS: In a 10-mm metastasis, the three isotopes
exhibited equivalent dose deposit after normalization
(1 MeV released per μm3). This dose was 154 Gy for
161Tb, 152 Gy for 177Lu and 155 Gy for 111In. Howev-
er, for smaller micrometastases (<500μm), 161Tb and
111In were more effective than 177Lu. For instance, in
a 50-μm micrometastasis, the dose was 31 Gy for both
161Tb and 111In vs. 13.6 Gy for 177Lu. In this 50-μm
metastasis, conversion and Auger electrons were respon-
sible for 75% of the dose from 161Tb and for 20% of
the dose from 177Lu. A specific advantage of 111In
emerged only for single cells. In a cell of 10-μm diam-
eter, doses from 111In, 161Tb and 177Lu were 20.7 Gy,
11.5 Gy and 3.5 Gy, respectively. CONCLUSION:
Choosing the appropriate isotope is fundamental to
achieve an effective irradiation of micrometastases. Our
study shows a selective advantage of 161Tb over 177Lu,
especially for metastases <500μm, resulting from an
emission spectrum rich in low-energy conversion and
Auger electrons. 111In appears advantageous for killing
single-cells, but has the drawback of having a larger
fraction of photon emission compared to 161Tb.
OP280
Alpha radioimmunotherapy using 213Bi-anti MISRII
mAb in ovarian cancer
R. LADJOHOUNLOU, Jr.1,2,3, A. PICHARD1,2,3, V.
BOUDOUSQ1,2,3, N. CHOUIN4, F. BRUCHERTSEIFER5,
A. MORGENSTERN5, I. Navarro-Teulon1,2,3, J. Pouget1,2,3;
1Inserm U1194, MONTPELLIER, FRANCE, 2IRCM, Institut
de Recherche en Cancérologie de Montpellier, Montpellier,
FRANCE, 3Université de Montpellier, Montpellier,
F-34090,, Montpellier, FRANCE, 4AMAROC, ONIRIS,
NANTES, FRANCE, 5European Commission, Joint Research
Centre, Institute for Transuranium Elements, Karlsruhe,
GERMANY.
Hypothesis:We assessed in vitro the therapeutic efficacy of the
newly developed anti-MISRII mAbs (16F12 and 12G4) la-
beled with 213Bi in the therapy of ovarian cancer. In vivo,
we explored their potential use during brief intraperitoneal
radioimmunoptherapy (BIP-RIT). Methods: In vitro,
clonogenic survival of SK-OV-3 cells expressing MISRII re-
ceptor were evaluated. Briefly, SK-OV-3 cells (donor cells)
were incubated for 90 min with increasing activities (0-
0.5MBq/mL) of anti MISRII 213Bi-16F12, 213Bi-12G4
mAbs or irrelevant 213Bi-Rituximab. We used the standard
medium transfer protocol between donor cells and recipient
cells (grown in non-radioactive medium previously incubated
for 2hwith donor cells) to evaluate bystander cytotoxic effects.
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Uptake of radioactivity per cell together with appropriate cel-
lular S-values were determined for absorbed dose assessment.
Radiation-induced biological effects were measured in both
donor and recipient cells as the yield of DNA double strand
breaks (DSBs) through immunofluorescent detection of
gamma-H2AX and 53BP1. In vivo we assessed in nude mice
bearing intraperitoneal 2-3 mm SK-OV-3MSIRII tumors nod-
ules the biodistribution of radiolabeled antibodies (IP-RIT, 0-
2.96MBq; 37MBq/mg) or BIP-RIT (5.5-12.9MBq; 37MBq/
mg). BIP-RIT consisted of intraperitoneal injection of
radiolabeled mAbs followed by washing of the peritoneal xe-
nograft cavity with saline solution. After, the biodistribution of
radiolabeled antibodies was investigated after IP and BIP-RIT.
Results: In vitro we showed the strong efficacy of 213Bi-12G4
and 213Bi-16F12 mAbs. Bystander cytotoxicity was mea-
sured in all recipient cells for the three radiolabeled mAbs. In
agreement with DNA DSBs formation, uptake of radioactivity
by donor cells was shown to be higher for 213Bi-16F12 than
for 213Bi-12G4. DNADSBs yield was lower in recipient cells
and preliminary results indicate that their complexity might be
lower than the one measured in donor cells. In vivo, maximum
tolerated activity of 213Bi-16F12 was about 2.9MBq and
12.9MBq after IP-RIT and BIP-RIT, respectively. Moderate
hematological toxicity was observed in groups treated with
the highest amount of activity. Biodistribution studies indicat-
ed that the tumor-blood uptake ratio was 1.4 and 6.3 one hour
after IP and BIP-RIT, respectively. This ratio was decreased to
0.2 and 3.7, three hours post treatment, respectively. Thera-
peutic efficacy of 213Bi-12G4 and 213Bi-16F12 mAbs after
IP-RIT and BIP-RIT is ongoing. Conclusions: In vitro, we
showed the strong therapeutic efficacy of anti-MISRII
213Bi-16F12 mAb against ovarian cancer cells. We also
showed that bystander effects were involved. In vivo, the fea-
sibility of BIP-RIT using high activities of 213Bi-mAbs was
demonstrated. We are now assessing its therapeutic efficacy
using 213Bi-16F12.
OP281
Monte Carlo evaluation of Auger-electron emitting
radionuclides in 3-D cellular models
N. Falzone1,2, S. Able1, S. Terry1, J. M. Fernández-Varea3, K.
A. Vallis1; 1University of Oxford, Oxford, UNITED KING-
DOM, 2Tshwane University of Technology, Department of
Biomedical Science, Pretoria, SOUTH AFRICA, 3Universitat
de Barcelona, Facultat de Física (ECM and ICC), Barcelona,
SPAIN.
Aim Auger-electron emitting radionuclides are ideal molecu-
larly targeted radiotherapeutic (mTRT) agents when treating
disseminated cancer cells and micro-metastasis. In the present
study we evaluate the spatial distribution as well as clonogenic
survival (SF) of two mTRT strategies in an in-vitro based 3-D
tumour spheroid model; 111In-DTPA-hEGF (a peptide
targeting the epidermal growth factor-EGF) and 111In-
Trastuzumab (an antibody directed against the human epider-
mal growth factor receptor-2, HER2/neu). This information is
then used to validate Monte Carlo (MC) simulations of a close
packed 3-D cellular model in predicting tumour control prob-
ability (TCP). Materials and Methods Spheroids were formed
from three tumour cell lines, MDA-MB-468 and MDA-MB-
231/H2N breast cancer and SQ20B head/neck cancer cells,
using a hanging droplet method. Spheroids were treated with
111In-DTPA-hEGF (8 MBq/μg, 40 nM), and 111In-
Trastuzumab (6 MBq/μg; 10 nM) and evaluated 1 h and
24 h after treatment. SF was determined using a clonogenic
assay and distribution was evaluated by cellular fractionation
and micro-autoradiographic (MAR) staining of spheroid sec-
tions. The 3-D spheroid models were generated by a closed
packed algorithm and MC software, PENELOPE was used to
model radiation transport. Results Clonogenic survival corre-
lated with radionuclide penetration, with the smallest SF noted
in cell lines expressing the highest number of receptors; for
EGFR targeting with 111In-DTPA-EGF, the least survival was
noted in MDA-MB-468 spheroids, while the lowest SF was
noted in MDA-MB-231/H2N spheroids treated with 111In-
Trastuzumab. SQ20B form very tightly packed spheroids
and although expressing a high number of EGFR, it showed
little radionuclide penetration and corresponding greater sur-
vival. MAR staining showed two distinct spatial distribution
patterns, i.e. outer rim of activity (1 h post treatment) or uni-
form distribution (24 h post treatment). TCP depended strong-
ly on spatial distribution of the radionuclides, with uniformly
distributed radionuclides achieving TCP1. Conclusion Tu-
mour spheroids offer a viable model for investigating the pen-
etration and spatial distribution of radiolabelled probes in tu-
mour cells. Data was employed to inform mathematical
modelling, in order to be able to use in silico methods to
simulate drug distribution in tumour cells.
OP282
Potential radioprotectors and radiosensitizers
in neuroendocrine tumor cells
S. Exner1, S. Poenick1, V. Prasad2, C. Grötzinger1; 1Charité -
Universitätsmedizin Berlin, Gastroenterology, Berlin, GER-
MANY, 2Charité - Universitätsmedizin Berlin, Nuclear Med-
icine, Berlin, GERMANY.
Aim: Neuroendocrine tumors (NETs) express somatostat-
in receptors that are currently utilized for diagnostic and
therapeutic approaches. For peptide receptor radionuclide
therapy (PRRT), somatostatin analogs like octreotide, are
coupled to radionuclids like yttrium 90 or lutetium 177,
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which after injection are bound and taken up specifically
by NETs. PRRT can deliver radiation doses of up to
250 Gy to the tumors. Nevertheless, complete remission
is extremely rare, compared to similar radiotherapies for
thyroid cancer and non-Hodgkin lymphoma. One hy-
pothesis potentially explaining the discrepancies between
expected result and observed outcome of PRRT might
be that somatostatin analogs induce a G1 arrest in
NET cells, thereby making them radioresistant. Materials
and Methods: To investigate this, NET cell lines were
incubated with or without agonists and exposed to dif-
ferent radiation doses from a 137Cs source between 0
and 50 Gy. Cells were harvested at distinct timepoints,
stained with propidium iodine and the cell cycle distri-
bution was assessed by FACS analysis. Results: Initially,
the somatostatin receptor expression (SSTR1-5) of five
neuroendocrine tumour cell lines (BON, H727, QGP-1,
LCC18, UMC11) was analyzed by quantitative real time
PCR to assess the cell specific expression patterns of the
different receptor subtypes. In radiation experiments all
of five tested NET cell lines showed a radiation-induced
decline in G1 cells as well as a G2/M arrest. Also, the
percentage of apoptotic cells in sub-G1 phase increased
time- and dose-dependently. Pretreatment with a poten-
tial G1 inhibitor resulted not only in an expected G1
arrest but also in a decrease of radiation-induced G2/M
arrest. Moreover, a reduction of cells in sub-G1 was
observed in two of five cell lines. In contrast, the com-
bination of octreotide treatment with radiation showed
no difference compared to radiation alone, not
supporting the initial hypothesis. Conclusion: Further ex-
periments are needed to better understand the influence
of somatostatin agonists and other intrinsic or extrinsic
factors on neuroendocrine tumor cells to pave the way
for a significant increase in the overall therapeutic effi-
cacy of PRRT.
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Pharmacokinetic analysis of [11C]PBR28 in the rat model
of herpes encephalitis: comparisonwith (R)-[11C]PK11195
for pre-clinical imaging
P. Kopschina Feltes1, A. Parente1, D. Vállez Garcia1, J. W. A.
Sijbesma1, C. M. Moriguchi Jeckel2, R. A. J. O. Dierckx1, E.
F. J. de Vries1, J. Doorduin1; 1University of Groningen, Gro-
ningen, NETHERLANDS, 2Pontifícia Universidade Católica
do Rio Grande do Sul, Porto Alegre, BRAZIL.
Aim: [11C]PBR28 is a second generation translocator pro-
tein (TSPO) ligand with supposedly better imaging charac-
ter i s t ics than the most commonly used t racer
[11C]PK11195. Surprisingly, only limited studies have eval-
uated the pharmacokinetic and binding profile of
[11C]PBR28 in neuroinflammatory models in rodents. For
this reason, [11C]PBR28 was evaluated and compared to
[11C]PK11195 for the detection and quantification of neu-
roinflammation for pre-clinical research. Materials and
methods: Herpes simplex encephalitis (HSE) was induced
in male Wistar rats by intranasal inoculation of the herpes
simplex type-1 virus, resulting in neuroinflammation. At 6-
7 days post inoculation, 60-min dynamic [11C]PBR28 or
[11C]PK11195 PET scans were performed. During the
scans arterial blood samples were taken to generate blood
and metabolite-corrected plasma input curves for pharma-
cokinetic modeling. Differences between control and HSE
rats were assessed by voxel-based analysis, using standard-
ized uptake values, and volume-of-interest analysis, using
the reversible two-tissue compartment model to determine
the binding potential (BPND). Results: Voxel-based analysis
showed that [11C]PBR28 was able to detect overexpression
of TSPO in brain areas that are known to be affected in
the HSE rat model. [11C]PBR28 had a faster metabolism
than [11C]PK11195, with 50% of metabolites in plasma
present at 5 min and 21 min, respectively. [11C]PBR28
demonstrated a higher sensitivity than [11C]PK11195 in
the detection of neuroinflammation. The BPND of
[11C]PBR28 was significantly higher (p<0.05) in the me-
dulla (150%), pons (121%), midbrain (94%), thalamus
(76%), hippocampus (65%), hypothalamus (44%) and cer-
ebellum (37%) of HSE rats when compared to control rats,
while a higher BPND of [
11C]PK11195 was only found in
the medulla (59%). Comparison of BPND between control
groups showed no statistical difference, suggesting that
non-specific binding of both tracers is similar. Conclusion:
[11C]PBR28 performed better than [11C]PK11195 in the
detection of TSPO overexpression in the HSE rat model,
as the BPND was found to be increased in more brain
regions. The results of this study suggest that
[11C]PBR28 is a better tool for pre-clinical research of
neuroinflammation.
OP284
Radiosynthesis and fundamental evaluation of (R)-[11C]
emopamil as a novel tracer for imaging enhanced
P-glycoprotein function in the brain
J. Toyohara1, M. Okamoto1,2, H. Aramaki2, Y. Zaitsu2, I.
Shimizu2, S. Hosokawa2, K. Ishiwata1; 1Tokyo Metropolitan
Institute of Gerontology, Tokyo, JAPAN, 2Waseda University,
Tokyo, JAPAN.
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Aim: A number of substrate for P-glycoprotein (P-gp),
such as [11C]verapamil ([11C]VER), was developed
for imaging P-gp function with positron emission to-
mography (PET). These substrates can measure de-
creased function of P-gp as an increased uptake of
tissue radioactivity. However, it would likely not be
able to measure enhanced P-gp function, because
base-line tissue radioactivity is already at most immea-
surable. Emopamil (EMP) is a calcium channel blocker
of the phenylalkylamine class, having high blood-brain
barrier permeability and weak substrate properties for
P-gp. These properties would be suitable for measuring
enhanced P-gp function in the brain. The purpose of
this study is to synthesize (R)- and (S)-[11C]EMP and
to characterize their properties as a P-gp tracer. Mate-
rials and Methods: The EMP includes a chiral quater-
nary carbon centre, and a previous research has indi-
cated that the optical isomers differ significantly in
their biological effects. Therefore, we first synthesized
(R) - and (S ) - [11C]EMP and compared the i r
biodistribution, peripheral metabolism, and effects of
P-gp inhibitor cyclosporine A (CysA). Then, we com-
pared the brain pharmacokinetics of (R)-[11C]EMP and
(R)-[11C]VER in base line and CysA pre-treatment
with small animal PET. Results and conclusion: (R)-
and (S)-[11C]EMP were synthesized from (R)- and
(S)-noremopamil, respectively, by methylation with
[11C]methyl triflate in the presence of NaOH at room
temperature. The yield of (R)- and (S)-[11C]EMP was
approximately 30%. The specific activity of (R)- and
(S)-[11C]EMP was >74 GBq/μmol and radiochemical
purity was >99%. The biodistribution of (R)- and
(S)-[11C]EMP in ddY mice demonstrated a significant-
ly higher uptake of (R)-[11C]EMP in the brain. The
regional brain distribution of (R)- and (S)-[11C]EMP
were homogeneous and no stereo-selective. (R)- and
(S)-[11C]EMP were rapidly metabolized to hydrophilic
metabolite. Unchanged form of (S)-[11C]EMP (39%)
was significantly lower than that of (R)-[11C]EMP
(46%) at 15 min after injection in plasma. In contrast,
over 88% of radioactivity in the brain was intact and
no stereo-selective. CysA pre-treatment increased brain
activity approximately 3-fold, however, no stereo-selec-
tive. Since (R)-[11C]EMP was metabolized less than
that of (S)-[11C]EMP, (R)-enantiomer was further eval-
uated with small animal PET. The base line area-
under-the-curve (AUC) of brain radioactivity (0-60
min) of (R)-[11C]EMP was 2-fold higher than that of
(R)-[11C]VER, but its AUC after CysA pre-treatment
was comparable to tha t of CysA pre- t rea ted
(R)-[11C]VER. In conclusion, (R)-[11C]EMP can be
used as a novel tracer for imaging P-gp function with
a higher base line uptake than (R)-[11C]VER.
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Discovery of a Fluorinated 4-Oxo-Quinoline Derivative
as a Potential PET Radiotracer for Targeting CB2
Receptor
L. Mu1, R. Slavik2, A. Herde Müller2, S. D. Krämer2, M.
Weber3, R. Schibli2, S. Ametamey2; 1UniversitätsSpital Zü-
rich, ZURICH, SWITZERLAND, 2ETH Zurich, ZURICH,
SWITZERLAND, 3Kantonsspital St. Gallen, ZURICH,
SWITZERLAND.
Objectives: The cannabinoid receptor type 2 (CB2) is part of
the endocannabinoid system and has gained growing attention
in recent years due to its important role in neuroinflammatory/
neurodegenerative diseases [1, 2].The PET imaging of CB2
has so far been unsuccessful. Recently, we reported on a
carbon-11 labeled 4-oxo-quinoline derivative, designated
RS-016 [3], as a promising radiotracer for imaging CB2. In
this report, three fluorinated analogues of RS-016 were de-
signed, synthesized and evaluated for their utility as imaging
agents for the CB2. Methods: Three fluorinated analogues of
RS-016 namely RS-030, RS-122 and RS-126 were synthe-
sized using a multi-step reaction sequence and their binding
affinities towards CB2 were determined using [3H]-CP-55,
940. The most potent compound, RS-126 ((N-(1-adamantyl)-
1-(2-(2-fluoroethoxy)ethyl)-8-methoxy-4-oxo-1,4-
dihydroquinoline-3-carboxamide), was radiolabeled with
fluorine-18 and further evaluated in autoradiographic studies,
biodistribution experiments and metabolic studies. Results:
The syntheses of RS-030, RS-122 and RS-126 were accom-
plished in overall chemical yields of 30%, 16% and 6%, re-
spectively and their binding affinities (Ki values) towards CB2
ranged from 72-1.2 nM. RS-126 exhibited the highest binding
affinity and selectivity towards CB2. [18F]RS-126 was obtain-
ed in ≥ 99% radiochemical purity with a specific radioactivity
of 98 ± 44 GBq/μmol (n = 15) at the end of synthesis. The
logD7.4 value was 1.99 and in vitro autoradiographic studies
with CB2-positive rat spleen tissue revealed high and
displaceable binding. [18F]RS-126 was stable in vitro
in rat and human plasma over 120 min, whereas 55%
intact parent compound was found in vivo in rat blood
plasma at 15 min p.i.. Biodistribution studies confirmed
accumulation of [18F]RS-126 in rat spleen with a spec-
ificity of 79% under blocking conditions. Conclusion:
The fluorinated CB2 radioligand, [18F]RS-126, demon-
strated high specificity towards CB2 receptor in vitro
and in vivo and is potentially a promising ligand for
imaging CB2 receptor expression. References: 1. Di
Marzo, V. (2009). Pharmacological Research 60:77-84
2. Pertwee, R.G. (2009). Br J Pharmacol 156:397-411
3. Slavik, R., Herde, A.M., Bieri, D., Weber, M.,
Schibli, R., Krämer, S.D., Ametamey, S.M., and Mu,
L. (2015). Eur J Med Chem 92:554-64
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PET imaging of P-glycoprotein function at the rodent
BBB: Diurnal fluctuations and impact of sleep deprivation
H. Savolainen1, P. Meerlo1, A. van Waarde1, P. Elsinga1, A.
D. Windhorst2, N. Colabufo3,4, G. Luurtsema1; 1University of
Groningen, UniversityMedical Center Groningen, Groningen,
NETHERLANDS, 2VU University Medical Center, Amster-
dam, NETHERLANDS, 3Università degli Studi di Bari, Bari,
ITALY, 4Biofordrug, Bari, ITALY.
Aim: Blood-brain barrier (BBB) contributes to brain homeo-
stasis by protecting the brain from harmful compounds. P-
glycoprotein (P-gp) is one of the major efflux transporters at
the BBB. P-gp function can be modulated by endogenous and
exogenous factors. Yet, little is known about fluctuations in P-
gp function across the sleep-wake cycle. Recent studies sug-
gest that substances accumulating during wakefulness may be
cleared from the brain during sleep, a process that is impaired
after sleep deprivation [1]. Therefore our research questions
were: Is P-gp function constant or does it fluctuate across the
day? Is P-gp function stronger during sleep and is it negatively
affected by sleep deprivation? Materials and methods: Four
groups of male Sprague-Dawley rats (n=6-8) were scanned
at different moments of the 12 h light - 12 h dark cycle to study
diurnal variations: early light phase (ZT 3, group 1), late light
phase (ZT 9, group 2), early dark phase (ZT 15, group 3) and
late dark phase (ZT 21, group 4). In two additional groups
(n=7), controls were allowed to sleep normally while the ex-
perimental animals were sleep-deprived for 10 h in a slowly
rotating drum during the light phase, which represents the
normal sleep period. All rats were scanned with a new P-gp
substrate tracer, [18F]MC225 ((5-(1-(2-fluoroethoxy))-[3-(6,7-
dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-
tetrahydronaphthalen). Arterial blood samples were drawn
during a 60 min scan. Afterwards, rats were terminated and
peripheral organs and brain regions were collected for
biodistribution analysis. Results: Distribution volumes (VT)
were calculated by a one-tissue-compartment model fit using
whole blood and metabolite-corrected plasma data as input
function. In all brain regions, group 3 had 1.2-1.8 fold higher
VT than other groups. Groups 1, 2 and 4 showed no significant
differences. In the biodistribution study, some peripheral or-
gans (e.g. testes) showed similar diurnal variation. Distribution
volumes in sleep-deprived animals and controls were not sig-
nificantly different. Conclusion: P-gp function in rats displays
a daily rhythm with reduced function at the beginning of the
dark phase or active phase. This rhythm is not dependent on
sleep since sleep deprivation had no effect. It may be that P-gp
function is modulated by the endogenous circadian clock via
other processes than sleep, such as rhythms in neurotransmit-
ters or cytokines. References: 1 He et al, J Neurosci 2014, 34,
14697-14706
OP287
Comparative Evaluation of Two PET Radioligands
for PDE10A, [11C]T-773 and [18F]FM-T-773-d2
in Nonhuman Primates
A. Takano1, V. Stepanov1, R. Nakao1, N. Amini1, H.
Kimura2, C. Halldin1; 1Karolinska Institutet, STOCKHOLM,
SWEDEN, 2Takeda Pharmaceutical Company, Limited., FU-
JISAWA, JAPAN.
Aim: Since PDE10A is distributed mainly in striatal regions, it
may be involved in psychiatric and neurodegenerative dis-
eases such as schizophrenia and Huntington’s disease. Here
we evaluated and compared two recently developed
radioligands for PDE10A [1], [11C]T-773, [1-[2-fluoro-
4-(tetrahydro-2H-pyran-4-yl)phenyl]-5-methoxy-3-(1-phenyl-
1H-pyrazol-5-yl)pyridazin-4(1H)-one] and a fluoromethyl an-
alog, [18F]FM-T-773-d2, in nonhuman primates. Materials
and methods: PET measurements (123 min) were performed
four times for each PET radioligand using six female rhesus
monkeys. Two monkeys had both radioligands and other four
had one radioligand. Arterial blood sampling was performed
to obtain the plasma input function. Protein binding was mea-
sured, and radio-metabolite analysis was performed for each
PET measurement. The putamen and caudate as the target
regions, and the cerebellum as a reference region, were delin-
eated on coregistered PET/MRI. Total distribution volume
(VT) was calculated by a two-tissue-compartment model
(2TC). Binding potential (BPND) was calculated as a ratio of
the VT between the target region and the reference region
minus one. BPND was also calculated with simplified refer-
ence tissue model (SRTM). The stability of the outcome mea-
sures was investigated using the truncated PET data. Results:
The whole brain uptake at peak was higher with [18F]FM-T-
773-d2 than with [11C]T-773 (4.5%ID vs 3.4%ID). Average
fractions of the parent compounds at 30 min were 57.3 ± 6.1%
with [11C]T-773 and 63.7 ± 1.6% with [18F]FM-T-773-d2.
No radio-metabolites more lipophilic than the parent com-
pounds were detected. Protein binding was higher with
[18F]FM-T-773-d2 than with [11C]T-773 (78.9 ± 3.1% and
56.7 ± 7.3%). VT of the cerebellum and putamen was 3.9 ±
0.5 and 11.9 ± 3.3 for [11C]T-773 and 4.8 ± 1.0 and 11.1 ± 0.8
for [18F]FM-T-773-d2, respectively. The BPND of the puta-
men obtained with 2TC and SRTMwas 2.0 ± 0.4 and 1.9 ± 0.4
for [11C]T-773, and 1.4 ± 0.3 and 1.3 ± 0.3 for [18F]FM-T-
773-d2. The duration of PET measurements was shortened
stably to 39 min for [11C]T-773 and 33 min for [18F]FM-T-
773-d2 for VT obtained with 2TC while it was shortened sta-
bly to 63 min for [11C]T-773 and 75 min for [18F]FM-T-773-
d2 for BPND obtained with SRTM. Conclusion: Both [11C]T-
773 and [18F]FM-T-773-d2 have good characteristics as PET
radioligands for PDE10A. Although the whole brain uptake at
peak was higher for [18F]FM-T-773-d2, BPNDwas higher for
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[11C]T-773. The duration of PET measurement can be short-
ened to 39 min for both radioligands if the VT of the striatal
regions obtained with 2TC is the outcome measure.
OP288
Quantification of Available NMDA (GluN) Receptor NTD
Drug Binding Sites with the GluN2B-targeting PET
Tracer [11C]NB1
S. D. Krämer1, T. Betzel1, L. Mu2, B. Tewes3, B. Frehland3,
D. Schepmann3, R. Schibli1, B. Wünsch3, S. M. Ametamey1;
1ETH, Zurich, SWITZERLAND, 2University Hospital Zurich,
Zurich, SWITZERLAND, 3Westfälische Wilhelms-
Universität, Münster, GERMANY.
Aim: NMDA receptors (GluN) are key regulators of CNS
plasticity and higher cognitive functions. We aimed at evalu-
ating the potential of our novel GluN2B-targeting PET tracer
[11C]NB1 (7-[11C]methoxy-3-(4-phenylbutyl)-2,3,4,5-
tetrahydro-1H-benzo[d]azepin-1-ol) for quantitative PET and
receptor occupancy studies. [11C]NB1 is structurally related to
drug candidates, such as ifenprodil, eliprodil and Ro-25-6981
that selectively bind to the GluN2 N-terminal domain
(NTD).Materials and Methods: [11C]NB1 was synthesized
from its phenolic precursor by [11C]methylation with
[11C]CH3I. Time-activity curves (TAC) for rat brain regions
were recorded by PET after intravenous injection of 20 to
67 MBq [11C]NB1. The blood TAC was simultaneously mea-
sured from a minimally invasive arterio-venous shunt. Data
were fit to compartment models and input-function indepen-
dent quantification methods were evaluated. To investigate the
influence of cerebral glutamate on [11C]NB1 PET, ketamine
(25 mg/kg) was injected intraperitoneally 15-20 min before
tracer injection. Receptor occupancy by eliprodil was charac-
terized after intravenous injection of various doses of eliprodil
1 minute before the tracer (n=14).Results:For experiments
with blood TAC recording (n=6; 1 blood TAC failed),
[11C]NB1 specific activity was 254-368 GBq/μmol (0.4-0.8
ng/kg injected dose). Data followed a 2-tissue compartment
model with scan-time independent VT from 10 min onwards.
Extraction from plasma to brain was close to 100%. At distri-
bution equilibrium, tracer concentration in the first, non-
specific compartment, was similar to the plasma concentra-
tion, resulting in VND ~1. Under baseline conditions (n=3),
average VT was between ≤ 4.8 for olfactory cortex and cere-
bellum grey matter and ≥ 6.0 for midbrain and thalamus. The
integrated standardized uptake value from 0 to 60 min (SUV0-
60min) was evaluated for quantification in the absence of an
input function. The comparison with VT revealed a Pearson’s r
for the 5 animals and 13 brain regions each, of 0.840. VT
values after ketamine challenge (n=2) were similar to baseline
values and values for SUV0-60min were not significantly
affected (n=3). Whole brain SUV0-60min after eliprodil injec-
tion followed a saturation function. The fit dose at 50% recep-
tor occupancy was 1.5 μg/kg (4.2 nmol/kg). Maximal
blocking by an excess of eliprodil, NB1 and Ro-25-6981
was 47% (fit), 46% (n=1) and 55% (n=1), respectively, in
agreement with ex vivo biodistribution results.Conclusion:
[11C]NB1 allows to quantify the availability of GluN2B
NTD binding sites in rat brain. Whole brain specific binding
is ~47% of total binding. Quantification is possible with and
without an input function. Receptor occupancy by GluN2B
NTD-targeting drugs can be quantified with [11C]NB1.
OP289
Autoradiography and microPET rodent evaluation
of the [18F]MCL-524 - an 18F-labelled dopamine D2/D3
receptor agonist
V. Stepanov1, J. Häggkvist1, M. Svedberg1, R. Krasikova2, S.
J. Finnema1, A. W. Sromek3, J. L. Neumeyer3, C. Halldin1;
1Karolinska Institutet, Stockholm, SWEDEN, 2N.P.
Bechtereva Institute of Human Brain, St.-Petersburg, RUS-
SIAN FEDERATION, 3McLean Hospital/Harvard Medical
School, Belmont, MA, UNITED STATES.
AIM: Carbon-11 labeled dopamine D2/D3 receptor agonist
radioligands have been shown to be sensit ive to
amphetamine-induced elevations in extracellular dopamine
concentration across species. Labeling with fluorine-18 further
increases usefulness of such radioligands for long duration
imaging scenarios. In view of this, a novel fluorine-18
radiolabeled dopamine D2/D3 receptor agonist - [
18F]MCL-
524 - was recently developed and evaluated successfully in
non-human primates (NHP) (Finnema et al., J Nucl Med.
2014, 55:1164-70). We here evaluated scope of usefulness of
[18F]MCL-524 for autoradiography, using post-mortem tissue,
as well as its potential for rodent PET imaging. METHODS:
[18F]MCL-524 was synthesized as described previously
(Finnema at al. 2014). For autoradiography evaluation, rat
and mouse brain slices (coronal sections, 14 μm thick) were
incubated with 0.02 and 0.2 MBq/ml of [18F]MCL-524 for 55
minutes in the absence and presence of 10 μM butaclamol,
washed and imaged on a Fujifilm BAS-5000. Rodent PET
imaging was conducted using rats with Mediso nanoScan®
PET/MRI and nanoScan® PET/CT cameras (imaging time of
63 minutes, average injection of 17±1 MBq [18F]MCL-524).
Striatal BPND values were estimated with SRTM, using
cerebellum as a reference region. RESULTS: In autora-
diography studies accumulation of [18F]MCL-524 was
observed in most regions of the brain, including cortex
and striatum, with little to none of the binding being
displaceable by butaclamol. The result is in-line with
other attempts to use carbon-11/fluorine-18 labeled D2/
S120 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
D3 receptor agonists for the purpose. In the rodent base-
line PET studies, average striatal BPND values were low,
0.29±0.23 (n=3), and a large variability between individ-
ual animals was observed. Pre-treatment with 1mg/kg of
raclopride decreased striatal BPND by ~70% (n=3).
CONCLUSIONS: The low BPND and high variability
in [18F]MCL-524 binding across animals limits its use-
fulness as an imaging tool for small animal PET. Com-
parison of the NHP and rodent imaging results indicates
that the kinetic behavior of dopamine D2/D3 receptor
agonist ligands in vivo differs significantly across spe-
cies. Great care should be taken when assessing PET
radioligands suitability for dopamine D2/D3 receptor im-
aging using different species.
OP290
Comparative evaluation of (R)-[11C]verapamil and [11C]
-N-desmethyl-loperamide to assess P-glycoprotein
function at the mouse blood-brain barrier
T. Wanek1, S. Mairinger1, J. Stanek1,2, M. Sauberer1, T.
Filip1, A. Traxl1, C. Kuntner1, J. Pahnke3, M. Müller2, O.
Langer1,2; 1AITAustrian Institute of Technology, Seibersdorf,
AUSTRIA, 2Medical University of Vienna, Vienna, AUS-
TRIA, 3University of Oslo (UiO) and Oslo University Hospi-
tal (OUS), Oslo, NORWAY.
Aim: Brain distribution of many drugs can be restricted by
efflux transport at the blood-brain barrier (BBB) mediated
by the adenosine triphosphate-binding cassette transporter
P-glycoprotein (Pgp). Pgp function has been shown to be
altered in neurological diseases such as epilepsy and
Alzheimer’s disease. Positron emission tomography
(PET) with the Pgp substrates (R)-[11C]verapamil
( [ 11C]VPM) and [11C] -N -desmethy l - loperamide
([11C]dLop) has been used to assess Pgp function at the
rodent and human blood-brain barrier (BBB). Aim of this
study was to directly compare [11C]VPM and [11C]dLop
for assessment of Pgp function at the mouse BBB. Mate-
rial and Methods: Imaging experiments were performed in
groups of isoflurane-anesthetized, female C57BL/6N mice
and homo- and heterozygous Pgp-knockout mice which
were pretreated 2 h prior start of PET with different doses
of the Pgp inhibitor tariquidar or vehicle solution. Dynam-
ic (0-60-min) PET scans were initiated at the start of in-
jection of either [11C]VPM or [11C]dLop. Brain uptake of
[11C]VPM or [11C]dLop, was expressed as the brain to
plasma ratio of radioactivityin the last PET frame (50-
60 min after injection). In separate groups of mice
radiolabelled metabolites of both radiotracers were ana-
lyzed in plasma and brain by radio-TLC.ResultsFollowing
injection, radioactivity in whole brain reached an
approximately 3-4 times higher peak concentration for
[11C]VPM than for [11C]dLop. [11C]VPM washed out
from brain whereas [11C]dLop appeared to be trapped in
brain tissue. In Pgp knockout mice, brain uptake of
[11C]VPM and [11C]dLop was 3.9- and 2.8-fold higher,
respectively, as compared with wild-type mice. In hetero-
zygous mice, which have 50% lower Pgp expression
levels at the BBB than wild-type mice, brain uptake of
[11C]VPM and [11C]dLop was increased by only 1.5-
and 1.1-fold, respectively, as compared with wild-type
mice. Both radiotracers showed tariquidar dose dependent
increases in brain distribution. Whereas brain distribution
of [11C]VPM reached in tariquidar-treated mice similar
levels as in Pgp knockout mice, this was not the case for
[11C]dLop. For both radiotracers, radiolabelled metabo-
lites were detected in plasma and brain with a higher per-
centage of radiolabelled metabolites for [11C]dLop than
for [11C]VPM. Conclusion: Both [11C]VPM and
[11C]dLop can be used to assess Pgp function at the mouse
BBB. However, both radiotracers displayed limited sensi-
tivity to assess small (<50%) variations of Pgp function at
the mouse BBB, with [11C]dLop being less sensitive than
[11C]VPM. Use of both radiotracers is compromised in
mice by significant peripheral metabolism and brain up-
take of radiolabelled metabolites.
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Noninvasive Quantification of Tumor Blood Flow
in Prostate Cancer using 82Rb PET/CT
L. P. Tolbod1, M. M. Nielsen1, H. J. Harms1, B. G. Pedersen2,
P. Borghammer1, M. Borre3, K. Bouchelouche1, J. Frøkiær1, J.
Sørensen1; 1Dept. Nuclear Medicine & PET-Centre, Aarhus
University Hospital, Aarhus N, DENMARK, 2Department of
Radiology, MR-Centre, Aarhus University Hospital, Aarhus
N, DENMARK, 3Dept. Urology, Aarhus University Hospital,
Aarhus N, DENMARK.
Objective: Tumor Blood Flow (TBF) is an indicator of tumor
aggressiveness in a variety of cancers and may aid in identifying
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aggressive prostate cancer and in monitoring treatment. The gold
standard for measuring TBF is 15O-H2O PET combined with
arterial blood sampling (BSIF). This is, however, logistically
challenging and requires an on-site cyclotron. We investigated
the accuracy of simplified TBF measurements using with image
derived input functions (IDIF) with 15O-H2O and the more
widely accessible tracer 82Rb. Method: 9 patients with prostate
cancer were included. Dynamic PET scans of the heart (for IDIF
extraction) and pelvis were performed with both 15O-H2O and
82Rb. During the 15O-H2O scans arterial blood sampling was
performed. On the same day, T2w and DWIMRI were acquired.
IDIFs were automatically extracted using cluster analysis. ROIs
of tumor, peripheral zone and transition zonewere drawn onMRI
images coregistered to the PET series. TBF was calculated using
BSIF or IDIF data from either the aorta, as obtained from the
separate heart scan, or the iliac arteries. Results: Automatic ex-
traction of IDIFs derived from the aorta/left ventricle (heart scans)
and the iliac arteries (pelvis scans) was successful in all cases.
Excellent correlations were found between TBF obtained using
blood sampler input and each IDIF (TBF(hear t
IDIF)=1.11xTBF(BSIF)+0.004, R2=0.96 and TBF(Iliac
IDIF)=5.23xTBF(BSIF)-0.16, R2=0.93) for the 15O-H2O scans.
Correcting for the flow-dependent extraction of 82Rb using the
Renkin-Crone model, a good correlation was found between
82Rb K1 and 15O-H2O TBF (R2=0.96). Furthermore, high cor-
relation was found between 82Rb K1 and 82Rb SUV
(SUV=7.82xK1(82Rb)+0.47, R2=0.83). In 5 patients, TBF was
elevated relative to the peripheral zone. However, in 4 patients
elevated blood flow was also seen in the transition zone, most
likely due to benign prostatic hyperplasia. Conclusion: Both
15O-H2O and 82Rb can be used for quantitative imaging of
tumor blood flow in prostate cancer without catheter-based arte-
rial blood sampling. Full pharmacokinetic analysis can be per-
formed without the need for arterial blood sampling by using the
automatically extracted IDIFs from either the iliac arteries or a
separate scan of the heart. In the former case, a scanner dependent
recovery factor is needed. Further simplification is possible by
using SUV values obtained from static images.
OP293
Phase I Safety and Biodistribution Study
of 124I-PEG-AVP0458 Diabody in Patients with TAG-72
Positive Ovarian and Prostate Cancer
A.M. Scott1,2, T. Akhurst3, F. Lee2, M. Ciprotti1, I. Davis1, A.
Weickhardt1, H. Gan1, P. Kocovski2, N. Guo2, D. Murphy3, R.
Hicks3, S. Lee1, G. O’Keefe1, S. Gong1, P. Hudson4; 1Austin
Health, Melbourne, AUSTRALIA, 2Olivia Newton-John Can-
cer Research Institute, Melbourne, AUSTRALIA, 3Peter
MacCallum Cancer Centre, Melbourne, AUSTRALIA,
4Avipep Pty Ltd, Melbourne, AUSTRALIA.
Background: The development of antibody therapeutics for
imaging and payload delivery is complex, and intact IgG have
long half-lives that impact on tumor:blood ratios and tumor
penetrance. Smaller molecular weight antibody constructs (eg
diabodies) have been developed for improved penetrance into
tumor, faster blood clearance, and enhanced tumor: normal
tissue uptake, however renal uptake may impact on imaging
and therapeutic effects. Through a novel pegylation strategy, a
diabody to TAG-72 (AVP0458) has been generated, and pro-
duced under cGMP for a first-in-human clinical trial.Materials
and Methods: We have conducted a Phase I, open label, first-
in-human trial of PEG-AVP0458. The primary study objective
was the safety of single dose of I-124 PEG-AVP0458 in pa-
tients (pts) with TAG-72 +ve relapsed / metastatic prostate or
ovarian cancer. Secondary study objectives were evaluation of
the biodistribution, tumor targeting, pharmacokinetics (PK)
and immunogenicity of I-124 PEG-AVP0458. Pts were in-
fused with I-124 PEG-AVP0458 (3-5mCi) at one of two dose
levels (1mg/m2 and 10mg/m2), and imaged sequentially over
a one week period. Safety, PK, and immunogenicity were
assessed up to 30 days post infusion.Results: Six pts (1F:5M;
age range 62-85yrs; 1 ovarian cancer, 5 prostate cancer) were
entered into the study, 3 at each dose level. I-124 PEG-
AVP0458 was well tolerated, with no infusion-related adverse
events, and no serious adverse events observed. There was
consistent biodistribution on PET imaging of I-124
PEGAVP0458, with no normal tissue uptake. High tumor up-
take was evident in metastatic disease in liver and lymph
nodes, with lesion uptake seen within 1-2 days post infusion.
PK analysis showed a T½β of 46.8 ± 12.4 hrs. There was no
impact of protein dose on biodistribution, tumor uptake or PK.
N o i mm u n o g e n i c i t y t o P EG - AVP 0 4 5 8 w a s
evident.Conclusions: I-124 PEG-AVP0458 is safe, and dem-
onstrates excellent, rapid targeting of tumor in-vivo, with no
normal organ uptake, and high tumor: blood ratios. This data
demonstrates the feasibility of using pegylated diabodies for
imaging and for payload delivery of radionuclides (RIT) or
cytotoxic drugs (ADC) in cancer patients.ANZCTR Number:
ACTRN12612000802808
OP294
Parasympathetic Imaging of Prostate Cancer using
11C-Donepezil PET.
M. Stokholm1, S. Høyer2, S. Jakobsen1, D. Bender1, M.
Borre3, J. Frøkiær1, P. Borghammer1; 1Department of Nucle-
ar Medicine & PET Centre, Aarhus University Hospital, Aar-
hus, DENMARK, 2Department of Pathology, Aarhus Univer-
sity Hospital, Aarhus, DENMARK, 3Department of Urology,
Aarhus University Hospital, Aarhus, DENMARK.
Background It was recently shown that high-grade prostate
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cancer (PC) is characterized by parasympathetic neuro-
neogenesis, which promotes cancer dissemination, and is as-
sociated with decreased survival. We have previously validat-
ed 11C-donepezil PET as a marker of parasympathetic inner-
vation. 11C-donepezil PETcould therefore have utility in risk-
stratification of PC patients, and may facilitate targeted biop-
sies or focal therapyObjectivesTo investigate 11C-donepezil
uptake in low- and high-grade PC as a marker of parasympa-
thetic neuro-neogenesis.MethodsThe 11C-donepezil uptake in
PC was investigated using autoradiography of prostatectomy
tissue from 13 patients and correlated to Gleason scores (GS).
In pilot PET-studies we aim to perform in vivo 11C-donepezil
PET imaging in two groups of 12 PC patients with low- and
high-risk PC based on biochemical and biopsy risk-
stratification.ResultsIn prostatectomy tissue, 11C-donepzil ex-
hibited increased uptake in high-grade PC compared to low-
grade and benign hyperplasia. The mean uptake ranged from
56% (GS3+3) to 409% (GS4+4). Preliminary in vivo 11C-
donepezil PET studies in five PC patients with low-grade PC
(GS≤7) demonstrated only slight uptake in the prostate
(SUVmax<4.6), whereas two patients with high-grade PC
(GS≥8) showed high focal uptake in the prostate (SUVmax
>7.5). Interestingly, high uptake was also seen in bone metas-
tases (SUVmax 7-12) and enlarged pelvic lymph nodes
(SUVmax 7-11) in two patients with disseminated
PC.ConclusionsIn autoradiography studies, the uptake in tu-
mor tissue of the cholinergic PET ligand 11C-donepezil cor-
related with GS. Preliminary PET studies suggest that 11C-
donepezil may be able to predict the GS in vivo. Parasympa-
thetic PET imaging may therefore have utility for targeted
biopsies in PC patients, and may aid in selecting patients for
radical prostatectomy.
OP295
Effect of androgen deprivation therapy on the results
of PET/CTwith [18F]fluciclovine in patients with prostate
cancer
T. Bach-Gansmo1, H. Sletten2, M. C. Småstuen2, A. M.
Løndalen1, T. V. Bogsrud1; 1Oslo University Hospital, Oslo,
NORWAY, 2Oslo and Akershus University College, Oslo,
NORWAY.
Purpose: Anti-androgenic hormonal treatment seems to re-
duce the sensitivity of 11C- and 18F-Choline PET (1).
[18F]-fluciclovine (FACBC) is a new radiopharmaceutical
for positron emission tomography (PET) of prostate can-
cer. We wanted to find out to which extent androgen dep-
rivation therapy (ADT) would influence the sensitivity of
FACBC PET in patients with metastatic disease. Methods:
This was a retrospective register trial performed in 350
patients with prostate cancer examined with FACBC, of
whom 76 received ADT. Informed consent was obtained
from all patients. The sensitivity of FACBC PET/CT in
patients on ADT was compared with the sensitivity for
the total material, 350 patients with primary or recurrent
prostate cancer with or without metastatic disease. Re-
sults: The number of PET positive cases in the total ma-
terial was 59%. The sensitivity was 71%, higher but not
statistically significant, in the subgroup receiving ADT,
and this whether the PSA was stable/declining (65% pos-
itive PET ) or rising (77% positive PET). Discussion/
Conclusion: Invitro studies have shown that anti-
androgen treatment causes downregulation of the LAT3
receptor, which in turn is responsible for an upregulation
of LAT1 and ASCT transporters (2), responsible for the
uptake of amino acids such as fluciclovine. ADT does not
render FACBC PET examinations negative, and as a result
FACBC may be particularly useful in this patient group.
Additionally FACBC may be less suitable for monitoring
the response to ADT. References: 1.Giovacchini G,
Picchio M, Coradeschi E, Scattoni V, et al. [11C]Choline
uptake with PET/CT for the initial diagnosis of prostate
cancer: relation to PSA levels, tumour stage and anti-
androgenic therapy. Eur J Nucl Med Mole Imaging
2008;35:1065-1073. 2. Wang Q, Tiffen J, Bailey CG, Leh-
man ML, et al. Targeting amino acid transport in metasta-
tic castration-resistant prostate cancer: effects on cell cy-
cle, cell growth, and tumor development. J Natl Cancer
Inst. 2013;105(19):1463-73.
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68Ga-DOTATATE compared with11C-Choline PET/CT
in patients with hormone-resistant prostate cancer
at biochemical relapse.
O. Alonso1,2, G. Dos Santos1,2, E. Savio1, M. Garcia-Fontes1,
H. Engler1; 1Uruguayan Centre of Molecular Imaging
(CUDIM), Montevideo, URUGUAY, 2Clinical Hospital, Uni-
versity of Uruguay, Montevideo, URUGUAY.
In hormone resistant prostate cancer (HRPC), neuroendo-
crine differentiation has been associated with up to 85% of
patients. These cells express somatostatin receptors
(SSTR) that can be targeted with 68Ga-DOTATATE.
Therefore, we present the preliminary results of a prospec-
tive trial aiming to compare the diagnostic values of
68Ga-DOTATATE and 11C-Choline PET/CT in patients
with HRPC at biochemical recurrence. The study involved
64 prostate cancer patients (median age: 65, range: 47-85
years) with PSA relapse under androgen deprivation ther-
apy, with a median trigger PSA level of 4.25 ng/mL
(range: 0.22-291 ng/mL). Within 1-2 weeks, a PET/CT
study was performed with 68Ga-DOTATATE and 11C-
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Choline with an approximately dose of 100 MBq and 400
MBq, respectively, using a 64-slice PET/CT with time-of-
flight correction. Correlative imaging, histopathology and/
or clinical follow-up (median follow-up time: 19 months,
range: 9-31 months), were considered as reference stan-
dard. Both techniques showed positive local, regional
lymph node and distant findings in 31 patients. Results
were concordant in 57 cases (89%), with discordant find-
ings observed in patients with bone (n=2) and regional
lymph nodes lesions (n=5). On a per patient basis, sensi-
tivity, specificity, positive and negative predictive values
with their 95% confidence intervals were the same for
both techniques: 0.82 (0.65-0.93), 0.90 (0.73-0.98), 0.90
(0.73-0.98) and 0.81 (0.65-0.93), respectively. Although a
trend toward a lower sensitivity was observed for patients
with lower PSA levels, the difference was not statistically
significant: 0.63 vs. 0.89, P=0.13, same values for both
tracers, for patients with PSA < 4.25 and ≥ 4.25 ng/mL,
respectively. False-positive lesions (n=5) were found, for
both tracers, in 3 patients and were located in the prostate
bed (n=1) and regional lymph nodes (n=4), being 3 dis-
cordant. In all cases, pathology revealed non-specific in-
flammatory lesions. 68Ga-DOTATATE and 11C-Choline
PET/CT seem to have complementary value for the eval-
uation of HRPC patients with biochemical relapse. Further
studies are needed to confirm these findings.
OP297
Two-phase 68Ga-PSMA-HBED-PET/CT in patients
with high-risk prostate carcinoma or PSA-relapse
C. Bouter, B. Meller, C. O. Ritter, J. Lotz, J. Meller, S. Hijazi,
C. O. Sahlmann; UMG Göttingen, Göttingen, GERMANY.
Aim: Current preclinical studies show increasing uptake of
Ga-68-PSMA over time indicating a better lesion/
background ratio in Ga-68-PSMA-PET/CT. The aim of
this study was the evaluation of the clinical value of
two-phase Ga-68-PSMA PET/CT in patients with high
risk prostate carcinomas (PC) or suspected recurrence of
disease. Methods: A retrospective study of 35 PC patients
(aged 48-76, median 71) that underwent two-phase Ga-68-
PSMA-PET/CT was performed. Acquisition was done 1h
and 3h after injection of 140-392 MBq (median 301 MBq)
Ga-68-PSMA with 10-11 bed positions on a Philips Gem-
ini TF16. Maximum standard uptake values (SUVmax) of
lesions were measured in both scans and lesions were
correlated with histology and / or diagnostic findings of
other imaging modalities. Results: Primary tumor showed
high SUVmax values 1h p.i. (range 4,3-64,4; median 10,
85) with significantly increased values after 3h p.i. (range
5,3-107,6; median 18,15). Histologically proven lymph
node (LN) metastases also showed high SUVmax values
1h p.i. (range 2-37,3; median 9,8) rising up to 3h p.i.
(range 3,7-52,7; median 15,2) whereas no correlation be-
tween size and SUVmax was detected. Radiologically
proven bone metastasis also featured significantly higher
SUVmax values in scans up to 3h p.i. (median 1h p.i.: 4,8;
median 3h p.i. 7,15). However, benign LN showed lower
SUVmax values 1h p.i. (range 0,8-2,5; median 1,4) with
decreasing values 3h p.i. (range 0,7-1,5; median 1,05).
Conclusions: Uptake of PC lesions in Ga-68-PSMA-
PET/CT increases significantly over time in vivo. Two-
phase Ga-68-PSMA-PET/CT may help to differentiate be-
tween benign lesions and PSMA-expressing PC-relapses
or -metastases.
OP298
A Direct Comparison Study of Ga-68-NODAGA-MJ9
(MJ9, Bombesin) to F-18-FCH (FCH) in Recurrent
Prostate Cancer
P. Mitsakis1, T. Zilli2, M. Kosinski3, J. Delage1, H. Maecke4,
R. Mansi4, J. Bourhis5, F. Buchegger1, R. Miralbell2,6, J. O.
Prior1; 1Department of Nuclear Medicine, Lausanne Universi-
ty Hospital, Lausanne, SWITZERLAND, 2Department of Ra-
diation Oncology, University Hospital of Geneva, Geneva,
SWITZERLAND, 3Institute of Radiation Physics, Lausanne,
SWITZERLAND, 4Department of Nuclear Medicine, Univer-
sity Hospital of Freiburg, Freiburg, GERMANY, 5Department
of Radiation Oncology, Lausanne University Hospital, Lau-
sanne, SWITZERLAND, 6Institut Oncològic Teknon, Barce-
lona, SPAIN.
Purpose: We aimed to compare the diagnostic accuracy of
68Ga-NODAGA-MJ9 (MJ9, a novel radiopharmaceutical
targeting the gastrin releasing peptide receptor) PET/CT
with 18F-FCH (FCH) in recurrent prostatic cancer
(PC).Materials and Methods: MJ9 was radiolabelled with
the eluate of a 68Ge→68Ga generator using an automatic
processor unit (PharmTracer). FCH PET/CTwas performed
with 18F-labelled fluoromethycholine. We included 33 PC
patients (age 68±6y [53-82y]) treated by prostatectomy
(27/33=82%) or radiation therapy without prostatectomy
(6/33=18%) with biochemical PC relapse (PSA 4.7
±4.1ng/mL [range 0.3-18.1]) and mean Gleason score 7.2
±0.9 [5-9]. They underwent within a 10-day period both
68Ga-NODAGA-MJ9 (200MBq) and 18F-FCH (200
MBq) PET/CT imaging at 70 min p.i. Lesions were classi-
fied of local, lymph node [LN] and osseous origins and
corresponding SUVbw_max (SUV) was recorded in each
lesions.Results: In total, 81 lesions (14 local, 39 LN, 24
bone) were detected in 29 pat ients using 68Ga-
NODAGA-MJ9 or 18F-FCH. In 4 patients (4/33=12%)
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no lesion was found with both tracers (n=4; PSA=1.2±1.0
[0.3-2.4]). Of the 77 remainder lesions, SUV was similar in
local lesions (n=14; MJ9=6.2±3, FCH=5.9±3.2, p=0.8),
while it was significantly higher for MJ9 in LN (n=39;
MJ9=9.3±8.3; FCH=5.7±4.8; p=0.004) and significantly
lower for MJ9 in bone lesions (n=24; MJ9=2.2±1.8;
FCH=6.1±3.6; p<0.0001). As compared to FCH, MJ9
missed 18/24 (75%) lesions in bone, 7/39 (18%) lesions
in LN, but detected 5/39 (13%) more lesions in LN. When
excluding bone lesions, MJ9 had +46% higher SUV than
FCH (n=53; MJ9=8.5±7.4; FCH=5.8±4.4; p=0.005).Con-
clusion: 68Ga-NODAGA-MJ9 uptake was greater than
18F-FCH PET/CT in local and lymph node lesions, while
18F-FCH seemed better for bone lesions in biochemical
relapse of prostate cancer patients.
OP299
A Novel Gallium-68-Labelled GRP Receptor Antagonist,
[68Ga]Sarabesin 3, for Prostate Cancer Imaging: First
Results in Therapy Naïve Primary Patients
I. L. Bakker1, A. C. Fröberg1, M. Busstra1, G. J. L. H. van
Leenders1, E. de Blois1, I. Schoots1, J. Veenland1, T. Maina2,
W. M. van Weerden1, B. Nock2, M. de Jong1; 1Erasmus MC,
Rotterdam, NETHERLANDS, 2National Center for Scientific
Research “Demokritos”, Athens, GREECE.
AIM: There is an unmet demand for more sensitive diagnostic
tools in patients with prostate cancer (PC), to improve staging
as well as tumour localisation in case of increased tumour
markers after treatment. Gastrin releasing peptide receptors
(GRPr), being overexpressed in PC but not in normal prostate
tissue or benign hyperplasia, could provide an excellent target
in PC. [68Ga]Sarabesin 3, a GRPr antagonist, was selected for
clinical translation after promising preclinical results in mouse
PC models, including high tumour uptake and favourable
tumour-to-background ratios. The aim of this trial is to validate
GRPr PET-CT imaging in patients with primary PC who are
scheduled for surgery. MATERIALS AND METHODS: As
yet, three patients with PC confined to the prostate have been
included; patients were imaged over a period of 3.5 h after
administration of [68Ga]Sarabesin 3 (147±14 MBq, 40±5
μg). PET-CT imaging included dynamic scanning, multiple
local images, and two total-body scans. The bladder was con-
tinually flushed, enabling optimal imaging of the prostatic re-
gion. PET-CT images were matched with the most recent MR
scans. Radiotracer stability, activity curves in blood and urine
as well as gastrin levels were measured. After prostatectomy,
the pathologist examined the tissue confirm tumour
localisations and autoradiography was performed to confirm
GRPr overexpression. RESULTS: [68Ga]Sarabesin 3 PET-CT-
scans showed focal uptake in the prostate first at 45min p.i.. At
earlier time points blood pool activity was too high to distin-
guish from focal accumulation. In all patients increased uptake
was seen corresponding to localisations of PC as determined
by pathology. One patient had a tiny tumour, which could only
be confirmed by a special biopsy procedure including 40 bi-
opsies; PC was found in only one needle core. Still, persistent
uptake was corresponding to this tiny lesion. In another patient
the MR identified unilateral tumour presence, while histology
confirmed results of the GRPr scan, showing tumour on both
sides. The GRPr-expressing pancreas showed high physiolog-
ical uptake. Diffuse and low uptake was seen in the whole
gastrointestinal tract and lower oesophageal and rectal sphinc-
ters. The liver showed almost no activity. Serial images and
urine specimens showed fast renal excretion. The compound
was very stable in blood and urine. Apart from some discom-
fort by the flush catheter, patients did not report any side ef-
fects. CONCLUSION: These first findings suggest
[68Ga]Sarabesin 3 PET-CT to have great potential as an imag-
ing tool in patients therapy naïve primary suffering from PC.
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OP300
Use of 18FDG-PET/CT to predict outcome in patient
with locally advanced pancreatic cancer
L. Locantore1, P. Mapelli1, E. Incerti1, P. Alongi2, V.
Gangemi3, P. Passoni4, N. Slim4, N. Di Muzio4, L. Gianolli1,
M. Picchio1; 1Nuclear Medicine Department, IRCCS San
Raffaele Scientific Institute, Milan, ITALY, 2University of Mi-
lano-Bicocca, Milan, ITALY, 3Nuclear Medicine Unit, Depart-
ment of Biomedical Sciences and of Morphologic and Func-
tional Images, University of Messina, Messina, ITALY, 4Ra-
diotherapy Department, IRCCS San Raffaele Scientific Insti-
tute, Milan, ITALY.
Aim. Despite the routinary use of chemotherapy (CH) in com-
bination with radiotherapy, patients with locally advanced
pancreatic cancer (LAPC) have a poor prognosis. Helical
tomotherapy (HTT) is a promising option for local control,
allowing a highly conformed radiation dose to the lesion, spar-
ing non-target organs. We investigated if routinary use of
18FDG-PET/CT (PET) could predict progression free survival
(PFS) in patients with LAPC. Materials and methods. Fifteen
patients with a mean age of 63 years (range: 45-81 years) were
enrolled and underwent to PET at basal time, after CH and
HTT treatment, for a total of 45 scans. Results were interpreted
in both a qualitative (visual examination) and semiquantitative
way (maximum and delta standard uptake value - SUVmax
and ΔSUV%). PET results were compared to clinical and
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radiological follow-up data (12 months). PFS using Kaplan-
Meier method and relative risk of progression (RRP) with Cox
regression analysis were estimated for all patients. A ΔSUV
cut-off of positivity for survival analysis was derived from
ROC curve analysis. Results. PET was positive in all patients
at basal time, in 10/15 after CH and in 11/15 after HTT.
SUVmax ranged from 2.3-13.4 (mean: 7.0) at basal time,
1.5-14.8 (mean: 5.0) after CH and 1.8-17.3 (mean: 4.9) after
HTT. ΔSUV values ranged from 31-88% (mean: 53%) after
CH and 11-79% (mean: 50%) after HTT. Twelve months
follow-up data showed stable disease in 8/15 and progression
of disease in 7/15 patients. On the basis of ROC analysis
results, a ΔSUV cut-off of threshold of 30% (ΔSUV30) was
chosen. PFS rates over 1-year in the PET group with
ΔSUV<30 after CH versus the PET group with ΔSUV>30
were 45% versus 53% (p= 0.360). PFS rates over 1-year in the
PET group with ΔSUV<30 after HTT versus the PET group
with ΔSUV>30 were 25% versus 75% (p= 0.075). Cox re-
gression analysis showed a high RRP for PET group with
ΔSUV<30 after HTT (HR 5.9; p= 0.064). Conversely, no
significant results was found on risk analysis for PET group
with ΔSUV<30 after CH. Conclusions. The routinary use of
PET after combined treatment demonstrated a predictive role
for therapy response assessment. ΔSUV% cut-off approach
might provide efficient risk stratification after HTT. Our re-
sults suggest a high prognostic value of PET using aΔSUV30
for HTT response assessment in prediction of RRP and PFS.
OP301
Predictive value of 18F-FDG PET/CT in patients
after primary radio-chemotherapy of head and nack
cancers.
I. SANDLER1, P. Castellucci1, R. Frakulli2, U. Caliceti3, G.
M. Lima1, J. J. Morigi1, A. Bellusci3, S. Cammelli2, S. Fanti1;
1Università di Bologna, Nuclear Medicine Unit, S.Orsola-
Malpighi Hospital, Bologna, ITALY, 2Università di Bologna,
Radiotherapy Unit, S. Orsola-Malpighi Hospital, Bologna, IT-
ALY, 3Università di Bologna, Head and Neck Unit , S. Orsola-
Malpighi Hospital, Bologna, ITALY.
Aims: The purpose of this retrospective study is to assess the
prognostic value of 18F-FDG PET/CT performed as treatment
response evaluation after primary concomitant radio-
chemotherapy (RT-CT) for locoregional advanced Head and
Neck squamous cell carcinoma (HNSCC). Methods: 151 pa-
tients, (108 males and 43 females, mean age 59 yo) underwent
18F-FDG PET/CT after RT-CT for HNSCC, between 2006-2013
to assess response treatment. The sites of HNSCC were oral
cavity (10%), nasopharynx (14%), oropharynx (53%), hypophar-
ynx (7%), larynx (7%), salivary glands (5%) and paranasal si-
nuses (4%). 18F-FDG PET/CT has been preformed from 6 to 36
weeks (median 21 weeks) after the end of RT-CT. Patients were
divided in three groups: 18F-FDG PET/CT performed from 6 to
14 weeks after the end of RT-CT (group-A; 31 patients), from 15
to 23 weeks (group-B; 89 patients) and from 24-36 weeks
(group-C; 31 patient). 18F-FDG PET/CT scans were performed
according to standard procedure then were visually analyzed by
two expert physicians and categorized as negative (“score-1”),
doubt negative (“score-2”), doubt positive (“score-3”) and posi-
tive (“score-4”). Patients were followed-up, based on clinic and
radiological and/or histological findings, up to 60 months and for
at least 12 months after end of therapy (median 38 months). 18F-
FDG PET/CT results were classified as true positive (TP), true
negative (TN), false positive (FP) and false negative (FN). Re-
sults: - Group A: showed “score-1” 14 patients, “score-4” 12
patients, therefore 18F-FDG PET/CT sensitivity 69%, specificity
77%, VPP 75%, VPN 71%, accuracy 0.73. This group showed
five doubt scans (16%) as “score-2”: two negatives and three
positives. No “score-3” - Group B: showed “score-1” 55 patients,
“score-4” 27 patients, therefore 18F-FDG PET/CT sensitivity
84%, specificity 98%, VPP 96%, VPN 91%, accuracy 0.93. This
group showed total seven (8%) doubt scans: three scans (3,5%)
as “score-2” (one negative and two positives) and four scans (4,
5%) as “score-3” (two negatives and two positives). - Group C:
showed “score-1” 24 patients, “score-4” 6 patients, therefore 18F-
FDG PET/CT sensitivity 100%, specificity 100%, VPP 100%,
VPN 100%, accuracy 1. This group showed only one doubt scan
(3%) as “score-2” that was find out to be negative. Conclusions:
According to our data, PET/CTwith 18F-FDG showed an excel-
lent prognostic value of treatment response to primary concomi-
tant RT-CT if performed at least after fourteen weeks following
the end of RT-CT. We observed also that the numbers of “doubt
scans” significantly decrease after fourteen weeks following the
end of RT-CT.
OP302
Predictive value of 18F-FDG PET/CT in restaging patients
affected by ovarian cancer: a multicenter study.
F. Caobelli1, P. Alongi2, L. Evangelista3, M. Rensi4, A.
Castello5, I. Laghai5, C. E. Popescu6, C. Dolci6, S. Seghezzi7,
Young AIMN Working Group; 1Hannover Medical School,
Hannover, GERMANY, 2University of Milano Bicocca,, Mi-
lan, ITALY, 3Istituto Oncologico Veneto, Padua, ITALY, 4Hos-
pital of Udine, Udine, ITALY, 5University of Florence, Flor-
ence, ITALY, 6Niguarda Hospital, Milan, ITALY, 7Hospital of
Treviglio, Treviglio (BG), ITALY.
Purpose: ovarian cancer is the eighth most common malignan-
cy among women and has a high mortality rate. Prognostic
factors able to drive an effective therapy are essential. 18F-
FDG PET/CT has been investigated in patients with epithelial
ovarian cancer and showed promise in diagnosing, staging,
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detecting recurrent lesions and monitoring treatment response.
Conversely, its prognostic role remains unclear. We aimed at
assessing the prognostic value of 18F-FDG PET/CT per-
formed in the restaging process in a multicentre study.
Methods: We evaluated 168 patients affected by ovarian car-
cinoma, who underwent a restaging 18F-FDG PET/CT. The
presence of local recurrences, nodal involvement and distant
metastasis was recorded as well as lesion dimensions, maxi-
mum and mean standardized uptake values (SUVmax and
SUVmean, respectively). Progression Free Survival (PFS)
and Overall Survival (OS) at 3 and 4 years were computed
by using Kaplan-Meier curves. Increased odds ratio was
assessed using Cox regression analysis testing all lesion pa-
rameters measured by PET/CT. Results: PFS was significantly
longer in patients with a negative than a positive restaging
PET/CT study (3- and 4-years PFS 64% and 53% vs. 23%
and 12%, respectively; p<0.001). Similarly, a negative study
was associated with a significantly higher OS rate after 4 years
of follow-up (67% vs. 25% in negative and positive group,
respectively; p<0.001). Nodal or distant involvement were al-
so independently associated with an increased risk of disease
progression (HR 1.6 and 2.2, respectively, p=0.003). More-
over, PET/CT showed an incremental prognostic value com-
pared to FIGO staging system, able to further stratify patient
risk within the same staging assignment. At ROC analysis, no
thresholds for semiquantitative parameters were predictive of a
worse outcome. Conclusion: 18F-FDG PET/CT has an impor-
tant prognostic value in assessing the risk of disease progres-
sion and mortality rate. An effective therapy planning might
therefore effectively rely on 18F-FDG PET/CT findings.
Semi-quantitative data were not proven to be an effective tool
to predict disease progression.
OP303
Early 18F-FDG uptake as a reliable imaging biomarker
of T790M-mediated resistance but not METamplification
in NSCLC
V. DeRosa1, F. Iommelli1, M.Monti2, C.Mainolfi2, R. Fonti1,
S. Del Vecchio2; 1Institute of Biostructures and Bioimages,
National Research Council, Naples, ITALY, 2Department of
Advanced Biomedical Sciences, University of Naples
“Federico II”, Naples, ITALY.
Aim: The two main mechanisms of resistance to EGFR tyrosine
kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC)
are the occurrence of T790M secondary mutation in the kinase
domain of EGFR andMETamplification.We previously showed
that 18F-FLT uptake is a reliable imaging biomarker of tumor
response in refractory NSCLC due to both mechanisms of resis-
tance. Here we tested whether 18F-FDG PET/CT is able to detect
the T790M- or MET-mediated resistance and to monitor the
reversal of such resistance by EGFR T790M or MET inhibitors
in tumor-bearing animals. Materials and Methods: Erlotinib-
resistant NSCLC cell lines (H1975 and H1993) were treated with
WZ4002, an EGFR T790M inhibitor, or the MET-inhibitor cri-
zotinib depending on themechanism of resistance. The levels and
phosphorylation status of key proteins in the glycolytic cascade
and oxidative phosphorylation were tested in response to treat-
ment along with 18F-FDG uptake. Then nude mice bearing
H1975 and H1993 xenografts were subjected to 18F-FDG PET/
CT scan before and after treatment (50 mg/kg p.o. for 3 days)
with erlotinib, WZ4002, crizotinib or vehicle. Three-
dimensional region of interest analysis was performed to
determine the percent change of 18F-FDG uptake in re-
sponse to treatment. At the end of imaging studies, tumors
were removed, counted and analysed for glycolytic and
mitochondrial proteins as well as signaling mediators. Re-
sults: H1975 cells showed a statistically significant reduc-
tion of 18F-FDG uptake in response to treatment with
WZ4002 (-61% ± 10%, p=0.02) whereas tracer uptake
remained unchanged in response to erlotinib. H1993
cells, despite their known MET-mediated resistance,
showed a decrease of 18F-FDG uptake in response to
erlotinib that became even stronger after treatment with
the MET inhibitor (-70% ± 11%, p=0.04). Western blot
analysis of glycolytic and mitochondrial proteins con-
firmed the different metabolic response of resistant
H1975 and H1993 cells to erlotinib. In agreement with
in vitro findings, imaging studies with 18F-FDG PET/CT
in H1975 tumor-bearing mice showed a strong reduction
of 18F-FDG uptake after treatment with WZ4002 where-
as an increase of 18F-FDG uptake was observed after
treatment with erlotinib. Conversely, H1993 tumors bear-
ing MET amplification showed a reduction of 18F-FDG
uptake after treatment with both crizotinib and erlotinib.
The reduction of in vivo 18F-FDG uptake was always
associated with downregulation of key glycolytic pro-
teins and upregulation of mitochondrial complexes in
excised tumors. Conclusion: 18F-FDG uptake is a reli-
able imaging biomarker of T790M-mediated resistance
and its reversal in NSCLC whereas it fails to detect
MET-mediated resistance.
OP304
Integrated 18F-FDG PET/MR imaging in the assessment
of soft tissue sarcoma: initial experience with surgical
and histopathological correlation
S. Vöö, D. Loeffen, R. Weijers, F. Mottaghy; Maastricht Uni-
versity Medical Center, Maastricht, NETHERLANDS.
Background. PET/MRI is an evolving hybrid imaging modality
which combines the inherent strengths of MR with a high soft-
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tissue contrast resolution and PET’s functional metabolic
capabilities.Goal. The objective of the present study was to eval-
uate whether integrated (18)F-FDG PET/MR imaging could im-
prove the diagnostic workup in patients with soft-tissue sarcoma
(STS) and its role in characterization and pre-operative staging of
STS in comparison toMR.Material andMethods. Eleven patients
(age range 42-72 years) with biopsy-proven STS who were re-
ferred for surgery were included in this prospective study. Pre-
operative FDG PET/MR was carried out in all patients with ac-
quisition of T1W, T2W, short tau inversion recovery (STIR), and
contrast-enhanced (ce) MR sequences. PET data were acquired
simultaneously with the MR scan after injection of 199±58MBq
of (18)F-FDG. In addition, a skull-to-knee PET/MR (DIXON
sequence) was acquired. Imaging results were correlated with
the surgical and histologic findings.Results. The most common
STS histologic type was malignant fibrous histiocytoma (30%).
With regard to tumor grading, MR-based findings were in agree-
ment with the PET findings in most of the cases (9/11, 81%). In 2
cases (19%) the metabolic findings on PETaccurately indicated a
low-grade STS, in agreement with histology and in contrast to the
high-grade tumor suggested on MR images (T2W, ceMR). Tu-
mor extent/invasiveness, as delineated on MR and PET,
corresponded to surgical and histopathologic findings in majority
of cases (7/11). However, in 4/11 cases the FDG-uptake on PET
extended beyond the tumor delineation on MR. Histologic anal-
ysis confirmed a larger gross tumor volume and a deeper tumor
invasiveness in the surrounding tissue in three cases, but reactive
inflammatory changes in one case. These yielded an overall stag-
ing accuracy of 64% forMR and 91% for the hybrid PET/MR. In
addition, PET/MR imaging revealed the presence of unexpected
distant metastases in 18% of cases.Conclusion. MR alone is a
robust modality in staging of STSs. However, combining (18)F-
FDG PETwithMR imaging on a hybrid PET/MR system results
in greater accuracy with regard to overall staging and tumor de-
lineation. Therefore, the combined modality of simultaneous
PET/MRI is a valuable noninvasive diagnosis tool that could
improve the clinical (pre-operative) decision in STS.
OP305
Evaluation of tumor hypoxia prior to and
during radiotherapy in intermediate-risk prostate cancer
using 18F-Misonidazole PET/CT
M. Dore1,2, S. Supiot1,2, C. Cheze-Le-Rest3, L. Ferrer1,2, G.
Delpon1,2, M. Hatt4, S. Guerif3, D. Visvikis4, C. Rousseau1,2;
1Institut de Cancerologie de l’ouest Nantes, Saint Herblain,
FRANCE, 2INSERM UMR 892 CRCNA, Nantes, FRANCE,
3University Hospital, Poitiers, FRANCE, 4INSERM UMR
1101 LaTIM, Brest, FRANCE.
Aim: Since hypoxia is a major factor of radioresistance of pros-
tate cancer (PC), we prospectively assessed hypoxia prior to and
during radiotherapy treatment using 18F-Misonidazole (FMISO)
PET/CT.Method: Inclusion criteria were intermediate-risk PC pa-
tients planned to receive high-dose (>74 Gy) radiotherapy to the
prostate without hormonal treatment. Prior to radiotherapy, all
patients underwent a FMISO1 PET/CT (45 min dynamic imag-
ing, and late static imaging at 2,5h and 3,5h post-injection of 4
MBq/kg), as well as a trans-pelvic coil 1.5 T MRI and
18FCholine-PET. All images were co-registered using
iPLANNET (Brainlab®). In FMISO1-positive patients, a
second FMISO2 PET/CT was acquired after a minimal
delivered dose of 18 Gy. FCholine and FMISO-positive
volumes were segmented by the automated Fuzzy Local-
ly Adaptive Bayesian (FLAB) method. In FMISO1-pos-
itive patients, a dynamic analysis of early tumor uptake
was performed. Results: Out of the 27 patients (median
age 76 [65-81]), 7 and 9 patients were considered pos-
itive at 2.5h FMISO1 PET/CT and 3.5h FMISO1 PET/
CT respectively. Median SUVmax and SUVmax tumor to
muscle (T/M) ratio were respectively 3.4, 3.6 [1.9-8.2]
for 2.5h FMISO1 PET and 3.2, 4.4 [2.2-15.6] for 3.5h
FMISO1 PET/CT. Median FMISO1-positive volume was
1.1 ml [0.4-2.4]. Time-activity curves extracted from dy-
namic images allowed to differentiate hypoxic volume
from urine artifacts in 3 patients who had underwent
transurethral resection of the prostate due to an abrupt
rise of the curve at 20 min. During radiotherapy,
FMISO2-positive volumes were no longer detected in
5/9 patients, and FMISO2-positive volume significantly
decreased in the remaining 4 patients (median volume
0.7 ml [0.3-1.8]). A weak correlation was observed be-
tween FMISO1-positive and MRI-, FCholine-positive
areas (median Dice’s coefficient=0.03 and 0.01 respec-
tively). Conclusion: To the best of our knowledge, this
is the first study showing that a small FMISO-positive
volume can be detected in one third of intermediate-risk PC
patients. Dynamic analyses could eliminate false positive areas
related to urine excretion. Decreased hypoxic volumes were
observed in all FMISO-positive patients, which suggests that
fractionated radiotherapy induces tumor reoxygenation.
OP306
Multimodal imaging agents for sentinel node mapping
as a means to (re)connect nuclear medicine to advances
made in robot assisted surgery.
G. H. KleinJan1,2, N. S. Van den Berg1,2, E. Wit2, E. Vegt2, F.
W. B. Van Leeuwen1, H. G. Van der Poel2; 1Leiden University
Medical Centre, Leiden, NETHERLANDS, 2NKI-AVL, Am-
sterdam, NETHERLANDS.
Introduction: Prostatectomies and complementary extended
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pelvic lymph node dissection (ePLND) of (sentinel)
lymph nodes (LN) at risk of containing metastases are
increasingly being performed using high-tech robotic
approaches. Although this technological evolution has
clear surgical advantages, the physical nature robotic
systems limits integrated use of routine radioguided
surgery technologies. This limitation has driven robotic
engineering efforts towards the integration of fluores-
cence rather than radioguidance. We here present an
attempt to reconnect the robotic developments to nucle-
ar medicine, by making use of a hybrid tracer (radio-
active and fluorescent) that allows for fully integrated
preoperative nuclear imaging and intraoperative fluores-
cence guidance towards sentinel nodes (SN). Methods:
Fifty patients with a Briganti nomogram-based risk
>10% of lymph node (LN) metastases were included.
After indocyanine green (ICG)- 99mTc-nanocolloid in-
jection, nuclear imaging was performed to locate the
SN(s). The 3D information of the SPECT-CT was used
by the surgeon to plan the operation with a da Vinci Si
robotic system equipped with a Firefly near-infrared
fluorescence endoscope. Intraoperatively, fluorescence
guidance was used to optically identify the preopera-
tively defined SN(s); fluorescence imaging (FI) could
be conveniently (dis)activated during the resection
using a simple hand-switch. The number and location
of the intraoperatively identified SNs, the in vivo and
ex vivo fluorescence-based SN identification rate and
radioactivity measurements, and the tumor status of
SNs and LNs removed with ePLND were recorded
and analyzed. Results: Based on SPECT-CT imaging a
total 201 SNs (median 4) were identified of which 54
(26.9%; median 1) were located outside the standard
ePLND. During surgery, 34 SNs could not be resected
based on their location (e.g mesorectal fascia) and/or
the risk of complications. FI was integrated into the
surgical process and thereby helped to identify 15 ad-
ditional SNs not previously identified on preoperative
imaging. In total, 182 SNs were intraoperatively ex-
cised of which 82% were identified with the Firefly
in vivo (ex vivo: 98%) could be identified with FI.
All excised SNs were radioactive. With ePLND an ad-
ditional 589 LNs were removed (median 10). Histo-
pathological evaluation revealed tumor-positive SNs in
26% of patients (n=13). In 11 of these, the SN(s) was
the only tumor-positive node. In two patients besides a
tumor-positive SN, additional tumor-positive LNs were
found. In one node positive patient, the SN was nega-
tive (false positive rate 7%). Conclusion: With the hy-
brid tracer preoperative SPECT/CT imaging information
can be integrated into state-of-the-art surgical robotics,
where i t complement s f luo re scence-based SN
identification.
OP307
68Ga-OPS202/177Lu-OPS201, a high performance
theranostic pair of radiolabelled somatostatin antagonists
for PET imaging and radionuclide therapy: translational
aspects
G. P. Nicolas1, R. Mansi1, F. Kaul1, S. Vomstein1, J.
Kaufmann2, H. Bouterfa2, D. Wild1, M. Fani1; 1University
Hospital Basel, BASEL, SWITZERLAND, 2OctreoPharm
Sciences GmbH, BERLIN, GERMANY.
Aim: To evaluate the somatostatin receptor (sst2)-antagonist
Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-
NH2 (JR11), for PET imaging and peptide receptor radionu-
clide therapy (PRRT) of neuroendocrine tumours (NETs) and
address translational aspects related to clinical applications.
Materials and Methods: Comprehensive in vivo evaluation of
177Lu-OPS201 (177Lu-DOTA-JR11) was performed in HEK-
hsst2 xenografts comparatively to 177Lu-DOTA-TATE. The
influence of the peptide mass was assessed by a mass escala-
tion study in HEK-hsst2 and AR42J xenografts. Various
biodistribution modifiers were tested, including kidney protec-
tion agents and i.v. injections of octreotide. In parallel, a phase
I/II clinical trial was initiated, comparing two microdoses (15
and 50 μg) of 68Ga-OPS202 (68Ga-NODAGA-JR11) PET/CT
with 68Ga-DOTA-TOC in the same 12 patients with NETs
(ClinicalTrials.gov NCT02162446). Results: 177Lu-OPS201
showed 2.6-times higher tumour dose and 1.8-fold higher kid-
ney dose, resulting in 34% more favourable tumour-to-kidney
dose ratio compared to 177Lu-DOTA-TATE. Biodistribution
and nanoSPECT/CT showed that escalating the injected pep-
tide mass of 177Lu-OPS201 from 10 to 200 pmol drastically
improved the tumour-to-background uptake ratios in HEK-
hsst2 and AR42J xenografts: tumour-to-liver increased from
16 to 52 and from 30 to 54, respectively and tumour-to-bone-
marrow from 25 to 97 and from 23 to 93, respectively, 4h p.i.
However, tumour-to-kidney ratios remained mostly un-
changed. Pre-injection of lysine, gelofusin or combination of
both decreased the kidney uptake of 177Lu-OPS201 about
40%. Interestingly, 200-fold excess of octreotide seemed to
have no influence on the distribution of the antagonist, includ-
ing the tumour uptake. In patients, both 68Ga-OPS202 doses
showed improved tumour-to-background ratios compared to
68Ga-DOTA-TOC PET/CT. Especially, matched liver metas-
tases (visible on all 3 scans) showed a factor of 2 increase in
tumour-to-liver-background uptake ratios (mean±σ) 4.4±3.5
(15 μg)/4.9±3.9 (50 μg) vs 2.1±1.5 for 68Ga-DOTA-TOC.
The 50 μg dose seemed to further decrease the uptake of
68Ga-OPS202 in the sst2-positive organs compared to 15 μg,
e.g. in the spleen (11.5±5.1/10.3±3.0), pancreas (2.7±1.1/2.3
±0.7) and intestine (3.6±1.5/3.0±0.9), compared to 68Ga-
DOTA-TOC (27.9±11.5, 4.1±1.5 and 5.5±1.2, respectively).
Conclusion: Increased image contrast of 68Ga-OPS202, along
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with an advantageous tumour-to-kidney dose ratio of 177Lu-
OPS201, is expected to improve sensitivity and diagnostic
accuracy of PET/CT imaging and safety window of PRRT in
NET patients, compared to the agonists. An optimized peptide
mass of the radiolabelled antagonist is likely to further enhance
the performance of this promising theranostic pair. First in vivo
pre-clinical data indicated that, when using sst2 antagonists for
PRRT, octreotide treatment may not be interrupted.
OP308
First results with Lu-177-PSMA617 in targeted
radionuclide therapy of patients with metastatic
hormone-refractory prostate cancer
C. Kratochwil1, F. L. Giesel1, A. Afshar-Oromieh1, M.
Benešová2, W. Mier1, M. Eder2, K. Kopka2, U. Haberkorn1;
1University Hospital Heidelberg, Heidelberg, GERMANY,
2Division of Radiopharmaceutical Chemistry, German Cancer
Research Center (DKFZ), Heidelberg, GERMANY.
Objectives:We report our clinical experience with PSMA
targeted radionuclide therapy of patients with metastatic
hormone-refractory prostate cancer in regard to toxicity and
treatment effects using Lu-177-PSMA617, a PSMA ligand
consisting of a DOTA-chelate tagged to the Glu-urea-Lys mo-
tif via an aromatic linker which further improves tumor accu-
mulation while reducing kidney uptake.Methods:We retro-
spectively evaluate 35 patients that received therapy with Lu-
177-PSMA617 in our department. All patients were hormone-
and taxan-refractory or taxanes were contraindicated and the
oncological status was progressive. A PSMA-positive tumor
phenotype was previousely validated with PSMA-PET/CT
(Ga-68-PSMA-11, Glu-urea-Lys-Ahx-HBED-CC), respec-
tively. Acute hematotoxicity was evaluated with lab tests and
clinical exam according to CTCEA criteria and response was
evaluated with PSA sampling and radiologic follow-
up.Results:In patients with multifocal bone lesions but no
bone marrow-carcinosis (no superscan in bone scintigraphy)
6 GBq Lu-177-PSMA617 every 2 months was found to be
tolerable in regard to hematotoxicity. Other common side ef-
fects were xerostomia, less common fatigue and seldom un-
specific intestinal disorders. Dosimetry presents kidney doses
of less than 1 Gy per 1 GBq Lu-177-PSMA617 and no renal
toxicity was observed, yet. Five patients, who were in end-
stage situation when receiving the therapy, died before
follow-up imaging. PSA-response was observed in the major-
ity of the patients. After 3 cycles (6-9 months) PSA progres-
sion re-occurred in ca. 50% of the patients. In the other 50%
sustainable biochemical and radiologic response was observed
including one patient with complete remission in PSMA-
PET.Conclusions:Radionuclide therapy with Lu-177-
PSMA617 demonstratesa favorable therapeutic range and
can induce biochemical as well as radiologic responses with
moderate acute toxicity. Clinical trials evaluating PFS and OS
are encouraged.
OP309
Baseline 18F-FDG PET/CT Predicts Progression-Free
Survival After Radium-223
E. Etchebehere, J. Araujo, G. Ray, D. Milton, N. Swanston,
H. Macapinlac, E. Rohren; The University of Texas MD An-
derson Cancer Center, Houston, TX, UNITED STATES.
AIM: The purpose of this study was to evaluate if whole-body
18F-FDG PET/CT is able to predict which patients will benefit
from Radium-223 therapy (Ra-223). MATERIALS AND
METHODS: We retrospectively reviewed 26 histologically
confirmed hormone-refractory prostate cancer patients (52-
84 y old; mean 69 ± 9 yrs.) with bone metastases (without
visceral metastases). The patients were submitted to an 18F-
FDG PET/CT scan prior to Ra-223. Overall survival (OS) was
the primary end point. Secondary end points were progression-
free survival (PFS) and bone event-free survival (BeFS). We
evaluated the presence of nodal metastases, the total number of
radium cycles (RaTot) and the following 18F-FDG PET/CT
parameters: the highest SUVmax of a bone metastasis (h-
SUVmax), the TLG of bone metastases (TLGBone) and TLG
of bone and nodal metastases (TLGAll). RESULTS: The me-
dian follow-up time was 6.14 months (0.36-9.72 months).
Eight (31%) patients presented nodal metastases prior to Ra-
223. Fourteen (54%) patients received all 6 Ra-223 cycles,
three (12%) were still in progress and 9 (35%) discontinued
Ra-223. Reasons for withdrawal from Ra-223 were: progres-
sion (n=6), hematologic toxicity (n=1), declining ECOG status
(n=1) and/or a bone event (n=1). During Ra-223, four patients
died, 11 (42%) progressed and six (23%) had a bone event.
The median OS was not reached (less than 50% of the patients
died), the median PFS was 5.91 months and the BeFS was
8.61months. In a univariate model, RaTOTwas associated with
OS (HR=0.38; p=0.018), PFS (HR=0.55; p<0.001) and BeFS
(HR=0.45; p=0.001). Each additional cycle of Ra-223 was
associated with a 62% reduction in the risk of death, a 45%
reduction in risk of progression or death and a 55% reduction
in risk of experiencing a bone event or death. PFS was signif-
icantly associated with hSUVmax (HR=1.39; p=0.002) and
marginally associated with TLGBone (HR=1.69; p=0.0520)
and TLGAll (HR=1.70; p=0.051). A hSUVmax cutoff ≥ 5.6
(p=0.003) and a TLGBone cutoff ≥ 240 (p=0.006) separated
patients with a shorter PFS. BeFS was not associated with
any of the FDG-PET/CT parameters nor with the presence of
nodal metastases. CONCLUSIONS: Baseline 18F-FDG PET/
CT is able to predict PFS during Ra-223. A one-unit increase
in hSUVmax was associated with a 39% increase in risk of
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progression or death. Patients with hSUVmax below 5.6 had a
longer progression-free survival. More Ra-223 cycles were
beneficial and reduced the risk of death, progression and the
risk of a bone event.
OP310
64Cu-ATSM PET/CT in solid tumours: a prognostic
evaluation for disease outcome
E. Lopci1,2, I. Grassi3, S. Cambioli3, A. Gamboni4, F. Salvi5,
G. Cicoria3, F. Lodi3, C. Dazzi6, S. Mattioli7, S. Fanti3;
1Humanitas Clinical and Research Hospital, Milano, ITALY,
2Alma Mater Studiorum University, Bologna, ITALY, 3Uni-
versity Hospital S. Orsola-Malpighi, Bologna, ITALY,
4Ospedale degli Infermi, Faenza, ITALY, 5Ospedale Bellaria,
Bologna, ITALY, 6Istituto Oncologico Romagnolo, Ravenna,
ITALY, 7Alma Mater Studiorum, Bologna, ITALY.
Purpose: 64Cu-ATSM is a well-known PET radiopharmaceu-
tical applied for tumour imaging of hypoxia. One of the ad-
vantages of this compound compared to other hypoxia-avid
tracers is the high tumour-to-background signal offered, which
guaranties a facilitated tumour delineation. The current study
aimed at analyzing optimal semi-quantitative and quantitative
parameters obtained by 64Cu-ATSM PET/CT in the same co-
hort of patients with special focus on their correlation to dis-
ease outcome. Materials and Methods: A prospective recruit-
ment of 18 consecutive patients (M:F=13:5; mean age 60.7
years) with locally advanced NSLCL (n=7) or head and neck
cancer (HNC) was performed. Each participant received 105-
500MBq of tracer according to body size and was scanned in a
3D-mode on a PET/CT tomograph 60 minutes after tracer
injection. PET images were reconstructed and visualized on
a GE Advanced 4.6 workstation for the definition of semi-
quantitative and quantitative parameters: SUVmax, SUVratio-
to-muscle, SUVmean, hypoxic volume (HV) and hypoxic burden
(HB=HV*SUVmean). These data were subsequently correlated
to disease outcome, expressed in terms of progression-free
survival (PFS) calculated on a follow-up period of median
14.6 months. Results: All patients showed a moderately to
highly increased uptake of 64Cu-ATSM in tumour lesions,
with a mean SUVmax of 5.2 (range 1.9-8.3), mean SUVratio
of 4.4 (range 1.6-6.8) and SUVmean of 2.8 (range 1.0-6.8).
Also a broad range of HVand HB was defined, with as mean
values 99.3cm3 (range 2.5-453.7) and 301 (4.2-1134), respec-
tively. The ROC analysis identified as reference cut-offs with
respect to disease outcome the following values: SUVmax >2.5
(AUC 0.57; sens. 88.9%; spec.50%), SUVratio ≤4.4 (AUC
0.60; sens. 50; spec. 83.3%), SUVmean >1.5 (AUC 0.61; sens.
88.9%; spec. 50%), HV >160.7cm3 (AUC 0.61; sens. 55.6%;
spec. 75%), HB >160.7 (AUC 0.67; sens. 58.3%;
spec.83.3%). In our cohort, tumour hypoxic burden (HB)
showed a statistically significant difference in terms of mean
values on the ANOVA test with respect to disease progression
(p=0,038). On univariate analysis, the Cox regression con-
firmed these findings and showed a significant correlation to
PFS for HB (p=0.05) and tumour hypoxic volume (p=0.019).
Conclusions: In our cohort, the definition of optimal semi-
quantitative and quantitative parameters on 64Cu-ATSM
PET/CTappears feasible and in line with previously published
data. However, when considering the prognostic role with
respect to disease outcome, the more robust parameters are
represented by hypoxic tumour volume (HV) and hypoxic
burden (HB).
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OP322
GLP-1 analogue liraglutide prevents decline of brain
glucose metabolism in Alzheimer’s Disease: Randomized,
placebo-controlled double-blinded clinical trial
M. Gejl1, L. Egejord2, A. Møller1, S. B. Hansen1, K. Vang1,
A. Rodell1, H. Brændgaard1, H. Gottrup1, A. Schacht1, N.
Møller1, B. Brock1, J. Rungby2, A. Gjedde3; 1Aarhus Univer-
sity Hospital, Aarhus, DENMARK, 2Aarhus University, Aar-
hus, DENMARK, 3University of Copenhagen, Copenhagen,
DENMARK.
Introduction: Type 2 Diabetes Mellitus (T2D) increases the risk
of Alzheimer’s disease (AD) and vice versa. Suggested common
pathophysiological mechanisms include deficient insulin and
glucagon-like-peptide-1 (GLP-1) signalling. In rodent models
of AD, the GLP‐1 receptor agonist liraglutide limits amyloid
(Aβ) deposition and inflammation, blocks memory deteriora-
tion, and may normalize glucose consumption. As a surrogate
marker of synaptic dysfunction and neuronal activity,
[18F]fluorodeoxyglucose ([18F]FDG) uptake in brain is sensi-
tive to disease progression. The decline of the cerebral metabolic
rate of glucose (CMRglc) is closely related to cognitive impair-
ment. We predicted that treatment with liraglutide would reduce
the accumulation of Aβ and improve CMRglc measured with
positron emission tomography (PET) of AD patients. Materials
and methods: In this 26-week, randomized, double-blind,
placebo-controlled trial, we randomized 38 patients with moder-
ately advanced AD to treatment either with liraglutide (n=18) or
with placebo (n=20) as add-on medication. We mapped the
changes of regional Aβ loads and cerebral blood flow (CBF)
values in brain from the early and late phases of tracer Pittsburgh
compound B ([11C]PIB) uptake and retention in brain, and the
changes of CMRglc from the uptake of FDG, bothwith PET.We
also monitored changes of cognition by means of the WMS-IV
scale. Results: During the 26 weeks, the [11C]PIB retention
increased significantly in the temporal lobes of both placebo (P
= 0.04) and liraglutide groups (P = 0.04), and in the occipital
lobe of the liraglutide-treated group (P = 0.04), but the increases
did not differ between the two groups (P ≥ 0.38). The expected
correlation between values of CMRglc and CBF, confirmed at
baseline and in the placebo-treated patients, was absent in pa-
tients treatedwith liraglutide. TheCMRglc declined significantly
in the placebo group (P<0.05) in precuneus (P = 0.009), and the
parietal (P = 0.04), temporal (P = 0.046), and occipital lobes (P =
0.009), and in cerebellum (P = 0.04). In contrast, patients treated
with liraglutide had a numerical, albeit insignificant, increase of
CMRglc after the six months of treatment. Cognition was un-
changed during the trial in both groups. Conclusion: In AD
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patients, liraglutide treatment prevented the decline of CMRglc
seen in placebo-treated patients where it signifies cognitive im-
pairment, synaptic dysfunction, and disease evolution. We ten-
tatively ascribe the loss of CBF-CMRglc coupling by liraglutide
to altered lactate signalling in the neurovascular unit.
OP323
A randomized, controlled, multicenter, international study
of the impact of florbetapir (18F) PET amyloid imaging
on patient management and outcome
M. Pontecorvo1, M. Grundman2, B. Dubois3, F. Nobili4, C.
Sadowsky5, A. McGeehan1, M. Lowrey1, A. Dudek1, M. Flit-
ter1, G. Dell’Agnello6, A. Chevrette7, W. Deberdt7, A. Arora1,
M. D. Devous Sr1, M. Mintun1; 1Avid Radiopharmaceuticals,
Philadelphia, PA, UNITED STATES, 2Global R&D Partners,
LLC and University of California, San Diego, San Diego, CA,
UNITED STATES, 3Salpêtrière Hospital, Paris, FRANCE,
4University of Genoa (DINOGMI), Genoa, ITALY, 5Nova
SE University, Fort Lauderdale, FL, UNITED STATES, 6Eli
Lilly Italia, Sesto Fiorentino, ITALY, 7Eli Lilly France, Paris,
FRANCE.
Aim: The study evaluated the impact of amyloid PET on patient
management and outcomes in a multicenter, randomized, con-
trolled study.M ethods: Physicians in France, Italy and the US
identified patients seeking diagnosis for MCI or dementia, where
AD was considered a possible (<85% certain) cause. They re-
corded a working diagnosis and management plan including any
plans for diagnostic and neuropsychological testing, follow-up
and referral visits, and any medications planned to improve cog-
nition. Patients underwent a florbetapir PET scan and were then
randomized to either immediate or delayed (1 year) feedback
regarding amyloid status (positive: Aβ+, negative: Aβ-). Patients
returned after 3 months and the physician updated the diagnosis
and constructed a summary of actual management, including
neuropsychological and diagnostic testing actually performed,
followup/referral visits that occurred and medications actually
used to treat cognitive impairment since the post-scan visit. Pa-
tients returned to the center one year post-baseline for assessment
of patient and caregiver outcome. Change in patient cognitive
status was assessed with the ADAScog (investigators were
blinded to the baseline ADAScog). Patient and caregiver health
outcomes and quality of life were assessed at both 3 months and
one-year with the RUD, EQ-5D, Geriatric Depression, QoL-AD,
Zarit Burden and the Self Efficacy for Managing Dementia
scales. It was hypothesized that outcomes would be worse for
Aβ+ than for Aβ- patients (i.e., reflecting the impact of
Alzheimer’s disease) and that this effect might be mitigated for
Aβ+ subjects in the immediate feedback group. Results: A total
of 618 subjects were randomized to the immediate (308) or to the
delayed (310) PET feedback arms, including 174 subjects in
France, 221 in Italy and 223 in the US. 599 completed the 3
month and 560 completed the one-year follow-up visits, with
the last visit conducted in April 2015. Analyses are ongoing.
Preliminary results indicate that the percentage of patients for
whom the actual management composite observed at 3 months
was different from the baseline management plan (the protocol
specified primary outcome) was significantly greater for the
group that received immediate feedback regarding amyloid status
than for those with delayed feedback. Three month and 1 year
results will be presented for both the study as a whole and for
individual European countries. Conclusions: This is the first large
multicenter randomized controlled study of the clinical impact
of amyloid PET and may help guide the use of amyloid
PET imaging at both the global and country level.
OP324
18F-Florbetaben PET Imaging of Morphologically
Distinct Amyloid β Deposits
O. Sabri1, A. M. Catafau2, H. Barthel1, J. Seibyl3, B. Ghetti4,
J. Leverenz5, J. W. Ironside6, S. Bullich2, W. Schulz-
Schaeffer7, A. Hoffmann8; 1Leipzig University, Leipzig,
GERMANY, 2Piramal Imaging, Berlin, GERMANY, 3IND,
New Haven, CT, UNITED STATES, 4Indiana University
School of Medicine, Indianapolis, IN, UNITED STATES,
5Cleveland Lou Ruvo Center for Brain Health, Cleveland,
OH, UNITED STATES, 6University of Edinburgh, Edinburgh,
UNITED KINGDOM, 7Georg August University Göttingen,
Göttingen, GERMANY, 8Bayer Pharma, Berlin, GERMANY.
Aim: Post mortem histopathology is still regarded as gold
standard to diagnose Alzheimer’s disease (AD). Morphologi-
cally distinct amyloid β(Aβ) deposits, such as diffuse or neu-
ritic Aβ plaques (DIFF, NEUR), and vascular Aβ (VASC)
may be present in this disorder. Aβ PET imaging recently
emerged as a promising alternative to potentially shift the gold
standard AD diagnosis to in vivo. 18F-Florbetaben (FBB) has
been validated as a biomarker of NEUR. It was the aim of this
project to investigate the impact of the different forms of Aβ
deposits on FBB PET scans. Materials and methods: Brain
tissue was collected from 87 end-of-life patients (age 80
±10yrs; 64 AD, 14 other dementia, 9 non-demented) who
underwent a FBB PET scan before death. Aβ immunohisto-
chemistry (IHC) was used for assessment of VASC. Aβ IHC
and Bielschowsky silver stain were used for assessment of
NEUR and DIFF in frontal, occipital, anterior cingulate and
posterior cingulate cortices. From the total of 87x4=348 sam-
ples, 329 were finally assessed, and classified as Aβ absent
(none or sparse) or present (moderate or frequent). Cortical
standardized uptake value ratios (SUVRs) were obtained in
all regions of interest (ROIs) using cerebellar grey matter as
reference region. A linear regression model was fitted for each
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S133
ROI as: SUVR=a0+an×n+ad×d+av×v, where a0, an, ad, av
are constants, and n=NEUR, d=DIFF and v=VASC. n, d,
and v were assigned two values: 0=Aβ absent; 1=Aβ present.
Results: In ROIs with high frequency of Aβ (frontal, posterior
cingulate cortex), both DIFF (ad=0.32 and 0.42) and NEUR
(an=0.27 and 0.21) contributed significantly to the SUVR. In
ROIs with low frequency of Aβ (occipital, anterior cingulate
cortex), only DIFF contributed significantly to the SUVR
(ad=0.24 and 0.55). The presence of VASC contributed signif-
icantly to the SUVR only in the occipital ROI (av=0.13). Con-
clusion: There was a significant impact of DIFF on FBB
SUVRs in brain regions with low Aβ load, supporting the
use of FBB in detecting early stages of Aβ deposition. The
impact of VASC on FBB SUVRs was only significant in the
occipital cortex. These results underline the importance of
measuring the topographic distribution of Aβ aggregates,
and suggest potential utility of FBB in detecting cerebral Aβ
angiopathy. Research support: Piramal Imaging, Berlin,
Germany
OP325
18F-Florbetaben beta-amyloid PET scan quantification:
Do cerebellar plaques influence SUVR?
A. M. Catafau1, S. Bullich1, J. Seibyl2, H. Barthel3, B.
Ghetti4, J. B. Leverenz5, J. W. Ironside6, W. J. Schulz-
Schaeffer7, A. Hoffmann8, O. Sabri3; 1Piramal Imaging
GmbH, Berlin, GERMANY, 2Molecular Neuroimaging,
New Haven, CT, UNITED STATES, 3Leipzig University,
Leipzig, GERMANY, 4Indiana University School of Medi-
cine, Indianapolis, IN, UNITED STATES, 5Puget Sound
Health Care System and University of Washington, Seattle,
WA, UNITED STATES, 6University of Edinburgh, Edin-
burgh, UNITED KINGDOM, 7Georg-August University
Göttingen, Göttingen, GERMANY, 8Bayer Pharma AG, Ber-
lin, GERMANY.
Aim: Standardized uptake value ratios (SUVR) using cerebel-
lar grey matter as the reference region are commonly used for
quantification of 18F-Florbetaben (FBB) scans. However, cer-
ebellar plaques may be present in Alzheimer disease (AD).
The aim of this study was to assess the influence of cerebellar
plaques in FBB SUVR, when using cerebellar grey matter as
the reference region. Materials and methods: Cerebral (frontal,
occipital, anterior and posterior cingulate) cortex and cerebel-
lar cortex tissue from 87 end of life patients (64 AD, 14 other
dementia, 9 non-demented aged volunteers; 80.4±10.2 yrs)
who unde rwen t a FBB PET be fo r e de a t h wa s
neuropathologically assessed using the Bielschowsky silver
stain and Amyloid β (Aβ) immunohistochemistry. Neuritic/
cored and diffuse plaques were rated as absent, sparse, mod-
erate and frequent. Cerebral cortical SUVRs were compared
among brains with different cerebellar plaque loads. Results:
None from the 83 evaluable cerebellar samples showed fre-
quent plaques. Sparse diffuse plaques were found in 33 sam-
ples, andmoderate diffuse plaques in 5. Only 1 sample showed
both sparse neuritic/cored and sparse diffuse plaques. Subjects
with higher cerebellar plaque loads showed higher cerebral
cortical Aβ loads and higher cerebral cortical standardized
uptake values. Thus, cerebral cortical SUVRs significantly
increased with cerebellar plaque load (range from 1.36 (cere-
bellar plaques absent) to 1.86 (cerebellar plaques moderate)
across regions, all p values <0.004). However, in cerebral cor-
tical regions with moderate or frequent Aβ plaques no signif-
icant SUVR differences were found among brains showing
different cerebellar plaque loads (all p values >0.39). Conclu-
sions: In brains with higher cerebral cortical Aβ loads, cere-
bellar plaques were found in 47% of cases, mostly as sparse
diffuse plaques (40%). The presence of cerebellar plaques did
not influence the SUVRs in subjects with moderate or frequent
cortical Aβ. Therefore, the effect of cerebellar plaques in FBB
SUVR appears to be negligible even in advanced stages of AD
with a high cortical Aβ load.
OP326
Clinical [18F]Florbetaben-PET Imaging - Benefit of Early
Acquisition
S. Daerr1, M. Brendel1, C. Zach1, A. Danek1, H. Barthel2, O.
Sabri2, P. Bartenstein1,A. Rominger1; 1University ofMunich,
Munich, GERMANY, 2University of Leipzig, Leipzig, GER-
MANY.
Objectives: In the last few years [18F]-labelled amyloid PET
radiotracers have been developed and recently received clini-
cal approval. We now report on our experience with a heter-
ogenous patient cohort using [18F]Florbetaben (FBB) PET. A
major goal was to investigate the benefit of an additionally
performed early post injection acquisition of the FBB-PET.
Methods: All subjects for amyloid imaging were recruited in
a clinical setting. Aside from undergoing a detailed neuropsy-
chiatric test battery, collection of biomarkers (MRI, CSF,
FDG-PET) was performed as well. Furthermore 300 MBq
[18F]Florbetaben were injected i.v. and PET scans were rou-
tinely acquired 90 min p.i., and an early acquisition starting
just after injection was performed in a subset of patients. Vi-
sual comparison and semiquantitative correlation analyses
were performed between FDG- and early FBB uptake. Re-
sults: A total of 105 patients (mean age 70.3±9.5y) were
scanned. In a subset of 44 patients an early acquisition of the
FBB-PETcould be performed, in 35/44 patients the individual
FDG-PETwas available. In 16/35 cases the regularly acquired
amyloid PET was read negative, 19/35 cases were amyloid-
positive. When the early acquisition of FBB was processed in
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Neurostat and compared to a normative database, the visual
interpretation resembled the pattern of the individual FDG-
PETs, irrespective of the amyloid-status in the late FBB-scans.
The semiquantitative correlation analyses ranged fromR=0.78
to R=0.94 (p<0.01) in different brain regions assessed, alto-
gether resembling good-to excellent correlation features be-
tween early FBB and FDG-metabolism. Conclusions: We re-
port on the clinical use of Florbetaben-PET in a non-selected
patient cohort. Early [18F]Florbetaben acquisitions as a
perfusion-like marker closely resembled FDG-PET findings.
These findings need to be further investigated in a larger pa-
tient cohort, but could potentially substitute an additional
FDG-PET scan in the future.
OP327
Resveratrol in Alzheimer’s disease: a PIB positron
emission tomography/computed tomography study
A. Damian1, A. de la Fuente2, G. Castellano3, E. Savio2, P.
Buccino2, B. Aguiar4, A. Quagliata1, F. Cano3, M. Gonzalez2,
S. Dansilio4, A. Kmaid5, I. Savio5, H. Engler2; 1Uruguayan
Centre of Molecular Imaging (CUDIM); Nuclear Medicine
Centre, University of the Republic, Montevideo, URUGUAY,
2Uruguayan Centre of Molecular Imaging (CUDIM), Monte-
video, URUGUAY, 3Department of Social and Preventive
Medicine, University of the Republic, Montevideo, URU-
GUAY, 4Department of Neuropsychology, University of the
Republic, Montevideo, URUGUAY, 5Department of Geriat-
rics, University of the Republic, Montevideo, URUGUAY.
Resveratrol (trans-3,5,40-trihydroxystilbene) is a polyphenol
that has shown potential beneficial effects in cardiovascular
and neurodegenerative disorders. Although it has been proved
that resveratrol promotes vasodilatation, the regional changes
in cerebral blood flow (CBF) induced by this polyphenol have
not been fully assessed yet. Pittsburgh Compound B (PIB) is a
lipophilic thioflavin derivative PET tracer used to detect amy-
loid depositions, for example in patients with Alzheimer’s
Disease (AD). The molecules of resveratrol and PIB have
structural similarities, which can indicate possible similar in-
teractions with amyloid depositions. Additionally, it has been
published that early images of the PIB scans can be used as an
indicator of CBF.Aim: To assess the possible effect of a short
treatment with resveratrol on the amyloid deposition images
with PIB PET and on a rough index of CBF.Materials and
methods: Prospective study that included twelve PIB positive
AD patients (58-85 years old, 5 men) that underwent clinical
and extensive neuropsychological examination. The mean
progression time from diagnosis was 2.6±2.2 (SD) years, with
a mean Mini-mental state examination score of 22.5±3. After
the first PIB positive scan, the patients were treated with oral
administration of 1 g trans-resveratrol daily during 8 days. A
second PIB scan was performed the last day of treatment.
Parametric images of the first 6 min (eSUVand ePIB normal-
ized to the cerebellum) and the last 20 min (tSUVand tPIB) of
the PIB scans were obtained and analyzed using predefined
Volumes of Interest (VOIs) and a voxel based approach with
the software Statistical Parametric Mapping (SPM8). Results:
The analysis of changes in amyloid depositions (tPIB and
tSUV) did not reveal significant differences before and after
the treatment with Resveratrol in any region of the cortex.
Voxel based analysis of the early images (eSUV) of the PIB
scans showed an increased uptake in the occipital cortex bilat-
erally after the treatment with Resveratrol (p<0.001, uncorrect-
ed for multiple comparisons, 100 voxels extent threshold) with
a minor extension to the left inferior parietal lobe. We couldn’t
f ind a signif icant correlat ion between eSUV and
ePIB.Conclusions: There were not changes in amyloid depo-
sitions after a week of treatment with Resveratrol. Changes in
the early distribution of PIB, interpreted as an increased CBF,
were observed in the occipital and inferior parietal cortex.
Further studies with specific CBF tracers are needed to study
the regional effect of resveratrol in brain perfusion.
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OP328
Partition model absorbed dose biases and variability due
to tumor-to-normal-liver ratios following 90Ymicrosphere
therapy
J. Mikell1,2, A. Mahvash1, W. Siman1,2, F. Mourtada3, S. C.
Kappadath1,2; 1UT MD Anderson Cancer Center, Houston,
TX, UNITED STATES, 2UT Graduate School of Biomedical
Sciences, Houston, TX, UNITED STATES, 3Christiana Care
Health System, Newark, DE, UNITED STATES.
Aim: Partition model (PM) assumes uniform distribution of
90Y microspheres within tumors (T) and non-tumoral (NT)
compartments. In addition, it assumes a single scalar (TNR)
to describe the relative activity concentration (AC) of 90Y
microspheres between T and NT. However, clinical reality
presents multiple tumors that have different uptake and non-
uniform AC. Monte Carlo (MC) provides voxel-based
absorbed dose distributions throughout T and NT volumes.
Only in the ideal case of uniform uptake to a single T and
uniform uptake to NT will the mean absorbed dose estimates
from PM equal MC. In this work we calculate 1) the differ-
ences between PM and MC for mean absorbed doses to T and
NT, and 2) the variability of PM doses on estimates of TNR.
Various TNR were calculated using 1) mean tumor AC
(meanT), 2) maximum tumor AC (maxT), and 3) four esti-
mates of mean NTAC. Materials and Methods: We analyzed
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21 90Y glass-microsphere cases; 7 were single tumor cases.
MC absorbed doses were calculated from quantitative 90Y
SPECT/CT. Tumors and livers were segmented by radiologist.
PM tumor uptake was characterized by meanT and maxT;
volume-weighting was used for multiple tumors. PM NT up-
take was characterized by mean AC of the entire NT VOI
(meanNT) and mean AC of three spheres (D=2.5cm) placed
in different locations within NT by radiologist. We generated
eight estimates of TNR and consequently eight estimates of
absorbed dose to T and NT. We assessed the differences (%Δ)
of PM absorbed dose estimates relative to MC and the vari-
ability (coefficient of variation, COV) of PM absorbed doses
due to TNR. Results: For single tumors using TNR=meanT/
meanNT, the average %Δ and (range) was 70%±24% (31% to
99%) for T and 71%±26% (23% to 90%) for NT. For multiple
tumors using TNR=volume-weighted-meanT/meanNT, the
average %Δ and (range) was 103%±119% (-28% to 476%)
for T and 54%±21% (20% to 99%) for NT. For single tumors
using TNR=maxT/meanNT, the average %Δwas 192%±89%
(53% to 295%) for Tand 2%±58% (-65% to 65%) for NT. The
PM absorbed dose COV due to TNR variability for single
(multiple) tumors was 0.32±0.17 (0.32±0.16) for T and 0.42
±0.29 (0.23±0.29) for NT. Conclusion: There are large biases
and high variability in PM absorbed dose estimates for T and
NT stemming from the uncertainties in the TNR that hold true
even in the best case scenario of single tumors. Grant support
NIH/NCI R01 CA138986.
OP329
99mTc-MAA SPECT/CT lung shunt estimations are more
accurate than those obtained from planar scintigraphy
J. Prince, A. F. van den Hoven, G. C. Krijger, N. de Wit, B. J.
van Nierop, M. N. G. J. Braat, M. A. A. J. van den Bosch, H.
M. Verkooijen, M. G. E. H. Lam; UMC Utrecht, Utrecht,
NETHERLANDS.
Aim: Shunting of yttrium-90 microspheres to the lungs can
preclude radioembolization if the estimated absorbed lung
dose after treatment is >30 Gy on 99mTc-MAA planar scintig-
raphy. The objective of this study was to investigate the valid-
ity of planar scintigraphy lung shunt after 99mTc-MAA com-
pared with SPECT/CT and to identify risk factors for a high
lung shunt. Materials and methods: Between March 2011 and
November 2013 patients eligible for radioembolization were
included in this retrospective, cross-sectional, single-center
study. The lung shunt fraction after 99mTc-MAA injection
was measured by dividing the counts in the lungs by the counts
in the lungs and liver. The absorbed dose (Gy) on SPECT/CT
was based on the estimated MBq/mL in the basal lung assum-
ing a homogeneous density and distribution. Univariable anal-
yses were used to test for association (p<0.05) between the
occurrence of lung shunting on planar scintigraphy or
SPECT/CT and the following risk factors: tumor type, tumor
burden in the target volume (in %), angioinvasion, extrahepat-
ic disease, and time between 99mTc-MAA injection and imag-
ing (in minutes). Results: A total of 139 99mTc-MAA injec-
tions were performed in 112 patients. A median lung shunt
fraction on planar scintigraphy of 5.5% (range 0.3-39%) was
found. The ability of both measurements to differentiate be-
tween patients (the reliability) was moderate, as the intraclass
correlation coefficient, ICCconsistency (ignoring systematic er-
ror), was 0.72; the ICCagreement was 0.59. Planar scintigraphy
overestimated the absorbed dose by a median of 1.4 Gy / GBq
yttrium-90 (range -2.2 - 14.9 Gy) compared to SPECT/CT. On
planar scintigraphy 4 cases exceeded the 30 Gy threshold.
However, SPECT/CT did not agree in 1 case and identified 4
extra cases ineligible for treatment. Univariable analyses iden-
tified the following risk factors both on planar scintigraphy
and SPECT/CT: angioinvasion, tumor burden, and time be-
tween 99mTc-MAA injection and imaging. Only planar scin-
tigraphy showed an association between lung shunt and
hypervascularity and extrahepatic disease. Conclusion: Planar
scintigraphy overestimates lung shunting compared to
SPECT/CT. A clinical significant threshold for lung shunting
should be defined for SPECT/CT and may be used in combi-
nation with risk factors for accurate patient selection.
OP330
Previsional dosimetry based on 99mTc-MAA SPECT
for radioembolization of liver lesions with 90Y-loaded
microspheres: impact of attenuation correction, scatter
correction and calibration
M. Pacilio1, C. Chiesa2, M. E. Ferrari3, F. Botta3, L.
Lorenzon1, M. Mira2, M. Ljungberg4, M. Cremonesi3;
1Azienda Ospedaliera San Camillo Forlanini, Roma, ITALY,
2Istituto Nazionale dei Tumori, Milano, ITALY, 3European
Institute of Oncology, Milano, ITALY, 4Lund University,
Lund, SWEDEN.
Background and a im: The rapy op t imiza t ion in
radioembolization (RE) with 90Y-loaded microspheres should
be pursued through treatment planning based on 99mTc-
MAA-SPECT image. The accuracy of the quantification de-
pends on differen issues. The aim of this study was to evaluate
the influence of attenuation and scatter corrections in the
99mTc-MAA-SPECT images for RE dosimetry of simulated
patients and clinical cases. Methods: Simulated and real
99mTc-MAA-SPECT images were reconstructed by OSEM
algorithm without corrections (NoAC_NoSC) or with scatter
(NoAC_SC), attenuation (AC_NoSC), scatter and attenuation
(AC_SC) corrections. Monte Carlo (MC) simulations
(SIMIND code) were performed for three different body size
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and different activity distribution (uniform activity in the
whole liver, or in a liver lobe, or with hot lesions with
lesions/normal liver ratio=5). 36 clinical cases were also stud-
ied with a relative calibration method. Lesions and healthy
parenchyma were manually contoured on the co-registered
CT-SPECT images. The absorbed dose distributions were cal-
culated at dose level from the activity maps, comparing results
obtained from different correction methods in terms of DVHs
and dose profiles. For simulated cases, the dose image derived
from the input activity map was the Gold Standard (GS) while
for clinical cases, the dose map from AC_SC was considered
as reference. Results: For simulated cases, differences vs. GS
decrease implementing AC and SC in the tomographic recon-
struction. Deviations from GS of D95%, D70%, D50% for
lesion and healthy parenchyma are lower for AC_NoSC, than
for NoAC_SC.In the clinical cases, deviations from GS of
D90%, D70%, D50%, are lower for AC_NoSC, than
NoAC_SC for lesions, while for healthy parenchyma the ab-
sence of attenuation correction is less critical than the absence
of scatter correction.Conclusions:All corrections are needed to
improve dosimetric accuracy.The difference in the results of
the healthy parenchyma between simulations and real patients,
as regards the influence of separate AC and SC, could be due
to the influence of patient motion (respiration, not present in
simulations) or variability of activity distributions in real
patients.However, for the most important side of the planning
strategy (safety=parenchyma dosimetry) the absence of atten-
uation correction (not available in all SPECT system) seems
less critical than the absence of scatter correction (available on
all system). Despite inaccuracies, the dosimetry approach pro-
vides a much safer (lower toxicity) and efficient (higher tu-
mour irradiation) approach showing therefore a better RE op-
timization than using others empirical methods indicated by
producers (BSA, tumor involvement, mean dose to lobe).
OP331
Effect of Data-Driven Respiratory Gating onRadioactivity
Quantification in Liver Lesions
for Pre-Radioembolization Tc-99m-MAA SPECT/CT
J. C. Sanders1,2, A. H. Vija3, T. Kuwert1, P. Ritt1; 1Clinic of
Nuclear Medicine, University Hospital Erlangen, Erlangen,
GERMANY, 2Pattern Recognition Lab, University of Erlang-
en-Nuremberg, Erlangen, GERMANY, 3Siemens Molecular
Imaging, Hoffman Estates, IL, UNITED STATES.
Aims: In single photon emission-computed tomography
(SPECT), comparatively long acquisition times may lead to
blurring and underestimation of radioactivity in foci moved by
respiration. This can bemitigated by respiratory gating, where-
by a surrogate signal representing the patient’s respiratory state
is used to subdivide the data into gates, within which motion is
assumed negligible. Individual gates can then be analyzed
separately. The aim of this study was to examine the extent
to which radioactivity in liver lesions varies after respiratory
gating is applied. Methods: After granting informed consent to
participate in the study, 7 patients (5M/2F) aged 64.9±5.8 Y
were injected intraarterially with 143.7±43.5 MBq Tc-99m-
MAA (microaggregated albulin) as part of our clinic’s stan-
dard Y-90 radioembolization planning protocol. A SPECT/CT
acquisition was then performed using a Symbia T2 (Siemens
Molecular Imaging) with 60 views (15 sec each). List-mode
data was acquired, and, using a fully-automated, data-driven
gating method, a respiratory-gated dataset with 5 gates was
generated in addition to the standard ungated dataset. Recon-
struction was carried out with a research version of xSPECT
Quant (20 iterations/1 subset). CT attenuation and scatter
correction, but no post-smoothing, was performed. Magnetic
resonance (MR) images were selected for each patient and
co-registered with SPECT reconstructions. Using the MRs,
volumes of interest (VOIs) were defined for each patient
around lesions exhibiting tracer uptake. Within each VOI,
the ratio R of activity in each gated reconstruction to that
in the ungated reconstruction was then computed. Results:
For 13 of the 16 VOIs assessed, R>1 for at least one gate,
indicating underestimation of activity in the ungated recon-
struction. Taking the maximum R for each lesion, the mean
across all VOIs was 1.15±0.22. Taking the minimum, the
mean was 0.82±0.10. For each lesion, the average deviation
across all gates was 0.09±0.09. Conclusion: In this study,
81.3% of examined lesions showed underestimation in the
ungated dataset, the average magnitude of which was 15%.
This implies that blurring due to respiratory motion incurs a
bias on ungated SPECT images. Variation across gates for
each lesion was due to activity passing in and out of the
static VOI as the patients breathed. Although not affecting
the lung/liver shunt currently used for radioembolization
planning, underestimation of tumor activity may have impli-
cations on future efforts to personalize therapy to maximize
tumor dose. One limitation of the study is the small number
of patients analyzed, which must be increased to reach a
definite conclusion.
OP332
Feasibility and safety of selective internal radiation
therapy (SIRT) procedure in one day
A. Dieudonné1, A. Siebert2, M. Abdel-Rehim2, S. Legendre1,
S. Sebahoun1, M. Ben-Reguiga1, V. Vilgrain2, R. Lebtahi1;
1Department of Nuclear Medicine, Beaujon Hospital, Assis-
tance Publique-Hôpitaux de Paris (APHP), Clichy, FRANCE,
2Department of Radiology, Beaujon Hospital, Assistance
Publique-Hôpitaux de Paris (APHP), Clichy, FRANCE.
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SIRT procedures are usually performed in two steps separated
by 7 to 14 days. Here we study the feasibility of performing the
procedure in day. Methods: From a 5 years experience of
SIRT, with 80 procedures, we had 4 cases for which a second
pre-therapeutic angiogram was performed the same day than
the therapeutic injection, followed by Tc-99m-labelled-macro-
agregated-albumin-particles (MAA) injection. For these pa-
tients a second pre-therapeutic angiogram was programmed
and new gastric arteries were identified and embolized. This
was followed by the injection of MAA to re-evaluate the lung-
shunt fraction, extra-hepatic uptake, the perfusion of the liver
and the dosimetry of the tumor and non-tumoral tissues. Due
to specific circumstances, this procedure was programmed the
same day than the therapeutic injection. After 185 MBq intra-
arterial injection of MAA, the patients were transferred to the
nuclear medicine department for a SPECT/CTacquisition with
the catheter in place. The images were analyzed during the
transfer of the patient back in the interventional room for the
microspheres injection that took 15minutes. Themicrospheres
(resin, SIRSPHERE, SIRTEX) were prepared and injected.
The quality control of the microspheres injection by brems-
strahlung SPECT/CT (50-150 keV, MELP) was done the day
after to avoid contamination of the Tc-99m peak. Results: For
all 4 patients, no complication related to the transfer back and
forth to the nuclear medicine department occurred. The time
between theMAA and microspheres injection varied from 1 to
1,5 hours. The comparison of MAA and microspheres showed
a very good agreement between MAA and microspheres,
meaning that the presence of MAA in the micro-vessels does
not perturb the perfusion of the microspheres and the injection
of microspheres can be done 1 to 1,5 hours after the MAA
injection.Conclusion: The “one day” SIRT procedure, done
under specific circumstances, highlights the feasibility and
safety of the process in term of patient management and the
very good agreement between microspheres and MAA
perfusion.
OP333
Regularized reconstruction results in a major
improvement of Y-90 PET/CT image quality after SIRT
with Y-90 microspheres
K. Tatsch1, J. Touati2, M. Leicht1, C. Puskas1, L. Maron1, H.
Arques Aguilo2; 1Municipal Hospital Karlsruhe Inc, Dept. of
Nuclear Medicine, Karlsruhe, GERMANY, 2GE Healthcare,
Buc, FRANCE.
Due to the physical properties of Y-90, Bremsstrahlung SPECT/CT
images after SIRT are hampered by low quality. PET/CT scans
might enhance image quality, however, due to the low count statis-
tics based on theY-90 inherent low positron emission decay, images
acquired at reasonable scanning times for the patient are generally
hampered by high noise levels. This study investigates whether an
advanced reconstruction algorithm (regularized reconstruction
aiming for full convergence; Q.Clear ) can significantly improve
image quality of Y-90 PET/CTscans following Y-90 SIRT therapy.
So far we investigated the PET/CT (GEDiscovery 710) Y-90 TOF-
scans of 14 patients after radioembolization of liver tumors and
metastaseswithY-90 SIR-Spheres. Six different iterative reconstruc-
tions were performed: Standard (Std) with routine parameters for
FDG scans (3 it, 24 sub, filter 6.4 mm, 256 matrix), 2 data sets
reconstructed in a 192 matrix (8 it, 16 sub, filter 9 (V1) and
17 mm (V2)) and 3 data sets using Q.Clear (Q) with different beta
values (750; 1000; 2000). All images were visually assessed by 4
readers (2 experts and 2 non-experts) with respect to 3 parameters:
visual image quality, noise level and lesion detectability. Rating was
based on a numeric scale from1 (worst) to 5 (best). Rating for Image
Qualitywas 1.4±0.3 for Std, 1.6±0.3 forV1, 2.4±0.3 forV2, 3.5±0.3
for Q.750, 4.0±0.3 for Q.1000 and 4.3±0.2 for Q.2000. Rating for
NoiseLevelwas 1.3±0.3 for Std, 1.6±0.3 forV1, 3.5±0.4 forV2, 3.0
±0.3 for Q.750, 3.7±0.3 for Q.1000 and 4.6±0.4 for Q.2000. Rating
for LesionDetectabilitywas 1.4±0.4 for Std, 1.6±0.3 forV1, 2.4±0.5
for V2, 3.6±0.4 for Q.750, 4.0±0.4 for Q.1000 and 3.9±0.4 for
Q.2000. There was no statistical difference between expert and
non-expert reads. Thus, in all three categories best results were ob-
tained forQ.Clear reconstructions.Q.Clear data using a beta value of
2000 delivered the best trade off. Image quality of Y-90 PET/CT
scans after SIRT can be dramatically improved by using Q.Clear, a
regularized reconstruction algorithm aiming for full convergence.
Thevery lownoise levels achieved allow for an excellent delineation
of the regional deposition of SIR-Spheres within the treated liver
lobes or segments, which is a prerequisite for using such data for
improved dosimetric calculations and comparisons with pre-
therapeutic FDG and MAA scans. Currently patients are followed
to additionally address whether these high quality scans may have
impact on a better prediction of treatment response.
OP334
A branching artery tree model in concordance
with microscopy observations of microsphere distribution
in liver following radioembolisation
J. Högberg1, M. Rizell1,2, R. Hultborn1,2, J. Svensson1,2, O.
Henrikson1,2, J. Mölne1,2, P. Gjertsson2, P. Bernhardt1,2; 1The
Sahlgrenska Academy at The University of Gothenburg,
Gothenburg, SWEDEN, 2Sahlgrenska University Hospital,
Gothenburg, SWEDEN.
Aim: Our previous investigations have demonstrated that large
clusters of resin microspheres are common in normal liver tissue
arteries after radioembolisation, causing more heterogeneity in the
absorbed dose distribution than can be explained by depositions
limited to the final arterioles. In order to reproduce microsphere-
clustering findings, we constructed a hepatic artery branching tree
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model. Materials and Methods: The virtual hepatic branching ar-
tery tree model consisted of a dichotomous (one vessel always
branching into two vessels) branching artery of 20 generations.
The inner artery diameter exponentially decreased from the lowest
to the highest generation. Three variable parameters were
optimised to obtain concordance between simulations and mea-
sured microsphere distributions: a combined artery coefficient of
variation (ACV) for the inner diameter of all artery generations and
the microsphere flow distribution at the nodes; a hepatic tree dis-
tribution volume (HDV); and an embolisation (EMB) parameter
that reduces the artery diameters. The model was tested against
previously measured activity concentrations in 16 biopsies, where
the microsphere distribution was determined via light microscopy
of 15 30-μm sections per biopsy (mean concentration, 14
microspheres/mg; distributionswere divided into three groupswith
meanmicrosphere concentrations of 4.6, 14, and 28 microspheres/
mg). Results: Optimisation of the simulations, by increasing mi-
crosphere concentrations and simultaneously increasing ACVand
EMB and decreasing HDV (from 130 to 22 cm^3), demonstrated
increasing cluster sizes in wider vessels with increasing micro-
sphere concentration. Conclusion: Simulations revealed thatmicro-
sphere clusters are larger and more common in volumes with high
microsphere concentrations, thereby able to reproduce the distribu-
tions found in our previous microscopy investigations, the latter
demonstrating that the absorbed dose distribution is more non-
uniform for resin microspheres than what has been hypothesized
or demonstrated by others. The non-uniform absorbed dose pattern
for glass spheres is expected to depend mostly on high activity per
microsphere, whereas microsphere clusters, caused by embolisa-
tion effects, are expected to be much more common for resin
sphere treatments. The always relatively small and yet decreasing
HDV with increasing microsphere concentration shows that our
dichotomous branching model is a simplified model of a native
hepatic branching artery tree, the latter demonstrated by anatomy
studies to be much more complex than our model. Our model
could be useful, though, when limited to small-scale analysis of
specific liver segments where the mean absorbed dose within the
segment is detected with Single-Photon Emission Computed To-
mography (SPECT) or Positron Emission Tomography (PET).
OP335
Reconstruction, volumetry and dosimetry optimisation
for 99mTc-SPECTand 90Y-PET images: towards reliable
DVH for SIRT treatments
M. Bernardini1, H. Thevenet1, C. Berthold2, A. Fischer3, A.
Petitguillaume4, A. Desbrée5, C. Smadja1, P. Weinmann1, N.
Ghazzar1; 1European Hospital Georges Pompidou, PARIS,
FRANCE, 2Gustave Roussy Institut, Villejuif, FRANCE,
3Philips GmbH Innovative Technologies, Aachen, GERMA-
NY, 4Cancéropole Grand Sud Ouest, Toulouse, FRANCE,
5LEDI, IRSN, Fontanay aux Roses, FRANCE.
Aim: Our purpose was to optimise image reconstruction and
volumetric delineation on MAA-99mTc-SPECT/CT and 90Y-
PET/CT images, in liver treatment with Selective Internal Ra-
diation Therapy (SIRT), in order to improve dosimetry calcu-
lations. The prediction power of MAA-99mTc for 90Y-
spheres treatments was also investigated as well as dose-
effect relationship relating DVHs with patients follow-up. Ma-
terials andmethods: Tominimise errors in volumes delineation
and quantification, 2 NEMA phantom studies were performed.
99mTc-MAA-SPECT/CT images were acquired with a hybrid
gamma camera Infinia-Hawkeye (GE) and 90Y-PET/CT im-
ages with a Discovery 690 VCT-TOF (GE). Phantom optimi-
sation results were applied to images of 10 patients treated
with 90Y-SIR-spheres® (SIRTEX): treatment planning
(99mTc-SPECT/CT), post-dosimetry (90Y-PET/CT) and
dose-effect relationship (ceCT, 18F-PET/CT) were investigat-
ed via DVHs and isodoses. Dosimetry was based on kernel
convolution (Imalytics, Philips). Results: 90Y and 99mTc
phantom studies enabled to establish the reconstruction param-
eters that minimise errors in volumes and quantification for
PET and SPECT images: optimised reconstruction and adap-
tive thresholding, allow decreasing average error in volumes
from -64.3% to 2.2%. Using the “best volumes” on the “best
quantification”, here called “cross volumes” technique, allows
decreasing error of mean concentration from -64.4% to -52.2%
in average. Partial volume effect correction (PVC) decrease
quantification error to -17.4% in average. For 90Y-PET im-
ages, optimising reconstruction parameters increase mean
absorbed dose of +88.1% in average (from +21.0% to +
235.9%, depending on volume). Applying PVC, mean
absorbed dose increases of +70.9% in average (from +
48.6% to 100.4% depending on volume). For 99mTc-
SPECT images, optimising reconstruction parameters does
not increase significantly quantification (maximum dose
difference is -4,0%). With PVC correction, mean absorbed
dose increase of +110% in average (from +74.2% to
162.8% depending on volume). These results were applied
to analyse patient’s images. Differences between lesions
delineate on ceCT (pre-therapeutic image reference) and
volumes threshold on 99mTc-SPECT and 90Y-PET, reach
320%. Intersections between volumes show important dis-
crepancies too. Absorbed doses in 90Y-PET and 99mTc-
SPECT volumes are higher than in ceCT lesions, pointing
out the problem of targeting in SIRT. DVH establish a re-
lationship between volume and dose, overtaking the inad-
equate information of mean absorbed dose. Conclusion: As
mean absorbed dose does not represent the irradiation and
radiobiological effects on lesions and organs at risk (paral-
lel organs), DVH is essential to optimise treatment plan-
ning and to evaluate dose-response effect. To obtain reli-
able DVH, optimisation of volumes delineation is manda-
tory as errors in volumes can be important and the impact
on dosimetry huge.
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Assessing the impact of clinically certified NEP and/or
ACE inhibitors on the in vivo profile of [111In-DOTA]
MG11: A comparative study in mice
A. Kaloudi1, E. Lymperis1, E. P. Krenning2, M. de Jong2,3, B.
A. Nock1, T. Maina1; 1Molecular Radiopharmacy,
INRASTES, NCSR Demokritos, ATHENS, GREECE, 2Insti-
tute of Nuclear Medicine, Erasmus MC, ROTTERDAM,
NETHERLANDS, 3Insitute of Radiology, Erasmus MC, Rot-
terdam, NETHERLANDS.
Aim: We have recently shown that treatment of mice with the
neutral endopeptidase (NEP)-inhibitor phosphoramidon (PA)
improves the bioavailability and tumor uptake of several
radiopeptides. For the truncated gastrin radiotracer [111In-
DOTA]MG11 ([(DOTA)DGlu10]gastrin(10-17)) this method
led to impressively high tumor-to-kidney ratios. Translation of
this concept in the clinic requires the use of clinically certified
NEP inhibitors, such as thiorphan (TO) and its orally adminis-
tered prodrug racecadotril (Race). On the other hand, both NEP
and angiotensin converting enzyme (ACE) have been shown to
participate in the catabolism of gastrin analogs. In the present
study, we first compare the effects induced on the biological
profile of [111In-DOTA]MG11 during NEP inhibition by: i) PA
(reference), ii) TO, or iii) Race. Furthermore, we investigated the
role of ACE in the catabolism of the radiotracer employing the
established ACE-inhibitor lisinopril (Lis). Materials and
Methods: [111In-DOTA]MG11 was co-injected with vehicle, or
with PA (300 μg), or TO (150 μg), or Lis (100 μg), or Race (2
mg; 30-40 min in advance via ip injection). Mouse blood col-
lected 5 min post-injection (pi) was analyzed by HPLC to assess
catabolism rates. Biodistribution was performed at 4 h pi in
SCID mice bearing AR42J xenografts after co-injection of
[111In-DOTA]MG11 with vehicle, or with PA, or TO, or Lis,
or PA+Lis, or Race (ip pre-injected). Results: Treatment of mice
with PA, TO or Race increased the levels of circulating [111In-
DOTA]MG11 from 5% to 70-75% at 5 min pi. During NEP-
inhibition, tumor uptake impressively increased from 1.8
±1.0%ID/g (controls) to 15.3±4.7%ID/g (PA) and 12.3
±3.6%ID/g (TO), while with Race tumor values reached 6.8
±2.8%ID/g. Conversely, Lis had no effect on tumor uptake
and no additive effect when co-injected with PA. In all cases
renal accumulation remained low and unaffected by any of the
above inhibitors. Conclusions: This study has shown that ACE
is not involved in the in vivo degradation of [111In-
DOTA]MG11, confirming NEP as the predominant degrading
enzyme of the radiotracer. NEP inhibition with the clinically
tested NEP inhibitors TO and Race resulted in significant
enhancement of tumor-to-kidney ratios versus controls. The fact
that TO, unlike its ip-administered prodrug Race, produced
comparable effects with PA highlights the importance of suffi-
cient NEP-inhibition for maximizing tumor targeting. Further
studies, to optimize doses, administration routes and inhibitor-
combinations, are currently in progress to advance translation of
this concept into the clinic.
OP337
A phage display derived stabilised bicyclic peptide
targeting MMP-14 shows high imaging contrast in small
animal PET imaging
M. Eder1, S. Pavan2, U. Bauder-Wüst1, K. van Rietschoten2,
L. Baldassarre2, U. Schierbaum3, O. Seibert3, K. Leotta3, S.
Campbell2, H. Harrison2, C. Stace2, E. Walker2, U.
Haberkorn3, K. Kopka1, D. P. Teufel2; 1Radiopharmaceutical
Chemistry, German Cancer Research Center, HEIDELBERG,
GERMANY, 2Bicycle Therapeutics Limited, Cambridge,
UNITED KINGDOM, 3CCU Nuclear Medicine, German
Cancer Research Center, HEIDELBERG, GERMANY.
Aim: Radiolabeled bicyclic peptide scaffolds represent highly
attractive molecules for PET imaging of various oncological
entities and for therapeutic applications due to their low mo-
lecular weight, high affinity and specificity. In the present
work, bicyclic peptides directed against the tumor associated
matrix metalloproteinase 14 (MMP-14, MT1-MMP) were
identified, preclinically characterized and further optimized
with regard to their in vivo stability and their clinical potential
as PET imaging agent. Materials and Methods: Thio-ether for-
mation via the three reactive cysteines of a randomized amino
acid sequence and fusion to the phage gene-3-protein generat-
ed a library of bicyclic peptides [1]. An affinity selection pro-
cess yielded several binders with variants showing single digit
nanomolar affinity and high specificity for MMP-14. The se-
lected Bicycle structure offers the ability to alter properties
through chemical modification and the addition of functional
groups via linkers without affecting the affinity, for example a
site-specific labelling with the radiochelator DOTA. This con-
struct was radiolabelled with Ga-68 or Lu-177, respectively,
and analyzed preclinically according to its cell binding and
in vivo tumor-targeting properties. In order to further improve
the pharmacokinetic and tumor targeting properties the Bicy-
clic peptide sequence was stabilized by chemical modification.
Results: The initially selected compound DOTA-N144 already
revealed high specificity and affinity (KD= 0.5 nM) as deter-
mined by fluorescence polarization competition assays.
MALDI-TOF analysis of wild-type N144 in mouse plasma
however indicated loop-opening potentially causing in vivo
instabilities. Several targeted chemical modifications of the
amino acid sequence led to a stabilised variant with retained
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affinity and specificity. Organ distribution at 1 h p.i. of
the optimal dose showed a significantly higher MMP14-
specific tumor uptake of 12.02 ± 2.37 %ID/g (0.12 ±
0.06 %ID/g for non-binding scrambled variant) as com-
pared to the non-stabilised compound (2.75 ± 0.88 %ID/
g). Both compounds showed fast background clearance
(<1 %ID/g for all organs except the kidneys) resulting
in high imaging contrast in the μPET studies. Conclu-
sions: The phage display selection of bicyclic peptides
was shown to be a highly flexible and attractive strategy
for generating and developing peptidic drug leads. The
stabilised bicyclic DOTA-lead compound revealed
MMP-14-selective tumor uptake in the xenograft model
and rapid clearance from non-target crucial organs
resulting in high imaging contrasts. The compound rep-
resents a highly promising radiotracer which could be
used as radiopharmaceutical for future clinical PET im-
aging and radioendotherapy of MMP14-expressing tu-
mors. References: [1] Heinis C, et al (2009) Nat Chem
Biol, 5(7), 502-07.
OP338
Sometimes, Less is More: Specific Activity
of Radiopharmaceuticals and its Impact
on Biodistribution and Imaging Contrast
J. Notni1, D. Reich1, J. Pollmann1, F. Hofmann1, M.
Weineisen1, T. Kapp2, F. Rechenmacher1, H. Kessler2, H.
Wester1; 1Pharmaceutical Radiochemistry, Garching, GER-
MANY, 2Center for Integrated Protein Research, Garching,
GERMANY.
For a fixed dose of a radiopharmaceutical (given in MBq), the
specific activity AS (e.g. in GBq/μmol), defined as radioactiv-
ity (A) divided by the total molar amount (n) of labelled and
unlabelled precursor, is determining the overall injected dose
of pharmacologically active compound (e.g., in mg/kg). Par-
ticularly for radiopharmaceuticals with saturable targets, such
as receptors, the latter can have a pronounced effect on both
target accumulation and general biodistribution, and therefore
on imaging results. While this is a known and well-described
phenomenon, its extent is often underestimated. Here, its man-
ifestation is illustrated on examples of current PET-tracer de-
velopment. TRAP-based trimers of a) cyclo(RGDfK),
targeting αvβ3 integrins, b) an acyclic pseudopeptide,
targeting α5β1 integrins, and c) a EuK-based ligand, targeting
PSMA, were synthesized from the alkyne-functionalized
monomers by one-pot click-chemistry (CuAAC) conjugation
to a tris-azide-functionalized TRAP chelator. Affinities (IC50)
were determined by ELISA on vitronectin/fibronectin
(αvβ3/α5β1), or displacement assays on LNCaP cells
(PSMA). Following fully-automated 68Ga labelling, the
compounds were administered to mice bearing M21
(integrins) or LNCaP (PSMA) xenografts, with specific activ-
ities ranging from 0.5 to 1500 GBq/μmol (approx. 35 nmol to
13 pmol for a 20 MBq injection), which underwent PET and
ex-vivo biodistribution studies. Trimerization of the receptor
ligands resulted in substantially increased target affinities
(αvβ3: 220 pM, α5β1: 80 pM, PSMA: 2 nM) compared to
the monomers (5, 2.3, and 36 nM, respectively). For all inves-
tigated tracers, variation of AS resulted in dramatic changes in
biodistribution and thus, tumor/organ and tumor/“back-
ground” ratios. For example, increasing the total dose of the
α5β1-targeting TRAP-trimer Ga-Aquibeprin from 16 pmol to
6 nmol resulted in improved PET tumor/muscle ratio from 5.3
to 12.4. Likewise, for 20 MBq of the 68Ga-labelled EuK tri-
mer, lowering AS from 540 to 20 GBq/μmol resulted in
strongly declining kidney uptake from 28.7 to 3.2 %ID/mL,
respectively, while LNCaP tumor uptake was just slightly de-
creased from 1.5 to 1.3 %ID/mL.Specific activity is an impor-
tant factor in tuning the in-vivo properties of radiopharmaceu-
ticals, allowing to improve tumor contrast and to manage spe-
cific uptake in other tissues. As such, it deserves more atten-
tion, particularly in view of substantial evidence for the fact
that lower AS (i.e., higher amounts of pharmacologically ac-
tive compound) can improve addressing of tumors, while
higher AS can result in more detailed physiological target vi-
sualisation. Thus, we advocate for a more detailed investiga-
tion of this parameter in radiopharmaceutical studies.
OP339
Assessment of the specificity of 99mTc-duramycin
in a mouse model of colorectal cancer
F. Elvas1,2, C. Vangestel1,2, K. Y. Pak3, S. Stroobants1,2, S.
Staelens1, L. wyffels1,2; 1University of Antwerp - Molecular
Imaging Center Antwerp, Wilrijk, BELGIUM, 2University
Hospital Antwerp - Department of Nuclear Medicine,
Edegem, BELGIUM, 3Molecular Targeting Technologies,
Inc., West Chester, PA, UNITED STATES.
Aim:Asmost cancer therapies available have a pro-apoptotic and
necrotic effect, the use of specific radiotracers allows for molec-
ular imaging of cell death. Duramycin is a small peptide
(MW~2kDa) that recognizes cell death by binding to the head
group of phosphatidylethanolamine (PE) with high affinity. Re-
cently, we showed the ability to image therapy-induced cell death
in a mouse model of colorectal cancer using 99mTc-labeled
duramycin(1). In the current study we aimed at assessing the
specificity of 99mTc-duramycin for imaging cell death in chemo-
therapy treated tumor-bearing mice by performing a blocking
study. Materials and Methods: Human colorectal cancer cells
(Colo205) were subcutaneously inoculated in both hind legs of
athymic nude mice. After the tumors reached 217 mm3, baseline
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static SPECT-CT scans were performed 4 h after injection of
99mTc-duramycin (36.0 ± 1.8 MBq). Chemotherapy consisted
of a combination of 80mg/kg irinotecan plus 5 mg/kg oxaliplatin
(q.d. in alternate days during one week) or the corresponding
vehicles for control mice (n=6 tumors/group). 99mTc-
duramycin (35.0 ± 4.7 MBq) was intravenously injected 24 h
after the last course of treatment, and following a 4 h radiotracer
uptake-period animals underwent static SPECT-CT imaging. For
blocking, duramycin (2 mg/kg as 0.8 mg/mL solution in saline)
was injected 30 min before the radiotracer. Radiotracer uptake in
the tumors was evaluated by SPECT (%ID/g/kg) and by γ-
counting of the tumors (%ID/g). Cleaved caspase-3 (CC3) and
TUNEL staining of the tumors will allow assessing cell death in
the tumor. Results: On the SPECT images, tumors showed an
increased accumulation of 99mTc-duramycin following combi-
nation chemotherapy (144.2 ± 19.1%ID/g/kg; p<0.001), com-
pared to control (40.6 ± 2.8%ID/g/kg). The binding of 99mTc-
duramycin was blocked by preinjection of nonlabeled duramycin
(32.9 ± 9.7%ID/g/kg; p<0.001). In treated tumors the radioactiv-
ity in the tumors positively correlated to CC3 (r=0.85, p<0.001)
and TUNEL (r=0.81, p<0.001) stainings. For the blocking, re-
gional distribution of radioactivity in the tumors will be deter-
mined by autoradiography, and correlated to CC3 and TUNEL
staining. Conclusion: Our results show that 99mTc-duramycin
specifically accumulates in apoptotic tumors in response to ther-
apy. 99mTc-duramycin holds promise as a radiotracer for early
treatment evaluation with potential clinical usefulness in the set-
ting of oncology. 1. Elvas F, et al. Characterization of
[99mTc]Duramycin as a SPECT Imaging Agent for Early As-
sessment of Tumor Apoptosis. Molecular imaging and biology :
MIB. Apr 21 2015. DOI: 10.1007/s11307-015-0852-6
OP340
Development of radiocobalt-labeled GRPR antagonist
NOTA-PEG2-RM26.
B. Mitran1, Z. Varasteh1, U. Rosenström2, V. Tolmachev3, G.
Lindeberg2, M. Larhed4, A. Orlova1; 1Preclinical PET Plat-
form, Department of Medicinal Chemistry, Uppsala Universi-
ty, Uppsala, SWEDEN, 2Organic Pharmaceutical Chemistry,
Department of Medicinal Chemistry, Uppsala University,
Uppsala, SWEDEN, 3Biomedical Radiation Sciences, Immu-
nology, Genetics and Pathology, Uppsala University, Uppsala,
SWEDEN, 4Science for Life Laboratory, Department of Me-
dicinal Chemistry, Uppsala University, Uppsala, SWEDEN.
Aim: High GRPR expression is associated with numerous can-
cers including those of the prostate and breast. Bombesin (BN)
analogues bind with high affinity to GRPR, having significant
potential for radionuclide imaging and therapy of GRPR-
expressing tumors. We have recently investigated a high-
affinity antagonistic analog of bombesin (RM26) conjugated to
NOTA chelator via a diethylene glycol (PEG2) spacer (NOTA-
PEG2-RM26), labeled with 68Ga, 111In and Al18F. 68Ga-
labeled NOTA-PEG2-RM26 showed favorable pharmacokinetic
properties. However, as seen for 111In-NOTA-PEG2-RM26, the
clearance of radioactivity from blood and receptor positive or-
gans, combined with long retention in tumors resulted in higher
tumor-to-background ratios at later time-points. The aim of the
current study was to develop a 55Co-labeled PET agent to visu-
alize GRPR. 55Co is a promising β+ emitting radioisotope, the
17.5 h half-life allowing transport to distant scanning centers and
imaging at later time-points, when better contrast can be
achieved. Materials and methods: The initial preclinical charac-
terization of NOTA-PEG2-RM26 was performed using 57Co as
a surrogate nuclide. Stability, in vitro binding specificity and cel-
lular processing were analyzed. In vivo binding specificity and
biodistribution were studied in NMRI mice. Results: NOTA-
PEG2-RM26 was successfully radiolabeled with 57Co with
yields exceeding 99% and demonstrated high stability under
EDTA challenge. The radiopeptide showed retained binding
specificity to GRPR in vitro. The internalization rate was very
slow, internalized radioactivity fraction reaching 12% of cell as-
sociated radioactivity 24 h after incubation start. 57Co-NOTA-
PEG2-RM26 biodistribution in mice was characterized by rapid
clearance of radioactivity from blood (1.3±0.2% IA/g) and nor-
mal non-GRPR expressing organs and low liver uptake (0.65
±0.05 % IA/g), 30 minutes after injection. The clearance was
predominantly renal, with low degree of radioactivity reabsorp-
tion (6.4±1.9 %IA/g, 30 minutes p.i.). In vivo binding specificity
studies showed a significant reduction of radioactivity uptake in
GRPR expressing organs (pancreas, small intestines, and stom-
ach) for mice co-injected with excess non-labeled peptide. Con-
clusions: The initial biological results suggest that radiocobalt-
labeled-NOTA-PEG2-RM26 is a promising tracer for the visual-
ization of GRPR-expressing tumors. The use of 55Co as label
might provide a probe for PET imaging.
OP341
68Ga-RM2 for imaging of prostate cancer - Successful
implementation of Synthesizer- and Kit-based production
methods
M. Zerna, A. Müller, M. Berndt; Piramal Imaging, Berlin,
GERMANY.
Aim: Prostate cancer (PCa) is the most common cancer in men
and the second most common cause in cancer-related deaths.
Current diagnostic methods are limited in the accurate detection
of primary prostate cancer. 68Ga-RM2 is a nona-peptide with
optimized binding sequence for Gastrin Releasing Peptide recep-
tor (GRPr) which is overexpressed in prostate cancer. 68Ga-RM2
has been identified from initial clinical studies as a potential im-
aging agent for detection of primary prostate cancer with high
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specificity due to its low uptake in normal prostate and in benign
hyperplasia. In order to support the ongoing systematic clinical
exploration of 68Ga-RM2 and its ability to improve pre-treatment
risk-assessment and therapy-planning, robust GMP compliant
manufacturing methods are needed using automated synthesizers
and “ready-to-use” lyophilized kits. Herein, we report on our
work in establishing a robust automated synthesis of 68Ga-RM2
which could be further simplified to a “shake-and-bake”method.
Materials and Methods: 68Ga was obtained from an IGG100
generator (Eckert&Ziegler). Automated production was per-
formed on a PharmTracer module (Eckert&Ziegler) using sterile
cassettes, pre-filled RM2-precursor vials (ABX) and a Ga-
labeling reagent kit (ABX/Eckert&Ziegler). The 68Ga-generator
eluate was trapped on a cation exchange cartridge. This cartridge
was eluted with 5M NaCl + 5.5M HCl into the reaction vial,
filled with RM2-precursor, sodium acetate solution and scaven-
ger. After labeling at 100-110°C, buffered saline was added and
the mixture was passed through a C18 cartridge. After washing
the cartridge with buffered saline, 68Ga-RM2 was eluted with
ethanol (50%) and diluted with buffered saline. The influence
of scavengers was investigated, as well as a process without the
C18 cartridge purification. In a second approach, a “shake-and-
bake” kit preparation was established. The 68Ga-generator eluate
was added directly into a vial containing RM2-precursor, sodium
acetate and scavenger. The vial was heated and optionally buffer
was added for pH-adjustment. Results: The automated synthesis
provided up to 850 MBq of 68Ga-RM2 in >70% uncorrected
yield in 20min including purification and formulation. The radio-
chemical purity was >97% (HPLC and TLC) if ascorbic acid was
used as scavenger. Without C18 cartridge purification, 68Ga-
RM2 was obtained in 14min in >76% uncorrected yield and
purity of >95%. The simple and easy to use “shake-and-bake”
kit approach provided 68Ga-RM2 in 90% uncorrected yield and
purity of >95%. Conclusion: 68Ga-RM2 can be reliably
manufactured on automated synthesizers as well as by a simple
“shake-and-bake” kit strategy. Both methods provided 68Ga-
RM2 in high yields and high radiochemical purity.
OP342
Kit formulation, preclinical evaluation and experimental
radionuclide therapy using CCK2 receptor targeting cyclic
minigastrin
E. von Guggenberg1, C. Rangger1, L. Balogh2, Z. Pöstényi2,
D. Pawlak3, R. Mikołajczak3; 1Department of Nuclear Medi-
cine, Innsbruck Medical University, Innsbruck, AUSTRIA,
2“Frédéric Joliot-Curie”National Research Institute for Radio-
biology and Radiohygiene (NRIRR), Budapest, HUNGARY,
3Radioisotope Centre POLATOM, National Centre for Nucle-
ar Research, Otwock, POLAND.
Aim: Radiolabelled cyclic minigastrin analogues belong
to the most promising candidates for possible clinical
application in diagnosis and therapy of cholecystokinin-
2 receptor (CCK2R) expressing tumours, mainly medul-
lary thyroid cancer (MTC) and small cell lung cancer.
Within an international collaboration of the IAEA we
have developed and preclinically evaluated specific kit
formulations for Tc-99m and Lu-177 labelling of two
cyclic minigastrin analogues, HYNIC/DOTA-cyclo[γ-D-
Glu-Ala-Tyr-D-Lys]-Trp-Met-Asp-Phe-NH2 (HYNIC/
DOTA-cyclo-MG1) and HYNIC/DOTA-cyclo[γ-D-Glu-
Ala-Tyr-D-Lys]-Trp-Nle-Asp-Phe-NH2 (HYNIC/DOTA-
cyclo-MG2). Materials and methods: Two different ly-
ophilized kit formulations were prepared for HYNIC-
and DOTA-peptides. The stability during storage and
after radiolabelling was examined at different time
points. Cell uptake studies were performed in A431 hu-
man epidermoid carcinoma cells stably transfected with
the human CCK2R (A431-CCK2R) and mock
transfected cells (A431-mock). The biodistribution in
xenografted mice (5 animals per group) was studied up
to 24 hours (Tc-99m) and 7 days (Lu-177). An experi-
mental radionuclide therapy (6 animals per group) was
carried out with 177Lu-DOTA-cyclo-MG1 and 177Lu-
DOTA-cyclo-MG2 at the dose level of 15 and 30
MBq. A dog with histologically confirmed MTC
underwent diagnostic imaging and radionuclide therapy
with HYNIC/DOTA-cyclo-MG1. Results and conclusion:
The kit formulations displayed a high stability during
storage. The radiochemical purity (RCP) at a specific
activity >100 GBq/μmol resulted to be >90% for both
99mTc-labelled HYNIC-peptides, >93% for 177Lu-
DOTA-cyclo-MG1 and >98% for 177Lu-DOTA-cyclo-
MG2. The RCP of the 99mTc- and 177Lu-labelled pep-
tides remained stable for 4 h and declined to ~95%
(177Lu-DOTA-cyclo-MG2) and ~90% (177Lu-DOTA-
cyclo-MG1) at 24 h after preparation. Cell uptake stud-
ies in A431-CCK2R cells confirmed a high receptor-
specific cell internalization (>20% at 2 h after incuba-
tion). Biodistribution studies in xenografted mice re-
vealed a tumour uptake of >3% ID/g for Lu-177 (4 h
p.i.) and Tc-99m (1 h p.i.) and a tumour to kidney ratio
of ~2 (Tc-99m) and ~3 (Lu-177). In the 15 MBq-group
the mean tumour volume doubling time was 1.8 (A431-
CCK2R) and 1.2 (A431-mock) times higher than in the
untreated control group. For the 30 MBq-group these
values resulted to be 2.6 (A431-CCK2R) and 1.7
(A431-mock). SPECT/CT imaging with 99mTc-HYNIC-
cyclo-MG1 in a dog confirmed local recurrence of
MTC. The first treatment with 177Lu-DOTA-cyclo-
MG1 was well tolerated. All together the obtained re-
sults are promising for a potential clinical application in
patients.
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OP343
Development & application of an [18F] anti-amyloid
peptide radiotracer
O. Morris1, J. Gregory1, A. Blykers2, D. Allsop3, M. Taylor3,
S. Allan1, A. McMahon1, H. Boutin1, C. Prenant1; 1The Uni-
versity of Manchester, Manchester, UNITED KINGDOM,
2Vrije Universiteit Brussel, Brussels, BELGIUM, 3The Uni-
versity of Lancaster, Lancaster, UNITED KINGDOM.
Aim: Development and automation of novel [18F] radiochem-
istry and its application in site-specifically radiolabelling an
amino(oxy)-functionalised anti-amyloid peptide (RI-OR2)
for use as an early-stage Alzheimer’s Disease (AD)
radiotracer.AD is a neurodegenerative disorder characterised
by a progressive decline in cognitive function. AD pathology
is identified by the formation of plaques, abnormal peptide
clusters, mainly comprising fibrillar β-amyloid (Aβ). Plaques
deposition leads to impaired synaptic transmission giving rise
to the expression of the recognised cognitive symptoms.RI-
OR2 is a novel brain-penetrant retro-inverso peptide inhibitor
of an Aβ oligomer sequence. It has been reported to reduce
amyloid deposition, associated oxidation and inflammation
whilst also having a marked stimulatory effect on
neurogenesis. This thereby demonstrates its potential thera-
peutic application. The retro-inverso D-amino-acid sequence
confers high resistance to proteolysis and in-vivo stability to
the RI-OR2. Unlike currently used AD radiotracers, RI-OR2,
presents as an interesting PET probe owing to its ability to bind
to early-, rather than late-, stage amyloid aggregates. In so
doing, this might permit detection of AD early in disease on-
set, allowing more effective therapeutic intervention.RI-OR2
has been functionalised with an amino(oxy) functional group,
permitting site-specific radiolabelling with the water-soluble
p r o s t h e t i c g r o u p , 2 - [ 1 8 F ] f l u o r o - 3 -
py r i d ineca rboxa ldehyde .Ma t e r i a l s & Methods :
2-[18F]Fluoro-3-pyridinecarboxaldehyde was produced by
[18F] f luo r ina t ion o f 3 -ca rboxa ldehyde -N,N,N-
trimethylpyridine-2-aminium bromide, obtained from 2-
bromopyridine-3-carboxaldehyde. The 18F-prosthetic group
was purified using SPE and reacted with amino(oxy)-RI-
OR2, in aqueous conditions. The chemical identity of
2-[18F]Fluoro-3-pyridinecarboxaldehyde was determined by
comparing its chromatographic properties with those of
the standard 2-Fluoro-3-pyridinecarboxaldehyde.Results:
2-[18F]Fluoro-3-pyridinecarboxaldehyde was produced
on a GE-Tracerlab FXFN within 40 min. achieving
RCY of 80% ± 5% (n=5). Preliminary results show in-
corporation of the prosthetic group into the RI-OR2
achieving RCY of 40% ± 5% (n=3) within 30 min., as
confirmed by SE-HPLC. 18F-labelled peptide was puri-
fied using SE-HPLC, RCP of >95% was obtained. In-
vitro stability tests have been performed and preliminary
study of the in-vivo biodistribution of this radiotracer
has been performed in wild type pre-clinical models. Conclu-
sion:We hereby present a novel [18F] radiolabelling technique
of RI-OR2 using an [18F] water-soluble prosthetic group. Site-
specific radiolabelling of RI-OR2 with 2-[18F] Fluoro-3-
pyridinecarboxaldehyde is efficient, high yielding and pro-
ceeds under mild conditions. Optimisation of RI-OR2
radiolabelling and pre-clinical investigation of the 18F-
labelled peptide in AD animal models (APPswe/PS1ΔE9
transgenic mice) is in progress and results will be
shown.
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Ga-68 macroaggregated albumin (MAA) Perfusion
PET/CT for lobar pulmonary function quantification:
comparison with anatomic method, volumetric CT
and planar scintigraphy.
P. Le Roux, T. Leong, S. A. Barnett, R. J. Hicks, P. Eu, J.
Callahan, R.Manser, M. S. Hofman; Peter MacCallum Cancer
Centre, Melbourne, AUSTRALIA.
Aim: Patients with lung cancer and borderline pulmonary func-
tion should have preoperative evaluation of predicted postoper-
ative residual lung function according to the European clinical
guidelines (ERS and ESTS) to determine suitability for radical
therapy. Several methods are currently used including anatomic
estimation based on counting the number of segments to be
removed, planar perfusion scintigraphy or volumetric CT. Pul-
monary perfusion PET/CT can be performed by substituting
labeling of macroaggregated albumin (MAA) with Ga-68 for
Tc-99m. The aim of this study was to compare lobar function
computed with PET-CT and the conventional methods. Mate-
rials and methods: Twenty two patients with lung malignancy
and lung function impairment (mean FEV1 1.93L ± 0.67, mean
DLCO 73 ± 21% predicted) underwent respiratory gated (4D)
PET-CT lung perfusion scans after injection of approximately
50MBq of Ga-68 MAA. Lobes were delineated on CT images
and segmentation was subsequently applied to the PET images
to determine lobar perfusion (MIM version 6.3 software).
Bland-Altman statistic was used to calculate agreement between
the lobar lung function in the lobe with tumour using PET
compared to anatomic estimation based on counting the number
of segments (anatomic method), volumetric CT, and planar per-
fusion scintigraphy. Scintigraphywas not available in 6 patients.
Results: Bland-Altman bias of PET compared to the anatomic
method, volumetric CTand planar scintigraphy was -2.3 ± 7.3, -
2.9 ± 4.6 and -1.6 ± 9.0, respectively. For some patients with
tumors resulting in distal vascular obstruction or severe emphy-
sematous change, there was major disagreement between ana-
tomic and functional methods. The absolute difference between
PET versus anatomic method, volumetric CT and planar scin-
tigraphy was higher than 5% of global lung function in 11/22
patients, 8/22 and 13/16 patients, respectively. The difference
was greater than 10% in 5, 1 and 6 patients, respectively. Con-
clusions: Lobar lung function computed with Ga-68MAA PET
lung perfusion imaging differs significantly in some patients
from anatomical, CT and planar scintigraphy methods. Further
studies are needed to assess if perfusion PET allows better
prediction of postoperative lung function and may influence
management of lung surgery patients.
OP352
The Importance Of Scintigraphic Pattern in the Suspected
Diagnosis Of Sjögren’s Syndrome.
B. Garcia-Garcia, M. J. Ribelles, E. F. Guillén, L. Sancho,M.
Rodriguez, M. J. García-Velloso, P. DeCastro, E. Ornilla, J. Á.
Richter; Clinica Universidad de Navarra, Pamplona, SPAIN.
AIM: To estimate the diagnostic contribution of Technetium
99m pertechnetate salivary gland scintigraphy (SGS) in referred
patients due to suspicion of Sjögren’s Syndrome (SS). The as-
sociation among the degree of involvement shown by SGS,
antibodies, biopsy result, and final diagnosis, was evaluated.
MATERIALS AND METHODS: 87 SGS were performed in
84 subjects, who were sent from different specialty physicians
(Neurology, Internal Medicine, and Rheumatology). All the pa-
tients underwent scintigraphy using a standardized protocol that
included a sequential acquisition of images (1 minute/frame)
and a salivary stimulation with citric acid 30 minutes later.
Curves and glandular uptake were assessed qualitatively. Re-
garding the number of affected glands (n), four scintigraphic
patterns were stablished: P-I (n=0), P-II (n=1), P-III (n=2), and
P-IV (n≥3). Salivary gland biopsy was made in 19 patients, and
ANA/ENA antibodies in 75. SS final diagnosis was confirmed
in 23 cases, as stated in the American-European Consensus
Criteria (AECC). RESULTS: Gland biopsy was positive in 9
patients (7 of which showed an altered uptake in SGS) and
negative in 4 patients. Nevertheless, 6 samples got inconclusive
results. ANA/ENA antibodies were detected in 42 cases, and
negative in 33. Normal scintigraphic uptake was pointed out in
20 subjects, and abnormal patterns were reported in 67: 13 P-II,
26 P-III, and 28 P-IV. In relation to the final diagnosis, SGS
globally depicted 84.6% sensitivity, 26.2% specificity, 32.8%
positive predictive value (PPV), and 80% negative predictive
value. These results were respectively modified by the four
aforementioned uptake patterns. P-II: 33.34%, 66.67%, 20%,
and 80%. P-III: 63.6%, 42.1%, 24.14%, and 80%. P-IV:
76.5%, 51.6%, 46.4%, and 80%. Assuming the antibodies pres-
ence as reference value, SGS result showed coincidence in 39
subjects, supporting or discarding SS diagnosis. There were
discordant results in 36 patients: 21 of them were considered
false-positive scintigraphy, 14 of which maintained
antisialogogue therapy; 9 were false-negative scintigraphic
cases, 3 referred previous sialoadenitis, 2 got a false-negative
result for antibodies, and there was 1 patient lost. CONCLU-
SION: SGS is a useful diagnostic tool for the diagnosis of SS.
Its performance improves significantly according to the number
of affected glands.When interpretating SGS results in suspected
SS, we may need to consider the coexistence of other
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circumstances which could modify salivary secretion, particu-
larly the concurrence with antisialogogue drugs.
OP353
Surgical planning issues of radio-guided sentinel node
biopsy (SNB) in patients (pts) with second primary
ipsilateral breast cancer (SPIBC)
C. Peterle, C. Cittanti, P. Carcoforo, M. Portinari, V. de
Cristoforo, I. Santi, S. Panareo, L. Feggi; S. Anna University
Hospital, Cona (FE), ITALY.
Background: Widespread of breast-conserving surgery and the
boost of life expectancy in these pts contribute in increasing the
number of women with SPIBC who have to undergo second
radio-guided SNB.The aim of this retrospective study was to
assess incidence and sites of possible altered lymphatic drainage
in pts who underwent SNB for SPIBC and its impact in the
increasing percentage of due conversion of the surgical treat-
ment from local anaesthesia to general anaesthesia.MethodsWe
re-eva lua ted a l l da ta about p t s who underwent
lymphoscintygraphy(LS)for detection of SNB since October
2012 to March 2015, dealing separately with pts with SPIBC:all
of them had previous breast-conserving surgery,with either SNB
o r S NB f o l l o w e d b y a x i l l a r y l y m p h - n o d e
dissection(ALND).The day before surgery we injected the
tracer(Nanocoll® 70MBq)with periareolar intradermal
technique(PA)if the surgeon was planning to remove SN only
in local anaesthesia,whereas intra and peritumoral
injection(IPT)was used if the surgeon was planning to remove
simultaneously SN and breast cancer.We considered SN in ab-
normal lymphatic drainage basin all the SN located in sites other
than ipsilateral axilla.We dealt separately with non-identified
SN.ResultsIn our NM Unit SN lymphoscintigraphy was per-
formed on 745 pts:722 to detect SN for primary breast cancer;23
because affected by SPIBC(3.09%).No SN was visualized in
8/722 pts(1.11%),while in 1 pt SN was not in the ipsilateral
axilla(1/722;0.14%).Among the 23 pts with SPIBC,in 6
pts(26.1%)SN was not found neither by LS nor during surgery
by gammaprobe(all these pts previously underwent ipsilateral
complete ALND);at least one SNwas removed in 17/23 pts.The
SN was found in ipsilateral axilla in 10/17 pts(58.82%:1 IPT;9
PA);in abnormal site in 7/17 pts(41.18%):contralateral axilla
3/17 pts(17.65%: 1 IPT, 2 PA);internal mammary 3/17
pts(17.65%:1 IPT,2 PA);anterior subcostal site 1/17 pts(5.88%
PA).19/23 pts underwent surgery in local anaesthesia(82.6%
PA),while 4/23 pts in general anaesthesia(17.4% IPT).In
3/17 pts(17.6%),in order to remove the LS-located SN in
deep sites,it became necessary to delay surgery to con-
vert from local to general anaesthesia.In one case (ante-
rior subcostal site) SPECT-CT was necessary to locate
SN during preoperat ive LS. Conclusions: This
preliminary study shows that surgical planning(based
on LS and SPECT-CT results)is critical in SPIBC
pts(compared to not previously operated pts),being
higher the percentage of SN non-visualized or in abnor-
mal site,which require general anaesthesia(26.1% vs
1.11%;41.18% vs 0.14%:p<0,01).In pts who already
underwent ALND,as expected,the rate of SN detection
is significantly reduced,thus leading to ineffective
surgery.
OP354
Factors influencing brown fat activation in FDG PET/CT:
a retrospective analysis of 21,000+ cases
J. Steinberg, E. Vegt; Netherlands Cancer Institute, Amster-
dam, NETHERLANDS.
Aim: Brown fat, or brown adipose tissue (BAT), is known to
exhibit high uptake of 18F-fluorodeoxyglucose (FDG) on posi-
tron emission tomography (PET), and can either be mistaken for
malignancy or obscure underlying malignancy. BAT activation
is associated with age, body mass index, gender, and ambient
temperature. Nuclear medicine physicians have sought ways to
reduce BAT activation, such as the administration of diazepam
prior to injection of FDG, which is thought to decrease BAT
activation via a reduction in sympathetic activity. The goal of
this study was to gain further insight into the relative contribu-
tion of factors that may influence the activation of BAT. Mate-
rials and methods: A retrospective study of FDG PET/CT scans
was performed using a database of PET/CT reports of 21,326
patients through the years of 2007-2014. The report contains
information regarding the date and time of the scan, the age
and gender of the patient, observed BAT activation, and the
administration of diazepam. The date of the scan was used to
determine average outdoor temperatures using data from that
National Climatic Data Center (Asheville, North Carolina, Unit-
ed States). The data were analyzed using software developed in-
house. Results: The number of patients with BATactivation was
864 (4.1%). BATactivationwas observed to be higher inwomen
than in men (6.2% vs. 1.6%, p < 0.0001), higher in patients
under 60 years old than over 60 years old (6.6% vs. 1.9%, p <
0.0001), higher when average outdoor temperatures were below
10°C than above 10°C (4.8% vs. 3.4%, p < 0.0001), and higher
for FDG injections in the morning than in the afternoon (4.6%
vs. 3.3%, p < 0.0001). Diazepam usage was associated with
much higher BAT activation (14.1% vs. 2.7%, p < 0.0001),
among both genders, all ages, and outdoor temperatures. Con-
clusion: This large retrospective study providesmore insight into
the relative importance of several factors known to influence
BAT activation. Using this information, additional measures
can be taken to reduce BAT activation among high-risk individ-
uals during FDG PET examinations. However, contradictory to
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our expectation, we observed much higher BAT activation in
patients who had received diazepam before the scan. This sug-
gests that diazepam increases the likelihood of BAT activation,
but it may also be due to the fact that patients at increased risk of
BAT activation were selected to receive diazepam. More pro-
spective studies are warranted to elucidate this finding.
OP355
Role of HIF-1 in Hypoxia Stimulated Glucose Metabolism
in Human Endothelial Cells
J. Paik1, j. Park2, K. Jung3, K. Lee4; 1samsung medical center,
seoul, KOREA, REPUBLIC OF, 2samsung medical center,
sungkyunkwan university, seoul, KOREA, REPUBLIC OF,
3Samsung medical center, Sungkyunhwan University, seoul,
KOREA, REPUBLIC OF, 4samsung medical center, Samsung
medical center, Sungkyunhwan University, seoul, KOREA,
REPUBLIC OF.
Aim-Hypoxia is a common denominator of many vascu-
lar disorders and can profoundly affect endothelial func-
tion and metabolism. In this study, we evaluated the ef-
fect of oxygen depletion on endothelial 18F-FDG uptake,
GLUT1expression and hexokinase activity, and investi-
gated the role of HIF-1α in this response. Methods and
Results― Human umbilical vein endothelial (HUVE)
cells under normoxia, hypoxia, and reoxygenation were
evaluated for 18F-FDG uptake, hexokinase activity, and
Western blot analysis of GLUT1 and HIF-1α protein.
The role of HIF-1α in hypoxia-stimulated 18F-FDG up-
take was assessed by stabilization with a HIF-1α inhibi-
tor. In addition, the effect of HIF-1α in hypoxia-
stimulated HUVE cells was measured by 18F-FDG up-
take and HIF-1α expression level with HIF-1α siRNA
transfection and HIF-1α inhibitor. Furthermore, HIF-1α
activation in hypoxic HUVE cells was assessed by HIF-
1α transcription factor assay. Involvement of potential
signaling pathways was investigated with respective pro-
tein kinase inhibitors. Exposure to hypoxia for 6 and 16
hr increased HUVEC 18F-FDG uptake to 181.0 ± 9.1%
and 196.4 ± 1.1% of controls, respectively. Reoxygena-
tion after 16 hr hypoxia gradually recovered 18F-FDG
uptake to 4 hr. Hypoxia also induced a 3.9 ± 0.7 fold
elevation of hexokinase activity, and a significant in-
crease in GLUT1 and HIF-1α levels. HIF-1α stabiliza-
tion with DMOG was sufficient to sustain hypoxia-
stimulated 18F-FDG uptake during reoxygenation and to
increase 18F-FDG uptake in normoxic conditions. Hyp-
oxic HUVE cells significantly increased HIF-1α activa-
tion using transcription factor assay to 2.51 ± 0.02 fold
elevation of controls. HIF-1α was activated by hypoxia
and inhibition of the protein with HIF-1α siRNA and
HIF-1α inhibitor completely abrogated the ability of hyp-
oxia to increase HIF-1α and FDG uptake. Cyclohexi-
mide, tyrosine kinase inhibition with genistein, and pro-
tein kinase C (PKC) inhibition with staurosporine
completely abolished hypoxia-stimulated FDG uptake by
inhibiting HIF-1α increase. PI3 kinase inhibition with
wortmannin blocked hypoxia-stimulated FDG uptake,
not by inhibiting HIF-1α increase but by attenuating
HIF-1α transcription activity. Conclusions― Hypoxia en-
hances endothelial cell glucose uptake by upregulating
hexokinase activity and GLUT1 expression. The findings
further indicate that HIF-1α plays a central role in this
metabolic response with dependence of its increase on
PKC and transcription activity on PI3K activities. Our
findings provide a molecular basis for the mechanism in
which ECs respond to acute hypoxia. The results of this
study suggest that cross-talk between AMPK and Akt is
essential for angiogenesis under conditions of hypoxic
stress, but dispensable for angiogenic cellular responses
in normoxic endothelial cells.
OP356
Initial Experience with PET/MRI in the Evaluation
of Diabetic Foot
D. Franceschi, K. Yaddanapudi, R. Matthews, V. Brunetti, B.
Martin; SUNY at Stony Brook, StonyBrook, NY, UNITED
STATES.
INTRODUCTION: Osteomyelitis is a common complica-
tion of diabetic foot Infections. Accurate diagnosis of
bone involvement in the setting of complicated diabetic
foot is a diagnostic challenge. We present our initial
experience with FDG PET/MRI to determine bone in-
volvement in diabetic patients with chronic foot infec-
tion. MATERIAL AND METHODS: Seven patients with
chronic foot infection and clinical suspicion of osteomy-
elitis underwent PET-MRI of the foot. The MR imaging
findings were graded as Grade 0 – normal signal, Grade
I - hazy reticulated, T1 hypointense signal, Grade II -
confluent T1 hypointense signal. Grade II, confluent sig-
nal was considered diagnostic of osteomyelitis. Reticu-
lated signal was believed to reflect edema on MRI. Ab-
normal focal increased FDG uptake localizing to the
bone on fused PET-MRI images was considered as os-
teomyelitis. Five of the seven patients subsequently
underwent surgery. Two patients diagnosed with osteo-
myelitis refused surgery and opted for conservative ther-
apy. RESULTS: All seven patients had osteomyelitis ac-
cording to PET- MRI findings. Five patients had osteo-
myelitis on histopathology and 2 patients according to
secondary clinical end points. Three cases with FDG
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uptake involving the bone on fused images had negative
MRI patterns (Grade I reticulated T1 hypointense signal
or no signal change). All the cases positive on MRI
were positive on FDG-PET. The sensitivity of PET-
MRI to diagnose osteomyelitis was 100% in this small
series of diabetic patients with chronic foot infection.
CONCLUSIONS: PET-MR proved to be highly sensitive
modality with high reader confidence for diagnosis of
osteomyelitis in diabetic foot infections, reflecting com-
plimentary nature of these modalities.
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OP357
Scatter correction requirements for quantitative I-131
SPECT: Triple Energy Window and full Monte Carlo
correction compared in phantom acquisitions
C. A. J. van Gils1,2, R. van Rooij1, C. Beijst1, H. W. A. M. de
Jong1; 1University Medical Center Utrecht, Utrecht,
NETHERLANDS , 2S t . An t o n i u s Z i e k e nhu i s ,
Nieuwegein, NETHERLANDS.
Aim: For accurate dosimetry in I-131 therapy, reliable quanti-
tative SPECT reconstructions are essential. However, due to
the complex emission spectrum of this isotope, accurate scatter
correction is not trivial. Especially downscatter from higher
energetic 606 keV gamma emissions in the 364 keV
photopeak energy window poses a challenge. The goal of this
research is to compare the effectiveness of two different scatter
correction methods, namely triple energy window (TEW) and
full Monte Carlo scatter correction. By doing this, scatter cor-
rection requirements for performing quantitative I-131 SPECT
can be derived. Materials and methods: A NEMA IEC body
phantom is used in which the two largest of the six fillable
spheres contain non-radioactive water, whereas the other
spheres contain I-131 solution in an activity concentration ra-
tio of approximately 10:1 compared to the background com-
partment. Acquisitions are performed using a Siemens Symbia
T16 utilizing the HE collimator over 120 angles. Total acqui-
sition duration is varied to investigate the influence of noise
and activity on the scatter correction performance. Using the in
house developed and validated reconstruction software
Utrecht Monte Carlo System (UMCS), reconstructions are
generated without scatter correction, with TEW scatter correc-
tion and with full Monte Carlo-based scatter correction. All
methods use OSEM reconstruction with 8 subsets with vary-
ing number of iterations (1-40). The resulting data is analyzed
along the NEMA NU 2-2007 guidelines, calculating hot- and
cold-sphere contrast, as well as the percentage of background
variability and the residual count error in the lung insert. Re-
sults: As expected, applying no scatter correction yields the
poorest results in all measured parameters. The TEW correc-
tion method results in overestimation of scatter contribution in
the photopeak window, leading to erroneous quantification
and unrealistically high recovery coefficients. Monte Carlo
scatter calculations on the other hand provided validated, ac-
curate scatter corrections, regardless of object geometry and
scan duration and resulted in a significant improvement of all
measured parameters over no scatter correction. Conclusion:
Scatter correction is important in accurate I-131 quantification.
Conventional TEW correction can yield overestimations of
scatter, potentially leading to consequent underestimation of
total uptake and apparent increase in hotspot uptake in clinical
scans. Therefore, extra caution should be exercised when
using TEW correction for quantification purposes. Full Monte
Carlo calculations provide object-specific scatter corrections
leading to the most accurate quantification. Therefore, it is
considered the method of choice for quantitative I-131
SPECT.
OP358
Absolute quantification in SPECT - a phantom study
J. Kupferschlaeger, J. Lott, L. Kuenzel, H. Dittmann, C. la
Fougère; University Hospital Tuebingen/Department of
Radiology/ Division of Nuclear Medicine, Tuebingen, GER-
MANY.
Aim: New software solutions like Q.Metrix® (GE Healthcare)
promise absolute quantification of SPECT data using attenua-
tion-, scatter correction and resolution recovery. Aim of this
study was to investigate the accuracy of quantification as well
as scatter correction, the determination of recovery coefficients
(RC) for partial volume correction (PVC), the influence of CT
high voltage (HV) and tube current on quantification. Material
and methods: IEC-Phantom with Hot-Sphere-Insert (6 hollow
spheres with diameters 10-37mm) and lung insert was filled
with 99m-Tc for three lesion to background ratios (LBR):
LBRinf (1:0), LBR4 (4:1), LBR8 (8:1). All measurements
were performed on a Discovery 670 NM/CT PRO® (GE)
SPECT/CT system. For each LBR we performed CTs with 3
HV-settings (140kVp, 120kVp, 100kVp) and for each HV
three tube-current settings (10mA, 30mA and 75mA, rotation
time 0.8 sec). Reconstruction was performed with OSEM al-
gorithm (2i10s, no pre- and postfiltering) including scatter-,
CT-based attenuation correction and resolution recovery. For
quantification we used the following VOIs: 2 VOIs in the
phantom background, 6 VOIs for the spheres using threshold
segmentation, 2 cylindrical VOIs in the (cold) lung insert and a
VOI for the whole phantom. For each VOI we determined
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average and maximum activity concentration in Bq/ml. Re-
sults: CT HVand tube current has minor influence on quanti-
fication: we observed a maximum deviation less than 1.6%
from the activity concentrations using a reference CT
(120kVp, 75mA) for attenuation correction. The total activity
in the phantom as well as the activity concentration in the
background could be reproduced excellently with a maximum
error of 5%. Resolution recovery improves the recovery for
volumes larger than 5 ml by approx. 20% but was limited for
volumes smaller than 5 ml. Maximum values from the VOIs
tend to be overestimated (RC-range 1.0 to 1.5 for large vol-
umes) depending on iteration parameters and the LBR. Aver-
age values depended on VOI type and accurate VOI-place-
ment. The smallest two spheres (10mm, 13mm) could hardly
be quantified or detected for LBR8 and LBR4. Scatter correc-
tion underestimates the scatter fraction: about 50% of the back-
ground activity concentration was found in the cold lung in-
sert. Conclusions/Discussion: Absolute quantification of
SPECT data using the Q.Metrix® software is possible if all
corrections are applied. This is valid for large structures like
organs but PVC should be applied for quantification of small
lesions. Further improvement of scatter correction is needed.
OP359
Absolute quantification in a commercial SPECT/CT:
Tc-99m Activity recovery in NEMA/IEC
and anthropomorphic phantoms.
S. Gnesin1, P. Leite Ferreira2, J. Malterre2, J. Prior2, F. Ver-
dun1; 1Institute of Radiation Physics, Lausanne University
Hospital, Lausanne, SWITZERLAND, 2Department of Nucle-
ar Medicine, Lausanne University Hospital, Lausanne, SWIT-
ZERLAND.
Aim: Similar to PET, absolute quantitative image modality is
becoming available in commercial SPECT/CT devices. The
goal of this study was to assess the quantitative accuracy of
activity concentration recovery as a function of image recon-
struction parameters using a NEMA/IEC and an anthropomor-
phic abdominal phantom. Materials and methods: We per-
formed quantitative 99mTc-SPECT/CT acquisitions (Siemens
Symbia Intevo) of a NEMA/IEC phantom (6 hot spheres,
10:1 sphere to background activity ratio, 1 lung insert) and
an anthropomorphic abdominal phantom (commercial Kyoto
Liver/Kidney phantom) including a liver insert (volume=1.8L)
with 3 hot-spheres (20-30-40mm diameter, 5:1 hot-sphere to
liver activity concentration ratio). Background activity con-
c en t r a t i on (ACb g ) wa s 33 / 104 kBq /mL in t h e
NEMA/abdominal phantom respectively. SPECT acquisitions
used 120 projections (20s/projection). Reconstructions were
performed with the proprietary iterative conjugate gradient
algorithm. Reconstruction parameters such as iteration number
(It range: 4-48, 6 subsets) and gaussian smoothing (FWHM
range: 0-10 mm) were varied. Recovery coefficients (RC,
mean and max), relative lung error (only for the NEMA phan-
tom) and image noise (COV) on the background were
assessed. Results: On the NEMA phantom, measured ACbg
was <6% from the expected true value for all tested cases.
RC increased less than linearly with iterations. RC relative
increment (mean/max) was 13/18%, 8.5/12%, 4/7.5% when
varying from It=4 to 8, 12 to 24 and 24 to 48 respectively.
It=20 and gaussian smoothing of 7.5mm limited the COV to
≤20%. In these conditions RC (mean/max) were 0.8/1.2 for
lesion size > 5 mL and 0.42/0.55 at 1 mL. Lung relative error
was fairly sensitive to It changes and ranged from 8 to 12%
with increasing smoothing levels. Comparable ACbg accuracy
and RC values were found for the abdominal phantom. In this
specific case, the higher activity concentration resulted in re-
duced background variability (COV=10% at It=20, FWHM =
7.5mm). Conclusions: Absolute quantification in commercial
SPECT/CT is becoming available. The tested device provided
a good accuracy in background activity recovery. Relative
lung error was comparable to PET levels assessing the efficient
integration of attenuation and scatter corrections with adequate
detector modeling. Reliable SPECT quantification has the po-
tential to improve clinical outcome and radiation dosimetry
assessments. Reconstruction parameters influence RC (and
thus SUV), and optimization is recommended in accordance
with clinical requirements.
OP360
Comparison of Image Reconstruction Techniques
for Single Photon Emission Computed Tomography
(SPECT)
M. Dimcheva, S. Sergieva, A. Jovanovska; Sofia Cancer Cen-
ter, Sofia, BULGARIA.
The aim of this study was to compare the performance of
filtered backprojection (FBP) and iterative reconstruction al-
gorithms available in clinical SPECT software. Materials and
Methods: SPECT images of a Jaszczak phantom with cold rod
inserts, hot and cold spheres and capillary line sources were
acquired on a dual-head SPECT-CT system Symbia T2, Sie-
mens. Image acquisition was performed using a 180° non cir-
cular orbit for each detector, with 120 projection angles, 500
000 counts per projections 128 × 128 matrix size, zoom = 1
and pixel size of 4.8mm. A symmetrical 15% wide energy
window for the acquisition was centered at 140 keV. The phan-
tom studies were acquired for 30 sec per projection angle. FBP
reconstructions were performed by use of the ramp filter lim-
ited at the Nyquist frequency (0.5 cycle per pixel). The differ-
ent type of filter using FBP reconstructions was also consid-
ered. The images reconstructed with OSEM were filtered with
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a symmetric 3-D Gaussian function having a full width at half
maximum of 1 pixel (4.8mm). Iterative reconstruction of these
images was halted after 12 iterations using 4 subsets. Each
combination of subsets and iterations was applied to the same
set of noisy projection data. The linear attenuation correction
was set to μ = 0.15 cm -1. Results: The effect of image
smoothing with the use of Gauss filter with different FWHM
=mm are shown. Application of Gauss post-filtering degrades
the contrast but did not affect the high quality of images. How-
ever, this result applies only if Gauss filter’s FWHM coeffi-
cient does not exceed a double value of the pixel size. Gener-
ally, iterative technique (OSEM algorithm) gives better out-
comes for both the qualitative and quantitative assessment of
SPECT studies in comparison to FBP method. Conclusion:
The quality of the image depends on several factors such as
spatial resolution, contrast and noise. Proper filter selection is
significant for the improvement of the image quality and there-
fore for the diagnostic evaluation.
OP361
Quantitative Yttrium-90 PET/CT acquisition
and reconstruction optimization: An anthropomorphic
phantom validation.
S. Gnesin1, L. Paterne1, A. Boubaker2, S. Adib2, M. Pappon2,
M. Kosinski1, J. Prior2, S. Baechler1, F. Verdun1; 1Institute of
Radiation Physics, Lausanne University Hospital, Lausanne,
SWITZERLAND, 2Department of Nuclear Medicine, Lau-
sanne University Hospital, Lausanne, SWITZERLAND.
Aim: Post-radioembolization 90Y spatial distribution and radi-
ation dosimetry can be obtained from clinical quantitative 90Y-
PET/CT and used to evaluate treatment outcome and validate
predictive dosimetry based on 99mTc-MAA SPECT/CT. We
aimed at determining optimal reconstruction parameters for
quantitative 90Y-PET/CT acquisition of an anthropomorphic
abdominal phantom. Materials and methods: We performed
10 sequential (1 per day) PET/CT scans (Discovery 690, GE-
Healthcare) of an anthropomorphic abdominal phantom in-
cluding a liver insert (volume=1.8L) with 3 hot-spheres (20-
30-40mm diameter). Hot-sphere to liver 90Y activity concen-
tration (ACbg) ratio was 5:1. Initial liver background activity
concentration was 1MBq/mL. The rest of the phantom being
water filled. ACbg linearity as a function of time was assessed
in the liver background. At each time point, recovery coeffi-
cients (RC, mean and max) and contrast-to-noise ratio (CNR)
in hot spheres and image noise (COV) in the liver background
were assessed as a function of different reconstruction param-
eters: OSEM iterations (It=1, 2, 3, subsets=24), frame duration
(Fd=20, 30, 45 min). The impact of Time-of-flight (TOF) in-
formation and point-spread-function (PSF) recovery where al-
so assessed. Results: TOF-based reconstructions provided
ACbg and RC convergence in 1 and 2 iterations respectively,
while 2/3 iterations where required for ACbg/RC to converge
to a stable value otherwise. Furthermore, TOF reconstructions
minimized spurious signal in regions without activity concen-
tration. Higher RCs were obtained for combined TOF+PSF
reconstructions regardless other reconstruction parameter
combinations (RCmean from 0.45 in 20-mm spheres; 0.5 in
30-mm spheres; 0.65 in 40mm spheres). Measured ACbg in
TOF+PSF reconstructions was <8% from the expected true
value down to 300 kBq/ml where no-TOF reconstructions
resulted in up to 20% ACbg underestimation. PSF-based re-
constructions (It=2, Fd=30 min) displayed COV≥40% for
ACbg<300kBq/mL; the same level of noise was found for
ACbg<450kBq/mL when no PSF recovery was applied. When
using TOF+PSF reconstructions (It=2, Fd=30 min), lesions
detectability (CNR>4) was possible down to 1000/800/600
kBq/mL on the 20/30/40mm sphere respectively. Conclusions:
Combination of TOF and PSF improves quantitative assess-
ment in intrinsically low-statistic 90Y-PET acquisitions. TOF+
PSF based reconstruction significantly reduced correlated
noise and improved activity recovery convergence and detect-
ability at matched frame duration.
OP362
FDG uptake quantification: a new approach using tumour
delineation on maximum intensity projections
A. de Jong1, B. A. Blomberg1, R. A. Nievelstein1, V. Frings1,
G. Kramer2, A. J. de Langen2, O. S. Hoekstra2, R. Boellaard2;
1UMC Utrecht, Utrecht, NETHERLANDS, 2VU Medical
Center, Amsterdam, NETHERLANDS.
Aim: To study the performance of a new approach for FDG
uptake quantification using tumour delineation on PET maxi-
mum intensity projections (MIPs). The tool is designed to
allow faster tumour delineation by minimizing user interaction
(i.e. it is not required to delineate each lesion in all PET image
slices). The tool specifically enhances workflow in case the
patient has a large number of lesions. Materials and methods:
A new tool was developed that generates FDG whole-body
PET/CT MIPs at 0 (coronal), 45, 90 (sagittal) and 135 degrees
(MIP tool). Next, tumours can be delineated manually with or
without intensity thresholds on these MIPs. These MIP delin-
eations are then back-projected to the FDG PET/CT images to
obtain an initial tumour mask per lesion. Final tumour delin-
eations are then derived by performing a region growing meth-
od starting at the maximum intensity voxel per lesion (within
these masks), using a background corrected 50% of maximum
threshold (A50%). From the final delineation SUVmax,
SUVmean, metabolic active tumor volume (MATV) and total
lesion glycolysis (TLG) are derived. The performance of the
method was tested using the NEMA NU 2 Image Quality
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phantom, and in eight FDG whole-body PET/CT scans of
therapy-naïve non-small-cell lung cancer patients. The phan-
tom study was performed according to EARL specifications
and the patients were examined following the EANM FDG
PET/CT guidelines (Boellaard et al EJNMMI 2015; 42: 328-
54). Phantom data will be compared using the expected uptake
parameters, and both phantom and clinical data will be com-
pared using an image based A50%method (Cheebsumon et al
EJNMMI 2012; 2: 56) to delineate tumours (VOI tool). Re-
sults: For the phantom study MIP tool SUVmax approached
real SUV by 96%. MIP tool SUVmean approached real SUV
by 77%. MIP tool MATV and TLG approached real volume
and real TLG by 83% and 65% respectively. For the phantom
study SUVmax and SUVmean were identical for both tools.
MATV as well as TLG differences were within 1% between
both tools. In the clinical studies, SUVmax as well as
SUVmean were identical between both tools. MATV and
TLG differences ranged between 0-4% and 0-3% respectively.
Conclusion: The MIP based delineation approach provided
comparable (<4%) results to those obtained using the image
based delineation approach. The method may require less user
interaction in case of multiple lesions and could be an interest-
ing alternative for assessing total tumour burden quickly.
OP363
The influence of ignoring higher bone attenuation
on pelvic and spinal lesions in [18F]NaF PET/MRI
examinations.
G. Schramm1,2, L. Oehme3, J. Maus2, F. Hofheinz2, J. Petr2,
A. Lougovski2, B. Beuthien-Baumann3, J. van den Hoff2; 1KU
Leuven, Leuven, BELGIUM, 2Helmholtz-Zentrum Dresden-
Rossendorf, Dresden, GERMANY, 3Universitaetsklinikum
Carl Gustav Carus, Dresden, GERMANY.
Aim: MRI-based attenuation correction (MRAC) in clinical
whole-body PET/MRI imaging routinely is based on tissue type
segmentation. Due to lack of MRI signal in cortical bone and the
varying signal of spongeous bone, standard whole-body segmen-
tation-based MRAC neglects the difference between the attenu-
ation coefficient of soft tissue and the (higher) one of bone
(MRAC-nobone). In the present work we have quantified the
bias caused by MRAC-nobone in spinal and pelvic lesions in
20 PET/MRI examinations with [18F]NaF using the reconstruct-
ed PET standard uptake value (SUV) as the relevant measure.
Methods: We reconstructed 20 PET/MRI [18F]NaF patient data
sets acquired with a Philips Ingenuity TF PET/MRI. First, we
used the vendor-provided MRAC-nobone algorithm to recon-
struct PET-nobone. Second, we used a threshold-based algorithm
developed in our group to automatically segment bone structures
in the [18F]NaF PET images. Subsequently, an attenuation coef-
ficient of 0.11 1/cm was assigned to the segmented bone regions
in the MRI-based attenuation image (MRAC-bone) which was
used to reconstruct PET-bone. The automatic bone segmentation
algorithm was validated in 6 PET/CT [18F]NaF examinations.
Finally, relative SUVmean and SUVmax differences between
PET-bone and PET-nobone of 8 pelvic and 41 spinal lesions,
and of other regions such as lung, liver, and bladder were calcu-
lated. Results: The comparison of [18F]NaF-based and CT-based
bone segmentation in the 6 PET/CT patients showed a Dice
similarity of 0.7 with a true positive fraction of 0.72 and a false
positive fraction of 0.35. The [18F]NaF-based bone segmenta-
tion worked well in the pelvis and spine. However, it showed
artifacts in the skull and in the extremities. The analysis of the 20
[18F]NaF PET/MRI examinations revealed relative SUVmax
differences between PET-nobone and PET-bone of (-8.7% ±
2.7%, p = 0.01) and (-8.1% ± 1.9%, p = 2.4e-8) in pelvic and
spinal lesions, respectively. A maximum SUVmax underestima-
tion of -13.7%was found in lesion in the third cervical spine. The
averaged SUVmean differences in volumes of interests in lung,
liver and bladder were below 3%. Conclusion: Neglecting higher
bone attenuation in MRAC leads to a systematic moderate SUV
underestimation in spinal and pelvic lesions. The developed au-
tomatic [18F]NaF PET-based bone segmentation allows to in-
clude higher bone attenuation in whole-body MRAC and thus
improves quantification accuracy for pelvic and spinal lesions in
[18F]NaF PET/MRI examinations enabling direct comparisons
to PET/CT examinations.
OP364
Evaluation of Siemens SMART Neuro AC Calculated
Attenuation Correction for FET PET
P. Ritt, T. Kuwert, C. von Gall; Clinic of Nuclear Medicine,
University Hospital, Erlangen, GERMANY.
Aim: Correction for photon attenuation (AC) in PET is essential
for quantitative imaging. Before hybrid PET/CT scanners were
available, emission-based, calculated AC was common. It is
generally accepted that for PETexaminations of the brain, hybrid
PET/CT often adds little benefit beyond AC. For this reason,
enhanced calculated ACmethods have been (re-)introduced into
hybrid PET/CT and PET/MRI scanners. We aimed for evaluat-
ing the accuracy of one of these calculated ACmethods, namely
Siemens’ SMARTNeuro AC, which has recently become avail-
able. Materials and MethodsFET PET/CTs were acquired for 17
patients (6 male, 11 female, mean age 36±15 y), suspected of
recurrent cerebral malignancies. The average injected dose was
200±50 MBq at 73±18 kg. The PET images were reconstructed
from the counts acquired between 30 and 60 min p.i. The recon-
struction was carried out with OSEM3D at 12 subsets, 4 itera-
tion, and 5.0 mm Gaussian smoothing. AC images were obtain-
ed using the CT data (CTAC), as well as by applying the
SMART Neuro calculated attenuation correction (calcAC).
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S151
Images that represent the difference between both AC strategies
were generated and non-rigidly registered to an MRI atlas. By
this, the differences between calcAC and CTAC were evaluated
in 19 MRI-defined brain regions. Additionally, the differences
for FET-positive lesions were assessed in terms of change of the
ratio of the lesion’s SUVmax to the SUVmean of a non-affected,
contralateral region. Results: CalcAC leads, on average, to an
underestimation of activity concentration when compared to
CTAC. Subsequently, the activity of calcAC images in the pari-
etal, occipital, frontal, temporal lobes, and in the cerebellumwere
90.0: 84.4: 94.6: 89.5: 87.9% of the CTAC images’ values re-
spectively. However, the differences were symmetrical in left-
right direction. Consequently, the deviations for the quotient
SUVmax/SUVmean were smaller, on average 2.8 percent and
ranging from 0.1 to 9.9%. This deviation did not lead to any
reclassification of the lesions as either benign or malignant when
a threshold of xwas used for this purpose. Conclusion: Although
finding slightly higher deviations between CTAC and calcAC
reconstructed images than reported by the manufacturer (99% of
brain pixels below 10% error), the bias will most likely not
influence diagnoses based on SUV ratios. This fact may be at-
tributed to the left-right symmetry of the bias. Nevertheless, one
has to keep in mind the potentially lower measured activity and
should be especially cautious when comparing to data obtained
with CTAC in prior examinations.
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Interim [18F]-FDG-PET in MALT lymphoma patients
treated with immunotherapy: which Deauville score is
the best predictor of end-of-treatment outcome?
T. Traub-Weidinger, M. Raderer, B. Kiesewetter, M. Weber,
G. Karanikas, M. Mitterhauser, M. Hacker, M. E.
Mayerhoefer; Medical University of Vienna, Vienna,
AUSTRIA.
Aim: To determine, which score of the 5-point Deauville treat-
ment response scale, as assessed by interim [18F]-FDG-PET, is
the best predictor of end-of-treatment outcome in patients with
FDG-avid MALT lymphoma undergoing immunotherapy.
Method: Our prospective study included patients with histolog-
ically verifiedMALT lymphoma scheduled to receive rituximab-
based immunotherapy and to undergo whole-body [18F]-FDG-
PET/CT before treatment, after three therapy cycles (interim),
and after six therapy cycles (end-of-treatment). Patients without
FDG avidity at pre-treatment [18F]-FDG-PETwere excluded. In
the remaining patients, treatment response of all nodal and extra-
nodal lymphoma lesions visible on pre-treatment [18F]-FDG-
PET was assessed on interim [18F]-FDG-PET, separately for
four different cut-off scores of the Deauville scale: score 2 =
uptake higher than the background activity, score 3 = uptake
higher than the mediastinal blood pool, but lower than the liver;
score 4 = uptake comparable to, or slightly higher than the liver,
score 5 = uptake clearly higher than the liver. For each of the four
lesion-based cut-off scores, the ICML/Lugano classification was
used for assigning each patient to an outcome class: complete
remission (CR), partial remission (PR), stable disease (SD), or
progressive disease (PD). These interim outcomes were then
compared to the end-of-treatment outcomes according to the
ICML/Lugano classification using kappa coefficients. Results:
Fifteen patients with 35 lesions met our participation criteria.
Using a Deauville cut-off score of 2, five patients were rated as
CR, six patients as PR and four as SD at interim restaging. Using
a Deauville cut-off score of 3, seven patients were rated as CR,
four patients as PR and four as SD at interim restaging. Using a
Deauville cut-off score of 4, eight patients were rated as CR,
three patients as PR and four as SD at interim restaging. Using
a Deauville cut-off score of 5, ten patients were rated as CR, two
patients as PR, and three as SD at interim restaging. The Deau-
ville scores 2, 3, 4, and 5 showed agreement with end-of-
treatment outcomes (nine CR, three PR, three SD, and no PD)
in 66.7%, 80%, 86.7%, and 86.7%, with kappa values of 0.5,
0.67, 0.77, and 0.75, respectively. Conclusion: Interim [18F]-
FDG-PET after three cycles of immunotherapy can predict the
end-of-treatment outcome in patients with FDG avid MALT
lymphoma using a Deauville cut-off score of 4.
OP366
The Deauville Criteria and Metabolic Parameters
as Prognostic Factors in Interim PET in Hodgkin
Lymphoma: a Single Centre Experience
M. Cuzzocrea1, L. Guerra2, F. Elisei2, C. Crivellaro1,2,3, E. De
Ponti4, S. Bolis5, L. Baratto1, S. Pacella1, M. Arosio2, C.
Landoni1; 1Department of Nuclear Medicine, University of
Milan-Bicocca, Milan, ITALY, 2Department of Nuclear Med-
icine, San Gerardo Hospital, Monza, ITALY, 3Tecnomed
Foundation, University ofMilan-Bicocca,Milan, ITALY, 4De-
partment of Medical Physics, San Gerardo Hospital, Monza,
ITALY, 5Department of Haematology, San Gerardo Hospital,
Monza, ITALY.
BACKGROUND AND AIM OF THE STUDY: 18-
Fluorodeoxyglucose (FDG) positron emission tomography/
computed tomography (PET/CT) is the most accurate tool for
staging, treatment monitoring, and response evaluation in
Hodgkin lymphoma (HL). The interim-PET (i-PET) is consid-
ered predictive of final response and prognosis; early determi-
nation of treatment sensitivity by i-PET is the best tool to guide
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individualized, response-adapted treatment. This study aimed to
explore the prognostic role of i-PET in patients with HL: Deau-
ville criteria, SUVmax and SUVpeak were respectively corre-
lated to disease free survival (DFS) and overall survival (OS).
METHODS: We retrospectively evaluated 83 patients (47 men,
36 women; mean age 40±14 years, range 20-73) with newly
diagnosed HL, stage I-IV disease (5 stage I, 39 stage II, 18 stage
III and 21 stage IV). All patients were studied with 18F-FDG
PET/CT prior to treatment (baseline PET), after two cycles of
chemotherapy (i-PET) and at the end of the treatment. Treat-
ment was not changed according to the results of the i-PET. i-
PET were qualitatively interpreted by two observers using the
Deauville five-point scale. A score of 1-3 was regarded as “neg-
ative” and 4 or 5 as “positive”. Lesions with the highest FDG
uptake on i-PET was selected as “reference lesion” and
SUVmax and SUVpeak were calculated. All datasets were cor-
related with DFS and OS. ROC curves were analysed to find
best SUVmax and SUVpeak thresholds predictive for complete
response and OS. Kaplan-Meier method was used to evaluate
DFS andOS. RESULTS: Themedian follow-upwas 36months
for DFS and 50months for OS. i-PETscan resulted negative for
66 patients (79.5%) and positive for 17 patients (20.5%). The
positive and negative predictive values of i-PET for predicting
treatment outcome were 47,0% and 93,9%, respectively. The
DFS and OS for positive i-PETand negative i-PETwere 58.2%
and 96.7% (p<0.0001), and 70.6% and 98.5% (p 3 were rele-
vant on OS (p=0.014 and p=0.022, respectively); no significant
differences were found in DFS. CONCLUSIONS: Early inter-
im PET/CT is a good predictor of outcome in patients with HL.
Deauville criteria using a cut off between 3 and 4 was reliable to
discriminate patients with poor from good prognosis. Similarly,
metabolic features of reference lesion (SUVmax ≤ 3 and
SUVpeak < 3) are predictors of good prognosis.
OP367
PET/FDG and Interleukin-10 as prognostic indicators
in Diffuse Large Type B-Cell Lymphoma
L. Tagliabue1, L. Ottobrini2, C. B. Colombo2, S. Seghezzi3, I.
Libani2, A. Moro1, M. Violati1, L. De Fazio4, A. Bertolini5, P.
Foa2, G. Lucignani2; 1AO San Paolo, Milano, ITALY, 2Uni-
versity of Milan, Milano, ITALY, 3AO Treviglio-Caravaggio,
Treviglio, ITALY, 4AO Lodi, Lodi, ITALY, 5AO Valtellina e
Chiavenna, Sondrio, ITALY.
AIM: Diffuse large B-cell lymphoma (DLBCL) is the most
common non-Hodgkin’s lymphoma. In these patients, FDG/
PET has been reported to be a good prognostic indicator when
performed during therapy (interim-PET/FDG) and more so at
the end-of-therapy. However, because of the still limited prog-
nostic accuracy of interim-PET/FDG and, to some extent, also
of end-of-therapy-FDG/PET, given the evidence of IL-10
involvement in DLBCL genesis and progression, we aimed to
evaluate the prognostic role of combined IL-10 serum assay and
PET/FDG. Patiens and methods: Twenty-four drug-naive pa-
tients with DLBCL Ann Arbor stage > I underwent both IL-
10 serum assay and PET/FDG evaluation three times: at the
time of diagnosis, after 2 cycles of R-CHOP (interim), and
again at the end-of-therapy. PERCIST criteria were used for
the assessment of PET/FDG studies. Results: Interim-PET/
FDG allowed us to discriminate two patient populations: one
with a complete metabolic response, i.e. PET/FDG-negative
(15/24 patients), and another with either partial metabolic re-
sponse or progressive disease, i.e. PET/FDG-positive (9/24 pa-
tients). At end-of-therapy, PET/FDG scanwas negative in 19/24
and positive in 5/24 patients, as PET/FDG became negative in 4
patients that were PET/FDG-positive at interim. A disease re-
lapse was observed within 36 months after therapy completion
in 2/19 patients and in 4/5 patients that were FDG/PET-negative
and FDG/PET-positive, respectively, at the end-of-therapy. IL-
10 serum levels, detectable in serum at staging but not after
therapy, did not appear to be significantly related to metabolic
response. The results of IL-10 assay and PET/FDG analyzed
together conveyed these novel findings: A) High IL-10 levels (>
than 10pg/ml) at staging were recorded among all the relapsing
patients (i.e. 4/5 PET/FDG-positive and 2/19 PET/FDG-
negative at the end-of-therapy). B) When values of IL-10 mea-
sured at staging are combined with either interim- or EOT-PET/
FDG results, it is possible to stratify patients with high/low
probability of relapse with the same accuracy. C) Low levels
of IL-10 appear to characterize a population of “slow re-
sponders with favorable prognosis”, i.e. patients PET/FDG-
positive at interim and PET/FDG-negative at end-of-therapy,
that do not relapse. Conclusions: In DLBCL patients, following
2 cycles of R-CHOP, the combination of IL-10 assays and PET/
FDG increases the prognostic accuracy by decreasing both false
negative and false positive prognoses, and, at the end-of-thera-
py, allows to identify patients at high risk for relapsing disease
among both PET/FDG-positive and PET/FDG-negative sub-
jects. IL-10 could be routinely used along with FDG/PET for
the prognostic assessment of DLBCL patients.
OP368
Assessing Bone Marrow Involvement in DLBCL:
Comparison of FDG PET and Bone Marrow Biopsy
V. Ptacnik, K. Benesova, E. Cmunt, J. Kubinyi, M. Trneny;
Charles University Prague, Prague, CZECH REPUBLIC.
Aim: FDG PET/CT is important imaging method for clinical
stage determination of DLBCL. According to new guidelines
(Cheson et. al., J Clin Oncol 2014) FDG PET can in majority
of cases substitute bone marrow biopsy for possible bone mar-
row involvement evaluation. Methods: Retrospective analyze
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of 217 consecutive patients was done. The group consists of
112 men and 105 women (median age 65 years) with newly
diagnosed DLBCL. All had available staging bone marrow
biopsy (BMB) and FDG PET. We compared results of PET
and BMB to establish the differences between positivity rates
of each method. Evaluation of PET was done visually, in-
creased FDG uptake was considered positive. Focal and dif-
fuse FDG hyperaccumulation was distinguished. BMB was
evaluated histologically to determine type of involvement
and percentage of malignant cells. The confrontation of find-
ings was done; impact to clinical stage (CS) and outcome of
treatment were compared. Results: Comparing PET and BMB
findings, 82% were congruent, 71.9% of them were negative
and 10.1% positive; 17.9% findings were contradictory:
13.4% were PET only positive and 4.6% BMB only positive.
Out of 10 BMB only positive patients 8 had discordant histo-
logical finding and 2 had concordant finding with low level of
bone marrow infiltration. Analyzing PETonly, 23.5% patients
were positive, BMB positive were 14.7% findings and positive
finding according to at least one method had 28.1% patients.
Seven patients had diffusely increased FDG uptake in bone
marrow, 4 of them had positive BMB finding, 3 had negative
bone marrow biopsy - these were considered as false positive.
PET driven clinical stage was downgraded from stage IV to
localized by BMB in 2 cases and upgraded from localized to
stage IV in 1 patient. 30 of 32 patients with initial bonemarrow
involvement had BMB after treatment, 2 (6.7%) remained
BMB+. 46 of 51 initially PET positive patients had restaging
PET after therapy, 4 (8.7%) remained positive. Two of 22
initially PET+/BMB+ patients lingered PET+/BMB+ after
therapy, none remained positive only with one method. Con-
clusions: PET compared with BMB increases finding of bone
marrow involvement from 14.7% to 23.5%, combining the
methods we get on 26.7% positive findings. PET misses BM
involvement in 4.6% of patients. Almost half of the diffuse
PET+ cases are false positive, therefore we recommend bone
marrow biopsy performance in these cases.
OP369
Prolonged overall survival in metastatic melanoma
with low tumor burden at anti-PD1 initiation: CT-scan,
18-FDG-PET and blood samples
L. Dercle, S. Ammari, M. Texier, E. Lanoy, S. Champiat, D.
Deandreis, M. Terroir, A. Marabelle, M. Schlumberger;
Gustave Roussy, Villejuif, FRANCE.
PURPOSE: Immunotherapies targeting the pathway of the pro-
grammed death-1 (“anti-PD1”) receptor lead to a delayed clini-
cal response that is sustained in only a fraction of patients with
metastaticmelanoma. The rationalization of the use of this costly
drug requires identifying patients with demonstrated clinical
benefit. Patients with serum LDH>250 (biologic tumor burden
[TB], blood sample) are considered at high risk by the AJCCM-
staging system. Our group demonstrate that a TB3D>202cm3
(anatomic TB, CT-scan) is classified high risk. The primary
objective was to characterize if biomarkers extracted from the
whole metastatic tumor volume by 18F-FDG PET at anti-PD1
initiation predict overall survival [OS]. METHODS: Patients
with metastatic melanoma prospectively included in phase I
trials were eligible. All the lesions measurable at baseline within
the whole tumor volume were measured on CT-scan (anatomic
TB: TB1D, TB2D, TB3D), on FDG-PET (metabolic TB: MTV;
glycolysis: TLG, SUVmax, SUVmean and HISUV). The respec-
tive effect on OS and PFS was evaluated and derived from Cox
proportional hazard models. RESULTS: Data were available in
28 patients with a median follow-up of 13.2 months. A signifi-
cant correlation of biomarkers of TB (p<.05) was demonstrated
for anatomic TB (TB3D vs TB1D: r=.78), metabolic TB (MTVvs
TLG: r=.93), MTV/TLG vs TB3D (r=.61/.62) andMTV/TLG vs
LDH (r=.37/.40). Patients with lower TB showed a prolonged
survival: TB1D <113 (p.0008), LDH<250 (p.01), MTV<21 cm3
(p.02) and TLG<171 (p.13). Hazard ratio of death for one SD
increase were: 2.07 [1.31; 3.27] for LDH (p<.01), 2.64 [1.57;
4.45] (p<.01) for TB1D, 2.09 [1.33;3.30] (p<.01) for TB2D, 2.32
[1.45; 3.72] (p<.01) for TB3D, 1.41 [0.87;2.26] (p=.16) for
MTV, 1.08 [0.67;1.75] (p=0.76) for TLG, .87 [.47;1.59]
(p=.21) for SUVmax, 1.10 [.37;3.32] (p=.86) for SUVmean
and 0.81 [.45;1.43] (p=0.46) for HISUV. CONCLUSION: Proof
of concept that a screening of good candidate for immunother-
apy is achievable by medical imaging: low TB (anatomic, met-
abolic and biologic) at the initiation of anti-PD1 show prolonged
survival. An increased TB on CT-scan (TB3D>202cm3,
TB2D>113mm), and/or 18F-FDG-PET (MTV) and/or blood
samples (LDH>250) might identify high risk patients and the
most accurate imaging modality might depend on the dominant
site of the metastases (e.g.: FDG-PET for bone, CT-scan for
liver). Biomarkers estimating the intensity of the glycolytic ac-
tivity within the tumor volume (SUVmax, SUVmean, HISUV)
are not prognostic of OS.
OP370
Cost-effectiveness analysis of sentinel node biopsy
in patients with primary cutaneous melanoma
P. Serra-Arbeloa1,2, Á. O. Rabines-Juárez1, S. Álvarez-Ruiz3,
F. Guillén-Grima2; 1Complejo Hospitalario de Navarra, Pamplo-
na, SPAIN, 2Universidad Pública de Navarra, Pamplona, SPAIN,
3Hospital Universitario Miguel Servet, Zaragoza, SPAIN.
Aim: To develop a cost-effectiveness analysis of the role of the
sentinel node biopsy (SNB) in patients with different Breslow
thickness primary cutaneous melanomas (CM) over a 10 year
time horizon, using the health care system perspective.Methods:
A decision tree model was used to compare two different
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strategies of management of patients diagnosed with CM, wide
excision with SNB followed by complete lymph node dissection
(SNB) and wide excision only (WE). The economic and clinical
outcomes, measured as mean total cost per patient, cost effec-
tiveness ratio (CER), incremental cost effectiveness ratio
(ICER), life years saved (LYSs) and quality-adjusted life years
(QALYs), were calculated from the model. Transition probabil-
ities of disease progression and survival rates were obtained
from the published literature after a systematic review, and the
costs from government official publications. A sensitivity anal-
ysis was performed to test the robustness of themodel, analysing
the changes in different variables of every branch of the tree.
Results: Base case analyses suggested that the mean total cost
per patient with intermediate thickness CM receiving the SNB
strategy was 25,822 €with 0.84 LYSs, 0.69 QALYs, and a CER
of 30,812 €/LYS and 37,125 €/QALY; being of 22,683 € with
0.81 LYSs, 0.67 QALYs, 28,143 €/LYS and 33,780 €/QALY
when the patient received the WE only. The ICER for SNB was
97,849 €/LYS and 130,508 €/QALY. In a patient with thick CM
themean total cost of the SNBwas 36,101 €with 0.63 LYSs and
0.46 QALYs, and a CER of 57,263 €/LYS and 77,896 €/QALY.
For a WE patient was 18,185 € with 0.67 LYSs, 0.49 QALYs,
27,264 €/LYS and 37,162 €/QALY. The ICER for SNB was -
490,202 €/LYS and -692,074 €/QALY (Northwest quadrant;
SNB dominated byWE). The mean cost of the patient with thin
CM was 25,980 € with 0.92 LYSs, 0.72 QALYs, 28,897 €/LYS
and 35,943 €/QALY for the first strategy, and 7,800 € with 0.92
LYSs, 0.83 QALYs, 8,877 €/LYS and 9,365 €/QALY for the
second one. The ICER was -9,217,203 €/LYS and -165,191 €/
QALY (Northwest quadrant). The sensitivity analysis showed
no significant differences in the results. Conclusion: SNB ap-
pears not to offer an improvement in health outcomes in terms of
LYSs and QALYs for patients with thick and thin CM, and a
slight benefit for those with intermediate CM. SNB seems not to
be cost-effective compared with WE in any CM thickness.
OP371
The role of preoperative lymph node ultrasound
in patients with primary cutaneous melanoma:
a meta-analysis
P. Serra-Arbeloa1,2, Á. O. Rabines-Juárez1, S. Álvarez-
Ruiz3, F. Guillén-Grima2; 1Complejo Hospitalario de Navarra,
Pamplona, SPAIN, 2Universidad Pública de Navarra, Pamplo-
na, SPAIN, 3Hospital Universitario Miguel Servet, Zaragoza,
SPAIN.
Aim: The objective of the study was to evaluate the diagnostic
accuracy of high-resolution ultrasound (US) in detecting nodal
involvement before performing the sentinel node biopsy
(SNB) in patients with primary cutaneous melanoma (CM).
Methods: A systematic review was conducted following the
Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) guidelines criteria. An electronic search
using the terms “melanoma” and “sentinel node” was per-
formed in MEDLINE, Scopus and Web of Knowledge
(WoK) databases. Studies were considered if they reported
data on preoperative lymph node US accuracy that allowed
creating a 2x2 table, excluding those with high risk of bias
(QUADAS-2 criteria). A meta-analysis was used to calculate
the pooled sensitivity and specificity with their 95% confi-
dence intervals (95%CI) and to test heterogeneity. Sensitivity
and subgroup analyses were performed to search the articles
that provided more heterogeneity. After the study, a level of
recommendation for the use of the technique, according to the
Scottish Intercollegiate Guidelines Network (SIGN) criteria,
was established. Results: Seven articles were included. Two
of them reported accuracy data per patient, 2 per node and 3
per patient and node. A total of 1,229 patients and 2,270 nodes
were considered, with a mean SN positivity rate of 11.9% and
a mean of false negative rate of 16,4%. In the results per pa-
tient, the weighted sensitivity was 33% (95%CI=24-36%) and
the weighted specificity 93% (95%CI=91-94%). When the
results were obtained per node, the weighted sensitivity and
specificity were respectively 16% (95%CI=13-20%) and 97%
(95%CI=96-97%). In both cases, a high heterogeneity be-
tween the studies was found. After sensitivity and subgroup
analysis, the heterogeneity persisted and when the articles that
provided more heterogeneity were excluded, the sensitivity of
the preoperative US per patient decreased up to 25%. Conclu-
sions: Preoperative ultrasonography to detect lymph node in-
volvement in patients with CM presents a very low sensitivity;
a negative ultrasonographic result does not exclude lymph
node metastases. US cannot replace SNB in the detection of
lymph node metastases. The maximum level of recommenda-
tion of US for this indication is C (being A the highest and D
the lowest).
OP372
Lymphoscintigraphy and Sentinel Lymph Node Biopsy
in Cutaneous Melanoma: Analysis of 201 Patients From
a Single Institution
L. Jaukovic, M. .Rajović, M. Radulovic, L. Kandolf-
Sekulovic; Military Medical Academy, Belgrade, SERBIA.
AIM: Sentinel lymph node biopsy (SLNB) is widely accepted
method in the management of clinically localized cutaneous
melanoma. The aim of this study was to report the results on
patients scheduled for preoperative lymphoscintigraphy and
SLNB. METHODS: At Medical Military Academy, Belgrade,
250 patients were identified for SLNB between 2010-2014.
Out of them, retrospective review of 201 patients with cutane-
ous melanoma was performed. Lymphoscintigraphy was used
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in all the patients and dual labeling method (blue dye/
nanocolloid) in less than one half of them. To delineate the
relation of patients’, tumors’ and scintigraphic characteristics
with positive SLN status, we examined all variables by uni-
variate logistic regression with odds ratios representing effect
size. RESULTS: Overall identification rate of SLN was
98.5%. Positive SLN (metastatic, one or more) was seen in
47 (23.4 %) patients. Drainage to one regional basin was seen
in 176 (87.6 %) and multiple drainage regions (up to three) - in
24 patients (11.9%). In transit lymph nodes were detected in
20 patients. Univariate regression analysis with 201 cases in-
cluded in model revealed Breslow thickness, nodular melano-
ma histological subtype and acral localization- to be signifi-
cant independent predictors of SLN status (p<0.05). CON-
CLUSION: Beside the well established primary tumor thick-
ness as the predictor of SLN positivity, we observed acral body
site location and nodular melanoma to significantly enhance
the risk for regional metastases. Our data confirm that multi-
disciplinary approach of SLNB is relevant as a diagnostic and
staging procedure in cutaneous melanoma patients.
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Established and Innovative Applications for Diagnosis
W. Weber, USA
OP374
Theranostics in Clinical Experience: From Nets to Prostate
Cancer
S. Ezzeddin, GERMANY
OP375
Theranostic Targeting Vectors and Nanoparticles
F. Kiessling, GERMANY
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OP376
Normal Knee Joint Biomechanics and Surgical Techniques
of Knee Arthroplasty
R. Nizard, FRANCE
OP377
What the Surgeon Wants to Know from Imaging in Painful
Knee Arthroplasty
M. T. Hirschmann, SWITZERLAND
OP378
Radiologic Imaging
A. Hirschmann, SWITZERLAND
OP379
Hybrid Imaging in the Painful Knee Arthroplasty: Role
and Limits
H. K. Mohan, UK
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OP380
Y-90 imaging for dosimetry in radioembolization:
comparison between scatter corrected bremsstrahlung
SPECT/CTand time-of-flight PET/CT
Y. K. Dewaraja1, P. M. Novelli1, J. A. Fessler1, M. U.
Feng1, R. Nelson1, J. Rothley1, M. Ljungberg2, P. L.
Roberson1, S. J. Wilderman1; 1University of Michigan,
Ann Arbor, MI, UNITED STATES, 2Lund University,
Lund, SWEDEN.
Aim: To compare quantitative imaging of Y-90 by
scatter-corrected bremsstrahlung SPECT (SPECT+SC)
and PET with time-of-flight (PET+TOF) for dosimetry
applications. Methods: A torso phantom with 0.74 GBq
of Y-90 in liver and 60 mL tumor (5:1 tumor-to-liver)
was imaged with a Siemens Symbia SPECT/CT and
Biograph mCT PET/CT using a prolonged acquisition
(90 min in both) such that the total counts were similar
to a 20 min patient scan with 4 times the activity, which
is typical for imaging following radioembolization with
glass microspheres. A high-energy collimator and 105-
165 keV window was used for SPECT. The in-house 3-
D OSEM SPECT reconstruction used an analytical pro-
jector coupled with object-specific scatter estimates from
Monte Carlo (MC) updated after 10 iterations. 3-D
OSEM PET reconstruction was performed with 1 - 5
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iterations (21 subsets) with resolution recovery and TOF.
The tumor and healthy liver activity was quantified
using a self-calibration based on the known liver activ-
ity. For PET, activity was also quantified directly using
the image Bq/mL values provided by the system. Post-
radioembolization SPECT/CT and PET/CT for 2 patients
were also reconstructed as above and quantified using a
calibration from the phantom experiment. 3-D dosimetry
was performed using a previously developed MC algo-
rithm. Results: Tumor contrast, background noise, tumor
quantification error and healthy liver quantification er-
rors were 56%, 14%, 30%, -8% respectively for SPECT
without scatter correction, but improved to 94%, 12%,
4, -1% respectively for SPECT+SC after just 3 updates
of the scatter estimate. The corresponding results for
PET+TOF (1 iteration, 21 subsets) were 100%, 24%, -
0.5%, 0.1%, without substantial improvement with more
iterations. At equivalent noise, SPECT+SC had better
contrast and quantification than PET+TOF. Using the
direct PET quantification, activities were underestimated
by up to 19%. In patients, the estimated liver activity
compared to ‘truth’ (total administered activity account-
ing for lung shunt) was within 14% for SPECT without
SC, 6% for SPECT+SC and 9% for PET+TOF. Using
the direct PET quantification, patient liver activity was
underestimated by up to 27%. There was good agree-
ment between SPECT and PET based tumor and liver
dose volume histograms only when SC was included
(mean doses agreed to within 12%). Conclusions: For
relatively large targets, quantitative accuracy and con-
trast of bremsstrahlung SPECT+SC approaches that of
PET+TOF, but with less noise. Similarly in patients,
dose estimates based on SPECT+SC agreed well with
estimates based on PET+TOF. Further studies with small
targets are needed to compare resolution.
OP381
Study of the impact of PSF and Noise on Dose Volume
Histograms (DVH) for the dosimetry of Y-90
H. Levillain,M. Sanchez-Garcia, A. Dieudonné; Department
of Nuclear Medicine, Beaujon Hospital, Assistance Publique-
Hôpitaux de Paris (APHP) & INSERM U1149, Clichy,
FRANCE.
Our aim was to evaluate the degradation of dose-volume his-
tograms (DVH) induced by partial volume effect (PVE) and
noise independently and for simulated SPECT and PET.
Methods: First, we have analytically modelled uniform
spheres (contrast=10) with different diameters: 1 cm, 5 cm
and 10 cm (S1, S2, S3 respectively). We have analytically
simulated the effects of PVE and noise. PVE was simulated
with the convolution of a Gaussian point spread function
(PSF) characterised by full width at half maximum (FWHM).
The noise was simulated by a log-normal distribution
characterised by relative standard-deviation (RSD). For the 3
spheres, PVE and noise were applied separately for distinct
analysis, with 2 PVE: FWHM=5mm and 10mm, and 2 noises
levels: RSD=0.10 and 0.3, representative of the clinical rou-
tine. Then we have simulated the degradation of SPECT and
PET devices, according to what is observed in clinical routine,
with respectively (FWHM=10 mm, RSD=0.10) and
(FWHM=5 mm, RSD=0.3). The DVHs were computed from
absorbed dose calculation using dose-point kernels (DPK) in
each generated activity map, including the non-degraded one,
with a homogenous water medium. Finally, DVHs were com-
pared to theoretical ones, for the following absorbed dose
criteria: D80, D50, Dmean and D20. Results: PVE decreased
D80, D50 and had no impact on the other absorbed dose
criteria, except for S1 for which D20 was underestimated of
66%. The more PSF was close to sphere’s size, the more the
effect of PVE was important. As an example, for all spheres,
D80 (for which one PVE had a major impact) was
underestimated between 38% and 8.1% and between 61%
and 20% for FWHM of 5mm and 10mm respectively. Noise
decreased D80 and increased D20 and had no influences
on D50 and Dmean. For the most degrading noise level
RSD=0.1, D80 was underestimated between 0.4% and
9.5%, D20 was overestimated for all spheres, between
6.4% and 12.2%. The simulated SPECT underestimated
D80 up to 80%, D50 up to 82%, Dmean up to 79%,
and D20 up to 78%. The simulated PET underestimated
D80 up to 21%, D50 up to 17%, Dmean up to 12%,
and D20 up to 4%. Conclusion: This study highlights
the impact of PVE and noise on the DVHs, showing the
importance of controlling and evaluating these effects to
set-up absorbed dose protocols.
OP382
An inter-operator study of the accuracy of Y-90/In-111
DOTATATE dosimetry using an anthropomorphic
phantom
T. Sanderson, J. Gear, A. Divoli, A. Craig, M. Gray, I. Mur-
ray, G. Flux; The Royal Marsden NHSFT, Sutton, UNITED
KINGDOM.
Aim: To determine the accuracy and inter-operator variability of
dosimetry performed on patients undergoing Y-90/In-111
DOTATATE radiopeptide therapy using a 3D printed anthropo-
morphic phantom. Method: The 3D printed phantom was based
on a cohort of neuroendocrine patients and contained liver,
spleen, kidney and spherical hepatic lesions. Organs and lesions
were filledwith a representative concentration of Y-90 and In-111
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to that observed clinically. SPECT/CT imaging was performed
using the clinical dosimetry imaging protocol and processed by 4
independent operators. Post therapy SPECT imaging was per-
formed on a Siemens Symbia Intevo SPECT/CT system at 24,
48 and 72 hours post administration with 15% energy windows
over the 171 and 245 keV In-111 peaks and 6% windows either
side of the peaks to enable triple energy window scatter correc-
tion. Siemens Flash 3D reconstruction was performed using a CT
attenuation correction. 6 subsets and 8 iterations were sufficient
for reasonable image quality without over amplifying image
noise or generating excess resolution recovery artefacts. Scatter
data was smoothed using a 12mmGaussian kernel and corrected
during reconstruction. Organ and lesion segmentationwas carried
out using the CT image. VOI counts were converted to activity
using a pre-acquired calibration dataset. Time-activity curves
were plotted and cumulated activity was determined
from the integral of a single exponential fit. Y-90 organ
S-factors for the standard reference man were scaled for
organ mass and lesion S-factors were interpolated from
unit-density sphere S-factors from Olinda. In addition a
digitally segmented image of the phantom was inputted
into the OEDIPE Monte Carlo dosimetry tool to provide
organ specific S-factors. Results: Absorbed doses mea-
sured by different operators was consistent for all VOIs
with a coefficient of variation below 20%. Mean per-
centage errors in activity quantification across all VOIs
ranged from 4% to 21% with an average deviation of
10%. Absorbed dose accuracy ranged from 4% for le-
sions and organs greater than 4 cm in diameter to 22%
for lesions 2 cm in diameter. The Percentage differences
when using mass scaled S-factors to that calculated
using Monte Carlo varied from 3 to 10%. Inaccuracies
due to not considering organ cross-dose were less than
1%. Conclusions: The accuracy and reproducibility of
dosimetry calculations should be determined to enable
dose-response relationships to be investigated. The re-
sults from this study compare favourably with absorbed
dose calculation accuracies suggested in the literature of
30-100% and are sufficient to validate the dosimetry
methodology employed.
OP383
Modelling of a Patient-Specific 177Lu-Dotatate Therapy
Renal Dosimetry Process for Investigation of Uncertainties
J. Gustafsson1, G. Brolin1, M. Cox2, M. Ljungberg1, L.
Johansson2, K. Sjögreen Gleisner1; 1Department of Medical
Radiation Physics, Clinical Sciences Lund, Lund University,
Lund, SWEDEN, 2National Physical Laboratory, Teddington,
UNITED KINGDOM.
AIM: The aim was to investigate the uncertainties in kidney
absorbed dose and biologically effective dose (BED) for SPECT/
CT-based patient-specific dosimetry in 177Lu-Dotatate therapy.
MATERIAL AND METHODS: A Monte Carlo method for un-
certainty propagation was applied to a computer model of the
dosimetry process. As basic tools, simulated SPECT images of
three anthropomorphic computer phantoms coupled to pharmaco-
kinetic models of 177Lu-Dotatate were used. The phantoms had
well-defined absorbed-dose rate curves for every structure and
hence reference values, corresponding to “true values”, of renal
absorbed doses and BED. From the reconstructed SPECT images
(60 projections, 45 s/projection, OSEM with compensation for
attenuation, scatter and distance-dependent resolution) the renal
absorbed-dose rate was determined at four time-points (0.5 h, 24
h, 96 h and 168 h) post injection. Curve fitting yielded estimates of
the absorbed dose and BED (α/β = 2.6 Gy, Trep = 2.8 h). Uncer-
tainties were introduced in different steps of the process, in partic-
ular in the a) estimation of system sensitivity, b) variability in
imaging time-points, c) SPECT projection noise, d) CT-derived
density map used for attenuation and scatter correction and for
absorbed-dose rate determination, e) 177Lu emission spectrum, f)
kidney VOI delineation, and g) recovery coefficient. The kidney
absorbed dose and BED were then quantified in 256Monte Carlo
realisations fromwhich themean and standard deviation (SD)were
derived. By sequential replacement of the individual variable pa-
rameters by fixed values, the decrease in dispersion was analysed
as a measure of the parameter’s influence on the combined uncer-
tainty in absorbed dose. RESULTS: The kidney absorbed dose
SDs were approximately 6 % for all phantom kidneys, with the
variability in kidney recovery coefficient and the camera sensitivity
being the most influential contributors. The derived deviations be-
tweenmean and reference absorbed dosewere between -0.4% and
6.7 %. The BED results were similar to the absorbed dose results.
CONCLUSIONS: Using the dosimetry process model with as-
sumed but plausible standard uncertainties in input parameters,
the standard uncertainty in kidney absorbed dosewas approximate-
ly 6 %. The most important contributors were effects which are
correlated between imaging time-points, e.g. the recovery coeffi-
cient and the system sensitivity, while uncorrelated effects, like
SPECT projection noise and kidney VOI delineation variability,
had marginal influence on the absorbed dose estimations. The
BED was not appreciably affected by variations in the absorbed-
dose rate curve beyond the associated uncertainty in absorbed
dose.
OP384
Dosimetry of Lu-177 DKFZ-PSMA-617 for the treatment
of metastatic prostate cancer using quantitative
SPECT/CT
A. Delker, W. Fendler, A. Brunegraf, A. Gosewisch, F.
Gildehaus, P. Bartenstein, G. Böning; University of Munich,
München, GERMANY.
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Aim: Estimation of radiation dose helps to determine the op-
timal activity to achieve best therapeutic effect in combination
with limited side effects. Our aim was to perform first image
based dose calculations for tumor tissue and critical organs
after application of Lu-177 DKFZ-PSMA-617 for the treat-
ment of metastatic prostate cancer. Methods: Whole-body pla-
nar images and SPECT/CTof the abdomen data were acquired
in 10 patients (mean age 70 years) at approximately 1h, 24h,
48h and 72h after administration of 3.7 GBq Lu-177 DKFZ-
PSMA-617 on a Siemens Symbia SPECT/CT. Quantitative
3D SPECT OSEM reconstruction was performed with correc-
tions for photon scatter, photon attenuation and detector blur-
ring. A camera specific calibration factor derived from phan-
tom measurements was applied. Total activity in the kidneys,
liver, spleen, salivary glands and 4 tumor lesions in each pa-
tient were calculated using a combination of linear approxima-
tion, exponential fit, and target-specific S values according the
MIRD concept. Results: The average estimated dose ± SDwas
2.4 Gy ± 0.6 Gy in the kidneys, (0.7 Gy/GBq), 0.4 Gy ±
0.2 Gy in the liver, 0.4 Gy ± 0.1 Gy in the spleen and 5.1 Gy
± 2.0 Gy in the salivary glands (1.4 Gy/GBq). Critical dose
limit for the kidneys was not reached in any of the patients.
Doses for tumor lesions up to 35.7 Gy were observed. An
increased uptake in the intestine was observed after approx.
24h with overlap to the kidneys by about 50-75% for planar
images. Conclusions: Critical organs are the salivary glands
and the kidneys. Kidneys, based on their vital function, are the
dose limiting organ in analogy to other Lu-177 based thera-
pies. Quantitative 3D SPECT improves accuracy of kidney
dose estimation due to reduced overlap by activity on the colon
on late images. Our results further suggest that the activity
administered for each cycle could be increased to optimally
exploit the tumor dose.
OP385
Accuracy of Triple Energy Window vs. Analytical Photon
Distribution Scatter Corrections in Lu-177 Studies
C. F. Uribe1,2, L. Frauenstein3,1, P. L. Esquinas1,2, J.
Tanguay1, M. Gonzalez4, A. Celler1; 1Medical Imaging Re-
search Group, University of British Columbia, Vancouver,
BC, CANADA, 2Department of Physics and Astronomy, Uni-
versity of British Columbia, Vancouver, BC, CANADA, 3De-
partment of Computer Science, Otto von Guericke University
of Magdeburg, Magdeburg, GERMANY, 4Vancouver Coastal
Health, Vancouver, BC, CANADA.
Aim: Accuracy of absorbed dose calculations in personalized
radionuclide therapy is directly related to the accuracy of ac-
tivity estimates obtained at each of imaging time-points. Our
objective was to compare the accuracy of 177Lu quantification
achieved using two scatter correction (SC) methods: 1)triple
energy window (TEW) and 2)analytical photon distribution
interpolated (APDI). Materials and Methods: Four series of
experiments were performed using objects filled with 177Lu:
(a) seven spheres [0.5-113mL] were scanned in air, and in a
cylinder filled with cold and hot water; (b) six bottles [8.5-
34mL] in air and hot water, (c) four bottles [33.9mL] in a
Thorax phantom filled with water ( lungs and spine inserts,
and additional beef bone created non-uniform density distri-
bution), (d) four bottles [34-200mL] in air and between four
2L water bags. SPECT/CT SymbiaT (Siemens-Healthcare)
camera with MELP collimator, and three energy windows
were used (208keV photopeak and two scatter windows).
OSEM reconstruction included attenuation correction (AC)
and resolution recovery (RR), and either TEW or APDI. Seg-
mentations for objects in air and in cold water used fixed
thresholds of 0.1% and 1%, respectively, while for hot back-
ground, a fixed 40% threshold and our iterative adaptive dual
thresholding (IADT) method were used. Four additional scans
(six objects [17-200mL] placed in a cylinder with four differ-
ent backgrounds) were performed to create an IADT calibra-
tion curve. Results: For objects placed in cold uniform-density
backgrounds (air, water) the accuracy of activity quantification
was similar for both SC methods. Depending on object size
and shape the errors ranged from 3-6% in air to 10-12% in
water. Although in scans of objects placed in hot background
the accuracy of total activity reconstruction was about 6%, the
quantification of individual objects was highly dependent on
their sizes and segmentation method. When using IADT seg-
mentation the errors ranged from 3% for large objects to over
30% for small spheres, using 40% fixed threshold resulted in
larger errors. For objects placed in non-uniform-density back-
ground the APDI method outperformed TEW by a factor of
three. Conclusion: For areas with uniform density (majority of
clinical situations), similar levels of activity quantification of
177Lu can be achieved when using TEW or APDI scatter cor-
rection (SC). Phantom experiments showed that for objects
≥34ml, activity can be reconstructed to within 10%. APDI
outperforms TEW in non-uniform-density areas (e.g. a tumor
close to the spine), but is more complex and requires more
computer time than TEW.
OP386
Towards a quality assurance for dosimetry in peptide
receptor radionuclide therapy (PRRT)
with 177Lu-DOTATATE
G. Marin, B. Vanderlinden, Z. Wimana, T. Guiot, I. Karfis, P.
Flamen; Institut Jules Bordet, Bruxelles, BELGIUM.
Aim177Lu-DOTATATE is the most commonly used
radiopeptide for PRRT. In order to establish a reliable dose-
response/toxicity correlation it is necessary to achieve a good
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precision on all measurements. The aim of this work was to
evaluate the precision of the dosimetric procedure.Materials
and methodsEight patients with neuroendocrine tumors re-
ceived 4 to 5 cycles of 177Lu-DOTATATE. Three SPECT/
CT (4, 24, 168h post-injection) and five blood samples (0, 1,
4, 24, 168h post-injection) were performed after each admin-
istration. Organs activities were calculated by multiplying the
volumic activities by the manually delineated CT volumes.
Time-activity curves (TAC) were obtained by fitting measured
activities with biexponential functions. Residence times (RTs)
were obtained by integrating the TACs.To avoid inter-patient
variability, RTs and volumes were normalized by the respec-
tive mean value of each organ for all cycles for each patient
(mean normalized value = 1).The precision of RTs and vol-
umes was evaluated with the standard deviations of the nor-
malized RTs (nRTSDs) and normalized volumes (nVSDs) for
each organ. As those SDs still contain both stochastic quanti-
fication errors and intra-patient inter-cycle variability, their
analysis will help discriminate between the two.ResultsFor
kidneys, nRTSDs of 0.14 and 0.10 were found respectively
for the right and left. A linear correlation (R2 = 0.78) was
found between the nRTSDs of each pair, suggesting that
nRTSDs are not completely explained by quantification
errors.For the spleen, a higher nRTSD of 0.18 was found,
partly due to diurnal volume modification because of the dy-
namical status of splenic blood supply, as highlighted by a
nVSD of 0.14 for spleen versus 0.04 for kidneys.For the liver,
nRTSD was 0.22. Two patients showed a systematic RT de-
crease over therapy cycles (corresponding to decreasing lesion
uptake). When they were discarded from the evaluation, the
liver nRTSD decreased to 0.08.For the total body, the higher
nRTSD (0.21) may come from low image statistic.For the
bone marrow, a different quantification procedure based on
blood samples lead to a nRTSD of 0.19.ConclusionOrgans
nRTSDs allowed estimation of the maximum stochastic errors
on dose quantification in PRRT. Intra-patient variability was
shown to be a source of overestimation, but can be reduced
with a quality assurance program driven by error analysis. This
will help identify methodological sources of error requiring
additional quality control, leading to better precision on
dose-response/toxicity correlations.
OP387
International Multicentre Evaluation of Absolute
Quantification in Planar and SPECT Imaging
B. E. Zimmerman1, I. Buvat2, E. C. Frey3, A. J. Green4, D.
Grošev5, M. Lassmann6, M. Ljungberg7, G. Poli8; 1National
Institute of Standards and Technology, Gaithersburg, MD,
UNITED STATES, 2Service Hospitalier Frédéric Joliot, Paris,
FRANCE, 3Johns Hopkins Medical Institutions, Baltimore,
MD, UNITED STATES, 4National Physical Laboratory,
Teddington, UNITED KINGDOM, 5University Hospital Cen-
tre Zagreb, Zagreb, CROATIA, 6Universitatsklinik Wurzburg,
Würzburg, GERMANY, 7Lund University, Lund, SWEDEN,
8International Atomic Energy Agency, Vienna, AUSTRIA.
Aim: Accurate quantitation of activity provides the basis
for internal dosimetry of targeted radionuclide therapies.
The International Atomic Energy Agency has recently
conducted a Coordinated Research Project entitled “De-
velopment of Quantitative Nuclear Medicine Imaging for
Patient Specific Dosimetry”. The main purposes of this
project were to investigate the quantitative imaging ca-
pabilities at sites with a variety of experience and equip-
ment and to assess the levels of errors in activity quan-
titation resulting from the use of SPECT and planar
imaging. Materials and methods: Participants from 10
countries took part in the intercomparison by quantifying
activities using planar, SPECT and SPECT/CT imaging.
Participants were provided with four epoxy-filled cylin-
ders containing 133Ba, chosen as a surrogate for 131I.
The 133Ba sources, with nominal volumes of 2, 4, 6
and 23 mL, were calibrated by the U.S. National Insti-
tute of Standards and Technology, with the activity un-
known to the participants. The sources were imaged in a
cylindrical phantom filled with water. In a first trial,
participants estimated the activities using local protocols.
In the second trial, participants repeated the measure-
ments using a standardized protocol, with acquisition
and processing methods more rigorously defined. Final-
ly, processing and analysis of the data from the second
trial was repeated centrally. Results: In the first trial,
true activities were underestimated by 15-20% with pla-
nar imaging, after rejection of outlying data. SPECT
with Chang’s attenuation correction data showed the
h ighes t va r i ab i l i t y and the t rue ac t iv i ty was
underestimated by 5-10%. SPECT/CT gave the best ac-
curacy and reproducibility in all trials. The second trial
showed some improvements in accuracy, variability and
outlying results. Planar imaging was subject to method-
ological errors, e.g., in the use of a transmission scan
for attenuation correction. The use of Chang attenuation
correction (AC) was essential for SPECT without CT-
based AC, and variability resulted from definition of
phantom contours.Conclusion: The project demonstrated
the need for training and standardized protocols to
achieve good levels of quantitative accuracy and repeat-
ability in a multicentre setting. Absolute quantification
of simple objects with no background activity was pos-
sible with errors of +8 % with planar imaging, -7 %
with SPECT (with Chang-AC) and better than 6 % for
SPECT/CT. CT-based AC was the best, and in a clinical
scenario would handle uniform and non-uniform attenu-
ation distributions. Processing for SPECT/CT was more
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standardized and less subject to errors and therefore
seems the best option for quantitative nuclear medicine
imaging.
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OP388
Insights into the DNA damage response can improve
peptide receptor radionuclide therapy outcomes
J. Nonnekens, C. Beerens, M. van Kranenburg, D. C. van
Gent, M. de Jong; Erasmus MC, Rotterdam, NETHER-
LANDS.
Aim: The targeted treatment of neuroendocrine tumors (NET)
with lutetium-labeled somatostatin analogues (peptide recep-
tor radionuclide therapy, PRRT) is successfully applied in clin-
ical trials, while similar approaches may also be feasible for
many other tumor types. PRRT of metastasized NETs is very
promising with improved patient outcome compared to other
treatments, but cure is reached only in very low percentages.
To achieve an even better tumor response, the administrated
dose cannot simply be increased because of dose limiting tox-
icity in bone marrow and kidneys. Therefore, in order to im-
prove the current treatment outcome, we investigated the DNA
damaging effects of PRRTwith the final aim to enhance these
effects through modulation of the DNA damage response. We
aim specifically to sensitize the (fast replicating) tumor cells
without further damage to healthy tissues using PARP inhibi-
tors. Materials and methods: All experiments were performed
with rat pancreatic CA20948 tumor cells expressing the so-
matostatin receptor subtype 2 or human tumor cells lines sta-
bly transfected with this receptor subtype. Cells were incubat-
ed for 4 hours with increasing doses of 177Lu-[DOTA,
Tyr3]octreotate (DOTA-TATE), followed by non-radioactive
chases for different periods until 5 days post treatment. Cells
were fixed and fluorescently stained with different antibodies
(53BP1, gamma-H2AX) to visualize the accumulation of
DNA repair proteins to the produced DNA double strand
breaks. Cell proliferation was measured using EdU incorpora-
tion and Click-iT labeling technology. Simultaneously, cells
were incubated during the chase period with the PARP inhib-
itor Olaparib. Furthermore, cells were subjected to different
doses of 177Lu-DOTA-TATE in the absence or presence of
Olaparib and cellular survival was measured using colony as-
say and sulforhodamine B colorimetric assay. Results: Cells
treated with 177Lu-DOTA-TATE showed accumulation of
53BP1 and gamma-H2AX in so-called foci, indicating the
production and repair of DNA double strand breaks. Foci were
visible up to 3 days after treatment. Interestingly, addition of
Olaparib led to increased and prolonged DNA damage, spe-
cifically in replicating cells. 177Lu-DOTA-TATE eradicated
cells in a dose dependent manner and cell killing was enhanced
by Olaparib. Conclusions: PRRT produced DNA single and
double strand breaks and triggered the DNA damage response
in our in vitro models. Through modulation of the DNA dam-
age response with Olaparib, we were able to enhance the
DNA-damaging effects of PRRT, specifically in replicating
cells. We expect that our results will eventually improve the
current PRRT outcome, leading to increased patient survival
rates.
OP389
Blocking DNA repair mechanism - the way to improve
alpha targeted therapy of glioblastoma multiforme ?
E. Rosiak1, H. Koziara2, R. Matyskiel1, B. Królicki2, L.
Królicki1; 1Department of Nuclear Medicine, Medical Univer-
sity of Warsaw, Warsaw, POLAND, 2Department of Neuro-
surgery, Maria Skłodowska-Curie Memorial Cancer Center
and Institute of Oncology, Warsaw, POLAND.
AIM: Recently the alpha targeted therapies using intracranial
delivery of 225Ac or 213Bi-labeled Substance P (SP) have
been developed. Our aim was to investigate the radiobiologi-
cal effects of alpha-particles from 213 Bi and 225Ac- on cell
survival, cell cycle progression and DNA ploidy in glioblasto-
ma multiforme (GBM) cells cultured in vitro under hypoxia
and normoxia condition.MATERIALS: Cultured cells in vitro
were obtained from tumor samples from 43 patients with his-
tologically confirmed of GBM. They were treated with 1 dose
of 1,2MBq 213 Bi-SP/1ml medium or 1 dose of 180kBq
225Ac-SP/ 1ml medium under normoxia and hypoxia (0,7-0,
8% O2). Non-irradiated cancer cells cultured under normoxic
and hypoxic condition were used as a control. METHODS:
The level of apoptosis and necrosis, measurement of cellular
DNA content and the analysis of the cell cycle we performed
by flow cytometry under aerobic and hypoxic conditions. Ex-
perimental data was obtained at 1 h, 3 h, 6 h, 12 h, 24 h, 48 h,
72 hours and 10 days after application of isotopes for cell
cultures. RESULTS: Alpha radiation induced cell cycle alter-
ations. Between 24 - 72 hr after the treatment with 213 Bi-SP
and 225Ac-SP under normoxia during S-phase cycle were
100%± 0.0% and 99.9%±0.12 % cells; under hypoxia during
S-phase were 99.88 %± 0.29% cells and 100%± 0% cells
respectively. 72 hours after treatment with 213 Bi-SP and
225Ac-SP under hypoxia and normoxia we observed en-
hanced self-renewal of cancer cells, DNA repair and signifi-
cantly decreased the population of cells in S phase with accu-
mulation of cells in G2/ M phase as well as radiation-induced
chromosomal damage, alterations in the structure and number
of chromosomes with high levels of tetraploidy or
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aneuploidy.10 days after treatment with 213 Bi-SP and 225Ac-
SP the ratio of G2/G1 cells increased significantly compared to
control cells: under normoxia ratio of G2/ G1 was
8.13%±4.38% and 9.33%±5.0%; under hypoxia ratio of G2/
G1 was 10.72%±2.90% and 11.02% ±3.10% respectively
(p<0.05)CONCLUSION: These results suggest that alpha
therapy induces DNA damage that are reflected in transient
arrest in S-phase up to 72 hours under hypoxic and normoxic
condition. This response can however be reduced by the ac-
tivities of DNA repair pathways observed after 72 hours. Al-
pha targeted therapy combined with blocking DNA repair
mechanisms could be therefore offer as a therapeutic strategy
for glioblastoma multiforme and further research will be
needed.
OP390
Radiation-Induced Media-Transferred Bystander Effect
in Breast Cancer Cells
K. L. Madsen, P. F. Høilund-Carlsen, B. B. Olsen; Odense
University Hospital, Odense, DENMARK.
Aim: In radiation biology, the term bystander effect refers to
the phenomenon that non-irradiated cells exhibit similar
changes as nearby irradiated cells, e.g., DNA double strand
breaks (DSBs), chromosomal instability, and cell death. The
aim was to investigate if this bystander effect could be media-
transferred to non-irradiated cells by incubation in irradiated
cell conditioned medium (ICCM). Material and methods: Hu-
man breast cancer MCF-7 cells in medium were irradiated
with 0, 1, 2, 4 or 8 Gy of external ionizing radiation. After
24 h, the ICCM was transferred to a new series of non-
irradiated MCF-7 cells to examine for a potential medium-
transferred bystander effect using three different endpoints: i)
DSBs visualized by γH2AX-foci after 18 h incubation with
ICCM, ii) number of micronuclei in binuclear cells as a marker
of chromosomal instability after 48 h of incubation with
ICCM, and iii) the effect on cell death after 7 days of incuba-
tion with ICCM as judged by the CellTiter-Blue Viability As-
say, which measures metabolic activity. Results: Re i: DSBs
were induced in the non-irradiated cells since the average
number of γH2AX-foci pr. cell was significantly increased
independent of radiation dose; 0 Gy 0,5±0,8, 1 Gy 1,7±1,6
(P < 0,001), 2 Gy 1,3±1,4 (P < 0,01), 4 Gy 2,7±2,7 (P < 0,
0001) and 8 Gy 3,9±3,5 (P < 0,0001). Re ii: The number of
micronuclei in binuclear cells was negligible with only a small
and insignificant increase upon incubation with ICCM, sug-
gesting the absence of chromosomal instability. Re iii: There
was no cell death upon incubationwith ICCM; on the contrary,
stimulating effects were observed on the metabolic activity
independent of radiation dose; 0 Gy 100%±3,1, 1 Gy
111%±2,0 (P < 0,01), 2 Gy 117%±1,0 (P < 0,001), 4 Gy
117%±1,4 (P < 0,001) and 8 Gy 108%±2,6 (not significant).
Conclusion: There was a significant radiation-induced medi-
um-transferred bystander effect with respect to DSBs, but
chromosomal instability was not significant in non-irradiated
cells incubated in ICCM. In addition, a somewhat surprising
and significant increase in metabolic activity was observed.
This apparently paradoxical increase warrants further
experiments.
OP391
Ex vivo tumor tissue culture to mechanistically examine
DNA-damage after peptide receptor radionuclide therapy
J. Nonnekens, C. Beerens, D. C. van Gent, M. de Jong; Eras-
mus MC, Rotterdam, NETHERLANDS.
Aim: Many studies to explore cellular mechanisms of antican-
cer therapies are performed on cell lines. However, morphol-
ogy, complexity and key parameters of actual tumors differ
considerably from cell lines grown in 2D culture. Moreover,
tumors from different patients differ in their response to ther-
apy, necessitating personalized treatment. To take analysis of
anticancer therapies to the next level, we have developed a
novel system to examine human tumor tissue ex vivo. Specif-
ically, we examined patient neuroendocrine tumors (NETs)
that will be treated with lutetium-labeled somatostatin ana-
logues (peptide receptor radionuclide therapy, PRRT). This
approach allows for detailed analysis of the cellular responses,
such as the DNA damage response, over prolonged periods of
time in the relevant tumor context. Materials and methods:
Fresh human tumor tissue derived from surgery or biopsies
was cut in thin slices (300 μm) with a Leica vibrotome. Cul-
turing of NET-slices was performed at 37°C on a rotating
platform (60rpm). Besides using human tumor tissue,
xenografted neuroendocrine tumors grown onmice were used.
These slices were grown on cell strainer inserts at 37°C. Slices
were incubated for 4 hours with various doses of
177Lu-[DOTA,Tyr3]octreotate (DOTA-TATE), followed by
non-radioactive chases for different periods. Slices were for-
malin fixed and paraffin embedded. 4m paraffin sections were
subjected to immunohistochemical stainings: hematoxylin and
eosin staining for morphology and fluorescent staining with
different antibodies (53BP1, gamma-H2AX) to visualize the
accumulation of DNA repair proteins to the produced DNA
double strand breaks. Cell proliferation was measured using
EdU incorporation and Click-iT labeling technology. Cell
death was measured using apoptotic TUNEL labeling. Re-
sults: In the current settings, the tissue slices could be kept
alive for approximately 1 week after dissection. Cells of slices
treated with 177Lu-DOTA-TATE showed foci formation of
53BP1 and gamma-H2AX, indicating the production of
DNA double strand breaks, up to for several days after
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treatment. Furthermore, the treatment reduced replication and
induced apoptosis. Conclusions: PRRT producedDNA double
strand breaks and triggered the DNA damage response in NET
tumor slices. These results give mechanistic insights into the
effectiveness of PRRT. We will apply this knowledge to im-
prove the current PRRT-protocols and increase patient survival
rates. Furthermore, looking from an animal welfare aspect; the
use of tissue slices as an intermediate step between in vitro cell
assays and in vivo mouse experiments will tremendously re-
duce the amount of laboratory animals needed.
OP392
Clinical Relevance of Targeting SSTR2, GRPR
and CXCR4 with Radioligands for Imaging and Therapy
in Breast Cancer
S. Dalm, A. Sieuwerts, M. Look, M.Melis, C. van Deurzen, J.
Foekens, M. de Jong, J. Martens; Erasmus MC, Rotterdam,
NETHERLANDS.
Introduction: Imaging and therapy using radioligands targeting
receptors expressed on cancer cells is successfully being used in
patients with neuroendocrine tumors. Previous studies have
demonstrated expression of the somatostatin receptor subtype
2 (SSTR2), the gastrin releasing peptide receptor (GRPR) and
C-X-C chemokine receptor 4 (CXCR4) on breast cancer (BC).
Since GMP-compliant radioligands targeting the SSTR2,
GRPR and CXCR4 are available, targeting these receptors on
BC might offer new imaging and therapy options. BC is a
heterogeneous disease consisting of multiple molecular sub-
types, which influence treatment and prognosis. We investigat-
ed the SSTR2, GRPR and CXCR4 mRNA levels of 915 BC
patients and correlated this with important clinico-pathological
factors and prognosis. Materials and Methods: SSTR2 and
GRPR expression of 13 clinical BC specimens was analyzed
by in vitro autoradiography using 111In-Octreotate and 111In-
AMBA, respectively, and correlated with corresponding
mRNA levels. Moreover, SSTR2, GRPR and CXCR4 mRNA
levels of 915 BC specimens (from lymph node negative (LNN)
and lymph node positive (LNP) patients) were determined
using RT-qPCR and associated with known clinico-
pathological factors (total patient group) and prognosis (LNN
patients). Results: A significant positive correlation was found
between binding of 111In-Octreotate and 111In-AMBA to the
BC specimens and SSTR2 (Rs=0.7348, P=0.0042) and GRPR
mRNA levels (Rs=0.9352, P<0.0001), respectively. Further-
more, in the total patient group high SSTR2 and high GRPR
mRNA levels were both associated with estrogen receptor (ER)
positive (P<0.0001) and progesterone receptor (PR) positive
tumors (P<0.0001). On the contrary, high CXCR4 mRNA
levels were associated with ER negative tumors (P<0.0001).
No association was found between SSTR2 and GRPR
expression and prognosis in the untreated LNN patients. Con-
trary to what expected, higher CXCR4 expression was associ-
ated with better prognosis in the LNN patient group (Hazard
ratio metastasis free survival=0.76 (0.64-0.90), P=0.001). Con-
clusion: SSTR2 and GRPRmediated imaging can be applied in
ER and PR positive tumors, while CXCR4mediated imaging is
best suited for ER negative tumors. Thus, ER positive patients
resistant to current standard lines of therapy might benefit from
radioligands targeting SSTR2 or GRPR, while in progressing
ER negative patients CXCR4 therapy might be considered, par-
ticularly those patients whose lesions are demonstrated positive
based on imaging using the respective ligands.
OP393
Increase of PSMA Expression by Androgen Deprivation
B. Meller, C. O. Sahlmann, S. Hijazi, C. Bouter, L. Trojan, J.
Meller, P. Thelen; Georg-August-University Göttingen,
Göttingen, GERMANY.
Aim: PSMA is novel and promising target for diagnostics and
therapy of prostate carcinoma (PC). The aim of this investigation
was to increase PSMA-expression for improved detection of
recurrent PC and its metastases in diagnostics as well as better
targeting for radiopeptide-therapy by use of standard PC drugs.
Material & Methods: Radiolabeling of 5 μg PSMA-HEBD-CC
(ABX) were performed withM = 1200MBq 68GaCl3 (iThemba
Labs) in a GRP Module (Scintomics). The human castration
resistant cell line VCaP (CRPC) was obtained from ATCC. Par-
allel cultures were treated with 1 nM testosterone andwith 5μM
abiraterone over 48 h. The androgen sensitive cell line (rev-
CRPC) was long-term sub-cultured with 1 nM testosterone. Par-
allel cultures were incubated without testosterone or received
additionally 5 μM abiraterone acetate for 48 h. To assess the
capacity of cells for the labeled compounds, 0.3 nM 68Ga-la-
beled peptide (100-300 kBq/ml) was simultaneously applied to
3 parallel cells cultures for each interval (1 - 3 hours) and each
cell line. Experiments were repeated for three times. Cells were
harvested and measured activity was correlated to the cell count.
Additionally, PSMA-mRNA expression was investigated by
qPCR. Results were statistically evaluated by non-parametric
tests. Results: Androgen sensitive cells (revCRPC) accumulated
the tracer significantly higher than the castration resistant sub-
type (CRPC, p<0.05). 68Ga-PSMA-HEBD-CC uptake almost
doubled during 3 h in all cell lines (p<0.01). Compared to
non-treated cells in parallel cultures the pre-incubation with
abiraterone over 48 h resulted in a significant increased uptake
in CRPC (p<0.001). In revCRPC pre-incubation with
abiraterone resulted in an eight-fold higher uptake after 3h.
Withdrawal of medium supplementation testosterone addition-
ally increased the uptake up to ten-fold (p<0.01). The influence
of abiraterone on PSMA-expression was confirmed by PCR
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data in both cell lines. Conclusions: We found an increasing
uptake of 68Ga-PSMA-HEBD-CC over time, probably based
on an increasing internalization rate. Our investigations verify
an increase of PSMA-mediated uptake by androgen deprivation
in CRPC and androgen sensitive cell lines. These results might
be useful in the early detection of PC recurrence as well as for
PSMA-mediated therapy. These results may contribute to the
development of improved protocols in PSMA-mediated imag-
ing and therapy sequencing.
OP394
Detrimental Effects of Radiation on the Fluorescence
of Fluorophores: Implications for Dual-Modality Imaging
R. Hernandez1, S. Heskamp2, M. Rijpkema2, D. M.
Goldenberg3, W. McBride3, A. Morgenstern4, F.
Bruchertseifer4, W. Cai1, O. Boerman2; 1University of Wis-
consin-Madison, Madison, WI, UNITED STATES, 2Radboud
University Medical Center, Nijmegen, NETHERLANDS,
3Immunomedics Inc., Morris Plains, NJ, UNITED STATES,
4Institute of Transuranium Elements, Karlsruhe, GERMANY.
Aim: Despite the large interest on nuclear/optical
multimodality imaging, the effect of radiation on the fluores-
cence properties of fluorophores remains unknown. Herein we
determined the radiosensitivity of the near infrared dye
IRDye800CW, and devised a strategy to ameliorate its nega-
tive impact for multimodality imaging. Materials and
Methods: Buffered aqueous solutions of IRDye800CW were
incubated in the presence of increasing activities of 111In,
68Ga, or 213Bi (γ, β, and α emitter, respectively) and its nor-
malized fluorescence (λex=740 nm and λem=796 nm) was de-
termined at different radiation exposure times. The radiopro-
tective effect of three hydroxyl radical scavengers (ethanol,
gentisic acid, and ascorbic acid (AA)), was examined. The
impact of other factors such as activity concentration, temper-
ature, type of buffer, and pH on the fluorescence properties of
IRDye800CWwas also determined. Similar experiments were
conducted on RDC018, a DOTA-conjugated IRDye800CW-
derivative used as multimodality imaging probe in
pretargeting. Results: A significant decrease of the fluores-
cence of IRDye800CW was observed upon incubation with
escalating activities of 111In, 68Ga or 213Bi. The effect was
dependent on the amount of activity as well as the type of
radiation, which supported our hypothesis of a free radical
mediatedmechanism. 68Ga showed the largest radiolytic effect
- the fluorescence signal of the fluorophore was reduced to
background levels within 30 min incubation with 20 MBq of
68Ga-, followed by 111In and 213Bi. IRDye800CW and
RDC018 presented similar radiosensitivity except for
213Bi-labelled RDC018, which exhibited enhanced radi-
olysis, presumably due to direct radiation damage
induced by α particles. The addition of scavengers pro-
vided a concentration dependent radioprotective effect.
Among all scavengers, AA provided the most robust
protection over a wide range of concentrations and pre-
served RDC018 fluorescence at much higher activity
levels. Interestingly, AA afforded only partial radiopro-
tection of 213Bi-RDC018, which further supported our
hypothesis of α particle-fluorophore direct interaction.
Conclusion: Herein we provide the first report on the
radiosensitivity of fluorophores, and outline a set of con-
ditions that minimize the deleterious effects of radiation
damage on nuclear/optical multimodality imaging
probes.
OP395
Characterisation and quantification of fluorescently
labeled Exendin for beta cell targeting and comparison
with radiolabeled Exendin
S. Ekim, D. Bos,M. Brom,M.Gotthardt; RadboudUniversity
Medical Centre, Nijmegen, NETHERLANDS.
Background and aims: Exendin can specifically bind to the
glucagon-like peptide 1 receptor (GLP-1R) which is expressed
on the beta cells in the pancreas. By targeting GLP-1R with
radiolabeled Exendin, it is possible to determine the beta cell
mass. However, the resolution of PET and SPECT is not suf-
ficient to examine tracer accumulation at the cellular level,
which could provide vital information about the specificity
of the tracer for beta cells. By using fluorescent labeled tracers,
it is possible to study the kinetics of radiotracer accumulation
at the cellular level. But quantification of the fluorescently
labeled tracers is difficult because of the limited penetration
depth of the fluorescent label and attenuation/absorption and
autofluorescence of organs. The aim of the study is developing
a sensitive and quantitative technique to measure accumula-
tion of fluorescently labeled tracers, comparing the
biodistribution of fluorescent labeled Exendin with
radiolabeled Exendin and evaluation of the effect of peptide
dose for both tracer.Materials and methods: GLP-1R over-ex-
pressing CHL cells were used in experiments. For in vitro
experiments 30nM Exendin-3-Cy5.5(Ex-Cy5.5) was incubat-
ed at 37°C degrees for 4 hours, and blocking experiment with
an 30 fold molar excess unlabeled Exendin-3 was performed
in 3 separate wells. The cell-bound fluorescence was measured
with ELISA-plate reader.Ex-Cy5.5 and Exendin-3-
DTPA-111In(Ex-DTPA-111In) biodistribution studies were per-
formed in BALB/c nude mice with a subcutaneous CHL-
GLP1R tumor. Mice were injected with 0,3-1-3-10μg of Ex-
Cy5.5 or Ex-DTPA-111In and after 4 hours the organs were
dissected and homogenized for fluorescence measurements.
Samples are measured in ELISA plate reader with organ
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specific standards.Results: Binding assay performed on CHL-
GLPl R(+) cells showed that Ex-Cy5.5 can specifically bind to
GLP1R at a percentage of 17% which is similar to Ex-
DTPA-111In. The uptake of Ex-3-Cy5.5 in the tumor was 8,
49±3,99 %lD/g when 0,3μg was injected and maximum rela-
tive uptake was observed at 1μg (21,04±6,35 %lD/g).
With higher doses lower tumor accumulation was
observed.Conclusion: A very sensitive and quantitative
technique for biodistribition studies of fluorescently la-
beled peptides was developed.By preparing organ specif-
ic standard curves, fluorescence signal detected from the
organs could be accurately quantified. The results
showed that the optimal dose for in vivo targeting of the
GLP-1R with Ex-Cy5.5 and Ex-DTPA-111In is different. This
should be taken into account while using the fluorescently
labeled tracers to study the kinetics of radiotracer accumula-
tion. ln vivo optimal dose for Ex-Cy5.5 is observed as 1μg,
while for Ex-DTPA-111In it is observed as 0,3μg.
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OP411
Adaptation of 13N-NH3 and 18F-FDG Imaging Protocols
for sarcoidosis for new scanner technology
C. Abreu1, J. O’Doherty1, S. Barrington1, S. Pereira1, L.
Alves1, J. John1, P. Schleyer2; 1PET Imaging Centre, King’s
College London, King’s Health Partners, St Thomas’Hospital,
London, UNITED KINGDOM, 2PET Imaging Centre, King’s
College London, London, UNITED KINGDOM.
Background. Perfusion 13N-NH3 and 18F-FDGviability studies
are performed as combined investigations to assess for possible
cardiac sarcoidosis. At our centre we perform a 1-day protocol
beginning with a dynamic rest 13N-NH3 (550 MBq) scan using
quantitative Patlak analysis and visual analysis followed by an
18F-FDG cardiac scan at 30 minutes and a half body scan at 60
minutes post injection. Recently we have installed 2 new GE
Discovery 710 PETCTscanners, and have subsequently adapted
our imaging protocol to capitalise on the new techniques avail-
able on these scanners. Methods. We performed 14 patient scans
for suspected cardiac sarcoidosis on a Discovery 710 PET/CT
scanner. The new imaging protocol was comparedwith that from
our previous scanner (GE Discovery VCT). The D-710 is differ-
ent in terms of crystal material (LYSO vs BGO), acquisition
mode (3D only), image reconstruction and ultra low dose CT
for attenuation correction (Q.AC). ECG gating was performed
on all 18F-FDG images, and respiratory motion correction was
also evaluated. Average cine CT images were used for attenua-
tion correction to reduce respiratory motion induced by PET/CT
misalignment. Further manual alignment was also required for
some patients. Results. Patient radiation exposure for the cine CT
was reduced using the Q.AC CT reconstruction algorithm by a
factor of 2.18 in both DLP (103.59 to 47.56) and CTDIvol. (6.47
to 2.97). Image quality was felt to be improved compared to the
D-VCT. Radiation dose due to CTattenuation correction ismark-
edly reduced using the new scanning technology. Further im-
provements to flow quantitation may be made by using compart-
mental modelling instead of Patlak analysis. Conclusion. Instal-
lation of new PET/CT scanners enabled a significant change in
cardiac acquisition protocol, which improves image quality, re-
duces radiation dose and can provide a more accurate CT regis-
tration for attenuation correction. It may be possible to further
reduce patient dose by lowering the administered 13N-NH3 ac-
tivity without compromising image quality due to the increased
sensitivity of the D-710 compared to the D-VCT.
OP412
Benign Iodine-131 Treatment - Passing tasks
from physician to technologist
H. C. Larsen, L. F. Grønnemark, P. C. Holdgaard, MD; De-
partment of Nuclearmedicine, Vejle Hospital - Part of
Lillebaelt Hospital, Vejle, DENMARK.
AIM: In Departments of Nuclear Medicine in Denmark the be-
nign Iodine-131 treatment is most often given by a physician.
Furthermore the physician gives the information about the treat-
ment to the patients. Previously at our department the physician
gave the information about the benign Iodine-131 treatment to
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each patient individually, including the precautions and possible
side effects. The physician used an entire working day
performing this procedure. The purpose of this project was to
pass some of the tasks from the physician to the technologists,
and thereby save physician time and give more responsibility
and new skills to the technologists. Methods and materials: In
a period of 2 months the task of giving information to the pa-
tients was handed over from the physicians to 2 technologists.
We also changed it to a common information session held by the
technologist for all the patients scheduled that day instead of the
physician gave the information individually to each patient. The
first common session were held by the physician and 2 technol-
ogists observed. After a while, it was one of the technologists
who did the common session, observed by the physician. Finally
when the technologists were familiar with the common session,
one of the 2 technologists did the session alone. Results: Now
the common information session is held by the technologist
about the precautions and possible side effects to the benign
Iodine-131 treatment and other practical information. The ses-
sion lasts 20 minutes and often includes 8 patients. Doing the
information session the patients are allowed to ask questions and
this might benefits the other patients. The physician has a short
individual conversation with each patient after the common ses-
sion. The physician still makes palpate the thyroid gland and
decides the Iodine-131 dose. The individual conversation takes
5-10 minutes per patient. Before the setup was changed the
physician spend an entire working day giving information to
the Iodine-131 patients. Now the physician only spends 2-3
hours talkingwith the Iodine-131 patients. Conclusion: By doing
a common information session and by passing some of the tasks
in benign Iodine-131 treatment from the physician to the tech-
nologist it is possible to considerably reduce the use of physician
time, which then can be allocated to other tasks. Additionally it
gives the two technologists more responsibility and additionally
skills, better understanding of this patient group and thereby a
more meaningful workday.
OP414
Methods for preparing and acquiring PET/CT exams
with 18F-Fluorodeoxyglucose
and 18F-Fluoromethycholine
R. Sanco, M. Zappalà, V. Arnoldo, L. Memo, E. Zaramella, A.
Carraro, L. Evangelista; Istituto Oncologico Veneto
I.R.C.C.S., PADOVA, ITALY.
Introduction. To date, the standardization of protocol for prep-
aration and acquisition of PET/CT images with 18F-
Fluorodeoxyglucose (FDG) and 18F-Fluoromethylcholine
(FCH) are missed. Because both the examinations are func-
tional, the patient preparation is critical. The aim of the present
prospective study was to determine the effect of patient
preparation on PET image quality, both visually and semi-
quantitatively. Materials e methods. We collected data from
87 patients: 60 underwent FDG PET/CT and 27 performed a
FCH PET/CT. Each patient was asked to compile a question-
naire that was based on food information, such as the type and
the amount. Moreover, technician data (i.e. true, random and
single coincidence, tracer dose, injection and acquisition time)
and semiquantitative features (such as maximum and mean
Standardized Uptake Value-SUVmax and SUVmean-, and
Standardized Uptake Lean Value-SUL) were collected and
correlated with clinical and demographic parameters. T-
Student test and ANOVA test were used for the statistical
analysis. Results. In 60 patients undergoing FDG PET/CT, a
higher singles coincidence rate was found in case of a fasting
>10h as compared to a fasting ranged between 5-10h ( 43.8
±5.7 x105 vs. 37.8±6.7x105; p=0.028). Moreover, the rate of
random and true coincidences was higher in patients with a
body weight (BW)>60 kg and in those who had a water con-
sumption >1liter before scan. At semiquantitative analysis,
patients with a body mass index (BMI) >25 showed a signif-
icantly higher liver SUVmax and SUVmean than those with a
BMI60kg than those with a BW<60kg, although not statisti-
cally significant. None of clinical parameters was associated
with semiquantitative data (SUVmax and SUVmean of liver
and kidney). Finally, we found that the bowel FCH uptake was
visually inferior in patients with a BMI<25 than those with a
BMI>25 (p=0.025). Conclusions. To improve the quality of
FDG and FCH PET images seems necessary to prepare the
patient as following: 1) to prolong the fasting time (>10 hours)
before the examination; 2) to avoid the assumption of carbo-
hydrate the evening before PET exams (to improve cardiac
evaluation; especially in case of thoracic disease) and 3) to
invite to drink at least 1 liter of water before the examination.
OP415
SPECT Myocardial Perfusion Imaging Quantification in
Obese Subjects: Influence of Attenuation Correction with
Computed Tomography Attenuation Maps
O. Stakhiv1, M. Clarke2, M. Aplin2, N. Singh2, K. Day2, S.
Dizdarevic2, M. Jessop2, E. Sousa1; 1Escola Superior de
Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lis-
boa, Lisbon, PORTUGAL, 2Nuclear Medicine, Department of
Imaging, Brighton and Sussex University Hospital NHS Trust,
Brighton, UNITED KINGDOM.
Introduction: Myocardial Perfusion Imaging (MPI) is a well im-
plemented technique for assessment of Coronary artery disease
(CAD. Obese subjects have a larger volume of soft tissue and
organs that attenuate gamma causing false positive results due to
attenuation artefacts. Aim: To evaluate the Influence of attenua-
tion correction with Computed Tomography Attenuation Maps
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(CTAM) in perfusion quantification for subjects with BodyMass
Index (BMI) between 30 and 35, and above 35. Methods: Four
groups of 72 subjects 47 with BMI between 30 and 35 Kg/m2
(27 male (GMI) and 20 female (GFI) ) and and 24 (13 male
(GMII) and 11 female (GFII)) with BMI between 30 and 35
Kg/m2 above 35 Kg/m2 who underwent stress-rest, SPECT
MPI of a two days protocol, by EANM guidelines protocol with
activity adjusted to subject’s mass (400 MBq for subjects 110
kg), with 99mTc-tetrafosmin, for suspected CAD, were analysed
with and without the incorporation of CTAM, for stress and rest
studies, the studies were reconstructed by OSEM/MLEM. All
images segmentation and quantification was done by myocardial
walls regions for perfusion: Anterior (Ant), Inferior (Inf), Lateral
(Lat), Septal (Sep) and Apical (Api), recurring to QGS/QPS.
Each study was processed three times by one operator, and aver-
age value was used. For statistical evaluation it was used Fried-
man test for nom parametrical pared samples. Results: Statistical-
ly significant differences were found in comparison of studies
with and without attenuation correction for: GFI group of stress
and rest studies respectively for Lat (p=0.006, and p=0.034), Inf
(p=0.000, and p=0.000) and Sep (p=0.074, and p=0.044); GFII
group in stress study in Lat (p=0.073) and in stress and rest
studies respectively for inferior wall (p=0.001, and p=0.008);
GMI group of stress and rest studies respectively for Lat
(p=0.000, and p=0.000), Inf (p=0.000, and p=0.000), Sep
(p=0.003, and p=0.001) and for rest study in Api (p=0.045).
GMII group of stress and rest studies respectively for Lat
(p=0.020, and p=0.014), Inf (p=0.000, and p=0.000), Sep
(P=0.003 and p=0.075). A significance level of 5% was used.
Discussion: The influence of attenuation correction with CTAM
is bigger within the groups with BMI between 30 and 35 Kg/m2,
formale and female. This influence is also seenmoremarkedly in
the male groups. Conclusion: Differences between the male and
female sets, agree with the ones described in literature.
OP416
[18F]-FDG SUVof reference regions in PET/MRI
following standard MR-based attenuation correction
I. Haidinger1, I. Rausch1, M. Mayerhöfer2, M. Hartenbach3,
T. Beyer1; 1Centre for Medical Physics and Biomedical Engi-
neering, Medical University of Vienna, Vienna, AUSTRIA,
2Division of Radiology, Department of Biomedical Imaging
and Image-guided Therapy, Medical University of Vienna,
Vienna, AUSTRIA, 3Division of Nuclear Medicine, Depart-
ment of Biomedical Imaging and Image-guided Therapy,
Medical University of Vienna, Vienna, AUSTRIA.
Aim: Standard MR-based attenuation correction (AC) in PET/
MRI is based on dedicatedMR images and thus, not intrinsically
representative of measured attenuation coefficients. This may
lead to a bias in the reconstructed PET activity values. Here, we
evaluate standardized uptake values (SUV) of reference regions
in FDG-PET/MRI whole-body (WB) imaging in dual-time point
examinations.Material and Methods: SUV of reference regions
(LI: liver, MD: mediastinum and MU: muscle) were defined in
two patient groups: single-injection, dual-scan (SI-DS) PET/CT-
PET/MR or single-injection, single-scan (SI-SS) PET/MR
examination.SI-DS group: WB-imaging of 77 patients was per-
formed 77±28min pi of 250MBq FDG on a Siemens Biograph-
TPTV and repeated 133±30min pi on a Biograph mMR PET/
MR. Standard acquisition, AC and reconstruction protocols were
used. For each patient volumes of interest (VOI) were defined
manually on the PET/CT images for LI (14mL), MD (4.5mL)
and MU (4.5mL). VOIs were transferred manually to co-
registered PET/MR image data.SI-SS group: WB-imaging of
30 patients was performed 93±19min pi of 250MBq FDG on a
Siemens Biograph mMR. Similar size VOIs were defined man-
ually on AC-PET images for LI (14mL), MD (4.3mL) and MU
(4.2mL). Mean and maximum SUVwere calculated for all scans
and regions. Paired and non-pairedWillcoxon tests (p<0.05)were
used to test differences in SUV for significance of PET/CT versus
PET/MR in SI-DS and PET/MR in SI-DS versus SI-SS,
respectively.Results: In SI-DS SUVmax in PET/CT and PET/
MR was 4.1(±0.8) and 2.4(±0.7) for LI, 3.1(±0.7) and 1.9(±0.7)
for MD and 1.6(±0.5) and 1.1(±0.5) for MU, respectively. Cor-
responding SUVmean values were: 2.6(±0.5) and 1.6(±0.4) for
LI, 2.0(±0.4) and 1.2(±0.4) for MD and 0.9(±0.3) and 0.6(±0.3)
for MU, respectively. Differences were statistically significant
(p<0.001).In SI-SS SUVmax was 2.2(±0.4) for LI, 2.0(±0.5)
for MD and 0.9(±0.3) for MU. Corresponding SUVmean values
were: 1.6(±0.3), 1.4(±0.3) and 0.6(±0.1), respectively. Differ-
ences to the corresponding SUV in the PET/MR data SI-DS
group were not statistically significant in the liver (p>0.05), but
statistical significance was found in MD (SUVmean) and MU
(SUVmax).Absolute SUV differences between PET/MR in SI-
SS and SI-DS examinations were similar to pi-time-dependent
differences reported in Cheng et al. (MIB 2013) and Laffon et al.
(JNMT 2011). Absolute differences between PET/CT and PET/
MR were larger, most likely due to differences in the AC
methods.Conclusion: Group-wise comparison of PET/CT and
PET/MR data indicates a systematic underestimation of SUVs
in reference regions of PET/MR images following standard MR-
AC compared to PET/CT.
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Do Metal Objects in the Topogram Influence the Patient
Dose?
K. Falch1, C. Baun1, S. Shanmuganathan1,M. Nikolajsen2, O.
Gerke1, P. Hoeilund-Carlsen1; 1Odense University Hospital,
Odense, DENMARK, 2University College Lillebaelt, Odense,
DENMARK.
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Aim: Patients scheduled for PET/CT are always requested to
remove metal objects if possible from their clothes and body
before the scan. However, quite often the planning CT
topogram reveals forgotten items such as dentures, jewelry,
keys, or coins. If these objects are removed before the diag-
nostic CT scan without performing a new topogram, the dose
modulation software miscalculates the mA, and the radiation
dose to the patient will increase.The aim of this study was to
assess the impact of metal objects in the topogram upon the
radiation dose to the patient if a new topogram is not per-
formed after removal of these high attenuation objects.
Methods and materials: The study was performed using an
Alderson phantom with a metal object present during the
topogram in a diagnostic CT protocol. Three objects were
used: a belt in the pelvic area, a key at the right thorax, and a
cell phone at the right thigh. For each object, 10 scans were
performed removing the object between the topogram and the
CT scan, thus, a total of 30 ‘with-object-scans’ were per-
formed. The results of these were compared to 10 scans per-
formed without any metal objects present during the
topogram. The CT dose for each scan was estimated by the
dose length product (DLP). An exploratory linear regression
model was applied on the dose-length product (DLP) using the
different circumstances as explanatory factor (‘without object’
(reference) vs. ‘with belt’ vs. ‘with key’ vs. ‘with cellphone’).
Results: Preliminary results based on the first 20 scans: Com-
pared to scout without object, mean DLP was increased by
2.26 mGy-cm (95% CI: 1.68-2.84; p<0.0001) in phantoms
with belt and decreased by 0.65 mGy-cm (95% CI: 0.07-
1.23; p=0.03) in phantoms with key. With cellphone, DLP
was increased by 1.26 mGy-cm, but not to a statistically sig-
nificant degree (95% CI: 0.68-1.84)). Adjusted R squared was
0.87. Conclusion: These preliminary data show that the dose to
the patient is increased when a larger metal object is present
during the topogram and no new topogram is performed after
removal prior to the diagnostic CT scan. This should encour-
age technologists to perform a new topogram, whenever
changes of the scanning circumstances have been made.
OP418
The Effect of Type of Collimation, Duration of Image
Acquisition and Scatter Correction
in Heart-to-Mediastinum Ratio of I-123-MIBG
Scintigraphy
S. Chaves, T. Vieira, A. Sá Pinto, V. Alves, A. Fernandes, J. G.
Pereira; Centro Hospitalar de São João, Porto, PORTUGAL.
Aim: Heart-to-mediastinum ratio (H/M) has been commonly
u t i l i z e d a s a n i n d i c a t o r o f myo c a r d i a l 1 23 I -
Metaiodobenzylguanide (123I-MIBG) uptake.However, esti-
mates of the H/M vary depending on the choice of acquisition
parameters and the application of corrections to physical phe-
nomena such as scattering.The purpose of this study was to
analyze how the choice of different acquisition times, collima-
tor types and scatter correction (SC) influences the H/M
calculation.Materials andMethodsWe randomly selected 6 pa-
tients that were sent to our Nuclear Medicine Department for
oncological evaluation. Images acquisition began 3 hours
post-injection of 123I-MIBG (185-370 MBq). First, were ac-
quired 2 sequential thoracic static (TS) images of 5 minutes
(5M) each, (LEHR collimators; 256x256 matrix; 20% energy
window was set on 159 keV); this step was repeated, in se-
quence, using ME collimators. After this, a whole body (WB)
scanning (LEHR collimators; 256x1024 matrix; speed of 10
cm/min) was acquired. SC was applied defining a second win-
dow (130 keV +/- 10%) during the acquisition of TS and WB
imaging, when using LEHR collimators. Ten minutes images
(10M) were obtained by the sum of the counts in the sequential
5 minute images. An irregular ROI was manually drawn over
the left ventricle (H) and a rectangular ROI (120 pixels) was
placed in the upper mediastinum (M). The H/Mwas defined as
the ratio of the average counts in the heart and mediastinum
ROI’s. H/M ratios were calculated for the eight images for
each patient: 10M/LEHR, 10M/LEHR/SC, 5M/LEHR, 5M/
LEHR/SC, 10M/ME, 5M/ME, WB, WB/SC. The correlations
of the H/M ratios of the eight images were determined.Results
and ConclusionMean H/M ratios for WB, 5M/LEHR, 10M/
LEHR, 5M/ME, 10M/ME, WB/SC, 5M/LEHR/SC, 10M/
LEHR/SC, were 1.75 ± 0.25, 1.82 ± 0.30, 1.82 ± 0.30, 2.43
± 0.48, 2.46 ± 0.49, 3.24 ± 0.95 3.46 ± 0.97, 3.92 ± 1.24,
respectively.There were no significant correlations of H/M ra-
tios of SC images with non-SC images.There were significant
correlations of H/M ratios obtained in images with 5M and
10M, for both type of collimators studied (rLEHR = 0.99,
errorLEHR = 0,01 and rME = 0.98, errorME = 0,09), with
10M/LEHR and WB (rWB = 0.91, erroWB = 0,15), with
10M/LEHR and 10M/ME (r10M = 0.97, error10M = 0,09)
and with 5M/LEHR and 5M/ME (r5M = 0.96, error5M= 0,
11).This research suggests that H/M ratios may be obtained
from images with smaller acquisition times, across different
types of collimators and administered activities.
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An automatic delineation method for bone marrow
absorbed dose estimations of 89Zr PET/CT studies
N. E. MAKRIS, R. Boellaard, C. W. Menke-van der Houven
van Oordt, A. A. Lammertsma, M. C. Huisman; VU Univer-
sity Medical Center, Amsterdam, NETHERLANDS.
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Purpose: To develop and validate an automatic delineation
method for estimating red marrow (RM) activity concentra-
tions and absorbed doses in positron emission tomography/
computed tomography (PET/CT) studies using 89Zr labelled
tracers. Methods: Five patients with advanced colorectal can-
cer received 37.1 ± 0.9 MBq [89Zr]cetuximab, 2 hours after
administration of a therapeutic dose of 500 mg m-2 unlabelled
cetuximab. For each patient, five PET/CT scans (1, 24, 48, 96
and 144 h post injection) were acquired using a Gemini TF-64
PET/CT scanner. Low dose CT data were used to manually
generate volumes of interest (VOI) in the lumbar vertebrae
(LV). In addition, LV VOI were generated automatically using
an active contour method applied to the low dose CT. This
method first identifies the outer bone structure of the LV, based
on local intensity information in the low dose CT image, and
subsequently partitions the LV between compact bone and
bone marrow. RM activity was then determined by mapping
the low dose CT derived RMVOI onto the corresponding PET
scans. Finally, these activities were used to derive residence
times and, subsequently, the self and total RM absorbed doses
using OLINDA/EXM 1.1. Results: High correlations
(r2>0.85) between manual and automated VOI methods were
obtained for both RM activity concentrations and total
absorbed doses. On average, the automatic method provided
values that were less than 5% lower than those obtained with
the manual method. Conclusions: An automated and efficient
VOI method, based on an active contour approach, was devel-
oped, enabling accurate estimates of RM activity concentra-
tions and total absorbed doses.
OP420
Phase II Study of Lutetium-177-labeled Anti Carbonic
Anhydrase IX Monoclonal Antibody Girentuximab
in Patients with Advanced Renal Cell Carcinoma.
C. H. J. Muselaers1, M. J. Boers-Sonderen2, T. J. van
Oostenbrugge1, O. C. Boerman3, I. M. E. Desar2, A. B.
Stillebroer4, S. F. Mulder2, C. M. L. van Herpen2, J. F.
Langenhuijsen4, E. Oosterwijk4, P. F. A. Mulders4, W. J. G.
Oyen3; 1Radboudumc, Dept. of Urology, Dept. of Radiology
and Nuclear Medicine, Nijmegen, NETHERLANDS,
2Radboudumc, Dept. of Medical Oncology, Nijmegen,
NETHERLANDS, 3Radboudumc, Dept. of Radiology and
Nuclear Medic ine , Ni jmegen, NETHERLANDS,
4Radboudumc, Dept. of Urology, Nijmegen, NETHER-
LANDS.
Aim: Despite recent advances in treatment of metastatic clear
cell renal cell carcinoma (ccRCC), the search for alternative
treatment modalities which induce durable response with
mi lde r tox i c i t y p ro f i l e s con t inues . A phase I I
radioimmunotherapy (RIT) trial with 177Lutetium (177Lu)-
girentuximab was initiated based on the encouraging results
of a phase I to evaluate the efficacy of this RIT approach in
patients with advanced ccRCC. Materials and methods: In this
uncontrolled, non-randomized phase II trial, patients with pro-
gressive metastatic ccRCC who met the inclusion criteria re-
ceived RITwith 177Lu labeled girentuximab if targeting of the
antibody was observed after a diagnostic injection with 111In-
dium labeled girentuximab. Patients were eligible for another
treatment cycle if no prolonged grade 4 hematological toxicity
and at least stable disease (SD) according to RECIST v1.1 was
observed on evaluation after 3 months. Retreatment was at
75% of the previous activity dose with a maximum of 3 treat-
ment cycles. Results: Between August 2011 and April 2014,
14 patients enrolled in the study and received at least one
infusion with 177Lu-girentuximab. SD after the first RIT was
observed in 8 patients (57%), partial regression (PR) was seen
in 1 patient (7%), whereas progressive disease (PD) was seen
in the other 5 (36%) patients. Of the 8 patients with SD and 1
with PR, 3 patients were not eligible for retreatment due to
prolonged hematological toxicity. After the second treatment
cycle, PD was observed in 1 out of 6 patients. The treatment
was generally well tolerated, but resulted in transient grade 3-4
hematological toxicity in all but 1 patient. Conclusion: RIT
with 177Lu-girentuximab resulted in disease stabilization in
the majority of patients with progressive ccRCC. Apart from
transient myelotoxicity, RIT was well tolerated.
OP421
Preliminary experience in treating high-risk
neuroblastoma using tandem high dose dosimetry-guided
131I-MIBG treatment combined with chemotherapy
G. Boni1, s. mazzarri1, M. Menconi2, A. C. Traino3, E. Borsò4,
S. Bernasconi2, G. Casazza2, C. Favre5, D. Volterrani1; 1Region-
al Center Of Nuclear Medicine, University Hospital Of Pisa,
pisa, ITALY, 2Division of Pediatric Onco-hematology, Univer-
sity Hospital, Pisa, Italy, pisa, ITALY, 3Health Physics Unit,
Section ofMedical Physics, University Hospital, Pisa, Italy, pisa,
ITALY, 4Nuclear Medicine Division, Sant’Andrea Hospital of
La Spezia, La Spezia, ITALY, 5Division of Pediatric Onco-he-
matology, Meyer Pediatric Hospital, Florance, Florance, ITALY.
Aim: To evaluate the feasibily and safety data of tandem high dose
dosimetry-guided 131I-MIBG infusions combined with chemo-
therapy in patientswith refractory neuroblastoma.Method: Patients
(age 8.5±4.4 yrs) with high-risk neuroblastoma refractory to mul-
tiple chemotherapy schedules and evidence of MIBG-avid disease
by 123I-MIBG scan received two “tandem” high-dose 131I-
MIBG treatments within 15 day. During the first infusion of
131I- MIBG, the patients received 12 mCi/Kg (mean 259 mCi,
range 230-320 mCi). A contemporary dosimetric study was per-
formed to calculate the absorbed dose by patient to estimate the
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activity require for the second 131I-MIBG treatment (the target is
to deliver a combined whole body radiation dose of 4 Gy). During
day 1-5 by the first administration, patients received Topotecan iv
0.7mg/m2 daily as cytotoxic drug and also as radiosensitiser. After
15 days patientswere retreatedwith 131I-MIBG, and betweenDay
15-19 Topotecan 0.7mg/m2 daily was administered again. Periph-
eral blood stem cells (PBSC) were available for transplantation in
all the patients.Post-treatment evaluations were performed every 6-
8weeks after the infusion, including a diagnostic 123I-MIBGscan,
tumor imaging studies (CT or MRI) as well as urine catechol-
amines, and a bone marrow aspirate and biopsy.ResultsFour pa-
tients with evidence of MIBG-avid disease were treated from De-
cember 2013 to date.All the patients completed the protocol
receving a second infusion of 131I-MIBG (mean activity 283
mCi, range 100-353 mCi) to deliver a total whole body absorbed
dose of 4 Gy The median time to second infusion was 16 days
(range 14-19 days). No important adverse events were observed
during both combined treatments. Expected bone marrow toxicity
reached grade 4 neutropenia in 3 patients, grade 3 thrombocytope-
nia in 2 patients - which were treated with platelet transfusions -
and grade 1 anemia in 2 patients. Bone marrow suppression
completely recovered two months after second cycle in all the
patients, without requiring PBSC transplantation. We observed a
response rate (CR+PR) in 2/4 patients 3 months after the comple-
tion of the combined therapeutic regimen. Regarding other two
patients, one case of stability and one of progression disease oc-
curred. Conclusion. Single-centre preliminary experience show the
feasibility of radiometabolic therapywith tandemhigh-dose dosim-
etry-guided of 131I-MIBG combined with chemotherapy. This
therapy seems to be a safe and effective treatment modality for
high-risk neuroblastomawith compromised organ functions. How-
ever, this was a small and heterogeneous cohort and further studies
are needed.
OP422
Compared therapeutic efficacy of 177Lu-HH1
and 177Lu-rituximab in non-Hodgkin B-cell lymphoma
A. Pichard, Jr.1,2,3, S. Marcatili4,5, A. Courteau4,5, R.
Ladjohounlou1,2,3, G. Cartron6, I. Navarro-Teulon1,2,3, A.
Repetto-Llamazares7, H. Heyerdahl7, M. Bardiès4,5, J. Dahle7,
J. Pouget1,2,3; 1Inserm U1194, Montpellier, FRANCE,
2IRCM, Institut de Recherche en Cancérologie deMontpellier,
Montpellier, FRANCE, 3Université de Montpellier, Montpel-
lier, FRANCE, 4UMR 1037 INSERM, Toulouse, FRANCE,
5Centre de Recherche en Cancérologie de Toulouse, Toulouse,
FRANCE, 66Département d’Hématologie, Unités Mixtes de
Recherche–Centre National de la Recherche Scientifique
5235, Centre Hospitalier Universitaire de Montpellier, Mont-
pellier, FRANCE, 7Nordic Nanovector ASA, Kjelsåsveien
168 B, Oslo, NORWAY.
Aims. We compared in vitro and in vivo the therapeutic
efficacy of a new antibody radionuclide conjugate
(ARC), namely Betalutin™ and of 177Lu-labeled ritux-
imab. Betalutin™ consists of the HH1 monoclonal anti-
body (mAb) radiolabeled with 177Lu and is directed
against the CD37 receptor expressed by B-lymphoma
cells. Materials and methods. In vitro, the therapeutic
efficacy of 177Lu-rituximab, Betalutin™ and of the
non-specific 177Lu-cetuximab was assessed in three dif-
ferent lymphoma cell lines (Ramos, DOHH2 and Rec-1)
exposed for 18 hours to increasing activities (0, 0.5, 1,
2, 4 and 6 MBq/mL) of radiolabeled mAbs or to
unlabelled mAbs (0-40μg/mL). Clonogenic survival was
then measured and the mean absorbed dose to the nu-
cleus was calculated using the MIRD formalism. Thera-
peutic efficacy and toxicities were also determined in
mice subcutaneously xenografted with Ramos cells after
intravenous administration of the three ARCs. SPECT-
CT imaging and conventional biodistribution studies
were performed and used for further tumour and organ
absorbed dose assessment. Results. The highest cytotox-
icity was observed for 177Lu-rituximab, followed by
177Lu-HH1 and the lowest for 177Lu-cetuximab. The
highest sensitivity to ARC was observed in human fol-
licular lymphoma cells (DOHH2) and the lowest for
Burkitt lymphoma cells (Ramos), with mantel cell lym-
phoma cells (Rec-1) in between. Unlabelled rituximab
was more efficient in killing cells than HH1 mAb main-
ly through apoptosis induction. The efficacies of the
unlabelled mAbs were subtracted from the therapeutic
efficacies of the ARCs to find the efficacies of the ra-
diation only. In DOHH2, 177Lu-HH1 was more toxic
per Gy than 177Lu-rituximab, 177Lu-cetuximab being
in between. No linear nor linear-quadratic model fitted
the data. The interpretation for Ramos survival curves
was less obvious and depended on the chosen regression
model: no differences in therapeutic efficacy of 177Lu-
rituximab, 177Lu-HH1 and 177Lu-cetuximab were ob-
served after linear-quadratic fit t ing (dose-effect
relationship) while significant differences were observed
when linear models were used (no dose-effect relation-
ship). A linear relationship could be established between
survival and the mean nucleus absorbed dose in both
DOHH2 and Ramos cells exposed to 177Lu-cetuximab.
In vivo, SPECT-CT study confirmed specific tumor
targeting of Betalutin™. Preliminary results highlight the ther-
apeutic efficacy of BetalutinTM associated with a lower tox-
icity than for 177Lu-rituximab. Conclusion. Our results
show that the nature of absorbed dose-effect relationship
associated with RIT of lymphoma depend on the nature
of both ARC and cell line. Lack of absorbed dose-effect
relationship may be explained by uncertainties inherent
to absorbed dose assessment or to bystander effects.
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Efficacy of radioembolization with holmium-166
microspheres; primary outcome of the phase II HEPAR
trial
J. Prince, B. A. Zonnenberg, J. F. W. Nijsen, M. L. J. Smits,
A. F. van den Hoven, F. J. Wessels, R. C. G. Bruijnen, M. N.
G. J. Braat, G. C. Krijger, M. G. E. H. Lam, M. A. A. J. van
den Bosch; UMC Utrecht, Utrecht, NETHERLANDS.
Aim: Microspheres containing holmium-166 in a poly L-
lactic acid matrix (166Ho) have been developed for
radioembolization. In a phase 1 dose-escalation study,
the maximum tolerated dose to the liver was found to
be 60 Gy. The aim of this phase II trial was to evaluate
the efficacy in patients with liver metastases. Materials
and Methods: Patients were included in this single-cen-
ter, single-arm study if they had liver-dominant metasta-
ses on baseline 18F-FDG-PET with triphasic liver CT
which were irresectable and refractory to systemic ther-
apy. Patients received whole liver treatment (aimed
absorbed dose 60 Gy, equal to 3.8 GBq/kg liver tissue).
The study had a sequential design with an interim anal-
ysis after 30 patients, and every 6 patients, until a max-
imum of 48 patients. The primary objective was tumor
response of two pre-specified target lesions on triphasic
liver CT at 3 months, per RECIST 1.1. The response
was calculated using evaluable patients (available case
analysis) and with missing data imputed as progressive
disease (imputed case analysis). Toxicity was scored
using CTCAE version 4.03. Follow up continued until
disease progression, or up to 12 months. Results: From
May 2012 until March 2015, 56 patients with various
primary tumors were included of whom 38 patients were
treated. Four patients’ outcomes were not evaluable due
to: no response consensus among 3 raters, no contrast
enhanced CT for evaluation, use of concomitant chemo-
therapy and death prior to imaging due to extrahepatic
disease recurrence. Four others have not reached 3
months follow up. Stable disease or partial response in
the liver after 3 months was detected in 20/30 patients
(67%, 95% CI 49 – 81%) for the available case analysis
and 20/34 (59%, 95% CI 42 – 74%) for the imputed
case analysis; both proportions were above the pre-
specified stopping boundary for treatment effect (40%),
so the inclusion was closed. Median survival was esti-
mated at 14 months (95% CI 8 – ∞ months). Clinical
toxicity of grade 3 or 4 at any time after treatment
consisted of: abdominal pain (18% of patients), nausea
(9%), liver abscesses (3%), paroxysmal atrial tachycardia
(3%), vomiting (3%), ascites (3%), gastric stenosis (3%),
thoracic pain (3%), and upper gastrointestinal hemor-
rhage (3%). Laboratory examination after treatment
showed grade 3 or 4 toxicities in levels of alkaline
phosphatase (70%), gamma-GT (78%), lymphocytes
(11%), and ALAT (4%).ConclusionRadioembolization
with holmium-166 microspheres induces a tumor re-
sponse in the liver with an acceptable toxicity profile.
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Prolonged overall survival after 99mTc-MAA SPECT
personalized treatment planning in radioembolization
of hepatocarcinoma with 90Y glass microspheres:
preliminary results of a 2 cohort study.
M. Maccauro1, C. Chiesa1, A. Facciorusso2, M. Mira3, C.
Spreafico4, R. Romito1, C. Morosi4, C. Sposito2, S. Bhoori2,
M. Migliorisi5, B. Padovano1, E. Seregni1, A. Marchiano’4, F.
Crippa1, V. Mazzaferro2; 1Nuclear Medicine, Foundation
IRCCS Istituto Nazionale Tumori, Milan, ITALY, 2Surgery
1, Foundation IRCCS Istituto Nazionale Tumori, Milan, ITA-
LY, 3Post graduate Health Physics School, University of Milan,
Italy, Milan, ITALY, 4Radiology 2, Foundation IRCCS Istituto
Nazionale Tumori, Milan, ITALY, 5Clinical engineering,
Foundation IRCCS Istituto Nazionale Tumori, Milan, ITALY.
Aim: to estimate the clinical impact of 99mTc-MAA SPECT
based personalized treatment planning in radioembolization
(TARE) of hepatocarcinoma (HCC) with 90Y glass micro-
spheres. Methods: 2 cohorts of intermediate/advanced HCC
patients were treated. The cohort 1 of 52 patients was enrolled
in a phase II prospective study (Mazzaferro 2013) with strict
exclusion criteria: tumor burden > 50%, anti-tumor therapy in-
cluding drug treatment within 30 days before TARE, previous
TACE. Complete occlusion of the main trunk of portal vein
affected few patients (4/29=14% PVT III, 1/29=3% PVT IV).
Therapeutic activity was chosen according to the device pam-
phlet in order to deliver 120 Gy to the injected lobe. In Child A
patients, a threshold for liver decompensation risk of 15% had
been determined at 75 Gy (absorbed dose averaged on the
whole parenchyma) with retrospective 99mTc-MAA SPECT
dosimetry. For a tumor control probability of 50%, threshold
was at 250 Gy for small lesions (10 gram) for larger lesions.189
sequential “real life” patients were enrolled in cohort 2, includ-
ing any tumor mass, concomitant sorafenib, previous TACE
and complete PVT. For a meaningful comparison, a subcohort
of cohort 2 was selected applying retrospectively the exclusion
criteria of cohort 1. The 90Y activity was personalized with
prospective 99mTc-MAA SPECT dosimetric treatment plan-
ning and the previous thresholds. Liver decompensation within
6 months clearly attributable to progression was not attributed
to the treatment. Results: treatment planning modified the ac-
tivity in 73% of patients with respect to pamphlet indications.
Activity was increased/decreased in 47%/25% of patients
(mean +100%/-30%). The prescription coincided with the
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device indication only in 28% of cases. The parenchyma
absorbed dose standard deviation was strongly reduced in co-
hort 2 (30 Gy vs 16.5 Gy). Tumor absorbed doses did not differ.
Treatment related liver decompensation incidence in Child A
patients of subcohort 2 (11/71=15.5%) was maintained as in
cohort 1 (6/43=14%), as programmed. Overall survival was
prolonged: 15 m, 95% C.I [12 - 18] of cohort 1 versus 17 m,
95% C.I [13 - 19] in subcohort 2. The same is confirmed in the
advanced patients with PVT: 13 m, 95% C.I. [9 - 17] versus 15
m, 95% C.I. [10 - 17]. Conclusion: in HCC patients without
complete obstruction of portal vein, treatment planning resulted
in fully personalized administrations, more homogeneous treat-
ment conditions, identical toxicity incidence and prolonged sur-
vival with respect to the fixed dose of 120 Gy to lobe.
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OP425
One-step radiosynthesis of 68Ga-DKFZ-PSMA at room
temperature
Z. Wimana, C. Artigas, P. Flamen, G. Ghanem; Institut Jules
Bordet, Université Libre de Bruxelles, Brussel, BELGIUM.
Germanium-68/Gallium-68 generator (68Ge/68Ga) has been
under investigation and constant improvement since the late
1970s to reach GMP and pharmaceutical grades lately. Up-to-
now, transchelation of 68Ga-cation at high temperatures has
been the method of choice to prepare many tracers; however,
more straight-forward radiosyntheses preferably at room tem-
perature are now being developed as interesting alternatives to
avoid the use of expensive equipment and lengthy procedures.
This could allow a significant reduction in production cost and
increase in the accessibility of Pet-based-molecular-imaging.
We present here a one-step-labelling procedure of DKFZ-
PSMA-11 ligand with 68Ga3+ at room temperature as a
ready-to-use all-in-one kit and its successful use in prostate
cancer patients.MATERIALS AND METHODS: A ready-to-
use GMP kit (ANMI SA, Belgium) consisting in one vial con-
taining lyophilized DKFZ-PSMA-11 (25μg), acetate buffer and
excipients received up to 10ml of 0.1M HCL 68Ge/68Ga gen-
erator eluate directly and was allowed to incubate for 8-10 min
at room temperature without any stirring. Radio-HPLC was
used to compare radiochemical purity (RCP) as well as the
stability of the tracer before and after SPE-C18 column purifi-
cation. The same parameters were compared with preparations
made with an automatic synthesizer with cassettes using Ga3+
purification/concentration on an ion exchanger, labeling at
95°C and C18 purification. RESULTS: The one-step method
to prepare 68Ga-DKFZ-PSMA proved to be both highly effi-
cient and reproducible. For the one step method we observed a
labeling yield of 97.6±2.2%, a RCP of 99.7±0.3% and specific
activity of 1.4±0.2 mCi/μg. In comparison, the tracer produced
with the automated method showed similar RCP (>99.5%),
specific activity (1.6±0.3 mCi/μg), but an important lower la-
beling yield (77.8±5.8%). The tracer producedwith the one step
method was stable in saline and serum over a course of 3h with
a chemical purity above 99%. Purification over a SPE-C18
column did not result into substantial differences in RCP
(99.9±0.1%) and stability (RCP at 3h>99%). No bacteriological
burden or endotoxins were demonstrated. The C18-purified fil-
ter-sterilized end-product was administered to patients. CON-
CLUSION: We report here an original procedure to prepare
68Ga-DKFZ-PSMA and its successful use in metastatic pros-
tate cancer patients for the first time.68Ga-DKFZ-PSMA is an
example as the same procedure may be adaptable for other
chelating groups and may considerably extend the variety of
tracers by avoiding heat. With the introduction of pharmaceu-
tical grade 68Ge/68Ga generators, would such methods mimic
the success story of 99mTechnetium chemistry five decades
ago is an open question.
OP426
Radiosyntheses and Preclinical Evaluation
of Radiofluorinated PSMA-Ligands
J. Cardinale, M. Schäfer, M. Benesova, U. Bauder-Wüst, D.
Komljenovic, M. Eder, M. E. Ladd, K. Kopka; German Can-
cer Research Center, Heidelberg, GERMANY.
Aim: Urea-based inhibitors of the prostate-specific membrane
antigen (PSMA) are well known and promising candidates for
the diagnosis (1,2) and therapy of prostate cancer. The aim of
the project was the development of fine-tuned F-18 labelled
PSMA-ligands affording an alternative ligand for the well-
known 68Ga-PSMA-617 and 68Ga-PSMA-HBED-CC
(68Ga-PSMA-11). Therefore the binding affinity and internal-
ization characteristics have been determined for the selection
of candidates for further in vivo biodistribution and PET ex-
periments. Materials and Methods: The PSMA binding-motif
Glu-NH-CO-NH-Lys was synthesized by a well-known meth-
od (3) on a solid phase (chlorotrityl-resin) and subsequently an
amino acid linker was build up by fmoc-based solid phase
peptide synthesis (SPPS). After separation from the resin and
deprotection the peptidomimetics were conjugated using
radiofluorinated prosthetic groups. The non-radioactive refer-
ence compounds were also prepared by SPPS. The Ki-values
of all compounds were determined by competitive binding
assays on LNCaP cells against 68Ga-PSMA-10 using the re-
spective cold reference compounds. Subsequently the internal-
ization of the radiofluorinated ligands was determined.
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Moreover, two of the novel radiotracers were evaluated by
dynamic PET experiments. Results: The no-carrier-added
radiofluorination of the new PSMA-ligands with selected
prosthetic groups was accomplished with good radiochemical
yields. The Ki-values of the most promising compounds
PSMA-1001, PSMA-1002 and PSMA-1003 were in the range
of 1.5-3.0 nM. The internalized activity per 10e5 cells was
approx. 3 % for PSMA-1001/1002 and approx. 7 % for
PSMA-1003, respectively. During dynamic PET PSMA-
positive LNCaP tumors could be visualized using
radiofluorinated PSMA-1001 and PSMA-1003 as early as
1 h p.i.. However, both tracers showed significant uptake in
the liver. Altogether PSMA-1003 led to the best results and the
structure is currently modified for further optimization of the
pharmacokinetics. Conclusions: The preparation of the precur-
sors by SPPS enables the build-up of a huge library of diverse
PSMA-targeted ligands. Based on PSMA-617, a series of
promising radiofluorinated PSMA ligands was developed
and evaluated in vitro and in vivo. After a further improvement
of the pharmacokinetics the novel 18F-labelled tracers may
lend themselves as promising compounds for first-in-man clin-
ical studies. Literature: (1) A. Afshar-Oromieh et al., Eur J
Nucl Med Mol Imaging. 2013, 40, 486-495. (Best Clinical
Paper, EJNMMI Prize 2014) (2) Z. Szabo et al., Mol. Imaging
Biol., Ahead of print, Doi.: 10.1007/s11307-015-0850-8 (3)
M. Eder et al., Bioconjugate Chem. 2012, 23, 688-697.
OP427
NODA-GA-PSMA : A versatile probe for SPECT/PET
imaging of PSMA-positive tumors.
E. Gourni1,2,3, V. Goncalves4, F. Denat4, P. T. Meyer2, H. R.
Maecke2; 1German Cancer Consortium (DKTK), Heidelberg,
GERMANY, 2Department of NuclearMedicine, UniversityHos-
pital Freiburg, Freiburg, GERMANY, 3German Cancer Research
Center (DKFZ), Heidelberg, GERMANY, 4Institut de Chimie
Moléculaire de l’Université de Bourgogne, Dijon, FRANCE.
Objectives: The type II integral membrane protein, prostate
specific membrane antigen (PSMA), is overexpressed on pros-
tate cancer as the stage and grade of the tumor progresses,
especially in androgen-independent, advanced and metastatic
disease. The ability to image PSMA by using 68Ga-HBED-
CC-PSMAwas proven to be successful preclinically and clin-
ically. The present study aims at developing and evaluating an
urea-based PSMA inhibitor suitable for labeling with 111In for
SPECT as well as 68Ga and 64Cu for PET imaging. Methods:
The urea-based PSMA inhibitor - lysine-urea-glutamate -
coupled to the spacer Phe-Phe-D-Lys(suberoyl) and function-
alized with the chelator 1,4,7-triazacyclononane, 1-glutaric ac-
id-4,7 acetic acid (NODAGA), to obtain NODAGA-Phe-Phe-
D-Lys(suberoyl)-Lys-urea-Glu (VG66). VG66 was
radiolabeled with 111In, 68Ga and 64Cu. The radioconjugates
were further evaluated in vitro and in vivo in LNCaP xeno-
grafts by biodistribution and PETstudies. Biodistribution stud-
ies were also performed with 68Ga-HBED-CC-PSMA and
111In-DKFZ-PSMA-617 for comparison. Results: 68Ga-
VG66, 64Cu-VG66 and 111In-VG66 were prepared in radio-
chemical purity >95% and specific activities 85, 30 and 10
MBq/nmol exhibiting a logDoctanol/PBS of -3.54±0.06, -3.33
±0.09 and -3.32±0.05, respectively. 68/natGa-VG66, 64/natCu-
VG66 and 111/natIn-VG66 exhibited high affinity for the
LNCaP cells, with Kd values of 19.3±2.5 nM, 25.1±2.0 and
5.5±0.9 nM, respectively. They revealed comparable internal-
ization profiles with approximately 75% of the total cell asso-
ciated activity internalized after 3h of incubation with the cells.
68Ga-VG66 showed very high stability after its administration
in mice and metabolite analysis of the mouse-plasma 15 min
p.i.. Tumor uptake of 68Ga-VG66 (14.5±2.9% IA/g) in LNCaP
xenografts at 1 h p.i is slightly lower than 68Ga-HBED-CC-
PSMA (15.8±1.4% IA/g) but statistically not significant
(P=0.67). The tumor-to-normal tissue ratios at 1 and 2 h p.i
of 68Ga-VG66 are comparable to 68Ga-HBED-CC-PSMA
(P>0.05). Tumor uptake of 111In-VG66 (28.5±2.6% IA/g) at
1 h p.i. is lower than 111In-DKFZ-PSMA-617 (52.1±6.5% IA/
g) (P=0.02). The tumor-to-normal tissue ratios of 111In-DKFZ-
PSMA-617 are significantly higher than 111In-VG66 at all
tested time points. Tumor uptake of 64Cu-VG66 at 1 h p.i
was 20.3±1.5% IA/g. Biodistribution studies at later time
points showed increasing tumor-to-background ratios with
time. This was also illustrated by the PET images. Conclusion:
VG66 can efficiently be labeled with 68Ga, 64Cu and 111In
leading to radiotracers with high affinity towards PSMA.
68Ga-VG66 is comparable to HBED-CC-PSMA in terms of
tumor uptake (P=67) and tumor to normal tissue ratios
(P>0.05) Their promising in vivo pharmacokinetic perfor-
mance may contribute to the improvement of the diagnostic
imaging of tumors overexpressing PSMA.
OP428
68Ga-PSMA11-PET/CT - a new technique with high
potential for the radiotherapeutic management of prostate
cancer patients
F. Giesel1, H. Fiedler1, M. Stefanova1, C. Kratochwil1, A.
Afshar-Oromieh1, K. Kopka2, J. Debus3, U. Haberkorn1, F.
Sterzing3; 1Radiologische Klinik / Abt. für Nuklearmedizin,
H e i d e l b e r g , G E R M A N Y , 2 D e u t s c h e s
Krebsforschungszentrum (DKFZ) / Abtei lung für
Radiopharmazeutische Chemie, Heidelberg, GERMANY,
3Radiologische Klinik / Abt. für Strahlentherapie, Heidelberg,
GERMANY.
AIM: Radiotherapy is the main therapeutic approach besides
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surgery of localized prostate cancer. It relies on risk stratifica-
tion and exact staging. This report analyses the potential of
[68Ga]Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA11) a
new PET-tracer targeting PSMA for prostate cancer staging
and individualized radiotherapy planning. MATERIALS &
METHODS: A cohort of 57 patients with prostate cancer
scanned with 68Ga-PSMA11 PET-CT for radiotherapy plan-
ning was retrospectively reviewed. 15 patients were at initial
diagnosis and 42 patients at time of biochemical recurrence.
Staging results of conventional imaging, including bone scin-
tigraphy, CT or MRI, were compared with 68Ga-PSMA Li-
gand PET-CT results and the influence for radiotherapeutic
management was quantified. RESULTS: 68Ga-PSMA
ligandPET-CT has had a dramatic impact on radiotherapy ap-
plication in the presented cohort. In 50.8% of the cases therapy
was changed. CONCLUSION: The presented Imaging tech-
nique of 68Ga-PSMA-PET-CT could be a key technology for
individualized radiotherapy management in prostate cancer.
OP429
The novel theranostic PSMA-ligand PSMA-617
in the diagnosis of prostate cancer by PET/CT:
biodistribution in humans, radiation dosimetry and first
evaluation of tumor lesions
A. Afshar-Oromieh1, H. Hetzheim2, C. Kratochwil1, M.
Benesova3, M. Eder4, O. Neels4, W. Kübler5, F. L. Giesel1,
W. Mier6, K. Kopka4, U. Haberkorn1; 1University Hospital of
Heidelberg, Heidelberg, GERMANY, 2Div. of Medical Phys-
ics in Radiology, German Cancer Research Center, Heidel-
berg, Germany, Heidelberg, GERMANY, 3Div. of Radiophar-
maceutical Chemistry, German Cancer Research Center, Hei-
delberg, GERMANY, 4Div. of Radiopharmaceutical Chemis-
try, German Cancer Research Center, Heidelberg, Heidelberg,
GERMANY, 5Div. of Radiation Protection and Dosimetry,
German Cancer Research Center, Heidelberg, Heidelberg,
GERMANY, 6Division of Radiochemistry, University Hospi-
tal of Heidelberg, Heidelberg, GERMANY.
Purpose: PET-imaging with the ligand of the prostate-specific
membrane antigen 68Ga-PSMA-11 is regarded as a significant
step forward in the diagnosis of prostate cancer (PCa). More
recently, a PSMA-ligand was developed which can be labeled
with 68Ga, 177Lu and 90Y. This ligand, named PSMA-617,
therefore enables both, diagnosis and therapy of PCa. The aim
of this evaluation was to investigate the distribution of PSMA-
617 in normal tissues and in PCa lesions as well as the radia-
tion exposure of PET-imaging with 68Ga-PSMA-617.
Methods: Nineteen patients with recurrent PCa were referred
to 68Ga-PSMA-617-PET/CT. Quantitative assessment of trac-
er uptake of several organs and 53 representative tumor lesions
was performed in 15 patients 1h and 3h p.i. In four additional
patients, the same procedure was conducted at 5min, 1h, 2h,
3h, 4h and 5h p.i. Based on the data of these four patients the
radiation exposure of a 68Ga-PSMA-617-PET/CTwas identi-
fied. Results: Intense tracer uptake was observed in kidneys
and salivary glands. In 14 of 19 patients (73.7%) at least one
tumor suspicious lesion was detected 3h p.i.. Of 53 represen-
tative tumor lesions selected at 3h p.i., 47 lesions were visible
at 1h p.i. Mean tumor-to-background ratios for SUVmax were
20.4 ± 17.3 (2.3 - 84.0) at 1h p.i. and 38.2 ± 38.6 (3.6 - 154.3)
at 3h p.i. Average radiation exposure (effective dose) is ap-
proximately 2.1E-2 mSv/MBq. Conclusion: Within healthy
organs, kidneys and salivary glands demonstrated the highest
68Ga-PSMA-617 uptake. The radiation exposure is relatively
low. 68Ga-PSMA-617 can show PCa-lesions with very high
contrast. Images conducted at 3h p.i. detected more PCa-
lesions compared to images at 1h p.i..
OP430
Value of Ga-68 PSMA PET/CT for Patient Selection
and Follow-up of Metastasized Prostate Cancer Patients
Undergoing Peptide Radioligand Therapy (PRLT)
with Lu-177 DOTAGA-PSMA Inhibitor
H. R. Kulkarni1, H. J. Wester2, A. Singh1, R. P. Baum1;
1THERANOSTICS Center for Molecular Radiotherapy and
Molecular Imaging, Bad Berka, GERMANY, 2Pharma-
ceutical Radiochemistry, Technical University Munich,
Munich, GERMANY.
Aim: Ga-68 PSMA-HBED-CC (Ga-68 PSMA) is a sensitive
and specific PET tracer for the detection of prostate cancer
recurrences and metastases. The aim of this study was to deter-
mine the role of Ga-68 PSMA PET/CT in patients with metas-
tasized castrate resistant prostate cancer (mCRPC) undergoing
peptide radioligand therapy (PRLT) using Lu-177 DOTAGA-
PSMA inhibitor (Lu-177 PSMA). Methods: Ga-68 PSMA
PET/CT (contrast-enhanced CT scan) was performed in 217
patients (mean Gleason score 7±1, mean age 63±11 years, me-
dian PSA 58.2, range 0.1-2223 ng/ml), and repeated in 31 pa-
tients for follow-up after 2-4 cycles of PRLT using Lu-177
PSMA. PET/CT findings were also correlated with post-
therapy Lu-177 PSMAwhole body scans and SPECT/CT stud-
ies performed during therapy. Retrospective analysis was per-
formed using our prospective database of patients undergoing
PRLT. Results: Metastatic disease with PSMA expression was
noted in 40 patients, including bone (n=35), two or more lymph
node sites (n=31), lung (n=5) and liver (n=5). All Lu-177
PSMA positive lesions (noted on post-therapeutic scans) were
previously also identified on PET/CT. Molecular response to
PRLT could be assessed after 2-4 cycles of PRLT by Ga-68
PSMA PET/CT in 31 patients. Molecular response (EORTC)
was noted in 14 patients, demonstrating strong correlation
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between change in SUVmax and change in serum PSA level
(r=0.84). On the other hand, morphological criteria (RECIST)
established objective response in 6 of 14 patients. Disease
remained stable in 7 and 15 patients, according to EORTC
and PERCIST, respectively, and progressed in 10 patients. Con-
clusions: Ga-68 PSMA PET/CT enables not only effective se-
lection of metastasized prostate cancer patients for therapy with
Lu-177 labeled DOTAGA-PSMA inhibitor, but also for the
assessment of objective therapy response, correlating well with
change in serum PSA. It may be useful for the early identifica-
tion of responders and non-responders, since molecular re-
sponse precedes morphological changes in tumors.
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OP431
FDG PET Imaging of a Rat Model of Autoimmune
Myocarditis: Comparison with Histological Analysis
R. A. Werner1,2, Y. Maya1,3, V. Jahns4, H. Wakabayashi1, M.
Nakajo1, K. Fukushima5, M. Javadi6, T. Yanagisawa7, R.
Jahns8, T. Higuchi1,2; 1Department of Nuclear Medicine,
Universitätsklinikum Würzburg, Würzburg, GERMANY,
2Comprehensive Heart Failure Center, Würzburg, GERMA-
NY, 3Research Centre, Nihon Medi-Physics Co., Ltd., Chiba,
JAPAN, 4Department of Pharmacology, Universitätsklinikum
Würzburg, Würzburg, GERMANY, 5Hyogo College of Med-
icine, Hyogo, JAPAN, 6Division of Nuclear Medicine, Johns
Hopkins University, MD, UNITED STATES, 7Department of
Cardio-angiology, Kitazato University School of Medicine,
Tokyo, JAPAN, 8Department of Internal Medicine I, Univer-
sity of Würzburg, Würzburg, GERMANY.
Aim: Reliable non-invasive tools to diagnose inflammatory ac-
tivity are clinically relevant in patients with myocarditis for op-
timization of therapeutic strategies. The aim of this study is to
assess the feasibility of serial monitoring of the inflammatory
activity in a rat model of acute myocarditis utilizing high reso-
lution small animal PET system and F-18 fluorodeoxyglucose
(FDG). Materials and Methods: Autoimmune myocarditis was
induced in Lewis rats by immunizing twice at a week interval
with 10mg/mL porcine cardiac myosin with Freund’s complete
adjuvant (n=12) or adjuvant alone as control (n=8). Rats re-
ceived serial imaging at week 1, 2 and 3 after first immunization
utilizing a micro PET system. At fasting condition (>12h), static
10min chest FDG PET scans were started 60min after tracer
administration. F-18 fluorobenzyl triphenyl phosphonium
(FBnTP)myocardial perfusion PET imagingwas also performed
to identify the localization of the FDG signal in subset of
animals. For post-mortem ex-vivo analysis (week 3), the hearts
were sliced into 20-μm short axis sections for autoradiography
and histological analysis with HE staining. Region of interest
(ROI) were set on the autoradiograms, and the uptake values
of each ROI were calculated as the background-corrected quan-
tum levels per unit area (QL/pixel). Results: Multiple focal car-
diac inflammatory lesions with intense macrophage infiltration
were histologically identified at week 3 after immunization in 10
of 12 animals and 0 of 8 adjuvant alone controls. FDG PET
showed multiple high-contrast focal tracer accumulation in all
histologically confirmed myocarditis hearts at week 3, while no
focal accumulation in controls (%ID/cc: 1.62±0.93 vs 0.25
±0.04, p<0.05). Serial FDG PET imaging provided time course
of the uptake signals (%ID/cc: 0.25±0.10, 0.28±0.11, 1.62±0.93,
p<0.05 at week 1, 2 and 3, respectively). Ex-vivo analysis con-
firmed co-localization of the area of FDG accumulation and
inflammatory lesions. Mean FDG activity (QL/pixel) at the in-
flammatory lesions identified by histology (223±99) was signif-
icant higher than remote control area (53±30, p<0.0001) and
control hearts (13±4, p<0.0001). Conclusion: Focal increased
FDG PET signals in the heart was well correlated with histolog-
ically identified inflammatory lesions in a rat model of autoim-
mune myocarditis. This FDG-PET imaging might be a promis-
ing approach for serial monitoring of the inflammatory activity,
and this experimental platform would be available for better
understanding of the inflammation dynamics for the develop-
ment of novel therapeutic strategies.
OP432
Assessment of radiolabeled methionine for imaging
myocardial inflammation in a rat model of autoimmune
myocarditis: Comparison with18F-FDG and histological
findings
Y. Maya1,2, R. A. Werner1,3, V. Jahns4, H. Wakabayashi1, M.
Nakajo1, K. Fukushima5, T. Yanagisawa6, R. Jahns7, T.
Higuch i 1 , 3 ; 1Depa r tmen t o f Nuc lea r Med ic ine ,
Universitätsklinikum Würzburg, Würzburg, GERMANY,
2Research Centre, Nihon Medi-Physics Co., Ltd., Chiba, JA-
PAN, 3Comprehensive Heart Failure Center, Würzburg, GER-
MANY, 4Department of Pharmacology, Universitätsklinikum
Würzburg, Würzburg, GERMANY, 5Hyogo College of Med-
icine, Hyogo, JAPAN, 6Department of Cardio-angiology,
Kitazato University School of Medicine, Kanagawa, JAPAN,
7Department of Internal Medicine I, University of Würzburg,
Würzburg, GERMANY.
Objectives: Myocarditis is thought to be one of the major causes of
heart failure and sudden cardiac death in young adults. Currently,
the definitive non-invasivemethod to detect andmonitor the cardiac
inflammatory lesions is missing, and invasive endomyocardial bi-
opsy is associated with inherent sampling error. In this study, we
S176 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
investigated the potential of radiolabeled methionine to assess the
inflammatory activity utilizing a rat model of autoimmune myocar-
ditis.Methods:Autoimmunemyocarditiswas induced inLewis rats
(150-210g) by immunizing twice at a 7-day interval with 10-mg/
mL porcine cardiac myosin with Freund’s complete adjuvant (my-
cobacterium tuberculosis) (n=4) or adjuvant alone as controls (n=4).
On day 21 after immunization, study was performed with dual-
tracer autoradiography to assess distribution of 14C-methionine
and 18F-FDG in the hearts. At fasting condition (>12h), both
18F-FDG (37MBq) and 14C-methionine (0.5MBq) were adminis-
trated 90 min and 20 min before euthanizing the rats, respectively.
The hearts were removed, frozen, and sliced into 20-μm short axis
sections for autoradiography and histological analysis with HE
staining. Region of interests (ROI) were set on the autoradiograms,
and calculated the uptake values of each ROI, as the background-
corrected quantum levels per unit area (QL/pixel) for 14C-
methionine and 18F-FDG. Results: Multiple focal cardiac inflam-
matory lesions were histologically identified in all hearts with my-
osin treatment group, while no lesions were seen in rats with adju-
vant alone. The autoradiographic images clearly demonstrated high-
density accumulation of 14C-methionine, corresponding to histo-
logically confirmed inflammatory lesions and focal 18F-FDG ac-
cumulation. The 14C-methionine uptake (mean binding signal in-
tensity, QL/pixel) in the inflammatory lesions was significantly
higher than remote non-inflammatory area (2561 ± 894 vs 1068
± 339, p<0.0001) and control hearts (2561 ± 894 vs 727 ± 97,
p<0.0001). Excellent positive correlation between intensity of
14C-methionine and 18F-FDG accumulation was observed (r2 =
0.93, p<0.0001). Contrast between inflammatory lesion and non-
inflammatory area was higher in 18F-FDG than in 14C-methionine
(3.45 ± 0.68 vs 2.07 ± 0.21, p<0.05). Conclusions: Using rat model
of autoimmune myocarditis, we confirmed focal increased of 14C-
methionine accumulation, co-localizing cardiac inflammatory le-
sions and 18F-FDG uptake. Further experiments using 11C-
methionine PET are warranted to investigate the feasibility and
robustness of in-vivo imaging and advantages over 18F-FDG
PET especially regarding physiological background uptake issue.
OP433
Imaging of myocardial inflammation with somatostatin
receptor based PET/CT - a comparison to cardiac MRI
C. Lapa1, T. Reiter1, X. Li2, R.Werner1, S. Samnick1, R. Jahns1,
A. K. Buck1, G. Ertl1, W. R. Bauer1; 1Universitätsklinikum
Würzburg, Würzburg, GERMANY, 2AKH Wien, Wien,
AUSTRIA.
Aims: Acute myocarditis as well as post-ischemic myocardial in-
flammation are associated with a profound activation of the im-
mune system that plays a pivotal role in the further clinical course.
Present non- invasive imaging modalities allow no direct visuali-
zation of the involvedmacrophage system.We aimed to investigate
the feasibility of somatostatin receptor (SSTR)-based positron
emission tomography / computed tomography (PET/CT) for de-
tecting acute inflammatory lesions in patients after myocardial in-
farction or peri-/myocarditis.MethodsOn a compassionate use ba-
se, 12 patients (7 males, 5 females) with active peri-/myocarditis
(n=6) or sub-acute myocardial infarction (n=6) underwent SSTR-
PET/CT imagingwith 68Ga-DOTA-TOC and cardiacMRIwithin
3-10 days after onset of symptoms (mean, 7±3 days; interval be-
tween PET/CT and MRI, 3±3 days). PET images were visually
scored. The AHA 17-segment model of the left myocardium was
used for localization and comparison of inflamed myocardium for
both imaging modalities. Using semi-quantitative analysis, tracer
uptake was calculated as mean andmaximum standardized uptake
value (SUVmean and SUVmax) and compared to infarcted/
inflamedmyocardiumwith both remote myocardium and left ven-
tricular (LV) cavity. Results: SSTR-PET/CT revealed areas with
mild or moderately increased tracer uptake in the myocardium or
the pericardium in all patients. In the 17-segment model, PET/CT
yielded 55 andMRI 47 positive segments. Overall concordance of
the 2modalities was 85.3% (174/204 segments analyzed). In 9.3%
(19/204), more positive segments were identified by PET/CT,
whereas in 5.4% (11/204), MRI detected more positive segments.
SUVmean and SUVmax in infarcted/inflamed areas were 3.5±0.9
and 4.0±1.1, respectively. The lesion-to-remote myocardium and
lesion-to-LV cavity ratios were 1.9±0.4 and 1.9±0.3 for SUVmean
and 1.8±0.3 and 1.7±0.3 for SUVmax, respectively. Conclusions:
The different imaging patterns of SSTR-directed radiotracers and
MRI suggest a complementary role of PET/CT for detecting/
imaging myocardial inflammation in the course of myocarditis
and/or sub-acute infarction. Our data warrant further analysis in
larger prospective clinical studies.
OP434
Disphosphonates Cardiac Uptake in Familial Amyloid
Neuropathy: Comparison between DPD and HMDP
H. Regaieg1, R. De Paola Chequer1, R. Ben Azzouna1, V.
Algalarrondo2, B. Mahida1, M. Slama2, D. Le Guludec1, F.
Rouzet1; 1Department of nuclear medicine, Bichat-Claude
Bernard university hospital, Paris, FRANCE, 2Department of
cardiology, Antoine Béclère university hospital, Clamart,
FRANCE.
Aims: Familial amyloid polyneuropathy (FAP) is a severe heredi-
tary disease, due to production by the liver of a genetic variant
transthyretin (TTR) resulting in tissue amyloid deposits. Cardiac
involvement is of major prognostic value. Diphosphonate scintig-
raphy has been proposed as a diagnostic tool for TTR-related
cardiac amyloidosis, but there is no consensus on the optimal
radiopharmaceutical. Consequently, we compared the cardiac up-
take of two 99mTc-labelled tracers: diphosphono-
propanedicarboxylic acid (DPD) and hydroxymethylene
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diphosphonate (HMDP) in patients with TTR-FAP. Methods: 122
consecutive patients with TTR-FAP were prospectively included
and received randomlyDPD or HMDP. Acquisitions (whole-body
(WB) and chest SPECT)were performed 3 hours after intravenous
injection of the tracer. Quantification of myocardial uptake onWB
acquisitions was performed by use of the ratio between the geo-
metric mean of either total or average counts of a region of interest
(ROI) drawn over the heart area and the WB total or average
counts (H/WBtotal or H/WBaverage). Quantification on SPECT
acquisitions was performed by the ratio between 3D isocount vol-
ume of interest generated over the myocardium and a standard
volume in the right lung (H/L).Quantification of soft tissues uptake
was performed by use of ratio between average counts of a ROI
drawn over the lumbar spine and a ROI drawn over soft tissues of
the lower limb (B/ST) on the WB acquisition. Results: the DPD
and HMDP groups of patients had similar age (62±15 vs. 59±14
years respectively; p=0.3), sex (males: 67% vs. 58% respectively;
p=0.4), TTR mutation (Val30Met: 70% vs. 80% respectively;
p=0.3) and activity of the tracer (DPD: 713±86 MBq vs. HMDP:
709±124 MBq; p=0.9). Quantitative parameters derived from
whole body acquisition were significantly greater with DPD com-
pared to HMDP (H/WBtotal: 3.8±2.7 vs. 2.4±2.1 respectively;
p=0.002 and H/WBaverage: 5.2±2.2 vs. 4.3±1.3 respectively;
p=0.01) as well as H/L derived from SPECT acquisition (3.9±3.7
vs. 2.0±1.9 respectively; p=0.001). The uptake by soft tissues was
also greater in the DPD compared to HMDP group (B/ST: 3.6±2.0
vs. 5.7±2.9 respectively; p<0.0001). Conclusions: The present
study shows that in patients with TTR FAP, the uptake of DPD
in heart and other soft tissues is superior to that of HMDP. This
suggests that DPD should be prioritized for initial assessment of
patients suspected of cardiac involvement of TTR-related amyloid-
osis. Further study is required to assess whether this difference
impacts the diagnostic performance and whether DPD is more
accurate for the assessment of therapy response.
OP435
Cardiac involvement in systemic sclerosis patients can be
detected by dual single-photon emission computed
tomography of thallium-201
and iodine-123-beta-methyl-p-iodophenyl-pentadecanoic
acid scintigraphy
S. Matsuo, K. Nakajima, S. Kinuya, K. Takahara; Kanazawa
University Hospital, Kanazawa, JAPAN.
Objective: Systemic Sclerosis (SSc) is a clinically heteroge-
neous connective tissue disorder. Heart involvements confer a
poor prognosis in patients with systemic sclerosis. Neverthe-
less, the prevalence of cardiac involvement is not fully evalu-
ated. The purpose of this study was to detect myocardial met-
abolic and perfusion abnormalities at rest using 123I-BMIPP
and 201Tl imaging in patients with systemic sclerosis patients.
Methods: We examined 82 patients of collagen disease
(male/female=18/64, mean age 55±14) (71 systemic sclerosis
(SSs) (8 limited cutaneous SSc), 4 systemic lupus erythema-
tosus (SLE), 5 mixed connective tissue disease (MCTD), 2
others). All patients underwent both resting 123I-BMIPP im-
aging and 201Tl imaging. Total defect score (TDS) of 123I-
BMIPP and perfusion were semi-quantitatively determined
with SPECT imaging using a 17-segment 5-point model and
Japanese normal database. Mismatch was defined the differ-
ence of the score more than 2 (123I-BMIPP>201Tl). Left ven-
tricular functional analysis was performed by QGS software.
Results: Thirty-three out of 82 (40.7%) patients with collagen
disease had metabolic abnormalities (defect score>3). TDS of
123I-BMIPP were 4.8±2.7 in patients with sclerosis and 201Tl
defect score was 2.4±2.8 in sclerosis. Mismatch between 123I-
BMIPP and 201Tl was found in 11 out of 82 patients (13.4%).
Left ventricular ejection fraction was 69±16%, and end-
diastolic volume 57±19ml, end-systolic volume 18±14ml.
There was no perfusion-metabolic mismatch in patients with
limited cutaneous SSc (n=8). Conclusion: Cardiac manifesta-
tion occurs earlier and frequently in an early stage systemic
sclerosis patients with normal systolic function. The 123I-
BMIPPmetabolic SPECTcan be utilized on systemic sclerosis
patients.
OP436
Value of FDG-PET/CT and cardiac MR for the diagnosis
and therapy monitoring in cardiac sarcoidosis.
B. SGARD, S. DJELBANI, J. TORDJMANN, G. POP, H.
NUNES, D. VALEYRE, V. EDER,M. SOUSSAN; University
paris XIII, Bobigny, FRANCE
Objectives: Cardiac sarcoidosis (CS) is associated with a poor
prognosis. There are currently no clear recommendations on
imaging strategy. The objective of this study was to compare
FDG-PET/CT (PET) and cardiac MR imaging (MR) for the
diagnosis and therapy monitoring of CS. Materials and
Methods: We conducted a single-center retrospective study
including 53 patients with histologically proven sarcoidosis
and a suspicion of CS. PET and MR were performed in all
patients in a maximum time interval of two months. PETwere
all performed after a low carbohydrate-high fat diet. A sub-
group of 16/53 patients (30%), were followed during therapy
using both MR and PET. MR was considered as positive if
there was a delayed gadolinium enhancement located in the
subepicardial area. PETwas considered as positive if there was
a focal or multifocal FDG uptake. The findings of PET and
MR, as well as the reversibility under treatment were com-
pared. Results: 36% of patients (n = 19/53) had a MR (+)
and 13% (n = 7/53) had a PET (+). All patients with PET (+)
had also an MR (+), with myocardial lesions located in the
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same locations in all cases. Among patients, 30% (n=16/53)
had residual physiological FDG uptake under therapy (diffuse,
basal, papillary muscle). Among patients having baseline MR
(+) and PET (+), 86% (n=6/7) had improving lesions on MR
and 100% (n=6/6) on PET. None of the lesions in patients with
MR (+) and PET (-) had modifications on follow-up MR.
Conclusion: PET should be identify inflammatory CS and po-
tential reversibility under treatment. PET should be systemat-
ica l ly associa ted with MR for improving les ion
characterization.
OP437
Relationship between active inflammation and myocardial
injury in patients with cardiac sarcoidosis as detected
by non-invasive multi-modality imaging
S. Kataoka, M. Momose, K. Fukushima, N. Serizawa, A.
Suzuki, C. Kondo, K. Abe, S. Sakai, N. Hagiwara; Tokyo
women’s medical university, Tokyo, JAPAN
Aim: 18F-FDG PET/CT (PET), cardiac magnetic resonance
(CMR) imaging and 123I-BMIPP/201TlCl dual myocardial
SPECT have been reported to be useful to diagnose as cardiac
sarcoidosis (CS), but the relationship between them is still
poorly understood. The aim of this study is to clarify the rela-
tionship between the three modalities for CS. Materials and
methods: We evaluated 16 patients (10 male, mean age 55±13
year old) with CS before steroid therapy who underwent PET,
CMR and dual gated SPECT. Left ventricular myocardium
was divided into 17 segments. BMIPP and TL defects were
scored in each segment visually using a 5-point grading sys-
tem: 0-4 (0,normal; 4,absent). BMIPP and TL total defect
score was also calculated as summed BMIPP defect (BMDS),
summed TL defect (TLDS) and summed mismatch score
(MS). Late gadolinium enhanced (LGE) CMR and PET im-
ages were fused using a syngo.via software. Segmental FDG-
SUVmax in the 17 regions as well as whole heart SUVmax
were measured, and segmental LGE were assessed according
to a 3-grading system (LGE0, no LGE; LGE1, partly positive
LGE; LGE2, transmural LGE) on the fused images. All
SPECT segments (17segs x 16 patients) were classified into
the 3 groups of LGE score. Segmental BMIPP, TL defect,
mismatch score and SUVmax were compared between the 3
LGE score groups using one-way ANOVA. Results: Whole
heart SUVmax in the 16 patients was 6.6±5.0 and summed
BMDS, TLDS, MS were 18.6±12.6, 12.9±10.9, 5.7±3.1, re-
spectively. Segmental based analysis revealed that BMDSs
were 0.49±0.95, 1.63±1.51, 2.57±1.60 in LGE0(n=156),
LGE1(n=81), LGE2(n=35) (LGE0 <LGE1 <LGE2,
p<0.001), and TLDSs were 0.33±0.76, 1.15±1.28, 1.86±1.44
in the 3 groups (LGE0 <LGE1 <LGE2, p<0.005), respective-
ly. MSs in LGE1 and LGE2 groups were significantly higher
than that in LGE0 group (LGE1, p<0.001; LGE2, p<0.001),
but there was no significant difference in MS between LGE1
and LGE2. SUVmax in LGE1 group was significantly higher
than that in LGE0 (p<0.025), but there was no significant
difference in SUVmax between LGE1 and LGE2 groups.
Conclusion: Higher SUVmax showing active myocardial in-
flammation was mainly located in the LGE region, where
BMIPP-TL mismatch was observed. BMIPP-TL mismatch
with higher FDG uptake still exists in the transmural LGE
induced by granuloma, which may reflect injured but viable
myocardium in the transmural LGE region among CS patients.
The combination of the three modalities makes it possible to
evaluate the morphological and pathophysiological aspects of
CS.
OP438
Impact of 18F-FDG PET/CT in the management
of patients with large vessel vasculitis associated
to polymyalgia rheumatica.
C. Lavado-Pérez, I. Martínez-Rodríguez, I. Banzo, R. Quirce,
J. Jiménez-Bonilla, M. De Arcocha-Torres, Z. Bravo-Ferrer,
M. Jiménez-Alonso, J. L. López-Defilló, F. Gómez de la
Fuente, D. Meza-Escobar, J. M. Carril; Nuclear Medicine.
Molecular Imaging Group (IDIVAL). Marqués de Valdecilla
University Hospital. University of Cantabria., Santander,
SPAIN
Aim: Polymyalgia rheumatica (PMR) may present associated
to large vessel vasculitis (LVV) that is often overlooked due to
non-specific signs and symptoms. These patients frequently
had a poor treatment response and need increased doses of
steroids or other immunosuppressive drugs. Our aim was to
evaluate the impact of 18F-FDG PET/CT in the management
of LVVassociated to PMR.Materials and methods: A prospec-
tive study including 40 consecutive patients with PMR (27
women/13 men, 68.10±10.27 years) was performed. An
18F-FDG PET/CT scan was requested on suspicion of associ-
ated LVV. PET/CT scan was obtained 180’ after 18F-FDG
intravenous injection. Images were evaluated using a visual
analysis and grading the intensity of the vascular uptake from
0 (no uptake) to 3 (intense uptake). Five vascular regions were
evaluated: supra-aortic trunks (SAT), thoracic aorta (TA), ab-
dominal aorta (AA), iliac arteries (IA) and femoral/
tibioperoneal arteries (FTA). A final diagnosis of LVV was
established in 26 out of the 40 patients (65%), 20 of themwere
under therapy at the time of PET/CT examination. Results:
The most frequently vascular region involved in the 26 pa-
tients with LVV was the TA (100%) followed by the SAT
(61.54%) and the FTA (53.85%). The highest intensity of
18F-FDG uptake was at the TA (grade 2 and 3 in 24 patients).
No uptake was visualized in any vascular region in 4 of the 14
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patients without LVV (28.57%) and in the other 10 patients
(71.43%) only a grade 1 uptake was observed in 1 or to 2
regions.18F-FDG PET/CT led to a therapeutic change in 17
out of the 20 (85%) treated LVV patients.Regarding the out-
come in the 26 patients with LVV, 19 (73.08%) had a good
clinical and biochemical response and a follow-up PET/CT
performed in 8 of them showed a decrease of uptake. Despite
an increase of treatment, 6 patients (23.08%) had a clinical and
biochemical worsening and the follow-up PET/CT performed
in 3 showed an increase of uptake. Finally, one patient (3.84%)
in whom the treatment was not changed suffered a
worsening.Conclusion: Our results confirmed the usefulness
of 18F-FDG PET/CT for the detection of LVV associated to
PMR. The most frequently involved region was the TA. The
detection of vascular inflammation using 18F-FDG PET/CT
had an important impact and led to a treatment change in a
high percentage of patients with LVV.
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OP439
Initial experience of DMSA SPECT-CT in the assessment
of paediatric renal calculi
Ashford1, E Joel1, G Heath1, N Smeulders2, M Easty1, L
Biassoni1Departments of Radiology1 and Urology2, Great
Ormond Street Hospital for Children NHS Foundation Trust,
London (UK)
Aim: Renal calculi are uncommon in children but, when they
occur, they represent a significant cause of renal damage. To-
day, they are usually removed by percutaneous nephro-
lithotomy (PCNL), uretero-renoscopy or extracorporeal shock
wave lithotripsy (ESWL). An abdominal radiograph and an
ultrasound are the usual initial investigations but the position
of the calculus may be incompletely defined. Aim of the study
is to present our initial experience on 99mTc-DMSA with
SPECT-CT in children with renal calculi. Methods: We per-
formed DMSA SPECT CT in 19 consecutive children (age
range 2–16 years, mean 9 years; 6 males, 13 females) with
renal calculi. Calculi were diagnosed with ultrasound and ab-
dominal x-ray. DMSA planar images were followed by
SPECT and a low-dose CT. The split renal function, the renal
parenchymal integrity, the number and position of calculi, and
the Hounsfield Unit (HU) value of each calculus were noted.
Two patients were scanned under general anaesthesia (GA); no
sedation or GAwas required in the other patients. The injected
activity was calculated in proportion to body weight, scaling
from a maximum of 100 MBq. The CTwas acquired with 50
mAs, 80 kVp, tube rotation 0.8, collimation 2 x 1.5 mm, pitch
1.3, scan slice thickness 2mm. A topogram covering the abdo-
men and pelvis to detect possible stones in the ureters and
bladder was performed in 11/19 (58%) patients (110 kVp, 36
mAs).Results: Renal scarring was demonstrated in 7/19 kid-
neys (37%), whilst 8/19 kidneys (42%) showed reduced renal
function. SPECT helped to assess the integrity of the renal
parenchyma adjacent to the calculus and to identify patients
with chronic irrecoverable damage. The CT aided the location
of the calculus within the collecting system. The stone density
was pivotal in planning management (if <1000HU the patient
was considered for ESWL, if >1000HU for PCNL). The ef-
fective dose equivalent (EDE) from the CT component was
low (mean 0.36 mSv, range 0.21-0.75). The EDE from the
topogram ranged between 0.016 and 0.032 mSv (mean
0.023). Conclusion: DMSA SPECT CT in paediatric patients
with renal calculi provides both anatomical and functional
information with very little extra radiation dose. These prelim-
inary results are promising and deserve further evaluation.
OP440
99mTc-DMSA in Biopsy Confirmed Paediatric Acute
Tubulointerstitial Nephritis
P. Zucchetta1, E. Miorin2, L. Murer2, F. Bui1, D. Cecchin1, E.
Vidal2; 1Nuclear Medicine Dept. - University Hospital - Pado-
va, Padova, ITALY, 2Paediatric nephrology, dialysis and trans-
plant - University Hospital - Padova, Padova, ITALY.
Acute tubulointerstitial nephritis (aTIN) is a frequent cause of
acute renale failure in adults and children, accounting for 15-
20% of acute kidney injury cases. Inflammatory cells infiltrat-
ing kidney interstitium, probably as a consequence of an
antigen-initiated cell-mediated response, characterize it. Expo-
sition to drugs, mainly non-steroidal anti-inflammatory drugs
and antibiotics, is the most frequent etiology (70%), followed
by viral and bacterial infections. Tubular dysfunction and a
progressive reduction in glomerular filtration rate lead to renal
impairment, which is usually reversed by timely treatment
(elimination of the offending drug and steroids). Nevertheless,
a delay in diagnosis and treatment may result in chronic
tubulointerstitial nephritis, which can be steroid refractory.
The clinical presentation is aspecific (fever, asthenia, etc) and
there are no validated biomarkers. Imaging studies offer little
contribution, since ultrasounds findings are usually not specif-
ic (kidney volumetric increase and diffuse cortical hyper-
echogenity) and 67Ga-citrate scintigraphy suffers of low
specifity (50-60%) and significant radiation exposure, com-
bined with long scanning times (48-72 h after injection). We
have studied 5 patients (M4, F1, age range 3-17 y, age mean 15
y) diagnosed with acute tubulointerstitial nephritis. All pa-
tients presented acute renal failure, persistent fever (2-4 wk)
and weakness. Diuresis was reduced in only one case.
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Inflammatory markers were raised in all cases, with clear signs
of acute kidney injury (creatinine clearance 55 ml/min/1.73
sqm) and tubular damage (glycosuria, elvated alfa1-
microglobulin and NAG). Three cases had no of detectable
causes (drugs, infection, immune system distrubances) and
were classified as “idiopathic”. One case developed uveitis
two months later and was therefore classif ied as
tubulointestitial nephritis-uveitis syndrome (TINU syn-
drome), whereas an Adenovirus infection was detected in
the last one. All patients underwent 99mTc-DMSA scintig-
raphy during the acute phase of the illness. The scan was
p e r f o rmed f o l l ow i n g t h e EANM pro c e du r a l
guidelines.Patchy hypofixation was observed in all cases,
similar to some acute pyelo-nephritis patterns, but with
b i l a t e r a l i n v o l v em e n t a n d a mo r e d i f f u s e
distribution.Kidney biopsy has been performed in 4/5 pa-
tients, with kidney injury lasting > 6 wk. Histopathologic
findings showed in all cases a typical inflammatory infil-
tration of the kidney interstitium.99mTc-DMSA scintigra-
phy could play a role in the diagnosis of acute
tubulointerstitial nephritis, shortening the diagnostic work
up and leading to a faster treatment. Considering the min-
imal radiation exposure and lack of invasivity it has prom-
ising perspectives also in the follow up of this
underdiagnosed illness.
OP441
Evaluation of Schwartz eGFR-Cr in comparison
with GFR measured by Tc-99m-DTPA clearance
in healthy and in children with urinary tract infection
with and without vesicoureteral reflux
M. Vlajković1, S. Ilić2, M. Rajić1, M. Stević1, M. Božinović1,
V. Živković3, M.Matović4; 1Center of NuclearMedicine,Clin-
ical Center Niš, Niš, SERBIA, 2Center of Nuclear Medicine,
Clinical Center Niš, Niš, SERBIA, 3Clinic for Physical Med-
icine,Rehabilitation and Prosthetic, Clinical center Niš, Niš,
SERBIA, 4Center of Nuclear Medicine,Clinical Center
Kragujevac, Kragujevac, SERBIA.
Objective: The aim of this study was to asses diagnostic per-
formance of estimated glomerular filtration rate (eGFR-Cr)
based on creatinine and body high equation originally devel-
oped by Schwartz. The assessment was done by means of
comparison between glomerular filtration rate (GFR) mea-
sured by Tc-99m-DTPA clearance in children with no
nephro-urological diseases, children with urinary tract infec-
tion without vesicoureteral reflux (VUR), and with VUR using
Bland-Altman analysis.Material and Methods: The study en-
rolled 451 pediatric patients (104 male and 347 female, mean
age 7.07±3.02 yrs, range 2-15 yrs), who were included in a
retrospective review of GFRmeasurement data from the single
institution’s database. Subgroups of patients were formed ac-
cording to the diagnosis as follows: control group (CG, n=64),
group with urinary tract infection without VUR (UTI, n=299),
and group with VUR (VUR, n=88). GFRwasmeasured by Tc-
99m-DTPA clearance method from a single blood sample
drawn 180 minutes after radiopharmeceutical administration.
eGFR was based on creatinine and body high equation. Re-
sults: Compared with GFR, the mean bias for eGFR-Cr in the
study groups was as follows: CG: 1.937ml/min/1.73m2 (95%
limits of agreement [LOA]: -36.759 to 40.633 ml/min/
1.73m2), UTI: -3.010ml/min/1.73m2 (LOA: -57.292 to
51.272 ml/min/1.73m2) and VUR: 2.183mL/min/1.73m2
(LOA:-64.019 to 68.385 mL/min/1.73m2). eGFR-Cr demon-
strated comparable accuracy to GFR in CG and UTI with 95%
and 82% of estimates within 30% of GFR, while the estimates
in VURwere less accurate, amounting to 68% of values within
30% of GFR.Conclusion: eGFR-Cr was found to be a reliable
alternative to GFR in healthy children, as well as in those with
urinary tract infection. However, it was found to be less accu-
rate in children with vesicoureteral reflux and renal
impairment.
OP442
Is the Clinical Diagnosis of Chronic Immune
Thrombocytopenic Purpura in Pediatric Population
Always Correct?
M. Todorovic-Tirnanic, D. Sobic-Saranovic, V. Artiko; Fac-
ulty of Medicine, University of Belgrade and Center of Nucle-
ar Medicine, Clinical Center of Serbia, Belgrade, SERBIA.
Aim: 1. to investigate patophysiological mechanism of throm-
bocytopenia with 111In-oxinate labeled autologous platelets in
children with clinical diagnosis of chronic immune thrombo-
cytopenic purpura (ITP); 2. to verify the diagnosis; 3. to pre-
dict the efficacy of the planned splenectomy. Material: 69 chil-
dren (44 girls and 25 boys) aged from 3.1 -18.0 yrs (median =
11 yrs), body height: 100 - 187 cm (mean = 147 cm), body
weight: 15 - 98 kg (median = 34 kg) were investigated.
Methods: 1) 69 autologous 111In-oxinate platelet (Pt) label-
ings; 2) 69 quality controls: a) general yield of labelling
(GYL), b) differential yields of labeling (DYL): Pt DYL, red
and white blood cell DYL, plasma DYL, c) initial platelet
accumulation in the liver (IPAL); 3) Pt lifespan (LS); 4) Pt
production index (PI); 5) Pt sequestration site and index esti-
mation were performed. Results: Mean Pt blood count was 23
G/l (range: 1-122 G/l); mean blood sample volume for Pt sep-
aration and labeling was 55ml (30 - 75ml); mean radioactivity
used for Pt labelling was 11.1 MBq; mean injected radioactiv-
ity was 6.7 MBq (2,6 - 10.1 MBq); mean GYL = 65.9 % (33.9
- 90.2 %); mean Pt DYL = 92.6 % (55.7 - 99.6 %); mean
RBC&WBC DYL = 1.6 % (0.0 - 41.5 %); mean plasma
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DYL =0.7 (0.2 - 7.3 %); mean IPAL = 11.9 % (3.0 - 35.8 %).
Mean Pt lifespan was 12 hours (0.7 - 216 h). In 63/69 children
(91.3 %) diagnosis of ITP was confirmed. In this group of
children mean Pt lifespan was 9.6 h (0.7 - 93.6 h); mean Pt
PI=1.8 (0.2 - 23.4); Pt sequestration site was: the spleen in 26
(42%), predominantly spleen in 9 (14%), liver in 3 (5%),
mixed (in liver and spleen equally) in 24 (39%). In 6/69 (8.7
%) children clinical diagnosis of ITP was excluded. All of
them had normal Pt lifespan: two had normal quantity of sep-
arated platelets (pseudothrombocytopenia) and four had inad-
equate Pt production (Pt PI ranged from 0.1 - 0.2). Conclusion:
1) In 6/69 children initial clinical diagnosis of ITP was
changed: 2/69 had pseudothrombocytopenia, 4/69 inadequate
platelet production. 2) In 63/69 children clinical diagnosis of
ITP was confirmed. 3) Help in decision whether to perform
splenectomy or not was enabled in 61% of confirmed ITP
patients (with splenic, predominantly splenic and hepatic Pt
sequestration).
OP443
Impact of colonic transit scintigraphy on clinical decision
making in severely constipated children
E. Medaer, I. Hoffman, W. Thimister; KU Leuven, Leuven,
BELGIUM
Aim: The objective of this study was to evaluate the diagnostic
yield and the impact on clinical decision making of colonic
transit scintigraphy in children with severe chronic functional
constipation. Materials and methods: From September 2014 to
March 2015, 7 patients (mean age 6.2 years, 4 girls and 3
boys) with chronic treatment-resistant functional constipation
received an 111indium-labeled diethylene triamine pentaacetic
acid (111In-DTPA) colonic transit scintigraphy in our institu-
tion. The scintigraphy was performed as part of the diagnostic
work-up, with the aim of providing information on gastric
emptying, small bowel transit and segmental colonic transit.
After an overnight fast, patients ingested a small amount of
water that was radiolabeled with 111In-DTPA. They underwent
repeated imaging in supine position between the detectors of a
gamma camera to obtain anterior- posterior abdominal scans
of 4 minutes duration each. The scans were taken at 4 h, 24 h
and 48 h post-ingestion. Five technetium position markers
were placed on anatomic landmarks to create a reference
frame. Processing of the images was performed using the Her-
mes Hybrid Viewer and geometric centers were calculated.
Results: Colonic scintigraphy showed normal transit time in
4 patients (57%), delay in the distal colon in 2 patients (29%),
and colonic inertia in 1 patient (14%). This led to a diagnostic
adjustment for 4 patients and a differentiation of the diagnosis
for the 3 others. The results of the scintigraphy had therapeutic
consequences for all of the patients. In 3 children (43%) the
pharmaceutical treatment could be optimized. For3 other pa-
tients (43%) the planned intervention was altered. In 1 patient
(14%) an operation could be avoided. Conclusion: This pre-
liminary study demonstrates the added value of colonic transit
scintigraphy in the investigation of functional constipation in
children and the high impact on clinical decision making.
Scintigraphic transit studies provide a noninvasive and safe
assessment of whole-colon and regional colonic transit. Be-
cause of the physiological design and the reliability of the
examination, we were able to offer diagnostic differentiation
for all patients.
OP444
Accuracy of 99mTcO4- Meckel’s Scan and Other
Diagnostic Indicators in Symptomatic Paediatric Meckel’s
Diverticulum
Mazin Al Janabi1, Madan Samuel2,Andrea Kahlenberg3,
SujithKumar41,4Department ofNuclearMedicine, 2Department
of Pediatric Surgery, 3Department of Anaesthesia, Mediclinic
City Hospital, Dubai, UNITED ARAB EMIRATES
Purpose: To evaluate the diagnostic accuracy of 99mTc-
pertechnetate scintigraphy in children with symptomatic
Meckel’s diverticulum. Methods: This was a prospective line-
ar observational study of 73 children with the diagnosis of
symptomatic Meckel’s diverticulum. Meckel’s diverticulum
scintigraphy was performed using 99mTc pertechnetate to eval-
uate ectopic gastric mucosa in MD in 61 (84%) children. Dy-
namic imaging was carried out for 60 minutes. Pharmacolog-
ical intervention was not adopted to enhance the result of
99mTc-pertechnetate. Independent variables assessed were
age, gender, weight-for-age z scores, clinical presentation,
complications of MD, laparoscopy findings, haematology
and biochemistry results, radiology, and histology. The sensi-
tivity, specificity, positive & negative predictive values and
accuracy of 99mTc-pertechnetate scintigraphy was assessed.
Results: The incidence of MD with complications was 44%.
The prevalence of ectopic gastric mucosa in histology speci-
mens was 84%. There was a good correlation between rectal
bleeding and presence of ectopic gastric mucosa (r = 0.94).
Hematochezia associated with drop in haemoglobin (>2 g/dL)
was diagnostic of MD with ectopic gastric mucosa in children
(n=42; 58%. p = 0.006). Bilious vomiting was diagnostic of
complicated MD (n=12; 16%. p = 0.007). 99mTc-pertechnetate
scintigraphy sensitivity was 84% and specificity 22%. Positive
predictive value was 0.64 and negative predictive value was
0.22. The accuracy of 99mTc-pertechnetate scintigraphy varies
from 46% to 90%. The sensitivity and specificity of 99mTc-
pertechnetate scintigraphy was dependent on the quantity and
functional quality of the heterotopic gastric mucosa. Preoper-
ative median z-scores was - 1.4 and postoperative median z-
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scores were - 1.2. Conclusions: 99mTc-pertechnetate scintigra-
phy had a truncated predictive value. Its contribution in clini-
cal decision making was poor. Clinical suspicion of MD
should be high in children presenting with hematochezia asso-
ciated with drop in haemoglobin by >2 g/dL. Laparoscopy is
an effective diagnostic tool.
OP445
Clinical Value of Cerebral Perfusion SPECT Imaging
in Children with Acute Sydenham’s Chorea
S. M. d. A. Giorgio1, M. G. Caprio1, A. Romano2, E.
Vergara1, G. Russo2, M. Alessio2, A. Cuocolo1; 1Department
of Advanced Biomedical Sciences, Naples, ITALY, 2Depart-
ment of Translational Medical Sciences, Naples, ITALY
Aim: Sydenham’s chorea is the most common form of acute
chorea during childhood ant it may be associated with cerebral
perfusion abnormalities at SPECT imaging, mainly hyperper-
fusion or, more rarely, hypoperfusion patterns. We evaluated
whether a better definition of cerebral perfusion patterns of the
cortical/subcortical structures by SPECT imaging improves
differential diagnosis and prognosis in pediatric patients with
acute autoimmune Sydenham chorea. Material and Methods:
Fifteen children (6 boys, age range 6-14 years) with a diagno-
sis of acute autoimmune chorea seen between 1999 and
2011 at our department were studied. Inclusion criteria were:
presence of choreic movements with acute autoimmune etiol-
ogy and age from 1 to 18 years. All patients had first a full
physical examination including a rheumatologic and neuro-
psychiatric assessment. All patients also underwent brain mag-
netic resonance imaging (MRI) and cerebral SPECT imaging.
MRI scan was performed with spin-echo T1 weighted, T2
weighted and FLAIR sequences. T1 weighted sequences were
also obtained after administration of intravenous paramagnetic
contrast (gadolinium). SPECT imaging was performed after
intravenous injection of Tc-99m ethyl cysteinate dimer (32
Mbq/Kg) using a dual-head gamma camera (E-cam, Siemens
Medical Systems) equipped with general purpose, low energy,
parallel-hole collimator. The analysis was performed by com-
paring tracer uptake in the basal ganglia with the uptake in a
control region. Results: At presentation, chorea was general-
ized in 9 patients and localized (hemichorea) in 6 patients. In
addition to chorea, 6 subjects showed decreased verbal fluency
and personality changes and one a left hemiparesis. Tests of
liver and kidney function, antinuclear antibody, and anti-
deoxyribonucleic acid were normal in all patients. Brain
MRI revealed normal findings in 13 and small foci of white
matter gliosis in 2 patients, without relevant clinical value.
Cerebral SPECT showed unilateral increased perfusion in the
basal ganglia in all 9 children with generalized chorea, while
the remaining 6 patients had normal perfusion pattern. No
relationship between the severity of the symptoms and the side
of increased perfusion was found. A follow-up SPECT, per-
formed during the recovery phase in 5 of the 9 patients with
perfusion abnormalities at the first study, showed normal per-
fusion in all. Conclusions: The evidence of increased basal
ganglia perfusion in during the active phase of the disease
suggests that this abnormality is a marker of inflammatory
chorea. Cerebral SPECT perfusion imaging could be an accu-
rate noninvasive tool to monitor the course of acute autoim-
mune chorea in childhood.
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OP446
Investigation of Image Quality with Sodium Pertechnetate
99mTc Produced by Cyclotron
S. V. Selivanova1,2, É. Lavallée1, O. Sarrihni1, B. Guérin1,2, É.
Turcotte1,2, R. Lecomte1,2; 1Sherbrooke Molecular Imaging
Center, CRCHUS, Sherbrooke, QC, CANADA, 2Université
de Sherbrooke, Sherbrooke, QC, CANADA.
Aim: Cyclotron production of technetium-99m (99mTc) is a
promising route to supply 99mTc-radiopharmaceuticals. The
main difference of cyclotron-produced 99mTc from generator
source is its intrinsic contamination with shorter half-life 93Tc,
94Tc and longer-lived 95Tc, 95mTc, 96Tc, and 97mTc, which may
affect image resolution and contrast. This study investigated
the contamination due to the high-energy radioisotopic impu-
rities present in sodium pertechnetate 99mTc produced with a
cyclotron. Methods: Capillary and Jaszczak phantom imaging
was performed using cyclotron-produced 99mTc (Ein = 24
MeV, 2 h irradiation, 99.815% 100Mo enrichment) and 99mTc
obtained from a generator up to 16 h after the end of production/
elution. Radionuclidic/radioisotopic purity of the formulation
was determined using gamma-ray spectrometry with calibrated
HPGe detector and decay corrected to the imaging time. Planar
images were acquired on a Discovery NM/CT 670 SPECT/CT
camera (GE) equipped with low-energy high-resolution colli-
mators. The energy windows were 140.5 keV ±7.5% (standard
for 99mTc), 117.0 keV ±10% (low energy), and 170.0 keV
±10% (high energy). Results: For the main energy window,
for a capillary filled with 99mTc-pertechnetate eluted from a
generator, planar image resolution at full width half-maximum
(FWHM) was 4.15±0.05 mm at 0 cm and 6.82±0.04 mm at
10 cm from the gamma-camera collimator. The FWHM resolu-
tion of images with cyclotron-produced 99mTc was 4.21
±0.06 mm at 0 cm and 6.83±0.09 mm at 10 cm from the colli-
mator. The resolution remained stable in time within measure-
ment error. Planar images of Jaszczak phantom were of
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S183
comparable quality without significant loss in spatial resolution.
On average, the contrast of images acquired using cyclotron-
produced 99mTc (n=7) was 1.16±0.02 with contrast-to-noise
ratio (CNR) of 10.47±0.26, which compares favorably to the
best of two values obtained for generator 99mTc: 1.14 (contrast)
and 10.28 (CNR). The relative count rate in high-energy win-
dow for the cyclotron-produced 99mTc increased up to 5-fold as
compared to the generator 99mTc due to increased proportion of
energetic 94Tc and 96Tc but remained below 10% of the total
counts over the entire imaging period. Only marginal increase
was observed in the low-energy window. Visually, two side-by-
side images acquired with 99mTc from generator and cyclotron
in the main energy window were found to be equivalent. Con-
clusions: At tested conditions, the scatter effect due to high-
energy radioisotopic impurities present in 99mTc-pertechnetate
produced with cyclotron did not influence visual image quality
in the standard for clinical applications energy window. Early
results of an ongoing clinical study (NCT02307175) confirm
these findings.
OP447
One Size Fits All? Assessment of the Use of a Simple
Calibration Protocol for Quantitative SPECT/CT Imaging
of 177Lu in European Hospitals
J. Merrett1,2,3, A. Fenwick2, J. Scuffham1,3, L. Johansson2,
A. Nisbet1,3; 1University of Surrey, Guildford, UNITED
KINGDOM, 2National Physical Laboratory, Teddington,
UNITED KINGDOM, 3Royal Surrey County Hospital,
Guildford, UNITED KINGDOM
The accuracy of molecular radiotherapy dosimetry calcula-
tions is critically dependent on the accuracy with which the
quantitative imaging of the patient can be performed. However,
there is no single established protocol for performing quantitative
imaging. Therefore, the aim of this work was to assess the ability
of a simple calibration protocol to quantify the activity in an
unknown comparison source, simulating a relatively large lesion
locatedwithin a patient in an area of warmbackground activity, in
a number of hospitals across Europe.Two 177Lu sources were
used at each hospital for this work, ranging from 30MBq to
100MBq at the time of imaging. All sources were filled at the
UK National Physical Laboratory so the activities and activity
concentrations were accurately known. A 16ml sphere was used
to perform the calibrationmeasurements: SPECT/CTacquisitions
were performed of the sphere in an elliptical Jaszczak phantom in
air, in water at the centre and in water off-centre. The comparison
source was a 26ml central sphere, surrounded by an 80ml outer
shell. The activity concentration ratio between the inner sphere
and outer shell was approximately 15:1, providing a warm back-
ground. For the comparison exercise, the SPECT/CTacquisitions
were also performed with the source positioned within a water-
filled elliptical Jaszczak phantom with the addition of an anthro-
pomorphic lung and spine insert and body contour rings that were
added to the outside of the phantom. All image reconstruction
was performed on a single Hermes Gold workstation using an
OSEM algorithm with 5 iterations and 10 subsets. Images were
corrected for scatter, attenuation and collimator-detector response.
No corrections were performed for deadtime or partial volume
effects due to the low activities and relatively large volumes used.
Spherical volumes of interest of the physical size of the sources
were used to extract total counts in all the SPECT images. A
calibration factor was derived from the mean value (cps/MBq)
of the three calibration measurements. This calibration factor was
subsequently used to determine the activity within the central
sphere in the comparison exercise. The data from the majority
of the hospitals enabled the activity within the comparison source
to be determined to within ±10%. This work demonstrated the
ability of a single calibration protocol to be used successfully at a
number of different hospital sites across Europe. It paves the way
for harmonised calibration protocols to be developed, ensuring
consistent patient treatment across all European hospitals.
OP448
Standardised Time-Dose Regimen for Ga-DOTANOC
PET Imaging
J. K. J. Archer, M. J. Carroll, S. Vinjamuri, E. Panagiotidis;
Royal Liverpool University Hospital, Liverpool, UNITED
KINGDOM
Aim: The Royal Liverpool University Hospital (RLUH) has
been established as a European Neuroendocrine Tumour So-
ciety (ENETS) Centre of Excellence for the last 5 years. Re-
cently the department becoming one of the first in the UK to
perform Gallium 68 (Ga68) DOTANOC PET as part of the
diagnosis, pre-PRRT workup and post PRRT evaluation of
such tumours. Although the local diagnostic reference level
(DRL) is set at 200MBq, the time intensive production process
and the short half-life of Ga68-DOTONOC (68minutes) result
in this rarely being achieved. At the RLUH the scanning radi-
ographer attempts to compensate for this by adjusting the bed
position times, resulting in highly variable image quality. This
is further compounded by more usual factors such as variation
in patient size. The aim of this project was to retrospectively
inspect the administered activities and subsequent image qual-
ity for these patients, and develop a formalised activity-bed
position time regimen that would help to standardise image
quality at a more consistent level. Materials and Methods: A
group of Ga68-DOTANOC patients (n = 50) scanned on the
GE Discovery 690 at the RLUH were used to retrospectively
inspect the variation in: injected activity, activity at scan start
time, image quality, bed position time and patient dependent
size parameters. Image quality was assessed by the signal-to-
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noise ratio (SNR) calculated from standardised uptake values
(SUV) measured in the spleen, an organ expressing homoge-
nous tracer uptake. Results: The average administered activity
was seen to be 132.6 ± 22MBq, the minimum activity being as
low as 90.3MBq and the maximum that of the local DRL. The
time from injection to scan start was seen to extend to a max-
imum of 36 minutes past the 1 hour window prescribed in the
current protocol, resulting in a loss of 30.7% of the activity
expected. 45 out of 50 patients exhibited a constant time per
bed position, whilst 5 exhibited different times per bed posi-
tion to optimise imaging of previously seen tumours. The
spleen SNR ranged from 3.55 to 15.85, with mean of 10.45.
Conclusions: Linear correlations have beenmadewith specific
indices that take into account the patient activity at scan time,
the time per bed position and patient dependent size parame-
ters. These indices have been rearranged to provide an opti-
mum bed position time based on all the aforementioned fac-
tors. These have been verified with retrospective list mode
reconstructions aiming for a consistent spleen SNR.
OP449
Evaluation of the Performance of a Biograph mCT-Flow
PET/CT System according to NEMANU2-2012 standards
I. Rausch1, J. Cal-Gonzalez1, T. Beyer1, G. Minear2; 1Center
for Medical Physics and Biomedical Engineering, Medical
University of Vienna, Vienna, AUSTRIA, 2Dept of Nuclear
Medicine, Landesklinikum St. Pölten, St. Pölten, AUSTRIA
Aim: To evaluate the physical performance of a Biograph
mCT Flow PET/CT system with sequential and continuous
patient table motion. Methods: We evaluated the performance
of the Biograph mCT Flow 64-4R PET/CT system (Siemens
Medical Solutions USA, Inc.). Spatial resolution, system sen-
sitivity, noise equivalent countrate (NEC) and physical image
quality (IQ) were assessed according to the NEMA NU 2-
2012 standards. Resolution measurements were performed
using an 18F-point source inside a glass capillary tube (inner
diameter: 0.9-1.0 mm; wall thickness 0.4 mm). Sensitivity
tests were performed with a 70cm long polyethylene tube
filled with 4.5 MBq of FDG. Scatter fraction and count rate
measurements were performed using a 70cm long polyethyl-
ene cylinder with a diameter of 20 cm, with a line source
(1.04 GBq of FDG) inserted axially into the cylinder at
4.5 cm off-center. The standard NEMA IQ phantom with 6
spheres (internal diameter (mm): 10, 13, 17, 22, 28 and 37)
was used for the evaluation of the IQ in whole-body imaging
mode. First, the phantom was scanned over a single bed (4
min) according to the NEMA protocol. Second, a 2-bed posi-
tion scan of 4 min each of the phantom with the image plane
containing the spheres centered in the overlap region followed
by a scan of the same axial scan field with Continuous
Table Motion (CTM) at a table speed of 0.6 mm/s was per-
formed. Image contrast and covariance for the six spheres in
sequential and CTM mode were compared according to NU2-
2012 regions. Measurements were done with a sphere-to-
background ratio 8 to 1 and 4 to 1. Results: Spatial resolution
measured as Full-Width-Half-Maximum (FWHM) was
4.3mm (r=1cm) and 7.8 mm (r=20cm). Measured sensitivity
was 9.4 kcps/MBq, both at the center of the FOV and 10 cm
off-centered. Measured peak NEC was 185 kcps at 29.0 kBq/
mL. Scatter fraction was 33.5%.Sphere contrast recovery
values (sphere-to-background of 8:1) varied from 42%
(10mm) to 78% (37mm) for the NEMA protocol. No differ-
ence in contrast recovery values was seen between sequential
and CTM acquisition. Background variability was slightly
higher in CTM (between 2.4 and 6.3) compared to sequential
mode (between 2.1 and 4.9). Conclusion: Basic performance
(resolution, sensitivity, scatter, NEC) of the mCT Flow was
equivalent to the performance of the predecessor mCTsystem.
Contrast recovery in sequential and CTM acquisitions was
similar, however, background variability was elevated slightly
in CTM acquisition.
OP450
The effect of image reconstruction parameters in Mediso
NanoScan PC PET/CT images obtained by two different
positron emitting tracers under NEMA standards NU
4-2008
A. Gaitanis1, E. Vlastou1, P. Bouziotis2, G. Kastis3, C. D.
Anagnostopoulos1; 1Biomedical Research Foundation of the
Academy of Athens (BRFAA), Athens, GREECE, 2Institute
of Nuclear and Radiological Sciences, Technology, Energy
and Safety (I.N.Ra.S.T.E.S.) N.C.S.R., Athens, GREECE,
3Research Center of Mathematics, Academy of Athens, Ath-
ens, GREECE
Aim: The Mediso NanoScan PC with 8 detector modules is a
new commercially available small animal PET/CT scanner,
suitable for both mice and rats imaging. To identify the opti-
mum reconstruction approaches, we have assessed different
image reconstruction parameters, for two different positron-
emitting tracers under NEMA standards NU 4-2008. Materials
and Methods: The scanner provides various reconstruction
algorithms, however, in preclinical imaging, 3D OSEM (in-
cluding a regularization method) is the most commonly used
option. In this study, the combination of subsets (1, 2 and 4)
and iterations (2, 4, 6, 8, 10) and the level total variation reg-
ularization (None, Low and High) were examined. All other
reconstruction parameters such as coincidence mode, energy
window, correction methods (attenuation and scatter) and vox-
el size were kept constant. For the image quality evaluation, all
requirements of the NEMA standards were followed. The IQ
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phantomwas filled with 3.7MBq of 18FDG and after IQ phan-
tom’s cleaning and checked for zero activity, it was filled with
5.4 MBq of 68Ga. The acquisition time was thirty minutes for
both positron emitters. For the quantitation of image quality,
the following parameters were calculated: i) Recovery Coeffi-
cient (RC), ii) image noise (%STD), iii) spillover ratio (SOR)
and iv) Contrast-to-Noise ratio (CNR). Results: The results
indicate that the selection of the number of subsets can affect
the RC values. As this number increases, the RC values in-
crease and after a number of iterations, they remain unchanged
(i.e. 2subsets/8iterations: RC1mm=0.05, RC2mm=0.22,
RC3mm=0.67, RC4mm=0.83, RC5mm=0.92, 4subsets/8iter-
ations: RC1mm=0.07, RC2mm=0.43, RC3mm=0.73,
RC4mm=0.92, RC5mm=0.93). Furthermore, the level of reg-
ularization does not affect the RC values. Lower image noise is
achieved using high level of total regularization (i.e. 4subsets/
4iterations: 17.6% (Low), 6.6% (High)). The SOR values are
improved as the number of subsets and iteration increases (i.e.
2subsets/2iterations: SORair & SORwater>0.25 and
4sub/2iter: SORair & SORwater <0.10). The CNR values de-
pend on the number of subsets and the level of regularization
( i . e . Low Regu la r i za t ion , 2subse t s /4 i t e r a t ions :
CNR1mm=0.18, CNR2mm=3.94, CNR3mm=15.76,
CNR4mm=22.42, CNR5mm=27.88, High Regularization,
4subsets/4iterations: CNR1mm=1.11, CNR2mm=11.60,
CNR3mm=28, CNR4mm=32.8, CNR5mm=35.2). Conclu-
sions: Our findings demonstrate that selection of reconstruc-
tion settings should be determined by imaging requirements.
To increased sensitivity, a 3D OSEM image reconstruction
should be performed with low regularization level, four sub-
sets and eight iterations. On the other hand, if high contrast
images in low noise level are required, 3D OSEM image re-
construction should be performed with high level of regulari-
zation, four subsets and four iterations.
OP451
Considerations for Interpreting SPECT SUVs: Image
Noise, Post-filter and SUV Metric
N. A. Bebbington1, L. C. Jenkins2; 1Queen Elizabeth Hospital
Birmingham, Birmingham, UNITED KINGDOM, 2HER-
MES Medical Solutions, London, UNITED KINGDOM
AIM: SUVs are used in PET to improve confidence in diag-
nosis and SPECT SUVs are now an emerging tool. Special
consideration should be given to image reconstruction and
interpretation of SPECT SUVs, due to inherent differences in
resolution and noise between PET and SPECT. The reporting
metric of choice may differ between these modalities:
SUVmax is favoured in PET, but may not be appropriate for
SPECT. The aim was to assess the effects of image noise and
reconstruction settings on SUVand determine the most appro-
priate reporting metric. MATERIALS ANDMETHODS: The
NEMA-IEC PET image quality phantom was filled with Tc-
99m with a 6.7:1 sphere:background ratio. SPECT-CT data
were acquired using a Siemens SymbiaT16/LEHR collimator
(120x30sec projections, step-and-shoot with auto-contouring).
Full-count SPECT data contained 8.4M counts. Poisson re-
sampling was performed for a range of clinically realistic
count densities (full down 1/16 counts). Data were reconstruct-
ed in HERMES HybridRecon v1.1B (with attenuation correc-
tion, scatter correction and resolution recovery) with a range of
equivalent iterations and post-filters. These were analysed in
HERMES HybridViewer v2.5. Spherical VOIs of nominal
size were assigned to SPECT spheres. Three spherical VOIs
(diameter 2.7cm) were placed in background. SUVmax and
SUVpeak (1cc) were measured for all datasets. RESULTS:
The true SUV of spheres was 6.7. Convergence: without
post-filter SUVpeak was consistent with >90 iterations
(>90% counts returned) for all spheres. At 30 iterations 55%
counts were returned. Without post-filter SUVmax was less
consistent with >90 iterations (>90% counts returned) for all
spheres. At 30 iterations only 55% counts were returned. In-
creasing iterations is required for convergence but this in-
creases noise. Variability: For the largest sphere (37mm diam-
eter), as counts reduce SUVmax and SUVpeak increase. For
an 8mm Gaussian post-filter SUVpeak increases by 51% from
full counts to 1/16 counts, compared with 63% for SUVmax.
This difference is reduced to 16% for a heavily filtered image.
SUVpeak is most robust to varying count densities. CON-
CLUSIONS: SPECT data is more subject to effects of image
noise and partial volume than PET, both of which cause vari-
ability in SUV. SUVpeak was the most robust SUV metric to
image noise and is preferred for SPECT. It is important that
noise and resolution are considered in the choice of post-filter.
For studies with a large range in expected noise level, smooth-
er filters are preferred.
OP452
Accurate model of a Capintec activity meter
with the Monte Carlo code Fluka
F. Zagni1, A. Evandri1, G. Cicoria1, A. Infantino2, S. Vichi2,
S. Costa3, M. Marengo1; 1Medical Physics Department, Uni-
versity Hospital “S.Orsola – Malpighi”, Bologna, ITALY,
2Montecuccolino Nuclear Engineering Laboratory, Depart-
ment of Industrial Engineering, University of Bologna, Bolo-
gna, ITALY, 3PET Radiopharmacy Unit, University Hospital
“S.Orsola – Malpighi”, Bologna, ITALY
Aim. In this work we developed and validated a Monte
Carlo model of one of the world’s most diffused
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radionuclide activity meters, using Fluka. Materials and
Methods. We modelled the Capintec CRC-15, a widely
diffuse model of activity calibrator. To this end, we used
Fluka, a general purpose simulation code for radiation
physics, covering an extended range of applications such
as accelerator shielding, dosimetry and detector design.
The main geometrical elements and materials of the ioniz-
ing chamber were included in the model. Thickness and
position of internal components was evaluated through
both direct measurements of external dimensions and CT/
X-ray imaging. The radioactive sources were carefully
modelled and located in the detector well; in the validation
a set of reference sources was used: 137Cs (22.7±1.5% MBq
at time of measure), 133Ba (1.3±1.5% Mbq), 131I (71.5
±1.5%), 57Co (74.4±3%), 68Ge “mock 18F” (7.5±1.65%)
and others. The container of each source and the correct
filling were suitably modelled and included in Fluka input
file. Calibration factors could be evaluated based on the
energy deposited in the Argon gas. The entire decay
scheme of each radionuclide was included in the simula-
tions, including low-energy X-ray emission and the energy
spectrum of beta particles. The results of the simulations
(statistical error below 1%) were normalized to the re-
sponse of the modelled 137Cs source. The dependence of
the sensitivity versus position of the source was also
assessed in a range of 15 cm. Results. An high accuracy
energy-response curve for the activity meter was calcu-
lated, allowing for prediction of an initial calibration
factor for new radionuclides. In the benchmark against
known standards, the ratio between simulated and mea-
sured relative response was: 133Ba 1.007±0.015, 68Ge
1.016±0.018, 131I 0.971±0.017, 57Co 0.970±0.035. The
sensitivity-position curve gave 4% as a maximum dis-
crepancy. Conclusion. An accurate model of a widely
diffuse activity meter has been validated for a variety
of gamma-emitting nuclides, covering a wide range of
energies and source positions, showing discrepancies be-
low 3% for all the tested sources. The Fluka code
proved to be a powerful tool for assessment of activity
meter’s calibration factors for radionuclides commonly
used in radiopharmacy facilities as well as for non-
conventional radionuclides, and for the easy assessment
of geometrical correction factors.
OP453
Phase I Trial comparing a Digital Detector PET/CT
System with current photomultiplier PET Technology
in Diagnostic Oncology
M. V. Knopp1, K. Binzel1, C. L. Wright1, V. Nagar1, P.
Bardos1, P. Maniawski2, J. Zhang1; 1The Ohio State
University, Columbus, OH, UNITED STATES, 2Philips
Healthcare, Cleveland, OH, UNITED STATES.
Objectives: The commercial introduction of a solid state, dig-
ital photon counting PET detector PET/CT system presents a
potential next generation leap that requires objective assess-
ment of clinical capabilities. This Phase I trial was performed
to demonstrate the potential clinical capabilities for oncologic
whole body imaging and to recommend acquisition ap-
proaches. Methods: 40 patients volunteered to participate in
an intra-individual matched pair comparison study using a
digital PET/CT (Vereos, Philips Healthcare Cleveland) while
their standard of care PET/CT exam was performed on a con-
ventional photomultiplier TOF PET/CT system (Gemini 64
TF) at 75 min p.i. PET imaging was performed using a stan-
dard of care 480 MBq FDG dose. Ultra-low dose CT attenua-
tion scans were acquired on the digital PET/CT using 120 KV,
50 mAs using iterative iDose4 reconstruction. PET emission
was acquired with 90s per bed position, 39% overlap and
164 mm z-axis FOVand reconstructed using TOF with default
4x4x4, 2x2x2 and 1x1x1 mm voxel volumes using PSF and
Gaussian filtering. The digital PET/CT system has also an
improved time of flight (TOF) timing resolution of 320 ps
vs. 550 ps in the comparator conventional system. Blinded
visual and clinical read assessment was performed by a three
reader panel independently. Results: All 40 patient stud-
ies were rated to be of evaluable image quality. The
digital PET comparator scan was classified preferable
in regard to count intensity and tissue delineation detail
in all case comparisons. The confidence of lesion detec-
tion increased on the DPET scans with increased recon-
struction matrix size, with significantly (p≤0.05) im-
proved lesion characterization between the 4 and 1 mm
comparators. Most pronounced differences were noted in
small and intense lesions such as lymphnode metastases
and small pulmonary nodules. No increase in non-
specific uptake of lesions was noted on the higher res-
olution reconstruction matrices. Faster and lower dose
acquisition approaches appear feasible as dose reduction
simulations of up to 70% did not impact diagnostic
assessability. Conclusions: The digital detector PET/CT
demonstrated consistently preferable imaging features in
the intra-individual comparison with improved lesion
characterization most notable in small, metabolically ac-
tive lesions. Whole body PET imaging with higher res-
olution matrix size appear readily feasible with digital
PET leading to substantially reduced partial volume ef-
fects, thus improving lesion detectability and characteri-
zation of heterogeneous lesions. The 2mm / 288 recon-
struction matrix appears to be the recommended standard
to be utilized with the 1mm / 576 available for high
definition images.
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The role of 18F-FDG PET/CT for the detection
of recurrent Osteosarcoma
F. Ceci1, A. Angelini2, P. Castellucci1, T. Graziani1, M.
Polverini2, P. Ghedini1, S. Israel1, R. Bonfiglioli1, P. Ruggieri2,
S. Fanti1; 1Nuclear Medicine - S.Orsola-Malpighi Hospital -
University of Bologna, Bologna, ITALY, 2Department of Or-
thopedics, Istituto Ortopedico Rizzoli, University of Bologna,
Bologna, ITALY.
Aim: To investigate the diagnostic accuracy of 18F-FDG-PET/
CT in osteosarcoma patients, with suspicious of disease recur-
rence after radical therapies. Materials and Methods: Inclusion
criteria were: a) radical surgical treatment for proven osteosarco-
ma and documented complete remission after therapy; b) 18F-
FDG-PET/CT during follow-up for clinical/diagnostic suspicious
of relapse; c) histological validation of 18F-FDG-PET/CT find-
ings. Thirty-seven osteosarcoma patients were retrospectively en-
rolled (20 male, 17 female; mean/median/range age 21/18/7-72
years-old). The primary sites of tumours were: femur (n=15);
tibia (n=13); humerus (n=3); soft tissue (n=3); pelvis (n=2); ulna
(n=1). 18F-FDG-PET/CT performance was assessed with a per-
patient and per-site evaluation of sensitivity, specificity, accuracy,
positive predicting value (PPV) and negative predicting value
(NPV). The sites of relapse were classified as local (local relapse
in bone and/or soft tissue), lung, lymph-nodes (LNs) and distant
(other skeletal segments and/or distant soft tissue). The disease
free survival (DFS) and the overall survival (OS) after 18F-FDG-
PET/CT were evaluated. Results: 18F-FDG-PET/CT was posi-
tive in 89.2% (33/37) of patients. Local uptake was observed in
35.1%patients (13/37); lung uptake in 18.9% (7/37); local and
lung in 2.7% (1/37); local and LNs in 10.8% (4/37); local, LNs
and distant 5.4% (2/37); LNs and distant in 2.7% (1/37); lung,
LNs and distant in 2.7% (1/37); local, LNs, lung and distant in
5.4% (2/37); lung and distant in 2.7% (1/37); only distant in 1/37
(2.7%). The per-site mean-SUVmax analysis resulted in: lo-
cal=10.2; LNs=8.2; lung=5.6; distant=9.8. In order to validate
18F-FDG-PET/CT findings, all patients underwent surgery on
the basis of 18F-FDG-PET/CT results. Histology resulted posi-
tive in 92% (34/37) of patients. A total of 51 pathologic lesions
were evaluated (22 local relapse, 11 lung metastasis, 10 metasta-
tic LNs, 8 distant metastatic lesions). On a per-patient analysis
18F-FDG-PET/CT showed a sensitivity, specificity, accuracy,
PPV and NPV of 91%, 75%, 89%, 97%, 50%. On a per-site
analysis the performance for local recurrence was 96%, 100%,
97%, 100%, 93%, while for lung recurrence detection was 80%,
100%, 92%, 100%, 88%. The mean follow-up after 18F-FDG-
PET/CTwas 21.5 months (range 1-82). At the end of follow-up
19% (7/37) of patients were death, 35% (13/37) were alive with
disease and 46% (17/37) had no evidence of disease. At 18
months after 18F-FDG-PET/CT the DFS was 46% and the OS
was 81%. Conclusion: 18F-FDG-PET/CT showed promising re-
sults for the recurrence detection in osteosarcoma patients with
suspicious of relapse after radical treatment, particularly in the
detection of local relapse and lung metastasis.
OP455
Initial FDG PET/CT predicts survival in adults ewing
sarcoma family of tumors.
J. B. Bastien; B Jamet1, T Carlier1,2, L Campion3, E
Bompas3, M Colombié4, D Rusu4, D Goulon4, V Fleury4,
F Kraeber-Bodéré1,2, C Rousseau2,4, 1Nuclear Medicine
Unit, University Hospital, Nantes, France, 2INSERM U892,
CRCNA, Nantes, France, 3Oncology Unit, ICO Cancer Cen-
ter, Saint Herblain, France, 4NuclearMedicine Unit, ICO Can-
cer Center, Saint Herblain, France
AIM: FDG PET/CT is a recommended tool for initial staging
and restaging of Ewing Sarcoma Family of Tumors (ESFTs).
However, the use of baseline FDG PET/CT as a tool for
assessing survival outcome was not yet reported. We evaluated
the benefit of using quantitative PET-based parameters to predict
the survival outcome of ESFTs patients. MATERIALS AND
METHODS: 20 adult patients (10 men and 10 women) with
ESFTs, treated according to Euro-Ewing 99 protocol, were ret-
rospectively included. The primitive lesion of each patient was
analyzed using different quantitative parameters: SUV (maxi-
mum, peak and mean), metabolic tumor volume (MTV) and
total lesion glycolysis (TLG) before treatment. Kaplan-Meier
method, Logrank tests and univariate Cox analyses were used
to calculate survival curves and to analyze whether imaging and
usual clinical prognostics factors (metastatic disease at presenta-
tion, axial tumor location, tumor size>10cm, sex and age≥20
years) could predict progression free survival (PFS) and overall
survival (OS). RESULTS: The median age was 23 years (range,
16 to 61). Twelve patients were initially metastatic (lungs or
bone marrow). For 10 patients, the disease location was osseous
and for 10 non osseous (4 of them were PNET). Parameters data
of 19 patients were interpretable. Univariate analysis showed
different imaging parameters as predictors of OS: SUVmax
(HR: 1.16; 95% CI: 1.02-1.33; P=0.021), SUVpeak (HR: 1.27;
CI: 1-1.61; P=0.047), SUVmean (HR: 1.31; CI: 1.04-1.66;
0.024). Three years OS was 53% for SUVmax< 17 vs 25% for
SUVmax>17 (P= 0.021). SUVmax (P=0.044), SUVpeak
(P=0.027) and SUVmean (P=0.027) were predictive of PFS
for univariate analysis. MTV and TLG were not predictive for
PFS and OS. For clinical parameters at baseline, metastatic dis-
ease (HR: 13.5; CI: 1.55-102.15; P<0.001) and male sex (HR:
6.01; CI: 1.24-29.14; P=0.026) shortened only PFS.
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CONCLUSION: At baseline, FDG PET with SUVmax,
SUVpeak and SUVmean measured on primitive lesion could
be a useful tool to predict OS and PFS for adult ESFTs patients.
OP456
Soft tissue sarcomas: Comparison between visual
assessment and metabolic parameters in FDG PET/CT
D. Lopez, A. Domenech, C. Achury, R. Jaller, J. Duch, M.
Estorch, A. Flotats, I. Carrió; Nuclear Medicine department.
Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN
PURPOSE: To compare metabolic tumor parameters (Maxi-
mum Standard Uptake Value [SUVmax], Mean Standard Up-
take Value [SUVmean], Metabolic Tumor Volume [MTV] and
Total Lesion Glycolisis [TLG]) derived from 18F-FDG PET/
CT with visual assessment in order to correlate with the clin-
ical course of soft tissue sarcoma. MATERIALS AND
METHODS: Eleven patients (p) [8 males; mean=49 y/o, range
23-67] with soft tissue sarcoma, histopathologically confirmed
(5 fusocellular, 1 leiomyosarcoma, 4 lyposarcoma and 1
myxofibrosarcoma), who underwent baseline (before chemo-
therapy, surgery and radiotherapy) and early (after treatment)
follow-up 18F-FDG PET/CT were retrospectively reviewed.
Visual and Quantitative analysis were done in baseline and
early follow-up PET/CT comparing the results with the late
follow-up scan visual analysis. Based on visual assessment
of the early follow-up PET/CT patients were considered to
be in local recurrence (LR), disease progression (DP), stable
disease (SD) and partial response to treatment (PR). Quantita-
tive measurements to track changes in tumor volume and met-
abolic activity were performed using Philips Tumor Tracking
Application, determining the SUVmax, SUVmean, MTV and
TLG. Late follow-up scans (PET/CT and/or MRI) performed
in a period of no more than 6 months after the last PET/CT
were reviewed in order to assess the clinical course of the
tumor. RESULTS: In the visual analysis, 2p were considered
in LR, 3 in DP, 3 in SD and 3 PR. In the quantitative analysis,
1p visually considered in LR and 2 of the 3 in DP presented an
increase in SUVmax, SUVmean, MTV and TLG, while the
remaining patients in LR and in DP presented an increase in
SUV values and a decrease in MTV and TLG. In 2 of the 3p
considered visually in SD, a decrease of all the metabolic
parameters was observed and no changes were seen in 1p.
Two of the 3p in PR presented a decrease in all values while
1 had a decrease in SUV values and a minimum increase in
TLG. Late imaging follow-up scans in the 2p with SD and a
decrease in metabolic tumor parameters showed PR while in
the remaining 9p no changes were seen between scans. Over-
all, a correlation between metabolic tumor parameters in the
baseline and early follow-up PET/CT with the late follow-up
scan visual analysis was observed in 63% (7/11) of the
patients. CONCLUSION: In addition to the visual analysis,
the metabolic parameters could be a useful tool to evaluate
with more accuracy the clinical course of soft tissue sarcomas.
OP457
Tumour heterogeneity for differentiation between tumour
and normal liver tissue in FDG-PET imaging
L. Jaritz1, H. Ahmadzadehfar1, M. Essler1, N. Zsoter2, L.
Papp2, F. Gaertner1, R. A. Bundschuh1, L. Thomas1; 1Depart-
ment of Nuclear Medicine, Universitaetsklinikum Bonn,
Bonn, GERMANY, 2Mediso Medical Imaging Systems, Bu-
dapest, HUNGARY
Introduction: In process of planning internal/external
radiation-therapy it is essential to determine tumour-volume
as accurate as possible. Therefore it is essential to differentiate
benign from malignant tissue best possible. FDG-PET/CT has
the ability to distinguish between metabolic active tumour and
surrounding tissue by means of measured activity-uptake. By
use of textural analysis based on a image-analysis of FDG-
PET/CT images, structural features can easily be extracted.
We investigated, if these textural parameters, which reflect
the heterogeneity, function as a tool for differentiation between
benign and malignant tissue and analysed the variability of
heterogeneity within a tissue. Methods: 43 patients with
liver-metastasis of colorectal-carcinomas have been examined
on baseline FDG-PET/CT-scans before their first selective in-
ternal radiotherapy. In FDG-PET images liver metastasis and
normal liver tissue were analysed with InterviewFusion-
software (Mediso). Three volumes-of-interest (VOIs) with a
fixed diameter of 25mm were drawn in healthy liver tissue,
whilst metastasis were manually delineated. For determination
of the tumour heterogeneity within these VOIs we calculated
30 different textural parameters including Entropy, Homoge-
neity and Contrast. For better comparison we measured
established parameters used in clinical routine (mean and
max standardized uptake values (SUVmean/SUVmax)). For
statistical analysis we compared the heterogeneity in terms of
intra-patient-variability and inter-patient-variability. Students-
T-test was used to compare the parameters for healthy and
pathological tissue. Results: The mean relative standard-
deviation as measure for intra-patient-variability was found
to be lowest for Busyness (2.4%), Homogeneity (5.1%), Cor-
relation (7.8%), and Entropy (8.0%). These values were com-
parable with the ones for routine parameters SUVmax (7.5%)
and SUVmean (6.9%). The mean inter-patient-variability was
found to be lowest for Busyness (3.8%), Correlation (6.1%),
Short Zone Emphasis (9.1%), and Homogeneity (11.9%).
These were lower than the variability for SUVmean (20.7%)
and SUVmax (18.9%). For differentiation between healthy
liver-tissue and tumour we found 26 of the 30 textural
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S189
parameters statistically significant (p<0.05), highest signifi-
cance was found for Homogeneity, Short Run Emphasis, In-
tensity Variation, and Short Zone Emphasis. SUVmean and
SUVmax also showed ability to differentiate but with a lower
statistical significance. Conclusion: In healthy liver tissue we
found a intra-patient-variability comparable to the convention-
al SUVmax and SUV mean while for inter-patient-variability
some textural parameters showed even lower values than the
routine parameters. Furthermore most of the textural parame-
ters showed better ability to differentiate between malignant
and healthy tissue than the SUVmean and SUVmax. Therefore
textural parameters are promising for classification lesions as
well as to delineate malignant tissue for treatment-planning or
response-evaluation.
OP458
Factors of FDG uptake in the liver and blood pool on PET
scans
K. Zhou, Sr.; West China Hospital of Sichuan University,
Chengdu, CHINA
Factors of FDG uptake in the liver and blood pool on PET
scansObjectives: It was reported that the standardized uptake
value (SUV) of 18F-FDG in children was lower than that of in
adults on PET. But the correlation between SUVand age was
unknown. The objective of present study was to find is there a
correlation between SUV and age. Methods: Three hundred
and seventy-eight patients (male 210, female 168) who re-
ceived whole body 18F-FDG PET scans were included based
on inclusion and exclusion creteria. In which, 230 had malig-
nancy(171 lymphoma), and the others were healthy but for
cancer screening. The age of them were 2-40 years (3 and 5
cases for 2 and 3 years, 10 cases for the rest). The correlations
between SUVmax and SUVmean from liver and blood and
gender, age, body weight, serum glucose and administration
dose were analyzed uni- and multivariately. Then the indepen-
dent factors were correlated with SUVs using curve estimation
regression. Results: Univariate analysis revealed that there
were positive correlations between SUVs and age, body
weight, serum glucose and administrat ion dose
(p<0.05). There was no correlation between gender and
SUVs (p=0.612). But only body weight and age had
positive impact on SUVs after multivaraite analysis
(p<0.05). Curve estimation showed the SUVs increased
along with the age before 25 years, then it reached a
platform. And the SUVs increased along with body
weight without a platform. Conclusion: Both Age and
body weight are independent factors on FDG uptake.
SUVs increase along with the age before 25 years, then
it reach a platform. And the SUVs increase along with
body weight without a platform.
OP459
18F-FDG PET/CT role in staging of gastric carcinomas:
comparison with conventional Contrast Enhancement
Computed Tomography.
C. Altini, A. Niccoli Asabella, A. Di Palo, M. Fanelli, D.
Rubini, C. Ferrari, A. Notaristefano, G. Rubini; Nuclear Med-
icine Unit, D.I.M., University of Bari “AldoMoro”, Bari, Italy,
Bari, ITALY.
Aim: to evaluate the role of 18F-FDG PET/CT in staging
gastric carcinoma comparing it with Contrast Enhancement
Computed Tomography (CECT) and if morphological and
functional parameters might give a contribution. Materials
and methods: This retrospective study included 45 patients
who underwent whole body CECT and 18F-FDG PET/CT
before any treatment. We calculated CECT and 18F-FDG
PET/CTsensitivity, specificity, accuracy, positive and negative
predictive values (PPV and NPV) for gastric, lymphnode and
distant localizations; furthermore we compared the two tech-
niques by McNemar test. Linear regression was performed to
evaluate SUVmax and SUVmean in relation to gastric lesion
size. The role of 18F-FDG PET/CT semiquantitative parame-
ters in relation to histotype, grading and site of gastric lesions
were evaluated by ANOVA test. Results: sensitivity, specific-
ity, accuracy, PPV and NPVof CECT and 18F-FDG PET/CT
for gastric lesion were respectively 92.11%, 57.14%, 86.66%,
92.11%, 57.14% and 81.58%, 85.71%, 82.22%, 96.88%,
46.15%. No differences were identified between the 2
techiques about sensitivity and specificity. No stastistical dif-
ferences were observed between PET parameters and
histotype, grading and site of gastric lesion. The mean value
of the maximum diameter was 52.59 mm (range 4 - ≥100).
Considering 30 mm, as a threshold value for maximum diam-
eter we divided patients in 2 groups: size ≤ 30 mm and size >
30. In 15/45 pts size was ≤ 30 mm and 18F-FDG PET/CT
sensitivity and specificity resulted respectively 33.33%
(95%CI: 7.88% to 69.93%) and 83.33% (95%CI: 36.10% to
97.24%). In 30/45 pts size was > 30 mm and 18F-FDG PET/
CT sensitivity and specificity resulted respectively 96.55%
(95%CI: 82.17% to 99.42%) and 100% (95%CI: 16.55% to
100%). SUVmax and SUVmean resulted positively related to
lesion dimension (SUV max=3.53+0.11*lesion size, F=8.91,
p=0.005; SUV mean=1.99+0.06*lesion size, F=7.07 p=0.01)
No stastistical differences were observed between PET param-
eters and histotype, grading and site of gastric lesion. The
results of CECT and 18F-FDG PET/CT about lymphnode in-
volvement were 70.83%, 61.90%, 66.66%, 68%, 65% and
58.33%, 95.24%, 75.55%, 93.33%, 66.67%. The results of
CECT and 18F-FDG PET/CT about distant metastases were
80%, 62.86%, 66.66%, 38.10%, 91.67% and 60%, 88.57%,
82.22%, 60%, 88.57%. 18FDG PET/CT specificity was sig-
nificantly higher both for lymphnode and distant metastases.
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Conclusions: the 18F-FDG PET/CT is a useful tool for the
evaluation of gastric carcinoma to detect primary lesion,
lymphnode and distant metastases using one single image
whole-body technique. Integration of CECT with 18F-FDG
PET/CT permits a more valid staging in these patients.
OP460
Utility of 18F-FDG PET/CT in Patients with Advanced
Squamous Carcinoma of Uterine Cervix Receiving
Concurrent Chemoradiotherapy: A Parallel Study
of a Prospective Randomized Trial
F. Liu1, C. Lai1, L. Yang1, C. Wang1, G. Lin1, C. Chang2, S.
Huang3, Y. Huang4, N. Peng5, J. Hong1, A. Chao1, H. Chou1,
Y. Chang1, T. Yen1; 1Chang Gung Memorial Hospital and
Chang Gung University College of Medicine, Taoyuan, TAI-
WAN, 2Chang Gung University, Taoyuan, TAIWAN, 3Chang
GungMemorial Hospital and Chang Gung University College
of Medicine, Kaohsiung, TAIWAN, 4Chang Gung Memorial
Hospital and Chang Gung University College of Medicine,
Chiayi, TAIWAN, 5Kaohsiung Veterans General Hospital,
Kaohsiung, TAIWAN
Aim: This study aimed to evaluate the utility of pre- and
during-treatment 18F-fluorodeoxyglucose (18F-FDG) PET/
CT in predicting failure patterns in patients with advanced
uterine cervical cancer receiving concurrent chemoradiotheray
(CCRT). Materials and methods: Patients with cervical squamous
carcinoma, FIGO stage III-IVA or pelvic/paraaortic lymph node
(LN) metastasis without other distant metastasis defined by 18F-
FDG PET/CT entering a randomized controlled trial of CCRT
(AGOG09-001) were eligible for this parallel study. PET/CTscans
were performed at baseline, during week 3 of CCRT and 2-3
months after CCRT. PET/CT parameters included maximal stan-
dardized uptake value (SUVmax), metabolic tumor volume
(MTV), SUVnode (largest SUVmax of all positive LNs),
SUVratio (during-treatment SUVmax / pre-treatment SUVmax *
100%), and MTVratio. The Mann-Whitney U test and receiver
operating characteristic curves were used to evaluate the potential
predictors, and another independent patient dataset was used for
validation. Results: Early treatment failure (within 6 months) was
noted in 9 of 55 (16.4%) patients eligible for analysis. Both pre-
and during-treatment cervical tumor volumes (P < .001) were sig-
nificant predictors of local failure (n = 4). During-treatment
SUVnode (P = .019) and maximal SUVratio of LNs (P = .024)
were significant predictors of regional failure (n= 4).Distant failure
was present in 5 patients, with during-treatment SUVnode (P =
.027) andMTVratio of the cervical tumor (P = .033) as significant
predictors. Conclusion: Pre- and during-treatment PET/CTmay be
useful in predicting early treatment failure patterns, thus early ther-
apeutic modifications (locoregional and systemic) can be applied
accordingly in hope for outcome improvement.
OP461
Face-To-Face 18F-FDG-PET/CT and CA125 (Serums
Levels and Kinetic Values) in Patients with Suspected
Recurrence of Ovarian Cancer.
A. Palomar Muñoz, J. M. Cordero García, G. A. Jiménez
Londoño, M. P. Talavera Rubio, M. E. Bellón Guardia, B.
González García, V. M. Poblete García, Á. Soriano Castrejón;
Hospital General Universitario de Ciudad Real, Ciudad Real,
SPAIN
PURPOSE: The aim of this study was to evaluate the capabil-
ity of 18F-FDG-PET/CT in the detection of recurrences in
ovarian cancer, when compared with CA125 serum levels, as
well as the diagnostic influence of CA125 velocity
(CA125v) and CA125 doubling time (CA125dt) in the
PET/CT results. METHODS: A total of 54 women with
suspicion of relapse, studied with a standard 18F-FDG-
PET/CT and CA125 serum level were retrospectively stud-
ied. Patients were grouped according to CA125 normal
serum levels before the PET/CT in 2 groups (1:
CA125<35 IU/ml, 2: CA125>35 IU/ml).The final diagno-
sis was obtained by histological analysis or clinical follow
up greater than 6 months. A total of 37 patients had at
least two determinations of CA125 levels, which allowed
to calculate CA125v and CA125dt, that were independent-
ly analysed. These patients were compared with the FDG-
PET/CT results, classified as positive (A) and negative (B).
RESULTS: PET/CT detected relapse in 45/54 (83.33%)
patients, and was negative in 9/54 (16.66%) women, with
only 1 false negative result, reaching a sensitivity of
97.83% and specificity of 100%. In contrast, attending to
the CA125 levels, 35/54 (64.81%) patients were included
in the group 1, and 19/54 (35.18%) in the group 2, with a
sensitivity of 73.33%, and a specificity of 77.78%. In the
group 1 (median 10.9, 5.2-33.9 IU/ml) PET/CT classified
correctly 18 patients (7 negative, 11 positive), and 1 false
negative. In the group 2 (median 69.9, 35.5-1950.9 IU/ml)
PET/CT detected disease in 33 patients, without misdiag-
noses. Regarding to the kinetic values, the A group com-
posed by 28 patients showed a median CA125v of 5.17 (-
0.05-87.03) and a median CA125dt of 3.71 (-175.03-
32.66). The nine women included in the B group had a
median CA125v of 0.27 (-0.56-364.05) and a median
CA125dt of 2 (-148.6-23.22). No statistical differences
were found between both groups concerning to the kinetics
parameters (CA125v p=0.2, CA125dt p=0.3). CONCLU-
SION: The 18F-FDG-PET/CT shows a high diagnostic
performance in the suspicion of ovarian cancer recurrence,
regardless the levels of CA125 and the kinetic values.
Thus, in case of clinical suspicion of ovarian cancer re-
lapse, seems to be essential to carry out an FDG-PETCT
study in all cases.
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Simultaneous PET/MR imaging with FDG
for the evaluation of symptomatic patients
with non-stenotic carotid atherosclerotic plaques
F. Hyafil1, A. Schindler2, D. Sepp3, T. Obenhuber2, S. Höhn2,
S. Nekolla1, M. Dichgans3, M. Schwaiger1, T. Saam2, H.
Poppert3; 1Department of Nuclear Medicine, Klinikum rechts
der Isar, Munich, GERMANY, 2Ludwig-Maximilians-Univer-
sity Hospital Munich, Institute for Clinical Radiology, Mu-
nich, GERMANY, 3Department of Neurology, Klinikum
rechts der Isar, Munich, GERMANY
Introduction. High-resolution magnetic resonance imaging
(MRI) can assess atherosclerotic plaque composition in carotid
arteries with good correlation to histopathology. 18Fluoro-
deoxyglucose (18F-FDG) is a positron emission tomography
(PET) radiotracer that accumulates in inflammatory cells present
in atherosclerotic plaques. The aim of this study was to investi-
gate in 18 patients with ischemic stroke classified as cryptogenic
and presenting non-stenotic carotid atherosclerotic plaques the
morphological and biological aspects of these plaques with MRI
and 18F-FDG-PET imaging. Methods. Carotid arteries were im-
aged 150 minutes after injection of 18F-FDG with a combined
PET/MRI system. American Heart Association (AHA) lesion
type and plaque composition were determined on consecutive
MR axial sections (n = 460) in both carotid arteries. 18F-FDG
uptake in carotid arteries was quantified using tissue-to-
background ratio (TBR) on corresponding PET sections.
Results. Prevalence of complicated atherosclerotic plaques
(AHA lesion type VI) detected with high-resolution MRI was
significantly higher in the carotid artery ipsilateral to the ische-
mic stroke as compared to the contralateral side (39% vs. 0 %; p
= 0.001). For all other AHA lesion types, no significant differ-
ences were found between ipsilateral and contralateral sides. In
addition, atherosclerotic plaques classified as high-risk lesions
with MRI (AHA lesion type VI) were associated with higher
18F-FDG uptake in comparison with other AHA lesions (TBR
= 3.43 ± 1.13 vs. 2.41 ± 0.84; respectively; p < 0.001). Further-
more, patients presenting at least one complicated lesion (AHA
lesion type VI) with MRI showed significantly higher 18F-FDG
uptake in both carotid arteries (ipsilateral and contralateral to the
stroke) in comparison with carotid arteries of patients showing
no complicated lesion with MRI (mean TBR = 3.18 ± 1.26 and
2.80 ± 0.94 vs. 2.19 ± 0.57; p < 0.05, respectively), in favor of
the presence of a diffuse inflammatory process along both carot-
id arteries associated with complicated plaques. Conclusions.
Morphological and biological features of high-risk plaques can
be detected with high-resolution MRI and 18F-FDG-PET in
non-stenotic atherosclerotic plaques ipsilateral to the stroke, sug-
gesting a causal role for these plaques in stroke. Combined 18F-
FDG-PET-MRI systems might help in the evaluation of patients
with ischemic stroke classified as cryptogenic.
OP472
Atherosclerotic Plaque 18F-NaF Uptake Predicts
its Subsequent Morphologic Evolution and Calcification
Density
F. Fiz1, M. Bauckneht1, G. Ferrarazzo1, A. Piccardo2, E.
Pestarino2, I. Calamia1, M. Cabria2, G. Villavecchia2, C. Ma-
rini3, S. Morbelli1, G. Sambuceti1; 1Nuclear Medicine Unit,
Department of Health Sciences, University of Genoa, Genoa,
ITALY, 2Nuclear Medicine Unit, Ente Ospedaliero Galliera,
Genoa, ITALY, 3CNR-IBFM, Milano, ITALY
Background and Aims: Evaluation of calcium deposition within
arterial calcifications (AC) can be performed using 18F-NaF
PET/CT; our previous experience demonstrated that AC density
at CT inversely correlates with its 18F-NaF uptake. We planned
the present study to investigate whether a higher tracer uptake, by
signaling an active calcium deposition, predicts a subsequent AC
evolution. Patients and Methods: We retrospectively included 50
patients (18women, mean age 68±9 years, age range 41-86) who
underwent at least two consecutive 18F-NaF PET/CT in the
course of follow-up of bone metastases from breast or prostate
cancer. Only scan spaced at least one year and at most two years
were included. In each scan we drew a volume-of-interest (VOI)
on each ACwithin the infrarenal aorta walls andwe calculated its
average Hounsfield density (HU), its blood-pool normalized av-
erage uptake (target-to-background ratio, TBR, obtained by
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normalizing AC SUVmean with the one of a 10-slice-thick VOI,
drawn within the inferior vena cava) and its Calcification Score
(CS, using an Agaston-like algorithm). We stratified all AC in
tertiles according to their baseline TBR in “cold” (lower tertile,
CP), “warm” (middle tertile, WP) and “hot” (higher tertile, HP)
plaques. We then calculated, on each consecutive scan and on a
plaque-by-plaque basis the percent difference in mean HU e CS
(defined as DHU% and DCS%, respectively). Results: 430 AC
were identified. In CP there wasn’t any significant increase nei-
ther in HU nor in CS at subsequent scans. Conversely, both
parameters significantly increased in WP and HP (p<0.01 and
p<0.001, respectively). Mean DHU%was progressively increas-
ing from CP to HP (11±9%, 36±16% and 67±32%, p<0.01 for
CP vs.WP and p<0.05 forWPvs. HP); averageDCS%showed a
similar pattern (p<0.05). As a consequence, there was a positive
correlation between TBR and both DHU% (R=0.75, p<0.01) and
DCS% (R=0.69, p<0.01). Conclusion: 18F-NaF uptake within
the atherosclerotic plaque, by tracing mineral turnover, can be
used as a hallmark of calcium deposition and can therefore pre-
dict whether any given plaque will subsequently evolve in size
and density.
OP473
18F-FDG-PET-CT assessed subclinical arterial
inflammation is positively associated with non-invasive
markers of arterial stiffness in recently diagnosed type 2
diabetes patients
S. A. de Boer1, M. C. Hovinga - de Boer2, J. D. Lefrandt1, H.
J. LambersHeerspink3, A.W. J.M.Glaudemans4, D. J.Mulder1,
R. H. J. A. Slart4,5; 1Department of Vascular Medicine, Univer-
sity Medical Center Groningen, University of Groningen, Gro-
ningen, NETHERLANDS, 2Department of Radiology &
Nucleair Medicine, Meander Medical Center, Amersfoort,
NETHERLANDS, 3Department of Clinical Pharmacy and Phar-
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Aim: Type 2 diabetes mellitus (T2DM) is accompanied by pre-
mature arterial stiffness. The underlying mechanisms are unclear.
We investigated the possible relation between subclinical arterial
inflammation, calcification, atherosclerotic risk factors, skin ad-
vanced glycation end products (AGEs)), and arterial stiffness in
T2DM. Materials & methods: 34 patients with recently diag-
nosed T2DM (RELEASE study: NCT02015299), without a his-
tory of cardiovascular disease and not using glucose lowering
drugs, were studied (age 63 (55-66) yrs, 65% male, HbA1c 46
±4.3mmol/mol (6.4±0.4%), 18% smokers). Arterial stiffness was
non-invasively assessed by aortic systolic blood pressure (aSBP,
mmHg) and aortic (carotid-femoral) pulse wave velocity (aPWV)
using applanat ion tonometry. A whole body 18-
Fluorodeoxyglucose positron emission tomography-(low dose)
computed tomography (18F-FDG-PET-CT) scan was performed
to assess arterial inflammation (standard uptake value (SUV)max
(according to EARL guidelines)) and CT-scored arterial calcifi-
cation (AC): visual score: 0 (no) to 4(>50% calcified plaque).
SUVmax and AC scores were calculated in 4 individual seg-
ments (carotid arteries, ascending aorta and aortic arch, descend-
ing and abdominal aorta, and iliac and femoral arteries) and for
the total aortic tree (aSUVmax, mean of 4 segments). Skin AGEs
were measured as skin autofluorescence (SAF). Results and con-
clusion: aSUVmax and AC were not associated. aSUVmax was
associated with atherosclerotic risk factors: BMI (r=0.64,
P<0.001), HbA1c (r=0.59, P<0.001), waist circumference
(r=0.55, P<0.001) but not with, age, gender, smoking, lipids,
and SAF. aSUVmax was associated with non-invasive markers
of arterial stiffness: aSBP (r=0.55, P=0.001) and tended to corre-
late with aPWV (r=0.33, P=0.059). After multivariate adjustment
(r2=0.79, P<0.001), only HbA1c, (β=0.36, P<0.001), waist cir-
cumference (β=0.49, P<0.001), aSBP (β=0.49, P<0.001), and
aPWV (β=0.24, P=0.014) remained significant. AC was associ-
ated with male gender (r=0.48, P=0.004), age (r=0.51, P=0.002),
BMI (r=-0.43, P=0.011), and SAF (r=0.37, P=0.036) and not
with other mentioned atherosclerotic risk factors. None of AC
scores correlated with aPWV, aSBP, or any of the SUVmax seg-
ments. After multivariate adjustment (r2=0.39, P=0.001) only
male gender (β=0.49, P=0.003) and SAF (β=0.34, P=0.033)
remained significant. These results show that in recently diag-
nosed T2DM patients 18F-FDG-PET-CT revealed subclinical
arterial inflammation but not calcification, and is positively asso-
ciatedwith determinants of arterial stiffness, glycemic control and
central obesity. Interessingly, while the extent of arterial calcifi-
cation did not show any relationwith arterial inflammation, it was
independently associated with skin AGEs, suggesting discordant
pathways at different stages of atherosclerotic disease.
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Evaluation of the radiotracer [68Ga]pentixafor targeting
the CXCR4 receptor with PET-MRI in a rabbit model
of atherosclerotic plaques
F. Hyafil1, I. Laitinen1, M. Schottelius2, M. Mohring1, A.
Poschenrieder2, J. Brandl3, C. Baumgartner3, J. Pelisek4, S.
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Munich, GERMANY, 5Pharmaceutical Radiochemistry,
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Introduction: The CXCR4 receptor is expressed at the surface of
lymphocytes, macrophages and neutrophils. [68Ga]Pentixafor is a
PET radiotracer that binds with a nanomolar affinity to the
CXCR4 receptor. The aim of this study was to test whether
[68Ga]Pentixafor binds specifically to CXCR4-expressing tissues
and allows for the detection of inflamed atherosclerotic plaques
induced in rabbits. Methods: Atherosclerotic plaques were in-
duced by endothelial abrasion of the right carotid artery and ab-
dominal aorta of 7 New ZealandWhite rabbits fed an atherogenic
diet. Three non injured rabbits fed a chow diet were used as
controls. Rabbits were imaged on a combined PET-MRI system
1 hour after injection of 15MBq/kg of [68Ga]Pentixafor. Tissue to
background ratios (TBRs) were measured with PET-MRI along
carotid arteries and in the abdominal aorta. After PET-imaging,
biodistribution studies were performed one hour after injection of
7.5 MBq/kg of [125I]Pentixafor. Tracer uptake was quantified on
20μmcryosections of arteries using autoradiography and normal-
ized to muscle uptake. In addition, blocking studies were per-
formed in two atherosclerotic rabbits with pre-injection of 2 mg
of the CXCR4 inhibitor AMD3100. Results: Biodistribution stud-
ies showed significantly higher accumulation of [125I]Pentixafor
in CXCR4-expressing tissues such as spleen (0.19 ± 0.07 % ID /
g), adrenal glands (0.30 ± 0.13 % ID/g) and bone marrow (0.16 ±
0.06 % ID/g), than in other tissues such as muscle (0.02 ± 0.01 %
ID/g) or heart (0.02 ± 0.01 % ID/g). [125I]Pentixafor binding in
CXCR4-expressing tissues was strongly decreased after injection
of the CXCR4 inhibitor AMD 3100. One hour after injection of
[68Ga]pentixafor, a clear signal was detected in vivo with PET-
MRI in atherosclerotic plaques of the abdominal aorta and right
carotid artery as compared to normal control arteries (average
TBR = 1.95 ± 0.51 vs. 1.22 ± 0.25 and TBR = 1.24 ± 0.38 vs.
0.96 ± 0.37 ; p < 0.05 for both). Consistently, higher tracer uptake
was measured by autoradiography in cryosections of atheroscle-
rotic plaques as compared to normal arteries. Conclusions:
[68Ga]Pentixafor accumulates specifically in CXCR4-
expressing tissues in rabbits. [68Ga]Pentixafor uptake was in-
creased in inflamed atherosclerotic plaques compared to normal
arteries. Hence, [68Ga]Pentixafor might emerge as a valuable tool
for the detection of high-risk atherosclerotic plaques with PET.
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Targeting Aminopeptidase N (CD13) for molecular
imaging of cardiac wound healing using
68Ga-NOTA-c(NGR) in experimental myocardial
infarction
S. Samnick1, M. Schneider1, J. Tillmanns2, D. Fraccarollo2, J.
Bauersachs2, A. Buck1; 1University of Wuerzburg, Wuerzburg,
GERMANY, 2HannoverMedical School,Hannover,GERMANY
Purpose: Aminopeptidase N (CD13) is a transmembrane pro-
tease involved in cell adhesion, migration, proliferation, dif-
ferentiation and angiogenesis. In myocardium, CD13 is over-
expressed in athophysiologic conditions such as acute myo-
cardial infarction (MI), where it facilitates inflammatory cell
infiltration. After MI, the wound healing phase is important for
successful tissue repair and improved remodeling. Molecular
imaging could help to understand activity and duration of the
repair processes in individual patients, and potentially allows
patient-specific administration of pharmacotherapy to improve
outcome after MI. On the other hand, peptides containing the
NGR (Asparagine-Glycine-Arginine) motif bind selectively to
CD13. This study investigates the potential of the radiolabeled
NGR-containing tracer 68Ga-NOTA-NGR as an imaging
probe for in vivo assessment of the early wound healing phase
after MI using PET. Methods: Myocardial ischemia/
reperfusion injury (MI/R) was induced in rats, and the uptake
of the novel 68Ga-labelled NGR peptide (68Ga-NOTA-NGR)
was evaluated in comparison with 68Ga-NOTA-RGD and 18F-
FDG at day 3, 7 and 21 post infarction using μ-PET and au-
toradiography. Expression of CD13, the molecular target of
NGR, and αvβ3, the molecular target of RGD, were assessed
in fibroblasts, inflammatory cells and endothelial cells in rat
hearts by immunohistochemistry, and correlated with radio-
tracer uptake. Results: Infarcted and surviving myocardium
was identified by 18F-FDG-PET in all animals. In the infarcted
myocardium, uptake of 68Ga-NOTA-NGR was maximal from
day 3 to 7 after MI/R, and correlated with fibroblast and in-
flammatory cell infiltration as well as 68Ga-NOTA-RGD up-
take. Conclusions: This study demonstrates for the first time
the feasibility of PETwith 68Ga-NOTA-NGR for noninvasive
and sequential determination of CD13 expression in rat heart
after MI/R. This will facilitate monitoring of CD13 in the
individual wound healing processes, allowing patient-
specific therapies to improve outcome after MI.
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Retrospective detection of remote and brief experimental
myocardial ischemia using 99mTc-Fucoidan SPECT
N.Mikail1, N. Anizan2, L. Louedec2, F. Al Shoukr1, J.Michel2,
D. Letourneur2, C. Chauvierre2, D. LE GULUDEC1, F.
Rouzet1; 1Nuclear Medicine Department, Bichat-Claude Ber-
nard Hospital, APHP, Paris, FRANCE, 2INSERM,U1148, Car-
diovascular Bioengineering, Paris, FRANCE
Aim: the retrospective identification of a remote acute coro-
nary syndrome is a diagnostic challenge. Because adhesion
molecules such as selectins persist on the endothelial surface
after ischemia has resolved, they represent a tissue “imprint”
of the prior ischemic event, referred to as ischemic memory.
The aim of this study was to assess whether 99mTc-fucoidan
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SPECT, a P-and E-selectin targeting agent, allows to detect
myocardial ischemic memory in a rat model of ischemia-re-
perfusion. Methods: Transient myocardial ischemia was in-
duced in male Wistar rats by coronary ligation. Ischemia du-
ration ranged from 5 min to 20 min and reperfusion duration
ranged from 2 to 24 hours. SPECT/CT acquisitions were per-
formed 2 hours after injection of 70 MBq 99mTc-Fucoidan.
Images were visually assessed for the presence of a focal tracer
uptake in the cardiac area. The animals were then sacrificed
and the heart explanted, frozen and cut in slices for autoradi-
ography (quantified using the uptake ratio between the area at
risk and remote myocardium) and histology/immunostaining
(P-/E-selectin expression). Results: For a constant delay of 2
hours of reperfusion, myocardial uptake of 99mTc-Fucoidan
was detected after ischemia duration ranging from 20 minutes
(3/3 rats), 10 minutes (3/4 rats) and 5 minutes (5/14 rats). On
autoradiography, the uptake ratio of 99mTc-Fucoidan was 7.6
[4.6-8.4] at 20 min, 5.6 [3.8-12.1] at 10 min and 4.6 [2.0-8.2]
at 5 min. Areas of 99mTc-Fucoidan increased uptake matched
with endothelial expression of P-selectin. After 6 hours of
reperfusion duration, the 99mTc-Fucoidan uptake was detect-
ed in 4/4 rats (10 min ischemia) and 3/5 rats (5 min ischemia).
After 24 hours of reperfusion duration, 99mTc-Fucoidan up-
take was detected in 3/7 rats (10 min ischemia) and 4/9 rats
(5 min ischemia). Conclusion: This preliminary study shows
that brief coronary occlusions (5 minutes) followed by reper-
fusion durations up to 24 hours are associated with P- and E-
selectin endothelial expression, detectable in vivo by 99mTc-
Fucoidan SPECT. Therefore, 99mTc-Fucoidan is a promising
agent that could be useful in the retrospective diagnosis of
acute coronary syndromes.
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Preparation of Carrier Free Yttrium-90 for Medical
Applications Using a Novel Home-Made Y-Imprinted
Sorbent
M. Abedi1, S. Shirvani Arani2, A. Bahrami Samani3, M.
Nabid1; 1Department of Chemistry, Faculty of Science, Shahid
Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC
OF, 2Assistant Professor Radiopharmaceutical Research and
Development Lab (RRDL), Tehran, IRAN, ISLAMIC RE-
PUBLIC OF, 3Radiopharmaceutical Research and Develop-
ment Lab (RRDL), Tehran, IRAN, ISLAMICREPUBLICOF.
Aim: Synthesis and characterization of a novel acryl amide-based
yttrium imprinted sorbent via the ATRP approach for the prepara-
tion of medical-grade 90Y. Materials and methods: 2,2-bis(2-bro-
mo-2-methylpropanoate)propane-1,3-disuccinate (L), which was
synthesized in three steps in our lab, was used as an excellent
chelating agent and also as an initiator for the preparation of a novel
acryl amide-based ion imprinted polymer (IIP) for selective sorp-
tion of radio-yttrium. The YIP was prepared via copolymerization
of the (Y- L) complex with acryl amide as the functional monomer
and N,N’-methylenebisacrylamide as a crosslinking agent using
the ATRP approach. The synthesized compounds were character-
ized, and sorption/desorption examination was performed. The
prepared Y-IIP was used as a sorbent for the selective separation
of 90Y from a synthetic solution of 90Y/Sr(natural, stable)/
Zr(natural, stable). To the best of our knowledge, this was the first
ionic-imprinted sorbent used to prepare carrier free 90Y. Results:
The data confirmed the perfect separation of Sr(II) and Zr(II) from
90Y, which was maintained successfully on the column and eluted
afterwards. As a result, the prepared, highly yttrium-selective sor-
bent can be used for the separation of Y-90 from its long-lived
parent, Sr-90. In addition, if there are any other impurities even
in trace amounts, such as Zr(II) that is a decay product of Y-90,
they can be removed effectively to prepare medical grade 90Y
from a long-lived 90Sr source via the least facility. Conclusion:
In this study, a new acryl amide-based sorbent was synthesized in
order to prepare medical-grade 90-yttrium. The synthesis was con-
ducted through atom transfer radical copolymerization of AAm
and MBAAm in the presence of BMPPS as the initiator and che-
lator for Y(III) ion that is capable of extracting and
preconcentrating traces of Y(III) ion. The effective parameters of
the yttrium (III) preconcentration were investigated. Due to the
high selectivity obtained by the aforementioned, new, acryl
amide-based sorbent, it can be used effectively for the selective
separation and pre-concentration of yttrium (III). In future studies,
we plan to utilize the prepared sorbent to fabricate a set of serial
columns for the preparation of a 90Sr/90Ycolumnchromatograph-
ic generator to obtain carrier-free 90Y. The freshly eluted radionu-
clide then can be used for radiolabeling of the peptides and anti-
bodies that are used in targeted therapy for various types of cancers
and solid tumors.
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Cyclotron production of 43Sc - new radionuclide for PET
technique
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Aim:The 43Sc (t1/2 = 3.89 h) is an idealβ
+-emitter in PETdiagnosis.
It can be used as an alternative to 68Ga, because 43Sc has longer half-
life and forms stable radiobioconjugates with a structure similar to
90Yand 177Lu, that is important in planning radionuclide therapy. In
comparison with 44Sc -other proposed isotope of scandium - 43Sc
has half-life and beta plus radiation similar to 44Sc, moreover
gamma-ray energy emission and intensity is much lower (372
keV, 23%) than in case of 44Sc (1157 keV, 99%) what is not negli-
gible for patient andmedical personnel. 43Sc can be produced via the
natCa(α,x)43Sc reaction in medium size cyclotrons or in reactions
43Ca(p,n)43Sc and 42Ca(d,n)43Sc carried in smallmedical cyclotrons.
The aim of our work was to find optimal parameters for target
irradiations in order to maximize the production of 43Sc with mini-
mal impurities and to develop a simple chemical procedure for
separation of 44Sc from the calcium target. Materials and methods:
In the present work, we used either high purity natural CaCO3 or
enriched 42CaCO3 and
43CaCO3 targets (Isoflex, Russia). The irra-
diations have been performed with the Scanditronix MC 40 Cyclo-
tron of the Joint Research Centre (Ispra, Italy), or U-200P and GE-
PETtrace cyclotrons of the Heavy Ion Laboratory, University of
Warsaw. Target materials for irradiation were compacted into the
specially designed aluminum capsules or were pressed into a rect-
angular pellet wrapped in the pre-formed aluminum foil and fixed to
a water cooled target holders. The activities of the samples were
measured with high resolution γ-ray spectrometry. CaCO3 targets
were dissolved in 0.2MHCl and an ion exchange resin Chelex 100
was used to separate 43Sc from target material.43Sc-DOTATATE
was synthesised with different amounts of the peptide and at various
pH. Results: The three proposed methods of 43Sc production allow
obtaining the high activity of the radionuclide. 43Sc was separated
from the targets on iminodiacetic resin with efficiency higher than
95% and eluted in volume of 0.3 ml. The recovery of the calcium
material is also very high (~90%). The level of Ca2+ in 43Sc fraction
is less than 3 μg/ml. Conclusions: The 43Sc radionuclide can be
produced in amount of several GBq. The proposed production pro-
cedures are simple and fast. The synthesis and purification procedure
can be simplified using C18 Sep-Pak® columns.
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Production of High Specific Activity 186Re for Cancer
Therapy Using WO3 Targets in a Proton Beam
M. E. Fassbender1, E. R. Birnbaum1, J. W. Engle1, M. D.
Gott2, K. D. John1, J. R. Maassen1, F. M. Nortier1, J.W. Lenz3,
C. S. Cutler4, A. R. Ketring4, S. S. Jurisson4, E. R. Balkin5, D.
S. W. Wilbur5; 1Los Alamos National Laboratory, Los
Alamos, NM, UNITED STATES, 2University of Missouri,
Columbia, MO, UNITED STATES, 3John Lenz and Associ-
ates, East Lansing, MI, UNITED STATES, 4Univeristy of
Missouri, Columbia, MO, UNITED STATES, 5Univeristy of
Washington, Seattle, WA, UNITED STATES
Rhenium-186 is aβ-γ emitter with a half-life of 90.64 h and aβ−
end-point energy of 1.07 MeV. The isotope is suitable to treat
cancers of small dimensions (mm range). Moreover, its γ-
emission at 137.15 keV is in the energy range favorable for both
γ-camera and SPECT imaging. Current production methods rely
on the neutron capture induced reaction 185Re(n,γ) in a reactor
and are associated with low specific activities (0.6 kCi/mmol),
thereby limiting the application of the isotope to palliative treat-
ments. Production via charged particle irradiation of enriched
186W results in a 186Re product with a much higher specific
activity; allowing its use in therapeutic nuclear medicine. Test
targets of both sintered and pressed natWO3 powder were proton
irradiated at the Los Alamos Isotope Production Facility (LANL-
IPF) to evaluate radionuclide product yields, impurities, irradia-
tion parameters and wet chemical Re recovery for a bulk produc-
tion. We demonstrated that 186gRe can be isolated in 97% yield
from irradiated natWO3 targets within 12 h of end of bombard-
ment (EOB) via an alkaline dissolution followed by anion ex-
change. Tungsten (VI) oxide can be easily recycled for recurrent
irradiations. Using a sintered target, 186Re batch yields of 42.7 +/
- 2.2 μCi/μAh (439 +/- 23 MBq/C) (with respect to 186W con-
tent) were obtained after 24 h of irradiation in proton beams. The
target entrance energy of the proton beam was determined to be
15.6MeV. The specific activity of 186gRe at EOBwasmeasured
to be 1.9 kCi (70.3 TBq)/mmol. Based upon our studies of
natWO3, a target of enriched 186WO3 irradiated in a proton
beam of 250 μA for 24h can provide batch volumes of roughly
250 mCi (9.25 GBq) of 186gRe at EOB with a specific activity
approaching the theoretical value of 35kCi/mmol (1295 TBq/
mmol).
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Direct production of 99mTc-Technetium using low energy
cyclotrons and radionuclidic purity: our results so far
using natMo-Molybdenum
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W. Gelbart4, J. Obermair5, C. Artner5, P. Lass6, G. Currie7, L.
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Introduction: Despite the global crisis concerning
99mTc delivering to Nuclear Medicine Departments
there isn’t yet a reliable solution. The cyclotron direct
production of 99mTc, using the 100Mo(p,2n)99mTc nu-
clear reaction is our attempt to approach the problem,
aiming to become efficient, reliable and sustainable
from points of view as reducing drastically the radio-
active waste being produced and becoming beneficial
for all the involved parts. Between several critical fac-
tors, radionuclidic purity of cyclotron-produced 99mTc
is being pointed as an issue of concern. Aim: This
paper aims to disseminate the results being obtained
so far in what concerns radionuclidic purity of the
99mTc already produced from natMo and some extrap-
olation calculi for the use of high-level of purity
100Mo. Material and Methods: natMo foils were
stacked into a solid target of aluminum and short irra-
diations (with ~1-2 to 20 μA proton beams, during 2
to 20 seconds) were performed, using our in-house de-
veloped targets and target holder systems, on three dif-
ferent cyclotrons (IBA Cyclone-18, ACSI TR19 and GE
PETtrace). Beam energy degraders based on aluminum
were developed in-house with thicknesses calculated
using SRIM/TRIM, allowing irradiations with 15 MeV
in the IBA and GE machines. Produced activity was
quantified using HPGe gamma spectroscopy to obtain
the overall amount of 99mTc produced, as well as the
different contaminants (such as 93Tc, 93mTc, 94Tc,
94mTc, 95Tc, 95mTc, 96Tc, 96mTc, 99Mo and 96Nb)
whose activity was analyzed in terms of ratios in order
to 99mTc activity. Novel ratios were extrapolated from
our experimental data to an ideal case of irradiations
using 100Mo enriched targets (with purities of 97,42%
and 99,5%). Results: It has been observed, that 19 and
18 MeV irradiations of natMo lead to an higher level
of contaminants, with produced yields of some contam-
inants much higher than those of 99mTc being pro-
duced (e.g.: 93Tc, 94Tc and 95Tc), however, extrapo-
lated contaminant ratios for enriched targets suffer a
reduction, even considering values deserving attention
(e.g.: 94Tc/99mTc ≥ 1% or 93Tc/99mTc ≥ 3%). On
other hand, our results confirm our hypothesis that
15 MeV irradiations could maintain considerable pro-
duction yields, with a significant decrease of contami-
nants, with almost all extrapolated ratios reaching
values ≤ 1%. Conclusion: Radionuclidic purity is a
critical issue for the implementation of alternative
routes for 99mTc production and our actual data points
that 15 MeV proton beams could be considered, since
drastically reducing contaminants while easing produc-
tion and purification processes.
OP481
Extremely rapid, kit-based biomolecule labelling
and molecular imaging with gallium-68:
tris(hydroxypyridinone) chelators
M. T. Ma1, J. D. Young1, C. Imberti1, C. Cullinane2, M. S.
Cooper1, L. Meszaros1, S. Y. A. Terry1, B. Paterson1, G. E. D.
Mullen1, J. R. Ballinger1, P. Roselt2, R. J. Hicks2, P. J. Blow-
er1; 1King’s College London, London, UNITED KINGDOM,
2Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA
The gallium-68 (68Ga) generator offers PET molecular imag-
ing to hospitals without a cyclotron if simple labellingmethods
are devised. Current 68Ga clinical radiopharmaceutical syn-
theses require high temperatures (greater than 90 °C), and
extended reaction times (5 - 20 min). We have previously
shown that tris(hydroxypyridinone) (THP) ligands rapidly la-
bel with 68Ga quantitatively under mild conditions (Chem
Commun, 2011; 47:7068). We now report the development
of one-step labelling methods equivalent to kit formulation
protocols, and the ability of 68Ga-THP peptide conjugates to
image expression of peptide receptors in tumours in vivo. The
THP-Ac chelator was labelled with 68Ga-generator eluate un-
der a range of THP-Ac concentrations (0.1-1000 μM), pH
values (4 - 7), buffers, and trace metal concentrations (Mg(II),
Fe(III), Zn(II)). At 10 μM, 20 °C and all pH values and times,
labelling efficiency of THP-Ac reached greater than 95% in
under 2 min, and was unaffected by contaminating Mg(II),
Zn(II) and Fe(III) at 30, 20, 0.3 mg/L, respectively. Vials con-
taining lyophilised THP-Ac and buffer salts gave quantitative
radiolabelling with unprocessed eluate in less than 5 min. New
bifunctional chelator isothiocyanate and carboxylate deriva-
tives of THP were synthesised and conjugated to (i)
cyclic(RGDfK) peptides for targeting αvβ3 integrin expres-
sion, (ii) Tyr3-octreotate (TATE) peptide for targeting SSTR2
expression in neuroendocrine tumours, (iii) a urea-containing
peptide targeting PSMA receptors for prostate tumours, and
(iv) the monoclonal antibody, trastuzumab for HER2 recep-
tors. All conjugates were labelled with 68Ga in greater than
95% radiochemical yield and high specific activity (up to 80
MBq/nmol at the point of administration) at 25 °C and formu-
lated to pH 6 - 7 in 2 - 5 min. Biodistribution of tested αvβ3-
and SSTR-targeting conjugates showed tumour-specific up-
take and retention of target receptor affinity. Excretion was
rapid and predominantly renal. Serum stability and
biodistribution experiments point to excellent in vivo stability
of the new radiotracers with respect to the 68Ga-THP com-
plex. Notably, in vivo tumour uptake and biodistribution of
68Ga-THP-TATE was comparable to that of the clinical radio-
p h a rm a c e u t i c a l , 6 8G a -DOTA -TATE .T h e n ew
tris(hydroxypyridinone) chelator and its conjugates enable
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rapid radiolabelling with 68Ga under mild conditions without
subsequent purification. The simplicity of radiochemical syn-
theses based on such conjugates is conducive to translation to
one-step kit-based radiosyntheses that would greatly facilitate
the expansion and adoption of 68Ga PET in hospitals.
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Microfluidics and Microwave Assisted Synthesis
of 99mTc(CO)3-MIP-1505, a ligand for carbonic
anhydrase IX (CAIX). Comparison to Conventional
Heating
J. Kelly, A. Amor-Coarasa, J. W. Babich; Weill Cornell Med-
ical College, New York, NY, UNITED STATES
AIM: To compare the formation of a 99mTc(CO)3 complex and
the subsequent labeling of MIP-1505, a ligand for carbonic
anhydrase IX, using a microfluidics system, a microwave re-
actor, and a conventional heating block. METHODS: The
microfluidics labeling experiments were undertaken on a
NanoTek LF system (Advion) with the reactor coil heated to
150°C. A 150 μg/mL solution of MIP-1505 in DMSO and a
3.7 GBq/mL solution of 99mTcO4
- in saline containing 6 mg
CH3BNa2O2 , 2 .9 mg Na2B4O7 .10H2O , 8 .5 mg
C4H4Na2O6.2H2O, 7.2 mg Na2CO3 (“Isolink kit”) were
passed through the reactor at a maximum combined flow rate
of 30 μL/min. Reaction times varied from 1-3 minutes accord-
ing to stoichiometry and flow rates. Labeling in the microwave
reactor (Biotage) was undertaken at 100°C, 125°C, and
150°C. Formation kinetics of the 99mTc(CO)3 complex were
evaluated in the absence of MIP-1505. A solution of 50 μg
MIP-1505 in 0.5 mL saline was added to the tricarbonyl kit,
and the reaction was heated for up to 20 minutes. Synthesis of
99mTc(CO)3-MIP-1505 on a heating block (ThermoFisher)
was undertaken over 60 min at 100°C[1].RESULTSIn 1 min-
ute, 3 μg MIP-1505 was labeled in 91.2±0.6% yield in the
microfluidics system. When reaction time was 2 minutes,
2.2 μg MIP-1505 was labeled in a similar yield. In both cases,
6-8% of the unbound 99mTc was in the form of the 99mTc(CO)3
complex. Rapid and nearly quantitative tricarbonyl formation
was observed after 1 minute of microwave heating at 125°C
(98.9±0.16%) and 150°C (99.9±0.2%), and after 2 minutes at
100°C (98.5±0.46%). Labeling ofMIP-1505 was most rapid at
150°C, reaching 58.5±4.1% after 5 minutes. At 125°C the
maximum labeling was 67.6±0.4% (10 minutes), while at
100°C the labeling was 51.1±3.4% (20 minutes). By conven-
tional heating, the labeling of MIP-1505 was 63±12% after 60
minutes. CONCLUSIONS: Synthesis by microfluidics pro-
vides 99mTc(CO)3-MIP-1505 in high specific activity and with
the greatest yield, though there is no time advantage relative to
microwave heating when a clinical dose (<185 MBq) is pro-
duced. Both microwave heating and microfluidics are signifi-
cantly faster than conventional heating with no significant dif-
ference in labeling yield. This is advantageous in the planning
of pre-clinical and/or clinical studies. Economy of time and
reagents makes microfluidics an attractive approach for the
production of 99mTc(CO)3-MIP-1505 for pre-clinical studies,
while microwave heating appears to be the most promising
route to a clinical dose.[1] Lu, et al. J. Med. Chem. 2013, 56,
510-520.
OP483
Microfluidics Assisted Labeling of 68Ga-DOTATOC:
Advantages and Limitations.
A. Amor-Coarasa, J. M. Kelly, J. W. Babich; Weill Cornell
Medical College, New York City, NY, UNITED STATES
Aim: To maximize 68Ga-DOTATOC specific activity (SA)
and minimize reaction time by using microfluidics (MFs)
assisted chelation chemistry. Materials and Methods:
Gallium-68 (68Ga) was obtained by eluting with 4 ml 0.05M
HCl a 1.85 GBq (50 mCi, at calibration) itG 68Ge/68Ga Gen-
erator. Labeling was performed in a NanoTek Microfluidic
Flow-Chemistry System (Advion, USA). The eluate was buff-
ered with 120 μl of 3N NaOAc (pH 4-5). DOTATOC was
prepared as a 100 μg/ml solution in the same buffer. The effect
of stoichiometry and temperature (95 or 150 °C) was studied.
Labeling was also performed in a conventional heater (CH) for
comparison. Radio-HPLC was used to determine radiochem-
ical yield (RCY) and purity. Results: The RCY of 68Ga-
DOTATOC using MFs was nearly 70% (68.3±2.4%) at
150°C as compared to 46.5±4.4% at 95°C. RCY was not sig-
nificantly dependent on DOTATOC mass within the 60 ng
(42.2 pmol) to 150 ng (105 pmol) range. At 95°C, MFs label-
ing of DOTATOC varied from 41.6±6.5% (60 ng) to 50.7
±3.5% (150 ng). The variation was similarly low at 150°C,
with RCYs of 65.7±2.1% (60 ng) and 70.3±1.8% (150 ng).
When the mass of DOTATOC was decreased to 15 ng, label-
ing yields decreased to 3.2±0.7% at 150°C and no labeling
was observed at 95°C. Despite the high labeling yields
(≈70% with 100 ng of DOTATOC at 150°C vs. <1% with
CH at 95°C) obtained in 1 minute with the microfluidics sys-
tem, the critical parameter for radiopharmaceutical production
is radionuclide concentration. The maximum activity that can
be produced in oneminute using the buffered generator elution
is 25.9 MBq (0.7 mCi), such that over 7 minutes are necessary
to produce a patient dose of 185 MBq (5 mCi). During this
time greater dose (lower SA) can be produced with CH. Use of
68Ga pre-concentration systems[1] allows the same patient
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dose in 3 min, however increased manipulation is needed. In
contrast preclinical doses can be obtained within seconds.
Conclusion: Microfluidics assisted reactions have great poten-
tial for preparation of high specific activity products minimiz-
ing precursor degradation at high temperatures. It shows clear
advantages for discovery applications and preclinical testing.
However clinical application is severely limited by low
activity/time production and high equipment costs. High po-
tential for flow interruption also reduces its reliability for ev-
eryday radiopharmaceutical production in a clinical setting.
References: 1: Alejandro Amor-Coarasa; Seza Gulec; Antho-
ny McGoron; Inexpensive and cGMP capable Ga-68 purifica-
tion system; J Nucl Med. 2012; 53 (Supplement 1):1742
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A Fast Optical Method for Radiochemical Purity
Evaluation
A. E. Spinelli1, C. R. Gigliotti1, F. Boschi2; 1San Raffaele
Scientific Institute, Milano, ITALY, 2University of Verona, Ve-
rona, ITALY
Aim: The standard technique to evaluate the radiochemical
purity (RCP) is the thin-layer chromatography. RCP is an im-
portant index for the radiopharmaceutical QA because identify
the percent of the total radioactivity present in the desired
chemical form in a radiopharmaceutical. This value is com-
monly obtained from the activity distribution measured with a
conventional radiation detector along the chromatographic
strip (CS). We propose here an alternative CCD-based ap-
proach to quickly image the CSs.Methods: We use a system
composed of cooled electron multiplied charge coupled device
(EMCCD) coupled with lens mounted on a light-tight box and
a high-resolution intensifying screen for radiation conversion.
CSs with 7 kBq of 68Ga-DOTANOC and 5 kBq of 99mTc-
HMDP were imaged. A photographic image is acquired and
then the samples are covered with the screen. The emissive
signal is acquired for 10s. In order to validate our approach, the
same strips were imaged with the Cyclone Plus Storage Phos-
phor system (Perkin-Elmer) based on a conventional PSP, rou-
tinely used to analyse CSs.Results and conclusion: From the
activity profile evaluated along the signal of the 68Ga-
DOTANOC acquired with the commercial system and with
our optical system, we measured a RCP equal to 97.9% and
to 96.8%, respectively. The 1.1% difference between the mea-
sured RCP shows a good accuracy of the optical approach.
The analysis of the images of two strips treated with 99mTc-
HMDP obtained with the two systems confirms the efficiency
of the optical method. We observe that a quantitative analysis
of CSs can be done using 10 sec (or even less) of exposure
time with an optical system For this reason, the optical ap-
proach provides a quicker method to evaluate RCP with
respect to the conventional one that takes few minutes. Fur-
thermore the fusion of photographic and emissive images al-
lows spatially localizing signals, permitting a convenient si-
multaneous analysis of different samples that cannot be done
using conventional methods. The results show that the inten-
sifying screen, even if is optimized for low energy X rays, can
be reliably used also for γ and β radiations conversion.
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Alpha- versus beta-emitting particles for pretargeted
radioimmunotherapy of CEA-expressing human colon
cancer xenografts
S. Heskamp1, R. Hernandez2, J. D. M. Molkenboer-Kuenen1,
M. Essler3, F. Bruchertseifer4, A. Morgenstern4, W. J. G.
Oyen1, C. Seidl5, W. McBride6, D. M. Goldenberg6, O. C.
Boerman1; 1Radboud University Medical Center, NIJME-
GEN, NETHERLANDS, 2University of Wisconsin, Madison,
WI, UNITED STATES, 3University of Bonn, Bonn, GERMA-
NY, 4Joint Research Centre – Institute for Transuranium Ele-
ments, Karlsruhe, GERMANY, 5Klinikum rechts der Isar der
Technischen Universität München, Munchen, GERMANY,
6Immunomedics, Morris Plains, NY, UNITED STATES
Aim: Pretargeted radioimmunotherapy (PRIT) with the anti-
CEA x anti-HSG bispecific antibody TF2, and 177Lu-labeled
di-HSG-DOTA peptide IMP288, can delay growth of CEA-
expressing xenografts. A phase I study has shown the safety
and feasibility of PRIT in colorectal cancer patients. The ther-
apeutic efficacy of PRIT may be improved by using alpha-
emitting radionuclides. The aim of this study was to compare
the therapeutic efficacy of 213Bi and 177Lu for PRIT of CEA-
expressing xenografts. Material and methods: The vitro bind-
ing characteristics (IC50, Kd, internalization) of
213Bi-IMP288
were compared to 177Lu-IMP288. Tumor targeting of 213Bi-
IMP288 and 177Lu-IMP288 was studied in mice with s.c.
LS174T tumors that were pretargeted with TF2. Finally, the
effect of 213Bi-IMP288 (6, 12, or 17 MBq) and 177Lu-IMP288
(MTD: 60 MBq) on tumor growth and survival was assessed.
Toxicity was determined by monitoring body weight and by
analyzing blood samples for haematological toxicity
(haemoglobin, leucocytes, platelets). Results: Binding charac-
teristics of 213Bi-IMP288 were similar to 177Lu-IMP288 (Kd =
0.8 nM). Tumor uptake was observed as early as 15 min post
injection (9.2 ± 2.0 %ID/g) and the peptide cleared rapidly
from the circulation. At 30 min post injection the blood level
of 213Bi-IMP288 was 0.44 ± 0.28 %ID/g. Uptake of 213Bi-
IMP288 in normal tissues was very low, except for some
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uptake in the kidneys (1.8 ± 1.1 %ID/g). The biodistribution
was comparable to 177Lu-IMP288. PRIT treated mice showed
significant inhibition of tumor growth and prolonged survival.
Mean tumor doubling time for the PBS, 6MBq 213Bi-IMP288,
12 MBq 213Bi-IMP288, and 60 MBq 177Lu-IMP288 group
was 3.3 ± 0.3, 6.5 ± 1.2, 11.1 ± 3.2, and 11.8 ± 9.3 days.
Median survival for the PBS and 6 MBq 213Bi-IMP288 group
was 22 and 31 days, respectively. The 12 MBq 213Bi-IMP288
and 60 MBq 177Lu-IMP288 groups did not yet reach the me-
dian survival at day 35. Mice receiving 17MBq 213Bi-IMP288
showed significant weight loss, resulting in a median survival
of 24 days. Tumor doubling time could not be reliably estimat-
ed for this group. No changes in haemoglobin, platelets, and
leucocytes were observed. Conclusion: This study showed that
PRITwith 213Bi-IMP288 is feasible and at least as effective as
177Lu-IMP288. Haematological toxicity and survival of mice
treated with 12 MBq 213Bi-IMP288 and 60 MBq 177Lu-
IMP288 were comparable. Future experiments should study
the effect of multiple cycles 213Bi- and 177Lu-IMP288 on tu-
mor growth, survival, and haematological and renal toxicity.
OP486
Targeted Radionuclide Therapy using high-LET particle
emitter-labeled vectors against alpha-v-beta6-expressing
cancers
S. PAILLAS1, A. DESAI2, I. QUETIER2, J. MARSHALL2,
J. POUGET3, J. SOSABOWSKI1; 1Centre for Molecular On-
cology, Barts Cancer Institute, London, UNITED KING-
DOM, 2Centre for Tumor Biology, Barts Cancer Institute,
London, UNITED KINGDOM, 3Inserm U1194, Montpellier,
FRANCE
Targeted radionuclide therapy (TRT) has emerged as an attractive
approach in cancer therapy since it allows the specific irradiation
of tumor cells while sparing healthy tissues. TRTof solid tumors
has a limited efficacy mainly because these tumors have high
radioresistance and take up limited amounts of radiolabeled vec-
tors. Strategies to overcome this include the use of small peptides
and radionuclides that emit highly cytotoxic particles, namely
high linear energy transfer (LET) particles such as alpha particles
andAuger electrons. The epithelial-specific integrin avb6 is weak
or absent on normal tissues but is upregulated in many cancers
and is strongly associated with reduced survival. We have previ-
ously shown in vivo tumour targeting using radiolabelled
A20FMDV2 a 20-mer avb6-specific peptide. Aims: The aim of
the study is to assess the efficacy and toxicity of TRT in mice
using both an internalising radiolabeled peptide and non-
internalising monoclonal antibody (mAb) against avb6. The sec-
ond aim is to validate in vivo gamma-H2AX (through γ-H2AX-
MDC1 interaction)measurement as an indicator of the efficacy or
toxicity of TRT by a novel quantitative and noninvasive imaging
approach.Materials and methods: The 20mer high affinity avb6-
targeting peptide, A20FMDV2 used in previous work has been
derivatised to contain a trimethylstannyl benzamide moiety so
that it can be radiolabelledwith high LET particle emitters: Auger
electron emitter 125I and alpha particle emitter 211At. The pep-
tide has been radiolabelledwith 125I and radioligand binding and
internalization assays have been carried out in cells that overex-
press avb6 and compared with that of the 111In-DTPA-
A20FMDV2 studied previously. In addition, lentiviral vectors
encoding the reporter genes (γ-H2AX/MDC1-Luc2) were made
by molecular cloning and used to coinfect avb6 expressing cells.
To verify that our γ-H2AX/MDC1-Luc2 reporter functions well
in tissue culture, stably infected cells were exposed to varying
degrees of stress and the activities of reporter genes was observed
by bioluminescence imaging and by western blot analyses of
phosphorylated H2AX or Nluc2-H2AX. Results and conclu-
sions: The peptide could be radiolabelled with radiolabelling ef-
ficiencies of 80-90% and purified to 100 % using Sep-Pak.
Radioligand saturation binding assays show Kd and internaliza-
tion rate comparable with that of the 111In-DTPA construct. Ro-
bust reporter activation can be observed in cells coinfected with
reporter genes γ-H2AX/MDC1-Luc2 by bioluminescence imag-
ing and western blot. These cells will be xenografted in mice to
evaluate double strand breaks in vivo after TRT.
OP487
Involvement of direct and indirect (bystander) cytotoxic
effects in alpha-RIT of small volume peritoneal
carcinomatosis using 212Pb-labeled mAbs
J. Pouget1, R. Ladjohounlou1, A. Pichard1, V. Boudousq1, S.
Paillas1, M. Le Blay1, C. Lozza1, M. Bardies2, S. Marcatili2,
N. Chouin3, J. Torgue4, I. Navarro-Teulon1; 1IRCM/
INSERMU1194, MONTPELLIER, FRANCE, 2UMR 1037
INSERM/UPS, TOULOUSE, FRANCE, 3AMAROC,
ONIRIS, Nantes, FRANCE, 4AREVA Med, BETHESDA,
WI, UNITED STATES
Hypothesis: We investigated in vitro and in vivo the relative
contribution of direct and indirect (bystander) effects in the
therapeutic efficacy of 212Pb-labeled mAbs used for treating
small volume peritoneal carcinomatosis.Methods: In vitro, we
investigated in A-431 cells exposed to increasing activities (0-
0.5 MBq/mL; 37 MBq/mg) of either 35A7 (anti-CEA),
Trastuzumab (anti-HER2) or PX (non-specific) 212Pb-
labeled mAbs the relative contribution to cell killing of direct
and bystander effects using standardmedium transfer protocol.
Biological end points included clonogenic survival and oxida-
tive DNA damage including DNA double strand breaks mea-
sured both in donor (direct effect) and in recipient cells (by-
stander effects). Mean absorbed dose to the nucleus of donor
cells was also determined using MIRD formalism. In vivo,
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nude mice with intraperitoneal (i.p.) 2-3 mm A-431 tumor
cells xenografts were i.p. injected with increasing activities
(370-1480 kBq; 37 MBq/mg) of the above mentioned anti-
CEA, anti-HER2 or non-specific 212Pb-mAbs. Determination
of radioactivity at the tissue level was done using digital
micro-autoradiography (DAR) and absorbed doses were cal-
culated. Biological markers including 53BP1, caspase 3 and
Ki67 proteins were also determined in tissue by immunohis-
tochemistry. Results: In vitro we showed in donor cells the
strong efficacy of 212Pb-35A7 and 212Pb-trastuzumab mAbs
and also to a lower extent of 212Pb-PX mAb. Significant
bystander cytotoxicity was measured in all recipient cells with
the three radiolabeled mAbs. The complexity of DNA damage
(53BP1 foci) observed in donor cells confirmed the high LET
cytotoxic effects of 212Pb-mAbs while less complex damage
were observed in recipient cells. In vivo, dose distribution was
calculated using DAR analysis and voxel dosimetry. Results
showed a strong dose gradient for anti-CEA 212Pb-mAbs
while it was much more homogeneous for anti-HER2 or for
the non-specific 212Pb-mAbs. These results explain the rela-
tive higher therapeutic efficacy previously reported in vivo for
anti-HER2 212Pb-mAbs compared with anti-CEA 212Pb-
mAbs. However, we also observed a similar formation of
DNA damage in tissue independently of tumour absorbed
doses thereby indicating that bystander effects could also be
involved. Conclusions: Our results showed in vitro and in vivo
the strong direct effects of 212Pb-labeled mAbs in killing tu-
mour cells. Heterogeneity in mAbs distribution would explain
the relative lack of efficacy per Gy (to the whole tumour) of
anti-CEA mAbs compared with anti-HER2 mAbs. However,
our preliminary data indicate that bystander effects would par-
ticipate to 212Pb-labeled mAbs efficacy.
OP488
Targeted Alpha Radionuclide Therapy of Prostate Cancer
Using a Small Molecule Inhibitor of Prostate-specific
Membrane Antigen (PSMA)
K. L. S. Chatalic1,2,3, S. Heskamp4, J. Nonnekens1,5, J. D. M.
Molkenboer-Kuenen4, D. van Gent5, F. Bruchertseifer6, A.
Morgenstern6, M. Weineisen7, H. Wester7,8, W. M. van
Weerden3, O. C. Boerman4, M. de Jong1,2; 1Department of Nu-
clear Medicine, Erasmus MC, Rotterdam, NETHERLANDS,
2Department of Radiology, ErasmusMC, Rotterdam, NETHER-
LANDS, 3Department of Urology, Erasmus MC, Rotterdam,
NETHERLANDS, 4Department of Radiology andNuclearMed-
icine, Radboud University Medical Centre, Nijmegen, NETH-
ERLANDS, 5Department of Genetics, Erasmus MC, Rotterdam,
NETHERLANDS, 6Joint Research Centre – Institute for Trans-
uranium Elements, Karlsruhe, GERMANY, 7Pharmaceutical Ra-
diochemistry, Technische Universität München, Munich, GER-
MANY, 8Scintomics GmbH, Fürstenfeldbruck, GERMANY
Objectives: PSMA is a well-recognized target for im-
aging and therapy of prostate cancer (PCa); it is
expressed in a very high percentage of PCa lesions.
Radiolabeled PSMA-inhibitors localize rapidly to tu-
mor lesions, including soft-tissue and bone metastases,
but show high uptake in kidneys and salivary glands.
The aim of the present study was to evaluate the
potential of the alpha emitter 213Bi coupled to PSMA
I&T, a DOTAGA-chelated urea-based PSMA inhibitor,
for therapy in PSMA-expressing tumor cells in vitro
and in vivo in mouse xenografts. Materials and
Methods: PSMA I&T was labeled with 111In or
213Bi. Pharmacokinetics of 111In-PSMA I&T were
evaluated in mice bearing subcutaneous PSMA-
expressing LNCaP tumors and PSMA-transfected
LS174T tumors. Biodistribution was determined 2h af-
ter 111In-PSMA I&T injection (0.1-10 nmol). Blocking
of PSMA-specific binding to kidneys was investigated
by co-injecting 2-(phosphonomethyl)pentane-1,5-dioic
acid (PMPA). The therapeutic efficacy of 213Bi-PSMA
I&T was tested in vitro in LNCaP cells and in vivo
in LNCaP-xenografted mice. Cells were incubated (20
min) with 213Bi-PSMA I&T, 213Bi-DTPA, or medium,
and fixed at 1, 2, 4, 24, and 48h after treatment.
Mice were injected with 213Bi-PSMA I&T (0.2 nmol,
5 MBq). Biodistribution was determined at 1h after
injection, whereas tumor and kidneys were dissected
at 1h and 24h after injection to study the therapeutic
DNA-damage response. Fixed tumor cells and dissect-
ed tissues were stained with anti-53BP1 and anti-
GEMININ antibodies and a TUNEL detection kit. Re-
sults: 111In-PSMA I&T showed dose-dependent uptake
in LNCaP and LS174T-PSMA tumors (t), kidneys (k),
spleen, adrenals, lung and salivary glands. Optimal
doses for tumor targeting were 0.1-0.3 nmol. Co-
injection of 10 nmol PMPA resulted in a decrease
in renal and tumor uptake of 60% and 17%, respec-
tively, improving t/k ratio. Treatment of LNCaP cells
with 213Bi-PSMA I&T caused a decrease in cellular
proliferation, induction of DNA double-strand breaks
and apoptosis. The biodistribution patterns of 213Bi-
PSMA I&T and 111In-PSMA I&T were similar.
213Bi-PSMA I&T induced DNA-double strand breaks
in LNCaP tumors, from which a significant amount
was not repaired at 24h after injection. Conclusion:
PSMA I&T is a promising targeting agent for radio-
nuclide therapy of PCa. In this study we showed
renal accumulation of this tracer to be efficiently re-
duced by co-injection of PMPA, while tumor uptake
was preserved. Our preliminary results reveal a good
targeting and therapeutic effect of 213Bi-PSMA I&T
in vitro and in vivo.*K.L.S.C. and S.H. contributed
equally to this work
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The next step in increasing the efficacy of PRRT:
Preclinical studies in vicvo and in vitro
with 213Bi-[DOTA0,Tyr3]-octreotate
H. S. Chan1, M. W. Konijnenberg1, E. de Blois1, S.
Koelewijn1, T. Anderson2, M. Nysus2, W. A. P. Breeman1,
R. W. Atcher3, A. Morgenstern4, F. Bruchertseifer4, J. P.
Norenberg2, M. de Jong1; 1Nuclear Medicine and Radiology,
ErasmusMC, ROTTERDAM,NETHERLANDS, 2College of
pharmacy, University of New Mexico, Albuquerque, NM,
UNITED STATES, 3Los Alamos National Laboratory, Los
Alamos, NM, UNITED STATES, 4European Commission,
JRC, Institute for Transuranium Elements, Karlsruhe, GER-
MANY
Peptide Receptor RadioTherapy shows a reasonable objective
response rate of 30-35% with the use of 177Lu-[DOTA0,Tyr3]-
octreotate (177Lu-DOTATATE). Alpha-particle emitters can
augment the therapeutic efficacy of PRRT and make it excep-
tional, especially in small tumours and metastasis cell clusters.
In preclinical studies with alpha-emitter labeled peptides high
specific activity is required, because of the high-affinity, but
low-capacity of tumour cell receptors. The stability of -particle
emitting radiopeptides should bemaintained until receptor me-
diated uptake, both in vivo as in vitro, to minimize off-targeting
effects. Also the radio-peptide should have rapid uptake, high
retention in tumour tissue and it should show high clearance
capacity from normal tissue. In this study we optimized the
application of 213Bi-DOTATATE for targeted alpha-particle
therapy in vitro and in vivo. We investigated for various so-
matostatin receptor-positive tumour models in mice the thera-
peutic efficacy of 213Bi-DOTATATE. The labeling procedure
for 213Bi-DOTATATE was chemically optimized for preclini-
cal applications. Materials and methods: Therapeutic effects
in vitro were compared between 213Bi-DOTATATE and
177Lu-DOTATATE, using CA20948 (rat pancreatic tumour)
and BON (human carcinoid) cell lines. Uptake in AR42J-
bearing nude mice was investigated. Specific peptide receptor
binding versus peptide mass, reduction of renal uptake by L-
lysine, and mitigation of renal damage after PRRTwere deter-
mined for 213Bi-DOTATATE. Therapeutic efficacy of 213Bi-
DOTATATE was also investigated in CA20948- and H69 (hu-
man small lung carcinoma)-bearing nude mice, bearing tu-
mours of different volumes. All experiments were guided by
dosimetry to estimate the dose limits in organs and tumours
and the relative biological effect of 213Bi-DOTATATE com-
pared to 177Lu-DOTATATE. Results: Labeling of 213Bi-
DOTATATE was optimized for preclinical applications under
physiologically acceptable conditions. 213Bi-DOTATATE
showed more effective cell killing in vitro in comparison to
177Lu-DOTATATE at comparable absorbed doses. Tumour up-
take in vivo depends on the peptide amount and therefore on
specific activity. Renal uptake and absorbed renal doses could
be decreased by pre-administration of L-lysine, thereby lead-
ing to higher tolerated activities and longer survival in nude
mice. The therapeutic responses of small and large tumours
after 213Bi-DOTATATE did not show differences; in both be-
ing highly efficacious. Tumour growth delays of 50 days and
more could be achieved compared to 30 days after 177Lu-
DOTATATE.Conclusions:213Bi-DOTATATE has proven to
be promising and safe in tumours with somatostatin receptor
expression over a range of tumour volumes in mice. Optimal
labeling conditions were determined for preclinical therapy
studies in mice and renal toxicity could be managed by addi-
tion of L-lysine.
OP490
Preclinical Comparison of Therapeutic response
to Treatment with 177-Lutetium labelled Somatostatin
Receptor Agonists and Antagonists
S. Dalm1, G. Doeswijk1, S. Koelewijn1, H. Maecke2, M. de
Jong1; 1ErasmusMC, Rotterdam, NETHERLANDS, 2Univer-
sity of Basel, Basel, SWITZERLAND
Introduction: Somatostatin receptor (SSTR) agonists are suc-
cessfully being used in the clinic for radionuclide-mediated
imaging and therapy of neuroendocrine tumors. Recently,
studies showed a higher tumor uptake of SSTR antagonists
compared to SSTR agonists. Furthermore, first studies on the
feasibility of imaging and therapy of patients with SSTR an-
tagonist showed promising results. However, to date no stud-
ies have been performed to compare the differences in thera-
peutic effect between SSTR agonists and SSTR antagonists.
The aim of this project was to determine differences in thera-
peutic response after treatment with 177Lu-Octreotate, an
SSTR agonist, and 177Lu-JR11, an SSTR antagonist, in pre-
clinical studies in an in vivo mouse model. Materials and
Methods: Male balb c nu/nu mice were subcutaneously inoc-
ulated with the SSTR-positive H69 cell line. For
biodistribution purposes mice were injected with ~30 MBq
177Lu coupled to 0.5, 1.0 and 2.0 μg JR11. At 4 time points
(4 h, 2 d, 4 d and 7 d) post injection, tumors and organs were
collected and radioligand uptake was determined. Also, thera-
py studies were performed comparing the effect of 177Lu-
Octreotate and 177Lu-JR11. Animals (n=6 each group) were
injected with either 0.5 μg/~30MBq 177Lu-JR11, 177Lu-
Octreotate, after injection of 4 mg Gelofusin to reduce renal
uptake, or received a sham injection. Animals were euthanized
when tumor size reached 2000 mm3. Results: Biodistribution
studies showed 0.5 μg/30 MBq 177Lu-JR11 to result in the
highest tumor radiation dose (1.8±0.7 Gy/MBq), with lowest
variation. Data was compared to previously performed
biodistribution studies using 177Lu-Octreotate in the same
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mouse model. 177Lu-JR11 tumor radiation dose was signifi-
cantly higher than the optimal tumor dose reported for 177Lu-
Octreotate (0.4±0.1 Gy/MBq). Tumor-to-kidney ratio of
177Lu-JR11 stayed the same for all peptide concentrations test-
ed, but was significantly higher for 177Lu-JR11 compared to
177Lu-Octreotate; 0.97±0.32 Gy/MBq vs. 0.14±0.05 Gy/MBq
respectively, using 0.5 μg/~30 MBq of both radiotracers. Five
weeks after injection of a therapeutic dose of 177Lu-JR11 or
177Lu-Octreotate, survival in the 2 groups was 80% and 17%,
respectively, while none of the animals of the control group
survived up to that time point. Growth delay time was superior
for animals treated with 177Lu-JR11 (68±5 d) compared to
177Lu-Octreotate (57±5 d) and control animals (41±6 d). Con-
clusion: The SSTR antagonist, JR11, showed higher uptake
and a better therapeutic effect compared to the SSTR agonist,
Octreotate, in H69 xenografts. Therefore, we conclude that the
SSTR antagonist, JR11, may positively contribute to SSTR
mediated imaging and therapy.
OP491
[177Lu]-OPS201 targeting somatostatin receptors: In vivo
biodistribution and dosimetry in a pig model
S. Beykan1, J. S. Dam2, U. Eberlein1, J. Kaufmann3, B.
Kjærgaard4, L. Jødal2, H. Bouterfa3, M. Lassmann1, S. B.
Jensen5; 1Department of Nuclear Medicine, University of
Würzburg, Würzburg, GERMANY, 2Department of Nuclear
Medicine, Aalborg University Hospital, Aalborg, DEN-
MARK, 3Octreopharm Science GmbH, Berlin, GERMANY,
4Biomedical Research Laboratory, Aalborg University Hospi-
tal, Aalborg, DENMARK, 5Department of Nuclear Medicine,
Aalborg University Hospital, Department of Chemistry and
Biochemistry, Aalborg University, Aalborg, DENMARK
Aim: OPS201 is a new somatostatin receptor antagonist with
high affinity towards the somatostatin receptor subtype sst2. In
combination with 177Lu it can potentially be used for peptide
receptor radionuclide therapy (PRRT) in patients with neuro-
endocrine tumors. Here we present the in vivo bio distribution
of 177Lu OPS201 in pigs as a model for human dosimetry.
Materials and Methods: All procedures involving animals
were performed after a written permission from the Danish
Animal Experiments Inspectorate. [177Lu]-OPS201 was pro-
duced on an E&Z Modular lab PharmTracer system by
reacting 24 nmol of OPS201 precursor with [177Lu]-Chloride
n.c.a. (ITG) in a sodium acetate / ascorbate buffer (pH 4.5) at
80°C for 20 minutes. In vivo biodistribution and dosimetry
studies with 100 MBq (+/-10 MBq) [177Lu]-OPS201 were
performed in anesthetized Danish Landrace pigs (2 female
and 3 male, age 3 months, weight: 28 kg (+/- 2 kg)). A series
of SPECT/CT scans were conducted until 10 days after intra-
venous injection. The physiological parameters were
monitored and if necessary, corrected during the scans. Blood
samples were taken to determine the time-activity curves in
blood. Time-activity curves and residence times were calculat-
ed for the organs showing visible uptake. Based on these data,
the absorbed organ dose coefficients for a 70kg patient were
calculated using the OLINDA/EXM software. Result: The ap-
plied radio labeling procedure yielded [177Lu]-OPS201 (62-
88%, non-decay corrected, RCP>98%). After injection, the
blood samples showed fast clearance of the compound from
the blood. Less than 5% of the injected activity was observed
in the blood 10min after injection. There was no visible uptake
in the spleen but measurable uptake in the spine. For humans
after an injection of 5 GBq [177Lu]-OPS201, the highest cal-
culated absorbed doses were registered in the kidneys
(13.7Gy), the osteogenic cells (3.9Gy), the urinary bladder
wall (1.8Gy), and the liver (1.0Gy). None of the absorbed
doses exceed organ toxicity levels. No metabolites of
[177Lu]-OPS201 were found by radio HPLC analysis. Con-
clusion: In vivo distributions and absorbed doses are generally
comparable to those obtained for other therapeutic somatostat-
in receptor ligands. However for a human study the potential
uptake to the spine and the spleen need to be analyzed care-
fully. The analysis shows no indication that a human study
leads to an overexposure of patients after giving a normal
treatment of 5-7 GBq with [177Lu]-OPS201.
OP492
Development and human absorbed dose estimation
of 47Scandium-anti-CD20 for radioimmunotherapy
L. Moghaddam-Bnaem1, A. Jalilian2; 1Amirkabir Technical
university, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Nucle-
ar Science and Technology Research Institute, Tehran, IRAN,
ISLAMIC REPUBLIC OF
Aim: In this investigation a new radiopharmaceutical using
47Scandium for labeling Anti-CD20 is performed. Rituximab
monoclonal antibody is selectively binds with high affinity to
CD20 antigen, a surface antigen common in B-cell of lym-
phoid tissue. Scandium-47 is a moderate energy β- emitter
(T1/2 = 3.42d, Eβmax= 441 keV ,%68; Eβmax= 600 keV ,
%32). Because the availability of 47Sc isotope is currently
extremely limited, we have performed preliminary studies
using 46Sc which is chemically identical. The chemical pro-
cedure, biodistribution in wistar rats and the absorbed dose of
radiation into human organs by using biodistribution data in
rats, after an intravenous administration of 47Scandium-la-
beled Rituximab, were estimated. Material and Methods: In
this work, Sc-46 chloride was obtained by thermal neutron
activation flux of natural metallic scandium sample followed
by dissolution in acidic media (radionuclidic purity via beta
and gamma ray spectroscopy, 99.9% ; radiochemical purity
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via ITLC, >99%) and used in radiolabeling of rituximab after
conjugation with DOTA-NHS-ester The radiochemical purity
(ITLC), stability studies (ITLC and size exclusion chromatog-
raphy), determination of average number of DOTA conjugated
per mAb (chelate: antibody ratio, 5.8:1) were determined
followed by biodistribution studies for 46Sc and [ 46Sc]Sc-
DOTA-anti-CD20 in wild type rats up to 72h. The
biodistribution data in rats were analyzed to estimate the
human’s organs uptake and source organ residence times and
cumulated activities. The dose calculation and estimation was
done for a certain group of organs of human following the
MIRD technique. As the S-factor is relevant to the particle
energy that emitted by radionuclide for dose calculation the
dose S-factor of 47Sc is used. Results and conclusion: The
binding of the radiolabeled antibody was showed to be 60%
on Raji cells. The final compound was stable in presence of
PBS at 37 °C and room temperature. The accumulation of the
radiolabeled antibody in liver, spleen, kidney, heart and other
tissues demonstrates a pattern similar to the other
radiolabeled anti-CD20 immunoconjugates. The accumula-
tion of the radiolabeled antibody in liver, spleen, kidney,
heart and other tissues demonstrates a pattern similar to the
other radiolabeled anti-CD20 immunoconjugates.The
absorbed dose of 47Sc -Riruximab in human is also esti-
mated. The absorbed dose in human by lung, stomach, S
intestine, liver, spleen, kidney and bone are 0.09, 0.06,
0.02, 2.94, 0.79, 0.13 and 0.27mGy/MBq respectively.
The present study shows the possibility of antibody label-
ing for future use in radioimmunotherapy by 47Sc.
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Clinical Impact of simultanous 18FET PET/MRI
for Pediatric CNS-tumors
L. Marner1, K. Nysom1, A. Sehested1, L. Borgwardt1, R.
Mathiasen1, P. S. Wehner2, M. Jørgensen1, P. Munck af
Rosenschöld1, C. Thomsen1, L. Bøgeskov1, H. Broholm1, D.
Scheie1, M. Juhler1, L. Højgaard1, I. Law1; 1Copenhagen Uni-
versity Hospital, Rigshospitalet, Copenhagen O, DENMARK,
2Odense University Hospital, Odense, DENMARK
Aim: We aim to investigate the diagnostic value of simultaneous
18F-flouro-ethyl-tyrosine positron emission tomography and
MRI (18F-FET PET/MRI) in comparison to MRI alone for pri-
mary CNS-tumors in children and adolescents at the time of
diagnosis, before and after surgery, and if relapse or progression
is suspected.Material and Methods: We aim to include 100 con-
secutive children and adolescents diagnosedwith a primaryCNS-
tumor before the age of 18, and have so far included 8 patients (3-
15 years). All but two required anesthesia and in half of the cases,
the 18F-FET PET/MRI replaced a regular MRI. Simultaneous
with MRI of the brain (+/- spinal canal), a 40 min dynamic
PET recording was performed using a 3T Siemens Biograph
mMR after injection of 3 MBq/kg 18F-FET. The PET images
were reconstructed using a low-dose CT for attenuation correc-
tion. A summed image of the last 20 min of the PET recording
was evaluated as PET uptake in tumor relative to unaffected gray
matter as described previously*. The clinical impact of the FET
PET/MRI was evaluated at a multidisciplinary team meeting by
first considering the MRI and deciding the future plan and sub-
sequently considering the PET/MRI and evaluating the possible
changes in plans. Results: For 10 of 14 eligible patients, the
parents have given consent for participation; 8 have been
scanned. The patients had pilocytic astrocytoma WHO grade I
(n=3, 2 with FET uptake, 1 without tumor residue), pilomyxoid
astrocytoma WHO grade II (FET uptake), DNET WHO grade I
(no FET uptake), ependymoma WHO grade II (FET uptake),
atypical teratoid/rhabdoid tumor WHO grade IV(FET uptake),
unbiopsied lesion suspected of tumor (no FET uptake). In 2 out
of 8 cases, FET PET/MRI had a major clinical impact or gave
support to a difficult clinical decision: One case changed the
operation procedure by including an extra tumor focus. In another
case, FET PET/MRI supported interpreting spinal changes as
being artifact and not indicative of dissemination, thus reducing
the radiation field from craniospinal to focal. Conclusion: The use
of simultaneous 18F-FET PET/MRI instead of MRI only is fea-
sible with minimal need for extra anesthesia. The preliminary
results show a major clinical impact of 18F-FET PET/MRI in 2
of 8 cases. If further data supports a high percentage of clinical
impact, we suggest amore regular use of thismodality in children
and adolescents with primary CNS-tumors.*Dunkl et al. (2015)
JNM 56:88-92.
OP495
Evaluation of Early Response to Neoadjuvant
Chemotherapy with FDG PET/CTand MRI in Pediatric
Patients with Bone Sarcoma
M. Caglar, B. Aydin, B. Ergen, E. Karabulut, C. Akyuz;
Hacettepe University, Ankara, TURKEY
Objective: 18F-FDG-PET/CT and diffusion-weighted MRI
were used for predicting response to treatment in patients with
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bone sarcomas in this study. Correlation between PET and
MRI parameters with histopathological response and clinical
outcome was assessed. Materials - Method: Sixteen patients (5
osteosarcoma, 11 Ewing’s sarcoma) aged between 5-16 years
were included in study. All patients underwent 18F-FDG-
PET/CT and diffusion MRI before (PET1 and MR1) and after
preoperative chemotherapy (PET2 and MR2) to assess the
radiological tumor response. The number and localization of
18F-FDG involvements, “maximum standardized uptake” val-
ue (SUVmax), metabolic tumor volume (MTV) and total le-
sion glycolysis (TLG) in 18F-FDG-PET/CT, and tumor vol-
ume and apparent diffusion coefficients (ADC) from three
separate areas within tumor on MRI were measured. Changes
in parameters before and after treatment were compared with
histopathological tumor response. Results: PET/CT at diagno-
sis showed 18F-FDG uptake in 1-32 different anatomical re-
gions. Median SUVmax1 and TLG1 values at baseline were
6.0 (ranged between 2.6-9.4) and 127.0 (ranged between 8.2-
573.3), respectively. Eight patients with good histologic re-
sponse had lower median post-chemotherapy FDG-PET/CT
parameters compared to those with poor response (1.7 vs 3.0
for SUVmax2 and 5.0 vs 62.5 for TLG2, respectively). The
correlation coefficients between tumor necrosis and
SUVmax2 and TLG2 were -0,647 and -0,656 respectively,
p<0,05). Based on ROC curve analysis, SUVmax2 and
TLG2 predicted a good pathological response. The optimal
cut-off values for SUVmax2 and TLG2 were 2,25 and 43,85
which yielded a sensitivity/specificity of 0,83/0,75 and 0,67/
100 respectively. Median diffusion MRI ADC changes were
found 27.6 and 46.9 in poor and good responders, respectively
(p>0.05, 8 patients). Conclusion: PET/CT can be used for
identification of metastasis in patients with bone tumors on
diagnosis and can predict the histopathological response after
neoadjuvant therapy.
OP496
Clinical impact of FDG PET-CT in pediatric soft tissue
sarcomas
M. Tuncel1, N. Kurucu2, P. Ö. Kıratlı1, B. Erbaş1, C. Akyüz2;
1Hacettepe University, Department of Nuclear Medicine, AN-
KARA, TURKEY, 2Hacettepe University, Department of Pe-
diatric Oncology, ANKARA, TURKEY
Aim: The use of positron emission tomography-computed to-
mography (PET-CT) for the evaluation of pediatric patients
with rhabdomyosarcoma has increased steadily over the last
decade. The management of these tumors needs multimodality
approach with accurate detection of disease burden. The aim
of this study was to evaluate the clinical impact of PET/CT in
pediatric patients suffering from rhabdomyosarcoma other osft
tissue sarcoma. Materials and Methods: Between December
2011 and March 2015, 23 consecutive patients [F/M: 10/13,
age median: 16±6.1 (range:3-22)] with 17 rhabdomyosarcoma
and 6 with other soft tissue sarcomas were referred for FDG
PET-CT. There were 40 referrals from 23 patients (9 for stag-
ing, 7 for equivocal conventional imaging, 13 for restaging
and 11 for therapy response). Patient management-follow-up
data, conventional imaging (CI) (30 with MRI, 4 with CT and
6 with both CT and MRI) and PET-CT results were than
interpreted with pediatric oncologist to determine the clinical
impact of the FDG PET-CT over CI and clinical evaluation.
Results: FDG PET-CT detected malign disease in 30 referrals
in 18/23 (78%) patients with median SUV max of 6±5
(range:2.5-24). In 5 patients FDG PET-CT was interpreted as
normal without active metabolic disease. When compared to
CI, FDG PET-CT has no clinical impact on patient manage-
ment in 25/40 (62,5%) referrals ( 4 for staging, 9 for restaging
and 11 for therapy response). In 15/40 (37,5%) referrals FDG
PET had a major clinical impact ( 5 for staging, 7 for equivocal
conventional imaging, 3 for restaging).In 7/15 (47%) of the
referrals; FDG PET-CTchanged treatment approach by chang-
ing the patients’ stage (6 upstaged and and 1 down-staged).
Therapy was ended due to true negative FDG PET-CT results
in 3/15 (20%) patients, in 2/15 (13%) patients true positive
PET leaded to more aggressive chemotherapy with the addi-
tion of radiotherapy. In 2/15 (13%) patients FDG PET-CT
prevented therapy change to more extensive therapy by
showing true negative results and in 1/15 (7%) patient
FDG-PET-CT guided biopsy by showing metabolically
active lesions. Conclusions: FDG PET/CT has a signifi-
cant impact on the management of pediatric patients
suffering from soft tissue sarcomas. It leads to a clinical
decision change in 37.5% of the referrals especialy those
referred due to equivocal CI. More studies are required
for identifying the subgroup of patients who might ben-
efit from a PET/CT.
OP497
Utility of PET/CT in children with Langerhans cell
histiocytosis.
R. Czepczyński, E. Jodłowska, O. Zając-Spychała, M.
Ruchała, J. Wachowiak; Poznan University of Medical Sci-
ences, Poznań, POLAND
Introduction: Langerhans cell histiocytosis (LCH) is a very
rare condition that primarily affects children. Its symptoms
are caused by single or multiple tumors composed of
Langerhans cells. Standard imaging modalities involved in
the management do not include PET/CT. Aim of the study:
To assess the utility of PET/CT in the management of children
with LCH.Materials and methods: The study included 15 pe-
diatric patients with LCH (age at diagnosis: from 3 months to
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17 yrs., mean 4.8 ± 5.6 yrs., median 5.1 yrs.). 5 children had
single system LCH, 10 children had multiple system LCH.
Patients were treated in accordance with the current guidelines
of Histiocyte Society (LCH-2009) using prednisone, vinblas-
tine and 6-mercaptopurine. PET/CT using 18F-FDG was per-
formed 60 min after injection of 18F-FDG using a routine
protocol with Discovery ST scanner (GE) and compared with
clinical status and other imaging modalities (CT, ultrasonog-
raphy, MRI). Results. PET/CT was performed for staging of
the disease (6 pts.), for the evaluation of treatment response (5
pts.), for the evaluation of treatment effect (10 pts.). Most
patients had more than one PET/CT scan. Altogether 33
PET/CT scans were retrospectively evaluated (max. 6 PET/
CT scans per one patient). In 5/6 cases the scan performed
for staging showed FDG-avid foci in the bones (5), orbita
(2), subcutaneous tissue (2) and liver (1). Only in one patient,
small subcutaneous lesions showed no uptake of FDG. In none
of the 3 patients with lung involvement pulmonary FDG up-
take was found. PET/CT performed during chemotherapy for
response evaluation, slight FDG activity was visible in
3/5 patients. Complete metabolic response was reported
in 2/5 patients. At the final treatment evaluation of these
5 patients complete metabolic response was found in 4
patients and persistent uptake in one patient (non-re-
sponder according to the early scan and progression
was observed in the subsequent PET/CT). The late eval-
uation showed disease recurrence in 2/10 children. Com-
parison with other imaging modalities showed that the
reduction of FDG uptake during treatment preceded
morphological remission and was a predictor of treat-
ment response. Conclusions: Despite the heterogeneity
of this small group, our experience confirms the utility
of PET/CT in the management of LCH. Prospective
studies are warranted to evaluate prognostic significance
of PET/CT, especially with regard to the interim and
post-therapy scans.
OP498
Value of FDG PET-CT in the therapy evaluation
of Hodgkin’s lymphoma
M. Tuncel1, T. M. Kutluk2, P. Ö. Kıratlı1, B. G. Aydın2, B.
Erbaş1, C. Akyüz2; 1Hacettepe University, Department of Nu-
clear Medicine, ANKARA, TURKEY, 2Hacettepe University,
Department of Pediatric Oncology, ANKARA, TURKEY
Aim: 18 FDG PET-CT is a validated tool for staging
and therapy response evaluation of Hodgkin’s lymphoma
(HL). FDG PET-CT offers several quantitative and qual-
itative parameters for the evaluation of therapy response.
However the optimal parameter for prediction of therapy
response and prognosis is yet to be determined. In this
study we aimed to share our experience with FDG PET-
CT in the management of patients with HLMaterial and
method:18 FDG PET-CT was performed in 45 pediatric
Hodgkin’s lymphoma (mean age: 12.6±4, range: 4-20
yrs) at baseline (1) and after 2-3rd cycles of chemother-
apy (interim)(2). End of therapy imaging (3) was avail-
able in 30 patients. The median follow-up was 20
months (4-46). Images were interpreted according to
the Deauville 5-point score (DS). In addition, SUVmax
values of the dominant lesion, diameter (dia) of the le-
sion on CT was measured. Percentage change of
SUVmax and diameter values were also measured. The
ROC curves were obtained to determine the AUC values
and the optimal cut-off of parameters to predict relapse.
Results: Interim PET-CT was normal in 75% of patients.
DS 4-5 was in 23% of group. Six patients had progres-
sion or relapse during follow-up. SUV2 [0.5 ± 1.1(0-4)
vs 6.6 ± 7.9 (0-5.2), p=0.024], SUV3 [ 0.6 ±1.4 (0-5.2)
vs 8.38 ±9.7 (2-25), p=0.001], CT3 [7.6 ±6.3 (0-23) vs
25.4 ±22 (10-61), p=0.022] values were different in re-
mission and relapse sub-groups. The AUC values were
0.78 (p=0.025) for SUV2, 0.936 (p=0.02) for SUV3,
and 0.82 (p=0.026) for Dia3, respectively. The best
cut-off values were 2.7, 2.2, and 10.5 mm. with a sens.,
spec., PPV, NPV of 66.7%, 94.9%, 66.7%, 94.9 % for
SUV2, 80%, 88%, 95.6%, %57.1 for SUV3, and 80%,
70.3%, 33%, 95% for Dia3., respectively. DS 4-5 had
83.3% sens., 66.7% spec., 36.4% PPV, 94.6% NPV. PFS
(progression free survival) in patients with DS 1-3 was
better than in patients with DS 4-5 (Log-rank, p=0.004).
Patients with values below the cut-off of SUV2, SUV3
and Dia3, had longer PFS than patients with higher
values (Log-rank, p=0.0001, p=0.001, p=0.032). Conclu-
sion: FDG PET-CT was useful for the evaluation of
pediatric patients with HL. Interim DS 4-5 and high
SUV 3 were the best predictors of shorter PFS. Our
results should be confirmed in studies with larger num-
ber of patients.
OP499
Pediatric Hodgkin Lymphoma: visual
and semiquantitative analysis of interim 18FDG-PET/CT
in predicting treatment response and outcome.
C. Ferrari1,A. Niccoli Asabella1, M. Fanelli1, N.Merenda1, T.
Perrillo2, P. Muggeo2, F. De Leonardis2, N. Santoro2, G.
Rubini1; 1Nuclear Medicine Unit, D.I.M., University of Bari
“Aldo Moro”, Bari, Italy, Bari, ITALY, 2Department of Pedi-
atric Hematology and Oncology, University of Bari “Aldo
Moro”, Bari, Italy., Bari, ITALY.
Background and aim: Interim 18FDG-PET/CT (PET-2) helps
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predict outcome and tailor treatment in adults with
Hodgkin Lymphoma (HL). In contrast, PET-2 data on
pediatric HL are rare, with discordant results. Visual
analysis using Deauville Score (DS) was proposed to
assess PET response. However a 5-point scale did not
preclude inter-observer reproducibility issues. Alternative
approaches were developed to improve the accuracy and
reproducibility of PET-2, mainly based on PET semi-
quantitative parameters. We investigated the clinical use-
fulness of PET-2, evaluating both visual and semiquan-
titative analysis, in pediatric HL patients referred to a
single center study. Materials and Methods: 18FDG-
PET/CT was performed in 27 HL patients (age ≤16;
average age: 12.8; 15 male:12 female) at baseline
(PET-0), after 2 cycles of chemotherapy (PET-2) and at
the end of treatment. PET response assessment was car-
ried visually according to the DS, as well as semiquan-
titatively by use of absolute decrease in semiquantitative
parameters from PET-0 to PET-2 (ΔsumSUVmax0-2,
Δ∑SUVmean0-2, Δ∑MTV0-2, Δ∑TLG0-2) and the
corresponding Response Indexes (RI%∑SUVmax0-2,
RI%∑SUVmean0-2, RI%∑MTV0-2, RI%∑TLG0-2).
Clinical response assessment was performed according
the Cheson’s Revised Response Criteria considering pa-
tients as responders (R) or non-responders (NR). Mean
follow up was 23.3 months. T-student test for unpaired
groups was performed to compare PET semiquantitative
parameters between R and NR. Chi-square and Fisher
exact test were performed to evaluate the association
among categorical variables. The prognostic capability
of 18FDG-PET/CT was calculated by ROC analysis
and expressed as area under curve (AUC).Results: 5/27
(18%) patients were NR at the end of therapy based on
clinical outcome and, among them, 2 became R in
follow-up; another one remained NR while other two
died. Visual assessment was: DS=1 in 14/27 (52%),
DS=2 in 1/27 (3%), DS=3 in 4/27 (15%), DS=4 in
8/27 (30%) patients. Differences between R and NR
were statistically significant for Δ∑SUVmax0-2
(t=2.45, p=0.026) and almost statistically significant for
Δ∑SUVmean0-2 (t=1.88, p=0.071). No significant dif-
ference was found for the other parameters. Any associ-
ation among Deauville evaluation and outcome at the
end of therapy was found (Fisher exact test p=0.136).
The better AUCs resulted for Δ∑SUVmax0-2 (0.836;
cut-off<12.5, sensitivity 80%, specificity 91%). Conclu-
sions: Semiquantitative analysis seems to be more accu-
rate than visual analysis to interpret PET-2 and predict
outcome in pediatric HL patients. In particular,
Δ∑SUVmax0-2 appears to be the best PET parameters
in predicting therapy response assessment in pediatric
HL patients. The integration of Δ∑SUVmax0-2 with
DS, could achieve to the best PET-2 performance.
OP500
Prognostic Value Of Different F-18 FDG PET/CT
Quantitative Analytical Methodologies In Pediatric
Hodgkin’s Lymphoma
A. A. Kandeel1, O. M. Serry1, M. A. Alhussieny1, W. O.
Soliman2; 1Kasr Alaini center of Oncology and Nuclear Med-
icine NEMROCK, Cairo, EGYPT, 257357 Children cancer
Hospital, Cairo, EGYPT.
Introduction and aim of work: Assessment of the indi-
vidualized SUVs, PET-derived total metabolic tumor
volume (TMTV) and the product of both parameters,
termed total lesion glycolysis (TLG) in both initial and
interim PET if it carries a better PPV in early assess-
ment of response to therapy in pediatric Hodgkin’s lym-
phoma (PHL) patients. Patients and Methods: Retrospec-
tive analysis of PET/CT results was performed on 60
patients (42 males and 18 females; mean age 8.7±4.2
years). To assess the prognostic value of initial and in-
terim 18F-FDG PET/CT, different semi-quantitative pa-
rameters such as SUVmax, SUVmean, Total lesion gly-
colysis (TLG) and TMTV of all lesions using SUVmax
& mean including SUV2.5 and 40% of SUVmax as cut-
off values were calculated. Follow up for 24 months
from initial treatment with calculation of Disease Specif-
ic Survival (DSS). According to the recommendations of
Deauville criteria interim PET (PET2) results were iden-
tified into three groups; PET2-negative (PET2-ve),
PET2-positive (PET2+ve), and PET2-minimal residual
uptake (PET2-MRU), the cut-off between PET2+ve and
PET2-MRU was 3-4 in the 5-point scale. Results: Out
of the 60 interim-PET scans, 50 scans were considered
as PET2-ve (83.3%), 5 scans as PET2+ve (8.3%) and 5
scans as PET2-MRU (8.3%). The risk of the disease and
the visual scoring assessment were significantly correlat-
ed with patient’s outcome (whether Negative or Residu-
al/Relapse) (p <0.0001). Different results were obtained;
the most important were TLGmax2.5 (cut-off 2.5),
TLGmean2.5 (cut-off 2) and TMTV2.5 (cut-off 0.75
ccm) in interim PET showed the highest sensitivity,
specificity, PPV and NPV (58.5%, 97.9%, 87.5% and
90.3% respectively for the 3 parameters). Conclusion:
TLGmax2.5, TLGmean2.5 and TMTV2.5 are the most
relevant parameters for predicting the outcome in pa-
tients with PHL, and can add a significant prognostic
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insight to interim PET response assessment. This may
guide clinicians in their choice of therapeutic strategy.
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G -SPECT-I: a full ring high sensitivity and ultra-fast
clinical molecular imaging system with < 3mm resolution
F. J. Beekman1, F. van der Have2, M. C. Goorden1, P. E. B.
Vaissier1, J. van Roosmalen1, H. During3, B. Vastenhouw1;
1TUDelft, Delft, NETHERLANDS, 2MIlabs, Utrecht, NETH-
ERLANDS, 3MILabs, Utrecht, NETHERLANDS
AIM: We developed G-SPECT-I, a full ring stationary clinical
SPECT system designed to enable -for the first time- clinical
imaging with isotropic resolution below 3 millimeter and with
unique capabilities for low-dose studies and imaging of fast tracer
dynamics. The aim of this paper is to present its initial results.
METHODS &MATERIALS: G-SPECT-I is based on a station-
ary ring consisting of nine large field-of-view cameras with 595 ×
472 mm NaI crystals, a 3D stage that allows optimal sampling
during scanning, and an interchangeable nonagon-shaped colli-
mator containing 54 pinhole apertures and with a bore diameter
of 398 mm that makes the system suitable for brain, extremity or
pediatric imaging. A proprietary graphical user interface
(MILabs, Utrecht, The Netherlands) enables preselection of the
field-of-view in three dimensions through optical images of the
patient. This allows focusing the pinholes on the desired area of
interest, thereby maximizing sensitivity and sampling density for
the imaging task at hand. SPECT images are obtained from list-
mode data usingmodel-based 3D pixel-based OSEM reconstruc-
tion that utilizes PSF models of system blurring and position-
dependent sensitivity to increase resolution. Using a Derenzo
hot rod phantom containing 45MBq Tc-99m, G-SPECT-I was
compared to a Siemens Symbia equippedwith LowEnergy High
Resolution (LEHR) collimators and using Flash3DOSEM recon-
struction with resolution recovery. Scan time on both systems
was 15 minutes. RESULTS: The smallest hot rods resolved by
G-SPECT-I had a diameter of 3 mm while the Siemens Symbia
recovered only 7 mm rods. Peak sensitivity of G-SPECT-I was
415 cps/MBq compared to 182 cps/MBq for the Symbia. With
G-SPECT-I dynamic imaging with time frames of <10s can be
performed for focused scans and ~30s for imaging the entire
brain. CONCLUSION: Initial G-SPECT-I images show a excel-
lent isotropic resolution. Given the field-of-view available for this
prototype and its unique potential for fast dynamic imaging first
ground-breaking applications are expected in brain, bone and
pediatric imaging, especially since -next to very high resolution-
very fast imaging will be possible.
OP502
Double-Sided Readout with Digital Photon Counters
Enables Millimeter Spatial Resolution and 150 ps Time
Resolution in 32 mm x 32 mm x 22 mmMonolithic
LYSO:Ce Crystals
B. J. Peet, G. Borghi, V. Tabacchini, D. R. Schaart; Delft
University of Technology, Delft, NETHERLANDS
Reducing PET scanning times and radiation exposure
while improving image quality and quantitative accuracy
requires detectors with better detection efficiency, spatial
resolution, and time resolution, all at the same time.
Digital photon counter (DPC) arrays are fully digital,
solid-state single-photon sensors. DPC arrays are almost
transparent to 511 keV gamma quanta, opening up new
degrees of freedom in PET detector design. This work
demonstrates the improvement in spatial and time reso-
lution that can be obtained by reading out a monolithic
LYSO:Ce crystal by means of two DPC arrays, coupled
to its front- and back surface in so-called dual-sided
readout (DSR) configuration, in comparison to conven-
tional back-side readout (BSR).DPC arrays consisting of
8 x 8 DPC pixels and having a total area of 32 mm x
32 mm were optically coupled to commercially available
LYSO:Ce crystals having dimensions of 32 mm x
32 mm x 22 mm. Both BSR or DSR configurations
were tested. The spatial-, time- and energy-resolutions
of both configurations were measured. In conventional
BSR configuration, a spatial resolution of ~1.5 mm
FWHM and a DOI resolution of ~4 mm FWHM was
obtained, averaged over the entire detector area. In
DSR configuration, a spatial resolution close to 1 mm
FWHM was achieved in combination with a depth-of-
interaction (DOI) resolution of < 2.5 mm FWHM. The
coincidence resolving time (CRT) in BSR and DSR con-
figurations were ~225 ps FWHM and ~150 ps FWHM,
respectively. Compared to BSR, the DSR configuration
significantly improves the time-, spatial- and DOI reso-
lutions of the detector. Monolithic scintillator detectors
with dual-sided DPC readout appear particularly promis-
ing for PET applications in which high spatial resolu-
tion, high time resolution, and high detection efficiency
all are crucial, such as in neurology and pediatric med-
icine. This work was supported in part by EU FP7
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project SUBLIMA, Grant Agreement No 241711 (www.
sublima-pet-mr.eu).
OP503
First measurements and Monte Carlo simulations
of a BGO-PMTs blocks array intended for continuous
energy spectrum tomography in bremsstrahlung imaging
M. Hesse1, S. Walrand1, R. Wojcik2, R. Lhommel1, F. Jamar1;
1Université Catholique de Louvain, Brussels, BELGIUM,
2Ray Visions, Inc, Yorktown, VA, UNITED STATES
Rationale: A conventional Anger camera is not adapted to
bremsstrahlung imaging: high energy x-rays may fall into the
acquisition energy window after scattering in the collimator
septa and also in the PMTs after going through the NaI crystal.
This increases noise, limits the contrast, and reduces the quan-
tification accuracy. The aim of this study is to experimentally
validate previous Monte Carlo (MC) simulations (Gate-
Geant4) showing that using BGO-PMT blocks with a high
energy pinhole collimator greatly reduces the scattering con-
tamination and enables the use of an extended energy window
ranging from 50 to 400 keV. This would allow the develop-
ment of a continuous energy spectrum tomography (CET) sys-
tem.Method: A simple readout board was developed to handle
an array of 2x3 BGO-4PMTs blocks coming from a retired
PET Exact HR+ (CTI, Knoxville, TN). The energy spectrum
of a 137Cs (662 keV) point source was acquired with this
simple setup (without collimator or lead shielding). The spec-
trum was compared to the one simulated by MC (Gate-
Geant4), and to the one acquired using a Triad XLT20
(Trionix, Twinsburg, OH) without collimator, equipped with
a ½”-thick NaI crystal. BGO blocks pixelization (4.3x4.0mm
pixels, 0.4mm-thick reflecting TiO2 separators) was modelled
in the MC simulation while the energy resolution of the BGO-
4PMTs block was approximated by a convolution with the
sum of 2 Gaussians with energy-dependent FWHM . Results:
The readout board was able to clearly identify all the BGO
pixels. The energy spectrum acquired with the BGO setup
was well reproduced by the MC simulations and displayed a
scatter contamination in the [50-400] keV energy window 5
times as low as that obtained with the NaI based conventional
camera Triad XLT20. The energy resolution of the BGO setup
was measured as 17% at 662 keV.Conclusion: First measure-
ments of the energy spectrum of a 137Cs point source on a
simple setup consisting of a 2x3 BGO-4PMTs blocks array,
confirm the advantage of BGO crystals over conventional NaI
based camera in bremsstrahlung imaging by strongly reducing
the scatter contamination in the energy window of interest
([50-400] keV). A dual head mobile CET prototype using a
front-plate pinhole collimator is under development. This ded-
icated bremsstrahlung CET system will enable the dose
optimization directly inside the catheterization room during
90Y liver radio-embolization which should result in an im-
provement of patient outcome.
OP504
Gamma-cube and X-cube: A New Scanner Generation
for Benchtop Small Animal SPECT/CT
R. VanHolen, K. Deprez, B. Vandeghinste, S. Vandenberghe;
Ghent University, Gent, BELGIUM
The first generation small animal imaging systems offer
molecular 3D imaging at sub millimetre spatial resolution
with SPECT and sensitivities in the order of several per-
cents using PET. These systems often have a large foot-
print because they are based on large to medium-size
detector technology, adopted from clinical scanners. The
next generation of systems aims at (i) improved image
quality, (ii) flexibility regarding installation and (iii) ease
of operation. Our group has been working on detector
hardware and collimator designs to perform SPECT and
CT imaging at a footprint of 1/4th of a square meter.
Using additive manufacturing of tungsten, lofthole colli-
mators and high-resolution detectors, we have designed
and constructed a benchtop microSPECT system. On the
other hand, using state-of-the-art CMOS X-ray detector
technology, a micro-focal X-ray tube and iterative image
reconstruction, we have designed and constructed a
benchtop microCT system. SPECT benchmarking has
been performed for the general-purpose mouse collimator
using performance measurements previously used to ob-
jectively determine spatial resolution, sensitivity, unifor-
mity and contrast-to-noise. CT quality control has deter-
mined spatial resolution, low-contrast detectability and
whole-body mouse imaging time. Results show that
SPECT spatial resolution is below 700um measured using
a line source. Image reconstruction from a hot-rod reso-
lution phantom separates all rods from 700 micron diam-
eter and larger. Point source sensitivity is above 1200cps/
MBq in a simultaneous cylindrical FOV of 3 cm diameter
and 1 cm height. Differential uniformity is 23% while
contrast to noise curves are in line with current commer-
cial systems’ performance. CT imaging at 80um is possi-
ble with a soft tissue contrast that outperforms current
systems. Whole body imaging of a mouse is possible
within 30 seconds, using compressive sensing for dose
reduction. All electronics and reconstruction servers are
within a cube of 54x54x54cm3 system and the systems
can be easily controlled using a tablet or a laptop. The
small animal bed supports anesthesia, ECG, respiratory
monitoring and heating. It can easily be transferred be-
tween both systems to obtain multi-modal SPECT-CT
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images. In conclusion, we have developed a SPECT/CT
imaging system that is competitive with the state-of-the-
art but that can be installed in any certified environment
on a table top.
OP505
Left ventricular function assessment using 123I/99mTc
dual isotope acquisition with two semi-conductor cadmium
zinc telluride (CZT) cameras: a dynamic cardiac phantom
study
T. Blaire1,2, A. Bailliez1,2, D. Legallois3, D. Agostini3, A.
Manrique1,3; 1EA 4650, Normandy University, Caen,
FRANCE, 2Nuclear Medicine Department, IRIS, Polyclinique
du Bois, Lille, FRANCE, 3Nuclear Medicine Department,
CHU Cote de Nacre, Caen, FRANCE
Objectives: New Cadmium-zinc-telluride (CZT) cameras dra-
matically increased sensitivity and energy resolution. Combin-
ing the use of 123I-metaiodobenzylguanidine with 99mTc
myocardial perfusion agents could allow simultaneous assess-
ment of myocardial perfusion, function and sympathetic inner-
vation in patients with dilated cardiomyopathy. This phantom
study compared the evaluation of left ventricular function in
dual isotope conditions using two CZT cameras (DNM 530c,
GE Healthcare and DSPECT, Spectrum Dynamics). Materials
and methods: The Amsterdam gated (AGATE) dynamic car-
d i a c phan tom (Vande rw i l t t e chn ique s , Box t e l ,
The Netherlands) was successively filled with a solution of
123I alone, 99mTc alone, and a mixture of 123I and 99mTc.
A total of 24 datasets on each CZTcamera were acquired using
both energy windows (99mTc or 123I), with the following
parameters: 10-minute acquisition, contraction rate of succes-
sively 70 and 85 bpm and ejection fraction (EF) set to 33%,
45% and 60%. End-diastolic (EDV), end-systolic (ESV) vol-
umes, ejection fraction (EF), regional wall thickening and mo-
tion (17-segment model) were assessed using QGS. A linear
model analysis included the effect of camera, acquisition type
(single vs. dual isotope) and isotope (123I vs. 99mTc) and the
interaction between isotope and camera type. Results: Myo-
cardial volumes using single (123I, 99mTc) and dual isotope
(reconstructed using both 123I and 99mTc energy windows)
acquisitions were respectively for EDV (mL): 89±24 vs. 89
±25 vs.91±24 vs. 90±24 for DNM and 64±12 vs. 81±20 vs.73
±17 vs. 77±18 for DSPECT, ESV (mL): 41±1 vs. 41±1 vs. 42
±1 vs. 42±1 for DNM and 29±4 vs. 35±2 vs. 31±3 vs. 34±3 for
DSPECT, EF (%): 52±12 vs. 51±11 vs. 51±12 vs. 51±11 (p=
NS) for DNM and 53±13 vs. 54±12 vs. 55±13 vs. 54±13 (p=
NS) for DSPECT, regional thickening (%): 48±21 vs. 46±20
vs. 46±21 vs. 45±20 for DNM and 38±19 vs. 43±19 vs. 43±20
vs. 42±19 for DSPECT, regional motion (mm): 6.8±2.5 vs. 6.6
±2.4 vs. 6.7±2.5 vs. 6.6±2.4 for DNM and 6.3±2.6 vs. 6.9±2.6
vs. 7.0±2.8 vs. 6.8±2.7 for DSPECT. There was a significant
difference between DSPECT and DNM for EDV (p<0,009)
and ESV (p<0,001) but not for LVEF (NS), regional motion
(NS) or regional thickening (NS). Using the DSPECT, there
was a significant difference for ESV between 99mTc and 123I
acquisitions (p<0,007). Conclusion: In this phantom study, the
two CZT cameras (DNM 530c and DSPECT) yielded signif-
icant difference between single and simultaneous dual isotope
acquisition for ESV and EDV but yielded no significant dif-
ference between LVEF, regional motion and thickening.
OP506
Is there mutual interference between preclinical APD-PET
and 3T MR in a sequential configuration ?
J. M. VRIGNEAUD1, P. M. WALKER2, B. BARBIER3, A.
CAMACHO4, A. OUDOT1, B. COLLIN1, F. BRUNOTTE1,5;
1Centre Georges-François Leclerc, DIJON, FRANCE, 2LE2i
CNRS UMR 5158, Faculty of Medicine, DIJON, FRANCE,
3Trifoil Imaging, DIJON, FRANCE, 4MR Solutions,
GUILDFORD, UNITED KINGDOM, 5LE2i CNRS UMR
5158, Faculty of Medicine, Dijon, FRANCE
AIM: The LabPET®/MRI system is a new preclinical imager
with sequentially-acquired PET/MR scans capabilities. The
dual modality system is composed of the digital APD-based
labPET4 subsystem (Trifoil Imaging), coupled with a
cryogen-free superconducting 3.0T MRI subsystem (MR so-
lutions). The objective of the study was to evaluate the perfor-
mance characteristics of each subsystem to identify the pres-
ence of mutual interference between the two modalities. MA-
TERIALS ANDMETHODS: For the PET subsystem, NEMA
NU-4-2008 performance characteristics were conducted with
static magnetic field switched on (ON) and off (OFF). The
following tests were performed: spatial resolution, counting-
rate performance, scatter fraction, sensitivity and image qual-
ity. A Jaszczak phantom was also acquired at three different
activity levels. For the MR subsystem, machine performance
was evaluated with the PET subsystem electronics ON and
OFF, as well as a third configuration in which the two subsys-
tems were uncoupled. Gadolinium-doped flood field and res-
olution phantoms were used, and tests were carried out using a
standard T1-weighted sequence with TR/TE 1000/20ms, ma-
trix 256x256, FoV 40mm, slice 1mm. SNR, non-uniformity,
circularity, ghosting, spatial resolution and phase/frequency
profiles were quantified. RESULTS: For the PET subsystem,
no significant differences were identified between the ON and
OFF configuration for the spatial resolution, Jaszczak phan-
tom and counting rate performance tests. However, peak ab-
solute sensitivity was found to be 0.87% in the ON configura-
tion versus 0.93% in the OFF configuration and sensitivity
performance was decreasing with increasing ambient
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temperature. Using the NEMA phantom, image uniformity
was 7.9%/7.5% and spill-over ratios of 13.1%/14.2% and
24.0%/24.3% were obtained in water and air (ON/OFF). For
the MR subsystem, no significant differences were observed
among the experimental conditions. SNRwas 49.7±0.5, image
signal non-uniformity 6.0±0.1%. and the ghosting coefficient
0.0025±0.0001. No differences in phase/frequency profiles
were observed. CONCLUSION: Whereas APD are known
to be insensitive to magnetic field variations, their gain factor
exhibits a strong dependence with temperature. In the operat-
ing configuration of the LabPET®/MRI system (ON), there is
a slight increase in ambient temperature (+1°C) compared to
the LabPET in the OFF configuration. This slight difference
might explain the observed PET sensitivity variation of up to
6% when the PET detectors are in the same calibration state.
Irrespective of the experimental conditions, the performance
of the MRI subsystem did not appear to be altered by the
physical and electrical presence of the PET subsystem.
OP507
Design of an Optimized Multi-pinhole Collimator
for Brain SPECT
L. Chen, G. S. Mok; University of Macau, Taipa, MACAO
Aim: SPECT imaging on dopaminergic system is a powerful
tool for diagnosing and staging Parkinson’s disease (PD).
Since pinhole SPECT provides superior trade-off between res-
olution and detection efficiency as compared to conventional
low energy high resolution (LEHR) parallel-hole collimator
for imaging small field-of-view (FOV), we propose to develop
and evaluate a multi-pinhole (MPH) collimator for PD brain
imaging based on a clinical SPECT/CT scanner. Materials and
methods: We set the target resolution to be 7.27 mm which is
the same as the resolution of LEHR at imaging distance of
10.5 cm, and the FOV was set to be 12 cm which is large
enough to cover the whole striatum and substantia nigra re-
gion. The constraints for system optimization include maxi-
mum and minimum detector to center-of-FOV (CFOV) dis-
tances for the scanner which were 34.5 cm and 13 cm respec-
tively, and the maximum and minimal imaging distances
which were 34 cm and 12.5 cm respectively. Based on the
work from Nillius et al. and the system constraints, we opti-
mized the detection efficiency and calculated the design pa-
rameters. All pinholes were knife-edge and tilted to the CFOV.
We then evaluated the imaging performance of the MPH and
standard LEHR collimators using the digital Human Brain
Phantom and analytical simulations. One hundred and
twenty-eight noise-free projections were generated using 3D
MPH/LEHR projectors over 360 degrees and reconstructed
using the 3D MPH/LEHR OS-EM method with up to 300
updates. Normalized mean square errors (NMSE) were
measured over the putamen region on the reconstructed im-
ages as compared to the original phantom. Results: The opti-
mized design parameters were 20 pinholes with aperture size
of 3.6 mm, acceptance angle of 56.4 degrees, 14.8 cm colli-
mator length and 12.7 cm imaging distance. The detection
efficiency of the proposed 20 pinholes collimator had 663%
improvement as compared to the LEHR collimator. Simula-
tions showed that there were no substantial artifacts observed
in the MPH images and the putamen region can be clearly
delineated. The NMSE for the MPH noise-free reconstructed
images was comparable to that of the LEHR. Conclusion: The
MPH collimator can provide six-fold detection efficiency at
the same resolution compared with LEHR collimator, which
can be traded for reduced acquisition time or lower injection
dose. MPH SPECT for brain imaging is feasible and has the
potential to improve PD diagnosis.
OP508
Design of shields for counting Cr-51 EDTA plasma
samples from patients having a Tc-99m imaging study
on the same day
N. Bird, D. Gillett; Addenbrooke’s Hospital, Cambridge,
UNITED KINGDOM
Aim: Patients are often referred for both a GFR and either a
MUGA or a DMSA study. Currently, if both studies are per-
formed on the same day, either the 4 hour GFR test with Cr-51
EDTA is completed before injecting the Tc-99m radiopharma-
ceutical or the two studies are performed concurrently and the
plasma samples for the GFR are left for a few days for the Tc-
99m to decay before counting. This is because a high activity
of Tc-99m in the samples causes pileup into the Cr-51 window.
The aim of this study was to devise a method whereby the two
studies can be performed concurrently and the plasma samples
counted the same day. Methods: Plasma samples from patients
were analysed to determine the maximum Tc-99m activity
likely to be present in samples when counted. Shields were
designed to surround the counting tubes to sufficiently atten-
uate the 140 keV gammas to prevent pileup and dead-time
problems, whilst limiting the reduction in sensitivity for
320 keV gammas from Cr-51. When using the shields the
counting time was optimised so there should be no increase
in uncertainty from counting statistics. 12 Samples from pa-
tients containing both isotopes were counted with the shields
and after allowing the Tc-99m to decay. Results: The maxi-
mum Tc-99m activity found in the plasma samples was 10
kBq. It was determined that optimally shields would be made
from 1 - 1.5 mm of lead. A set of 1.5 mm thick lead shields
were made, the transmission for Cr-51 is 44 % and for Tc-99m
is less than 1.5 %. These were found to be sufficient to erad-
icate the problem of pileup from up to 40 kBq of Tc-99m.
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There was no increase in uncertainty from counting statistics
when using the shields when counting time was increased to
5000 seconds per sample from 1500 seconds. There was good
agreement between the concentrations of Cr-51 measured with
shields and after decay of the Tc-99m.ConclusionUsing the
shields makes it possible to count plasma samples for Cr-51
EDTA containing Tc-99m from other imaging tests without
compromising the GFR test results. This has the advantage
of reducing the time that patients need to remain in the Nuclear
Medicine department without compromising how soon results
are available. This can be particularly important in cancer pa-
tients being worked up for chemotherapy.
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OP509
Blunted striatal dopamine release in cannabis dependence
E. van de Giessen1,2, J. Weinstein1, C. Cassidy1, M. Haney1,
M. Slifstein1, A. Abi-Dargham1; 1Columbia University Col-
lege of Physicians and Surgeons/New York State Psychiatric
Institute, NewYork, NY, UNITED STATES, 2AcademicMed-
ical Center, Amsterdam, NETHERLANDS
Aim: The active component of cannabis (THC) induces a do-
pamine release in the striatum. Dependence on other dopamine
enhancing substances of abuse is associated with blunted
striatal dopamine transmission. The aim of this study is to
measure striatal dopamine release capacity in a carefully se-
lected sample of severely cannabis dependent (CD) subjects,
who did not use other substances of abuse (including nicotine)
and had no other major psychiatric illnesses. Materials and
Methods: Eleven CD subjects and twelve healthy control
(HC) subjects completed two positron emission tomography
scans with [11C]-(+)-PHNO, before and after oral administra-
tion of d-amphetamine. Percent change in [11C]-(+)-PHNO
binding after amphetamine (change in nondisplaceable bind-
ing potential, ΔBPND) was compared between groups. CD
subjects stayed inpatient for 5-7 days prior to the PET scans
to control abstinence. Correlations with psychopathological
and neurocognitive parameters were examined. Results: CD
subjects used marijuana for 29.1 ± 3.6 days during the month
prior to inpatient admission and used an estimated 79.2 ± 72.7
grams during this month. CD subjects had significantly lower
ΔBPND in the striatum (CD: -18.4 ± 4.3%, HC: -24.9 ± 4.5%,
p = 0.002, effect size 1.48), specifically in the associative
striatum (CD: -14.6 ± 4.1%, HC: -21.1 ± 5.2%, p = 0.003)
and sensorimotor striatum (CD: -24.9 ± 6.1%, HC: -32.3 ±
4.2%, p = 0.003), and in the globus pallidus (CD: -13.0 ±
6.8%, HC: -22.6 ± 9.5%, p = 0.012, effect size 1.16). Lower
dopamine release in the associative striatum correlated with
more negative symptoms and higher inattention scores in CD
subjects and with poorer working memory and probabilistic
category learning performance in both CD and HC subjects.
Conclusion: Striatal dopamine release is lower in the associa-
tive striatum and sensorimotor striatum in severely cannabis
dependent subjects with no psychiatric comorbidities includ-
ing any other substance abuse. The lower dopamine release in
the associative striatum is related to more psychopathology
and reduced neurocognitive performance in cannabis
dependence.
OP510
Effect of chronic social defeat on neuroinflammation
in rats: a PET imaging study with [11C]PK11195
P. Kopschina Feltes1, E. F. J. de Vries1, C. M. Moriguchi
Jeckel2, E. Kurtys1, P. Michel1, R. A. J. O. Dierckx1, J.
Doorduin1; 1University of Groningen, Groningen, NETHER-
LANDS, 2Pontifícia Universidade Católica do Rio Grande do
Sul, Porto Alegre, BRAZIL
Aim: Stressful life events are considered to be predisposing
factors for the onset of psychopathologies such as anxiety and
depression. Psychosocial distress may disrupt fundamental in-
teractions between the immune system and the brain, ultimate-
ly leading to mood and behavior alterations. In this context, it
is hypothesized that chronic stress might trigger neuroinflam-
mation. The present study evaluated whether repeated social
defeat leads to neuroinflammation, using PET imaging.
Methods: From day 0-4 of the experiment, 8 weeks old male
Wistar rats (intruders) were placed in the home cage of an
aggressive dominant male Long Evans rat (resident) for a total
of 60 minutes each day. The intruders were attacked and
defeated by the residents as indicated by adopting a submis-
sive posture for at least 3 seconds. For the remaining time after
submission, the intruders were placed in a wire-mesh cage.
Control rats were exposed to a new cage without a resident,
considering the same time points as their experimental coun-
terparts. Behavioral alterations were assessed through a su-
crose preference test at a concentration of 1% and an open
field test, on day -2 and 5. On the 11th experimental day, an
i.v. injection of [11C]PK11195 was performed, followed by a
30-min static small animal PET scan 45 min after injection.
Differences between groups were tested using an independent
samples t-test on the standardized uptake value obtained from
volume of interest analysis. Within subject differences in be-
havioral tests were tested through a paired t-test. A p-value
<0.05 was considered statistically significant. Results: On
day 5, the percentage of preference for sucrose solution was
significantly decreased (21%, p<0.001) in defeated rats,
whereas no difference was found in control rats. In the open
field test, defeated rats had a significantly lower total distance
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moved (32%, p<0.001), while no statistical difference was
found in the control group between day -2 and 5. An increase
in uptake of [11C]PK11195 was found in the orbitofrontal cor-
tex (33%, p=0.006), cerebellum (26%, p=0.032), insular cor-
tex (22%, p=0.016), medial/prefrontal cortex (21%, p=0.007)
and hippocampus (21%, p=0.047) of defeated rats on day 11,
when compared to control rats. Conclusion: Repeated social
defeat resulted in depressive-like behavior. In addition, neuro-
inflammation, as shown with [11C]PK11195 PET, was found
in brain regions associated with depression. These results sug-
gest that neuroinflammation can arise from chronic exposure
to stress.
OP511
Dopamine transporter availability in alcohol-dependent
patients before and after deep repetitive transcranial
magnetic stimulation: a 123I-FP-CIT Study
D. Di Giuda1, F. Cocciolillo1, I. Bruno1, I. Marini1, M.
Zollino1, A. Ferrulli2, M. Antonelli2, G. Vassallo2, A.
Mirijello2, G. Addolorato2, A. Giordano1; 1Nuclear Medicine
Institute, Università Cattolica del Sacro Cuore, Roma, ITALY,
2Internal Medicine Institute, Università Cattolica del Sacro
Cuore, Roma, ITALY
AIM: Experimental and neuroimaging studies suggest a
striatal dopaminergic dysfunction in alcohol dependence. Re-
petitive transcranial magnetic stimulation (rTMS) is a new and
promising treatment for substance addiction. Preliminary data
in alcohol-dependent patients showed that rTMS of the dorso-
lateral prefrontal cortex increases dopamine release in the stri-
atum, reducing craving. We assessed DAT availability in ac-
tively drinking alcoholics before and after deep rTMS by 123I-
FP-CIT SPECT, investigating changes in DAT levels and clin-
ical parameters. MATERIALS&METHODS:We enrolled 14
untreated patients (12 M, mean age: 49 ± 10 years) with a
DSM-IV diagnosis of alcohol dependence in an active drink-
ing phase and without a major psychiatric disorder. After base-
line SPECT scan, 11/14 patients were randomised to a real
rTMS (n=5) or a sham stimulation (n=6). Each patient
underwent 12 rTMS sessions for one month and a second
SPECT scan was carried out at the end of treatment. Severity
of alcohol dependence and craving were assessed before and
after rTMSwith the Alcohol Dependence Scale, Penn Alcohol
Craving Scale and Obsessive Compulsive Drinking Scale.
Anxiety and depressionwere evaluated by the State-Trait Anx-
iety Inventory and Zung Depression Self-Rating Scale. The
alcohol Timeline Follow-back (TLFB) was used to estimate
daily drinking. A 123I-FP-CIT template was generated with
images of 20 healthy subjects (HS, 12 M, mean age: 47±16
years). Patient scans were spatially normalised to the 123I-FP-
CIT template by SPM8. The analysis was performed using
VOIs selected from a digital atlas; VOI mean activity concen-
tration was obtained through the Marsbar toolbox and Specific
Binding Ratios (SBRs) were calculated in the caudate nuclei
and putamina. RESULTS: At baseline, alcoholics showed
higher SBRs in the caudate nuclei and putamina (p<0.05) in
comparison with HS. An inverse correlation was found be-
tween SBR in the left caudate and anxiety levels (p<0.05).
After treatment, patients submitted to real rTMS had a reduc-
tion in SBRs and differences were no longer detected in com-
parison with HS. Conversely, patients undergoing sham stim-
ulation showed higher SBRs compared with HS (p<0.05) also
in the SPECT scan after treatment. When considering TLFB
data, a significant reduction in alcohol intake (p<0.05) was
detected only in patients submitted to real rTMS. CONCLU-
SION: Our preliminary data show that striatal DATavailability
was increased in alcohol-dependent patients, supporting the
assumption of a dysfunctional dopaminergic system. Notwith-
standing the small sample, an SBR “normalization” and a re-
duction in alcohol intake after real rTMS could suggest clinical
efficacy of deep rTMS.
OP512
Regional cerebral blood flow changes in acute
and transient psychotic disorders
R. Petrovic1, A. T. Golubic1, M. Rojnic2, T. Samardzic1; 1De-
partment of Nuclear Medicine and Radiation Protection, Uni-
versity Hospital Center Zagreb, Zagreb, CROATIA, 2Clinical
Department of Psychiatry, University Hospital Center Zagreb,
Zagreb, CROATIA
Aim: The aim of this study was to assess and evaluate brain
perfusion single-photon computerized tomography (SPECT),
as part of a continuing effort to understand the pathophysiolo-
gy of the brain in acute and transient psychotic disorders
(ATPD) and to correlate any abnormalities in the regional
blood flow with psychopathology of these disorders. They
present as an acute psychosis associated with acute stress, with
sudden onset and polymorphous symptomatology, including
psychotic symptoms such as hallucinations and delusions.
Method: Twenty (11 male, 55%) newly referred patients with
an ATPD diagnosis underwent regional cerebral blood flow
(rCBF) examination brain SPECT. Their mean age was 30.5
years, range 18-52. Brain rCBF SPECT data from age- and
sex-matched healthy volunteers were used as controls. Patients
were diagnosed following ICD-10 criteria and were off psy-
choactive medication. SPECT scans were started 30 minutes
after administration of 740 MBq of 99mTc-HMPAO in resting
state, eyes closed and with low ambient noise. Tomograms
were normalized to the mean brain activity and analyzed visu-
ally by two independent observers, unaware of clinical diag-
nosis. Results: Majority of our patients, 85%, had brain
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perfusion changes, from small regions of decreased perfusion
to widespread global cortical hypoperfusion and disseminated
cerebral blood flow defects. Seven patients had globally
hypoperfused cerebral cortex. In four patients hypoperfusion
was found exclusively in only one region, three left frontal, 1
right temporal. Thirteen patients (76%) had two or more
hypoperfused areas, 11 in the prefrontal lobes (55%), mostly
in the left lobe (n=6) and bilaterally (n=4). Seven patients had
hypoperfusion reported in temporal lobes, four in the right
hemisphere and two bitemporal. Additional, detailed neuro-
logic and laboratory examinations, including EEG and CT,
were within normal limits in all patients. Conclusions: Com-
pared with the normals, majority of patients with ATPD were
characterized by abnormal rCBF, predominantly affecting pre-
frontal cortex and the temporal lobes, and, in some cases,
whole cerebral cortex. Different factors might explain areas
of decreased rCBF, in part as the consequence of neurophys-
iological changes which reflects dysfunction in neuronal ac-
tivity responsible for psychotic symptoms such as hallucina-
tions and delusions, and/or the result of some associated symp-
toms such as associated acute stress. However, perfusion im-
aging findings may be used as an additional diagnostic tool to
guide psychiatrists searching for a definite diagnosis.
OP513
Pedophilia and Child Sexual Abuse: Evidence for Altered
Serotonergic Function in Pedophilic Offenders
G. Berding1, G. Tenbergen2, F. Wilke3, F. Paesler1, L.
Geworski3, F. M. Bengel1, T. H. C. Kruger2; 1Department of
Nuclear Medicine, Hannover Medical School, Hannover,
GERMANY, 2Clinic of Psychiatry, Socialpsychiatry and Psy-
chotherapy, Hannover Medical School, Hannover, GERMA-
NY, 3Department of Medical Physics and Radiation Protec-
tion, Hannover Medical School, Hannover, GERMANY
Aim: Altered serotonin transporter (SERT) function has been
demonstrated in subjects with higher impulsivity [1,2]. Re-
duced SERT function has been described in anxiety and de-
pression disorders [3,4], which are typically associated with
risk avoidance. The purpose of this study was to test the hy-
pothesis of altered SERT function and impulsivity in
paedophilic patients with histories of Child Sexual Abuse
(CSA). Materials and methods: In this study 26 paedophilic
patients (11 with CSA, 15 without) and 17 age matched
healthy control subjects were enrolled. In each patient anxious
and depressive symptoms were rated with the Hamilton Anx-
iety Scale (HAM-A) and Hamilton Depression Scale (HAM-
D). To assess impulsive decision-making, the Information
Sampling Task (IST) from the Cambridge Neuropsychological
Test Battery (CANTAB) was used. I-123-ß-CIT SPECT
(using a dual head SPECT/CT) was performed 4 hours post
injection for measurement of SERT. Data was spatially nor-
malized based on a template in Talairach space. Volumes of
interest from theWFU pick-atlas were used to extract counts in
regions with specific binding (thalamus, hypothalamus, mid-
brain and pons) and a cortical reference region for calculation
of binding ratios. Results: SERT binding ratios for the mid-
brain region in paedophilic patients with CSA (2.00±0.12)
were significantly (p=0.0477) elevated compared to the con-
trol subjects (1.88±0.14). In patients without CSA none of the
regions SERT binding ratios were significantly different com-
pared to control subjects. In patients with CSA a significant
negative correlation between SERT binding in the thalamus
and HAM-A score (r=-0.90, p=0.0001) as well as HAM-D
score (r=-0.82, p=0.0022) was observed. Furthermore, a sig-
nificant positive correlation between SERT binding in the pons
and errors in the IST was found (r=0.64, p=0.0343). Conclu-
sion: Our data indicate that increased SERT bindingmight be a
characteristic of paedophilic offenders against children. In-
creased SERT binding in these patients was especially associ-
ated with fewer anxiety symptoms on the HAM-A and more
impulsive decision-making as measured by the IST. These
findings underline the relevance of the serotonergic system
in paedophilia and child sexual abuse. References[1] Lesch
et al. (2000) Behavioral Sciences and the Law, 18:581-604.
[2] Rylands et al. (2012) Biol Psychiatry, 72:1004-11. [3] Oliv-
ier et al. (2008) Neuroscience, 152:573-84. [4] Staley et al.
(2006) Biol Psychiatry 59:40-7.
OP514
Altered Regional Cerebral Blood Flow in Chronic
Whiplash Associated Disorder
D. Vállez Garcia1, A. Otte2, A. T. M. Willemsen1, R. A. J. O.
Dierckx1, J. Doorduin1, G. Hostege3; 1University Medical
Center Groningen, Groningen, NETHERLANDS, 2Offenburg
University of Applied Sciences, Offenburg, GERMANY,
3University of Queensland, Brisbane, AUSTRALIA
Aim:Whiplash trauma in one of the most frequent consequences
ofmotor vehicle accidents.While initial symptoms resolvewithin
a few weeks in many cases, some patients develop persistent
symptoms that include pain, headache, visual, and/or psycholog-
ical disturbances, termed as Whiplash-associated disorder
(WAD). Although there is evidence supporting tissue lesion and
central hyperexcitability, the pathophysiology is not well under-
stood. In the current study, possible alterations in the regional
cerebral blood flow (rCBF) were explored with PET imaging.
Material and Methods: Twelve female patients diagnosed with
WAD grade I/II were included 5±2 years after the accident, in
addition to eight healthy matched volunteers. PET scans (ECAT
HR+, Siemens) were acquired after injection of 500 MBq
[15O]H2O for rCBF measurement. During acquisitions the
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volunteers received a non-painful electrical stimulation of the
neck (DS7A, Digitimer). Sensitivity thresholds were individually
determined. Four condition were used: rest state, placebo-like
state (current was expected but not generated), stimulation above
perception threshold, and stimulation below pain or muscular
contraction. These conditions were repeated three times, resulting
in twelve scans. All participants completed a neurological inter-
view, the Hospital Anxiety and Depression Scale, the Neck Dis-
ability Index (NDI), the Whiplash Disability Questionnaire, and
rated pain on the visual analogue scale. Voxel-based analysis was
performed on the scans with SPM8 in combination with SwE
toolbox to account for repeated measurements. Level of signifi-
cance was set to p<0.005 uncorrected, with an extent threshold of
100 voxels. Correlations between the rCBF of WAD patients in
the significant clusters and the scores from questionnaires were
analyzed using the Generalized Estimating Equations model in
SPSS, with p<0.05 considered significant (Bonferroni-Holm).
Results: In all the questionnaires WAD patients scored higher
(p<0.001) than healthy volunteers. No significant differences in
rCBF were found between conditions. In WAD patients, com-
pared with healthy controls, a significant increase in the
rCBF was found in the right superior parietal gyrus
(T=3.52±0.51). In addition, a decreased rCBF was found
in the left insula (T=3.66±0.72), right insula (T=3.62
±0.68), and right thalamus (T=3.54±0.47). Within the
WAD group, a negative association (p<0.02) was found
in these regions between NDI scores and rCBF. Conclu-
sion: WAD symptoms might be the result of a mismatch
between the proprioceptive information from the cervical
spinal cord and the information integrated in regions
such as mesencephalon, thalamus and insula. Further
investigation of the functional brain alterations present
in WAD patients must, however, be performed for a
better understanding of the pathophysiology.
OP515
Genetic influences in FDG uptake in precuneus
and posterior cingulate cortex: a PET study
in non-demented twins
S. Watanabe1, H. Kato1, E. Shimosegawa2, J. Hatazawa1,
Osaka Twin Research Group; 1Department of Nuclear Medi-
cine and Tracer Kinetics, Osaka University Graduate School
of Medicine, Suita, Osaka, JAPAN, 2Department of Molecular
Imaging in Medicine, Osaka University Graduate School of
Medicine, Suita, Osaka, JAPAN
Purpose: The Alzheimer disease (AD) is the most common de-
mentia. It is known as a multifactor disease, and many factors
including genetic and environmental factors have been reported
to be concerned in the onset of the disease. FDG-PET studies
have been revealed the characteristic glucose metabolic patterns;
decreased metabolism especially in precuneus and posterior cin-
gulate cortex, even in the early stage of the disease. Some previ-
ous FDG-PET studies targeting for discordant (demented and
non-demented) twin pairs reported reduced glucose metabolism
in the non-demented co-twins, suggesting preclinical pathogene-
sis or contribution of genetic factors. We investigated whether
genetic influences were observed in glucose metabolism in
precuneus and posterior cingulate cortex using clinically non-
demented concordant twins including young and middle aged
subjects, and attempted to quantify the genetic and/or environ-
mental influences. Methods: This research was carried out as a
part of the twin research of our institution. FDG uptake was
studied in 59 pairs of right-handed volunteer twins (41 monozy-
gotic pairs (mean age 60.4 ± 11.9 years, age range 35-88 years)
and 18 dizygotic pairs (mean age 64.9 ± 15.4 years, age range 32-
85 years)) aged 30 years or over. The brain PET images were
analyzed by voxel-based statistical analysis with automated
region-of-interest setting. The mean FDG uptake in precuneus
and posterior cingulate cortex was semi-quantified. We first re-
ferred Mini Mental State Examination (MMSE) scores and com-
pared the scores with the regional glucose metabolism. Next,
structural equation modeling (SEM) was applied to investigate
the degrees of genetic, shared environmental, and unique envi-
ronmental influences on the regional FDG uptake. Results: Al-
though all the subjects were independent in the daily life, the
MMSE scores were ranged between 22 and 30. However, no
apparent differences in FDG uptake in precuneus or posterior
cingulate cortex were observed between low MMSE score sub-
jects and highMMSE score subjects. The SEM estimated genetic
contribution to regional FDG uptake as 0.39 (95%CI: 0.11-
0.66) in left precuneus, 0.28 (however, 95%CI of genet-
ic parameter estimate include 0) in right precuneus, and
0.30 (95%CI: 0.25-0.66) in right posterior cingulate cor-
tex, while common environmental rather than genetic
influences were indicated in left posterior cingulate cor-
tex (the relative importance was estimated as 0.43
(95%CI: 0.19-0.78).). Conclusion: We demonstrated not
only environmental but also genetic contributions to the
FDG uptake in precuneus and posterior cingulate cortex
even in younger non-demented subjects, suggesting the
essential genetic influence in these regions.
OP516
Decreased frontotemporal cerebral blood flow
in congestive heart failure.
C. Pascovich1, R. García2, A. Damian1, M. Langhain1, E.
Angarita2, R. Ferrando1; 1Nuclear Medicine Centre, Clinical
Hospital, University of the Republic, Montevideo, URU-
GUAY, 2Fundación Cardiovascular de Colombia., Bucara-
manga, COLOMBIA
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Background: Congestive heart failure (CHF) is one of the ma-
jor public health problems with great impact on mortality and
morbidity. Studies have shown that patients with CHF have
cognitive impairments. Cerebral hemodynamic changes
resulting from decreases in left ventricular ejection fraction
(LVEF) as well as brain microinfarctions secondary to
microembolisms could be underlying mechanisms. Reduced
oxygen levels may cause neurotoxicity, particularly in certain
areas more vulnerable to hypoxia like hippocampus, amygda-
la, frontal lobes and cerebellum. Aim: To evaluate the presence
of regional cerebral blood flow decreases in patients with
CHF.Materials and methods60 patients with CHF (42-82
years, mean 65.4±9.8; 38 male; functional class I-IV; LVEF
10-68%, mean 33.7±15.7%) and 40 normal controls (32-89
years, mean 61.9±16.4, 18 male) were evaluated using brain
SPECT with 99mTc-ECD. Groups did not differ significantly
in age and gender. Previous neurological or psychiatric pathol-
ogy was excluded. Image analysis was performed in SPM8.
Clusters greater than 100 volxels with p<0.01 FWE corr at the
voxel level were reported (p<0.001 uncorr was considered if
no results were found). Subsequent comparisons were per-
formed excluding patients with ischemic heart disease (39/
60) and possible depression (antidepressant medication or el-
evated CES-D scores) (10/60). Possitive correlations with
LVEF and negative correlationswith duration of the CHFwere
also assessed. Results: Patients with HCF showed extensive
bilateral frontal hypoperfusion. Anterior temporal poles, mid-
brain and pons were also affected. Frontal, temporal and pon-
tine changes remained after excluding patients with ischemic
heart disease and possible depression. LVEF correlated posi-
tively with bilateral superior frontal perfusion. Negative corre-
lation with duration of CHF showed a trend to statistical sig-
nificance in dorsal frontal and posterior parietal cortex (p<0.01
uncorr). Conclusions: Patients with CHF have extensive fron-
tal hypoperfusion as well as anterior temporal and brain stem
hypoperfusion. Frontal changes correlated positively with
LVEF. These findings are probably the result of chronic brain
hypoxia due to CHF and can not be explained only by depres-
sion or atherosclerotic cerebrovascular disease. The results
provide a neural basis for the presence of cognitive impairment
in CHF, as frontal and temporal function is crucial for memory,
attention and executive performance.
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OP523
The so-called thyroid stunning effect: quantitative
radiobiological analysis and prediction of the remnant
control probability.
S. Walrand, M. Hesse, F. Jamar; Université Catholique de
Louvain, Brussels, BELGIUM
Aim: The origin of the reduction in thyroid uptake after a low
activity iodine scan, so-called stunning effect, is still contro-
versial. Two explanations prevail: an individual cell stunning
that reduces its capability to store iodine without altering its
viability or a significant cell killing fraction that reduces the
number of cells in the tissue still taking up iodine. Our aim is to
analyze whether this last assumption could quantitatively ex-
plain the observed reduction.Methods: a general expression of
the cell survival fraction as a function of the mean absorbed
dose was derived from the dose volume histogram measured
in thyroid metastases by 124I PET. Afterwards, the survival
fractions were computed for 124I, 131I and 123I using the radio-
sensitivities of normal and tumor human thyroid cell assays
reported in the literature. Results: the computed survival frac-
tions were in line with the uptake reduction observed after a
2 mCi 131I scan by Lassmann et al. (2004) and observed after
a 5 mCi 123I scan by Hilditch et al. (2002), as well. Contrary to
a commonly accepted opinion, small absorbed dose, about 15
times lower than those delivered for ablation, already kill a
significant fraction of cell. This results from the Poisson sta-
tistics governing the tissue control probability (TCP) (Brahme
and Agren 1987). As a result the control a few grams of tissue
requires high absorbed dose providing survival fraction lower
than 10-9. This feature was experimentally observed in mega-
colony cell assay (Kappler et al. 2007). Furthermore, the com-
puted TCP quantitatively explained the administered activity
needed for thyroid remnant ablation. Conclusion: The quanti-
tative radiobiological analysis, based on radiosensitivities
measured in thyroid cell assays, shows that the uptake reduc-
tion effect can be purely explained by the cell killing fraction.
This supports the non-existence of an individual cell stunning
effect that, if present, should induce an additional uptake re-
duction resulting in much larger decreases than those ob-
served. The study shows that the three radioiodines isotopes
(i.e. 124I, 131I, 123I) induce a significant uptake reduction after a
low activity scan. As the β/α ratio is very low, this effective
fractionation of the therapy should not impact the patient out-
come in agreement with recent studies. As a result, a pre-
therapeutic dosimetry study makes sense in order to optimize
the administered activity in function of the uptake of the thy-
roid remnants that is highly patient dependent.
OP524
Measuring the radiation dose to the thyroid with a simple
collar detector system in patients with radionuclide
therapy; A feasibility study
P. Brinks, D. B.M. Dickerscheid, E. Kranenborg, J. Lavalaye,
J. B. A. Habraken; St. Antonius hospital, Nieuwegein,
NETHERLANDS
An important parameter for successful treatment of thyroid
diseases with I-131 radionuclide therapy is the radiation dose
delivered to the thyroid. To obtain the desired radiation dose,
the administered patient-activity is calculated using thyroid
uptake values, determined from pre-therapeutic uptake mea-
surements of I-123. The actual radiation dose to the thyroid
with therapy can be determined by measuring the activity in
the thyroid at various time intervals after administration of the
therapeutic dose of I 131, using gamma camera imaging. Be-
cause transporting the patient to the nuclear medicine facility is
challenging (from a radiation safety point of view) and repeat-
ed measurements are time-consuming, the actual radiation-
dose is typically not determined. We present a simple device
that consists of a collar with a special dosimeter placed around
the patient’s neck, designed to continuously measure the ac-
tivity of I-131 in the thyroid. Uptake can be measured without
transporting the patients and repeated use of expensive diag-
nostic setups is also not required, thereby enabling the possi-
bility to measure the actual delivered radiation dose in a simple
and effective manner. The collar therapy indicator (CoTI) de-
vice, fabricated by AG Medical, contains up to 4 independent
gamma radiation detectors, of which two are placed in a collar
that is positioned around the patient’s neck. The detectors are
based on single Silicon Photo-Multiplier devices with a
CsI(Tl) scintillation crystal. Data are temporarily stored on a
lightweight and portable control unit and sent via a wireless
connection to a tablet for storage and display. We present a
feasibility study of CoTI for measuring the delivered radiation
dose to the thyroid for I-131 radionuclide therapy patients. To
demonstrate the working principle of CoTI for thyroid uptake
measurements a comparison study between CoTI and a Sie-
mens ECAM camera was performed, involving 20 patients.
The results provided a good correlation between the two dif-
ferent methods, as confirmed by the obtained R2 value of 0.87,
which clearly demonstrates the working principle of CoTI for
thyroid uptake measurements. Additionally, we will present
measurements of the uptake curve during I-131 radionuclide
therapy. These results can be used to calculate the effective
half-life and the actual radiation dose, assisting in the evalua-
tion of radionuclide therapy. In conclusion, a new measure-
ment device that is embedded in a collar around the patient’s
neck is presented. This device can be used to continuously
measure the thyroid iodine uptake and thereby the radiation
dose delivered during I-131 radionuclide therapy.
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OP525
Relationship between circulating anti-thyroglobulin
antibody (TgAb) and tumor metabolism in patients
with Differentiated Thyroid Cancer (DTC): diagnostic
and prognostic implications
E. Pomposelli1, F. Pupo2, I. Calamia1, G. Ferrarazzo1, G.
Pesce2, F. Fiz1, G. Bottoni1, M. Giusti3, G. Sambuceti1, M.
Bagnasco2, S. Morbelli1; 1Nuclear Medicine Unit, IRCCS
San Martino - IST, University of Genoa, Genoa, ITALY, 2Au-
toimmunity Unit, IRCCS San Martino - IST, University of
Genoa, Genoa, ITALY, 3Endocrinology Unit, IRCCS San
Martino - IST, University of Genoa, Genoa, ITALY
TgAb concentrations respond to changes in the mass of
Tg-secreting thyroid tissue. It has been suggested that
TgAb concentration may have clinical value as surrogate
DTC tumor-marker. Recent evidence suggest a link be-
tween TgAb titers and DTC aggressiveness. DTC metab-
olism as assessed by 18F-FDG PET is a well-recognized
prognostic indicator. AIM: to evaluate the relationship
between TgAb levels and tumor glucose metabolism in
patients with DTC. Methods: 71 patients with DTC who
underwent 18F-FDG PET/CT scan were included in the
present study. Indications for PET were negative iodine-
131 whole-body scan and elevated TgAb level or
restaging in high risk patients for diagnostic and prog-
nostic purposes. Radioiodine avidity of DTC lesions was
established on the bases of recent patients’ history (post-
therapeutic 131I scan was available for all patients).
TgAb levels were measured with ELISA within 15 days
from FDG-PET scan. On the bases of the results of
FDG-PET, post-therapy 131I scans and Tg levels, pa-
tients were divided in two groups according to the evi-
dence (ED) or absence (NED) of disease. ED patients
were further divided in three subgroups: 1. radioiodine
avid with posit ive FDG PET (PET+/131I+). 2.
Radioiodine refractory with positive FDG PET (PET+/
131I-) 2. Radioiodine avid with negative FDG-PET
(PET-/131I+). Mean standardize uptake values of all
FDG-avid lesions was assessed and averaged for each
patient. T-test was performed to assess the difference
between TgAb levels in ED and NED patients as well
as between NED patients and PET+/131I+, PET+/131I-
and PET-/131I+ subgroups independently. Linear regres-
sion was performed to assess relationship between TgAb
on one side and SUVmean in the three subgroup of ED
patients on the other. Results: TgAb levels (IU/L) were:
33 (range 9-117) in NED and 37 (range 2-416) in ED
patients (p=ns); however this value raised to 94 (range
79-416) in PET+/131I+ subgroup (p<0.003 with respect
to NED) while was significantly lower in PET+/131I-
subgroup (24 IU/L; p<0.04 versus NED). Only one
patient belonged to PET-/131I+ subgroup (Tgab were
47 IU/L). Finally, only in PET+/131I+ subgroup,
SUVmean was directly correlated with TgAb levels
(R2=0.76). Conclusions: Significantly higher TgAb in
radioiodine avid DTC with positive FDG-PET support
the role of TgAb levels as surrogate tumor marker in
DTC patients (at least when radioiodine avidity and thus
Tg-secretion is preserved). The correlation with tumor
metabolism suggests that increased TgAb level may also
have prognostic implications in the follow-up of DTC
patients.
OP526
The Survival and Outcome of Recurrent Differentiated
Thyroid Carcinoma: Results of a Long-Term Follow-up
Study
J. Mihailovic, E. Matovina, N. Klicov; Oncology Institute of
Vojvodina, Sremska Kamenica, SERBIA
Aim: To analyze the survival and outcome of recurrent
differentiated thyroid carcinoma (DTC) treated with
I-131. Patients and methods: Among 351 DTC patients
treated with I-131 between 1977-2000, we analyzed 99
patients with recurrent disease (RD)(74 females, 25
males; 41 patients <45 years, 58 patients ≥45 years);
median follow-up=12 years (range,1-39yr); 27 follicular,
70 papillary carcinomas and 2 undetermined histology;
TNM stage I, II, III and IV included 4, 7, 24 and 48
patients, respectively while 16 patients were not staged.
Initial nodal metastases (N1), distant metastases (M1)
and combined metastases (N1M1) were presented in:
39, 53 and 1 patients, retrospectively, while 58 patients
initially had no metastases (N0M0). Disease specific sur-
vival was analyzed by Kaplan-Meier method. Results:
Among 351 DTC, RD was detected in 99 (28.2%) pa-
tients, median time of appearance was 67 monhts (range,
6-272 months). Recurrences were treated by RAI in 31
pts; surgery (S) in 9 pts, S+RAI in 38 pts; chemother-
apy (CH) was performed in 1 patient; S+CH+external
beam radiotherapy (EBRT) in 2 pts; CH+RAI in 2 pa-
tients; EBRT+S+RAI was performed in 9 pts; EBRT+S
in 2 patent and EBRT+RAI in 1 patient; in 4 patients
recurrences were not treated. At last check up, out of 99
patients with RD 49 (49.5%) patients were alive, 41
(41.4%) patients died due to disease related deaths,
and 9 (9.1%) patients died from other causes. The 5-,
10-, 20- and 39-year disease specific survival was: 0.904
±0.30; 0.756±0.46; 00.525±0.62, and 0.287±0.126, re-
spectively. Conclusion: Careful monitoring of DTC pa-
tients is necessary for detection and treatment of recur-
rence. Patients with recurrent disease have worse
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prognosis than those without recurrence, but may be
cured if treated on time and properly (surgery with ad-
ditional RAI, if necessary).
OP527
The effect of post-ablation 131I SPECT/CT on the staging
and initial risk-stratification of children
with differentiated thyroid cancer
B. Liu, R. Tian; Department of Nuclear Medicine, West China
Hospital, Sichuan University, Chengdu, CHINA.
Purposes: Over the past decade, there is emerging litera-
ture that attempts to address the role of radioiodine
SPECT/CT in the evaluation of differentiated thyroid can-
cer (DTC). Most of these studies have studied adult pa-
tients and experience derived from children patients is
still scarce. In this retrospective study, we attempted to
investigate the utility of post-ablation 131I SPECT/CT
on the impact of staging, and initial risk-stratification of
children with DTC. Methods: Sixty-two children (45 fe-
male, 17 male; mean age, 14.5 ± 6.2y,range,6-21y) with
DTC referred for initial postsurgical 131I ablation were
retrospectively included. In addition to planar whole body
scanning performed approximately 5 days after the thera-
peutic administration of 2,220-5,550 MBq (60-150 mCi)
of 131I, SPECT/CT scanning of the neck and other
suspected areas of abnormal radioactivity uptake noted
on planar scans were acquired. Sites of uptake seen on
planar and SPECT/CT images were categorized as thyroid
remnants, cervical lymph nodes, and distant metastases.
Each patient was initially staged using the 7th edition
of the AJCC/UICC staging system (stage I, or II) and
risk-stratified using the risk of recurrence stratification
system proposed by the American Thyroid Association
(low-, intermediate-, or high-risk), based on clinical and
pathology information, and then re-classified, taking into
account additional findings from post-ablation 131I
SPECT/CT. Results: By addition of SPECT/CT, post-
ablation 131I scans detected cervical lymph node metas-
tases and distant metastases in 9 (14.5%) and 4 (6.5%) of
62 patients, respectively. Such additional findings noted
from post-ablation 131I SPECT/CT helped to alter the
staging and initial risk-stratification in 4 (6.5%) patient
and 5 (8.1% ) patients, respectively. Conclusion: Our
study indicates that post-ablation 131I SPECT/CT scans
have potential to identify regional and distant metastases,
providing an important contribution to staging and initial
risk-stratification in children with DTC. This work was
supported by the National Natural Science Fund of China
Grant No. 81401445, 81471693.
OP528
Red marrow and blood dosimetry in 131I treatment
of metastatic differentiated thyroid carcinoma:
comparison in patients with repeated treatments
E. Richetta, M. Pasquino, C. Cutaia, A. Giostra, R. Pellerito,
M. Stasi; AO Ordine Mauriziano di Torino, Turin, ITALY
Aim. Radioiodine treatment of metastatic differentiated thy-
roid carcinoma is often limited by red marrow toxicity. In
our institution 131I administered activity is individually
planned: dosimetry to red marrow and blood is performed
before therapy (PT) to determine the maximum tolerable ac-
tivity (<2Gy) and after treatment (IT). In this study we com-
pared the results of the dosimetries performed on patients with
subsequent therapies to investigate the possibility of using the
first dosimetry as a reference for the following treatments as
well. Materials andMethods. For 32metastatic patients PTand
IT doses (d1) to red marrow and blood, evaluated according to
AIFM protocol during a first 131I treatment, were compared
with doses (d2) calculated in the later treatment (14 ± 7months
after). PT dosimetry was performed one week before
radioiodine therapy by administering a 131I tracer-activity: 4
blood samples were acquired and AP-PAwholebody measure-
ments were performed by using a NaI counter 2h, 24h, 48h and
96h after the administration. For IT dosimetry detectors placed
on patients’ beds providing wholebody AP counts (every 2h,
from 8.00 a.m. to 22.00 p.m. during patient’s hospitalization)
and 4 blood samples were acquired with the same PT time
scheduling. 64 couples of doses (30 PT and 34 IT) (Gy/GBq)
were compared : percentage dose differences were calculated
and a t-test for paired samples was applied.Results. Mean
(±1Dev.St) percentage differences between d1 and d2 for the
30 PT paired data was -0.4%±14% [-19÷20] for red marrow
and -5.2%±17% [-34÷25] for blood respectively. Good cor-
relation coefficient r was found between d1 and d2, con-
firmed also by paired samples t-test (red marrow r=0.94,
p=0.87 and blood r=0.83, p= 0.22). Similar results were
found evaluating the 34 IT paired doses: red marrow mean
difference 6%±11% [-14÷24], r = 0.95, p =0.15 and blood
4%±19% [-35÷39], r = 0.75, p =0.98. Conclusion. We
performed a comparison between pre-treatment and in-
therapy red marrow and blood doses evaluated in two
subsequent treatments on 32 patients treated with 131I
for metastatic differentiated thyroid carcinoma. The prelim-
inary results show mean differences between the paired PT
and IT doses not significantly different and percentage
variations within the experimental error of the calculation
method. The good correlation between the first calculate
dose and the later result could confirm the possibility to
use the first dosimetry as a reference for following treat-
ment, avoid in such a way to repeat the very time expen-
sive dosimetric procedure.
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OP529
Pre-therapy Bone Marrow And Lesion Absorbed Dose
Estimation Using Different Dosimetry Models In
Metastatic Differentiated Thyroid Cancer
M. M. Abuqbeitah, H. Tanyildizi, I. Çavdar, M. Demir, N.
Yeyin, B. Vatankulu, L. Kabasakal; Istanbul University, Istan-
bul, TURKEY
Aim: Dosimetry is an alternative strategy to the adminis-
tration of fixed radioactive iodine in metastatic thyroid
cancer therapy. Pretherapy dosimetry is increasingly rec-
ommended to calculate the maximum tolerable Activity
for each patient in order to deliver absorbed dose not
exceed 2 Gy for the red bone marrow and meanwhile
optimization the response level of desired targeted lesions.
Materials And Methods: 14 patients (10 female ,4 Male
and Mean age 44±15.84 y ,TSH 65±43 μIU/ml,HTC
38.43±3.81 ng/ml) suffering from metastatic differentiated
thyroid cancer were submitted to pretherapy maximum
safe activity and lesion absorbed dose protocol to estab-
lish successive therapy using OLINDA/EXM Software
and five different dosimetry Methods for comparison pur-
poses. Dual head scintillation camera was utilized to mea-
sure whole body and lesions activities by drawing region
of interest adjacent to whole body and lesion contours
and performing attenuation correction Besides to Blood
samples collection which were measured in Well-Gama
Counter at several time points; 2.6.24.48.72.96.144hours
after oral administration of Radioiodine tracer (2mCi).To
verify normal background count rate, 1 minute acquisition
was performed before each whole body scan and
subtracted from the related scan’s count. The necessary
data were collected and modified according to the param-
eters of the dosimetry methods adopted by OLINDA/
EXM, Wessels et al,Traino et al,Siegel et al,Shen et al
,and Keizer et al . Results: According to OLINDA/EXM
software mean absorbed dose from tracer activity was
3.11±1.76mGy/mCi ,Wessels et al was 3.27±1.9mGy/
mCi,Traino et al was 2.68±1.53 mGy/mCi,Kiezure et al
was 2.2±1.16mGy/mCi,Siegal et al was 2.56±1.86 mGy/
mCi , and Shen et al was 4.05±3.4 mGy/mCi. Mean
absorbed dose to distal metastatic lesions was 6,31Gy/
mCi. The deviation between the results of OLINDA/
EXM software and the other dosimetry methods was var-
iable 5.1%, -13.8%, 30%, -17%, and -29%. Conclusion:
Absorbed dose and maximum safe activity determination
by OLINDA/EXM software is non-invasive method and
can be used in clinical routines easily. It seems that com-
bination between red marrow absorbed dose and lesion
absorbed dose in the dosimetry protocol is very advanta-
geous to accomplish highly successive therapy and com-
plete remission of the lesions.
OP530
111In-CP04 - A Novel CCK2/Gastrin Receptor-Localizing
Radiolabelled Peptide Probe for management of Patients
with Progressive/Metastatic Medullary Thyroid
Carcinoma (MTC): Rationale, Study Design
and the Initial Promising Results of a Multicentre First
Phase Study.
A. Hubalewska-Dydejczyk1, C. Decristoforo2, P. Erba3, R.
Mikolajczak4, H. Maecke5, K. Zaletel6, P. Kolenc-Peitl6, T.
Maina7, P. Garnuszek4, I. Virgollini2, G. Geobel2, M.
Konijnenberg8, M. Hendriks-deJong8, L. Froberg8, W.Lenda-
Tracz1, C.Rangger2, A.Kunzmann5,A.Sowa-Staszczak1,
M.Trofimiuk-Muldner1,M.Tomaszuk1; 1Jagiellonian Univer-
sityMedical College, Krakow, POLAND, 2InnsbruckMedical
University, Innsbruck, AUSTRIA, 33Azienda Ospedaliero-
Universitaria Pisana, Pisa, ITALY, 4Radioisotope Centre
POLATOM, National Centre for Nuclear Research, Otwock,
POLAND, 5University Hospital Freiburg, Freiburg, GERMA-
NY, 6University Medical Centre Ljubljana, Ljubljana, SLO-
VENIA, 7INRASTES, NCSR “Demokritos”, Athens,
GREECE, 8Erasmus University Medical Center, Rotterdam,
NETHERLANDS
The prognosis for patients with MTC is relatively good, how-
ever nonoperable/recurrent disease develops in approximately
50% of patients. The diagnostic and therapeutic algorithms in
MTC cases still need to be optimized, as imaging techniques
will not show any disease until serum calcitonin approaches at
least 150 pg/ml as well as patients with surgically unresectable
disease are left with few therapeutic options with low efficacy.
CCK2 receptor is overexpressed in MTC with high density
and >90% incidence. Since 1990, a variety of CCK2 receptor
related peptides were studied; the DOTA-(DGlu)6-Ala-Tyr-
Gly-Trp-Met-Asp-Phe-NH2 (CP04) showed the most promis-
ing characteristics (high receptor affinity, high stability and
low kidney retention) and was selected for further clinical
evaluation.The aim of the project is to establish the multina-
tional cooperation in the innovative field of targeted radionu-
clide therapy using a CCK-2/gastrin receptor-seeking ligand
CP04 radiolabelled with Indium-111 as an imaging
biomarker.Methods: The study consists of two stages: WP1-
Radiopharmaceutical development and WP2-Clinical trial.
The goal of WP1 was to establish a clinically useful formula-
tion for the preparation of 111In-CP04 including
radiolabelling and stability testing and the extended single
dose toxicity study including haematology, blood chemistry
and histopathology.Minimally 20 patients with progressive/
metastatic nonoperable histologically proven MTC with posi-
tive 18F-FDG-PET-CT/CT/MRI or positive calcitonin dou-
bling time will be enrolled in the clinical study.The objective
is to establish the safety of i.v. administration of a therapeutic
amount of 111In-CP04 and to assess the tracer ’s
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biodistribution and dosimetry in MTC and normal tissues and
to determine critical organs. The evaluation of the potential of
CCK2 receptor scintigraphy to detect cancer lesions for diag-
nostic (10ug) and therapeutic peptide dose (50ug) and the
decrease of kidney dose after co-administration of gelofusine
(nephroprotective agent) are planned. Results:We demonstrat-
ed that radiolabelling of CP04 with 111In could be effectively
translated into a clinically useful formulation based on a sim-
ple kit procedure. The planned peptide dose allows clinical
administration based on preclinical toxicity data. Standard Op-
erating procedures for radiolabelling and imaging methods as
well as the Study Protocol and documents to obtain the ethics
committee’s approvals for all participating centres are being
finalized. The study will recruit patients soon. Conclusion:
The project may become the first step in establishing a more
selective and efficient strategy for the diagnosis, early detec-
tion and therapy of recurrent/metastatic MTC patients leading
to reduction ofmortality as well as improvement in life quality.
GRAN-T-MTC is the ERA-NET part (TRANSCAN, EC-
FP7).
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OP531
Measurement of sorafenib concentrations using PET
imaging in patients with advanced solid malignancies
L. H. Mammatas, M. Yaqub, N. H. Hendrikse, O. S.
Hoekstra, R. J. Honeywell, M. Meijerink, L. A. Schwarte, G.
J. Peters, A. A. Lammertsma, H.M.W. Verheul, C.W.Menke-
van der Houven van Oordt; VU University Medical Center,
Amsterdam, NETHERLANDS
Aim: Sorafenib is an oral protein kinase inhibitor targeting
VEGFR, PDGFR and Raf kinases. It is currently registered
for the treatment of metastasized hepatocellular carcinoma,
renal cell cancer and iodine-refractory differentiated thyroid
cancer. However, sorafenib leads to a response in only a sub-
group of patients, while all are exposed to potential toxicity.
Positron emission tomography (PET) may provide a non-
invasive technique to predict which patients will benefit from
this treatment. We hypothesize that response to sorafenib is
dependent on achieving pharmacological active drug levels
in tumor tissue and that quantitative PET imaging using
radiolabeled sorafenib can predict these tumor concentrations.
Materials and methods: At our center the GMP-synthesis of
[11C]sorafenib has been developed. In this single center, proof
of concept study, adult patients with advanced, biopsy acces-
sible malignancies are included for which standard palliative
treatment with sorafenib is indicated. [11C]Sorafenib dynamic
PET is performed before and after two weeks of standard
treatment. Pharmacokinetic modeling is applied to describe
the tissue distribution and tumor uptake of [11C]sorafenib.
Moreover, the amount of tracer uptake in tumor and blood
measured with PET imaging is compared to the actual phar-
macological active drug concentrations in tumor biopsies and
blood samples after 2 weeks of treatment measured with liquid
chromatography-tandem mass spectrometry (LC-MS/MS).
Results: Six patients have been included: 1 patient with me-
tastasized hepatocellular carcinoma, 4 patients with metasta-
sized renal cancer and 1 patient with metastasized iodine-
refractory follicular thyroid cancer. There was high physiolog-
ical uptake of [11C]sorafenib in liver, gallbladder and kidneys
due to metabolism and excretion of sorafenib, respectively.
[11C]sorafenib uptake in tumor lesions was observed in 2/6
patients. The correlation between PET uptake and tumor and
blood concentrations of sorafenib after two weeks of treatment
will be shown. Conclusion: This study is the first step neces-
sary to assess the feasibility of [11C]sorafenib PET as a quan-
titative predictive tool in cancer treatment.
OP532
Early and late evaluation of solid tumours
with 64Cu-ATSM PET/CT: a computer-aided fractal
analysis
E. Lopci1,2, F. Grizzi1, I. Grasso3, C. Russo1, G. Cicoria3, S.
Cambioli3, F. Lodi3, A. Chiti4, S. Mattioli5, S. Fanti5;
1Humanitas Clinical and Research Hospital, Milano, ITALY,
2Alma Mater Studiorum University, Bologna, ITALY,
3Ospedale S. Orsola-Malpighi, Bologna, ITALY, 4Humanitas
University, Milano, ITALY, 5Alma Mater Studiorum Bologna
University, Bologna, ITALY
Purpose: 64Cu-ATSM is a well-known PET radiopharmaceu-
tical applied for tumour imaging of hypoxia. Due to the long
half-life of the radionuclide, early and delayed images can be
acquired. However, no real evidence exists on the consistency
of these two point-in-time acquisitions. The current study
aimed at analyzing early and delayed acquisition on 64Cu-
ATSM PET/CT in the same cohort of patients by comparing
the information obtained from parametrical and computer-
aided fractal geometry based analysis of the DICOM images.
Methods: Five patients with pathologically proven head and
neck cancer (HNC) or locally advancedNSLCLwere included
in the study. Each participant received 105-500MBq of tracer
according to body size and was scanned in a 3D-mode on a
PET/CT tomograph 60 minutes (early) and 16 hours (late)
after injection. PET images were reconstructed and visualized
on a GE Advanced 4.6 workstation for the definition of semi-
quantitative and quantitative parameters: SUVmax, SUVratio-to-
muscle, SUVmean, hypoxic volume (HV) and hypoxic burden
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(HB=HV*SUVmean). DICOM data retrieved from both scans
were subsequently analyzed using an ad-hoc computer-aided
software to determine the Mean Intensity Value (MIV), Stan-
dard Deviation (SD), Relative Dispersion (RD), 3DHistogram
Fractal Dimension (3DHIST FRDIM) and 3D Fractal Dimen-
sion (3DFD). Differences in between the parameters were
compared using the Student’s t-test, by considering as statisti-
cally significant p-values <0.05. Results: All patients showed
an increased uptake of 64Cu-ATSM in tumour lesions, with a
SUVratio-to-muscle at early imaging of median 4.42, median
SUVmax of 5.3, median SUVmean of 2.8. The HV and HB at
early imaging resulted respectively of median 41.4cm3 and
161.2cm3. All these semi-quantitative and quantitative data
obtained at 1 hour resulted consistent with the same data ob-
tained on delayed imaging (p>0.05). However, a statistically
significant difference was found when compared the SUVmax
of the muscle (p=0.045). Fractal analysis demonstrated that all
parameters considered at early and late acquisition showed no
statistically significant differences (p>0.05). A borderline val-
ue was obtained for MIV (p=0.075). This latter finding is
mainly attributable to the limited series of analyzed patients,
and the difference reported on muscle SUVmax applied as ref-
erence tissue for tumour contouring. Conclusions: Our find-
ings support the reliable and consistent use of 64Cu-ATSM
PET/CT obtained at early and delayed acquisition for the as-
sessment of tumour hypoxia. Some attention might be paid
when utilizing the data for radiotherapy contouring, because
reference tissue uptake such as muscle SUVmax can show
some difference in between the two scans.
OP533
Molecular imaging of neuroendocrine tumors
with Scandium-44: a novel tool for THERANOSTICS
A. Singh1, R. P. Baum1, I. Klette1, N. P. van der Meulen2, C.
Mueller3, A. Tuerler2, R. Schibli3; 1THERANOSTICS Center
for Molecular Radiotherapy and Molecular Imaging, ENETS
Center of Excellence, Zentralklinik Bad Berka, Bad Berka,
GERMANY, 2Laboratory for Radio- and Environmental
Chemistry, Paul Scherrer Institute (PSI), Villigen, SWITZER-
LAND, 3Center for Radiopharmaceutical Sciences, Paul
Scherrer Institute (PSI), Villigen, SWITZERLAND
Aim: Scandium-44 (44Sc) is a novel β+-emitting radionuclide
for PET imaging. Chemically, Sc3+ is similar to lanthanides
and rare earth elements (90Y3+, 177Lu3+) in its ability to
form DOTA complexes. Given the physical properties, it
may complement the use of Galium-68 (68Ga; short-lived,
t1/2 = 68 min) for molecular imaging of neuroendocrine tu-
mors (NETs). We report molecular imaging data using 44Sc-
DOTATOC PET/CT in three patients with metastatic
NETs.Materials and Methods:44Sc (t1/2 = 3.97 h, Eβ+
1475.4 keV, 94.34%) was cyclotron-produced at PSI Villigen
(Switzerland), transported over 600 km by road to ZBB (Ger-
many), and radiolabelled with the somatostatin analogue
DOTATOC (DOTA0,Tyr3-octreotide) with a specificity of
10 MBq 44Sc/nmol DOTATOC, and a high radiolabelling
efficacy (99% ± 1.6; pH range = 3-4.5). 44Sc-DOTATOC
(78, 96, and 130 MBq) was administered to 3 male patients
(age range 57-70 years) with GEP-NETs presenting for re-
staging. Whole-body PET/CT (Biograph mCT Flow 64) scans
were performed at variable time intervals from 10 min to 24 h
p.i. and target-to-non-target uptake ratios were determined.
The total number of SSTR-positive lesions was counted and
SUV were determined in normal organs and metastases. Im-
aging results were compared to US, MRI, and 68Ga-
DOTATOC PET/CT.Results: Molecular imaging with PET/
CT following injection of 44Sc-DOTATOC demonstrated
high specific tracer uptake in liver and lymph node me-
tastases, with best target-to-non-target ratios seen at 2 to
4 h p.i. Two patients were diagnosed with progressive
disease (PD): five additional metastases were detected in
one patient, and one new metastasis was revealed in the
other patient, compared to the previous 68Ga-DOTATOC
PET/CT study. One patient had a single new small me-
tastasis, but overall regressive tumor burden. No adverse
effec ts were observed in any of the pa t ients .
Conclusions:44Sc is a highly promising positron-
emitting radioisotope for the molecular imaging of
NETs. When produced centrally, several patient doses
can be delivered to PET imaging centers at a distance
of over 1,000 kilometers. In this series, 44Sc-DOTATOC
was found safe for human use, exhibited high target-to-
non-target ratios, and delayed imaging up to 24 h p.i
was possible. 44Sc-DOTATOC provides high diagnostic
sensitivity and excellent image quality for PET imaging,
and also demonstrates significant prominence as a
THERANOSTIC radionuclide, since pre-therapeutic im-
aging and dosimetry by 44Sc-DOTATOC may be
followed by radiopeptide therapy using the β–emitting
Scandium-47 (47Sc).
OP534
Determination of chemokine receptor CXCR4
by 68-Ga-Pentixafor PET in patients with adrenocortical
carcinoma
C. Bluemel1, S. Hahner1, B. Heinze1, A. Schirbel1, M.
Schottelius2, C. Lapa1, S. Kropf3, K. Lückerath1, B. Allolio1,
M. Fassnacht1, H. Wester2, A. K. Buck1, K. Herrmann1;
1Universitätsklinikum Würzburg, Würzburg, GERMANY,
2Technische Universität München, München, GERMANY,
3Scintomics GmbH, Fürstenfeldbruck, GERMANY.
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Aim: The chemokine receptor CXCR4 and its chemokine ligand
12 are key factors for angioneogenesis, metastasis and tumour
growth in several human cancers and also overexpressed in ad-
renocortical neoplasia. Recently, 68-Ga-Pentixafor PET for
in vivo CXCR4- imaging was introduced. The aim of the present
study was to evaluate 68-Ga-Pentixafor for in vivo determination
of CXCR4-expression in patients with adrenocortical carcinoma
(ACC) to select suitable patients for CXCR4-directed therapies in
a theranostic concept. Methods: 22 consecutive patients with his-
topathological proven metastasized ACC were examined with
68-Ga-Pentixafor-PET/CT and 18-F-FDG-PET/CT. Results of
both imaging methods were compared and patients were classi-
fied as suitable or unsuitable for CXCR4-directed therapy. Re-
sults: In all patients 18-F-FDG-PET/CT and 68-Ga-Pentixafor-
PET/CTwere rated positive (100%), 48% had a local recurrence,
52% peritoneal/mesenterial, 33% retroperitoneal tumour lesions,
29% had lymph node metastases and 86% haematogenous me-
tastases. Visual comparison of both tracers resulted in comparable
findings in 7 (32%) patients and 4 (18%) patients in complemen-
tary findings. In 9 patients (41%) 18-F-FDG-PET/CT identified
more lesions with visually higher uptake compared to CXCR4-
imaging, whereas in 2 patients (9%) 68-Ga-Pentixafor-PET/CT
identified more metastatic lesions than 18-F-FDG. The corre-
sponding mean SUVmax value for 18F-FDG was 12.28±8.35
(range, 2.17-47.04) and thus significantly higher than the
SUVmax for 68Ga-Pentixafor (mean, 8.40±5.77; range, 1.75-
34.18). Overall, 12 out of 22 patients (54%)were rated as suitable
and 3 patients (14%) as potentially suitable CXCR4-directed
therapy, e.g. 177-Lu/90-Y-labelled Pentixafor analogues. Conclu-
sions: CXCR4 is overexpressed in a subgroup of ACC patients
allowing for CXCR4-directed therapies in 67% of patients in the
present cohort. 68-Ga-Pentixafor-PET/CT provides excellent im-
aging quality and allows for selection and therapy monitoring of
patients suitable for CXCR4-directed therapy.
OP535
Diagnostic value of (68)Ga - PSMA PET/CT
in biochemical recurrence of prostate carcinoma with low
PSA levels
E. Demirci1,2, J. Nematyazar1, R. Akyel1, B. Razavi1, A.
Aygun1, M. Ocak3, M. Halac1, A. Araman3, L. Kabasakal1;
1Department of Nuclear Medicine, Cerrahpasa Medical Facul-
ty, Istanbul University, Istanbul, TURKEY, 2Department of
Nuclear Medicine, Sisli Etfal Training and Research Hospital,
Istanbul, TURKEY, 3Department of Pharmaceutical
Technology, Pharmacy Faculty, Istanbul University, istanbul,
TURKEY.
Purpose: 68Ga-DKFZ-11 (68Ga-PSMA) has been suggested as a
novel tracer for detecting of PCa relapses and metastases. How-
ever there is a limited number of publications about the timing of
PSMA PET/CT scan. The aim of the study is to evaluate the
diagnostic value of PSMA PET/BT in the diagnosis of recurrent
prostate cancer with low PSA levels. Materials andMethods: We
performed a retrospective analysis in patients who underwent
PSMA PET/CT from November 2013 to December 2014 in
our department. 53 out of 178 patients who had rising PSA levels
(still lower than 5ng/ml), and did not have knownmetastasiswere
included in this study. Results: Patients had an average PSA of
1.41 ng/ml. A total of 31 patients (58%) showed at least one
extraprostatic or prostatic lesions. Intense pathologic radiotracer
uptake was observed in 15 patients (28%) at the site of primary
tumor. Lymph node metastases were detected in 19 patients
(36%) and bone metastases were detected in 8 patients (15%).
A PET positivity rate of 31% (n=4), 54 % (n=13) and 88%
(n=14) observed in patients with PSA level of <0.2, 0.2-2 and
2-5 ng/ml respectively. Those with PSA level PSA <0.2, 0.2-
2and 2-5 ng/ml had 8% (n=1), 21% (n=5), 56% (n=9) local
recurrence 15% (n=2), 42% (n=10), 44% (n=7) lymph node me-
tastasis and%15 (n=2), 8% (n=2), 25% (n=4) bone metastasis. A
positive correlation observed between positivity rate and gleason
scores (%15 for Gleason 6, %55 for Gleason 7, 75% for Gleason
8 and 77% for Gleason 9). PSMAPET/CT positivity’s confirmed
with biopsy (n=3), follow-up (n=26) and conventional imaging
studies at the time of the PET/CT (n=11) or during follow up
(n=13). According to patient-based analysis of 44 cases
%57(n=25) of patients had true positive, %23(n=10) of patients
had true negative, %2(n=1) patient had false positive, %18(n=8)
of patients had false negative findings which are leading to a
sensitivity of 58.1% (95%CI:42.1-72.9%) specificity of 90%
(%95CI:%48.6-98.5). Within the patients who had PSA levels
from 0.2 to 5, the sensitivity was %79.3 (%95 CI: %60-91.9).
Conclusion: PET/CT with 68Ga PSMA is a valuable tool for
assessing recurrence of PCa with a high sensitivity (%79.3) with-
in the patients who has PSA levels between 0.2-5 ng/ml. Addi-
tionally PSMA PET/CT can be used in patients with very low
(<0.2 ng/ml) but increasing PSA levels, which in many cases
may influence the further clinical management.
OP536
Preliminary comparison of PET/CTand PET/MRI hybrid
systems using a Ga-68 labeled PSMA ligand for initial
staging of prostate cancer
S. Lütje1, B. Gomez1, J. Cohnen1, B. M. Schaarschmidt2, R.
Reichel1, S. Rosenbaum-Krumme1, A. Bockisch1, T. D.
Poeppel1, A. Wetter3; 1Clinic for Nuclear Medicine, Universi-
ty Hospital Essen, Essen, GERMANY, 2Department of Diag-
nostic and Interventional Radiology, Medical Faculty, Univer-
sity Düsseldorf, Düsseldorf, GERMANY, 3Department of Di-
agnostic and Interventional Radiology and Neuroradiology,
University Hospital Essen, Essen, GERMANY.
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Aim: Despite improvements in diagnostic and therapeutic ap-
proaches, prostate cancer remains one of the leading causes of
cancer-related death in men in the Western world. 68Ga-la-
beled HBED-CC-PSMA is a highly promising new tracer for
imaging of PCa. The aim of this study was to evaluate the
feasibility of PET/MRI with this tracer for detection and
locoregional staging of PCa at initial diagnosis in comparison
to PET/CT. Materials and methods: Ten high-risk patients
(mean serum prostate-specific antigen 12.0 ± 9.2 ng/ml)
among which seven were suspected with PCa in transrectal
biopsy, underwent PET/CT 66 ± 17 min after injection of the
68Ga-HBED-CC-PSMA ligand (mean 102 ± 18 MBq/patient)
followed by PET/MRI at 153 ± 66 min postinjection. Data
from the two investigations were analyzed separately and
compared regarding tumor detection rate and radiotracer up-
take in tumor lesions and muscle tissue. Uptake was quantified
in terms of the maximal standardized uptake value (SUVmax)
within a spheroidal volume of interest (VOI). SUVs of PET/
CTand corresponding PET/MRI were compared to each other
with paired t tests. Reference VOIs were drawn in the gluteal
muscles on the right side. The native SUVmax of the lesions
were normalized to the SUVmax in the reference region. Tumor
lesions within the prostate visualized by both techniques were
correlated to histopathological analyses. Results: With both
techniques, 8 histologically proven tumor lesions were identi-
fied in 7 patients. In three patients with negative transrectal
biopsy results, no tumor lesions were identified with PET/
CTand PET/MRI. Even though SUVs in PET/CTwere slight-
ly higher (mean SUVmax 12.7 ± 9.1, n=8) compared to PET/
MRI (mean SUVmax 9.6 ± 5.8, n=8), PET/MRI provided sig-
nificantly higher tumor-to-muscle ratios compared to PET/CT
(mean 15.8 ± 9.7 and 8.1 ± 5.1, respectively, p=0.0016). Con-
clusion: PET/MRI is as reliable as PET/CT for detection and
locoregional staging of patients with PCa at initial diagnosis.
OP537
Evaluation of the role of F-18 FDG PET/CT in childhood
rhabdomyosarcoma - preliminary results
R. K. Gupta, Jr., M. Tripathi, S. Bakshi, N. Damle, K.
Kumar, R. Bhayana, C. Bal; All India Institute of Medical
Sciences, New Delhi, INDIA.
INTRODUCTION: The management of rhabdomyosarcoma
(RMS) depends on risk stratification at diagnosis & treatment
response. The methods used for initial evaluation include his-
topathology (HP), magnetic resonance imaging (MRI), con-
trast enhanced computed tomography (CECT), chest X-ray
(CXR), non-contrast computed tomography (NCCT) chest,
Technetium-99m Methylenediphosphonate (Tc-99m MDP)
bone scan (BS) and bone marrow biopsy. Fluorine-18
Fluorodeoxyglucose (FDG) PET/CT has emerged as a useful
modality for staging malignancies. In this study we compared
F-18 FDG PET/CTwith conventional imaging (CI) modalities
for the staging of RMS. MATERIALS AND METHOD:
Twenty two children (16 males) with mean age 8.13 years
(range 2 to 17 years) were prospectively enrolled in this study.
All patients were biopsy proven RMS with positive desmin
and myogenin. Each patient underwent CECT and/or MRI of
the primary tumour site, CXR and/or NCCTchest and Tc-99m
MDP BS. The disease was staged according to TNM Pretreat-
ment Staging Classification1. Each patient also underwent
F-18 FDG PET/CT within one week of the MRI/CECT and
were restaged using the information obtained from PET/CT.
Nodal status and metastases as obtained by conventional im-
aging and after PET/CT were compared. RESULTS: F-18
FDG PET/CT detected additional lesions in 59 %( 13/22) pa-
tients. In comparison to CI, F-18 FDG PET/CT detected addi-
tional nodes in 13% (3/22)patients and ruled out nodal in-
volvement in 4%(1/22) patients. Additional distant metastatic
sites in lung and bone marrow were detected in 9 % (2/22)
patients. N stage changed in 31 %( 7/22) patients, M stage
changed in 9% (2/22) patients. Overall TNM staging changed
in 18 %( 4/22) patients. CONCLUSION: This study suggests
that F-18 FDG PET/CT has potential to increase initial staging
accuracy, specifically detection of nodal involvement and dis-
tant metastatic spread. REFERENCE: 1. Lawrence W, Jr, An-
derson JR, Gehan EA, et al. Pretreatment TNM staging of
childhood rhabdomyosarcoma: A report of the Intergroup
Rhabdomyosarcoma Study Group. Children’s cancer study
group. Pediatric oncology group. Cancer. 1997;80:1165-1170.
OP538
Impact of 18F-FDG PET/CT in the diagnosis
and therapeutic response of histiocytosis
L. M. Vija1, G. Bera2, J. Haroche2, F. Cohen1, P. Chaumet-
Riffaud1, A. Prigent1, P. Maksud2; 1Paris Sud University, Le
Kremlin-Bicetre, FRANCE, 2Groupe Hospitalier La Pitié-
Salpêtrière, Paris, FRANCE.
Objectives: Histiocytosis (with its heterogeneous group of
Langerhans cell histiocytosis (LCH) and subtypes of non-LCH
histiocytoses) is a rare inflammatory and systemic disorder of
unknown origin, characterized by infiltration of histiocytes in
the affected tissues. The objective of this study was to assess
the impact of 18F-FDG PET/CT for the diagnosis and metabolic
response to immunomodulatory treatments.Patients and
methods:We retrospectively analyzed baseline and follow-up
18F FDG PET/CT exams as it follows: 406 exams in 85 patients
with Erdheim-Chester disease (ECD), 15 exams in 5 patientswith
Rosai-Dorfman disease (RDD), 55 exams in 20 patients with
LCH, 102 exams in 14 patients with combined forms of
histiocytoses (LCH+ECD, LCH+RDD), as well as 6 exams in
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3 patients with xanthogranulomatoses. As the gold standard (his-
tological confirmation of all the metabolic localizations) cannot
be achieved, 18F FDG PET/CT exams, were compared with
organ/system based radiological (CT/MRI) findings (for exam-
ple: thorax, abdomen and pelvis CT, brain MRI, cardiac MRI,
bone MRI), specific for every patient. Metabolic responses to
treatments (41 patients on interferon-α, 13 patients on
vemurafenib and 7 patients on infliximab) were assessed by the
ΔSUVmax (baseline-final)/baseline of the highest-uptake lesion.
Concordances between 18F FDG PET/CT and CT/MRI were
assessed by the kappa (κ) coefficient. Results: Besides a whole-
body topographical characterization, 18F FDG PET/CT showed
an overall sensitivity and specificity ranging from 33 to 100%
and from 60 to 100% respectively, according to the organ or
system explored. Highest rates of metabolic uptake detection by
18F FDG PET/CT in histiocytosis lesions of both ECD and
mixed forms, compared with CT/MRI, concerned long bone le-
sions (80%vs 73% for ECD, 93%vs 86% formixed forms), with
an excellent concordance (κ=0,96 for ECD, κ=1 for mixed
forms) between imagistic methods. 18F FDG PET/CT identified
17metabolic responses (41%) on interferon-α (24-monthmedian
follow-up), one complete response and 8 (62%) partial responses
on vemurafenib (12-month median-follow-up), as well as a par-
tial response on infliximab (15-month median follow-
up).Conclusions:The results of this large retrospective study sug-
gest that whole-body 18F FDG PET/CT is informative at diag-
nosis for a better whole-body staging (rapid and more exhaustive
identification of localisations) for each histiocytosis subtype and
for the evaluation of the metabolic response to various immuno-
modulatory treatments.
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Increased myocardial 18F-FDG uptake
after doxorubicin-based chemotherapy in Hodgkin
disease: an early predictor of cardiotoxicity?
M. Bauckneht1, G. Ferrarazzo1, F. Fiz1, P. Ghione2, F.
Bongioanni1, A. Nieri1, M. Pennone1, S. Morbelli1, P.
Spallarossa2, C. Marini3, G. Sambuceti1; 1Nuclear Medicine,
IRCCS AUO San Martino IST, Genova, ITALY, 2Department
of Internal Medicine, Chair of Cardiology, University of Gen-
oa, Genova, ITALY, Genova, ITALY, 3Institute of Bioimaging
and Molecular Physiology, CNR, Milan, Genoa Section, Ge-
nova, ITALY, Genova, ITALY.
Aim. Doxorubicin-induced cardiotoxicity is related to many
pathophysiological mechanisms, including oxidative stress
and increased endothelin-1 serum levels. Previous in vitro
studies documented that both these mechanism promote
GLUT expression in cardiomyocite’s sarcolemma. The aim
of the present study was to verify whether this phenomenon
can increase FDG uptake in the left ventricular myocardium of
patients with Hodgkin disease (HD) treated with Doxorubicin-
based chemotherapy scheme. Materials and Methods. We ret-
rospectively analyzed FDG PET/CT scans of 24 patients with
HD (mean age was 34±13) selected according to the following
inclusion criteria: 1) absence of any history of cardiovascular
disease; 2) full remission after two ABVD cycles; 3) availabil-
ity of at least 4 consecutive PET/CT scan performed for stag-
ing (PET1), interim (PET2), post-therapy (PET3) and six
month follow up (PET4) evaluation. Time points of PET/CT
scan were thus at baseline and at 2, 6 and 12 months, respec-
tively. Volumes of interest were manually drawn on the left
ventricular myocardium and on skeletal muscle (paraspinal) to
estimate mean (SUVmean) and maximum (SUVmax) stan-
dardized uptake values that were normalized for SUVmean
determined by drawing a 1-cm oval region of interest in the
aortic arch as an index of blood pool tracer concentration.
Results. Normalized myocardial SUVmean was 2.08±1.29 at
baseline and showed a progressive increase that became sig-
nificant at PET3 (3.31±2.66, p<0.05) to remain stable in
PET4 at 3.55±2.53 (p<0.05 vs PET1, p=ns vs PET3, respec-
tively). Conversely, muscle SUVmean increased from PET1
(0.34±0.12) to PET3 (0.49±0.28, p<0.05); however, it
returned to baseline values at PET4 (0.37±0.13) (p=ns vs
PET1, p<0.05 vs PET3, respectively). Consequently,
SUVmean increased from PET3 to PET4 in the myocardium,
while it dropped in the skeletal muscle, as demonstrated com-
paring the PET4/PET3 ratio in these two tissues (p<0.05). The
same results were obtained when compared myocardial and
skeletal muscle normalized SUVmax. Conclusions. Present
data demonstrate a divergent metabolic pattern between myo-
cardium and skeletal muscle in young patients treated with a
Doxorubicin-based chemotherapy for HD. Intriguingly, the
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main difference between myocardial and skeletal muscle FDG
uptake was detected at follow-up analysis when compared to
staging and post-therapy evaluation. Although our protocol
does not imply a sugar free diet in the days preceding the
scans, the increased myocardial uptake trend and the divergent
muscular metabolic performance could be at least partially
explained by a Doxorubicin-induced myocardial GLUT
overexpression.
OP541
Reverse mismatch in a patient cohort undergoing
18F-FDG/82Rb dual isotope PET for assessment
of myocardial viability: Is it a significant clinical problem?
A. K. Hansen, M. Gejl, K. Bouchelouche, L. P. Tolbod, L. C.
Gormsen; Aarhus University Hospital, Aarhus, DENMARK.
Background: Dual isotopemyocardial positron emission tomog-
raphy (PET) with perfusion (e.g. 82Rb PET) and metabolism
tracers (18F-FDG viability PET) during hyperinsulinemia is cur-
rently widely used when myocardial viability is assessed. The
technique is used to identify viable but underperfused myocar-
dium (hibernating myocardium) in order to guide potential re-
vascularization efforts. 18F-FDG viability PET relies on the as-
sumption that all viable tissue takes up 18F-FDG when suffi-
ciently stimulated by hyperinsulinemia. This may, however, not
always be the case. It has thus been demonstrated that patients
with type 2 diabetes (T2D), as well as patients with dilated
cardiomyopathy, has severely depressed myocardial glucose up-
take. In a clinical setting, this is highly unfortunate since 1)
viable but non-FDG avid myocardium may appear
hypometabolic , and 2) a large fraction of patients with heart
failure suffer from either diabetes or dilated cardiomyopathy.
Perfused but apparently hypometabolic myocardium is termed
”reverse mismatch”. Aim: To assess the fraction of patients with
reverse mismatch in a mixed patient cohort undergoing 18F-
FDG viability PET. Materials and methods: 92 heart failure
patients (25 with diabetes) undergoing 18F-FDG viability were
retrospectively reviewed. Resting perfusion was assessed by
82Rb PET (1110 MBq) followed by 18F-FDG PET scans
(400MBq) of the heart region. 18F-FDG uptake was stimulated
by a total of 2 hours hyperinsulinemic-euglycemic (HE) clamp
(1mIE/kg/min). Percentage of hypoperfused and hypometabolic
myocardium was calculated based on a 5-point score (17-
segment model) divided by the maximum points obtainable.
The difference between percentage hypoperfused and
hypometabolic myocardium was calculated (DIF_PERF_MET)
and interpreted as reverse mismatch if normal perfusion was
observed with depressedmetabolism. Coincident hypoperfusion
and hypometabolism was considered scar whereas hypoperfu-
sion with normal metabolism was considered hibernation. Re-
sults: In 31/92 patients hypometabolic myocardium significantly
exceeded the percentage of hypoperfused myocardium (RE-
VERSE PATIENTS) indicat ing reverse mismatch
[DIF_PERF_MET (%): 30.7 +/- 13.5 (REVERSE PATIENTS)
vs. 11.4 +/- 7.1 (SCAR AND HIBERNATION), p<0.001]. No
correlation was observed between left ventricle volume and de-
gree of reverse mismatch and no impact of diabetes status on
reverse mismatch was observed. Hibernating myocardium was
demonstrated in only one patient. Conclusion: In amixed patient
cohort undergoing HE-clamp and 18F-FDG viability PET, re-
verse mismatch was observed in 34 % of studies regardless of
diabetes status. Since underestimated viability may severely im-
pact the decision to revascularize patients, 18F-FDG PET via-
bility studies should be interpreted cautiously and preferably in
conjunction with results from other modalities (e.g. MRI).
OP542
Assessment of cardiac sympathetic nerve system in the rat
heart using 11C-HED
Y. Maya1,2, R. Werner1,3, H. Wakabayashi1, M. Nakajo1, K.
Fukushima4, C. Lapa1, K. Herrmann1, T. Higuchi1,3; 1Depart-
ment of Nuclear Medicine, Universitätsklinikum Würzburg,
Würzburg, GERMANY, 2Research Centre, Nihon Medi-
Physics Co., Ltd., Chiba, JAPAN, 3Comprehensive Heart Fail-
ure Center, Würzburg, GERMANY, 4Hyogo College of Med-
icine, Hyogo, JAPAN.
Objectives: The sympathetic nervous system of the heart plays
a crucial role in various cardiac diseases including ischemic
heart diseases and heart failure. High-resolution small-animal
PET enables noninvasive and quantitative evaluation of the heart
in rodent models of human diseases. In this study, we investigate
the feasibility of assessing sympathetic nerve system activity with
11C-HED PET in rat hearts. Methods: To confirm the specificity
of 11C-HED uptake in rat myocardium, 11C-HED with a wide
range of specific activities was injected (48.7+/-9.7MBq, ranged
0.2-60.4μg/kg coldmass) into healthy rats (n = 14) via a tail vein.
Dynamic 23-frame PET images were started just before the tracer
administrations, and obtained over 30 min. Time activity curves
were generated for myocardial tissue region of interest (ROI) at
mid ventricular level and blood activity at left atrial cavity ROI.
Cardiac 11C-HED retention index (%/min) was calculated as
myocardial tissue activity at 20-30min divided by the integral
of the blood activity curves. In rat model of transient ischemia
(7 days after 20 min left coronary occlusion and reperfusion,
n=2), 11C-HEDPETand following 18F-FDGPETas a reference
of myocardial viability was performed to evaluate the feasibility
of assessing the local sympathetic nerve damage. Results: In
healthy rat hearts, dynamic PET demonstrated stable, high con-
trast and homogeneous left ventricular myocardial uptake within
5 min after intravenous tracer injection. In different 11C-HED
specific activities, the estimated retention index decreased as
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loading cold mass increased. These data were well fitted by a
dose-response model (r2=0.92), and the estimated IC50 value
(95% confidence intervals) was 46.3 (34.6-62.0) μg/kg. In rat
model of transient ischemia, PET imaging clearly visualized the
11C-HED uptake defect in the anterolateral wall, while 18F-FDG
uptake was preserved throughout the ventricle at the 11C-HED
defect area. Post mortem tissue analysis with HE staining and
tyrosine hydroxylase nerve staining confirmed denervation but
viable myocardium after transient coronary occlusion. Conclu-
sions: Cold mass effect of cardiac 11C-HED uptake measured
as retention index by PET showed specificity of the imaging
signal in the rat heart. Furthermore, local impairment of 11C-
HED uptake despite preserved 18F-FDG uptake indicates feasi-
bility of regional assessment of sympathetic nerve damage in rat
model of ischemia. A combination of serial 11C-HED PET im-
aging and rat model of cardiac disease would be one of the
promising approaches to investigate further insight into the dy-
namic pathophysiology of sympathetic nervous system of the
heart.
OP543
Value of attenuation correction in stress-only myocardial
perfusion imaging using CZT-SPECT
J. D. van Dijk1,2, M. Mouden1, J. Ottervanger1, J. A. van
Dalen1, S. Knollema1, C. H. Slump2, P. L. Jager1; 1Isala hos-
pital, Zwolle, NETHERLANDS, 2MIRA: Institute for Bio-
medical Technology and Technical Medicine, University of
Twente, Enschede, NETHERLANDS.
Purpose: Attenuation correction (AC) has been shown to en-
hance conventional stress-only SPECT myocardial perfusion
imaging (MPI). However, it remains unknown whether the
same holds true when using the newest generation cadmium
zinc telluride (CZT)-based cameras. The aim of this study was
to determine the value of attenuation correction on stress-only
MPI using a CZT-SPECT camera. Methods: A retrospective
analysis was performed including 107 consecutive stable, low
to intermediate risk patients (age 60 ± 12 years, 43% male
gender and BMI 28.1 ± 4.7 kg/m2) who underwent clinically
indicated MPI CZT-SPECT/CT (Discovery NM/CT 570c, GE
healthcare). The stress scans were reconstructed with and with-
out CT-based attenuation correction (AC). Three types of im-
ages were created for interpretation; only displaying recon-
structed data without AC (NC), only with AC, and with both
NC and AC (NC+AC). Next, two experienced physicians vi-
sually interpreted by consensus these 321 randomized images
for diagnostic outcome (normal, equivocal, abnormal scan)
without knowledge of patient’s history or other clinical find-
ings. We have recorded all relevant events, in example, late
coronary revascularization (>60 days), non-fatal myocardial
infarction and all-cause death, in a mean follow-up time of
47.7 ± 9.8 months. Results: The percentage of normally
interpreted scans increased from 45% using the NC images
to 72% and 67% using the AC and NC+AC images, respec-
tively (p<0.001). The percentage of images interpreted as
equivocal decreased when including attenuation correction
from 43% to 20% and 24% for the AC and NC+AC images,
respectively (p<0.001). In addition, comparable hazards ratios
on the recorded events were observed between the normally
interpreted NC and AC (1.16, p=0.86), or NC+AC (0.99,
p=0.99). Conclusion: The use of AC decreases the need for
rest imaging in CZT-based SPECT cameras. This has the po-
tential to reduce the cumulative radiation dose and improves
laboratory efficiency. Although we did not assess the direct
diagnostic accuracy, patient outcome seems unaffected.
OP544
Characterization of a dedicated myocardial cardio-centric
SPECT-TC System: a preliminary phantom study
E. Richetta, M. Pasquino, C. Cutaia, G. Brusasco, G.
Santopolo, I. Trabucco, A. Guida, R. Pellerito, M. Stasi; AO
Ordine Mauriziano di Torino, Turin, ITALY.
Aim: The increasing need of faster myocardial perfusion im-
aging and dose patient reduction are nowadays satisfied by a
novel dedicated cardiac equipment. At our institution a
SPECT-CT was recently installed: cardio-centric multifocal
collimators combinedwith a dedicated reconstruction software
increased sensitivity and allows shorter image acquisition
times or lower patient dose. With the aim to define the best
acquisition protocol, a cardiac phantom was scanned with dif-
ferent frames and times. Semi-quantitative analysis was per-
formed and images were qualitatively evaluated by two expe-
rienced physicians. Materials and methods: A thoracic phan-
tom (Biodex) with a cardiac insert, simulating a focal perfu-
sion deficit in heart wall, was filled with 99mTc uniform ac-
tivity (37 GBq, dose-rate 5-6 kcps); acquisition was performed
with cardio-centric collimators (Siemens SMARTZoom, ma-
trix 128x128, angle 59°-104°, zoom1), varying the number of
views (#frame:32, 30, 28,26, 22, 20, 18,10) and acquisition
time per view (20, 15, 10, 5 s). A CT thoracic scan was then
executed to correct images for scatter and attenuation. Recon-
struction was performed with dedicated myocardial algorithm
(Siemens IQSPECT-Iterative Flash3D, 8iteration, 4subset).
Images were qualitatively inspected by two experienced phy-
sicians. For a semiquantitative analysis, a 17-segments QPS-
model was adopted to evaluate perfusion polar maps; perfu-
sion index, deficit extent, TPD, stress score SS and S% were
analyzed as function of number of views and time per view;
results were correlated to acquisition time. Results: Qualitative
analysis of images showed an improved uptake-to-background
ratio for a 18 frame-20s acquisition; for acquisition time less
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than 20 s a poor statistic was found. The 17-segment analysis
showed no significant variations at varying the number of
views from 32 to 18. Scores range showed minimal fluctua-
tions when number of views was changed (extent [42-45],
TPD [30-33], SS [23-25] S%[34-37]), confirming the qualita-
tive analysis performed by physicians. Reducing time per
views, the difference becomes higher (extent [42-50] , TPD
[31-37], SS [23-28] S%[34-41]). Finally, reducing frames
from 32 to 18, the acquisition time decreases up to 60% with
a substantially equal image quality. Conclusions: The best ac-
quisition protocol was defined to optimize the procedure (18
frame-20s), according to qualitative and quantitative analysis.
This operating mode, feasible only with this dedicated myo-
cardial cardio-centric SPECT-TC System, allows to reduce
acquisition time (or dose to patients) up to 40%, compared to
standard protocols with an improved image quality.
OP545
Gated Myocardial Imaging: The impact of FBP
and OSEM Image Reconstruction and Filtering on values
of Left Ventricle function calculated with a commercial
program - QGS*
D. S. Rosário; Karolinska Institutet, Stockholm, SWEDEN.
Aim: MPI tomographic (GSPECT) images are acquired syn-
chronized with a patient’s ECG for both stress and rest phases.
These are reconstructed, processed and compared to detect
changes in myocardial perfusion and left ventricular (LV)
function. MPI image quality is strongly affected by the filter-
ing process executed in GSPECT reconstruction. The optimal
choice and selection of filter parameters is still considered a
problem in the reconstruction process. The aim of this study
was to evaluate how the change of filter parameters in Filtered
Back Projection (FBP) and Ordered Subset Expectation Max-
imization (OSEM) reconstruction techniques affect the LV
functional values calculated by QGS, a commercial program
and the accuracy of the values as compared to ultrasound mea-
surements. Methods: Thirty patients were included in study.
GSPECT images were acquired in the stress and rest phases. A
two days protocol was used and the radiopharmaceutical for
both phases was 99mTc-sestamibi. The LV functional values
(ejection fraction (LVEF), end diastolic volume (EDV) and
end systolic volume (ESV)) were calculated with the QGS
program for 8 different reconstruction procedures: FBP recon-
structions and a Butterworth filter, using the same order, equal
to 5, but changing the cut-off frequencies, which were: 0.20,
0.30, 0.40 and 0.50. For OSEM, all reconstructions were made
with 4 iterations with 8 subsets and a Gaussian filter with
different FWHM (mm), which were: 4, 8, 14 and 20. Refer-
ence LVEF values were calculated from ultrasound studies
using Simpson’s method. Results: There was a good
correlation between functional values for most of the filter
functions between phases and for LVEF against ultrasound,
irrespective of reconstruction method. For FBP with a
Butterworth filter with cut-off frequency 0.20 and OSEMwith
a Gaussian filter with FWHM 20, however, all correlations
were poor. Discussion and Conclusions: LV functional values
were shown to fairly independent of reconstruction method
and filter function unless a very low pass filter was used.
The good correlation between stress and rest phases showed
that values were reproducible provided the perfusion distribu-
tion and LVEF were similar for both phases. There was also a
good correlation between LVEF values measured with
GSPECT and ultrasound. The best correlation was obtained
with filters that resulted in noisy images. Since there were
individual variations in LV functional values that could have
affected a diagnosis, it may be better to choose reconstruction
parameters that produce images that can be qualitatively
assessed to ensure that the calculated are reasonably correct.
OP546
Feasibility of an eighth-time gated myocardial perfusion
SPECT functional imaging using IQ-SPECT system.
F. Caobelli1, J. T. Thackeray1, A. Soffientini2, F. M. Bengel1,
C. Pizzocaro2, U. P. Guerra2; 1Hannover Medical School,
Hannover, GERMANY, 2Fondazione Poliambulanza, Brescia,
ITALY.
Background: IQ-SPECT, an add-on to general purpose cam-
eras based on multifocal collimation, can reduce scan acquisi-
tion time to one fourth of standard procedures (12s/view) in
myocardial perfusion imaging (MPI). In a phantom study, a
reduction to one eighth of standard acquisition time (6s/view)
was demonstrated as feasible. It remains unclear whether such
a reduction could be extended to clinical practice. Methods:
Fifty patients with suspected or diagnosed CAD underwent a
two-day stress/rest 99mTc-sestamibi MPI protocol. Two con-
secutive SPECT acquisitions (6 and 12s/view) were per-
formed. Electrocardiogram-gated images were reconstructed
with and without attenuation correction (AC).Polar maps were
generated and visually scored by 2 blinded observers for im-
age quality and perfusion in 17 segments. Global and regional
summed stress (SSS), summed rest (SRS) and summed differ-
ence scores (SDS) were determined. Left ventricular volumes
and ejection fraction were calculated based on automated con-
tour detection. Results: Image quality was scored higher for
12s/view scans, both with and without AC. Summed scores
were statistically comparable between 6 and 12s/view acqui-
sitions, either globally or in individual coronary territories (e.g.
in AC images 6s vs 12s/view: SSS 6.6±8.3 vs 6.2±8.2, p=0.10;
SRS 3.9±5.6 vs.3.5±5.3, p=0.19; SDS 2.8±5.7 vs. 2.6±5.7,
p=0.59). Both acquisitions allowed an MPI-based diagnosis
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of CAD in 25/50 patients (AC). End diastolic and end-systolic
calculated volumes were modestly higher from 6s/view acqui-
sitions compared to 12s/view (EDV +4.8 ml at rest and +
3.7 ml after stress,p=0.003; ESV +4.1 ml at rest and +2.6 ml
after stress,p=0.01), whereas ejection fraction did not differ (-
1.2% at rest, p=0.20 and -0.9% after stress, p=0.27). Conclu-
sion: Image quality and LV functional parameters acquired at
one eighth time were statistically comparable to the previously
validated one fourth time protocol using IQ-SPECT. Shorter
acquisition times without loss of diagnostic accuracy provides
for improved patient comfort and streamlined departmental
efficiency.
OP547
Impact of Data-Driven Respiratory-Motion Correction
on the Extent/Severity of Myocardial Perfusion Defects
of MPI SPECTAcquired with Discovery NM 530c:
REGAT Software
D. Daou1,2, R. Sabbah3, H. Bouladhour3, C. Coaguila4; 1Co-
chin Hospital, APHP, Paris, FRANCE, 2EA 7334 REMES,
Université Paris-Diderot, Sorbonne Paris-Cité, Paris,
FRANCE, 3CHU Jean Minjoz, Besançon, FRANCE, 4Centre
Hospitalier de Bigorre, Tarbes, FRANCE.
Aim: We previously developed a data-driven respiratory-mo-
tion (RM) correction method for conventional SPECT
gamma-cameras (REGAT) and adapted it to CZT multi-
pinhole detector gamma camera (Discovery NM 530c). We
recently reported that REGAT is clinically feasible, easily ap-
plicable and presents interesting impact on image characteris-
tics when applied to myocardial perfusion SPECT imaging
(MPI) realized with Discovery NM 530c. In this preliminary
evaluation, we aimed to study whether REGATapplied toMPI
(Discovery NM 530c) impacts the extent/severity of MPI de-
fects (MPD). Materials and Methods: Were included 25 pa-
tients addressed for stress/rest MPI. All patients had prone
stress MPI (2 MBq/Kg 99mTc-Tetrofosmin) than prone rest
MPI 3-hours later (n=24/25 pts, 6 MBq/Kg). All acquisitions
were made on Discovery NM 530c. Each list mode acquisition
was processed to generate a dynamic SPECTacquisition study
of 500 msec duration. Each dynamic SPECT study was proc-
essed to generate its corresponding data-driven RM curve.
This curve was used to generate a mean RM GSPECT study
which was reconstructed on Xeleris workstation. The corre-
sponding reconstructed RM gated volumes were summed ei-
ther without realignment (nonR-SPECT) or after rigid realign-
ment (R-SPECT). These nonR-SPECT and R-SPECT studies
(49 = 25 stress+24 rest) were classified by an experienced
observer as presenting an impact (G1) or no impact (G2) on
severity/extent MPD: an impact was considered present if ≥ 1
LV segment presented a modification ≥ 1 score (LV: 17
segments; 5 point scoring). Were noted the maximal RM in
the 3 axis of reoriented LV: anterior/inferior (A-I), septal/
lateral (S-L) and basal-apical (B-A) axis. Was also calculated
variation of LV myocardial counts (LV-Max, %) between both
R-SPECTand nonR-SPECT LV-Max. Results: A_I movement
was the dominant movement (n=49): A-I, S-L and B-A axis
were 9.7±4.6 mm, 1.8±1.1 mm, 3±2.3 mm. Variation in LV-
Max (n=49) was 2.75±3.61 %. G1 consisted of 7/49 studies
(14%). In G1 vs G2, variations in LV-Max were 3.7±7.9 % vs
2.6±2.4% (NS), and A_I movement were 15.7±3.5 mm vs 8.7
±4 mm respectively (P<0.01). The cumulative % studies pre-
senting with a positive impact on MPD (Cum) was correlated
to the A_I movement: Cum (%) = 0.0043*A_I2 - 0.0325*A_I
+ 0.2099 (r2=0.9725, P<0.0001). In 13/49 studies (27%) with
A_I >12 mm, 6/13 (46%) presented an impact on MPD. Con-
clusion: Data-driven respiratory-motion correction of MPI
with Discovery NM 530c appears to impact MPD in a sub-
stantial number of studies. Its incidence is related to the mag-
nitude of RM.
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OP548
The Influence of 68Ga-DOTATATE PET/CT Imaging
in the Management Decision of Patients
with Neuroendocrine Tumors
E. Skoura1, O. M. AlMukhalid1, E. Panagiotidis1, M. Al
Harbi1, I. Kayani1, S. Michopoulou1, R. Syed1, P. J. Ell1, M.
E. Caplin2, J. Bomanji1; 1UCLH, London, UNITED KING-
DOM, 2Royal Free Hospital, London, UNITED KINGDOM.
Aim: 68Ga-DOTATATE PET/CTscan is a widely acceptedmeth-
od for imaging of neuroendocrine tumors (NET). This study
evaluates the role of 68Ga-DOTATATE PET/CTscan to influence
management decisions in patients with NETs and evaluates any
possible correlation between 68Ga-DOTATATEPET/CT findings
and patients’ survival data. Materials and methods: Clinical out-
come, survival, and change in management after 68Ga-
DOTATATE PET/CTwere evaluated. Data from NET multidis-
ciplinary team (MDT) minutes, patient discharge summaries and
correspondence was reviewed to evaluate the influence of 68Ga-
DOTATATE PET/CT scan on patients’ treatment plan. Results:
During eight year time, more than 1000 68Ga-DOTATATE PET/
CTscans were performed in patients with confirmed or suspected
NETs. The findings of 68Ga-DOTATATE PET/CTscans changed
the patients’ treatment plan in about 41%of the cases. The change
in therapeutic management consisted mainly of resection of a
previously unknown primary tumor, initiation of chemotherapy
or peptide receptor radionuclide treatment (PRRT) due to
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recurrence, change to chemotherapy instead of surgery or change
to PRRT instead of chemotherapy. The most frequent manage-
ment change was observed in patients with lung NET and med-
ullary thyroid carcinoma while in patients with unknown site of
primary NET, the change in treatment plan was lower. Further-
more, Kaplan Meier analysis has shown that the survival rates at
3 and 5 years after the 68Ga-DOTATATE PET/CT scan was sig-
nificantly better in patients with negative scans compared to those
with positive scans (p<0.01). Conclusion: This large study dem-
onstrates that 68Ga-DOTATATE PET/CT scan can change the
treatment plan in a significant percentage of patients with NET.
Also, it is shown that a negative 68Ga-DOTATATE PET/CTscan
is associated with significantly better survival
OP549
Do we need full-dose contrast-enhanced CT
for extra-hepatic staging using
Gallium-68-DOTATATE-PET/CT in patients
with neuroendocrine tumors (NET)?
A. Heinzel1, D. Albanus1, F. Verburg1, F. Behrendt1, F.
Mottaghy1,2, Z. Erdem3, O. Erdem3, J. Apitzsch4; 1UK Aa-
chen, Aachen, GERMANY, 2Maastricht University Medical
Center, Masstricht, NETHERLANDS, 3Bülent Ecevit Univer-
sity, Karaelmas, TURKEY, 4UK Gießen and Marburg, Mar-
burg, GERMANY.
Aims: Previous studies have demonstrated that PET/CT with
68Ga-labeled somatostatin analogues is helpful in the assess-
ment of the presence of metastatic disease in in patients with
neuroendocrine tumors (NET) especially with regard to extra-
hepatic metastases such as bone and lymph node metastases. It
has to be noted that the PET in combination with full-dose
contrast-enhanced CT (ceCT) exposes the patients to a high
dose of radiation (up to 25Smv) whereas the non-contrast-
enhanced low-dose CT (ldCT) might reduce the radiation to
about 10mSv and at the same time avoid potential side effects
of the contrast agent. Thus, we aimed to determine whether
ceCT can be omitted in the assessment of extra-hepatic metas-
tases in patients with NET. Methods/Materials: We retrospec-
tively compared the performance of PET/ldCT versus PET/
ceCT in 54 patients (26 male, 28 female) who underwent a
Gallium-68-DOTATATE-PET/CT in our clinic. Patients were
selected according to following criteria: available ldCT and
ceCT; histologically confirmed NET; available follow-up of
at least 6 months (median 12.6 months; range 6.1-23.2).
PET/ldCT and PET/ceCT images were analyzed separately.
The review process focused on metastases to bones and lymph
nodes. Afterwards, the PET/ldCT and PET/ceCT results were
compared to the reference standard consisting of clinical
follow-up data to evaluate the diagnostic performance. Re-
sults: In PET/ceCT 139 true positive bone-lesions were
detected compared to 140 in PET/ldCT, 106 true positive
lymph node metastases (PET/ceCT) vs. 90 (PET/ldCT). On a
per patient basis ld and ce PET-CTachieved similar sensitivity
(both 100%) however, specificity was lower for PET/ldCT
(89% vs. 77%). For lymph nodes PET/ceCT showed superior
sensitivity and specificity (sensitivity 92% vs. 80% and spec-
ificity 83% vs. 65%). The positive predictive value (PPV) and
negative predictive value (NPV) of PET/ceCT were 81% and
100% for bone metastases as well as 82% vs. and 92% for
lymph node metastases. In contrast, PET/ldCT showed 91%
PPVand 100% NPV for bone metastases as well as 78% PPV
and 68% NPV for lymph node metastases. Conclusions: We
demonstrate that ceCT should not be omitted for extra-hepatic
staging using Gallium-68-DOTATATE-PET/CT in patients
with neuroendocrine tumors. With regard to the detection of
lymph node metastases ceCT is helpful to minimize false pos-
itive lesions. However, if only bone metastases are considered
PET/ceCT and PET/ldCT show similar diagnostic
performance.
OP550
The clinical role of Ga-68 DOTATE PET-CT in patients
with neuroendocrine tumors
M. Tuncel1, S. Kılıçkap2, E. Akdemir1; 1Hacettepe University,
Department of Nuclear Medicine, ANKARA, TURKEY,
2Hacettepe University, Department ofMedical Oncology, AN-
KARA, TURKEY.
AİM: The introduction of Ga-68DOTATE PET-CT for the
evaluation of neuroendocrine tumors(NETs) has significantly
improved the diagnostic work-up. However impact on patient
management is yet to be determined. We aimed to evaluate the
clinical impact of the Ga-68DOTATE PET-CT in our patients
suffering from NETs. Material & METHODS: The clinical
and imaging data of 61 consecutive patients (F/M:35/26;
agemedian:56±14years,range:22-82) with diagnosis of NET
(9 carcinoids,2 pheochromocytomas,3 paragangliomas,4 med-
ullary thyroid carcinomas,2 poorly and 41 well-differentiated
gastroenteropancreaticNETs) were studied. All patients
underwent Ga-68DOTATE PET-CT imaging for staging(n=9),
restaging-suspected reccurence(n=48) and therapy response
evaluation(n=4). Both PET-CT and conventional imaging
(CI) were than interpreted together with medical oncologist
to determine the clinical impact of the Ga-68DOTATE PET-
CT. As a standard of reference clinical and imaging follow-up
data were used (median:14mo; range:9-48mo). RESULTS: In
11 patients, PET-CT detected additional lesion sites (15 lesion
sites in 10 patients), that are not detected by CI(3
endobronchial,5 lymph node,2 intestinal,2 pancreas and 3
bone, medianSUVmax:7[3-16], lesion size:10mm[5-20]).
SUVmax values of lesions were higher in patients in whom
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more lesions were seen by PET-CT (SUVmaxmedian:5.5 vs
20p<0.0001). Thirteen (21%) patients were interpreted as no
evidence of disease by both PET-CTand CI. In 18/61(30%)pa-
tients, although detected malign lesions, Ga-68DOTATE PET-
CT had no clinical impact over CI. PET-CT changed clinical
management in 30/61(49%) patients;peptide receptor radionu-
clide therapy(PRRT) was considered as a systemic therapy
option other than chemotherapy in 12/30(40%) patients due
to high (tumor/liver SUVmax>2.2 ) radiotracer uptake, PRRT
was prevented in 8/30(27%) patients due to low radiotracer
uptake. PRRT was decided in 3(10%) patients instead of
surgery/local ablative therapy due to systemic disease detected
by PET-CT, 4/30(13%) patients underwent surgery for recur-
rence detected by PET, instead of follow-up with somatostatin
analogue, systemic chemotherapy was decided instead of local
therapy in 2/30(7%) patients, and radiofrequency ablation was
decided for equivocal liver lesion on CI due to positive PET
findings in 1/30(3%) patient. Among these 61 patients 17 pa-
tients also had FDG PET-CT in 2 months of Ga-68DOTATE
PET. There was a negative correlation between FDG PET-CT
and Ga-68DOTATE PET-CT (Spearman correlation coeffi-
cient-0,372 p:0,156). CONCLUSION: Ga-68DOTATE PET-
CT has a major clinical impact in 49% of pts with NETs. It has
detected more lesions than CI especially in patients with high
radiotracer uptake and negatively correlated with FDG-PET.
Our results indicate Ga-68DOTATE PET-CT as a mandatory
procedure to guide patient management
OP551
Validation of parametric net influx rate images
of 68Ga-DOTATOC and 68Ga-DOTATATE
E. Ilan, M. Sandström, I. Velikyan, A. Sundin, M. Lubberink;
Section of Nuclear Medicine and PET, Department of Surgical
Sciences, Uppsala University, Uppsala, SWEDEN.
Objectives: 68Ga-DOTATOC/68Ga-DOTATATE are
radiolabelled somatostatin analogues used for diagnosis of so-
matostatin receptor(SSTR)-expressing neuroendocrine
tumours.In addition, their use in treatment follow-up has been
proposed. However, for these tracers SUV does not correlate
linearly with the net influx rate(Ki), assumed to reflect SSTR
density. Changes in Ki may better reflect treatment effects than
changes in SUV, and it would be desirable to be able to com-
pute parametric images showing Ki at the voxel level. The aim
of this study was to evaluate parametric methods for compu-
tation of Ki images, and to compare image contrast in terms of
tumour to liver ratio for parametric Ki images and SUV im-
ages. Materials and methods: Ten patients with metastatic neu-
roendocrine tumors underwent a 45-min dynamic scan follow-
ed by a whole-body (WB) PET/CT scans at 1 h post injection
of 68Ga-DOTATOC and 68Ga-DOTATATE on consecutive
days.The Ki was determined by nonlinear regression of an
irreversible two-tissue-model as well as the Patlak method,
using a descending aorta input curve. Parametric Ki images
were made using a basic function method (BFM) implemen-
tation of the two tissue irreversible compartment model and
Patlak method, and mean tumor Ki values were determined for
50% isocontour VOIs. Liver VOIs were drawn over WB and
Ki images and tumour to liver ratios were calculated. The
relation between the ROI-based and parametric Ki values were
evaluated by using linear regression. Results: The correlation
(R2) between the ROI based (irreversible two-tissue-model)
and parametric based (BFM) Ki images were 0.83 and 0.97
for 68Ga-DOTATOC and 68Ga DOTATATE, respectively with
a slope of 1.0 in the both fits. The correlation (R2) between the
ROI based (Patlak) and parametric based (Patlak) Ki images
were 0.95 and 0.76 for 68Ga-DOTATOC and 68Ga
DOTATATE respectively with a slope of 1.1 in the both fits.
The contrast between tumour and liver is 1.7 and 1.8 times
higher in the parametric Ki images based on BFM than in the
1h WB images for 68Ga-DOTATOC and 68Ga-DOTATATE
respectively. For parametric Ki images based on Patlak meth-
od the contrast is 2.4 and 2.7 times higher for 68Ga-DOTATOC
and 68Ga-DOTATATE respectively. Conclusion: A good cor-
relation and agreement between the parametric and ROI-based
Ki values was found, showing that parametric Ki images are
quantitatively accurate. In addition, tumour to liver contrast
was higher in the parametric Ki images than in the 1h WB
images both for 68Ga-DOTATOC and 68Ga DOTATATE.
OP552
68Ga-DOTA-NOC PET/CT SUVmax in patients
with pancreatic NET: is it prognostic?
V. Ambrosini1, G. Polverari1, D. Campana2, G. Cacciari2, C.
Peterle1, S. Diodato1, C. Nanni1, G. Montini1, P. Tomassetti2,
S. Fanti1; 1Nuclear Medicine, University of Bologna,
S.Orsola-Malpighi Hospital, Bologna, ITALY, 2Internal Med-
icine, University of Bologna, S.Orsola-Malpighi Hospital, Bo-
logna, ITALY.
Aim: to investigate the role of SUVmax measured on 68Ga-
DOTA-NOC PET/CT as a potential prognostic factor in patients
(pts) with pancreatic NET (pNET) . Materials and methods:
Among the pts who underwent 68Ga-DOTANOC PET/CT from
September 2006 to October 2014, those with pathologic confir-
mation of well differentiated pNET (WHO 2010: G1 or G2),
documented disease at both 68Ga-DOTA-NOC PET/CT and
CT (performed within a month) and a minimum clinical-
radiological follow-up of 6 months (mo) were included in the
study. Radiological follow-up consisted of a CT scan every 3
mo during the first year and every 6 mo afterwards. Pts with
MEN syndrome were excluded. To evaluate the potential role
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of SUVmax on prognosis, we divided the pts on the basis of the
disease status at 24 months follow-up: pts with progressive dis-
ease (PD) were compared to those with stable disease (SD) or
partial response (PR). Results: Overall 43 pNET pts were includ-
ed (male:female=22:21; mean age=61.0±11.7 [35-81] years). In
35/43 (81,4%) the tumour was non-functioning while 8/43 (16,
3%) presented a clinical syndrome. Ki67 was ≤5% in 22/43 pts
and >5% in 21/43 pts. TNM stagewas III in 7 pts (16,3%) and IV
in 36 (83,7%). Overall 18 pts (41,8%) had SD/PR while in 20
(46,5%) the disease progressed. SUVmax values were signifi-
cantly higher (p=0.022) in pts presenting SD/PR (median 49.8,
IQR25-75%:44.9-78.8) as compared to those with PD (median
33.4, IQR25-75%:26.1-52.4). At univariate analysis, risk factors
for disease progression during follow-up included ki67>5%
(p=0.009), SUVmax <37.8 (p=0.003) and medical therapy alone
(as compared to medical therapy associated with PRRT,
p=0.018). Stage IV (p=0.026), ki67>5% (p=0.009),
SUVmax<37.8 (p=0.043) and medical therapy alone (p=0.015)
were also confirmed at multivariate analysis. Conclusions: Our
data provide evidence of the role of SUVmax as an accurate non-
invasive parameter of disease prognosis in pts with pNET. Al-
though not an objective of our study, our data also confirm the
role of PRRT in pts clinical management.
OP553
Head-to-head comparison of 68Ga-DOTA-NOC
and 18F-FDG PET/CT in neuroendocrine tumours:
correlation between maximum standard uptake values
and Ki67 proliferation index
R. Ferreira1, R. Silva1, A. Moreira1, P. Lapa1, P. Lapa1, G.
Costa1, G. Costa1, J. Lima2; 1Serviço de Medicina Nuclear do
Centro Hospitalar e Universitário de Coimbra, Coimbra, POR-
TUGAL, 2Instituto de Ciências Nucleares Aplicadas à Saúde,
Coimbra, PORTUGAL.
Introduction: Neuroendocrine tumours (NETs) have a hetero-
geneous biological behaviour that poses many clinical chal-
lenges and may compromise accurate diagnostic management,
with consequences in treatment decision and prognosis
evaluation. It is usually accepted that 68Ga-DOTA-NOC
PET/CT is more useful in tumours with Ki67≤20% and that
18F-FDG PET/CT is more accurate when Ki67>20%. Aim:
To compare 68Ga-DOTA-NOC and 18F-FDG PET/CT
maximum standard uptake values (SUVmax) and correlate
them with Ki67-indexes, in both primary and metastatic target
(most relevant) lesions, in NETs. Materials and methods: We
retrospectively reviewed patients with NETs, subjected to
PET/CTwith both 68Ga-DOTA-NOC and 18F-FDG, between
March/2013 and March/2015. Both studies were performed
2.3±2.0 months apart. The patient’s management and disease
condition did not change during that period. Sixteen patients
[13 male, 3 female; mean-age 68.2±12.4years(39-92); 11
gastroenteropancreactic-NETs and 5 lung-NETs] were select-
ed. In 12 patients (75%), both exams were performed during
staging and in 4 cases (25%) during follow-up. Primary tu-
mour was present in all staging cases and was absent in all
follow-up studies. Metastases were detected in 9 patients (5 in
staging; 4 in the follow-up). SUVmax was recorded in 33
lesions (12 primary and 21 target metastases). Primary lesions
were divided into two groups regarding Ki67: Group-1
(Ki67≤20%;n=5) and Group-2 (Ki67>20%;n=7). The 21
target metastases were also divided into two groups regarding
Ki67 of the primary tumour: Group-A (Ki67≤20%;n=9) and
Group-B (Ki67>20%;n=12). Results: The mean±SD
SUVmax for 68Ga-DOTA-NOC and 18F-FDG was, respec-
tively, 14.5±10.2 and 4.8±5.5 in Group-1, and 4.6±1.6 and
25.0±8.0 in Group-2. When comparing SUVmax between
the two groups, we found a statistically significant difference
with 68Ga-DOTA-NOC (p<0.05), but not with 18F-FDG
SUVmax (p=0.17). In both groups, no significant tendency
for higher SUVmax values of either of the radiopharma-
ceutical was observed (p=0.23;p=0.13). For target meta-
static lesions, we conducted a similar analysis and found
a statistically significant difference for 68Ga-DOTA-NOC
SUVmax between Groups A and B (p<0.05) but not with
18F-FDG SUVmax(p=0.06). In Group-1 patients with
metastases (5 cases), no statistically significant differ-
ences were observed in SUVmax values (for both
68Ga-DOTA-NOC and 18F-FDG), between primary and
metastatic target lesions. Conclusion: Our data are con-
sistent with the well-documented functional heterogeneity
of NETs. They suggest that there is no direct association
between somatostatin-receptor expression and metabolic
degree of activity in these tumours. Therefore, we may
conclude that these patients might benefit, despite de
Ki67 proliferation index, from a complementary evalua-
tion of both 68Ga-DOTA-NOC and 18F-FDG PET/CT.
OP554
68Ga-DOTANOC PET/CT imaging in localizing
the primary site in patients presenting with metastatic
neuroendocrine tumors and its impact on clinical decision
making: Experience from a tertiary care centre in India
A. Pruthi, P. Pankaj, R. Verma, A. Jain, E. S. Belho, H.
Mahajan; Sir Ganga Ram Hospital and Research Centre,
New Delhi, INDIA.
Neuroendocrine tumours (NETs) are rare, heterogeneous
group of tumours originating from small, occult primary
sites and are characterized by over-expression of somato-
statin receptors (SSTRs).Purpose: To retrospectively eval-
uate the efficacy of 68Ga-DOTANOC PET/CT imaging
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in detecting the primary site in patients with metastatic
neuroendocrine tumours of unknown origin and its im-
pact on clinical decision making in such patients.
Methods: Between December 2011 and September 2014,
a total of 263 patients underwent 68Ga-DOTANOC PET/
CT study in our department for various indications. Out
of them, 68 patients (45 males, 23 females, mean age
54.9 +/- 10.7 years, range 31-78 years) with histopatho-
logically proven metastatic neuroendocrine tumours and
unknown primary si te on conventional imaging
underwent 68Ga-DOTANOC PET/CT as part of their
pre-treatment staging work-up. Histopathology (wherever
available) and/or follow-up imaging with biochemical
markers were taken as reference standard. Quantitative
estimation of SSTR expression in the form of maximal
standardized uptake value (SUVmax) of detected primary
and metastatic sites was calculated. Follow-up data of
individual patients was collected through careful survey
of electronic medical records and telephonic interviews.
Results: Maximum patients presented to our department
with hepatic metastasis (50 out of 68 patients) and grade
I neuroendocrine tumours (>50%). 68Ga-DOTANOC
PET/CT scan identified primary sites in 40 out of these
68 patients i.e. in approximately 59% patients. Identified
primary sites were: Small intestine (19), Rectum (8), Pan-
creas (7), Stomach (4), Lung (1) and one each in rare
sites in Kidney and Prostate. In one patient, 2 primary
sites were identified (one each in stomach and duode-
num). Mean SUV max of the detected primary sites
was 25.1 +/- 18.0 (median 16.25, range 2.1-150). Signif-
icant positive correlation was found between SUV max
of primary tumor and histopathologically proven sites of
metastasis (r = 0.662; p < 0.0001). Based on the findings
of the 68Ga-DOTANOC PET/CT scan, 3 out of 40 pa-
tients underwent definitive treatment for their primary
tumour (1 gastric, 1 ileal and 1 prostatic tumour). 1 pa-
tient was being planned for resection of primary rectal
lesion. 32 / 68 patients were started on long acting so-
matostatin analogues or chemotherapy or targeted thera-
py. 1 patient underwent multiple cycles of peptide recep-
tor radionuclide therapy (PRRT) using 90Y and 177Lu
labeled somatostatin analogues. Conclusion: Our findings
indicate that 68Ga-DOTANOC PET/CT is a promising
imaging modality in patients with metastatic neuroendo-
crine tumours of unknown origin for detection of the
primary site and in guiding their therapeutic management.
OP555
F-18 DOPA PET/CT in patients with neuroendocrine
tumors
A. T. Golubic, D. Huic, A. Mutvar, M. Zuvic; Department of
Nuclear Medicine and Radiation Protection, University Hos-
pital Center Zagreb, Zagreb, CROATIA.
Aim: The aim of this study was to examine and study the
impact of F-18 DOPA PET/CT imaging in patients with med-
ullary carcinoma and other neuroendocrine tumors. Materials
andMethods: Twenty patients were referred to our Department
for staging or restaging neuroendocrine tumors. They were
scanned with F-18 dihydroxyphenylalanine (DOPA) PET/CT
fromNovember of 2012 to January 2015. In 13 of our patients,
medullary carcinoma was diagnosed at least 11 months earlier;
mean period from diagnosis to PET/CT was 5 years. Other
neuroendocrine tumorswere diagnosed in 7 patients (three with
insulinoma, two with paragangliomas, one had pheochromocy-
toma and in one patient undefined NET was suspected). Be-
cause of elevation of tumor markers and/or equivocal findings
of morphological imaging methods (i.e. ultrasound, MSCT or
MRI), functional diagnostic imaging was proposed. The mean
follow up period was 11.3 months. Results: An increased ab-
normal F-18 DOPA uptake was found in 12 patients (60%). In
9 out of 13 medullary carcinoma patients, a positive finding
was reported, mostly due to metabolically active metastases in
neck and mediastinal lymph nodes. Mean SUV value was 5.5,
ranging from 2.6 to 9.5. Three patients referred with other NET
diagnoses had a positive DOPA PET/CTscans and were spared
further diagnostic procedures and unnecessary treatments. Two
patients benefited greatly from an F-18 DOPA scan, as they
were completely cured after surgical resection (one with
insulinoma and one more with paraganglioma). Comparing
with other imaging modalities used in our patient population
(CT, MR, bone scintigraphy, Octreoscan, or Tc-99m-DMSAV
scintigraphy), F-18 DOPAwas found to be the most sensitive in
discovering various disease locations, especially for medullary
carcinoma. After F-18-DOPA PET/CTscan, surgical extraction
of metabolically active tissues was performed , in seven pa-
tients. Conclusions: F-18-DOPA PET/CT is a novel, still
emerging molecular diagnostic imaging method for staging
and restaging neuroendocrine tumors. Both positive and nega-
tive scan findings were of significant use in our patient’s further
management, modifying therapy options to better suit the needs
of each patient individually.
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Maps of serotonin transporter distribution in the human
brainstem obtained using high-resolution PET correlates
with post-mortem autoradiography data (ARG).
P. Fazio1, M. Schain1, K. Varnäs1, C. Halldin1, L. Farde1,2, A.
Varrone1; 1Karolinska Institutet, Department of Clinical Neu-
roscience, Centre for Psychiatry Research, Stockholm, SWE-
DEN, 2AstraZeneca Translational Science Centre at
Karolinska Institutet, Stockholm, SWEDEN.
Aim. The human brainstem is a complex structure with a multi-
tude of small nuclei and neural pathways of interest in the patho-
physiology of CNS-disorders. In common with other monoamin-
ergic systems, serotoninergic neurons originate from a group of
nuclei located in the brainstem. The present studywas designed to
validate a methodology for in vivo quantification of radioligand
binding to the serotonin transporter (5-HTT) in the human
brainstemusing high-resolution PET (HRRT) by comparisonwith
post-mortem autoradiography (ARG). Methods. 3T-MR images
and parametric 11C-MADAM binding potential (BPND) images
from 10 control subjects were used to generate a functional PET
template of 5-HTTavailability. An automatedMRbased two-step
normalization procedure using various tools of the FMRIB Soft-
ware Library (FSL) was employed to obtain accurate brainstem
normalization. ROIs for different brainstem nuclei were defined
using a threshold-based ROI-delineation method based on ana-
tomical references and on 5-HTT availability patterns. BPND esti-
mates in sub-cortical regions (putamen, nucleus caudatus and
amigdala) were obtained by applying the AAL template. The
ROIs were then transformed and applied individually to BPND
images of 16 healthy subjects (14M/2F, 20-64 y). The in vivo
distribution of BPND values was compared with the in vitro bind-
ing data using autoradiography studies of the human brain post-
mortem and 3H-MADAM as radioligand. Similar ROIs as those
used in the PET study were delineated on ARG sections. Pearson
correlation analysis was used to evaluate the relationship between
the in vivo and in vitro binding data obtained in brainstem and sub-
cortical regions. Results. The template-based method provided
reliable BPND estimates in different regions of the brainstem.
The highest BPND was found in the dorsal raphe (2.48±0.43),
followed by the median raphe (2.20±0.47), superior colliculi
(2.05±0.44), ventral midbrain (1.85±0.34) and the caudal raphe
(1.12±0.18). BPND estimates obtained in vivowith high resolution
PET in the ROIs were correlated to (r=0.78, p<0.05) the binding
density (pmol/g) values obtained in vitro byARG, althoughvalues
for the ventral midbrain were somewhat discrepant. Conclusions.
The in vivo distribution of 5- HTT availability in the human
brainstem measured using a template-based analysis applied to
HRRT-PET data was consistent with 5-HTT quantification using
post-mortem ARG. The proposed template-based methodology
appears to be suitable for applied studies focused on the human
brainstem.
OP557
Simplified quantification of the dopamine transporter
using [18F]FE-PE2I in PD patients and control subjects
I. Sonni1,2, P. Fazio1, M. Schain1, C. Halldin1, P.
Svenningsson1, L. Farde1, A. Varrone1; 1Department of Clin-
ical Neuroscience - Karolinska Institutet, Stockholm, SWE-
DEN, 2Sapienza - University of Rome, Rome, ITALY.
Introduction: [18F]FE-PE2I is a novel PET radioligand for
in vivo imaging of the dopamine transporter (DAT). Validated
non-invasive methods for DAT quantification using [18F]FE-
PE2I rely on dynamic PETacquisition, but in a clinical setting
a more simplified protocol consisting in one acquisition per-
formed after tracer injection is preferable. The aim of this study
was to identify the optimal acquisition time window providing
the specific binding ratio (SBR) in closest agreement with the
binding potential (BPND) estimated with parametric imaging.
Methods: Ten Parkinson’s disease patients (PD) and ten con-
trol subjects (CS) were examined with [18F]FE-PE2I. A 93-
min dynamic PETmeasurement was performed using the high
resolution research tomograph (HRRT). The measurement
was smoothed to the resolution of a clinical PET system
(ECAT EXACT HR) to resemble a clinical setting. ROIs for
caudate (CAU), putamen (PUT), ventral striatum (VS),
substantia nigra (SN) and cerebellum (CER) were drawn on
co-registered MR images. SBR was computed for 8 different
time windows, using CER as a reference region. Linear regres-
sion analysis was used to compare the SBR to BPND values
obtained with the wavelet-aided parametric imaging (WAPI)
software. The optimal acquisition time window was selected
using the SBR values obtained from the HRRT dynamic mea-
surement (HRRT-SBR). The selected acquisition time window
was used to create an average lower-resolution image and to
measure SBR (HR-SBR), as a clinical outcome measure. Ef-
fect sizes of SBR and BPND were calculated to assess differ-
ences between CS and PD patients. Results: SBR values ob-
tained from the HRRT that correlated best toWAPIBPNDwere
obtained for the time window between 16.5 and 42 min (R2 =
0.98). A significant correlation was also observed with HR-
SBR (R2 =0.95 in CS and R2= 0.97 in PD patients). In the
striatum, HR-SBR values underestimated BPND by 37%±3%
in CS and by 29%±10% in PD patients, and in the SN by 22%
in CS and by 14% in PD patients. Similar effect sizes for BPND
and HR-SBR were found in CAU (both 0.6), PUT (1.7 and
1.4), VS (both 0.7), and SN (0.5 and 0.4). Conclusions: The
optimal acquisition time window for simplified DAT
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quantification using [18F]FE-PE2I is between 16.5 and 42min.
Despite underestimation of BPND, and possibly decreased sen-
sitivity to detect nigrostriatal deficit, the SBR can be viewed as
a valid quantification method for DAT using [18F]FE-PE2I for
diagnostic purposes, since it provides similar differentiation as
BPND between CS and PD patients.
OP558
Translational Imaging Improves Diagnostic Power
of FP-CIT SPECT in Parkinsonian Syndrome
C. Paschetta, F. Buttari, A. Skanjeti, D. Gned, V. Podio; San
Luigi Gonzaga Hospital, Orbassano (TO), ITALY.
Aim: Neurodegenerative disease incidente is forecast to increase
in next years; early diagnosis could help in slowing disease
progression and in avoiding side effects from incorrect treat-
ments. Parkinsonian Syndromes (PS) are a common degenera-
tive disorder and their early assessment requires molecular im-
aging with cocaine-analogue radiopharmaceuticals (FP-CIT
SPECT) since symptoms are aspecific and MR imaging can
identify morphological alterations that could be related to symp-
toms. Our aim was to detect if integration of MR can increase
sensitivity, specificity and accuracy of SPECT in assessment of
PS.Materials and Methods: Sixty-three subjects with suspected
PS (age 66±11, 33M) underwent both FP-CIT SPECTand brain
MR imaging in amean time of 6months. After at least two-years
neurological follow-up, PS was confirmed in 33 patients; analy-
sis compared findings from these patients and the 30 PS-free
subjects. SPM8 was used to normalize SPECT and MR images
on our home-made and built-in template respectively. For each
imaging modality, SPM8 analysis defined VOIs including
voxels with differences between PS patients and PS-free sub-
jects. VOIs data were extracted by SPM8 with MarsBaR tool-
box. Data were evaluated by multivariate logistic regression to
identify significant relationships with diagnosis.Results: At
SPECT, SPM8 identified significant difference between PS pa-
tients and PS-free subjects in basal ganglia; at logistic analysis
diagnostic power was good (Se=73%, Sp=90%, Acc=81%,
p<0.00001).MR analysis detected differences in thalami, anteri-
or cingulate, posterior parietal and occipital area. In all occur-
rencesMR shows accuracy lower than SPECT; best results ware
obtained from thalami (Se=79%, Sp=57%, Acc=68%, p=0.005).
The integration of MR VOIs data from thalamic region in
SPECT analysis improved accuracy from 81% (SPECT alone)
to 89% and halved incorrect results by increasing sensitivity to
85% and specificity to 93%. Conclusion: When movement dis-
orders occur, semi-quantitative analysis of FP-CIT is essential
but not adequate for an optimized assessment. SPECT and MR
integration by automatic voxel-based morphometric analysis re-
sult in a significant accuracy improvement.Translational imaging
allows the development of synergies between structural and
functional methods resulting in a positive impact on quality
and cost of care.
OP559
Age- and sex-related differences in 18F-FDG brain
metabolism in healthy subjects using a PET-driven partial
volume effect correction method
S. Bonte1,2, P. Vandemaele2, S. Verleden3, K. Audenaert3, K.
Deblaere2, I. Goethals2, R. Van Holen1; 1Ghent University:
MEDISIP (Department of Electronics and Information Sys-
tems), Ghent, BELGIUM, 2Ghent University Hospital: De-
partment of Radiology and Nuclear Medicine, Ghent, BEL-
GIUM, 3Ghent University Hospital: Department of Psychiatry,
Ghent, BELGIUM.
Introduction: Several authors have investigated the age- and sex-
related differences in 18F-FDG PET scans in healthy subjects.
Most authors reported a reduced metabolism in the ageing brain,
especially in the frontal regions. However, when correcting for
structural atrophy using a MRI-based method, some authors re-
ported that all age-related changes disappeared, while others
observed a true decreased metabolism with increasing age. The
goal of our study was to apply a purely PET-driven partial vol-
ume effect correction (PVEc) method to investigate age- and
sex-related differences in the healthy brain. Materials and
methods: 79 carefully selected healthy subjects were enrolled
in this study. They underwent, among other investigations, a
18F-FDG brain PET and MRI. PET images were corrected for
the intensity diffusion caused by the point spread function of the
PET-scanner using a post-reconstruction iterative deconvolution
method with the use of the Huber prior for denoising, as present-
ed by B.A. Thomas (Ph.D. dissertation, UCL 2012). Both the
original and corrected image are normalised to MNI-space and
smoothed using SPM12. The software is also used for a
voxelwise multiple regression analysis with age and sex as co-
variates. Results: The analysis of all subjects with sex as a co-
variate yields no significant clusters with more than 100 voxels
at the p < 0.05 significance level, both before and after PVEc.
There are however negative correlations between metabolism
and age, which survive PVEc, especially in the frontal lobes.
When the female subgroup is investigated separately, there are
no clusters that survive PVEc. In the male subgroup, there are
two clusters that survive PVEc, comprising (part of) the caudate
and the anterior and medial part of the superior frontal gyrus and
cingulate bilaterally. Discussion: Most frequently used partial
volume effect correction methods rely on a co-registered and
segmented MRI-image to take structural atrophy into account.
These methods are prone to registration and segmentation errors
and assume a uniform uptake in various brain regions.Moreover,
structural and functional information are not always directly cor-
related. In contrast to thesemethods, we have used a purely PET-
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driven PVEc method. Using this method, we found decreasing
metabolism with increasing age in large parts of the (medial)
frontal lobes. We also documented a different ageing process
in women and men. The absence of clusters after PVEc in the
female brain should however be interpreted with caution, be-
cause results are only borderline significant.
OP560
Age-related changes in FDG brain uptake are more
accurately assessed when applying an adaptive template
to the SPM method of voxel-based quantitative analysis
A. Van Der Gucht1, A. Verger1, E. Guedj2, G. Malandain3, G.
Hossu4, Y. Yagdigul1, V. Roch1, S. Poussier1, L. Maillard5, G.
Karcher1, P. Marie1; 1CHU Nancy, Nuclear Medecine &
Nancyclotep Experimental Imaging Platform, Nancy,
FRANCE, 2AP-HM, Hospital “La Timone”, Department of
Nuclear Medicine, Marseille, FRANCE, 3INRIA Sophia
Antipolis-Méditerranée, Sophia Antipolis, Valbonne,
FRANCE, 4INSERM, CIC-IT 1433, Nancy, FRANCE,
5CHU-Nancy, Department of Neurology, Nancy, FRANCE.
The impact of age is crucial and must be taken into account
when applying a voxel-based quantitative analysis on brain
images from [18F]-fluorodesoxyglucose Positron Emission
Tomography (FDG-PET). This study aimed to determine
whether age-related changes in brain FDG-PET images are
more accurately assessed when the conventional Statistical
ParametricMapping (SPM) normalisation method is usedwith
an adaptive template, obtained from analysed PET images
using a Block-Matching (BM) algorithm in order to fit with
the characteristics of these images. Methods. Age-related
changes in FDG-PET images were computed with linear
models in 84 neurologically healthy subjects (35 women, 19
to 82 y-old), and compared between results provided by the
SPM normalisation algorithm applied on its dedicated conven-
tional template or on the adaptive BM template. A threshold P-
value of 0.05 was used together with a family wise error
(FWE) correction. Results. The age-related changes in FDG-
PET images were much more apparent when computed with
the adaptive template than with the conventional template as
evidenced by: 1) stronger correlation coefficients with age for
the overall frontal and temporal uptake values (respective R2
values of 0.20 and 0.07) and 2) larger extents of involved areas
(13% and 5% of whole brain template volume respectively),
leading to reveal several age-dependent areas (especially in
dorsolateral prefrontal, inferior temporal/fusiform and primary
somatosensory cortices). Conclusion. Age-related changes in
brain FDG uptake may be more accurately determined when
applying the SPMmethod of voxel-based quantitative analysis
on a template that best fits the characteristics of the analysed
TEP images.
OP561
Head-to-head comparisons of semi-quantification tools
for brain FDG-PET in diagnosis of prodromal Alzheimer’s
disease.
S. Morbelli1, M. Pagani2, F. De Carli3, J. Öberg4, A.
Buschiazzo1, G. Frisoni5, A. Drzezga6, B. N. van Berckel7, E.
Guedj8, A. Picco9, D. Arnaldi9, M. Ferrara9, A. Chincarini10, F.
Nobili9, A. Brugnolo9; 1Nuclear Medicine Unit, IRCCS San
Martino - IST, University of Genoa, Genoa, ITALY, 2Institute
of Cognitive Sciences and Technologies, Consiglio Nazionale
delle Ricerche (CNR), Rome, ITALY, 3Institute of Bioimaging
and Molecular Physiology, Consiglio Nazionale delle Ricerche
(CNR), Genoa, Italy, Genoa, ITALY, 4Department of Hospital
Physics, Karolinska Hospital, Stockholm, SWEDEN, 5Universi-
ty Hospitals and University of Geneva, Geneva, SWITZER-
LAND, 6Department of Nuclear Medicine, University of Co-
logne, Cologne, GERMANY, 7Department of Nuclear Medicine
& PET Research, VU University Medical Center, Amsterdam,
NETHERLANDS, 8APHM, CHU Timone, Service de
Médecine Nucléaire, CERIMED, INT CNRS UMR7289 , Aix-
Marseille University, Marseille, FRANCE, 9Clinical Neurology,
Department of Neuroscience, Rehabilitation, Ophthalmology,
Genetics, and Mother-Child health (DINOGMI), University of
Genoa, IRCCS AOU, San Martino-IST, Genoa, ITALY, 10Na-
tional Institute for Nuclear Physics (INFN), Genoa, ITALY.
AIM: In the last years, several semi-quantitative automatic
analysis methods have been developed to analyze brain
18Fluorodeoxyglucose Positron Emission Tomography (18F-
FDG-PET) data with the aim to differentiate MCI subject due
to AD (MCI-AD) from MCI due to other causes. The aim of
the present work was to compare the accuracy of three differ-
ent methods for the identification of MCI patients due AD.
The three tested methods were 1. a ROI-based analysis within
SPM8, 2.PALZ score provided by PMOD 3. a new metaROI
method analyzed with the support of vector machine (SVM)
METHODS: Sixty-two subjects with aMCI who during
follow-up have developed AD dementia (MCI-AD, months
follow-up range=6-84 mean=25.43±15.64; age=72.38±8.15;
education=10.22±4.37; MMSE score = 27.0±1.58) and one
hundred-nine healthy subjects (CTR; age=66.8±6.51; educa-
tion=11.6±3.78; MMSE score = 29.25±1.2) were enrolled in
five centers of the European Alzheimer’s Disease Consortium
(EADC). All subjects underwent clinical-neuropsychological
evaluation, structural neuroimaging and 18F FDG-PET when
they were at the aMCI stage. SPM8 was used to obtain the
Regions of Interest extracted from i) the comparison between
CTR and MCI-AD (ROI-1) and ii) from the correlation be-
tween brain metabolism and delayed recall in the Rey Audito-
ry Verbal Learning Test (RAVLT) in an independent group of
fifty-four elderly subjects with mild cognitive decline (ROI-2
based on a previous study of our group). In fact delayed recall
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impairment is a typical feature of MCI-AD. Brain metabolism
within each of the two ROIs was computed and normalized on
cerebellar counts. Similarly, PALZ score and SVM were used
to classify the patients as MCI-AD. ROC curves were used to
evaluate the accuracy of ROI-1, ROI-2, PALZ and SVM in
discriminating CTR from MCI-AD. RESULTS: The accuracy
values were:; ROI-1:AUC=0.826; ROI-2:AUC=0.833PALZ
score: AUC=0.867; SVM: AUC=0.947. The areas under the
ROC curves (AUC) were compared between each pair of clas-
sification methods by means of the z-score (according to
Hanley and McNeil, 1983). SVM method gave a significantly
higher AUC than the three other methods (SVM vs ROI-1
p=0.0029; SVM vs ROI-2 p=0.0019; SVM vs PALZ
p=0.0187), according to FDR criterion for multiple compari-
sons, while the other methods were not significantly different
from each other. DISCUSSION: The study confirms the high
accuracy of 18F-FDG-PET for the identification MCI due to
AD and also demonstrates that different accuracy values are
obtained even using the same imaging biomarker but applying
different metrics. A non-linear, automatic classifier based on
SVM performs better than both SPM and PALZ.
OP562
Agreement of brain amyloid PET interpretation
between automated diagnosis using support vector
machine and visual assessment by expert readers
I. Matsunari1, J. Komatsu2, M. Samuraki2, M. Noguchi-
Shinohara2, T. Hamaguchi2, K. Ono2, I. Kuji3, M. Yamada2,
S. Kinuya2; 1SaitamaMedical University Hospital, Iruma-gun,
JAPAN, 2Kanazawa University, Kanazawa, JAPAN, 3Saitama
Medical University InternationalMedical Center, Hidaka, JAPAN.
Aim: In clinical practice, interpretation of brain amyloid im-
aging often relies on visual analysis by expert readers, which is
not always available. Machine-learning based pattern recogni-
tion techniques such as support vector machine (SVM) have
recently been utilized to neuroimaging modalities as an aid for
automatic and objective diagnosis. The aim of this study was
to assess the diagnostic performance of SVM for the detection
of amyloid burden on C-11 Pib PET as compared with the
visual interpretation as a reference standard. Methods: A total
of 108 subjects (56 patients with cognitive disorder and 52
normal subjects) underwent C-11 Pib PET and structural
MRI on a single day. Each PET image was assigned amyloid
positive or negative by 2 expert readers. For SVM analysis,
PET images were spatially standardized using SPM8 and co-
registered MRI, followed by count normalization to cerebel-
lum. Leave-one subject out approach was applied as a cross-
validation method. Results: By visual analysis, there were 47
positive and 67 negative C-11 Pib PET scans. An excellent
overall agreement (105/108 scans: 97%) was obtained
between SVM and visual analysis. Using the results of visual
reading as a reference standard, the SVM had sensitivity, spec-
ificity, positive predictive value, and negative predictive value
of 94%, 100%, 100%, and 95%, respectively. Conclusion: Our
results indicate that the machine-learning based automated
analysis such as SVM may serve as an accurate diagnostic
alternative to visual reading by experts for the detection of
brain amyloid burden using C-11 Pib PET.
OP563
Comparison of Reference Regions to Semiquantitatively
Analyse 18F-Florbetaben PET Images
H. Barthel1, S. Bullich2, O. Sabri1, J. Seibyl3, V. Villemagne4,
C. Rowe4, N. Koglin2, A. Stephens2, A. M. Catafau2; 1Leipzig
University, Leipzig, GERMANY, 2Piramal Imaging, Berlin,
GERMANY, 3IND, New Haven, CT, UNITED STATES,
4University of Melbourne, Melbourne, AUSTRALIA.
Aim: Recently, amyloid β (Aβ) plaque PET imaging of
Alzheimer’s disease (AD) became available for clinical rou-
tine application. Binary visual interpretation is the standard
assessment method in this regard. This also refers to 18F-
Florbetaben (FBB). Semiquantitative PET data analysis might,
however, be necessary in borderline cases or for follow-up
evaluation. For relative FBB uptake quantification approaches
like neocortical standardized uptake value ratio (SUVR) deter-
mination, the cerebellar grey matter (CGM) has so far consis-
tently been used as reference region (RR). This investigation
aimed at comparing CGM-FBB-SUVRs with those obtained
using alternative RRs. Materials and methods: Regional and
composite neocortical SUVRs were determined using CGM,
whole cerebellum (WC), pons (P), and cerebral white matter
(WM) as RRs in scans of three FBB PET imaging studies: (a)
271 scans of the close to clinical routine FBB Phase 2 study
(composite SUVRs, standard of truth (SoT): visual assessment
by 5 independent readers). (b) 88 scans of the FBB Phase 3
study (SUVRs of 4 ROIs per scan, SoT: post mortem
histopathology by Bielschowsky si lver s taining/
immunohistochemistry for neuritic and diffuse Aβ plaques).
(c) 32 scans (16 subjects) of the FBB test-retest study (com-
posite SUVRs, endpoints: test-retest variability (TRTV) and
intra-class correlation (ICC)). Results: In (a), CGM-SUVRs
correlated with WC-SUVRs (ρ=0.89 (95%CI: 0.87-0.91)),
P-SUVRs (ρ=0.82 (0.77-0.85)), and WM-SUVRs (ρ=0.75
(0.69-0.80)). Effect sizes which ranged from 2.41 to 3.06
in (a), as well as correlation coefficients which ranged
from 0.78 to 0.84 in (a) and from 0.42 to 0.60 in (b) did
not differ, with overlapping CIs, for the SUVRs as obtain-
ed by the different RRs. Likewise, no significant differ-
ences were found in TRTV which ranged from 3.17 to
4.44 in (c) or ICCs which ranged from 0.95 to 0.98 in
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(c) across the different RRs. Conclusion: CGM continues
to be recommended as the RR of choice to analyse FBB
PET scans, due to the biological advantage of not being
involved in AD-related atrophy. Regional and composite
neocortical SUVRs of FBB scans are, to a large extent,
robust with regard to the selection of the RR. Research
support: Piramal Imaging, Berlin, Germany
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OP574
Selective internal radiatiotherapy (SIRT) in hepatic
metastases from uveal melanoma. Treatment response
in comparison to transarterial chemoembolization (TACE)
with Fotemustin
H. Duan1, G. Berzaczy2, F. Waneck3, M. Funovics3, C.
Hoeller4, M. Hoffmann1; 1Medical University of Vienna, De-
partment of Biomedical Imaging and Image-guided Therapy,
Division of Nuclear Medicine, Vienna, AUSTRIA, 2Medical
University of Vienna, Department of Biomedical Imaging and
Image-guided Therapy, Division of General Radiology, Vien-
na, AUSTRIA, 3Medical University of Vienna, Department of
Biomedical Imaging and Image-guided Therapy, Division of
Cardiovascular Radiology, Vienna, AUSTRIA, 4Medical Uni-
versity of Vienna, Department of Dermatology, Vienna, AUS-
TRIA.
Aim: Uveal melanoma is a rare tumor, which metastasizes
primarily into the liver. Once hepatic metastases occur, the
prognosis is bleak: The median survival rate 1 year after de-
tection is <30%. SIRT with Y-90 resin microspheres is suc-
cessfully used in the treatment of primary or secondary liver
tumors. This study aims to evaluate the efficacy of SIRT in
hepatic metastases derived from uveal melanoma. The results
concerning time to progression and overall survival are com-
pared to a cohort of similar patients treated with Fotemustin
via TACE. Methods: Hitherto we included 20 patients, who
received SIRT for hepatic metastases from uveal melanoma.
Imaging with CT or MRI was performed before SIRT and 6
weeks after intervention to assess tumor response and after-
wards every 3 months. All patients underwent Tc-99m macro-
aggregated albumin SPECT/CT 1 week prior to SIRT for pre-
treatment evaluation. Response to treatment and progression-
free survival as well as overall survival was calculated and
compared to a cohort of patients suffering from the same dis-
ease in similar conditions who were treated with Fotemustin
via TACE. Results: After 1 SIRT, 7 patients showed partial
response (PR) with a median time to progression of 7 ± 2.9
months (range: 3 to 25 mo) and 6 patients showed stable dis-
ease with a median time to progression of 8 ± 1.9 months
(range 3 - 14 mo). 5 patients showed progressive disease
(PD). 10 patients died within the observation period with a
mean overall survival time of 8.5 ± 3.9 months (range: 1 to
32 mo). Concerning TACE with Fotemustin, the included 21
patients required up to 6 interventions and showed a mean
progression free survival of 7.3 months (3.3 - 11.3 months).
Comparing to 1 intervention with SIRT, the results are quite
similar, but concerning safety and adverse events, with SIRT,
patients showed only minor symptoms like pain and nausea
during the intervention while with TACE, patients had heavier
and longer lasting symptoms like fever, pain and nausea,
which required medication. Additionally, multiple interven-
tions were required. Conclusion: With these preliminary re-
sults we could show the efficacy and safety of SIRT in hepatic
metastases derived from uveal melanoma in comparison to
TACE with Fotemustin. Especially concerning adverse events
and quality of life, the results of SIRT were superior to TACE
with equal efficacy.
OP575
Comparison of different dosimetric methods for tumor
and normal tissue predicted absorbed dose calculation
in liver radioembolization: preliminary results
M. FINESSI1, E. GALLIO2, E. RICHETTA3, M. STASI3, R.
PELLERITO4, R. ROPOLO2, G. BISI1; 1S.C. Medicina
Nucleare U, A.O.U. Città della Salute e della Scienza, Torino,
ITALY, 2S.C. Fisica Sanitaria, A.O.U. Città della Salute e della
Scienza, Torino, ITALY, 3S.C. Fisica Sanitaria, A.O. Ordine
Mauriziano, Torino, ITALY, 4S.C. Medicina Nucleare, A.O.
Ordine Mauriziano, Torino, ITALY.
AIM: Radioembolization with 90Y-microspheres is an effec-
tive treatment for unresectable hepatic malignancies. Two
types of 90Y-microspheres are available: resin (SIR-Spheres®)
and glass (Theraspheres®). The treatment is preliminary sim-
ulated by planar and SPECT 99mTc-MAA acquisitions to
avoid gastric and lung shunt and to determine the optimal
90Y therapeutic activity. Empirical (fixed-activity, body-sur-
face-area) and multi-compartmental methods are suggested for
resin microspheres. For glass microspheres only mono-
compartmental is proposed. Analysing 99mTc-MAA SPECT
images, it is possible to forecast tumour and normal tissue
absorbed doses: multi-compartmental MIRD or voxel dosim-
etry are used. AAPM (American Association of Physicists in
Medicine) recommendations suggest instead planar images.
The aim of this study is to compare these different methods
proposed to predict absorbed doses, with discrimination be-
tween tumour and normal tissue. MATERIALS AND
METHODS: Four patients were treated with glass micro-
spheres. According to the company, the prescribed dose was
120 Gy to entire lobe. Four patients were treated with resin
microspheres to the aim of 120 Gy to lesion and 40 Gy to
normal liver. For both groups, the predicted tumour and nor-
mal tissue doses were calculated with three different methods.
For AAPMmethod on planar images a ROI was drawn on the
anterior and posterior images encompassing the tumour; the
same ROI was moved over the normal liver. For the other
methods 99mTc-MAA SPECT-TC attenuation (glass) and
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99mTc-MAA SPECT-TC attenuation and scatter corrected im-
ages (resin) were employed. For MIRD compartmental two
VOIs, tumour and normal liver, were drawn to estimate up-
takes and volumes. For voxel based calculations SPECT 3D
counts matrix was exported to perform dosimetry with a
MATLAB code developed at our departments. RESULTS:
For glass microspheres patients average doses were signifi-
cantly lower with AAPMmethod compared toMIRD (tumour
-28%, normal liver -86%) and to voxel (tumour -41%, normal
liver -89%); high discrepancies were found also for resin mi-
crospheres: MIRD (tumour -35%, normal liver -43%) and to
voxel (tumour -14%, normal liver -37%). MIRD compartmen-
tal methods compared to voxel dosimetry showed instead
more comparable results with a smaller range of variation:
for glass microspheres(tumour -28%, normal liver +14%)
and resin microspheres(tumour +25%, normal liver +19%).
CONCLUSION: AAPM method seems less accurate for dose
estimation. Instead, MIRD and voxel based dosimetry are
more confident each other. Dose variations can be determined
by non-homogenous activity distribution with only voxel ap-
proach. This preliminary results must be confirmed by further
ongoing investigation with a larger patient dataset.
OP576
Reduced lymphocyte proliferation and IFN-γproduction
after Selective Internal Radiotherapy
A. Domouchtsidou1, M. Lindemann1, J. Best2, J. Ertle2, S. P.
Mueller3, S. Bedreli2, P. A. Horn1, A. Bockisch3, V.
Barsegian4; 1Institute for Transfusion Medicine, University
Hospital Essen, GERMANY, 2Department of Gastroenterolo-
gy and Hepatology, University Hospital Essen, GERMANY,
3Department of Nuclear Medicine, University Hospital Essen,
GERMANY, 4Institute of Nuclear Medicine, Helios Kliniken
Schwerin, GERMANY.
Selective Internal Radiotherapy (SIRT) is an innovative ther-
apy with yttrium-90 radioactive glass microspheres for the
treatment of hepatocellular carcinoma and colorectal liver me-
tastases. It has been described that the use of ionized radiation
leads to significant lymphocytopenia. However, the data on
the effect of beta rays on the immune function remain diverse.
In a recent study we have shown that radioiodine therapy in
patients with thyroid carcinoma does not lead to cellular im-
munodeficiency, but a shift from TH-2 to TH-1 response was
observed. Furthermore, the use of yttrium-90-radiolabelled so-
matostatin analogues (Y-90 DOTATOC) in patients with neu-
roendocrine tumors decreases the lymphocyte proliferation
and the proinflammatory immune responses causing an immu-
nosuppression. Unlike the above two mentioned tumor radio-
therapies, where the radionuclides circulate in the blood-
stream, in SIRT the yttrium-90 radioactive glass microspheres
become trapped in the tumor capillary bed and leave the ma-
jority of the healthy nearby tissue intact. Nevertheless, consid-
ering the high dosage administrated and the fact that approx-
imately 12% of the total blood volume is in the liver, an unin-
tended low dose to the immune system is possible. The aim of
our study is to gain insight into the modifications that take
place following a SIRT treatment at the level of the lympho-
cyte proliferation as well as to identify a possible anti-
microbial immunological impairment. Thus, in 20 patients
treated with SIRT lymphocyte proliferation and the production
of pro- and anti-inflammatory cytokines (interferon-γ and in-
terleukin-10) after stimulation with mitogens and recall anti-
gens are tested immediately prior to therapy and at day 1, day
2, day 7 and day 28 after therapy using lymphocyte transfor-
mation test and ELISpot. Preliminary data in 16 patients indi-
cate that from day 1 until day 28 after therapy lymphocyte
proliferation and interferon-γ production are significantly (P
< 0.05) reduced. The most prominent finding was a pro-
nounced reduction of anti-microbial immune responses. In
conclusion, according to our current results there is a severe
impairment of immune function after SIRTwhich seems to be
more intense than after radioiodine therapy or Y-90
DOTATOC treatment.
OP577
Retrospective analysis of dose-response for HCC lesions
treated with 90Y resin microspheres
C. Pettinato1, C. Mosconi2, A. Cappelli2, S. Civollani1, P.
Pini3, F. Monari4, C. Galaverni2, B. Angelelli5, F. Trevisani3,
R. Golfieri2; 1Medical Physics Unit - AOU di Bologna, Bolo-
gna, ITALY, 2Radiology Unit - AOU di Bologna, Bologna,
ITALY, 3Internal Medicine Unit - AOU di Bologna, Bologna,
ITALY, 4Radiotherapy Unit - AOU di Bologna, Bologna, IT-
ALY, 5Oncology Unit - AOU di Bologna, Bologna, ITALY.
Aim: We retrospectively analyzed 50 patients affected by
HCC and treated with 90Y resin microspheres. The aim of this
study was to evaluate the correlation between tumor dose and
local tumor response.Materials andMethods: From Septem-
ber 2010 to October 2014 46 patients affected by HCC have
been treated with 90Y resin microspheres. All patients re-
ceived an intra-hepatic infusion of 150 MBq of 99mTc-
MAA to calculate lung and extra-hepatic shunts and to per-
form lesion and whole liver dosimetry using the MIRD for-
malism. The activity to be injected was calculated using the
BSA formula and was modulated based on tumor and normal
liver doses, limiting the dose to whole normal liver to about 30
Gy. Results: The mean injected 90Y activity was 1.5 ± 0.5
GBq. The mean tumor volume was 288 cc ranging from
43 cc to 2566 cc, while the average dose was 258 Gy ranging
from 13 to 858 Gy. Tumors with smaller volumes received
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higher doses. The average doses to tumors with volumes be-
low 100 cc, between 100-300 cc, between 300-500 cc and
above 500 cc were respectively 436 Gy (95% IC: 359.2 -
795.2 Gy), 265 Gy (95% IC: 225.7 - 490.7 Gy), 135 Gy
(95% IC: 127.6 - 262.6 Gy) and 108 Gy (95% IC: 92.6 -
200.6 Gy). 24/46 patients received an average tumor dose
greater than 200 Gy. Among them 10 patients showed a com-
plete response and an average survival > 12 months. 5/24
patients had a good response at 9 months follow-up, while
9/24 patients had a worsening of the disease due to progression
of non treated lesions. 7/22 patients, that received less than 200
Gy, had stable or good response of treated lesions 9 months
after treatment. 6 out of these 7 patients had lesion volumes
greater than 300 cc. How results suggest that big tumors (>300
cc) are responsive to lower average doses because whole tu-
mor volume, including also “non-active” or necrotic parts typ-
ical of large lesions, is considered in the average dose calcula-
tion. Conclusions: Average tumor dose based on 99mTc-MAA
SPECT images is a good prognostic value to predict tumor
response to 90Y resin microspheres treatments in patients af-
fected by HCC. Our results showed that 42% of tumors that
received more than 200 Gy had complete response while 67%
of tumors had stable or good response for more than one year.
OP578
PET-CT in the post-treatment evaluation of a HCC patient
treated with Yttrium-90 radioembolization
R. Stoico, L. Dellavedova, M. Carletto, L. Maffioli; A.O.
Ospedale Civile di Legnano, Legnano, ITALY.
The aim of the present study was to evaluate PET-CT scan
method in terms of image quality and dosimetry, in a HCC
patient, treated with Y90 transarterial radioembolization
(TARE). The patient underwent Y90-TARE to treat a single
lesion of 52.5 cm3. Pre-treatment planning 150 MBq Tc99m-
MAA SPECT-CT scan was performed in order to calculate
injection activity, tumor dose and to evaluate visceral shunt.
Percentage lung shunt fraction was calculated with planar
whole-body acquisitions. The planned activity was calculated
by the use of compartmental method. The tumor and non-
tumor doses were calculated as injected activity multiplied
by 50 divided by the mass. The injected activity was 3.4
GBq; the tumor and non-tumor doses were 932 Gy and
62 Gy respectively (reference values). Therasphere (Nordion,
Canada) treatment was performed. No radioprotection prob-
lem during treatment angiographic procedure for health oper-
ators was recorded. The day after the treatment PET-CT
(Philips Gemini TF 16 slices, CT: 120 kV, 100 mAs, Z-
DOM low dose alghorithm, PET: nuclide Y90, 15 min/bed,
2 bed positions to cover the liver) scan was performed. OSEM
TOF iterative algorithm (3 iterations, 33 subsets) was used. A
quantitative evaluation on reconstructed images was made by
the use of Philips software. The image quality was evaluated in
terms of volume definition. Tumor and non-tumor thresholds
ROIs were used to calculate volumes (mm3) and activity con-
centration (MBq/ml). Tumor and non-tumor doses were ob-
tained by the use of the same dosimetric planning method.
Lung shunt fraction was not considered (percentage value
was zero). Percentage difference between reference and scan
values for image quality and dosimetric analysis was calculat-
ed. The quantitative analysis about image quality showed per-
centage difference in volume calculation of -5%. The dosimet-
ric analysis showed that calculated tumor dose was 993 Gy
and non-tumor dose 52 Gy. Differences between calculated
and planned dose values were +6.5% to tumor, -16.5% to
non-tumor. In our experience, after Y90-TARE, PET-CT was
considered the optimal scan method due to high image reso-
lution and low time consumption. The evaluation of PET-CT
scan method post-Y90 radioembolization in terms of image
quality showed a comparable volume definition with reference
CT by the use of threshold ROI method; in terms of dosimetry
a comparable evaluation of tumor dose but an underestimation
of non-tumor one. This preliminary result put in evidence the
importance to perform a pre-treatment dosimetric plan because
the non-tumor dose is a significant parameter to evaluate liver
complications post-treatment.
OP579
Comparison of Survival, Safety and Efficacy After Chemo
and Radioembolization of BCLC Stage B-C
Hepatocellular Cancer Patients.
C. Soydal, M. F. Arslan, N. O. Kucuk, R. Idilman, S. Bilgic;
Ankara University Medical Faculty, Ankara, TURKEY.
Aim: We aimed to compare overall survival times, long-term
complicat ion and recurrence rates of chemo and
radioembolization for BCLC Stage B-C hepatocellular cancer
patients. Materal and Method: 80 BCLC Stage B-C hepatocel-
lular cancer patients who received chemo or radioembolization
were retrospectively included to the study. Overall survival
times, long-term complication and disease recurrence rates of
two groups were compared. Additionally prognostic role of
gender, age, presence of underlying chronic liver disease,
BCLC stage, dimension and number of liver lesions, tumor
load and presence of extra-hepatic disease for each group were
analyzed. Results: 40 (27M and 13F; mean age: 41.9±21.9)
patients were analyzed in each group. During follow-up peri-
od, twenty-two and 30 patients were died in radio and
chemoembolizations groups, respectively. Overall mean sur-
vival of whole patient group was calculated as 37.31±3.94
months (30.46-44.1, %95CI). It was 30.63±3.68 months
(23.42-37.84, %95CI) for chemo and 39.24±4.62 months
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(30.18-48.29, %95CI) for radioembolization groups, respec-
tively (p=.0.014). One and two years survival rates were 72%
vs 74% and 47% vs 59% for chemo and radioembolization
groups. There was no significant difference between chronic
complication (p=0.32) and disease recurrence (p=0.65) rates
of groups. While dimension of the largest lesion was the most
significant predictor (p=0.01) in radioembolization group, fe-
male gender (p=0.008), dimension of the largest lesion
(p=0.03) and BCLC stage (p=0.01) were significant for
chemoembolization group. Conclusion: While chemo and
radioembolization for BCLC Stage B-C patients are similar
in safety and efficacy, they differ in overall survival. Patients
seem to live longer after radioembolization. The dimension of
the largest liver lesion is predictor for both treatments. Addi-
tionally gender and BCLC stage are significant factors in
chemoembolization group.
OP580
Safety of 90Y-glass microspheres therapy in hepatic
malignancies, our experience.
P. Borrelli, P. Bello Arqués, P. Olivan Sasot, C. Igua Sáenz, V.
Vera Pinto, J. Vercher-Conejero, J. Loaiza Góngora, C. Ruiz
Llorca; Hospital Universitario y Politecnico La Fe, Valencia,
SPAIN.
AIM: To follow-up clinically patients with hepatocellular carci-
noma and/or unresectable liver metastasis, treated with 90Y glass
microspheres using intraarterial hepatic radioembolization, and
describe immediate (less then 24 hours after treatment) and later
complications onset.Materials andmethods: BetweenApril 2009
and January 2015, 54 treatments were performed in 49 patients
(36 men/18 women), medium age 58.22 years (28-85). 43 treat-
ments were carried out due to hepatocellular carcinoma, 5 neuro-
endocrine tumor metastasis, 2 colonic carcinoma metastasis, 2
medullary thyroid carcinoma metastasis and 2 cholangiocarcino-
ma. Prior to treating patients a simulation study was performed
using 99mTc-albumin macroagregates (99mTc-MAA), through
the same tumor nurturing arterial vessel. Bremsstrahlung images
were acquired in every post-treatment, to evaluate radiopharma-
ceutical distribution and extrahepatic leaks, if any. Since
May 2013 (34 patients) were also evaluated using PET/CT. All
patients received prophylactic treatment including oral steroids
and proton bomb inhibitor. Results: Average follow-up was
13.65 months, during this period 30 patients (55,5%) died due
to underlying disease complications. In just one case extrahepatic
leak was found in the gallbladder walls, although no symptoms
were shown afterwards. At the 99mTc-MAA pre-treatment test,
medium pulmonary shunt was 5,58% (0.03-34.5) and gastroin-
testinal leak 2,12% (0-4.8). 90Y-glassmicrospheresmedium dose
administered was 2.86GBq (0.55-6.42) At the first 24 hours after
radiopharmaceutical administration only 3 cases (5.55%)
presented complications, two of them pain in the right
hypochondrium and one cirrhotic decompensation. Eight patients
(14.8%) presented asthenia and/or fever during the first month
after treatment, probably due to radioembolization although it
could represent symptoms associatedwith the underlying disease.
Conclusion: Hepatic methastasic or tumoral radioembolization
has proven to be a safe palliative therapy, without immediate
major secondary effects. Late and non-specific secondary effects
are being studied to, if feasible, identify its origin, due to the
underlying progressive disease or due to late therapy effects.
OP581
Yttrium-90 Radioembolisation for Colorectal Cancer
Liver Metastases: Circulating Angiogenic Factors
and Treatment Response
C. E. N. M. Rosenbaum; University Medical Center Utrecht,
Utrecht, NETHERLANDS.
Aim: Yttrium-90 radioembolisation (90Y-RE) of liver metastases
results in radiation damage and hypoxia in liver tissue, which is a
powerful trigger for the systemic release of angiogenic factors
that stimulate angiogenesis and may enable (extra hepatic) tu-
mour growth. Our aim was 1) to investigate predictive value for
response of baseline values of several angiogenic factors, and 2)
to examine changes in serum levels of these factors following
90Y-RE. Materials and Methods: A prospective cohort study
was conducted in 42 patients with unresectable colorectal cancer
liver metastases, refractory to systemic therapy. Blood samples
were taken at baseline, and at 0, 1, 3, 7 and 30 days after treat-
ment. Response was measured withMR and FDG-PET imaging,
at baseline, one and three months after treatment and subsequent-
ly at three-month intervals until progressive disease. Angiogenic
factors included vascular endothelial growth factor (VEGF), he-
patocyte growth factor (HGF), angiopoietin-2, basic fibroblast
growth factor (FGF-b), platelet-derived growth factor (PDGF-
BB), stromal cell-derived factor 1 (SDF-1a) and
thrombospondin-1. Results: Thirty patients had liver only disease
and 12 patients had limited extrahepatic disease (EHD). Patients
were treated with whole liver / one session resin 90Y-RE (median
administered activity 1.5 GBq per BSAmethod). Median overall
survival was 9.2 month (95%-confidence interval 6.0 - 12.4
months). Median time to progressive disease of liver lesions
was 3.0 months, with a significant difference between patients
with versus without EHD at baseline (1.4 versus 3.5 months;
p=0.001). At three months follow up, 22 patients showed pro-
gressive disease of liver lesions, which was caused by occurrence
of new lesions in 19 patients and in only 3 patients by growth of
baseline lesions. Baseline serum levels of several angiogenic fac-
tors varied considerably among patient groups, e.g. higher base-
line levels of angiopoietin-2 and HGF were observed in patients
with kRAS mutation as compared to patients without this
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mutation, suggesting differences in tumour biology and behav-
iour. Furthermore, heterogeneity was also seen in responders ver-
sus non-responders, for example lower baseline values for serum
VEGFwere seen in patients with partial response at three months
follow up. Several patterns of changes in angiogenic serum levels
were observed, with 10/42 patients showing a distinct peak in e.g.
VEGF at 7 days after treatment. Conclusion: Our findings sug-
gest that even in this macroscopically homogenous patient group,
tumour biology may vary considerably among individuals, and
should be weighed carefully for individualized treatment.
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OP582
The use of radiocobalt as a label improves PET imaging
of EGFR using DOTA-conjugated affibody molecules.
J. Garousi1, K. Anderson2, J. H. Dam3, B. B. Olsen3, A.
Orlova4, J. Buijs1, S. Ståhl2, H. Thisgaard3, V. Tolmachev1;
1Department of Immunology, Genetics and Pathology, Uppsa-
la University, Uppsala, SWEDEN, 2Department of Protein
Technology, KTH - Royal Institute of Technology, Stockholm,
SWEDEN, 3Department of Nuclear Medicine, Odense Uni-
versity Hospital, Odense, DENMARK, 4Department of Me-
dicinal Chemistry, Uppsala University, Uppsala, SWEDEN.
Aim. Epidermal growth factor receptor (EGFR) is the molecular
target for monoclonal antibodies cetuximab and panitumumab,
and tyrosine kinase inhibitor gefitinib. Radionuclide molecular
imaging of epidermal growth factor receptor (EGFR) expression
might facilitate stratification of patients for EGFR-targeting ther-
apies. We have demonstrated earlier that 111In-labelled anti-
EGFR DOTA-ZEGFR:2377 affibody molecule can image spe-
cifically EGFR-expressing xenografts. This affibody molecule
has similar affinity to both murine and human EGFR. The use
of PET may further improve sensitivity of EGFR imaging. We
evaluated two positron-emitting nuclides, 68Ga (T½=67.7 min)
and 55Co (T½=17.5 h min) as labels. The aim of this study was
to evaluate influence of radiogallium and radiocobalt labels on
biodistribution of DOTA-ZEGFR:2377. Materials and methods.
55Cowas produced by the 54Fe(d,n)55Co nuclear reaction using
isotopically enriched target and separated from target material
using anion exchange on Dowex 1x8. 57Co was used as a sur-
rogate for 55Co in some experiments. Conjugates were evaluated
in vitro using EGFR-expressing A431 cells. In vivo studies were
performed in BALB/C nu/numice bearing A431 xenografts. The
injected dose of all conjugates was 40 μg/mouse. Results.
DOTA-ZEGFR:2377 was labelled with 68Ga and with
radiocobalt with yields >98%. Both 68Ga- and 55/57Co-
labelled DOTA-ZEGFR:2377 demonstrated specific binding to
A431 cells in vitro. IC50 values were 0.58±0.19, 0.70±0.15, and
0.53±0.15 pM for natGa, natIn, and natCo-loaded DOTA-
ZEGFR:2377, respectively. Biodistribution of 68Ga-DOTA-
ZEGFR:2377 resembled biodistribution of 111In-DOTA-
ZEGFR:2377. At 3 h pi, uptake of 68Ga-DOTA-ZEGFR:2377,
in tumour, blood and liver was 2.7±0.1, 0.42±0.9, and 6.2
±0.3%ID/g, respectively. In the case of 57Co-DOTA-
ZEGFR:2377, the tumour uptake was increased to 5.8±0.6%ID/
g, and liver uptake decreased to 1.85±0.6%ID/g. The blood con-
centration was 0.48±0.02 ID/g. Tumour-to-blood and tumour-to
liver rations were 7±2 and 0.44±0.03 for 68Ga-DOTA-
ZEGFR:2377, and 12±2 and 3.1±0.5 for 57Co-DOTA-
ZEGFR:2377. At 24 h pi, the tumour-to-blood ratio for 57Co-
DOTA-ZEGFR:2377 increased to 32±7. The biodistribution data
were confirmed by in vivo imaging. Conclusion. The use of
radiocobalt improves targeting properties of anti-EGFR affibody
molecules DOTA-ZEGFR:2377. The exact nature of this phe-
nomenon is not quite clear for us. We can speculate that the
hepatic uptake of anti-EGFR affibody depends on both EGFR
expression in liver and properties of the molecule. The use of
divalent cobalt instead of trivalent gallium or indium increases a
negative charge at C-terminus. This might reduce hepatic uptake
and makes more tracer available for tumour targeting.
OP583
223Ra-NaA-silane-PEG-SP(5-11) radiobioconjugate
as a new potential radiopharmaceutical for targeted α
therapy of glioblastoma multiforme
A. Majkowska-Pilip1, P. Koźmiński1, A. Piotrowska1, F.
Bruchertseifer2, A. Morgenstern2, M. Bonelli3, M. Laurenza3,
A. Bilewicz1; 1Institute of Nuclear Chemistry and Technology,
Warsaw, POLAND, 2European Commission, Joint Research
Centre, Institute for Transuranium Elements, Karlsruhe, GER-
MANY, 3Dept. Physiology and Pharmacology, Sapienza Uni-
versity of Rome, Rome, ITALY.
Aim: Despite all current forms of treatment such as advanced
surgery techniques, radiation therapy and chemotherapy, the life
expectancy of patients diagnosed with glioblastoma multiforme
(GBM) is 12 to 15 months displaying the worst median overall
survival among all human neoplasms. According to the cancer
stem cell hypothesis, malignant gliomas arise from mutated, de-
velopmentally arrested multipotent progenitor cells (“glioma stem
cells”) that sustain tumor growth and are intrinsically resistant to
radio- and chemotherapy. Targeted alpha therapy has been shown
to overcome chemo- and radioresistance in vitro and thus presents
a promising approach for therapy of GBM. The aim of this study
is to investigate the use of radiobioconjugate - 223Ra-NaA-silane-
PEG-SP(5-11) for targeted α therapy of gliomas. Materials and
methods: Sodium form of an A type of nanozeolite (NaA) was
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synthesized using the hydrothermal method. Size distribution and
shape of NaA nanozeolite particles were characterized by dynam-
ic light scattering analysis (DLS), scaning elektron microscopy
(SEM) and transmission emission spectroscopy (TEM). PEG link-
er (2000 kDa) comprising the silane group at one end and N-
succinimid ester (NHS) at the second was used for synthesis of
silane-PEG-SP(5-11) bioconjugate. The obtained bioconjugate
was characterized by thermogravimetric (TGA) andDLS analysis.
Next the NaA-silane-PEG-SP(5-11) bioconjugates were labelled
with 223Ra by exchange of Na+ cation and stability of obtained
radiobioconjugates were tested in various biological fluids. Cell
viability was assayed using the MTS colorimetric assay. Results:
Nanosized zeolites were successfully prepared through hydrother-
mal synthesis. The TGA results has shown that silane-PEG-SP(5-
11) molecules are covalently attach to the NaA nanozeolite sur-
face. 223Raα-particle emitting radionuclide, has been absorbed in
the nanometer-sized NaA zeolite (30-70 nm) trough simple ion
exchange. The 223Ra labeled nanozeolite bioconjugate success-
fully retain 95% fraction of the daughter products without
compromising the tumoricidal properties of the radiation. It is
worth to notice, that the release of the decay product from
223Ra is a negligible problem, because 75% of the α-particles
energy are emitted within a 4 seconds after the 223Ra decay.
Cytotoxicity assays showed a reduction of viability of GBM cells
as well as GBM stem cells after incubation with 223Ra-NaA-
silane-PEG-SP(5-11) in a dose dependent manner. Cell viability
also decreased with increasing incubation times. Conclusion:
Targeted alpha therapy with 223Ra-NaA-silane-PEG-SP(5-11) is
a promising approach for treatment of GBMwhich is resistant for
conventional therapies and warrants further investigation in vivo.
OP584
Gold Nanoparticle-Substance P(5-11) Conjugate
as a Carrier for 211At in Alpha Particle Therapy
A. Bilewicz1, &. Janiszewska1, P. Kozminski1, M. Lyczko1,
M. Pruszynski1,2, J. Jastrzębski2, J. Choinski2, A. Stolarz2, A.
Trzcińska2, K. Szkliniarz3, W. Zipper3; 1Institute of Nuclear
Chemistry and Technology, Warsaw, POLAND, 2Heavy Ion
laboratory, University of Warsaw, Warsaw, POLAND, 3Insti-
tute of Physics, Department of Nuclear Physics, University of
Silesia, Katowice, POLAND.
Aim: The 211At might be a particularly useful radionuclide in
targeted radiotherapy, as it decays by the emission of short-
range high-energy α-particles. However, many astatine com-
pounds that have been synthesized are unstable in vivo, providing
motivation for seeking other 211At labeling strategies. In ourwork
we propose to utilize formation of strong bond between metallic
gold and astatine to bind the 211At to biomolecules. Materials and
methods: The gold nanoparticles with diameter of 2 and 20 nano-
meters were synthesized by Turkevich and Brust-Schiffrin
methods. All types of the nanoparticles were characterized by
TEM technique. The average particle size in solution and zeta
potential were determined by DLS technique. The obtained gold
nanoparticles were conjugated to substance P - short peptide
having high affinity to NK1 receptors on the glioma cells. In first
step polyethylene glicol with disulfide or thioctic acid with N-
succinimidyl ester as a linkers were conjugated with substance P.
After twenty four hours product was purified, lyophilized and
spontaneously bound to gold nanoparticles. The synthesis of
the bioconjugate was monitored by HPLC technique. The Au-
PEG-SP bioconjugates were labelled with 211At produced in cy-
clotron at the Heavy Ion Laboratory, University of Warsaw. Be-
fore labeling astatine was reduced to At- using 0.01 M Na2SO3
solution. Stability of the obtained radiobioconjugates were tested
in biological fluids: sodium chloride, cysteine, glutathione and
human serum for 2, 4 and 19 hours. Results: The Au- PEG-SP
(5-11) bioconjugates were successfully synthesized. The HPLC
analysis has shown that thiol-PEG-N-Substance P bioconjugate
are covalently attached to the gold surface. using the thiol ap-
proach. 211At,α-particle emitting radionuclide, has been strongly
absorbed in the 211At-Au-PEG-SP bioconjugates. The bioconju-
gates nearly quantitatively retains the 211At in all solutions stud-
ied. Less than 0.1% of the 211At radioactivity was found in solu-
tion. Also preliminary in-vitro biological studies indicate that
211At-labeled bioconjugates exhibit high cytotoxicity to glioma
cells. Conclusion: We have shown that gold nanoparticles la-
belled with 211At and functionalized with substance P presents
a prospective solution for the use of the 211At as a therapeutic tool
for targeting glioma cells. This work was supported by National
Science Center of Poland (Grant 011/01/M/ST406756).
OP585
Synergistically Enhanced Tumor Uptake via
Dual-Targeting of CD105 and EGFR Using a “Click”
Heterodimer
R. Hernandez, H. Luo, H. Hong, S. A. Graves, R. J. Nickles,
W. Cai; University of Wisconsin-Madison, MADISON, WI,
UNITED STATES.
Objective: Dual-targeting is expected to give higher targeting
efficacy/specificity. Herein we designed and synthesized a het-
erodimer using 2 antibody Fab fragments (i.e. Cetuximab Fab
and TRC105 Fab) for dual-targeting of the epidermal growth
factor receptor (EGFR) and CD105. Expression of EGFR was
mostly on the tumor cells, whereas expression of CD105 was
primarily on the actively proliferating tumor vasculature. The
synergistic dual-targeting effect of Cetuximab Fab-TRC105
Fab vs. single-targeting Fab (i.e. Cetuximab Fab or TRC105
Fab) was comprehensively compared in vitro and in vivo.
Methods: Cetuximab Fab-TRC105 Fab (i.e. heterodimer) was
synthesized by mixing Cetuximab Fab-tetrazines and TRC105
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Fab-trans-cyclooctenes via Click chemistry. It was purified by
HPLC with Sephacryl S-100 HR column, conjugated to 2-S-(4-
isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid
(p-SCN-Bn-NOTA) and labeled with 64Cu for positron emission
tomography (PET) imaging. Dual-receptor binding studies were
performed in U87MG human glioblastoma cells (expressing both
EGFRandCD105) and tumor-bearingmice. Blocking experiments
and ex vivo histology studieswere performed to confirm the in vivo
results. In addition, optical imaging using near-infrared fluorescent
dye labeled heterodimer was also investigated for optical image-
guided tumor resection. Results: Purified Cetuximab Fab-TRC105
Fab was confirmed by SDS-PAGE (~100 kDa band), whereas the
two Fab fragments were at ~50 kDa. Flow cytometry studies
showed much higher fluorescence signal for the hetorodimer when
compared with each Fab alone. In U87MG mice, 64Cu-NOTA-
Cetuximab Fab-TRC105Fab had significantly higher tumor uptake
(32.0±6.9, 47.5±6.7, 46.0±3.3 and 44.1±9.4%ID/g at 3, 15, 24, and
36 h post-injection, respectively; n=3) than that of 64Cu-NOTA-
Cetuximab Fab and 64Cu-NOTA-TRC105 Fab (<15%ID/g for
both). Blocking studies using either Cetuximab or TRC105 both
led to significantly reduced U87MG tumor uptake of 64Cu-NOTA-
Cetuximab Fab-TRC105 Fab, confirming that the very high tumor
uptake of 64Cu-NOTA-Cetuximab Fab-TRC105 Fab was indeed
due to dual-targeting of EGFRandCD105 in the tumor tissue (both
tumor vasculature and tumor cells). Furthermore, low liver and
kidney uptake was observed for the heterodimer (<10 %ID/g),
which gave excellent tumor-to-normal tissue ratio. In addition,
64Cu-NOTA-Cetuximab Fab-TRC105 Fab was able to non-
invasively detect small tumor nodules of <20 mg in size by PET,
and fluorescently labeled Cetuximab Fab-TRC105 Fab was suc-
cessfully employed for optical image-guided tumor removal. Con-
clusions: Successful dual-targeting of EGFR and CD105, via a
“click” heterodimer of 2 Fab fragments, leads to synergistic en-
hancement of tumor uptake over either Fab alone which could
improve future cancer diagnosis and therapeutic efficacy.
OP586
Affibody-based bioorthogonal chemistry-mediated
radionuclide pretargeting: proof-of-principle.
M. Altai1, M. Tsourma1, B.Mitran2, H. Honarvar1, A. Perols3,
M. Robillard4, R. Rossin4, W. ten Hoeve5, M. Sandström6, A.
Orlova2, A. Eriksson Karlström3, V. Tolmachev1; 1Department
of Immunology, Genetics and Pathology, Uppsala, SWEDEN,
2Preclinical PET Platform, Uppsala, SWEDEN, 3Division of
Protein Technology, KTH, Stockholm, SWEDEN, 4Tagworks
Pharmaceuticals, Eindhoven, NETHERLANDS, 5Syncom
B.V., Gröningen, NETHERLANDS, 6Akademiska sjukhuset,
Uppsala, SWEDEN.
Aim: The use of radiometal-labelled affibody molecules in
targeted radionuclide therapy is hindered by the high uptake
and retention of radioactivity in the kidneys. Commonly
used methods for reduction of renal radioactivity were in-
efficient in the case of affibody molecules. Pretargeting is
an efficient approach to improve biodistribution profiles.
One promising approach is the use of bioorthogonal chem-
istry based on a reaction of trans-cyclooctene (TCO) and
radiolabeled tetrazine. We propose affibody-based TCO-
tetrazine mediated pretargeting for the reduction of renal
uptake. Radiometal-labelled tetrazine clears rapidly from
normal tissues including kidneys. The fast blood clearance
and slow internalization rate of affibody molecules should
allow sufficient TCO tags to be available on the surface of
cancer cells at the time of tetrazine injection. If proven, the
use of affibody-TCO/Tetrazine based pretargeting would
give higher tumour-to-kidney uptake of radioactivity. This
will permit the use of affibody molecules in radionuclide
therapy. Methods: The maleimido-derivative of TCO was
conjugated to the anti-HER2 affibody molecule, Z2395
through site-specific thiol directed chemistry. The conju-
gate was labelled with 125I. Tetrazine-DOTA was labelled
with indium-111 in 0.25M acetate pH, 5.5 (n=6). Binding
specificity to and cell retention by HER2-expressing cells
of 125I-Z2395-TCO was studied. The feasibility of in vivo
pretargeting of HER2-overexpressing SKOV-3 ovarian
carcinoma xenografts in Balb/C nu/nu female mice
was studied. For this mice were injected with 30μg
(4.1nmol) 125I-Z2395-TCO followed by the injection
of equimolar concentration of 111In-tetrazine, 4h later.
Mice were then dissected at 1h p.i. of 111In-tetrazine.
Control experiments included pre-saturation of HER2 in
xenograf t s and in jec t ion of te t raz ine wi thout
preinjection of Z2395-TCO. Results: Tetrazine-DOTA
was labelled with indium-111 with a yield of 99.3
±0.4% (n=5). 125I-Z2395-TCO bound specifically to
HER2 (KD=45±16pM) and showed high cellular reten-
tion up to 24h. The uptake of 125I-Z2395-TCO in tu-
mour xenografts was high (17±2 %ID/g at 5 h p.i.) and
HER2-specific. Tumour uptake of 111In-tetrazine 1h af-
ter the injection was 60-fold higher for the pretargeted
(9.7±1.6 %ID/g) than the non-pretargeted group (0.16
±0.02%ID/g). The tumour uptake was reduced (2.9
±0.4%ID/g) when mice were injected with large excess
of non-labelled-tetrazine, suggesting specificity of TCO/
tetrazine-reaction. Kidney uptake in pretargeted group
was 57-fold lower compared to the previously studied
111In-labeled affibody molecule, 111In-DOTA-Z2395 (5
±2 vs. 284±22%ID/g). The tumour-to-kidney ratio
exceeded two. Gamma-camera imaging performed at
1h post-111In-tetrazine injection showed that the tu-
mour is the only site with prominent accumulation of
radioactivity. Conclusion: This study provides proof-of-
principle for bioorthogonal chemistry mediated
affibody-based pretargeting.
S246 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
OP587
Technetium-99m radiolabeled aptamer as a potential
agent capable of identifying tumor in vivo
L. KANG; PEKING UNIVERSITY FIRST HOSPITAL,
BEIJING, CHINA.
Aim: Aptamers are small molecule DNA or RNA fragments that
fold into well defined 3D structures with high specificity and
affinity towards target molecules. Aptamers are emerging as a
new class of molecules for radiopharmaceutical development.
In this study a new tumor-targeted agent of radiolabel aptamer
with technetium-99m (99mTc) was developed, and further its
distribution and imaging in breast tumor bearing mice.Materials
and methods: We used AS1411 in this study, a DNA aptamer
specifically binding to nucleolin that is overexpressed on the
plasma membrane of multiple cancer cells. The six carbon amine
group was linked at the end of AS1411 so that the aptamer was
radiolabeled with 99mTc via the conjugation to NHS-MAG3.
Radiochemical purity and stability were evaluated by HPLC.
Cellular uptake assays were carried out in the MCF-7 cell line
to evaluate tumor uptake in vitro. MTT assay was used to assess
the anti-cancer ability in vitro. Moreover, in vivo imaging of
99mTc radiolabeled aptamer were performed in breast cancer
tumor models.Results: Aptamer AS1411 was successfully la-
beled with 99mTc in high radiochemical yields, showing high
stability in the mixture of fresh human serum. In cellular uptake
assay, the radiolabeled aptamer showed significantly higher up-
take in MCF-7 cells than 99mTc-pertechnetate. 99mTc
radiolabeled aptamer showed strong inhibitory ability in tumor
cell lines, whereas 99mTc-pertechnetate had no inhibition by
MTTassay. After the system administration, the in-vivo imaging
results revealed the significant difference between radiolabeled
aptamer and 99mTc-pertechnetate inMCF-7 tumor bearingmice,
which suggested the specific binding and tumor detective ability
of radiolabeled aptamer in vivo.Conclusion: The tumor-targeted
aptamer directly labeledwith 99mTc could be considered a prom-
ising agent capable of identifying tumor in vivo.
OP588
89Zr-Affibody for specific detection of EGFR expression
in HNSCC
T. Burley, C. D. Martins, C. Da Pieve, R. L. Paul, D. M.
Ciobota, G. Smith, K. Harrington, G. Kramer-Marek; The In-
stitute of Cancer Research, Sutton, UNITED KINGDOM.
Aims: Although, present in normal cells, epidermal growth
factor receptor (EGFR) is overexpressed in many human ma-
lignancies including head and neck squamous cell carcinoma
(HNSCC). Clinical findings suggest that elevated levels of
EGFR expression indicate poor prognosis and reduced
survival in HNSCC patients. So far, EGFR-targeted agents
have only had limited success as monotherapies. Therefore,
identifying the presence of the molecular target is crucial in
achieving an optimal outcome with molecularly targeted
drugs. In this study, we have focused on strategies to develop
and characterise a potential molecular imaging agent for
in vivo quantification of EGFR expression.Materials and
Methods: ZEGFR:3115Affibody molecules were conjugated to
desferrioxamine (DFO) and labelled with 89Zr. In vitro
radioligand binding specificity and affinity was evaluated by
a panel of HNSCC cells expressing different levels of EGFR.
In vivo studies were conducted in NCr nude mice bearing
subcutaneous EGFR+ve HNSCC tumours. Mice were injected
with 1-5 μg (2-5 MBq) of 89Zr-ZEGFR:3115Affibody. For
biodistribution studies, mice bearing CAL27 (EGFR+++)
and Detroit 562(EGFR+) tumours were sacrificed 1, 3, 24,
48hr following the administration of the radioconjugate spiked
with 0 or 10 μg of nonradioactive ZEGFR:3115Affibody. Select-
ed organs were dissected and their radioactivity measured
using a γ-counter. The in vivo imaging profile of 89Zr-
ZEGFR:3115Affibody was further investigated with a spiked
dose at 3, 24 and 48hr post radioligand injection. The EGFR
expression and distribution of the tracer was assessed ex vivo
by IHC and autoradiography.Results: In vitro assay confirmed
high-affinity binding of the 89Zr-ZEGFR:3115Affibody probe to
CAL27 cells (Kd = 6.4±0.64 nM). Pre-incubation with non-
labelled Affibody inhibited the binding of the radioconjugate
to the cells in a dose-dependent manner. In vivo studies
showed high accumulation of the radioactivity in CAL27 tu-
mours (spiked with 10 μg) as early as 1 hr post tracer injection
(%ID/g = 5.2). Tracer was eliminated quickly from the blood
and normal tissues, producing high tumour-to-blood and
tumour-to-muscles ratios (24hr: T/B = 8.5; T/M = 18.5). As
expected, the highest normal tissue concentration of radioac-
tivity was seen in the kidneys. Very good correlation was ob-
served between PETand ex vivo estimates of tracer concentra-
tion and the receptor expression in the tumour tissue, as
assessed by radioact ivi ty accumulat ion and IHC
respectively.Conclusion: Our results suggest that the described
89Zr-ZEGFR3115Affibody may be used to assess different levels
of EGFR expression in vivo.
OP589
Strategies for the development of high specific activity
affibody based probes for the detection of HER3 positive
tumours
C. Da Pieve1, L. Allott1, C. D. Martins1, L. Carroll2, R. L.
Paul1, E. O. Aboagye2, G. Kramer-Marek1, G. Smith1; 1Insti-
tute of Cancer Research, London, UNITED KINGDOM, 2Im-
perial College London, London, UNITED KINGDOM.
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Background: Human epidermal growth factor type 3 (HER3)
is a transmembrane receptor of which expression in breast
cancer is associated with a more resistant phenotype and poor
prognosis. PET imaging of HER3 expression could aid in the
identification of patients who could benefit from HER3-
targeted therapy. Imaging HER3 is challenging due to modest
over-expression of the receptor (typically <40,000 receptors/
cell). Therefore, the development of affibody based tracers,
exhibiting high target affinity and high specific activities, are
necessary to image and quantify HER3 expression
in vivo.Materials and Methods: An anti-HER3 affibody
(ZHER3:8698, AffibodyAB, Sweden) was used as high affin-
ity targeting molecule. Radiolabelling strategies, including the
use of various radioisotopes (18F, 68Ga, and 89Zr) and chem-
istries, ([18F]AlF and inverse-electron demand Diels-Alder
(IEDDA)), have been investigated in order to produce high
specific activity products and limit thermal degradation of
the protein. The stability and affinity for the HER3 receptor
were tested in vitro using MCF7 breast cancer cells.Results:
The affibody conjugates NOTA-ZHER3:8698 and DFO-
ZHER3:8698 were synthesized, purified and radiolabelled
with 18F and 89Zr respectively. The specific activity of these
affibodies as [18F]AlF-NOTA and 89Zr-DFO conjugates were
0.8 MBq/μg (7.8 GBq/μmol) and 2.8 MBq/μg (22 GBq/
μmol) respectively. Using the IEDDA reaction between
tetrazine and trans-cyclococtyne, exemplified using 68Ga
and 18F, resulted in a specific activity of 2.5 MBq/μg (20.8
GBq/μmol) for the 68Ga-DOTA-tetrazine and no labelling for
the [18F]AlF-NODA-tetrazine reacted with TCO functional-
ized affibody. However, the reaction of [18F]AlF-NODA-
TCO with the tetrazine functionalized affibody improved the
specific activity of the product to 2.5 MBq/μg (20.8 GBq/
μmol). All tracers were isolated with a RCP >97% and their
binding affinities to HER3 were determined to be in the
subnanomolar range (ca 0.44 nM).Conclusions: The labelling
of the HER3 targeting affibody, using either a long lived ra-
dioisotope as 89Zr or a labelling strategy as IEDDA, could
produce high specific activity tracers enabling the in vivo de-
tection of HER3 positive tumours. Moreover, the developed
IEDDA synthetic strategies can be applied to radiolabel other
molecules allowing moderately expressed targets to be
imaged.
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OP590
Identification of biomarkers including 18FDG-PET/CT
for early prediction of response to neoadjuvant
chemotherapy in Triple Negative Breast Cancer
O. Humbert1,2, J. Riedinger1, C. Charon-Barra1, A. Berriolo-
Riedinger1, I. Desmoulins1, V. Lorgis1, S. Kanoun1,2, C.
Coutant1, P. Fumoleau1, F. Brunotte1,3,2, A. Cochet1,2; 1Centre
Georges-François Leclerc, DIJON, FRANCE, 2Université de
Bourgogne, UMR CNRS 6306, Dijon, FRANCE, 3Centre
Hospitalo-Universitaire, Dijon, FRANCE.
Purpose: To investigate the value of metabolic and
p e r f u s i o n p a r am e t e r s , d e r i v e d f r om 1 8 F -
fluorodeoxyglucose positron emission tomography
(FDG-PET) exams, compared with clinico-biological
markers to predict pathological complete response
(pCR) to neoadjuvant chemotherapy (NAC) in women
with triple-negative breast cancer (TNBC). Material
and methods: Fifty consecutive women with TNBC
and an indication for NAC were prospectively includ-
ed. Different pre-treatment clinical, biological and
pathological biomarkers, including SBR grade, the
Ki-67 proliferation index, androgen receptor expres-
sion, epidermal growth factor receptor (EGFR) and
cytokeratin 5/6 staining, were assessed. Tumor glucose
metabolism at baseline and its change after the first
cycle of NAC (ΔSUV) were assessed using FDG-
PET. Changes in blood flow (ΔBF) were measured
with FDG-PET using a dynamic first-pass model. Re-
sults: The pCR rate was 42%. In univariate analysis,
a high Ki-67 proliferation index (p=0.03), negative
EGFR status (p=0.04), high tumor ΔBF (p=0.02)
and ΔSUV (p=0.001) were predictors of pCR. Tumor
ΔSUV was the most accurate biomarker to predict
pCR (threshold=-60%; PPV=80.0%; NPV=75.9%; ac-
curacy=77.3%). In multivariate analysis, both negative
EGFR status (Odds ratio=9.3; p=0.034) and high
ΔSUV (Odds ratio=6.8; p=0.049) were independent
predictors of pCR. Combining these two parameters
could predict non-pCR with an accuracy of 92%.
Conc l u s i o n : I t i s impo r t a n t t o d e f i n e t h e
chemosensitivity of TNBC to NAC early. Combining
EGFR status and the metabolic response assessed with
FDG-PET can help the physician to predict early the
probability of achieving pCR or not. Given these re-
sults, the interest of response-guided tailoring of the
chemotherapy might be tested in multicenter trials.
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OP591
Fusion of prone FDG PET/CT and MRI improves staging
of patients with breast cancer
M. J. Ribelles, M. Rodriguez, L. Sancho, F. Guillen, L. J.
Pina, M. Idoate, F. Martinez Regueira, M. Santiesteban, J. A.
Richter, M. J. Garcia-Velloso; CLINICAUNIVERSIDADDE
NAVARRA, PAMPLONA, SPAIN.
Objective: To analyse the value of prone FDG-PET/CT, Mag-
netic Resonance Imaging (MRI), and PET/MRI fused images
in preoperative staging of patients with newly diagnosed
breast cancer. Material and Methods: From November 2012
to February 2015, 61 patients (mean age 52 ± 11 years) with
histologically proven breast cancer were included. MRI and
FDG PET/CT thoracic scans were performed with the patient
in prone position using the same MRI breast array coil. FDG
PET/CT was performed with point spread function (PSF) and
time of flight (TOF). Both studies were reviewed independent-
ly, and fused PET/MRI images were evaluated by consensus.
The quality of fused PET/MRI images was scored as excellent
(full coincidence), acceptable (<10 mm displacement) or poor.
The histopathology was the reference standard. Sensitivity,
specificity, PPV, NPV and accuracy for each technique and
for PET / MRI fusion images were calculated. Results: Le-
sions’ mean diameter on MRI was 23±17 mm (range 3.5-84
mm). On histopathology, 102 out of 142 (75%) lesions were
malignant, 5 patients had bilateral disease, 47 tumours were
focal, 13 tumours were multifocal, and 6 tumours were
multicentric. Clinicopathologic subtype was available in 61
patients, and luminal was the most common subtype (43 pa-
tients, 70.5%), followed by 7 HER2 (11.5%) and 11 triple
negative (18%). The quality of fused PET/MRI images was
excellent in 37 (61%) cases, acceptable in 16 (26%) cases, and
poor in 8 (13%) cases. Sensitivity, specificity, PPV, and NPV
of MRI were 95%, 55%, 84%, 81% respectively, compared to
90%, 48%, 81%, 86% for FDG-PET / CT and 98%, 75%,
91%, 94% for PET/MRI fusion. Eight lesions with luminal
subtype, one lesion triple negative and one lesion HER2 pos-
itive were false-negative FDG-PET/CT. Fused PET/MRI im-
ages enabled correct diagnosis of 13 false positive MRI le-
sions. MRI detected axillary nodal disease in 19 patients,
whereas FDG-PET/CT detected axillary nodal disease in 33
patients, internal mammary nodal disease in 3 patients, and
unsuspected distant metastases in 6 patients. Conclusions:
The fusion of prone MRI and 18F-FDG PET images is a fea-
sible technique. In patients with newly diagnosed breast can-
cer, MRI had better sensitivity for the primary tumour. PET/
MRI fusion increased the sensitivity, specificity, predictive
values and accuracy, and could have avoided biopsies in be-
nign lesions. FDG-PET/CT had added value in the detection of
unsuspected lymph node and distant metastases.
OP592
Comparison of dedicated hanging breast PET
and standard whole body PET/CT for primary tumour
visualization in breast cancer patients
S. Teixeira1, J. Ferrér Rebolleda2, B. B. Koolen1, J.
Wesseling1, R. Sánchez Jurado1, M. P. M. Stokkel1, M. del
Puig Cózar Santiago2, V. van de Noort1, E. J. T. Rutgers1, R.
A. Valdés Olmos1; 1Netherlands Cancer Institute - Antoni van
Leeuwenhoek Hospital, Amsterdam, NETHERLANDS,
2ERESA, General university hospital of Valencia, Valencia,
SPAIN.
Purpose: Comparison of the performance of a dedicated PET
for hanging breast imaging (MAMMI-PET) and whole body
PET/CT for the visualization of breast cancer lesions in two
European hospitals. Materials and methods: A total of 230
female patients (age: mean 52 y, range 24-82y) with ≥ 1 his-
tologically confirmed primary breast cancer lesion (=index
lesion) were included prospectively between March 2011
and March 2014. All patients were scanned with the standard
whole body PET/CT (Philips, Eindhoven, Netherlands)
followed by the MAMMI-PET (Oncovision, Valencia, Spain)
after injection of 180-240 MBq. All index lesions were scored
0, 1 or 2 for quantity of FDG uptake. MAMMI-PET findings
were further tested in relation to histological (ductal, lobular)
and molecular (ER/PR/Her2) breast cancer subtype, tumour
grade, breast length, maximal tumour diameter and affected
breast quadrants. Results: Totally 234 affected breasts were
scanned (lesion diameter 5-170 mm). Twenty-four lesions
(10%) near the pectoral muscle did not reach the MAMMI-
PET scanning range. Of 19 lesions that MAMMI missed com-
paring to PET/CT, 18 were outside its scanning range. For
lesions located within its scanning range the MAMMI sensi-
tivity was 98.6%. PET/CT missed 15 of the index lesions
depicted by MAMMI (p=0.61). MAMMI-PET detected 41
additional lesions of which 16 where proven malignant
(39%), 15 (36.6%) seen on other modalities, and 14 (34,2%)
only visible on MAMMI-PET. Lesion visibility was influ-
enced by tumour grade (p=0.034) but not by cancer subtype
(p=0.83). Conclusion: When breast cancer is located within its
scanning range MAMMI-PET is able to detect almost all
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primary tumour lesions. Compared to PET/CT MAMMI-PET
finds more cancer lesions provided that these are not too dor-
sally located in the breast.
OP593
Predictive value of dynamic and dual-phase 18 FDG
PET/CT parameters in the assessment of neoadjuvant
chemotherapy response in locally advanced breast cancer:
A comperative study with dynamic contrast enhanced
MRI.
O. Kupik, M. Tuncel, P. Kiratli, M. Akpinar, K. Altundağ, F.
Demirkazık, B. Erbas; Hacettepe University, Ankara, TUR-
KEY.
AIM: Several studies have shown promising results for the
prediction of pathological complete response (pCR) to neoad-
juvant chemotherapy (NAC) in patients with locally advanced
breast cancer (LABC) using 18 FDG PET/CT. Dynamic con-
trast enhanced magnetic resonance imaging (dCE-MRI) can
assess the response to NAC by providing information on the
angiogenesis and morphology of the tumor. This study was
planned to compare the predictive value of semi-quantitative
paratemers obtained by dCE-MRI, dynamic and dual-phase
18FDG-PET/CT in LABC patients receiving NAC. MATE-
RIALS and METHODS: Fortysix patients with LABC
underwent dCE-MRI and 18FDG-FDG/PET at baseline and
after 2-3 cycles of NAC (interim). Tumor diameter, spherical
(SV), angiographic volumes (AV), peak signal intensity (PSI),
rapid and medium component of initial rise, percentage of
Type I, Type II, Type III curves were calculated. Dynamic
18FDG and dual phase images were recorded in the prone
position. Using 18FDG dynamic data, SUVmax values for
2nd, 5th and 30th minutes were measured. In addition,
SUL2peak, metabolik volume (Per2V) and total lesion glycol-
ysis (Per2TLG) values were measured for the first 2 minutes
data. For early (E) and late (L) images, SUVmax, SUVmean
and SUVpeak, TLG and metabolic tumor volume (MTV) was
measured using adaptive (adp) and 42% thresholding method.
Baseline and interim studies were used to calculate percentage
changes and compared according to the surgery results; pCR
vs non-pCR. ROC curves were obtained to calculate the AUCs
for the prediction of pCR. Optimal treshold values to discrim-
inate between pCR and non-pCR were calculated. RESULTS:
Late prone images had higher sensitivity and specificity to
detect the residual tumor (91%, 71.4%) and residual lymph
node (62.5%, 87.5%) compared to MRI (84%, 37.5%, LN:
37.5%, 57.5%) and early prone images (84.5%, 75%, LN:
50%, 83%). PET/CT parameters were significantly different
between pCR and non-pCR groups, except MTV-42 values.
MRI parameters were different for diameter%, SV% and
PSI%. Higher AUC values were obtained for SV% (0.83),
Per2V% (0.826), MTV (% 0.79), TLG% (0.785), and TTLG
% (0.828). Optimal cut-off values (sens, spec.and acc.) values
were -65% for SV% ( 80%, 73%, 75%), -67.6% for Per2V%
(87%, 78%, 80.7%), -73% for MTV% (78%, 86%, 84%), -
88% for TLG% (78%, 81%, 80%), and -88% for TTLG (78%,
86%, 84%), respectively. CONCLUSION: Semi-quantitavite
parameters for 18 FDG PET/CT and volumetric changes ob-
tained with dCE-MRI can predict response to NAC. Percent-
age changes in MTV, TLG and Per2V can identify
nonresponding patients better than other parameters.
OP594
Treatment response evaluation by 18F-FLT positron
emission tomography/ computed tomography
after neoadjuvant chemotherapy in patients with locally
advanced breast cancer
B. R. Mittal, J. Shukla, G. Singh, A. Bal, D. Kumar, M.
Kumar, R. Vatsa, P. Bhusari, N. Rana, N. Khandelwal; Post-
graduate Institute of Medical Education & Research, CHAN-
DIGARH, INDIA.
OBJECTIVE: Breast cancer is a common cancer in women.
18F-fluorothymidine (FLT) is tracer for proliferation imaging.
The aim of this prospective study was to assess the role of 18F-
FLT PET/CT in early changes in SUVmax to NACT response
and to correlate with final clinical and pathological response to
NACT. Methods: 18F-FLT was synthesized and quality con-
trol was performed. 44 patients (mean age 47.5±8.54 years) of
LABC were enrolled. Patients received 4 cycles of
anthracycline based chemotherapy at 3 weeks interval follow-
ed by a Taxane based therapy for next 4 cycles at 3 weeks
interval. 18FLT PET/CT scans were performed before therapy
and was repeated after 1st, 4th and 8th chemotherapy cycles.
The receptors (ER, PR, Her2) and Ki-67 expression was stud-
ied on biopsy or surgical samples after each PET/CTscan. The
SUVmax of 18 patients was calculated. The correlation be-
tween 18FLT PET/CT at various time points and post therapy
response was studied. Results: Of the 44 patients, only 19
patients completed NACT. Out of 19, 3 were triple negative
(ER/PR/Her2), 3 with ER/PR with Her2, rest were ER/PR.
The surgery was performed for 17 patients, one patient was
not operated due to uncontrolled diabetes and one opted to
withdraw. Out of 17 patients, 6 patients showed complete, 6
partial, 2 no response and 3 showed progression of disease on
18FLT PET/CTafter end of therapy. No correlation was found
with receptor expression. These results were well correlated
with pathological assessment. After Ist chemocycle SUVmax
in 4 patients increased. Two of the 4 showed complete re-
sponse, one partial (56%) and one showed disease progres-
sion. 18F-FLT PET/CT after completion of Antracyclin thera-
py (4 cycles) showed complete response in 3 patients, partial in
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13 patients and minimal in 2 patients (3%, 7%). However FLT
scan done at the completion of Taxane therapy, showed disease
progression in 2 patients, decreased response from previous
therapy in 4 patients (3% to(-22%); 90 to70%, 40 to30%, 20
to(-40%), improved response in 5 (1-56%, 3-22%, 19-77%, 7-
52%, 28-55%), no change was seen in 2 patients, 5 patients
showed complete response on PET/CT. 4 out of 5 could be
correlated with pathological response. The initial data demon-
strate i) there is no correlation between type of receptor ex-
pression and outcome of therapy; ii)18F-FLT PET/CT after Ist
cycle of chemotherapy does not predict response; iii)18F-FLT
PET/CTafter 4th cycle plays an important role in assessing the
responders and non-responders.
OP595
Prognostic value of maximum standardized uptake value
measured on F-18 FDGPET/CT in patients with recurrent
epithelial ovarian cancer.
X. Palard; University Hospital of Brest, Brest, FRANCE.
OBJECTIVE: This study aimed to evaluate the prognostic
value of maximum standardized uptake value (SUV max)
measured on F-18 FDG PET/CT (FDG PET/CT) at the time
of relapse in patients with epithelial ovarian cancer (EOC).
METHODS: 41 consecutive relapsed EOC patients were ret-
rospectively analysed from April 2006 to April 2014. SUV
max was measured on FDG PET/CT at the time of relapse.
Post-relapse overall survival (PRS) was calculated from the
date of FDG PET/CT to the date of death or last follow-up.
ROC analysis was used to test the statistical significance of the
differences among patient characteristics. Univariate and mul-
tivariate analysis for PRS were performed using Cox propor-
tional hazards regression model. RESULTS: Median follow-
up was 20.4 months. 19 patients died during the follow-up
period (median: 15.5 months). ROC analysis revealed that
SUVmax > 11.7 yielded the best prediction of death (AUC =
0.761). On univariate analysis, SUVmax > 11.7, non serous
carcinoma, positive macroscopic residual tumor after initial
surgery, time of relapse after initial surgery < 24 months and
treatment of recurrence with chemotherapy alone were all sig-
nificantly associated with PRS. On multivariate analysis,
SUVmax > 11.7 (HR, 7.059; 95% CI, 1.620 - 30.764;
p=.009), non serous carcinoma (HR, 3.892; 95% CI, 1.377 -
11.003; p=.010) and time of relapse after initial surgery < 24
months (HR, 5.180; 95% CI, 1.280 - 20.964; p=.021) were
independently and significantly prognostic factors for PRS.
Patients with SUVmax > 11.7 showed significantly longer
duration of PRS than patients with SUVmax ≤ 11.7 (Log rank
test, χ2 = 9, p=0.002). CONCLUSION: Our results suggest
that SUV max measured on FDG PET/CT at the time of the
relapse was found to be an independent predictive value for
PRS in patients with recurrent epithelial ovarian cancer.
OP596
Impact of the FDG PET/CT in the primary staging
of locally advanced Cervical Squamous Cell Carcinoma
(CSCC).
A. Alessi1, A. Lorenzoni1, D. Lorusso2, A. Cerrotta3, V.
Chiappa2, B. Pappalardi3, B. Padovano1, G. Serafini1, F.
Raspagliesi2, F. Crippa1; 1Nuclear medicine PET Unit
Fondazione IRCSS Istituto Nazionale Tumori, Milano, ITA-
LY, 2Gynecologic Oncology Unit - Fondazione IRCSS Istituto
Nazionale Tumori, Milano, ITALY, 3Radiotherapy Unit -
Fondazione IRCSS Istituto Nazionale Tumori, Milano, ITA-
LY.
Locally advanced Cervical Squamous Cell Carcinoma
(CSCC) has a higher rate of recurrence and worse survival
than early stage CSCC. Predictors of disease recurrence in-
clude stage and lymph node status at the time of initial diag-
nosis. Accurate staging is important both for selecting appro-
priate therapy and for prognosis. Aim The objective of this
retrospective study was to evaluate the impact of FDG PET/
CT in the pretreatment imaging work-up of patients with lo-
cally advanced CSCC and management change in treatment
intend or radiotherapy planning. Materials and methods 35
patients with newly diagnosed locally advanced CSCC (FIGO
stage IB2 to IVA) were included in the study. Each patient has
been evaluated with pre-therapeutic FDG PET/CT and pelvic
MRI. Patients were treated with concomitant chemoradiation
and brachytherapy and/or adjuvant chemotherapy or radical
surgery depending on staging results. The para-aortic region
was included in RT planning in case of FDG PET evidence of
disease in para-aortic lymph nodes. FDG PET findings were
compared to those obtained with MRI, histopathological re-
sults or other imaging modalities in case of extra-pelvic evi-
dence of disease on FDG PET. Results FDG PET-CTandMRI
findings were concordant in 69% of patients (24/35 pts). In 20
patients FDG-PET identified only primary tumor with no ev-
idence on lymph node involvement and in 4 patients also hy-
permetabolic pelvic lymph node were shown, according to
MRI. In the remaining 11 patients (31%) FDG PET-CT iden-
tified extra-pelvic disease. In 5 out of 11 patients FDG PET-CT
revealed retroperitoneal para-aortic (3/5) and mediastinal
lymph node involvement (2/5). In 6/11 patients FDG PET-
CT detected distant metastatic disease (hepatic, pulmonary,
peritoneal and/or bone disease). FDG PET-CT had major clin-
ical impact in 31% of the cases (11/35): in 3 patients with para-
aortic node involvement radiotherapy field was extended and
in the remaining 8 patients with metastatic disease treatment
intend changed to palliative therapy instead of radically
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curative. Conclusion Our results showed that FDG PET-CT
has an important impact on the primary staging of locally
advanced CSCC leading to a substantial changes in treatment
planning in 31% of patients.
OP597
Determinants of sentinel node localization failure
in gynaecological cancers: a retrospective cohort study.
E. Odouard1, A. Tescaru1, F. Giammarile1, C. Bournaud1, S.
Lancelot1,2; 1Hôpitaux de Lyon, Lyon, FRANCE, 2Lyon Neu-
roscience Research Center, Université Claude Bernard Lyon 1,
INSERM,CNRS, Lyon, FRANCE.
Aim: Sentinel lymph node (SLN) examination is a standard of
care for patients with breast cancer and melanoma. The lack of
consensus does not permit standardization of the technique in
endometrial or cervical cancer. This retrospective study
assessed the determinants of SLN detection failure in
gynaecological indications.Material and methods:We
reviewed all patients who underwent preoperative
lymphoscintigraphy and peroperative SLN (Patent Blue injec-
tion followed by lymphadenectomy and SLN mapping) local-
ization for early cervical or endometrial cancer in our center
(from 2005 to 2015). SLNs were ultra-staged on final
pathology.We evaluated the impact of various factors on the
SLN localizat ion : the radiopharmaceutical used
([99mTc]rhenium sulfide nanocolloid, Nanocis® or
[99mTc]albumin nanocolloid, Nanocoll®), the preoperative
imaging modality (planar lymphoscintigraphy or SPECT-
CT), and the delay between the radiopharmaceutical injection
and the peroperative SLN localization (short in one-day or
long in two-day protocol).We defined SLN detection as an
examination where at least one sentinel node was identified
in both sides.Results: One hundred and nineteen patients with
cervical cancer were included. SLNs were detected in both
s i d e s i n 78 pa t i e n t s ( 6 5 . 5%) i n p r e op e r a t i v e
lymphoscintigraphy, and 80 patients (67.2%) in the operating
room. The SLN detection reached 83.5% (66/79) with
[99mTc]rhenium sulfide nanocolloid, versus 58.3% (14/24)
with [99mTc]albumin nanocolloid (p=0.009).Fifty-seven pa-
tients with endometrial cancer were included.SLNs were de-
tected in both sides in 25 patients (44%) in preoperative
lymphoscintigraphy, and 27 patients (54%) in the operating
room. The SLN detection reached 57.5% (23/40) with
[99mTc]rhenium sulfide nanocolloid, versus 37.5% (3/8) with
[99mTc]albumin nanocolloid (not significant).For both indica-
tions, no significant differences were observed between one-
day-protocol and two-day-protocol for SLN detection. The
SLN detection was higher with SPECT-CT imaging compared
to planar lymphoscintigraphy (not significant).Conclusion:To
our knowledge, this is the first time that the role of the
radiopharmaceutical and the delay of the procedure were stud-
ied. This study revealed that the radiopharmaceutical choice
could be a factor influencing the success of SLN localization
in cervical cancer. The SLN procedure should be performed
with the [99mTc]rhenium sulfide nanocolloid in the cervical
cancer.As described in the literature, preoperative SLN imag-
ing with SPECT-CT should result in a superior overall SLN
detection when compared to planar lymphoscintigraphy.
These results must be confirmed by further studies.
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OP598
Diagnostic and prognostic value of 18F-DOPA PET
and 1H-MR Spectroscopy in pediatric supratentorial
infiltrative gliomas: a comparative study.
M. Massollo1, A. Piccardo1, G. Morana2, M. Puntoni3, C.
Milanaccio4, M. Garrè4, A. Rossi2, M. Cabria1, A. Raso5, I.
Bossert1, M. Cabria1; 1Nuclear Medicine Unit E.O. Galliera
Hospital, Genoa, ITALY, 2Neuroradiology Unit, Istituto G.
Gaslini, Genova, Italy, Genoa, ITALY, 3Clinican Trial Unit,
Scientific Directorate, Ospedali Galliera, Genova, Genoa, IT-
ALY, 4Neuro-oncology Unit, Istituto G. Gaslini, Genova, Italy,
Genoa, ITALY, 5Neurosurgery Unit, Istituto G. Gaslini, Geno-
va, Italy, Genoa, ITALY.
A IM : 1H -MR Spe c t r o s c o p y (MRS ) a nd 18F -
dihydroxyphenylalanine (DOPA) PET are noninvasive imag-
ing techniques able to assess metabolic features of brain tu-
mors. The aim of this study was to analyze metabolic infor-
mation obtained by 18F-DOPA PET and 1H-MRS in a popu-
lation of children with supratentorial infiltrative gliomas or
non-neoplastic brain lesions initially suspected to be gliomas
on conventional MRI. Specifically, we aimed (1) to compare
sensitivity, specificity and accuracy of 1H-MRS and 18F-
DOPA PET in distinguishing brain gliomas from non-
neoplastic lesions, (2) to assess the ability of 1H-MRS and
18F-DOPA PET in discriminating low-grade from high-
grade gliomas, and (3) to evaluate the relationship between
these different metabolic biomarkers and patient’s outcome
in terms of progression-free survival (PFS) and overall surviv-
al (OS). MATERIALS AND METHODS: We retrospectively
analyzed 27 pediatric patients with supratentorial infiltrative
brain lesions on conventional MRI (21 gliomas and 6 non-
neoplastic lesions) who underwent 18F-DOPA PET and 1H-
MRS within 2 weeks of each other. 1H-MRS data (Choline/
Nacetylaspartate, Choline/Creatine ratios, and presence of lac-
tate) and 18F-DOPA uptake parameters (Lesion/Normal tissue
and Lesion/Striatum ratios) were compared and correlated
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with histology, WHO tumor grade, and patient’s outcome.
RESULTS: 1H-MRS and 18F-DOPA PET data were positive-
ly correlated. Sensitivity, specificity, and accuracy in
distinguishing gliomas from non-neoplastic lesions were
95%, 83%, and 93% for 1H-MRS and 76%, 83%, and 78%
for 18F-DOPA PET, respectively. No statistically significant
differences were found between the two techniques (p>0.05).
Significant differences regarding 18F-DOPA uptake and 1H-
MRS ratios were found between low- and high-grade gliomas
(p≤0.001 and p≤0.04, respectively). On multivariate analysis,
18F-DOPA uptake independently correlated with progression
free survival (p≤0.05) and overall survival (p=0.04), whereas
1H-MRS did not show significant association with outcome.
CONCLUSION: 1H-MRS and 18F-DOPA PET provide use-
ful complementary information for evaluating pediatric brain
lesion metabolism. In view of its better availability, lower
costs, and lack of radiation exposure, 1H-MRS represents the
method of first choice in differentiating brain gliomas from
non-neoplastic lesions. 18F-DOPA uptake better discriminates
between low- and high-grade gliomas, and is an independent
predictor of PFS and OS.
OP599
[18F]-fluciclovine (FACBC) PET/CT as a Supplement
to MRI in Patients with Suspected Recurrent Gliomas
A. Londalen, T. Bach-Gansmo, C. Saxhaug, P. Brandal, T. V.
Bogsrud; Oslo University Hospital, Oslo, NORWAY.
Aim: Early detection of recurrence or residual disease after
treatment of gliomas with advanced oncological imaging tech-
niques can positively influence the course of disease and over-
all survival. Post-therapeutic tissue changes which mimics tu-
mor recurrence (pseudoprogression) and radiation necrosis are
common problems. MRI has limited ability to differentiate
pseudoprogression and radiation necrosis from tumor recur-
rence. Preliminary clinical studies demonstrated high tumor
specific accumulation of the synthetic leucine analog, trans-1-
amino-3-[18F]fluoro-cyclobutyl-carboxylic acid (fluciclovine,
often called FACBC) in small numbers of glioblastomas. The
aim of this study is to evaluate fluciclovine PET/CT as a sup-
plement to MRI to help differentiate tumor recurrence from
pseudoprogression and/or radiation necrosis. Methods: Ten
consecutive patients previously treated for gliomas with
suspected tumor recurrence were included in this study (4 fe-
males and 6 males) with a median age of 55 years (range 41-63
years). All patients signed a written informed consent form.
Tumor diagnoses consisted of grade II in three, grade III in
one and grade IV gliomas in six patients initially. The patients
first underwent MRI (structural and functional imaging se-
quences), which were performed as part of the clinical routine;
and then they underwent fluciclovine PET/CT because of
suspected tumor recurrence or pseudoprogression/radiation ne-
crosis. Tumor to background ratios (TBR) were calculated.
Eight of these patients went through surgery because of
suspected tumor recurrence and histological results were ob-
tained. Results: In eight of the ten patients who underwent
surgery, recurrent glioma was confirmed by histopathology.
Fluciclovine PET/CT had high tracer uptake in all 8 patients
preoperatively (TBRs 4,7-45 median 14,3). MRI was not con-
clusive in four of them and suspected tumor recurrences were
noted in the other four. Two patients were followed-up. MRI
showed possibly radiation necrosis in one (TBR 14,2 on PET/
CT) and possible recurrence in the other (TBR=2.8 on PET/
CT). Both showed clinical signs of progression, and they died
40 days and 6 months after the fluciclovine PET/CT, respec-
tively. Conclusion: In our study fluciclovine PET/CT showed
high TBRs in histopathologically confirmed tumor recurrences
of gliomas. Our results indicate that fluciclovine PET/CTmight
be used as a supplement to MRI to differentiate tumor recur-
rence from treatment induced changes.
OP600
PET/MR versus PET/CT in the Initial Staging of Head
and Neck Cancer
T. Sekine1,2, F. Barbosa1, F. Kuhn1, I. Burger1, G. von
Schulthess1, P. Veit-Haibach1, M. Huellner1; 1University Hos-
pital Zurich, Zurich, SWITZERLAND, 2Nippon Medical
School, Tokyo, JAPAN.
Purpose: To compare the diagnostic accuracy of PET/MRwith
PET/CT for newly diagnosed head and neck cancer. Materials
and Methods: This prospective study was approved by the
institutional review board and by national government author-
ities. In this study, sequential contrast-enhanced PET/CT-MR
was performed in 27 patients (median age 66, 16 males) with
newly diagnosed head and neck cancer. MR sequences were:
LAVA-Flex (whole body); axial T2-weighted, axial T1-
weighted with and without contrast, sagittal and coronal T1-
weighted with contrast, and DWI (head and neck). PET/CT
and PET/MR were evaluated separately, and the TNM stage
and factors that could impact on the potential resectability
were assessed. Wilcoxon signed-ranks test was used. Results:
The T/N/M staging by PET/CT was correct in 17 patients
(63.0%) / 19 (70.4%) / 22 (81.5%), equivocal in 8 patient
(29.6%) / 3 (11.1%) / 3 (11.1%), and incorrect in 2 patients
(7.4%) / 5 (18.5%) / 2 (7.4%). The T/N/M staging by PET/MR
was correct in 20 patients (74.1%) / 21 (77.8%) / 26 (96.3%),
equivocal in 6 patients (22.2%) / 2 (7.4%) / 1 (3.7%), and
incorrect in 1 patient (3.7%) / 4 (14.8%) / 0 (0%). Consistently,
the TNM staging by PET/MR was comparable to PET/CT (T:
p = 0.331, N: p = 0.453, M: p = 0.034). The sensitivity/spec-
ificity/accuracy of resectability-defining factors by PET/CT
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and PET/MRwere 0.68/0.93/0.97, and 0.80/1.00/0.99, respec-
tively. Conclusion: Whole-body staging with PET/MR yields
at least equal diagnostic accuracy as PET/CT in determining
the stage of head and neck cancer.
OP601
11C-methionine PET-CT for contouring and response
evaluation of Head and Neck Adenocystic Carcinoma
treated with CIRT (Carbon Ion Radiation Therapy)
L. Olivari1, M. Bonora2, M. Rodari3, M. Fiore2, V. Vitolo2, E.
Lopci3, F. Valvo2, P. Fossati2, R. Orecchia1, A. Chiti4; 1Uni-
versity of Milan, Milano, ITALY, 2Division of Radiation On-
cology and Radiobiology, National Center for Oncological
Adrontherapy (CNAO) Foundation, Pavia, ITALY, 3Depart-
ment of Nuclear Medicine, Humanitas Research Hospital, Mi-
lano, ITALY, 4Humanitas University, Milano, ITALY.
INTRODUCTION: Adenocystic carcinoma (ACC) is a rare
radio resistant head and neck cancer that usually locates close
to critical structures. CIRT, which shows some advantages to
treat radio resistant tumours, needs precise target definition.
Previous studies reported that 11C-methionine PET-CT
(MET) could be an effective alternative to FDG, due to its
low uptake in normal brain and in inflammatory tissue.
METHODS: In this prospective study, 47 patients affected by
ACC and treated with CIRTwere investigated with MET. Pre-
treatment MET, registered and fused with simulation CT, was
employed as a visual aid in target contouring. MR images (T2
weighted, T1 weighted and contrast enhanced T1 weighted)
were also used. Volumes with MET uptake comparable with
parotid glands were included in the Clinical Target Volume
(CTV); asymmetric findings with an uptake value between pa-
rotid and brain were also included, but treated with a lower
dose. Pre-treatment MET failed to show abnormal uptake in 7
patients (15%). In patients with elevated initial uptake, a post
treatment MET was performed one month after completion of
CIRT. Semi-quantitative tumour to normal brain ratio (T/B) and
volumetric change in METuptake were evaluated in both MET
exams. Dimensional response was investigated with MR every
3 months since the end of CIRT.The minimal follow up period
was 5 months (range 5-22). RESULTS: Forty patients with
ACC performed pre and post treatment MET. Sixteen patients
had previous history of ACC (recurrent disease) while 26 had a
newly diagnosed ACC. Twenty-three patient underwent
surgery before CIRT. CIRT was well tolerated and none of the
patient had G3-G4 toxicity three months after treatment. T/B
ratio showed a mean reduction of 55% (range -100% to +
14.6%) and MET volumetric change showed a mean reduction
of 72.9% (range -100% to +172%). Fifteen patients had MET
complete response after CIRT, confirmed at follow-up. MET
after CIRT detected progressive disease in 9/10 patients. One
patient had a negative MET while MR was inconclusive. Dis-
ease was detectable six months after the end of CIRT. Fifteen
patients had partial response on both METand MR, with stable
disease at follow-up. CONCLUSIONS: When used together
with MR, MET demonstrated to be useful in target delineation
and early response evaluation of patients affected by ACC treat-
ed with CIRT. T/B ratio and tumour volumetric changes
assessed with MET, are able to increase the diagnostic accuracy
of the pure qualitative image evaluation.
OP602
Value of FDG volumetric imaging parameters
before radiotherapy treatment in inoperable Head
and Neck cancer (HNC)
L. Olivari1, E. Lopci2, A. Poletti3, R. Cavina4, C. Arturo5;
1University of Milan, Milano, ITALY, 2Department of Nuclear
Medicine, Humanitas Research Hospital, Milano, ITALY,
3Department of Otorhinolaryngology, Humanitas Research
Hospital, Milano, ITALY, 4Department of Oncology,
Humanitas Research Hospital, Milano, ITALY, 5Humanitas
University, Rozzano, Milano, ITALY.
INTRODUCTION: Inoperable head and neck cancer (HNC) are
treated with concurrent chemo-radiotherapy (CCRT) alone or
associated with induction chemotherapy: docetaxel, cisplatin, 5-
fluorouracil (DCF). The aim of this studywas to evaluatewhether
metabolic tumour volume (MTV) and total lesion glycolysis
(TLG) of the primary tumour and nodes before CCRT and
DCF-CCRT can predict outcome for patients with inoperable
HNC.METHODS AND MATERIALS: Sixty-three consecutive
patients with biopsy-proven, newly diagnosed, non operable
HNC were included in this retrospective study. None of these
patients had history of radiation therapy in head and neck district.
All patients underwent FDG PET-CT before radiotherapy. An
automatic algorithm, based on adaptive thresholding, delineated
primary tumour and nodes. With this technique we calculated:
MTV, TLG, SUVmax, SUVmean. The primary endpoint was
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progression free survival (PFS). Univariate Cox regression
models and Kaplan Meir with respect to PFS were
performed.RESULTS: The cohort consisted of 19 female, 44
male; mean age 62,2±12.8 years. The distribution of patients by
the AJCC stage of the cancers included stages I (n=3), II (n=9),
III (n=15), IVa (n=34), IVb (n=1) IVc (n=1). Histology was:
squamous cell carcinoma (n=49), undifferentiated carcinoma
(n=12), adenocarcinoma (n=2). Tumour localization was:
rhinopharynx (n=19) oropharynx (n=28), hypopharynx (n=8)
and larynx (n=8). The mean follow-up was 23 months (range,
5-52 months). Six patients performed follow up in other centres.
Two patients died during follow up of unrelated cancer disease.
Progressive disease (PD) was demonstrated in 13 patients after a
mean interval of 12.7 months (range, 7-33 months). PD occurred
mainly in advanced cancer (stage IV at the diagnosis: n=8) and
the primary tumour localization was mainly rhinopharynx (n=7).
Cox regression demonstrated that MTV of the primary tumour
value is a significant predictor with respect to PFS (p<0.05).
Kaplan Meier analysis showed that MTVof the primary tumour
less than 4.3 indicates good median PFS (p<0.05) with a sensi-
tivity and specificity of 82%and 70% respectively. No correlation
was found between PFS and MTVof lymph nodes. No correla-
tion was found between PFS and SUVmax, SUVmean and TLG
of the primary tumour and of the lymph nodes.CONCLUSION:
In this patient population, MTV provided information of disease
burden and tumour metabolic activity. High baseline primary
tumour MTV (pre CCRT) was associated with worst outcomes
in patients with inoperable HNC. Pre-radiotherapy MTVof pri-
mary tumours provides independent prognostic information and
the threshold of 4.3 seems to predict PFS in inoperable HNC.
OP603
Predictive role of FDG-PET/CT in patients with locally
advanced oropharyngeal cancer undergoing tomotherapy
with dose escalation
E. Incerti1, I. Dell’Oca2, M. Kirienko3, C. Fiorino4, P.
Alongi3, S. Broggi4, P. Mapelli1, N. Di Muzio2, L. Gianolli1,
M. Picchio1; 1Nuclear Medicine Department, IRCCS San
Raffaele Scientific Institute, Milan, ITALY, 2Radiotherapy De-
partment, IRCCS San Raffaele Scientific Institute, Milan, IT-
ALY, 3University of Milano-Bicocca, Milan, ITALY, 4Medical
Physics Department, IRCCS San Raffaele Scientific Institute,
Milan, ITALY.
Aim: To evaluate the clinical outcome in patients affected
by locally advanced oropharyngeal cancer undergoing in-
tensity modulated radiation therapy, by means of helical
tomotherapy (HTT), with dose escalation to FDG-PET/
CT positive tumor volumes using the simultaneous inte-
grated boost (SIB). Materials and Methods: We analyzed
38 patients studied by FDG-PET/CT and treated between
2005 and 2013 for squamocellular oropharyngeal stage III-
IVB disease in our Institution. HTT was delivered with the
SIB technique (HTT-SIB) in 30 fractions at different dose
levels concomitantly: 69 Gy (2.3 Gy/day) to the gross tu-
mor volume PET-positive (GTV-PET) for lymph nodes
(LN) and primary tumor (T), 66 Gy (2.2 Gy/day) to the
clinical target volume (CTV) for LN and T, 54 Gy (1.8
Gy/day) to the clinical negative neck region. Thirty-one
patients received concurrent chemotherapy (cisplatin 75-
100 mg/m2/21 days for 23 patients, cisplatin 30-40 mg/
m2/week for 6 patients and cetuximab for 2 patients). The
2.5-year overall cancer specific (OS), local tumor disease-
free (LTDFS), local node disease-free (LNDFS) and distant
metastasis-free (DMFS) survivals were calculated. Correla-
tions between PET volumetric parameters and 2.5-year OS,
LTDFS, LNDFS and DMFS were assessed. The PET/CT
metabolic parameters of T include GTV-T-PET, metabolic
tumor volume (MTV-T), MTV thresholds 40%-50%-60%
(MTV-T-40, MTV-T-50, MTV-T-60) and mean standard-
ized uptake value (SUVmean). Results: The median
follow-up was 28 months (range: 3-109 months). All pa-
tients completed the treatment as scheduled. The 2.5-year
OS, LTDFS, LNDFS and DMFS were 88%, 83%, 88% and
77%, respectively. Multivariate Cox regression analyses
revealed that GTV-PET and GTV-T-PET are predictors for
OS with a best-cut-off value equal to 30.9 cc (p=0.022) and
22.4 cc (p=0.029) respectively; while MTV-T-40, MTV-T-
60 and SUVmean are predictors for OS with a best-cut-off
value equal to 21.3 (p<0.0001), 13.3 (p<0.0001) and 9.2
(p=0.01), respectively. Temporary treatment interruption
due to acute toxicity, mainly mucosae, was observed in 8
patients. Conclusions: The use of HTT-SIB with dose es-
calation to FDG-PET/CT positive tumor volumes, even
with concurrent chemotherapy, allows very promising
2.5-year disease control rates in patients affected by locally
advanced squamocellular oropharyngeal cancer. Moreover
PET/CT metabolic volumetric parameters have a predictive
value for the survival outcomes, thus FDG-PET/CT may
represent the basis for more personalized treatments.
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OP604
Diagnostic accuracy of F18-FDG-PET/CT
for the detection of perineural spread in head and neck
cancer
L. Dercle, S. Ammari, L. Rozenblum, D. Deandreis, M.
Terroir, M. Schlumberger, F. Bidault; GUSTAVE ROUSSY,
Villejuif, FRANCE.
Background: Head and neck cancer (HNC) spread loco-
regionally by direct extension, lymphatic dissemination,
and neurovascular spread. The accuracy of FDG-PET/CT
for the diagnosis of perineural spread (PNS) remains to
be determined because it could improve risk stratifica-
tion, staging, treatment planning, and follow-up. Two
limiting factors exist: the limited resolution of PET (par-
tial volume effect) and the physiological FDG-uptake of
the nearby brain. This report evaluates the accuracy of
FDG-PET/CT and describes clinical, morphological (CT-
scan), and metabolic patterns (18F-FDG-PET) attributed
to neoplastic involvement along the cranial nerves
(CN).Methods: Twenty-five patients were retrospectively
included. MRI was used as the reference-standard.
Thirty-two PNS were diagnosed. PNS was proved histo-
logically (surgery) or suspected according to a typical
evolution on long term follow-up (443±492 days). Quan-
titative results are expressed as mean ± SD.Results: The
sensitivity of FDG-PET/CT for the detection of PNS was
88%. Two false negatives were noted and explained by a
low FDG-uptake of the primary tumor due to 1/ the his-
tological subtype, 2/ an excellent response to radio-
chemotherapy.They are 5 morphological and metabolic
patterns observed in PNS: 1/ A typical topography of
the lesion along CN: CNV1 (8%), CNV2 (50%), CNV3
(54%), and CNVII (8%). 2/ A significant enlargement
along the CN (PNS: 9±5 mm, doubling size of the nerve:
Se84%, ratio CNabnormal/normal: 4.3±3.1 which is above
PET-resolution and is measurable on CT-scan). 3/ An
asymmetrical increased FDG-uptake (Se88%; significant-
ly different from the physiological brain uptake;
SUVmaxPNS: 20±11; SUVmaxbrain: 17±5). 4/ An Hetero-
geneity Index of the SUV of the CN similar to the tumor
and significantly increased in comparison with the phys-
iological brain uptake (HISUVtumor: 1.5±0.2, HISUVPNS:
1.5±0.1, HISUVbrain: 1.2±0.1, HISUVPNS/primary: 1.0±0.1,
HISUVPNS/brain: 1.3±0.1); 5/ An enlargement of the fo-
ramina in the base of skull (doubling size of the foramen:
Se64%, ratio foramenabnormal/normal: 2.6±1.6).Conclusions:
FDG-PET/CT is accurate for the detection of PNS. The
diagnostic accuracy of five direct and indirect signs of
PNS on FDG-PET/CT was described.
OP605
Head and neck cancer: can 18F-FDGPET/CTstaging scan
improve the predictive value of post-treatment 18F-FDG
PET/CTassesment
I. Sandler1, G. M. Lima1, P. Castellucci1, U. Caliceti2, S.
Cammelli3, V. Allegri1, A. Morganti3, S. Fanti1; 1Università
di Bologna, Nuclear Medicine Unit, S.Orsola-Malpighi Hos-
pital, Bologna, ITALY, 2Università di Bologna, Head and
Neck Unit , S. Orsola-Malpighi Hospital, Bologna, ITALY,
3Università di Bologna, Radiotherapy Unit, S. Orsola-
Malpighi Hospital, Bologna, ITALY.
Aims: The purpose of this retrospective study is to evaluate
whether a staging or pre-treatment 18F-FDG PET/CT scan
may improve the predictive value of 18F-FDG PET/CT in treat-
ment response assessment after primary radio-chemotherapy
(RT-CT) for loco-regional advanced Head and Neck squamous
cell carcinoma (HNSCC). Methods: We enrolled 138 patients
with a diagnosis of advanced HNSCC (96 males and 42 fe-
males, mean age 58 yo) who performed a 18F-FDG PET/CT
between 2006-2013. Disease sites were oral cavity (10%), na-
sopharynx (14%), oropharynx (53%), hypopharynx (7%), lar-
ynx (7%), salivary glands (5%) and paranasal sinuses (4%). All
patients have been treated with primary RT-CT. All patients
underwent a 18F-FDG PET/CT to assess treatment response,
preformed from 6 to 36 weeks (60% between 10-15 weeks)
after the end of RT-CT. In 84 patients (60%) a 18F-FDG PET/
CT staging or pre-treatment scan have been also performed
(group A) while for the remaining 54 patients (40%) a staging
18F-FDG PET/CTwas not available (group B). There were no
significant differences in terms of risk stratifications between the
two groups. 18F-FDGPET/CTscans were performed according
to standard procedure and were visually analyzed by two expert
physicians and categorized as negative or positive for residual
disease. Patients were followed-up, based on clinic and radio-
logical and/or histological findings, up to 60 months and for at
least 12 months after end of therapy (median 38months). At the
end of follow-up, 18F-FDG PET/CT results were classified as
true positive (TP), true negative (TN), false positive (FP) and
false negative (FN). Results: - Group A (84 patients) showed:
30 TP (36%), 46 TN (54%), 3 FP (4%) and 5 FN (6%). There-
fore 18F-FDG PET/CT sensitivity 86%, specificity 94%, PPV
91%, NPV 90%, accuracy 0.9. - Group B (54 patients) showed:
11 TP (20%), 38 TN (70%), 1 FP (3%) and 4 FN (7%). There-
fore 18F-FDG PET/CT sensitivity 73%, specificity 97%, PPV
91%, NPV 90%, accuracy 0.9. Conclusions: According to our
data, 18F-FDG PET/CT scan in staging of HNSCC does not
improve significantly the Positive and Negative predictive
values of post-treatment PET/CT. These results should be con-
firmed by larger studies.
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OP609
3D patient absorbed dose estimation of monoclonal
antibody targeting synovial sarcoma
D. Sarrut, J. Badel, A. Halty, D. Kryza, A. Giraudet;
CREATIS / LUMEN, Lyon, FRANCE.
Aims: Frizzled homologue 10 (FZD10) is transmembrane receptor
overexpressed in synovial sarcoma (SS). We investigated the pa-
tient absorbed dose distribution of OTSA101-DTPA-90Yttrium, a
radiolabeled monoclonal antibody (mAb) targeting FZD10 devel-
oped by Oncology Therapy Science, in relapsing metastatic SS
patients included in a first-in-man phase I clinical trial based on a
theranostic procedure.Materials and Method: Biodistribution was
analysed in 20 patients on SPECT-CTacquisitions repeated at 1, 5,
24, 48, 72 and 144 h post-injection of 185 MBq/1.5 mg
OTSA101-111Indium. In case of significant tumors uptake, greater
than mediastinum, and favourable biodistribution, patient was
treated with OTSA101-90Y. Retrospectively, volume of interest
(VOI) were drawn on H1 CT in various lesions, mainly lung
metastases, and normal tissues (liver, kidneys, heart, bone marrow,
spleen). Deformable image registration was performed between all
CT time-points and used to warp all SPECT time-points onto the
same coordinate system allowing pixel-by-pixel time-activity-
curves (TAC) analysis. Time-integrated activities were computed
frommono-exponential fit of TAC in all pixels and used to compute
the 3D estimated absorbed doses of OTSA101-90Y with Monte-
Carlo simulation (GATE) at a pixel level.Results: Tumor tracer up-
take appeared to be highly heterogeneous on an inter-patient, as well
as an intra-patient and inter-lesions based analysis independently of
tumor size. Estimated doses to the 95 lesions ranged from
[0.01;0.82] cGy by injected MBq (median 0.22). Uptake intensity
was considered to be greater thanmediastinum inhalf of the patients,
observed as soon as H1 for 2 patients or only at H144 for 2. There
was a trend for mAb accumulation in the tumors signing specific
mAb tumor uptake. Time-integrated activities appeared to be the
highest in the liver with a total estimated dose ranging from
[0.34;1.19] cGy/MBq (median: 0.78) ; bone marrow and kidney
estimated dose ranged from [0.02;0.19] and [0.06;0.32] cGy/MBq.
Conclusion:We confirm FZD-10 antigen expression in SSmetasta-
ses. OTSA101 lesions uptake is heterogeneous and appeared suffi-
cient for radionuclide therapy for half of the patients. However,
estimated dose could not reflect real received dose because of po-
tential difference between OTSA101-111In and OTSA101-90Y. A
comprehensive patient-specific absorbed dose estimation combining
SPECT-CT acquisitions at several time-points, deformable registra-
tion and pixel-based 3D Monte-Carlo computation has been pro-
posed and applied in clinical context.
OP610
Implementation and validation of a collapsed cone
superposition algorithm for radiopharmaceutical
dosimetry of radionuclides with photon component
M. Sanchez-Garcia1, I. Gardin2, R. Lebtahi1, A. Dieudonné1;
1Department of Nuclear Medicine, Beaujon Hospital, Assis-
tance Publique-Hôpitaux de Paris (APHP) & INSERM
U1149, Clichy, FRANCE, 2Department of Nuclear Medicine,
Henri Becquerel Cancer Center and Rouen University Hospi-
tal, & QuantIF – LITIS [EA 4108], Rouen, FRANCE.
Objectives: A collapsed cone (CC) superposition algorithm
(CCS) has been recently implemented for radiopharmaceutical
absorbed dose (AD) calculation of beta emitters (Sanchez-
Garcia et al. Phys Med Biol 2014). This paper presents the
implementation for radionuclides with a photon component.
Methods: The superposition relies on a water dose kernel
(DKw) that is linearly scaled by radiological distance between
source and target voxels, taking into account tissue density
heterogeneities. CC provides an acceleration of the superposi-
tion by approximating the energy transport to a finite number
of directions. Our CCS implementation was extended to pho-
tons and validated on 2 radionuclides used in diagnostic nu-
clear medicine, F-18 and Tc-99m, and another 2 used in
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therapy, I-131 and Lu-177. The DKws were generated for each
radionuclide with MCNPMonte Carlo simulations (MC). The
validation was done against MCNP in 6 phantoms constituted
of 2 concentric (radii of 4 and 8 cm) spheres representing
tissue interfaces between soft-tissue, lung and bone. The
absorbed dose was scored in concentric shells of 1 mm thick-
ness for CCS andMC, leading to a plot of AD according to the
radial coordinate. The metrics used for comparison were the
percentage of points in the plot satisfying the γ(3%, 3mm) and
γ(5%, 5 mm) criterions, i.e. the percentage of points satisfying
a tolerance of 3% (or 5%) in dose or 3 mm (or 5 mm) in
distance to agreement. Results: For F-18, γ(3%, 3 mm) was
100% for all phantoms. For Tc-99m, γ(3%, 3 mm) was be-
tween 71 and 97%, except for the bone/lung interface
(7%), and γ(5%, 5 mm) was over 99% except for the
bone/lung phantom too (57%). For I-131, γ(3%, 3 mm)
was between 99 and 100%, except for the bone/lung phan-
tom (92%), but γ(5%, 5 mm) was 100% for all phantoms.
For Lu-177, γ(3%, 3 mm) was between 89 and 100%,
except again for bone/lung phantom (59%), but γ(5%, 5
mm) was over 97% for all phantoms. Calculation times
were between 3.5 and 4 minutes on a 3.2 GHz Intel Core
i5 machine with 4 cores. Conclusion: Our results show
that the CC superposition algorithm has a good agreement
with MC simulations for various tissue interfaces and com-
mon radionuclides. This study confirms that CC superpo-
sition is a reliable alternative to MC simulations in radio-
pharmaceutical dosimetry.
OP611
Targeted photodynamic therapy of insulinomas
and congenital hyperinsulinism by Exendin-700DX
S. Ekim1, D. Bos1, F. Andreae2, M. Brom1, M. Gotthardt1;
1Radboud University Medical Centre, Nijmegen, NETHER-
LANDS, 2PICHEM, Graz, AUSTRIA.
Background and aims: lnsulinomas are tumors of the pancreas
that are derived from beta cells. Because the tumor produces
excess amounts of insulin, it can lead to hypoglycemia. Con-
genital hyperinsulinism is a disease that causes high levels of
insulin and hypoglicemia. Exendin is a peptide which can
specifically bind to the glucagon-like peptide 1 receptor
(GLP-1R) which is expressed in the beta cells in the pancreas.
700DX can create free radicals and singlet oxygen that can be
fatal to the cells, when it is subjected to laser irradiation. La-
beling Exendin with 700DX can be a promising way to pro-
duce a new agent for laser induced photodynamic therapy
(PDT) of insulinomas and congenital hyperinsulinism, aimed
at selective destruction of diseased beta cells. With this thera-
py, it would be possible destroy diseased beta cells in a specific
area of pancreas and leave a sufficient amount of beta cells to
prevent diabetes. Materials and methods: Exendin-3 (Ex-3)
and Exendin-700DX (Ex-700DX) were used in the experi-
ments. The therapeutic effect was examined on islets isolated
from C3H mice, rat insulinoma cells (lNS-1E) and GLP-1R
expressing CHL cells. ln vitro PDT experiments, were per-
formed by incubating islets with 165 nM Ex-700DX, 165
nM Ex-3 and medium only (control) for 3 hours at 37°C.
The islets were irradiated for 30 min at 60 Watt, with a LED
laser system that emits radiation in the 690nm spectral band
while the control plate was not irradiated.An hour after the
PDT, cell titer glo assay was performed to detect the islet
death. The effect of internalization of Ex-700DX was exam-
ined using CHL-GLP1R(+) cells by incubation at 0°C (no
internalization) or 37°C (internalization). Results:Nearly 60%
islet death was detected after PDT, on the Ex-700DX treated
group of islets. No islet death was observed with Ex-3 and
vehicle incubated groups after PDT, which proves that the
compound and laser irradiation itself does not cause any islet
death. The percentage of cell death after PDTwas calculated as
44% when Ex-700DX internalized into the cells, while 21%
cell death was observed when Ex-700DX was only bound to
GLP-1R on the cells. Conclusion:First trials on mice islets and
GLP-1R(+) tumor cells showed that PDT with Ex-700DX ef-
ficiently destroys the target cells. For efficient PDT, Ex-
700DX should be at least bound to GLP-1R and the efficiency
of the therapy increases nearly 2 times when Ex-700DX is
internalized into the cells.
OP612
Integration of micro- and macro-dosimetry for calculation
of radiation doses to the islets of Langerhans due
to radionuclide imaging with exendin
I. van der Kroon1, W. Woliner-van der Weg1, M. Brom1, L.
Joosten1, C. Frielink1, M. W. Konijnenberg2, E. P. Visser1, M.
Gotthardt1; 1Radboud University Medical Center, Nijmegen,
NETHERLANDS, 2Erasmus Medical Center, Rotterdam,
NETHERLANDS.
Aim: Radiolabeled exendin, targeting the GLP-1 receptor, is
used for quantification of the insulin producing beta cells lo-
cated in the islets of Langerhans. High accumulation of the
radiolabeled exendin in the islets has lead to concerns about
radiation-induced damage to the islets. Standard methods or
models to estimate the radiation-induced damage to the islets
are not yet available. Commonly used macro-dosimetry
methods, such as OLINDA/EXM, do not contain the islets as
a separate compartment, therefore these models are not able to
provide the radiation dose to single islets. Because of the high
accumulation of radiolabeled exendin in islets compared to
surrounding tissue, islets need to be included as a separate
compartment. In our work, a model was developed to calculate
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the islet radiation dose due to the use of 111In-exendin (150
MBq) and 68Ga-exendin (75MBq) in patients with differences
in gender, islet size, beta cell mass and kidney uptake. Mate-
rials and Methods: The model includes the radiation dose to
the islets due to accumulation of the radiotracer (i) in the kid-
neys, (ii) in surrounding islets and exocrine tissue in the pan-
creas (together: remainder of the pancreas) and (iii) in the islet
(islet self-dose). The contribution of the remainder of the pan-
creas and the kidneys to the islet radiation dose was calculated
using the standard S-value based approach as implemented in
OLINDA/EXM. For the islet self-dose, Monte Carlo simula-
tions were performed for a small sphere model (diameter 50-
400 μm). As input for the model both data from a clinical
study (organ distribution of the tracer) and data from a preclin-
ical study with biobreeding diabetes prone rats (endocrine-
exocrine uptake ratio), was used. Results: The islet radiation
dose was found to be small ranging from 49.3 to 74.3 mGy for
111In-exendin and ranging from 1.61 to 2.35 mGy for 68Ga-
exendin. The activity in the islets contributed up to 45% to the
total islet radiation dose for 111In-exendin and up to 22% for
68Ga-exendin. Due to the high accumulation of radiolabeled
exendin in the kidneys, the kidneys have the largest contribu-
tion to the total islet radiation dose (49-81%). Conclusion: The
calculated islet radiation doses suggest that even repeated
exendin imaging will not harm the islets since the maximum
islet radiation dose is much smaller than the one known to
cause serious islet damage (10 Gy as observed with external
beam radiation).
OP613
The intrinsic absorbed dose resolution concept in voxel
dosimetry - Application to 90Y microsphere
radioembolization
C. Chiesa, M. Mira, M. Maccauro, E. Seregni, F. Crippa;
Nuclear Medicine, Foundation IRCCS Istituto Nazionale
Tumori, Milan, ITALY.
Aim& background: In radioembolization dosimetry, the analysis
of uncertainties is simple, since a single acquisition of a tomo-
graphic image is sufficient. Under the local deposition hypothesis,
voxel absorbed dose is simply proportional to voxel counts. Im-
age noise (σ/N) was investigated, since it is numerically the level
of uncertainty on voxel absorbed dose (intrinsic absorbed dose
resolution).Methods: In uniformly filled phantoms, absorbed
dose in voxels should be uniform, i.e. the DDVH should be
Dirac’s delta. The statistical voxel fluctuation should follow a
Poissonian dependence on N , σ=√N. The dependence of noise
on the number of iterations #ITand the number of subsets #SUBS
was studied on a high statistic (N=8100) 99mTc 20 cm diameter
uniform cylinder (several CT attenuation corrected OS-EM
SPECT reconstruction (Siemens e.soft work station) without
additional postfilter). A 2000 mL plastic bottle simulating liver,
filled with a typical liver concentration of 99mTc-MAA (150
MBq/1000 mL), surrounded by non radioactive water, was ac-
quired with clinical scan duration (15 s/projection, 900 s). Its
noise was studied by varying the number of updates
P=#ITx#SUBS.A TOF LYSO PET scanner was used to study
an 90Y bottle in air filled with 90Y-DOTATOC solution with a
concentration corresponding to a 40 Gy mean dose, with scan
duration of 15 min and 60 min.Results: In 99mTc SPECT, noise
was dependent on the number of updates P, and independent on
different combinations giving the same P. The larger contribution
to noise came from reconstruction. Fixed N=2500 in the bottle
simulating liver, the evaluation showed a gaussian shapedDDVH
whose width (dose uncertainty) was dependent on the square root
of P (R2=0.99), with remarkable voxel dose uncertainty of 5.5%,
9%, 37% for P= 4x4, 8x8, 30x30. After optimization of recon-
struction (fixed P=8x8 Chiesa et al 2015), such uncertainty could
be slightly reduced increasing N (higher activity or longer acqui-
sition time). In the 90Y PET (blob reconstruction, 3 IT, 28 sub-
sets) reconstruction and Poisson noise were comparable. The
poor N=16 cannot be improved (using LYSO), since the thera-
peutic activity is fixed and scan duration cannot be longer than
30 min for 2 bed positions. At a simulated dose of 32 Gy,
voxel dose uncertainty is 41%. This reach an acceptable
value of 11% for dose larger than 1000 Gy.Conclusion:
noise from statistics and reconstruction intrinsically limit
the accuracy of voxel dosimetry, which is strongly pe-
nalized in 90Y-PET with LYSO.
OP615
Improved treatment planning in radioimmunotherapy
with 90Y-anti-CD66 antibody using population based
modelling
C. Maaß1, P. Kletting2, D. Hardiansyah1, B. Mahren3, D.
Bunjes2, A. Beer2, G. Glatting1; 1Medical Radiation Physics/
Radiation Protection, Medical Faculty Mannheim, Heidelberg
University, Mannheim, GERMANY, 2Department of Nuclear
Medicine, Ulm, GERMANY, 3Department of Nuclear Medi-
cine, Würzburg, GERMANY.
Aim: Accurate estimation of time-integrated activity coeffi-
cients is essential for treatment planning in radioimmunotherapy
(RIT). Recently it was shown that for the estimation of these
coefficients, the application of physiologically based pharmaco-
kinetic (PBPK) models is advantageous over the standard ap-
proach (sums of exponential functions) [1, 2]. However, the
prediction accuracy of therapeutic biodistributions needs to be
further improved. Including knowledge about the population
itself, e.g. population specific Bayesian parameters, may serve
this purpose. Therefore, the aims of this work were 1) to esti-
mate population parameters and 2) to show the effect of these
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parameters on prediction accuracy of therapeutic
biodistributions. Materials and Methods: Population parameters
were estimated two-fold, i.e. using the standard and iterated
two-stage (STS, ITS) algorithms. For each algorithm, a PBPK
model was fitted to pre-therapeutic (gamma camera and serum)
and therapeutic (serum) measurements simultaneously. The es-
timated population values (STS, ITS) were implemented as
Bayesian information. The model parameters of each patient
were fitted to pre-therapeutic data only, therapeutic
biodistributions simulated. Prediction accuracy of the therapeu-
tic serum curve was validated comparing the simulated and
fitted time-integrated activity coefficients. Results: The relative
deviations RDs between pre-therapeutic and therapeutic serum
time-integrated activity coefficients are (-25 ± 16) %. When
using no Bayes parameters prediction accuracy was RD = (-3
± 20) %. Using population based parameters as Bayesian infor-
mation improved RD to (8 ± 16) %) and (0 ± 10) % for the STS
and ITS algorithm, respectively. Conclusion: Estimation and
subsequent application of population values used as Bayesian
parameters for RIT using a PBPK model for 90Y labeled anti-
CD66 antibodies improves prediction accuracy substantially.
Literatur: 1. Maaß C andKletting P, Reske SN, Beer A, Glatting
G. Physiologically Based Pharmacokinetic Modeling is Essen-
tial in 90Y-labeled Anti-CD66 Radioimmunotherapy. PLoS
ONE, accepted, 20/04/2015. 2015; 2. Kletting P, Kull
T, Bunjes D, Mahren B, Luster M, Reske SN, et al.
Radioimmunotherapy with Anti-CD66 Antibody: Im-
proving the Biodistribution Using a Physiologically
Ba s ed Pha rmacok ine t i c Mode l . J Nuc l Med .
2010;51(3):484-91. doi: 10.2967/jnumed.109.067546.
OP616
Metrology for molecular radiotherapy: what did
the MetroMRT project achieve?
V. Smyth1, C. Bobin2, L. Johansson1, L. Joulaeizadeh3, M.
D’Arienzo4, M. Capogni4, H. Rabus5, M. Cox1, J. Šolc6; 1Na-
tional Physical Laboratory, Teddington, Middlesex, UNITED
KINGDOM, 2Laboratoire National Henri Becquerel/
Commissariat à l’Energie Atomique (LNE-LNHB), Gif-sur-
Yvette Cedex, FRANCE, 3VSL, Dutch Metrology Institute,
Delft, NETHERLANDS, 4National Institute of Ionizing Radi-
a t ion Met ro logy, ENEA-INMRI, Rome, ITALY,
5Physikalisch-Technische Bundesanstalt (PTB), Braun-
schweig, GERMANY, 6Czech Metrology Institute (CMI),
Prague, CZECH REPUBLIC.
The MetroMRT project was funded through the European
Metrology Research Programme (EMRP http://www.
emrponline.eu/). It ran from June 2012 to May 2015, and
this was the first time that the measurement of radiation
absorbed dose to target and normal tissues in the modality of
molecular radiotherapy (MRT) had been addressed within the
discipline of metrology. The problems of standardisation of
procedures, traceability to primary standards, and uncertainty
in dosimetry for external beam therapy was covered in the UK
by the HPA [1983] and then internationally by IAEA [1987].
This positions MRT approximately 30 years behind external
beam therapy in establishing dosimetry to achieve uniformity
in practice from one centre to another, or one country to an-
other, and so that absorbed dose in MRT can become a legal
quantity able to be specified in regulations.The structure of the
MetroMRT project was based on the links in the measurement
chain required to obtain absorbed dose within a volume of
interest (VOI) in a patient undergoing a typical MRT proce-
dure:1.Measurement of the administered activity;2.Definition
and delineation of the VOI (target tissue; normal tissue);3.
Quantitative imaging (QI) procedure (tracer activity, full ther-
apy activity, surrogate) to determine activity in the VOI rela-
tive to the administered activity;4.Determination of biokinetics
from a time sequence of activity measurements interpolated/
extrapolated to give an activity-time curve; then obtain total
disintegrations within defined VOI by integrating under the
curve;5.Calculation of absorbed dose within the VOI (Gy/
MBq).Workpackages in the project showed that traceability
can be established within links 1, 3, and 5 to primary standards
of radioactivity and radiation absorbed dose. A separate
workpackage investigated the uncertainty entailed in the
choice of how links 2 and 4 were carried out, and showed that
by adopting best practice procedures the overall uncertainty in
the measurement of absorbed dose can be evaluated.The pro-
ject has therefore demonstrated that it is technically feasible to
formulate a dosimetry protocol for MRT and has given strong
recommendations to the relevant international bodies (IAEA,
ICRP) that the process should be initiated.HPA, Revised Code
of Practice for the dosimetry of 2 to 25 MV X ray, and of
137Cs and 60Co gamma-ray beams, Phys. Med. Biol. 28
(1983) 1097-1104.IAEA, Absorbed Dose Determination in
Photon and Electron Beams: An International Code of Prac-
tice, Technical Reports Series No. 277, Vienna (1987).
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OP617
Synthesis and evaluation of Androgen Receptor
radioligand [18F]enzalutamide: comparison with [18F]
FDHT
I. F. Antunes1, R. Dost2, A. van Waarde1, R. Dierckx1, D.
Samplonius3, W. Helfrich3, D. Burg4, E. de Vries1, I. de Jong2;
1NMMI, UniversityMedical Center of Groningen, Groningen,
NETHERLANDS, 2Department of Urology, University
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Medical Center of Groningen, Groningen, NETHERLANDS,
3Surgical Research Laboratory, University Medical Center of
Groningen, Groningen, NETHERLANDS, 4Astellas Pharma
Europe, Leiden, NETHERLANDS.
Aim: 16β-[18F]fluoro-5α-dihydrotestosterone ([18F]FDHT) is a
PET tracer that has been investigated for the assessment of an-
drogen receptor (AR) density in prostate cancer. Being an agonist,
[18F]FDHT intrinsically poses the risk pharmacological response,
which is undesirable for a PET tracer. Recently, enzalutamide
(formerly MDV3100) was introduced as an AR signaling inhib-
itor. Here we present the synthesis of [18F]enzalutamide and its
in vitro and in vivo behavior in comparison to [18F]FDHT.
Methods: The nitro-precursor was obtained by multistep synthe-
sis starting with the nitrobenzoic acid. [18F]enzalutamide was
obtained by fluorination of the corresponding nitro precursor.
Competition assays with [18F]enzalutamide and [18F]FDHTwere
conducted in the LnCaP (AR+) cell line to evaluate the affinity
for AR. In vitro cellular uptake of both tracers were performed
with LnCaP (AR+) and HEK293 (AR-) cells. In vivo PET imag-
ing, ex vivo biodistribution and metabolite studies with
[18F]enzalutamide and [18F]FDHT were conducted in athymic
nude mice bearing a subcutaneous LnCaP xenograft. Results:
The nitro precursor was produced with an overall yield of 2%.
[18F]Enzalutamide was obtained in 1.2% radiochemical yield
with an apparent specific activity of 487 ± 347 GBq/mmol.
[18F]FDHT was obtained in 2% with a specific activity >
25.000 GBq/mmol. Co-incubation of [18F]enzalutamide or
[18F]FDHTwith an excess of DHTor enzalutamide significantly
reduced cellular uptake of both tracers to about 50% in AR+
LnCaP cells, whereas co-incubation of both tracers with an ex-
cess of DHTor enzalutamide did not lead to reduction of cellular
uptake in the AR- HEK293 cell line. [18F]enzalutamide and
[18F]FDHT biodistribution studies in male mice bearing a
LnCAP xenograft showed 2.5 times higher [18F]Enzalutamide
uptake in tumor than [18F]FDHT. In addition, metabolite analysis
indicated that 99% of [18F]Enzalutamide remains intact versus
only 3% of [18F]FDHT at 60 min p.i. Conclusion: Based on our
results, [18F]enzalutamide seems to have more favorable proper-
ties for AR imaging than [18F]FDHT. Additional evaluation in
various oncological animal models is warranted to confirm its
ability to monitor AR expression.Funding: Prostate Cancer Mo-
lecular Medicine 030-203.
OP618
Comparison of [11C]Choline and [18F]Galacto-RGD
as pharmacodynamic biomarker for therapy response
assessment of avastin therapy in a PC-3 Prostate Cancer
Xenograft Model
S. Schwarzenböck1,2, M. Souvatzoglou1, M. Heuschkel2, R.
Nawroth3, U. Treiber3, T. Schuster4, R. Senekowitsch-
Schmidtke1, M. Schwaiger1, S. I. Ziegler1, G. Henriksen5, H.
Wester5, A. J. Beer1, B. J. Krause1,2; 1Technical University
München, Department of Nuclear Medicine, München, GER-
MANY, 2Rostock University Medical Centre, Department of
Nuclear Medicine, Rostock, GERMANY, 3Technical Univer-
sity München, Department of Urology, München, GERMA-
NY, 4Technical University München, Institution of Statistics,
München, GERMANY, 5Technical University München,
Pharmaceutical Radiochemistry, Garching, GERMANY.
Introduction:In prostate cancer molecular imaging develop-
ment and evaluation of new tracers with higher sensitivity
and specificity for diagnosis as well as therapy response as-
sessment is necessary. The use of 18F-labeled Galacto-RGD
([18F]RGD) - targeting the integrin alpha-v-beta-3 as a key
molecule in angiogenesis and tumour metastasis - is a promis-
ing approach for prostate cancer imaging and therapy response
assessment.Aim:The aim of this study was to compare the
properties of [18F]RGD and [11C]Choline ([11C]CHO) as
imaging biomarker and to assess response to an anti-
angiogenesis avastin therapy avastin in a PC-3 human prostate
cancer xenograft mouse model.Methods:We carried out a dual
tracer small animal PET/CT study comparing the properties of
[18F]RGD and [11C]CHO in prostate cancer imaging as well
as in avastin therapy response assessment (9 untreated mice, 7
avastin therapy mice (5 i.p. injections within 10-13 days, dose
of 5 mg/kg bodyweight each), 3 PBS i.p. control mice). The
androgen-independent human prostate tumour cell line PC3
was implanted subcutaneously in the flanks of SCID mice. 6
weeks post xenografting all mice underwent dynamic PET/CT
scanning after injection of 37 MBq [11C]CHO and 14 MBq
[18F]RGD, respectively, via the tail vein on two separate days.
5x5x5 mm VOIs were placed in transaxial slices in tumour,
muscle (thigh), liver, kidney and blood. Image analysis was
performed calculating tumour-to-muscle (T/M) ratios based on
summed images.Tumour volumes were measured using a
caliper.Results:In untreated mice the mean [18F]RGD T/M
ratio was significantly higher compared to [11C]CHO (4.62
+/- 2.20 vs. 1.44 +/- 0.39, mean difference +3.18, 95% CI:
2.12 - 4.25, p<0.001), in the PBS control group comparable
results were obtained. In contrast, there was a tendency of an
increase in both [18F]RGD and [11C]CHO uptake in the
avastin treated group. Measurement of tumour volumes
showed a decreased tumour growth in avastin treated mice
compared to the control group.Conclusion:Excellent tumour
visualization is possible in this PC-3 xenograft model using
[18F]RGD. [18F]RGD uptake was significantly higher com-
pared to the clinically utilized [11C]CHO. In the avastin treated
group there was an increase in [11C]CHO as well as in
[18F]RGD uptake (compared to untreated and PBS control
mice) indicating a stimulating effect of the humanized monoclo-
nal antibody avastin in the early stage of anti-angiogenesis ther-
apy. Further studies using clinically relevant therapies for
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S261
prostate cancer are recommended to assess the general suitability
of [18F]RGD therapy response assessment of prostate cancer.
OP619
Broadcasting the HER3 receptor status in vivo
C. D. Martins, C. Da Pieve, D. M. Ciobota, R. L. Paul, T.
Spinks, G. Smith, G. Kramer-Marek; The Institute of Cancer
Research, London, UNITED KINGDOM.
Background:Amongst the human epidermal growth factor recep-
tor (HER) family, HER3 is a key node in the activation of the
PI3K/AKT pathway, implicated in promoting cell survival, pro-
liferation and metastasis. Overexpression of HER3 correlates
with advanced disease stage and is involved in resistance to other
anti-HER therapies. Multiple anti-HER3 mAbs are being tested
in clinical trials, highlighting the potential of HER3 inhibition to
improve patient care. We investigated the potential use of
affibodymolecules targetingHER3 (ZHER3:8698) for PET imaging
of different receptor levels in HER3+ve breast cancer models.
The ultimate goal is to promote ZHER3:8698-based imaging agents
as tools for patient stratification for anti-HER3 targeted therapies.
Materials and methods: ZHER3:8698 molecules were conjugated
via the C-terminus cysteine with NOTA-Maleimide and DFO-
Maleimide for 18F and 89Zr radiolabelling respectively. The
probes were characterised in vitro using a panel of human breast
adenocarcinoma cell lines with different receptor levels (MDA-
MB-231HER3<MDA-MB-361HER3<BT-474HER3<MCF-7HER3).
BALB/c nu/nu mice bearing BT-474 and MDA-MB-231 xeno-
grafts were used for in vivo evaluation of the probes. Mice were
injected via the tail vein with either of the radioconjugates (1-5
μg, 0.8-14MBq depending on the tracer). Biodistribution as well
as imaging studies were performed 1, 3 and 24 h following 89Zr-
DFO-ZHER3:8698 injection, and 1, 2 h post
18F-AlF-NOTA-
ZHER3:8698 administration. Results: The Kd of both
18F and 89Zr
conjugates was determined to be within 0.44 + 0.044 (nM). Pre-
incubation with either unlabelled affibody or heregulin reduced
binding of both tracers in vitro, confirming the specificity of the
probes. There was no significant accumulation of the 18F
radioconjugate in BT-474 tumour bearing mice 2 h post 18F-
AlF-NOTA-ZHER3:8698 injection, most likely due to low specific
activity of the conjugate (SA: 0.8 MBq/μg). However, the 89Zr
probe (SA: 2.8 MBq/μg) specifically accumulated in BT-474
xenografts (2%ID/g) as early as 1 h post tracer injection, but
not inMDA-MB-231 tumours (TBT-474/TMDA-MB-231: 3.4). Rapid
clearance was observed in BT-474 bearing mice leading to high
tumour to blood and muscle ratios (TBT-474/Blood: 7, TBT-474/
Muscle: 23, TMDA-MB-231/Blood: 0.81, TMDA-MB-231/Muscle:
4.4). IHC and ELISA receptor evaluation showed correlation
with PET signal, ex vivo autoradiography, and radioactivity mea-
surements. Conclusion: Our data shows that 89Zr-DFO-
ZHER3:8698 molecules accumulate with high specificity in
HER3+ve tumours, providing real time information about the
receptor expression. Various strategies to develop higher SA
18F-radiolabelled ZHER3:8698 molecules are being pursued.
OP620
PET Imaging of c-Met in Cancer with 64Cu-Labeled
Hepatocyte Growth Factor
H. Luo, H. Hong, S. Shi, S. A. Graves, R. J. Nickles,W. Cai;
University of Wisconsin-Madison, MADISON, WI, UNITED
STATES.
Objective: The hepatocyte growth factor (HGF) and its recep-
tor, c-Met, are actively involved in tumor progression/
metastasis and associated closely with poor prognostic out-
come of cancer patients. Development of positron emission
tomography (PET) agents for assessing c-Met expression
would be extremely useful for diagnosis of cancer and subse-
quent monitoring of responses to c-Met-targeted therapies.
Herein we report the expression and characterization of recom-
binant human hepatocyte growth factor (rh-HGF) as a PET
tracer for non-invasive imaging of c-Met expression.Methods:
rh-HGF was expressed in human embryonic kidney (HEK)
293 cells and purified by nickel-nitrilogriacetic acid (Ni-
NTA) affinity chromatography. The concentrated rh-HGF
was conjugated to 2-S-(4-isothiocyanatobenzyl)-1,4,7-
triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA)
and labeled with 64Cu. c-Met binding evaluation by flow cy-
tometry was performed in both U87MG and MDA-MB-231
cell lines, which have high and low level of c-Met, respective-
ly. PET imaging and biodistribution studies were performed in
nude mice bearing U87MG and MDA-MB-231 xenografted
tumors. Ex vivo histopathology were performed to elucidate
the expression patterns of c-Met in different tissues/organs and
used to validate the in vivo results. Results: The rh-HGF ex-
pression yield was 150-200 μg protein per 5×106 cells after
48 h transfection with purity of > 85%. Flow cytometry exam-
ination confirmed strong and specific binding capacity of rh-
HGF to c-Met. After labeled with 64Cu, PET imaging revealed
specific and prominent uptake of 64Cu-NOTA-rh-HGF in c-
Met positive U87MG tumors (6.7 ± 1.8 %ID/g at 9 h post-
injection; n = 4) and significantly lower uptake in c-Met neg-
ative MDA-MB-231 tumors (1.8 ± 0.6 %ID/g at 9 h post-
injection; n = 4). Heat-denatured rh-HGF (termed as dnrh-
HGF) had significantly lower uptake in U87MG tumors,
which confirmed the c-Met specificity of 64Cu-NOTA-rh-
HGF. Based on fluorescence staining of c-Met, c-Met expres-
sion was prominent on the U87MG tumor cells but absent on
the MDA-MB-231 cells and rh-HGF can target c-Met with
high specificity. c-Met staining of mouse liver and muscle
gave a low signal, indicating that these tissues do not express
high level of c-Met. Thus, uptake of 64Cu-NOTA-rh-HGF in
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the liver was mostly due to hepatic clearance of the tracer
rather than c-Met binding. Conclusion: Herein we report the
purif icat ion of rh-HGF, the character izat ion and
in vitro/in vivo investigation of 64Cu-NOTA-rh-HGF for
in vivo PET imaging of c-Met expression. Fast, prominent
and c-Met-specific uptake of 64Cu-NOTA-rh-HGF in the
U87MG tumors was observed, which was validated by various
in vivo/ex vivo experiments.
OP621
The PET tracer [18F]-tetrafluoroborate allows reporter
gene-afforded metastasis tracking.
S. Diocou1, G. Fruhwirth1, K. Chuamsaamarkkee1, M.
Jauregui-Osoro1, L. Livieratos1, P. Blower1, T. Ng1,2, G. Mul-
len1; 1King’s College London, London, UNITED KING-
DOM, 2University College London, London, UNITED
KINGDOM.
Purpose: We aim to non-invasively track metastasis in a mu-
rine breast cancer model by PET/CT. The approach is based on
a radionuclide-optical fusion protein as previously described
(1). Metastasis tracking has not been shown before using NIS-
based PET imaging. Here we compare the PET radiotracer
[18F]-BF4- (2) with the SPECT radiotracer [123I]-iodide for
NIS reporter gene imaging-afforded detection and monitoring
of metastasis. Another goal was to compare metastasis detection
and tracking of this NIS-RFP-afforded PET approach with [18F]-
FDGPET in this preclinical model.Methods: Breast adenocarcino-
ma cells (MTLn3E) were engineered to stably express the sodium
iodide symporter (NIS) fused to a fluorescent protein for multi-
modal multi-scale imaging. Furthermore, we transduced
MTLn3E.NIS-RFP cells with full-length or truncated CXCR4
(3E.FL-NIS and 3E.Δ-NIS, respectively). The resultant cell lines
served as a model for tumor xenografts that showed a low or very
high propensity for spontaneous metastasis (3). Xenografts were
established orthotopically in the lower mammary fat pad of female
SCID/Beige mice. Dynamic radionuclide scanning using [18F]-
BF4-, [123I]-iodide and/or [18F]-FDG tracers was performed by
PET/CTand SPECT/CTas appropriate. Specificity and sensitivity
of metastasis detection were measured by comparing radionuclide
scans with confocal fluorescence microscopy of biopsied lymph
node tissues.Results: Uptake of both [18F]-BF4- and [123I]-iodide
in primary tumors was rapid, reaching 12.1 and 11.0 %ID/g for
[18F]-BF4- and [123I]-iodide, respectively, after 12min, and 56.9
and 60.5 %ID/g, respectively, after 120min. Clearance of [18F]-
BF4- from the blood was faster (falling to 0.06 %ID/g at 36 min)
than clearance of [123I]-iodide (3.1 %ID/g at 36 min). 100% of
lymph nodes (LN) that were detected via [18F]-BF4 PET were
also confirmed positive for 3E.Δ-NIS tumor cells using confocal
fluorescence microscopy of biopsied material. Furthermore, all
LNs that were not detected by [18F]-BF4 PET were confirmed
to be free of metastasis. LNs detected by [18F]-BF4- and con-
firmed to be positive for tumor metastases were not detected
using [18F]-FDG in >95% of the cases.Conclusion: [18F]-
BF4- PET showed more favorable tracer kinetics and signal-to-
background as compared to [123I]-iodide SPECT. Furthermore,
it showed much higher sensitivity and specificity for metastasis
detection as compared to [18F]-FDG. This preclinical model is
particularly useful for studying spontaneous cancer metastasis
and for evaluating the treatment response of anti-cancer and
particularly anti-metastatic therapeutics.References:(1)
Fruhwirth J Nuc Med 2014; 55(4):686-94.(2) Jauregui-Osoro
Eur J Nucl Med Mol Imaging, 2010; 37(11):2108-16.(3) Ver-
meer J Proteome Res 2012; 11(5):2996-3003.
OP622
Molecular imaging of EGFR and EGFRvIII for prediction
and response monitoring of HSP90 inhibition in an in vivo
squamous cell carcinoma model
D. Spiegelberg1, A. C. Mortensen1, R. K. Selvaraju2, O.
Eriksson2, B. Stenerlöw1, A. Scott3, M. Nestor1,4; 1Depart-
ment of Immunology, Genetics and Pathology, Uppsala Uni-
versity, Uppsala, SWEDEN, 2Preclinical PET Platform, Upp-
sala, SWEDEN, 3Ludwig Institute for Cancer Research, Olivia
Newton-John Cancer Research Institute, and La Trobe Univer-
sity, Melbourne, AUSTRALIA, 4Department of Surgical Sci-
ences, Academic hospital, Uppsala, SWEDEN.
Aim: The novel HSP90 targeting drug AT13387 has been
shown to reduce tumor growth, angiogenesis and spreading
of the disease in patients with solid cancers. Remaining chal-
lenges are to increase response rates and prolong response
duration by refining treatment dose and schedules. Molecular
imaging of biomarkers involved in disease progression is a
useful noninvasive tool to obtain this goal. Biomarkers that
are over expressed or tumor specific in several malignancies
are e.g. the epidermal growth factor receptor (EGFR) and the
epidermal growth factor receptor variant III (EGFRvIII). The
overall goal of this study was to identify if EGFR or EGFRvIII
expression monitoring in squamous cell carcinomas (SCC)
could be used in order to follow the disease status during
AT13387 treatment. Materials and methods: Cancer cell pro-
liferation, cell toxicity assays and radio-immunoassays using
radiolabelled monoclonal antibodies targeting EGFRvIII and
EGFR, were used to quantify the effect of AT13387 on antigen
expression in vitro. Inhibitor effects were then assessed in vivo
in mice xenografts bearing dual SCC tumors with high or low
EGFR expression, and low EGFRvIII expression. Animals
were treated 5 times on 5 consecutive days with AT13387
(50 mg/kg), and were then imaged either with 18F-FDG
(30 min p.i.), 124I-labelled EGFR-targeting mAb Cetuximab,
or with an 111I-labeled anti-EGFRvIII antibody (48 h p.i.).
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Imaging was performed with a small animal PET/CT or
SPECT/CT, and was followed by ex vivo biodistribution and
autoradiography measurements and immunohistochemical
analysis. Results and conclusion: We could demonstrate for
the first time that the HSP90 client protein EGFRvIII is down-
regulated, approximately by 30% in our models, by AT13387.
We could also verify that EGFR is downregulated byAT13387
in SCC, approximately by 75% and 40% in our high- and low-
EGFR-expressing models respectively. 18F-FDG was neither
able to clearly detect nor distinguish between EGFR expres-
sion. We conclude that the 111In-labelled EGFRvIII-targeting
antibody and 124I-cetuximab are promising tracers for
EGFRvIII and EGFR expression analysis respectively, and
could be useful tools for treatment response monitoring in
combination with HSP90 inhibition in SCC patients.
OP623
Efficacy of the sequentially combined vinorelbine
and gefitinib in Non-Small Cell Lung Cancer cell lines,
an “in-vivo” study.
G. Bottoni1, M. Dal Bello2, A. Alama2, S. Morbelli1, C. Ma-
rini3, F. Grossi2, G. Sambuceti1; 11.Nuclear Medicine Unit,
IRCCS-IST San Martino, University of Genoa, Genova, ITA-
LY, 2Lung Cancer Unit IRCCS-IST San Martino, Genova,
ITALY, 33.Institute of Bioimaging and Molecular Physiology,
CNR, Milan, Genoa Section, Genova, ITALY.
Aim: The current standard of care for advanced NSCLC is
based on systemic chemotherapy or epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKI) for patients
with tumors harboring EGFR mutations. Preclinical studies
suggest that EGFR-TKI may have additive effects on chemo-
therapy even in cancers without EGFR mutations. Our study
tested, in vitro and in vivo, the anti-proliferative activity of
different treatment schedules with gefitinib (GEF) and vino-
relbine (VNB) in EGFR-TKI resistant NSCLCs.Methods: We
studied CD1-Nude mouse subcutaneously inoculated with 3
millions H1975 cells in the dorsal hip. In each mouse, cancer
growth was estimated by conventional caliper methods, while
lesion glucose consumption was estimated by means of a dy-
namic PET scans at day 14 after tumor implantation. To this
purpose, a bolus of 3-6 MBq of 18F-FDG was injected
through a tail vein during a list mode acquisition lasting one
hour using a dedicated microPET system. After framing rate
optimization, pixelwise maps of cancer glucose consumption
(MRGlc) were created using a dedicated software (PMOD)
and applying Patlak graphical approach.Results: In vitro short
and long-term studies demonstrated that the sequence of VNB
followed by GEF was more effective than GEF followed by
VNB or the concurrent administration of the two drugs. More-
over, the increased antitumor activity of the sequence VNB
followed by GEF was confirmed in vivo by a significant inhi-
bition of the H1975 tumor growth ( 0,13 ml vs 0,95 ml in
treated and untreated lesions, respectively, p<0.05). This bio-
logical effect was correctly predicted by FDG-based measure-
ment of lesion MRGlc that was 2,81±0,04 umol/min/100gr in
untreated and 5.65±2.71 umol/min/100gr in treated mice, re-
spectively (p<0.008).Conclusion: Our preclinical findings in
NSCLC with EGFRT790Mmutation showed that the sequen-
tial treatment with VNB followed by GEF can induce signif-
icant antitumor benefit to be tested in a clinical trial for TKI
resistant NSCLC patients.
OP624
Oncologic Applications of High Resolution In Situ
Correlations between Histopathology and FDG Tracer
Uptake Obtained by Quantitative Autoradiography
of Biopsy Specimens (QABS)
A. S. Kirov1, L. M. Fanchon1,2, S. Dogan1, C. Czmielewski1,
E. Yorke1, H. Schöder1, J. O. Deasy1, J. L. Humm1, S. B.
Solomon1; 1Memorial Sloan-Kettering Cancer Center, New
York, NY, UNITED STATES, 2INSERM, UMR1101, LaTIM,
Brest, FRANCE.
Purpose. To use autoradiography to determine the distribution
of a PET radiotracer in biopsy specimens obtained under PET/
CT guidance for correlation with histopathology and to iden-
tify the potential and the limitations of this method for different
applications in oncology.Methods. Autoradiography (ARG)
using imaging plates was performed on 32 core needle biopsy
specimens obtained from different body locations under FDG
PET/CT guidance in an interventional suite equipped with a
PET/CT scanner. In this institutional review board-approved
study, the specimens were extracted using 11G, 13G, 18G and
20G core needles and the response of the plates for 18G and
20G needles was calibrated using gelatin based standards with
known activity prepared using the same needles. The quality
of the autoradiography image, the preservation of the shape of
the specimen during pathology processing, the location of the
needle with respect to the PETavid region, the effect of motion
on the accuracy of the fused PET/CT image, and the post
biopsy management of the patient were all considered in the
evaluation of the methodology for different oncologic
applications.Results. Of the 32 cases, 18 were found useful
for high resolution in situ correlations of tracer uptake with
histopathology. Such correlations allowed separating malig-
nant from benign liver lesions based on the activity contained
in the specimens which was expressed as SUVARG (Fanchon
et al, JNM, 56, p. 538, 2015). A potential application of this
result is evaluating the adequacy of PET guided biopsy needle
placement. Eight of the 18 cases were found adequate for
calibrating the PET display window and for providing a
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ground truth point for evaluation of lesion segmentation con-
tours on the PET image. Two cases showed correlation with
inflammation in a normal tissue specimens, and 1 showed
uptake in the absence of histopathologic changes in the inves-
tigated slices. The percentage of specimen autoradiographs,
which can be accurately correlated with histopathology has
increased due to improvements of the method since implemen-
tation and further increase is expected. Thirty of the patients
were treated in our institution. Investigating correlations of
QABS findings with treatment outcome is possible for radia-
tion therapy (2 cases), ablation (6 cases) and chemo or anti-
body therapy (14 cases).Conclusions. QABS is a promising
method for providing knowledge which may have an impact
on PET tracer validations for nuclear medicine, on the accura-
cy of interventional radiology and radiotherapy procedures,
and on increasing the sensitivity of histopathology assessment
of biopsy specimens.
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OP625
Textural analysis of baseline 18F-FDG PET for predicting
treatment response and prognosis in patients with locally
advanced esophageal cancer
X. Sun, L. Sun, L. Xing; Shandong Cancer Hospital and In-
stitute, Jinan, CHINA.
PURPOSE: Textural features on baseline 18F-FDG PET have
shown the potential role in predicting treatment response in mixed
stage esophageal cancer. This study is aim to investigate the value
of this new technique for locally advanced esophageal squamous
cell cancer (ESCC) receiving chemoradiotherapy. METHOD
AND MATERIALS: Under a waiver from institutional review
board, 48 patients with newly diagnosed locally advanced ESCC
who treated with concurrent chemoradiotherapy were retrospec-
tively reviewed. Thirty-nine patients with early stage ESCC were
included as control. All patients underwent pretreatment whole-
body 18F-FDG PET/CT. Fifty-four texture indices describing
global, local, and regional features were measured in addition to
5 conventional indices as standardized uptake values (SUVs, in-
cluding maximum, peak, and mean SUV), metabolic volume
(MV), and total lesion glycolysis (TLG). Patients were classified
as responders (R, complete or partial response) and non-responders
(NR, stable or progressive disease) according to RECIST1.1.
Progression-free survival (PFS) and overall survival (OS) were
recorded. The prognostic significance of parameters was examined
using receiver-operating-characteristic curves, Kaplan-Meier anal-
ysis, and Cox regression analysis. RESULTS: Both intratumor
heterogeneity andmean/peak intensity of FDG uptake were signif-
icantly higher in locally advanced ESCC than those in early stage.
Thirty-four texture indices, MV, and TLG showed the ability to
differentiate R from NR. Nine texture indices showed higher sen-
sitivity (76.7%~86.7%) and specificity (77.8%~94.4%) than MV
(76.7% and 83.3%) and TLG (73.3% and 83.3%). Ten texture
indices and MV were hazard factors of PFS and OS. Large-zone
emphasis, one of the regional texture indices, was the only inde-
pendent predictor of survival, with hazard ratio of 4.22
(95%CI:1.83~9.72) for PFS and 3.90 (1.74~8.79) for OS. None
of the SUVs could predict treatment response and survival. CON-
CLUSION: FDG PET texture indices provide better predictive
information than conventional parameters for locally advanced
ESCC. Therefore, the clinical application of FDG PET texture
analysis could be an important step in personalized treatment of
esophageal cancer.
OP626
The predictive value of 18F-FDG PET-CT for assessing
the clinical outcomes in locally advanced NSCLC patients
after a new induction treatment: “low-dose” fractionated
radiotherapy with concurrent chemotherapy
M. Mattoli1, M. Massaccesi2, V. Scolozzi1, A. Castelluccia2,
G.Mantini2, A. Giordano1, M. Calcagni1; 1Institute of Nuclear
Medicine, Rome, ITALY, 2Department of Radiation Oncolo-
gy, Rome, ITALY.
Aim: Many patients with locally advanced non-small-cell lung
cancer (NSCLC) have a poor prognosis, despite the use of two
cycles of induction chemotherapy performed before the standard
treatment (chemo-radiotherapy). It is emerging that the addition
of “low-dose” fractionated radiotherapy (LD-RT) to the induc-
tion chemotherapy can enhance tumor cells chemo-sensitivity
and improve its effects. Aim: to evaluate whether the metabolic
response assessed by 18F-fluoro-deoxyglucose positron
emission/computed tomography (18F-FDG PET-CT) after in-
duction chemo-LD-RT can predict clinical outcomes in locally
advanced NSCLC patients. Materials and methods: Forty-two
consecutive locally advanced NSCLC patients (32 males, mean
age 66±7.9years; 25 stage IIIA; 17 stage IIIB) underwent LD-
RT (40cGy twice daily) to primary tumor and involved lymph-
nodes concurrently with two cycles of induction chemotherapy,
before undergoing standard chemo-radiotherapy treatment. 18F-
FDG PET-CT was performed before (mean 5.7±2 weeks) and
after chemo-LD-RT (mean 4.6±1.5 weeks). SUVmax of prima-
ry tumor and of the most active lymph-node was evaluated in
both PET-CT to obtain the metabolic changes (ΔSUV). To as-
sess the metabolic response, PERCIST criteria were used. Pa-
tients with complete and partial metabolic response were classi-
fied as responders; patients with stable and progressive disease
as non-responders. Disease free survival (loco-regional, distant
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or global) and overall survival were calculated with Kaplan-
Meyer method. Results: Twenty out of 42 locally advanced
NSCLC patients (48%) were classified as responders: 22/42 as
non-responders. Two years loco-regional failure free survival
was 54%: 84.4% in responder and 24.8% in mom-responders
(p=0.001). Two years distant failure free survival was 48.2%:
70.4% in responders and 22.8% in non-responders (p=0.001).
Two years global failure free survival was 34%: 63.4% in re-
sponders and 0.8% in non-responders (p=0.0003). Two years
overall survival was 58.2%: 73.5% in responders and 43.9%
in non-responders (p=0.009). SUVmax of primary tumor and
lymph-node was significantly reduced at PET-CT after chemo-
LD-RT (p=0.004 and p=0.0002, respectively). No significant
difference in SUVmax between stage IIIA and stage IIIB was
found, either at diagnosis or after chemo-LD-RT.Conclusion: in
patients with locally advanced NSCLC, 18F-FDG PET-CT is
useful for assessing metabolic response after a new induction
treatment, such as“ low-dose” fractionated radiotherapy with
concurrent chemotherapy. Metabolic response predict clinical
outcomes: patients with complete or partial metabolic response
have a better prognosis than those with progressive or stable
disease. These findings allow to personalize therapy, selecting
patients for standard treatment or for intensified treatment.
OP627
Comparison of EORTC criteria and PERCIST for FDG
PET/CT response evaluation of patients with metastatic
breast cancer treated with a first line of systemic therapy.
E. Depardon1, S. Kanoun1,2, O. Humbert1,2, J. Riedinger1, M.
Lasserre1, M. Toubeau1, A. Berriolo-Riedinger1, I. Dygai-
Cochet1, P. Fumoleau3, F. Brunotte1,2, A. Cochet1,2; 1Depart-
ment of Nuclear Medicine, Centre Georges-Francois Leclerc,
Dijon, FRANCE, 2Le2i CNRS UMR 6306, Dijon, FRANCE,
3Department of Medical Oncology, Centre Georges-Francois
Leclerc, Dijon, FRANCE.
Aim : To compare European Organization for Research and
Treatment of Cancer (EORTC) criteria with PET Response
Criteria in solid Tumors (PERCIST) for response evaluation of
patients with newly diagnosed metastatic breast cancer treated
with a first line of systemic therapy.Methods : From December
2006 to august 2013, 57 patients who were referred to our insti-
tution for a newly diagnosed metastatic breast cancer were retro-
spectively included (41 HR+/HER2-, 9 HER2+, 7 triple nega-
tive). FDG-PET/CT was performed within one month before
treatment and 3 to 9 months following start of a first line of
systemic therapy: polychemotherapy (n=20), bevacizumab-
based therapy (n=16), hormone therapy (n=12) or trastuzumab-
based therapy (n=9). Response evaluation with FDG-PET/CT
was retrospectively performed according to both EORTC criteria
and PERCIST, classifying the patients into 4 response groups:
complete metabolic response (CMR), partial metabolic response
(PMR), stable metabolic disease (SMD), and progressive meta-
bolic disease (PMD). The kappa statistic was used for agreement
analysis. Overall survival (OS) within every response categories
was determined by Kaplan-Meier method after a median follow
up of 30 months. A multivariate analysis was also performed by
Cox model to assess independent predictors of survival.Results:
Average time delay between baseline and follow-up PET/CTwas
5 months. With EORTC criteria, 22 patients had CMR, 17 had
PMR, 6 had SMD and 12 had PMD.With PERCIST, 20 patients
had CMR, 15 had PMR, 10 had SMD and 12 had PMD. There
was agreement between EORTC and PERCIST in 84% of the
patients, and the corresponding kappa-coefficient was 0.78. Thir-
ty patients died during follow up (8 CMR, 12 PMR, 2 SMD, 8
PMD with EORTC; 7 CMR, 10 PMR, 4 SMD, 9PMD with
PERCIST). By log-rank analysis, metabolic response evaluated
with both EORTC and PERCIST was able to predict survival
(p=0.028 and 0.002 respectively). Patients in the CMR group
had longer median OS than patients in the combined PMR+
SMD+PMD group (60 vs 26 months; p=0.009 with EORTC;
p=0.006 with PERCIST). By multivariate analysis, CMR either
with EORTC or PERCIST, stratified by age and phenotype,
remained an independent predictor of survival.Conclusion: In
the setting of metastatic breast cancer treated with a first line of
systemic therapy, metabolic response evaluation with EORTC
criteria and PERCIST gave similar response and outcomes with
good agreement and similar significant differences in median OS
between response groups.
OP628
Monitoring Tumour Response to Neoadjuvant
Chemotherapy using MRI and 18F-FDG PET/CT
in Breast Cancer Subtypes
A. M. T. Schmitz1, K. E. Pengel2, C. E. Loo2, W. Vogel2, J.
Wesseling2, S. C. Teixeira2, E. J. T. Rutgers2, R. A. Valdés
Olmos2, G. S. Sonke2, S. Rodenhuis2, M. T. F. D. Vrancken-
Peeters2, K. G. A. Gilhuijs1; 1University Medical Centre
Utrecht, Utrecht, NETHERLANDS, 2Netherlands Cancer In-
stitute - Antoni van Leeuwenhoek Hospital, Amsterdam,
NETHERLANDS.
Aim: To establish a practical guideline on the use of MRI and/or
PET/CT for response monitoring of the primary tumour, taking
into account the breast cancer subtypes. Material &Methods:We
included 188 women with stages II/III breast cancer. Baseline
histology was assessed from biopsy. Primary tumours were strat-
ified into ER-positive/HER2-negative (ER-positive), HER2-pos-
itive, and ER-negative/HER2-negative/PR-negative (triple-
negative) subtypes, and treated with pre-operative neoadjuvant
chemotherapy (NAC) according to subtype. MRI and 18F-
FDG-PET/CT were acquired before and during NAC. Primary
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endpoint was pathological complete response (pCRmic) defined
as no or only small numbers of scattered invasive tumour cells.
Multivariate analyses assessed the association of patient, tumour
and imaging characteristics with pCRmic. Using post-hoc analy-
sis, six imaging scenarios were evaluated; MRI only, PET/CT
only, and combinations of both. We used receiver operating char-
acteristics analysis with assessment of areas under the curve
(AUC) to determine optimal imaging scenarios and we selected
high specificity (90%) as operating point to propose clinical
guidelines per subtype. Results: A pCRmic was found in 35/46
(76.1%) of HER2-positive, 11/87 (12.6%) of ER-positive, and
31/55 (56.4%) of triple-negative tumours. Before NAC, age
(p<0.001) and subtype (p<0.001) were the only predictors of
response. During NAC, MRI yielded the strongest predictor for
HER2-positive tumours (AUC: 0.735; sensitivity 36.2%)
outperforming PET/CT (AUC: 0.543; p=0.04) comparable to
results of combined imaging (AUC: 0.708). In ER-positive tu-
mours, the combination of MRI and PET/CT yielded the stron-
gest predictor (AUC: 0.818; sensitivity 55.8%) compared toMRI
(AUC: 0.742) or PET/CT (AUC: 0.791) alone. For triple-
negative tumours, MRI (AUC: 0.855; sensitivity 45.4%), PET/
CT (AUC: 0.844) or a combination of both showed comparable
results (AUC: 0.868). Conclusion: For response monitoring in
ER-positive primary tumours the combination of PET/CT and
MRI may be the most optimal choice. For HER2-positive and
triple-negative tumours, MRI has high specificity but moderate
sensitivity to monitor response. PET/CTwill provide comparable
results with MRI in triple-negative but not in HER2-positive
breast cancer tumours.
OP629
Planning of radiotherapy with PET: Volumes only?
M. Beresova, J. Mucientes Rasilla, B. Rodriguez Alfonso, I.
Zapata Paz, A. De la Torre Tomas, J. Romero Fernández, M.
De Teresa Herrera, I. Plaza De Las Heras, M. Mitjavila Casa-
novas; HUPH Majadahonda, Madrid, SPAIN.
Aim: We assess the percentage of cases in which findings of
distant disease through 18F-FDG PET/CT for radiotherapy
planning lead to changes in the modality and/or intent of the
treatment, or change in stage IV.Material and methods: All the
studies derived from the Radiotherapy department were retro-
spectively analysed. Those performed for radiotherapy plan-
ning were selected. Cases with distant disease findings were
assessed, investigating changes in the modality or intent of
treatment and change in stage IV.One thousand four hundred
seventy six studies were derived from the Radiotherapy depart-
ment between April/09 and December/13. Three hundred and
seventy three (25,3%) were performed for radiotherapy plan-
ning (267 males and 106 females, mean age 68.2 years). The
intention of radiotherapy was for radical treatment
planning.Results: In 45 of these studies (12%) there were pre-
viously not suspected findings that suggested an upstage of the
patients to a clinical stage IV. The unexpected disease was lo-
cated more frequently in bone (12 patients), followed by lung (9
patients), liver (10), distant adenopathy (6 patients), brain (4
patients), adrenal glands (4 patients), spleen (1 patient) and
multiple progression (1 patient).In twenty-six (26/45, 7%) of
these patients the findings of 18F-FDG PET/CT were con-
firmed as true positive for distant metastasis with complemen-
tary examinations. In sixteen (16/26) of them the modality of
treatment was changed. In ten of them (10/26) the intent of
treatment was changed from curative to palliative. In three pa-
tients a second primary tumour was confirmed.In remaining
sixteen (16/45) patients the results of 18F-FDG PET/CT could
not be initially confirmed. The confirmation was made by mon-
itoring progression in eleven patients, one patient remainedwith
stable disease and four patients died without being able to con-
firm the findings.Conclusions: 18F-FDG PET/CT studies in
radiotherapy planning improve the staging of patients, leading
to an upstage in a significant number of patients. Based upon
the findings of 18F-FDG PET/CT, the modality or the intent of
treatment may radically change, (making unnecessary radia-
tion) or changing the intent to palliative.
OP630
Feasibility and clinical utility of 4D PET/CT for SBRT
planning of liver tumors
E. Deshayes1, L. Santoro1, M. Eberle1, S. Guillemard1, F.
Marre1, N. Aillères2, P. Fenoglietto2, D. Azria2, P. Kotzki1,
O. Riou2; 1Nuclear Medicine Department - Institut Cancer
Montpellier, Montpellier Cedex 5, FRANCE, 2Radiotherapy
Department - Institut Cancer Montpellier, Montpellier Cedex
5, FRANCE.
Aim: the aim of this study was to assess the feasibility of
4D PET/CT for patients with liver tumors, and its clinical
utility for stereotactic body radiation therapy (SBRT) plan-
ning. Material and methods: we retrospectively analyzed
in this study all the consecutive patients who underwent
4D PET/CT for liver SBRT radiotherapy planning in treat-
ment position. The patients were included between Janu-
ary 2014 and February 2015. Patients with hepatocellular
carcinoma could have undergone either FDG or F-Choline
PET/CT. 4D PET/CT images were produced using a Real
time Position Management system (RPM, Varian Medical
System) and separated in 10 phases (bins). Each phase
was then coregistered with each of the 10 phases of the
radiotherapy planning 4D CT. All images were indepen-
dently reviewed by a radiation oncologist and a nuclear
medicine physician. Evaluation criteria were: to assess if
uptake was significant on 3D PET, on 4D PET, the added
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S267
value of 4D PET over 3D PET (leading to a change in
target volumes). Impact of PET/CT on treatment decision
was also reported. Results: 15 patients (14 males, 1 fe-
male) were included: 10 primary tumors (3 patients with
hepatocellular carcinoma performed a F-Choline PET/CT;
7 had FDG PET/CT: 5 hepatocellular carcinoma and 2
cholangiocarcinoma) and 5 metastatic liver lesions (3 from
colorectal cancer, 1 from breast cancer and 1 from renal
cell carcinoma). Mean age was 73.6 years (+/- 7.3). Final
analysis was performed on 13 patients as PET/CT led to
exclude 2 patients for SBRT (discovery of multiple un-
known distant metastases). Among the 13 remaining pa-
tients, the nuclear medicine physician found a significant
and useful 4D PET/CT liver uptake as compared to 3D
PET/CT for 7 patients (54 %), and the radiation oncologist
for 9 patients (the same 7 patients and 2 more) (69 %).
Among those 9 patients, 4D PET/CT led to an effective
change in radiotherapy volumes for 8 patients. For the 7
patients whose 4D PET/CT was considered as useful for
both nuclear medicine physician and radiation oncologist,
the mean SUVmax of the liver lesions determined on 4D
acquisition was 12,4 mg/mL (+/- 2,8) versus 10,6 g/mL
(+/-2,3) on 3D PET/CT. Conclusion: 4D PET/CT appears
to be feasible and useful for stereotactic body radiation
therapy planning of hepatic tumors.
OP631
Other than restaging phase: Serial FCHPET/CTscans can
predict the response to chemotherapy in castrate-resistant
prostate cancer?
L. Evangelista1, U. Basso1, A. Guttilla2, F. Zattoni2, A.
Cervino1, M.Maruzzo1, V. Zagonel1, F. Zattoni2, G. Saladini1;
1Istituto Oncologico Veneto I.R.C.C.S., PADOVA, ITALY,
2University of Padua, PADOVA, ITALY.
Objectives. The present study aimed to evaluate the utility of serial
FCH PET/CT scans to predict the response to chemotherapy in
patients with castrate-resistant prostate cancer (CRPCa).Materials
and methods. We collected FCH PET/CT data from a consecutive
series of 21 CRPCa pre-treated patients (median age: 73 years)
who meet the inclusion criteria (mainly, visceral and no-visceral
metastasis with a clear uptake on a baseline FCHPET/CTscan and
no fewer than two scans separated by at least onemonth and by no
more than 12 months while receiving chemotherapy), in our Insti-
tute from June 2010 to October 2014. All patients had at least two
FCH PET/CT scans, before and after or during chemotherapeutic
treatment (taxanes in 17 patients and abiraterone acetate in 4 pa-
tients). Change in FCH uptake (SUVmax of the index lesion;
ΔSUVmax) during the course of treatment was compared with
clinical assessment response and PSA change (ΔPSA). The corre-
lations were evaluated by using Kruskal-Wallis test for K
independent variables, linear regression analysis and Kendall rank
correlation coefficient. A p<0.05 value was considered statistically
significant.Results. The median interval time between PET scans
was 5 months (3-11 months). Median (range) PSA value and
SUVmax of the index lesion were 25 (1.2-1040) ng/mL, 15.7
(5.9-30.2), 22.9 (2.3-1699) ng/mL and 5.5 (3.2-12.2) respectively
at the time of baseline and 2nd PET/CT scan. The medianΔPSA
and ΔSUVmax were -49.9 and 8.3, respectively. No correlation
between ΔPSA and ΔSUVmax was found (R=0.046; p=0.843).
In accordance with the clinical assessment, 8 (38%) patients were
responders, 4 (19%) had a stable and 9 (43%) a progressive dis-
ease. A significant overlap was reported for ΔPSA and clinical
categories of response (p=0.685). Conversely, ΔSUVmax was
significantly different in patients with response to chemotherapy
as compare to those with stable and progressive disease
(p=0.005).Conclusions. The change in SUVmax, rather than
ΔPSA, represents an importantmeasure of response to chemother-
apy and should be useful to stratify the prognosis of CRPCa pa-
tients.A largemulticenter prospective study is necessary to confirm
these findings.
OP632
Role of 11C-CHOLINE PET/CT in the Radiotherapy
Treatment Planning of Prostate Cancer Patients
E. Lopci, G. R. D’Agostino, C. Franzese, E. Villa, M. Rodari,
M. Scorsetti, A. Chiti; Humanitas Clinical and Research Hos-
pital, Rozzano (Milano), ITALY.
Purpose: In the era of image-guided radiotherapy (IGRT),
consisting evidence demonstrates that PET imaging can play a
significant role in tumour delineation for several neoplasia. How-
ever limited data are available on the use of 11C-Choline PET/CT
in radiotherapy (RT) planning for prostate cancer patients. The
aim of this study was to verify the impact of this imaging modal-
ity in treatment planning of patients eligible for RT.Materials and
Methods: For the analysis, we enrolled 37 consecutive patients
(mean age 70 years, range 53-85) referred to our Institution for
radiation therapy planning with a radical intent (n=7), as salvage
therapy (n=15) or in order to plan a re-irradiation (n=15). Patients
were submitted to a single-day protocol, including dedicated CT
scan of the pelvis and 11C-Choline PET/CT scan. Clinical-tumor
volumes (CTV), planning-tumor volumes (PTV) and organs at
risk (OAR) were outlined on CTslices with Eclipse Varian Med-
ical System software, whereas Gross tumor volume (GTV)-PET
was defined as the area of pathologic uptake and contoured with
PETVCAR software on Advantage GE workstation. Results:
Among the 7 patients undergoing 11C-Choline PET for a radical
radiation treatment, 5 (72%) pts received the planned RT, includ-
ing 1 pt (14%) with a negative PET. Two (28%) pts showed
evidence of positive nodes therefore a boost of dose on patholog-
ic lymphnodes was also delivered. Of the 15 pts candidate to a
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salvage RT, 4 (26%) had a negative PET and were irradiated on
the prostatic bed as planned. Among the 11 pts with positive PET,
1 (9%) was irradiated only on prostatic bed as planned, 7 (64%)
received also a boost on positive nodes, 3 (27%) were not sub-
mitted to RT because of the evidence of metastatic disease (2
lungs, 1 bone). Of 15 pts already submitted to RT, and undergo-
ing 11C-Choline PET/CTwith a re-irradiation intent, 9 (60%) had
a confirmed indication to the planned RT, 1 pt (7%) did not
receive RT as planned, having the PET scan showed evidence
of lung metastases, 5 (33%) because of a negative exam. Con-
clusion: In our experience 11C-Choline PET/CT proved to have a
significant impact on RT planning of prostate cancer patients, by
determining a change in the therapeutic decision in up to 48% of
cases, in all the therapeutic settings.
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OP633
Initial experience in the management of radiation
protection in clinical use of Ra-223
G. CICORIA1, F. ZAGNI1, A. INFANTINO2, A.
CORAZZA1, D. PANCALDI1, M. MARENGO1; 1Medical
Physics Department, University Hospital “S.Orsola - Malpi-
ghi”, Bologna, ITALY, 2Department of Industrial Engineering,
Montecuccolino Laboratory, University of Bologna, Bologna,
ITALY.
Introduction: 223Ra chloride (Xofigo®) is a novel radiopharma-
ceutical, currently approved for the treatment of bone metastases
of prostate cancer. In this work we studied different radiation
protection issues, relevant for both patients and workers, namely
the emanation of gaseous 219Rn during the manipulation of the
product, the calibration of surface contamination monitors and
the presence of long-lived contaminants in the radiopharmaceu-
tical solution. Materials & methods: Presence of 219Rn in the air
gap of the vial containing Xofigo was quantified by carefully
connecting the vial containing Xofigo and an 11 ml evacuated
vial; the procedure was repeated after 5 and 15 minutes. The vial
containing the sampled air was then measured in gamma-ray
spectrometry. Surface contamination monitors were calibrated
by uniformly contaminating three different Rad-Wipe® Smears
with amean activity of (2.18±0.12) kBq of 223Ra and evaluating
counts in different positions of the sensitive windows. The inves-
tigated instruments were a Berthold LB-124 zinc-sulphide scin-
tillator, Eberline PRM-6GMdetector (HP-210 probe) and a Tema
Sinergie CPS-51 (TPG46 GM detector). Radionuclidic purity
was evaluated by gamma spectrometry of different batches of
Xofigo® analyzed 2, 6 and 10 month after the calibration date.
All the radioactivity measurements were performed with a spec-
trometry system equipped with a HPGe detector and multi-
channel analyzer. The system was properly calibrated in the 59-
1836 keV range by means of a multi-radionuclide certified refer-
ence solution. Results: 219Rn emanation was 1.2% of the 223Ra
activity, at the sampling time. Comparable amounts were found
in the samples taken after 5 and 15 minutes. Calibration factors
for the probeswere (0.013±0.001), (0.09±0.02) and (4.7±0.4) Bq/
cps/cm2 for LB124, PRM-6 and CPS-51 respectively. No signif-
icant activity of contaminants was detected in the measurements
taken at 2 and 6 months after reference date. After 10 months
only 227Th was detected (1.7±0.1 Bq). Minimum detectable
activity for 226Ra and 228Th was 0.3 Bq. Conclusions: The
presence of 219Rn and the quick release from liquid to air makes
necessary to dispense 223Ra under ventilated hoods. Calibration
of surface contamination meters provided a simple and reproduc-
ible way to usefully use these instruments to a first evaluation of
surface and skin contamination. The very high radionuclidic pu-
rity found for this radiopharmaceutical avoids unjustified dose to
patients and allows for easy management of both licensing and
waste management issues.
OP634
Risk of Contamination and Incorporation
during Preparation and Administering
Radium-223-Dichlorid [XOFIGO]
L. Thomas1, C. Scholl2, S. Kürpig3, R. Bundschuh3, M.
Essler3, H. Ahmadzadehfar3; 1Universitätsklinikum Bonn,
Kl in im für Neklearmediz in , Bonn, GERMANY,
2Landesinstitut für Arbeitsgestaltung des Landes Nordrhein-
Westfalen, FG 1.3 Strahlenschutz, Düsseldorf, GERMANY,
3Universitätsklinikum Bonn, Klinik für Nuklearmedizin,
Bonn, GERMANY.
Introduction: 223Radium-dichloride(Xofigo) is approved in
the EU since November 2013 for treatment of bone metastases
of prostate-carcinoma. Xofigo improves the overall survival
and is the first alpha-emitter routinely used in medical-appli-
cation. In most clinically used isotopes external radiation is the
main source for radiation-exposure of the staff. However, Ra-
223 gives most significant exposure when incorporated.
Therefore the aim of this study was to estimate the risk of
incorporation for medical staff handling Xofigo. Methods:
During 6 month 92 applications with a total administered
amount of 528MBq Ra-223 were performed. For risk-
estimation of incorporation we measured the contamination
in the air with aerosol filters. One in the laminar-air-flow-
box(LAF) in which the preparation took place, one attached
to the physician and one placed at the patient chair. The latter
placed in the height of the face of the physician and the patient
respectively. Two days after administration of Xofigo a stool-
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sample of the physician was measured as Xofigo is secreted
dominantly this way. Gloves worn in the LAF, during injection
and cleaning-up were measured for contamination as well as
the surgical mask which was worn all the time. At each appli-
cation day all work-steps were performed by the same physi-
cian. Results: Filters from the LAF had a mean activity of 6E-
4Bq/l meaning no significant aerosol concentration. The other
filters did never show an activity over the quantification limit.
In none of the stool samples Xofigo was found over the quan-
tification limit of the method. Contamination measurement of
the gloves showed measureable amount of Xofigo when
gloves were used during preparation and cleaning-up (1E-1
to 1E4Bq). For the surgical mask in 3 cases a measureable
amount of Ra-223 were found (two times 1Bq, 1 time
15Bq), this was most probably caused by cross-
contamination when removing the mask. Based on the results
of stool-samples and air-filters placed at the physician together
with the total activity handled the incorporations factor was
estimated according the ICRP model. Conclusion: Stool-
samples and filters from the physician and from the
application-room let conclude that there is no increased risk
of incorporation of Xofigo. However, measurements of the
LAF-filter indicated that this is only true for preparation in a
LAF. Therefore the use of a incorporation-factor ak=10-7 is
justified. Increased activity of Xofigo was found at the gloves,
therefore two pairs of gloves with a change of the upper pair
between all working steps is strongly recommended to avoid
cross-contamination.
OP635
18F-FDGwhole body PET/CT: evaluation of effective dose
in pediatric patients
F. Zito1, G. Galetta2, L. Rossi2, L. Florimonte1, E. Orunesu1,
M. Castellani1, C. Canzi1, F. Voltini1, R. Benti1;
1FONDAZIONE IRCCS CA’ GRANDA Ospedale Maggiore
Policlinico, Milan, ITALY, 2Scuola di Specializzazione in
Fisica Medica Università di Milano, Milan, ITALY.
Aim: To evaluate 18F-FDG PET/CT absorbed dose in pediatric
patients to optimize CT acquisition parameters and to improve
protect ion of this high-radiation-sensit ive young
population.Materials and methods: Eight pediatric patients (age
1-7 years) were retrospectively evaluated. For PET examinations
18F-FDG activity was scaled according to PETscanner sensitivity
and body weight of patients (on average 5 MBq/kg) but 37 MBq
minimumwas injected.Whole-body scans, from head to toe, were
acquired after 1 h from the administration with the Biograph
TruePoint system(Siemens)having 21.6 cm axial FOV. Images of
3mm slice thickness were reconstructed with 2 iterations 8 subsets
AWOSEM algorithm. All CT scans were carried out with: -
automatic control of tube current by setting 60 mAs of reference
current, -pitch 0.8, -24x1.2mmbeam collimation and -0.5s rotation
speed. For four patients CTscanswere performedwith 120 kVand
for the other four with 100 kV. PETeffective dose was assessed by
multiplying the injected MBq with the ICRP 80 18F-FDG factors
(mSv/MBq,interpolated factors to each patient age were used.
Based on AAPM report 204, patient-specific-size CTDIvol
(CTDIvol_AAPM) was calculated by correcting the scanner
CTDIvol with AAPM factors relative tomeasured patient effective
diameter on CT images. CT effective doses were estimated with
ImPACT dosimetry calculator, doses referred to adult patient were
scaled to pediatric by linear interpolation of Khursheed’s factors.
Two expert nuclear physicians scored CT image quality based on
1-3 scale, sufficient-good -excellent.Results: The four patients
scanned at 100 kV kV had on average 40% reduction of CTDIvol
with respect those at 120 kV, without reduction of CT image qual-
ities. The CTDIvol_AAPM corrected for patient specific size was
twofold the CTDIvol referred to the standard 32cm phantom size.
The sum of PET and CT effective doses ranged from 6.4 to 8.6
mSv; the CTcontribute assessedwith ImPACTwas for six patients
on average one half that of PET and was similar to PET for two
patients who had CT scans at 120 kV. CT image quality scores
were good and excellent, independently on tube kV.Conclusion:
This study, even if includes only 8 young patients, confirms the
importance to consider the specific body size to estimate exposure
dose for PET/CTexaminations in young patients. The reduction of
kVand then of exposure doses without affecting CT image quality
has encouraged our PET/CT Unit to perform CT scans at 100 kV
for patients 1-7 years old.
OP636
Efficacy of Clinical Audit on administered activities
to paediatric patients undergoing dynamic renal
scintigraphy
V. de Sousa1, F. Lourenço1, P. Pepê2, G. Cardoso1, A. I. San-
tos1,3, J. G. Santos1; 1Hospital Garcia de Orta, Almada, POR-
TUGAL, 2Escola Superior de Tecnologia e Gestão – Instituto
Politécnico de Portalegre, Portalegre, PORTUGAL, 3Nova
Medical School - Universidade Nova de Lisboa, Lisboa, POR-
TUGAL.
Introduction/Aim: In Europe, every year, more than 6 million
paediatric patients, which are more radiosensitive than adults,
between 2 to 10 times, undergo a Nuclear Medicine procedure.
Thus, there is a need to audit administered activities, in order to
evaluate its compliance with adopted Guidelines focused on
radiation dose optimization. This study aims to evaluate the
efficacy of awareness of technical staff to the results of a pre-
vious clinical audit on administered activities to paediatric
patients. Methods: A sample of 26 99mTc-MAG3 DRS per-
formed to children between July 2014 and April 2015 was
collected and a retrospective analysis of gender, age, weight,
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administered activity (reported at the time of administration)
and reference activity was performed. By reference activity we
mean the activity calculated with the Paediatric EANM dosage
card, adopted by the Department since its first publication. The
results obtained were compared with the ones resulting from a
similar analysis performed previously on a sample collected be-
tween July 2011 and June 2014 and presented to the staff. Non-
parametric tests were used, considering the size of the samples
and/or the Non Gaussian distribution of the values. Results: The
sample collected between July 2011 and June 2014 comprised 39
females and 50 males with a median age of 36 [8, 108] months
and amedianweight of 15.0 [8.8, 30.5]Kg.Applying theRelated-
Samples Signed Rank Test (for a non Gaussian non symmetrical
distribution) it was obtained a strong evidence that the statistical
median of the differences between the administered and the refer-
ence activities was different from zero (p<0.001). The median
administered activity was 39.5 [31.3, 53.2] MBq and the median
reference activity was 28.0 [20.3, 43.3] MBq. These results were
presented and discussed with the staff. The second sample, col-
lected between July 2014 and April 2015 comprised 10 girls and
16 boys, with a median age of 11 [3.8, 99] months and median
weight of of 9.8 [6.2, 27.2] Kg. Using the Related-Samples
Wilcoxon Test (for a nonGaussian symmetrical distribution) there
was a statistical evidence that the median of the differences be-
tween the administered and the reference activities is equal to zero
(p<0.07). The median administered activity was 24.1 [18.1, 39.6]
MBq and the median reference activity was 21.8 [17.8, 34.4]
MBq. Conclusion: Considering the results obtained we confirm
that a very simple audit procedure improves awareness and opti-
mization of the practices, and allows acknowledging compliance
to Guidelines formally adopted.
OP637
Cumulative Radiation Dose Received by Diagnostic
Imaging During Staging and Treatment of Primarily
Operable Ewing Sarcoma in Patients Diagnosed
in Norway 2005-2012.
B. Johnsen1, K. Fasmer1, K. Boye2, K. Rosendahl3,4, M.
Biermann1,4, C. Trovik5,4, S. M. Aukland3,4; 1Centre of Nu-
clearMedicine and PET, Department of Radiology, Haukeland
University Hospital, Bergen, NORWAY, 2Department of On-
cology, The Norwegian Radium, OSLO, NORWAY, 3Pediatric
Section, Department of Radiology, Haukeland University
Hospital, Bergen, NORWAY, 4Department of Clinical Medi-
cine,University of Bergen, Bergen, NORWAY, 5Ortopedic
Section, Department of Surgery, Haukeland University Hospi-
tal, Bergen, NORWAY.
Objective. Ewing sarcoma is a malignant tumour mainly affect-
ing children and young adults. Planar X-ray, Ultrasound, Com-
puted tomography (CT), Magnetic Resonance Imaging and
Skeletal Scintigraphy constitute the conventional” imaging
methods. Methods reflecting the biology of the tumour, like
F18 FDG PET-CT, are now emerging. During treatment, studies
evaluating renal (glomerular filtration rate (GFR), radioisotope
renography) and cardiac function (Multi Gated Acquisition
Scan (MUGA)) is performed. There is a growing awareness
of potential secondary radiation induced malignancy in chil-
dren and young adults cured of their primary cancer. This na-
tional, population based study summarizes all radiological and
nuclear medicine (NM) imaging including F18 FDG PET-CT
in diagnostics and treatment of patients with primarily operable
Ewing sarcoma. Material and methods. 61 patients below 30
years diagnosed with Ewing Sarcoma in Norway in the period
2005-2012 were identified from the Scandinavian Sarcoma
registry in Malmoe. Of these, 20 patients met the inclusion
criteria: primarily operable Ewing sarcoma, preoperative che-
motherapy with operation in week 11, no metastasis or residual
disease in a minimum follow up period of 1 year after diagno-
sis. The mean age was 15 years (range 4-27). The radiation
doses the patients received from all radiological (planar X-
ray and CT) and nuclear medicine imaging (MUGA, GFR,
radioisotope renography, skeletal scintigraphy and PET-CT) 4
months prior to biopsy date to 12 months after biopsy date, was
calculated for each patient using dedicated Monte Carlo based
dose estimation software tools. Results. The mean (range) es-
timated cumulative radiation dose a patient received from all
radiological and nuclear medicine imaging including PET-CT
was 39 (6-86) mSv. Of this total planar X-ray imaging counted
for 3 (0-16) mSv, CT imaging 13 (2 - 28) mSv, nuclear medi-
cine imaging (excluding PET-CT) 17 (2 - 51)mSv and PET-CT
6 (0 - 23) mSv. Conclusion. In this study of children and young
adults diagnosed with primarily operable Ewing Sarcoma in
Norway in the period 2005-2012, the estimated cumulative
radiation dose a patient received during the first year after di-
agnosis was 39 mSv. Compared to the total radiation burden,
the contribution from nuclear medicine imaging was 59 %
while PET- CT imaging alone contributed to only 15% of the
total radiation dose. This study revealed a wide range, both
regarding which diagnostic imaging modalities and examina-
tion that is performed on this patient group and also regarding
the cumulative doses resulting from these examinations.
OP638
Practical assessment of local diagnostic reference levels
for PET/CT scans with 68Ga-DOTA peptides
G. Lucconi1,2, M. Ranaldo2, F. Zagni2, G. Cicoria2, S. Fanti3,
M. Marengo2; 1Alma Mater Studiorum - Bologna University,
Bologna, ITALY, 2Medical Physics Department, S.Orsola–
Malpighi University Hospital, Bologna, ITALY, 3Nuclear
Medicine Department, S.Orsola-Malpighi University Hospi-
tal, Bologna, ITALY.
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Aim: to establish local Diagnostic Reference Levels (DRL) for
PET/CT studies with 68Ga-DOTA peptides. Materials &
Methods: a sample of 50 patients undergoing 68Ga-
DOTANOC PET/CT was retrospectively studied. Scans were
acquired using a Discovery 710 and two Discovery STE PET/
CTscanners (GEHealthcare) in a period of threemonths. The CT
acquisition was performed following a “low dose” protocol hav-
ing the following parameters: 120 kV, 80 mA, 0.8 s/tube rotation,
pitch 1.75, collimation 20 mm, and 3.75 mm slice thickness; the
PET acquisition lasted 3 min for each bed position, having a
length of 15 cm and a superposition of 1.1 cm. Unitary patient
doseswere automatically dispensed by aμDDS-A system (Tema
Sinergie S.p.A.), scaled according to the weight of the patient and
measured with a CAPINTEC CRC 15 PET activity meter. The
accuracy of the activity meter was assessed using a NIST trace-
able standard source of 68Ge/68Ga.DRL for CTacquisitionwere
assessed as the 75th percentile of the distribution of the values of
CTDI and DLP. DRL for the administered activity were set as the
mean activity in the patients’ sample, obtained from the normal
distribution fitted to observed activity values. These values were
then used to estimate the effective and organ doses for a standard
patient through ImPACT CT patient dosimetry calculator and the
dose-activity coefficients reported in the literature. Results: since
the differences in CTDI values observed among the three scan-
ners were small, the data were pooled, giving DRL of 3.82 mGy
for CTDI and 381MBq cm for DLP. DRL for 68Ga-DOTANOC
activity resulted 103MBq and 1.5 MBq/kg, which is close to the
inferior limit stated by international guidelines, revealing the ca-
pability ofmodern PETscanners to obtain diagnostic imageswith
a relatively low amount of radioactive tracer. Effective doses of
5.4 mSv and 2.6 mSv were calculated for the CT and PET part
respectively. The organs receiving the highest dose were thyroid,
bone surface and thymus (8.5, 7.8 and 6.7 mGy) for the CT
acquisition, while kidneys, urinary bladder wall and spleen (9.1,
8.5 and 7.4 mGy) for 68Ga-DOTANOC administration. Conclu-
sions: local DRL have been assessed for 68Ga-DOTANOCPET/
CT scans, according to international guidelines. These levels and
the dosimetric evaluation performed may be a useful tool for
optimization and comparison for other centers approaching this
technique.
OP639
External radiation exposure of nuclearmedicine personnel
using an automatic 18F dispenser
R. Matheoudf, D. Lizio, G. Sacchetti, M. Brambilla; AOU
Maggiore della Carità, novara, ITALY.
Aim. Personnel working with radiopharmaceuticals in nuclear
medicine are subject to radiation exposure, and fingers are likely
to receive the highest dose, especially when handling beta+ emit-
ting radionuclides used in PET imaging. Recently, fully
automated systems have been introduced to partition 18F activity
from the mother vial directly into syringes ready for automatic
patient injection, to reduce both external irradiation and the risk of
contamination. The aim of this work was to evaluate the radiation
exposure of nuclear medicine personnel during the 18F-
fluorodeoxyglucose (FDG) loading and partition procedures per-
formed using the automatic 18F dispenser Karl100™
(TemaSinergie, SpA). Materials and Methods. Dose rate (DR)
at close contact to Karl100 was monitored with the inbuilt Geiger
Mueller detector (LND71210) for loading, dilution and flushing
phases of 18FDG transferring from mother vial into Karl100 dis-
pensing kit and for syringe preparation, on a 4 months period.
Finger dose (FD) was measured for both the technician operating
on Karl100 and for physician who injected patients with the
semiconductor dosimeter NED (Unfors Instruments, Inc.)worn
on the finger tip of the non dominant hand and on the finger tip
used for activation of automatic patient injector, by the technician
and physician, respectively, on a 15 days period. Results. The
highest DR were measured during 18FDG mother vial loading
phase (mean 25.7 μSv/h, range 9.6-37.3 μSv/h) that lasted about
1 minute. DR during syringe preparation was lower (mean 7.0
μSv/h, range 4.3-13.0 μSv/h). FD were in the range 15-87 μSv/
GBq of 18FDG activity (mean 42μSv/GBq) and 33-83μSv/GBq
(mean 56 μSv/GBq) for technicians and physicians, respectively,
and corresponded to the daily workload. These values resulted
inferior to the lower FD ranges reported in ORAMED study in
2012.onclusion. Karl100™ guarantees a high level of radiation
protection of the workers. In the cautelative hypothesis that the
same technician stands at close contact to the Karl100 during
both mother vial loading and 18FDG partition of 12 doses per
day, by using the highest DR measured, this would result in an
effective dose of about 230 μSv/y. In the hypothesis of the same
technician working on Karl100, he would have an extremity
equivalent dose of 17mSv/y,while for the same nuclearmedicine
physician injecting all the patients he would receive 3.6 mSv/y.
OP640
Skin dose saving of the staff in 90Y/177Lu PRRT therapy
with the Automatic Dose-Dispenser (ADD)
F. Fioroni1, E. Grassi1, G. Cavatorta2, S. Rubagotti1, G.
Feliciani1, M. A. Sarti1, A. Filice1, A. Versari1, M. Iori1;
1IRCCS-ASMN, Reggio Emilia, ITALY, 2University of Bolo-
gna, Bologna, ITALY.
Purpose: Labelling and administration of 90Y-DOTATOC and
177Lu-DOTATOC are very hazardous procedures because of
the skin exposure to beta radiation. A variety of methods to
decrease this risk has been looked for and the outcome of one
of them is hereby evaluated. Aim was to investigate the equiv-
alent dose saving of the staff working with 177Lu and 90Y in a
nuclear medicine unit, when changing from an essentially
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manual radiolabelling procedure to a semi automatic synthe-
sizer ADD.Methods: Chemist and physician are the figures
exposed. They were asked to wear TLDs on their fingertips,
to evaluate the quantity Hp(0.07) to the skin and to replace
them after each labelling and administration procedure.Data
collected from 2009 to 2014 were divided into two groups:
before introducing ADD (NoADD) and after introducing
ADD (ADD), considering 52 procedures (177Lu) , 41 (90Y)
in NoADD; 67 (177Lu) and 48 (90Y) in ADD. The mean
handled activity: 23.57GBq(177Lu) and 14.31GBq(90Y) in
NoADD, 30.11Gq(177Lu), 15.11GBq(90Y) in ADD.Though
ADD affects only chemist work, it was considered the same
division even for medical staff doses, feeling confident to
identify a learning curve.Data were analysed with simple
statistical tests (t-test and Wilcoxon-Mann-Whitney, p=0.05)
and shown separately for chemist and physician.Results: For
the chemist, Hp(0.07) mean values (95% percentile) for ADD
and NoADD are 0.019(0.076) and 0.030(0.099) mSv/GBq
respectively for 90Y, while 0.007(0.023) and 0.022(0.037)
mSv/GBq respectively for 177Lu. T-test provided P<<0.05
for both isotopes.The relative differences before and after
ADD collected for every finger and considered separately for
each isotope were treated with Wilcoxon test. P-value<0.05 .For
the medical staff, Hp(0.07) mean values (95% percentile) for
ADD and NoADD are 0.0143(0.0565) and 0.021(0.0762) mSv/
GBq respectively for 90Y, while 0.0009(0.00263) and
0.0011(0.00196)mSv/GBq respectively for 177Lu. T-test provid-
ed P<0.05 for both isotopes.The relative differences before and
after ADD collected for every finger and considered separately
for each isotope were treated with Wilcoxon test. P-
value>0.05.ConclusionsADD affects positively the dose saving
of the chemist in handling both isotopes and the dose saving
depends on the isotope used, when data are analysed finger by
finger.For the reason mentioned above, ADD doesn’t affect
strongly the medical staff dose saving. However, the mean value
analysis shows a learning curve of theworkers to inferior doses in
more recent time. The difference in doses doesn’t depend on the
isotope used, when data are analysed finger by finger.
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Evaluation of nigrostriatal oxidative stress intensity
in patients with Parkinson’s disease using [Cu-62]ATSM
PET and FP-CIT SPECT
H. Okazawa1, M. Ikawa1, T. Tsujikawa1, T. Mori1, A.
Makino1, Y. Kiyono1, M. Yoneda2; 1University of Fukui,
FUKUI, JAPAN, 2Fukui Prefectural University, FUKUI,
JAPAN.
Introduction: To evaluate degree of oxidative stress and mito-
chondrial dysfunction in the nigrostriatal dopaminergic neu-
rons of Parkinson’s disease (PD), positron emission tomogra-
p h y ( P E T ) w i t h [ C u - 6 2 ] d i a c e t y l - b i s ( N 4 -
methylthiosemicarbazone) (Cu-ATSM) and dopamine trans-
porter (DaT) imaging were applied to patients with PD.
Methods: Nine patients with PD (69 ± 5y) who showed lateral
dominant symptoms at onset underwent Cu-ATSM PET. They
also underwent [I-123]FP-CIT SPECT to evaluate presynaptic
nigrostriatal dopaminergic deficit as well as DaT density. Dy-
namic PET data acquisition was performed, and standardized
uptake value (SUV) images were calculated from the delayed
phase data of 10-20 min frames after the injection. Multiple
circular regions of interest (ROIs) were drawn on the bilateral
striata and mean values from each side were used for analysis.
The striatum-to-cerebellum SUV ratio (SCR) was calculated
from the SUVs of the striatum and the cerebellar cortex. The
same striatal ROIs were applied to the [I-123]FP-CIT SPECT
images and distribution volume ratio (DVR) was calculated.
Finally, SCR to DVR ratio (SDR) were obtained and used for
further analysis. Results: The means of SCR, DVR and SDR
of the bilateral striata in patients were 1.04 ± 0.04, 1.20 ± 0.08
and 0.88 ± 0.05, respectively. The mean values of the striatum
contralateral to the initially affected body side (the dominant
striatum) were lower in DVR and greater in SCR and SDR
compared to the contralateral side. Although the difference in
SCR was not significant, DVR and SDR showed significant
difference between the bilateral striata (P < 0.05). The SDR of
the dominant striatum showed a positive correlation with the
Unified Parkinson’s Disease Rating Scale (UPDRS) rat-
ing (r = 0.67, P < 0.05), indicating oxidative stress
increased according to the progression of disease sever-
ity in the dominant striatum. Conclusions: Degree of
oxidative stress calculated from accumulation ratios of
Cu-ATSM to [I-123]FP-CIT in PD patients revealed that
the dominant striatum suffered from intense oxidative
stress which correlated well with the severity of symp-
toms. These findings indicates that oxidative stress asso-
ciates with striatal neurodegeneration in PD.
OP642
FDG-PET/CT in presymptomatic and symptomatic
Huntington’s disease: Possible predictor of disease
progression?
D. Lopez1, V. Camacho1, A. Fernandez1, J. Perez Perez2, S.
Martinez-Horta2, F. Sampedro3, C. Achury1, R. Jaller1, A.
Montes1, I. Carrió1; 1Nuclear Medicine department. Hospital
de la Santa Creu i Sant Pau, Barcelona, SPAIN, 2Neurology
department. Movement Disorder Unit. Hospital de la Santa
Creu i Sant Pau, Barcelona, SPAIN, 3Universitat Autonoma
de Barcelona, Barcelona, SPAIN.
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PURPOSE: To assess metabolic changes in cerebral 18F-FDG
PET/CT in presymptomatic (preHD) and symptomatic (sHD)
Huntington’s disease (HD) patients, to assess patterns of FDG
uptake, and to correlate PET/CT findings with clinical evolu-
tion. MATERIALS ANDMETHODS: Thirty three patients (8
male, mean age=44, range [26-69]) carrying the HD mutation
(mean CAG=43) were prospectively included. Based on the
Unified Huntington’s Disease Rating Scale (UHDRS) motor
score and Total Functional Capacity, patients were classified as
presymptomatic (preEH=16; UHDRS <4) and symptomatic
(sEH=17; UHDRS>4). Subsequently, preHD patients based
on Langbehn formula were classified as near (preHD-A=8)
and far (preHD-B=8) to onset of clinical manifestations. A
separate group of 18 healthy subjects, matched with patients
by age and gender, was used as control (4 male, mean age=48
[32-69]). Brain PET/CT was performed 60 minutes after i.v.
injection of 277 MBq of 18-FDG on a Philips Gemini TF.
Images were initially assessed by 2 nuclear medicine physi-
cians identifying qualitative metabolic changes in the striatum
and cerebral cortex. Analysis and quantitative assessment of
regional cerebral activity was performed using the Statistical
Parametric Mapping (SPM8). For the regional quantitative
analysis, the clusters of interest were extracted and computed
to the relative standard uptake value (SUVr) of the regions of
interest related to the stage of the disease. RESULTS: In the
visual analysis, sHD patients presented a significant
hypometabolism in striatum compared to preHD patients and
controls. Quantitative analysis demonstrated a significant
striatal hypometabolism in sHD respect to preHD-A and
preHD-B [p<0.05 (FWE), EVTk=100 voxels]. Additionally,
a significant decrease in metabolism of striatum in both preHD
groups respect to GC was demosnstrated, showing a
hypometabolic pattern in striatum that progressively declines
across disease stages [p<0.001 uncorrected, k=10 voxels]. In
addition, a significant hypermetabolism in the sHD patients
was shown in the prefrontal cortex and cerebellum [p<0.001
uncorrected EVTk=10 voxels]. CONCLUSION: HD patients
presented a significant progressive hypometabolism in stria-
tum across the disease stages compared to controls. sHD pre-
sented a marked hypometabolism with respect to preHD. In
sHD patients, a significant hypermetabolism in prefrontal cor-
tex and cerebellum was seen probably related with movement
disorder. FDG-PET/CT seems to be an early predictor for dis-
ease progression in HD.
OP643
Frequency of 123I FP-CIT image characteristics differ
between movement disorder and Lewy Body dementia
referrals
A. Nicol1, R. Jampana2, C. Santosh2, M. T. Hansen2; 1South
Glasgow Universi ty Hospital , Glasgow, UNITED
KINGDOM, 2Institute of Neurological Sciences, South Glas-
gow University Hospital, Glasgow, UNITED KINGDOM.
123I FP-CI T imaging is used to evaluate the loss of functional
dopaminergic neuron terminals in the striatum of patients with
movement disorders (including Parkinson’s disease, essential
tremor, drug induced tremor) or Lewy Body dementia. The
frequency of 123I FP-CIT image characteristic appearances
for the different referral groups will be assessed. Consecutive
patients over a four month period were included (n=179).
Scanning was performed on a Mediso four head scanner ap-
proximately three hours after administration of 185MBq 123I
FP-CIT. Referrals were divided into three categories: move-
ment disorders, Lewy Body Dementia (DLB), clinical infor-
mation including a mixture of these two categories. Scans
were evaluated visually, using striatal:occipital ratio quantifi-
cation as an adjunct as required. Images were categorised as
follows: (a) normal (b) reduced uptake:putamen < caudate
(c) balanced reduced uptake (weak comma) or (d) other
(none of above). Clinical referrals were received for move-
ment disorders in 151 of cases (84%), DLB in 17 cases
(10%) and mixed referral information in 11 cases (6%).
Normal image appearances were obtained in 54% of move-
ment disorder referrals, 53% of DLB referrals and 73% of
mixed clinical referrals. Of the abnormal scans, reduced
uptake: putamen < caudate & balanced reduced uptake
(weak comma) appearances were obtained in 38% & 3%
of movement disorder referrals; 12% & 29% of DLB refer-
rals and 0% & 9% of mixed referrals. ‘Other’ appearances,
dominated by the presence of vascular components, oc-
curred in 5% of movement disorder referrals, 6% of DLB
referrals and 18% of mixed referral information . A chi
squared test of homogeneity was performed for the move-
ment disorders and Lewy Body Dementia referrals
(n=168). This rejected the null hypothesis that the frequen-
cy of normal : putamen < caudate : balanced reduced up-
take (weak comma) appearances was identical in these two
patient referral groups (p<0.01) These results indicate that
the frequency of 123I FP-CIT image characteristics differ
between movement disorders and Lewy Body Dementia
referrals. This is critically important when clinically evalu-
ating scans.
OP644
[11C]Donepezil PET demonstrates parasympathetic
denervation in the gut of most patients with de novo
Parkinson’s disease (PD).
T. Fedorova1, L. Seidelin1, S. Jakobsen1, E. H. Danielsen2, D.
J. Brooks1, P. Borghammer1; 1Department of Nuclear Medi-
cine & PET Centre, Aarhus University Hospital, Aarhus C,
DENMARK, 2Department of Neurology, Aarhus University
Hospital, Aarhus C, DENMARK.
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Background: We recently demonstrated that most PD patients
at a moderate disease stage display decreased [11C]donepezil
PETsignal in the small intestine, and 2/3 of patients displayed a
similar decrease in the pancreas (Gjerløff et al, Brain 2015). It is
thought that parasympathetic denervation may predate motor
symptoms in PD, and parasympathetic PET imaging may
therefore be a potential diagnostic marker at pre-motor stages
of the disease. Objective: We used the acetylcholinesterase
PET ligand [11C]donepezil to estimate the peripheral parasym-
pathetic innervation in de novo PD. Methods: So far 17 PD
patients at an early disease-stage (mean 1 year disease duration)
and 10 matched control subjects were enrolled. All study par-
ticipants were PET/CT scanned using [11C]donepezil. The
PET signal in the myocardium, gastrointestinal tract, and pan-
creas was compared between groups. Results: The de novo PD
patients displayed significantly decreased [11C]donepezil SUV
values in the small intestine (-24%, p<0.0001), but not in the
pancreas (p=0.75). A trend towards decreased signal was seen
in the myocardium (-11%, p=0.07). Conclusions: The data im-
plies that marked parasympathetic denervation in the gut of PD
patients is established already at the time of diagnosis, whereas
pancreatic denervation may be a secondary phenomenon.
[11C]donepezil PET could therefore have application as a di-
agnostic marker in PD - maybe already at the pre-motor stage.
We are currently initiating a longitudinal [11C]donepezil PET
study of pro-dromal PD patients with REM sleep disorder to
test this hypothesis
OP645
Brain metabolic changes in patients with Essential Tremor
and progressive gait ataxia under thalamic deep brain
stimulation
J. Brumberg1, G. Marotta2, M. Reich3, F. Steigerwald3, N.
Pozzi3, C. Lapa1, S. Samnick1, K. Herrmann1, J. Volkmann3,
A. Buck1, I. Isaias3; 1Department of Nuclear Medicine, Uni-
versity Hospital Würzburg, Würzburg, GERMANY, 2Depart-
ment of Nuclear Medicine, Fondazione IRCCS Ca Granda -
Ospedale Maggiore Policlinico, Milano, ITALY, 3Department
of Neurology, University Hospital Würzburg, Würzburg,
GERMANY.
AIM:We investigated brain metabolic changes under different
deep brain stimulation (DBS) parameters in patients with Es-
sential Tremor (ET). We aimed to disentangle the effect of
thalamic stimulation from disease progression in the evolution
of gait- or limb-ataxia. MATERIALS AND METHODS: We
investigated five subjects with ET (two males; median age: 74
years, range: 63-84 years) under stable bilateral thalamic DBS
(no stimulation changes in the last four weeks) with progres-
sive and severe gait-ataxia (unable to walk unassisted) by
means of 18F-fluorodeoxyglucose (FDG) and two sequential
cerebral positron emission tomographies (PET). PET scans
were conducted stim-on and 72h after stimulation holidays
(stim-off) according to a standardized protocol. Patients were
fully relaxed in a lying position without any voluntary move-
ment between the FDG injection and the scan.We performed a
statistical parametric mapping voxel-by-voxel group compar-
ison (stim-on vs. -off) applying the proportional global mean,
threshold at p<0.1 and corrected for Family wise-error (FWE).
RESULTS: At 72h stim-off, gait ataxia improved in all sub-
jects (all were able to walk unassisted), whereas tremor
reappeared with a pre-surgery severity. Compared to 72h
stim-off, FDG uptake in stim-on was significantly increased
selectively in the flocculonodular lobe of cerebellum (T=6.40,
p<0.01) and reduced in the right medial frontal and bilateral
precentral gyri (right BA 6, p<0.001 and left+right BA 4,
p<0.001). CONCLUSIONS: Multiple PETs can play a rele-
vant role in defining brain metabolic changes in different clin-
ical or therapeutic (e.g. DBS) settings. Our findings are evoc-
ative of an antidromic effect of thalamic DBS on outflow path-
ways of the vestibulocerebellum in patients with ET. Accord-
ingly, in these patients, gait-ataxia might be interpret as a
stimulation side effect rather than an additional sign of
this disease.
OP646
18F-FDOPA PET reveals a rostro-ventral striatal
dopaminergic depletion in Parkinson’s disease patients
with impulse control disorder.
A.Marí Hualde, E. Prieto, L. Sancho,M. Ribelles, C. Juri, M.
Rodríguez-Oroz, J. Obeso, J. Arbizu; Clinica Universidad de
Navarra, Pamplona, SPAIN.
Background: Many Parkinson’s disease (PD) patients experi-
ence non-motor symptomatology. Impulse control disorders
(ICDs), including compulsive gambling, buying, sexual be-
haviour, and eating, is a severe complication difficult to diag-
nose that can occur in a significant number of PD population
(6,1-31,2%). While these abnormal behaviours are associated
with dopaminergic treatments, a differential pattern of nigro-
striatal dopaminergic denervation has been suggested by find-
ings in DAT-scan. Functional brain differences in PD patients
with and without ICD remain poorly understood. Objective:
To ascertain the striatal pattern of dopaminergic depletion by
L-3,4-Dihydroxy-6-[18F] fluorophenylalanine (18F-FDOPA)
Positron Emission Tomography (PET) in PD patients with and
without ICD. Methods: 60 PD 18F-FDOPA PET scans were
studied (30PD-ICD and 30 PD without a life history for ICD),
as well as 16 healthy controls (HC). 12 of the PD-ICD patients
had a previous basal 18F-FDOPA PET. Disease severity was
ascertained with the UPDRS and the Questionnaire for
Impulsive-Compulsive Disorders in PD (QUIP) and Levodopa
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equivalent dose (LED) was calculated in each patient. Avoxel-
based-analysis (SPM) was applied to measure 18F-FDOPA
uptake (Ki) between all of them. Results: PD-ICD and PD
without ICD, did not differ in age or UPDRS punctuation.
All PD patients showed a typical striatal denervation pattern
with predominance reduction in 18F-FDOPA uptake in the
caudal putamen. 18F-FDOPA uptake was significantly re-
duced in the anterior and ventral striatum in ICD-PD patients
compared to those without ICD (p<0,01). But no difference
was found between PD previous to ICD symptomatology
scan, when compared to 12 PD without life history of ICD
paired by age, LEDs and PD progression time. Total LED
was higher (p=0,006) in ICD-PD patients (mean 957,2) com-
pared to the non- ICD group (mean 501,27). No significant
difference was found in the mean dose of dopaminergic ago-
nist LEDs. Conclusions: This study confirms a significant re-
duction in ventral striatal dopaminergic activity in ICD-PD
patients by 18F-FDOPA PET in advanced disease but not in
basal conditions. However, the ICD-PD group received higher
dose of dopaminergic agents. The interaction between dener-
vation and treatment probably defines the origin of ICD in PD.
OP647
Correletion between 123I-FP-CIT SPECT and cognitive
outcome in Parkinson’s disease: 5 years of follow-up
G. Puccini1, R. Ceravolo2, F. Guidoccio1, D. Frosini2, S.
Chiacchio1, M. Gennaro1, U. Bonuccelli2, D. Volterrani1; 1Re-
gional Center of Nuclear Medicine, University of Pisa, PISA,
ITALY, 2Neurology Unit, Department of Clinical and Experi-
mental Medicine, University of Pisa, PISA, ITALY.
Aim: Dopamine transporter (DAT) imaging is a common di-
agnostic tool for Parkinson’s Disease (PD) but also evaluated
as prognostic marker for both motor and non motor outcomes.
The ability of coping an intersecting pentagons is considered
an important clinical predictors of global cognitive decline. In
this study we evaluated the prognostic role of DAT imaging
and pentagon copy for cognitive outcome in a cohort of PD
patients with a follow up of five years. Materials and methods:
Ninety-five de novo PD patients underwent DAT imaging at
baseline. Striatal semiquantitative indices were calculated with
basal ganglia matching tool. All the patients were assessed
with Unified Parkinson’s Disease Rating Scale (UPDRS) part
III for motor related impairment and Mini-Mental State Exam-
ination (MMSE) for cognitive functions at baseline and each
year of the five years of follow up. The occurrence of dementia
in the five years of follow up was collected. According with
MMSE and pentagon test score we further divided the subjects
into two sub-groups. Results: During follow up 18% of pa-
tients developed dementia. Patients developing dementia in
the follow up period had lower striatal binding at baseline
(p<0.01). The frequency of impairment in pentagon copy
was significantly higher in PD patients developing dementia
(χ2=9.9, p<0.001). Rather not statistically significant, patients
developing dementia showed higher level of motor impair-
ment (UPDRS III 22 vs 18 respectively for PD with dementia
and not developing dementia) and lower MMSE at baseline
(MMSE 26 vs 28 respectively for PD developing dementia
and not developing dementia). Binary logistic regression anal-
ysis was performed dichotomizing striatal uptake value ac-
cording to striatal median uptake (2.3). The model contained
two independent variables (striatal uptake and pentagon copy),
the full model was statistically significant (χ2=20.7, p<0.001)
and as whole was able to predict the 35% of the variance in
cognitive status. Both variable independently contribut ed to
the model with an Odd Ratio respectively of 15.9 and 4.9 for
low striatal baseline uptake and pentagon copy impairment.
Conclusion: Our findings show that DAT imaging performed
at baseline and visuospatial and constructional ability as eval-
uated by pentagon copy intersection performance are associ-
ated with cognitive outcome in PD patients. Multiple variables
have been associated to the risk of dementia in PD. In line with
previous findings our data confirm that the integration of do-
paminergic deficit and the dysfunction of cortical posterior
area are associated with the risk of cognitive impairment.
OP648
Initial Evaluation of [18F]GE-180 PET Imaging
in Relapsing-Remitting Multiple Sclerosis Patients
S. Sridharan1, C. Buckley2, W. Trigg2, W. Trigg2, K.
Heurling2, P. Sherwin2, D. Brooks2, J. Crouch3, J. Crouch3,
M. Lawler3, R. Hinz1, R. Paulseth3, S. Amodeo3, K.
Gulenchyn3; 1University of Manchester, Manchester, UNIT-
ED KINGDOM, 2GE Healthcare, Amersham, UNITED
KINGDOM, 3St. Joseph’s Hospital, Hamilton Health Sci-
ences, Hamilton, ON, CANADA.
Introduction: Multiple sclerosis (MS) is characterised by
demyelination, but it is known from pathology studies that
inflammation, evidenced by infiltrating immune cells and
activated microglia in normal appearing white matter
(NAWM), is also present at different disease stages. The
effects of inflammation on MS progression are not yet
understood; positron emission tomography (PET) offers the
opportunity to monitor these effects and thus aid patient
stratification and guide therapy selection, adding to the
information already available from MRI techniques.The
18 kDa translocator protein (TSPO) is upregulated in activated
microglia, which are present in inflammatory lesions and
NAWM in MS. [11C]-(R)-PK11195 is a TSPO-PET ligand
which is known to show localisation and extent of inflamma-
tion in many brain diseases, including MS1, but suffers from a
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poor signal to noise ratio (SNR) and short (20 minutes) half-life.
[18F]GE-180 is a novel TSPO-PET ligand which has shown
improved SNR and lower non-specific binding than [11C]-(R)-
PK11195 in pre-clinical models2. Here, we present initial re-
sults from a phase 1 study in relapsing-remitting MS
(rrMS) and healthy control subjects (HVs).Methods: HVs
and rrMS subjects were assessed for binding status. One
non-binder in each group was included. Subjects
underwent T1 pre and post gadolinium enhanced MRI
scans and T2 scans additionally. 90 minute dynamic
[18F]GE-180 PET scans were performed typically within
1 month. PET and T1 pre-contrast MR images were co-
registered in the software package PMOD, and the Ham-
mers atlas3 was applied to acquire standardised uptake
values (SUVs) for regions of interest (ROIs). Selected
areas of T2 hyperintensity were defined manually to give
MS lesion SUVs. A cortical composite grey matter (GM)
region was chosen as reference for SUVRs.Results: No
Gd-enhancing lesions were identifiable from T1 post-
contrast MRIs. With [18F]GE-180, whole WM uptake
(SUVRGM) was slightly higher in rrMS than HVs, while
a lesion-rich periventricular (PV) area yielded SUVRs
which were approximately 10% higher in rrMS than
HVs. PET-defined lesions in rrMS showed an elevation
of 20 - 40% compared to HVs.Conclusion: Preliminary
results suggest that [18F]GE-180 is able to identify areas
of inflammation in PET images which are non-Gd-
enhancing in T1.1 Rissanen, E. et al. 2014, J. Nucl.
Med., 55: 1-62 Boutin, H et al. 2015, Eur. J. Nucl. Med.
Mol. Imaging, 42: 503-5113 Hammers, A. et al. 2002,
Hum. Brain Mapp., 15: 165-174.
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PW001
18F-5-FPN, a Novel PET Imaging Probe Targeting
Malignant Melanoma
X. Lan, H. Feng, X. Xia, Y. Song, C. Qin, Q. Liu, Y. Zhang;
Union Hospital, Tongji Medical College, Huazhong Universi-
ty of Science and Technology, Wuhan, CHINA.
Aim: Melanoma is one of the most aggressive skin cancers, and
early diagnosis and accurate staging are important for planning
therapeutic intervention to improve patient outcomes. Radiolabeled
benzamides (BZAs) are attractive candidates for targeting melano-
ma because they bind to melanin and exhibit high tumor uptake
and retention. In this study, we synthesized a BZA analog, 5-bro-
mo-N-(2-[diethylamino]ethyl) picolinamide, labeled it with 18F,
and named it 18F-5-FPN. We evaluated its binding affinity to,
and specificity for, melanin, and its in vivo pharmacokinetics, to
assess its potential value in diagnosing and staging melanoma.
Methods: (N-[2-Diethylamino] ethyl)-5-fluoropicolinamide and
its bromo- precursors were prepared, and radiofluorination of
18F-5-FPN with a radio-synthesis module (GE TraceLab FXFN
GE Healthcare, Milwaukee, WI, USA) was performed and puri-
fied. Its binding specificity was measured in vitro in two different
melanoma cell lines, one pigmented (B16F10 cells) and one
nonpigmented (A375m cells), and in vivo in mice xenografted
with the same cell lines. Dynamic and static positron-emission
tomography (PET) images using 18F-5-FPN were obtained in
the tumor mice, and the static images were compared with those
acquired with 18F-fluorodeoxyglucose (18F-FDG). Lungmetasta-
sesmice bearingB16F10 tumorwere also performedPETimaging
with 18F-5-FPN. Results: 18F-5-FPN was successfully prepared
with radiochemical yields of 5%-8%. Cellular uptake study re-
vealed that binding of 18F-5-FPN to B16F10 cells was much
higher than that to A375m cells. Dynamic PET images showed
that B16F10 tumor could be seen about 1min after injection of the
tracer, and the uptake gradually increased over time. 18F-5-FPN
was rapidly excreted by the kidneys. Static images acquired 1 and
2 h after injection revealed clearly visible B16F10 tumors, with
high uptake values of 24.34 ± 6.32 and 16.63 ± 5.41% ID/g (n=5)
in the biodistribution study, and tumor-to-muscle and tumor-to-
blood ratios reached to 43.90 ± 9.09 and 65.52 ± 10.76 at 2 h,
respectively. In contrast, there was no visible uptake by theA375m
tumors. 18F-5-FPN and 18F-FDGPETimagingwere compared in
B16F10 tumor xenografts, and the tumor-to-background ratio of
18F-5-FPN images were 10 times higher that of 18F-FDG (35.22
± 7.02 vs 3.29 ±0.53, n=5). 18F-5-FPNPETimaging also detected
simulated lung metastases measuring 1-2 mm. Conclusions: 18F-
5-FPN specifically targeted melanin in vitro and in vivo with
higher retention, affinity and favorable pharmacokinetics. 18F-5-
FPNmay be an idealmolecular probe formelanoma diagnosis and
staging. This work was supported by NSFC 81371626.
PW002
PET imaging of a feeding center using [11C]BU99008
with ultra-high specific activity
K. Kawamura1, Y. Shimoda1, J. Yui1, Y. Zhang1, T.
Yamasaki1, H. Wakizaka1, M. Fujinaga1, K. Kumata1, L.
Xie1, A. Hatori1, M. Ogawa1,2, Y. Kurihara1,2, N. Nengaki1,
2, M. Zhang1; 1National Institute of Radiological Sciences,
Chiba, JAPAN, 2SHI Accelerator Service, Tokyo, JAPAN.
Aim: I2-imidazoline receptor (I2R) is involved in various central
nervous systems disorders, but function associated with I2R is
unknown. I2R was found throughout the brain, particularly in the
arcuate nucleus of hypothalamuswith a high density [1]. Nutt et al.
previously reported that selective I2R ligands promoted food intake
[2], which is presumed to be an effect of eating function through
the arcuate nucleus of the hypothalamus known as a feeding center.
We recently reported that [11C]FTIMD with ultra-high specific
activity (SA; mean 4470 GBq/μmol) for imaging of I2R showed
higher specific binding than [11C]FTIMD with conventional SA
(about 100 GBq/μmol) in the hypothalamus. More recently,
Kealey et al. developed [11C]BU99008 as a more potent PET
ligand for I2R imaging [4]. [11C]BU99008 displayed a relatively
high brain penetration and specific binding in the porcine and
rhesus brain [4,5]. In this study, to image the feeding center, we
evaluated the usefulness of PET study using [11C]BU99008 with
ultra-high SA. Materials and methods: [11C]BU99008 was pre-
pared by methylation of the BU-precursor and [11C]methyl iodide,
which was produced by iodination of [11C]methane using the
single-pass method [6]. Brain PET studies were conducted in SD
rats and Zucker fatty rats. Results: [11C]BU99008 with ultra-high
SA were successfully synthesized in the range of SA at
5400∼16600 GBq/μmol (n = 7) at the end of synthesis. In SD
and Zucker fatty rats, the radioactivity after injection of
[11C]BU99008 with ultra-high SAwas highly accumulated in the
hypothalamus. Pretreatment with BU224 (a high affinity I2R li-
gand, 1 mg/kg) significantly decreased the radioactivity (AUC30-
60 min) in the hypothalamus to 86% of control radioactivity. Con-
clusion: [11C]BU99008 with ultra-high SA showed high specific
binding in rat brain. PET study using [11C]BU99008 with ultra-
high SAwould contribute to in vivo imaging of the eating function
with small change.References: [1] Lione LA, et al. Eur J
Pharmacol. 1998;353:123-35. [2] Nutt DJ, et al. Ann NY Acad
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Sci. 1995;763:125-39. [3] Kawamura K, et al. Nucl Med Biol.
2012;39:199-206. [4] Kealey S, et al. J Nucl Med. 2013;54:139-
44. [5] Parker CA, et al. J NuclMed. 2014;55:838-44. [6] Noguchi
J, et al. Nucl Med Biol. 2003;30:335-43.
PW003
Radiosynthesis of a [18F]-quinuclidine 1,2,3-triazole
derivative as PET radioligand for neuroimaging
of the α7-nicotinic acetylcholine receptor
J. Sarasamkan1,2, S. Fischer1, M. Scheunemann1, P. Brust1,
O. Vajracupta2; 1Helmholz-Zentrum Dresden-Rossendorf,
Leipzig, GERMANY, 2Mahidol University, Bangkok, THAI-
LAND.
Aim: The α7-nicotinic acetylcholine receptor (α7-nAChR) is
well recognized as a key receptor involved in memory formation
and cognition which implicates its involvement in the pathophys-
iology of neurodegenerative disorders. Currently, this receptor
subtype is one of the most attractive targets for neuroimaging to
monitor the etiology and progression of brain diseases such as
schizophrenia and Alzheimer’s disease (AD). Therefore, a new
positron emission tomography (PET) radioligand selective toα7-
nAChR was developed in this study. The structure of the devel-
oped ligand is based on a novel potent and selective α7-nAChR
agonist, 3-(4-hydroxyphenyl-1,2,3-triazol-1-yl) quinuclidine
(QND8) which demonstrated cognitive enhancement in mice.
Materials and methods: The structure of the radioligand (18F-
QND) was modified from QND8 by replacing the hydroxyl
group with fluorine. After synthesis of the starting quinuclidine
azide and aryl alkyne, F-QND and its precursor were synthesized
by copper-catalyzed azide-alkyne cycloaddition (CuAAC) or
click chemistry. Their structures were confirmed by 1H-NMR,
13C-NMR and mass spectrometry (MS). 18F-QND was
radiolabeled by nucleophilic substitution of the nitro pre-
cursor. Altered amounts of kryptofix and various condi-
tions (solvent and temperature) were chosen to improve
the radiolabeling yield. The radiolabeled compound was
separated and purified by chromatography. The radio-
chemical yield and radiochemical purity were analyzed
by radio-thin layer chromatography and radio-high per-
formance liquid chromatography. Non-radioactive refer-
ences were used to confirm the stereochemistry of the
nitro-precursor and F-QND. Results: The chemical yields
of the nitro-precursor (NO2-QND) and the reference
standard (F-QND) were 21% and 11%, respectively,
with purity higher than 95%. The radiolabeling yield
of 18F-QND was 7% with radiochemical purity > 98%
and specific activity of 65 GBq/μmol. The stereochem-
istry study approved that both compounds were optically
active. Therefore, the developed radiochemical processes
can be applied for the radiosynthesis of further 18F-
QND-derivatives. Conclusion: Radiosynthesis of 18F-
QND was accomplished by nucleophilic substitution of
the phenyl-nitro compound. However, at high tempera-
ture partial racemization cannot be excluded.
PW004
[11C]Me@HAPTHI - A Novel PET-ligand for the Nor-
epinephrine Transporter: Target Affinity and
Radiosynthesis
C. Rami-Mark1, N. Berroteran-Infante1, A. Hoepping2, M.
Hacker1, M.Mitterhauser1,W.Wadsak1; 1Medical University
of Vienna, Vienna, AUSTRIA, 2ABX - Advanced Biochemi-
cal Compounds, Radeberg, GERMANY.
The norepinephrine transporter (NET) has been demonstrated
to be relevant to a multitude of neuropsychiatric and cardio-
vascular pathologies. Due to the wide range of possible appli-
cations for PET imaging of the NET together with the limita-
tions of currently available radioligands, novel NET-PET
tracers are seriously needed.METHODS:Precursor, HAPTHI
( (S ) -1 - (4 -amino-3 -hydroxybu ty l ) -3 -pheny l -1 ,3 -
dihydrobenzo[c] [1,2,5]thiadiazole-2,2-dioxide), and refer-
ence compound, Me@HAPTHI ((S)-1-(3-hydroxy-
4-(methylamino)butyl)-3-phenyl-1,3-dihydrobenzo[c][1,2,
5]thiadiazole 2,2-dioxide), were custom-synthesized by
ABX.For optimization of radiosynthesis conditions, small-
scale reactions (<2GBq) were performed. The influence of
various reaction conditions, i.e. reaction temperature, solvent
and base, precursor concentration and radiomethylation agent,
was investigated. The automation of the N-11C-methylation
reaction was done on a TRACERlab FX C Pro synthesizer
(GE Healthcare).The affinity of new radiolabeled ligand was
determined in a NET-expressing membrane binding
protocol.RESULTS:In the radiochemical evaluation, best re-
sults were obtained with sodium hydroxide catalysis in 2-
butanone(MEK) as solvent for 2min at 75°C using 2mg/mL
precursor HAPTHI. Thereby, 54.0 ± 8.3% radiochemical in-
corporation yield was achieved. These optimum reaction pa-
rameters were subsequently used in the fully automated
radiosynthesizer. So far, 9 large-scale radiosyntheses were per-
formed, yielding 1.5 ± 0.5GBq (10.9 ± 4.9%, corrected for
decay) of sterile, formulated [11C]Me@HAPTHI within
36min. A mean specific activity of 71.4 ± 26.3 GBq/μmol
was found. Full radiopharmaceutical quality control took
5min and showed that radiochemical purity always exceeded
98%.Affinity of reference compounds, Me@HAPTHI, using
human NET membranes evinced a Kd of 0.21 ± 0.07nM
(n=9). For determination of selectivity, additionally the affinity
towards human DAT and SERT membranes were measured
and revealed >10μM for DAT and 409 ± 43nM for SERT,
respectively, (n=5). Hence, selectivity of Me@HAPTHI
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towards NET was determined as DAT/NET>1947.6 and
SERT/NET=9757. CONCLUSION: This study confirms an
outstanding affinity and selectivity of the title compound to-
wards human NET as well as its feasible radiochemical prep-
aration for further preclincal evaluations ans future in-vivo
applications.
PW005
Bringing radiotracing to titanium-based antineoplastics:
automated synthesis, PETand ex-vivo evaluation of [45Ti]
(salan)Ti-derivatives
F. Zhuravlev; G. W. Severin, C.H. Nielsen, J. Fonslet, A.
Ingemann, A. Kjaer,Hevesy Laboratory, Roskilde,
DENMARK.
Introduction: Recent advances in titanium-stabilizing ligands
have led to a new class of cytotoxic Ti-based antineoplastics.
Implementation of 45Ti PET (45Ti: 85% positron branch, 3.1 h
half-life) and radiotracing early in preclinical development
could aid in determining the mechanism of action, and evalu-
ate dosing and drug formulation. Aim: We aimed at develop-
ing a novel solid-phase based 45Ti radiolabeling methodology
and the implementation of 45Ti-PET in titanium-based anti-
neoplastics using hydrolytically stable [45Ti](salan)Ti com-
pounds. This development was intended to allow elucidation
of the biodistribution and pharmacokinetics of promising
new Ti-based therapeutics. Materials and Methods: 45Ti
was produced by the 45Sc(p,n)45Ti reaction and recovered
o n H y p oG e l 2 0 0 d i o l r e s i n . A s e r i e s o f
[45Ti](salan)Ti(dipic) derivatives was synthesized by on-
column complexation of resin-bound 45Ti with the corre-
sponding ligands. HPLC/radioHPLC and TLC/radio-TLC
were used to confirm the identity of the radioproducts.
Imaging and biodistribution studies of the parent
[45Ti](salan)Ti(dipic) were carried out with NMRI nude
mice bearing dual-flank HT-29 xenograft tumors using in-
travenous (iv) and intraperitoneal (ip) injections. For the iv
injection, dynamic PET data were obtained for 1h follow-
ing injection. The ip injections were followed by static
PET scans at 1 and 7h pi and conventional ex-vivo
biodistribution studies. Results: 45Ti was isolated from bulk
scandium on HypoGel 200 column with 93 ± 3% recov-
ery. The introduction of salan and dipic were performed by
passing the solutions of ligands in pyridine sequentially
through the HypoGel 200 column at 25oC and 100oC
correspondingly giving chemically and radiochemically
pure products in overall 10-20% RCY. The dynamic 45Ti
PET performed after iv injection demonstrated rapid (3.8
min) blood clearance. The ip injections demonstrated the
biliary excretion and negligible tumor accumulation. How-
ever ex vivo biodistribution, gave a quantifiable signal in
the tumors with concentration estimated at 257 pmol/g.
Conclusion: The automated solid-phase radiosynthesis of
[45Ti](salan)Ti(dipic) derivatives was efficient and is ex-
pected to be applicable to a broad range of supporting
and terminal ligands. 45Ti PET and radiotracing allowed
elucidation of the in vivo behavior of promising titanium
compounds encouraging its adoption as a tool in Ti
theranostics.
PW006
[11C]Me@HAPTHI - A Novel PET-ligand
for the Norepinephrine Transporter: Preclinical
Evaluation
C. Rami-Mark1, W. Wadsak1, C. Philippe1, C. Vraka1, A.
Hoepping2, M. Hacker1,M.Mitterhauser1; 1Medical Univer-
sity of Vienna, Vienna, AUSTRIA, 2ABX - Advanced Bio-
chemical Compounds, Radeberg, GERMANY.
The norepinephrine transporter (NET) has been demon-
strated to be pivotal in many neuro-psychiatric and car-
diovascular pathologies. [11C]Me@HAPTHI, a novel
potential NET-PET tracer, was shown to have a high
target affinity and selectivity. Hence, further in vitro
evaluation regarding blood-brain-barrier (BBB) penetra-
tion, stability and binding properties in autoradiography
on different tissues is required. METHODS: LogD was
assessed using HPLC (Donovan & Pescatore J Chrom
A, 2002). Immobilized artificial membrane (IAM) chro-
matography was performed using a standard method
(Vraka C et al. EJNMMI, 2014) to achieve Pm
(permeability) values.For evaluation of stability, incuba-
tion with human liver microsomes was performed. Plas-
ma protein binding was determined quantifying the free
fraction (ff) in human pooled plasma (Huang Y et al. J
Cereb Blood Flow Metab, 2002).In vitro autoradiogra-
phy was performed on human brain tissue (cortex, thal-
amus, hippocampus, cerebellum, and hypothalamus) as
well as rat heart. Non-specific binding was determined
with excess Nisoxetine (10μM). For competition, non-
radioactive FMeNER-D2 and Me@HAPTHI were
added. After 1h at room temperature, incubation was
stopped and slices were processed on phosphor imaging
films. Post-autoradiographic processing of the slices
was done by Nissl staining in order to facilitate mor-
phological mapping. Immunohistochemical (IHC) stain-
ing experiments were performed on rat and human tis-
sue cryo-sl ices, vicinal to the sl ices used for
autoradiography.RESULTS:Excellent affinity (KD =
0.21±0.07nM) and selectivity (DAT/NET>1940;
SERT /NET=9 7 0 0 ) w e r e a l r e a d y s h own f o r
[11C]Me@HAPTHI. Both logD (2.27±0.01) and Pm
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(1.15±0.25) were found to be in a range for expectable
BBB penetration. After 60min incubation with human
liver microsomes, 99.6±0.3% of the tracer were still
intact. ff was found to be 8.2±0.3%.In the autoradio-
g r a p h i c e x p e r i m e n t s , h i g h e s t u p t a k e o f
[11C]Me@HAPTHI was observed in NET-rich regions
identified with IHC and a concentration dependent
binding displacement was seen for both competitors.
CONCLUSION: Besides its high affinity & selectivity,
we now demonstrated [11C]Me@HAPTHI’s stability, ex-
pectable BBB penetration and specific binding in auto-
radiography. This encourages us for in vivo application
in small animal PET experiments and future clinical
trials.
PW007
Preparation of 6-[18F]Anle138b: a novel PET-tracer
potentially suitable for imaging of neurodegenerative
and prion diseases
F. Zarrad1,2, B. D. Zlatopolskiy2, B. Neumaier1,2; 1Institute of
Neuroscience and Medicine, Nuclear chemistry (INM-5),
Forschungszentrum Jülich, Jülich, Jülich, GERMANY, 2Insti-
tute of Radiochemistry and Experimental Molecular Imaging,
University Clinic Cologne, Cologne, GERMANY.
Objective: Anle138b is a novel compound that binds
selectively to the deposits of aggregated proteins found
in neurodegenerative diseases like Parkinson’s and
Alzheimer’s as well as in prion disease. This work
aim to prepare a 18F-labeled analog of Anle138b using
1,3-dipolar cycloaddition between the radiofluorinated
phenyldiazomethane generated in si tu and the
appropriate terminal alkyne.Method:As a prototype
r e a c t i o n 1 , 3 - d i p o l a r c y c l o a d d i t i o n b e twe e n
4-[18F]fluorophenyldiazomethane prepared from the cor-
responding tosylhydrazone and 4-fluorophenylacetylene
was optimized with respect to reaction time and tem-
perature, base and solvent . 6-[18F]Fluoro-3,4-
methylendioxybenzylidene tosylhydrazone ([18F]1) was
p r e p a r e d v i a t h e r e a c t i o n o f k n o w n
6-[18F]fluoropiperonal ([18F]2) with tosylhydrazide.
The corresponding 18F-labeled diazomethane was gen-
erated in situ by the thermolysis of the salt of [18F]1
in the presence of base. This 1,3-dipole reacted with
3 ’ - b r o m o p h e n y l a c e t y l e n e t o g i v e
6-[18F]Anle138b.Results:4-[18F]Fluorobenzylidene
tosylhydrazone was prepared from 18F- in 62% RCY
and with 93% RCP via one-pot two-step preparation
procedure using SPE purification and allowed to react
with 4-fluorophenylacetylene. Under the optimized reac-
tion conditions (LiOtBu in MeCN, 95 °C, 25 min)
RCC of the appropriate 18F-labeled 3,5-disubstituted
pirazole amounted to 67%. Using the same set of con-
ditions 6-[18F]Anle138b was prepared in RCCs of 27-
34%.Conclusion:An efficient method for the regioselec-
tive preparation of radiofluorinated 3,5-disubstituted
pyrazoles was developed. This procedure allowed to
produce 6-[18F]Anle138b, a potential tracer for protein
deposition in brain, in activity amounts sufficient for
preclinical studies.
PW008
Radio-synthesis and biological evaluation in animal
models of [11C] 1-(4-Fluorophenil)-3-(2-methoxyethyl)
-2-methyl-5-(4-methyl-sulfonyl) phenil)-1H-pyrrole (VA
426), a highly selective Cyclooxygenase-2 inhibitor
A. Carpinelli1, G. Di Grigoli1, A. Di Capua2, A. Cappelli2, M.
Biava3, A. Coliva4, M. C. Gilardi1, L. Gianolli5, M. Anzini2,
R. Moresco6; 1CNR-IBFM, Milan, ITALY, 2Università di Si-
ena, Siena, ITALY, 3Università La Sapienza, Rome, ITALY,
4Università Vita-Saluta S.Raffaele, Milan, ITALY, 5Ospedale
S. Raffaele, Milan, ITALY, 6Università Bicocca, Milan, ITA-
LY.
Introduction: Cyclooxygenase (COX) enzymes catalyze the
conversion of arachidonic acid to prostaglandins. COX-2 is
considered an important target for prevention and cancer ther-
apy, due to its major contribution in the inflammatory response
and cancer progression. Non-invasive monitoring of COX-2
expression by molecular imaging techniques may provide
unique opportunities to obtain information about disease pro-
gression and COX-2 potential role in pathogenesis. In this paper
1-(4-fluorophenyl)-3-(2-methoxyethyl)-2-methyl-5-(4-
methylsulfonyl)phenyl) 1H pyrrole (VA426) has been synthe-
sized and a preliminary in vivo brain and periphery
biodistribution in healthy rats was evaluated. Materials and
methods: No carrier added [11C]CO2 was produced via the
14N(p,α)11C reaction using IBA Cyclone 18/9 cyclotron and
transferred into a Ge Healthcare TracerlabFXc-Pro module
where it was catalytically hydrogenated to form [11C]CH4.
Methane was iodinated to form [11C]CH3I and then transformed
in the highly reactive [11C]methyl triflate by an on line flow-
through process. [11C]methyl triflate was bubbled into the reac-
tor where 1-3 mg of the precursor [VA425] was dissolved in
anhydrous DMSO containing 1-3 mg NaH. The crude mixture
was purified by semi-preparative radio HPLC system equipped
with a reversed phase column (ACE C18 250x10 mm, 10 mi-
cron, CPS). Acetonitrile/ammonium acetate 0.05M pH t.q. (60/
40, v/v) was used as the mobile phase and followed by formu-
lation through a tC18 SPE cartridge. Final solution was sterile-
filtered (Millex GP, Millipore). CD rats were injected in the tail
vein with 9.25 ± 1.25 MBq of [11C]VA4226. At 10, 30, 60
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minutes, rats (n=3 for each time point) were sacrificed and
blood was collected into a heparinised tube. Plasma was sepa-
rated by centrifugation and 100 μL of blood and plasma were
counted in a gamma-counter (LKB Compugamma CS 1282).
Immediately after sacrifice, peripheral tissues and central areas
were sampled and washed with cold saline. Tissues where
placed in pre-weighed tubes and counted. Radioactivity concen-
tration was calculated as percentage of the injected dose per
gram of tissue (% ID/g tissue). Results: Radiochemical yield
based on triflate activity was 7 ± 3% n.d.c.. Radiochemical
purity was > 99% and specific activity was 2+0.5 Ci/μmol.
[11C]VA4226 was progressively taken up and retained in
tissues rich in COX-2 such as heart, lungs, kidneys and
intestine. In the Central Nervous System [11C]VA426
reached higher distribution in pons, cerebellum and cortex.
Conclusion: Preliminary study encouraged us to further
validate this tracer by testing it in animal models of cancer
and neuroinflammation. Acknowledgements: Supported by
FP7/2007-2013, agreement n° HEALTH-F2-2011-278850
(INMiND).
PW009
18F Labeling of a new naphthalene derivative as potential
Alzheimer Disease PET imaging agent. Synthesis
and preclinical studies.
L. Fernandez-Maza1, S. Rivera-Marrero2, M. Balcerzyk1, I.
Fernandez-Gomez1, A. Parrado-Gallego1, M. Sablon-
Carrazana2, R. Perez-Perera2, O. Diaz-Garcia2, A. Perera-
Pintado3, A. Prats-Capote3, C. Rodriguez-Tanty2; 1University
of Seville, CSIC, Junta de Andalucía, Seville, SPAIN, 2Centro
de Neurociencias (CNEURO), La Habana, CUBA, 3Centro de
Isótopos (CENTIS), La Habana, CUBA.
Introduction: Radiotracers for β-amyloid plaques PET
imaging with best results include naphthalene derivative
structures. CNEURO has developed and patented some
naphthalene derivative molecules for the diagnosis of
Alzheimer Disease at early stages (CU/P/2009/57, CU/P/
2013/27, EP 2 436 666 A20, South Africa P58243ZA00.
A successful 18F-labelling of such molecules by
nucleophilic substitution synthesis was developed at
CNA, for β-amyloid plaques PET imaging. Matherial
and methods: 3-(6-methoxy-2-naphtyl )propyl-4-
methylbenzenesulphonate was used as precursor for the
labelling process. 18F- was obtained from a Cyclone 18/
9 MeV cyclotron (IBA, Belgium) and nucleophilic
substitution took place in a modified TracerLab FXFN
module (GE, USA). Azeotropic distillation was per-
formed at 100°C in vacuum and with helium flushing.
Fluorination of precursor took place at 70°C for ten
minutes, with subsequent acidic hydrolysis and neutrali-
zation using NaOH 1N. The intermediate compound
(before hydrolysis) was dried to avoid any presence of
acetonitr i le (precursor solvent) . The radiotracer
2-(3-[18F]fluoropropyl)-6-methoxynaphtalene was puri-
fied by solid phase extraction cartridges (SPE),
connecting two alumina Sep-Pack and a SCX Sep-Pack
to retain unreacted 18F- and cationic impurities. The la-
beled compound was retained in a C18 Sep-Pack, and
eluted in absolute ethanol. The solution of radiotracer
was diluted with saline for injection. Quality controls
were performed before injection to the animals; pH, ab-
sence of particles, and radiochemical purity (RCP). RCP
was determined with a Dionex HPLC system and a
coupled radiation detector. The stationary phase was a
C18 reverse phase analytical column and acetonitrile/
water (75/25) as mobile phase. Two transgenic mice
APPSwe/PS1dE8 with amyloid plaques and two wild
type mice for control were injected with the radiotracer
f o r PET /CT s t ud i e s . Who l e body image s o f
biodistribution were obtained, and kinetic curves of ra-
dioactivity at several cerebral regions were performed.
Results: Radiochemical yield reached 49,8% (uncorrected
decay), and radiochemical purity was higher than 95% in
all batches. In vitro stability cromatograms demonstrated
that 2-(3-[18F]fluoropropyl)-6-methoxynaphtalene is sta-
ble for more than ten hours. Comparison between trans-
genic and control mice was established by cortex-
cerebellum SUVratio (SUVr) curve. Conclusions:
Rad i o syn the s i s o f 2 - ( 3 - [ 18F ] f l uo rop ropy l ) - 6 -
methoxynaphtalene by nucleophilic substitution of tosyl
group at the precursor gives good radiochemical yields
and radiochemical purity higher than 95%, which makes
the radiotracer useful for brain β-amyloid PET imaging.
Its in vitro stability (more than 10h) allows several pa-
tient studies from the same batch. PET/CT studies show
that 2-(3-[18F]fluoropropyl)-6-methoxynaphtalene crosses
blood brain barrier, with higher brain uptake in transgenic
mice, in comparison with control animals.
PW010
Efficient synthesis of [18F]FEDAC, and evaluation
of non-clinical safety and stability tests for clinical
application.
K. Kawamura1, M. Ogawa1,2, M. Takei1, K. Kumata1, K.
Furutsuka1,2, T. Yamasaki1, J. Yui1, L. Xie1, A. Hatori1, Y.
Zhang1, N. Nengaki1,2, K. Hirano3, M. R. Zhang1; 1National
Institute of Radiological Sciences, Chiba, JAPAN, 2SHI Ac-
celerator Service, Tokyo, JAPAN, 3NMP Business Support
Company, Chiba, JAPAN.
Aim: [18F]FEDAC has potent binding affinity and selectivity
for translocator protein (18 kDa, TSPO) [BMCL
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2009;19:1707], high signal for neuroinflammation [JNM
2010;51:1301], and high sensitivity and specificity for fatty
liver diseases progression [JH 2012;57:1076]. We had previ-
ously synthesized [18F]FEDAC by 18F-fluorethylation with
[18F]fluoroethyl bromide at two steps using a modified 18F-
labelling synthesizer. In this study, we simplified and im-
proved synthesis of [18F]FEDAC by direct [18F]fluorination
using a 18F-labelling synthesizer, and performed non-clinical
safety and stability tests for clinical study. Materials and
methods: [18F]FEDAC was prepared direct fluorination by
heating the tosylate precursor with [18F]F- in DMSO at 110
°C for 15 min. Evaluation experiments were performed for the
radiation dose estimate in mice, the extended single-dose tox-
icity study in rats, and in vitro stability tests in the injection and
human liver microsomes. Results: [18F]FEDAC was obtained
with sufficient radioactivity and suitable quality for injection
in clinical study. The radiochemical yield of [18F]FEDAC
using 1 and 5 mg precursor based on 18F- was 13 ± 5% (n =
5) and 35 ± 3% (n = 3), respectively, at end of synthesis (EOS)
within 65 min of an overall synthesis time. The estimated
effective dose equivalent in human was 0.022 mSv/MBq,
which was comparable to [18F]FDG injection (0.019 mSv/
MBq). [18F]FEDAC injection was stable for 180 min after
EOS (over 99% radiochemical purity). In human liver micro-
somes, [18F]FEDAC was metabolized gradually by CYPs
(4.2% parent at 60 min after incubation). A single-dose toxic-
ity of [18F]FEDAC injection was not observed for 14 days
after injection in rats. Conclusion: We successfully synthe-
sized [18F]FEDAC by fluorination of the tosylate-precursor
with 18F-. [18F]FEDAC injection will be applicable to a clin-
ical study with PET.
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Efficacy of Gated-SPECT in Risk Stratification of Major
Adverse Cardiac Events in Patients Over 60 Years
with Known or Suspected Coronary Artery Disease
Undergoing Noncardiac Surgery
M. Vakhromeeva, F. Chanakhchyan, E. Denisenko-Kankiya,
N. Bolomatov; Pirogov National Medical Surgical Center,
MOSCOW, RUSSIAN FEDERATION.
AIM: To evaluate the prognostic value of myocardial perfu-
sion imaging with gated-SPECT (MPI/SPECT) in patients
over 60 with known or suspected coronary artery disease
(CAD) before noncardiac surgery. MATERIALS AND
METHODS: Overall 225 patients were studied (average age
of 66,1±1,1). Patients were classified into 3 groups according
to age: 1) <65 years, 2) 65-74 and 3) >75. The Cardiac Risk
Index was used to assess patient cardiac risk and included 6
clinical variables. All of them were referred to “stress/rest”
MPI/SPECT using two-detector rotating gamma-camera
(“Discovery NM/CT 670”, GE) before noncardiac surgery. A
20-segment model of the LV was applied. “Summed stress
score” (SSS) was used which reflects reduced perfusion in
stress. Normal myocardial perfusion was considered if
SSS<4; slightly abnormal: SSS=4-7; moderate and significant-
ly abnormal: SSS≥8. The degree of ischemia was assessed by
“summed difference score” (SDS): SDS<2 - no ischemia,
SDS=2-7 moderate ischemia and SDS>7 - significant ische-
mia. RESULTS: 160 (71,1%) were proceeded to noncardiac
surgery after MPI/SPECTwithout any additional cardiac test-
ing. The rest 65 (28,9%) patients weren’t allowed to operations
due to high risk for major adverse cardiac events (MACE) in
peri- and/or postoperative periods. Coronary angiography
(CAG) was performed to 48 (73,8%) from them, and 46 (95,
8%) had hemodynamically significant stenosis at least in one
coronary artery. Myocardial revascularization (MR) was made
to 23 (47,9%) patients (15 patients-stenting, 8 patients-
CABG). On the whole, SSS and SDS were statistically higher
in patients, whom operations were cancelled (p<0,05). More-
over, SSS and SDS were significantly higher in patients over
75 years old (p<0,05). There was significantly reduction of
SSS and SDS (p=0,009) when comparing results of MPI/
SPECT before and after MR. Noncardiac surgeries were per-
formed to all patients after MR without any MACE. However
from 160 patients, whom noncardiac surgeries were performed
directly after MPI/SPECT MACE occurred in 13 (8,1%).
Myocardial perfusion analysis showed significantly high rates
of SSS (7,77±3,79), SDS (3,38±1,68) in these patients com-
pared with those without MACE (p<0,05). In rest 143 patients
without MACE SSS and SDS were below 4 and 2, respective-
ly. CONCLUSIONS: MPI/SPECT is an important tool in pre-
diction of MACE in peri- and/or postoperative periods in pa-
tients with known or suspected CAD undergoing noncardiac
surgery. It is also a reliable method for screening patients with
stable CAD for CAG. CAG with subsequent MR should be
considered in SSS>4 and SDS>2 in patients with high cardiac
risk.
PW012
Hybrid PET/MR viability imaging compared
with metabolism/perfusion pattern in acute myocardial
infarction
I. Cho, E. Kong, K. Chun, S. Kwon; Yeungnam University
Hospital, Daegu, KOREA, REPUBLIC OF.
Purpose : We evaluated simultaneous FDG and late gadolinium
enhanced (LGE) PET/MR viability imaging and compared with
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metabolism/perfusion patterns.Materials andMethods : Ten con-
secutive patients diagnosedwith acutemyocardial infarctionwere
underwent hybrid FDG/LGEPET/MRI examination andTc-99m
MIBI myocardial perfusion SPECT. According to the 17-
segment model, FDG uptake, LGE, and Tc-99m MIBI uptake
were visually assessed for each segment. Infarcted segments were
divided into transmural LGE (involving >50% wall
thickness)and subendocardial LGE (involving <50% wall thick-
ness). Results: In 170 segments, 40(23.5%) were rated as infarc-
tion on LGE images in which match, mismatch and reverse-
mismatch perfusion/metabolism defects were 13( 32.5%),
25(62.5%), and 2(5%)segments, respectively. 13(100%) of the
match defects appeared as transmural LGE, 23(92%) of the mis-
match defects did as subendocardial LGE. Two revese defects
showed transmural LGE. conclusion:Perfusion/Metabolism
match and mismatch defects might be well correlated with
transmural and subendocardial LGE, respectively.
PW013
Metabolic scintigraphy with radiolabeled fatty acid
in prognosis of cardiac resynchronization therapy
in patients with dilated cardiomyopathy
Y. B. Lishmanov1,2, M. O. Gulya2,1,K.W. Zavadovsky2,1, S.
I. Sazonova2,1, D. I. Lebedev2, V. S. Skuridin1, V. D.
Fillimonov1; 1National Research Tomsk Polytechnic Univer-
sity, Tomsk, RUSSIAN FEDERATION, 2Federal State Bud-
getary Scientific Institution “Research Institute for Cardiolo-
gy”, Tomsk, RUSSIAN FEDERATION.
Purpose of the study was to study perfusion and metabo-
lism of the left ventricular (LV) myocardium in patients
with idiopathic dilated cardiomyopathy (DCMP) and to
identify the scintigraphic predictors of the efficacy of car-
diac resynchronization therapy (CRT). Methods. The
study comprised 63 patients with DCMP and NYHA class
III-IV chronic heart failure. Before CRT, all patients re-
ceived scintigraphy with 99mTc-MIBI and with 123I-
BMIPP for evaluation of myocardial perfusion and metab-
olism, respectively. Before CRT and twelve months after,
all patients underwent echocardiography study to estimate
intracardiac hemodynamics. Results. Patients were divided
into two groups 6 months after CRT: (1) responders - LV
ESV decreased by ≥ 15% (n = 39);(2) non-responders -
LV ESV decreased by < 15% (n = 24). Prior to CRT, no
statistically significant differences were found between
groups in hemodynamic parameters (LVEF, end-diastolic
volume, end-systolic volume), intra- and interventricular
dyssynchrony. Significant differences were found in the
following preoperative scintigraphic parameters: myocar-
dial perfusion defect size and metabolic defect size. Cor-
relation analysis demonstrated the presence of significant
association (r =-0.37, p < 0.5) between the sizes of metabolic
defect and changes in the values of LV ESV after 6 months
the implantation of CRT device. Metabolic scintigraphy
showed higher diagnostic efficacy in determination of indi-
cations for CRT compared with perfusion scintigraphy (AUC
0.722 and AUC 0.612, respectively). The best metabolic
defect size threshold value of 7.35% predicted CRT efficacy
with the sensitivity and specificity of 77.8% and 66.7%,
respectively. We also mad an analytical review of methods
for obtaining of radiopharmaceuticals that are based on
99mTc -labeled fatty acids and their use in cardiology. We
make conclusion about efficiency of application and investi-
gation of 99mTc fatty acids radiopharmaceuticals that con-
tain chelate groups EDTA or DTPA. In this study, quantum-
chemical modeling of one of such conjugate is conducted
and its bioavailability is thus confirmed. Conclusions. The
results of myocardial metabolic scintigraphy with 123I-
BMIPP may be used as the secondary criteria for selection
of patients for CRT and for prediction of the efficacy of this
interventional treatment modality in patients with DCMP.
This work was financially supported by Federal Target Pro-
gram №14.604.21.0071(project unique identif ier
№RFMEFI60414X0071).
PW014
Association between radiation dosimetry of the heart
and the myocardial fatty acid metabolic impairment due
to chemoradiation-therapy : Prospective study using I-123
BMIPP SPECT/CT
K. Takanami1, R. Umezawa2, N. Kadoya2, A. Arai1, K.
Jingu2, K. Takase1; 1Department of Diagnostic Radiology,
Tohoku University Hospital, Sendai, JAPAN, 2Department
of Radiation Oncology, Tohoku University Hospital, Sendai,
JAPAN.
Aim: The purpose of this study was to clarify the temporal
change of the myocardial fatty acid metabolic impairment
due to chemoradiation-therapy (CRT). Materials and
methods: This study was approval by Institutional Review
Board and the informed consent was obtained from all the
patients. Twelve patients (3 females, mean age of 63.4 ±
7.1 years (53-79)) who underwent radical CRT for an ear-
ly esophageal cancer. At pre-CRT, pre-boost irradiation
during CRT, 3 months after CRT, and 1 year after CRT,
I-123 BMIPP SPECT / CT was scanned. The myocardial
BMIPP uptake in each of 17 segments of the left ventricle
was visually scored from 0 (normal uptake) to 4 (no up-
take) and semi-quantitatively assessed using “%uptake”,
which is a segmental mean uptake relative to the maximal
myocardial uptake. A correlation between radiation do-
simetry of the heart and the change of myocardial BMIPP
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uptake after CRT was assessed. P < 0.05 was considered
as statistically significant. Results: One patient died of
pneumonia during the course of observation, and 11 pa-
tients were followed for 1 year after the completion of
CRT. The total dose to the primary tumor was 60-70 Gy.
The average dose of the left ventricle was 15.7 ± 6.9 Gy,
and mean V40 (a percentage of the left ventricle that had
been irradiated 40 Gy or more) was 15.9 ± 15.0. Temporal
decreases of the BMIPP uptake after CRT were observed.
At pre-boost irradiation during CRT, 3 months and 1 y
after CRT , the changes of total visual grade of the left
ventricle were 1.1 ± 1.9, 2.7 ± 2.6, and 4.5 ± 4.1, respec-
tively, and the changes of total %uptake of the left ventri-
cle were -22.2 ± 50.4, -38.5 ± 54.3, and -81.1 ± 69.9,
respectively. At 3 months after CRT, significant correlations
were observed between V40 and both the total visual grade (r
= 0.63, p <0.05) and the total %uptake (r = -0.74, p <0.01) ,
while, no significant correlation was observed 1 year after
CRT. At pre-boost irradiation, a significant correlation was
observed between V40 and only the total %uptake (r = -0.64,
p <0.05). Conclusion: Although a myocardial metabolic im-
pairment after CRT is associated with radiation dosimetry of
the heart in the short-term, other factors are likely to affect a
myocardial metabolism in the long term.
PW015
The first clinical experience with combined PET-CT
myocardium in patients with multivessel coronary disease.
I. Shurupova, I. Aslanidis, A. Chernova, V. Makarenko, V.
Bereznitskiy, E. Derevyanko, I. . Ekaeva; Bakoulev Scientific
Center for Cardiovascular Surgery, Moscow, Moscow, RUS-
SIAN FEDERATION.
The aim was the comparison the perfusion abnormalities and
the severity of coronary atherosclerosis in patients with
established coronary heart disease based on hybrid positron
emission tomography with N13-ammonia (ammonium-PET)
and multidetector computed tomography with noninvasive
coronary angiography (MDCT-CA). Materials: 18 patients
(44 to 80 years, 62,6 ± 9,8) underwent MDCT-CA,
ammonium-PET stress - rest study on hybrid scanner
Biograph-64 and invasive coronary angiography (Rg-CA),
which was accepted as the “gold standard”. A total of 42
coronary artery (CA) segments were taken for consideration.
The hybrid imaging (MDCT-CA + ammonium-PET) and
MDCT-CA allow results were compared with Rg-CA. Steno-
sis ≥75% was considered as significant lesion for invasive and
non-invasive angiography. The result of the hybrid technology
is considered true-positive if significant changes was detected
by at least one of the non-invasive methods, negative if in the
presence of intact arteries or stenosis <75% there is no the
defect of perfusion (DP). Results. According to MDCT-CA
stenosis in 14/19 arteries were properly verified revealed by
Rg-CA. In the group of arteries with insignificant changes
according to Rg-CA coincidence of the results indicated in
31/34 cases, one artery were excluded due to the artifacts.
The sensitivity of MDCT-CA in identifying functionally sig-
nificant stenosis was 73%, specificity - 91%, positive predic-
tive value (PPV) - 82%, negative PV (NPV) - 86%. A sensi-
tivity hybrid analysis amounted to 94%, specificity- 829%,
PPV - 75%, NPV - 96%. Stenotic segments with the presence
and absence of stress-induced DP were analyzed individually.
According to PET DP were noted in 1/16 of the arteries with
stenosis <50%, in the l 5/20 arteries in the group with stenosis
50-74%, in 11/17 arteries with stenosis ≥75%. In whole group
(n=18) perceptions of the hemodynamic significance changes
identified in the CA, based on invasive coronary angiography
and on the basis ofMSCT-AG + PET, coincided in 10 patients.
The presence of significant stenoses was confirmed in 4 pa-
tients, absence hemodynamic significance was confirmed in 6.
The initial view of the hemodynamic significance of a steno-
sis, compiled only on the basis of its size, have changed in 8/18
patients (44%). Conclusions. Hybrid studies allow to increase
the sensitivity of diagnosis of significant stenosis. Lower spec-
ificity of hybrid researches is due to the lack of hemodynamic
significance of some stenosis more than 75%. Generally hy-
brid researches allowed to change the perception of the steno-
sis hemodynamic relevance in 44% patients.
PW016
Assessment of Right Ventricular Myocardial Perfusion
and Fatty Acid Metabolism Using Planar Imaging
in Patients with Chronic Thromboembolic Pulmonary
Hypertension
H. Miyauchi1, T. Iimori2, K. Sawada2, Y. Kuwabara1, S.
Sakao1, K. Tatsumi1, Y. Kobayashi1; 1Chiba University Grad-
uate School of Medicine, Chiba, JAPAN, 2Chiba University
Hospital, Chiba, JAPAN.
[Background] In patients with chronic thromboembolic pul-
monary hypertension (CTEPH), right ventricular (RV) over-
load may result in RV enlargement and hypertrophy, which
consequently increases the RV myocardial perfusion. Howev-
er, there is little information on the RV myocardial fatty acid
metabolism in patients with CTEPH. [Aim] The aim of this
study was to quantitatively evaluate the RV myocardial perfu-
sion and fatty acid metabolism using 201Thallium (201Tl) and
123I-labelled 15-(p-iodophenyl)-3-R, S-methylpentadecanoic
acid (123I-BMIPP) planar imaging in patients with CTEPH.
[Materials and Methods] The study groups included 23 pa-
tients with CTEPH and 30 healthy controls. Mean pulmonary
artery pressure (mPAP) by right heart catheterization was
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obtained in all CTEPH patients. 201Tl and 123I-BMIPP pla-
nar and SPECT myocardial imaging were performed in all
participants. Planar acquisition was performed by obtaining
the angle that best separated the RV and the left ventricle
(LV) on transverse imaging. In the planar image, we measured
the total counts of 201Tl and 123I-BMIPP in both the RVand
LV, and calculated their relative counts of the RV to LV (ab-
breviated as HR/HL(Tl) and HR/HL(BMIPP) , respectively) to
determine the index of myocardial perfusion and fatty acid
metabolism, respectively. [Results] HR/HL(Tl) was signifi-
cantly elevated in the CTEPH patients compared with control
(0.60 ± 0.14 vs. 0.36 ± 0.07, p <0.01). HR/HL(BMIPP) was
also elevated in the CTEPH patients (0.55 ± 0.14 vs. 0.34 ±
0.06, p <0.01). In the CTEPH patients, average mPAP was
42.0 ± 9.52 mmHg, which was significantly correlated with
HR/HL(Tl) (r=0.61, p<0.01) and HR/HL(BMIPP) (r=0.65,
p<0.01). [Conclusions] In patients with CTEPH, RV myocar-
dial perfusion was increased and RV myocardial fatty acid
metabolism was upregulated with the elevation of mPAP.
201Tl and 123I-BMIPP planar imagingmay be useful to quan-
tify the severity of PH.
PW017
Diagnostic performance of attenuation corrected SPECT
myocardial perfusion imaging for coronary artery disease:
a systemic review and meta-analysis
J. Huang1,2, M. Cheng1, C. Lu1,2, Y. Wu1,3,4, R. Yen1, K.
Tzen1, K. Chien3,2; 1Department of NuclearMedicine, Nation-
al Taiwan University Hospital and National Taiwan University
College of Medicine, Taipei, TAIWAN, 2Institute of Epidemi-
ology and Preventive Medicine, College of Public Health, Na-
tional Taiwan University, Taipei, TAIWAN, 3Division of Car-
diology, Department of Internal Medicine, National Taiwan
University Hospital and National Taiwan University College
of Medicine, Taipei, TAIWAN, 4Department of Nuclear Med-
icine and Cardiology Division of Cardiovascular Medical
Center, Far Eastern Memorial Hospital, New Taipei,
TAIWAN.
PURPOSE / INTRODUCTION: Coronary ar te ry
disease(CAD) is one of the major causes of mortality and mor-
bidity throughout the world. Single photon emission computer
tomography (SPECT) myocardial perfusion imaging (MPI) is a
well established diagnostic tool for CAD. However, the full
clinical potential of MPI has not been realized due to many
factors of artifacts. Soft tissue attenuation is one of the most
common artifacts. The aim of this study is to determine and
compare the diagnostic performance of AC and non-AC
SPECT MPI, using coronary angiography as the reference
standard. SUBJECTS & METHODS: We search Medline and
Embase for English-language literature published from the ear-
liest available date till March 20, 2015 evaluating AC SPECT
MPI for diagnosis of CAD. Extraction of information including
author, journal, details of study design, patient characteristics,
stressor used for MPI, radiotracer, CAD definition, numbers of
true positive (TP),false positive (FP), true negative (TN) and
false negative (FN) was performed. Assess methodological
quality using the Quality assessment of Diagnostic Accuracy
Studies (QUADAS) tool. All data from each eligible study were
sorted out by Cochrane’s Review Manger. For each study, the
sensitivity, specificity, and the diagnostic odds ratio, along with
the 95% confidence interval (CI), were calculated to express the
diagnostic accuracy of AC and non-AC SPECT MPI. Because
methodological heterogeneity between included studies was an-
ticipated, a random-effects (DerSimonian and Laird) model was
used for pooling the data. Statistical analysis was performed
using STATA and Meta-DiSc. RESULTS: Original search
yielded 201 articles. On the basis of title and abstract, we
exclude 158 articles. One the basis of full text, we exclude
26 articles for various reasons, such as study for rick strat-
ification, reference standard other than coronary, etc. Sev-
enteen studies were identified, with a total of 1763 patients;
5 studies with 582 patients used computed tomography AC
(CTAC); 12 studies with 1181 patients used radionuclide
source AC; 12 studies with 1605 patients reported non-AC
results. Meta-analysis yielded pooled sensitivities of 0.748
[95%CI, 0.698-0.794], 0.810 [95% CI, 0.0.784-0.834] and
0.786 [95% CI, 0.757-0.812] for CTAC, all AC and non-
AC, respectively, and pooled specificities of 0.82 [95% CI,
0.768-0.867], 0.817 [95% CI, 0.786-0.844] and 0.705 [95%
CI, 0.668-0.739], respectively. DISCUSSION / CONCLU-
SION: Attenuation correction SPECT MPI with either
CTAC or radionuclide source AC showed improvement in
both sensitivity and specificity. Our results suggested that
AC should be applied in SPECT MPI for better diagnosis of
CAD.
PW018
Systematic Underestimation of High Values of Coronary
Flow Reserve Provided with Multi-Detector Computed
Tomography: a Comparison with SPECT Technology.
M. Bauckneht1, G. Ferrarazzo1, F. Fiz1, S. Seitun2, C.
Zawaideh3, F. Ticconi1, I. Calamia1, S.Morbelli1, C. Brunelli3,
C. Ferro2, G. Bezante3, G. Sambuceti1, C. Marini4; 1Nuclear
Medicine, IRCCS AUO San Martino IST, Genova, ITALY,
2Department of Radiology and Interventional Radiology,
IRCCS-University Hospital San Martino-IST, Genova, ITA-
LY, Genova, ITALY, 3Department of Internal Medicine, Chair
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of Cardiology, University of Genoa, Genova, ITALY, Genova,
ITALY, 4Institute of Bioimaging and Molecular Physiology,
CNR, Milan, Genoa Section, Genova, ITALY, Genova,
ITALY.
Aim. Diagnostic information provided by multi-detector com-
puted tomography (MDCT) has been recently enriched with
myocardial perfusion imaging (MPI) and the possibility to
assess coronary flow reserve (CFR). However, the accuracy
of this method has so far poorly evaluated and reported nor-
malcy values are markedly lower with respect to correspond-
ing measurements with gold standard techniques. The present
study was planned to compare performance of MDCT and
SPECT in CFR quantification since this numeric descriptor
of coronary physiology represents the theoretical basis of
MPI diagnostic accuracy. Materials and Methods. Thirty-five
patients (29 males, mean age 69 years) referred for chest pain
and/or dyspnea to our Institute underwent dipyridamole stress/
rest MPI with MDCT and SPECT. MDCT approach implied
the use of a commercially available software able to diplay
parametric maps of myocardial blood flow using a two-
compartment model in LV myocardial tissue. SPECT mea-
surements were instead performed, according to the validate
method that implies the normalization of myocardial tracer
uptake for the corresponding input function. For both ap-
proaches CFR values were compared with the anatomy of
related coronary branch as depicted by CT coronary angiogra-
phy. Results. Overall, CFR values at SPECT and MDCT im-
aging were similar (1.51±0.46 vs 1.50±0.37, respectively,
p=ns) and showed a fair segment-by-segment correlation
(r=0.63, p<0.001). At SPECT analysis, CFR was 1.64±0.31
in the 164 segments supplied by normal arteries (control re-
gions), while it significantly decreased in the 114 areas sup-
plied by vessels with intermediate stenosis (≤50%) (interme-
diate: 1.50±0.32, p50%) (critical: 1.33±0.22, p<0.01 vs con-
trol regions). MDCT-CFR was 1.65±0.32 in control regions
and significantly decreased to similar values in intermediate
(1.40±0.33 p<0.01 vs control regions) and in critical ones
(1.36±0.26, p<0.01 vs control regions). At Bland-Altman
analysis, a proportional bias was identified by the regres-
sion between delta (SPECT CFR - MDCT CFR) and mean
CFR value that was significant (p<0.01) and displayed a
positive slope of 0.288 with 95% confidence limits rang-
ing from +0.21 to +0.31. Conclusions. MDCT-MPI and
SPECT provide similar values of regional CFR in a pop-
ulation with suspected CAD. However, MDCT displays a
limited accuracy in measuring high maximal MBF and
CFR values. This limitation can be recognized even by
the comparison with SPECT technology, which is known
to markedly underestimate high MBF and CFR values. An
accurate validation of MDCT diagnostic performance
should be completed encompassing a normalcy database
to optimize its diagnostic use.
PW019
Cardiac Sympathetic Innervation Assessed
with 123I-MIBG Retains Prognostic Utility in Diabetic
Patients with Severe Left Ventricular Dysfunction
Evaluated for Primary Prevention Implantable
Cardioverter-Defibrillator
M. COZAR SANTIAGO1, P. GARCIA GONZALEZ2, R.
SANCHEZ JURADO1, R. SANZ LLORENS1, J. AGUILAR
BARRIOS1, F. RIDOCCI SORIANO2, J. FERRER
REBOLLEDA1; 1ERESA-NUCLEAR MEDICINE DE-
PARTMENT. GENERAL UNIVERSITARY HOSPITAL,
VALENCIA, SPAIN, 2ERESA-CARDIOLOGY DEPART-
MENT. GENERAL UNIVERSITARY HOSPITAL, VALEN-
CIA, SPAIN.
OBJECTIVES: We analyze if the evaluation of cardiac sym-
p a t h e t i c i n n e r v a t i o n (CS I ) w i t h i o d i n e - 1 2 3 -
metaiodobenzylguanidine (123I-MIBG) retains prognostic
utility in diabetic patients with heart failure (HF) evaluated
for primary prevention implantable cardioverter-defibrillator
(ICD).BACKGROUND: Scintigraphy with 123I-MIBG is a
noninvasive tool for the assessment of CSI that has proven to
be an independent predictor of survival. In addition, recent
studies have shown that diabetic patients with HF have a
higher deterioration in CSI. It is unknown if 123I-MIBG has
the same predictive value for diabetic and nondiabetic
patients.METHODS: Seventy-eight consecutive HF patients
(48 diabetic and 30 nondiabetic) evaluated for primary preven-
tion ICD implantation were prospectively enrolled and
underwent 123I-MIBG to assess CSI (Heart-to-mediatinum
ratio (HMR), cardiac wahout rate). A Cox proportional haz-
ards multivariate analysis was used to analyze the influence of
123I-MIBG images for prediction of cardiac events in both
diabetic and non-diabetic patients. The primary end-point
was a composite of arrhythmic event, cardiac death or HF
hospitalization.RESULTS: During a mean follow-up of 19.5
[9.3-29.3] months, the primary end-point occurred in 24 (31%)
patients. Late HMR was significantly lower in diabetic pa-
tients (1.30 vs 1.41, p=0.014). Late HMR ≤1.30 was an inde-
pendent predictor of cardiac events in diabetic (hazard ratio
4.53; p = 0.012) and non-diabetic (hazard ratio 12.31; p =
0.023) patients.CONCLUSIONS: Diabetic patients with HF
evaluated for primary prevention ICD show a higher deterio-
ration in CSI than non-diabetics; nevertheless 123I-MIBG im-
aging retained prognostic utility for both diabetic and non-
diabetic patients
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18F-FDG PET-CT in the Diagnosis of Infective
Endocarditis over Native and Prosthetic Valves
A. Jiménez-Ballvé1, M. J. Pérez-Castejón1, M. Matínez de
Bourio1, C. Sánchez-Enrique2, I. Vilacosta2, C. Riola Parada1,
A. Ortega Candil1, C. Olmos2, J. L. Carreras-Delgado1,3; 1Nu-
clear Medicine Department, Hospital Clinico San Carlos, Ma-
drid, SPAIN, 2Cardiology Department, Hospital Clinico San
Carlos, Madrid, SPAIN, 3Universidad Complutense, Madrid,
SPAIN.
Aim: The aim of this study was to assess the usefulness of
PET-CT with 18F-FDG in the diagnosis of infective endocar-
ditis (IE) looking for differences among native and prosthetic
valves. Materials and methods: In this prospective study we
included 52 patients with initial suspicion of definitive or pos-
sible IE according to Dukes criteria, from November 2012 to
April 2015. PET-CTwas considered positive when present-
ed 18F-FDG uptake in the region of interest (ROI) greater
than the background and persisted in the non-corrected im-
ages. On the other side, it was considered negative if there
was no uptake difference between the ROI and the back-
ground or did not persist in the non-corrected images. Anat-
omy was the gold standard in patients who underwent
cardiac surgery. In those cases without surgery, final diag-
nosis was done by clinical consensus of the endocarditis
team (independently from the PET-CT results). Results: In
the 52 PET-CT studies, we analyzed 69 foci as regions of
interest, 42 prosthesis valves and 27 native valves. The sus-
picion of IE was 38 definitive and 31 possible. PET-CTwas
positive in 39 cases (57%) and negative in the other 30
(43%). 21 valve replacements were performed: 19 definitive
IE (11 on prosthesis and 8 on native valves, with a PET-CT
success rate of 100% and 38%, respectively) and 2 rejected
IE (fibroelastoma and marantic IE, both on native valve
with a PET-CT success rate of 100%). sensibility,
specifity, positive predictive value (PPV), negative pre-
dictive value (NPV) and accuracy of PET-CT in global
IE (prosthesic+natives) were 79%, 73%, 79%, 73% and
77%, respectively. When we just analyzed prosthesis, we
achieved a very high sensibility and NPV (100%), with
a specifity of 70%, PPV of 79% and an accuracy of
86%. By contrast, when we analyzed independently na-
tive valves, we obtained a sensibility of 52%, specifity
of 80%, PPV of 81%, NPV of 50% and an accuracy of
63%. Conclusion: 18F-FDG PET-CT seems to be useful
in the diagnosis of infective endocarditis, especially in
patients with prosthesis valves, having better accuracy
than in native valves.
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[18F]DPA-714: peripheral metabolism in healthy
volunteers and patients.
M. Peyronneau1, C. Letaillandier1, S. Lavisse2, B. Kuhnast1,
C. Baron1, B. Jego1, P. Gervais1, F. Dollé1, B. Bodini3, B.
Stankoff3, M. Sarazin3, P. Rémy2, M. Bottlaender4; 1CEA-
DSV-I2BM-SHFJ-IMIV, Orsay, FRANCE, 2CEA-DSV-
I2BM-Mircen, Orsay, FRANCE, 3APHP, Paris, FRANCE,
4CEA-DSV-I2BM-Neurospin-IMIV, Orsay, FRANCE.
Objectives: The translocator protein (TSPO) is weakly expressed
in the healthy human brain and overexpressed in several neuro-
degenerative pathologies. [18F]DPA-714 is currently under clin-
ical investigation in Alzheimer, Parkinson andMultiple Sclerosis
diseases by PET.We have previously reported species differences
in the metabolism of [18F]DPA-714 in rats and non-human pri-
mates and the involvement of human CYP3A4 in its biotransfor-
mation (Peyronneau et al., Drug Metab Dispos, 2013). In this
study, we aimed to investigate the peripheral metabolism of
[18F]DPA-714 in healthy volunteers (HV) and patients (P) and
evaluate the influence of age, gender, diseases, concomitant
medication and binder affinity for TSPO.Methods: Venous
blood samples were collected from 145 subjects (54 HV-91
P) during PET and arterial samples in 20 HV. [18F]DPA-
714 and metabolites fractions were determined by a devel-
oped solid phase extraction method and used for the correc-
tion of individual input functions. Results: As expected,
[18F]DPA-714 peripheral metabolism was similar in arteri-
al and venous plasma samples (54.8±9.7% vs 54.5±9.6% of
[18F]DPA-714 at 90 min). No gender differences were ob-
served but [18F]DPA-714 metabolism decreased with age
(45±10% to 35±10% of radiometabolites; 20-90 years,
p<0.05). No significant differences were detected between
healthy volunteers and patients, except for those co-
medicated with known CYP3A4 inducers/inhibitors, for
whom an increase (up to 66%) or a decrease (down to
12%) of radiometabolites were observed. Finally, while no
major difference in the metabolism was found whatever the
TSPO affinity genetic status, the parent plasma concentra-
tion (input function) displayed a 4-fold and 1.3-fold in-
c r e a s e i n l ow a n d m i x e d c omp a r e d t o h i g h
binders.Conclusions: [18F]DPA-714 metabolism may con-
tribute to interindividual variations of the input function
used for the quantification of the tracer brain uptake.
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A Novel SPECT-based Approach Reveals Early Effects
of Systemic Inflammation on Brain Injury and Peripheral
Organs After Cerebral Ischemia
D. Mathe1, K. Szigeti2, D. Veres2, B. Martinecz3, N. Lenart3,
N. Kovacs1, A. Marta2, M. Semjeni1, A. Denes3,4; 1CROmed
Ltd, Budapest, HUNGARY, 2Dept. Biophysics and Radiation
Biology Semmelweis University, Budapest, HUNGARY,
3Laboratory of Molecular Neuroendocrinology, Institute of
Experimental Medicine, Budapest, HUNGARY, 4Faculty of
Life Sciences, University of Manchester, Manchester, UNIT-
ED KINGDOM.
Introduction. Inflammation that develops in the brain and pe-
ripheral organs after stroke contributes profoundly to the out-
come of patients. Clinical decision making would highly ben-
efit from rapid assessment of central and peripheral inflamma-
tory changes after acute brain injury, but appropriate medical
imaging tools are not available yet. Here we show that single-
photon emission computed tomography combined with MRI
(NanoSPECT/CT Plus, nanoScan MRI/SPECT) allows early
visualization of blood brain barrier injury and inflammation in
the brain after experimental stroke, well before signs of brain
injury can be detected with magnetic resonance imaging
(MRI).Materials and Methods. Whole-body 99mTc-DTPA
SPECT/CT; 99mTc-HMPAO SPECT and MRI imaging was
performed in groups of 5 mice with middle cerebral artery
occlusion (MCAO) for 30 or 60 minutes. In one group LPS-
induced systemic inflammation was present before the MCAO
to model pre-existing inflammatory diseases. Imaging was
done 1, 3, 6 and 24, 72 hours post MCAO and was validated
by IgG, CD45 and Iba1 immunofluorescent microscopy and
H&E staining in respective brains and peripheral
organs.Results. Penetration of 99mTc-DTPA into the brain
parenchyma overlaps with areas of brain injury and perfusion
deficits after cerebral ischemia. Systemic inflammation pre-
ceding experimental stroke leads to very early perfusion defi-
cits and increased blood brain barrier injury (within 2 h) after
the onset of ischemia. Acute brain injury also leads to infec-
tious complications in peripheral organs such as the lung. We
detected that SPECT imaging reveals early (within 1-3 h)
changes in perfusion, barrier function and inflammation in
the lungs and the gut of all mice after experimental stroke,
with good predictive value for outcome. Discussion. Our re-
sults suggest that early inflammatory changes as detected by
SPECT/MRI, SPECT/CTwhole-body imaging precede injury
in the brain and peripheral organs. Thus these hybrid nuclear
medicine imaging methods are proposed to support decision
making in the clinic.
PW023
Effect of Normobaric Hyperoxia (NBO) on Hypoxic
Volume and Infarct Volume Following Middle Cerebral
Artery Occlusion (MCAo): An 18F-Fluoromisonidazole
(FMISO) PET, MR and TTC Study
T. D. Fryer, S. Ejaz, D. J. Williamson, U. Jensen-Kondering,
S. J. Sawiak, F. I. Aigbirhio, Y. T. Hong, J. Baron; University
of Cambridge, Cambridge, UNITED KINGDOM.
Aim: Whether NBO is effective in reducing infarct volume in
ischemic stroke remains inconclusive. NBO modestly increases
arterial oxygen content, which in turn may not significantly alle-
viate tissue hypoxia. We determined the impact of NBO in two
rat strains with different leptomeningeal collaterals. Materials and
Methods: 6 Wistars and 7 SHRs underwent distal permanent
MCAo (pMCAo) under either normoxic or hyperoxic conditions.
Dynamic FMISO PET data were acquired for 3hrs ~5min after
occlusion. Hypoxic volumes were defined on SUV2-3hrs maps.
Kinetic modeling was applied to the hypoxic volume signal.
Lesion volume was defined immediately after PET by T2w-
MR and TTC. Additional rats were used to measure arterial
PO2 (PaO2) and MCA cortex PO2 (PtO2) using an O2 probe
during cycles of normoxia/NBO. Results: In SHRs, NBO in-
creased PaO2 ~4-fold from normoxia; non-ischemic cortex
PtO2 rose from mean 24 to 50mmHg in SHRs (n=5; p=0.04),
and from 46 to 78mmHg in Wistars (n=4; p=0.001). During
MCAo, in SHRs compared to Wistars PtO2 was lower in
normoxia (2.5 vs 15mmHg) and increased less with NBO:
6mmHg (p=0.08) vs 26mmHg (p=0.09), respectively. FMISO
hypoxic volume was much larger in SHRs than Wistars, but
was not significantly different between normoxia and NBO in
either strain (mean 207 vs 349mm3 in SHRs, and 11 vs 9mm3 in
Wistars). FMISO influx rate (Ki) was significantly increased
(p<0.03) in the hypoxic volume compared to a mirror ROI for
both rat strains under both conditions, with trapping rate (k3) also
increased in SHRs (p<0.05) with a similar trend in Wistars
(p<0.09). However, mean SUV, Ki and k3 in the hypoxic volume
were not significantly different between normoxia and NBO in
either strain. A similar pattern was found for TTC (mean 136 vs
179mm3, and 18 vs 11mm3, respectively) and MR (mean 91 vs
103mm3, and 7 vs 3mm3, respectively) lesion volumes. There
were strong (p<0.001) correlations among lesion volumes from
TTC, MR and FMISO. Conclusion: Regardless of strain, there
was no protective effect of NBO against tissue hypoxia and in-
farction. The latter is consistent with previous pMCAo studies, all
in Sprague-Dawleys. However, here we directly show no effect
on FMISO lesion volume and only mild effects on tissue PtO2.
Early reperfusion is probably necessary for NBO to show benefit,
even with good collaterals. The worse tissue hypoxia during
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MCAo in SHRs is consistent with their intrinsically poorer vas-
cular architecture, apparent from their lower non-ischemic hemi-
sphere PtO2 under normoxia.
PW024
Regional cerebral blood flow changes after accelerated
repetitive transcranial magnetic stimulation of the canine
frontal cortex.
R. Dockx1, C. Baeken2, R. Duprat2, F. De Vos3, B. De
Spiegeleer3, A. Dobbeleir1, J. H. Saunders1, I. Polis1, K.
Audenaert2, K. Peremans1; 1Faculty of Veterinary Medicine,
University Ghent, MERELBEKE, BELGIUM, 2Faculty of
Medicine, University Ghent, Ghent, BELGIUM, 3Faculty of
Pharmaceutical Sciences, University Ghent, Ghent, BEL-
GIUM.
Repetitive transcranial magnetic stimulation (rTMS) is a non-
invasive, FDA approved treatment for depression. Neverthe-
less, this treatment’s neurobiological mechanisms remain un-
clear. Aim: To compare the regional cerebral bloodflow prior
and after High Frequency accelerated Repetitive Transcranial
Magnetic Stimulation (HF-arTMS) of the normal canine left
frontal cortex. Material and Methods: Eight dogs underwent a
3 Tesla MRI scan at the Ghent University Hospital. This scan
was the basis for pointer-based neuronavigation (Brainsight 2,
Rogue Resolutions, LTD), a technique used to externally
locate the stimulation site. Each dog’s left frontal cortex was
subjected to 5 consecutive stimulation sessions a day with a
figure 8 coil (Magstim Company Limited, Wales, UK) at 20
Hz. The sessions consisted of 40 trains of 1.9 seconds dura-
tion, separated by a 12 second intertrain interval (1560 pulses
per session). The stimulation intensity was set at 110% of the
motor threshold. One day prior and after the last stimulation
session, a 99mTc-HMPAO SPECT scan was acquired under
general anaesthesia. SPECT data were acquired with a triple
head gamma camera (Trionix, Triad) 30 minutes after tracer
injection (step and shoot, 120 steps of 3 deg, 10” per step). The
data were reconstructed with OSEM reconstruction and appli-
cation of resolution recovery algorithms (Hybrid, Hermes,
NUD, Sweden). A BW filter was applied (cut-off 1.6 cycles/
cm, order 5). The perfusion indices (PI) in the frontal, parietal,
temporal, rostral cingulate and caudal cingulate cortex as well
as subcortical regions (thalamus, striatum) were obtained by
semi quantification (normalization to total brain counts). A
Wilcoxon signed rank test was used to analyze the perfusion
indices. Significance level was set at p ≤ 0.05. Results: The
stimulation sessions caused a significantly increased PI in the
left frontal cortex (p = 0.01) and a decrease in the right parietal
cortex (p = 0.03). No significant differences were noted for the
other regions compared to baseline. Conclusions: Accelerated
HF-rTMS of the frontal cortex in dogs provokes an increase in
rCBF at the stimulation site. This finding is line with its effects
in humans and implies that rTMS may be used as a treatment
for canine behavioral disorders. Further investigation is need-
ed to evaluate the stimulation parameters and long-term effects
of such stimulation.
PW025
Metabolism of the Spinal Cord in Patients With
Amyotrophic Lateral Sclerosis: A FDG-PET/CT Study.
E. Pomposelli1, G. Sambuceti1, M. Piana2, C. Campi2, M.
Pennone1, A. Buschiazzo1, A. Cistaro3, F. Bongioanni1, A.
Chiò4, F. Nobili5, C. Caponnetto6, C. Marini7; 1Nuclear Med-
icine Unit, Department of Health Sciences, University of Gen-
oa and IRCCS AOU San Martino-IST, Genoa, ITALY, 2De-
partment of Mathematics, University of Genoa, Genoa, ITA-
LY, 3Positron Emission Tomography Centre IRMET S.p.A.,
Euromedic inc, Turin, ITALY, 4Department of Neuroscience
“Rita Levi Montalcini”, University of Turin, Turin, ITALY,
5Clinical Neurology, IRCCS AOU San Martino-IST, Genoa,
ITALY, 6Department of Neuroscience, IRCCS AOU San
Martino-IST, Genoa, ITALY, 7CNR Institute of Bioimages
and Molecular Physiology, Section of Genoa, Genoa, ITALY.
Aim. Amyotrophic lateral sclerosis (ALS) is a fatal late-onset
neurodegenerative disorder of adult life, characterized by a pro-
gressive impairment of motor function. Its pathological feature is
characterized by selective cell loss in the anterior horns of the
spinal cord (SC) and in the lower motor cranial nerve nuclei as
well as by cortico-spinal tract degeneration. We recently devel-
oped new software able to identify compact bone profile in PET/
CT images and thus able to recognize the spinal canal and SC
tracer uptake. The aim of our study was to investigate whether
this method permits to identify abnormalities in SC metabolism
in ALS patients. Materials and Methods. We studied 41 ASL
patients at different clinical stage, submitted to FDG-PET/CT
imaging. Patient population was compared with matched healthy
controls, randomly selected from a published normalcy database.
Image analysis was performed according to a previously validat-
ed method. The algorithm first identified the skeleton on the
whole body CT images by assuming that compact bone was
the structure with the highest X-ray attenuation coefficient in
the human body. Once identified the skeletal border, all vertebrae
were extracted from the image data set. The spinal canal was
automatically identified as the non-osseous spacewithin the spine
volume. The output of the software was therefore the extraction
and the 3D-representation of spinal canal volume that served as a
mask to recognize SC using a segmentation algorithm based on
Hough transformation. Thereafter, mean standardize uptake value
(SUV) of cervical and dorsal SC, normalized to the liver, was
evaluated in comparison with normal subjects. Cervical and dor-
sal SUV-mean normalized was considered in ASL patient both
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untreated and treated with riluzole. Results. Mean SC SUV was
significantly higher in ALS patients than controls in cervical
(0.97±0.39 vs 0.85±0.20, p<0.05) and dorsal (0.71±0.21 vs
0.67±0.15, p<0.05) SC segments. This increase was virtually
abolished in the 21 patients submitted to riluzole respect to un-
treated patients in both cervical (0.85±0.25 vs 1.11±0.46, p<0.05)
and dorsal (0.65±0.14 vs 0.77±0.25, p<0.05) segments. By con-
trast no differences were found in SC volume between patients
and controls or treated and untreated patients. Conclusion. This
new computational FDG-PET/CT analysis provided evidence of
relative increase metabolism in SC of ALS patients with respect
to controls. Moreover, riluzole therapy seems to reduce SC FDG
uptake. This method could improve our understanding of SC
response to ALS and the effect of new possible therapeutic
approaches.
PW026
Imaging of Brain TSPO Expression in a Mouse Model
of Amyotrophic Lateral Sclerosis with [18F]DPA-714
and Micro-PET/CT.
S. Gargiulo1,2, S. Anzillotti3, A. Coda1, M. Gramanzini1,2, A.
Greco4,2, M. Panico1, F. Dollé5, G. Pignataro6, M.
Quarantelli1, L. Annunziato6,3, A. Brunetti4,2, M. Salvatore3,
S. Pappatà1; 1Institute of Biostructure and Bioimaging, CNR,
Naples, ITALY, 2Ceinge, Biotecnologie Avanzate s.c.a r. l.,
Naples, ITALY, 3SDN IRCCS, Naples, ITALY, 4Department
of Advanced Biomedical Sciences, University Federico II,
Naples, ITALY, 5CEA, Institute for Biomedical Imaging,
Orsay, FRANCE, 6Department of Neuroscience, Reproduc-
tive and Dentistry Sciences, Naples, ITALY.
Aim: Amyotrophic lateral sclerosis (ALS) is a progres-
sive neurodegenerative disease affecting the motor sys-
tem. Transgenic SOD1G93A mice, carrying an ALS-
linked mutant human superoxide dismutase gene, provide
a relevant tool to investigate in vivo neuroinflammation
with translocator protein (TSPO, 18 kDa) radioligands.
We evaluated the feasibility of imaging microglial activa-
tion in SOD1G93A mice using [18F]DPA-714. Material
and Methods: 5 non-carr ier and 9 hemizygous
SOD1G93A mice (aged 71-137 days) were evaluated at
different symptomatic clinical stages (CS, score range:
0.5-4). High-resolution PET/CT (GE Healthcare eXplore
Vista, resolution: 1.8 mm FWHM/200 μm) were per-
formed under inhalant anesthesia (isoflurane 2%, oxygen
2 L/min). Images were acquired in dynamic mode over
30 minutes starting 20 minutes after tail vein injection of
5.55-7.00 MBq of [18F]DPA-714 (SRA: 200-800 GBq/
μmol), and were processed using a 2D-OSEM iterative
algorithm including random, scatter, dead time, and de-
cay correction. Counting rates were converted to Stan-
dardized Uptake Values (SUV=Tissue activity (MBq/cc)/
[Injected dose (MBq)/body weight (g)]). ROIs were de-
fined based on PET/CT fusion images on the cerebellum,
brainstem, cervical spinal cord and frontal cortex using
OsiriX software. Cerebellar, brainstem and cervical spinal
cord SUV were normalized to those of the frontal cortex.
Statistical analysis was performed using Mann-Whitney
test and Pearson’s correlation. Immunostaining and con-
focal immunofluorescence were performed on brain and
spinal cord sections using rabbit anti-TSPO and mouse
anti-Iba1 antibodies. Results: In the SOD1G93A symp-
tomatic mice the region/frontal cortex ratio was signifi-
cantly increased (p=0.012) in the brainstem (2.340
±0.784) compared to non-carriers (1.576±0.287). There
was no significant correlation between [18F]DPA-714
brainstem/frontal cortex ratio and clinical scores. Prelim-
inary results of immunofluorescence studies showed in-
creased TSPO expression in the spinal cord, in the facial
nucleus and in the nucleus ambiguus of symptomatic
SOD1G93A mice that colocalizes with increased Iba1
staining. Conclusions: The preliminary results suggest
that increased [18F]DPA-714 uptake can be measured
with high resolution PET/CT in a mouse model of ALS
in the brainstem, a region known to be the site of degen-
eration and increased microglial activation. Immunostain-
ing results showed that TSPO expression is increased in
brainstem nuclei and suggest that increased microglial
activation might be the cellular counterpart of in vivo
increased [18F]DPA-714 uptake. Acknowledgement: The
research leading to these results has received funding
from the European Union’s Seventh Framework Pro-
gramme (FP7/2007-2013) under grant agreement n°
HEALTH-F2-2011-278850 (INMiND).
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Positive correlation between neuromelanin accumulation
in the substantia nigra and striatal dopaminergic
innervation in patients with Parkinson’s disease
G. Marotta1, I. U. Isaias2, A. Costa1, P. Trujillo1, P. Sum-
mers1, G. Pezzoli3, R. Benti1; 1Fondazione IRCCSCa’Granda
Ospedale Maggiore Policlinico, Milano, ITALY, 2Department
of Neurology, University Hospital, Wurzburg, GERMANY,
3Parkinson Institute, Istituti Clinici di Perfezionamento, Mila-
no, ITALY.
Objectives: Parkinson’s disease (PD) is a progressive
neurodegenerative disorder in which the major patho-
logic substrate is a loss of dopaminergic neurons form
the substantia nigra (SN). Our main objective was to
determine in PD patients the correspondence between
SN changes, evident in neuromelanin (NM)- and iron-
sensitive MRI images, and dopaminergic striatal
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innervation loss. Methods: The study involved 18 sub-
jects with PD (13 males; median age: 64 years, range:
46-77 years) and a control group of 18 neurologically
intact adults (HC; 11 males; median age: 58 years,
range: 47-77 years). All subjects were examined at 3T
MRI by means of NM-sensitive and T2*-weighted
multi-echo gradient echo sequences. Using NM-MRI,
we measured the volume of the SN (Volsn) and the
mean contrast-to-noise-ratio (CNRsn) between SN and
a background region. The susceptibility (χ) and R2*
of the SN were calculated from multi-echo T2* images.
Striatal dopaminergic innervation was measured as den-
sity of dopamine reuptake transporters (DAT) by means
of FP-CIT SPECT, on the basis of VOIs defined by
means of the Basal Ganglia Matching Tool. Results:
When compared to a pre-existing group of HC, all
PD patients had significantly reduced striatal DAT bind-
ing values in both putamen (PT) and caudate nucleus
(CN). The reduction was greater on the side contralat-
eral to the most affected hemibody. PD patients showed
a reduced Volsn and CNRsn and both positively corre-
lated with the corresponding striatal DAT density. R2*
and χ values of SN did not differ between PD and
HC. The best predictor of DAT reduction was Volsn
(p<0.001, Press value=9.33). With reference to our
HC cohort, the probability of having PD was 100%
when Volsn-contra<0.35 cm3 and 32% if Volsn-con-
tra≥0.35 cm3. Conclusions : NM-MRI is a means of
quantifying SN pathology in PD patients that closely
correlates with dopaminergic striatal innervation loss.
It may serve as an imaging marker of PD, in particular
regarding SN neuron loss, although further longitudinal
multi-imaging studies, possibly involving subjects at
risk of PD, are required.
PW028
Quantification of Amyloid-β Deposition Using
18F-FC119S PET in Human Brains: A Phase 0-1 Study.
B. Byun1, B. Kim1, I. Lim1, C. Choi1, S. Park2, J. Ha2, K.
Lee3, K. Kim3, S. Lim1; 1Department of Nuclear Medicine,
Korea Cancer Center Hospital, Korea Institute of Radiological
and Medical Sciences, Seoul, KOREA, REPUBLIC OF, 2De-
partment of Neurology, Korea Cancer Center Hospital, Korea
Institute of Radiological and Medical Sciences, Seoul, KO-
REA, REPUBLIC OF, 3Molecular Imaging Research Center,
Korea Institute of Radiological and Medical Sciences, Seoul,
KOREA, REPUBLIC OF.
Aim: 11C-PIB has been developed and used to measure
amyloid-β deposit in the brain, which can be applied for early
diagnosis and evaluation of progression of Alzheimer’s
disease (AD). However, several 18F-labeled radiotracers with
a longer half-life were introduced in clinical practice with dif-
ferent characteristics. The aim of the present phase 0/1 study
was to obtain information about dosimetry, toxicity, pharma-
cokinetics, optimal dose, and optimal scan time of 18F-
FC119S, a new amyloid-β radiotracer.Materials and methods:
Eleven control subjects (mean age = 23.0 y) and 8 clinically-
diagnosed AD patients (mean age = 70.6 y) were enrolled (M:
F = 9: 10). In phase 0 study, we acquired a 120 min dynamic
brain PET image (3 control subjects and 3 AD patients) or 5
times of whole-body PET images during 4 hr (for dosimetry
evaluation in 3 control subjects) after injection of 185 MBq of
18F-FC119S. In phase 1 study, we acquired a 60 min dynamic
brain PET image in 5 control subjects and 5 AD patients after
injection of 370 MBq of 18F-FC119S. The ratios of cerebral
graymatter uptake to cerebellar uptake of 18F-FC119S (C/Cbr)
were automatically calculated on each PET dataset. Then, PET
data acquired for 10 min, 20 min, and 30 min after the plateau
of C/Cbr were respectively reconstructed. Quality of these
r e c o n s t r u c t e d im a g e s w a s v i s u a l l y a s s e s s e d
(good/acceptable/poor) and a case with higher or equivocal
gray matter uptake compared to the white matter uptake on
visual analysis was considered as a PET+.Results: The esti-
mated whole-body radiation dose was 14.7 μSv/MBq and the
highest uptake was observed in the liver or gallbladder. No
adverse event was observed. C/Cbr continuously increased
during the first 30 min after injection of 18F-119S then did
not change over 120 min. The mean C/Cbr of AD patients
and control subjects at plateau phase was 1.57 and 1.11, re-
spectively. All the PET images acquired during 30-60 min
irrespective of injected dose and all the PET images acquired
during 30-50 min after injection of 370 MBq of 18F-FC119S
showed good image quality, while others showed poor or ac-
ceptable image quality. On visual analysis, 6 of 8 AD patients
(75%) and 0 of 8 control subjects (0%) showed PET+.Conclu-
sion: 18F-FC119S is safe and its kinetic behavior is suitable for
measuring amyloid-β in the brain. PET images acquired dur-
ing 30-50 min after injection of 370 MBq of 18F-119S showed
good image quality.
PW029
Comparison of Visual and Quantitative 18F-Florbetaben
PET Scan Assessment
J. Seibyl1, S. Bullich2, D. Jennings1, M. Sabbagh3, A. Ste-
phens2, H. Barthel4, O. Sabri4, A. Catafau2; 1Molecular Neu-
roimaging, New Haven, CT, UNITED STATES, 2Piramal Im-
aging, Berlin, GERMANY, 3Univ of Arizona, Phoenix, AZ,
UNITED STATES, 4Univ Leipzig, Leipzig, GERMANY.
Background: Visual interrogation of 18F-Florbetaben (FBB)
PET scans is currently recommended for clinical practice,
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while quantification using SUVRs is a research tool which has
been considered a potentially important adjunct to aid overall
scan assessment. However, the added value of quantification
for the clinical scan report is unknown. This study aims to
compare both assessment methods for FBB PET scans to de-
termine whether analysis of concordance/discordance between
the assessments offers insight into how a visual-quantitative
assessment algorithm might perform. Methods: A total of 190
FBB scans were evaluated. 109 scans were from n=70 young
(27.7 ± 5.1 yrs) cognitively normal subjects (HVs) assumed to
be devoid of brain beta-amyloid and n=39 subjects with Down
syndrome (DS) > 40 yrs old (46.3 ± 4.7 yrs), and an additional
81 subjects scans were from a Phase 3 histopathology confir-
mation study. All scans were visually assessed by 3 readers
using the brain amyloid plaque load (BAPL) scoring system,
where negative scan=BAPL 1, and positive scan is either
BAPL 2=moderate or BAPL 3= pronounced tracer uptake.
Positive or negative scan agreement in ≥2 readers was consid-
ered as the result. A composite SUVR using cerebellar cortex
as reference was obtained from the average SUVR in 6 cortical
regions, using an automated grey/white matter MRI segmen-
tation and PET-MRI co-registration. Composite SUVR ≥1.45
were considered positive. Results: All scans from HVs were
visually assessed as negative. 91.1% of the scans were equally
classified as positive or negative by both visual and quantita-
tive approaches. Both methods were significantly and strongly
related (X2 = 125, p < 0.0001; Cohen’s Kappa = 0.81). In the
17 scans showing discrepancy, SUVRs range from 1.01-1.67,
and readers gave divergent BAPL scores in half these cases.
These challenging scans exhibited different features: poor
technical quality, motion, and atrophy. In the histopathology
cohort, for 6 cases with severe cortical atrophy the visual reads
were more concordant with histopathology than quantitation.
Conclusions: These findings support the use of either visual or
quantitative assessment of FBB scans. Further investigation is
required to determine the clinical utility of SUVR quantifica-
tion in challenging scans.
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Striatal dopamine transportermodulation after rotigotine:
results from a pilot SPECT study in a group of early
Parkinson’s disease patients.
E. Filidei1, C. Rossi2, D. Genovesi1, P. Marzullo1, A.
Giorgetti1, G. U. Corsini2, U. Bonuccelli2, R. Ceravolo2;
1Fondazione Toscana G. Monasterio, Pisa, ITALY, 2Azienda
Ospedaliero-Universitaria Pisana, Pisa, ITALY.
Introduction. Several in vitro data reported negative in-
terference by dopamine-agonists on the expression of
dopamine transporter (DAT) whereas from the most im-
aging studies nor L-dopa or dopamine-agonist resulted
to interfere with DAT availability. The investigation on
DAT expression by rotigotine in vivo has been not in-
vestigated yet. Methods. We evaluated presynaptic
nigrostriatal function in 8 de novo Parkinson’s disease
(PD) patients (age 59±6.2 years; M/F 5/3) using FP-CIT
SPECT before and after 3 months of treatment with
rotigotine (mean dose 7.75±1.98 mg). For data analysis,
specific (left and right caudate, left and right putamen)
to non-specific (occipital cortex) binding ratios, putamen
to caudate ratios and asymmetry indexes were calculat-
ed. Results. After rotigotine all patients improved motor
symptoms (UPDRS III mean score 11.88±2.59 vs 7.63
±1.92 on therapy, p=0.0022). Striatal FP-CIT levels
showed a significant improvement in each patient at
the follow-up scan. Comparisons between the whole
group before and after treatment showed a significant
improvement in FP-CIT uptake in both caudate and pu-
tamen (p<0.001 in each nucleus). Putamen to caudate
ratio and asymmetry indexes did not show a significant
difference before and after treatment. Discussion. We
found although in a small study population a DAT over-
expression after a chronic treatment with rotigotine pre-
sumably related to its pharmacological profile. The DAT
upregulation by rotigotine with an opposite direction
with respect to early PD compensatory mechanisms
might reduce the risk of dyskinesia, but it could imply
a less motor benefit because of a less stimulation by
dopamine itself on dopaminergic receptors.
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Τhe role of 68Ga-DOTATATE PET/CT imaging
in the decision of Peptide Receptor Radionuclide Therapy
(PRRT) administration
E. Skoura1, S. Michopoulou1, O. M. AlMukhalid1, E.
Panagiotidis1, M. Al Harbi1, I. Kayani1, R. Syed1, P. J. Ell1,
M. E. Caplin2, J. Bomanji1; 1UCLH, London, UNITED
KINGDOM, 2Royal Free Hospital, London, UNITED KING-
DOM.
Aim: Peptide receptor radionuclide therapy (PRRT) con-
sists of the systemic administration of a synthetic pep-
tide, labeled with a suitable β-emitting radionuclide,
able to irradiate tumors and their metastases. PRRT, with
ei ther 90Y-octreot ide or 177Lu-octreota te , has
established to be an efficient and effective therapeutic
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modality that provides objective responses in neuroendo-
crine tumors (NET), and is well tolerated with moderate
toxicity. This study was performed to reveal if 68Ga-
DOTATATE PET/CT can influence the decision of
PRRT administration in NET patients.Materials ad
Methods: Data from patients with NET who received
P RRT o r w e r e c a n d i d a t e f o r P RRT w e r e
analyzed.Results: Between May of 2005 and August of
2013, 1246 68Ga-DOTATATE PET/CT scans were per-
formed in patients with confirmed or suspected NET. In
13.4% of these cases (in 167 cases), radioisotope thera-
py, either as PRRT- 177Lutetium (177Lu)-DOTATATE
and 90Yttrium (90Y)-DOTATOC- or 131I-MIBG was
received after 68Ga-DOTATATE PET/CT scans. In this
patient group, PRRT was decided as new treatment in 85
cases (6.8% of the total cases). In these 85 cases, 68Ga-
DOTATATE PET/CT imaging showed extensive
unresectable and/or metastasized disease with intense
68Ga-DOTATATE uptake. In two cases (0.2%) the
PRRT was rejected as treatment because of the low trac-
er uptake. In detail, 177Lu-DOTATATE was administrated in
46 cases, 90Y-DOTATOC in 25 cases, while in 14 cases the
given radiopharmaceutical for PRRT is not known to us
(177Lu-DOTATATE or 90Y-DOTATOC). Finally, in 4 cases
treatment with 131I-MIBG was decided, as the MIBG uptake
in diagnostic 123I-MIBG scan, was more intense that the
68Ga-DOTATATE uptake in 68Ga-DOTATATE PET/CT
scan.Conclusion: PRRT is established treatment in patients
with advanced and/or progressive NET and 68Ga-
DOTATATE PET/CT imaging is necessary prior PRRT to tar-
get the somatostatin receptors. Our study reveals that PRRT
could be decided as new treatment in a significant percentage
of NET patients, when 68Ga-DOTATATE PET/CT scan
shows extensive unresectable and/or metastasized disease with
intense uptake.
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Radioguided laparoscopic surgery of occult colonic lesions
G.Manca1, G. Boni1, R. Spisni2, S. Chiacchio1, S. Mazzarri1,
E. Tardelli1, M. Biricotti2, D. Volterrani1; 1Regional Center of
Nuclear Medicine, Pisa, ITALY, 2Department of Surgery, Uni-
versity of Pisa, Pisa, ITALY.
Introduction: intraoperative localization, during laparoscopic
surgery, of small occult colonic lesions situated in particular
areas and/or with concomitant inflammatory bowel disease,
such as diverticulosis, perivisceritis, etc., can be problematic.
We investigated the feasibility of radioguided occult colonic
lesion identification during laparoscopic surgery after an ade-
quate phase of preoperative labelling. Subjects & methods:
patients presenting with colonic lesions difficult to detect for
their size and location were considered eligible for our study.
These patients were first submitted to coloscopy on the same
day or 24 hours prior to surgery, in order to administer the
radiopharmaceutical into the submucosal layer around the co-
lonic lesion. At least two injections (each containing an activ-
ity of 20-40 MBq in a volume of 2 ml) of 99mTc-labelled
albuminmacroaggregates were administered through a dispos-
able sclerosing syringe around the lesion. During surgery the
search for the radiolabelling colonic lesionwas carried out by a
11-mm orthogonal-view wireless laparoscopic gamma-
detection probe. The site of the lesion was marked with a clip
or with a suture. The pathologic features of the lesion deter-
mined the type and extension of the surgery to be adopted for
each patient. Results: a total of nine colonic lesions, one for
each of nine patients, were appropriately marked before sur-
gery and were all intraoperatively detected by laparoscopic
gamma-detection probe (identification rate = 100%). Accord-
ing to the surgeon’s opinion, this method to detect the colonic
lesion was technically feasible, rapid, safe and efficient, and no
lengthy learning curve was necessary. Conclusion: our study
demonstrates that preoperative endoscopic radiolabelling of
occult colonic lesions by injecting 99mTc-labeled albumin
macroaggregates followed by surgical detection with a dedi-
cated laparoscopic gamma probe is an accurate, efficient and
useful clinical approach, also safe both for the patient and the
medical staff in the operating room.
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Is K-ras mutation affecting 18F-FDG uptake in colorectal
cancer?
A. Ozen1, M. Tokocin1, E. Namal2, E. Gokmen1, T.
Vartanoglu1, F. Celebi1; 1Bagcilar Training and Research Hos-
pital, Istanbul, TURKEY, 2Istanbul Bilim University, Istanbul,
TURKEY.
AimThe colorectal cancer (CRC) is the third most common
cancer worldwide and the fourth leading cause of cancer-
related mortality. Current metastatic CRC therapy uses mono-
clonal antibodies such as cetuximab against the epidermal
growth factor receptor pathway that regulates cell survival,
motility and proliferation, as well as angiogenesis and metas-
tasis. This treatment is only useful in the absence of K-ras gene
mutations. The aim of our study was whether K-ras mutation
affects 18F-FDG uptake in colorectal cancer.Materials and
methodsThis study included 10 male (mean age: 52.2±17.21)
and 7 female (mean age: 49.14±13.88) patients with CRC. The
stages of patients were I in 1(5.9%), IIA in 1(5.9%), IIIB in
1(5.9%), IVA in 9 (52.9%), and IVB in 5 patients (29.4%). The
K-ras mutation status was mutant in 5 patients and wild in 12
patients. Furthermore, the patients divided two groups accord-
ing to CEA level at diagnose time as high at ≥50 and low at
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<50. The 18F-FDG PET/CT study was performed pre-
operatively in all patients. The SUVmax was calculated from
images at 1-hour (SUV1) and 3-hours (SUV2) after i.v. injec-
tion of 18F-FDG. Furthermore, retention index (RI) was cal-
culated in 11 patients following formula; RI=100 x (SUV2-
SUV1) / SUV1.ResultsThe SUV1, SUV2 and RI in K-ras
mutant patients were 9.448±3.247, 9.16±0.878, and
27.32%±1.56%, respectively. These values in K-ras wild pa-
tients were 13.545±6.054, 21.69±9.99, and 43.89%±16.57%,
respectively. There was no statistically difference between K-
ras mutant and wild patients for SUV1 (p:0.140), SUV2
(p:0.066), and RI (p:0.221). According to CEA level, There
was no statistically difference between high value and low
value for SUV1 (p:0.923), SUV2 (p:0.855), and RI
(p:0.465).ConclusionWe found that K-ras gene mutation was
not affected 18F-FDG uptake in CRC. But, our study included
a small number of patients. We thought that there is need for
additional research in large series of patients.
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Evaluating the risk of postoperative liver failure using
preoperative 99mTc-GSA SPECT/CT fused imaging
M. Yoshida1, S. Shiraishi2, N. Tsuda2, F. Sakamoto2, S.
Tomiguchi3, T. Beppu4, H. Baba4, Y. Yamashita2; 1Amakusa
Medical Center, Amakusa, JAPAN, 2Department of Diagnos-
tic Radiology, Graduate School of Life Sciences, Kumamoto
University, Kumamoto, JAPAN, 3Department of Diagnostic
Medical Imaging, School of Health Faculty of Life Sciences,
Kumamoto University, Kumamoto, JAPAN, 4Department of
Gastroenterological Surgery, Graduate School of Life Sci-
ences, Kumamoto University, Kumamoto, JAPAN.
Aim: Evaluating the risk of postoperative liver failure is
important for safe hepatectomy. Liver Uptake Value
(LUV) calculated from preoperative 99mTc-GSA
SPECT/CT fused imaging is useful for evaluating func-
tional reserve of remnant liver. Therefore we compared
the LUV indices with preoperative clinical risk factors
of postoperative liver failure. Methods: We enrolled 560
patients (mean age 66.5±10.6 years) who were per-
formed 99mTc-GSA SPECT/CT before hepatectomy. Ac-
cording to the ISGLS criteria, 27 of 560 patients
showed postoperative liver failure. From 99mTc-GSA
SPECT/CT, we calculated whole liver LUV and remnant
LUV. The cut off value of two indices were calculated
from ROC analysis. Older age (>70 years), portal vein
hypertension, hepatitis, severe fibrosis, massive bleeding
(>700ml), and postoperative complication (> grade 3 of
Clavian Dindo classification) were decided as clinical
risk factors. Results; The odds ratios of various indices
were as follows; low remnant LUV (OR: 18.4; 95%CI:
3.9 - 70.5), low whole liver LUV (OR 4.7; 95%CI 2.0 -
10.9), hepatitis (OR 2.7, 95%CI 0.8 - 9.1), older age
(OR 1.2, 95%CI 0.5 - 2.8), portal vein hypertension
(OR 2.5, 95%CI 1.1 - 5.7), severe fibrosis (OR 4.4,
95%CI 1.7 - 11.2), massive bleeding (OR 2.7, 95%CI
1.2 - 6.1), and postoperative complication (OR 15.7,
95%CI 6.2 - 39.7). The odds ratio of combination low
remnant LUV and low whole liver LUV was 19.9
(95%CI 6.8 - 58.5) and low remnant LUV and postop-
erative complication was 41.2 (95%CI 17.1 - 99.1).
Conclusion; LUV indices calculated from 99mTc-GSA
SPECT/CT fused image obtained before hepatectomy
were useful for evaluating the risk of postoperative liver
failure.
PW035
Can Potassium Perchlorate and Sodium Iodine influence
Iodine-131 uptake in Cholangiocarcinoma?
A. F. Brito1, T. Puga1, R. Teixo2,3, A. Fernandes2,4,5, A. F.
Brito2,4,3, A. M. Abrantes2,4,3, L. F. Metello1,6, J. G.
Tralhão2,4,7, M. F. Botelho2,4,3; 1Nuclear Medicine Depart-
ment, High Institute for Allied Health Technologies, Polytech-
nic Institute of Porto, Vila Nova de Gaia, PORTUGAL, 2Bio-
physics Unit, Faculty of Medicine, University of Coimbra,
Coimbra, PORTUGAL, 3CNC.IBILI, Faculty of Medicine,
University of Coimbra, Coimbra, PORTUGAL, 4Center of
Investigation on Environmental, Genetics and Oncobiology
(CIMAGO), Faculty of Medicine, Coimbra, PORTUGAL,
5Gastroenterology Department, CHUC, Coimbra, PORTU-
GAL, 6Nuclear Medicine Department, IsoPor SA, Ermesinde,
PORTUGAL, 7Surgical Department, Surgery A, CHUC, Co-
imbra, PORTUGAL.
Aim: Cholangiocarcinoma (CC) is a malignancy with
poor prognostic, high mortality and limited treatment
options, reason why the development of novel treatment
strategies by exploiting new targets might be considered
as consensually relevant. In fact, it was shown that CC
expressed the sodium iodine symporter (NIS), which is
responsible for iodine uptake by the cells. NIS is also
the responsible for the uptake of iodine-131 (131I) in
thyroid tumor and benign diseases, enabling the meta-
bolic radiotherapy and opening possibilities of new treat-
ment approaches for CC.Aim: This work aims to study
the uptake profile of 131I mediated by NIS, in two
human CC cell lines from distinct origins. The uptake
specificity was tested using NIS inhibitor potassium per-
chlorate (KClO4) as well as the effect of sodium iodide
(NaI) on 131I uptake.Material and Methods: Two human
CC cell lines were used: TFK-1 from extra-hepatic CC
and HuccT1 from intrahepatic CC. In order to study the
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131I uptake profile, we incubated 2 x 106 cells/mL with
9.25 x 105 Bq of 131I for 120 minutes. During this peri-
od, several samples were collected and the respective
counts per minute (CPM) registered. Furthermore, the
NIS specificity for 131I was assessed in the presence of
the inhibitor KClO4. For this purpose, the cells were pre-
incubated with KClO4 (1 to 100μM) for 0, 30 and 60
minutes before adding 131I. The effect of NaI was tested
using same protocol and same concentrations. The uptake
of 131I was measured after 30 minutes incubation with the
radiopharmaceutical.Results: It was observed 131I uptake
in both cell line cell lines (TFK-1 and HuccT1). The up-
take peak was between 5 and 30 minutes, remaining stable
after that. Moreover, KClO4 reduced the NIS mediated
131I uptake levels, in both cell lines, when introduced in
culture medium at the same time, suggesting that 131I
uptake is dependent of plasma membrane functional NIS
proteins. Preliminary results showed no differences in the
131I uptake, in both cell lines, when different stable iodine
concentrations are present in the medium.Conclusions: Dif-
ferent types of human CC cell lines have the capacity to
accumulate 131I, based on plasma membrane functional
NIS expression. However the uptake is not influenced by
the presence of NaI. These preliminary results seem to
show the potential that metabolic radiotherapy with 131I
could have for CC treatment.
PW036
Clinical Value of Metabolic Parameter for Evaluation
of LN Metastasis in Clinical N0 Gastric Cancer
S. Choi, S. Lim, C. Na, J. Kim, Y. Han, H. Jeong, M. Sohn;
Chonbuk National University Medical School and Hospital,
Jeonju, Jeonbuk, KOREA, REPUBLIC OF.
Purpose: Predicting lymph node metastasis in gastric
cancer has the crucial role because its possibility to
changing therapeutic method either endoscopic resection
or surgical gastrectomy. Preoperative CT scan has the
limit to evaluate LN metastasis, which depends on size
and shape, anatomically. The purpose of the study is to
evaluate regional LN status by primary gastric tumor
using i ts metabol ic s tandardized uptake value
(SUVmax) in radiologic No gastric cancer. Material
and methods: We retrospectively reviewed 201 patients
which were confirmed as gastric cancer from July 2012
to December 2012. All patients had done preoperative
F-18 FDG PET/CT. Among the various histological gas-
tric tumors, only adenocarcinoma showing FDG uptake
evidently on PET scan is evaluated because of its
accessability to measure metabolism. Among 201 pa-
tients, ninety-three patients (M : F= 61 : 32, age: 60.0
± 12.3 yrs) show no discernible or below 0.6 cm sized
regional LNs in preoperative CT scan, also having no FDG
uptake which was interpreted as N negative. Dividing by two
groups, 37 patients have pathologically confirmed as N posi-
tive and 56 patients have the result of N negative. Statistical
analysis is performed by using student T-test and ROC curves
to compare primary tumor SUVmax between two groups. Re-
sult: The mean values of SUVmax for pathologically con-
firmed as N positive and N negative groups are 7.39±3.4 and
5.77±2.5 each. There is significant difference between the two
groups (P= 0.01). The cut-off value of SUV max in predicting
LN metastasis is above 5.56. The other 69 of 201 patients,
except above 93 patients, presenting FDG uptake in regional
LN show high FDG uptake in primary gastric tumor, mean
SUVmax= 11.91±6.7. Conclusion: The result shows higher
FDG uptake in primary gastric tumor with LN metastasis than
that of without LN metastasis. Furthermore, primary gastric
tumor metabolism is much higher in the group which shows
FDG uptake in regional lymph node. To clarify the correlation
of FDG-avid LN with the other various factors, further studies
should be needed. Predicting LN metastasis by means of mea-
suring primary tumor metabolism could be the ancillary option
to decide therapeutic plans in gastric cancer patients.
PW037
Comparative Analysis of Metabolic Response to Clinical
Outcome in Metastatic Pancreatic Adenocarcinoma
following Modified Dose Folfirinox.
A. Boustani1, V. Patel1, X. Cong2, I. Doddamane1; 1Yale Uni-
versity School of Medicine, New Haven, CT, UNITED
STATES, 2Yale University School of Public Health, New Ha-
ven, CT, UNITED STATES.
Aim: To compare early metabolic response with clinical pro-
gression free survival (PFS) and overall survival (OS) in pa-
tients with metastatic pancreatic adenocarcinoma following
attenuated dose FOLFIRINOX. Methods: Of the 43 patients
enrolled in the study between 11/2011 and 01/2014 29 patients
were evaluated by both baseline and follow-up F18-FDGPET/
CT. Medical reasons and technical issues limited accurate
evaluation by F18 FDG PET/CT. 14 of the patients were ex-
cluded. A baseline PET/CT scan was obtained before treat-
ment. It was followed by a second PET/CT after two cycles
of chemotherapy with modified dose Folfirinox. Based on
SUV max corrected for background, metabolic response of
the lesions was categorized as stable, mild, significant, or as
progression. Using Chi square test, Fisher’s exact test, and
Kaplan-Meier methods, PFS and OS were associated with
PET response. Results: There were a total of 105 primary
and metastatic lesions in 29 patients. 24 patients responded,
3 progressed, and 2 were stable. 5 patients did not respond.
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Clinically, 24 of 29 patients were associated with PET response.
14 of 29 patients had significant response (48%, metabolic
change by >50%). For statistical analysis, patients were also
grouped as responders (83%, metabolic response by >25%)
and non-responders (17%, metabolic response <25%). There
was no association between PFS and OS and overall metabolic
response (0.42 for both). Conclusion: An attenuated dose of
Folfirinox was used for the treatment of metastatic pancreatic
cancer in order to evaluate its efficacy while improving its tol-
erability. There was a high percentage of metabolic response at
follow-up (83%). However, this did not correlate with clinical
outcome. Larger sample sizes are required for further evaluation.
PW038
Role of FDG-PET/CT in predicting response
to neoadjuvant therapy in esophageal cancer. Correlation
with pathological response and survival. Preliminary
study.
J. J. Robles-Barba1, C. Gámez-Cenzano1, J. L. Vercher-
Conejero1, A. Sabaté-Llobera1, M. Cortés-Romera1, L.
Rodríguez-Bel1, L.M. Gràcia-Sánchez1, F.Martínez-Torrens2,
R. Mast-Vilaseca2, M. J. Paules-Villar3, M. Miró-Martín4, A.
M. Boladeras-Inglada5, M. Calvo-Campos6, M. Galán-
Guzmán6; 1PET-CT Unit, Institut de Diagnòstic per la Imatge
(IDI). Bellvitge Hospital., L’Hospitalet de Llobregat, SPAIN,
2Radiología. Bellvitge Hospital., L’Hospitalet de Llobregat,
SPAIN, 3Anatomía Patológica. Bellvitge Hospital.,
L’Hospitalet de Llobregat, SPAIN, 4Cirugía General. Bellvitge
Hospital., L’Hospitalet de Llobregat, SPAIN, 5Oncología
Radioterápica. Institut Català d’Oncologia, L’Hospitalet de
Llobregat, SPAIN, 6Oncología Médica. Institut Català
d’Oncologia, L’Hospitalet de Llobregat, SPAIN.
AIM: To assess the correlation between metabolic re-
sponse with FDG-PET/CT and pathological response in
patients with locally advanced esophageal cancer treated
with neoadjuvant chemoradiotherapy, and to study FDG-
PET parameters for prediction of pathological response
and outcome. MATERIAL AND METHODS: Twenty-
five patients (22 male; age range 45-79 y.o) with locally
advanced esophageal cancer (stage III; 10 squamous cell
and 15 adenocarcinoma) underwent 2 FDG-PET/CT scans
at 2 time points: 1( Initial staging and 2) 4 weeks after
neoadyuvant chemoradiotherapy. FDG uptake in the pri-
mary tumor was calculated in the 2 scans with the follow-
ing parameters: SUVmax, SULpeak and TLG. Metabolic
response was assessed according to the reduction of PET
parameters (%): complete response (mCR=100%), partial
response (mPR≥50%) and no response (≤50%). Patholog-
ical response obtained after surgery, was also classified as
complete (pCR), partial (pPR) or no response (pNR).
Patients were followed up (range 8 - 99 months) determin-
ing free-disease interval (FDI) and overall survival (OS).
RESULTS: Two patients were excluded of our study due
to exitus for non-esophageal related causes. Metabolic re-
sponse was observed in 18 of the 23 remaining patients (3
mCR and 15 mPR), of which 12/18 patients showed path-
ological response (3 pCR and 9 pPR). Major discrepancy
was observed in 2 of PET non-responders patients (5) who
achieved pPR. FDI and OS were apparently longer in pa-
tients with metabolic response than non-responders (18,5
and 28 months vs 12 and 20 months) but no statistical
difference was found in this small group. No significant
correlation was found between PET parameters (including
the % of reduction) and the pathological response, FDI
and OS. CONCLUSION: FDG-PET/CT is a useful tech-
nique to assess response to neoadjuvant chemoradiothera-
py in esophageal cancer. Althoug in this preliminary study
with a small number of patients, no correlation between
metabolic and pathologic response was found and no sta-
tistical differences between responders and non-responders
were observed, a tendency of a longer FDI and OS was
apparently found in responders patients.
PW039
Maximum standardized uptake value on FDG PET is
associated with overall survival in limited-stage small cell
lung cancer
S. Lee1, S. Kwon1, S. Hyun2, Y. Oh1, J. Choi1, K. Park1; 1Ajou
University School ofMedicine, Suwon, KOREA, REPUBLIC
OF, 2Sungkyunkwan University School of Medicine, Seoul,
KOREA, REPUBLIC OF.
Aim: We evaluated the prognost ic value of 18F-
fluorodeoxyglucose positron emission tomography (FDG
PET) parameters for limited-stage small-cell lung cancer
(LS-SCLC). Materials and Methods: We enrolled 59 LS-
SCLC patients who underwent pretreatment FDG PET/CT.
Various PET parameters were measured in all malignant le-
sions, and we recorded the highest maximum standardized
uptake value (SUVmax), and sum of metabolic tumor volume
(MTVsum) and total lesion glycolysis (TLGsum). The relation-
ship between SUVmax and volumetric PET parameters was
evaluated. The prognostic significances of PET parameters
and clinical variables were assessed using Cox’s proportional
hazard regression analysis. Overall survival (OS) and
progression-free survival (PFS) were assessed by the Kaplan-
Meier method. Results: The SUVmax of the highest metabolic
lesion had a significant positive correlation with MTVsum and
TLGsum (P < 0.0001). Upon multivariate analysis, SUVmax
was an independent predictor of OS (HR: 1.133, P = 0.003)
and MTVsum was a significant prognostic factor of PFS after
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adjusting for age, sex, performance status, tumor stage, and
treatment modality. SUVmax tended to be a significant prog-
nostic factor for PFS (HR: 1.078, P = 0.053). Patients with
higher SUVmax (≥11) were also characterized by a significant-
ly shorter median OS (P = 0.0001) and PFS (P = 0.0017)
compared with patients with lower SUVmax. Conclusion:
The highest SUVmax is an independent prognostic factor for
survival in LS-SCLC patients.
PW040
The correlation between 18F-FDG uptake and Glut-1,
Stat-1 and Stat-3 in non-small cell lung cancer patients.
H. Kaida1, K. Azuma2, A. Kawahara2, S. Hattori2, S.
Takamori2, E. Sadashima2, K. Fujimoto2, M. Kage2, S.
Kurata2, Y. Hirose2, K. Ishii1, T. Murakami1, M. Ishibashi3;
1Kinki University Faculty of Medicine, Osakasayama City,
JAPAN, 2Kurume University School of Medicine, Kurume
City, JAPAN, 3Fukuoka Tokushukai Hospital, Kasuga City,
JAPAN.
Aim. The purpose of this study was to assess the cor-
relation between 18F-fluorodeoxyglucose (18F-FDG) up-
take and glucose transporter-1 (Glut-1), signal transducer
and activator of transcription-1 (Stat-1) and Stat-3 ex-
pression in completely surgically resected non-small cell
cancer (NSCLC) patients. Materials and Methods. Our
patients consisted of 52 patients [31 men and 21 wom-
en]. The median age of these patients was 72.5 (range,
42-91) years. The patients with tumors diameter less
than 10 mm and the patients who underwent neoadju-
vant chemotherapy before surgery were excluded from
this study. Histopathologically, there were 38 adenocar-
cinomas and 14 squamous cell carcinomas. The clinical
stages of all patients were as follow: stage IA (n=27),
IB (n=8), IIA (n=7), IIB (n=6) and IIIA (n=4). 18F-
FDG positron emission tomography (PET) was per-
formed, and the maximum standardized uptake value
(SUV max) of primary tumor was measured. Pathologi-
cal tumor size was estimated by measuring the maxi-
mum diameter of the tumor, and pathological TNM stag-
ing was determined after operation. Excised tumor tissue
was analyzed immunohistochemistry using monoclonal
antibodies for Glut-1, Stat-1, and Stat-3. Spearman’s
rank correlation test and Kruskal-Wallis test were per-
formed to assess any association between 18F-FDG up-
take and each histopathlogical or immunohistochemical
factor. Results. The median value of SUV max of pri-
mary tumor was 4.76 (range 0.83-15.39). The median
value of immunohistochemistry staining for Glut-1,
Stat-1 and Stat-3 was 30% (range, 0-80%), 1% (range,
0-15%) and25% (range, 0-70%), respectively. SUV max
positively correlated with Glut-1 expression (r=0.685,
P<0.001) and Stat-1 expression (r=0.295, P=0.03).
SUV max inversely correlated with Stat-3 expression
(r=-0.579, P<0.001). Glut-1 positively correlated with
Stat-1 expression, however, inversely with Stat-3 expres-
sion [r=0.35, P=0.01, Stat-1, r=-0.377, P=0.006]. Patho-
logical tumor size positively correlated with SUV max
(r=0.327, P=0.018) and Glut-1(r=0.54, P<0.001), howev-
er inversely correlated with Stat-3(r=-0.318, P=0.022).
High SUV max tended to be advanced pathological T
stage (P=0.01), pathological lymph node metastasis
(P=0.015) positive and advanced pathological Stage
(P=0.024). Conclusion. Glut-1 expression, Stat-1 and
Stat-3 may be associated with SUV max of primary
tumor. High Glut-1 and Stat-1 expression, low Stat-3
expression and cellularity may be related with high
18F-FDG uptake in NSCLC.
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PW041
Development of a new quantification method using
the I-123 MIBG myocardial single photon emission
tomography
Y. Kamiya1,2, S. Okumiya1, A. Takaki3, K. Yamashita3, S.
Ito1; 1Kumamoto University, Kumamoto, JAPAN, 2Chibana
Clinic, Okinawa, JAPAN, 3Fujifilm RI Pharma Co.,Ltd., To-
kyo, JAPAN.
[Objective]Iodine-123 metaiodobenzylguanidine (123I-MIBG)
myocardial scintigraphy has been used to evaluate cardiac
sympathetic denervation in Lewy body disease (LBD) includ-
ing Parkinson’s disease (PD) and dementia with Lewy bodies
(DLB). The heart-to-mediastinum ratio (H/M) in PD and DLB
is significantly low compared to that in Parkinson’s plus syn-
dromes (PPS) and Alzheimer’s disease (AD). The H/M is use-
ful for distinguishing LBD from AD. However, the distinction
of AD and the PPS is difficult due to narrow H/M range.
Additionally, accuracy of this method is limited, as the H/M
is obtained by a two-dimensional image analysis. Therefore, a
new quantification method using the 123I-MIBG single photon
emission tomography (SPECT) image analysis is required for
clinical routine study in order to guarantee repeatability and
reproducibility. The purpose of this study was to develop a
new quantification method with a simple determining protocol
for 123I-MIBG SPECT uptake measurement.[Materials and
methods]The 123I-MIBG input function was obtained by using
integrated lung washout ratio and the input counts of the
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pulmonary artery (PA). These were obtained by analyzing the
time activity curve of the lung and PA. The 123I-MIBG output
function was obtained by using the 123I-MIBG SPECT counts
on the polar map. The uptake was obtained by dividing the
output function by the input function.Thirty-nine patients
underwent 123I-MIBG SPECT at 15 min after the tracer injec-
tion and clinical features such as Hoehn and Yahr (H-Y) clas-
sification. The H/M and the uptake of 123I-MIBG were calcu-
lated, and correlation with the clinical features was
analyzed.[Result]The H/M of LBD (median 1.75) was signif-
icantly lower than in PPS (median 2.85, p<0.01). The discre-
tion of AD (median 2.65) and PPS (median 2.85) was impos-
sible. The uptake of LBD (median 2.09%) obtained by the new
method was significantly lower than in PPS (median 7.94%,
p<0.01). The uptake ratios of AD (median 5.62%) was signif-
i c a n t l y l o w e r t h a n i n P P S (m e d i a n 7 . 9 4% ,
p<0.05).[Conclusion]The new quantification method was de-
veloped by using 123I-MIBG SPECT and integrated lung
washout ratio and the input counts of the PA. The AD, LBD
and PPS can be clearly distinguished by using this method.
This finding indicates the possibility of clinical routine study.
PW042
Application of Novel Phase Parameters
for Characterisation of Ventricular Mechanical
Dyssynchrony with Radionuclide Ventriculography
K. Jones, N. E. R. Goodfield, J. Robinson, W. Martin, C. A.
Paterson; NHS Greater Glasgow and Clyde, Glasgow, UNIT-
ED KINGDOM.
Aim: Assessment of left ventricular function is known to
be a powerful prognostic indicator of cardiovascular dis-
ease. Synchrony (S), entropy (E) and sample approxi-
mate entropy (SampEn) are novel indices to characterise
dyssynchrony, which have been shown to give additional
independent prognostic information. Synchrony is a
measure of ventricular contraction coherence and entro-
py describes the degree of randomness of ventricle
phase disorder. SampEn is a measure of entropy which
takes into account regional phase similarly of adjacent
pixels. The aim of this study is to establish a normal
range of synchrony, entropy, SampEn, the correlation of
each parameter with ejection fraction (EF) and their abil-
ity to discriminate between normal studies and those
with mechanical dyssynchrony. Methods: 526 clinical
gated planar list-mode RNVG studies were retrospective-
ly re-analysed using in-house software. The studies
analysed consisted of 250 normal studies (QRS < 120
ms, normal myocardial perfusion scan, normal RNVG
scan, normal EF), 164 with myocardial infarction (MI),
112 with left bundle branch block (LBBB). Synchrony,
entropy and SampEn were calculated from phase infor-
mation extracted from the first order Fourier harmonic
fit to the RNVG time-activity curve. Results were
analysed using receiver operating characteristic analysis
(ROC) and area under the ROC curve (AUC) values
were obtained. Results and Conclusion: Synchrony and
entropy values were found to be significantly different
when comparing normals with both MIs and LBBBs (p
< 0.005). SampEn values were significantly different
between normals and MIs but not between normals
and LBBBs (p=0.1). Overall good diagnostic accuracy
was found for detection of MIs based on dyssynchronous ven-
tricular contraction; AUC = 0.79 for S, AUC = 0.86 for E and
AUC = 0.70 for SampEn. Correlation with ejection fraction
was R = 0.67 for S, R = -0.72 for E and R = -0.52 for SampEn.
This study has established the normal range for synchrony,
entropy and SamEn for a large cohort of normal studies and
demonstrated their potential for quantifiable assessment of
ventricular function. Future work will optimise and further
characterise these parameters. The MI group will be further
sub-categorised by size and alternative metrics for mechanical
dyssynchrony will also be assessed.
PW043
Improved scatter correction applying factor analysis
P. Knoll1, M. Ljungberg2, S. MIrzaei1, M. Samal3;
1Wilhelminenspital, VIenna, AUSTRIA, 2Department of
Medical Radiation Physics, Clinical Sciences, Lund Universi-
ty, Lund, SWEDEN, 3Department of Nuclear Medicine, First
Faculty of Medicine, Charles University, Prague, CZECHRE-
PUBLIC.
Aim: Obtaining quantitative data is a crucial task in nuclear med-
icine. In order to achieve this goal the various interactions of
photons with matter have to be observed, modelled and consid-
ered. A problem in gamma camera imaging is the inclusion of
scattered photons within the photopeak energy window used for
acquisition. Many methods for scatter correction have been pro-
posed in the past but in this work we use a novel setup applying
factor analysis (FA).Material and Methods: Monte Carlo sim-
ulations using the SIMIND software package were used to sim-
ulate planar (99m Tc point source, 99m Tc MDP bone) and
tomographic acquisitions. Furthermore a Jaszczak phantom study
and patient 99m Tc MDP bone studies were performed using a
large-field of view gamma camera. In order to use FA for scatter
correction we subdivided the applied energy window in 28 si-
multaneous sub-windows which serves as input data. The
Jaszczak phantom was acquired using General Electric’s Infinia
Hawkeye (acq. parameters: 360° SPECT, 6°/frame, 40 sec./
frame) using the same number of sub-energy windows. The
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tomographic data (simulation and measurement) were processed
for each angular position resulting in a photopeak and a scatter
data set. The reconstructed transaxial slices were quantified using
an ImageJ plugin. Results: FA results in two factor images
(photopeak, scatter) and two factor curves. The data obtained
by factor analysis showed good agreement with the simulated
energy spectra, photopeak and scatter images obtained byMonte
Carlo simulation for all simulated data sets. The cold sphere
contrast of the Jaszczak phantom applying no scatter correction
ranges from -47.67 to -4.75 and with scatter correction applying
FA from - 51.48 to -7.52. The cold sphere sector contrast ranges
from -16.61 to -0.18 for the non-scatter corrected data and for the
FA data from -16.61 to -0.23.Conclusion: Factor analysis can be
used as a user-independent approach for scatter correction for
planar and tomographic imaging.
PW044
Quantification of striatal uptake in DaTscan dopamine
transporter imaging: Effect of systematically reduced
count density on diagnostic accuracy
C. Paterson, J. Robinson, S. Smith,W.Martin; Glasgow Roy-
al Infirmary, Glasgow, UNITED KINGDOM.
Outline and Aims: [123I]-FP-CIT (DaTscan) is a radioligand
developed for the imaging of dopamine transporters with
SPECT. Its use as an in-vivo pre-synaptic imaging agent to
detect degeneration of the dopaminergic nigrostriatal pathway
and to characterize Parkinson’s Disease (PD) has been well
established. Quantification of striatal uptake has the potential
to further increase diagnostic accuracy and reduce the number
of equivocal reports. Increases in numbers of referrals and
difficulties with subject tolerance of long imaging times has
prompted consideration of reducing the administered activity
and/or acquisition time. This study aims to investigate the
effect that simulating a reduction in administered activity has
on the quantification of the striatal specific binding ratio (SBR)
and its diagnostic accuracy. Methods: 85 clinical studies (44
positive for PD based on a surrogate gold standard of previous
clinical interpretation) were retrospectively re-analyzed. Re-
duction in administered activity to 75%, 66%, 50% and 25%
of the original activity was simulated by reducing the number
of counts in every pixel of the raw data projections. A Poisson
noise generator was then used to add an appropriate level of
statistical noise back into each image. Once the data were
transformed to the reduced count densities two experienced
operators independently reconstructed, processed and
analysed each image for calculation of SBR.Results: The
SBR technique for calculation of striatal uptake was found to
have excellent inter-operator reproducibility at all count den-
sities (R > 0.92; Bland-Altman bias < 1.19 and limits of agree-
ment < 1.62) and there was excellent correlation between the
SBR values calculated at the different count densities for both
operators (R > 0.94; Bland-Altman bias < 0.47 and limits of
agreement < 1.92). Furthermore, receiver operating character-
istic analysis (ROC) found no significant change in the area
under the ROC curve (AUC) for each count density (AUC >
0.84).Summary: Overall, the study proves the robustness of
the SBR quantification technique at reduced count densities
both in terms of the diagnostic accuracy of the technique and
the inter-operator variability. This gives confidence that [123I]-
FP-CIT imaging with quantification can be performed with
reduced administered activities (or reduced acquisition times).
Further work will assess how visual clinical assessment of the
images is affected by reduced activity, and whether or not
diagnostic performance at low count densities can be im-
proved through the use of advanced reconstruction algorithms
and machine learning based interpretation.
PW045
Statistical variance in standardised striatal uptake ratio
in [123I]FP-CIT SPECT imaging
A. Niñerola-Baizán1,2, J. Gallego2, A. Cot1,2, F. Lomeña3,4,
D. Ros1,2, J. Pavía1,3; 1Centro de Investigación Biomédica en
Red en Bioingeniería, Biomateriales y Nanomedicina
(CIBER-BBN), Barcelona, SPAIN, 2Unitat de Biofísica i
Bioenginyeria, Facultat de Medicina, Universitat de Barcelo-
na, Barcelona, SPAIN, 3Servicio de Medicina Nuclear, Hospi-
tal Clínic, Barcelona, SPAIN, 4Centro de Investigación
Biomédica en Red de SaludMental (CIBERSAM), Barcelona,
SPAIN.
INTRODUCTION: [123I]FP-CIT SPECT is a widely used tool
for the in vivo evaluation of the dopaminergic system in move-
ment disorders including Parkinson’s disease (PD). To objective-
ly assess striatal dopamine transporter (DaT) binding, a semi-
quantitative analysis including standardisation is recommended.
Standardisation enables us to compare the findings from
multicentre trials and to generate a comprehensive reference da-
tabase. However, uptake quantification and standardisation de-
pend on noise in projections and reconstruction parameters.
AIM: To determine the reconstruction parameters and postfilters
that yield the minimum variance in the standardised results. MA-
TERIALS AND METHODS: [123I]FP-CIT SPECT studies
were simulated by using the SimSET Monte Carlo code. The
activity maps were obtained from 3D T1-weighted MR images
corresponding to 23 subjects free of cerebral abnormalities. The
FIRST segmentation tool from FSL was used to select caudate
and putamen nuclei from MR images. Specific Uptake Ratio
(SUR) values between 1 and 10 for caudate and putamen were
selected. Three million counts in projections were simulated. Re-
construction was performed using OSEM (8 subsets and 1 to 30
iterations) with attenuation correction, PSF correction and an
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ideal scatter correction with only the primary photons in the sim-
ulated projections. Reconstructed images were filtered by using a
set of Gaussian post-filters with FWHM of 0 (i.e. no post-filter),
2, 4, and 6 mm. SUR values were calculated using the MRI
original ROIs. Standardised SUR values were obtained by apply-
ing the inverse of the regression line relating calculated to true
SUR values. The linear regression analysis allowed us to evaluate
the variance of the results by calculating the standard error of the
estimate (SSy) and the Root Mean Square Deviation (RMSD)
between standardised and true values. RESULTS: Small differ-
ences in the minimum RMSD value were found for all post-
filters. Thus, the minimum of RMSD (0.239) was achieved at
13 iterations without post-filter, whereas RMSD was 0.225 at 30
iterations when a post-filter of 6mm FWHM was applied. The
number of iterations diminished to 4 and 8, respectively, if differ-
ences of 5% between actual RMSD and RMSDmin were con-
sidered. The SSy value at 8 and 30 iterations with the 6mm
FWHMpost-filter was 0.238 and 0.226, respectively. CONCLU-
SIONS: Monte Carlo simulation allowed us to estimate the var-
iance in standardised striatal uptake ratio due to methodology. A
minimum RMSD of 0.225 and a SSy of 0.226 should be consid-
ered as the methodological error to be complemented with that
caused by the physiological variability.
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Is a system calibration requiredwhen using a I123-FP-CIT
Normal Database?
J. C. Dickson1, L. Tossici-Bolt2, K. Tatsch3; 1University Col-
lege London Hospital NHS Foundation Trust, London, UNIT-
ED KINGDOM, 2University Hospital Southampton NHS
Foundation Trust, Southampton, UNITED KINGDOM,
3EANM EARL ENCDAT Imaging Consortium, Vienna,
AUSTRIA.
Introduction: Normal databases offer the potential of improv-
ing the diagnostic performance of imaging tests such as I123-
FP-CIT. It has been suggested to make best use of an I123-FP-
CIT database; there should be a reference calibration of a sys-
tem to allow normal range values to be tailored to that partic-
ular system. This paper studies the diagnostic performance of a
normal database with and without this reference calibration,
and also assesses the possibility of replacing a bespoke cali-
bration with an existing calibration for the same system type.
Methods: The ENCDAT normal database was reconstructed
using iterative reconstruction with corrections for attenuation
and scatter as per the ENCDAT protocol [1]. Once reconstruct-
ed age dependent normal ranges of quantitative uptake were
derived for a GE Infinia system on which 44 patient studies
with three year follow-up information had been acquired. Nor-
mal ranges were defined using (1) a bespoke calibration of the
system (BES), (2) an existing library calibration of the same
system type (LIB), (3) no calibration for the imaging system
(NO). Using three-year follow-up information as the gold-
standard diagnosis, sensitivity and specificity of the different
calibration strategies were calculated using striatal uptake as
the diagnostic marker, and using putaminal uptake as the di-
agnostic marker. Results: With striatal uptake as a diagnostic
marker there was no significant difference in sensitivity across
the three strategies 85.7% (BES & LIB), 76.2% (NO). There
was also no significant difference in specificity 87.0% (BES&
NO), 78.2% (LIB). Similarly, when putaminal uptake was
used as a diagnostic marker, there was no significant different
between calibration strategies. Sensitivity was 85.7% (BES &
NO), 90.5% (LIB), and specificity 82.6% (BES), 78.3% (LIB),
and 87.0% (NO). Conclusions: In our single-site sample of 44
patients there was no diagnostic advantage to be gained from
calibrating the system with either a bespoke or library calibra-
tion. References: [1] Varrone A et al. European multicentre
database of healthy controls for [(123I]FP-CIT SPECT
(ENC-DAT): age related effects, gender differences and eval-
uation of different methods of analysis. Eur J Nucl Med Mol
Imaging. 2013 Jan;40(2):213-27
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The effect of different reconstructions algorithms
on the diagnostic performance of a 123-FP-CIT SPECT
database
J. C. Dickson1, L. Tossici-Bolt2, K. Tatsch3; 1University Col-
lege London Hospital NHS Foundation Trust, London, UNIT-
ED KINGDOM, 2University Hospital Southampton NHS
Foundation Trust, Southampton, UNITED KINGDOM,
3EANM EARL ENCDAT Imaging Consortium, Vienna,
AUSTRIA.
Introduction: The use of quantitative information from healthy
control databases offers an improvement in the diagnostic per-
formance of imaging tests such as I123-FP-CIT SPECT. How-
ever, it is not known how the use of different SPECT recon-
structions affects the performance of these databases. The aim
of this study was to explore this issue.Methods: The ENCDAT
normal database [1] and patient data from 77 patients from two
different centres and with three-year follow-up information
were used in this study. All data was reconstructed using iter-
ative reconstruction with corrections for attenuation and scat-
ter (IRACSC), without corrections (IRNC), and with filtered
back projection (FBP). Quantitative normal ranges using Her-
mes BRASS were set using the database for these reconstruc-
tions, with patient data normality assessed quantitatively on a
striatal and putaminal level. Using clinical follow-up as our
gold standard, sensitivity/specificity and ROC analysis were
performed to assess the diagnostic accuracy of databases re-
constructed in different ways. Results: Using striatal uptake as
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a diagnostic marker, sensitivity was similar for different recon-
structions at 83.7% (ACSC), 81.4% (IRNC) and 81.0% (FBP).
Similarly specificity was not significantly different 85.3%
(ACSC), 82.4% (IRNC) and 77.14% (FBP). ROC analysis
confirmed that there was no significant difference in the diag-
nostic performance of the different reconstructions with AUC
if 0.898 (ACSC), 0.913 (IRNC), and 0.880 (FBP). There were
similar findings when putaminal uptake was used as a diag-
nostic marker with sensitivities of 81.4% (ACSC), 78.6%
(IRNC), and 78.6% (FBP) and specificities of 82.4% (ACSC),
85.7% (IRNC), and 77.1% (FBP). ROC analysis derived AUC
were 0.907 (ACSC), 0.917 (IRNC), and 0.893 (FBP). Conclu-
sions: In our sample of 77 patients we found no significant
difference in the diagnostic performance of a normal database
using different reconstruction algorithms. References: [1]
Varrone A et al. European multicentre database of healthy
controls for [(123I]FP-CIT SPECT (ENC-DAT): age related
effects, gender differences and evaluation of different methods
of analysis . Eur J Nucl Med Mol Imaging. 2013
Jan;40(2):213-27
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Investigation of the Factors Affecting Quantification
of Heterogeneity derived from PET Images of the Torso
NEMA Phantom
M. Tamal, C. Robinson, D. Clarke, J. Anton-Rodriguez, D.
Morris, A. Jackson, M. Asselin; The University of Manches-
ter, UK, Manchester, UNITED KINGDOM.
Introduction: Radiotracer tumour uptake is often heteroge-
neous and quantification of heterogeneity has the potential to
be used as a biomarker of prognosis. Textural features account-
ing for both spatial and intensity information have recently
been applied to FDG-PET images and used to predict treat-
ment response[1]. However, textural features have been pre-
dicted to strongly depend on volume using simulated data[2]
and confirmed on clinical data[2],[3]. Other factors affecting
textural features such as segmentation and quantization have
previously been investigated on clinical data where the actual
tumour volume is unknown[4] while image contrast and noise
have not been assessed systematically. This study aims to in-
vestigate the relationships between textural features and these
factors using phantom data.Methods: The torso NEMA phan-
tom was filled with 18F solutions to yield different contrasts
between the six hot spheres (0.5-27ml) and the colder uniform
background (2:1, 4:1, 8:1) and scanned on the TrueV PET-CT
scanner for 120min. Images were reconstructed using OSEM
(4 iterations, 21 subsets) for different scan durations (15-
120min) and smoothed with a 4-mm Gaussian filter. Spheres
were first delineated at the exact boundaries based on their
known diameters and secondly using a 40% fixed threshold.
Textural features were derived from the co-occurrence matrix
using different quantization levels (8-256).Results: Some tex-
tural features (contrast, dissimilarity, entropy, correlation) in-
crease while others (homogeneity, energy) decrease with quan-
tization at different rates depending on sphere volume. When
using the exact delineation, contrast and scan duration (noise)
have a lesser effect on textural features than sphere volume.
When applying the same exact regions on the uniform back-
ground (no partial volume), the relationships between textural
features and volume are comparable to when applied to the
respective spheres except for correlation. On images with very
low noise (120min) and high contrast (8:1), thresholded re-
gions underestimate sphere volumes >5ml by ≈10% and thus
yield textural features similar to those using the exact delinea-
tion. However, because larger thresholded regions are seg-
mented as contrast is lowered, textural features become con-
trast dependent when using a fixed threshold.Conclusion: Ho-
mogeneous regions appear heterogeneous on PET images as
quantified by textural features. Since textural features differ-
entially vary with volume, regions should be segmented using
methods that are robust to variations in contrast and noise and
their volume reported.References:[1]Chicklore S. et al (2013)
Eur.J.Nucl.Med.Mol.Imaging 40(1):133-40[2]Brooks F.J.,
Grigsby P.W. (2015) PLoS One 10(2):e0116574[3]Hatt M.
et al (2015) J.Nucl.Med. 56(1):38-44[4]Orlhac F. et al (2014)
J.Nucl.Med. 55(3):414-22
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Quantification Challenges in Dual-Time PET Scans
T. Nguyen, S. B. Christlieb, P. F. Hoeilund-Carlsen; Dept. of
Nuclear Medicine, Odense University Hospital, Odense,
DENMARK.
Aim: Dual-time PET to detect temporal changes in a
lesion depends on a reliable comparison of region-of-
interests (ROIs) between time points. Commercial soft-
ware tools like ROVER (ABX, Radeberg, Germany)
require the user to encircle the analysis area with a
mask, based on which a background corrected peak-
based threshold is estimated for subsequent ROI
(lesion) segmentation within the mask. The reliance on
mask placement can thus introduce observer and seg-
mentation variability, especially in heterogeneous tissue.
If the same mask is used, mask-related variation be-
tween scans is minimized, but requires that the scans
are spatially aligned. Hence, inevitable inter-scan patient
movement necessitates image alignment procedures that
use mathematical interpolation of image intensities to
transform one image to spatially match another with
the risk of altering the PET data. We evaluated these
aspects for lymphoma assessment. Materials and
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Methods: Dual-time (1h - 3h) FDG-PET scans of 14
patients (seven with malignancy, seven benign) were
analyzed retrospectively. The ROVER software was
used for ROI detection with background corrected glob-
al lesion-based (LT) and local voxel-based (VT) thresh-
olds and rigid (translation/rotation operations only) im-
age volume alignment. ROI detection to yield ROI
values of SUVmax, SUVmean, and metabolically active
volume (MAV) was performed in two analyses: 1) Sep-
arate masks and segmentations of lesions (lymph
node/conglomerate) in the 1h and 3h scans. 2) Same
1h mask also used for segmentation on the 3h scan
after rigid alignment of the 3h scan to the 1h scan.
Results: With separate masks, SUVmax in the 1h (mean
± sd: 18.2 ± 10.4) and 3h scans (23 ± 12.9) was
reproducible, but SUVmean and MAV varied between
LT and VT methods. Here, all three measures showed
intra-observer variation ≦ 18%. In the 3h scans, align-
ment procedures resulted in consistently significant
changes in SUVmax (8.6% -21.8%) and SUVmean (LT:
6.9%-23.4%, VT: 4.7%-44.4%) and variably significant
MAV increases (LT: 0.2%-60%, VT: 5.4%-71.3%).
Measured with separate masks, SUVmax and SUVmean
generally increase significantly between scans (p <
0.001), but this increase is reduced (p = 0.03-0.11)
when measured on the aligned scans using the same
mask. Conclusion: Opting for separate masks for dual-
time analysis, the observed test-retest variability and
dependence on segmentation method entails doubly bi-
ased measurements that can affect temporal comparabil-
ity. Using the same mask on both scans after alignment
of the scans introduces unreliable scan transformation-
induced measurement changes. Thus, a better analysis
technique to ensure comparability is needed.
PW050
The clinical application of absolute quantification SUV
SPECT 99mTc-MIBI myocardial perfusion imaging
to translate myocardial viability
W. He, W. Yu, W. Zhai, J. Xi; Huadong Hospital, Shanghai,
CHINA.
Objectives: To investigate the relation of SUV values
between 99mTc-MIBI and PET/CT in cardac imaging
to evaluate myocardial viability. Materials and Methods:
32 consecutive patients with previous MI and left ven-
tricular (LV) dysfunction (35±6%), mean±SD, who
underwent 99mTc-MIBI SPECT and FDG PET/CT. Re-
sults of the two studies were divided into two types :
myocardial perfusion match (group 1 MM) and myocar-
dial perfusion mismatch (group 2 M ). The SPECT/CT
images were acquired using the standard clinical acqui-
sition protocol (1800 scan arc, 64 frames in step-and-
shoot mode, 25s per frame). The raw projection data
was r econs t r uc t ed us ing the so f twa r e ‘SUV-
SPECT™’(HERMES MEDICAL SOLUTIONS). The re-
construction parameters were set to 16 subsets and 5
iterations. Corrections were applied for CT attenuation
correction, Monte Carlo-modeled scatter correction, res-
olution recovery, scaling for injected dose and radioac-
tive decay. The units of counts-per-voxel were scaled to
activity per unit volume (Bq/cc) based on previously
performed phantom calibration work to allow for SUV
measurements and scaling of different myocardial seg-
ments and compare with FGD PET/CT SUV. Results :
23 patients were mismatch , while 9 match . The value
of SUV 99mTc-MIBI myocardial perfusion was Inferior
( 4.1±0.3), septum (2.8±0.4), anterior (4.3±0.3) lateral
(3.9±0.2),apex 2.3±0.1) , SUV in 30 Mismatch segments
between SPECT/CT and PET/CT was no statistical dif-
ference , but SUV in 32 match segments was 20% to 55
%difference , which has signicant difference statistically.
Conclusions : Absolute quantification SUV SPECT
99mTc-MIBI myocardial perfusion imaging can be a
translator to evaluate myocardial viability , The multi
center study planned to be built up to explore SUV
cut off in 99mTc-MIBI myocardial perfusion imaging
to evaluate viable myocardium.
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One Pot Al18F Radiofluorination
of GLU-UREA-LYS(AHX)-HBED-CC PSMA Ligand.
S. Boschi1, F. Lodi1, G. Cicoria2, M. Marengo2, S. Fanti1;
1Nuclear Medicine, Bologna University Hospital, Bologna,
ITALY, 2Medical Physics, Bologna University Hospital, Bolo-
gna, ITALY.
Aim: Prostate cancer (PC) is the most commonly diagnosed
cancer and the second leading cause of cancer death in men.
Among PET radiopharmaceuticals 11C-choline and 18F-
Fluorocholine have been proposed for the diagnosis, staging
and restaging of PC although specificity and sensitivity of
these tracers are not ideal. Recently 68Ga-labelled-PSMA li-
gands have been shown excellent results in detecting PC re-
currence and metastases with high sensitivity and specificity. It
is also well known that Fluorine-18 is the most popular and
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attractive radionuclide for PET because of half-life and imaging
characteristics; fluorinated tracers usually allow a higher patient
throughput and the possibility of distribution of radiopharma-
ceutical to different users. Aim of this study was to label with
Fluorine-18, via Al18F approach, the ligand Glu-Urea-
Lys-(Ahx)-HBED-CC, which has been demonstrated to be of
diagnostic value when labelled with Gallium-68. Results: Op-
timal condition for labelling Glu-Urea-Lys-(Ahx)-HBED-CC
with Fluorine-18 using Al18F chemistry, in aqueous/ethanolic
solution was investigated. The effect of ethanol concentration,
reaction temperature, peptide amount on the labelling with
Al18F as well as the effect of pH on the stability of the final
product were studied. 100 μL (200-300 MBq) of 18F-fluoride
in Acetate buffer 0.5M, 30 nanomoles of AlCl3 and increasing
ethanol amount (30-180 μL) has been used. As demonstrated
for other trivalent radiometals like 68Ga, the effect of increas-
ing concentration of ethanol in the reaction mixture was to
markedly increase the radiochemical yield (RCY). Increasing
in RCY allowed a decrease in peptide concentration and in
reaction temperature (30% of RCY with 90 μg of peptide at
100°C without ethanol compared to >90% labelling with 30μL
of ethanol at 50°C). Increasing ethanol amount from 30μL to
180μL in the reaction mixture led to >90%RCYat 50°C using
20 μg (21 nanomoles) of peptide. The labelled compound was
further purified on SepPak C18 light cartridge, was stable for 3
hours in buffer pH 6.8 but not in saline. Two molecular forms
(presumably diastereoisomers) were found, in agreement with
Gallium-68 labelling data. Conclusion: These data demon-
strates the feasibility of Al18F labelling of Glu-Urea-
Lys-(Ahx)-HBED-CC. Radiofluorination of Glu-Urea-
Lys-(Ahx)-HBED-CC was successfully obtained using the de-
scribed method. The use of ethanol facilitates an efficient
radiolabeling and could represent an important step toward
the kit-type synthesis. Nevertheless, since automation of the
synthesis is mandatory for radioprotection as well as for quality
assurance issues, studies are in progress to transfer the synthesis
on a fully automated cassette module.
PW052
We can do it without! Synthesis of F-18-labeled aromatic
compounds without azeotropic drying, base and other
additives
R. Richarz1,2, P. Krapf1,2, F. Zarrad1,3, B. D. Zlatopolskiy1,2,
E. A. Urusova1, B. Neumaier1,3,2; 1Institute for Radiochemis-
try and Experimental Molecular Imaging, Cologne, GERMA-
NY, 2Max Planck Institute for Metabolic Research, Cologne,
GERMANY, 3Forschungszentrum Jülich INM-5 Short-lived
radionuclides for life sciences, Jülich, GERMANY.
Aim: The classic 18F labeling method via azeotropic drying of
an aqueous [18F]KF/cryptand system is time-consuming and
error-prone. Furthermore, owing to highly basic raction con-
ditions, base-sensitive precursors cannot be used. Published
alternative labeling strategies of aromatic systems without
azeotropic drying step are limitedly suitable for preparation
of clinically relevant doses of PET-tracers. The aim of this
work was to develop a novel radiolabeling approach using
only onium precursors and [18F]fluoride. Methodology: [18F]
fluoride is eluted from an anion exchange catridge with a so-
lution of the appropriate onium precursor in different alcohols.
After evaporation of the alcohol, a suitable solvent was added
to the remaining onium (trimethylanilinium, diaryl iodonium
or triarylsuilfonium, [18F] fluoride) and the resulting solution
was heated to provide the corresponding 18F-labeled product.
Results: Elution of 18F- with MeOH and EtOH solution of
onium salt precursors proceeded almost quantitatively. Low-
boiling MeOH colud be completely removed at 70 °C within
2-3 min. 2-, 3- and 4-[18F]FBAwere prepared in RCCs of 38-
94% from the corresponding onium precursors. 28 GBq of
4-[18F]FBAwas prepared from 32 GBq [18F] fluoride in high
radiochemical purity (>98%) within 15 min. Different useful
radiolabeling synthons, such as 4-[18F]fluoroiodobenzene, the
S F B a n a l o g u e 2 , 3 , 5 , 6 - t e t r a f l u o r o p h e n y l
4-[18F]fluorobenzoate as well as the model peptide 4-
[18F]fluorobenzoyl-βAla-Phe-OMe were produced from the
corresponding sulfonium, anilinium and iodonium salt precur-
sors in good RCCs in a single step. Conclusion: The minimal-
ist 18F labeling strategy is a completely new approach to the
synthesis of various 18F labeled compounds avoiding
azeotropic drying as well as application of base and any other
additives. The broad applicability of the novel procedure was
demonstrated through the successful production of several
useful radiolabeling synthons, as well as the one-step synthesis
of a radiofluorinated model peptide. It was found, that MeOH
and EtOH solutions yielded nearly quantitative [18F] fluoride
elution.
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Microscale Radiolabelling of Antibodies
with Zirconium-89 for Positron Emission Tomography
J. C. Knight1, S. J. Paisey2, C. Marshall2, B. Cornelissen1;
1University of Oxford, Oxford, UNITED KINGDOM, 2Car-
diff University, Cardiff, UNITED KINGDOM.
Aim: Over the last decade, several antibodies have been
labelled with the radioisotope zirconium-89 (89Zr) for
positron emission tomography (PET) studies. The radio-
chemical properties of zirconium-89 (particularly its ra-
dioactive half-life [t1/2 = 3.2 days]) make it well-suited
to antibody imaging and 89Zr-labelled antibodies have
been used successfully in clinical settings as tools for
early detection and characterisation of certain cancers,
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and as companion diagnostics during therapy. The most
widely cited method for desferrioxamine (DFO)-conjuga-
tion and radiolabelling of antibodies with 89Zr requires
multi-milligram (2-10 mg) quantities of protein in order
to achieve adequate radiolabelling yields (>85%). During
the research and development process, obtaining anti-
bodies in such quantities can be cost-prohibitive when
the antibody has to be sourced from a commercial sup-
plier. This can also be a hindrance when the availability
of the antibody in question is limited. To circumvent
this limitation in the current method and aid in the pre-
clinical evaluation of 89Zr-labelled antibodies, we
sought to develop an 89Zr-radiolabelling procedure that
would provide high radiochemical yields at the micro-
s c a l e . Ma t e r i a l s a n d Me t h od s : To c i l i z umab
(RoActemra®) (200-500 μg) was modified with a 10-
fold molar excess of p-SCN-Bn-DFO and prepared at a
concentration of 2 mg/mL in phosphate buffered saline
(pH 7.4). Zirconium-89 in 1 M oxalic acid was adjusted
to pH 7-8 by the addition of 1 M sodium carbonate and
the resul t ing solut ion was added to the DFO-
Tocilizumab solution to achieve a ratio of 0.1 MBq to
1 microgram of antibody. The reaction mixtures were
incubated at room temperature for 1 h and the radio-
chemical yield was determined by iTLC using an eluent
of 50 mM DTPA (pH 7). The reaction was performed
using decreasing amounts of antibody in the range 100
to 10 μg. Results: Radiochemical yields of 96±4%, 80
±11%, 68±27%, 71±16%, and 63±18% were obtained
using 100, 75, 50, 25, and 10 μg of DFO-Tocilizumab,
respectively. Conclusions: The reported method results
in excellent radiochemical yields using 100 μg of
DFO-antibody which compares very favourably with
other methods in the literature. Using even smaller
amounts of antibody provided lower, albeit still adequate
radiochemical yields for preclinical research applications.
Furthermore, this approach does not require access to
specialised equipment and can be readily implemented
in research facilities with minimal radiochemistry infra-
structure. Research support: This work received financial
support from Cancer Research UK.
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Direct production of 99mTc with a cyclotron
M. Aboudzadeh Rovais; Nuclear Science and Technology
Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.
Introduction: Technetium-99m (99mTc) is commonly ob-
tained from 99Mo/99mTc generators. Recent shortages
of 99Mo have led to an examination of alternative pro-
duction methods that could contribute to a more robust
supply. A cyclotron has been used to produce 99mTc.
Production conditions such as beam and target charac-
teristics and purification need to be optimized in order
to maximize the amount of 99mTc and minimize impu-
rities. The focus of this manuscript is on the cyclotron
production of 99mTc. Method: The cross section calcu-
lations and proton project rangewere performed using
the computer codes Talys-1.6 and SRIM, respectively.
99mTc was produced with newly designed and
manufactured shuttle and canister target system. Essen-
tial target thickness and production yield were calculat-
ed. The 100Mo target was irradiated with 19 MeV pro-
tons for 1h at up to 50 μA. Solvent extraction method
using MEK/NaOH system followed by an acidic alumina
column chromatography was employed for the radio-
chemical separation and purifications. Results and dis-
cussion: A simple and quick procedure has been pro-
posed and assessed for the 99mTc production with a
cyclotron. Thick target calculations suggested that a
large quantity of cyclotron-produced 99mTc via
100Mo(p,2n) reaction is possible. Integration of the ex-
citation function for protons degraded from 19→9 MeV
using 100% isotopic enriched 100Mo suggests the max-
imum production yield of 377 MBq•μA-1•h-1. The av-
erage production yield was measured to be 356
MBq•μA-1•h-1. In comparison, the practical yield ob-
tained in this work is very close to the calculated yield.
The 99mTc obtained by the combined solvent extraction
and alumina column chromatography had good quality
in terms of radionuclidic, radiochemical and chemical
purity. It has been shown that the QC parameters were
within the USP specifications. Keywords: Cyclotron •
99mTc production • targetry • simulation.
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Determination of nickel in 64Cu-ATSM preparations:
development and validation of a colorimetric method
as impurity limit test
S. Costa, C. De Nicolo, G. Cicoria, C. Malizia, S. Fanti, F.
Lodi; S.Orsola-Malpighi University Hospital, Bologna, ITA-
LY.
Aim. 64CuATSM is a radio-pharmaceutical used for revealing
hypoxic areas and predict treatment efficacy. 64Cu is produced
by (p,n) reaction on metallic 64Ni. The synthesis is performed
by means of a complete automatic module that allow to purify
the 64Cu from enriched 64Ni. Due to the high amount of the
target material (120 mg), traces of nickel could be found in the
final formulation. Quality parameters defined in European
Pharmacopoeia include Nickel maximum concentration that
should not exceed 25 μg in the maximum injectable volume.
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S305
A fast colorimetric method was developed and validated as
impurity limit assay. Materials and Methods. In this method
a sample containing an unknown amount of nickel, and a
reference standard containing 5 μg/ mL of nickel are diluted
1:20. After that they are both treated with a solution containing
I-/I2 in order to oxidize Ni
n+ to Ni4+ and then pH is bring up to
10 - 12 with a NH3 watering solution. A dimethylglyoxime
solution is added and Ni4+ forms a red-brown soluble complex
with dimethylglyoxime (stoichiometry 1:1). The standard and
the sample solutions are then compared. A commercial color-
imetric kit for nickel quantification in water substrates was
used as starting point; the reference method was the inductive-
ly coupled plasma mass spectrometry (ICP-MS). Specificity
and limit of detection were determined according to the
ICH Q2 guidelines: interferences of the whole matrix
(ethanol 10%v/v, NaCl 0.9% w/v in ultra pure water)
and the matrix single components at different concentra-
tions were evaluated; interference of copper ions at dif-
ferent concentrations was also investigated. The lower
detectable concentration was experimentally determined.
Results. Matrix does not interfere with the test, while
copper does at concentration higher than 0.75 mg/L.
The assay limit of detection in our experimental condi-
tions was 0.04 mg/L. The nickel limit test was then
successfully applied to four different 64Cu-ATSM
batches. The results were in accordance with those
found with ICP-MS. Conclusions. The colorimetric nick-
el limit test is faster and cheaper than other methods
(i.e. ICP-MS) and can be well applied to the Quality
Control determination of Ni in 64CuATSM preparations.
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Synthesis of 68Ga Radiopharmaceuticals for Cell
Radiolabelling Using Anion Exchange Column
A. Socan1, P. Kolenc Peitl1, M. Kroselj1, C. Rangger2, C.
Decristoforo2; 1University Medical Centre Ljubljana, Ljublja-
na, SLOVENIA, 2University Clinic for Nuclear Medicine,
University for Medicine, Innsbruck, AUSTRIA.
AIM: 68Ga labelled radiopharmaceuticals are gaining increas-
ing importance in the field of PET nuclear medicine imaging,
due to availability of several synthesis modules and
68Ge/68Ga generators on the market enabling users to pro-
duce radiopharmaceuticals according to current pharmaceuti-
cal standards. Studies showed that although the half life of
68Ga is a limiting factor, 68Ga radiolabelled cells could be
used in certain clinical indications. The aim of our study was
to develop a novel, versatile approach to prepare 68Ga radio-
pharmaceuticals (oxine, tropolone) for cell labelling using
concentration of 68Ga on an anion exchange column (SepPAK
QME). MATERIALS: Column was washed with 2 ml of
water. Samples of 68Ga-acetate (Na-acetate, 155mg/ml), -
HEPES (1M HEPES) and -citrate (0,1M Na-citrate, pH 5)
solutions, samples varying in pH (4-7) and volume, were pre-
pared and applied on column. Activity retained on, activity
washed from column and pH of solution was measured. Sam-
ple of 0,3 ml ligand solution (tropolone:1mg/ml, water;
oxine:1mg/ml, 20% ethanol) was applied on column and in-
cubated for 10 minutes. Column content was washed from
column with 2 ml of PBS. Activity and pH measurements
were performed as described above. 68Ga-complex forma-
tions were analyzed using extraction method into octanol. RE-
SULTS: Yield of activity retained on columnwith 68Ga-citrate
varied 17-96% and was pH and volume dependent. Yield de-
creased with volumes applied greater than 2 ml and pH bellow
4,5. Yield of 68Ga-tropolone solution was above 75%with pH
between 4,4-5 and extraction into octanol above 89%. Yield of
68Ga-oxine solution was between 27-83%with pH between 5,
2-6,7 and extraction into octanol above 94%. With 68Ga-
acetate yield of activity retained on column was above 95%
and was not pH (3,8-5,9) and volume dependent (0,5-6ml).
Yield of 68Ga-tropolone solution was above 81% with pH
between 5,4-6,8 and extraction into octanol abobe 90%. Yield
of 68Ga-oxine solution was between 40-65% with pH be-
tween 4,8-6,3 and extraction into octanol above 92.2%.
68Ga-HEPES yield of activity retained on column was above
89% and was not pH (3,7-7,3) and volume dependent (0,5-2,
5ml). Yield of 68Ga-oxine solution was between 43-77%with
pH between 6,1-7,4 and extraction into octanol above 96%.
CONCLUSIONS: Concentration of 68Ga in various buffer
systems on an anion exchange column allows on-column for-
mation of lipophilic complexes (oxine, tropolone) in very
small volumes suitable for cell labelling with high yields and
quality. This is a versatile and promising tool to prepare 68Ga-
precursors for cell labelling potentially suitable for automated
systems.
PW057
A real-time in vitro assay as a potential predictor of in vivo
tumour imaging properties
D. Spiegelberg1, J. Stenberg1, A. Haylock2, M. Nestor1,2;
1Department of Immunology, Genetics & Pathology, Uppsala,
SWEDEN, 2Unit of Otolaryngology and Head & Neck Sur-
gery, Department of Surgical Sciences, Uppsala, SWEDEN.
Aim: Predicting in vivo tumour binding properties of molecu-
lar imaging agents with reliable in vitro assays is a useful
approach to increase preclinical knowledge and limit the use
of laboratory animals. To our knowledge, no in vitro analysis
methods have yet been established to accurately estimate the
performance of radiolabelled binders in tumour xenografts.
AbD15179 is a promising antibody fragment for molecular
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imaging of CD44v6, a non-internal is ing ant igen
overexpressed in head- and neck carcinomas. In this study,
we investigated if real-time in vitro kinetics of AbD15179
receptor binding on CD44v6-expressing tumour cells could
be used to predict aspects of the in vivo tumour imaging prop-
erties. Materials and Methods: Antibody fragment (Fab)
Abd15179 was either labelled with 125I using Chloramine T
or with 111In using CHX-A”-DTPA. Interactions of labelled
fragments with receptors in vitro were measured over time on
high- (A431) and intermediate (H314) CD44v6 expressing
tumour cells with LigandTracer. Using a dual isotope ap-
proach, the same batch of 111In- or 125I labelled Fab conjugates
were injected in twenty mice bearing both A431 and H314
tumour xenografts. Tumour uptake as well as sensitivity and
specificity of conjugates could then be measured while elimi-
nating inter-subject variability. Simultaneous characterisation
of the same conjugates in vitro and in vivo reduced potential
bias from batch variability and specific activity. Results: Bind-
ing of radiolabelled AbD15179 to cells in vitro mainly
consisted of two interactions: one high-affinity binding event
with slower dissociation and one low-affinity binding event
with faster dissociation. The proportion of high-affinity
binders was considerably higher for 111In-Fab than for 125I-
Fab, leading to a slower release of 111In-Fab than 125I-Fab
from tumour cells. Clear differences in signal intensity for
111In-Fab binding were present between CD44v6 high-
(A431) and moderate (H314) expressing cells. In contrast, no
differences between the two cell lines could be seen for 125I-
Fab. In accordance with in vitro results, 111In-labeled frag-
ments dissociated slower from tumours compared to 125I-Fab
and also made it possible to distinguish between A431 and
H314 xenografts in vivo. Conclusion: Interaction properties
in vitro correlated strongly with in vivo conjugate binding for
CD44v6-targeting Fabs. Thus, time-resolved experiments on
living cells could in this case adequately predict the perfor-
mance of radiolabelled binders onmouse xenografts. If proven
general, this finding may lead to a reduction of laboratory
animal use in future development of tumor targeting
compounds.
PW058
44Sc- and 177Lu-labeling of DKFZ-617 for dosimetry
and therapy of prostate cancer
E. Eppard1, A. de la Fuente2, S. Kuerpig1, F. Roesch2, M.
Essler1; 1University Hospital Bonn, Bonn, GERMANY,
2Johannes Gutenberg-University, Mainz, GERMANY.
OBJECTIVES: Radiolabeling of the prostate-specific mem-
brane antigen (PSMA) inhibitor, Glu-NH-CO-NH-Lys
(Ahx), using DOTA as chelator, a broad pool of radionuclides
becomes available for labeling. These possible variations
allow the visualization of the biological behavior over differ-
ent periods of time depending on the half-life of the used
radionuclide (68Ga t1/2 = 68 min; 44Sc t1/2= 3.9 h). Addi-
tionally, the usage of different imaging modalities or
endoradiotherapies can be applied depending on the employed
radionuclide. METHODS: DKFZ-PSMA-617 was obtained
from ABX (Radeberg, Germany). 44Sc was obtained from a
44Ti/44Sc generator in Mainz, where 44Ti decays with a half-
life of 60 d to no-carrier-added (n.c.a) 44Sc. Radiolabeling
with 44Sc was performed in 3 mL 0.25 M ammonium acetate
buffer with varying amount of ligand at 95°C. 177Lu was
obtained from IDB Holland and labeling was performed in a
gentisinic acid/sodium ascorbate solutionwith varying amount
of ligand at 95°C. Purification (if needed) was performed
using C-18 cartridges for both compounds. Quality control
was performed using radioHPLC and radioTLC. Stability
studies were performed at 37°C in different media (human
serum, NaCl) over one half-live. RESULTS: 44Sc-DKFZ-
PSMA-617 and 177Lu-DKFZ-PSMA-617 were effectively la-
beled at 95 °C. Subsequent cartridge-based solid-phase-
extraction (C-18) resulting in a radiochemical purity of the
final tracers of ≥98% can be applied for both compounds.
Stability studies in different media (human serum, NaCl etc.)
were successfully performed and both compounds showed
high stability over a period of one half-live or longer. Radio-
chemical purity could be analyzed effectively using
radioHPLC and radioTLC. 177Lu-DKFZ-PSMA-617 is uti-
lized using the optimized labeling protocol for patient treat-
ment since November 2014. CONCLUSIONS: The
radiolabeling of DKFZ-PSMA-617 with the new generator-
derived PET radionuclide 44Sc was investigated in detail.
44Sc-DOTA-PSMAwas investigated in vitro. Further investi-
gations including cell studies, biodistribution and small animal
μPET are planned. Also radiolabeling of 177Lu-DKFZ-
PSMA-617 was optimized with regard to therapeutic applica-
tion and successfully integrated in clinical routine.
PW059
Development of [18F]Fluoro-sugar based prosthetic
groups for the PET imaging of radiolabel peptides
C. Collet1,2, F. Maskali1, S. Poussier1,2, A. Mohamadi3,2, V.
Regnault3,2, P. Lacolley3,2, Y. Chapleur1,2,4, P. Marie1,2,3, G.
Karcher1,2, S. Lamandé-Langle4,2; 1Nancyclotep, Vandoeuvre
les Nancy, FRANCE, 2Université de Lorraine, Vandoeuvre les
Nancy, FRANCE, 3Inserm UMR 1116, Vandoeuvre les Nan-
cy, FRANCE, 4UMR 7565, Vandoeuvre les Nancy, FRANCE.
Introduction: The direct 18F-labelling of biomolecules, such as
proteins, peptides or oligonucleotides, is not possible under
harsh conditions, but it may be obtained through a prosthetic
group, a small molecule that may be labelled, with 18F and
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subsequently coupled in mild condition to the biomolecule.
We aimed to develop sugar based prosthetic groups in this
setting, a method that is likely to improve the bioavailability,
pharmacokinetic and in vivo clearance properties of peptide/
protein.Materials & Methods: The prosthetic carbohydrate de-
rivatives should have a good leaving group allowing an easy
substitution by fluorine-18. A Huisgen cycloaddition was
planned for coupling the prosthetic group with the biomole-
cule. Some peptides containing a cysteine residue were initial-
ly tested. S-propargylated derivatives were easily obtained
thanks to the high nucleophilicity of the thiol function. The
f u l l y a u t o m a t e d r a d i o s y n t h e s i s o f t h e s e
[18F]fluoroglycopeptides was performed on an AllInOne
(Trasis®) module. In the same time the biological activity of
these glycopeptides was evaluated in vitro (platelet aggrega-
tion assay). IC50 values were determined from concentration-
response curves fitted with an exponential decay equation.
PET scans will be performed using a small-animal INVEON
tomograph.Results: The synthesis of suitable precursors of
these prosthetic groups and the radiolabelling of some model
peptides (glutathione, RGDC, c(RGDfC)) could be success-
fully achieved by a two step strategy for the radiolabelling of
p e p t i d e s u s i n g s u g a r b a s e d p r o s t h e t i c
group[18F]Fluoroglycopeptides were obtained in 10-30% ra-
diochemical yield (dc). PET-scan images were obtained in
animals. In vitro studies of ADP-induced platelet aggregation
inhibition show that introduction of a carbohydrate moiety on
linear RGD peptides strongly enhances the inhibitory
activity.Discussion/Conclusion: The 18F-labelling of peptides
is possible in good yields by using prosthetic groups constitut-
ed of 6-fluoro sugars, equipped with an azido arm at the
anomeric position. Biological evaluations are very promising.
PW060
Cyclotron production of 51Cr for clinical application
M. Aboudzadeh Rovais; Nuclear Science and Technology
Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.
Introduction: 51Cr(27.7d) is one of the attractive medical
r ad ionuc l ide tha t decays v ia e l ec t ron cap tu re
(EC=100%). The 51Cr is used to label red blood cells
and quantify gastrointestinal protein loss. Sodium chro-
mate (Na2
51CrO4) and chromium chloride (
51CrCl3) are
suitable for diagnostic applications. In this article, a se-
lection of different reactions for production of 51Cr, the-
oretical production yield through the excitation functions
for 51V(p,n)51Cr, 51V(d,2n)51Cr, 48Ti(α,n)51Cr, 52Cr(n,
2n)51Cr using TALYS 1.6, ALICE-91 and ALICE-ASH
computer codes have been studied. The experimental
yield as well as the production method for 51V(p,n)51Cr
reaction are presented. Also, the essential target thickness
was calculated by SRIM computer code. Method: The
production of 51Cr following direct 51V(p,n)51Cr reaction,
250mg V2O5(99.99% Merck) were compressed into pel-
lets. A novel shuttle and target system was developed for
the production of 51Cr. The incident energy of the proton
beam was 11MeV at the 20μA current for 1hr. The irra-
diated target was dissolved in 4N HCl(2ml) containing
10mg of ferric nitrate. The solution was added slowly
to the boiling 4N NaOH(2ml). 51Cr was precipitated with
Fe3+ as a co-precipitation. The precipitate was separated
from the solution by filtration and then it was dissolved
in 12N HCl(10ml). The solution was passed through a
chromatography column that filled with Dowex 1X8 an-
ion exchange resin (mesh 100-200). Fe3+ was retained by
the resin while the Cr3+ was passed through. Results and
discussion: Different products and theoretical production
yield of 51Cr in different nuclear reaction were studied
through the excitation functions using the previously
mentioned computer codes. Although the direct 51V(p,
n)51Cr reaction doesn’t have the best 51Cr production
yield, this reaction is the only one that can produce no
career-added 51Cr and pure as the final product. The av-
erage of the experimental yields of 51Cr over the opti-
mum energy range Ep=11→3 MeV for
51V(p,n)51Cr re-
action was 2.3MBq/μAh. The theoretical yield of 51Cr
was calculated as 2.7, 2.9 and 2.5 MBq/μAh for TALYS,
ALICE-91 and ALICE-ASH codes, respectively. Conclu-
sion: The 51V(p,n)51Cr reaction was selected because of
the 51Cr could be produced free of the other radionu-
clides. A novel targetry system was developed for this
production method. The experimental production yields
are close to the theoretical yields especially the one cal-
culated from the ALICE-ASH code. Keywords: 51Cr,
Production yield, Pellet target, Simulation.
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Brown adipose tissue: Preclinical imaging beyond FDG?
M. Bauwens1, G. Hendrikx1, V. Schrauwen-Hinderling1, J.
Slenter1, S. van Hoof1, A. Vogg2, I. Pooters1, B. Brans1, F.
M. Mottaghy1,2; 1MUMC, Maastricht, NETHERLANDS,
2UKAachen, Aachen, GERMANY.
Introduction: The metabolic activity of brown adipose tissue
(BAT) can have a significant effect on homeostasis, but is
difficult to non-invasively quantify in vivo. In this study, we
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performed a comparison of different non-invasive imaging
techniques in a preclinical setting. Methods: 40 Wistar rats
(male, 8-12 weeks old) and 42 NMRI mice (male, 6-9 weeks
old) were used during the study. In rats, dynamic PET and
SPECT images using [18F]-FDG, [18F]-FTHA, [123I]-
MIBG, [99mTc]-MIBI and [123I]-IPAwere acquired in differ-
ent temperature conditions: room temperature, exposure to
acute cold (4°C for 4h) or acclimatized to cold (4°C for 6h
per day during 28 days). MRI/MRS was set up using a dedi-
cated protocol to assess BAT temperature in 5 room tempera-
ture and cooled rats. In NMRI mice, static PET images were
acquired using [18F]-FDG and [18F]-FTHA and using differ-
ent temperature conditions (room temperature, thermoneutral
conditions and 4°C) as well as a different diet (chow or high-
fat diet). In addition, CT images were acquired in these mice
and used as a cross-reference for the PET images. Finally,
mRNA of several genes was analyzed from BAT and WAT.
Results: In rats, [18F]-FDG, [18F]-FTHA, [123I]-MIBG,
[99mTc]-MIBI but not [123I]-IPA allowed to visualize BAT
and showed higher uptake in cold-stimulated animals. When
compared to a single cold-exposure, the effect of cold-
acclimatization yielded a larger volume of active BAT, indi-
cating growth of BAT. MRI clearly showed BAT in T2
weighed images. MRS could quantify BAT temperature, but
did not reveal a temperature difference between BAT and a
reference region. In mice, [18F]-FDG and [18F]-FTHA could
visualize BAT. However, only [18F]-FDG showed clear
images and allowed a comparison between different
groups, and showed the impact of the high-fat diet (lower
uptake compared to chow) as well as temperature condi-
tions (cold-stimulated animals showed more uptake). CT
images clearly showed BAT, improving BAT delineation
on PET images, but yielded no further additional infor-
mation. mRNA confirmed the identity of BAT in all an-
imals, and showed a clear correlation between mRNA
expression and related tracer uptake. Summary: PET,
SPECT, CT and MRI/MRS are all able to visualize
interscapular BAT. The lack of good quantitative infor-
mation from the SPECT makes it a currently suboptimal
technique . In our current study, [18F]-FDG outperforms
any other tracer. The combination of PET/CT and PET/
MRI is nevertheless superior to only PET, due to better
target delineation.
PW062
Pilot study of a novel peptide targeting GPC3 for HCC
D. Zhu1, Y. Qin1, L. Zhang2, S. Zou1, J. Wang2, L. Zhu2, X.
Zhu1; 1Department of Nuclear Medicine & PET, Tongji Hos-
pital, Tongji Medical College, Huazhong University of Sci-
ence and Technology, Wuhan, CHINA, 2State Key Laboratory
of Molecular Vaccinology and Molecular Diagnostics &
Center for Molecular Imaging and Translational Medicine,
School of Public Health, Xiamen University, Xiamen,
CHINA.
Purpose: Glypican-3 (GPC3) is a heparan-sulfate proteoglycan
over-expressed in most hepatocellular carcinoma (HCC). A
peptide binds to GPC3 with high specificity and affinity will
facilitate targeted diagnosis and/or therapy of HCC.Methods:
A Ph.D.-12TM phage display library was used to screen the
high affinity peptide against the human recombinant GPC3
protein. A 12-mer peptide GPC3-TJ12P1 was synthesized ac-
cording to the DNA sequence of selected GPC3 binding
phage. The binding affinity between GPC3-TJ12P1 and the
human recombinant GPC3 protein was determined by ELISA.
Specificity of GPC3-TJ12P1 to GPC3was confirmed by west-
ern blot and cell florescent on cells with (HepG2) or without
(PC3) GPC3 expression. In vivo, near-infrared fluorescent
(NIRF) imaging and biodistribution studies were performed
in nude mice bearing HepG2 and PC3 tumor xenografts to
evaluate the target ability of Cy5.5-GPC3-TJ12P1 to GPC3.
Furthermore, Cy5.5- GPC3-TJ12P1 was used to detect the
GPC3 expression in patient’s tumor tissues with HCC, chol-
angiocarcinoma (CCA) and normal adult liver tissues respec-
tively using western blot and immunohistochemical
staining.Results: The binding assay of the GPC3-TJ12P1 to
GPC3 protein exhibited Kd value of 280.4 ± 33.51nM.
Western blotting confirmed that GPC3-TJ12P1 was able to
effectively detect GPC3 expression in HepG2 and PC3
cells. Cy5.5-GPC3-TJ12P1 mainly attached to HepG2 cells
surface under confocal microscopy, while there were less
fluorescent on the PC3 cells membrane. A weak signal
was observed when GPC3 expressed on HepG2 cells were
blocked by free GPC3-TJ12P1 before Cy5.5-GPC3-TJ12P1
labeling. In vivo NIRF study showed that HepG2 xenograft
tumors had a higher accumulation of Cy5.5-GPC3-TJ12P1
than that of control group, blocking group and PC3 xeno-
graft tumors (n=3 or 4), respectively. Tumor/muscle fluo-
rescent intensity ratio reached 3.98 ± 0.36 at 4h post-
injection in HepG2 tumor models. Ex vivo study also con-
firmed that an enrichment of Cy5.5-GPC3-TJ12P1 at 4h in
the HepG2 dissected tumors. For patient’s tissues, only
GPC3 protein strip from HCC tissues was displayed with
fluorescent on PVDF membrane, and there was a heavier
staining in HCC slices than that of in CCA and normal adult
liver slices, which confirmed using anti-GPC3 mAb
simultaneously.Conclusions: A novel peptide, GPC3-
TJ12P1, targeting GPC3 was obtained using phage display
library and identified in vitro and in vivo. It can be applied
for further studies, such as peptide mediated multifunctional
molecular imaging and drug deliveries as well as a new
promising molecular probe for early HCC diagnosis and
intervention.[Keywords]phage display library; Peptide;
GPC3; HCC; Optical imaging
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A new lactam bridge 99mTc-α -melanocyte-stimulating
hormone analog for diagnosis of metastatic melanoma
D. Beiki1, D. Shamshirian2, M. Erfani3, B. Fallahi1; 1Research
Center for Nuclear Medicine, Shariati Hospital, Tehran Uni-
versity of Medical Sciences, Tehran, IRAN, ISLAMIC RE-
PUBLIC OF, 2Department of Radiopharmacy, School of Phar-
macy, Tehran University of Medical Sciences, Tehran, IRAN,
ISLAMIC REPUBLIC OF, 3Radiation Application Research
School, Nuclear Science and Technology Research Institute,
Tehran, IRAN, ISLAMIC REPUBLIC OF.
Introduction: Over 80 % of human metastatic melanomas
were reported to overexpress MC1 receptors. Since mela-
noma cause more than 75% of deaths from skin cancer,
there is a need to develop new radiopharmaceuticals which
allow diagnosing this type of tumor in an early phase. This
study presents the synthesis of a new lactam bridge
99mTc-α-MSH analogue. Methods: A new [HYNIC-
GABA-Nle]-CycMSHhept derivative was conveniently
synthesized by solid phase peptide synthesis on sieber am-
ide resin via Fmoc strategy. Then peptide radiolabelling was
performed by 99mTc via HYNIC chelator and tricine as co-
ligand. Also, stability in human serum, receptor bound in-
ternalization, protein binding, partition coefficient and tis-
sue biodistribution in tumor bearing nude mice were thor-
oughly investigated. Results: The new peptide derivative
was obtained in an overall yield of 35% with the purity of
>98%. Radiolabeling with 99mTc was performed at high
specific activities (163MBq/nmol) with an acceptable label-
ing yield (>98%). Also, stability studies in aqueous solution
and human serum showed radiolabeled complex with no
significant release of 99mTcO4− or peptide degradation
up to 6 h. Protein binding and calculated partition coeffi-
cient for the radiolabeled peptide were 37% and log
P=−1.31 ± 0.12 %, respectively. Also, the radioligand
showed specific internalization into B16/F10 cells (13.35
± 0.9% at 4 hours). In biodistribution studies, a receptor-
specific uptake was observed in MC1 receptor positive or-
gan so that after 4 hours the tumor uptake was 4.51±0.11 %
ID/g. Predominant renal excretion pathway with a highest
accumulation of activity in tumor was observed for this
radiopeptide. Conclusion: This new designed labeled pep-
tide conjugate showed high accumulation in tumor as a pos-
itive MC1 receptor targeted tissue followed by excretion via
the kidney and can be a suitable candidate for diagnosis of
metastatic melanomas.
PW064
Multispectral fluorescence imaging during robot-assisted
laparoscopic sentinel node biopsy - a first step towards
a real-time intraoperative patient-specific anatomical
roadmap
N. S. van den Berg1,2, G. H. KleinJan1,2, T. Buckle1, E. M.
Wit2, H. G. van der Poel2, F. W. B. van Leeuwen1,2; 1LUMC,
Leiden, NETHERLANDS, 2AVL-NKI, Amsterdam, NETH-
ERLANDS.
Introduction:The clinical translation of hybrid tracers, e.g. the
sentinel node (SN) tracer indocyanine green (ICG)-99mTc-
nanocolloid, that are composed of a radioactive- and optical
signal has strongly expanded the working-field of nuclear
medicine by providing real-time fluorescence guidance during
surgery. Limiting, however, is that surgical guidance remains
restricted to a single feature such as the SN. If real-time surgi-
cal guidance can be provided for multiple parameters at once,
it may help create a paradigm shift in the way surgery is per-
formed. For this multispectral imaging concept multiple (spec-
trally complementary) fluorescent tracers have to be adminis-
tered to a single patient. Also a fluorescence camera is required
that allows for separate detection of the two signals. Following
an initial evaluation in mice, in the current study we clinically
evaluated this approach using ICG-99mTc-nanocolloid (SN;
near-infrared (NIR)) and fluorescein (lymphangiography; vis-
ible fluorescence).Methods:For the first-in-human application,
8 prostate cancer patients with a Briganti nomogram-based
risk >10% of lymph node metastases were included. Patients
were scheduled for robot-assisted radical prostatectomy with
extended pelvic lymph node dissection and SN biopsy. Fol-
lowing a transrectal ultrasound-guided intraprostatic ICG-
99mTc-nanocolloid injection (2.0mL; 3h prior to surgery) pre-
operative lymphoscintigraphy and SPECT-CT imaging were
performed. Fluorescein (2.0mL; 200mg) was injected into the
prostate directly after anesthetizing the patient. Intraoperative-
ly both fluorescent signatures were identified using a tailored
multispectral fluorescence laparoscope.Results:Preoperative
SPECT-CT imaging revealed on average 3.9 SNs (range 1-6)
per patient. Intraoperatively, 24 of 28 SNs (85.7%) could be
detected using the NIR settings. In 5 patients, the fluorescence
signal of fluorescein could be used to specifically highlight the
draining lymphatic ducts to 10 SNs.The accuracy and bright-
ness with which fluorescein could be detected in vivo was
remarkable. However, compared to the hybrid tracer, with
fluorescein a higher background staining was seen (predomi-
nantly bowel, urine). Also this study underlined that the
S310 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
guidance provided by a dedicated SN tracer is superior over
the gu idance p rov ided by a lymphang iography
tracer.Discussion:This study illustrated the first-in-human use
of a multispectral fluorescence guidance approach using two
complementary fluorescent tracers. The promising results pro-
vide a first step towards a fluorescence-based anatomical/
molecular road map able to visualize multiple surgery-related
anatomical structures simultaneous.
PW065
Effect of different injection routes in tumor accumulation
and biodistribution of radiolabeled Pluronic P94 unimers
C. Santini1, A. Arranja2, A. Denkova3, F. Schosseler2, K.
Morawska4, P. Dubruel4, E. Mendes5, M. de Jong1, M.
Bernsen1; 1Erasmus MC, Rotterdam, NETHERLANDS,
2CNRS, Institute Charles Sadron, Strasbourg, FRANCE,
3TU Delft, Radiation Science and Technology,, Delft, NETH-
ERLANDS, 4UGhent, Polymer Chemistry and Biomaterials
Group (PBM), Gent, BELGIUM, 5TU Delft, Department of
Chemical Engineering, Delft, NETHERLANDS.
Introduction. Pluronic P94 unimers (P94) are amphiphilic
block copolymers with high in vivo stability and relatively
long circulation times. Due to the enhanced permeability and
retention (EPR) effect, P94 can accumulate in the tumor tissue
and therefore be potentially used as drug carrier. For various
macromolecules it has been shown that following IVadminis-
tration, limited tumor accumulation occurs versus undesired
high liver uptake and clearance via the mononuclear phago-
cyte system (MPS). Intratumoral (IT) injection might over-
come this limitation by avoiding the systemic circulation and
therefore improving the retention in the tumor. In this study we
compared IT versus IV administration routes of radiolabeled
P94 in terms of biodistribution profiles and tumor accumula-
tion and retention in a mouse tumor model.Materials and
methods. P94 was modified with a DTPA chelator, labeled
with 1In-111 and injected in tumor-bearing mice either IV
(N=8, 0.2 mg/mouse, ~10 MBq/animal) or IT (N=8, 0.1 mg/
mouse, ~5 MBq/animal). Molecular imaging with SPECT/CT
was performed at different time points post injection (pi): 30
min, 24h, 48h and 96h pi. Ex vivo biodistribution was deter-
mined in isolated organs at 48h and 96h pi.Results. Following
IV injection, accumulation in the liver was visible already
30 min pi, while tumor accumulation could be visible only
starting from later time points. Ex vivo biodistribution, con-
firmed a reduced tumor uptake of ~1 % injected dose per gram
(ID/g), whereas accumulation in the liver was ~15 %ID/g. In
contrast, following IT injection most of the signal is concen-
trated in the tumor rim and limited liver accumulation is de-
tected in the first hour pi. Furthermore, ex vivo biodistribution
following IT injection, showed that the tumor retention in-
creased to over 20 %ID/g, with limited uptake in off-target
tissues, while liver uptake was reduced to ~10 %ID/g. The
results also indicated that, independently from the injec-
tion route, the tumor could retain P94 over time, while
the majority of other tissues show a significant reduction
in tracer retention between 48h and 96h. The effect is
however larger after IT injection.Conclusion. IV injec-
tion of radiolabeled P94 resulted in limited tumor up-
take, whereas IT administration substantially increased
the uptake and the retention in the tumor. The minimal
involvement of off-target tissue, including liver, and the
tracer retention over time especially for IT administra-
tion, confirmed the potential of P94 to be used as a
carrier for therapeutic radionuclides.
PW066
A multiprobe approach to monitoring therapy response
in rheumatoid arthritis
S. Y. A. Terry1, M. I. Koenders2, T. K. Nayak3, A. Freimoser-
Grundschober4, C. Klein4, W. J. Oyen2, O. C. Boerman2, P.
Laverman2; 1King’s College London, London, UNITED
KINGDOM, 2Radboud UMC, Nijmegen, NETHERLANDS,
3Roche Pharmaceutical Research and Early Development, Ba-
sel, SWITZERLAND, 4Roche Pharmaceutical Research and
Early Development, Zurich, SWITZERLAND.
Introduction: Rheumatoid arthritis (RA) is an autoimmune
disease leading to chronic synovial inflammation. Monitoring
therapy response by molecular imaging may allow optimiza-
tion of therapy regimens and/or improve therapeutic outcome.
Etanercept is a soluble fusion protein consisting of human p75
TNF-α and the Fc portion of human IgG and is often given to
RA patients if methotrexate is contra-indicated or withdrawn
due to adverse events. Here, we focused on imaging three
different targets that play a role in arthritis, namely fibroblast
activation protein (FAP), macrophages, and integrinαvβ3, and
on determining whether specific imaging of these targets could
monitor response to etanercept in RA mice. Methods: Male
DBA/1Jmicewith collagen-induced arthritis were treated with
anti-TNFα therapy (etanercept 10 mg/kg, 3x/week, i.p.).
SPECT/CT scans were acquired of treated and untreated mice
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at 1, 24 and 48 hours after injection of 111In-RGD2 peptide
(targeting integrin αvβ3; 1 μg/mouse),
111In-anti-F4/80 anti-
body (targeting macrophages; 10 μg/mouse), or 111In-28H1
antibody (anti-FAP; 50 μg/mouse), respectively. Mice were
dissected after the last scan to determine the biodistribution.
Coinjection of an excess of RGD2 with
111In-RGD2 or injec-
tion of 111In-labeled control antibodies (rat IgG2b or DP47GS)
served as controls to determine nonspecific tracer uptake. Re-
sults: RA was imaged with 111In-28H1, 111In-anti-F4/80, and
111In-RGD2. Treatment with etanercept was successful as mac-
roscopic scores of RAwere lower in treated mice than in un-
treated mice (Figure 2). At day 6 after start of therapy, average
RA scores were 3.99 ± 1.67 in untreated mice and 1.84 ± 1.08
in treated mice. Tracer uptake in joints correlated with RA
score in biodistribution studies and quantitative SPECT; up-
take decreased from 28±15%ID/g, 8±4%ID/g, 2±1%ID/g to
11±11%ID/g, 4±4%ID/g, 1±0%ID/g in treated and untreated
mice for 111In-28H1, 111In-anti-F4/80, and 111In-RGD2, re-
spectively (p<0.001). Joint uptake of 111In-28H1, 111In-anti-
F4/80, and 111In-RGD2 is antigen/receptor-mediated as when
competing uptake of these tracers with either antibody controls
or excess of peptide, joint:blood values decreased. RA-to-
blood ratios (in mice with arthritis score 2) were higher for
111In-28H1 (6±1, lowest population), 111In-anti-F4/80 (10
±4), and 111In-RGD2 (7±1) than for control
111In-DP47GS (1
±1), 111In-rat IgG2b (1±0), or coinjection of excess RGD2, (4
±0). Conclusions: The three tracers can be used to specifically
monitor the response to therapy in RA at the molecular level.
PW067
The imaging study of a new 99mTc-labeled PSMA
inhibitor
X. Xu; J. Zhang, S. He, J. Luo, Y. Zhang *Department of
Nuclear Medicine, Fudan University Shanghai Cancer Center,
Shanghai, ChinaDepartment of Oncology, Shanghai Medical
College, Fudan University, Shanghai, ChinaCenter for Bio-
medical Imaging, Fudan University, Shanghai, ChinaShanghai
Engineering Research Center for Molecular Imaging Probes,
Shanghai, CHINA
Aim: Prostate-specific membrane antigen (PSMA) is a well-
established target for developing radiopharmaceuticals for im-
aging and therapy of prostate cancer (PCa). We have synthe-
sized an amino-functionalized PSMA inhibitor(Lys-Urea-Glu)
and labeled technetium-99m via HYNIC. The in vivo target
capacity of the new molecular imaging pobe was evaluated in
animal model and compared with 18F-FDG and 11C-Choline
which were the mostly used in clinical.Material and method:
The small-molecular inhibitor was based Lys-Urea-Glu core
which linked 99mTc chelator HYNIC through 6-aminocaproic
acid. We assessed the new molecular imaging probe in SCID
mice bearing PC-3 and LNCaP tumor xenografts on Nano-
SPECT/CT. The comparative experiment of 18F-FDG
and 11C-Choline imaging was done in the LNCaP tumor
xenografts on Micro-PET/CT. The T/B data was obtain-
ed by the analysis software accompanying with Nano-
SPECT/CT and Micro-PET/CT respectively.Results and
conclusion: The imaging results showed that the metab-
olism of the radioactive probe 99mTc-HYNIC-Acs-Lys-
Urea-Glu was very fast. Kidney was the primary excre-
tory organs and little radioactive uptake was found in
intestines. There were no significant uptake in other or-
gans. The PC-3 tumor doesn’t have any radioactive up-
take, the LNCaP tumor had very high radioactive uptake
and the T/B (tumor to muscle) was 20.4. The blocking
experiment that the probe was blocked by the excessive
2-PMPA on LNCaP tumor xenografts showed that the
tumor uptake reduced significantly. This illuminated the
probe exactly targeted PSMA. The T/B data obtained
from the PET/CT imaging were 2.1 and 2.6 for 18F-
FDG and 11C-Choline respectively which was much less
than 99mTc-HYNIC-Acs-Lys-Urea-Glu.The probe 99mTc-
HYNIC-Acs-Lys-Urea-Glu with fast metabolism and
high tumor uptake was a promising molecular imaging
probe targeted PSMA. It was superior to 18F-FDG and
11C-Choline in PCa.
PW068
Preclinical evaluation of selected 68Ga labelled peptides
for glioblastoma imaging
M. Petrik1, J. Stepankova1, Z. Crlikova1, R. Trojanec1, J.
Drymlova2, M. Hajduch1, Z. Novy1; 1Faculty of Medicine
and Dentistry, Palacky University Olomouc, Olomouc,
CZECH REPUBLIC, 2Department of Nuclear Medicine, Uni-
versity Hospital Olomouc, Olomouc, CZECH REPUBLIC.
Aim: Glioblastoma multiforme (GBM) is the most aggressive
type of primary brain tumors in humans with more than 90% 5-
year mortality. Early diagnosis may be the key factor for improv-
ing patient survival rates through the prevention of tumor growth.
Radiolabelled regulatory peptides continue to hold promise for
early diagnosis of many human diseases, including GBM. Here
we report on the preclinical evaluation of two 68Ga labelled
peptides as potential agents for GBM imaging and in vivo com-
parison with clinically used 18F labelled radiopharmaceuticals.
Materials and methods: 68Ga labelling of selected peptides
(NODAGA-cRGDyK dimer and DOTA-substance P) was per-
formed in acetate buffer using fractionated method. The labelling
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conditions were optimized concerning temperature, peptide
amount and reaction time. For in vitro characterization, partition
coefficient, protein binding properties and stability values in dif-
ferent media were determined. Ex vivo biodistribution and PET/
CT imaging was studied in normal Balb/c and tumor (U87MG)
Balb/c nude mice. Results: Both peptides were labelled with
68Ga with high radiochemical purity (>95%). 68Ga-
NODAGA-cRGDyK dimer showed hydrophilic properties and
was stable in vitro in human serum, concentrated iron(III) and
DTPA solutions as well as at pH = 7 and in vivo. In contrast,
68Ga-DOTA-substance P displayedmuch lower in vitro stability,
especially in concentrated iron(III) and DTPA solutions and was
rapidly metabolized in vivo. Protein-bound activity of 68Ga-
NODAGA-cRGDyK dimer after 120 min incubation
(3.9%±1.9) was found to be 7-fold lower than for 68Ga-
DOTA-substance P. In normal mice, both 68Ga labelled
tracers revealed mainly renal elimination with low blood
values (0.10±0.01%ID/g RGD and 0.28±0.03%ID/g S-P)
90 min p.i., while 18F-FLT and 18F-FDG showed much
slower kinetics and not only renal, but also gastrointes-
tinal excretion. Moreover 18F-FDG displayed significant
radioactivity retention in metabolically active tissues
(brain, brown adipose tissue and heart). In tumor mice,
68Ga-NODAGA-cRGDyK dimer was highly accumulat-
ed in tumor (5.59±2.10%ID/g, 30 min p.i. and 3.13
±0.79%ID/g, 90 min p.i.), whereas metabolically degrad-
ed 68Ga-DOTA-substance P showed much lower accu-
mulation in tumor (2.14±0.17%ID/g, 30 min p.i. and
0.72±0.04%ID/g, 90 min p.i.). In comparison with 18F-
FLT and 18F-FDG, 68Ga-NODAGA-cRGDyK dimer re-
vealed more favourable pharmacokinetics and compara-
ble accumulation in tumor confirmed also by μPET/CT.
Conclusion: Studied peptides bound 68Ga with high af-
finity, and 68Ga-NODAGA-cRGDyK dimer, especially,
displayed high stability and excellent pharmacokinetics.
Moreover 68Ga-NODAGA-cRGDyK dimer showed su-
perior in vivo properties compared to 18F-FLT and
18F-FDG, while maintaining a similar uptake in tumor.
68Ga-NODAGA-cRGDyK dimer seems to be a promis-
ing agent for glioblastoma imaging.
PW069
Preclinical evaluation of two DOTA-coupled minigastrin
analogues (Met and corresponding Nle congener)
M. Kroselj1, L. Claessens Joosten2, R. Mansi3, J. Reubi4, H.
Maecke3, P. Laverman2, O. Boerman2, P. Kolenc Peitl1; 1De-
partment of Nuclear Medicine, UMC Ljubljana, Ljubljana,
SLOVENIA, 2Department of Radiology and Nuclear Medi-
cine, Radboud University Medical Center, Nijmegen,
NETHERLANDS, 3Department of NuclearMedicine, Univer-
sity Hospital Freiburg, Freiburg, GERMANY, 4Division of
Cell Biology and Experimental Cancer Research, Institute of
Pathology, University of Berne, Berne, SWITZERLAND.
Aim: The stability of the minigastrin analogues is highly influ-
enced by the charge and the stereochemistry of the amino acid
sequence constituting the spacer. It was recently shown that in-
troduction of non-ionic (6 D-Gln) or ionic (6 D-Glu) D-amino
acid spacers results in remarkable improvement in metabolic sta-
bility. The analogue with the ionic D-Glu spacer showed the best
in vitro and in vivo properties andwas chosen as themost suitable
tracer for phase I clinical study for diagnosis and therapy ofMTC
patients. The aim of this work is to evaluate the properties of a
new analogue, PP16(Met11), having as spacer the sequence of
the mixed ionic/non-ionic amino acids (D-Gln-D-Glu)3. Since it
is well known that methionine is prone to oxidation that can
significantly influence the binding affinity, the Nle congener
PP16B(Nle11) was developed for comparison. We radiolabeled
two DOTA-conjugated minigastrin analogues with 111In under
same reaction conditions and compared their in vitro and
in vivo characteristics. Material and Methods: The minigastrin
analogues (DOTA-(D-Gln-D-Glu)3-Ala-Tyr-Gly-Trp-Met/Nle-
Asp-Phe-NH2) were synthesized manually on solid phase.
CCK-2R affinities were determined by receptor autoradiography
using 125I-CCK as radioligand. 111In-labeled peptides were eval-
uated in vitro in AR4-2J cell line and in human serum. In vivo
behaviour was studied using female athymic BALB/c mice with
s.c. A431-CCK2R tumors. SPECT imaging was performed at 1h
and 4h p.i and organs, blood and tissues of interest for
biodistribution were collected 4h p.i. Results: Both peptides
showed high binding affinity to the CCK-2/gastrin receptor
with IC50 values in low nM range (0.5±0.06 Nle11 and 0.5
±0.1 Met11). Nle11 showed higher receptor-specific inter-
nalization (15.1±0.8% vs. 10.4±0.9% at 4h), but lower en-
zymatic stability in human serum (85±68 vs. 141±68 h).
Tumor uptake at 4h p.i. for Nle11 was 2.06±0.86%ID/g
and 1.22±0.66%ID/g for Met11 (p=0.111). Tumor retention
of Nle11 was 82.2% at 4h and 90.02% of Met11 (p=0.271).
Conclusion: Two DOTA-coupled minigastrin analogues
with the same mixed ionic/non-ionic spacer and alteration
in C-terminal part (Met/Nle) were developed. Changing the
natural Met for Nle had no influence on binding affinities of
these molecules to CCK-2R. In addition, the replacement
had no significant effect on tumor and kidney uptake. Both
radiolabeled peptides demonstrate good tumor retention of
radioactivity. We showed that both analogues have similar
in vivo characteristics. Since Nle11 is not oxidized during
the radiolabeling with radiometals, the radiolabeling step is
more straightforward and thus making the Nle11 a better
candidate for a possible clinical use.
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Auger Electron Radioimmunotherapy
with 111In-Bn-DTPA-Nimotuzumab Inhibits the Growth
of EGFR-Positive Human Breast Cancer Tumours inMice
at Doses that are Non-Toxic to Normal Tissues
C. Chan1, H. Fonge1, K. Lam1, R. Reilly1,2,3; 1Department of
Pharmaceutical Sciences, University of Toronto, Toronto, ON,
CANADA, 2Department of Medical Imaging, University of
Toronto, Toronto, ON, CANADA, 3Toronto General Research
Institute and Joint Department of Medical Imaging, University
Health Network, Toronto, ON, CANADA.
Aim: To evaluate the tumour growth inhibition properties
and no rma l t i s sue t ox i c i t y o f Auge r e l e c t r on
radioimmunotherapy (RIT) of human breast cancer xeno-
grafts overexpressing EGFR in CD1 athymic mice using
111In-Bn-DTPA-nimotuzumab. Methods: Normal tissue
toxicity was first evaluated in non-tumour bearing mice
following i.v. injection of 8.8 or 28.2 MBq (3 mg/kg) of
111In-Bn-DTPA-nimotuzumab. Control mice were treated
with unlabeled Bn-DTPA-nimotuzumab or normal saline.
The body weight index (BWI) was determined every few
days by dividing the body weight by that prior to treat-
ment. Complete blood cell counts (CBC), hematocrit and
hemoglobin, and serum alanine aminotransferase (ALT)
and creatinine (Cr) were measured at 2 weeks p.i. RIT
was then performed in CD-1 athymic mice bearing s.c.
MDA-MB-468 human breast cancer xenografts (1 x 106
EGFR/cell) by administering two doses i.v. (15.5 MBq; 3
mg/kg) of 111In-Bn-DTPA-nimotuzumab separated by two
weeks. Control mice were treated with unlabeled Bn-
DTPA-nimotuzumab, i r re levant 111In-Bn-DTPA-
trastuzumab or normal saline. The tumour growth index
(TGI) was determined weekly by dividing the tumour vol-
ume at selected time points by that prior to treatment. The
slope of the TGI vs. time curve was calculated for each
group. BWI was also measured. Results: ALT levels in
non-tumour bearing mice injected with 8.8 or 28.2 MBq
of 111In-Bn-DTPA-nimotuzumab were 32.8±5.0 or 77.3
±31.9 U/L, respectively, compared to 29.8±4.3 or 24.8
±6.3 U/L in mice receiving unlabeled Bn-DTPA-
nimotuzumab or saline, respectively (p>0.05). Cr in mice
injected with 8.8 or 28.2 MBq of 111In-Bn-DTPA-
nimotuzumab were 63.3±33.9 or 128.6±71.7 μmol/L, re-
spectively, compared to 22.1±14.5 or 24.5±10.0 μmol/L in
mice administered unlabeled Bn-DTPA-nimotuzumab or
saline, respectively (p>0.05). No differences in BWI were
noted for any groups. There was no effect of 8.8 MBq of
111In-Bn-DTPA-nimotuzumab on CBC but leukocyte
counts were lower for mice administered 28.2 MBq (3.5
±0.6 K/μL) compared to saline treated mice (8.2±0.9
K/μL; P=0.012). An intermediate dose of 15.5 MBq of
111In-Bn-DTPA-nimotuzumab was selected for RIT. The
slope of the TGI vs. time curve over 84 days was lower
(p<0.05) for tumour-bearing mice treated with two doses
(15.5 MBq each) of 111In-Bn-DTPA-nimotuzumab (0.010
±0.005 d-1) compared to mice injected with unlabeled Bn-
DTPA-nimotuzumab (0.064±0.011 d-1), irrelevant 111In-
Bn-DTPA-trastuzumab (0.049±0.010 d-1) or normal saline
(0.066±0.010 d-1). There was no difference in BWI among
the groups. Conclusion: 111In-Bn-DTPA-nimotuzumab is a
promising new treatment for EGFR-overexpressing breast
cancer. Supported by a grant from the Canadian Institutes
of Health Research. Nimotuzumab was provided by YM
Biosciences, Inc.
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Bone scan and MRI in Chronic Recurrent Multifocal
Osteomyelitis
L. Biassoni; Great Ormond Street Hospital for Children NHS
Foundation Trust, London, UNITED KINGDOM.
Aim: Chronic Recurrent Multifocal Osteomyelitis (CRMO) is
a rare inflammatory bone disorder presenting with relapsing
and remitting episodes of bone pain. MRI is the imaging mo-
dality of choice; however, long waiting lists often prevent
patients to have access to MRI in a timely fashion. Aim of this
study was to compare the diagnostic yield of the bone scan
(BS) versus MRI in CRMO and to correlate the findings with
inflammatory markers and clinical symptoms/location of pain.
Materials and Methods: Retrospective review of the clinical
notes of children with a confirmed diagnosis of CRMO who
had both bone scan and MRI between 2009 and 2014, and
within 9 weeks of each other. Nine patients (7 females, 2
males, age range 7-13 years, mean 9.6) had both BS and
MRI less than 9 weeks apart. We recorded for each patient:
inflammatory markers at time of scans (ESR, CRP andWCC),
clinical symptoms, pain location, number and location of le-
sions for BS and MRI. Patients were excluded if BS and
MRI were done more than 9 weeks apart, or if there
was any change to treatment in-between scans. BSs
were acquired as a whole body sweep, with high count
spot views of the areas of interest and SPECT CT when
necessary. MRI scans were limited to the area of interest
(only 1 patient had whole body MRI) and were acquired
using T1, T2, and STIR sequences (and contrast en-
hanced in 6 patients). Results: Pain was always associ-
ated with a bone lesion on imaging. BS was always
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positive at the site of symptoms. MRI consistently de-
tected more lesions than BS (45 lesions versus 31 with
BS), especially in the spine. However, several lesions,
mainly suggestive of bone marrow oedema, were asymp-
tomatic, and their clinical significance was questionable.
BS was better at detecting rib lesions. MRI and BS
were concordant in 69% of cases. The inflammatory
markers were non-specific. Conclusion: MRI and BS
were concordant in a high number of cases. MRI detect-
ed more lesions than BS; however, several lesions were
asymptomatic and of doubtful clinical significance. BS
was always positive at the site of symptoms. BS can be
considered in CRMO if MRI is not readily available.
PW072
Scintigraphic functional evaluation of intrathecal drug
infusion devices
G.Garraffa1, V. Scaglione2, F. Felice1, R. Ricapito1; 1Nuclear
Medicine Unit, A.R.N.A.S. “Ospedale Civico, Di Cristina e
Benfratelli”, Palermo, ITALY, 2Neurosurgery Unit, A.-
R.N.A.S. “Ospedale Civico, Di Cristina e Benfratelli”, Paler-
mo, ITALY.
Scintigraphic evaluation of intrathecal drug infusion
devices.GARRAFFA G.1, SCAGLIONE V.2, FELICE F.1,
RICAPITO R.1 AND ARNONE G.1.1 Nuclear Medicine
Unit, A.R.N.A.S. “Civico, Di Cristina e Benfratelli”, Palermo,
Italy. 2 Neurosurgery Unit, A.R.N.A.S. “Civico, Di Cristina e
Benfratelli”, Palermo, Italy.Introduction and aim: intrathecal
infusion devices are used for pts. with pain and spastic dis-
eases. These are made by a pump with a reservoir for the drug
allocated in the abdominal subcutaneous space and connected
to a catheter ending in the spinal subaracnoid space.
Malfunctioning of the infusion system or progression of pain
disease causes increasing infusion rates or drug amount. Ad-
ministration of a not-absorbed radionuclide (99mTc-DTPA) in
the pump reservoir and sequential scanning allow to follow the
progression of the radionuclide along the catheter to the spine.
The images show any interruption/delay of the system radio-
nuclide progression and, if the flow rate of the pump device is
programmable, quantitative evaluation of the flow itself along
system. Aim: to evaluate the effectiveness of 99mTc-DPTA
infusion within the device in order to detect malfunctioning
and to correlate the results with patient management and
outcome.Methods: 8 patients already studied with 99mTc-
DTPA scintigraphy were retrospectively reviewed. All of them
had surgically implanted Medtronic® SynchroMed intrathecal
(baclofen or ziconotide) infusion pump systems, because of
severe spasticity (n=5) or intractable pain (n=3). About
400 MBq 99mTc-DPTAwas injected into the pump reservoir,
then planar serial static abdominal scans were performed every
three hours for 24 hours to follow tracer progression. Once the
tracer arrived in the spinal liquoral system, whole-body scans
were performed.Results: no adverse effects on heat conditions
correlated with 99mTc-DPTA were registered. 1 pt. showed
regular device functioning without interruption of progression
and with delivery flow corresponding to the programmed flow.
6 pts. showed interrupted progression along the abdominal
portion of the catheter, one of which also with subcutaneous
dispersion of the radionuclide. 1 pt. showed quantitative alter-
ation of the flow rate, too slow respect to the programmed
delivery flow rate. Pts. with flow stop were re-operated and
operative findings confirmed the scintigraphic data. Patient
with flow reduction presented pump failure, while pt. with
normal flow had psychiatric disorders.Conclusions: intrathecal
infusion system scintigraphy is an useful tool in non-invasive
evaluation of functioning of implants with programmable
pump. Use of 99mTc-DPTA radionuclide allows satisfactory
and good-quality study conduction, without any adverse ef-
fects and with lower dosimetric load than 111In-DTPA.
PW073
99mTc-HDP bone SPECTwith voxel-based evaluation
for temporomandibular asymmetry detection in diagnosis
of the idiopathic condylar hyperplasia
D. Chroustova, J. Sebek, J. Trnka, J. Kubinyi; General Uni-
versity Hospital and 1st Faculty of Medicine Charles Univer-
sity, PRAGUE 2, CZECH REPUBLIC.
Aim: Idiopathic condylar hyperplasia (ICH) is characterized
by persistent or accelerated growth of the mandibular condyle,
when growth should be slowing or ended. 99mTc-HDP bone
SPECT and voxel-based mathematical analysis is used to ver-
ify the activity of condylar growth. The aim of the study was to
verify temporomandibular asymmetry in diagnosis ICH and
according the results to choose suitable surgery: condylar
shaving or conventional orthognathic surgery. Treatment of
patients with active condylar growth only with classical
orthognathic surgery methods could lead to relapse of asym-
metry. Materials and methods:106 patients (67 female a 39
male) aged 13-47 (average 21) years with laterogenia
underwent bone SPECTwith the right to left ratio assessment
of the temporomandibular joints (TMJ) uptake using the
voxel-based method. 18 patients were investigated repeatedly.
Bone SPECTwas performed 2-3 hours after injection of 300-
700MBq 99mTc-HDP on dual-heads gamma camera Infinia
GE using a low-energy, high-resolution collimator, with fol-
lowing acquisition parameters:120 projections, 20sec/projec-
tion, matrix 128x128. Voxel-based analysis of the right to left
TMJ uptake ratio: The VOIs of the temporomandibular joints
were defined using a combination of two spatial voxel masks.
One mask was defined via an intensity threshold and served to
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separate out the background. The other mask was defined by
an origin and a radius and served to separate out objects out-
side the corresponding sphere. An intersection of these two
masks defined desired volume of interest. Total counts from
each corresponding VOI came without background correction
as inputs to the default formula: L=NL/(NR+NL).100%,
R=NR/(NR+NL) .100%. For the evaluation we considered
10% difference (in terms of percentage points) of 99mTc-
HDP uptake between mandibular condyles as a sign of active
ICH. Results: 44 subjects had uptake difference higher than
10%. These scans confirmed indication of 36 patients for con-
dylar shaving to stop the condyle growth. Additional
orthognathic surgery for fine-correction of asymmetry was
needed in 7 patients and in 14 cases dental compensation of
occlusion was sufficient treatment. 85 subjects had uptake dif-
ference 10% or lower. These results disproved working diag-
nosis of ICH in 70 patients and in 26 cases conventional
orthognathic surgery was performed. No relapse was wound
within 2 years postoperatively. Conclusion: 99mTc-HDP bone
SPECT with voxel-based evaluation of the mandibular con-
dyle accelerated growth is crucial in diagnosis of ICH. Finding
with an asymmetrical TMJ growth is indicated to treatment
with condylar shaving in the first phase and orthognathic sur-
gery later.
PW074
Assessment of ACLGraft Viability byDynamic FDGPET:
A Phase I Study
K. Binzel1, R. Magnussen1, C. Kaeding1, W. Wei1, M. U.
Knopp2, D. C. Flanigan1, M. V. Knopp1; 1The Ohio State
University Wexner Medical Center, Columbus, OH, UNITED
STATES, 2Pepperdine University, Malibu, CA, UNITED
STATES.
In cases of a complete tear, injury to the anterior cruciate lig-
ament (ACL) typically requires reconstruction with a graft.
Patients having received a graft are at risk of re-injury, with
no available imaging methodologies to assess ligamentization
of the graft. In a first-in-human study, we demonstrate the
capability of a combined imaging approach using dynamic,
ultra-low dose positron emission tomography (PET) and
MRI for evaluation of graft healing following reconstructive
surgery. 20 patients post-ACL graft reconstruction had dynam-
ic PETon a Gemini TF 64 and/or new digital detector PET/CT
system, Vereos TF. An in-house constructed foam cushion was
used to place both knees in matched positions to that of the
dedicated MR knee coil during PET acquisitions. Using an
ultra-low dose (<111 MBq) 18F-fluorodeoxyglucose (FDG)
protocol, a single bed position centered on the knees was ac-
quired continuously for 75 minutes. Standard of care MRI was
performed on a Philips 3T Achieva (all systems Philips
Healthcare, Cleveland, OH). PET images were co-registered
to MRI for quantification. Standardized uptake values (SUV)
were measured for regions of interest (ROI) in the proximal,
middle, and distal portions of the graft, the tibial and femoral
tunnels, the posterior cruciate ligament (PCL), and the quadri-
ceps muscle for reference. Matched measurements were taken
in each contralateral knee. The slope of the enhancement curve
over the 75 minute acquisition was calculated for each ROI.
Patients were grouped according to time since surgery, from 0-
6 months, 6-12 months, 12-24 months and 24+. Dynamic PET
images were readily co-registered to MRI for all patients. In
the 0-6 month group the average slope of the metabolic uptake
curve was 0.20 in the distal graft, 0.21 in the mid graft, 0.27 in
the proximal graft, and 0.14 in the tibial tunnel. In contralateral
healthy knees the average slopes were 0.06, 0.09, 0.05, and
0.05, respectively. These healthy values were similar to mea-
surements seen in the 12-24 and 24+ month groups. Patients
with longer healing times were also found to have absolute
SUVs increasingly approaching healthy values as well. Quan-
titative evaluation of ACL graft ligamentization using an ultra-
low dose PET protocol with co-registration to MRI was dem-
onstrated. The digital PET enables even further dose reduc-
tions with improved image quality and quantitative accuracy.
A combined low dose FDG PET/MRI exam to assessment of
ACL graft healing appears to promising tool.
PW075
High Therapeutic Impact in New Indications of 18F-FDG
PET/CT in High/Intermediate Recurrence Risk
Differentiated Thyroid Carcinoma Patients
E. M. Triviño-Ibáñez1, M. A. Muros1, E. Torres-Vela2, J. M.
Llamas-Elvira1; 1Virgen de las Nieves University Hospital,
Granada, SPAIN, 2San Cecilio University Hospital, Granada,
SPAIN.
INTRODUCTION: Little is known about clinical benefits and
the therapeutic impact of fluorine-18-fluorodeoxyglucose pos-
itron emission tomography/computed tomography (18F-FDG
PET/CT) performed early after radioactive iodine (RAI) abla-
tion in differentiated thyroid carcinoma (DTC). AIM: Investi-
gate whether 18F-FDG PET/CT performed early after RAI
ablation is useful in detection of disease and influence therapy
in new indications of high/intermediate risk of DTC. PA-
TIENTS and METHODS: A prospective study was carried
out (June 2007 to December 2013) on 81 patients with
high/intermediate risk of recurrence differentiated thyroid car-
cinoma, treated with surgery and radioidine ablation. Our pa-
tient selection was not based exclusively on TNM classifica-
tion and included broad risk criteria (ATA guidelines 2009,
etc.) [8], such as locoregional invasion, inadequate high Tg
value and aggressive histological subtypes.Demographic data,
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surgery and pathology report, neck ultrasound and 131I-whole
body scan results and biochemical test lab report were collect-
ed. We performed 18F-FDG- PET/CT just before or
inmediately after surgery. We confirmed 18F-FDG- PET/CT
results with other imaging techniques, pathology report, first
year whole body scan, neck ultrasound or follow-up. We used
modified Hicks criteria for evaluate 18F-FDG- PET/TC results
impact. RESULTS: 81 patients with high/intermediate-risk of
recurrent DTC. Forty-one (50.6%) had positive uptake in 18F-
FDG PET/CT, with negative 131I WBS. Sensitivity, specific-
ity and diagnostic accuracy of PET/CT were 92.5%, 90.2%
and 91.4% respectively. PET/CT results had an impact on
therapy in 38.3% of patients. One year after initial therapy,
45.7% showed excellent response, 8.6% acceptable and
45.7% incomplete response. We found statistically significant
relationship between negative PET/CT and excellent response
(80 vs. 12.2%, p <0.001; OR: 52.8). CONCLUSIONS: 18F-
FDG PET/CT performed early in surveil lance of
high/intermediate-risk thyroid carcinoma provides informa-
tion fundamental to patients follow-up. A wide patient selec-
tion of high/intermediate risk DTC improves 18F-FDG PET/
CT results and determines a high therapeutic impact.
PW076
17 years follow-up from 1998 to 2015 of 123 medium-size
(2-4 x normal) EU-and Hyperthyroid (EU, HT) goitres
after treatment by 131I (RIT)
C. ALS, N. LENERS; Hôpitaux Robert Schuman -
Zithaklinik, Luxembourg, LUXEMBOURG.
OBJECTIVE: We present a long-time follow-up of patients
(pat) with medium-size goitres (2-4x normal), (normal =
♀:18 mL, ♂:25 mL) treated by RIT in a reference centre.
MATERIALS AND METHODS: (med=median, mima=min-
max, ↓=decreased, <0.0005=*). Out of 673 patients treated by
131I (1998-3.2010), 123 pat (92♀, 27-90 (med 69) years (Y)
and 31♂, 22-83 (med 70) Y), with a medium-size goitre by
ultrasound (♀:36-72mL, ♂:50-100mL, 6 pat excluded (1
emigration/ 5 Basedow post-131I)), were followed until
03.2015, i.e., 0.9-8.8 Y post-131I (mean/med 4.1/3.9 years).
Simulation was at 6h/24h/100h: calculation (MIRD, 100-300
Gy), therapeutic activity 131I (370-1295MBq, mean/med 785/
800MBq). Out of 123 pat: 10 had HT Basedow (B) (med TSH
0.01 mU/L), 18 had EU goitre (med TSH 1.03 mU/L), 95 had
HT functional autonomy (FA, med TSH 0.12 mU/L). RE-
SULTS : At 4 months (mo)/1Y/endpoint, thyroid (T) vol had
resp.↓ by 41.3%/55.2%/61.9% (all*), without a ♀-♂differ-
ence. Vol. normalisation 1 Y post-RIT was found in ♀41%,
♂32%. At 4 mo/1 Y, TSH: (B) 40.0/15.8 mU/l (p=0.4), EU
goitre 2.52/1.88mU/L (p=0.48), FA 1.03/1.25mU/L
(p=0.008). 81% pat were EU at 1Y (♀: 83%, ♂: 74%). RIT
was repeated with 2 pat. Death occurred in 24 pat (survival 9-
148.8 mo, med 70 mo). Clinically better subjective feeling
after 12 mo in 100% pat. Hormone substitution was required
in 10%/45%/61.5% of pat after 4mo/12mo/endpoint. Thyroid
volumes before RIT (Mima=36-98mL, mean=55.7mL,
med=52mL) were respectively at 4mo (6-78mL, 33.51mL,
30mL*), at 1Y (2-75mL, 27.31mL, 25mL*), at >1Y (2-
100ml, 21.4ml, 17mL*), in ♀med respectively (50mL,
28ml*, 22ml*, 14mL*), in ♂med respectively (68.5mL,
41.5mL*, 32.5mL*, 32mL*). TSH value before RIT respec-
tively was (0-5.4mU/L, 0.5mU/L, 0.2mU/L), at 4mo (0-
89mU/L, 5.2mU/L, 1.1mU/L), at 1Y (0.1-72mU/L, 3.7mU/
L, 1.5mU/L), at >1Y (0.1-36mU/L, 2.33mU/L, 1.49mU/L).
Med TSH changes in ♀ and ♂ were ns. CONCLUSIONS:
Compared with other thyroid pathologies, ♂ have relatively
more goitres 2-4x normal than ♀. RIT is a safe and efficient
method for thyroid vol ↓ and HT eradication, equally efficient
with♀ and♂. HypoT and need for hormonal supply increases
with time after RIT. Vol ↓ significantly proceeds over several
years. Volume change after RITwas equally efficient in♀ and
♂.
PW077
The Clinical Outcome and Mortality Rates in patients
with Differentiated Thyroid Carcinoma with bone
metastasis: Results of a 15- year clinical follow-up.
G. Ucmak, B. Demirel, B. E. Akkas, A. K. Fidan, N.
Ercakmak; Ankara Oncology Research and Training Hospital
Department of Nuclear Medicine, Ankara, TURKEY.
In this study, we evaluated the treatment response and
clinical outcome of Differentiated Thyroid Carcinoma
(DTC) patients with bone metastases. Method: DTC pa-
tients treated in our department from 1990 to 2014 were
retrospectively evaluated, 43 patients with bone metasta-
sis were included in this study (28 F, 15 M, mean age:
53 years). All patient records, treatment history, labora-
tory and clinical information were evaluated. The final
status of the patients was defined according to clinical
follow-up data. The total follow-up time ranged from 13
to 178 months (median: 65 months). Results: 43 patients
(21 papillary, 18 follicular, 3 poorly differentiated, 1
Hurthle cell carcinoma) were included. Thirty-five pa-
tients (81%) had bone metastasis at the time of diagno-
sis whereas 8 patients were progressed with bone metas-
tasis. All patients had elevated serum Thyroglobulin
(Tg) levels (>500 ng/ml with TSH stimulation) at the
time of diagnosis. Twenty-seven patients (63%) had
multiple sites of bone metastasis. Fourteen patients had
organ metastasis (33%) as well. 4 patients underwent
surgical resection for metastatic foci. Inoperable iodine-
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avid metastases are treated with multiple administrations
of radioiodine with empirical activities of 200-250 mCi
each. The cumulative doses were ranged from 200 to
1600 mCi. Twenty-six patients (60%) received external
radiation therapy. The response of therapy was evaluated
with serum Tg levels, anti-Tg antibody levels and
radioiodine body scans. The final status of patients
was defined on the basis of a long term follow-up, up
to 178 months. Five patients (12%) had complete bio-
chemical and clinical remission, 13 patients (35%) had
partial remission with significant drop in serum Tg
levels. Two patients had stable disease. Six patients
had progressive disease, 17 patients (40%) were died
of disease on follow-up. The time to exitus ranged from
1-to-11 years with a mean of 4.8 years after the diag-
nosis of metastatic disease. All patients with disease
specific mortality had organ and multiple sites of bone
metastasis mostly located on the vertebral colon. The
main cause of mortality was the complications arisen
from spinal cord compression due to tumoral involve-
ment. Results: Bone metastases of DTC have poor prog-
nosis. The mortality rate was 40% in our series. We
observed that, mortality was higher in patients with ver-
tebral colon metastasis. However, our results showed
that, with combined and intensive treatment modalities,
up to 12% of complete remission, 35% of good thera-
peutic responses and partial remission can be achieved,
the quality of life can be improved.
PW078
Evaluation of a fast and a standard protocol for bone
scintigraphy SPECT/CT in patients suspected for having
bone metastasis
K. Knudsen, A. Bekker, S. Jentoft Kramer, P. Iversen, A.
Arveschoug; Aarhus University Hospital, Noerrebrogade,
AARHUS, DENMARK.
Background: Bone scintigraphy including SPECT/CT
compared to wholebody scintigrams has been shown to
increase the specificity, to a minor extent the sensitivity,
and observer confidence in the evaluation of bone me-
tastasis in cancer patients. Several studies have demon-
strated that the proportion of indetermined bone lesions
can be reduced significantly by using SPECT/CT. In
order to optimize the examination time as well as the
fact that many patients with bone metastasis have diffi-
culties lying still for longer periods of time, has
prompted us to optimize our bone scintigraphy SPECT/
CT protocol. Aim: To evaluate whether a fast SPECT
protocol could substitute the standard SPECT protocol
for SPECT/CT bone scintigraphy. Methods: Thirty
patients referred for bone scintigraphy, 28 suspected for
having bone metastasis, were included in the study. All
patients were injected with a standard dose of
99mtechnetium-labeled diphosphonate (Teceos, DPD)
and had a planar wholebody scan. In each of the three
regions head-neck-thorax, mid trunc and pelvic-proximal
femoral area, 10 patients were scanned twice with a fast
and standard SPECT/CT protocol, respectively, on a Sie-
mens Symbia T16 SPECT/CT camera (Siemens AG, Er-
langen, Germany). The fast protocol in a continuous
mode and total scan time of 31 minutes for the trunc,
the standard protocol in a step and shoot mode and total
scan time of 50 minutes for the trunc. Three indepen-
dent observers analyzed the standard and fast SPECT/
CT over each region, anonymized and randomized. All
foci in each region were scored on a 5-point scale as normal
lesion, probably normal lesion, equivocal lesion, probably ma-
lignant lesion or malignant lesion. The wholebody scans were
evaluated accordingly. Results: Independent of both observer,
region and nature of foci, the total number of foci detected on
the wholebody scan were considerably lower compared to
both standard and fast SPECT/CT. Furthermore, the data
showed a trend towards a lower total number of detected foci
in the fast SPECT/CT protocol scans compared to the standard
protocol scans. The difference were more pronounced in the
mid trunk region, although not significant for any of the three
observers in any of the three regions (p > 0.05). Conclusion: In
this study we found no significant differences in the observers
ability to detect and describe the bone pathology in a fast and a
standard SPECT/CT bone scintigraphy protocol, respectively.
However, the limited population size of the current study may
increase the variability of the data to produce a false-negative
difference.
PW079
Nephrotic Syndrome with pulmonary embolism: the role
of lung scintigraphy
i. G. E. el bez, A. EZZINE, B. LTAIEF, I. SLIM, D. BEN
SELLEM, l. zaabar, I. MEDDEB, I. YEDDES, b. dhaoudi, A.
MHIRI, M. BEN SLIMENE; institut salah azaiez, tunis, TU-
NISIA.
Patients with nephrotic syndrome (NS) have an in-
creased tendency to develop thrombosis and even to
progress to pulmonary embolism (PE).This study was
performed to determine the incidence of PE in NS and
to evaluate the role of perfusion lung scans in these
patients.Materiel and methods: Thirty-four patients with
NS and risk factors for PE were studied. Eight patients
had a renal failure. In all patients, the probability of PE
was assessed based on the results of perfusion lung
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scans (Tc-99m MAA). The perfusion scan was repeated
in patients having a PE. The lung scans were judged
using the modified Prospective Investigation of Pulmo-
nary Embolism Diagnosis criteria. The patients’ clinical
symptoms and signs on initial examination were report-
ed. Additional examinations included electrocardiograms,
chest radiography, and biological tests such as creati-
nine, albuminemia.Results: Based on the findings of
lung scans, 22 (64.7 %) of the patients were categorized
as having a high probability of PE. 12 (35.3%) patients
had a normal perfusion lung scan. CT angiography was
performed in 26 patients and showed the same results
that lung scan.Two weeks after the administration of
intravenous heparin for anticoagulative therapy, twenty
cases had a recovery or an improvement.Conclusion:
The results of this study suggest that PE is not a rare
complication in patients with NS. The occurrence of PE
did not appear to be always correlated with the clinical
or biological severity of NS. Perfusion lung scans may
provide valuable clues in the evaluation of these
patients.
PW080
Lung V/Q scintigraphy and perfusion SPECT
in the diagnosis of chronic thromboembolic pulmonary
hypertension
J. A. MARROQUÍN GÁLVEZ, D. SANCHEZ FUENTES,
A. SAVIATTO, A. C. HERNANDEZ MARTINEZ, J. P.
PILKINGTONWOLL,M. J. TABUENCAMATEO, S. RUIZ
SOLIS, J . M. ESTENOZ ALFARO; HOSPITAL
UNIVERSITARIO 12 DE OCTUBRE, MADRID, SPAIN.
AIM: To evaluate the efficacy of lung ventilation/
perfusion (V/Q) scintigraphy and perfusion SPECT in
the initial screening of Chronic Thromboembolic Pulmo-
nary Hypertension (CTEPH). MATERIALS AND
METHODS: Retrospective study including 32 patients
(9 male and 23 female), with age ranging from 23-82
years (54.56 ± 19.12), with suspected diagnosis of
CTEPH, referred by the CTEPH unit of our hospital,
between April and December 2014.Lung V/Q scans
were performed using 99mTc-Technegas and 99mTc-
MAA (Macroaggregated Albumin) respectively, includ-
ing anterior, posterior and right and left posterior
oblique projections. Perfusion SPECT was also acquired
in all of them.EANMMI guideline criteria (positive, neg-
ative or indeterminate) was applied when reporting the
findings.CT pulmonary angiography and/or thoracic CT
was also performed to all patients as part of the
study.Pulmonary angiography by right heart catheteriza-
tion was used as the gold standard for the final
diagnosis. RESULTS: Twenty one out of 32 patients
were diagnosed of CTEPH by pulmonary angiography.
Planar lung V/Q scan and perfusion SPECT were posi-
tive in 23/32 patients (2 false positive for Primary Pul-
monary Hypertension). The other 9/32 patients were re-
ported as negative. We did not obtain any false negative
or indeterminate result.The V/Q scan and perfusion
SPECT for the diagnosis of CTEPH had a sensitivity
of 100%, specificity of 81.82%, positive predictive value
of 91.30%, negative predictive value of 100%, and an
accuracy of 93.75%. CONCLUSION: In our study, lung
V/Q scan and perfusion SPECT had a high sensitivity
and negative predictive value for CTEPH diagnosis with
an accuracy value around 95%, demonstrating their
strong efficacy in the initial screening of CTEPH.
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Sentinel node detection with ferromagnetic particles
in breast cancer. Preliminar results
U. Granados, S. Vidal-sicart, X. Caparrós, M. Alonso, P.
Fernandez, P. Perlaza, A. Tápias, F. Lomeña; Hospital Clínic,
Barcelona, SPAIN.
Aim: To compare two techniques for sentinel lymph node
(SLN) detection in patients with breast cancer (BC): ra-
dioactive tracer (99mTc-Nanocoll®) and ferromagnetic
particles (SentiMag®) and to analyze the correlation be-
tween two different injection sites and time spent for SLN
location. Material and Methods: We have studied prospec-
tively 29 BC patients, scheduled for SLN Biopsy, with a
mean age of 60.7 years. The injection of the radiotracer
(111 MBq in 0.5 mL) was mainly intra / peritumoral the
day before surgery. Lymphoscintigraphic images (30 min
and 2 h) were subsequently performed. No external mark
in SLN skin projection was drawn. In the operating room,
5 ml of ferromagnetic particles ( Sienna+®) were admin-
istered by periareolar injection followed by a 5 minutes
massage. The surgeon used a magnetometer and the nu-
clear medicine physician used the gamma radiation detec-
tion probe. The transcutaneous signal was evaluated with
SentiMag (surgeon) and with gamma probe (nuclear med-
icine physician).The skin incision was performed after
reaching a clear transcutaneous signal with SentiMag®.
The correlation between the magnetic source and the ra-
dioactivity was checked. Results: In 26 patients was locat-
ed at least one SLN with both techniques. In 3 patients the
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detection of SLN with ferromagnetic particles was not
possible (1 patient had previous surgery). In 13 cases both
techniques located the same SLN (44.8%). When the in-
jection site was the same, the correlation observed for both
techniques was 63.6%; when radioactive tracer was
injected intra / peritumoral this concordance droped to
33.3%. SentiMag® was faster in the location of SLN in
9 patients, in 6 patients a greater number of SLN were
detected. In 13 patients the conventional gamma probe
detected SLN more easily and in 3 patients was the only
technique that located the SLN. The mean operating time
was 44 min with SentiMag® vs 38 min with the radiotrac-
er. Conclusions: SentiMag® detects a discrete higher num-
ber of SLN. When the injection site differs there is a major
discrepancy in SLN detection between techniques. In
some cases the SLN has been detected only with the con-
ventional technique.
PW082
Gastrin-releasing peptide receptor expression is associated
with estrogen receptor status in breast cancer: Findings
of a PET/CT pilot study
C. Stoykow1,2,3, T. Erbes4, S. Bulla1, H. Mäcke1, V. Drendel5,
P. Bronsert5,6, M. Werner5,6, E. Stickeler4, P. T. Meyer1; 1Uni-
versity Medical Centre Freiburg, Department of Nuclear Med-
icine, Freiburg, GERMANY, 2German Cancer Consortium
(DKTK), Freiburg, GERMANY, 3German Cancer Research
Center (DKFZ), Heidelberg, GERMANY, 4University Medical
Centre Freiburg, Department of Gynecology and Obstetrics,
Freiburg, GERMANY, 5University Medical Centre Freiburg,
Department of Clinical Pathology, Freiburg, GERMANY, 6Ger-
man Cancer Consortium (DKTK), Heidelberg, GERMANY.
The gastrin-releasing peptide receptor (GRPR) is
overexpressed in several human tumors. The purpose of the
present study was to evaluate GRPR imaging as a novel diag-
nostic approach in breast cancer. We employed positron emis-
sion tomography (PET) and the novel GRPR antagonist
[68Ga]RM2, which has been developed by our group.
[68Ga]RM2 possesses a low nanomolar affinity for GRPR
and has already been successfully studied in prostate cancer.
Fourteen female patients with histologically confirmed, locally
advanced primary breast carcinoma (3 bilateral tumors)
underwent PET/CT for pre t rea tment s tag ing on
compassionate-use basis. PET/CT was acquired 1h after
injecting 150-200MBq [68Ga]RM2. In vivo GRPR binding
was correlated with estrogen (ER) and progesterone (PR) ex-
pression, HER2/neu status and MiB-1 proliferation index of
biopsy specimens. Normal breast tissue showed an inter-
individually variable, moderate heterogeneous GRPR binding
(SUVMAX 2.27±1.02), while physiological uptake of most
other tissues/organs was considerably less (SUVMEAN liver,
muscle and fat: 1.10±0.32, 0.38±0.10 and 0.19±0.04) except
pancreas (52.7±11.6). 12/17 tumors were clearly visualized by
strongly increased uptake compared to normal breast tissue
(PET-positive). Noteworthy additional findings included the
detection of small internal mammary lymph nodes (2-3mm)
with strong GRPR binding, a contralateral axillary lymph node
metastasis (n=1; verified by biopsy) and bone metastases not
detected by other imaging modalities (n=1). All PET-positive
tumors were ER- and PR-positive, in contrast to only 1/5 PET-
negative tumors (Fisher’s exact test p=0.002; SUVMAX 10.80
±6.21 and 2.31±0.97 in ER-positive and ER-negative tumors,
respectively). In a multivariate analysis including ER, PR,
HER2/neu and MiB-1, only ER expression predicted GRPR
binding (R2=0.56, p<0.05). This pilot study demonstrates that
GRPR PET/CT is a promising diagnostic modality in ER-
positive breast cancer. GRPR imaging may serve as a possible
surrogate marker for ER expression with putative therapeutic
and prognostic importance.
PW083
Measurement of early treatment response in patients
with recurrent or metastatic breast cancer with 18F-FLT
and 18F-FDG PET/CT: a pilot study
T. Su, S. Chan, K. Lui, J. Huang; Chang-Gung Memorial
Hospital Keelung Branch, Keelung, TAIWAN.
Aim: 18F-FLT and 18F-FDG PET have been proved
useful in monitoring treatment response of recurrent or
metastatic carcinoma. However, combination of 18F-FLT
and 18F-FDG PET in assessing treatment outcome of
recurrent/metastatic breast cancer has not been reported.
In this prospective study, we investigated the imaging
biomarkers, 18F-FLT and 18F-FDG, to measure early
treatment response in recurrent/metastatic breast cancer
after the first and second cycles of taxane- or cisplatin-
based chemotherapy. Materials and methods: Eleven pa-
tients with recurrent or metastatic breast cancer, who
were about to commence a new pharmacological treat-
ment regimen, were recrui ted. Each individual
underwent 18F-FLT and 18F-FDG PET/CT at baseline,
and after the first and second cycles of the new regi-
men. Treatment response was based on the results of 3-
month post-therapy conventional work-up, with criteria
of the Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1. Variables from 18F-FLT and 18F-FDG
PET scans were correlated with the conventional imag-
ing results. Results: Treatment response determined by
RECIST 1.1 showed 5 responders and 6 non-responders.
In all responders, systemic treatment had resulted in de-
creases in both 18F-FDG and 18F-FLT uptake
S320 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
(SUVmax): -15.0±8.0% and -24.5±28.7% after one cy-
cle; -50.6±26.0% and -37.8±39.7% after two cycles.
Among non-responders, however, 5 subjects (5/6, 83%)
also had decreased 18F-FDG uptake, and the changes of
SUVmax were -12.3±14.4% and -24.0±14.2% after the
first and second course of chemotherapy. In contrast, the
corresponding 18F-FLT SUVmax uptake in non-
responders showed increased tendencies compared to
the baseline images (0.0±28.6% and 16.3±61.6%). In
subjects with pure bony metastases (2/11), the 18F-
FDG-avid bone lesions which showed no 18F-FLT up-
take ended in good response to treatment, and the 18F-
FDG PET could not correctly predict the good response.
Conclusion: Tumor uptake assessed by 18F-FLT PET
early after initiating systemic therapy appears to be a
superior marker than 18F-FDG PET to predict treatment
response in patients with recurrent/metastatic breast
cancer. For solely bony metastasis group, presentation
of 18F-FLT-photopenic lesions may be a good
prognosticator.
PW084
Sentinel-node in cervical cancer patients: preoperative
assessment with SPET/CT and comparison
with intra-operative gamma-probe and methylene
blue-dye
M. Cuzzocrea1, F. Elisei2, C. Crivellaro1, C. Dolci1, A.
Buda3, M. Signorelli3, L. Guerra2, D. Giuliani4, M. Arosio2,
R. Milani5, C. Landoni5; 1University of Milan-Bicocca, Nu-
clear Medicine, Milan, ITALY, 2Nuclear Medicine Depart-
ment, San Gerardo Hospital, Monza, ITALY, 3Gynaecology
Department, San Gerardo Hospital, Monza, ITALY, 4Univer-
sity of Milan-Bicocca, Gynaecology, Milan, ITALY, 5Univer-
sity of Milan-Bicocca, Milan, ITALY.
BACKGROUND AND AIM OF THE STUDY: Lymph-node
status is a major prognostic factor in cervical cancer (CC).
Sentinel lymph-node (SLN) biopsy has been reported in CC,
even if not yet a standard-of-care procedure. Aim of this study
was to compare preoperative SPET/CTwith gamma-probe and
methylene blue-dye (MBD) in identification of SLN in early-
stage CC. METHODS: 25 clinically early-stage CC women
(66.7±9.7years, stage I-IB2) underwent preoperative
lymphoscintigraphy. Tc-99m albumin nanocolloid was
injected submucosally at 4 points of the cervix. After about 3
hours all patients underwent SPECT/CT study. MBD was
injected into the cervix just before surgery under general an-
esthesia. All patients underwent hysterectomy, bilateral
salpingo-oophorectomy, and radical pelvic nodal dissection.
SPET/CT findings were compared to gamma-probe and
MBD techniques. RESULTS: The detection rate of at least
one SLN resulted 100% (25/25 patients) with SPET/CT,
92% (23/25) intra-operatively with gamma-probe and 84%
(21/25) with MBD. Only in 18/25 (72%) patients a bilateral
migration was obtained with all considered modalities. In par-
ticular, bilateral detection was achieved in 16 patients with
SPET/CT (64%), in 11 patients with gamma-probe (44%)
and in 8 patients with MBD (32%). The concordance site
between SPET/CT and intra-operatively gamma probe result-
ed 80% (in 20/25 patients: 9 bilateral and 11monolateral SNs);
while concordance site with MBD was found in 32% (21/25
patients: 6 bilateral, 15 monolateral SNs). In the only 2/25
cases with failed SN detection by gamma probe, SPET/CT
had revealed nodal uptake, however the intra-operative SN
recognition was obtained with MBD. Overall 677 LNs were
dissected (mean 27 LNs per patient), among which 74 SLNs
(mean 3 SLNs per patient). Of 74 SLNs: 34were “hot and blue
(HB)”, 15 blue only and 25 hot only. Eleven/74 SNs resulted
positive for metastases in 5 patients (5 HB, 3 hot only and 3
blue only), with an incidence of LN metastases of 20%. Five
positive non-SLNs were found in 2 patients, all with concom-
itant metastatic SLNs. False negative rate was 0%. CONCLU-
SIONS: Detection rate of at least one SLN was 100% with
SPET/CT, 92% intra-operatively with gamma-probe and
84% with MBD. SPET/CT achieved the highest rate of opti-
mal node mapping (bilateral migration 64%). Of 74 dissected
SLNs, 34% were recognized by isotopic technique only, 20%
by MBD only and 46% by both, confirming the complemen-
tary role of dual technique.
PW085
Comparison of imaging modalities (CT, FDG-PET/CT)
in head and neck cancer patients
Z. Besenyi1, S. Urbán2, K. Hideghethy3, T. Séra1, Z. Lengyel4,
L. Pávics1; 1University of Szeged Department of Nuclear
Medicine, Szeged, HUNGARY, 2University of Szeged,Insti-
tute of Informatics, Szeged, HUNGARY, 3University of Sze-
ged Department of Oncology, Szeged, HUNGARY, 4Positron
Diagnostics Ltd, Budapest, HUNGARY.
Introduction: The aim of this study was to evaluate the role of
FDG-PET/CT in head and neck cancer patient treatment strat-
egy. Gross tumor volumes delineation methods based on pos-
itron emission tomography and conventional topoCT were
compared. The impact of tumor volumes were evaluated in
overall and disease specific survival. Methods: 70 oncologic
patients with primary head-neck cancer were enrolled in the
current study. Within 3 weeks difference CT and FDG-PET/
CT image acquisition were completed separately in planned
irradiation position. Gross tumor volume were determined by
manually contouring independently both on conventional CT
based topometric slices and FDG-PET/CT images.
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Radiotherapy target volume was calculated (GTV-pet GTV-ct
[cm3]) using both modalities and numerical and geometrical
comparisons were assesed. For a geometrical comparison
manually contoured tumor shapes intersection divided by
union ratio was calculated. This I/U ratio is a value between
0 and 1, where a value of 1 means full overlap and value of 0
means no overlap. Results: In regards to the total population
radiotherapy target volume as assessed by FDG-PET/CT dif-
fered in 98 % (69/70) from target volumes calculated by
topoCT. According to metabolic information the planned irra-
diation field was greater in 10 cases (14 %) and smaller in 59
cases (84 %). Significant differences were seen between CT
and PET/CT based tumor volume (paired t-test p<0.0001). In
point of geometrical view the calculated I/U ratio was average
0.37 ± 0.20 SD. Maximum value: 0.8, minimum: 0.014. The
geometrical comparison showed large variation and the aver-
age ratio shows weak overlap. After average 6.4 years follow
up the overall and disease specific survival showed close cor-
relation with GTV-pet (p=0.0001). Conclusion: The CT and
FDG-PET/CT based tumor target volumes differed signifi-
cantly from each other. Differences between two modalities
were even more apparent when not only tumor volume but
geometric dimensions were also calculated. Our results
showed that CT based morphologic information overestimates
the tumor volume in larger lesions and can underestimate it in
smaller target lesions in head and neck cancer. Radiotherapy
planning based on the combination of structural and metabolic
information with implementation of modern radiotherapy
techniques may improve the efficacy of cancer therapy.
PW086
Clinical Value of FAZA-PET/CT in Head and Neck
Cancer Patients
T. Saga1, M. Inubushi2, M. Koizumi3, K. Yoshikawa1, M.
Zhang1, T. Obata1, R. Harada4, T. Uno4; 1National Institute
of Radiological Sciences, Chiba, JAPAN, 2Kawasaki Medical
School, Kurashiki, JAPAN, 3Cancer Institute Hospital, Tokyo,
JAPAN, 4ChibaUniversity Graduate School ofMedicine, Chi-
ba, JAPAN.
Aim: The presence of hypoxia in cancer tissue is known to
increase not only their refractoriness to treatment, but also their
malignant potential. The information of cancer hypoxia, there-
fore, is important for the management of cancer patients such
as prediction of treatment response and the selection of appro-
priate treatment strategy. The aim of the present study was to
evaluate the clinical value of PET/CTwith FAZA, a PET probe
to detect cancer hypoxia, in head and neck cancer patients,
especially on the prediction of patients’ prognosis. Materials
and Methods: Twenty-nine patients with head and neck cancer
(stage I: 1 patient, stage II: 2 patients, stage III: 8 patients, stage
IV: 18 patients; squamous cell carcinoma (SCC): 26 patients,
non-SCC: 3 patients) received FAZA-PET/CT before treat-
ment. Patients were followed to determine the treatment re-
sponse and survival. Uptake parameters of FAZA (tumor-mus-
cle ratio at 2 hours post-injection (T/M)) in primary lesion and
lymph node metastasis were compared with various clinical
parameters. Progression-free survival (PFS) was compared
with clinical and FAZA uptake parameters in SCC patients
who received chemoradiation therapy (CRT). Study protocol
was approved by the institutional review board, and informed
consent was obtained from all patients. Results: Among SCC
cases, there was a significant correlation between FAZA pri-
mary T/M and maximal diameter of primary lesion (P = 0.007,
r = 0.517). FAZA primary T/M was significantly higher in
stage IV patients than in stage I ~ III patients (P = 0.003),
and was significantly higher in T2 ~ 4 patients than in T1
patients (P = 0.009). Although not statistically significant,
SCC patients who developed disease progression after CRT
tended to show higher FAZA primary T/M than those who did
not develop disease progression (1.70 ± 0.30 vs. 1.48 ± 0.36, P
= 0.095). Kaplan-Meier analysis with Log-Rank test has
shown that, among various clinical and PET parameters, only
FAZA primary T/M was a significant predictor of PFS (P =
0.010), in which patients with FAZA primary T/M > 1.565
showed significantly worse PFS rate than those with FAZA
primary T/M ≤ 1.565. Conclusion: FAZA primary T/M was a
significant predictor of PFS in head and neck SCC patients
receiving CRT. Pretreatment FAZA-PET/CT can afford useful
information on the management of head and neck cancer
patients.
PW087
Diagnostic accuracy of 18F-FDG PET/CT in primary
staging of cutaneous malignant melanoma according
to Breslow thickness: a preliminary study
S. Diodato1, S. De Vivo1, C. Baraldi2, G. Veronesi2, E. Dika2,
S. Fanti2,1, A. Patrizi2, S. Vaccari2; 1Nuclear Medicine,
Policlinico S.Orsola-Malpighi, University of Bologna, Bolo-
gna, ITALY, 2Dermatology Unit, Policlinico S.Orsola-Malpi-
ghi, University of Bologna, Bologna, ITALY.
Aim: The purpose of this study was to assess sensitivity and
specificity of 18F-FDG PET/CT to detect lymph node and soft
tissue/visceral metastasis in the primary staging of cutaneous
malignant melanoma (CMM). Materials and methods: We ret-
rospectively evaluated 76 patients, 52 male and 24 female,
mean age 62 y.o. (range 28-93), with a histological diagnosis
of CMM, who underwent initial staging 18F-FDG PET/CT
between april 2004 and november 2011 at Nuclear Medicine
Unit, University of Bologna. Histological features of the pri-
mary tumors were available for all patients. Patients were
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classified into 3 groups: group A (Breslow thickness <0,75
mm, 11 pts), group B (Breslow thickness 0,76-1,5 mm, 15
pts) and group C (Breslow thickness >1,5 mm, 50 pts). The
results of the PET/CT scans were compared with those obtain-
ed by further histopathologic evaluations and/or clinical and
radiological investigations, up to 3-6 months. Results: Overall
sensitivity and specificity were respectively 61,5% and 93,5%.
In group A and B sensitivity was 100% both for N- and M-
staging. Specificity in group A was 100% for detection of
lymph node metastasis and 90% for distant metastasis: the
unique false positivity was observed in a patient presenting a
cutaneous/subcutaneous moderately hypermetabolic lesion,
that resulted a sebaceous cyst at histological examination.
Specificity in group B was 100% for M-staging and 93% for
N-staging. In group C sensitivity was 55,5% for N-staging and
66,7% for M-staging: a false negative result was observed in a
patient with a pulmonary nodule without increased FGD up-
take, that further resulted as a metastasis from CMM in the
radiological follow up. Specificity was 100% for distant me-
tastasis and 94,9% for lymph node metastasis. Diagnostic ac-
curacy in group A, B and C were respectively 91%, 93% and
84%. Conclusion: Sensitivity and specificity of 18F-FDG
PET/CT in N- and M-staging of CMM seem to be higher in
patients with Breslow thickness <1,5 mm. These results are
quite in contrast with the trend of studies in literature that
reported a better diagnostic performance of PET/CT in high
risk patients with CMM. Further studies including a larger
number of patients with lower Breslow thickness are necessary
to assess the potential role of PET/CT in primary staging based
on Breslow’s depth. Other prognostic factors , such as the
number of mitoses and the presence or absence of ulceration
on the histopathologic evaluation of the primary melanoma
should be evaluated together with Breslow thickness.
PW088
Comparison of 123I-IMP SPECT, 18F-FDG PET,
and 18F-FDOPA PET in Detection of Uveal Malignant
Melanoma
K.Kato1, S. Tsuchiya1, Y. Koshiba1, T. Odagawa1, S. Abe2, T.
Kubota3, H. Terasaki1, S. Naganawa1; 1Nagoya University
Graduate School ofMedicine, Nagoya, JAPAN, 2NagoyaUni-
versity Hospital, Nagoya, JAPAN, 3Nagoya Medical Center,
National Hospital Organization, Nagoya, JAPAN.
Aim: Previously we showed that 123I-IMP SPECT is a sensi-
tive and accurate method for the detection of uveal malignant
melanoma. The feasibility and usefulness of 18F-FDOPA PET
for detection of uveal malignant melanoma have not yet been
established. The purpose of this study is to compare the use-
fulness of 123I-IMP SPECT, 18F-FDG PET, and 18F-FDOPA
PET for detection of uveal malignant melanoma. Materials
and Methods: Forty-six patients with suspected uveal malig-
nant melanoma were examined by 123I-IMP SPECT, 18F-
FDG-PET/CT, and 18F-FDOPA PET/CT. Results: In 29 of
46 study patients, 123I-IMP SPECT showed markedly in-
creased uptake in the site corresponding to the ocular tumor.
In 26 of the 29 patients showing increased uptake of 123I-IMP,
the ocular tumors were confirmed histopathologically or clin-
ically to be uveal malignant melanoma. The ocular tumors in
the other 3 patients showing increased uptake of 123I-IMP was
diagnosed as small choroidal melanocytic lesions. The 17 123I-
IMP SPECT-negative cases comprised 7 small melanocytic
lesions, 1 choroidal hemangioma, 1 adenoma, and 2
melanocytoma, 2 metastases, 3 hemorrhages, and 1 unknown
benign lesion. Nineteen of 20 of uveal malignant melanoma
showed positive uptakes in 18F-FDG PET and 18F-FDOPA
PET. The uptakes of both 18F-FDG and 18F-FDOPA were
much weaker than that of 123I-IMP. The range and mean ±
SD of SUVmax for 18F-FDG and 18F-FDOPA in uveal malig-
nant melanoma were 1.70-10.35, 3.78 ± 0.88 and 0.74-4.63,
1.18 ± 0.06, respectively. The difference between the uptakes
of both tracers was statistically significant. Thus the uptake of
18F-FDOPA was weaker than that of 18F-FDG. Conclusion:
123I-IMP SPECT is superior to 18F-FDG and 18F-FDOPA
PET for the detection of uveal malignant melanoma. Efficacy
of 18F-FDOPA PET is for the detection of uveal malignant
melanoma is low compared with 18F-FDG PET because of
its weak uptake into uveal malignant melanoma.
PW089
Potential impact of 18F-Fluorothymidine PET/CT
in lymphoma patients with suspect residual disease
or relapse.
L. Zanoni1, A. Broccoli2, C. Nanni1, C. Pellegrini2, F. Lodi1,
C. Fonti1, P. Ghedini1, S. Cambioli1, P. Zinzani2, S. Fanti1;
1Nuclear Medicine, University Hospital S’Orsola-Malpighi,
Bologna, ITALY, 2Hematology “L. e A. Seràgnoli”, Universi-
ty Hospital S’Orsola-Malpighi, Bologna, ITALY.
AIM: To evaluate the role of 18F-fuorothymidine (FLT) PET/
CT in patients (pts) affected by lymphoma, presenting with
positive or inconclusive 18F-deoxyglucose (FDG) PET/CT
at end-treatment or follow-up. MATERIALS AND
METHODS: Mono-centric prospective study. From
May 2010 to March 2015, overall 40 pts were enrolled. They
all underwent FLT PET/CT within 3 weeks from a previous
positive or inconclusive FDG scan at end-treatment or follow-
up and, when possible, biopsy confirmation as standard of
reference to define PET results (true positive-TP; true
negative-TN; false positive-FP; false negative-FN). The
highest lesion SUVmax was measured with both tracers. RE-
SULTS: Pts characteristics: mean age 55 (range 20-76); 24
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males and 16 females; 30 non-Hodgkin (NHL) and 10 Hodg-
kin lymphoma (HL); stage at diagnosis: 8 II, 8 III, 24 IV; 6 pts
were evaluated at end-treatment and 34 during follow-up/
restaging. FDG-PETwere judged positive in 36 out of 40 cases
(mean SUVmax=10.1; range 3-31). 8/36 scans resulted also
FLT positive (mean SUVmax= 7.8; range 3-16.8): 16/28 pts
had the most active lesion biopsied, demonstrating 15 TP but 1
FP (HL patient presenting with FDG-SUVmax 6.9 and FLT
6.8 in cervical node: reactive follicular hyperplasia) whereas
the remaining 12/28 pts could not be biopsied for ethical/
practical reasons but subsequent follow-up data and final clin-
ical evaluation (CE) confirmed 11 TP and 1 FP(reactive cer-
vical node). 8/36 scans resulted FLT inconclusive in the light
of lesion distribution and relatively lower SUVmax values
(mean 4.8; range: 1.7-11.7): 5/8 were defined as TP at biopsy
(2) or CE (3), whereas 3/8 represented inflammatory tissue ( 1
histologically-proven sarcoidosis-like reaction in mediastinal
and supraclavicular nodes; 2 reactive axillary-mediastinal
nodes and supraclavicular lymphadenopathy, respectively, at
CE). The remaining 4/36 FDG-PET were considered incon-
clusive (mean SUVmax=7.2; range 4.9-8.8). 3 out of 4 were
also defined inconclusive at FLT (mean SUVmax=4; range
2.6-4.9), but the final CE excluded lymphoma (1 reactive cer-
vical node, 1 supra-diaphragmatic nodal sarcoid-like disease, 1
aspecific pericecal finding). The remaining 1/4 resulted FLT
positive (SUVmax 6.9 and 6.5 for FDG and FLT, respectively)
and was confirmed TP at CE. CONCLUSION: In the particu-
lar setting of residual/recurrent lymphoma, our preliminary
data suggest that FLT might be complementary although not
alternative to FDG. The elimination of inconclusive PET find-
ings still represents a controversial step, therefore biopsy con-
firmation remains mandatory. Further lesion/semi-quantitative
(i.e. target to background/mediastinal blood pool/liver ratio)/
Ki67 correlation analyses are ongoing.
PW090
Comparison of 18F-FDG PET/CT and PET/MRI
for the assessment of multiple myeloma
C. Sachpekidis1, J. Hillengass2, H. Goldschmidt2, J.
Mosebach3 , H. Schlemmer3 , U. Haberkorn4 , A.
Dimitrakopoulou-Strauss1; 1Clinical Cooperation Unit Nucle-
ar Medicine, German Cancer Research Center, Heidelberg,
GERMANY, 2Medical Clinic V, University of Heidelberg,
Heidelberg, GERMANY, 3Department of Radiology, German
Cancer Research Center, Heidelberg, GERMANY, 44Division
of Nuclear Medicine, University Clinic Heidelberg, Heidel-
berg, GERMANY.
Objective: The aims of this prospective study are to evaluate
the feasibility of 18F-FDG PET/MRI in detection of myeloma,
and to investigate the reproducibility of bone marrow lesions
detection and quantitative data of 18F-FDG uptake between
the functional (PET) component of PET/CT and PET/MRI in
MM patients. Patients and methods: The study includes 29
patients diagnosed with MM according to the International
Myeloma Working Group criteria. All patients initially
underwent 18F-FDG PET/CT (60 min after tracer injection),
followed by PET/MRI (120 min after tracer injection). PET/
CT and PET/MRI data were assessed and compared based on
qualitative (lesion detection) and quantitative (SUV) eval-
uation. Results: The hybrid PET/MRI system provided
good image quality in all cases without artefacts. PET/
MRI identified 59 of the 63 lesions, which were detectable
with PET/CT (93.7%). Three focal rib lesions and one
lesion in os ilium in three patients were missed by PET/
MRI. Quantitative PET evaluations showed the following
mean values in MM lesions: SUVaverage=5.6 (median
5.1) and SUVmax=8.1 (median 7.1) for PET/CT;
SUVaverage=4.1 (median 3.9) and SUVmax=6.0 (median
5.7) for PET/MRI. According to Wilcoxon matched-pairs
signed rank test, both SUVaverage (p<0.0001) and
SUVmax (p<0.0001) derived from MM lesions were sig-
nificantly higher on PET/CT than on PET/MRI. Spearman
correlation analysis demonstrated a strong correlation be-
tween both lesional SUVaverage (r=0.755, p<0.0001) and
lesional SUVmax (r=0.864, p<0.0001) values derived
from PET/CT and PET/MRI. Conclusion: Our study dem-
onstrated that the PET/MRI hybrid system provides good
image quality in MM and detected 93.7% of the PET/CT
lesions. In terms of tracer uptake quantitation, a strong
correlation between the two techniques was demonstrated,
despite the statistically significant differences in lesional
SUVs between PET/CT and PET/MRI.
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The thyroid stunning effect: according to Poisson statistics,
a small fraction of an ablative dose already kills a large
fraction of cells.
S. Walrand, M. Hesse, F. Jamar; Université Catholique de
Louvain, Brussels, BELGIUM.
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Aim: The origin of the reduction in thyroid uptake after a low
activity iodine scan, so-called stunning effect, is still contro-
versial. Two explanations prevail: an individual cell stunning
that reduces its capability to store iodine without altering its
viability or a significant cell killing fraction that reduces the
number of cells in the tissue still taking up iodine. Our aim is to
analyze whether this last assumption could quantitatively ex-
plain the observed reduction. Methods: tumor (or tissue) con-
trol probability (TCP) is governed by Poisson statistics
(Brahme and Agren 1987), i.e: TCP(A) = exp (-Nc x
Sf(D(A))) = exp(-Nc x exp(-α D(A))) (1) where Nc is here
the number of cells alive before ablation (about 4x107 for 1 g
of remnant tissue), Sf the survival fraction, α the cells radio-
sensitivity and D the mean delivered dose which is nearly
proportional to the administrated activity A. Recent studies
showed that a single administration of 30 mCi of I131 pro-
vides a TCP of about 75% and that a diagnostic dose of 2 mCi
of I131 can induce in a following administration an uptake
reduction ranging from 20 to 90%. Results: straight inversion
of eq. 1 gives: Sf(A) = exp(-α D(A)) = -ln(TCP(A)) / Nc (2)
Using TCP(30mCi) ≈0.75 and eq. 2, we get for 1 g of tissue:
Sf(30mCi) ≈ 7x10-9 and Nc x Sf ≈ 0.3. However even if Nc x
Sf < 1, due to the random nature of radiation killing, in 25% of
30 mCi-treatments there remain enough surviving cells to al-
low remnants relapsing. As D(2mCi) ≈D(30mCi)/15, one has
Sf(2 mCi) ≈ exp(-a D(30mCi)/15) = (Sf(30mCi))1/15 ≈ 29%
which is sufficient to induce a uptake reduction of 70% in a
scan following a 2 mCi-diagnostic scan. Furthermore, this sta-
tistical demonstration, showing that a small fraction (1/15) of
an ablative dose already kills a significant fraction of cells
(≈70%), was experimentally proved in mega-colony cell assay
(Kappler et al. 2007). Conclusion: The statistical analysis
shows that the uptake reduction effect can be purely explained
by the cell killing fraction. This supports the non-existence of
an individual cell stunning effect that, if present, should induce
an additional uptake reduction resulting in much larger de-
creases than those observed. As the β/α ratio measured in
thyroid cancer cell assay is very low, this effective fraction-
ation of the therapy should not impact the patient outcome in
agreement with recent studies.
PW092
Thyroid remnant ablation in differentiated thyroid cancer:
searching for the most effective radioiodine activity
and stimulation strategy ina real life scenario
A. Campenni’1, L. Giovanella2, S. Pignata1, M. Murè1, M.
Siracusa1, F. Cosentino1, L. Sturiale1, P. Coppolino1, M.
Ruggeri3, S. Baldari1; 1Nuclear Medicine Unit of Messina,
Messina, ITALY, 2Nuclear Medicine and PET/CT centre, On-
cology Institute of Southern Switzerland, Bellinzona, Switzer-
land., Bellinzona, SWITZERLAND, 3Department of Clinical
and Experimental Medicine and Pharmacology, Section of En-
docrinology, University of Messina, Messina, Italy, Messina,
ITALY.
AIM: Differentiated thyroid cancer (DTC) is rare but in-
cidence has been increasing in the last few decades. Early
treatment is based on surgery and thyroid remnant ablation
(TRA) by radioiodine therapy. Despite radioiodine being
widely used for decades, the choice of ablative activity is
generally empirical and no consensus has been reached to
date. The aim of our study was to compare the efficacy
and safety of different radioiodine activities. In addition,
we compared the ablation rate in patients treated in hypo-
thyroid state or after recombinant human TSH (rhTSH)
administration.MATHERIAL AND METHODS: We
reviewed, retrospectively, the records of 471 patients
(376 Female, 95 Male; F:M 3.9:1; mean age 46.5±10.8
years, ranges 16-74) affected by DTC and admitted to
our University Hospital. Among 471 patients, 394
(83.6%) were papillary histotype (PTC), 77 (16.4%) were
follicular histotype (FTC); 84 (17.8%) were pT1N0M0,
232 (49.2%) were pT2N0M0, 155 (32.9%) were
pT3N0M0. Inclusion criteria were: age > 16 years, no
loco-regional or distant metastases, not pregnant. All pa-
tients underwent radioiodine therapy (RAIT) after total or
near-total thyroidectomy. Fifty-seven per cent of patients
underwent RAIT after thyroid hormone withdrawal to
achieve a serum thyrotropin (TSH) level above 30 μUI/
ml. The remaining patients were treated after rhTSH-
stimulation (0.9 mg daily for two consecutive days admin-
istered by intra-muscular injections). The patients were
divided into three groups according to different
radioiodine activity administered (A: 1110 MBq, B: 2220
MBq, C: 3700 MBq). Such activities were established by
the attending physician on the basis of age, sex, TNM
staging, histological variant, coexisting Hashimoto thy-
roiditis. All patients underwent neck-ultrasonography be-
fore RAIT, and those treated in hypothyroid state also at
radioiodine uptake, obtained 24 hours after administration
of radioiodine tracer activity (1.8 MBq). RESULTS: The
success of TRA was evaluated twelve months later. TRA
was obtained in: 62/79 (78.5%) in Group A (1110 MBq in
hypothyroid state), 183/190 (96.3%) in Group B
[2220 MBq in hypothyroid state or after rhTSH-
administration: 87/90 (97%) and 96/100 (96%), patients
respectively], 199/202 (98.5%) in Group C [3700 MBq
in hypothyroid state or after rhTSH-administration:
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9 8 / 1 0 0 ( 9 8% ) a n d 1 0 1 / 1 0 2 ( 9 9% ) , p a t i e n t s
respectively].CONCLUSIONS: Our data demonstrate that
2220 and 3700 MBq radioiodine are more effective than
1110 MBq in TRA, without significant differences be-
tween 2220 and 3700 MBq or between hypothyroidism
and euthyroidism. We suggest rhTSH-aided TRA with
2220 MBq 131-radioiodine as this approach permits effi-
cacious treatment reducing side effects, absorbed dose to
body and hospital stay.
PW093
Selenium as a radiation protector of salivary glands
in radioiodine remnant ablation therapy
M. Marx, S. Fastenmeier, M. Zuhayra, U. Lützen;
Universitätsklinikum Schleswig-Holstein, KIEL, GERMANY.
Aim: Salivary gland impairment following high-dose
radioiodine treatment is well known. This study investigates
the effect of selenium to salivary glands of patients with well
differentiated thyroid carcinoma receiving a radioiodine rem-
nant ablation therapy (RAA). Furthermore the influence to
remnant ablation was examined. Methods: 13 patients (group
A) aged 26 - 75 years (mean 50,2 years) received 1000 μg
selenium 30 minutes prior to application of 3,0 to 6,0 GBq
I-131 (mean 3,4 GBq). A matched controll group (group B)
aged 22 - 81 years (mean 50,9 years), received 3,0 to 6,0 GBq
(mean 3,3 GBq) without selenium. The salivary gland function
was investigated by salivary gland scintigraphy with Tc-99m-
Pertechnetat prior to therapy and 3 months after RAA. The
selenium concentration in serum was measured prior to and
72 h after therapy, also thyroglobulin (TG) before therapy as
well as 3 and 6 months after therapy. Six months after RAA a
radioiodine whole body scan (WBS) with I-131 was per-
formed. Results: The patients in group A showed an average
selenium concentration in serum of 75,15 mg/dl (57,0-92,0) at
baseline with an significant increase to 102,0 mg/dl (73-134)
72 h after administration of selenium (p=0,00015). Prior to
therapy in group A an uptake of Tc-99m in salivary glands
(SG) of 0,20%±0,11% (0,10%-0,41%) was measured com-
pared with 0,19%±0,08% (0,07%-0,33%) three months after
therapy. In group B SG-uptake was determined 0,15%±0,06%
(0,04%-0,24%) prior to and 0,08%±0,03% (0,05%-0,17%) af-
ter therapy. There was no significant change of salivary func-
tion in group A (p=0,85) but in the control group B (p=0,
0016). The success of ablation therapy (no measurable TG,
no remnant tissue in WBS) was not affected by selenium ad-
ministration. Conclusions: This first results indicate that dam-
age to salivary glands induced by radioiodine therapy can be
reduced significantly by selenium. A placebo controlled study
with a greater number of patients is necessary and in planning.
PW094
Association between iodine intake and treatment outcomes
of radioiodine remnant ablation in patients
with intermediate risk papillary thyroid cancer
Y. Sun, W. Ouyang; Department of Nuclear Medicine,
Zhujiang Hospital,Southern Medical University, Guangzhou,
CHINA.
Aim To evaluate the association between iodine intake and
treatment outcomes of radioiodine remnant ablation in Amer-
ican Thyroid Association (ATA)-intermediate papillary risk
thyroid cancer(PTC) patients, and to investigate the determi-
nants related to the ablation efficacy. Materials andMethods A
total of 95 ATA-intermediate PTC patients were enrolled into
the retrospective study. All patients had undergone total thy-
roidectomy and 2-4 weeks of low iodine diet (LID) before
init ial 131I therapy. According to urinary iodine
excretion(UIE) of patients, they were divided into 3 groups:
moderate-severe iodine deficient(UIE<50 ug/L, n=30), mild
iodine deficient(UIE 50~100ug/L, n=26), adequate iodine
(UIE 100~300 ug/L, n=39). Patients were followed up for 8
to 12 months after ablation, successful ablation was defined
using the definition: no visible uptake in the thyroid bed on a
follow-up scan and a stimulated thyroglobulin(sTg) level <2
ng/mL. Chi-square test, t-test, Mann Whitney rank-sum test
and multivariate binary logistic regression analysis were per-
formed. Results 84.2%(80/95)of patients were successfully
ablated. The successful rates in the three different iodine intake
groups were 96.7%(29/30), 84.6%(22/26), 74.4%(29/39), re-
spectively, with significant difference among three groups.
Besides UIE, univariate analysis revealed that TSH, sTg, rem-
nant thyroid at ablation affected ablation efficacy. Logistic
regression showed that sTg(OR=1.120) and adequate iodine
intake(OR=3.473) were independent factors of ablation effica-
cy. Conclusion Adequate iodine intake during 131I remnant
ablation is one of important factors of treatment outcomes.
Thyroid remnant is more successfully ablated if we make rea-
sonable LID protocols according to the iodine nutritional sta-
tus in ATA-intermediate PTC patients before treatment.
PW095
Prognostic significance of early thyroglobulin release
after radioiodine therapy under rhTSH for thyroid cancer
M. EBERLE1, E. GALL2, S. GUILLEMARD1, C.
ESPITALIER1, I. RAINGEARD2, C. CARTIER2, M.
S326 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
JARLIER1, H. DE FORGES1, P. KOTZKI1, E. DESHAYES1;
1ICM Val d’Aurelle, MONTPELLIER, FRANCE, 2CHU,
MONTPELLIER, FRANCE.
Aim: The main objective of our study was to determine
if serum thyroglobulin values after radioiodine ablation
therapy performed with recombinant human thyrotropin
(rhTSH), at 3 days (TgD3) and 6 days (TgD6) post
rhTSH injection, and the ratio TgD6/ TgD3, were pre-
dictive for disease free status at 6-12 months following
therapy. The secondary objective was to determine if
remnant tissue uptake was correlated to these thyroglob-
ulin values, and would influence their interpretation. Pa-
tients and Methods: We included retrospectively all con-
secutive patients who underwent radioiodine ablation
therapy under rhTSH after surgery for thyroid cancer
in our department between January 1st of 2011 and
June 1st of 2013. Thyroglobulin was measured at D3
(i.e. 24h after the second rhTSH injection), just before
radioiodine administration, and at D5 or D6 (48h or 72h
after I131 administration). Whole-body scan was per-
formed at the same time. Remnant tissue was estimated
by measurement of thyroid bed uptake on whole-body
scintigraphy performed at D5 or D6. Thyroid bed uptake
values were divided into 3 strata (defined by the 33th
and 66th percentiles). According to current guidelines,
patients were considered disease-free at 6-12 months
follow-up if neck ultrasound showed no abnormalities
and stimulated thyroglobulin was below 1 ng/mL (or
below 0.3 ng/mL if stimulated thyroglobulin was not
available). Patients with positive thyroglobulin-
antibodies were excluded. Results: 102 patients were
included (22 men, 80 women), with a median age 57
[17-87]. According to European guidelines for risk as-
sessment, risk level was very low in 18, low in 62, and
high in 22 patients. At 6-12 months follow-up, 86 pa-
tients were disease-free and 16 had persistent or recur-
rent disease (PRD). Significantly higher TgD3 levels
were observed in the PRD group (3.1 ng/ml [0.2-132]
vs 0.4 ng/ml [0.2-47.5]; p=0.0026) whereas TgD6 and
ratio TgD6/TgD3 were not significantly different be-
tween the two groups. Radioiodine uptake in the thyroid
bed (remnant tissue) was positively and significantly
correlated to TgD3, TgD6 and ratio TgD6/TgD3
(p<0.001). TgD3 remained predictive of PRD only in
strata 1 and 2 (lowest values of uptake in thyroid bed,
p<0.0001). TgD6 was not significantly different between
the 2 groups. Higher levels of ratio TgD6/TgD3 were
observed in strata 3 in disease-free group (p=0.044).
Conclusion: RhTSH stimulated thyroglobulin just before
radioiodine ablation is predictive for disease-free status
at 6-12 months. However, high values of early thyro-
globulin release should not be considered of poor prog-
nosis in patients with high thyroid remnant uptake.
PW096
Low-dose radioiodine therapy versus reoperation
in patients after non-radical thyroidectomy
with differentiated thyroid cancer.
E. Vasilenko, M. Karalkina, I. Lagozhina, D. Fomin; Russian
Scientific Center of Roentgenoradiology, Moscow, RUSSIAN
FEDERATION.
Aim: Comparative evaluation of the effectiveness of the
final thyroidectomy and low radioiodine activities (1.2
to 2.0 GBq) in patients with differentiated thyroid can-
cer with significant thyroid remnant after non-radical
primary surgery.Materials and Methods: The study in-
cluded 90 patients (85 female, 5 male) of the age group
18-75 years with a mean age of 47 years. All patients
diagnosed with DTC confirmed by histological tests (63
papillary carcinoma cases and 27 follicular thyroid can-
cer cases were identified, stage T1-T3, N0-N1, M0).
According to postoperative scintigraphy, all patients
had significant thyroid remnant. They were, depending
on the treatment tactics, divided into 2 groups. The main
group consists of 45 patients, for which radioiodine ther-
apy with decreased activity (in the range of 1.2 to 2.0
GBq) was performed to ablate residual thyroid tissue.
Repeated surgical treatment in these cases was not held
due to the severe clinical state of patients, or due to the
patients’ refusal from surgery. The control group includ-
ed 45 patients to whom was applied traditionally com-
plete thyroidectomy as a preparation for radioiodine
therapy. Then, patients in both groups were carried out
a radical radioiodine activities from 3.0 to 4.5 GBq. A
year after the administration of radical radioiodine, mea-
surements of Tg, anti‐Tg antibodies together and whole‐
body scintigraphy were performed. The success of abla-
tion is determined by negative whole body I 123 scan
and serum thyroglobulin level less than 2 ng/
mL.Results: Successful ablation (negative stimulation
test) achieved after low-dose radioiodine therapy in 33
patients (73%) after the complete thyroidectomy in the
case of 32 patients (71%). During the first year of ob-
servation recurrences were detected respectively in 4 and
6 cases. The number of complications in the control
group after reoperation increased to 44%, mainly due
to permanent hypoparathyroidism, paresis of the larynx,
a tracheostomy. All complications after low-dose
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radioiodine therapy were transient and do not require
additional appointments.Conclusions: The use of low-
dose radioiodine therapy to eliminate excess volume of
functioning thyroid tissue after surgery is equally effec-
tive as re-surgical treatment and is accompanied by few-
er complications.
PW098
Thyroid remnant ablation of differentiated thyroid
carcinoma: a comparison of ablation success with high
and low doses of radioiodine (I-131)
S. A. A. Elrasad1, Y. Abdelhafeez2, M. A. Husseini1, R. A. A.
Amin1, S. Elrefaei1; 1Cairo university, Cairo, EGYPT, 2Assuit
University, Assuit, EGYPT.
Aim of study: To assess efficiency of low dose I131 in
thyroid remnant ablation of patients with differentiated
thyroid cancer after surgical treatment. Material and
Method: A randomized double-armed trial comparing
low-dose and high-dose radioiodine ablation. 128 pa-
tients (age 20-75 years) with differentiated thyroid can-
cer, tumor stage T1 to T3, with disease confined to the
thyroid or cervical lymph nodes were treated with I131
after total thyroidectomy and pathologic lymph node re-
section, if present. Results were available for 88 cases.
39 patients received low dose [1110MBq (30mCi)] and
49 patients received high dose [2960-3700 MBq (80-
100mCi)]. Six months after the administration of
radioiodine, measurements of Tg, anti-Tg antibodies to-
gether with neck ultrasound exam and I131 whole-body
scan were performed. The success rate of ablation is
determined by negative whole body I131 scan, negative
neck ultrasonography and serum thyroglobulin level less
than 2 ng/mL. Results: Successful ablation reported in
23 out of 39 cases (58.9 %) in the group receiving
low-dose radioiodine [1110 MBq] versus 37 out of 49
cases (75.5 %) in the group receiving the high dose
[2960-3700 MBq]. (P value= 0.098). Six months later
(1 year after the ablative dose) a second follow up was
performed for the cases who had successive ablation
from both groups. In the low dose group it was
available for 12 out of 23 patients (52%), all of them
didn’t show disease recurrence, versus 17 cases out of
37 from the high dose group, 16 of them didn’t had
recurrence (43.2%), while in one case there was a re-
current disease at the thyroid bed. Conclusion: Initial
results show no significant difference in successful ab-
lation with low and high dose of 131-iodine. This is
work in progress.
PW099
Theoretical model for release of patients with benign
thyroid disease based on parameters obtained
from EANM Standard Operational Procedures
for Pre-Therapeutic Dosimetry II.
M. Salas1, E.Mora2; 1NuclearMedicine Department, Hospital
México., San Jose, COSTARICA, 2Nuclear Medicine Depart-
ment, Hospital San Juan de Dios., San Jose, COSTA RICA.
Aim: To establish individualized restricted period for
patients with benign thyroid disease treated with 131I
has been a topic of great importance for Radiation Pro-
tection. This work focuses on the use of dosimetry mod-
el of two compartments (blood pool and target tissue)
that propose the EANM Dosimetry Committee Series on
Standard Operational Procedures for Pre-Therapeutic
Dosimetry II. Dosimetry prior to Radioiodine Therapy
of Benign Thyroid Diseases, based on the biokinetic of
the thyroid gland, and jointly with the model proposed
by the United States Nuclear Regulatory Commission
(U.S.NRC, NUREG – 1556 Vol. 9, Rev. 2) for release
of patients.Materials and methods: Calculus of residual
activity that not exceed the dose constraint: Using the
equation suggested by U.S.NRC, with the parameters of
two compartment model. Rewriting this equation in term
of radioactivity, the residual radioactivity (activity
contained in patient that not exceed that exposure dose
constrain for population groups -children, pregnant
women, adults, coworker-) was calculated. This equation
present some disadvantages such as, it doesn’t include a
correction for the attenuation of the gamma emission of
the blood pool, for this reason an attenuation correction
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factor for 131I (extrathyroidal component) was intro-
duced, also it considers the patient like a point source,
a correction to improve the calculus considering a line
source distribution was introduced. To complete the pa-
rameters of the equation, an adequate exposure dose
limit constraint, occupancy factor and expected distance
(patient-population group) were chosen, trying to repro-
duce the family and working environment of the
patient.Calculus of restriction time: Using two compart-
ment model, a time to radioactivity contained in patient
goes from the Administer Activity (t = 0) to the residual
activity (tres) was calculated, this difference in time
gives the Restricted Period (time necessary for the pa-
tient follow instructions)Results and conclusion: Follow-
ing the described procedure, restricted periods according
to the population group and socioeconomic conditions
can be calculated. If we consider a set of possible
values kB=0.1429h
-1, kT=0.00525h
-1, kt= 0.1297h
-1, Thy-
roid-Mass=20g, Administer-Activity = 247.19MBq,
Maximum-UptakeThyroid =80%, DoseTarget= 250Gy, Pa-
tient-Height=1.74m, Attenuation-FactorBlood-pool=0.62,
Exposure-Rate-Constant= 5.65x10-5mSv m2 h-1 MBq-1.
For a case of children up to two years old (1mSv Dose
Constraint) at 0.3m distance (holding babe) and Occu-
pancy factor of 0.25, the restriction time is 3.92
days.This work propose a model to calculate the indi-
vidualized restricted period, considering all the possible
correction that have been recommend in relation to the
release of patient with hyperthyroidism treated with 131I
PW100
Standardisation of Dosimetry for a Multicentre trial
of Selumetinib Enhanced Radioiodine Therapy
for Thyroid Cancer
R. Gregory1,2, A. Fenwick3, J. Merrett4,3, J. Scuffham4, J.
Gear1,2, D. Rushforth1,2, I. Murray1,2, G. Flux1,2; 1Royal
Marsden NHS Foundation Trust, Sutton, UNITED KING-
DOM, 2Institute of Cancer Research, Sutton, UNITEDKING-
DOM, 3National Physical Laboratory, Teddington, UNITED
KINGDOM, 4Royal Surrey County Hospital, Guildford,
UNITED KINGDOM.
The MEK inhibitor Selumetinib can enhance the uptake
of 131I NaI in patients with iodine refractory thyroid
cancer enabl ing them to benef i t f rom fur ther
radioiodine therapy. In this multicentre trial 123I imag-
ing is to be used to identify patients with uptake, for
whom dosimetry using SPECT/CT scans will aim to
predict the absorbed dose to tumours from the resulting
131I NaI therapy. Dosimetry during therapy will allow
assessment of the absorbed doses achieved following
Selumetinib.To ensure the dosimetry results from all
the centres are accurate and comparable the SPECT/
CT systems are to be calibrated and validated for
radioiodine imaging. There are currently no definitive
standards for dosimetry. Therefore the aim of this work
was to optimise the calibration procedures for practical
accurate quantitative imaging.Methods:Seven sites are
participating in the trial with 9 SPECT/CT systems in
total. Six cylinders ranging from 1 cm to 5 cm in
diameter and length were imaged separately and with
3 cylinders together, positioned in a 20 cm diameter
11 cm long cylinder of inactive water. The cylinders
were fil led with known activity concentrations
(~1MBq/ml) of 123I or 131I, then the calibration factor
to convert count concentrations to activity concentra-
tions was calculated for each cylinder size and arrange-
ment. Factors to correct for the dead time in 131I im-
ages of a uniformly filled 20 cm diameter cylinder,
filled with activities ranging from 10 MBq to 3 GBq
were also measured. Doses received to the 4 members
of staff performing this measurement were also
assessed.Results: The factors to convert count concen-
trations to activity concentrations were comparable be-
tween separate images of the cylinders and images con-
taining multiple cylinders for both 123I and 131I. The
Siemens Intevo and GE Optima 131I dead-time correc-
tion curves were similar up to 20 kcps at 1GBq. The
staff performing these measurements rece ived
acombined whole body dose of 120 μSv.Conclusions:
Calibration factors can be acquired from images of
multiple cylinders so accurate calibration can be faster
and more practical. Results from these measurements
should help to establish good practice in planning and
verifying molecular radiotherapy absorbed doses.
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NTCP calculations for Selective Internal RadioTherapy
(SIRT) - demonstration of the methodology
E. M. Abbott1, A. J. Craig2, J. M. Franklin3, A. Denis-
Bacelar2, N. Syed3, G. Flux2, R. Sharma1, K. A. Vallis1, N.
Falzone1,4; 1MRC/CRUK Gray Institute for Radiation Oncol-
ogy and Biology, Department of Oncology, University of Ox-
ford, Oxford, UNITED KINGDOM, 2Physics Department,
Royal Marsden NHSFT, Sutton, UNITED KINGDOM, 3Nu-
clear Medicine, Churchill Hospital, Oxford University Hospi-
tals NHS Trust, Oxford, UNITED KINGDOM, 4Tshwane
University of Technology, Department of Biomedical Science,
Pretoria, SOUTH AFRICA.
Aim: The aim of this study is to propose a method for
applying radiobiologic models for the calculation of Tu-
mour Control Probability (TCP) and Normal Tissue
Complication Probability (NTCP), based on dosimetric
and clinical data from a retrospective study. This is done
to adequately interpret the local response and liver tox-
icity of 90Y-microsphere treatment of liver metastases
from colorectal cancer (CRC), hepatocellular carcinoma
(HCC) and intrahepatic cholangiocarcinoma (ICC).
Methods: 3-D activity distributions obtained from
SPECT/CT images are combined with Monte Carlo dose
voxel kernel calculations using an in-house dosimetry
software package (Qrius™). Absorbed dose distribution
maps (differential dose volume histograms - DDVHs)
and the mean dose to healthy liver and tumour in each
patient is determined using Qrius™. The Biologically
Effective Dose (BED) distribution is calculated and the
Equivalent Uniform Biologically Effective Dose
(EUBED) is obtained from the spatial BED distribution
in the volume of interest. TCP and NTCP are then cal-
culated from the EUBED estimates. Results: Using a
retrospective 90Y-microsphere SPECT/CT scan, we dem-
onstrate how a differential dose volume histogram
(DDVH) generated with the Qrius™ software tool is
reduced to a single dose (EUDBED) delivered to the
entire volume. This functionality provides the possibility
to calculate TCP and NTCP distributions. Conclusion:
DVH metrics are known to correlate with patient toxic-
ity outcomes. Adding the functionality of a convenient
computational module to the Qrius™ toolkit for estima-
tion of TCP and NTCP based on patient-specific dosim-
etry could facilitate patient-specific treatment planning,
thus improving 90Y-microsphere treatment of liver
metastases.
PW102
Radiobiological Studies of Cancer Cell Using Novel
External Alpha-Particle Irradiation Set-up.
J. Nilsson1, J. Nilsson2, M. Posaric Bauden3, S. Strand3, J. H.
Elgqvist3; 1Institute for Clinical Sciences, Gothenburg, SWE-
DEN, 2Institute for Clinical Sciences, Malmö, SWEDEN, 3In-
stitute for Clinical Sciences, Lund, SWEDEN.
Aim. An external alpha-particle irradiation system was de-
signed and constructed enabling irradiation of cells. The radio-
sensitivity of prostate and pancreas cancer cells after alpha-
particle irradiation was investigated and compared with exter-
nal Cs-137 irradiations.Materials andMethods. The irradiation
system was constructed based on a circular 241-Am dish on
top at which well inserts containing cells growing in monolay-
er were placed. The source’s total radioactivity, homogeneity,
and alpha spectrum were measured via HPGe-detector, digital
autoradiography, and PIPS-detector measurements, respec-
tively. Monte-Carlo simulations were used for LET (linear
energy transfer) spectras and dosimetry calculations. Cell sur-
vival studies were performed for both prostate and pancreas
cancer cells. The cancer cell lines LNCaP, Capan-1, and
HPAF-II were irradiated using the in-house developed external
alpha-particle irradiator set-up. The cells were subjected to
absorbed doses equal to 0, 1, 2, or 3 Gy during the alpha-
particle irradiations, or up to 10 Gy regarding the Cs-137 irra-
diations. For evaluation of cell survival the tetrazolium-based
WST-1 assay was used. After irradiation WST-1 solution was
added to each well, incubated, and then measured for level of
absorbance at 450 nm, indicating the amount of viable
cells.Results. Compared to Cs-137 photon irradiations, a pre-
liminary RBE of 4-5 is observed for the alpha-particle irradi-
ations of the LNCaP and Capan-1 cells, at 37% cell survival.
These studies are still on going and additional results, includ-
ing results for HPAF-II, are continuously added.Conclusion.
The study shows the feasibility to construct a long-lived rela-
tively low cost alpha-particle irradiation set-up that could be
used for cell survival studies in most laboratories. The results
also shows a high degree of cell inactivation after alpha-
particle irradiation for all three cancer cell lines, compared to
Cs-137 irradiations.
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Assessing radiobiological effects of low doses of ionizing
radiation on zebrafish muscle by two-dimensional gel
electrophoresis
J. Lemos1, A. Campos2, M. Carneiro2, T. Ribeiro2, F. Ponte3,
P. Costa3, L. Cunha4, A. Carvalho5, L. Metello4; 1ICBAS.UP
& ESTSP.IPP, Porto, PORTUGAL, 2CIIMAR/CIMAR.UP,
Porto, PORTUGAL, 3Júlio Teixeira SA., Porto, PORTUGAL,
4ESTSP.IPP & IsoPor SA., Porto, PORTUGAL, 5FCUP.UP &
CIIMAR/CIMAR.UP, Porto, PORTUGAL.
Introduction: This work relates with the application of
zebrafish - Danio rerio - to the study of radiobiological
effects of low doses of ionizing radiation. In recent years,
the use of zebrafish has grown considerably, pointing
more and more as a very interesting model in biomedical
research, essentially because of the level of homology
shared with the human genome, complemented by an
easy and reasonably affordable practical side. The two-
dimensional gel electrophoresis (2DGE) is a method used
for the analysis of complex protein mixtures from biolog-
ical samples. This method allows the detection of differ-
ences in protein expression under different conditions, so
allowing creating relations between those differences and
the irradiations that were in their basis. The present work
aimed at evaluating proteome changes in the zebrafish
muscle caused by low doses of X-rays exposure. Material
and Methods: Animals were externally irradiated with
three distinct dose protocols (100 mGy, 500 mGy and
1.000 mGy). One day after the irradiation, the animals
were sacrificed and a muscle sample was collected.
2DGE was then used to identify proteins that showed a
differential expression after X-rays exposure. Results:
About 85 ± 21 protein spots were identified in every
gel. The statistical analysis of protein expression recog-
nized differences between the control and the irradiated
groups (27 spots to 1000 mGy; 22 spots to 500 mGy; 3
spots to 100 mGy). Most differentially expressed proteins
were down-regulated in irradiated groups when compared
to the control group. Conclusions: The present work
seems to confirm that the 2DGE based methodology
might be considered as an adequate analytical tool for
study radiobiological effects at the molecular level in
zebrafish. It has been found that a large number of pro-
teins were down-regulated, suggesting that a remodelling
of the muscle proteome occurs after the exposition to low
doses of X-rays. Mass spectrometry analysis should be
performed in order to allow the identification of those
proteins that were affected by exposition to ionizing
radiation. This identification would most probably con-
tribute for a deeper insight concerning the metabolic
and physiological consequences of the exposition to X-
ray.
PW104
Gamma Camera Calibration for SPECT Based
Quantitative Imaging with LU-177:
M. D’Arienzo1,2, M. Cazzato3, S. Ungania3, L. Cozzella1, G.
Iaccarino3, M. D’Andrea3, L. Strigari3, A. Fenwick4, L.
Johansson4, M. Cox4, P. De Felice1; 1National Institute of
Ionizing Radiation Metrology, Via Anguillarese 301, 00123
Rome, ITALY, 2Department of Human Anatomy, Histology,
Forensic Medicine and Orthopedics, Sapienza University of
Rome, Via Borelli 50, 00161 Rome, ITALY, 3Laboratory of
Medical Physics and Expert Systems, Regina Elena National
Cancer Institute, Via Elio Chianesi 53, 00044 Rome, ITALY,
4National Physical Laboratory NPL, Hampton Road,
Teddington, Middlesex, TW11 0LW, UK, UNITED
KINGDOM.
Over the last 15 years 177Lu has been successfully applied to
peptide receptor radionuclide therapy in the form of 177Lu-
DOTATATE or 177Lu-DOTATOC to treat neuroendocrine tu-
mors and other somatostatin-receptor expressing neoplasms.
The general consensus is that the collection of quantitative
data is a critical step in dosimetry and treatment planning in
molecular radiotherapy. In fact, inaccuracies in absolute quan-
tification are likely to result in reduced efficacy or increased
incidence of adverse side effects. Absolute gamma camera
calibration procedures are currently performed either in-air or
in-water using a radionuclide source with a known amount of
activity concentration. However, at present there are no vali-
dated standard protocols or any established methods for cali-
bration and verification of system performance. The aim of
this work was to develop and evaluate an approach to gamma
camera calibration for absolute quantification in tomographic
imaging with 177Lu. Calibration studies were performed on a
Philips IRIX and Philips AXIS gamma camera. For both sys-
tems the calibration coefficient was assessed using four refer-
ence geometries: a point source in air, a 16 mL Jaszczack
sphere surrounded by non-radioactive water, a 16 mL
Jaszczack sphere in air and a 20 cm diameter cylinder filled
with water uniformly mixed with radioactive 177LuCl. Atten-
uation correction was performed using Chang’s algorithm
while scatter correction was obtained applying the triple ener-
gy window technique. We validated our method in non-
reference geometry using an anthropomorphic phantom
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provided with liver cavity filled with 177LuCl. Acquisitions
performed with the IRIX gamma camera provided better re-
sults, with agreements within 5% for all geometries for acqui-
sitions at 208 keV. The use of a Jaszczak sphere in water
provided sensitivity values capable of recovering the activity
in anthropomorphic geometry within 1% for the 208 keV
peak, for both gamma cameras. However, for both systems
the activity in anthropomorphic geometry was recovered with
an agreement in the range -11.9%/+7.1% for acquisitions at the
208 keV photo peak. As a general rule, acquisition at the lower
photopeak provided results with larger deviations from the
measured activity concentration. Scatter and attenuation play
a major role at 113 keV and are likely to hinder an accurate
absolute quantification. In the clinical practice acquisition on
the higher photopeak are therefore recommended, provided
that a good counting statistic can be achieved. The research
leading to these results has received funding from the Europe-
an Commission, Grant Agreement N° 217257 between the EC
and EURAMET under the Seventh Framework Programme.
PW105
The Impact of Registration Method on 3D Dose
Distributions
E. Page1,2, J. Tipping1, D. Hamilton1, A. Robinson2, D.
Cullen2, C. Oldfield2; 1The Christie NHS Foundation Trust,
Manchester, UNITED KINGDOM, 2The University of Man-
chester, Manchester, UNITED KINGDOM.
Aims To evaluate the impact of registration algorithm on 3D
dose distributions.MaterialsThree post 177Lu Dotatate thera-
py SPECT- CT image series were processed using four differ-
ent registration algorithms.MethodsThe effect on the dose dis-
tribution of using direct rigid body registration of SPECT im-
ages was compared to using rigid body registration of the CT
images and applying the transformation to the SPECT images.
The effect of registering specific organs using a VOI mask on
the SPECT images rather than using the whole images was
also attempted. Additionally, non - rigid registration of the
SPECT images using an affine registration algorithmwas eval-
uated. Dose calculation was performed using MATLAB
scripts written in house using the Voxel S Factor
method.ResultsPreliminary results demonstrate that rigid
body registration of the whole SPECT image is inadequate to
register all organs intra-fraction in at least one patient example
(clear misalignment of the spleen at the second time point). In
another patient case SPECT to SPECT registration produced
an improved alignment of the SPECT activity compared to
CT-CT guided SPECT registration. A comparison of direct
SPECT rigid body registration to affine registration found a
difference in mean organ voxel dose that ranged from -6 to +
6% for one patient, but individual voxel doses of as much as
much as -61 to 330% for a particular organ. Affine registration
produced a better alignment of patient organs as a whole but
distorted some of the smaller tumour activity distributions
(resulting in a ‘stretched’ appearance not apparent in the orig-
inal images).ConclusionsRigid body registration was inade-
quate for aligning all organs using the whole image. The de-
cision to align the SPECT-CT time series using the SPECT or
guided by the initial registration of the CT may need to be
made on a patient by patient basis. Non- rigid body registration
can produce overall improvement in organ alignment but may
result in activity distribution and hence dose map distortion.
Differences in registration method can result in a ± 6% differ-
ence in organ mean dose, but at an individual voxel level may
result in differences of up to 330%. When considering hetero-
geneity of dose at the voxel level, the underlying method of
registration can have a significant impact.
PW106
Optimal sampling times for quantitative imaging
M. KOTZASARLIDOU1, M. COX2, V. SMYTH2, V.
HATZIPAVLIDOU1; 1“THEAGENIO” Cancer Hospital,
THESSALONIKI, GREECE, 2National Physical Laboratory
(NPL), Middlesex, London, UNITED KINGDOM.
Introduction: According to the MIRD schema, mean absorbed
dose D [Gy] in a volume of interest (VOI) is D = ÃS. Ã [Bq.s]
is the area under the time activity curve (TAC) and S is the
mean absorbed dose per unit cumulated activity [GyBq-1s-1].
The uncertainty for an estimate of Ã depends on the time
points selected for fitting the TAC. A process for determining
an optimal set of time points using the criterion that this un-
certainty is minimized has been developed in the European
joint research project MetroMRT (http://projects.npl.co.uk/
metromrt/). Aim: This study tested the process of time point
optimization using blood samples from patients to be treated
with 131I for differentiated thyroid cancer (DTC). Materials &
Methods: A tracer dose of 15 MBq of 131I was administered
orally to seven patients with DTC and a 131I standard source
was prepared simultaneously. Blood samples (2ml) were taken
at four or five time points post administration. Aliquots of 1 ml
were prepared from each blood sample and counted in a
Captus® 3000 Well Counting System. Blood activities were
normalized to the administered activity and the retention per
ml of blood was calculated. A data set was selected as repre-
sentative of the seven data sets. A biexponential model was
fitted, the area under the TACwas estimated, and optimal time
points using the above criterion were obtained. Four, five and
six time points were so determined, TACs formed and standard
uncertainties compared. This procedure was performed for
activity uncertainties either constant or proportional to activity.
Results: For constant activity uncertainties, reductions
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(compared with the use of the original TAC based on the
prescribed five time points) in TAC area uncertainty were
14%, 27% and 36% for 4, 5 and 6 optimal time points, respec-
tively. For uncertainties proportional to activity, corresponding
reductions were 22%, 31% and 38%. The largest time point
selected did not vary with the number of points. Conclusions:
TAC area uncertainties decrease usefully as the number of time
points increases. One time point was consistently chosen to be
as large as possible to ensure that the tail of the TAC is
modelled accurately. This method of determining optimal time
points will be tested further to confirm whether these
favourable results apply more widely.
PW107
Comparison of Sequential SPECT and CT for Targeted
Radionuclide Therapy Dosimetry
T. Li, K. Leong, E. Ao, G. S. Mok; University of Macau,
Taipa, MACAO.
Aim: Previously we showed that non-rigid registration in se-
quential SPECT images improved the 3D dosimetric accuracy
for targeted radionuclide therapy (TRT). This study aims to
investigate the potential improvement on dose estimation
when co-registered sequential SPECTand CT images are both
available for image segmentation and registration. Materials
and methods: We modeled 3 anatomical variations each with
3 In-111 Zevalin activity distributions, i.e., a population of 9
phantoms, using the digital 4D Extended Cardiac Torso
(XCAT) phantom. Local deformations of the liver, kidneys,
spleen and lung were modeled of up to 5 pixels/degrees with
<5% volume change, combined with whole body rigid motion
of up to 5 pixels/degrees of translation/rotation among imag-
ing at 1, 12, 24, 72 and 144 hrs post-injection. One hundred
and twenty-eight realistic noisy projections for a medium en-
ergy general purpose parallel-hole collimator were generated
over 360° by an analytical projector based on a system cali-
bration factor of 1.43×10-4 counts s-1 Bq-1, modeling atten-
uation, scatter and collimator-detector response and then re-
constructed using OS-EM with 128 updates including full
compensations. The corresponding attenuation maps of the
phantoms served as the CT images. Using the 24-hr time point
SPECT/CT images as the reference, we performed affine + b-
spline non-rigid registration on organs semi-automatically seg-
mented from sequential SPECT and CT images respectively.
For CT registration, the acquired motion vectors were later
applied to register the SPECT images. Voxel-by-voxel integra-
tion was performed on registered images over 5 time points,
followed by convolution with a Y-90 dose kernel to generate
dose images. Organ dose, differential and cumulative dose
volume histograms (DDVH & CDVH) were generated for
liver, spleen, kidneys and lungs. Results: For spleen, the organ
dose error and normalized absolute error of DDVHwere -9.22
±6.59% and 32.71±7.34% for SPECT registration, while they
were -3.63±1.47% and 20.08±5.67% for CT registration. For
liver, the organ dose error and normalized absolute error were
−2.19±2.81% and 22.57±10.18% for SPECT registration,
while they were -2.44±1.19% and 14.68±6.01% for CT regis-
tration. For CDVH, the CT registration method generally
approached more to phantoms with no misalignment as com-
pared to SPECT registration for all organs. Conclusion: We
conclude that if both sequential SPECT/CT scans are avail-
able, organ-based CT registration method can more effectively
improve the 3D dose estimation as compared to SPECT reg-
istration. Sequential low dose CTscans might be considered to
be included in the standard TRT protocol.
PW108
Radiation protectio impact of radioiodine therapy
for hyperthyroidism after a patient specific dosimetric
study
C. Canzi, V. Longari, M. Castellani, F. Buffoni, F. Zito, F.
Voltini, R. Benti; Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico Milano, milano, ITALY.
In patients with hyperthyroidism, the treatment with 131I should
rapidly obtain a nonhyperthyroid status. There is an ongoing
discussion on the establishment of the method to determine
the activity that can be recommended for clinical practice: esti-
mation (the so-called “fixed dose”) versus calculation (based on
radioiodine uptake measurements), however the optimization
principle states that a patient should be given the minimum
activity necessary to obtain the clinical goal. In our Nuclear
Medicine Department all hyperthyroid patients are submitted
to a patient specific pretreatment study to calculate the mini-
mum activity to administer in order to achieve euthyroidism,
in the case of nodular autonomies, and hypothyroidism, in the
case of Graves’ disease. Aim: to retrospectively evaluate the
radiation protection impact of outpatients radioiodine therapies
for hyperthyroidism after patient specific dosimetric studies,
with respect to the standard administration of 600MBq (maxi-
mum activity allowed by Italian radiation protection law). Ma-
terials and methods: 503 patients were considered (187 Graves
and 316 nodular autonomies, 364F, median age= 66y [range 17-
89y], mean iodine uptake=39%). They all reached a
nonhyperthyroid status within 1 year from the administration.
Results: The median 131I therapeutic orally administered activ-
ity was 396 MBq (10.7 mCi) with a range between 66 and
629 MBq (1.8-17.0 mCi). The total administered activity was
214 GBq (5.8 Ci). If the standard activity of 600MBq had been
administered to all patients the total activity would have been
302 GBq (8.2 Ci), an amount 41% greater than the really used
one. This obviously acts also on the patient mean effective dose
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S333
equivalent and on the mean absorbed dose to the stomach wall
(critical organ for 131I iodide) (ICRP 53) that were 6 Sv instead
of 9 Sv and 0.20 Gy instead of 0.28 Gy respectively, with a
maximum of dose saving (8 times) for the patient who was
given the minimum activity of 66 MBq. The reduction of 131I
administered activity also acts on the radiation exposure of the
nuclear medicine unit staff and of population: the mean dose
rate at 1 m at the dismission time is 12 μSv/h instead of 20 μSv/
h. This approach involves also the environment, as in the first 24
hours the 60% of the administered activity is excreted by the
body. Conclusion: the application of a patient specific pretreat-
ment dosimetric study can reduce of more than 40% the radia-
tion protection impact of radioiodine treatments of hyperthy-
roidism with optimal clinical results guaranteed.
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Estimates of exposure dose to the nuclear medicine staff
from inpatient 131I therapy of differentiated thyroid
carcinoma
B. Liu, R. Tian; Department of Nuclear Medicine, West China
Hospital, Sichuan University, Chengdu, CHINA.
Inpatient 131I therapy is still necessary for some pa-
tients with differentiated thyroid carcinoma (DTC). It is
necessary to consider the potential radiation burden to
the nuclear medicine staff, the present study was thus
designed to estimate the radiation exposure to the nucle-
ar medicine staff from inpatient 131I therapy of DTC on
the basis of the actual measurements of patient-specific
whole body dose-rates.Forty-seven patients (7 males, 40
females; age range: 23-56 years, average age: 41±13
years) with DTC were randomly and prospectively re-
cruited in this study. At 1, 12, 24, 48, and 72 h after
administration of 3.7 GBq of 131I, whole body dose-
rate was serially measured with a radiation-survey meter
at 1.0 m from the upright patients and the DR-time
curve was fitted by exponential function. On the as-
sumption that a nuclear medicine physician or nurse
typically spends 10 min at a distance of 1.0 m per day
during the first 5 days after administration, the nuclear
medicine staff’s exposure dose was estimated.The mean
whole body dose-rate at 1.0 h after administration of
131I was 27.88 μSv/h/GBq, ranging from 15.81 to
46.48 μSv/h/GBq. The exposure dose to a nuclear med-
icine physician per contacting a DTC patient was pre-
dicted to be 4.02-28.35 μSv.The predicted exposure
doses to the nuclear medicine staff are relatively low
from short periods of contact with DTC patients under-
going 131I therapy.This work was supported by the Na-
tional Natural Science Fund of China Grant No.
81401445, 81471693.
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Correlation of Clinical Outcomes with Bremsstrahlung
and Y-90 PET/CT Imaging Findings Following Y-90
Radiation Synovectomy
T. Barber1,2, A. Powell3, M. Cherk1,2, K. Yap1, V. Kalff1,2;
1Department of Nuclear Medicine & PET Centre, The Alfred
Hospital, Melbourne, AUSTRALIA, 2Department of Medi-
cine, Monash University, Alfred Hospital Campus, Mel-
bourne, AUSTRALIA, 3Department of Rheumatology, The
Alfred Hospital, Melbourne, AUSTRALIA.
Aim: To correlate clinical outcomes following radiation
synovectomy with bremsstrahlung and Y-90 PET/CT
imaging findings.Methods: A total of 48 joints in 39
patients underwent bremsstrahlung planar and Y-90
PET/CT imaging following radiation synovectomy. The
Y-90 distribution pattern on bremsstrahlung planar im-
aging was classified as diffuse or non-diffuse and com-
pared with the intra or extra-articular location of activ-
ity on Y-90 PET/CT. Treatment response was assessed
by patients and clinicians at 6 months using a compos-
ite change index (CCI) with a score ranging from 0-12.
A successful overall response was defined as CCI > 6.
In patients who underwent bremsstrahlung SPECT, side
by side image comparison with PET was performed
with image quality/resolution compared and scored
using a five point scale.Results: Bremsstrahlung planar
images were classified as diffuse in 31/48 (65%; 95%
CI: 51-78%) and non-diffuse in 17/48 (35%; 95% CI:
22-49%). There was no association between overall
treatment response in patients with diffuse compared
to non-diffuse bremsstrahlung planar imaging patterns
[8/31 (26%) vs 6/17 (35%) p = 0.49]. PET/CT con-
firmed an intra-articular location in all 31 diffuse scans
and an extra-articular location in three non-diffuse
scans. Of the three patients with extra-articular activity
none had any response to treatment. Excluding these
three patients, there remained no association between
the bremsstrahlung planar imaging pattern and overall
treatment response (p = 0.25). Of the 41 joints imaged
with SPECT, PET image quality was classified as su-
perior to SPECT in 40 and inferior in one. In one
patient with extra-articular activity on PET/CT,
SPECT/CT was unable to definitively localise the activ-
ity to the intra or extra-articular space.Conclusion: The
distribution pattern on bremsstrahlung planar imaging
did not correlate with overall clinical outcome follow-
ing radiation synovectomy in our study population.
However, a non-diffuse planar imaging pattern should
be further assessed with Y-90 PET/CT to exclude extra-
articular activity with PET providing superior image
quality compared to SPECT.
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Acquisition parameters optimization for imaging
with Ra-223
A. Corazza1,2, G. Cicoria2, F. Zagni2, G. Lucconi1,2, D.
Pancaldi2, M. Marengo2; 1Postgraduate School in Medical
Physics, University of Bologna, Bologna, ITALY, 2Medical
Physics Department, University Hospital “S.Orsola - Malpi-
ghi”, Bologna, ITALY.
Introduction: Ra-223 is an alpha emitter radionuclide with an
half life of 11.43 days and a reduced emission of betas and
gammas (about 5%) per decay. Its chemical affinity with cal-
cium and the high dose delivered locally make Ra-223
dichloride (Xofigo®) a relevant radiopharmaceutical for
targeting areas of increased bone turnover (standard injected
activity is 50 kBq/kg). This work studied acquisition parame-
ters for post-treatment Ra-223 imaging. Material and methods:
Images of Ra-223 were acquired using three windows, at 82,
154 and 269 keVwith a width of 10%, 10% and 8%, and using
Low Energy High Resolution (LEHR), Medium Energy Low
Penetration (MELP) and High Energy (HE) collimators. The
Line Spread Function (LSF) was measured by imaging for 120
minutes a 1.3 mm capillary, filled with 190 kBq of Ra-223 and
placed at a distance of 10 cm from the collimator. Activity was
carefully measured using a MP-DC activity meter
(Mecmurphil, Italy), specifically calibrated for Ra-223. Image
contrast was evaluated separately for the three windows, vary-
ing the width of the 82 keV peak from 10% to 20%. Planar
images of a Jaszczak phantom, with the “rods” sector posi-
tioned at several distances on top of different collimators
were acquired for > 12 hours. Static images of the rods
sector were then analyzed using ImageJ. Results: Visual
inspection on the three images showed that MELP col-
limators produce an acceptable image quality. For MELP
and HE collimators, the FWHMs were 12 and 13 mm
and the FWTMs were 26 and 28 mm. Quantitative eval-
uation of MTF was possible only for MELP (90% and
50% at 0.12 cm-1 and 0.36 cm-1), since for HE colli-
mator the image was affected by evident artifacts. The
sensitivity measured were of 2.30, 0.35 and 0.24 cps/
kBq with LEHR, MELP and HE collimators respective-
ly. Analysis on rods images showed that extending win-
dow width from 10% to 20% reduced contrast by 15%
and increased counts by 79%. Adding peaks at 154 keV
and 269 keV reduced contrast but increased sensitivity
by 77%. Conclusions: Image quality obtained with Ra-
223 is realtively poor, but sufficient to confirm the
biodistribution of the radiopharmaceutical. According to
our results, MELP collimators should be used; most of
the information is acquired in the 82 keV window, the
154 and 269 keV contributing to total statistics but with
a limited contrast modulation.
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Comparison and evaluation of the effectiveness of α- [
Ra-223 Dichloride] and β- particle emission treatments
[combined Re-186 HEDP / Sr-89 Chloride and/or Sm-153
EDTMP/ Sr-89 Chloride] on Tc-99m-MDP scintigraphic
series in pts with painful osseous metastases due
to castration-resistant prostate adeno-carcinoma
G. S. Limouris1, M. Paphiti2, S. Synefia1, M. Lyra1, L.
Moulopoulou1, V. R. McCready2; 1Nuclear Medicine Div - I
Radiology Dept-, ‘Aretaieion’ Hosp, Athens Univ Medical
Faculty, Athens, GREECE, 2Nuclear Medicine Dept, Royal
Sussex County Hosp, Brighton, UNITED KINGDOM.
Aim: We aimed, by the present to evaluate and highlight the
efficacy of the therapeutic application of alpha radiation on
follow-up [Tc-99m] MDP scintigrams and compare them with
respective scans in patients after beta-emission treatments,
using combined Sm-153 EDTMP / Sr-89 Chloride, since im-
provement in follow up [Tc-99m] MDP scintiscans after the
use of beta-emission, rarely had been observed in the
pastMaterial and Methods: In the last decade, approx 8000
whole-body [Tc-99m]MDP bone scintiscans have been per-
formed on a follow up basis program. Forty-two (group A)
pts with known history of hormone-resi-stant prostate adeno-
carcinoma were treated with combined Sm-153 EDTMP/ Sr-
89 Chloride application, in a dosage of 37 MBq x kgr -1 and
148 MBq respectively. Approx a year later, in 4(group B) out
of 42 pts, Ra-223 Dichloride was additionally injected in a
dosage of 50 x kgr -1 in monthly sessions x 6, following the
same MDP whole-body follow up basis program. The scinti-
graphic series of both groups were compared and evaluated by
two independent Nuclear-Medicine-physicians. Dosimetry
was performed in both cohorts from planar images on gamma
energy windows of Sm-153 (27.9 %) and Ra-223 (1.1%).
Absorbed doses calculations were performed using OLINDA
1.1 software. Blood samples were collected 0.30 min, 2, 4, 8
and 24h r s p . i . .U r i n e [24 h r s ] co l l e c t i on was
performed.Results: The visual (qualitative) comparison of
the MDP follow up series [120 defects, before therapy] in
the β-emission irradiated 42 pts depicted in only 2 cases an
obvious reduction of the osseous defects [117/120, 32 mo post
therapy, p > 0.5]. The comparison in the α-emission irradiated
4 pts [18 defects, before therapy] showed a marked reduction
[12 defects, 8 mo post therapy, p < 0.01]. The dosimetric
(quantitative) comparison for Sm-153/Sr-89 vs Ra-223 was
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0.018 Gy/MBq and 1.16 Gy/MBq for osteogenic cells respec-
tively, whereas for red marrow was 0,004 Gy/MBq and 0.14
Gy/MBq.Conclusion: The qualitative (visual) study of these
twoMDP follow up series assesses the efficacy and superiority
of the effectiveness of a-particles due to marked LET differ-
ences between β- and α- treated cohorts. The use of Ra-223
Dichloride in castration-resistant prostate adeno-carcinomas in
these preliminary results and the scintimaging follow-up, be-
sides the clinical course of the disease, proved that reasonably
by the use of α-emission the concept “palliative treatment”
might be substituted by “curative treatment” according to the
conceptual meaning of the Greek word for therapy, i.e. ίασις
(iasis).
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Clinical benefit of routine application
of Rhenium-188-HEDP in patients with painful bone
metastases from prostate or breast cancer
R. Lange1, F. Overbeek1, A. M. van den Berk1, J. M. H. de
Klerk1, P. C.M. Pasker-de Jong1, R. ter Heine1,2, M.M. L. van
der Westerlaken1, C. J. Rodenburg1, N. H. Hendrikse3, H. J.
Bloemendal1; 1Meander Medical Center, Amersfoort, NETH-
ERLANDS, 2Radboud University Medical Center, Nijmegen,
NETHERLANDS, 3VU University Medical Center, Amster-
dam, NETHERLANDS.
Introduction: At our hospital, the therapeutic radiopharmaceu-
tical Re-188-HEDP has been developed for treatment of pain-
ful osteoblastic bone metastases. Since Re-188-HEDP is an
unlicensed radiopharmaceutical, proper pharmacovigilance is
of utmost importance. This prospective study evaluates the
effect of Re-188-HEDP on pain palliation, quality of life and
hematological toxicity when applied in routine clinical care.
Methods: Patients were eligible for inclusion when they re-
ceived Re-188-HEDP treatment for treatment of painful bone
metastases of prostate or breast cancer as a part of routine
clinical care in our hospital. Pain palliation was assessed using
the visual analogue pain score (VAS) and measuring opioid
intake before treatment and 4 and 8 weeks afterwards. A re-
sponse in pain palliation was defined as a minimal decrease of
two points in VAS after either 4 or 8 weeks and no increase in
opioid intake. Quality of life was evaluated using the EORTC
QLQ-C30 questionnaire before treatment and 4 and 8 weeks
afterwards. Changes in each scale were assessed and response
in quality of life was defined as a minimum increase of ten
points on the global health status/QoL-scale after either 4 or 8
weeks.Nadirs from blood counts of thrombocytes and leuko-
cytes were used to assess hematological toxicity, graded ac-
cording to the CTCAE criteria. Results: Seventy-five patients
with painful metastatic prostate (n=50) or breast (n=25) cancer
were included in this study, of which 38 and 42 patients were
evaluable for pain palliation and quality of life, respectively.
Twenty-four patients received multiple injections. For this
analysis only first treatments were evaluated. The response
rate on pain reduction was 66%. VAS-scores decreased signif-
icantly at 4 weeks (p<0.01) and 8 weeks (p=0.01), with a
mean(±SD) decrease of 2.9±3.1 and 2.3±3.6 points, respec-
tively. For the overall quality of life the response rate was
69%. The mean(±SD) increase of the global health status/
QoL was 16±21.9 (p<0.01) at 4 weeks and 8±25.1 (p=0.06)
at 8 weeks, respectively. Significant improvement was seen in
several symptom scales. No significant differences were ob-
served between the responses in patients with prostate and
breast cancer.The treatment was well tolerated. Hematological
side effects were mild and transient. Grade III thrombocytope-
nia and leukopenia occurred in 2 (3.8%) and 1 (1.8%) pa-
tient(s), respectively. There were no grade IV hematological
adverse effects. Conclusion: The clinically relevant response
of Re-188-HEDP application on pain reduction and quality of
life and the limited side effects support the use of Re-188-
HEDP in routine clinical care.
PW114
Does cooling of the salivary glands reduce uptake
of radiolabeled PSMA-ligands?
F. C. Gaertner, H. Ahmadzadehfar, R. A. Bundschuh, S.
Kürpig, E. Eppard, M. Essler; University Hospital Bonn,
Bonn, GERMANY.
Aim: One major concern of PSMA-targeted PRLT (peptide
radionuclide ligand therapy, e.g. using Lu-177-labeled
PSMA-binding constructs) in patients with advanced
castration-resistant prostate cancer (CRPC) is xerostomia due
to the high physiologic uptake of PSMA-ligands in the sali-
vary glands. We evaluated if a physical intervention (cooling)
has a significant impact on tracer uptake in the salivary glands
using PET imaging with a Ga-68-labeled PSMA-ligand. Pa-
tients and Methods: 92 patients undergoing PET/CTwith Ga-
68-HBED-CC (PSMA-ligand) were evaluated. 44 patients
started cooling the salivary glands using ice-packs (4°C) about
15 minutes before tracer injection until the start of the PET
acquisition. The remaining 48 patients did not use cooling.
Injected activity was approx. 2 MBq / kg body weight.
SUVmean and SUVmax were measured in the salivary and
lacrimal glands, as well as physiologic tracer uptake in the
brain, mediastinum, liver, spleen, muscle, bone, kidneys and
bladder contents. Results: 34 patients with high tumor load
were excluded from analysis due to concerns of a possible
tumor sink effect, reducing uptake in normal organs. There-
fore, 25 patients with cooling and 33 patients without cooling
could be analyzed. With cooling, SUVmean was reduced by
12% in the parotid glands (11.03 ± 2.59 vs 12.60 ± 3.06; p <
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0.01) and by 15% in the submandibular glands (12.05 ± 2.98
vs 14.21 ± 4.24; p < 0.01). Regarding SUVmax, the values
were 17.14 ± 4.04 vs 19.46 ± 4.36; p < 0.01 for the parotid
glands and 18.36 ± 4.49 vs 22.42 ± 6.67; p < 0.01 for the
submandibular glands. Also, the ratios SUVmax-to-liver-
background showed significant differences for the parotid
glands (4.16 ± 1.04 vs 5.01 ± 1.75; p < 0.01) and for the
submandibular glands (4.54 ± 1.22 vs 5.33 ± 1.64; p < 0.01).
On the other hand, no significant differences were observed
for the lacrimal glands, sublingual glands, and the remaining
normal organs mentioned above (p > 0.05). Conclusion:
Cooling of the salivary glands resulted in a small, but never-
theless significant reduction of PSMA-ligand uptake in the
parotid and submandibular glands. Therefore, cooling of the
salivary glands seems to be a simple, non-invasive approach to
achieve a slight reduction of radiation dose to the salivary
glands when performing PRLT with radiolabeled PSMA-
ligands.
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The impact of imaging and dosimetry methodology on 18F
NaF PET-based molecular radiotherapy treatment
planning
A. M. Denis-Bacelar1, G. D. Flux2; 1Institute of Cancer Re-
search, London, UNITED KINGDOM, 2Royal Marsden Hos-
pital, London, UNITED KINGDOM.
Aim: 18F NaF PET/CT scans are increasingly used for patients
with bone involvement. Comparable mechanisms of uptake
with radionuclide-labelled bisphosphonates and 223Ra, make
sodium fluoride scans suitable for dosimetry-based treatment
planning in bone targeted therapies. The aims of this study
were to investigate the influence of attenuation correction
and dosimetry calculation methods upon the prediction of the
absorbed doses to bone for typical bone-seeking radiopharma-
ceuticals (153Sm-EDTMP, 177Lu-EDTMP and 188Re-
HEDP).Materials and Methods: 18F NaF PET/CT scans from
9 patients with prostate cancer and suspected or known bone
involvement were obtained from the Cancer Imaging Archive
[1]. The PET scans were reconstructed using a RAMLA iter-
ative OSEM algorithm with 3 iterations and 33 subsets, with
(CTAC) and without (NAC) CT attenuation correction. Voxel
absorbed doses were predicted for the three radionuclides
using convolution and full Monte Carlo (MC) methods from
the NAC and CTAC scans. Decay spectra were obtained from
the RADTABS/MIRD software. Dose-kernels for a uniform
soft-tissue medium were generated using an in-house EGSnrc/
EGS++ MC code and convolved with the PET scan normal-
ised to 1 MBq·s. Full MC simulations were carried out in
EGSnrc/EGS++ from the PET uptake distribution and the
CT segmented into cortical bone, spongiosa, soft-tissue,
adipose-tissue and air according to the Hounsfield units. The
energy in each voxel was converted into absorbed dose assum-
ing physical half-life and 1 GBq of activity for all radionu-
clides. Results: Full MC shows that 67%, 67% and 66% of the
total energy was deposited in cortical bone for 153Sm, 177Lu
and 188Re respectively when the absorbed doses were predict-
ed from attenuation-corrected scans. These were reduced to
56%, 58% and 55% when the non-attenuation-corrected scans
were used. Preliminary comparisons show that the mean
absorbed dose deposited in cortical bone obtained from the
MC predicted distribution was underestimated by 84%, 47%
and 45% for 153Sm, 177Lu and 188Re respectively when the
NAC scans were used. Ratio maps between the MC and con-
volution distributions show mean ratios in cortical bone of
1.04(1.4), 1.0(1.4) and 0.93(1.3) for 153Sm, 177Lu and 188Re
respectively.Conclusion: 18F NaF PET/CT bone scans have
the potential to be used for treatment planning in molecular
radiotherapy of bone metastases. Therefore, accurate knowl-
edge of the impact of imaging and dosimetry methods upon
the prediction of absorbed doses is required. On-going work
comprises the improvement of the CT segmentation to better
define source and target volumes, including the metastatic le-
sions.[1] http://www.cancerimagingarchive.net/
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Radiation Toxicity Concerning Salivary and Lachrymal
Glands Caused by Peptide Radioligand Therapy Using
a Lu-177 PSMA Inhibitor (I & T) in Patients
with Metastasized Prostate Cancer: First in Human
Studies
A. Özkan1, C. Schuchardt2, H. Kulkarni2, M. Shahinfar2, M.
Sayeg2, R. Baum2; 1Yildiz Technical University, Physics De-
partment, Istanbul, TURKEY, 2Zentralklinik Bad Berka,
Theranostics Center for Molecular Radiotherapy and Molecu-
lar Imaging (PET/CT), Bad Berka, GERMANY.
Aim: PRLT is a promising new therapy option in metastatic,
castration resistant prostate cancer (mCRPC). The objective of
this study was to determine the uptake, half-life (kinetics) and
the mean absorbed dose in salivary and lachrymal glands dur-
ing PRLT of patients with mCRPC using a Lu-177 labelled
DOTAGA-PSMA inhibitor (I & T). Methods: 10 mCRPC
patients (aged 74+/-8 years) were examined. The injected ac-
tivity was 5.9+/-1.3 GBq Lu-177 PSMA I & T. Post-
therapeutic dosimetric assessments of salivary glands and
lachrymal were performed (MIRD scheme). Planar whole
body scans at 0.5, 3, 24, 48 and 72 h p.i. were analyzed by
region of interest (HERMES WHOLE BODY DISPLAY).
Time-dependent tissue activities were determined with
Microsoft EXCEL™. Half-life (based on fit to exponential
function) and cumulated activity of the glands were calculated
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with ORIGIN PRO 8.1G™, mean absorbed doses were esti-
mated using the OLINDAEXM™. Uptakes were expressed as
percent of injected activity (% IA). The mean target volumes
were measured using a 64 slice CT scanner or taken from
literature: 14 ml for the right, and 16 ml for the left parotid
gland and 1.2 ml for lachrymal glands. Results: High uptake of
the tracer was found in the salivary glands as well as signifi-
cant uptake in the lachrymal glands in all 10 patients. The
time-dependent tissue activities showed an exponential de-
cline after 20 h p.i. Maximum uptake in the parotid glands
was 1.2% IA (immediately after administration) and decreased
with a mean half-life of 38+/-24 hours (11-118 hours). Based
on CT volumes, the absorbed dose to parotid glands was 8+/-
6 Gy (maximum 23 Gy). Lachrymal glands showed a maxi-
mum uptake of 0.2% IA and a fast wash-out with half-lives of
36+/-16 hours (12-71 hours). Assuming a mean volume of 1.2
ml, a mean absorbed dose of 9.5+/-4.9 Gy (5-25 Gy) was
estimated. Clinically, no adverse effects were observed
(follow-up up to 24 months) in any of the patients concerning
salivary gland function (no dry-eye-dry-mouth syndrome).
Conclusions: As no side effects occured, we conclude that
PRLT using Lu-177 PSMA I & T exhibits no (or very low)
toxicity to the salivary and lachrymal glands which is most
probably due to the fast wash-out and the low beta energy of
Lu-177. Further studies in a larger patient cohort as well as
serial salivary gland scintigraphies are planned to confirm the
safety of PRLT in mCRPC.
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Response Evaluation Criteria in Solid Tumours (RECIST)
in a group of patients submitted toY-90 resinmicrospheres
radioembolization
L. G. da Costa, J. A. M. Santos, B. Gonçalves, L. Violante, F.
G. S. Lopes, O. Soares, J. P. Teixeira, I. S. Lucena, A. F. Costa,
L. H. T. Duarte; Instituto Portugues de Oncologia do Porto
Francisco Gentil, EPE, Porto, PORTUGAL.
Aim: One reports on eligibility, safety and response to treat-
ment of a group of patients with primary tumours and meta-
static hepatic disease treated with 90-Y resin microspheres
(Sirtex Sir-Spheres). Matherial and Methods: All cases re-
ferred to our department for 90-Y resin microspheres treatment
between December 2011 and January 2015 were retrospec-
tively reviewed. All patients, except hepatocellular carcino-
mas, had previous 18-F:FDG PET/CT scans for disease strat-
ification. The location of the primary tumour was accessed as
well as a previous 99m-Tc:MAA distribution evaluation to
envisage the possibility of gastric reflux, pulmonary shunt,
and Y-90 microspheres distribution inside the liver. RECIST
(Response Evaluation Criteria in Solid Tumours; version 1.1)
response after 3 months was evaluated for all treated patients.
Results: Thirty three (33) patients were referred for
radioembolization: colorectal tumours (15 patients), hepato-
cellular carcinoma (12), breast cancer (3), cholangiocarcinoma
(1), Hepatic Neuroendocrine Tumour (1), and medullar thy-
roid carcinoma (1). Eight (8) patients were excluded: metasta-
tic disseminated disease accessed by PET/CT (2), Pulmonary
shunt > 20% (2), absence of 99m-Tc:MAA in the tumour (3),
and more localized disease than it was previously predicted
(1). Twenty five patients were treated (18 to the two lobes and
7 to one lobe) with activities ranging from 0,7 GBq to 2,4
GBq. Pulmonary shunts were found to be between 2% and
15%. Patients were assessed by RECIST: partial response
(8), stable disease (7), and disease progression (8). No patient
presented a complete response. One patient had disease pro-
gression and died before evaluation could be completed. Some
lateral effects were observed. Conclusion: These results
showed a partial response or stable disease in two thirds of
this group of patients. The evaluation result showed a reason-
able agreement with those reported so far in the literature [1-3].
References: 1. Bieke Lambert, Emiel Sturm, et al. Intra-arterial
treatment with 90-Y microspheres for hepatocellular carcino-
ma: 4 years experience at the Ghent University Hospital, Eur J
Nucl Med Mol Imaging (2011) 38: 2117-2124 2. Charlotte
E.N.M. Rosenbaum, Helena M. Verkooijen, et al.
Radioembolization for Treatment of Salvage Patients with Co-
lorectal Cancer Liver Metastases: A Systematic Review, The
Journal of Nuclear Medicine, (2013) 54: 1890-1895. 3. Robert
J. Lewandowski, Jeet Minocha, et al. Sustained safety and
efficacy of extended-shelf-life 90-Y glass microspheres:
long-term follow-up in 134-patient cohort, Eur J Nucl Med
Mol Imaging (2014) 41: 486-493
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Optimising methodologies for comparison of 99mTc-MAA
and 90Y-microsphere distributions
A. J. Craig1, I. Murray1, A. M. Denis-Bacelar2, N. Khan3, A.
Maenhout3, B. Rojas-Fisher4, L. Hossen4, G. Flux1; 1Royal
Marsden NHSFT & The Institute of Cancer Research, Sutton,
UNITEDKINGDOM, 2The Institute of Cancer Research, Sut-
ton, UNITED KINGDOM, 3Chelsea & Westminster NHSFT,
London, UNITED KINGDOM, 4Royal Brompton NHSFT,
London, UNITED KINGDOM.
The aim of this work is to optimise a methodology to assess
the extent to which 90Y-microsphere distribution can be pre-
dicted by the 99mTc-MAA study for Selective Internal Radia-
tion Therapy (SIRT). It is postulated that differences in the pre-
therapy 99mTc-MAA SPECT and post-therapy 90Y-brems-
strahlung SPECT scans will either be due to inherent differ-
ences in the respective imaging processes or due to differences
in the underlying distribution of the MAA and microspheres.
S338 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
Therefore any comparison methodology should be indepen-
dent of the differences in the imaging processes. Method:
99mTc-MAA SPECT scans were convolved with a 20mm
Gaussian point spread function in order to match them with
the resolution of the 90Y-bremsstrahlung scans. The blurred
99mTc-MAA SPECTscans were assumed to represent a dataset
of bremsstrahlung scans known to have the same underlying
distribution of activity as the original 99mTc-MAA SPECT
scans. The original and blurred 99mTc-MAA SPECT scans
were used as a control dataset to test comparison methodolo-
gies. Spearman rank correlation and histogram intersection
were tested as comparison methodologies. 12 patients with
either primary liver cancer or liver metastases underwent
90Y-microsphere SIRT therapy. The 99mTc-MAA and 90Y-
bremsstrahlung SPECT scans from these patients were then
compared. Results: Spearman rank values for the control
dataset with matching distributions were in the range 0.88-
0.94. Control values for the histogram intersection were in
the range 0.48-0.72. Histogram intersection comparisons were
not undertaken for 99mTc-MAA and 90Y-bremsstrahlung
SPECTscans as the control measured highlighted this measure
as unreliable. Spearman rank coefficients for comparing
99mTc-MAA and 90Y-bremsstrahlung scans were 0.32-0.82.
Conclusion: Analysis of the control dataset validated the
Spearman rank correlation coefficient as a test invariant to
the differences in the imaging processes. However, the control
dataset showed the histogram intersection not to be indepen-
dent of the imaging process and thus not appropriate for this
use. Spearman rank correlation coefficients of pre and post
therapy SPECT scans showed a large range in the distribution
differences.
PW120
Comparison of absorbed dose calculations
for non-uniform activity distributions obtained via
90Y-PET/CT after liver radioembolization
M. D’Arienzo1,2, M. Tapner3, E. Spezi4, N. Patterson5, P.
Chiaramida6, L. Filippi7, M. Ahrens8, T. Paulus9, O. Bagni7;
1National Institute of Ionizing Radiation Metrology, Via
Anguillarese 301, 00123 Roma, ITALY, 2Department of Hu-
manAnatomy, Histology, ForensicMedicine and Orthopedics,
Sapienza University of Rome, Via Borelli 50, 00161 Rome,
ITALY, 3Research & Development at Sirtex, North Sydney
2060, NSW, Australia, AUSTRALIA, 4Cardiff University,
Cardiff CF10 3XQ, UNITED KINGDOM, 5Department of
Medical Physics, Velindre Cancer Centre, Velindre Road,
Whitchurch, Cardiff, CF14 2TL, UNITED KINGDOM, 6GE
Healthcare Medical Systems, Milano, ITALY, 7Nuclear Med-
icine Department, Santa Maria Goretti Hospital, Latina, ITA-
LY, 8Philips GmbH Innovative Technologies, Research Labo-
ratories, Pauwelsstr. 17, 52074 Aachen, GERMANY, 9Philips
Technologie GmbH Innovative Technologies, Research Lab-
oratories, Pauwelsstr. 17, 52074 Aachen, GERMANY.
Hepatic selective internal radiation therapy (SIRT) using
either resin or glass 90Y microspheres is an established
catheter-based therapy for the treatment of unresectable
primary and metastatic tumors with the potential of de-
livering a high radiation dose directly to tumor areas
meanwhile sparing healthy tissues. In the last years
90Y PET/CT has been shown to provide a superior
post-administration evaluation of the treatment due to
its improved spatial resolution. Furthermore activity
maps obtained from quantitative PET data can be con-
verted into absorbed dose maps, thus predicting treat-
ment efficacy. In recent years there has been an intensi-
fying debate revolving around the most accurate dosi-
metric approach for three-dimensional dosimetry in mo-
lecular radiotherapy. The aim of the present work is to
evaluate the absorbed dose to lesions from 90Y-PET
images using different dose calculation algorithms in-
cluding: I) Direct Monte Carlo radiation transport using
Raydose II) Kernel-convolution using Philips Stratos III)
Local deposition algorithm IV) Monte Carlo technique
(MCNP) considering a uniform activity distribution V)
MIRD approach. A body-shaped anthropomorphic phan-
tom with lung, liver and spine inserts was used in the
present study. A cylindrical home-made PMMA insert
was manufactured and fixed into the liver insert to sim-
ulate a hepatic lesion (17 mL, approximately). Measure-
ments in anthropomorphic geometry were performed
using a GE Discovery ST PET/CT scanner with a 6:1
tumor to background activity concentration ratio. The
first scan was performed with an activity concentration
of 5.5 MBq/mL for the lesion insert and 0.89 MBq/mL
for the liver background. The anthropomorphic phantom
was then acquired at days 4, 5, 6 and 12 (according to
the scanner availability) down to an activity concentra-
tion of 0.31 MBq/mL for the lesion insert and 50 kBq/
mL for the liver background. Preliminary results indicate
that despite 90Y-PET is likely to provide high-resolution
images, the 90Y low branch ratio may produce non-
uniform activity maps, possibly leading to activity and
dose underestimations when a non optimised image re-
construction protocol for 90Y is used. All dose algo-
rithms provided satisfactory results, the worst case sce-
nario providing an agreement between absorbed dose
evaluations within 20%. Additional work is needed to-
wards the development of 90Y specific PET reconstruc-
tion protocols to allow proper image quantification for
dosimetry. The research leading to these results has re-
ceived funding from the European Commission, Grant
Agreement N° 217257 between the EC and EURAMET
under the Seventh Framework Programme
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Quantitative Texture Analysis on a PET-CT…With
Texture Standardization in Mind!
J. Cortes-Rodicio, G. Sanchez-Merino, R. Lope-Lope, J.
Ruiz-Pomar, T. Martin-Gonzalez, M. Garcia-Fidalgo;
Osakidetza, Vitoria-Gasteiz, SPAIN.
INTRODUCTION AND OBJECTIVES: Texture parameters
are important features commonly used for pattern recognition,
image classification and, more recently in the field of
“radiomics”, where more useful information might be extract-
ed from medical images. Anyway, texture quantification is
affected by many technical and physiological factors. The pur-
pose of this work is to study the textural performance of a
Philips Gemini TF PET as a function of the reconstruction
protocol and FDG activity concentration to set a baseline for
future clinical heterogeneity studies. METHODS AND MA-
TERIALS: Nineteen series from a cylindrical phantom filled
with different FDG activity concentration (max. 23,5kBq/mL,
min. 0,66kBq/mL) have been acquired in a Philips GEMINI
TF PET/CT. For each acquisition the raw PET data were re-
constructed using three different protocols: WB-CTAC
(BLOB-OS, TOF, 4mm), HN-CTAC (BLOB-OS, TOF,
2mm) and WB-CTAC-R3D (3DRAMLA, non-TOF, 4mm).
Seventy-two texture features were extracted using Chang
Gung Image Texture Analysis toolbox for MatLab. Fractal
dimension and lacunarity features were calculated using the
free plugin FracLac of ImageJ. On the one hand, for each
texture feature and reconstruction protocol, the variability with
FDG activity concentration was calculated as the ratio between
the mean values divided by the standard deviation. On the
other hand, a Pearson correlation analysis between the fractal
features and activity concentration were performed using
StatGraphics Centurion XVI software. RESULTS: Only nine
of the seventy-two texture features analyzed show small vari-
ability (<5%) with activity concentration. These are entropy
(Haralik-1973, Sun-1983, Horng-2002); short-run-emphasis
and run-percentage (Loh-1988); the homogeneity, intensity,
inverse-difference-moment and code-entropy (Horng-2002);
and short-zone-emphasis and zone-percentage (Thibault-
2009). These features seem to be suitable for textural quanti-
fication of tumors and further classification of them. Features
presenting large variations are not recommended for
heterogeneity quantification. With respect the fractal dimen-
sion and lacunarity features, we find a significant statistical
quadratic and linear correlation, respectively (p<0.05) between
them and the activity concentration for all the reconstruction
protocols. CONCLUSIONS: This study shows that it is feasi-
ble to apply textural and fractal analysis methods to study the
heterogeneity of tumors, but taken into account the technical
factors that will lead to variations on the results, in our case
activity concentration and reconstruction protocol. It is man-
datory to establish a reference performance of different PET in
order to allow comparison of multicenter studies. Anyway,
further studies should be carried out to improve the statistical
power of the analysis.
P002
Performance assessment of the Albira tri-modal
pre-clinical PET system
A. Attarwala1, Y. W. Karanja1, C. Romanó1, M. Roscher2, C.
Maaß1, B. Wängler2, G. Glatting1; 1Medical Radiation
Physics/Radiation Protection, UniversitätsmedizinMannheim,
Medical Faculty Mannheim, Heidelberg University, Mann-
heim, GERMANY, 2Molecular Imaging and Radiochemistry,
Institute for Clinical Radiology and Nuclear Medicine, Medi-
cal Faculty Mannheim, Heidelberg University, Mannheim,
GERMANY.
Aim: Quantitative molecular imaging with a pre-clinical pos-
itron emission tomograph (PET) is a prerequisite in treatment
planning, monitoring and development of new diagnostic and
therapeutic radiopharmaceuticals. This study analyzes the per-
formance characteristics of the Albira PET sub-system and
measures the response of the system for the commonly used
radionuclides (18F and 68Ga) in small animal imaging. Mate-
rials and Methods: The Albira tri-modal system (Bruker
BioSpin MRI GmbH, Ettlingen, Germany) is a pre-clinical
device with a PET, SPECT and CT. The PET sub-system is
made up of single continuous crystal detectors of lutetium
yttrium orthosilicate (LYSO) coupled to position-sensitive
photomultipliers (PSPMTs). The detector assembly consists
of three rings with each ring having 8 detector modules. The
trans-axial field of view (FOV) is 80mm and the axial FOV is
148mm.Imaging was performed with the NEMANU-4 image
quality phantom (Data Spectrum Corporation, USA) having
five rods with diameters 1-5mm and a uniform central region.
Measurements with 18F and 68Ga were performed with a
starting activity concentration of 500kBq/ml and a list mode
acquisition of 10h.An energy window of 358-664keV and a
coincidence time window of 5ns were selected. The data were
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reconstructed with a maximum likelihood expectation maxi-
mization (MLEM) algorithm; voxel size of 0.5mm with in-
creasing iterations from 5 to 50 (step-size 5) and corrections
for randoms/scatter was included within the system. System
sensitivity, count rate linearity, algorithm convergence and re-
covery coefficients were analysed. Convergence was assessed
based on region of interest (ROI) analysis of activity concen-
tration within the rods and uniform region. All analyses were
performed with PMOD software (PMOD Technologies Ltd.,
Switzerland).Results: The overall sensitivities for the entire
FOV were 2.79%±0.01% and 3.21%±0.01% for 68Ga and
18F, respectively. The net true coincidences with dead-time
correction were linear for ≤10MBq (68Ga, R2 = 0.9999) and
≤11.5MBq (18F, R2 = 0.9999). Above these activities, system
performed an overcorrection for dead-time effects. The algo-
rithm converged after 35 iterations for both 68Ga and 18F. The
recovery coefficients for the 5, 4, 3 and 2mm rods with an
activity concentration of 110kBq/ml were 0.50±0.13, 0.41
±0.09, 0.25±0.06, 0.24±0.04 for 68Ga and 0.80±0.25, 0.72
±0.21, 0.56±0.20, 0.34±0.10 for 18F, respectively.Conclusion:
The Albira pre-clinical PETsystem has an acceptable sensitiv-
ity range and the system linearity is suitable for the range of
activity used for pre-clinical imaging. The next step would be
to test the system for additional radionuclides that could be
used for pre-clinical imaging.
P004
Comparison of time-of-flight PET-CT results for micro
hollow spheres from 31 microliter to 8 milliliter
for Fluorine-18, Gallium-68 and Yttrium-90
S. Kerschbaumer1, L. Hofbauer2, H. Kvaternik1, C.
Gstettner1, R. M. Aigner1; 1Medical University, Division of
Nuclear Medicine, Graz, AUSTRIA, 2University of Applied
Science, Division of Radiography, Graz, AUSTRIA.
The aim of this study was to examine the positron-range-effect
simulating focal nodular lesions based on micro-hollow-
spheres for Fluorine-18, Gallium-68, and Yttrium-90. The var-
ied kinetic energy of the emitted positrons influences the re-
construction, the quantitative measurement and the visual im-
pression of the resulting sectional images. The measurement
procedure uses a target/background ratio of 10:1 and 30:1. A
Jaszczak-phantom-body was equipped with micro-hollow-
spheres from 31 microliter (4mm diameter) to 8 milliliter
(25mm diameter). The images were acquired on a Siemens
Biograph-40mCT PET-CT and reconstructed respecting the
CT for attenuation-correction (780mm field-of-view, 120keV,
16mA-effective, 5mm slice-thickness, pitch 1.3). Osem-3D
and point-spread-function-recovery (HD-PET) were used with
and without time-of-flight (TOF) with matrices 256, 400 and
512 with 3 or 4 iterations and 21 (TOF) and 24 (non-TOF)
subsets. The acquisition time was altered between 1min to
10min. The maximum and average activity concentration
and the threshold-based volumes were evaluated on a Siemens
Syngo MMWP. The blurring contribution for different nu-
clides is effected by the positron-range-effect due to the differ-
ent maximum positron energy (Fluorine-18 635keV, Gallium-
68 1899keV, Yttrium-90 800keV). The measured volume at
high contrast, HD-PET and 256-matrix with a 50% threshold
was 0,81 (81%) for the 8ml sphere down to 0,50 for the 2ml
sphere within 5% deviation independent from the nuclide. For
125μl the measured volume-ratio for Fluorine, Gallium and
Yttrium were 1.28, 0.80 and 0.96 measured. The evaluated
volume for a threshold of 10% overestimates the lesion in
general. Because of the similar positron-range the factor was
in a rage of 1.6 for Fluorine and Yttrium. For Gallium-68, the
factor was 1.71 for the 8mm sphere and rose continuously for
smaller spheres to 3.18 for 500μl, which correlates with an
underestimation of the concentration in smaller spheres. The
decay corrected average and maximum concentration is wide-
ly independent of the acquisition time, where the maximum
value raises slightly due to counting statistics for harder recon-
struction kernel, smaller voxels and also for lower contrast.
For a specific reconstruction algorithm, the measured volume
and concentration is not affected by time-of flight. The HD-
PET-algorithm compared to the OSEM-algorithm shows
higher concentrations and smaller volumes. Image blurring is
nonlinear affected by the acquisition system together with the
reconstruction algorithm, the lesion and the patient, the nu-
clide, and the tracer. While some influences can be corrected,
for clinical practice it is crucial to understand the effects and
characteristics close the physical limits of quantitative func-
tional PET imaging.
P005
Conflicting measures of uniformity on a Siemens Symbia
gamma camera
M. J.Memmott, I. S. Armstrong, K. J. Saint, A. Bradley, R. S.
Lawson, H. A. Williams, C. M. Tonge; Central Manchester
University Hospitals NHS Foundation Trust, Manchester,
UNITED KINGDOM.
Gradual worsening of the uniformity of two Siemens Symbia
gamma cameras (one Symbia S and one Symbia T6, installed
in 2009) has been observed when using the measurement
method as described in IPEM Report 86. This method uses a
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point source at 5xFOV and assesses the uniformity by pixel
coefficient of variation, corrected for Poisson noise, and has
been used throughout the department on a variety of camera
systems with consistent results. The manufacturer’s recom-
mended procedure, using a 1.0 MBq Tc-99m point source at
a distance of approximately 40 cm from the detector and cal-
culating uniformity using the NEMANU1 standard, has failed
to demonstrate similar trends over the same time interval. The
closeness of the source in the manufacturer’s method requires
the application of a curvature correction to the image. This
does not apply to the IPEM method. Both gamma cameras
have recently had new energy and linearity correction maps
generated. Uniformity for each method was assessed before
and after new correction map generation, and differences
assessed using a Mann-Whitney U test for non-parametric da-
ta. The mean (SD) uniformity value using the IPEM method
prior to new correction maps for the Symbia S was 1.10 (0.05)
% and 1.48 (0.09) % for detector 1 and 2 respectively. Post
correction map generation, the mean value was 0.58 (0.04) %
and 0.62 (0.05) % for detector 1 and 2 respectively. The dif-
ference between uniformity values pre- and post-correction
map generation was significantly different, p < 0.001. Con-
versely, for the manufacturer recommended method, the mean
(SD) integral uniformity value in the CFOV prior to new cor-
rection map generation was 1.75 (0.20) % and 1.66 (0.13) %
for detector 1 and 2 respectively. Post correction map genera-
tion, the values were measured to be 1.74 (0.13) % and 1.58
(0.06) % respectively. There was no significant difference (p >
0.30) for either detector. Results for the Symbia T6 followed a
similar trend. Two methods for assessing the uniformity of a
Siemens Symbia gamma camera show discrepant results over
time and show significantly different responses after genera-
tion of new energy and linearity correction maps. Discrepan-
cies between the two methods implemented in this work high-
light the importance of independent assessment of gamma
camera performance.
P006
A Novel Method for Krypton-81m Intrinsic Uniformity
Measurement
H. A.Williams, M. J. Memmott, R. S. Lawson; Nuclear Med-
icine, Manchester, UNITED KINGDOM.
Background: Gamma camera behaviour varies with the energy
of the detected photons. Therefore, uniformity assessments
and corrections derived using Tc-99m (140keV photons)
may not necessarily be applicable at the higher gamma emis-
sion energy of Kr-81m (190keV), widely used for lung
ventilation imaging. Kr-81m SPECT is particularly sensitive
to minor uniformity variations. The rise of V/Q SPECT
heightens the need to evaluate uniformity with Kr-81m, al-
though this is challenging due to its short half-life and gaseous
nature.We have designed a simple phantom to provide a point-
like source for Kr-81m intrinsic uniformity measurement.
Methods: A balloon was connected to a commercial Rb-81/
Kr-81m generator, with reference activity 300 MBq at 12:00
CET, housed in the shielded control room adjacent to a GE
Optima NM/CT 640 gamma camera, with an exhaust tube
feeding into a second, adjacent shielded gamma camera room.
The generator and tubing were shielded using lead bricks and
pots modified for the purpose. The balloon reached an average
diameter of 2cm, and was positioned more than 2 metres (~5
gamma camera fields of view) from the uncollimated detector
surface, and standard 15Mct test image acquired. For compar-
ison, a 30 MBq Tc-99m point source (0.1ml in an LP4 tube)
was positioned at the same location and another 15 Mct test
image acquired. The average count-rate per head was noted.
Results: The Kr-81m balloon source resulted in a average
count rate of 16.1 kcps, allowing the test image to be acquired
in 15.5 minutes. The Tc-99m point source resulted in a count
rate of 29.8 kcps, allowing a uniformity test image to be ac-
quired in 8.6 minutes. Image uniformity for Kr-81mwas found
to be acceptable and comparable with that for Tc-99m, al-
though a slight gradient was seen across both images which
infers source positioning requires further optimisation. Con-
clusion: The phantom which we have developed has potential
to provide a quick and simple means of collecting Kr-81m
uniformity data. Accurate positioning of the balloon and
shielding of the generator and tubing from the uncollimated
gamma camera is non-trivial, and will depend on local depart-
ment layout. A series of measurements are underway to refine
source positioning, and assess reproducibility, stability and
correlation of Kr-81m uniformity with results for Tc-99m
using a Tc-99m source in a similar geometry. Provided that
this can be achieved, Kr-81m floods could become a routine
QC procedure.
P007
Metrology for 89Zr in the clinic
A. J. Fenwick1,2, L. Johansson1, E. Spezi3,2, W. Evans4,2, C.
Marshall4,2; 1National Physical Laboratory, Teddington,
UNITED KINGDOM, 2Cardiff University School of Medi-
cine, Cardiff, UNITED KINGDOM, 3Velindre NHS Trust,
Cardiff, UNITEDKINGDOM, 4Wales Research&Diagnostic
Positron Emission Tomography (PET) Imaging Centre, Car-
diff, UNITED KINGDOM.
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Despite an increasing number of applications under investiga-
tion using the novel PET radionuclide 89Zr, no efforts have so
far beenmade to improvemeasurements of absolute activity or
nuclear data that are required for accurate quantification of the
activity in radionuclide calibrators and imaging modalities.
The determination of activity by means of a radionuclide cal-
ibrators prior to injection is essential to safeguard patients and
to enable comparison of results from potential clinical trials. In
addition, the determination of activity distribution within pa-
tients using quantitative imaging techniques is needed to de-
termine doses received and ensure clinical decisions such as
staging of cancer are made correctly. 89Zr decays by electron
capture and positron emission to both the ground state and
various excited states of 89Y with a half-life of 78.42 (13)
hours. The electron capture decay to a metastable state of
14ms at 909 keV presents challenges in the absolute
standardisation and appropriate corrections must be consid-
ered. In this work, 89Zr was standardised by several liquid
scintillation methods including Triple-to-Double Coincidence
Ratio (TDCR), CIEMAT/NIST efficiency tracing and 4πß-γ
coincidence counting with efficiency extrapolation and results
were shown to be in agreement within uncertainties. Second-
ary standards in the form of calibration factors and dial settings
for both NPLmaintained and commercially used systems have
also been determined for clinically relevant geometries. A new
half-life value of 78.366 (78) hours was also determined and
shown to be in good agreement with the currently evaluated
value. These are the first measurements of the absolute activity
of 89Zr and further work in this area is encouraged to give
confidence in these results and ensure traceability of this novel
and important radionuclide.
P008
Usefulness of Mean Standardized Uptake Value for Liver
as a Reference Organ on F-18 FDG PET/CT: Comparison
with Standardized Uptake Values Corrected by Various
Imaging and Clinical Parameters.
J. Choi1, S. Lee1, J. Lee2; 1Soonchunhyang University Hos-
pital Cheonan, Cheonan, KOREA, REPUBLIC OF, 2Catholic
Kwandong University International St. Mary’s Hospital, In-
cheon Metropolitan City, KOREA, REPUBLIC OF.
Introduction/purpose: The use of liver as a reference organ for
extrahepatic fluorodeoxyglucose (FDG) uptake on F-18 FDG
positron emission tomographic/computed tomographic (PET/
CT) scan is well known. Previous studies about relations be-
tween hepatic FDG uptake and various parameters including
hepatic fat and blood glucose have been contradictory. The
aim of the study is to assess the valid standardized uptake
values for liver as a comparator for extrahepatic FDG uptake
on F-18 FDG PET/CT scan. Materials and Methods: Consec-
utive F-18 FDG PET/CTscan obtained in 186 healthy subjects
from October 2012 to November 2014, were retrospectively
reviewed. Mean standard uptake value (SUVmean) and max-
imum SUV (SUVmax) were measured for liver. Other SUVs
were also obtained as followings: (1) SUVLBM; SUVs were
normalized by lean body mass, (2) fat-adjusted SUVmean
(SUVfat); SUVmean was adjusted for hepatic fat using a for-
mula equating percentage fat to CT density, (3) normalized
glucose corrected SUVmax and SUVmean (SUVglc); SUVs
were normalized for blood glucose level assuming a normal
blood glucose level of 5.55 mmol/L. CT densities (in Houns-
field units) were measured in liver and spleen with identical
regions of interest used for the CT and PET examinations.
Fatty liver was defined as CT density of liver was less than
that of spleen. Patients were divided in 5 groups on the basis of
blood glucose. The correlation between hepatic FDG uptake
and various clinical factors including glucose, liver function
test, total cholesterol, triglyceride, erythrocyte sedimentation
rate(ESR), and high sensitive C-reactive protein (hs-CRP)
were also assessed. Results: SUVfat and SUVglc of fatty liver
were significantly higher than those of non-fatty liver but no
difference in SUVmax, SUVmean, or SUVLBM. Liver CT
density significantly correlated with SUVmax before and after
correcting by normalized glucose, SUVLBM, and SUVfat.
Blood glucose significantly correlated positively with liver
SUVmax, SUVglc, SUVLBM but not with SUVfat. Liver
SUVmax also significantly correlated with BMI, AST, ALT,
GGT, and TG. Liver SUVmean correlated neither CT density
nor blood glucose. Conclusion: Liver SUVmean correlated
neither CT density nor blood glucose while liver SUVmax is
influenced by blood glucose and fatty liver. On the basis of
these data, liver SUVmean is valid as a comparator for extra-
hepatic foci of increased FDG uptake in patients with abnor-
mal level of blood glucose or fatty liver.
P009
Evaluation of Qualitative Expressions in Bone Scan
Reports
P. Martineau, E. Saidenberg, W. Zeng; The Ottawa Hospital,
Ottawa, ON, CANADA.
Background Purpose: The diagnostic report serves as the pri-
mary means of communication between nuclear medicine
physicians and referring clinicians. Little is known about the
variability in clinicians’ interpretation of nuclear medicine
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physicians’ reporting terminology relating diagnostic confi-
dence. Bone scans are the most commonly performed imaging
modality in nuclear medicine; however, reporting is poorly
standardized because of non-quantitative visual assessment
and frequent non-specific findings. Qualitative report text,
such as “likely due to” or “suspicious for” may have substan-
tially different meanings when used by different reporting phy-
sicians, and can be understood differently by different refer-
ring physicians. These differences in interpretation may have
important impacts on patient’s management. In this study we
propose to survey nuclear medicine and referring physicians
regarding their assessment of expressions of probability in
bone scan reporting. Methods: A review of bone scan reports
on Ottawa Hospital cancer patients identified 12 phrases com-
monly used to communicate likelihood of the presence of
skeletal metastases: ‘consistent with’, ‘possible’, ‘suspicious
for’, ‘cannot rule out’, ‘suggestive of’, ‘compatible with’, ‘in
keeping with’, ‘likely’, ‘no convincing evidence’, ‘probably’,
and ‘could be’. A survey regarding qualitative expressions of
diagnostic confidence in bone scan reporting was used to in-
vestigate referring and reporting physicians’ interpretations of
these phrases commonly used in bone scintigraphy reports.
The survey asked respondents to indicate the probability of
disease presence implied by each of the 12 expressions on a
numerical scale divided into 0.05 wide bands centred from 0.0
to 1.0 with 0.0 indicating that the condition is definitely not
present and 1.0 indicating complete certainty of disease
presence.Results: The results of this survey show that there
exists substantial heterogeneity in the perceived meaning of
standard phrases amongst both referring and reporting physi-
cians.We believe that the results of this study may help inform
the process of standardization of bone scan report findings
among nuclear medicine physicians.
P010
Semi-quantitative Evaluation of Image Quality in Low
Dose 18F FDG PET/CT
S. C. Kapur, Arvind K Sinha,VP Sajjith,Donald Teh and
Vijay Sharma; National University Hospital, Singapore,
SINGAPORE.
Aim: Quantitative evaluation of tumor metabolism by
SUV is increasingly used for evaluation of therapy re-
sponse of a chemotherapy or radiation treatment. In
view of clinical relevance of accuracy and reproducibil-
ity of SUV max, SUV peak in PET/CT imaging, it is
important to look into these variables at low dose 18 F
FDG / CT protocol. This study will evaluate 18 F FDG
uptakes in liver, thigh and shoulder and correlate with
parameters related to PET/CT image quality. Method and
Material: Cumulative radiation dose measurements were
made in 150 patients who underwent whole body PET/
CT examination with a low dose CT protocol and an
average 18F dose of (3.51+0.8MBq/kg), ensuring opti-
mal image quality interpretable by physician. It was op-
timized by quantitative measurement of SUV max / SD,
SUV peak and SNR in PET and CT images of the liver,
shoulder and thigh in cases with nearly same BMI and
normal blood glucose. Only patients with no observed
cancerous lesions were chosen. A spheroid region of
interest (ROI) was placed over five selected areas of
liver parenchyma in orthogonal plane. The coefficient
of variation (CV) for SUV max and SNR was measured
in the liver. The Image quality was evaluated by two
nuclear medicine physicians in a 5 point Likert Scale
Score.- Result and Discussion: This study showed sub-
stantial variations in both SUV peak and SUV max for
18F FDG distribution in liver, thigh and shoulder. The
image quality at baseline was compared with dose ad-
justed conditions. Secondly, as a measure of image qual-
ity, we evaluated only SUV max , SUV peak and SNR
in above organs and SD of the pixel values inside the
ROI was used for image noise. It was noted that SUV
max was uniformly distributed in the liver, shoulder and
thigh in the same scale as SUV peak. The uptake ratio
between shoulder and liver, thigh and liver were within
same narrow range. The image quality evaluated by the
physicians had a score of 4.5/5.0. Patient-specific factors
influenced the accuracy and reproducibility of SUV max
and SUV peak. The scan quality and diagnostic accura-
cy was not affected, inspite of reduction in 18F FDG
dose and low dose CT parameters. The average whole
body effective dose was 9.81+ 2.8mSv, which is reason-
able as compared to published data.
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Shielding gamma-rays from nuclear medicine rooms:
Monte Carlo simulations of ceiling scatter in the diagnostic
and therapeutic use of 99mTc, 131I and 18F
R. S. Schnerr1, A. de Jong2, C. R. L. P. Jeukens1, G. Landry3,
R. Wierts1; 1Maastricht UMC+, Maastricht, NETHER-
LANDS, 2Amphia, Breda, NETHERLANDS, 3LMU,
München, GERMANY.
Aim: In the design of diagnostic and therapeutic treatment
rooms for Nuclear Medicine, an important consideration is
the shielding required for blocking the ionizing radiation from
the radioactive isotopes. The primary radiation, possibly with
build-up correction, can be calculated analytically. However,
little data is available to estimate the radiation dose contribu-
tion of ionizing radiation that travels over the (lead) shielding
in the wall and scatters of the ceiling; so-called skyshine. We
aim to determine the contribution of this skyshine to the radi-
ation dose received by people outside Nuclear Medicine
rooms. Materials and Methods: Monte-Carlo simulations were
performed with Gate/Géant for different heights of the lead
shielding in the wall, and different ceiling heights. A point
source of Tc-99m (141keV), I-131 (365keV) or F-18
(511keV) was placed free in air, 1m above the floor, 3m from
the wall. We used lead shielding of 2mm (Tc-99m) and 8mm
(I-131 and F-18). In total 165 simulations were run; for each
isotopes we varied the shielding height (1.8-5.0m) and ceiling
height (3.0-5.0m). These simulations allow us to compare the
contribution of the direct radiation (through the shielding), and
skyshine (over the shielding). Results: We find that the
skyshine contribution to the total radiation dose varies greatly
(from <2% to ~100%), and strongly depends on photon ener-
gy. For low photon energies (e.g. Tc-99m) skyshine is often a
dominant factor. For higher photon energies (e.g. F-18),
shielding of the primary radiation is typically the most impor-
tant concern.Conclusion: We have performed simulations that
allow an estimation of the contribution of skyshine to the ra-
diation dose outside a room, based on room use (occupancy,
total radioactivity used for treatment), ceiling- and shielding
height and the isotope used. For lower photon energies (e.g.
Tc-99m) this can be a major contribution, which, if neglected,
can result in insufficiently shielded rooms. This research will
allow for safer and better optimized shielding designs in Nu-
clear Medicine departments , as the contribution of scattered
radiation from the ceiling can be properly accounted for.
P012
Measurement of radioactivity in breast milk following
maternal administration of 111Indium-Pentetreotide
R. Bidder, C. Humphreys, S. Evans, A. Smakovs, P. Ali;
ABMU Health Board, Swansea, UNITED KINGDOM.
Introduction and Aim: Radiopharmaceuticals administered
to breast feeding patients may excrete into breast milk. The
purpose of this study was to measure the radioactivity con-
centration of 111Indium-Pentetreotide in breast milk and to
estimate the potential effective dose to a breast feeding pre-
term infant. A breast feeding patient with a carcinoid tu-
mour of the lung was referred for an 111Indium-
Pentetreotide investigation to assess disease extent. We re-
port the results of measurements made on breast milk sam-
ples following 111Indium-Pentetreotide administration.
Methods: 101.6MBq 111Indium-Pentetreotide was adminis-
tered intravenously. Breast milk samples were collected on
the day of 111Indium-Pentetreotide administration and on
days 1, 4, 5, 6, 7 and 8 days post-administration. 3ml ali-
quots were assayed using a 10 well automatic gamma coun-
ter (Perkin Elmer 2470 Wizard2). Prior to counting, the re-
sponses of the 10 detectors were normalised using a stan-
dard sample of 111Indium. Activity concentrations (Bq/ml)
were corrected for decay between measurement and the
time at which the breast milk sample was taken. The poten-
tial effective dose to our preterm infant was estimated by
adjusting the ICRP value for effective dose per unit activity
(mSv/MBq) by the ratio of the standard adult body weight
(70kg) to the infants’ body weight. Results and Discussion:
Planar imaging taken at 24hrs post-injection showed that
the 111Indium-Pentetreotide was taken up by the carcinoid
tumour of the left lung and there was increased activity
within both breasts. The activity concentration in the sam-
ples measured 348Bq/ml and 3Bq/ml on day 1 and day 8
respectively. Assuming an ingestion of 180ml/kg/day of
breast milk, the total potential effective dose to the preterm
infant from breast milk ingestion would be 0.529mSv in the
first 8 days. Three published articles have reported the level
of 111Indium in breast milk following intravenous adminis-
tration of 111Indium-labelled white cells and 111Indium-
Pentetreotide respectively. The range in the activity concen-
tration (per administered activity (MBq)) in the first
24hours was 0.09-0.31Bq/ml for the 111Indium-labelled
white cells and 0.01-0.02Bq/ml for the 111Indium-
Pentetreotide. Our range was 2.03-3.42Bq/ml per adminis-
tered activity (MBq). Our results are much higher than these
previous studies. This difference may be related to several
factors including chemical form, low numbers of patients
involved in the study and the difference in breast milk
intake.
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Patient Increase Doses From Hybrid Spect-Ct: Evaluation
In Common Clinical Practice
T. Ben Ghachem, A. Mhiri; M. Ghezaiel; I. Slim; M. F. Ben
Slimène; Nuclear Medicine department; Salah Azaiez Insti-
tute, Tunis, TUNISIA.
Introduction: The Single-photon emission tomography com-
bined with computed tomography (SPECT-CT) is a hybrid
imaging technique that integrates functional and anatomical
data. It is a valuable complement to conventional scintigraphy.
With these hybrid devices widely used, patient irradiation is
not only related to the administered radiopharmaceuticals, but
also to the CT component. That is why supporting physician
and patient awareness in addit ional dosimetry is
necessary.Purpose: The aim of this work is to estimate patient
doses from hybrid single-photon emission computed tomog-
raphy (SPECT) and computed tomography (CT)
procedures.Methods: The study involved a dual-headed
SPECT unit with an integrated 2-slice CT scanner (Symbia T
E-Cam, SiemensMedical Systems, Erlangen, Germany) in the
ISA (Salah Azaiez Institute) cancer center. Effective dose was
estimated for about 146 patients. Data from 168 scans of com-
mon nuclear medicine procedures (123I-MIBG, 99mTc-MIBI
parathyroid, 111 Inoctreotide,131I post therapy scan, 67 Gal-
lium and 99mTc-MDP bone scan) were presented in this study.
The CT parameters used were: tube current of 30 - 90 mAs,
slice thickness of 3-5 mm, and tube voltage of 110-130 kV. For
each patient the CT was acquired immediately after SPECT;
the patient being kept in the same position to minimize offsets
due to movement and allow proper registration on fused
imaging.Results: One hundred and forty six consecutive
patients and 168 SPECT/CT examinations were involved in
this study. The average age of patients was 56 years (27-83),
the sex ratio was 0.53. The total effective dose received by
each patient for SPECT-CT examination was estimated in
accordance with the recommendations of the ICRP 53 and
80.The average effective dose have ranged according to
type of the exam: 1927,1 mSv for 131I-post therapeutic
scans, 7,65 mSv for bone scans and 5.42 mSv for 123I-
MIBG scans, and the anatomical region explored: 0.32 for
Head and neck region and 4.78 for pelvis. The percentage
increase of effective dose by the inclusion of the CT was
about 125% for 123I-MIBG scans, 83 % for bone scans,
whereas it was negligible in case of treatment with 131I
(0.15%).Conclusion: In our study, the increased risk in-
duced by the additional CT with low dose settings in line
with SPECT examination, is not significant and does not
exceed 0.026%. By weighing the diagnostic value of
SPECT/CT examination with that of a stand-alone SPECT
examination dosimetric incremental cost is justified be-
cause of its direct clinical benefit conveyed to the patient.
P014
A DifferentMethodology Concept ForMeasurements And
Release Criteria In Thyroid Therapy Procedures
V. R. Mc Cready1, M. PAPHITI1, G. S. LIMOURIS2; 1Nu-
clear Medicine Dept, Royal Sussex County Hosp, Brighton,
UNITED KINGDOM, 2“Aretaieion” Hospital, Athens Uni-
versity Medical Faculty, Athens,, GREECE.
Aim: Patients treated with I -131, are potentially a signif-
icant source of radiation hazard to their family members
and public. It is aimed, by the present, to evaluate the
hospital release parameters of these patients by employing
a different (from the commonly adopted) methodology.
Methods: Thirty five post-operative thyroid-cancer pa-
tients were included in the study and divided into two
groups: Group A included patients with metastatic thyroid
disease and Group B pts with no metastases. For both
groups the range of administered I-131 activity was
2220-5550 MBq and dose rate levels were measured ac-
cording to a 4-day basis program. Each group employed a
different methodology of measurements: For those cases
with metastatic disease, the exposure rate was carried out
at the surface of the body, just under the mattresses at the
side of the main metastases, whereas, in group B measure-
ments were performed at a distance of 1 meter from them,
in upright position. By employing the “inverse square law
method” for the A group measurements, the results were
in concordance with those of group B, and hence a reli-
able comparison could be obtained. Dose rates were plot-
ted as a function of time and fitted using a bi-exponential
model, so as to derive the teff. Since the first post uptake
hours are crucial, the teff-fast part and the teff-slow one,
have been tabulated. Additionally, the “retained activity”
and the “isolation time” have been calculated, according
to the specific data of each patient. Results: Both methods
showed a difference of 0.6% between them. The variabil-
ity of “isolation times” among patients indicates a strong
relationship of teff on biological half-life and shows no
relationship to the administered activity. In addition, the
teff-fast ranges from 1 up to 11 hours and in order to
avoid a possible radiation risk, thorough care of conse-
quent measurements should be applied. Conclusion: Mea-
surements performed at the surface of the body are reliable
and suitable for metastatic disease cases, whereas for non-
metastatic ones, thyroid is considered as point source and
measurements should be applied at a distance of 1 meter
from patient, in standing position. According to our expe-
rience, in order to ensure that the treated patient will not
expose any individual or the environment to levels greater
that the dose limit, a strict dose rate of < 10 μSv/hr at 1
meter and a retained activity <200 MBq should be adopted
and established by the authorities.
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Hand Phantoms for Optimization of Radiation Protection
of Nuclear Medicine Personnel
M. Fulop1, J. Hudzietzová2, J. Sabol3, P. Ragan4, P. Povinec5;
1SlovakMedical University, Bratislava, SLOVAKIA, 2Faculty
of Biomedical Engineering of CTU, Kladno, CZECH RE-
PUBLIC, 3Faculty of Safetz management of PACR, Prague,
CZECH REPUBLIC, 4Slovak Centre of Scientific and Tech-
nical Information, Bratislava, SLOVAKIA, 5NuclearMedicine
Clinic BIONT, Bratislava, SLOVAKIA.
AimWhen handling the radiopharmaceuticals, the skin expo-
sure of hands is assessed based on results of routine monitor-
ing using a ring dosimeter. However, the position of the ring
dosimeter often does not correspond with the location where
the exposure reaches its maximum. It is therefore necessary to
determine the relationship between the response of the ring
dosimeter reading in terms of the personal dose equivalent
Hp (0,07) and the skin dose equivalent at the location with
the maximum exposure Hp,max (0,07). This relationship can
be determined by using hand phantoms simulating specified
effects of operations with radiopharmaceuticals which signif-
icantly contribute to hand exposure.Materials and methods-
The position of Hp,max (0,07) on hands is determined by map-
ping of the skin dose equivalent due to gammas and positrons
using thermoluminescent dosimeters (TLDs) of type MCP-Ns
placed at 11 locations on the surface of hands of workers
handling the radiopharmaceuticals. The effects of radiophar-
maceutical handling that significantly contribute to the hand
exposure have been specified by deconvolution of integral
dose equivalent map across all single operations performed
during the FDG preparation and administration.The five single
procedures that contributed to the dominant values Hp,max(0,
07) during the preparation and administration of FDG to pa-
tients have been selected: the application by a shielded and
unshielded syringe, hand holding a vial with forceps, holding
a container, and hand holding an infusion tube. Physical, voxel
and mathematical hand phantoms for all 5 selected operations
were constructed.Results and conclusionThe use of hand
phantoms reduces personnel constraints during dose equiva-
lent Hp(0,07) mapping on their hands. Measurement of the
dose equivalent distribution for the physical, voxel and math-
ematical hand phantom proved good agreement with uncer-
tainty lower than 20%. The relationship between the ring do-
simeter response and the results of skin dose equivalent mon-
itored at specific locations can be assessed by means of hand
phantoms, which simulate single acts that significantly con-
tribute to Hp, max (0,07). By comparing the physical, mathe-
matical and voxel phantoms hand, it was demonstrated the
significance of physical phantoms for the determination of
relationship of the ring dosimeters response and Hp,max(0,
07). The results have shown advantages of the use of
mathematical phantoms for optimization of radiation protec-
tion in nuclear medicine departments.Acknowledgements:
This work has been carried out and support by the projects
SGS15/114/OHK4/1T/17 and APVV-0241-011.
P016
Estimation of likely Radium-223 releases
into the environment from filtration based sewage systems.
D. G. Morgan, A. Hallam; Oxford University Hospitals NHS
Trust, OXFORD, UNITED KINGDOM.
This work developed a calculation method for estimating the
activity of 223Radium Chloride in a filtration based sewage
system, and the likely activity that may be released into the
environment from these systems. A patient was referred to our
hospital for 6 treatments of 223Ra Chloride as a treatment for
bone metastases (from castration resistant prostate cancer). The
treatment schedule was monthly injections of 3.5 MBq of
223Ra. The patient had a sewage filtration system at their prop-
erty with waste water leaving the system and flowing into a
network of pipes under the garden of the property, where the
waste water disperses into the soil. Our calculations modelled
the activity entering and leaving the system during the sched-
uled treatments and for 3 months after. The activity entering the
systemwas by direct excretion from the patient, in faecal matter,
during the first 7 days after intravenous administration. The
calculations showed that for an administered activity of
3.5 MBq (for a typical patient weighing 70 kg), the maximum
concentration within the sewage tank of 0.33 kBq/l. After cal-
culating the rate that the radioactivity enters and leaves the
system per day during the week after administration, it was
estimated that the waste removed from the system would lead
to a maximum activity of 0.9 MBq in the soil in the patients’
garden. We modelled the activity dispersed in the soil and esti-
mated that the concentration of activity in the soil is of the order
of 0.6 kBq/l. The conclusion from this calculation model is that
due to the relatively long physical half-life, moderate activities
of 223Ra may be released into the environment from filtration
based sewage systems. This will require consideration of pa-
tients’ home circumstances, and specific advice must be given
to ensure safety of members of the public and the patient’s
family, particularly if food is consumed from garden produce.
P017
Preclinical small animal PET/MRI
for radiopharmaceutical dosimetry
M. Kranz1, B. Sattler2, M. Patt2, W. Deuther-Conrad1, S.
Fischer1, R. Smits3, A. Hoepping3, O. Sabri2, P. Brust1;
1Helmholz-Zentrum Dresden-Rossendorf, Institute of
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Radiopharmaceutical Cancer Research, Leipzig, GERMANY,
2Dept. Nuclear Medicine, University Hospital Leipzig, Leip-
zig, GERMANY, 3ABX advanced biochemical compounds,
Radeberg, GERMANY.
Aim:To assess the radiation risk after injection of new PET
radiotracers small animal PET/MRI provides the essential
whole body biodistribution data for image based dosimetry
(ibD). In this study, we investigate ((S)-(-)# and (R)-(+
)##-[18F]fluspidine, a PET radioligand for neuroimaging of
σ1 receptors in mice. Organ doses (OD) and the effective dose
(ED) were determined using PET/MR ibD to assess the radia-
tion risk to humans. The results will be compared to those
previously acquired for (-)-*and (+)-** [18F]flubatine, to proof
the concept of small animal PET/MRI for incorporation dosim-
etry to assess the radiation exposure to humans by
radiopharmaceuticals.Materials and methods: Six female CD1
mice (weight: 30.9±1.3 g) were injected i.v. with 13.2
±3.0 MBq (#, n=3) or 12.6±1.4 MBq (##, n=3), respectively.
A dynamic 2 h animal PET/MRI protocol was performed
(MEDISO nanoScan®, Hungary). All relevant organs were
defined by volumes of interest. Time- and mass-scales were
adapted to the human anatomy; exponential curves were fitted
to the time-activity-data (%ID/organ). The ODswere computed
using the adult male model with OLINDA and the ED using
tissue weighting factors (ICRP103). The results were compared
to previously acquired data of post mortem biodistribution
(PMB) studies in mice for (-)-[18F]flubatine (n=27, ∅28.2 g)
and [18F]fluspidine (n=28#/n=22##,∅29.6 g).Results:The ex-
creting organs (kidneys, liver and urinary bladder) received
the highest ODs. Subsequently, these organs provide the
largest contribution to the ED. The overall radiation risk
to humans based on animal biodistribution data acquired
with ibD would be 12.9# and 14.0## as compared to
16.7#; 18.4## based on PMB. Comparable results were
estimated for [18F]flubatine: 12.5*(PMB), 12.1**(ibD).
All conversion factors in μSv/MBq.Conclusion: ibD of
[18F]fluspidine reveals significant differences between
the two enantiomers. Both in ibD and PMB the tracer
with higher affinity and slower kinetics (##) causes a
higher radiation exposure than its enantiomeric counter-
part (#). Furthermore, the ibD shows lower ED values
compared to the PMB due to the intrinsic methodologi-
cal differences. Small animal ibB is feasible and its re-
liability needs to be further investigated and confirmed.
P018
Beta+ emitters: workers absorbed doses
G. Tosi1, F. Provenzano1, G. Testanera1, A. Chiti2; 1Istituto
Clinico Humanitas, Rozzano, ITALY, 2Humanitas University,
Milano, ITALY.
Aim of this study was to measure and analyze absorbed doses
for different workers operating in a nuclear medicine depart-
ment starting from patient administered activity for PET ex-
aminations. In our department, radiopharmacists are in charge
of synthesis and quality control of radiopharmaceuticals;
nurses are in charge of collecting histories, preparing patients
and administering radiopharmaceuticals; technicians are in
charge of position patients, acquiring images and discharging
patients. Radiation therapy technicians are involved when
PET-CT is used for radiation treatment planning, where they
help in positioning the patients.Material and MethodWe
collected data for 3 beta+ emitters: 11C, 18F and 68Ga and
we registered administered activity for 50 patients per
radioisotope.For absorbed dose measurements we used an
electronic dosimeters (Thermo EPD mk2) that measures
equivalent doses in term of Hp(10) and Hp(0.07) and has an
energy range between 15 keVand 10 MeV.ResultTable below
shows data of mean administered activity for different
radioisotopes.RadioisotopeMean administered activity
(MBq)11C 332.618F 349.468Ga 129.2In the second table data
of equivalent doses per unit of activity are shown (nSv/
MBq).11C 18F 68GaHp(10)Nuclear medicine technician 2.4
6 5.8Radiotherapy technician / 5.4 /Nurse / 8.6 /
Radiopharmacists 9.6 15.5 73.5Hp(0.07)Nuclear medicine
technician 2.3 6.3 9.7Radiotherapy technician / 5.7 /Nurse /
5.7 /Radiopharmacists 10.819.5 439.6ConclusionDosimetric
data shows that higher doses are absorbed from
radiopharmacists, expecially for 68Ga manually synthesis.
Moreover, for all workers, measured doses give a confortable
result from radioprotection point of view as bring annual
absorbed doses within law limits.
P019
Radiation protection in a veterinary nuclear medicine
facility.
C. Pettinato1, D. De Zani2, M. Longo2, G. Ravasio2, M. Di
Giancamillo2, D. Zani2; 1Medical Physics Unit, Bologna, IT-
ALY, 2DIVET, University of Milano, Milano, ITALY.
Nuclear Medicine is becoming an important imaging modality
in veterinary medicine. The setup of a Veterinary Nuclear
Medicine facility is quite simple but requires specific attention
to radiation protection of staff and environment. The aim of
this work was to describe the radiation protection issues related
to a nuclear medicine facility in a veterinary hospital.The nu-
clear medicine facility is located in a veterinary hospital inside
the Radiology Unit. A dual headed gammacamera has been
refurbished as follow: one detector head was removed from
the gantry and attached on a pensile on the room ceiling, the
second detector head was left on the gantry and used as a
single headed gammacamera. The pensile camera is used for
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big animals standing in front of the detector (primarly horses),
while the single head camera is used as a conventional planar
and SPECT system for small animals (dogs, cats, felines, rab-
bits and pigs). An hot room is used for radiopharmaceutical
labeling.The floor under the pensile area is equipped with a
grid able to collect urine from the animals. Ionization cham-
bers and contaminameters are used to detect surface
contamination.From a radiation protection point of view there
are the following majors concerns:1) Activity injected to hors-
es is about 6-7 GBq/animal;2) Urine produced by horses can
seriously contaminate surfaces and staff members;3) Horses
are usually sedated but need the care of staff people that use
to stay very close to the animals during scans (bone scintigra-
phy: 2 hours/scan);4) Small animals need general anesthesia
and continuous monitoring during the scans;Staff members,
usually veterinary physicians, use to wear lead aprons during
scans and their personal monitoring is performed using TLD
detectors for whole body and extremity dosimetry.Mobile bar-
riers are used tomonitor small animals under anesthesia during
all scans.The major risks are related to horses care because of
the high radiation exposure rate that they emit. Actually we
measured about 25 microGy/hour, 20 microGy/hour and 18
microGy/hour respectively at one meter from the head, the
thorax and the animal abdomen. A person standing very close
to the animal, holding its head could receive more than 200
microGy per scan.A veterinary nuclear medicine facility is
feasible and major concerns in terms of radiation protection
are related to irradiation but also to possible contamination.
Workers have to be very well trained on radiation protection
issues.
P020
Recommended Administered Activity for Ga-68 labelled
peptides in Pediatric Nuclear Medicine
J. S. Machado, Jr., S. Beykan, M. Lassmann; Department of
Nuclear Medicine, University of Würzburg, Würzburg,
GERMANY.
Aim: The aim of this study is to suggest values for calculating
administered activities for Ga-68 labelled peptides based on
the weight-independent effective dose model proposed by the
EANM Pediatric Dosage Card for application in pediatric nu-
clear medicine. Methods: Time-integrated activity coefficients
(“residence time”) for Ga-68-DOTATATE and Ga-68-
DOTATOC were taken from Sandström et al. (JNM 2013),
for Ga-68-DOTATOC and Ga-68-Pentixafor from Hartmann
et al. (Nuklearmedizin 2009) and Herrmann et al. (JNM 2015),
respectively. With these values, the effective doses were cal-
culated by using OLINDA/EXM for the standard series of
phantoms (Adult, 15y, 10y, 5y, 1y, newborn). The weight-
dependent effective dose coefficients based on these results
were rescaled according to the formalism described by Jacobs
et al. (EJNMMI 2004), to determine the radiopharmaceutical
class of Ga-68 labelled peptides (“multiples” as defined in the
EANM dosage card) and to calculate the baseline activities
based on an upper limit of the administered activity (185
MBq) for an adult. With the baseline activity value and the
corresponding class, the administered activity for Ga-68 pep-
tides related to pediatric diagnostic scans can be calculated by
using the EANM Pediatric Dosage Card formalism: A admin-
istered [MBq] = Baseline Activity x Multiple. Results: All
calculated normalization factors of the effective doses results
in the range of -0.9176 and -1.0339. These values suggest that
the 68Ga labeled peptides belong to class “B” of radiophar-
maceuticals. According to our analysis, the baseline activity
for all compounds is 12.8 MBq. As a minimum activity, we
recommend 14MBq in analogy to F-18-fluoride. For illustra-
tion, we provide the activities and the corresponding weight-
dependent effective doses for Ga-68-DOTATATE for a child
with 60kg (163MBq, 3.8mSv), 40kg (114MBq, 3.9mSv),
20kg (62MBq, 4.1mSv), 10kg (35MBq, 4.4mSv) and 3kg
(13MBq 5.06mSv). Conclusion: For pediatric nuclear medi-
cine with Ga-68 labelled peptides, we suggest determining the
activities to administer based on the formalism proposed in
this work, so that the effective dose for these procedures can
be considered as almost age-independent.
P021
Whole-body Biodistribution, Dosimetry and Metabolite
Correction of 11C-palmitate: A PET Tracer for Imaging
of Fatty Acid Metabolism
N. L. Christensen, S. Jakobsen, O. L. Munk, S. Nielsen, L. C.
Gormsen; Aarhus University Hospital, Aarhus C,
DENMARK.
Aim: Positron emission tomography (PET) with fatty acid
(FA) or FA analogue tracers has been used extensively to study
metabolic processes. For example, 11C-palmitate is used to
image FA metabolism in the myocardium, brain and liver,
but despite its widespread use in human studies, no published
dosimetry, biodistribution or metabolite correction data exist.
Dosimetry estimates for 11C-palmitate are based on ICRP
106, where estimates for 11C tracers are listed. These esti-
mates assume that a large proportion of the radiotracer is ex-
creted via urine and that the bladder receives significant radi-
ation resulting in high dosimetry estimates. Typical radiation
burden often exceeds 1 mSv per injection in human experi-
mental studies, which limits the use of 11C-palmitate for youn-
ger and healthy individuals. However, FAs are rapidly taken
up by most tissues, are evenly distributed in the body and not
excreted in urine. Hence, the actual radiation burden is proba-
bly of a magnitude that enables serial human studies. Our aim
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was to correctly calculate 11C-palmitate dosimetry, with a sec-
ondary aim to publish population based metabolite correction
data. Methods: For dosimetry and biodistribution studies, two
pigs and two healthy volunteers underwent a low-dose CT
scan and immediately thereafter serial whole-body PET scans
(~300 MBq 11C-palmitate) with frame durations 1, 1.5, 2, 2.5
and 3 minutes per bed position. Mean effective dose and stan-
dard internal dose exposure in each organ was calculated using
OLINDA/EXM software. In the human subjects, a bolus in-
jection of 9,10-3H-palmitate was used to measure the fraction
of labelled palmitate incorporated into complex lipids during a
typical dynamic study. This fraction was compared to a larger
patient cohort, where the fraction of 11C-palmitate in complex
lipids was estimated by Sep-Pak. Results: In the pig study,
mean effective dose was 3.0 μSv/MBq, with the liver (19.1
μSv/MBq) and kidneys (7.42 μSv/MBq) receiving the highest
absorbed doses. In the human study, mean effective dose was
3.2 μSv/MBq, with the liver (27.5 μSv/MBq) and heart wall
(10.6 μSv/MBq) receiving the highest absorbed doses. Incor-
poration of 9,10-3H-palmitate into complex lipids was com-
parable to estimates obtained by 11C-palmitate with approxi-
mate fractions at 10, 20, 30, 40 and 50 minutes reaching 92,
64, 30, 17 and 12%. Conclusion: Mean effective dose of 11C-
palmitate was ~3.0 μSv/MBq, resulting in a total dose of
~1 mSv per human study, allowing multiple FA scans. In ad-
dition, little variation in free tracer was observed in the human
studies allowing population based metabolite correction.
P022
Dosage in Pediatric Nuclear Medicine Diagnostics in Daily
Practice
J. S. Machado, S. Beykan, M. Lassmann; Department of Nu-
clear Medicine, University of Würzburg, Würzburg,
GERMANY.
Aim: In pediatric nuclear medicine in daily practice, it is high-
ly recommended to review retrospectively the activities ad-
ministered to patients for further optimization of the diagnostic
procedures. The aim of this study, therefore, was to analyze
retrospectively the administered activities and effective doses
in pediatric patients undergoing nuclear medicine examina-
tions in our department and compare the results to national
and international recommendations. Methods: We collected
demographic data and administered activities for the last three
years and the two most frequent types of pediatric diagnostic
scans in our department (F-18-FDG PET/CT scans and kidney
scans with either 99mTc-MAG3 or 99mTc-DMSA). The re-
sults were compared to the weight-dependent administered
activities calculated from national and international recom-
mendations (EANM 2008 Dosage Card [EANM2008], North
America Consensus Guideline [NACG], EANM/SNMMI
2014 Harmonization Document [EANM2014], and German
National Recommendation [BfS2012]). In addition, we ana-
lyzed the patients’ age-weight-dependent resulting effective
doses taken from the corresponding ICRP data tables. Results:
For F-18-FDG PET/CT scans we performed 88 exams in 44
patients (21 younger than 10 years old). The administered
activity ranged from 29MBq to 345MBq; the corresponding
effective doses were between 3mSv and 7.1mSv. The mean
deviation of the administered activities from the values sug-
gested by EANM2008 was +12.9%, for NACG -33%, for
EANM2014 -39%, and for BfS2012 +11.4%. Related to renal
scans, there were 242 exams, 216 of 99mTc-MAG3 scans (177
patients) and 26 of 99mTc-DMSA scans (24 patients). A total
of 179 patients were younger than 10 years and 129 patients
younger than 2 years. The administered activities ranged from
11MBq to 146MBq, the corresponding effective doses be-
tween 0.16mSv and 1.62mSv. The mean deviation of the ad-
ministered activities for 99mTc-MAG3 were +6.3%
(EANM2008), -51.4% (NACG), +3.7% (EANM2014), and
+16.6% (BfS2012). The corresponding values for 99mTc-
DSMA were -24% (EANM2008), -7% (NACG), and +3.2%
(EANM2014). No values for 99mTc-DMSA are recommend-
ed in BFS2012. Conclusion: The administered activities
showed good agreement with EANM2008 and BfS2012, larg-
er differences were observed for NACG and EANM2014 for
F-18-FDG PET-CT scans, because of the slightly higher rec-
ommended activities. For renal scans (99mTc-MAG3 and
99mTc-DMSA) the results show a good agreement with the
EANM recommendations. The effective corresponding effec-
tive doses are low. The results of this study show that no
change in daily practice is needed.
P023
Automated Dispensing and Injection of 18F-FDG
Decreases Personnel Radiation Burden
L. Beels, F. Lavent, D. Nicolaij, O. Gheysens, C. Van de
Wiele, A. Maes; AZ Groeninge, Kortrijk, BELGIUM.
Aim: In nuclear medicine departments with a positron emis-
sion tomography (PET) system, the personnel doses have in-
creased over the last decade due to an increasing number of
PET procedures. In AZ Groeninge, the increasing personnel
dose emphasized the need for optimizing the individual work-
load in order to keep the radiation exposure as low as possible.
Therefore, an automated dispensing and injection system was
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installed and an additional PET shift was implemented. The
aim of our study was to evaluate the personnel whole-body
and extremity doses after implementation of the extra shift and
automated infusion system in comparison to historical data.
Materials and methods: A Medrad IntegoTM automated dis-
pensing and injection system was used to administer 18F-
fluoro-deoxy-glucose (FDG) to the patients. Personnel doses
were evaluated using a breast dosimeter provided by SCK-
CEN and an extremity dosimeter provided by AIB Vinçotte
Controlatom. Both types of dosimeters are thermo lumines-
cence dosimeters (TLD’s), that were read out monthly. The
radiation dose per PETshift was calculated because not every-
body had the same number of PETshifts every month. Results:
The reference value of the whole-body and extremity dose is
respectively 38.48 μSv and 377.48 μSv per PET shift. After
implementation of the extra PET shift (in casu 3 PET shifts
instead of 2 shifts per day) the extremity dose decreased to
254.85 μSv per PET shift (32.5% reduction), whereas the
whole-body dose remained constant (40.90 μSv per PET
shift). The second optimisation consisted of using the automat-
ed dispensing and injection system. The whole-body dose de-
creased from 38.48 to 27.27 μSv per PETshift (29.11% reduc-
tion) and the extremity dose decreased from 377.48 to 154.66
μSv per PET shift (59.03% reduction). Conclusion: In AZ
Groeninge, the personnel radiation burden has decreased by
adding an extra shift for PET examinations and by using an
automated dispensing and injection system. Optimizing radia-
tion burden is an on-going process and further analyses are
necessary to keep decreasing the personnel whole-body and
extremity dose.
P024
Proposal of correction factors for the assessment
of the maximum exposure to hands of workers handling
radiopharmaceuticals labelled with F-18: Based on studies
in CR and SR
J. Hudzietzova1, M. Fülöp2, J. Sabol3, J. Doležal4, J.
Kubinyi5, P. Povinec6, I. Makaiová7, A. Vondrák8; 1Faculty
of Biomedical Engineering, CTU Prague, Kladno, CZECH
REPUBLIC, 2SlovakMedical University, Bratislava, SLOVA-
KIA, 3Faculty of Safety Management of PACR, Prague,
CZECH REPUBLIC, 4Department of Nuclear Medicine,Uni-
versity Hospital, Hradec Králové, CZECH REPUBLIC, 5In-
stitute of Nuclear Medicine of GUH, Prague, CZECH RE-
PUBLIC, 6NuclearMedicine Clinic, BIONT, Bratislava, SLO-
VAKIA, 7Oncology Clinic of St. Elizabeth, Bratislava, SLO-
VAKIA, 8Isotope Centre, Nitra, SLOVAKIA.
Aim: The local exposure of the skin on hands averaged over 1
cm2 constitutes a limiting factor in handling radiopharmaceuti-
cals. In most cases, the maximum local exposure is at the tip of
the index finger. The aim of this paper is to determine the correc-
tion factors (CFs) to modify the value of the personal dose equiv-
alent Hp(0.07) measured in places where finger dosimeters are
worn (root index, middle or ring finger) in order to assess realis-
tically the maximum local exposure of workers at selected PET
nuclear medicine clinics in the Czech Republic (CR) and Slovak
Republic (SR).Materials and methods: The group under inves-
tigation included the workers which were preparing or applying
radiopharmaceuticals labeled with F-18 (three PET clinics in CR
and SR). The quantity Hp(0.07) was determined based on TLDs
where altogether 12 pairs of TLDs (MCP-Ns and MCP-7) on
each operator’s hands were used. The results were related to the
activity manipulated by the worker (about 10 GBq). Up to now,
164 measurements on 27 persons (CR) and 80 measurements on
8 persons (SR), were completed, respectively. The CFs, the ratio
of maximum exposure to the result obtained from finger dosim-
eter monitoring (root of the index finger), were determined for
each PET clinic, as well as for individual professional groups.
Results: Based on measurements using TLDs, the maximum
exposure was found on top of index fingers in about 63% of
workers in CR and in 47% workers in SR. The CFs were deter-
mined taking into account not only procedure (preparation, ap-
plication) but also technological equipment at the clinic (semiau-
tomatic dispensing stations, semiautomatic applicators). The
values of the CFs also differ in various groups in each clinic for
right and left hand. In some cases, the CFs reached values up to
13 (CR) and 16 (SR)while averageCFswere 3.2 inCR and 2.5 in
SR.Conclusion: The experimentally obtained values of Hp(0.07)
have shown that the maximum local exposure was usually found
in the place where finger dosimeters are not routinely worn (the
tip of the index finger). Underestimation of local exposure may
amount in some cases up to a factor of 13 in CR and factor 16 in
SR. Therefore, it is recommended to consider the introduction of
appropriate correction factors for various categories of workers
who may not all handled radiopharmaceuticals the same
way.Acknowledgements: This work was partially supported by
the projects SGS15/114/OHK4/1T/17 and APVV-0241-011.
P025
Assessing the effect of the amount of injected
99mTC-MIBI on the calculated cardiac volume
in the myocardial Gated-SPECT, A clinical survey
S. Entezarmahdi1, A. Kamali-asl1, M. Haghighatafshar2, F.
Gheisari2, M. Hemmatpour2, F. Khajerahimi2; 1Radiation
Medicine Engineering Department, Shahid Beheshti
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University, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Nu-
clear Medicine Department, Shiraz University of Medical Sci-
ence, Shiraz, IRAN, ISLAMIC REPUBLIC OF.
In recent years nuclear cardiology has been rapidly extended
and so many myocardial scanning perform daily. In this manner
the public awareness and public concern with regard to radia-
tion exposure in relation to this popular scanning protocol has
been raised in the last decade. Accordingly with the implemen-
tation of new imaging techniques and systems, the needed dose
per examining could be reduced. In this work we tried to find
whether the reduction in injected dose can affect on calculated
cardiac volume.Seventy five patients with the known probabil-
ity of coronary artery disease who was referred to our ward
enrolled in this study. To make different amount of radioactive
deposited in a same myocardium, we repeated each patients’
scan twice after one injection. The second Gated-SPECT scan
was performed when the deposited 99mTc in the myocardium
decayed up to 30 percent. Assuming that MIBI has not any
significant redistribution in this time, the only parameter which
has been changed is the amount of radioactivity within the
myocardium. In this way we have two different images with
different deposited dose in the myocardium from each patient.
All the images reconstructed and processed similarly. End dia-
stolic and end systolic volumes (EDV, ESV) was calculated by
Corridor-4DM software.With reduction of radioactivity within
the myocardium, as the images declare, because of partial vol-
ume effect the mid-myocardium points do not change substan-
tially. On the other side the standard deviation of count profile
decreases meaningful. Consequently, the calculated cavity vol-
umes increased as the radioactivity decreased in the myocardi-
um. Our results show that, with 30 percentages reduction of
radioactivity within the myocardium can lead to up to
39.00 ml growth in calculated EDV (mean difference 2.84 ml,
p-value=0.010) and up to 24.00 ml growth in calculated ESV
(mean difference 2.35 ml, p-value=0.007).In summary we
showed that, reduction in used radioactivity for myocardial per-
fusion scan with Gated-SPECT, could lead to statistically sig-
nificant growth in calculated cavity volume both in end diastole
and end systole phase.Key Words: Myocardial Perfusion Im-
age, Gated-SPECT, Injected dose, Cavity Volume
P026
Transportation of radioactive material for Nuclear
Medicine: risk assessment in the area of Bologna
S. Vichi1, G. Cicoria2, D. Pancaldi2, A. Infantino1, C. Po3, D.
Mostacci1, M. Marengo2; 1Montecuccolino Nuclear Engineer-
ing Laboratory, Department of Industrial Engineering, Univer-
sity of Bologna, Bologna, ITALY, 2Medical Physics Depart-
ment, “S. Orsola-Malpighi” Hospital, Bologna, ITALY,
3Servizio Sanità Pubblica, Regione Emilia Romagna, ITALY.
IntroductionTransportation of radioactive material is regulat-
ed at International level by specific standards and procedures
to ensure an adequate level of safety of people and the envi-
ronment. However, no widely applicable guidelines about
emergency procedures in case of accident have been approved
and published by international organisms. The aim of this
work is to collect statistical information on transportation of
radioactive materials in the area of Bologna (Italy) and to
evaluate the potential radiological risk for the population and
first responders in case of accident; data were used to create a
model for risk assessment as a support for the definition of an
emergency protocol.Materials &methodsAn investigation of
transportation of radioactive materials in the area of Bologna
was conducted collecting data on authorized carriers, con-
signees, itineraries, type of package transported (excepted,
type A / B), radioactive content of each package (radionuclide,
physical form, activity), population density, vehicle traffic
density and accident rate. Risk was assessed using
INTERTRAN2 package, a computer code system developed
by AMC Konsult AB (Bromma, Svezia) in the scope of an
IAEA Coordinated Research Program. An event tree analysis
was conducted to identify the most representative cases to be
simulated by INTERTRAN2. To take into account the differ-
ent levels of danger of an accident, severity categories were
defined; the probability that an accident belonged to a defined
severity category was assessed and, for each severity category,
the package response was defined in terms of the release of
radioactive material.ResultsMore than 200 different scenarios
were studied. As an example of a typical situation, we evalu-
ated an accident involving a vehicle carrying 5 packages of
123I (activity per package (a.p.p) 8.91E+08 Bq), 10 packages
of 131I (a.p.p. 2.92E+10 Bq), 5 packages of 125I (a.p.p. 9.25E+
08 Bq) and 1 package of 99Mo (a.p.p. 2.25E+11 Bq). The
evaluated population risk in terms of collective dose was
5.05E-10 person*Sv. On the basis of the studied cases, the
average risk in transportation associate with each consignee
for the S. Orsola-Malpighi Hospital was evaluated as 3.41E-
10 person*Sv.ConclusionsAs a general result, risk assessment
analysis of radionuclide sources in the area of Bologna showed
a low risk for the population in case of accident. All informa-
tion collected and results led to the implementation of a data-
base for risk assessment, with reasonable and realistic assump-
tions. Moreover, this framework can be also applied to differ-
ent scenarios and environment.
P027
Promotion of measures to counter radiation health
concerns using the comic (manga)
k. ohno1, T. Higashi2, C. Okuyama3, Y. Nakamoto4, K. Endo1;
1Kyoto Collage of Medical Science, Nantan, JAPAN, 2Shiga
Medical Center Research Institute, Moriyama, JAPAN,
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3Image Communiation Corporation, kyoto, JAPAN, 4Gradu-
ate School of Medicine Kyoto University, kyoto, JAPAN.
[Aim]Since the Fukushima Daiichi Nuclear Power Plant acci-
dent, four years have passed. However, Japanese people do not
have most of enough opportunity to study the basic informa-
tion about the radiation effect. Nuclear physicians created in-
formative comic (manga) to promote measures to counter ra-
diation health concerns.[Materials and Methods] All questions
and answers were collected related to inquiries from the gen-
eral public that were posted to reliable websites from
March 2011 to November 2012.More than sixty classes and
dialogs had been held at eight prefectures from October 2012
to January 2014. All the questions from participants were
collected.[Results and Conclusion]The questions could be
broadly classified into health effects, food safety and
radiation-related knowledge. To put out accurate information
about these questions, informative manga were produced, tak-
ing ideas from educational activities implemented at junior
high school in Fukushima. This comic (manga) will be pre-
sented in this meeting. This comic (manga) will be useful to
help people think about the issue of radiation effect.
P028
Radiation Protection Recommendations for Releasing
Patients Treated with 131I for Thyroid Cancer
E. Mora Ramirez; Caja Costarricense del Seguro Social /
Universidad de Costa Rica, San Jose, COSTA RICA.
The Nuclear Medicine Department at the San Juan de Dios
Hospital has considered radiation protection guidelines
given by the IAEA for releasing patients after 131I treat-
ments for thyroid cancer, in the Safety Report Series No.
63, “Release of patients after radionuclide therapy”, pub-
lished in 2009. However, IAEA guidelines are based on
the administrated activity and it does not take into account
bio-kinetics of the 131I into patient body, distance be-
tween patients and its relatives, etc. Our goal is to estab-
lish patient specific recommendations considering dose
limits to relatives and caregivers, also bio-kinetics of thy-
roid and extra - thyroid compartments, taking into account
NUREG-1556, Vol 9, Rev. 2 from USNRC considerations.
For 47 patients (female 44), age range from 79 - 20 years
old; effective half - life for thyroid and extra - thyroid
compartments have been estimated, occupation factor, dis-
tance and effective dose have been set. Preliminary re-
sults, for average data, showed good agreement with
IAEA guidelines for ablation patients in restrictions for
children under 2 years old, time off work and sleep apart,
however, restrictions for children from 2 to 11 years old
and are not similar; on the other hand, for follow-up pa-
tients, in our case this means patients with recurrence or
metastatic diseases, results are very different from the
IAEA guidelines for all restrictions, our results showed
that restriction times have to be increased, this means that
patients specific bio-kinetics have to be take it into ac-
count. Therefore a method to establish patient specific
radiation protection recommendations can be applied in a
Nuclear Medicine Department taking into account bio-
kinetics of 131I.
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Standard OSEM vs. Regularized PET Image
Reconstruction: Qualitative and Semi-Quantitative
Comparison
A. Iagaru, J. Lantos, E. Mittra, C. Levin; Stanford University
School of Medicine, STANFORD, CA, UNITED STATES.
Introduction: A PET image reconstruct ion tool
(Q.Clear®) has been recently introduced that allows
more iterations of the raw PET data than the standard
OSEM image reconstruction, to enable contrast recovery
without amplifying noise. Here we qualitatively and
semi-quantitatively compared Q.Clear® with the standard
OSEM image reconstruction available on our clinical
PET/CT scanners (GE Discovery 600 and 690) using
patient data. Materials and methods: PET datasets from
30 previously acquired clinical research scans (16 68Ga-
DOTA TATE, 11 18F-FPPRGD2, 1 18F-FLT, 2 18F-
FSPG) were reconstructed using Q.Clear® (25 iterations
with 3 different regularization strength or “beta” values)
and compared to standard reconstruction for Discovery
600 (2 iterations and 32 subsets; with PSF modeling)
and 690 (2 iterations and 24 subsets; with PSF model-
ing) scanners. Each of the 4 reconstructions/scan were
reviewed blindly by 2 experienced nuclear medicine
physicians and scored 1-5 (1 poor, 5 excellent quality).
The SUVmax of the smallest lesion detected in each
patient was also measured for comparison. The paired
Welch t-test was used for statistical analysis. Results:
Significant differences (P <0.01) were noted on visual
analysis for 2 beta values (350 and 450) vs. OSEM (the
mean visual scores were 3.59±0.65, 3.88±0.42, 3.89
±0.28 and 3.36±0.56 for Q.Clear® with the 3 beta
values and the OSEM, respectively). SUVmax values
were significantly higher (P <0.01) on Q.Clear® recon-
structions, resulting in increased conspicuity for some
small lesions. In 2 cases, lesions were only identified
on Q.Clear® reconstructions and confirmed on follow-
up MRI. Conclusion: Q.Clear® with a higher number
of iterations maintains image quality. Visual analysis
confirmed that overall image quality is improved and
may allow for improved detection of small lesions as
compared to the image quality from the standard OSEM
algorithm.
P030
How Does Increasing the Matrix Size / Reducing Voxel
Volume Impact Quantification in FDG PET? A Detailed
Analysis for Optimizing the Clinical Utility of Next
Generation Digital PET/CT
K. Binzel1, J. Zhang1, B. Zhang2, Z. Hu2, P. Bardos1, M. V.
Knopp1; 1The Ohio State University Wexner Medical Center,
Columbus, OH, UNITED STATES, 2Philips Healthcare,
Cleveland, OH, UNITED STATES.
The introduction of solid-state PET detectors with improved
count rates as well as spatial resolution facilitates the use of a
larger reconstruction matrix and smaller voxel volumes. This
study analyzes the impact of reduced voxel volumes on lesion
quantification in whole body oncologic PET/CT independent of
the visual appearance and the impact of iterative reconstruction
parameters.Philips Vereos TF 64 PET/CT (Cleveland, OH)
listmode data of 15 clinical patients were acquired after average
injection of 480 MBq 18F-fluorodeoxyglucose (FDG). Patients
were imaged from the skull to mid-thighs with 90 seconds per
emission volume. Default image reconstruction used a 4 x 4 x 4
(64) mm3 voxel volume, 144x144 matrix. Additionally, data
were reconstructed using a 2 x 2 x 2 (8) mm3 voxel volume,
288x288 matrix, and a 1 x 1 x 1 (1) mm3 voxel volume,
576x576 matrix. Image sets were also reconstructed using dif-
ferent iterative parameters. Using the 4mm images as reference,
target lesions as well as physiologic uptake in background tis-
sues were assessed by region of interest SUVmax on each im-
age set by multiple independent readers.Utilization of a larger
reconstruction matrix leads to substantially increased
SUVmax’s in smaller metabolically active tissues. For 8 mm3
voxel images, the average percent difference from default
SUVmax was a 16% increase, with a range for target lesions
from 0.2% to 48%. For 1 mm3 voxel images, the average per-
cent difference from default SUVmax was an 86% increase,
with a range for target lesions from 25% to 186%. There is an
observable trend that the increase in SUVmax is most pro-
nounced in smaller or more heterogeneous lesions. This obser-
vation concurs with a prior phantom assessment. The quantita-
tive impact of the range of variable number of subsets per iter-
ative reconstruction was minimal. We determined the following
to be preferential: 144x144 matrix 3 iterations 15 subsets,
288x288 matrix 3 iterations 13 subsets and 576x576 matrix
3 iterations 11 subsets.Digital PET/CT appears to enable
larger matrix size / reduced voxel volume reconstruction
that impacts quantification especially in smaller, metaboli-
cally active lesions. This observation is consistent with im-
proved recovery coefficients in phantom data. Larger matrix
reconstruction appears to be promising in digital PET by
reducing partial volume effects and thus not only improving
detectability but also quantitative accuracy.
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Optimisation of ventilation/perfusion (V/Q) SPECT
reconstruction utilising advanced reconstruction methods:
a phantom study
M. J. Memmott; Central Manchester University Hospitals
NHS Foundation Trust, Manchester, UNITED KINGDOM.
Introduction: Advanced image reconstruction methods
implementing resolution recovery (RR) and regularisation
(REG) have been exploited in various areas of nuclear medi-
cine with the aims of improving image quality and reducing
administered activity and/or acquisition time. This phantom
study aimed to investigate their potential use in ventilation/
perfusion (V/Q) lung SPECT. Methods: The background vol-
ume and spheres of a NEMA image quality phantom were
filled with an equal Tc-99m activity concentration, equivalent
to clinical ventilation SPECT. After acquisition on a GE Opti-
ma 640, using ELEGP collimators, the background activity
concentration was increased by a factor of 5 to mimic perfusion
SPECT, with the spheres representing mismatched defects. Re-
duced count SPECT datasets were also simulated via Poisson
sampling to give 25 - 100% of the clinical count rate.
Attenuation-corrected reconstructions were performed using
variants of the GE Evolution Toolkit; implementing ordered-
subset expectation-maximisation (OSEM), OSEM with RR
and OSEM with RR and REG (currently reserved only for
cardiac studies). The contrast for each sphere was derived from
the mean voxel count in a spherical volume of interest (VOI)
andmean background voxel value from 12 additional spherical
VOIs. Background noise was measured using the mean coeffi-
cient of variation in background VOIs. The ratio between con-
trast and background noise (CNR) was calculated for each
sphere. The optimal reconstruction parameters were derived
through blinded interpretation of a subset of clinical reconstruc-
tions by a Consultant Nuclear Medicine Physician. Results:
Reconstruction implementing OSEM with RR and REG gave
highest CNR in all spheres when compared with OSEM alone,
due to the noise limiting effect of regularisation. Reconstruc-
tion using OSEM with RR however gave the greater contrast
overall. Optimal reconstruction parameters were found to be
with 5 iterations and 10 subsets. When compared to the optimal
OSEM derived data, equivalent quantitative image quality was
achieved when implementing RR and RR with REG using
approximately 50% of the acquired data. Conclusions: Image
quality of reconstructed data acquired from a phantommimick-
ing a V/Q SPECT acquisition was found to be enhanced when
implementing both RR and RR with REG, giving increased
contrast or reduced noise respectively. Half of the clinical
count-rate was required to give an equivalent image quality to
OSEM, indicating that either acquisition times and/or adminis-
tered activity have the potential to be reduced in clinical prac-
tice when implementing advanced reconstruction methods.
P032
Q. Freeze Software for Respiratory Motion Correction
in PET/CT: A Preliminary Investigation
with a Respiratory Motion Phantom
G. Havariyoun, D. Ruiz, E. Kalogianni, B. Corcoran, A.
Eccles, N. Mulholland, G. Vivian; King’s College Hospital,
LONDON, UNITED KINGDOM.
Aim: PET/CT imaging of the lung and abdominal region
can often lead to apparent increase in tumour volume, un-
derestimation of measured standardized uptake value
(SUV), and mismatched PET and CT images due to respi-
ratory motion. GE Healthcare Q.Freeze software uses 100%
of the detected events and can perform respiratory phase
matching of gated PET and low-dose 4D-CT data to mini-
mize respiratory motion artefacts. This investigation aimed
to assess the effectiveness of the Q.Freeze software. Mate-
rial and methods: The GE Discovery 710 PET/CT scanner
was used to scan the Quasar® Respiratory Motion Phantom
(QRMP) with two in-house constructed inserts. The QRMP
inserts consisted of 4ml and 1ml 18F-FDG filled spheres in
air and water to model spherical lesions in lung and liver
respectively. Scans were performed with a sinusoidal respi-
ratory waveform of 20 breaths per minute (bpm) with 20mm
amplitude and a single patient specific respiratory cycle
pattern. Varian’s Real-Time Position Management System
was used to monitor the phantom’s motion. Images acquired
when the QRMP was motionless were used as benchmark.
For each motion experiment three sets of images were re-
constructed; ungated PET (UG-PET), Q.Freeze PET only
gated (4D-PET) and finally Q.Freeze PET with cine CT
(4D-PET/CT). Images obtained were quantitatively
assessed for background variability (BV), sphere volume
and SUVs. All analysis was performed on a Hermes® nu-
clear medicine workstation. Results: UG-PET images had
the largest increase in volume and reduction in SUV when
compared to benchmark in all images. 4D-PET and 4D-
PET/CT improved accuracy by increasing SUVmax by a
mean of 33% and 31% and decreasing volume by a mean
of 216% and 211% when compared to UG-PET respective-
ly. The improvement was greater in all cases for 4D-PET
compared to 4D-PET/CT, apart from in air where 4D-PET/
CT showed marginal enhancement by increasing SUVmax
by 5% and decreasing volume by 14% compared to UG-
PET. BV was largest for the 4D-PET/CT in all acquired
images. Conclusion: Preliminary results clearly indicate
that Q.Freeze largely improves SUV and volume figures
when compared to UG-PET images. These results do not
justify the extra radiation exposure to patients if 4D PET/
CT was performed. The next step of this study will involve
the construction of an insert that will replicate lesions on the
liver-lung boundary.
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Reproducibility of quantification in F-18 FDG PET
clinical application varying protocols parameters
and lesions dimension
A. Zorz1, E. De Ponti1, L. Guerra2, S. Morzenti1, M.
Cuzzocrea3, C. Crivellaro3, A. Crespi1, M. Arosio2, C.
Landoni3; 1Medical Physics, A.O. San Gerardo, Monza, ITA-
LY, 2Nuclear Medicine, A.O. San Gerardo, Monza, ITALY,
3Nuclear Medicine, University of Milano Bicocca, Milano,
ITALY.
Aim: Measurements of tumor metabolism is used to evaluate
response to treatments using quantitative parameters as
SUVmax and SUVpeak. However, they are strongly influ-
enced by various technical features of the the scanner system,
injected activity, acquisition time, reconstruction parameters
and lesion’s characteristics as dimension. Aim of the study
was to investigate SUV variability between different size le-
sions and reconstructed images with a newest high sensitivity
PET/CT scanner (Discovery IQ from GE Helthcare) equipped
with the new Q-Clear regularised reconstruction algorithm. Q-
Clear algorithm incorporates a factor (i.e. Beta parameter) able
to modulate the noise allowing the algorithm to reach the full
convergence of the data without excessively increasing the
noise, as usually found with standard OSEM reconstruction
(VPHD). Material and Methods: GE Discovery IQ scanner
was used for acquisition of list data and regularised reconstruc-
tion (Q.Clear) was used with different regularization beta pa-
rameter (from 500 to 200 units). SUVmax and SUVpeak of
both Q-Clear and VPHD were calculated and compared in 60
lesions. Lesions were stratified according to injected activity
(standard dose 3.7 or half dose 1.8 MBq/kg) and lesion dimen-
sion (range 6-50mm, cut-off 15mm). SUVmax and SUVpeak
variability was analysed as a function of the acquisition time
(from 45s to 2min/FOV for standard dose and from 2min to
4min/FOV for half dose) and different beta parameters. Pa-
tients’ height, weight and BMI were also balanced between
compared datasets. Results: SUVmax and SUVpeak showed a
complete overlap between measurements with decreasing ac-
quisition time/FOV in both VPHD and Q-Clear reconstruc-
tions (maximum difference below 5% and linear regression
model p<0.0001). Quantification was not affected by time of
acquisition/FOV both in small and larger lesions, whereas
SUVmax and SUVpeak were significantly influenced by var-
iation of beta values and differences were higher in small le-
sions (37% and 15% for SUVmax and SUV peak, respective-
ly) with respect to larger ones (14% and 6%). A maximum
difference of 38.5% between VPHD and Q-Clear was mea-
sured for SUVmax quantification in smaller lesions group.
Conclusion: Our data showed that SUVs were not affected
by acquisition time/FOV with this new high sensitivity PET/
CT system, both for small and large lesions. According to our
results, quantification stability could allow the therapy re-
sponse assessment with different acquisition time, condition
sometime requested by patient compliance or clinical
workflow.
P034
Impact of a new Bayesan penalised likelihood
reconstruction algorithm on 68Ga-DOTA-TOC PET/CT
imaging
M. Scarlattei1, G. Baldari1, S. Migliari1, C. Ghetti2, C.
Cidda1, G. Serreli2, L. Ruffini1; 1Nuclear Medicine Dept, Uni-
versity Hospital of Parma, Parma, ITALY, 2Medical Physics,
University Hospital of Parma, Parma, ITALY.
In PET reconstruction standard iterative algorithms have dif-
ferent numbers of iterations, subsets and filters. It is now avail-
able a new Bayesian penalised likelihood reconstruction algo-
rithm (QC, GE Healthcare, Milwaukee, USA) that requires
only one input the penalisation factor (named beta).Aim of
our study was to investigate clinical impact of QC algorithm
compared to standard reconstruction approach (VP) in PET/
CTstudy with 68Ga-DOTA-TOC.Nineteen patients (7 men, 12
women; 13-80 years) with known or suspected NETs and tu-
mours other than NETs underwent 68Ga-DOTA-TOC PET/
CT. All studies were performed on a Discovery IQ scanner
(GE healthcare, Milwaukee, USA). Patients did not receive
medical treatment before exam. Main indications for NETs
were staging, follow-up and recurrence; for the suspected
NETs increased tumor markers, clinical symptoms, and find-
ings in conventional imaging; for non-NETs lesions indication
was the SST receptor status for receptor radiotherapy with
labeled SST analogues.Whole body PET/CT was performed
according to the standard protocol (head-to-mid-thighs) 60
minutes after 68Ga-DOTA-TOC injection (130-220 MBq).
Images were processed using QC for a range of different beta
values (100-1000) and standard VP reconstruction (2 itera-
tions, 24 subsets, 6.4mm filter).We analyzed images in a qual-
itative and semiquantitative way. Lesion and liver SUVmax,
and liver SUV mean were measured on VP and QC images,
using a VOI drawn on the PET transaxial slice presenting the
highest uptake value. The maximum diameter of each lesion
was measured on transaxial CT images.68Ga-DOTA-TOC
PET/CT was positive in 6/19 patients (31.6%). Lesions were
visually localized in the meninges, lung, small bowel, lymph
nodes, bone and sympathoadrenal system.A lesion-by-lesion
analysis was performed and in patients with multiple foci le-
sion with the highest uptake was assessed. Mean lesion
SUVmax was 26.3 and 32.4 in VP and QC images, respec-
tively, Mean liver SUVmax and SUVmean were 11.03 and
11.3, 7.7 and 7.8 in VP and QC images. Mean lesion diameter
was 24 mm (9-70). Micrometastases of the bone were not
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completely visualized by VP images (1 patient with two bone
lesions on QC images and uncertain VP; SUVmax 1.8 and 3.5
in VP and QC images)Conclusion: the Bayesian penalised
likelihood reconstruction algorithm (QC) achieves a signifi-
cant increase of SUVmax values measured in the lesions com-
pared to the VP (32.4 vs 26.3) on 68Ga-DOTA-TOC PET/CT
images. QC shows higher sensitivity in the detection of bone
lesions. This new algorithm is likely to improve global cancer
detection, especially for small lesions.
P035
Quantification with the new regularized reconstruction
algorithm QClear in 4D and QFreeze acquisition
A. Zorz1, S. Morzenti1, L. Guerra2, M. Cuzzocrea3, E. De
Ponti1, A. Crespi1, M. Arosio2, C. Landoni3; 1Medical Phys-
ics, A.O. San Gerardo, Monza, ITALY, 2Nuclear Medicine,
A.O. San Gerardo, Monza, ITALY, 3Nuclear Medicine, Uni-
versity of Milano Bicocca, Milano, ITALY.
Aim: The aim of this study is to evaluate how the quantifica-
tion of lung and hepatic lesions changes when the new regu-
larized reconstruction algorithm QClear in different motion
management protocols and 3D standard acquisition is applied.
Material and Methods: The latest generation of the Discovery
PET/CT family (GE Healthcare - Milwaukee; WI-US) is
equipped with the new regularized reconstruction algorithm
QClear, an iterative algorithm that performs 25 iterations to
reach full convergence. Image noise could be optimized set-
ting the beta parameters according to the data statistics. This
preliminary evaluation is performed on 13 patients submitted
to a 3D scan of 1.5minutes/FOV with a 9 minutes 4D FOV
integrated into the WB scan. Data are acquired in list mode in
order to perform different reconstruction: a standard 3D image
of 1.5 minutes with beta 350 (WB), a 4D image of 6 phases
each of 1.5 minutes with beta 350 (4D-QC350) and a 4D
image of 6 phases each of 30 seconds with beta 450 (4D-
QC450). These last data are also processed with the QFreeze
algorithm, that performs a non rigid coregistration of all the 4D
bins to obtain motion corrected static images (QFreeze).
Values of SUVmax and SUVmean of 13 lesions are collected.
Results: The mean values of SUVmax of WB, 4D-QC350,
4D-QC450 and QFreeze are respectively 7.30, 9.39, 9.41,
7.24. The same values for the SUV mean are 4.44, 5.80,
5.79, 4.68. For the 4D reconstructions, the highest SUV values
among all bins are reported. For both parameters, the compar-
ison of QFreeze versus 4D-QC350 is statistically significant
(p<0.0001 for SUVmax and p=0.0001 for SUVmean respec-
tively), while the differences between QFreeze and WB and
between 4D-QC350 and 4D-QC450 are not statistically sig-
nificant. Conclusion: Using the QClear algorithm, the same
quantification is obtained both in a standard WB protocol
and in a motion management protocol based on a non rigid
coregistration (QFreeze). However, 4D protocol permits to
measure the highest SUVmax and SUVmean values. Further-
more, no changes in quantification are observed in 4D recon-
structions reducing the acquisition time from 9 minutes/bed to
3 minutes/bed and optimizing the beta parameters.
P036
Quantitative SPECT/CT imaging using a commercial
software
L. D’Ambrosio1,2, L. Aloj1, P. Chiaramida3, V. Cerciello2, P.
Gaballo1, A. Prisco1, S. Lastoria1; 1SC Medicina Nucleare,
Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS,
Napoli, ITALY, 2UOSD Fisica Sanitaria, Istituto Nazionale
Tumori Fondazione G. Pascale - IRCCS, Napoli, Italy, Napoli,
ITALY, 3GE Healthcare, Rome, ITALY.
Aim Routine SPECT imaging lacks quantitative information.
The use of CT attenuation correction and lesion localization
based on the fusion of diagnostic CT and SPECT datasets can
improve accuracy. This work aims to validate commercially
available software (Q.Metrix, GE Healthcare) that provides
absolute quantification (SUV) and investigates the feasibility
of applying this software in clinical practice. Materials and
methods For absolute quantification Q.Metrix needs data of
patients, injected activity information and camera sensitivity.
This software includes tools for performing reconstruction of
SPECT/CT data with attenuation, scatter and collimator depth-
dependent three-dimensional resolution recovery correction.
Furthermore it includes also segmentation tools both on CT
and NM images. All acquisitions were performed using hybrid
dual-head SPECT-CT camera (Discovery 670, GE
Healthcare). Camera sensitivity was evaluated for Tc99m
and I131. Accuracy of activity quantification was performed
on a large homogeneous source with addition of attenuating/
scattering medium. A NEMA/IEC body phantom was utilized
to measure recovery coefficients. Studies of patients undergo-
ing Tc99m MAA lung perfusion scans and I131 in post-
therapy scans were analyzed. Results Tc99m (I131) sensitivity
factor was 71.4 (26.1) counts/MBq*s using a source in a petri
dish and planar acquisitions as recommended by the manufac-
turer. A simulation utilizing homogeneous phantoms contain-
ing activities yielding SUV values of 1 for the two nuclides
providedmeasured SUVmean values of 1.08 for Tc99m and of
0.75 for I131. Recovery coefficient varied from 0.88 (26.5 ml)
to 0.27 (1.15ml) for Tc99m and from 0.53 (26.5 ml) to 0.10 (1,
15 ml) for I131. Preliminary patient studies performed show
the feasibility of quantitatively assessing lobar distribution of
Tc99mMAA in the lungs and absolute quantitation of lesion
uptake in post-therapeutic I131 scans. Conclusions Although
inferior in accuracy to PET/CT this method can be applied on
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clinical SPECT-CTsystems and can yield reproducible results.
The possibility of performing absolute quantitation of tracer
uptake in Bq/ml opens the way for novel clinical and research
a p p l i c a t i o n s u s i n g s i n g l e p h o t o n l a b e l e d
radiopharmaceuticals.
P037
Optimization of acquisition time of 68Ga-PSMA-ligand
PET/MRI in patients with local and metastatic prostate
cancer
S. Lütje1, S. Blex2, B.M. Schaarschmidt3, A. Bockisch1, T. D.
Poeppel1, A. Wetter2; 1Clinic for Nuclear Medicine, Universi-
ty Hospital Essen, Essen, GERMANY, 2Department of Diag-
nostic and Interventional Radiology and Neuroradiology, Uni-
versity Hospital Essen, Essen, GERMANY, 3Department of
Diagnostic and Interventional Radiology, Medical Faculty,
University Düsseldorf, Düsseldorf, GERMANY.
Aim: Prostate cancer (PCa) causes significant morbidity and
still is the second leading cause of cancer-related deaths in men
in the Western world. 68Ga-labeled HBED-CC-PSMA is a
highly promising new tracer for imaging of PCa. The aim of
this study was to optimize the acquisition time of 68Ga-PSMA
positron emission tomography/magnetic resonance imaging
(PET/MRI) in patients with local and metastatic prostate can-
cer. Materials and methods: Eleven patients were adminis-
tered intravenously with the 68Ga-HBED-CC-PSMA ligand
(116 ± 25 MBq) and subsequently underwent PET/MRI at
159 ± 57 min after injection. PET and MR imaging data were
acquired simultaneously. PET acquisition was performed in
list mode and PET images were reconstructed at different time
intervals (1, 2, 4, 6, 8, and 10 min). Data were analyzed at
these time intervals regarding PET image quality and radio-
tracer uptake in tumor lesions and muscle tissue. Uptake was
quantified in terms of the maximum and mean standardized
uptake value (SUVmax, SUVmean) within a spherical volume of
interest (VOI). Reference VOIs were drawn in the gluteus
maximus muscle on the right side. PET image quality was
evaluated visually by experienced nuclear physicians/
radiologists based on a 1 - 5 (excellent - insufficient) scale.
Results: Both SUVmax and SUVmean correlated inversely with
acquisition time and reached a plateau at acquisition times of
4 min and longer. PET image quality showed a linear correla-
tion with increasing acquisition time, reaching a plateau at 4-
6 min of image acquisition. Conclusion: The optimal acquisi-
tion time of 68Ga-PSMA-ligand PET/MRI in patients with
local and metastatic PCa appears to be 4 min per bed position.
At this acquisition time, PET image quality reaches its maxi-
mumwhile SUVs do not change significantly beyond this time
point.
P038
Development of advanced data acquisition methods
for quantitative single photon emission computed
tomography
K. MATSUMOTO1,2,3, Y. Takahashi4,2, A. Takaki5, K.
Murase2, Y. Wada3, Y. Watanabe3, K. Endo1; 1Kyoto College
of Medical Science, Kyoto, JAPAN, 2Osaka University Grad-
uate School of Medicine, Suita, JAPAN, 3Center for Life Sci-
ence Technologies, RIKEN, Kobe, JAPAN, 4Gunma Prefec-
tural College of Health Sciences, Maebashi, JAPAN, 5Fujifilm
RI Pharma Co., Ltd., Tokyo, JAPAN.
Aim: The cerebral blood flow and metabolism SPECT im-
ages require high signal to noise ratio and spatial resolution
for precise evaluation of the abnormal radioactive tracer
distribution in the brain. The asymmetric SPECT acquisi-
tion such as an odd number of projections is significantly
improved reconstructed image quality, because for an odd
number of projections the sampling interval is half of the
angular step of the detector and the number of angular sam-
pling points is doubled. The interpolated projection data
estimation (IPDE) method also improve the image quality,
but the spatial resolution is degraded. On the other hand, the
DRAMA (Dynamic RAMLA) is an iterative algorithm sim-
ilar to the RAMLA, provides fast convergence with a rea-
sonable signal to noise ratio by updating the image with
row-action by applying the subset-dependent relaxation pa-
rameter. The purpose of this study was to develop a Hybrid
SPECT reconstruction method by a combination of the
asymmetric SPECTacquisition, IPDE method and modified
DRAMA reconstruction algorithm. Methods:A Hybrid
SPECT reconstruction method was evaluated to a two-
dimensional Shepp-Logan head numerical phantom with
statistical noise and a Hoffman 3-D brain phantom. A gam-
ma camera, GE Healthcare Millennium MG, were used to
scan images of a Hoffman 3-D brain phantom. For 360°
SPECT, we simulated 16, 32 and 64 projections with an
array 128 pixel per projection. Attenuation and scatter cor-
rections of the Hoffman 3-D brain phantom SPECT image
were performed using Chang’s method and a modified triple
energy window, respectively. Quality of the reconstructed
images was evaluated in terms of mean structural similarity
(MSSIM) values and a two dimensional power spectrum
analysis. Results:As for the numerical phantom, the MSSIM
values of each projections were 0.9584±0.0151 (16 projec-
tions), 0.9595±0.0308 (32 projections) and 0.9511±0.0433
in the 64 projections, respectively. In the radial distribution
function of a two dimensional power spectrum analysis,
each phantom SPECT images quality using Hybrid SPECT
reconstruction method were approximately 1.5 times better
than conventional method. Conclusions:The Hybrid
SPECT reconstruction method showed faster resolution
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recovery with lower noise than the asymmetric SPECT ac-
quisition and IPDE method and yielded acceptable images
in 2 or 3 iteration.
P039
Effects of mis-registration of CT attenuation-corrected
on myocardial perfusion images acquired using
multi-focus fan beam collimator SPECT/CT
and conventional SPECT
H. ONISHI1, K. Nakamoto2, S. Kenda3, Y. Kangai1, N.
Yada1, T. Saho1, T. Sakai3, D. Hasegawa3, M. Fukunaga3, H.
Amijima4; 1Program in Biological System Sciences, Graduate
School of Comprehensive Scientific Research, Prefectural
University of Hiroshima, SHOBARA, HIROSHIMA, JA-
PAN, 2Department of Radiology, Hiroshima prefectural Hos-
pital, HIROSHIMA, HIROSHIMA, JAPAN, 3Program in
Health andWelfare Sciences, Graduate School of Comprehen-
sive Scientific Research, Prefectural University of Hiroshima,
MIHARA, HIROSHIMA, JAPAN, 4Graduate school of nurs-
ing,Hyogo University of Health Sciences, KOBE, HYOGO,
JAPAN.
Aims: Algorithms for attenuation correction in SPECT/CT
systems have potential for mis-registration. The present study
compares mis-registration of computed tomography attenua-
tion correction (CTAC) in IQ-SPECT and conventional (180°
apart: C-mode) myocardial perfusion images (MPI). Methods:
Images were acquired from seven healthy volunteers who in-
dependently underwent SPECT/CT using 740 MBq of 99m-
Tc-tetrofosmin, a parallel-hole collimator (LEHR) and the
same system with IQ-SPECT (IQ-mode) modification using
SMARTZOOM. C-mode images were acquired over 180°-
contoured orbits with 30 views/detector for 12.5 s into 64 x
64 matrices and 4.8-mm pixels. We acquired IQ-SPECT im-
ages over 208°-cardiocentric orbits with 17 views/detector for
6.25 s/view into 128 x 128 matrices and 4.8-mm pixels. Both
images were attenuation-corrected using CT images. The re-
construction software was Flash3D and specific Flash3D
(OSCGM) for IQ-mode. The MPI SPECT/CT registration
shifted the CT data by ±1, ±2, ±3 pixels along the cephalad/
caudal, dorsal/ventral and left/right axes. The % uptake in 5-
wall AC-MPI polar maps was scored for each region and the
direction of the shift along each axis was statistically analyzed
using Student’s t test. We compared regions of mismatch on
non-shifted images in C- and IQ-modes. Results: The % up-
take did not significantly differ between shifted and non-
shifted images when mis-registration affected only 1 or 2
pixels. The most significant effects on % uptake on AC polar
maps were 16.6% and 5.2% changes in the lateral wall caused
by a 3-pixel ventral shift in C (p = 0.002) and IQ (p = 0.29)
modes, respectively. A 3-pixel dorsal shift resulted in
statistically significant 13% (p = 0.0001) and 3.6% (p =
0.43) septal changes in C and IQ-modes, respectively. The
significant change in IQ-mode was caused by three (p =
0.009) and two-pixel (p = 0.04) cephalad shifts. The mismatch
in IQ-mode was increased by 10% - 20% compared with that
in C-mode without changes in the septum and inferior wall
caused by a right shift. A 3-pixel right shift increased the
mismatch of the septum and inferior wall to 49.5% in IQ-
mode. However, the mismatch in IQ-mode was improved by
52.2% compared with a 3-pixel ventral shift in the lateral and
inferior wall in C-mode. Conclusion: Excessive mis-
registration along the dorsal/ventral axis affected the quality
of AC myocardial perfusion images most significantly. These
findings suggested that mis-registration affects IQ-mode less
than C-mode in MPI SPECT/CT images.
P040
Optimisation and clinical impact of PSF modelling
reconstruction in PET-CT
B. J. Corcoran, C. Scott, D. RUIZ, E. Kalogianni, A. Eccles;
King’s College Hospital, London, UNITED KINGDOM.
Aims: To quantify the impact on PET image quality of PSF
modelling in the reconstruction of time-of-flight PET/CT.
Method: Images of a NEMA Image Quality phantom contain-
ing 6 spherical inserts, activity ratio of 4:1 hot spheres to back-
ground, were acquired on a GE Discovery 710 PET/CT scan-
ner. The data was reconstructed with the existing clinical pro-
tocol: VPFX (VUE point FX, 2 iterations, 24 subsets). Further
reconstructions then included the SharpIR (GE Healthcare)
PSF modelling: VPFX+PSF (VUE point FX + SharpIR, 1/2/
3/4/5 iterations and 24 subsets). Image quality parameters
were calculated: coefficient of variation (CoV), signal to noise
ratio (SNR) and contrast recovery (CR). Following the phan-
tom study 19 patients were retrospectively reconstructed using
VUE point FX (2 iterations, 24 subsets) with and without
SharpIR correction. SUVmax and CoV were assessed in the
liver. A 60mm diameter circular region was drawn on 3 differ-
ent slices in the liver for each patient and the average calculat-
ed. Changes in SUVmax were calculated for all identified
lesions. Results: Visual analysis of the phantom data, contrast
recovery curves and SNR curves for the 6 inserts identified the
optimum image quality for the reconstruction with VPFX+
PSF (2 iterations, 24 subsets). In the patient study; for the
VPFX+PSF reconstruction compared to the VPFX reconstruc-
tion, the mean difference in the CoVof liver regions was -9.2%
and the SUVmax was -0.7%. For the lesions identified (n=56)
the measured changes in SUVmax: increased (41), no change
(6), decreased (9). Conclusion: We have optimised our recon-
struction for time-of-flight plus PSF corrected acquisition. As
shown by other authors the signal to noise is reduced in the
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S359
image by the application of PSF correction. The uncertainty in
the effect on the SUVmax presents a challenge for its routine
clinical use in quantitative analysis. Further work will investi-
gate the effect of the PSF correction on tumour detectability.
P041
Influence of SPECT reconstruction algorithm
on diagnostic accuracy of parathyroid scintigraphy:
comparison of iterative reconstruction with filtered
backprojection
G. Kara Gedik, O. Sari; Selcuk University Faculty of Medi-
cine, Department of Nuclear Medicine, Konya, TURKEY.
Aim:The purpose of this study was to evaluate retrospectively
t h e v a l u e o f t e c h n e t i u m - 9 9 m ( T c - 9 9 m )
methoxyisobutylisonitrile (MIBI) single photon emission
computed tomography (SPECT) and to compare the diagnos-
tic accuracy of iterative reconstruction (IR) and filtered
backprojection (FBP) reconstruction algorithms about locali-
zation of parathyroid lesions. Materials and methods:Forty-
four patients with primary hyperparathyroidism (37 women
and 7 men, age range: 26-76 years, mean age: 53.75±12.39
years), in whom histopathological correlation could be per-
formed and who were cured after resection of abnormal para-
thyroid glands were included into the study. Mean serum PTH
and calcium levels were 241.97±210.7 (range: 65-940 pg/ml,
reference value: 12-65 pg/ml,) and 11.30±0,88mg/dl (range:
10-14.4 mg/dl, reference value: 8.4-10.2 mg/dl), respectively.
Dual phase Tc-99m parathyroid scintigraphy, in which planar
views were obtained 20 and 120 minutes after injection of 740
megabecquerel(MBq) Tc-99m MIBI, was performed with a
dual-headed gamma camera (Siemens, Ecam signature) in all
patients. Tomographic images were acquired 120minutes after
the administration of radiopharmaceutical. The SPECT datas
were evaluated using an IR (ordered subsets expectation
maximation) as well as a FBP algorithm. In 23 of 44 patients
SPECT acquisitions were performed in 64x64 matrix, in the
remaining 21 patients, tomographic datas were collected in
128x128 matrix. The imaging results were compared to path-
ological findings and sensitivities of both reconstruction algo-
rithms and planar views were calculated. Results:Using planar
MIBI scans, abnormal parathyroid glands were correctly lo-
calized in 75% of the cases. Sensitivity increased to 77% using
SPECT with FBP and rose to 84% with IR. When the sensi-
tivities were further calculated according to the acquisition
matrix, it is found that in patients in whom 128x128 matrix
was used, the sensitivities were 95% (20/21) and 85% (18/21)
for IR and FBP, respectively. The sensitivities were lower in
patients who were imaged with 64x64 matrix; with IR it was
calculated as 74% (17/23) whereas with FBP, the sensitivity
was 70% (16/23). Conclusion:In conclusion, compared to
planar scintigraphy, Tc-99m MIBI SPECT is a more sensitive
diagnostic modality in the detection of abnormal parathyroid
tissues. Image quality and sensitivity further improves when
larger matrices with IR are used instead of FBP algorithm.
P042
Optimization of image processing for better anatomical
analysis of the striatum for SPECT scans of [99mTc]
TRODAT-1
A. C. Trevisan1, L. A. Santos2, F. A. Pitella2, E. N. Itikawa1,
M. Kato2, V. Tumas2, M. M. C. M. Brito2, L. Wichert-Ana2;
1Universidade de São Paulo, São Carlos, BRAZIL,
2Universidade de São Paulo, Ribeirão Preto, BRAZIL.
AIM: Parkinson’s disease (PD) is characterized by chronic,
progressive and degenerative disorder. Brain SPECT scans
using 99mTc-TRODAT-1 radiotracer evidence the striatal den-
sity of Dopamine Transporters (DAT). This is particularly im-
portant in the evaluation of PD. However, there was a need for
standardized protocols for image reconstruction and process-
ing, looking for a high image quality, and the reliability of
medical reports. Particularly important are the identification
of striatal morphology and the use of appropriated spatial res-
olution, contrast and noise. This study aimed to investigate the
better image processing parameters associated with high mor-
phological identification of striatal body. MATERIALS AND
METHOD: Data were acquired in the BrightView XCT -
PHILIPS using an anthropomorphic striatal phantom RS-
900T, and the reconstruction algorithm was the iterative algo-
rithm OSEM (Ordered Subsets Expectation Maximization).
By choosing the iterations(i) (2,0 to 60,0) and subsets(s) (4,0
- 8,0 -16,0) by one independent specialist with grades 0-5, very
bad to very good. After that the projections were reconstructed
by varying the cutoff (0.1 - 0.3 - 0.5 - 0.7 - 1.0 - 1.5 - 2.0) and
order (0.0 - 1.0 - 2.0 - 4.0 - 6.0 - 8.0 - 10.0) of the Butterworth
filter, totaling 49 images. In a descriptive analysis of 3 special-
ists, there was the application in 0-10 grades, also was divided
to very bad to very good. RESULTS: According to the analy-
sis, using 3i 8s, it ensures higher quality reconstruction, differ-
entiating the putamen and head of the caudate nucleus. It also
found that the greater the number of iterations, worst was the
image, with a higher incidence of noise and low spatial reso-
lution; similarly, the higher the number of subsets, also worst
was the image. Through a linear regression, with the average
grade of 3 experts, we found that the best cutoff independent
variable was 0,5 and the best order independent variable was 0,
0. But the image built with both variables, got better. Then the
proposed range to obtain a quality image was 1.2 to 1.5 cutoff
and varying the order of 0.0 to 10.0. CONCLUSIONS: This
study found that the variables cutoff and order are not so good
when it work independent. The above proposed range of cutoff
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and order assured images with high contrast, high spatial res-
olution and low noise. This processing protocol enable the
accurate differentiation of putamen and the head of the caudate
nucleus, helping specialists to better delineate the striatal body.
P04 - Sunday, October 11, 2015, 4:00 PM - 4:30 PM, Hall 3,
Poster Exhibition
Phys ics & Instrumentat ion & Data Analys i s :
Instrumentation
P043
Continuous-spectrum Emission Tomography (CET)
for quantifying the absorbed dose of in-vivo
bremsstrahlung
S. Vandenberghe1, H. W. A. De jong2, M. Bardies3, D.
Borys4, M. de Jong5, S. Walrand6; 1MEDISIP, Department
of Electronics and Information Systems, Ghent University,
iMinds Medical IT-IBiTech, Gent, BELGIUM, 2University
Medical Center Utrecht, Utrecht, NETHERLANDS, 3Institut
national de la santé et de la recherche médicale, Toulouse,
FRANCE, 4 Silesian University of Technology, Comprehen-
sive Cancer Centre, Gliwice, POLAND, 5Department of nu-
clear medicine, Erasmus Medical center, Rotterdam, NETH-
ERLANDS, 6Department of nuclear medicine, UCL, Brussels,
BELGIUM.
Introduction: Personalized dosimetry based on quantitative
images of radiopharmaceutical distribution in the body can
substantially improve the effectiveness of radionuclide thera-
py. Current nuclear medicine imaging systems are optimized
for diagnostic radionuclides and suboptimal for bremsstrah-
lung X- rays emitted by therapeutic radionuclides.Materials
and methods:We present a novel molecular imaging modality,
called CET (based on elements from CT, SPECT and PET)
and specifically designed for collimating and detecting the
high-energy secondary body generated bremsstrahlung X-ray
photons. To efficiently detect incoming high-energy X-ray
photons, conventional NaI SPECT detectors are replaced with
high-density scintillators from PET. A first step in the design
of the complete system is the evaluation of monolithic high-
resolution detectors for this modality. LYSO, the most com-
monly used PET scintillator, is intrinsically radioactive due to
the presence of Lu-176. This leads to a continuous background
in the energy spectrum, making this scintillator not suitable for
CET. Therefore simulations (using the input of the continuous
Spectrum of Y-90) and measurements of high-density thick
PET BGO crystals are compared to the results of conventional
NaI detectors. CETalso combines these detectors with pinhole
collimators (from small animal SPECT), with small accep-
tance angles and minimal penetration.These are specifically
designed for a wide energy spectrum and with the primary
aim to reduce scatter and collimator penetration. To efficiently
construct these complex collimators with high stopping power,
additive manufacturing (3D printing) of tungsten powder will
be used. Since no scatter windows can be used for X-rays,
quantitative reconstructions will be obtained by modeling the
remaining contamination in Monte Carlo-based image recon-
struction. Finally Monte Carlo or other approaches will pro-
vide the information on the absorbed radiation dose.Results. A
BGO detector of 2 inch has a high stopping power of more
than 70% for all energies up to 1 MeV. The conventional 3/8
inch NaI works well at low energies but has only 17 % stop-
ping power at 1 MeV. The main advantage of BGO comes
from the high amount of direct photo-electric interactions
and resulting smaller amount of Compton interactions arriving
in lower energy window. A disadvantage of BGO is the small-
er amount of scintillation light resulting in reduced energy
resolution at lower energies (>30% at 100 keV and 15 % at 1
Mev).Conclusions. All components for building a CETsystem
with specific use in radionuclide therapy have been identified
and can be combined into a new molecular multimodality
imaging system.
P044
Myocardial innervation and perfusion mismatch using
cardiac dual isotope (123I-MIBG/99mTc-tetrofosmin)
acquisition on two different CZT cameras: a phantom
study
T. Blaire1,2, A. Bailliez1,2, D. Legallois3, D. Agostini3, A.
Manrique1,3; 1EA 4650, Normandy University, Caen,
FRANCE, 2Nuclear Medicine Department, IRIS, Polyclinique
du Bois, Lille, FRANCE, 3Nuclear Medicine Department,
CHU Cote de Nacre, Caen, FRANCE.
Purpose: New Cadmium-zinc-telluride (CZT) cameras have
dramatically increased sensitivity and energy resolution. This
phantom study assessed the impact of dual isotope acquisition
on the assessment of 123I/99mTc mismatch using two CZT
cameras (DNM 530c, GE Healthcare and DSPECT, Spectrum
Dynamics).Materials andmethods:We used the anthropomor-
phic torso phantom (Data Spectrum, Hillsborough, NC) with
the cardiac insert, successively filled with a solution of 99mTc
alone, 123I alone and a mixture of 123I and 99mTc. Two
defects were used: one (13mL) always filled with cold water
(mimicking a matched defect) and one (5,4mL) filled with
99mTc when 99mTc solution was in the cardiac insert (mim-
icking a mismatched defect). A total of 12 datasets on each
CZTcamera was acquired using both energy windows (99mTc
or 123I) with increasing acquisition times (7, 11, 22 and 33
minutes). Segmental uptake (%) for 99mTc and 123I and mis-
match (difference of both segmental isotope uptake) were
assessed using Corridor 4DM (INVIA Michigan) and a 17-
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segment model. Statistical analysis used ANOVA and a linear
model including the effect of camera, acquisition type (single
vs. dual isotope), isotope (123I and 99mTc) and the interaction
between camera type and isotope. Results: There was a slight
but significant difference between the 2 cameras (DSPECT-
DNM) in assessing 123I-99mTc mismatch in segments
encompassing the mismatched defect (segment #5: mean dif-
ference: -3.12%, p<0,05; and segment #11: mean difference: -
2.25%, p<0,05) . There was no difference in other segments.
The linear regression model showed no impact of camera type
and acquisition time on the magnitude of the mismatch. Lin’s
concordance correlation coefficient (CCC) showed an excel-
lent concordance for single and dual isotope acquisition for the
assessment of 123I uptake between DNM and DSPECT
(CCC>0,82 and 0,93 respectively) and between single and
dual isotope within each camera type (CCC>0.98 in DNM
and CCC>0.84 in DSPECT). Conclusion: In this phantom
study, the two CZT cameras (DNM 530c and DSPECT), with
higher energy resolution and sensitivity yielded no significant
difference between single (successive) isotope and simulta-
neous dual isotope acquisition and in the evaluation of myo-
cardial innervation and perfusion mismatch.
P045
Ultrafast Bone SPECT Imaging of the Hands Using a Solid
State CZT SPECT Camera
A. Frenkel, M. Kurash, O. Israel, J. A. Kennedy; Rambam
Medical Center, HAIFA, ISRAEL.
Aim: To assess the feasibility of fast bone SPECT studies of
the hands using a solid state camera (CSS) dedicated for car-
diac imaging. Materials and Methods: A Discovery 570c
SPECT/CT device (GE Healthcare) was used for phantom
simulations and clinical fast SPECT imaging of the hands. Fast
SPECTstudies were performed using a 350 mL hand phantom
filled with 37 MBq Tc99m-pertechnetate and with a 1.5 MBq
5 μL source that simulated a focus of abnormal uptake. Four
patients referred for evaluation of pain in their hands were
imaged at 2 hours after injection of 925 MBq Tc-99m MDP
using a standard camera (Infinia Hawkeye 4, GE Healthcare)
for a 10 min spot planar scan of the hands and performed an
additional fast, 3 minutes SPECT study of each hand on the
CSS. Image quality and diagnostic accuracy of the SPECT
studies were assessed and referenced to the standard acquisi-
tions. Results: List mode reconstructions using default regu-
larization in the phantom study on CSS provided images with
counting statistics consistent with total activity of 46, 9, and
3 MBq in one hand. The phantom-simulated uptake was clear-
ly visible in low-count images without a negative effect on
resolution or contrast. In patient studies, fast acquisition CSS
provided good quality tomographic images. Three of the eight
hands evaluated in the four patients had a normal appearance
on the both the planar and SPECT studies. Six sites of in-
creased focal uptake were found in the additional five hands.
Findings on planar and SPECT studies concurred in three foci
in the MCPJs and three in the PIPJs. Three foci of abnormal
uptake in the MCPJs and one focal uptake in the PIPJ were
detected only on SPECT. Conclusions: Phantom simulation
studies and clinical studies in 4 patients using the solid state
CZT device suggest that bone SPECT of a small anatomical
region such as the hand can be successfully achieved provid-
ing high quality images and a higher lesion detectability rate
associated with a 40 % reduction in acquisition time as com-
pared to standard planar scintigraphy.
P046
18F-Choline intravenously infusion with an automatic
combined dispenser and injector system.
A. MORETTI1, P. CAROLI2, R. GALASSI1, V.
D’ERRICO3, C. DONATI4, L. FANTINI2, V. MAUTONE2,
G. GUALTIERI2, G. BATTARA2, G. PAGANELLI2, F.
MATTEUCCI2; 1NUCLEAR MEDICINE UNIT AUSL RO-
MAGNA, FORLI’, ITALY, 2NUCLEAR MEDICINE IRST,
MELDOLA, ITALY, 3MEDICAL PHYSICS UNIT tIRST,
MELDOLA, ITALY, 4PHARMACY UNIT IRST,
MELDOLA, ITALY.
In nuclear medicine, the doses of radiopharmaceuticals are
extracted from multidose vials, using multipurpose fraction-
ators contained within a leaded cell and are then administered
to the patient with a manual injection. All these activities cause
exposure to radiations to the involved personnel: in order to
reduce this exposure, while ensuring the sterility of the prepa-
rations and the precision of the administered dose, we evalu-
ated the use of an integrated system for fractionation / injection
(Intego® Bayer, Inc., Warrendale, PA, USA).METHODS:We
evaluated the fractionating and injecting process of 18F-
choline by comparing the automatic mode performed with
the Intego® apparel with the usual manual mode of adminis-
tration of the dose, simulating the above steps for 84 times in a
period of two weeks . This simulation involved a total of four
operators : three radiology technicians and one nurse; in order
to obtain the most accurate and precise meausure of the expo-
sure the personal was monitored by using TDL dosimeters
placed on the fingertips both in the Intego® and in the manual
mode.Sterility was evaluated by using media fill tests. In order
to verify the correspondence between the required dose and
fractionated dose, both in the automatic mode than in the man-
ual one, it has been used the same counter properly
calibrated.RESULTS:The verification with the media fill test
has confirmed the sterility both in the procedure of fraction-
ation / traditional injection than in the one that has used
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INTEGO.The accuracy of the fractional dose and subsequent-
ly measured in the counter showed a difference between the
traditional method and the one with INTEGO lower than the
value determined by EANM guidelines (<3%).Compared to
traditional methods, the administration with INTEGO showed
a much lower (1 MBq than 7 MBq) residual activity in the
patient administration set (PAS).From a dosimetric point of
view, the comparison between the data of exposure of the
involved personnel showed a 75 % reduction (2.36 +/-
0.8 mSv at 0, 6 +/- 0.3 mSv / year).CONCLUSION:Intego®
is a useful tool in the operations of fractionation and injection
of 18F-choline ensuring accurate and sterile doses and
allowing in the same time a significant reduction in the expo-
sure of the personnel
P047
Development of Radionebulizer Equipment for Diagnostic
in Nuclear Medicine
A. F. Viana1, P. Nabinger1, R. Madke1, P. Madke1, P. R.
Fereira2, R. Anele, Filho3; 1Grupo RPH, Porto Alegre, BRA-
ZIL, 2Bhiosupply, Porto Alegre, BRAZIL, 3CETA/SENAI,
Porto Alegre, BRAZIL.
Ventilation/perfusion (V/Q) SPECT (Single-photon
emission computed tomography) of lung are indicated
for the diagnostic of pulmonary embolism (PE), alveoli-
tis, chronic obstructive pulmonary disease (COPD),
among others. The combination of the ventilation and
perfusion exams not only improves the diagnostic accu-
racy of the method but also facilitates the application of
advanced image-processing techniques. In Brazil, many
Nuclear Medicine Services are no longer performing the
ventilation exam due to the cost of the devices neces-
sary for the inhalation of radioaerosol. The objective of
this project was to develop an affordable and easy to
use radioaerossol nebulizer device for diagnostic use in
nuclear medicine. The radioaerosol production technolo-
gy is based on the Venturi principle, in which the appa-
ratus is coupled to a source of compressed air producing
a suitable aerosol particle (<1.5 microns) to produce
pulmonary diagnostic image. The device consists of a
ready-to-use blister composed of 2 chambers with isolat-
ing valves. This design allows the simple injection of
the radiopharmaceutical, its nebulization and the decan-
tation of the particles bigger than the defined size. The
blister has two breathing hoses, one for the inhalation
and other for exhalation. The system is also composed
of a lead shield that accommodates the blisters perfectly,
and protects the patient and operator from energies of
140 KeV, and a mechanism to hinder the reutilization of
the blister, avoiding crossed contamination between
patients. Our team was able to develop an inexpensive
blister and lead shield that is reimbursed by the Brazil-
ian Heath Care System (SUS). This project was support-
ed by a Brazilian Federal grant from SENAI/SESI and
has the patent deposit number BR 10 2014 029318 3.
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Monte Carlo Simulations of Beta Particle Measurement
Using Cerenkov Luminescence Imaging or Beta Detection
L. Altabella, C. R. Gigliotti, A. E. Spinelli; San Raffaele Sci-
entific Institute, Milano, ITALY.
Aim: Recently Cerenkov luminescence imaging (CLI) has
been introduced as a novel tool to image in vivo the bio-
distribution of beta plus and beta minus emitters for both
human and animal models. CLI is normally performed
using a CCD detector in combination with a set of lens
and filters. In this work we investigated through Monte
Carlo simulations the feasibility of beta imaging of small
animals with CLI or direct and indirect beta detection
using beta emitters commonly used in Nuclear Medicine.
CLI is based on the detection of Cerenkov photons gener-
ated in the medium when beta particles travel with a ve-
locity greater then the speed of light in the medium. Direct
and indirect beta detection are based on direct interaction
with the detector or a conversion into light by means of a
scintillator.Materials and methods: Monte Carlo simulations
were implemented using Gamos plug-in for Geant4. We
considered a slab of mouse muscle and a radioactive point
sources of 32P and 90Y placed at different depth from
1 mm to 3 mm. Cerenkov photons and beta particles are
collected at the exiting surface in detector direction. For
indirect detection a 0.2 millimeter CsI(Tl) scintillator has
been positioned at the top detector.Results: Direct beta
detection show a better resolution (FWHM 2.32 mm for
32P and 2.44 mm for 90Y at 1 mm depth) with respect to
CLI (FWHM 3.69 mm for 32P and 3.98 mm for 90Y at
1 mm depth) in spite of less counts. For superficial
sources and direct beta detection no significant differences
are found in resolution between 32P and Y90, while 32P
shows a better resolution for CLI with respect to 90Y at
deeper source (about 1 mm difference for 3 mm source
depth). For indirect beta detection, we obtain a FWHM of
2.71 mm with 1 mm source depth.Conclusion: Direct or
indirect CCD beta detection represents a good set up in
terms of spatial resolution for beta radionuclide imaging
however only a limited field of view (FOV) can be usu-
ally covered with this imaging setting. On the other hand
CLI allow a much larger FOV (several cm) using conven-
tional small animals optical imaging systems and is thus a
more flexible approach.
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Attenuation Correction in Planar Scintigraphy Using
Transmission Measurement with Flood Source
M. Samal, V. Sirova, D. Skibova, J. Trnka, V. Ptacnik, J.
Kubinyi; Charles University Prague, Prague, CZECH
REPUBLIC.
In planar scintigraphy, Tc-99m flood source is used for trans-
mission measurement and subsequent attenuation correction
(AC) in Tc-99m emission data. Alternative Co-57 flood source
is faster, safer and easier to use but emits lower energy radia-
tion. The aim of the phantom study was to test Co-57 flood
source for AC in Tc-99m emission data. Methods: Two 100 ml
plastic vials were attached to the rods of Jaszczak phantom and
filled with 2 different activities of Tc-99m. Volume of the
phantom was filled with inactive and active water back-
grounds (1:8 and 1:4 with respect to a weaker vial). Emission
measurements were made simultaneously by 2 camera detec-
tors in upper and lower positions. Transmission measurements
(with inactive phantom) were performed using Tc-99m and
Co-57 flood sources placed below the phantom on elevated
edges of lower detector. Acquisition was performed in
photopeak and scatter windows. Two types of transmission
images were recorded with each flood source: (a) with and
without phantom by upper detector only, (b) with phantom
by lower and upper detectors simultaneously. Recorded data
were checked for registration and corrected for decay, table
attenuation and detector sensitivity. Geometric mean (GM)
of emission data was corrected for attenuation and back-
ground. Scatter was compensated using dual-energy window
(DEW) or broad-beam (BB) attenuation coefficient. Recovery
of total activity in both vials and relative activity in the vial
with higher activity were calculated as percentage of simulated
activity and percentage of total measured activity in both vials.
Results: Phantom thickness calculated pixel-wise reflected
well mechanical dimensions of the phantom. Tc-99m and
Co-57 thickness maps were applied to correct GM data. With-
out AC, only 30% of simulated activity was recovered. Recov-
ery increased to 91-92% using BB attenuation coefficient 0.12
and to 100-104% using DEWand attenuation coefficient 0.15.
Best recovery (100-101%) was obtained using BB attenuation
coefficient 0.13. No significant differences were found be-
tween Tc-99m and Co-57 maps and the 2 methods of trans-
mission measurement. Regardless of AC, relative activity of
stronger source (65%) was recovered accurately with mean
absolute error of 0.97%. Estimated dose to the patient from
1-minute exposure to Co-57 flood source of medium activity
was below 5 microSv. Conclusion: Pixel-wise maps of object
thickness obtained by transmission measurements using both
Tc-99m and Co-57 flood sources are sufficiently accurate to
correct for attenuation in geometric-mean Tc-99m emission
data. Using the simple method, planar scintigraphy can
approach quantitative accuracy comparable with more sophis-
ticated techniques.
P050
The Influence of Cardiac ROIs Contour Definition
at Heart-to-Mediastinum Ratio in 123I-MIBG
Scintigraphy
A. Sá Pinto, T. Vieira, S. Chaves, V. Alves, T. Faria, A.
Oliveira, A. Fernandes, M. Pérez, J. Pereira; Centro Hospitalar
de São João, Porto, PORTUGAL.
Aim: Metadiodobenzylguanidine labelled with 123I (123I-
MIBG) is used for assessing the myocardial adrenergic sys-
tem. Despite its highly independent prognostic value in heart
failure, it is important to improve standardized acquisition
methods and assessment criteria. We aim to study the correla-
tions of the heart-to-mediastinum ratios (H/M) obtained
through the application of different regions of interest (ROIs)
at the heart, and with different acquisition methods.Methods
and Material: Six patients sent to our Nuclear Medicine De-
partment for oncological evaluation were randomly selected.
Images’ acquisition started 3 hours post-injection of 123I-
MIBG (185-370MBq). Twosequential thoracic static (TS) im-
ages, of 5 minutes (5M) each, were acquired (LEHR collima-
tors; 256x256 matrix; 20% energy window set on 159 keV);
immediately after, this step was repeated using ME collima-
tors. Then, a whole body (WB) scanning was acquired (LEHR
collimators; 256x1024 matrix; scan speed of 10 cm/min).
Scatter Correction (SC) was applied defining a secondwindow
(130 keV +/- 10%), during the acquisition of TS and WB
imaging, when using LEHR collimators. Ten minute images
(10M) were obtained summing the counts in the sequential 5
minute images. Three different types of cardiac ROIs were
drawn by one experienced observer (irregular manual
[MAN], elliptical [ELI, 900 pixels area] and circular [CIR,
21 diameter]) while one rectangular ROI (120 pixels area)
was placed at the mediastinum (M). Eight images were used
to calculate H/M ratio for each patient (MAN/M, ELI/M and
CIR/M): 5M/LEHR, 5M/LEHR/SC, 10M/LEHR, 10M/
LEHR/SC, 5M/ME, 10M/ME, WB, WB/SC. MAN/M, ELI/
M and CIR/M ratios were defined as the ratio of average
counts at the heart and mediastinum. The correlations of
MAN/M with ELI/M (C1), MAN/M with CIR/M (C2) and
ELI/M with CIR/M (C3) were analyzed using IBM SPSS ver-
sion 22.0.Results: Concerning C1, we obtained rs = 1 (p <
0.001) for the 8 images. Regarding C2, rs = 0.943 (p <
0.005) for images 5M/LEHR, 5M/LEHR/SC, 10M/LEHR
and WB; for images 10M/LEHR/SC, 5M/ME, 10M/ME and
WB/SC the rs = 1 (p < 0.001). C3 had a rs = 0.943 (p < 0.005)
for images 5M/LEHR, 5M/LEHR/SC, 10M/LEHR and WB;
for 10M/LEHR/SC, 5M/ME, 10M/ME and WB/SC the rs = 1
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(p < 0.001).Conclusion: H/M ratio values obtained with dif-
ferent methods of cardiac contour in 123I-MIBG scintigraphy
seem to have excellent correlation across several methods of
image acquisition. Collimation and electronic SC, as well as
the duration of acquisition, may influence ROIs’ definition.
P051
Performance Evaluation of a Gamma-Probe for High
Energy source (131-Iodine) for Oncologic Purposes
E. N. I. Itikawa1,2, L. A. S. Santos1,3, D. K. S. Sonvenso1,3, M.
K. Kato1,3, F. A. P. Pitella1,3, C. E. P. B. Baltazar1,4, A. C. T.
Trevisan1,2, E. R. M. Moraes1,5, L. W. A. Wichert-Ana1,2,3;
1Ribeirão Preto School of Medicine, Ribeirão Preto, BRAZIL,
2Post-Graduation Program Interunits Bioengineering
EESC/FMRP/IQSC-USP, São Carlos, BRAZIL, 3Postgradua-
tion Program in Internal Medicine, Ribeirão Preto, BRAZIL,
4Faculty of Philosophy, Sciences and Literature of Ribeirão
Preto, Ribeirão Preto, BRAZIL, 5Faculty of Philosophy, Sci-
ences and Literature of Ribeirão Preto, Ribeirão Preto,
Ribeirão Preto, BRAZIL.
AIM: To evaluate spatial, angular and energy resolution;
shielding and sensitivity of a high energy gamma-probe ac-
cording to international standards for non-imaging intraopera-
tive probes. The objective was to assure its usefulness in sen-
tinel lymph node localization and reminiscent thyroid cancer.
MATERIAL AND METHODS: We tested the wide-range
energy isotope (0.11-1 MeV) CsI-Tl probe. Low activity
sources of 99m-Tc and 131-I were used in the performance
tests. Spatial, angular and energy resolution were calculated in
terms of FWHM. Shielding was calculated based on the intrin-
sic sensitivity in the probe axis. The collimator device was
used to evaluate shielding; angular and spatial resolution. All
the tests of this study were designed as suggested by interna-
tional standards for non-imaging intraoperative probes and
studies in the literature.
RESULTS: The probe was capable to solve two closely
sources of 131-I and 99m-Tc only by using the collimator
device in the spatial resolution test. Values of 18.3 and
10.91-FWHM(mm) were achieved, respectively. Angular res-
olution showed similar performance for 131-I and 99m-Tc,
with better results by using the collimation. We found values
of 51.4 and 29.2-FWHM(°), respectively. Energy resolution
showed a value of 13.2-FWHM(%) for 131-I. Shielding test
showed that the probe tip was not capable to stop high-energy
photons of 131-I as desirable, even increasing lateral thickness
with the collimator device. Better results were obtained with
99m-Tc. The sensitivity test showed a value of 682 and 276-
c p s /MBq fo r 1 31 - I a nd 99mTc , r e s p e c t i v e l y.
CONCLUSIONS: Consistent results in the tests were
achieved only by using the collimator device. Meanwhile,
the use of the intraoperative probe without the collimator
should not be discarded. We must consider that the tested
high-energy gamma-probe needs a robust design such as a
thicker lateral shielding. Furthermore, it could not be achieved
without increasing the size of the crystal detector because
thicker and high-density crystals tend to effectively stop
high-energy photons. On the other hand, it affects geometric
parameters of detection, i.e. spatial and angular resolution.
Thus, the collimator was prior to improve spatial and angular
resolution as it reduces the field of view of the crystal detector.
Our study design is according to international standards for
evaluation of non-imaging gamma probes and showed feasible
results that corroborates to accurate localization in oncological
intervention, i.e. melanoma, thyroid and breast cancer.
P052
Evaluation of Physical Detection Parameters of a Gamma
Probe for Sentinel LymphNode Localization inMelanoma
and Breast Cancer.
E. N. I. Itikawa1,2, L. A. S. Santos1,3, D. K. S. Sonvenso1,3, M.
K. Kato1,3, F. A. P. Pitella1,3, C. E. P. B. Baltazar1,4, A. C. T.
Trevisan1,2, E. R. M. Moraes1,5, L. W. A. Wichert-Ana1,2,3;
1Ribeirão Preto School of Medicine, Ribeirão Preto, BRAZIL,
2Post-Graduation Program Interunits Bioengineering
EESC/FMRP/IQSC-USP, São Carlos, BRAZIL, 3Postgradua-
tion Program in Internal Medicine, Ribeirão Preto, BRAZIL,
4Faculty of Philosophy, Sciences and Literature of Ribeirão
Preto, Ribeirão Preto, BRAZIL, 5Faculty of Philosophy, Sci-
ences and Literature of Ribeirão Preto, Ribeirão Preto,
Ribeirão Preto, BRAZIL.
AIM: To evaluate angular, spatial and energy resolution, side
and back shielding and the final sensitivity according to inter-
national standards of quality control for non-imaging probes.
The objective in our work was to assure its usefulness in sen-
tinel lymph node localization in patients with melanoma and
breast cancer patients.
MATERIAL AND METHODS: We used a CZT probe de-
tector EUROPROBE II ® (Eurorad, Italy) for low energy iso-
tope (20 ~ 170 keV). The tests were performed with low ac-
tivity 99m-Tc radiation sources (12 MBq upper) and also,
acrylic devices for point sources and scatter medium simula-
tors were developed to run the tests. Count acquisition was
performed through time integration mode. Shielding, angular,
spatial and energy resolution were also evaluated by using a
collimator, a device that increases the lateral shielding and
decreases the sensitive area of the detector tip, in the shielding,
angular, spatial and energy resolution tests. RESULTS: The
probe showed 31.4° and 31.6°-FWHM for 3 and 30
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centimeters-distance, respectively, in the angular resolution
test. Spatial resolution showed the capability of the probe to
solve two closely sources of radiation through a scatter
medium of 10 mm as well as the resolution test, which
demonstrated a 20.5-FWHM(%) and proved to correctly
discriminate the photopeak of 99m-Tc (140-keV). The
gamma probe also showed good intrinsic sensitivity of
510 counts per second per unit of activity (cps/MBq),
value within the suggested by its guideline in similar
conditions of detection. Finally, the side and back
shielding test proved that the probe tip is efficient to
stop photons that come from residual or background
radiation. We observed similar performance in the tests
when using the collimator. As expected, the reduction of
the sensitive area by the device improved the visualiza-
tion of both point sources in the spatial resolution test,
and reduced the FWHM values in the angular resolution
test. CONCLUSION: The tested gamma probe showed
results which are according to the international guideline
for non-imaging intraoperative probes and results found
in the literature. Gama probe has an important rule to
access sentinel lymph nodes under difficult conditions of
localization. Indeed, this tool is expected to have detec-
tion parameters consistent to this purpose and, through
the results of our study, which is according to the inter-
national standard of quality criteria for non-imaging
probes, we can attest its feasibility for applications in
oncology.
P53
The General Idea and the Functionality Behind Real-time
Handheld Emission Spot Allocator (rthESA)
for Simultaneous Fusion Imaging with Ultrasound
C. Kühnel, T. Winkens, M. Freesmeyer; Jena University Hos-
pital, Jena, GERMANY.
Objectives: First, to report on initial experiences and
technical parameters of a newly developed real-time
handheld emission spot allocator (rthESA), and second,
to report on the simultaneous acquisition of rthESA and
US data as rthESA/US fusion images. Methods: The
rthESA consisted of five semiconductor-detectors made
of Cd-Zn-Te arranged in alternate position in two rows.
This design allowed the examination of focal activities
in the same plane as US. The signals were interpreted
by an ad hoc software (algorithm) and the real-time
allocation of spot radiation sources within air- and water
phantoms was investigated for 99mTc, 131I, and 18F. A
compact intraoperative US probe (39mm transducer) was
fixed in plane with the rthESA and connected to a stan-
dard US equipment. Experiments with a liver phantom
were performed to verify the integration of 99mTc-
rthESA data and US images. Results: The allocation
proved to be successful for all radionuclides. The system
showed a noticeable performance latency, most pro-
nounced for positions far from the detector (1cm dis-
tance: 0.7 ± 0.5 sec; 4cm distance: 6.1 ± 3.2 sec). With-
in the liver phantom, the rthESA enabled the correct
allocation of a spot radiation source within a live US
image. Conclusions: The rthESA allowed an exact local-
ization of spot radiation sources in single plane, with
additional consideration of the distance from the detec-
tor, leading to real-time allocation and simultaneous
overlay with US images. In spite of clear technical lim-
itations in need of further development, this proof-of-
concept study shows that this hybrid detector has the
potential to provide integrated simultaneous nuclear
medicine and US images.
P54
Hybrid Integration of Real-Time Ultrasound
and Freehand-SPECT: First Experiences and additional
informations about Radiation Exposure of the Investigator
C. Kühnel, T. Winkens, T. Opfermann, M. Freesmeyer; Jena
University Hospital, Jena, GERMANY.
Objectives: Hybrid imaging has been a successful way to
overcome the limitations of functional imaging. However,
no integrated concept for combining ultrasound with nucle-
ar medicine imaging has been presented up to date. We
investigated the feasibility of a quasi-integrated free-hand
single photon emission tomography/ultrasound (99mTcO4-
fhSPECT/US) fusion imaging concept in patients with thy-
roid diseases. Additionally, the radiation exposure of the
investigators’ hand was assessed during 99mTcO4-
fhSPECT/US of the thyroid. Methods: Thirty four patients
were examined. After application of 75 MBq 99mTc
pertechnetate intravenously, fhSPECT was performed using
declipseSPECT® (SurgicEye, Munich, Germany) and nav-
igated ultrasound using LOGIQ® E9 (GE Healthcare, Mil-
waukee, WI, USA). Three-dimensional SPECT data were
reconstructed and transferred to the ultrasound system. The
combination of two independent positioning systems en-
abled real-time fusion of metabolic and morphologic infor-
mation during ultrasound examination. Conventional do-
simetry was performed by rings with thermoluminescence
detectors (TLD) and compared with the ambient dose rate,
which was measured by dose rate meters (DRM), and the
measurement time. Results: All examinations were techni-
cally successful. Only minor limitations in fusion offset
occurred. The fhSPECT system’s poor spatial resolution
was the reason for further limitations. The mean
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exposure per investigation was 7.53 μSv by ring dosim-
e t r y a n d 9 . 0 2 μ S v b y DRM . C o n c l u s i o n :
FreehandSPECT/ultrasound fusion concept proved feasi-
ble and applicable; however, technical improvements are
necessary. The hand exposure in clinical routine is not
expected to add a relevant risk.
P55
An integrated framework of recovering triple coincidence
for enhancing PET sensitivity
H. Lin, Z. Wei, C. Chiang, K. Chuang; National Tsing Hua
university, Hsin Chu, TAIWAN.
Aims: Triple events caused by simultaneously detection
of three photons are usually discarded as the annihila-
tion information being mixed with another detection in-
duced from one of the annihilation photons scattering
(inter-detector scattering triple, IDS) or from an annihi-
lation photon from a separate decay (random triple,
RnT). In addition, for non-pure positron emitter, a par-
ticular positron-gamma (β+γ) triple can be produced
due to the presence of the cascade gamma ray. The
majority of the triple coincidence contains the true pho-
ton pair that can be possibly recovered. To this end, we
proposed an integrated framework of recovering triple
coincidence events to enhance the sensitivity of PET
i m a g i n g f o r p u r e a n d n o n - p u r e p o s i t r o n
emitters.Materials and Methods: Multiple energy window
settings were first used to classify the triple event into
IDS, RnT and β+γ events. Then, different recovering
strategies for IDS, RnT, and β+γ triple using combined
likelihoods based on energy, temporal and double coin-
cidence information were developed to identify the true
LOR. A Biograph mCT PET scanner was modeled with
a house-made GATE/MPHG Monte Carlo code. We
evaluated the performance of the proposed method on
a NCAT phantom at various activity levels of F-18,
I-124, and Br-76.Results: Preliminary results using the
simulated data show that the accuracy of recovering tri-
ple coincidence can achieve around 87% for IDS, 90%
for RnT, and 82% for β+γ at 10 mCi. We found that
about 15% of the triple coincidence for F-18 can be
recovered using the proposed method, while increasing
this ratio substantially for non-pure emitters (28% for
I-124 and 43 % for Br-76).Conclusion: We conclude
that the proposed integrated framework can improve
the counting statistics of clinical PET imaging for pure
and non-pure positron emitters, especially in high activ-
ity PET imaging.
P56
Monte Carlo Modelling and Experimental Verification
of a GE Optima SPECT System: Towards
Characterisation of Collimator Response
A. Grimwood1, T. Kostou2, P. Papadimitroulas2, G. Loudos2,
L. Livieratos3, J. Scuffham1; 1Royal Surrey County Hospital,
Guildford, UNITED KINGDOM, 2Technological Educational
Institute of Athens, Athens, GREECE, 3King’s College Lon-
don, London, UNITED KINGDOM.
Aim: Monte Carlo simulations are an effective tool for
characterising detector performance [1].We employ the GATE
application to model the GE Optima SPECT system. Our goal
is to characterise detected photons by their interactions (direct,
scattered and septal penetration) through simulation. This in-
formation can be used to optimise reconstruction of real image
data [2]. To be effective, there must be good agreement be-
tween simulated and experimental results. This project is a
verification between the clinical system and simulated model.
Materials and methods: The Royal Surrey County Hospital
operates a GE Optima NM/CT 640 for I-131 sentinel lymph
node imaging. High energy scatter and septal penetration arte-
facts are prevalent and can obscure features in these images.
Using manufacturer specifications, the Optima system was
modelled in GATE 7.0, a Monte Carlo simulation application
built upon GEANT4, using a standalone PC. Simulated spec-
tra were acquired from point sources for both Tc-99m and
I-131 to characterise system performance in three configura-
tions (intrinsic, extrinsic and in-phantom). The simulated spec-
tra were then compared with experimental data to verify the
model. Finally, spectra for direct, scatter and septal penetration
detections were acquired from the simulation results and used
to characterise their relative contributions to the overall spec-
trum. This in turn enabled us to model the collimator-detector
response function.
Results: Good agreement has been achieved between the sim-
ulated and experimental spectra for both Tc-99m and I-131
sources. The separate contributions of direct, scatter and septal
penetration detection events have been identified. It is demon-
strated that these adequately describe features including: the
characteristic lead X-ray peak, scatter peak and photopeaks.
From the spectral data, collimator-detector response function
was described for a simple point source planar image.
Conclusion: An effective Monte Carlo model of a clinical
SPECT system has been constructed and used to characterise
imaging performance using modest computing resources. Ex-
perimental verification has established the validity of the model.
This sets the foundation for using the simulation as a tool in
future work to optimise image acquisition and reconstruction
parameters, such as energy windowing and resolution recovery.
References: [1] S. Jan, et al, GATE: a simulation toolkit for
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PET and SPECT, Phys. Med. Biol., 49 (19), 2004, p4543 [2]
N.G. Sakellios, et al, Monte-Carlo simulation for scatter correc-
tion compensation studies in SPECT imaging using GATE soft-
ware package, Nuclear Instruments and Methods in Physics
Research Section A: Accelerators, Spectrometers, Detectors
and Associated Equipment, 569 (2), 2006, pp404-408
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Preclinical validation of automated DXA- and CT-based
body composition measurements
J. Devriese1, L. Beels2, A. Maes2, C. Van de Wiele2, O.
Gheysens2, H. Pottel1; 1KU Leuven campus Kulak, Kortrijk,
BELGIUM, 2Department of Nuclear Medicine, AZ
Groeninge, Kortrijk, BELGIUM.
Aim: Semi-quantitative evaluation of tumor metabolic activity
is possible through calculation of the standardized uptake val-
ue (SUV), defined as the ratio of measured radioactivity con-
centration to the injected dose per unit of volume of distribu-
tion. SUV is traditionally normalized for body weight. Lean
body mass (LBM) has also been proposed as volume of dis-
tribution, since e.g. 18F-FDG distribution in fatty tissues is
limited. LBM can be estimated by predictive equations, or
measured by e.g. dual-energy X-ray absorptiometry (DXA)
or computed tomography (CT). Accurate LBMmeasurements
would lead to accurate and reproducible LBM-normalized
SUVs. The purpose of this study is to determine and validate
a set of Hounsfield unit (HU) ranges to segment CT images
into tissue types and to test the validity of DXA tissue seg-
mentation on pure, unmixed porcine tissues. Materials and
methods: This preclinical prospective study was approved by
the local ethical committee. Different quantities of porcine
bone tissue (BT), lean tissue (LT) and adipose tissue (AT) were
scanned using DXA and CT. Tissue type segmentation in two
equal type DXA devices was performed via the standard clin-
ical protocol and in CT through two different sets of Houns-
field unit (HU) ranges (Baracos et al., 2010, Clarys et al.,
2010). Percent coefficients of variation (%CV) were used to
assess precision while % differences of observed masses were
tested against zero using the Wilcoxon signed-rank test. Re-
sults: Total mass is significantly underestimated by both DXA
devices from true mass by 6.8% and 8.1% (p = 0.016). Total
mass estimated by CTusing both sets of HU ranges differ from
true mass by 1.7% and 2.0% (p = 0.69). Both DXA devices
systematically underestimate tissue type masses (BT, LT, and
AT). BT mass differs from true BTmass by 78.2% and 75.8%,
and for other tissue types masses are underestimated by 10.4%
and 8.1% (LT) and 8.3% and 11.3% (AT). CT does not sys-
tematically over or underestimate tissue type mass. There are
smaller differences from true mass, ranging from -8.8% to
10.4%. Conclusion: Automated tissue segmentation using
CT images and a solid set of HU ranges is a valuable method,
since these measurements were reproducible and accurate.
This technique offers several possibilities in future research
and clinical settings, and can become a valuable tool in quan-
titative nuclear medicine.
P58
Evaluation of image quality on PET/CTwith Flow motion
technology –Does it keep quantitative performance
and uniformity ? -
K. Murakami, T. Nakahara, Y. Ogata, Y. Iwabuchi, M.
Katagiri, Y. Matsusaka; Keio University, Tokyo, JAPAN.
Øbject: To compare image quality obtained by continuous
table motion (Flow motion technology; FMT) to conventional
method (Step and shoot; SS).This time we focused to compare
quantitative performance and uniformity by analyzing SUVof
liver.Materials and Methods: Biograph mCT Flow
Motion(Siemens) enables us to obtain image both by using
FMT and SS. After injection of FDG with 3.5MBq/kg, we
acquired PET image 2 hours later using FMTand SS. To avoid
influence of time difference, patients ware divided two groups
at random. One group was obtained image using SS first fol-
lowing FMT, and another group was FMT first following SS.
All patients had no abnormality in the liver. ROI was settled in
right lobe of the liver with 2cm in diameter. Total number of
patients were 30 cases. SUVmax and SUVstd were measured
and analyzed.Results: By using SS, SUVmax=2.77±0.46,
SUVstd=0.248±0.058,by using FMT, SUVmax=2.61±0.45,
SUVstd=0.208±0.062. Consequently, SUVmax of FMT is
lower compared to SS about 5.7%, and SUVstd also lower
in FMT.Conclusion: SUVmax of FMT is a little bit lower
compared to that of SS. One of the reason may improvement
of uniformity in FMT to reduce SUVstd.
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18F-Fluorodeoxyglucose (18F-FDG) PET pulmonary
imaging: comparative methodology in COPD patients
A. M. Fletcher1, G. Choudhury1, T. Clark1, M. Connell1, S.
Fergusson1, R. Rabinovich1, N. Weir1, B. Whitcher2, I. Kilty2,
B. Vennart2, E. J. R. van Beek1, W. MacNee1; 1University of
Edinburgh, Edinburgh, UNITED KINGDOM, 2Pfizer World-
wide Research and Development, Cambridge, MA, UNITED
STATES.
Aim: To establish the optimum imaging and analysis protocol
for FDG PET/CT imaging of lung inflammation in COPD
patients in combination with quantitative CT analysis of em-
physema. If successful the methodology could potentially be
used to assess inflammation in the lungs to investigate the
modulation of the FDG PET/CT signal as a biomarker of lung
inflammation in drug development. Materials and Methods:
Single-centre, exploratory, open-label study, of cross-
sectional design to assess quantitative FDG PET-CT imaging
in stable COPD patients. 20 patients with moderate-to-severe
COPD underwent dynamic FDG PET imaging and high reso-
lution CT (HRCT), combined with blood sampling to deter-
mine the localized plasma activity time curve twice 4 weeks
apart. Images were analysed in the following manner: lung
regions (lungs, thirds, lobes) were segmented on full inspira-
tion HRCTand whole lung relaxed expiration attenuation cor-
rection (AC) CT using Apollo (VIDA Diagnostics, Coralville,
USA). Twomethods for removing emphysema were evaluated
- eliminating areas below -950HU on inspiration CT (standard
for RA950) and removing the same relative area on relaxed
expiration CT. Lung segmentation VOIs were transferred from
full inspiration CT to PET by non-rigid registration of the full
inspiration CT to the attenuation correction CT using
ANTs(PICSL,UPenn). Arterial input functions (AIFs) were
derived from either blood sampling or images. Finally the
regional pulmonary FDG uptake was determined by SUV
for 50-60 minutes. Patlak analysis of FDG time-activity curves
from the lung VOIs (PMOD) generated estimates of slope
(influx constant Ki) and intercept (initial volume of distribu-
tion). Results: Patlak intercept and SUV are correlated with
lung density, and removing emphysema (particularly large
contiguous regions) results in an increase in patlak intercept
and SUV. There are issues with venous blood sampling, and
image-derived AIFs when movement occurs. Conclusion: An
optimum analysis protocol has now been determined.Methods
of correcting for the density effect in quantitative PET lung
studies require further investigation.
P060
Correlation of texture parameters with conventionally
used semi quantitative parameter: standard uptake values,
metabolic tumor volume and total lesion glycolysus
in 18F-FDG PET/CT examination for breast cancer
N. Rana1, K. Agrawal1, D. Dhawan2, A. Bhati2, B. Mittal1;
1Post-Grad. Inst. of Med. Education & Research, PGIMER,
CHANDIGARH, INDIA, 2Panjab University, CHANDI-
GARH, INDIA.
Background: Texture analysis (TA) is a set of computation
methods that extract information from image on the basis of
inter-relationships of pixels giving better insight of tumor
heterogenity. Since metabolic heterogenity is a recognized
characteristic of malignant tumor, TA is emerging as an im-
portant tool for evaluation of tumor uptake in PET studies.
However, it needs to be established which indices could be
of use and how they relate to conventionally used parameters.
In our study we have classified texture parameters on the basis
of their correlation with Standardized Uptake Values (SUVs),
Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis
(TLG) in cases of breast tumor. Methods: Thirty-three patients
with breast cancer who underwent whole-body PET/CTexam-
ination were included. TA in these patients was done using
CGITA-Chang-Gung Image Texture Analysis toolbox, a soft-
ware package based on MATLAB for texture analysis of mo-
lecular images having all built in functions for deriving differ-
ent matrices like NGTDMs, GLRLMs, GLSZMs. PET/CT
images in DICOM format of each patient were loaded on this
software and sixty-nine texture parameters other than SUVs,
MTVand TLG were derived by placing semi-automated ROI
around active primary tumor. Conventional quantitative pa-
rameters like SUVmax, SUVmean2.5, MTV2.5, TLG2.5 (thresh-
old of SUVmean = 2.5g/ml) and SUVmean40, MTV40, TLG40
(threshold of 40% of SUVmax) were also calculated for prima-
ry tumor using another semi-automated software for VOI
placement to validate the SUVs value obtained using CGITA
software. Linear correlation of each texture index with
SUVmax, SUVmean2.5, SUVmean40, MTV2.5, MTV40 and
TLG2.5, TLG40 was computed individually to study correla-
tion between texture features and conventionally used quanti-
tative parameters. Results: Texture parameters were classified
as highly correlated (correlation coefficient | r | ≥ 0.90), mod-
erately correlated (0.7≥| r |≤0.85) and mildly correlated | r
|<0.7. Only three first order texture parameters were highly
correlated to SUVmax and SUVmean2.5. All texture parameters
had | r |<0.50 with SUVmean40. Fourteen texture parameters
were highly correlated and ninteen were moderately correlated
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with MTV2.5. Twenty-two were moderately correlated and
none was highly correlated with MTV40. Thirteen texture pa-
rameter were highly and twelve were moderately correlated
with TLG2.5. Only one texture parameter was moderately cor-
related with TLG40. Conclusion: Only few parameters had
high correlation with SUV values, MTV40 and TLG40 indicat-
ing that a large number of texture parameters derived provide
additional information. However level of significance of addi-
tional information provided by these texture parameters need
to be tested further.
P061
Comparison of 3D texture features and metabolic
parameters obtained from 18-F FDG-PET/CT images
for evaluating tumor stage and subtype in non-small cell
lung cancer
S. Karacavus1, B. Yilmaz2, O. Kayaalti3, A. Tasdemir4, E.
Kaya5, S. Icer6, O. Ayyildiz2, K. Eset6, E. Vardareli5, M. H.
Asyali7; 1Bozok University, School of Medicine, Department
of Nuclear Medicine, Yozgat, TURKEY, 2Abdullah Gul Uni-
versity, Department of Electrical and Electronics Engineering,
Kayseri, TURKEY, 3Erciyes University, Develi Hüseyin
Şahin Vocational College, Department of Computer Technol-
ogies, Kayseri, TURKEY, 4Kayseri Educational and Research
Hospital, Department of Pathology, Kayseri, TURKEY,
5Acıbadem University, School of Medicine, Department of
Nuclear Medicine, İstanbul, TURKEY, 6Erciyes University,
Department of Biomedical Engineering, Kayseri, TURKEY,
77Department of Biomedical Engineering, Yıldız Technical
University, İstanbul, TURKEY.
Aim: The purpose of this study was to compare three-
dimensional (3D) texture features and metabolic parameters
(maximum standardized uptake value (SUVmax, SUVmean),
metabolic tumor volume (MTV), total lesion glycolysis (TLG)
obtained from 18-F FDG-PET/CT images for evaluating tu-
mor stage and subtype in non-small cell lung cancer (NSCLC).
Materials and methods: Forty-two patients with NSCLC
were included in this study. 3D texture features were extracted
by first order statistics (FOS), gray-level co-occurrence matrix
(GLCM), gray-level run-length matrix (GLRLM), and Laws’
texture filters using custom MATLAB codes on 18-F FDG
PET/CT images of all patients. The correlations between the
3D textural features and SUVmax, SUVmean, MTV, TLG,
tumor TNM stage and subtype (adenocarcinoma (ADC) and
squamous cell carcinoma (SqCCs)) were analyzed. Results:
Significant moderate correlations were observed between
MTV, TLG and GLRLM_GLN (r=-0.5; p=0.002),
GLRLM_RLN (r=0.7; p<0.001) and Laws’_mean (r=0.5;
p=0.002). While means of these texture features showed
statistical significantly difference between TNM stage groups,
there were no difference in the means of SUVmax, SUVmean,
MTV and TLG values. SUVmax, SUVmean, GLCM_energy
and homogeneity, GLRLM_SRLGE and LRLGE were nota-
bly different between tumor subtypes. Conclusion: Three-
dimensional (3D) texture features of 18-F FDG images might
be used as an objective tool to provide identifying tumor stage
and subtype in NSCLC.
P062
The role of SUV SPECT perfusion defect quantification
of the lung as a predictor of severe cardiovascular events
in a cohort of patients with congestive heart failure
W. He, W. Yu, J. Xi, W. Zhai; Huadong Hospital, Shanghai,
CHINA.
Objectives : The aim of this study was to investigate the use of
SUV SPECT to quantify lung perfusion defects in both non-
CHF and CHF patients and to explore its correlation index as
an outcome predictor for CHF patients. Methods : 30 patients
were enrolled in the study. 17 CHF patients were followed for
16±5 mo (mean±SD) and 13 patients were a non-CHF control
group. All patients underwent a lung perfusion scan, an inde-
pendent diagnostic CT plus echocardiography. The lung per-
fusion scanwas reconstructed using the software to convert the
recorded counts per voxel into activity per unit volume to
allow for SUV calculations. The diagnostic CT was co-
registered with the SPECT perfusion scan in order to relate
the perfusion function to anatomy. Using the software ‘Hybrid
3D Lung Lobe Finde r ’ . ( HERMES MEDICAL
SOLUTIONS)The lungs where further split semi-
automatically into individual lobes by placing 10 to 15 points
along each fissure. Using the computed anatomical volumes it
was possible to record the total SUVand volume of each lung
and lobe. The SUV difference between the CHF group and the
control group were compared. Cardiac death, acute MI, unsta-
ble angina, and late revascularization (>3 mo) experienced by
the patients during follow-up were defined as cardiac events.
Multivariate Cox regression analysis was applied for cardio-
vascular events patients and different SUV index. Results :
Preliminary results showed that there were no significant dif-
ferences between the total lung SUVof the two groups. There
were 10 patients (33.3%) who had cardiac events, including 2
acuteMI, 3 late coronary artery bypass grafting, and 5 unstable
angina pectoris during the follow-up. Conclusions : SUV
SPECT perfusion defect quantification of the lung is a
promising method for assessing pathology, physiology
state and the rate of severe cardiovascular events in
CHF patients.
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P063
Diagnostic accuracy of quantitative bone scintigraphy
with artificial neural network in patients with breast
cancer
A. Inaki, K. Nakajima, S. Watanabe, S. Kinuya; Kanazawa
University Hospital, Kanazawa, JAPAN.
Bone scan index (BSI) calculated by artificial neural net-
work (ANN) was developed as automatic and quantitative
evaluation of bone metastasis. Some studies demonstrated
the prognostic value of the BSI with regard to prostate
cancer. The aim of this study was to assess the diagnostic
value of the BSI in patients with breast cancer. MATE-
RIALS AND METHODS We retrospectively evaluated
66 patients with breast cancer who underwent bone scin-
tigraphy and FDG-PET with the intervals of less than 4
weeks between both examinations. RESULTS The BSI
with and without bone metastasis were 1.57 ± 1.73 and
0.15 ± 0.34, and there were significant differences between
2 groups (p < 0.001). Mean follow-up period was 1535 ±
749 days and the number of patients of no evidence of
disease (NED), alive with disease (AWD) and died of
disease (DOD) were 28, 16 and 20, respectively. The sen-
sitivity and the specificity of the BSI was 86.4% and
81.8% with a cut-off value of 0.185. The Kaplan-Meyer
curve showed that the patients with higher level of the BSI
had significantly lower prognosis than with lower level of
the BSI. In the Cox proportional hazards model, the BSI
was a good prognostic factor with a hazard ratio of 1.24
(1.13 - 1.36, 95%CI). CONCLUSION The BSI will play
a important role on not only detecting bone metastasis
but also predicting prognosis in patients with breast
cancer.
P064
Cerenkov Radiators for Preclinical Optical Imaging
C. R. Gigliotti, L. Altabella, A. E. Spinelli; San Raffaele Sci-
entific Institute, Milano, ITALY.
Aim: Cerenkov luminescence imaging (CLI) is a molecular im-
aging technique that combines nuclear and optical imaging, de-
tecting Cerenkov radiation produced by beta-emitting radionu-
clides. Due to the faint emission, the use of a Cerenkov radiator
(CR) can be useful to enhance the detected signal and conse-
quently reducing the acquisition time. Since the energy threshold
for Cerenkov production (CP) decreases increasing the medium
refractive index (RI), the first approach is the use of high RI
material to exploit the beta particles exiting from the tissue. Nev-
ertheless, in the low energy field, other parameters have to be
taken into account for the optimization of CLI. The goal of this
work is to investigate the efficiency of different materials by
studying the effect of their characteristics on CP. Methods: We
performedMC simulations usingGAMOSplug-in forGEANT4.
As a proof of principle, we considered mouse muscle tissue in
which, at different depths, is placed a low,mediumor high energy
beta-emitter used in nuclear medicine (NM) and a CR of variable
thickness is superimposed to the tissue. In order to investigate the
role of the material characteristics on CP, we simulated PMMA
and high RI transparent ceramic. The dependence of RI and of
density on CP was also investigates by slightly varying them
from the true values. Results and conclusion: The higher percent-
age of exiting photons is observed for low density ceramic, with
the same RI of the real ceramic, which shows nearly half of the
efficiency, while the PMMA with a lower RI shows a halfway
efficiency. The results show that the RI of a material is not the
crucial parameter that affects the efficiency of CR, whereas the
density seems to be the one that mainly affects the CR. We
believe that such an effect is due to the way the electrons lose
energy in matter that influences the change of particle velocity.
Comparing the results obtained with different β-emitters, we ob-
serve the major production gain for the 32P source. We conclude
that the ideal material for a CR optimized to CLI has low density
and high RI and that the major enhancement of the signal is
expected for medium energy β-emitter. Further investigation in
order to take into account the CR effects on spatial resolution are
now under implementation.
P065
Striatum specific F-18 FP-CIT analysis in Parkinson
disease
J. S. Oh1, I. Lee1,2, H. Moon1, J. Kim2, M. Oh1, J. Kim1;
1Department of Nuclear Medicine, Asan Medical Center, Uni-
versity of Ulsan College of Medicine, Seoul, KOREA, RE-
PUBLIC OF, 2Department of Nuclear Engineering & Radio-
logic Science, College of Health Science, Korea University,
Seoul, KOREA, REPUBLIC OF.
Aim: Conventional volume of interests (VOIs) analysis of
F-18 FP-CIT PET usually employed conventional spatial nor-
malization using whole brain PET images. Due to VOI mis-
match caused by spatial normalization error, researchers need-
ed to manually modify the VOIs for more accurate analysis, in
turn, lead to labor intensiveness and inter-observer reliability
issue caused by manual VOI adjustment. To better localize the
VOIs, we suggest new spatial normalization method called
striatum-specific SPM (SSPM) using a mask encompassing
striatum and midbrain.
Materials and methods: One hundred forty subjects (23 nor-
mal controls (NC), 117 patients with Parkinson disease (PD))
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underwent F-18 FP-CIT PET. Image acquisition was started
3 h after intravenous injection of 18F-FP-CIT (185 MBq).
Spatial normalization was conducted using SPM8 and VOI
analysis was conducted using our in-house FP-CIT PET and
VOI templates. Then, we applied spherical mask with a 28
voxel (5.6cm) radius to exclude regions other than midbrain/
striatum on not only FP-CIT template but also the resulting
individual spatially-normalized FP-CIT PET images.An itera-
tive spatial normalization using study specific template (SST)
was conducted. Finally, mean uptake values of 12 striatal VOI
templates (bilateral ventral striatum [VS], anterior caudate
[AC], posterior caudate, anterior putamen, posterior putamen
[PP], and ventral putamen [VP]) and that of reference region
(i.e., occipital lobe) were estimated automatically by our in
house software called ANTIQUE. For the ground-truth infor-
mation of mean VOI uptake and VOI location, one of us (IL)
manually adjusted the VOI under supervision of 20 year
experiencedboard-certified nuclear medicine physician (JK).
We compared FP-CIT SSPM method and conventional meth-
od in terms of VOI uptake % error and VOI location accuracy.
VOI uptake % error values were calculated for each VOI
using (automatic method-based uptake - manual method-
based uptake)/(manual method-based uptake) x 100 (%).
VOI location inaccuracy was estimated for each VOI using
the mean distance between automatic VOI and manually-
adjusted VOI.
Results: Except bilateral AC in NCs, the uptake % error
between SSPM auto and SSPM manual is smaller than that
between whole brain manual and SSPM manual (p<0.001)
in both groups.In both group, all VOIs but VP of PD (a
relatively small VOI) showed significantly decreased VOI
displacement (p<0.05) by FP-CIT SSPM than conventional
method.
Conclusion: SSPM outperform than conventional spatial
normalization-based approach in terms of significantly less
% error and more accurate VOI location. We suggest our
SSPM may serve as a new automatic VOI analysis method
of FP-CIT PET.
P066
Quantitative Evaluation of Scattered Photons
in a Myocardial Pinhole SPECT Imaging
K. Ogawa, N. Aitani, Y. Hemuki; Hosei University, Tokyo,
JAPAN.
Aim: Multi-pinhole collimators have been recently used in
myocardial SPECTsystems.Myocardial imaging with pinhole
collimators may acquire many undesirable photons such as
primary and scattered photons originating in the liver. This
study aimed to quantify the effect of these undesirable pho-
tons. Materials and Methods: The DMCAT phantom was used
in Monte Carlo simulations. The size of the phantom was 128
x 128 x 128 voxels and the size of a voxel was 2.5 x 2.5 x 2.5
mm3. We emitted photons with an energy of 140 keV from the
liver, myocardium and blood regions, and the numbers of pho-
tons were 0.8, 0.8, and 0.05 Mega/voxel, respectively. As a
reference we also simulated the case without liver activity. The
distance between the center of the phantom and pinhole was
18 cm and that between the pinhole and NaI detector was 9.9
cm. The diameter of a pinhole was 3 mm and the aperture
angle of the pinhole collimator was 60 degrees. We rotated
the pinhole detector system around the DMCAT phantom
and the number of projection data was 360. The energy reso-
lution of the detector was 10 % FWHM at 140 keVand we set
an energy windowwith a width of 20%. The reconstruction of
an image was performed with the OS-EM method. We as-
sumed that all regions inside the phantom except for the lungs
consisted of water, and attenuation correction was performed
in the process of image reconstruction. We evaluated the effect
of scattered photons with a contrast ratio of the myocardial
area between the conditions with and without the liver activi-
ties. Results: The myocardial images were blurred with
scattered photons originating in the liver. The contrast ratios
of reconstructed activities in the myocardial area to the blood
area were 0.65 (without liver activities) and 0.43 (with liver
activities). Conclusions: The scattered photons originating in
the liver affect the quality of reconstructed myocardial images,
making it very important that the scattered photons in the
pinhole SPECT image be considered.
P067
Image noise estimation using sub-reconstructions
of clinical Whole Body PET/CT data
A. K. Krizsan1, A. Forgacs2, G. K. Nagy1, M. Szolik1, M.
Dahlbom3, L. Balkay1; 1University of Debrecen, Medical
Center, Department of Nuclear Medicine, Debrecen, HUN-
GARY, 2ScanoMed Nuclear Medicine Centers, Debrecen,
HUNGARY, 3University of California at Los Angeles, David
Geffen School of Medicine, Department of Molecular and
Medical Pharmacology, Ahmanson Biological Imaging Cen-
ter, Los Angeles, CA, UNITED STATES.
Aim: The estimation of image noise defined as pixel-wise
Signal-to-Noise on Whole Body PET images can be routinely
performed on series of phantom scan image data. Simply Re-
gion of Interests’ (ROIs) can be used to calculate the Signal (as
Mean) and the Noise (as Standard Deviation) values. Howev-
er, in case of a clinical patient scan the activity distribution is
heterogeneous and the use of multiple scans is typically limit-
ed. A new method we propose to estimate pixel-wise noise of
clinical PET images from a single raw data with series of sub-
reconstructions.
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Materials and Methods: A uniform cylindrical phantom set
with increasing diameter and an anthropomorphic thorso
phantom were scanned with 18F-FDG using clinical scanning
protocols, the latter to mimic human non-uniform imaging
conditions. Furthermore, Whole Body PET image data of
two patients with elongated scan times were involved in the
investigation. From the single list mode files sub-
reconstruction series were generated with different time dura-
tions and using these image data, noise was estimated pixel-
wise with linear regression interpolation. As a gold standard,
we used extended PET scans in all cases and determining the
image noise pixel-wise by using image sets of the clinical
routine scan durations.
Results: The Standard Deviation/Mean data showed qualita-
tive similarities in terms of image patterns. Using ROI analysis
the difference between the conventional and new estimation
method of image noise remained under 10% in case of the
uniform cylinder and under 15% for both the anthropomorphic
phantom and patient studies even in case of using post filtering
on the images. This good correlation suggests further consid-
erations on optimizations of the method and extending on a
larger population of patient data.
Conclusion: The preliminary results indicate that this new
method could be used for pixel-wise noise estimation of clin-
ical PET scans without the need for repeated scans.
P068
Looking for physiological factors affecting texture analysis
on clinical PET… with texture standardization in mind!
J. Cortes-Rodicio, G. Sanchez-Merino, R. Lope-Lope, J.
Ruiz-Pomar, T. Martin-Gonzalez, M. Garcia-Fidalgo;
Osakidetza, Vitoria-Gasteiz, SPAIN.
INTRODUCTION AND OBJETIVES: Texture parameters
are important features commonly used for pattern recognition,
image classification and, more recently in the field of
“radiomics”, where more useful information might be extract-
ed from medical images. Anyway, texture quantification is
affected by many technical and physiological factors. The pur-
pose of this work is to study the texture features of non-
pathological livers as a function of the anatomical and physi-
ological properties of the patients undergoing PET studies.
METHODS AND MATERIALS: The data for 15 patients
showing non-pathological liver were acquired on a Philips
GEMINI TF PET/CT. Patients were injected with a linear
FDG dose regime of 2.5MBq/kg after 6h of fasting and ac-
quired after 60 min at rest. Raw PET data were reconstructed
using a BLOB-OS reconstruction protocol with attenuation
correction resulting a grid size of 4mm. Anatomical and phys-
iological features like patient’s weight, height, body mass in-
dex, liver volume and glucose level in blood, were also
registered. A liver covering ROI were delineated in each pa-
tient. To avoid variability due to reconstruction protocols and
activity concentration, only texture features that showed to be
robust on a previous study with phantoms were analyzed using
Chang Gung Image Texture Analysis toolbox for MatLab.
Those were entropy (Haralik-1973, Sun-1983, Horng-2002);
short-run-emphasis and run-percentage (Loh-1988); the ho-
mogeneity, intensity, inverse-difference-moment and code-
entropy (Horng-2002); and short-zone-emphasis and zone-
percentage (Thibault-2009). Finally, a multivariate Pearson
correlation analysis was performed using StatGraphics Centu-
rion XVI software.
RESULTS There is a high statistical correlation between liver
volume and entropy (p-value<<0.05). Entropy feature is, in-
deed, correlated (p-value<0.05) with all patient’s parameters,
except body mass index. The only textural features that do not
seem to be correlated (p-value>0.05) with any of the anatom-
ical or physiological parameters are run-percentage (Loh-
1988), short-zone-emphasis (Thibault-2009) and intensity
(Horng-2002), making them suitable for quantitative textural
analysis.
CONCLUSIONS: Textural feature analysis allow for a
deeper knowledge of tumor uptake in 18F-FDG PET/CT stud-
ies but they present an intrinsic variability due to technical and
physiological factors that should be taken into account. Most
of the textural features analyzed are correlated with these fac-
tors and are, therefore, more prone to errors in quantifying
changes or classifying patients. Only three of them seemed
to be suitable for this purpose. Even though, further studies
should be carried out in order to improve the statistical power
of the analysis.
P069
Repeat (R)-[11C]PK11195 brain PET scans in glioma
M. Bauer1,2, Z. Su1, F. Roncaroli3, A. Gerhard1, F.
Turkheimer4, K. Herholz1, R. Hinz1; 1University of Manches-
ter, Manchester, UNITED KINGDOM, 2Medical University
of Vienna, Vienna, AUSTRIA, 3Imperial College London,
London, UNITED KINGDOM, 4King’s College London,
London, UNITED KINGDOM.
Aim: The analysis of human brain PETscans with tracers binding
to the 18-kDa mitochondrial translocator protein (TSPO) is ham-
pered by the absence of an anatomical brain region free of specific
binding. We previously reported a comparison between two
referencing approaches, cerebellar grey matter (GM) reference
input function and supervised cluster analysis with six classes
(SVCA6)1, in glioma patients scanned with (R)-[11C]PK111952.
Here we compare these two input functions in repeat scans. Ma-
terials and Methods: Three patients with clinically stable glioma
(WHO grade: subject: 1 III, subject 2: II, subject 3: II) were
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scanned twice with (R)-[11C]PK11195, at 23, 6 and 8 months after
the initial PET scan. Parametric maps of binding potential
(BPND)were generated with the simplified reference tissue model
using either a cerebellar GMor a SVCA6 input function. Regional
BPND differences ΔBPND = BPNDscan2 - BPNDscan1 were cal-
culated in the following regions: frontal, temporal, parietal, occip-
ital lobe, thalamus, hippocampus and tumour cold region. T-tests
were performed to assess statistical significance. Results: BPND
with SVCA6 input functionwere systematically smaller than those
with cerebellar GM input function (p=0.0317, paired t-test).
ΔBPNDderivedwith SVCA6were significantly larger than those
with cerebellar GM input function (p=0.0002, paired t-test). One-
sample t-tests performed on the regional ΔBPND for the three
patients revealed no difference with the cerebellar GM input func-
tion (p1=0.0822, p2=0.3595, p3=0.6793) but statistically significant
increases with SVCA6 (p1= 0.0003, p2=0.0055, p3<0.0001). Con-
clusion: Of the two reference tissue input functions considered
here, only the data-led approach SVCA6 reported statistically sig-
nificant changes in BPND in the follow up scans. The cerebellum
GM as an anatomically defined reference region failed to reveal
changes of significance in BPND in other parts of the brain in
conjunction with the simplified reference tissue model. Acknowl-
edgments: Imaging of Neuroinflammation in Neurodegenerative
Diseases (INMiND), a collaborative project in the Seventh Frame-
work Programme of the European Union. References:
1 Turkheimer, FE et al. J Nucl Med 2007 48(1):158-67. 2 Su, Z
et al. Eur J Nucl Med Mol Imaging 2013 40(9), 1406-19.
P070
Segmentation gross tumor volume on positron emission
tomography by a method combined with numerical
approximation and local gradient _ an animal study
Y. CHEN; Quanzhou First Hospital of Fujian Medical Uni-
versity, quanzhou, CHINA.
Segmentation gross tumor volume on positron emission to-
mography by a method combined with numerical approxima-
tion and local gradient—an animal studyPurpose: A scheme,
named SUV_Shape 2.0, drawing gross tumor volume (GTV)
on PET images was made by a numerical approximation method
combined with maximal local gradient, and evaluated during this
study.Methods: Five rabbits implanted VX2 squamous carcino-
mas kept fasting at least 4h before [18F]-FDG imaging. 37MBq
[18F]-FDGwas administrated following their blood glucose level
detection. Their 3D PET data were acquired at 10min-120min
after injection by a PET/CT scanner (Discovery ST8, GE
Healthcare, USA). Euthanasia was done in the next 24h. Each
VX2 tumors was resected, and its maximal perpendicular diam-
eters were measured by a caliper. Its volume was computed fol-
lowing the equation of spheroid volume, SUV_Shape, and
SUV_Shape 2.0, then labeled as GTVt, GTVs1, and GTVs2,
respectively. The Spearman’s rho and paired t-test among GTVt,
GTVs1 and GTVs2 were done.Results: Eight VX2 tumor nodes
or masses were included in this study. Their GTVt were 29.26,
0.41, 4.22, 24.15, 21.44, 1.26, 0.21, and 1.63mL. Their tumor-
nontumor ratio were 16.1, 3.7, 1.63, 16,1, 4.65, 6.16, 4.58, and
1.5. The relationship betweenGTVt andGTVs1was significant (
Spearman’s rho=0.976, P<0.01 ), and they were not significant
difference (t=1.43, P=0.195). The correlation between GTVt and
GTVs2 was significant (Spearman’s rho=0.929, P<0.01), and
they were not significantly different (t=0.088, P=0.933). The re-
lation between GTVs1 and GTVs2 was significant (Spearman’s
rho=0.952, P<0.01), and they were not significant difference (t=-
1.42, P=0.199). The GTVof VX2 tumor masses (2/3) were ob-
viously underestimated by SUV_Shape1 (GTVs1 vs GTVt:
14.95 vs 29.26 mL, 23.52 vs 24.15mL, and 13.40 vs
21.44mL); while they were partly corrected by SUV_Shape2.0
(GTVs2 vs GTVt: 27.50 vs 29.26 mL, 31.6 vs 24.15mL, 18.5 vs
21.44 mL). However, the difference between GTVs1 and GTVt
among VX2 tumor nodes were smaller than the difference be-
tween GTVs2 and GTVt.Conclusions: The SUV_Shape 2.0
scheme was good for tumor masses delineation, while
SUV_Shape was good for tumor nodes outline.Key words: gross
tumor volume; segmentation; positron emission tomography
P071
Computer-aided Diagnosis System to Assess Metastatic
Disease Presence and Evolution
I. V. Popa1, I. Grierosu1,2, A. Statescu1, M. Gutu1,2, R.
Gherasim1, S. Bilha1, R. Olaru1, C. Cijevschi-Prelipcean1,2,
C. Mihai1,2, L. Ionescu1,2, C. Vulpoi1,2, C. Luca1,2, C.
Stefanescu1,2; 1“St. Spiridon” Hospital, Iasi, ROMANIA,
2Medicine Faculty, “Grigore T. Popa” University of Medicine
and Pharmacy, Iasi, ROMANIA.
AIMS: Our aim was to develop a computer-aided diagnosis
(CAD) system able to evaluate the presence and quantitatively
assess the evolution of the metastatatic disease (MTSD) on
repeated radiotracer scans.MATERIAL and METHODS: We
worked on 99mTc HDP whole body images of MTSD. The
method was developed using Matlab® and has three steps.
The first, preprocessing step, brings scan images at the same
contrast level. The second, processing step, identifies areas of
interest using the watershed method improved by a series of
accessory methods. The third, postprocessing step, is about
manually eliminating hyperfixing areas, automatically
encircled, that are certainly not metastases (like the joints im-
ages etc.). On the final image, several descriptive quantitative
parameters (both global and local) were calculated. The global
parameters were: ratio between the area occupied byMTS and
entire skeleton surface (RM) and the MTS number (NM). The
local parameters, in order to characterize each lesion in
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evolution, were: region gravity center coordinates, area, width,
height, maximum intensity pixel value, mean value and stan-
dard deviation, calculated for both anterior and posterior
incidences.RESULTS: We exemplified the results obtained
for a MTSD patient in evolution, for the first bone scan and
for the repeated bone scan, after three years. For the first im-
age, anterior incidence, we obtained RM = 15.28% and NM =
41. For the image in evolution we got RM = 16.01% and NM
= 42. Regarding the local descriptors, as an example, one
hyperfixing metastasis has an area of 24 pixels at first exami-
nation and a 70 pixels area at the second. Also, it can be seen
how some lesions have disappeared, some have emerged,
some have grown in size and some others decreased in size.
The descriptors are saved in the patient history archive, in
order to compare them with the same descriptors from subse-
quent examinations of the same patient. The system automat-
ically represents graphically both global and local values.
CONCLUSIONS: Our CAD system proved to be efficient
for quantitative assessment of MTSD in evolution on whole-
body scans, but could also be applied in other scan types - for
example, in the case of MTSD that uptake other radiotracers,
99mTc MIBI or 131I. This system represents an automated so-
lution capable of helping the doctor in identifying metastases
and in calculating quantitative parameters in evolution, ensur-
ing both objectivity and rapidity in the MTSD evaluation.
P072
Practical measures of dynamic 18 FDG time-activiy
curves.
M. Tuncel, O. Kupik, P. Kiratli, B. Erbas; Hacettepe Univer-
sity, Ankara, TURKEY.
AIM: Kinetic measures of dynamic 18 FDG PET/CT studies
have been proposed being superior compared to static mea-
sures such as SUVmax values. Dynamic parameters have been
used in the early assessment of therapy response in oncological
patients. However, complexity of kinetic analysis may limit its
application in the rutine clinical studies. Therefore, this study
was planned to analyze the dynamic data in an easy and prac-
tical way. MATERIALS and METHODS: Dynamic images
were recorded following i.v. injection of 18 FDG. Study group
had 30 patients. Time-activity curves were obtained from re-
gions of interest drawn on the tumoral tissue and on the aortic
arc as an input function. Using, lineer regression analysis of
time-activity curves, slope (SL) values were calculated for sev-
eral time intervals, i.e, 0-2 min (SL2), 0-5. min. (SL5), 0-10
min.(SL10), 0-30. min. (SL30), respectively. Similarly,
SUVmax values for 2nd min (SUV2), 5th min (SUV5), 10th
min (SUV10), and 30th min. (SUV30) were measured. For the
first 2 minutes, data were added and SUVmean (SUV2mean),
SULpeak (SUL2peak), perfusion volume (Per2V) and total
lesion glycolysis (TLG2) values were calculated. For compari-
son, 2-tissue compartmental analysis was performed and K1-k4
values were measured. In addition, Ki values were calculated.
Two-compartmental parameters were compared to the other
measured parameters. RESULTS: SL2 had correlation with
K1, whereas SL5 (r=0.64, p=0.0001), SL10 (r=0.76,
p=0.0001), and SL30 (r=0.85, p=0.0001), values showed in-
creasing correlation coeffiencient with Ki values. K3 values
had correlation with SL5 (r=0.38, p=0.04), SUV10 (r=0.54,
p=0.03), and SL30 (r=0.66, p=0.0001) values. SUV2 showed
a good correlation with K1 (r=0.83, p=0.0001). Correlation
between SUV5 (r=0.62, p=0.0001), SUV10 (r=0.44,
p=0.0001), SUV30 (r=0.42, p=0.0001), and K1 was decreasing
with time. SUV values were also correlated with Ki values
(SUV5 r=0.65, p=0.0001, SUV10 r=0.85, p=0.0001, SUV30
r=0.88, p=0.0001), except SUV2 value. SUV2mean,
SUL2peak, Per2V and TLG2 values were correlated with K1
and K2. SUL2peak and SUV2mean had highest correlation
coefficient with K1 ( r=0,93, p=0.0001, and r=0.88,
p=0.0001, respectively). CONCLUSION: Slope and SUVmea-
surements of dynamic curves showed good correlation with 2-
compartmental analysis parameters. Those measures can be
easily applied and give information about the 18FDG dynam-
ics. Further studies are needed to explore its clinical relevance.
P073
Early X-Ray CT Radiomic Identification of Lung Tissue
Harm Origins in Mice
D. Mathe1, F. Budan1, C. Korom2, D. Veres3, K. Szigeti3;
1CROmed Ltd, Budapest, HUNGARY, 2Dept. Radiology
Semmelweis University Budapest, Budapest, HUNGARY,
3Dept. Biophysics and Radiation Biology Semmelweis Uni-
versity, Budapest, HUNGARY.
Introduction. Lung diseases (resulting from air pollution) re-
quire a widely accessible method for risk estimation and early
diagnosis to ensure proper and responsive treatment. Radiomic
fractal dimension-based analysis of X-ray computed tomogra-
phy (CT) attenuation pattern in chest voxels of mice exposed
to different air polluting agents was performed to model dis-
ease establish differential diagnosis and discern sources of
harm to lung tissue. To model different types of air pollution,
the following Balb/CBYJ mouse groups were exposed: ciga-
rette smoke combined with ozone, sulfur dioxide gas, and a
control. Two weeks after exposure, the frequency distributions
of image voxel attenuation data were evaluated. Specific cut-
off ranges were defined to group voxels by attenuation. Each
cut-off ranges were binarized and their spatial pattern was
associated with calculated fractal dimension, then abstracted
by the fractal dimension-cut-off range mathematical function.
Each cut-off range versus fractal dimension function plot was
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found to contain two distinctive Gaussian curves. The ratios of
the Gaussian curve parameters distinguished the three expo-
sure groups statistically significantly. A new radiomic evalua-
tion method was established based on analysis of CT voxel
datadistribution and fractal dimension of the resulting lung CT
data segments. The resulting attenuation values of voxels
cor responded to spec i f ic t i s sues as wel l as the
calculatedparameters to the inflammation- and mucus-
patterns to air pollution exposures. Most likely those specific
attenuation patterns calculated with our method could diag-
nose and monitorcertain lung diseases, such as chronic ob-
structive pulmonary disease (COPD), asthma, tuberculosis or
lung carcinomas.
P074
development of metabolic tumor volume measurement
based on suvpeak
K. Koyama1,2, T. Mitsumoto1, K. Inoue2, K. Tsuda3, K.
Kotaka1, K. Yoshikawa1, K. Hatano1, M. Fukushi2; 1Tokyo
Bay Advance Imaging & Radiation Oncology Clinic-
MAKUHARI, Chiba, JAPAN, 2Tokyo Metropolitan Univer-
sity, Tokyo, JAPAN, 3Tsukuba International University,
Ibaraki, JAPAN.
Aim: FDG-PET/CT allows determination of metabolic tumor
volume (MTV) and total lesion glycolysis(TLG) which pro-
vides prognostic and predictive value in oncology. MTV is
commonly measured based on maximum standard uptake val-
ue (SUVmax). However SUVmax is affected by noise and
statistical error. To achieve stabile MTV measurement we de-
veloped a new method based on peak standard uptake value
(SUVpeak). Materials and methods: The Discovery 710 PET/
CT device was used in this study. The participants comprised
13 patients with lung lesions (lesion size 24.5 ± 10.3 mm,
lesion volume 6.6 ± 5.6 ml). A volume of interest (VOI) in-
cluding the tumor threshold by 40%, 42%, 50%, 60%, 70%
and 80% of SUVpeak within the VOI was used to measure
MTV. MTVerrors were assessed using CT tumor volume as a
standard and compared with conventional methods based on
SUVmax threshold by 42% and 50%. Results and conclusion:
The MTV error base on SUVpeak40% was -0.54±3.0 (95%
confidence interval : -2.4 - 1.3, range: 11.8) ml and the best
agreement with CT volume. The MTV error based on
SUVmax42% and SUVmax50%was -3.4±3.3 ml (95% confi-
dence interval : -5.4 - -1.3, range: 12.3) and -4.3±4.0 ml (95%
confidence interval : -6.9 - -1.8, range: 14.8). The MTV based
on SUVpeak40%, SUVpeak42% and SUVpeak50%were sig-
nificantly improved as compared with SUVmax42% (One-
Way Repeated Measures ANOVA P < 0.05). New method
based on SUVpeak reduced MTV error and statistical error.
It was shown that new method based on SUVpeak reduced
MTVerror and was achieved stabile MTV measurement.
P075
Analysis of Inter-Detector Scattering in PETwith Various
Energy Window Settings
K. S. Chuang, Z. J. Wei, H. H. Lin; National Tsing-Hua Uni-
versity, Hsin-Chu, TAIWAN.
[Aim] In conventional positron emission tomography (PET)
an energy window of [425 650] keV is commonly used. A
large amount of useful information is lost due to the partial
deposition of energy of the annihilation gamma in the detector
generating inter-detector scattering (IDS) triple events in PET.
These events are caused by one of the annihilation photons
deposits energy in more than one detector. IDS are not record-
ed because the events are not in the energy window. Some of
these events are recoverable, i.e. the correct line of responses
(LOR) can be identified and added to the data stream. It is
possible to employ a wider energy window to include and
recover the IDS and increase the system sensitivity.
[Materials and Methods] However, several factors cause the
degrading of the image quality when a lower threshold of
energy window is used. (1) The number of random events
increases. This can be corrected using traditional delayed win-
dow techniques but with the cost of increasing noise in the
data. (2) The number of multiple scattering events becomes
significant. The conventional scatter correction technique i.e.
single scatter simulation (SSS) might fail. (3) The IDS events
produce three ambiguous LORs. Techniques can be developed
to identify correct LOR. Wrongfully recovery of the IDS
events will blur the image.
[Results] A NURBS-based cardiac-torso (NCAT) phantom
was simulated at various activity levels. Preliminary results
show that IDS remains as a constant percentage at the range
of activity tested while the random triple increases with the
increase of activity. We will investigate the effects on image
quality and sensitivity at various energy window settings
based on Monte Carlo simulation. Noise equivalent count rate
(NECR), spatial resolution, coefficient of variance, and
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coefficient of recovery will be used to gauge the effects of
energy window setting on image quality.
[Conclusion] A best energy window that is a tradeoff between
image quality and system sensitivity can be determined from
this study.
P076
Optimisation of automatic image segmentation for tumour
volume determination in 18F-FDG PET/CT for patients
with liver lesions
D. Ruiz, E. Kalogianni, B. Corcoran, A. Eccles, N.
Mulholland, G. Vivian; King’s College Hospital NHS Foun-
dation Trust, London, UNITED KINGDOM.
Aim: There is a need for the optimisation of thresholding
used for automatic PET image segmentation for lesions
that lie within organs with variable background activity
such as the liver. The aim of this study was to determine
suitable threshold levels for use in measuring tumour
volume and uptake values for assessment of respiratory
gated PET for imaging liver lesions.Method: Images of a
PET NEMA Image Quality phantom containing 6 spheres
with volumes ranging from 0.5 - 26.5 ml were obtained
using a GE Discovery 710 PET/CT scanner. The phantom
was filled with 18F activity corresponding to that clini-
cally observed in liver lesions and normal liver back-
ground. The background activity concentration was kept
constant at approximately 7 kBq/ml, while the activity of
the spheres was varied to obtain lesion-to-background
(L/B) ratios of 1.5, 2.3, 2.7, 3.2, 3.6 and 4.4. The opti-
mum threshold level for image segmentation was deter-
mined from phantom images by selecting that which re-
sulted in the minimum difference between the actual and
measured volume for each sphere size and L/B
ratio.Results: Analysis of phantom images showed that
for spheres with a volume greater than 5 ml the optimum
threshold for image segmentation begins to converge for
all except the lowest L/B ratios of 1.5 and 2.3. The op-
timum threshold was found to depend on the L/B ratio
and ranged from 49 % to 95 % for the 26.6 ml sphere
with L/B = 4.4 and 0.5 ml sphere with L/B = 2.3 respec-
tively. Generally, the optimum threshold value increased
with decreasing L/B ratio. The three smallest spheres
were not visible in images of the phantom with the low-
est L/B ratio.Conclusion: The use of appropriate
threshold levels for PET image segmentation is essential
for the accurate definition of lesion volume and quantita-
tion. While more sophisticated image segmentation algo-
rithms are required for applications such as radiotherapy
treatment planning and dosimetry calculations, these re-
sults will improve the accuracy of liver lesion volume
determination for evaluation of PET imaging techniques.
Further work is required to validate this method for use
on patient images, and implement it for assessment of
respiratory gated PET.
P077
Aspects on quantification and detectability in 111In
SPECT/CTand 68Ga PET/CT images of neuroendocrine
tumours
A. Stenvall1, E. Mattsson1, E. Larsson1, T. Ohlsson1, C.
Hindorf1, L. Jonsson2; 1Radiation Physics, Skane University
Hospital, Lund, SWEDEN, 2Medical Radiation Physics, Lund
University, Lund, SWEDEN.
AimNuclear medicine imaging of neuroendocrine tumors
(NET) is performed either by SPECT/CT imaging, using
111In-octreotide or by PET/CT imaging using 68Ga-
radiolabelled somatostatin analogs. The two imaging tech-
niques will give different image quality and thereby different
detection thresholds for tumours, depending on size and activ-
ity uptake. Often a subjective evaluation is performed to com-
pare tumour uptake with the activity uptake in the liver to
decide whether the patient could be eligible for radionuclide
therapy.The aim of this study was to evaluate the image quality
for 111In SPECT/CT and 68Ga PET/CT imaging, i.e. the
smallest volume possible to visualize for different source-to-
background activity ratios. The accuracy of quantification of
lesion volume and activity was also investigated to develop an
ob j ec t i v e eva l u a t i on fo r r ad i onuc l i d e t he r apy
eligibility.Materials and methodsThe phantom study was per-
formed using the IEC Body Phantom with six hot spheres
having inner diameters of 10, 13, 17, 22, 28, and 37 mm, filled
with either 68Ga or 111In with sphere-to-background (S/B)
ratios of no background activity, 10:1, 5:1, 2.5:1, 1.67:1 and
1.25:1. These S/B ratios were chosen as representative values
of tumour-to-background ratios in patients. Activity ratios of
1.25:1 and 2.5:1 are clinically found for lesions close to liver
and spleen. Clinical acquisition and reconstruction protocols
were applied. Line profiles were drawn to evaluate the smallest
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detectable volume within a given S/B ratio. Recovery curves
based on threshold segmentation were obtained for all combi-
nations of S/B ratios and sphere diameters, allowing for
quantification.ResultsThe line profiles showed that the
10 mm sphere was not possible to detect in SPECT images.
It was detectable in PET images for S/B ratios of 2.5:1. In a
background corresponding to the activity uptake in the liver
(S/B 2.5:1 and 1.25:1) spheres larger than 22-37mm were
detectable in the 111In-SPECT images and spheres larger than
13-22mm were detectable in the 68Ga-PET images.The max-
imum activity concentration was accurately quantified for
spheres larger than 22mm in the PET images however the
quantification was impaired by sphere size and background
activity.ConclusionIt was not possible to detect the 10mm
sphere in any of the SPECT images. In a background corre-
sponding to the activity uptake in the liver, spheres larger than
approximately 30mmwere visible in the 111In-SPECT images
and spheres larger than approximately 17mm were visible in
the 68Ga-PET images. Sphere diameter and background activ-
ity strongly affect the possibility of a correct quantification.
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Optimisation of Y-90 post-SIRT PET imaging on GE
Discovery systems
L. M. Rowley, D. R. McGowan, K. M. Bradley, A. Hallam;
Oxford University Hospitals NHS Trust, Oxford, UNITED
KINGDOM.
Aim: To optimise image reconstruction parameters for 90Y
using phantoms and patients on our GE Discovery 690 and
710 PET-CT scanners for both standard OSEM and a new
Bayesian penalised likelihood reconstruction (BPL) algorithm
(Q.Clear, GE Healthcare, Milwaukee, USA). Methods: Fol-
lowing radioembolisation for the treatment of liver tumours
using 90Y, users may choose to perform either Bremsstrahlung
imaging or PET-CT, to visualise the deposition of the activity
and note any extra-hepatic activity. The BPL reconstruction
has beta, a noise suppression term as the only user-input var-
iable, unlike OSEM which has iterations, subsets, and filters.
BPL includes point spread function (PSF) modelling
(SharpIR) as part of the reconstruction. A NEMANU-2 Image
Quality (IQ) phantom was filled with 4.2GBq 90Y, with a
sphere to background ratio of 8:1 in each of the six spheres.
This was scanned over 9 nights on the GEDiscovery 710 PET-
CT scanner. Data was rebinned into 15 minute frames and
reconstructed using both time of flight (ToF) BPL and ToF
OSEM. For BPL this was using beta values 1-10,000. For
OSEM this was using 1-5 iterations, 8-32 subsets, 0-10 mm
Gaussian filter and with SharpIR both on and off. Contrast
recovery (CR) and background variability (BV) were calculat-
ed as per the NEMANU 2-2007 standard. A subset of the best
performing reconstructions parameters for both BPL and
OSEM were applied to ten patient images. Each set of patient
images were ranked by an experienced radiologist blinded to
the reconstruction parameters. Results: From the best
performing phantom BPL reconstructions (beta 2,000-4,000)
the patient images with a beta of 3,000 ranked highest. For this
beta the CR of the 37mm sphere was 81% ±3.9% and BV 7%
± 1.5% for a total phantom activity of 2.7GBq, and CR 74%
±8% and BV 19% ±4% for a total image activity of 0.9GBq.
These values were higher than the optimised OSEM recon-
struction. The beta value was appropriate over the range of
activities scanned (4.2GBq - 0.47GBq). Dead time was appar-
ent at activities above 3.5GBq with contrast recoveries re-
duced by 23% at 4.2GBq. Clinical images using BPL with a
beta of 3,000 appeared superior to optimised OSEM and
Bremsstrahlung images. Conclusion: The use of BPL with
90Ypost-SIRT images achieves an increase in contrast recov-
ery and decreased background variability compared to OSEM.
P079
Analysis of Radiation-Induced Liver Disease (RILD)
and Evaluation of Relationship Between Therapeutic
Activity and Liver Clearance(C) Rate
with Tc-99m-Mebrofenin(M) in Y-90 Microspheres
Treatment(MT)
H. Tanyildizi, M. Abuqbeitah, L. Kabasakal, M. Demir; Is-
tanbul University, Istanbul, TURKEY.
Objectives : Whole liver radiation has modest benefit in treat-
ment of unresectable hepatic metastases but the radiation doses
must keep in control. In this study, we aimed to calculate
amount of max permissible activity (MPA) and critical organ
doses with MIRD, to evaluate tumour doses for treatment re-
sponse and whole liver doses for RILD and to find optimal
liver function test additionally. Methods : This study includes
29 patients who attended our nuclear medicine department
suffering from Y-90 MT. 10 mCi Tc-99m MAA was applied
to patients for dosimetry. After injection, whole body SPECT/
CT images were taken in one hour. The min therapeutic tu-
mour dose is on the point of being 120 Gy1, the amount of
MPAs were calculated with MIRD considering volumetric
tumour/liver rate. A sub-working group was created with 11
patients randomly and liver C rate with Tc-99m-M was calcu-
lated according to Ekman formalism2. Results : The volumet-
ric tumour/liver rates were found between 33-66%
(Maksimum Tolarable Dose (MTD) 48-52Gy3) for 4 patients,
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less than 33% (MTD 72Gy3) for 25 patients. According to
these results the average amount of MPA, mean liver dose
and mean tumour dose were found 1793.9±1.46 MBq, 32.86
±0.19 Gy and 138.26±0.40 Gy. RILD was not observed in any
patient. In sub-working group, the relationship between Bili-
rubin, Albumin, INR (which show presence of liver disease
and its degree), liver C with Tc-99m-M and calculated MPAs
were found r=0.49, r=0.27, r=0.43, r=0.57 respectively. Con-
clusions : The min tumour dose was found 120 Gy for positive
dose-response relation. If volumetric tumour/liver rate was
>66%, dose 30 Gy; if 33-66%, dose escalation 48 Gy; if
<33%, dose 72 Gy. These dose limitations did not create
RILD. CL measurement with M was concluded that the best
method to determine the liver function. Therefore, liver CL
rate with Tc-99m-M should be considered in calculation of
Y-90 microspheres dosimetry.
P080
Monte Carlo simulations to evaluate dose for possible
treatment of brain cancers by boron neutron capture
therapy
Z. Jovanovic1, D. Krstic1, D. Nikezic1, M. Matovic2, R.
Krstic3; 1University of Kragujevac, Faculty of Science,
Kragujevac, SERBIA, 2Clin Ctr Kragujevac, Kragujevac,
SERBIA, 3KVARK Company, Kragujevac, SERBIA.
Monte Carlo simulations were performed to evaluate dose for
possible treatment of cancers by boron neutron capture therapy
(BNCT). The computational model of male Oak Ridge Na-
tional Laboratory (ORNL phantom) was used to simulate tu-
mour in the brain. Calculations have been performed bymeans
of the MCNP5/X code. In this simulation, epithermal neutrons
were considered. Boron neutron capture therapy (BNCT) is
radio therapeutic modality, based on nuclear capture reaction
that occurs when non-radioactive boron (10B) is irradiated
with neutrons of the appropriate energy to yield high energy
alpha particles and recoiling lithium (7Li) nuclei. Since these
particles have path lengths of approximately one cell diameter,
their lethality is primarily limited to boron containing cells.
The selective boron uptake in the brain metastases comparing
to normal tissuemakes BNCTa potentially advantageous tech-
nique, especially if the whole organ has be treated. In clinical
application of BNCT, 10B compounds such as BPA
(Boronophenylalanine) and BSH (Sulfhydryl borane) have
been widely used as short-range alpha particle-producing
agents. The obtained results indicate that the brain cancer
could be treated by BNCT under the assumptions of
calculations.References1. Brandão F S & Campos PR T. Do-
simetric analysis of BNCT - boron neutron capturetherapy -
coupled to 252Cf brachytherapy. International Nuclear Atlan-
tic Conference - INAC 2009 Rio de Janeiro,RJ, Brazil,
September 27 to October 2, 2009.2. Eckerman K F, Cristy
M, Ryman J C. Oak Ridge National Laboratory. Oak Ridge,
TN 37831, USA; 1996. Updated 08 April (2009). http://
ordose.ornl.gov/resources/Mird.pdf.3. Voyant C, Roustit R,
Tatje J, Biffi K, Leschi D, Briançon J, Lantieri Markovici C.
Therapeutic potential of atmospheric neutrons. Rep. Pract.
Oncol. Radiother. 16:21-31, 2011.4. Verbeke J M, Vujic J,
Leung K-N. Neutron beam optimization for Boron Neutron
Capture Therapy using the D-D and D-T high-energy neutron
sources. Nucl. Technol. 129:257-258, 2000.5. X-5 Monte
Carlo Team. MCNP-a General Monte Carlo N-Particle Trans-
port Code, Version 5 Vol. I: Overview and Theory. Los
Alamos, NM: Los Alamos National Laboratory; LA- UR-
03- 1987; (2003).
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What is the sensitivity of 90Y SPECT to microscale dose
distribution?
C. Oldfield1, D. Cullen1, D. Hamilton2, E. Page2, A. P. Rob-
inson1, J. Tipping2; 1University of Manchester, Manchester,
UNITED KINGDOM, 2The Christie NHS foundation trust,
Manchester, UNITED KINGDOM.
90Y microsphere treatments provide significant benefits for the
therapy of some cancers, e.g. metastatic colorectal cancers. Cur-
rent administration guidelines make no use of tumour dosimetry
despite promising work quantifying tumour dose response for
90Y microsphere therapies [1].The nature of microsphere treat-
ments results in a unique dose distribution due to the discrete
nature of the activity localisation. This allows the dose distribu-
tion to be specified down to a cellular level, far below the reso-
lution of conventional imaging modalities.Tumour microsphere
distributions based on existing data coming from analysis of his-
tological thin slices [2] describing the statistical nature of individ-
ual microsphere distributions have been generated. Using these
distributions as input to a Monte Carlo model it is possible to
calculate doses throughout a tumour at a micrometre scale.This
provides the basis of a Monte Carlo simulation study investigat-
ing how the microscale distribution of spheres is reflected in
macroscale SPECT and PET imaging and subsequent
dosimetry.Results showing the theoretical sensitivity of SPECT
and PET to the underlying structure of microsphere distri-
bution and its impact on dosimetry will be presented.Dose
calculations based on observed microsphere distribution
for SIR-sphere and Therasphere treatments are com-
pared.[1] Y H Kao et al, Post-radioembolization yttrium-
90 PET/CT - part 2: dose-response and tumor predictive
dosimetry for resin microspheres, EJNMMI, 2013[2] A M
Campbell et al, Analysis of the distribution of intea-
arterial microspheres in human liver following hepatic
yttrium-90 microsphere therapy, Phys. Med. Biol. 2000
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A comparison of the utility of F18 Choline and Ga68
PSMA PET/CT in identifying distant disease in high risk
prostate cancer patients being considered for radical
prostatectomy
S. A. Ali1,L. Emmett1, J.Wang1, P. Van Leeuwen2, D. Stark1,
J. Morigi1, P. Stricker2; 1St Vincents Public Hospital, Sydney,
AUSTRALIA, 2Garvan Institute for medical research, Sydney,
AUSTRALIA.
AIM:To identify the extent of metastatic prostate cancer outside
the standard operative or radiotherapy field in high-risk patients
undergoing pre-treatment staging with F18 Fluoromethyl-
Choline (FMC) and Ga68 PSMA (Prostate specific membrane
antigen).MATERIALS:All patients undergoing a pre-operative
PET CT (F18 Choline or Ga68 PSMA) were analysed using a
prospectively accrued ethics approved database. Gleason score,
T staging, PSA and prior imaging results were documented.
PSMA and FMC PET/CT plus diagnostic CT scans were un-
dertaken and independently assessed by 2 readers blinded to
clinical and imaging results. Management impact information,
minor (change in delivery or site of the selected treatment) or
major (change of selected treatment) change was documented.
Histopathology was documented in all patients.RESULTS:27
patients with FMC and 19 patients with PSMAwere included.
36/46 pre- radical prostatectomy and 10/46 pre external beam
radiotherapy. Mean Gleason score 8.12 (+/-1.17 SD)(FMC) and
8.53 (+/-1.01 SD)(PSMA). PSA (ng/mL) 20.36 (+/-24.52
SD)(FMC) and 14.81 (+/-18.94 SD)(PSMA). With FMC pa-
tients (27), 15 were identified as having disease localized to
within the standard operative field (9/15 prostate alone; 6/15
prostate+ local pelvic nodes). 12/27(44%), of whom 4/12
(33%) had bone and 8/12 (%66) distant nodal involvement
(above common iliac). With PSMA patients, 13/19 had disease
within the standard operative or radiotherapy field (10/13 pros-
tate alone, 3/13 prostate+ pelvic lymph nodes). 6/19 (31%)
PSMA had bone lesions with no distant nodes identified
(PSMA). Management impact and histopathology results are
in process.CONCLUSION:A significant proportion of men
with high risk prostate cancer undergoing pre- treatment F18
Choline or Ga68 PSMA demonstrated disease outside of the
standard surgical or radiotherapy field (particularly in bone with
PSMA) leading to a significant change in management. Ga68
PSMA identified a higher proportion of men with metastatic
bone disease than F18 Choline in the high risk pre-operative
setting. Further large studies investigating the value of Ga68
PSMA in the high risk preoperative group is warranted.
P083
Targeting VPAC1 for Imaging Prostate Cancer
M. L. Thakur, E. J. Trabulsi, S. Tripathi, S. Kim, P. McCue,
R. Birbe, A. Gandhe, P. Kumar, C. Intenzo, L. Gomella;
Thomas Jefferson University, Philadelphia, PA, UNITED
STATES.
Objectives: Throughout the world, prostate cancer (PC) takes
hundreds of thousands of lives each year. Although a large num-
ber of minimally invasive and invasive procedures are available
for detection of PC, there remains a compelling need for imaging
PC and its metastatic and recurrent lesions. As a result, for PET
and SPECT imaging of PC, many novel radiopharmaceuticals
are being investigated. VPAC1 receptors (combined for vasoac-
tive intestinal and pituitary adenylate cyclase active peptide) are
expressed in high density on PC cells at the onset of oncogenesis
and play an active role in cell proliferation, differentiation, and
cell survival. On stroma, normal cells, and benignmasses, only a
few VPAC1 receptors are expressed. The goal here was to de-
termine the ability of a VPAC1 receptor-specific biomolecule,
64Cu-TP3805, to image biopsy-proven PC in vivo, and evaluate
the findings with pathologic examination.
Methods and Materials: Twenty-five men (age 44-74 yrs,
mean 63.4±7.6 yrs) scheduled for radical prostatectomy
(Gleason 7) and who signed an IRB approved consent form
received 148 mBq (±10%) 64Cu-TP3805 preoperatively. PET
images were performed at 30 min. and 2 hrs. post injection.
Standardized uptake values (SUVs) were determined, malig-
nant lesions (SUV >1.0) were counted, and data were compared
with histological findings. In addition, 9 deparaffinized
wholemount pathology slides from 3 benign prostatic hyperpla-
sia (BPH) patients were incubated with 64Cu-TP3805, washed
with PBS, dried, and subjected to digital autoradiography
(DAR). Slides were then H&E stained, read by pathology, and
DAR images were compared with histological findings.
Results: By PET imaging in 25 patients, 127 malignant lesions
were identified by histology, all of which were positive by im-
aging (SUV max range 1.1-8.8). In addition, there were 85
additional lesions with SUV max >1.1. Consistent with histol-
ogy, DAR was normal for all 9 BPH slides. The pathologic
nature of 85 PET lesions is being investigated.
Conclusion: PET imaging with 64Cu-TP3805 accurately visu-
alized all malignant lesions determined by histology. Consis-
tent with histology, DAR examinations of 9 slices from 3 BPH
patients showed absence of 64Cu-TP3805 uptake, confirming
a lack of VPAC1 receptors on non-malignant, normal cells. It
is, therefore, reasonable to consider that the additional 85 PET
lesions may not be false positive, but were either missed by
histology ormay be histologically pre-malignant, such as pros-
tatic intraepithelial neoplasia (PIN), the precursor of PC. 64Cu-
TP3805 is worthy of further investigation. Support: NIH/NCI
R01 CA157372 (MLT)
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The incremental value of FDG PET/CT over MDP bone
scan in staging of Ewing’s group of tumors
r. K. kavindran, Sr., s. shah; TMH, mumbai, INDIA.
Introduction: Routine staging for Ewing’s group of tumors
includes a Tc99m MDP bone csan, CT thorax and a MRI of
the local region. FDG PET/CTscans are being increasing used
for stgaing various malignancies. Aim: The evaluate the incre-
mental value of F18 FDG PET/CT over Tc99m MDP bone
scintigraphy in Ewing’s group of tumors. Materials and
methods: This is a retrospective analysis of 66 histological
proven untreated cases of Ewing’s group of tumors. A 99m
Tc MDP planar bone scan and FDG PET/CTscan were done
within a span of five days. Abreath hold CT chest was done
after completion of the PET/CT study. Abnormalities on a
MDP bone scan at primary and metastatic sites and the areas
of abnormal FDG uptake in the skeletal system on a PET/CT
study in all the patients were noted. A comparsion of the skel-
etal lesions identified by both modalities was done.Additional
sites of metastases on a FDG PET/CT were also evaluated.
Results: MDP bone scan identified in 4/66(6%) patients while
FDG PET/CT identified skeletal disease in 12/66(18%). 50%
(6/12) of the leisons identified on PET/CTwere purely marrow
lesions. FDG PET/CT delineated 22 (33/3) patients with non
skeletal metastases (15-lung and 7 nodes),this group consisted
of 19 (28.8%) patients who showed only non skeletal metas-
tases while 3 patients had both skeletal and non skeletal me-
tastases. Conclusion: FDG PET/CT in view of its better sensi-
tivity ( incremental value of 12%) in delineating skeletal
metastses over MDP bone scan and its ability to detect non
skeletal metastses ( which acconted for 33% in our study)
should be considered as a useful modality for stgaing Ewing’s
group of tumors.
P085
[18F]PR04.MZ for Dopamine Transporter Quantification
in Low Density Regions - Complete Evaluation
and Dosimetry in Healthy Volunteers
V. Kramer1, R. Pruzzo2, E. Hernandez2, P. Chana3, C. Juri4, P.
Riss5, F. Rösch6, H. Amaral1; 1PositronPharma SA, Santiago
de Chile, CHILE, 2Nuclear Medicine and PET/CT Center
FALP, Santiago de Chile, CHILE, 3Universidad de Santiago
de Chile, Santiago de Chile, CHILE, 4Universidad Catolica,
Santiago de Chile, CHILE, 5University of Oslo, Oslo, NOR-
WAY, 6Johannes Gutenberg-Universität Mainz, Mainz,
GERMANY.
Objectives: Deterioration of dopaminergic cells in the
Substantia Nigra and subsequent dopaminergic deficiency in
striatal regions is the main hallmark of Parkinson’s Disease.
Quantification of the cellbodies in this area remains difficult
due to low dopamine transporter concentrations and partial
volume effects. 18F-PR04.MZ is a new, high affinity
radioligand for dopamine transporters, currently under inves-
tigation at our center. Aim of this study was to perform a
complete evaluation and dosimetry study with 18F-PR04.MZ
in healthy volunteers.Methods: 5 healthy volunteers (mean
age 23 ± 2 a) underwent a dynamic PET scan (Siemens
mCT) for a duration of 180 min after bolus injection of 203
± 21 MBq (mean ± SD) [18F]PR04.MZ. PET scans were co-
registrated to T1 weighted MRI scans and normalized to a
brain template. Blood input function was recorded via auto-
mated online blood sampling (Twilite/Swisstrace) and plasma
and parent fraction was determined by a HPLC method. Dis-
tribution volumes and binding potentials were determined by
different invasive and non-invasive methods. 5 healthy volun-
teer underwent serial whole body PET scans for 2h to deter-
mine biodistribution and estimate internal radiation
dose.Results: [18F]PR04.MZ showed a relatively fast kinetic
and very high specific uptake in DATcontaining brain regions.
Peak uptake in putamen was reached after 25 minutes follow-
ed by slow washout. Distribution volumes were determined
using 2TCM and were well correlated with non-invasive
methods like SRTM. Stepwise reduction of scan duration from
180 to 90 min showed stable estimates for most binding po-
tentials. The biodistribution study revealed urinary bladder
and gastrointestinal system as main excreting organs and bone
uptake was observed due to defluorination. Results from the
dosimetry study are currently under evaluation but preliminary
est imates showed no cr i t ica l levels of radia t ion
burden.Conclusions: [18F]PR04.MZ is a promising tool for
precise quantification of striatal and extrastriatal dopamine
transporters and its kinetic provides suitable and stable esti-
mates after only 90 min of scan duration. Studies including
REM sleep disorder patients and early PD patients are current-
ly ongoing to estimate DAT density in different brain regions
in early phases of PD.
P086
The potential impact of congestive heart failure (CHF)
on FDG PET/CT studies
M. Ahmed1, R. Muzaffar1, M. M. Osman1,2; 1Saint Louis
University, Saint Louis, MO, UNITED STATES, 2Saint Louis
VA, Saint Louis, MO, UNITED STATES.
Objective:Congestive heart failure (CHF) is not uncommon
among cancer patients undergoing FDG PET/CT. When pres-
ent, CHF may induce reactive mediastinal adenopathy with or
without cardiac cirrhosis (congestive hepatopathy). Therefore,
CHF may be a source of false positive mediastinal nodes and
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affect the standard uptake value (SUV) of the liver, a frequent-
ly used internal reference point in FDG PET/CT scans. We
aimed to assess if CHF results into reactive mediastinal
adenopathy and or affect liver SUV.Method:A retrospective
study was conducted comprising of 82 patients with known
CHF who had FDG PET/CT examination. Patients with ma-
lignant mediastianal lymphadenopathy, no measurable lymph
nodes or completely calcified nodes were excluded resulting in
a total of 31 CHF patients. They were compared with 35 age
and gender matched non-CHF controls. A log was created to
record the number of measurable mediastinal lymph nodes
(LN), short axis size measurements, SUV max and mean
Hounsfield Units (HU) of the nodes from PET/CT scans. A
region of interest (ROI) was also drawn over the posterior right
hepatic lobe to measure the SUV max.Results:A total of 66
cases were reviewed (31 female, 35 male, mean age of CHF
group 69, mean age range of non-CHF group 70, total age
range 57-90 yrs.). Mean values of the CHF vs non-CHF group
are as follows:HU (mean): CHF 46.5 +/- 25.40 vs Non-CHF
47.79 +/- 24.94; p-value 0.77SUV max: CHF 1.96 +/- 0.94 vs
Non-CHF 1.95 +/- 0.64; p-value 0.94LN short axis(mm): CHF
8.87 +/- 3.95 vs Non-CHF 7.67 +/- 2.66; p-value 0.04Liver
SUVmax: CHF 2.79 +/- 0.62 vs Non-CHF 3.13 +/- 0.66; p-
value 0.002A two tailed test of significance demonstrated a
statistically significant difference in the size of LN for the 2
groups but was still below 10 mm in diameter, which is con-
sidered a cut-off in size for assessing lymphadenopathy. How-
ever, the t-test for Liver SUV was also significant with a p-
value of 0.002.Conclusion:We conclude that the presence of
CHF does not result in statistically significant reactive medi-
astinal adenopathy; however, it does result into lower liver
SUV compared to age and gender matched controls without
CHF. Therefore, the mediastinum may serve as a better refer-
ence point than the liver in patients with CHF. Further studies
are needed to elucidate the CHF-induced hepatopathology and
potential impact on FDG PET/CT exams.
P087
The Effect of Pulmonary Hypertension on Standardized
Uptake Values of the Liver and Pulmonary artery in FDG
PET/CT Imaging
M. Mikhayel1, N. Parkar1, R. Muzaffar1, P. Kelly1, M. M.
Osman1,2; 1Saint Louis University, Saint Louis, MO, UNIT-
ED STATES, 2Saint Louis VA, Saint Louis, MO, UNITED
STATES.
Objective: Pulmonary hypertension (PH) is not uncommon
among cancer patients who routinely undergo FDG PET/CT
for evaluation and follow up of their malignancy. Other risk
factors for the development of PH include drugs and toxins,
including chemotherapeutic drugs, as well as underlying portal
hypertension. Liver and mediastinal blood pool are being used
as internal reference points in FDG PET/CT examinations.
The objective of this study was to evaluate potential impact
of PH on standardized uptake values (SUV) within the liver
and mediastinal blood pool in cancer patients undergoing
PET/CT.
Materials and Methods:The study was approved by the In-
stitutional Review Board. FDG PET/CT scans for 38 patients
(2 groups) were retrospectively reviewed; 19 patients (group
A) (12 male, 7 female) of which had a confirmed diagnosis of
PH along with 19 control without PH (group B), matched for
age and gender to group A. To define PH, the pulmonary artery
diameter (PAD) was measured from the non-contrast CT from
the PET/CT. A measurement of 2.9 cm was used to define
pulmonary hypertension. The SUV values were also measured
in the liver (right hepatic lobe) and in the main pulmonary
artery within the two groups using matched volumetric regions
of interest (ROI). A log was kept to record our findings.
Results: A two-sample pooled t-test for unequal variances
was used to compare SUV of the liver and pulmonary artery
among the two groups. There was no significant difference in
the SUV measured in the liver in group A vs. group B (P >
0.3975). There was also no significant difference in the SUV
measured in the main pulmonary artery between group A and
group B (P > 0.5522).
Conclusion: There is no significant difference in the SUVof
the liver and pulmonary artery between patients with PH and
those without PH. Therefore, the presence of PH does not
preclude the use of liver and/or mediastinal blood pool as
internal reference points in FDG PET/CT examination.
P088
Dynamic whole body distribution of FBPA in humans
studied with 3D PET/CT
K. Isohashi1, H. Kato1, G. Horitsugi1, S. Naka1, I. Mochida1,
E. Shimosegawa2, J. Hatazawa1; 1Nuclear Medicine and Trac-
er Kinetics, Osaka University Graduate School of Medicine,
Suita, JAPAN, 2PET Molecular Imaging Center, Osaka Uni-
versity Graduate School of Medicine, Suita, JAPAN.
Objective: Boron neutron capture therapy (BNCT) is a binary
cancer treatment system that requires the selective delivery of
a boron-containing drug to the tumor and then irradiation with
neutrons to yield high-linear-energy-transfer a particles and
recoiling 7Li nuclei. Successful application of BNCT requires
the selective delivery of 10B to the tumor. In order to evaluate
10B accumulation in the tumors, 4-borono-2-18 F-fluoro-
phenylalanine (FBPA) PET has been employed. Although
the indicators of T/N ratio (normal tissue 10B concentration
ratio in the tumor T with respect to N) and T/B ratio (10B
concentration ratio of tumor venue for blood B) are used, the
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method of obtaining these are not standardized in clinical lev-
el. We examined dynamic whole body distribution of FBPA in
humans by means of 3D PET/CT visually and quantitatively.
Methods: Sequential whole-body FBPA PET/CT (Eminence
SOPHIA SET-3000BCT/X, Shimadzu) was performed in 5
normal adults (3 males/2 females, mean age=34) after they
had fasted for at least 4 h. After whole-body CT for attenuation
correction and intravenous bolus injection of FBPA (3.7MBq/
kg), the subjects were scanned from the parietal to the groin
(data acquisition: 455 sec). The scanning was repeated seven
times (interval: 48 sec). Decay of radioactivity during the PET
scan was corrected to the time of initiation of the first scan.
FBPA radioactivity in whole blood was measured at back-
ground, 30 sec, 1, 3, 5, 10, 20, 30 and 50 min using a PET
device and a well counter corrected mutually. Spherical volume
of interest with a diameter 10 mm was drawn on tomographic
images within ascending aorta, aortic arch, pulmonary trunk,
left and right ventricle, and inferior vena cava, and FBPA radio-
activity was measured. The value of FBPA radioactivity of each
site on the images and that in whole blood in the similar time
was compared, respectively. This study was approved by the
institutional ethics committee. Results: The FBPA uptake in the
spleen, pancreas, blood (ventricle) and salivary gland peaked
early after the injection and steadily decreased thereafter. The
FBPA uptake in kidney and urinary radioactivity were persis-
tently higher. There were correlations between FBPA radioac-
tivity of each site on the images and that in whole blood in a
similar time (p < 0.001, spearman). Conclusion: In the FBPA
PETstudy, the scan initiation 60 min after FBPA administration
provides a stable systemic image. It is possible to obtain a stable
B value in T/B ratio from the image.
P089
Uptake of 68Ga-DOTATATE and 68Ga-DOTATOC
in Primary Neuroendocrine Tumors, Metastases,
and Normal Liver Tissue - is there a Significant
Difference?
M. Todorovic-Tirnanic1, M. Gajic2, R. Baum3; 1Faculty of
Medicine, University of Belgrade and Center of Nuclear Med-
icine, Clinical Center of Serbia, Belgrade, SERBIA, 2Institute
of Statistics, Faculty ofMedicine, University of Belgrade, Bel-
grade, SERBIA, 3Theranostics Center for Molecular Radio-
therapy and Imaging, Zentralklinik, Bad Berka, GERMANY.
Aim: In vivo distribution comparison of the two 68Ga-labeled
somatostatin analogues [TOC and TATE; TOC exhibiting higher
affinity for human somatostatin receptor 3 and 5, lower for 2 than
TATE] by determining maximal standardized uptake values
(SUVmax) in normal liver, primary gastroenteropancreatic neu-
roendocrine tumor (NET) and metastases.
Materials and methods: 76 PET/CT studies in 38 patients (1
duodenal NET, 18 pancreatic, 2 coecal, 12 ileal, 3 jejunal, 1
mesenterial, 1 in appendix) with stable disease were analyzed.
68Ga-DOTATATE and 68Ga-DOTATOC PET/CT were per-
formed at consecutive controls. Injection to acquisition time
was identical for both studies (±10 min). Mean SUVmax values
were determined and compared.
Results: 225metastases (98 in the liver, 67 in lymph nodes, 43 in
bones, 17 in soft tissue), 18 primaries and normal liver were
analyzed on both PET/CT studies. Mean SUVmax values in
68Ga-DOTATATE / 68Ga-DOTATOC groups were: normal liver
6.8±1.7 / 6.9±1.8, primary tumor 20.4±13.7 / 24.2±20.1, liver
mets 15.4±9.4 / 17.9±11.4, soft tissue mets 15.3±16.4 / 17.3
±18.8, lymph node mets 12.0±9.5 / 15.2±13.3, bone mets 7.5
±5.7 / 9.9±8.0. 68Ga-DOTATOCuptakewas always higher: high-
ly significantly in primaries, liver and lymph node metastases,
significantly in bone metastases, not significantly in soft tissue
metastases. 68Ga-DOTATOC and 68Ga-DOTATATE accumulat-
ed higher in primaries compared to metastases. The highest met-
astatic uptake was in liver and soft tissue metastases (not signif-
icantly different compared to primaries), intermediate in lymph
nodes (significantly lower than in primaries) and the lowest in
bone metastases. Normal liver tissue showed the lowest uptake.
Conclusion: Both radiopharmaceuticals had the highest uptake
in primary tumor and three (68Ga-DOTATATE) to 3.5 fold (68Ga-
DOTATOC) lower in the normal liver tissue. For both radiophar-
maceuticals liver and soft tissuemetastases had the highest uptake
amongmetastases, lymph node intermediate and bonemetastases
the lower. There was no difference between 68Ga-DOTATOC
and 68Ga-DOTATATE accumulation in the liver, which could
be related to the normal peptide metabolism in the liver. Higher
uptake of 68Ga-DOTATOC in the primary tumor and metastases
could be beneficial when theranostic approach is considered.
P090
18FDG-PET/CT Imaging in Suspected Acute Renal
Allograft Rejection
P. Lovinfosse, L. Weekers, C. Bonvoisin, C. Bovy, S. Grosch,
J. Krzesinski, R. Hustinx, F. Jouret; CHU of Liege, Liege,
BELGIUM.
The diagnosis procedure for kidney transplant recipients
(KTR) with suspected acute rejection (AR) relies on needle
biopsy. Noninvasive tests to predict nonrejection would be
preferable. AR is associated with a recruitment of activated
leukocytes into the transplant, which are characterized by a
high metabolic activity and an increased uptake of glucose
analog, 18Fluoro-deoxy-glucose (18FDG). Thus, 18FDG-
Positron emission tomography coupled with computed tomog-
raphy (PET/CT) may help noninvasively detect renal AR.
From January 2013 to February 2015, we prospectively per-
formed 32 18FDG-PET/CT in 31 adult KTR with suspected
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renal AR who underwent a biopsy. Biopsies were categorized
as “normal”, “borderline”, “AR” or “others” according to
Banff classification. PET/CT imaging was performed within
201 ± 18 minutes after i.v. administration of 3.2 ± 0.2 MBq/kg
of 18FDG, before any modification of immunosuppression.
The mean standard uptake values (SUV) of both upper and
lower renal poles were measured, with no threshold activity.
Biopsies were diagnosed as “normal”, “borderline”, “AR” or
“others” in 8, 10, 8 and 6 (including 3 polyoma-BK nephrop-
athies) cases. Mean SUV respectively reached 1.5 ± 0.2, 1.6 ±
0.3, 2.9 ± 0.8, 2.2 ± 1.2 in each category. Mean SUVof biopsy-
proven AR was significantly higher than “normal” cases
(p<0.01). No difference was found between “normal” vs. “bor-
derline”, or between “AR” vs. “others” histopathology. Still, a
positive correlation between mean SUV and acute composite
(g+i+t+v+ptc) Banff score was found, with a coefficient of
0.70 (p<0.001). Sensitivity and specificity of 18FDG-PET/
CT in detecting pathological biospies were respectively 92.3
and 36.8, with a mean SUV threshold at 1.4. 18FDG-PET/CT
imaging may help discriminate nonrejection, thereby avoiding
unnecessary transplant biopsy in KTR with suspected AR.
P091
Effects of Long Acting Somatostatin Analogue Therapy
on 68Ga-DOTA-Octreotate PET/CTuptake
in Neuroendocrine Tumour Patients
M. H. Cherk, R. J. Hicks, M. S. Hofman; Centre for Cancer
Imaging, Peter MacCallum Cancer Centre, Melbourne,
AUSTRALIA.
Aim: To evaluate the effects of long-acting somatostatin ana-
logue (SSA) therapy on 68Ga-DOTA-octreotate (GaTate) up-
take at physiological and metastatic sites in neuroendocrine
tumour (NET) patients and potential implications for peptide
receptor radionuclide therapy (PRRT).Materials andMethods:
Twenty-one patients (8 F; 13 M, Age 30-89) with metastatic
neuroendocrine tumour (NET) who had undergone baseline
and repeat imaging following long-acting SSA therapy with
GaTate PET/CT scans were retrospectively reviewed. Maxi-
mum standardized uptake values (SUVmax) were measured
for the thyroid, spleen, liver, pituitary, adrenals and salivary
glands in all patients and for 49 metastatic lesions in 12 pa-
tients with stable disease which were then compared. Serum
chromogranin-A (CgA) levels were available for correlation
between scans in 17/21 patients. Results: Mean thyroid, spleen
and liver SUVmax decreased significantly following SSA
therapy from a baseline of 5.9 to 3.5 (p=<0.0001), 30.3 to
23.1 (p=<0.0001) and 10.3 to 8.0 (p=<0.0001) respectively.
Mean pituitary SUVmax increased from 10.2 to 11.0 (
p=0.004). Adrenal and salivary gland SUVmax did not
change. Tumour SUVmax increased in 7 of 12 patients with
stable disease; CgA was stable of decreasing in 5 of these
patients.] 30/49 (61%) metastatic lesions had an increase in
SUVmax and metastatic lesion:liver uptake ratio increased in
40/49 (82%) following SSA therapy. Conclusion: Long-acting
SSA therapy decreases GaTate uptake in the thyroid gland,
spleen and liver but in most cases increases metastatic
lesion:liver uptake ratio. This has significant implications for
interpretation of GaTate PET/CT as SSA therapy may thereby
increase Krenning Score or other quantitative parameters
resulting in apparent progression. It also increases the likeli-
hood of a patient being deemed suitable for PRRT. Our find-
ings also suggest pre-dosing with SSA prior to PRRT may
enable higher doses to be delivered to tumour whilst decreas-
ing dose to normal t issues, potent ia l ly reducing
myelosuppression as a consequence of lower splenic
irradiation.
P092
Ga-68 labelled PSMA ligand based PET/CT scan
for the detection of recurrence in prostate cancer patient
and comparison with F-18 choline-based PET/CT scan
in a tertiary care center
B. R. Mittal, J. Shukla, R. V. Parghane, R. K. Phulsunga, R.
Vatsa, P. Bhusari, N. Rana, A. Sood, A. Bhattacharya, S. K.
Singh; Postgraduate Institute of Medical Education & Re-
search, PGIMER, CHANDIGARH, INDIA.
Background: Prostate cancer (PC) is the second most frequent
cancer and the sixth leading cause of cancer death in men
worldwide. Detection of recurrence in prostate cancer is a
major challenge for all conventional imaging. The prostate-
specific membrane antigen (PSMA) is over-expressed in PC
cells therefore providing a promising target for specific imag-
ing in these patients. The aim of this study was to detect re-
currence in patients with PC by using a (68)Ga-labelled PSMA
ligand based PET/CT scan and compared this finding with
(18)F-choline-based PET/CT scan. Material and Methods: A
total of 12 confirmed cases of prostate cancer were analyzed
retrospectively. All patients underwent (68)Ga-labelled PSMA
PET/CT scan and (18)F-choline-PET/CT scan within 2 weeks
interval. Radiotracer distributions in whole body images were
assessed visually in both PET/CTscans. The semi-quantitative
analysis was performed by measuring the maximum standard-
ized uptake values (SUVmax) in prostatic bed, pelvic and
abdominal lymph nodes, bone and other lesions detected on
both scans. In addition, target to background ratio for all le-
sions detected on both scans were also analyzed. Results: The
mean prostate-specific antigen (PSA) value in these patients
was 9.07 ng/ml (range 0.3-38 ng/ml). A total of 19 lesions
were detected in 68Ga-PSMA PET/CT while 12 lesions were
detected using choline PET/CT, in 10 patients. All lesions
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were confirmed on histopathological examination, MRI, bone
scan and clinical follow up. All these finding on both scan
were localized in four regions: prostatic bed (PSMA=8, cho-
line=5), pelvic lymph nodes (PSMA=5, choline=4), abdomi-
nal lymph nodes (PSMA=2, choline=1), bony lesions
(PSMA=4, choline=2) and were analyzed semi-quantitatively
using maximum standardized uptake values (SUVmax) in
these four regions. In 2 patients no lesion was found on both
scans. All lesions detected by 18F-choline PET/ CTwere also
seen by 68Ga-PSMA PET/CT. In 68Ga-PSMA PET/CT
SUVmax was clearly (>10 %) higher in 19 lesions and the
tumour to background ratio was clearly (>10 %) higher in 19
lesions when compared to 18F-choline PET/CT. Conclusions:
Our results indicate that 68Ga-PSMA PET/CT is better to
detect recurrence in patients with PC. Moreover, more number
of lesions and high SUVmax value, target to background ratio
and improved contrast is achienvd as compared to 18F-choline
PET/CT.
P093
Breslow thickness and 18F-FDG PET-CT result in initial
staging cutaneous melanoma: can a cut-off point be
established?
A. Ortega Candil, C. Rodriguez Rey, E. Cala Zuluaga, M.
Cabrera Martin, M. Perez Castejon, A. Jimenez Ballve, A.
Serrano Palacio, L. Leon Ramirez, C. Riola Parada, M. Garcia
Garcia-Esquinas, L. Lapeña Gutierrez, J. Carreras Delgado;
Clinico San Carlos Hospital, Madrid, SPAIN.
Aim: to establish a Breslow Thickness (BT) cut-off
point for indication of PET-CT in initial staging of cu-
taneous melanoma and evaluate its prognostic value.
Methods: retrospective analysis of 347 PET-CT studies
with diagnosis of melanoma undertaken in our institu-
tion from 01/01/2011 until 31/01/2015, 108 were initial
staging; 26 patients were excluded (6 metastases of un-
known origin, 16 non-cutaneous melanomas and 4 cases
with unknown BT) and a final sample of 82 patients
remained. To establish an optimal cut-off point, we un-
dertook a ROC curve analysis based on the Youden
index (J). For evaluation of prognostic value, a survival
analysis was done considering as main event death as-
signable to melanoma. Results: Forty nine (59.76%) of
all 82 patients selected were men and 16 (19.51%) had
a positive PET-CT result. Mean age was 64.89±15.61
years old. The mean BT in patients with a negative
PET-CT result was 3.73±2.82mm and in the positive
group 7.81±4.21mm (p=0.0016; t Student). In the ROC
curve analysis (AUC 0.843, SE 0.045) we obtained an
optimal value of 5 mm BT (J 0.725) with the following
values: sensitivity specificity 93.8%, 78.8%, NPV
98.1%, PPV 51.7%, diagnostic OR 55.7 and accuracy
81.7%. Median follow-up was of 1.48±1.17 years detect-
ing 2/53 (3.77%) deaths in BT<5mm group, and 9/29
(31.03%) in BT≥5mm group. Survival curves between
both groups were significantly different (Log-rank,
p=0.0003). Conclusions: BT average was significantly
higher in patients with positive PET-CT. A 5 mm cut-
off point correctly distinguishes those patients with pos-
itive PET-CT from those with negative results, reducing
the number of PET-CT studies by 64.63%. Patients with
BT≥5mm present a significantly worse prognosis.
P094
Positron Emission Tomography (PET) Imaging
of Chemokine Receptor CXCR4 in Patients with Solid
Cancers: First Results
T. Vag1, C. Gerngross1, U. Keller2, H. Wester3, M.
Schwaiger1; 1Clinic of Nuclear Medicine, Klinikum Rechts
der Isar, Munich, GERMANY, 2III Medical Department,
Klinikum Rechts der Isar, Munich, GERMANY, 3Institute of
Pharmaceutical Radiochemistry, Munich, GERMANY.
Objective: CXCR4 is a chemokine receptor that is
overexpressed in various human cancers and is involved
in tumor metastasis. The aim of this feasibility study was
to preliminary estimate the potential of CXCR4-targeted
Positron Emission Tomography (PET) as a novel diagnos-
tic modality in patients suffering from solid cancers. Ma-
terial and Methods: 21 patients with histologically proven
pancreatic cancer, laryngeal cancer, non-small cell lung
cancer (NSCLC), prostate cancer, melanoma, breast cancer,
hepatocellular carcinoma (HCC), glioblastoma, sarcoma or
cancer of unknown primary (CUP) underwent PET imag-
i n g u s i n g t h e n ov e l CXCR4 nuc l e a r p r o b e
[68Ga]pentixafor. Maximum standardized uptake values
(SUVmax) of the liver, spleen and bone marrow were
measured for determination of physiological tracer distribu-
tion. For evaluation of in vivo CXCR4 expression on tu-
mors, SUVmax and tumor-to-background ratios (T/B ratio)
were determined in a total of 43 malignant lesions includ-
ing 8 primary tumors, 3 local recurrent tumors and 32
metastases. When available, SUVmax of malignant lesions
was compared to corresponding SUVmax measured in
standard routine [18F]FDG PET. Results: Moderate tracer
uptake was detectable in the liver, bone marrow and
spleen with a mean SUVmax of 3.1, 3.7 and 5.6, respec-
tively. By visual interpretation criteria, 9 of 11 primary and
local recurrent tumors were detectable, exhibiting a mean
SUVmax of 4.7 (range 2.1 to 10.9) and a mean T/B ratio
of 2.9. 20 of 32 evaluated metastases were visually detect-
able (mean SUVmax of 4.5, range 3.2 to 13.8; mean T/B
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ratio of 2.8). Spearman’s correlation revealed a low corre-
lation between SUVmax and number of lesions per patient
(r=0.3). Compared to [18F]FDG PET additionally obtained
in 10 patients, tracer uptake in [68Ga]pentixafor PET re-
vealed a lower SUVmax in all measured malignant lesions.
Conclusion: PET Imaging of CXCR4 in patients with solid
cancers is feasible. Based on the experience gained within
this small number of patients, SUVmax of malignant solid
tumors seems to be in general lower in [68Ga]Pentixafor
PET compared to [18F]-FDG PET. Moreover, CXCR4 ex-
pression in solid malignancies seems to be highly hetero-
geneous depending on factors, that have to be elucidated
in further studies. CXCR4 expression profile could also
become interesting in near future, when considering
[68Ga]pentixafor as a selection marker for CXCR4 direct-
ed treatment.
P095
Colorectal pulmonary metastasis candidate to surgical
resection: Preoperative prognostic value of 18F-FDG
PET/CT SUVmax
E. Puta1, O. Rena2, F. Orsini1, L. Leva1, E. Papalia2, C.
Casadio2, G. Sacchetti1; 1Nuclear Medicine Department,
AOU “Maggiore della Carità”, Novara, ITALY, 2Thoracic Sur-
gery Department, AOU “Maggiore della Carità”, Novara,
ITALY.
Aim: Surgical resection is a well established therapy in pa-
tients with lung metastases. Literature data show that patients
with single metastasis and a disease-free interval (DFI)>2
years have the best survival rate. Currently there are no bio-
logical predicting factors affecting prognosis. 18F-FDG-PET/
CT imaging enables in-vivo visualization, characterization and
measurement of biological process in tumor at the molecular
and cellular level. The aim of this study was to evaluate the
prognostic value of 18F-FDG PET/CT SUVmax in patients
with colorectal lung metastasis submitted to surgical
resection.Materials and Methods: Forty-two consecutive pa-
tients (12♀, 30♂; age range 40-79 yr, mean 65) with colorectal
pulmonary metastases underwent 18F-FDG PET/CT from
2004 to 2012 prior to lung surgery. A total of 50 lesions were
removed. All 42 scans were reviewed. SUVmax of each lung
lesion was calculated. In patients with more than one lesion,
the highest SUVmax of all nodules was considered. In order to
identify factors affecting the long-term prognosis age, sex, 18F-
FDG-PET/CT SUVmax of lesions, DFI, preoperative serum
CEA level, number and size of resected metastases, type of
surgery and the presence of lymph nodes metastasis were ret-
rospectively analyzed.Results: 18F-FDG PET/CT SUVmax
was 7.13±5.1 (range 1-22, median 5.35). DFI was 30 months
(range 3-78). Preoperative CEA level>5 ng/dL occurred in 14/
24 cases. Lesion mean diameter was 2.4cm (range 1-5cm).
Wedge resection and lobectomy were performed in 40 and
10 lesions respectively. Mediastinal lymph nodes were sam-
pled in 28 cases with metastasis detection in 10/28. Five-year
disease free survival (DFS) and 5-year disease-correlated sur-
vival (DCS) were 48% and 55% respectively. According to
univariate analysis, factors favorably affecting prognosis were
single metastasis, DFI>24months, the absence of mediastinal
lymph node metastases and SUVmax<5.35. According to
multivariate analyses, independent prognostic factors were
single metastasis, DFI>24 months and SUVmax<5.35. Pa-
tients with DFI>24 months showed 5-year DFS of 65% and
5-year DCS of 68%. Patients with SUVmax<5.35 showed 5-
year DFS of 65% and 5-year DCS of 70%. Kaplan-Meier plot
demonstrated a significant lower 5-year DFS in patients with
preoperative SUVmax>5.35(Log-rank test P=0.018). Patients
with single metastasis (n=10), DFI>24 months and
SUVmax<5.35 (n=15), showed 5-year DFS of 72%.Conclu-
sion: According to our results the preoperative value of
SUVmax<5.35 in patients with colorectal lung metastases is
a significant independent prognostic factor affecting favorably
long-term survival. The combination of the three parameters
SUVmax<5.35, DFI>24months and single metastasis identify
the subgroup of patients with the best 5-year DFS.
P096
Correlation between Proliferation Index and Metabolic
Activity at the biopsy site in newly diagnosed NHL
V. Agarwal, B. SUNEETHA, S. PANDE; MEDANTA THE
MEDICITY HOSPITAL, GURGAON, INDIA.
Background: In recent years, positron emission tomography
(PET),particularly with [18F] fluorodeoxyglucose (FDG),
has emerged as an alternative to computed tomography (CT)
not only in treatment evaluation but also in the staging of
lymphomas. It enables the assessment of the extent of lympho-
ma with a higher sensitivity than that of CT. In lymphoma, Ki-
67 proliferating index (MIB-1 labeling index) indicates the
proliferation potential of tumor cells, which often affects the
prognosis. Although the correlation between the standardized
uptake value (SUV) on PET and the proliferation potential of
tumor cells has been reported in several tumors such as brain
tumors, head and neck cancer, lung cancer, and bone and soft
tissue tumors, only few studies have elucidated this in the case
of malignant lymphoma, which is one of the most sensitive
tumors to therapy. It is important to know the proliferation
potential and, in turn, determine the speed of tumor growth
to decide the appropriate regimen of initial chemotherapy.
Method: We did a retrospective study on the 47 patients (45
were aggressive lymphomas and 02 were mantle cell) referred
for initial staging of lymphoma to our nuclear medicine
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department in last 1 year. Inclusion criteria were newly diag-
nosed biopsy proven lymphoma with complete pretreatment
evaluation including history, physical examination and stan-
dard laboratory tests, Whole-body FDG PET/CT for pre-
treatment staging and biopsy samples evaluation using immu-
nohistochemical staining to look for Ki-67 expression. Recur-
rent cases of lymphoma were excluded. Results: All the cases
exhibited high SUVs at the site of biopsy (ranging from 8.8-
59.43) and high Ki-67 index, ranging from 40-100%. In 17 of
the 47 patients, the biopsy site was discordant with the maxi-
mum SUV site. In the remaining 30 patients, biopsy site and
the site for maximum SUV were same. Bx SUVmax showed
significant positive correlation with the Ki-67 proliferation
index (r=0.56; p < 0.01). Significant positive correlation was
also detected between the Bm SUV max and the Ki-67 prolif-
eration index (r=0.52; p < 0.01). Conclusion: The
BxSUV(max) correlated with the Ki-67 proliferation index,
and a correlation was detected as well between the maximum
SUVof the whole-body (BmSUV(max)) and the Ki-67 prolif-
eration index, indicating that tumor proliferation potential
might be predicted in vivo by FDG-PET/CT images and thus,
PET/CT may be useful to guide biopsy by selecting sites with
the BmSUV(max) when clinically appropriate.
P097
Complementary diagnostic role of Somatostatin Receptor
Scintigraphy (SRS) and 18-F-FDG-PET-CT
in neuroendocrine tumors management
M. Catalano, G. Annunziata, D. Scala, V. Ippolito; AORN,
Naples, ITALY.
Complementary diagnostic role of Somatostatin Receptor
Scintigraphy (SRS) and 18-F-FDG-PET-CT in neuroendo-
crine tumors management
Aim The complementary diagnostic role of Somatostatin Re-
ceptor Scintigraphy (SRS) and 18-F-FDG-PET-CT in patients
(pts) affected with neuroendocrine tumors (NET) was evalu-
ated correlating the proliferation index as determined by Ki67
to functional imaging data.
Materials and MethodsWe enrolled 41 pts (27 male, average
age 61.2 ± 12.6 ) affected with NET tumors (27 GEP , 11
pulmonary NET and 3 different origin NET) from October
2013 to December 2014. Pathological data (WHO 2010 clas-
sification) identified 14 pts, 17 pts, 10 pts as G1, G2, G3
respectively . They underwent to SRS and 18F-FDG-PET-
TC within about 40 days.
ResultsIn the first group SRS was positive in 9 pts (64%) and
negative in 5 pts (36%) whereas 18F-FDG PET-CT was
positive in 4 pts (29%) and negative in 10 pts (71%) ;
in the second group SRS was positive in 14 pts (82%)
and negative in 3 pts (18%) whereas 18F- FDG PET-CT
was positive in 9 pts (53%) and negative in 8 pts (47%)
; in the third group SRS was positive in 4 pts (40%)
and negative in 6 pts (60%) while FDG PET-CT was
positive in 8 pts (80%) and negative in 2 pts (20%).
According to literature data, in NET G1 SRS has a
better diagnostic accuracy than 18F-FDG PET-CT. On
the other hand FDG PET-TC was able to better recog-
nize tumor and metastasis in NET G3. In the pts cate-
gorized as NET G2, we found positive SRS and some-
times unexpected positive FDG PET-CT and the number
of positive and negative PET scan was the same.
Conclusion The real sensitivity of 18F-FDG PET-CT in
NET management has not been enough investigated. Be-
yond the 18F-FDG PET-CT affirmed role in G3 NET
staging and restaging, it can become a routine investiga-
tion method in G2 NET because heterogeneous
phatological data are not able to characterize tumor bi-
ology and the linked therapeutic approach. Instead NET
tumor characteristics can be well highlighted by 18F-
FDG-PET-CT and SRS functional imaging. Furthermore
FDG PET-CTscan positivity could perhaps identify more
aggressive tumors.
P098
A Comparison between PET/CT and CT in Head&Neck
Radiotherapy Treatment Planning
O. Ferrando1, F. Foppiano1, T. Scolaro2, A. Ciarmiello3;
1Medical Physics Department, St Andrea Hospital - ASL5
Spezzino, La Spezia, ITALY, 2Radiotherapy Department, St
Andrea Hospital - ASL5 Spezzino, La Spezia, ITALY, 3Nucle-
ar Medicine Department, St Andrea Hospital - ASL5
Spezzino, La Spezia, ITALY
Aims. The present study aims to evaluate the added value of
PET/CT respect to conventional CT in radiotherapy treatment
planning of head and neck tumours.
Methods and Materials. We have selected and analysed a set
of 18 patients with histological diagnosis of head and neck
cancer who underwent conformal-3D Radiotherapy. Patients
were divided in three categories of head and neck disease:
oropharyngeal, laryngeal and oral cavity cancer. PET/CTscans
were performed in the treatment position. Gross tumor vol-
umes were delineated on CT images by an expert radiation
oncologist blinded to PET data. Successively another set of
target volumes was defined taking into account the combined
PET/CT information. The CT and PET/CT volumes were
compared at the aim to validate the hypothesis of a more ac-
curate target definition in PET/CT. The study also analysed
how the therapeutic scheme in terms of total dose and irradi-
ated volumes can be changed by PET information.
Results. In the cohort of analysed patients 4 had the nodal
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stage changed from N0 to N+ when small lymph nodes iden-
tified on CT scans as insignificant were found to be FDG avid
on PET/CT. 1 patient had negative PET/CT and for 1 patient
PET reveals distant metastasis. For two patients gross tumour
volumes should not being identified without PET information.
Mean values of PET/CT gross tumour volumes were smaller
than CT volumes: 109 ±110 cm3 versus 130 ± 98 cm3 (p <
0.015). The mismatching fraction between CT volumes and
PET/CT volumeswas 0.41. From the therapeutic point of view
for 14 patients the total therapeutic dose was not changed by
PET data but the irradiated volumes in PET-CT based treat-
ment and CT-based treatment are different. Two patients had
the total therapeutic dose changed by PET/CT information.
BTV (biological target volume) identified by PETwas boosted
in 5 patients for whom a focal dose escalation was considered
clinically relevant.Conclusions. In radiotherapy treatment
planning of head and neck disease PET/CT compared with
CT provide a more precise target definition and prevent exclu-
sion of pathologic areas not detectable on CT. In our popula-
tion addition of PET information to CT lead to a modification
of the irradiated target in 61% of the patients analysed. The
ability of PET/CT to identify the metabolic part of the tumour
allows a dose escalation focused on the more aggressive part
of the disease..
P099
3DVolumetric lymph node assessment based on CT versus
PSMA11-PET/CT in recurrent prostate cancer
F. Giesel1, F. Sterzing2, H. Fiedler1, M. Rius3, M. Stefanova1,
A. Afshar-Oromieh1, K. Kopka4, J. Debus2, U. Haberkorn1, C.
Kra tochwi l 1 ; 1Rad io log i sche Kl in ik / Ab t . fü r
Nuklearmedizin, Heidelberg, GERMANY, 2Radiologische
Klinik / Abt. für Strahlentherapie, Heidelberg, GERMANY,
3Joint Research Centre – Institute for Transuranium Elements,
Karlsruhe, GERMANY, 4Deutsches Krebsforschungszentrum
(DKFZ) / Abteilung für Radiopharmazeutische Chemie, Hei-
delberg, GERMANY.
AIM: PSMA11-PET/CT is a powerful new method of detect-
ing early nodal metastases in recurrent prostate cancer. The
purpose of this retrospective investigation was to evaluate
the volume and dimensions of nodes identified by Glu-urea-
Lys-(Ahx)-[68Ga(HBED-CC)] (68Ga- PSMA-11) in the set-
ting of recurrent prostate cancer. MATERIAL & METHODS:
All PET/CT image acquisitions were performed 60 ± 10 mi-
nutes after i.v. injection of 68Ga- PSMA-11 (mean dose 176
MBq). Forty nine PSMA-positive lymph nodes were identi-
fied in 21 patients with recurrent prostate cancer and rising
PSA. Using a semi-automated lymph node segmentation soft-
ware (MeVis, Bremen, GER), node volume and short and long
axis dimensions were measured and compared to the
maximum standardized uptake values (SUVmax). Round
nodes greater than or equal to 0.8cm were considered positive
by morphologic criteria alone. The percentage of nodes iden-
tified by elevated SUVmax but not by conventional morpho-
logic criteria was determined. RESULTS: The mean volume
of 68Ga-PSMA-positive nodes was 0,5 ml (range 2,3-0,2mL);
mean short axis diameter was 5,8mm (range 2,4-13,3mm). In
7 patients (33,3%) with 31 PSMA positive nodes only
11(36%) were morphologically positive based on diameters
>8mm on CT. In the remaining 14 patients (66,6%) 18
(37%) of PSMA positive lymph nodes had short axis diame-
ters <8mmwith a mean short axis diameter of 5,0mm (range 2,
4-7,9). Moderate correlations of SUVmax were observed with
node diameter, volume and PSA level. Thus, in this Population
68Ga-PSMA-PET/CT detected nodal recurrence in two thirds
of patients who would have been missed by conventional mor-
phologic criteria. CONCLUSION: 68Ga-PSMA-11 PET is
more sensitive than CT based 3D volumetric lymph node eval-
uation in determining the node status of patients with recurrent
prostate cancer and is a promisingmethod of restaging prostate
cancers in this setting.
P100
FDG uptake quantification: comparison of different
delineation strategies and software platforms
A. de Jong1, B. A. Blomberg1, R. A. Nievelstein1, V. Frings1,
G. Kramer2, A. J. de Langen2, O. S. Hoekstra2, R. Boellaard2;
1UMC Utrecht, Utrecht, NETHERLANDS, 2VU Medical
Center, Amsterdam, NETHERLANDS.
AimTo determine the accuracy of different tumor delineation
strategies and software platforms to derive FDG uptake
parameters.Materials and methodsMaximum, mean and peak
standardized uptake values (SUVmax, SUVmean and
SUVpeak), metabolic active tumor volume (MATV) and total
lesion glycolysis (TLG) were determined in the NEMA NU 2
Image Quality phantom, and in eight FDG whole-body PET/
CTscans of therapy-naïve non-small-cell lung cancer patients.
The phantom study was performed according to EARL spec-
ifications, and patients were examined following the EANM
FDG PET/CT guidelines (Boellaard et al EJNMMI 2015; 42:
328-54). Uptake parameters were determined using a 50%
isocontour with background correction (A50%) as implement-
ed in four different software platforms: ROVER (ABX soft-
ware, Radeberg, Germany), KEOSYS (Keosys, Saint-
Herblain, France) and two custom tools developed at the VU
Medical Center. One of these tools attempts to enhance delin-
eation workflow using a new approach based on initiating
tumor delineation directly on the PETmaximum intensity pro-
jections (MIPs).ResultsFor the phantom study there were no
differences in SUVmax between the various tools. For
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SUVmean and SUVpeak differences up to 15% were found,
while MATV and TLG differed up to 47% and 37%, respec-
tively. In the clinical studies, differences were found for
SUVmax up to 3%, SUV mean up to 7%, SUVpeak up to
16%, MATV up to 28% and TLG up to 23%.ConclusionFor
most uptake parameters large differences were found between
the various software platforms, despite using a similar delin-
eation method. This study reveals that only SUVmax can be
obtained reliably in a multivendor software platform setting.
There is an urgent need for standardizing software platforms
before MATV and TLG can be used as quantitative imaging
biomarkers in a multisoftware setting.
P101
Sequential dynamic PET and dynamic MR imaging
in N-staging of lung cancer patients
P. Flechsig, D. Rath, C. Heußel, C. Kratochwil, H. Kauczor,
U. Haberkorn, F. Giesel; University Hospital Heidelberg, Hei-
delberg, GERMANY.
Purpose:For therapy stratifications, staging of lung cancer
is typically performed with FDG-PET/CT. In the context
of new established integrated PET/MR-scanners, the
combination of well-established dynamic contrast en-
hanced (DCE) MRI imaging with dynamic PET might
be an upcoming imaging modality. In order to evaluate
potential perfusion changes between benign and malig-
nant lymph nodes in lung cancer patients, DCE MRI
was correlated to microcirculatory and sub cellular dy-
namic parameters in FDG-PET/CT.Materials and
Methods:According to the clinical routine, a total number
of 14 patients with lung cancer were examined sequen-
tially with FDG-PET/CT (Siemens Biograph 6) and DCE
MRI (Gadovist®, Bayer, Germany; Siemens Magnetom
Aera, 1,5T) prior to surgery. Findings were correlated to
the histological gold standard.Results:14 lymph nodes
(six malignant, eight benign) could clearly be histological
analyzed and were correlated with findings in MRI and
PET/CT. In DCE MRI, malignant lymph nodes showed
early and generally increased perfusion values compared
to benign ones, with typical signs for washout 60 seconds
after contrast injection. Benign lymph node reached the
typically plateau phase after 60 seconds with steady state
during the first 180 seconds.This correlated well with
microcirculatory and sub cellular parameters in dynamic
PET according to a two compartment model, especially
with changes in k3 and k4.Conclusion:The sub cellular
parameters k3 and k4 in dynamic PET are correlating
with changes in DCE MRI, indicating k3 and k4 as po-
tential surrogate parameter for malignant lymph node in-
filtration in lung cancer patients.
P102
Development of PET in Europe
A. Stevens; Medical Options, London, UNITED KINGDOM.
AIMS: To track the development of PET in Europe. The
provision of PET and PET/CT in Europe is extremely
heterogeneous with a large variation in scans per head
of population between countries; while within countries
workload varies widely between different providers. The
high level of variation between facilities, the number of
new installations and the rapid growth in workload at
existing sites precluded a sampling approach and re-
quired identification of all European PET providers.
MATERIALS AND METHODS: Facilities with PET,
PET/CT and or cyclotron(s) were identified from a num-
ber of sources including records of the IAEA, manufac-
turers of diagnostic equipment and sites providing nucle-
ar medicine services. Sites were invited to describe their
operation including their equipment profile, the number
and types of patient studies performed and their use of
radiotracers. We were able to identify over 95% of the
PET, PET/CT and cyclotrons operating in Europe. Over
65% of these sites provided workload numbers for 2014.
To project total workload we employed a segmentation
scheme for each country or region which identified ten
types of facility allowing us to estimate more accurately
patient numbers at sites who did not contribute work-
load data. RESULTS: In 2014 there were 680 providers
of PET and/or PET/CT in Europe of which 18 were
mobile. PET/CT accounted for 93% of the installed sys-
tems. PET cameras were located primarily in research
departments and in countries where reimbursement or
replacement was regulated. PET/MR accounted for
3.6% of systems. FDG accounted for 93% of the stud-
ies. 91.0% were oncology, 4.6% neurology and 3.5%
infection or inflammation. Fluorinated molecules made
up the majority (51%) of other compounds and are used
at ~63% of sites. F-Choline accounted for 62% of these
fluorinated studies. Gallium 17%, buoyed by the intro-
duction of PMSA, and Carbon 16% were the other sig-
nificant nuclei in use. Scan numbers rose by 20.7%
from the 1.27m scans estimated for 2012 versus 27.1%
between 2010 and 2012. There are wide variations
across Europe both in terms of scans performed and
patient throughput. In some cases this is due to reim-
bursement and in others working practices and patient
catchment.CONCLUSIONS: Across Europe there is an
opportunity to double the use of FDG if the proportion
of patients in regions with low adoption meets that of
high adopters. The growing use of compounds other
than FDG bodes well for the introduction of new mo-
lecular entities over the coming years.
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Feasibility of Accelerating Yttrium-90 PET by Optimizing
PET Volume Overlap
J. Zhang1, C. Wright1, K. Binzel1, E. J. Wuthrick1, P.
Maniawski2, M. V. Knopp1; 1The Ohio State University, Co-
lumbus, OH, UNITED STATES, 2Philips Healthcare, Cleve-
land, OH, UNITED STATES.
Objectives: Yttrium-90 (90Y) microsphere radioembolization is in-
creasingly being used as targeted treatment of unresectable liver
malignancies. Nowadays while SPECT of 90Y bremsstrahlung is
still the standard imagingmodality for biodistribution, PET has also
been utilized for post-radioembolization imaging for better spatial
resolution and improved quantification however being limited by
long table time due to that is predominantly aβ− emitter. This study
investigated the feasibility of accelerating PET by reducing and
optimizing PET volume overlap to further improve patient
comfort.Methods: An ongoing clinical validation trial was initiated
to perform and proof the feasibility of reducing PET volume over-
lap for 90Y imaging. PET/CTof 5 patients in 26±2 hours post 90Y
microsphere radioembolization (3.1±0.2 GBq into hepatic lobes)
were performed on a Gemini TF 64 system (Philips Healthcare)
with 7min/bed from diaphragm downwards to cover the entire liver
under 40% and 20% PET overlaps, respectively. All coincidence
eventswere recorded in listmode. PETdatawas reconstructed using
a 3DTOFOSEMalgorithmwith a voxel size of 4 x 4 x 4mm3 in a
144 x 144matrix. Images were blinded reviewed by a reader panel.
Quantitative assessment of volumes and total activity of 90Y mi-
crosphere biodistributions for each of the PET data sets was
performed.Results: The 90Y PET data demonstrated no significant
impact on the visual grade between 40% overlap and 20% overlap.
The 20% overlap PET for the given FOV saved ~33% table time
compared to using 40%overlap. Quantitative volume segmentation
assessment resulted in equivalent volume determinations of 90Y
biodistributions (variances=0.5%±5.0%). No significant counts var-
i a n c e s w e r e f o u n d b e tw e e n b o t h PET s c a n s
(variances=0.5%±1.3%).Conclusions: 90Y PET imaging can be
considerably accelerated by reducing PET volume overlap as is
clinically demonstrated in this trial without degradation of image
quality or significantly impact on quantification. Further validation
byoptimizingPEToverlap togetherwith appropriate usage of frame
duration is ongoing with the goal of improving image quality with
less motion artifacts and shortest patient table time.
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Role of 18F-FDG PET/CT and a new score system
to measure the pre-test clinical risk in patients suspected
of paraneoplastic neurological syndrome
F. J. Pena Pardo1, A. Palomar Muñoz1, A. M. García
Vicente1, C. H. Vega Caicedo1, M. Amo Salas2, J. F. López-
Fidalgo2, J. A. Garrido Robles3, J. Á. de Ayala Fernández4, P.
del Saz Saucedo5, M. Muñoz Pasadas6, Á. M. Soriano
Castrejón1; 1Nuclear Medicine Sv. Hospital General
Universitario, Ciudad Real, SPAIN, 2Mathematics Dep.
Universidad de Castilla La Mancha, Ciudad Real, SPAIN,
3Neurology Sv. Complejo Hospitalario de Toledo, Toledo,
SPAIN, 4Internal Medicine Sv. Complejo Hospitalario de Al-
bacete, Albacete, SPAIN, 5Neurology Sv. Hospital la Mancha
Centro, Alcázar de San Juan (Ciudad Real), SPAIN, 6Neurol-
ogy Sv. Hospital de Puertollano, Puertollano (Ciudad Real),
SPAIN.
AIM: To assess the diagnostic impact of 18F-FDG PET/CT in
patients suspected of paraneoplastic neurological syndrome
(PNS) based on our own pre-test risk score (PRS) system. MA-
TERIAL AND METHODS: A multicenter retrospective longi-
tudinal study of patients with suspicion of PNS from 2006 to
2014 was conducted. The clinical pictures were classified into
classical (CS) and non-classical syndromes (NCS). The location
of nervous system disorder was recorded as central, peripheral, in
the neuromuscular junction or combined. Onconeural antibodies
(and their type) and tumour markers were registered, when avail-
able.We designed a seven-point scoring system using the clinical
syndrome characteristics and its location, onconeural antibodies
and tumour markers. Patients were classified as low (PRS 0-2),
intermediate (3-4) and high (5-7) risk of PNS. FDG-PET/CT
imaging assessment was performed classifying the studies as:
normal, probably malignant or indeterminate (difficult to estab-
lish its correspondence with malignancy or inflammation). Final
diagnosis according Graus’ criteria (definite, possible or no PNS)
was established after a minimal follow-up of 12 months from
the PET/CT. Relation between clinical and PET/CT results
was studied. RESULTS: 73 patients (47M/26F) with a mean
age of 61 years (19-83) were included, with a follow-up time
of 33 months (12-96). Eleven (15%) patients were finally
diagnosed with neoplasm (8 invasive cancers). Ultimately,
13 (18%) and 24 (33%) subjects were diagnosed as definite
or possible PNS (36 non-PNS). All the patients with final
diagnosis of neoplasm had a CS (p=0.005). A significant
relationship between location of neurological disorder and
diagnosis of definite or possible PNS was also noticed, with
a higher prevalence of central involvement with respect to
non-PNS. PET/CT was helpful to diagnose 6/8 (75%) inva-
sive cancers. PET/CT findings were associated with the final
diagnosis of neoplasm (p=0.003) and the diagnosis of PNS
attending to Graus’ criteria (p=0.019). PRS showed signifi-
cant association with final diagnosis of neoplasm. All the
patients diagnosed of neoplasm had intermediate/high risk
(p=0.001). There was also association with PET/CT
(p<0.001) with a higher proportion of intermediate/high risk
cases in probably malignant PET/CT comparing with negative
or indeterminate results (6/7, 28/48 and 6/18 respectively).
CONCLUSION: PET/CT detected malignancy in a
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significant proportion of patients with invasive cancer. Our
PRS seems to be a valid tool to select candidates for PET/
CT imaging in this setting.
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Repeatability of Quantitative [18F]Fluoromethylcholine
PET/CT Measurements in Prostate Cancer
D. E. Oprea-Lager, G. M. Kramer, P. M. van de Ven, A. J. M.
van den Eertwegh, R. J. A. van Moorselaar, O. S. Hoekstra, A.
A. Lammertsma, R. Boellaard; VUUniversityMedical Center,
Amsterdam, NETHERLANDS.
Aim: Quantification is essential for monitoring treatment re-
sponse in prostate cancer (PC) using [18F]fluoromethylcholine
([18F]FCH) PET/CT. Recently, it has been reported that SUV
normalized to the area under the curve of the blood activity
concentration (SUVAUC) provides better correlation with full
kinetic analysis than standard SUV (Verwer et al, JNM 2015).
However, precision of SUVAUC (and SUV) is not known yet.
The purpose of this study was to assess repeatability of various
quantitative [18F]FCH parameters in PC.
Material andMethods: Twelve patients (64±8 years) with me-
tastasized PC underwent 2 sets of [18F]FCH PET/CT scans on
two successive days. Each set consisted of a 30 minutes dy-
namic scan of the chest followed by a whole body (WB) PET/
CT scan, 40 minutes post injection (p.i.). Patients received
200 MBq [18F]FCH at the start of the dynamic scan. This scan
was used to derive the AUC of the blood activity concentration.
Next, lesion uptake was derived from the WB scan using var-
ious volumes of interest (VOI): maximum, peak and mean.
SUVmean was obtained using a background corrected 50%
of maximum isocontour. Each of these parameters was normal-
ized to injected activity/weight, AUC of blood activity concen-
tration and blood concentration at 40 minutes p.i. itself,
resulting in SUV, SUVAUC and SUVTBR. Test-retest repeatabil-
ity of these metrics was studied as function of VOI, VOI size,
tissue type (bone/ lymph node) and anatomical localization
(intrathoracically/ abdominal). Repeatability coefficients were
defined as 1.96 times the standard deviation of the percent
differences between test and retest data.
Results: We identified 67 choline avid metastases, 44 bone and
23 lymph node lesions, mean 4±2 per patient. 12 metastases
were localized intrathoracically. In case of SUVmax, repeatabil-
ity coefficients for SUV, SUVAUC and SUVTBR were 26, 30
and 45%, respectively. Similar values were obtained for
SUVpeak and SUVmean. Moreover, tissue type and tumour lo-
calization did not affect repeatability. VOIs > 5 cm3 had com-
parable repeatability with the smaller ones (30 versus 40%,
p=0.267). Repeatability did not differ between lesions with
SUVmax > 10 and SUVmax < 10 (22 versus 28%, p=0.265).
The repeatability of SUVAUC for maximum, peak and mean
values were comparable with those of SUV.
Conclusion: The repeatability of SUVAUC was comparable to
that of SUVand indicated that [18F]FCH PET/CT uptake differ-
ences of 30% or more are likely to represent treatment effects.
Observed repeatabilities are within the range seen with other
commonly used radiotracers, such as [18F]FDG and [18F]FLT.
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Effect of motion in the quantification of lesion
heterogeneity with Positron Emission Tomography
M. Carles1, U. Nestle1, A. Schaefer2; 1Department of Radia-
tion Oncology, University Medical Center, 79106 Freiburg,
Germany, Freiburg, GERMANY, 2Department of Nuclear
Medicine, Saarland University Medical Center, D-66421
Homburg, Germany, Freiburg, GERMANY.
The aim of this work was to study the effect of motion on the
reproducibility of heterogeneity features derived from Positron
Emission Tomography (PET). For the measurements we
employed four spheres with fluordeoxyglucose (FDG) solu-
tion inserted within a NEMA phantom: one commercial
fillable glass insert (G) and three homemade alginate phan-
toms (A). The FDG concentrations (C) were C1=36kBq/ml,
C2=18kBq/ml and C3= 8kBq/ml and the background was set
to Bg=1.7kBq/ml. Two spheres with diameter φ=37mm pre-
sented FDG uptake of C1: glass insert (G.C1) and an alginate
phantom (A.C1). Each of the other two alginate inserts was
composed by two concentric spheres (ϕin=10mm, Cin and
ϕout=37mm, Cout) with different activity concentrations
(A.CinCout: A.C1C2 and A.C1C3). Three different measure-
ments were carried out: 1 static and 2 dynamic with irregular
breathing patterns (P1 and P2) which were generated by use of
a respiratory motion platform (QUASAR by Modus). The pa-
rameters for heterogeneity quantification were derived from
the volume segmented with a threshold of 40% of the maxi-
mum intensity. Heterogeneity quantification involved: coeffi-
cient of covariance(COV), Skewness(Sk), Kurtosis(Kr) and
Intensity-Volume(IV90-IV10/μ), derived from the intensity
h i s t o g r am ; and ene rgy (E ) , c o n t r a s t (C ) , l o c a l
homogeneity(LH) and entropy(S), derived from the co-
ocurrence matrix (with intensity levels M=32, between con-
secutive voxels d=1 and along the 26 connected neighborhood
in 3D space). These 8 features (F) were measured on the
ungated (UN-) image and each of the 10 retrospectively gated
(4D-) frames resulting from each of the dynamic measure-
ments and on the image resulting from the static measurement
(ST-). The comparison of the heterogeneity quantification ob-
tained for different target movements (UNP1 vs UNP2, 4DP1
vs 4DP2) showed reproducibility in 2/8 features with UN-
image (Sk: p<0.01, Δ=100(FP1-FP2)/(( FP1+FP2)/2)=37
±8% and Kr: p<0.01, Δ=7±3%) and in 6/8 with 4D-image
(Sk: p<0.05, Δ=1±2%; Kr: p<0.02, Δ=0±1%; E: p=0.02,
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Δ=4±2%; C: p<0.02,Δ=1±2%; LH: p<0.02,Δ=0±1% and S:
p<0.01, Δ=1±1%). The ranking of heterogeneity (phantoms
ordered from 1 to 4 based on feature values) obtained in ST-
image quantification was reproduced in 4D-quantification by
Sk, Kr, E and LH. The variability (SD/μ:standard deviation/
mean) observed among the 4D-frames was: Sk 0.02-0.05, Kr
0.27-7.8, E 0.10-0.23 and LH 0.04-0.09. These results allow
the conclusion that compared to UN-imaging the impact of
motion on quantification of lesion heterogeneity is significant-
ly minimized in 4D-imaging. Furthermore, the reproducibility
obtained for Sk, Kr, E and S with 4D-images allows to recom-
mend their use for heterogeneity quantification in lesions af-
fected by respiratory motion.
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Comparison between Gallium-68 citrate PET-CT
and Gallium-67 citrate scintigraphy for infection imaging
T. Segard1, L. Morandeau1, M. Dunne2, O. Robinson2, R.
Murray1, E. Geelhoed3, R. J. Francis3; 1Sir Charles Gairdner
Hospital, Nedlands, AUSTRALIA, 2Royal Perth Hospital,
Perth, AUSTRALIA, 3University of Western Australia,
Crawley, AUSTRALIA.
Aim: Preliminary studies have reported promising results for
the utility of Gallium (Ga)-68 citrate PET-CT for infection
imaging. There are several potential benefits of Ga-68 citrate
PET-CTover the current ’gold standard’ nuclear imaging tech-
nique Ga-67 citrate scintigraphy: reduced radiation dose to
patients, shorter time between injection and imaging and re-
duced time for image acquisition. The aim of this study was to
prospectively evaluate Ga-68 citrate PET-CT, in a multicentre
public hospital setting and to compare it with Ga-67 citrate
scintigraphy to ascertain whether Ga-68 citrate PET-CT is of
equivalent diagnostic efficacy for bone and joint infection or
pyrexia of unknown origin (PUO) and to assess image quality
and reporter confidence for the interpretation of Ga-68 citrate
PET-CT compared to Ga-67 citrate scintigraphy.Materials and
methods: Patients with PUO and suspected bone or joint in-
fection were eligible for enrolment. In addition to planar
wholebody and SPECT-CT images obtained 48 to 72h follow-
ing Ga-67 citrate administration, patients were injected with
98MBq of Ga-68 citrate for PUO and imaged 1h after from
vertex to below knees or 140MBq for bone and joint infection
with localised PET-CT imaging at the site of suspected infec-
tion. Patients were followed up for 3 months post-imaging to
record subsequent treatment and results: antibiotic therapy,
surgery, biopsy results when performed, radiological and clin-
ical responses to therapy.Results: Sixty patients have been re-
cruited: thirty-two for bone and joint infection, twenty-eight
for PUO. The results show an overall sensitivity of 81% for
Ga-67 citrate scintigraphy and 69% for Ga-68 citrate PET-CT
imaging. The specificity was 79% for Ga-67 citrate and 67%
for Ga-68 citrate. The results were concordant for 76% of the
participants. Analysis of reporting physician confidence scores
for the diagnosis of infection demonstrated significantly lower
confidence for Ga-68 citrate than Ga-67 citrate imaging
(p<0.05). Reduced Ga-68 PET-CT reporter confidence was
frequently due to prominent physiologic blood pool activity
adjacent to the site of infection.Conclusion: In our study, the
sensitivity and specificity obtained with Ga-68 citrate PET-CT
for the detection of bone and joint infection or PUOwas found
to be consistently lower than with Ga-67 citrate scintigraphy,
although this relationship did not reach significance. Addition-
ally, due to the insufficient level of confidence of the reporting
physicians for the Ga-68 citrate studies, this imaging technique
could not currently be recommended to replace Ga-67 scintig-
raphy for routine clinical practice.This study was supported by
a WA SHRAC research grant.
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Do LargerMatrix Sizes in Positron Emission Tomography
always result in Increased Image Noise?
C. McKeown, G. Gillen, M. Dempsey, C. Findlay; NHS
GG&C, GLASGOW, UNITED KINGDOM.
Aim: As part of a PET image quality assessment it was found
that reconstructions with a 256 matrix had lower noise values,
as assessed by the Coefficient of Variation (COV), than a 192
matrix - a surprising result. The aim of this study was to de-
termine the combined effect of altering post reconstruction
filter width and matrix size on image noise.
Materials and Methods: A uniform 68Ge flood phantom was
used to assess COVon images produced using a GEDiscovery
690 PET-CT system. Post-reconstruction Gaussian filter full
width half maximum (FWHM) was varied between 0mm
and 10mm. Reconstructed field of view (FOV) was fixed at
700mm with 128, 192 and 256 matrices applied. Other recon-
struction parameters were also examined to determine if they
affected the relative noise performance of the different matrix
sizes - effective iterations were varied between 18 and 540,
and reconstructions were repeated with/without Time of Flight
(TOF) and with/without Point Spread Function correction
(PSF).
Results: Relative COV for the three matrix sizes behaved as
expected at low filter widths (FWHM 0 - 2mm). The 256
matrix produced the highest COVs and the 128 matrix pro-
duced the lowest. From an example reconstruction using TOF
+PSFwith 54 effective iterations: COV256 = 13.7%, COV192 =
13.1% and COV128 = 11.4%. When the filter width was be-
tween 2mm and 4mm, the relative COV of the three matrix
sizes became unpredictable - larger matrix sizes did not always
produce the largest COV results. For example: FWHM =
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3mm, COV256 (11.9%) was less than COV192 (12.6%). When
the filter width was between 4mm and 8mm, the relative
COVs of the three matrix sizes were the reverse of expected
i.e. COV128 were highest and COV256 were lowest. For exam-
ple: FWHM = 5mm, COV256 = 8.9%, COV192= 9.1%.
COV128= 10.2%. All matrix sizes produced very similar
COVs for FWHM above 8mm. All relative COV results were
consistent regardless of the number of iterations or the appli-
cation of TOF and/or PSF. The relative differences became
more pronounced, however, as the number of iterations in-
creased (i.e. at higher overall noise levels). Conclusions: The
relationship between image noise and matrix size is not
straightforward when post reconstruction filtering is applied.
Care is therefore required when different matrix sizes are used
clinically.
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Influence of Slice Overlap on Positron Emission
Tomography Image Quality
C. McKeown, G. Gillen, M. Dempsey, C. Findlay; NHS
GG&C, GLASGOW, UNITED KINGDOM.
Aim: PET scans are acquired using overlapping frames to
correct for reduced sensitivity at frame edges. Some vendors
have fixed overlapswhile others allow operators to select over-
lap size. The optimum overlap for the GE Discovery 690 has
not been established. This study aims to assess how image
quality is affected by slice overlap. In particular it compares
a 23% overlap with the maximum 49% overlap, with reference
to recent EANM guidelines.
Materials and Methods: A uniform flood phantom was used
to assess noise (Coefficient of Variation, COV) and voxel ac-
curacy (activity concentrations, Bq/ml). A NEMA body phan-
tomwith hot/cold spheres in a background activity was used to
assess mean Contrast Recovery Coefficients (CRCs) and Sig-
nal to Noise Ratios (SNR). Hot sphere phantoms were filled
using both 4:1 and 2:1 sphere-to-background ratios.
Results: COVs for 49% and 23% overlaps were 10% and 13%
respectively. This increased noise was difficult to visualise on
the 23% overlap images. Mean voxel activity concentrations
were not affected by overlap size. No clinically significant
differences in hot or cold CRCs were observed as the overlap
was altered, regardless of sphere-to-background ratio or phan-
tom activity. Visualisation and SNR of low contrast small
spheres, however, may be affected by overlap size in low
count studies. The 2:1 ratio 13mm diameter sphere was visible
on 5/6 acquisitions with 49% overlap (average SNR = 6.4) but
was only visible on 3/6 acquisitions with 23% overlap (aver-
age SNR = 3.9). However, detectability of the 13mm sphere
was only affected when the phantom background activities
were below those typically observed in patient livers. EANM
guidelines for weight-based FDG administrations suggest that
minimum injected activities should be doubled when <30%
overlap is used. This experiment demonstrated little difference
in image quality either side of this 30% overlap threshold.
Conclusions: There was minimal detectable influence on im-
age quality in terms of noise, mean activity concentrations or
mean CRCs when comparing 23% overlap with 49% overlap.
Detectability of small, low contrast lesions may be affected in
low count studies - however, this is a worst-case scenario. The
marginal benefits of increasing overlap from 23% to 49% are
likely to be offset by the disadvantages of increased patient
scan times. A 23% overlap is therefore appropriate for clinical
use for the GE Discovery 690. The 30% overlap threshold
suggested by EANM guidelines when calculating weight-
based FDG administrations may require revision.
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Normalized uptake fraction: a new approach for image
quantification
P. Alves1,2, A. F. Silva3, M. F. Botelho1; 1Faculty of Medicine,
University of Coimbra, Coimbra, PORTUGAL, 2IPOCFG,
Coimbra, PORTUGAL, 3IEETA, University of Aveiro,
Aveiro, PORTUGAL.
Aim: Functional imaging has become a valuable tool in On-
cology although quantification remains a controversial issue.
SUVis affected bymultiple variables, making difficult to com-
pare exams from different patients and different labs or to use
in radiotherapy planning. Our goal was the development of a
new methodology for quantification that, despite remaining
semi-quantitative, is less operator’s dependent.Material and
Methods: We studied 32 women with locally advanced cervi-
cal cancer, with 18F-FDG PET/CT pre-radiochemotherapy.
PET/CT came from two different labs. Radiotherapy volumes
(GTV) were obtained, using Velocity AI®, by two indepen-
dent experts, in a blind study, from anatomic data and from
functional imaging. Images were included in MEVISLAB®
platform and we obtain parametric images of the distribution
of, what we called, normalized uptake fraction (NUF).Results:
Statistical analysis of GTV’s showed a strong positive corre-
lation, with statistical significance. However it seems that
functional information had no impact in final volume delinea-
tion, at least for planning purposes. Our PET/CT images had
great variability in acquisition methodology, as well as SUV
calculations and reports, and it seems necessary to develop a
new procedure of quantification. We calculate a normalized
uptake fraction per voxel (NUF) and build a parametric image
of its distribution. The visualization of NUF images was fur-
ther conditioned by a lower bound corresponding to the aver-
age NUF values at the thigh muscles, which were excluded of
the visualization. This approach allows to obtain parametric
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images of NUF distribution per voxel, with visual optimiza-
tion, including re-sampling with 3D reconstruction.The prob-
lem of bladder radiotracer retention was solved by a bladder
mask delineated on CT images constructed from 3D interpo-
lation of sectional contours and posterior subtraction.Besides
standard planar views, a re-sampling with 3D reconstruction
was performed which was the major point of interest among
experts. The new visualization method allowed the observers
to select the best scenarios, and it seems consistent in evaluat-
ing areas of uptake related to metabolism of tumor and lym-
phatics, with excellent topographic orientation.Images of NUF
distribution per voxel, corresponding to tumor volume, trans-
lated heterogeneous metabolism of 18F-FDG, matching with
the concept of biological conformality.Conclusions: We ob-
tained a new approach, through visual navigation in PET/
CT-mode after NUF application that allows the analysis of
quantification images of PET/CT, from different patients and
different equipments, without the controversial ROI or VOI
definition and respective SUV calculation. For radiotherapy
planning the proposed method seems to improve delineation.
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Influence of morphine exposure and withdrawal
on the brain kinetics of [18F]DPA-714 and classical
biomarkers of inflammation
S. AUVITY1, S. GOUTAL1, B. THEZE1, B. KUHNAST1, B.
HOSTEN2, W. SABA1, R. BOISGARD1, S. CISTERNINO3,
N. TOURNIER1; 1CEA, Orsay, FRANCE, 2INSERMU1144,
PARIS, FRANCE, 3INSERM U1144, Paris, FRANCE.
OBJECTIVES: Recently, studies have reported that morphine
analgesic effects may be modulated by the brain immune re-
sponse induced by morphine itself. This property was also
shown to promote tolerance and dependence observed after
prolonged use of morphine in the context of chronic pain or
opioid abuse*. Positron Emission Tomography (PET) using
radioligands of the Translocator Protein 18 kDa (TSPO) is
the most advanced strategy for the non-invasive detection of
glial activation in the human brain**. The aim of this study is
to investigate the relevance of TSPO PET imaging for the
detection of potential glial activation after chronic morphine
exposure and withdrawal in rats, and the potential correlation
to the expression of classical biomarkers of inflammation.
METHODS: Sprague-Dawley rats (n=6) were administered
escalating doses of morphine (10 mg/kg increasing to 40 mg/
kg, i.p twice a day during 5 days) to achieve a withdrawal
syndrome (behavioral validation) after morphine discontinua-
tion. Control rats were administered NaCl 0.9% instead (n=6).
DynamicmicroPET imaging (Siemens Inveon) was performed
during 68 min, 60h after the last dose of morphine using the
TSPO radioligand [18F]DPA-714. Data are expressed as areas
under the curve (SUV.min) obtained from the elimination
phase of the time activity curves (SUV).The kinetics of glial
cell activation biomarkers Iba1, GFAP and CD68 were also
assessed using immunohistochemistry (IHC) on brain slices
during 14 days after chronic morphine exposure. RESULTS:
The brain distribution of [18F]DPA-714 was similar in the
control (AUC30-68min= 9.79E-05 ± 7.31E-06 SUV.min)
and morphine treated (AUC30-68min= 1.06E-04 ± 1.40E-05
SUV.min) groups (p = 0.15). IHC revealed the absence of
modification in the Iba1, CD68 and GFAP levels of expression
after chronic morphine exposure and morphine withdrawal.
These glial biomarkers also remained at the same levels during
14 days after morphine discontinuation. CONCLUSION:
[18F]DPA-714 TSPO PET imaging may not be a relevant
approach to investigate the brain immune response to mor-
phine exposure and withdrawal. Moreover, conventional inva-
sive biomarkers of glial activation were not measurably im-
pacted either. This study questions the nature of neuroimmune
events that may be related to morphine tolerance and depen-
dence. REFERENCES: * Opioid activation of Toll-Like Re-
ceptor 4 contributes to drug reinforcement. Hutchinson et al,
2012; ** Molecular imaging of microglial activation in amyo-
trophic lateral sclerosis. Corcia et al, 2012.
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Non-completed PET/CT scans - assessing its impact
on service quality and patient experience
A. Nunes, G. Beynon, C. Strickland, W. Wong; Paul
Strickland Scanner Centre, Mount Vernon Hospital - East
and North Herts NHS Trust, London, UNITED KINGDOM.
Purpose: NHS England currently commissions around 50,000
PET/CT scans for patients in England each year.1 The non-
completion of a PET/CT scan has significant repercussions.
For patients, these include erosion of the patient experience
and delay in vital treatment, and for service providers waste of
radiopharmaceutical doses and increased waiting lists. The
aims of the study was [1] to analyse the main reasons for
non-completed PET/CT scans, [2] to identify causes which
can be potentially minimized and [3] to determine the impact
of these events in the department (both financially and opera-
tionally) and on the patient’s experience and clinical pathway.
Methods and Materials: PET/CT scans booked for the finan-
cial year of 2013-2014 from a single provider were analysed.
The different reasons for non-completion were categorized in
two groups (clinical and non-clinical) with specific sub-divi-
sions. The financial impact of non-completion of the scans was
studied. Semi-structured interviews were obtained from pa-
tients to assess the effect of the non-completions on the pa-
tient’s social and clinical contexts. Results: Of the 3121 PET/
CTs booked, 171 PET/CT bookings were not completed
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[5.4%]. The three main reasons for non-completion were non-
clinical (appointment cancellation [2.2%], scanner breakdown
[1.2%] and patient not attending (DNA) [1.2%]). Other rea-
sons were both clinical (unacceptable blood glucose levels
[0.3%] and patients being unwell for the scans [0.1%]), and
non-clinical (radiopharmaceutical production problems
[0.2%]). A detailed analysis of the implications of the non-
completed scans will be presented including documentation
of its negative impact on the patient experience and the finan-
cial savings [up to £154.000 potentially for the provider in the
period studied] if non-completion of scans was avoided. Con-
clusion: The total number of not completed PET/CTs made up
only a small fraction of the total. Notwithstanding, some of the
causes such as appointment cancellation, DNAs and unaccept-
able blood glucose levels are potentially preventable.
Preventing these causes will contribute to reduce the number
of non-completed PET/CT scans, improve the patient experi-
ence and lead to improvement in quality of the PET/CTservice
as well as some potential financial savings. 1 NHS England
website (http://www.england.nhs.uk/ourwork/commissioning/
spec-services/npc-crg/group-b/b02/) accessed on 26/04/2015
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A Hybrid random walk algorithm with spatial fuzzy
C-mean clustering for segmentation of liver tumors
in FDG PET imaging
M. Soufi1, A. Kamali Asl1, P. Geramifar2, M. Khazaee
Moghadam1; 1Radiation Medicine Department, Shahid
Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC
OF, 2Research Center for Nuclear Medicine, Shariati Hospital,
Tehran University of Medical Sciences, Tehran, IRAN, IS-
LAMIC REPUBLIC OF.
Aim: Hard decision making in Random Walk image segmen-
tation algorithm could be a source of challenge, especially in
low contrast boundaries. Therefore we are going to incorporate
the advantages of spatial fuzzy C-means clustering in decision
making step of random walk probabilities to improve the seg-
mentation of liver tumors in Positron Emission Tomography
(PET) images.Materials and Methods: Tumor delineation in
PET images is a challenging task because of statistical noisy
nature. Random walk image segmentation technique has reli-
able noise robustness, fast computation and editing properties
that makes it a strong tool in PET tumor delineation
purposes.The random walk segmentation algorithm has been
implemented usingMATLAB. The results have been validated
by 4D-NCAT phantom with different spherical lesions (20 to
80 mm diameter). For background and tumor seed localiza-
tion, pixels with more than 70% maximum Standardized Up-
take Value in the interested region have been considered as
foreground. For background seeds, pixels with the
concentration less than 35% maximum Standardized Uptake
Value in eight directions around each foreground seed were
searched and included. Then random walk probabilities have
been calculated. In decision making step, Spatial Fuzzy C-
mean clustering (SFCM) has been incorporated and its results
have been compared with conventional random walk in which
50% cut-off is applied on the calculated probabilities.For
quantitative performance evaluation of the proposed tech-
nique, a clinical data set containing nine liver tumors in whole
body FDG-PET/CT images has been used. Manual expert de-
lineation of lesion areas has been considered as ground truth.
The results of lesion segmentation with the conventional ran-
dom walk and proposed method have been compared quanti-
tatively with the ground truth using Dice Similarity Coeffi-
cients (DSC).Results: The Hybrid Random Walk algorithm
with SFCM could improve the results of conventional random
walk delineation with mean DSC difference of 8% ± 11%. The
large amount of Standard Deviation is mainly because of sig-
nificant difference between two techniques in low contrast
tumors.Conclusion: The results of this study show the combi-
nation of random walker with SFCM can improve liver lesion
delineation in FDG-PET images with suitable precision and
accuracy especially in low uptake tumors where the edges are
not sharp and decision making of conventional random walk
with 50% probability cut-off could be a challenging task.
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Utility of Delayed 18 FDG PET/CT Imaging for Lesions
Detection Enhancement
F. Y. RISHEQ,M. F. ALRISHEQ, S. J. AL-SADOON, A. A.
QWARIK; NUCLEAR MEDICINE, PET/CT, BMD,
Dr.FARID RISHEQ CENTER, AMMAN, JORDAN.
Introduction: PET captures the level of metabolic activity of
fluorine-18 fluorodeoxyglucose (18F-FDG) uptake and re-
ported as a standardized uptake value (SUV). Delayed imag-
ing of 18F-FDG can improve delineation of metastasis from
normal tissue. Objective: Investigate improvement of lesion
detection by delayed 18F-FDG imaging and decide on best
imaging protocol. Subjects and Methods: Seven patients with
average age 43.7±13.8y, average weight 67.7±10.3Kg under-
gone 18F-FDG-PET/CT scans with injection dose 240
±50.1MBq, (7-8) bed/130sec. Early scan performed at 65.5
±3.1min, and delayed scan at 170.4±3.9min. from 18F-FDG
injection time. Thirty two lesions of different cancer diseases
(HL,NHL,Ca-Breast,Ca-Colon) were investigated. Early and
delayed SUVmax of each lesion were determined and reten-
tion index RI%=100*(SUVmax.delayed - SUVmax.early) /
SUVmax.early was calculated. Results: A plot of
SUVmax.delayed versus SUVmax.early showed linear rela-
tion with slope ~1.44 and R2~0.84. Two lesions with reduced
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SUVmax.delayed (negative RI%) considered inflammatory
a n d w e r e e x c l u d e d . Av e r a g e SUVmax . e a r l y
(SUVmaxAverage.early) =10.3(±7.5,1.9-30.4), and
SUVmaxAverage.delayed =15.7(±10.1,4.9-43) indicating
clear increase in SUVmaxAverage.delayed with RI%Average
=74.4% (±66.1,2.3-239.5). For lesions with SUVmax.early
≤5.5 (11 lesions), the corresponding values were: 3.8(±1.4,
1.9-5.5), 7.8(±3.1,4.9-12) and 117.2(±77.9,25.5-239.5); and
for lesions with SUVmax.early >5.5 (19 lesions), these were
respectively: 14.0(±7.0,7.8-30.4), 20.3(±9.9,8.1-43.0) and
43.5(±43.5,2.3-159.6). Normal brain and liver showed signif-
icant decrease in SUVmaxAverage.delayed with negative
RI%Average= -0.5±19.7 and -23.1±18.1 respectively. Lung
showed increased SUVmaxAverage.delayed =0.86±0.15 com-
pared to SUVmaxAverage.early =0.71±0.06 with
RI%Average =22±22.7. No difference in behaviour was ob-
served in relation to cancer diseases. Discussion: Delayed im-
age RI%Average =74.4% reflects its utility in improving
SUVmax of lesions. Lesions with SUVmax.early ≤5.5 have
RI%Average =117.2 which is 2.7 times RI%Average =43.5 for
SUVmax.early lesions >5.5. This is beneficial for the detection
of lesions in their early stages (border SUVmax). Brain and
liver showed negative RI%Average, being unable to retain
18F-FDG. Two patients had positive brain RI% due to anxiety.
Positive RI%Average for lung is caused by breathing motion,
and is within normal tissue SUVmax. Our results showed that
accumulated dose of 18F-FDG is retained inside malignant
lesion cells and continue for a considerable time being unable
to escape to the blood stream. Radiation damage effect
(energy:2γ=1.022MeV, β+=0.635MeV) could extend beyond
the ten half- lives physical decay (18.3hr) and could have
oncology stimulation effect. Conclusion: 18F-FDG dose of
240±50.1MBq provide high quality images as compared to
370MBq; lowering patients’ radiation hazards. Delayed 18F-
FDG imaging ~3hr is more helpful than ~1hr for evaluating
suspicious malignant lesions with SUVmax ≤5.5. Retained
18F-FDG inside malignant cells could have oncology stimu-
lating effect.
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Assessment of reconstruction parameters impact
on quantification of low dose Yttrium-90 activity based
on PET-CT Imaging in radioembolization
M. Khazaee Moghadam1, A. Kamali Asl1, P. Geramifar2, M.
soufi1; 1Shahid Beheshti University, Tehran, IRAN, ISLAMIC
REPUBLIC OF, 2Research Center for Nuclear Medicine,
Shariati Hospital, Tehran University ofMedical Sciences, Teh-
ran, IRAN, ISLAMIC REPUBLIC OF.
Aim: Yttrium-90 is known to have a low positron emission
decay with abundance of about 32 pairs per million. This
characteristic can be helpful in accurately evaluating the activ-
ity distribution of 90Y particles in radioembolization of liver
tumors using PET. In this study, we investigated optimal re-
construction parameters for quantifying low dose 90Y pre-
therapy PET-CT imaging as a function of both hot-sphere size
and activity concentration. Materials and Methods: The study
was performed using a Siemens Biograph 6 True Point PET-
CT scanner. A jaszczak phantom containing five hot syringes
with different sizes and target-to-background ratio of 40:1 was
imaged over 45 min. This phantom was initially imaged with a
hot-sphere activity concentration of 7.2 MBq/mL and a back-
ground concentration of 0.18 MBq/mL. It was then serially
imaged at multiple time points down to hot-sphere and back-
ground concentrations of about 2.53 and 0.06 MBq/mL, re-
spectively. The attenuation and scattered corrected sinograms
were reconstructed considering different iterations as well as
subsets with and without resolution recovery. The assessment
of noise was evaluated using multiple statistically independent
region of interest (ROI). Results: For the range of applied
activities, scanner linearity was confirmed. Activity was cal-
culated in hot phantom regions based on SUV. The relative
differences between calculated activities and known activity
was observed between 1.36% and 11.2%. The most accurate
result was achieved with 2 iterations and 21subsets, consider-
ing resolution recovery as well. The least background noise of
about 8% was obtained using these parameters. Conclusion:
For precise activity quantification of lesions, 2 iterations, 21
subsets and resolution recovery would give the best perfor-
mance. Accuracy was improved by increasing subset size in
the reconstruction. On the other hand, further increasing the
number of iterations would worsen the estimated activity and
the conversion from one to three iterations significantly en-
hanced the noise in the reconstructed images. In general as-
sessment of 90Y activity distribution based on PET-CT imag-
ing in pre-therapy can be further improved by utilizing adapted
parameter setups.
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Clinical utility of 18F-fluorocholine positron-emission
tomography/computed tomography (PET/CT) in prostate
cancer patients and comparing with18 F-FDG PET/CT
and conventional imaging modality
R. K. Phulsunga, Jr., R. Parghane, sr, J. Shukla, Consultant,
B. Mittal, Prof; PGIMER, Chandigarh, INDIA.
Aim: The aim of this study was to evaluate the clinical utility of
18F-fluorocholine positron emission tomography/computed to-
mography (FCH PET/CT) in detecting prostatic bed lesion,
lymph nodes and skeletal involvement in prostate cancer pa-
tients and comparing these finding with 18F-FDG PET/CT and
conventional imaging.Material and Methods: The study
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retrospectively evaluated 32 patients who had undergone FCH
PET/CT, bone scan in prostatic cancer patients. At the same
time, 27 of the 32 patient’s undergone 18F-FDG PET/CT, 7
of 32 patient MRI and 25 of the 32 patients had abdominal-
pelvic diagnostic CT. The sensitivity, specificity and accuracy
of FCH PET/CT, 18F FDG PET/CT and abdomino-pelvic CT
were evaluated on a per-patient basis. Histological examination,
second time PET or clinical follow-up data were used as gold
standard for lesions characterization in prostatic cancer
patients.Results: The overall accuracy of FCH PET/CT to de-
tect lesion was 70%. The sensitivity and specificity of FCHwas
high as compared to18 F-FDG PET/CT and conventional ab-
dominal pelvic CT scan i.e sensitivity of FCH, FDG and con-
ventional CTwas 69%, 44% and 45% and specificity was 80%,
67% and 80% respectively. Moreover, the sensitivity and spec-
ificity of FCH PET/CTwere higher than 18F-FDG PET/CT to
detect prostatic bed lesion, lymph nodes and skeletal lesions in
prostatic cancer patients.Conclusions: Our result shown that,
FCH PET/CTwas very useful in detecting prostatic bed lesion,
lymph-nodes and skeletal lesion in prostate cancer patients as
compared to 18F-FDG PET/CT and conventional imaging
modality.
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Qualitative evaluation of respiratory artifacts on PET/CT
images
M. Shamsaie Zafarghandi, F. Gholami, B. Teimourian;
Amirkabir University of Technology, tehran, IRAN, ISLAM-
IC REPUBLIC OF.
AimIn earlier years PET/CT has an important role for detect-
ing tumors, planning radiation treatment and evaluating re-
sponse to therapy. But difference in respiratory motion be-
tween PET and CT scans causes breathing artifacts on PET/
CT images. The purpose of this paper was investigation of the
qualitative error due to respiratory artifacts on tumors of the
lung.Material and methodThe 4D XCAT phantom and STIR
were used for all simulation in this study. Three phases of CT
breathing cycle including CT image in the end exhalation
(EE), end inhalation (EI) and respiration-averaged CT (ACT)
image were used for PET image attenuation correction. The
magnitude of induced errors in volume for different breathing
phases were investigated by considering ACTas gold standard
a n d a t h r e s h o l d o f 5 0 % m a x i m u m v o x e l
intensity.ResultComparing PET/EECT and PET/EICT with
PET/ACT for upper, middle and lower right and left lungs,
the maximum percentage error was observed in smaller lesions
with 35-mm diaphragm motion amplitude. In upper lung, vol-
ume was overestimated. Also the lesion volume error was
gradually decreased with increasing the lesion size. The max-
imum error in the middle lobe of right lungwas 95% in 10-mm
lesion with 35-mm diaphragm motion and decreased with le-
sion size to a minimum amount of 2.1% for 25-mm lesion.The
measurements showed a maximum error of 65.36% in PET/
EICT for the lower lobe of right lung that causing an underes-
timation of lesion volume. The error reduction trend was ob-
served with increasing lesion size from 65.36% to 57.51%.
However this reduction was observed for lesion larger than
12-mm in the PET/EECT. Also in the lower lobe of left lung,
the maximum error of 95% was observed in the 8-mm lesion
with 35-mm diaphragm motion in PET/EICT and the error
reduced to an amount of 39% for 25-mm lesion. Unlike
PET/EICT, in PET/EECT the error increased with increasing
the diaphragm motion amplitude.DiscussionThese results rep-
resent that respiratory motion has a minor effect on upper
regions of the lung. Mismatch caused by respiratory motion
has considerable effect on small tumor which placed close to
diaphragm. Decreasing of errors with increasing the tumor size
indicates negligible effect of respiratory motion on large tu-
mor. Investigations show that for all upper and lower tumor of
right and left lung end expiration is the best phase for attenu-
ation correction.
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Serial monitoring of denervated muscle with 18F-FDG
PET
K. Pak, M. Shin, I. Kim; Pusan National University Hospital,
Busan, KOREA, REPUBLIC OF.
Purpose: We aimed to evaluate the serial change of glu-
cose hypermetabolism in denervated muscle with 18F-
Fluorodeoxyglucose (FDG) Positron emission tomogra-
phy (PET). Methods: Right sciatic nerve was resected
in 6 male rats (7wk old). From 1 to 10 weeks after
denervation, PET scans were acquired for 5 times (1/2/
5/8/10 weeks). Muscle denervation was confirmed by
electrophysiologic and histologic studies. Region of in-
terest (7mm diameter circle) were drawn in the axial
section of lower legs. The ratio of right to left leg
ROI weas calculated with both SUVmax and SUVmean.
Results: Muscles of right lower leg showed hypermetab-
olism in 1 week after denervation (ratio: SUVmax 3.61
±1.71, SUVmean 3.56±1.66). The ratio of FDG uptake
in 2 weeks showed difference with that of 1 week
(p=0.05, SUVmax 1.51±0.99, SUVmean 1.41±1.03). Un-
til 10 weeks, the ratio of FDG uptake showed no sig-
nificant difference comparing with that of 2 weeks.
Conclusions: Hypermetabolism in denervated muscle
was observed in 1 week after resection of nerve. After
1 week, the ratio decreased and showed no significant
difference until 10 weeks.
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Usefulness of F-18 Flouromethylcholine (FCH) Positron
Emission Tomography/Computed Tomography (PET/CT)
in Evaluation of Bone Metastases in Suspected Recurrent
Carcinoma Prostate and Comparative Role of Computed
Tomography (CT) in Lesion Detection
S. Z. Ali, C. J. Tan, L. W. C. Winnie; Singapore General
Hospital, Singapore, SINGAPORE.
PURPOSE: To study the usefulness of F-18 Flouromethylcholine
(FCH) positron emission tomography/computed tomography
(PET/CT) in detection of bone metastases in suspected carcinoma
prostate with biochemical recurrence and evaluate the comparative
role of computed tomography (CT) in lesion detection.
METHODS: This retrospective study consisted of evaluating 70
patients with referral for F-18 Flourocholine PET/CT, between
2010 and 2014 for evaluation of suspected recurrent prostate carci-
noma with rising serum prostate-specific antigen (PSA) levels.
PET/CT imaging was performed with intravenous administration
of F-18 FCH, with initial acquisition of the pelvis performed 2
minutes (early) followed by delayed imaging from the skull to the
upper thigh at 30 minutes (delayed), after tracer administration.
Non-contrast CTwas performed for purpose of attenuation correc-
tion and anatomical localization. RESULTS: Among the 70 pa-
tients, there were 10 patients with 30 foci of bony uptake of F-18
FCH, suggestive of tracer-avid bone metastases. The maximum
standardized uptake value (SUVmax) of the tracer-avid bone le-
sions measured from 3.3 to 14 with mean SUVmax=7.8 (standard
deviation = 3.0). CTattenuation of such lesions ranged from 171 to
1164 Hounsfield units (HU) with mean CT HU value of 608.9
(standard deviation=293.1). The maximum CT attenuation mea-
surement of an index lesion with FCH uptake (in skull) was 1164
HU,with corresponding SUVmax=8.4.The highest SUVmax=12.7
was noted in a lesion in lumbar vertebrawith correspondingCTHU
value of 286. The Pearson correlation coefficient between the FCH
uptake of bone metastatic lesions and correponding CT HU values
was estimated as -0.438. CONCLUSION: Due to wide variation in
CT HU values, CT alone is not accurate for detection of bone
metastases in prostate carcinoma. Functional imaging with F-18
FCHPET/CTis better technique for detection of skeletalmetastases
in suspected recurrent prostate carcinoma.
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PET/CT Use With Abdominal Compression Arch For
Stereotactic Radiosurgery Planning With Arrested Lung
And Extracorporeal Circulation
D. M. Ruiz Hernández, J. Nogueiras Alonso, F. Zelaya
Reinquet, C. Castillo Berrio, M. Castrillón, A. Serena Puig,
L. Campos Villarino, R. Guitian Iglesias; ESG36555100, Pon-
tevedra, SPAIN.
AIM: An important number of studies have shown that the
use of PET/CTwhen compared against the use of isolated CT,
produces a statistically significant increment in the definition
accuracy (GTV). This accuracy increment can be up to 42% in
highly conformal radiotherapy for non-small cell lung cancer.
This increment optimizes the therapeutic ratio by maximizing
the dose in the tumor target whilst minimizing it in the neigh-
boring organs. In addition, it reduces interobserver variability.
MATERIAL AND METHODS: Three patients, with previ-
ously limited lung functional reserve, were diagnosed with a
new NSCLC, so any suitable treatments were rejected for
them. An ALART (Arrested Lung Ablative Radiotherapy)
protocol was designed with the purpose of reducing as much
as possible, the lung motion movement, hence, the patient was
assisted with a systems of extracorporeal circulation. Aiming
to reproduce to the maximum the conditions for immobiliza-
tion lung, the volumes to be radiated were delineated based on
18F-FDG PET/CT images, which was acquired with a trolley
with abdominal compression device ((SIHO©)) (figure 1).
RESULTS: Procedure consisted of hypofractionated stereotac-
tic radiotherapy for the first patient; original prescription for
the second patient, was modified because onset of activity at
hiliar node that was not previously known (figure 2), them
stereotactic radiosurgery was performed in a single session
(34Gy in the node and 21Gy in adenopathy); and stereotactic
radiosurgery too, for the third one. First patient remains
asymptomatic after 9 months, with partial metabolic response
in PET/CT control, the second showed complete response in
tumor and nodal partial on PET/CT control, with progression
to bone metastases and died as a complication of lung infec-
tion. The third is still asymptomatic, waiting for the first PET/
CT control. CONCLUTIONS: We consider interesting the de-
scription of cases to the author’s knowledge, this is the first
bibliographic description of the use of PET/CT 4D with arc
abdominal compression in stereotactic radiotherapy planning
with arresting lung and extracorporeal circulation. Although
randomized controlled studies are needed, so that this proce-
dure could be considered an alternative and effective treatment
in those services that are not gating or devices for PET/CT
monitoring and/or incorporated into the accelerator.
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Motion management in clinical practice on Discovery IQ -
GE PET/CT scanner
S. Morzenti1,A. Zorz1, F. Elisei2, E. De Ponti1, L. Guerra2, A.
Crespi1, M. Arosio2, C. Landoni3; 1Medical Physics, A.O. San
Gerardo, Monza, ITALY, 2Nuclear Medicine, A.O. San
Gerardo, Monza, ITALY, 3Nuclear Medicine, University of
Milano Bicocca, Milano, ITALY.
Aim: The new scanner Discovery IQ provides innovative
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solutions for respiratory motion management to help enhance
image quality. The aim of this study is to compare different
motion correction techniques available in standard clinical prac-
tice: QStatic and Motion Correct.Material and Methods: QStatic
is a motion management solution fully integrated into the WB
PET protocol. It permits to acquire motion free images in the
thorax-abdominal region FOV selecting PET data only from the
quiescent phase (end expiration) of the patient’s respiratory curve
registrated with a Respiratory Management System (RPM -
Varian). The relative attenuation map is calculated from a total
body CT performed in the end expiration phase. In order to have
a statistical counts comparable to the other FOVs QStatic bed is
acquired for a double time.Motion Correct is a technique that
calculates the attenuation map matching a WB standard helical
CT and a low dose cine CT performed in the border zone be-
tween the chest and the abdomen.Two nuclear medicine physi-
cians compare 60 images obtained with QStatic and 30 images
obtained with Motion Correct to the standard free breathing
PET/CT acquisitions, giving a score from 1 (necessity to repeat
the acquisition for clinically inadequate image quality) to 3
(good image quality without artefacts).Results: The comparison
of the QStatic protocol to the standard PET/CT acquisition
shows that in the 31% of the cases the score does not change
and in the 41% of cases it increases.Moreover, the Motion Cor-
rect protocol allows to obtain a better results respect to the stan-
dard acquisition in the 48% of cases and a comparable image
quality in the 50% of cases. The dose increase due to the cine CT
is less than 13% of the total PET/CT effective dose.Conclusion:
Both QStatic and Motion Correct protocols provide a better im-
age quality than the standard acquisition without conditioning
the clinical workflow.Nevertheless, Motion Correct should be
useful for motion management in non compliant patients be-
cause this technique does not require an increased acquisition
time.
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Optimization of Dual Time Point Delayed Regional 18F
FDG PET CT Protocol With Site Specific Interventions
M. SARMA, P. SUBRAMANYAM, P. SUNDARAM;DEPT.
OF NUCLEARMEDICINEAND PET CT, AMRITA INSTI-
TUTE OF MEDICAL SCIENCES AND RESAERCH CEN-
TRE, AMRITA VISHWA VIDYAPEETHAM, COCHIN,
INDIA.
Aims: Possible optimization of the dual time point delayed
regional FDG PET/CT protocol with various site specific in-
terventions.Materials andMethods: Initial WB (at ~ 60 min)
and delayed regional (~2 hours post FDG injection) FDG-
PET/CT images (2013 -March,2015) of 88 patients were ret-
rospectively analysed. Interventions included (a). head/neck
imaging with hands down position in TENIS patients (Group
I), (b). 1 L oral contrast administration 15 min prior to delayed
imaging (Group II), (c).distention of small or large bowel
loops with 1-1.5 L oral contrast over a extended time of 1 hour
(Group III), (d).forced diuresis with excess oral hydration and
furosemide intervention 20 min prior to delayed imaging
(Group IV) and (e). bladder distention with excess hydration
and withholding urine (Group V). Suspected abnormalities
were characterized based on (a). rising/stable dual-time point
changes in SUVmax and/or (b). visualization/better character-
ization/disappearance of initial CT suspected abnormality.
Findings were compared with subsequent HPE, other imaging
/clinical follow-up. Results: Gr.I(n=19): 4 lymphnodes
(SUVmax < 2.0 g/ml) in 3 patients showed SUVmax > 2.0
g/ml, later proven to be metastatic. Gr.II(n=11): In 4 patients,
diffuse FDG uptake in the stomach wall seen initially was not
appreciable on delayed scan. 2 patients showed better delinea-
tion of pyloric area thickening post distention with retained
FDG uptake. Suspicious thickening of stomach wall on initial
CT (with no FDG uptake) was not subsequently appreciable in
5 patients. Gr.III(n=38): Focal FDG uptake in small intestine
was localized to a lymphnode (not appreciable on initial CT) in
1 patient. In 7 patients incidental focal FDG uptakewas seen to
retain/increase with no definite CT abnormality. Colonoscopy
detected malignancy in 1 patient. 10 other patients who had
suspicious thickening/abnormality of intestinal walls initially,
did not show any abnormality after distention of the loops. In
rest of the patients, there was significant reduction of SUVmax
or disappearance of the uptake. Gr.IV(n=11): better visualisa-
tion of focal FDG uptake in kidneys in 2 patients subsequently
proved to bemalignant lesions. Gr.V(n=9): Better appreciation
of FDG uptake in CT detected bladderwall thickening in 3
patients and subsequently lesions were proven malignant. In
2 patients suspicious wall thickening did not show FDG up-
take. Patients are on follow up. In rest of the 4 patients, suspi-
cious CT abnormality with inconclusive FDG uptake showed
no CT abnormality or FDG uptake post distention.
Conclusions: FDG-PET/CT dual time point imaging can be
optimised with site based specific interventions.
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Performance of PET/CT for detecting the primary tumors
of cervical metastases from unknown primary carcinoma:
a systematic review and meta-analysis
G. Shen, Z. Jia, H. Deng; West China Hospital of Sichuan
University, Chengdu, CHINA.
Aim: Growing evidence shows that 18F FDG PETor PET/CT
is superior to conventional imaging methods in the detection
of primary tumors in patients with cervical metastases from
unknown primary carcinoma (UPC). The aim of this meta-
analysis was to assess the clinical usefulness of 18F FDG
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PET/CT in the detection of occult primary tumors in UPC
patients with cervical metastases. Materials and methods:
Studies about whole-body PET/CT for the detection of prima-
ry site in cancer patients with cervical metastases from UPC
were systematically searched in PubMed, EMBASE, EBSCO,
Web of Knowledge and Cochrane Library and four Chinese
databases. Based on the data extracted from the included stud-
ies, we determined pooled sensitivities and specificities across
studies, calculated positive and negative likelihood ratios, and
constructed summary receiver operating characteristic curves
with area under the curve (AUC) and Q* obtained. We also
analyzed the heterogeneity between studies based on the
subgroup-analysis and publication bias analysis. Results: In
total, 39 studies involving 1468 patients met the inclusion
criteria. PET/CT detected the primary lesion in 599, with a
detection rate of 40.8%; and in these TP results, with regard
to the locations of primary tumors, tumors of lung, tonsil, base
of tongue, and nasopharynx were the most prevalent with rates
of 24.2%, 12.9%, 10.6% and 13.1%, respectively. The pooled
sensitivity and specificity were 0.90 (95% confidence interval
[CI], 0.87-0.92) and 0.79 (95% CI, 0.75-0.81), respectively.
Likelihood ratio syntheses yielded overall PLR of 3.50 (95%
CI, 3.00-4.08) and NLR of 0.20 (95% CI, 0.15-0.26). The
AUC and Q* index were 0.8930 and 0.8238, respectively.
The between-study heterogeneity was only significantly ob-
served in sensitivity, and the results of subgroup analyses
showed that only the type of imaging modality did statistically
significantly influence the reported sensitivities of PET/CT (P
< 0.05), while study design, quality score, and reference stan-
dard did not (P > 0.05). In addition, the funnel plot seemed
slightly asymmetrical with a P value of 0.001, which sug-
gested no major publication bias. Conclusions: PET/CT is
beneficial in the overall assessment of primary tumors in
UPC patients with cervical metastases. Large, multicenter,
and prospective studies with standard protocols are now need-
ed to investigate the true value of PET/CT for detecting pri-
mary tumors of cervical metastases from UPC and the broad
application of this method in clinical practice.
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Is 18F-FDG PET/CT Suitable for Selecting Lung Cancer
Patients for Brain MR Under the Suspicion of Brain
Metastasis?
k. hjorthaug, Sr.1, J. Hojbjerg1, M. Knap1, A. Tietze1, A.
Haraldsen1, S. Kramer1, H. Zacho2, P. Borghammer1; 1Aarhus
University Hospital, Aarhus, DENMARK, 2Aalborg Univer-
sity Hospital, Aarhus, DENMARK.
Aim: Brain metastases are very common in lung cancer.
Whole-body FDG PET/CT is used for general staging, but
MR is the best modality for characterising brain abnormalities.
We aimed to determine if PET/CT is suitable for selecting
patients to MR on the suspicion of brain metastases.Materials
and methods: FDG PET/CT was performed in 1108 consecu-
tive patients suspected of lung cancer. The final diagnoses
were extracted from medical records as lung cancer, with or
without brain metastases, other kinds of cancers, or no cancer.
The sensitivity, specificity and positive predictive values for
detecting brain metastases were calculated. Inter-observer var-
iation was tested in a subset of 88 PET/CT scans. Results:
Five-hundred-and-ninety-six of 1108 referred patients had
lung cancer. Sixty-six had brain metastases. One PET/CT
was false positive. Thirty-one scans were true positive among
the 43 patients, who were diagnosed with brain metastases in
the time interval one month before to 3 months after PET/CT
(metastases prevalence 7.3%). Twelve PET/CT scans were
false negative. Sensitivity, specificity, and positive predictive
values were 72 %, 100 %, and 97 %, respectively. Inter-
observer agreement between two experienced observers was
high (κ=0.83) whereas agreement between the experienced
and the inexperienced observer was poor. Conclusions: The
sensitivity of brain PET/CT for detecting brain metastases in
lung cancer was above 70%, and specificity was very high.
Thus, PET/CTmay be suitable for selecting patients for MR in
diagnostic centers, which do not perform routine MR in the
pre-therapeutic staging work-up. The agreement among expe-
rienced readers was very high.
P125
Diagnostic Accuracy of 18F-FDG PET-CT for Detection
of Primary Tumors in Patients with Cervical Metastases
of Unknown Origin
A. Serrano Palacio1, M. Cabrera Martín2, C. Riola Parada1,
O. Salsidua Arroyo1, M. Pedrera Canal1, M. Martínez de
Bourio1, E. Cala Zuluaga1, M. García García-Esquinas1, J.
Carreras Delgado2; 1Nuclear Medicine Department. Hospital
Clínico San Carlos, Madrid, SPAIN, 2Nuclear Medicine De-
partment. Hospital Clínico San Carlos. Universidad
Complutense, Madrid, SPAIN.
Aim: To assess the ability of 18F-FDG PET-CT in the detec-
tion of primary tumors in patients with cervical metastases of
unknown primary in clinical examination.Materials and
methods: An observational retrospective study was performed
between December 2008 and January 2015, including 63 con-
secutive patients who underwent 18F-FDG PET-CT studies
for cervical lymph node metastases of unknown primary after
clinical examination.Results: 63 patients were included, mean
age 62 years (range 37-92), 48 males (76.2%). PET-CT iden-
tified the primary tumor and staged disease in 35 patients.
PET-CTsuggested lymphoproliferative syndrome in 3 cases
(large B-cell non-Hodgkin Lymphomas). Identification rate
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of primary tumors with PET-CT was 60.3%. In 29 patients
(82.8%) PET-CT suggested head and neck primary tumors,
all of them with histopathological confirmation (25 squamous
cells carcinomas, 2 adenocarcinomas, and 2 undifferentiated).
The most frequent location was oropharynx (15 cases). Other
locations were: oral cavity (2), nasopharynx (3), hypopharynx
(4), larynx (3) and salivary glands (2). Primary lung tumor was
diagnosed in 5 cases (3 adenocarcinomas and 2 squamous
cells carcinomas) and pancreatic cancer in 1 case (adenocarci-
noma). In 17 patients (27%) additional metastases were
found.In 2 patients with negative PET-CT results, primary tu-
mors were identified by randomized biopsies (floor of mouth
and left amygdala).In 22 cases the primary tumor has not been
identified in clinical and imaging (PET-CT, MRI) follow-up
(mean follow-up 12 months, range 1-60).Conclusion: 18F-
FDG PET-CT is a useful tool to locate the primary tumor in
cases with cervical metastases of unknown primary after clin-
ical examination, with high impact in clinical management.
Due to the high percentage of head and neck tumors, it could
be useful the performance of specific acquisitions of this ana-
tomical region.
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Multiparametric Comparative Analysis of Positron
Emission Tomography, Difussion Weighted Imaging
and Difussion Tensor Imaging at 3T MRI: An Attempt
to Provide More Accurate Data in Lung Cancer Patients
Diagnosis
S. Lucic1, I. Djan1, M. Bjelan1, S. Pena-Karan2, A. Peter1, O.
Sveljo1, D. Kozic1, M. A. Lucic1; 1Oncology Institute of Voj-
vodina, Sremska Kamenica, Novi Sad, SERBIA, 2Institute of
Pulmonary Diseases of Vojvodina, Sremska Kamenica, Novi
Sad, SERBIA.
Aim: To explore the possible correlation and interconnection
between the values of apparent diffusion coefficient (ADC), ob-
tained by diffusion weighted imaging (DWI), mean diffusivity
(MD) obtained by diffusion tensor imaging (DTI), and standard-
ized uptake value (SUV), obtained by 18F-FDG PET/CT in the
lung cancers patients.Materials andMethods: Thirty three newly
diagnosed lung cancer patients with verified adenocarcinoma,
and before combined radiotherapy/chemiotherapy treatment,
underwent chest MRI examination on 3T MRI unit (Magnetom
Trio, Siemens, Erlangen, Germany) that included DWI (3
diffusion-encoding gradient directions, with 2 b values (0 and
1000 s/mm2), TR 5000ms/TE 80ms, slice thickness 4mm, inter-
slice gap 0.8mm, and respiratory triggering), and DTI (30
diffusion-encoding gradient directions, with 2 b values (0 and
1000 s/mm2), TR 4460ms/TE 80ms, and isotropic resolution of
3mm, and respiratory triggering) measurements, followed by
18F-FDG PET/CT examination (Biograph 64, Siemens,
Erlangen, Germany) on the very same day. A region-of-interest
(ROI), covering the exactly same area of the tumour in each
single patient was determined and maximal standard uptake val-
ue (SUVmax), mean ADC value (ADCmean), and mean diffusiv-
ity value (MDmean) were analyzed and measured by one inde-
pendent radiologists, one nuclear medicine specialists and one
both nuclear medicine specialist and radiologist, and the numer-
ical data sets from both diagnostic modalities were obtained. The
data sets were statistically analyzed by use of Pearson’s correla-
tion coefficient (r), Spearman’s rank correlation coefficient (ρ),
and multiple regression analysis (MANOVA) with Statistica
software package (v.12.0), and the level of confidence deter-
mined at p<0.05.Results: We found that SUVmax demonstrated
a statistically significant negative correlation with ADCmean val-
ue in the whole group of patients (ρ=-0.339, and r=-0.286).
MDmean showed negative statistical significant correlation with
maximal tumour diameter (ρ=-0.400 and r=-0.391). Multiple
regression analysis indicated statistically significant interconnec-
tion between ADCmean and SUVmax (b=-0.016, p<0.05),
ADCmean and MDmean (b=1.580, p<0.05), as well as MDmean
and maximal tumour diameter (b=-0.002; p<0.05).Conclusions:
Our results are indicating SUVmax and ADCmean as two highly
interconnected parameters, suggesting their importance in the
lung cancer metabolism and cellularity detection. MDmean value
appears to be slightly less interconnected with SUVmax values,
but still helpful. Noticed significant correlationbetween MDmean
and maximal tumour diameter needs further evaluation, for this
correlation in our opinionmight demonstrate further contribution
in lung cancer monitoring and therapy response.
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The distribution of F-18-labeled Histone deacetylase
inhibitor (HDACi) by PET/CT imaging
C. Y. Hu; Institute of Nuclear Energy Research, Taoyuan,
TAIWAN.
Background and aim: Histone deacetylases (HDACs) play im-
portant roles in a wide range of cellular functions, including
proliferation, apoptosis, differentiation and aging. A variety of
HDAC inhibitors have been approved for anticancer therapy.
The aim of this study is to identify the in vivo imaging of F18-
labeled HDACi(NC109) by using molecular imaging tech-
niques. Method: HDACi(NC109) was synthesized and F-18-
labeled by the fluorination method: H-F18 pass through QMA
Sep-Pak (conditioned with 0.5MK2CO3 and H2O). And elut-
ed with Kryptofix2.2.2 solution (dissolved with K2CO3
2.7mg and Kryptofix2.2.2 15mg). Precursor (5mg) was dis-
solved in anhydrous DMSO (0.9 mL) and injected into the
glass beaker. Reacted at 140°C for 20 minutes. And purified
by Radio-HPLC using C18 semi-prepare column, elute solvent:
40% H2O/ACN isocratic and retention time was 14.7 minutes.
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Bio-distribution study of F18-NC109 in male C57BL/6 mice
weighing 20 ± 4 g was performed after the administration of
F18-NC109 via the tail vein injection. Organs of interest and a
sample of blood were collected, weighed, and counted, together
with an injection standard. The PET/CT images were obtained in
static mode. Mice were anesthetized under 1.5-2% isoflurane in
medical-grade air for radiotracer injection and PET imaging. The
static images were generated immediately following the tail vein
injection of 7.4MBq of 18F-NC109 in 0.1mL normal saline. The
residual syringe activity of F18-NC109 was measured to verify
the injected dose. Then, whole-body PET/CT images were ac-
quired and scanned for one hour. Results and Conclusion: After
tail vein injection, F18-NC109 accumulated mainly in the bone.
The uptake value was 0.119±0.075%ID/g at one hour after injec-
tion. Liver uptake was measured as 0.066±0.012% ID/g at one
hour after injection, with the uptake being much lower than bone.
The result of PET/CT imaging studies showed that F18-NC109
primarily appeared in the bone and liver, observed at one hour
after injection. These results correlate well with the results of the
bio-distribution study. By gathering dynamic absorption in each
organ,we can obtain the very informative in vivo data, particularly
on tissue distribution for clinical purpose.
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Value of Metabolic and Volumetric Indices of 18F-FDG
PET-CT for the Prediction of Neoadjuvant Chemotherapy
Outcomes in Locally Advanced Breast Cancer
O. Salsidua-Arroyo1, M. García García-Esquinas2, A.
Jiménez-Ballvé1, M. N. Cabrera-Martín1,3, A. Ortega Candil1,
C. Rodriguez Rey1, M. J. Pérez-Castejón1,3, A. Serrano-
Palacio1, J. L. Carreras-Delgado1,3; 1Nuclear Medicine
Department.Hospital Clinico San Carlos, Madrid, SPAIN,
2Nuclear Medicine Department/Radiology Department. Hos-
pital Clinico San Carlos, Madrid, SPAIN, 3Nuclear Medicine
Department. Hospital Clínico San Carlos. Universidad
Complutense, Madrid, SPAIN.
Aim:The aim of this study was to investigate metabolic and
volumetric indices value of PET-CT with 18F-FDG for the
evaluation of tumor and ganglionar response to neoadjuvant
chemotherapy (NACT) in stages II and III breast cancer
patients.Material and methods: It was a retrospective study
of forty-three women with breast cancer in stages II or III.
Two 18F-FDG PET-CT scans were performed to each patient,
before and after NACT. To evaluate the response, the percent-
age difference of SUVmax (ΔSUVmax), metabolic tumor vol-
ume (MTV) and total lesion glycolisis (TLG) between the two
studies were evaluated. Final histopathology following sur-
gery after six cycles of NACT served as reference.Results:
The ΔSUVmax was higher in the tumors ([P50:100; P25:95,
2-P75:100]) and when considering the locoregional disease
[P50:100; P25:96,4-P75:100] in patients with pathologic com-
plete response (pCR) ([P50:76,6; P25:53,3-P75:100] compar-
ing with no responders [P50:76,6; P25:55,5-P75:100]) with
p=0,031 and p=0,028 respectively. No significant differences
in ΔMTV and ΔTLG were observed between both groups
(p=0,072). No differences in the parameters on the pretreat-
m e n t s t u d y ( S UVm a x , M TV y T LG ) w e r e
detected.Conclusion: ΔSUVmax of pre and postreatment
studies may be useful to predict pCR after NACT patients with
locally advanced breast cancer. More sophisticated methods,
such as MTVand TLG do not seem valuable in this context.
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Assessment of bone healing in allogenic sternal graft
with 18F-Fluoride PET/CT
S. Diodato1, I. Sandler1, S. De Vivo1, H. Svirydenka1, A.
Dell’Amore2, V. Pettinato1, P. Guidalotti1, F. Stella2, S. Fanti1;
1Nuclear Medicine, Policlinico S.Orsola-Malpighi, University of
Bologna, Bologna, ITALY, 2Thoracic Surgery Unit, Policlinico
S.Orsola-Malpighi, University of Bologna, Bologna, ITALY.
Aim The purpose of this study was to evaluate 18F-Fluoride
PET/CT as an indicator of bone metabolic activity in patients
who underwent allogenic sternal transplant, considering max-
imum standardized uptake value (SUVmax) variation as a pre-
dictor factor of bone graft healing.Materials and methods4
consecutive patients, 1 male and 3 females, mean age 51 y.o.
(range 39-68) were included in the study. 3 patients had sternal
metastasis (2 breast cancer, 1 ovarian cancer) and 1 had medi-
an sternotomy dehiscence after aortocoronary bypass surgery.
All patients underwent surgical sternal excision with replace-
ment of sternal allograft, and then performed two 18F-Fluoride
PET/CT scans during follow-up to assess bone graft healing.
First 18F-Fluoride PET/CTscanwas performed between 8 and
15 months (mean period 11.3 months) and second 18F-
Fluoride PET/CT scans from 20 to 27 months (mean period
24.5 months) after surgery. 18F-Fluoride PET/CT data were
analysed by “volume of interest” (VOI) placed over the inter-
face areas between the native bone and the graft: 1 patient had
4 VOIs (as for total sternectomy) and 3 patients had only 1
VOI (partial sternectomy). SUVmax were reported for every
bone contact area and were compared between the first and
second scan considering the same VOI. After the second scan
the patients were followed up by clinical and radiological
methods up to 19 months (mean time 12.5, range 3-19
months).Results 3 patients have shown significant reduction
of the VOI’s SUVmax between the two 18F-Fluoride PET/CT
scans, in particular: SUVmax mean reduction of 42.9% in the
patient with 4 VOIs (range 23.2-66.3%), 20.3% and 16.3% in
the other 2 patients. These PET/CT data corresponded to un-
complicated bone healing and good clinical and radiological
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outcome within the patient’s follow-up. Our forth patient, fe-
male that underwent radiotherapy right after surgery, has
shown increase of 13.9% in the VOI’s SUVmax. She referred
persisting clinical symptoms (chest pain and chills) for over
2.5 years after transplant and her radiological and clinical fol-
low up signs indicate delayed bone healing.Conclusions 18F-
fluoride-PET/CT imaging may be useful to assess bone
healing in allogenic sternal bone graft according to SUVmax
measurements of bone fluoride metabolic activity. In particu-
lar, decreasing of SUVmax over time may indicate a good
incorporation of bone graft and therefore might have a prog-
nostic value for implant fixation.
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The effect of urinary activity on radiation dose in patients
undergoing PET/BT
s. s. gul1, O. Dilek Ciftci2, Z. Hasbek3, B. Ozturk1, T. Sahiner2;
1gaziosmanpasa university medicine faculty, tokat, TURKEY,
2The Ministry Of Health, Public Hospitals Association, Istan-
bul, TURKEY, 3cumhuriyet university medicine faculty, sivas,
TURKEY.
Aim: Positron Emission Tomography / Computed Tomogra-
phy (PET/CT) has an increasing importance in oncological
diseases. The most common clinical indications include onco-
logic diagnosis, staging, re-staging and evaluation of response
to therapy. The aim of this study was to determine the amount
of radiation to which patients undergoing PET/CTare exposed
due to the activity retention accumulated in the bladder and to
identify the factors affecting this process.Material-Methods: A
total of 303 patients (109F and 194M; mean age 62±13 years)
referred from the oncology outpatient clinic for F-18
fluorodeoxyglucose PET/CT were included in the study. The
patients with at least 4 hours of fasting were examined for
physical parameters including body height and weight, and
blood glucose level. Patients were asked to drink 1 liter of
drinking water within 45 min before the scan. Patients were
divided into groups according to the oncological diagnosis. In
all patients, radioactivity was measured by Geiger Muller de-
vice from a distance of 1 meter when the bladder is filled and
emptied. Then, percentage of radioactivity excretion was cal-
culated. Results were analyzed by statistical analysis
program.Results: When all groups were analyzed together,
the average excretion of radioactivity was 16.2±11%. Excre-
tion of radioactivity was 17.9% vs. 7.1% in patients with head
and neck cancer compared to those with bladder/urethral can-
cers, with a statistically significant difference between these
two groups (p=0.000). The distribution of all groups is illus-
trated in Figure 1. There was a significantly positive correla-
tion between body mass index and percentage of radioactivity
excreation.Conclusion: Modern imaging techniques aims to
achieve the most detailed images without causing any damage
to the body or with the least possible harm. The radioisotopes
are excreted via the urinary system in patients undergoing
PET/CTscan. Therefore, in the context of biological excretion,
the radioactivity concentration and dose value is high in the
bladder. Moreover, the positive correlation found between
body mass index and percentage of radioactivity excretion
was considered to be related to the lower 18-FDG uptake in
the adipose tissue. It was concluded that it is important for the
control of radioactivity in patients undergoing PET/CT scan to
empty their bladder frequently.
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Partial Volume Effect Impact On PET Preclinical
Dosimetry: An Analytical Simulation Study
A. Seret1, M. Bahri1, C. Comtat2,3,4, F. Bretin1, A.
Plenevaux1; 1University of Liege, Liege, BELGIUM, 2CEA,
DSV, I2BM, SHFJ, Orsay, FRANCE, 3UMR 1023 Inserm/
CEA/Université Paris Sud, Orsay, FRANCE, 4ERL 9218
CNRS, Orsay, FRANCE.
Aim. The limited spatial resolution of positron emission tomog-
raphy (PET) strongly impacts preclinical dosimetry. It was pro-
posed to combine dynamic imaging and organ harvesting in
order to scale the PET time activity curve based on ex-vivo
measurements. It was also suggested for the organ region of
interest (ROI) to substitute centred small (3-mmdiameter) spher-
ical ROI (SROI) for the ROI based on organ anatomy (AROI).
We aimed here to evaluate these twomethods using an analytical
PET simulator (APS) and a mouse phantom. Materials and
Methods. The geometry of the microPET Focus 120 was intro-
duced in the APS and the resolution was fine tuned in order to
get recovery coefficients for the NEMANU4 IQ phantom close
to measured values. A numerical and physical mouse phantom
was designed: the body was assimilated to a cylinder and the
main organs (brain, heart, lungs, liver, pancreas, spleen, kidneys
and bladder) were assimilated to ellipsoids. Attenuation
corrected PET data were simulated and reconstructed using 3D
filtered backprojection. First the activity per unit volume (A)
was set identical in all organs and to zero in the lungs. Data were
obtained with the microPETand APS.Moreover APS data were
generated for different organ to background ratios (R) ranging
from no background to R = 2. Second, A was extracted from
experimental results obtained for F-DOPA, F-Tyr and UCB-H at
two early and the last time points and used as APS inputs. Awas
measured on the reconstructed images using SROI and AROI
and used to compute the recovered activity (RA) defined as the
ratio between measured and expected A. Results. Experimental
and simulated A matched to within 10%. For identical A simu-
lations, RA increased with R (0.65-1.25) in a clear organ size
dependent way with AROI. With SROI the dependency (0.80-
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1.15) was still present for the bladder and the spleen and almost
disappeared (0.95-1.05) for the other organs. For data simulating
the tracers, RA depended on the time point for AROI with
variations of up to 20% and more for the bladder and sometimes
for one time point of one specific organ. The dependency did
almost disappear for SROI. The RA clearly dependent on Rwith
AROI but only to a very limited extend with SROI. Conclusion.
SROI and post-scan organ harvesting minimize the impact of
partial volume effect in preclinical PET dosimetry providing that
organ harvesting could be considered as gold standard.
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Normal SUV values measured from Ga-68 labeled
somatostatin analogue DOTATE PET/CT in patients
with neuroendocrine tumors
U. Elboga1, H. Komek2, M. Basıbuyuk1, S. Altındag2, Y.
Celen1; 1Gaziantep University, Gaziantep, TURKEY, 2Diyar-
bakır Training and Research Hospital, Nuclear Medicine De-
partment, Diyarbakır, TURKEY.
OBJECTIVE The objective of the study was to determine the
normal biodistribution of Ga-68 labeled somatostatin analogue
DOTATE; to establish the range of its uptake in liver, bone and
lymph node metastases in patients with neuroendocrine tumors
(NET); to establish the cut-off value for differentiating between
physiological uptake and tumor related somatostatin expression in
the processus uncinatus of pancreas.MATERİAL AND
METHODS Maximum standardized uptake values (SUVmax)
of Ga-68 labeled somatostatin analogue DOTATE were deter-
mined in normal organs of 81 NET patients undergoing receptor
PET/CT. In addition, SUV(max) of primary neuroendocrine tu-
mors, liver, bone and lymph node metastases were
evaluated.RESULTSSUVmax (mean + or - standard deviation)
were determined in: pituitary gland 2.5 + or - 1.1, thyroid: 3.8 +
or - 1.2, lung: 0.9 + or - 0.7, normal liver: 6.3 + or - 1.5 , spleen: 20
+ or - 11.0, adrenal 4.9 + or - 2.2, kidney: 12.7 + or - 3.6, gastro-
intestinal tract 2.6 + or - 1.1, gluteal muscle:1.1 + or - 0.2, femur
0.9 + or - 0.4, blood pool 2.7 + or - 1.3 and processus uncinatus of
pancreas 5.6 + or - 2.3. SUV(max) of Ga-68 labeled somatostatin
analogue DOTATE was 22.4 + or - 11.2 (N=21) in liver metasta-
ses, 11.3 + or - 9.1 (N=7) in lymph nodesmetastasis, 9.4 + or - 5.3
(N.=8) in bone lesions, and 18.1 + or - 9.2 (N=3) in neuroendo-
crine primary tumors. Target to non target (T/NT) ratios were 3.1
+ or - 1.8 for liver metastases.CONCLUSION Ga-68 labeled
somatostatin analogue DOTATE is an excellent tracer for the im-
aging of tumours expressing somatostatin receptors on the tumour
cell surface, which, due to the high target to non-target ratios,
allows the detection of very small lesions, especially of lymph
node and bone metastases. There is a broad range of somatostatin
receptor expression in metastastic lesions and in NET.
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Detection of gastrointestinal cancer using 4’-[methyl-11C]
thiothymidine PET/CT for proliferation imaging:
comparison with 18F- FDG PET/CT
Y. Fukuda1, Y. Yamamoto1, H. Yamamoto2, R. Ishikawa3, S.
Akamoto4, J. Toyohara5, Y. Nishiyama1; 1Department of Ra-
diology, Kagawa University, Kita-gun Kagawa, JAPAN, 2De-
partment of Medical Physics, Kagawa University, Kita-gun
Kagawa, JAPAN, 3Department of Diagnosis Pathology, Kaga-
wa University, Kita-gun Kagawa, JAPAN, 4Department of
Gastroenterological Surgery, Kagawa University, Kita-gun
Kagawa, JAPAN, 5Research Team for Neuroimaging, Tokyo
Metropolitan Institute of Gerontology, Tokyo, JAPAN.
Aim: 4’-[methyl-11C]-thiothymidine (4DST) has been devel-
oped as an in vivo cell proliferation marker based on the DNA
incorporation method. The purpose of this study was to investi-
gate the feasibility of 4DST PET/CT for the detection of gastro-
intestinal cancer, in comparison with 2-deoxy-2-18F-fluoro-D-
glucose (FDG) PET/CT, and determined the degree of correla-
tion between two radiotracers and proliferative activity as indi-
cated by the Ki-67 index. Materials and Methods: A total of 9
patients with newly diagnosed gastrointestinal cancer were ex-
amined with both 4DST and FDG PET/CT studies. Tumor le-
sions were identified as areas of focally increased uptake, ex-
ceeding that of surrounding normal tissue. For semi-quantitative
analysis, the maximal standardized uptake value (SUV) was
calculated. Proliferative activity as indicated by the Ki-67 index
was estimated in tissue specimens. Immunohistochemical find-
ings were correlated with SUVs. Results: In all 9 patients, gas-
trointestinal cancer were detected by both 4DSTand FDG PET/
CT studies. Although the mean (±SD) SUV for 4DST (6.43
±2.13) was lower than that for FDG (16.00 ± 14.24), the differ-
ence was not statistically significant (p=0.051). A significant
correlation was observed between 4DST SUV and FDG SUV
(r=0.856, P<0.004). A significant correlation was observed be-
tween 4DST SUVand Ki-67 index (r=0.757, P<0.018) and for
FDG SUV (r=0.717, P<0.030). Conclusion: These preliminary
results indicate that 4DST PET/CT seems to be useful in detect-
ing gastrointestinal cancer and in the noninvasive assessment of
proliferation, as similar as FDG PET/CT.
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Lung invasive fungal infection (IFI) in acute myeloid
leukemia (AML) patients: has 18-FDG-PET/CT
an additional role with respect to CT scan?
L. Baratto1, F. Elisei2, C. Crivellaro1,2,3, E. De Ponti4, L.
Verga5, F. Farina6, C. Dolci3, C. Zarcone1, L. Guerra2, C.
Landoni1; 1Department of Nuclear Medicine, University of
Milan-Bicocca, Milan, ITALY, 2Department of Nuclear
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Medicine, San Gerardo Hospital, Monza, ITALY, 3Tecnomed
Foundation, University ofMilan-Bicocca,Milan, ITALY, 4De-
partment of Medical Physics, San Gerardo Hospital, Monza,
ITALY, 5Department of Haematology, San Gerardo Hospital,
Monza, ITALY, 6Department of Haematology, University of
Milan-Bicocca, Milan, ITALY.
BACKGORUND: Combined anatomic and functional imag-
ing with (18)F-FDG PET/CT is slowly gaining foothold in the
management of various infective pathologic abnormalities.
AIM: To evaluate the potential additional role of FDG PET/
CT with respect to conventional CT scan, in acute myeloid
leukemia (AML) patients with lung invasive fungal infection
(IFI). MATERIALS AND METHODS: Twelve patients with
AML and suspected lung IFI performed chest CT scan (CT1)
followed by PET/CT (PET1) scan, before antimicotic treat-
ment. CT and PET/CT were repeated 2 months after the be-
ginning of treatment (n= 10 pts) and compared to basal eval-
uations to assess treatment efficacy (CT2, PET2): lesion with
the highest FDG uptake was selected as “reference lesion” and
SUVmax was calculated for PET1 and PET2. Metabolic re-
sponse (MR) was measured as follow: complete MR (CMR,
uptake ≤ than mediastinal blood-pool), partial MR (PMR, par-
tial reduction of the lesion uptake > than mediastinal blood-
pool), progressive disease (PD, increase uptake and/or new
lesions). RESULTS: In 12/12 cases (100%) PET1 and CT1
were positive for IFI. Themean SUVmax was 6.5 ± 2.4 (range
3.3-11.8). PET2 (n = 10) showed 4 CMR, 2 PMR, (with a
mean reduction of SUVmax=53%), 2 PD and 2 with both
PMR of reference lesion and concomitant new PD lung lesions
with FDG uptake (PMR/PD). In the same group of 10 patients,
CT2 was concordant with PET2 in 8/10 cases (80%), while in
2 cases CT2 showed partial reduction of lung lesions and a
CMR on PET2. Of the 8 concordant patients, 5 died because of
infections (2PMR, 2PD, 1 both PMR/PD), and 3 are alive,
median follow-up 356 days from PET/CT1, (2 CR and 1 PR/
PD). Of the 2 discordant patients 1 died because of sepsis, and
1 patient is on follow-up (150 days). CONCLUSION: In mon-
itoring treatment efficacy of IFI in AML patients, CTand PET/
CT were concordant in 80% of cases (8/10), while in 2 cases
PET showed a complete metabolic response in a persistent
lung lesion at CT. However these preliminary data cannot
support a relevant additional role of PET with respect to CT
scan; further follow-up and larger studies are needed.
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Prognostic value of post-treatment 18F-FDG PET/CT
imaging in patients undergoing radio-chemotherapy
for inoperable lung cancer
H. Svirydenka, S. Diodato, S. Sanfilippo, S. Cambioli, E.
Tabacchi, C. Nanni, P. Castellucci, S. Fanti; Nuclear Medicine,
Policlinico S.Orsola-Malpighi; University of Bologna, BO-
LOGNA, ITALY.
Aim: Evaluation of the prognostic value of post-treatment 18F-
FDG PET/CT correlated with overall survival and progression
free survival in patients with inoperable lung cancer treated with
concomitant radio-chemotherapy . Material and Methods: We
retrospectively studied 31 patients (pts) with stage IIB e IIIA
of NSCLC lung cancer ineligible for surgery because of tumor
characteristics and/or concomitant disease. All patients, 18 male
and 15 female with mean age of 68 y.e. (range 58-86 y.e.),
underwent definitive concurrent radio-chemotherapy between
2008 and 2014. For patients received multiple courses of radio-
therapy, only the first coursewas included. Staging and restaging
after completion of treatment 18F-FDG PET/CT scans were
performed at our institution. The SUVmax in the mediastinal
blood pool and the normal liver was confirmed to be stable
between the pre-treatment and post-treatment scan. Response
evaluation with PET/CT was performed according to the
EORTC criteria. We based on PET/CT and/or clinical-
radiological follow up. Progression free survival (PFS) was de-
termined from the date of completion of therapies until the post-
treatment PET/CT. Overall survival (OS) was calculated from
the date of completion of treatment until the date of last follow-
up. Results: The mean time after completion of therapy and
post-treatment PET/CT was 3.7 months. At a mean PET
follow-up of 12.1 months (range 3 - 30 months) according to
criteria EORTC progression disease (PD) was observed in 14
out of 31 pts (45.2%); CR (complete response) in 7 out of 31 pts
(22.6%); PR (partial response) in 10 of 31 pts (32.2 %); no pts
presented SD (stabile disease). Mean PFS was 3.4 (range 1-10)
months and OSwas 12.9 (range 2- 39) months.We observed the
worst OS (mean OS of 7.4 months) in pts with progressive
disease on post treatment PET/CT. Mean OS in pts with CR
was 21.7 months. Mean OS in PR was 13.9 months. Conclu-
sion: PD according to EORTC criteria of 18F-FDG PET/CT
seems to be correlated with worst OS in lung cancer pts treated
with concurrent radio-chemotherapy, suggesting a prognostic
role of PET/CT scan. Because of small number of included
patients further studies are necessary to confirm our findings.
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Comparison of C-11 Choline and C-11 Acetate PET/CT
imaging for tumor detection and localization in patients
with prostate cancer
R. Haloi, L. G. Jordan, III, B. J. Kemp, N. Tosakulwong, S. D.
Weigand, M. Nathan, R. C. Murphy, E. D. Kwon, V. J. Lowe;
Mayo Clinic, Rochester, MN, UNITED STATES.
Objective: Prostate cancer is the most prevalent type of non-
skin cancer in men and the second highest cause of cancer-
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related death in men. Prostate tumor cells have increased cho-
line and acetate uptake due to elevated synthesis of phospha-
tidylcholine and lipids, respectively. As a result, choline and
acetate labeled with the positron emitter, carbon-11 (C-11), can
be used for clinical imaging of prostate cancer. Our objective
was to prospectively compare image interpretation of C-11
choline and C-11 acetate PET/CT in patients with either local-
ized prostate cancer or known metastatic prostate
cancer.Methods: Eight subjects (5 with localized cancer; 3
with metastatic cancer), each having C-11 choline and a
C-11 acetate PET/CT performed on the same day were evalu-
ated. Isolated C-11 choline and C-11 acetate PET images (and
corresponding unenhanced CT images) of 14 selected lesions
were anonymized and randomized. Independent evaluation
was performed by two experienced readers blinded to all other
information, including the radiotracer identity. Each reader
used a 3 point scale to independently score each lesion for
conspicuity, image quality, and confidence in malignancy (5
point scale). Two weeks later, the images were permuted for
re-evaluation by the same reviewers. The maximum standard-
ized uptake value (SUV max) was calculated for the lesions
and the paired differences were analyzed with a linear mixed
effects model with a random intercept. Ordinal logistic regres-
sion analysis with a random subject-specific intercept was per-
formed to model the relative odds of a higher score for C-11
Choline PET/CT readings.Results: For the lesions evaluated,
the mean ± SE SUV max values were higher for C-11 choline
(6.2 ± 0.7) in comparison to C-11 acetate (4.8 ± 0.7). The mean
SUV difference of 1.5 ± 0.4 was significant (p=0.01). An
increased odds ratio (OR) was observed in C-11 choline vs
C-11 acetate for confidence in malignancy diagnosis (OR
3.8, 95% CI 1.3 to 10.7, p=0.01), lesion conspicuity (OR
4.6, 95% CI 1.1 to 19, p = 0.03), and overall image quality
(OR 3.6, 95% CI 1.6 to 7.8, p = 0.001).Conclusion: In this
small, prospective blinded comparison study, C-11 choline
PET/CT demonstrated higher lesion-to-lesion comparison
SUVmax values. Reader diagnostic confidence in malignancy
was higher with C-11 choline vs C-11 acetate PET/CT and
enhanced overall image quality and lesion conspicuity for
C-11 choline PET/CTwas seen. These data support C-11 cho-
line as the preferred PET/CT tracer agent for evaluating pros-
tate cancer patients.
P137
Biodistribution of Ga-68 labelled PSMA ligand in normal
tissues with PET/CT imaging
H. Komek1, U. Elboga2, C. Can1, M. Basıbuyuk2, Y. Celen2;
1Diyarbakır Training and Research Hospital, Nuclear Medi-
cine Department, Diyarbakır, TURKEY, 2Gaziantep Universi-
ty, Department of Nuclear Medicine, Gaziantep, TURKEY.
Objective: Prostate-specific membrane antigen(PSMA) is a
type II transmembrane protein with high expression in prostate
carcinoma cells. Recently, Ga-68 labelled Glu-NH-CO-NH-
Lys-(Ahx)-[Ga-68(HBED-CC)](Ga-68 PSMA) is a highly
promising tracer for imaging recurrent prostate cancer. Our
initial experience with Ga-68 PSMA suggests that this novel
tracer can detect prostate carcinoma relapses and metastases
with high contrast by targeting PSMA The aim of this study
was to investigate its biodistribution in normal tissues. Mate-
rial and Methods: A total of 43 patients with prostate carcino-
ma and rising prostate specific antigen levels underwent Ga-68
PSMA PET/CT. Quantitative assessment of tracer uptake was
performed 1 post-injection by analysis of mean and maximum
standardized uptake values (SUVmean/max) of several organs
were calculated. Results: Visual evaluation revealed intense
radiotracer uptake in the lacrimal and salivary glands, as well
as in the spleen, liver, small intestines, kidneys and urinary
tract. Some uptake was also seen in the large intestine. The
highest uptake was observed in the kidneys and salivary gland.
The SUVmax for the kidneys and salivary gland was 49.3 ±
16.1 and 22.2 ± 4.3, respectively. The SUVmax for the intes-
tines, spleen, liver, lacrimal glands and prostate was 14.5 ± 5.9,
11.8 ± 5.3, 13.7 ± 3.1, 9.3 ± 4.5. and 4.8 ± 3.2, respectively.
Quantitative assessment revealed excellent contrast between
tumour lesions and most normal tissues. Conclusion: The
biodistribution of the Ga-68 PSMA tracer was analysed in
43 patients. Within healthy organs, kidneys and salivary
glands demonstrated the highest radiotracer uptake, whereas
lacrimal gland, liver, spleen and bowel showed relatively mod-
erate uptake. This study has certain limitation such as its small
patient population.
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Metabolic Tumor Volume and Total Lesion Glycolisis
in 18F-FDG PET-CT Studies. Are they Useful to Predict
Recurrence in Locally Advanced Breast Cancer Patients?
O. Salsidua-Arroyo1, A. Jiménez-Ballvé1, M. García García-
Esquinas2, C. Rodriguez Rey1, A. Ortega Candil1, M. Pedrera-
Canal1, J. A. García Saenz3, C. Riola-Parada1, J. L. Carreras-
Delgado4; 1Nuclear Medicine Department. Hospital Clinico
San Carlos, Madrid, SPAIN, 2Nuclear Medicine Department/
Radiology Department. Hospital Clinico San Carlos, Madrid,
SPAIN, 3Oncology Department. Hospital Clinico San Carlos,
Madrid, SPAIN, 4Nuclear Medicine Department. Hospital
Clinico San Carlos. Universidad Complutense Madrid, Ma-
drid, SPAIN.
Aim: The aim of this study was to investigate the prognostic
value of metabolic tumor volume (MTV) and total lesion
glycolisis (TLG) in patients with locally advanced breast can-
cer (LABC). Material and methods: A retrospective study with
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35 LABC patients between December 2009 and November
2010 was performed. SUVmean, MTV and TLG were calcu-
lated (cutoff 2.0). After neoadyuvant chemoterapy all patients
had surgery and were followed up until January 2015. Results:
83% (29/35) of the patients were disease-free and 17% had
recurrence (2 with locoregional disease and 4 with distant
metastasis). No significant differences in SUVmean were
found according to the recurrence status. Although differences
in SUVmax were found, they were not clinically relevant. The
differences in MTV and TLG where statistically significant
(p=0.02 and p=0.026, respectively). Using ROC curves we
calculated a cutoff of 20.9 for the MTV and 108 for the
TGL, to predict recurrence with a sensibility of 83% for both
values, and a specificity of 72% for the MTVand 76% for the
TGL . A Cox proportional hazards model, showed that the
recurrence risk was 9,6 times more when the VMTwas equal
or greater than 20,9 and of 11,2 times more when TGL was
equal or greater than 108. A concordance between VMT and
TGL was observed in all cases except one. Conclusions: The
MTVand TLG could be useful to predict which patients with
LABC have more probability to have a recurrence. Both pa-
rameters have a good concordance.
P139
Comparison between FDG-PET and DWIBS
in Diagnosing Neuroblastoma of Child
H. Ishiguchi, S. Ito, Y. Sakurai, H. Kawai, K. Kato, S.
Naganawa, A. Hama, H.Muramatsu, Y. Takahashi, S. Kojima;
Nagoya University Graduate School of Medicine, Nagoya,
JAPAN.
Aims: To compare the efficacy of F-18 fuluoro-2-D-glucose
positron emission tomography with CT (FDG-PET/CT) and
whole-body diffusion-weighted MRI called diffusion-
weighted whole-body imaging with background body signal
suppression (DWIBS) for the detection of lymph node metas-
tases and bone metastases in child patients with neuroblasto-
ma. Materials and methods: Subjects in this retrospective
study comprised 16 patients (7 men, 9 women; mean age,
2.8±2.0 years old) with neuroblastoma who underwent both
FDG-PET and DWIBS between January 2008 and February
2015. All patients were diagnosed as neuroblastoma based on
pathological findings. Eight regions of lymph nodes and 17
segments of skeleton in all patients were evaluated. I-123
MIBG scintigraphy, bone scintigraphy and CT performed at
the same time as FDG-PET and DWIBS were used for diag-
nosis of lymph node and bone metastasis. Two radiologists
evaluated the uptake of lesions in PET-CT and the signal-
intensity of lesions in DWIBS visually. The sensitivities and
specificities of FDG-PET and DWIBS were calculated.
McNemer test was used to compare the sensitivities and
specificities of FDG-PET and DWIBS. P value less than
0.05 was considered statistically significant. Result: Lymph
node metastases were confirmed in 38 of 127 regions. For
detecting lymph node metastasis, the sensitivities of FDG-
PET and DWIBS were 92.1%(35/38) and 81.5%(31/38), re-
spectively, and the specificities of themwere 100%(89/89) and
100%(89/89), respectively. No significant difference was ob-
served in these values. Bonemetastases were confirmed in 103
of 266 segments. For detecting bone metastasis, the sensitivi-
ties of FDG-PET and DWIBS were 75.7%(78/103) and
93.2%(96/103), respectively, and the specificities of them
were 93.2%(152/163) and 84.2%(137/163), respectively. The
sensitivity of DWIBS was significantly higher than that of
FDG-PET (P<0.01) and the specificity of FDG-PET was
higher than that of DWIBS significantly (P<0.05). Conclu-
sion: For detecting lymph node metastasis, the sensitivities
and specificities of both FDG-PETand DWIBS indicated high
values. For detecting bone metastasis, DWIBS was more sen-
sitive than FDG-PET, whereas FDG-PET was more specific
than DWIBS. In patients with neuroblastoma, FDG-PET and
DWIBS possibly play a complementary role each other for
detecting bone metastasis.
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18FDG PET/CT in initial staging of lung cancer :
experience of a tertiary medical center in Casablanca
Morocco
S. TALEB, G. CHERKAOUI SALHI, M. AIT IDIR, S.
CHOUKRY, A. GUENSI; Nuclear medicine department, CA-
SABLANCA, MOROCCO.
Lung cancer is the most frequently diagnosed malignancy in
males. It represents more than 25% of all cancer deaths. In
Morocco, its incidence rates are estimated to 25.9 and 2.9/
100,000 in males and females respectively. Among different
imaging tools, PET/CT using 18-FDG is now described by
many studies as the best imaging test for its staging and treat-
ment monitoring. The aim of this study was to report the ex-
perience of a Moroccan tertiary medical center in 18 FDG
PET/CT use in the management of patients with lung cancers.
Between December 2012 and December 2014, A total of 89
patients underwent a 18 FDG PET/CT for a suspicion or a
confirmed lung cancer. Sex ratio was 10. Mean age 60.2 ± 9
years. Among these patients, 56% were sent for metabolic
characterization of a solitary pulmonary mass (group 1) and
44% were sent for initial staging of a biopsy-proven lung can-
cer (group2); epidermoid carcinoma in 37%, adenocarcinoma
in 54%, and small cell lung cancer in 9%. In the group 1, PET-
CT results showed a high uptake in the solitary pulmonary
masse in all cases associated to distant metastases in 87% of
cases. In the group 2, distant metastases were noted in 86% of
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cases. Mean initial tumour SUV max was 13.4 (+/- 7). PET/
CT upstaged 19% of patients showing nodal extension in 7%
of cases and distant metastasis in 10% of cases which were not
noted in the prior CT-scan. 18FDG PET /CT is an interesting
tool in lung tumors management. Its systematic use for initial
staging would allow a more precise staging and hence a more
adapted treatment. Unfortunately, the lack of nuclear centers in
our context retards its routine use in lung cancer patients’
management.
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Associations between brain global hypometabolism
and various clinical parameters in healthy subjects
H. Nam1, S. Jun2; 1Samsung Changwon Hospital,
Sungkyunkwan University School of Medicine, Changwon,
KOREA, REPUBLICOF, 2Kosin University Gospel Hospital,
Kosin University College of Medicine, Busan, KOREA, RE-
PUBLIC OF.
Purpose: We investigated the correlations between the
degree of brain fluoro-2-deoxy-D-glucose (FDG) uptake
and various physical, and laboratory parameters to de-
f i n e t h e p r e d i c t o r s r e l a t e d t o b r a i n g l o b a l
hypometabolism. Methods: We retrospectively reviewed
188 consecutive subjects who underwent a general
health check-up including F-18 FDG positron emission
tomography/computed tomography (PET/CT) scan. After
an overnight fast, peripheral blood was drawn to mea-
sure the levels of laboratory parameters. All measure-
ments were conducted on the same day on which F-18
FDG PET/CT scan was performed. The 25th percentile
of maximal standardized uptake value (SUVmax) of the
brain in all subjects was 13.265 and we chose this value
as the cut-off for dividing subjects into two groups.
Results: Subjects with lower FDG uptake in the brain
were older, and had higher serum triglyceride, fasting
blood glucose (FBG), Hb1Ac levels than those with
higher uptake. Brain FDG uptake of 32 subjects
(17.0%), who were diagnosed with metabolic syndrome,
was lower than that of subjects with non-metabolic syn-
drome (14.26 ± 2.96 vs 15.88 ± 3.17, P=0.0083). Brain
FDG uptake was negatively correlated age, FBG level,
Hb1Ac, mean blood pressure. No positive correlation
was between brain FDG uptake and clinical parameters.
Under multiple regression analysis, FBG level and age
we r e s i gn i f i c an t p r ed i c t o r s f o r b r a i n g l oba l
hypometabolism. Conclusion: the brain may show low
FDG uptake without any brain disease when F-18
FDG PET-CT was performed in an older subject with
diabetes mellitus or hyperglycemia.
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Assessment of heart injury induced by radiation therapy
for esophageal cancer using FDG-PET/CT
K. Hanaoka, M. Hosono, M. Inada, K. Sakaguchi, K.
Shimomura, M. Tamura, K. Matsumoto, H. Monzen, Y.
Nishimura; Kinki University, Osaka Sakai-city, JAPAN.
Objectives: There have been numerous reports on radiation-
inducedmyocardial damage after radiation therapy. The aim of
this study is to evaluate the feasibility of FDG-PET/CT for the
detection of radiation-induced myocardial damage. Methods:
Thirty patients (5 females and 25 males, mean age: 66.7 ± 8.6
years, range: 62-81 years) with histologically confirmed
esophageal cancer who underwent radiation therapy between
January 2007 and November 2011 were enrolled in this retro-
spective study. All patients underwent pre- and post-
therapeutic FDG PET/CT. The fasting period before intrave-
nous administration of FDG was at least 4 hours. Bull’s eye
maps of myocardial FDG uptake were generated by Quantita-
tive Perfusion SPECT. On radiation dose charts gererated by a
3-demensional radiation therapy planning system, the maxi-
mum dose to the left ventricle and radiation dose distribution
were estimated. Changes of FDG accumulation on the left
ventricle before and after radiation therapy were compared
with the radiation dose distribution. Results: The proportion
of the left ventricle volume receiving at least 20, 30, 40, and
50 Gy were 29.66±20.66, 16.64±16.89, 9.05±12.62, and 3.30
±5.82%, respectively. Maximum dose in the left ventricle were
47.45±15.63 Gy (range: 14.28 - 62.63). Focal increased FDG
uptake in the irradiated field of myocardium was seen in 5
patients. On the other hand, the maximum dose to the left
ventricle or radiation dose distribution was not significantly
correlated with the shift of FDG accumulation. Conclusions:
We demonstrated the feasibility of evaluating myocardial
damage by the comparison of Bull’s eye map of FDG and
radiation dose charts. This method could be useful in the man-
agement of patients with radiation-induced heart injury.
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Molecular imaging of HER2 postive tumor cell by HER2
specific 18F-labeled aptamer
h. kim, Y. Cho, J. Chae, J. Park, W. Kang; yuhs, Seoul, KO-
REA, REPUBLIC OF.
Receptor tyrosine-protein kinase erbB-2, or HER2, is a mem-
ber of the human epidermal growth factor receptor family.
HER2 regulates a variety of cell functions associated with
cancer cell proliferation and opposes apoptosis through acti-
vating signal transduction pathways such as MAPK (mitogen-
activated protein kinase) and/or PI3K (phosphoinositide 3-
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kinase). Amplification or aberrant expression of the HER2
occurs in several breast, ovarian, gastric and other cancers.
HER2-positive tumors associated with a higher rate of recur-
rence and poor prognosis. Thus, a variety of HER2 specific
antibodies and small molecules have been assessed. Aptamer
is small single-stranded oligonucleic acid that binds to a target
molecule avidly and specifically. Hence, it is regarded as ideal
biomarker to recognize and represent expression of the target
molecule. The aim of this study is to elucidate the usefulness
of HER2 specific 18F-labeled aptamer as molecular imaging
prove. In this study, fluorescence-labeled HER2 specific
aptamer was conjugated the HER2 positive and negative cell
line for evaluate binding affinity in vitro. And we labeled
radioisotope, 18F to the HER2 specific aptamer for in vivo
molecular imaging. We intravenously injected 18F-labeled
HER2 aptamer into mice tumor model and performed PET
imaging by Siemens Inveon PET. The 18F-labeled HER2 spe-
cific aptamer microPETshowed significantly increased uptake
at HER2 positive than negative tumor in vivo. Uptake of
HER2 in histologic sections correlated with immunohisto-
chemistry of tumor tissue. The 18F-labeled aptamer visualized
HER2 expression of breast cancer cell line and tumorigenesis
in mice. And these data suggest potential use of radiolabeled
aptamer as a theragnostic tool for HER2 positive cancer.
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F-18 FDG PET metabolic parameters in nasopharyngeal
carcinoma patients with and without distal metastases
W. Huang1, K. Lee2, S. Li3, Y. Kuo4, L. Wong1, K. Ma4, C.
Cheng4, B. Hsieh2, M. Chen3; 1Departments of Nuclear Med-
icine, Changhua Christian Hospital, Changhua, TAIWAN,
2Departments of Medical Imaging and Radiological Sciences,
Central Taiwan University of Science and Technology, Tai-
chung, TAIWAN, 3Departments of Otorhinolaryngology,
Changhua Christian Hospital, Changhua, TAIWAN, 4Depart-
ments of Biology and Anatomy and Nuclear Medicine, Na-
tional Defense Medical Center, Taipei, TAIWAN.
Aim: Nasopharyngeal carcinoma (NPC) is a common malig-
nancy in southern Asia with different staging stratification
from other cancers. About 20% of metastatic free (M0) NPC
patients, however turned to distant failure (M1) in 3 years after
completion of treatment resulting in patient mortality (Kam
et al, 2004). We thus analyzed the relationship between meta-
bolic parameters of F-18 FDG PET in NPC patients with and
without metastases (i.e. M0 and M1). Materials: Eighty pa-
tients in all stages including 36 in stage IV were studied. They
were devided intoM0 vs. M1 (n=69 vs. 11 in all stages; and 25
vs. 11 in stage IV). F-18 FDG PET was performed using an
integrated PET/CT (Gemini GXL). The FDG metabolic pa-
rameters including SUVmax and SUVmean, primary and total
tumor volume and glycolysis (i.e. PTV, PLG, TTV and TLG)
were calculated using PMOD software. A threshold of 42% of
the SUVmax was applied to delineate the PTV or TTV. The
PLG or TLG was calculated as mean SUV multiplied PTVor
MTV. Metastases were considered by histology or various
images with a clinical concordance. Results: Significant dif-
ferences in PTV, PLG, TTVand TLG were found betweenM0
and M1 in patients covering all stages. However, only TTV
and TLG revealed significant difference in the stage IV sub-
group (Mo vs. M1: 26±14 vs. 88±54 and 213±160 vs. 615
±160; p<0.01, each). The SUVmax and SUVmean of primary
tumors showed no statistical significance between M0 andM1
in either the all stage group or the stage IV subgroup. Conclu-
sion: TTV and TLG may play a role in evaluating metastatic
status of patients with NPC, either in all stages or in stage IV
subgroup.
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Study of game-theoretical image segmentation algorithm
for PET imaging
D. Borys, D. Pierscinska, M. Danch-Wierzchowska; Silesian
University of Technology, Gliwice, POLAND.
Aim: Image segmentation is very useful and not trivial step in
image analysis. One example could be tissues separation or
tumour delineation in medical imaging. Among broad number
of segmentation algorithms, we used those, based on cluster-
ing. For segmentation purpose the notion of evolutionary
games theory was used. Materials and method: Data has been
obtained with Philips Gemini hybrid PET/CT device at De-
partment of PET Diagnostics, Maria Sklodowska-Curie Me-
morial Cancer Center and Institute of Oncology Gliwice
Branch. Used phantom was a standard cylinder with five
spheres of different radius and volume (diameter from
1.3 cm up to 4 cm). Spheres have been filled with F-18 with
constant concentration. For segmentation purpose, an algo-
rithm, introduced by M.Pellilo was implemented and tested.
Main idea is to represent image as edge-weighted graph, where
vertices correspond to individual pixels and their weights re-
flect similarity between them. The clustering algorithm uses
replicator dynamics. Pixels are allocated to the cluster which is
removed from the graph. Described process will be repeated
until all pixels are assigned to corresponding clusters. The
algorithm determines number of clusters in the image. We
applied the method to segment intensity images and compare
it with other popular medical images processing methods
(threshold based: absolute SUV 2.5 threshold, fixed and adap-
tive threshold range of 41-70% of maximum value and
contrast-oriented method). Results obtained for each segmen-
tation were compared to CT image based reference mask by
using a Jaccard index, which has range [0,1] and 1 corresponds
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to full similarity of sets. Results: The Jaccard index obtained
for tested methods has mean value of 0.52 with range (0.28,
0.77). The most exact methods were SUV 2.5 threshold with
accuracy value of 0.7 and proposed game theoretic based
method with accuracy value of 0.77. Methods based on fixed
and adaptive thresholds were far less precise. Conclusion: The
highest similarity to reference mask obtained from CT images
was obtained using proposed game theoretic method. Howev-
er, this method is a graph based method and size of analysed
images could be problematic. For bigger images inefficient
graph representation causes insufficient memory problem.
Further work will be concentrated on improving the efficiency
of the algorithm and process automation. Acknowledgment:
Grant No. UMO-2011/03/B/ST6/04384.
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Investigation of how the activity quantification using
different blood pool volume of interests and reconstruction
methods influence the absolute myocardial blood flow
determined with 13N-NH3 cardiac PET
S. Akil1, F. Hedeer1, J. Jögi1, H. Engblom1, C. Hindorf2; 1Dept
of Clinical Physiology, Lund University, Lund University
Hospital, Lund, SWEDEN, 2Radiation Physics, SkåneUniver-
sity Hospital, Lund, SWEDEN.
Aim: Accurate quantification of the activity in blood is crucial
for the determination of absolute myocardial blood flow
(MBF) from dynamic cardiac PET. The aim of this study
was to investigate quantification of absolute MBF by cardiac
PETwith different positions of left ventricular (LV) blood pool
volume of interests (VOI), in patients and in a phantom, using
two different reconstruction methods. Methods: Twelve pa-
tients diagnosed with coronary artery disease underwent car-
diac PETwith 13N-NH3 at rest and in stress (24 cardiac PET
studies). An acquisition in dynamic mode was performed dur-
ing the first 4 minutes (12x10 s, 2x30 s and 1x60 s) after
administration of 550 MBq of 13N-NH3. Images were recon-
structed using ordered subset expectation maximization
(OSEM) and filtered back projection (FBP). The VOI to quan-
tify the activity in the myocardial wall (epicardial and endo-
cardial borders) was kept constant for each study while the
activity in the blood was quantified within three different VOIs
drawn within the LV blood pool: 1) small basal 2) small apical
and 3) large extending from base to apex of the LV. The abso-
lute MBF was determined by the deGrado compartmental
model within the Carimas software (Turku, Finland) for the
three different blood pool VOIs. The MBFapical VOI/ MBFbasal
VOI andMBFLVVOI/ MBFbasal VOI (median; interquartile range)
were calculated. For the cardiac phantom, the myocardial wall
was filled with 13N-NH3 and the activity was determinedwith
the three VOIs previously described. Results: MBFapicalVOI/
MBFbasalVOI ratio was highest with both OSEM (1.28; 0.33)
and FBP (1.34; 0.29).MBFlargeVOI/MBFbasalVOI ratio was low-
est with both OSEM (1.10; 0.11) and FBP (1.09; 0.10). The
MBF determined with a basal VOI and FBP generally over-
lapped the MBF determined with the same VOI and OSEM.
For the phantom, 16% of the activity in the myocardial wall
was detected for a small apical VOI, 14% for a LV VOI and
5% for a small basal VOI despite the absence of activity in the
ventricular lumen. Conclusions: The absolute myocardial
blood flow determined with dynamic cardiac 13N-NH3 PET
gave similar results for the two reconstruction algorithms
(OSEM and FBP), but the MBF depends on the position of
the blood pool VOI. The VOI should, according to the phan-
tom study, be kept constant preferably in the basal part of the
LV blood pool, to enable accurate comparisons between ex-
aminations and patients.
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PET probe detecting acquired drug resistance
against EGFR targeted molecular therapy
A. Makino1,2, A. Miyazaki2, A. Tomoike2, H. Kimura2, M.
Hirata3, Y. Ohmomo3, M. Ono2, H. Okazawa1, Y. Kiyono1, H.
Saji2; 1University of Fukui, Eiheiji-cho, Yoshida-gun, Fukui,
JAPAN, 2Kyoto University, Kyoto, JAPAN, 3Osaka Universi-
ty of Pharmaceutical Sciences, Takatsuki, Osaka, JAPAN.
Aim: Epidermal growth factor receptor (EGFR) is related to
tumor cell survival and proliferations, and utilized as a molec-
ular target for tumor therapy. Gefitinib, which is a representa-
tive EGFR tyrosine kinase (EGFR-TK) inhibitor, shows cura-
tive effect against single mutated L858R EGFR-TK, and used
for non-small cell lung cancer (NSCLC) treatment. However,
it is reported that the following T790M mutation during the
chemotherapy causes the drug resistance. Repeated evaluation
of the EGFR-TK subtype expressed on tumor is important for
the facile treatment, but the problem is the methodology is
limited to invasive biopsy. In clinical practice, acquired drug
resistance by the second EGFR-TK mutation is mainly judged
by the therapeutic response. Therefore, development of a new
PET tracer detecting second EGFR-TK mutation is on
demanded. Materials and methods: Thienopyrimidine struc-
ture was selected as a base structure for a new PET tracer,
and five compounds (FTPs1~5) were designed and synthe-
sized. Utilizing ADP-Glo kinase assay kit (Promega, USA),
inhibitory activities of these compounds against L858R and
double mutated (L858R/T790M) EGFR-TKs were examined.
FTP3 was radiolabeled by 18F, and in vivo imaging was
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performed by animal PET system using mice bearing human
non-small cell lung cancer cells of NCI-H3255 and NCI-
H1975. Results and conclusion: FTPs1~5 were synthesized
by conventional organic chemical method. IC50 value
(EGFR-TK inhibition) of Gefitinib against EGFR-TK(L858R)
and EGFR-TK(L858R/T790M) was 0.021 and 7.11 mM, re-
spectively. Importantly, IC50 value of FTPs1~5 against EGFR-
TK(L858R/T790M) was over 10 mM, indicating FTPs1~5
could not bind to the double mutated EGFR-TK. On the other
hand, IC50 of FTPs3~5 against EGFR-TK(L858R) was lower
or comparable to that of Gefitinib. Then, [18F]FTP3 was syn-
thesized, and i.v. injected to tumor-bearing mice. In this study,
NCI-H3255 (EGFR-TK(L858R)), NCI-H1975 (EGFR-
TK(L858R/T790M)) were used for the model production,
and PET images were acquired at 3 h post-injection. Signal
intensity from H1975 was lower than that from H3255. The
following ex vivo study indicated tumor/muscle signal intensi-
ty ratio was 6.0 (H3255) and 2.0 (H1975). In conclusion,
[18F]FTP3 is a promising PET tracer to detect NSCLC, which
can be subjected to the EGFR targeted molecular therapy.
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PETwith 89Zr-anti-MT1-MMP in an orthotopic mouse
model of pancreatic ductal adenocarnima
M. A. Morcillo1, A. Garcia-Lucas1, F. Mulero2, P. P. Lopez-
Casas2, M. Oteo1, E. Romero1, A. Martínez1, A. G. Arroyo3,
M. Hidalgo2, J. Martinez-Torrecuadrada2; 1CIEMAT, Madrid,
SPAIN, 2CNIO, Madrid, SPAIN, 3CNIC, Madrid, SPAIN.
Pancreatic Ductal Adenocarcinoma (PDAC) is associated to a
high stroma (desmoplastic reaction) around the tumor. Type 1-
matrix metalloproteinase (MT1-MMP) is a membrane-
anchored protein overexpressed in different tumors as a mean
of invasion and metastasis, including PDACs; here, MT1-
MMP overexpression has been showed to be particularly
prominent in areas of the tumor with intense desmoplastic
reaction. The aim of the study was the in vivo validation of
MT1-MMP as a biomarker for PET imaging in PDAC to as-
sess diagnosis using an 89Zr-labeled specific monoclonal an-
tibody (mAb). For this purpose an anti-MT1-MMP mAb was
functionalized with a derivative of deferoxamine (p-SCN-Bn-
Deferoxamine) as chelator to form DFO-mAb-MT1-MMP,
prior to 89Zr labeling. After radiolabeling, the purification of
89Zr-mAb-MT1-MMP from small-molecule radiolabeled im-
purities was achieved using size-exclusion chromatography
(PD-10 column). The radiolabeling yield was 91% and the
specific activity was 92.5 MBq/mg (2.5 mCi/mg). Human tu-
mor xenografts were surgically implanted in nude mice as
pieces of primary tumors, coated with Matrigel. The site of
implantation was in pancreas, the same organ as the original
tumor (orthotopic implantation) to ensure that tumors develop
in the same anatomic microenvironment. Mice bearing
orthotopically implanted PDAC tumors were intravenously
injected with 125 μCi (50 μg mAb; 2.5 mg/Kg body weight)
of 89Zr-mAb-MT1-MMP. PET images were acquired using an
Argus small-animal PET/CT at 1, 3, 6 and 8 days post-injec-
tion. Immuno-PET imaging showed high tumor uptake
(SUVmax 2-7) in implanted PDAC tumors. The ratio of tumor
SUVmax to the blood pool SUV increased with time and
reached more than 3 at 6 days. The results suggest that 89Zr-
mAb-MT1-MMP could be a promising probe for future diag-
nosis of PDAC tumors by immuno-PET.
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Evaluation on pancreatic tumor model of 68Ga-labeled
somatostatin derivatives using SnCl2-based 68Ge/68Ga
generator
S. Pesnel1, D. Prince2, C. Naidoo2, S. Bénard1, V. Méneyrol1,
F. Gimié1, E. Jestin1,3,4; 1GIP CYROI, Saint Denis, RÉ-
UNION, 2iThemba LABS, SomersetWest, SOUTHAFRICA,
3Inserm, UMR 1188 Diabète athérothrombose Thérapies Ré-
union Océan Indien (DéTROI), plateforme CYROI, Saint De-
nis, RÉUNION, 4Université de La Réunion, UMR 1188, Saint
Denis, RÉUNION.
Aim: The purpose of this study was to assess various 68Ga-
labeled somatostatin derivatives used for the management of
neuroendocrine tumors (NETs) after an elution from a SnCl2-
based 68Ge/68Ga generator coupled directly with a fully au-
tomated radiosynthesis. Materials&Methods: Three DOTA-
somatostatin derivatives were radiolabeled (-TATE,-TOC,-
NOC) and NOTA-NOC. A 68Ge/68Ga generator (iThemba
LABS, SA) was eluted with 0,6N HCl and 68Ga was directly
sucked up to fully automated labeling and purifying processes
on a Tracerlab FX FN. The stability was tested in buffer and in
plasma during 2h. The four labeled peptides DOTA-(Tyr3)-
octreotate, DOTA0-(Phe1-Tyr3)octreotide, DOTA-[Nal3]-
octreotide and NOTA-[Nal3]-octreotide were injected to nude
mice with AR42J pancreatic tumor xenografted. All the ani-
mals were injected intravenously with 15±3MBq. The PET
acquisitions were performed during 15min using a
microPET/CT system 30min post-injection. CT scans were
performed right after the PETacquisitions on the same device.
For all images, a ROI was drawn around the tumor and other
ROIs with the same size were defined on the muscle and the
liver to determine tumor-to-muscle (T/M) and tumor-to-liver
(T/L) ratios. Results: After a 30min labeling process, the
radiolabeling yields were up to 70% with a specific activity
range from 9.5 to 13.5 GBq/μmol and radiochemical purity up
to 90%. All the peptides were stable in buffer and plasma for at
least 2h. The peptides were distributed in the whole mice and a
renal excretion was predominantly observed after injection.
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Liver uptake was significantly higher with 68Ga-DOTANOC
than with 68Ga-DOTATOC, 68Ga-DOTATATE and 68Ga-
NOTANOC. No significant difference between tracers was
found for percentage of injected dose in muscle. No differ-
ences were found in the T/L ratio between 68Ga-
DOTATATE and 68Ga-DOTATOC, both of which had a
higher fraction than 68Ga-DOTANOC and 68Ga-
NOTANOC. The T/M ratio was higher with 68Ga-
DOTATATE than with the other peptides. Conclusion: This
study shows the ability to labeled somatostatin analogues with
68Ga coming from a SnCl2-based 68Ge/68Ga generator. The
imaging results are similar to the results obtained with peptides
labeled with commercial generator, that is to say that the up-
take was higher with 68Ga-DOTATATE in the tumor than with
68Ga-DOTANOC, 68Ga-DOTATOC and 68Ga-NOTANOC.
For comparison, the tumor bearing mice were imaged after
injection of 18F-FDG which is the main tracer used in clinic
for oncology. The results show a very low uptake in tumor
with a T/M ratio of only 1.5. This result shows the importance
to have other tracers to image NETs.
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In vivo SPECT of neuro-endocrine tumour on chicken
CAM
J. de Swart, S. J. Koelewijn, M. R. Bernsen, A. M. Bahnerth,
R. S. de Bruijn, M. de Jong; Erasmus MC, Rotterdam,
NETHERLANDS.
Aim: In several fields of research the chorioallantoic mem-
brane (CAM) in chicken egg is applied as an in vivo tumour
model. This model could provide a robust, rapid, low cost, and
ethically preferable alternative to the mouse model, which has
been the standard for in vivo oncology research, also for pre-
clinical evaluation of novel radiopharmaceuticals. Here we
investigate to feasibility of animal SPECT/CT to study tumour
uptake characteristics of tracers in a CAM tumour model. Ma-
terials and methods: In normal farm chicken eggs 1.3 million
CA20948 (somatostatin receptor-positive rat pancreatic tu-
mour) cells were inoculated ten days after fertilization. One
week after inoculation 12 MBq 111In-DOTA,Tyr3-octreotate
(111In-octreotate) was injected into a CAM vein. 1h and 4h
after injection, 30-minute and 45-minute SPECT scans were
acquired respectively in list mode. Imaging was performed on
a MILabs USPECT/CT system using a rat collimator with
1.0mm pinholes. SPECT was followed by a CT scan. During
the scans the eggs were warmed in a foam holder in an upright
position, with the air chamber on top. Anaesthesia was not
used. SPECT data sets were reconstructed using the POSEM
algorithm; 30 iterations, 4 subsets, and a voxel size of 0.4mm.
CT was reconstructed using FBP. SPECT and CT were regis-
tered and the SPECT data were corrected for attenuation using
the CT data. The resulting data was analysed using Invicro
Vivoquant software. Results: In the eggs the CA20948 tumour
could be clearly visualised on the SPECT scans at both time
points. Uptake in the tumour could be clearly discriminated
from that in the chick. The uptake of 111In-octreotate in the
tumour was 1.1±0.7%IA (injected activity), uptake in the
chick was 59.5±12.5%IA. The remaining injected activity
was in other egg structures surrounding the chick. The chicks
endured the imaging procedures well. There were no notice-
able motion artefacts at the tumour site. Conclusion and dis-
cussion: It is feasible to use micro SPECT to image and quan-
tify the uptake of radioactive compounds into a tumour inoc-
ulated in a chicken CAM, with the rigid shape of the egg and
the homogeneous content facilitating robust attenuation cor-
rection. Anaesthesia does not seem to be necessary to image
tumours in the CAM.The CAM tumour model is fast and
inexpensive, providing in combination with SPECT a fast
way to evaluate tracer tumour uptake characteristics. Because
of the tiny structures in this model SPECT is preferable over
PET because of the higher spatial resolution achieved.
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X-Ray CT Imaging of Stomach Passage
of Contrast-Enhanced Floating Tablets in a New Rat
Model
D. Mathe1, F. Budan1,2, S. Pal3, I. Kiss2, P. Dios2, K. Szigeti4;
1CROmed Ltd, Budapest, HUNGARY, 2Dept. Public Health
Medicine, University of Pecs, Pecs, HUNGARY, 3Institute of
Pharmaceutical Technology and Biopharmacy, University of
Pecs, Pecs, HUNGARY, 4Dept. Biophysics and Radiation Bi-
ology Semmelweis University, Budapest, HUNGARY.
Introduction. Cost-effective in vivo animal models are war-
ranted to be developed to test modified drug delivery systems
with the purpose to optimize those medical agent carriers. In
this study, a novel rat model was evaluated to gain information
about attributions of floating drug delivery systems (FDDS)
practically in form of small sized tablets. X-ray computed
tomography (CT) was performed.Materials and Methods. So-
dium alginate as a biodegradable swelling polymer to create
coherent frame of the tablets, sodium bicarbonate as carbon
dioxide (CO2) creating agent and barium sulfate (BaSO4)
contrast material to enhance X-ray CT. Partly anaesthetized
rats were made to swallow tablets. In vivo imaging was per-
formed at the following sampling times: 15min, 1 h, 2 h, 3 h, 4
h, 6 h, 24 h and 48 h. Additionally, a maximum intensity
projection (MIP) was rendered at 30 min after administration
to provide fine resolution of spatial and temporal details about
FDDSs in situ behavior using an adequate selected lookup
table (LUT).Results. tablets with 10% BaSO4 content enabled
quantitative in vivo imaging. These pharmaceutical agent
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carriers formed CO2 bubbles 15 minutes after the administra-
tion and remained floating in the stomach for at least 24 hours.
48 hours after administration tablets were observed to be
disintegrated mostly in the small intestine. Thus, the tablet’s
putative obstruction in stomach can be excluded. So the model
can be considered as cheap, representative and capable to in-
terpret results better.Conclusions.We can suppose that this
newly developed rat model will be useful to provide compre-
hensive data about certain factors (e.g. food effect, posture,
etc.) influencing gastrointestinal behavior of FDDS in future
experiments by tracking their properties.
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Is enteral radioiodine administration the best route
for radiotherapy in thyroid diseases? A preclinical study
K. Chatti1,2, T. Pourcher3,1,2, J. Guglielmi1,2, J. Darcourt4,1,2;
1UNS, Nice, FRANCE, 2TIRO, Nice, FRANCE, 3CEA, Nice,
FRANCE, 4CAL, Nice, FRANCE.
Aim: For iodine radiation therapy, the enteral route is cur-
rently used in clinical practice. Here we studied the differ-
ences in thyroid tissue uptake after eneral and parenteral
administration of radio-iodine 123I- or 99mTcO4
- in mice
measured by in vivo MicroSPECT/CT. Materials and
methods: We used adult C57Bl6 mice under normal iodine
diet (NID) or low iodine diet (LID) (8-6mice/experience)
and nude mice with subcutaneous tumor expressing NIS
under NID (simulating iodide avid metastasis; 3mice/ex-
perience, each mouse was its own control). Gavage (GV)
with gastric tube was used for enteral administration. We
used intraperitoneal (IP) administration as parenteral route
(shown to be equivalent to intravenous). 3D high resolu-
tion whole body SPECT/CT (eXplorer speCZT CT 120,
GE) imaging was performed using 123I- or 99mTcO4
-. Dy-
namic SPECT/CT were acquired for the first hour with
99mTcO4
- or 123I- and 48h sequential acquisitions were
added with 123I-. Semi quantification expressed the rate
of administered activity in the target organs after decay
correction. T student paired test was used for statistics.
Results: Thyroid uptake was significantly more intense
in case of parenteral (IP) radiotracer administration than
in case of enteral (GV) administration with both radio-
tracers, in NID and LID (p<0.05). In tumors expressing
NIS, 99mTcO4
- accumulation was 1.7 fold more intense
with IP administration route compared to GV. Conclusion:
Thyroid uptake and accumulation was significantly higher
when parenteral administration route was used in mice.
These results suggest that parenteral administration could
be more efficient in man for thyroid disease radio-iodine
treatment.
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Investigation of 18FDG uptake in common carp (Cyprinus
carpio) using PET/CT imaging
G. Trencsényi1, S. Zaheri-A2, R. Csipkés2, A. Forgács1, I.
Komlosi2, I. Garai1; 1University of Debrecen/Scanomed Ltd.,
Debrecen, HUNGARY, 2University of Debrecen, Department
of Animal Husbandry, Debrecen, HUNGARY.
Aim: Positron Emission Tomography (PET) is a non-invasive
diagnostic tool that provides tomographic images and quanti-
tative parameters of glucose metabolic activity of tissues. The
most important and commonly used tracer in PET is 18FDG.
PET/CT is usually used in cancer studies and in these days
there are many studies rely on mammals such as dogs and
rodents and recently on fish. Our objectives of this survey by
using 18FDG PET/CT are to optimize and determine the
18FDG uptake in common carp (Cyprinus carpio). Further-
more we investigated the effect of different fish diets on the
18FDG uptake.Materials and methods: 1.5 kg weighted com-
mon carps (Cyprinus carpio) were used in our experiments
(n=3 for each group). Fish were fed with three different types
of food for four weeks (basic fish meal, probiotic and vita)
before the measurements. 10±1 MBq 18FDG was injected
via the caudal vein under anaesthesia (10 drops of clove oil
in 20 litre water). After 50 min incubation time whole body
18FDG PET/CT scans were made by using a clinical PET/CT
scanner (Mediso AnyScan PET/CT) with 10 min acquisition
time. The CT parameters were: 120kV, 100mA. For the quan-
titative analysis InterView Fusion Medical Imaging Software
was used.Results: By taking the standardized uptake values
(SUVmean) we found that the glucose uptake of the liver
and intestines of fish were more similar to those of humans
than rats or mice. The 18FDG uptake of the fish brain was
significantly lower than the SUVmean values of rodent and
human brain. By comparing the effect of the three different
fish diet on glucose uptake we found relatively lower
SUVmean values of the major organ systems in fish fed by
probiotic diet than that of those fed by vita and basic fish
meal.Conclusion: We found that 18FDG PET/CT is a useful
tool for nutritional experiments using fish. Our results may
offer us in studies of metabolism and screening for effects of
nutrients to focus on body development.
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The role of ADAMTS-12 gene on the pathogenesis
of radioiodine-induced salivary gland damage
M. SADIC1, M. KORKMAZ1, S. S. GÜLTEKIN2, K.
DEMIRCAN3; 1Ministry of Health Ankara Training and Re-
search Hospital, ANKARA, TURKEY, 2Kastamonu School of
Medicine, Hacettepe University and Ministry of Health
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Diskapi Training and Research Hospital, ANKARA, TUR-
KEY, 3Turgut Ozal University, School of Medicine, Depart-
ment of Molecular Biology, ANKARA, TURKEY.
Aim: A disintegrin-like and metalloproteinases with
thrombospondin type-1 motif (ADAMTS)-12 is a member of
a gene family with 19 subtypes. This study aims to determine
effects of ADAMTS-12 gene on pathogenesis of the
radioiodine I-131 (RAI)-induced salivary gland damage.
Methods: Study group consists of total 30 Wistar male albino
rats (260 ± 45 grams, 6-month-old) in five groups. By the
polymerase chain reaction method, ADAMTS-12 gene ex-
pression levels were studied on parotid and submandibular
salivary gland specimens. Quantitative analyses were carried
out using 2-ΔΔct method. In control subjects (Group 1; 6/30
rats) genetic examinations were performed 24 h after removal
of tissues. A 3 mCi (111 MBq) dose of RAI was administered
to each rat in Groups 2,3,4 and 5 (24/30; six rats in each group)
and excised salivary glands’ samples obtained at respectively 4
h, 24 h, 7 d and 30 d after the RAI administration were eval-
uated by genetic examinations. Final data was evaluated by
statistical analysis.Results: In different time periods (Group 2-
5) and same time periods (Group 1 vs. 3), according to the
measurements of ADAMTS-12 gene expression in the sam-
ples, reduction at the level of gene expression over time or
difference was statistically significant (p<0.05) for the parotid
gland but not statistically significant (p>0.05) for the subman-
dibular gland.Mean and standard deviation values were 1,00 ±
0,00 in Group 1, 0,38 ± 0,30 in Group 2, 0,11 ± 0,05 in Group
3, 0,10 ± 0,07 in Group 4 and 0,18 ± 0,29 in Group 5 for the
parotid glands and 1,00 ± 0,00 in Group 1, 1,59 ± 1,92 in
Group 2, 1,57 ± 0,36 in Group 3, 1,03 ± 0,32 in Group 4
and 1,00 ± 0,67 in Group 5 for the submandibular
glands.Conclusions: We thought that lower expression of
ADAMTS-12 gene may have a role on mechanism of RAI-
induced damage in the rat parotid gland. We didn’t observe
meaningful effect of ADAMTS-12 on RAI-induced damage in
submandibular gland.
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Impact of quantification accuracy on dosimetric
calculations in small animal preclinical imaging: a study
in sodium/iodide symporter (NIS) radiotracers
K. Chuamsaamarkkee1,2, P. J. Blower1, L. Livieratos1,3;
1King’s College London, Division of Imaging Sciences and
Biomedical Engineering, London, UNITEDKINGDOM, 2Di-
vision of NuclearMedicine, Department of Radiology, Faculty
of Medicine Ramathibodi Hospital, Mahidol University,
Bangkok, THAILAND, 3Nuclear Medicine Dept, Guy’s &
St Thomas’ Hospitals NHS Foundation Trust, London, UNIT-
ED KINGDOM.
Background: Preliminary dosimetric data from animal studies
is a basis for going forward with clinical trials in development
of new radiotracers. Typically in vivo tracer kinetics are ex-
trapolated to estimate human-equivalent dosimetry. However,
quantification of small organ activities may be impaired by
partial volume effects (PVE). This study aims to examine the
influence of PVE in preclinical quantification of small-objects/
organs and its impact on subsequent dosimetric calculations
for sodium iodide symporter (NIS) radiotracers. Methods: A
mouse-size equivalent micro hollow sphere (MHS) phantom
was filled with different amounts of radiotracer (Tc-99m, I-123
and Re-188) and scanned with the nanoSPECT/CT preclinical
system using the 3 mm. aperture collimators. Volume-of-
interest (VOI) based quantification accuracy was plotted
against sphere volume fitting curves with a second order poly-
nomial equation to obtain volume-dependent correction fac-
tors (CFs). In vivo imaging of healthy controls (Scid/Beige
mice, n=3 for each tracer) was performed dynamically for
4 h and also at 8 and 24 h post injection. Images were analysed
and dosimetric results were calculated using OLINDAversion
1.0. Organ volumes (thyroid, salivary glands, stomach and
bladder) were obtained from VOIs applied to high resolution
CT images and appropriate CF were defined for each organ
based on volume and data from the phantom study. Dosimetric
data were calculated with and without the volume-dependent
PVE correction. Percentage differences of absorbed doses
were compared to evaluate the impact of quantification accu-
racy and PVE. Results: Thyroid absorbed doses were mostly
affected due to its small size. The application of applied CF
increased the calculated dose by approximately 20% for Re-
188, 10% for Tc-99m and 2% for I-123 compare with uncor-
rected PVE data. Similarly, the salivary gland absorbed doses
were raised in a similar fashion. For stomach, the absorbed
doses were increased by 13.60% for Re-188, 1.7% for Tc-
99m whereas decreased about 2% for I-123. Similar trends
were also found in urinary bladder. PVE correction had min-
imal impact on red-marrow absorbed doses for all isotopes.
Application of CFs increased calculated effective dose values
by approximately 13%, 3% and 1.5% for Re-188, Tc-99m and
I-123 respectively. Conclusion: This study demonstrates the
influence of PVE on the dosimetric calculations from small-
animal preclinical imaging. An organ volume dependent cor-
rection based on standard geometrical phantom measurements
has been proposed.
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Preclinical Dosimetric Comparison of 186Re-
and 188Re-perrhenate versus 131I-NaI for Treatment
of Non-thyroidal NIS-expressing Tumour
K. Chuamsaamarkkee1,2, S. Diocou1, P. J. Blower1, L.
Livieratos1,3; 1King’s College London, Division of Imaging
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Sciences and Biomedical Engineering, London, UNITED
KINGDOM, 2Division of Nuclear Medicine, Department of
Radiology, Faculty of Medicine Ramathibodi Hospital, Bang-
kok, THAILAND, 3Nuclear Medicine Dept, Guy’s & St
Thomas’Hospitals NHS Foundation Trust, London, UNITED
KINGDOM.
Background: The potential for radioiodine (131I-NaI) treat-
ment in non-thyroidal tumour has been speculated upon fol-
lowing successful cloning and gene transfer of sodium iodide
symporter (NIS) in a variety of cell types. However,
radioiodine has practical limitations such as radiation safety
restrictions to patients, the public and its therapeutic efficiency
may be restricted by rapid efflux due to lack of organification
in non-thyroidal tumours. Therefore, there is a window in
which rhenium isotopes (186Re-, and 188Re) in the form of
perrhenate (which is also a substrate of NIS) may offer greater
therapeutic advantages due to shorter half-life, more energetic
betas, longer soft-tissue range and lower photon abundance.
This study aims to evaluate the dosimetric profile of potential
isotopes for treatment of non-thyroidal NIS-expressing tu-
mours. Methods: Rat mammary adenocarcinoma (MTLn3E)
overexpressing truncated CXCR4 and hNIS were grafted at
the flank of female SCID/Beige mice (n=3 for each radiotrac-
er; 99mTc-pertechnetate, 188Re-perrhenate and 123I-NaI).
Whole-body SPECT was acquired continuously for 4 h post
injection (PI) with additional scanning at 8h and 24h. Percent-
age injected activity was derived from images and extrapolated
using SUV-preserving linear-mass scaling to derive human-
equivalent time-activity curves, tracer residence times and then
applied to OLINDA to estimate dosimetry. Results: Percent-
age uptake per gram of tumour (%ID/g) in 188Re-perrhenate
was 5-15 %ID/g, compared with 45-55 %ID/g of 99mTc-
pertechnetate and 42-62 %ID/g of 123I-NaI at 4 h PI. Al-
though kinetics of 188Re-perrhenate and 99mTc-
pertechnetate were very similar, however based on phantom
data, lesion-to-background contrast for 188Re-perrhenate
might be underestimated due to scatter and elevated back-
ground from Bremsstrahlung. Due to the complexity of the
proprietarymulti-pinhole withmultiplexed-projections, imple-
mentation of the triple-energy-window correction is not cur-
rently possible. Hence, 99mTc kinetics were used instead of
rhenium isotopes and a 123I as a surrogate for 131I-NaI to
achieve reasonably quantitative and accurate dosimetry esti-
mation. Results show that tumour absorbed doses were 6.33
and 8.68 times higher for 186Re and 188Re when compared to
131I. Additionally, the therapy indexes (tumour to effective-
dose and tumour to thyroid ratio) for both rhenium isotopes
were greater than 131I. Red-marrow absorbed doses produced
by rhenium were lower than radioiodine (0.27 and 0.50 times
for 186Re and 188Re respectively). Conclusion: This work
demonstrates the ability of 188Re-perrhernate for imaging
and treatment of non-thyroidal NIS expressing tumour. A
superior therapeutic dose ratio has been predicted for both
rhenium isotopes which resulted at higher tumour absorbed
dose together with lower thyroid and whole-body doses.
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Quantitative Imaging of 89Zr on a pre-clinical PET/CT
system
A. Fenwick1,2, C. Marshall3,1, E. Spezi4,1, W. Evans3,1, L.
Johansson2; 1Cardiff University School of Medicine, Cardiff,
UNITED KINGDOM, 2National Physical Laboratory,
Teddington, UNITED KINGDOM, 3Wales Research & Diag-
nostic Positron Emission Tomography (PET) Imaging Centre,
Cardiff, UNITED KINGDOM, 4Velindre NHS Trust, Cardiff,
UNITED KINGDOM.
The use of the novel radionuclide 89Zr in the field of mAbs and
PRRT imaging has become of great investigational interest
during the past few years with many publications showing
the benefits of this PET radionuclide. Despite the high level
of interest, no traceable measurement has yet been made of the
activity either at production sites or in the clinical setting
which could eventually lead to contradicting results when this
product reaches clinical trials. Quantification in images is im-
portant to determine activity distribution for not only patient
safety and dosimetry but to ensure staging and treatment effi-
cacy can be accurately determined. Pre-clinical imaging is a
critical step on the pathway to human trials and quantification
at this stage is equally important to ensure novel radiotracers
can successfully progress to future trials. A Pre-clinical PET/
CT camera has been traceably calibrated in terms of activity
for the first time with an associated uncertainty budget and
corrections for partial volume. The calibration protocol in-
cludes measurements of various activity distributions and
phantom components in order to determine an associated un-
certainty and range of parameters for which the calibration is
valid. The paper also describes methods for filling phantoms
and reasons for the choice of phantom design used in the
calibration. The results show that if care is taken to ensure
traceability is maintained throughout the imaging process, an
accurate and robust calibration can be made of a typical pre-
clinical system and maintained during with routine practice
and QA.
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Biodistribution study of EGFR targeting monoclonal
antibody [177Lu]-Nimotuzumab
M. Kropacek, M. Tomeš, K. Kontrová, J. Zimová, M.
Mirzajevová, F. Melichar; RadioMedic Ltd., REZ, CZECH
REPUBLIC.
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Introduction: Nimotuzumab (hR3) is a humanized mono-
clonal antibody (mAb) with the affinity towards the epi-
dermal growth factor receptor (EGFR), which is
overexpressed in the majority of solid tumors, including
breast and ovarian cancer, colon cancer, head-and-neck
cancer and non-small cell lung cancer. The aim of this
work was to carry out first part of biodistribution study
on healthy rats. Material and Methods: Monoclonal an-
tibody Nimotuzumab (hR3) was purchased from
Oncoscience AG (Wedel, Germany), bifunctional ligand
p-SCN-Bn-DOTA was purchased from Marocyclics
(Dalas, USA), Lu-177 n.c.a. was obtained from ITG
(Munich, Germany). Biodistribution study was provided
by Biological Testing Laboratory ÚJV Řež a.s. Native
Nimotuzumab was conjugated with p-SCN-Bn-DOTA
(10-fold molar excess) at pH=8.3 (0.1 M phosphate
buffer) two hours at room temperature. After first hour
of conjugation, reaction mixture pH was checked and
readjusted, when needed. Prepared immunoconjugates
were purified by ultrafiltration on Vivaspin 6. Concen-
tration of immunoconjugate was determined by Bradford
assay. Labelling with Lu-177 was carried out 0.05 M
ammonium acetate buffer (pH 7.0) at 42°C for 60 mi-
nutes. Biodistribution was done on the rats (Wistar,
n=52). Injected activity of Lu-177 was 3.37 MBq/
animal and organs accumulation was observed 1, 24,
48, 72, 120 and 168 hours after administration. Immu-
noreactivity was checked using ELISA method before
administration. Results: [177Lu]-Nimotuzumab was ob-
tained with specific activity 200 MBq/mg and radio-
chemical purity > 90%. All preparation steps met the
GMP rules and conditions. Biodistribution study showed
the highest activity accumulation in the liver 48 hours
after injection (63.46%). Another critical organ spleen
accumulated 3.61% of injected activity 48 h and the
accumulation remained stable until 168 h after injection.
Level of activity in the lungs reached maximum 1 hour
after injection (32.29%) and then decreased to 0.55%
after 24 hours. Activity in blood decreased from
43.41% (1 h) to 18.17% (24 h) and then to 7.33%
(168 h) after application. Conversion, where the weight
of rat blood is approximately 7% of animal’s weight
was applied. All activity accumulation was calculated
per organ. Conclusion: First part of biodistribution study
verif ied physiological accumulation of [177Lu]-
Nimotuzumab. Activity in critical organs liver and
spleen indicated accumulation of product due to the bi-
ological degradation and elimination. Activity in the
lung was consistent with the expectation of increased
distribution due to intensive blood circulation in this
organ. Biodistribution results in healthy rats were prom-
ising for next part of study carried out on immuno-
deficient mice with EGFR expressing tumors.
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Synthesis and evaluation of Gallium-68 labeled Fe3O4 -
Citric acid nanoparticles for dual modality.
B. Cho1, M. Moon1, J. Lee2, J. Park2, M. Hur2, K. Yu1;
1Dongguk university-seoul, Seoul, KOREA, REPUBLIC
OF, 2Korea Atomic Energy Research Institute, Jeongeup, KO-
REA, REPUBLIC OF.
Aim: Dual modality imaging is powerful tools to obtain valu-
able information on function in biomedicine. In this present
work, we report the development of nano-bio targeting com-
posites using Fe3O4 nanoparticles and Ga-68 radioisotope for
dual modality of PET and MRI applications. Materials and
methods: FCNP (Fe3O4-Citric acid nanoparticles) was syn-
thesized by one step process using citric acid as surfactant.
FCNP exhibits several attractive properties such as strong
magnetic, controllable particle size and stability in water.
Nano-bio composites (NHFCNP and NFHFCNP) were ob-
tained by combining the surface modified FCNP and NOTA
as bi-functional chelating agent with Ga radio isotope and
Folic acid by single step. The structure and morphological
properties of nano-bio composites were characterized by
XRD,TEM, IR and UV analysis. 68GNFHFCNPs was pre-
pared by the reaction of NFHFCNP with Ga-68 from an in-
house generator. Radio-TLC analysis confirmed the
radiolabeling of 68Ga-NOTA complex. Cell viability and cel-
lular uptake studies were performed on CT-26, SK-BR-3. Re-
sults and conclusion: The final compound, GNHFCNP
(GNFHFCNP) with stable gallium isotope showed good bio-
compatibility and 68GNHCNPs(68GNFHCNPs) with radio
gallium isotope have high uptake on CT-26 and SK-BR-3.
The cellular uptake of 68GNHFCNP was maximum of 8.778
% at 120 min for CT-26 and 15.491 % at 120 min for SK-BR-
3.that of 68GNFHFCNP was maximum of 9.764 % at 60 min
for CT-26 and 13.591 % at 120 min for SK-BR-3.
68GNHCNPs(68GNFHCNPs) shows higher cellular uptake
on the SK-BR-3 compared to CT-26. In summary, The
68GNFHFCNPs were successfully synthesized by simple
chemical technique. The biological evaluation of
68GNHFCNPs confirm that as potential material for
radiopharmaceuticals.
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High Frequency Ultrasound for the development of an
Orthotopic mouse model of Human Follicular Thyroid
Carcinoma
S. Albanese1,2, L. Auletta3, A. Zannetti4, G. Di Maro3, P.
Mirabelli3, C. D’Alterio5, G. Salvatore2,3,6, A. Soricelli3,6,
M. Salvatore3, A. Greco7,2; 1Università Parthenope, Naples,
ITALY, 2Ceinge, Biotecnologie Avanzate, Scarl, Naples,
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ITALY, 3IRCCS-SDN, Naples, ITALY, 4Istituto di Biostrutture
e Bioimmagini – CNR, Naples, ITALY, 5Dipartimento di
Immunologia Oncologica- Istituto Nazionale per lo Studio e
la Cura dei Tumori “Fondazione Giovanni Pascale”- IRCCS,
Naples, ITALY, 6Dipartimento di Scienze Motorie e del
Benessere, Università Parthenope, Naples, ITALY,
7Dipartimento di Scienze Biomediche Avanzate,Università
degli studi di Napoli Federico II, Naples, ITALY.
Aim: Thyroid carcinoma is the most common endocrine ma-
lignancy, with increasing incidence and mortality rate (1).
High Frequency Ultrasound (HFUS) has the ability to detect
structures as small as 30μm, a property that has been exploited
for thyroid visualization and analysis in mice (2). Aim of this
study, was to generate a novel orthotopic mouse model of
Human Follicular Thyroid Carcinoma (FTC) using HFUS-
guided system and to compare this method to the orthotopic
surgical model.Materials and Methods: Ten 6 weeks-old, fe-
male, balb/C nude mice underwent to a surgical orthotopic
implantation of 2 x 106 FTC-133 in the right lobe of the thy-
roid and ten mice were injected in the right lobe of the thyroid
with 2 x 106 FTC-133 using HFUS-guided system. Two
weeks after injection all mice underwent HFUS imaging,
HFUS and tumor volumes (TV) examinations were repeated
weekly. Hematoxylin and eosin (H&E) analysis of formalin
fixed paraffin embedded mouse tissues was performed at the
end of the experiment. TVs were compared between the two
orthotopic mouse models (surgically and HFUS-guided
injected) using a Mann-Whitney’s U test.Results: All the
echoguided inoculated mice survived up to 40 days and
cancerogenesis primarily involved the right thyroid lobe. Me-
tastasis in salivary gland and lymph nodes were detectable.
H&E analysis confirmed accurate placement of FTC-133 cells
by echoguided intrathyroid injection. Mice inoculated by sur-
gery had 100% mortality at 30 day. FTC developed in an
invasive way, early metastasis were detectable, with obvi-
ous infiltrates in the muscle and salivary gland as evident
from the histological images of the neck. In the surgical
orthotopic model in some cases there was an evident in-
volvement of the not injected contralateral lobe of the
thyroid. A difference in TVs between the two orthotopic
techniques was detected (significant at day 13, surgically
18.4 ± 1.8 vs. HFUS 32.4 ± 4.7; P=0.01).Conclusion: In
our study, we develop a novel echoguided orthotopic
mouse model of FTC and we compared it with the surgical
orthotopic model. HFUS - guided orthotopic model is
technically feasible and easily reproducible allowing
prolonged monitoring of the disease, since the animals
showed an increased survival rate.References1. Howlader
N, et al. SEER Cancer Statistics Review, 1975-2008, Na-
tional Cancer Institute.2. Mancini M, et al 2009 Morpho-
logical Ultrasound Microimaging of Thyroid in Living
Mice. Endocrinol 150:4810-4815.
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PET and SPECT imaging of breast cancer xenografts
using optimized CMKLR1-targeted DOTA-conjugated
peptide tracers
S. Poenick1, N. Beindorff2, E. Koziolek2, J. Castillo Gómez2,
I. Apostolova2, R. Michel2, S. Hallmann1, A. Wagener1, V.
Prasad2, S. Bandholtz1, P. Schulz1, B.Wiedenmann1,W. Bren-
ner1, C. Grötzinger1; 1Charité - Universitätsmedizin Berlin,
Gastroenterology, Berl in, GERMANY, 2Charité -
Universitätsmedizin Berlin, Nuclear Medicine, Berlin,
GERMANY.
Aim: With cancer being still one leading cause of death, there
is an urgent need for personalized diagnostics and therapies.
One promising target is the chemokine-like receptor 1
(CMKLR1), with its peptide ligand chemerin being an encour-
aging molecular entity for tracer development. Aim of this
study was the utilization of our optimized and validated
chemerin tracers for nuclear in vivo imaging with positron
emission tomography, single photon emission computed to-
mography and complementary biodistribution studies. Mate-
rials and Methods: Highly specific and affine peptide ligands
for the G protein coupled receptor CMKLR1were obtained by
substitution of wild type chemerin-9 and analysis of the
structure-activity relationship. In consequence, we designed a
panel of peptide conjugates with different linkers and chelator
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid) to gain novel tracers for tumor targeting. The combina-
tion of radiolabeled (68Ga, 111In) peptide tracers and an
established target positive tumor model in immunodeficient
nude mice enabled tumor-specific imaging in vivo. Therefore,
we acquired small animal PET/MR and SPECT/CT images
and assessed biodistribution by ex vivo measurements. Re-
sults: Our novel chemerin peptide tracers demonstrated signif-
icantly improved properties compared to the wild type peptide
concerning biological activity, affinity and metabolic stability.
Their target is known to be over-expressed in different pathol-
ogies, including cancer. Beside other tumor entities like esoph-
ageal or pancreatic cancer, we could demonstrate CMKLR1
overexpression in the breast carcinoma cell line Du4475. After
establishment of different target-positive cancer models along
with target negative tumors, PET/MR and SPECT/CT imaging
revealed a strong CMKLR1 specific uptake of the targeted
radiolabeled tracers in tumor tissue within one hour (68Ga)
or twenty-four hours (111In). Furthermore, the tracer conju-
gates cleared rapidly by predominantly renal excretion. As
probe biodistribution strongly depended on hydrophilic prop-
erties as plasma protein binding, our ligand conjugates exhib-
ited different in vivo tumor uptake. Sixty-eight hours after
injection, the tumor uptake of 111In-radiolabeled tracer was
about 1% ID/g and could be blocked with a 100-fold excess of
unlabeled conjugate. In addition, expression analysis of the
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ex vivo tissue confirmed the target selectivity. Conclusion: We
found CMKLR1 to be overexpressed in different tumor enti-
ties such as breast cancer. With the cell line Du4475, we had a
model endogenously expressing our target to evaluate our op-
timized chemerin peptides as stable ligands with high affinity.
PET and SPECT imaging using novel 68Ga- or 111In-labeled
tracers revealed high and specific tumor uptake, thus we de-
veloped promising candidates for potential clinical translation.
P162
Comparison of murine and chimeric version
of the anti-CD37 antibody HH1 used
for antibody-radionuclide-conjugate (ARC) therapy
of Non-Hodgkin Lymphoma
J. Dahle1, A. Repetto-Llamazares1, K. B. Melhus1, A.
O’Shea1, R. Generalov1, J. Andersen2, H. Heyerdahl1; 1Nordic
Nanovector ASA, OSLO, NORWAY, 2Oslo University Hos-
pital, OSLO, NORWAY.
Introduction: The novel antibody-radionuclide-conjugate
(ARC) 177Lu-DOTA-HH1 (Betalutin™) is currently in clini-
cal phase II trial for treatment of Non-Hodgkin Lymphoma
(NHL). The HH1 antibody is a murine anti-CD37 antibody
and has a lower binding affinity to Fc receptors than a chimeric
or humanized antibody and consequently a shorter biological
half-life. A biological half-life similar to the half-life of the
radionuclide will optimize irradiation of the tumor and result
in lower irradiation of normal tissues. Internalization of a chi-
meric ARC in normal tissues expressing the neonatal Fc re-
ceptor may also result in unwanted irradiation of normal tis-
sues. There are, however, benefits of using a chimeric anti-
body: 1) Reduced level and severity of human anti-drug anti-
body response; 2) Additional and possibly synergistic thera-
peutic effect from antibody dependent immunological toxicity
and complement dependent cytotoxicity. This study was per-
formed in order to investigate the similarities and differences
of the murine and the chimeric version of the anti-CD37 ARC.
Materials and Methods: Both the murine HH1 and the chHH1
antibodies were conjugated with p-SCN-Bn-DOTA using dif-
ferent DOTA:Ab ratios. Binding and internalization of the
ARCswere measured using fluorescence confocal microscopy
and biochemical assays. Binding to Fc-receptors and comple-
ment was measured using ELISA and recombinant Fc recep-
tors. ADCC and CDC were measured using NK-cells and
serum, respectively, from donor blood. Tissue cross reactivity
(TCR) was measured by immunohistological staining of tissue
sections from human and animal donors. Biodistribution of the
ARCs was measured after injection in mice with NHL xeno-
grafts. The therapeutic and toxic effects of the two ARCs were
compared in a NHLmousemodel. Results: The two antibodies
showed similar binding and internalization. TCR studies
showed that both antibodies bound selectively to lymphoid
tissues. The chimeric antibody bound to all the classical hu-
man Fc-receptors, while the murine antibody only bound to
FcγR IIa and IIb, which is expressed on B-cells. HH1 bound
weaker to human C1q than the chimeric antibody. The binding
of HH1 to C1q, FcγR IIa and IIb, did, however, not result in
any complement dependent cytotoxicity or antibody depen-
dent cellular cytotoxicity, while it did for the chimeric anti-
body. Both ARCs had a relevant biodistribution in mouse
models, however the tumor uptake of the chimeric ARC was
higher than for the murine ARC. More details of the therapeu-
tic and toxic effect of the two ARC’s will be included in the
presentation at the meeting.
P163
In vivo evaluation of inhibitory role of microRNA
on glucose transporter by micro-PET in hepatocellular
carcinoma xenografts
L. KANG; PEKING UNIVERSITY FIRST HOSPITAL,
BEIJING, CHINA.
Aim: MicroRNA (miRNA) has exhibited regulatory functions
in numerous cellular processes including proliferation, differ-
entiation and apoptosis, especially in carcinogenesis. In malig-
nant tumors, the increased glucose metabolism is due to high
expression of glucose transporters (GLUTs) and phosphoryla-
tion by hexokinase. The objective is to investigate the role of
miRNA in the regulation of glucose transporter and further
evaluate by FDG micro-PET in hepatocellular carcinoma
(HCC) xenografts. Materials and methods: The HepG2 cells
stably overexpressing miRNA and empty vector were con-
structed by lentiviral vector transfection. The expression of
insulin-like growth factor-1 receptor (IGF-1R), phosphatidyl-
inositol-3-kinase (PI3K), AKT, and GLUT1 in HepG2 cells
were evaluated byWestern blotting assay. FDG cellular uptake
and proliferated activity were evaluated. FDG micro-PETwas
performed to show the in-vivo ability of miRNA in HepG2
xenografts. Furthermore, the expression of glucose related
proteins in tumor tissue were evaluated as well. Results: The
hepG2 cells with stable expression of miRNAwere construct-
ed and identified by sequencing. The decreased proliferated
ability was shown in miRNA over-expressed HCC cells
in vitro, as well as FDG cellular uptake. Western blotting re-
sults showed the expression of IGF-1R, PI3K, AKT and
GLUT1 protein were inhibited in miRNA over-expressed
cells. For HepG2 tumor xenografts, small-animal PET clearly
showed the significantly decreased FDG accumulation in
miRNA tumors, which was verified by the suppressed FDG
uptake and IGF-1R/PI3K/AKT pathway of ablated tumors.
Conclusion: MiRNA exhibits a negative role in the regulation
of glucose transporter via the inhibition of IGF-1R/PI3K/AKT
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pathway. FDG micro-PET is useful for evaluating the role of
miRNA in vivo.
P164
18F-FES and 18F-FDG micro-PET/CT imaging
for the evaluation of nanovectorized radiotherapy
with 188Re in a murine model of endometrial cancer.
C. Lefebvre-Lacoeuille1,2,3, A. Genin1,3, F. Bouchet1,4, N.
Chouin5,6, A. Croué1, L. Preisser1,7, F. Hindré2,8,1, P.
Descamps1,3, O. F. Couturier1,2,4,F. Lacoeuille1,2,4; 1LUNAM
Université, Angers, FRANCE, 2Inserm UMRS_1066 MINT,
Angers, FRANCE, 3Department of Obstetrics and Gynaecol-
ogy, CHU Angers, Angers, FRANCE, 4Nuclear Medicine De-
partment, CHU Angers, Angers, FRANCE, 5LUNAM
Université, Nantes, FRANCE, 6AMaROC, ONIRIS, Nantes,
FRANCE, 7Inserm U892, Angers, FRANCE, 8PRIMEX
Plateforme de Radiobiologie et d’Imagerie Expérimentale,
Angers, FRANCE.
Aim: To evaluate changes in tumour glycolysis measured by
positron emission tomography (PET) with [18F]fluoro-
desoxyglucose ([18F]-FDG) and in steroid hormone receptor
expression measured by PET with 16α-[18F]fluoro-17β-
oestradiol ([18F]-FES) following internal radiotherapy with
nanoparticles loaded with rhenium-188 (LNC-188Re-SSS) in
a preclinical murine model of human endometrial cancer. Ma-
terials and methods: Ishikawa endometrial carcinoma cell lines
were implanted subcutaneously in nude mice (n=10). D28
after inoculation, mice (n=5) were treated with an intra-
tumor injection of LNC-188Re-SSS. Treatment efficiency in
the LNC-188Re-SSS group was compared to control group
(n=5) in term of tumour growth assessed by clinical palpation
and micro-PET/CT imaging. For each mouse, two [18F]-FDG
and two [18F]-FES micro-PET/CT were performed on sepa-
rate imaging days, at baseline before therapy, and two weeks
later. Results: Fourteen days after treatment with LNC-188Re-
SSS, tumour progression was significantly inhibited compared
to the control group (p<0.006). [18F]-FDG uptake remained
stable in the treated group (p=0.9) and was significantly lower
than in control group (p=0.03), in which [18F]-FDG tumour
uptake increased significantly (p=0.003). An excellent corre-
lation was observed between [18F]-FDG tumour uptake and
tumour volume (r=0.88, p=0.0016). At baseline focal [18F]-
FES uptake corresponding to the known subcutaneous tumour
were observed in both group of mice, and after treatment no
significant [18F]-FES uptake difference was observed be-
tween the treated and untreated groups (p=0.75). The [18F]-
FES tumor uptake was not correlated with the tumour volume
(r=0.1613, p=0.68). A significant correlation was found be-
tween tumour ERα-score, measured by immunohistochemis-
try, and [18F]-FES uptake (r=0.6821, p=0.043). Conclusion:
Because after treatment, significant changes in tumour uptake
was observed only with [18F]FDG and not with [18F]-FES,
[18F]-FES does not appear to be able to monitor the therapeu-
tic effect of internal radiation with LNC-188Re-SSS.
P165
PET imaging of CD-30 positive lymphomas using
radiolabelled antibodies
S. Rylova1,2,3, C. Klingeberg1, L. Del Pozzo1,2,3, R.
Tonnesmann1, A. Illert1, P. T. Meyer1,2,3, H. Maecke1, J. P.
Holland1,2,3; 1Freiburg University Hospital, Freiburg, GER-
MANY, 2DKTK, Heidelberg, GERMANY, 3DKFZ, Heidel-
berg, GERMANY.
Aim: The anti-human CD-30 antibody drug conjugate,
brentuximab vedotin, is approved for treatment of relapsed
refractory Hodgkin lymphoma and systemic anaplastic large
cell lymphomas (ALCL), and has a reported overall response
rate of 70%. Since CD-30 expression can vary among different
types of lymphoma, and may also change during the course of
the treatment, companion diagnostic imaging of CD-30 could
be a valuable tool in optimizing patient-specific brentuximab
vedotin treatment regimens. Material and Methods. The AC-
10 mouse anti-human CD-30 antibody was conjugated with a
desferrioxamine B (DFO) chelate and radiolabeled with the
positron-emitting radionuclide 89Zr, the reaction was moni-
tored using HPLC and radio ITLC. The pharmacokinetic of
89Zr-DFO-AC-10 was evaluated in Balb/c Nude mice bearing
subcutaneous human ALCL tumors (CD-30 positive) or A431
tumors (CD-30 negative) using PET/CT imaging and
biodistribution studies. Results and conclusion: The anti-CD-
30 antibody was conjugated with DFO chelate and
radiolabeled with 89Zr to give formulated 89Zr-DFO-AC-10
with a radiochemical yield (RCY) of 74.5% and radiochemical
purity (RCP) of 100%. The specific activity of 89Zr-DFO-AC-
10 was 99.3MBq/mg. Time activity curves (TAC) derived
from longitudinal PET imaging in CD-30 positive model
(100 μL i.v.; 6.9 - 7.4 MBq/mouse; imaging 24 - 144 h post-
injection) demonstrated highest tissue localization in tumors
with an average uptake of 21.4±2.7 %IA/g at 24 h p.i. reaching
a maximum uptake 26.1±8.8 %IA/g at 120 h p.i. Among nor-
mal organs the highest uptake of radioactivity was in liver with
11.0±1.3%IA/g at 24 h, which persisted throughout the exper-
iment (10.48±1.32 %IA/g at 144 h p.i.). The average uptake in
CD-30 negative tumors was 12.6±1.2 %IA/g at 24h and
remained constant throughout the imaging ( 10.8±1.0 %IA/g
at 144 h p.i). Tumor-to-blood ratios in CD-30 positive model
increased from 2.7 to 11,8 from 24 to 144 h, respectively.
Tumor-to-muscle ratios increased from 2.7 to 45.1 between
24 and 144 h p.i. Biodistribution studies performed at 72 h
p.i revealed 37.9±8.2 %IA/g uptake in the ALCL tumor versus
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11.4±0.4 %IA/g in A431 tumors, 11.8±2.4 in liver, 8.2±0.8.1
%IA/g in spleen, 5.1±0.4%IA/g in bone and 6.4±0.5%IA/g in
blood. Collectively, our data indicate that 89Zr-DFO-AC-10
can be used as a sensitive PET imaging agent for measuring
CD-30 expression in tumors.
P166
Imaging of CDH17-positive gastric cancer xenografts
with 64Cu-labeled anti-CDH17 IgG PET
K. Fujiwara1, K. Koyama1, K. Suga2, M. Takahashi1, O.
Kusano-Arai3, K. Mitsui3, H. Akiba4, H. Iwanari3, K.
Tsumoto4, T. Hamakubo3, T. Momose1; 1Department of Radi-
ology, Graduate School ofMedicine, TheUniversity of Tokyo,
Tokyo, JAPAN, 2SANKYO LABO SERVICE Co., Ltd., To-
kyo, JAPAN, 3Department of Quantitative Biology and Med-
icine, Research Center for Advanced Science and Technology,
The University of Tokyo, Tokyo, JAPAN, 4Department of
Bioengineering, School of Engineering, The University of To-
kyo, Tokyo, JAPAN.
Aim: Cadherin 17 (CDH17) is a membrane protein that con-
tributes cell-cell adhesion. CDH17 may have potensial as a
target protein of immunotherapy or radioimmunotherapy
(RIT) for gastric cancer, because CDH17 is specifically
expressed at high levels in gastric cancer. In order to perform
immunotherapy or radioimmunotherapy, it is necessary to
identify and quantify the expression of target protein in the
cancer tissues before the treatment. ImmunoPET is useful for
this purpose, because PET can evaluate non-invasively and
quantitatively the expression of target protein in cancer tissues.
In this study, we performed PET study using 64Cu-labelled
anti-CDH17 IgG monoclonal antibody against gastric cancer
models. We evaluated the possibility of 64Cu-anti-CDH17
IgG as a PET agent for gastric cancer. Materials and Methods:
The specificity of anti-CDH17 IgG for CDH17 antigen was
evaluated by flow cytometry. CDH17-positive human gastric
cancer AGS xenograft nude mice were used in this study. We
conjugated anti-CDH17 MAb with 1, 4, 7-triazacyclononane-
1, 4, 7-triacetic acid (NOTA), and the conjugates were labelled
with 64Cu. AGS xenograft mice were injected 7 MBq of
64Cu-anti-CDH17MAb via tail vein. PET/CTscans were per-
formed using small animal PET scanner. Image data were re-
constructed by use of OSEM2D. Region of interests were de-
fined in tumor, mediastinum and liver. The percentage of
injected dose per gram of tissue (%ID/g) was calculated for
each organs. Results: Flow cytometry demonstrated the spec-
ificity of anti-CDH17 IgG for CDH17 antigen. In addition, we
confirmed that NOTA conjugation and radiolabelling did not
impair the affinity for anti-CDH17 IgG. In the PET study,
64Cu-anti-CDH17 IgG showed a clear image of a CDH17-
positive AGS tumors. The uptake of 64Cu-anti-CDH17 IgG
in tumors increased gradually over time, and the maximum
uptake was 26.6 ± 4.3 %ID/g at 72 hours after injection. The
uptake to mediastinum and liver decreased gradually over
time. The uptake to mediastinum and liver was 5.64 ± 2.3
%ID/g and 5.53 ± 1.1 %ID/g at 72 hours after injection, re-
spectively. Conclusion: 64Cu-anti-CDH17 IgG is a promising
PET probe for evaluating the expression of CDH17 antigen in
gastric cancer. This agent has the potential to facilitate the
selection of appropriate patients who would benefit from
anti-CDH17 IgG therapy or RIT.
P167
Preclinical evaluation of a novel bombesin peptide analog
for targeting bombesin receptor expressing tumors
S. Okarvi, I. Jammaz; King Faisal Specialist Hospital & Re-
search Centre, Riyadh, SAUDI ARABIA.
Aim: Over the last few years bombesin (BN) receptors have
attracted a great clinical attention as molecular target for diag-
nosis and therapy as all three BN receptor subtypes are
overexpressed in various human cancers. Despite substantial
developments the limitations enforced by BN peptide pharma-
cokinetics related to binding and clearance kinetics suggest
that significant improvements of these radiolabeled BN ana-
logs are still needed. The aim of this study was to develop a
BN analog having wide receptor affinity and favorable phar-
macokinetics and able to be labeled both with diagnostic and
therapeutic radionuclides to produce a potential theranostics
for targeting BN receptor-positive tumors.Materials and
Methods: We have designed a unique BN peptide composition
consisting of a GGC sequence to facilitate complexation with
99mTc and DOTA for labeling with 68Ga/177Lu. A hippurate-
type spacer (aminobenzoyl-Gly) was also introduced between
binding and chelating site to enhance excretion through renal
system. DOTA-Abz-Gly-Gly-Cys-Gln-Trp-Ala-Val-Cha-His-
Nle-Met-NH2 was synthesized by solid phase following
Fmoc/HBTU chemistry. Labeling with 99mTc and 68Ga was
performed by stannous-tartrate and in the presence of 2.5M
NaOAc buffer (pH 4-5). In vitro cell-binding was conducted
on MDA-MB-231, T47D breast and PC3 prostate cancer cell
lines and pharmacokinetics was evaluated in balb/c mice at 1
and 4 h p.i.Results and Discussion: The structure of DOTA-
BN was confirmed by mass spectrometry and MALDI and its
purity by HPLC. BN analog labeled efficiently with
99mTc/68Ga under mild conditions (labeling efficiency ~90%)
as confirmed by HPLC. Tumor cell binding indicated the high
affinity and specificity of 99mTc/68Ga-BN towards breast and
prostate cancer cell lines with binding affinity below 25nM.
Also significant internalization (~20%) into breast and prostate
cancer cells was observed. In mice 99mTc/68Ga-BN exhibited a
rapid clearance from the blood and excretion by renal route
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(~67% ID) possibly due to the presence of a hippurate-like
moiety in the peptide. Likewise a low uptake and retention
by the kidneys was observed (<4% ID/g). The enhanced uri-
nary excretion and low hepatobiliary clearance suggest the
pronounced effect of hippurate-like spacer on the biokinetics.
The uptake in the lungs, stomach, liver, intestines and pancreas
was low (<5% ID/g) both at 1 and 4 h p.i.Conclusion: The
findings of our initial study suggest that BN peptide under
investigation holds certain promising in vitro/in vivo proper-
ties as a tumor targeting agent and seems a potential candidate
for further evaluation. Tumor targeting studies in xenografts
models are in progress and will be reported.
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Monitoring of re-differentiation effect of radio-iodine
refractory thyroid cancer using the new tracer F-18-TFB
J. Nagarajah, A. Boländer, C. Irwin, J. A. Fagin, W. A. We-
ber; MSKCC, New York, NY, UNITED STATES.
Background: Re-differentiation through inhibition of MAPK
pathway is a promise attempt to treat progressive radio-iodine
refractory thyroid cancer. However, it is challenging to select
the optimal time window to apply I-131 to those patients.
F-18-TFB is a new tracer, which binds to sodium-iodine-
symporter (NIS) and can be used to image the expression of
this symporter. Aim: Monitoring of the re-differentiation effect
of mice with knock-in BRAFV600E thyroid cancer (TPO-Cre/
LSL-BRAF-V600E mice) treated with AZD6244 (MEK-
inhibition) and CKI27 (MEK and BRAF inhibition) using
F-18-TFB. Method: Three groups of mice (group 1:
AZD6244 50 mpk, group 2: CKI27 1.5 mpk and group 3:
vehicle; each n=5) were treated for 22 days. All mice
underwent ultrasound volumetry of thyroid on day 0, 5, 16
and 22, respectively. F-18-TFB was synthesized according to
Jauregiu-Osoro et al. and PETscans were performed on day 0,
1, 2, 4, 9, 12 and 21, respectively using a dedicated animal
PET/CT (Inveon, Siemens) about 30 minutes after injection of
about 4 MBq F-18-TFB. Results: Ultrasound: Group 1 and 2
showed on average a thyroid volume reduction from day 0 to 6
(47.4 to 31.5 mm3 and 41.7 to 20.7 mm3, respectively) where-
as the volume in group 3 remained rather unchanged (41.9 to
40.0 mm3). On day 22 the thyroid volume of group 1 in-
creased to 50.6 mm3 and of group 2 to 27.3 mm3 whereas
the group showed no change (42.1 mm3). F-18-TFB: The
volume corrected average uptake (calculated in %ID/mm3)
data showed an increase of F-18-TFB up to about 9-12 days
after begin of treatment and a decrease to day 21 in both treated
groups. The group 2 (CKI27) showed remarkable higher up-
take values than the group 1 (AZD6244). The following num-
bers are given in %ID/mm3 for the seven F-18-TFB scanning
time points. Group 1: 78; 100; 78; 116; 128.8; 99; 158. Group
2: 78; 206; 208; 318; 159; 214; 181. Group 3: 45; 72; 83; 80;
91; 67; 73. Conclusion: Treatment of radio-iodine refractory
thyroid cancer withMEK/BRAF inhibitors show different lev-
el of NIS expression in a time dependent manner. F-18-TFB is
therefore suitable to select an optimal time window to perform
I-131 treatment.
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18F-FLT versus 18F-FDG for the assessment
of therapeutic response to a BRAF inhibitor
in a melanoma xenograft model
L. S. Vercellino1, A. Martineau1, C. Lebbé2,3, E. Barré1, F.
Cartigny1, S. Mourah4,3, P. Merlet1,3; 1Service de Médecine
Nucléaire Hôpital Saint Louis Assistance Publique Hôpitaux
de Paris, Paris, FRANCE, 2Service d’Onco-dermatologie
Hôpital Saint Louis, Paris, FRANCE, 3Université Paris-Dide-
rot, Paris, FRANCE, 4Laboratoire de Pharmacologie
Génétique Hôpital Saint Louis, Paris, FRANCE.
Aim: To evaluate the therapeutic response to a BRAF inhibitor
of a model of a melanoma xenograft with molecular imaging.
To compare the relevance of 18F-FLT and 18F-FDG micro
PET/CT for this therapeutic evaluation. Materials and
methods: Xenografts were obtained by injecting 5*10^6
BRAF mutated human melanoma cells A375 subcutaneously
in nude mice. When tumours became palpable, baseline micro
PET imaging was performed. Mice were imaged with 18F-
FLT, then with 18F-FDG on the following day. 18F-FLT and
18F-FDG were injected intravenously, and a 90 minutes dy-
namic acquisition was performed. Mice were then treated by a
BRAF inhibitor, dabrafenib, at the dose of 100mg/kg given
orally once daily for 14 days. At the end of treatment a second
imaging session (micro PET/CTwith 18F-FLT then FDG) was
perfomed. Mice were then sacrificed and tumours harvested
for further histological and immnuno-hisotological analysis.
Mean relative tumour volume (RTV) was calculated, by estab-
lishing a ratio between the size of tumours before onset of
treatment and at the end of the treatment period. Initial image
analysis was performed by determining the SUVmax within
the tumours and SUVmean in the liver at 60 minutes post-
injection. The ratio of SUVmaxTumour/SUVmeanliver was
then calculated. Results: Mean RTV at day 15 was 2.23 in
the control group, and 1.17 in the dabrafenib-treated group.
In the control group mean FDG SUVmax was 1.1 and
remained stable at day 15. In the treated group mean FDG
SUVmax at baseline was 1.55, and 0.85 at day 15, with a mean
decrease of SUVmax of 38%. The SUVmaxTumour/
SUVmeanliver ratio increased by 4% in the control group,
whereas it decreased of 26% in the treated group. For the
FLT studies, imaging analysis yielded the following results:
in the control group mean baseline SUVmax was 1.77, and
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S421
increased to a mean 2.3 at day 15, with a mean increase of
32%. The SUVmaxTumour/SUVmeanliver ratio increased of
21%. In the dafrafenib treated group mean baseline SUVmax
was 1.98 and increased to a mean 2.4, corresponding to a mean
increase of 16%, whereas the SUVmaxTumour /
SUVmeanliver ratio increased of 6%. Conclusion: Our prelim-
inary results show that tumours treated by dabrafenib had a
slower progression than control and a decrease of FDG uptake,
whereas no significant modification of FLT uptake was ob-
served with static imaging. Further analysis of FLT dynamic
imaging data and confrontation to histological data may pro-
vide additional information on this tracer relevance in this
setting.
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Evaluation of 99mTc-duramycin for imaging
conatumumab-induced tumor apoptosis: a comparative
study with 18F-FDG
F. Elvas1,2, C. Vangestel1,2, N. Challouk1, K. Y. Pak3, S.
Staelens1, S. Stroobants1,2, L. wyffels1,2; 1University of Ant-
werp, Wilrijk, BELGIUM, 2University Hospital Antwerp -
Department of Nuclear Medicine, Edegem, BELGIUM, 3Mo-
lecular Targeting Technologies, Inc., West Chester, PA, UNIT-
ED STATES.
Aim: Early assessment of response to cancer therapy repre-
sents one of the biggest challenges in oncology. 18F-FDG is
currently the gold standard for tumor detection and therapy
evaluation within clinical nuclear medicine. However, it has
some limitations such as uptake in inflammatory cells and thus
it lacks specificity. Imaging of cell death offers a more specific
tool for treatment evaluation. Duramycin is a polypeptide that
selectively binds to phosphatidylethanolamine (PE) in apopto-
tic and necrotic cells. Our group has recently demonstrated that
99mTc-duramycin is able to selectively detect chemotherapy-
induced cell death in a mouse model of colorectal cancer(1). In
the current study we further explored the potential of 99mTc-
duramycin for early therapy response evaluation using
conatumumab, a fully human monoclonal antibody directed
against human DR5 that induces apoptosis in sensitive tumor
cells.Materials and Methods: Colo205 cells (1.0E6) were
injected subcutaneously in the right hind leg of female CD1
nu/nu mice aged 6-7 weeks. When the tumors reached 182
mm3, baseline 99mTc-duramycin (37MBq) static SPECT-CT
(4 h post radiotracer injection) and 18F-FDG (18.5MBq) PET-
CT scans (30 min post radiotracer injection) were performed.
The next day conatumumab or IgG1 control antibody (30μg;
Amgen Inc., USA) were administered by intraperitoneal injec-
tion (n=4/group). Twenty-four hours after treatment, the ani-
mals underwent static 99mTc-duramycin SPECT-CT (n=4)
and 18F-FDG PET-CT imaging (n=2). Radiotracer uptake in
the tumors was obtained by γ-counting of the tumors (%ID/g)
and will be quantified from the SPECT and PET images. Cell
death in the tumors will be determined by cleaved caspase-3
(CC3) and TUNEL staining.Results: No difference was found
between the volumes of treated tumors and controls. A signif-
icantly increased 99mTc-duramycin uptake was detected in
conatumumab treated tumors (6.7-fold increase; p=0.002)
compared to IgG1 treated tumors while 18F-FDG uptake
was decreased compared to the controls (2.8 ± 0.57%ID/g vs
5.5 ± 2.0%ID/g; non-significant). The regional distribution of
99mTc-duramycin in the tumors will be determined by auto-
radiography and wil l be corre la ted to his to logy
results.Conclusion: We demonstrated that 99mTc-duramycin
specifically accumulates in conatumumab-responding tumors.
99mTc-duramycin is potentially a more specific alternative to
18F-FDG for early assessment of response to therapy.1.Elvas
F, Vangestel C, Rapic S, Verhaeghe J, Gray B, Pak K, et al.
Characterization of [99mTc]Duramycin as a SPECT Imaging
Agent for Early Assessment of Tumor Apoptosis. Molecular
imaging and biology : MIB. April 2015. doi: 10.1007/s11307-
015-0852-6. PubMed PMID: 25896815.
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Development of short and specific MC1R-targeted
DOTA-conjugated peptide tracers for PET imaging
of melanoma xenografts
J. Körner1, J. Castillo Gómez2, N. Beindorff2, E. Koziolek2, V.
Prasad2, B. Wiedenmann1, W. Brenner2, C. Grötzinger1;
1Charité - Universitätsmedizin Berlin, Gastroenterology, Ber-
lin, GERMANY, 2Charité - Universitätsmedizin Berlin, Nu-
clear Medicine, Berlin, GERMANY.
Aim: Cutaneous malignant melanoma is one of the most lethal
forms of cancer. Its incidence is increasing rapidly, making it a
significant public health threat. The most important approach
for improvement of survival of patients still remains early
diagnosis. The melanocortin receptor 1 (MC1R) is
overexpressed in most melanomas making it a promising mo-
lecular target for both diagnosis and therapy. Because of their
very low molecular weight, and hence their low immunoge-
nicity and excellent tumor penetration, radiopeptides have
attracted steadily increasing interest in receptor-mediated tu-
mor targeting. Aim of this study was the development of short
and specific MC1R-targeted tracers with an improved serum
half-life for nuclear in vivo imaging with positron emission
tomography. Materials and Methods: Structure-activity rela-
tionship of more than 80 short peptides was investigated in
functional cyclic AMP and radioligand receptor binding as-
says. Next to an optimized specificity and affinity towards
the target, an improvement of the serum half-life of the short
peptides was sought-after. Therefore, stability against serum or
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plasma peptidases was analyzed by HPLC. Specific and affine
peptide ligands for the G protein-coupled receptorMC1Rwere
obtained. The most promising tracers were coupled to DOTA
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) for
later nuclear imaging applications. DOTA was conjugated to
various sites of the peptide and its impact towards specificity
and affinity was investigated. Several human and murine tu-
mor cell lines were screened by using radioligand binding
assays for their potential use as positive (MC1R expressing)
or negative control (lack of MC1R) for in vivo PET imaging.
Results: We developed several peptide tracers with a high
affinity towards our target MC1R (subnanomolar Ki). These
novel molecules show clear improvements over the naturally
occurring α-Melanocyte stimulating hormone in terms of size
(<2 kDa), stability (>2 h) and in particular specificity (>3000x
towards the other 4 MC receptors). DOTA conjugation, for
nuclear imaging, had virtually no negative impact on specific-
ity or affinity. The in vitro binding of our tracers to several
human and murine tumor cell lines could be shown. Next to
the known MC1R-overexpressing tumor entity of cutaneous
melanoma we identified several other cell lines from conjunc-
tival melanoma and neuroendocrine tumors. Results of
biodistribution and PET/MR imaging studies in mouse xeno-
grafts will be presented. Conclusion: These new molecules
should enable MC1R-specific PET imaging in the future.
Acknowledgement/ReferencesThis study was supported by a
grant from the German Federal Ministry of Education and
Research (BMBF), Unternehmen Region 03IPT614A.
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Evaluation of [18F]BR420 and [18F]BR351 as potential
PET radiotracers for MMP-9 imaging in a colorectal
cancer tumor model
N. Vazquez1,2, S. Missault1, C. Vangestel1,2, D. Thomae1,2, P.
Van Der Veken1, S. Staelens1, S. Dedeurwaerdere1, w.
Leonie2; 1University of Antwerp, Antwerp, BELGIUM, 2Uni-
versity Hospital Antwerp, Antwerp, BELGIUM.
Aim: Matrix metalloproteinases (MMPs) are a family of Zn-
dependent endopeptidases involved in the proteolytic degra-
dation of components of the extracellular matrix. Their expres-
sion is known to increase in various inflammatory, malignant
and degenerative diseases. MMP-9 is of particular interest for
its potential contribution to cancer invasion and metastasis1.
The purpose of this study was to evaluate the potential of
[18F]BR4202 and [18F]BR3513 for in vivo visualization of
MMP-9 in a Colo-205 tumor model. Materials and Methods:
[18F]BR420 was synthesized on a Veenstra FluorSynthon I
synthesis module that was adapted for fully automated produc-
tion of the radiotracer via a novel one-step synthesis strategy.
[18F]BR351 was synthesized following a published
methodology3. Xenografts bearing MMP-9 expressing Colo
205 tumors were injected with [18F]BR420 (150 μCi, n =4
or 1 mCi, n =1) or [18F]BR351 (100-200 μCi, n =5). They
underwent a 60min dynamic μPET scan followed by static
scans at 2h and 4h post injection (pi). Tumor uptake was de-
termined on PET images (SUVmean) and ex vivo by γ-
count ing . MMP-9 express ion was eva lua ted by
immunohistocheistry (IHC) and in sity zymography (ISZ).
Results: [18F]BR420 and [18F]BR351 were obtained in good
radiochemical yield (15.51±3.40% and 12.4±2.6%, respec-
tively, decay corrected to EOB), with specific activities rang-
ing between 37 and 311 GBq/μmol (EOS) and high RCP
(>98%). μPET imaging indicated the highest tumor uptake
for [18F]BR420 at 2h pi (SUVmean=0.49g/cc) and at 11min
(SUVmean=0.36g/cc) pi for [
18F]BR351. However, metabolite
analysis indicated rapid metabolism of [18F]BR351 with only
19.44±6.18% intact tracer remaining in plasma at 15min pi.
[18F]BR420 was more stable with 79.56±3.12% intact remain-
ing in plasma at 2h pi. IHC and ISZ confirmed MMP-9 ex-
pression in the tumors. Conclusions: Both, [18F]BR420 and
[18F]BR351 bind to MMP-9 expressing tumor tissue and
might be promising PET radiotracers for in vivo imaging of
MMP-9 in tumors and other MMP-9 related disorders.
References:[1]Mook, OR et al. Biochim. Biophys. Acta,
2004, 1705, 69-89. [2]Breyholz HJ et al. ChemMedChem.
2010, 5, 777-789. [3]Wagner S et al. J. Med. Chem. 2007,
50, 5752-5764.
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Estimation of tumour volumes by [11C]MeAIB and [18F]
FDG PET in an orthotopic glioblastoma model
C. Aaberg-Jessen1, B. Halle2,3,4, H. Thisgaard1,4, S.
Hvidsten1, J. H. Dam1, A. S. Thykjær4, P. F. Høilund-
Carlsen1,4, M. K. Schulz2, C. Andersen2, B. W. Kristensen3,
4; 1Odense University Hospital, Department of Nuclear Med-
icine, Odense, DENMARK, 2Odense University Hospital, De-
partment of Neurosurgery, Odense, DENMARK, 3Odense
University Hospital, Department of Pathology, Odense, DEN-
MARK, 4University of Southern Denmark, Institute of Clini-
cal Research, Odense, DENMARK.
Introduction: Brain tumour volume assessment is a diagnostic
challenge. Positron emission tomography (PET) may be a
promising modality for this. We compared the agreement be-
tween PET- and histology-derived tumour volumes in an
orthotopic glioblastoma model with a solid non-infiltrating
(U87MG) and a non-solid, highly infiltrating (T87) tumour
phenotype. Methods: Rats with U87MG- and T87-derived
glioblastomas were continuously PET scanned for 1 hour im-
mediately after injection of [11C]methylaminoisobutyric acid
([11C]MeAIB). One hour later, [18F]fluorodeoxyglucose
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([18F]FDG) was injected followed by a 3 hour dynamic PET
scan. Images were reconstructed using ordered subset expec-
tation maximization in two dimensions (OSEM2D) and max-
imum a posteriori in three dimensions (MAP3D) algorithms.
In addition, a parametric image, encompassing the entire tu-
mour kinetics in one single image, was calculated based on the
[11C]MeAIB images. All reconstructed images were segment-
ed by fixed thresholding of maximum voxel intensity (VImax)
and based on mean background intensity (MBI). The agree-
ment between PET- and histology-derived tumour volumes
and intra- and inter-observer agreement of the PET-derived
volumes were evaluated using Bland-Altman plots. Results:
By PET, the mean U87MG tumour volumes were 35.0 mm3
and 34.1 mm3 using [18F]FDG and [11C]MeAIB, respective-
ly, and 33.7 mm3 by histology (p<0.999). For T87, corre-
sponding volumes were 122.1 mm3, 118.3 mm3, and 125.4
mm3, respectively (p<0.999). The best agreement, between
PET- and histology-derived U87MG tumour volumes was
achieved with [11C]MeAIB, MAP3D reconstruction, and
fixed thresholding of VImax (95% LOA -9.8-7.9, bias -1.0,
SD of bias 4.5, R2 0.994). For T87 tumours, the best agree-
ment was obtained using [18F]FDG, MAP3D reconstruction,
and fixed thresholding of MBI (95% LOA -46.1-52.6, bias
3.2, SD of bias 25.2, R2 0.814). The agreement when using
[11C]MeAIB, parametric imaging and fixed thresholding of
VImax was slightly inferior, while the intra- and inter-observer
agreement was superior. The histological intra-observer agree-
ment was high for U87MG (95% LOA -1.7-1.0, bias 0.3, SD
of bias 0.7, R2 0.998) and T87 tumours (95%LOA -16.0-14.4,
bias 0.8, SD of bias 7.7, R2 0.998). The inter-observer agree-
ment was equally high for U87MG (95% LOA -1.8-2.3, bias
0.3, SD of bias 1.0, R2 0.976) and T87 tumours (95% LOA -
6.1-9.6, bias 1.7, SD of bias 4.0, R2 0.992). Conclusion: Vol-
ume estimation of solid non-infiltrating brain tumours by PET
was accurate and reproducible, whereas volume estimation of
non-solid infiltrating brain tumours was difficult and hard to
reproduce. PETevaluation of infiltrating brain tumours should
be further developed.
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Identification of a set of imaging procedures
for the accurate assessment of tumour progression
and response to treatment in a Glioma animal model
C. Martelli1,2, S. Valtorta3,4, L. S. Politi5, R. Isabella4,6, D.
Cecilia7,8, B. Sara3,4, S. Sudati4, G. Di Grigoli4,3, G.
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lular Imaging-IMAGO, University of Milan, Segrate, ITALY,
3IBFM-CNR, Segrate, ITALY, 4Experimental Imaging Center,
IRCCS San Raffaele Scientific Institute, Milano, ITALY,
5Neuroradiology Department & Neuroradiology Research
Group, IRCCS San Raffaele Scientific Institute, Milano, ITA-
LY, 6Department of Health Sciences, University of Milano-
Bicocca, Milano, ITALY, 7Department of Medical-Surgical
Physiopathology and Transplants, University of Milan,
Segrate, ITALY, 8Supported by a fellowship from the Doctor-
ate School of Molecular Medicine, University of Milan,
Segrate, ITALY, 9Department of Health Sciences, University
of Milan, Milano, ITALY, 10San Paolo Hospital, Department
of Diagnostic Services, Unit of Nuclear Medicine, Milano,
ITALY.
AIM: Glioma represents the most aggressive primary brain
tumour characterized bywide necrotic areas, resistance to ther-
apy, high invasiveness and a poor prognosis for the patient.
Hypoxia is considered a major driving force for glioma pro-
gression and HIF-1α plays a crucial role in this context. The
gold standard therapy is temozolomide (TMZ) associated to
radiotherapy but the prognosis remains poor. Its efficacy relies
only upon the evaluation of MGMT promoter methylation
even if it is not fully predictive of patient response to treatment.
Here we aimed at identifying non-invasive potentially
theragnostic biomarkers involved in the regulation of tumour
growth and response to treatment for early assessment of tu-
mour sensitivity to specific therapeutic regimens using in vivo
imaging strategies in a mouse model of glioma. METHODS:
Orthotopic murine model was obtained by stereotaxic injec-
tion glioma cells (U251-HRE expressing Luciferase reporter
gene under the control of multiple copies of an hypoxia
responsive element) in female nude mice of 7-8 weeks of
age (d0). Animals at 21 days from cell injection were
subdivided in control (vehicle) and treated (temozolomide,
400 mg/kg o.s.) groups. Tumor growth was monitored
in vivo with MRI, BLI and FLI before and after (2 and 7 days)
treatment. Moreover, ex vivo preliminary studies were per-
formed using autoradiography with [99mTc]HMPAO and
[99mTc]MIBI. As regards MRI it was performed on a Bruker
Pharmascan instrument equipped with a 7.0 T horizontal mag-
net. Images sequences of 1h of the coronal plane were ac-
quired as follows: EPI-DTI (Diffusion Tensor), Turbo Spin
Echo T2, Rare T1 Map, Dynamic Contrast Enhancement
(DCE) Dynamic Susceptibility Contrast (DSC) and T1 post-
contrast (0.2 μL/g of gadobutrole). All BLI/FLI acquisitions
were carried out with IVIS SPECTRUM/CT instrument.
HypoxiSense680 fluorescent probe and IntegriSense750 were
intravenously administered to mice and after 24 h, fluores-
cence imaging (FLI) was performed. RESULTS: Temozolo-
mide treatment induced a reduction of tumour volume reported
by MRI and autoradiography one week after treatment. Treat-
ment efficacy was detectable using also DWI and DCE se-
quences. [99mTc]MIBI uptake resulted significantly lowered
after TMZ treatment allowing the identification of responsive
tumours. These data correlate with those already obtained by
BLI and FLI. CONCLUSIONS: This study suggests that
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U251-HRE orthotopic murine model may be proposed as a
predictive and reliable tool to evaluate processes involved with
HIF-1α activity. Clinically translational procedures as MRI
sequences and [99mTc]MIBI-SPET could be useful markers
for tumour progression and early response to treatment.
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imaging of response to CXCR4 new cyclic peptide
antagonist with conventional chemotherapy in colorectal
cancer mice model
A. Greco1,2, C. D’Alterio3, L. Auletta4, S. Albanese5,2, M.
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di Napoli Parthenope, Napoli, ITALY, 6Institute of
Biostructures and Bioimages of the National Council of Re-
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Introduction CXCR4 plays a key role in the progression and
metastatization of many tumors. The prognostic role of
CXCL12/CXCR4–CXCR7 was previously shown in colorec-
tal cancer (CRC) (1). Recently, a new family of CXCR4 in-
hibitors that showed anti-tumor activity has been developed
and characterized (2). High frequency ultrasound (HFUS) is a
non invasive, cost-effective, imaging modality that allow lon-
gitudinal evaluation of xenograft tumor in mice models. Aim
of the present study is to evaluate the effect on tumor growth
and angiogenesis of anti-CXCR4 Peptide R alone or combined
with conventional chemotherapy in mice model of colorectal
cancer.Materials and methodsAthymic balb/C nude mice, 5-6
weeks old (4 mice/group) were subcutaneously injected with
human colorectal cancer cell lines HCT116 (2x106). Tumor
volume (TV) was measured using the electronic caliper inte-
grated on 2D ultrasonographic images. The HFUS procedure
was performed under general anaesthesia with isoflurane and
oxygen. The 3D integrated software associated with color
doppler was used to monitor the antiangiogenic effects of the
therapy. Treatment groups were: 1) Peptide R alone [5 mg/kg];
2) 5FU [30 mg/kg] + OX [4.2 mg/kg]; 3) 5FU [30 mg/Kg] +
OX [4.2 mg/kg] + Pep R [5mg/kg]; 4) PBS [100 μL/mice]. All
therapies were administered i.p. daily, 5 days/week for 2
weeks.Results and discussionHFUS showed larger tumors in
controls compared to all treated groups. Group 3) had smaller
TV compared to both groups 1) and 2). The 3D reconstruction
software showed a reduction of angiogenesis in all treated
groups compared to the controls. Combination treatment of
conventional chemotherapy with Peptide R determined a
dramatic reduction in primary tumor growth. Nonetheless,
both chemotherapy alone and Peptide R alone inhibited pri-
mary tumor growth, suggesting that the Peptide could act on
all cells overexpressing CXCR4 involved in the tumor
microenviroment.Conclusions: Our study showed that
CXCR4 new antagonist Peptide R, alone or in combination
with conventional chemotherapy, caused a reduction of CRC
growth in mice model. Imaging by HFUS demonstrated to be
feasible for longitudinal studies and it gave intriguing infor-
mations on tumor growth as well as on angiogenesis, in re-
sponse to anticancer therapy.1)D’Alterio C. et al. 2014, Int. J.
Cancer: 135, 379–3902)Portella L. et al. 2013, PLoSOne 8(9):
e74548
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Establishment of a Chinese Lung Adenocarcinoma Cell
Line CPA-Yang1 with Osteolytic, Brian Metastases
Properties by Molecular Imaging
C. Chang, B. Lei, C. Liu, J. Cao, G. Tao, G. Tao, W. Xie, W.
Xie, S. Yang, S. Yang; Shanghai Chest Hospital, Shanghai,
CHINA.
Establishment of a Chinese Lung Adenocarcinoma Cell Line
CPA-Yang1 with Osteolytic, Brian Metastases Properties by
Molecular ImagingCheng Chang, Bei Lei, Ciyi Liu, Jie Cao,
Guangyu Tao, Wenhui Xie, Shunfang YangAim: To establish
a Chinese lung adenocarcinoma cell line with complicated
metastases potency.Methods: The cell came from the pericar-
dial effusion of a fifty years old male patient with lung adeno-
carcinoma and diagnosis of metastasis in temporal bone and
temporal lobe by CT. Primary culture the cells were obtain
success after three days. Approximately 0.8 x 106 cancerous
cells were injected into left cardiac ventricle or tail vein of
immunodeficient mice, respectively. Combination of micro
pinhole bone scintigraphy, micro SPECT/CT, micro PET/CT
scanners, magnetic resonance imaging (MRI) and human con-
ventional radiography (X ray).The gene expression was mea-
sured by cRNA microarray and real-time quantitative
PCR.Result: Start to appear lower limb paralysis and spine
swelling deformation in the mice after inoculation three
weeks. The temporal lobe brain metastasis was appeared six
weeks later. Combination of micro pinhole bone scintigraphy,
micro SPECT/CT, micro PET/CT scanners, magnetic reso-
nance imaging (MRI) and human conventional radiography
(X ray) can not only sensitive to detect the lesions but also
identify the type of bone metastasis (BM), osteoblastic,
osteolytic or mixed BM. Affymetrix U133 plus 2.0 gene chips
with 54675 probe sets and RT-PCR were used to select and
confirm expression of the genes. It’s important that lung can-
cer, especially lung adenocarcinoma, frequently develops os-
teoblastic and mixed BM, rare pure osteolytic and brain
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metastases in immunodeficient mice. TFF1 and CDH1 maybe
is a novel candidate gene involved in osteolytic and brain
metastases for lung adenocarcinoma, respectively.Conclusion:
Self-established Chinese lung adenocarcinoma cell line is a
highly published immortalized human blood-brain barrier
(BBB) and osteolytic metastases cell line. That is a suitable
model of BBB physiology and osteolytic metastasis. This is a
crystal of our scientific research and the precious wealth of all
mankind.
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Development of a DOTA-conjugated peptide tracer
targeted against gastric inhibitory polypeptide (GIP)
receptor for PET imaging of neuroendocrine tumor
xenografts
J. Körner1, J. Castillo Gómez2, N. Beindorff2, E. Koziolek2, V.
Prasad2, B. Wiedenmann1, W. Brenner2, C. Grötzinger1;
1Charité - Universitätsmedizin Berlin, Gastroenterology, Ber-
lin, GERMANY, 2Charité - Universitätsmedizin Berlin, Nu-
clear Medicine, Berlin, GERMANY.
Aim: To improve the overall survival of cancer patients, an
early and sensitive diagnosis is pivotal. In neuroendocrine tu-
mor (NET) patients the finding of overexpressed somatostatin
receptors and the use of somatostatin peptide analogues has
led to a vast improvement in diagnosis and therapy. Unfortu-
nately, only around two thirds of the tumors show the desired
high uptake in somatostatin receptor scintigraphy. There is an
urgent need for novel molecular targets in NETs. The aim of
this work was to identify new target structures in neuroendo-
crine tumors for the use in clinical diagnostic and therapeutic
applications. After validation of an overexpressed receptor, the
development of a DOTA-conjugated peptide tracer was con-
ducted for future use in positron emission tomography. Mate-
rials and Methods: A microarray-based approach was used to
identify overexpressed G protein-coupled receptors in pancre-
atic NET samples. A high expression similar to somatostatin
receptor 2 was found for the Gastric inhibitory polypeptide
receptor (GIPR) and validated in real-time qPCR experiments.
Neuroendocrine cell lines were investigated for their function-
al expression of GIPR in cyclic AMP and radioligand-receptor
binding assays. The natural occurring ligand GIP1-42 was
modified to enhance its size and serum- and plasma stability
while maintaining its low nanomolar affinity towards GIPR.
Stability was investigated by incubation in serum or plasma
and analysis of the intact peptide in reverse phase HPLC.
Binding constants were determined by in vitro radioligand
receptor studies with GIPR expressing cells. Results: We iden-
tified gastric inhibitory polypeptide receptor (GIPR) as
overexpressed in pancreatic and ileal neuroendocrine tumors
(more than 30 fold compared to surrounding tissue). The
mRNA expression levels were comparable to the gold stan-
dard SSTR2. In a following step, the development of tracer
molecules for PET imaging was advanced. In parallel, neuro-
endocrine tumor cells were screened for a functional GIPR
expression. We were able to identify two of six tested cell lines
which react to a GIP stimulus. Results of biodistribution and
imaging studies using DOTA conjugates will be presented.
Conclusion: Gastric inhibitory polypeptide receptor represents
a novel molecular target for neuroendocrine tumors. Develop-
ment of DOTA-conjugated GIP analogues can be utilized in
new diagnostic approaches for nuclear imaging and therapy
such as PET and PRRT. Acknowledgement/References: This
study was supported by a grant from the German Federal Min-
istry of Education and Research (BMBF), Unternehmen Re-
gion 03IPT614A.
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Biological characterisation and [18F]FDG microPET/CT
monitoring of relevant orthotopic preclinical models
of malignant pleural mesothelioma
D. J. Colin1, C. D’Amato-Brito2, S. Germain1, F. Triponez2,
Y. Seimbille3, V. Serre-Beinier2; 1Centre for Biomedical Im-
aging, University of Geneva, Geneva, SWITZERLAND,
2Thoracic Surgery Unit, University Hospitals and University
of Geneva, Geneva, SWITZERLAND, 3Cyclotron Unit, Uni-
versity Hospitals of Geneva, Geneva, SWITZERLAND.
Aims:Malignant Pleural Mesothelioma (MPM) is an asbestos-
related cancer and one of the most resistant and aggressive
cancer. Its incidence is still increasing especially in countries
lacking worker protection and persisting with asbestos use.
Early diagnosed MPM is primarily treated by surgery, but
the best current palliative treatment (cisplatin and pemetrexed)
for patients with invasive MPM allows a median survival of
only 9 to 18 months from diagnosis. Conversely, no relevant
orthotopic models in rodent which could be non-invasively
monitored have been described to date. This work describes
the in vivo 1) tumorigenicity of four human and one mouse
MPM cell lines injected subcutaneously or into the pleural
cavity of immunodeficient or syngeneic mice; 2) phenotypes
of the subcutaneous and or orthotopic MPM tumours; 3)
growth monitoring by 2-deoxy-2-[18F]fluoro-D-glucose
([18F]FDG)-microPET and CT scans. Materials and methods:
MPM human H28, H2052, MSTO-211H, JL-1 and mouse
AB12 cells were cultured in vitro according to standard de-
scribed procedures, and injected subcutaneously or
orthotopically into the pleural cavity of athymic BALB/c mice
(for human cells) or of syngeneic BALB/c mice (for AB12
cells). Epithelioid and sarcomatoid phenotypes, growing prop-
erties and vasculature of MPM tumours were analysed by RT-
qPCR, western blotting and immunohistochemistry.
S426 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
[18F]FDG-microPET/CT scan was used to monitor the growth
of the different models. Results: MSTO-211H and AB12 tu-
mours grew similarly and quickly when injected subcutane-
ously or orthotopically; JL-1 cells produced fast growing sub-
cutaneous tumours but slow growing orthotopic tumours;
H2052 cells grew very slowly in both sites of injection; H28
cells did not generate viable tumours. Although tumorigenic-
fast growing H2052-derived cells could be derived from initial
orthotopic tumours, no growing models could be isolated from
H28 cells even in highly immunodeficient SCID mice. Pheno-
typic analyses showed that all the tumours contained epitheli-
oid and sarcomatoid malignant cells expressing calretinin and
vimentin proteins. Orthotopic MPM tumours as small as 1
mm3 could be detected by microPET/CT. The [18F]FDGmean
SUVs increased in a growth-dependent manner and the
tumour-to-muscle ratios above 8 allowed a good visualisation
of the tumours in all the models. Conclusions: Three models of
relevant orthotopically xenografted human MPM models in
immunodeficient mice were developed. Moreover, a syngene-
ic murine AB12 model which would preserve immune prop-
erties is described. These models mostly showed biphasic phe-
notypes in vivo. The use of [18F]FDG-microPET/CT scan
allowed the monitoring of their development and could there-
fore serve to non-invasively study new therapeutic strategies
of MPM in preclinical settings.
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The impact of single or dual NEP/ACE-inhibition
on the performance of 99mTc-labeled neurotensins in mice
bearing human WiDr xenografts
T. Maina1, A. Kaloudi1, E. Lymperis1, A. Tatsi1, E. P.
Krenning2, M. de Jong2,3, B. A. Nock1; 1Molecular
Radiopharmacy, INRASTES, NCSR Demokritos, ATHENS,
GREECE, 2Institute of NuclearMedicine, ErasmusMC, ROT-
TERDAM, NETHERLANDS, 3Instistute of Radiology, Eras-
mus MC, Rotterdam, NETHERLANDS.
Aim: The neurotensin (NT) radiotracers 99mTc-DT1 ([99mTc-
N4-Gly
7]NT(7-13)) and 99mTc-DT6 ([99mTc-N4-βAla
7,Dab8,
Tle12]NT(7-13)) were previously studied for potential use in
the imaging of human tumors expressing the NT subtype 1
receptor (NTS1R). Despite the higher stability of double-
stabilized 99mTc-DT6 in vitro, the radiotracer failed to reliably
visualize NTS1R-positive lesions in patients, presumably due
to rapid in vivo degradation. Neutral endopeptidase (NEP) and
angiotensin converting enzyme (ACE) have been implicated
in the degradation of NT analogs. In the present study, we
report the effects induced by coinjection of the NEP-inhibitor
phosphoramidon (PA), or the ACE-inhibitor Lisinopril (Lis),
or both PA+Lis with 99mTc-DT1 or 99mTc-DT6 on radiotracer
profile in mice bearing humanWiDr xenografts. Materials and
Methods: Either 99mTc-DT1 or 99mTc-DT6 was coinjected in
mice with: a) vehicle (control), or b) PA (300 μg), or c) Lis
(100 μg), or d) PA+Lis (300 μg + 100 μg, respectively).
Mouse blood collected 5 min post-injection (pi) was analyzed
by HPLC to measure radiotracer degradation. Biodistribution
for 99mTc-DT1 and for 99mTc-DT6 was performed at 4 h pi in
SCID mice bearing human WiDr xenografts; mice were
coinjected with vehicle or inhibitor, as described above. Re-
sults: 99mTc-DT1was totally consumed inmouse circulation in
5 min, while >52% of 99mTc-DT6 was detected intact. Thus,
double Arg8/Dab8 and Leu12/Tle12 substitution in the native
NT(8-13) motif improved stability. Treatment of mice with PA
led to full stabilization of 99mTc-DT6, whereas only 25% of
99mTc-DT1 remained intact. On the other hand, only 99mTc-
DT1 could profit from Lis (>16% intact) or both PA+Lis
coinjection (56% intact). These results are in line with the
uptake of each radiotracer in WiDr xenografts at 4 h pi. Thus,
tumor uptake of partially stable 99mTc-DT6 in controls (1.7
±0.3%ID/g) significantly increased by PA (3.9±0.7%ID/g),
while no further improvement was observed with PA+Lis
(3.5±0.3%ID/g). On the other hand, tumor uptake of unstable
99mTc-DT1 in controls (1.2±0.2%ID/g) advantageously in-
creased with PA (4.6±0.5%ID/g) and with the PA+Lis combi-
nation it reached outstanding values (7.7±1.2%ID/g). Interest-
ingly, the renal uptake of 99mTc-DT6 unfavourably increased
by PA (from 6%ID/g to 12%ID/g), but remained low in the
case of 99mTc-DT1 (<3%ID/g). Conclusions: This study has
shown that in situ NEP and/or ACE inhibition represents a
powerful tool to improve the bioavailability, tumor targeting
and overall pharmacokinetics of NT(8-13)-based radiotracers
without requiring time-consuming compound development.
This approach warrants further validation in the field of
NTS1R-targeted tumor imaging and therapy.
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μPET as non-invasive read-out for a novel human
organotypic lung tumor model
D. Fecher1, G. Dandekar1, S. Nietzer1, R. A. Bundschuh2, H.
Walles1, A. K. Buck3,M. Steinke1,K.Lückerath3; 1Uniklinik
Würzburg, Department of Tissue Engineering and Regenera-
tive Medicine, Würzburg, GERMANY, 2Uniklinik Bonn, Nu-
clear Medicine, Bonn, GERMANY, 3Uniklinik Würzburg,
Nuclear Medicine, Würzburg, GERMANY.
Reliable in vitro tumor models are indispensable tools for tai-
lored drug-development and -testing. To meet this demand, we
developed a complex lung tumor test system based on
decellularized rat lungs. As a prerequisite we established a
decellularization protocol that preserves the lung architecture,
important ECM components and the basement membrane.
Human tumor cells seeded on our scaffold formed clusters,
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exhibited an up-regulation of the carcinoma-associated marker
mucin1 and a reduced proliferation rate.Furthermore, tumor
nodules were detected and could be tracked over time
employing 2-deoxy-2-[18F]fluoro-D-glucose positron emis-
sion tomography (FDG-PET)-imaging, a clinically-relevant
method to monitor tumor growth and metabolism. This ap-
proach enabled non-invasivemonitoring of a clinically applied
targeted tyrosine kinase inhibitor therapy in the lung tumor
model over a 72 h treatment period. Surprisingly, single tumor
clusters showed diversity in response rates to the therapy in
FDG-PET, indicating heterogeneity in the lung tumor model.
Using dynamic PETacquisition with simulation of FDG bolus
injection and a 3-compartment model with k4 equivalent to
zero, FDG-kinetics were found to resemble those observed
in living rodents with optimal tumor-background intensities
after 60 min.Additionally, a lung specific bioreactor was de-
signed mimicking the biomechanical pulmonary microenvi-
ronment which allowed revascularization of the lung scaffold
with human endothelial cells.Thus, our organotypic lung tu-
mor model should allow for preclinical testing of therapeutic
regimens and the development of strategies against resistant
sub clones. In combination with PET-imaging, longitudinal
studies regarding tumor growth, metabolism and spread as
well as monitoring of response to treatment are feasible.
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Realistic Multi-cellular Dosimetry for 177Lu labelled
Antibodies: Model and Application
S.Marcatili1, A. Pichard2, A. Courteau1, R. Ladjohounlou2, I.
Navarro-Teulon2, A. Repetto-Llamazares3, H. Heyerdahl3, J.
Dahle3, J. Pouget2, M. Bardiès1; 1Centre de Recherche en
Cancérologie de Toulouse, UMR 1037 INSERM, Toulouse,
FRANCE, 2Institut de Recherche en Cancérologie de Mont-
pellier, U 1194 INSERM, Montpellier, FRANCE, 3Nordic
Nanovector ASA, Kjelsåsveien 168, Oslo, NORWAY.
Aim: Current preclinical dosimetric models often fail to give
account of the complex nature of energy distribution in cells.
For this reason survival is often expressed as a function of
added activity rather than absorbed dose delivered to the
cell/cell nucleus. We propose a multi-cellular dosimetric mod-
el that takes into account realistic cell distributions, for the
establishment of survival curves as a function of the absorbed
dose. Materials andMethods:We developed software tools for
the generation of realistic 3D cell culture geometries based on
experimentally determined parameters (cell density, cluster
density, average cluster size). Non-overlapping multiple clus-
ters and isolated cells were randomly placed in a cylindrical
volume whose radius is of the order of the maximum range of
beta particles emitted by 177Lu. The cumulated activity in the
cell was also randomized according to experimentally pre-
determined values. The absorbed dose to the cell was calculat-
ed considering if the radioactivity was located a) within the
cell (with different hypotheses of internalization or lack there-
of); b) in the culture medium; and c) from surrounding cells.
The absorbed dose to the cell/cell nucleus was also averaged
over a large number of geometrical configurations. A mixture
ofMonte Carlo and analytical approachwas applied in order to
achieve as accurate as possible results while reducing calcula-
tion time. The model was applied to clonogenic survival ex-
periments carried out with and without 177Lu labelling, to
compare the efficacy of a novel antibody conjugate
(BetalutinTM) for the treatment of non-Hodgkin lymphoma,
to those of a CD20-specific (rituximab) and an antibody that
not bind to B-cells (cetuximab) on 2 different cell lines (Ramos
and DOHH2). Results: Most of the absorbed dose to the target
cell was due to non-internalised radiation (half of the total
absorbed dose). Cross-irradiation was twice as higher than
self-irradiation. Radiopharmaceutical distribution within the
cell had a negligible impact on the average cell absorbed dose.
In the case of Ramos cells, survival expressed per Gy in the
nucleus is independent of the vector (when corrected for
unlabelled antibody toxicity), demonstrating that cell death
mechanism is mainly radiative. For DOHH2 cell lines, surviv-
al curves expressed per Gy in the nucleus are still well sepa-
rated, thereby indicating that cell death mainly depends on
cold antibody toxicity. Conclusions: Our 3D cellular model
allowed a better understanding of the radiative and non-
radiative processes associated to cellular death in the case of
clonogenic survival experiments with 177Lu labelled
antibodies.
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Development of 47Scandium-Bleomycin and estimation
of absorbed dose as an antibiotic tumor seeking
radiopharmaceutical
L. Moghaddam-Banaem; Amirkabir Technical university,
Tehran, IRAN, ISLAMIC REPUBLIC OF.
Introduction: Bleomycins are tumor seeking antibiotics that
are used in cancer chemotherapy. We hereby report prepara-
tion, stability tests, biodistribution and dosimetry of 47Sc-
BLM as a potential therapeutic complex. Scandium-47 is a
moderate energy β- emitter (T1/2 = 3.42d, Eβmax= 441 keV ,
%68; Eβmax= 600 keV,%32). Because the availability of
47Sc
isotope is currently extremely limited, we have performed pre-
liminary studies using instead 46Sc which is chemically iden-
tical. Material andMethods: 46Sc was produced with a specific
activity of 3.15 mCi/mg and radionuclide purity of 98% . The
radionuclidic purity of the solution was tested for the presence
of other radionuclides using beta spectroscopy as well as
HPGe spectroscopy for the detection of various interfering
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beta and gamma emitting radionuclides. The radiochemical
purity of the 46ScCl3 was checked using 2 solvent systems
for ITLC (A: 10mM DTPA pH.5 aq. solution and B: %10am-
monium acetate:methanol (1:1)). Bleomycin was prepared at
activity of 1.258 MBq was administered to five mice that were
euthanized at 4, 24, 48, 72 h post administration. The data
were analyzed to estimate the human’s organs uptake and
source organ residence times and cumulated activities. The
dose calculation and estimation was done for a certain group
of organs of human following the MIRD technique. As the S-
factor is relevant to the particle energy that emitted by radio-
nuclide and the particle energies of 46Sc is different from 47Sc,
for dose calculation the dose S-factor of 47Sc was used. Re-
sults: The biodistribution studies carried out inWistar rats. The
estimated absorbed dos as percent of injected dose (%ID) is
shown on table 1. The absorbed dose by organs are also esti-
mated and shown in table 2. The maximum cumulative activ-
ities are for liver, blood, bone, spleen, lung and kidney with
23.52, 8.65, 4.06, 2.59, 1.44, 1.22 as percent of injected activ-
ity respectively. Conclusion: In the present study 46Sc -
Bleomycin complex were prepared with high radiochemical
purities (>98%) under optimized reaction conditions. The ra-
diochemical purity was >99%. The radio-labeled complex was
stable for 48 hours. A significant accumulation took place in
liver, spleen and kidneys which is in accordance with the
biodistribution of other reported radiolabeld bleomycin com-
pounds. The estimation of 47Sc-BLM dose in human was
performed. Keywords: Bleomycin, Scandium-47,
Biodistribution, Dosimetry Table 1: Extrapolation of absorbed
dose(%ID) in human
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The effect of 1-day melatonin and pulse magnetic field
administration on PET/CT scan and testicular
scintigraphy in a rat model of testicular torsion-detorsion
S. S. Gul, M. Uysal, S. Gurgul, F. Erdemir; Gaziosmanpasa
university medicine faculty, Tokat, TURKEY.
Aim: Testis torsion is one of the important causes of acute
scrotum in childhood. It is defined as obstruction of the blood
flow to the testes and accessories depending on the rotation of
the spermatic cord. Testicular torsion is an emergent clinical
condition in which there is a reversible damage in the
spermatogenetic cells with an immediate intervention within
6 hours while the risk of irreversible damage increases when
this time period is exceeded. The aim of this study was to
evaluate the effectiveness of 1-day melatonin and pulse mag-
netic field administration on ischemic damage in a rat model of
testicular torsion-detorsion. Material-Methods: Rats were di-
vided into 4 groups of control, sham, melatonin and pulse
magnetic field. In all groups except for the control group,
under general anesthesia, the left testis was rotated in clock-
wise for 720 degrees for a total of 2 hours. Then, 10mg/kg
intravenous melatonin and pulse magnetic field for 4 hours
were administered to melatonin and pulse magnetic field
groups, respectively. Sham rats did not receive any treatment
after the torsion. Following a 4-hour period, PET/CTwas per-
formed by using 1 mCi F-18 FDG and testicular scintigraphy
was performed by using 1 mCi TC-99m pertecnetate (Fig-
ure 1). After the completion of the two imaging methods,
left/right testicular rates were calculated by drawing the re-
gions of interest (ROI) in the both testicular region. Moreover,
histopathological examination of both testicular tissues was
performed. Results: All groups were analyzed in terms of glu-
cose metabolism and perfusion. There was a significant scin-
tigraphic difference between the control and sham groups
(p<0.005). No significant difference was found between the
groups in terms of glucose metabolism (p>0.005) (Table 1).
The testicular damage was shown in histopathological exam-
ination. Conclusion: Testis torsion is one of the causes of acute
scrotum in children and adolescents. The degree of testicular
torsion affects the changes observed in the testis. Moreover,
many of the patients with testicular torsion report a history of
recurrent, sudden onset of scrotal pain, suggesting previous
intermittent periods of torsion. In this study, 1-day melatonin
and pulse magnetic field administration were found to have no
contribution to the prevention of ischemic damage in testicular
torsion. Further studies with longer periods of treatment are
warranted.
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Enhancing the effect of radiotherapy in cultured tumour
cells using p53 therapy
A. C.Mortensen1, D. Spiegelberg1, A. M. Scott2, D. P. Lane3,
M. Nestor1,4; 1Department of Immunology, Genetics and Pa-
thology, Uppsala, SWEDEN, 2Ludwig Institute for Cancer
Research, Olivia Newton-John Cancer Research Institute,
and La Trobe University, Melbourne, Victoria, AUSTRALIA,
3p53Lab, Agency for Science Technology and Research
(A*STAR), Singapore, SINGAPORE, 4Department of Surgi-
cal Sciences, Uppsala, SWEDEN.
Background: Radiotherapy, external as well as radio-
immunotherapy (RIT), is an established concept for cancer
therapy, and the role of p53 in cancer has been extensively
studied. However, the possibility of enhancing the effects of
radiotherapy by targeting the p53-mdm2 interaction, using
peptides such as PM2 or Nutlin, is a novel concept. Especially
the combination of p53-therapy and RIT may provide an in-
novative and unique opportunity to utilize p53 as part of the
radiation response during treatment. This could result in
radiosensitized cancer cells and enhanced therapeutic effects.
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Aim: To assess whether p53 therapy in combination with ra-
diotherapy can increase the radiation sensitivity in cultured
squamous cell carcinoma (SCC) cells, using both 2D- and
3D-cell cultures. Materials & Methods: A panel of SCC cell
lines was first investigated regarding p53 and HPV status, as
well as for colony formation abilities and spheroid forming
abilities. The presence of various antigens suitable for RIT
was characterized on selected cells and tumour xenografts.
An EGFRvIII-targeting antibodywas then optimized for label-
ling with e.g. 111In using CHX-A”DTPA. The effects of radi-
ation (external or RIT), p53 therapy, as well as a combination
of treatments were then assessed using e.g. cell survival, cell
viability, and cell growth assays. Both short-term and long-
term effects were studied, and effects were assessed using both
2D and 3D cell cultures. Results: Radiolabelled RIT conju-
gates demonstrated an effect on cell viability and growth at
selected activities, whereas negative controls did not. Further-
more, the combination of p53 therapy and radiotherapy had a
greater impact on cell survival and viability than either treat-
ment alone, with synergistic effects for some combinations.
Conclusion: p53 therapy in combination with radiotherapy
decreases cell survival and viability in cultured SCC cells.
The combination of p53 therapy with RIT may enhance
in vivo potency even further if an antibody demonstrating
anti-tumour effects on its own is used.
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131I labelled multifunctional dendrimers for targeted
SPECT imaging and radiotherapy of cancer
Y. Cheng1, J. Zhu2, L. Zhao1, Y. Tang3, X. Shi2, J. Zhao1;
1Department of Nuclear Medicine, Shanghai General Hospi-
tal, Shanghai Jiaotong University, shanghai, CHINA, 2State
Key Laboratory for Modification of Chemical Fibers and
Polymer Materials, Donghua University, shanghai, CHINA,
3Experiment Center, Shanghai General Hospital, School of
Medicine, Shanghai Jiao Tong University, shanghai, CHINA.
Aim: Recent advances in nanotechnology have promoted a
rapid development in building various platforms for diagnose
and treat cancer. In this study, we report the utilization of 131I-
labelled multifunctional dendrimers conjugated chlorotoxin
(CTX) for targeted cancer single-photon emission computed
tomography (SPECT) imaging and radiotherapy. Materials
and methods: The dendrimers were made of PEG-acetylated
amine-terminated poly(amidoamine) dendrimers of generation
5 (G5.NHAc) and 3-(4’-Hydroxyphenyl)propionic Acid-OSu
(HPAO). CTX, an excellent ligand targeted to matrix
metalloproteinase-2 (MMP-2), was modified onto the surface
of dendrimers to enable nanoparticles specifically binding to
tumor cells. Followed by radiolabeling with 131I and purifica-
tion using PD-10 columns, 131I labelled multifunctional
dendrimers (131I-G5.NHAc-HPAO-PEG-CTX) was synthe-
sized and the possibilities of targeted imaging and therapeutic
efficacy to cancer cells were demonstrated both in vitro and in
vivo. Results: The formed nanoprobes were stable and could
be completely dissolved in aqueous solution. The radioactive
131I was able to be efficiently labeled onto the dendrimer plat-
form with good stability and high radiochemical purity. The
CTX-conjugated nanoprobe displayed a higher accumulation
in the perinuclear region of cytoplasm than G5.NHAc in con-
focal assay. The radioactive signal of C6 rat glioma cells and
tumor implanted in nude mice treated with CTX-modified
nanoprobe was significantly stronger than that of unmodified
nanoprobe. 131I-G5.NHAc- HPAO-PEG-CTX was able to tar-
get selectively and display much stronger inhibitory effect on
C6 cells growth than others which were unbounded CTX,
while unradiolabeled nanoprobes had no cytotoxicity. Finally,
tumor biopsies by histochemically staining exhibited CTX-
enabled nanoprobe selectively binded to glioma tissues, and
not appreciablely binded to normal tissues. Tumor reduction
was achieved in vivo when using 131I-G5.NHAc-HPAO-PEG-
CTX. Conclusion: With the modification of CTX ligands, the
efficient labeling of radioactive 131I on the dendrimers exhib-
ited an ability for targeted SPECT imaging and radiotherapy of
MMP-2 receptor-overexpressing cancers. Keywords:
PAMAM dendrimers, chlorotoxin, targeted imaging and ra-
diotherapy, cancer
P187
The effect of omeprazole usage on the viability of random
pattern skin flaps in rats
H. SEN1, M. ORUC1, V. M. ISIK1,M. SADIC2, H. SAYAR3,
M. KORKMAZ2, U. KOCER1; 1Department of Plastic and
Reconstructive Surgery, Ministry of Health Ankara Training
and Research Hospital, ANKARA, TURKEY, 2Ministry of
Health Ankara Training and Research Hospital, ANKARA,
TURKEY, 3Kahramanmaras Sutcu Imam University, Depart-
ment of Pathology, Kahramanmaras, TURKEY.
Object: Proton pump inhibitors (PPIs) are widely used to pre-
vent NSAIDs-induced gastrointestinal injury in surgical rou-
tine. It’s well known that PPIs block the secretion of gastric
acid as a result serum gastrin levels increase which might
induces angiogenesis. The aim of this study was to evaluate
topographically, scintigraphically, and histopathologically the
effect of the omeprazole on the viability of skin flaps in rats.
Material and Methods: 35 Winstar-Albino type (18 weeks
old), weighing between 161-210 gr female rats were divided
into 5 equal groups randomly. McFarlane random-pattern skin
flaps were raised in all groups. Group I was the control group,
Group II was received 10 mg/kg daily omeprazole intraperito-
neally for 14 days. Group III was received 40mg/kg daily
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omeprazole intraperitoneally for 14 days. Group IV was re-
ceived 10mg/kg daily omeprazole and group V was received
40mg/kg daily omeprazole intraperitoneally after the seventh
day for 7 days. The viability of flaps was observed by ditigal
imaging and scintigraphically with use of 1 mCi of
technetium-99m pertechnetate. Specimens collected from the
proximal (A), middle (B) and distal part (C) of the flap and the
number of vascular structures were determined by histopatho-
logic analysis. Results: Digital imaging and radionuclide study
images showed that all omeprazole recieved groups flap ne-
crosis percentages outcome was statistically significant lower
than that of the control group (p<0.001). There was no statis-
tically significant diference between the omeprazole received
groups (p>0.05). Flap necrosis percentage was evaluated with
sintigraphic imaging and the value of each group was deter-
mined respectively (group I % 48,2±6,4, group II % 7,6±3,3,
group III % 7,4±3,3, group IV % 6,7±1,3 and group V % 8,1
±3,6). There was statistically significant difference between
the each study group compared with the control group
(p<0.001). Histopathologic examination showed that the mean
numbers of vessels in A and C region in the study groups
showed a significant increase compared with the control group
(p<0.001). There was statistically significant difference be-
tween the each omeprazole received groups compared with
the control group (p<0.05). There was no statistically signifi-
cant diference between the omeprazole received groups
(p>0.05). Conclusion: Our study showed that use of parenteral
administration of omeprazole in skin flap surgery increases
flap viability not dependent on dose and time. We believe that
use of omeprazole before or at the time of flap surgery can
increase flap viability and decrease flap necrosis rate.
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Ex Vivo Perfusion of Tumorous Kidneys
with a Dual-Modality Tumor-Targeting Imaging Probe
M. Hekman, P. Mulders, M. de Weijert, D. Bos, E.
Oosterwijk, H. Langenhuijsen, O. Boerman, M. Rijpkema;
Radboudumc, Nijmegen, NETHERLANDS.
Introduction: Complete tumor resection might be improved by
targeted intraoperative imaging techniques providing addition-
al information about tumor localization and extent. For this
purpose dual-labeled antibodies containing both a near-
infrared fluorescent dye (IRdye 800CW) and a radioactive
label (Indium-111) can be used. Girentuximab is an anti-
CAIX antibody that can be used to target clear cell renal can-
cers (ccRCC), as the cell surface antigen carbonic anhydrase
IX (CAIX) is expressed in 95% of these tumors. This study
aimed to assess the feasibility of dual-modality imaging in
ccRCC by ex vivo perfusion of tumorous kidneys using
dual-labeled girentuximab.Material andMethods: Five tumor-
ous kidneys from patients were used in the perfusion experi-
ments. Directly after nephrectomy the renal artery was con-
nected to a pump via a catheter. The kidney was perfused with
1.2 mg 111In-DOTA-girentuximab-IRdye800CW (3.6-5.2
MBq) in 350 ml Ringer’s lactate (4 °C, 10-15 h). This protein
concentration is comparable to the serum concentration in pa-
tients. Next, the kidney was rinsed with Ringer’s lactate (2.5-4
h) to wash out unbound antibody. Subsequently, a 5-mm thick
slice of the kidney was analyzed by autoradiography and fluo-
rescence imaging. The antibody accumulation was determined
quantitatively by measuring the activity in 1 cm3 cubes of
tumorous and normal tissue in a gamma counter. The tissue
cubes were subsequently analyzed (immuno)histochemically.
Results: All tumors expressed CAIX and uptake of the dual-
labeled tracer could be clearly visualized by autoradiography
and fluorescenceimaging. There was an excellent match be-
tween the radioactive/fluorescent signal and CAIX expression.
Maximum uptake of the antibody in the tumor tissue cubes
was 0.33 % of the injected dose per gram (mean 0.12 %ID/g).
Maximum uptake in normal kidney tissue cubes was 0.04
%ID/g (mean 0.02 %ID/g). Conclusion: Dual-labeled
girentuximab accumulated preferentially in ccRCC tissue
and dual-modality imaging could be used to visualize ccRCC.
The concentration of dual-labeled girentuximab in vital tumor
regions ex vivo was in the same range as the concentration of
radiolabeled girentuximab after intravenous administration in
patients. These observations warrant a clinical study to evalu-
ate the added value of intraoperative dual-modality tumor-
targeted imaging in patients with ccRCC to assess its value
for intraoperative tumor visualization and radical tumor
resection.
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Intraoperative fluorescence guidance under ambient light
conditions using a new modified fluorescence camera
N. S. van den Berg1,2, G. H. KleinJan1,2, M. Miwa3, T. Sato3,
Y. Maeda3, B. Karakullukcu2, S. Horenblas2, F. W. B. van
Leeuwen1,2; 1LUMC, Leiden, NETHERLANDS, 2AVL-
NKI, Amsterdam, NETHERLANDS, 3Hamamatsu Photonics
KK, Hamamatsu, JAPAN.
Introduction: The introduction of fluorescence-labeled tracers
into the operation room has revolutionized the field of image-
guided surgery. Initially, fluorescence imaging (FI) was used
to optically confirm lesion localization after temporarily dim-
ming the ambient light in the operation theatre. Clearly, it
would be preferable if surgical procedures can be performed
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with real-time fluorescence guidance. We set out to investigate
a camera that allows real-time fluorescence guidance under
ambient light conditions and evaluated its value during
fluorescence-guided sentinel node (SN) biopsy. Methods: 36
Patients scheduled for SN biopsy for head-and-neck melano-
ma (n=16), melanoma of an extremity (n=2), oral cavity car-
cinoma (n=7), and penile cancer (n=11) were included after
obtaining written informed consent. Following a peritumoral
hybrid tracer (indocyanine green (ICG)-99mTc-nanocolloid)
injection, lymphoscintigraphy and SPECT-CT imaging were
performed to determine the number and location of the SN s).
Intraoperatively, a combination of gamma tracing and fluores-
cence guidance was used to localize the preoperatively defined
SN. In 6 patients the modified-PhotoDynamicEye (PDE) fluo-
rescence camera was compared to the conventional-PDE fluo-
rescence camera for sensitivity in SN detection. In 30 addition-
al patients the modified-PDE was further evaluated. Intraoper-
ative fluorescence-based SN identification rates were scored
and the experiences of the surgeon(s) were evaluated. Results:
Preoperative SPECT-CT imaging revealed 97SNs (mean 2.7,
range 1-7). Intraoperatively, FI allowed optical identification
of all SNs defined on preoperative imaging. In the camera
comparison, in 6 patients (20SNs evaluated), the modified-
PDE was found superior in performance compared to the con-
ventional-PDE. Even in ambient light conditions, weak SNs
that could not be detected with the conventional-PDE, were
picked up easily. Bright SNs could be picked up easily with
both PDE-systems. Experience in the additional 30 patients
underlined the modified-PDEs ability to guide SNs resection
in real-time under ambient light conditions. Continuous guid-
ancewasmade evenmore convenient by the possibility to alter
between white light and FI mode. With the modified-PDE in
13 patients SNs were already visualized transcutaneously and
tumor draining lymphatic ducts could be accurately visualized
in 11 patients. Pseudo-coloring of the fluorescence signal to
green in the modified-PDE provided better contrast with the
background and increased the detectability compared to the
black-and-white image in the conventional-PDE. Conclusion:
The optimized FI system expands fluorescence guidance in
open surgery to ambient light conditions and enables the sur-
geon to link fluorescence findings directly to the anatomical
background information.
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Hybrid guidance towards the sentinel node; a comparison
of fluorescence- and blue dye- based optical detection
in 458 patients
G. KleinJan1,2, N. S. Van den Berg1,2, E. Van Werkhoven2, J.
A. Van der Hage2, S. Horenblas2, W. M. N. Klop2, R. A.
Valdes Olmos2, F. W. B. Van Leeuwen1; 1Leiden University
Medical Centre, Leiden, NETHERLANDS, 2NKI-AVL, Am-
sterdam, NETHERLANDS.
Introduction: Conventional sentinel node (SN) biopsy is
performed using a combination of a radiocolloid and an
intraoperative injection of blue dye. However, it has
been shown that blue dye does not always stain SNs.
In 2009 the hybrid tracer indocyanine green (ICG)-
99mTc-nanocolloid was clinically introduced as dedicat-
ed SN tracer. This tracer is both radioactive and fluores-
cent, allowing preoperative SN mapping and intraopera-
tive optical verification of the SN. This study aimed to
evaluate the hybrid approach in 458 patients that
underwent SN biopsy using the hybrid tracer; specifical-
ly, in a sub-analysis we compared blue dye-based SN
visualization to fluorescence-based SN visualization. Ma-
terials and Methods: 458 patients scheduled for SN bi-
opsy were included. The histopathological diagnosis
were skin melanoma of the head and neck (H&N)
(n=113), extremity (n=20), and trunk (n=36), or Merkel
cell carcinoma of the H&N (n=6), or carcinoma of the
penis (n=175), vulva (n=21) and oral cavity (n=47), or
adenocarcinoma of the prostate (n=40). A median
81 .8 MBq (IQR 73.5-89 .8 MBq) ICG-99mTc-
nanocolloid was injected in 3-4 deposits surrounding or
a t t h e p r i m a r y t u m o r s i t e , f o l l o w e d b y
lymphoscintigraphy and SPECT-CT imaging. The opera-
tion was carried out 3-27 hours post-tracer injection and
preceded by the injection of vital blue dye. No blue dye
was used in the prostate and oral cavity cancer groups.
Intraoperatively SNs were initially located based on their
radioactive signature; SNs were then evaluated for de-
tection using fluorescence and/or blue dye. In a subset
of our patient cohort, a recurrence rate analysis was
performed using a Log-rank test. Results: In the overall
group, SPECT-CT visualized 1216 SNs (median 3 SNs
per patient). In the 458 patients, 1460 SNs were re-
moved during surgery.Focusing on patients in which
blue dye was used (total 797 nodes) evaluated in 273
patients, in vivo 5.4% of the removed SNs were not
blue nor fluorescent, 40.4% was fluorescent but not
blue, 50.7% was fluorescent and blue, and 3.5% was
only blue. For the first time survival analysis of multi-
modal guidance during different SN biopsy procedures
was obtained, showing some promising results. For ex-
ample in the H&N melanoma patients, the group with-
out blue dye showed a decreased recurrence rate with
ICG-99mTc-nanocolloid (Log-rank test; p=0.0043). Con-
clusion: The “hybrid approach” allows for an integrated
pre- and intraoperative SN biopsy procedure using a
single tracer. Overall, the ability to intraoperatively iden-
tify the SN using the fluorescent signature of the hybrid
tracer was superior to blue dye-based-identification.
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Fluorescent lectins for peripheral nerve visualization
during surgery
G. H. KleinJan, D. M. VanWilligen, M. N. Van Oosterom, F.
W. B. Van Leeuwen, T. Buckle; Leiden University Medical
Centre, Leiden, NETHERLANDS.
Introduction: Damage to the peripheral nervous system is a
surprisingly common complication during e.g. prostatectomy,
colorectal surgery and the removal of head and neck tumors. In
all cases such damage can lead to chronic function loss and, as
such, it can negatively influence the quality of life of patients.
Intraoperative visualization of these structures could potential-
ly help decrease the level of accidental surgical damage. This
preclinical study compares the nerve staining capabilities of
lectin related fluorescent imaging agents. Methods: Wheat
germ agglutinin (WGA), Peanut lectin (PNA), Red kidney
bean (PHA-L), Tomato lectin (LEL) and Cholera Toxin sub-
unit B (CTB) were functionalized with Cy5 (λex max 640 nm;
λem max 680 nm). After local (intramuscular) injection, the
migration of the individual imaging along the sciatic nerve was
evaluated in Thy1-YFP mice (n = 30). Nerve staining was
evaluated in vivo using an IVIS Spectrum animal fluorescence
scanner. Migration distance and signal intensity were quan-
tified by analyzing the normalized peak intensities using raw
IVIS data with MATLAB software. The location of tracer
uptake in the nerve was microscopically evaluated ex vivo.
Results: All five lectins showed retrograde movement and
staining with a signal-to-muscle ratio of around two.With an
average of 0.95cm (SD 0.20cm) the longest transfer distance
was obtained with CTB-Cy5 giving a migration distance
along the sciatic nerve of 1.00 cm (SD 0.38cm). In a direct
comparison for the peak intensities of the CTB-Cy5 and
WGA-Cy5 signal, the peak intensity signal was higher for
CTB-Cy5 in all cases. With confocal microscopy the Cy5
signal could be located on the epineurium of the nerve for all
lectins. Conclusion: Local administration of the fluorescent
CTB was shown to be a potential candidate for in vivo vi-
sualization of peripheral nerves. This said in the current
setting, the migration distance along the nerve remains lim-
ited to <1cm.
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Evaluation of the optical and physical properties
of symmetric NIR dyes towards intraoperative fluorescent
markers
S. van der Wal, J. Kuil, R. R. P. M. Valentijn, F. W. B. van
Leeuwen; Leiden University Medical Center, Leiden,
NETHERLANDS.
Aim: Near-infra-red (NIR) dyes, most notably indocyanine green
(ICG), have been used in fluorescence-guided surgical proce-
dures that are complementary in many ways to radioguidance
techniques. Similar to radiotracers, the photophysical and physi-
cal properties of the fluorescent tracer are critical to the successful
application of the tracer in intraoperative settings. Moreover, the
relatively larger size and thus influence of the fluorescent dye
comparedwith radioisotopesmakes validation of these properties
even more critical. Another potentially limiting feature of fluo-
rescent dyes is their tendency to interact (stack) with each other or
serum proteins by Van derWaal’s forces. This can lead to clusters
of dye molecules with aberrant photophysical properties leading
to a loss of fluorescence.The aim of this study was to evaluate the
stacking properties of a set of symmetrical NIR cyanine dyes and
relate this to the photophysical properties both as free dye and as
monoclonal antibody (mAb) conjugate with the aim of retaining
high brightness upon conjugation and limiting nonspecific pro-
tein interactions. Material and methods: A small set of negatively
charged symmetrical heptacyanine dyes based on the parental
ICG structure were synthesized to obtain different charge distri-
butions and hydrophobicity. Modifications include the aromatic
ring size and both location and number of the negative charge.
The design of the dyes incorporated a central C-C bond that is
stable in physiological conditions. The stacking behaviour and
non-specific protein interactions of these dyes were evaluated by
spectroscopicmethods in differentmedia and further correlated to
the physical properties of the dye-mAb-conjugates. Results:
Stacking, measured by an extra ~50-80 nm blueshifted peak in
the absorbance spectrum was most pronounced at high concen-
trations and under saline conditions. This phenomenon was asso-
ciatedwith a loss of brightness. The dye carrying indolenine rings
and the highest number of negative charges (4) showed substan-
tially reduced stacking, presumably due to coulombic repulsion
of the charges. Nevertheless, stacking was still observed with the
most optimal dye researched. Conjugation of these dyes to mAbs
generally resulted in stacking of the dyes on the mAb, which
resulted in concomitant precipitation of conjugates in the most
extreme cases. Conclusions: Symmetrical centrally-C-C-bonded
heptacyanine dyes are prone to stacking despite the presence of
negative charges, which reduce dye-dye interactions. The molec-
ular properties of the dye have a distinct influence on the conju-
gation chemistry, fluorescence brightness and non-specific pro-
tein interactions. These finding underline the potential challenges
in generating fluorescent tracers for in-vivo use.
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(Near-infrared) fluorescence guidance during surgery:
What is the detection limit?
G. H. KleinJan1,2, A. Bunschoten1, T. Engelen1, N. S. van
den Berg1,2, R. A. Valdés Olmos1,2, H. Wester3, F. W. B. van
Leeuwen1,2; 1LUMC, Leiden, NETHERLANDS, 2AVL-NKI,
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Amste rdam, NETHERLANDS, 3TUM, Mun ich ,
GERMANY.
Introduction: (Near-infrared (NIR)) fluorescence guided surgery
was introduced in the clinic with the promise to allow for highly
sensitive (molecular) lesion visualization. However, most studies
report high doses of fluorescent tracers. As a result there has been
quite some debate regarding the ability to detect fluorescent
tracers at a microdose level (<100μg). Limiting herein is the
ability to adequately quantify fluorescent signal intensities and
thus the percentage injected dose (%ID) that ends up in tissue
samples. Multimodal (or rather hybrid) imaging agents that com-
bine a radioactive and fluorescent signature allow to quantitative-
ly investigate that question. From our clinical trials with the hy-
brid tracer indocyanine green (ICG)-99mTc-nanocolloid for sen-
tinel node (SN) biopsy we estimated the surgical detection sensi-
tivities in relation to the %ID in the SNs.MethodsIn this retro-
spective analysis 47 patients were included that had undergone
ICG-99mTc-nanocolloid-based SN biopsy for melanoma in the
head and neck (MHH; n=21, 112SNs) and penile cancer (PenC;
n=26, 58SNs). SPECT-CT images, acquired two hours post-hy-
brid-tracer-injection, served as golden standard for the number
and location of the SNs as well as the quantification of the
%ID. For this evaluation we estimated that the volume of a SN
was 1mL. Percentage of tracer uptake in the SN was then corre-
latedwith intraoperative SN visualization or non-visualization via
fluorescence imaging.ResultsFrom the SPECT data the ICG-
99mTc-nanocolloid uptake in the SN could be divided in three
categories: cat. I) 0-1%ID (0-84.8nM ICG); cat. II) 1-2%ID
(84.8-169.6nM ICG); and cat. III) >2 ID (>169.6nM ICG). All
these SNs could intraoperatively be identified via gamma tracing.
Fluorescence-based SN detection, however, varied between the
three categories. In cat. I, which had the lowest %ID, detection
was 91.1% for MHH, and 89.6% for PenC. Visualization rates
increased for cat II, giving 98.3% and 99.1%, respectively. For
patients in cat. III all the SNs could be visualized intraoperatively
using fluorescence.ConclusionBased on the approximations
employed (quantifications by SPECT, each SN = 1mL),
fluorescence-based detection of SNs during surgery was possible
in the nM tracer range.
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Multimodal Optical System from Macro to Micro
Bioluminescence Imaging
C. R. Gigliotti, L. Altabella, M. Crippa, A. E. Spinelli; San
Raffaele Scientific Institute, Milano, ITALY.
Aim: Multimodal imaging instruments are becoming a strong
demand in preclinical studies. Different combined systems are
now commercially available even though they do not fully
allow modifying the experimental set-up according to the
specific needs. Preclinical researches include not only
in vivo imaging, but also in vitro cells analysis, usually per-
formed with dedicated microscope. We proposed a unified
CCD-based approach suitable for the detection of a wide spec-
trum of radiation (Spinelli et al., Biomed. Opt. Exp., in press)
using a system composed by a cooled EMCCD mounted on a
light-tight box. In this work we demonstrate that our system,
coupled with a macro lens, allows also cell bioluminescence
microscopy. In particular, we focus on a method to further
improve the spatial resolution, overcoming light diffusion.
Methods: The method consists of acquiring several frames of
few seconds, rather than only one single image with long ex-
posure time. The sum of the signal obtained in the individual
frames was used as a prior for the localization of the principal
sources. A Gaussian fit for each source in each frame was
performed after a smoothing of the noise with a Gaussian filter.
The peak location and intensity of the corresponding fits were
then used to reconstruct a high-resolution image. We per-
formed a feasibility study with Monte Carlo simulation of
bioluminescent cells, using GAMOS plug-in for GEANT4.
Experimental data were acquired using our optical system,
with the macro lens. As a proof of principle, a dish of
luciferase-tagged mesothelioma cell line was imaged after
the injection of D-luciferin in the growth medium, acquiring
short frame images and long exposure image used as compar-
ison. Results and conclusion: The post processing of the Mon-
te Carlo simulated frames allowed halving the FWHM with
respect to the image that simulates a continuous acquisition. In
particular with our approach, the FWHM shrank to the phys-
ical dimension of the simulated cells (50μm). The improve-
ment of the spatial resolution is confirmed by applying our
method to experimental images. The FWHM of the signal in
the long exposure image is 150 μm, while we reach a FWHM
of 50 μm processing the frames. These preliminary results
show the feasibility of a unified optical platform for macro
and micro imaging. In particular, the acquisition method and
the analysis procedure allow doubling the spatial resolution
overcoming the intrinsic light diffusion.
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Optical Imaging of Radiation-Induced Light Emission
of Luminophores
A. K. Kondakov1, I. L. Gubskiy1, E. Y. Prokop’eva1, I. A.
Znamenskiy1,2; 1Pirogov RNRMU, Moscow, RUSSIAN
FEDERATION, 2CCH RAS, Moscow, RUSSIAN
FEDERATION.
It is known that luminescence of some fluorophores, such as
fluorescein, may be induced by gamma-radiation or X-rays.
Aim of this study was to estimate radiation-induced lumines-
cence of known luminophores by means of CCD-based optical
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imaging device. Materials and methods. All experiments were
carried out by means of CCD-based device IVIS SpectrumTM
(Caliper Life Sciences, USA) that was used in bioluminescent
mode. 100MBq of 99mTc-pertechnetate (100μL)was added in
one well of black plastic microwell plate, while other wells were
filledwith 100μL of double-distilledwater. Imagewas acquired
with the following parameters: f-stop=1, bining 16, time of
exposition - 5 min. After that, into well with 99mTc-
pertechnetate and into 3 adjacent consecutive wells 20 μL of
fluorescein solution was added and image acquisition repeated.
The same experiment protocol was used for investigation of
luminol (20 mmol solution in DMSO). Average radiance and
its change were measured on resulting images. In order to esti-
mate spectral distribution of visible light intensity, consecutive
images were acquired with use of emission filters in wavelength
range of 500 to 840 nm with resolution of 20 nm. For these
images, exposition time was extended for 10 min. Results. Av-
erage radiance increased after fluorescein (threefold) and
luminol (by 3,7 times) addition to 99mTc-pertechnetate solu-
tion. Average radiance in wells with fluorescein decreased with
increasing of squared distance from well containing 99mTc-
pertechnetate. On the contrary, luminol luminescence was very
weak in wells, adjacent to well containing 99mTc-pertechnetate.
It is known, that luminol experiences chemiluminescence in
presence of hydrogen peroxide in solution. Hydrogen peroxide
is produced during gamma- and beta-irradiation of water. About
11% of 99m-technetium isotopes decay by means of isomeric
transition with ejection of electrons. It was assumed that chemi-
luminescence of luminol is maintained by high production of
hydrogen peroxide and other reactive oxygen species due to
beta-irradiation. Spectral distributions in range of of 540-
800 nm don’t differ from usual for both luminophores. As a
conclusion, we assume that different fluorophores may emit
weak light in visible range. This light emission is due to direct
radioluminescence (in case of fluorescein) or by irradiation-
induced chemiluminescence (in case of luminol). It was noticed,
that water solutions of pertechnetate are able to produce weak
light emission too. Studying of these kinds of light emission by
means of CCD-based optical devices may be used in wide range
of biomedical research.
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The clinical efficacy of endometriosis diagnosis using I-123
MIBG SPECTand MRI image fusion
K. Utsunomiya1, K. Yasuda2, Y. Kono3, Y. Ueno3, S. K. Ha-
Kawa3, A. Stundzia4, N. Tanigawa3; 1Department of
Radiology, Takii hospital, Kansai Medical University,
Moriguchi, JAPAN, 2Department of Gynecology, Takii hospi-
tal, Kansai Medical University, Moriguchi, JAPAN, 3Depart-
ment of Radiology, Kansai Medical University, Hirakata, JA-
PAN, 4Tomographix, Toronto, ON, CANADA.
Purpose: To determine if fusion images of I-123
metaiodobenzylguanidine (MIBG) SPECT and MRI can detect
endometriosis in the pelvic cavity along with extensions.
Methods: Four healthy female volunteers (mean age: 42.5
±6.4) and four patients diagnosed with endometriosis (mean
age: 45.5±4.8) were enrolled in this study. Two of the four
patients were previously diagnosed, using ultrasound and
MRI, with endometriotic lesions in the uterus (Group C). The
other two patients had been similarly diagnosed with both
endometriotic uterine lesions and bilateral ovarian lesions
(Group E). In these latter cases, ovarian lesion adhesion to the
intestine precluded laparoscopic resection. All patients also had
findings of small to medium uterine myomas. I-123 MIBG
SPECTwas performed at 15minutes (early acquisition), 3 hours
(late), and 6 hours (delayed) after 167MBq I-123 MIBG injec-
tion. Same day MRI was also performed. The I-123 MIBG
SPECTandMRI data were coregistered to create fusion images.
(SYNAPSEVINCENTVersion 4; FujiMedical, Tokyo, Japan).
Results: Healthy volunteers: Trace I-123 MIBG accumulation
was observed in the uterus of one volunteer in the fused late
images with no I-123 MIBG accumulation in the intestine dur-
ing any time of image acquisition. No I-123 MIBG accumula-
tion was observed in either the uterus or intestine of the other
three volunteers across all image acquisition times. Endometri-
osis patients: Group C. I-123MIBG uptake was observed in the
uterus of both patients and in the left parametrium of one pa-
tient. The I-123MIBG uptake peaked in early image acquisition
(15min) and decreased thereafter. No intestinal uptake was
found in this group at any acquisition time. Group E. I-123
MIBG uptake was observed in the fused images in the uterus,
parametrium, and intestine across all image acquisition times.
The I-123 MIBG was found to be time dependent, increasing
with increasing post-injection time, especially in the intestine.
Conclusion: Image fusion of I-123 MIBG SPECT and MRI
may prove to be a clinically useful tool for the diagnosis and
localization of endometriosis.
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Simultaneous respiratory gating in PET/MR: clinical
quantification of neoplastic lesions and physiological
structures
F. G. BARBOSA1, G. DELSO2, M. HUELLNER1, P.
STOLZMANN1, E. TERVOERT1, P. VEIT-HAIBACH1; 1ZU-
RICH UNIVERSITY HOSPITAL, ZUERICH, SWITZER-
LAND, 2GE HEALTHCARE, ZUERICH, SWITZERLAND.
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Purpose: Respiratory motion is a significant challenge for ac-
curacy in PET images especially concerning variation of up-
take measurements (SUV) and lesion mismatch in PET/MR
fusion images. The aim of the study is to evaluate the impact
on SUV-measurement in simultaneously respiratory gated
PET/MR acquisition of the thorax in physiological structures
and neoplastic lesions. Methods: Twenty seven oncological
patients referred for staging/restaging were prospectively en-
rolled and imaged with a simultaneous PET/MRI-system (Sig-
na PET/MR, GE Healthcare, 17 M/ 10 F; mean age 61 ± 12y).
PET data were evaluated semiquantitatively (SUVmax and
mean) in physiological structures and neoplastic lesions
(n=45), comparing two data sets: static PET acquisition (stan-
dard shallow breathing) and respiratory gated simultaneous
PET/MR acquisition. The respiratory cycle was divided in
six bins, all bins were reconstructed in PET accordingly.
SUVmax/mean was evaluated in both settings (static and gat-
ed). For the gated studies, the bin with the least motion was
selected (“best bin”) for comparison. Furthermore, PET/MR
images were compared concerning artifacts and mismatch be-
tween both settings. TheWilcoxon’s test was used to assess the
correlation of the SUV values of tumor lesions and physiolog-
ic tissues, mismatch of PET/MR images and artifact score.
Results: There is no significant statistical difference (p>0.05)
in SUV values between static and gated PET acquision in
tumoral lesion (primary, lymph node and metastase) and in
most of physiologic tissue, except in lung parenchyma
(p<0.05) where SUV values were slightly higher in static
(SUVmax=0.71; SUVmean=0.43) than in gated PET
(SUVmax=0.65; SUVmean=0.39). The mismatch distance in
fused PET/MR images was statistically significant different
(p<0.01) between static (mean=4.3mm;SD=2.6) and to gated
PET acquisition (1.8mm;SD=1.2), predominantly in cranio-
caudal orientation. The artifact score in gated PET acquisition
was statistically significantly superior (mean=1.14; SD=0.35)
compared to static PET-images (mean=1.74; SD=0.58)
(p<0.01). Conclusion: In simultaneous respiratory gated
PET/MR no statistical significant difference in SUV value of
the tumoral lesion and in most of the physiologic tissue was
found. However, gated PETacquisitions had a significant low-
er mismatch and showed significantly less artifacts.
P198
Evaluating carotid plaque inflammation in patients
with active rheumatoid arthritis (RA) using 3T magnetic
resonance imaging (MRI) and Fludeoxyglucose(18F) PET
(18FDG-PET) : a pilot study
S. Skeoch1,2,H. A.Williams3, P. Cristinacce4, P. Hockings5,6,
J. James3, Y. Alexander7, J. Waterton8, I. Bruce9; 1Arthritis
Research UK Centre for Epidemiology, University of Man-
chester, Manchester, UNITED KINGDOM, 2NIHR
Manchester Musculoskeletal Biomedical Research Unit, Uni-
versity of Manchester, Manchester, UNITED KINGDOM,
3Nuclear Medicine, Manchester, UNITED KINGDOM, 4Bio-
medical Imaging Institute, University of Manchester, Man-
chester, UNITED KINGDOM, 5Drug Safety and Metabolism,
Astrazeneca, Mondal, SWEDEN, 6MedTech West, Chalmers
University of Technology, Gothenburg, SWEDEN,
7Healthcare Science Research Institute, Manchester Metropol-
itan University, Manchester, UNITED KINGDOM,
8Personalised Healthcare and Biomarkers, Astrazeneca, Man-
chester, UNITED KINGDOM, 9Kellgren Centre for Rheuma-
tology, NIHR Manchester, Manchester, UNITED
KINGDOM.
Emerging evidence suggests RA patients may have more in-
flammatory, higher risk atherosclerotic plaque. We aimed to
investigate carotid plaque in RA patients using MRI and
18FDG PETCT.Patients with active RA, defined as the Dis-
ease Activity Score in 28 joints (DAS28) score of more than
3•2, were recruited to a single centre study in the UK. Patients
underwent clinical and serotological evaluation, and those
with carotid plaque of thickness > 2.5mm on ultrasound
underwent carotid MRI, followed by 18FDG PETCT (at 2
hours p.i. of 200 MBq FDG) within 1 week. Head and neck
position for MRI was replicated for PET using comparable
supports, head alignment and neck extension. PET images
were reconstructed using time-of-flight information and reso-
lution recovery. PETCT scans were registered to T1-weighted
MRI to co-localise plaque-specific signals, prior to volume of
interest analysis around the artery sections containing plaque
by a physicist (HW) who was masked to clinical information.
The maximum standardised uptake values (SUVmax) in the
plaque volumes were obtained and the association of SUVmax
with DAS28, C-reactive protein (CRP), and CD4+CD28- T-
cell frequency tested using non-parametric statistics.13 pa-
tients (9F, 4 M) underwent MRI and 18FDG PETCT, with
median age 60 years (IQR 57-65), disease duration 11 years
(6-25), and DAS28 score 4•52 (4•32-5•13). None had a history
or symptoms of clinical cardiovascular disease or took statins.
All plaques caused less than 70% stenosis, and accumulated
18FDG. Median SUVmax was 2•18 (IQR 2•00-2•65). All
cases had an SUVmax greater than 1.6 (the published thresh-
old for defining carotid plaque inflammation, although it is
noted that this threshold may not be applicable to advanced
PET reconstructions using time-of-flight and resolution recov-
ery). There was a significant association with SUVmax and
CRP (r=0•58, p=0•04) and quartiles of CD4+CD28- T-cell
frequency (p=0•045) but not with low-density lipoprotein con-
centrations (r=-0•49, p=0•09) or DAS28 score (r=0•38,
p=0•20). No association was found with age (r=0•13,
p=0•69) or sex (p=0•64).In this small pilot study, 18FDG ac-
cumulation by carotid plaque was seen in all patients and cor-
related with CRP. Whether this finding represents
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simultaneous joint and plaque inflammation, which might im-
prove on treatment of joint disease, remains to be determined.
CD4+CD28- T-cells are known to predict cardiovascular
events in patients with angina, which suggests a possible role
in cardiovascular risk prediction in RA. Larger studies are
warranted to investigate these findings further.
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Performance of an Ultralow-Dose High-Resolution
Pediatric TOF-PET Scanner Based on Monolithic
Scintillators
E. Mikhaylova1, V. Tabacchini2, G. Borghi2, W. Vogel3, P.
Mollet1, E. D’Hoe1, D. Schaart2, S. Vandenberghe1; 1Univer-
sity of Ghent, Ghent, BELGIUM, 2Delft University of Tech-
nology, Delft, NETHERLANDS, 3Netherlands Cancer Insti-
tute, Amsterdam, NETHERLANDS.
Introduction. A novel high sensitivity TOF-PET scanner will
be built for multimodal in vivo molecular low dose imaging of
cancer, cardiac and neurological diseases, inflammation, and
hyperinsulinism in children.Materials and methods. The sys-
tem was realistically modeled in the GEANT4 Application for
Tomographic Emission (GATE) software and is composed of
monolithic LYSO (3.2 x 3.2 x 2.2 cm) detector blocks (dual
side readout, DSR) arranged in a cylindrical shape adapted to
children up to the age of 12 years (54 cm diameter bore and
53 cm axial length). The simulated performance model of the
detector (spatial FWHM of 1.5 mm, depth-of-interaction
FWHMof 2.5 mm and TOF of 150 ps) was based on extensive
measurements of LYSO blocks. The realistic child is modeled
using the XCAT phantom software. A realistic FDG (40 MBq
in total) distribution with 5, 10 and 20mm hotspots (8 x higher
than soft tissue value) was simulated for 3 min total acquisition
time. The acquired list-mode (LM) data (without scatters) were
reconstructed using the LM-OSEM algorithm with modeling
of TOF kernel. The same object and distributionwas simulated
on the clinical reference system Philips Gemini TF (600 ps,
same activity and total acquisition time).Results. The total
number of counts on the pediatric PET was 15 times higher
due to the increased solid angle. The new system achieves
much higher image contrast and better identification of struc-
tures due to lower noise and better spatial resolution. In the
pediatric PET images , we can distinguish all 5, 10 and 20 mm
hot lesions in liver and lung while in the GEMINI TF scanner
only 20 mm and 10 mm hot spheres in lungs can be
detected.Quantitative data. The contrast recovery coefficient
(CRC) is chosen as a measure of image quality. The pediatric
PET shows significantly higher CRC values for all hot lesions
than the GEMINI TF scanner: 28.5%, 54.6% and 86.5% for
the 5, 10 and 20 mm spheres in lungs respectively for the
pediatric PET versus 3.3%, 8.7% and 27.6% for the same
hot lesions for GEMINI TF.Conclusions. The pediatric PET
system shows the ability to obtain low-noise, high-resolution
and high-contrast images with a very limited dose in a short
total acquisition time.
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Incorporation of TOF information reduces artifacts
in simultaneous TOF PET/MR scanning
E. ter Voert1,2, H. Davison1,3, F. de Galiza Barbosa1,2, M.
Huellner1,2, S. Ahn4, F. Wiesinger5, C. Levin6, A. Iagaru6,
G. Zaharchuk6, G. Delso7, P. Veit-Haibach1,2; 1University
Hospital Zurich, Zurich, SWITZERLAND, 2University of Zu-
rich, Zurich, SWITZERLAND, 3Royal United Hospitals Bath
NHS Foundation Trust, Bath, UNITED KINGDOM, 4GE
Global Research, Niskayuna, NY, UNITED STATES, 5GE
Global Research, Munchen, GERMANY, 6Stanford Universi-
ty, Stanford, CA, UNITED STATES, 7GE Healthcare, Wauke-
sha, WI, UNITED STATES.
Introduction: In simultaneous PET/MR scanning, MR data is
employed for PET attenuation correction (MR-AC). Bone or
metal implants could lead to inconsistencies in the MR-AC
maps, thereby affecting the PET images. Lesions close to bone
or metal implants might become difficult to assess properly or
might even bemissed completely. A possible solution could be
the inclusion of time-of-flight (TOF) information into the PET
image reconstruction algorithm. This study aims to evaluate
the influence of TOF information on artifact reduction and
PET image quality improvement in clinical simultaneous
PET/MR scanning. Methods: A total of 63 patients (median
age 58 years) underwent a PET/MR examination in a new
simultaneous TOF PET/MR scanner (GE SIGNA). TOF and
non-TOF PET datasets were reconstructed, assessed clinically
and compared by radiologists/nuclear medicine physicians.
Differences in the image quality, particularly those related to
(implant) artifacts, were assessed using a 5-point scale, rang-
ing from 0 (no artifact) to 4 (severe artifact, impaired reader
confidence). To quantify differences, reconstructions were re-
peated in 7 patients after the introduction of artificial signal
voids in the attenuation map. These virtual artifacts simulated
clinically relevant metal artifacts in the maxilla, humeral head,
chest, sternum, thoracic spine, lumbar spine and the femoral
head. Results: A total 87 image artifacts were detected and
evaluated. Four patients had large and 8 patients had small
implant-related artifacts, 27 patients had artifacts related to
dental implants/fillings, and 48 patients had implant-
unrelated artifacts. Overall, the average score was 1.14 ±
0.82 (mean ± SD) for the non-TOF PET images, and 0.53 ±
0.66 for the TOF images (P<0.01). In all simulated cases the
magnitude of the virtual artifact was reduced (range: 20-60%)
when TOF information was included in the reconstruction.
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Discussion: From a clinical point of view, the use of TOF
significantly improved the image quality and the reader confi-
dence close to artifacts. TOF information reduced the impact
of artifact-related errors in all metal implant cases. TOF not
only improves e.g. signal-to-noise ratio, accuracy, lesion de-
tectability and the convergence rate of the iterative algorithm,
its inclusion also makes the system become better-conditioned
and therefore less sensitive to errors in the attenuation map.
The use of TOF in conjunction with other (MR) techniques for
metal artifact correction could possibly further improve the
overall image quality and clinical reader confidence. Conclu-
sion: Our results suggest that PET imaging significantly ben-
efits from the incorporation of TOF information in simulta-
neous PET/MR scanning.
P201
Brain PET/MR attenuation correction for pediatric
patients
C. Ladefoged, J. B. Andersen, L. Marner, A. E. Hansen, I.
Law, L. Højgaard, F. L. Andersen; Dept. of Clinical Physiol-
ogy, Nuclear Medicine and PET, Rigshospitalet, Copenhagen,
DENMARK.
AIM: Brain PET/MRI is challenged by inaccurate attenuation
correction (MRAC). Several methods have been suggested in
the literature, where the majority is based on registration to an
atlas, followed by a back-warp of an average CT image, lim-
iting the applicability to pediatric patients. The purpose of this
study was to evaluate the accuracy of our newMRACmethod
(MR-AC_UPSTAIRS) based on the ultra-short echo time
(UTE) MR sequence in pediatric patients. METHODS. Brain
scans were performed on eight pediatric patients using the
Siemens PET/MR scanner. Six patients with PET positive
brain tumors (Group A, 4-8 years, 76±22 MBq [18F]-FET),
and two healthy volunteer patients (Group B, 2-3 days,
15 MBq [15O]-labeled-water). For Group A only, a 120 kVp
low-dose CT was obtained and used as reference
(MRAC_CT). We compared the performance of standard
MRAC_DIXON, MRAC_UTE (Siemens VB20P), and
MRAC_UPSTAIRS, a fully automatic method that segments
air, brain, cerebrospinal fluid and soft tissue voxels on the UTE
images, and uses a mapping of R2* values to Hounsfield units
to obtain a patient specific continuous bone density value. For
Group A, we analyzed the effect of each MRAC method on
the tumors. The tumor was defined by isocontouring as activ-
ity > 1.6 times the mean value of a background region. We
measured the averaged %-deviation of SUV_MEAN and vol-
ume of the tumor, relative to PET corrected with MRAC_CT.
For both groups, we measured the mean %-deviation in six
consecutive homeomorphic regions extending from the cortex
to the center of the image plane. RESULTS. For
PET_DIXON/PET_UTE/PET_UPSTAIRS, the averaged %-
deviation from PET_CT was -10%/-9%/-5% for T_MEAN
and +9%/+22%/-2% for the tumor volume. The regional anal-
ysis showed a radial gradient effect when using Dixon and
UTE, from -20% to -5% and -21% to -3%, respectively, from
the cortex to the center. When using UPSTAIRS the radial bias
is significantly reduced (-7% to -2%). For Group B, we com-
pared Dixon to UPSTAIRS. Here, a radial bias of -14% to -6%
is also present. This is similar to the Group A patients (-12% to
-3%), suggesting that the performance is comparable to that
measured for Group A. CONCLUSIONS. The MRAC meth-
od UPSTAIRS is able to provide continuous bone density
values for brain attenuation maps in pediatric patients, which
has not previously been reported. The method shows im-
proved performance over Dixon and UTE when used for clin-
ical purposes, and is very similar to that of CT.
P202
Combined 18F NaF/18F FDG and TOF simultaneous
PET/MRI: One-Stop Shop Staging of Patients with Breast
and Prostate Cancers
R. Minamimoto, A. Loening, P. Obara, V. Taviani, S. S.
Gambhir, S. Vasanawala, A. Iagaru; Stanford University
School of Medicine, STANFORD, CA, UNITED STATES.
Introduction: We previously reported the pilot evaluation of a
simultaneous PET/MRI scanner with TOF capability, as well
as the use of combined 18F NaF/18F FDG PET/CT in cancer
patients. Here we prospectively compared the combined 18F
NaF/18F FDG PET/ MRI against 99mTc-MDP in patients
with breast and prostate cancers for the detection of metastatic
disease. Materials and methods: Fifteen patients referred for
99mTc-MDP bone scans were prospectively enrolled from
Oct 14 - Mar 15. The cohort included 7 men with prostate
cancer and 8 women with breast cancer, 41 - 85 year-old (av-
erage 61 ± 13). 18F NaF (0.7-2.2 mCi, mean: 1.2 mCi) and
18F FDG (3.8-5.2 mCi, mean: 4.2 mCi) were subsequently
injected from separate syringes. The PET/MRI was done 6-
30 days (average 9.3 ± 3.2) after bone scan. The whole body
MRI protocol consisted of T2-weighted, DWI, and contrast-
enhanced T1-weighted imaging. Lesions detected with each
test were tabulated and the results were compared. Results:
All patients tolerated the PET/MRI exam, and PET image
quality was diagnostic despite the marked reduction in the
administered dosage of radiopharmaceuticals (80% less for
18F NaF and 67% less for 18F FDG compared to standard
protocols). Five patients had no bone metastases identified
on either scans. Bone scintigraphy and PET/MRI showed os-
seous metastases in 9 patients, but more numerous bone find-
ings were noted on PET/MRI than on bone scintigraphy in 3
patients. One patient had negative bone scan, but bone
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metastases were seen on PET/MRI. Lesions outside the skel-
eton were identified by PET/MRI in 3 patients. Conclusion:
The combined 18F NaF/18F FDG PET/MRI is superior to
99mTc-MDP scintigraphy for evaluation of skeletal disease
extent. Further, it detected extra-skeletal disease that may
change the management of these patients, while allowing a
significant reduction in radiation exposure from lower dosages
of PET radiopharmaceuticals administered. A combination of
18F NaF/18F FDG PET/MRI may provide the most accurate
staging of patients with breast and prostate cancers prior to the
start of treatment.
P203
68Ga-DOTATATE PET/CT vs PET/ MRI
in neuroendocrine tumours: A comparative study
A. Alshammari, E. Skoura, S. Michopoulou, F. Fraioli, R.
Syed, J. Bomanji; Nuclear medicine department, UCL hospi-
tal, London, UNITED KINGDOM.
Introduction: Studies are emerging about the utilization of
PET/magnetic resonance imaging (PET/MRI) in NETs. From
the existing studies PET/MRI is believed, to have significant
advantages in body areas where MRI is better over CT, includ-
ing central nervous system, upper abdominal, urogenital sys-
tem and head and neck imaging. The aim of this study is to
compare 68Ga-DOTATATE PET/CT with 68Ga-DOTATATE
PET/MRI imaging in patients with known neuroendocrine tu-
mours, and assess the confidence in anatomic lesion detection
and localization. Furthermore, the value of each sequence of
MRI was evaluated separately.Methods: We retrospectively
analysed the data of 38 NET patients. Both 68Ga-DOTATE
PET/CT and PET/MRI scans were performed. MR sequences
undertaken were T1and T2 weighted, HASTE MR, and
diffusion-weighted imaging (DWI).Results: Interobserver re-
liability was equally very good in both modalities. All lesions
considered as malignant in PET/CT were equally depicted
in PET/MRI in most of the visualized areas. Significant
inter observer correlation between 68Ga-PET/CT and
PET/MRI SUV max values for both primary and liver
lesions was also observed. However, 68Ga-DOTATATE
PET/MRI recognized more liver lesions in 3 patients.
The contrast and DWI sequence of PET/MRI did not have
a significant effect on final outcome, however in a select-
ed number of cases these images confirmed and helped to
further characterize and detect more lesions. There was no
significant correlation between DWI mean values and
SUV max for the same lesions.Conclusion: This study
demonstrates the potential of 68Ga-DOTATOC PET/MRI
in patients with NET, with special advantages in the char-
acterization of liver lesions.
P204
Diagnostic accuracy of whole-body PET/MRI for tumor
staging in patients with various cancers: a meta-analysis
G. Shen, A. Kuang; West China Hospital of Sichuan Univer-
sity, Chengdu, CHINA.
Aim: Recently published clinical studies using PET/MRI in
oncological patients have confirmed its feasibility for cancer
staging and have shown image quality comparable to the im-
age quality with PET/CT for lesion detection. The aim of this
study was to determine the staging accuracies of PET/MRI for
different malignant diseases. Materials and methods: Relevant
articles about PET/MRI for cancer staging were systematically
searched in PubMed, EMBASE, EBSCO and the Cochrane
Library. Two researchers independently selected studies, ex-
tracted data and assessed the quality of included studies ac-
cording to the QUADAS tool. For both per-patient and per-
lesion, pooled sensitivity, specificity, diagnostic odds ratio
(DOR), positive likelihood ratio (PLR), and negative likeli-
hood ratio (NLR) were calculated using STATA and Meta-
Disc software. We also constructed summary receiver-
operating characteristic (SROC) curves with the area under
the curve (AUC) and Q* estimates obtained. In addition, with
regard to the explanation of between-study heterogeneity, we
performed the subgroup analysis, threshold effect analysis and
publication bias analysis. Results: A total of 35 studies ful-
filled the inclusion criteria, totally involving 1482 patients.
On a per-patient analysis, the pooled sensitivity and specificity
with 95% confidence interval (CI) were 0.92 (0.90-0.94) and
0.91 (0.88-0.94), respectively. On a per-lesion basis, the cor-
responding estimates were 0.80 (0.78-0.82) and 0.93 (0.92-
0.94), respectively. Other estimates were presented in Table 1.
Conclusions: According to our results, PET/MRI has excellent
diagnostic performance for the overall assessment of cancer
staging in patients with various cancers, and has the potential
to be broad applied in clinical practice.
P205
Comparison of 18F-FDG-PET/MRI
and 18F-FDG-PET/CT for initial staging in pulmonary
carcinoma
S. Lütje1, V. Ruhlmann1, A. Bellendorf1, T. D. Poeppel1, K.
Beiderwellen2, P. Heusch3, B. M. Schaarschmidt3, H. H.
Quick4, J. Nagarajah1, B. Gomez1; 1Clinic for Nuclear Medi-
cine, University Hospital Essen, Essen, GERMANY, 2Depart-
ment of Diagnostic and Interventional Radiology and Neuro-
radiology, University Hospital Essen, Essen, GERMANY,
3Department of Diagnostic and Interventional Radiology,
Medical Faculty, University Düsseldorf, Düsseldorf,
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GERMANY, 4High Field and HybridMR Imaging, University
Hospital Essen, Essen, GERMANY.
Aim: At present, patients with pulmonary carcinoma are
staged using whole-body low-dose 18F-fluoro-deoxyglucose
(FDG) positron emission tomography (PET)/computed to-
mography (CT) as well as cranial magnetic resonance imaging
(MRI) for exclusion of cerebral metastases. So far, several
clinical studies have investigated the role of whole-body 18F-
FDG-PET/CT compared to whole-body 18F-FDG-PET/MRI
in detection and quantification of tumor lesions. In these stud-
ies, 18F-FDG-PET/MRI was performed first, followed by 18F-
FDG-PET/CT scanning. Overall, lower maximum standard-
ized uptake values (SUVmax) were observed with
18F-FDG-
PET/MRI as compared to 18F-FDG-PET/CT. In the present
study, the effect of performing these techniques in reversed
order on the capacity of detection and quantification of tumor
lesions has been evaluated. In addition, the role of cranial MRI
was evaluated. Materials and methods: Eighteen patients with
pulmonary carcinoma received i.v. injection of 18F-FDG (302
± 61 MBq) and underwent PET/MRI (1h p.i.) and subsequent
PET/CT (2h p.i.). Regions of interest (ROI) encompassing the
entire tumor lesion were drawn into 18F-FDG-PET/CT and
18F-FDG-PET/MR images to determine the maximum and
mean standardized uptake value. Data were analyzed quanti-
tatively regarding the detection of tumors lesions and by
SUVmax determination in the primary tumor as well as in met-
astatic lesions. In addition, cranial MRI images were eval-
uated upon presence of cerebral metastases. Results:
Sixty-two tumor lesions were detected with both tech-
niques (n=21 primary tumors, n=19 lymph node metasta-
ses, n=15 bone metastases, n=7 pulmonary/soft tissue me-
tastases). Median SUVmax were 10.9 (range 2.3 - 39.6)
and 13.0 (range 3.8 - 33.3) for 18F-FDG-PET/MRI and
18F-FDG-PET/CT, respectively. For both techniques,
SUVmax derived from
18F-FDG-PET/MRI and 18F-FDG-
PET/CT correlated well. One cranial tumor lesion was
visualized in contrast-enhanced cranial MRI which was
not detected using low-dose 18F-FDG-PET/CT. Conclu-
sion: In line with previous studies, lower SUVmax were
observed for 18F-FDG-PET/MRI, even when both tech-
niques are performed in reversed order. However, 18F-
FDG-PET/MRI might have additional value in the detec-
tion of cranial tumor lesions as compared to low-dose 18F-
FDG-PET/CT.
P206
Analysis of simultaneous FDG image and DWI acquired
with hybrid PET/MRI in thyroid cancer
I. Cho, E. Kong, K. Chun, S. Kwon; Yeungnam University
Hospital, Daegu, KOREA, REPUBLIC OF.
Purpose: The aim of this study was to compare the detectabil-
ity of thyroid cancer of simultaneous FDG images and
diffusion-weighted magnetic resonance imaging (DWI) of hy-
brid PET/MRI system and to clarify the association between
metabolic activity and restricted diffusion of thyroid cancer.
Methods: Twenty nine consecutive patients diagnosed with
solitary thyroid cancer were included. The size less than 1cm
or more than 2cm were excluded. Simultaneous FDG image
and DWI were acquired by hybrid PET/MRI before thyroid-
ectomy. FDG uptake and apparent diffuse coefficient (ADC)
values of thyroid cancer were analyzed. Results: DWI acqui-
sition was failed in 3 patients and showed 2 false negative
(n=29). FDG PET showed one false negative due to high
FDG uptake in thyroid parenchyma detected in DWI (n=29).
SUVmax, SUVmean and ADCmean of thyroid cancer were
6.89±4.28, 4.46±2.51 and 955.37±84.10x10-3 mm2/s, respec-
tively. The ADCmean presented a significant correlation with
SUVmax (r=-0.50, p<0.01) and SUVpeak. (r=-0.42, p<0.01)
Conclusion: Hybrid PET/MRI detected all thyroid cancers and
made multimodality imaging for metabolic activity and re-
stricted diffusion in thyroid cancer.
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[123/131I](R)-1-[1-(4-Iodophenyl)ethyl]
-1H-imidazole-5-carboxylic acid azetidinylamide
(IMAZA) a novel radiotracer for diagnosis and treatment
of adrenocortical tumours - first clinical experience
A. Schirbel1, K. Herrmann1, C. Bluemel1, B. Heinze2, H.
Haenscheid1, M. Fassnacht2, A. K. Buck1, B. Allolio2, S.
Hahner2; 1University Hospital of Wuerzburg; Department of
Nuclear Medicine, Wuerzburg, GERMANY, 2University Hos-
pital of Wuerzburg; Endocrinology & Diabetes Unit, Depart-
ment of Internal Medicine I, Wuerzburg, GERMANY.
Aim[123/131I]Iodometomidate (IMTO), which selectively
binds to the aldosterone synthase (CYP11B2) and 11ß-hy-
droxylase (CYP11B1), has been proven to be useful for mo-
lecular imaging in adrenal incidentalomas and radiotherapy in
adrenocortical carcinoma (ACC). Due to the observation that
IMTO is rapidly inactivated by endogenous esterases which
may impair target tissue to background activity ratios and ac-
cordingly therapeutic efficacy, >80 new IMTO derivatives
have been designed und evaluated. Here we report the first
clinical experience with the best derivative, [123/
131I]IMAZA, in patients with advanced ACC.Materials and
MethodsIn our ongoing study we examined 17 patients with
S440 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
known advanced ACC. Biodistribution and pharmacokinetics
were studied by SPECT/CT and planar images up to 24 h after
injection of 185 MBq [123I]IMAZA. Blood levels of tracer
and metabolites were determined by radio-HPLC. Dosimetry
with 40 MBq [131I]IMAZA was performed over 4 days and
targeted endoradiotherapy was performed on compassionate
use basis in 3 selected patients.Results[123I]IMAZA proved
to be a tracer that specifically accumulates in adrenocortical
tissue. As is the case with IMTO, IMAZA showed heteroge-
nous uptake in the tumour lesions. We observed rapid clear-
ance of unbound tracer and an up to 5-fold higher tumour
uptake compared to IMTO, which significantly improved im-
aging quality. IMAZA enabled the visualization of very small
metastasis, which could not be detected with IMTO. Analysis
of blood samples by radio-HPLC demonstrated a significant
higher metabolic stability of the tracer. Dosimetry showed, that
the bone marrow was the critical organ; when using 2 Gy as
target effective dose very high therapeutic activities of more
than 60GBqwere calculated. Three patients received extreme-
ly high doses of 26-28 GBq [131I]IMAZA. Due to the high
selective and long lasting uptake of [131I]IMAZA, tumour
doses up to 265 Gy were reached. Treatment was well tolerat-
ed in all patients. Comparison of FDG-PETand low-dose CTs
before and 9 weeks after treatment revealed SD in one patient
and PD in two patients.ConclusionsWe successfully devel-
oped a new radiotracer, IMAZA, a compound with better
and more selective binding properties and favourable metabol-
ic stability than the reference iodometomidate. [123/
131I]IMAZA is a highly promising radiotracer for molecular
adrenal imaging and radiotherapy of adrenocortical carcino-
ma. The highly specific uptake in the target tissue lead to
superior imaging quality and therapeutic potential compared
to IMTO.
P208
Study of Novel Molecular Probe 99mTc-3PRGD2
in Diagnosis of Rheumatoid Arthritis
C. Huang, Q. Zheng, W. Miao; the 1st Affiliated Hospital of
Fujian Medical University, Fuzhou, CHINA.
Objective: The main objective of this study is to evaluate the
value of cyclic RGD (Arg-Gly-Asp) peptide conjugate with
9 9 m T c r a d i o l a b e l e d , 9 9 m T c ( H Y N I C - 3 P -
RGD2)(tricine)(TPPTS) ( 99mTc-3P-RGD2 : HYNIC=6-
hydraz inon ico t iny l ; RGD2=E[c (RGDfK)]2 ; 3P-
RGD2=PEG4-E[PEG4-c(RGDfK)]2; PEG4=15-amino-4,7,
10,13-tetraoxapentadecanoic acid; TPPTS= trisodium
triphenylphosphine-3,3’,3”-trisulfonate ), in diagnosis of rheu-
matoid arthritis (RA). Methods: 99mTc-3PRGD2 was synthe-
sized by HYNIC-3PRGD2 lyophilized kit with 99mTcO4-
labeling. Biodistribution and planar imaging studies were
performed in RA rat model. The ankles were marked by ar-
thritis index (AI) scores (from 0 score to 3 score), according to
the degree of ankle swelling, and compared the ankle uptake of
99mTc-3PRGD2. Immunohistochemical staining was used to
test the expression of integrin αvβ3 in the ankle tissue, ana-
lyzing the correlation between uptake of 99mTc-3PRGD2 and
receptor expression. Results: Planar imaging of arthritic ankles
became visible at 30min postinjection of 99mTc-3PRGD2 and
was still clear at 6 hour postinjection. AI score increased, along
with the uptake of 99mTc-3PRGD2. Biodistribution study
showed that 99mTc-3PRGD2was excreted by urinary system.
The uptake of ankles with different AI scores were 0.64
±0.07%ID/g (0 score), 1.10±0.07%ID/g (1 score), 1.30
±0.04%ID/g (2 score), and 1.73±0.05%ID/g (3 score) respec-
tively at 1 hour postinjection, suggesting that the ankle uptake
rosed with the increase of AI score. There was a linear positive
correlation relationship (r=0.852, P<0.05) between the ankle
uptake of 99mTc-3PRGD2 and the integrin αvβ3 expression
levels in immunohistochemical study. Conclusion: 99mTc-
3PRGD2 is a promising radiotracer for the diagnosis of rheu-
matoid arthritis.
P209
SPECT/Low Dose CT Perfusion Study in the Investigation
of Suspected Pulmonary Embolism
T. Pipikos, F. Vlachou, A. Nikaki, K. Dalianis, V.
Prassopoulos; Nuclear Medicine Department Hygeia SA, Ath-
ens, Marousi, GREECE.
AIM: Ventilation/Perfusion lung scintigraphy is a valuable
tool in the assessment of pulmonary embolism, especially with
the addition of V/Q SPECT. In some cases because of patient’s
general condition or even of logistic and technical reasons,
ventilation study cannot be performed. Modern γ-cameras
with flat panel source, give the possibility of performing
SPECT/low dose CT study of the lung. In this study, we eval-
uate the performance of this method in the assessment of
PE.Material and methods: We studied 72 patients who
underwent V/Q lung planar and SPECT study and perfusion
SPECT/low dose CT study. Criteria for a positive V/P planar
and SPECT study were mismatch of at least one segment or
two sub segments that correspond to pulmonary vascular anat-
omy, while the study was interpreted as non PE when the
perfusion was normal and when there was a match or reverse
mismatch(larger defects in ventilation). The rest of the patterns
were interpreted as non-diagnostic. The perfusion SPECT/CT
study was diagnosed as PE when a segmental or at least two
sub segmental perfusion defects with no parenchymal lesions
on the low dose CT were found.RESULTS: 21 patients were
diagnosed with PE with V/P planar and SPECT method, 1
study was equivocal, while 50 patients were diagnosed as
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not having PE. With the perfusion SPECT/CT study 23 pa-
tients were diagnosed with PE, 48 were normal while 1 was
equivocal. Overall SPECT/CT performed quite well in the
assessment of suspected PE, with two false positive findings,
one regarding a patient with central located lung cancer which
caused disturbance of vascular flow and pressure to the bron-
chi. SPECT/CT perfusion study had more over the advantage
of revealing the cause of defects (emphysema, pleural effu-
sions, atelectacis, etc.)CONCLUSION: Perfusion SPECT/
low dose CT study seems to perform quite well in the diagno-
sis of PE. Although it can’t be as accurate as V/P SPECT, it can
be of great value in cases that the ventilation study cannot be
performed or is unavailable.
P210
Evaluation of Cerebral Circulatory Compensation With
Tc99m-HMPAO SPECTAnd Bilateral Transcranial
Doppler Monitoring Of Middle Cerebral Artery In
Patients With Chronic Carotid Artery Occlusions
I. S. Kostina, A. V. Scherbinin, D. V. Ryzhkova; North-West
Federal Research Center, Saint-Petersburg, RUSSIAN
FEDERATION.
Aim: to compare perfusion brain SPECT and bilateral trans-
cranial doppler monitoring of middle cerebral artery blood
flow for evaluation of the circulatory compensation capacity
in patients with chronic carotid artery occlusions. Materials
and methods: In 10 patients (9 man, 1 female; 61±5 years
old) with the history of ischemic stroke and CT-
angiographically proven chronic total carotid artery (CA) oc-
clusions were included in the study. Six patients had complete
occlusion of single internal CA at extracranial segment and 4
patients additionally showed the occlusions of single vertebral
artery. All patients underwent perfusion brain single-photon
em i s s i o n c ompu t e d t omog r a phy w i t h 99mTc -
hexamethylpropyleneamine oxime at rest and after cerebral
vasodilatation by intravenous administration of adenosine
(0.14 mg/kg/min body weight over 4 minutes). The cortico/
cerebellar ratio (CCR) and the asymmetry index were
calculated for evaluation of the regional cerebral perfu-
sion abnormalities at resting conditions and during aden-
osine test. Middle cerebral artery blood flow was
assessed with bilateral transcranial doppler monitoring
(TCDM) during hypo- and hypercapnia tests. Results:
The decrease of cerebral blood flow during hypo- and
hypercapnic tests were detected in all patients by
TCDM, that indicated on the abnormality of cerebral
flow autoregulation. In all 10 brain rest perfusion
SPECT scans the areas of moderate-to severe hypoper-
fusion were detected in the cortex, supplied by occluded
internal CA - in 17% - parietal lobes, in 13% - frontal,
5% - temporal and 65% - both frontal and parietal lobes
were affected. During adenosine test the asymmetry in-
dex increased in all cases, as well as CCR moderately
reduced in the areas with lower resting cerebral perfu-
sion compared with the normally perfused contralateral
site. In 2 patients, we observed the reversible perfusion
defects in hemispheres, supplied by non-occluded cere-
bral arteries because of steal syndrome in the territory of
the artery-donor of collaterals. Conclusion: The bilateral
transcranial doppler monitoring of middle cerebral artery
blood flow identifies dysfunction of cerebral flow auto-
regulation, while brain SPECT during pharmacological
test allows to assess the severity and extent of stress-
induced ischemia in patients with chronic carotid artery
occlusions.
P211
Comparison of SPECT/CT, SPECT, and Planar Imaging
in the Management of Primary Hyperparathyroidism: A
Systematic Review and Meta-analysis
W Wei, q. luo; Shanghai Sixth People’s Hospital, Shanghai,
CHINA.
Purpose: Successful performance of minimally invasive
parathyroidectomy (MIP) is based on the reliability of
preoperative parathyroid localization studies. Despite the
various methodologies that are available, no consensus has
been reached so far on the optimal imaging technique. The
aim of our meta-analysis was to determine the accuracy of
SPECT/CT, SPECT and sestamibi scintigraphy for preop-
erative localization of parathyroid lesions. Methods: Pub-
lications were screened by a comprehensive computer
search of PubMed and EMBASE. Data were extracted
from included articles and forest plots of sensitivity and
positive predictive value (PPV) were calculated to inves-
tigate the diagnostic accuracy of three imaging methodol-
ogies. Results: SPECT/CT had pooled sensitivity and PPV
of 84% (95% CI: 78%-90%) and 95% (95% CI: 92%-
98%), respectively. SPECT had pooled sensitivity and
PPV of 66% (95% CI: 57%-74%) and 82% (95% CI:
73%-89%), respectively. For the diagnostic utility of pla-
nar scintigraphy, the pooled sensitivity and PPV were 63%
(95% CI: 51%-74%) and 90% (95% CI: 96%-99%), re-
spectively. Conclusion: Our present meta-analysis sug-
gests that with the anatomical information on CT
highlighted by functional abnormalities on SPECT,
SPECT/CT may be the optimal imaging methodology for
patients with primary hyperparathyroidism. And we firmly
believe that this technology will become more widely
available and a larger number of patients will be able to
benefit from combined SPECT/CT imaging.
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Nuclear Medicine Imagine of aseptic loosenig of joint
protheses: new data
V. Soukhov1, K. Zaplatnikov2; 1Military Medical Academy,
ST. PETERSBURG, RUSSIAN FEDERATION, 2MAZ Clin-
ic for Nuclear Medicine, Nurnberg, GERMANY.
Introduce: Implantation of joint prostheses is becoming in-
creasingly common, especially for the hip and knee. Aseptic
loosening is considered to be the most devastating of
prosthesis-related complications in early time and over more
than one year later. In frames of this investigation different
methods was used to determine correct diagnosis: radiography,
bone scan with semiquantitativ methods and, on occasion,
SPECT/CT. Methods: We reviewed 59 cases of patients (38
pts with hip and 21 pts with knee protheses) admitted all ex-
amination for bone scintigraphy with a clinical suspicion of
aseptical loosening in a hip/knee prostheses during the period
2006-2015. All pts were compared with a reference painless
group in which scintigraphy performed related to other indica-
tions. Bone metabolism within prosthesis was uniformly
assessed by zones, and was strictly different between
cementfree and cemented: by hip - acetabulum, trochanter ma-
jor/minor, lateral/medial site from prosthesis, by knee as well
medial/lateral femoral and tibial components. Bone uptake
higher as 3,3 for cementfree, and 3,5 for cement protheses
was suspious for loosening. Anterior and posterior/side views
of both joints with semiquantitatively performed analysis were
taken and was verified by means of radiography (59 pts),
SPECT/CT (14 pts), histopathological findings (7 pts), intra-
operative sections (3 pts), and clinical follow-up (59 pts). RE-
SULTS: Of 59 scintigraphies, 35 were visually negative and
24 were positive, semiquantitatively: 40 negative and 19 pos-
itive. In SPECT/CT : 9 positive, 5 negative. In radiology anal-
ysis: 40 negative, 19 positive. There were in combination 80%
true positive, 92% true negative, 5% false positive, and 14%
false negative outcomes. RESUME: Bone scintigraphy with
additional semiquantitative methods is an effective tool for
differentiation of aseptical loosening in painful pts after joints
arthroplasty. Next Stepp of investigation will be assesssment
of absolute uptake data for joint prostheses by means of new
calibrated SPECT/CT.
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Evaluation of SPECT/low dose CT Imaging
in the assesment of equivocal spine lesions in planar bone
scintigraphy
T. Pipikos1, F. Vlachou1, A. Nikaki1, K. Dalianis2, R.
Efthymiadou3, V. Prassopoulos1; 1Nuclear Medicine Depart-
ment Hygeia SA, Athens, Marousi, GREECE, 2Medical
Physics Department ,Hygeia S.A., Athens, Marousi,
GREECE, 3CT- MRI Department Hygeia SA, Athens,
Marousi, GREECE.
AIM: Bone scintigraphy is being used for whole body skeletal
staging in the diagnosis and follow up of cancer patients. One of
the main disadvantages of the modality is low specificity, with
high percentage of equivocal lesions, especially in the spine.With
the usage of hybrid SPECT/low dose CT devices, there is the
possibility of anatomic localization and further characterization of
abnormal tracer uptake foci. In this study we evaluated the effect
of SPECT/low dose CT imaging in the assessment of spine scin-
tigraphy abnormalities. MATERIAL AND METHODS: We
reviewed the planar and SPECT/low dose CT images of 91 pa-
tients who underwent bone scan in our department over the last
year for malignancy staging and had equivocal spine findings in
planar imaging. We examined if SPECT/CT lead to confident
diagnosis or diagnosis remained equivocal. Planar and SPECT/
CT images were reviewed blinded to each other, by the same
nuclear medicine physician. Imaging was performed with a
Philips BrightviewXCTsystem. RESULTS:With the application
of SPECT/CT, confident diagnosis was established in 71/
91(78%) initially equivocal on planar images cases. In 62 cases
a benign cause of abnormal tracer accumulation was established,
with the majority of them being of degenerative origin. In 9 cases
diagnosis was changed to bone malignancy. In 20 patients
SPECT/CT results did not change equivocal status. Tracer uptake
in these cases did not correspond to pathological lesions in low
dose CT that could help diagnosis and was not located in a joint
surface. CONCLUSION: Bone imaging with SPECT/low dose
CTsystem increases diagnostic confidence and reduces the num-
ber of equivocal spine lesions. Equivocal status was preserved in
only the 22% of the scans. Themajority of the lesions that caused
diagnostic problem were proven to be of degenerative origin.
P214
Interpolated CT for Respiratory Gated SPECT
Attenuation Correction
D. Zhang, C. Y. Ho, G. S. Mok; University of Macau, Taipa,
MACAO.
Aim: Respiratory gated 4D SPECT with phase-matched CT
improves attenuation correction (AC) and reduces respiratory
artifacts in cardiac SPECT. This study aims to develop and
investigate the effectiveness of the interpolated CT (ICT)
method for improved cardiac SPECT AC. Materials and
methods: We modeled a male patient with normal 99mTc-
sestamibi activity distribution using the digital 4D Extended
Cardiac Torso phantomwith respiratory motion amplitude of 2
and 4 cm. The respiratory cycle was 6 s and was divided into
96 frames which were grouped to simulate 6 respiratory
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phases. The average attenuation and activity maps in each
phase represented gated CT (GCT) and SPECT respectively,
while the 8th and 56th frame of attenuation maps represented 2
helical CTs (HCT-in and HCT-ex). The average of all attenu-
ation maps represented the cine average CT (CACT). We used
affine plus b-spline registration method combined with an em-
pirical sinusoidal function to generate interpolated phases be-
tween HCT-in and HCT-ex. Sixty noise-free and realistic noisy
projections were generated using an analytical projector over
180 degrees from RAO to LPO with attenuation modeling to
model a low energy high resolution parallel-hole collimator.
Projections in each gate were reconstructed with different AC
maps (GCT, CACT, HCTs and ICT) using OS-EM method
with up to 200 updates. Reconstructed images in each phase
were registered to the end-inspiration or end-expiration phases
separately and then averaged to generate the polar plots. Rel-
ative difference (RD) of the average intensity was computed
for each segment using the original phantom as the reference
in the 17-segment analysis. Results: For motion amplitude of 2
cm, the RDmax for AC using GCT, ICT, CACT, HCT-in and
HCT-ex were 1.38%, 2.51%, 3.31%, 13.57% and 6.80%when
images were registered to end-inspiration. The RDavg of 17
segments were 0.48%, 0.96%, 0.93%, 4.21%, and 2.41% re-
spectively. For images registered to end-expiration, RDmax
were 1.26%, 3.05%, 5.19%, 19.94% and 3.67%, and RDavg
were 0.50%, 1.34%, 1.78%, 6.86% and 1.61% respectively.
The RD of HCTs deviated from the phantom notably in the
basal inferior and lateral regions especially for higher motion
amplitude. Conclusion: TheGCT/ICT-AC improves the image
quality and quantitative accuracy for respiratory gated cardiac
SPECT as compared to CACT/HCT-AC, while using ICT can
potentially further reduce the radiation dose.
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Accuracy of Quantification Methods for Renography
with 99mTc-MAG3: A Study on Virtual and Clinical
Image Data
I. Ceric1, J. Bartosik2, M. Ljungberg1, G. Brolin3, M. Sydoff4;
1Medical radiation physics, Lund, SWEDEN, 2Clinical Phys-
iology and Nuclear Medicine, Helsingborg, SWEDEN, 3Med-
ical Radiation physics, Lund, SWEDEN, 4Radiation physics,
Lund, SWEDEN.
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The application of MIBI-Tc99m SPECT/CT scintigraphy
in the diagnosis of thyroid - 5 years follow-up
M. H. Listewnik, H. Piwowarska-Bilska, M. Chosia, K.
Jasiakiewicz, A. Dobrowolska, B. Birkenfeld; Pomeranian
Medical University in Szczecin, Szczecin, POLAND.
Introduction:Thyroid nodules are a relatively common prob-
lem. In 5-8% of patients with nodular goiter, a malignant neo-
plasm is found. Problems with not conclusive results of fine
needle aspiration biopsy (FNAB), contraindications to the sur-
gery like an advanced age or concomitant diseases, general
patient’s reluctance to radical treatment account quite often
on an outpatient basis. In the further diagnosis of these groups
of patients technetium 99m labeled metoxyisobutylisonitrile
(MIBI-99mTc) is used.Aim:The aim of the study was to estab-
lish the value of double phase MIBI-Tc-99m SPECT/CT scin-
tigraphy in the diagnosis of nodular goiter and to assess the
uptake of the tracer in focal lesions in relation to normal thy-
roid parenchyma using available methods of scintigraphy data
processing.Methods: Altogether 44 (36F, 8M, AVG. 65 years)
patients were recruited to the study. The diagnosis of nodular
goiter and Hashimoto disease was established in 35 (80%) and
9 (20%) patients, respectively. FNAB showed benign lesions,
suspicion of follicular tumors or a non-diagnostic result in
13(30%), 15(34%) and 15(34%) of cases, respectively. In
1(2%) case, no data about the result of FNAB was obtained.
They were followed-up between 2009-2013 after their scintig-
raphy examination. Additionally, the tumor/background ratio
(TBR) based on planar scintigraphy in early and delayed phase
was calculated.Results: In the initial qualitative report, the ex-
amination was assessed as positive in 23 (52%) and negative
in 21 (48%) cases. Four patients from the group with a positive
result had surgery and no malignancy was found. If retrospec-
tive quantitative analyze for all patients was employed, the
TBR varied between 1.00-2.24 (AVG. 1.2) in the early phase
and 1.02-2.17(AVG. 1.18) in the delayed phase for nodular
goiter. For Hashimoto disease the TBR varied between 1.06-
1.33 (AVG.1.14) in the early phase and 1.09-1.19 (AVG. 1.14)
in the delayed phase, respectively.Summary: 1. Negative dou-
ble phase MIBI-Tc-99m SPECT/CT scintigraphy is a suitable
way to avoid unnecessary surgery.2. It was showed that quan-
titative approach based on planar scintigraphy allows to avoid
misinterpretation in the diagnosis.
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Determination of functional reserve capacity with fusion
SPECT-CT examination after hepatic resection
H. Papp, K. Dede, Z. Egyed, F. Salamon, A. Bursics, Z.
Galler; Uzsoki Teaching Hospital, Budapest, HUNGARY.
OBJECTIVESThe goal of our study was to determine the
changes of functional activity and functional volume of the
liver after hepatectomy in correlation with preoperative
chemotherapy.METHODS40 patients were enrolled in the
study mainly with colorectal liver metastasis (36/40 pts.).
The chemotherapy was terminated at least 6 weeks before
the surgery. All patients had normal preoperative liver function
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without any sign of obstructive hepatobiliary pathology. We
performed single photon emission computed tomography
(with Tc-99m Mebrofenin (BrIDA)) and computed tomogra-
phy and used fusion imaging method was performed to eval-
uate the preoperative, residual, early postoperative (1 week
after surgery) and late postoperative (6 and 12 weeks after
surgery) functional reserve capacity.RESULTSPatients were
separated in two groups according to the type of resection
(minor: <3 segments or major ≥3 segments). The regeneration
was examined in further two subgroups of patients in accor-
dance whether they received or not preoperative chemothera-
py. The residual liver volume and activity significantly in-
creased in all patients groups one week after operation. This
increase was significantly higher in the major group than in the
minor (minor without chemotherapy:ΔAav=36%, minor with
chemotherapy: ΔAav=45%, major without chemotherapy:
ΔAav=113%, major with chemotherapy: ΔAav=120%). Sig-
nificant regeneration between 1st and 6th weeks could be ob-
served only in case of patients presenting low increment on the
first week. Hasn’t been experienced significant changes in the
late postoperative period.CONCLUSIONIn all patients the
majority of the liver functional capacity was recovered in the
first postoperative week and reached the original level until the
6th week. Preoperative chemotherapy had no effect on the
recovery of the functional activity and functional volume after
liver resection.
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A Pilot Study of 99mTc-3PRGD2 in Diagnosis of Primary
Hepatic Carcinoma
Z. jieling, M. weibing; Department of Nuclear Medicine, First
Affiliated Hospital of Fujian Medical University, Fuzhou City,
Fujian Province, CHINA.
Aim:The purpose of this study was to explore the feasibility of
applying the radioactive molecular probe 99mTc-3PRGD2 in
primary hepatic carcinoma, thus supplying a new method of
early diagnosis of hepatic carcinoma and guiding the anti-
a n g i o g e n s i s t a r g e t e d t r e a t m e n t o f h e p a t i c
carcinoma.Methods:The animal model was established by
subcutaneous injection of 5×107/ml HepG2 cells into the
shoulder flank of each mouse. Biodistribution study was per-
formed with sixteen animals. Another twelve animals with
various tumor sizes(0.056-1.0g) were injected intravenously
with 10uCi of 99mTc-3PRGD2, each tumor was counted on
γ-counter after 1h of the injection, integrin αvβ3 expression
levels were determined by immunohistochemical staining, an-
alyzing the correlation between the tumor uptake and receptor
expression. In 8, 12, 16, 20 and 24 days after the inoculation of
HepG2, two animals were injected intravenously with 1.5mCi
of 99mTc-3PRGD2 and 1.0mCi of 18F-FDG, a 45-min
SPECT/PET acquisition was obtained by Versatile Emission
Computed Tomography System(VECT or+/CT, Milabs,
Utrecht, the Netherlands), starting 50 min after injecting. The
tumor uptakes of 99mTc-3PRGD2 and 18F-FDG were sepa-
rately quantified, assessing the advantages and disadvantages
of 99mTc-3PRGD2 and 18F-FDG for imaging diagnosis of
HCC.Results:Biodistribution study showed the tumor uptakes
in different time were 4.301±0.313% ID/g (0.5 h), 6.902
±0.717%ID/g (1 h), 5.045±0.193%ID/g (2 h) and 2.099
±0.388%ID/g (4 h) respectively, which were high and last
for a long time. There was a good Linear relationship
(r=0.928,P<0.05) between the tumor uptake and the integrin
αvβ3 expression levels. Multimodal imaging study indicated
that 99mTc-3PRGD2 SPECT/CT could sensitively detected
subcutaneous tumors in 8 days after inoculation of HepG2,
when the tumor size was only 0.046cm3 and the uptake of
99mTc-3PRGD2 could reach 10.67%ID/cm3. Subcutaneous
tumors were visualized clearly under SPECT/CT fusion imag-
ings, the contrast between tumor and muscle was quite good.
The uptakes of 99mTc-3PRGD2 increased untill tumor tissue
necrotized. On the contrary, 18F-FDG PET/CT could not ac-
curately detected subcutaneous tumors in 8-16 days after in-
oculation of HepG2, the uptakes of 18F-FDG were obviously
below the uptakes of 99mTc-3PRGD2 at the same
time.Conclusion:99mTc-3PRGD2 is a promising radiotracer
in early diagnosis of primary hepatic carcinoma, and it can
offer reliable scientific basis on guiding the anti-angiogensis
targeted treatment of hepatic carcinoma.
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Utility of 99mTc HYNIC-TOC SPECT/CT
in Neuroendocrine tumors
K. Kamaleshwaran, n. sudhakar, s. paulvannan, A. shinto;
Kovai medical center and hospital limited, Coimbatore,
INDIA.
Aim:The objective of this study was to evaluate the use of
99mTc HYNIC-TOC SPECT/CT in the diagnosis, staging
andmanagement of gastroenteropancreatic neuroendocrine tu-
mors (GPNETs). Methods: 40 patients (median age, 55 years)
with histologically proven GPNETs underwent 99mTc
HYNIC-TOC whole body scintigraphy and regional SPECT/
CT as indicated. Images were evaluated by two experienced
nuclear medicine physicians both qualitatively as well as semi
quantitatively (tumor to background and tumor to normal liver
ratios on SPECT -CT images). Results of SPECT/CT were
compared with the results of conventional imaging. Histopa-
thology results and follow-up somatostatin receptor scintigra-
phy with 99mTc HYNIC TOC or conventional imaging with
biochemical markers were considered to be the reference stan-
dards. Results: 10 patients had pancreatic tumor with liver
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metastasis,15 patients with liver and bonemetastasis,8 patients
had lung metastasis and other 7 patients with nodal
metatsasis.99mTc HYNIC TOC showed sensitivity and spec-
ificity of 92.5% and 90.7%, respectively, for primary tumor
and 98% and 89% for metastasesIt showed better results than
conventional imaging modalities for the detection of both pri-
mary tumor (P<0.001) and metastases (P<0.0001). manage-
ment strategy was changed in 10 patients (25%) and supported
management decisions in 10 patients (25%). Conclusion:
99mTc HYNIC TOC SPECT/CT appears to be a highly sen-
sitive and specific modality for the detection and staging of
GPNETs. It is better than conventional imaging for the evalu-
ation of GPNETs and can have a significant impact on patient
management and planning further therapeutic options.
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Impact of hybrid imaging SPECT / CT in the first staging
of children’s neuroblastoma
I. Meddeb, I. Slim, I. Yeddes, H. Boudriga, A. Mhiri, M. Ben
Slimène; Salah Azaiez Institute, Tunis, TUNISIA.
Aim: Neuroblastoma is a malignant tumor derived from prim-
itive neural crest cells that normally develop into cells of the
sympathic nervous system. It is the most common extracranial
solid tumor of the first decade of childhood. The MIBG scin-
tigraphy allows us, to evaluate the tumor mass and its exten-
sion. The single photon emission computed tomography/
Computed tomography (SPECT/CT) improves the sensitivity
of the examination. The purpose of our work is to illustrate the
contribution of SPECT/CT in addition to the planar 123-I
MIBG scintigraphy in the first staging of neuroblastoma. Ma-
terials and methods: 23 children with neuroblastoma (aged 3
months - 6 years) were studied to evaluate the accurate staging
at the time of diagnosis. All patients underwent whole body
scintigraphy and hybrid SPECT/CT images of the involved
sites, 24 h after intravenous 123-I MIBG injection. Patients
were asked to discontinue any medication interfering with
I-123 MIBG uptake before the study. All images were ac-
quired with Symbia Gamma Camera fitted with a low energy
general purpose collimator. The whole body images were ac-
quired at a speed of 8 cm/min. SPECT images were acquired in
64 × 64 matrix. Following the SPECT acquisition, CT was
acquired. Hybrid SPECT/CT images were examined by eval-
uating the individual SPECT images, CT images and the fused
SPECT/CT images. Results: Planar MIBG images demon-
strated primary tumors in all patients; Overall, SPECT/CT
provided additional information in 18 of the 23 cases (78%):
SPECT/CT images gave us most detailed information about
the local tumor extent in 10 cases showing particularly an
extension to the spinal canal in two cases, and showed more
metastatic lymph nodes involved in primary tumor in 6 of 23
patients. Concerning metastatic lesions they showed many
more foci, as to bone and bone marrow lesions in 8 cases
and hepatic metastases in 3 cases. Finally, SPECT / CT
allowed us to reclassify five initially considered non-
metastatic patients, showing bone metastasis in 3 cases and
liver metastasis in two cases. Conclusion: The MIBG scintig-
raphy is a simple, non invasive examination that has excellent
sensitivity and specificity in detection and staging of neuro-
blastoma in childhood. The hybrid SPECT/CT imaging im-
proves the performance of the planar scintigraphy as well in
sensibility toward the deep and small lesions, and in specificity
for foci poorly identified on planar imaging.
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SPECT/CTand planar bone scintigraphy in the evaluation
of vascularised graft reconstruction of the mandible; our
experience
S. Rodriguez Martinez de Llano, I. Candal Casado, P. Pais
Silva; Centro Oncologico de Galicia, Coruña, SPAIN.
Aim.Bone scint igraphy has been used to assess
revascularisation of bone,because positive uptake reflects pat-
ent anastomoses and viability of the grafted bone.Comparison
of planar bone scintigraphy,SPECT and SPECT/CT in the as-
sessment of bone grafts in mandible reconstruction. Material
and methods.A three year retrospective study was conduct-
ed(2012-2015),selecting patients referred to our department
to perform a bone scintigraphy to assess revascularized man-
dibular bone grafts.Three-phase bone scan followed by
SPECT/CT imaging took place 3 hours after intravenous in-
jection of Tc-99m MDP(740 Mbq).Results were assessed
qualitatively by three experienced nuclear physicians.For the
evaluation of the grafts,a six-grade scoring system was ap-
plied,based on a comparison of tracer uptake between graft
and the cranium.The uptake was defined as increasing from
grade 6 to grade 1.In addition,the degree of agreement among
nuclear physicians was studied(Cohen’s kappa).Follow-up
was used as gold standard. Results.11 patients were included,
all submitted from the Oral and Maxillofacial surgery
department.Four women and 7 men(mean age 58.72
years).Nine with cancer(epidermoid carcinoma n= 7,osteosar-
coma n=2)and 2with osteoradionecrosis.Mandible reconstruc-
tions were performed with vascularized autogenous microvas-
cular grafts from the fibula(n=5),cranial-parietal(n=5)and iliac
crest(n=1).Three-phase bone scintigraphy and SPECT/CT
were ob ta ined in a l l pa t i en t s ,19 .09 days (mean
value)postoperatively.Nine of the 11 grafts had an uncompli-
cated clinical course.Complications in the graft occurred in 2
p a t i e n t s w i t h b o n e n e c r o s i s ( w i t h s u r g i c a l
confirmation).Patients with uncomplicated healing showed in
planar scintigrams increased uptake in 5 grafts(grade 1-3).Four
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s h owed g r a d e 5 - 6 ,w i t h s i g n i f i c a n t o v e r l y i n g
inflammation.Follow-up studies showed in two of these pa-
tients a final grade of 1 and 4(49 and 11 days after surgery
respectively).In the failed 2 grafts,decreased uptake was
observed(grade 5 and 6).SPECT changed the grade in one
patient(from 5 to 4)and SPECT/CT in three, from 5 to 6.There
was less indeterminate ratings with SPECT/CT than with pla-
nar scintigrams and SPECT.For planar scintigrams sensitivity
was 56% and 67% for SPECT and SPECT/CT,specificity was
100% for all techniques.The degree of agreement among nu-
clear physicians was very good(Cohen’s kappa 0.88)for this
grading method. Conclusions.Three-phase bone scintigraphy
is useful to monitor the viability of vascularized bone
grafts.SPECT/CT is also recommended.It may contribute to
interpretation of the studies and to precise assessment of graft
viability(helped by CT bone window),separating the overlying
soft tissues with hyperemia in the recent postoperative period
from the bone.Graft-cranium uptake grading method is
feasable with a very good degree of agreement between
physicians.Caution using early scintigraphy decrease uptake
results should be taken into account in the absence of compli-
cations after surgery,follow-up studies are advisable in these
cases.
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Complex 99mTc-PDA-DTPA for myocardial imaging
E. A. Nesterov1, S. I. Sazonova2, V. S. Skuridin1, S. M.
Minin3, E. S. Stasyuk1, N. V. Varlamova1, E. A. Ilina1, A. A.
Nesterov4, V. I. Otmakhov5; 1Tomsk Polytechnic University,
Tomsk, RUSSIAN FEDERATION, 2Research Institute of
Cardiology, Tomsk, RUSSIAN FEDERATION, 3Novosibirsk
Research Institute of Circulation Pathology, Novosibirsk,
RUSSIAN FEDERATION, 4Sibnuclon Ltd, Tomsk, RUS-
SIAN FEDERATION, 5Tomsk State University, Tomsk, RUS-
SIAN FEDERATION.
T h e 1 2 3 I - l a b e l e d f a t t y a c i d s s u c h a s 1 2 3 I -
Iodophenylpentadecanoic acid and 123I-Beta-methyl
iodophenylpentadecanoic acid are the agents used clinically
for myocardial imaging. Fatty acids are the major source of
energy for the normal myocardium. However, under ischemic
conditions the myocardial cells switch to glucose metabolism
for their energy needs. Fatty acids undergo prolonged meta-
bolic stunning in patients with reversible ischemia, thereby
helping in early diagnosis of coronary artery disease in high-
risk patients [Anupam Mathur,a Madhava B. Mallia etc // J.
Label Compd. Radiopharm 2010, 53 580-585]. High cost and
limited availability of cyclotron-produced 123I, makes
99mTc-labeled fatty acids more desirable for the purpose. In
diagnosis the dominant radionuclide is 99mTc. It is estimated
that it is involved in about 85% of all imaging procedures in
nuclear medicine. The method for preparation of new 99mTc-
fatty chemical systems based on modified diethylene triamine
pentaacetic acid (DTPA) molecule has been elaborated in this
work . The main advantage using DTPA as chelate agent for
radioactive label, is the molecule or it’s derivative ability to
form sufficiently stable complexes with different radioactive
metals including technetium-99. Moiety of pentadecanoic acid
addition gave the ability to prepare modified complex of
DTPA. In a labeling procedure, freshly eluted Na99mTcO4
(20mCi) was added to a mixture of cysteine, stannous chlo-
ride, PDK-DTPA and ethanol in a vial. On keeping the reac-
tion mixture at 90 0C for 30 min, [99mTc-PDK-DTPA] radio-
pharmaceutical was formed. Thereafter, the reaction mixture
was cooled over ice and characterized by HPLC. The result of
dynamic scintigraphic research showed, that after being
injected, the substance is actively acumulated into myocardi-
um. Eventually one can say that modified DTPA-moleculs are
functionally suitable for myocardial imaging. This work was
supported by the Russian Federation represented by the Min-
istry of Education and Science of Russia (project №
RFMEFI60414X0071).
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Quantification of left ventricular function using gated
SPECTwith two different automated software packages
and cardiac MRI
K. Koyama1, K. Kubota1, M. Mochiki1, T. Ogura1, H.
Hoshizaki1, S. Oshima1, T. Higuchi2, Y. Tsushima2; 1Gunma
Prefectural cardiovascular center, Maebashi, JAPAN, 2Gunma
faculity of medicine, Maebashi, JAPAN.
(Aim)We compared quantification of left ventricular function
using gated SPECT with two different automated software
packages and cardiac MRI(Material and Methods)Fifty pa-
tients with coronary artery disease were examined at rest
SPECT and cardiac MRI. Left ventricular end-diastolic vol-
ume (EDV), end-systolic volume (ESV) and ejection fraction
(LVEF) were obtained by analyzing SPECT data with two
different automated software packages: Quantitative Gated
SPECT (QGS) and Cardio REPO. (Results) High correlation
were noted in cardiac MRI and both two SEPCT data in EDV;
QGS(r:0.81), Cardio REP(r:0.84), ESV; QGS(r:0.97), Cardio
REPO(r:1.12) and LVEF; QGS(r:0.87), Cardio REPO(r:0.84)
Cases of smaller ESV than 50ml inMRI, ESVof Cardio REPO
showed larger than that of QGS. Cases of larger ESV than
50ml in MRI, ESVof Cardio REPO showed smaller than that
of QGS. And cases of smaller LVEF than 60% in MRI, LVEF
of Cardio REPO appeared larger than that of QGS and larger
than 60%, LVEF of Cardio REPO smaller than that of
QGS.(Conclusions)It may be useful to take this information
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into consideration when determining values of left ventricular
function in a clinical field.
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Value of Hybrid Imaging with 111In-Pentethreotide
in Endocrine Tumors
D. BEN SELLEM, L. ZAABAR, B. DHAOUADI, B.
LETAIEF, M. F. BEN SLIMENE; Nuclear Medicine Depart-
ment, Salah AZAIEZ Institute, TUNIS, TUNISIA.
Aim: Endocrine tumors are rare. The purpose is to show the
value of Somatostatin Receptor Scintigraphy (SRS) with hy-
b r id imag ing in the managemen t o f endoc r ine
tumors.Materials and methods: 111 patients (56 males and
55 female) aged 51.77+/-15.71 years (12 to 87 years, median
age 54 years) underwent 119 SRS.Indications were as follows,
search for a primitive and staging in 23(19.23%) cases, preop-
erative with known primitive in 16(13.4%) cases, post opera-
tive in 13(10.9%) cases, tumoral characterization in 33(27.7%)
cases, therapeutic evaluation in 9(7.6%) cases and search for
recurrence in 25%(21%) cases.Results: In search for a primi-
tive and staging, SRS was negative in three cases, diagnosed
the primitive in 12 cases in whom 10 metastases were diag-
nosed. It failed to determine the primitive in 8 cases but
e s t ab l i shed l e s ions ca r t og r aphy among these s
latter’s.Among the 16 patients with primary known le-
sions, SRS revealed abnormal radiotracer uptake in 12
patients with 10 metastatic sites, and was negative in 4
patients, in whom 2 metastatic sites were revealed.Post
operative evaluation was negative in 8 patients and posi-
tive in 5 patients (with 3 distant metastases, one lymphatic
node metastasis and one residual tumor site).In post-
therapeutic evaluation, SRS concluded to remission in
one patient, stabilization in 7 patients and progression
for the last patient.In the evaluation of recurrent disease,
SRS was negative in 14 patients and established the car-
tography of metastases in 11 patients.In the tumor charac-
terization, SRS was negative in 25 cases. But revealed a
primary location in 8 cases associated to distant metastasis
in one case and to 3 lymph node metastases.Conclusion:
SRS imaging with 111In-pentetreotide plays an important
role in the diagnosis, the detection of extension and the
follow up of patients with endocrine tumors.
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SPECT/CT in metastatic skeletal lesions
O. V. Solodyannikova; Institute of Oncology AMS of
Ukraine, KIEV, UKRAINE.
Background: Single-Photon Emission Tomography/
Computed Tomography (SPECT/CT) using 99mTc-
methylenediphosponate (99mTc-MDP) became more useful
for the diagnostic of the skeleton lesions. It created wide pos-
sibilities for simultaneous assessment of morphological, func-
tional and molecular processes in examined tissues and could
increase diagnostic accuracy of the method in comparisonwith
separately held SPECT and CTacquisition. The determination
of abundance and scintigraphic differences of the lytic and
sclerotic metastatic lesions is very important, because of their
metabolic features. Our aim was to determine scintigraphic
accordance of different kinds of the metastatic lesions by
SPECT/CT. Materials and methods: 43 patients from 36 to
82 years old (mean 60,1±8,2) with metastatic bone lesions
were examined. All patients had been done SPECT/CT of
the lesions. Results: There were found 55 bone metastatic
lesions.We divided all lesions into 4 samples by CT: 1-
sclerotic clear-cut focuses (15 lesions, 27,2%), 2-sclerotic
patchy lesions (11 lesions, 20%), 3- lytic lesions without clear
margins (25 lesions, 45,5%), 4- lytic focuses with clear scle-
rotic rim (4 lesions, 5,8%). It was analyzed correlation X-ray
and scintigraphic images on the combined scans. All lesions
had bigger area on the SPECTscans then on corresponding CT
scans.There are correspond intensive homogeneous 99mTc-
MDP uptake to 12 sclerotic clear-cut lesions, and3 lesions
from the first group hadn’t any uptake in it. These 3 lesions
evaluated as the sponges bone condensations - “bone islets”.
All 11 of sclerotic patchy lesions had intensive or moderate
intensity of 99mTc-MDP accumulation. All lytic lesions
hadn’t uptake of 99mTc-MDP in the middle of them, but they
had moderate uptake near that lesions in the bone tissues. Lytic
focuses with clear sclerotic rim had high intensive inhomoge-
neous uptake. Moreover, some zones of moderate uptake of
99mTc-MDP have not corresponding CT abnormalities. Con-
clusion: SPECT/CT is the useful method for size and features
evaluation of bone metastatic lesions. It defined that area of
metabolic abnormalities always is bigger than structural
changes. Scintigraphic images of lytic and sclerotic lesions
had some difference that shows divergent intensity and local-
ization of pathologic process in them. There were benign scle-
rotic focuses that had not accumulate 99mTc-MDP. Metastatic
lesions could be detected by Scintigraphy earlier than on the
X-ray examination.
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The influence of age, sex and circadian rhythm on kidney
function in mice measured by Tc-99m-MAG3 SPECT
K. P. Huang, I. G. Steffen, M. Lukas, C. Lange, C. Rosner, W.
Brenner, N. Beindorff; Charite - Universitaetsmedizin Berlin,
Berlin, GERMANY.
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Aim: The aim of this longitudinal study was to establish stan-
dard values for the time activity curves (TAC) of Tc-99m-
MAG3 for the evaluation of kidney excretion as a function
of age, sex and circadian rhythm in healthy mice. Materials
and methods: Six female and 6 male C57BL/6 mice were
housed under standardized conditions (12 h light versus 12 h
darkness). In anesthetized animals (isoflurane), a CT scan was
used to position both kidneys within the 14-mm axial FOVof
the dynamic semi-stationary SPECT (nanoSPECT/CTplus,
Mediso). The SPECT acquisition consisting of 10 frames of
20 s followed by 25 frames of 50 s was initiated at the time of
intravenous Tc-99m-MAG3 injection (23-77 MBq). Each
mouse was imaged in follow-up studies up to 12 months (A:
1 month, puberty; B: 3 months, sexual mature, but not fully
grown; C: 6 months, fully grown; D: 12 months). In order to
monitor circadian rhythm, animals were imaged during day
(sleeping phase (SP)) as well as during night conditions
(awake phase (AP)). Image viewing and quantification were
performed using InVivoScope 2.00 (Bioscan). Kidney excre-
tion is expressed as time to peak (Tmax) in minutes (median
[interquartile range; IQR]). Differences between groups were
tested using Friedman, Mann-Whitney-U or Wilcoxon test.
Results: Tmax was 1.6 [1.3-1.9] in all mice. Females showed
a significantly later Tmax than males (1.6 [1.3-2.0] versus 1.3
[1.3-1.6]; P<0.001). With respect to age, this gender effect
could be observed from 6 months onwards: A (female 1.5
[1.3-1.7], male 1.5 [1.0-1.9]; P=0.19), B (female 1.3 [1.3-
1.4], male 1.3 [1.3-1.4] P=0.37), C (female 1.6 [1.6-2.0], male
1.3 [1.0-1.3]; P<0.001), D (female 2.0 [1.8-2.4], male 1.6 [1.4-
1.9]; P<0.001). In general, mice showed an age-dependent
Tmax with significantly increasing values after 6 months of
age: A 1.5 [1.3-1.9], B 1.3 [1.3-1.4], C 1.6 [1.3-1.6], D 1.9
[1.6-2.2]; P<0.001). Circadian rhythm revealed a significant
impact on Tmax in males (SP 1.6 [1.3-2.0], AP 1.3 [1.0-1.6];
P=0.02), while in females no significant difference could be
observed so far (SP 1.6 [1.3-2.1], AP 1.7 [1.6-2.0]; P=0.13).
Conclusion: This study showed a significant impact of age,
sex, and partially of circadian rhythm, on kidney excretion of
Tc-99m-MAG3. The limited effect of circadian rhythm might
be due to the small number of animals so far. In summary, it
seems essential for kidney analysis in mice to consider the
impact of age, sex and circadian rhythm.
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Preclinical SPECT-CT imaging studies with cyclotron
produced Tc-99m
G. Pupillo1, A. Boschi2, P. Martini3, L. Uccelli2, M. Pasquali2,
A. Duatti2, G. Di Domenico3, M. Loriggiola1, M. Giganti2, A.
Taibi3, M. Gambaccini3, A. Salvini4, L. Strada4, M. Prata4, M.
Marengo5, G. Lucconi5, S. Manenti6, F. Groppi6, G. Cicoria5,
M. Bello7, N. Uzunov8, J. Esposito1; 1Legnaro National
Laboratories of the Italian Institute of Nuclear Physics (INFN),
Legnaro (Padova), ITALY, 2Department of Morphology, Sur-
gery and Experimental Medicine, University of Ferrara, Fer-
rara, ITALY, 3Department of Physics and Earth Science, Uni-
versity of Ferrara, Ferrara, ITALY, 4Applied Nuclear Energy
Laboratory and Department of Chemistry, University of Pavia,
Pavia, ITALY, 5Nuclear Medicine S. Orsola Hospital, Bolo-
gna, ITALY, 6Accelerator and Applied Superconductivity Lab-
oratory and Physics Department, University of Milano, Mila-
no, ITALY, 7Department of Physics and Astronomy, Universi-
ty of Padova, Padova, ITALY, 8Faculty of Natural Sciences,
Shumen University, Shumen, BULGARIA.
Aim: This work reports results of a preclinical study aimed at
evaluating the diagnostic quality of radiopharmaceuticals pre-
pared using cyclotron-produced Tc-99m as compared to
generator-produced Tc-99m analogues. Material and methods:
Enriched (99.05%) Mo-100 metallic targets were irradiated
with a proton beam having energies within the range 19−17
MeV. Purification of Tc-99m from the irradiated targets was
carried out by solvent extraction using methyl-ethyl ketone
(MEK) having a well-established selective affinity for the
pertechnetate ion. Further chromatographic purification
afforded Tc-99m in physiological solution that was subse-
quently employed for the preparation of a number of Tc-99m
radiopharmaceuticals for perfusion cardiac and brain imaging.
Radionuclidic purity (RNP) of the Tc-eluate was measured by
γ-spectrometry and radiochemical purity (RCP) of Tc-
radiopharmaceuticals was checked by radio-TLC and HPLC.
Anesthetized Wistar rats were injected into the jugular vein
and in vivo whole-body SPECT-CT images were collected
with a hybrid YAP(S)PET-CT small-animal scanner. SPECT-
images were corrected for injection time and activity. Results:
Radionuclidic purity of accelerator-produced Tc-99m was in
the range 99.3 ± 0.2% at the end of bombardment (EOB) and
99.5 ± 0.2% at the end of chemical extraction (6 hours after
EOB). Main radionuclidic impurities originated from the pres-
ence of the γ-emitting Tc-isotopes Tc-93, Tc-94g, Tc-95g and
Tc-96g. This caused a detectable scatter effect on SPECT im-
ages mostly generated by the interaction of these parasite γ-
rays with the high-resolution collimator of the small-animal
scanner. For this reason, a scatter-correction method, based
on the definition of different energy ranges, was implemented
on these images. Considering the efficiency of the correction
approach and the high-capacity of biological sites targeted by
Tc-99m perfusion imaging agents, the impact on the image
quality was negligible when compared with the same images
collected with generator-produced Tc-99m. Conclusions:
In vivo SPECT-CT preclinical imaging study in a rat animal
model using a high-resolution small-animal scanner confirmed
a superimposable biodistribution behavior of heart and brain
perfusion Tc-99m radiopharmaceuticals labeled with both
cyclotron- and generator-produced Tc-99m. However, it
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should be noted that the effect of scattered high-energy γ-rays,
generated by the decays of technetium radioisotopes impuri-
ties in cyclotron-produced Tc-99m, strongly depends on the
specific imaging system and, therefore, extrapolation to im-
ages obtained with available SPECT cameras for human stud-
ies is not straightforward. This points to the need of conducting
dedicated imaging tests with conventional SPECT imaging
equipment employed in a clinical setting.
P228
Development of cancer-targeted Nuclear/NIRF/PTT
multi-modality theranostic probe
C Peng1, Y. Shih1, T. Luo1, M. Shieh2; 1Institute of Nuclear
Energy Research, Taoyuan, TAIWAN, 2Institute of Biomedi-
cal Engineering, National Taiwan University, Taipei,
TAIWAN.
Aim: Cancer is one of the leading death causes in the world.
Cancer-targeted multifunctional probe labeled with the radio-
nuclide has been developed to provide multi-modalities for
NIR fluorescence and nuclear imaging (SPECT) and for
photothermal therapy (PTT) of cancer.Materials and methods:
In this study, synthesis, characterization, in vivo biological
evaluation of a heptamethine cyanine-based SPECT/NIRF/
PTT multi-modality theranostic probe were described. The
NIR dye, heptamethine cyanine, allowed the probe to have
multi-functions in cancer NIR imaging and photoththermal
therapy (PTT).Results: The radionuclide-labeled probe en-
abled imaging by NIR fluorescence and by nuclear imaging
(SPECT) to monitor in real-time the tumor accumulation,
intra-tumoral distribution, and to guide the PTT.Conclusion:
In summary, the radionuclide-labeled theranostic probe offer
multi-modalities for NIR fluorescence and nuclear imaging
and for PTT of cancer.
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Synthesis and Evaluation of a Novel Tc-99m Labeled
HGK-containing Hexa-Peptide for Non-Invasive Tumor
Imaging
D. Kim1, W. Kim2, M. Kim1, C. Kim1; 1Wonkwang Univer-
sity School Of Medicine, IKSAN, JEOLLABUK-DO, KO-
REA, REPUBLIC OF, 2Seoul National University Hospital,
Jongno-Gu, Seoul, KOREA, REPUBLIC OF.
Aim: Domain 5 of kinin-free high molecular weight kininogen
inhibits the adhesion of many tumor cell lines and it has been
reported that the histidine-glycine-lysine (HGK)-rich region
might be responsible for inhibition of cell adhesion. Despite
the good property of HGK peptide binding specifically to
tumor cells, the development of imaging agent using HGK
peptide had not been reported until now. The authors devel-
oped HGK-containing hexapeptide, glutamic acid-cysteine-
glycine (ECG)-HGK to target tumor cells, and evaluated the
feasibility of Tc-99m ECG-HGK as a molecular imaging
agent. Materials and Methods: Hexapeptide, ECG-HGK was
synthesized using Fmoc solid-phase peptide synthesis.
Radiolabeling efficiency was evaluated using radio-high-
performance liquid chromatography (radio-HPLC) and instant
thin layer chromatography (ITLC). The uptake of Tc-99m
ECG-HGK within HT-1080 cells was evaluated in vitro by
the calculation of cellular binding affinity and confocal mi-
croscopy. In HT-1080 tumor-bearing mice, gamma images
were acquired and tumor-to-muscle uptake ratio was calculat-
ed, and a biodistribution study was also performed. Results:
After radiolabeling procedures with Tc-99m, the complexes
Tc-99m ECG-HGK was prepared in high yield (>95%). The
Kd of Tc-99m ECG-HGK determined by saturation binding
was 263.7 ± 63.0 nM and the value of Bmax was 3329.0 ±
335.8 nM. Confocal microscopy images of HT-1080 cells
showed strong intersperse fluorescence of FITC-ECG-HGK
in cytoplasm of the tumor cells. The gamma camera imaging
in the murine model showed that Tc-99m ECG-HGK was
accumulated substantially in the HT-1080 tumor and the tu-
moral uptake was blocked by the co-injection of excess HGK.
The tumor-to-normal muscle uptake ratio of Tc-99m ECG-
HGK reached 5.7 ± 1.4 at 4 h (2.8 ± 0.8, 3.6 ± 0.2, 4.9 ± 0.4
and 5.7 ± 1.4 at 30 min, 1 h, 2 h and 4 h, respectively). The
%ID/g value in the tumor was 1.37 ± 0.61, and tumor uptake
was suppressed by co-injection of free HGK (0.37 ± 0.09).
Tumor-to-normal muscle ratios of %ID/g were 4.8 ± 3.9 and
it was decreased by co-injection of free HGK (1.4 ± 1.3, p <
0.05). Conclusion: This study successfully had developed Tc-
99m ECG-HGK as a new tumor imaging agents in HT-1080
tumor. Tc-99m ECG-HGK showed a significant uptake in the
tumor, and it is a good candidate for tumor imaging.
P230
SPECT/CT Imaging of Radionuclide-carrying Liposomes
Predict Therapeutic Effects of Liposomal Anti-cancer
Agents in Mouse Xenograft Models
I. O. Umeda1, K. Ito2, S. Hamamichi1, M. Asano2, M. Iwata2,
J. Matsui2, Y. Hori2, Y. Funahashi2, H. Fujii1; 1National Can-
cer Center, Kashiwa, JAPAN, 2Eisai Co., Ltd., Tsukuba,
JAPAN.
Objectives: Liposomal anti-cancer agents can effectively deliver
drugs to tumor lesions and enhance therapeutic effects in the
limited number of cancer patients. Appropriate biomarkers to
identify responder are crucial for effective treatment. Here, we
generated radiolabeled liposomes; i.e., liposomes encapsulating
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111In-DTPA, with lipid composition and size identical to
Doxil®, liposomes encapsulating doxorubicin, and evaluated
their usefulness to predict therapeutic effect of Doxil by
SPECT/CT tumor images before the initiation of the treatment.
Methods: Anti-tumor effects of Doxil to four human ovarian
cancer xenograft models (Caov-3, SK-OV-3, KURAMOCHI,
and TOV-112D) were evaluated though comparison of the tu-
mor size suppression with free doxorubicin. Histopathological
studies were also performed.111In-labeled liposomes were pre-
pared by using remote loading method, and their tumor accu-
mulation after intravenous administration was determined quan-
titatively by measurement of their radioactivities ex vivo and by
in vivo SPECT/CT imaging. Results: Anti-tumor activities of
Doxil was drastically enhanced in Caov-3, moderate in SK-
OV-3, and minimum in other two tumors. Doxil-perfusion as-
say, by observation of the autofluorescence of Doxil in the tu-
mor, suggested that the tumor accumulation of Doxil was much
higher in Caov-3 and relatively higher in SK-OV-3 than in
others. The microvessel density and vascular perfusion were
high in Caov-3 and SK-OV-3. The tumor accumulation of
111In-labeled liposomes at 72 h after administration was high
in Caov-3 and SK-OV-3 (4.0 - 4.3 % of administered dose/g of
tumor, %AD/g), while it was less than 1.5 %AD/g in other two
tumors. Area under the curve values over 72 h was the highest
in Caov-3, followed by SK-OV-3. It was very low in other two
tumors. These results were consistent with the aforementioned
retention and therapeutic efficacy of Doxil in these 4 tumors.
Importantly, since both Doxil effects and radiolabeled liposomal
accumulation varied especially among SK-OV-3 tumor groups,
we individually obtained SPECT/CT images of each SK-OV-3
bearing mouse (n=11) and then administered Doxil to them. A
clear correlation between the liposome tumor accumulation and
the effects of Doxil was confirmed (R 2=0.73). Discussion:
These results indicated that anti-tumor activities of Doxil
depended on its tumor accumulation which was closely related
to the microvessel density and vascular perfusion. Tumor accu-
mulation of radiolabeled liposomes evaluated in SPECT images
should predict the anti-tumor activities. Conclusions:
Radiolabeled liposomes would be a promising imaging bio-
marker to predict the therapeutic efficacy of liposomal anti-
cancer drugs, such as Doxil.
P231
Imaging somatostatin receptor expression
on macrophages in osteoarthritis models
S. T. van Tiel, J. de Swart, L. Utomo, M. de Jong, M. R.
Bernsen; ErasmusMC, Rotterdam, NETHERLANDS.
Introduction: Macrophages are present ubiquitously in the
body and they can be polarized in a dynamic way towards
different physiologies (M1, M2a-d) that negatively or
positively affect many different disease processes. The ability to
non-invasively determine the activation type of disease-
associated macrophages may therefore aid in earlier or more pre-
cise diagnostics/prognostics of disease. A variety of tracers have
been suggested for this purpose. A number of studies have indi-
cated that the somatostatin receptor subtype 2 (SSTR2) is
expressed on the M1, inflammatory response inducing, macro-
phages. 111In-Octreoscan (111In-DTPA-octreotide) is a well-
known tracer for tumour imaging, binding SSTR2 with good
affinity. The aim of this study was to study the feasibility of
111In-Octreoscan for M1 macrophage SPECT imaging in two
osteoarthritis (OA) mouse models, which differ in inflammation
severity. Materials and methods: Male C57Bl/6 mice were used.
Osteoarthritis was induced by: 1) CIA = Collagenase Induced
Arthritis; injection of collagenase (10 U/ 6 μl) in the knee, caus-
ing a severe form of OA. For control purposes the contra-lateral
knee was injected with 6 μl water for injection, 2) DMM =
Destabilization of the Medial Meniscus, causing a milder form
of OA. The contra-lateral knee underwent sham surgery for con-
trol purposes. At different time points post surgery the mice were
imaged (between 1 day and 8 weeks), 2 hours after intravenous
injection of 60 MBq 111In-Octreoscan. After the last scan the
knees were prepared for histological staining. Results: Uptake of
111In-Octreoscan was observed in the diseased knee and almost
never in the contralateral control knee. Uptake appeared to be
model and time dependent. Comparing the severe form of OA
with the mild form of OA the most lesion-associated uptake is
seen in the severe model. Lesion-associated uptake is also seen
more often when OA development progresses in time, in both
models. Currently we are validating the imaging findings using
histological analysis and correlating the findings to disease sever-
ity, especially the inflammatory status. Conclusions: Imaging of
SSTR2 in mouse models of osteoarthritis showed lesion-
associated uptake, and is therefore promising to become a rele-
vant marker to non-invasively detect and monitor disease state.
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The Metabolic Role of Carbenoxolone in Cancer:
a Possible Interference in Glucose Metabolism and FDG
Uptake Through the Inhibition of the Endoplasmic
Reticulum Hexose-6-Phosphate Deydrogenase.
A. Orengo1, A. Buschiazzo1, G. Sambuceti1, S. Ravera2, S.
Bruno3, F. Fais3, C. Ghersi1, G. Bianchi4, R. Martella4, L.
Raffaghello4, C. Marini5; 1Nuclear Medicine Unit, Department
of Health Sciences, University of Genoa and IRCCS AOU San
Martino-IST, Genoa, ITALY, 2Department of Pharmacy, Univer-
sity of Genoa, Genoa, ITALY, 3Department of Experimental
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Medicine, University of Genoa and IRCCS AOU San Martino-
IST, Genoa, ITALY, 4Laboratory of Oncology, G. Gaslini Insti-
tute, Genoa, ITALY, 5CNR Institute of Bioimages andMolecular
Physiology, Section of Genoa, Genoa, ITALY.
Aim. Hexose-6-phosphate dehydrogenase (H6PD) is a house-
keeping enzyme dedicated to the redox homeostasis of the endo-
plasmic reticulum (ER). Differently from its cytosolic counterpart
glucose-6-phosphate dehydrogenase (G6PD), H6PD recognizes
the phosphorylated forms of both glucose and 2-deoxyglucose as
substrates. It can thus contribute to FDG retention. To test this
hypothesis, we studied the effect of carbenoxolone (CBX), a
specific H6PD inhibitor, on FDG uptake and distribution in two
murine cell lines of colon (CT26) and breast (4T1) carcinoma.
Materials and Methods. In both cell lines, the effect of 24 hours
CBX exposure was evaluated by comparing response of FDG
uptake with the measurement of glucose disappearance from su-
pernatant. Glucose concentration of administered medium was
11.1 mM and sugar disappearance was monitored for 24 hours.
FDG uptake was tested through 30 minutes, using a glucose free
medium and a tracer concentration of 37 kBq/mL. Western blot
and spectrophotometric analysis were applied to cell lysates to
study abundance of GLUT1 as well as expression and enzymatic
activity of hexokinases, H6PD and its cytosolic counterpart
G6PD. Results. Preliminary experiments with purified enzymes
confirmed that H6PD is active on both G6P and 2DG6P. On the
contrary, the unique substrate for G6PD was G6P. CBX did not
alter H6PD expression while it significantly inhibited enzyme
activity reducing cell lysate capability to dehydrogenate 2DG6P
by 53±2% and 51±3% of control values in CT26 and 4T1 cells,
respectively (p<0001). On the contrary, G6PD function (mea-
sured using G6P as substrate) was not affected by drug exposure
in both cell lines. Moreover, with respect to untreated cells, CBX
reduced to a similar degree glucose consumption (89±2% and 67
±5%) and FDG uptake (78±2% and 61±4%) in CT26 and 4T1
cells, respectively. Finally, the role of H6PD in cancer glucose
consumption and FDG retention was confirmed by the evidence
that the fluorescent 2DG analogue (2NBDG) was actually se-
questered within the ER. In both cell lines, CBX decreased
2NBDG colocalization with ER vital probe by more than 50%.
Conclusion. H6PD enzymatic function accounts for a significant
part of cancer glucose consumption and FDG uptake in cancer
cells.
P233
Inhibiting hexose-6-phosphate dehydrogenase gene
expression significantly reduces 18F-fluorodeoxyglucose
uptake and cancer cells proliferation in two experimental
models of colon and breast carcinoma.
C. Marini1, G. Sambuceti2, S. Bruno3, A. Orengo2, A.
Buschiazzo2, S. Ravera4, A. Democrito2, G. Bianchi5, L.
Raffaghello5, G. Caviglia6, F. Fais3; 1CNR Institute of
Bioimages and Molecular Physiology, Section of Genoa, Gen-
oa, ITALY, 2Nuclear Medicine Unit, Department of Health
Sciences, University of Genoa and IRCCS AOU San
Martino-IST, Genoa, ITALY, 3Department of Experimental
Medicine, University of Genoa and IRCCS AOU San
Martino-IST, Genoa, ITALY, 4Department of Pharmacy, Uni-
versity of Genoa, Genoa, ITALY, 5Laboratory of Oncology, G.
Gaslini Institute, Genoa, ITALY, 6Department ofMathematics,
University of Genoa, Genoa, ITALY.
Aim. The autosomally linked enzyme hexose-6-phosphate de-
hydrogenase (H6PD) catalyzes the first two reactions of pen-
tose phosphate pathway transforming glucose-6-phosphate
(G6P) to 6-phospho-gluconate within the endoplasmic reticu-
lum (ER). Differently from its cytosolic counterpart, sex-
linked G6P dehydrogenase, H6PD can process a large number
of substrates beyond G6P including glucose, galactose-6P and
2-deoxyglucose-6P (2DG6P). Aim of this study was to evalu-
ate whether this enzyme feature might contribute to 18F-
fluorodeoxyglucose (FDG) retention in cancer.Materials and
Methods. H6PD activity was studied in CT26 and 4T1 cell
lines as models of murine colon and breast carcinoma. Gene
silencing was obtained by transfection with 75 nM H6PD
siRNA or SilencerTMNegative Control siRNA as a scramble.
The protocol implied a validation phase measuring the re-
sponse of 2DG6P dehydrogenation in lysates of treated and
control cells. Once optimized siRNA administration proce-
dure, effect on glucose consumption was evaluated by mea-
suring glucose disappearance from culture mediumwith a glu-
cose concentration set at 11 mM. FDG uptake was measured
using a validated procedure with tracer administration for 30
minutes at a concentration of 37 KBq/mL in a glucose-free
medium. Finally, fluorescent 2DG probe 2-[N-(7-nitrobenz-
2-oxa-1,3-diazol-4-yl)amino]-2-deoxyglucose (2NBDG) was
used to evaluate metabolite distribution and its co-
localization with vital probes for ER detected by confocal
microscopy and analyzed by a specif ic software
(ImageJ).Results. In CT26 and 4T1 cells, gene silencing re-
duced H6PD enzymatic activity to 12.16% and 17.18% of
control values (p<0.001), respectively. As a functional corre-
late, siRNA decreased glucose consumption (to 73%±5% and
74%±5%, p<0.01) and even more FDG uptake (to 54±3% and
49±2%, p<0.001). Scramble siRNA did not exert any effect on
glucose metabolism nor on FDG retention. Fluorescent
2NBDG experiments documented a high co-localization of
2DG6P and ER signals in untreated cells (54±2% in CT26
and 58±4% in 4T1 cells). This pattern was markedly modified
by H6PD silencing that decreased this match to 12±1% and 16
±2%, respectively (p<0.001 vs controls). Finally, the de-
creased tracer uptake and the cytosolic localization of
2DG6P predicted a significant reduction of cell proliferation
in the 72hours of gene silencing (to 58% in CT26 and 17% in
S452 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
4T1 cells respect to controls, p<0.001).Conclusion. Taken to-
gether, our data suggest a fundamental role for H6PD enzy-
matic function in FDG uptake mechanism and proliferation
rate of two different models of colon and breast carcinoma.
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The Metabolic Role of Metformin in Cancer:
the Divergent Effect Between FDG Kinetic and Glucose
Consumption on Cancer Aggressiveness
A. Buschiazzo1, A. Orengo1, S. Ravera2, B. Salani3, U.
Pfeffer4, F. Pastorino5, A. Brizzolara6, L. Raffaghello5, G.
Bianchi5, F. Bongioanni1, G. Sambuceti1, C. Marini7; 1Nucle-
ar Medicine Unit, Department of Health Sciences, University
of Genoa and IRCCS AOU San Martino-IST, Genoa, ITALY,
2Department of Pharmacy, University of Genoa, Genoa, ITA-
LY, 3Department of Internal Medicine, University of Genoa,
Genoa, ITALY, 4Department of Integrated Molecular Patholo-
gy, IRCCS AOU San Martino-IST, Genoa, ITALY, 5Laborato-
ry of Oncology, G. Gaslini Institute, Genoa, ITALY, 6Depart-
ment of Experimental Medicine, University of Genoa and
IRCCS-AOU San Martino-IS, Genoa, ITALY, 7CNR Institute
of Bioimages and Molecular Physiology, Section of Genoa,
Genoa, ITALY.
Aim.Previous studies demonstrated a metformin effect on mi-
tochondrial respiration through the inhibition of Complex I in
different cancers. The aim of this study is to determine if the
inhibition of respiratory chain causes a reduction in cancer
cells energy asset. Materials and Methods.We evaluated cells
culture in 5 ml of DMEM medium with a 11.1 mM glucose
concentration for 48 hours. Glucose consumption was evalu-
ated by monitoring sugar disappearance from supernatant over
24 hours under control condition and under metformin expo-
sure (5 mM for 24 hours). FDG uptake was tested through 30
minutes using a glucose free medium and a tracer concentra-
tion of 37 kBq/mL. 5’ AMP-activated protein kinase (p-
AMPK) was measured by Western blotting, lactic dehydroge-
nase (LDH) spectrophotometrically, oxygen consumption
using a thermostatically controlled oxygraph apparatus and
ATP concentration by the luciferin/luciferase chemilumines-
cent method. Results.Metformin virtually abolished oxygen
consumption through Complex I-III-IV in two murine cell
lines of colon and breast carcinoma, CT26 and 4T1. Despite
a preserved activity of pathway II-III-IV this action severely
impaired ATP synthesis eventually leading to a fall in ATP
availability and a decrease in ATP/AMP ratio. This severe
energy depletion was confirmed by the expected reaction of
energy sensor mechanisms, by the accelerated phosphoryla-
tion rate of p-AMPK and by marked decrease in cell prolifer-
ation rate. Metformin increased glucose consumption to 190
±5% and 268±7% of controls in CT26 and 4T1, respectively
(p<0.001). The corresponding increase in glycolytic flux was
documented by the marked increase in lactate production (2.1
±0.1 to 4±0.2 and 1.8±0.1 to 3.2±0.16 uM/106cells, p<0.01)
and release (2±0.1 to 2.5±0.12 and 1.1±0.05 to 2.3±0.1 uM,
p<0.01) in both cell lines, despite invariance of LDH activity.
On the contrary, drug exposure decreased FDG uptake to 24
±2% and 39±3% of baseline values in the same cell lines,
respectively (p<0.001). The combined analysis of glucose
consumption and FDG uptake confirmed this paradoxical di-
vergence in broad panel of human cancer cell lines represen-
tative of NSC lung, breast and prostate carcinomas, melanoma
and neuroblastoma. All these models confirmed the divergent
response of glucose consumption and FDG uptake. Conclu-
sion.Metformin directly inhibits mitochondrial respiration and
depletes ATP asset of cancer cells. The consequent accelera-
tion in glycolytic disposal faces an opposite response FDG
uptake that is markedly decreased by the biguanide. Different-
ly from glycolysis, FDG kinetic response to metformin direct-
ly predicts cancer cell proliferation, indicating a direct corre-
lation between FDG uptake and cancer aggressiveness inde-
pendent from glucose consumption.
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Cellular uptake and localization of a novel NSCLC
penetrating peptide
H. Zhou, P. Dong, H. Cai, X. Wu, L. Li; West China Hospital,
Chengdu, CHINA.
Objectives : CendR motif peptide (CRMP) has high affinity to
neuropilin-1 (NRP-1), which is a widely expressed tumor
marker in lung cancer, breast cancer, and colon cancer, etc.
In this study, a novel NSCLC-targeting (Non-small cell lung
carcinoma) peptide was designed and its penetrating capability
was initially tested in vitro. This peptide was comprised with
three motifs: CS motif which binds to NSCLC cells, peptidase
restriction site, and cryptic CendR motif. Once CS motif has
brought peptide to tumor, peptide is proteolytically cleaved
and expose the CenR sequence; the truncated peptide lose its
affinity for primary receptor but binds to NRP-1, and activat-
ing tissue-penetrating pathway. A tyrosine was added to N-
terminal of comprised peptide for future radio-labeling.
Methods : NRP-1 binding peptide CRMP-1, NSCLC binding
peptide CS, and novel designed peptide YCCS were N-
terminal FITC labeled. Human NSCLC cell A549 (NRP-1 +
), human breast cancer cell MDA-MB-231 (NRP-1 +), normal
human bronchial epithelium HBE135-E6E7 (NRP-1 -) and
human liver cell HL-7702 (NRP-1 -) were used for binding
test. Each one was inoculated into 96-well plate and 3 kinds of
peptides were respectively added as 20μM. After 4h incuba-
tion, the cellular binding and localization of CRMP1, CS and
YCCS were assessed by fluorescent microscope. Results :
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CRMP-1 fluorescent signals were detected in A549 and
MDA-MB-231 cells, while marginal in HBE135-E6E7 or
HL-7702. Our novel multifunctional YCCS peptide showed
significant fluorescent signals in A549 cells, which revealed
good NSCLC binding affinity and that tyrosine addition for
potential radioisotope labeling did not show influence to its
binding capability. However, no captured signal of FITC-
YCCS in MDA-MB-231 indicated that NSCLC binding motif
blockage successfully inhibited the cryptic CRMP-1 binding
unless primary motif cleavage and improved selectivity of our
peptides to unexpected cells. Conclusions : The novel YCCS
peptide indicated a promising strategy for improving tumor
penetrating peptide with delivery capability of radiopharma-
ceutical drugs to NSCLC cells.
P236
Effect of Metformin on Cancer Glucose Metabolism:
Correlation Between FDG Escape
and Glucose-6-Phosphatase Activity in the Endoplasmatic
Reticulum.
A. Buschiazzo1, G. Sambuceti1, A. Orengo1, S. Ravera2, F.
Fais3, S. Bruno3, E. Monteverde1, L. Garaboldi1, G. Bottoni1,
L. Raffaghello4, G. Bianchi4, M. Piana5, S. Garbarino5, G.
Caviglia5, C. Marini6; 1Nuclear Medicine Unit, Department
of Health Sciences, University of Genoa and IRCCS AOU
San Martino-IST, Genoa, ITALY, 2Department of Pharmacy,
University of Genoa, Genoa, ITALY, 3Department of Experi-
mental Medicine, University of Genoa and IRCCS AOU San
Martino-IST, Genoa, ITALY, 4Laboratory of Oncology, G.
Gaslini Institute, Genoa, ITALY, 5Department ofMathematics,
University of Genoa, Genoa, ITALY, 6CNR Institute of
Bioimages and Molecular Physiology, Section of Genoa, Gen-
oa, ITALY.
Aim. In most solid cancers the high needs of ATP result in an
accelerated rate of glucose consumption. The exploitation of
this glycolytic phenotype became a standard to diagnose can-
cer and to monitoring its aggressiveness by 18F-
fluorodeoxyglucose (FDG) imaging. This glucose analogue
enters the cell and is phosphorylated through the same GLUT
carriers and the same hexokinases active on glucose. However,
FDG-6-phosphate (FDG6P) is a false substrate for down-
stream enzymes triggering glycolysis and pentose phosphate
pathway and is thus accumulated within the cytosol according
to the overall glucose consumption. Critical to this model is the
irreversible nature of FDG phosphorylation that prevents its
loss from cytosol. However, most mammalian cells express
different isoforms of G-6P-phosphatase (G6Pase) that might
recognize FDG6P as a substrate. The present study aimed to
verify whether cancer cells express G6Pase and whether this
enzyme can alter FDG trapping mechanism. Materials and
Methods. We studied murine colon (CT26) and breast carci-
nomas (4T1) cells, cultured in 5ml of DMEM medium with a
11.1 mM glucose concentration for 48 hours. To modify cell
glucose consumption we used metformin (MTF, 5 mM for 24
hours) administration due to the drug capability to virtually
abolish mitochondrial Complex 1 function. Glucose disap-
pearance from extracellular medium was calculated by moni-
toring medium glucose concentration over 24 hours. FDG up-
take was tested through 30 minutes using a glucose free me-
dium and a tracer concentration of 37 kBq/mL. Nature of
supernatant radioactivity was analyzed by using thin layer
chromatography. G6Pase activity and expression were mea-
sured by spectrophotometric and Western blot techniques, re-
spectively. Results. In all experiments, MTF significantly in-
creased glucose consumption by more than 50%. However,
this response faced a consistent reduction in FDG uptake that
almost halved in both cell lines. Thin layer chromatography
ruled out any breakdown of 18F- from FDG. By contrast,
G6Pase activity was well represented in both CT26 and 4T1
cell lines. Enzyme affinity for G6P and 2DG6P were remark-
ably similar. However, MTF decreased G6Pase expression and
overall activity. Conclusion. These experiments represent the
first unexpected evidence of a significant G6Pase activity
within murine cell lines representative of colon and breast
carcinoma. This enzyme can process FDG6P and might con-
tribute to tracer release. The mismatch between glucose con-
sumption and tracer uptake toMTF strongly suggests the pres-
ence of a pathway downstream hexokinases sensitive to
biguanide whose FDG6P processing capability contributes to
ultimate tracer retention limiting tracer handling by G6Pase.
P237
Changes of glycolytic pathway and upregulation
of oxidative phosphorylation in BCR-ABL-driven human
leukemia cells treated with imatinib
M. Monti1, V. De Rosa2, F. Iommelli2, R. Fonti2, F. Pane1, S.
Del Vecchio3; 1Hematology Division, University of Naples
“Federico II”, Naples, ITALY, 2Institute of Biostructures and
Bioimages, National Research Council, Naples, ITALY, 3De-
partment of Advanced Biomedical Sciences, University of Na-
ples, Naples, ITALY.
Aim: Since many oncogenes including BCR-ABL may pro-
mote the acquisition of the glycolytic phenotype, we reasoned
that by inhibiting BCR-ABL signaling to which tumor cells
are addicted, may cause in addition to growth arrest and apo-
ptosis, an early metabolic switch from aerobic glycolysis to
mitochondrial oxidative phosphorylation. Imatinib is a potent
and selective inhibitor of several tyrosine kinases including
BRC-ABL and KIT and for this reason it is used for the first
line therapy of patients with chronic myeloid leukemia (CML)
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and gastro-intestinal stromal tumors. Here we investigated the
changes of glucose metabolism in BCR-ABL-driven human
leukemia cells treated with imatinib. Materials and methods:
BCR-ABL-driven K562 cells were incubated with increasing
concentrations of imatinib ranging between 0.01-10 μM for
48-72 h and subjected to toxicity and apoptosis assays to test
drug sensitivity. Then untreated and treated cells were lysed
and analyzed for levels of BCR-ABL signaling mediators and
key proteins of glycolytic cascade and oxidative phosphoryla-
tion. In particular levels of GLUT1, GLUT3, Hexokinase
(HK) I and II, Pyruvate Kinase (PK) M1 and M2 were deter-
mined before and after 48 h treatment with imatinib. Further-
more glucose consumption and levels of mitochondrial com-
plexes (I-V) subunits were tested. Results: as expected BCR-
ABL-driven K562 cells were highly sensitive to imatinib
showing an IC50 < 1 μM. Inhibition of BCR-ABL caused a
concomitant reduction of p-AKT, pSTAT3 and cyclin D1. Fur-
thermore a strong reduction of the phosporylated form
(Tyr105) of PKM2 was observed in response to imatinib treat-
ment whereas levels of HK1 and HK2 remained substantially
unchanged. Glucose consumption expressed as μg/106 cells
was reduced after treatment in a dose-dependent manner and
western blot analysis of whole cell lysates showed a strong
upregulation of all mitochondrial complexes subunits in treat-
ed cells as compared to untreated controls. Conclusion: Ima-
tinib treatment of BCR-ABL-driven human leukemia cells
causes an early reduction of glucose consumption through
the glycolytic cascade and an upregulation of mitocondrial
complexes indicating a possible switch from aerobic glycoly-
sis to mitochondrial oxidative phosphorylation.
P238
Glucose metabolism and lactate production in-vitro.
T. Bach-Gansmo1, T. V. Bogsrud1, T. A. Saga2, E. Munthe3;
1Oslo University Hospital, Oslo, NORWAY, 2Norwegian Cy-
clotron Center, Oslo, NORWAY, 3Oslo Cancer Cluster, OUS.,
Oslo, NORWAY.
Aim: Most cancer cells have a high glucose metabolism, the
basis of fluorodeoxyglucose (FDG) positron emission tomog-
raphy. The glucose metabolism is however, not primarily for
the production of energy, but a substantial proportion of glu-
cose is metabolized to pyruvate and transformed to lactate.
Lactate is then excreted into the cells microenvironment, pro-
ducing only 2 instead of potentially 32 ATPs if the pyruvate
was metabolized through the citric acid cycle. There are two
main hypothesis tenting to explain the high glucose consump-
tion. The first hypothesis claims that glucose, being readily
available, is a supply of carbon and small molecules for the
de-novo synthesis of new biomolecules. The second hypothe-
sis explains the high glucose metabolism as a mean for lactate
production. The secreted lactate reduces the pH in the local
microenvironment and hence give malignant cells, more apt to
thrive in acidic environments, a proliferative advantage. It is
also known that certain rapidly dividing fetal cells have a high
glucose metabolism. The aim of this in-vitro study was to
perform a comparison of the glucose metabolism and lactate
production in a highly malignant and a rapidly proliferative
non-malignant cell-line. Materials and methods: Cell cultures
of the human non-tumorigenic embryonic kidney cell line
293T and a triple negative breast cancer cell-line MDA-MB-
231 were incubated with FDG for one hour, washed, and the
FDG content in the cell was measured in a well counter. The
experiment was performed with various FDG concentrations,
with 0,5 x 10*6 and 10*6 cells in culture. Three parallels were
performed. Lactate, the end product of the anaerobe glycolysis
was measured in the supernatant. Results: The FDG uptake
was consistently higher in the fetal cell-line. The measure-
ments of lactate, Ph and glucose in the supernatant gave iden-
tical results for both cultures. Conclusion: Fetal cells can have
at least as high glucose uptake and lactate production as ma-
lignant cells. This is an argument for the high glucose con-
sumption being instrumental in retrieving intermediates for de-
novo biosynthesis in rapidly proliferation cells. If hypothesis
two is correct, why does a benign fetal cell-line acidifies its
micro environment?
P239
Papillary thyroid carcinoma tissues and clinical
significance of GRIM-19
Z. Zhao, G. Shen, H. Cai; West China Hospital of Sichuan
University, Chengdu, CHINA.
Aim: To investigate the expression and clinical significance of
apoptosis-related genes (GRIM-19) in papillary thyroid carci-
noma (PTC). Materials and methods: The expression of
GRIM-19 and STAT3 in 18 specimens of PTC with corre-
sponding adjacent normal lung tissues was examined by im-
munohistochemistry. In this study, immunohistochemical
staining of standard criteria: in tissue sections stained nucleus
or cytoplasm light yellow to brown as positive cells; each slice
select five horizons, counting 100 cells per field, the percent-
age of positive cells derived, according to a comprehensive
score and percentage of positive cells stained depth. In addi-
tion, the expression of GRIM-19 was measured by Western
blotting in 18 PTC tissues and corresponding nontumorous
tissues. Results: The immunohistochemical results show that
the expression of GRIM-19 protein in adjacent normal tissues
is mainly localized in the cytoplasm, brown particles; and
GRIM-19 protein expression in thyroid carcinoma localized
in the nucleus, a small amount in the cytoplasm. The positive
rate of GRIM-19 in the adjacent tissues was 89% (16/18), and
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that of tumor tissue was 44% (8/18), which indicated that there
was significant differences (P<0.05). GRIM-19 gene expres-
sion is closely correlated with the expression of STAT3 pro-
tein. GRIM-19 gene positive, STAT3 gene tends to negative;
on the contrary, GRIM-19 gene-negative, STAT3 gene tends to
be positive. The positive rate of GRIM-19 was significantly
related to the tumor stage, but not to age, gender, tumor size
and lymph node metastasis. In addition, western-blotting re-
sults also show that GRIM-19 protein expression in thyroid
carcinoma was significantly lower than that of normal tissues.
Conclusion: The decline in GRIM-19 expression is the process
of papillary thyroid cancer, which is an important event that
may occur and progress with papillary thyroid carcinoma.
P240
Assessment of tumor IGF1- and insulin receptor
expression and its linkage to anti-receptor treatment
response
M. H. Vendelbo, M. Busk, D. A. Bender, A. B. Iversen, N.
Jessen, J. Frøkiær, A. Morsing; Aarhus University Hospital,
Aarhus, DENMARK.
Background: Insulin-like Growth Factor-1 (IGF1)- and Insulin
receptors (IGF1R and IR) are increased in various cancers.
Receptor stimulation leads to enhanced glucose consumption
and protein synthesis and thus tumor growth through the Akt/
mTOR pathway. The IGF1R and IR inhibitor OSI906 has
shown promising results and is undergoing clinical
testing.Aim: We set out to investigate if IGF1R and IR inhibi-
tion is associated to decreased Akt/mTOR pathway activation,
glucose uptake and proliferation of cancer cells, and to devel-
op a PET detectable probe for IGF1R and IR based on chem-
ical modification of OSI906.Methods: OSI906 was used to
detect Insulin and IGF1 sensitive cancer cells. Effect of inhi-
bition was assessed with 18F-FDG uptake, measurements of
glycolysis, proliferation and site specific phosphorylations of
proteins in the Akt/mTOR pathway during receptor stimulated
and non-stimulated conditions. Furthermore, OSI-906 was
used as a precursor to produce [11C]-methyl-OSI906 and
b ind ing in t i s sue s amp l e s we r e a s s e s s ed w i t h
autoradiography.Results: Metabolic in vitro assays based on
18F-FDG and extracellular flux analysis revealed that both
insulin and IGF stimulated glucose uptake and lactic acid for-
mation in most cell lines. These changes were effectively
inhibited by OSI906. The most pronounced effect was detect-
ed in SW948 colon cancer cells. In accordance with metabolic
data, site specific phosphorylations in the Akt/mTOR pathway
could be stimulated by IGF1 and insulin in the SW948 cells.
Furthermore, Akt/mTOR pathway activation and proliferation
were effectively inhibited by OSI906 during receptor stimu-
lated and non-stimulated conditions. Non-radioactive methyl-
OSI906 (backbone for the PET tracer) was able to block re-
ceptor stimulation and OSI906 was able to block [11C]-meth-
y l -OSI906 b ind ing in SW948 xenogra f t t umor
tissue.Conclusions: Present results demonstrate that IGF1R
and IR inhibition reduce Akt/mTOR signaling, glycolysis,
proliferation and 18F-FDG uptake in SW948 colon cancer
cells. Furthermore, [11C]-methyl-OSI906 may detect cells re-
sponsive to IGF1R and IR inhibition, which could allow for
rational individualized therapy.
P241
Inverse correlation between hexokinase activity
and glucose-6-phosphatase activity in ovarian cancer
B. B. Olsen1, M. H. Vilstrup1, I. B. G. Johnsen2, G. Neu-
mann3, A. Alavi4, P. F. Høilund-Carlsen1; 1Odense University
Hospital, Dept. of Nuclear Medicine, Odense C, DENMARK,
2Odense University Hospital, Dept. of Clinical Pathology,
Odense C, DENMARK, 3Odense University Hospital, Dept.
Gynaecology and Obstetrics, Odense C, DENMARK, 4Uni-
versity of Pennsylvania, Dept. of Radiology, Philadelphia, PA,
UNITED STATES.
Aim: Increased glycolysis is considered a hallmark of rapidly
growing cancer cells (i.e., the Warburg effect) and 18F-fluoro-
deoxyglucose (18F-FDG) PET provides clinical evidence of
theWarburg effect in malignant tumours. The aim of this study
was to investigate the underlying biological mechanisms of
18F-FDG uptake on PET in ovarian cancer. Materials and
Methods: Fourteen patients aged 49 - 87 years (median 69
years) with ovarian cancer who had undergone an 18F-FDG-
PET/CT prior to surgery, and from whom fresh frozen tissue
was available, were included. The fresh frozen tumour tissue
was mechanically disrupted and the proteins were extracted.
The enzymatic activity of hexokinase was determined in a
colorimetric assay and the enzymatic activity of glucose-6-
phosphatase was determined in a spectrophotometric assay.
In addition the maximum standardized uptake value
(SUVmax) of 18F-FDG-PET was determined. Results: The
activity of hexokinase ranged from 1.57 - 14.5 μmoles min-
1mg-1 and the activity of glucose-6-phosphatase ranged from
0.07 - 0.59 μmoles min-1mg-1, whereas the SUVmax varied
between 1.9 and 43.9. There was a significant inverse correla-
tion between the activity of hexokinase and the activity of
glucose-6-phosphatase (Pearson’s r = -0.65; P = 0.01). How-
ever, no significant correlations were found between 18F-FDG
uptake and the activity of hexokinase (r = 0.39; P = 0.16) or the
activity of glucose-6-phosphatase (r = 0.20; P = 0.49). Con-
clusion: There was no significant correlation between 18F-
FDG uptake and the activity of either hexokinase or glucose-
6-phosphatase in ovarian cancer, which supports the notion
that 18F-FDG uptake, is complex and that no single step
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(phosphorylation or dephosphorylation) controls 18F-FDG
uptake. There was, however, a significant inverse correlation
between the activities of the two enzymes which warrant fur-
ther investigation.
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Production and characterization of chitosan-198Au
nanocomposite with high radionuclide purity: A
Comparative study on activity of gold-198 and its
nanoparticles
M. Aboudzadeh Rovais, M. Sadeghi, M. Sahafipour, F.
Bolouri; Nuclear Science and Technology Research Institute,
Tehran, IRAN, ISLAMIC REPUBLIC OF.
Aim: Gold-198 nanoparticles (198AuNPs) can be
engineered with precise size, shape, composition, surface
chemistry and radioactivity for clinical applications of
nuclear medicine. The overall objective of the current
research with respect to biomedical applications of nano
radioisotopes is to develop the method for production of
198AuNPs@chitosan using non- radioactive precursor.
Method: In the present work, chitosan-capped AuNPs
were prepared by exposing HAuCl4 to acidic chitosan
solution under appropriate conditions and then irradiated
in Tehran Research Reactor (TRR). The formation of
198Au@chitosan nanocomposites were characterized by
UV-vis absorption spectroscopy, FTIR spectroscopy,
gamma-ray spectroscopy, scanning electron microscopy
(SEM) and dynamic light scattering (DLS). The impact
of the reduction process of Au3+ to nanoparticulate Au0
on the activity of gold-198 was evaluated. Results and
discussion: The results showed that coating of gold with
chitosan can be lead to neutron scattering and decrement
of activity. The SEM photograph clearly indicated that
gold nanoparticles are spherical shape with an average
size ~61.7 nm. FTIR studies performed for controlling
of degradation effects in radiation processing of
AuNPs@chitosan showed the optimum neutron flux of
3×1012 n cm-2 s-1 for 30 min. 198AuNPs with high ra-
dionuclide purity produced using the epithermal neutron-
capture reaction, 197Au (n,γ) 198Au, are especially useful
for medical purposes. So in this study, the secondary
neutron-capture reaction reduced using a cadmium foil
(0.05 cm) as a thermal-neutron absorber. Key words:
Gold-198 nanoparticles; Chitosan; High radionuclide
purity
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Validation of solid phase extraction (SPE) coupled
with autoradiochromatography for 99mTc-MAG3
radiochemical purity determination and comparison
with traditional TLC
M.Di Franco1, S. Tamburri2, A. Filieri1, V. Podio2; 1Ospedale
San Luigi Gonzaga, Orbassano (TO), ITALY, 2Università
degli Studi, Torino, ITALY.
AIM 99mTc-MAG3 is the most used radiopharmaceutical for
nefro-urological studies. The two main analytical techniques
for Radiochemical Purity (RP) control are Thin Layer Chro-
matography (TLC) and Solid Phase Extraction (SPE); differ-
ent methods are suggested by Pharmacopoeia, technical data
sheets and literature. All SPE analysis are detected by dose
calibrator, often located in a high background area. We aimed
to validate SPE using autoradiochromatography, a modern de-
tection method for RP controls. We also compared the equiv-
alence between TLC and SPE (from US kit datasheet) for
analysis of MAG3 from various labeling procedures. MATE-
RIALS AND METHODS MAG3 (1.1 GBq/10 ml and 1.5
GBq/2.5 ml) RP was checked by ITLC-SG (acetonitrile/water
60/40 and ethylacetate/butanone 60/40) and SPE (C18 car-
tridges with HCl 0.001 M and ethanol/saline 50/50). SPE
was performed comparing wet and dried columns. Detection
was by autoradiochromatography and for SPE samples also by
gammacamera imaging (autoradiochromatography/
gammacamera equivalence for TLC had been previously dem-
onstrated). SPE samples volumes were 100 μl (standard), 75
and 50 μl. Statistical analysis was performed by Mann-
Whitney U test (one tail, non-parametric), analysis of variance
(one-way ANOVA test) and unpaired t-test with Welch’s cor-
rection. RESULTS Comparison between wet and dried col-
umns in SPE analysis evidenced higher repeatability of results
from dried columns (SD 0.74% vs 4.48% from wet columns);
SPE results were not influenced by detection method (p =
0.42); results from volume reduction (50 and 75 μl vs 100
μl) were scattered and did not show any trend. Wet columns
and SPE data obtained with lower volumes were excluded
from further analysis. TLC results were better than SPE data
(98.04% ± 0.80% vs 93.66% ± 5.51%, p < 0.0001) and not
influenced by labeling procedure. On the opposite, SPE anal-
ysis with Welch’s correction detected difference between re-
sults of RP from the two procedures: 97.32% ± 0.27% for the
lower radioactive concentration vs 92.39% ± 2.07% for the
higher concentration labeling (p < 0.05). CONCLUSIONS
SPE validation for 99mTc-MAG3 RP quality control has been
performed and dried column as well as 100 μl volume have
been confirmed as reference. Equivalence between
gammacamera and autoradiochromatography has been dem-
onstrated also for SPE analysis. TLC remains the reference
method for repeatability and time-saving procedure despite
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its unability to detect high molecular weight or lipophylic im-
purities except 99mTcO2. When such impurities are
suspected, SPE should be used. It is still unclear which chem-
ical factor(s) could determine low SPE repeatability (O2,
Sn2+,⋯).
P244
Production of 81Rb for the 81Rb/81mKr generator by Kr
gas tar
M. Aboudzadeh Rovais; Nuclear Science and Technology
Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.
Introduction: The 81Rb/81mKr generator is widely used in nu-
clear medicine. 81mKr(13sec) is an ideal tracer for the diagno-
sis of any chronic obstructive lung diseases because of its ease
of production, short-half life and single low-energy γ ray. In
this article, a selection of different reactions for production of
81Rb(4.6hr), theoretical and experimental production yield
through the excitation functions for natKr(p,xn)81Rb using
ALICE and TALYS computer codes as well as the production
method are presented. The essential target thickness was cal-
culated by SRIM computer code. Method: The aluminum tar-
get was designed in a semi conical shape. The length of the
target chamber was calculated to be 251mm with the volume
of 323cm3. It was equipped with an external water cooling
circuit. The gas target was pressurized with natural krypton
at 5 bars. The incident energy of the proton beam was
26.5MeV at the 20μA current for 1hr. The target gas was
quantitatively recovered using liquid nitrogen. A given
amount of vaporized water was abruptly transferred into the
target and 81Rb solution was quickly transferred to a reservoir
fromwhich dispensed into generator columns by an automated
dispenser. The 81Rb/81mKr column generator was filled with
AG 50W-X8 mesh (100-200) cation exchange resins as the
support for Rb. Results and discussion: The average of the
experimental yields of 81Rb over the optimum energy range
Ep=26.5→20.8 MeV was 245 MBq/μAh. The theoretical
yield of 81Rb was calculated to be 271 and 315 MBq/μAh
from TALYS and ALICE codes, respectively. There is rela-
tively large difference between the predicted of yield by
ALICE and experimental results. The calculated cross section
byALICE is total for 81Rb that is including the cross section of
81mRb and 81Rb. This is the main difference between of the
results obtained from this code and the experiments. Conclu-
sion: The reported production system for preparation of the
81Rb/81mKr generator showed a good reliability during the
irradiation. The ease of loading and unloading of the Kr gas
is the advantage of this system. If the 90% enriched 82Kr gas is
used as the target, the production yield could be enhanced by a
factor of about 4. Keywords: 81Rb, Production yield, Gas tar-
get, Simulation.
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Labelling procedure of autologous leukocytes
with 99mTc-HMPAO using Leukokit: Description of our
hospital experience
A. Kolindou1, M. Papachristou2, A. Velidaki1, A.
Evagellatou1, G. Bramis1, I. Datseris3, E. Kitsiou1; 1Nuclear
Medicine Department, GHA “LAIKO”, Athens, GREECE,
2Nuclear Medicine Department-PET/CT, GHA, Athens,
GREECE, 3Nuclear Medicine Department-PET/CT, GHA
“Evaggelismos”, Athens, GREECE.
Introduction: Scintigraphy with labelled autologous white
blood cells (WBC) is used to detect suspected sites of acute
inflammation or infection with or without localizing signs or
clinical symptoms. Radiolabelling of WBCs with 99mTc is
preferable over 111In due to its favourable physical character-
istics, availability, cost and lower radiation burden. Aim: De-
scription of labelling procedure of autologous leukocytes with
99mTc-HMPAO based on our hospital experience. Materials
and methods: Thirty labelling procedures were performed
based on the protocol of ISORBE(1). Leukokit provides all
components and reagents in a closed sterile environment. Pro-
cedure lasts 2 hours including quality control of the adminis-
trated cells and includes 5 phases: - Cell plasma preparation:
We collect 40 ml blood in a syringe with anticoagulant and we
set reagent through a closed sterile environment for red blood
cells sedimentation - We transfer WBC plasma into the sepa-
ration vessel via a close sterile connection -:For WBC purifi-
cation we centrifuge, aspirate supernatant and obtain a clean
WBC pellet maintaining the intact sterile environment - Cell
labelling for patient administration: resuspend pellet in PBS
and quantitate recovered cell avoiding any microbial and ra-
dioactive contamination. Scanning takes place 2h, 4h and 24h
after injection with whole body, planar and SPECT images.
Results: The WBC scan was conclusive to all patients and
helped detection as well as differential diagnosis between in-
fection and inflammation. Labelling efficiency of the radio-
pharmaceutical was 95% - 99% and yields of radiolabelled
leukocytes were 55%- 68%. The administrated dose ranged
between 4 - 7 mCi. Conclusion: Based on our experience
procedure of autologous leukocyte labelling using Leukokit
is easy, well defined and leads to correct clinical results.
P246
The experimental study of nano-colloidal
radiopharmaceuticals based on modified molecules
of DTPA labeled wih technetium
S. Sazonova1, V. S. Skuridin2, E. Stasuk3, N. V. Varlamova3,
Y. A. Nesterov3, A. S. Rogov3, V. L. Sadkin3, Y. Lishmanov1,
J. N. Ilushenkova1; 1Institute of Cardiology, Tomsk,
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RUSSIAN FEDERATION, 2Politechnikal University, Tomsk,
RUSSIAN FEDERATION, 3Polytechnic University, Tomsk,
RUSSIAN FEDERATION.
Medical applications of radioactive nano-colloidal materials
opens up opportunities for highly informative diagnostic tests
in nuclear medicine. In present study we tried to perform
radiolabeling of nano-colloidal substance with 99mTc by dis-
solving the dry residues of SnCl2 and DTPA in 99mTc solu-
tion. For this purpose preliminarily solutions of SnCl2 and
DTPAwere prepared separately and then evaporated. The col-
loidal solution of DTPAwas performed by the following way:
28 mg of DTPAwas transferred quantitatively into a volumet-
ric flask of 50 ml and dissolved in 20 ml of 5% NaHCO3
solution when heated to 800S. After this volume was adjusted
to the mark with the same solution (concentration 0.55 mg /
ml). The particles size was determined by the optical density of
the colloidal systemsm using a spectrophotometer Unico 2802
(S). The average radius of the particles was 93 nm. In order to
reduce the particle size up to 55 nm the suspension was heated
to 70 ° C and treated with the ultrasound for 40 minutes. To
prepare the feed solution of reducing agent 35 mg of Sn (II)
SnCl2 2H2O was dissolved in 100 l of 1 M HCl and the
solution volume was adjusted to 5 ml of distilled water (con-
centration 7 mg / ml). Subsequently the resulting solutions
were mixed in various proportions and evaporated. Dry resi-
dues were added to vials with 99mTc, mixed and
chromatographed. As mobile phases for chromatography we
used different mixtures: a) chloroform: methanol: water: acetic
acid (ice) = 4: 4: 0.1: 0.3 (the system number 1), the chroma-
tography time 20min; b) chloroform: methanol: ammonia = 5:
5: 1 (number 2 system), chromatography time 60 min; c) ace-
tone, chromatography time 10 min. The peak of for initial
99mTc solution in all solvent systems was Rf = 0.9. The same
is observed in the direct interaction of 99mTcwith DTPA (Rf =
0.9). indicating the absence of interaction of DTPA with
99mTc (VII). In contrast, when the 99mTc was mixed with
the reducing agent Sn (II) the main peak was Rf = 0.1, sug-
gesting the formation of reduced 99mTc complex with Sn. Not
be ruled out as a radionuclide chemisorption on the surface of
colloid produced by the hydrolysis of SnCl2 2H2O. The stain
of non labelled nano-colloidal substance at Rf = 0.5 was not
found. This work was supported by Federal Target Program
№ 1 4 . 6 0 4 . 2 1 . 0 0 7 1 ( p r o j e c t u n i q u e i d e n t i f i e r
№RFMEFI60414X0071).
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Preparation of 99mTc-TRODAT-1 with high specific
activity for dopamine transporter imaging of brain
M. Erfani, M. Shafiei; Radiation Application Research
School, Nuclear Science and Technology Research Institute
(NSTRI), P.O.Box: 14395-836, Tehran, IRAN, ISLAMICRE-
PUBLIC OF.
Introduction: In recent years, imaging of CNS dopamine trans-
porters using positron emission tomography (PET) and single-
photon emission tomography (SPECT) has been demonstrat-
ed. In spite of the promising results reported on PET and
SPECT imaging, both techniques employ radionuclides, 11C
and 123I, that are produced by a cyclotron. Recent success in
development of 99mTc-TRODAT-1 has opened up a new and
convenient road for studing DAT in the brain. Preparation of
99mTc-TRODAT-1 previously reported as a multistep method
in high temperature (120 °C) with low specific activity. To
meet the requirement for a widespread clinical application of
99mTc-TRODAT-1, it is highly desirable to develop a simpli-
fied formulation which could be labeled with high specific
activity in low temperature. The optimized formulation
(10 μg TRODAT-1, tricine, SnCl2, mannitol) was labeled with
radioactivity of 1850MBq of 99mTc in 95° C. Radiochemical
analysis involved ITLC and HPLCmethods. The stability was
checked in the presence of human serum at 37 °C up to 24 h.
Biological evaluation of radiolabeled ligand was performed in
rats. The radiochemical purity of >95% was obtained with the
specific activity of 64.3MBq/nmol. The stability of >95%was
found for labeled radiopharmaceutical formulation in aqueous
solution and serum even after a 24 h period. The results
showed high uptake in kidney, liver, muscle, skin, lung and
brain. The brain uptake was 0.51 ± 0.05% ID/g at 2 min and at
4 h after injection the ratio of ST/CBwas found to be 4.25. The
clinical investigation of this new formulation is under way.
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Validation of Multidose Protocol of 99mTc-HMPAO
to Label Autologous Leukocytes
T. Scotognella1, V. Lanni1, I. Salvatori2, M. Maussier1, A.
Giordano1; 1Policlinico A. Gemelli - Institute of Nuclear Med-
icine, Rome, ITALY, 2Catholic University of Sacred Heart,
Rome, ITALY.
Aim: 99mTc-hexamethylpropyleneamine oxime (99mTc-
HMPAO) is one of the most commonly used radiopharmaceu-
tical to label autologous leukocytes for evaluation of inflam-
mation and infection. The European Guidelines (Eur J Nucl
Med Mol Imaging (2010) 37:842-848) and some scientific
papers suggest to label a single kit of HMPAO with an higher
technetium-99m activity than the one reported in the radio-
pharmaceutical package insert. We aimed at validating a
multidose procedure using a single vial of HMPAO for leuko-
cytes labelling.Materials and methods: Our procedures are
based on papers dealing with high technetium-99m activity
for labelling a HMPAO kit (Eur J Nucl Med (1998) 25:797-
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S459
799; NuclMed and Biol 34 (2007) 933-938) and was validated
according to the European Guidelines, performing mediafill
tests. For each vial we checked the radiochemical purity
(%RCP) of 99mTc-HMPAO as quality control; three consec-
utive RCP tests were performed for each preparation immedi-
ately after the labelling and at 15, 30 and 45 minutes after
labelling. We subsequently evaluated the labelling efficiency
(LE) and cells viability by the Trypan blue exclusion test. In
addition, we measured technetium-99m cell efflux after 1
hour; three tests were performed for each preparation and ar-
ithmetic mean was calculated for every sample. Finally we
checked the sterility and the apyrogenicity of our labelling
product on three consecutive samples.Results: The results of
mediafill tests demonstrated complete sterility of labelling pro-
cedure. We tested 6 vials of 99mTc-HMPAO with twelve
blood samples from healthy volunteers. The radiochemical
purity of 99mTc-HMPAO always resulted higher than the min-
imum limit reported in the radiopharmaceutical package insert
(>80%). In the 91,7% of cases, the labelling efficiency was
within guidelines limits (40% < LE < 80%). Also cell viability,
assed by Trypan blue exclusion test, was within the regulatory
limits (<4% of dead cells). In the 83,3% of cases the measure-
ment of cell efflux of Tc-99m was within the accepted limits
(release of Tc-99m < 10%). Finally, the sterility test showed no
contamination from aerobic bacteria and mycetes; pyrogen
levels were lower than the limits allowed by current Italian
Pharmacopoeia (the endotoxin concentration limit is 175 EU/
ml, per injected ml per kg).Conclusions: We obtained accept-
able results by labelling two blood samples using a single
HMPAO vial, in accord to European Guidelines “Guidelines
for the labelling of leucocytes with 99mTc-HMPAO”; this
experimental protocol, allows to optimize the working time
of the operator and the costs, without reducing the efficiency
of labelling procedure.
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One step synthesis of a radioiodinated tumor-targeted
oligonucleotide and preliminary in vivo evaluation
in tumor xenografts
L. KANG; PEKING UNIVERSITY FIRST HOSPITAL,
BEIJING, CHINA.
Aim: Anti-miRNA oligonucleotide (AMO) has been used
most widely to inhibit miRNA for loss-of-function studies
and function as therapeutic agents. The application of iodine-
131 radiolabeled AMO is a potential novel approach to play
double therapeutic role by inhibiting the oncogenic miRNA at
molecular level, however it was rarely reported previously.
This study is to prepare a radioiodinated anti-microRNA oli-
gonucleotide by one step synthesis and evaluate its role in vivo
tumor xenografts. Materials and methods: A convenient
strategy for iodine labeled oligonucleotide was developed
without a bi-functional coupling agent here. A tyrosine was
conjugated to 3’ end of AMO via a C6 linker for labeling with
radionuclide iodine-131. AMO was labeled with 131I by the
chloramine-T method and different reaction condition was op-
timized. The radiolabeled product was verified by gel electro-
phoresis and measured its radioactive distribution. Its stability
in serum was evaluated by gel electrophoresis in vitro. In vivo
single photon emission computed tomography (SPECT) im-
aging of 131I-AMO was used to evaluate the distribution in
tumor xenografts. Results: Based on the solid-phase standard
Boc strategy to an amino-ON CPG method, AMO targeting
miR-21 was synthesized with the conjugation of tyrosine and
modification of 2’OMe and PS. It was purified by HPLC and
confirmed by MOLDI-TOF. The iodine labeled yield was as
high as 96%-98% within 2 min without heating. The iodine-
labeled product was shown only one peak in radioactive frac-
tions as expected. It was shown that the radioactive distribu-
tion of iodinated AMO located at exactly where the DNA band
was by gel electrophoresis. Furthermore, this radiolabeled
AMO presented high stability in fresh human serum during
24 h. After i.v. administration in mice, radioactivity concentra-
tion was found primary in abdomen where liver and kidneys
located. Tumors were clearly visualized, especially at 24 h.
Conclusions: 131I radiolabeled AMO can be prepared by
one step synthesis of tyrosine conjugation. Furthermore, it
provides a potential value in targeted imaging and dual therapy
in vivo.
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Remotely controlled solvent extraction of high purity
Tc-99m produced by conventional medical cyclotrons
P. Martini1,2, A. Boschi3, L. Uccelli3,4, M. Pasquali3, G.
Cicoria5, M. Marengo5, M. Giganti3, G. Di Domenico1, G.
Pupillo2, A. Taibi1, A. Duatti6, J. Esposito2; 1Department of
Physics and Earth Sciences, University of Ferrara, FERRA-
RA, ITALY, 2Legnaro Laboratories of the Italian National In-
stitute for Nuclear Physics (INFN), Legnaro (Padova), ITALY,
3Department of Morphology, Surgery and Experimental Med-
icine, University of Ferrara, FERRARA, ITALY, 4Nuclear
Medicine S. Anna Hospital, Ferrara, ITALY, 5Nuclear Medi-
cine S. Orsola Hospital, Bologna, ITALY, 6Department of
Chemical and Pharmaceutical Sciences, University of Ferrara,
FERRARA, ITALY.
Aim. Purpose of this work was to develop an automated mod-
ule for the extraction of high-purity Tc-99m from a Mo-100
enriched target irradiated by a proton beam in a conventional
medical cyclotron. The separation process was based on the
well-established selective affinity of the methyl-ethyl ketone
(MEK) solvent system for the pertechnetate ion. Materials
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and methods. Enriched (99.05%) Mo-100 metallic targets
were irradiated in a medical cyclotron and transferred into
the reactor vial of the automated module filled with 30% v/v
hydrogen peroxide and 6-N NaOH where it was dissolved
under a helium stream. Addition of MEK caused the selective
extraction of [99mTcO4]
- into the organic phase, which was
further purified by two successive passages through silica
and alumina columns. Finally, [99mTcO4]
- was collected from
the alumina columnwith saline. Radionuclidic and radiochem-
ical purity of the eluate were checked with γ-spectroscopy and
chromatography (TLC, HPLC), respectively. Residual MEK
was measured with gas-chromatography. Results. The overall
separation process lasted for approximately 60 minutes and
recovery of the initial activity from the target was 90.1 ±
2.5%. Radionuclidic purity of the final [99mTcO4]
- was in the
range 99.5 ± 0.2% at the end of chemical extraction. No sig-
nificant amount of MEK was detected in the purified Tc-99m
solution. Automation of the whole procedure was achieved
using a simple interface resulting from the simplicity of the
selected purification method. As a result, the automated mod-
ule has a particularly simple and adjustable structure that could
be easily adapted and further optimized through the introduc-
tion of single-use, consumable cassettes. Conclusions. As ex-
pected, the separation efficiency of the water/MEK solvent
system was excellent due to the well-known high affinity of
[99mTcO4]
- for this organic phase. Radionuclidic purity of the
final Tc-99m was approximately 99% and this value compares
well with that of generator-eluted Tc-99m, which was set at
99.99% by Pharmacopeia standards. In conclusion, the Tc-
99m obtained through cyclotron irradiation of highly enriched
Mo-100 metal, and purified using the automated module de-
scribed here, constitutes a valuable alternative to generator-
produced Tc-99m. In particular, it could provide a convenient
source of this important diagnostic radionuclide in the event of
a shortage of the conventional production route based on the
decay of fission Mo-99. Acknowledgement. This work was
carried out within the Techn-OSP program supported by the
Italian National Institute of Nuclear Physics (INFN).
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99mTc-Labeled Estradiol: Preparation and Preclinical
Evaluation as an Estrogen Receptor Probe
Y. Zhang, X. Xia, H. Feng, X. Lan; Union Hospital, Tongji
Medical College, Huazhong University of Science and Tech-
nology, Wuhan, CHINA.
Objective: Most breast cancers express estrogen receptors
(ERs). Noninvasive imaging of ER expression may be helpful
for therapy planning. We developed a new ER-binding probe,
9 9 m T c l a b e l e d e s t r a d i o l ( E D L ) w i t h
diethylenetriaminepentaacetic acid (DTPA) as a chelating
ligand, named it 99mTc-DTPA-EDL, and assessed its
targeting ability in vitro and in vivo. Methods: 3-aminoethyl
estradiol (EDL) was synthesized by two steps from estrone,
followed by 99mTc labeling. The labeling compound, 99mTc-
DTPA-EDL, was purified by Sep-Pak C-18 cartridge and the
labeling efficiency was calculated. Then, the radiochemical
purity was determined using instant thin-layer chromatogra-
phy. Western blotting and immunofluorescence staining were
used to detect the expression of ER in MCF-7 and MDA-MB-
231 breast cancer cells. Saturation binding and internalization
experiments were performed by incubating MCF-7 cells with
increasing concentrations of 99mTc-DTPA-EDL. Cell uptake,
efflux, and blocking assays were also performed. To test
99mTc-DTPA-EDL in vivo, nude mice bearing either MCF-
7- or MDA-MB-231-derived tumors were injected with
99mTc-DTPA-EDL, and subjected to single-photon emis-
sion-computed tomography (SPECT) imaging. Mice injected
with excess unlabeled DTPA-EDL were used as specific con-
trols. Ex vivo gamma-counting of dissected tissues from nor-
mal and tumor-bearing mice was used to evaluate the
biodistribution of 99mTc-DTPA-EDL. Results: The labeling
efficiency and radiochemical purity of 99mTc-DTPA-EDL
were 64.5 ± 5.8% and 98.3 ± 2.3% (n=3), respectively. West-
ern blotting and immunofluorescence staining confirmed that
ERs were expressed extensively by the MCF-7 cells, and less
extensively by MDA-MB-231 cells. 99mTc-DTPA-EDL
displayed high binding affinity with MCF-7 cells (Kd = 15.1
± 2.1 nM)with a > 45% specific rate of total cell uptake. SPECT
images and the results of the biodistribution study showed sig-
nificantly higher uptake of the tracer by MCF-7 tumors (6.06 ±
0.38 %ID/g) than by MDA-MB-231 tumors (1.57 ± 0.28 %ID/
g) (n=5). Pre-injection ofMCF-7 tumor-bearing nude mice with
excess unlabeled DTPA-EDL significantly reduced tumor up-
take of 99mTc-DTPA-EDL (2.24 ± 0.28% ID/g). These data
suggest that 99mTc-DTPA-EDL specifically targets ERs in tu-
mors. Conclusions: 99mTc-DTPA-EDL can be easily synthe-
sized with satisfactory labeling efficiency and stability. 99mTc-
DTPA-EDL specifically targeted estrogen receptors in vitro and
in vivo with favorable pharmacokinetics, which allows the ex-
pression of estrogen receptors to be assessed with SPECT im-
aging. This work was supported by the National Natural Sci-
ence Foundation of China (No. 30970853, 81071200),
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[111In]-DOTA-anti-MUC1 for SPECT applications,
the production and quality control
B. Alirezapour1, S. Abbas Abadi2, I. Kertesz3, J.
Mohammadnejad4 , A. Ja l i l i an1 , E . Maadi1 , M.
Hashemizadeh1, N. Soltani1, S. Moradkhani1; 1Department
of Radiopharmacutical, Nuclear Science and Technology In-
stitute, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Faculty of
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pharmacy, University of Debrecen, Debrecen, HUNGARY,
3Department of Nuclear Medicine, University of Debrecen,
Debrecen, HUNGARY, 4Department of Life Science Engi-
neering, Faculty of New Sciences & Technologies, University
of Tehran, Tehran, IRAN, ISLAMIC REPUBLIC OF.
Introduction: Radioimmunoscintigraphy (RIS) has attracted
considerable clinical application in tumor detection which
has greatly improves the survival rate. Underglycosylated
MUC1 antigen is one ofthe early hallmarks of tumor genesis
and is overexpressed in more than 80% of breast cancers.
PR81 is a new murine anti-MUC1 monoclonal antibody
(mAb). In this study, as the first step towards the use of this
antibody for imaging purposes, we have developed an efficient
indirect labeling method of PR81 with 111In (T1/2 = 67h, gam-
ma emitting major photo peak at 171 keV) through using
DOTA-NHS bifunctional chelator and performed preliminary
bio-distribution studies in rats. Methods: Anti-MUC1 was
conjugated with DOTA-NHS-ester (Macrocyclics), the aver-
age number of DOTA conjugated per mAb was calculated and
total concentration was determined by spectrophotometrically.
DOTA-Anti-MUC1 was labeled with 111In then Radiochem-
ical purity and immunoreactivity, internalization study by
MCF7 cell line and serum stability of 111In-DOTA-Anti-
MUC1 were determined. The biodistribution studies and
radioimmunoscintigraphy were performed in female BALB/c
mouse bearing breast carcinoma tumor (111In -DOTA-Anti-
MUC1 i.v.,100 μl, 25±5μgmAb , 12, 24, 48 and 72h). Result:
111In-DOTA-PR81 was prepared (RCP >95% ± 0.5, Specific
activity 4.6 ± 1.2 μCi/μg). Conjugation reaction of chelator
(50 molar excess ratio) to antibody resulted in a product with
the average number of chelators attached to a mAb (c/a) of 3.4
± 0.3. Labeling yield with 111In in 400 μg concentration of
bioconjugate was 94.8% ± 1.6. immunoreaction of 111In-
DOTA-PR81 complex towards MUC1 antigen was deter-
mined by RIA and the complex showed high immunoreactiv-
ity towards MUC1. In vitro and in vivo stability of
radioimmunoconjugate was investigated respectively in PBS
and blood serum by RTLCmethod. In vitro stability was more
than 93% ± 1.23 in PBS and 84% ± 1.33 in serum over 24 h.
The Immunoreactivity of the radiolabeled Anti-MUC1 to-
wards MCF7 cell line was done by using Lindmo assay pro-
tocol. Under these conditions, the immunoreactivity of the
radioimmunoconjugate was found to be 0.76. The
iodistribution of 111In-DOTA- Anti-MUC1 complex in the
mice with normal and breast tumor at 12, 24, 48 and 72 h after
intravenous administration, expressed as percentage of
injected dose per gram of tissue(%ID/g). Biodistribution and
imaging studies at 12, 24, 48 and 72 h post-injection revealed
the specific localization of complex at the site of tumors. Con-
clusion: 111In -DOTA-Anti-MUC1 is a potential compound
for molecular imaging of SPECT for diagnosis and follow up
of MUC1 expression in oncology.
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Myocardial perfusion in patients with severe
hypercholesterolemia
L.Martirosyan1,2, I. Sergienko3, A. Ansheles4, A. Popova5,
K. Ivanov3, V. Sergienko5; 1 Yaroslavl state medical Acade-
my, Moskou, RUSSIAN FEDERATION, 2Russian Cardiolo-
gy Research Complex., Russian Cardiology Research Com-
plex. Moscow, RUSSIAN FEDERATION, 3 Russian Cardiol-
ogy Research Complex., Russian Cardiology Research Com-
plex. Moscow, RUSSIAN FEDERATION, 4Russian Cardiol-
ogy Research Complex., Moskou, RUSSIAN FEDERATION,
5Russian Cardiology Research Complex., Russian Cardiology
Research Complex. Moscow, RUSSIAN FEDERATION.
Objective: To evaluate myocardial perfusion characteristics in
patients with severe hypercholesterolemia. Materials and
Methods: We included 26 patients with a total cholesterol
(CH) 7.5 mmol/l and LDL-CH ≥ 4.9 mmol/L, without coro-
nary artery disease. All patients, as well as 10 healthy volun-
teers were examined by myocardial 99mTc-MIBI SPECT
(protocol rest/stress with CT attenuation correction). In addi-
tion to the standard quantitative indicators of perfusion (rest,
stress, reversibility extents, SRS, SSS, SDS) we have intro-
duced two new parameters to assess the left ventricular perfu-
sion heterogeneity: severity sigma and heterogeneity sigma (σ
sev, σ het). σ sev and σ het calculated as standard deviations of
perfusion in each of the 17 segments relative to 100% (σ sev)
and relative to arithmetic mean (σ het).Results: Stress tests in
all cases were negative for myocardial ischemia. According
SPECT, there were no significant stability and/or reversible
perfusion defects in hypercholesterolemic patients. With a
qualitative assessment, inhomogeneous RFP was detected in
23 patients (88%). The difference between standard perfu-
sion indicators in hypercholesterolemia patients and
healthy volunteers were not found: Rest extent - 8.3
(5.0-11.0) and 8.0 (6.4-11.2), p = 0.67, Stress extent -
11.3 (6.5- 14.0) and 7.5 (6.5-12.5), p = 0.52, Reversibility
extent - 5.0 (2.5-8.0) and 3.5 (2.9-7.1), p = 0.85, SRS - 3.5
(2.0 - 5.5) 2,9 (0.75-6.0 ) p = 0.94, SSS - 7.3 (4.5-9.5),
and 6.5 (5.1-8.3), p = 0.87, SDS - 2.5 (2.0-6.0), and 4.0
(2.9-5.1), p = 0.42, respectively. At the same time in pa-
tients with hypercholesterolemia compared with healthy
volunteers σ sev and σ het were significantly higher: σ
sev - 22.6 (18.9-25.2) vs. 15.6 (15.5-21.4), respectively, p
= 0.04, at the rest study. At the stress study: σ sev - 22.3
(19.2-24.4) and 17.3 (16.7-18.6), respectively, p <0.01. σ
het - 7.8 (7.0-9.3) and 6.1 (5.2-7.2), p = 0.053 at the rest,
σ het - 7.9 (7.0-9.3) and 5.8 (5.5-6.8), p = 0.015 at the
stress. Conclusion: In patients with severe hypercholester-
olemia observed initial defects of perfusion. Our proposed
parameters can be useful for left ventricular perfusion het-
erogeneities assessment.
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Preparation of radionuclide labeled anti-microRNA-155
oligonucleotide and its role as a potential tumor imaging
probe in multiple tumor bearing mice
L. KANG; PEKING UNIVERSITY FIRST HOSPITAL,
BEIJING, CHINA.
Aim: MicroRNAs (miRNAs) have exhibited great potential for
diagnosing and treating diseases as a novel type of biomarkers
and therapeutic targets. MicroRNA-155 (miR-155) has been
proved to overexpress in various tumors and promotes tumor
growth and metastasis and considered as a biomarker of malig-
nant tumors. Specific binding and inhibition of miR-155 using
anti-miRNA antisense oligonucleotide (AAM) can be a potential
imaged and therapeutic strategy for tumors in which miR-155 is
overexpressed.Methods and results: 99mTc radiolabeled AAM
with partial 2’-OMe and PS chemical modification was prepared
via the conjugation to NHS-MAG3 for miR-155 targeted imag-
ing. The modified AAM was revealed highly stable against deg-
radation and radiolabeling in human serum. Western blotting re-
sults showed that the unconjugated, unlabeled and labeledAAMs
up-regulated the expression of C/EBPβ protein, one of target
proteins of miR-155, in tumor cells, proving a good ability in
the specific binding and inhibition. Furthermore, fluorescent pro-
tein labeled AAM displayed its ability of specific distribution in
tumor cells and a good stability in cellular level. After the system
administration of 99mTc-AAM, the distribution and in vivo im-
aging revealed the significant difference between AAM and
scramble control probe in multiple tumor xenograft models,
which suggested the specific binding and detective ability of
AAM in vivo. Conclusion: Therefore, this study supports the
effectiveness of the noninvasive imaging method by radiolabeled
AAMwith 99mTc to track the location ofmiR-155 in tumors and
suggests a prospective candidate for future tumor imaging.
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Influence of DOTA - Rituximab conjugates on their
biodistribution in mice
U. Karczmarczyk, W. Wojdowska, E. Laszuk, M. Maurin, P.
Garnuszek, R. Mikolajczak; Radioisotope Centre POLATOM,
National Centre for Nuclear Research, Otwock, POLAND.
Introduction: Rituximab, a chimeric mAb against human
CD20 antigen, which is expressed on B-cell lymphocyte and
on the majority of B-cell lymphoid malignancies, was selected
as model MoAb for inter-laboratory comparison under the
IAEACRP “Development and pre-clinical evaluations of ther-
apeutic radiopharmaceuticals based on 177Lu and 90Y la-
belled monoclonal antibodies and peptides”. Our results of
Rituximab conjugation with p-SCN-DOTA and evaluation of
90Y- and 177Lu labelled conjugates obtained from the freeze-
dried formulation were already described [1]. Herein we pres-
ent the comparative biological evaluation of 90Y- and 177Lu-
labelled DOTA-SCN and DOTA-NHS conjugated Rituximab
in normal and tumour-bearing mice. Materials and methods:
DOTA-SCN and DOTA-NHS (Macrocyclics) were conjugat-
ed to anti-CD20 antibody (Rituximab, MabThera) and the
conjugates were used in the freeze-dried kits for radiolabelling
[1]. The kits were labelled with 177LuCl3 (ca) and 90YCl3
(n.ca) after incubation at 37oC for 1 h and radiochemical pu-
rity (RCP) and stability were checked byHPLC and ITLC-SG.
Biodistribution of 177Lu- and 90Y-labelled DOTA(SCN)-Ri-
tuximab and DOTA(NHS)-Rituximab was evaluated in in nor-
mal Balb/c mice in order to determine tissue localization and
excretion route and in tumor-bearing (Raji s.c.) Rj:NMRI-
Foxn1nu/Foxn1nu mice. Groups of 3-4 mice were injected
i . v . ( t a i l v e i n ) w i t h 6 MBq ( 1 0 μ g ) o f t h e
radioimmunoconjugates, then sacrificed at 4, 24, 48 and 72 h
p o s t - i n j e c t i o n . R e s u l t s a n d Con c l u s i o n : A l l
radioimmunoconjugates were obtained with high
radiolabelling yield (RCP > 98%) and specific activity at the
level of 0.6 GBq/mg. The conjugates were stable in human
serum and in 0.9% NaCl, however, progressive aggregation
was observed with time, in particular for DOTA(SCN) conju-
gates. Both 177Lu- and 90Y-DOTA(SCN)-Rituximab re-
vealed slow blood clearance (for 177Lu ca. 29, 19 and 16
%ID/g; while for 90Y ca. 41, 23 and 16 %ID/g after 1, 24
and 72 h, respectively). The highest radioactivity uptake was
observed in the liver and spleen, confirming the hepatobiliary
excretion route. Generally, similar distribution pattern was ob-
served for 177Lu- and 90Y-DOTA(NHS)-Rituximab, with no
statistically significant differences in radioactivity uptake in
the respective tissues. For 177Lu-DOTA(SCN)-Rituximab
and 177Lu-DOTA(NHS)-Rituximab a progressive accumula-
tion of radioactivity in tumor tissue was observed (ca. 9 %ID/g
and 7 %ID/g after 72 h p.i., respectively), with high tumour to
muscle ratios (ca. 8-9) for both preparations. References: [1]
Wojdowska W., et al. Current Radiopharmaceuticals, 2015, 8.
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Synthesis and radiolabeling of HYNIC-conjugated
LIKKPF peptide with 18F-FDG for the detection
of apoptosis
D. Beiki1, S. Khoshbakht2, S. Shahhosseini3, F. Kobarfard3,
O. Sabzevari2, M. Amini4; 1Research Center for Nuclear
Medicine, Tehran University of Medical Sciences, Tehran,
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S463
IRAN, ISLAMIC REPUBLIC OF, 2Dpartment of
Radiopharmacy, School of Pharmacy, Tehran University of
Medical Sciences, Tehran, Iran, Tehran, IRAN, ISLAMICRE-
PUBLIC OF, 3Dpartment of Medicinal Chemistry, School of
Pharmacy, Shahid Beheshti University of Medical Sciences,
Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF,
4Dpartment of Medicinal Chemistry, School of Pharmacy,
Tehran University of Medical Sciences, Tehran, Iran, Tehran,
IRAN, ISLAMIC REPUBLIC OF.
Aim: Apoptosis, or programmed cell death, plays important
roles in the physiology and pathology of a variety of human
conditions including neurodegenerative diseases, ischemic
damage, autoimmune disorders and many types of cancer.
LIKKPF is a hexapeptide with high phosphatidylserine (PS)
binding affinity in order to visualize cell death. 18F-FDG has
so far been the most utilized radiotracer in positron emission
tomography (PET) imaging. We herein report the synthesis of
18F-FDG-LIKKPF as a tracer for the detection of
apoptosis.Materials and Methods: The peptide was synthe-
sized by standard Fmoc solid phase synthesis and the
HYNIC-conjugated LIKKPF was considered for the
radiolabeling procedure with 18F-FDG. In order to optimize
labeling efficiency, a series of studies including changing the
amount of HYNIC-peptide ligand, adjustment of the reaction
pH and vary ing the reac t ion tempera tu r e were
performed.Results: The radiochemical purity >50% was
achieved for the radiolabelling procedure with 18F-FDG, in
the presence of glucose (100-250 μg/mL). Also, stability stud-
ies in aqueous solution and human serum showed radiolabeled
complex with no significant release of F-18 or peptide degra-
dation up to 6 h.Conclusion: Our results showed the high
potential of 18F-FDG as 18F-fluorinated prosthetic group, to
be clinically accepted for the radiolabelling of peptides such as
LIKKPF for the detection of apoptosis.
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Combined targeting of somatostatin receptor subtypes 2
and 5 with a novel 68Ga-labelled somatostatin agonist
R. Mansi1, G. P. Nicolas1, K. A. Abid2, E. Grouzmann2, J.
Watson3, D. Wild1, M. Fani1; 1University of Basel Hospital,
Basel, SWITZERLAND, 2University Hospital of Lausanne,
Lausanne, SWITZERLAND, 3Somtheranostics, Epalinges,
SWITZERLAND.
Aim: Somatostatin receptor (SSTR) targeting, specifically of
subtype 2 (SSTR2), is an established method to image and
treat neuroendocrine tumors. The aim of our work is to devel-
op somatostatin analogs with affinity to more receptor sub-
types than SSTR2. These analogs will potentially target a
broader spectrum of tumors and/or increase the tumor uptake,
as several receptor subtypes may be concomitantly present.
We are presenting herein the development and preliminary
evaluation of the somatostatin analog G02113, having high
affinity for the subtypes 2 and 5 (SSTR2 and SSTR5), as
68Ga-PET imaging probe. Materials and methods: G02113
((4-amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-
Cys]-Thr-NH2) was coupled to the chelator DOTA at the N-
terminus and labeled with 68Ga. The peptide-chelator conju-
gates DOTA-TATE and DOTA-NOC were also synthetized as
reference compounds. The affinity of the three natGa-
complexes for the SSTR2 and SSTR5 was determined by re-
ceptor binding assay using 125I-SS14 as radioligand. Agonis-
tic potency of the compounds was assessed by cAMP assays.
The three conjugates were labeled with 67Ga and character-
ized in vitro using the HEK cell line stably transfected with
plasmids encoding the human SSTR2 and SSTR5 (HEK-
SSTR2 and HEK-SSTR5) and the naturally expressing SSTR2
cell line AR4-2J. Proof-of-concept PET/CT images with
68Ga-DOTA-G02113 were acquired in HEK-SSTR2 and
HEK-SSTR5 xenografts. Results: natGa-DOTA-G02113 ex-
hibited higher affinity for the SSTR2 and SSTR5 compared to
natGa-DOTA-NOC (IC50 = 0.32 vs 0.70 and 1.86 vs 3.38 nM,
respectively). natGa-DOTA-TATE had the highest affinity
among all three metallated conjugates for the SSTR2 (IC50 =
0.15 nM), however very low affinity for the SSTR5 (IC50 = 69
nM). The internalization rate of 67Ga-DOTA-G02113 was
similar to 67Ga-DOTA-NOC (12.4±1.6 vs 16.6±2.3, at 4h),
while their externalization rate was found in the same level
(40-50%within 4 h). The effect on forskolin-stimulated cAMP
accumulation using SS-14 as agonist control showed that
natGa- DOTA-G02113 had the same potency for SSTR2 as
the highest affinity compound natGa-DOTA-TATE (EC50 =
0.46 and 0.47 nM, respectively) and slightly better than
natGa-DOTA-NOC (EC50 = 0.59 nM). Preliminary imaging
studies illustrated the high uptake of 68Ga-DOTA-G02113 in
both, SSTR2- and SSTR5-expressing tumors in vivo, they in-
dicated renal excretion of the PET probe and they demonstrat-
ed an excellent tumor-to-background contrast. Conclusion:
The initial evaluation of the new somatostatin analog 68Ga-
DOTA-G02113 reveals its potential as PET probe for in vivo
imaging of a broad spectrum of somatostatin receptor express-
ing tumours, including SSTR2 and SSTR5. Financial support:
CTI Project Nr. 16403.2 PFLS-LS
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Adaptive self-assembling dendrimers for theranostics:
a proof of concept on angiogenesis
P. GARRIGUE, A. MOYON, X. LIU, C. LIU, P. ROCCHI,
L. PENG, D. TAIEB, B. GUILLET; Aix-Marseille Université,
Marseille, FRANCE.
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Nanoparticle-based drug delivery aims at specifically de-
livering therapeutic and/or diagnostic agents to the right
site at the right time, in order to improve the outcome
while reducing adverse effects. Many validated or experi-
mental therapeutic drugs simulate or inhibit angiogenesis
in cardiovascular or oncology applications: as companion
tools, agents enabling non-invasive angiogenesis evalua-
tion are an actual necessity. In this work, we introduced a
proof of concept of 68Ga-radiolabellable adaptive self-
assembling amphiphilic dendrimersomes for angiogenesis
imaging on a rodent hind limb ischemia model.An αvβ3-
integrin-targeting dendrimersome was designed, synthe-
sized and radiolabelled with indium-111 for validation.
The dendrimersome resulted from the self-assembly of 2
different dendrimer conjugates: one for imaging
([111In]In-NOTA conjugate, 92 MBq/100μg) and one for
specific targeting (C18-PEG-RGD conjugate) or aspecific
targeting (C18-PEG conjugate). 7 days after hind limb is-
c h em i a i nduc t i o n on Ba l b / c m i c e , l o ng t e rm
biodistribution studies were carried out by μSPECT/CT
imaging and a blood kinetic was performed: both early
dynamic planar acquisitions (T+0 to T+20’ post-IV injec-
tion of 5-10 MBq, 7.5s frames) and late multi-pinhole
SPECT/CT (T+120’, D+1 and D+2 or D+3 post-IV) were
performed using a Bioscan NanoSPECT/CTplus camera.
Autoradiography was also carried out on 3 other mice right
after the imaging on the day of the injection. Animal ex-
periments were carried out in accordance to Helsinki Dec-
laration and underwent the local preclinical ethics commit-
tee agreement.We reached a radiolabeling yield >95%. The
dendrimersomes were mainly eliminated through the uri-
nary system at an early stage, with a biological half-life of
24 minutes. Late T+120’ and D+1 SPECT/CT imaging
showed significant (P<0.05) higher uptake on the ischemic
site between the untargeted 111In-dendrimersomes (i/c
1.40±1.0% at the day of the injection, 2.59±0.07% one
day after) and the 111In-RGD-dendrimersomes (i/c 6.29
±0.6% at the day of the injection, 5.25±0.6% one day
after) (n=3/group). Autoradiography analysis of gastrocne-
mius sections showed a significant uptake of the 111In-
RGD-dendrimersomes in the ischemic hind limb (85573
± 8778 DLU/mm2, n=3) compared to the contralateral
hind limb (11462 ± 931 DLU/mm2, n=3) (P<0,01).Prelim-
inary results with these radiolabelled nanovectors showed
great promises in specific targeting to the site of interest.
Additionally, dendrimers have numerous side advantages:
high drug payload, stable formulation and controllable
structure. Therefore, if our results are further confirmed
on preclinical tumor models, these dendrimer-based
nanocarriers could constitute novel and effective means
for the delivery of radiopharmaceuticals and other biomed-
ical imaging agents or therapeutic medicines, with obvious
outlooks in theranostics.
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Radiolabeling of antibody for epitope of human carbonic
anhydrase IX (IgG M75) by 61Cu and 64Cu and its
biological testing
A. Čepa1,2,3, J. Ráliš2, A. Pavelka4, L. Marešová4, M.
Kleinová4, D. Seifert2, I. Sieglová5, V. Král5, M. Polášek2,
O. Lebeda2, M. Paurová6, M. Lázníček1; 1Faculty of Phar-
macy in Hradec Kralove, Charles University in Prague,
Hradec Králové, CZECH REPUBLIC, 2Nuclear Physics In-
stitute of the CAS, v. v. i.,Řež, CZECHREPUBLIC, 3Institute
for Clinical and Experimental Medicine, Prague, CZECH RE-
PUBLIC, 4ÚJV Řež a. s., Řež, CZECH REPUBLIC, 5Insti-
tute of Molecular Genetics of the CAS, v. v. i., Prague,
CZECH REPUBLIC, 6Faculty of Science, Charles University
in Prague, Prague, CZECH REPUBLIC.
Aim: The subject of the work was conjugating antibody IgG
M75 for epitope human carbonic anhydrase IX with non-
commercial new chelator denoted as “phospinate” specific
for copper isotopes. Human carbonic anhydrase IX is a mem-
brane enzyme that is significantly expressed in some types of
cancer cells. The antibody IgG M75 was successfully conju-
gated with phosphinate, the conjugation method was opti-
mized and is well-reproducible. The conjugate was then la-
beled with two positron emitting copper radioisotopes, 61Cu
(3.333 h) and 64Cu (12.701 h). Labeled conjugates were tested
in vivo in mice with colorectal cancer xenografts. Materials
and methods: Copper radioisotopes were produced via
natNi(d,x)61Cu and 64Ni(p,n)64Cu reactions (natNi,
99.999%, Goodfellow; 64Ni, 99.09%, Isoflex) on external
beams of the Cyclone 18/9 and U-120M cyclotrons. Specific
activity of 61Cu was 1 GBq/mg Cu and more, which was
satisfactory for labeling purposes. All reagents were analytical
grade that were purified prior labelling with chelex-100 in
sodium form, 100-200 mesh (Sigma-Aldrich, Germany) from
metals surplus. Chelator ,,phospinate“ was synthesized and
characterized in our laboratories. Antibody IgG M75 was pre-
pared by genetic engineering methods. Immunoconjugates
(IgG M75-SCN-phospinate) were separated with use of PD
10 Desalting Columns (GE Healthcare, UK) and analyzed
using size exclusion chromatography column BioSep SEC-
S-3000 (Phenomenex, USA). We compared positive cell line
for human carbonic-anhydrase IX human colorectal adenocar-
cinoma (HT-29) and negative mouse standard fibroblast (NIH/
3T3). Adult males of mice Nude Foxn1NU were used in the
experiment. Results: The conjugate M75-SCN-phosphinate
was labeled successfully with both 61Cu (96% yield) and
64Cu (97% yield). Specific activities of 61Cu-phosphinate-
IgG M75 and 64Cu-phosphinate-IgG M75 were 7.4 and 1.0
MBq/μg, respectively. Biodistribution experiments revealed
high uptake of both labelled compounds in tumour tissue:
61Cu-labeled conjugate showed uptake of about 10 % ID/g
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after 6 hours, while 64Cu-labeled about 24 % ID/g even after
48 hours. Conclusion: The labelling resulted in the product of
high specific activity (1.0 and 7.4 MBq/μg, respectively) and
of high radiochemical purity (>95%). The labelled molecule
has considerable potential as a radioimmunopharmaceutical
suitable for imaging of tumors expressing carbonic anhydrase
IX by positron emission tomography (PET). The study was
supported by the Charles University Grant Agency, project no.
1752314 and by the Technology Agency of the
Czech Republic, program Alfa, project no. TA02010797.
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Panitumumab Modified With Metal Chelating Polymers
(MCPs) For Dual Labeling With 111In and 177Lu
as a Potential Theranostic For Pancreatic Cancer
S. Aghevlian; University of Toronto, Toronto, ON,
CANADA.
Aim: Our objective was to develop a novel “theranostic” agent
that combines SPECT imaging of EGFR-positive pancreatic
cancer (PnCa) with radioimmunotherapy (RIT). In order to
maximize the specific activity to obtain a robust therapeutic
response and improve the sensitivity for imaging,
panitumumab (PmAb), a fully human anti-EGFR monoclonal
antibody was modified with novel hydrazino nicotinamide
metal chelating polymers (HyNic-MCP) that harbor 13 DOTA
chelators for high specific activity (SA) radiolabeling with
111In and 177Lu as well as 10 polyethyleneglycol (PEG)
groups to minimize liver and spleen uptake. 111In is a -
emitter [t1/2 = 2.8 days; Eγ=171, 245 keV] useful for SPECT
imaging and also emits subcellular range Auger electrons for
RIT of micrometastases. 177Lu is a -emitter [Eβ(max) =498,
385 and 176 keV] for RIT of millimeter-sized tumours, but
also emits -photons for imaging [Eγ=113,208 keV]. Methods:
PmAb was reacted with N-succinimidyl-4-formylbenzamide
(S-4FB) to install aldehyde groups for derivatization with
HyNic-MCP which forms a UV-measureable (354 nm) bis-
arylhydrazone bond. The reaction was terminated when on
average two MCPs were conjugated to PmAb. Purity and
MCP conjugation were confirmed by SDS-PAGE. PmAb-
HyNic-MCP was labeled with 111InCl3 or/and 177LuCl3 in
0.1M HEPES pH 5.5. For comparison, PmAb was modified
with 4.0 ± 0.2 DOTA and labeled with 111In and 177Lu.
Labeling efficiency was measured by ITLC-SG in 0.1M sodi-
um citrate. Stability was studied in the presence of a 500-fold
excess of EDTA for 1 h at 25 °C and in plasma at 37°C for 1
week by size-exclusion HPLC and ultrafiltration. EGFR bind-
ing affinity was assessed in a saturation binding assay using
EGFR-overexpressing MDA-MB-468 human breast cancer
cells. Results: The purity of PmAb-HyNic-MCP was >96%.
P mA b - H y N i c - M C P a n d P mA b - NH S - DO TA
immunoconjugates were labeled with 111In and/or 177Lu in
high labelling yield (>96%) and the maximum theoretical SA
was achieved in practice. Radioimmunoconjugates were stable
in plasma and to EDTA challenge. EGFR binding assays re-
vealed a dissociation constant (Kd) of 2.2 ± 0.6 nM for 177Lu-
PmAb-HyNic-MCP vs Kd of 1.0 ± 0.4 nM for 177Lu-PmAb-
NHS-DOTA. Conclusions: Novel PmAb-HyNic-MCP conju-
gates were constructed and labeled with 111In and/or 177Lu in
high labeling yield and high SA. 177Lu-PmAb-HyNic-MCP
exhibited preserved EGFR binding affinity. Studies are
planned to evaluate the biodistribution and imaging properties
of these theranostic agents in preclinical models of PnCa. Re-
search Support: This study was supported by a grant from the
Cancer Research Society.
P261
Ga-68 NODAGA RGD: A PET radiopharmaceutical
for integrin αvβ3imaging
R. Vatsa1, P. Bhusari2, S. Kumar1, G. Singh1, S.
Chakraborty3, A. Dash3, D. K. Dhawan2, J. Shukla1, B. R.
Mittal1; 1Postgraduate Institute of Medical Education & Re-
search, PGIMER, CHANDIGARH, INDIA, 2Panjab Univer-
sity, PU, CHANDIGARH, INDIA, 3Bhabha Atomic Research
Centre, BARC, Mumbai, INDIA.
AIM: Angiogenesis plays a key role in the growth and metas-
tases of solid tumors which is strongly regulated by integrin
αvβ3. Over expression of integrin αvβ3 is noted in various
carcinomas including lung, prostate and breast. Radiolabeled
RGD tripeptide can be used to image the over expression of
this integrin non-invasively. The aim of the present study was
to image αvβ3 over expression in breast and lung carcinoma
patients using in-house radiolabeled Ga-68 NODAGA-RGD.
Materials andMethod: Radiolabeling of NODAGA-RGDwas
optimized in-house using Ga-68. Radiolabeling was per-
formed at room temperature for 20 min and at 95°C for 5
min. Radiochemical yield was assessed by ITLC. Characteri-
zation of radiolabeled product was done by radio-HPLC and
MALDI-TOF mass spectrometry. Patients before any defini-
tive treatment (Chemotherapy/Surgery) were enrolled in the
study after obtaining clearance from institute ethics committee
and written informed consent from patients (breast n=40, lung
n=5). Whole body acquisition was done 45 min post intrave-
nous administration of 111MBq-185MBq of Ga-68-
NODAGA-RGD on a dedicated hybrid PET-CT scanner with
90 sec per bed position. Attenuation correction of the emission
images was done using CT. Results: The radiolabeling yield at
room temperature was 50-60%. However yield was more than
90% after 5 min heating at 95°C.radio-HPLC showed good
radiolabeling. Increase in molecular weight near the weight of
Ga-68 onMALDI-TOF reconfirmed attachment of Ga-68with
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NODAGA-RGD. The post purification radio-ITLC showed
>99% radiochemical purity. All the samples were found to
be sterile on sterility test with the endotoxins content <4 EU/
ml. The residual ethanol content was <2500ppm in all sam-
ples. Physiological uptake of radiotracer was seen in ventri-
cles, salivary glands, thyroid, liver and spleen with excretion
through the kidneys. Variable radiotracer uptake was with the
SUVmax ranging from 2.89 to 21.12 in breast carcinoma and
1.40 to 7.82 in lung carcinoma. Metastatic lesions were also
detected in patients.No adverse reactions were seen post ad-
ministration of the radiopharmaceutical. Conclusion:Ga-68 la-
beled NODAGA-RGD synthesis is quick with good radio-
chemical purity. Good tumor to background ratio was ob-
served in breast and lung carcinoma patients. Metastatic le-
sions were well visualized. The study indicated that Ga-68
labeled NODAGA-RGD have great potential for imaging
angiogenesis.
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Improving EGFR imaging by use of an anti-EGFRvIII
monoclonal antibody: characterizations in an in vivo
squamous cell carcinoma model
D. Spiegelberg1, A. C. Mortensen1, R. K. Selvaraju2, J.
Stenberg1, A. Scott3, M. Nestor1,4; 1Department of Immu-
nology, Genetics and Pathology, Uppsala University, Uppsala,
SWEDEN, 2Preclinical PET Platform, Uppsala, SWEDEN,
3Ludwig Institute for Cancer Research, Olivia Newton-John
Cancer Research Institute, and La Trobe University, Mel-
bourne, AUSTRALIA, 4Department of Surgical Sciences, Ac-
ademic hospital, Uppsala, SWEDEN.
Aim: Molecular imaging of biomarkers involved in cancer
progression is a valuable non-invasive tool of modern oncol-
ogy and nuclear medicine. The epidermal growth factor vari-
ant III (EGFRvIII) is a truncated mutant form of EGFR. It is
associated with enhanced tumourigenicity and increased
chemo- and radio-resistance, and is commonly overexpressed
in glioma cells. It may however also be a suitable target for
molecular imaging in several solid diseases such as squamous
cell carcinoma (SCC), despite the relatively sparse antigen
expression, due to the tumour specific expression pattern of
the antigen. For this purpose, a monoclonal antibody (mAb),
targeting an epitope of EGFR only accessible in tumours that
express EGFRvIII or with wild-type EGFR amplification, may
be a suitable tracer. This antibody has demonstrated reduced
binding and reduced toxicity to non-target tissues compared to
ordinary EGFR targeting drugs. The aim of this study was to
assess the feasibility of the use of 111In-labelled anti-
EGFRvIII mAb to obtain high SCC tumour contrast SPECT
images, even in tumour xenograft models displaying relatively
low amounts of the antigen. Materials and methods: The
antibody was labelled with 111In using the CHX-A”-DTPA
chelator to quantify antigen expression in vitro and to evaluate
tumour uptake in vivo. Radio-immunoassays and real time
binding assays combined with interaction analyses were per-
formed using 111In-mAb on SCC cancer cell lines with vary-
ing antigen expression. Mouse SCC xenografts using two
SCC cell lines with low but clear antigen expression were
imaged either with 111In-mAb806 (48 h p.i.), or with 18F-
FDG (30 min p.i.) using a small animal SPECT/CT or PET/
CT, respectively, followed by ex vivo biodistribution, autora-
diography and immunohistochemical analysis.Results and
conclusion: Binding studies revealed high affinity binding of
the antibody on antigen expressing cells with slow off rate.
Interaction map analysis demonstrated two binding interac-
tions, one high- and one low affinity. This may correspond to
the antibody binding to both EGFRvIII and wild-type EGFR
amplification epitopes on the cells, or to different conforma-
tional forms of wild-type EGFR. 111In-mAb clearly imaged
the SCC tumours, despite the low antigen expression, with
favourable biodistribution. High and homogeneous tumour
uptake was confirmed by autoradiography analysis. We con-
clude that 111In-mAb is a promising tracer for SCC tumour
imaging, also in low antigen expressing tumours.
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A neurotensin derivative with increasedmetabolic stability
labeled with 99mTc for tumors imaging
M. Erfani, M. Shafiei; Radiation Application Research
School, Nuclear Science and Technology Research Institute
(NSTRI), P.O.Box: 14395-836, Tehran, IRAN, ISLAMICRE-
PUBLIC OF.
Peptide receptors are overexpressed on various cancer cells
and illustrate interesting targets for tumour imaging and ther-
apy. Neurotensin (NT) receptors were overexpressed in a va-
riety of human tumors such as breast, pancreatic, prostate, lung
and colon. Based on this fact targeting the NT receptor with
optimized analogue of neurotensin is very important for imag-
ing of pancreatic, lung and colon tumors. In the present study,
we investigated a new neurotensin derivative with increased
metabolic stability also HYNIC chelator was conjugated to the
N-terminus of peptide which can be labeled with a more de-
sirable radionuclide such as 99mTc. Radioconjugate
99mTc-[HYNIC]-Neurotensin analogue was prepared and
quality control tests were down via ITLC and HPLC methods.
The receptor bound internalization rate was studied in
neurotensin receptor expressing HT-29 cells. Biodistribution
of radiconjugate was studied in C57 nude mice bearing HT-29
tumor cell. Radiochemical yield 90% was achieved, and a
very low amount of 99mTc-pertechnetate and 99mTc-
radiocolloid was observed. In RP-HPLC analysis we observed
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S467
a single peak which also confirms lack of any impurities.
Radioconjugate was stable up to a 24 h post labeling period
in the room temperature. Specific internalization (11.14 ±
1.76% up to 4 h) and metabolic stability in human serum up
to 24 h after labeling and incubation were observed. High
kidney uptake and accumulation in tissues like the intestines
(1.21 ± 0.07% at 1 h post injection) and HT-29 tumor (1.11 ±
0.05% at 1 h post injection) was observed. The tumor and
intestine accumulation and pharmacokinetic behavior such as
low tendency to accumulate in liver followed by its high kid-
ney excretion are the major advantages of this radioconjugate.
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68Ga(DO3A-lysine) as a New PET Tracer
for Biodistribution Study
C. YANG1, P. Chandrasekharan2, P. Padmanabhan1, J.
Carlstedt-Duke1, B. Gulyás1,3, C. Halldin4,3; 1Lee Kong
Chian School of Medicine, Nanyang Technological Universi-
ty, Singapore, SINGAPORE, 2Singapore Bioimaging Consor-
tium, Agency for Science Technology and Research, Singa-
pore, SINGAPORE, 3Karolinska Institutet, Department of
Clinical Neuroscience, S-171 76, Stockholm, SWEDEN,
4Nanyang Technologica l Univers i ty, Singapore ,
SINGAPORE.
Aim: A new ligand DO3A-lysine (DO3A conjugated with
lysine derivative, see Scheme 1) has been developed as a pro-
spective bimodal MRI/PET probe. Its Gd(III) chelate,
Gd(DO3A-lysine) has demonstrated to be a useful intravascu-
lar MRI contrast agent for tumor angiography (1-3). Now we
have showed that Ga-68 labeled 68Ga(DO3A-lysine) can be
used as a positron emission tomography (PET) probe for
biodistribution studies. Methods and materials: 68Ga(DO3A-
lysine) was prepared by reaction of 68GaCl3 in 0.05 N HCl
with DO3A-lysine in Hepes Buffer (pH = 4) at 95 °C for 15
mins. The product was purified by C-18 Sep-pak column to
remove unreacted 68Ga and characterized by radioHPLC, ra-
diochemical purity >90%, radiochemcal yield: 68% (not decay
corrected). The biodistribution characteristics of 68Ga(DO3A-
lysine) were conducted using SCIDmice bearing U87MG and
HT1080 xenografts tumors. Typically 1-2 MBq of
68Ga(DO3A-lysine) was administered as a bolus injection
via the tail vein. Blood was drawn by terminal cardiac punc-
ture procedure under anesthesia. Organs were excised from
euthanized animals and the radioactivity accumulated in each
organ was measured using a gamma counter. Results and
Discussion: Organ-to-muscle ratios for 68Ga(DO3A-lysine)
were 3.86, 2.24, and 6.4 for blood, tumor and kidney, respec-
tively, whereas for 68Ga(DOTA) they were 2.4, 2.12 and
23.67 for blood, tumor and kidney, respectively, after 30 mi-
nutes post injection. 68Ga(DO3A-lysine) demonstrated 1.6
times higher retention in blood and significantly lower accu-
mulation in the kidneys compared to its analog 68Ga(DOTA)
at 30 mins post-injection. However, 68Ga(DOTA) had a 3.7
fold increase in the kidneys compared to 68Ga(DO3A-lysine)
at 30 mins post-injection. Biodistribution data of
68Ga(DO3A-lysine) showed higher tumor uptake and longer
accumulation in the tumor and kidneys compared to that of
68Ga(DOTA). Conclusion: Biodistribution study of
68Ga(DO3A-lysine) in SCID mice bearing U87MG and
HT1080 xenografts tumors demonstrated high retention in
blood, high tumor uptake and low accumulation in the kid-
neys. These observations further support the desired properties
of Gd(DO3A-lysine) in MRI tumor angiography study. Refer-
ences: [1] Yang C-T, Bates RW, et al.ChemMedChem.2011, 6,
781. [2] Yang C-T, Chuang K-H, et al, Biomaterials, 2014, 35,
327. [3] Chandrasekharan P, Yang C-T, et al, Contrast Media
& Molecular Imaging. 2015, Accepted.
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A novel, specific PET-radiotracer for bacterial infections
S. M. Schneefeld1, J. Thackeray1, N. Murthy2, J. P.
Bankstahl1, F. M. Bengel1, G. Meyer1, T. L. Ross1; 1Medical
School Hannover, Hannover, GERMANY, 2University of
California, Berkeley, CA, UNITED STATES.
Aim: The differentiation between bacterial infections and
aseptic inflammation represents a great challenge in diagnos-
tics. The objective of this work was to develop a new specific
tracer for non-invasive PET imaging of bacterial infections.
Maltohexaose is the major energy source for bacteria, and its
cellular uptake is facilitated through the bacteria-specific
maltodextrin-transporter. Since mammalian cells show no ex-
pression of this transporter, it is particularly suitable as specific
target. Using optical imaging and a fluorescence labelled
maltohexaose derivative, this concept has already been proved
(1). Materials and Methods: An azido-maltohexaose was
linked via click-chemistry to the DOTA-chelator, followed
by labelling with 68Ga. The new radiotracer 68Ga-DOTA-
maltohexaose was evaluated in vitro with E. coli and in vivo
using healthy mice. The in vivo-biodistribution and pharma-
cokinetics were valued with μPET-CT and the metabolites
were analyzed in blood and urine. In in vitro-studies, the up-
take of the new radiotracer into bacterial cells was measured.
Results and Conclusions: Excellent radiochemical yields of
≥90% were obtained under labelling conditions of 100 °C,
10 min, and 1.5 M HEPES. A specific uptake of the new
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radiotracer into E. coli was found. The in vivo studies showed
a fast and exclusively renal clearance without any significant
unspecific background. After 50-60 min over 90 %ID/g was
found in the bladder. No radiometabolites were detected in
blood or urine during the first 20 min. The new 68Ga-
maltohexaose shows a perfect pharmacological profile for
the translation into human. The present data support further
exploration of the new radiotracer for specific in vivo targeting
of bacterial infections via PET imaging. References: (1) Ning
X, et al. (2011) Nat. Mater., 10, 602-7
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A Fully Automated Procedure for the GMP-Synthesis
of 68Ga-NODAGA-Exendin-4 Using a Cationic
Purification Method
G. M. Franssen, M. Brom, S. M. A. Willekens, P. Laverman,
C. M. van Rij, M. Gotthardt, O. C. Boerman; Radboud Uni-
versity Medical Center, Nijmegen, NETHERLANDS.
Aim: Our objective was to develop a safe, fast and reproduc-
ible method for the automated radiolabeling and purification
of 68Ga-exendin-4-NODAGA. The procedure should result in
a GMP-compliant, sterile and purified product with high yields
for clinical studies. Material and methods: The synthesis of
68Ga-NODAGA-exendin-4 was performed on a Scintomics
GRP module (Scintomics GmbH, Fürstenfeldbruck, Germa-
ny) connected to a GMP grade 68Ge/68Ga generator,
1850 MBq (IGG101, Eckert and Ziegler, Berlin, Germany).
Elution of the generator, concentration of the 68Ga eluate,
radiolabeling and purification of the 68Ga-NODAGA-
exendin-4 was performed using a modified Scintomics reagent
and hardware kit for synthesis of 68Ga-peptides using cationic
purification (ABX, Radeberg Germany). Briefly, the
68Ge/68Ga generator was eluted with 0.1 N HCl and 68Ga
was trapped on a preconditioned PS-H+ cartridge (Machery-
Nagel GmbH, Düren, Germany). The concentrated and puri-
fied 68Ga, eluted with 1.3 ml 5 M NaCl/0.1 N HCl was added
to 10μg of exendin-4-NODAGAwith 0.475 ml 2.5MHEPES
buffer, pH 7.0 and 50 μl 5.5 M ascorbic acid. The reaction
mixture was heated for 10 min at 95 °C. After cooling down,
2.0 ml 50 mM EDTA, 0.15% Tween80 was added and the
mixture was loaded onto an activated Oasis HLB Plus car-
tridge (Waters, Etten-Leur, The Netherlands). The purified
product was eluted with 2 ml 100% ethanol, diluted with
20ml PBS and subsequently filtered through a 0.22μmvented
filter unit into a closed sterile glass type I vial. Quality control
was performed by RP-HPLC, ITLC and pH determination.
68Ge breakthrough was checked by gamma spectroscopy. En-
dotoxin content was determined according to Ph Eur. using
Endo s a f e e qu i pmen t (Ch a r l e s R i v e r , L e i d e n ,
The Netherlands), sterility was assessed according to Ph Eur.
Results and conclusion: Sterile 68Ga-NODAGA-exendin-4
was obtained in reproducible amounts of 407 ± 19 MBq
(yields of 75%, decay corrected). Radiochemical purity was
≥ 95%, with 5% 68Ga colloid and < 2% unbound 68Ga. No
68Ge was detected by gamma spectroscopy after decay
(<0.001%). The pH was 7.0 ± 0.5 and endotoxin levels were
< 10 EU/mL. Total time of synthesis, including 68Ge/68Ga
generator elution, sterile filtration and formulation, was less
than 45 min. In conclusion, we developed a fully automated,
GMP-compliant method to produce 68Ga-NODAGA-
exendin-4 in a stable and reproducible manner with high yields
for clinical use.
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Chelator-free 89Zr-labeling of mesoporous silica
nanoparticles with superb in vivo radiostability
F. Chen, S. Goel, H. F. Valdovinos, S. Shi, T. E. Barnhart, W.
Cai; University of Wisconsin-Madison, MADISON, WI,
UNITED STATES.
Aim: To show that 89Zr (t1/2=78.4 h) can be labeled to meso-
porous silica nanoparticles (MSN) with superb in vivo stability
in a chelator-free manner. Materials and Methods: MSN with
controllable particle/pore sizes was synthesized as oxygen do-
nor for chelator-free 89Zr-labeling, via simple mixing of 89Zr-
oxalate withMSN at pH 7-8 for 2 h. Dense silica nanoparticles
(dSiO2) were also prepared as control. 89Zr-labeling yield of
MSN and dSiO2 was studied via radio-thin layer chromatog-
raphy (TLC). Serum stability of 89Zr-labeled samples was
studied at 37 °C for 48 h. In vivo long-term stability of 89Zr-
MSN and 89Zr-dSiO2 was studied by monitoring the dynamic
uptake change in both liver (native tropism of 89Zr-labeled
nanoparticles) and bone (detached 89Zr) with serial PET
scans. Biodistribution on Day 21 (~7 t1/2 of 89Zr) post-
injection (p.i.) was studied. Results: Detailed particle size,
morphology, and specific surface area characterizations con-
firmed successful synthesis of MSN and dSiO2. We observed
~70% of 89Zr-labeling to MSN at 75 °C in only 15 min, with
<30% yield for dSiO2. Labeling yield was temperature depen-
dent: higher yield at higher temperature. Serum stability test-
ing confirmed high stability (>95%) of both 89Zr-MSN and
89Zr-dSiO2 for 48 h. Surprisingly, in vivo PET scans showed
superb stability of 89Zr-MSN with <1 %ID/g of 89Zr in the
bone onDay 7 p.i., which remained low for 3 weeks. For 89Zr-
dSiO2, >10-fold higher bone uptake was observed on Day 7
p.i., indicating detachment of 89Zr from 89Zr-dSiO2 hence
lower stability of 89Zr on the outer surface of dSiO2. As ex-
pected, liver/spleen had high uptake of 89Zr-MSN, which
remained stable over 3 weeks. No obvious kidney/bladder
uptake of 89Zr-MSN was observed, confirming superb
in vivo stability of such chelator-free 89Zr-labeling of MSN.
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Conclusion: We report the first example of chelator-free 89Zr-
labeled MSN, with superb radiostability in vivo. With long t1/2
of 89Zr and high potential of MSN for molecular imaging and
drug delivery, this method offers a novel, simple, and accurate
way for future PET image-guided drug delivery.
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Synthesis and biological evaluation
of 68Ga-DOTA-capsaicin as a imaging agent for MCF-7
J. PARK1, S. LEE1, M. HUR1, S. YANG1, S. KIM2, K.
YU3; 1Korea Atomic Energy Research Institute, Jeongeup-
Si, KOREA, REPUBLIC OF, 2Dongguk University-
Gyeongju, Gyeong-ju, KOREA, REPUBLIC OF, 3Dongguk
university-Seoul, Seoul, KOREA, REPUBLIC OF.
Aim : Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide), a
significant pungent ingredient in a variety of red peppers of the
genus capsicum, is a type of vanilloid. It has been shown to
induce apoptosis in many cell types. Especially, capsaicin is
selective effect to binding with estrogen receptor.In this study,
[68Ga](t1/2=68min)-labeled capsaicin using DOTA (1,4,7,10 -
tetraazocyclododecane-N,N’,N”,N”’-tetraacetic acid) deriva-
tive was developed for the diagnosis of estrogen receptor over-
expression inMCF-7.Material and Methods : The DOTA-cap-
saicin, Chelated by 69Ga,was characterized by spectroscopic
analysis method and mass spectrometry. [68Ga3+] was eluted
from a 68Ge/68Ga generator by 0.1 N HCl and used directly
for the reaction after adjusting the pH 3. The labeling of
[68Ga3+](111Mbq) was performed in a 1M sodium acetate
buffer with DOTA-capsaicin(4μmol) and the mixture was
heated at 100°C for 10 min. The compound was purified by
RP-HPLC. To determine the lipophilicity of [68Ga]DOTA-
capsaicin was dissolved in a mixture of saline and 1-octanol
in the E.P tube. The cellular uptake of [68Ga]DOTA-capsaicin
was evaluated using MCF-7, SK-BR-3 and CT-26 cells. And
then, PET imaging radioactivity was measured inMCF-7 bear-
ing balb/c mice at 15 to 120 min.Results and Conclusions: The
products were obtained in >70% radiochemical yields with a
radiochemical purity of >98% as checked by radio-TLC. The
partition coefficient (logP) was measured as -2.32, which is an
indication of the hydrophilic nature of the agent.Cellular up-
take values of [68Ga]DOTA-capsaicin was MCF-7, SK-BR-3
and CT-26 cells over incubation periods of 15, 30, 60 and 120
min. (MCF-7 : 0.16% at 15 min, 0.93% at 30 min, 0.07% at
60 min and 0.14% at 120 min, SK-BR-3 : 0.03% at 15 min,
0.46% at 30 min, 0.02% at 60 min and 0.01% at 120 min,CT-
26 : 0.03% at 15 min, 0.46% at 30 min, 0.04% at 60 min and
0.04% at 120 min). PET imaging radioactivity was measured
in MCF-7 uptake at 30 min. In this study, we successfully
designed and synthesized a [68Ga]DOTA-capsaicin derivative
as a probe for the PET detection of MCF-7 cell, and this
compound was showed significant uptake in MCF-7. PET
imaging of measurement result the highest uptake was ob-
served at 30 min and rapid clearance occurred at 60minThese
results suggest that this [68Ga]DOTA-capsaicin could be a
potential MCF-7 targeted agent for PET imaging.
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Cation exchanged based post-processing of Ga-68
chloride: Comparison of three different SPE-cartridges
on their suitability to DOTA-NOC, NODAGA-RGDfk
and HBED-CC-PSMA.
V. Ladenbauer, J. Obermair, P. Lam, C. Artner; IASON
GmbH, Graz, AUSTRIA.
Aim: By cation-exchanged post-processing of Ga68-generator
eluate, Ga68-chloride can be concentrated and Ge68 impuri-
ties can be reduced. However, dependent on the used cation-
exchanger this process is influencing the incorporation of
Ga68 into its chelator in a negative way. The aim of this work
was to evaluate the effect of the cation-exchange cartridges
BondElut-SCX (Agilent); ChromafixPS-H+(S) (Macherey-
Nagel) and StrataX-C (Phenomenex) on the incorporation-
yield of the precursors DOTA-NOC; Nodaga-RGDfk and
HBED-CC-PSMA and to evaluate the Ge-68 separation.Ma-
terials and Methods: The Ga68-generator IGG100
(Eckert&Ziegler) was eluted with 5mL 0.1M HCL by use of
the Ga68-Elusynth (IASON). The activity was adsorbed on
the cation-exchange cartridges. Subsequently the cartridges
were eluted with a mixture of 5,0M NaCl in Water 5%
5.5 M HCL. With sodium-acetate, the pH of the reaction-
solution was adjusted to 3.6 for DOTA-NOC and Nodaga-
RGDfk and 4.0 for HBED-CC-PSMA. For labeling 25μg
DOTA-NOC; 25μg NODAGA-RGDfk and 5μg HBED-CC-
PSMAwere added. After a reaction time of 7 minutes at 95°C
the incorporation-yields were determined by means of iTLC.
The Ge68 separation was analyzed by gamma-spectrometry.
Results: Like described by Schultz, M.K. et al. 2012, the elu-
tion of the BondElut-SCX (Agilent) is characterized by a full
desorption within 0.5mL of the eluent and a Ge68 separation
of 90-95%. The incorporation-yield for HBED-CC-PSMA is
up to 60%, for NODAGA-RGDfk and DOTA-NOC up to
50%. Using 0.5 mL eluent on the Strata X-C, up to 90% of
Ga68 can be desorbed and 20-87% of Ge68 impurities can be
removed. The incorporation-yield is up to 50% for DOTA-
NOC, 60% for NODAGA-RGDfk and 45-95% for HBED-
CC-PSMA. An elution-rate of up to 90% can be achieved
using 1.5 mL of the eluent on the Chromafix PS-H+(S).
Ge68 impurities can be reduced by 95%. No Ga68 gets eluted
within the first 0.5 mL. This volume can be discarded if vol-
ume reduction is necessary. The incorporation-yield for
NODAGA-RGDfk is up to 30% for DOTA-NOC 40% and
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for HBED-CC-PSMA 50-80%. By increasing the precursor
amount of NODAGA-RGDfk and DOTA-NOC to 50 μg
yields >90% can be achieved with all cartridges. Also increas-
ing the precursor amount of HBED-CC-PSMA to 10 μg leads
to stable labeling-yields of >95%.Conclusion: Using fraction-
ated synthesis methods the brought in precursor last for quan-
titative incorporation-yields. However, labeling with cationic
post-processed Ga68-eluate requires more precursor for stable
incorporation. For Ge68 reduction the cation-exchange car-
tridges BondElut-SCX and Chromafix PS-H+(S) are suitable.
Like with fractionated methods high labeling-yields and high
chemical purity can be achieved.
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Synthesis of Gallium-HBED-CC-EDBE-Folate available
PET diagnosis agent against folate receptors
overexpressed in cancel cells
P. Choi1, J. Park2, D. Chang3, T. Kim2, S. Lee4, S. Kim1;
1Dongguk University, gyeongju, KOREA, REPUBLIC OF,
2Korea Atomic Energy Reaserch, Jeongeup, KOREA, RE-
PUBLIC OF, 3Sunchon Univerity, Sunchon, KOREA, RE-
PUBLIC OF, 4Daegu Gyeongbuk Institute of Science and
Technology, Daegu, KOREA, REPUBLIC OF.
Aim: Gallium-68 is well known positron emitting radiometal
produced easily in 68Ge/68Ga generator with a half-life of 68
min, hence suitable for PET diagnosis. Trivalent Ga3+ ion is
regarded as a hard acid so rapidly react with hard base donor
ligards such as macrocyclic ligands DOTA and NOTA. Bi-
functional acyclic chelate HBED-CC (N,N’-bis[2-hydroxy-
5-(carboxyethyl)benzyl] ethylenediamine-N,N’-diacetic acid)
was represented to have a high stability constant (pKf : 30) and
to enable to label rapidly with DOTA or NOTA in room tem-
perature for Ga3+ ion. Moreover, its other end can easily be
linked to the biological compound such as peptides, antibod-
ies, amino acids, and etc. In this research, we selected folic
acid as a biological material because of its high affinity with
folate receptors over-expressed in various cancel cells such as
ovarian, breast, colorectal, renal, nesopharyngeal, cervical.
Therefore we conjugated folic acid with HBED-CC attached
mini -PEG l ingker EDBE (2,2 ’ - (e thy lenedioxy) -
bis-(ethylamine)). Before labeled 68Ga in precursor, standard
compound of 69Ga-HBED-CC-EDBE-Folate was made for-
mation to identify 68Ga labeling conditions.Materials and
Methods: We synthesized standard compound 69Ga-HBED-
CC-EDBE-Folate. First, precursor was synthesized by organic
reactions that coupling reactions between HBED-CC and
Folic acid formed amide bond using HBTU. 69Ga chelating
in precursor was performed at room temperature, pH 4, RT 10
min. This complex was characterized by spectroscopic analy-
sis as well as liquid chromatographic analysis. The stability in
human serum and lipophilicity using PBS buffer and 1-octanol
were also measured.Results: Synthesis of precursor was con-
firmed through NMR, HR-MS, reverse-HPLC. Purification
was successfully performed by preparative-LC. Labeling pro-
cedure was completed within 10 min at room temperature, pH
4 for standard compound. This complex was near hydrophilic
and labeling yield, thermodynamic stability was above
90%.Conclusions: We have successfully synthesized 69Ga-
HBED-CC-EDBE-Folate and preparation and evaluation of
68Ga-HBED-CC-EDBE is under progress using tumor
cells.Keywords : Ga-68, HBED-CC, folate receptor, Folic acid
conjugate
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Preparation of 68Ga-DOTA peptides in a fully automated
system using two generators sequentially connected
I. Vaccaro1, F. Giurgola1, S. Grugni1, G. Tarullo1, K.
Marzo1, A. Chiti2; 1IRCCS Istituto Clinico Humanitas,
Rozzano, ITALY, 2Humanitas University, Rozzano, ITALY.
AIM: The aim of this study was to develop a fully automated
method to produce 68Ga-DOTA-peptides with a single elution
from two different generators, sequentially connected. This
technique was supposed to increase the starting activity as well
as the final product of the synthesis. MATERIAL AND
METHODS: The fully automated synthesis of 68-Gallium
DOTA-peptides, made with the ModularLab™ (Eckert
Ziegler, Berlin, D) requires two 68Ge/68Ga generators loaded
with 1850 MBq of Germanium-68 at calibration date. 68Ge is
adsorbed over a TiO2 resin and 68GaCl3 eluted with 0.1 N
HCl. For the elution of the two generators connected in series,
we tested an alternative fractionated technique. This method
allows collecting the total activity from both generators, but
increases the volume of the eluate up to 12 ml. The rather large
volume of the eluate requires a pre-concentration of the activ-
ity to label the peptides, so we modified the standard elution
doubling the fractioning process. This ensures to collect the
total activity in 6 ml, compatible volume for the synthesis.
After buffering with sodium acetate, the eluate is used directly
for the radiolabeling of the DOTA-peptides. Reaction param-
eters such as buffer conditions, pH range, reaction tempera-
ture, time and volume of reaction solution were optimized for
DOTATOC labeling. Reaction yields, pH, radiochemical puri-
ty, sterility, endotoxins, breakthrough of 68Ge and final 68Ge
content were determined. RESULTS: Connecting a new gen-
erator loaded with 1850 MBq of Germanium-68 and a gener-
ator used for six months (about after 300 elution), we elute
approximately 1200+/-70 MBq from the first one and 740+/-
40 MBq of 68GaCl3 from the second one. Therefore, the
starting activity for the synthesis was 60% more we get from
a single generator. The new method allowed to produce about
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1280+/-70 MBq of 68Ga-DOTA-TOC instead of 780+/-
40 MBq obtained with a new single generator, before the
modification. CONCLUSION:We demonstrated that after
about 600 elutions the metallic impurities and 68Ge levels
were in line with Ph.Eur. dossier requirements. This method
allows to delay the disposal of generator extending its clinical
use until one year. This double fractionated method does not
contemplate a pre-purification, therefore acetone and SPE
based approaches are not required. Moreover the new method
guarantees high peptide bound percentage (>99%) and high
specific activity.
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Good manufacturing practice in using an automatic
module of synthesis for 68Ga-labeled molecules
S. Migliari1, G. Serreli2, O. Ortenzia2, J. Ŝimeĉek3, C.
Cidda1, G. Baldari1, M. Scarlattei1, C. Ghetti2, L. Ruffini1;
1Nuclear Medicine and Molecular Imaging Department, Uni-
versity Hospital of Parma, Parma, ITALY, 2Medical Physics
Unit, University Hospital of Parma, Parma, ITALY,
3Scintomics GmbH, Fürstenfeldbruck, Germany,
Fürstenfeldbruck, Germany, GERMANY.
Generator-produced 68Ga for radiolabelling peptides used in
PET applications have gained much attention due to favorable
imaging characteristics. A lot of semi-automated systems con-
nected with 68Ge/68Ga generator were born for practical rou-
tine preparation of 68Ga-radiopharmaceuticals.Moreover at-
tention has been dedicated to the influence of metal contami-
nants in the 68GaCl3 eluate, water, buffers and hydrochloric
acid that aretypical components of a labelling procedure. Be-
sides the inevitable contaminant Zn2+, the 68Ga3+ decay
product, the metals frommatrix materials (SnIV, TiIV), Fe3+,
Al3+ and Cu2+are found in the eluate. Each of them is a
competitor for 68Ga3+ in binding to a chelator, especially
Fe3+.Our goal was to reach and validate a method to increase
the radiochemical purity (RCP) and yield of the 68Ga-
DOTATOC synthesis.An automated radiopharmaceutical syn-
thesis device (SCINTOMICS GRP®) was installed in our
radiopharmacy on November 2014.A TiO2-based generator
was eluted with 0.1M HCl and the 68GaCl3 purified using a
cationic exchanger. DOTATOC could be labeled in almost
quantitative yield by heating 13 nmol peptide for 10 minutes
in 1.5M HEPES buffer solution and then purified with
reversed-phase cartridge. RCP was measured by instant thin-
layer chromatography and high-performance liquid chroma-
tography (HPLC Ultimate 3000 Thermofisher), according to
Ph. Eur. We also evaluated the reaction yield, pH, sterility,
endotoxins and breakthrough of Ge-68.We collected the
RCP and decay corrected yields of the synthesis from Decem-
ber 2014 to March 2015 (18 synthesis).The first synthesis (S1)
a f te r the f i r s t e lu t ion in the week (E0) showed
a61.57%±0.08yield with a RCP of 98.77%±0.01. The synthe-
sis (S2), on the second day with a second elution (E1)yield was
68.81%±0.05 and RCP 99.04%±0.01. The third synthesis (S3)
after third elution (E3) showed a yield of 73.38%±0.05 and
RCP 99.10%±0.01.We measured the peaks related to second-
ary metal impurities complexes for each synthesis: 1.33%±0.6
for S1, 0.97%±0.6 for S2 and 0.82%±0.12 for S3.Our study
showed a progressive increase of RCP and reaction yield re-
lated to continuous generator use, due to a decreasing amount
of metal contaminants in the eluate: they compete strongly
with Ga3+ to coniugate the DOTAby forming secondary com-
plexes. Therefore it’s a good practice toeluate every day
68Ga/68Ge generator to obtain an eluate poor of metal impu-
rities and to have better results of RCP and reaction yields.The
use of an automated module allows a simple and efficient
preparation of 68Ga-DOTA-derivatized peptides for clinical
practice.
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Evaluation of Zr-89 oxalate as a PET Tracer
for Inflammation, Tumor and Rheumatoid Arthritis
Model
J. Park, Y. Lee, J. Lee, R. Yoo, U. Shin, K. Lee, B. Kim, K.
Kim, G. Ahn, J. Kim; Korea Institute of Radiological &Med-
ical Sciences, Seoul, KOREA, REPUBLIC OF.
Purpose The aim of this study was to evaluate inflammation
and tumor imaging with Zr-89 oxalate in comparison with
[F-18]FDG and [F-18]NaF.Methods Human brain glioblasto-
ma xenografts and turpentine oil-induced inflammation were
inoculated in the same mouse. Cell uptake examination to
mouse macrophage cell line RAW 264.7 and human brain
glioblastoma cell line U87MG with Zr-89 oxalate,
[F -18 ]FDG and [F-18]NaF were accompl i shed .
Biodistribution, macro PET imaging, autoradiography and his-
tological analysis of Zr-89 oxalate, [F-18]FDG and [F-18]NaF
were performed. Results Zr-89 oxalate exhibit remarkably
higher uptake macrophage cell than tumor cell. The inflamma-
tory lesions and tumor were clearly visualized by Zr-89 oxa-
late and autoradiography. Compared with [F-18]FDG and
[F-18]NaF, Zr-89 oxalate has high selectivity index to tumor
at the early time after injection and to inflammation at the
delay time (24 h p.i.). Large number of macrophage and neu-
trophils were found in the highest Zr-89 oxalate uptake tumor
lesion demonstrating by histological examination. In the RA
mouse model, Zr-89 oxalate clearly revealed high accumula-
tion in the inflammatory lesion. Conclusions The Zr-89 oxa-
late provide a new strategy for monitor not only tumor imaging
but also inflammation process.
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Correct Procedures for the synthesis of Ga68
radiopharmaceuticals.
I. Baldazzi, Sr., G. Franchi, F. Trapasso, S. Tetti, M. Martini,
C. Del Mastro, P. Ragni, A. Lenza, F. Scopinaro; Az. Osp.
Sant’ Andrea, Roma, ITALY.
Bkg: The availability of 68Ge/68Ga generators provid-
ed with regular EMEA authorization enables the rou-
tine use of 68Ga- radiopharmaceuticals. Aim: To ex-
plain the actions for producing 68Ga- DOTA Peptides,
e.g. 68Ga- DOTA NOC, the most used 68Ga- radio-
pharmaceutical for the study of neuroendocrine tu-
mours. Material and Methods: As for every β+ ra-
diopharmaceutical, for the correct synthesis of Ga68-
Dotanoc we need a Category A, laminar flux hot cell.
The dedicated synthesis device is located inside the
hot cell. The synthesis module has to be cleaned be-
fore and after the synthesis of the radiopharmaceutical.
The module is connected to the 68Ge/68Ga generator
and to an Argon gas bottle for the activation of all the
pneumatic process inside the device .A flux of 0.1N
HCl, elutes the 68Ga from the generator; as happens
in every elution, only the high specific activity part,
that is the central part of the eluate, is used for the
labelling process. Even if the process is automated,
the technician has to pay attention to the selection of
the peack eluate with high specific activity. Ethanol
(EtOH), water for injection and saline are needed for
the successive, labelling phase. The fraction of max
activity is sent to the reaction cell, where pH, temper-
ature and reaction time have to be regulated and opti-
mized. After labelling the radiopharmaceutical can be
purified by sterile, inverse phase tC18 column and
EOTH. After the production of the tracer, the qualitity
control is performed by ITLC and the Ga68- Dotanoc
can be injected to patients. Sterility is continuosly
monitored, so that it is possible to use the results of
the preceeding sinthesis performed 24-48 h before.
Results: The best results we obtained are: 99% label-
ling yield for DOTA NOC, with 60% of the initial
activity in the final vial. The above results have been
obtained after having set the following parameters for
the reaction cell: pH 4.5, temp 95°, reaction time 7.5
min, 1.2 ml peack eluate fraction. It was possible to
standardize the process by saving steps and parameters
in the memory of the dedicated PC that serves the
synthesis module. Conclusion: The Technician, thanks
to standardization of the procedures, can safely per-
form the process of synthesis of Ga68- Dotanoc, to
standardize the process and register it on manual ap-
proved by hospital ethic committee.
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68Ga-based radiopharmaceutical preparation using NaCl
method: collected results and preliminary data on ethanol
influence in labelling performances
M. Riondato, O. Ferrando, M. Gaeta, F. Montagnani, A.
Ciarmiello; S. Andrea Hospital, La Spezia, ITALY.
Gallium-68 labelled peptides have been extensively used in
the last decade for PET imaging as a tool to diagnose neuro-
endocrine tumours. More recently 68Ga PSMA-HBED-CC
has gained increasing attention as a radiopharmaceutical for
the detection of prostate cancer lesions. For meeting clinical
and research needs several labelling strategies have been de-
veloped and applied to routine productions. Our facility has
been recently implemented with an automated synthesizer for
the production of Gallium-68 labelled peptides based on the
“NaCl method”. This work aims to present our experience
with the production of some popular radiopharmaceutical for
clinical use, 68Ga-DOTATOC -DOTANOC and -PSMA-
HBED-CC, introducing the observed benefits by increasing
ethanolcontent in the labelling reaction.DOTATOC,
DOTANOC, PSMA-HBED-CC were labelled using a
Modular-Lab PharmTracer module coupled with a 30 mCi
68Ge/68Ga IGG100 IPL generator (E&Z Europe). According
to the NaCl method, generator eluate was first processed by the
use of a SCX cartridge, facilitating activity concentration and
germanium breakthrough removal. Gallium-68 was eluted
with 0.5 mL (NaCl 5M plus HCl) and reacted with the precur-
sor (45 microg for DOTATOC/DOTANOC or 10 microg of
HBED-CC) in a buffered sodium acetate solution (95°C,5
min). Crude product was then processed by Sep Pak purifica-
tion (C18) and the desired product was recovered from the
cartridge using Ethanol/Water. The final product was ready
for clinical use after dilution with saline. The original 68Ga-
DOTANOC preparation protocol was sub sequentially modi-
fied increasing the ethanol content in the labelling mixture
from 10% up to 50% v/v (ethanol/water). Yields were moni-
tored in order to reduce the amount of needed precursor.68Ga-
radiopharmaceuticals were produced following the standard
protocols in 16 min with high yields (Ys) and radiochemical
purity (RCP). 68Ga-DOTATOC (Ys dc=82.1%±4.4%,
RCP=99.1%±0.7%, n=42), 68Ga-DOTANOC (Ys dc=85.1%
±3.5%, RCP=99.4% ±0.5%, n=10) and 68Ga-PSMA-HBED-
CC (Ys dc=83.2% ±3.5%, RCP=95.1% ±1.3%, n=5). The best
results for 68Ga-DOTANOC preparation with the modified
protocol were obtained usinga labelling mixture of ethanol
40% (v/v): the required amount of precursor was 10 microg
(7 nmol), ensuring high yield reproducibility (Ys
dc=85.2%±2.3%, n=3) and enhancing the Specific RadioAc-
tivity up to 80 MBq/nmol.In conclusion we confirm that
“NaCl method” is robust, reliable and suited for routine auto-
mated synthesis of the most used 68Ga-radiopharmaceuticals.
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Furthermore the use of ethanol for 68Ga-DOTANOC prepara-
tion displayed a favourable role in reducing the precursor
amount maintaining reliable yields and allowing to reach
higher SRAwith respect the standard applied protocol.
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Synthesis and Evaluation of Novel [Cu-64] Labeled
Dimeric c(RGD-ACH-K) Conjugates for Tumor PET
Imaging
K. Lee, J. Park, J. Lee, U. Shin, G. An, S. Lim, B. Kim, J.
Kim; Korea Institute of Radiological and Medical Sciences,
Seoul, KOREA, REPUBLIC OF.
Object: In a recent reports on the application of dimeric RGD
peptides for detecting of angiogenesis and targeting of tumors
have demonstrated that the dimeric RGD peptides is better
targeting capability in vivo and enhanced receptor-binding af-
finity in vitro because of the increased αvβ3 integrin recogni-
tion ability as compared with the monomeric cyclic RGD pep-
tide[1, 2]. The purpose of our study, thus, is to design and
synthesis a noble 64Cu-labeled dimeric cyclic RGD Peptide
conjugates for an efficient tumor imaging, with its evaluation
in vitro and in vivo. Methods: The two derivatives of novel
DOTA (or NOTA)-cyclic RGD-ACH-K dimer are prepared by
solid-phase peptide synthesis as shown in the scheme below,
applied by previously our researches [3]. After 64Cu-labeling
of two conjugates, it is confirmed through Radio-TLC scanner
and HPLC system. The radiochemical stability and PET im-
aging of these conjugates is evaluated in serum and tumor-
bearing mouse for 48 h. Result: The radiochemical stability
of above two conjugates was very stable over 98% for 48 h by
the analysis of radio-TLC method and HPLC system, and was
showed the PET tumor-imaging in mouse. Conclusion: We
introduced two novel conjugates of 64Cu-labeled cyclic
RGD peptides for PET diagnosis and therapy in tumor, having
the highly radiochemical stability in serum and a specific
tumor-uptake in vivo. Acknowledgements: This research was
supported from National Reaserch foundation of Korea(NRF)
grant funded by the Korean government(MEST) (2011-
0030161, 2011-0030162) References: [1] Yun Wu, et al
(2005) J Nucl Med, 46, 1707-1718. [2] Zi-Bo Li, et al
(2008) Eur J Nucl Med Mol Imaging, 35, 1100-1108. [3] Ji-
Ae Park, et al (2014) ACS Med. Chem. Lett., 5, 979-982.
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(68)Ga processing in the preparation of (68)Ga-citrate
H. Kvaternik , C. Barowitsch, D. Hausberger, S.
Kerschbaumer, R. M. Aigner; Medical University of Graz,
Graz, AUSTRIA.
Aim: Since more decades (67)Ga is established for the imag-
ing of inflammation and infection lesions with SPECT. After
(68)Ga becomes more and more available, (68)Ga-citrate is an
option for inflammation imaging with PET (1). In the clinical
preparation of (68)Ga-citrate, there is a challenge to concen-
trate the (68)Ge/(68)Ga generator eluate and to remove the
(68)Ge breakthrough. Therefore, two post-processingmethods
were tested for feasibility.Material and Methods: The (68)Ge/
(68)Ga generator (1,85 MBq)was obtained from iThemba
LABS and was eluted with 10 mL 1 M HCl. The eluate was
diluted to 19 mL with water and (68)Ga was collected onto an
SCX cartridge (Machery Nagel). The elution of the generator
was carried out semiautomatic by a GRP synthesis module
(Scintomics). Using the first method, the SCX was eluted with
2 mL of a 5 M NaCl/ 0.25 M HCl mixture (2). Using the
second method (3), the SCX was eluted with 2 mL 2.5 M
HCl/ 50% ethanol and was directly transferred to a SAX car-
tridge (Machery Nagel). After purging the SAX with nitrogen
to remove traces of ethanol, the purified (68)Ga was recovered
from SAX by desorption with 2 mL 0.1 M HCl.Results: The
first method provided a purified (68)Ga with a recovery from
SCX up to 92%, well appropriate for peptide labelling. How-
ever, due to the high NaCl content, this purified (68)Ga is
unsuitable for further processing to (68)Ga- citrate. Experi-
ments for desalination by ion exchange were not effective.
First results of the second method showed a combined recov-
ery from SCX and SAX of about 60%. The purified (68)Ga,
obtained in an HCl matrix, is easy to turn into an isotonic
(68)Ga-citrate solution. The process is now optimized and
developed to a fully automatization with respect to the good
manufacturing practice (GMP) rules for hospital preparation
of radiopharmaceuticals.Conclusion: Applying a new (68)Ga
post-processing method by ethanolic hydrochloric acid, a pro-
duction route of (68)Ga-citrate for clinical inflammation im-
aging is under development. The benefit of this pathway is to
prevent organic solvents, were a quantitative elimination is
required, in conjunction with a robust and simple
process.(1)Rizzello A, et al. Nucl Med Commun 2009; 30:
542-545(2)Mueller D, et al. Bioconjugate Chem. 2012; 23:
1712−1717(3)Larenkov AA, et al. J Radioanal Nucl Chem
2015; DOI 10.1007/s10967-015-4089-2
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Experimental implementation and proof of principle
for a Radionuclidic Purity test solely based on half life
measurement
T. Jørgensen, M. Jensen; Technical University of Denmark,
Roskilde, DENMARK.
Aims: The purpose of this work was to examine an experimental
implementation of a new method to test the radionuclidic purity
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(RNP) of F-18 compounds and find the overall limitations and
possible impacts on this test.Materials and methods: Two dif-
ferent kinds of counter setups were used to collect data. One with
a scintillation counter containing a NaI crystal and one with a
liquid scintillation counter (LSC). The LSC was preferred over
other detector systems due to the detectability of all radioisotopes.
The data were obtained by measuring the decays of a number of
FDG samples, that were assumed to be pure and also on samples
that were contaminated manually. The counts were measured
within full energy spectrum, since the test is based on a compar-
ison of total activities of two isotopes according to the definition
of RNP. The test was also carried out on simulated data. The test
procedure is based on a comparison of normalizedmeasured data
with corresponding theoretical data created from the test param-
eters (statistical confidence of 97.5%). Results: We have tested
several samples of FDG and found that things like background,
dead time and systematic errors have crucial impacts on the test
result, if not taken care of. On the other hand when these param-
eters are taken into account the test seems to work perfectly. The
RNP = 99.9% level can be assured in less than 5 hours for all
impurities with half-lives ≥ 2 times the half-life of F-18. The test
cannot be used to determine, which contaminating isotope that is
present. It only states whether or not the sample is pure on the
basis of the test parameters with a statistical confidence of 97.5%.
The production and test procedures should be planned in a way
that gives as few corrections to the data set as possible in order to
have the best sensitivity in the test - e.g. the correction of system-
atic time errors could be avoided with a better time resolution in
the counting system. We have developed a GUI application writ-
ten in MATLAB in order to make the RNP test easy to handle in
everyday practice.Conclusion:We conclude that this application
for the RNP test works with real data and does comply with the
requirements in the European Pharmacopoeia, while other
methods like direct gamma spectroscopy will not in general de-
tect impurities to this degree.
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GMP compatible synthesis, dosimetry and in vivo stability
of the selective αvβ6 tracer [18F]IMAFIB for clinical use
M. Onega, C. Plisson, S. Ashworth, S. Lanzarone, J. Ramada-
Magalhaes, S. Moz, N. Keat, J. Passchier; Imanova Limited,
London, UNITED KINGDOM.
Background/Aim: The expression levels of the epithelial-specific
integrin αvβ6 may increase following injury as well as in differ-
e n t c a r c i n o m a s a n d f i b r o s i s . T h e p e p t i d e
NAVPNLRGDLQVLAQKVART (A20FMDV2), derived from
the foot and mouth disease virus, has been identified as a potent
selective binder of αvβ6. Initial studies in animal models have
indicated that [18F]FBA-A20FMDV2 ([18F]IMAFIB) is a
promising tool compound for non-invasive imaging of αvβ6
expression in vivo.1. Herein we report the methods that were
developed for the automated andGMP compliant synthesis, qual-
ity control and metabolite analysis of [18F]IMAFIB for human
clinical studies, and the results from the preclinical dosimetry
study. Materials and Methods: [18F]IMAFIB was labelled with
fluorine-18 by conjugation of the resin bond precursor
(A20FMDV2peptide on rink amide resin) to the prosthetic group
[18F]-fluorobenzoic acid ([18F]FBA), followed by acidic cleav-
age from the resin, purification by semi-preparative HPLC and
reformulation in saline. The synthetic procedure of [18F]IMAFIB
was adapted from a previously describedmethod.1An automated
procedure was developed in-house using an Eckert and Ziegler
Modular-Lab system coupledwith a semi-preparative HPLC sys-
tem. Quality control methods for clinical batches of
[18F]IMAFIB were developed in accordance to EP guidelines.
Plasma metabolite analysis was performed using the ‘Hilton
method’.2 Suitability of themethodwas determined using plasma
samples from rats injected with [18F]IMAFIB. A whole body
distribution of [18F]IMAFIB in healthy Sprague-Dawley rats
was performed to estimate the radioactivity exposure in humans
using OLINDA. Rodent tissue data were adjusted to reflect hu-
man values based on the different proportions of organ to total
body mass in rat and human. Using these data, dosimetry calcu-
lations provided the individual organ doses and the whole body
effective dose. Results and Conclusion: An automated GMP syn-
thesis of [18F]IMAFIB has been successfully implemented on an
Eckert & Ziegler Modular-Lab system. To our knowledge this is
the first solid-phase [18F]-radiolabeling of a peptide to GMP
standards. The current automated process allows reliable produc-
tion of [18F]IMAFIB in suitable quantities for use in clinical PET
studies. QC and metabolite analysis methods have been devel-
oped and [18F]IMAFIB routinely meets specified criteria. Final-
ly, an estimated human effective dose of 0.026 mSv/MBq of
injected activity was determined from the rodent preclinical do-
simetry study. Clinical studies are ongoing and will be reported
separately. References: [1] S. H. Hausner et al., Cancer Research
2007, 67, 7833. [2] J. Hilton et al., Nucl. Med. Biol., 2000, 27,
627.
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Effects of chemotherapeutic agents on 18F-FDG uptake
in various tumour cells: Implication for 18F-FDG PET
P. Ubl, X. Gao, F. Girschele, S. Birkmann, M. Hacker, G.
Hamilton, S. Li; Medical University of Vienna, VIENNA,
AUSTRIA.
Aim: 18F-FDG positron emission tomography (PET) has been
widely used for evaluation of the chemotherapy response of
different tumours. However, the effect of chemotherapeutic
agents on 18F-FDG uptake in tumour cells may be quite dif-
ferent. The purpose of this study is to investigate the 18F-FDG
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incorporation in various tumour cells in response to conven-
tional and novel chemotherapeutics. Materials and Methods:
Cells derived from human small cell lung cancer (SCLC)
(NCl-H417 and DMS153) and human colon cancer cell line
(COLO 320DM) were incubated with different chemothera-
peutic agents for 72 hours. The treatment with chemotherapeu-
tic agents was terminated by wash the tumour cells with phos-
phate buffered saline (PBS) three times before 18F-FDG was
added in PBS. Control cells were incubated without chemo-
therapeutic agents. Cell counts, viability and cell cycle distri-
bution were also determined. Results: As compared with con-
trol cells, a significant decrease of 18F-FDG uptake was found
in human SCLC (NCI-H417) cells after pre-incubation with
satraplatin and in DMS153 cells after treatment with
satraplatin and doxorubicin as well as 5-Fluorouracil and vin-
blastine. Significantly decreased uptake of 18F-FDG was also
demonstrated in human colon cancer cell line (COLO 320DM)
after pre-incubation with cisplatin and doxorubicin. Interest-
ingly, the treatment with doxorubicin has led to a significant
increase of 18F-FDG incorporation in NCI-H417 cells, simi-
larly, a significant increase of 18F-FDG was also found in
DMS153 cells after pre-treatment with cisplatin and
dichloroacetate. Conclusion: Our results demonstrated that
treatment with different chemotherapeutic agents results in
diverse degrees of incorporation of 18F-FDG into tumour
cells. Chemotherapeutic agents, such as cisplatin, satraplatin,
5-Fluorouracil, doxorubicin and vinblastine decrease 18F-
FDG uptake in human colon cancer and human SCLC cells.
Whereas, cisplatin, doxorubicin and dichloroacetate may in-
crease 18F-FDG uptake in human SCLC cells. These results
may have implications for clinical evaluation of chemotherapy
response by using 18F-FDG PET.
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Radiosynthesis of the [18F]-FHBG and Uptake Study
with Transfected Cells
M. Beaurain1, A. Salabert1, L. Vaysse1, Q. Dardonville2, V.
Pottier2, M. Alonso2, I. Loubinoux1, P. Payoux3, M. Tafani2;
1Inserm UMR825, Toulouse, FRANCE, 2Radiopharmacy
Department - CHU Toulouse, Toulouse, FRANCE, 3Nuclear
Medicine Department, Toulouse, FRANCE.
Aim: Cell transplantation therapy is an innovative therapeutic
approach particularly in neurology to compensate the neural
loss after stroke. Multimodal molecular imaging enables real-
time longitudinal monitoring of transplant survival. First, the
cells will be transfected with a gene encoding a thymidine
kinase (HSV1-tk). Then, we will use [18F]-FHBG as a report-
er probe to image the expression of this enzyme. HSV1-tk
phosphorylates [18F]-FHBG to its monophosphate form lead-
ing to intracellular accumulation. In order to develop this tool
in our center, we worked on the [18F]-FHBG radiosynthesis
optimization and we studied its capture by transfected cells.
Materials and Methods: We developed an automated
radiosynthesis of [18F]-FHBG using a Synchrom R&D auto-
mat (Raytest®): the first step is a nucleophilic substitution of a
tosylate group with an 18F atom followed by an acid hydro-
lysis step. Next, we performed an HPLC purification. To max-
imize the synthesis efficiency, we varied the nucleophilic sub-
stitution temperature from 90°C to 100°C, 110°C and 120°C.
Finally we also determined the specific activity and log D
(octanol/ buffer). We developed the transfection on Neuro2a
cells with a plasmid containing the HSV1-tk and a neomycin
resistance gene for the selection of stably-transfected cells.
Then, we measured the percentage of [18F]-FHBG captured
by these cells and compared it with that of the non-transfected
cells. Results: An optimal synthesis efficiency (12%) was ob-
tained with a temperature of 110°C. The elution solvent used is
a mixture of sodium acetate and ethanol (90:10) which shows
compatibility when in contact with cells and in injection
in vivo. The specific activity exceeds 3.2 GBq/μmoles, and
the average activity synthetized is 1850 MBq. The log D is -
0.88, as such, this molecule is hydrophilic. The uptake rate of
transfected cells is 30 times higher than that of non-transfected
cells. Conclusion: With a nucleophilic substitution tempera-
ture of 110 °C, we obtained a sufficient amount of [18 F]-
FHBG to be compatible with a human or animal injection.
Its uptake by transfected cells appears to be effective. In spite
of its high hydrophilic character which limits its passage across
the blood-brain barrier, we are planning to use it for tracking
the fate of grafted cells after stroke because the BBB is
disrupted. However, the long-term monitoring could be affect-
ed by the restoration of this BBB. Before evaluating this tracer
in vivo in rats, we plan to perform an in vitro calibration to
determine how many cells correspond to the emitted signal
intensity.
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Promising chemical delivery system into the central
nervous system of [18F]FLT for PET imaging studies
of low-grade brain tumours.
F. Gourand1, A. Henry2, M. Ibazizène1, M. Dhilly1, C.
Papamicaël2, V. Levacher2, L. Barré1; 1CEA/DSV/I2BM/
UMR ISTCT 6301/LDM-TEP, Cyceron, Caen, FRANCE,
2Normandie Univ, COBRA, UMR 6014 et FR 3038; Univ
Rouen; INSA Rouen; CNRS, IRCOF, Mont-Saint Aignan,
FRANCE.
Aim: [18F]FLT (3’-deoxy-3’-18F-fluoro-L-thymidine), an an-
alogue substrate of thymidine, has been developed as a tracer of
proliferation in oncological PET studies. Low-grade brain tu-
mours are poorly visualized and vectorisation of [18F]FLT
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through the intact blood-brain barrier (BBB) could provide the
opportunity to detect these tumours at an early stage. A chemical
delivery system (CDS) based on Bodor’s approach has been
developed to enable the penetration of [18F] FLT into the brain.
Materials andMethods: FLT has been linked to a lipophilic 1,4-
dihydroquinoline carrier (CDS) that enables the transport across
the BBB. The synthesis of CDS-FLT has been developed and in
order to evaluate the potential of this CDS, we have undertaken
its labelling with carbon-11 (t1/2 : 20.4 min). The radiolabelling
was performed as a one-pot two-step procedure starting from the
quaternarization of the quinoline with [11C]methyl triflate
followed by a regioselective reduction with 1-benzyl-1,4-
dihydronicotinamide (BNAH) to afford the corresponding
[11C]CDS-FLT . The in vivo behaviour of [11C]CDS-FLT was
carried out in healthy Sprague-Dawley rats to measure the
injected dose per gram in the brain as a percentage (ID%).
Results: The incorporation of [11C]methyl triflate to the quino-
line was 85-90% and reduction with BNAH provided
[11C]CDS-FLT with a conversion rate of 50-60% (based on
HPLC profiles). The radiosyntheses were performed using
TRACERLab FX MeI and M synthesizers. After HPLC purifi-
cation and formulation, [11C]CDS-FLTwas obtained in 50 min
with 15% decay-corrected yields based on [11C]methyl iodide.
The in vivo evaluation in healthy rats demonstrated that this CDS
is amarkedly efficient lipophilic carrier; indeed, the BBB passage
was increased by a factor of 15 when compared to [18F]FLT
injected alone. Conclusion: In vivo studies in healthy rats dem-
onstrated the potential of 1,4- dihydroquinoline as a carrier to
enable FLT to cross the intact BBB. These encouraging results
warrant further studies into rats bearing low-grade brain tumours.
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Evaluation of [11C]EA10 to image GluN2B-containing
NMDA receptor subunits
L. A. Wells1, S. Kealey2, O. Howes3, G. Henriksen4, J.
Passchier1, E. Arstad5; 1Imanova Centre for Imaging Sciences,
London, UNITED KINGDOM, 2Imperial College London,
London, UNITED KINGDOM, 3Psychiatric Imaging, MRC
Clinical Sciences Centre, London, UNITED KINGDOM,
4Norwegian Medical Cyclotron Centre and Institute of Basic
Medical Sciences, University of Oslo, Oslo, NORWAY, 5De-
partment of Chemistry, UCL, London, UNITED KINGDOM.
The neurotransmitter glutamate acting via the N-methyl-D-
aspartate receptor (NMDAR) plays a significant role in cognitive
processes and memory formation. Abnormal glutamate neuro-
transmission and decreased expression of the NMDAR has been
reported in the pathophysiology of diseases including schizophre-
nia andAlzheimer’s Disease1,2. Here, we evaluate [11C]EA10, a
selective antagonist for the GluN2B-subtype of the NMDAR, as
a potential PET radioligand. The affinity of EA10 was
determined in the presence of the GluN2B antagonist
[3H]Ifenprodil (8nM) and sigma-receptor block GBR12909
(3uM) with unlabelled EA10 (0.05-100nM) using radioligand
binding techniques. [11C]EA10 was produced byO-methylation
of the desmethyl precursor using [11C]methyl iodide. A rat was
injected with 8MBq [11C]EA10 prior to receiving two dynamic-
PET:CT scans with and without a cold dose of EA10 (1 mg/kg).
Plasma was taken and the level of radiometabolites assessed.
Scans were reconstructed (2D-FBP:scatter corrected) and time
activity curves (TACs) generated for the cortex and cerebellum.
The central distribution of [11C]EA10 was assessed in conscious
versus anesthetised animals (rats n=2 per group, mice n=4 per
group) with and without 1 mg/kg EA10. Animals received
8 MBq [11C]EA10; after 60 min the activity associated with
brain nuclei was assessed by a gamma counter and the standard
uptake values (SUV) derived. In vitro, EA10 competed for the
[3H]Ifenprodil binding site with a sub-nanomolar affinity com-
pared to unlabelled Ifenprodil (EA10 Ki 0.4-0.7nM compared
with Ifenprodil Ki 6.3nM). The decayed EA10 radiochemical
productions competed for the [3H]Ifenprodil binding site within
the same affinity range. EA10 was successfully radiolabelled
resulting in good yields and specific activity (n=7, end of synthe-
sis: activity=2006±546MBq, specific activity=67±29GBq/umol).
The PET:CT image displayed a homogeneous uptake of
[11C]EA10 in the CNS, no differences were observed in the
TACs generated for the cortex and cerebellum during baseline
conditions. No differences were observed in TACs from the base-
line scan compared with the scan after administration of 1 mg/Kg
EA10. The uptake of [11C]EA10 was unchanged in anesthetised
compared with conscious animals with and without the adminis-
tration of 1 mg/Kg EA10. EA10, a novel ligand with specific
binding characteristics for GluN2B, was labelled and produced in
yields relevant for clinical imaging. [11C]EA10 enters the brain
however the in vivo distribution did not reflect the known distri-
bution of GluN2B. Pretreatment with a high dose of cold EA10
did not lead to decreased binding. Due to the high in vitro affinity
of EA10, the contribution of the mass dose warrants further
investigation.1.Beneyto et al,2007. 2.Kravitz et al,2013. 3.Arstad
et al,2006.
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Radiosynthesis and Evaluation of 2-[18F]Fluoroethyl
4-Nitrobenzyl Carbonate for Imaging Tumor Hypoxia
with Positron Emission Tomography
Z. Zhang, J. Lau, N. Colpo, F. Bénard, K. Lin; BC Cancer
Agency, Vancouver, BC, CANADA.
Objectives: 4-Nitrobenzyl carbonate derivatives of anti-cancer
agents have been reported to undergo bioreductive activation
specifically in hypoxic tumor tissues. Reduction of the nitro
group leads to the fragmentation of prodrugs, and the subsequent
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release of active anti-cancer agents. Previously, we reported the
trapping of 2-[18F]fluoroethanol in mouse tissues after iv injec-
tion. The trapped radioactivity in most tissues/organs did not
decrease over a 1 h period. Based on this observation, we inves-
tigated if 2-[18F]fluoroethyl 4-nitrobenzyl carbonate can undergo
fragmentation under hypoxia to release 2-[18F]fluoroethanol for
cancer imagingwith positron emission tomography.Methods: 2-
Fluoroethyl 4-nitrobenzyl carbonate and the radiolabeling precur-
sor (2-bromoethyl 4-nitrobenzyl carbonate) were synthesized by
coupling 4-nitrobenzyl chloroformate with 2-fluoroethanol and
2-bromoethanol, respectively, in dichloromethane with 4-
dimethylaminopyridine as the base. 18F labeling was performed
in acetonitrile at 60 °C for 15 min using tetrabutylammonium
bicarbonate as the base. Stability of 2-[18F]fluoroethyl 4-
nitrobenzyl carbonate was assessed in mouse plasma and moni-
tored by HPLC. PET imaging and biodistribution studies were
performed in NODSCID/IL2RKO mice bearing HT-29 human
colon cancer xenografts. Results: Both 2-fluoroethyl 4-
nitrobenzyl carbonate and 2-bromoethyl 4-nitrobenzyl carbonate
were obtained in 69% yield. 2-[18F]Fluoroethyl 4-nitrobenzyl
carbonate was obtained in 90 min synthesis time with > 99%
radiochemical purity. Stability assay showed that
2-[18F]fluoroethyl 4-nitrobenzyl carbonate was metabolized ex-
tremely fast in mouse plasma with only ~ 1% remaining intact
after 1min incubation. From the biodistribution and PET imaging
data, there was minimal clearance of 2-[18F]fluoroethyl 4-
nitrobenzyl carbonate. At 3 h p.i., high (>5 %ID/g) and sustained
uptake was observed in many tissues including blood, intestines,
kidney, heart, tumor, and brain. HT-29 tumor xenografts (6.90 ±
0.27%ID/g) were readily visualized in PET images. Despite high
tumor uptake, tumor-to-blood and tumor-to-muscle ratios were
suboptimal at 1.21 ± 0.03 and 1.93 ± 0.30 respectively. The
highest activity was observed in bone (10.1 ± 1.54 %ID/g) sug-
gesting a significant degree of defluorination in vivo.
Conclusion: Although high tumor uptake was observed,
2-[18F]fluoroethyl 4-nitrobenzyl carbonate failed to clear from
non-target tissues. In vivo hydrolysis of the carbonate tracer
yielded 2-[18F]fluoroethanol as a radiolabeled metabolite, which
contributed to high background uptake. Poor pharmacokinetics
and tracer instability render 2-[18F]fluoroethyl 4-nitrobenzyl car-
bonate unsuitable for targeting tumor hypoxia.
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A Comparison of [18F]fluorotetrafluoroborate with [124I]
Iodide for imaging human sodium iodide symporter
S. Samnick1, I. Israel1, M. Schiller1, M. Mix2, A. Schirbel1,
A. Buck1; 1University of Wuerzburg, Wuerzburg, GERMA-
NY, 2University of Freiburg, Freiburg, GERMANY.
Aim: The human sodium iodide symporter (hNIS) has been
historically the most important target for imaging and therapy
in the nuclear medicine. However, current hNIS imaging
methods have severe limitations in terms of resolution and
sensitivity. Therefore, there is an increased interest in develop-
ing more specific radiotracers for imaging hNIS using the
more sensitive positron emission tomography (PET) tech-
nique. This study evaluates experimentally the feasibility of
P E T w i t h t h e n o v e l f l u o r i n a t e d a g e n t
[18F]Fluorotetrafluoroborate ([18F]TFB) in hNIS-expressing
tumours. Methods: [18F]TFB was investigated in hNIS ex-
pressing tumor cells in cultures and compared with the
established radioactive hNIS agents sodium [123I]iodide
([123I]NaI), and [99mTc]pertechnetate ([99mTcO4). The
specificity of the [18F]TFB uptake into hNIS-expressing cells
was assessed by competitive inhibition studies using KClO4
and non-radioactive sodium iodide (NaI), known as specific
hNIS substrates. Furthermore, the potential of [18F]TFB for
imaging hNIS-expressing tumors was tested on hNIS-
expressed tumours xenografted in nude mice in comparison
with sodium [124I]iodide ([124I]NaI), using μ-PET. Results:
In vitro, [18F]TFB accumulated intensively in hNIS-
expressing tumor cells. Radioactivity incorporation into cells
following a 15-min incubation at 37°C was 15 ± 3% of the
total loaded activity per 106 cells for hNIS-expressing cells,
which was significant higher than accumulation of the clini-
cally established [123I]NaI and [99mTcO4 (6 ± 2% and 10 ±
3%). In comparison, the [18F]TFB uptake into non-hNIS-
expressing control cells remained insignificantly low
(<0.2%). The uptake of [18F]TFB into hNIS-expressing cells
was inhibited up to 90% by KClO4 or non-radioactive
Na[127I]iodide, confirming the specificity of the [18F]TFB
uptake for hNIS. Finally, PET studies using [18F]TFB and
[124I]NaI in the samemice demonstrated a higher and specific
accumulation of [18F]TFB in hNIS-expressing tumours xeno-
grafts, resulting to a significantly better delineation of the tu-
mours in vivo. Conclusions: The specific and high-level ac-
cumulation of [18F]TFB in hNIS- transfected tumor cells
in vitro and in vivo strongly indicates that [18F]TFB is a
promising candidate as imaging probe for hNIS expressing
tumors using PET. Our PET data suggest advantages of
[18F]TFB over [124I]NaI as radiotracer for imaging hNIS-
expressing tumours.
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Automated GMP compatible synthesis of 3-[18F]
Fluoro-5-[(pyridine-2-yl)ethynyl]benzonitrile ([18F]
FPEB)
S. Hader; King’s College London, London, UNITED
KINGDOM.
Hader, Stefan; Fortt, Robin; Twyman, Frazer; Gee, Antony*
Division of Imaging Sciences and Biomedical Engineering,
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King’s College London,UK.Aim: 3-[18F]Fluoro-5-[(pyridine-
2-yl)ethynyl]benzonitrile ([18F]FPEB) is a metabotropic glu-
tamate receptor subtype 5 (mGluR5) antagonist used in pre-
clinical and clinical PET neuroimaging of disorders of the
CNS including schizophrenia and autism [1]. We describe
herein a fully automated GMP compatible thermal method
for the synthesis of [18F]FPEB utilising the 3-nitro-
5-[(pyridin-2-yl)ethynyl]-benzonitrile precursor on an Ecker
& Ziegler Modular-Lab. Materials and Methods: An aque-
ous [18F]fluoride solution (600 μl, 20 Gbq) was delivered
from the cyclotron and trapped on a QMA-carbonate SPE
cartridge. The [18F]fluoride was eluted with a solution of
K2CO3 (0.7 mg) and Kryptofix 2.2.2 (12 mg) in water (200
μL) and acetonitrile (800 μL). The solution was evaporated to
dryness using a combination of vacuum and nitrogen flow at a
temperature of 110°C over an 8 minute period. Following
evaporation, the precursor (2 mg) in DMSO (1 mL) were
added and the labelling reaction was conducted at 150°C for
15 minutes. Purification was achieved by semi-preparative
HPLC on a Phenomenex Luna C18 HPLC column (4.6 x 30
mm, 5 μm) with an isocratic mobile phase of 65:35 H2O:ACN
+ 0.1% TFA at a flow rate of 5 ml/min. The fraction corre-
sponding to [18F]FPEB (tR= 18 min) was collected and
reformulated by extraction onto a preconditioned Waters C18
plus SPE cartridge and eluted with 1 mL of ethanol into a
sterile vial containing 9 mL of PBS and passed through a
0.22 μm sterile filter. Results and Conclusions: The fully
automated GMP compatible synthesis of [18F]FPEB was
effected in 5% EOS yield utilising the Ecker & Ziegler Mod-
ular-Lab. Acknowledgements: The authors acknowledge fi-
nancial support from the Department of Health via the Nation-
al Institute for Health Research (NIHR) comprehensive Bio-
medical Research Centre award to Guy’s & St Thomas’ NHS
Foundation Trust in partnership with King’s College London
and King’s College Hospital NHS Foundation Trust. This
work was also supported by the InnovativeMedicine Initiative
Project EU-AIMS (115300). References: [1] Wang J-Q,
Tueckmantel W, Zhu A, Pellegrino D, Brownell A-L,
(2007), Synapse, 61, 951-961.
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Implementation of Routine Production of [18F]-Fallypride
on the TRASIS All-in-One Universal Synthesizer.
C. Marshall, K. Drandarov, S. H. Bukhari, D. Hardwick, V.
Costanza, P. Llewelyn, K. Probst, A. Dabkowski; Cardiff Uni-
versity, CARDIFF, UNITED KINGDOM.
[18F]-Fallypride, a high affinity dopamine D2/D3 receptor
antagonist, is a useful PET tracer imaging tool for the quanti-
tative studies of the D2/D3 receptor sites in the brain. [18F]-
Fallypride is used in the diagnostics of a number of
neurological and neuropsychiatric disorders. Our centre has
recently acquired the Trasis All-In-One Universal Synthesizer
and reports on the implementation of a routine GMP
radiosynthesis of [18F]-Fallypride.The Trasis All-In-One Uni-
versal Synthesizer is an automated instrument dedicated for
the labelling of PET tracers. Due to its graphical interface
control it is quick and easy to programme new synthetic se-
quences likev 18F]-Fallypride. The synthesis sequence in-
cludes the introduction of the [18F]-label using [18F]-fluoride
ions. The production of [18F]-Fallypride is performed using
Tosyl-Fallyprideas starting material and prep HPLC purifica-
tion. The set-up is GMP compliant as single-use cassettes were
compiled specifically for this [18F]-Fallypride synthesis and
[18F]-Fallypride is synthesised within 40 mins as a saline
solution.At the end of the synthesis the yield varied between
40-45% (not decay corrected) with a radiochemical purity of
>99% measured by HPLC. The QC is performed and accord-
ing to the general guidelines of the European Pharmacopeia
and the tests include appearance, pH, half-life, bacterial endo-
toxins, kryptofix, radiochemical purity, radionuclidic purity
and residual solvent analysis, all of which meet the required
standards..We have successfully implemented the[18F]-
Fallypride as a new tracer on the TRASIS All In One system
to the standards required by GMP.
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Towards nucleophilic synthesis of alpha-[18F]
Fluoromethyl-p-tyrosine
R. Krasikova1, O. Kuznetsova1, V. Orlovskaja1, O.
Fedorova1, V. Maleev2, Y. Belokon2, A. Geolchanyan3, A.
Saghyan3, L. Mu4, S. Ametamey4, R. Schibli4; 1N.-
P.Bechtereva Institute of Human Brain Russian Academy of
Science, St.-Petersburg, RUSSIAN FEDERATION, 2A.N.
Nesmeyanov Institute of Organoelement Compounds Russian
Academy of Science, Moscow, RUSSIAN FEDERATION,
3SPC Armbiotechnology NAS, Yerevan, ARMENIA, 4BIO,
Paul Scherrer Institute, Villigen-PSI, SWITZERLAND.
Aim. During the last decade considerable progress has been
made to overcome difficulties in producing ring-fluorinated
analogues of aromatic amino acids such as 6-[18F]fluoro-L-
DOPA via the nucleophilic route. In this work we evaluated a
nucleophilic approach to obtain 18F-labelled tyrosine deriva-
tive carrying monofluoro methyl group at the alpha position,
as potential molecular probe for estimating activity of tyrosine
hydroxylase, the rate-limiting enzyme in the biosynthesis of
catecholamine neurotransmitters. Previous studies described
ring-fluorinated 3-[18F]fluoro-α-fluoromethyl-p-tyrosine
(Dejesus et al, 1994) and 6-[18F]fluoro-α-fluoromethyl-m-ty-
rosine (Murali et al. 2003) via electrophilic radiofluorination.
A nucleophilic method has been recently suggested for the
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synthesis of racemic α-[18F]fluoromethyl phenylalanine
using cyclic sulfamidate precursor that was prepared from D,
L-benzylserine (Huang et al., 2013). The present work de-
scribes an approach for the enantiomerically pure
α-[18F]Fluoromethyl-p-tyrosine synthesis that could be per-
formed via the direct nucleophilic fluorination of the NiII com-
plex as radiolabeling precursor.Methods. Radiosynthesis was
based on the nucleophilic displacement of the α-MeSO2
(mesyl) leaving group in a labeling precursor following hydro-
lysis of 18F-fluorinated intermediate and deprotection of hy-
droxyl group of tyrosine. The precursor, NiII complex of
Schiff base of (2S)-1-benzyl-N-(2-formylphenyl)pyrrolidine-
2 - c a r b o x a m i d e w i t h ( S ) - 2 - a m i n o -
2 - ( m e t h y l s u l f o n y l o x y m e t h y l ) - 3 - ( 4 -
methylsulfonyloxyphenyl)propanoic acid (Ni-(S)-BBA-(S)-
MsOmethyl-TyrOMs (I)), was prepared in a two steps synthe-
sis from the corresponding NiII complex of Schiff base of
(2S)-1-benzyl-N-(2-formylphenyl)pyrrolidine-2-carboxamide
with (S)-tyrosine (Ni-(S)-BBA-(S)-Tyr). Radiofluorination of
(I) was performed in various solvents (acetonitrile, dichloro-
benzene, DMSO, DMF, acetone) at 60-140°C in the presence
of different phase transfer catalysts (kryptofix/K2CO3,
kryptofix/KH2PO4, 18 crown-6/KHCO3, TBACO3,
TBAHCO3). Results. Despite multiple attempts to substitute
the α-MeSO2-group in (I) by [18F]fluoride under a wide va-
riety of conditions, 18F-labeling efficiencywas very poor (0.5-
3% according to radioTLC of reaction mixture). The highest
fluorine-18 incorporation rate of 16% was achieved by carry-
ing out the radiofluorination in acetone (kryptofix/K2CO3,
60°C, 10 min). Conclusion. The poor fluorination efficiency
of (I) may be caused by the steric hindrance at the α-carbon
atom of the tyrosine moiety. Work is now in progress to opti-
mize the precursor structure. Acknowledgement. This study
was supported by the SNF grant IZ73ZO_152360/1.
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New Approach to Production of [18F]Flumazenil
for Central Benzodiazepine Receptors Imaging by PET
N.Gomzina1, D. Vaulina1,M. Nasirzadeh2; 1N.P.Beсhtereva
Institute of the Human Brain Russian Academy of Sciences
(IHBRAS), St. Petersburg, RUSSIAN FEDERATION, 2Saint
Petersburg State University, St. Petersburg, RUSSIAN
FEDERATION.
AIM[18F]flumazenil ([18F]FMZ) is a well-known radiophar-
maceutical for the assessment of the central benzodiazepine
receptor (cBZR) concentration by PET. These receptors are
involved in many neurological and psychiatric disorders, such
as epilepsy, panic disorder, acute stroke, alcoholism. Synthesis
of [18F]FMZ by nucleophilic substitution of nitro group in
molecule of nitromazenil with [18F]fluoride had been
introduced in 2005 (Ryzhikov N.N. et al). The semi-
preparative HPLC used to separate [18F]FMZ from precursor,
because the physical-chemical properties of flumazenil are
similar to those of nitromazenil. The aim was to develop the
SPE purification method of [18F]FMZ instead of time-
consuming HPLC.METHODS [18F]Fluoride was produced
via 18O(p,n)18F nuclear reaction in [18O]H2O water target
of GE PETtrace cyclotron. [18F]FMZwas prepared by heating
of 1-2 mg of nitromazenil (ABXGmbH, Germany) in DMF at
150°C in the presence of kryptofix 2.2.2/K2CO3. Purification
step involved derivatization of nitro-precursor and following
isolation of [l8F]FMZ using reversed phase cartridges. After
[18F]fluorination step potassium methoxide in methanol was
added to the reaction mixture. Under strong base conditions
the precursor converted to less lipophilic species that easily
removed by SPE, whereas [l8F]FMZ was much more stable.
Then the reaction mixture was cooled and diluted with water
and the activity trapped on a HLB 3cc column (Waters). The
column was washed and eluted by 35% of ethanol/water. This
eluate was diluted with water and passed through a tC18 light
cartridge (Waters) and finally eluted by 1-2 ml of 15% ethanol/
acetic buffer.RESULTS With using of new approach
[18F]FMZ was obtained with non-optimized radiochemical
yield of 10% (EOB) in less than 60min. Radiochemical purity
of [18F]FMZ was more than 97%, the amount of nitromazenil
in the final product was negligible (≤1μg/mL) and
otherchemicals impurities were under the limits set by the
European harmacopoeia. All procedures were implemented
i n t o T r a c e r l a b F X N P r o m o d u l e ( G E
Healthcare).CONCLUSION The suggested approach to pro-
duction of [18F]FMZhas been allowed to replace HPLC puri-
fication with more attractive for automated SPE procedure
using commercially available cartridges with the efficient sep-
aration of radioligand from radiochemical and chemical impu-
rities. Work is now in progress to optimize all the developed
procedures.
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Use of Potassium tert-Butoxide in the Synthesis of [11C]
Flumazenil, [11C]PK11195 and [11C]-(+)-DTBZ
S. F. Garcia-Arguello; Centro de Investigaciones Medico-
Sanitarias (CIMES), Malaga, SPAIN.
AimAlkali metal hydroxides and sodium hydride are the pre-
ferred bases in [11C]methylations. However, they have certain
limitations such as poor solubility in organic solvents and hy-
drolytic activity. Potassium tert-butoxide (KOtBu) is a non-
nucleophilic base that is soluble in various organic solvents.
The use of this reagent in the [11C]methylation of amide or
phenol moieties has not been reported. Therefore, the goal of
this work was the evaluation of KOtBu in the synthesis of
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[11C]f lumazeni l , [11C]PK11195 and [11C]- (+)-
DTBZ.Materials and Methods[11C]CO2 was produced in a
GE PET Trace cyclotron and [11C]iodomethane was synthe-
sized in a Tracerlab FX-Cmodule using the gas-phase method.
Dry solvents, hydroxides, sodium hydride 60 % dispersion in
mineral oil and potassium tert-butoxide solution 1M in THF
were obtained from Sigma-Aldrich. Desmethyl precursors (1
mg) were purchased from ABX. Analytical radiochemical
yields (decay-corrected) were analyzed using the radiochro-
matograms obtained in the semi-preparative HPLC purifica-
tion of the labelled products. The identities of the [11C]radio-
pharmaceuticals were confirmed in an analytical HPLC by co-
inject ion with the corresponding non-radioactive
compounds.ResultsThe synthesis of [11C]flumazenil was car-
ried out in DMF using aqueous NaOH or KOtBu as the base.
Both NaOH and KOtBu gave excellent radiochemical yields
(75-85 % and 65-70 % respectively), although KOtBu provid-
ed somewhat inferior results due to the formation of a radio-
active side product that eluted a few minutes after
[11C]flumazenil.Tetrabutylammonium hydroxide (TBAOH,
1M in methanol and 1M in water), NaOH, NaH and KOtBu
were compared in the synthesis of [11C]PK11195. Besides
that, DMF and DMSO were compared as reaction solvents.
The best results were obtained using NaH suspension/DMSO,
but the hydride degraded with time and blocked the tubing of
the synthesis module. KOtBu gave moderate but reliable ra-
diochemical yields (30-35% in DMF or DMSO), whereas low
and irreproducible yields were obtained with TBAOH and
NaOH (5-10%).[11C]-(+)-DTBZwas produced in dry DMSO
using NaOH, KOH and KOtBu. In this case, the highest ra-
diochemical yield was achieved with KOtBu (75-80 %), with
hydroxides giving slightly lower conversions (60-65
%).ConclusionThe syntheses of [11C]flumazenil ,
[11C]PK11195 and [11C]-(+)-DTBZ were carried out with
[11C]iodomethane and KOtBu in DMSO or DMF using the
captive solvent method. Commercially available THF solu-
tions of KOtBu were stored at room temperature and provided
consistent radiochemical yields for several months. Compari-
son studies showed that the efficiencies of the [11C]methyla-
tion reactions with KOtBu were equivalent or greater than
those achieved with other bases.
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Direct nucleophilic synthesys of 18F-fluoroethylated
arylbenzotiazole as a new potential PET probe for breast
cancer imaging
C. L. Chen1, G. Y. Li1, F. C. Meng1, R. S. Liu1,2, H. E.
Wang1, V. V. Orlovskaja3, D. D. Vaulina3, O. F. Kuznetsova3,
O. S. Fedorova3, R. N. Krasikova3; 1Department of Biomed-
ical Imaging and Radiological Sciences, National Yang-Ming
University, Taipei, TAIWAN, 2National PET/Cyclotron
Center, Veterans General Hospital, Taipei, TAIWAN, 3N.P.
Bechtereva Institute of Human Brain Russian Academy of
Science, St.-Petersburg, RUSSIAN FEDERATION.
Aim. The substituted arylbenzotiazoles (BT) represent a class
of compounds that have shown selective and effective inhibi-
tion of tyrosine kinase overexpressed in the wide range of
cancers. Among them 2-(3,4-dimethoxyphenyl)-5-
fluorobenzothiazole (PMX 610) exhibited very potent (GI50
< 0.1 nM) and selective in vitro antitumor properties in human
breast cancer cell lines MCF-7 and MDA-468 (Mortimer et al,
2006). Based on this BT scaffold several 11C-labelled ana-
logues have been prepared as PET diagnostic agents (Wang
et al., 2006), however their further evaluation was not report-
ed. In this work we intend to develop corresponding 18F-
fluoroethylated derivative, 2-(3,4-dimethoxyphenyl)-
6-(2-[18F]fluoroethoxy) benzothiazole, to allow its preclinical
evaluation as potential diagnostic agent for breast cancer im-
aging by PET. Methods. Radiosynthesis of 2-(3,4-
dimethoxyphenyl)-6-(2-[18F]fluoroethoxy) benzothiazole
was performed in one step via a Kryptofix-assisted
radiofluorination of the corresponding tosyl precursor in
DMF at 110-130 degC for 10-20 min. The precursor and cold
reference were prepared in two synthetic approaches starting
from 4-aminophenol and fully characterized by 1HNMR, 13C
NMR, EI/ESI-MS and HRMS techniques. Results. After opti-
mization of reaction conditions a fluorine-18 incorporation
rate of 60% (according to radioTLC of reaction mixture) was
achieved by carrying out radiofluorination at 130 degC for 20
min. This one step synthesis procedure suits well for the auto-
mation and provides radiotracer in amounts and purity suffi-
cient for the preclinical application. Conclusion. The synthesis
of 2-(3,4-dimethoxyphenyl)-6-(2-[18F]fluoroethoxy)
benzothiazole has been developed via direct nucleophilic dis-
placement of tosyl group in customized precursor.
Radiopharmacological evaluation in mice bearing MDA 468
(ER-) and MCF-7 (ER+) breast tumors using small animal
PET is underway. Acknowledgement. This study was support-
ed by RFBR grant 15-54-52026/15 and MOST 104-2923-B-
010 -001 -MY2
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F-18 Radiolabelling of Chitosan-Based Nanoparticles
and its Modelling Reaction
A. LIMA OUBIÑA1, T. MIKLOVICZ1, J. VARGA1, J.
BORBÉLY2, P. MIKECZ1; 1Department of Nuclear Medi-
cine, University of Debrecen, Debrecen, HUNGARY, 2BBS
NanoTech, Debrecen, HUNGARY.
AIM: The aim of this work was to label chitosan-based nano-
particles via [F-18]-4-fluorobenzaldehyde ([18F]-FBA) on
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one of its amine groups. The reaction was modelled on one of
its components, Glucosamine (GlcN), instead of the use of the
whole polymer. Subsequently, the developed procedure was
applied to chitosan radiolabeling. MATERIALS AND
METHODS: [18F]-FBA was synthesized from 3 mg 4-For-
myl-N,N,N-Trimethylanilinium triflate , in a 5 minutes reac-
tion at 80°C, using SCX cartridge to remove side products. To
model chitosan labelling, direct and indirect reductive
amination were used, between the carbonyl group of [18F]-
FBAwith the amine group of GlcN and 1,3,4,6-Tetra-O-Ace-
tyl-2-amino-GlcN (TAGlcN), at different temperatures:
110°C, 70°C, 50°C and room temperature, during 30 minutes.
NaBH3CN was employed as reducing agent. To study the
possible aldol side products, we performed the same experi-
ments with N-Acetyl-GlcN and glucose. The modelling reac-
tion concluded to use direct reductive amination at elevated
temperatures (70°C and 50°C) for the labelling of the polymer.
The reaction was followed by TLC analysis with samples tak-
en at 5, 10, 20 and 30 minutes. RESULTS: [18F]-FBA radio-
chemical yield was 56±10%, with >95% radiochemical purity.
For the reaction between FBA and TAGlcN via direct reduc-
tive amination, the HPLC-determined conversion yields were:
110°C: 7±1%, 70°C: 42±0.7%, 50°C: 41±4%, room tempera-
ture: 20±8% In case of indirect reductive amination, (with TA-
GlcN), at 110°C the results are similar, 8±1%, as with direct
reductive amination at the same temperature. Room tempera-
ture yield was 41±12%, but it took longer time (1h). The re-
actions with N-Acetyl-GlcN and glucose gave significantly
different compounds of less than 5 % of activity. When
radiolabeling chitosan via [18F]-FBA, using direct reductive
amination, radiochemical conversion was at 50 °C: 33±3%, 46
±2%, 60±2%, 68±1%; and at 70°C: 54±4%, 65±2%, 71±1%,
72±1% after 5, 10, 20 and 30 min, respectively. CONCLU-
SIONS: Modelling reaction of direct and indirect reductive
amination showed that [18F]-FBA reacts mainly with the
NH2 group of GlcN or TA-GlcN, with high yields at 70°C
and lower temperatures. In case of absence or blocked amine
group, we observed low yield aldol side reactions. These re-
sults were successfully applied to chitosan radiolabeling. Both
at 50°C and 70°C, after 30 minutes approximately 70% of
FBAwas built in, but the reaction was faster at higher temper-
ature. This method may be employed for radiolabeling chito-
san, or other nanoparticles based on a polymer rich in amine
groups. ACKNOWLEDGEMENTS: This work was support-
ed by FP7-PEOPLE-2012-ITN (316882 RADIOMI project).
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An efficient radiosynthesis of [18F]Fluoro-inositol
derivatives dedicated to PET imaging
C. Collet1,2, S. Schmitt3,2, S. Lamandé-Langle3,2, F.
Chrétien3,2, F. Maskali1, S. Poussier1,2, P. Marie1,2, Y.
Chapleur1,3,2, G. Karcher1,2; 1Nancyclotep, Vandoeuvre les
Nancy, FRANCE, 2Université de Lorraine, Vandoeuvre les
Nancy, FRANCE, 3UMR 7565, Vandoeuvre les Nancy,
FRANCE.
Introduction: Recent results have shown that inositols deriv-
atives could be an interesting scaffold for the preparation of
new radiotracers usable for the diagnostic of cancer or inflam-
mation but also brain diseases. However, preliminary studies
demonstrated that the 1-fluoro-scyllo-inositol have very low
brain penetration. We have therefore planed the synthesis of
new myo- and scyllo-inositol derivatives radiolabelled with
fluorine-18 which could be more likely to cross the Blood
Brain Barrier.Two types of inositol based radiotracers were
considered. The first one bearing a [18F]fluoro-arm directly
branched on the cycle. In this case the six hydroxyl groups
could be conserved. The second one involved an ether linkage
to add the arm carrying the fluorine-18.Materials &Methods:
Precursors of radiolabelling and cold references were synthe-
sized using acetate as protecting group according to multistep
strategies starting from myo-inositol. The 18F-labelling was
performed using standard labelling conditions (K222/K2CO3,
~10 μmol precursor in acetonitrile, 85-95°C, 5-15 min) on an
AllInOne (Trasis®) module. The radiolabelled compounds
were purified by semi preparative HPLC (conditions: 45/55
ACN/H2O). After evaporation either a deprotection (saponifi-
cation using 2M NaOH) at room temperature for 5 min or a
formulation with EtOH 10%was realized. Mice-Balbc bearing
a 4T1 breast cancer were used as animal models for PET
imaging performed using smal l-animal INVEON
tomograph.Results: Precursors were synthesized in eleven
steps in ~3% yield and the fluorinated references in twelve
steps in ~2% yield. Incorporation of fluorine-18 was per-
formed in 30 to 45 % yield (dc). The corresponding hydrox-
ylated forms were obtained after an efficient deprotection
(90% yield dc). Eight injectable inositol based radiotracers
(scyllo- and myo- configuration, protected and free) were so
obtained in good yield and injected. PET-scan images were
obtained in animals.Discussion/Conclusion: We developed
an efficient automated strategy for inositol radiolabelling with
fluorine-18. Scyllo- and myo-[18F]fluoro-inositol based radio-
tracers were obtained in good radiochemical yield. Their po-
tential application as PET imaging agents is currently under
investigation.
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18F-labeling and in vivo evaluation of PEG modified
polystyrene micelles via PET imaging
J. M. Postema1, L. Jennings2, J. Thackeray3, J. Banksthal3,
G. Waton2, F. Schosseler2, E. Mendes4, T. L. Ross1; 1Radio-
pharmaceutical Chemistry, Department of Nuclear Medicine,
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Hannover Medical School, Hannover, GERMANY, 2Institute
Charles Sadron, CNRS-University of Strasbourg, Strassbourg,
FRANCE, 3Preclinical Molecular Imaging, Department of
Nuclear Medicine, Hannover Medical School, Hannover,
GERMANY, 4, Department of Chemical Engineering, Ad-
vanced Soft Matter, Delft University of Technology, Delft,
NETHERLANDS.
AimMacromolecular structures as drug-delivery-systems
are gaining more and more interest. Their ability to carry
drugs such as chemotherapeutic agents or therapeutic radio-
nuclides to the required site, and their unlimited modifica-
tion possibilities make them perfect for a wide range of ap-
plications from non-invasive molecular imaging to targeted
tumor therapy. One of themost powerful imaging techniques
to study such structures in vivo is PET. In this study we have
focused on the direct 18F-labeling of dimethylsilicium chlo-
ride terminated polystyrene included in PEGmodified poly-
styrene micelles and their subsequent in vivo evaluation in
rodents.Materials and MethodsDimethylsilicium chloride
terminated polystyrene was labeled with [18F]fluoride in
the presence of Kryptofix 2.2.2 and K2CO3 at room temper-
ature in chloroform. Purification of the polymer was
achieved by cartridge-based solid phase extraction. Stability
of the purified micelles was tested against saline over 15
minutes.Micelles made out of PEG modified polystyrene /
dimethylsilicium chloride terminated polystyrene (90/10)
were labeled at 60 °C in chloroform in the presence of
Kryptofix 2.2.2 and K2CO3. Purification was accomplished
by size exclusion chromatography. The 18F-labeled mi-
celles were applied to in vivo PET-imaging in rat and
mouse.ResultsLabeling of dimethylsilicium chloride termi-
nated polystyrene proceeded with yields of up 70 percent at
room temperature within 5 minutes. After purification, the
product was obtained in an excellent radiochemical purity of
≥ 98% (radio TLC). During stability testing the polymer
showed no defluorination or degradation over a period of
15 minutes.The direct 18F-labeling of the provided micelles
proceeded with yields of up to 35% in 15 minutes. The la-
beled micelles were used for preliminary in vivo PET imag-
ing which showed a promising tumor uptake in a tumor
bearing rat. Further in vivo studies with the 18F-labeled mi-
celles in mice are currently underway.ConclusionWe have
successfully labeled dimethylsilicium chloride terminated
polystyrene with 18F under mild conditions. Furthermore,
we have been able to label micelles in one-step with 18F. The
new 18F-micelles were applied in first in vivo studies in a
tumor bearing rat, which showed very promising tumor up-
take with very low unspecific background in healthy tissue.
Further studies are ongoing.This work was funded by the
People Program (Marie Curie Actions) of the EU FP7/
2007-2013 (No. PITN-GA-2012-317019 ‘TRACE ‘n
TREAT’).
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An adapted GMP-compliant production of [18F]FAZA
on a cassette based synthesis unit for the detection
of hypoxia using positron emission tomography (PET)
O. C. Neels, Y. Remde, U. Hennrich, K. Kopka; German
Cancer Research Center, Heidelberg, GERMANY.
Aim: [18F]FAZA ([18F]Fluoroazomycin Arabinoside) is a
well-known radiopharmaceutical that has been successfully
used for the detection of hypoxia using PET. Due to its use-
fulness for radiation therapy planning the aim of this project is
to set up a quick and reliable method for the fully automated
synthesis of [18F]FAZA on a cassette based synthesis unit.
Materials and Methods: An aqueous solution containing
[18F]fluoride was obtained by nuclear reaction (18O(p,
n)18F) from a Scanditronix MC32NI cyclotron, transferred
to a Trasis All in One synthesis module, trapped on and eluted
from a QMA cartridge using standard procedures (Kryptofix/
K2CO3 in water/acetonitrile). After azeotropic drying, 10 mg
of precursor 1-(2,3-Diacetyl-5-tosyl-(-D-arabinofuranosyl)-2-
nitroimidazole in 1 mL anhydrous DMSO were added and
heated for 10 minutes at 120°C. The reaction mixture was
cooled down to room temperature and protecting groups were
removed by addition of 1 mL 1 M NaOH solution for 3 mi-
nutes. pH was adjusted with 1 mL 0.4 M NaH2PO4 solution,
diluted with 2 mL 10 mM NaH2PO4/EtOH (90:10) solution
and injected onto a semi-preparative HPLC column (Luna 5μ
C18, 100Å, 250 x 10 mm, 10 mMNaH2PO4/EtOH (90:10), 4
ml/min). [18F]FAZA was eluted from the column after 28
minutes and sterile filtered ready for injection. Quality
control and determination of specific activity was done
using an Agilent HPLC system. Results and Conclusion:
[18F]FAZA can be obtained in decay corrected radio-
chemical yields higher than 25% on a new automated cas-
sette based synthesis module in radiochemical purities >
95% after HPLC purification and good specific activities
within less than 60 minutes after end of radionuclide pro-
duction and is now used for preclinical imaging experi-
ments. Work is in progress to reduce the synthesis time
using a cartridge based purification process to prepare the
clinical transfer of this promising hypoxia imaging PET
tracer.
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The role of 64CuCl2 PET/CT scan in patients
with outspreadedHodgkin Lymphoma. Is the 64CuCl2 apt
to plan a rescue radionuclide therapy?
E. Capasso, Jr.1, S. Massidda2, C. Meleddu1; 1U.O.C. Nu-
clear Medicine, Cagliari, ITALY, 2U.O.C. Hematology and
Bone Marrow Transplantation, Cagliari, ITALY.
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INTRODUCTION AND AIM: 18F-fluorodeoxyglucose pos-
itron emission tomography (18F-FDG-PET) is performed for
staging, restaging and follow up of patients with Hodgkin
Lymphoma. According to new Lugano classification PET-
CT can also replace the bone marrow biopsy (BMBx) for
HL. The FDG-PET is although essential for the best manage-
ment of patients, for instance to identify responders and non-
responders, early during treatment. Infact the use of FDG-PET
imaging to detect residual metabolically active disease is well
validated as a surrogate biomarker for chemoresistance. Since
‘90s the monoclonal antibody (Lym-1) labeled with 67Cu was
used for radioimmunotherapy in non Hodgkin Lymphoma pa-
tients. Nowadays also copper-64-DOTA-Rituximab is of inter-
est in NHL. But what about Hodking Lymphoma? Is 64CuCl2
PET/CT scan apt to study patients with outspreaded Hodgkin
Lymphoma? MATERIALS AND METHODS: Two patients
(P1: 69y Male and P2: 70y Female) affected by refractory
Hodgkin Lymphoma in progression disease neverthless
chemioterapy, radiotherapy and allogenic transplantation
underwent to a diagnostic 64CuCl2 PET/CTwithin two weeks
after a FDG PET/CT. Administered activities were: P1-FDG
372 MBq and P2- FDG 230 MBq. P1 and P2- 64CuCl2 were
370 MBq. The FDG PET/CT scans were obtained from base
of skull to the upper thigh of the patients with a scan/speed of
2,5 min/bed; 1 hour after the radiopharmaceutical administra-
tion. The 64CuCl2 PET/CT scans icluded also the skull vertix,
were performed 3 hours after the administration with a
scan/speed of 2,5 min/bed. The scans were analyzed by two
different physicians. RESULTS AND CONCLUSIONS: All
the avid FDG lesions showed high concentration of 64CuCl2
bo th in the P2 ( r i gh t l ung l e s i ons ) and in P1
(sovradiaphragmatic nodes, left lung and bone areas as left
ribs and L1 vertebrae). The bone areas presented a lower
FDG uptake, didn’t shown 64CuCl2 accumulation (in the left
hip for the P2).These data suggest it could be possibile use
64CuCl2 PET/CT scan in patients with outspreaded Hodgkin
Lymphoma despite best-fulfilled therapy to plan out a tailored
radionuclide therapy. These are preliminary data and it’s nec-
essary to increase the study population.
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A specific fluorescein-combined media fill test
for validation of aseptic radiopharmaceutical preparations
and assessment of good radiopharmacy practice.
A . CHANTRY1 , C . FANTON D ’ANDON1, A .
GOUILLET1, P. GARRIGUE2,1, B. GUILLET1,2; 1AP-
HM, Marseille, FRANCE, 2Aix-Marseille Université, Mar-
seille, FRANCE.
Regularly qualifying the operators constitutes a major lead in
quality management of the radiopharmaceutical unit. Simula-
tion tests like the media fill test (MFT) have already demon-
strated their usefulness and power in the field of
radiopharmacy, assessing the operators’ technique and the en-
vironmental adequacy to produce a sterile drug by aseptic
processing, according to the current Good Radiopharmacy
Practice guidelines (cGRPP). Still, no specific simulation test
exists to match the radiopharmaceutical preparation routine in
terms of volume sampling, specific handled materials and ra-
dioprotection. We developed a simulation test of radiopharma-
ceutical preparations, from the eluate sampling to the syringe
conditioning. Combining fluorescein to a MFT enabled the
additional assessment of the operator’s ability to avoid con-
taminations on the working area. We intend to use this simu-
lation protocol as an initial and periodic qualification method
for the radiopharmaceutical staff. A sterile fluorescein solution
was added to tryptic soy broth in strict aseptic conditions to
enable a final fluorescein concentration of 10 mg/mL. The
protocol consisted in 3 phases, to simulate direct sampling
from the eluate, a 1-step and a 2-step radiopharmaceutical
preparation process in routine conditions under a controlled
environment (shielded class-A hot cell). Right at the end
of each preparation, fluorescein contamination was eval-
uated around the working area using an UV-lamp, and
photographs were taken. Prepared units were incubated
following the manufacturer’s instructions and the ab-
sence of turbidity was visually monitored daily. The op-
erator’s qualification was defined by the absence of mi-
crobiological contamination at day 14. In case of any
microbiological contamination, germ identification would
have been performed. To date, three simulation tests
were carr ied out by a pharmacy technician, a
radiopharmacist, and a pharmacy resident. No microbio-
logical growth occurred. Discreet fluorescein traces were
observed for all three operators on the working area.
Though, as no hazardous handling was observed for
any of the three operators, these insignificant traces
seemed to be rather in relation with the use of open
free needles in our preparation process, in the absence
of any commercialized closed system transfer device
(CSTD) adapted to the radiopharmacy practice. Hence,
all three operators were successfully validated. A wider
use of this simulation test is already intended in two
other radiopharmacies. Still, the tests we performed
highlighted the contamination risks with our current
preparation process, despite working according to the
cGRPP. The necessity of CSTDs should also be bal-
anced with the quantification of this latent contamination
for radioprotection matters.
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Comparison between two compounds of exametazime
produced by different laboratories for labeling
of leukocytes
A. Almarcha Gimeno1, L. Díaz Platas1, M. Romero Otero1,
R. Díaz Exposito2; 1Unidad de Radiofarmacia. Hospital
Clínico Universitario de Valencia, Valencia, SPAIN, 2Servicio
Medicina Nuclear. Hospital Clínico Universitario de Valencia,
Valencia, SPAIN.
AIM: The objective of this study was to compare two com-
mercial compounds of exametazime used in leukocytes label-
ing by evaluating their radiochemical purity (RP) and stability
with time, and the quality of the scintigrafic images obtained
on each of them. MATERIALS ANDMETHODS: 26 patients
with diagnosed prosthetic infection, normal body mass index,
and no antibiotic treatment were selected and divided in two
homogeneous groups. The diagnosis was performed by scin-
tigraphy with 99mTc-exametazime labeled leukocytes and
clinically or microbiologically confirmed. Two different com-
mercial compounds of exametazime, Ceretec® (group A) and
Exametazime-Radiopharmacy® (group B), were used for la-
beling leukocytes in each group of patients. In both cases the
radiochemical purity, the labeling yield and cell viability
were determined. In order to study the stability over time,
one vial of each compound was labeled with and without
cobalt stabilizer solution, and periodic determinations of
the RP were performed during 7 hours after labeling. The
quality of the images was quantitatively assessed by cal-
culating the specific uptake ratio (SUR) between the re-
gions of interest (ROI) corresponding to the lesion zone
and to the contra-lateral symmetric region. The back-
ground image was also evaluated. The data analysis of
the images was performed by one-way ANOVA with
Bonferroni test and expressed as the mean ± SEM. The
correlation index between RP and time was determined by
t-test, using GraphPad Software Inc (San Diego, CA,
U.S.A.). Significance was accepted when p<0.05. RE-
SULTS: There were no statistical differences (p < 0.001)
in the values obtained for the RP (A: 93.98 ± 1.12; B:
91.57 ± 3.14), the SUR (A: 1.466 ± 0.40; B: 1.427 ±
0.53), and the labeling yield (A: 69.58 ± 5.72; B: 57.33
± 10.82). RP decreased over time in all cases, as shown by
correlation indexes between RP and time (A: 0.9831, B:
0.9521, A with cobalt: 0.8903, B with cobalt 0.9397).
CONCLUSION: The results show that there are no differ-
ences be tween both compounds (Cere tec® and
Exametazime Radiopharmacy®), when used for leuko-
cytes labe l l ing . The s tab i l i ty for Exametaz ime
Radiopharmacy® is higher than for Ceretec®, as indicated
in the technical summary. The stability is also higher when
using cobalt as stabilizer.
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Qualitative Determination of Human Antibodies
Against Mouse Immunoglobulin (HAMA)
Before the Administration of 99mTc-Scintimun® Using
the MILLENNIA® QUIKLINE Kit
E. López, E. Ariza, F. Cuevas, M. Cardoso, Y. Santaella, P.
Valderas, F. Martin; SAS, Algeciras, SPAIN.
Aim: To determine in vitro of HAMA from Millennia
®Quikline kit in a radiopharmaceutical unit before the admin-
istration of 99mTc-Scintimun.Materials /Methods: We have
a kit that consists of: - Analysis device HAMA (HAMATest
Unit): membrane covered with mouse IgG combined with
gold nanoparticles.-Buffer of detection (Chase Buffer): pH
7.2 buffer. Card assessment (Evaluation Cards) The method
involves/is to: 1) Add 50 μl of serum on the pad dish analysis
device 2) Add 1 drop of buffer. 3) Incubation: 10 minutes at
room temperature (18-28°C) 4) Qualitative evaluation with the
evaluation card that is included in this package. This device
contains two lines: C Line control and T Line analysis. Inter-
pretation: -If it is Positive: if the T line analysis shows the same
colour or darker than the evaluation line card colour. - If it is
Negative: if the T line analysis shows a lighter colour or a
weaker faded shadow than the line card rating. If no line T is
observed, it is also negative. The C line control should always
appear (it is an operational control and cannot be used to in-
terpret the line of analysis) Results: 15 tests were performed,
and two tests of these were positive and the remaining two
were negative. In 100% C line was obtained as an operating
control. Of these 15, 8 no T line patients were obtained, and
therefore we obtain the negative result of HAMA. In the re-
maining 6, we had to use the card rating for the result of
HAMA (in our case a negative result was obtained). The 1
positive result of the two lines are clearly obtained.
Conclusion: with this kit, we facilitate the determination of
human IgG antibodies in vitro mouse, immediately in
radiopharmacy unit, reducing the economic cost involved in
sending it to external laboratories, such as reducing the waiting
time to perform the test scintigraphy 99mTc-Scintimun and
obtaining improvements for patients.
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Application of Molecular Modelling to Elucidate Liver
Uptakes of 99mTc-Labelled Quinolone Antibiotics
M. Salahinejad, M. Aboudzadeh; Nuclear Science and Tech-
nology Research Institute, Tehran, IRAN, ISLAMIC REPUB-
LIC OF.
Introduction: Metal-based radiopharmaceuticals are of partic-
ular interest and play an outstanding role in both therapeutic or
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diagnostic medicinal purposes. 99mTc-labeled compounds, as
most commonnly used radiopharmaceuticals, are highly desir-
able due to suitable physical properties, nuclear characteristics,
and instant availability and low cost. The aim of this study was
to investigate the application of three-dimensional quantita-
tive-activity relationships (3D-QSAR) methods to elucidate
the liver clearance of 99mTc-labelled quinolone antibiotics.
Material and Methods: Experimental data of the liver up-
takes of 21 99mTc-labelled quinolone antibiotics were taken
from the recently published papers. The distribution data col-
lected in rats and mice and experimentally induced infection
using Staphylococcus aureus or E. coli.Comparative molecu-
lar field analysis (CoMFA), as a powerful method in 3D-
QSAR approach was used for molecular modelling. The
CoMFA descriptors, as independent variables correlated with
the log value of liver uptakes of 99mTc-labelled quinolone
antibiotics as dependent variable, employing Partial least
squares (PLS) regression analysis to construct 3D-QSAR
models. Results: The CoMFA model yielded a leave-one-out
cross-validated Q2 = 0.58 with six components, non-cross-
validated or calibrated, R2 (cal) of 0.98 with standard error of
estimation, SEE=0.03 and predicted R2(pred)=0.6 with stan-
dard error of prediction SEP=0.14 for biodistribution of anti-
biotics in liver uptakes. The large size of the sterically
unfavored yellow region around quinolone backbone indicat-
ed that the steric effects have an important impact on liver
uptakes of antibiotics. Blue contours represent regions where
positive charge increases liver uptakes of antibiotics, whereas
red regions represent areas where the negative charge en-
hances it. Conclusion: Combining chemoinformatics and 3D
molecular modeling approaches might be very useful for the
development of new ligand in metal complexation. They pro-
vide alternative, robust and computationally cheap prediction of
desired property in the absence of extensive experimental or
computed data. These models could provide some invaluable
information in the design and development of new 99mTc-
labelled radiopharmaceuticals with focusing on the modification
and optimization of known biologically active ligand structure.
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Assessment of microbiological monitoring
for the evaluation of GMP-compliance at a department
of Nuclear Medicine and Molecular Imaging
of the University Medical Center Groningen
M. Beugeling1, F. Ekoume2, H. J. Woerdenbag3, G.
Luurtsema1, M. N. Lub-de Hooge1, D. J. Touw1, S. M.
Rubow4, H. H. Boersma1; 1University of Groningen,
UMCG, Groningen, NETHERLANDS, 2Hôpital General de
Yaoundé, Yaoundé, CAMEROON, 3University of Groningen,
Department of Pharmaceutical Technology and Biopharmacy,
Groningen, NETHERLANDS, 4University of Stellenbosch,
Tygerberg Hospital, Department of Nuclear Medicine,
Cape Town, SOUTH AFRICA.
Objective: The purpose of our study was to assess trends and
deviations from microbiological monitoring in de cleanroom fa-
cilities at the department of Nuclear Medicine and Molecular
Imaging of the University Medical Center Groningen over the
past five years. This was done to evaluate the status of GMP-
compliance.Methods: Data from active air sampling, passive air
sampling, particle counting and contact prints from microbiolog-
ical monitoring performed over the past five years were collected
from our data bases. These tests are carried out routinely to com-
ply with the applicable GMP-regulations. The data were retro-
spectively analyzed by counting the number of measurements
and calculating the number of crossings of the set limit for each
sampling location and each test. Statistical analysis was done by
performing a Fisher’s exact test (P < 0.05, 2 sided) to assess
statistically significant differences between the years. Results:
For evaluation, data of 40 sampling locations were analyzed.
The number of measurements carried out in 2014 complied with
the number of measurements indicated in the Standard Operation
Procedure ‘Monitoring clean rooms NMMI’, except for the con-
tact prints. This means that, when the recent data were compared
to older data, many improvements were seen in the environmen-
tal monitoring results. This is particularly demonstrated by the
microbiological data for one of the grade A with the grade B
background hotcells. Comparing the environmental monitoring
data of 2012 and 2014, most parameters (including particle
counts, settle plates and active air sampling) markedly improved
(>5 times decrease of limit crossings) and were statistically sig-
nificant (p<0.01). Similar results were found in most other areas.
However, in general, the results of the contact prints did not
correlate with these results, indicating that the cleaning and
disinfecting procedures still have to be improved. Conclusion:
We subscribe the obtained improvements to the fact that the
department demonstrated to be able to improve the premises,
skills, training and attitude of the staff in the course of the period
under investigation. Themain weak point in environmental mon-
itoring results for the department relates to contact prints. Both
frequency and outcome need to be adjusted. Employees have to
be re-trained in performing this sampling.Moreover, the cleaning
and disinfecting procedures are to be improved, which can be
achieved by additional training as well. In conclusion, the long-
term evaluation of combined results from routine monitoring is a
useful tool in continuous Quality Assurance.
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Labelling of leucocytes with 99mTc-HMPAO: a plasma
gelled story
S. Bulcourt, E. Malek, M. Lamballais; Valenciennes Hospital,
Valenciennes, FRANCE.
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AimIn our Nuclear Medicine Department, the labelling of autol-
ogouswhite blood cells (WBCs)with 99mTc-HMPAO is awide-
ly used method to detect sites of infection. Each step of the
process are carried out in sterile conditions in a laminar flow
cabinet (class A). WBCs are isolated by sedimentation of eryth-
rocytes and centrifugation of leucocyte-rich plasma. After label-
ling, the radioactive WBCs suspension is infused to the patient,
therefore planar scintigraphy and SPECT/CT are
performed.Materials and methodsUsually, the pellet containing
the labelled mixed leucocytes is resuspended in cell-free plasma.
Sometimes, this last step did not go as planned.In November, it
has happened that the cell-free plasma has gelled during isolation
and labelling of WBCs. For this reason, it was impossible for us
to use this plasma for labelled mixed leucocytes
resuspension.ResultsIn absence of validated data concerning
WBCs viability in pellet, we are in emergency to find a proper
solution for this last step of preparation. That’s why the use of
0.9% aqueous solution of sodium chloride (saline) seems to be
relevant in order to proceed to a successful infusion for our
patient.Our quality assurance system is based on failure modes
and effects analysis. Then, we investigated this case with multi-
disciplinary point of view (pharmacist, radiopharmacist, biologist
and physicians). The hypothesis of cold agglutinin disease was
tested, therefore we incubated the cell-free plasma gelled at 37°C
for one hour. As the plasma start to liquefy back, we confirmed
this hypothesis.ConclusionAfter this event and this analysis, we
modified our standard operation procedure for WBCs pellet re-
suspension. In normal condition, cell-free plasma keep to be the
reference material for resuspension step. But, we formalize the
use of saline solution in several situations, for example, cold
agglutinin disease. Besides, we extended the saline solution use
in case of hemolysis of the cell-free plasma.
P303
Bacterial Endotoxin and Sterility Testing of Active
Pharmacological Ingredients used in the production
of different Fluorine-18, Gallium-68 and Lutetium-177
labeled Radiopharmaceuticals
A. Mitra, S. Lad, S. Kulkarni, M. G. R. Rajan; Medical Cy-
clotron Facility, Radiation Medicine Centre, BARC & BRIT,
TMH Annexe, Parel, Mumbai, INDIA.
AIM: The aim of the present study was to validate biological
quality control tests, viz., bacterial endotoxin test (BET) and
sterility test of the active radiopharmaceutical ingredients
(API) viz., precursors, reagents and solvents used in the
radio-synthesis of different [F-18], [Ga-68] and [Lu-177] la-
beled radiopharmaceuticals. The validation is a requisite as per
the CGRP guidelines. MATERIALS: Acetonitrile, Acetone,
DMSO, Ethanol, TBAHCO3(75mM), CH3COONa(0.2M),
CH3COONH4(0.1M ) NaCl(10%), NaH2PO4(1M),
HCl(1N/0.1N), NaOH(0.33N), Ethanolic-water(50-8%),
HCl(0.02N)/acetone(98%), Mannose-triflate, ethylene-di-tos-
ylate, L-Tyrosine, Ni(II)-FBPB-Tyrosine-OTs, 4-nitro-benzal-
dehyde, Anhydro-DMTr-Thymidine, Lysate(λ:0.125/0.03EU/
ml), Tris-base/HCl(0.25/0.5/0.1N). Cultures of s.aureus,
p.aeruginosa, b.subtilis, c.albicans were obtained from Micro-
biologics Inc, Minnesota, USA. METHODS: The endotoxin
limit (EL) for API’s was fixed at 1EU/mg(precursor), 5EU/
ml(reagents) and 2EU/ml(solvents) based on concentration,
volume used and alteration limit. BET assays were performed
by gel-clot method using two sensitivities of lysate. MVDwas
calculated considering the sensitivity of lysate, EL, concentra-
tion and volume of API’s used for radiosynthesis. Sterility
testing was validated by direct inoculation(DI) method using
FTM and SCD media. Positive controls for s.aureus,
p.aeruginosa, b.subtilis, c.albicans were set up at bacterial con-
centration <100CFU (serial dilution- spread plate method) and
corresponding negative controls were set up with and without
APIs. RESULTS: In BET, HCl, NaOH, CH3COONa,
CH3COONH4, HCl/acetone exhibited inhibition due to ex-
treme pH. However, inhibition could be resolved by neutral-
izing with sterile and endotoxin negative (<0.25EU/ml) Tris-
base/HCl at first dilution. BET assay of organic solvents did
not demonstrate any inhibition, since the test volume is 1.0/
1.5ml (typical volume used in radiosynthesis). However, with
the increase in test volume of organic phase, MVD was de-
creased resulting in inhibition in the assay, which was reversed
by short evaporation step at corresponding boiling point.
NaCl, NaH2PO4, TBAHCO3 and ethanolic-water (8 - 50%)
did not show interferences. In sterility testing, luxuriant
growth was observed for positive control culture in the pres-
ence of 1ml of any of acetonitrile, acetone, ethanol or DMSO
following incubation for 24 hour (s.aureus, p.aeruginosa) and
72 hours (b.subtilis, c.albicans). Growth of all these microor-
ganisms were partially inhibited (<100 CFU) in HCl(1N) and
TBAHCO3(75mM). However, good growth were observed
on neutralization with sterile and endotoxin negative Tris-
buffer (0.5N) and addition of polysorbate-80(0.05%) respec-
tively. Mannose-Triflate and other reagents exhibited no inhi-
bition with all the above strains. No growth was seen in all
APIs without the addition of above microorganisms (negative
controls). CONCLUSIONS: Standardizing of sterility and
BET for various APIs used in radiopharmaceuticals’ produc-
tion was carried out using suitable methods that are validated.
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In vitro stability study of 90 Yttrium-microsphere
for the treatment of hepatocellular carcinoma
V. Ardisson, N. Lepareur, E. Garin; CLCC Eugène Marquis,
Rennes, FRANCE.
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Aim: Hepatocellular carcinoma (HCC) ranks third in cancer-
related deaths worldwide. Trans-arterial radioembolization
(TARE) with 90 (Y-90)-microspheres provides an opportunity
for the direct deposition of radiation into malignant HCC tu-
mors and represents a new generation of therapeutics in inter-
ventional oncology. The physical and chemical stability of the
Y-90 microspheres are critical to ensure the radiation dose
remains at the desired site of action, thereby minimizing the
possibility of systemic Y-90 exposure and undesirable bone
fixation. Therefore, the objective of this study was to charac-
terize the stability properties of various Y-90 microsphere
products by measuring their levels of in-vitro Y-90 leaching
from various mediums like saline or human serum samples.
Methods: Leaching was studied with resin and glass micro-
spheres in different media: saline or human serum at 37 ° C in
the presence and absence of sample stabilizers such as 1N
HCL or Yttrium 89. These additive compounds were added
to limit the precipitation of yttrium as the form of hydroxyl or
the bounding to serum proteins. Free 90Y was determined in
the medium at 37 °C for 0, 1, 24, 48 and 72 hours by gamma
counting. Measurements were taken after centrifugation of an
aliquot of the supernatant. Results: We found about 0.6% of
free Y-90 in the product shipment medium. In 0.9% NaCl
solution, 0.05% of Y-90 leached from glass microspheres
and up to 1.59% from the resin microsphere. After incubation
of the resin spheres in serum, leaching increases from 0.2 to
5% from 1 to 72 h. However in the presence of yttrium 89, 15
to 60% free yttrium found in the supernatant. No physical
degradation of the spheres was observed by optical microsco-
py. After incubation of the glass spheres in the serum, leaching
increases by 0.15 to 2% from 1 to 72 h. Conclusion: Yttrium-
90 is directly integrated glass formulation, and showed a
higher stability than the resin microspheres product, where
the Y-90 is immobilized with weaker ionic interaction. Solu-
bilization of yttrium-90 from the microspheres can depend on
many parameters which can leads to a large variability in the
results. The addition of yttrium 89 (or other strong cations) in
the serum to saturate the serum protein causes a massive re-
lease of yttrium 90 from resin microsphere. In this situation,
leaching is much more significant with resin microsphere than
glass microsphere.
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Quality control validation of 16β-[18F]
fluoro-5α-dihydrotestosterone produced with the FlexLab
radiosynthesiser
J. G. Chan, K. Young, U. Ackerman, H. Tochon-Danguy, A.
Scott; Austin Health, HEIDELBERG VIC, AUSTRALIA.
Background: The 18F labelled 16β-[18F]fluoro-5α-dihydro-
testosterone (18F-FDHT) analog has been identified as a
promising PET tracer for imaging the androgen receptor. The
complex synthesis was performed using a FlexLab
radiosynthesizer (iPHASE Technologies), which has proven
to be reliable for the radiolabelling of other complex mole-
cules. A fully automated and reliable synthesis for 18F-
FDHT was developed with overall radiochemical yields of
18-23% (decay corrected). Aim: In this study the 18F-FDHT
automated production method was validated for use in human
studies. Method: Validation was performed with the usual
physiochemical and biological testing which included endo-
toxin, sterility, residual solvents, radionuclidic identity and pH.
Radiochemical purity was performed using a Shimadzu Prom-
inenceHPLC system. The stationary phase was a Phenomenex
Gemini NX C18, 5μ RP column, 150 x 4.6 mm. Acetonitrile/
water (55:45) was used as the mobile phase at a flow rate of 1.0
mL/min. Specific activity was measured at UV 220 nm wave-
length. Stability testing was observed for 5 hours. Result: 18F-
FDHTwas produced with a radiochemical purity >98% and a
specific activity > 55.5 GBq/μmol (1.5 Ci/μmol). The final
product passed all physiochemical tests as well as endotoxin
and sterility tests. The product is stable for at least 5 hours.
Conclusion: The fully automated production of 18F-FDHT
using the FlexLab radiosynthesizer was successfully validated
for use in human studies.
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A Study of the Influence of Physicochemical Reaction
Parameters on the Radiolabelling Efficiency and Stability
of Two Types of 99mTc Radiolabelled Nanoparticles
C. Stefanescu1,2, G. Dodi3, A. Cazacu4, C. M. Uritu5, M.
Pinteala5, A. Timofti2, V. Ghizdovat1,2, I. C. Grierosu1,2;
1Department of Biophysics and Medical Physics, Faculty of
Medicine, “Grigore T. Popa” University of Medicine and
Pharmacy, Iasi, ROMANIA, 2Department of Nuclear Medi-
cine, “St. Spiridon” Hospital, Iasi, ROMANIA, 3Faculty of
Chemical Engineering and Environmental Protection, “Gh.
Asachi” Technical University, Iasi, ROMANIA, 4Department
of Sciences, University of Agricultural Sciences and Veteri-
naryMedicine, Iasi, ROMANIA, 5Advanced Research Centre
in Bionanoconjugates and Biopolymers, “Petru Poni” Institute
of Macromolecular Chemistry, Iasi, ROMANIA.
Aim: 99mTc radiolabelled nanoparticles are promising radio-
tracers both for nuclear medicine diagnosis and treatment,
great efforts being made to achieve stable and effective sys-
tems. In this context, the aims of this study are to better define
the relation between different physicochemical reaction pa-
rameters and the radiolabelling efficiency of two types of
nanoparticles with 99mTc, in order to develop an optimal pro-
tocol for new radiopharmaceuticals obtaining.Materials and
methods: Two types of nanoparticles were used, namely PEG
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and PEI coated gold nanoparticles (AuNPs-PEG-PEI) and
PEI-derivative fullerene (C60-PEI). As radioisotope for label-
ling, 99mTc was used. Na+ 99mTcO4- was eluted from a
99Mo/99mTc Drytec Generator system, supplied by GE
Healthcare. The 99mTc-NPs coupling was realised by reduc-
ing, in a first step, Na+ 99mTcO4- with sodium borohydride
(NaBH4) in the NPs solutions. The radiolabelling efficiency
was assessed by using instant thin layer chromatography
(ITLC). The parameters taken into account for this study were:
the variation of the reducing agent concentration (12.5, 25, 50,
75 and 100 mg/mL) and the variation of the Na+ 99mTcO4-
dose used (1, 3 and 5 mCi). 99mTc-NPs coupling stability in
time (0 - 4 h) was also assessed.Results: The radiolabelling
efficiency was different for the two types of NPs used. This
could be related to the functional groups existent on the NPs
surface. The best radiolabelling efficiency was obtained in the
case of AuNPs-PEG-PEI (92.81%). By ranging the NaBH4
concentration, we found that the optimal concentration to be
used is 12.5 mg/mL, the radiolabelling efficiency ranging, ini-
tially, from 77.20% (for 100 mg/mL NaBH4) to 92.81% (for
12.5 mg/mL NaBH4). We also found that, in the absence of
active NaBH4 the radiolabelling efficiency decrease dra-
matically (less than 5%), for both types of NPs. Regarding
the coupling stability in time, was noted that the
radiolabelling efficiency increased slightly, most probably
because of the continuous reducing agent action. Also, our
experiments showed that best radiolabelling results were
obtained for the Na+ 99mTcO4- dose of 1 mCi, both for
AuNPs-PEG-PEI and C60-PEI.Conclusion: These studies
showed that the radiolabelling of NPs systems, as new
promising radiopharmaceuticals, is greatly dependent on
physicochemical reaction parameters. Optimum parame-
ters can be established for each type of radiolabelled
NPs. AuNPs-PEG-PEI seems to be more easi ly
r a d i o l a b e l l e d w i t h 9 9 m T c t h a n C 6 0 -
PEI.Acknowledgements: This work was financially sup-
ported by PN-II-ID-PCCE-2011-2-0028 and POSDRU/
159/1.5/S/133652 projects.
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Evaluation of in vivo and in vitro stability
of Lu-177-DKFZ-617 for systemic radionuclide therapy
in patients with castration resistant prostate cancer
M. Ocak1, A. Aygun2, N. Yeyin2, E. Demirci3, E. Karayel2,
A. Araman1, L. Kabasakal2; 1Department of Pharmaceutical
Technology, Pharmacy Faculty, Istanbul University, istanbul,
TURKEY, 2Department of Nuclear Medicine, Cerrahpasa
Medical Faculty, Istanbul University, istanbul, TURKEY,
3Department of Nuclear Medicine, Sisli Etfal Training and
Research Hospital, istanbul, TURKEY.
Introduction & Aim: Recently Lu-177-DKFZ-617 PSMA li-
gand has been shown as a promising novel radioligand for
systemic radionuclide therapy in patients with castration resis-
tant prostate cancer (1). For effective and safe targeted radio-
nuclide therapy in vivo and in vitro stability of the radioligands
is one of the most important parameters. Therefore the aim of
this study was to evaluate in vivo stability of Lu-177-DKFZ-
617 PSMA ligand in patients with castration resistant prostate
cancer and to determine the in vitro stability in prepared pa-
tient dose. Materials and Methods: 177Lu-DKFZ-617 (~100
mci, n=4 ; ~200 mci, n=3) was applied to the patients and after
application stability of 177Lu-DKFZ-617 in urine analyzed up
to 24h. Stability of 177Lu-DKFZ-617 in blood analyzed 0.,
30., 60., 120., and 180. min post administration. For determi-
nation of the in vitro stability of 177Lu-DKFZ-617, prepared
patient dose incubated up to 48 h at 37°C in saline. Stability
analysis of 177Lu-DKFZ-617 at different time points in dif-
ferent media was performed by using radio-reversed-phase
high-performance liquid chromatography (radio-RP-HPLC).
Results:We found that radioligand was always remained intact
in urine, blood and saline at all testing time points, giving 99%
of radiolabelling stability in all samples and excreted through
urine without any damage to the compound. Conclusion:
177Lu-DKFZ-617 PSMA ligand stayed very stable at
in vitro and in vivo conditions during the tested time points
and no radiometabolites were detected confirming the good
metabolic stability of this radioligand.
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Qualitative and quantitative evaluation of a single eluate
from two 68Ge/68Ga generators sequentially connected,
without any pre-purification
I. Vaccaro1, F. Giurgola1, S. Grugni1, G. Tarullo1, K.
Marzo1, A. Chiti2; 1IRCCS Istituto Clinico Humanitas,
Rozzano, ITALY, 2Humanitas University, Rozzano, ITALY.
AIM: The aim of our study is to validate the possibility to
synthesize 68Ga-DOTA peptides using the elution of two
Eckert-Ziegler 68Ge/68Ga generators sequentially connected
avoiding prepurification methods. MATHERIAL AND
METHOD: We used two 68Ge/68Ga generators loaded with
1850 MBq of Germanium-68 at calibration date. 68Ge was
adsorbed over a TiO2 resin and 68GaCl3 was eluted with
0.1NHCl. For this study we connected two generators through
a PTFE tubing between the outlet of the first generator and the
inlet of the second one: a singlemobile phase bottle is linked to
the inlet line of the first generator and the eluate is collected at
the outlet port of the second generator. Total activity obtained
from both generators can be used for radiopharmaceutical syn-
thesis. The elution is done with a 10ml syringe in two different
steps. The volume of 12 ml of 0.1N HCl required to remove
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the total activity from both generators is aspirated in two dif-
ferent steps of 6 ml, using the 10ml syringe. This elution is
done by an automatic system created by Eckert-Ziegler for a
single generator by means of a fractionated method. Usually it
allows to use only the central fraction of elution, the one witch
contains the peak of radioactivity. The initial and final frac-
tions are discarded due to the presence of impurities. For the
elution of two different generators we reduced the speed of the
syringe and we changed the volume of the mechanical elution.
In this way, we collected the two different central fractions in a
single rate containing total radioactivity available for the label-
ing without any pre-purification steps. RESULTS: Reducing
the syringe speed we obtained a high elution reproducibility in
terms of volume and activity: 12±0.1ml and 33±0.2mCi. The
ability to eluate two generators sequentially connected allowed
us to sum the activity from single generators and maximize the
yield of elution. The Germanium-68 breakthrough is compli-
ant with the Eu.Ph. dossier requirements. CONCLUSION:
This technique allows to use the generator for a more than
300 elutions and postpone its disposal. The production of
DOTA-peptides is possible because the eluate of the older
generator maintains its purity characteristics even after the
300 elutions and the volumes are compatible with the
synthesis.
P309
99mTc-MAA preparation for radioembolization;
from just-in-time to just-in-case
J. Prince, M. G. E. H. Lam, N. de Wit, R. R. de Roos, A. D.
Barten - van Rijbroek, M. A. A. J. van den Bosch, G. C.
Krijger; UMC Utrecht, Utrecht, NETHERLANDS.
Aim: Macroaggregates of 99mTc-albumin (99mTc-MAA)
serve as scout dose for radioembolization. In most cases,
99mTc-MAA are prepared when requested by the interven-
tional radiologist. This preparation (30 minutes handling time)
hampers logistics and increases total procedure time. The aim
of this study was to evaluate the stability of 99mTc-MAA after
preparation when during routine preparations. Materials and
methods: The study was designed in two parts: 1) 99mTc-
MAA stability was analyzed in vitro, and 2) 99mTc-MAA
stability was analyzed in vivo by correlating lung shunt to time
interval between preparation and administration. 99mTc-
MAA (Technescan LyoMAA,MallinckrodtMedical B.V.) sta-
bility was analyzed after 0, 0.5, 1, 2, 4, 8, and 24 hours (3
syringes per timeslot). The hypothesis was that the stability
decreased over time due to disintegration and/or oxidation to
pertechnetate (99mTcO4-). The particle size distribution was
analyzed using both the Coulter principle (Multisizer,
Beckman Coulter) and the automated count of the longest
diameter on 100x magnification optical microscopy (ImageJ,
U.S. NIH). Both methods were calibrated using spheres with a
known size of 30 μm (NIST standard reference material poly-
styrene spheres). The presence of pertechnetate was measured
using thin layer radiochromatography (iScan, CANBERRA).
In vivo, 112 patients, undergoing 139 infusions, were eligible
for radioembolization between March 2011 and November
2013 and were included in the retrospective study. The lung
shunt was determined on SPECT-CT. The correlation between
lung shunt and time interval between preparation and admin-
istration was analyzed using Pearson’s correlation coefficient.
Results: More than 99% of the particles had an acceptable
diameter 5-40 μm (volume-based), except for 1 out of 3 mea-
surements on t=0.5h (97%) and 1 out of 3 measurements on
t=2h (84%). Automated counting showed a mean longest di-
ameter of 23 μm (SD 10) at t=0h. It did not increase after 24
hours (mean 21μm, SD 11). The presence of pertechnetate fell
within specifications (<7%) in all 21 syringes. The median
time interval between preparation and administration was 23
minutes (range 9-91min). Themedian absorbed lung dose was
1 Gy / GBq 90Y (range 0.2-18 Gy / GBq 90Y). No correlation
was found; the coefficient was -0.09 (95% CI -0.26 - 0.08, p-
value = 0.29). Conclusion: No significant disintegration or
oxidation of 99mTc-MAA was found in vitro, nor was time
interval between preparation and administration correlated to
an increased lung shunt in vivo. 99mTc-MAA can be prepared
during routine syringe preparations instead of on demand.
P310
Labeling and quality control of a heterocyclic nitrogen
containing side chain bisphosphonate with 99mTc
as a skeletal imaging agent
M. Erfani, S. Shirmardi; Radiation Application Research
School, Nuclear Science and Technology Research Institute
(NSTRI), P.O.Box: 14395-836, Tehran, IRAN, ISLAMICRE-
PUBLIC OF.
Diphosphonates are categories of drugs that used for treatment
of osteoporosis and similar diseases. They have a firm tenden-
cy for calcium phosphates and for hydroxyapatite. They have
been labeled with gamma emitting radionuclides to image the
bone metastases. Nevertheless, it is unclear that which bis-
phosphonate is the best option when it is labeled with techne-
tium-99m.A last bisphosphonate generation, 2-(3-pyridinyl)-
1-hydroxyethane diphosphonic acid which has heterocyclic
nitrogen containing side chain, was labeled with 99mTc. La-
beling was performed at room temperature for 15 min and its
radiochemical analysis included was TLC method. The stabil-
ity of radiconjugate was checked in the presence of human
serum at 37 °C up to 6 h. Biodistribution was studied in
mice.Labeling yield of more than 98% was obtained corre-
sponding to a specific activity of 92 MBq/μmol. The
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radioconjugate showed good stability in the presence of hu-
man serum. Biodistribution studies in mice showed that
radioconjugate accumulated in bone with high uptake (7.47
± 0.25% ID/g at 4 h post injection). In addition, the bone to
liver uptake ratios of radioconjugate was 11.67 at 4 h post
injection.These high bone activity values, especially evident
in time passage, could be due to the potent binding to hydroxy-
apatite crystals in bone and high stability of radioconjugate.
These characteristics could be supposed as the major advan-
tages of this radioconjugate as a candidate for skeletal imaging
and tumor metastases in bone.
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Research to create a miniature generator
of technetium-99m
A. Rogov, V. Sкuridin, E. Stasyuk, E. Nestwrov, E. Ilina;
National Research Tomsk Polytechnic University, Tomsk,
RUSSIAN FEDERATION.
Currently, radiopharmaceuticals based on the short-lived ra-
dionuclides technetium-99m (99mTc) are used for diagnostic
research in many areas of medicine. Most of the global market
accounted for chromatographic 99mTc generators, which are
easy to operate and can be transported over long distances. For
their manufacture requires high activity 99Mo (200 Ci/g), ex-
tracted from fission products of uranium-235 by costly and
environmentally dangerous technologies. An alternative pos-
sibility for production of 99Mo is its receipt by the radiative
capture (n,γ) by irradiation of molybdenum-98 neutron nucle-
ar reactor. This technology has virtually no waste, but the
resulting product has a low specific activity of 99Mo at 7-9
Ci/g. In this regard, it becomes necessary to use a large amount
of Mo, about 150-190mg. In world practice for the manufac-
ture of generators sorption of technetium-99m, as a sorbent,
are applied different forms of aluminum oxide. Capacitance by
Mo adsorbent has a limit within 22-25mg of activated Mo per
gram of sorbent. For this reason, for placement on the surface
of the sorbent 190 mg of Mo is necessary to use 7.6 to 8.6g of
the sorbent, which increases the size of the column and the
device, respectively. To investigate the possibility of creating a
sorption generator in a small version, conducted a series of
studies for increasing sorption capacity of the sorbent. De-
pending on pretreatment aluminas becomes possible to pre-
pare the sorbent capacity of at Mo approximately equal to
34mg/g. This is achieved by using a set of measures for the
preparation of the sorbent and methods of filling sorbent con-
taining the Mo solutions. As a result, there is a significant
reduction in weight required for the application of sorbent
from 8.6g before 5.6g leads to a reduction of the column and
the generator frame. As a result of the research a number of
proposals to create a compact design technetium generator and
a number of methods by their manufacture. This work was
performed on the unique scientific IRT-Tequipment and finan-
cially supported by Government represented by the Ministry
of Education and Science of the Russian Federation
(RFMEFI59114X0001).
P312
Cost Effective and Integrated Capture Systems
for Radioactive Gases Generated During Automated C-11
and F-18 Radiopharmaceutical Synthesis
D. H. R. Stimson, A. J. Pringle, D. Maillet, A. R. King, S. T.
Nevin, T. K. Venkatachalam, D. C. Reutens, R. Bhalla; Centre
for Advanced Imaging, the University of Queensland, St
Lucia, QLD, AUSTRALIA.
Aims:The emphasis on the reduction of radioactive emissions
associated with PET radiochemistry laboratories has increased
due to the greater number of facilities worldwide. Historically,
various radioactive gas management strategies have been re-
ported including gas compression systems. These systems
however, may be incompatible with flammable gases and
can be prohibitively expensive. More recently, the use of gas
sampling bags has been reported (Schweiger, 2011). This ap-
proach however, lacks any safety signal feedback putting the
system at risk if overfilling occurs or if the bag is
unattached.The aims of this work are to develop and imple-
ment a cost-effective gas capture strategy that is suitable for (a)
multiple F-18 radiosynthesis modules and (b) use with indi-
vidual C-11 radiosynthesis modules. The 2 different gas cap-
ture systems should have feedback, be integrated with the
Cyclotron Safety System and have the capability of being
safely emptied of radio-decayed gases without disconnection
from the exhaust lines of the radiopharmaceutical
synthesizers.Materials and Methods:(a) The exhaust lines of
the F-18 radiosynthesis modules were connected to a large gas
capture bag located in the cyclotron vault. The bag is fitted
with a sensor arm to indicate the bag status. A manual 3-way
valve with micro-switch is fitted to the bag inlet which allows
the bag to be either filled during cyclotron target transfer/
radiosynthesis or emptied.(b) A 4-port/2 way automated
switching valve with position sensor was installed in the
C-11 synthesizer. The synthesizer exhaust was connected to
the switching valve so that gases are directed to a gas capture
bag. The alternative valve position allows the bag to be emp-
tied and directs exhaust gases to ventilation during module
clean cycles. Similar to (a), the bag is fitted with a sensor
arm.For (a) and (b), the valve position and bag status signals
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are sent to microprocessors that are integrated with the Cyclo-
tron Safety System. This prohibits the transfer of radioactive
gas unless the bag is empty and the valve is in the correct
position (“Ready to Receive” signal).A series of target trans-
fers and radiosyntheses were conducted with exhaust stack
monitoring used to detect any release of radioactive gas from
the systems.Results and Conclusion:A cost-effective gas cap-
ture strategy was developed and implemented that is fully
integrated with the Cyclotron Safety System. The gas capture
system can be emptied without disconnection from the synthe-
sizer. Stackmonitoring data demonstrate that the system is safe
and effective.
P313
A New Model of Ge-68/Ga-68 Generator
M. Li, H. Chu, C. Lee, H. Chang; Institute of Nuclear Energy
Research, Taoyuan, TAIWAN.
Objectives : A Gallium-68(Ga-68) radioisotope generator in-
cludes a generating column and a citrate eluent. The generat-
ing column is at least partially filled with ion-exchange resin
with glucamine groups to absorb Ge-68 and Ga-68 radioiso-
topes. The citrate eluent is conducted to the generating column
to desorb the Ga-68 radioisotope and thereby generate an elu-
ent containing the Ga-68 radioisotope in the form of citrate
gallium. A Ga-68 radioisotope generating method is also
disclosed. Conclusions : In summary, a Ga-68 radioisotope
generator and a method applied in the same in accordance with
the present invention are characterized by the use of an organic
resin (i.e. ion-exchange resin with glucamine groups) and its
selective absorption for Ga-68 in comparison with Ge-68 to
generate Ga-68 nuclide. The apparatus in accordance with the
present invention is simple designed, easily operated and suit-
able for various hospitals and research institutes to provide the
public better clinic diagnosis in the field of nuclear medicine
and increase social welfare. Results : As shown in FIG. 1,
when the amount of the added citrate eluent is sufficient, such
as 10 ml, the 0.1 or 0.2M citrate eluent (illustrated as the
curves labeled with rhombuses and triangles respectively) or
the 0.1 or 0.2M citrate eluent at specific pH value (pH 9,
illustrated as the curves labeled with squares and crosses re-
spectively) can perform a high level of the Ga-68 elutriation
rate (at least close to 50%). Taking the 0.2M citrate eluent
10 ml as an example, its elutriation rate is 4.5×10-3%. Oppo-
sitely, the elutriation rate of the Ga-68 radioisotope is up to
75.5%. Methods: To achieve the above objective, a Ga-68
radioisotope generator in accordance with the present inven-
tion includes a generating column and a citrate eluent. The
generating column is at least partially filled with an ion ex-
change resin with glucamine groups to absorb Ge-68 radioiso-
tope and Ga-68 radioisotope. The citrate eluent is added into
the generating column to desorb the Ga-68 radioisotope and
form an eluent containing the Ga-68 radioisotope in the form
of Ga-68 citrate.
P314
Determination of the pH of the Radiopharmaceutical
Products in Saline
J. Laine, T. Lipponen, K. Bergström; HUS Medical Imaging
Center, Helsinki, FINLAND.
Aim: In our routine production of 68Ga-Dotanoc, the pH in-
dicator strips are used for the determination of pH of the prod-
uct as it is recommended in the monograph of the gallium
(68Ga) edotreotide injection in European Pharmacopoeia 8.0.
The pH indicator strips are validated with NIST standard buff-
er solution as also recommended in Pharmacopeia. During
several years of production, we have seen only a little variation
in the pH and when the variation is detected, this correlates
with the higher acetone content of the product. Thus the reli-
ability of the pH strips was questioned. Materials andmethods:
Different pH determination methods were compared for ana-
lyzing the pH of saline, 68Ga-dotanoc and 68Ga-Citrate solu-
tions. Two kinds of pH-indicator papers and four kinds of
plastic pH-indicator strips from Merck and Macherey-Nagel
were tested and compared with Thermo Scientific Orion Star
111 pH meter and two kinds of pH electrodes; standard Ag/
AgCl-electrode and 8220BNWP PerpHecT ROSS microelec-
trode. Results and conclusion: The pH values of the solutions
were measured with the pH meter, pH indicator strips and pH
papers, and the results were cross-checked. Nearly all tested
pH papers and plastic strips gave correct values when testing
NIST standard buffer solutions pH 4, 7 and 10. Although the
pH papers and plastic strips were validated correctly, they gave
different pH values from the tested solutions when compared
to each other. The variation of the pH of the pure saline solu-
tions could not be seen with the tested pH papers and plastic
strips, although the variation of pH was seen with the pH
meter. In addition, some of the tested pH papers and pH strips
gave the same result with all tested solutions. When the vari-
ation of the pH was seen with the pH meter, the variation with
the pH paper and the pH strips did not correlate with the re-
sults. According to this study, reliable determination of pH can
be done only with the potentiometric pH meter and the appro-
priate microelectrode intended for small volume. If the pH
strips are used for the determination of pH of the radiophar-
maceutical product, the pH strips should be validated carefully
in the same solvent as the studied product and in different pH.
When the commercial standard solutions in saline are not
available, the reliability of the pH strips should be checked
against the appropriate pH meter and the pH electrode.
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Labelling of leukocytes with 18F-FDG: Quantification
of radiation damage
E. Miñana1, D. Ramos2, P. Campos1, T. Martinez2; 1Virgen
de la Arrixaca Hospital, Murcia, SPAIN, 2Santa Lucia Hospi-
tal, Cartagena, SPAIN.
Aim: The aim of our work is to quantify the radiation
damage in lymphocytes after labelling with 18F-FDG
using the cytokinesis block micronucleus assay
(CBMN) and to establish a correspondence between
micronuclei scored and the characteristics of the radio-
nuclide. Materials and methods: Blood from 5 healthy
donors were taken in heparin to sedimentation for 90
minutes with 9 ml of starch; the cell-rich plasma was
centrifuged at 150 g, 5 minutes resulting in a mixed
leukocyte pellet. Cell suspensions of 105,5± 13,18·106
leukocytes were radiolabelled with 40,57 ± 2,46 MBq
of 18F-FDG, incubated for 25 minutes in a water-bath
at 37°C shaking at 5 minutes intervals. Simultaneously,
9,54 ± 2,05·106 leukocytes in 0.5 ml of cell free plas-
ma were taken as control sample for CBNM. For the
CBMN assay, lymphocytes were cultured at 37°C for
72h at an initial density of 1.53x106 / ml in a selective
culture medium. Cytochalasin B of 6 μg/ml was added
44 h after the beginning of the culture. The cells were
harvested, treated with a hypotonic solution and fixed
with absolute ethanol:glacial acetic acid (3 : 1). Slides
were stained with Giemsa at 5% and micronuclei were
scored in 1000 binucleated cytokinesis-blocked cells
based on the criteria summarized by Fenech et al.
For dosimetric calculations, homogeneity in the up-
take of radiopharmaceutical by the cell suspension
was assumed. The cells were considered to be spher-
ical with radium of 10 um (nucleus of 5-7 um), and
with homogeneous distribution of the radiopharma-
ceutical in the cytoplasm. ICRP 106 guideline was
followed for absorbed dose calculations. Results
and conclusion: Lymphocytes exposed to 18F-FDG
have significantly higher micronucleus frequencies than
unlabelled ones (956 ±172 versus 20±13). Studies with
other radiopharmaceuticals pointed out the importance
of Auger electron in cellular radiation damage, but for
the F-18 not Auger electron (low energy (0.52 keV))
neither 511 keV photons had a clear contribution to the
absorbed dose. Our dosimetric calculations show
634 keV positron emission is the main source of radi-
ation damage, with an absorbed dose in the nucleus of
the cell of 0.39 Gy. As expected, 18F-FDG labelling of
mixed leukocytes causes severe radiation damage to the
cells, mainly related to the 634 keV positron of the
F-18.
P316
Referential of radiopharmacy risks elaboration
A. VERREY, D. Martinez, C. Smadja; Hôpital Européen
Georges Pompidou, Paris 15ème, FRANCE.
Aim: After the decree of 6 April 2011 about quality
management of support drug and medicine in health in-
stitutions, our radiopharmacy unit decides to conduct a
risk study. No specific tool is actually available, there-
fore our objective is to propose an evaluations risk tool
called referential adapte to radiopharmacy activity. Ma-
terials and methods: A questionnaire produces by
ACOMEN (Action COncertée en Médecine Nucléaire)
is used as base for the referential elaboration. Further-
more, a retrospective analysis of 137 non-compliances
observed between 2007 and 2013 has permit to improve
the questionnaire and to adapt it on radiopharmacy. An
increase critically to 3-5 is given for each question ac-
cording to gravity. The questions are regrouping in dif-
ferent radiopharmacy topics. There are 2 types of an-
swer: - A1: Binary responses (yes/no) - A2: Scaled an-
swers (“disagree”, “moderately agree”, “strongly agree”,
“don’t know”) For each topic, a score is calculated with
positive response (Yes for A1 and “moderately agree”
and “strongly agree” for A2). Results and conclusion:
The elaborated referential is an auto-evaluation in 145
questions (Vs 43 in ACOMEN’s questionnaire) divided
in 11 topics who reflect the radiopharmacy process
based on the medication circuit. The type A1 (Yes/no
answer) permit to create a risk mapping at the moment
T0 (initial analysis) and to evaluate in time the risk
evolution after correctives actions. When a topic score
is >75%, it’s called “develop” and when a topic score is
<50%, it’s called “to improve”. The action plan should
make the topics “to improve” better and keep the topics
“develop” on the same level or higher. The type A2
(scaled questions) estimate the feeling of the team. The
risk mapping could be different between the two types
(A1-A2). There are two legislations in radiopharmacy:
drugs and radioelement in non-sealed source. This spec-
ificity make risk referential used in pharmacy like
ArchiMed unusual. A specific referential elaboration is
difficult because the radiopharmacy is linked with nucle-
ar medicine. Therefore, the responsibility is hard to elab-
orate and the risk classification in process is debatable.
To our knowledge no specific referential was created
before this study. The referential elaborate has permit
to create the radiopharmacy risk mapping. By using
the non-compliance analysis, this tool is more exhaus-
tive and pragmatic. Moreover, the comparison of two
answers forms highlights the importance of communica-
tion and knowledge of the team in there activity.
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How stable is stable?
L. Nics1, A. Hahn1, O. Langer1, C. Vraka1, F. Girschele1, B.
Steiner1, R. Lanzenberger1, K. H. Wagner2, M. Hacker1, W.
Wadsak1, M. Mitterhauser1; 1Medical University of Vienna,
Vienna, AUSTRIA, 2University of Vienna, Vienna,
AUSTRIA.
Objectives: Results from preclinical experiments should be
predictive for following clinical applications. In-vitro data help
to explain in-vivo experiments and provide important informa-
tion whether a tracer has clinical potential or not. From a phar-
macokinetic point of view it is of utmost importance to learn
about the metabolic fate of radioligands on their path to and at
the target region. Aim of this study was to compare stability
data from in-vitro experiments with data from clinical in-vivo
studies for several tracers (WAY100635, DASB, Harmin, Ve-
rapamil, Tariquidar and Elacridar) in order to determine the
predictive quality of these methods. Methods: Tracers were
incubated with human plasma as well as human liver micro-
somes (CYP-450), which belong to the main locations for
metabolic activity. Incubations took place under physiological
conditions (37°C, pH 7.4). Time-endpoints to stop enzymatic
activity were adjusted to the blood sampling timepoints of
respective studies. Determination of measured values were
based on an established protocol [1]. Results: Degradation of
tracers in-vitro by CYP-450 (n=3): WAY100635 after 50min
of incubation: 8.1%±2.8, DASB (70min): 4.7%±6.7, Harmin
(80min): 85.1%±8.5, Verapamil (60min): 0%, Tariquidar
(60min): 17.8%±5.6, Elacridar (60min): 0%; No degradation
for all tracers in-vitro in plasma was observed (n=3). Degra-
dation of tracers in-vivo (at the same timepoints):
WAY100635: 94.2%±0.9 (n=8), DASB: 83.8%±3.4 (n=8),
Harmin: 62.5%±11.8 (n=10), Verapamil: 59.3%±5.7 (n=5)
[2], Tariquidar: 24.4%±12.3 (n=6) [3], Elacridar:
14.0%±5.1% (n=5) [3]. Conclusions: The degradation pattern
in-vitro of the selected tracers is not comparable to respective
in-vivo data. None of the investigated methods using plasma
or enzymatic families generate data that correlate to in-vivo
degradation in the living organism. Data of in-vitro stability as
a prediction for in-vivo stability of a tracer are commonly used,
but from our data this predictability seems far-fetched. The
implication of the word ”stable” should therefore be
questioned in that context. References: [1] Nics et al.,
Nuklearmedizin, 2012; [2] Wagner et al., Clin Pharmacokinet,
2011; [3] Bauer et al., J Nucl Med, 2013
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A stable and remote 111In-labeling of DTPA-DSPE
long-circulating liposomes
T. van der Geest1, D. Gerrits1, G. M. Franssen1, J. M.
Metselaar2,3, G. Storm2,4, P. Laverman1, O. C. Boerman1;
1Department of Radiology and Nuclear Medicine, Radboud
university medical center, Nijmegen, NETHERLANDS, 2De-
partment of Targeted Therapeutics, MIRA institute, University
of Twente, Enschede, NETHERLANDS, 3Department of Ex-
perimental Molecular Imaging, University Clinic and Helm-
holtz Institute for Biomedical Engineering, RWTH-Aachen
University, Aachen, GERMANY, 4Department of
Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences,
Utrecht University, Utrecht, NETHERLANDS.
Aim:Long-circulating liposomes (LCL) are often used as a
drug carrier system to improve the therapeutic index of
water-soluble drugs. To track these LCL in vivo, they can be
radiolabeled with 111In-oxine. For this labeling method, gen-
erally DTPA is incorporated in the aqueous phase of LCL,
however it is still unknown whether incorporation of DTPA
in the vesicles improves the loading capacity and stable reten-
tion of 111In-oxine by the vesicle. Alternatively, LCL can be
labeled with 111InCl3 by incorporating DTPA-conjugated
DSPE in the lipid bilayer. Here, we compared in vitro proper-
ties of DTPA-DSPE LCL with those of DTPA and empty
LCL. Additionally, we compared in vivo properties of
DTPA-DSPE LCL with those of DTPA LCL. Material and
methods:DTPA-DSPE-, DTPA- and empty LCL were pre-
pared by injection of ethanolic lipid solution into an aqueous
dispersion medium, followed by extrusion. Size distribution of
resulting liposomes was determined by dynamic light scatter-
ing. DTPA- (88 nm) and empty (84 nm) LCL were labeled
with 111In-oxine, and DTPA-DSPE-PEG LCL (83 nm) were
labeled with 111InCl3. Labeling efficiency at increasing spe-
cific activity was determined. In vitro stability of labeled LCL
was determined in human serum at 37°C. In vivo properties of
111In-labeled LCL were examined in mice with a S. Aureus
infection in the thigh muscle. Image acquisition, blood sam-
pling and biodistribution studies were performed 1, 4 (only
blood sampling), 24, 48 and 72 h p.i. of 111In-labeled LCL.
Results: The DTPA-DSPE LCL could be labeled with high
yields at a higher specific activity than DTPA- and empty
LCL: yields were >90% at 15 GBq/mmol, >90% at 150
MBq/mmol and <65% at 150 MBq/mmol, respectively.
111In-labeled DTPA-DSPE LCL and DTPA LCL were stable
in human serum for at least 48 h at 37°C (>98% radiolabel
retention). In contrast, only 68% radiolabel was retained in
empty LCL after 48 h. In vivo targeting of 111In-DTPA-
DSPE LCL to the abscess was comparable with targeting of
111In-DTPA LCL (3.5 ± 0.9 %ID/g and 3.4 ± 0.9 %ID/g
abscess uptake respectively, 48 h p.i.). Furthermore, 111In-
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DTPA-DSPE LCL show comparable blood clearance profiles
as that of 111In-DTPA LCL. Conclusion: In vivo targeting
properties of 111In-labeled DTPA-DSPE LCL were compara-
ble to those of 111In-labeled DTPA LCL. In vitro stability
studies also revealed a similar stability for both LCL prepara-
tions. However, the maximum specific activity of the 111In-
labeled DTPA-DSPE LCL was much higher, making this for-
mulation most optimal for use in future experiments.
P319
Methotrexate labeling with 99mTc - Preclinical studies
M. Papachristou1, P. Bouziotis2, G. Kastis3, S.
Xanthopoulos2, I. Datseris1; 1Nuclear Medicine Depart-
ment-PET/CT, GHA “Evaggelismos”, Athens, GREECE,
2Radiochemical Studies Laboratoty, INRaSTES,NCSR
“Demokritos”, Athens, GREECE, 3Research Center of Math-
ematics, Academy of Athens, Athens, GREECE.
Aim: Methotrexate is a structural analogue of folic acid and
one of the most widely used antimetabolites in cancer chemo-
therapy.1 At low doses (up to 25 mg/ml) it is also part of the
established treatment of many autoimmune disorders, like
Rheumatoid Arthritis where it has nowadays became the stan-
dard of care.2 The present paper has two targets: a) Oncology:
accumulation of drug in breast Ca and in skeletical lesions. b)
Rheumatology: i) find the “plateau” of therapeutic dosage, ii)
imaging inflammatory site of rheumatoid or/and arthritis in
general, in bones and mainly in joints. Methods - Results:
On microscopic level, the labelling of MTX with 99mTc was
accomplished via Tc-glucoheptonate.3 The yields were 95-
98%. For the radiochemical control TLC and HPLC were
used. The compound was stable in vitro up to 6 h at RT, as
well as in the presence of serum. Ex vivo animal experiments
were performed in Swiss Albino mice (n = 3 animals per time-
point). The animals were injectedwith 700μCi radiotracer and
sacrificed at 2 and 24 h post-injection. Apart from the kidneys,
nomajor uptake in all analyzed tissues is observed (≤1.5 % ID/
g from 2 h p.i.). The bone to blood ratio significantly increased
from 2 to 24 h (0.93 and 14.8 respectively), thus leading to a
pronounced differentiation between bone and non-osseous tis-
sue. In vivo planar scintigraphy was performed with a small
Anger-type camera on 2 Swiss mice injected with 700 μCi
radiotracer, at 2 and 24 hours p.i.. The images illustrate in-
creased uptake of the tracer at the bones at both 2h and 24h
post injection. The increased uptake is more evident at the
spinal cord and knee joints. Conclusion: The preclinical stud-
ies show that the compound accumulates in the spinal cord, in
the joints and bones. The results are promising and in the
future the labelingmethodwill be transferred intomacroscopic
level in order for the compound to be indentified by spectro-
scopic methods (NMR, MS, Crystalography ). Biodistribution
and imaging studies in pathological breast cancer models are
in progress. References 1. Rang HP, Dale MM, Ritter JM,
Flower RJ, Rang & Dale’s Pharmacology: with STUDENT
CONSULT Online Access, 7e. Churchill Livingstone;
2011:792. 2. Weinblatt ME. Methotrexate in rheumatoid ar-
thritis: a quarter century of development. Trans Am Clin
Climatol Assoc. 2013;124:16-25. 3. Dar K.U, Khan U.I, Janed
M et al, Hell J Nucl med;15 (2):120-124.
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Effects of erlotinib therapy on [11C]erlotinib kinetics
M. Yaqub, I. Bahce, E. F. Smit, O. S. Hoekstra, R. Boellaard,
H. N.M. Hendrikse, A. A. Lammertsma; VUUniversityMed-
ical Center, Amsterdam, NETHERLANDS.
AIMRecently, it has been shown that [11C]erlotinib kinet-
ics in non-small cell lung cancer (NSCLC) patients can
best be quantified using the volume of distribution (VT)
derived from a reversible two tissue compartment (2T4k)
plasma input model. In addition, there was good correla-
tion between the tumour to blood ratio (TBR) and VT,
potentially enabling simplified analyses of clinical studies.
The purpose of the present study was to assess the effects
on of erlotinib therapy on kinetic simplified analyses of
[11C]erlotinib kinetics.METHODSBoth full kinetic and
simplified analyses of [11C]erlotinib kinetics were assessed
in NSCLC patients (N=10) before and after erlotinib ther-
apy. In 7 of these patients dynamic [15O]H2O scans were
available before and after erlotinib therapy to assess the
relationship between [11C]erlotinib uptake and tumour
blood flow. Finally, apart from arterial blood, also venous
blood samples were collected to assess possible omission
of arterial cannulation.RESULTSErlotinib therapy resulted
in a substantial (on average 59%) decrease in tumour VT
of [11C]erlotinib. Although the reduction in TBR was
smaller (on average 32%). There was no correlation (R2
< 0.01) between tumour VT and blood flow. TBR showed
good correlation with VT both before (R2=0.93) and after
(R2=0.96) erlotinib treatment. Finally, there was a reason-
able correlat ion (R2>0.79) between VT values
o b t a i n e d u s i n g v e n o u s a n d a r t e r i a l b l o o d
data.CONCLUSIONFurther studies are needed (1) to as-
sess whether the reduction in VT is due to treatment re-
sponse and/or to occupancy of the EGF receptor by cold
erlotinib, and (2) to investigate the relationship between
the initial reduction in VT and clinical response. Depend-
ing on the accuracy needed, studies can possibly be per-
formed without arterial sampling. The good relationship
between VT and TBR indicates that whole body studies
might be feasible in order to investigate (interlesional) het-
erogeneity of response.
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Nanocolloid Radiopharmaceutical on the Based
of Modified DTPA Labeled Technetium-99M
V. Chernov1, A. Rogov2, V. Sкuridin2, E. Stasyuk2, E.
Nestwrov2, N. Varlamova2, R. Zelchan3, V. Sadkin2, E.
Ilina2, L. Larionova2; 1FSBI, Tomsk, RUSSIAN FEDERA-
TION, 2National Research Tomsk Polytechnic University,
Tomsk, RUSSIAN FEDERATION, 3Cancer Research Insti-
tute of Siberian Вranch of the Russian Academy of Medical
Sciences, Tomsk, Tomsk, RUSSIAN FEDERATION.
The use of radioactive nanocolloids in oncology based on the
possibility effectively identify “sentinel” lymph nodes (SLN),
which are the “trap” for the cells, so their biopsy is an objective
diagnostic criterion for malignancy spread. In recent years, the
best method is to use SLN identification labeled with
technetium-99m (99mTc) nanoscale colloids for scintigraphy
or radiometric determination of lymph node localization. Ra-
dionuclides technetium-99m is by far the most popular for
such diagnostic tests. Primarily this is due to its nuclear-
physical characteristics: a relatively short half-life (6.02 h)
and 0.140 MeVenergy of the radiation, providing a low expo-
sure dose, and at the same time sufficient penetration to the
radiometric study. As сolloid-forming substance were taken
based compound chemically modified molecule DTPA, show-
ing a certain affinity with the protein molecule - the presence
of an amide (peptide) bond, the existence of a zwitter-ionic
form. Presupposition for use as a chelator DTPA tracer is the
ability of both the molecule DTPA and its derivatives, to form
sufficiently stable complexes with various metals, including
the compounds of technetium-99m. The studies identified
the requirements for obtaining radioactive nanopreparations
on a modified molecule DTPA. It is shown that the direct
interaction of the solution with a solution of 99mTc eluate
mixture DTPAmod and SnCl2 content radiochemical impurities
unrestored 99mTc (VII) in the preparation of the labeled
nanocolloids is 4.7%, and the yield nanocolloids with a size
of 100-50 nm is about 80%. Preliminary studies on experimen-
tal animals, using scintigraphy, allowing to see that the drug
enters the lymphatic system, and remains in the affected lymph
node. Studies show the drug functionality of modified
nanocolloids for lymphoscintigraphy and visualization “Sen-
tinel” nodes. This work was performed on the unique scientific
IRT-T equipment and financially supported by Government
represented by the Ministry of Education and Science of the
Russian Federation (RFMEFI59114X0001).
P19 - Monday, October 12, 2015, 4:00 PM - 4:30 PM, Hall 3 –
Poster Exhibition
Radiopharmaceuticals & Radiochemistry: Radiometals &
New Targets
P322
QSPR study on the Complexation of Radiometals
with Bifunctional Coupling Agents
for Radiopharmaceuticals Applications
M. Salahinejad, M. Aboudzadeh; Nuclear Science and Tech-
nology Research Institute, Tehran, IRAN, ISLAMIC REPUB-
LIC OF.
Introduction: Diagnostic metal radiopharmaceuticals are
used for single photon emission computed tomography
(SPECT) and positron emission tomography (PET) appli-
cations as imaging agents. Bifunctional coupling or che-
lating agents (BFCs) are typically used as ligands to con-
struct, radiolabeling and target-specific delivery of
radiometal-based radiopharmaceuticals.67/68Ga(III),
64Cu(II) and 111In(III) complexes have attracted great
attention among metal-based PET radiopharmaceuticals.
Quantitative structure-property relationships (QSPR) stud-
ies, as progressive tools in modeling and prediction of
many physiochemical properties, allow cost savings by
reducing the laboratory resources needed and the time
required to investigate and design new compounds by
desired properties The aim of the present study, is to
QSPR modelling of the stability constant between a di-
verse set of BCFs and 64Cu(II), 67/68Ga(III) and
111In(III) radiometal ions. Material and Methods: Exper-
imental data of the stability constants of a set of diverse
structural BFCs containing acyclic, hetrocyclic and macro-
cyclic ligands were taken from the recent comprehensive
published reviews. VolSurf is a computational procedure
that generates useful quantitative 2D descriptors from the
3D maps of molecular interaction field (MIF) between
different probes and all the atoms in a target molecule.
Multi Linear regression (MLR) and support vector ma-
chine (SVM) have been utilized to construct linear and
non-linear QSPR models. Results: As SVM analysis tak-
ing into accounts both linearity and non-linearity in model
construction, therefore it yielded more predictive models
than MLR analysis in prediction of complexation constant
of Cu(II), Ga(III) and 111In(III) radiometal ions.
Conclusion: Considering the variables contributed in
QSPR models, it’s concluded the ability of H-bonding,
shape/configuration of BCFs and hydrophilicity interac-
tions play important roles in the complexation formation
of 67Ga(III), 64Cu(II) and 111In(III) radiometal ions with
BCFs of diverse structure containing acyclic, hetrocyclic
and macrocyclic. The obtained results could be led to the
design and development of new high efficient BFC ligand
with high log KML values which allow cost savings by
reducing the laboratory resources needed and the time
required to investigate and design new compounds by
desired properties.
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Selecting the best buffer for 68Ga labelling: a theoretical
molecular approach towards a rational choice
M. I. Prata1, S. Rodrigues2; 1IBILI and ICNAS, Coimbra,
PORTUGAL, 2Coimbra Chemistry Centre UC, Coimbra,
PORTUGAL.
Introduction - It is now well established that the labelling
of 68Ga in medical applications involving the formation of
complexes such as GaDOTA-TOC and GaDOTA-NOC is
significantly enhanced by the presence of N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES)
buffer [1] and that better performance is obtained using
HEPES buffer as compared with other buffers [1-2]. At
the time HEPES was first used [3], this finding was not
obvious, but now HEPES buffer is widely used and al-
ready accepted by the European Pharmacopeia. To explain
the enhancement in labelling using HEPES it was pro-
posed [1] the formation of weak GaHEPES complexes,
which maintain gallium available in solution, prior to the
formation of the much more stable, but kinetically slow
forming, GaNOTA and GaDOTA complexes (as well as
its derivatized moieties). As the presence of other buffers
such as succinate and acetate (Ac) [2] and citrate (Cit) [4]
is also considered beneficial in labelling, a similar mecha-
nism of weaker intermediate complexes formation is ex-
pected to be involved [4]. Nevertheless, as the presence
of HEPES shows to be superior in enhancing the labelling,
an attempt to understand this finding seems worth to a
better rationalization of the labelling process. Methods -
The present work extend previous studies on GaHEPES
[1] to a wider range of complexes involving Ga3+ and
ligands L=HEPES, Cit, Ac, and NOTA, including com-
plexes as GaNOTA-L, using density functional theory
(DFT) and the conductor-like polarizable continuum model
(C-PCM) for the water solvent. Results and Conclusions -
It was found theoretically that the estimated relative ener-
gies of GaHEPES and GaNOTA-HEPES complexes in the
process of forming GaNOTA appear to follow a more
favourable step-like mechanism that it is followed by com-
plexes involving Ac and Cit. This finding, that is in agree-
ment with experimental results, provide an explanation for
HEPES buffer better performance and calls the attention
for the interest in using molecular modelling methods,
when possible and appropriate, to complement processes
of labelling development and optimization. [1] Martins,
A.F.; Prata, M.I.M.; Rodrigues, S.P.J.; Geraldes, C.F.G.C.;
Riss, P.J.; Coarasa, A.A.;Burchardt, C.; Kroll, C.; Roesch,
Contrast Media Mol. Imaging 2012, 8, 265-273. [2]
Bauwens, M.; Chekol, R.; Vanbilloen, H.; Bormans, G.;
Verbruggen, Nucl. Med. Commun. 2010, 8, 753-758. [3]
Eisenwiener, K.P.; Prata, M.I.M.; Han-Wen, Z.;
Buschmann, I.; Santos, A.C.; Reubi, J.C.; Wenger, S.;
Maecke, H.R. Bioconjugate Chem. 2002, 13, 530-541.
[4] Morfin, J.F.; Toth, E. Inorg. Chem. 2011, 50, 10371-
10378.
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Excitation function determination for 45Ti production
using 45Sc(p,n)45Ti reaction in low energy cyclotrons
P. Costa1, L. F. Metello2, L. Cunha2, R. R. Johnson3, W.
Gelbart4, J. Obermair5, B. Dietl5, R. Nausching5, C. Artner5,
P. Lass6, G. Currie7, S. Carmo8, F. Alves8, M. D. Naia9;
1Nuclear Medicine Department, ESTSP.IPP & CEMUC®,
Physics Department, ECT-UTAD, Vila Nova de Gaia & Vila
Real, PORTUGAL, 2Nuclear Medicine Department,
ESTSP.IPP & IsoPor SA, Vila Nova de Gaia, PORTUGAL,
3Best Cyclotron Systems Inc, Vancouver, BC, CANADA,
4Advanced Systems Design, Garden Bay, BC, CANADA,
5IASON Gmbh, Graz, AUSTRIA, 6Medical Faculty, Univer-
sity of Gdansk, Gdansk, POLAND, 7School of Dentistry and
Health Sciences, Charles Sturt University, Wagga Wagga,
AUSTRALIA, 8Institute for Nuclear Sciences Applied to
Health, Univ. Coimbra, Coimbra, PORTUGAL, 9CEMUC®
- Physics Department, ECT-UTAD, Vila Real, PORTUGAL.
Introduction: There are several different radioisotopes known
and almost all of them may be artificially produced, however
actual clinical routine applications of PET imaging are still
based on 18F, 11C, 13N and 68Ga. This trend might change
in the near future, since several groups worldwide are busy
developing very promising new processes using unconven-
tional radionuclides, aiming to contribute for spreading the
use and efficacy of clinical diagnostic using Nuclear Medicine
imaging techniques, mainly in the direction of personalized
medicine. Our group is busy studying 45Ti, assuming it as a
potential candidate, since it presents many interesting proper-
ties: physical half-life of 3.09h, together with relevant chemi-
cal properties, that enable radiolabelling with bifunctional che-
lates, ligands or even to radiolabel titanium (di)oxide nanopar-
ticles. Aim: This work aims to disseminate the experimental
results obtained during the determination of excitation func-
tion (which adequate characterization has been considered
mandatory for radionuclide optimal production) of 45Sc(p,
n)45Ti nuclear reaction, that is being studied as a potential
route to efficiently produce 45Ti in low energy cyclotrons.
Material and Methods: Excitation function of 45Sc(p,n)45Ti
nuclear reaction was experimentally determined using the
stacked foil technique, with 99,5% pure Sc foils mounted on
an aluminum target holder and interspaced in some positions
with 99,999% pure Cu foils, with short irradiations (~1μA
during 100 seconds) using 16 MeV and 18 MeV cyclotrons.
Results of this activation study were evaluated using HPGe
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spectroscopy (always considering dead time losses ≤ 5%).
Results: Results concerning the excitation function of the main
route under study were collected, with the addition of some
information regarding concurrent reactions leading to 44mSc
and 44Sc. Experimental results were also compared with the
Monte Carlo simulation results obtained before, based on
TALYS code calculations, having found some discrepancies
in the shape and in the overall quantitative results, suggesting
that TALYS might overestimate cross-sections for this partic-
ular reaction. Conclusion: Considering our results, the produc-
tion of 45Ti seems feasible in low energy cyclotrons, with the
maximum yields obtained for 12-15 MeV proton beams.
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Synthesis and Evaluation of metal phosphate as column
material for the 68Ge/68Ga generator
J. PARK1, J. Lee1, M. Hur1, S. Yang1, S. Lee2, S. kim3;
1Korea Atomic Energy Research Institute, Jeongeup-Si, KO-
REA, REPUBLIC OF, 2Daegu Gyeongbuk Institute of Sci-
ence & Technology, Daegu, KOREA, REPUBLIC OF,
3Dongguk University-Gyeoungju, Gyeoungju-Si, KOREA,
REPUBLIC OF.
Aim : 68Ge/68Ga generator provides an alternative and often
more convenient sources of isotopes compared to complex
facilities such as accelerators and nuclear reactors. 68Ge/68Ga
generator is constructed on radiative equilibrium between a
long-lived parent radionuclide (t1/2= 271 d) and its short-
lived daughter radionuclide (t1/2= 68 min). Gallium-68 has
been used in nuclear medicine diagnostic for positron emission
tomography agent. In order to find much more suitable gener-
ator adsorbents, we synthesized metal phosphate. Materials
and methods : The ability of the adsorbent to adsorb various
metal phosphate {Ti(HPO4) 2, ZrTi(HPO4) 2, Zr(HPO4) 2} was
investigated in order to evaluate the possibility of its use in
germanium adsorption and gallium desorption. Metal oxides
were fully characterized byXRD, DLS, TEM, SEM, Zetasizer,
FT-IR. The plastic syringe (5mL, 12.46mm) chromatographic
column fitted with polyethylene frit (polyethylene, pore: 20
μm) at the bottom was packed with 200 mg of adsorbents.
Germanium-68 solution (30 μCi/5 μL) containing germanium
and gallium impurities were passed through the metal oxide
column at a flow rate of 1 mL/min and the effluent was col-
lected. All radio activity was measured by dosimeter. Results
and Conclusion : A Zr(HPO4)2 based 68Ge/68Ga gener-
ator has been composed and evaluation. High purity of
68Ga elution was obtained within 1 minute as a 1.0 mL
volume of 0.1 N-HCl fractions. We were successfully
achieved a high radiochemical purity and low break-
through of 68Ge using a Zr(HPO4)2 as the column
material.
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Titanium-45 as a Candidate for PET Imaging:
Cyclotron-Based Production &
Functionalized-Hydroxamate Column Separation &
Purification
R. I. Price1,2, R. W. Sheil1, R. K. Scharli1,2, S. Chan1, P.
Gibbons1, L. Morandeau1; 1RAPID PET Labs, Sir Charles
Gairdner Hospital, Perth, AUSTRALIA, 2School of Physics,
University of WA, Perth, AUSTRALIA.
INTRODUCTION. Transferrin (TF) and its receptor TFR1
mediate recruitment by cancer cells of factors for their multi-
plication, adhesion, invasion and metastatic potential. Though
primarily designed to bind iron and then be internalised into
cells with its receptor, TF can also bind most transition metals
including titanium. Under certain conditions TF binds Ti (IV)
even more tightly than it does Fe, and this occurs at the N-lobe
(as distinct from C) of apoTF. Indeed, Fe(C-lobe)Ti(N-lobe)-
TF may mediate Ti cellular entry via TFR1 (Nuevo-Ordoñez
et al., Metallomics 3, pp. 1297-1303, [2011). Thus, the PET-
tracer isotope 45Ti (T1/2 =3.08hr; beta+ ratio = 85%; mean
beta+ energy = 439keV) may elucidate biological mechanisms
involving TF-binding and internalization, at least in preclinical
(animal) models. AIM. Produce high-purity no-carrier-added
45Ti at sufficient specific-activity for imaging. METHOD.
45Ti was produced using the nuclear 45Sc(p,n)45Ti reaction
by irradiating 100 micron-thick scandium (Sc) discs at
11.6MeV using an 18MeV cyclotron and in-house solid
targetry, including a beam degrader (Scharli et al., AIP Conf
Proc 1509, pp.101-107; [2012]). This degraded beam-energy
abolishes ‘contaminating’ reactions 45Sc(p,n+p)44Sc and
45Sc(p,2n)44Ti. Separation and purification of product Ti,
mainly from target Sc, was achieved with hydroxylamine
hydrochloride-functionalised resin (Gagnon et al., AIP Conf
Proc 1509, pp.211-215; [2012]). Discs were dissolved in 2mL
6MHCl, then diluted to 2M, then eluted through the column to
waste-fraction-1 (w1). Then 6mL 2M HCl was eluted through
the column to w2, followed by 6mL traceSELECT H20 to w3.
Finally, Ti trapped in the column was eluted into successive
1mL product-fractions (p1-4) using 5mL 1Moxalic acid; (total
time~1hr). 45Ti radionuclidic purity was measured using gam-
ma-spectroscopy. Sc elemental abundance in all vials (w1-3;
p1-4) was determined using ICP-MS.RESULTS. Typical pro-
duction (40microA proton-beam; 60min) yielded 1.8GBq, at
EOB. Radionuclidic analysis revealed 44Sc (<0.19%) as the
only contaminant. Only 30% of the original activity of 45Ti
(EOB-corrected) was acquired in the product (p1-4) vials, with
the vial of highest activity (p1) containing 14%. The elution-
profile for (cold) Sc mass (ICP-MS) was negligible in all p-
vials (total p1-4 <0.017%), remaining (78%) in w1 and (22%)
in w2. CONCLUSIONS. Despite substantial 45Ti loss into
waste (total 53%, EOB-corrected), 45Ti of acceptable specific
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activity and radionuclidic purity was produced from 45Sc(p,
n)45Ti, with separation/purification by hydroxamate-column
chemistry. Two 0.100 micron-thick Sc target-discs yield iso-
tope as the oxalate, following 40 microA-hours of beam, of
adequate activity without need for concentration, for subse-
quent radiolabelling and preclinical imaging.
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Cyclotron production of 99mTc from highly enriched
100Mo
D. Pawlak, W. Wojdowska, J. L. Parus, I. Cieszykowska, T.
Janiak, K. Jerzyk, M. Mielcarski, T. Barcikowski, P.
Garnuszek, R. Mikołajczak; National Centre for Nuclear Re-
search, Otwock, POLAND.
AimThe 99mTc worldwide needs are practically covered now-
adays by its production from fission of 235U. Due to aging of
nuclear reactors delivering it on one hand and the necessity to
use low enriched uranium on the other, alternative methods of
99mTc production are being developed. One of the most
promising and intensely progressing in the last few years is
the use of proton accelerators and highly enriched targets of
100Mo. The biggest advantage of this method is the absence
of high level active wastes, while the disadvantage is a very
short processing and delivery time required. Our goal was to
develop technology suitable for 99mTc production in a medi-
cal, 16MeV cyclotron, and its further separation.Materials and
methodsMolybdenum target was prepared by pressing metal
powder containing 99.815% of 100Mo into pellet of 12 mm in
diameter and mass of 0.723 g. After sintering in hydrogen
atmosphere at 16000C for 60 min, the pellet was loaded into
aluminum holder which was mounted in GE PETtrace 840
cyclotron (at HIL, University of Warsaw) proton beam and
irradiated for 2 h at 2 μA current to total activity of 1.6 GBq
at the EOB. The target was automatically disassembled into
transportation container.Results and discussionAfter releasing
from holder the target was dissolved in 30% H2O2 and
alkalized with 10M NaOH (both reagents added in about 2
mL portions) to total volume of 19 mL. 99mTc was separated
in 3 columns connected in series containing AnaLig, Dionex
and alumina beds. The 99mTc recovery yields amounted to
76.3% and losses were 8.2%, 13.2% and 2.3% at each column
respectively. The 99mTc solution was free of molybdenum.
Method is further optimized to increase separation
yield.AcknowledgmentsWe are thankful to the staff of the
Heavy Ion Laboratory of the University of Warsaw for target
irradiation. This work was supported by National Centre for
Research and Development from public funds, realized within
the Applied Science Program NCBiR Nr PBS1/A9/2/2012
and IAEA CRP contract 17419.
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Development of a cell labelling technique using
zirconium-89 for inflammation imaging with positron
emission tomography (PET)
M. Fairclough1, B. Ellis2, G. Brown1, H. Boutin1, A.
McMahon1, A. Gennari1, A. Jones1, C. Prenant1; 1University
of Manchester, Manchester, UNITED KINGDOM, 2Central
Manchester University Hospitals NHS Foundation trust, Man-
chester, UNITED KINGDOM.
Aim: Radiolabeled leukocyte scintigraphy is a widely used
clinical procedure for assessment of inflammatory diseases.
However Positron Emission Tomography (PET) offers superi-
or quantification and sensitivity and is attractive for monitor-
ing the regional signal from migrated radiolabelled cells to
pathological tissue in infectious and inflammatory diseases.
The aim of this work is to develop a method for labelling white
blood cells with the positron emitting isotope zirconium-89
(89Zr, t1/2=78.41 h). Chitosan nanoparticles (CN) are used to
transport 89Zr in to the cell via pinocytosis or phagocytic
engulfment. Chitosan is a linear polysaccharide consisting of
randomly distributed D-glucosamine and N-acetyl-D-
glucosamine units with the ability to chelate metal cations.
Methods: CN formed spontaneously upon addition of a
polyanion to a chitosan solution in acetic acid via an ionotropic
gelation mechanism. CN loading with 89Zr and white blood
cell uptake and retention up to 24 h were studied for various
CN constructs. [89Zr]-loaded CN were incubated with white
blood cells at various incubation times and the labelling was
terminated by the addition of cell free plasma (CFP). Next the
cell pellet was collected and measured for radioactivity. To
measure the rate of loss of 89Zr from white blood cells, the
cell pellet was re-suspended in CFP and incubated for a set
time before the pellet and supernatant were collected and mea-
sured for radioactivity. Results: Analysis of CN generated
from 15kDa chitosan showed particles with an average size
distribution of 342.7nm in diameter (polydispersity index =
0.376) and a zeta potential of 45.7±3.96mV. Cell uptake of
[89Zr]-loaded CN proceeds in two-steps an initial adhesion
to the cell membrane followed by cell internalisation. The
second step shows a slower kinetics compared to the initial
adhesion step. The fast initial loss of 89Zr from cells shows the
release of [89Zr]-CN from the cell membrane with the remain-
ing [89Zr]-CN being internalised. However the stability of the
89Zr in the cell observed after 5h up to 24h is very promising
for PET imaging. These results are observed for 2-5x107 cells
loaded with 6-9MBq of 89Zr. Slight cytotoxicity of [89Zr]-
CN, possibly due to radiolysis, was observed (87% viable
cells) . Conclusion: [89Zr]-CN are a simple tool for labelling
mixed leukocyte cells to use as a probe for inflammation im-
aging with PET. [89Zr]-loaded CN uptake in to leukocyte cells
is slow but stable once internalised. The imaging probe will be
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S499
eventually applied to an animal model of inflammation for
PET scan.
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Evaluation of Layered Double Hydroxide as a Drug
Delivery Carrier using Co-57
J. PARK1, J. LEE1, T. KIM2, J. OH2; 1Korea Atomic Energy
Research Institute, Jeongeup-Si, KOREA, REPUBLIC OF,
2Yonsei University, Wonju, KOREA, REPUBLIC OF.
ABSTRACTAim : Layered double hydroxide (LDH) has
been of great interest as cellular drug delivery carriers be-
cause of their potential applications in medical and biolog-
ical fields. Especially, LDH contained the radioactive metal
isotopes will be able to be used as a novel imaging agent. In
this study, we have successfully incorporated either non-
radioactive Co(II) and radioactive 57Co(II) into MgAl-
layered double hydroxide (LDH) nanomaterials and carried
out celluar uptake and biodistribution.Material and Method
: Pristine MgAl-LDHs with uniform size and morphology
was obtained through conventional coprecipitation follow-
ed by hydrothermal treatment. In order to substitute non-
radioactive Co(II) into LDH lattice, suspension of MgAl-
LDHs were added to Co(II) solution and hydrothermally
treated at 150 °C. We applied the same hydrothermal reac-
tion to incorporate radioactive [57Co](II) into LDH lattice.
It was revealed that radioactive Co(II) could be successful-
ly incorporated into LDHs. Comparision of cellular uptake
using LDHs for tumor cell lines {CT-26 (Mouse colon),
MCF-7 (Breast cancer), HepG2 (Liver hepatocellular car-
cinoma)}. CT-26 bearing balb/c mice of 7 weeks old
weighing 25-30 g were used for the biostudies of
[57Co]LDHs .Results and Conclusion : LDH was deter-
mined to have typical hydrotalcite-like structure, uniform
150 nm size and hexagonal plate-like morphology using X-
ray diffraction patterns and electron microscopy. The incor-
poration saturated at 12 hours showing Mg(II)/Co(II)/
Al(III) in the LDH lattice of 1/1/1 with the inductively
coup led p lasma-a tomic emiss ion spec t roscopy.
[57Co]LDHs was synthesized within 90 min at radiochem-
ical yield (>27%). The cellular uptakes and biodisribution
of [57Co]LDHs increased in a time dependent manner for
cancer cell line.
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Radiotherapy metabolic with 131I, a new promise
for cholangiocarcinoma treatment?
A. M. Abrantes1,2,3, R. Teixo1,3, A. F. Brito1,2,3, A. I.
Fernandes1,2,4, A. C. Ribeiro1, M. Laranjo1,2,3, J. G.
Tralhão1,2,5, M. F. Botelho1,2,3; 1Biophysics Unit, Faculty
of Medicine, University of Coimbra, Coimbra, PORTU-
GAL, 2Center of Investigation on Environmental, Genet-
ics and Oncobiology (CIMAGO), Faculty of Medicine,
Coimbra, PORTUGAL, 3CNC.IBILI, Faculty of Medi-
cine, University of Coimbra, Coimbra, PORTUGAL,
4Gastroenterology Department, CHUC, Coimbra, POR-
TUGAL, 5Surgical Department, Surgery A, CHUC, Co-
imbra, PORTUGAL.
Aim: Cholangiocarcinoma (CC) is a malignancy with
poor prognosis and a reduced survival rate. It was
shown that intrahepatic CC, has increased sodium-
iodide symporter (NIS) expression. NIS is responsible
for cellular iodine uptake and is a key molecule in the
metabolic radiotherapy with iodine-131 (131I). This
study aims to evaluate therapeutic efficacy of metabolic
radiotherapy with 131I in two human CC cell lines (an
intrahepatic cell line and an extrahepatic cell line) as
well as in a human cholangiocytes cell line. Materials
and methods: Two CC cell lines (TFK1 - extrahepatic
CC and HuCCT1 - intrahepatic CC) and another of nor-
mal cholangiocytes (H69) were used. It was evaluated
the NIS expression by immunofluorescence. Subsequent-
ly, the cells were irradiated with 131I increasing doses
(0.35 to 60Gy), in order to evaluate and characterize
metabolic radiotherapy effects using different techniques
of molecular biology. Results: It was observed that all
cell lines express NIS, however, this expression was
strongest in the membrane of TFK-1 cells. Therefore,
the following studies were performed only in TFK-1 cell
line. 131I treatment induced cell viability decrease in a
dose dependent manner only in TFK-1 cells. The pre-
dominant cell death type was apoptosis, followed by
BAX/BCL2 ratio increase. A cytochrome C release and
mitochondrial membrane depolarization were also ob-
served. Two hours after irradiation, it was observed an
intracellular peroxides production increase, but there
were no differences in superoxide anion production.
Forty-eight hours after irradiation differences were not
detected in both intracellular peroxides and superoxide
anion production. Nevertheless differences were ob-
served in superoxide dismutase production, 2 and 48
hours after irradiation. Concerning glutathione a de-
creased production 48 hours after irradiation with higher
doses was observed. It was also verified that 131I in-
duced DNA breaks in TFK1 cells in a dose dependent
manner. Conclusion: 131I treatment induces cell viability
decrease in TFK1 cells followed by cell death by apo-
ptosis. Intracellular peroxides seem to be involved. This
is the first study realized in a human extrahepatic CC
cell line, and proves that this therapeutic approach is
also a possibility for this type of tumor.
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Synthesis of Novel 124I-Rhodamine: a Potential PET
Myocardial Imaging Agent
I. Aljammaz, B. Alotaibi, s. alyanbawi, f. alrumayan, s.
okarvi; King Faisal Spec. Hosp. & Research Centre, Riyadh,
SAUDI ARABIA.
Myocardial infarction is the leading cause of death in most of
the countries, and myocardial perfusion imaging (MPI) is an
important tool in evaluation of myocardial ischemia and in-
farction. Currently, MPI are usually performed using single-
photon radiopharmaceuticals such as 99mTc-MIBI, 99mTc-
tetrofosmin and 201Tl-chloride. Unlike SPECT, PET based
imaging offers several advantages in MPI application includ-
ing better sensitivity, higher spatial resolution and an improved
attenuation correction. The currently used PET tracers for MPI
studies (13NH3, 82Rb and 15O-water) have limitations such
as high cost or the need of on-site cyclotron for production.
Rhodamine dyes are known to accumulate in the heart; there-
fore, 68Ga-NOTAGA rhodamine conjugate was prepared and
demonstrated its potential as MPI agent using PET. Due to the
ideal physical properties of fluorine-18, various 18F-tracers for
MPI were developed. Recently, [18F]-FDG-rhodamine conju-
gate showed high myocardial uptake and favorable pharmaco-
kinetics asMPI agent using PET. Thus, as part of our on-going
research effort to develop novel radiotracers for MPI studies,
we here report the synthesis and preclinical evaluation of new
124I-rhodamine conjugates. The synthetic approaches for the
preparation of [124I]iodobenzene and pyridine rhodamine
conjugates entailed sequence of reactions. The key precursors
N-hydroxysuccinimide 3-tri-n-butylstannyl-benzoate and 3-
tri-n-butylstannyl-pyridine carboxylate were radioiodinated
using classical method involving 0.1% acetic acid/methanol,
iodogen and Na124I (50 MBq) at room temperature. The N-
succinimidyl-p-[124I]-iodobenzoate ([124I]-SIB) and N-
succinimidyl-m-[124I]-iodopyridine carboxylates ([124I]-
SIP) were purified using Sep-pak silica cartridge. EDA-
rhodamine was then reacted with [124I]-SIB and [124I]-SIP
to give [124I]-SIB- and [124I]-SIP-rhodamine conjugates. Ra-
diochemical yields were quantitative and synthesis times were
ranging between 30-40 min. Radiochemical purity was also
greater than 98% without HPLC purification. The metabolic
stability of [124I]-SIB- and [124I]-SIP-rhodamine conjugates
were determined in human plasma and revealed that
these radioconjugates remained stable during incubation
at 37°C for at least 24 h. Initial in vivo characterization
in normal Fischer rats at 60 min p.i., showed high
myocardial uptake (~5% ID/g) and favorable pharmaco-
kinetics. Initial cardiac imaging study using animal im-
aging modality, demonstrate that these radioconjugates
may be useful for MPI studies using PET. However,
further evaluation is warranted.
P332
Effect of dipyridamole infected for myocardial perfusion
imaging on blood glucose concentration: a preliminary
study
A.Khorasanchi1,M. Arabi1, A. Akhavein2,M. Eftekhari1, H.
Javadi3, M. Seyedabadi4, M. Assadi4; 1Imam Hossein Hos-
pital, Faculty of Medicine, Shahroud University of Medical
Sciences, Shahroud, IRAN, ISLAMIC REPUBLIC OF, 2Is-
lamic Azad University Tehran Medical Branch, TEHRAN,
IRAN, ISLAMICREPUBLICOF, 3Golestan Research Center
of Gastroenterology and Hepatology (GRCGH), Golestan
University of Medical Sciences (GUOMS), Gorgan, IRAN,
ISLAMIC REPUBLIC OF, 4The Persian Gulf Nuclear Med-
icine Research Center, Bushehr University of Medical Sci-
ences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.
Objective: Dipyridamole inhibits adenosine reuptake and
increases cyclic adenosine monophosphate (cAMP)
levels in platelets, erythrocytes and endothelial cells,
all of which influence blood glucose. Acute hyperglyce-
mia reduces endothelium-dependent vasodilation and
suppresses coronary microcirculation; which, in theory,
can alter the outcome of a radionuclide scan. In this
study, we investigated the acute effect of dipyridamole
on blood glucose. Subjects and methods: A total of 299
patients (87 men and 212 women, age: 60.52±0.60
years) were included in the study. Fasting blood glucose
(FBG) was measu r ed be fo r e and 8min a f t e r
dipyridamole (0.568 mg/kg) injection during myocardial
perfusion imaging. The data in different groups were
analyzed by paired t-test, and are presented as mean±
standard error of the mean (SEM). Results: There was
not a significant difference between first (106.89
±1.11mg/dL) and second (106.30±1.14mg/dL) FBG mea-
surements (P= 0.587). However, when the patients were
grouped based on the quartiles of first measurement, we
observed an increase in FBG following dipyridamole
injection in the first quartile (mean difference: 9.22
±2.57, P<0.001); in contrast, FBG levels showed a sig-
nificant decrease after dipyridamole administration in the
4th quartile (mean difference: -9.53±2.11, P<0.001). The
differences in 2nd and 3rd quartiles were negligible. The
patients were divided into normal, ischemic and fixed
lesions based on the outcome of scans, then the possible
correlation of dipyridamole-induced FBG alteration and
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scan results were investigated. There were no significant
difference between the FBG values before and after
dipyridamole injection and the final outcome of scan 9.
Conclusion: Dipyridamole may increase, decrease, or not
influence blood glucose depending on its initial level.
Considering the effects of acute hyperglycemia on coro-
nary vasodilation and microcirculation, initial blood glu-
cose must be observed in the interpretation of
dipyridamole-stress scans, especially in those with FBG
less than 96 or above 115 mg/dL.
P333
Measurement of concentration-dependent effect
of sevoflurane on myocardial oxygen consumption using
11C acetate PET in rats
K. Matsunaga1, T. Watabe1, A. Nakae2, H. Kang2, Y.
Kanai3, K. Isohashi1, H. Kato1, E. Shimosegawa1,3, J.
Hatazawa1; 1Department of Nuclear Medicine and Tracer Ki-
netics, Osaka University Graduate School of Medicine, Suita,
JAPAN, 2Department of Anesthesiology and Intensive Care,
Osaka University Graduate School of Medicine, Suita, JA-
PAN, 3Department of Molecular Imaging in Medicine, Osaka
University Graduate School of Medicine, Suita, JAPAN.
Objectives: The objective of this study is to evaluate the
concentration-dependent effect of sevoflurane on myo-
cardial oxygen metabolism using 11C acetate PET in
rats. Methods : Total 18 normal male SD rats (8 weeks
old, BW 244±27g) were anesthetized with different con-
centration of inhaled sevoflurane (1.5, 2.5 and 4.0%:
n=6 in each group) in 3 L/min air. 11C-acetate 30-min
dynamic PET scan was performed. As a measure of
oxygen consumption, the clearance rate constant
(kmono) of 11C-acetate over myocardium was calculat-
ed. The slope of the myocardial SUV time activity curve
before peak was used as an index of myocardial blood
flow (iMBF). Results : Kmono of 1.5, 2.5 and 4 %
sevoflurane group were, 0.32±0.03, 0.33±0.05 and 0.28
±0.08 /min, respectively. Decreasing trend of kmono
against sevoflurane concentration was observed in some
rats although there is no statistically significant differ-
ence. iMBF of 1.5, 2.5 and 4 % sevoflurane group
were, 5.50±1.22, 6.56±0.93 and 8.17±1.83 /min, respec-
tively. There was a statistically significant difference in
iMBF between 4% and 1.5% group (p=0.01). Kmono
divided by iMBF, an index of oxygen extraction frac-
tion, of 1.5, 2.5 and 4 % sevoflurane group were, 0.061
±0.014, 0.051±0.005 and 0.037±0.016, respectively.
There was a statistically significant difference between
4% and 1.5% group (p=0.03). Conclusions: Cardiac ox-
ygen consumption was not significantly influenced by
sevoflurane concentration although some rats showed de-
creased kmono with higher dose. The high concentration
of sevoflurane decreased oxygen extraction fraction with
increased blood flow, suggesting the protecting effect
against myocardial ischemia during high-dose anesthesia
of sevoflurane.
P334
Myocardial Insulin Resistant
under Hyperinsulinemic-Euglycemic Clamp in a Rat
Model
K. Fukushima1,2, P. Arias1, H. Wakabayashi1, T. Shinaji1,3,
R. Werner1,3, H. Pelzer1, T. Higuchi1,3; 1Würzburg Univ,
Würzburg, GERMANY, 2Hyogo College of Medicine,
Hyogo, JAPAN, 3Comprehensive Heart Failure Cener,
Würzburg, GERMANY.
Insulin resistance, an impaired ability to invoke glucose uptake
by insulin stimulation, has been suggested to be an important
etiologic factor for diabetic patients. Aim of this study was to
assess local cardiac insulin resistance using two-tissue com-
partment model kinetic analysis of 18F-FDG PET, as a surro-
gate maker for glucose metabolism, combining with dedicated
high-resolution small animal PET system and a rat model of
diabetes mellitus.Methods: Zucker diabetic fatty (ZDF) rats
(n=5), a model of type 2 diabetes mellitus, and Zucker lean
(ZL) control rats (n=4) were studied at age 13 weeks. Under
hyperinsulinemic-euglycemic clamp, approximately 37MBq
of 18F-FDG were administered via the tail vein, followed by
a dynamic 35 minutes PET acquisition (8sec x 15frames,
60sec x 3frames, 300sec x 4frames, 600sec x 1frame) using
dedicated small animal PET system (SIEMENS INVEON).
Image derived input functions from heart ventricles and myo-
cardial time-activity curves were obtained. Previously well
described 2 tissue compartment model had been used for esti-
mating values for individual rate constants represented as in-
ward transport (k1), outward transport (k2), and phosphoryla-
tion (k3).Results: Systemic insulin resistant of the ZDF diabet-
ic rats was confirmed by increased measure of insulin sensi-
tivity (M value) compared with ZL controls. Myocardial 18F-
FDG accumulations under hyperinsulinemic-euglycemic con-
ditions decreased significantly in ZDF rats than ZL controls.
Both 18F-FDG total influx constant Ki = (k1*k3/(k2+k3) (ZL
vs ZDF ; 0.0057 ± 0.0022 vs 0.0029 ± 0.0010, p<0.05) and
distribution volume of free tracer = k1/k2 (0.94 ± 0.27 vs 0.64
± 0.06, P<0.05) were significantly lower in ZDF diabetic rats,
while phosphorylation fraction = k3/(k2+k3) (0.077 ± 0.061
vs 0.065 ± 0.035, ns) d id not show signi f icant
differences.Conclusion: We successfully estimated increased
myocardial insulin resistance by dynamic 18F-FDG PET ki-
netic modeling in rat model of diabetes.
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Higher Event Rate in Patients with Known CAD
Despite a Normal Myocardial Perfusion Scan
M. u. Zaman1, N. Fatima2, U. Zaman3, A. Zaman3, R.
Zaman3; 1AKUH, Karachi, PAKISTAN, 2Dr Ziauddin Hos-
pital, Karachi, PAKISTAN, 3Dow University of Health Sci-
ences (DUHS), Karachi, PAKISTAN.
Objective: The negative predictive value of a normal single-
photon emission computed tomography (SPECT) myocardial
perfusion imaging (MPI) is very high. However, prognostic im-
plication of a normal SPECT MPI in patients with known coro-
nary artery disease (CAD) is not clear. Objective of this study
was to evaluate the cardiac event rate in patients with known
CAD who had a normal stress SPECT MPI. Methods: This
prospective study accrued 428 consecutive patients with a histo-
ry of CAD (revascularization or previous myocardial infarction)
who had a normal stress (dynamic exercise or dipyridamole
intervention) and rest Tc-99m-MIBI SPECTMPI. These patients
were followed for 2-5 years (median: 3.1 years) for all- cause and
cardiac mortality and non-fatal myocardial infarction. Univariate
and multivariate analyses were performed to identify predictors
of outcome. Results: During a follow-up period, all-cause mor-
tality was found in 60 patients (14%) and 41 (10%) died of
cardiac reasons. Non-fatal myocardial infarction (MI) was found
in 77 (18%) patients. Annualized cardiac mortality and non-fatal
MI rates were 2% and 3.6% respectively. Smoking, CCF and
failure to achieve 85% age predicted heart rate were found to be
predictors for all-cause and cardiac mortality. Diabetes, dyslipid-
emia, smoking and limited functional capacity (<7 METS) were
found to be predictors for non-fatal MI. Conclusions: Patients
with known CAD had higher cardiac event rates despite a nor-
mal stress SPECT MPI. Diabetes, dyslipidemia, smoking and
limited functional capacity were the predictors for fatal and
non-fatal cardiac events. A cost effective but comprehensive
surveillance strategy is warranted.
P337
High Negative Predictive Value of Workload ≥7 METS
on Exercise Testing in Patients with Normal Gated
Myocardial Perfusion Imaging: Was Imaging Really
Required?
M. u. Zaman1,2, N. Fatima2,3, U. Zaman4, A. Zaman4, R.
Tahseen4; 1AKUH, Karachi, PAKISTAN, 2Karachi Institute
of Heart Diseases (KIHD), Karachi, PAKISTAN, 3Dr
Ziauddin Hospital, Karachi, PAKISTAN, 4Dow University
of Health Sciences (DUHS), Karachi, PAKISTAN.
Purpose: to evaluate negative predictive value (NPV) of func-
tional capacity during treadmill exercise in patients with nor-
mal gated myocardial perfusion imaging (GMPI) in Pakistani
population. Methods: This was a prospective study conducted
at Nuclear Cardiology Department of Karachi Institute of
Heart Diseases (KIHD), Karachi, Pakistan during December
2008- December 2011. It included 1318 individuals with nor-
mal exercise GMPI. On the basis of maximal age predicted
heart rate (MAPHR) and metabolic equivalents (METS)
achieved, these patient were divided into Group A: ≥ 85%
MAPHR and ≥7 METS (714 patients), Group B: ≥85%
MAPHR and <7METS (145 patients), Group C: <85%
MAPHR and ≥7 METS (289 patients) and Group D: <85%
MAPHR and <7 METS (170 patients). These patients were
followed up on telephone (15 ±3 months) for fatal or non-fatal
myocardial infarction (MI). Results: Follow-up data revealed
no evidence of MI in any group and non-fatal MI in Group A
and C. Non-fatal MI was reported in 2.07% in Group B and
2.35% in Group D. NPV of a normal GMPI in relation with
functional capacity was found to be 100% for Group A and C
(≥7METS), 97.9% and 97.6% for Group B and D (<7METS)
respectively. Conclusion: We conclude that (1) patients with
≥7 METS with normal GMPI had 100% NPV for fatal and
non-fatal MIs; (2)patients with <7 METS with normal GMPI
had NPVof about 98% for non-fatal and 100% for fatal MIs;
(3) Omitting GMPI in patients with ≥7METS would save cost
and avoid radiation exposure.
P338
Temporal Trends in Results of 9170 Myocardial Perfusion
Imaging Studies (2004 to 2013)
N. Fatima1,2, M. u. Zaman3,2, U. Zaman4, A. Zaman4, R.
Tahseen4; 1Department of Nuclear Medicine, Dr Ziauddin
Medical University, Karachi, PAKISTAN, 2Karachi Institute
of Heart Diseases (KIHD), Karachi, PAKISTAN, 3AKUH,
Karachi, PAKISTAN, 4Dow University of Health Sciences
(DUHS), Karachi, PAKISTAN.
Background: To assess the frequency of normal and abnormal
myocardial perfusion imaging (MPI) in a consecutive cohort
of patients over a period of 8.5 years from Pakistan. Material
and Methods: We assessed 9170 patients who had undergone
stress-rest MPI between January 2004 and June 2013. Patients
were assessed for change in demographics, risk factors, and
frequency of abnormal and normal MPI. Results: Overall
mean age and male predominance of studied cohort was ≈
55 year and ≈ 55:45 (M:F) respectively with no appreciable
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decline or rise. Marked decline in exercise as mode of stress
(from 71% to 35%, p value significant) was noted during the
study period. Regarding the risk factors for CAD, only hyper-
tension was noted to have a significant rising trend during the
study period. Trend of MPI results over study period was
found non-significant from 2004 till 2006 but from 2007 on-
ward (except 2008), a marginal but significant decline in ab-
normal MPIs (from 45% to 42%; significant p value) and rise
in normal MPI (from 55% to 58%; significant p value) was
noted. Conclusions:We conclude that over the past 8.5 years, a
marginal but significant decline in abnormal and a rise in nor-
mal MPIs trend have been observed. An exorbitant rise in use
of vasodilator as stressor than exercise was also observed. We
envisaged a follow-up study to ascertain lower negative pre-
dictive value of vasodilator as a possible reason and till than
results of this and other such studies must be read cautiously.
P339
Comparison of hemodynamic effects and negative
predictive value of normal adenosine gated myocardial
perfusion scan with and without caffeine abstinence
N. Fatima1,2,M. u. Zaman3,2; 1Department of NuclearMed-
icine, Dr Ziauddin Medical University, Karachi, PAKISTAN,
2Karachi Institute of Heart Diseases (KIHD), Karachi, PAKI-
STAN, 3AKUH, Karachi, PAKISTAN.
Objective: For vasodilator stress myocardial perfusion imaging
(MPI) at least 12 hour caffeine is recommended as it attenuates
cardiovascular hyperemic response of adenosine and
dipyridamole. However, many published conflicting results have
shown no significant effect upon perfusion abnormalities inMPI
performed without caffeine abstinence. The aim of this study
was to compare the hemodynamic changes and negative predic-
tive value (NPV) of normal MPIs with adenosine stress per-
formed with and without caffeine abstinence. Methods: This
was a prospective study which accrued 50 patients from
May 2013 till September 2013 and followed till November
2014. These patients had a normal adenosine-gated-MPI with
99mTc-MIBI after 12 hour caffeine abstinence (No-caffeine).
Next day, all patients had a repeat adenosine stress within 60
minutes after ingestion of a cup of coffee (about 80 mg of caf-
feine) followed by no MPI in 30 patients due to concern about
radiation dose (Prior-caffeine adenosine No-MPI; Group A).
Twenty patients opted for a repeat MPI (Prior-caffeine
adenosine-MPI; Group B). Adenosine induced hemodynamic
response and NPV of normal MPI with No-caffeine and Prior-
caffeine protocols were compared. Results: The mean age of the
study cohort was 57 ± 09 years with a male to female ratio of
76:24% and mean body mass index (BMI) of 26.915 ± 4.121
Kg/m2. Prevalence of hypertension, diabetes, dyslipidemia and
positive family history was 76%, 20%, 22% and 17%
respectively. Comparison of Group A with Group B revealed
no significant difference in demographic parameters, hemody-
namic or ECG parameters or left ventricular function parameters
during adenosine intervention with Prior-caffeine and No-
caffeine protocols. During follow no fatal MI was reported but
06 non-fatal MIs based upon history of short hospitalization for
chest pain but without biochemical or ECG criteria for infarction
(03/30 in Group A and 03/20 Group B). Event free survival
(EFS) for fatal MI was 100% for both groups while EFS for
non-fatal MI was 90% for Group A and 85% for Group B
(non-significant p values). Kaplan Meier’s survival plot also
depicted non-significant EFS for non-fatal MI. Conclusion: This
study did not find any significant attenuation effect upon aden-
osine induced hemodynamic response and similar negative pre-
dictive value of a normal GMPI in patients with and without
caffeine abstinence. We assume that better designed prospective
studies are required to validate findings of our study and provide
justification for revision of guidelines about caffeine abstinence.
P341
Direct Voxel-by-Voxel Comparison of Tomographic
Images from Nuclear Cardiology
J. Trnka, A. Fikrle, D. Zogala; General University Hospital,
Prague, CZECH REPUBLIC.
INTRODUCTION: Traditional assessment of myocardial perfu-
sion SPECT based on polar maps and comparison against nor-
mal database suffers from several serious drawbacks: 1) normal
data may have been acquired under other conditions than the
study on-site, 2) manual reformatting of stress and rest data
may lead to mis-registration, 3) comparison of both stress and
rest data against their own normal databases may lead to artifacts
in assessment. Moreover, viability assessment based on 50% rest
perfusion threshold may not be robust enough regarding multi-
modality comparison with metabolic PET study. The aim of this
work was to construct three-dimensional difference maps be-
tween rest and stress SPECT perfusion images as well as be-
tween rest SPECTand metabolic PET to overcome these limita-
tions. MATERIAL ANDMETHOD: The whole procedure was
performed by locally developed algorithm, which had been pre-
viously verified in clinical practice in the field of nuclear neurol-
ogy. The algorithm consists of three fundamental steps: 1) auto-
matic spatial registration, 2) intensity normalization to compen-
sate for differences in image counts, 3) subtraction, i.e. voxel-by-
voxel calculation of differences in an appropriate form. The nor-
malization can be based either on the mean activity within a
defined volume or on an arbitrarily selected mutual voxel. The
system is also capable to estimate tissue volume affected by an
uptake defect or another quantitative abnormality. RESULTS
AND DISCUSSION: The proposed method was tested on sev-
eral patients who had undergone myocardial perfusion 99mTc-
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MIBI/Tetrofosmin SPECT with or without clear conclusion
based on traditional assessment. It often introduced useful addi-
tional information to help clinicians make or improve the deci-
sion. The automatic spatial registration worked very well. The
displayed difference maps well corresponded to visual experi-
ence and it was easy to verify their correctness. Using proper
filtration andmore advanced registration it was possible tomatch
both images of the multi-modality (99mTc-SPECT/18FDG-
PET) study for visual and semi-quantitative viability assessment.
CONCLUSIONS: The developed method is suitable for direct
comparison between rest and stress SPECT myocardial perfu-
sion images. It may provide additional information useful for a
clinician to improve the study evaluation. It is also promising for
myocardial viability assessment using comparison of SPECT vs.
PET images.
P342
A Useful and Easy to Develop Combined Stress Test
for Myocardial Perfusion Imaging: Regadenoson
and Isometric Exercise, Preliminary Results
l. janvier, Jr.1,2; 1CHU Bordeaux, Bordeaux, FRANCE,
2CHU Nancy, Nancy, FRANCE.
Background: Regadenoson a selective A2a receptor agonist is
a vasodilator increasingly used in myocardial perfusion imaging
(MPI). Adjunction of isometric exercise is a simple method that
could improve side effect profile while providing better image
quality. Methods: Patients undergoing SPECT MPI were pro-
spectively enrolled in handgrip-Regadenoson (HG-Reg test, N=
20) and Regadenoson (Reg) stress test (N= 40). Investigator
blinded to stress test analyzed clinical data and images.Results:
Heart rate (HR) increase was statistically higher in the HG-Reg
group (27±9 vs 22±15 bpm, p=0.019). Decrease in systolic
blood pressure (SBP) was less frequent in the HG-Reg group
than in the Reg group (55% vs 85.5%, p=0.005), there were less
drops >10 mmHg (45% vs 77.7%, p=0.012). During stress test-
ing, fewer subjects reported at least one side effect in the HG-
Reg compared to Reg group (70% vs 92.5%, p=0.021). Images
were more often classified as good in the HG-Reg group (75%
vs 60% in the Reg group, p=0.251). Conclusions: Adjunction
of handgrip exercise to Regadenoson administration is a well-
tolerated and easy method, without loss of time. Furthermore,
image quality seems to be better.
P343
Myocardial perfusion imaging pattern in patients
with intermediate and significant coronary artery stenosis
K. W. Zavadovsky1,2, M. O. Gulya1,2, V. V. Saushkin1, Y.
V. Saushkina1,2, Y. B. Lishmanov2,1; 1Federal State
Budgetary Scientific Institution “Research Institute for Cardi-
ology”, Tomsk, RUSSIAN FEDERATION, 2National Re-
search Tomsk Polytechnic University, Tomsk, RUSSIAN
FEDERATION.
Aim. To assess the state of myocardial perfusion in pa-
tients with coronary artery disease and intermediate cor-
onary artery stenosis. Materials and Methods: The study
group consisted of 58 patients (age: 63.1±7.1 years).
Inclusion criteria were the clinical signs of CAD. Ex-
cluding criteria were: acute coronary syndrome, previous
myocardial infarction, any type of coronary artery
revascularisation, cardiomyopathies, inflammatory cardi-
ac diseases and contraindication for MDCT coronary an-
giography. All patients underwent MDCT coronary angi-
ography and myocardial perfusion imaging at rest and in
combination with pharmacological adenosine stress test.
All investigations were performed on GE Discovery
NM/CT 570C with cadmium-zinc-telluride detectors. Ac-
cording SPECT data the were analysed summed stress
rest, different score, severity and extent maps. According
MDCT data the were analysed the presence of coronary
artery stenosis, degree of strenosis (by minimal diameter
and by area). According MDCT data all patient where
divided in two groups: 1) main group - with angio-
graphically intermediate coronary artery stenosis (70%);
2) with angiographically significant coronary artery ste-
nosis (>70%). Results. According correlation analysis we
found significant correlation between stress summed
score and stenosis degree by minimal diameter (r=0.28;
p<0.05;) and by area (r=0.25; p=<0.05;). Also we found
a correlation between stenosis degree by area and
summed different score (r=0,31; p=;) and reversibility
on extent maps (r=0,31; p=;). The SPECT indexes of
myocardial perfusion in patients with intermediate and
significant coronary artery stenosis were follows:
summed stress score (6.7±4.4% and 13.7±1.8%; p<0,
05); stress extent (7.6±6.2% and 26.6±3.4%; p<0,05);
stress severity (0.3±0.1SD and 1.0±0.2SD; p<0,05);
summed rest score (2.7±1.2% and 3.3±0.9%; p=not sig-
nificant); rest extent (9.0±4.6% and 16.3±10.2%; p<0,
05); rest severity (0.4±.2. and 0.8±0.4; p=not signifi-
cant); summed different score (3.6±2.1SD and 9.8
±2.5SD; p<0,05); reversibility extent (8.1±4.4% and
23.6±5.5%; p<0,05); different severity (1.8±1.1SD and
3.8±0.7SD; p<0,05). We established that 20±12.7% pa-
tients with intermediate coronary artery stenosis had
scintigraphic pattern similar to that of patients with cor-
onary artery stenosis more than 70%. Conclusion. In
patients with intermediate coronary artery stenosis de-
gree of coronary artery stenosis has a weak relationship
with impaired myocardial perfusion. CHD patients with
coronary ar tery stenosis greater than 70% are
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characterized by a significantly more severe impaired
myocardial perfusion, compared with patients with inter-
mediate coronary artery stenosis. 20±12.7% patients with
intermediate coronary artery stenosis had scintigraphic
pattern similar to that of patients with coronary artery
stenosis more than 70%. The study was supported by a
grant from the Russian Science Foundation (№14-15-
00178).
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A new approach to assessment of myocardial perfusion
in patients with hypercholesterolemia according
to the single-photon emission computed tomography
L. Martirosyan, Doctor, I. Sergienko, A. Ansheles, A.
Popova, K. Ivanov, V. Sergienko; FGBU RC NPC MH RF,
Moskou, RUSSIAN FEDERATION.
The SPECT is quantitative, reproducible, safe and afford-
able. Objective: the Study, using the method of SPECT, the
characteristics of the perfusion of the myocardium with
99mTc-MIBI in combination with the stress test in patients
with total cholesterol (TC) ≥ 7.5 mmol/l and/or cholesterol
are low density lipoprotein (LDL-CH) ≥ 4.9 mmol/l, but
without obvious clinical manifestations. Materials and
methods: the study involved 26 patients aged 30-68 years.
14 men, 12 women. All patients underwent a SPECT of the
myocardium with 99mTc-MIBI in combination with the
stress test, followed by evaluation and comparison of per-
fusion at rest and after exercise. In addition to the standard
indicators for assessing perfusion:rest, stress, reversibility
extents, SDS, SRS, SSS, we used a statistic - the standard
deviation - σ sev and σ het. Results: Stress tests in all cases
were negative for myocardial ischemia. According SPECT,
there were no significant stability and/or reversible perfu-
sion defects in hypercholesterolemic patients. With a qual-
itative assessment, inhomogeneous RFP was detected in 23
patients (88%). The difference between standard perfusion
indicators in hypercholesterolemia patients and healthy
volunteers were not found: Rest extent - 8.3 (5.0-11.0)
and 8.0 (6.4-11.2), p = 0.67, Stress extent - 11.3 (6.5-
14.0) and 7.5 (6.5-12.5), p = 0.52, Reversibility extent -
5.0 (2.5-8.0) and 3.5 (2.9-7.1), p = 0.85, SRS - 3.5 (2.0 -
5.5) 2,9 (0.75-6.0 ) p = 0.94, SSS - 7.3 (4.5-9.5), and 6.5
(5.1-8.3), p = 0.87, SDS - 2.5 (2.0-6.0), and 4.0 (2.9-5.1), p
= 0.42, respectively. At the same time in patients with hy-
percholesterolemia compared with healthy volunteers σ sev
and σ het were significantly higher: σ sev - 22.6 (18.9-
25.2) vs. 15.6 (15.5-21.4), respectively, p = 0.04, at the rest
study. At the stress study: σ sev - 22.3 (19.2-24.4) and 17.3
(16.7-18.6), respectively, p <0.01. σ het - 7.8 (7.0-9.3) and
6.1 (5.2-7.2), p = 0.053 at the rest, σ het - 7.9 (7.0-9.3) and
5.8 (5.5-6.8), p = 0.015 at the stress. Conclusion: the Use of
the protocols of the metric of the standard deviation com-
pared with the standard indicators of transient ischemia
allows us to have more reliable judgement of the initial
processes of redistribution of blood flow in the myocardi-
um, which is an important aspect in the diagnosis of initial
pre - clinical manifestations of coronary heart disease in all
its manifestations.
P345
Interchangeability of cardiac volumetric and phase
analysis parameters between two software (CardioRepo
and Heart Function View)
T. Kudo, R. Ideguchi, M. Uetani, Y. Koide, K. Maemura;
Nagasaki University, Nagasaki, JAPAN.
Puropse: QGS (quantitative gated SPECT) is long considered
as gold standard for ECG gated myocardial perfusion imaging
(MPI) analysis. However, several other programs those also
have phase analysis capability were on the market recently.We
compare two software for ECG gatedMPI named CardioRepo
(CRepo: Fuji filmRI pharma and Exini Diagnostics) and Heart
Function View (HFV: Nihon Mediphysics).Method: Consec-
utive 98 patients who underwent stress/rest gated MPI were
analyzed with CRepo and HFV: Nihon Mediphysics. All the
MPI was performed one-day protocol using Tc-99m labeled
perfusion agents (tetrofosmin or MIBI). Gated MPI was ob-
tained using E-cam (Siemens) with 180 arc orbit, 16 frames/
beat, without attenuation correction. Two phase parameters,
bandwidth and phaseSD were compared between those two
software. Volumetric parameters such as EDV, ESV and EF
were also analyzed.Results: For functional parameters,
EDV and EF showed slightly but significantly large value
in CRepo (EDV; 101±42 vs 94±47 ml, p<0.01. EF; 68
±10% vs 65±12, p<0.01 for CRepo and HFV, respectively).
ESV showed slightly smaller value for CRepo (34±25 vs
37±33 ml, p<0.01) but CRepo showed larger volume in
small heart subjects. For phase parameters, CRepo and
HFV showed very good correlation (Bandwidth; R-
square=0.65, p<0.01, PhaseSD; R-square=0.70, p<0.01)
but absolute number are quite different between two soft-
ware (Bandwidth; 65.4±51.3 vs 39.1±27.1, p<0.01,
PhaseSD; 15.9±11.9 vs 11.2±8.3, p<0.01 for CRepo and
HFV, respectively).Conclusion: Those two software
showed significant difference but the difference is very mi-
nor in volumetric parameters. Thus, for volumetric param-
eters, those two software are considered as interchangeable.
However, for phase parameters, the difference is very large.
Thus, regarding phase parameters, those two software are
not interchangeable.
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Radionuclide assessment of myocardial flow reserve
in patients with multivessel coronary artery disease
K. W. Zavadovsky1,2, A. Mochula1, S. Andreev1, Y.
Lishmanov2,1; 1Federal State Budgetary Scientific Institution
“Research Institute for Cardiology”, Tomsk, RUSSIAN FED-
ERATION, 2National Research Tomsk Polytechnic Universi-
ty, Russian Federation, Tomsk, RUSSIAN FEDERATION.
Purpose. To assess the myocardial flow reserve in patients with
multivessel coronary artery disease (MVCAD) by dynamic
SPECT using semiconductor (cadmium-zinc-telluride)-based
gamma camera. Material and methods. This work included fif-
teen patients (11 males and 4 females; mean age 63.3±12.6
years) with MVCAD with the presence of stenosis greater than
50% according to invasive coronary angiography. Control
group consisted of 7 men and 2 women (25±4 years) without
any cardiac diseases (healthy volunteers). All patients and vol-
unteers underwent myocardial SPECT using semiconductor
(cadmium-zinc-telluride)-based gamma camera. We used
99mTc-MIBI as a radiopharmaceutical. Acquisition protocol
was as follows: (1) rest radiopharmaceutical injection (volume
1 mL; dose 185 MBq); 5-min list-mode acquisition; (2) stress
radiopharmaceutical injection (volume 1ml; dose 740 MBq)
followed by two-minute adenosine infusion (160 mcg/kg/
min); then additional two-minute adenosine infusion (160
mcg/k/min). List-mode (5-min duration) was started simulta-
neously with the injection of the radiopharmaceutical. All scin-
tigraphic images were acquired on the hybrid SPECT/CT unit
(GE Discovery NM/CT 570C). Using dedicated software (Dy-
namic Analysis Tool), we received dynamic data reflecting the
passage of the radiopharmaceutical in the walls and in the cavity
of the left ventricle. To assess myocardial flow reserve, we
calculated the ratio of the mean counts value from the left ven-
tricular myocardial region (apex, anterior, lateral, and septal
wall) to the integral under the curve from the left ventricular
cavity. The index of myocardial blood flow reserve was calcu-
lated by dividing the ratio acquired in stress test by the ratio
obtained at rest. Results. The average values of the myocardial
flow reserve index for the left ventricle (in general) in a
MVCAD group and in a group of healthy volunteers were sig-
nificantly different: 1.41±0.48 and 1.88±0.43, respectively
(p<0.05). Regional myocardial blood flow reserve index was
also significantly different in patients with MVCAD and in
healthy volunteers: 1.34±0.43 and 1.88±0.38 for the apex of
the left ventricle, respectively (p<0.05); 1.44±0.41 and 1.95±
0.45 for the lateral wall, respectively (p<0.05); 1.32±0.44 and
1.63±0.43 for the anterior wall, respectively (p<0.05); and 1.44
±0.77 and 2.06±0.38 for the septal wall, respectively (p<0.05).
Conclusion. Dynamic myocardial rest-stress SPECT using
semiconductor (cadmium-zinc-telluride)-based gamma camera
allows for identifying low myocardial flow reserve in patients
with multivessel coronary artery disease. It can be helpful in
assessment of severity of myocardial perfusion abnormality in
these patients. These preliminary results require verification and
comparison with other modalities. The study was supported by
a grant from the Russian Science Foundation (№14-15-00178).
P347
Side Effects of Adenosine as a Pharmacologic Stress Agent
for Myocardial Perfusion Scan in a local setup
H. AMER; King Abdulaziz Hospital National Guards Health
Affairs, Al Ahsa, SAUDI ARABIA.
Selection of the most appropriate stress method is one of the
keys to success in myocardial perfusion scintigraphy. Adeno-
sine infusion is not without side effects which may range from
minor effects to major consequences. The frequency of their
occurances raised the necessity of a comparative study with
the international literature available.Methods: This was a ret-
rospective observational registry performed in a single center
in the Kingdom of Saudi Arabia. The data were collected from
the nuclear medicine database identifying all the reported Gat-
ed myocardial perfusion SPECT with adenosine stress tests
between January 2013 and January 2014.The adenosine dose
were fixed with all patients based on body weight and was
given as a continuous infusion of 140 mcg / kg / min over a
6-minute period. A shorter-duration adenosine infusion, last-
ing 4 minutes, was applied occasionally. Injection of cardiac
radiopharmaceuticals was given at 3 minutes for a 6- minute
protocol, and at 2 minutes for a 4-minute protocol. Results:
There were 346 patients identified with cardiac nuclear scans
in the pre-specified time frame who subjected to adenosine
stress scan. 152 of these patients were male accounting for
44% of the total population. Average age at the time of exam-
ination was 60.82±11.29 years. Patients were presented with
one or more risk factors. Most of the side effects encountered
during adenosine infusion are related to ECG changes 22%
(77), the other side effects are chest pain seen in 19% (66) ,
shortness of breath ,7% (25), flushing,2% (8), dizziness,3%,
headache,2% (8), palpitation,0.7% (3),cough,0.5% (2), and
sore throat,0.3% (1) , 10% (37) developed abdominal discom-
fort . The ECG changes were of ischemic types as ST and T-
wave changes in (40) 52%. Other changes were non ischemic
as 2nd degree heart block in (16) 21%, 10%, PVC’s in (11),
14%, 1st degree heart block in (7) 9%, APC’s,RBBB and
bradycardia,1% each. No reported case of death or myocardial
infarction in this study period. Conclusion: The frequency of
side effects seen secondary to adenosine administration are
matched with the international literature available and the mi-
nor differences noted could be related to the different age
group in the study population and frequency of the risk factors
they are carrying.
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Prediction of occult coronary artery disease in patients
with normal myocardial perfusion scintigraphy using
myocardial perfusion reserve on dynamic thallium-201
single-photon emission computed tomography
with a semiconductor gamma camera
S. Shiraishi1, N. Tsuda1, F. Sakamoto1, M. Yoshida2, S.
Tomiguchi1, Y. Yamashita1; 1Kumamoto University, Kuma-
moto City, JAPAN, 2Amakusa medical center, Hondo City,
JAPAN.
Purpose: Nuclear myocardial perfusion imaging (MPI)
may fail to detect balanced ischemia. We recorded the
myocardial perfusion reserve (MPR) by using a 3-
dimensional (3D) dynamic approach with a high sensi-
tivity cadmium zinc telluride (CZT) camera to determine
whether it could predict occult coronary artery disease
(CAD) in patients without drug-induced myocardial is-
chemia on conventional MPI. Methods: We subjected
165 consecutive patients with suspected CAD to thalli-
um (201Tl) chloride adenosine stress and rest MPI-
dynamic single photon emission computed tomography
(SPECT) and coronary angiography. We enrolled 63 pa-
tients with minimal ischemia (less than 5% ischemic
myocardium) on conventional MPI. The MPR index
was calculated using the standard two-compartment ki-
netic model. We analyzed the utility of the MPR index,
other SPECT findings, and various clinical variables for
predicting occult CAD. Results:Multivariate analysis
showed that the MPR index and the HDL-cholesterol
level were predictive. The value of the area under the
receiver operating characteristic curve of the MPR index
was 0.80, it was 0.65 for HDL-cholesterol, and 0.82
when the combined MPR index was added to HDL-cho-
lesterol. We determined that a combined index value ≥ 0
yieled the highest diagnostic accuracy. Sensitivity, spec-
ificity, and accuracy were 89%, 65%, and 79%, respec-
tively, for the combined index; these values were 76%,
81%, 78% for the MPR index, and 86%, 50%, and 71%
for the HDL-cholesterol. Conclusion: Quantification of
myocardial perfusion and the perfusion reserve using
dynamic SPECT with a CZT camera may help to iden-
tify occult CAD in patients without drug-induced myo-
cardial ischemia on MPI.
P349
Large myocardial injury attenuates a response to steroid
therapy in patients with cardiac sarcoidosis
M. Momose1, K. Fukushima1, C. Kondo1, N. Serizawa2, A.
Suzuki2, K. Abe1, N. Hagiwara2, S. Sakai1; 1Department of
Diagnostic Imaging and Nuclaer Medicine, Tokyo Women’s
Medical University, Tokyo, JAPAN, 2Department of Cardiol-
ogy, Tokyo Women’s Medical University, Tokyo, JAPAN.
Aim: Steroid therapy is well known to have an anti-
inflammatory effect for active cardiac sarcoidosis (CS).
However its response has not been fully discussed so
far because of no useful standard of a response to the
therapy. FDG-PET/CT(PET) is recently reported to be
useful tool to evaluate inflammation activity; therefore it
may be also possible to assess a response to the steroid
therapy in CS patients. The aim of the present study is to
assess which imaging parameters before the therapy af-
fect the therapeutic response. Methods: Twenty patients
with CS diagnosed based on Japanese Ministry of Health
and Welfare clinical criteria (JMHW), FDG-PET and/or
cardiac MRI were retrospectively enrolled in the study.
All patients underwent PET, 123I-BMIPP(BMIPP) and
201TL(TL) dual gated SPECT before steroid therapy.
As indexes of inflammation activity by PET, SUVmax,
higher metabolic activity volume in the heart (HMAV
activated >2.5 in SUV) and total lesion glycolysis
(TLG=HMAV x SUVmean within the activated region)
were obtained using syngo.via software (Siemens).
BMIPP and TL SPECT images were divided into 17 seg-
ments where each segmental defect score (0,normal; 4,
absent) was graded to generate summed BMIPP and TL
defect score (BMDS, TLDS). End-diastolic volume
(EDV) and ejection fraction (EF) were generated by gat-
ed SPECT. All patients were treated with 30mg/day of
prednisone, which was tapered to a maintenance dosage
of 10-20mg/day. All the patients underwent another PET
in 6-12 months to evaluate a response to the therapy, and
the inflammation indexes were generated again. We clas-
sified the response to the therapy into partial (PR) and
complete (CR) responses with a threshold value of 10 in
TLG (CR<10). We compared the generated image param-
eters between PR and CR. Results: As for the PET pa-
rameters, SUVmax, HMAV and TLG were 8.34±4.31,
154±93 and 603±416 before the therapy, which were de-
creased to 3.16±0.88, 13.10±23.6 and 39±71 at the sec-
ond scan, respectively. BMDS, TLDS, EDV(mL) and
EF(%) before therapy showed 14.2±11.1, 9.6±9.1, 104
±50 and 44±15, respectively. Seven patients were judged
as PR. BMDS and TLDS were significantly higher in PR
than in CR group (BMDS, 23±13 vs. 9.0±5.9, p=0.004;
16±11 vs. 5.8±4.9 p=0.013), but other imaging parame-
ters before the therapy were not significant. Sensitivity
and specificity for the detection of PR were 92 and
71% using >14 in BMDS. Conclusion: The preliminary
data suggested that large myocardial injury assessed by
BMIPP and TL may attenuate a response to steroid ther-
apy in patients with cardiac sarcoidosis.
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Visualization of Acute Myocardial Infarction of Right
Ventricle Free Wall after Cardiac Surgery by Gated
SPECTwith Phase Images
E. N. Ostroumov1, E. D. Kotina2, V. A. Ploskikh2, A. V.
Babin2, A. S. Ivanov1, A. V. Rodionov1, O. M. Mas’1; 1Ac-
ademician V.I. Shumakov Federal Research Center of
Transplantology and Artificial Organs, Moscow, RUSSIAN
FEDERATION, 2Saint-Petersburg State University, Saint-Pe-
tersburg, RUSSIAN FEDERATION.
Aim. Myocardial-like infarction ECG changes and a signifi-
cant rise in the level of cardiac enzymes require the exclusion
of acute myocardial focal changes. Such a situation can some-
times occur after cardiac surgery. Visualization of these chang-
es is required to assess the prognosis. The absence of such
changes in LV myocardium already shows a good prognosis,
however, it does not explain the problems of clinical and in-
strumental signs. Material and Methods. During 5 years of
research from more than 1500 patients had been undertaken
a cardiac surgery we had 9 cases of changes in ECG, enzymes
and clinics after cardiac surgery. Three patients underwent
aortic valve replacement (one in combination with coronary
anastomosis), 2 patients - multiple stenting of coronary arter-
ies, one patient after multiple coronary artery bypass surgery, 2
patients underwent multiple stenting after heart transplantation
and 1 with congenital heart defect. All patients underwent
gated SPECT with the phase image not only of the left but
also of the right ventricle. Results. All patients after surgery
showed myocardial like infarction ECG changes and / or car-
diac enzymes accompanied by clinical signs of right ventricu-
lar heart failure. In one case proximal lesion in the right coro-
nary artery (RCA) was revealed, in the second case there was a
congenital absence of RCA. In the remaining 7 cases the cor-
onary arteries were intact. During the gated SPECT right after
surgery no patient showed any focal changes in LV myocardi-
um. However, while analyzing the images of the right ventricle
in all 9 patients we identified focal reduction of perfusion and
function, topographically coinciding with areas of pathologi-
cal myocardial asynchrony. Conclusion. The appearance of
clinical and instrumental signs of acute myocardial infarction
after cardiac surgery without focal changes in LVmyocardium
may be associated with focal changes in the myocardium of
the right ventricle even if coronary arteries are intact.
P351
Is increased septal perfusion an indicator of asymmetrical
septal hypertrophy?
S. OZDEMİR1, Y. TAN1, E. GAZI2, F. CELİK1;
1Canakkale Onsekiz Mart University,Faculty of Medicine.
Department of Nuclear Medicine, Canakkale, TURKEY,
2Canakkale Onsekiz Mart University,Faculty of Medicine.
Department of Cardiology, Canakkale, TURKEY.
ABSTRACT: Background: In this study, we have compared
scintigraphic and echocardiographic data in order to investi-
gate whether increased septal perfusion represents asymmetri-
cal septal hypertrophy which is a symptom followed in the
scintigraphy of myocardial perfusion. As a secondary objec-
tive, we have analyzed the correlation of the size of left ven-
tricular and dimensions obtained from echocardiography.
Method: The study consists of a total of 186 patients (120
female and 66 male with an average age of 59.45 ± 11.54
years) who had normal myocardial perfusion scintigraphy
and echocardiography examinations. Statistical comparison
of septal wall thickness measurements obtained from echocar-
diography and septal-to-lateral wall ratios (S/L ratio) was per-
formed scintigraphically. Left ventricular mass values were
obtained as both scintigraphically and echocardiographically
and their correlations were evaluated in order to assess the
presence of left ventricular hypertrophy. Results: In statistical
analyses, the values of IVSd, LVPWd, LVM and LVMI were
found to be significantly higher in the Group2 (S/L ratio>1)
compared to the Group1 (S/L ratio<1). In addition, S/L ratio is
significantly correlated with echocardiographic IVSd,
LVPWd, LVM, LVMI and scintigraphic LVM (rest) values.
Furthermore, echocardiographic LVM, LVMI values were sig-
nificantly correlated with LVM, LVMI values obtained from
scintigraphy. Conclusion: It should be known that increased
S/L wall ratio that can be monitored during scintigraphic stud-
ies can be an indicator of septal hypertrophy and/or left ven-
tricular hypertrophy and further examination and close follow
ups should be performed in necessary cases.
P353
Added value of coronary calcium scoring as part
of myocardial perfusion scan
A. Notghi, S. Tomas Hernandez, J. O’Brien; Sanwell and
West Birmingham Hospitals NHS Trust, Birmingham, UNIT-
ED KINGDOM.
Aim: With hybrid SPECT cameras it is now possible to per-
form a coronary calcium scoring (CCS) in patients undergoing
myocardial perfusion scan (MPS). CCS is normally recom-
mended for patients with low probability (<30%) coronary
artery disease (CAD). Here we have looked how useful is
CCS when used in conjunction with MPS in patients with
intermediate probability of CAD (30-60%). Method: All pa-
tients referred for MPS with no previous angiogram were
marked for CCS. GE Discovery 670 SPECT camera with 16
slice CT was used. SPECT acquisition was immediately
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followed by gated CCS acquisition (2 minutes additional
time). Results: In initial pilot study 45% of CCS could not
be performed because of high heart rate (>70 bpm). We now
administer oral beta-blocker to all patients with resting heart
rate of >70 after they are stressed. This has enabled all eligible
patients to have CCS. During 12 months period (2013-2014)
1713 patients had MPS. Of these 926 (54%) also had CCS
with MPS. Median age was 61 (range 18 to 89 year). 394/
926 (42%) had a calcium score of 0. The remaining 58% had
calcium score ranging from 1 to 11800 Agatston Units (medi-
an CCS=181 AU). Discussion: Calcium score of 0 increased
the confidence in reporting normal scans (MPS lesion 3% or
less at stress with calcium score of 0 do not need rest study).
These patients were subsequently discharged from cardiac
clinics. Patients with calcium score of 0 who had >3% defects
on MPS were referred for CTCA/angiogram to exclude soft
plaques. Patients with CCS of ≥ 1 and normal MPS, did not
come back for rest study. All patients with MPS defect had a
rest study regardless of the size. A positive CCS changed the
clinical management in all patients with no evidence of flow
restricting disease as they were given dietary advice and ag-
gressive control of risk factors. Those with abnormal MPS and
positive CCS were referred for angiography with a view for
stenting. Conclusion: CCS is a quick and easy addition to an
MPS study. It can reduce the number of unnecessary rest stud-
ies (saving patient radiation and time for department), it en-
hances the confidence of reporting and changed the clinical
management of patients leading to overall improvement in
patient diagnosis and management. MPS+CCS is now part
of our routine MPS study.
P354
Myocardial perfusion scintigraphy in patients undergoing
cardiac rehabilitatation
S. Rizkallal Monzon1, B. Theillac2, B. Navarro Martinez2, J.
Castro Beiras2, M.Martinez Gomez2; 1Hospital Universitario
La Paz, Madrid, SPAIN, 2Hospital Universitario Ramon y
Cajal, Madrid, SPAIN.
AIM: Cardiac Rehabilitation (CR) includes physical exercise
that has proven to improve collateral recruitment. Therefore
collateral circulation could be a new therapeutic target. The
aim of this study is to evaluate the utility of myocardial perfu-
sion scintigraphy (MPS) to measure ischemic change in coro-
nary artery disease patients undergoing CR. MATERIAL
AND METHODS: A total of 43 patients (6 women) were
enrolled in the study (aged 59±10 years). None of them were
subjected to revascularization procedures during CR. Two
MPS were performed in every patient one before and the other
after concluding CR. The average duration of the CR was 79
±27 days. Quantitative perfusion and functional data were
obtained in both studies. The results were expressed as mean
± standard deviation, considering them statistically relevant if
p≤0.05. RESULTS: Average stress perfusion defect in the first
MPS was 28.3±16 %, while in the second MPS was 22.3±15
% (p≤0.01). We did not find significant difference in post-
stress left ventricular ejection fraction (53.4±12 vs 54.7±1%
NS) nor in rest MPS results (22.3±15 vs 20.5±14 NS). How-
ever when patients with low left ventricular dysfunction
(<50%) were grouped (n: 18) the results showed improvement
in their poststress ventricular function (42.0±7 % vs 45.1±9%
NS (p≤0.08)). CONCLUSION: MPS has proven to be really
useful evaluating changes in myocardial perfusion of patients
undergoing CR. This improvement in myocardial perfusion is
probably related to development of collateral circulation. Pa-
tients with previous low ventricular function showed increase
in their left ventricular ejection fraction, however further stud-
ies are needed to confirm this trend.
P355
Clinical Impact of Myocardial Perfusion Scintigraphy
in Patients with Previous Percutaneous Coronary
Intervention
S. Czibor, M. Moravszki, K. Buga, M. Toth, R. Joba, I.
Szilvasi; Hungarian Defence Forces Medical Centre, Dept.
of Nuclear Medicine, Budapest, HUNGARY.
Aim: The purpose of this study was to evaluate the clinical
usefulness of myocardial perfusion scintigraphy (MPS) to de-
tect restenosis or stenosis in a new localisation in patients with
previous percutaneous coronary intervention (PCI). Materials
and methods: We compared the findings of MPS and invasive
coronary angiography (CAG) of patients with clinically
suspected restenosis. ECG-gated MPS were performed using
the one-day protocol. In 142 patients MPS was followed by
CAG because of stress-induced reversible perfusion defects
(in 102 cases) or persistent severe clinical signs (in 40 cases)
within 8±5 weeks. Age of the patients (38 women and 104
men) was 63.0±9.8 years. The median of the time interval
between the last PCI and the MPS was 13,5 months. Results:
Out of the 142 MPS studies, reversible perfusion defects were
shown in 102 cases and were not present in 40 cases (10 with
normal scans and 30 with fixed perfusion defects). Haemody-
namically significant stenoses were found by CAG in 99 cases
and they were absent in 43 cases. The 102 MPS studies show-
ing ischaemia proved to be true positive in 83 (81,37%), and
false positive in 19 cases (18,36%). Out of the 40 MPS exam-
inations without ischaemia 24 were true negatives (60%) and
16 were false negatives (40%) based on CAG. An agreement
in the findings ofMPS and CAGwas present in 107 out of 142
(75,35%) patients. The presence of ischaemia on the MPS had
a considerably high positive predictive value (81,37%) for
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restenosis or stenosis in a new localisation (OR: 6,55; p<0,
0001). Invasive CAG was performed significantly earlier
(within an average of 7 weeks) in those who had ischaemic
findings on MPS than in those without ischaemia (within an
average of 12 weeks); p<0,0001. Conclusion: Our study has
shown that MPS accurately predicts the presence of instent
restenosis or stenosis in a new localisation in patients with
clinically suspected myocardial ischaemia after previous PCI.
It is a clinically useful tool in selecting patients for invasive
CAG.
P356
Value of ECG-gated study during dipyridamole stress
in myocardial perfusion PET
K. Nakagawa1, S. Onodera2, T. Uchida2, Y. Ozaki2, H.
Henmi2, Y. Uchino2; 1Tokyo Seaside Clinic, Tokyo, JAPAN,
2Chiba Ryougo Center, Chiba, JAPAN.
[Purpose] Previous studies reported that intensive medical
treatment combined with life-style modification for coronary
artery disease (CAD) could improve coronary perfusion and
prognosis. However, effect of treatment to cardiac function has
not been reported. Thus, we measured cardiac function by
ECG-gated PET and compared the values before treatment to
those after treatment. [Methods] Baseline myocardial perfu-
sion PET with N-13 ammonia was performed for 28 CAD
patients at rest and during dipyridamole stress. For all the
patients, intensive medical treatment combined with life-style
modification was introduced for more than one year and the
follow-up PETwas performed after the treatment. Myocardial
perfusion images were visually interpreted and its changes
before and after the medical treatment were evaluated. PET
data were also acquired by ECG-gated mode and ejection frac-
tion (EF), end-diastolic volume (EDV) and end-systolic vol-
ume (ESV) were measured both at rest and during
dipyridamole stress. Values before the treatment were statisti-
cally compared to those after the treatment. [Results] Of 28
patients, 13 showed improved myocardial perfusion during
dipyridamole stress after the treatment (Group A), suggesting
regression of coronary atherosclerosis. On the other hand, 8
patients remained unchanged (Group B) and 7 showed wors-
ened myocardial perfusion (Group C). In the patients who
showed improved myocardial perfusion (Group A), mean EF
during dipyridamole was improved from 66.5% to 68.5%
(p=0.005), mean EDV was changed from 92.2ml to 82.2ml
(p=0.007) and mean ESV was changed from 31.5ml to 26.5ml
(p=0.002). Mean EDVand ESVat rest in Group A also tended
to decrease but not statistically significant (p=0.058 and 0.082,
respectively). On the other hand, mean EF, EDV and ESV in
Group B were similar both at rest and during dipiridamole
(p>0.05). The mean values were also statistically unchanged
in Group C (p>0.05). [Conclusion] ECG-gated myocardial
PET is useful to evaluated cardiac function and size during
dipyridamole stress in addition to myocardial perfusion. And
improved cardiac function and decreased cardiac size were
associated only to those who were improved in their myocar-
dial perfusion after the medical treatment.
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The Value of Semiquantitative Analysis in Myocardial
Perfusion Imaging using Multifocal Collimator
SPECT/CT: IQ-SPECT
M. Trogrlic, M. Medvedec, S. Tezak; University Hospital
Centre Zagreb, Zagreb, CROATIA.
AIM: to identify diagnostic value of semiquantitative analysis
in MPI obtained with a multifocal collimator, IQ-
SPECT.MATERIALS AND METHODS: 68 patients (46
males and 22 females; age group 34-90 years, mean age 65
±10 years) with high post stress coronary artery disease prob-
ability and visually abnormal SPECT findings were included
in this prospective study. All patients underwent two-day pro-
tocol perfusion scan (Gated IQ SPECT/CT) after stress test
and at rest. Acquisition was performed on a Symbia T
(Siemens) equipped with a dual-headed gamma camera sys-
tem and with a multifocal smartzoom collimator. Acquisition
was done in 128x128 matrix, 50 min after tracer injection
(370MBq Tc-99m sestamibi), 17 views per head, 20 sec/view.
Flash 3D iterative reconstruction was done. Expert in nuclear
cardiology qualitatively (visually) assessed all myocardial per-
fusion images. Using 4D-MSPECT software, stress and rest
data sets of 68 patients were analyzed in fully automatic oper-
ation mode. Summed stress score (SSS), summed rest score
(SRS), and resulting summed difference score (SDS) were
calculated semiquantitative by comparing tracer uptake with
values from gender-specific normal databases provided by
manufacturer (databases with and without attenuation correc-
tion (AC)). Individual segmental scores and summed scores
analysis was performed on a standardized 17-Segment model
(AHA). Segment by segment comparison between qualitative,
visually assessed results, and semiquantitative perfusion pa-
rameters was done. Semiquantitative parameters, with AC
and without AC, were also compared and statistically
analyzed.RESULTS: Agreement degree on the diagnostic ac-
curacy between qualitative and semiquantitative analysis
based on SSS parameter was: 0.76 for stress studies without
AC, 0.74 for stress studies with AC, based on SDS parameter
was: 0.76 for studies without AC, 0.85 for studies with AC.No
significant difference was recorded between qualitative and
semiquantitative results regarding total number of affected
segments with perfusion abnormalities (qualitative analysis:
177 segments, semiquantitative without AC: 167, with AC:
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196).SSS calculated from normal databases without and with
ACwere significantly different: SSSwithout AC 5.8±3.3; SSS
with AC 6.4±4.5. SDS results were also significantly different:
SDS w i t h o u t AC 3 . 4±2 . 2 ; SDS w i t h AC 3 . 8
±3.0.CONCLUSIONS: Semiquantification of MPI is often
performed to assist physicians in detecting CAD and to im-
prove diagnostic confidence levels. Semiquantitative analysis
might potentially improve diagnostic accuracy of MPI when
using IQ SPECT. Semiquantitative methods with AC slightly
overestimated number of affected segments, while methods
without AC slightly underestimated number of affected seg-
ments. Perfusion abnormalities scores obtained without AC
are significantly different than scores obtained with AC.
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What is the impact of apparently minimal dipyridamole
response to the acuracy of myocardial perfusion
scintigraphy?
A. Doumas1, I. Iakovou1, V. Mpalaris1, D. Mpountas2, V.
Athanasiou1, D. Katsaboukas1, S. Georga1, K. Badiavas1, D.
Lo Presti1; 1Academic Nuclear Medicine dpt, Papageorgiou
hsp, THESSALONIKI, GREECE, 2Nuclear medicine dpt
“Hippokrates”, THESSALONIKI, GREECE.
Aim: To investigate the accuracy of myocardial perfusion im-
aging (MPI) for the detection of coronary artery disease, in
patients who can not increase their heart rate or lower their
blood pressure after dipyridamole administration. Method:
We retrospectively compared the results of MPI with the cor-
onary angiography in 103 patients (73male, mean age 63+/-8
years), who underwent dipyridamole MPI, under no b-
blockers medication. These patients were divided into two
groups, depending of the mean blood pressure (BP) and heart
rate (HR) that they reached at the end of dipyridamole admin-
istration. Group A consisted of 62 individuals who increased
their HR at least 20% and decreased their mean BP at least
10% from their baseline values, whilst Group B (41 patients)
failed to achieve at least one of the two targets. Sensitivity,
specificity and accuracy was estimated in the two groups, tak-
ing as a gold standard the presence of at least 50% stenosis in
one of the three main vessels in the coronary angiography.
Results: There was no significant difference between the two
groups, concerning age and sex. The severity of CAD, defined
as the number of the diseased vessels, was similar in the two
groups (70% and 71% respectively, p>0.05). The sensitivity
and specificity of MPI for the detection of CAD was 87% and
81% in group A and 84% and 79% in group B with no statis-
tically significant difference. The overall accuracy was also
nearly identical (95% in group A and 93% in group B). Con-
clusion: We conclude that both BP and HR are not good pre-
dictors of adequate pharmacologic response during
dipyridamole administration. The hyperemic response to the
myocardium seems not to differ between patients who achieve
at least 20% increase in HR and 10% fall in their mean BP and
those that fail to achieve one or both of these goals. On the
other hand, usually younger patients and predominantly male,
are able to achieve an apparently good pharmacologic re-
sponse, which however plays no role in the accuracy of the
scintigraphic result.
P359
Splenic switch-off in Rb82 myocardial perfusion imaging:
an indication of adequate vasodilatation?
M. J. Memmott, P. Arumugam, C. M. Tonge; Central Man-
chester University Hospitals NHS Foundation Trust, Man-
chester, UNITED KINGDOM.
Introduction: Achieving adequate stress is paramount for the
interpretation of myocardial perfusion imaging. Current
methods include observation of side-effects during the adeno-
sine infusion, or analysis of the myocardial perfusion reserve
via quantitative dynamic PET imaging. It has recently been
reported that attenuated perfusion within the spleen at stress
can provide a potential marker for adequate vasodilatation. We
propose a simple method to assess efficacy of vasodilatation
based on the evaluation of splenic uptake in Rb82 PET imag-
ing. Methods: A total of 23 patients referred for a Rb82 PET
myocardial perfusion study, with a low pre-test likelihood of
CAD and normal patterns of perfusion, were retrospectively
analysed. Of these, 17 (Group 1) demonstrated side-effects
consistent with adequate adenosine vasodilatation and 6
(Group 2) did not. All patients had their myocardial blood flow
(MBF) and perfusion reserve (MPR) measured as per routine
protocol. Rate-pressure product (RPP) correctedMBF at stress
(SMBF) and rest (RMBF) was calculated using Siemens
Syngo MBF. Patients with significant motion during their dy-
namic acquisition were excluded. Uptake in the spleen was
measured in the same location for both stress and rest studies
for the 4.5 minute static acquisition, using a 2cm spherical
volume of interest (VOI). The ratio between uptake in the
spleen at rest and stress (Splenic Uptake Ratio, SUR) was
calculated. Results: All patients in Group 1 had an SUR greater
than 1.0 (median 1.58) and the majority (16/17) had a MPR of
greater than 2.0 (median 2.67). In Group 2, both the median
SUR and MPR were significantly lower (p < 0.006) than for
Group 1, at 1.06 and 1.22 respectively. One patient underwent
repeat imaging due to suspicion of caffeine intake, with the
initial scan showing an SUR of 1.05 and MPR of 1.06. The
repeated study demonstrated an increased SUR and MFR of
1.51 and 3.34 respectively. Conclusions: This small, prelimi-
nary study indicates that splenic switch-off is observed in
Rb82 studies, can be evaluated using a simple ratio, and
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correlates well withMPR and reported side-effects.Whilst this
is an interesting observation in dynamic Rb82 PET imaging,
the extension of this work to modalities where quantitative
assessment of vasodilator response is not possible, such as
SPECT imaging, could provide an promising indicator of ad-
equate stress, although technical challenges remain to be
overcome.
P360
One year outcome of the myocardial infarcted areas seen
immediately post primary percutaneous transluminal
coronary angioplasty (PTCA)
A. Doumas1, T. Christoforidis1, I. Iakovou1, V. Mpalaris1,
D.Mpountas2, D. Katsaboukas1, V. Athanasiou1, S. Georga1,
D. Lo Presti1, N. Karatzas1; 1Academic Nuclear Medicine
dpt, Papageorgiou hsp, THESSALONIKI, GREECE, 2Nucle-
ar medicine dpt “Hippokrates”, THESSALONIKI, GREECE.
Aim: Areas of myocardial infarction are evident after primary
PTCA in patients hospitalized due to chest pain and elevated
enzymes. The extend of the existing scar seen immediately (2-
3 days) post successful primary PTCAwas estimated one year
after the procedure. Method: Primary PTCAwas performed in
64 male patients (mean age 63+/- 12 years) suffering from
acute myocardial infarction (MI) due to one vessel coronary
artery disease. The time interval between the onset of pain and
the admission was less than 4 hours in all the patients. The area
of the scar was evaluated using 99mTc-SESTAMIBI Gated-
SPECT myocardial imaging (MPI), 2-3 days post PTCA and
one year after. The scar area was assessed quantitatively from
the rest images, using the Cedars-Sinai quantitation program
and expressed as a percentage of the total myocardial mass
(TMM), while the final reduction of the infarcted area was
expressed as the percentage of the initial one. Depending of
the infarcted area, the patients were divided into 2 groups:
Group Awith an area less than 20% of the TMM and in Group
C with area more than 20% of the TMM. The patency of the
angioplastized vessel was evaluated a year after, using either
CT or invasive coronary angiography. Results: There was pa-
tency of the responsible for ΜΙ vessel in 92% of the patients.
The infarcted area was reduced between 60-100% (mean value
84+/-9.8%) in group A and 20-60% in group B (mean value
34+/-22%%). Conclusion: We conclude that primary PTCA is
extremely useful in patients with small to intermediate size rest
perfusion defects, seen early after the procedure. The better
salvage result that observed to these patients is probably due
to high proportion of stunned myocardium existing during the
first days after primary PTCA that is recovering thereafter. On
the other hand, the extent of stunned myocardium seems to be
less when infarction involves large areas of underperfused
myocardium.
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Does observer-dependence influence the reliability
of supine/prone stress-only MPI with cardiac dedicated
CZT scanner?
S. Osiecki1, S. Piszczek1, P. J. Kwasiborski2, A. Mazurek1,
M. Dziuk1; 1Military Institute of Medicine, Warsaw, PO-
LAND, 2Medical University of Warsaw, Warsaw, POLAND.
Aim: Cardiac SPECT imaging is a procedure of great value in
CAD diagnostics. In patients with normal stress MPI the
stress-only protocol has been proven to be safe an efficient.
Furthermore it allows to reduce the radiation exposure and
costs. The aim of this study was to investigate how
interpreter-dependent stress MPI is, especially considering
stress-only protocol.Materials and Methods:203 consecutive
patients having undergone cardiac SPECTwith prone and su-
pine imaging were enrolled. If possible stress only protocol
was applied. Each stress MPI was assessed by 3 independent
experienced physicians and assigned to one of three groups: 1-
no rest MPI needed, the question of referring clinician can be
answered with stress only, 2- the question of referring clinician
probably can be answered with stress only protocol, but for
safety rest MPI should be performed, 3- rest MPI is definitely
required. In case of discrepancy between interpreters, for fur-
t h e r c l i n i c a l p r o c e e d i n g s t h e c on s e n s u s wa s
established.Patients were divided in two groups: stress only
(n=94) and stress-rest (n=109). In these two groups and in
the whole cohort the agreement between physicians was
assessed using kappa inter-rater agreement statistic. Of pa-
tients with consensus 1 (meaning no rest MPI is required)
the subgroup of 20 who had although undergone rest MPI
was divided and taken under more detailed analysis.Results:In
the whole cohort the agreement between 3 independent phy-
sicians was substantial with 77,83%, κ=0.696546. However in
the stress-only group the agreement was significantly higher
with 92.55%, κ=0.202424, compared to 65.14%, κ=0.405877
in the stress-rest group.Of 95 patients whose stress MPI was
assessed by consensus to be sufficient to answer the clinical
question, 20 had undergone rest procedure. In this subgroup
there were no significant ischemia cases (no reversible defects
>10% of myocardium). 8 patients had insignificant perfusion
reversibility, one of them had <10% perfusion reversibility in
the inferior wall, while LAD region was to be assessed - with
no abnormalities in the investigated artery area of
supply.Conclusions:The study has shown that, though highly
sensitive and specific, in some cases myocardial perfusion
may be still observer-dependent. Thus, if any doubts appear,
assessment limited to the stress-only protocol should be cho-
sen by consensus of experienced interpreters. The higher
agreement in stress-only group, and lack of significant ische-
mia in the consensus 1 stress-rest subgroup indicate, however,
that used carefully it is a safe protocol.
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Myocardial blood flow quantification with 82-Rubidium
PET/CT for the diagnosis of cardiac sarcoidosis
Q. Gillebert1, R. Chequer1, R. Ben Azzouna1, S. Leygnac1,
N. Mikail1, F. Hyafil1, C. Chapelon-Albric2, B. Crestani3, D.
Le Guludec1, F. Rouzet1; 1Department of Nuclear Medicine,
Bichat University Hospital, Département Hospitalo-
Universitaire FIRE, Assistance Publique-Hôpitaux de Paris,
University Paris Diderot-Paris 7, Paris, FRANCE, 2Depart-
ment of Internal Medicine II, CHU Pitié Salpêtrière, Univer-
sity Pierre et Marie Curie, Assistance Publique-Hôpitaux de
Paris, Paris, FRANCE, 3Department of Pulmonology, Bichat
University Hospital, Assistance Publique-Hôpitaux de Paris,
University Paris Diderot-Paris 7, Paris, FRANCE.
Objectives: The early diagnosis of cardiac involvement of sar-
coidosis remains challenging. The aim of the study was to
evaluate the additional value of myocardial blood flow
(MBF) over uptake quantification with 82-Rubidium (82-Rb)
PET/CT for the diagnosis of early stage of cardiac sarcoidosis
(CS).Methods : Thirty-seven patients (age: 48±12 years ;
males: 60%; left ventricular ejection fraction: 51±8%) without
history of cardiovascular disease were prospectively included
in 5 tertiary care centres if they had a histological proven
sarcoidosis and a suspicion of cardiac involvement based on
symptoms, EKG or echocardiography. Patients underwent 82-
Rb PET/CT in addition to routine investigations that included
Holter monitoring, cardiacMRI, 18-FDG PETand myocardial
perfusion SPECT. 82-Rb PET/CT (list mode acquisition after
bolus injection of 10 MBq/kg over 30 sec, Discovery VCT
690, GEMS) was performed at rest and after injection of
Dipyridamole (0.7 mg/kg). After reconstruction, static and
EKG-gated slices were analysed both visually and automati-
cally (FlowQuant software). Dynamic data were further proc-
essed (FlowQuant software) in order to provide rest and stress
MBF and flow reserve. Absolute uptake and/or flow were
considered abnormal in a segment if the mean value in this
segment was <75% of the maximal value in the myocardium.
The diagnosis of CS was based on the decision of a multidis-
ciplinary team (MDT) that was allowed to review patients’
medical record but was blinded to 82-Rb PET/CT result. We
then compared 3 strategies for data analysis: 1/completely au-
tomated quantification of tracer uptake and MBF; 2/visual
analysis alone of 82-Rb uptake (without MBF values); 3/visu-
al analysis combined with MBF results only in equivocal seg-
ments. The results of 82-Rb PET were compared with MDT
decisions.Results: Cardiac sarcoidosis was considered definite
in 11 patients, excluded in 21 and possible in 5 (excluded from
further analysis) according toMDT decision. Patients with and
without CS had similar clinical characteristics. The sensitivity,
specificity and accuracy (respectively) were: 91%, 33% and
53% for completely automated analysis; 91%, 91% and 91%
for visual analysis alone, and 100%, 81% and 88% for the
combined analysis.Conclusions: the present study suggests
that 82-Rb PET is useful in the early diagnosis of cardiac
sarcoidosis with good sensibility and specificity. The strategy
combining visual analysis andMBF quantification seems to be
the more relevant in order not to overlook the diagnosis with
only a mild decrease of specificity compared to visual analysis
alone.
P363
Impact of prone-position acquisition of 123I-MIBG
cardiac imaging on heart-to-mediastinum ratio
T. Pellegrino1, V. Piscopo2, A. Boemio2, R. Carotenuto2, B.
Russo2, S. Pellegrino2, G. De Matteis2, A. Cuocolo2; 1Insti-
tute of Biostructures and Bioimages, Naples, ITALY, 2Univer-
sity of Naples - Federico II, Naples, ITALY.
Background: Cardiac 123I-metaiodobenzylguanidine (MIBG)
innervation imaging has been widely used to estimate cardiac
sympathetic innervation in various forms of cardiac disorders.
Although normal cardiac MIBG distribution includes a rela-
tively low uptake in the inferior wall, the substantial uptake of
the tracer in the liver could overlap the inferior left ventricular
wall. Prone images might improve the relative tracer uptake in
the inferior wall reducing diaphragmatic attenuation and
avoiding intense uptake by the liver. This study assessed
whether MIBG prone-position acquisition can change heart-
to-mediastinum (H/M) values compared to supine acquisition.
Methods: Forty-five patients (34 men, mean age 58±15 years)
were enrolled (34 patients with heart failure and 11 with An-
derson Fabry disease). All patients underwent planar 123I-
MIBG cardiac imaging after intravenous administration of
111 MBq. Ten-minute planar images were acquired from an
anterior thoracic view 15 minutes (“early” image) and 3 hours
and 50 minutes (“late” image) after tracer administration in
both supine and prone positions. Early and late H/M ratios
were computed and washout rate (WR) was calculated using
the standard formula background and decay corrected. Using
the mean relative uptake, the inferior to anterior uptake ratios
were also calculated on early and late images for both supine
and prone positions. Results: Early (1.8±0.3 vs. 1.9±0.3,
p=0.3) and late (1.7±0.4 vs. 1.7±0.3, p=0.8) H/M ratios, and
WR (35±17.6% vs. 35±16.4%, p=0.9) were not different be-
tween supine and prone position. On early images, inferior/
anterior uptake ratio in the supine position was significantly
lower as compared to prone position (0.96±0.12 vs. 1.01
±0.08; p<0.02). Conversely, on late images inferior/anterior
uptake ratio was not different between supine and prone posi-
tions (0.99±0.15 vs. 1.01±0.08, p= 0.4). Conclusions: The
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results of the present study show that the prone-position ac-
quisition did not change early and late H/M ratios and WR
compared to supine-position acquisition. However, the inferior
to anterior uptake ratio increased using the prone-position ac-
quisition only in early images.
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Preliminary report of long term follow-up withmyocardial
perfusion scan in breast cancer patients after external
beam radiation therapy.
M. Eftekhari1, F. Kalantari1, M. Abbasi2, S. Farzanefar2, A.
Fard-Esfahani1, B. Fallahi1, D. Beiki1, A. Hassanzadeh-
Rad1, A. Emami-Ardekani1; 1research center for nuclear
medicine, Tehran university of medical sciences, Tehran,
IRAN, ISLAMIC REPUBLIC OF, 2Nuclear Medicine De-
partment, Vali-asr Hospital, Tehran University of Medical Sci-
ences, Tehran, IRAN, Tehran, IRAN, ISLAMIC REPUBLIC
OF.
Aim: Radiotherapy induced myocardial injury may increase
cardiovascular morbidity and mortality especially in left sided
breast cancer. To evaluate the prevalence of myocardial perfu-
sion abnormalities following radiation therapy, in left and
right-sided breast cancer patients, short and long term MPI
findings were compared. Materials and methods: Patients with
low 10-year Framingham risk scoring of coronary artery dis-
ease were included in the study to minimize confounding fac-
tors. All patients treatment plan were modified radical mastec-
tomy and postoperative 3D Conformal Radiation Therapy
(CRT) to the surgical bed with an additional 1-cm margin,
delivered by 46-50 Gy (in 2 Gy daily fractions) over a 5-
week course and the same dose-adjusted chemotherapy regi-
men (including anthracyclines, cyclophosphamide and taxol)
was given. 3 years after radiation therapy, all patients
underwent cardiac SPECT for the evaluation of myocardial
perfusion. These patients have been evaluated for short term
effect 6 months after radiotherapy. General linear model for
repeated measures was designed to assess the ischemic change
over time. Results: Up to now 26 patients with a mean age of
43.7±6.9 years [13 patients with left sided breast cancer
(exposed) and 13 patients with right-sided cancer (controls)]
were enrolled. Dose-volume histogram (DVH) [showing the
percentage of the heart exposed to >50% of radiation] was
significantly higher in patients with left-sided breast cancer.
The prevalence of ischemia didn’t change in subjects with left
mastectomy (6 out of 13 from baseline to follow-up). But this
prevalence is decreased from 3 (21.3%) to 1 (7.7%) from the
baseline to the second study in right sided mastectomy group.
Not only the prevalence of ischemia was higher among sub-
jects with left mastectomy in baseline study, significant
interaction effect was also observed for the side of mastectomy
and the result of MPI during the period of the study (partia Eta
Square= 0.18, P=0.36). Conclusion: Radiation induced myo-
cardial perfusion injury in patients treated with radiotherapy
on the left hemi thorax is not low. It is advisable to apply
precise radiation planning techniques to minimize the volume
of the heart in the field of radiation therapy and also to screen
these clinically asymptomatic patients with MPI-SPECT, as
early treatment may improve cardiac outcome.
P365
Effect of Low Dose CTAttenuation Correction
in the Incidence of Ischemia During Myocardial Perfusion
Scintigraphy
T. Pipikos1, F. Vlachou1, A. Nikaki1, L. Koletti1, K. Gogos2,
K. Dalianis2, V. Prassopoulos1; 1Nuclear Medicine Depart-
ment Hygeia SA, Athens, Marousi, GREECE, 2Medical Phys-
ics Department ,Hygeia S.A., Athens, Marousi, GREECE.
AIM: Attenuation artifacts can lead to false diagnosis during the
interpretation of myocardial perfusion studies. These artifacts
can be corrected with the usage of SPECT/low dose CT γ-
camera systems. In this study we evaluated the effect of low
dose CT based attenuation correction (with the usage of flat
panel x-ray source) in the performance of myocardial perfusion
sc in t igraphy in the inves t iga t ion of myocardia l
ischemia.Material and methods: We compared the findings of
attenuation corrected and non attenuation corrected images of
93 patients who underwent myocardial perfusion scintigraphy
in our department in the last 2 years and also underwent coro-
nary angiography. Scintigraphy results of ischemia were evalu-
ated as true positive in the patient group with coronary stenosis
over 70%, while in patients with less severe stenosis, ischemia
findings were evaluated as false positive. Imaging was per-
formed with a Philips Brightview XCT γ-camera system. Inter-
pretation of the studies was blinded between corrected and non-
corrected images, as well as between scntigraphy and
angiography.RESULTS: Twenty-six (26) patients had stenosis
over 70% in coronary angiography. Both methods identified
correctly 24/26 cases. In the group of 67 patients without severe
coronary stenosis, there were 25 false positive for ischemia non
attenuated scans, while with attenuation correction only 9 false
positive scans were found. Sensitivity and specificity for non-
attenuated images were respectively: 92% and 62%. For low
dose CT attenuated images the values were: 92% and 86%.
Sensitivity was high for both series of images, but diagnosis
was more specific with attenuation corrected images. False pos-
itive findings of ischemia were found mainly in the inferior and
inferior lateral wall, being much less in number in the corrected
images.CONCLUSION: Attenuation corrected images using
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low dose CT, improves the performance of myocardial perfu-
sion scintigraphy, with less false positive findings. Diagnosis is
more accurate and confident, which can lead to reduction of
unnecessary cardiac catheterizations.
P366
Regadenoson safety and tolerability in myocardial
perfusion imaging
M. Catalano, G. Annunziata, A. Sasso, R. Gottilla, D. Scala,
V. Ippolito, I. Valenti; AORN, Naples, ITALY.
Aim: Myocardial perfusion imaging (MPI) is a widely used
imaging technique for coronary artery disease diagnosis
and post-revascularization follow-up. Pharmacological
stress agents are used in patients (pts) unable to adequate
exercise stress because of physical limitations or left bun-
dle branch block (LBBB) at basal ECG, but the use is
limited in pts with chronic obstructive pulmonary disease
(COPD) or chronic kidney disease (CKD). In these pts,
Regadenoson, a A2A selective coronary vasodilator, could
be alternative to adenosine or dipyridamole because of
greater A2A receptor affinity and lower adenosine receptor
subtypes affinity with lower bronchoconstriction risk in pts
with reactive airways. This study investigates regadenoson
safety and tolerability in pts with COPD or CKD. Material
and methods: 20 Pts, over 18 years of age (average age 70.5
± 8.2; 80% male) affected with COPD and/or CKD, with-
out COPD exacerbation in the last 30 days, were enrolled.
Informed consent was obtained from pts. No corticoste-
roids, steroid combination, long-acting beta2 agonist or an-
ticholinergic were admnistred before test. Subjects had to
abstain from taking drugs, foods and beverages containing
methylxanthine or theophylline within 12 hours prior MPI.
Subjects received regadenoson intravenous bolus (0.4 mg/5
ml) in 10 seconds, followed by 0.9% saline 5 ml flush and
99mTc-tetrofosmin 600 MBQ . Blood pressure (BP) and
ECG were monitored before test beginning, after 2 minutes
and many times until BP and ECG returned to baseline. Pts
were asked to report adverse symptoms or discomfort. Re-
sults: 14/20 pts were affected with COPD and the remain-
ing with CDK. Risk factors were diabetes (10 pts), hyper-
tension (18 pts) and cigarettes smoking (10 pts) ; many pts
had more than one risk factor. A rapid increase in heart rate,
about 2 minutes after regadenoson administration, that
returned to baseline within 4 minutes, was observed. BP
values decreased in 10 pts, remained unchanged in 4 pts
and slightly increased in 6 pts. Adverse reactions were
mild, transient (usually resolving within 20 minutes after
the beginning of the pharmacological test), and required no
medical intervention, except 2 pts that required theophyl-
line (250mg e.v.). Adverse events were mild tachypnea (8
pts), flushing (6 pts), dry mouth (6 pts), headache (2 pts),
chest pain (2 pts). Conclusions: Regadenoson is well toler-
ated because of low incidence of adverse events and can be
safety performed in pts with COPD or CKD because of
limited adverse events due to low adenosine receptor sub-
types affinity.
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Adenosine stress Myocardial Perfusion Scintigraphy
and Adenosine stress echocardiography in post arterial
switch operation patients: A mid-term follow up.
K. Kumar, S. G. Roy, C. D. Patel, S. Ramakrishnan, R.
Kumar, A. K. Bisoi; All India Institute of Medical Sciences,
New delhi, INDIA.
Aim: To assess myocardial perfusion abnormalities by adeno-
sine Tc99m Sestamibi (MIBI) SPECT and coronary flow re-
serve (CFR) by adenosine stress echocardiography in patients
post arterial switch operation (ASO). Materials and Methods:
In this single centre study we evaluated 14 male asymptomatic
children, (mean age: 6.64+1.32 yrs, range: 5-9yrs) post ASO.
All children’s were operated at mean age of 81.7±114.9days
(range 16-365 days). Stress echocardiography was performed
during continuous intravenous adenosine infusion (140ug/kg/
min) over 4 minute. In the same sitting, Tc99mMIBI (0.2mCi/
kg body weight) was injected at the end of 2 minute of infu-
sion. Coronary diastolic flow was measured in proximal Left
anterior descending artery (LAD) in both resting and stress
condition. CFR was calculated as the ratio of peak hyperaemic
and basal mean diastolic velocities. Stress myocardial perfu-
sion imaging (MPI) was performed 30-45 minutes after radio-
tracer injection. Rest images were acquired 2-3 hours after the
stress images. Results:The average increase in heart rate over
the basal heart rate after adenosine stress was 59.7 ± 17.0%.
Adenosine infusion was terminated prematurely in two pa-
tients due to bradycardia and Atrioventricular block. Ejection
fraction increased after adenosine infusion in all patients and
no regional wall motion abnormality appeared during the
stress. Mean coronary diastolic velocity increased to 66.2
±18.8 cm/sec during stress from 39.9±15.6cm/sec under rest-
ing condition. Mean CFR in proximal LAD was 1.78±0.46.
None of the patients demonstrated myocardial perfusion de-
fects on Tc99m MIBI myocardial perfusion SPECT, either at
rest or after adenosine stress. Conclusion: In this ongoing
study of asymptomatic post ASO patients, no perfusion abnor-
malities were detected on Tc99m-MIBI Myocardial Perfusion
Scintigraphy (MPS) and all the patients demonstrated good
CFR and normal contractile reserve on echocardiography, in-
dicating adequacy of corrective surgery and good mid-term
prognosis in this group of patients.
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Calculation of left ventricular ejection fraction using
cardiac gated parametric blood volume images
from a dynamic 15O-water PET/CT scan
J. Nordström, T. Kero, C. Widström, J. Sörensen, M.
Lubberink; Department of Surgical Sciences, Radiology, Upp-
sala, SWEDEN.
BackgroundDynamic 15O-water PETscans are considered the
gold standard for myocardial blood flow measurements. How-
ever, due to the low contrast between the myocardium and the
blood, calculation of left ventricular ejection (LVEF) fraction
is not possible from static uptake images. If LVEF is of interest
the patient has to undergo an additional PETscan with another
tracer or an examination with another modality. Therefore, the
aim of this study was to investigate the possibility of LVEF
calculations from a single dynamic 15O-water PET/CT scan
u s i n g c a r d i a c - g a t e d p a r am e t r i c b l o o d p o o l
images.MethodsEleven patients underwent dynamic cardiac-
gated 15O-water and static cardiac-gated 11C-acetate PET/CT
scans. Eight patients also underwent a cardiac MRI scan. 15O-
water parametric blood pool images for each gate were con-
structed using a basis function implementation of the single
tissue compartment model with corrections for spill-over and
perfusable tissue fraction. Arterial input functions were de-
fined on non-gated data using cluster analysis in Cardiac VUer
software. LVEF from 15O-water was calculated using Cedar
Sinais Blood Pool Gated SPECT application with automatic
segmentation using surface, count and volume based methods.
LVEF calculations from 11C-acetate-PET were performed
using the Myovation application for automatic segmentation
and LVEF calculations from MRI were performed using
ViewForum. All LVEF calculations were performed by an
experienced nuclear medicine physician. Correlation between
LVEF based on 15O-water with values based on 11C-acetate
and MRI were assessed using the correlation coefficient (R2)
and intraclass correlation (ICC).ResultsCorrelations (R2) be-
tween LVEF for the surface, counts and volume based
methods between 15O-water and 11C-acetate were 0.84,
0.91 and 0.86, respectively. R2 for the three different methods
between 15O-water and MRI were 0.42, 0.61 and 0.61, re-
spectively. ICC between LVEF based on 15O-water and
11C-acetate were 0.91, 0.94 and 0.91, and ICC between
15O-water and MRI were 0.64, 0.77 and 0.73, respectively
for the three different methods. The lower R2 and ICC relative
to MRI values are partly explained by the smaller range of
LVEF values in the eight patients that underwent MRI (53-
75) compared to the whole pa t i en t g roup (35 -
75).ConclusionThe good correlation between 15O-water-
based LVEF values and more established methods shown in
the present study points towards a possibility to calculate the
LVEF from a single dynamic-gated 15O-water PET/CT scan.
However, the method does require some hands-on work by the
physician and further work is needed to make the method
feasible for clinical use on daily basis.
P369
Perfusion Vector - A NewMethod to Quantify Myocardial
Perfusion Scintigraphy Images
M. Senneby1, D. Minarik2, P. Wollmer1, L. Edenbrandt1, K.
Sjöstrand3, E. Trägårdh1; 1Clinical Physiology and Nuclear
Medicine, Skåne University Hospital, Lund University,
Malmö, Sweden, Malmö, SWEDEN, 2Radiation Physics,
Skåne University Hospital, Lund University, Malmö, Sweden,
Malmö, SWEDEN, 3Informatics and Mathematical Model-
ling, Technical University of Denmark, Copenhagen, Den-
mark, Malmö, SWEDEN.
Aim: Myocardial perfusion scintigraphy (MPS) is an
established imaging modality used for the diagnosis of pa-
tients with ischemic heart disease. Software packages for
quantification of perfusion data and computer-aided diagno-
sis systems have been developed in order to make the inter-
pretation of MPS studies more standardized but still it large-
ly relies on visual assessment by the physician. We have
previously introduced the concept of the perfusion vector
as a new objective quantitative method for further assisting
the visual interpretation and tested this concept using simu-
lated images with promising results. The aim of this study
was to test the concept in patient studies. Materials and
methods: The perfusion vector is based on calculating the
difference between the anatomical centroid and the perfusion
center of gravity of the left ventricle. The centroid is the
geometric center of gravity in a three-dimensional figure.
The anatomical centroid of the left ventricle is calculated
from MPS images setting the voxels in the myocardium of
the left ventricle to 1 and the others to 0. The perfusion
center of gravity is calculated by giving the voxels in the
left ventricle weights corresponding to their intensity. If the
perfusion in the left ventricle is homogeneous these positions
will coincide. If not the perfusion center of gravity will de-
viate from the anatomical centroid thus creating a perfusion
vector between these two positions. The size of this vector
would then correspond to the severity and extent of the per-
fusion defect and the direction would reflect the location of
the defect. 40 normal and 80 abnormal patient studies were
included in the patient study. Perfusion vectors were com-
pared between normal and abnormal (apical, inferior, anterior
and lateral ischemia or infarction) studies and also correlated
to defect size. Results: When comparing normal and abnor-
mal patients there was a statistically significant difference for
the stress perfusion vector on the x-axis (septal-lateral
direction) for apical and lateral defects, on the y-axis
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(anterior-inferior direction) for apical, inferior and lateral de-
fects, and on the z-axis (basal-apical direction) for apical,
anterior and lateral defects. A significant difference was
shown for the difference vector magnitude (stress/rest) be-
tween normal and ischemic patients (p=0.001). The correla-
tion between defect size and stress vector magnitude was
also found to be significant (p<0.001). Conclusion: The con-
cept of the perfusion vector is shown to have potential in
assisting the visual interpretation in patient MPS studies.
Further studies are needed to validate the concept.
P370
Is Data-Driven Cardiac Gating Possible with REGAT
Software Applied to SPECT Myocardial Perfusion
Imaging Acquired with Discovery NM 530c?
D. Daou1,2, R. Sabbah3, H. Bouladhour3, C. Coaguila4;
1Cochin Hospital, APHP, Paris, FRANCE, 2EA 7334
REMES, Université Paris-Diderot, Sorbonne Paris-Cité, Paris,
AUSTRIA, 3CHU Jean Minjoz, Besançon, FRANCE, 4Cen-
tre Hospitalier de Bigorre, Tarbes, FRANCE.
Aim: We previously developed a data-driven respiratory-mo-
tion (RM) correction method for conventional SPECT
gamma-cameras (REGAT) and adapted it to CZT multi-
pinhole detector gamma camera (Discovery NM 530c). We
recently reported that RM correction with REGAT applied to
CZT myocardial perfusion SPECT imaging (MPI, Discovery
NM 530c), is clinically feasible, easily applicable, presents
interesting impact on image characteristics, and impacts sub-
stantially myocardial perfusion defects. In this preliminary
evaluation, we aimed to study whether REGAT applied to
MPI (Discovery NM 530c) is capable of generating a data-
driven (DD) cardiac gating signal allowing the generation of
valid global left ventricular (LV) function parameters (EDV:
end diastolic volume; ESV: end systolic volume; EF: ejection
fraction). Materials and Methods: Were included 7 patients
addressed for stress/rest MPI. All patients had prone stress
MPI (2 MBq/Kg 99mTc-Tetrofosmin) than prone rest MPI
3-hours later (6 MBq/Kg). All acquisitions were made on Dis-
covery NM 530c. Each list mode acquisition was processed
with REGAT to generate a dynamic SPECT acquisition study
of 50 msec duration. Each dynamic SPECT study was proc-
essed to generate its corresponding DD cardiac gating signal.
This DD cardiac signal curve was used to generate a mean DD
cardiac GSPECT study (GSPECT-DD). In parallel, a mean
ECG cardiac GSPECT study was generated using the ECG
trigger signal provided by traditional ECG monitor
(GSPECT-M). The 2 generated cardiac GSPECT studies were
reconstructed on Xeleris workstation and processed with
Emory Cardiac Toolbox (ECT). LV EDV, ESV and EF were
compared between cardiac GSPECT-DD and GSPECT-M.
Results: The population consisted of 5 males and 2 females
with a mean age of 52±11 years. Mean body weight was 72
±12 Kg and mean height was 1.73±0.66 m2. Stress LV EDV,
ESV, and EF were 91±24 ml, 29±13 ml, and 68±10% vs 95
±23 ml, 29±12 ml, and 70±11% with GSPECT-DD vs
GSPECT-M respectively (all P: NS). Mean±SD stress heart
rate was 84±16 bpm vs 84±16 bpm for GSPECT-DD vs
GSPECT-M respectively. Rest LV EDV, ESV, and EF were
97±21 ml, 32±10 ml, and 67±6% vs 101±21 ml, 31±10 ml,
and 69±6% with GSPECT-DD vs GSPECT-M respectively
(all P: NS). Mean±SD rest heart rate was 74±16 bpm vs 74
±16 bpm for GSPECT-DD vs GSPECT-M respectively. Con-
clusion: Data-driven cardiac gating of MPI with Discovery
NM 530c processed with REGAT appears to be clinically fea-
sible. It provides LV global systolic function parameters sim-
ilar to those provided by the traditional clinically used ECG
monitor gating.
P371
Tetrofosmin-Tc-99m Right Ventricular to Left Ventricular
Uptake Ratio as a New Surrogate Marker of Subclinical
Pulmonary Arterial Hypertension in Rheumatoid
Arthritis
T. S. Vieira, M. Bernardes, E. Martins, V. Alves, A. Sá Pinto,
A. Fernandes, A. Oliveira, T. Faria, M. Perez, J. G. Pereira;
Centro Hospitalar de São João, Porto, PORTUGAL.
Aim: Cardiovascular diseases are a leading cause of death in
patients with rheumatoid arthritis (RA). Pulmonary arterial
hypertension (PAH) associated with rheumatic diseases carries
a particularly grim prognosis, which may be explained by an
underlying inflammatory component. New noninvasive pa-
rameters would be helpful to assess early subclinical PAH
and direct therapeutic efforts. It was recently published that
right ventricular to left ventricular uptake ratio (RV/LV) from
SPECT myocardial perfusion images of an unselected popu-
lation can identify patients with high pulmonary artery pres-
sure or right ventricular hypertrophy; however that study in-
cluded patients with abnormal ejection fraction. We aimed to
study the usefulness of RV/LVas a new marker of subclinical
PAH in a RA population with normal LV perfusion and
function.Materials and Methods:Clinical caracteristics and
blood samples were collected in a monitoring visit. Portuguese
version of the Standford Health Assessment Questionnaire
(HAQ), Disease Activity Scores (DAS28-CRP(3v), DAS28-
CRP(4v), DAS28-SR(3v) and DAS28-SR(4v)), 68 tender and
66 swollen joint counts were obtained. They also performed a
tetrofosmin-Tc-99m gated myocardial perfusion SPECT with
adenosine. All patients had normal SPECT LV perfusion and
ejection fraction. For RV/LV calculation an investigator with
no knowledge of the clinical and analytical data placed 6×6
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pixel ROIs in the RV and LV free walls of a mid-ventricular
short-axis SPECT slice. RV/LV was calculated as the ratio of
myocardial counts in each ROI. A Spearman’s analysis was
conducted to study the correlations of RV/LV with clinical and
analyt ical parameters of the disease.Resul ts and
Conclusion:We evaluated 84 RA patients, 66 (79%) women,
44 (52%) under biologics, age 54±12 years, 13±10 years of
disease duration, mean BMI of 26.30±4.72kg/m2, mean
DAS28-CRP(4v) of 3.84±1.34 and a mean HAQ of 1.307
±0.689. There were significant positive correlations of RV/
LV with DAS28-CRP(4v) (r=0.231; p<0,05), 68 tender joint
count (r=0.279; p=0,01), and patient global disease activity
assessment (r=0.221; p<0,05). In a multivariate modelling (af-
ter adjusting for age, age at diagnosis, BMI, DAS28-CRP(4v),
glycemia and homocystinemia), patients under methotrexate,
leflunomide, bisphosphonates and folic acid supplements had
lower values of RV/LV, while patients under biologic agents
and NSAIDs had higher RV/LV values. Further, patients under
CCB revealed higher values of RV/LV, whereas patients under
diuretics, ACEIs, ARAII and BB revealed lower RV/LV
values. RV/LV from tetrofosmin-Tc-99m myocardial perfu-
sion SPECT is related with inflammatory disease activity and
may be an useful new early marker of subclinical PAH in RA.
P372
Does MPI with CZT cardiac gamma camera show
significant abnormalities in presence of intermediately
stenosed coronaries with normal adenosine/regadenoson
FFR - preliminary results
S. Piszczek, K. Tkaczewski, A. Mazurek, S. Osiecki, M.
Dziuk; Military Institute of Medicine, Warsaw, Szaserów
Street 128, POLAND.
Aim: Hemodynamic evaluation of intermediate stenoses in
coronary arteries has recently become substantial in order to
provide invasive treatment. Fractional flow reserve (FFR) as-
sessment plays essential role in making decision of percutane-
ous coronary intervention. The aim of the study was to inves-
tigate, whether there are any significant perfusion abnormali-
ties in left ventricle supplied by intermediately stenosed artery
with adenosine/regadenoson FFR >0.75 regarded as
normal.Materials and Methods: From the first 10 patients (me-
dian age 67) with intermediate (40-70%) stenoses in coronary
angiography, normal left ventricular ejection fraction (LVEF)
and adenosine/regadenoson normal FFR, seven subjects with
supine and prone diagnostic MPI were analyzed. Patients with
normal FFR but left bundle branch block and ventricular pac-
ing were initially excluded. FFR was measured during adeno-
sine infusion (140μg/kg/min) and after normalization of he-
modynamic conditions, another measurement with
regadenoson bolus (400 μg per patient) was done. No later
than 2 months after hemodynamic assessment myocardial per-
fusion imaging (MPI) on CZT gamma camera was performed
with two day exercise stress/rest protocol (rest imaging was
performed when stress study was abnormal). Each study was
estimated by two independent interpreters experienced in nu-
clear cardiology. Perfusion and LV motion were also assessed
semiquantitatively on 20-segment polar maps in the segments
corresponding with regions supplied by stenosed coronaries
(the basal anteroseptal and inferoseptal segments were exclud-
ed from analysis). Perfusion abnormalities were considered
true when observed in supine and prone MPI.ResultsThere
was no significant perfusion abnormalities in the regions of
interest (5 patients - normal perfusion in visual analysis, 2
patients - mild reversible perfusion abnormalities). Additional
semiquantitative perfusion evaluation of segments corre-
sponding with regions supplied by intermediately stenosed
arteries was performed, leading to similar findings. No signif-
icant LV functional abnormalities were detected in these pa-
tients (the mean LVEF 64%, no contractility dysfunction).
Intermediate stenoses were detected in left anterior descending
artery in 5 patients, one stenosis in circumflex artery and one in
right coronary artery.ConclusionIntermediate stenoses in cor-
onary arteries with adenosine/regadenoson FFR >0.75 pro-
duce no significant perfusion abnormalities (defined as revers-
ible perfusion defect greater than 10% of LV myocardium)
were observed. Further studies should elucidate whether
CZT MPI may serve as the surrogate for the FFR
measurements.
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Cardiac 13N-Ammonia PET in Left Ventricular Systolic
Dysfunction without Obstructive Coronary Artery Disease
A. Monroy-Gonzalez1, L. Juarez-Orozco1, E. Berrios-
Barcenas2, E. Flores-Gonzalez2, R. Cruz-Mendoza2, R.
Tio1, R. Slart1,3, R. Dierckx1, E. Alexanderson2,4; 1Univer-
sity Medical Center Groningen, Groningen, NETHER-
LANDS, 2Instituto Nacional de Cardiologia “Ignacio
Chavez”, Mexico City, MEXICO, 3University of Twente, En-
schede, NETHERLANDS, 4Unidad PET/CT UNAM, Mexi-
co City, MEXICO.
BACKGROUND: Left ventricular systolic dysfunction
(LVSD) is generally divided into ischemic and non-ischemic
etiology. In non-ischemic LVSD an abnormal perfusion is the
result of territories with histological/dynamic changes such as
myocardial fibrosis and/or abnormalities of myocardial blood
flow (MBF) in the absence of obstructive coronary artery dis-
ease (CAD). Moreover, impairment of MBF in patients with
LVSD is associated with an increased risk of mayor adverse
cardiovascular events (MACE). The aim of this study was to
analyze the role of 13N-Ammonia PET in patients with LVSD
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and no obstructive CAD.METHODS:We included 124 patients
without obstructive CAD, ruled out by Coronary Computed
Tomography Angiography (CCTA) who underwent PET with
13N-ammonia during rest and pharmacological stress with
adenosine. Detection of LVSD was performed by gated 13N-
Ammonia PET. We compared the quantitative and semi-
quantitative assessment of 13N-Ammonia PET among patients
with LVEF <50% and preserved LVEF.RESULTS: 11 patients
with LVSD (mean LVEF 40% ± 9%) and 114 with preserved
LVEF (mean LVEF 69% ± 7%) composed our population.
Mean age was 62 ± 11 years, 53% were male, 72% hyperten-
sive, 16% diabetic, 64% dyslipidemic, 49% presented angina,
and median BMI was 27 ± 4 kg/m2.Median SSSwas 2 (min: 0,
max: 27) and median SDSwas 0 (min: -6, max: 22). There were
no statistically significant differences in these characteristics
among groups. We also did not find a static significant differ-
ence in rest MBF or myocardial flow reserve; however, hyper-
emic MBF was lower in patients with LVSD compared to those
with normal LVEF (1.8 ± 0.6 vs. 2.3 ± 0.6 ml/g/min respective-
ly; p=0.02). Furthermore, patients with LVSD presented an in-
creased total perfusion deficit (TPD) when compared to those
with normal LVEF, both in rest (8% [min: 6%, max: 53%] vs.
4% [min: 0%, max: 53%] respectively; p<0.001) and in stress
(7% [min: 0%, max: 51%] vs. 1% [min: 0%, max: 33%] respec-
tively; p=0.002).CONCLUSIONS: In patients with systolic
dysfunction without obstructive CAD we found that hyperemic
MBF was diminished and TPD was increased when measured
by 13N-Ammonia PET, our results may be related to the ven-
tricular remodeling and adaptation seen in this group of patients.
We believe that hybrid imaging with 13N-Ammonia PET and
CCTA represents a useful tool for the assessment of patients
with LVSD as it can rule out the existence of obstructive
CAD and objectify the presence and degree of microvascular
or endothelial dysfunction.
P374
Long-term Follow-up in Hypertensive Patients With
Normal Stress Myocardial Perfusion Imaging:
a Parametric Analysis
C. Nappi1, E. Zampella1, R. Assante1, R. Green1, N. Frega1,
D. D’Arienzo1, G. DeMatteis1, S. Daniele2,W. Acampa2,M.
Petretta3, A. Cuocolo1; 1Department of Advanced Biomedi-
cal Sciences, University of Naples Federico II, Naples, ITALY,
2Institute of Biostructure and Bioimaging, National Council of
Research, Naples, ITALY, 3Department of Translational Med-
ical Sciences, University of Naples ‘Federico II’, Naples,
ITALY.
Aim: We assessed the relationship between arterial hypertension
and temporal characteristics of cardiac risk at long-term follow-
up in hypertensive patients with a normal stress myocardial
perfusion single-photon emission computed tomography
(MPS). Materials and Methods: We evaluated 471 consecutive
hypertensive patients without known coronary artery disease
(CAD) and normal perfusion at stress MPS. All patients were
followed for a mean 76±21 months. End-point events were car-
diac death or nonfatal myocardial infarction. The univariable and
multivariable associations with cardiac events were determined
by Cox proportional hazards regression analysis. A parametric
survival model was used to identify how the variables influenced
time to event and to estimate the risk-adjusted event rates during
the follow-up. Results: Of the overall population, 299 (63%)
patients underwent exercise stress test and 172 (37%) patients
pharmacologic stress test with dipyridamole. At Cox analysis,
age (hazard ratio 1.1, P<0.005) and stress test type (hazard ratio
2.7, P<0.005) were independent predictors of cardiac events. In
patients undergoing exercise stress test, peak systolic arterial
pressure (PAS) (hazard ratio 1.1, P<0.005) resulted as predictor
of cardiac events. At parametric analysis, patients <60 years old
who performed exercise stress test remained at low risk for the
entire length of follow-up, while the highest probability of events
and the major risk acceleration was observed in patients >60
years old who underwent pharmacologic stress test. In the 299
patients undergoing exercise stress test, only those who reached
PAS <160 mmHg remained at low risk for the entire length of
follow-up. In contrast, time to achieve a cumulative cardiac risk
level of 3% was 49 months in the presence of PAS 160-180
mmHg, 35 months for PAS 180-200 and only 10 months for
PAS>200mmHg. Conclusions. In hypertensive patients without
known CAD, a normal stress MPS should be considered
reassuring in subjects <60 years old who performed exercise
stress test and in those who reached a peak PAS <160 mmHg
independently on age. On the other hand, patients who
underwent exercise stress test and reached peak PAS >200 and
those submitted to pharmacologic stress test should be consid-
ered for a more aggressive management.
P375
Evaluation of myocardial blood flow in patients
with myocardial bridging: A 13N-ammonia PET study
A. Monroy-Gonzalez1, L. Juarez-Orozco1, E. Berrios-
Barcenas2, C. Gonzalez-Padilla2, M. Martinez-Aguilar2, G.
Guinto-Nishimura2, R. Dierckx1, R. Tio1, R. H. J. A. Slart1,
3, E. Alexanderson2,4; 1University Medical Center Groning-
en, Groningen, NETHERLANDS, 2National Institute of Car-
diology, Mexico City, MEXICO, 3University of Twente, En-
schede, NETHERLANDS, 4Unidad PET/CT UNAM, Mexi-
co City, MEXICO.
BACKGROUND: Myocardial bridging (MB) is a coronary ab-
normality seen in up to 16% of invasive coronary angiographies.
Although it is generally considered a benign condition, it has
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been suggested MB can be associated to angina, arrhythmias,
myocardial infarction and sudden cardiac death. Positron emis-
sion tomography with coronary computed tomography angiog-
raphy (PET/CCTA) provides the reference standard for quantifi-
cation of myocardial blood flow (MBF) and myocardial perfu-
sion reserve (MPR) as well as anatomical information of the
coronary artery tree. The aim of this study was to detect quanti-
tative and semi-quantitative myocardial perfusion defects
(MPD) by 13N-ammonia/PET in patients with MB.
METHODS: We retrospectively included 17 patients with MB
in the left anterior descending artery (LAD) and 51 controls
patients without coronary artery disease who underwent hybrid
PET/CCTAwith 13N-ammonia during rest and adenosine stress
for suspected ischemic heart disease. Semi-quantitative MPD,
stress MBF, and MFR were analyzed in the vascular territory
of theMB. Normal, mildly abnormal, moderately abnormal, and
severely abnormal perfusion was considered if Summed Stress
Scorewas <2, 2-3, 4-8, or >8 respectively. Normal LAD regional
stress MBF and coronary flow reserve (MFR) were considered
as ≥ 2.3 ml/gr/min, and ≥ 2.5 ml/gr/min values respectively.
RESULTS: In our population, mean age was 62 ± 9 years,
31% were male, 65% hypertensive, 17% diabetic, 59% dyslip-
idemic, and 38% reported active smoking. Mean stress MBF in
the LAD was 2.3 ml/g/min ± 0.8 and mean MFR in the LAD
was 2.7 ml/g/min ± 1.0. We did not find a statistically significant
difference among groups. However, we found an increased pro-
portion of reduced MFR in the LAD in the presence of a MB
compared to controls 53% (n=9) vs. 39% (n=20) showing a
trend towards significance (p=0.054), furthermore, we found a
statistically significant increase in mild reversible MPD in the
territory of the LAD in the presence of a MB against controls
29% (n=5) vs. 6% (n=3) respectively, p=0.02. CONCLUSION:
In this restricted population, we found an increased frequency in
mild reversibleMPD and a decreasedMFR in patients withMB,
our findings suggest that coronary vasodilator capacity impair-
ment might be present in MB. Our results support the role of
PET/CCTA in the assessment of MB as it could guide the
decision-making in this scenario; nevertheless, further studies
are needed to fully understand the hemodynamic impact of MB.
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Prognostic value of cardiac gated SPECT combined
with coronary calcium score in patients with end-stage
kidney disease
M. Kaminek1,2, M. Havel1, I. Metelkova1, M. Budikova1,
L. Henzlova1, P. Koranda1, J. Zadrazil1, V. Kincl2; 1Faculty
of Medicine and Dentistry, Palacky University Olomouc and
University Hospital Olomouc, Olomouc, CZECH REPUB-
LIC, 2International Clinical Research Center, Center of Mo-
lecular Imaging, St. Anne’s University Hospital, Masaryk Uni-
versity, Brno, CZECH REPUBLIC.
Introduction: The cardiovascular diseases are the main cause
of morbidity and mortality in patients with end-stage renal
disease (ESRD). Coronary artery disease (CAD) is highly
prevalent in this setting, owing to clustering of traditional
and uremic-specific risk factors. Asymptomatic course is com-
mon. In the current study, we assess the impact of the myocar-
dial perfusion imaging (MPI) by gated-SPECT and added val-
ue of coronary artery calcium (CAC) score measurement for
the risk stratification in ESRD patients. Materials and
methods: We examined 84 ESRD subjects by gated-SPECT
MPI, 69 of them underwent CAC score measurement by
multi-detector computed tomography (MDCT) system. CAC
scores were stratified into two groups, CAC score ≥ 1000 and
< 1000. During the median follow-up period of 33 months the
cardiac events (CE) defined as cardiac death or nonfatal MI or
the necessity of coronary revascularization were recorded. Re-
sults: We encountered 17 CE during the follow-up, which
were associated with significantly higher summed stress
scores on MPI, higher percentage of ischaemic myocardium,
higher occurrence of defects in multiple territories and higher
CAC scores (P = 0.0001, P = 0.0014, P < 0.0001, P = 0.0045
respectively). Functional parameters as left ventricular ejection
fraction and volumes did not show significant impact. CEwere
more frequent in subjects with severe or mild perfusion abnor-
mality, in comparison with patients with normal perfusion
findings on SPECT (P = 0.0030, P < 0.0001). There were 4
subjects with normal perfusion SPECTand encountered CE, 3
of them had CAC score values ≥ 1000 (P = 0.0408). There was
no any CE in patients with normal perfusion, function and zero
CAC score. Conclusion: Combined perfusion, function and
CAC score evaluation can help to identify ESRD patients in
high-risk for CAD. CAC score brings added value for future
CE prediction in subjects with normal perfusion patterns.
P377
The index of the maximum accumulation 99mTc-DPD
in the myocardium of patients with transthyretin (TTR)
cardiac amyloidosis and of older people without known
heart disease
M. Buncová, A. Čepa, M. Kubánek, A. Krebsová; Institute
for Clinical and Experimental Medicine, Prague, CZECH
REPUBLIC.
Aim: evaluation and comparison by using a custom quantita-
tive index (Mc) of the local maximum accumulation of
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99mTc-DPD in the myocardium in patients with TTR cardiac
amyloidosis and in control group of persons over the age of 70
years without known heart disease, assessment depending Mc
on the age and gender too. Materials and Methods: 3,3-
diphosphono-1,2-propanedicarboxylic acid (DPD,
TECEOS®, CIS Bio International, France) is kit for prepare
of radiopharmaceutical which standard used for bone scintig-
raphy, where it delineates areas of altered osteogenesis.
99mTc-DPD was preparedby instruction for preparation of
radiopharmaceuticals from SPC. In this study 1 woman and
4 men with confirmed TTR cardiac amyloidosis and the con-
trol group of 41 women and 36 men over 70 years of age,
without known heart disease, in which at the same time
99mTc-DPD scintigraphy ruled out bonemetastasis, were test-
ed. For about 3-5 hours after application 99mTc-DPD (740
MBq) was done SPECT/CT of the chest. A quantitative index
of local maximum accumulation 99mTc-DPD in the myocar-
dium (Mc) consisted in the determination of the ratio of the
highest count/voxel in the area of heart to the reference count
density. The reference count density is the average value, cal-
culated from the highest count/voxel values established on the
2-8. The ribs on the right side of the chest in the coronary plane
identical to the localization of max. count/voxel in the myo-
cardium. Results: the value Mc of the patients with TTR car-
diac amyloidosis was 6.11-8.71 (7.17/-1.11) IE. significantly
higher than in the control group, where Mc 0.81/-0.35. For
women without TTR cardiac amyloidosis Mc was insignifi-
cantly higher than in men. This is because the lower the accu-
mulation 99mTc-DPD in the bones, but also the ascendent
trend of the accumulation 99mTc-DPD in myocardium in
women. The dependency Mc has been not evident on the
age for persons over 70 years. Conclusion: Mc may contribute
to the detection, identification, determination of the degree of
disability of the myocardium and development of TTR cardiac
amyloidosis.
P378
The prognostic value of baseline 18F-FDG PET/CT
in steroid-naïve large-vessel vasculitis: introduction
of volume-based parameters
L. Dellavedova, L. S. Maffioli; AO Ospedale Civile di
Legnano, Legnano, ITALY.
Aim: To analyze if a baseline 18F-FDG PET/CTscan, in large-
vessel vasculitis (LVV) patients, is able to predict the course of
the disease, not only in terms of presence/absence of final
complications but also in terms of favourable/complicated
progress (response to steroid therapy, time to steroid suspen-
sion, relapses,⋯).Materials and Methods: 46 consecutive pa-
tients, undergone 18F-FDG PET/CT between May 2010 and
March 2013 for FUO or suspected vasculitis (before starting
corticosteroid therapy), were enrolled. The diagnosis of LVV
was confirmed in 17 patients by temporal artery biopsy, other
imaging techniques and a follow-up of at least 2 years. Con-
sidering follow-up data, positive LVV patients (17 out of 46)
were divided in two groups, one characterized by favourable
(9) and the other by complicated progress (8), on the basis of
presence/absence of stenotic-occlusive complications,
presence/absence of at least another positive PET/CT during
follow-up and impossibility to comply with the tapering-
schedule of the steroid, due to biochemical/symptomatic re-
lapse. Vessel FDG uptake in subjects of the two groups was
compared, not only in terms of intensity (SUVmax of the
vessel wall and Vessel-to-Liver ratio) but also of extension.
To evaluate the extent of active disease, we introduced the
volume-based parameters metabolic “tumor” volume (MTV)
and total lesion glycolysis (TLG). The threshold used to cal-
culate MTV on vessel walls was obtained by Vessel-to-Liver
ratio (the semiquantitative parameter with the highest diagnos-
tic accuracy at ROC analysis) and was setted at 0.92 x Liver
SUVmax in each patient. With this threshold, a semi-
automatic ROI was drawn on thoracic and abdominal aorta,
supra-aortic trunks and common iliac vessels to get the values
of extension (cm3), of mean SUV and of TLG.Results: Mea-
sures of tracer uptake intensity (SUVmax of the vessel wall
and Vessel-to-Liver ratio) were significantly higher in patients
with complicated progress compared to those with a
favourable one (p < 0.05). Differences in measures of disease
extension were even more significant and TLG emerged as the
best parameter to separate the two groups of patients (p =
0.01). No statistically significant differences were found in
inflammatory markers.Conclusion: In LVV patients, baseline
18F-FDG PET/CT seems to be not only a diagnostic tool. The
combined evaluation of the intensity and the extension of ves-
sel involvement can predict the clinical course of the disease,
separating patients with favourable or complicated progress:
this information could help clinicians in the choice of person-
alized therapeutic approaches and follow-up planning.
P379
[18F]-FDG PET/СT imaging for detection
of the inflammation in the calcified atherosclerotic plaques
D. V. Ryzhkova, D. A. Pavlova; North-Western Fedral Med-
ica l Research Cent re , S t .Pe te rsburg , RUSSIAN
FEDERATION.
The aim of the study was to assess how often the inflammation
can be identified in calcified atherosclerotic plaque in the pa-
tients in the patients of different age. Methods: We retrospec-
tively studied 51 patients who underwent [18F]-FDG PET/CT
for detection malignancy. Whole body scan was performed 60
m i n u t e s a f t e r i n t r a v e n o u s a dm i n i s t r a t i o n o f
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radiopharmaceutical. The average plaque density in Houns-
field units and maximum standardized uptake value
(SUVmax) were evaluated in calcified atherosclerotic plaques
in aorta. Results: The increase of [18F]-FDG uptake was ob-
served in 95 (43%) from 220 calcified atherosclerotic plaques
in aorta, that were titled FDG-positive plaques. The ratio of
FDG-positive and FDG-negative calcified plaques was equal
for the different parts of aorta: 50% vs 50% for the ascending
aorta; 48% vs 53% for the aortic arch; 44% vs 56% for the
descending thoracic aorta as well as the abdominal aorta. The
all patient were divided into 3 groups in conformity with their
age: younger than 40 years (16 pts.), 41-60 years (18 pts.) and
older than 60 years (17 pts.). We observed only two calcified
plaques (one FDG-positive and one FDG-negative) in the pa-
tients younger than 40 years. The patients, who were 40-60
years and older than 60 years had the equal ratio of FDG-
positive and FDG-negative calcified plaques (29 (43%) vs 37
(57%) and 65 (43%) vs 86 (57%) respectively). We found a
positive correlation between the amount of calcified plaques
and patient age (R=7,83; p<00,5). The correlation between
SUVmax and plaque density was not obtained. Conclusion:
The increase of [18F]-FDG uptake as a marker of inflamma-
tion was visualized in 43% of aortic calcified plaques in pa-
tients older 40 years. We have not found a correlation between
calcification and inflammation of atherosclerotic plaque.
P380
Influence of the peptide receptor radionuclide therapy
(PRRT) on the inflammatory activity in atherosclerotic
plaques based on the initial 68Ga-DOTA -TATE (DOTA)
uptake
M. J. Zacherl1, A. Todica1, G. Rubinstein1, P. Bartenstein1,
M. Hacker2, S. Lehner1; 1University of Munich, Munich,
GERMANY, 2Medical University of Vienna, Vienna,
AUSTRIA.
Aims: Previous studies suggest that PRRT has an anti-
inflammatory effect on atherosclerotic plaques. The aim of this
study was to investigate the influence of the initial level of
DOTA uptake on the inflammatory activity after performing
PRRT. Methods: Patients from an oncological cohort, who
received 4 cycles of 177Lu-DOTA-TATE therapy (n = 37 ,
age 59 ± 10 ; 23m, 14f) were retrospectively included in the
study. We performed a baseline DOTA PET/CT as well as a
follow-up scan after two and four cycles of PRRT. Patients
who received a DOTA PET/CT scan three times, but had no
therapy with 177Lu-DOTA-TATE (n = 20, age 63 ± 12 ; 9m,
11f), served as control group. In 8 arterial segments (ascending
aorta, aortic arch, thoracic aorta, abdominal aorta, right and left
common iliac artery, right and left common carotid artery), the
“target-to-background-ratio” (TBR) was determined. The
“overall vessel uptake” (OVU) was calculated from the sum
of all TBRs. Additionally, the calcium score was determined.
Results: In the therapy- (TG) and the control group (CG) we
found no significant change in OVU (TG : 18.5 ± 6.7 to 18.0 ±
4.1 ; P = n.s.; KG: 19.7 ± 5.7 to 20.2 ± 4.5 ; P = n.s.). Subse-
quently the patient groups were divided into tertiles. In the
tertile with the highest initial OVU we found a decrease in
OVU (23.7 ± 7.4 to 18.7 ± 3.8, P < 0.05) after 4 cycles of
PRRT. In the tertile with the lowest initial OVU a stable OVU
was observed after 4 cycles of PRRT (14.8 ± 1.4 and 16.0 ±
3.0, P = n.s.). There was a significant correlation of age and
calcium score (R = 0.592 , P = 0.01) with only a moderate
correlation of TBR with calcium score (R = 0.288 , P = 0.05).
Conclusion: The reduction of the inflammatory activity by a
PRTT is dependent on the initial DOTA uptake in the vascular
plaque. Patients with higher inital DOTA uptake show a sig-
nificant reduction in inflammatory activity after 4 cycles of
PRRT. A high calcium load does not necessarily imply a high
inflammatory activity.
P381
Feasibilty of Annexin A5 for ex vivo imaging of human
fresh and frozen atherosclerotic plaques
S. A. de Boer1, J. van Hoek2,3, D. J. Mulder1, H. J. de Haas2,
N. A. Jager4, J. G. W. Kosterink3, C. J. Zeebregts5, C. P. M.
Reutelingsperger6, P. H. Elsinga2, R. H. J. A. Slart2,7, H. H.
Boersma2,3; 1Department of Vascular Medicine, University
Medical Center Groningen, University of Groningen, Gro-
ningen, NETHERLANDS, 2Department of Nuclear Medi-
cine, University Medical Center Groningen, University of
Groningen, Groningen, NETHERLANDS, 3Department of
Clinical and Hospital Pharmacy, University Medical Center
Groningen, University of Groningen, Groningen, NETHER-
LANDS, 4Department of Rheumatology and Clinical Immu-
nology, University Medical Center Groningen, University of
Groningen, Groningen, NETHERLANDS, 5Division of Vas-
cular Surgery, Department of Surgery, University Medical
Center Groningen, University of Groningen, Groningen,
NETHERLANDS, 6Department of Biochemistry, University
of Maastricht, Maastricht, NETHERLANDS, 7Faculty of Sci-
ence and Technology, Biomedical Photonic Imaging, Univer-
sity of Twente, Enschede, NETHERLANDS.
Background and aim: In 2004 Kietselaar and others demon-
strated the feasibility of technetium-99m-labeled annexin A5
for assessing atherosclerotic plaque instability in a clinical pi-
lot. Annexin A5 is a plasma protein with a strong affinity for
phosphatidylserine exposed on apoptotic cells. Since they
evaluated only four patients (in vivo) the aim of the current
study was to validate the use 99mTc-labelled Annexin A5 in
ex vivo fresh and frozen human carotid endarterectomy (CEA)
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specimens in order to confirm the results of the previous clin-
ical study. Materials & methods: 15 patients with elective ca-
rotid endarterectomy because of significant symptomatic ca-
rotid artery stenosis, were included. 8 CEA specimen were
used within 2 hours after CEA, and 7 specimenwere used after
defrosting.All CEA specimen were incubated for one hour
with 99mTc-Annexin A5 and scanned with μSPECT for one
hour. Tracer uptake was calculated as percentage incubated
dose per gram (%inc/g) for the whole CEA specimen. A
beam-shaped region of interest (ROI) was drawn around the
CEA specimen and the mean and maximum tracer uptake was
determined. Around the hotspot a ROI was defined as 70% of
the maximum tracer uptake. Anxmax was calculated by divid-
ing the mean tracer uptake in the hotspot by the mean tracer
uptake in the whole CEA specimen. Histological immuno-
staining with anti-annexin was semiquantitatively evaluated.
to confirm uptake. Results and conclusion:The mean weight of
all CEA specimens was 0,78±0,52 g, for fresh CEA specimen
0,60±0,39 g and for frozen CEA specimen 0,99±0,59 g. In
both fresh and frozen CEA specimens, significant 99mTc-
Annexin A5 uptake with heterogeneous distribution was seen.
The mean %inc/g for all CEA specimens was 2,9±1,6. For the
fresh CEA specimens mean %inc/g was 2,9±1,8, and for fro-
zen CEA specimen 2,8 ±1,4. No significant uptake difference
in %inc/g between fresh and frozen CEA specimens (t = 0,11;
P > 0,05) was demonstrated. Mean Anxmax of all CEA spec-
imen was 6,8±1,4 for fresh CEA specimen 6,7± 1,6 and for
frozen CEA specimen 6,9±1,2. Also for these uptake values,
no significant difference was found (t = -0,232; P > 0,05). A
congruent pattern was observed between tracer uptake and
histology immunostaining. This study demonstrates that
Annexin A5, as a cell death tracer, is a valid method for
ex vivo imaging of atherosclerotic plaques in fresh and frozen
atherosclerotic CEA specimen.
P382
Quantitative assessment of intermediate stenosis
of coronary arteries by single photon emission computed
tomography with attenuation correction compared
fractional flow reserve
V. Solomyanyy; Russian cardiology research and production
complex, Moscow, RUSSIAN FEDERATION.
Aims and objectivesFractional flow reserve (FFR) is currently
used to determine the management of intermediate coronary
artery stenosis. FFR more 0.80 used in clinical practice to
guide revascularization. Advances in nuclear medicine single
photon emission computed tomography with attenuation cor-
rection (SPECT/CT) require revaluation quantitative parame-
ter noninvasive imaging in compared with FFR in the diagno-
sis of the functional significance intermediate stenosis
coronary arteryMethods and materialsIn this study, 70 patients
(mean age 57±5 years, 50 men, and 20 women) with ischemic
heart disease and 50% to 70% coronary stenosis (target ves-
sel). All perfusion scans were performed using a camera
(BrightView XCT Philips) equipped with a low-energy,
high-resolution collimator and with cardiac gating.
Antianginal medication was discontinued 48 hours before
the study, and patients abstained from caffeine for 24 hours
prior to the study protocol one day stress (bicycle test)/rest use
with 900 MBq (25 mCi) of technetium 99m-MIBI.
Coronaroangiography (CAG), which was defined as angio-
graphic moderate (50-70%), was assessed by quantitative cor-
onary angiography (QCA) and pressure wires received
FFRResultsNormal FFR > or =0.8. Summed difference scores
(SDS) in the left anterior descending (LDA), right coronary
artery (RCA) and ramus circumflexus (RCX) artery territory
according to the 17 segment model were calculated with atten-
uation correction (AC) and no correction (NC). In order to
evaluate the sensitivity and specificity used ROC- analysis.
NC value SDS > 3 predicts the existence of a reliable, persis-
tent perfusion defects with a sensitivity of 96.4% and a spec-
ificity of 84.2%, the images attenuation correction (AC) SDS
> 4 (96.7% and 90.1%, respectively)ConclusionMethod of
SPECT/CT can be used to determine the hemodynamic signif-
icance of intermediate coronary artery stenosis. Quantitative
assessment of myocardial perfusion SDS determined at
SPECT/CT with attenuation correction is more sensitive and
specific for the coronary artery stenosis evaluation
P383
18F-FDG uptake in main arterial branches of patients
with large vessel vasculitis: visual and semiquantitative
analysis.
M. CASTELLANI1,M. VADRUCCI1, L. FLORIMONTE1,
M . CARONNI2 , E . ORUNESU1 , R . BENTI1 ;
1FONDAZIONE IRCCS CA’GRANDA OSPEDALE
MAGGIORE POLICLINICO Nuclear Medicine Department,
MILAN, ITALY, 2FONDAZIONE IRCCS CA’GRANDA
OSPEDALE MAGGIORE POLICLINICO Referral Center
for Systemic Autoimmune Diseases, MILAN, ITALY.
Purpose: Over the last decade, the contribution of 18F-FDG
(FDG) PET/CT imaging to the diagnosis of large vessel vas-
culitis has been widely investigated. Aim of this study was to
evaluate a more extensive role for PET/CT in grading vascular
inflammation in patients with different clinical stages of
disease.Methods: The images of 66 PET/CT studies of 34 pa-
tients, performed at diagnosis and/or during follow-up were
reviewed. FDG uptake in different regions of aorta and of its
major branches was visually (regional Score: rS) and semi-
quantitatively (regional SUVmean: rSUV) assessed. The
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global vascular uptake was also evaluated for each study by
summing all rSs (summed Score; sS) and averaging rSUVs
(averaged SUV; aSUV). FDG uptake in 15 PET/CT studies
of control age-matched subjects without signs or symptoms
of vasculitis was also analyzed.Results: Higher levels of re-
gional and global FDG uptake were found at diagnosis in
comparison with follow-up studies (p<0.01). In the latter
group, the highest values were observed in patients with dis-
ease relapse and partial response to therapy whereas a lower
uptake was found in patients fully responsive (p<0.01), whose
FDG levels were similar to those of the control subject group.
At ROC analysis, optimal cut-off levels of regional and global
FDG vascular uptake provided a good discrimination between
patients at diagnosis and control subjects (aSUV greater than
0.6977; PPV=92.3; NPV=92.9). A major overlap was ob-
served between FDG levels of follow-up patients with active
disease and remission (aSUV greater than 0.6532; PPV=58.3;
NPV=94.1). Slight differences in the performances of visual
and semiquantitative analyses were found when the corre-
s p o n d i n g a r e a s u n d e r c u r v e s ( AUC s ) w e r e
compared.Conclusion: 18F-FDG PET/CT may detect differ-
ent grades of inflammation in patients with large arteries vas-
culitis. Nevertheless, the simple analysis of FDG vascular
levels may be not sufficient to separate patients with active
and inactive disease.
P384
18F-FDG-PET/CT imaging in Giant Cell Arteritis: Are we
still unable to “light up” temporal arteries?
Z. Rehak1, J. Vasina1, J. Ptacek2, P. Nemec3, Z. Fojtik4;
1MasarykMemorial Cancer Inst., Brno, CZECHREPUBLIC,
2University Hospital, Olomouc, CZECH REPUBLIC, 3St.
Anne’s University Hospital, Brno, CZECH REPUBLIC,
4University Hospital, Brno, CZECH REPUBLIC.
Introduction: 18F-FDG (FDG)-PET/CT imaging could be use-
ful in patients with fever of unknown origin and could detect
giant cell arteritis (GCA) in extracranial large arteries. In the
case of temporal arteries, it is usually assumed that they cannot
be visualized with a PET/CT scanner due to their small diam-
eter. Aim: We tried to visualize high FDG uptake in temporal
arteries in patients with clinical symptoms of temporal arteritis
using a hybrid PET/CT scanner in a manner that could im-
prove detection capabilities. Methods: Three patients with
clinical signs of temporal arteritis were examined using a stan-
dard whole body (WB) PET/CT protocol (skull base-mid
thighs) followed by a head PET/CT scan using a brain acqui-
sition protocol. Results: A high FDG uptake in the aorta and
main arterial branches in 3/3 pts. was detected with WB PET/
CT scan. Furthermore, using the brain protocol, a high FDG
uptake was also detected in head arteries - temporal arteries
(3/3 pts.), occipital arteries (2/3 pts.) and vertebral arteries (3/3
pts.), and even in branches of temporal arteries (3/3 pts.). All 3
patients underwent excision of temporal artery branches in 10
days after PET/CT examination with positive evidence of
GCA and were treated with prednisone. Conclusions: Head
imaging with brain acquisition protocol enabled us to visualize
metabolically active inflammation in temporal arteries and
their branches in all 3 patients with GCA. We succeeded to
obtain this result probably by extending acquisition time (brain
acquisition protocol) on a scanner with relatively good param-
eters (small reconstructed pixel size, high sensitivity and good
spatial resolution).
P385
Identification of complicated carotid plaques by adding
functional FDG-PET imaging to morphological
characteristics on CT angiography
N. Mikail1, F. Hyafil1, M. Mazighi2, E. Meseguer3, C.
Guidoux3, L. Cabrejo3, P. Lavallée3, K. Benali1, F. Rouzet1,
D. Le Guludec1, G. Lesèche4, P. Amarenco3; 1Bichat Univer-
sity Hospital, Department of Nuclear Medicine, PARIS,
FRANCE, 2Lariboisière University Hospital, Department of
Neurology, PARIS, FRANCE, 3Bichat University Hospital,
Department of Neurology, PARIS, FRANCE, 4Bichat Univer-
sity Hospital, Department of Vascular Surgery, PARIS,
FRANCE.
Aim. Complicated plaques have specific morphological and
biological characteristics. Morphological aspects associated
with complicated plaques identified with CT angiography
(CTA) such as hypodense areas (<30 Hounsfield units) or
plaque ulceration lack sensitivity. In this study, we developed
a simple semi-quantitative score for the analysis of carotid
plaques with FDG-PET-CTA imaging and tested whether
adding functional imaging criteria extracted from FDG-PET
imaging to morphological plaque characteristics identified
with CTA might improve the detection of complicated
plaques.Material and methods. Twenty-eight patients sched-
uled for carotid endarterectomy were first imaged with PET
2 hours after injection 4 MBq/ kg of FDG followed by CTA of
the supra-aortic trunks. Morphological aspects of plaques
identified with CTA and metabolic activity quantified with
FDG-PET (Tissue to Background ratio, TBR) were measured
in the region of the operated carotid artery with the highest
degree of luminal stenosis and graded using semi-quantitative
CT (maximal score = 6) and PET scores (maximal score = 4).
A combined score was then calculated for each carotid artery
by summing CT and PET scores (maximal score = 10). After
carotid endarterectomy, vascular surgeons classified carotid
plaques macroscopically as complicated (presence of fresh
thrombus, intra-plaque haemorrhage, plaque rupture) or non-
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complicated.Results. Twenty-eight carotid arteries were oper-
ated in 26 patients (24 symptomatic patients). Sixteen plaques
were classified macroscopically as complicated. CTA detected
hypodense regions and ulcerations in 81 % and 25 % of com-
plicated plaques, and in 33 % and 0% of non-complicated
plaques, respectively. Hypodense areas on CTA identified
complicated plaques with a sensitivity of 87 % and a specific-
ity of 67 %. Mean TBR with FDG-PETwas measured at 2.2 ±
0.4 in complicated plaques and 1.9 ± 0.3 in non-complicated
plaques (p < 0.05). Values for the semi-quantitative score
based on plaques characteristics with CTA and FDG-PETwere
5.4 ± 1.7 in complicated plaques and 2.5 ± 2.4 in non-
complicated plaques (p < 0.05). A combined PET-CT score
≥ 3 identified complicated plaques with a sensitivity of 100
% and a specificity of 67 %.Conclusions. In this study, we
have developed a simple semi-quantitative score for the anal-
ysis of combined FDG-PET-CTA imaging of carotid plaques.
Adding FDG-PET imaging criteria to morphological charac-
teristics of plaques on CTA improved sensitivity to identify
complicated plaques.
P386
[18F]-Sodium Fluoride Uptake in Takayasu Arteritis
E. Alexanderson1,2, A. Monroy-Gonzalez3, L. Juarez-Oroz-
co3, R. Tio3, A. W. J. M. Glaudemans3, E. Estrada4, O.
Garcia4, A. Meave1, R. H. J. A. Slart3,5, M. E. Soto-
Lopez5; 1National Institute of Cardiology, Mexico City,
MEXICO, 2Unidad PET/CTUNAM,Mexico City,MEXICO,
3University Medical Center Groningen, Groingen, NETHER-
LANDS, 4National Institute of Cancer, Mexico City, MEXI-
CO, 5University of Twente, Enschede, NETHERLANDS.
BACKGROUND: Studies have shown the role of Positron
Emission Tomography (PET) with 18F-fluorodeoxyglucose
(18F-FDG) in diagnosing and monitoring clinical disease ac-
tivity in vascular structures affected by Takayasu Arteritis
(TA). Because inflammation is a serious risk factor for athero-
sclerosis it is necessary to prevent complications of atheroscle-
rosis in patients with TA. 18F-sodium fluoride (18F-NaF) has
already been successfully used to identify high-risk atheroscle-
rotic plaques in patients with increased cardiovascular risk.
However, the relationship of 18F-NaF/PET and TA has not
yet been studied. The aim of this case series is to describe
the 18F-NaF uptake in patients with TA.METHODS:We pres-
ent 5 patients with confirmed diagnosis of TA by the 1990
American College of Rheumatology Classification Criteria,
who were referred to our unit. All patients underwent PET
whole body scan with both 18F-FDG and 18F-NaF in order
to explore the localizations and correlation of 18F-NaF and
18F-FDG uptake. SUVmax of 18F-FDG (corrected for blood
glucose levels) and 18F-NaF uptake along the aorta was
obtained. Diagnosis of current metabolic active disease was
based on increased 18F-FDG uptake. Mann-Whitney U test
was used to compare difference in means of SUVmax among
18F-FDG and 18F-NaF. We performed a Spearman’s Rank
Order Correlation (rho) to describe the strength and direction
o f t he l i ne a r r e l a t i on sh ip be tween con t i nuous
variables.RESULTS: Our population was composed of 4 fe-
male and 1 male patients, median age was 29yr (min: 19, max:
63), and all patients were non-diabetic. Median 18F-NaF
SUVmax was 1.1 (min: 0.5, max: 1.5) and median 18F-FDG
SUVmax was 2.5 (min: 0.1, max: 2.8); there was no statistical
difference between the two tracers (p=0.69). 18F-NaF uptake
showed to be increased in the aorta in all of our patients, even
in patients without active metabolic disease demonstrated by
18F-FDG. One of our patients without established active dis-
ease showed increased uptake of 18F-FDG and 18F-NaF,
however, increased uptake of 18F-FDG was attributed to ath-
erosclerosis. Finally, we found a negative correlation between
18F-NaF and 18F-FDG uptake r=-0.87 (p=0.054).CONCLU-
SIONS: In TA patients it is possible to document active aortic
micro-calcification by 18F-NaF, even in the absence of active
metabolic disease measured by 18F-FDG or symptoms. We
propose that 18F-NaF/PET could be a non-invasive method
for the assessment of atherosclerosis and cardiovascular risk
stratification in TA patients. These results may allow preven-
tive measures, even in asymptomatic patients; however, fur-
ther studies are needed to fully understand the role of 18F-NaF
in TA.
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Radionuclide evaluation of cardiac function
and dyssynchrony in children with idiopathic ventricular
tachycardia
K. W. Zavadovsky1,2, V. Saushkin1, Y. Lishmanov1,2;
1Federal State Budgetary Scientific Institution «Research In-
stitute for Сardiology», Tomsk, RUSSIAN FEDERATION,
2National Research Tomsk Polytechnic University, Tomsk,
Russian Federation, Tomsk, RUSSIAN FEDERATION.
Background: The aim of the study was to evaluate the impact
of idiopathic ventricular tachycardia and premature ventricular
beats on cardiac function and dyssynchrony and to elucidate
relationships between data of scintigraphic and intracardiac
electrophysiology studies. Methods: The study comprised 64
patients with idiopathic ventricular arrhythmias (VA) (mean
age of 13.2 ± 3.14 years). Control group comprised 20 patients
(mean age of 13.2 ± 3.6 years) without cardiac arrhythmias.
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Electrophysiological study (EPS) and radiofrequency ablation
(RFA) procedure for VA were performed in 21 children ac-
cording to indications. The functional state of the right ventri-
cle was assessed by GBP-SPECT before and after RFA in all
patients. Results: Patients with VA had local areas of asynchro-
nous myocardial contraction (AMC). Compared with control
group, patients with VA had significantly higher values of the
end-diastolic and end-systolic volumes, and lower indices of
contractility. Negative association was found between the total
number of AMC areas and cardiac contractility indices. Ectop-
ic foci localization (based on EPS data) was associated with
topography of AMC areas (based on GBP-SPECT). Radiofre-
quency ablation procedure significantly improved cardiac con-
tractility indices; AMC areas completely disappeared or de-
creased in a number compared with the preoperative condi-
tions. Conclusion: In patients with VA, AMC areas localized
mostly in the right ventricle. Comparison of the results of
GBP-SPECT and EPS studies showed a relationship between
AMC localizations and ectopy topography. The fact that AMC
zones disappeared after RFA supports the hypothesis stating
that the presence of AMC zones is a scintigraphic symptom of
ectopy. The study was supported by grant from the Russian
Science Foundation (N 14-15-00178).
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The utility of 99mTc-Pyrophosphate SPECT in diagnosis
of latent myocarditis in patients with atrial fibrillation
S. Sazonova1,2, Y. Ilyushenkova1,2, R. Batalov1, Y.
Rogovskaya1, Y. Lishmanov1,2; 1Institute of Cardiology,
Tomsk, RUSSIAN FEDERATION, 2National Research
Tomsk Polytechnic University, Tomsk, RUSSIAN
FEDERATION.
Aim: to compare results of 99mTc-Pyrophosphate myocardi-
um SPECT with histology data in patients with isolated per-
sistent atrial fibrillation (AF) Materials& methods: We exam-
ined 40 patients (pts) (27 males and 13 females, mean age
48.72±11,1) with isolated persistent AF. After complete clini-
cal and instrumental examination, all patients underwent
SPECT with 99mTc-Pyrophosphate (99mTc-PYP ) 18 hours
post injection (delayed SPECT), following by SPECT with
99mTc-MIBI at the rest condition. Both images were then
combined to define more exactly the localization of 99mTc-
PYP uptake in the heart and to exclude ventricles blood pool.
Accumulation of 99mTc- PYP was accepted as pathological
when focus localized in myocardium area, focus/background
ratio exceeded 1.4. In 22 pts Cardiac Magnetic Resonance
(CMR) with gadolinium was performed. Endomyocardial bi-
opsy (EMB) samples were taken during catheter ablation of
AF. Scintigraphic results were compared with the EMB and
immunohistochemical findings. Results: According to
histological data active lymphocytic myocarditis was verified
in 5 pts (13%), the remaining 35 pts had signs of
ca rd iosc l e roses in combina t ion wi th myolys i s ,
histiolymphocytic infiltration or lipomatosis. Immunohisto-
chemical study detected the presence of viral antigens (gerpes
simplex of 1 and 2 types, enterovirus) in myocardium samples
of every patient with histologically confirmed myocarditis.
The pathological uptake of 99mTc-PYP was found in 11 pa-
tients. The number of true-positive results was 3, true negative
28, false-positive - 6, false negative 1. The sensitivity was
80%, specificity 82%, accuracy 80%. Late gadolinium en-
hancement at CMR was marked at 19 of 22 pts, but neither
of pts matched to «Lake Luise Criteria» of myocarditis. The
sensitivity was 67%, specificity 77%, accuracy 64%. Correla-
tion analysis according Spearman’s criterion revealed a close
relationship between CMR and SPECT with 99mTc-
Pyrophosphate (r=0,64, p<0.05). Comparative evaluation of
diagnostic efficacy of SPECT with 99mTc-Pyrophosphate
and CMR by comparison of ROC curves showed lower values
of AUC for CMR (0.702) than for SPECT (0.808). Conclu-
sion: The results of our study have shown that in 13% of
patients with isolated AF had latent myocarditis. Cardiac
SPECT with 99mTc-PYP has a potential as an effective non-
invasive tool of diagnoses of latent myocarditis in pts with
isolated AF.
P389
Interpretation of myocardial perfusion SPECT
with CT-based attenuation correction
A. Ansheles, L. Martirosyan, I. Sergienko, V. Sergienko; Rus-
sian Cardiology Research Center, Moscow, RUSSIAN
FEDERATION.
Aim. Assessment of CT-based attenuation correction (AC)
impact on cardiac perfusion images, revealing factors that in-
crease visual difference between AC and nAC-images. Mate-
rial and methods. 167 patients underwent myocardial perfu-
sion SPECTwith (AC) and without (nAC) CT-based attenua-
tion correction. Differences between AC and nAC-images
were analyzed visually, visual differences groups (VDG) were
formed: group 1 - absent difference, group 2 - subtle differ-
ences, that did not change interpretation, group 3 - equivocal
differences, and group 4 - reliable differences. Groups 3-4
required profound analysis of both sets to make conclusion,
they were divided to “-” and “+” subgroups, relating to worse
or better AC-perfusion in reference to nAC-images, and also
“±”-groups, that meant presence both better and worse seg-
ments in AC-images. Factors that increase visual AC/nAC-
images difference were studied from the standpoint of classi-
fying them to a certain VDG. Results. Groups 3-4, were AC/
nAC-images differed visually significantly, involved 68% of
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all cases. In 80% of these cases, AC restored perfusion homo-
geneity, cancelling “defects” visible at nAC-images, located
mostly at inferior LV wall. However, AC-images had their
specific artifacts (false defects) compared to nAC-images, lo-
cated mostly in apex. Factors that increased AC/nAC-images
difference included: weight, large LV, male gender, patients
with small focal perfusion defects and transient ischemia, in-
sufficient activity administered (all p(s)<0.05). SRS, SSS
values and transient ischemia area (reversibility extents in %)
were significantly higher at AC-images than in nAC-images:
6.8 (2.5-10.6) against 4.5 (2.0-6.7), p<0.01, 8.1 (3.0-13.7)
against 5.3 (2.4-7.2), p<0.01, 5.5% (3.2-7.6) against 3.3%
(1.7-5.1), p<0.01, respectively. Septal perfusion defect extent
was higher in AC-images: 31.1% (16.1-44.2) against 6.6%
(2.6-15.3), p<0.01. In patients with transmural perfusion de-
fects, maximum defect severity was higher in AC-images - 8.3
sigmas (5.6-11.4) against 6.3 (4.3-9.3), p=0.056. Artifacts due
to bright liver/stomach appeared more often in rest AC-images
(12% against 2.7%, p<0.05). Summary/discussion. CT-based
AC increases myocardial perfusion SPECT diagnostic value,
makes interpretation more confident, reduces number of false-
positive/equivocal results. However, normal ranges of
summed scores and extent parameters for AC-images require
modifying, since they are higher in AC-images (perhaps due to
more precise normal databases). In addition, both AC- and
nAC-images showed their own artifacts patterns. In effort to
minimize influence of those false perfusion “reductions” on
quantitative assessments, it is discussable to take relative per-
fusion values for each segment as maximal numbers of both
AC and nAC images, instead of using values only from one
(AC or nAC) set.
P390
the efficacy of myocardial perfusion image morphing
combined with computed tomography coronary
angiography in the diagnosis of silent myocardial ischemia
C. Chang, W. Xie, B. Lei, L. Wang, R. Li, Z. Zheng, s. yang;
Shanghai Chest Hospital, Shanghai, CHINA.
Accruate assessment of silent myocardial ischemia is the im-
portant value in the diagnosis and treatment of Coronary Ar-
tery Disease.The current study aims to compare the diagnostic
efficacy of combined myocardial perfusion imaging morphing
(MPI morphing) and computed tomography coronary angiog-
raphy (CTCA) with MPI morphing or CTCA alone in silent
myocardial ischemia (SMI). Forty-five outpatients diagnosed
with ischemic ST segment abnormality (depression of ST seg-
ment larger than 0.05 mV) by ECG in the clinic or by physical
examination from March 2011 to September 2014 were retro-
spectively studied. There were 24 males and 21 females aged
38-78 years (average age: 60.13 + 7.58 years), who were
informed of the procedures and signed an informed consent
prior to the examinations. All patients underwent conventional
dobutamine stress/resting MPI and CTCA imaging, followed
by coronary artery angiography (CAG) within a month. CAG
combined with MPI morphing was used as a standard to eval-
uate the efficacy of MPI morphing, CTCA and MPI combined
with morphing CTCA in the diagnosis of SMI.For MPI
morphing combined with CTCA, MPI morphing and CTCA,
the diagnostic sensitivities for SMI were 92.41%, 81.43% and
73.58%, respectively; the specificities were 92.86%, 73.85%
and 71.95%, respectively; the accuracies were 92.59%,
77.78% and 72.59%, respectively; the positive predictive
values were 94.81%, 77.03% and 62.90%, respectively; the
negative predictive values were 89.66%, 78.69% and
80.82%, respectively. The Kappa values of MPI morphing
combined with CTCA, MPI morphing, and CTCA in the di-
agnosis of SMI were 0.85, 0.55 and 0.44, respectively.CTCA
can clearly show morphological changes in the coronary ar-
tery, while MPI morphing can determine the occurrence of
myocardial ischemia in the striated coronary artery. The com-
bination of CTCA and MPI morphing could improve the di-
agnostic efficacy of SMI.
P391
99mTc-HMPAO labeled leukocyte SPECT/CT
in evaluation of cardiac device infection
M.Kostkiewicz, K. Holcman,W. Szot, B.Malecka; Intitute of
Cardiology,Jagiellonian University, Hospital John Paul II,
KRAKOW, POLAND.
Introduction. The number of device implantations has in-
creased two- to three-fold across the last 10-15 years Unfortu-
nately, the rate of devices infections has increased in parallel .
Cardiovascular implantable electronic devices (CIED) endo-
carditis are associated with a poor prognosis. Imaging investi-
gations traditionally used for diagnosis of IE and PVE are
transthoracic echocardiography (TTE) and transesophageal
echocardiography (TEE), with a very high sensitivity. Howev-
er, the diagnostic value of echocardiography in IE diagnosis is
operator-dependent and its sensitivity can decrease in presence
of intracardiac devices, severe preexisting lesions, and very
small or no vegetation.Aim. The aim of this study was to
evaluate the accumulation of autologous radiolabeled leuko-
cytes 99mTc-HMPAO in patients with CHED and with
suspected infective endocarditis using SPECT/CT. Methods.
The study group included 30 consecutive patients with
suspected infective endocarditis (IE) involving a cardiac de-
vice. On all patients we performed clinical evaluation and
laboratory tests (e.g. complete blood cell count, creatinine,
C-reactive protein, procalcitonin, fibrinogen, blood cultures).
Each pat ient underwent t ransthoracic as well as
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transesophageal echocardiogram. Afterwards all patients had
performed SPECT/CTwith prior administration of autologous
leukocytes labeled with 99mTc-hexamethylpropyleneamine
oxime (99mTc-HMPAO-WBC). Images was obtained after
4-6 and 20-24 hours after reinfusion. The scintigraphic studies
was classified as positive for infection when there will be
observed at least one focus of abnormal uptake characterized
by a time-dependent increase in radioactivity. Clinical follow-
up will last 6 months. During this time patients had control
transthoracic echocardiogram. Results. The very good corre-
lations between the accumulation of 99mTc-HMPAO-WBC
and exacerbation of clinical symptoms, and echocardiographic
findings was found. 99mTc-HMPAO-WBC scintigraphy was
totally negative in 5 patients for CIED sites of focal uptake
indicating infection The SPECT/CT study, when positive, was
very useful in diagnosis the region of infection in patients with
cardiac device and clinical symptoms of endocarditis. There
w e r e o n e f a l s e p o s i t i v e s c a n w i t h C I E D .
Conclusions.99mTechnetium-HMPAO-SPECT/CT, have
been demonstrated to be effective imaging options in the man-
agement of IE especially in patients with high clinical suspi-
cion of IE, in order to confirm the diagnosis in doubtful cir-
cumstances and/or to detect sites of inflammation.
P392
Dual radionuclide myocardial perfusion SPECT may be
planned with much lower radiation doses on CZTcameras
V. ROCH1,2, L. IMBERT1,2,3, W. DJABALLAH1,2, M.
PERRIN1,2, A. VERGER1,2, H. BOUTLEY1,2, G.
KARCHER1,2,3, P. MARIE1,2,4; 1CHU NANCY Hopital
Brabois Adultes, Vandoeuvre-lès-Nancy, FRANCE,
2Nancyclotep experimental imaging platform, Nancy,
FRANCE, 3CRAN, UMR 7039, Université de Lorraine -
CNRS, Vandoeuvre-lès-Nancy, FRANCE, 4INSERM,
U1116, Nancy, FRANCE.
High effective doses, around 29 mSv, constitute a main limit
for myocardial perfusion SPECT imaging (MPI) scheduled
with a dual 99mTc/201Tl radionuclide method on convention-
al cameras. This study was aimed at assessing a lower dose
dual radionuclide MPI method applied on a CZT camera with
a stress first 99mTc-Sestamibi MPI followed only if necessary
by a rest 201Tl one.Methods. Eighty-two patients, who had a
low dose stress MPI with 99mTc-Setamibi on a CZT camera
and for whom a rest 99mTc-Setamibi MPI was subsequently
prescribed, also had as a part of the protocol, a rest-MPI
with201Tl (36 to 63 MBq) at one hour from stress imaging.
The 201Tl images were processed for spill-over and scatter
corrections and uptake differences with stress-MPI were ana-
lyzed: 1) for the 201Tl (ΔTl) and 99mTc-Sestamibi (ΔTc) rest
acquisitions and 2) in segments for which a definite diagnosis
of ischemia or necrosis was achieved with the combined anal-
ysis of 99mTc-Sestamibi SPECT and gated-SPECT. Results.
Mean effective dose was 13.9±1.4 mSv for the dual radionu-
clide procedure.ΔTl was dramatically higher in the 42 ische-
mic segments than in the 89 necrotic ones (14.5±10.2% vs. 6.5
±8.9%, p<0.001). However, the corresponding uptake levels
were much lower for ΔTc (8.4±6.4% and 2.5±7.2%, respec-
tively, p<0.001 for all comparisons), presumably because of
the higher background counts of 201Tl compared to 99mTc
rest images (background-to-myocardium count ratio: 0.33±0.9
vs. 0.27±0.15, p<0.001). Finally, the best threshold to separate
ischemic from necrotic segments was higher for the dual ra-
dionuclidemethod (ΔTl > 13%) than for the single 99mTc one
(ΔTc>8%). Conclusion. A dual 99mTc/201Tl radionuclide
method may be applied on last-generation CZT cameras with
a ≥ 50% decrease in radiation doses, compared with conven-
tional protocols (14 vs. 29 mSv). However, this stress-first
99mTc-Setamibi protocol requires adapting diagnostic criteri-
on to the higher noise level of 201Tl rest images.
P393
Evaluation of simultaneous Tc-99m and I-123 dual-isotope
SPECT imaging using cardiac CZT camera
T. Niimi1, M. Sugimoto1, M. Nanasato1, H. Maeda2; 1Na-
goya Daini Red Cross Hospital, NAGOYA, JAPAN, 2Nagoya
University, NAGOYA, JAPAN.
Purpose: A recently introduced, high-speed, single-photon
emission computerized tomography (SPECT) device based
on cadmium-zinc-telluride (CZT) detectors (D-SPECT;
Spectrum Dynamics, Israel) shows high-sensitivity collima-
tion and high-energy resolution for cardiac imaging. In partic-
ular, its high-energy resolution provides a new possibility for
simultaneous dual-isotope SPECT imaging, such as using Tc-
99m and I-123 (Tc-99m/I-123), which was impossible in the
conventional Anger SPECT (A-SPECT).We assessedwhether
the simultaneous Tc-99m/I-123 dual-isotope SPECT imaging
of D-SPECTwas accurate using phantom experiments. Mate-
rials and Methods: We evaluated the energy resolution such as
for Tc-99m, I-123, and Tl-201 of D-SPECT by phantom ex-
periments using a simultaneous dual-isotope (SDI) phantom.
Corresponding measurements of Tc-99m and I-123 were also
performed on an A-SPECT. The full width at half maximum
(FWHM), which is an index of energy resolution, was mea-
sured using a tube phantom (line sources) placed at the same
locations in each system. Simultaneously, the Tc-99m/I-123
and Tl-201/I-123 data were acquired in energy windows cen-
tered at 140 keV for Tc-99m, 159 keV for I-123, 167 keV for
the upper Tl-201 line (10%), and 69-80 keV for the main Tl-
201 emission. The data from these energy windows were ob-
tained using the CZT or Anger camera acquisition system at
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the same time. Results: The energy resolution (FWHM) values
of the D-SPECT system for Tc-99m/I-123 and Tl-201/I-123
were 5.5%/5.2% and 10.9%/5.2%, respectively; the corre-
sponding values in A-SPECT for Tc-99m/I-123 were 9.1%/
9.3%. The D-SPECTsystemwith Tc-99m/I-123 had an energy
resolution that was twice that of the A-SPECT. The influence
of cross talk on the simultaneous dual Tc-99m/I-123 SPET
imaging could not be detected by visual inspection in the
SDI phantom imaging. Otherwise, the influence of cross talk
on the SDI acquisition between Tl-201 and I-123 was caused
by the upper peak of Tl-201 (167 keV, 10%). The influence of
cross talk on the simultaneous dual Tl-201/I-123 SPECT im-
aging could be detected by visual inspection of the SDI phan-
tom imaging. Conclusion: The D-SPECT system with Tc-
99m/I-123 had better energy resolution than the A-SPECT.
The simultaneous Tc-99m/I-123 dual-isotope SPECT imaging
of D-SPECTwas reliable, which showed the further potential
of the CZT camera for SDI acquisition.
P394
Optimization of radioactive dose for dipyridamole
and exercise myocardial perfusion Gated-SPECT.
F. Ticconi1, A. Nieri1, M. Bauckneht1, G. Ferrarazzo1, F.
Fiz1, M. Pennone1, S. Morbelli1, F. Bongioanni1, C. Marini2,
G. Sambuceti1; 1Nuclear Medicine, IRCCS AUO San
Martino IST, Genova, ITALY, 2Institute Of Bioimaging and
Molecular Physiology, CNR, Milan, Genoa Section, Genova,
ITALY.
Aim: According to the fractionation principle, the ratio between
myocardial uptake (Mup) of technetium labeled tracers and cor-
responding coronary blood flow (CBF) in each segment is di-
rectly related to the ratio between administered dose and cardiac
output. Stress SPECT imaging implies tracer injection during
either exercise (EX) or pharmacological vasodilation. However,
while physical effort increases cardiac output, dipyridamole
(DIP) selectively raises CBF. Accordingly, for any given admin-
istered dose, eventual Mup should be higher under DIP than
during EX. Aim of the present study was to verify this hypoth-
esis in order to optimize injected dose according to stress proto-
col. Materials and Methods: We retrospectively analyzed 60 pa-
tients with negative single day stress/rest G-SPECT myocardial
perfusion imaging. Patients were divided into two groups based
on the type of stress test: 30 patients underwent DIP and 30 EX
stress test, respectively. For each patient sex, age, weight as well
as administered doses (MBq) at stress and rest were recorded. By
using a specific software (Myovation Evolution) a 3D-region of
interest (ROI) was drawn on the left ventricular myocardium to
estimate average and maximal counting rate as an index ofMup.
Obtained values weremultiplied for patient’s weight and divided
for administered dose. Results: Mup index significantly
increased from rest to stress both in EX (0.09±0.03 to 0.14
±0.04, p<0.01) and in DIP patients (0.10±0.04 to 0.13±0.04,
p<0.05). No significant difference was observed in stress Mup
index between the two groups. However, % increase of Mup
index was higher in EX patients with respect to DIP ones (175
±65% vs 129±46%, respectively, p<0.01). Conclusions: EX and
DIP result in similar Mup values. Tracer retention increases even
more during physical exercise than under DIP despite the obvi-
ous difference in cardiac output response to the two stressors.
These data do not support the rationale to reduce radioactive
dose in case of pharmacological vasodilation.
P395
Reference values for right ventricular and lung uptake
in relation to left ventricular uptake in 99mTc-tetrofosmin
myocardial perfusion SPECT/CT imaging
T. M. Laitinen1, A. Corovai1,2, H. Hämäläinen1,2, T.
Laitinen1,2; 1Kuopio University Hospital, Kuopio, FIN-
LAND, 2University of Eastern Finland, Kuopio, FINLAND.
Aim: According to current guidelines, adequate interpretation of
myocardial perfusion study includes review of tomograms, left
ventricular ejection fraction and volumes but also visual inter-
pretation of lung uptake and right ventricular uptake from raw
data. Increased lung uptake and right ventricular uptake are
thought to reflect reduction of cardiac function, right ventricular
hypertrophy or generalized reduction of left ventricular uptake.
Interpretation of lung and right ventricular uptake based on
inspection of raw data is just approximate and therefore addi-
tional quantitative analysis might be useful, especially in cases
with borderline abnormality. The aim of this study was to define
reference values for quantitative measures of lung uptake and
right ventricular uptake in relation to left ventricular uptake
(lung to left ventricular uptake ratio [L/LV] and right ventricular
to left ventricular uptake ratio [RV/LV]).Materials and methods:
We evaluated data of 384 consecutive patients who were sent to
99mTc-tetrofosminmyocardial perfusion SPECT/CTstudy dur-
ing the year 2012 in the Department of Clinical Physiology and
Nuclear Medicine, Kuopio University Hospital. Exclusion
criteria were 1) previously diagnosed cardiac disease, 2) abnor-
mal ECG at rest, 3) signs of advanced coronary artery calcifi-
cation in CT, and 4) abnormal myocardial perfusion in stress/
rest myocardial perfusion SPECT study. Final study population
consisted of 48 subjects (38 women and 10 men) aged 42-84
years. Also 5 patients with severe heart failure were used to
validate the reference values. Transverse reconstructions with
attenuation and scatter compensation were made. Regional up-
takes were calculated for left ventricular wall, right ventricular
wall and lungs as an average of respective ROIs in two repre-
sentative slices.Results: Age, gender, blood pressure and body
mass index did not correlate statistically significantly with L/LV
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and RV/LV. At rest an average L/LVwas 0.149 and RV/LV was
0.400. According tomean + 2SD, limit of the highest normal for
L/LV was 0.219 and for RV/LV 0.550. Among the 5 heart
failure patients, 4 had abnormal L/LVand 2 had abnormal RV/
LV. Only 1 patient had both L/LV and RV/LV within the refer-
ence limits.Conclusions: We report reference values for L/LV
and RV/LV, which demonstrate quite well increased lung and
right ventricular uptake in heart failure patients according to the
preliminary results.
P396
Comparison of Phase analysis among three kinds
of soft-ware (QGS, ETB and Heart function view)
in diagnosing ischemic heart disease
S. Nagamachi, MD1, H. Onizuka, MD2, R. Nishii, MD1, Y.
Mizutani, MD1, T. Hirai, MD1, K. Kitamura, MD3; 1Depart-
ment of Radiology, MIyazaki University,, Miyazaki, JAPAN,
2Department of 1st Internal Medicine, Miyazaki University,,
Miyazaki, JAPAN, 3Department of 1st Intenal Medicine, Mi-
yazaki University,, Miyazaki, JAPAN.
(Background and Purpose) For differentiating myocardial
Dyssynchrony, various software is available evaluating phase
analysis. However, there are few reports addressing the com-
patibility of phase analysis indexes calculated by each soft-
ware. In the current study, we compared the phase analysis
indexes of the same patient data of Tl-201 myocardial gated
SPECT using by ETB, HFV and QGS2006 retrospectively.
Then we evaluated the compatibility of phase analysis indexes
calculated among QGS2006, ETB, and HFV. (Methods) The
patients included 97 cases (70 men, women 27, average age
71.4 years old) those gated Tl-201 myocardial SPECT were
conducted for the purpose of differentiating ischemic heart
disease. We calculated both Band Width (BW) and phase SD
(SD) by using three kinds of software and compared each
correlation, %difference and Bland-Altman plot analysis. In
addition, we divided all patients into the normal group, the
ischemia group, the infarction group, the infarction with ische-
mia group. Then we compared the phase analysis indexes
among four groups both at rest and at stress condition.
(Results) The correlation of the phase analysis indexes among
three kinds of software at stress was moderate ( from 0.49 to
0.64). However, they deteriorated at rest conditions (from 0.27
to 0.49). Around 40-50% of % differences in phase SD or BW
were noted among three groups. They increased on the de-
layed images around 50-60%. By Bland-Altman plot analysis,
both indexes tended to be higher at rest conditions, and 95%
CI distributed over the range of +/-30 degrees at stress and +/-
45 degrees at rest. When we compared the phase analysis
indexes among ischemic patients, both values of SD and BW
in the infarction and ischemia group were significantly higher
than those of normal group or ischemia group. Although some
differences were noted among three kinds of software, both the
infarction group and the infarction with ischemia group
showed highest values at stress and at rest conditions. How-
ever, any statistical significance was not noted between the
ischemia and the normal group in three kinds of software.
(Conclusion) In the phase analysis on Tl-201myocardial gated
SPECT, the compatibilities of phase analysis indexes were fair
in ETB, HFV and QGS2006. However, we should use three
kinds of software in considering the limit of their
compatibilities.
P397
Assessment of left ventricular function with a fast low-dose
recording protocol planned on a semi-conductor
gamma-camera
M. Claudin, Sr., W. Djaballah, Sr., L. Imbert, Sr., N. Veran,
Sr., S. Poussier, Sr., V. Roch, G. Karcher, Sr., P. Marie, Sr.;
Centre hospitalo-universitaire de Nancy, Vandoeuvre-les-Nan-
cy, FRANCE.
Introduction. New gamma cameras, equipped with Cadmium-
Zinc-Telluride (CZT) semiconductor detectors, provide an en-
hanced image quality, as well as an enhanced count sensitivity
allowing to reduce imaging time and injected doses. The pur-
pose of this study was to compare the assessment of left ven-
tricular function obtained through a fast low-dose recording
protocol on a CZT camera (the “D-SPECT” camera) with the
reference assessment obtained through cardiac MRI.Methods.
We retrospectively included patients with known or suspected
cardiomyopathy and who had undergone both: 1) myocardial
perfusion imaging (MPI) on D-SPECT camera with a low-
dose protocol (120MBq of Sestamibi-99mTc for stress and
360 MBq at rest for a body weight of 75 kg) and 2) a cardiac
MRI at a < 2-months interval time fromMPI. The left ventric-
ular function was assessed at rest MPI with 8-interval-frames
and by using the QGS® software.Results. Seventy-seven pa-
tients were included among whom, 43 (66%) had an history of
myocardial infarction. Mean ejection fraction was 45±13% at
MRI (from 12 to 69 %). For the D-SPECT recordings, on
average, myocardial activity was 527±104 kcps, recording
time, 3.5±2.2 min and total injected activity (stress and rest),
420±185 MBq, corresponding to an effective dose of 3.7±1.6
mSv.Correlations between D-SPECTandMRI were very good
to excellent for ejection fraction (r=0.88) and for end-diastolic
(r=0.90) and end-systolic (r=0.96) volumes, but with signifi-
cant underestimations (-5% for ejection fraction, -16% for end-
d i a s t o l i c v o l ume a n d - 2 4% f o r e n d - s y s t o l i c
volume).Conclusion. The evaluation of left ventricular func-
tion using this CZT camera and a fast low-dose protocol cor-
relates well with the reference assessment provided by cardiac
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MRI, even if volumes and ejection fraction remain
underestimated, similarly to what was previously documented
with conventional Anger cameras.
P398
Long-term survival of patients with manifested coronary
artery disease with and without diabetes undergoing
myocardial viability assessment.
G. Rendl , P. Keinrath, K. Krommes, G. Barth, J.
Holzmannhofer, C. Pirich; Department of Nuclear Medicine
and Endocrinology, Paracelsus Medical University Salzburg,
Salzburg, AUSTRIA.
Aim: to analyze the impact of myocardial viability assessment
on survival might improve clinical decision making in patients
with manifested coronary artery disease (CAD) with potential
implication on survival. Material and Methods: 80 patients (9
females and 71 males) with a mean age of 71.3 ± 9.8 years
were included in this study. All patients with angiographically
documented coronary artery disease underwent myocardial
perfusion scintigraphy using Tc99m-tetrofosmin and imaging
of myocardial viability by F-18 FDG PET/CT using combina-
tion of hyperinsulinemic-euglycemic clamp protocol in com-
bination with acipimox. 12 patients had 1 vessel disease (VD),
15 patients 2 VD and 49 patients 3 VD, respectively. Revas-
cularization was intended when the amount of hypoperfused
but viable myocardium exceeded 10 % of left ventricular area.
Results: Mean follow-up was 62.4 ± 33.2 months after viabil-
ity testing.Median survival was 69.3months (95 CI: 60.1-77.9
months) in non-diabetics as compared to 46.5 months (95 CI:
32.7-60.3 months) in patients with diabetes (p=0.003). Diabet-
ic patients had fewer percent of scar tissue (16.0 ± 12.0) as
compared to non-diabetics (25.7± 18.7), while the amount of
hypoperfused and viable myocardium was not significantly
different (14.5 ± 12.6 vs. 9.8 ± 12.0). Patients with diabetes
had significantly more commonly 3 vessel disease than pa-
tients without diabetes (83 % vs. 52 %). The number of revas-
cularization in patients with and without diabetes was statisti-
cally not significantly different (71 % vs. 54 %). Conclusion:
CAD patients with diabetes exhibited significantly shortened
overall survival compared to patients without diabetes though
having less scared and equal amounts of viable myocardium as
indicated by PET.
P399
Is CMR reproducible enough to replace Gated Blood Pool
SPECT for the follow-up of RVEF?
T. Giraudmaillet1, F. Mokrane2, C. Zadro2, H. Rousseau2, L.
DERCLE3; 1CHU Toulouse, Toulouse, FRANCE, 2CHU
TOULOUSE, TOULOUSE, FRANCE, 3Gustave Roussy,
Villejuif, FRANCE.
PURPOSE: The estimation of right ventricular ejection frac-
tion (RVEF) is crucial in order to establish the diagnosis, the
risk stratification, the prognosis, and the response to treatment
in a wide range of heart disease. Cardiac MagneticResonance
Imaging (CMR) is the reference-standard for the evaluation of
RV volumes but the manual delineation of endocardial border
leads to a significant operator-dependency. This report inves-
tigates if new MRI techniques are reproducible enough to be
considered as the reference-standard for the follow-up of
RVEF (in 12 subgroups of heart disease), in comparison with
the most reproducible technique: gated blood pool single pho-
ton emission computed tomography (GBPS). METHOD
AND MATERIALS: 94 CMR and 99 GBPS were measured
by two physicians. GBPS was performed using 2 automatic
algorithms: BP-SPECT and QBS and a semi-automatic algo-
rithm: TOMPOOL. Relative Inter-Observer Variability (IOV)
was defined as the absolute difference between the two calcu-
lated measurements normalized to their average and expressed
as a percentage. RESULTS: The overall IOV (%) was greater
using semi-automatic GBPS procedure (TOMPOOL: 16
±20%) than CMR (12±14%) or automatic GBPS algorithm
(QBS: 8±12%, BP-SPECT: 6±6%). The IOV of CMR chal-
lenged GBPS in 2 subgroups of heart disease treated arrhyth-
mia (6±5% vs 8±9%) and hyperdynamic cardiomyopathy /
cirrhosis (4±3% vs 4±4%). Overall, the IOV on CMR was
especially important in comparison with GBPS in dilated car-
diomyopathy (20±20% vs 4±2%), LVEF<50% (17±18% vs 6
±4%), RVEF<45% (20±18% vs 7±6%), and left or right valve
dysfunction (17±20% vs 5±3%). CONCLUSION: The most
reproducible procedure is automatic GBPS. Changes occur-
ring during the follow-up should be interpreted cautiously on
CMR (IOV: 12%) or semi-automatic GBPS (IOV: 16%) in
case of valve regurgitation, altered ejection fraction and en-
largement of the left ventricle. The reproducibility of CMR
challenged GBPS in treated arrhythmia and hyperdynamic
heart disease.
P400
How the change in time interval between 99mTc-sestamibi
injection and image acquisition may effect on quantitative
data of gated SPECT myocardial perfusion imaging
at stress phases
M. Haghighatafshar1, S. Entezarmahdi2, S. Mortazavi1, F.
Khajerahimi1; 1NuclearMedicineDepartment, Shiraz Univer-
sity ofMedical Science, Shiraz, IRAN, ISLAMICREPUBLIC
OF, 2Radiation Medicine Engineering Department, Shahid
Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC
OF.
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According to several recent studies in favor of delayed 99mTc
methoxy-isobutyl-isonitrile (99mTc-MIBI) redistribution, the
aim of this study was to find whether different time intervals
between 99mTc-MIBI injection and image acquisition could
affect quantitative data of Gated-SPECT myocardial perfusion
imaging (MPI). Sixty Patients with known pretest probability
of coronary artery disease according to “Framingham Risk
Score” enrolled in the study. Myocardial perfusion imaging
with Gated-SPECT was performed on the basis of two-day
protocol. The stress-phase imaging repeated four times after
15, 60, 120, and 180 minutes post injection of 99mTc-MIBI.
The injected dose was 666 to 814 MBq according to the pa-
tients’ weight. All the images were reconstructed and filtered
in the same way. The reconstructed images were analyzed by
Corridor-4DM software package. The quantitative data was
extracted and compared. Results showed that the calculated
end diastolic and systolic volumes (EDV, ESV) change statis-
tically significant in an upward. As the time interval increase
the calculated EDV raise 2.84 ml (p = 0.010) and the calculat-
ed ESVraise 2.35ml (p = 0.008). As both of the EDVand ESV
change almost in a same manner, their difference called stroke
volume (SV) does not change significant; while the calculated
ejection fraction decrease about 1.52 percentages (p = 0.042).
The rest of quantified parameters such as sums stress score,
sum motion score, and sum thickening score does not change
statistically significant as the time passes from the injection
point. In this work we tried to find whether delay in scanning
the myocardium with Gated-SPECT at stress phase can effect
on calculated quantitative parameters. According to the results,
just the EDV, ESV, and EF change statistically significant,
while we found that these changes are not clinically
significant.Key words: Myocardial Perfusion Image, Quanti-
tative Parameters, Redistribution
P401
Would SPECT/CT be a must for attenuation correction
in gated-SPECT myocardial perfusion imaging?
L. Ali1, A. Al-Saffar1, I. Loutfi2; 1Faculty of Allied
HealthSciences, Kuwait University, Kuwait, KUWAIT, 2Fac-
ulty of Medicine, Kuwait University, Kuwait, KUWAIT.
Introduction: Gated SPECT (G-SPECT) myocardial perfusion
imaging (MPI) using Tc-99m lipophilic chelates is universally
used for evaluation of coronary artery disease (CAD). Image
interpretation can be affected by attenuation artifacts in the an-
terior wall of the left ventricle from the breasts in women and in
the inferior wall due to diaphragm. Recently, the advent of
SPECT/CT hybrid imaging has allowed localization of lesions
and correction for attenuation especially in bone imaging. The
objective of this study was to use the CTattenuation maps in G-
SPECT/CT to allow for attenuation and to check whether it
made a significant impact on the interpretation in terms of pres-
ence and severity of the lesions. Materials and Methods: Forty-
five G-SPECT/CT MPI stress studies were selected retrospec-
tively from a pool of patients referred for evaluation of CAD.G-
SPECT/CT MPI acquisition was performed on a hybrid
SPECT/CT dual-head gamma camera (Discovery NM/CT
670). Uncorrected (NC) and corrected (AC) SPECT images
for attenuation were analyzed for presence and severity of per-
fusion defects. Seventeen and 20 segment polar maps were used
for semi-quantitation of the lesions in terms of the summed
stress score (SSS) and associated percentage count for the seg-
ments affected to the average in the total, to gauge the severity
of the lesions. The abnormalities were visually scored by 2
nuclear medicine physicians using a 4-point scale (1 normal, 2
p robab ly norma l , 3 p robab ly abno rma l , and 4
abnormal).Results: The inferior wall of the left ventricle was
the area most commonly affected by diaphragm attenuation.
In 22 (48%) of the studies, there was a difference in the visual
perfusion score.McNemar test showed that visual improvement
in perfusion with attenuation correction was seen in 29 out of 45
patients (64%) in which marked difference in perfusion were
seen in 20 patients (44%). Moderate agreement was seen (Kap-
pa = 0.60). The quantitative SSS was 10.51 ± 6.89 NC and 7.38
± 6.29 AC and the corresponding stress perfusion counts (SPC)
for the affected segments, were, 59.98 ± 10.7 (NC) vs 70.76 ±
6.61 (AC) (P<0.0005). Conclusions: Discordance between AC
and NC images in the inferior wall of the left ventricle as judged
by the readers and the quantitative analysis were sufficient to
consider G-SPECT/CTas a routine imaging approach leading to
significant change in study interpretation.
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Frequent incidental CT findings during Rubidium-82
myocardial perfusion PET
J. A. van der Heide, J. Esser, A. M. van den Berk, E. A. de
Vrey, B. J. G. L. de Smet, J. M. H. de Klerk; Meander Medical
Centre, Amersfoort, NETHERLANDS.
Background: We recently introduced Rubidium-82 myocardi-
al perfusion PET as a standard procedure at our institute for
myocardial perfusion imaging.We frequently observe inciden-
tal findings on low dose CT, performed during Rubidium-82
myocardial perfusion PET for attenuation correction.
Methods: We prospectively reported incidental findings on
low dose CT, and advised cardiologists about follow-up. Inci-
dental findings were defined as new and unexpected findings,
that were likely to require a change in patient management.
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Retrospectively, we analyzed findings during follow up; min-
imum duration of follow up was 3 months. Results: Of 815
patients (56%males) who underwent Rubidium-82 myocardi-
al perfusion PET from February 25th to December 31st 2014,
71 (8,7%; 54% males) showed incidental findings. Patients
with incidental findings were significantly older than those
without (67±10 vs 71±9 years, p=0,003). Pulmonary abnor-
malities were found in 50 patients (22 of whom had pulmonary
nodules), liver abnormalities in 4, breast abnormalities in 6,
and miscellaneous findings in 11 patients. Clinical analysis
revealed malignancy in 7 patients (4 lung, 2 breast, 1 kidney),
benign pulmonary nodules in 15, miscellaneous benign dis-
ease in 10,and no abnormalities in 3 patients. Follow-up
remained inconclusive in 9 patients. In 4 patients, follow up
is pending at the time of writing of this abstract. In 20 patients,
no follow-up was pursued by the cardiologist. Of the 7 patients
in whom previously undetected malignancy was diagnosed, 2
received therapy with curative intent, and 5 palliative/
supportive care. Conclusions: Incidental CT findings during
Rubidium-82 myocardial perfusion PET are frequent: 8,7%.
Previously undiagnosed malignancy occurred in 7 patients (0,
9%), of whom 2 received therapy with curative intent. Inade-
quate follow-up occurred in 28%. Therefore, careful examina-
tion of the low dose CT is warranted in patients who undergo
Rubidium-82 myocardial perfusion PET.
P403
The Value of Transient Ischemic Dilatation after Coronary
Revascularization
S. S. Gültekin1, M. Sadic2, M. Bilgin3, E. Yeter3, G. Koca2,
S. Açıkel3, M. Korkmaz2; 1Hacettepe University, Kastamonu
School of Medicine and Dışkapı Yıldırım Beyazıt Training
and Research Hospital, Ankara, TURKEY, 2Ankara Training
and Research Hospital, Ankara, TURKEY, 3Dışkapı Yıldırım
Beyazıt Training and Research Hospital, Ankara, TURKEY.
Aim: Transient ischemic dilation (TID) of the left ventricle on
myocardial perfusion imaging (MPI) can be used a predictor of
severe coronary artery disease (CAD) or future cardiac events.
However, the meaning of elevated TID after a cardiac revascular-
ization (CR) has not been evaluated. We investigated the value of
TID as a predictor for CAD in patients undergoing CR. Methods:
Study group consists of 104 (75m, 29 f. median and range age; 60
and 37-83 y) patients retrospectively selected from a database of
2316 patients. Patients underwent a percutaneous coronary inter-
vention (PCI) in 62/104 (60%) and a coronary artery bypass graft
operation (CABG) in 42/104 (40%) for CAD. After the prior CR,
they were evaluated due to new cardiac events by gated single-
photon emission computed tomography (GSPECT)MPI and cor-
onary angiography (CA).We examined on these data to determine
the value of TID. Results: Mean and median TID values were
1.17 ± 0.40 and 1.15 (0.65 - 3.62). There was a strong negative
correlation between TID and DLVEF values (r=0.77, p<0.01). In
addition, we determined positive correlations between TID mea-
surements with severity of CAD in GSPECT MPI (r=0.59,
p<0.01) and CA (r=0.77, p<0.01). To show meaningful CAD,
the best cut-off TID, sensitivity and specificity values were found
to be 1.16, 82% and 64% according to GSPECT MPI and 1.21,
91% and 97% according to CA, respectively. Conclusions: In
patients with CR, a high TID value was found to be well-
correlated with the meaningful CAD. It may provide additional
information to select the high risk patients.
P404
Usefulness and safety of adenosine stress myocardial
perfusion SPECT for patients with “inactive” bronchial
asthma.
T. Kasai1, M. Aiga1, Y. Iwasaki1, K. Oshima1, Y. Sasaki1, Y.
Fujita1, N. Tanaka1, A. Yamashina2; 1TokyoMedical Univer-
sity Hachioji Medical Center, Tokyo, JAPAN, 2Tokyo Medi-
cal University, Tokyo, JAPAN.
Aim: As elderly population grows, exercise stress testing tends to
be insufficient. Although adenosine is contra indication for pa-
tients with bronchial asthma (BA) in Japan, it could be used for
“inactive” BA patients safely. Materials and methods: We retro-
spectively investigated the frequency of insufficient stress testing,
adverse effects, and sensitivity to detect coronary artery disease
(CAD) in the setting of myocardial perfusion SPECT between
2011-2012 (1031 cases) and 2013-2014 (1252 cases). Invasive
coronary arteriography (CAG) was recruited as a gold standard.
Sensitivity was calculated from the patients’ data who underwent
both SPECT and CAG within 3 months. Adenosine was never
used for BA patients in the former period. On the other hand,
adenosine was positively used for “inactive” BA patients in the
latter period. “Inactive” was judged based on a medical history
check list at stress testing laboratory. Results: As for stress
methods, adenosine, exercise, and dobutamine in the former
and latter periods were 925 (89.7%) vs. 1232 (98.4%);
(p<0.001), 97 (9.4%) vs. 13 (1.0%); (p<0.001), and 72 (0.7%)
vs. 75 (0.6%); (n.s.), respectively. Exercise has been reduced and
adenosine increased in the latter period. Incidence of insufficient
stress testing was frequent in the former period (20 (1.9%) vs. 6
(0.5%); p=0.001). BA patients were involved more in the latter
period (19 (1.8%) vs. 60 (4.8%); p<0.001), and insufficient stress
testing was also frequent in the former period (7 (36.1%) vs. 5
(8.1%); p<0.05) among BA patients. No severe adverse effects
were observed. Sensitivity for detection of CAD was superior in
the latter period (84.1% vs. 67.4%, p<0.001). Conclusion: Aden-
osine stress myocardial perfusion SPECTcan be performed safe-
ly for patients with “inactive” BA and improves diagnostic
sensitivity.
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Contraction synchronicity and work measured in patients
with coronary artery disease
T. Niimi1, M. Nanasato1, H. Maeda2; 1Nagoya Daini Red
Cross Hospital, NAGOYA, JAPAN, 2Nagoya University, NA-
GOYA, JAPAN.
Purpose: The regional contraction synchronicity and
work were evaluated in patients with a reduced ejection
fraction due to coronary artery disease (CAD). Mate-
rials and Methods: We evaluated 104 patients (54 with
CAD a n d 5 0 n o rm a l c o n t r o l s ) u s i n g r e s t
electrocardiographic-gated 99mTc-tetrofosmin single-
photon emission computed tomography (ECG-SPECT).
The contraction amplitude, synchronous contraction in-
dex (SCI), and contraction work were evaluated using
the quantification of a segmental function by solving
the Poisson equation (QSFP). The cardiac wall was
divided into 17 segments, and the accumulation of per-
fusion agents, contraction amplitude, SCI, and contrac-
tion work were calculated for each segment and plotted
on polar maps. Results: The QSFP accuracy was
thought to be satisfactory compared to that of quantita-
tive gated SPECT (QGS) for the measurement of the
left ventricular ejection fraction (LVEF), which had a
correlation value of 0.92. The average contraction am-
plitude, SCI, and contraction work values in the 17
segments were 33.8% ± 4.1%, 96.6% ± 1.4%, and
6.9 ± 1.0 mJ·cm^−2/beat, respectively, in the normal
individuals, and 26.1% ± 7.3%, 82.1% ± 16.8%, and
5.4 ± 1.6 mJ·cm^−2/beat, in the patients with CAD.
These values were 17.9% ± 4.0%, 63.0% ± 18.4%,
and 3.5 ± 1.1 mJ·cm^−2/beat in CAD patients with
LVEF < 40% (n = 14). The contraction amplitude,
SCI, and contraction work were significantly lower in
patients with CAD than in the controls (p < 0.005),
and were also significantly lower in the CAD patients
with LVEF < 40% (n = 14) compared to the mean of
the patients with CAD (p < 0.05). The contraction am-
plitude, SCI, and contraction work showed good corre-
lation with LVEF in patients with CAD, with values of
0.91, 0.78, and 0.88, respectively. Areas of LV
dyssynchrony could be visually delineated on the polar
maps. Conclusion: The LV dyssynchrony associated
with CAD could be detected using the contraction am-
plitude and SCI, and the mechanical work during
dyssynchrony could be determined as the value of the
contraction work. Moreover, these values could be a
useful tool for the early detection of CAD, and also
clarify the process for decreasing the LVEF. An assess-
ment of myocardial viability from a mechanical per-
spective provides a more accurate diagnosis.
P406
Effect of Methamphetamine on perfusion and functional
indices of the left ventricle using gated myocardial
perfusion SPECT
V. Dabbagh, B. Dadpour, R. Afshari, S. Mohajeri; Mashhahd
University of Medical Sciences, Mashhad, IRAN, ISLAMIC
REPUBLIC OF.
Background: Prevalence of methamphetamine abuse in-
creased quickly in these years. According to researches,
methamphetamine abuse has adverse effects on func-
tional statue of myocardium. Most of the studies inves-
tigate the effects of methamphetamine on nervous sys-
tem and few studies assessed myocardium effects of
methamphetamine. In our study we evaluated effects
of methamphetamine on perfusion and functional status
of myocardium of the left ventricle using gated myo-
cardial perfusion SPECT.Method: In a cross sectional
study we studied 13 abuser of methamphetamine. Inclu-
sion criteria were: 1. one year using of methamphet-
amine; 2. Positive urine test; 3. Dependency to meth-
amphetamine according to DSM IV criteria. Exclusion
criteria were: 1. History of congenital heart disease; 2.
History of heart disease before starting methamphet-
amine abuse; 3. Pregnancy. Demographic data (age
and sex) and information about methamphetamine abuse
(period of addiction and amount of that) was obtained
and after that Two-day Dipyridamole stress/rest gated
myocardial perfusion SPECT was done. Qualitative
and quantitative analysis was performed using 17-
segment scoring system, QPS and QGS software. Re-
sults: Thirteen abuser of methamphetamine (mean age
39.9 ± 9.5 years) participated in our study. The average
use of methamphetamine was 0.9 gr and average period
of addiction was 3.4 years. All participants reported
daily use of methamphetamine. No evidence of ische-
mia and infarction was seen on gated myocardial per-
fusion SPECT of participants. Ejection fraction, end
systolic volume and end diastolic volume of gated
myocardial perfusion SPECT in all participants reported
in normal range in both stress and rest steps (Stress
step: respectively mean ± SD: 63.8 ± 8.9, 29.1 ±
10.9 and 78.6 ± 16.6; Rest step: respectively mean ±
SD: 60.1 ± 8.1, 35.8 ± 11.8 and 88.0 ± 16.2). Also
average of myocardial thickening score and myocardial
motion score of gated myocardial perfusion SPECT in
both steps was in normal range.Conclusion: according
to our results, methamphetamine abuse can’t lead to a
significant perfusion abnormality on GSPECT and
therefore, dilated cardiomyopathy that was reported in
most of the studies may be related to other causes or
longer period of methamphetamine consumption.
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Activity of cardiac sympathetic nervous system in patients
with atrial fibrillation before and after catheter ablation
B. Chrapko, M. Pachowicz, A. Głowniak, A. Nocuń, M.
Wójcik, A. Wysokiński; Medical University of Lublin, LU-
BLIN, POLAND.
The cardiac sympathetic dysfunction is observed in arrhyth-
mogenic disorders. Aim: We investigated the activity of cardi-
ac sympathetic nervous system (CSNS) by use of iodine-123
meta-iodo-benzylguanidine (123I-mIBG) before and after
catheter ablation of atrial fibrillation (AF) Materials and
methods: AF group consist of 10 patients (3F/7M; age 54.2
±10.7 years). Patients in poor general condition, with diabetes
mellitus, amyloidosis and neoplastic diseases were excluded
from the study. In all patients cardiac sympathetic scintigraphy
was performed after injection of 370 MBq 123I-mIBG. Anti-
arrhythmic drugs were not withdrawn before the study in AF
patients. Cardiac sympathetic functions were evaluated semi-
quantitatively as routine heart to mediastinum ratio (H/M): 15
minute (early eH/M) and 4 hour (delayed dH/M) post admin-
istration as well as washout rate (WR). Results: Cardiac sym-
pathetic indices before catheter ablation eH/M=1.69±0.25;
dH/M=1.58±0.28, WR=49±22; after catheter ablation eH/
M=1.73±0.24; dH/M=1.71±0.33, WR=36%±24. The signifi-
cant differences were observed in dH/M (Wilcoxon test
p=0.02) and WR (Wilcoxon test p=0,009) before and after
catheter ablation. Conclusions: In patients with AF after cath-
eter ablation in adrenergic nervous function (WR) tend to nor-
malize as well adrenergic nervous distribution (dH/M).
P408
Usefulness of 18F-FDG PET-CT for Diagnosis of Cardiac
Device Infection
A. Jiménez-Ballvé1, M. J. Pérez-Castejón1, M. Martínez de
Bourio1, C. Sánchez-Enrique2, I. Vilacosta2, L. Lapeña Gu-
tiérrez1,3, E. Cala Zuluaga1, D. Vivas2, J. L. Carreras-
Delgado1,3; 1Nuclear Medicine Department, Hospital Clinico
San Carlos, Madrid, SPAIN, 2Cardiology Department, Hospi-
tal Clinico San Carlos, Madrid, SPAIN, 3Universidad
Complutense, Madrid, SPAIN.
Aim: The aim of this study was to assess the usefulness of
PET-CT with 18F-FDG in patients with cardiac device (CD)
infection, distinguishing between local device infection and
cardiac device-related infective endocarditis. Materials and
methods: In this prospective study we included 21 patients
with suspicion of having CD infection from April 2013 to
March 2015. Duke criteria were used to classify them into
definitive or possible infective endocarditis (IE); and clinical
criteria if there were local symptoms of infection over the
pocket side. PET-CT was considered positive when presented
an abnormal uptake of 18F-FDG in any portion of the CD and
persisted in the non-corrected images. We differenced three
locations of the uptake: pocket generator and local subcutane-
ous tissue, endovascular extracardiac portion and
endovascular intracardiac portion of the electrode. It was con-
sidered negative when 18F-FDG uptake was not evidenced or
did not persist in the non-corrected images. Anatomy was the
gold standard in patients who underwent cardiac surgery. In
those cases without removal of the CD, final diagnosis was
done by clinical consensus of the endocarditis team (indepen-
dently from the PET-CT results). Results: The initial suspicion
reported 10 (48%) possible IE, 8 (38%) definitive IE and 3
(14%) cutaneus/superficial CD infection. PET-CTwas positive
in 12/21 (57%) patients: 6 with endovascular intracardiac elec-
trode uptake, 1 with endovascular extracardiac electrode up-
take, 4 with uptake in both pocket and endovascular
extracardiac electrode and 1 with uptake over the three parts
of the CD. In the other 9 (43%) cases, PET-CTwas negative. In
4 patients, PET-CT also showed extracardiac findings compat-
ible with septic emboli (3 in lung, 1 spondylodiscitis and 1 in
spleen). Anatomy diagnosed 6 IE, 3 pocket infection and
rejected 1 IE. Final diagnosis by clinical team was of 2 defin-
itive EI and dismissed infection in other 2 patients. Comparing
with final diagnosis, PET-CT results were true positive in 10,
true negative in 9, and false positive in 2. There were no false
negatives cases. Conclusion: This preliminary data suggest
that PET-CT could be a good diagnostic tool in the diagnosis
of CD infection and IE related to it.
P409
Cardiac 99mTc-DPD uptake in subjects with Glu89Gln
transthyretin genemutation: is it the earliest sign of disease
development?
F. Minutoli1, A. Mazzeo1, G. Di Bella1, A. Sindoni2, L.
Gentile1, G. Vita1, S. Baldari1; 1University of Messina, Mes-
sina, ITALY, 2AOU “Policlinico P. Giaccone”, Palermo,
ITALY.
AIM: Many transthyretin (TTR) gene mutations are
amyloidogenic being responsible for systemic deposition of
TTR variants, especially in the peripheral nervous system
and heart. A considerable phenotypic variation originates from
different TTR gene mutations. Presenting symptoms in pa-
tients with Glu89Gln TTR gene mutation are related to periph-
eral and autonomic nervous system damage; nevertheless,
Glu89Gln TTR gene mutation seems to be responsible for
early and severe cardiac involvement. The aim of our study
was to evaluate the capability of 99mTc-3,3-diphosphono-1,2-
propanodicarboxylic acid (DPD) scan to detect cardiac
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amyloid deposition in asymptomatic subjects with Glu89Gln
TTR gene mutation as an early sign of amyloidosis develop-
ment. MATERIALS AND METHODS: Seven asymptomatic
subjects (3M and 4F; mean age 42 years) with Glu89Gln TTR
gene mutation, normal values of cardiac biomarkers (N-termi-
nal pro-B-type natriuretic peptide (NT-proBNP) and troponin-
I), and no electrocardiographic or echocardiographic signs of
amyloidosis were enrolled in the study. Each subject
underwent 99mTc-DPD scintigraphy at enrollment and was
followed-up by cardiological and neurological clinical exam-
inations, electrocardiography, echocardiography and measure-
ment of cardiac biomarkers yearly for 5-8 years. Scintigraphic
images were analyzed visually according to a routine scoring
system: grade 0, no abnormal localization of the radiotracer;
grade 1, myocardial radiotracer uptake lower than bone up-
take; and grade 2, myocardial radiotracer uptake higher than
bone uptake. RESULTS: In two patients, 99mTc-DPD scan
revealed grade 2 radiotracer uptake; this finding preceded the
appearance of instrumental or laboratory signs of cardiac am-
yloidosis and of neuropathic symptoms which developed in
the following 2 years. On the other hand, five patients showed
no cardiac 99mTc-DPD accumulation; instrumental or labora-
tory signs of cardiac amyloid deposition appeared only in 3/5
patients 4-8 years later whereas neuropathic symptoms ap-
peared in 4/5 patients 2-6 years after normal 99mTc-DPD
scan. CONCLUSION: Cardiac uptake of 99mTc-DPD may
precede clinical, instrumental or laboratory signs of amyloid-
osis; it may represent the earliest sign of amyloidosis in sub-
jects with Glu89Gln TTR gene mutation.
P410
The prognostic role of Fetuin-A serum levels in patients
with Coronary Artery Disease. Corellation
with myocardium scintigraphy.
A. Zissimopoulos1, A. Psomiadou2, L. Baloka2, E.
Karathanos1, A. Thomaidou3; 1Nuclear Medicine Depart-
ment,Democritus University of Thrace, Alexandroupolis,
GREECE, 2School of Molecular Biology and Genetics,De-
mocritus University of Thrace, Alexandroupolis, GREECE,
3Cardiology Clinic, Univ. Hospital of Alexandroupolis ,De-
mocritus University of Thrace, Alexandroupolis, GREECE.
Introduction: Fetuin-A an acidic glycoprotein is produced in
the liver, as an inhibitor for cysteine protease. The gene is
founded in chromosome 3 (3q27). It is involved in various
physiological and pathological conditions. These include vas-
cular decalcification, bone metabolism, insulin resistance, pro-
tease function control, neurological illnesses, and multiplica-
tion of breast cancer cells. Studies on individuals with clinical
cardiovascular disease supported that lower levels of fetuine-A
are released with coronary artery circulation (CAC) and the
function of the heart valve. Aim: The evaluation of Fetuin-A
values of the patients with coronary artery disease, as a prog-
nostic factor of the disease, in correlation with SPECT myo-
cardium scintigraphy. Patients and Methods: We studied 40
patients, 25 male and 15 female, with a mean age 48 ± 8 years
(range 36 to 69), with coronary heart disease, which were
subjected to myocardium scintigraphy, in the Nuclear Medi-
cine Dept of University Hospital of Alexandroupolis. At the
same time blood samples were drawn for the determination of
Fetuin-A Serum fetuin A levels were measured by a commer-
cially available sandwich ELISA (Epitope Diagnostics, Inc.,
San Diego, CA). Results: The average values of Fetuin-A
range between 140-297 mg/L, as it is derived from the current
bibliography and our laboratory tests. In normal individuals,
pathological values were considered to be under 140mg/ L. 25
patients with positive SPECT imaging for myocardium necro-
sis (scars) had low Fetuin values (45-148mg/ L), 10 of them
passing away within 6 months, while the rest of them were
showing an encumbered clinical condition (p<0.005). 10 pa-
tients with reversible ischemia showed relatively low values
(125-302mg/L) (p<0.005). 5 patients with a normal
myocardiac scintigraphic imaging showed normal values of
Fetuin-A (165-508mg/L) (p<0.005). Conclusions: Patients
with myocardium necrosis demonstrated very low values of
Fetuin. Patients with ischemia show low amounts while pa-
tients with a negative Scintigram for ischemia showed normal
results of Fetuin. The 10 patients that passed away in 6 months
showed very low amounts of Fetuin. Fetuin-A is supported to
be a reliable prognostic factor in monitoring patients with cor-
onary heart disease.
P411
Continued validation of metallic artefact reduction (MAR)
algorithms for reducing the likelihood of false positive
cardiac implantable device infection (CIED) investigations
M. J.Memmott, J. M. James, F. Z. Ahmed; Central Manches-
ter University Hospitals NHS Foundation Trust, Manchester,
UNITED KINGDOM.
Introduction: High and low density streak artefacts in the CT
data acquired for attenuation correction of [18F]-FDG PET/
CT studies can cause artefactual changes in the quantification
of metabolic activity around cardiac implantable electronic
devices (CIEDs). Previous phantom work at our institution
has shownmetallic artefact reduction (MAR) algorithms cause
an underestimation of SUVmax values around CIEDs, and
hence reduce the impact of these effects. Here we present an
initial patient series further evaluating the impact of these al-
gorithms on quantitation. Methods: A total of 7 patients (mean
age 70 years; 2/5 male/female) referred for evaluation of
suspected CIED infection were included in the analysis to
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date. Patients were imaged at both 90minutes and 180minutes
post administration of [18F]-FDG on a Siemens Biograph
mCT. Reconstructions were performed both with and without
the manufacturer’s MAR algorithm enabled using time-of-
flight (TOF) with 2 iterations, 21 subsets and a 5mm Gaussian
post-filter. All patients demonstrated multiple foci of uptake in
various locations along the length of the device. In total, 33
foci of interest were observed and in each case the SUVmax
was recorded in identical locations for both image reconstruc-
tions using a 1cm spherical volume of interest (VOI). Differ-
ences between the SUVmax values with and without MAR
enabled were evaluated using the Mann-Whitney U Test for
non-parametric data. Results: All foci had significantly lower
SUVmax values (p < 0.001) for the MAR enabled reconstruc-
tions, when compared to those without MAR, and correlated
well with the non-attenuation corrected (NAC) data. No foci of
interest had a higher SUVmax value on the MAR enabled
reconstructions. Conclusion: This growing patient series ex-
pands on previous case reports and phantom work which dem-
onstrate that reconstructions with MAR algorithms enabled do
not overestimate [18F]-FDG uptake in regions around CIEDs.
The likelihood therefore of false positive results in attenuation-
corrected PET images, due to CT based artefacts, is signifi-
cantly reduced. Conversely, if MAR techniques are not avail-
able the likelihood of false-positive results is significantly in-
creased; in this scenario it is imperative to use the NAC data
for reporting. These implications would also extend to patients
with metallic prosthetic valves.
P412
Correlation of QRS complex duration in 12-lead
electrocardiography and cardiac systolic asynchrony
assessed by gated SPECT myocardial perfusion imaging
M. Pachowicz , MD , K. Kosecka, A. Kocun, M.
Zarobkiewicz, A. Roszkowska, L. Swierszcz, M. Belz, MD,
B. Chrapko, MD PhD; Medical University of Lublin, Lublin,
POLAND.
Introduction: Cardiac systolic asynchrony is a major clinical
problem significantly affecting left ventricle ejection fraction
and resulting in heart failure. Aim of the study: The aim of our
study was to analyze correlation between the QRS complex
duration and cardiac asynchrony assessed by gated SPECT
myocardial perfusion imaging. Material and methods: 38 pa-
tients (all males) were enrolled into the study. 15 patients had
normal stress/rest perfusion scan (excluded cardiac ischemic
disease), 22 patients had various fixed perfusion defects. The
left ventricle function was analyzed using Corridor 4DM soft-
ware (INVIA, Ann Arbor, Michigan, USA). Rest studies were
used. Cardiac asynchrony was calculated with two protocols
provided by the software: time to peak thickening (TPT) and
time to peak contraction (TPC) and expressed as histogram
standard deviation and 95% histogram width (TPT +/-,
TPT95, TPC +/-, TPC95 respectively). The patients’ electro-
cardiograms were independently evaluated by five observers
with various experience in ECG reading. The mean QRS du-
ration was calculated for each ECG lead. The correlation was
analyzed with Spearman test. Results: There was variable pos-
itive correlation between cardiac asynchrony and QRS dura-
tion in all leads. For time to peak thickening algorithm the
strongest correlation was observed with QRS duration in lead
I (R = 0,82 for TPT +/-, R = 0,80 for TPT95; p<<0,001) as
well as aVR (R = 0,66 for both; p<<0,001) and aVF (R = 0,60
for both; p<<0,001). For time to peak contraction algorithm
the strongest correlation was observed with QRS duration in I
lead (R = 0,82 for TPC +/- and R = 0,78 for TPC95; p<<0,
001). Conclusions: In the analyzed group of patients the stron-
gest correlation between cardiac asynchrony and QRS com-
plex duration was observed in lead I, followed by aVR and
aVF. Increased QRS duration in these leads may be the stron-
gest predictor of cardiac systolic asynchrony and decreased
left ventricle ejection fraction.
P413
Equilibrium Isotopic Ventriculography in the Diagnosis
and Follow-Up of Patients with Drugs Induced
Cardiotoxicity
J. Orozco-Cortés1, I. Casáns-Tormo1, R. Díaz-Expósito1, S.
Prado-Wohlwend1, H. Bowles-Antelo1, B. Bermejo-de las
Heras2, M. Romero-Otero1; 1NUCLEARMEDICINE. HOS-
PITAL CLINICO UNIVERSITARIO, VALENCIA, SPAIN,
2ONCOLOGY. HOSPITAL CLINICO UNIVERSITARIO.,
VALENCIA, SPAIN.
OBJECTIVE: Equilibrium isotopic ventriculography (EIV) is
the most reproducible method to determine the left ventricular
ejection fraction (EF), so it is specially indicated in the assess-
ment of patients receiving potentially cardiotoxic chemother-
apy. We have evaluated our results in diagnosis and follow-up
of these patients. MATERIAL ANDMETHODS: We analyze
1,674 EIV from 2010 to 2012, obtained in the best septal LAO
projection, all of them with the same gammacamera and the
same semiautomatic processing software to determine EF. All
patients had a basal EF (bEF) ≥50% before the treatment, and
we considered as cardiotoxicity a decrease ≥10% of its bEF or
an EF<50% during treatment. We found 85 patients (84 wom-
en), with mean age 58±13 (32-88) y/old, 51.7% of them with
≥8 performed EIV, with a total of 724 EIV. The administered
treatment was trastuzumab and/or taxol (n:33-group 1) or
trastuzumab, taxol and/or antraciclines (n:52-group 2). During
follow-up, we assessed the first cardiotoxic EF (fcEF), the
highest cardiotoxic EF (hcEF) and the last one performed EF
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(lEF), establishing three groups according to the EF recovery:
complete recovery 100% compared to bEF (CR) , incomplete
recovery (IR) :<100% but with an EF ≥50%, and non recovery
(NR):EF <50%. RESULTS: The mean bEF was 62.1
±5.3%(50-76%), being ≥55% in 80/85(94.1%) of patients,
the mean fcEF:49.8±4.9%(36-61%), with a mean decrease of
19.8±6.3% from bEF. We found an EF<50%(31-49%) during
the treatment in 49/85(57%) of the patients. The mean hcEF
was 47.9±5.4%(31-61%), with a mean decrease of 23.0±8.4%
from bEF. We found EF recovery in 60/85 patients: CR(6)+
IR(54) and NR in 25 patients. Patients with EF recovery
showed higher values of bEF comparing with NR patients
(63.2±5.3 vs 59.2±3.9,p:0.001), fcEF (50.6±7 vs 47.8±4.9,
p<0.02), hcEF (49.7±4.6 vs 43.6±5.0,p<0.001) and lower de-
crease from bEF of hcEF (21.3±5.7 vs 27.2±11.8,p:0.003) and
lEF (11.4±6.8 vs 21.9±11.1,p<0.001). Between G1 and G2
there were NS differences. Patients with bEF ≥60%(n:60)
showed higher fcEF (51.4±4.3 vs 46.0±4.2, p<0.001) and
hcEF (49.2±5.5 vs 44.8±3.9, p:0.001) than patients with
bEF<60(n:25).CONCLUSION: The assessment of the EF var-
iations by EIV during treatment with cardiotoxic drugs could
detect significant decrease of EF in subclinical phase, when the
interruption of the treatment can make the recovery of the EF
possible. Necessary requisites are to have always a basal de-
termination of EF and the use of the same technical equipment
to obtain and process the images during follow-up of the
patients.
P414
Improvement in myocardial perfusion induced
by subendocardial stem cell injection in patients
with advanced heart failure
L. Lezaic1, A. Socan1, P. Kolenc Peitl1, G. Poglajen1, M.
Sever1, F. Haddad2, B. Vrtovec1; 1Klinicni center Ljubljana,
LJUBLJANA, SLOVENIA, 2Stanford University Medical
Center, LJUBLJANA, CA, UNITED STATES.
Background: Stem cell transplantation (SCT) is an emerging
treatment option in patients with advanced heart failure. Aim:
To assess potential improvement in myocardial perfusion in-
duced by subendocardial SCT. Materials, methods: In 26 pa-
tients with advanced heart failure (18 patients, nonischaemic
cardiomyopathy; 8 patients, ischaemic cardiomyopathy;
NYHA III-IV; LVEF<35%), hematopoietic stem cells
(CD34+) were peripherally collected after G-CSF stimulation
and subendocardially injected in dysfunctional, yet viable LV
areas using NOGA-XP(c) system under guidance of electro-
mechanical LV mapping and myocardial perfusion SPECT/
CT (99mTc-tetrofosmin, viability protocol with nitrate en-
hancement). A small proportion of stem cells (20%vol) was
labeled with 99mTc-HMPAO and resuspended with non-
labeled portion prior to injection. Imaging of SCT was per-
formed 1h (planar, SPECT/CT) and 18h (planar) after injec-
tion for assessment of stem cell retention and (re)distribution.
Myocardial perfusion imaging was repeated 6 months after
SCT; both series were quantified using 17-segment model
and perfusion defect scoring (0-4). Wilcoxon signed rank test
and Pearson correlation coefficient were used for data compar-
ison and correlation, as appropriate. Results: Subendocardial
injection was effective in stem cell delivery to the myocardi-
um: myocardial retention at 1h ranged from 0,3 to 23,3 (me-
dian 4,9)%. There was significant efflux of stem cells from
injection site at 18h (13,5 to 41,7%, median 32,2% of initial
retention; p<0,01). Myocardial perfusion improved signifi-
cantly with reduction in perfusion defect score (from pre-
SCT range 2 to 30 to post-SCT range 2 to 29, median pre-
SCT 10,5 to post-SCT 8,0; p<0,01). Improvement in perfusion
defect score inversely correlated significantly with stem cell
efflux from the myocardium (p<0,01, r=-0,57). Conclusion:
Subendocardial SCTappears to improve myocardial perfusion
in patients with advanced heart failure. Efflux of injected stem
cells from the delivery site is inversely correlated to perfusion
improvement.
P415
Evaluation of early changes in left ventricular volumes
in women with breast cancer treated with adjuvant
trastuzumab
C. Haase, B. Zerahn, A. Polk, D. Nielsen; Herlev Hospital,
Herlev, DENMARK.
Aim: Treatment with trastuzumab is reported to be associated
with cardiotoxicity. The purpose of this study was to evaluate
early changes in left ventricular volumes and ejection fraction
using CZT-SPECT radionuclide ventriculography during ad-
juvant treatment with trastuzumab in patients with primary
breast cancer. Materials and methods: 77 women with primary
breast cancer treated with trastuzumab as an 8 mg/kg loading
dose followed by 6 mg/kg every 3 weeks were evaluated ret-
rospectively at 6 months after initiation of treatment. The fol-
lowing variables were recorded: Left ventricular end systolic
and end diastolic volumes (LVESVand LVEDV), left ventric-
ular ejection fraction (LVEF) and the incidence of a reduction
in LVEF to ≤ 0.5 from pre-trastuzumab therapy values. LVEF
was determined by steady state 550MBq 99mTc-HSA gated
(16 frames per R-R interval, 600 beats) equilibrium radionu-
clide ventriculography with a dedicated cardiac SPECT cam-
era with CZT-detectors (Discovery 530c, GE). Results: One
patient had a LVEF of less than 0.5 at baseline and was ex-
cluded from the study. Two patients had a decline in LVEF to ≤
0.5 at 90 days follow up. These patients were subsequently
treated for heart failure. 17 patients has not yet completed 180
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S539
days follow-up. The remaining 57 had a decline in LVEF from
66.1% to 61.5 % (p<0.001) due to increases in LEDV (86.3 to
93.0ml (p< 0.001)) and LESV (29.9 to 37.0ml (p<0.001)). No
significant changes in systolic or diastolic blood pressure or
heart rate were recorded. Conclusions: In this retrospective
study we found that the decline in LVEF during trastuzumab
treatment was due to an increase in left ventricular volumes.
This finding may contribute to identify the underlying patho-
physiological mechanism behind trastuzumab cardiotoxicity.
P416
Effects of anthracycline and trastuzumab chemotherapy
on diastolic function and mechanical synchrony
V. M. Alves, T. Vieira, A. Oliveira, A. Fernandes, A. Pinto, T.
Faria, B. Perez, J. Pereira; São João Hospital Centre, Porto,
PORTUGAL.
Aim: To investigate the effects of anthracycline and
trastuzumab on left ventricular diastolic and systolic function,
including intra- and inter-ventricular systolic synchrony. Ma-
terials and methods: Thirty-four female patients from a popu-
lation with early-stage or locally advanced, HER-2 positive
breast cancer were consecutively enrolled in a retrospective
longitudinal study. These patients underwent systemic treat-
ment with chemotherapy according to five different treatment
schemes, three of them included anthracyclines. Patients re-
ceived trastuzumab for about 11 months, concurrent with or
following the chemotherapy scheme. Equilibrium radionu-
clide ventriculography (ERV) was performed before and after
chemotherapy, and subsequently every 3 months until the end
of trastuzumab (5-6 scans per patient). Informations such as:
cardiovascular risk factors, chemotherapy dosage, radiothera-
py, cardiac symptoms and trastuzumab discontinuation were
collected from the medical records. Each ERV was processed
and left ventricular ejection fraction (LVEF), heart rate (HR),
right (RV) and left (LV) ventricular peak phase, RV and LV
phase standard-deviation, peak filling rate (PFR) and time to
peak filling rate (TPFR) were collected. Inter-ventricular syn-
chrony was calculated. Baseline and post-treatment parame-
ters were compared. The difference between the lowest
follow-up LVEF and the baseline LVEF (Δlf-bLVEF) was de-
termined for each patient and correlations were performed
with baseline and others equivalent (Δlf-b) imaging parame-
ters (i.e., at the same time points as the Δlf-bLVEF) as well as
with clinical and treatment variables. Results: The mean age
was 50 years. Eleven patients were treated with anthracyclines
(doxorubicine n=6; epirubicine n=5). There was a significant
decreasing of the LVEF (mean: 69.7% vs. 64.9%, p= 0.002),
HR (mean: 80.3 bpm vs. 71.7 bpm, p<0.001), LV peak phase
(median: 169.0° vs. 155.0°, p=0.05), VD peak phase (median:
166.0° vs. 157.0°, p=0.001) and PFR (median: 3.64 EDV/s vs.
3.18 EDV/s, p=0.001) between the baseline and the post-
trastuzumab exams. No significant change was noted for
intra- or inter-ventricular synchrony parameters or TPFR dur-
ing the follow-up. The Δlf-bLVEF was only positively corre-
lated with Δlf-bLV peak phase (rs=0.346, p=0.048) and Δlf-
bTPFR (rs=0.413, p=0.017). Additionally, anthracycline che-
motherapy was associated with interventricular dyssynchrony
(p=0.028).Conclusion: Chemotherapy protocols that include
trastuzumab and eventually anthracyclines were associated
with impairment of systolic and diastolic ventricular function.
Anthracyclines regimens were specifically associated with in-
terventricular dyssynchrony.
P417
Association between body mass index and left ventricular
mechanical dyssynchrony in patients with chronic kidney
disease
V. M. Alves, A. Fernandes, T. Vieira, A. Oliveira, A. Pinto, T.
Faria, B. Perez, J. Pereira; São João Hospital Centre, Porto,
PORTUGAL.
Introduction: End-stage kidney disease is independently asso-
ciated with left ventricular mechanical dyssynchrony
(LVMD), which provides an important prognostic value in this
population. LVMD has also been found in patients with met-
abolic syndrome (diabetic or not) or with obesity. The aim of
this study was to find any association between body mass
index (BMI) and LVMD in two different populations: chronic
kidney disease (CKD) and non-CKD patients. Methods: We
conducted a retrospective analysis of consecutive patients who
performed 99mTc-tetrofosmin gated myocardial perfusion im-
aging (g-MPI), with adenosine stress testing, in a 2-day proto-
col, during 2013. We included every patient who presented
with normal left ventricular perfusion and function (summed
stress score=0; ejection fraction ≥45%, respectively). The ex-
clusion criteria were heart disease, arrhythmia, conduction
(namely QRS >120ms) and repolarization disorders, electro-
cardiographic criteria of left ventricular hypertrophy, heart
transplantation and poor quality g-MPI scans. The following
data were collected from the medical records: demographics,
weight, height, cardiovascular history, current therapy and
global and regional LV function parameters at stress (QGS/
QPS® software). LVMD at stress [phase standard-deviation
(PSD) and histogram bandwidth (PHB)] were obtained by
reprocessing of the g-MPI on the Emory Cardiac Toolbox®
software. We analyzed the association between LVMD and the
variables included, before and after stratification by CKD. Re-
sults: Twenty-nine patients were included (14 females; mean
age: 56±16 years; mean BMI: 25.0±5.1; 15with CKD; 17with
hypertension; 10 with diabetes, 13 with dyslipidemia; 6 with
peripheral arterial disease, and 5 smokers). Dyssynchrony pa-
rameters were similar for CKD and non-CKD groups (PSD:
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10.2 vs. 11.4, p=0.278; PHB: 33.5 vs. 37.1, p=0.342; respec-
tively).We found an association between LVMD and BMI, but
only in the CKD group (PSD vs. BMI: rs=0.532; p=0.041;
PHB vs. BMI: rs=0.596; p=0.019). We found no association
between LVMD and the remaining cardiovascular risk factors,
even after stratification by CKD. Conclusion: In a population
of CKD patients without heart disease, LVMD was not in-
creased, but we found a positive association between BMI
and LVMD. Additional studies may disclose a synergic effect
between overweight and CKD on the development of LVMD.
P418
Post-stress worsening of LV mechanical dyssynchrony is
more frequent in CAD patients but has low diagnostic
accuracy
Y. Chang, C. Hsu; Kaohsiung Chang Gung Memorial Hospi-
tal, Kaohsiung City, TAIWAN.
Aim: Previous studies showed that myocardial ischemia in-
duces post-stress worsening of left ventricular mechanical
dyssynchrony (LVMD) obtained from thallium-201 (Tl-201)
gated SPECT myocardial perfusion imaging (MPI). The dif-
ferent dyssynchrony pattern between ischemic and normal
myocardium at early post-stress may aid the diagnosis of cor-
onary artery disease (CAD). The aim of this study is to assess
the accuracy of stress-induced LVMDworsening, either global
or territorial, in the diagnosis of CAD. Materials and Methods:
The Tl-201 gated MPI data of 74 patients were retrospectively
analyzed. All patients received coronary angiography with at
least 50% luminal diameter narrowing as significance of CAD.
The perfusion images were interpreted by two experienced
observers in consensus. Two LVMD parameters, phase histo-
gram bandwidth (PHB) and phase standard deviation (PSD),
were calculated territorially and globally. Patients showed
post-stress increasing in either PSD or PHB, were defined as
post-stress worsening of LVMD.Results: Among the 74 pa-
tients, 52 patients had significant coronary artery stenoses
(CAD patients) and 22 patients had no significant CAD (nor-
mal patients). In normal patients, the global post-stress LVMD
parameters were significant lower as compared to LVMD pa-
rameters at rest (PSD 8.88 vs 11.52, p<0.01 and PHB 34.1 vs
45.3, p<0.01, respectively). In CAD patients, only post-stress
PSD were significantly lower than rest PSD (9.73 vs 11.18,
p<0.05).Global post-stress worsening of LVMDwas observed
in 3 of 22 normal patients (13.6%) and was more frequent in
CAD patients (22 of 52, 42.3%, p<0.01). On territory-based
analysis, post-stress worsening of LVMD was observed in 19
territories (19/66, 22.3%) of normal patients. There were more
frequently noted in CAD patients at either coronary stenotic
territories (47/102, 46.1%, p<0.01) or remote normal terri-
tories (26/54, 48.1%, p<0.01).By using perfusion defect in
any one vessel territory as criteria, the sensitivity, specificity,
and accuracy for CAD were 92.3%, 81.8%, and 89.2%, re-
spectively. By using global stress-induced worsening of
LVMD parameters, the sensitivity, specificity, and accuracy
for CAD were 51.9%, 81.8%, and 60.8%, respectively. By
territory-based analysis of LVMD parameters, the sensitivity,
specificity, and accuracy for CAD were 78.8%, 54.5%, and
71.6%, respectively.Conclusion: Stress-induced worsening
LV mechanical dyssynchrony, either globally or territorially,
was observed more frequently in patients with CAD. Howev-
er, the diagnostic accuracy of stress-induced worsening of LV
mechanical dyssynchrony for coronary artery stenosis was
low.
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Test-retest reproducibility of adenosine A1 receptor
imaging in rats, using microPET, the tracer 11C-MPDX,
repeated arterial blood sampling and kinetic modeling
J. W. A. Sijbesma1, X. Zhou1, J. Doorduin1, M.
Houwertjes2, C. Kwizera1, B. Maas1, P. Meerlo3, R. A. J.
O. Dierckx1, R. H. J. A. Slart1, P. H. Elsinga1, A. Van
Waarde1; 1University of Groningen, University Medical Cen-
ter Groningen, Department of Nuclear Medicine and Molecu-
lar Imaging, GRONINGEN, NETHERLANDS, 2University
of Groningen, University Medical Center Groningen, Depart-
ment of Anesthesiology, GRONINGEN, NETHERLANDS,
3University of Groningen, Department of Behavioral Physiol-
ogy, GRONINGEN, NETHERLANDS.
OBJECTIVES: Adenosine A1 receptors (A1AR) in the brain
of experimental animals can be visualized using radiolabeled
xanthines and positron emission tomography (PET). We were
interested in the reproducibility of quantitative A1AR scans
with the tracer 11C-MPDX, in order to evaluate whether this
technique is capable of detecting subtle changes of A1AR
availability. Unfortunately, a reference region without specific
binding is not available in the rodent brain. For this reason,
test-retest studies with 11C-MPDX demand repeated arterial
cannulation and rapid arterial blood sampling. METHODS: A
minimally invasive technique for arterial cannulation was de-
veloped, which can be repeatedly applied and allows longitu-
dinal microPET studies in rodents with full kinetic modeling.
A thin cannula was inserted in a superficial branch of a femoral
artery and moved up through this blood vessel until the main
artery was reached. After the scan, the cannula could be pulled
back and the rather minor wound was surgically closed. Ani-
mals then received analgesia (subdermal bupivacaine 2.5 mg/
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kg). Eight rats (healthy males, Wistar strain) were scanned
twice with 11C-MPDX at an interval of 1 week, and rapid
arterial blood sampling was performed in both cases. The trac-
er (39±18 and 26±13 MBq at scan 1 and scan 2, respectively)
was administered as a slow (1 min) bolus, using an injection
pump. PET images were fused with an MRI template, using
the program PMOD, and regions-of-interest (ROI) for relevant
brain regions were copied from MRI to PET. Tracer distribu-
tion volume (VT) in these brain regions was calculated by
Logan graphical analysis, 1 tissue-compartment and 2-tissue-
compartment model fitting. RESULTS: The cannulation pro-
cedure resulted in rapid wound healing and only minor dis-
comfort to the animals. Body weight was 306±40 g at scan 1
and 325±36 g at scan 2. Test-retest reproducibility of VTwas
dependent on the volume and position of the ROI besides
regional levels of A1AR expression, but was generally excel-
lent. A test-retest reproducibility better than 5% was observed
in cerebellum, cerebral cortex, hippocampus, striatum and
thalamus. Reproducibility values between 5 and 10% were
noted in amygdala, medulla, midbrain, olfactory and pons.
Only in hypothalamus, variability was greater than 10%.How-
ever, if animals damaged their wound sutures and needed ad-
ditional anesthesia and suturing, reproducibility suffered a lit-
tle. CONCLUSIONS: Repeated arterial blood sampling in ro-
dents is possible with this new technique, and the tracer 11C-
MPDX may allow longitudinal, quantitative in vivo imaging
studies aimed at detecting minor changes of apparent A1AR
availability.
P420
Effect of mTOR inhibition on epileptogenesis in the rat
epilepsy model
A. CULLIER1, F. MASKALI1, A. CLEMENT1, S.
POUSSIER1, G. KARCHER, Pr.1, P. MARIE, Pr.1, E.
RAFFO2; 1GIE-NANCYCLOTEP, VANDOEUVRE-LES-
N A N C Y, F R A N C E , 2 N E U R O P E D I AT RY
DEPARTEMENT, HOSP ITAL OF BRABO IS ,
VANDOEUVRE-LES-NANCY, FRANCE.
TheMesial Lobe Temporal Epilepsy (mLTE) is the most drug-
resistant epilepsy. Its natural history, reconstructed by the
lithium-pilocarpine in rats model, starts with the SE followed
by a histological restructuration within the hippocampal and
para-hippocampal regions, which creates a hyper-excitable
neo-circuit implementing recurring spontaneous seizures.
The mTor pathway is a proteical intracellular complex that
regulates synaptogenesis, neuronal plasticity, inflammation
and proliferation of cerebral gliosis. This specific pathway is
activated at different stages of the mLTE. The goal of the
present pre-clinical study was to evaluate the impact of
inhibit ing the mTor pathway by Rapamycin over
epileptogenesis and neuroprotection in the lithium-
pilocarpine model. For this study, 44 adult rats were divided
into 3 groups: treated SE (i), untreated SE (ii) and healthy
witnesses (iii). Each of them received Rapamycin per os at 3
stages: H+2 at 6 mg per kg per day, then D1 and D2 at 3 mg
per kg per day. The treatment was evaluated by studying met-
abolic modifications, using positon emission tomography and
2-[18F]-fluoro-2-deoxy-D-glucose, at H+4, D2 and D8 (1),
the research for spontaneous crisis fromD8 (2), and eventually
by counting neurons in the interest regions after sacrifice at
D60 (3). In the acute phase, we show an increase of conse-
quences of the SE on glucose local cerebral metabolism, in the
hippocampus and parahippocampal cortex, by the use of
Rapamycin. However, an increased hippocampal
hypometabolism at D2 suggests that Rapamycin may have a
neuroprotecting potential, which has to be confirmed by his-
tological study. We don’t observe any treatment effect at D8.
We don’t show either any influence of Rapamycin treatment
over epileptogenesis. Our results along with previous studies
outcomes recommend evaluating Rapamycin administration
from the beginning of SE and by the intra-peritoneal pathway,
as well as treatment prolongation during the whole
epileptogenesis silent phase.
P421
Are there gender differences in P-glycoprotein function
at the rat blood-brain barrier ?
S. MARIE, G. POTTIER, S. GOUTAL, S. AUVITY, I.
BUVAT, R. BOISGARD, F. DOLLE, F. CAILLE, N.
TOURNIER; IMIV, UMR 1023 Inserm/CEA/Université Paris
Sud - ERL 9218 CNRS, CEA, DSV, I2BM, Service
Hospitalier Frédéric Joliot, Orsay, F-91401, FRANCE.
AIM: Many studies have reported gender differences in both
toxicity and therapeutic outcome of medications, including
CNS drugs, where females consistently present with greater
toxicity. P-glycoprotein (P-gp) is a major efflux transporter
which restricts the distribution of many compounds across
the blood-brain barrier (BBB). Therefore, reduced P-gp func-
tion in females relative to males would provide a pharmacoki-
netic (PK) explanation for differential CNS sensitivity to drugs
identified as P-gp substrates. We recently validated
[11C]metoclopramide, a specific P-gp substrate with signifi-
cant baseline brain uptake and no detectable radiometabolites
in the brain, even in the presence of P-gp inhibition. The pur-
pose of this study is to test the hypothesis of a functional
difference in P-gp function at the BBB between male and
female rats, the major animal model used for PK
s t u d i e s . M AT E R I A L S A N D M E T H O D S :
[11C]metoclopramide microPET imaging (37 MBq IV;
30 min scan, Siemens Inveon) was performed in male Wistar
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rats in the presence (n = 4) and the absence (n=5) of P-gp
inhibition (tariquidar 8 mg/kg IV, 5 min before tracer injec-
tion). Data were compared to those obtained in female Wistar
rats without P-gp inhibition (n = 5). Brain time-activity curves
(TACs) obtained in each condition were used to estimate the
total volume of distribution (VT; mL.cm-3) using
[11C]metoclopramide arterial input function corrected from
radiometabolites (Logan plot analysis).RESULTS: PET data
confirmed [11C]metoclopramide as a P-gp substrate at the
BBB: [11C]metoclopramide brain distribution was higher (p
< 0.05) in tariquidar-treated males (VT = 8.8 ± 1.6 mL.cm-3)
compared to control males (VT = 2.6 ± 0.4 mL.cm-3). TAC
shapes appeared similar in both the male and female groups.
We found lower [11C]metoclopramide distribution in control
females compared to control male rats, although non-
significant (VT = 2.4 ± 0.3 mL.cm-3).CONCLUSION: We
found no significant difference of P-glycoprotein function at
the rat BBB between male and female rats. This information
suggests that gender is not a confounding factor to study P-gp
function at the rat BBB using PET.
P422
A [11C]preladenant PET study of Striatal adensoine A2A
receptor occupancy by KW-6002 in rats
X. Zhou, P. Elsinga, R. Dierckx, E. de Vries; University Med-
ical Center Groningen, Groningen, NETHERLANDS.
Aims: The first aim of the study was to assess the suitability of
[11C]preladenant-PET for studying the A2AR occupancy by
an A2AR specific antagonist, using KW-6002 as a typical ex-
ample. The second aim was to determine the optimal acquisi-
tion time and the reference region in a simplified reference
tissue model (SRTM).Materials and methods: Eight baseline
PET scans and 12 scans after i.p. administration of various
doses (between 0.01 and 1 mg/kg) of KW-6002 were per-
formed. Rats were i.v. injected with [11C]preladenant 15-
25 min after KW-6002 or vehicle administration, and a
90 min dynamic PET scan was started. The binding potential
(BPND) in striatum was obtained by SRTM with 90 min or
60 min acquisition, using midbrain or cerebellum as the refer-
ence tissue. Receptor occupancy was calculated by the follow-
ing equation: Occupancy(%)=100*(BPND, baseline-BPND,
blocking)/BPND, baseline. The in-vivo ED50 of KW-6002 was es-
timated by fitting the dose-occupancy curve with a single bind-
i n g s i t e mode l u s i n g t h e f o l l ow i ng f o rmu l a :
Occupancy(%)=100*Occmax*D/(D+ED50), where Occmax is
the maximum occupancy, ED50 is the drug dose correspond
to 50% occupancy, and D is the drug dose.Results: BPND
estimates in striatum at baseline were slightly but significantly
(p<0.05) higher with 60 min acquisition, compared with
90 min acquisition. BPND values were 5.96±0.62 and 6.08
±0.52 for the 90 and 60 min acquisition, respectively, using
midbrain as the reference tissue, and were 5.48±0.56 and 5.56
±0.47 for the 90 and 60 min acquisition, respectively, using
cerebellum as the reference tissue. Pretreatment of KW-6002
decreased the tracer uptake in striatum in a dose-dependent
manner (10-98% occupancy correspond to 0.01-1 mg/kg
blocker). The ED50 for i.p. injection of KW-6002 was estimat-
ed to be 0.056 and 0. 060 mg/kg for the 90 and 60 min acqui-
sition, respectively, using midbrain as the reference tissue; and
of 0.060 and 0.062 mg/kg for the 90 and 60 min acquisition,
respectively, using cerebellum as the reference tissue. Thus,
comparable estimates of occupancy and ED50 were obtained
when either cerebellum or midbrain were used as the reference
tissue. Therefore, these brain regions are equally well applica-
ble as the reference region. Furthermore, a 60 min acquisition
seems to be slightly better than a 90 min acquisition, in terms
of higher BPND values with lower standard deviation obtained
from a 60 min acquisition.Conclusions: [11C]Preladenant-
PET is suitable to estimate striatal A2AR occupancy in the
brain with SRTM, using cerebellum or midbrain as the refer-
ence tissue.
P423
Comparing 123I-Ioflupane (DatScan) SPECTusing
LEHR and Fan-Beam Collimators - an Initial
Investigation into Clinical Impact
H. A. Williams, G. Al-Bahrani, J. James; Nuclear Medicine,
Manchester, UNITED KINGDOM.
Methods: Patients attending for DatScan were invited to un-
dergo additional FB SPECT following the standard 185 MBq
DatScan and LEHR SPECT at 4 hours post-injection. 17
consented (7 female, 8 male), 2 withdrew after initial LEHR
SPECT. All images were acquired using a dual-headed GE
Millenium VG gamma camera, both SPECT procedures used
120 views over 360°but FB SPECT used 21s views compared
to 30s for LEHR, reducing the overall scan time by 9
minutes.LEHR SPECTwas reported as usual. The FB SPECT
images were visually evaluated by the same reporting clini-
cian, who assessed overall quality, noise, edge definition, con-
trast, amount of detail, and how apparent any well-defined
features and hot-spots were and whether this improved with
FB. Clinicians were also asked whether FB SPECT would
have altered or improved confidence in the clinical conclusion
from LEHR SPECT. Results: The overall quality of the FB
images compared to the LEHR images was rated better in
33.3% of cases, worse in 13.3% and similar in 53.3%. Partic-
ular aspects of image quality were scored as follows:Noise -
FB better, 40%; both the same 26.7%; LEHR better
33.3%Edge definition - FB better, 73.3%; both the same
13.3%; LEHR better 13.3%Contrast - FB better, 53.3%; both
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the same 33.3%; LEHR better 13.3%Amount of detail visible -
FB better, 93.30%; both the same 6.7%; LEHR better 0%How
apparent the defects/hot-spots are - FB better, 53.3%; both the
same 46.7%; LEHR better 0%How clearly defined the defects/
hot-spots are - FB better, 86.7%; both the same 6.7%; LEHR
better 6.7%FB images gave the reporting clinician more con-
fidence in their diagnosis in 53.3% of cases, with confidence
being similar in 26.7% and LEHR giving greater confidence in
20%. However, viewing FB images did not alter the reporting
clinician’s clinical conclusion in any of the 15 cases. The cli-
nicians initially reported that the different appearance of the
FB images made comparison difficult, but quickly adjusted.
Conclusion: FB SPECT images were considered superior to
LEHR SPECT, particularly with regard to edge and feature
definition, which increased confidence in the clinical report
based on the LEHR images although the clinical findings were
unaltered.We are now looking to translate these findings to the
gamma camera currently used for DatScan SPECT (Siemens
Symbia T6).
P424
Revealing asymmetric activations in the auditory cortex
in rats with FDG PET
M. Mamach1,2, G. Berding1,2, J. P. Bankstahl1, F. M.
Bengel1, S. Kurt1,2; 1Medical School, Hannover, GERMA-
NY, 2Cluster of Excellence “Hearing4All”, Oldenburg,
GERMANY.
Aim:Lateralization of activation in the auditory cortex in rats
was previously shown using histological and electrophysio-
logical approaches. We assessed the functional asymmetry of
the auditory cortex (AC) using in-vivo FDG PET imaging in
normal hearing, healthy rats.Methods:Three separated F-18-
fluorodeoxyglucose (FDG, 16-20 MBq) PET (Inveon, Sie-
mens) scans were performed in each of 12 adult female
Sprague Dawley rats for three sound conditions: 55 dB back-
ground noise (BG55), 65 dB continuous white noise (WN65)
and 95 dB pulsed rippled noise (RN95). These conditions were
presented for 41 min, beginning 1 min before intravenous
injection of FDG to trained, awake animals, which were
placed into a motion restricting tube in a sound attenuated
box. PET scans were acquired 1 h after tracer injection across
30 min. Data were reconstructed iteratively (OSEM) including
Co-57-transmission-source-based attenuation correction. Spa-
tial normalization and brain activity normalization were per-
formed using a mask and FDG template of PMOD3.6. Mean
normalized activities in volume of interest (VOI) were obtain-
ed based on Schwarz’s VOI atlas for the AC, the inferior
colliculus (IC) and a control region, the olfactory nuclei
(ON). Differences of means (left - right) were analyzed using
paired t-tests for each VOI and each stimulus condition.
Results were compared without smoothing ([0.0mm]3) and
with [2.0mm]3 Gaussian smoothing.Results:Individual left-
right differences in the auditory cortex varied over all condi-
tions from -12% to +10% without and -6% to 7% with
[2.0mm]3 smoothing. Using the RN95 stimulus, the auditory
cortex expressed a FDG uptake asymmetry with increased
uptake in the left cortex 4.0±0.8% (p<0.001) for [0.0mm]3
and 3.4±0.6% (p<0.001) for [2.0mm]3. During WN65 stimu-
lation, asymmetry was observed with increased left AC’s up-
take of 3.4±1.4% (p<0.05, [0.0mm]3) and 3.4±0.9% (p<0.05,
[2.0mm]3), respectively. In BG55 environment, asymmetry
amounted to 2.1±0.7% (p<0.05, [0.0mm]3) and 2.8±0.5%
(p<0.001, [0.2mm]3) with increased uptake in the left AC.
For IC and ON no s ign i f i c an t a symmet ry was
observed.Conclusions:Statistical analyses of auditory cortex
in normal hearing rats with PET revealed functional activation
in AC with prevalence of the left side, but not in the IC or the
ON. A tendency of larger left side prevalence in louder sound
conditions was observed. The left side prevalence being a
random effect is highly unlikely as the significant prevalence
was observed with and without filtering. Functional asymme-
try of the AC during different auditory sound conditions could
be determined using FDG PET.
P425
Metabolic and Neurovascular Coupling in brain SPECT
and PETof patients with epilepsy and normal 3T MRI
E. N. I. Itikawa1,2, D. K. S. Sonvenso1,3, L. A. S. Santos1,3,
M. K. Kato1,3, F. A. P. Pitella1,3, C. E. P. B. Baltazar1,4, A. C.
T. Trevisan1,2, V. A. J. Junior1,3,5, L. W. A. Wichert-Ana1,
2,3; 1Ribeirão Preto School of Medicine, Ribeirão Preto,
BRAZIL, 2Post-Graduation Program Interunits Bioengineer-
ing EESC/FMRP/IQSC-USP, São Carlos, BRAZIL, 3Post-
graduation Program in Internal Medicine, Ribeirão Preto,
BRAZIL, 4Faculty of Philosophy, Sciences and Literature of
Ribeirão Preto, Ribeirão Preto, Ribeirão Preto, BRAZIL, 5De-
partment of Neurology, Ribeirão Preto, BRAZIL.
AIM: To evaluate the neurovascular (99mTc-ECD SPECT)
and metabolic (18F-FDG PET) coupling in patients with re-
fractory epilepsy associated to normal MRI.MATERIAL
AND METHODS: Twenty-seven patients with refractory ep-
ilepsy and normal MRI from the Epilepsy Surgery Center
(CIREP) were screened to this study. All patients underwent
interictal 99m-Tc-SPECT, 18F-FDG-PET and 3T MRI acqui-
sition. Two nuclear medicine specialists visually evaluated
functional images. Concordance inter-observer was evaluated
through weighted kappa (κw). Brain regions were divided in
frontal, temporal, parietal, occipital lobes, basal ganglia thala-
mus and cerebellum. Hypoperfusion and hypometabolism
were scored as 0: normal uptake; 1: mild ; 2: moderate and
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3: severe. Neurovascular and metabolic coupling were evalu-
ated either through intersection of brain regions or the same
level of decreased uptake using results of semiology, interictal
and ictal video-EEG as a reference for seizure localization/
lateralization. Fisher’s exact test was used for this purpose.
Posteriorly, localization hypothesis for epileptogenic zone
was based on the congruence of clinical data and results of
ictal and interictal video-EEG confronted with functional neu-
roimaging findings.RESULTS: Mean age was 34.55 years (sd
= 12.25; range: 19-60 years old). Risk factor for epilepsy in-
cluded encephalitis (n=1); neonatal hypoxia (n=1); obstetric
complications (n=2), status epilepticus (n=1) and 22 showed
no risk factors. Four patients showed mild mental retardation
on neuropsychological examination. All patients showed ab-
normalities in the interictal SPECT while in 5, PET was nor-
mal. We found good concordance between the observers for
interictal SPECT in temporal lobe, basal ganglia, thalamus and
cerebellum. For PET images, there was no discordance in tem-
poral and occipital lobes, thalamus and basal ganglia. Regions
of hypoperfusion and hypometabolism were the same as the
reported by video-EEG in 73% of the patients. The occurrence
of same hypoperfusion/hypometabolic regions was not asso-
ciated to a focal or diffused video-EEG profile, though. Re-
gions of maximum neurovascular coupling were the same as
the regions reported by video-EEG in 75% of the patients.
Nevertheless, the occurrence of neurovascular coupling was
not assoc ia ted to a focal or d i ffuse video-EEG
profile.CONCLUSION: Good concordance between the ob-
servers was achieved in the functional images evaluation.
Interictal SPECTand PETshowed regions of abnormal uptake
and neurovascular coupling congruent to video-EEG in most
of patients. Despite the qualitative approach in our study, we
encourage further quantitativeanalysis of functional data such
as SPM in the study of neurovascular coupling using SPECT
and PET images.
P426
Quantification of GABA-A receptor binding
in the auditory system of rats using F-18-Flumazenil PET
M.Mamach1,2, G. Berding1,2, J. P. Bankstahl1, T. L. Ross1,
F. M. Bengel1, S. Kurt1,2; 1Medical School, Hannover, GER-
MANY, 2Cluster of Excellence “Hearing4All”, Oldenburg,
GERMANY.
Aim: The GABAergic inhibitory neurotransmitter system is
known to play a major role in the auditory systems and its
disorders such as hearing loss and tinnitus. F-18-Flumazenil
(FMZ) PET has been used to visualize GABA-A-receptor
binding. The purpose of this study was to explore the feasibil-
ity to obtain quantitative measures of GABA-A-receptor bind-
ing in small animals. Besides this, this approach might reveal
new insights in auditory diseases, based on dynamic PET im-
aging and bio-kinetic modeling of the GABAergic system.
Methods: Scans were performed in 6 normal hearing female
Sprague Dawley rats using FMZ (6-20 MBq) PET (Inveon,
Siemens). The tracer was injected via tail vein in isoflurane
anaesthe-tized animals simultaneously with the start of dy-
namic scans lasting 45min. Data were reconstructed iteratively
including 57Co-transmission-source-based attenuation cor-
rection for 31 time consecutive frames (5x2s, 4x5s, 3x10,
8x30s, 5x60s, 5x5min, 1x10min). Motion correction, spatial
normalization and VOI-wise modelling were performed using
PMOD3.6. For each scan a VOI was manually placed in the
hearts left ventricle to obtain the whole blood time activity
curves as input functions. Mean parametric volumes of distri-
bution (Vt) were calculated based on the Logan plot model for
auditory regions (inferior colliculus (IC), mediate geniculate
body (MGB) and auditory cortex (AC)) as well as reference
regions (PONS, cerebellum (CB) and somatosensory cortex
(SC)) using Schwarz’s VOI atlas. Binding potentials (BP)
were calculated with respect to the PONS. Results: All plots
showed a good agreement of model and data. FMZ revealed a
high uptake in the brain. The PONS, as a reference, showed
the lowest Vt 1.22±0.34. In the auditory regions, we detected
higher Vts compared to the PONS: for the AC 2.58±0.47 and
the IC 2.71±0.53. The corresponding mean BPs were in the
AC 2.11 and in the IC 2.22. The SC showed similar values of
Vt 2.63±0.54 and BN 2.16. In the thalamic MGB, values of
2.00±0.38 for Vt and 1.64 for BN were detected. The CB’s
means of Vt and BP were 1.76±0.33 and 1.44, respectively.
Conclusions: Our data indicate that calculation of distribution
volumes and binding potentials based on dynamic PET mea-
surements of FMZ distribution in rats provides consistent re-
sults with acceptable variation. Binding in regions with specif-
ic tracer uptake clearly exceeded compared to the reference
areas. We conclude from these results, that in-vivo FMZ-
PET is a promising method for the evaluation of hearing dis-
order in small animals.
P427
Quantification of 5HT2A-Receptors in the Human Brain
with [18F]MHMZ
V. Kramer1, M. Herth2, E. Hernandez3, C. Juri4, R. Pruzzo3,
F. Rösch5, H. Amaral1; 1PositronPharma SA, Santiago de
Chile, CHILE, 2University of Copenhagen, Copenhagen,
DENMARK, 3Nuclear Medicine and PET/CT Center FALP,
Santiago de Chile, CHILE, 4Universidad Catolica, Santiago
de Chile, CHILE, 5Johannes Gutenberg-Universität Mainz,
Mainz, GERMANY.
Objectives: PET quantification of 5HT2A-receptors is an im-
portant tool for drug occupancy studies and of major interest in
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different psychiatric disorders and as biomarker for neuronal
integrity. For decades 18F-Altanserin and 11C-MDL-100907
were clinically used for quantification despite their disadvan-
tages related to extensive metabolism and half-life. 18F-
MHMZ (or 18F-FE-MDL-100907) was developed as 18F-
version of MDL-100907 to overcome these disadvantages
and to provide the possibility of precise quantification of
5HT2A receptors in sub-cortical brain regions. We herein re-
port the GMP compliant synthesis and a First-In-Man study in
healthy volunteers. Methods: 18F-MHMZ was produced as
previously described by the indirect, two step labeling ap-
proach via 18F-Fluoroethyl tosylate. The synthesis was vali-
dated on a cassette based platform under GMP conditions. 3
healthy volunteers underwent a dynamic PET scans (Siemens
mCT) for a duration of 180 min after bolus injection of 185 ±
19 MBq (mean ± SD) [18F]MHMZ. T1 weighted MRI scans
were acquired for each volunteer for co-registration, normali-
zation and VOI-outlining. Blood input function was recorded
by online blood sampling (Twilite/Swisstrace) and plasma and
parent fraction were determined. Distribution volumes and
binding potentials were determined by different invasive and
non-invasive methods. Results: Starting activities of 10-
40 GBq were used for labeling and 18F-MHMZ was obtained
in high radiochemical puritiy (>95 %) and uncorrected RCYs
of 15-30 % in 90 min. 18F-MHMZ revealed a relatively slow
kinetic and high tracer uptake in cortical areas as expected.
Lower uptake was observed in striatal areas, amygdala and
cerebellum. The reliability of different invasive and non-
invasive quantification methods is currently under evaluation.
Nevertheless, first data indicate that stable estimates for bind-
ing potentials in different brain regions can be obtained after
180 min scan duration using 2TCM. Conclusions: 18F-
MHMZ is a promising tool for 5HT2A receptor quantification
in cortical and sub-cortical areas of the human brain.
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Introducing the Glucose Metabolism to Amyloid
Deposition Ratio Image
K. Ishii1, R. Takahashi2, Y. Wakabyashi1, C. Hosokawa1, H.
Kaida1, T. Murakami1; 1Kinki University, Osakasayama, JA-
PAN, 2Hyogo Prefectural Rehabilitation Hospital at Nishi-
Harima, Tatsuno, JAPAN.
OBJECTIVE: Alzheimer’s disease (AD) is characterized by
increased cortical amyloid deposition in the prodromal stage
and subsequent decrease of cerebral glucose metabolism with
disease progression. The present study introduces voxel-wise
metabolism into amyloid deposits ratio (MAR) imaging in
order to evaluate its reliability in the diagnosis of AD.
METHODS: 324 consecutive subjects with 143 AD and 181
normal subjects were included in this study from the
Alzheimer’s disease neuroimaging initiative (ADNI) database.
The MAR image was created by dividing each FDG-PET
image by corresponding AV-45 PET image using voxel-wise
inter-image computation. We examined voxel wise compari-
son in the MAR images between AD subjects and normal
subjects and compared the diagnostic performances between
the MAR image and FDG-PET and AV-45 image. RESULTS:
MAR images of AD subjects exhibited severe and extensive
decreases compared with normal subjects in the affected re-
gion in AD. The highest t-value was equivalent to the FDG-
PET and the voxel extent was much greater than the other
images. The diagnostic accuracies were 82.6%, 80.7%, and
78.8% for the MAR image, FDG-PET, and AV-45, respective-
ly. AUC for the MAR image was 0.904, and was larger than
those for FDG-PET (AUC: 0.884), and AV-45 (AUC: 0.847).
CONCLUSION: MAR image reflects not only amyloid depo-
sition, but cerebral hypometabolism and can successfully clas-
sified subjects with AD. MAR imaging techniques might be a
more appropriate marker for monitoring disease progression of
AD.
P429
The brain SPECT perfusion rating using Neurogam
program for diagnostics of early onset Alzheimer disease
R. Pichova1, A. Bartos2, O. Samokhvalova2, J. Kotoucova2,
D. Ripova3; 1Charles University Prague, 3rd Medical Faculty,
CZECH REPUBLIC, 2Charles University Prague, 3rd Medi-
cal Faculty, National Institute ofMental, CZECHREPUBLIC,
3Charles University Prague, National Institute of Mental
Health, CZECH REPUBLIC.
Aim: To develop a simple regional semi-quantification of 3D
brain SPECT perfusion using Neurogam program for early
Alzheimer disease (AD) diagnostics and to assess interindivid-
ual concordance of the results. Introduction: It is hypothesised,
the SPECT perfusion image changes should correspond with
the anatomical cascade atrophy in AD: mediotemporal →
temporoparietal → frontal area. Subjects and Methods: 35
cognitively normal controls (NC) were enrolled in the study
- Mini-Mental State Examination (MMSE) 29±1 points, an
average age 69 years (y), an average education 15 y. 33 pa-
tients with mild cognitive impairment (MCI) or mild dementia
due to Alzheimer disease (AD) were examined - MMSE 26±3
points, an average age 77 y, an average education 14 y. 99mTc-
HMPAO brain SPECT images were transformed into 3D tem-
plates using NeuroGamTMSegami software. Perfusion of pa-
rietal lobe convexity, cingulum, temporo-parietal,
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mediotemporal and frontobasal regions were rated 0 (normal),
1 (border), 2 (reduced) in both hemispheres. These data were
combined into a single bilateral score ranging 0 (normal), 1
(border), 2 (reduced on one side), 3 (reduced on both sides).
Results: Patients with MCI and mild AD did not differ in age,
gender, education, MMSE. They were merged into one AD
patient group. In comparison with the NC group, these patients
had significantly higher score of hypoperfusion in parietal or
temporoparietal region on one side or bilaterally. All other
regions including mediotemporal ones were perfused in these
patients and in the controls similarly. The interindividual con-
cordance was found in 62 out of 68 (91 %) patients. Conclu-
sions and discussion: Semi-quantification of the visual rating
of 3D Neurogam brain SPECT perfusion is a simple and con-
venient tool for routine clinical practice. The early onset AD
patients already had incipient perfusion alterations in temporo-
parietal regions on one or both sides. Surprisingly,
mediotemporal mild changes were common even in normal
seniors and were indistinguishable from those found in AD
patients. This pattern for early diagnosis needs further explo-
ration. Assessment has satisfactory interindividual rate reli-
ability. Supported by grant IGA NT 13183, PRVOUK 34/
LF3 and DRO (PCP, 00023752).
P430
SUVratio(SUVr)-independent semiquantification of brain
amyloidosis: a software-aided integration of visual
and quantitative analyses
S. Morbelli1, F. Nobili2, F. Sensi3, U. Guerra4, L. Rei3, I.
Bossert1, A. Chincarini for the ADNI3; 1Nuclear Medicine
Unit, IRCCS AOU San Martino - IST, Genoa, ITALY, 2De-
partment of Neurology, IRCCS AOU San Martino - IST, Uni-
versity of Genoa, Genoa, ITALY, 3National Institute for Nu-
clear Physics (INFN), Genoa, ITALY, 4Nuclear Medicine
Unit, Fondazione Poliambulanza, Brescia, ITALY.
Background: In-vivo quantification of brain beta-amyloid de-
position using positron emission tomography (PET) is likely
to play a pivotal role in upcoming clinical trials of disease
modifying agents. Because of the non trivial visual assess-
ment, a more sophisticated approach is required in form of
reliable automatic quantification methods.Aims: to compare
the fundamental approaches to amyloid-PET quantification
and introduce a novel, comprehensive procedure that com-
bines visual and automatic quantification, procedural
operationalization and conflict resolution.Methods: We set a
reference images base of Florbetapir scans of 244 subjects
from the ADNI archive. Subjects were selected to have at least
two scans (at baseline and after an approximately 2 years of
follow-up).Subjects clinical evaluation was taken to be the
closest diagnosis to the baseline PET scan date. Cohorts are
grouped by the ADNI core clinical criteria as: normal subjects
(NS, N=70), early mild cognitively impaired (EMCI, N=86),
mild cognitively impaired (MCI, N=26), late mild cognitively
impaired (LMCI, N=51) and Alzheimer’s diseases (AD,
N=11).These scans were independently and blindly evaluated
by three expert readers with a visual procedure according to
Florbetapir guidelines and their expertise.On these scans we
compare the performance, reliability and result quality of three
SUVr-based quantification methods plus the novel non-SUVr
based approach we developed. This method evaluates the
brain as a whole and delivers a geometrical/intensity score
for each image, to be used in dichotomic assessment and
ranking.Results: Analyses show that the proposed SUVr inde-
pendent approach has the potential to out-perform standard
SUVr based methods, resulting in excellent agreement with
visual rating on a single scan rating-bases(AUC ~ 0.94 /
0.98).Longitudinal analyses were though plagued by image
quality and acquisition protocol consistency, requiring three
or more scans to deliver a reliable trend. This effect was more
pronounced on the SUVr-independent algorithm because of
t h e i n h e r e n t d e p e n d e n c e o n l o c a l i m a g e
characteristics.Conclusions: The need for automatic quantifi-
cation methods in amyloid-PET is dire, particularly for one
that integrates visual and software assessment in a structured,
procedural approach. With the delivery of procedural recom-
mendations, we expect to significantly improve the diagnosis
time and accuracy in clinical practice, where the judicious use
of the quantification software will be instrumental to a more
efficient decisional process and patient follow-up.
P431
18F-FDGPET/CT:ANewTool to Evaluate the Interaction
between Cognitive Reserve (CR) and CSF-Biomarkers
in Alzheimer Disease (AD) Patients
E. Carapelle, S. Modoni, G. Rotondo, L. Specchio;
OSPEDALI RIUNITI, FOGGIA, ITALY.
Aim: To examine the effect of the correlation between CSF-
biomarkers, education (a proxy of CR) on brain
[18F]fluorodeoxyglucose positron emission tomography
(PET) metabolism in patients with early/moderate Alzheimer
Disease (AD). Methods: Twenty-seven patients with probable
AD and twenty-five neurologically normal subjects (HS),
matched for age and sex, were studied. CSF β-amyloid1-42
(Aβ1-42), 181p-tau and Tau concentrations were measured in
AD by Innotest ELISA. 18-FDG-PET/TC was performed in
AD and HS 40 minutes after i.v. administration of radiophar-
maceutical (3,7 MBq/kg). Mini Mental State Examination
(MMSE) was performed in AD patients. CR was measured
as years of education: AD patients were classified as High
Educated-AD (HE-AD) if education in years was > 5 versus
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Low Educated-AD (LE-AD) if education in years was ≤ 5. By
using a voxel-wise approach, we first investigated differences
in the cerebral glucose uptake (GU) between AD and HS, then
we assessed the correlation between education, CSF-
biomarkers on FDG-PET metabolism in the patient groups.
Results: No significant demographic differences were found
between AD and HS. Significant clusters of low GU were
observed in the posterior cingulate gyrus, in the precuneus,
in the inferior and medial temporal gyrus, in the inferior pari-
etal lobule bilaterally in AD but not in HS. No significant
difference in age and MMSE was found between AD groups.
By using a voxel-wise approach no significant differences in
the mean values of GU were observed in HE versus LE-AD.
Conversely, in the right orbital frontal cortex the mean values
of GU was significantly higher in HE-AD versus LE-AD
(p=0.02). A significant interaction was found between groups
(HE e LE) and Aβ1-42 values in the inferior and medial tem-
poral gyrus bilaterally. Conclusions: Decreased glucose me-
tabolism in regions typically targeted by AD pathology (i.e.,
medial temporal lobes) and increased metabolism in the right
orbital frontal cortex might reflect compensation mechanisms
due to CR, which contrasts the neurodegeneration as assessed
by CSF Aβ1-42. We hypothesized that CR could be a com-
pensatory mechanism and it could modify the effect of Aβ
plaques on cognitive activity of these regions assessed by brain
metabolism.
P432
Different patterns of brain glucose consumption related
to the age of onset in Alzheimer’ s disease
A. Chiaravalloti1, D. Di Biagio1, R. Danieli1, B. Di Pietro1,
G. Koch2, A. Martorana2, P. Abbatiello1, O. Schillaci1; 1De-
partment of Biomedicine and Prevention, University Tor
Vergata, Rome, ITALY, 2Department of Neurosciences, Uni-
versity Tor Vergata, Rome, ITALY.
Aim: To investigate the relationships between age of onset of
Alzheimer’s disease (AD) and brain glucose consumption as
detectable by means of 2-deoxy-2-(18F) fluoro-D-glucose
(18F-FDG) Positron Emission Tomography/Computed To-
mography (PET/CT). Materials and methods: We examined
81 newly diagnosed probable AD patients according to the
NINCDS-ADRDA criteria (46 women and 36 men; mean
age 69 ± 7 years). All the subjects underwent a cerebrospinal
fluid (CSF) assay for levels of p-Tau, t-Tau and Aβ1-42 amy-
loid peptide ~ 1 month before PET/CT examination. A stan-
dard Magnetic Resonance has been performed in all the sub-
jects enrolled in the study. Relationships between age of onset
of AD an brain glucose consumption have been assessed by a
regression analysis in Statistical ParametricMapping version 8
(SPM8) using gender, Mini Mental State Examination
(MMSE) and CSF levels of p-Tau, t-Tau and Aβ1-42 amyloid
peptide as covariates. Results: MMSE, p-Tau, t-Tau and Aβ1-
42 amyloid peptide were equal to 18.52± 6, 81.29± 47, 678.8±
322 and 321.2± 127 respectively with no differences in gen-
ders. SPM8 regression analysis showed a significant decrease
(with a statistical threshold of p=0.001, family wise error
(FWE)-corrected) of glucose consumption in a wide portion
of the left parietal lobe (BA7, BA31 and BA 40) in those
patients with an early onset of the disease. No areas of signif-
icant reduction of brain glucose consumption have been found
in those subjects with a late onset of the disease. Conclusions:
the results of our study show that an early age of onset of AD is
related to a selective metabolic pattern that involves mainly the
left parietal cortex. This pattern is independent from CSF bio-
markers that are commonly used in the evaluation of AD.
P433
The impact of education on FDG PET single subject
analysis for Alzheimer’s dementia diagnosis
I. Mainta, G. Amzalag, O. Ratib, G. B. Frisoni, V. Garibotto;
University Hospital of Geneva, GENEVE, SWITZERLAND.
Purpose: FDG PET is a widely used biomarker of dementias,
able to identify the metabolic changes associated with the re-
gional distribution of pathology, namely in Alzheimer’s Dis-
ease (AD).Education, among others, is known to increase the
so-called “reserve capacity” of the brain, which modulates the
association between hypometabolism and clinical expression,
namely reducing the clinical severity for a given level of pa-
thology by recruiting alternative and redundant networks. Aim
of this study is to measure the impact of education on the
threshold to define FDG PET abnormality and on its diagnos-
tic accuracy.Materials and methods: We selected 45 healthy
controls and 51 AD patients from the ADNI database. In order
to provide an objective metric of the presence of AD type
hypometabolism, we extracted mean relative glucose metabo-
lism, within a set of regions typically affected, normalized to
the activity in the cerebellar vermis and corrected for age
(metaROI). We divided the AD population in two subgroups
with respect to the median of years of education, thus identi-
fying patients with a lower (23) or higher (28) reserve.We used
a Receiver Operating Characteristic (ROC) curve
approach.The area under the curve (AUC) of the two ROC
was compared with a t-test.Results: The AUC of the metaROI
values was 0.89 in patients with lower reserve, compared to
controls, and 0.90 in patients with higher reserve. The differ-
ence between the two groups was not significant. The cut-off
value providing a minimum sensitivity of 80% was -0.76 in
subjects with lower reserve and -1.10 (indicating amore severe
reduction) in subjects with higher reserve.ConclusionsFDG
PET has a high diagnostic accuracy both in patients with
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higher and with lower reserve. However, in order to achieve a
comparable sensitivity, a different threshold for abnormality
has to be used in the two groups, namely a less conservative
threshold in patients with lower reserve. These results under-
line the importance of integrating image interpretation with
patient’s demographics and clinical presentation and to devel-
op personalized analysis tools.
P434
Proposal of a Method to Estimate Normal Threshold
Values of Summed Z-scores in the Specified Regions for Z
Sum Analysis for Diagnosing Alzheimer’s Disease
with Voxel-based Control Database of I-123 IMP SPECT
N. Shuke1, C. Miyazaki1, A. Ando1, T. Onishi1, K. Saito1, J.
Sato2, A. Okizaki2, K. Nishikawa3; 1Kushiro Kojinkai Me-
morial Hospital, Kushiro, JAPAN, 2Asahikawa Medical Col-
lege, Asahikawa, JAPAN, 3Imaging Information Technology
Center, Nihon Medi-Physics Co., Ltd., Osaka, JAPAN.
Objective: Using generalized extreme studentized deviate
many-outlier procedure (ESD), voxel-based control database
(CDB) could be generated from clinical patient’s data (pts’) for
statistical brain SPECT analysis. The objective of this study
was to propose a method for estimating normal threshold
values of summed Z-scores in the specified regions (bilateral
parietal, precuneus / posterior cingulate, medial occipital, and
lateral occipital regions) for Z sum brain SPECTanalysis (Ishii
K, et. al. Computer-assisted diagnostic system for neurodegen-
erative dementia using brain SPECT and 3D-SSP. Eur J Nucl
Med Mol Imaging. 33: 575-583, 2006) on CDB with 3D-SSP.
Method: I-123 IMP SPECT data from 117 pts (70±;7 y old ,
M/F=50/67) were studied. CDBwas generated using ESD and
prior pts’ data selection based on Euclidean distance to the
sample mean SPECT image. To estimate normal threshold
values of summed Z scores, pts’ data in which all voxels in
the specified regions contributed to CDB were selected. Mean
and SD of Z sums for each specified region were then calcu-
lated fromZmaps fromCDB and selected pts’ data (method 1)
and from CDB and 34 normal volunteers’ data as a standard
reference method (method 2). Calculated mean and SD of Z
sums were then compared between two methods. Results:
Twenty-three pts’ data were selected by the criterion
and used for calculating mean and SD of Z sums in
the method 1. Both mean and SD of Z sums were not
significantly different (P<0.05) in all but bilateral medial
/ lateral occipital regions. Conclusion: These results in-
dicated that proposed method (method 1) could be use-
ful to estimate normal threshold values of summed Z-
scores in the specified regions for Z sum analysis with
voxel-based CDB from clinical pts’ data.
P435
Correlation between brain perfusion SPECT
and neuropsychological test in the diagnosis of dementia
M. J. Ibáñez Ibáñez1, L. Mohamed Salem1, M. V. Godoy
Bravo1, L. F. Álvarez Nieto1, R. Reyes Marlés1, M. I.
Castellón Sánchez1, L. Frutos Esteban1, J. L. Navarro
Fernández1, J. Marín Muñoz2, C. Antúnez Almagro2, M. A.
Claver Valderas1; 1Servicio de Medicina Nuclear. Hospital
Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN,
2Unidad de Demencias. Hospital Clínico Universitario Virgen
de la Arrixaca, Murcia, SPAIN.
AIM: To study the correlation between the results of brain
perfusion SPECT and neuropsychological tests in the diagno-
sis of patients with clinical suspicion of neurodegenerative
dementia. MATERIAL ANDMETHOD: We study retrospec-
tively 100 patients with brain perfusion SPECT with 99mTc-
HMPAO, with clinical suspicion of neurodegenerative demen-
tia conducted between January and June 2014. All were re-
ferred from the Dementia Unit of our hospital where they
performed neuropsychological tests. They were classified into
6 subgroups according to clinical diagnosis: 13 without de-
mentia, 26 with mild cognitive impairment (MCI), 22 with
Alzheimer’s disease (AD), 7 with frontotemporal dementia
(FTD), 6 with primary progressive aphasia (PPA) and 26 with
other diagnoses (psychiatric illness, depression, etc). The cor-
relation between the results of SPECTand neuropsychological
test is assessed. RESULTS: We found correlation of SPECT
and neuropsychological test results in 77 of the 100 patients
studied (77%). The results for diagnostic subgroups are: there
is a correlation between brain perfusion SPECTand neuropsy-
chological tests findings in 13 of 13 without dementia (100%);
in 19 of 26 with DCL (73%); in 19 of 22 EA (86.3%); in 4 of 7
with DFT (57.1%) and in 6 of 6 with APP (100%).CONCLU-
SION: The good correlation between brain perfusion SPECT
and neuropsychological tests findings (besides its availability
and low cost) shows a proof of high diagnostic yield and
recommends his routinary use in earlier stages of neurodegen-
erative dementias.
P436
11C-PIB Retention Patterns in Amnestic and Nonamnestic
Mild Cognitive Impairment Patients. Comparison
with 18F- FDG PET/CT
Z. Bravo- Ferrer, J. Jiménez-Bonilla, M. De Arcocha-Torres,
I. Banzo, I. Martínez-Rodríguez, R. Quirce, C. Lavado-Pérez,
J. L. López-Defilló, M. Jiménez-Alonso, D. Meza-Escobar, F.
Gómez-de la Fuente, J. M. Carril; Nuclear Medicine. Molec-
ular Imaging Group (IDIVAL). Marqués de Valdecilla Univer-
sity Hospital. University of Cantabria, Santander, SPAIN.
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Aim: In a preliminary study we have comparedof the PIB reten-
tion patterns and glucose metabolism in amnestic and non-
amnesticMild Cognitive Impairment (MCI) patients and in the
control population. Theresults were encouraging and we present
here the current results in a muchlarger population of MCI pa-
tients. Methods: The study group included 81consecutive pa-
tients: 36 male and 45 female. The average age was 67.25+
7.84years. All patients were referred from the Cognitive Impair-
ment Unit of ourhospital, and classified according to the clinical
diagnosis into non-amnesticMCI (NA-MCI) (n=17)
andpredominantly amnestic MCI (A-MCI) (n=64).All patients
had a 30 minutes PET/CT acquisition 60 minutes after
intravenousinjection of 555MBq of 11C-PIB and 24 hours later,
a 15 minutesPET/CT, 20 minutes after intravenous injection of
185 MBq of 18F-FDG wasacquired. Visual analysis of the stud-
ies was performed by two nuclear medicinephysicians with ex-
perience in brain amyloid scan. A blind interpretation of the
randomlydistributed images was done. A study was considered
positive when there wasuptake in Gray Matter (GM) > White
Matter (WM). Regional PIBretention was classified according
the following patterns: PatternA (frontal,anterior cingulate, lateral
temporal and basal ganglia) and Pattern B (retention),and com-
pared with the FDG results. Results: 45/81 patients (55.5%)
werepositive and 36/81 were negative (44.5%). Of the 64 A-
MCI, 42 showed 11C-PIB positive scan (66%) and negativein
22 (34%) (p<0.001). Of the 42 PIB positive, FDG was positive
only in 10patients; however in the 22 PIB negative FDG was
negative in all on them. Onthe other hand of the 42 A-MCI
PIBpositive patients, 12 showed in A-pattern and in all on them
FDG was negative;however for the B-pattern only 20 of the 30
were FDG negative. Of the 17 NA-MCI patients, 14 were PIB
negative,and all of them were also FDG negative. Conclusion:
Overall, theproportion of PIB positive and PIB negative was
similar. In the amnestic MCIgroup the number of PIB positive
doubled the PIB negative and all the 22 PIBnegative, were also
FDG negative.In non-amnestic MCI patients, PIB positive
ishighly unlikely, however in the amnestic MCI patients with
pattern A, FDG isexpected to be negative, and therefore FDG
could not be indicated in thesepatients.
P437
Hypometabolism in posterior and temporal areas
of the brain is associated with cognitive decline
in Parkinson’s disease
F. DEMAILLY1, C. TARD2, P. LENFANT1, F. SEMAH1,
C. MOREAU3, K. DUJARDIN3; 1Service de Médecine
Nucléaire, CHRU Lille, Lille, FRANCE, 2Service de
Neurophysiologie, CHRU Lille, Lille, FRANCE, 3Service
de Neurologie et pathologie du mouvement, CHRU Lille,
Lille, FRANCE.
Objective: The primary objective was to determine whether a
specific brain metabolic pattern is associated with cognitive
decline in Parkinson’s disease (PD).Methods: Sixteen ad-
vanced PD patients were screened for the absence of cognitive
impairment (according to the Mattis dementia rating scale,
MDRS) and underwent [18F]-Fluorodeoxyglucose positron
emission tomography brain imaging in the “off drug” state.
The MDRS was scored again about two years later, categoriz-
ing patients as having significant cognitive decline (decliners)
or not (stables). The two groups were then compared in terms
of their brain metabolism at inclusion.Results: There were six
decliners and ten stable patients. Significant hypometabolism
in the two precunei (Brodmann area (BA) 31), the left middle
temporal gyrus (BA21) and the left fusiform gyrus (BA37)
was found in the decliner group compared with the
stables.Conclusion: In advanced PD, a particular metabolic
pattern may be associated with the onset of significant cogni-
tive decline.
P438
Role of Tc-99m HMPAO brain SPECT in the differential
diagnosis of vascular and other dementias
A. T. Golubic1, R. Petrovic1, T. Samardzic1, N. Klepac2, F.
Borovecki2; 1Department of Nuclear Medicine and Radiation
Protection, University Hospital Center Zagreb, Zagreb, CRO-
ATIA, 2Clinical Department of Neurology, University Hospi-
tal Center Zagreb, Zagreb, CROATIA.
Aim: The aim of this study was to examine the value and
importance of brain SPECT in the differential diagnosis of
cognitive decline. Establishing a correct diagnosis is often
challenging and is frequently dependent solely on clinical
evaluation. Functional neuroimaging is emerging as an addi-
tional clinicians’ aid in correctly diagnosing dementia patients
and providing the appropriate therapy.Method: Sixty-nine pa-
tients (39 female)with various forms of newly reported cogni-
tive decline were referred to our Department from November
2014 toMarch 2015, mostly (68%) with unspecified cognitive
decline as a working diagnosis. Twelve patients (17%) were
suspected to have Alzheimer’s disease (AD) and eight (11.6%)
were assumed to have vascular dementia. Their mean age was
71 years (range 51-89). They underwent regional cerebral
blood flow (rCBF) examination with single-photon emission
computerized tomography (SPECT), using standardized
EANM protocol .Resul ts : Decreased perfusion in
temporoparietal cortex, usually bilaterally, characteristic for
AD, was found in 12% of patients. Patchy, irregular tracer
uptake with significant reductions of rCBF in majority of ce-
rebral regions, differing in size and severity, left to right
asymmetries and even globally diminished perfusion with
changes in the cerebellum, characteristic for vascular dementia
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(VD)was found in the majority of our patients, 52%.A third of
our patients were reported to have the above mentioned AD
perfusion pattern with the addition of nonuniform VD pattern,
indicating a mixed dementia. Six patients had the perfusion
pattern of frontotemporal and Lewy body dementia, and two
had a normal finding. SPECT data were compared with clin-
ical and psychometric data. A significant number of patients
found to have mixed dementia had a positive history for high
blood pressure (80%) and hyperlipoproteinemia (76%). A
more specific diagnosis (AD, FTLD, LBD perfusion pattern,
mixed dementia)was determined in 42% of patients. In 50
patients detailed follow-up was obtained, which indicated an
altered clinical diagnosis in 23, and confirmation of the work-
ing diagnosis in additional 9 patients, with modification in
patient management due to brain SPECT data in 64% of pa-
tients with follow up neurology exam.Conclusion: HMPAO
brain SPECT has been presented as an immensely valuable
functional neuroimaging method in differentiating patients
with various cognitive decline symptoms. It presents an af-
fordable and accessible tool which enables early and correct
diagnosis and influences further patient management and
therapy.
P439
Brain perfusion differences between early and late onset
Alzheimer’s disease
V. Valotassiou1, J. Papatriantafyllou2, N. Sifakis3, C.
Tzavara1, S. Alexiou1, I. Tsougos1, D. Psimadas1, A. Ziaka1,
E. Baniora1, P. Georgoulias1; 1Department of Nuclear Medi-
cine, University Hospital of Larissa, Larissa, GREECE,
2Memory & Cognitive Disorders Clinic, Neurology Dpt.,
“G. Gennimatas” Hospital, Athens, GREECE, 3Nuclear Med-
icine Dpt, “Alexandra” University Hospital, Athens,
GREECE.
Aim: Early (<65 years) onset Alzheimer’s disease (EAD) dif-
fer from late (>65 years) onset AD (LAD) in clinical symp-
toms, genetics and neurophycological, neurochemical and
neuropathological characteristics. There is limited literature
with contradictory results about the influence of age onset on
brain perfusion in AD patients.The aim of our study was the
evaluation of brain perfusion in specific Brodmann areas (BA)
in EAD and LAD patients, using an automated 3D-voxel-
based processing software (Neurogam).Materials-methods:We
studied 53 consecutive patients from an outpatient Memory
Clinic. We used the established DSM-IV criteria for the diag-
nosis of dementia and the specific established criteria
(NINCDS-ADRDA) for the diagnosis of AD. All the patients
had a neuropsychological evaluation with a battery of tests
including the mini-mental state examination (MMSE). The
EAD group included 20 patients (8 men, 12 women, age±SD
63.1±5.5, MMSE±SD 18.1±6.1, education±SD 11.5±4.5
years) and the LAD group consisted of 33 patients (8 men
and 25 women, age±SD 74.7±5.7 years, MMSE±SD 19.3
±5.9, education±SD 8.4±4.5 years). All the patients underwent
a brain SPECT scan 20 min after the intravenous administra-
tion of 740MBq of 99mTc-HMPAO. We applied the
NeuroGamTM software on the reconstructed data, for the
semi-quantitative evaluation of brain perfusion in BA in the
right (R) and left (L) hemispheres. Perfusion values in BA
were expressed as mean±SD percentage of mean perfusion
of the cerebellum. Statistical analysis was performed using
Qui-square and Mann-Whitney test.Results: Compared with
EAD, LAD patients had statistically significantly lower perfu-
sion in right anterior prefrontal cortex (BA 10R p=0.045), left
orbitofrontal area (BA 11L p=0.05), inferior frontal gyrus (BA
44L p=0.029, BA 44R p=0.045, BA 45R p=0.016, BA 47L
p=0.046, BA 47R p=0.014) and right dorsolateral prefrontal
cortex (BA 46R p=0.014).Conclusion: We found frontal lobe
hypoperfusion in LAD patients, compared with EAD patients.
Our findings would be related with older age in the LADgroup
or with specific heterogeneities between the groups. Further
brain perfusion SPECT studies with automated data analysis
softwares could contribute to a better understanding of the
underlying processes in EAD and LAD.
P440
FDG-PET study of psychophysiological mechanisms
of aggression in patients with vascular dementia
J. Khomenko, D. Susin, G. Kataeva, T. Reznikova, N.
Seliverstova, B. Lipovetsky; N.P.Bechtereva Institute of the
Human Brain, RAS, St.Peterburg, RUSSIAN FEDERATION.
Introduction. It is known that patients with dementia suffer
from not only cognitive but also emotional disturbances that
can manifest in increase of aggression in behavior and self-
aggression. It is of great importance to reveal and treat such
disturbances in time because they can result in decrease of the
quality of life and personal disorders. For the effective correc-
tion it is necessary to understand psychophysiological mecha-
nisms of different types of aggression.The aim of this study
was investigation of interconnections of different types of ag-
gression (according to the Buss-Durkee method) and regional
glucose metabolism rates in patients suffered from vascular
dementia.Methods. PET-FDG was performed in 20 patients
with vascular dementia (age 51-86) on Scanditronix scanner
and standard protocol, relative estimation of regional glucose
cerebral metabolic rate (rCMRglu) in regions of interest cor-
responding to Brodmann areas (BA) were calculated by WFU
PickAtlas. Psychological examination of aggression was per-
formed with Buss-Durkee test included subscales estimating
levels of physical, verbal, displaced and total aggression,
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irritancy, negativism, soreness, suspicion, sense of guilt and
hostility.Results. Significant correlations between rCMRglu (
p<0,05 ) and aggression scores were revealed. In both hemi-
spheres rCMRglu in frontal cortex (BA 9,10,11,46) and ante-
rior cingulate cortex (ACC) (BA 24, 32) negatively correlated
with hostility, suspicion and soreness (r=-0,5-0,6), whereas
verbal and total aggression positively correlated with CMRglu
in ACC and amygdala (r=0,7 for left and 0,6 for right hemi-
sphere). Also CMRglu in left BA 40 and 24 positively corre-
lated with irritancy (r=0,6).Conclusions. Thus, injury of fron-
tal cortex in patients with vascular dementia can result in de-
crease of inhibition effect and manifestation of those types of
aggression in behavior and emotional state which are more
related with personal feeling. Obtained results are in agree-
ment with role of prefrontal cortex in executive control of
behavior including aggression through the inhibition of the
limbic system. At the same time, positive correlation of others
subscale scores (as verbal and total aggression) with functional
activity in ACC, amygdala and BA 40 is in agreement of
finding of connection of increased rCMRglu in these struc-
tures during emotional speech and negative words
encoding.Therefore, different types of aggression were associ-
atedwith different brain structures that is in agreement with the
results of our previous research revealed similar connections in
epileptic patients.
P441
Diagnostic value of regional myocardial adrenergic
imaging using 123I-MIBG compared to SPECT-HMPAO
perfusion and cerebrospinal fluid biomarkers
to differentiate Lowy Body Dementia and Alzheimer
Disease
f. hamza1, i. jardak1, w. amouri1, f. kallel1, n. bouzidi2, s.
charfeddine1, e. turki2, m. maaloul1, c. mhiri2, f. guermazi1;
1Nuclear Medicine Departement, Habib Bourguiba Hospital,
Sfax, TUNISIA, 2Departement of Neurology, Habib Bourgui-
ba Hospital, Sfax, TUNISIA.
Aim:LBD is the second leading cause of degenerative demen-
tia after AD in the elderly population. An early differentiation
of LBD from other dementias, particularly AD, is important
because LBD has a different course and prognosis. The aim of
this study is to determine the potential diagnostic value of
regional myocardial adrenergic 123I- metaiodobenzyl guani-
dine (MIBG) compared to Single Photon Emission Tomogra-
phy (SPECT) perfusion and cerebrospinal fluid protein (CSP)
levels for differential diagnosis between LowyBodyDementia
(LBD) and Alzheimer disease (AD).Materials and
methods:We report prospectively the data of 5 patients initially
evaluated by a neurologist for suspicion of AD. The clinical
symptoms were ambiguous; it was difficult to disentangle
LBD from AD. All patients underwent SPECT-HMPAO per-
fusion that confirms the diagnosis of a neurodegenerative dis-
ease without discrimination AD/LBD. For that, cerebrospinal
fluid protein dosage (amyloid-beta42, tau and Ptau) and cardi-
ac 123I-MIBG scintigraphy were performed.All patients re-
ceived an intravenous administration of 111 MBq of 123I-
MIBG. Static images were acquired using a dual-head scintil-
lation camera equipped with low- to energy general-purpose
(LMEGP) parallel-hole collimators. A 5-min static acquisition
was made in the anterior view at 15 min (early) and 3 hours
(delayed) after the injection of 123I-MIBG. To assess the car-
diac MIBG uptake, the delayed heart to mediastinum ratio
(HMR) was calculated after manually drawing regions of in-
t e r e s t o v e r t h e e n t i r e h e a r t a n d t h e u p p e r
mediastinum.Results:In the first case, the cardiac uptake was
normal with a CSP profile of an AD (amyloid-beta42 =300 pg/
ml, tau=701 pg/ml, Ptau=75 pg/ml). The HMR was signifi-
cantly diminished in 3 cases in accordance with cerebrospinal
fluid protein (CSP) levels, particularly a normal level of the
protein amyloid-beta42 reflecting a LDB disease. However, in
the last case, the reduced uptake in cardiac MIBG scintigraphy
was mismatched with a reduced level of the protein amyloid-
beta42 and elevated levels of the protein tau and its phosphor-
y l a t e d i s o f o rm s u g g e s t i n g t h e d i a g n o s i s o f
AD.Conclusion:Our study supports the usefulness of MIBG
myocardial scintigraphy in the diagnosis of LBD. However,
false positive can be observed and may be age-related because
myocardial MIBG uptake has a significant age-related
decrease.
P442
FDG-PET in the evaluation of brain metabolic changes
induced by Cognitive stimulation in aMCI subjects
E. Giovannini, E. Borsò, F. Benso, E. Carabelli, M. Del Sette,
A. Ciarmiello; Sant’Andrea Hospital, La Spezia, ITALY.
Cognitivetraining has reported to improve cognitive perfor-
mance in Mild CognitiveImpairment (MCI) as well as in older
healthy subjects. 18F-FDG-PET is widelyused in the diagno-
ses of dementia for his abil i ty to ident i fy ear ly
metabolicchanges. This study was aimed to assess the effect
of cognitive stimulation onbrain metabolic network and clini-
cal cognitive performance. Thirty amnestic MCI(aMCI) sub-
jects were enrolled in the study and allocated in two groups
matchedfor cognitive profile, sex and schooling and then ran-
domly assigned to thetraining arm or to the placebo arm. All
subjects underwent toneuropsychological assessment and PET
imaging before and af ter intervent ion. Wefound
significantassociation between brain metabolism and cogni-
tive stimulation in treated aMCIsubjects. Brain metabolic
changes include Brodmann areas reported to be involvedin
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working memory and attentive processes and executive func-
tions. Our study shows that metabolic changes occurearlier
than possible clinical changes related to the intervention.
18F-FDG-PET could provide a useful biomarker of response
to identify a populationof aMCI suitable to respond to treat-
ment, according to most recent data ondefault network mode
and its adaptivity to external stimuli.
P443
Graph-theoretical analysis for comparison of functional
brain networks between very early Alzheimer’s disease
and healthy volunteers
H.Matsuda, E. Imabayashi, J. Rokicki, N. Maikusa; National
Center of Neurology and Psychiatry, Kodaira, JAPAN.
Graph-theoretical analysis was applied to brain perfusion
SPECT using 99mTc-ECD for comparison of functional brain
networks between very early Alzheimer’s disease (AD) and
healthy volunteers. Sixty healthy controls (28 men and 32
women; 54-83 years of age; mean,71.5;SD,8.3) and 29 pa-
tients with very early AD (13men and16women; 57-85 years
of age; mean, 70.9; SD, 7.8) at the stage of amnestic type of
mild cognitive impairment (MCI), who showed progressive
cognitive decline and eventually fulfilled the diagnosis of
probable AD during the subsequent follow-up period of 2-6
years, were included in this study. MCI patients corresponded
to 0.5 in the Clinical Dementia Rating. The Mini-Mental State
Examination (MMSE) score ranged from 24 to 28 (mean,
25.8; SD, 1.5) at the initial visit. Control subjects were healthy
volunteers without memory impairment or cognitive disorders
whose MMSE scores ranged from 26 to 30 (mean, 28.5; SD,
1.4). They did not differ significantly in age or education from
the patients with AD. Group analysis using statistical paramet-
ric mapping revealed significant perfusion decrease in bilateral
posterior cingulate gyri and precunei and parietal cortices in
very early AD as compared to healthy volunteers. Graph-
theoretical analysis using Graph Analysis Tool(Hosseini SM,
et al. PLoS One. 2012;7:e40709)running on Matlab for ana-
lyzing between-group differences in parcellated brain perfu-
sion SPECT using automated anatomical labeling revealed
significant betweenness centrality changes of decrease in left
cingulate gyrus, left inferior parietal cortex, right hippocam-
pus, left inferior frontal cortex and of increase in right middle
temporal cortex, right middle frontal cortex and right inferior
occipital cortex in very early AD group as compared to healthy
volunteers. On the other hand, very early AD group demon-
strated significant clustering changes of decrease in bilateral
posterior cingulate gyri and bilateral insula and of increase in
bilateral inferior parietal cortices and left precuneus as com-
pared to healthy volunteers. Moreover, very early AD group
demonstrated significant degree changes of decrease in left
frontal cortex, left hippocampus, bilateral olfactory cortices,
and of increase in right temporal and frontal cortex, bilateral
occipital cortex and left fusiform gyrus as compared to healthy
volunteers. These results revealed an alteration in small-world
characteristics of the brain networks in very early AD. Com-
pensating mechanism for damaged network in posterior cin-
gulate gyri and hippocampus may work more prominently in
right cerebral hemisphere.
P445
Pilot data on 11C-PiB PET in major depressive disorder
E. Imabayashi1, H. Baba2, H. Matsuda1, I. Kuji3; 1National
Center of Neurology and Psychiatry, TOKYO, JAPAN,
2Juntendo University, TOKYO, JAPAN, 3Saitama Interna-
tional Center, Saitama Medical University, SAITAMA,
JAPAN.
PURPOSE:Many risk factors for dementia have been epidem-
ically investigated with the hope of preventing or delaying the
onset of Alzheimer’s disease (AD). Depression is one of these
risk factors. In this study, the 11C-PiB slight retention in major
depression in the convalescent stage was compared with that
i n n o rm a l c o n t r o l s ( NC ) u s i n g v o x e l b a s e d
analysis.METHODS: Four patients (4 men, 48.5 ±4.2y.o.)
withmajor depression and four NC (4men, 56.3±2.5y.o.) were
focused on this study. 555MBq of 11C-PIB was injected and
70 minutes acquisition was performed using PET/CT equip-
ment with high spatial resolution (Biograph 6 Hi-Rez; Sie-
mens Medical Systems, Inc.). Distribution volume ratio
(DVR) images referenced to cerebellum were generated using
noninvasive Logan graphical analysis. The CTcortical images
were extracted and normalized to anatomically standardized
space using DARTEL algorithm in Statistical ParametricMap-
ping (SPM) 12 (http://www.fil.ion.ucl.ac.uk/spm/). Individual
11C-PIB DVR images were normalized with the same param-
eter as the CT normalization. The normalized 11C-PIB images
were then smoothed. These processed images were analyzed
with SPM12, using absolute DVR value. Voxel based group
analysis of DVR between the depression patients and NC was
performed using t statistics. Main effects used whole-brain
analyses with a threshold at a voxel level of p<0.01 and a
cluster false discovery rate of p<0.05 for the multiple compar-
ison correction. Volume of interest (VOI) analysis was also
applied using Automated Anatomical Labelling (AAL) soft-
ware. VOI values in each cortical areas of parcellation map on
the normalized 11C-PiB DVR images are obtained. DVR
values are compared with t-statistics in each area. RESULTS:
In the left brain of MDD, 11C-PiB retention increased in hy-
pothalamus, caudate, globus pallidus, putamen, uncus, insula,
and superior temporal gyrus. In the right brain, it increased in
anterior cingulate, subcallosal gyrus, posterior cingulate,
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caudate, globus pallidus, lingual gyrus, amygdala, uncus,
parahippocampal gyrus, insula, and superior temporal gyrus.
No absolutely higher 11C-PiB retention in NC comparing with
depression subjects. In VOI analysis of the whole brain, corti-
cal global mean DVR of MDD and NC was 0.929 and 0.934
respectively and with no significant difference. CONCLU-
SION: 11C-PiB retention was increased in MDD in areas
where had been reported to be damaged in MDD; Brodmann
area 24 and subcallosal gyrus. It was observed both in VOI
analysis and voxel based analysis. Whether this 11C-PiB re-
tention is irreversible or not should be confirmed.
P446
Impact of PET Brain Imaging Using F18-FDG
and F18-FLORBETAPIR In Patients With Cognitive
Impairment
C. GAMEZ-CENZANO1, J. J. ROBLES-BARBA1, L.
RODRIGUEZ-BEL1, J. GASCON-BAYARRI2, M.
CORTES-ROMERA1, A. SABATE-LLOBERA1, L. M.
GRACIA-SANCHEZ1, I. ROMERO-ZAYAS1, M. ROCA-
ENGRONYAT1, J. L. VERCHER-CONEJERO1, C.
MAJOS-TORRO1, C. SORIANO-MAS3, C. AGUILERA-
GRIJALVO1, I. RICO-PONS4, R. REÑE-RAMIREZ4;
1IDI-Hospital de Bellvitge-IDIBELL, L’Hospitalet de
Llobregat, SPAIN, 2Neurología-Hospital de Bellvitge-
IDIBELL, L’Hospitalet de Llobregat, SPAIN, 3Hospital de
Bellvitge-IDIBELL, L’Hospitalet de Llobregat, SPAIN,
4Neurologia-Hospital de Bellvitge-IDIBELL, L’Hospitalet
de Llobregat, SPAIN.
Aim: To describe the impact of brain FDG-PET and Amyloid-
PET scans in the differential diagnosis of patients with cogni-
tive impairment, including the suspicion of Alzheimer’s dis-
ease (AD).Materials and Methods: Prospective study includ-
ing 37 patients (24 women) with mean age of 64 years (range:
51-80) with cognitive impairment (MMSEmean=23), includ-
ing suspected dementias as AD. All subjects underwent FDG-
PET, Florbetapir-PET, CTor MRI of the brain and a battery of
neuropsychological tests. The APOE genotype was available
in 10 patients.The FDG-PET brain imaging analysis was visu-
al and quantitative (CORTEX ID. GE Healthcare). Abnormal
FDG-PET brain studies were classified in 2 patterns:
temporoparietal hypometabolism (AD) and other (non-
AD).The Amyloid-PET images were classified as positive or
negative by visual interpretation.The FDG-PET and Amyloid-
PET results were compared to establish concordances and dis-
crepancies between both types of scan and the probable clin-
ical diagnosis. Differences in MMSE in subgroups according
to PET results were calculated.Results: FDG-PETstudies were
abnormal in 12/37 patients (32%): 8 AD (8/8 positive Amy-
loid-PET) and 4 non-AD (1/4 positive and 3/4 negative
Amyloid-PET, one of them with primary progressive aphasia).
FDG-PET studies were normal in 25/37 (68%), but 9 of them
had a positive Amyloid-PET (3 APOE of risk).Amyloid-PET
studies were positive in 18/37 patients (49%); 9 of them with
abnormal FDG-PETscan (8 AD; 1 non-AD).TheMMSEwere
significantly lower in patients with abnormal FDG-PET com-
paring with the normal scans (mean: 19 vs 25), but there were
no differences between positive Amyloid-PET and negative
scans (mean: 22 vs 23).Conclusions: Brain PET is a useful
diagnostic tool in patients with cognitive impairment. Brain
FDG-PET (more available and cheaper) allows to identify
the typical pattern of AD, especially when MMSE <20, where
an additional Amyloid-PET is not needed (all positive in this
study). Brain Amyloid-PET may have a major impact in pa-
tients with negative or abnormal FDG-PET with non-AD
pattern.
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A comparative analysis of SERT function
in neuropsychiatric disorders
S. Nikolaus, H. Müller, H. Hautzel; University Hospital
Düsseldorf, DÜSSELDORF, GERMANY.
Aim: Impairment of serotonin transporter (SERT) is increas-
ingly recognized to play a major role in the pathophysiology of
neuropsychiatric diseases including anxiety disorder (AD),
major depressive disorder (MDD), bipolar disorder (BD) and
schizophrenia (SZ). In the present investigation, we compared
SERT binding by subjecting all available in vivo binding data
on AD, MDD, depressed state of BD (BDdep), manic state of
BD (BDman) and SZ to a retrospective analysis. Materials &
Methods: In patients with AD (n=207),MDD (n=694), BDdep
(n=60), BDman (n=1) and SZ (n=46) SERT was assessed in
various cortical and subcortical regions with either PET or
SPECT and compared to healthy individuals. Studies were
pooled and median values and interquartile ranges of
percentual differences relative to controls were determined
for the individual brain regions. Differences to controls were
assessed with the Wilcoxon-signed-rank-test. Differences be-
tween disorders were assessed using the Mann-Whitney-U-
test. Results: In AD, SERTwas significantly reduced in thala-
mus (-10%), amygdala (-7%) and midbrain (-13%) relative to
controls. In MDD, SERT was significantly decreased in
straitum (-6%), thalamus (-12%), prefrontal cortex (-15%),
amygdala (-15%) and midbrain (-8%), whereas in the insula
(+9%), a significant elevation was observed. In BDdep, SERT
was significantly elevated in cingulate (+19%) and insula (+
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13%), while, in BDman, SERT was significantly elevated in
the midbrain (+18%). In SZ, SERT was not significantly al-
tered relative to controls. Comparison between disorders
yielded no significant differences of SERT binding. Conclu-
sion: The most extensive decline of SERT relative to controls
was observed in MDD involving both neocortical and subcor-
tical regions. In AD, SERT decline relative to controls was
confined to midbrain, thalamus and amygdala, whereas no
decline of SERT binding was observed in SZ. Moreover, in
contrast to AD and SZ, increases of SERT relative to healthy
individuals were detected in the insula of MDD, and in cingu-
late and insula of BDdep patients, while investigations on
BDman yielded an elevation of midbrain SERT. Taken togeth-
er, findings showed that AD, MDD, BD and SZ differ as to
affected brain region(s) and extent as well as direction of
SERT dysfunction, which may be related to differences in
serotonin levels.
P448
Anxiety disorder, major depression, bipolar disorder
and schizophrenia show different patterns of 5-HT1A
receptor dysfunction
S. Nikolaus, H. Müller, H. Hautzel; University Hospital
Düsseldorf, DÜSSELDORF, GERMANY.
Aim: Impairment of 5-HT1A receptor (5-HT1AR) function is
increasingly implied in the pathophysiology of neuropsychiat-
ric diseases including anxiety disorder (AD), major depressive
disorder (MDD), bipolar disorder (BD) and schizophrenia
(SZ). In the present investigation, we compared 5-HT1AR
binding by subjecting all available in vivo binding data on
AD, MDD, depressed state of BD (BDdep) and SZ to a retro-
spective analysis. Materials & Methods: In patients with AD
(n=37), MDD (n=245), BDdep (n=95) and SZ (n=100) 5-
HT1AR were assessed in various cortical and subcortical re-
gions with either PET or SPECT and compared to healthy
individuals. No investigations of 5-HT1AR were conducted
in the manic state of BD. Studies were pooled, and medians
and interquartile ranges of percentual differences relative to
controls were determined for the individual brain regions. Dif-
ferences to controls were assessed with the Wilcoxon-signed-
rank-test. Differences between disorders were assessed using
the Mann-Whitney-U-test. Results: In AD, 5-HT1AR were
significantly reduced in frontal cortex (-13%), cingulate (-
24%), hippocampus (-15%), amygdala (-22%), insula (-23%)
and midbrain (-29%) relative to controls. In MDD, 5-HT1AR
were significantly elevated in parahippocampal gyrus (+23%),
whereas a significant reduction was observed in the midbrain
(-17%). In BDdep, 5-HT1AR were significantly increased in
h i p p o c ampu s ( + 2 1% ) , amygd a l a ( +1 9% ) a n d
parahippocampal gyrus (+32%). In SZ, 5-HT1AR were
significantly decreased in temporal cortex (-6%), occipital cor-
tex (-5%), amygdala (-12%) and midbrain (-5%). 5-HT1AR
were significantly diminished in frontal cortex (-11%), cingu-
late (-8%), amygdala (-49%) and insula (-21%) of AD com-
pared to MDD patients. Moreover, 5-HT1AR were signifi-
cantly lowered in frontal cortex (-16%), cingulate (-6%) and
midbrain (-19%) of AD compared to SZ patients and in the
insula (-24%) of AD compared to BDdep patients. There were
no significant differences of 5-HT1AR binding betweenMDD
and SZ and between BDdep and SZ. Conclusion: Compari-
sons between disorders revealed that, in AD, frontal 5-HT1AR
were decreased relative to controls as well as relative to MDD
and SZ (where they were unaltered). Moreover, in AD, frontal,
cingulate, amygdalar and mesencephalic 5-HT1AR were
lowered relative to controls as well as relative to SZ. Addition-
ally, in AD, temporal 5-HT1AR were not different from
healthy individuals but elevated compared to SZ patients
(where they were unaltered). From this may be inferred that
frontal and limbic inhibition - as exerted via 5-HT1AR binding
sites - is lower in AD relative to MDD and SZ, whereas tem-
poral inhibition is augmented (relative to SZ).
P449
Different patterns of 5-HT2A receptor dysfunction
in anxiety disorder, major depression, bipolar disorder
and schizophrenia
S. Nikolaus, H. Hautzel, H. Müller; University Hospital
Düsseldorf, DÜSSELDORF, GERMANY.
Aim: Impairment of 5-HT2A receptor (5-HT2AR) func-
tion is increasingly implied in the pathophysiology of
neuropsychiatric diseases including anxiety disorder
(AD), major depressive disorder (MDD), bipolar disor-
der (BD) and schizophrenia (SZ). In the present investi-
gation, we compared 5-HT2AR binding by subjecting all
available in vivo binding data on AD, MDD, manic
state of BD (BDman) and SZ to a retrospective analysis.
Materials & Methods: In patients with AD (n=33),
MDD (n=287), BDman (n=10) and SZ (n=199) 5-
HT2AR were assessed in various cortical and subcortical
regions with either PET or SPECT and compared to
healthy individuals. No investigations of 5-HT2AR were
conducted in the depressed state of BD. Studies were
pooled, and medians and interquartile ranges of
percentual differences relative to controls were deter-
mined for the individual brain regions. Differences to
controls were assessed with the Wilcoxon-signed-rank-
test. Differences between disorders were assessed using
the Mann-Whitney-U-test. Results: In AD, 5-HT2AR
were significantly elevated in the temporal cortex (+
8%) relative to controls. In MDD, 5-HT2AR were
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S555
significantly decreased in prefrontal (-6%), frontal (-6%)
and occipital cortex (-4%) as well as cingulate (-7%). In
BDman, 5-HT2AR were significantly decreased in fron-
tal, parietal, temporal and occipital cortex as well as
cingulate. insula and fusiform gyrus (-20%, each). In
SZ, 5-HT2AR were significantly diminished in frontal
(-25%), temporal (-19%) and occipital cortex (-5%). In
AD, 5-HT2AR were significantly increased in the tem-
poral cortex (+10%) compared to MDD patients and in
the frontal (+27%) and temporal cortey (+27%) com-
pared to SZ patients. Moreover, 5-HT2AR binding in
the frontal cortex (+20%) was significantly augmented
in MDD compared to SZ patients. Conclusion: In AD,
temporal 5-HT2AR were elevated relative to controls as
well as relative to MDD (where they were unaltered)
and to SZ (where they were decreased compared to con-
trols). Moreover, frontal 5-HT2AR were elevated in AD
compared to normal subjects as well as relative to SZ
(where they were decreased compared to controls). Ad-
ditionally, in MDD, frontal 5-HT2AR were reduced rel-
ative to controls and elevated relative to SZ (where they
were decreased compared to controls). From this may be
inferred that frontal and temporal excitation - as exerted
via 5-HT2AR binding sites - is higher in AD relative to
MDD and SZ, and higher in MDD relative to SZ. It can
be hypothesized that region-specific alterations of sero-
tonin binding sites are related to specific disturbances in
the processing of emotion and memory in the individual
disorders.
P450
Brain perfusion single photon emission computed
tomography (SPECT) in pateints
with attention-deficit/hyperactivity disorder (ADHD)
using 99mTc-ECD: a report of three cases and review
of the literature
M. Taghizadeh Asl1, F. Yousefi2, R. Nemati3, M. Assadi2;
1Department of Nuclear Medicine, Kasra Hospital, Tehran,
IRAN, ISLAMIC REPUBLIC OF, 2The Persian Gulf Nuclear
Medicine Research Center, Bushehr University of Medical
Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF,
3Department of Neurology, Bushehr Medical University Hos-
pital, Bushehr University of Medical Sciences, BUSHEHR,
IRAN, ISLAMIC REPUBLIC OF.
Attention-deficit/hyperactivity disorder (ADHD) is one
of the most prevalent developmental disorder in chil-
dren. The main symptom of the disorder is inattention,
hyperactivity, and impulsivity, and is among the most
prevalent of childhood disorders. Only a limited number
of studies have investigated cerebral metabolism or
perfusion in these pateints , therefore , such indices
are not fully understood yet. In this study, three cases
of ADHD underwent brain perusion SPECT to evaluate
cerebral perfusion. All three patients showed abnormal
cerebral perfusion on brain SPECT while had normal
MRI. The pateints 1 was a 5 years old girl with ADHD.
The SPECT showed moderate frontal hypo perfusion
and bilateral inferior temporal hypoperfusion. The pa-
tient 2 was a 14 years old girl with ADHD. The SPECT
showed generalized diffuse cortical hypoperfusion more
prominently on the superior pre-frontal cortex and also
moderate hypo perfusion of cerebellar hemispheres. And
patheint 3 was a 7 years old girl with ADHD. The
SPECT showed mild hypoperfusion of the right
parietal-temporal region and sub-cortical structures . In
conclusion , the study showed the frontal lobe is a key
structure in ADHD that another area of the brain may
contribute to the disease with various severity.
P451
Our institutional pictorial essay on brain perfusion
SPECT in various neuro-psychiatric disordsers
and intoxication: Though practical , it is not very
commonly used
M. Taghizadeh Asl1, R. Nemati2, M. Assadi3; 1Department
of Nuclear Medicine, Kasra Hospital, Tehran, IRAN, ISLAM-
ICREPUBLICOF, 2Department of Neurology, BushehrMed-
ical University Hospital, Bushehr University of Medical Sci-
ences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF, 3The
Persian Gulf Nuclear Medicine Research Center, Bushehr
University of Medical Sciences, BUSHEHR, IRAN, ISLAM-
IC REPUBLIC OF.
Structural and functional images of the brain play an
important role as powerful adjuncts in the management
of an increasing number of neurologic and psychiatric
diseases. Brain SPECT, in particular, with perfusion
agents or with neuroreceptor imaging radiopharmaceuti-
cals, is rapidly becoming a clinical tool in many places.
For many neurologic and psychiatric conditions, this im-
aging modality has been used in diagnosis, prognosis
assessment, evaluation of response to therapy, risk strat-
ification, detection of benign or malignant viable tissue,
and choice of medical or surgical therapy. We will pres-
ent our institutional experience formatting a pictorial re-
view on of brain perfusion SPECT on more than 20
types of different neurologic and psychiatry diseases
such as dementias, epilepsy, cerebral palsy, head injury,
brain tumor , Herpes encephalitis, hypoxic brain damage
, vacuities, depression, CO poisoning , cocaine abuse
and also elemental mercury poisoning.
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Evaluating the brain status of serotonin transporters
in depression-like rat model using 4-[18F]-ADAM/animal
PET
C. Cheng1, K. Ma2, S. Lu1,3, C. Shiue1, W. Huang4; 1De-
partment of Nuclear Medicine, Tri-Service General Hospital,
National Defense Medical Center, TAIPEI, TAIWAN, 2De-
partment of Biology and Anatomy, National Defense Medical
Center, TAIPEI, TAIWAN, 3Graduate Institute of Medical
Sciences, National Defense Medical Center, Taipei, TAIWAN,
4Departments of nuclear medicine and medical research,
Changhua Christian Hospital, CHANGHUA, TAIWAN.
Aims: Depression may lead to enormous loss of society
and economy. Previous studies have demonstrated that
depression may cause the decrease of brain serotonin
transporter (SERT) density. The aim of this study was
to assess the effects of chronic mild stress (CMS) on
serotonin transporters in the depression-like rat model
using the animal positron emission tomography (animal-
PET) coupled with 4-[18F]-ADAM. Materials and
methods: Twelve male Sprague-Dawley rats (weighted in
350±10 g) were divided into the control and CMS
groups. A five weeks protocol of unpredictable CMS
was applied to those rats of CMS group. The body
weight measurement and depression-related behavioral test
(force swimming test, FST) were used to evaluate the
depression-like symptoms in CMS rat. Moreover, the con-
centration of corticosterone in blood was also measured
with liquid chromatography-tandem mass spectrometry
(LC-MS/MS). The 4-[18F]-ADAM (targeting to serotonin
transporters) coupled with animal positron emission topog-
raphy (animal-PET) was used to examine the status of
serotonin transporters in depression-like rat model and
the images were calculated and expressed as specific up-
take ratios (SURs). Results: Five weeks after the opera-
tion of CMS protocol, the CMS rat showed obvious dec-
rement of body weight than that in control rat. The data
of FST showed that the CMS rats had longer immobility
time than that of control rats. We also found that the
concentration of corticosterone in CMS rat is higher than
control value. The 4-[18F]-ADAM SURs in various brain
regions of CMS rat were obviously lower than those of
controls. Conclusion: These results suggest that CMS may
induce the depression-like symptoms and cause the reduc-
tion of serotonin transporters in rat brain. In addition, the
4-[18F]-ADAM coupled with animal-PET may be a fea-
sible way for evaluating the condition of serotonin trans-
porters in depression.
P453
SPECT scanning of brainstem serotonin transporter
availability reveals association with circulating
inflammatory tumour necrosis factor
R. Krishnadas1,A.Nicol2, J. Sassarini3, N. Puri2, S. Pimlott2,
D. Hadley2, I. McInnnes3, J. Cavanagh1; 1Sackler Institute of
Psychobiological Research, Institute of Health and Wellbeing,
University of Glasgow, Glasgow, UNITED KINGDOM,
2NHS Greater Glasgow & Clyde, Glasgow, UNITED KING-
DOM, 3University of Glasgow, Glasgow, UNITED
KINGDOM.
Depression is common in patients suffering from inflammato-
ry diseases. Among the medically ill, people with inflamma-
tory diseases are at greater risk of developing a major depres-
sive illness compared to the general population. In patients
with arthritis treated with tumour necrosis factor (TNF-α) an-
tagonists, an antidepressant effect is seen, independent of the
improvement of arthritis. In addition, pre-clinical studies in
rodent models have shown that pro-inflammatory cytokines
increase serotonin transporter availability and function, lead-
ing to depressive symptoms. The aim of the present study was
to investigate associations between plasma TNF-α and
brainstem serotonin transporter (SERT) availability using
123I-beta-CIT SPECT imaging. Healthy subjects and subjects
with psoriasis (Ps) / psoriatic arthritis (PsA) undergoing treat-
ment with TNF-α antagonist (etanercept) were included. Plas-
ma TNF-α and brainstem SERT availability was assessed in
thirteen healthy females (13 F, mean age 57 years, range 45-65
years). Twelve patients with Ps/PsAwere also included in the
study (6M, 6F, mean age 48 years, range 30-65 years). The Ps/
PsA patients underwent investigation up to 14 days before and
6 - 8 weeks after treatment with TNF-α antagonist (etanercept
50mg once weekly). Plasma TNF-α was measured using
ELISA. 123I-beta-CIT SPECT (Neurofocus 900 scanner)
was used to measure brainstem SERT availability. Scanning
was performed 3-4 h post 123I-beta-CIT administration (150
MBq) and specific to non-specific beta-CIT uptake ratios were
computed using ROI templates drawn over the brainstem and
occipital region (reference region). For the healthy subjects,
plasma TNF showed a significant correlation with brainstem
5-HTT availability (corrected for age) (Spearman’s rho=0.61;
p=0.03).For the subjects with Ps/PsA, baseline plasma TNF-α
was significantly correlated with baseline brainstem SERT
availability (rho=0.76; p=0.004). TNF blockade treatment
with etanercept was associated with a reduction in 123I-beta-
CIT SERT binding (t=2.09; p=0.03). A relationship between
brainstem SERT availability and circulating inflammatory tu-
mour necrosis factor is indicated by these findings. These
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findings support a potential mechanistic pathway that link cir-
culating inflammatory markers to the pathophysiology under-
lying major depression.
P454
Resting-state Functional Connectivity in Social Anxiety
Disorder Compared to Healthy Controls and the Effect
of Pharmacotherapy
A. G. G. Doruyter1, C. Lochner1, P. Dupont2, D. Stein1, J.
Warwick1; 1Stellenbosch University, Cape Town, SOUTH
AFRICA, 2Katholieke Universiteit Leuven, Leuven,
BELGIUM.
Aim: Neuroimaging research has identified differences in rest-
ing state networks between participants with Social Anxiety
Disorder (SAD) and healthy controls. It has been hypothesized
that network disruptions in SAD (particularly to the default
mode network) may be correlated with differences in social
cognition in the disorder. The effect of pharmacotherapy on
these resting-state networks in SAD has thus far received little
attention. Our aim is to test for effect of pharmacotherapy on
resting-state functional connectivity in SAD. Materials and
methods: A retrospective analysis of Tc-99mHMPAO SPECT
data (obtained in previous research) of patients meeting DSM-
IV criteria for SAD and healthy controls (HCs) was per-
formed. SAD participants were scanned at baseline and after
an 8-week course of pharmacotherapy (either with citalopram
or moclobemide). Image data were collated and reconstructed
using optimal techniques (iterative algorithms including cor-
rections for attenuation, scatter and collimator blurring). Scans
were then pre-processed using SPM12. Analyses (seed-based
and using a priori regions of interest) are currently ongoing to
compare resting functional connectivity in the three groups
(SAD at baseline; HCs; and SAD post-treatment). Results:
Twenty-seven SAD patients (of which 20 underwent follow-
up scanning post-treatment) and 18 age and gender-matched
HCs were included. Initial analyses indicate several differ-
ences in perfusion-based connectivity across groups. Final re-
sults of group connectivity differences, including the effect of
pharmacotherapy on functional connectivity in SAD will be
presented. Conclusion: The results will be discussed in the
light of existing studies of functional connectivity in SAD,
and in the light of emerging hypotheses about the role of the
default mode network in social cognition. In particular these
data will be analysed in terms of the putative role of altered
social cognitive function in the aetiology of SAD.
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Imaging Mutant Huntingtin Aggregates: Development
of Potential PET Ligands
C. J. Brown1, M. Prime1, D. Clark-Frew1, S. Schaertl2, J.
Häggkvist3, C. Halldin3, V. Stepanov3, A. Varrone3, K.
Varnäs3, M. Svedberg3, I. Munoz-Sanjuan4, V. Khetarpal4,
J. Bard4, J. Wityak4, C. Dominguez4; 1Evotec UK Ltd,
Abingdon, UNITED KINGDOM, 2Evotec AG, Hamburg,
GERMANY, 3Karolinska Institutet, Stockholm, SWEDEN,
4CHDI, Los Angeles, CA, UNITED STATES.
Aim: Develop a PET ligand for mutant huntingtin (mHTT)
Aggregates. Aggregates of mHTT form in some brain cells
of Huntington’s disease (HD) patents and can be observed
by post-mortem analysis. Huntington’s disease (HD) is a rare,
fatal, autosomal dominant inherited disease caused by a CAG
repeat expansion in the huntingtin gene which results in an
expanded polyglutamine tract in the mutant huntingtin protein.
Clinical manifestations of the disease include motor and cog-
nitive impairment, psychiatric disturbances, as well as meta-
bolic abnormalities, with disease onset typically occurring be-
tween the ages of 30 and 50, and death within 15 to 20 years.
There are currently no biomarkers for mHTT aggregates
in vivo. The ability to track the appearance, quantity and loca-
tion of mHTT aggregates in HD patients is of critical impor-
tance. Such a biomarker may have the potential to monitor the
progress of mHTT lowering therapies independently of a clin-
ical assessment. Methods and Materials: Radioligand binding
assays were used to develop novel compounds that bind to
Exon1-Q46 aggregates. SAR led to compounds with good
properties for autoradiography (ARG), leading to candidates
for 11C-labelling. Results from micro-PET imaging of 11C-
labelled lead compounds in the Q175 mouse model of HD are
presented. Conclusions: Trends were identified from analysis
of the ARG results that allow development of compounds with
better non-specific binding and specific binding to mHTT ag-
gregates. An 11C-labelled lead compound was identified with
suitable properties for progression into human PET studies.
P457
The comparison of I-123-ioflupane dopamine transporter
imaging with I-123-MIBG cardiac imaging in Parkinson’s
disease and Lewy body disease
M. Momose; Matsumoto Medical Center, Matsumoto,
JAPAN.
Purpose; to create the flow chart of diagnosis for Parkinson’s
disease (PD) and Lewy body disease (LBD) by means of
I-123-ioflupane dopamine transporter (DAT) imaging and/or
I-123-metaiodobenzylguanidine (MIBG) cardiac imaging.
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Materials and methods; 27 cases of PD and 2 cases of LBD
performed DAT imaging and MIBG imaging. For DAT imag-
ing clearly comma-shaped accumulation and specific binding
ratio (SBR)≥4.5 were negative, and the others were positive.
For MIBG imaging early heart to mediastinum ratio
(H/M)≥2.1 and delayed H/M≥2.3 were negative, and the
others were positive. Result; the positive ratio of DAT imaging
was 23/29 (79.3%), and that of MIBG imaging was 17/29
(58.6%). The agreement of the both imaging findings was
19/29 (65.5%). The 2 cases of DAT negative and MIBG pos-
itive were considered to be the scan without evidence of do-
paminergic deficit (SWEDD), and the 8 cases of DAT positive
and MIBG negative were considered to be the Parkinson’s
syndrome (PS) other than PD. Conclusion; the DAT imaging
has better to be performed first, and the MIBG imaging to be
performed second to differentiate PD from PS.
P458
Functional correlates of cerebrospinal fluid levels of lactate
dehydrogenase in Alzheimer’s Disease: a 18F FDG
PET/CT study
A. Chiaravalloti1, M. Pierantozzi2, C. Liguori2, C. Di
Russo1, A. Fiorentini1, R. Catalano1, S. Pizzi1, O. Schillaci1;
1Department of Biomedicine and Prevention, University Tor
Vergata, Rome, ITALY, 2Department of Neurosciences, Uni-
versity Tor Vergata, Rome, ITALY.
Aim: To investigate the relationships among cerebrospinal flu-
id (CSF) levels of lactate dehydrogenase (LDH) and brain
glucose consumption as detectable by means of 2-deoxy-
2-(18F) fluoro-D-glucose (18F-FDG) Positron Emission
Tomography/Computed Tomography (PET/CT) in a popula-
tion with Alzheimer’s disease (AD). Materials and methods:
The study included 33 newly diagnosed AD patients accord-
ing to the NINCDS-ADRDA criteria (15 males and 18 fe-
males, mean age 70±7 years old) with a disease duration of
2.7 years (mean). All the subjects underwent a cerebrospinal
fluid (CSF) assay for levels of LDH, p-Tau, t-Tau, Aβ1-42
amyloid peptide ~ 1 month before PET/CT examination.
Moreover the Apo E phenotype of the entire population has
been assessed. A standard Magnetic Resonance has been per-
formed in all the subjects enrolled in the study. The relation-
ships were evaluated by means of regression analysis model,
Statistical Parametric Mapping (SPM8) using gender, age, dis-
ease duration, Mini Mental State Examination (MMSE) and
CSF levels of p-Tau, t-Tau and, Aβ1-42 amyloid peptide and
Apo E phenotype as covariates. Results: We did not find dif-
ferences in the clinical and CSF parameters in genders. Low
CSF levels of LDH are related to a decreased 18F-FDG uptake
in left Brodmann area (BA) 10,11 and 35 while no areas of
increased 18F-FDG uptake related to LDH levels have been
detected. Conclusions: The results of our study suggests that
increased LDH concentrations in CSF are related to a wide
cortical dysfunction that involves the left frontal and temporal
lobe. This pattern is independent from CSF and genetic bio-
markers that are commonly used in the evaluation of AD.
P459
Is amyloid deposition related to the age of onset
of Alzheimer disease?
A. Chiaravalloti1, A. Lacanfora1, R. Danieli1, A.
Fiorentini1, L. Cravello2, F. Di Iulio2, C. Caltagirone2, O.
Schillaci1; 1Department of Biomedicine and Prevention, Uni-
versity Tor Vergata, Rome, ITALY, 2IRCCS Santa Lucia,
Rome, ITALY.
Aim: To investigate the relationships between age of onset of
Alzheimer’s disease (AD) and brain amyloid deposition as
detectable by means of 18F Florbetapir Positron Emission
Tomography/Computed Tomography (PET/CT).Materials
and methods: We examined 55 newly diagnosed probable
AD patients according to the NINCDS-ADRDA criteria (25
women and 30 men; mean age 75 ± 6 years). A standard
Magnetic Resonance has been performed in all the subjects
enrolled in the study before a 18F Florbetapir PET/CT scan.
Relationships between age of onset of AD an brain amyloid
distribution have been assessed by a regression analysis in
Statistical ParametricMapping version 8 (SPM8) using gender
and Mini Menta l Sta te Examinat ion (MMSE) as
covariates.Results: MMSE resulted equal to 23±4 respectively
with no differences in genders. SPM8 regression analysis
(with a statistical threshold of p=0.001, family wise error
(FWE)-corrected) did not show a significant relationship be-
tween age o f onse t and amylo id depos i t i on in
brain.Conclusions: the results of our study show that amyloid
deposition in brain do not differ in those patients with an early
or late onset of AD.
P460
Initial experience of the dopamine transporter SPECT
in three pediatric patients with rare neurodegenerative
disorder
I. Mochida, K. Matsunaga, S. Watanabe, K. Isohashi, T.
Watabe, M. Tatsumi, H. Kato, E. Shimosegawa, J. Hatazawa;
Osaka University Graduate School of Medicine, Suita-shi,
Osaka, JAPAN.
[Introduction]Dopamine transporter imaging with I-123 FP-
CIT SPECT visualizes distribution of dopamine transporter
in the striatum which is the postlude of the substantia nigra-
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striatum dopaminergic system nerve. I-123 FP-CIT SPECT
began in January, 2014 in Japan. We experienced three chil-
dren with iron deposition in the brain studied with I-123 FP-
CIT. [Cases]Case 1:A 15 year-old-female. Case 2 and 3 : Both
6 year-old-boy (twin).These 3 cases had no history of severe
birth trauma or ischemic condition. They had no family history
of movement disorders, dementia, or psychiatric illness. They
had psychomotor retardation from about 2 or 3 years old, and
movement disorder was getting worse. Case 1 was diagnosed
as SENDA (Static Encephalopathy of childhood with Neuro-
Degeneration in Adulthood), and Case 2 and 3 were
INAD(Infantile Neuro-Axonal Dystrophy)by genetic analy-
ses. Their MRI examination of the brain was performed sev-
eral times. In all cases, gradually symmetrical hypointensity
was shown in the mid brain, bilaterally, on T1-, and T2-
weighted MR images. All of I-123 FP-CIT SPECT findings
were within normal range, but unexpected asymmetrical de-
crease of I-123 FP-CIT accumulation in lentiform nuclei was
found in Case 2 and 3. [Discussions]The reports about the
relation between ‘ iron accumulated in the midbrain and do-
pamine transporter in the striatum’ are not found yet. There is a
report that levodopa had an effect on a patient who showed
parkinsonism, regarded as SENDA, seen in the iron accumu-
lated in substantia nigra of the brain1. Dopamine treatment
may start early if we can detect a substantia nigra change in
the follow-up I-123 FP-CIT SPECT. The mid brain abnormal
signal area was not substantia nigra in Case 2 and 3, normal
accumulation was expected in DAT scan, but recognized
laterality for accumulation. The normal image data base in
the growth process of child was not studied yet, as a result,
the judgment was difficult, and it was necessary to accumulate
knowledge continuously. 1.Gregory A, et al. J Med Genet
2009;46:73-80
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Investigating the co-grafted effects of porcine ventral
mesencephalic tissue and mesenchymal stem cells
in Parkinson’s disease rat model using [18F]
-FDOPA/animal PET
K. Ma1, T. Liu1, Y. Jhao1, S. Weng1, K. Tzen2, R. Yen2, W.
Huang3; 1Department of Biology and Anatomy, National De-
fenseMedical Center, TAIPEI, TAIWAN, 2Department of Nu-
clear Medicine, National Taiwan University Hospital, TAIPEI,
TAIWAN, 3Departments of nuclear medicine and medical re-
search, Changhua Christian Hospital, CHANGHUA,
TAIWAN.
Aim: Parkinson’s disease (PD) is a progressively neurodegen-
erative disease characterized by a loss of dopaminergic neu-
rons in the nigrostriatal pathway. Transplantation of human
fetal ventral mesencephalic (hfVM) tissue has been considered
as an effective treatment for PD, but the ethical issues limit the
clinical application. Porcine fetal ventral mesencephalic
(pfVM) tissue might be an alternative source for xenografting
treatment in neurodegenerative diseases. However, the im-
mune rejection in this xenograft method needs to be resolved.
Recently, mesenchymal stem cells (MSCs) have been reported
to possess immunomodulatory effects that reduced attack by
immune cell in animal model. MSCs can also produce growth
factors and provide an appropriate micro-environment in situ.
In this study, we evaluated the co-grafted effects of porcine
ventral mesencephalic tissue and mesenchymal stem cells in
Parkinson’s disease rat model using [18F]-FDOPA/animal
PET. Materials and methods: The hemiparkinsonian rats were
created by injecting the neurotoxin 6-hydroxydopamine into
the median forebrain bundle. The E27 pfVM tissue and/or rat
MSCs were grafted into striatum of hemiparkinsonian rat.
Apomorphine-induced contralateral rotations test were per-
formed to reflect the lesion severity at 1, 2 and 3 months after
the transplantation. The [18F]-FDOPA coupled with small an-
imal PET was used to evaluate the status of dopaminergic
system. Three months after the transplantation, the immuno-
histochemical staining of tyrosine hydroxylase were per-
formed and the results were compared with those of the PET
images. In addition, T-cell staining was executed to clarify
whether MSCs could provide immune modulation in grafted
region of brain. Results: The data of rotation behavior showed
that the number of rotations in pfVM-grafted group reduced
after 1 month, but increased at 2 and 3 month after transplan-
tation. In the group of co-grafted pfVM tissue with rat MSCs,
the rotation numbers were reduced at all 3 months after the
transplantation. The PET imaging results showed that both in
pfVM group and co-graft group, the grafted area revealed
obviously [18F]-FDOPA uptakes. In addition, the results of
immunohistochemistry studies paralleled to those of PET im-
aging studies. Conclusion: Our results demonstrated that co-
transplantation of pfVM and MSCs may exert beneficial ef-
fects for treatment of the Parkinson’s disease.
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Cerebral cortex glucose metabolism correlates
with the MRS findings in white matter in HIV positive
patients
E. Gromova, J. Khomenko, G. Kataeva, A. Bogdan, I.
Kotomin; N.P.Bechtereva Institute of the Human Brain,
RAS, St.Peterburg, RUSSIAN FEDERATION.
IntroductionIt is well known that human immunodeficiency
virus (HIV) after penetrating in CNS initializes the cascade of
immunological responses accompanied by inflammation that
result in HIV induced white and gray matter damage and even
atrophy with cognitive consequences. In our previous studies
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(both with PET-FDG and MRS), metabolism reduction in an-
terior cingulate cortex occur early after disease onset was re-
vealed. It is also known that significant associations between
the tractography metrics and cognitive performance in HIV+
patient exists. The complex multimodal examination with neu-
roimaging methods could better elucidate relationship be-
tween HIV media ted CNS injury and cogni t ive
dysfunction.The aim of this study is comparison of brain met-
abolic changes revealed by PET-FDG andMRS.MethodsTwo
groups of HIV+ patients (age 25-40) were studied: 38 without
neurological or cognitive deficit and other pathology and 17
with opportunistic infection out of brain. PET-FDG was per-
formed on Gemini TF Base scanner and standard protocol,
relative estimation of glucose cerebral metabolic rate
(CMRglu) in regions of interest (ROI) corresponding to
Brodman areas (BA) were calculated by WFU PickAtlas.
Multivoxel MRS of brain was performed on Achieva 3T scan-
ner, Philips (2D PRESS H-МРС, TE/TR=144/1500 ms) and
included supraventricular white matter (WM) and medial cor-
tex. Anatomical localization was taken into consideration: area
of MRS study (8*9 voxels (10*10*15 mm), whole volume
80*90*15 mm) was divided into 9 ROIs: 6 in WM (3 ROIs:
anterior, medium and posterior for each hemisphere) and 3
ROIs in medial cortex. NAA/Cr, (NAA - N-acethyl aspartate,
Cr - creatine) were analyzed.Results. Significant correlations
between CMRglu and NAA/Cr not only in adjacent zones in
one hemisphere, but even more prominent between contralat-
eral ROIs were revealed. In left hemisphere NAA/Cr in ante-
rior WMROI were correlated with CMRglu in BA 5,6 and 24
(r=0,4; p<0,05); NAA/Cr in medium WM - with BA 6,8,9,24
and 32 (r 0,4-0,5; p<0,05), and NAA/Cr in posterior WM -
with BA 7 (r=0,4; p<0,05). Similar correlations revealed be-
tween WM of right hemisphere and CMRglu in left hemi-
sphere, but not in ispilateral hemisphere. NAA/Cr in left ante-
rior WM correlated with CMRglu in contralateral BA8 and 32
(r=0,4; p<0,05).Conclusion. Since NAA/Cr is neuronal mark-
er, it is possible to suggest that integrity of neural tracts con-
stituent WM coupled with the state of corresponding cortex
areas, and atrophy in gray matter is associated with damage of
subcortical conduction tracts.
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Effect of mTOR inhibition on epileptogenesis in the rat
epilepsy model
A. CULLIER1,2, F. MASKALI1, A. CLEMENT1, S.
POUSSIER1, G. KARCHER1, P. MARIE1, E. RAFFO3;
1GIE-NANCYCLOTEP, VANDOEUVRE-LES-NANCY,
FRANCE, 2hospital of brabois, Vandoeuvre les nancy,
FRANCE, 3hospital of brabois, VANDOEUVRE-LES-NAN-
CY, FRANCE.
Aim: The Mesial Lobe Temporal Epilepsy (mLTE) is the most
drug-resistant epilepsy. Its natural history, reconstructed by the
lithium-pilocarpine in rats model, starts with the SE followed
by a histological restructuration within the hippocampal and
para-hippocampal regions, which creates a hyper-excitable
neo-circuit implementing recurring spontaneous seizures.
The mTOR pathway is a proteical intracellular complex that
regulates synaptogenesis, neuronal plasticity, inflammation
and proliferation of cerebral gliosis. This specific pathway is
activated at different stages of the mLTE. The goal of the
present pre-clinical study was to evaluate the impact of
inhibiting the mTOR pathway by Rapamycin over
epileptogenesis and neuroprotection in the lithium-
pilocarpine model. Methods: For this study, 44 adult rats were
divided into 3 groups: treated SE (i), untreated SE (ii) and
healthy witnesses (iii). Each of them received Rapamycin per
os at 3 stages: H+2 at 6 mg per kg per day, then D1 and D2 at
3 mg per kg per day. The treatment was evaluated by studying
metabolic modifications, using positon emission tomography
and 2-[18F]-fluoro-2-deoxy-D-glucose, at H+4, D2 and D8
(1), the research for spontaneous crisis from D8 (2), and even-
tually by counting neurons in the interest regions after sacrifice
at D60 (3). Results: In the acute phase, we show an increase of
consequences of the SE on glucose local cerebral metabolism,
in the hippocampus and parahippocampal cortex, by the use of
Rapamycin. However, an increased hippocampal
hypometabolism at D2 suggests that Rapamycin may have a
neuroprotecting potential, which has to be confirmed by his-
tological study. We don’t observe any treatment effect at D8.
We don’t show either any influence of Rapamycin treatment
over epileptogenesis. Conclusion: Our results along with pre-
vious studies outcomes recommend evaluating Rapamycin ad-
ministration from the beginning of SE and by the intra-
peritoneal pathway, as well as treatment prolongation during
the whole epileptogenesis silent phase.
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The influence of gender on brain perfusion in patients
with Alzheimer’s disease.
V. Valotassiou1, J. Papatriantafyllou2, N. Sifakis3, C.
Tzavara1, I. Tsougos1, S. Alexiou1, D. Psimadas1, E.
Baniora1, A. Ziaka1, P. Georgoulias1; 1Department of Nucle-
ar Medicine, University Hospital of Larissa, Larissa,
GREECE, 2Memory & Cognitive Disorders Clinic, Neurolo-
gy Dpt., “G. Gennimatas” Hospital, Athens, GREECE, 3Nu-
clear Medicine Dpt, “Alexandra”University Hospital, Athens,
GREECE.
Aim: Several studies have shown sex differences in clinical
symptoms in Alzheimer’s disease (AD) patients, suggesting
that gender may modify perfusion deficits patterns in AD.
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The aim of our study was the evaluation of brain perfusion in
specific Brodmann areas (BA) in men and women with AD,
using an automated 3D-voxel-based processing software
(Neurogam). Materials-methods: We studied 52 consecutive
patients from an outpatient Memory Clinic. We used the
established DSM-IV criteria for the diagnosis of dementia
and the specific established criteria (NINCDS-ADRDA) for
the diagnosis of AD. All the patients had a neuropsychological
evaluation with a battery of tests including the mini-mental
state examination (MMSE). The study group consisted of 16
men (age±SD 68.7±7.9 years, MMSE±SD 18.7±6.5, educa-
tion±SD 12.5±4.6 years), and 36 women (age±SD 71±8 years,
MMSE±SD 18.9±5.8, education±SD 8.3±4.2 years). All the
patients underwent a brain SPECT scan 20 min after the intra-
venous administration of 740MBq of 99mTc-HMPAO. We
applied the NeuroGamTM software on the reconstructed data,
for the semi-quantitative evaluation of brain perfusion in BA
in the right (R) and left (L) hemispheres. Perfusion values in
BAwere expressed as mean±SD percentage of mean perfusion
of the cerebellum. Statistical analysis was performed using
Mann-Whitney test. Results: Compared with women, men
had statistically significantly lower perfusion in somatosenso-
ry association cortex bilaterally (BA 7L and 7R, p=0.016 and
p=0.009, respectively), right middle temporal gyrus (BA 21R,
p=0.016), anterior temporal gyrus bilaterally (BA 22L and
22R, p=0.035 and p=0.017, respectively), ventral posterior
cingulated cortex bilaterally (BA 23L and 23R, p=0.002 and
p=0.001, respectively), right subgenual area (BA 25R,
p=0.019), right dorsal posterior cingulated cortex (BA 31R,
p=0.05), fusiform gyrus bilaterally (BA 37L and 37R,
p=0.034 and p=0.005, respectively), angular gyrus bilaterally
(BA 39L and 39R, p=0.005 and p=0.009, respectively),
supramarginal gyrus bilaterally (BA 40L and 40R, p=0.005
and p=0.011, respectively), pars opercularis bilaterally (BA
44L and 44R, p=0.012 and p=0.025, respectively) and left pars
triangularis (BA 45L, p=0.05). Conclusion: More severe hy-
poperfusion in temporoparietal and frontal lobes in men with
AD, may reflect underlying neuropathological sex differences
and/or other gender-related factors. Patient gender maybe
should be considered when interpreting brain perfusion
SPECT studies.
P465
Application of CT based spatial normalization
by DARTEL to quantitative assessment of 123I-FP-CIT
SPECT.
K. Yokoyama, E. Imabayashi, H.Matsuda; National Center of
Neurology and Psychiatry, Kodaira, JAPAN.
PURPOSE: 123I-FP-CIT is used for assessment of the dopa-
mine transporter (DAT) to assess the nigrostriatal function in
patients with parkinsonian syndrome (PS). In this study, to
diagnose degenerative PS accurately, precise estimation of
distribution of DAT, Diffeomorphic Anatomical Registra-
tion Through Exponentiated Lie Algebra (DARTEL)
algorism is applied to SPECT using CT images.
METHODS: Retrospective study. Eighty four patients
(39 women and 45 men, 67.1 ±12.3y.o.) with PS were
focused on this study. Among them 56 were clinically
diagnosed as Parkinson’s disease (PD) (24 women and
32 men, 68.5 ± 10.7 y.o.). The other 28 non-PD patients
(13 women and 15 men, 64.3 ± 14.5 y.o.) included such as
essential tremor, psychogenic disorders, drug induced PS
and so forth. After injection of 167MBq of 123I-FP-CIT,
SPECT images were obtained using SPECT/CT equipment
(Symbia T6; Siemens Medical Systems, Inc.) with
LMEGP collimator, CT based attenuation collection and
without scatter collection. First, the gray matter is extract-
ed using statistical parametric mapping 12. Spatial nor-
malization to this gray matter images applied with the
DARTEL algorism. Second, SPECT images were normal-
ized with the same parameter as the CT normalization.
Finally, 123I-FP-CIT images in Montreal Neurological In-
stitute space are obtained. Then the volumes of interest
(VOIs) were written in right, left, bilateral striatum, cau-
date nucleus, putamen and occipital, and the putamen was
divided to anterior and posterior segments using plane
rectangle to AC-PC plane (VOIs derived from a probabi-
listic brain atlas previously validated by Hammers et al.
Hum Brain Mapp, 15:165-174, 2002). Specific binding
ratios (SBR) referenced to occipital lobe were calculated.
We compared the method without spatial normalization
using a bilateral whole stratium VOI and whole brain as
a reference, a measurement technique Tossici-Bolt, et al.
suggested (Eur J Nucl Med Mol Imaging, 2006
Dec;33(12):1491-9). RESULT: Mean SBR of PD and
non-PD using DARTEL algorism and Tossici-Bolt method
was 1.67 ± 0.20, 3.10 ± 0.61 and 3.20 ± 1.11, 6.71 ± 1.44.
Sensitivity, Specificity and Accuracy of the discrimination
between PD and non-PD in each method were 98.2%,
100%, 98.8% and 90.9%, 100%, 94.0%, respectively.
SBR of posterior segment of putamen was more useful
to differentiate PD from the other, and had a good contrast
between each disorder group than that of whole stratium.
CONCLUSION: These data suggest that DARTEL nor-
malization are useful for spatial normalization of 123I-
FP-CIT images. VOI template for posterior putamen im-
proved the sensitivity and accuracy from that of the whole
stratium.
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Is Dynamic [11C]Raclopride PET Scanning needed
to Distinguish Patients from Healthy Controls?
P. Gykiere, N. Van Laeken, A. Dobbeleir, F. De Vos, I. Goe-
thals; University Hospital Ghent, Ghent, BELGIUM.
Objective: Striatal dopamine D2 receptor PET imaging
with [11C]raclopride may be helpful in the differential
d i agnos i s o f c l i n i c a l pa rk in son i sm. Dynamic
[11C]raclopride acquisition allows calculating the bind-
ing potential (BP) of postsynaptic dopamine D2 recep-
tors using a simplified reference tissue model. However,
dynamic scanning requires a long acquisition time dur-
ing which may be prone to movement bias of the sub-
ject. Here, the aim was to investigate whether dynamic
scanning has higher diagnostic value compared to a
short 10-min static PET scan obtained during transient
equilibrium 30 minutes after tracer injection. Methods:
[11C]raclopride PET was performed in 19 patients with
clinically inconclusive parkinsonism (mean age 62.6
years, SD 12.7) and in 14 healthy volunteers (mean
age 22.6 years, SD 4.1). Patients were free of dopami-
n e r g i c med i c a t i o n s t h a t may i n t e r f e r e w i t h
[11C]raclopride binding. For the dynamic acquisition,
the BP was calculated as the ratio of striatal activity in
a VOI defined by 40% of the maximum left and right
striatal activity to the reference region, namely the oc-
cipital cortex and the cerebellum. Similary, in the static
scan the ratio striatal activity in a VOI defined as 40%
of the maximum left or right striatal activity to the oc-
cipital cortex was calculated. Additionally, a resolution-
independent specific uptake size index (SUSI) calcula-
tion was applied for measuring the specific to non-
specific binding ratio, as also used in 123I-FP-CIT scans
. ROC-analysis was used for all methods to investigate
which method was best suited to discriminate patients
from volunteers. Results: By using a 40% threshold
VOI in the dynamic scan, an AUC value of 0.926 and
0.910 for respectively the occiput and cerebellum as
reference region was obtained to discriminate patients
from healthy volunteers. In the static scan, using 40%
of striatal activity resulted in AUC value of 0.536, but
SUSI calculations applied on the data provided an AUC
of 0.883. Conclusion: This report suggest that a
discrimination between patients and healthy volunteers
is feasible by applying simple SUSI calculations on a
10-min static scan. Nevertheless, a small improvement
of the diagnostic value of [11C]raclopride PET may be
obtained by a dynamic scan analysis together with spe-
cific software.
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Relationship between dopamine deficit and the expression
of depressive behavior resulting from alteration serotonin
system
M. Lee1, Y. Ryu2, J. Choi2, W. Cho3, I. Hyun1; 1Inha Uni-
versity Hospital, Incheon, KOREA, REPUBLIC OF, 2Yonsei
University, Gangnam Severance Hospital, Seoul, KOREA,
REPUBLIC OF, 3Yonsei University College of Medicine,
Wonju, KOREA, REPUBLIC OF.
Depression frequently accompanies in Parkinson’s dis-
ease (PD). Previous research suggested that dopamine
and serotonin systems are closely linked with depression
in PD. However, comprehensive studies about the rela-
tionship between these two neurotransmitter systems are
limited. Therefore, the purpose of this study is to eval-
uate the effect of dopaminergic destruction on the sero-
tonergic system. The interconnection between motor
symptoms and depression was also examined. Two
PET scans were performed in the 6-hydroxydopamine
(6-OHDA) lesioned and sham operated rats: [18F]FP-
CIT for dopamine transporters and [18F]Mefway for se-
rotonin 1A (5-HT1A) receptors. Here, 6-OHDA is a neu-
rotoxin for dopaminergic neurons. Behavioral tests were
used to evaluate the severity of symptoms: rotational
number for motor impairment and immobility time, ac-
quired from the forced swim test for depression. Region-
of-interests were drawn in the striatum and cerebellum
for the dopamine system and hippocampus and cerebel-
lum for the 5-HT system. The cerebellum was chosen as
a reference region. Non-displaceable binding potential in
the striatum and hippocampus were compared between
6-OHDA and sham groups. As a result, the degree of
dopamine depletion was negatively correlated with rota-
tional behavior (R2 = 0.79, p = 0.003). In 6-OHDA
lesioned rats, binding values for 5-HT1A receptors was
22 % lower than the sham operated group. This decre-
ment of 5-HT1A receptor binding was also correlated
with the severity of depression (R2 = 0.81, p =
0.006). Taken together, this research demonstrated that
the destruction of dopaminegic system causes the
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reduction of the serotonergic system resulting in the ex-
pression of depressive behavior.
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123-I-MIBG cardiac scintigraphy quantitative analysis
in Parkinson’s disease (PD) and Parkinsonism (P)
differential diagnosis: a classification tree (CIT) classifier
additional contribute.
S. Nuvoli1, B. Palumbo2, M. L. Fravolini3, B. Piras1, G.
Dachena1, S. Cascianelli2, A. Spanu1, G. Madeddu1; 1Unit
of Nuclear Medicine, University of Sassari, Sassari, ITALY,
2Section of Nuclear Medicine, Dept of Surgical and Biomed-
ical Sciences. University of Perugia, Perugia, ITALY, 3Dept of
Engineering, University of Perugia, Perugia, ITALY.
AIM: Recently the usefulness of 123I-MIBG cardiac
scintigraphy as diagnostic method in detecting autonom-
ic nerve disturbances in neurodegenerative movement
disorders has been reported resulting particularly impor-
tant given the difficulty in discriminating between PD
and P in some cases. In the present study, we performed
123I-MIBG cardiac scintigraphy in patients with move-
ment disorders also applying the artificial neuronal net-
work classifier CIT which consists of logical rule set
organized as decision tree to product clear data classifi-
cation providing numerical cut-off values able to differ-
entiate different clinical groups. METHODS: We en-
rolled 106 consecutive patients,61 males and 45 females,
aged 55-81 years, 35 classified as PD and 71 as P. In all
patients, cardiac planar scintigraphy was performed after
111 MBq 123I-MIBG i.v. injection using a dual head
gamma camera, in anterior and left anterior oblique
views, in both early (15 min.) and delayed (240 min.)
phases. Semiquantitative analysis was also performed
calculating heart/mediastinum (H/M) ratio by mean
count density measurement in manually drawn ROIs in
anterior view. With regard to CIT for the 1.000 experi-
ments, 11 patients were randomly selected as the train-
ing set, while the remaining 95 validated the trained CIT
computing the validation data percentage of the correctly
classified patients. The expected performance of an av-
erage performance CIT was calculated. RESULTS: The
probability of a correct classification for CIT was 90
±9.20% in PD pts and 88.35±15.26% in P patiens. The
decision rule gave the early H/M ratio value of 1.56
±0.01 for CIT. These results mean that patients with
early H/M ratio values <1.56 were classified as PD,
while patients with values >1.56 were classified as P.
Moreover, delayed H/M ratios did not add significant
information to classify the patients. CONCLUSIONS:
The results of the present study demonstrated that the
additional CIT use to 123I-MIBG cardiac scintigraphy
quantitative analysis provided reliable and disease-
specific numerical cut-off values able to differentiate
PD from P patients and this is clinically remarkable
for both diagnostic and therapeutic purpose. Moreover,
it has also been demonstrated that the early H/M ratio
values alone may be sufficient to obtain the final diag-
nosis avoiding further late scan necessity.
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Contribution of cardiac 123-I metaiodobenzylguanidine
(MIBG) scintigraphy of combined whit FP-CIT SPECT
in the differential diagnosis of the Parkinson disease
and atypical parkinsonian syndromes.
G. Martinez Pimienta, R. Gomez Llopico, M. Bajén, A.
Benitez Segura, O. Puig, J. Rojas Camacho, M. Boya-Roman,
J. Rodríguez-Rubio, E. Noriega, J. Mora; Hospital
Universitario de Bellvitge, Barcelona, SPAIN.
INTRODUCTION: The differential diagnosis between
Parkinson’s disease (PD) and atypical parkinsonian syndromes
(multiple-system atrophy, MSA; progressive supranuclear
palsy, PSP; Lewy body dementia, LBD) is established with
clinical criteria. Imaging of the dopamine transporter with
123I-FP-CIT successfully visualizes presynaptic dopaminer-
gic degeneration of the nigrostriatal tract in the PD and atyp-
ical parkinsonian syndrome but does not differentiate the var-
ious types of degenerative Parkinsonisms (PD, MSA, PSP,
LBD). In PD and in LBD there is a cardiac sympathetic de-
nervation, so imaging of the 123I-MIBG myocardial uptake
can be helpful in the differential diagnosis of different
Parkinsionian syndromes. OBJECTIVES: Evaluate the com-
bined use FP-CIT-SPECT and cardiac 123-I MIBG Scintigra-
phy in the differential diagnosis of the Parkinson’s disease and
atypical parkinsonian syndromes. MATERIALS AND
METHODS: We studied retrospectively 48 patients with par-
kinsonian syndrome and atypical initial presentation. A FP-
CIT -SPECT and cardiac 123-I MIBG scintigraphy was per-
formed in all patients. The FP-CIT -SPECT was assessed vi-
sually by two observers and reported as pathological or non-
pathological. The cardiac 123-I MIBG uptake was evaluated
by drawing standardized ROIs (heart-to-mediastinum ratio) on
planar images 4 h after injection and it was considered normal
if the ratio was >1.5. The FP-CIT -SPECT, cardiac 123-I
MIBG and joint interpretation of both tests according to ex-
pected patterns were evaluated Diagnostic pattern expected:
PD: FP-CIT -SPECT: pathological; Cardiac 123-I MIBG:
pathological. LBD: FP-CIT -SPECT: pathological; Cardiac
123-I MIBG: pathological. MSA: FP-CIT -SPECT: patholog-
ical; Cardiac 123-I MIBG: non-pathological. PSP: FP-CIT -
SPECT: pathological; Cardiac 123-I MIBG: non-pathological.
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RESULTS: Final clinical diagnostic: PD: 31patients; LBD: 7
patients; MSA: 7 patients; PSP: 4 patients CONCLUSION:
The FP-CIT -SPECTwas positive in 98% of the patients with
Parkinsonian syndrome but it could not differentiate between
PD and atypical Parkinsonisms. The combination of FP-CIT-
SPECTand Cardiac 123-I MIBG scintigraphy was concordant
to the expected pattern in 85% of the patients and it helped in
their differential diagnosis. The correlation of these two tech-
niques with the expected pattern was higher in PD or LBD
than in patients diagnosed of MSA or PSP.
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Correlation between tracer injection latency and seizure
duration with the accuracy in detection of epileptogenic
zone by SPECT and SISCOM
M. Suarez-Piñera1, A. Mestre-Fusco1, S. Medrano2, M.
Ley3, G. Conesa4, R. Rodrigo3; 1Hospital del Mar Barcelona.
Nuclear Medicine Department, Barcelona, SPAIN, 2Hospital
del Mar Barcelona. Neuroradiology Department, Barcelona,
SPAIN, 3Hospital del Mar Barcelona. Epilepsy Unit. Neurol-
ogy Department, Barcelona, SPAIN, 4Hospital del Mar Bar-
celona. Neurosurgery Department, Barcelona, SPAIN.
Aims: SPECT and subtraction ictal SPECT coregistered to
MRI (SISCOM) play an important role in seizure onset zone
detection during the presurgical evaluation of patients with
drug-refractory epilepsy. Injection latency (time between the
onset of seizures and ictal tracer injection) and seizure duration
have been two factors related to the accuracy in detection
seizure onset area. This study has aimed to establish the cor-
relation between injection latency and seizure duration with
successfully epliptogenic zone detected by SPECT and
SISCOM. Methods: Tc 99m- HMPAO SPECT ictal-interictal
(dual-headed camera) and SISCOM (FocusDET) was per-
formed in 16 refractory epilepsy patients (10 F, 38±10.8 yrs)
candidates for surgical treatment. Tracer for ictal SPECT was
injected manually by an expert technician in epilepsy monitor-
ing unit. Seizure duration and injection latency was carefully
noted. SPECT (visual and SISCOM) images were analyzed
independently by two nuclear medicine physicians. SPECT
results were compared to gold-standard; resected area locali-
zation and surgical outcome using Engel scale or with stereo-
EEG (SEEG). True positive was considered SPECT results
concordant with the resected area and a good clinical output
( Engel I ó II) . False positive was considered spect results no
concordant with resected area or suboptimal Engel (>Engel II)
. Histolopathological findings of the resected areas are
showed. A two-way ANOVA test was used to assess differ-
ences between injection latency and seizure duration with
SPECT results. Results: Latency time ranged between ( 7-53
s). Seizure duration ranged between( 31 and 170s). In 13/16
(81%)patients SPECT and SISCOM (together information)
supported the localization of epileptogenic focus. SEEG
showed multifocality in one patients and surgery was
desestimated. The epileptic focus was not found in one patient.
Other patient was classified as Engel III after surgery. No
statistically significant differences were found between the
different injection latency and seizure duration and epileptic
focus localization. Our preliminary results showed the major-
ity of the epileptic focus in temporal lobe (4 right and 3 left
temporal lobe). Conclusions: SPECT and SISCOM provide a
valuable diagnostic tool to localizate the epileptogenic zone in
patients with medically refractory epilepsy. The findings of
this study showed similar accurancy in the detection of epilep-
togenic zone independent of injection latency and seizure du-
ration. These results are not in agreement with other published
by other groups. A possible explications could be the
homogenecity of the sample. Additional studies are needed
to clarify the relationship between this factors and SPECT/
SISCOM results.
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Importance of different modalities (SPECT/CT, MRI)
in the quantitative assessment of DaTscan findings
S. Szekeres1, N. Kovacs2, G. Perlaki3, G. Orsi3, L. Papp4, B.
Suha5, E. Schmidt1, K. Zambo1; 1University of Pecs Depart-
ment of NuclearMedicine, PECS, HUNGARY, 2University of
Pecs Department of Neurology, PECS, HUNGARY, 3MTA-
PTE Clinical Neuroscience MRI Research Group, PECS,
HUNGARY, 4Mediso GmBH, Budapest, HUNGARY, 5Uni-
versity of Pecs Medical Faculty, PECS, HUNGARY.
Aim: The 123-I-Ioflupan as a presynaptic dopamine receptor
analog molecule plays an important role in the determination of
receptor density of the striatum. The method is useful to differen-
tiate between the essential tremor (ET) and the different types of
Parkinson-syndrome (Parkinson-disease (PD), Multiple System
Atrophy (MSA) and Progressiv Supranuclear Palsy (PSP) and it
is helpful for setting up the early and accurate diagnosis of
Parkinson-disease. The aim of the present study is to compare a
well-establised visual assessment and the results of different
quantitativemethods.Materials andmethods: Examinations were
performed in 40 patients with ET, with PD (in early or advanced
stage and severe PD with Duodopa therapy) and in patiens with
MSA and PSP. During the visual evaluation a well-establised
(Ottaviani, S. et al., 2006) visual scale was applied (normal, ab-
normal grade I, II, III) by two independent experts. Three differ-
entmethodswere introduced for the quantitative evaluation: 1. on
the SPECT/CT image of a patient with normal distribution of
dopamine receptors 4 VOIs in the striatum and 2 VOIs in the
occipital lobe (6 optimal VOIs) were circumscribed and these
were applied in all patients; 2. on the SPECT/CT image of all
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patients individual 6 optimal VOIs were determined; 3. after co-
registration of CT and MRI pictures an MRI mask was used on
the SPECT image in the different regions. Results: There was
considerable agreement between the visual scores by the two
observers and the visual score correlated significantly with the
clinical stage of PD. We found a significant overlap between the
visual scores and the automatic MRI-based evaluation. Compar-
ing the two different types of quantitative nuclear medicine
methods with each-other and the automatically determined MRI
binding values presents a good choise to achieve the best suitable
parameters. Conclusion: Based on our preliminary results, the
quantitative methods may support the visual assessment of
DAT binding. We hope that the introduction of these methods
would be an excellent possibility to establish the differential di-
agnosis of movement disorders as well as to comfirm the diag-
nosis of Parkinson-disease. This work was supported by Hungar-
ian Brain Research Program - Grant No. KTIA_13_NAP-A-II/
10.
P472
Exploring the feasibility and potential advantages
of applying CT-based attenuation correction
in 123I-FPCIT and 123I-IBZM SPECT studies. Our first
experience
K. Badiavas, I. Iakovou, V. Athanasiou, K. Mihailos; Nuclear
Medicine Department, Aristotle University, “Papageorgiou”
General Hospital, Thessaloniki, GREECE.
Aim. Our aim was to explore the feasibility and potential ad-
vantages of applying CT-based attenuation correction at the
123I-FPCIT and 123I-IBZM SPECT studies performed in
our department, using our newly installed SPECT/CT imaging
system.Materials and methods. The usual process when
performing 123I-FPCIT or 123I-IBZM SPECT studies in our
department is to use a dual-head γ-camera (Discovery 630
NM, Xeleris 3 workstation, GE Healthcare). After the instal-
lation of a SPECT/CT imaging system (Optima 640 NM/CT,
Xeleris 3 workstation, GE Healthcare) we decided to apply
CT-based attenuation correction at a limited number of 123I-
FPCIT and 123I-IBZM SPECT studies who were followed by
low-dose CT in order to explore the feasibility and potential
advantages. For the two different approaches (CT-based AC
Vs SPECT alone) we reconstructed the data (OSEM,
Butterworth filtering) and applied the “manual positioning
ROIs” quantification method that, according to our previous
works, proved to be the best among others methods examined.
ROIs were created by the same experienced user. The group of
patients examined consisted of 23 patients having 123I-FPCIT
SPECT scan (14 men and 9 women, aged 61.7±12.4 years)
while 6 of them had also 123I-IBZM SPECT scan (5 men and
1 woman, aged 67.2±5.1 years).Results. After visual
assessment, two experienced observers agreed that the
resulting images after AC had better “Contrast-to-Noise ratio”
leaving, though, the diagnosis that was based at the SPECT
alone examination, unaltered. Data quantification produced
greater values (at a mean value of 30.5%) for the specific
uptake at the striatum, caudatum and putamen while leaving
the Putamen-to-Caudate ratio (P/C) almost unaltered. Again,
the diagnosis was not altered in any of the examined
cases.Conclusion. The application of CT-based attenuation
correction after a low-dose CT at 123I-FPCIT and 123I-
IBZM SPECT studies definitely provides images with better
“Contrast-to-Noise ratio” than SPECTalone examination. The
specific uptake ratios for the striatum, caudatum and putamen
against the occipital uptake (background) are all elevated but,
fortunately, the Putamen-to-Caudate ratio (P/C is a ratio that
we consider important) seems to be unaltered. There was no
change in diagnosis for the patients we studied and consider-
ing the additional patient’s radiation dose for, even a low-dose,
CT scan plus the extra machine-time needed, we decided to
stick to the SPECT alone examination followed by visual as-
sessment and data quantification. Further studies are needed,
so we have already programmed a series of experiments with
123I and the, well known, striatal phantom.
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The clinical usefulness of I-123-Ioflupane SPECT
(DaTscan) in patients with equivocal diagnosis
of Parkinson’s disease
S. Czibor1, D. Nagy1, M. Moravszki1, L. Duffek1, E.
Takacs2, E. Kalameny3, Z. Szeplaki4, A. Takats4, I. Szilvasi1;
1Hungarian Defence Forces Medical Centre, Dept. of Nuclear
Medicine, Budapest, HUNGARY, 2Semmelweis University,
Dept. of Nuclear Medicine, Budapest, HUNGARY, 3Hungar-
ian Defence Forces Medical Centre, Dept. of Neurology, Bu-
dapest, HUNGARY, 4Semmelweis University, Dept. of Neu-
rology, Budapest, HUNGARY.
Aim: Our purpose was to evaluate the clinical usefulness of the
DaTscan examination in patients with equivocal diagnosis of
extrapyramidal movement disorders with tremor and/or rigidity
or failing response to therapy based on previous clinical diagno-
sis. Degeneration of the presynaptic dopaminergic neurons in the
negro-striatal system can be detected by DaTscan
examination.Materials and methods: Between 2009 and 2014
34 patients (9 women and 25 men, mean age 64,7±12,4 years)
were studied in two large neurological departments. Patients had
symptoms of either Parkinson’s disease, essential tremor or ex-
trapyramidal movement disorders but the diagnosis based on
clinical-radiological findings and neurological tests was equivo-
cal or they had insufficient response to standard therapy. Tremor
was present in 26 cases (9 of those asymmetrical and 17
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symmetrical), while rigidity, Negro-sign, bradykinesis and pos-
tural instability was documented in 19, 19, 8 and 3 patients,
respectively. The DaTscan examinations were performed accord-
ing to the guideline of the EuropeanAssociation of NuclearMed-
icine. The visual and semiquantitative calculations were per-
formed by two experienced independent nuclear medicine
specialists.Results: The DaTscan study confirmed early-stage
Parkinson’s disease in 19 cases. In 6 equivocal cases essential
tremor was diagnosed. 3 patients treated for Parkinson’s disease
with insufficient response to therapy, diagnosis changed to essen-
tial tremor. Parkinson’s disease was diagnosed in 1 patient with
previously assumed sleep apnoe syndrome and in 1 patient with
suspected essential tremor. Diagnosis of Parkinson’s disease was
dismissed at 2 patients, one of them had sleep apnoe syndrome
and the other had DOPA-responsive dystonia. In 2 patients, the
previously suspected diagnosis of periodic limb movement dis-
order and Lewy-body dementia was confirmed.Conclusion: Our
study has shown that the DaTscan SPECT has a clinically impor-
tant role in equivocal diagnosis of Parkinson’s disease and other
neurological disorders with tremor. It has particular diagnostic
value in early-onset Parkinson’s disease and could be useful in
demented patients to detect Lewy-body dementia. In patients
unresponsive to therapy, DaTscan has an impact on clinical man-
agement and consequently on expenditures of the healthcare
system.
P474
Diagnostic value of MIBG cardiac scintigraphy
for the diagnosis of Parkinson disease.
M. Abbasi1, A. Tafakhori2; 1Department of Nuclear Medi-
cine , Vali-e-asr Hospital, Tehran University of Medical Sci-
ences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Depart-
ment of Neurology, Imam-komeini Hospital, Tehran Univer-
sity of Medical Sciences, Tehran, IRAN, ISLAMIC REPUB-
LIC OF.
MIBG uptake is reduced in the myocardium of patients with
Parkinson disease. We intended to study the accuracy of
MIBG cardiac scintigraphy for discrimination of Parkinson
disease from other causes of Parkinsonism. The data of 19
patients with retractable Parkinsonism or obscure diagnosis
referred for MIBG cardiac imaging were completed for this
preliminary report. Planar imaging of the chest and cardiac
SPECT were done 2 hours after injection of 0.7 to 1 mCi
I131-MIBG. The planar and SPECT images were reviewed
visually in addition to ROI analysis in planar images. The
ROIs were drawn around the heart and the lung fields exclud-
ing the heart in both anterior and posterior images. The geo-
metric means were employed and the optimal heart to lung
ratios were calculated based on the shortest distance to the
optimal point on the ROC curve. Patients were followed until
the neurologist came to his final decision about the diagnosis
of the patients based on the course of the disease, other diag-
nostic images and response to therapy. The diagnostic self
confidences of interpreters were evaluated with the use of a 4
point visual scale from poor to optimal confidence. 10 patients
(7 males) aged 66 +- 6 years had Parkinson disease and 9
patients ( 5 males) had other causes of Parkinsonism including
ardive dyskinesia (3 cases) , essential tremor (3 cases) , multi-
system atrophy (2 cases) and corticobasal degeneration ( 1
cases). MIBG scans were reported positive for Parkinson dis-
ease in 9 patients with Parkinson disease and negative for
Parkinson disease in 8 out of patients with other diagnoses.
The sensitivity, specificity and accuracy of the MIBG scan
were 90%, 88.9% and 89.4% respectively. The optimal cutoff
value of the heart to lung uptake ratios was about 1.3 at which
the diagnosis of all non-Parkinson disease subjects were pos-
sible in addition to correct diagnosis of 9 Parkinson diseases
out of 10 (accuracy of 94.7%). The interpreters evaluated the
quality of planar I131 MIBG images optimal for the detection
of MIBG uptake with good diagnostic confidence (mean= 3.8;
median = 4). We found cardiac MIBG scan is a valuable tool
for differentiation of Parkinson disease in cases with diagnos-
tic problems. In addition we found the quality of I131 imaging
acceptable for this purpose which could be used instead of
I123 when unavailable.
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Absolute quantitative evaluation of 123I-FP-CIT: is it
possible?
F. Scalorbi1, S. Bressan2, S. Favaretto3, S. Berti1, S.
Pompanin3, A. Cagnin3, A. Antonini3, C. Gabelli4, P.
Zucchetta1, F. Bui1, D. Cecchin1; 1Department of Nuclear
Medicine of Padova, Padova, ITALY, 2Hospital of Padova,
Padova, ITALY, 3Department of Neurology of Padova, Pado-
va, ITALY, 4Centro regionale per la cura dell’invecchiamento
cerebrale, Padova, ITALY.
Aim: 123I-FP-CIT (DaTSCAN) SPECT studies of the nigro-
striatal pathway are a valuable tool in the diagnosis of movement
disorders. Qualitative analysis of such data, however, is problem-
atic cause it depends on the subjectivity of the operator. Semi-
quantification of data improve things but lacks the possibility of a
reliable comparison among different centers. Aim of this study is
to present an innovative open source and JAVA-based program
(named SUQS: Striatal Uptake Quantification System), tested on
Win, Mac and Linux, providing absolute quantitative evaluation
of the striatal uptake of 123I-FP-CIT. To validate it we have tested
the system on phantoms and patients. Material andMethods: The
method automatically segments DICOM transaxial, filtered and
attenuation corrected images then, using correction factors de-
rived from multiple acquisitions of a fully tissue-equivalent
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anthropomorphic striatal phantom (RDS) it coverts counts in
MBq. Furthermore corrections for attenuation, partial volume
effect and radius of percentages of the injected dose rotation, have
been incorporated. It derives then the percentage of the injected
dose. An RDS at different radius of rotation and at the same
radius for 24 hours has been obtained to validate the system.
Furthermore we tested it on 85 patients (46 males, 40 females,
mean age 68.85 years, range 35-86) who underwent 123I-FP-
CIT SPECT (mean activity 178.7 MBq) from 2006 to 2009 at
theNuclearMedicineDepartment, UniversityHospital of Padova
(Italy). This time span has been chosen because we have a long
follow-up for all this patients. At the moment of the scan 55
patients were classified as PD (Parkinson Disease), 7 as Parkin-
sonism (3 Cortical Basal Degeneration, 2PSP-P, 1 MSA, 1 Vas-
cular Parkinson), 7 as Essential Tremor, 3 as Psychiatric Disor-
ders, 11 as Extrapiramidal Syndrome, 1 as AD (Alzheimer Dis-
ease), 1 as DBL (Lewy Body Disease). Being a retrospective
evaluation only the Hoehn and Yard scale was available (33
patients were classified as I, 43 as II , 8 as III, 1 as IV, none as
stage V). Results and preliminary Conclusions: Although the
validation is ongoing preliminary data on phantoms provided
excellent results in measuring the real activity both at different
radius and also considering decay over a long time (24 hrs).
Preliminary data on patients seems to show that absolute quanti-
tative evaluation is superior to qualitative and semi-quantitative
evaluation in predicting the state of patients at follow-up.
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Cut-off values to diagnose Parkinson’s disease by means
of 123I-FP-CIT brain SPECT semiquantitave data
as evaluated by Classification Tree algorithm
B. Palumbo1, S. Cascianelli2, I. Sabalich1, A. Santonicola1,
T. Buresta1, M. L. Fravolini2, N. Tambasco3, S. Nuvoli4, A.
Spanu4, G. Madeddu4; 1Department of Surgical and Biomed-
ical Sciences- Nuclear Medicine and Health Physics-
University of Perugia, PERUGIA, ITALY, 2Department of
Engineering-University of Perugia, PERUGIA, ITALY, 3Unit
of Neurology, Department of Medicine, Perugia University
Hospital, PERUGIA, ITALY, 4Unit of Nuclear Medicine, De-
partment of Clinical and Experimental Medicine, University
of Sassari, Sassari, ITALY.
Aim: To identify cut-off values of radiopharmaceutical uptake
ratios in basal ganglia able to differentiate PD and other con-
ditions, we applied a Classification Tree algorithm (ClT) to
123I-FP-CIT brain SPECT semiquantitave data. A ClT is an
automatic classifier consisting of a set of logical rules, orga-
nized as a decision tree to produce an optimised threshold
based classification of data, thus providing discriminative
cut-off values. Methods: We performed 123I-FP-CIT brain
SPECT (Millenium VG, G.E.M.S.) with semiquantitative
analysis with Basal Ganglia (BasGan) V2 software according
to EANMguidelines in 115 patients with movement disorders;
73 were diagnosed as PD (36 M and 37 F; range of age: 60-81
yrs, Hoehn and Yahr score (HY): 0.5-1.5; Unified Parkinson
Disease Rating Scale (UPDRS) score: 6-38] and 42 resulted as
non-PD (Essential Tremor and drug-induced PD, 20M and 22
F; range of age 60-80 yrs). The final diagnosis was confirmed
by a clinical follow-up of at least 6 months. A 10-fold cross
validation was applied by repeating 1000 random experi-
ments. This allowed the statistical evaluation the “average per-
formance” of ClT. Results: For ClT, the probability of correct
classification in patients with PD was 78.97±15.62% (mean
±SD) and in non-PD patients 92.63±9.30%. For ClT, the first
decision rule gave a value for the right putamen (RP) of 2.44
±0.09, thusmeaning that if RP values were lower patients were
classified as PD, while if RP values were higher patients were
classified as non-PD. More complex ClT structures, including
caudate nuclei and left putamen values, were tested to refine
the classification performance, but in our data these additional
features appeared to be less significant. Conclusion: ClT was
able to classify PD and non-PD patients by means of 123I-FP-
CIT brain SPECT data; furthermore it allowed to identify re-
liable cut-off values able to contribute to the differential diag-
nosis of these categories. RP uptake values in our patients
seemed to be the most discriminant for the diagnosis, probably
due to a certain number of patients with initial prevalence of
left clinical symptoms.
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Evaluation of 99mTc-TRODAT-1 SPECT in the diagnosis
of Parkinson’s disease and its differentiation
from the other types of parkinsonism syndroms - A pilot
study
D. Beiki1, A. Esmaeili1, B. Fallahi1, S. Oveisgharan2, H.
Noorollahi-Moghaddam3, M. Erfani4, A. Tafakhori5, M.
Rohani6, A. Fard-Esfahani1, A. Emami-Ardekani1, M.
Eftekhari1; 1Research Center for Nuclear Medicine, Tehran
University of Medical Sciences, Tehran, IRAN, ISLAMIC
REPUBLICOF, 2Department of Neurology, Shariati Hospital,
Tehran University of Medical Sciences, Tehran, IRAN, IS-
LAMIC REPUBLIC OF, 3Shariati Hospital, Tehran Universi-
ty ofMedical Sciences, Tehran, IRAN, ISLAMICREPUBLIC
OF, 4Radiation Application Research School, Nuclear Science
and Technology Research Institute, Atomic Energy Organiza-
tion of Iran, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUB-
LIC OF, 5Department of Neurology, Imam Khomeini Hospi-
tal, Tehran University of Medical Sciences, Tehran, IRAN,
ISLAMIC REPUBLIC OF, 6Department of Neurology,
School of Medicine, Rasoul Akram Hospital, Iran University
of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC
OF.
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Aim: Parkinson disease (PD) is one of the most common
movement disorders. Sometimes, essential tremor (ET) and
the other parkinsonian syndromes may manifest the same mo-
tor symptoms. In these cases, definite clinical diagnosis may
be difficult. We conducted a study to determine the diagnostic
value of 99mTc-TRODAT-1 scan to differentiate PD from ET
and other cases of parkinsonism syndromes.Methods and Ma-
terials: This study was prospectively performed on 35 patients
including 15 PD, 12 ETand 8 patients with other parkinsonian
syndromes (PS). A new analogue of 99mTc-TRODAT-1 was
used for basal ganglia (BG) imaging. A dual-head SPECT-CT
was used to perform imaging for all patients following admin-
istration of at least 950 MBq 99mTc-TRODAT-1. The images
were reconstructed and processed using neuroimaging soft-
ware for the SPECT modality. Drawing ROIs on the BG, the
uptake values were estimated and normalized to whole brain
uptake. Results: Among three groups of patients, ET cases
show significantly higher values of normalized BG uptake
(p<0.05) as compared to PD and PS groups; however, no sig-
nificant difference was noted between PD and PS groups. In
qualitative assessment, all ET cases showed normal and sym-
metrical uptake in BG. From 15 PD patients, 9 cases (60%)
revealed greater loss of uptake in putamen vs. cudate. On the
other hand, in PS patients, 6 out of 8 patients (75%) had uni-
form pattern of decreased uptake in bilateral putamen and
cudate and only two patients (25%) showed greater loss of
uptake in putamen bilaterally, one symmetrical and the other
one asymmetrical. Conclusion: The preliminary quantitative
data reveals that 99mTc-TRODAT-1 scan is a very appropriate
method to differentiate PD or PS vs. ET cases. However, the
BG uptake values alone could not identify PD vs. PS cases.
The pattern of uptake may add to diagnostic value of the test;
however, the present results are equivocal and thus further
investigations with more cases are needed to reach more suit-
able criteria for this reason.
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123I-MIBG cardiac scintigraphy in discriminating
Parkinson’s disease (PD) from vascular parkinsonism
(VP) using Classification tree (CIT) classifier together
with conventional quantitative analysis.
S. Nuvoli1, A. Spanu1, B. Palumbo2, M. L. Fravolini3, G.
Dachena1, B. Piras1, G. Madeddu1; 1Nuclear Medicine Unit;
University of Sassari, Sassari, ITALY, 2Section of Nuclear
Medicine, Dept of Surgical and Biomedical Sciences. Univer-
sity of Perugia, Perugia, ITALY, 3Dept of Engineering Univer-
sity of Perugia, Perugia, ITALY.
AIM. Parkinson’s disease (PD) is characterized by basal ganglia
abnormalities and peripherical autonomic nerve disturbances.
123I Ioflupane SPECT represents reference diagnostic method,
but basal ganglia vascular damage could reduce its specificity. In
this study, we used 111I-MIBG cardiac scintigraphy to discrim-
inate different movement disorders in patients with basal ganglia
vascular abnormalities. METHODS. Among large PD patient
group, we selected 25 consecutive patients clinically classified
as PD, 21 stage 1 and 4 stage 2 (Hoen-Yahr scale). Three of 25
patients were never treated, while 22 were on dopamine agonist
therapy, but with partial/poor response. In all cases, MRI evi-
denced basal ganglia vascular lesions and 123I Ioflupane SPECT
had uncertain interpretation. Cardiac planar scintigraphy was per-
formed after 111 MBq 123I-MIBG i.v. injection using dual head
gammacamera, anterior and left anterior oblique views, in both
early (15 min.) and delayed (240 min.) phases. Data were evalu-
ated by qualitative and semiquantitative analyses calculating
heart/mediastinum (H/M) ratio by mean count density measure-
ment inmanually drawnROIs in anterior view. Quantitative H/M
ratio evaluation was performed also applying an artificial neuro-
nal network classifier, Classification Tree (CIT), trained in a pre-
vious our study to classify patients with movement disorders
obtaining 1.56 as cut off: patients with H/M 1.56 as parkinsonism
(P). RESULTS. At qualitative analysis, normal 123I MIBG car-
diac uptake, in early and delayed phases, was evidenced in 7/25
cases (group A), markedly reduced in 11/25 (group B), and
slightly reduced in the remaining 7/25 (group C). H/M was high
in group A, being >1.56 in all cases in both early (1.72±0.15) and
delayed (1.75±0.12) phases, low in group B with values < 1.3
(1.2±0.04 and 1.14±0.07, respectively) and slightly reduced in
group C with values between 1.3 and 1.56 (1.41±0.18 and 1.45
±0.07 respectively). No statistical difference was found between
early and delayed H/M mean values in all groups. CIT classified
groups B and C as PD and Group A as P; thus, final clinical
diagnosis of this latter group patients, 6/7 of whom already on
d r u g t h e r a p y w i t h p o o r r e s p o n s e , w a s V P.
CONCLUSIONS.123I-MIBG cardiac scintigraphy proved reli-
able diagnostic method which can contribute to differentiate PD
from P. In particular, in the present study, the procedure was able
to obtain VP diagnosis in patients with positive MRI but uncer-
tain 123I-Ioflupane scintigraphy interpretation. Moreover, the ad-
ditional CIT employment to conventional quantitative analysis
gave an useful contribute also using early phase alone.
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Importance of myocardial MIBG scintigraphy
in differentiating idiopatic Parkinson’s disease from other
neurodegenerative diseases
R. Petrovic1, A. T. Golubic1, T. Samardzic1, N. Klepac2, S.
Telarovic2, S. Tezak1; 1Department of Nuclear Medicine and
Radiation Protection, University Hospital Center Zagreb, Za-
greb, CROATIA, 2Clinical NeurologyDepartment, University
Hospital Center Zagreb, Zagreb, CROATIA.
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Aim: The aim of this study was to explore and evalute the use-
fulness of I-131 MIBG myocardial scintigraphy in patients with
idiopathic Parkinson’s disease and other neurological conditions
with similar symptoms. Because of common overlapping in signs
and symptoms of these neurodegenerative syndromes, especially
in the early stages, the differential diagnosis can be troublesome.
Materials and Methods: Sixty-one patients (age from 35 to 86,
mean 59) with rigidity, tremor, hypokinesia and other related
symptoms, with diverse neurological working diagnoses,
underwent MIBG scintigraphy. Planar chest MIBG imaging
was performed 15 min, 2, 3, 4 and 24 hours after tracer injection.
Myocardial MIBG activity was quantified by calculating heart to
mediastinum ratio (H/M ratio). H/M value over 1.8 was consid-
ered normal, between 1.31 -1.79 decreased, and less than 1.3
severely decreased. None of the patients in this study had heart
disease or any other medical condition which can influence
MIBG uptake. Results: In total, H/M ratio from early and delayed
MIBG scintigraphy was pathologically decreased in 42 (69%)
patients. In 77% of cases of IPD suspected patients we have
confirmed the main working diagnosis, thus establishing a high
degree of diagnostic certainty. H/M ratios in IPD patients was not
significantly correlatedwith disease duration and theHY scale. In
8 patients with MSAwe changed initial diagnosis to IPD (73%).
Three patients confirmed as MSA had normal HM ratios. In 16
patients with extrapyramidal symptoms we had 10 normal find-
ings, and because of pathological HM ratio we changed final
diagnosis to IPD in 6 patients. Of 4 other patients, 3 had patho-
logical HM ratios, thus changing their final diagnosis to IPD.
Conclusions: According to our findings, cardiac autonomic ner-
vous system dysfunction is common in IPD, but not in other
neurological conditions, especially not in MSA. We report that
myocardial MIBG scintigraphy can be a powerful, yet very sim-
ple and affordable method in differential diagnosis of IPD, thus
greatly assisting in diagnosing impaired peripheral adrenergic
activity. Also, myocardial MIBG imaging can be of great help
in establishing final diagnosis in patients with extrapyramidal
symptoms, especially when nigrostriatal dopamine transporter
imaging is not available. Longitudinal follow-up studies are need-
ed in order to evaluate the effects of myocardial MIBG imaging
as an indispensable method of prognostic value in routine clinical
practice and management of patients with various neurological
conditions.
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Correlation among freezing of gait , falls
and dopaminergic dysfunction in Parkinson’s disease:
evidences of a five years follow-up.
F. Guidoccio1, R. Ceravolo2, G. Puccini1, D. Frosini2, G.
Manca1, U. Bonuccelli2, I. Paglianiti1, D. Volterrani1; 1Re-
gional Center of Nuclear Medicine, University of Pisa, PISA,
ITALY, 2Neurology Unit, Department of Clinical and Exper-
imental Medicine, University of Pisa, PISA, ITALY.
Aim:Freezing of gait (FOG) is characterized by difficulty in
initiating or maintaining locomotion, frequently associated
with falls in advanced disease, often related to the OFF state,
and may be responsive or unresponsive to dopaminergic ther-
apy. The role of dopamine depletion is still debated in the
pathogenesis of FOG and Falls.We aimed to evaluate the role
of I123-FP-CIT-SPECT imaging in predicting FOG and falls
in a cohort of Parkinson Disease (PD) de-novo patients follow-
ed up for five years. Materials and Methods: Ninety-four PD
de-novo patients underwent 123I-FP-CIT SPECT at baseline.
Basal ganglia matching tool 2, was used to obtain semiquan-
titative measures of caudate and putamen uptake. Each patient
was assessed with Unified Parkinson’s Disease Rating Scale
(UPDRS) part II and III and Mini Mental State Examination
(MMSE) at baseline and each year in the follow up. FOG and
falls were assessed through UPDRS III.We compared baseline
clinical, demographic, and SPECT indices between patients
who developed FOG and falls and subjects who did not. Re-
sults: During follow-up, 47% patients developed FOG, 15%
falls. No significant statistical differences in UPDRS III and
MMSE at baseline were found between patients with FOG and
Falls and those without these features. Patients with FOG had
a decreased uptake at baseline in putamen (right 1,42 vs. 1,86;
p <0,002, left 1,67 vs. 1,97; p<0,05) and in caudate (right 2,77
vs. 3,32; p<0,005; left 3,02 vs. 3,38; p<0,06). No significant
differences in baseline striatal uptake were observed in rela-
tionship with the risk of falls. Conclusion: A baseline lower
uptake value of striatum seems to be predictor of FOG and this
evidence might support, a link between FOG and dopamine
depletion both in caudate and putamen, at least in the early
stage of disease. Risk of Falls, although often associated with
FOG in PD, doesn’t relate to dopaminergic dysfunction,
supporting the hypothesis of its complex multifactorial
genesis.
P481
99mTc-TRODAT-1 SPECT in the evaluation
of Parkinson’s disease progression and severity
A. Damian1, C. Pascovich1, D. Muñoz1, M. Langhain1, I.
Amorin2, A. Lescano2, R. Buzo2, R. Ferrando1; 1Nuclear
Medicine Centre, Clinical Hospital, University of the Repub-
lic, Montevideo, URUGUAY, 2Neurology Institute, Clinical
Hospital, University of the Republic, Montevideo,
URUGUAY.
Parkinson’s disease (PD) is a neurodegenerative disorder char-
acterized by the loss of dopaminergic neurons in the substantia
nigra pars compacta and their projections to the striatum.
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99mTc-TRODAT-1 is a widely available SPECT tracer with
high affinity to dopamine transporters (DATs) in dopaminergic
nerve terminals in the striatum. Although some studies with
limited number of patients have assessed the diagnostic per-
formance of 99mTc-TRODAT-1 in PD, the use of this tracer to
reveal disease progression and severity is still a matter of dis-
cussion. Aim: to assess the performance of 99mTc-TRODAT-
1 in the evaluation of progression and severity of PD. Material
and methods: Retrospective study of 92 PD patients (25-80
years old, 46 women, mean disease progression 6.2±5.0
[SD] years) and 9 controls that underwent 99mTc-TRODAT-
1 SPECT scan between 2011 and 2015. Specific striatal,
putaminal and caudate nucleus binding uptake ratios (SUR,
striatal mean counts - occipital mean counts/occipital mean
counts) and asymmetric index (2 x [(ipsilateral SUR - contra-
lateral UR)/(ipsilateral SUR + contralateral SUR)] x 100) were
calculated in all subjects and compared with clinical presenta-
tion, time of progression and Hoehn and Yahr scale (HYS) of
disease severity. Spearman rank order correlation and ANOVA
with Dunnett C post-hoc analysis was performed for statistical
comparison. P<0,05 was considered significant. Results:
Asymmetric index was higher in PD patients (31.3±28) in
comparison with controls (5.1±5, p<0.001). Clinical laterali-
zation was associated with imaging lateralization (p=0.002).
Striatal SUR showed a significant negative correlation with
time of progression of the disease (p<0.00001, correlation co-
efficient -0.43) and HYS (p<0.00001, correlation coefficient -
0.48). All HYS groups had lower striatal SUR in comparison
with controls (p<0.001). SUR in HYS I to IV were 0.5±0.23
(mean±SD), 0.37±0.16, 0.31±0.11, 0.24±0.12 respectively (p
= 0.001). Post hoc analysis discriminated between HYS I and
III (p=0.009) and beetween HYS I and IV (p=0.005). Conclu-
sion: The SPECT tracer 99mTc-TRODAT-1 performs well in
the clinical evaluation of PD patients with good correlation
with disease progression and severity that support its use in
clinical practice. Further prospective clinical trials with large
number of patients comparing the performance of this tracer
with 123I-FP-CIT are needed.
P482
Pupillometry and I-123-DaTSCAN imaging
in Parkinson’s disease-a comparative study.
G. Gerasimou1, E. Giza2, S. Bonstanjioloulou2, Z.
Katsarou3, E. Moralidis1, E. Papanastasiou1, P. Ioannidis1,
A. Gotzamani-Psarrakou1; 1AHEPA University Hospital,
THESSALONIKI, GREECE, 2Papanikolaou Hospital,
THESSALONIKI, GREECE, 3Hippokration Hospital,
THESSALONIKI, GREECE.
Aim: The aim of this study was the evaluation of pupil light
reflex (PLR) in patients with Parkinson’s disease (PD) by
using a modern pupillometry system and the investigation of
its potential relationship with dopamine transporter imaging
(DaTSCAN), which is an objective method for the evaluation
of presynaptic dopaminergic system.<br Materials and
Methods: PLR was evaluated using pupillometry in 35 pa-
tients with PD without clinical evidence of autonomic dys-
function and 44 healthy matched controls or individuals with
essential tremor. PLR was elicited using a fully automated
pupillometry system and six parameters were measured. Do-
pamine transporter imaging was performed using I-123 tagged
ioflupane- I-123-FP-CIT (DaTSCAN). A significant increase
in latency and a significant decrease in amplitude, maximum
constriction velocity, as well as maximum acceleration were
observed in PD patients. There was no significant difference in
initial radius and minimum radius values. Investigating the
relationship between pupillometry parameters and (123)I-FP-
CIT binding values, we correlated values from the semiquan-
titative analysis of radioligand uptake with pupillometry pa-
rameters, but we found no significant correlation.<br Conclu-
sion: This study demonstrates PLR impairment in patients
with PD without overt autonomic dysfunction. This impair-
ment does not seem to correspond to the reduction of
radioligand binding in the striatum as the result of presynaptic
dopaminergic dysfunction, suggesting a different deterioration
rate of these systems.
P483
Difference in striatal dopamine transporter availability
and psychiatric symptoms in Parkinson’s disease
subtypes: 123I-FP-CIT SPECT results
F. Cocciolillo1, D. Di Giuda1, S. Annunziata1, V. Scolozzi1,
F. Bove2, M. G. Vita2, C. Piano2, D. Fortini1, A. R.
Bentivoglio2, G. Camardese3, A. Giordano1; 1Nuclear Med-
icine Institute, Università Cattolica del Sacro Cuore, Roma,
ITALY, 2Neurology Institute, Università Cattolica del Sacro
Cuore, Roma, ITALY, 3Psychiatric and Psychology Institute,
Università Cattolica del Sacro Cuore, Roma, ITALY.
Aim: Parkinson’s disease (PD) subtypes may be associated
with different disease progression, neuropsychiatric and neu-
ropathological features. However, there are conflicting results
on differences in pre-synaptic dopaminergic damage. We
assessed dopamine transporter availability by 123I-FP-CIT
SPECT in tremor-dominant type (TDT) and akinetic-rigid type
(ART), using Statistical Parametic Mapping (SPM) and auto-
matic volumes of interest (VOIs). Relationships between im-
aging and psychiatric findings were investigated. Material &
Methods: We included 37 drug-naïve PD patients with abnor-
mal 123I-FP-CIT SPECT scans. According to the UPDRS-III,
patients were classified into 18 TDT (15 M, mean age:62±13
years; H&Y stage:1.7±0.4; UPDRS-III:17±6) and 19 ART (10
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M, mean age:61±13 years; H&Y stage:1.8±0.5; UPDRS-
III:19±8). At the time of SPECT, psychometric assessment
included the Hamilton Depression Rating Scale (HDRS),
Hamilton Anxiety Rating Scale (HARS) and Snaith Hamilton
Pleasure Scale (SHAPS). A 123I-FP-CIT template was gener-
ated with parametric images of 20 healthy subjects, using a
Montreal Neurological Institute template of 18F-DOPA as ref-
erence. Patient scans were spatially normalised to the 123I-FP-
CIT template by SPM8. Analysis was performed using VOIs
selected from a digital atlas and placed over the caudate and
putamen, bilaterally, and over the occipital cortex. The mean
activity concentration was obtained for VOIs and Specific
Binding Ratios (SBRs) were calculated through Marsbar tool-
box. Results: No differences were found in age, gender, dis-
ease duration, H&Y stage and UPDRS-III score between sub-
types. In comparison with ART, TDT patients showed higher
SBRs in the caudate contralateral and ipsilateral to the most
affected side (p<0.05). SPM statistics confirmed VOI results,
revealing a lower uptake in the caudate nuclei of ART patients
(p<0.01). In the whole sample, bradykinesia and rigidity, but
not tremor scores were related to SBRs (p<0.05). Relevant
depression symptoms were found in 6 TDT (33%) and 13
ART (68%) patients (p<0.05); HDRS and SHAPS scores were
higher in ART than TDT patients (p<0.05). An inverse corre-
lation was found between SBRs in the ipsilateral caudate and
HDRS or SHAPS scores in the overall sample (p<0.05). Con-
clusion: Our results indicate that ART patients have a more
severe dopaminergic deficit in the caudate nuclei than TDT
patients at the same disease stage. This finding is consistent
with the more favourable prognosis of TDT patients, related to
a less dopaminergic impairment and/or an involvement of oth-
er pathways. The association of DAT availability in the ipsi-
lateral caudate with depression and anhedonia severity support
the role of caudate dopamine function in the pathophysiology
of psychopathological symptoms.
P484
The significance of the posterior part of the putamen
in I-123-FP-CIT SPECT scanning and the early diagnosis
of Parkinson’s disease.
G. Gerasimou1, E. Papanastasiou1, E. Moralidis1, Z.
Katsarou2, P. Ioannidis1, M. Arnaoutoglou1, N. Grigoriadis1,
T. Tegos1, G. Liaros1, M. Gkirgkoudis1, A. Vasileiadis1, S.
Bonstanjiopoulou3, A. Gotzamani-Psarrakou1; 1AHEPAUni-
versity Hospital, THESSALONIKI, GREECE, 2Hippokration
Hospital, THESSALONIKI, GREECE, 3Papanikolaou Hos-
pital, THESSALONIKI, GREECE.
Aim: Parkinson’s disease (PD) is a neurodegenerative disorder
affecting the presynaptic dopaminergic pathway. PD starts
from degeneration at the posterior part (PP) spreading to the
whole of the putamen (P) and in the caudate nucleus at more
advanced disease. Differential diagnosis from essential tremor
(ET) is of clinical value in terms of early diagnosis and initia-
tion of treatment or confirmation of benign tremor. We try to
evaluate the significance of PP insult in the early diagnosis of
PD.Methods: We studied 99 individuals with confirmed ET
plus 67 patients with suspicion of PD presenting atypical
and/ or unilateral symptoms. After clinical evaluation I-123-
FP-CIT scan (DaTSCAN) was performed to all. ROI’s were
drawn over the whole of the striatum (S) plus to the CN, P and
anterior plus PP. The occipital cortex was used as the back-
ground area. The PP was considered the posterior third of the
whole P. The equation ROI-bg/bg was used for semi-
quantitative evaluation and the Mann-Whitney test for statis-
tical analysis.Results: A crescent-shaped S was formed n ET
patients, whilst an heterogeneity was mentioned at the P and a
deficit at the PP, more prominent at the contra-lateral side of
the affected limb. Values derived from semi-quantitative eval-
uation were higher in ET than in PD individuals. A significant
correlation was found between values at the PP in ET and PD
patients (p<0.0001), as well as, at the P and whole S
(p<0.001), even at the ipsilateral side.Conclusion: The value
of DaTSCAN in the differentiation of ET and PD is indisput-
able and can even predict the clinical symptoms. The role of
the PP is not clearly elucidated accordingly to the above men-
tioned data and probably more series of patients candidate for
PD should be included for a clearer outcome.
P30 - Monday, October 12, 2015, 4:00 PM - 4:30 PM, Hall 3 –
Poster Exhibition
Neurosciences: Data Analysis & Quantification
P485
In vivo quantification of the [11C]-DASB binding
in the normal canine brain using Positron Emission
Tomography
O. Taylor1, N. Van Laeken2, F. De Vos2, I. Polis1, T.
Bosmans1, I. Goethals3, R. Achten3, A. Dobbeleir3, E.
Vandermeulen1, C. Baeken3, J. Saunders1, K. Peremans1;
1University of Ghent (Faculty of Veterinary Medicine),
Merelbeke, BELGIUM, 2University of Ghent (Faculty of
Pharmaceutical Sciences), Ghent, BELGIUM, 3Ghent Univer-
sity Hospital, Ghent, BELGIUM.
Aims: [11C]-DASB is currently the most used radiotracer for
PET quantitative studies of the serotonin transporter (SERT) in
the human brain but has never been validated in dogs. The first
objective was to evaluate the regional distribution of the SERT
in the normal canine brain using this radiotracer. The second
objective was to determine the correlation between a reference
tissue method using a dynamic scan and regions to cerebellum
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ratio values from a single static acquisition. Materials and
Methods: The imaging was performed with a Gemini PET/
CT system and a 3T MRI system on 5 healthy dogs. A PET
summation image of all dynamic images was co-registered to
each individual MR images with PMOD. The regional radio-
activity in 20 ROIs was quantified using MRTM2 and a semi-
quantitative method. The values showed least variability be-
tween 40 and 60 minutes of scanning. A semi-quantitative
method measuring the ratio of the radioactivity within the
ROI over the radioactivity within the cerebellumwas therefore
performed using the data in this time interval. The coefficient
of determination R2 was calculated to estimate the correlation
between the two methods. Results: For the regional analysis,
the highest radioactivity concentration of [11C]DASB was
observed in the hypothalamus, raphe nuclei and thalamus, in-
termediate levels were observed in the basal ganglia, hippo-
campus and frontal cortex, modest levels in the anterior and
posterior cingulate gyri and temporal cortex, and low levels in
the parietal cortex, occipital cortex and cerebellum. Scanning
between 40 and 60minutes was set as the optimal time interval
for [11C]DASB quantification in the canine brain. The corre-
lation (R2) between the MRTM2 and the static ratio method
using the data between 40 and 60 minutes was 98.64%. Con-
clusion: The results from the regional analysis are consistent
with the previous human and animal studies, with the highest
radioactivity concentration observed in the hypothalamus, ra-
phe nuclei and thalamus. Reference tissue models and the
static scan ratio method provide a more convenient alternative
to invasive arterial sampling models in the evaluation of the
SERTof the normal canine brain. The optimal time interval for
scanning is set at 40 to 60 minutes after tracer injection.
P486
Automated PET-only quantification of amyloid deposition
with adaptive template and amyloid-specific
region-of-interest
G. Akamatsu1,2, Y. Ikari1, A. Ohnishi1, T. Nishio1, H.
Nishida1, K. Aita1, Y. Yamamoto3, M. Sasaki1, M. Sasaki2,
M. Senda1; 1Institute of Biomedical Research and Innovation,
Kobe, JAPAN, 2Kyushu University, Fukuoka, JAPAN, 3Kobe
University, Kobe, JAPAN.
Purpose: Amyloid PET is useful for early and/or differential
diagnosis of Alzheimer’s disease (AD). Quantification of am-
yloid deposition has been performed to improve diagnosis and
monitoring of AD, particularly in research. Although MRI is
often used for segmentation of gray matter and for spatial
normalization into standard Montreal Neurologic Institute
(MNI) space where region-of-interest (ROI) template is de-
fined, 3D MRI is not always available in clinical practice.
The purpose of this study was to examine possibility of
quantification for amyloid PET images without MRI or CT
using adaptive template and amyloid-specific ROI. Materials
and Methods: A total of 30 subjects (10 AD subjects; 11 MCI
subjects; 9 normal control subjects) who underwent brain 11C-
PiB PETwere examined. A 20-minutes emission scan, starting
50 minutes after injection of 571.1±24.5 MBq was performed.
The PiB images were spatially normalized to the standard
MNI T1 atlas using PET-MRI coregistration and the spatial
normalization for the MRI. The automatic-anatomic-labeling
(AAL) template was applied to the PET images. All voxel
values were normalized by the mean value of cerebellar cortex
to generate the SUVR scale images. Eleven typical positive
images and five typical negative images were normalized and
respectively averaged to be used as the adaptive template.
Positive and negative masks were created as the set of voxels
with SUVR > 2.0 on each averaged image. Amyloid-specific
regions were generated by subtracting negative mask from
positive mask. As for the PET-only technique, all PiB images
were non-rigidly normalized to both positive and negative
templates and the one having higher cross-correlation was
adopted. Amyloid-specific ROI was then inversely trans-
formed to individual PET images. We evaluated correlation
of SUVR between standard MR-based method and PET-only
method on 20 of 30 subjects. We also compared the PET-only
method with visual interpretation by qualified nuclear physi-
cian on the 30 PiB images. Results: Significant correlation was
observed between the SUVRs obtained by MR-based method
and PET-only method (Spearman correlation coefficient:
ρ=0.97, P<0.01). All but one subject were correctly catego-
rized into positive and negative using cutoff value of 1.5 based
on either MR-method or PET-only adaptive template method.
The PET-only SUVR were 2.22±0.34 and 1.35±0.06 for pos-
itive and negative images by visual interpretation. Conclusion:
The PET-only amyloid quantification method with adaptive
template and amyloid-specific ROI provide accurate, robust
and simple amyloid quantification without MRI.
P487
Fully Parametric Imaging for Reversible Tracer of FLT
within Reasonable Time
N. Kudomi, A. NIshiyama, Y. Maeda, T. Hatakeyama, Y.
Yamamoto, Y. Nishiyama; Faclty Of Medicine, Kagawa Uni-
versity, KAGAWA, JAPAN.
Objectives: PET enables us to quantitatively image of func-
tions such as rate constants of uptake (K1), washout (k2),
phosphorylation (k3) and dephosphorylation (k4), by applying
the reversible two tissue compartment model. However there
are, so far, no feasible computational strategies for imaging all
those rate constants within reasonable computation time. We
propose a new method to compute all those rates within a
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reasonable time, namely, less than 1 min. Methods: A set of
differential equations for the reversible two tissue compart-
ment model was converted to one formula which expressed
as tissue and plasma curve terms involving derivative, integral
and convolution terms. Feasibility was tested by applying clin-
ical data with 18F-FLT PET (ECAT HR+) for patients with
glioma (n=38). Then the images of those rates were obtained
using the present developed imaging method from dynamic
scan image. To test validity, regions of interest (ROI) were
placed on regions with glioma on a summed image of the scan
image. Parametric values of those rate constants were extract-
ed from the obtained images. Also, time activity curve was
extracted from the placed ROIs and those rate values were
computed by the non-linear fitting method (Gauss-Newton
method). The obtained rate values were compared between
the methods. Results: Computation time was around 30 s
and quality of generated images was reasonably acceptable.
Obtained values for K1 were 0.15 ± 0.08 and 0.16 ± 0.08
ml/min/g for image and ROI based methods, respectively.
Those were 0.18 ± 0.12 and 0.18 ± 0.11 min-1 for k2, 0.11 ±
0.08 and 0.10 ± 0.06 min-1 for k3, 0.017 ± 0.014 and 0.018 ±
0.012 min-1 for k4, respectively. Paired t-test showed no sig-
nificant differences between the methods in those rate values.
Regression analysis showed correlations as: r=0.94, 0.86, 0.71
and 0.52 for K1, k2, k3 and k4, respectively. Conclusion: The
present results suggested that the full parametric images can be
obtained within reasonable time, with reasonable accuracy and
quality.
P488
Comparison with cerebral blood volume
on 15Ogas-PET/CT in patients with chronic
cerebrovascular disease
N. Morita, A. Shimizu, Y. Terakawa, K. Kajimoto, T. Uehara,
D. Maruyama, J. Nakagawara, H. Iida; National Cerebral and
Cardiovascular Center, Suita, JAPAN.
(Aim) As represented by Powers classification, increasing ce-
rebral blood volume (CBV) suggests moderately severe ische-
mia and has possibility to move to severe ischemia with in-
creasing oxygen extraction fraction (OEF). However, there has
no consensus on the degree of increasing CBV by the type of
disease or ischemic condition. The purpose of our study was to
compare the degree of increasing CBV among patients with
chronic ischemic cerebrovascular disease. (Materials and
methods) Among patients who have been taken 15O-gas
PET/CT study in our institution from Oct.2013-Sep.2014,
130 patients (50 female, mean age 65.0 y.o.) who fulfilled
our criteria were recruited in our study. We divided into 3
groups of asymptomatic internal carotid artery (ICA) disease
(asICA; n=55, 71.4±8.19y.o.), symptomatic ICA disease
(sICA; n=36, 72.8±8.69 y.o.) and moya moya disease
(MMD;n=39, 50.9±11.43y.o.). Also, normal database
(NDB;n=10, 71.2±4.35y.o.) was applied as reference. We ap-
plied clinical PET/CT machine (Biograph-mCT; Siemens,
Knoxville, USA) and original workstation (Q-view software;
Research Institute, National Cerebral and Cardiovascular
Center, Osaka, Japan) was used for data processing. PET ex-
amination was taken followed by dual-tracer autoradiography
(DARG) method and CBV value was measured by a single
inhalation of C15O. 8 ROIs were set in both MCA area (ante-
rior and posterior), and measured mean CBV value (ml/100g/
min) in affected side. Data was compared by unpaired t-test
and ROC analysis was applied to evaluate the optimal cutoff
value between ICA disease and MMD. (Results) Mean CBV
value of NDB, asICA, sICA and MMD were 2.73±0.31, 2.97
±0.43, 2.92±0.53 and 3.68±0.95, respectively. Mean CBV val-
ue in MMD showed statistically higher than others and there
was no statistical difference between both ICA disease and
NDB. In ROC analysis, the optimal CBV value was 3.21 with
sensitivity of 65.4%, specificity of 72.9% between ICA dis-
ease and MMD. (Conclusion) In measuring CBV, nondiffus-
ible tracers cannot obtain reliable values of tissue perfusion,
CBV value would be mostly affected the turnover rate of the
regional blood pool. We should take it into consideration of
this specific feature in evaluating for CBV in chronic ischemia
on 15Ogas-PET study.
P489
Evaluation of increasing cerebral blood volume
on 15Ogas-PET/CT in patients with severe ischemic
cerebrovascular disease
N. Morita, A. Shimizu, Y. Terakawa, K. Kajimoto, T. Uehara,
D. Maruyama, J. Nakagawara, H. Iida; National Cerebral and
Cardiovascular Center, Suita, JAPAN.
(Aim) As represented by Powers classification, increasing ce-
rebral blood volume (CBV) suggests moderately severe ische-
mia and has possibility to move to severe ischemia with in-
creasing oxygen extraction fraction (OEF). However, there has
no consensus on the degree of increasing CBV by the type of
disease. The purpose of our study was to evaluate the degree of
increasing CBV in severe ischemic cerebrovascular disease
with increasing OEF. (Materials and methods) 130 patients
(50 female, mean age 65.0 y.o.) who fulfilled our criteria were
recruited in our study. We divided into 3 groups of asymptom-
atic internal carotid artery (ICA) disease (asICA;n=55), symp-
tomatic ICA disease (sICA;n=36) and moya moya disease
(MMD;n=39). Normal database (NDB;n=10) was applied as
reference. 8 ROIs were set in both MCA area (anterior and
posterior), and measured mean CBV value (ml/100g/min) and
OEF (%) in affected side. Positive OEF (increasing OEF) was
S574 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
determined when OEF value was more than 2SD in NDB. We
measured mean CBV value and compared the differences be-
tween positive and negative OEF group. Data was compared
by unpaired t-test and ROC analysis was applied to evaluate
optimal cutoff value between negative and positive OEF. Also
we evaluated correlation between each quantitative CBV and
OEF value. (Results)Fifty seven patients (43.8%) showed pos-
itive OEF. Regardless the OEF finding, the mean CBV value
in MMD shows statistically higher than other disease
(p<0.01). CBV value in every patient group showed higher
in OEF positive groups, but the degree of increasing CBV
was small and these are mostly overlapped. In ROC analysis,
CBV value of 4.03 might be threshold with higher specificity
of 0.925 in MMD. There was no correlation between these
CBV and OEF value in every type of disease. (Conclusion)
On 15Ogas PET study, CBV would be mostly affected the
turnover rate of the regional blood pool, and increasing CBV
in patients with chronic vessel disease indicates the long-term
ischemia or collateral development. To obtain reliable values
of tissue perfusion on 15Ogas-PET study, technical improve-
ment would be expected.
P490
Deformable registration for 18F-florbetapir PET
quantification
L. Sibille, C. Hutton, J. Declerck; Siemens Molecular Imag-
ing, Oxford, UNITED KINGDOM.
Aim: The aim of this study was to compare the performance of
a novel PET-based deformable registration method with PET-
based affine registration and to assess the impact on 18F-
florbetapir PET quantification by calculating cortex-to-
cerebellum standard uptake value ratios (SUVr) following
the different registration methods. Materials and methods:
The PET-based deformable registration method is based on a
deformable database feature matching (DFM) algorithm
which matches points of interest in the patient brain against
an existing database of points of interest covering a range of
medical conditions and subject age. 18F-florbetapir PET and
MR images were obtained from the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI). In 39 subjects, PET images were
registered to MNI (Montreal Neurological Institute) atlas
space (Evans et al., 1993) using DFM registration as well as
PET-based affine registration which is implemented in sPAP
(syngo.PET Amyloid Plaque, Peyrat et al., SNM, 2012), a
previously validated PET quantification method (Hutton
et al., EJNMMI, 2014). Anatomical regions of interest (ROI)
were defined using an independent deformable registration
method based on the subject MRI (SPM, http://www.fil.ion.
ucl.ac.uk/spm/). Overlap (using Dice Coefficient) was
calculated between ROIs resulting from the PET-based
registration methods and those defined anatomically. The
DFM method was also used to register PET images from
604 subjects to MNI space prior to calculation of cortex-to-
cerebellum SUVr (Fleisher et al., 2011). The DFM registration
results were visually assessed and SUVrs were compared with
those calculated in a previous study using sPAP (Hutton et al.,
EJNMMI, 2014). Results: Dice Coefficient averaged over the
anatomical ROIs was 0.7 or more in 27/39 of the cases follow-
ing DFM registration, but only in 7/39 cases following affine
registration. In [Hutton et al., 2014], 14 cases required manual
registration adjustments following affine registration. Using
DFM, only one of those cases required manual adjustment.
The resulting SUVrs were correlated, with r=0.99 and the lin-
ear regression of DFM SUVr values on sPAP SUVr was y = 1.
0318x - 0.01. Conclusion: The novel PET-based deformable
registration resulted in improved local matching of the patient
brain to MNI space. Resulting SUVrs were highly correlated
and in good agreement using the different registration
methods.
P491
Total Metabolic Index; Inter-Rater Variability
in Quantifying Cerebral Hemispheric GlucoseMetabolism
in the Course of Treatment of Glioma
E. A. Segtnan1, P. Grupe1, J. O. Jarden2, S. B. Christlieb1, J.
E. Pedersen1, C. Constantinescu1, O. Gerke1, S.
Houshmand3, S. Hess1, A. Alavi3, P. F. Høilund-Carlsen1;
1Dept.of Nuclear Medicine, Odense University Hospital,
Odense, DENMARK, 2Dept. of Neurology, Herlev University
Hospital, Copenhagen, DENMARK, 3Division of Nuclear
Medicine, University of Pennsylvania, Philadelphia, PA,
UNITED STATES.
Aim: Maximum standardized uptake value (SUVmax) is the
most used semi-quantitative parameter in cerebral FDG-PET
imaging. However, it may not be ideal for characterizing gli-
omas due to tumour and tissue heterogeneity, limited PET
resolution, and technological and biological confounders dur-
ing the management course. With “Total Metabolic Index
(TMI)”, we aimed to establish a method to quantify the meta-
bolically most active regions of each hemisphere using FDG-
PET. Here, we present data on inter-rater variability (IRV)
from five time points in the course of management of glioma
patients. Material and methods: In total 49 FDG-PET scans
from fourteen glioma patients followed for one year (or until
death) were prospectively collected before treatment (A), after
resection/biopsy (B), after radio-chemotherapy (C), during
chemotherapy (D), and after treatment (E). Three independent
observers applied regional 3D-masks using dedicated software
to segment the hemispheres ipsilateral and contralateral to the
tumour (IH and CH), and the total cerebellum (Ce) to obtain
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SUVmax and partial volume corrected SUVmean
(cSUVmean) of the regions with the highest metabolism (cut
off 40% of max). The total volume of these high activity re-
gions (HAV) was multiplied by cSUVmean of its own HAV to
yield cSUVtotal for IH, CH and Ce, respectively. Indexed
hemispheric glucose metabolism was obtained by division of
hemispherical cSUVtotal by cerebellar cSUVtotal (TMI).IRV
was assessed using the coefficient of variation. Results: IRV
for SUVmax was 1% for both IC and HC and 1-2% for Ce at
all time points. IRV for the HAV was 3%, 3%, 6%, 2%, and
4% for IH; 3%, 3%, 5%, 3%, and 3% for CH; and 7%-13% for
Ce at time points A-E, respectively. IRV for cSUVmean was
3%, 3%, 6%, 2%, and 4% for IH; 3%, 3%, 5%, 3%, and 3% for
CH, and 7-13% for Ce at time points A-E, respectively. IRV
for cSUVtotal was 3%, 3%, 6%, 2%, and 4% for IH; 3%, 3%,
5%, 3%, and 3%, for CH, and 7-13% for Ce for time points A-
E respectively. IRV for the TMI was 9%, 11%, 14%, 12%, and
13% for IH; 9%, 13%, 13%, 14% and 14% for CH at time
points A-E, respectively. Conclusion: The SUVmax,
cSUVmean, HAV, and cSUVtotal were highly reproducible
for both the cerebral hemispheres regardless of course of man-
agement. Cerebellar values had the highest IRV. Overall, “To-
tal metabolic index (TMI)”was reproducible and is most likely
applicable for quantitative analysis in other diseases of the
brain.
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Efficiency Changes of Cerebral Blood Flow Network
in Response to Hypercapnia Show Early Abnormal Status
in Mild Cognitive Impairment: a Graph Analysis Study
C. Sánchez Catsús1, G. Sanabria-Diaz2, R. Dierckx3, L.
Melie-García2; 1CIREN, Havana, CUBA, 2Cuban Neurosci-
ence Center, Havana, CUBA, 3Department of Nuclear Medi-
cine & Molecular Imaging, Medical Imaging Center, Univer-
sity Medical Center, Groningen, NETHERLANDS.
There is growing support that microvascular reactivity to hy-
percapnia is reduced in Alzheimer’s disease. However, it is
less clear in patients with mild cognitive impairment (MCI).
Subtle abnormal response in MCI might not be appreciated by
standard metrics of cerebrovascular reactivity (CVR), espe-
cially in patients with low vascular burden. Previously, using
graph analysis, we demonstrated that the cerebral blood flow
(CBF) network follows ‘small-world’ attributes in normal cog-
nition state at basal condition (Neuroimage. 2013
Jan 1;64:173-84), similar to other brain networks. Aim: here,
using the same methodology, our aim was to investigate
changes of nodal (Enod), local (Eloc) and global (Eglob) effi-
ciencies of the CBF networks in response to hypercapnia, in-
duced by acetazolamide (ACZ) in MCI and normal cognition
states. Materials and methods: four networks were
constructed: two based on CBF SPECT data at basal condition
and post- ACZ, respectively, obtained from a group of 26MCI
patients with low vascular profiles; and the two corresponding
networks from a group of 26 matched healthy controls. Re-
sults: we found that nodes in the temporal lobes and prefrontal
cortices showed Enod decrease in the MCI CBF network in
response to ACZ; while the control CBF network showed
nodes with Enod decrease in temporal lobes, like MCI, but
also nodes with Enod increase in prefrontal cortices and
precunei. Moreover, Eloc decreased and Eglob increased in
the MCI CBF network. In contrast, the control CBF network
showed no changes. CVR showed no differences between
groups. Conclusion: we demonstrated that changes of nodal,
local and global efficiency of the CBF network in response to
hypercapnia are different in the MCI state compared with the
normal cognition state, which was not detected by standard
CVR metrics. This suggests an early abnormal status of the
reactivity of brain microvascular network in MCI, specifically
in MCI patients with low vascular burden. This could help to
clarify early microvascular abnormalities in MCI.
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Attenuation correction by CT can improve detectability
of lesions by voxel based statistical analysis of brain
SPECT
H.Kato1, E. Shimosegawa1, K. Fujino2, J. Hatazawa1; 1Osa-
ka University Graduate School of Medicine, Osaka, JAPAN,
2Osaka University Medical Hospital, Osaka, JAPAN.
Objectives: SPECT-CT enables the non-uniform attenua-
tion correction (AC) using built-in CT instead of con-
ventional uniform AC. Although the result of the voxel-
based statistical analysis based on Z-score is thought to
be influenced by difference in the AC methods, the ef-
fect has not been clarified. We aimed to assess the dif-
ference in detectability for SPECT count reduction by
voxel based statistical analysis depending on the AC
methods. Methods: Fifteen patients with chronic cerebral
infarctions and 35 healthy volunteers underwent quanti-
tative N-isopropyl-p-(I-123) iodoamphetamine (I-123
IMP) SPECT. Image reconstruction was performed using
3D-OSEM with two different AC methods: Chang’s
method and CT AC method. Normal database for the
analysis was constructed by the 25 randomly selected
from the 35 normal SPECT data. Voxel based z-test
was performed by using statistical parametric mapping
8 (SPM8) to detect significant regional reduction in the
SPECT count of the remaining 10 normal volunteers or
the patients. Results: The z-score indicating SPECT
count decrease in the infarct lesions was significantly
higher in the images reconstructed using CT AC method
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than Chang’s AC method (p = 0.003). As for the 10
normal volunteers, mean absolute value of the z-score
in the intact brains was significantly lower in the images
reconstructed using CT AC method than Chang’s AC
method (p = 0.005). Conclusions: Sensitivity for SPECT
count reduction by voxel based statistical analysis was
shown to be significantly improved, and non-specific
SPECT count reduction was significantly mitigated by
using CT AC instead of conventional method.
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Detection of Regional Cerebral Blood Flow disturbance
with the assistance of statistical parametric mapping
(SPM): a 99mTc-ECD brain perfusion SPECT study
in Alzheimer’s and Multiple Sclerosis diseases
N. Chabi1, M. Taghizadeh Asl2, M. Assadi1; 1The Persian
Gulf Nuclear Medicine Research Center, Bushehr University
of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUB-
LIC OF, 2Department of Nuclear Medicine, Kasra Hospital,
BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.
Aim: Visual analysis is often used for rCBF SPECT
images interpretation which has many limitations. So,
automated methods are a necessity in this area. SPM is
one of the most widely used software in quantitative
assessing of functional brain imaging like PET, fMRI,
SPECT that is mostly employed for comparison between
groups in research analysis while is rarely used for in-
dividual assessmen. We used this software for individual
assessment of brain SPECT images of different patients
who suffered from various illnesses such as Multiple
Sclerosis and Alzheimer disease in order to find perfu-
sion abnormalities in cerebral SPECT examinations. Ma-
terials and methods: SPM was used to compare 17 dif-
ferent patient images (5 Multiple Sclerosis, 12
Alzheimer) with 12 normal brain SPECT images using
statistical threshold of p < .001 . Results: Most of the
obtained results are in agreement with visual assessment
of a nuclear medicine physician. Also, the results were
mapped onto the anatomical brain image such as T1 or
T2 to better localize existing disorder. Moreover, Auto-
mated Anatomical Labelling (AAL) software in SPM
provides an effective tool to better investigate the abnor-
malities locations. Conclusion: The automated quantifi-
cation method such as SPM could be more useful in a
better and more precise decision taken by physician and
it could be a complementary to visual inspection of the
physician in the clinical practice. Also, mapping the re-
sults on an anatomical space in addition to using AAL
software can help the physician for a better recognition
of the abnormalities location.
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Machine learning model targeting 11C-PiB PET images
in diagnosis of Alzheimer’s Disease
Z. Huang1, X. Shu2, J. Jiang2, Y. Guan1; 1Huashan Hospital,
Fudan University, Shanghai, CHINA, 2Institute of Biomedical
Engineering, School of Communication and Information
Technology, Shanghai University, Shanghai, CHINA.
Aim: As one successful biological indicator for amyloid-
beta peptide (Aβ), Carbon 11-labeled Pittsburgh com-
pound B Positron Emission Tomography (11C-PiB PET)
has been widely used for the diagnosis of Alzheimer’s
disease (AD). However, the accurate diagnosis of AD
base on this technique still remains a challenge for radi-
ologists, especially in differentiating AD, Mild Cognitive
Impairment (MCI) and healthy control (HC) groups. Vi-
sual assessment (VA) is the most commonly used clinical
method, which is time-consuming, and the diagnostic ac-
curacy can be varied due to clinical experience. This
paper proposed a machine learning model targeting 11C
PiB PET images, trying to improve current method. Ma-
terials and Methods: The machine learning model in-
cludes four parts: (1) Aβ 3D segmentation by adapted
level set method (LSM) and Lattice Boltzmann Method
(LBM) based algorithms; (2) original feature de-
correlations by principle component analysis (PCA); (3)
feature extraction by independent component analysis
(ICA); (4) classification by support vector machine
(SVM). Subject: 26 groups of PiB PET images from
Shanghai Huashan hospital and 120 groups of data from
ADNI database. (1) All PiB PET images were smoothed
and normalized; (2) 73 PCs which can represent 95% of
the whole data were selected. All date were de-correlated
by PCA; (3) 80 ICs were chosen as final feature to guide
a classification test, and RBF kernel SVM classifiers
were used; (4) The classification performance was tested
in three steps: training, cross-validation and test. Cross
validation was achieved by means of the leave-one-out
method; (5)Two senior radiologists, with over 7-years
PiB PET reading experiences from Shanghai HuaShan
Hospital, were invited to provide VA results based on
original DICOM images. Results: The proposed machine
learning model can yield 94.34% accuracy in differenti-
ating AD groups from HC groups; and 93.27% accuracy
in differentiating MCI groups from HC groups; if both
AD and MCI groups were considered as one positive
group, the diagnosis accuracy was 91.67%. By compari-
son, the accuracy by VA was 79.3%, 68.71% and
57.45%. Conclusion: Machine learning techniques are
able to aid radiologists to improve diagnostic accuracy
of AD based on PiB PET images. The proposed machine
learning model in this paper is effective and efficient.
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Quantitative comparison between different methods
for measurement Dopamine Transporters (DAT): An
assessment of the accuracy and precision in DAT-SPECT
images
L. Alexandre-Santos1, E. N. Itikawa2, D. K. Sonvenso1, A.
C. Trevisan2, M. Kato1, F. A. Pitella1, C. E. P. Baltazar1, E. R.
Moraes3, O. Baffa3, L. Wichert-Ana1,2; 1Ribeirão Preto
School of Medicine - University of São Paulo, Ribeirão Preto,
BRAZIL, 2Bioengineering Post Graduation Programe - São
Carlos School of Engineering - University of São Paulo, São
Carlos, BRAZIL, 3Faculty of Philosophy, Sciences and Let-
ters at. Ribeirão Preto, Ribeirão Preto, BRAZIL.
AIM: Molecular imaging of DAT gives differential informa-
tion in research of neurodegenerative diseases, such as
Parkinson’s Disease (PD), when properly approached quanti-
tatively. Yet, each method used in clinical routine may give, or
not, different results when the quantifications are applied in
images of several activity levels. Hence, this study assessed
the accuracy and precision of DAT-SPECT quantification
methods, based in ROIs.MATERIALS AND METHODS:
Twenty three DAT-SPECT images were acquisitions of an-
thropomorphic striatal phantom filled with different activity
concentrations of 99mTc. For each acquisition performed,
the specific chambers (caudate and putamen chambers) to
large chamber (simulating nonspecific background activity)
was filled with solutions activity of different specific to non-
specific ratios (10, 8, 6, 4 and 2 to 1). The images were recon-
structed by an iterative algorithm, corrected to attenuation ef-
fects. The extracted values were analyzed by the specific bind-
ing ratio (SBR). Five quantification DAT-SPECT methods
using ROIs were assessed: Manual technique: (A) draw free-
hand ROIs on SPECT images. Standard size ROIs: (B)
TwoBox and (C) ThreeBox Methods. VOIs using structural
images: (D) MRI and (E) CT. Accuracy of methods applied
were assessed by concordance correlation coefficient (CCC)
and precision by Pearson’s coefficient and linear
regression.RESULTS: Quantified SBR for both individual
specific chambers and striatal chamber using all methods re-
sulted in a CCC increase, with decrease of the nominal values
used. For lower SBR values, the D and E methods evidenced
the maximum values of CCC in assessment of caudate
(CCCMRI_CA = 0.89 e CCCCT_CA = 0.84) and putamen
(CCCMRI_PU = 0.86 e CCCCT_PU = 0.82). However, striatal
assessments the B method highlights a maximum accuracy
between all methods applied (CCCTWOBOX_ST = 0.95), for
low values of SBR. A high Pearson’s coefficient was found
in the correlation between all methods, report thereby a good
precision between them.CONCLUSION: The five quantifi-
cation DAT-SPECT methods showed a high precision quanti-
fication even when applied in images with different activity
solutions. However, investigations that need a more accurate
quantification process seeking putamen evaluation and cau-
date nucleus separately, structural methods showed a progres-
sive improvement in its quantification as there is a decrease of
filling nominal index. To assess striatal chamber in the absence
of structural information, the TwoBox method showed excel-
lent agreement with all nominal values.
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Distribution of the Dopamine Transporter (DAT)
in the nigro-striatal pathway examined in vivo with [18F]
FE-PE2I and high-resolution PET
P. Fazio1, Z. Cselényi1,2, C. Halldin1, L. Farde1,2, A.
Varrone1; 1Karolinska Institutet, Department of Clinical Neu-
roscience, Centre for Psychiatry Research, Stockholm, SWE-
DEN, 2AstraZeneca Translational Science Centre at
Karolinska Institutet, Stockholm, SWEDEN.
Aim. The aim was to develop new methodology for in vivo
quantification of dopamine transporter (DAT) availability
along the nigro-striatal projections.Methods. High-resolution
wavelet-aided parametric images (PIs) of the binding potential
(BPND) in brain were generated from 11 healthy control sub-
jects (CS) having participated in PET measurements with
[18F]FE-PE2I using the HRRT system. To obtain a functional
based DAT template, individual PIs were spatially normalized
using a two-step normalization procedure using various tools
of the FMRIB Software Library (FSL), which enables accurate
normalization of the mesenchepalic and dienchepalic regions.
The template enabled visualization of DAT binding along dif-
ferent and distinct efferent fibers projecting from the substantia
nigra (SN). Template-based ROIs were delineated manually
for nigro-striatal (NST), nigro-pallidal (NPT), nigro-thalamic
tracts (NTT), SN and striatal regions (caudate, putamen, ven-
tral striatum), and then applied to each parametric image to
obtain individual BPND estimates. Pearson correlation analysis
was used to compare the estimates obtained in the SN and the
striatum with the estimates obtained for the different tracts.
Results. The highest BPND values along the tracts were found
in NST (0.49±0.07), followed by the NTT (0.35±0.13) and by
the NPT (0.31±0.12). Those BPND values were lower than the
values measured in the striatum (4.08±0.54) and in the SN
(0.81±0.10). A positive correlation was found between BPND
in NPT and BPND in SN (r=0.648, p<0.02) and striatum
(r=0.862, p<0.001) and between BPND in NST and BPND in
SN (r=0.621, p<0.05) and striatum (r=0.633, p<0.05). No sta-
tistically significant correlations were found for the
NTT.Conclusions. The estimates along the tracts of interest
confirmed, in vivo, the distribution of DAT along axons orig-
inating from the SN and the feasibility to quantify them with
HRRT and [18F]FE-PE2I. The results are consistent with
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previous observations in vitro that DAT is expressed along the
axons originating from the SN. Despite the low density of
DAT in these regions, its availability can be measured in vivo
using high resolution DAT PETwith [18F]FE-PE2I, providing
the possibility to image the entire dopaminergic nigro-striatal
pathway.
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Evaluation of the uniform attenuation correction in ictal
SPECT images in Frontal Lobe Epilepsy: A quantitative
approach through SPM
L. Alexandre-Santos1, H. T. Amaral-Silva1, E. N. Itikawa2,
D. Sonvenso1, A. C. Trevisan2, T. R. Velasco1, F. A. Pitella1,
V. Alexandre, Jr.1, M. Kato1, L. Wichert-Ana1,2; 1Ribeirão
Preto School of Medicine - University of São Paulo, Ribeirão
Preto, BRAZIL, 2Bioengineering Post Graduation Programe -
São Carlos School of Engineering - University of São Paulo,
São Carlos, BRAZIL.
AIM: The Attenuation Correction (AC) of gamma photons
poses a clinical problem in the evaluation of ictal SPECT in
Frontal Lobe Epilepsy. The main issue is that mesially located
seizure focus may be underestimated. This study aimed to
evaluate the impact of the AC on brain SPECT images in
patients with Frontal Lobe Epilepsy (FLE). MATERIALS
AND METHOD: The ictal SPECT of 10 patients diagnosed
with FLE were analyzed using SPM. The brain SPECT of 12
healthy subjects were used as a control group. All SPECT
images were divided in two groups: a group containing
SPECT images corrected for the effects of gamma-ray photons
(AC), by Chang’s Method (0.12/cm), and another group with-
out the AC (nAC). The Statistical Parametric Mapping (SPM)
was used to compare the signal changes of the AC and nAC
images. To the hypothesis test to this study (Two sample, t-
test), two comparison models were specified: single patient
(nAC) versus control group average (nAC) and single patient
(AC) versus control group average (AC). Each patient was
compared with the average image of the control group due to
variations of epileptogenic zones locations among the ten pa-
tients. The threshold p-value used was to values p<0.001, with
Z >3.08, and cluster size value k=20. From each selected clus-
ter we analyzed the cluster size, pick value, and the corrected
p-value for each inference level. All these clusters were evi-
denced in a MRI standard template for better view of the re-
sults. RESULTS: We found differences between the averaged
signals of each comparison performed on both sets of images
of interest, AC and nAC. Those clusters than survived the
multiple comparisons test were considered. They showed that
by applying the AC, the epileptogenic or propagation zones
located mesially in the brain were better evidenced, either vi-
sually or quantitatively. Otherwise, the nonlinear weight in the
SPECT image used by Chang’s Method decreased the visual-
ization of the seizure activated regions located in the peripheral
or lateralized areas of the brain. CONCLUSIONS: We con-
cluded that the uniform Attenuation Correction method ap-
plied in brain SPECT images is an effective tool in the inves-
tigation of FLE cases. The AC contributed to the exhibition of
epileptogenic and propagation zones located mesially within
the brain. However, the non AC images should also be clini-
cally used once activated areas in the peripheral or lateralized
brain regions may be underestimated with the AC techniques.
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Standardization of normative data as ‘reference data’
in a single institute for the qualitative and quantitative
DaTSCAN evaluation
G. S. Limouris1, E. Konstantinidis2, N. Triantafyllou2, M.
Paphiti3, I. Valais4, G. Paraskevas2, E. Kapaki2; 1Nuclear
Medicine Div, I Radiology Dept, ‘Aretaieion’ Hosp, Athens
Univ Medical Faculty, Athens, GREECE, 2Neurologic Clinic,
‘Aeginiteion’ Hospital, Athens Univ Medical Faculty, Athens,
GREECE, 3Nuclear Medicine Dept, Royal Sussex County
Hosp, Brighton, UNITED KINGDOM, 4Bioengineering
Dept,TEI Athens, Athens, GREECE.
Purpose: Dopamine transporter (DAT) imaging with [123I]
FP-CIT (DaTSCAN) is an established radio-molecular diag-
nostic tool for the evaluation of tremor-related symptoms in
neuro-psychiatric disorders, and more specific in parkinson-
ism and dementia. Although qualitative (visual) scintigraphic
criteria are used for the assessment of the diagnosis,
DaTSCAN quantification is important for an accurate comple-
tion, differentiation and research of the final evaluation. For
this reason the availability of normative data, obtained from
studies performed in our facilities and thorough discussions,
between the specialties involved [i.e. Nuclear Medicine, Neu-
rology and Psychiatry] is more than crucial. The aim of our
universitary Institutions was to create for first time in Greece a
large database of [123I]FP-CIT SPECT scans to be used as
reference data of normal ranges. Methods: In 113 healthy con-
trols (67 men, 46 women; age range 38-73 years) DaTSPECT
studies were performed in a single Institute [‘Aretaieion’ Univ
Hospital’] from March 2007 to October 2014, with main pts’
tank of origin the Neurology and Psychiatric Clinics of
‘Aeginiteion’ Univ Hospital. Brain SPECT imaging was ac-
quired using a single-head gamma camera (Elscint Apex SPx-
4) equipped with a low-energy, all-purpose, parallel-hole col-
limator. One hundred and twenty tomographic images, every 3
degrees in a total of 360 degrees, of 128x128 pixels matrix, on
a step & shoot mode, were acquired for each patient. Images
were then normalized to 64x64 pixels matrix for inter-
processing compatibility. Normalized data were reconstructed
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by filtered back projection and a standardMetz filter was used.
Attenuation correction was performed using Chang’s method
with a 0.12 attenuation coefficient. Images were displayed in
the transaxial, coronal and sagittal planes for interpretation.
Region-of-interest analysis was performed using the
CBRREC Elscint software (caudate, putamen and striatum,
drown manual-ly).The outcome measure was the specific
binding index (SBI). Results: Normative data according re-
gions were as follows: stiatum (2.4 ± 0.3), caudate (2.6 ±
0.5), putamen (2.2 ± 0.4). No statistically significant ranges
were found among gender and ages except a 4.8 % loss, no-
ticed in over 68 year of age in putamen and stiatum. Conclu-
sion: For fist time in a single Institute normative DaTSCAN
data for patients of Greek origin was created. Statistically sig-
nificant ranges among genders and ages were not observed. A
4.8 % decline was depicted in putamen and stiatum over the
age of 68.
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Comparison of an Atlas-based Method of DaTscanTM
Quantification to Manual Volume of Interest Definition
A. S. Nelson, A. Pilla, M. Horvat, J.W. Piper; MIM Software,
Cleveland, OH, UNITED STATES.
Purpose: To compare an atlas-based method for volume of
interest (VOI) definition to manual VOI definition in the eval-
uation of Parkinson’s disease using DaTscan (123-I Ioflupane)
SPECT. Methods: Nineteen subjects with T1W MRI and
DaTscan SPECT scans were selected from the Parkinson’s
Progression Markers Initiative (PPMI) database (www.ppmi-
info.org/data). Ten subjects were from the Parkinson’s Disease
(PD) cohort and nine subjects were from the Healthy Control
(HC) cohort. VOIs were manually defined on all MRI scans
for the: caudate, putamen, posterior putamen, anterior puta-
men, striatum, and occipital lobe. Manual VOIs were applied
to the rigidly registeredDaTscan SPECTscans andmean ratios
relative to the occipital lobe were recorded. For the automated
method the DaTscan SPECT scans were aligned to a template
brain in a two step process. First, a global affine registration
was performed followed by a separate affine for the right and
left hemispheres. Once aligned to the template brain, atlas
defined VOIs were applied to the subjects brain and mean
ratios were recorded. Correlation of mean ratios between
methods were calculated as well as the ability to classify sub-
jects into PD vs HC using mean ratios and asymmetries (cau-
date/putamen, anterior putamen/posterior putamen, L/R
asymmetries for all VOIs). Results: The correlation between
atlas and manual methods were caudate (0.927), putamen (0.
933), anterior putamen (0.906), posterior putamen(0.927), and
striatum(0.930). The best method of classification for the atlas-
based method was the posterior putamen mean ratio with an
accuracy of 10/10 for PD and 9/9 for HC (100% overall). The
best method of classification for the manual method was the
posterior putamenmean ratio with an accuracy of 10/10 for PD
and 9/9 for HC (100% overall). Conclusions: The atlas-based
method for DaTscan quantification was found to correlate well
with a manual method for VOI definition and provided the
same high level of accuracy.
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Application of PET, MRI and invasive EEG in patients
with drug-resistant epilepsy
I. Kostadinova1, K. Minkin2, P. Dimova2, D. Zlatareva3, V.
Hadjiiska1; 1Clinic of nuclear medicine, Medical University,
Sofia, BULGARIA, 2Clinic of neurosurgery, Medical Univer-
sity,Sofia, BULGARIA, 3Clinic of radiology,Medical Univer-
sity,Sofia, BULGARIA.
Comprehensive presurgical evaluation is mandatory for pa-
tients with drug-resistant epilepsy. Presurgical work-up in-
cludes first line diagnostic methods such as long term video-
EEG monitoring and MRI, but difficult cases need additional
examinations to define the epileptogenic zone like PET,
SPECT and invasive EEG. The aim of our study was to share
our first experience in application of PET and MRI, compared
to invasive EEG as methods of epileptogenic zone localiza-
tion. Our study has included 22 patients with drug-resistant
epilepsy who were evaluated with MRI,18FDG PET/CT /
18F-FDG activity 150-200 MBq / and invasive EEG from
2010 to 2014. Eleven of them were with temporal epilepsy
and 11-with extratemporal. All patients were evaluated with
dedicated MRI epilepsy protocol. PET/CT study was fused
with 3D MRI study using FSL or GE software. During inva-
sive EEG monitoring, seizures were recorded in all patients.
Long term invasive video EEG monitoring has lasted from 2
days to 2 weeks. BothMRI and PETwere normal in 4 patients.
From the remaining 18 patients there were 5 patients with
normal MRI and abnormal PET-CT demonstrating
hypometabolism. There was partial or complete congruence
between the zones of PET hypometabolism and the seizure
onset zone defined by invasive EEG in 17/18 patients with
hypometabolism on PET/CT. There was only 1 patient with
discrepancy between the zone of hypometabolism on PET/CT
and the seizure onset zone defined by invasive EEG. MRI was
normal in 9 patients and structural lesions were identified in 13
patients. Partial or complete overlapping between the lesion
and the seizure onset zone was observed in 11/13 cases with
MRI lesion. In other 2 cases there was no overlapping between
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the data from invasive EEG and the MRI lesion. Fourteen
patients were operated on and satisfactory seizure control
was achieved in 10 patients. All 10 patients with satisfactory
outcome have partial or complete congruence between the
invasive EEG and PET/CT hypometabolism. We could con-
clude, that 18FDG PET/CT is a sensitive non invasive tool for
defining the epileptogenic zone in patients with drug-resistant
epilepsy and according to our first experience it is more accu-
rate than MRI. It has to be applied in all cases with normal
findings on MRI.
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Functional/Anatomic Brain Volume Mismatch Can Serve
as a Predictive Parameter for Post Stroke Patient’s
Candidacy for Hyperbaric Oxygen Therapy
H. Golan1, B. Makogon2, O. Volkov3, Y. Smolyakov4, E.
Ben-Jacob5, R. Boussi-Gross6, S. Efrati6; 1NuclearMedicine,
Assaf Harofeh Medical Center, Beer Yaakov, ISRAEL, 2Ra-
diology, Assaf Harofeh Medical Center, Beer Yaakov, ISRA-
EL, 3Assaf Harofeh Medical Center, Beer Yaakov, ISRAEL,
4Department of Medical Physics and Informatics, Chita State
Medical Academy, Chita, RUSSIAN FEDERATION, 5The
Raymond and Beverly Sackler Faculty of Exact Sciences,
School of Physics and Astronomy, Sagol School of Neurosci-
ence, Tel-Aviv University, Tel-Aviv, ISRAEL, 6Hyperbaric
Medicine Institute, Research and Development Unit, Assaf
Harofeh Medical Center, Beer Yaakov, ISRAEL.
Background: Hyperbaric oxygen treatment (HBOT) has been
recently shown to induce a significant improvement in neuro-
logical status, life quality and daily functioning in post stroke
patients. The purpose of this work was to determine whether
the correspondence of the brain anatomical volume as demon-
strated on CT scan and the brain’s functional volume as ob-
tained by rCBF-SPECT can be used as a predictive index for
post stroke patients who can benefit from HBOT. Materials
and methods: A retrospective review of 97 subjects with
chronic ischemic cerebral stroke patients, more than 6 months
from the acute event, who had HBOTwith pre and post treat-
ment brain SPECT. All subjects had pre-intervention brain CT
scan (“anatomical” evaluation). Brain rCBF-SPECT (a “func-
tional” evaluation) and Clinical evaluation including neuro-
logical assessment (NIHSS), activities of daily living check
(ADL) and quality of life indices (questionnaires EQ-5D and
EQ-VAS) were performed before and after HBOT. The follow-
ing brain imaging parameters were analyzed: 1. Anatomical
brain volume based on the pre-intervention CT scan (BVCT).
2. CT qualities of the brain infarct including: location as relat-
ed to white or cortical matter (CD2-CT) and size. 3. Functional
brain volume based on the pre-intervention SPECT exam,
using two scales: one by a threshold of 30% (BVS30), and
the other by threshold of 40% (BVS40). The statistical analy-
sis was performed using Statistica (StatSoft Inc), and correla-
tion tests were performed using the following methods:
Pearson’s correlation, Spearman’s rank correlation, Principal
component analysis, General discriminant analysis, neural net-
work modeling and General linear models. Results: The study
included 31 subjects that met the inclusion criteria (10 females
and 21 males). A strong relation was found between: age, ratio
of functional brain volume to anatomical brain volume
(BVS40/BVCT), type of brain damage (cortical or sub-
cortical) to the improvement in activity in daily living (ADL)
after HBOT. The degree of clinical improvement in ADL after
HBOT was in good correlation with smaller functional brain
volume, as measured by SPECT, in relation to the anatomical
volume measured by CT. Thus the degree of response to
HBOT is more significant when the volume ratio of SPECT/
CT is lower. Conclusions: SPECT/CT (physiology/anatomy)
mismatch, marks metabolic dysfunction brain regions where
neuroplasticity can be inducedwith HBOTeven years after the
acute insult. This ratio can be expressed mathematically and
used as a prediction index for post stroke patient’s candidate
for neuroplasticity by HBOT.
P504
Calorie consumption and brain glucose metabolism
in the patients with chronic severe brain injury - A study
using brain 18F-FDGPET -
Y. Uchino; Chiba Ryogo Center, CHIBA CITY, JAPAN.
[Purpose]In the chronic severe brain injury (cs-TBI) patients, it
is known that their requirement level of intake and consump-
tion calories is lower as compared to healthy subjects. Their
low physical activity and reduction of muscle mass has been
mentioned as one reason of low calorie consumption, but a
decrease in brain glucose metabolism can be considered as
another important factor. In the cs-TBI patients, we compared
the actual calorie intake and semi-quantitative values obtained
from brain FDGPET, and examined the relationship between
brain glucose metabolism and calorie intake. [Method] This
study included 39cases with cs-TBI patients, age ranging 20 to
75 years (41±16yrs, mean±SD). For brain glucose metabolism
measurement method by FDGPET, we placed the volume of
interest (VOI) in the whole brain automatically, and the aver-
age standardized uptake value (SUV) was obtained. Then the
SUVavg was multiplied by the brain volume. We defined it as
the “total value of whole brain uptake” (WBu) (WBu =
SUVavg×brain volume). Basal energy expenditure (BEE),
considering the active factor, was calculated by the Harris
Benedict Equation. Physical and psychological activities of
patients were evaluated by using patients’ level determination
score (CHIBA score). We classified the patients into two
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groups (low WBu (WBu<50): A group, 27 cases, moderate
WBu (WBu≧50): B group, 12 patients). And we examined the
relationship among WBu, calorie intake, activity. [Results] In
38 cases out of 39, calorie intake was below the BEE (average
-330Kcal). But there was no problem in their nutritional con-
dition. Calorie intake and activity of each group was signifi-
cantly higher in the group B (calorie, A: 1093±200Kcal, B:
1390±266Kcal,(p<0.01) activity, A: 20±17, B: 53±20
(p<0.01)). Regard to calorie intake and activity level, a posi-
tive correlation was observed (R^2=0.51), and correlation was
also observed between calorie intake and WBu (R^2=0.53).
[Conclusion] In the chronic severe brain injury patients, there
is a relationship between the calorie consumption and the de-
gree of brain glucose metabolism. Physical activity in the pa-
tients is generally low, so the proportion of calorie consump-
tion of the brain is high degree that cannot be ignored against
that of the whole body. Therefore, by knowing the degree of
cerebral glucose metabolism reduction of the patients, it is
possible to estimate their proper calorie intake.
P505
99mTc-ECD brain perfusion SPECT imaging
for assessment of the effect of hyperbaric oxygen therapy
on secondary progressive multiple sclerosis patients
with a moderate to severe stage of disease
M. Taghizadeh Asl1, R. Nemati2, M. Assadi3; 1Department
of Nuclear Medicine, Kasra Hospital, Tehran, IRAN, ISLAM-
ICREPUBLICOF, 2Department of Neurology, BushehrMed-
ical University Hospital, Bushehr University of Medical Sci-
ences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF, 3The
Persian Gulf Nuclear Medicine Research Center, Bushehr
University of Medical Sciences, BUSHEHR, IRAN, ISLAM-
IC REPUBLIC OF.
Objective: The present study was performed to assess cerebral
perfusion in multiple sclerosis (MS) patients with a moderate
to severe stage of disease. Some patients underwent hyperbaric
oxygen therapy and brain perfusion between before and after
that was compared. Methods: A total of 25 secondary progres-
sive (SP)-MS patients were enrolled in this study. In total, 16
patients underwent oxygen therapy. Before oxygen therapy
and at the end of 20 sessions of oxygen treatment, 99mTc-
ECD brain perfusion single photon emission computed to-
mography (SPECT) were performed again then the results
were evaluated and compared. Results: A total of 25 SP-MS
patients, 14 females (56%) and 11 males (44%) with a mean
age of 38.92 ± 11.28 years participated in the study. The mean
disease duration was 8.70 ± 5.30 years. Of the 25 patients, 2
(8%) had a normal SPECT and 23 (92%) had abnormal brain
perfusion SPECT studies. The study showed a significant as-
sociation between severity of perfusion impairment and
disease duration, but did not show any significant association
with Expanded Disability Status Scale score (P>0.05). There
was a significant improvement in pre- and post-treatment per-
fusion scans (P<0.05), but this did not demonstrate a signifi-
cant improvement in the clinical subjective and objective eval-
uation of patients (P>0.05). Conclusions: This study demon-
strated decreased cerebral perfusion in SP-MS patients with a
moderate to severe disability score. In addition, this study
showed the effect of hyperbaric oxygen therapy in the im-
provement of cerebral perfusion in MS patients.
P506
Comparison of diagnostic value of brain perfusion SPECT
with CT scan, EEG and MRI modalities in pediatric
seizure setting
A. Shirkani1,M. Taghizadeh Asl2, F. Hafezi1, R. Nemati3,M.
Assadi4; 1Department of Pediatrics, Faculty of Medicine, Bu-
shehr University of Medical Sciences, BUSHEHR, IRAN, IS-
LAMIC REPUBLIC OF, 2Department of Nuclear Medicine,
Kasra Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF,
3Department of Neurology, Bushehr Medical University Hos-
pital, Bushehr University of Medical Sciences, BUSHEHR,
IRAN, ISLAMIC REPUBLIC OF, 4The Persian Gulf Nuclear
Medicine Research Center, Bushehr University of Medical
Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.
Background: Seizure is the most common neurologic disorder
among children. Multiple neuroimaging modalities are avail-
able to localize the eliptogenic focus. Precise localization of
the eliptogenic focus is imperative before planning surgical
intervention; therefore, a proper modality is strongly needed.
Brain perfusion SPECT is a functional neuroimaging modality
which shows the eliptogenic focus by increasing and decreas-
ing of the of the radiopharmaceutical, substance uptake. Meth-
od: In this prospective study, the population included children
with seizure (n=43) and mean age (8.76 ± 3.53)who came to
the pediatric hospital affiliated university during 2010-
2011.All of them were underwent EEG,CT Scan, MRI and
SPECT in Intricate phase by their parents consent; All the
results were documented in each code sheet. Result: Brain
perfusion SPECTwas abnormal in a significant higher propor-
tion of children, 36 cases(83.7%), then either scalp EEG 12
cases(27.9%)or CT Scan and MRI in 1 cases (2.3%).In com-
parison with SPECT,EEG got 27.8% sensitivity(95%CI=13-
41) and 71.4% specificity (95%CI=38-100); PPVof CT scan
was =83.3% and negative PPV =16.1% and MRI also got
2.8% sensitivity (95%CI=o-6) and 100% specificity by a pos-
itive PPV =100% and negative PPV =16.7% compared to
SPECT. Conclusion: The present study may represent that
interictal SPECT indentified more focal changes in children
with recurrent seizure as compare to interictal scalp EEG,CT
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Scan and MRI, hence it has the best diagnostic value among
other modalities.
P507
Plaque Inflammation Imaging in severe carotid stenosis
and recurrent cerebral ischemia/strokes.
A. SINHA, V. sharma, S. Kapur, S. Pillai, D. Teh; National
University Hospital, SINGAPORE, SINGAPORE.
OBJECTIVE: Symptomatic carotid stenosis increases the
risk of early stroke recurrence compared to other stroke sub-
types. Current carotid imaging techniques rely on estimating
plaque-related lumen narrowing but do not evaluate intra-
plaque inflammation, a key mediator of plaque rupture and
t h r omb o emb o l i sm . U s i n g c omb i n e d ( 1 8 ) F -
fluorodeoxyglucose positron-emission tomography (FDG-
PET)/computed tomography, we investigated the relation be-
tween inflammation-related FDG uptake and stroke recurrence
in small group of the patients. METHODS: Consecutive pa-
tients with a recent stroke and ipsilateral carotid stenosis
(≥50%) were included in this study. FDG uptake was quanti-
fied asmean standardized uptake values (SUVs). Patients were
followed prospectively for stroke recurrence. RESULTS: Ten
patients were included. Three patients had stroke recurrence
within 90 days. FDG uptake in ipsilateral carotid plaque was
greater in patients with early recurrent stroke (mean SUV, 2.5;
standard deviation [SD], 0.44 vs 1.58; SD, 0.32, p = 0.02). On
life-table analysis, 90-day recurrence rates with mean SUV
greater than a 2.14 threshold were 80% (95% confidence in-
terval [CI], 41.8-99.2) versus 22.9% (95% CI, 12.3-40.3) with
SUV ≤2.14 (log-rank, p < 0.0001). In a Cox regression model
including age and degree of stenosis (50-69% or ≥70%), mean
plaque FDG uptake was the only independent predictor of
stroke recurrence (adjusted hazard ratio, 6.1; 95% CI, 1.3-
28.8; p = 0.02). CONCLUSION: Inflammation in a previously
stable carotid plaque is an important event that leads to local
thrombosis and cerebral embolization. This phenomenon can
be reliable imaged with F-18 FDG PET for better risk stratifi-
cation and therapeutic strategizing in carotid stenosis.
P508
Value of the ictal and interictal Perfusion-SPECT
in the localization of the epileptic focus in drug-resistant
epilepsy
M. Boya-Román1, O. Puig1, R. Julio1, J. Rojas1, I. Gil1, P.
Saldaña2, G. Plans1, J. Miró1, J. Mora1; 1Hospital
Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN,
2Institut Català d’Oncologia, Barcelona, SPAIN.
Objective:To evaluate the effectiveness of the ictal and
interictal SPECT in the presurgical assessment of drug-
resistant epilepsy patients.Material and method:A retrospec-
tive study of 25 patients (p) with drug resistant epilepsy who
underwent an ictal and interictal SPECT and MRI.Prior to the
ictal SPECT, the patients were monitored with continuous vid-
eo-EEG. 740MBq 99mTc-HMPAO were injected within the
first minute of the seizure onset. The interictal SPECT was
performed with the same dose and radionuclide three weeks
after ictal SPECT and after a minimum period of 24 hours
seizure free. The SPECT were evaluated visually by at least
two specialists.The SPECT scan was compared with MRI and
the analysis of the surgical specimen. The minimum postoper-
ative follow-up was 8 months and the outcome was assessed
with the modified Engel scale.Results:The SPECT/MRI/ST-
results agreed in 19 out of 25p(76%).The ictal/interictal
SPECT correctly located the seizure focus in 21 out of 25p
(84%). Among the 4p with a negative SPECT, 2 has a positive
MRI and in 1 the MRI was also negative and the surgery was
guided by EEG. The remaining patient had a bilateral temporal
hiperperfusion in the SPECT and the MRI showed only right
temporal lesions, he had a resection of the right parietal lobe
and the rate of seizures was reduced by 75%.MRI detected
abnormalities in 22 out of 25 patients (88%). 17 out of 25p
(68%) had a mesial temporal sclerosis. In 2 out of 3 patients
with negative MRI the epileptic focus was localized with the
SPECT.19 out of the 21p (90%) with a positive SPECT had a
surgical outcome Engel 1 whereas 2 out of 4 patients with
nega t i ve SPECT were c l a s s i f i ed a s Enge l I I I -
IV.Conclusion:The ictal and interictal SPECT is useful in the
preoperative assessment in patients with drug-resistant epilep-
sy correctly locating the epileptic focus in 84% of patients.
Patients whose epileptic focus was localized by SPECT
showed better postoperative outcome.
P509
Three Months Follow-Up of Mild Traumatic Brain Injury
in Rats: A Combined [18F]FDG and [11C]PK11195 PET
Study
D. Vállez Garcia1, A. Otte2, R. A. J. O. Dierckx1, J.
Doorduin1; 1University Medical Center Groningen, Groning-
en, NETHERLANDS, 2Offenburg University of Applied Sci-
ences, Offenburg, GERMANY.
Aim: Mild traumatic brain injury (mTBI) is the most common
cause of head trauma and it is especially relevant in adoles-
cents and sport activities. However, the time course of its func-
tional pathology is not well defined. In this study the conse-
quences of mTBI were evaluated in a rat model over a period
of 3 months. The presence of neuroinflammation
([11C]PK11195) and changes in brain metabolism
([18F]FDG) were determined using small animal PET
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S583
imaging. Material and Methods: A weight-drop mTBI model
was used to replicate the pathological features seen in humans.
Male Sprague-Dawley rats were divided into sham (n=8) and
trauma (n=8) groups. PET imaging and behavioral tests (i.e.
open field, object recognition and Y-maze) were performed at
different time points after induction of the trauma: acute stage
(9-12 days), 1 and 3 months. Differences between groups in
the bodyweight and behavioral scores were analyzed using the
Generalized Estimating Equations model and p<0.05 were
considered significant. Differences in tracer uptake were ana-
lyzed with a voxel-based analysis. T-maps were interrogated
with uncorrected p<0.005 and 200 threshold voxels; only clus-
ters with FDR-corrected p<0.05 were considered significant.
Results: Trauma induction did not result in death, skull frac-
ture or neurological suppression of reflexes. A statistically
significant decrease in gained body weight was observed in
mTBI group (p=0.003). No statistical differences were found
between groups in any of the behavioral tests. In the voxel-
based analysis, a comparison between mTBI and sham groups
was performed at each time point. A neuroinflammatory pro-
cess was detected only in the acute phase, with significantly
higher [11C]PK11195 uptake located bilaterally in the pons,
medulla, cerebellum, hypothalamus, caudate, putamen, and
the right amygdala. Increased regional [18F]FDG uptake in
mTBI rats was detected in all time points bilaterally in the
medulla, in addition to an increased uptake at 3 months in
the left motor, somatosensory, visual and parietal cortices.
Moreover, decreased uptake was detected during the follow-
up period in the thalamus, internal capsule, amygdala, caudate,
putamen, globus pallidus, hippocampus, and somatosensory
cortex. Conclusion: Alterations in the regional glucose metab-
olism of the brain extend for a period of at least 3 months in
regions that seem to present an acute neuroinflammatory re-
sponse to the trauma. The presence of these long-lasting func-
tional alterations must be considered carefully in the context of
mTBI, especially in sports and recreational activities where
patients may be exposed to a repeated head trauma.
P510
Baseline Right Hemispheric Metabolic Activity Predicts
Improvement in Aphasia Severity and Visual Attention
Tasks in Persons with Aphasia Treated with a Cholinergic
Agent
A. L. Gutiérrez Cardo1, N. Roé Vellvé1, F. Alfaro Rubio1,
G. Dávila2, M. J. Torres-Prioris2, M. L. Berthier2;
1Fundación General de la Universidad de Málaga, Málaga,
SPAIN, 2Universidad de Málaga, Málaga, SPAIN.
Cognitive control mechanisms including attentional re-
sources are implicated in recovery from post-stroke apha-
sia. It is known that cholinergic systems are engaged
during visual attentional tasks and that cholinergic enhanc-
ing drugs improve language deficits in persons with apha-
sia (PWA). Aim: To analyse the metabolic correlates of
response to the cholinergic agent donepezil in aphasia se-
verity and visual attention tasks with brain 18F-FDG PET
in PWA with chronic stroke. Methods: An 8-week open-
label study of donepezil (10 mg/day) was performed in 10
PWA with chronic stroke lesions restricted to the left hemi-
sphere identified by structural MRI. Resting 18F-FDG PET
was performed in all patients at baseline (week 0) and
endpoint (week 8). PET data was analysed with SPM 8.
Several ROIs from the AAL atlas were examined in both
hemispheres excluding lesional areas, white matter and
CSF. PWA improving > 5 points on the Aphasia Quotient
of the Western Aphasia Battery were considered “re-
sponders” to treatment. Visual attention was tested with
the California Computerized Assessment Package. Results:
Five PWA were responders to treatment. Baseline metabol-
ic activity was increased in responders compared to 25
healthy control subjects (HCS) in the right medial occipital
cortex, superior temporal cortex, medial cingulum and pu-
tamen (p < 0.05). By contrast, baseline metabolic activity
was significantly reduced in non-responders in comparison
with HCS in right caudate, posterior cingulum, and
precuneus (p < 0.05). The whole group of PWA (n =
10) showed decreased metabolism compared to the HCS
in right posterior cingulum, inferior parietal cortex (both p
< 0.1) and precuneus (p < 0.05). Comparisons of re-
sponders versus non-responders showed that the former
group had increased baseline metabolism in several right
hemisphere regions (posterior cingulum, medial occipital
cortex, superior temporal cortex, caudate, putamen, and
whole right hemisphere) (p < 0.05). Significant improve-
ments in visual sequential reaction time in the whole sam-
ple of PWA (n = 10) at endpoint correlated with increased
metabolic activity in right cingulum (anterior and posteri-
or), insula, posterior temporal cortex, putamen and thala-
mus. Conclusions: Increased baseline metabolic activity in
brain areas (default mode network, basal ganglia and thal-
amus) innervated by the right cholinergic systems predicts
improvement in visual attention tasks in PWA with chronic
stroke lesions restricted to the left hemisphere. Post-
treatment increases in metabolic activity in these regions
correlated with gains in visual attention.
P511
99mTc-HMPAO Brain SPECT in Rabbits: Preliminary
Results on CBF Variation by Different Anaestethic Drugs
M. Longo1, C. Pettinato2, D. De Zani1, G. Ravasio1, M. Di
Giancamillo1, D. Zani1; 1DIVET, University of Milano, Mi-
lano, ITALY, 2Medical Physics Unit, Bologna, ITALY.
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Aim: The aim of this study was to evaluate general
brain perfusion in rabbits through a non-invasive nuclear
medicine technique, before and after the administration
of two different anesthetic protocols.Materials&Methods:
Ten male New Zeland White rabbits were enrolled in
the prospective study. All subjects underwent CT studies
of the skull in order to exclude any gross malformations
or lesions and to acquire images for CT/SPECT fusion.
99mTc-HMPAO brain SPECT scans were acquired with
a single head gamma camera: circular orbit, continuos
rotation 10 seconds/step and 120 steps. During the first
session 99mTc-HMPAO was IV injected in two groups
of five awake rabbits, with a randomized selection. The
first one was subsequently anesthetized with propofol
and the other with dexmedetomidine. The same proce-
dure was repeated 21 days later, injecting the radiophar-
maceutical after the induction of general anaesthesia.
The brain perfusion uptake index (BPUi), expressed as
total counts in the brain per unit of injected activity, was
calculated.ResultsRabbits anesthetized with propofol
showed exactly the same tracer distribution in both in-
jection condition: awake or asleep. The radiopharmaceu-
tical was concentrated in the brain but a generalized
distribution was observed also in the facial muscles for
the propofol groups and for the group of subjects ad-
ministered with dexmedetomidine after 99mTc-HMPAO
injection. On the contrary when dexmedetomidine was
used before the 99mTc-HMPAO injection a generalized
reduction of the uptake was observed especially in extra-
encephalic tissues.The average BPUi values were respec-
tively 16.5 counts/KBq and 16.7 counts/KBq for rabbits
anesthetized with propofol and with dexmedetomidine
after the 99mTc-HMPAO injection. Animals injected
with 99mTc-HMPAO after the anesthesia induction
showed respectively 16.1 counts/KBq and 12.5 counts/
KBq using the propofol and the dexmedetomidine
protocol.Discussion and conclusions: Although the major
limitation of our study is the small number of subjects
analyzed, our results showed that when propofol is used
as anesthetic drug, any difference in brain perfusion oc-
curred if the radiotracer was injected prior or before
anesthesia.On the contrary the vasocostriction of
dexmedetomidine is responsible of a mild reduction of
the radiopharmaceutical uptake in the brain and a good
inhibition of tracer uptake in other tissues.These prelim-
inary data suggest that the use of propofol in uncooper-
ative patients, that need sedation before brain perfusion
studies, could not influence the CBF. On the other hand
the results of the CBF in rabbits medicated with
dexmedetomidine before tracer injection, suggest a pos-
sible neuronal protective proprieties of this drug.
P512
The potential role of [18F]-FDOPA PET/CT in proton
treatment planning for glioblastoma: preliminary
experience
D. Donner1, D. Amelio2, S. Agostini1, G. Carbone1, A.
Palucci1, S. Vennarini2, U. Rozzanigo3, M. Erini1, E.
Bagatin1, M. Amichetti2, M. Recla3, F. Chierichetti1; 1Nu-
clear Medicine Dpt - S. Chiara Hospital - APSS, TRENTO,
ITALY, 2Proton Center - APSS, TRENTO, ITALY, 3Radiolo-
gy Dpt - S. Chiara Hospital - APSS, TRENTO, ITALY.
Aim of the study:Proton Therapy (PT) is an advanced external
radio treatment that allows to keep low the radiation burden on
the healthy tissues beyond the target.According to a joint de-
cision with proton radiation oncologist, both high and low
grade gliomas, after surgery for partial resection, were studied
with 18F-DOPA PET/CT for contouring purpose in radiation
treatment planning.In this study we considered only
patients(pts) affected by glioblastoma (GBM) to assess the
potential role of PET/CT in PT. Methods:13 GBM lesions
(9pts) were studied 1 hour after i.v. injection of [18F]-FDOPA
(3MBq pro Kg). Reconstructed images were visually exam-
ined and, evaluating the SUVmax tumor/normal tissue ratio,
semi-quantitatively examined. The collected PET data were
provided to radiation oncologist who compared them to the
standard ones, established by MRI, and two dose paintings
were performed and assessed. 3 months after the completion
of PT, up to now, in 2(4 lesions) out of 9 pts, 18F-DOPA PET/
CT was repeated, and, for each lesion, the SUV percentage
change pre-treatment(tr) vs post-tr, was calculated.Results:
semi-quantitative analysis on 18F-DOPA PET/CT, before PT,
produced mean values of SUVmax (tumor=2.55, normal tis-
sue =0.91) and tumor/normal tissue ratio (2.8), similar to the
data of a recent pubblication (Hermann K et al, Neuro-Oncol-
ogy,2014), even if with different acquisition timing.18F-DO-
PA PET/CTchanged the expected planning, as determined just
by MRI, in more than half of lesions, determinig GTV(Gross
Tumor Volume) boost sub volumes in the overall planned area
of treatment and showing more tumor tissue than MRI,too.
About the two pts that completed PT, in spite of an enlarge-
ment of lesions, as shown by post-treatment MRI, there was a
decrease in 18F-DOPA uptake: for both pts a reduction of 30%
respect to basal study. Conclusions:our data confirm previous
studies showing that 18F-DOPA identifies more tumor respect
to MRI in GBM (Ledezma CJ et al, EurJRadiol, 2009), but, in
our experience, GBM proved to be suitable to be studied by
18F-DOPA PET/CT using different acquisition protocol, with-
out lost of sensitivity, too.PT is beneficial for a better quality of
life of pts and, even if we do not have enough data about the
final outcome, we can argue that a dose painting based on
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functional imaging, may be more effective for a longer
survival.Finally, even if few pts completed the treatment, it
seems that 18F-DOPA PET/CT could be a reliable tool in the
assessment of response to PT.
P513
Cisternoscintigrahy in cerebrospinal fluid fistula
and intracranel hypothension syndrome
M. Castrillon; Sergas, Vigo, SPAIN.
The cisternoscintigraphy is a test that can assess the dynamics
of cerebrospinal fluid from an anatomical and functional
standpoint. We review those performed in our department with
the suspected of cerebrospinal fluid fistula or intracranial
hypopresion syndrome,to determine its usefulness to confirm
/ rule out its presence and its concordance with the clinical
context and other complementary tests. Material and methods:
Descriptive retrospective study (2006-2015). 111In- 1mCi in-
trathecal administration of DTPA. Planar images (tracking and
static) at least at 3 and 6 hours pi, and according to findings
every 24 hours until 72 hours pi. Placing cotton plugs in FN /
CAE depending on clinical suspicion, renewed after each set
of images obtained. Comparison of the activity at study end
caps to the present in plasma. Results: 40 studies were
reviewed: -11 Positive: 10 PT consistent with other tests
(RM / MieloTC) and / or response to treatment performed;
one discordant withMRI findings, determined as false positive
after reviewing images (diagnosed as a cause of hipopresión
CFS LUES). -29 Negative, all TN: 16 congruent with RM
(negative) and clinical outcome (spontaneous or conservative
treatment decision). 7 requested as a single test for the pres-
ence of fistula in patients with a history of TCE, which
remained asymptomatic at follow-up. 3 for control asymptom-
atic patients with TBI who had submitted prior to discharge
and positive clinical MRI, with resolution of symptoms with
conservative treatment. 2 for asymptomatic control patients
after surgical repair of fistula, confirming its resolution. A
patient with nasal discharge on HIC lumboperitoneal shunt
valve, which showed the same malfunction but not fistula.
Conclusions: In our review the cisternoscintigraphy is a tech-
nique that presents an adequate diagnostic accuracy in the
assessment of CSF fistula and intracranial hipopresión
syndrome
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Characterization of 18F-DOPA-Uptake in Various
Tumour Cells: Implication for the 18F-DOPA PET
M. Delivuk, P. Ubl, F. Girschele, M. Hacker, G. Hamilton, S.
Li; Medical University of Vienna, VIENNA, AUSTRIA.
Aim: The visualization of neuroendocrine tumours (NET) by
18F-DOPA-PET based on the capability of NET to take up,
decarboxylate, and store monoamine precursors such as
dihydroxyphenylalanine (DOPA). In this study we have inves-
tigated the 18F-DOPA-uptake in different NET cells and in
human prostate cancer as well as breast cancer cells and hu-
man embryonic kidney cells. Methods: Human small cell lung
cancer (SCLC) cell lines (DMS 153, NCI H417), rat pheochro-
mocytoma cell line (PC-12), human prostate cancer cell line
(PC-3) and human breast cancer cell line (T47D) as well as
human embryonic kidney cell line (HEK 293) were used in
this study. 18F-DOPA was produced via the novel synthesis
method. Standard 18F-DOPA accumulation assays were per-
formed. Results: Significant accumulation of 18F-DOPAwas
found in PC 12 and DMS 153 cells. Moderate uptake of 18F-
DOPA were shown in PC 3 and NCI H417 cells. Very low
accumulation of 18F-DOPA was demonstrated in the T47D
and HEK 293 cells. The rank-order of potency for 18F-
DOPA uptake was PC12 cells (18.2% of total counts) >
DMS 153 cells (17.9%) > PC 3 cells (5.9 %) > NCI H417
cells (4.5%) > T47D cells (2.1%) > HEK 293 (1.9%). The
uptakes of 18F-DOPA in these cell lines were shown to be
specific since the 18F-DOPA accumulations were inhibited
by addition of unlabeled DOPA. Conclusion: Our results show
that not only NET cells but also some other tumour cells such
as human prostate cancer cells can accumulate specifically
18F-DOPA. Very low 18F-DOPA-uptake was also found in
human breast cancer cells. Different NET cells have different
capacities of accumulation of 18F-DOPA. These results may
have clinical implications for the 18F-DOPA PET.
P515
Intraobserver variability in gross tumor volume
delineation on PET/CTworkstation and EclipseTM
radiation therapy planning system of head and neck
cancers
S. Sediene, I. Kulakiene, V. Rudzianskas; Lithuanian Hospital
of Health science Kauno clinics, Kaunas, LITHUANIA.
Background. Precise gross tumor volume (GTV) delineation is
very important for radiation therapy planning. Usually it is
done by means of computed tomography. Although, there
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are many different visual diagnostic procedures, it is dif-
ficult to quantify the tumor burden directly and systemat-
ically. FDG PET/CT incorporates functional criteria, there-
fore, it may allow systematically measure tumor burden
and be more direct and reliable method. The aim of this
study was to evaluate accuracy of different GTV delinea-
tion methods with FDG PET/CT images on distinct work-
stations, to compare and find out most precise method.
Precise GTV delineation enables to plan treatment accu-
rately and could reduce rate and severity of treatment
complications.Methods. Ten patients with head and neck
cancer were retrospectively chosen for the study. All pa-
tients were histologically proven squamous cell carcinoma,
stage III or IV disease, without distant metastases. Pa-
tients underwent pretreatment FDG PET/CT and received
neoadjuvant chemotherapy. Two weeks post neoadjuvant
chemotherapy all the patients underwent follow-up FDG
PET/CT, to have as low as possible inflammatory alter-
ations. After everything all patients received definitive
chemoradiotherapy. Contouring was performed by nuclear
medicine specialist manually on two different workstations
(GE advanced and EclipseTM treatment planning system)
and semi-automatically in three dimensions by GE soft-
ware. The measurements of GTV were done by visual
target contouring.Results. The mean GTV volumes prior
neoadjuvant chemotherapy were as follows: manually by
GE ADW 18,49±17,06, manually by EclipseTM 24,93
±20,68, semi-automatically by GE ADW 12,9±12,41.
The mean GTV volumes after neoadjuvant chemotherapy
were: manually by GE ADW 6,76±11,86, manually by
EclipseTM 6,73±14,39, semi-automatically by GE ADW
7,79±10,52. According ANOVA repeated measurement
there is statistically significant difference between GTV
volumes measured manually by EclipseTM and semi-
automatically by GE ADW workstations prior neoadjuvant
chemotherapy (p=0,024). There are no statistically signif-
icant difference between GTV volumes measured manual-
ly by GE ADW and manually measured by EclipseTM,
semi-automatically by GE ADW workstations prior neo-
adjuvant chemotherapy (as follows: p=0,119; p=0,441).
There are no statistically significant difference between
GTV volumes measured manually by GE ADW and
EclipseTM and semi-automatically by GE ADW after
neoadjuvant chemotherapy (p=0,872).Conclusion. All three
delineation methods are reliable for gross tumor volume
measurements after neoadjuvant chemotherapy. Manual
GTV delineation by EclipseTM and semi-automatic three
dimension delineation by GE ADW workstations are not
so accurate after neoadjuvant chemotherapy while com-
pared to manual delineation by GE advanced worksta-
tions. Prior neoadjuvant chemotherapy more reliable
GTV measurement method is manual by GE ADW
workstation.
P516
Development and characterization of microspheres
contained with different polymers for hepatoma therapy
P. Chiang, C. Peng, Y. Chu, T. Luo; Institute of NUclear
Energy Research, Taoyuan, TAIWAN.
Aim:The purpose of this study is to develop biodegradable
microspheres which combined with chemotherapy to become
applications such as transcatheter arterial embolization/
chemoembolization (TAE/TACE) or local injectable forms.
By locally and slowly release of chemotherapeutic agents,
the effect of cancer treatment can be extended. Materials and
methods:In the experiment, we used biodegradable polymer
Poly(D,L-lactide-co-glycolide)(PLGA) prepared amino sur-
face modification micron particles. By double emulsion, the
microspheres contain water-soluble polymers, including car-
boxymethylcellulose sodium salt, poly(sodium 4-
styrenesulfonate), poly(4-styrenesulfonic acid) ammonium
salt solution and Poly(vinylsulfonic acid, sodium salt) solu-
tion. The functional groups of those polymers will dissociate
into -SO3- or -COO- in water. Doxorubincin can be loaded
into the beads using an ionic exchange process between the
protonated primary amine on the drug and the negatively
c h a r g e d g r o u p s , a n d i t c a n s l ow l y r e l e a s e .
Results:Experimental results show that 50mg 25% PVSAS/
PLGA microspheres absorbed 2.5mg doxorubincin within an
hour had the best absorption efficiency. Microspheres were
labeled with 111In and performed in a rat hepatic embolization
model. NanoSPECT/CT imaging and bio-distribution showed
the drugs were still in the liver after 72 hours. Conclusion:The
microspheres may offer the advantage of chemotherapy local-
ly injection or embolism formulation platform. In the future,
the amino surface modification micron particles can graft che-
lator and label therapeutic radionuclide to maximize their ef-
fects on hepatocellular carcinoma.
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The prognostic impact of FDG PET/CT imaging
in the early postoperative work-up of differentiated
thyroid carcinoma patients with elevated Thyroglobulin
levels
G. Ucmak, B. Demirel, B. E. Akkas, A. K. Fidan; Ankara
Oncology Research and Training Hospital Department of Nu-
clear Medicine, Ankara, TURKEY.
Introduction: The aim of this study was to evaluate the impact
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of FDG PET/CT imaging in the early postoperative work-up
of differentiated thyroid carcinoma patients with elevated Thy-
roglobulin levels out of proportion to the identified
disease.Method: Among DTC patients who were referred to
our clinic for radioiodine ablation/therapy, 35 patients (22 F,
13 M, age: 48±16 yr) with significantly elevated serum Thy-
roglobulin (Tg) levels which were out of proportion to the
identified disease, were included in this study. FDG PET/CT
was performed to define disease extent as a part of initial work-
up. Patient management was planned based on clinical, labo-
ratory and PET/CT findings. The contribution of PET/CT
findings to patient management and clinical outcome was
evaluated.Results: PET/CT detected metastatic cervical and/
or mediastinal lymph nodes in 16 patients, lung metastasis in
15 patients, bone metastasis in 2 patients and multiple sites of
metastasis in 2 patients. In the light of PET/CT findings, 12
patients were referred to surgery for focused neck dissection or
completion compartmental neck dissection and/or
metastatectomy, 4 patients received external beam radiothera-
py for bone metastasis. Then, all patients received I-131
radioiodine therapy with doses of 150-250 mCi. Of these,
PET/CT detected non-radioiodine avid lung and mediastinal
metastasis in 5 patients. Findings of PET/CTand post-ablation
radioiodine whole body scan were comparable in others. PET/
CT provided a change in treatment plans for patients who were
referred to surgery/radiotherapy (15/35 patients, 43%). After
36±16months ofmedian follow-up, 4 patients had progressive
disease, 8 patients had stable disease, 22 patients had clinical/
biochemical remission.Conclusion: As a part of initial staging
algorithm, FDG PET/CT has an important role on the man-
agement of patients with high risk DTC. We consider that,
especially in patients with high Tg levels out of proportion to
the identified disease, PET/CT provides unique opportunity to
select patients who has surgically amenable disease and help to
increase therapeutic response to further radioiodine therapies
which all result in an improvement of progression-free
survival.
P518
The Role of Postoperative Diagnostic I123 SPECT-CT
in Low and Intermediate Risk Profile Patients
with Differentiated Thyroid Carcinoma
O. Bessolova, O. Perfileva, Y. Kizhaev, V. Vidioukov, N.
Vyrenkova; Russian Medical Academy of Postgraduate Edu-
cation, Moscow, RUSSIAN FEDERATION.
Aim: To evaluate the postoperative diagnostic I123 SPECT-
CT contribution to management strategy in low and interme-
diate risk profile patients with differentiated thyroid carcinoma
(DTC). Materials and methods: A total of 98 patients (81
women and 17 men) with mean age of 42,1 years with DTC
(79 papillary, 19 follicular) were evaluated 4-8 week after thy-
roidectomy. Patients were subdivided retrospectively into two
groups according to the histological data: group 1 of low risk
profile with 38 patients included, and group 2 of intermediate
risk profile with 60 patients. Whole body study (WBS) and
SPECTof the neck and upper chest area were performed in all
patients. In cases of increased uptake foci SPECT-CT was
done (GE Infinia Hawkeye 4). The I123 studies were per-
formed after 3 week thyroid hormone withdrawal or without
medication postoperatively, 24 hour after intravenous I123
isotonic. Serum thyroglobulin (TG), anti-TG, TSH and ultra-
sound were evaluated. Results: We detected 83 increased up-
take foci in the neck and upper mediastinum region. In group
1, 35 foci were found in 24 patients. In group 2, 48 foci were
detected in 35 patients. Only SPECTstudy was responsible for
detecting 3 foci in group 1 and 8 foci in group 2 independently
and in addition to WBS. SPECT-CT accurately determined
residual thyroid tissue in 34 and 39 foci of group 1 and group
2 respectively. Lymph node involvement was identified by
SPECT-CT in 1 case of group 1 and in 8 cases of group 2. In
1 case of group 2 SPECT-CT revealed distant metastases in the
lung. In all low and intermediate risk profile patients with
residual thyroid tissue radioiodine ablation was performed.
SPECT-CT data caused the change in N/M status, risk strati-
fication status and radioiodine therapy planning with indica-
tion for surgical removal of lymph nodes in 1(3%) patient of
group 1 and in 8(13%) patients of group 2. Conclusion: Low
and intermediate risk profile patients with differentiated thy-
roid carcinoma have a need for residual thyroid tissue and
lymph node involvement screening after thyroidectomy.
SPECT-CT technique is a useful modality in accurate locali-
zation of the lesion and interpretation of uptake in cervical
region. The unique capabilities of I123 SPECT-CT provide
individual therapy and follow-up.
P519
The clinical significance of thyroid incidentaloma
on FDG-PET/CT - one centre’s experience
P. Martineau, M. Pelletier-Galarneau, W. Zeng, X. Pham;
The Ottawa Hospital, Ottawa, ON, CANADA.
Background: Incidental thyroid uptake is not an infrequent
finding in patients undergoing FDG-PET/CT for staging of a
non-thyroid malignancy. Two types of pattern are typically
seen: diffuse uptake, usually reported to be associated with
thyroiditis, and focal uptake, which raises the suspicion of
malignancy. The existing literature shows a significant hetero-
geneity in terms of the incidence of these findings, and their
significance. Methods: We reviewed all FDG-PET/CT reports
from our institution dated between 9/1/2012 and 4/2/2015
(N=4280) and identified all cases of reported abnormal thyroid
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uptake. For all patients with abnormal thyroid FDG uptake,
follow-up imaging, pathology, medications, medical histories,
and available blood-work were reviewed. Results: 109 patients
with abnormal thyroid FDG uptake (mean SUV 7.0, range 1.9-
53) were identified, resulting in an overall incidence of 2.5%.
A diffuse pattern of uptake was noted in 36 (33%) of these
cases and follow up imaging and/or relevant clinical informa-
tion was available for 19 (53%) of them. Of patients with a
diffusely increased thyroid uptake, 13 (36%) were receiving
thyroid hormone supplementation, another 2 (6%) were noted
to have a history of hypothyroidism without evidence of thy-
roid hormone supplementation, and another 2 (6%) had ultra-
sound findings consistent with chronic thyroiditis; of note, 2 of
these patients had normal thyroid function tests. In addition, 82
FDG-avid focal thyroid lesions (mean SUV 6.5, range 1.9-53)
were identified in 78 patients. Of these, follow-up characteri-
zation by ultrasound was available in 34 (44%) cases, with
biopsy performed in 26 cases. Pathology results revealed 10
(38%) malignancies (4 papillary thyroid carcinomas (mean
SUV 13.8; range 5.0-39.1), 3 Hurthle cell carcinomas (mean
SUV 3.8; range 3.3-4.5), 1 follicular neoplasm (SUV 2.9), and
2 malignancies not otherwise specified (mean SUV 10.2,
range 5.8-14.5). Conclusions: Our review of abnormal FDG
findings in the thyroid demonstrates that all focal thyroid le-
sions harbour a significant risk of malignancy which is inde-
pendent of SUV. In particular, well-differentiated lesions ex-
hibited a wide-range of FDG avidity. For patients with diffuse
uptake, chronic lymphocytic thyroiditis was the most likely
diagnosis in a significant proportion; however, no clear etiol-
ogy could be determined for the majority of cases.
P520
Role of 18F-FDG-PET/CT Scan in the Follow-Up
of Patients with Differentiated Thyroid Carcinoma.
Significance of Thyroglobulin and Anti-Thyroglobulin
Antibody Levels
F. S. Zelaya Reinquet, J. M. Nogueiras Alonso, D. Ruiz
Hernández, C. Castillo Berrio, M. A. Castrillón Sánchez, A.
Serena Puig, L. Campos Villarino, R. Guitián Iglesias; Hospi-
tal Do Meixoneiro, VIGO, SPAIN.
Objective/Aim:Differentiated Thyroid Carcinoma(DTC)
has a good prognosis and high cure rate with 10-year
survival rate of 80-90%. Recurrence may occur even
late(up 20%), so that a long-term monitoring with cer-
vical US, 131I whole body scan(I-WBS) and thyroglob-
ulin plasma levels(TG) is mandatory. The coexistence of
negative I-WBS and high TG levels suggest dedifferen-
tiation with Na-I symporter loss a circumstance that is
often associated with increased glucose metabolism.
FDG-PET/CT has proved useful in these patients but
criteria involving optimal use should be adequately
defined.Our goal in this paper is to relate the findings
of FDG-PET/CT performed in DTC patients with nega-
tive I-WBS, with serum levels of thyroglobulin and anti-
thyroglobulin antibodies to determine the cut-offs that
l e a d t o i n c r e a s e d d i a g n o s t i c a c c u r a c y a n d
performance.Material and methods:Since March 2009,
77 18F-FDG-PET/CT were performed in 43 (negative
I-WBS) patients with suspected DTC recurrence by ele-
vated levels of TG. 18F-FDG-PET/CT was performed on
the third day after stimulation with rh-TSH and evaluat-
ed by two nuclear physicians. PET findings were corre-
lated with the levels of TG-antibodies (normal
value<60UI/ml) and stimulated TG (NV<0.5ng/ml). Ac-
cording to these two groups were defined; group
A(59cases) Positive-TG stimulated levels, negative anti-
TG-AB and group B(15 cases): Positive anti-TG-AB.
PET findings were confirmed (true/false) by histology
and/or results of other diagnostic tests or clinical fol-
low-up.Results:43 patients with 74 scan (21♂-53♀/
age24-81years). Pathology at diagnosis: 53-papillary;
18-follicular, 3-undifferentiated histology. Confirmation
of the hypermetabolic foci by pathological study in
35scan, by another method of image or follow-up in
26.Group A46PET(+): 31 True Positive(TP), 8 False
Positive(FP), 7 not confirmed (NC). 13PET(-):13(TN9;
FN1; 3NC). 1Deceased. Mean TG:132ng/ml (0,86-
2860ng/ml). PET positive predictive value:79%; negative
predictive value:90%. (considering only confirmed
cases).Group BPET(+)15: 10TP; 1FP; 4NC. Average
TG:94ng/ml, Mean anti-TG-AB (rank 61-2530Ul/ml):
504Ul/ml. PET positive predictive value:90%.PET per-
formance according to TGstimulated levels.ROC
analysis(AUC:0.69).15 ng/ml cut-off: S:58%; Sp:76%;
PPV:75%; NPV:59%. Accuracy:66%.20 ng/ml cut-off:
S : 5 2 % ; S p : 8 8 % ; P P V : 8 4 % ; N P V : 5 9 % .
Accuracy:68%.ConclusionsFDG-PET is a procedure that
is justified in patients with DTC and negative I-WBS.
According to our results it modifies the therapeutic ap-
proach in 75% of cases. Its greatest value is achieved in
patients with TG levels higher than 15-20ng/ml or with
very high levels of antiTG even with undetectable
thyroglobulin.
P521
Predictors of malignancy in thyroid incidentalomas seen
on 18F-FDG PET/CT scanning in patients not known
to have thyroid cancer
H. Nasr1,2; 1Prince Sultan Military Medical City, Riyadh,
SAUDI ARABIA, 2Kasr El-Aini Cairo University Hospital,
Nuclear Medicine Unit, Cairo, EGYPT.
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S589
Objectives: To assess the frequency of incidental thyroid
abnormalities detected on 18F-FDG PET/CT and to de-
termine the most powerful parameters that are capable to
differentiate benign from malignant lesions. Methods: We
retrospectively reviewed 3304 18F-FDG PET/CT scans
for 1909 patients. Patients known to have thyroid malig-
nancy were excluded. Patients who were found to have
thyroid metabolic or morphologic abnormalities were fur-
ther analyzed. Data analyzed included; age, sex,
SUVmax, tissue density in Hounsfield units (HU) of
the non-enhanced CT portion of the study, lesion size,
presence of calcification and thyroid gland morphology.
To differentiate benign from malignant lesions SUVmax
cutoff of >4.7 and HU cutoff of >42 based on ROC
analysis were used. The various parameters were com-
pared to histopathological findings from either fine nee-
dle aspiration biopsy (FNAB) &/or thyroidectomy. Sensi-
tivity, specificity, PPV, NPV and accuracy in detecting
malignancy were calculated. Multivariate regression anal-
ysis was performed to assess the most powerful predic-
tors for malignancy. Results: Thyroid abnormalities were
detected in 120 patients of whom 78 had increased focal
or diffuse FDG activity. Histopathology was available for
30/120 patients (25%). The most common primary diag-
nosis of these patients in descending order was lympho-
ma (25%), breast cancer (18%), gynecological malignan-
cies (14%) and head & neck cancers (14%). Thyroid
malignancy was confirmed in 13/30 (43.3%) (10 (77%)
females) while benign thyroid lesions were noted in 15/
30 (50%) (8 (32%) females). Thyroid malignancies in-
cluded 10 papillary, 1 follicular, 1 Hurthle cell neoplasm
and 1 lymphoma. Benign lesions were 11 benign follic-
ular or colloid nodules and 4 autoimmune thyroiditis,
while in 2/30 FNAB was undetermined or inadequate.
The mean SUVmax and lesion tissue density (HU) were
both significantly higher in patients with malignant ver-
sus benign lesions (7.7±6.8 Vs. 3.6±1.6, p=0.032) and
(44.3±13.2 Vs. 32.5±12.6, p=0.039) respectively. None
of the other factors were statistically significant. There
was weak non-significant positive correlation between
SUVmax and HU. The sensitivity, specificity, PPV,
NPV and accuracy to predict malignancy for
SUVmax>4.7 versus HU>42 were 76.9%, 86.7%,
83.3%, 81.3 & 82.1% and 75.0%, 90.9%, 90.0%, 76.9
& 82.6% respectively while the combined both parame-
ters revealed further improvement compared to either pa-
rameter alone with sensitivity, specificity, PPV, NPV and
accuracy of 92.3%, 80.0%, 92.3%, 80.0% and accuracy
of 85.7% respectively. Conclusion: SUVmax and tissue
density (HU) are valid parameters capable of predicting
malignancy in thyroid gland insidentalomas and when
combined are more powerful with risk of malignancy
reaching 80-90% when criteria are fulfilled.
P522
99mTc-Methoxy-isobutyl-isonitrile (MIBI) Scintigraphy is
an useful and cost-effective tool for assessing the risk
of malignancy in thyroid nodules with indeterminate fine
needle cytology (FNAC)
A. Campenni’1, L. Giovanella2, S. Giovinazzo3, F. Di
Mauro1, S. Pignata1, M. Mure’1, M. Stipo1, M. Siracusa1,
M. Ruggeri3, S. Baldari1; 1Nuclear Medicine Unit of Messi-
na, Messina, ITALY, 2Nuclear Medicine and PET/CT Centre,
Oncology Institute of Southern Switzerland - Bellinzona,
Switzerland., Bellinzona, SWITZERLAND, 3Endocrinology
Unit, University of Messina, Messina, ITALY.
Aim. Nodular thyroid disease is a common clinical
problem. The diagnostic algorithm include laboratory
test, thyroid ultrasound, thyroid scintigraphy and
ultrasound-guided fine needle aspiration cytology
(usFNAC), if the nodule is cold. Not rarely, the results
of usFNAC are nondiagnostic (Thyr 1) or unconclusive
(Thyr 3). This is a very important problem in the man-
agement of patients because the risk of under or over-
treatment is high.The aim of our work was to verify if
99mTc-metossi-isobutil-isonitrile (99mTc-MIBI) scan can
be employed in Thyr1-Thyr3 patients how diagnostic
test to differentiate benign from malignant thyroid nod-
ules by qualitative and quantitative analysis. Material
and Methods. This prospective study was conducted on
105 patients (F= 80, M= 25; mean age 47.9 ± 12.6
yea r s ) w i t h co ld thy ro id nodu l e s a t 99mTc-
pertechnetate scintigraphy, greater than 1.5 cm in diam-
eter (mean size: 26.2 mm; range 15-45). The patients
had underwent FNAC, with indeterminate results: Thyr1,
n= 5 and Thyr3, n= 100. sestaMIBI scintigraphy was
acquired 20 and 40 minutes after tracer administration
(370 MBq) by static images of the thyroid.MIBI uptake
in thyroid nodules was evaluated both qualitatively
(compared with that in controlateral thyroid lobe) and
quantitatively, by using region of interest that were cre-
ated around nodule and outside the thyroid (background
activity subtraction). All patients underwent total-thy-
roidectomy. Results. All the cold nodules were MIBI-
positive, with different intensity of MIBI uptake at qual-
itative analysis: low (n= 35 patients), moderate (n= 46
patients) and high (n= 24 patients). By quantitative anal-
ysis, the patients were subdivided in three groups: A
(n=29) with a wash-out index (woi) ≥ -40%; Group B
(n=41): woi between -20 and -40%; Group C (n=35):
woi ≤ -20%. We assumed that a woi ≤ -20% was sus-
picious for malignancy, while a woi ≥ -40% was predic-
tive of a benign lesion. Compared to hystopathology, all
patients of the group A were negative for thyroid cancer
[sensitivity and negative-predictive-value: 100%]. In
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Group B were included all except seven patients affect-
ed by benign adenomas (sensitivity: 85.4%). Finally, 28
out of 35 patients of the Group C had a papillary thy-
roid carcinoma [specificity and positive-predictive-value:
80.0%]. All false positive patients were affected by ad-
enoma with oxyphil cell. Conclusions. We suggest the
use of MIBI-scan (by using quantitative analysis) in the
work-up of cold nodule with indeterminate cytology to
better stratify the risk patients’ to have a malignant le-
sion, so reducing the number of patients refereed to
surgery
P524
68Ga-DOTATATE-PET in MTC patients with elevated
calcitonin but normal radiological examination
Z. Wygoda, D. Handkiewicz-Junak; Centre of Oncology -
MSC Institue, GLIWICE, POLAND.
Early detection of medullary thyroid cancer (MTC) recurrence
can results in effective cancer treatment. Biochemical follow-
up with calcitonin measurements is the most sensitive method
for early detection of MTC persistent disease or recurrence,
but is not informative on its localisation. On the other hand
radiological examination (US, CT or MR) are sometimes neg-
ative for years before biochemical recurrence turns into clini-
cal one.Aim. This is a retrospective study to evaluate role of
molecular imaging in MTC patients with biochemical
recurrence.Material. Thirty eight patients diagnosed with
MTC and elevated calcitonin level were included into this
study. All patients were operated with radical thyroidectomy
and neck limfadenectomy in case of lymph node metastases.
In all patients radiological examinations (neck US and CT/
MR) were negative for MTC recurrence.68Ga-DOTATATE
and 18FDG were prepared on site according to GMP proce-
dures. Acquisition was performed on PET-CT Gemini GXL16
(Philips®) PET-CT mCT (Siemens®) one hour after 107,3 -
225,7 MBq of 68Ga-DOTATATE (median: 181,3 MBq) and
136,9 - 462,5 MBq (mediana: 296 MBq of 18FDG).Results.
68Ga-DOTATATE-PET was performed in 38 patients diag-
nosed with MTC. Seven of them had also 18FDG PET/CT.
In 7 (18%) patents there was an in increase in 68Ga-
DOTATATE uptake in14 anatomical localisation, seven of
them (50%) were also visible in 18FDG PET/CT. During
68Ga-DOTATATE examination medial calcitonin level was
546 ng/ml (range 315 to 1250). There was no correlation be-
tween calcitonin concentration and PE/CT results. During me-
dian follow up of 32 months none of the patients suffered from
clinical or radiological recurrence.Conclusions: 68Ga-
DOTATATE-PET/CT do not increase detection rate of recur-
rent MTC in patent with elevated calcitonin concentration and
negative radiological examination.
P525
131I SPECT/CT in differentiating neck iodine fixing foci
in patients with differentiated thyroid carcinoma (DTC)
A. Spanu, I. Gelo, L. Mele, S. Contu, B. Piras, S. Nuvoli, G.
Madeddu; Unit of Nuclear Medicine, University of Sassari,
Sassari, ITALY.
AIM. Regional lymph node spread from DTC is common
par t icula r ly in papi l la ry carc inoma, inc luding
microcarcinoma,with adverse prognostic influence mainly
in older patients. In a retrospective study we investigated
131I-SPECT/CT diagnostic role in DTC patients to also
evaluate whether the procedure may have an incremental
value than planar. METHODS. Among 735 DTC patients,
we selected 204 cases with neck iodine fixing foci; 63
patients were at high risk (H), 53 at low risk (L) and
88 at very low risk (VL). In 190 cases in chronic follow
up, 48 h after diagnostic 185 MBq dose and in 56 cases
after thyroidectomy (42 including in the 190 pts) 5 days
after first radioiodine therapy, planar WBS followed by
SPECT/CT over neck/chest and other suspect regions was
performed using hybrid dual gammacamera with high en-
ergy, parallel hole collimators and with low dose x-ray
tube (INFINIA-GE-Medical System), for total 294 exams.
RESULTS. SPECT/CT evidenced 560 iodine fixing foci in
the 204 patients,while planar 422 in 162 patients, all con-
firmed by SPECT/CT. Planar classified as residues 364/422
foci and unclear 59/422. SPECT/CT confirmed 356/364
residues while classified 8 foci as lymph node metastases
and characterized unclear foci as 17 lymph node metasta-
ses, 23 residues, 17 physiologic structures and 2 bone
metastases. Moreover, SPEC/CT evidenced 137 foci occult
at planar characterizing 68 lymph node metastases, 68 res-
idues and one physiologic uptake. Thus, SPECT/CT iden-
tified 90 lymph node metastases (24 only single) in 49
patients, while planar 25 in part wrongly classified as res-
idues or unclear foci. According Tg levels, 18/49 patients
(5H, 3L, 10 VL) had undetermined Tg levels (10 ng/ml.
Furthermore, 11 VL patients, whose Tg levels were unde-
termined or < 2.5 ng/ml and 3 VL patients with Tg be-
t w e e n 2 . 5 - 5 . 0 n g / m l w e r e T 1 a N 0 M 0 .
CONCLUSIONS.131I-SPECT/CT proved reliable diagnos-
tic tool localizing and characterizing neck fixing lymph
node metastases with incremental value (49.5% of cases)
than planar, with more correct patient classification and
management (26 % of cases) and avoiding unnecessary
therapy with single physiologic foci not classified by pla-
nar (6.9 % of cases). SPECT/CT superiority than planar is
particularly significant when the latter is inconclusive and
Tg levels are undetermined or very low, which cannot
exclude metastasis in lymph node, mainly in VL cases
with T1aN0M0 and even more with single metastasis.
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Successful slowing of tumour growth by sequential use
of different tyrosine kinase inhibitors in a patient
with poorly differentiated follicular thyroid carcinoma
A. Becherer, T. G. Böhler, W. Furlan, A. A. Hofmann, F.
Karakolcu, H. Wiederin; Academic Teaching Hospital
Feldkirch, Feldkirch, AUSTRIA.
Case report: A male patient, 47 years old, was diagnosed
with poorly differentiated follicular carcinoma (FTC) pT4
(UICC 1996), pT3 (UICC 2002) Nx, Mx. He underwent
left lobectomy and subtotal resection of the right lobe,
followed by radioiodine ablation with 5,5 GBq I-131. 3
Years later he had a relapse in the jugular fossa, again
treated by surgery and 5.5 GBq I-131. At that time, no
radioiodine avid tissue was seen. The following year he
had another jugular relapse on which he was operated
again with subsequent radiochemotherapy (50 Gy). His
thyroglobulin (TG) level remained stable then about 4
ng/ml for 3 years. After 4 years, a slow rise in TG to 9
was noted without response to TSH stimulation. A small
solitary right-sided lung lesion was diagnosed by FDG-
PET, showing progression 9 months later. He underwent
successful metastasectomy. 7 months later TG started to
rise again and FDG-PET/CT revealed 3 new foci in the
right lung and one in the left lung. The left lung was
treated by hypofractionated radiotherapy (7x8 Gy) while
the right lung was operated two times more within one
year. 2 months after last surgery FDG-positive lesions
were seen, TG 9. Another 7 months later FDG-PET/CT
displayed quantitatively and qualitatively progressive dis-
ease, TG 544. Therapy with the multikinase inhibitor
(MKI) sorafenib was begun. After a short drop in TG to
90 accompanied by a slight improvement of FDG-PET/CT
findings 2 months after starting with sorafenib, TG started
to rise again. After 4 months sorafenib, TG was 274 and a
new bone lesion showed up with FDG. After one year
sorafenib, TG was again 604 and therapy was switched
to pazopanib. TG fell to 387 after 3 months pazopanib
and increased then continuously to 1210 1.5 years later.
FDG-findings deteriorated as well. Therapy was changed
to the next MKI, lenvatinib. 4 months later, FDG-PET/CT
was at least stable and TG was 572. Nevertheless, it con-
tinued to rise and was 753 after 6 months under
lenvatinib. Discussion: This case shows that the sequential
use of different MKIs is effective in slowing tumour
growth in poorly differentiated FTC. Despite the tumour
becomes more aggressive and escapes every new MKI
over time, there is an improvement in TG-levels and
sometimes even in FDG-uptake after using a new MKI.
The future course will show, whether returning to the first
MKI is an option when third line therapy fails.
P527
Prognostic value of CEA and Calcitonin compared
to image-based monitoring of MTC patients undergoing
TKI treatment
R. A. Werner1,2, C. Bluemel1, D. Muegge3, T. Higuchi1,2,
J. S. Schmid1, C. Reiners1, K. Herrmann1,4, A. K. Buck1, C.
Lapa1; 1Department of NuclearMedicine, University Hospital
Würzburg, Würzburg, GERMANY, 2Comprehensive Heart
Failure Center, University Hospital Würzburg, Würzburg,
GERMANY, 3Institute of Psychology, University of Inns-
bruck, Innsbruck, AUSTRIA, 4Department of Molecular and
Medical Pharmacology, David Geffen School of Medicine at
UCLA, Los Angeles, CA, UNITED STATES.
Objectives: Treatment options for advanced medullary thy-
roid cancer (MTC) remain limited. Recently, tyrosine ki-
nase inhibitors (TKI) such as vandetanib have shown clin-
ical effectiveness and have been recommended as standard
therapy in patients with disseminated symptomatic disease.
The predictive role of tumor markers (CEA, calcitonin,
CTN) and tumor marker kinetics in the course of TKI
treatment has not been fully eludicated yet.Methods: The
study included 21 patients (male, 16, female, 5; mean
age, 49±13y) with progressive MTC receiving vandetanib
300 mg orally per day. Onset of tumor progression (PD)
was defined according to RECIST 1.1 criteria based on
follow-up CT scans performed in intervals of 3 months
(510±350 days, n=9±6 examinations). Additionally, CEA
(ug/l) and CTN (pg/ml) were measured at the day of CT
examination (n, 162-178 samples). A potential relationship
between the findings at image-based follow-up and tumor
marker levels were investigated to evaluate the predictive
role of image-based PD as compared to tumor marker
kinetics.Results: Both CEA and CTN showed an increase
(CEA, 331±630, CTN, 6394±16383) over time indicating
PD in all patients (increase compared to previous CEA,
14±67%; CTN, 3±39%). However, image-based PD did
not correlate with tumor marker kinetics (CEA, r=0.006;
CTN, r=0.07) whereas results of CT tended to positively
correlate with CTN measurement at the same and at the
following time point of blood collection (r, 0.24, r, 0.28,
p<0.01, respectively). A CTN cut-off value of ≥40% (de-
fined by receiver operating characteristic analysis) had a
sensitivity of 70.6% and a specificity of 83.2% in
predicting a CT-based PD with an accuracy of 82.0%
(area under the curve, 0.76). On the other hand, alter-
at ions in CEA levels were not predict ive for
PD.Conclusions: A CTN cut-off value of ≥40% predicts
the development of PD with an accuracy of 82% with
RECIST serving as reference for PD. However assessment
of CEA was not predictive and may be therefore
abundant.
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Incremental Value of SPECT/CT Over Planar Imaging
in Recombinant TSH I-131 Scanning of Follow up Patients
M. Al Janabi, Sr.; Mediclinic City Hospital, Dubai, UNITED
ARAB EMIRATES.
OBJECTIVE: The purpose of this study was to deter-
mine the added value of SPECT/CT over planar imaging
in Recombinant TSH I-131 scanning of follow up pa-
tients with differentiated thyroid carcinoma, post thy-
roidectomy and RAI ablation. MATERIALS AND
METHODS: Fifty patients undergone whole body Iodine
-131 scan as follow up, post total thyroidectomy and
RAI ablation. Males (10), Females (37), Age (27-62
years; Median-41.30 years).46 patients were with Papil-
lary Thyroid Carcinoma and 4 were with Follicular Thy-
roid Carcinoma. 45 patients were injected with Thyrogen
and two with Thyroid Hormone Withdrawal. Blood
levels of TSH, Thyroglobulin and Anti Thyroglobulin
Antibodies were obtained pre and post Thyrogen injec-
tion. Whole body, Planar and SPECT/CT scans of neck
& chest were obtained for all patients at 48 hours post
oral administration of diagnostic dose (185 MBq) of
Radio Iodine. SPECT images as well as CT images were
acquired for localization purpose, from nasal region to
stomach level covering the entire chest. Nuclear Medi-
cine physician interpreted the planar scans and SPECT/
CT images to assess the incremental diagnostic value
with respect to localization and characterization of focal
activity. Scan interpretation compared with blood values
and Ultra sound scan findings. RESULTS: 39 patients
had negative Iodine scan, as observed in planar and
SPECT/CT and from Thyroglobulin levels, out of which
one had localized pulmonary uptake, which was likely
to represent underlying inflammatory or infective pro-
cess. Three patients had negative Iodine scans, as shown
by both planar as well as SPECT CT images but with
raised thyroglobulin levels. Planar scans depicted mod-
erate neck uptake in 5 patients, suggestive of remnant
thyroid tissue. Raised Thyroglobulin level and SPECT/
CT confirmed the same. Three patients had raised Thy-
roglobulin levels, but negative planar images. SPECT/
CT images of the neck revealed foci of uptake sugges-
tive of metastatic cervical lymph node. Because of su-
perior lesion localization and additional anatomic infor-
mation derived from the low-dose CT component, incre-
mental diagnostic value with SPECT/CT over planar im-
aging was observed in three cases, where planar imaging
failed to show up the lesions. CONCLUSION: Recom-
binant TSH Iodine 131 SPECT/CT of neck and thorax is
useful for accurate evaluation of regional & distant ac-
tivity localization and characterization of foci as residual
thyroid tissue, nodal, pulmonary metastasis or bone me-
tastasis, especially in follow up patients.
P529
Thyroid cancer in patients with hyperthyroidism
S. Choukry, G. Cherkaoui Salhi, s. taleb, A. Guinsi; IBN
ROCHD UNIVERSITY HOSPITAL, Casablanca,
MOROCCO.
The aim of this study is to describe characteristics of patients
admitted for DTC and presenting a concomitant hyperthyroid-
ism. Materials and methods: the study enrolled all patients
admitted for a DTC between January 2012 and June 2013 in
the Nuclear Medicine Department. Among the 700 cases in-
cluded, 52 presented a concomitant clinical and biological
hyperthyroidism. Results: Mean age was 43 years old (+/-
11), all patients were women. Hyperthyroidismwas the reveal-
ing sign in 53% of cases. It was associated to a thyroid nodule
in 23% of cases, and to a nodular goitre in 19% of cases. Total
thyroidectomy examination showed papillary thyroid
histotype 98 % of cases and one case presented a trabecular
variant of papillary carcinoma. Pathological study showed also
a thyroiditis in 21% of cases and nodular dystrophy in 17%of
cases. The fifth of the subjects were stages very low risk re-
cording to the European consensus and didn’t require any
additional therapy. Low risk and high risk represented respec-
tively 60% and 20% of cases, these have received adjuvant
therapy by radioiodine. The follow up showed a complete
remission in 96% of cases, persistent disease with lung metas-
tases in one case, and one patient who was initially staged
T4NxMx has deceased before any adjuvant treatment. Con-
clusion: Although its scarcity, the co-occurrence of DTC and
hyperthyroidism has always to be considered.
P530
Effectiveness of aromatherapy on Physiology
and Psychology in patients undergoing I-131 ablation
with differentiated thyroid cancer.-Using Physiological
and Sensory evaluation-
M. Nakayama1, A. Okizaki1, S. Ishitoya1, T. Uno2, T.
Suzuki2, Y. Mikami2, J. Sato2, K. Takahashi1; 1Asahikawa
Medical University, ASAHIKAWA, HOKKAIDO, JAPAN,
2Asahikawa Medical University Hospital, ASAHIKAWA,
HOKKAIDO, JAPAN.
Objectives: The aim of this study was to investigate the phys-
iological and psychological effects of aromatherapy in patients
undergoing radioactive iodine (I-131) ablation with differenti-
ated thyroid cancer (DTC). Methods:The subjects were 67
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patients with DTC. They were divided into aromatherapy
group (10 men, 24 women, age 60.5 ± 12.7 years) and a con-
trol group (7 men, 26 women, age 61.1 ± 15.6 years). We
blended 1.0 ml of lemon (top note) and 0.5 ml of ginger (base
note) essential oils. The patients in the inhalation aromathera-
py group inhaled this blend oil and those in the control group
inhaled distilled water as placebo for 10min during admission.
Some physiological and psychological indices were measured
before and during I-131 ablation. Physiological effect was
measured using body weight, body temperature, blood pres-
sure, heart rate, salivary amylase activity and psychological
effect was measured using the State Trait Anxiety Inventory-
Form JYZ (STAI). Data analysis was performed with statisti-
cal softwarewere (XLSTAT2015, Addinsoft, Paris, France).
Results: As a result, the mean activty of salivary amylase in
the aromatherapy group was 42.0 ± 10.9 and in the control
group was 32.0 ± 5.2 before the intervention, which changed
after the intervention to 40.0 ± 10.1 and 51.0 ± 14.3,
respectively.The mean State-Anxiety score in the aromathera-
py group was 38.0± 1.1 and in the control group was 39.0 ±
1.3 before the intervention, which reduced to 35.0 ± 1.1 and
37.5 ± 1.4, respectively after the intervention. We found that
the aromatherapy group statistically significant decreased
(P<0.03) State-Anxiety score in STAI, and suppressed
(P<0.03) the increase of salivary amylase activity after the
intervention. There was no statistically significant difference
in other physiological data between the aromatherapy and con-
trol groups. Conclusions: The aromatic effects may alleviate
negative emotional stress, which, at least in part, would con-
tribute to the suppression of sympathetic nervous system
activity.
P531
Lung metastasis from differentiated thyroid carcinoma:
Characteristics and prognosis factors
A. Ezzine1,2, M. Ben Fredj1,2, C. Jabeur1, S. Melki1,2, R.
Sfar1, M. Guezguez1; 1Nuclear medicine department, Sousse,
TUNISIA, 299/UR/08-64, faculty of Medicine Sousse, Uni-
versity of Sousse, Sousse, TUNISIA.
Objectives: The aim of this study was to investigate the phys-
iological and psychological effects of aromatherapy in patients
undergoing radioactive iodine (I-131) ablation with differenti-
ated thyroid cancer (DTC). Methods:The subjects were 67
patients with DTC. They were divided into aromatherapy
group (10 men, 24 women, age 60.5 ± 12.7 years) and a con-
trol group (7 men, 26 women, age 61.1 ± 15.6 years). We
blended 1.0 ml of lemon (top note) and 0.5 ml of ginger (base
note) essential oils. The patients in the inhalation aromathera-
py group inhaled this blend oil and those in the control group
inhaled distilled water as placebo for 10min during admission.
Some physiological and psychological indices were measured
before and during I-131 ablation. Physiological effect was
measured using body weight, body temperature, blood pres-
sure, heart rate, salivary amylase activity and psychological
effect was measured using the State Trait Anxiety Inventory-
Form JYZ (STAI). Data analysis was performed with statisti-
cal softwarewere (XLSTAT2015, Addinsoft, Paris, France).
Results: As a result, the mean activty of salivary amylase in
the aromatherapy group was 42.0 ± 10.9 and in the control
group was 32.0 ± 5.2 before the intervention, which changed
after the intervention to 40.0 ± 10.1 and 51.0 ± 14.3,
respectively.The mean State-Anxiety score in the aromathera-
py group was 38.0± 1.1 and in the control group was 39.0 ±
1.3 before the intervention, which reduced to 35.0 ± 1.1 and
37.5 ± 1.4, respectively after the intervention. We found that
the aromatherapy group statistically significant decreased
(P<0.03) State-Anxiety score in STAI, and suppressed
(P<0.03) the increase of salivary amylase activity after the
intervention. There was no statistically significant difference
in other physiological data between the aromatherapy and con-
trol groups. Conclusions: The aromatic effects may alleviate
negative emotional stress, which, at least in part, would con-
tribute to the suppression of sympathetic nervous system
activity.
P532
Pre-therapy I-131 uptake value as a prediction method
for metastatic lymph node status in patients
with differentiated thyroid carcinoma
G. Ege Aktas, S. Soyluoglu Demir, F. Ustun, A. Sarikaya, G.
Durmus Altun; Trakya University Medical Faculty Hospital
Nuclear Medicine Department, Edirne, TURKEY.
Aim: Differentiated thyroid carcinoma (DTC) presents with
cervical lymph node metastases (LNM) in nearly 50% of pa-
tients. Pretreatment assessment of the cervical lymph node
status still remains an unsolved problem.We hypothesized that
lymph node status would affect I-131 uptake due to patho-
physiological behavior of benign and malign thyroidal tissue.
This study was designed to assess whether 24th hour I-131
uptake value (24RIU) would predict presence of LNM in pa-
tients with DTC. Material and Methods: We reviewed the re-
cords of 121 DTC patients, aged between 16- 80 (mean: 48±
14 years), whom received postoperative I-131 ablation (mean
dose: 122± 28mCi) therapy. Age, TSH, thyroglobulin (Tg),
anti- thyroglobulin (Anti-Tg) level, ultrasonography, 2nd and
24th RIU, I-131 dose and post ablative I-131 scans of the
patients were assessed. Patients’ data were evaluated retro-
spectively and each group was separated into three subgroups
according to exchange of 2nd and 24th RIU status: Unchanged
RIU was notified as group 1(n=13), decreased was group 2
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(n=49) and increased was group 3 (n=59). Results: The sub-
groups of patients were significantly different in respect of
their mean TSH, Tg, 2nd and 24th hour RIU; mean 83.7
±3.4, 92.6±2.9, 78.1±2.9 (p:0,04), 1.2±2.5, 11.5±4.6, 18.3
±5.4 (p:0,001), 3.7±2.8, 2.2±2.7, 3.3±2.3 (p: 0,001), 2.2±3.1,
0.9±1.7, 11.7±1 (p:0,001) respectively. More patients had
LNM in the increased uptake group (group 1=4/13, group
2=13/49, group 3=29/59; p: 0,04).There was no difference
between ages, TSH, Tg, anti-Tg levels and 2 hr RIU of patients
with and without LNM. 24RIU was higher in patients with
LNM (8.1±1.2 vs. 4.8±6.9, p: 0,05). The ±95% confidence
interval of the 24RIU for patients with LNM was 4.9 to 11.7.
A 24RIU 4.9 identified 34 of 46 patients with LNM and
correctly detected patients without LNM in 57 of 75 patients.
When a 24RIU of 4.9 was accepted as the cut-off value, the
sensitivity, specificity and overall diagnostic accuracy were,
74%, 76%, and 75% respectively. Conclusion: Our results
suggest that, I-131 24 hour uptake can be helpful in predicting
lymph node metastasis in patients with DTC. The mean
24RIU of the patients with LNMwas significantly higher than
without LNM.A cut-off value of 24RIU 4.9 yielded sensitivity
of 74%, a specificity of 76%, and overall diagnostic accuracy
of 75% for detecting LNM.
P533
The 18F-FDG-PET/CT for localization of tumor foci
in patients with elevated thyroglobulin antibodies
J. M. Nogueiras Alonso, F. Zelaya Reinquet, D. M. Ruiz
Hernández, C. Castillo Berrio, M. A. Castrillón Sánchez, L.
Campos Villarino, A. Serena Puig, R. Guitián Iglesias; Hospi-
tal Do Meixoneiro, VIGO, SPAIN.
The differentiated thyroid carcinoma DTC has a good progno-
sis and high cure rate with survival rate at 10-year of 80-90%,
but with a recurrence of 20%, it can be ruled by: negative
cervical US, negative 131INa-whole body scan (I-WBS) and
undetectable thyroglobulin (Tg). With a negative I-WBS, the
positivity of antiTg-Ab interferes and invalidates the proper
determination of Tg, knowing that if the tissue is
dedifferentiated and decreased iodine uptake ability by con-
trast increases glucose metabolism of the tumor cell, in this
sense F18-FDG/PET able to locate disease. We analyzed pro-
spectively the use of 18F-FDG-PET/CT in follow up of pa-
tients with elevation antiTg-Ab and negative131INa-
WBS.Material and methodsFrom 77 patients with DTC, neg-
ative I-WBS and detectable Tg followed since 2009, we found
15 patients with detec-table antiTg-Ab. 18F-FDG-PET/CT
wasmade at 3rd day of stimulation with Thyrogen®, analytical
(TSH, Tg and an-tiTg-Ab) basal and stimulated (3rd day),
reviewed by two nuclear physicians.ResultsPatients: 15 histo-
logical types: papillary (10), follicular (4), (9♀-5♂) mean age
56,85y (31-79y).Eleven patients had metastatic lymph node
involvement at initial diagnosis. After Thyrogen® all patientes
showed elevated TSH (25.30 to 173.4 mIU/ml) and detectable
antiTg-Ab (61-2530ul/ml), Tg(0.5-391.7ng/ml).31 Pathologi-
cal hypermetabolism foci were obtained in 15 patients located
in cervical region(25), supraclavicular(3), mediastinal(4),
bone(1) with SUVmax of 1.5g/ml to 23.3g/ml.In 9 patients
were confirmed metastatic DTC with pathological study
(TP), one patient died and the result is pending in 5
patients.Conclusions18F-FDG-PET/CT shows high sensitivi-
ty (100%), detecting tumor foci susceptible to cleavage with a
good diagnostic accuracy it could be considered as a suitable
diagnostic method in patients with elevated antiTg-Ab and
negative I-WBS. The sample is still very small, and is required
a larger sample to correlate the values of antiTg-Ab with sen-
sitivity and specificity PET/CT.
P534
Incidental Findings of Hypermetabolic Thyroid Lesions
in PET-CT Studies and Their Clinical Significance
D. Villasboas-Rosciolesi, Jr, A. García-Burillo, MD, C.
Zafón Llopis, MD,M. Salcedo-Pujantell, Jr, M. VelascoNuño,
Jr, J. Monturiol Duran, Jr, J. Castell-Conesa, MD; Hospital
Universitari Vall d’Hebron, Barcelona, SPAIN.
AIM: To describe the incidence of hypermetabolic lesions in
non-directed thyroid PET-CT studies and their clinical signif-
icance. MATERIAL AND METHODS: Between January
2013 and October 2014, from 4207 studies, Seventy-one stud-
ies were selected, 24 males and 47 females, 36-92 years-old
(70 ± 12), who received non-directed PET-CTstudies aimed to
thyroid disease, in which there were uptake increments detect-
ed, both focal and diffuse ones. After intravenous administra-
tion of 3.7 MBq/kg of 18F-FDG, PET-CT acquisition (Sie-
mens Biograph ® 64) was performed according to the standard
acquisition protocol. Ultrasound-guided fine needle aspiration
biopsy (FNAB) of the thyroid lesions was recommended in
focal uptakes. RESULTS: Three of the seventy-one studies
(4.2%, all women) showed mean SUVmax 8.11 (6.08-9.95)
increased diffuse thyroid uptake. Sixty-four of the seventy-one
studies (90.4%, 24 men and 40 women, 33.8% and 66.2%,
respectively) showed increased focal uptake. In 19 out of 71
patients (26%) a FNABwere performed. In the men group, the
mean SUVmax was 7.4 (±5.9) and 7 of them underwent ultra-
sound-FNAB, 2 (28.5%), of which showed Bethesda I, 2
(28.5%) Bethesda II, 1 (14.5%) Bethesda IV and 2 (28.5%)
Bethesda VI. In the women group, mean SUVmax was 7.27
(±6.2) and 12 of them had ultrasound-FNAB performed. In
this group 2 (16.7%) patients showed Bethesda I, 4 (33.3%)
Bethesda II, 1 (8.3%) Bethesda III, 2 (16.7%) Bethesda IV, 1
(8.3%) Bethesda Vand 2 (16.7%) Bethesda VI. Four out of the
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seventy-one studies (5.4%, all women) showed increased dif-
fuse and focal uptake (mean SUVmax 6.96, 4.6-11.7).
Ultrasound-FNAB was performed on 2 cases, showing Be-
thesda I and II, respectively. Finally, thyroidectomy was per-
formed on 4/71 (5.4%) patients (2 men and 2 women), and 2
more women (2.8%) are on waiting list for surgery. Two pap-
illary carcinoma (one of classic and another one follicular var-
iants) were present in men group. In two women, one
corresponded to a oncocytic follicular adenoma, and the other
one was papillary carcinoma. CONCLUSIONS: - The
SUVmax of hyper-uptake thyroid lesions is too variable and
it cannot distinguish between benign and malignant lesions. -
Ultrasound-guided FNAB were performed in 26% of patients
with thyroid increased uptake with a 16% of tumour
prevalence.
P535
Primary mucoepidermoid carcinoma and sclerosing
mucoepidermoid carcinoma with eosinophilia
of the thyroid gland: a report of two cases, one
with aggressive clinical course and other with good
prognosis
P. Petranović Ovčariček1, M. Franceschi1, T. Jukić1, N.
Dabelić1, B. Krušlin2, Z. Kusić1; 1University Hospital Center
“Sestre milosrdnice”, Department of Oncology and Nuclear
medicine, Zagreb, CROATIA, 2University Hospital Center
“Sestre milosrdnice”, Department of Pathology “Ljudevit
Jurak”, Zagreb, CROATIA.
A 33-year old male presented with a rapidly enlarging left
thyroid lobe. Neck ultrasonography (US) revealed enlarged
asymmetric thyroid gland with the hypoechoic nodule 5cm x
4,7cm x 3,6cm in size, in the left thyroid lobe. The patient was
euthyroid and scintigraphy with Tc 99m pertechnetate showed
cold nodule in the same lobe.Fine needle aspiration cytology
(FNA) revealed a poorly differentiated carcinoma. Total thy-
roidectomy was performed. Patohistological diagnosis was
primary mucoepidermoid carcinoma of the thyroid gland.
The tumor was 5,5 cm in size and was not encapsulated; it
invaded the surrounding thyroid parenchyma and adjacent soft
tissues.Immunohistochemically tumor was negative for thyro-
g l o b u l i n a n d c a l c i t o n i n , a n d p o s i t i v e f o r
cytokeratin.Postoperative neck US did not show suspected
mass in thyroid bed or suspected lymph nodes. Four month
later, US showed extensive recurrence and ipsilateral neck
metastases.Six months after the initial treatment, ipsilateral
radical neck dissection revealed 31 positive out of 50 lymph
nodes. Computed tomography (CT) performed a month later
revealed a large tumor located behind the larynx, compressing
the trachea, with retrosternal spread into the mediastinum. The
patient underwent radiotherapy (6000 cGy) and achieved
partial tumor regression. Three months later progression was
detected again and patient died soon after. This is a case, which
shows the aggressive clinical course of primary thyroid
mucoepidermoid carcinoma.The second case is that of a 65-
year old woman who underwent regular endocrinological
checkup because of lymphocytic thyroiditis and was under
thyroxin therapy. US showed a mildly enlarged and diffusely
changed thyroid gland with small nodules in both lobes.Fine
needle aspiration cytology of a small nodule (13mm in size), in
the left lobe, suggested Hashimoto thyroiditis with
mesenhimal cell proliferation.Total thyroidectomy was per-
formed. Patohistological diagnosis was sclerosing
mucoepidermpid carcinoma of the left thyroid lobe with eo-
sinophilia. It was 0,9 cm in size, infiltrating the surrounding
thyroid parenchyma but not invading the thyroid capsule.
Immunohistochemically, the tumor was negative for thyro-
globulin and calcitonin, and positive for cytokeratin. Postop-
erative US have not showed any suspected lymph nodes. She
is now a live and with stable disease.This case, unlike the
previous one, shows good clinical prognosis of sclerosing
mucoepidermoid carcinoma with eosinophilia.
P536
Evaluation of factors effecting health-related quality
of life, levels of anxiety and depression in patients
with thyroid cancer
G. Ucmak1, D. H. Yalvac2,B. E. Akkas1; 1Ankara Oncology
Research and Training Hospital Department of Nuclear Med-
icine, Ankara, TURKEY, 2Ankara Oncology Research and
Training Hospital Department of Psychiatry, Ankara,
TURKEY.
The aim of this study was to evaluate the factors effecting
health-related quality of life (HRQOL), in terms of anxiety
and depression, on the follow-up of patients with differentiated
thyroid cancer (DTC). Method: 518 DTC patients (446F,
72M, mean age: 46.6±11.8, 84% papillary, 16% follicular can-
cer) underwent total thyroidectomy and radioiodine treatment
(RIT). On follow-up all patients were on L-thyroxine treat-
ment. On interview, they were asked to take the European
Organization for Research and Treatment of Cancer Quality
of Life Questionnaire Core 30 (EORTC QLQ-C30) on routine
control. This scale evaluated functional domains, symptom
scales and a global health quality of life. Hospital Anxiety
and Depression Scale (HADS) was used to measure anxiety
and depression levels. Scale results were correlated with
social-demographic characteristics where higher scores repre-
sented better HRQOL. Results: According to HADS, in 31%
and 52% of patients’ anxiety and depression levels were above
threshold, respectively. Male patients had elevated functional-
scale scores whereas symptom-scale scores were not. Patients
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with a family history of cancer had lower points of physical,
role, emotional, cognitive and social function scores (p:0.006),
whereas they had higher HADS-A (p:0.001) and HADS-D
(p:0.035) scores compared to patients without. Well-educated
patients had higher physical and cognitive scores compared to
under-educated patients (p:0.003). The latter had higher pain
and financial difficulty scores compared to the former. Patients
with social support (p:0.015) had better global health scores
than single ones. The ones with anxiety and depression levels
above threshold had lower global health scores and functional
scale scores, higher symptom scale scores compared to others.
Conclusion: Although disease specific survival is high in
DTC, they experience a significantly decreased HRQOL.
Anxiety and depression are major determinants of decreased
HRQOL. The integration of supportive psychological care in-
to management may increase the HRQOL of patients with
DTC.
P537
Descriptive study of 1855 patients with differentiated
thyroid carcinoma treated in the period 1998-2012 in 11
hospitals of Catalonia
A. García-Burillo1, D. Villasboas1, C. Zafón1, J. González2,
M. Ysamat2, J. Castell1; 1Hospital General Universitari Vall
d’Hebron, BARCELONA, SPAIN, 2Mutua de Terrassa, Ter-
rassa, SPAIN.
OBJECTIVE: The Consortium for the Study of Thyroid Can-
cer (CeCAT) has been created as a working group of the Cat-
alonian Society of Endocrinology and Nutrition (SCEN) of
Catalonia. One of the first initiatives of CeCATwas to perform
a retrospective descriptive study of the characteristics of pa-
tients undergoing Differentiated Thyroid Cancer (DTC) in the
period 1998-2012. MATERIALS ANDMETHODS: To iden-
tify the centers with active databases on CDT, to update data-
bases, to select the variables to include, to merge in the data-
bases, and to perform statistical analyses. RESULTS: N: 1855
patients from 11 hospitals in Catalonia, 79.25% women,
20.75% male. Average age: 47.7 ± 15.7 years. Histology:
89% papillary cancer (PTC), 11% follicular cancer (FTC)
11%. Variants: 63% classical, 25% follicular, 12% others.
Mean size: 21.5 ± 16 mm (20 ± 14.5 mm on women, 26.6 ±
20.3 mm on men, p = 0.000). Micro carcinomas: 30%. Multi-
focal: 31%. Invasion: 26%. Thyroiditis: 33%. N1: 39.4%
(mean number of nodes: 12.5 ± 12 removed, 3.6 ± 5.6 infil-
trated). Radioiodine treatment: 84.2% (117.4 ± 35mCi). Mean
follow-up period: 5.5 ± 3.78 years. Persistence/recurrence:
23.8%. Metastases: 5.78%. Current status: 78.6% with no ev-
idence of disease, 17.6% with persistence/recurrence, 3.76%
dead. CONCLUSIONS: This collaborative project has en-
abled the description of the widest series of DTC patients with
follicular lineage in our country. The patient characteristics are
similar to those described elsewhere in the world. The typical
patient profile in the series is: female, 47 years old, with PTC
of classical variant, size of 21.5 mm, treatment by total thy-
roidectomy plus ablation with 131I and good prognosis (80%
cure rate at 5 years).
P538
Correlation Between Day 3 and Day 5 Blood Test Results
After Thyrotropin Alfa (Thyrogen) Injection In
Differentiated Thyroid Cancer Patients
S. Sager, Dr, C. Nisli, O. E. Sahin, R. Akyel, B. Rezavi, J.
Nemetyazar, E. Kaymakci, B. Vatankulu, M. Halac, H.
Sayman, I. Uslu, K. Sönmezoglu; Istanbul University,
Cerrahpasa Medical School, Istanbul, TURKEY.
Objection and Aim:The standart treatment of differentiated
thyroid cancer is total thyroidectomy, followed by radioactive
iodine-131 therapy and thyroid hormone suppressive therapy.
For radioactive iodine therapy TSH>30 is recommended. It is
necessary to raise serum TSH levels either endogenously by
thyroid hormone withdrawal (THW) or exogenously by ad-
ministration of recombinant human TSH (rhTSH). Thyrotro-
pin alfa (thyrogen) has many advantages over THW. However
one of the main disadvantege of using Thyrogen is I-131 radi-
ation dose to staff. While drawing blood for test, mostly nurses
or other staff may derived radiation from the patient. Our aim
is to compare day 3 and day 5, TSH, tg and anti-tg levels after
thyrogen injection in differentiated thyroid cancers.Method:In
this study we had 14 differentiated thyroid cancer patients with
a mean age of 50.5±12.3 and Thyrogen was used in all pa-
tients. Eight patients dose was 5mCi for ablation control and
for whole body imaging. Three patients dose was 150mCi and
3 of others was 200 mCi. Blood tests were performed on day 3
and day 5 after first day injection. All patients supressed TSH,
Tg, Anti-tg, Ft3 and Ft4 levels were performed 1 month before
thyrotropin alfa injection. All blood tests were routinely
permormed in the same labarotory standards.Results:Our pre-
liminary data shows that day 3 TSH level is always higher than
day 5 TSH level after first day thyrogen injection. The mean
TSH is level 96.3 for day 3 and 27.9 for day 5. For whole body
imaging and ablation control with 5 mCi I-131, Tg and anti-tg
levels are nearly the same. So whole body imaging is more
important than tg and anti-tg levels in these group of patients.
For therapy doses with 150 or 200 mCi, day 5 thyroglobulin
levels are higher than day 3. The mean tg level is 137.6 for day
3 and 320.5 for day 5.Conclusion:Exogenous stimulation with
recombinant human thyrotropin (rhTSH) is approved for Tg
testing or for diagnostic radioiodine scintigraphy in patients on
thyroid hormone suppressive therapy. After first day thyrogen
injection, day 5 blood test is not necessary. On day 3 before the
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5mCi or high dose radiactive iodine application, blood test for
tg, anti-tg, TSH, Ft3 and Ft4 can be done. However for abla-
tion control with 5 mCi, if tg and anti-tg level is suspicious,
blood test can be repeted on day 5 with whole body imaging.
P539
Vesicular cancer on ectopic lingual thyroid (In a case
report and literature review)
S. Choukry, G. Cherkaoui Salhi, s. taleb, a. Guinsi; IBN
ROCHD UNIVERSITY HOSPITAL, Casablanca,
MOROCCO.
The ectopic thyroid is a result of an abnormal embryological
development and/or migration of the thyroid gland. Vesicular
carcinoma development within it is extremely rare. The pur-
pose of this study was to report our first experience with ve-
sicular carcinoma on ectopic thyroid lingual. Patient’s age was
32 years old with no particular medical history, consulted for a
progressive installation of dysphonia. The neck scanner
showed a tumor of the epiglottis and the thyroid cartilage.
Thyroid scintigraphy showed no uptake at the level of the
thyroid associated to a relatively high uptake, above the thy-
roid lodge. The indication for surgical resection was decided,
the patient underwent a tumor and hyoid bone resection. His-
tological examination confirmed the thyroid origin and the
presence of a vesicular carcinoma within it. The tumor showed
neither capsular invasion nor vascular emboli. Adjuvant treat-
ment using radioiodine therapy (RIT) has been administered, it
was dosed 3,7GBq. Whole body scan using iodine 131 six
months after RIT associated to thyroglobulin’s level measure-
ment showed a complete remission.
P540
Familial Forms of Papillary Thyroid Carcinoma: a Case
Report
S. Kusacic Kuna1, J. Filipovic2, G. Horvatic Herceg1, T.
Samardzic1, M. Despot1, D. Huic1; 1Clin. Dept of Nucl
Med, University Hospital Centre Zagreb, Zagreb, CROATIA,
2Department of Nuclear Medicine, General Hospital Pula,
Croatia, Zagreb, CROATIA.
The majority of differentiated thyroid carcinomas are sporadic,
but rare forms of familial tumors are also reported. The entity
of familial thyroid non-medullary cancer (NMTC) is defined
by the presence of follicular-cell origin tumors in three or more
first-degree relatives. It seems that these tumors are often mul-
tifocal with local spreading, appear at a younger age with some
more aggressive behaviour when compared with sporadic tu-
mors. A hereditary basis for this familial NMTC is assumed,
but specific genetic defect remains unknown. The aim of re-
port is to present a case of a family with five papillary thyroid
cancer affected members, with comparing the clinical and
pathohistologic findings of each patient. A 30-year old women
referred for ultrasound examination because of enlarged thy-
roid lasting one year before. An ultrasound of the neck showed
hypoechogenic nodes in both lobes with suspected metastatic
nodes in neck region. Fine needle-aspiration biopsy (US-
FNAB) revealed papillary thyroid carcinoma in the both thy-
roid lobes and several metastatic neck lymph nodes. Patient
underwent total thyreoidectomy with functional neck dissec-
tion of both sides of the neck, and patohistology confirmed
diagnosis. During regular follow-up patient complied that her
sister living abroad also operated because of same disease and
after a while her second 45-year old sister admitted at the
Department of nuclear medicine because of thyroid carcino-
ma. Bearing in mind the possibility of appearance of familial
forms of papillary thyroid carcinoma in these three sisters,
ultrasound of the thyroid region was suggested in family mem-
bers and revealed localy advanced thyroid cancer in their 72-
aged father as well as in the 24-year old son of one female
patient. The extensive imaging material with a detailed demo-
graphic data, clinical history and histopathological features of
the tumor are presented in this report. Processing of other close
family members are in progress. In conclusion, a familial var-
iants of papillary thyroid carcinoma are rare forms of disease
that sometimes could be easily overlooked. Detailed anamnes-
tic family data may provide earlier recognition of the familial
nature of disease, with faster diagnosis and adequate treatment
in family members.
P541
Correlation of perceived social support with psychological
distress and the levels of anxiety and depression
in differentiated thyroid cancer patients
before hospitalization for radioiodine therapy
G. Ucmak1, B. E. Akkas1, D. H. Yalvac2, I. Ozer2, O.
Yuncu2, A. Caykoylu2; 1Ankara Oncology Research and
Training Hospital Department of Nuclear Medicine, Ankara,
TURKEY, 2Ankara Oncology Research and Training Hospital
Department of Psychiatry, Ankara, TURKEY.
The correlation of hypothyroidism and depression and/or anx-
iety is well established. Patients with differentiated thyroid
carcinoma (DTC) experience a 2-to-4 weeks of hypothyroid-
ism before radioiodine treatment (RIT). Anxiety and depres-
sion may exacerbate psychological distress that DTC patients
may experience during the hospitalization period for RIT. The
aim of this study was to evaluate the psychological status of
DTC patients before hospitalization for RIT and examine the
correlation of their perceived social support with
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psychological distress and the levels of anxiety and
depression.Method: 143 DTC patients were enrolled in this
study. All patients had physical and psychological examina-
tions on the day of hospitalization. We interviewed with the
patients and asked them to take a questionnaire which involves
social-demographic characteristics as well as patient history.
Three validated questionnaires (Distress Thermometer [DT],
Hospital Anxiety and Depression Scale [HADS] and TheMul-
tidimensional Scale of Perceived Social Support [MSPSS])
were used. The thresholds for validated Turkish version for
anxiety and depression subscales were considered as 11 for
anxiety (HADS-A) and 8 for depression (HADS-D). The DT
consists of an 11-point scale with endpoints labeled ‘No dis-
tress’ (0) and ‘Extreme distress’ (10). The DT cut-off score
was considered as 4 in Turkish cancer patients.Scores higher
than thresholds were indicated as distress.Results: Depression
and anxiety were diagnosed in 13% and 11 % of patients
respectively. These patients had higher DT, HADS-A and
HADS-D scores and lower social support scale scores com-
pared to patients without psychological problems (p<0.0001).
Patients with additional health problems and patients with a
positive family history of malignant disease had higher DT,
HADS-A and HADS-D scores. Patients with higher DTscores
above threshold had more familial (p:0.001), emotional
(p:0.0001) and physical distress. Patients with HADS scores
below threshold had higher social support scores
(p:0.002).Conclusion: The results of this study demonstrate
that these patients have substantial levels of psychopathology
at a rate of 24% and these scales used in this study play im-
portant role in recognizing risky patients for psychological
distress. Higher scores for anxiety and depression and lower
scores in perceived social support scales are observed in DTC
with different psychological problems. SelectingDTCwho are
under psycho-pathological risk may demonstrate the need for
psycho-oncological support during hospitalization period for
RIT. Noticing psychiatric symptoms on time and arranging
prompt treatment will therefore also decrease the workload
of the treatment team.
P542
Not all DTC patients with N positive disease deserve
the attribution “high risk”.Contribution of the MSDS trial
A. Vrachimis, C. Wenning, B. Riemann; University Hospital
Muenster, Muenster, GERMANY.
Background and Objectives: To investigate if patients having
N1a disease are at the same risk with N1b using the collective
of the well-defined European prospective Multicentre Study
Differentiated Thyroid Cancer (MSDS). Methods: Overall
(OS) and event free survival (EFS) were calculated.Cox mul-
tivariable regression analysis was performed in order to
calculate Hazard ratios (HR). Results: EFS was significantly
decreased only in patients with N1b metastasis as compared to
N0 patients and became worse when N1a was concomitantly
affected. A superior survival in favor of N1a patients as com-
pared to N1b patients with regard to EFS was also
observed.The patients having N1a disease showed no differ-
ences in the EFS as compared to N0. OS did not differ signif-
icantly in any of the groups. There was an increased HR for
events with regards to histology,T-stage, tumor size, UICC
stag and cervical lymph node metastasis. Tumor size showed
a significantly increased risk for OS. Conclusion: Patients with
pT3b and pT4a tumors with N1b are of higher risk for relapse,
albeit not affecting overall survival. Patients with N1a are of
no higher risk. The risk stratification of these patients may be
adapted accordingly.
P543
“High stimulated thyroglobulin on first follow
up in differentiated thyroid cancer patients is really
worrisome?”
M. Gupta, Jr.; RAJIV GANDHI CANCER INSTITUTE
AND RESEARCH CENTRE, DELHI, INDIA.
Objective: To study clinical significance of elevated
stimulated thyroglobulin (sTg) with normal imaging in
differentiated thyroid cancer (DTC) patients during first
follow-up. Study design and methods: Retrospective
analysis of DTC patients with five years follow-up or
till recurrence was done. Patients were divided into
group 1 (n-35) with disease free status on first follow-
up and group 2 (n-29) with high sTg (>2μg/l) with
normal imaging. Patients were categorized into low, in-
termediate and high risk based on pathological & diag-
nostic 131I scan findings. Statistical Analysis: Histology,
stage & risk-categories of both groups were correlated
with p value. Best sTg cut off for predicting recurrence
was generated by ROC curve. Odd ratio for sTg trend
was also analyzed for risk of recurrence in group 2.
Independent T test was used for progression free surviv-
al (PFS) comparison in groups. Results: No statistical
differences were seen in histology, stage and risk cate-
gory distributions in groups. Group 2 patients with high
sTg (Range 81-2.5 μg/ml, Mean 20.5 μg/l) on first
follow-up had higher risk of recurrence (odd ratio
4.304) but p value is insignificant (p value 0.090).
86.2 % of group 2 patients showed decreasing trends
and 62.1% patient’s sTg become normal. Indeed, de-
creasing trends in sTg reduced the risk of recurrence
(odd ratio 1.3939, p value 0.7912). ROC analysis
showed sTg > 11μg/l was the best cutoff in predicting
recurrence with sensitivity 100% & specificity 56.52%.
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S599
High sTg was not associated with lower PFS (p value
0.232), however progressive sTg had significant low
PFS (p value <0.005). Conclusion: High sTg with neg-
ative DxWBS don’t warrant an aggressive diagnostic
and therapeutic approach. 86.2% patients showed down-
ward trends with no higher risk of recurrence and lower
PFS.
P544
Radiation dose rate of I-131 in patients with differentiated
thyroid carcinoma; effect of administrated activity,
admission number and TSH level on retention curve
M. Moslehi1, A. Mahmoud Pashazadeh2, M. Assadi2; 1De-
partment of Nuclear Medicine, Seyedoshohada Hospital,
Isfahan University of Medical Sciences, Isfahan, IRAN, IS-
LAMICREPUBLICOF, 2The Persian Gulf Nuclear Medicine
Research Center, Bushehr University of Medical Sciences,
BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.
Background: Outcome of the radioiodine therapy of pa-
tients with Differentiated Thyroid Carcinoma [DTC] de-
pends on the retention of the activity in the body of the
patient. Several factors may influence retention time of
radioiodine in the blood and body of these patients.
Therefore, the aim of present study was to assess effects
of administered activity, serum thyroid stimulating hor-
mone [TSH] level and also patients’ admission number,
number of times they have been admitted in our nuclear
medicine center to receive radioiodine therapy, on the
retention of I-131 in the body of patients with
DTC.Methods: This study was performed in Nuclear
Medicine Department of Seyedoshohada Hospital in
2014. Number of 92 DTC patients, with different TSH
levels, was treated with different I-131 activities ranged
from 1850 MBq to 7400 MBq. Then post-therapy do-
simetry of patients was performed immediately, 6 hours,
12 hours, 24 hours and one week after the administra-
tion of I-131.Results: Based on our findings, clearance
rate of the activity was higher for those patients who
had received higher amounts of I-131 in comparison to
those who had received lower activities. Also, those pa-
tients who had been admitted for the third time in our
nuclear medicine center had higher clearance rate as
compared to those who had their first or second admis-
sion. Serum TSH level showed no effect on the amount
o f r a d i o i od i n e r e t a i n e d i n t h e body o f t h e
patients.Conclusions: Administered activity and admis-
sion number had significant effect on the retention of
I-131 in the body of patients. Any correlation was not
observed between serum TSH level and retention of
I-131.
P545
Predictive factors for the outcome of I-131 1110MBq
ablation therapy in the patients with differentiated thyroid
cancer: urinary iodine, serum thyroglobulin, and uptake
to thyroid bed
S. Ito1, S. Iwano1, K. Kato2, S. Naganawa1; 1Department of
Radiology, Nagoya University Graduate School of Medicine,
Nagoya, JAPAN, 2Deparment of Radiological and Medical
Laboratory Sciences, Nagoya University Graduate School of
Medicine, Nagoya, JAPAN.
Aim: In Japan, which is surrounded by sea, people take much
iodine for daily meals. Low iodine diet ahead of radioiodine
remnant ablation therapy (I-131 ablation) is essential for Jap-
anese patients with differentiated thyroid cancer (DTC). The
aim of this study was to evaluate the effectiveness of the mea-
surement of urinary iodine concentration in I-131 ablation.
Additionally, we evaluated the influence of the intensity of
radioiodine uptake to thyroid bed and serum thyroglobulin
(Tg) level on I-131 ablation. Methods: Forty-seven consecu-
tive DTC patients (18 males, 29 females; age 55±11 years old)
who underwent I-131 ablation with a dose of 1110MBq en-
rolled in this prospective study. Patients took low iodine diet
for two weeks with two methods: self-management diet, or
rigorous diet with market-sold food. Urinary iodine concentra-
tion and Tg level were measured on the day of I-131 ablation.
The intensity of uptake was visually evaluated and classified
into three categories: very high, high, and low. Post-
therapeutic scintigraphy was performed in six to eight months
after I-131 ablation, and absence or residual of I-131 accumu-
lation to thyroid bed was determined. Results: Urinary iodine
concentration before the beginning of low iodine diet was
334.5 ± 508.5 μg/L. On the day of I-131 ablation after contin-
uation of low iodine diet, urinary iodine concentration of rig-
orous diet group (56.0 ± 26.3μg/L) indicated lower value than
that of self-management diet group (104.90 ± 141.83μg/L),
but there was no significant difference between both groups
(p=0.08). Thirty-one cases (66%) showed absence of uptake
(absence group), and sixteen cases (34%) showed residual of
uptake (residual group) with the post-therapeutic scintigraphy.
Urinary iodine concentrations of absence and residual groups
were 93.4±72.7μg/L and 68.6±54.5μg/L, respectively. Tg
levels of absence and residual group were 29.8±82.6 ng/mL
and 38.0±81.8 ng/mL, respectively. There were no significant
difference between absence and residual groups in both uri-
nary iodine concentrations and Tg levels (p=0.25 and 0.76,
respectively). Six cases (13%) showed low uptake of
radioiodine to thyroid bed in scintigraphy performed in I-131
ablation, and all of them were included in absence group.
However, no significant difference was observed between ab-
sence and residual groups in uptake to thyroid bed (p=0.08).
Conclusion: Although strict low iodine diet is indispensable
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for Japanese DTC patients in I-131 ablation, the current Japa-
nese method of low iodine diet was shown to be sufficient to
prepare for I-131 ablation. Low I-131 uptake of thyroid bed
suggested the successful outcome of I-131 ablation.
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Correlation of Standardized Uptake Value Derived Indices
with Tumoral Aggressiveness of Gliomas in Static
18F-FDOPA PET: Use in Clinical Practice
l. Janvier, Jr., A. Verger; CHU Nancy, Nancy, FRANCE.
Purpose. Glioma grading is necessary for prognostic
evaluation and optimal treatment decisions. The aim of
this study was to establish whether a correlation between
18F-FDOPA uptakes with tumor grade was observed and
to determine which of the SUV derived indices was the
best correlated. Methods. Thirty-one patients were retro-
spectively included (aged 36.8 ± 12.1 years) including
21 proven low-grade tumors due to histology, imaging
and clinical follow up and 10 histologically proven
high-grade tumors. Static PET acquisitions were post-
reconstructed between 10th and 30th minute after injec-
tion of 18F-FDOPA. Regions of interest (ROI) of
20 mm were applied to tumors and isocontoured vol-
umes were defined at levels of 50 and 80% of the peak
intensity voxel. Background was quantified with 30 mm
diameter ROIs on contralateral striatum and centrum
semi-oval. Tumoral uptake was evaluated with standard-
ized uptake value (SUV) derived indices: SUVmax,
SUVmean, SUVmean of isocontoured volume, tumor/
striatum (T/S) and tumor/normal brain (T/N) SUVmax
and SUVmean ratio. Results. All the SUV derived indi-
ces tested were significantly correlated with tumor
grade, considering low-grade and high-grade groups
(p< 0.05), except for the SUVmean 50%. The 2 best-
correlated indices were SUVmean T/N and SUVmean
T/S, with correlation coefficients of 0.561 and 0.522
respectively. Receiver-operating characteristic analysis
defined optimal thresholds of 1.33 and 1 for sensitivity
and specificity of 71% and 100% and 67% and 100%,
respectively. Conclusions. 18F-FDOPA PET SUV de-
rived indices are routinely available information that en-
ables accurate discrimination of low-grade and high-
grade gliomas. The best-correlated indices were
SUVmean T/N and SUVmean T/S with thresholds of
1.33 and 1.
P547
Role of 11C-Methionine PET for the Molecular
Characterization of Primary Brain Tumours Eligible
for Surgery
E. Lopci, M. Riva, L. Bello, L. Olivari, F. Raneri, M. Rodari,
A. Chiti; Humanitas Clinical and Research Hospital, Rozzano
(Milano), ITALY.
Background and Aim: biological characterization of primary
brain tumours is becoming increasingly relevant, thus deter-
mining the future implementation of specific molecular
markers into glioma classification. The possibility to deter-
mine noninvasively these characteristics by using molecular
imaging is greatly appealing. The aim of our study was to
investigate the role of 11C-methionine PET imaging in molec-
ular characterization of primary brain tumours, with as specific
focus on patient outcome.Materials andMethods: for the anal-
ysis we enrolled 85 consecutive patients (M:F=57:28; mean
age 46, range 17-77 years) affected by pathology proven gli-
omas and referred to our Institution for tumour resection. Be-
fore surgery, patients underwent 11C-methionine PET-CT,
performed according to standard procedure. In all cases
semi-quantitative and quantitative analyses were obtained by
taking into consideration SUVmax, SUVratio, metabolic tu-
mour volume (MTV) and tumour burden (MTB). These data
were subsequently correlated to disease outcome, expressed in
terms of progression-free survival (PFS), and compared to
other clinical and biological information obtained from pathol-
ogy. All patients were followed up for a median period of 16.8
months. Results: according to WHO classification, we
analysed 34 low-grade gliomas (LGG: 3 grade I & 31 grade
II), and 51 high-grade gliomas (HGG: 32 grade III & 19 grade
IV). All PET parameters considered showed a statistically sig-
nificant association to tumour grade, with HGG having a
higher SUVmax, SUVratio, MTV and MTB compared to
LGG (p<0.01). Based on semi-quantitative analyses, we de-
termined a statistically significant correlation between
SUVmax and SUVratio versus IDH1 mutation (p=0.002 and
0.001, respectively), but not versus 1p/19q co-deletion and
MGMT promoter methylation. When considering disease out-
come, we identified as prognostic factors to longer PFS tu-
mour grade, MIBI%, IDH1 mutation, 1p/19q co-deletion,
SUVmax and SUVratio (p<0.05). On multivariate analysis,
the Cox regression did identify a potential independent prog-
nostic factor IDH1 mutation (p<0.05). Conclusions: molecular
characterization on 11C-methionine PET significantly corre-
lates with histological grading in primary brain tumours and
IDH1 mutation status. With respect to disease outcome, tu-
mour grading, MIBI%, IDH1 mutation, 1p/19q co-deletion,
SUVmax and SUVratio resulted prognostic factors to PFS,
with IDH1 mutation being a potential independent predictor
to outcome in this cohort of patients candidate to surgery.
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Comparison of PET/CT and Difusion/Perfusion Weighted
Magnetic Resonance Imaging Findings in Malignant
Brain Tumors
M. Sipahi; BAKIRKOY DR. SADI KONUK EDUCATION
AND RESEARCH HOSPITAL, ISTANBUL, TURKEY.
In this study, our aim was to determine if there was a relation-
ship between the metabolic activity obtained from 18F FDG
PET imaging (SUVmax) and diffusion coefficient (ADC) in
diffusion weighted magnetic resonance imaging (DW-MRI)
and relative cerebral blood volume (rCBV) obtained from per-
fusion magnetic resonance imaging in malignant brain tumors;
to investigate the contribution of FDG PET imaging in differ-
entiating grade 4 glioblastoma from metastatic cerebral mass
lesions. A retrospective analysis was performed in 20 cases, 9
male and 11 female, who presented to Akdeniz University
Medical Faculty Hospital Neurosurgery clinic with intracrani-
al mass lesion diagnosis/pre-diagnosis. Patients who had con-
ventional MR and FDG PET/CT images were included in the
study. Patients whowere operated previously, however, had no
recurrence or residual mass in subsequent examinations and
patients with extra axially located mass lesions were excluded
from the study. A statistically significant negative correlation
between the ADC value of the primary lesion and the ratio of
metabolic activity in the late images to the metabolic activity
of contralateral cortex (GSUV/ GSUVK) was determined
(p<0.05, r =-0.52). Also, a statistically significant negative
correlation was found between the perfusion of primary tumor
(rCBV) and the percentage changes in SUVmax values of the
mass in the late images (GSUV- ESUV/100* ESUV) (p<0.01,
r = -0.63). Besides these, it was observed that late imaging has
a diagnostic value in differentiating grade 4 glioblastoma from
metastatic cerebral mass lesions (100% sensitivity, 75%
specifity). According to the results obtained from our study,
FDG PET provides an additional contribution to intracranial
mass lesion diagnosis, and we believe that specially late im-
aging should be performed in brain lesions.
P549
Correlation of 4’-[Methyl-11C]-Thiothymidine Uptake
with Ki-67 Immunohistochemistry in Patients with Newly
Diagnosed and Recurrent Gliomas: Comparison
with 11C-Methionine Uptake
Y. Yamamoto1, K. Tanaka1, H. Yamamoto1, N. Kudomi1, T.
Hatakeyama1, J. Toyohara2, Y. Nishiyama1; 1Kagawa Uni-
versity, Kagawa, JAPAN, 2Tokyo Metropolitan Institute of
Gerontology, Tokyo, JAPAN.
A novel radiopharmaceutical, 4’-[methyl-11C]thiothymidine
(11C-4DST), has been developed as an in vivo cell prolifera-
tion marker based on the DNA incorporation method. The
purpose of this study was to evaluate 11C-4DST uptake in
patients with newly diagnosed and recurrent gliomas and to
correlate the results with proliferative activity, in comparison
with L-[methyl-11C]-methionine (11C-MET). Methods: 11C-
4DSTand 11C-MET PET/CTwas investigated in 36 lesions of
33 patients, including 23 with newly diagnosed gliomas and
13 with recurrent gliomas that had been treated previously.
The standardized uptake value (SUV) was determined by
region-of-interest analysis. The maximal SUV (SUVmax) for
tumor (T) and the mean SUV for contralateral normal brain
tissue (N) were calculated and T/N ratio was determined. Pro-
liferative activity as indicated by the Ki-67 index was estimat-
ed in tissue specimens. Results: 11C-4DST and 11C-MET
PET/CT detected 33 and 35 of 36 brain gliomas, respectively.
In newly diagnosed gliomas, linear regression analysis indi-
cated a significant correlation between SUVmax (r = 0.48, P <
0.03) and T/N ratio (r = 0.45, P < 0.04) using 11C-4DST and
the Ki-67 index. In recurrent gliomas, no significant difference
between SUVmax and T/N ratio using 11C-4DST and the Ki-
67 index. In newly diagnosed and recurrent gliomas, no sig-
nificant difference between SUVmax and T/N ratio using 11C-
MET and the Ki-67 index. Conclusion: 11C-4DST PET/CT
seems to be useful in the noninvasive assessment of tumor
proliferation in newly diagnosed glioma compared with 11C-
MET.
P550
PET/CT Using [11C]Methionine in Differential Diagnosis
of Intramedullary Tumors from Non-neoplastic Spinal
Cord Lesions
T. Skvortsova, Z. Savintseva, L. Prakhova, D. Zakhs, S.
Medvedev; N. P. Bechtereva Institute of the Human Brain of
Russian Academy of Sciences, Saint-Petersburg, RUSSIAN
FEDERATION.
The aim of the study was to evaluate the ability of PET/CT
with [11C]methionine (PET/CT-Met) to differentiate between
intramedullary tumors and non-neoplastic lesions of spinal
cord. Materials and methods. PET/CT-Met was performed in
20 patients (median age 39 years) with suspected
intramedullary tumor according to results of previous
contrast-enhanced MRI. Final diagnosis included primary or
recurrent intramedullary gliomas (14), glioblastomametastasis
(1), recurrent secondary lymphomas of the brain and spinal
cord (1). Other 4 patients suffered from ischemic myelopathy
associated with dural spinal AVM (1), LETM (2), Sjögren’s
syndrome involving spinal cord (1). Diagnosis was proven
histologically in 7 patients with glioma (low-grade-4, high-
grade- 3) or by clinical-radiological findings (n=13).
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Additionally in 7 patients diffusion-tensor imaging (DTI) was
performed to assess white matter fiber tracts. The analysis of
PET/CT images was based in addition to the visual assessment
on semiquantitative calculations as the ratio of the SUVmean
of the lesion to the that in the intact spinal cord. Results. MRI
demonstrated intramedullary contrast-enhanced masses in 17
patients and nonenhancing mass-lesions in 3 patients. All tu-
mors except 2 were well differentiated from spinal cord by
visual inspection of fused PET/CT images as the lesion with
increased tracer accumulation. The mean [11C] methionine
uptake index was 3,3±1,2. The SUV ratio was variable in all
cases without the significant difference between benign and
malignant tumor type. Absolute magnitudes of SUV in unaf-
fected spinal cord significantly differed among patients due to
differences in time interval between injection and PET/CT
scanning (range 10-30 min.) so SUV in the lesions had no
diagnostic value. In PET-positive tumors the increased [11C]
methionine accumulation was observed in the part of the le-
sion which was almost compatible with contrast enhancement
on MRI. The nonenhancing intramedullary gliomas (n=2)
were characterized by negative [11C]methionine uptake. In 3
from 4 patients with non-neoplastic myelopathy [11C]methi-
onine accumulation did not differ from the unaffected part of
the spinal cord. Only ischemic vasculopathy associated with
Sjögren’s syndrome demonstrated slightly increased [11C]me-
thionine uptake (UI=1,8). Tracts of the spinal cord rounded the
tumor nodules and were expanded in all other myelopathies. In
tumors with negative [11C] methionine uptake MR-
tractography results were crucial to confirm the neoplastic na-
ture of the lesion. Conclusion. In cases of complicated differ-
ential diagnosis between neoplastic and non-neoplastic
intramedullary spinal cord lesion PET/CT with [11C]methio-
nine and diffusion-tensor MR imaging can provide significant
additional information.
P551
FET PET in the evaluation of indeterminate brain lesions
on MRI: differentiating glioma form other non-neoplastic
causes
D. L. Chan, G. P. Schembri, M. Back, D. L. Bailey, P. J.
Roach, H. Wheeler, R. Cook, J. Parkinson, A. Lee, D.
Jayamanne, J. Drummond, E. Hsiao; Royal North Shore Hos-
pital, St Leonards, AUSTRALIA.
Aim: FET PET had demonstrated excellent diagnostic perfor-
mance in the assessment of cerebral gliomas. The study aims
to investigate the clinical utility of FET PET in differentiating
glioma from non-neoplastic lesions such as cortical dysplasia
or demyelination. Methods: We reviewed 172 patients who
underwent FET scanning at Royal North Shore Hospital be-
tween February 2011 and April 2014. Patients without prior
histological diagnosis of CNS malignancy were identified.
Histology (if available) and follow-up data were obtained.
All studies were acquired on a Siemens Biograph mCT fol-
lowing administration of ~150MBq FET with 20-minute dy-
namic and 10-minute static acquisitions. Results: 20 patients
had brain lesions on MR imaging (15 cerebrum, 2 corpus
callosum, 2 brainstem, 1 cerebellum) which were of uncertain
aetiology with differentials including glioma, demyelinating
plaque or cortical dysplasia. Median age was 53 years and
the clinical presentations included seizures (5), headache (4),
dizziness (3) and visual changes (2). The patients were follow-
ed up for a median of 113 days. 8 out of 20 patients (40%)
demonstrated increased uptake on FET PET. Five underwent
surgery/biopsy which revealed three low grade gliomas, one
g l i o b l a s t oma mu l t i f o rm e a n d on e a n a p l a s t i c
oligodendroglioma. The rest of FET positive patients were
observed; two remained well and one commenced temozolo-
mide for a presumed high-grade glioma (clinical and radiolog-
ical progression). The 12 FET negative patients did not under-
go biopsy. Of these, six had stable changes on MRI. Two had
resolving changes on repeat MRI with clinical diagnoses of
stroke and seizure. Three are clinically and radiologically sta-
ble. All have remainedwell without progression except for one
patient who died after two months of progressive neurological
deterioration. The patient was suspected to have high-grade
glioma with neither biopsy nor autopsy confirmation. 15 pa-
tients underwent FDG PET within 28 days of FET PET. Two
(13%) showed increased uptake on FDG PET. These patients
were diagnosed on biopsy with anaplastic oligodendroglioma
and glioblastoma multiforme respectively. All 8 patients with
normal FDG and FET PET have remained clinically well with
stable lesions on observation. Conclusions: FET PET demon-
strates a high positive predict value for glioma in patients with
indeterminate brain lesions on MRI. The combination of neg-
ative FET and negative FDG PET scans predicts an indolent
clinical course. The results suggest that FET PET may have a
potential role in guiding surgical management in this cohort.
P552
Use of 11C-methionine PET for the immunohistochemistry
characterization of gliomas
A. Mestre-Fusco1, F. Alameda2, M. Suárez-Piñera1, S.
Mojal3, M. Martínez-Garcia4, G. Conesa5, Neurooncology
PSMar Group; 1Nuclear Medicine department. Hospital del
Mar. Parc de Salut Mar, Barcelona, SPAIN, 2Pathology de-
partment. Hospital del Mar. Parc de Salut Mar, Barcelona,
SPAIN, 3Institute of Medical Research IMIM. PRBB, Barce-
lona, SPAIN, 4Neurooncology department. Hospital del Mar.
Parc de Salut Mar, Barcelona, SPAIN, 5Neurosurgery depart-
ment. Hospital del Mar. Parc de Salut Mar, Barcelona, SPAIN.
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Introduction: 11C-methionine PET (MET PET) has been
used to study tumoral gradation, cell proliferation and perfu-
sion in gliomas. Aim: Our aim was to compare metabolic
activity of MET PET and immunohistochemical biomarker
of tumor aggressiveness in glioma: Expression analysis of
p53, p16, WT1, Beta-catenin, CD34, CD44 and EGFR. Ma-
terial and methods: MET PET was performed in nineteen
patients clinically and MRI (3-Tesla equipment) suggested of
glioma and confirmed by surgery (n = 13 males, 29-75 years).
PET MET images were analyzed visually and quantitatively
(ROI) and Ratio T/N was calculated of each lesion (SUVmax
tumour/SUVmax or SUVavg normal tissue on contralateral
cortex regions). An immunohistochemical study of expression
of tumor aggressiveness markers was calculated (%) includ-
ing: p53, p16,WT1 (suppression), CD44 (activation), vascular
CD34 and Beta-catenin (perfusion) and EGFR (growth). Gli-
omas were classified as low or high grade (WHO classifica-
tion) using a cut-off point of Ratio T/N = 2.07. In case of Ratio
T/N > 2.07 glioma was classified as high grade. Mean, SE and
statistical significance between Ratio T/N more or less than
2.07 was estimated for each immunohistochemical variables
(Mann-Whitney test, p < 0.05).Results: One patient with neg-
ative MET PET was diagnosed as gliosis. Five patients with
Ratio T/N < 2.07 were diagnosed as low grade glioma (II) and
one patient as high grade (III). Twelve patients diagnosed as
high grade glioma showed Ratio T/N > 2.07 (one anaplastic
astrocytoma and eleven glioblastomas). A significant correla-
tion between Ratio T/N < 2.07 and low expression of suppres-
sion markers p53, p16 and WT1 of gliomas was observed. A
large expression variability of these markers was observed in
case of Ratio T/N > 2.07. A lineal correlation between vascular
CD34 expression in case of low glioma or Ratio T/N < 2.07
was observed. No differences were found between expression
of Beta-catenin, CD44 and EGFR and PET Ratio T/N.
Conclusion: Metabolic activity ofMET PET is correlatedwith
a lower expression of immunohistochemical suppression
markers in low grade gliomas.
P553
18F-fluorocholine PET/CT in the assessment of brain
primary tumors
A.Montes1, A. Fernandez1, V. Camacho1, J. Craven-Bartle2,
C. De Quintana3, O. Gallego4, R. Jaller1, A. Flotats1, M.
Estorch1, D. Lopez1, I. Carrio1; 1Nuclear Medicine Depart-
ment. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN,
2Radiation Oncology Department. Hospital de la Santa Creu i
Sant Pau, Barcelona, SPAIN, 3Neurosurgery Department.
Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, 4On-
cology Department. Hospital de la Santa Creu i Sant Pau,
Barcelona, SPAIN.
Purpose:Diagnosis of brain primary tumors can be challeng-
ing, and the usefulness of 18F-FDG PET/CT is limited, prin-
cipally in low grade tumors. This study was aimed to evaluate
the utility of 18F-fluorocholine in the assessment of different
brain primary tumors.Materials and methods:Brain PET/CT
with 18F-fluorocholine was performed in 13 patients. Primary
brain neoplasm was suspected in 3 patients and the other 10
patients were studied in order to assess recurrence of a known
brain tumor. Pathological tracer uptake was evaluated to study
the benign or malignant nature of the lesions. Results were
confirmed by histology (6 patients) and/or by clinical and con-
ventional imaging follow-up (7 patients).Results:18F-
fluorocholine uptake suggesting malignancy was observed in
10 of 13 patients. Three patients did not present with 18F-
fluorocholine uptake.Positive PET/CT patients were histolog-
ically diagnosed with: astrocytoma grade IV (3 patients), as-
trocytoma grade III (1 patient), oligodendroglioma grade III (1
patient), oligodendroglioma grade II (1 patient with negative
1p/19q deletion), oligoastrocytoma grade II (1 patient),
gliomatosis cerebri (1 patient), meningioma (1 patient) and
brain abscess (1 patient). Significant differences in 18F-
fluorocholine uptake with regard to histological tumor type
were not observed.One patient without PET/CT pathological
findings was finally diagnosed with oligodendroglioma grade
II, with positive 1p/19q deletion. The other PET negative pa-
tients, who had a previous history of oligodendroglioma grade
III and oligoastrocytoma grade II, did not show suspicion of
recur rence 9 months a f t e r pe r fo rming the PET
studies.Conclusions:This preliminary study indicates that
18F-fluorocholine PET/CTmay be helpful in the initial assess-
ment, recurrence or progression of primary brain neoplasms,
independently of histology or tumor grade. A possible associ-
ation of 18F-fluorocholine PET negativity with positive 1p/
19q deletion, a known genetic marker of favorable prognosis,
is suggested.
P554
Differentiation of Pseudoprogress and Actual Progress
in Glioblastoma Multiforme by Textural Inhomogeneity
Parameters in [18F] -Fluoroethyltyrosine PET
Z. Khurshid1, S. Kebir2, U. Herrlinger2, L. Papp3, N.
Zsótér3, F. Gaertner1, M. Essler1, R. Bundschuh1; 1Depart-
ment of Nuclear Medicine, Uniklinikum Bonn, Bonn, GER-
MANY, 2Center for Neuro-oncology, Department of Neurol-
ogy, Uniklinikum Bonn, Bonn, GERMANY, 3Mediso Medi-
cal Imaging Systems, Budapest, HUNGARY.
Objective: The main objective of the study was to differentiate
between pseudoprogress (PSP) from actual progress in pa-
tients of glioblastoma multiforme (GBM) by studying the tex-
tural inhomogeneity parameters in [18F] -Fluoroethyltyrosine
S604 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
PET (FET-PET). GBM being the commonest and one of the
most aggressive primary brain tumors, often shows the phe-
nomenon of PSP after chemoradiotherapy. For therapy deci-
sions and therefore overall survival it is crucial to differentiate
between PSP and real progress as early as possible.Materials
and methods: 21 patients with histopathologically confirmed
GBM and having suspected pseudoprogress were included in
the study. Retrospective analysis was performed. For entire
analysis InterView FUSION, Mediso system was used. 3D
volumes of the lesions (VOIs) were manually delineated in
FET-PET. In addition, a semiautomatic segmentation in FET-
PET was performed based on background activity (estimated
in 5 regions of interest (ROIs), with a fixed diameter of 15 mm
placed in the normal cortex, tumor delineation cutoff was tak-
en as 1.6 times the mean value of background ROIs). In addi-
tion to conventional PET parameters, 17 PET based heteroge-
neity parameters were also determined. Results obtained were
then compared with clinical outcomes.Results: In differentia-
tion of PSP versus actual progress the uptake of FET remark-
ably showed a negative predictive value of 100%. The positive
predictive value was calculated to be 47%. In quantification
several heterogeneity parameters showed statistically signifi-
cant ability to differntiate PSP versus actual progress e.g., De-
viation (0.001), COV (0.005), entropy (0.003), homogeneity
(0.015), contrast (0.021), size and intensity variation (0.007),
and complexity (0.041) in comparison to the conventional
PET parameters.Conclusions: It was concluded that the FET-
PETshows potential for early differentiation between PSP and
real tumor progress, being a good indicator of negative predic-
tive value. Various heterogeneity parameters showed the abil-
ity to further differentiate FET-PET uptake to improve the
positive predictive potential. These results can be verified fur-
ther by taking a larger patient population as study group and
analyzing the delayed outcomes of patients.
P555
Usefulness of Preoperative Dual-Phase thallium-201
SPECT and Imaging Fusion with SPECT and MRI
in Predicting Histopathology of Meningiomas
and Hemangioblastomas
A. Abe1, S. Abe2, S. Oya1, T. Matsui1; 1Saitama Medical
University, Kawagoe, JAPAN, 2Mitsui Memorial Hospital,
Tokyo, JAPAN.
Backg round and Aim : Bo th men ing i omas and
hemangioblastomas are intracranial hypervascular tumors
demonstrating tumor stains on digital subtraction angiography
(DSA) with high frequency. The preoperative differential di-
agnosis between them is still a challenge, even after utilizing
diagnostic imaging methods such as computed tomography
(CT), magnetic resonance imaging (MRI) and DSA. The aim
of this study is to investigate the usefulness of preoperative
thallium-201 chloride brain single photon emission tomogra-
phy (Tl-SPECT) in predicting the histopathology of meningi-
omas and hemangioblastomas. Materials and Methods: In this
retrospective study, histopathologically proven 67 cases of
meningiomas (3 with angiomatous, 6 with fibrous, 16 with
transitional, 30 with meningothelial, 6 with atypical and 6 with
unknown menigiomas) and 8 cases of hemangioblastomas
were reviewed. The early-phase images at 15 minutes after
the injection of 111MBq of thallium-201 chloride and the
delayed-phase images at 3 hours after the injection and T2
signal weighted images (T2WIs) of MRI were obtained before
neurosurgical resection. The regions of interest (ROI) were
precisely placed on the uptake of the tumors (T) and contra-
lateral normal brain parenchyma as background uptake (N) on
the fusion images with Tl-SPECT and T2WIs of MRI. The
thallium uptake indices of the early-phase imaging (ER) and
the delayed-phase imaging (DR) were defined as follows: thal-
lium uptake index = mean counts per pixel in T / mean counts
per pixel in N. The retention indices (RI) of Tl-SPECT were
calculated as follows: RI = (DR - ER) / ER. Results: ER, DR
and RI values of hemangioblastomas (4.69±1.70, 1.58±0.40, -
0.64±0.12) were significantly lower than those of meningio-
mas (12.33±7.33, 5.41±3.03, -0.49±0.21), respectively (P =
0.0064, 0.0006 and 0.0523, respectively). With the combina-
tion of ER less than 7.3 and RI between -0.8 and -0.4, the
sensitivity, specificity and accuracy for diagnosing
hemangioblastoma were 100%, 91% and 92%, respectively.
DR and RI of angiomatous meningiomas were significantly
lower than those of the other pathological types of meningio-
mas (P = 0.0194, 0.0069, respectively). No significant differ-
ences of ER, DR and RI were observed among the other his-
topathological groups of menigiomas including atypical me-
ningiomas. Conclusion: The dual-phase imaging of Tl-SPECT
and ROI analysis using imaging fusion with Tl-SPECT and
MRI are useful to differentiate the hemangioblastomas from
meningiomas preoperatively, thus reducing the risk of the in-
vasive DSA.
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FDG PET/CT and MRI in oral cavity carcinomas:
anatomical considerations
H. Munechika, T. Saginoya, Y. Miura, S. Takekawa, K. Seto,
K. Watanabe; Southern Tohoku General Hospital, KORIYA-
MA, JAPAN.
Introduction and purpose: Anatomical structures of the oral
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cavity are prone to be defective in demonstration in FDG PET/
CT because of streaky artefacts caused by metals of the teeth.
The oral cavity carcinomas are FDG avid. However, MRI is
expected to have an additional imaging modality to FDG PET/
CT for adequate evaluation of the oral cavity carcinomas. The
aim of this study is to find the anatomical landmark of the oral
cavity for comprehending appropriately the location and ex-
tent of carcinomas in PET/CT. Subjects and methods: In car-
cinomas of the tongue root, sublingual glands, retromolar
trigone, gingiva, buccal mucous membrane, oral floor mucous
membrane and soft palate, the anatomical structures adjacent
to carcinomas are re-evaluated retrospectively in the axial,
coronal and sagittal images of FDG PET/CTand MRI in order
to find the useful anatomical landmark of the oral cavity. Re-
sults and discussion: The geniohyoid muscle, myohyoid mus-
cle, genioglossus muscle, hyoid bone, submandibular glands,
and sublingual glands are useful for anatomical landmarks in
evaluation of carcinomas locating the inferior region of the
oral cavity. The mandibular angle, buccinator muscle, medial
pterygoid muscle, masseter muscle and digastric muscle are
useful for anatomical landmarks in evaluation of carcinomas
locating the lateral region of the oral cavity. Carcinomas of the
superior or posterior region of the oral cavity can be evaluated
by FDG PET/CT alone without help of MRI. Conclusion:
Comprehension of the anatomical landmark in MRI is useful
for evaluation of FDG PET/CT in some cases with the oral
cavity carcinomas. The representative cases are presented.
P557
Semi-quantitative analysis of FDG-PET/CT images
to assess residual nodal disease in patients with squamous
cell carcinoma of the head and neck (HNSCC)
after (chemo)radiotherapy (CRT): can it improve
accuracy and prognostic value?
N. Helsen1,2, T. Van den Wyngaert1,2, L. Carp1,2, D. Van
den Weyngaert1,3, S. Stroobants1,2; 1University of Antwerp,
Wilrijk (Antwerp), BELGIUM, 2Antwerp University Hospi-
tal, Edegem, BELGIUM, 3Middelheim hospital, Antwerp,
BELGIUM.
Background: FDG-PET/CT has been proven effective in de-
tecting residual disease in patients with HNSCC after CRT.
The aim of this study is to investigate whether the accuracy
and prognostic value of this technique can be improved by
using semi-quantitative parameters based on the standardized
uptake value (SUV). Patients and Methods: Image data from
HNSCC patients receiving whole body FDG-PET/CT for as-
sessment of disease after completing CRTwere retrospectively
analyzed. The following SUV based parameters of all residual
lesions on PET were measured: the maximum SUVmax,
SUVpeak, and the SUV at 50% (SUV50) and 90% (SUV90) of
the maximum. In absence of nodes on PET the paraspinal
muscle uptake was used. Background region of interest
(ROI) included the liver, aortic arch, and the trapezius and
paraspinal muscles, and were employed to calculate relative
uptake ratios. The reference standard was histological confir-
mation when available, otherwise 1 year negative follow-up,
time of death or confirmation by subsequent imaging was
used. The diagnostic accuracy of absolute and relative SUV
values were compared using ROC analysis. Kaplan-Meier and
multivariable Cox regression were used to study survival. Re-
sults: 129 scans from 128 patients were included (105 patients
had node involvement at diagnosis). 22/129 FDG-PET/CT
scans were positive for disease after therapy, while disease,
according to the reference standard, was present in 25 patients.
ROC analysis identified the SUV90 value (AUC=0.949; cutoff
2.88; SD=2.16) and the ratio of SUV90/trapezius
muscle(SUV90trap), (AUC=0.970; cutoff 3.42; SD=3.08) as
the most performant absolute and relative parameter, respec-
tively. The sensitivity of the qualitative assessment was 76.0%
(95% CI: 54.9-90.6%), compared to 88.0% (95% CI: 68.8-
97.3%, p=0.25) and 92.0% (95% CI: 73.9-98.8% p=0.125)
for the absolute and relative SUV parameter, respectively. Less
variance was observed for the specificity (range 97.1-98.1%).
All absolute and relative SUV parameters were significantly
associated with disease free, disease specific, and overall sur-
vival. In contrast, none of the baseline characteristics (stage,
age, therapy, lymph involvement) were prognostic. The adjust-
ed hazard ratios of SUV90 and SUV90trap, were 1.9 (95% CI:
1.5-2.4, p<0.001) and 2.0 (95%CI: 1.5-2.5, p<0.001) meaning
that every increase of SUV90 or SUV90trap with one standard
deviation was associated with an approximate twofold in-
crease in the hazard of death. Conclusions: The current study
indicates that the use of a semi-quantitative measures could
reduce the number of false negative FDG-PET/CT scans after
(chemo)radiotherapy and contributes clinically meaningful
prognostic information.
P558
Meta-analysis of 18F-FDG PET/CT for diagnosis
of residual/recurrent nasopharyngeal carcinoma
after radiotherapy
H. Zhou, Y. Zhou, L. Li; West China Hospital, Chengdu,
CHINA.
Objective: To assess the diagnostic value of 18-fluoro-2-
deoxyglucose positron emission tomography/computed to-
mography (18F-FDG PET/CT) in detecting residual/
recurrent nasopharyngeal carcinoma. Method: The literatures
published between January 1990 and September 2013 were
searched in PubMed, EMBASE, EBSCO, Web of Science,
CBM, CNKI, VIP and Wanfang databases. Two researchers
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independently selected studies, extracted data and assessed the
quality of included studies according to the QUADAS tool.
Summary sensitivity, specificity, diagnostic odds ratios
(DOR), and receiver-operating characteristic (SROC) curves
were obtained using Meta-Disc software. Subgroup analysis
was also conducted. Result: Twenty-six studies were included
in this meta-analysis, involving 1203 patients. The pooled
sensitivity, specificity and diagnostic odds ratios (DOR) were
0.92 [95% confidence interval (CI), 0.89-0.94], 0.87 (95% CI,
0.84-0.90) and 51.10 (95%CI, 34.29-76.15), respectively. The
area under the curve (AUC) and Q* index estimate for PET/
CT were 0.9494 and 0.8897, respectively. The results of sub-
group analysis showed no significant difference between
subgroups(P>0.05). Conclusion: In a word, 18F-FDG PET/
CT performed well for diagnosis of residual/recurrent naso-
pharyngeal carcinoma, with relatively high sensitivity and
specificity.
P559
Diagnostic performance of time-of-flight system to detect
neck small lymph node using 18F-FDG PET/CT
H. Saito, A. Yamane, S. Imai, E. Orita, K. Hakozaki, K.
Akiyama, K. Ishihara, S. Kumita; Nippon Medical School,
Bunkyo-ku, Tokyo, JAPAN.
Objective:It is difficult to differentiate FDG concentration of
metastatic lymph nodes from that of inflammatory lymphade-
nopathy, especially assessing small lymph node less than 1 cm.
In head and neck cancer, it is critical for therapeutic strategy
whether the presence or absence of metastatic lymph node. In
head and neck cancer, 18F-FDG PET/CT has been reported to
have less than 50% sensitivity to diagnose N category in the
cases with missed lymph nodes by palpation. Time-of-flight
(TOF) PET technology has improved signal-to-noise ratio in
whole-body oncologic application. Few studies, however,
have elucidated the impact of TOF on diagnostic performance
to discriminate malignant uptakes from benign ones in small
nodes.The purpose of this study was to compare the diagnostic
performance of metastatic lymph node less than 1cm in cases
with pharyngeal cancer between TOF and non-TOF (3D-
RAMLA) PET systems.Materials and Methods:In this study,
total 96 small neck lymph nodes consisted of 49 metastatic
lymph nodes in 35 patients with pharyngeal cancer and 47
reactive lymph nodes confirmed in 29 healthy cases undergo-
ing 18F-FDG PET/CT for self-health care. All lymph nodes
were from 5mm to 10mm in long-axis diameter. The TOF and
non-TOF images were reconstructed using the same PET data
and the maximum of the standardized uptake value (SUVmax)
was measured based on region of interest, respectively. The
area under the ROC curve, sensitivity and specificity to differ-
entiate metastasis from reactive change were compared
between TOF and non-TOF images.ResultThe SUVmax of
metastatic lymph nodes was 4.02±1.02 in TOF and 3.96
±1.06 in non-TOF. On the other hand, reactive lymphadenop-
athy using TOF and non-TOF showed 2.62±0.48 and 2.40
±0.43 of SUVmax, respectively. The SUVmax of metastatic
lymph node was significantly greater than that of reactive
lymphadenopathy in either image (p< 0.01). Although there
were not significant differences of the AUC between TOF and
non-TOF, TOF showed greater AUC than non-TOF (0.94 vs.
0.90) and thus TOF showed more excellent diagnostic perfor-
mance with sensitivity of 95% and specificity of 88% than
non-TOF with sensitivity of 85% and specificity of 80%
.ConclusionAlthough TOF elevated both FDG uptakes of ma-
lignant and benign lesions, TOF enabled us to differentiate
metastatic lymph nodes compared with non-TOF. TOF may
show more power to assess tiny nodes less than 5mm.
P560
Texture analysis of pre-treatment 18F-FDG PET/CT
images predicts for overall and recurrence-free survival
of patients with locoregional advanced nasopharyngeal
carcinoma after concurrent chemoradiotherpay
S. Chan1, K. Chang2, C. Lin2, T. Yen2; 1Keelung Chang
Gung Memorial Hospital, Keelung, TAIWAN, 2Linkou
Chang Gung Memorial Hospital, Taoyuan, TAIWAN.
Background: Texture analysis is a promising method of
analyzing imaging data to improve diagnostic accuracy.
This method involves measurement of pixel intensity
variation that provides information concerning tumor
heterogeneity. We assessed whether 18F-FDG PET im-
aging texture analysis would correctly the prognosis of
patients with advanced nasopharyngeal carcinoma
(NPC). Material and method: A cohort of 68 patients
with primary stage III-IVb NPC was prospectively eval-
uated by 18F-FDG PET/CT. Overall survival (OS) and
recurrence-free survival (RFS) were the main outcome
measures. In an exploratory analysis, a standardized up-
take value of 2.5 (SUV 2.5) was taken as the cut-off
value for the detection of tumour boundaries. The tex-
tural features of pretreatment 18F-FDG PET/CT images
were extracted from histogram analysis, normalized
gray-level cooccurrence matrix (uniformity, entropy, dis-
similarity, contrast, homogeneity, and inverse different
moment), and neighborhood gray-tone difference matrix
(coarseness, contrast, busyness, complexity, and
strength). Result: Up to the date of analysis, 31 patients
died and 27 patients experienced recurrences. The 5-year
OS and RFS were 56.5% and 55.9%, respectively. Tex-
ture parameter contrast was significantly associated with
T status (p<0.0001) and tumor stage (p=0.007).
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Coarseness was significantly associated with T status
(p<0.0001), N status (p=0.039), and tumor stage
(p=0.004). In multivariate analysis, contrast (p=0.021),
coarse (p=0.036), and complex (p=0.02) were indepen-
dently associated with RFS. Tumor stage (p=0.04) and
coarse (0.032) were significantly associated with OS.
Conclusion: Texture parameters, contrast and coarseness,
are primarily associated with clinical stage. In addition,
these parameters can aid in the prediction of overall and
recurrence-free survivals of advanced NPC patients.
P561
A Comparative Study of FDG PET/CT and MRI
in Clinical/Pathological T4-stage Buccal Squamous Cell
Carcinoma
C. Lo1, P. Kao1,2, J. Weng1; 1Chung Shan Medical
Univeristy Hospital, Taichung, TAIWAN, 2Chung Shan Med-
ical Univerisity, School of Medicine, TAIWAN.
Introduction: Buccal cancer is highly related to betel nut
and tobacco use in Asia. Poor oral hygiene and dental
disease with metallic implant may cause imaging inter-
pretation difficulty. This retrospective study is to evalu-
ate the diagnostic accuracy of FDG PET/CT and MRI in
detecting surrounding soft tissue in clinical and/or path-
ological T4 staging buccal cancer in this area. Materials
and Methods: This retrospective study has approved by
IRB. We review 31 clinical and/or pathological T4 stag-
ing buccal cancer in our hospital from 2008 to 2015. All
patients have MRI scan and 22 patients have FDG PET/
CT within one month before surgery. Pathological results
were used as gold standard. For T4-staging, the maxilla
bone, mandible bone, and pterygoid muscle and masse-
ter muscle involvement was concerned. Result and Dis-
cussion: Among them, the MRI T-staging of these pa-
tients include: 21 T4a, 8 T4b, 1 T2, and 1 T3; the FDG
PET/CT T-staging include: 12 T4a, 6 T4b, 1 T1, and 3
T3; and the pathological results were 18 T4a, 2 T4b, 4
T1, 5 T2, and 2 T3. The overall T- staging accuracy of
[18F]FDG PET/CT and MRI are 59% and 45%, respec-
tively. For T4 staging, the accuracy of [18F]FDG PET/
CT and MRI are 61% and 46%, respectively. Cortical
bone involvement was better delineated on attenuation
CT imaging of PET/CT than MRI. Review clinical his-
tory, all patients have betel nut use result in poor oral
hygiene and dental problem which may cause MRI and
PET/CT imaging artifact. Both imaging modalities tend
to overestimate the T-staging. Conclusion: Buccal cancer
as an endemic cancer in high betel nut use area, the
accuracy of MRI and FDG PET/CT in diagnosis of T4
staging is affected by accompanied dental disease.
P562
Clinical value of SPECT/CT for evaluation of bone
metastasis in patients with head and neck cancer
P. Arıcan, B. Okudan Tekin, R. Şefizade, S. Naldöken; An-
kara Numune Education and Research Hospital, Ankara,
TURKEY.
The bone metastasis is the second common side of distant
metastasis in patients with head and neck cancer. The detection
of bone metastasis influences the selection of treatment mo-
dality. Bone scintigraphy is higher sensitivity for the detection
of suspected skeletal metastasis. But it can be difficult to dis-
tinguish between metastasis and other conditions such as post-
operative, degenerative and traumatic changes, due to compact
bone structure on the head and neck region. The aim of our
study was evaluated the role of SPECT/CT in bone scintigra-
phy for the diagnosis of bone metastasis in patients with head
and neck cancer.Methods and Materials:We retrospectively
analysed 25 head and neck cancer patients (19 men, 6 women;
mean range 55 years) who suspected bone metastasis with
clinic-radiologic findings and referred to our department for
bone scan between 2012 and 2014. Whole body and static
images were performed at 3 hours after 740 MBq Tc-99m
methylene diphosphonate (MDP) injection. Subsequently,
SPECT/CT was performed from cervical and thoracic region
in 22 patients, cranium in 2 patients, and pelvis in one patient.
First planar bone scan was separately assessed by two nuclear
medicine physicians. Second fusion images were evaluated
and SPECT/CT findings were compared with the findings of
planar images. The findings of planar bone scan and SPECT/
CT were categorized as definitely benign, definitely malign
and equivocal. The final diagnosis was verified by clinical-
radiologic follow up.Results and Conclusion:There were def-
initely benign lesions (n=12) (%48), definitely malign lesion
(n=1) (%4) and equivocal lesions (n=12) (%48) on planar
bone scan, definitely benign (n=16) (64%), and definitely ma-
lign lesions (n=8) (32%), and equivocal lesion (n=1) (4%) on
SPECT/CT. SPECT/CT was provided to the accurate diagno-
sis in 9 of the 12 patients with equivocal bone findings (2
malign, 7 benign). Sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV), and accuracy
were calculated for planar bone scan, and SPECT/CT. The
sensitivity of planar bone scan and SPECT/CT was 33.3%,
and 100%. The specificity was 52.6%, and 88.8% respectively.
PPV was 18.1%, and 75%, respectively. NPV was 71.4%, and
100%, respectively. Accuracy was 48%, and 88%,
respectively.SPECT/CT is better than planar bone scan for
the diagnosis of bonemetastasis in patients with head and neck
cancer by providing accurate anatomic localization and mor-
phologic characteristic. SPECT/CT is superior for characteriz-
ing equivocal bone lesions on the head and neck region and
can have a significant impact on patient’s management.
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Prognostic value of pre-treatment 18F-FDG PET/CT
volumetric parameters in patients with locally advanced
larynx carcinoma treated with concurrent
chemo-radiotherapy
G. Paone, V. Espeli, F. Martucci, L. Ceriani, A. Richetti, L.
Giovanella; Oncology Institute of Southern Switzerland, Bel-
linzona, SWITZERLAND.
Aim: the aim of this study was to assess the prognostic value of
volumetric parameters measured on 18F-FDG PET/CT deter-
mining event free survival (EFS) and overall survival (OS) in
patients with locally advanced larynx carcinoma treated with
concurrent chemo-radiotherapy. Material and method: we ret-
rospectively analyzed 31 patients who performed a staging
PET/CT for larynx carcinoma between 2008 and 2011. All
patients had stage III-IV squamous cell carcinoma of the lar-
ynx treated with IMRT and concurrent chemotherapy. MTV,
SUV max/mean and TLG were recorded. Univariate and mul-
tivariate analyses in association with Kaplan-Meier method
were used to evaluate the prognostic value of these parameters
considering EFS and OS. Results: In the univariate analysis,
MTV (>20cm3) using a 2,5 SUV threshold had the best prog-
nostic value than the other PET/CT parameters. We found a
significant difference for predicting EFS (p<0,0001) and OS
(p>0,0001) between the high MTV 2.5 (>20 cm3) and low
MTV 2.5 (≤20cm3). In multivariate analysis, MTVand visual
interpretation of local invasion remained significantly associ-
ated with EFS and OS (p= 0.012) while SUV max and TLG
became non-significant (p=0.4 for EFS and p=0.7 for OS). At
median follow up of 40 months the relapse rate was 42% (13/
31 pts). Conclusion: Our data suggest that the pre-treatment
18F-FDG PET/CT MTV (>20cm3) provide better prognostic
information in patients with locally advanced larynx cancer
than other PET/CT parameters. 58% cure rate in this high-
risk population is encouraging and confirm that chemo-
radiation may be a therapeutic option.
P564
SPECT-CT in Patients with Parathyroid and Thyroid
Comorbidities
O. Bessolova, O. Perfileva, Y. Kizhaev, V. Vidioukov; Russian
Medical Academy of Postgraduate Education, Moscow, RUS-
SIAN FEDERATION.
Aim: To evaluate the role of SPECT-CT in detection and pre-
operative localization of parathyroid adenomas with 99mTc
MIBI (dual-phase study) in patients with parathyroid and con-
comitant nodular thyroid pathology. Materials and methods:
Our study included 37 female patients with mean age of 44
±6.1 with laboratory features of hyperparathyroidism. Ultra-
sound revealed solitary/multiple 10-48 mm nodes in one/both
thyroid lobes in all patients. Scintigraphy (GE Infinia Hawk-
eye 4) included dual-phase planar scans 15min and 2hrs after
intravenous 555 MBq 99mTc MIBI respectively and SPECT
after second phase study. In case of increased uptake foci on
planar/SPECT images fusion SPECT-CT study was addition-
ally performed. Results: In 21 patients increased uptake soli-
tary foci in the thyroid lobes projection were detected indepen-
dently of thyroid pathology localizations. Scintigraphically
negative patients were managed according to conventional
algorithms. SPECT-CT allowed precise thyroid contour delin-
eation and increased uptake foci localization beyond it in 18 of
21 patients. These findings were solitary with typical (16) and
atypical (2) location, retrosternal and paratracheal, respective-
ly, and corresponded to parathyroid adenomas postoperatively.
In 3 patients uptake foci were localized within nodular thyroid
gland tissue on SPECT-CT. Fine needle biopsy (FNB) on ul-
trasound guidance was performed to evaluate underlying pa-
thology in these patients. Parathyroid adenoma, follicular thy-
roid adenoma, follicular thyroid cancer were found respective-
ly. Conclusion: Сombined SPECT-CT can accurately localize
pathological parathyroid glands and estimate their size. In case
of intrathyroid uptake foci on SPECT-CT FNB should be per-
formed to clarify underlying pathology and optimal surgery
planning.
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Diagnostic accuracy of F-18 FDG PET/CT performed
after radiation therapy in patients with head and neck
cancer
W. Choi1, E. Han2, W. Lee3, Y. Park1; 1St. Vincent’s Hospi-
tal, College of Medicine, The Cathoic University Of Korea,
Suwon, KOREA, REPUBLIC OF, 2Deajeon St. Mary’s Hos-
pital, College of Medicine, The Catholic University of Korea,
Deajeon, KOREA, REPUBLIC OF, 3Chungbuk National
University Hospital, Cheongju, KOREA, REPUBLIC OF.
Purpose: To determine the diagnostic accuracy of F-18 FDG
PET/CT for locoregional recurrent or residual tumor in pa-
tients with head and neck cancer who underwent previous
radiotherapy.Methods and Materials: FDG PET/CT images
from patients with head and neck cancer who previously
underwent radiotherapy were reviewed retrospectively. Only
cases with histological confirmation within 4 weeks of diag-
nosis by FDG PET were included. Maximum standardized
uptake values were recorded and the FDG PET/CT findings
were compared with the histology results.Results: Of 181
cases, 114 (63.0%) were histologically confirmed as malig-
nant, and 67 (37.0%) as benign. The sensitivity, specificity,
and accuracy of FDG PET/CT for diagnosis were 93.9%,
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62.7%, and 82.3%, respectively. Of the 27 FDG PET/CTscans
performed within 12 weeks after the completion of radiother-
apy, there were 5 false-positive cases and there were no false-
negative cases. The sensitivity, specificity, and accuracy of
FDG PET/CT performed within 12 weeks were 100%,
55.6%, and 85.2%, respectively. The interval from radiation
therapy to PET/CT scan of the false positive cases ranged
widely from 5 days to 15 years. Of the 160 tissues with de-
tectable FDG uptake, FDG uptake in malignant tissues was
significantly higher than that observed in benign tissues (p
<0.001).Conclusions: FDG PET/CT could aid the diagnosis
of residual or recurrent malignant tumors in patients with head
and neck cancer patients who received radiotherapy, but the
diagnostic accuracy might be limited, especially by false-
positive results. Inflammation was the main cause of false
positive results even years after radiotherapy. To ensure an
accurate diagnosis for treatment planning strategies, patholog-
ic verification of tumor status is warranted.
P566
Intra-operative lymphatic mapping and sentinel node
biopsy in laryngeal carcinoma: preliminary results
R. Sadeghi1, E. Khadivi2, M. Daghighi2, K. Khazaeni2, V.
Dabbagh Kakhki1, L. Zarifmahmoudi1; 1Nuclear Medicine
Research Center, Mashhad University of Medical Sciences,
MASHHAD, IRAN, ISLAMIC REPUBLIC OF, 2Sinus and
Surgical Endoscopic Research Center, Mashhad University of
Medical Sciences, MASHHAD, IRAN, ISLAMIC REPUB-
LIC OF.
Introduction: Sentinel node mapping has been used for laryn-
geal carcinoma in several studies with excellent results thus
far. In the current study, we reported our preliminary results on
sentinel node mapping in laryngeal carcinoma using intraop-
erative peri-tumoral injection of the radiotracer.Material and
Methods: Ten patients with biopsy-proven squamous cell car-
cinoma of the larynx were included in the study. The day of
surgery, after induction of anesthesia, 2 mCi/0.4 cc Tc-99m-
Phytate in four aliquots was injected in the sub-mucosal peri-
tumoral location using a suspension laryngoscopy. After
waiting for 10 minutes, the sentinel nodes were searching for
using a portable gamma probe. All patients underwent laryn-
gectomy and modified radical bilateral neck dissection. All
sentinel nodes and removed non-sentinel nodes were exam-
ined by H&E staining.Results: Ten patients with laryngeal
carcinoma were included. At least one sentinel node could
be detected in 5 patients (bilateral in four patients). One patient
had pathologically involved sentinel and non-sentinel node
(no false negative cases).Conclusion: Sentinel node mapping
in laryngeal carcinoma is technically feasible using intra-
operative radiotracer injection. In order to evaluate the
relationship of T stage, and laterality of the tumor with accu-
racy of the technique larger studies are needed.
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Juvenilenasopharyngeal angiofibromas - in vitro
and in vivo examinations of somatostatin receptors
expression
J. Kunikowska1, W. Kukwa2, A. Cyran-Chlebicka2, D.
Pawlak3, R. Matyskiel1, &. Koperski4, Z. Gronkiewicz2, B.
Górnicka5, L. Królicki1; 1Nuclear Medicine Department,
Medical University of Warsaw, Warsaw, POLAND, 2Depart-
ment of Otorhinolaryngology, Czerniakowski Hospital, Med-
ical University of Warsaw, Warsaw, POLAND, 3Radioisotope
Centre POLATOM, National Centre for Nuclear Research,
Otwock, POLAND, 4Department of Pathology, Medical Uni-
versity of Warsaw,, Warsaw, POLAND, 5Department of Pa-
thology, Medical University of Warsaw, Warsaw, POLAND.
Juvenile nasopharyngeal angiofibroma (JNA) is a rare and
benign disease, locally aggressive nasopharyngeal tumor,
which is mainly found in adolescent male subjects. The pre-
liminary data suggested that somatostatin receptors (SSTR)
are overexpressed on JNA cells. The high density of SSTR
subtype 2 on tumor cells enables the application of somato-
statin (SST) analogues in diagnosis and therapy making it a
promising new target for therapy of the unresectable or recur-
rent JNA. The aim of this study was the analysis of SSTR2
expression on JNA cells measured by the maximum Standard-
ized Uptake Value (SUVmax) - a semiquantitative parameter
derived from 68Ga DOTATATE PET/CT and correlation it
with histopathological examination. METHODS: immunohis-
tochemical examination was performed in seven male patients
( age 17±7). The analysis of SSTR2 expression was done with
light microscopy according to immunoreactive score (IRS)
using polyclonal antibody (Sigma Aldrich). The average per-
centage of positive stained cells was estimated in 4 fields using
40x objective. PET/CT with 68 Ga DOTATATE PET/CT for
evaluation of density of SSTR2 measured by standardized
uptake value (SUVmax) was performed in all patients (Sie-
mens Biograph 64). RESULTS: In all cases immunohisto-
chemical examination showed presence of SSTR2 with in-
tense reaction. The range of positive stained cells was from
73% to 100% (IRS - 8, 12). SSTR2 distribution on JNA cells
was observed only in cytoplasm with increased density around
nuclei and emphasis on the nuclear membrane. Reaction on
cell membrane was positive only on few cells it correspond to
the visual analysis on PET/CT 68Ga DOTATATE where only
slightly increased uptake was observed. Semiquatitative anal-
ysis revealed SUVmax 4.6±1.5. On the other hand physiolog-
ical uptake was noted, where SUVmax values were the highest
in the pituitary gland 11 ±4.5, spleen18.9 ±6.6, adrenal 14.0
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±5.6, and critical organ for PRRT kidneys 14.2± 3.6. CON-
CLUSIONS: Density of SSTR2 receptor located on surface of
cells was observed only in few cells which correlated with low
uptake seen in vivo examination with 68GaDOTATATE PET/
CT. However, immunohistochemical examination showed in-
tense reaction of SSTR2 on JNA cells, but due to mainly
cytoplasmic localization these are not available for in vivo
examinations.
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Value of 18F-FDGPET/TC in the Evaluation of Treatment
Response in Head and Neck Cancer
M. Salcedo- Pujantell, C. Lorenzo-Bosquet, MD, G.
Cuberas-Barrós, S. Siurana-Montilva, MD, A. Rovira-
Cañellas, MD, J. Castell-Conesa, MD; Hospital Universitari
de Vall d’Hebronn, Barcelona, SPAIN.
AIM: To compare 18F-FDG PET/TC and MRI in the evalua-
tion of treatment response in Head and Neck Cancer, for more
than 9-12 weeks after the end of the oncologic treatment, with
histopathologic and/or clinical and imaging follow-up. MA-
TERIAL AND METHODS: Retrospective and descriptive
study of 70 patients(pts) (48 men), mean age 62.3 ± 11.1 years,
with Head and Neck Cancer, who had underwent 18F-FDG
PET/TC and MRI studies. 5 pts had nasopharynx tumours, 47
pts had oral cavity tumours/ oropharynx, 11 pts had hypophar-
ynx tumours and 7 in the salivary glands. 64 pts had squamous
cell carcinomas, 3 pts had adenocarcinomas and 3 pts had
acinars cells carcinoma. RESULTS: 26/70 of the pts (37%)
had residual primary tumour. For the detection of residual local
disease, the Kappa Coefficient between PET/TC andMRI was
0.72 (p<0.05). PET/TC showed a sensivity of 92%, a specific-
ity of 97%, a positive predictive value (PPV) of 96% and a
negative predictive value (NPV) of 95%. For the MRI we
found a sensivity of 84%, a specificity of 91%, a PPV of
85% and a NPV 90%. 27/70 of all pts included (38.5%) had
residual metastatic lymph node. For the detection of them, the
Kappa Coefficient between both techniques was 0.66
(p<0.05). PET/TC had showed a sensivity of 100%, a speci-
ficity of 97%, a PPVof 96% and NPVof 100%. For MRI we
found a sensivity of 74%, a specificity of 90%, a PPVof 83%
and a NPVof 85 %. 18F-FDG- PET/TC had good diagnostic
performance in detecting metastases in 18/70 of all pts includ-
ed and in 6/70 of the pts it was capable of detecting synchro-
nous second primary tumour. MRI only detected perineural
spread in 1/70 of all the pts included, which was not detected
with PET/TC. The results were correlated with its histopatho-
logical evaluation and/or clinical and imaging follow-up (47
months ± 20m). CONCLUSION: PET/TC is superior in de-
tecting regional lymph node metastasis and local disease.
Moreover, it has a good diagnostic performance in detecting
metastases and synchronous second primary tumour in pa-
tients with HNC. However, MRI seems to be superior in de-
tecting perineural spread.
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Are contouring time and multimodality imaging
prognostic factors for radiation therapy of advanced head
and neck cancer?
M. Schmuecking1, O. Elicin2, B. Bojaxhiu2, R. Bigler2, J.
Tille2, S. Fankhauser2, H. Thöny3, B. Klaeser4, A.
Geretschläger5; 1StrahlenzentrumHamburg/CyberKnife Cen-
ter Hamburg, Hamburg, GERMANY, 2Inselspital Bern, Dept.
of Radiation Oncology, Bern, SWITZERLAND, 3Inselspital
Bern, Dept. of Radiology, Bern, SWITZERLAND,
4Inselspital Bern, Dept. of Nuclear Medicine, Bern, SWIT-
ZERLAND, 5St. Clara Spital Basel, Dept. of Radiation On-
cology, Basel, SWITZERLAND.
Aim: In the DEGRO-Quiro Trials correlation of clinical out-
comewith contouring time in the planning process of radiation
therapy and the amount of multimodality imaging has not been
analyzed. To evaluate if contouring time and multimodality
imaging are prognostic factors for radiation therapy of ad-
vanced head and neck cancer 207 patients were analyzed ret-
rospectively between 2001 and 2012.Materials and Methods:
Before 2007 radiation treatment planning CT was done with-
out contrast enhancement, MR imaging and 18F-FDG PET/
CT as additional imaging modalities were used only occasion-
ally. From 2007 contrast enhanced planning CT in addition to
multimodality imaging consisting of MR imaging (including
DWI and ADC) and 18F-FDG PET/CTwas used routinely for
every head and neck cancer patient. Additionally, in unclear or
equivocal imaging findings of lymph nodes a re-report was
performed with a higher sensitivity at the expense of specific-
ity to minimize geographical miss in the contouring procedure
for radiation treatment and to maximize the binary decisions
for each lymph node (malignant vs. benign). The re-reports
were done in conjunction with radiooncologists, nuclear phy-
sicians and radiologists. Before 2007 the mean contouring
time was 60 min before 2007, and 150 min after 2011 (includ-
ing the time for a re-report). Clinical outcome (local, regional
and locoregional control) of advanced oropharyngeal, laryn-
geal and hypopharyngeal cancers with lymph node metastases
was assessed in two groups (group I: 2001-2007 vs. group II:
2008-2012).Results: Group I: n = 113, group II: n = 94. Re-
gional recurrence was significantly reduced in group II (log-
rank-test p = 0.03). Regional control after 1, 2 and 3 years was
88%, 79% and 76%, respectively as compared to 95%, 92%
and 88%, retrospectively. Locoregional control for 207 pa-
tients shows no difference in survival (p = 0.08), inclusionof
340 patinets leads to a p-value p < 0.05.Conclusion: Imaging
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findings of multimodality imaging and a critical re-report of
these imaging findings in conjunction with a longer
contouring time may have an impact on clinical outcome.
However, this overtime is not reimbursed. A close collabora-
tion of radiooncologists, nuclear physicians and radiologists in
the radiation treatment planning process may have a benefit for
patients with advanced head and neck cancer.
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Impact of 18F FDG PET CTon Initial Management
of Patients Presenting with Secondaries in Neck from an
Unknown Primary
M. SARMA, P. SUBRAMANYAM, P. SUNDARAM;DEPT.
OF NUCLEARMEDICINEAND PET CT, AMRITA INSTI-
TUTE OF MEDICAL SCIENCES AND RESEARCH CEN-
TRE (AMRITA VISHWA VIDYAPEETHAM), COCHIN,
INDIA.
AIM: To assess the impact of 18F FDG PET CT on initial
management of patients presenting with cervical nodal metas-
tases from an unknown primary. MATERIALS &
METHODS: 38 patients (M:F=30:8, age =32-80 years, mean
age= 57.9 ± 13.39 years) with palpable histologically malig-
nant neck node(s) were prospectively evaluated with FDG
PET CT. Their initial physical examination, endoscopies and
anatomical imaging to look for an unknown primary malig-
nancy were negative. Lymphomas, haematopoietic malignan-
cies, patients with history of previous treatments for head/neck
malignancies or any other malignancy were excluded. Data of
neck lymph nodal level by clinical examination, findings of
FNAC/histopathology of lymphnodes, CT/MRI , FDG PET
CT, FNAC or endoscopic findings from PET guided biopsies
of suggested occult primaries and subsequently therapeutic
decisions based on the PET CT results were analysed. RE-
SULTS: PET CT findings changed the initial management in
12/38 patients (31.5%). Among 11 patients whowere detected
with a primary malignancy, management changed in 8 pa-
tients. In 27 patients where the primary was not identified,
there was change in management in 4/27 patients. The leading
changes were in the radiation therapy (RT) field in 15 .7 %
patients followed by initiation of palliative chemotherapy in
7.8% of patients. Patients with all N staging (AJCC 2010) had
management change, except in N2a staging. Fisher Exact Test
was performed to see the if there was any association between
pre PET CT N staging (compared between N1/N2a and N2b,
N2c, N3) and management change. P value of 0.644 (>0.05)
suggested that there is no association between lower or higher
pre PET CT N staging (multiplicity/ bilaterality/ large nodal
size) and possibility of change of management upon investi-
gation with FDG PET CT. 2 out of 12 (31.5%) patients pre-
senting with supraclavicular lymphnodes had change in their
subsequentManagement. CONCLUSION:Management strat-
egy gets individualised when the exact status of a possible
primary (either detected or not), presence of contralateral met-
astatic nodes and presence/absence of distant nodal or organ
metastases is accurately determined. Value of FDG PET CT in
patients presenting with supraclavicular lymphnodal metasta-
ses from an adenocarcinoma or a poorly differentiated carci-
noma needs to be further critically evaluated.
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Analysis of 18F-FDG PET/CT parameters in patients
with head and neck soft tissue sarcoma
S. Baek, D. Yoon, E. Yun, Y. Seo, K. Lim, J. Kim; Kangdong
Seong-Sim Hospital, Hallym University College of Medicine,
Seoul, KOREA, REPUBLIC OF.
Purpose: Head and neck soft tissue sarcoma (HNSTS) is
an extremely rare malignancy. The clinical use of 18F-
fluorodeoxyglucose (FDG) positron emission tomogra-
phy (PET) has been well demonstrated in head and neck
squamous cell carcinomas (HNSCCs) but is unclear in
HNSTS. The purpose of this study was to analysis
quantitative parameters seen on PET/CT using 18F-
FDG for understading of tumor charateristics in patients
with HNSTS.Materials and Methods: 14 patients (10
males and 4 females; mean age, 45.1 ± 18.8 years;
age range, 18 to 86 years) with pathologically proven
HNSTSs were included in this retrospective study. PET/
CT parameters_maximum standardized uptake value
(SUVmax), mean standardized uptake value (SUVmean),
and metabolic tumor volume (MTV), total lesion glycol-
ysis (TLG)_were recorded. The association between the
PET parameters and histologic grade and disease-free
survival (DFS), were assessed.Results: The most com-
mon histologic type was Undifferentiated pleomorphic
sarcoma (n = 4),i leimyosarcoma (n = 3), and
angiosarcoma (n = 3). And the most common location
of HNSTSs is the paranasal sinus (n = 7) in our study
population. The SUVmax of primary tumors was 7.1 ±
3.7 (range, 3.4-16.7;), the SUVmean was 4.7 ± 2.8
(range, 2.2-12.1), the MTV was 18.3 ± 18.7 cm3 (range,
1.4-66.5cm3), and the TLG was 75.1 ± 64.0 g (range,
6.0-1707.8 g). All of FDG PET/CT parameters, includ-
ing SUVmax, SUVmean, MTV and TLG, did not statis-
tically correlate with the histologic grade of sarcoma (P
> 0.05). The SUVmean (>5) of the primary tumor were
significantly associated with negative effects on DFS (P
< 0.01), where as other parameters were not.Conclusion:
Our data indicate that the pretreatment PET/CT parame-
ters may be useful for understanding of tumor and
predicting prognosis in patient with HNSTSs
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Soft Tissue Sarcoma of the Head and Neck: CT, MRI,
and FDG-PET/CT Imaging Findings
S. Baek, D. Yoon, J. Kim; Kangdong Seong-Sim Hospital,
Hallym University College of Medicine, Seoul, KOREA, RE-
PUBLIC OF.
Purpose: Head and neck soft tissue sarcoma (HNSTS) is an
extremely rare malignancy. The purpose of this study was to
describe the imaging features of HNSTS. Materials and
Methods: Nineteen patients (11 males and 8 females; mean
age, 48.4 ± 22.3 years; age range, 3 to 86 years) with patho-
logically proven HNSTSs were included in this retrospective
study. Imaging studies including computed tomography (CT)
(n = 19), magnetic resonance imaging (MRI) (n = 16), and
fluorodeoxyglucose (FDG) positron emission tomography/
CT (PET/CT) (n = 14) were reviewed for characteristics of
tumors, such as shape, size, margin, MRI signal intensity, cal-
cification, pattern and degree of enhancement, local tumor
invasion, lymph node metastasis, and maximum standardized
uptake value (SUVmax). Results: HNSTSs were most com-
monly located in the paranasal sinus (n = 5) and skeletal mus-
cle (n= 3). The most common histologic type was rhabdomyo-
sarcoma (n = 6), undifferentiated pleomorphic sarcoma (n = 3),
and angiosarcoma (n = 3). Most masses had lobular shape
(37%), size >5 cm (42%), well-defined margins (53%), iso-
signal intensity on T1-weighted image (88%), high signal in-
tensity on T2-weighted image (63%), homogeneous (63%)
and marked (58%) enhancement, local tumor invasion
(63%), and SUVmax of 5.0-10.0 (50%). One (5%) patient
had cervical lymph nodes metastases and distant metastases
to bones. Conclusion: The imaging features for HNSTS are
variable, thus are often indistinguishable from other tumors.
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Diagnosis of distant recurrent breast cancer: head-to-head
comparisons of FDG-PET/CT, contrast enhanced CT,
and bone scintigraphy
M. G. Hildebrandt1, O. Gerke1, C. Baun1, K. Falch1, J.
Ansholm1, Z. Farahani1, L. Larsen1, S. Duvnjak1, K. Soe1,
A. B. Jylling1, M. Ewertz1, A. Alavi2, P. Hoilund-Carlsen1;
1Odense University Hospital, Odense, DENMARK, 2Univer-
sity of Pennsyalvania, Philadelphia, PA, UNITED STATES.
Aim: Recommendations for diagnostic work-up in patients
with suspected recurrent breast cancer are yet undefined. The
aim of this study was to investigate the diagnostic accuracy for
distant recurrence of dual time point FDG-PET/CT compared
to contrast enhanced CT (ceCT) and bone scintigraphy (BS) in
patients with suspected recurrent breast cancer. Material and
methods: In this prospective study, 100 female patients with
suspected recurrent breast cancer underwent 1 hour (1h) and 3
hour (3h) FDG-PET/CT, ceCT, and BS within a median time
interval of 10 days. Images were interpreted visually, and
readers were blinded to other test results. Biopsy, clinicians’
decision of treatment, and clinical follow-up (median 17
months, range: 0, 36) served as reference standard. Patient
based accuracy results were calculated, including measures
of area under the receiver operating curve (AUC-ROC, based
on visually interpreted 4-point assessments, and with 95%
confidence intervals (95% CI). Results: Twenty-two patients
(22%) suffered distant recurrence, 18 (18%) with bone in-
volvement. The accuracy of 1h and 3h FDG-PET/CT imaging
was similar; therefore, only 1h results have been presented
below. The AUC-ROC, sensitivity, specificity, and likelihood
ratios for positive and negative tests were for FDG-PET/CT
0.99 (95% CI: 0.97-1), 1 (0.85-1), 0.91 (0.83-0.96), 11.1 (5.5-
22.6), and 0 (N/A); for ceCT 0.84 (0.73-0.94), 0.77 (0.57-
0.90), 0.83 (0.74-0.90), 4.6 (2.7-8.0), and 0.3 (0.1-0.6); and
for ceCT+BS 0.86 (0.77-0.94), 0.91 (0.72-0.97), 0.72 (0.61-
0.81), 3.2 (2.2-4.7), and 0.1 (0.03-0.5), respectively. Conclu-
sion: The overall accuracy was significantly higher with FDG-
PET/CT than with ceCT and ceCT+BS, and so without differ-
ence between conventional imaging at one hour than at three
hours after FDG-injection. FDG-PET/CT was excellent in
ruling out distant recurrence and did so with only few false
positives. Thus, molecular imaging in the shape of FDG-PET/
CT may be the modality of choice for imaging in suspected
breast cancer recurrence.
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Visualization of internal mammary sentinel lymph nodes
in patients with breast cancer - the corn stone
for radiotherapy planning
S. N. Novikov, S. Kanaev, P. Krzhivitsky; N.N. Petrov Insti-
tute Oncology, St Petersburg, RUSSIAN FEDERATION.
Background: lymphoscintigraphy can be used as effective tool
for visualization of sentinel lymph nodes (LN) localized in
internal mammary (IM) region and in combination with clin-
ical risk factors help to estimate the risk of IMLN metastatic
invasion by breast cancer (BC). Objective: On the basis of
scintigraphic data and known clinical risk factors to calculate
probability of IMLN metastatic invasion in patient included in
randomized and observation studies analyzing clinical value
of radiotherapy to IMLN. To evaluate clinical value of
lymphoscintigraphy as the guide for irradiation of IMLN.
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Methods. Using the data of 8 published studies that analyzed
lymph flow from primary BC (4541 patients) after intra-
peritumoral injection of nanosized 99mTc-colloids we deter-
mined probability of lymph flow from internal/central and
lateral primary BC to IMLN. In 7 studies (4359 women) axil-
lary staging was accompanied by IMLNbiopsy that helps us to
estimate probability of IMLN metastatic invasion in relation
with the status of axillary LN. Finally we estimated probability
of IMLN invasion by BC in 4 randomized and 2 observation
studies that analyzed effect of IMLN irradiation on overall
survival. In these pts we calculated possible additional gain
survival if they would be treated according to lymph flow
guided radiotherapy to IMLN. Results: Lymph-flow from
internal/central BC to IMLN was detected in 16% (727/
4541), from lateral lesions - in 35% (1589/4541). In women
with negative axillary LN metastases in IMLN were revealed
in 7.8%, in patients with positive axillary nodes - in 38.1%.
Calculated probability of IMLN metastatic invasion in “high
risk patients” include in all evaluated studies didnt exceed
10%. If lymphoscintigraphy would drive decision whether to
irradiate IMLN or not than 72.1%-76.8% of “high risk pa-
tients” would escape RT to IMLN. In remained 23.2%-
28.9% patients with lymph flow to IMLN their irradiation
would improve overall survival from 1.6%-3.3% to 6.9%-
14.2% Conclusion: performed analysis proves that radionu-
clide visualization of lymph flow from DC plays an important
role in decision making about usefulness of IMLN irradiation.
In patients with lymph flow to IM LN irradiation of IMLN can
dramatically (6.9%-14.2%) improve 5 and 10 yeas overall
survival.
P575
Role of MUGA scan in diagnosis of the effect
of trastuzumab (Herceptin) on global and segmental left
ventricular ejection fraction in patients with breast cancer
S. M. W. Yassin1, K. Salman1, A. Mostafa1, M. Abd El
Kareem2,W. Mohamerd1, A. Abd El Samee2, Y. Mohamed2,
E. Abo El-Naga1, S. Abd El Razek3; 1King Abdulla Medical
City (KAMC), Jeddah, SAUDI ARABIA, 2Cairo University,
Cairo, EGYPT, 3Assuit University, Assuit, EGYPT.
Intrduction: Trastuzumab (Herceptin) is a monoclonal anti-
body target therapy in positive HER2 breast cancer patients.
Cardiac dysfunction is the side effect of greatest clinical con-
cern of trastuzumab, probably because it blocks the HER2
receptors which protect adult cardiomyocytes. Cardiac toxicity
reported to be 4% in patients on trastuzumab alone, increasing
up to 13% if given with paclitaxel and up to 27% with
anthracycline plus cyclophosphamide. Cardiac dysfunction
was reported to be mild and asymptomatic in majority of pa-
tients. MUGA scan with evaluation of ejection fraction (EF) is
the most commonly used tool for cardiac monitoring during
therapy. Aim: To study effect of trastuzumab on global and
segmental EF using MUGA scan. Patients and methods: 32
females with breast cancer and no history of cardiac problems
and normal base line MUGA scan treated with trastuzumab,
with asymptomatic reduction of global EF in follow up
MUGA scan were included in the current study. Patients were
followed up prior to each cycle byMUGA scan. The degree of
reduction of global and segmental LVEF were calculated.
Treatment was interrupted if EF is reduced below normal lev-
el(50%). Results: Reduction of global EF ranges from 1-17%
with a mean value of 7.6%. Global EF reduction was below
5% in 16 patients( 50%), from5-10% in 11 patients (34.4%)
and from 10% to < 20% in the remaining 5 patients (15.6%).
EF below normal value (50%) was reported in 3 patients
(9.4%), which was reversible in follow up MUGA scanning
2-3 months post cessation of trastuzumab . The reduction of
segmental EF was reported in all myocardial walls. The degree
of EF diminution in anterior, anteroseptal, inferoseptal, inferi-
or, inferolateral and superolateral left ventricular myocardial
walls was reported with values of 9.03%, 5.7%,5.9, 9.6%,
9.9% and 9.8% respectively. with statistically significant less
diminution of EF in septal myocardial segments compared to
rest of myocardial segments. Conclusion: . Reduction of EF in
patients treated with trastuzumab is below 10% in majority of
patients ( 84.4% ) and from 10- <20% in the remaining 15.6%
patients, with a mean value of reduction of global EF of 7.6%.
Reversible EF diminution below normal that necessitates in-
terruption of trastuzumab therapy occurs in 9.4% of patients.
Variable degrees of diminution of segmental EF in all myocar-
dial wall segments was reported, significantly less evident re-
duction of segmental EF was reported in anteroseptal and
inferoseptal segments, impressive of less cardiotoxic effect
of trastuzumab on the thinner septum.
P576
Therapy Response Evaluation of Patients with Locally
Advanced and Metastatic Breast Cancer: Comparison
of Anatomic and Metabolic Criteria for Early
and Accurate Response Assessment
B. Gunalp1, M. Erdogan2, S. Ince1, E. Balkan1, E. Alagoz1,
A. Ayan1, N. Arslan1; 1Gulhane Military Medical Academy
and Medical Faculty, ANKARA, TURKEY, 2Diskapi
Yildirim Beyazit Egitim ve Arastirma Hastanesi,, ANKARA,
TURKEY.
Objectives: Therapy response evaluation is important for
avoiding ineffective toxic and expensive chemotherapies in
early phase of treatment and changing therapy regimen to
more effective ones. Anatomic (RECIST 1.1) and metabolic
(EORTC and PERCIST 1.0) criteria have been proposed for
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the therapy response evaluation in solid tumors. Therapy re-
sponse evaluation in specific tumor types with FDG-PET/CT
using both anatomic and metabolic criteria is limited in the liter-
ature. In this retrospective study, we try to determine the most
applicable and accurate criteria for the therapy response evalua-
tion in locally advanced (LABC) and metastatic breast carcino-
ma (MBC) patients. Methods: Twenty two LABC and 34 MBC
patients underwent baseline and at least one FDG-PET/CTscans
for response assessment, between 2011 and 2014 were included
in this study. Baseline and follow-up PET/CT scans were ana-
lyzed measuring the dimensions on CT and SUV Max, SUL
peak of up to 5 lesions on PET. These criteria were compared
with clinical, pathological findings and progression free survival
rates of the patients for evaluation of therapy response. Results:
After neoadjuvant chemotherapy in LABC patients PET classi-
fied as complete response (CR) in 4 (18%), partial response (PR)
in 5 (22%), stable disease (SD) in 6 (27%) and progressive
disease (PD) in 7 (31%) patients. PET and CT sensitivity and
specificity for the response evaluation were found 85%, 80%
and 65%, 60% respectively. In MBC group, twelve (64%) pa-
tients had bone, six patients (17%) had liver, 5 patients (14%)
had lung, 3 patients (8%) had brain metastases, 2 patients (5%)
had chest wall invasion and malign pleural effusion. According
to PERCIST 1.0 and EORTC criteria, there were CR in 4 (10%),
PR in 8 (21%), SD in 2 (5%), PD in 12 (31%) and mixed
response in 12 (33%) patients. Bone lesions in 10 patients
(83%), liver lesions in 4 patients (66%) and chest wall invasions
and malign pleural effusions were not measurable anatomically
on CT. Conclusion: PERCIST 1.0 and EORTC criteria were
found more accurate and applicable than RECIST 1.1 criteria
in early response assessment and therapy response evaluation
of bone metastases, chest wall invasions, malign pleural effu-
sions and liver metastases. On the other hand RECIST 1.1
criteria were superior in response assessment of lung metastases.
FDG-PET/CTovercomes limitations of both anatomic and met-
abolic criteria alone and gives the opportunity to revise treatment
and improve outcome in breast cancer patients.
P577
Prognostic Value of Semiquantitative Tumor Uptake
on Tc-99m Sestamibi Breast-Specific Gamma Imaging
in Invasive Ductal Breast Cancer
S. Jang1, H. Yoon2, Y. Kim3, B. Kim2; 1Dep. nuclear med-
icine, Sheikh Khalifa Specialty Hospital, Ras al Khaimah,
UNITED ARAB EMIRATES, 2Dep. nuclear medicine, Ewha
Womans University School of Medicine, Seoul, KOREA, RE-
PUBLIC OF, 3EwhaWomans University School of Medicine,
Seoul, KOREA, REPUBLIC OF.
Objectives: This study investigated the prognostic value of
preoperative breast-specific gamma imaging (BSGI) uptake
measured by a semi-quantitative method in invasive ductal
carcinoma (IDC). Methods: One hundred sixty-two women
with IDC who underwent preoperative BSGI were retrospec-
tively enrolled. The tumor-to-normal tissue ratio (TNR) was
measured on BSGI and correlated with histologic prognostic
factors. The prognostic impact of TNR was tested with regard
to progression-free survival (PFS) and compared with
established prognostic factors. Results: High TNR was signif-
icantly correlated with tumor size >2 cm (p<0.001), high nu-
clear grade (p=0.04), high histologic grade (p=0.01), axillary
node positivity (p=0.04), ER negativity (p=0.03), HER2 pos-
itivity (p=0.01), and highMIB-1 index (p=0.001). Among 162
patients, 14 experienced recurrence during mean the
follow-up time of 34.7±14.9 months. In Kaplan-Meier
survival analyses, high TNR (p<0.001), high nuclear
grade (p=0.02), high histologic grade (p=0.007), ER/PR
negativity (p=0.003 and p<0.001, respectively), HER2
positivity (p=0.01), triple negativity (p=0.02), and high
MIB-1 index (p=0.02) showed a significant relationship
with poor prognosis. Among them, high TNR was an
independent poor prognostic factor in a multivariate re-
gression analysis (p=0.01). Conclusions: High BSGI up-
take measured by a semi-quantitative method was corre-
lated with diverse poor histologic prognostic factors and
was an independent poor prognostic factor in invasive
ductal cancer. (This research was supported by the Na-
t i ona l Res ea r ch Founda t i on (NRF) o f Ko rea
(2012R1A1A1012913 and 2012M3A9B6055379)).
P578
Breast cancer patients with bone metastases reveled
by FDG-PET showed worse long-term survival than those
reveled only by bone scan.
Y. Huang, P. Lee, M. Liu; Koo-Foundation, Sun Yat-Sen Can-
cer Center, Taipei, TAIWAN.
Aim: The discrepancy between bone scan and FDG-PET in
detecting bone metastasis of breast cancer had been well
established. The FDG-PETshowedmore promising sensitivity
in osteolytic lesion while the bone scan is better for osteoblas-
tic group. This retrospective study is aim to compare the long-
term survival of the patients with bone metastases reveled by
FDG-PET and those with bone metastases reveled only by
bone scan. Material and method: Between January 2006 and
September 2010, 130 patients with advanced nodal status or
locally advanced breast cancer performed both bone scan and
FDG-PET performed within 7 days. The status of bone metas-
tases were carefully reviewed and linked to the survival data
base in March 2015. A total of 100 patients have sufficient
information for statistical analysis. The patients were classified
as three groups: A. negative for bone metastases on both
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studies; B, bone metastases revealed by bone scan only; C.
bone metastases revealed by FDG-PET with or without bone
scan uptake. Result: Twenty out of the 100 patient (20%) were
found to have bone metastases while 80 patients (group A)
were free of bonemetastases. In 7 out of the 20 (35%) patients,
the bone metastases revealed only on the bone scan (group B),
and the rest 13 (65%) patients revealed FDG-PET positive
bone metastases (group C). The 10-year survival of group A,
B, and C were 69.4%, 42.9% (p=0.1152; HR=2.4, 0.8-7.0),
and 18.5% (p=0.0005; HR=3.6, 1.8-7.5), respectively. Con-
clusion: Compared to the bone metastases free patients, breast
cancer patients with bone metastases revealed by FDG-PET
had significant worse long-term survival than those with bone
metastases revealed only by bone scan. Thus, FDG-PET may
serve better prognostic value.
P579
Comparison of FDG PET/CT and bone scan for diagnosis
of metastatic bone involvement in breast carcinoma
patients: A retrospective analysis
B. Yazici, A. Oral, Z. Ozcan; Ege University Medical Faculty
Deparment of Nuclear Medicine, Izmir, TURKEY.
Aim: In this study, the value of F-18 FDG PET/CT for the
detection of bone metastasis in breast cancer (BC) was evalu-
ated and compared with Tc-99m MDP bone scan (BS) which
is a common but poor specific modality. Materials and
Methods: A total of 83 patients (F/M: 79/4, mean age: 55.7)
with BC in whom FDG PET/CTand BS were performed with-
in 3 months were included. The diagnosis of bone metastasis
was established by combining all imaging findings and clinical
follow-up. Histopathology, Ki-67 index, CA15-3, SUVmax
values were reviewed. Statistical significance was tested by
Mann-Whitney U and Pearson Chi-square tests. The ability
of FDG PET, FDG PET/CT and BS to detect bone metastasis
was assessed by ROC analysis. As regard to area under the
curve (AUC), parameters were classified as inaccurate
(AUC<0.50) , low (AUC=0.50-0.70) , moderately
(AUC=0.70-0.90) or as highly accurate (AUC>0.90). Results:
A total of 267 bone lesions were detected in 83 patients. In 16
patients, 217 lesions were accepted as metastasis considering
all the clinical data. In 67 patients there were no bone metas-
tases. The frequency of elevated CA15-3 (>25 U/mL) (84.6%)
was higher in metastatic patients (P<0.01). Ki-67 index differ-
ence between the groups was insignificant (P=0.64). Of the
217 metastatic bone lesions, 203 (93.5%) were FDG
(P<0.01) and 132 (60.8%) were MDP avid (P=0.49). The
mean value of SUVmax (7.2±5.3) in metastatic foci was sig-
nificantly higher than non-metastatic bone lesions (P<0.01). In
the metastatic lesions, 149 (68.7%) were osteolytic and 68
(31.3%) were sclerotic. The frequency of lytic metastasis in
FDG avid and the frequency of sclerotic metastasis in MDP
avid metastases were significantly high (P<0.01). Of the lytic
metastases, 98.7% were FDG avid but only 49.7% were MDP
avid. On the other hand, avidity of FDG and MDP in sclerotic
metastasis was not very different (82.4% and 85.3% respec-
tively). While FDG PET/CTwas highly accurate (AUC>0.90)
for the detection of bone metastasis, BS showed poor accuracy
(AUC<0.50). Sensitivity of BS, FDG PET and FDG PET/CT
were 60.8%, 93.6% and 100%; specificity were 34.0%, 93.6%
and 96.0% respectively. Conclusion: It is noted that while lytic
metastases showing low avidity for MDP may lead to low
sensitivity on BS, those non-metastatic bone lesions with high
MDP uptake cause poor specificity. The results of the current
study suggest that the accuracy of FDG PET/CT is higher than
BS in the detection of metastatic bone diseases in BC.
P580
Pathological Correlation of Mild Focal Uptake
on the Tc-99m MIBI Breast specfic gamma camera
imaging.
S. Yoon; DanKook University College of Medicine, Cheil
General Hospital, Women’s Cancer Center, Seoul, KOREA,
REPUBLIC OF.
Purpose: In our hospital, 303 cases were pathologically con-
firmed by only routine early images, the sensitivity and spec-
ificity of BSGI were 90% and 60% because of many false
positive lesions such as fibroadenoma, etc. BSGI using Tc-
99m MIBI showed lower specificity due to many benign le-
sions. Images were usually categorized as score 1-5. Scores of
1, 2, and 3 were classified as negative, and scores of 4 and
5were classified as positive. In this study, we investigated the
clinical significance of mild focal uptake(Score 4) on the im-
age using breast specific gamma camera image for differenti-
ation of benign and malignant breast lesions. Methods: Pa-
tients were injected with 925-1110 MBq of Tc-99m MIBI in
the ante-cubital vein of the contralateral arm of the breast le-
sion. Imaging was performed 10 minutes after injection with a
dedicated high-resolution, breast-specific gamma camera
(Dilon 6800, Dilon Technologies, USA). Standard
craniocaudal and mediolateral oblique views for each breast
were obtained for five minutes each. We categorized images
by visual analysis A total of 20 patients underwent pathologic
confirmation with mild focal uptake on routine breast gamma
camera imaging were evaluated. Results: Pathological results
of malignancy and benign were then correlated with the image
analysis to have mild focal uptake on the scintimammography.
Nine (45%) among 20 patient underwent pathologic examina-
tion were malignant lesions, 7 of which were invasive ductal
carcinoma and 2 were adenoid cystic cancer and mucinous
cancer each. There were 11 false-positive lesions (55%),
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defined as a BSGI examination with positive findings and 10
fibroadenomas were the most common pathologic finding
showing the false positive results. Finally fibroadenomas were
50% of all mild focal uptake and 91% of false positive benign
lesion. Conclusion: Although only small number of patients,
mild focal uptake by degree of uptake criteria for differentia-
tion of benign vs malignant lesion using BSGI may be causes
of many false positive imaging interpretation. About half
breast lesion with mild focal uptake were not malignant lesion.
The most common pathologic lesions inducing many false
positive interpretation were fibroadenoma. Further studies will
be needed to define usefulness of BSGI in large population.
P581
Contralateral axillary sentinel lymph node in breast
cancer patients: an uncommon lymphatic drainage
T. Tanaka, S. Sato, R. Inai, A. Tada, S. Kanazawa; Depart-
ment of Radiology, Okayama University Hospital, Okayama,
JAPAN.
[aim] For the lymphatic mapping of breast cancer, the methods
using radioisotope with or without blue dye injection are su-
perior to those using blue dye only. Sometimes we encounter
the occult sentinel lymph nodes in preoperative scintigraphy
that are difficult to find out in other modalities. Uncommon
sentinel lymph nodes poses management dilemma for clini-
cians. The purpose of this study was to review atypical sentinel
lymph nodes, especially contralateral axillary lymph node, in
breast cancer patients. [materials and methods] We reviewed
942 breast cancer patients who performed preoperative senti-
nel lymph node scintigraphy at Okayama University Hospital
between April 2004 and March 2015. In all patients, Tc-99m
stannous phytate was injected peritumourally, and the injec-
tion sites were massaged. We evaluated lymphoscintigraphy
results and patient characteristics, such as age, primary tumour
location, pathological result and past medical history. [results]
The contralateral sentinel lymph nodes were detected in 3
patients (0.32%). Two patients with contralateral sentinel node
had lower medial tumours and the other patient had a lower
lateral tumour. Bilateral lymph nodes were visualized in 2
patients, and 1 patient showed contralateral axillary lymph
node only. The patients with contralateral sentinel lymph node
have no previous chest or breast surgery. No local recurrence
of the contralateral axillary lymph node was observed. Other
atypical lymph nodes including infra- or supraclavicular were
visualized in 5 patients (0.53%), and parasternal lymph nodes
were detected in 21 patients (2.22%). [conclusion] Although
the visualization of contralateral axillary lymph nodes was rare
as previous reports, we need to pay attention for the existence
of contralateral axillary lymph nodes in preoperative sentinel
lymph node biopsy for precise staging.
P582
Comparison of Subareolar Injection Lymphoscintigraphy
with the 1 Day and the 2 Day Protocol for the Detection
of Sentinel Lymph Nodes in Patients with Breast Cancer
E. Lee, J. Seok; Department of Nuclear Medicine, Chung-Ang
University, Colleage of Medicine, Seoul, KOREA, REPUB-
LIC OF.
Objectives: Lymphoscintigraphy and sentinel node biopsy
were used for the detection of axillary lymph node metastasis
in breast cancer patients. We compared the results of
subareolar injections on the day of surgery (1 day protocol)
with injections the day before surgery (2 day protocol).
Methods: This study included 813 breast cancer patients
who underwent surgery between 2001 and 2015. For the
1 day protocol 0.8 ml of Tc-99m Tin-Colloid (37MBq) was
injected in 500 patients in the subareolar region on the morn-
ing of the surgery. For the 2 day protocol 0.8 ml of Tc-99m
Tin-Colloid (185MBq) was injected in 313 patients on the
afternoon before surgery. Lymphoscintigraphy was performed
in the supine position and sentinel node identification was
performed by hand-held gamma probe during surgery.
Results: Among 500 patients with the 1 day protocol, 471
cases (94.2%) were ident i f ied by sent ine l node
lymphoscintigraphy, and 475 cases (95.0%) were identified
by gamma probe. Among the 313 patients, in the 2 day proto-
col, 290 cases (92.7%) had the sentinel node identified by
lymphoscintigraphy, and 280 cases (89.5 %) had the sentinel
node identified by the gamma probe. There was no significant
difference in the identification rate of the sentinel node be-
tween the 1 day and 2 day protocol by lymphoscintigraphy
and the gamma probe. Conclusions: The results of the identi-
fication of the sentinel node according to 1 day or 2 day pro-
tocols showed no significant differences. Because the 2 day
protocol allows for an adequate amount of time to perform the
lymphoscintigraphy, it is a more useful protocol for the iden-
tification of sentinel nodes in patients with breast cancer.
P583
Comparison of the Efficiency for Tc-99m Tin-Colloid
and Tc-99m Phytate in Sentinel Node Detection in Breast
Cancer Patients
E. Lee, J. Seok; Department of Nuclear Medicine, Chung-Ang
University, Colleage of Medicine, Seoul, KOREA, REPUB-
LIC OF.
Lymphoscintigraphy and sentinel node biopsy has become a
standard method for detection of axillary lymph node metas-
tasis in breast cancer patients, but the standard radiopharma-
ceutical was not prepared. About detection of axillary lymph
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node metastasis by lymphoscintigraphy and sentinel node bi-
opsy in breast cancer patient, we compared the results of Tc-
99m Tin-colloid and Tc-99m Phytate by subareolar injection.
Methods: This study included 813 breast cancer patients who
were performed operation during 2001-2015. Four hundred
twelve patients were injected 0.8 ml of Tc-99m Tin-colloid
(37-185 MBq) by subareolar injection. Four hundred one pa-
tients were injected 0.8 ml of Tc-99m Phytate (37-185 MBq).
Lymphoscintigraphy was performed in supine position and
sentinel node localizationwas performed by hand-held gamma
probe in operation. Results: Among 412 patients by Tc-99m
Tin-colloid, 374 cases (90.8%) were localized the sentinel
node by lymphoscintigraphy and 367 cases (89.1%) were lo-
calized by gamma probe. Among 401 patients by Tc-99m
Phy ta t e , 387 case s (96 .5%) we re loca l i zed by
lymphoscintigraphy and 388 cases (96.8%) were localized
by gamma probe. The detection rate by lymphoscintigraphy
and gamma probe was superior for Tc-99m Phytate compared
to that for Tc-99m Tin-colloid, with a statistically significant
difference. (p<0.05, p<0.05) Conclusions: Tc-99m Phytate is
a better choice for localization of sentinel node than Tc-99m
Tin-colloid in breast cancer patients.
P584
The addictional value of 18F-FDG PET/CT in pre
and post-operative setting in patients with locally
advanced breast cancer
L. Evangelista, A. Cervino, S. Michieletto, T. Saibene, E.
Bezzon, F. Pomerri, F. Bozza, C. Ghiotto, G. Saladini; Istituto
Oncologico Veneto I.R.C.C.S., PADOVA, ITALY.
Purpose: the primary end-point of the present study was to
determine the additional value of FDG PET/CT in patients
with breast cancer at high risk of recurrence, in pre and post-
operative setting. The secondary purpose was to determine the
impact of FDG PET/CTon treatment planning in these patient
subsets. Materials and methods: we prospectively collected
data from 255 women (age: 53±12 years; range:23-85 years)
with a diagnosed locally advanced breast cancer (LABC) who
performed FDG PET/CT examination before (n=137, 53.7%)
or after surgery (n=118; 46.3%). The mean period between
surgery and PET/CT was 45±22 days. The images were visu-
ally and semiquantitatively analyzed and compared with other
imaging modalities, biopsy or histology, as appropriate. The
treatments were planned by a multidisciplinary team, accord-
ing to the current recommendation. True positive rate (TPR)
and false positive rate (FPR) were calculated by standard
methods. The differences between categorical data were
assessed using Yates-corrected chi-square test. Results: FDG
PET/CTwas positive in 36 (30.5%) and doubtful in 13 (11%)
among post-operative subjects, while it resulted positive in all
pre-operative patients. In this latter group, PET/CT showed an
abnormal FDG-uptake in breast and breast with homolateral
axillary lymph nodes in 30 (22.1%) and 55 (40.4%) patients,
respectively. Moreover, additional sites of disease were
depicted in 29 (21.3%) and 22 (16.2%) patients, respectively
for extra-axillary lymph nodes and distant organs. Conversely,
7 (16.3%) patients of post-operative subset showed a positive
PET/CT at breast level, 10 (23.3%) in homolateral axillary
lymph nodes, 14 (32.6%) in extra-axillary lymph nodes and
12 (27.9%) in distant organs. TPRs and FPRs in detecting
distant metastases and/or residual disease, in pre and post-
operative settings were 94% and 81% vs. 6% and 19%, respec-
tively. Finally, the change in treatment was reported in 35
(13.7%) patients, 17 in pre-operative and 18 in post-
operative group (12.4% vs. 15.3%, respectively; p=0.510).
Conclusions: FDG PET/CT scan in the evaluation of LABC
appears necessary either before or after surgery, being associ-
ated with a high TPR in depicting extra-axillary lymph nodes
and distant organ involvement. In particular, the treatment
change results higher in post-operative than in pre-operative
group, although not statistically significant. Anyway, a reduc-
tion in health costs could be obtained.
P585
Impact of radioguided occult lesion localization plus
sentinel node biopsy after neoadyuvant chemotherapy
in breast cancer.
I. Cepedello Boiso, M. Ureña Lara, J. Jiménez Anula, C.
Ramírez Tortosa, J. Díaz Alarcón; Complejo Hospitalario de
Jaén, Jaén, SPAIN.
AIM:. Neoadyuvant chemotherapy in breast cancer could be a
valuable method to determine the efficacy of chemotherapy
and potentially downsize the primary tumor, wich facilitates
breast-conserving therapy. The aim of this study was to inves-
tigate the feasibility, accuracy and clinical significance of
radioguided occult lesion localization plus sentinel node biop-
sy after neoadyuvant chemotherapy. MATERIALS AND
METHODS: Prospective study performed from January
2009 to April 2015. Radioguided occult lesion localization
plus sentinel node biopsy was performed after neoadyuvant
chemotherapy in patients with breast cancer ( tumor size >
3 cm or tumor size < 3 cm not suitable for breast-conserving
surgery and axilary node negative). Axillary status was
established by physical examination, ultrasound-guided core
needle biopsy of any suspicious lymph node. SNOLL were
carried out using standard 99mTc-colloid (activity of 3 mCi
and 0,2-0,5 ml volumen) injected directly into the lesion (ste-
reotactic or ultrasound guindance) and in the cases of no lym-
phatic migration, realised subdermal injection. An intraopera-
tive macroscopic examination of the specimen with margins
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evaluation was always performed. The Sentinel Lymp Node
(SLN) were analysed by One-Step Nucleic Acid Amplifica-
tion (OSNA). SLN was considered to be positive if
macrometastases or micrometastases were found, and in such
cases axillary dissection was consequently implemented.
Clinic-radiological monitoring and assessment of the status
of patients was conducted. RESULTS: 31 patients was record-
ed (all woman, 37-66 years old, mean age 49,32 years).
SNOLL located all the occult breast lesions successfully. In
25 out of the 31 patients (80,6%), the breast specimen had
clear and large margins. Despite intraoperative examination
of the specimen, a total of 19, 4% (6 out of 31) patients re-
quired a second re-excision procedure for involvedmargin and
in the all cases had finally clear margins. Lymphocistingraphy
showed axillary drainage in every patients and 38 SLN sam-
ples (1,23 SLN/patient) were analyzed. Axillary lymph nodes
were histologically negative in 25 patientes (80,6%) and pos-
itive in 6 patients (17,4%). Monitoring Period was a range
from 34 to 56 months. Two out of 31 patients had metastasis:
one axillary recurrence (31 month/ axillary lymph node dis-
section) and other pulmonary recurrence (24 month/ chemo-
therapy). All patients are in complete remission at present.
CONCLUSION: Performing radioguided occult lesion locali-
zation plus sentinel node biopsy after neoadyuvant chemother-
apy to be a successful and reliable tecnique in patients with
breast cancer. However, further research taking account of
larger samples an longer post-surgery monitoring time are
needed.
P586
Reliable I-125 seed localization after neo-adjuvant
chemotherapy to identify breast lesions in combination
with sentinel node biopsy
D. Koopman1,2, D. Lots1, A. B. Francken3, H. Arkies1, P. L.
Jager1, C. H. Slump2, J. A. van Dalen4; 1Isala, department of
Nuclear Medicine, Zwolle, NETHERLANDS, 2MIRA Insti-
tute for Biomedical Technology and Technical Medicine, En-
schede, NETHERLANDS, 3Isala, department of Surgery,
Zwolle, NETHERLANDS, 4Isala, department of Medical
Physics, Zwolle, NETHERLANDS.
Background: An increasing number of breast cancer patients
undergo breast-conserving surgery using I-125 seeds for tu-
mour localization, combined with sentinel node biopsy using
Tc-99m. In patients who received neo-adjuvant chemotherapy,
identification of the seed with a gamma probe may be ham-
pered, as time to surgery increases and I-125 activity may be
less than 10% of its original activity during surgery. The com-
plexity gets worse for combined I-125/Tc-99m procedures due
to Tc-99m Compton scatter. The aim of this study was to
determine the maximum allowed ratio between Tc-99m and
I-125 during surgery. Method: We performed a phantom study
using 3 syringes each containing 17.4 MBq Tc-99m and one
I-125 seed of 6.0MBq, resulting in activity ratios (ARs) of 2.9,
5.8 and 8.7. To simulate breast tissue attenuation, we used
perspex with varying thicknesses (T=10-50mm). Measure-
ments were performed with a gamma probe (Neoprobe
GDS). Counts per second from Tc-99m down-scatter were
determined in the I-125 window (CPSscatter). Next, the I-125
seed was added and measurements were repeated (CPScomb).
We hypothesized that R=CPScomb/CPSscatter should be > 2 to
successfully identify the seed. R was calculated as a function
of the 3 ARs. Furthermore, we studied 10 patients who
underwent combined I-125/Tc-99m surgical procedures with
low activity seeds (0.3-0.6MBq) under well-standardized con-
ditions. At time of surgery, Tc-99m activity was approximately
23 MBq. Thereby, AR ranged from 35 to 78. Results: The
phantom study showed that ratio R decreased from 5.6
(T=10mm) to 1.5 (T=50mm) for AR=8.7. These values de-
creased linearly with decreasing AR. Up to 40mm perspex,
we could successfully identify the I-125 seed (R>2) when
AR=8.7. Furthermore in 8 out of 10 patients (AR<46), it was
possible to localize the I-125 seed on the skin during surgery.
In 2 patients (AR>46), the seed could not be detected on the
skin. However, after incision we were able to pinpoint the seed
with the gamma probe. Conclusion: The phantom study sug-
gests a maximum Tc-99m/I-125 activity ratio of 9 during sur-
gery. In practice, combined procedures with activity ratios up
to 46 were performed successfully. This discrepancy may be
related to differences in the geometrical configuration of the
Tc-99m deposits and I-125 seed. It is recommended to keep
the activity ratio as low as possible, by reconsidering the ac-
tivities that are used for Tc-99m and I-125, and if possible to
shorten the time between seed placement and surgery.
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18F-FDG PET/CT is a prognostic bio-marker in patients
affected by bone metastases from breast cancer.
Comparison with 18F-NaF-PET/CT.
A. Piccardo1, M. Massollo1, V. Altrinetti1, S. Morbelli2, F.
Bongioanni2, M. Iacozzi1, G. Sambuceti2, A. Gennari3, R.
Gonella4, M. Puntoni5, A. Decensi3, M. Cabria1; 1Nuclear
Medicine Unit E.O Ospedali Galliera, Genoa, ITALY, 2Nucle-
ar Medicine Unit SanMartino IST, Genoa, ITALY, 3Oncology
Unit E.O Ospedali Galliera, Genoa, ITALY, 4Department of
Internal Medicine San Martino IST, Genoa, ITALY, 5Clinical
Trial Research Unit, Galliera Hospital,, Genoa, ITALY.
Abstract: Aim: To assess the association between 18F-FDG
PET/CT and progression-free survival (PFS) and overall sur-
vival (OS) in patients with documented bone metastases from
breast cancer (BC) and to compare the prognostic value of
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S619
18F-FDG PET/CTwith that of 18F-NaF-PET/CT and of other
initial prognostic parameters that influence the outcome of
breast cancer patients. Methods:We retrospectively investigat-
ed 32 women with BC and documented bone metastases. All
patients underwent 18F-FDG PET/CT and 18F-NaF PET/CT
within 60 days of each other and no treatment was adminis-
tered between the two scans. Semi-quantitative parameters
were applied to 18F-FDG PET/CT and 18F-Na-PET/CT in
order to evaluate disease extent and tumour metabolism. Elec-
tronic medical records were reviewed to determine known
prognostic variables, including age, proliferative index Ki-
67%, presence of visceral metastases, current hormone thera-
py, duration of bone disease and response to first-line therapy,
as well as PFS and OS, which was calculated from the date of
initial diagnosis scans to the date of either death or last follow-
up. Results: The sensitivity of 18F-NaF-PET/CT (100%) was
higher (p<0.05) than that of 18F-FDG-PET/CT (72% and
72%). None of the 18F-FDG-PET/CT-negative patients
showed disease progression at the end of follow-up. After
adjustment for age, Ki-67 levels, presence of visceral metasta-
ses, hormone therapy, duration of bone disease and response to
first-line therapy, only 18F-FDG SUV mean [HR 15.7, 95%
confidence interval (CI) 1.15-214.5] and 18F-FDG whole-
body bone metabolic burden (WB-B-MB) (HR 16.9; 95%CI
1.87-152.2) were independently and significantly associated
with OS. None of the 18F-NaF-PET/CT parameters were as-
sociated with OS. None of the conventional clinical prognostic
parameters remained significantly associated with OS after the
inclusion of PET/CT parameters in the model. Conclusion: our
data showed that 18F-FDG PET/CT scores were highly and
independently associated to PFS and OS in patients affected
by bone metastases from BC. Their prognostic impact seems
to be higher than that of the other clinical and biological prog-
nostic factors included in the study. 18F-NaF PET/CT scores,
despite the higher diagnostic sensitivity of this modality, are
not independently associated to OS. The prognostic value of
18F-FDG seems to be similar to, or slightly higher than, the
combined value of 18F-NaF and 18F-FDG.
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18F-Fluoroestradiol positron emission tomography
in breast cancer patients: systematic review
of the literature & meta-analysis
L. Evangelista1, M. Dieci1, A. Cervino1, G. Saladini1, P.
Conte1,2, V. Guarneri1,2; 1Istituto Oncologico Veneto
I.R.C.C.S., PADOVA, ITALY, 2University of Padua, Padova,
ITALY.
Introduction: the aim of the study was to determine the corre-
lation between 16α-18F-fluoro-17β-estradiol (18F-FES) up-
take and the expression and functionality of estrogen receptors
(ERs), as well as to evaluate the ability of 18F-FES PET to
predict the response to hormonal therapy (HT) in patients with
locally advanced or metastatic breast cancer (BC). Methods:
Literature searches in the major literature databases were car-
ried out in order to select English-language articles dealing
with 18F-FES PETand BC. Studies that included patients with
BC undergoing 18F-FES PET alone or in combination with
other imaging modalities and included the absolute numbers
of true-positive, true-negative, false-positive and false-
negative test results were selected. Reviews, clinical reports
and editorial articles were excluded. All journal articles were
re-assessed before qualitative and quantitative analysis. Re-
sults: We found 23 journal articles, published between 1988
and December 2014, that critically evaluated the role of 18F-
FES PET in BC patients. Two separate meta-analyses were
carried out: the first to assess the correlation between 18F-
FES uptake and ER expression and the second to determine
the predictive value of FES in response to HT. For the first
meta-analysis, we considered nine selected studies with a total
of 238 patients. The meta-analysis provided a pooled sensitiv-
ity of 82% (95% CI: 74-88%) and a pooled specificity of 95%
(95% CI: 86-99%) for the evaluation of ER functional status
by 18F-FES PET. The diagnostic odds ratio (DOR) was 38.79
(95%CI: 13.0-115.4). Seven studies, with a total of 226 pa-
tients, were considered eligible for the analysis of prediction
for response. The pooled sensitivities and specificities were
59.3% (95% CI: 38.8-77.6%) vs. 66.7% (95% CI: 52.1-
79.2%), and 29.1% (95% CI: 17.6-42.9%) vs. 62.1% (95%
CI: 48.4-74.5%), for a SUV cut-off of 1.5 and 2.0, respective-
ly. Conclusion: from the present systematic review and meta-
analysis, a good correlation between 18F-FES uptake and ER
expression by immunohistochemistry emerges, while the role
of 18F-FES in predicting the response to endocrine therapy in
advanced BC remains undetermined.
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The Value of Molecular Breast Imaging in the Initial
Work-up ofWomenwith Proven Breast Cancer Scheduled
for Breast Conserving Therapy
A. Collarino1,2,3, L. M. Pereira Arias-Bouda2,3, F. Smit2,3,
P. Neijenhuis4, L. M. H. Wijers5, A. F. Van der Hoeven3, K.
Hofkes-Fillekes5, A. Zeillemaker4, R. A. Valdés Olmos2; 1In-
stitute of Nuclear Medicine, Università Cattolica del Sacro
Cuore, Roma, ITALY, 2Department of Nuclear Medicine, Lei-
den University Medical Center, Leiden, NETHERLANDS,
3Department of Nuclear Medicine, Alrijne Hospital,
Leiderdorp, NETHERLANDS, 4Department of Surgery,
Alrijne Hospital, Leiderdorp, NETHERLANDS, 5Department
o f R a d i o l o g y, A l r i j n e Ho s p i t a l , L e i d e r d o r p ,
NETHERLANDS.
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Aim: The purpose of this retrospective study was to inves-
tigate the additional value of dedicated Molecular Breast Im-
aging (MBI) using 99mTc-Sestamibi as an adjunct modality to
mammography (MG) and ultrasound (US) in assessing multi-
focal and/or multicentric disease in the clinical work-up of
patients with proven breast cancer (BC) scheduled for breast
conserving therapy (BCT). Materials and Methods: A total of
378 patients (mean age 60, range 30-88y) with proven BC,
scheduled for BCT, were included in this analysis. All patients
underwent MBI using a high-resolution small-field-of-view
gamma camera (Dilon 6800, Dilon Technologies, Newport
News, VA) in order to determine additional tumor lesions.
After injection of 600 MBq of 99mTc-Sestamibi into an
antecubital vein contralateral to the breast lesion, planar im-
ages in two standard projections (cranio-caudal and latero-
oblique) of both breasts were performed, followed by an ad-
ditional image (medial or lateral) of the breast with the index
lesion. The scintigraphic images were directly compared with
the most recent MG and interpreted according to a locally
developed modified functional BI-RADS classification. In
case of suspicious additional lesions on MBI, second-look
US followed by US-guided biopsy was performed. If
second-look US showed no substrate, follow up was agreed
in these cases. Results: In 44/378 (12%) patients, MBI detect-
ed 62 additional lesions occult on MG/US. Histopathology
confirmed 22 additional breast cancer lesions in 20 patients:
14 (64%) invasive ductal carcinoma, 2 (9%) lobular carcino-
ma, and 6 (27%) ductal carcinoma in situ. Five patients had
benign lesions and in 19 patients, lesions remained unknown.
In ten of 20 patients, additional malignant lesions were located
in a different quadrant compared to the index lesion, in two
patients both in a different quadrant and contralateral, and in
one patient only contralateral. Due to the identification of ad-
ditional cancer lesions, surgical management was adjusted in
13 patients. Conclusion: MBI seems to be a very useful imag-
ing modality in revealing multifocal/multicentric lesions and
bilateral disease not seen in other modalities. Incorporation of
this modality to the work-up may lead to select patients who
could benefit of breast conserving surgery.
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Diagnostic value of 99mTc-bombesin scintigraphy
for differentiation of malignant from benign breast lesions
K. Aryana, F. shariati, A. Fattahi, A. Azarian; Mashhad uni-
versity of medical scinences, Mashhad, IRAN, ISLAMIC RE-
PUBLIC OF.
Objective: In this study, we evaluated the diagnostic accuracy
of 99mTc-bombesin scintigraphy for differentiation of benign
from malignant palpable breast lesions.99mTc-Bombesin is a
tracer with high affinity for gastrin releasing peptide receptor,
which is over expressed on a variety of human tumors includ-
ing breast carcinoma.Materials and methods:We examined 33
consecutive women who were referred to our center with sus-
picious palpable breast lesions but had no definitive diagnosis
in other imaging procedures. A volume of 370-444MBq of
99mTc-bombesin was injected and dynamic 1-min images
were taken for 20 min immediately after injection in anterior
view. Thereafter, two static images in anterior and pronelateral
views were taken for 5 min. Finally, single-photon emission
computed tomography images were taken for each patient.
Definitive diagnosis was based on biopsy and histopathologi-
cal evaluation. Results: The scan findings were positive in 19
patients and negative in 11 on visual assessment of the planar
and single-photon emission computed tomography images.
Pathologic examination confirmed breast carcinoma in 12 pa-
tients with positive scans and benign pathology for 18 patients.
The overall sensitivity, specificity, negative and positive pre-
dictive values, and accuracy of this radiotracer for diagnosis of
breast cancer were 100, 66.1,100, 63, and 76%, respectively.
Semiquantitative analysis improved the specificity of the visu-
al assessment from 66 to 84%. Conclusion: Our study showed
that 99mTc-bombesin scintigraphy has a high sensitivity and
negative predictive value for detecting malignant breast le-
sions, but the specificity and positive predictive value of this
radiotracer for differentiation of malignant breast abnormali-
ties from benign ones are relatively low
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Predictive and Prognostic Value of FDG-PET/CT Imaging
and Different Response Evaluation Criteria after Primary
Systemic Therapy of Breast Cancer
T. Tokes1, K. Kajáry2, G. Szentmártoni3, Z. Lengyel2, T.
Györke4, L. Torgyík3, K. Somlai5, A. Tőkés6, J. Kulka7,
M. Dank8; 1Semmelweis University, Budapest, HUNGARY,
2Pozitron PET/CT Center, Budapest, HUNGARY,
3Semmelweis University, 1st Dept. of Medicine, Oncological
Division, Budapest, HUNGARY, 4Semmelweis University
Department of Nuclear Medicine and Scanomed Ltd, Buda-
pest, Budapest, HUNGARY, 5Surgical Division of the StMar-
garet Hospital, Budapest, HUNGARY, 6MTA-SE Tumor Pro-
gression Research Group, 2nd Department of Pathology, Bu-
dapest, HUNGARY, 7Semmelweis University 2nd Depart-
ment of Pathology, Budapest, HUNGARY, 8Semmelweis
University, 1st Dept. of Internal Medicine, Oncological Divi-
sion, Budapest, HUNGARY.
Objective: We introduced a simplified, PET Response Criteria
in Solid Tumors (PERCIST) based 18F-fluoro-deoxy-glucose
positron emission tomography and computerized tomography
(FDG-PET/CT) score (Method 1) and a novel, combined
FDG-PET/CT score supplemented with the morphological
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results of the Response Evaluation Criteria in Solid Tumors
(RECIST) system (Method 2) to define clinical complete re-
mission (CR) after primary systemic therapy (PST) in breast
cancer. We assessed the accuracy of these criteria in the pre-
diction of pathological complete remission (pCR) and evalu-
ated their prognostic value for progression free survival (PFS)
and overall survival. Methods: Seventy-one patients were en-
rolled in the study who underwent FDG-PET/CT imaging be-
fore and after PST. PET/CTs were evaluated by changes in
maximum Standardized Uptake Value (SUVmax) and tumor
size. Method 1 and 2 were applied to predict pCR and their
prognostic value for survival were assessed. Because tumor
metabolic behavior could vary between biological subtypes,
effects of biological subtypes on tumor response and its eval-
uation were also analyzed. For survival analyses, Kaplan-
Meier product limit methods were performed with log-rank
tests. Results: A total of 23/71 patients showed pCR
(32.4%). Comparing pCR/non-pCR patient groups significant
differences were detected by changes in SUVmax (p<0.001)
and tumor size (p<0.001) regarding the primary breast lesions.
For detection of pCR,Method 2 had higher sensitivity (75% vs
43.75%) and negative predictive value (60% vs 43.75%) with
lower false negativity rate (12 vs 27) than Method 1. Despite
the significant differences detected between the biological sub-
types regarding changes in primary tumor SUVmax and size
parameters (p=0.004; p=0.035, respectively), the subtypes
showed no significant impact on response evaluation with
Method 1 and Method 2. In our study, neither clinical nor
pathological CR was predictor of longer survival. Conclu-
sions: Our results suggest that combined criteria are more pre-
dictive of pCR than the simplified PERCIST-based response
evaluation. The effect of biological subtypes should still be
taken into consideration during the response evaluation; how-
ever they had no impact on the assessment with Method 1 and
Method 2.
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Can 18F FDG PET/CT be a new tool in the prognostic
armamentarium of carcinoma breast ? Correlating 18F
FDG uptake values with histopathological markers
in primary breast cancer
M. Ravina1,2, M. Chauhan2, M. Jacob2, A. Pandit2, N.
Sanchety2; 1Sanjay Gandhi Post Graduate Institute ofMedical
Sciences, Lucknow, Uttar Pradesh, INDIA, 2Army Hospital
Research and Referral, New Delhi, INDIA.
O b j e c t i v e s : T h e c o r r e l a t i o n b e t w e e n 1 8 F -
Fluorodeoxyglucose(FDG) standardized uptake values with
histopathological prognostic markers in patients with primary
breast cancer was studied.Methods: 115 patients (113 females
and 2 males) of biopsy proven primary breast cancer
underwent 18F FDG PET/CT scan. Standardised uptake
values (SUV) were compared with various clinicopathological
variables.Results: In a univariate analysis ‘T’ stage/tumor size
correlated significantly with SUV max values. T1 (n=10; me-
dian SUV, 3.8), T2 (n=49; median, 5.9), T3 (n=11; median,
8.2), T4 (n=42; median,9.1) (p=.009). Mean SUV (max) of
metaplastic lesions (8.6) were higher than that of ductal (8.0)
& lobular (2.9) carcinoma. Median SUV (max) of high grade
tumors were 8.2 vs. 4.9 of low grade tumors. Progesterone
receptor (PR) negative tumors (n=75; median, 8.3) had high
SUV max values than PR receptor positive tumors (n=37;
median,5.4) (p< .001). High uptake values were noted in es-
trogen recptor negative lesions (n=72;median,8.2) as com-
pared to ER positive lesions (n=40;median,6.2)(p=.011). No
significant correlation was noted between SUV max values
and Her2Neu receptor status, perineural & lymphovascular
invasion. Median SUV max of triple negative breast cancers
(n=38;median,8.8) was higher than that of ER+/PR+/Her2-
(n=31;median,4.9 , P 0.001) lesions. Multivariate analyses
showed tumor size and progesterone receptor negativity were
significantly correlated with SUV in primary breast cancer (P ,
0.046 and ,0.009, respectively).Conclusions: High tumoral
SUV levels may serve as a pretherapeutic indicator of aggres-
siveness of breast cancer & poor prognosis. Preoperative pre-
diction of patient prognosis is important in a setting of neoad-
juvant chemotherapy.
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Clinical utility of 18F-FDG PET/CT scan in younger than
40 years breast cancer patients
R. V. PARGHANE, Sr., R. Phulsunga, Jr, K. Agrewal, Sr., B.
Mittal, Prof., A. Bhattacharya, Prof., A. Sood, Consultant;
PGIMER, CHANDIGARH, INDIA.
Aim: 18F-FDG PET/CT is useful only in clinical stage III
breast cancer patients as per NCCN guidelines. However,
TNM staging should not be the only factor in clinical evalution
of breast cancer patients and age of patient may be considered
as additional factor. As young breast cancer patients often have
more potential for early metastases. Younger breast cancer
patients are likely to die than older patients; this is may be
due to higher rate of metastatic disease undetected by conven-
tional staging method. So, aim of this study was to evaluate the
role of 18 F-FDG PET/CT in staging, restaging and changes in
management of younger breast cancer patients.Material and
Methods: Total 3100 breast cancer patients undergone PET/
CT from April 2010 to December 2013, were reviewed retro-
spectively. Out this, only 122 breast cancer patients younger
than 40 years were included in this study. Clinical staging of
all younger breast cancer patients were determined based on
physical examination, mammography, ultrasound and other
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imaging before PET/CT. PET/CTwas done within 2 weeks of
clinical staging to evaluate extra-axillary lymph nodal, distant
metastases and changes in patient management.Results: Total
122 younger diagnosed patients of breast cancer were ana-
lyzed with mean age of 30 years (range 22-40 years) and
clinically stage I in 12 patients,stage II in 68 patients and stage
III in 42 patients were found in this study. PET/CT was used
for initial staging in 54 patients, restaging/ response evalution
in 34 patients and recurrence detection in 34 patients. 40 pa-
tients were undergone second time/ follow up PETscans. PET/
CT detected abnormal extra-axillary lymph nodes in 67 pa-
tients, lung lesions in 15 patients, bone lesions in 30 patients,
liver lesions in 7 patients and PET/CT scan changes in clinical
stage from II/III to stage III/IV in 52 patients. The lesion found
on PET/CT was confirmed byhistopathologically; follow up
PET / conventional imaging and clinical follow up. Based on
PET/CT finding patient’s management were changed in 31
patients, out this 9 patients undergone additional surgery, 3pa-
tients undergone chemo-radiotherpy and 19 patients under-
gone additional/changes in chemotherapy after PET/
CT.Conclusions: Our result show, PET/CTscans detected dis-
tant metastases in 35 patients and changes management in 31
patients. Therefore our results show, usefulness of PET/CT in
younger than 40 year breast cancer patients with clinical stage
I/II and PET/CT can avoid unnecessary therapy and reduce
morbidity and cost of patients management.
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[18F]FDG-PET/CT results predict outcome in breast
cancer
M. Sollini1, B. Zangheri1, L. Calabrese1, M. Di Paolo2, A.
Versari2, M. Gasparini1; 1IRCCS; MultiMedica, Sesto San
Giovanni, ITALY, 2Santa Maria Nuova Hospital IRCCS, Reg-
gio Emilia, Reggio Emilia, ITALY.
Aim: Breast cancer (BC) is the most commonly diagnosed
cancer among women. The role of [18F]FDG-PET/CT in the
management of BC patients is increasing. We aimed to assess
the role of [18F]FDG-PET/CT to stage and to predict outcome
in breast cancer.Materials and methods: 48 female (one bilat-
eral) with histology proven breast cancer (ductal 46, lobular 3)
were retrospectively analysed. Staging [18F]FDG-PET/CT
was performed pre- (39) or post-surgery (9). [18F]FDG upatke
in primary tumor (T), lymph node(s) (N) or distant (M) metas-
tases was considered. Patients were divided in group 1 (PET/
CT positive for N and/or M and any T) and group 2 (PET/CT
negative for N or M and any T). Patients were followed by
clinical/instrumental examinations. Disease-free survival
(DFS) was calculated. P-value <0.05 was considered signifi-
cant. Multivariate analysis was performed to assess the
indipendent prognostic role of PET/CT along with the
following factors: age at diagnosis, histology, ki-67 index
and triple negative hormonal status. Kaplan-Mayer curves
were analysed.Results: Mean DSF was 701±444 days. 36 pa-
tients had negative follow-up, 10 patients had progressive dis-
ease and 2 patients had stable disease. [18F]FDG-PET/CT
resulted completely negative in 14/48 patients. [18F]FDG up-
take was seen only in T in 16 patients, only in N in 3 cases, in T
+ N in 10 cases, in T +M in 1 case, in T + N +M in 4 patients,
and in N +M in 1 case. Sensitivity, specificity and accuracy of
PET/CTwere 82%, 100%, 86% for T, 61%, 95%, 76% for N,
and 100%, 95%, 95% for M parameter respectively. PET/CT
changed stage of disease (all upgraded) and management in
6/48 and 4/48 patients, respectively. DFS was lower (893±110
versus 1944±173 days, p <.05) in group 1 compared to group
2. Survival analysis demonstrated a significant difference be-
tween group 1 and group 2 (Log Rank= .033). At multivariate
analysis only a positive PET/CTat staging for N and/orM (any
T) was independently associated with prognosis (p= .041),
while other parameters were not retained.Conclusion: Our re-
sults demonstrated the potential useful role of [18F]FDG-PET/
CT to stage and assess prognosis in breast cancer. Despite
these preliminary data have to be confirmed by prospective
larger studies, our findings support the clinical use of this
approach.
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Quantification of Dual Time Point FDG-PET/CT in Bone
Lesions in Breast Cancer Recurrence
J. A. Hansen1, M. G. Hildebrandt1, O. Gerke1, C. Baun1, K.
Falch1, S. Duvnjak2, A. Alavi3, P. F. Høilund-Carlsen1; 1De-
partment of Nuclear Medicine, Odense University Hospital,
Odense C, DENMARK, 2Department of Radiology, Odense
University Hospital, Odense C, DENMARK, 3Division of
Nuclear Medicine, University of Pennsylvania, Philadelphia,
PA, UNITED STATES.
Aim: The role of FDG-PET/CT in the diagnosis of morpho-
logically different types of bone lesions is undefined. The aim
of this study was to estimate the partial volume corrected mean
standardized uptake value (cSUVmean) in different types of
bone lesions using dual time point (DTP) FDG-PET/CT. Ma-
terial and methods: As part of a larger prospective study in
suspected recurrent breast cancer, 14 patients underwent
DTP FDG-PET/CT with 1 hour (1h) and 3 hour (3h) images.
All had bone recurrence verified by biopsy, clinicians’ deci-
sion of treatment, and/or follow-up. An experienced radiolo-
gist categorized the bone lesions according to CT into
osteolytic, osteosclerotic, mixed, or not CT-detectable metas-
tases. Dedicated software (ROVER, ABX, Radeberg, Germa-
ny) was used to determine cSUVmean1h and cSUVmean3h.
The FDG avid volumes (cm3), the difference (ΔcSUVmean)
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between 1h and 3h images, and the relative change
(%Change=(ΔcSUVmean /cSUVmean1h)*100) were calcu-
lated. Wilcoxon analysis was used to test for differences be-
tween 1h and 3h cSUVmean and one-way ANOVA to test for
difference between bone lesion types. Results: A total of 229
lesions in 14 patients were detected with a median of 2.5 le-
sions per patient (range 1-98). Classification of lesions by CT
showed 54 (23.6%) osteolytic, 14 (6.1%) osteosclerotic, 92
(40.2%) mixed, and 69 (30.1%) not CT-detectable. The medi-
an cSUVmean1h was 7.1 (range 0.9-13.8), 8.2 (3.5-17.0), 7.5
(2.1-19.9), and 5.7 (1.2-15.9) in osteolytic, osteosclerotic,
mixed and not CT-detectable lesions, respectively, and the cor-
responding median volumes were 8.1 (4.9-11.4), 6.3 (2.8-9.7),
6.7 (4.8-8.7), and 4.7 (3.5-6.0). Themedian cSUVmean3hwas
8.9 (1.1-20.1), 10.0 (4.2-14.2), 10.5 (2.9-36.3), and 6.5 (2.4-
19.1) with corresponding median volumes of 9.3 (8.0-10.5),
9.7 (7.9-11.4), 11.1 (10.0-12.3), and 7.8 (6.9-8.7), respectively.
There was statistically significant increase for all lesion types
from cSUVmean1h to cSUVmean3h (p<0.0001). The median
%Change was 31.4 (32.4-209.2) for osteolytic, 19.6 (-34.7-
111.4) for osteosclerotic, 39.5 (-63.8-366.7) for mixed and
25.0 (-66.0-170.8) for not CT-detectable lesions. Mixed and
not CT-detectable lesions were statistically different with re-
gard to cSUVmean1h (p= 0.003), cSUVmean3h (p<0.001),
and ΔcSUVmean (p= 0.043). No statistically significant dif-
ferences were found for other groups or %Change. Conclu-
sion: Morphologically different bone lesions had relatively
high FDG uptake, all with a significant increase from 1h to
3h imaging. Our results showed only minor difference in FDG
uptake between morphologically different bone lesions, hence
FDG-PET/CT has proven worthy in detection of any type of
bone recurrence.
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Effectiveness and cost-effectiveness analysis of radical
axillar lymphadenectomy after a positive sentinel node
in breast cancer
P. Serra-Arbeloa, Á. O. Rabines-Juárez, F. Domínguez-
Cunchillos, C. de Miguel-Medina, C. Artieda-Soto; Complejo
Hospitalario de Navarra, Pamplona, SPAIN.
Aim: The aim of this study was to determine the effectiveness
and cost-effectiveness of the radical axillar lymphadenectomy
(RAL) compared with no RAL and observation only (NRAL)
in breast cancer patients after a conservative surgery and axil-
lary sentinel node biopsy with a maximum of 2 positive sen-
tinel nodes (SNs), over a 5 year time horizon and using the
health care system perspective. Methods: A tree decision mod-
el was used to estimate the direct costs and the effectiveness
measured in life years saved (LYSs), quality-adjusted life years
(QALYs), and the presence of adverse events, such as
lymphedema, of the two studied strategies (RAL vs. NRAL).
Different costs and utility values were assigned to their respec-
tive model health states. Model input parameters, including
relapse rates, mortality rates, utility values and costs, were
obtained from the published literature and the government
official publications. Results: Usual care (RAL) had the
highest expected costs, 22,269 €/patient and the lowest effec-
tiveness, 4.31 LYSs and 2.71 QALYs. The alternative strategy
(NRAL) had lower costs, 17,597 €/patient, and higher effec-
tiveness in both LYSs, 4.38, and QALYs, 2.81. The incremen-
tal cost effectiveness ratio for RAL was estimated to be -69,
209 €/LYs and -46,369 €/QALYs (Northwest quadrant; RAL
dominated by NRAL). Taking into account adverse events,
apart from the decrease in quality of life of patients following
RAL, an increase of 87 € per treated patient is associated with
the lymphedema. Conclusions: NRAL appears to be a more
cost-effective strategy compared with RAL. NRAL allows re-
ducing the cost with no decrease of quality of life in breast
cancer patients.
P597
Defining the nodal status in the initial staging of patients
with locally advanced breast cancer:Where must PET/CT
stand?
B. E. Akkas, B. Demirel, G. Ucmak, S. Demirtas; Ankara
Oncology Research and Training Hospital Department of Nu-
clear Medicine, Ankara, TURKEY.
In this study, we aimed to investigate the impact of FDG PET/
CT at initial staging of patients with locally advanced breast
cancer (LABC) and compared PET/CT performance with that
of conventional distant work-up.Methods: 52 patients with
LABC underwent FDG PET/CT for initial staging and includ-
ed in this retrospective study. All patients had clinical T3-T4 or
N2 disease. The performance of PET/CT was compared with
that of a conventional staging approach including bone scan,
chest radiography, abdominal and pelvic ultrasound or
contrast-enhanced CT.Results: 47 patients had invasive ductal
carcinoma, 1 had inflammatory carcinoma and 4 patients had
other subtypes. Clinically; 3 patients had stage 2, 42 patients
had stage 3 and 7 patients had stage 4 disease. PET/CT con-
firmed N2 disease in 29 patients and revealed unsuspected N3
nodes (infraclavicular, supraclavicular, or internal mammary)
in 19 additional patients. PET/CT detected supraclavicular
lymph nodes (LN) in 7 patients, internal mammarian LN in 4
patients, both supraclavicular and internal mammary LN in 6
patients and metastatic LN in the contralateral axilla in 2 pa-
tients. Almost all distant lesions detected by conventional im-
aging were depicted with PET/CT, which also showed addi-
tional lesions. In addition, PET/CT detected distant metastasis
in 12 patients that were not diagnosed by conventional
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techniques. The sites of metastatic disease were as follows;
bones (n:7), mediastenum (n:1), contralateral breast (n:1) and
multiple sites (n:3). Following PET/CT, clinical stage was
upstaged in 19 patients (36.5%) of whom N3 disease was
diagnosed in 7 patients and M1 disease was detected in 12
patients. Additionally, PET/CT excluded metastatic disease
in 4 patients who had equivocal findings on conventional im-
aging modalities.Conclusion: Breast cancer stage at presenta-
tion is an important factor in prognosis and treatment. Nodal
status in patients with LABC is one of the major factors that
may alter treatment plan. FDG PET/CT has the advantage of
scanning whole body in a single session and may change the
clinical stage in a considerable percent of patient population.
In our study, by providing accurate initial staging, PET/CT
changed clinical management in 36.5% of patients with
LABC. We conclude that PET/CT must be performed in all
patients with clinical T3 and T4 tumors.
P598
Diagnosing bone metastasis in recurrent breast cancer:
dual time FDG-PET/CT compared to contrast enhanced
CTand bone scintigraphy
M. G. Hildebrandt1, J. Ansholm1, O. Gerke1, C. Baun1, K.
Falch1, Z. Farahani1, S. Duvnjak1, L. Larsen1, I. Buskevica1,
S. Bektas1, A. Alavi2, P. Hoilund-Carlsen1; 1Odense Univer-
sity Hospital, Odense, DENMARK, 2University of
Pennsyalvania, Philadelphia, PA, UNITED STATES.
Aim: The optimal modality for diagnosing bone metastases in
breast cancer has been debated in literature. The aim of this
study was to investigate the role of dual time FDG-PET/CT in
diagnosis of bone recurrence in breast cancer compared to
contrast enhanced CT (ceCT) and bone scintigraphy
(BS).Material and methods: In a prospective design, 100 fe-
male patients with suspected recurrent breast cancer
underwent 1hour (1h) and 3hour (3h) FDG-PET/CT, ceCT
and BS within a median time interval of 10 days. Images were
interpreted visually, and readers were blinded to other test
results. Biopsy, clinicians’ decision of treatment, and clinical
follow-up served as reference standard. Patient based accuracy
results were calculated, including measures of area under the
receiver operating curve (AUC-ROC), based on visually
interpreted 4-point assessments, including 95% confidence in-
tervals (CI). Further, in 14 patients with verified bone recur-
rence preliminary lesion based analyses were made. The bone
lesions were categorized according to the CT images as
osteolytic, osteosclerotic, mixed, or as not detected; hence le-
sion based sensitivity was obtained for stratified groups of
bone lesions. Patients with a BS ‘superscan’ were considered
positive in all lesions.Results: Eighteen patients (18%) were
confirmed to have bone recurrence. Patient based analyses
revealed no difference between 1h and 3h FDG-PET/CT.
AUC-ROC, sensitivity, specificity, and likelihood ratios for
positive and negative tests for FDG-PET/CT was 0.99 (0.98-
1), 1 (0.82-1), 0.98 (0.92-0.99), 41.0 (10.4-161.0), and 0
(N/A); for ceCT, 0.82 (0.71-0.94), 0.61 (0.39-0.80), 0.99
(0.93-1), 50.1 (6.9-364.0), and 0.4 (0.2-0.7); for BS, 0.86
(0.77-0.96), 0.78 (0.55-0.91), 0.87 (0.78-0.92), 5.8 (3.2-
10.6), and 0.3 (0.1-0.6); and for the combined ceCT+BS
0.89 (0.81-0.97), 0.83 (0.61-0.94), 0.85 (0.76-0.91), 5.7 (3.3-
10.0), and 0.2 (0.1-0.6), respectively. A total of 229 lesions in
14 patients were detected (median number of lesions per pa-
tient: 2.5; Range: 1-98). Classification of lesions by CT
showed 54 (23.6%) osteolytic, 14 (6.1%) osteosclerotic, 92
(40.2%) mixed, and 69 (30.1%) not detected by CT. The lesion
based sensitivity was 99.1% (95% CI: 96.9-99.9) for FDG-
PET/CT 3h, 98.3% (95.6-99.5) for FDG-PET/CT 1h, 87.8%
(82.8-91.7) for BS, and 69.9% (63.5-75.7) for ceCT. BS de-
tected significantly less of the lytic metastases (30/54) than of
other bone metastatic types (171/175); p<0.0001.Conclusion:
The overall patient based accuracy for diagnosing bone recur-
rence was significantly higher with FDG-PET/CT than with
conventional imaging technology. With inconsiderable differ-
ence between 1h and 3h imaging, FDG-PET/CT detected sig-
nificantly more metastatic bone lesions than did BS or ceCT.
P599
18F-FDG PET/CT is most cost-effective for screening
distant metastases in stage II/III breast cancer patients
S. C. Teixeira, A. Miquel Cases, R. A. Valdes Olmos, E. J. T.
Rutgers, W. van Harten; Netherlands Cancer Institute - Antoni
van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.
Aim: 18F-FDG Positron Emission Tomography with Comput-
ed Tomography (PET/CT) has recently been shown to have a
high sensitivity and specificity for detecting distant metastases
in breast cancer patients before start of pre-operative systemic
treatment (PST). Nevertheless PET/CT is insufficiently ac-
cepted in current medical practice, mainly due to its higher
costs. Our aim is to assess the cost-effectiveness of 18F-FDG
PET/CT for distant metastasis screening in stage II/III breast
cancer compared to the golden standard assessment in the
Netherlands (X-thorax, liver sonography and bone scan). Ma-
terials and methods: We included protectively collected data
from all primary stage II/III breast cancer patients treated in the
Netherlands Cancer Instiute - Antoni van Leeuwenhoek (NKI-
AVL) hospital from 2007 to 2013 with PST and who received
PET/CT for distant metastasis screening (n=545). We con-
structed four Markov decision models to compare the health-
economic consequences of performing distant metastasis
screening with 18F-FDG PET/CT or with the ‘golden stan-
dard’ in four subtypes (ER+/HER2-, HER2+/ER+, HER2+/
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ER-and HER2-ER-). Sensitivity and specificity of both imag-
ing scenarios were calculated using data from 2013 as a proxy
to determine the type of systemic (neo-adjuvant & adjuvant)
and local (surgery & radiotherapy) treatments administered.
Costs were derived from tariffs in 2013. Epidemiological
(i.e., patterns of metastasis per subtype), survival and utility
data were estimated from literature or by making assumptions
based on our database.Model outcomes (incremental life years
(LY), quality-adjusted-life years (QALYs), costs (€), and cost-
effectiveness ratio (ICER)) were calculated at a time horizon
of 5-years. Cost-effectiveness was determined against the pre-
vailing threshold of €80.000/QALY for severe diseases in the
Netherlands. Results: PET/CT had a higher sensitivity (53%
vs. 15%) and specificity (97% vs. 94%) than did the golden
standard. Compared to the golden standard, performing distant
metastasis screening with PET/CT would result in 0.02 life-
years gained or 0.01 after adjusting for quality-of-life. These
gains were expected similar across the subtypes. The addition-
al costs of distant metastasis screening with PET/CT ranged
between €325 and €532 (ER+/HER2-:€532; ER+/HER2+
:€450; ER-HER2-:€370; ER-/HER2+:€325). In all subtypes,
the increase of costs of screening with PET/CT was
outweighed by the health benefits achieved thus resulting in
cost-effective results (all ICERs were below €80.000/QALY;
ER-/HER2+:€26.587/QALY; ER-HER2-:€31.212/QALY;
ER+/HER2+:€48.587/QALY; ER+/HER2-:€59.475/QALY).
Conclusion: While PET/CT does increase the costs for distant
metastasis screening in stage II/III breast cancer, these seem to
be outweighed by an increase on health outcomes resulting
from improved diagnostic performance. Importantly, this is
expected for all breast cancer subtypes.
P600
Sentinel lymph node biopsy in breast cancer in patients
with previous breast surgery
J. Orozco-Cortés1, R. Díaz-Expósito1, I. Casáns-Tormo1, S.
Prado-Wohlwend1, H. Bowles-Antelo1, A. Caballero-
Garate2, A. Almarcha-Gimeno3; 1Hospital Clínico
Universitario. Servicio de Medicina Nuclear, Valencia,
SPAIN, 2Hospital Clínico Universitario. Servicio de Cirugía
General, Valencia, SPAIN, 3Hospital Clínico Universitario.
Unidad de Radiofarmacia, Valencia, SPAIN.
AIM: The previous breast surgery could produce changes in
the lymphatic drainage. We have analyzed our results in the
sentinel lymph node biopsy in patients who have had this
precedent. MATERIAL AND METHODS: Retrospective
study in 69 women, age 29-86(53) years old, with palpable
lesions in 10 and non-palpable in 59, 49(71%) with infiltrative
carcinoma. Our patients were classified in three groups.
Group 1:13(18.8%) patients with breast implants; group 2:
47(68.1%) patients with previous tumorectomy for various
reasons and one month to the SLNB realization; group 3:
8(11.5%) patients with breast reduction surgery. One patient
had tumorectomy and breast implant. We administered 2 mCi
of 99m-Tc albumin nanocolloid by intratumoral injection in
19 patients (27.5%) with periareolar reinjection in 5 (palpable
lesion and ultrasound guided or stereotaxy in the non-palpable
lesions) and periareolar in 50 (72.4%), at the same day of
surgery, performing planar lymphoscintigraphy (PL) in differ-
ent projections, intraoperative detection with hand held
gammaprobe, intraoperative pathologic analysis of the SN
(OSNA) and differed inmunohistochemistry. RESULTS:
The global sentinel node detection was 89.9%(62/69):
92.3%, group 1, 87.2%, group 2 and 100%, group 3. The
detection in the groups without tumorectomy (1 + 3) was
higher (95 .2%) than in the tumorec tomy group
(87.2%)(p<0.05). The detection after intratumoral injection
was 78.9%(15/19) against 88%(44/50) when the injection
was periareolar. The axillary migration was homolateral in
61 patients, in 3 with additional internal mammary lymph
nodes migration and in 1 with additional contralateral axillary
migration. In one patient the migration was in the internal
mammary lymph nodes exclusively. We didn’t detect sentinel
nodes with lymphoscintigraphy in 7 patients although there
was surgical detection in 1. The characteristics of these 7
patients were: 6 with previous tumorectomy, 1 with
tumorectomy and mammary implant, average age 61.2 years
old, non palpable lesions in all. When the sentinel node was
removed there was pathological involvement in 11/
62(17.7%). The lymphadenectomy was made in 10 and
showed involvement, in addition to sentinel node, in 4/10
patients. In the 7 patients without sentinel node migration
only one showed lymph involvement(micrometastasis) after
lymphadenectomy. CONCLUSIONS: Although the sentinel
node global detection in patients with previous breast surgery
was slightly lower than the optimal value (95%), it is still
useful in order to avoid unnecessary lymphadenectomies.
The patients with previous tumorectomy showed lower detec-
tion values because of possible alterations in the lymph drain-
age. We haven’t found an increase in the extra axillary
drainage.
P601
Combined use of portable gammacamera
and mammography for the margin delimitation
in Radioguided Occult Lesion Localization (ROLL)
in breast cancer.
H. Rodriguez, L. Marbello, P. Abreu, M. Reyes, D. Balaguer,
E. Caballero, T. Mut, C. Plancha; University Hospital Dr.
Peset, Valencia, SPAIN.
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Objective: Inadequate surgical margins in breast neo-
plasia require a reoperation. Our goal is to assess the
added value the portable gammacamera images bring
to mammography alone in surgical margin delimitation
in non-palpable breast tumors. Material and methods:
We conducted an ambispective study of 70 consecu-
tive patients with ROLL (Radioguided Occult Lesion
Localization) in non-palpable breast cancer. 37-
148 MBq of 99mTc-nanocolloid albumin in 0.3 ml
were injected intratumorally guided by ultrasound. Af-
ter tumor resection, clear margins (CM) of the surgi-
ca l spec imen were de te rmined wi th por tab le
gammacamera (Sentinella®) placed 10 cm away from
the sample, considering 3 images: surgical bed, ex-
cised tumor and tumor margins with the aid of an
external point source; CM were considered when the
images of the tumor and its contour drawn by an
external point source didn’t contact. Then, mammogra-
phy of the tumor was done. Margins were extended
during the same surgery when insufficient CM were
suspected after using either of the two techniques. If
histology resulted in a surgical margin of 1 mm or
less, delayed reoperation was mandatory. The ability
to predict positive margins using both methods was
checked against histology. Tumors were classified at-
tending to their size, morphology, localization and ra-
diotracer placement. False negatives (FN) were consid-
ered relevant as were the discrepancies between
gammacamera images and mammography and the
causes of error. Results: Portable gammacamera im-
ages recommended to extend surgical margins in 37
out of 70 surgeries; mammography recommended ex-
tended surgery in 33 out of 70. There were discrep-
ancies between both methods in 14 cases. Compared
to histology, the portable gammacamera images had S:
75% E: 54% PPV: 32% NPV: 88%, and mammogra-
phy S: 56% E: 55%, PPV: 27% and NPV: 81%. FN
ratio (mammography/gammacamera)=7/4 = 1.75.
McNemar’s test was applied to paired data showing
no significant difference between the two techniques
(P> 0.05), but the gamma images prevented 3 out
of 70 reoperations, while mammography had 3 FN.
Bo th t e chn i que s ag r e ed on 3 o th e r FN : 1
microcalcifications, 1 carcinoma in situ on surgical
margin and 1 after neoadjuvant therapy. 1 FN oc-
curred solely with the portable gammacamera on a
bilobed tumor. Conclusion: Portable gammacamera im-
ages combined with mammography reduce reoperation
caused by positive margins. Tumors with irregular
contours are more prone to insufficient resection.
P602
Analysis of the metabolic heterogeneity of breast tumors
with FDG-PET/CT
B. Farkas; University of Debrecen, Debrecen, HUNGARY.
Objective: F18-FDG PET/CT examinations are part of the
oncological diagnostic algorithm in the majority of malig-
nant diseases. Judging the metabolism of tumors is not
only substantial in the differentiation between benign and
malignant lesions but also has prognostic importance. In
clinical practice usually different standard uptake value
(e.g. mean, maximum) and metabolic tumor volume based
parameters are used for the characterization of tumor me-
tabolism. The analysis of intratumoral heterogeneity is a
new concept in the quantification of metabolism. We
would like to examine the correlation between heteroge-
neity parameters and clinical stage, hormone receptor sta-
tus, and other molecular pathological markers. Methods:
We retrospectively evaluated the initial FDG-PET/CT
scans of 32 patients examined in our institute. Exclusion
criteria were tumor size smaller than 30 cm3 and previ-
ous therapy. We calculated the following heterogeneity
parameters considering the segmented voxels of the lesion
with SUV higher than 2.5% of SUVmax: Entropy, Con-
trast, Correlation, Homogeneity, and Covariance. Thereaf-
ter, we utilized Mann-Whitney U probe and Kruskal-
Wallis test to find correlation between the certain hetero-
geneity parameter and estrogen-, progesterone-, Her2-
receptor status, Ki-67 proliferation index, the number of
primary lesions as well as the local and distant advance
of the disease. Results: Generally, we found no correspon-
dence between the examined heterogeneity parameters and
Her2-receptor status, Ki-67 proliferation index, number of
the primary lesions, and the presence of local/distant me-
tastases. The value of Correlation as heterogeneity param-
eter was significantly larger (10.35->18.63; p=0.09) in
progesterone-receptor positive tumors, while other hetero-
geneity parameters proved to be unrelated. The values of
Entropy (9.89->16.95; p=0.017), Contrast (10.36->16.36;
p=0.043), and Correlation (10.07->16.73; p=0.025) proved
to be elevated, while the degree of Homogeneity de-
creased (15.57->9.73; p=0.49) in estrogen-receptor positive
cases. Conclusion: In this study we found correlation be-
tween certain heterogeneity parameters and hormone-
receptor status. However, further investigations are needed
to clarify the clinical relevance of these findings. No
obvious connection was proved between the other exam-
ined clinicopathological markers and studied heterogeneity
parameters.
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FDG-PET/CT versus CT in local recurrent breast cancer
and the standardized uptake value in local and distant
recurrent breast cancer
C. B. Petersen1, M. G. Hildebrandt1, J. A. Hansen1, C.
Baun1, K. Falch1, O. Gerke1, A. B. Jylling1, A. Alavi2, P.
F. Høilund-Carlsen1; 1Odense University Hospital, Odense C,
DENMARK, 2University of Pennsylvania, Philadelphia, PA,
UNITED STATES.
Aim: This study aimed to estimate the accuracy of FDG-PET/
CT versus contrast enhanced CT (ceCT), in diagnosing local
recurrent breast cancer and to see if delayed FDG-PET/CT
imaging improved sensitivity. Furthermore, to assess the
FDG-uptake (expressed by the maximum standardized uptake
value (SUVmax)) in local and distant recurrence using 1 hour
(1h) and 3 hour (3h) imaging. Materials and methods: In a
prospective design, 100 female patients with suspected recur-
rent breast cancer underwent 1h and 3h FDG-PET/CT and
ceCT within a median time of 10 days. Readers were blinded
to other test results, however, they were aware of the diagnosis
of local recurrence from the referral text. Biopsy, choice of
treatment and clinical follow up served as reference standard.
Patient based accuracy results were calculated, including mea-
sures of area under the receiver operating curve (AUC-ROC),
based on visual 4-point assessment. SUVmax was obtained
from the most FDG-avid metastatic lesion of each patient.
Four patients with local recurrence had no FDG-avid lesions
and were excluded from the SUV analysis. A Wilcoxon
matched-pairs signed-ranks test was applied for the differences
of 1h and 3h SUVmax in patients with local and distant recur-
rence. A Wilcoxon rank sum test was used to test for differ-
ences in SUVmax between groups. Results: Nineteen women
had local and 22 distant recurrent disease. The AUC-ROC,
sensitivity and specificity for patients with local recurrence
was 0.88 (95%CI: 0.78-0.99), 0.74 (0.51-0.88) and 1.00
(0.94-1.00) for FDG-PET/CT1h, 0.88 (0.78-0.99), 0.72
(0.49-0.88) and 1.00 (0.94-1.00) for FDG-PET/CT3h, and
0.59 (0.45-0.74), 0.37 (0.19-0.59) and 0.90 (0.80-0.95) for
ceCT, respectively. Patients with local recurrent disease had a
median SUVmax3h of 5.2 (range 0.8-12.3), which was signif-
icantly higher than the median SUVmax1h: 3.8 (range: 0.9-
8.7) (p=0.007). Likewise, patients with distant recurrent dis-
ease had a median SUVmax3h of 15.1 (range: 7.1-29.7),
which was significantly higher than SUVmax1h: 10.2 (range:
4.2-19.3) (p=0.0001). There was a statistically significant dif-
ference between local and distant recurrent lesions with regard
to SUVmax1h (p<0.0001) and SUVmax3h (p<0.0001). Con-
clusion: In diagnosing local recurrent breast cancer, all
diagnostic values were higher with FDG-PET/CT than ceCT,
although the difference was statistically significant for the
AUC-ROC only. Delayed imaging was associated with signif-
icantly higher FDG-uptake in both local and distant recurrent
lesions, but did not improve sensitivity, which as expected was
relatively low, yet significantly higher than with ceCT. The
FDG-uptake was significantly higher in distant than local re-
current lesions suggesting change of cancer aggressiveness.
P604
Preliminary findings of our institute on initial staging
of breast cancer with FDG-18 PET/CT
T. CAKIR, E. ABAMOR, A. CAKIR, P. BASIM, C.
GEZEN, M. EVREN, T. ATASEVER; MEDIPOL UNIVER-
SITY, ISTANBUL, TURKEY.
AIM: Aim of our study is to investigate the pathology
results of breast cancer patients, whom are initially eval-
uated using FDG-18 PET/CT. MATERIALS AND
METHODS: Newly diagnosed breast cancer patients in
our institute, that was founded two years ago, were eval-
uated in this study using FDG-18 PET/CT. Maximum
Standard Uptake Values (SUVmax) of primary breast
lesions and axillary lymph nodes were noted. Pathology
reports were retrieved from archives if accessible. Final
diagnosis of the tumors, size of the tumors, histological
grades, estrogen (ER), progesterone (PR), CERB-B2 re-
ceptor expression, Ki67 values and lymph node involve-
ments were noted. SUVmax of tumors were compared
according to histological features. RESULTS AND
CONCLUSION: Total number of 119 patients was ret-
rospectively included to this study. Sixty-three of 119
have pathology reports in our system. Average ages of
the patients were 49 (25-82). 46 patients were diagnosed
as invasive ductal carcinoma. Only 4 patients have in-
vasive lobular carcinoma. 6 patients have mix type car-
cinomas. 4 patients have triple negative breast cancer. In
this 63 patients 14 was ER negative, 18 was PR nega-
tive and 29 was CERB-B2 negative. 32 patients have
occult or micro metastasis to axillary lymph nodes. 8
of this 32 patient were false negative in PET/CT exam-
ination. Only two patients with mildly increased FDG
uptake were negative in pathological investigation. Five
patients histological grade is one, and average SUVmax
is calculated as 8. Thirty patients’ grade is 2 with aver-
age SUVmax of 8.5. Twenty-seven patients’ grade is 3,
with average SUVmax of 12.4. Ki-67 percentage and
SUVmax of the primary lesions were statistically corre-
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lated (p<0.0001), unlike Ki-67 percentage and SUVmax
of the lymph nodes. Distant metastasis is present in
fifteen cases. Average SUVmax of primary lesion of
these patients was 12.9, while non-metastatic patients
have lower average SUVmax of 9.0. Correct initial eval-
uation of the breast cancer is vital for the patient. FDG
PET/CT have important role in the evaluation of breast
cancer as well as other cancers. Further investigation of
the breast cancer including subgroup analyzes with larg-
er number of patients is planned in our institute.
P605
Is 18F-FDG uptake and apparent diffusion coefficient
obtained from diffusion weighted magnetic resonance
imaging correlate on the primary tumour of breast
carcinoma?
A. Ozen, T. Sayin, S. Altinay, A. Celik, O. Ekmekcioglu, E.
Bastug, A. Muhammedoglu, R. Albayrak; Bagcilar Training
and Research Hospital, Istanbul, TURKEY.
Aim: The breast carcinoma in female population is the most
common type of cancer. Diffusion-weighted magnetic reso-
nance imaging (dw-MRI) provides additional information
about microstructural characteristics of tissue and it is increas-
ingly performed in the evaluation of tumours. Furthermore, the
apparent diffusion coefficient (ADC) value obtained from dw-
MRI was useful in differentiating between benign and malig-
nant breast lesions, such as differentiating ductal carcinoma
from fibroadenoma. Restricted water movement in tumors
with high cellularity usually results in smaller ADC value.
On the other hand, 18F-FDG uptake and cellularity in breast
carcinoma are positively correlated. Therefore, SUVmax and
ADC were expected to be in an inversely proportional corre-
lation. The aim of this study was to evaluate whether 18F-FDG
uptake and ADC correlate for the primary tumour of breast
carcinoma. Material and methods: This retrospective study
included 43 lesions in 42 female patients (mean age, 51,30
±12,26 years; age range, 29-78 years) with breast carcinoma.
Thirty eight patients had invasive ductal carcinoma, one of
them with sarcomatoid differentiation, 1 invasive lobular car-
cinoma, 1 mixed type, 1 mucinous and 1 medullar breast car-
cinoma. After pre-operative staging with 18F-FDG PET/CT
and dw-MRI, mastectomy or breast conserving surgery with
axillary lymph node disection or sentinel lymph node biopsy
was performed. The SUVmax was calculated from 18F-FDG
PET/CT images at 1-hour (SUV1) and 3-hours (SUV2) after
i.v. injection of 18F-FDG. Furthermore, retention index (RI)
was calculated in 40 lesions following formula; RI=100 x
(SUV2-SUV1) / SUV1. The ADC values from primary breast
tumour were obtained automatically by measuring the intensi-
ty of the region of interest on the ADC maps. The correlation
with ADCwas tested by Spearman’s correlation coefficient for
SUVmax values, and tested by Pearson correlation coefficient
for RI. Results: The mean tumour size was 2.43±0.98cm
(range 1.1-5cm). The mean SUV1, SUV2, RI and ADC for
the breas t tumours were 6 .38±5.03 , 8 .06±6.61 ,
22.78%±19.84%, and 1.092×10-3mm2/sn±0.452×10-3mm2/
sn, respectively. The ADC values were not correlated with
SUV1 (r:0.092, p:0.563), SUV2 (r:0.166, p:0.300) and RI
(r:0.262, p:0.102). Conclusion: The correlation between
SUVmax and ADCwas found in some tumors such as primary
cervical cancer, pancreatic adenocarcinoma, and lymph node
metastasis of non-small cell lung carcinoma. Even though we
found no correlation between ADC and 18F-FDG uptake in
our study, these two imaging modalities might play a
suplemantary role in detecting of breast carcinoma.
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The Contribution of FDG PET/CT in Diagnosis
and Staging of Breast Cancer
E. ARSLAN1, T. ÇERMIK1, F. CAN TRABULUS2, E.
KELTEN TALU3, S. TUTER BASARAN4; 1ISTANBUL
RESEARCH AND EDUCATIONAL HOSPITAL CLINIC
OF NUCLEAR MEDICINE, ISTANBUL, TURKEY, 2IS-
TANBUL RESEARCH AND EDUCATIONAL HOSPITAL
CLINIC OF GENERAL SURGERY, ISTANBUL, TURKEY,
3ISTANBUL RESEARCH AND EDUCATIONAL HOSPI-
TAL CLINIC OF PATHOLOGY, ISTANBUL, TURKEY,
4ISTANBUL HASEKI RESEARCH AND EDUCATIONAL
HOSPITAL CLINIC OF PATHOLOGY, ISTANBUL,
TURKEY.
Aim: In treatment selection and prediction of prognosis
of the breast cancer, accurate disease staging is the most
important requirement. In this study we aimed to inves-
tigate the contribution of FDG PET/CT to the initial
diagnosis of breast cancer. Materials and methods: We
have evaluated retrospectively 234 women (242 breast
lesions, mean ± SD: 54.6±13.8 y) with breast cancer.
PET/CT was performed 1 hour after the F-18 FDG in-
jection with I.V. contrast if there were no contraindica-
tions. Primary tumor, axillary and other nodal metastatic
foci and distant metastasis evaluated visually and semi-
quantitatively. SUV max values were calculated for T
and N. Final staging was confirmed with histopatholog-
ical results and/or follow-up PET/CT. Results: The
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primary tumors’ mean±SD SUVmax was 11.5±8.9. Up-
take threshold was accepted SUVmax≥2, sensitivity of
PET/CT for T was 97.1% (235/242). PET/CT was pos-
itive in 159 to 180 pathologically or clinically confirmed
patients with axillary metastasis. Fifty two to 61 patho-
logically confirmed axillary negative patients were neg-
ative on PET/CT. With these results; Sensitivity, speci-
ficity, positive predictive value and negative predictive
value of PET/CT for axillary metastasis were 88.3%,
85.2%, 94.6%, 71.2% respectively. There were 48
(20.5%) distant nodal metastatic patients, 27 of them
had additional distant organ metastasis in PET/CT imag-
ing. Fifty eight (24.7%) patients had distant organ me-
tastasis which had 40 bone-bone marrow,14 liver, 8
lung, 6 skin, 1 brain and 1 muscular metastasis. In pa-
tient with distant metastasis, primary tumors’ and axil-
lary lesions’ mean±SD SUVmax values were calculated
14.3±11.3, 10.6±5.5 respectively. However, same values
were calculated 10.6±7.8 and 6.9±7.8 respectively in pa-
tients without distant metastasis. There were statistically
significant differences for primary tumors (p=0.003) and
axillary metastasis (p=0.001) between two groups. Con-
clusion: This study results show that PET/CT had very
high sensitivity for primary tumor diagnosis. Although
PET/CT had high sensitivity, specificity, and positive
predictive value for the diagnosis of axillary metastasis,
the negative predictive value was not adequate in initial
staging. Because of one third of our patients had distant
organ and/or nodal involvement, we suggested that PET/
CT have strong impact on disease management in pa-
tient with breast cancer in initial staging.
P607
Relationship between primary tumor FDG SUVmax,
histologic grade, receptor and C-erbB2 status and value
in breast Cancer
E. ARSLAN1, T. ÇERMIK1, F. CAN TRABULUS2, E.
KELTEN TALU3, S. TUTER BASARAN4; 1ISTANBUL
RESEARCH AND EDUCATIONAL HOSPITAL CLINIC
OF NUCLEAR MEDICINE, ISTANBUL, TURKEY, 2IS-
TANBUL RESEARCH AND EDUCATIONAL HOSPITAL
CLINIC OF GENERAL SURGERY, ISTANBUL, TURKEY,
3ISTANBUL RESEARCH AND EDUCATIONAL HOSPI-
TAL CLINIC OF PATHOLOGY, ISTANBUL, TURKEY,
4ISTANBUL HASEKI RESEARCH AND EDUCATIONAL
HOSPITAL CLINIC OF PATHOLOGY, ISTANBUL,
TURKEY.
Aim: Histological grade and receptor status are impor-
tant criteria for the prognosis and treatment selection in
breast cancer. In this study, relationship between primary
tumor SUVmax value in PET/CT, histologic grade, es-
trogen and progesterone hormone receptors and C-erbB2
oncogene presence was investigated. Materials and
methods: We have evaluated retrospectively 234 women
(242 breast lesions, mean ± SD: 54.6±13.8 y) with his-
tologically proven breast cancer. PET/CT was performed
1 hour after the F-18 FDG injection with I.V. contrast if
there were no contraindications. Primary tumor evaluated
visually and 235 PET positive lesions’ SUVmax were
calculated semi-quantitatively. The modified Scarff-
Bloom-Richardson grading system was used for histo-
logical assessment (Grade 1-2-3), and also four groups
were separated for the estrogen and/or progesterone hor-
mone receptor status and the presence of C-erbB2 onco-
gene; Hormone(+)C-erbB2(+) (H+C+), Hormone(+) C-
erbB2(-) (H+C-), Hormone(-) C-erbB2(+) (H-C+) and
Hormone(-) C-erbB2(-) (H-C-). Results: One hundred
thirty lesions were assessed with the modified Scarff-
Bloom-Richardson grading system and 21 were grade
1, 59 were grade 2 and 50 were grade 3. These 3
groups’ mean±SD SUVmax values were 6.2±3.7, 10.1
±7.2 and 14.6±8.8 respectively. There were statistically
significant differences between 3 groups (group 1 vs 2
p=0.013; group 1 vs 3 p=0.001; group 2 vs 3 p=0.002).
Hormone receptor and C-erb B2 oncogene status defined
for 234 lesions in which 77 were H+C+, 110 were H+
C-, 23 were H-C+ and 24 were H-C. Comparison results
between four subgroups were shown at table. Although
there was no statistically significant difference between
H-C+ versus H-C- groups, significant differences were
found between other groups. Conclusion: In this study,
concordance of tumor grading with SUVmax value
showed that SUVmax could be used as a prognostic
indicator. Also, significant differences between hormone
receptor and C-erbB2 oncogene status subgroups’
SUVmax values suggested that SUVmax value may con-
tribute to the management of breast cancer.
P608
Comparison between 18F-FDG uptake patern
and apparent diffusion coefficient value obtained
from diffusion weighted magnetic resonance imaging
on the detection of primary tumour and axillary
metastases in breast carcinoma
A. Ozen, T. Sayin, O. Ekmekcioglu, S. Altinay, E. Bastug, A.
Muhammedoglu, A. Celik, R. Albayrak; Bagcilar Training
and Research Hospital, Istanbul, TURKEY.
Aim: Breast carcinoma (BC) is the most common type
of cancer in female population. Breast magnetic reso-
nance maging (MRI) detects increased blood flow and
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tissue resolution in order to diagnose cancer, thus, being
more sensitive and accurate than mammography and ul-
trasonography. When breast MRI findings are suspi-
cious, diffusion-weighted magnetic resonance imaging
(dw-MRI) provides additional information about micro-
structural characteristics of tissue and it is increasingly
performed in the evaluation of tumours. Furthermore,
the apparent diffusion coefficient (ADC) value obtained
from dw-MRI was useful in differentiating between be-
nign and malignant breast lesions. Our objective was to
compare SUVmax patern in 18F-FDG PET/CT and ADC
value of dw-MRI for the detection of primary tumour
and axillary lymph node (ALN) metastases of BC. Ma-
terials and methods: This retrospective study included 42
female patients (mean age, 51,30±12,26 years; age
range, 29-78 years) with BC. Thirty eight patients had
invasive ductal carcinoma, one of them with sarcomatoid
differentiation, 1 invasive lobular carcinoma, 1 mixed
type, 1 mucinous and 1 medullar BC. After pre-
operative staging with 18F-FDG PET/CT and dw-MRI,
mastectomy or breast conserving surgery with ALN
disection or sentinel lymph node biopsy was performed.
For histopathologic evaluation, Modified Bloom Rich-
ardson grading system was used. Furthermore, oestrogen
(ER), progesteron (PR) receptor expression and Her-2/
neu statuses were determined. SUVmax was measured
from primary tumour, metastatic ALN, the normal paren-
chymas of breast, lung and liver. Also, ADC was mea-
sured from breast tumour and metastatic ALN. SUVmax
ratios was calculated following as: •TumourSUVmax/
breas tSUVmax, •TumourSUVmax/ lungSUVmax,
•TumourSUVmax/liverSUVmax. Results: Results showed
that the primary lesion detection rate for PET/CT and
dw-MRI was 95.3%. The 18F-FDG PET/CT scan had
lower sensitivity in detecting of ALN metastases than
dw-MRI, while their specificities were equal. Higher
SUVmax and/or SUVmax ratios correlated with stage
T2 tumours, with histologic grade 3, and with negative
ER and PR receptor status. There was no correlation
between ADC and SUVmax or SUVmax ratios both
primary tumour and metastatic axillary lymph node.
Conclusion: Our study suggested that a) the primary
lesions detection rate of both 18F-FDG PET/CT and
dw-MRI was high, 95.3%. b) Both modalities had the
same specificity for the detection of ALN metastases,
but the 18F-FDG PET/CT scan had lower sensitivity
than dw-MRI and c) SUVmax and SUVmax ratios were
more compatible with pathological parameters than ADC
value. These two imaging modalities might play a
supplemantary role in the detection of BC and ALN
metastases.
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Accuracy of 18F-FDG-PET/CT in staging, restaging,
and treatment response in patients withmale breast cancer
B. Vatankulu1, S. Kuyumcu2, P. Ç. Kocael1, E. G. Işık2, S.
Asa1, S. Sağer1, M. Halaç1, C. Türkmen2, K. Sönmezoğlu1;
1İstanbul University Cerrahpaşa Medical Faculty, İstanbul,
TURKEY, 2İstanbul University İstanbul Medical Faculty, İs-
tanbul, TURKEY.
Aim: Male breast cancer, which has very different structural
features than the female breast cancer, is a scarce disease. FDG
PET / CT is considered to be the most important imaging
methods in staging, restaging and management of female
breast cancer. However there are few studies of the contribu-
tion of FDGPET / CT inmanagement of male breast cancer. In
this study we aimed to determine the significance of the FDG
PET / CT findings of male breast cancer in staging, detection
of recurrent disease and evaluation of response to the therapy.
Materials and Methods: Between January 2008 and December
2014, patients with breast cancer who underwent FDG PET/
CTwere examined retrospectively. Patients were divided in 3
groups: initial staging; recurrence of the disease; to evaluate
the response to treatment. FDG PET / CT findings were eval-
uated with histopathology and clinical outcomes of patients
with at least 6 months . Results: A total of 6842 study with
FDG PET/CT performed for breast cancer were examined.
Male breast cancer was found in only 27(0.39%) patients. 34
FDG PET CT imaging were performed in these patients with
diagnosed male breast cancer. PET/CT were performed in 10
of 27 (37%) for initial staging, 10 of 27 (37%) for restaging
and 7 of 27 (26%) for evaluating to response to the therapy. 18
of 27 patients were diagnosed with invasive ductal carcinoma,
4 of 27 were diagnosed with invasive cribriform carcinoma.
The histopathological results could not be found in 5 of 27
patients. Estrogen receptor was positive in all patients who
had histopathology results. The progesterone receptor was
positive in 20 patients and cerb - b2 gene expression was
positive only in 8 patients. PET / CT imaging sensitivity ,
specificity , positive predictive value , negative predictive val-
ue and accuracy of detection of distant metastases were calcu-
lated as 100 %, 69% , 84 % , 100 % and 92 % respectively.
Conclusion: Primary tumors and distant metastases were de-
tected with high accuracy with FDG PET / CT in male breast
cancer. FDG PET / CT was a powerful imaging technique in
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initial staging, determining the presence of recurrency and
response to therapy in patients with male breast cancer.
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Evaluation of 18F-FDG PET/CTand low-dose CT
performance in diagnosing lymph node metastases
among NSCLC patients.
J. Teodorczyk1, B. Brockhuis1, G. Romanowicz1, W.
Cytawa1, I. Wenzel1, J. Kozłowska1, L. Cunha2,3, A. Silva3,
L. Metello2,3, P. Lass1,4; 1Department of Nuclear Medicine,
Medical University of Gdansk, Gdansk, POLAND, 2Depart-
ment of Nuclear Medicine, ESTSP.IPP, Porto, PORTUGAL,
3Department of NuclearMedicine, IsoPor SA, Porto, PORTU-
GAL, 4Division of Molecular Spectroscopy, Institute of Ex-
perimental Physics, University of Gdansk, Gdansk,
POLAND.
Objective: The aim of our study is to assess the efficacy of
lymph node staging in NSCLC, with particular emphasis on
operability, using 18F-FDG-PET-CT and low-dose CT. Mate-
rial and methods: PET-CT and CT results were compared to
pathological analysis of operatively excised material, which
were used as a “gold standard”. The initial part of our study
included scanning and follow-up of 89 patients and 238 nodal
stations diagnosed with 18F-FDG-CT in Department of Nu-
clear Medicine of UCC in Gdansk and treated operatively with
pulmonectomy/lobectomy in the Department of Thoracic Sur-
gery, UCC Gdansk in years 2010-2014. Our study aims to
answer the following questions: what is accuracy of 18F-
FDG-PET-CT and CT in defining the lymph node status;
how valuable diagnostically is low-dose CTco-registered with
PET study; how to modify the criteria for the evaluation of
mediastinal lymph nodes in 18F-FDG-PET-CT and CT to ob-
tain more accurate diagnosis; what is optimal SUV cutoff val-
ue to minimize false results; how strong is the need for motion
correction; how strong is the need for partial volume effect
correction; what are differences in diagnostic quality of PET-
CT/CT between particular lymph node stations; what is the
optimal algorithm for staging and operability assessment in
patients with NSCLC; to what extent PET-CTmodifies patient
management; what is level of agreement between observers in
18F-FDG-PET-CT nodal staging; what is prognostic value of
detected glucose metabolism intensity. Results: We confirmed
the high specificity of 18F-FDG-PET-CT in diagnosing lymph
node metastases reaching 92%. Sensitivity reached 53% and
was reduced probably due to the high fraction of
micrometastases in early stages of disease. Sensitivity of
low-dose CT in detection of lymph node metastatic disease
was only 33%, probably due to the high number of
micrometastases in our group, but the specificity of low-dose
CTwas surprisingly high - 87%. The minimum of false (pos-
itive plus negative) results of 18F-FDG PET-CT was reached
by SUVmax cutoff value 5.2. Our study confirmed high agree-
ment between PET-CT observers - 0,885 and between obser-
vations of PET-CT and CT - 0,896. Conclusions: 18F-FDG-
PET-CT has relatively high specificity but moderate sensitivity
in detection of mediastinal and hilar lymph node metastases in
patients with NSCLC. 18F-FDG-PET-CTwasmuchmore sen-
sitive than CT, but only moderately more specific. Minimum
of false results (FP+FN) was obtained using relatively high
SUVmax cutoff value (5.2) for discrimination of benign and
malignant lymph nodes. Interobserver agreement in 18F-
FDG-PET-CT evaluation was high.
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The value of different 18F-FDG PET/CT baseline
measurements in predicting response
to chemo-radiotherapy in advanced NSCLC
H. N. M. Abdelwahab1, Y. G. Abdelhafez2, R. A. Amin1, A.
O. Azab1, S. El-Refaei1; 1Cairo University, Cairo, EGYPT,
2South Egypt Cancer Institute, Assiut, EGYPT.
Objectives: To investigate the predictive value of the pre-
treatment 18F-FDG PET/CT tumor measurements (SUVmax,
SUVmean, SUVpeak, MTV and TLG) regarding response to
treatment in advanced inoperable NSCLC patients receiving
chemotherapy ± radiotherapy. Patients and Methods: This ret-
rospective study included thirty patients with newly diagnosed
advanced NSCLC who were referred to our center for whole
body 18F FDG-PET/CT as a baseline staging method before
therapy and later referred again to monitor the response to the
therapy taken. For each patient, maximum, mean and peak
SUVs, metabolic tumor volume (MTV) and total lesion gly-
colysis (TLG) of the primary tumor were determined at the
pre-treatment scan. The tumor volume was measured using a
semi-automatic contouring software. The selected volumes
were based on the PERCIST threshold level (drawn on the
right lobe of the liver). Two weeks after the end of treatment,
the metabolic response of the primary tumor was evaluated
using the EORTC response criteria. The correlation between
each parameter and the response was done using Student’s T-
test. Receiver operating characteristic methodology was used
to assess the performance of the different parameters to differ-
entiate responders from non-responders (which included
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progressive and stable metabolic disease). Results: ROC anal-
ysis identified SUVmax value of 8.7, MTV value of 12.18 and
TLG value of 283.9 as the best predictive cut-off values for the
presence of response. These values gave modest sensitivity of
67%, 42% and 67% and specifity of 56%, 78% and 62%
respectively. Though not high, the accuracy of TLG (61%)
was highest in predicting the tumor response to therapy, and
next was the accuracy of MTV (58%), indicating that volume-
based PET parameters are more accurate than SUVmax (49%)
in identifying future responders from non-responders prior to
treatment. Conclusion: Baseline TLG has better predictive val-
ue than SUVmax for the response to chemo-radiotherapy in
advanced NSCLC, however this value is statistically non-
significant.
P612
Dual-phase F-18 FDG PET diagnosis of pulmonary
adenocarcinoma smaller than 3 cm
K. Hayasaka1, T. Nihashi2, H. Inoue1, T. Saitoh1, Y.
Shiraishi1, K. Yoshimori1, H. Gotoh1; 1Fukujyuuji Hoaspital,
Tokyo, JAPAN, 2Nagoya Graduate Scholl of Medicine, Na-
goya, JAPAN.
Objective: To evaluate the applicability of SUVmax to pulmo-
nary adenocarcinoma subtypes < 3 cm excluding variants.
Materials and Methods: We used FDG-PET to evaluate 187
nodules in 185 patients (86 male, n = 86; female, n= 99; age,
68.7 y; SD, 9.9 y) with pathologically proven pulmonary ad-
enocarcinomas (excluding variants) less than 3 cm. The nod-
ules were classified as pre-invasive (Group 1), minimally in-
vasive and invasive lepidic-predominant adenocarcinoma
(Group 2) and invasive adenocarcinoma other than invasive
lepidic-predominant adenocarcinoma (Group 3) according to
the International Association for the Study of Lung Cancer
(IASLC)/the American Thoracic Society (ATS)/the European
Respiratory Society (ERS) (IASLC/ATS/ERS) 2011. Dual
phase FDG-PET imaging proceeded one and two hours after
FDG injection. The maximum standardized uptake value
(SUVmax) on 1-h (E-SUVmax), 2-h (D-SUVmax) images
and the ratio of changes in the SUVmax (%CR-SUVmax)
were compared between the two time points. All information
was obtained from a retrospective review of medical records,
PET findings and other data. All data were statistically ana-
lyzed using SPSS Version 11.0 software (SPSS Inc., Chicago,
IL, USA). Statistical significance was set at p < 0.05. Results:
The mean (SD) sizes of nodules were 12.8 (5.46), 15.9 (5.35)
and 18.6 (5.85) mm in Groups 1, 2 and 3, respectively. Differ-
ences in nodule size were statistically significant between
Groups 1 and 3, and between Groups 2 and 3. The means
(SD) of the E-SUVmax, D-SUVmax and the %CR-SUVmax
in Groups 1, 2 and 3 were 1.08 (1.06), 1.09 (0.40) and 3.04
(12.5), 1.81 (1.12), 1.93 (1.37) and 8.44 (16.9), and
4.41(3.44), 5.34(4.31) and 19.1(20.3), respectively. Differ-
ences were statistically significant for D-SUVmax between
Groups 1 and 2, 1 and 3, and 2 and 3, and for in E-SUVmax
and %CR-SUVmax between Groups 1 and 3, and 2 and 3.
Conclusions: The %CR-SUVmax was not enhanced among
subtypes of pulmonary adenocarcinoma, but delayed FDG
PET was more useful than early FDG PET for differentiating
adenocarcinoma subtypes < 3 cm except variants. Dual-phase
F-18 FDG PET imaging might offer improved diagnostic per-
formance for each subtype of pulmonary adenocarcinoma <
3 cm excluding variants.
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Role of F-18 FDG PET in the differential diagnosis
between mediastinal malignant lymphoma and thymic
epithelial tumors
T. Yamane, A. Seto, I. Matsunari, I. Kuji; Saitama Interna-
tional Medicial Center, Saitama Medical University, Hidaka,
JAPAN.
[Aim] Although differentiating lymphoma from other epithe-
lial tumors are extremely important in the initial management
of mediastinal tumors, there has been a limit in the conven-
tional imaging modalities. The aim of this study is to evaluate
the capability of F-18 FDG PET in the diagnosis of mediasti-
nal tumor. [Materials and Methods] Patients with mediastinal
tumors who underwent F-18 FDG PET/CT before treatment
were enrolled in this study. After confirmation of histological
diagnosis, patients with 4 representative diseases (49 female
and 43 male, age range 17-84, median 58) were analyzed; 14
cases of thymic cyst (CY), 46 of thymoma (TM), 22 of thymic
cancer (CA) and 16 of malignant lymphoma (ML). Hodgkin’s
lymphoma and primary mediastinal large B-cell lymphoma
were included in the group of ML. Maximum standardized
uptake value (SUVmax) of the tumors were measured and
compared among the tumor groups. In addition, the data of
patients’ age was added to the analysis. Wilcoxon’s test and
receiver operating characteristic (ROC) analysis were used to
compare each element and to determine cut off points. [Re-
sults] There were significant differences in SUVmax between
the groups of CYand TM, TM and CA, and CA and ML (P <
0.001, respectively). In addition, there were significant differ-
ences in ages between ML and each group (P < 0.001, respec-
tively). Based on the results of the ROC analysis, categoriza-
tion for each group was defined as follows: CY = SUVmax <
1.45, ML = SUVmax ≥ 11.16 and age < 47.5 y, CA =
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SUVmax ≥ 7.26 and age ≥ 47.5, and TM = the others. Sensi-
tivity, specificity, positive predictive value and negative pre-
dictive value of each group were 92.0%, 100%, 100%, and
98.8% in CY, 91.3%. 88.5%, 87.5% and 92.0% in TM,
81.8%, 92.1%, 76.0% and 94.5% in CA, and 81.3%, 100%,
100% and 96.5% in ML, respectively. [Conclusions] Medias-
tinal tumors can be distinguished by the SUVmax of F-18
FDG PET. Information of patients’ age can increase the diag-
nostic capability of differentiating malignant lymphoma from
thymic cancer.
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Whole-Body Bone Scintigraphy and SerumConcentration
of Bone Resorption Marker in Patients with Lung Cancer
J.Weissensteiner1, E. Babusikova2; 1Department of Nuclear
Medicine, Hospital Poprad, SLOVAKIA, 2Comenius Univer-
sity in Bratislava, Jessenius Faculty of Medicine in Martin,
Department of Medical Biochemistry, Martin, SLOVAKIA.
Introduction: Lung cancer is one of the most common and
serious types of cancer. Beta-carboxyterminal cross-linking
telopeptide of type I collagen (β-CTx) is marker of bone re-
sorption and is a specific marker for the degradation of mature
type I collagen in bone. The aim of this study was to correlate
serum concentration of β-CTx with the presence of bone me-
tastases detected by whole-body bone scintigraphy in patients
with lung cancer. Material and methods: We estimated serum
concentration of biochemical marker of bone metabolism ß-
CTx and we did whole-body bone scintigraphy in 60 patients
(46 men, 14 women) with lung cancer and in 10 patients with-
out malignant disease - control group. A whole-body bone
scintigraphy were obtained by using of a hybrid SPECT/CT
scanner. The study populations included 50 non-small-cell
lung cancers (NSCLC), 9 small-cell lung cancers (SCLC)
and 1 patient with typical carcinoid of lung. Results: The bone
metastases by whole-body bone scintigraphy were in 15 cases
(25 %), probably bone metastases were in 11 cases (18.33 %)
and 34 patients (56.67 %) were without bone metastases. We
did not observed significant difference inβ-CTx concentration
between patients and control subjects (p=0.09). The serum
concentrations of ß-CTx were above reference range in 9 cases
from 60 patients (15 %) - 7 cases were patients with NSCLC
(4/10 with bone metastases, 1/7 probably bone metastases,
2/33 without bone metastases), 2 cases were patients with
SCLC with bone metastases. The concentrations below refer-
ence range were observed in 8 cases from 60 patients (13.33
%) - in 7 cases with NSCLC (2/10 with bone metastases, 2/7
probably bone metastases, 3/33 without bone metastases), in 1
case with SCLC (1/4 with bone metastases). We observed
significant difference in β-CTx concentration between pa-
tients with bone metastases and control subjects (p=0.02).
Patients with bone metastases had higher concentration of β-
CTx than control subjects and slightly increased than patients
without bone metastases (p=0.06). Conclusion: The serum
concentration of ß-CTx correlated with bone metastases find-
ing by bone scintigraphy in patients with lung cancer. Deter-
mination of beta-carboxyterminal cross-linking telopeptide of
type I collagen could be a diagnostic marker in lung cancer
patients with suspected bone metastases.
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NSCLC: Comparison of PET-CT and contrast enhaced
CT in mediastinal staging and PET-CT diagnosis of lung
cancer recurrence-impact on patient management
N. Beslic, A. Sadija, T. Ceric, R. Milardovic, S. Ceric, A.
Beganovic, S. Kristic; University Clinical Center, Sarajevo,
BOSNIA AND HERZEGOVINA.
INTRODUCTION: NSCLC is any type of epithelial
lung carcinoma other than SCLC. The possibility of a
surgical cure is dependent upon the extent of disease,
particulary mediastinal staging. Accurate staging of me-
diastinal lymphnodes provides important prognostic in-
formation and is mandatory in determining treatment
strategy. CT as a standard method of diagnosis and stag-
ing of lung cancer provides very good morphological
data, but it has limitations in differentiating benign from
malignant lesions. PET-CT based on metabolic activity
has shown superiority in nodal staging and is very sen-
sitive for diagnosis of recurrent NSCLC with a signifi-
cant effect in change of management. MATERIALS
AND METHODS: Total of 54 patients with NSCLC
were retrospectively evaluated and divided in two
groups. In I group we evaluated 26 patients in medias-
tinal nodal staging comparing contrast enhaced CT and
PET-CT findings. Group II included 28 patients where
we evaluated changes in patient management after PET-
CT diagnosis of recurrent lung disease. DISCUSSION:
In group I we found no differences in nodal staging in
50% patients comparing PET-CT vs CT. Other 50% of
patients have been upstaged or downstaged after PET-
CT study comparing to previous CT with 27% of pa-
tients who had an impact on further management. In
group II we found 36% patients with no signs of recur-
rent disease. PET-CT detected local recurrence in 64%
patients with 54% patients having qualitative change in
therapy after PET-CT study. CONCLUSION: The accu-
rate staging of NSCLC is important in planning optimal
treatment strategy. Integrated PET-CT combining the
benefits of both is a mandatory tool for initial nodal
staging. PET-CT improved the diagnosis of recurrent
NSCLC and this resulted in a significant impact and
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change in further patient management in both patient
groups.
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Prognostic Value of Early Response Assessment Using
FDG PET/CT in Chemotherapy-Treated Patients
with Non-Small Cell Lung Cancer
E. Han1, W. Lee2, W. Choi3, S. Kim4; 1Daejeon St. Mary’s
Hospital, College of Medicine, The Catholic University of
Korea, Daejeon, KOREA, REPUBLIC OF, 2College of Med-
icine, Chungbuk National University, Cheongju, KOREA,
REPUBLIC OF, 3St. Vincent Hospital, College of Medicine,
The Catholic University of Korea, Suwon, KOREA, REPUB-
LICOF, 4Seoul St. Mary’s Hospital, College ofMedicine, The
Catholic University of Korea, Seoul, KOREA, REPUBLIC
OF.
Purpose: To evaluate the prognostic value of early response
assessment using a volumetric [18F]-fluoro-2-deoxy-glucose
(FDG) positron emission tomography (PET) analysis in pa-
tients with non-small cell lung cancer (NSCLC) treated using
first-line chemotherapy. Methods: We retrospectively
reviewed 33 patients with NSCLCwho received first-line che-
motherapy and performed FDG PET/computed tomography
before (baseline PET) and after 2 cycles of chemotherapy (in-
terim PET). The maximum standardized uptake value
(SUVmax) and metabolic tumor volume (MTV) of the total
malignant lesion were measured in baseline (SUV1 and
MTV1) and interim (SUV2 and MTV2) PET images, and
percentage changes in SUVmax (ΔSUV) and MTV (ΔMTV)
were calculated between the two PET images. We compared
PET parameters and clinicopathologic variables such as age,
sex, performance status, smoking history, histologic subtype,
and TNM stage in terms of 2-year overall survival (OS). Re-
sults: The median follow-up period was 15 months and 2-year
OS was 34%. In PET images, the mean SUV1,MTV1, SUV2,
MTV2, ΔSUV, and ΔMTV were 13.1 ± 4.5, 307.9 ± 340.0
cm3, 9.5 ± 5.1, 180.4 ± 29.6 cm3, 27 ± 28%, and 42 ± 65%,
respectively. In univariate analysis, M stage, TNM stage, and
all 6 PET parameters correlated significantly with OS. Corre-
lations with MTV1 and ΔMTV remained significant in mul-
tivariate analysis (P < .05). Conclusion: A smaller baseline
MTV and greater decrease in MTV between baseline and in-
terim PET images correlate statistically with a significantly
prolonged OS in chemotherapy-treated patients with NSCLC.
Avolume-based FDG PETanalysis would facilitate prediction
of clinical outcome and identification of treatment-resistant
patients early during chemotherapy and could thereby be ap-
plied to personalized treatment approaches for patients with
NSCLC.
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Surprising 18F-FDG PET/CT scan findings in patient
with elevated CA125
A. Mazurek1,2, M. Dziuk1,2, E. Witkowska-Patena1, S.
Piszczek1,2, A. Gizewska1,2; 1Military Institute of Medicine,
Department of Nuclear Medicine, Warsaw, POLAND,
2Affidea Masovian PET/CT Center., Warsaw, POLAND.
The aim of the case report is to present the utility of 18F-FDG
PET/CT in a patient with elevated CA125 levels. A 51-year-
old female patient was diagnosed with recurring transudate
fluid in the right pleural cavity. Her medical history was neg-
ative for smoking or exposure to asbestos, without any features
of cardiovascular insufficiency or infection. Transvaginal ul-
trasound showed cyst-like focal lesion in the right ovary. Lab-
oratory tests revealed elevated blood CA125 levels. The pa-
tient was referred for 18FDG PET/CT scan with suspected
ovarian cancer (suspected Meigs’ syndrome). However, no
signs of pathological accumulation of the tracer in the right
ovary were observed. Surprisingly, 18FDG-PET/CT scan
showed increased focal uptake of 18FDG in right pleural cav-
ity with a significant amount of fluid. Thoracoscopy based on
PET/CT findings revealed multiple nodules of right pleura.
Histopathological examination of these lesions yielded the di-
agnosis of mesothelioma. As pleural effusion can result from
many medical conditions, including cancer, finding its cause
may pose a major challenge to physicians. Although elevated
CA125 levels are mainly observed in ovarian malignancy, the
marker is not specific for this type of cancer only. Elevated
CA125 may be observed in numerous types of cancer, includ-
ing pleural mesothelioma. In our case report, the medical his-
tory and performed tests results were suggestive of ovarian
cancer as the cause of patient’s symptoms. It was only 18F-
FDG PET/CT scan that suggested the diagnosis of
mesothelima, which was further confirmed by histopatholog-
ical examination.
P618
The diagnostic value of 18FDG-PET/CT and DWI
for the detection of mediastinal nodal metastasis in lung
cancer: Which is better?
G. Shen, Z. Jia, H. Deng, A. Kuang; West China Hospital of
Sichuan University, Chengdu, CHINA.
Aim: Accurate clinical staging of mediastinal lymph nodes of
patients with lung cancer is important in determining therapeu-
tic options and prognoses.We aimed to compare the diagnostic
performance of diffusion-weighted magnetic resonance imag-
ing (DWI) and 18F-fluorodeoxyglucose positron emission
tomography/computed tomography (18F-FDG PET/CT) in
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detecting mediastinal nodal metastasis in patients with lung
cancer. Materials and methods: Relevant studies about
18FDG PET/CTand DWI for detecting mediastinal nodal me-
tastasis in lung cancer were systematically searched in the
MEDLINE, EMBASE, PUBMED and Cochrane Library da-
tabases from January 2001 to December 2014. We determined
sensitivities and specificities across studies, calculated positive
and negative likelihood ratios (PLR and NLR), and construct-
ed summary receiver operating characteristic (SROC) curves
with Q* index obtained. The methodologic quality was
assessed using the Quality Assessment of Diagnostic Accura-
cy Studies tool (QUADAS 2). In addition, the publication bias
was assessed by Deek’s funnel plot of the asymmetry test. The
potential between-study heterogeneity was explored by sub-
group analyses and meta-regression analyses. Results: A total
of 46 studies (39 studies for 18F-FDG PET/CT and 7 studies
for DWI) met the inclusion criteria involving 6207 patients.
The pooled sensitivities and specificities of PET/CTwere 0.70
[95% confidence interval (CI): 0.61-0.77] and 0.92 (95% CI:
0.87-0.94), respectively. The corresponding values of DWI
were 0.71 (95% CI: 0.54-0.84) and 0.94 (95% CI: 0.82-
0.98), respectively. For DWI, the overall PLR was 12.38
(95% CI: 4.17-36.81) and the NLR was 0.31 (95% CI: 0.19-
0.50). For PET/CT, the PLR was 8.18 (95% CI: 5.55-12.04)
and the NLR was 0.33 (95% CI: 0.26-0.43). The results of the
funnel plot asymmetry test for publication bias revealed no
major publication bias (p=0.579, bias=-6.00 for PET/CT vs.
p=0.958, bias=-2.11 for DWI). In addition, the study design
(retrospective or prospective) was a potential cause for the
heterogeneity. Conclusions: Both 18F-FDG PET/CT and
DWI are beneficial in detecting mediastinal lymph nodes me-
tastases in lung cancer. However, there was no significant dif-
ference of diagnostic performance between these two
modalities.
P619
Correlation of [18F]FDG Uptake with Clinical
and Laboratory Parameters in Patients with Lung Cancer.
M. Boudali1, E. Skoura2, S. Michopoulou2, I. E. Datseris1,
K. N. Syrigos3; 1Evangelismos General Hospital, Athens,
GREECE, 2UCLH, London, UNITED KINGDOM, 3Oncol-
ogy Unit GPP, University of Athens, School of Medicine,
Athens, GREECE.
Aim: This prospective study aimed to evaluate the correlation
between [18F]FDG uptake in PET/CT imaging, measured by
maximum standardized uptake value (SUVmax), with several
tumor markers and histopathological results in patients with
lung cancer. Materials and Methods: Patient demographics
data, indications for [18F]FDG PET/CT and the correlation
of SUVmax values with histopathological data and with
several tumor markers level- CEA, Ca 125, Ca19-9, Ca15-3,
AFP, NSE- were assessed. Results: During two year time, a
total of 189 patients with lung cancer were included in this
prospective study. The group included 137 males and 52 fe-
males with a mean age of 63.9 years old. The majority of the
patients’ clinical indication was the initial staging. Regarding
the correlation of SUVmax with laboratory and histopatholog-
ical data, there was no significant difference for SUVmax
values across the histological types identified (adenocarcino-
ma, squamous cell carcinoma and small cell lung carcinoma).
By contrast, a significant difference in CEA values, between
the three different histological types, was found, with the
highest values identified in adenocarcinomas (p<0.05). Fur-
thermore, no significant correlation was identified between
the SUVmax value and the levels of six different tumor
markers-CEA, Ca 125, Ca19-9, Ca15-3, AFP, and NSE. Con-
clusion: This prospective study showed no significant differ-
ence regarding the SUVmax values in different histologic sub-
types of lung cancer or any correlation with the levels of sev-
eral tumor markers examined for lung cancer. On the contrary,
there was a significant difference in CEAvalues for the differ-
ent histopathological categories identified, with the highest
values in adenocarcinomas.
P620
PET/CT imaging artifacts after talc pleurodesis - a clinical
case.
Z. Dancheva, P. Bochev, B. Chaushev, T. Yordanova, A.
Klisarova; St Marina University Hospital , Varna,
BULGARIA.
Introduction. Talc pleurodesis is a reliable therapy, preventing
recurrent pleural effusions and pneumothoraces. As it is based
on local granulomatous inflammation, it is a potential source
of pitfalls and artifacts on PET/CT images. Case and discus-
sion. We present a 67 year old woman with a PET/CT positive
scan seven months after talc pleurodesis, performed after met-
astatic effusion. The patient has held six chemotherapy courses
with Paclitaxel and Carboplatin. She was in a good perfor-
mance status ECOG 1, without significant pleural effusions
and no computer tomography signs of progression. We per-
formed a PET/CT scan after the last chemotherapy course for
restaging. At MIP images there were many metabolically ac-
tive linear, nodular and diffuse patterns of high metabolic ac-
tivity in both pleurae and out of the thoracic cavity, mimicking
implantation metastases. The SUVmax of the findings was up
to 7.0. As the patient had a previous medical history for met-
astatic pleuritis, a progression was suspected at first sight. The
PET positive findings were associated with CT images of
high-attenuation pleural plaques, located in the left anterior
and posterior costophrenic angle, and diffusely engaging the
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diaphragm pleura in the left. In the right there was a band of
linear radionuclide uptake in the subcutaneous tissues,
forming a submuscular high attenuation deposits. A metabol-
ically active fistula through the intercostal space was found,
where some of the hyperdence deposit passes through and
could be visualized in the interlobar space between lower
lobes. No parenchymal metastases and enlarged and metabol-
ically active thoracic lymph nodes were found. The high at-
tenuation deposits raised a suspicion of a talc induced inflam-
mation, which was confirmed after biopsy and histology ex-
am. Conclusion. Talc pleurodesis produces increased FDG
uptake on PET and high-density areas of pleural thickening
on CT. When PET detects increased uptake in the pleural
space, correlation with CT is recommended to detect the pres-
ence of pleural thickening of increased attenuation that sug-
gests talc deposits rather than tumor. Key words: talc
pleurodesis, metastatic pleuritis, PET/CT, arfifacts
P621
The metabolic change of dual-time-point 18F-FDG
PET/CT in patients with suspected of having lung cancer
J. Lee1, S. Jang1, J. Lee2, E. Kim2, H. Jeong2, J. Rho3, S.
Cho4; 1Department of Nuclear Medicine, CHA Bundang
Medical Center CHA University, Seongnam, KOREA, RE-
PUBLIC OF, 2Department of Internal Medicine, CHA
Bundang Medical Center CHA University, Seongnam, KO-
REA, REPUBLIC OF, 3Department of Radiology, CHA
Bundang Medical Center CHA University, Seongnam, KO-
REA, REPUBLIC OF, 4Department of Pathology, CHA
Bundang Medical Center CHA University, Seongnam, KO-
REA, REPUBLIC OF.
The purpose of this study is to investigate the role of metabolic
percentage variation in dual-time-point (DTP) (18)F-FDG
PET/CT scans for differentiating diagnosis in patients diag-
nosed as or suspected of having lung cancer. A total 73 DTP
(18)F-FDG PET/CT studies in patients suspected of having
lung cancer patient were evaluated, retrospectively. The values
of maximum standardized uptake (SUVmax), metabolic tumor
volume (MTV), total lesion glycolysis (TLG) of lung lesion
using a threshold derived mediastinal blood pool activity were
obtained in early phase (early SUVmax, early MTV, early
TLG) and delayed phase (delayed SUVmax, delayed MTV,
delayed TLG) and the %ΔSUVmax, %ΔMTV, and %ΔTLG
were calculated. These values were compared between benign
and malignant tumors and between histological subtypes (ad-
enocarcinoma (ADC), squamous cell carcinoma (SqCC),
small cell lung cancer (SCLC), and inflammatory lesion) by
the Mann-Whitney U test. The 64 cases were malignancy
(87.6%) and histological subtype of ADC was most common
(51.5%) in the cancer patient. The values of early MTV and
delayed MTV were significant difference between malignant
and benign tumors (p = 0.035, p = 0.029), while there were no
significant differences in the values of %ΔSUVmax,
%ΔMTV, and %ΔTLG. Among histological subtype groups,
the %ΔSUVmax value in ADC group was significant lower
than the %ΔSUVmax in SqCC group (p = 0.016) and SCLC
group (p = 0.025), whereas other values were not statistically
significant between histological subtypes. The metabolic
change of DTP (18)F-FDG PET/CT is not useful for discrim-
inating between benign and malignant lungmasses or nodules.
The SUVmax percentage variation in ADC is likely to be
lower than other types of cancer.
P622
Prognostic Significance of Changes of Volumetric
Metabolic Parameters in 18F-FDG PET/CT During and
After Radiotherapy in Stage III Non-Small Cell Lung
Cancer
N. Chiu, W. Su, H. Guo, B. Lee, H. Chen; National Cheng
Kung University Hospital, Tainan, TAIWAN.
Aim: We conducted this prospective study to explore the pre-
dictive value of volumetric metabolic parameters determined
by during and after radiation-based therapy 18F-FDG PET/CT
in stage III non-small cell lung cancer (NSCLC) patients. Ma-
terials and methods: Patients with stage III NSCLC planned to
receive definitive chemo-radiation or radiotherapy were eligi-
ble. 18F-FDG PET/CTwas performed before (PET 1), during
(at the 5th week, PET2) and after treatment (3 months later,
PET3).Metabolic tumor volume (MTV) and tumor total lesion
glycolysis (TLG) were measured and correlated with treatment
response and survival. ΔMTV was calculated by subtracting
the MTVof PET1 from MTVof PET2 or PET3 and dividing
by MTV of PET1. ΔTLG was calculated by subtracting the
TLG of PET1 from TLG of PET2 or PET3 and dividing by
TLG of PET1. Univariate analysis was performed to assess the
prognostic significance of ΔMTVand ΔTLG. Results: There
were 30 patients enrolled initially, but 5 patients were excluded
due to multiple metastases or double cancer. Twenty three
received concurrent chemoradiotherapy and 2 patients re-
ceived radiotherapy alone. The median radiotherapy dose
was 70 Gy. During radiotherapy PET/CT and post-treatment
PET/CT were performed in 25 and 19 patients, respectively.
The median follow-up time was 34 months. The estimated
median progression-free survival (PFS) was 8 months. Using
the median of these parameters as a cut-off, during radiother-
apy ΔTLG (cut-off: 65%) was a significant prognostic factor
for PFS and overall survival (all P = 0.02). While during ra-
diotherapyΔMTV (cut-off: 40%), post-treatmentΔTLG (cut-
off: 80%), and post-treatmentΔMTV (cut-off: 65%) were not.
Conclusion: Changes of TLG determined by during
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radiotherapy 18F-FDG PET is promising for predicting out-
come of patients with stage III NSCLC. It has the potential to
facilitate early response-adapted treatment strategies.
P623
Maximum standardized uptake value cutoff point
of the lymph nodes metastases in NSCLC detected
by FDG-PET/CT - a prognostic value
N. Georgieva1, Z. Dancheva2, P. Bochev2, B. Chaushev2, T.
Yordanova2, A. Klisarova2, K. Peeva3; 1Department of Phys-
ics, Biophysics, Roentgenology and Radiology Medical Fac-
ulty, Trakia University, Stara Zagora, BULGARIA, 2Nuclear
Medicine Department, St. Marina University Hospital, Varna,
BULGARIA, 3Department of Social Medicine and Health
Management, Medical Faculty, Trakia University, Stara
Zagora, BULGARIA.
Aim: To determine the prognostic diagnostic value of the in-
creased lymph nodes SUVmax in NSCLC patients and its
relation to their survival. Materials and Methods: We studied
73 pre-treatment patients with NSCLC using 18FDG-РЕТ/
СТ. There were 53 men (72,6%) and 20 women (27,4%), in
the range of 18-79 years old. Increased pathologic SUVmax
was detected in 184 lymph nodes. Patients were staged accord-
ing to TNM and final diagnosis registered in Bulgarian Na-
tional Cancer Registry (BNCR). Disease beginning in the
BNCR was considered either the date of registration or the
operation date. Patients who presented with NSCLC between
July 2009 and July 2012 were included in18FDG-РЕТ/СТ
pre-treatment examination and survival was followed-up until
April 2014. The distribution in BNCR according to N was as
follows: 18 patients had N0 (24,7%), 10 had N1 (13,7%), 21
had N2 (28,8%), 11 had N3 (15,1%) and 13 patients had Nx
(17,8%). The correlations between the primary tumor
SUVmax and the lymph nodes SUVmax were evaluated by
Spearman correlation coefficient. A cutoff point was defined
through the log-rank test and the Wilcoxon test. The survival
was evaluated by the Kaplan-Meier method. Comparison be-
tween study groups was performed by the Mantel-Cox Log
Rank with level of significance P<0.05. Results: Between
the primary tumor SUVmax and the lymph nodes SUVmax
there was statistically significant (Р<0,05) positive weak cor-
relation (r=0,297). Between the lymph nodes SUVmax and the
survival there was statistically significant (Р=0,0001) moder-
ate inverse correlation (r=-0,311). At cutoff point equal to 4,5
for the lymph nodes SUVmax, the following NSCLC patients
survival rate was estimated in months: for SUVmax<4,5,
Mean=23,1, Median=16,8; for SUVmax≥4,5, Mean=10,5,
Median=7,1. The studied factor lymph nodes SUVmax was
considered as a dichotomous variable. It influenced statistical-
ly significant the survival of the NSCLC patients (Р=0,0001).
Statistically significant correlation was not established be-
tween the survival, the presence of lymph nodes with in-
creased SUVmax and the histology of the primary tumor. Con-
clusion: The survival of the NSCLC patients is significantly
dependent on the regional lymph nodes SUVmax before treat-
ment. Regional lymph nodes SUVmax before treatment over
4,5 is a cutoff point which defines risk for worse survival and
in operable patients it implies additional treatment options af-
ter the surgical intervention.
P624
Value of Tc99m-Thyrosine-Octreotide in characterization
of lung masses
B. Mahmoudian1, S. D. Oskoei1, M. Nazemiyeh2, R.
Javadrashid3; 1Division of Nuclear Medicine, Imam Reza
Hospital, Faculty of Medicine, Tabriz University of Medical
Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF, 2Tuber-
culosis and Lung Research Center, Imam Reza Hospital, Fac-
ulty of Medicine, Tabriz University of Medical Sciences, Ta-
briz, IRAN, ISLAMIC REPUBLIC OF, 3Department of Ra-
diology, Imam Reza Hospital, Faculty of Medicine, Tabriz
University ofMedical Sciences, Tabriz, IRAN, ISLAMICRE-
PUBLIC OF.
Aim: The aim of our study was to assess the value of Tc99m-
Thyrosine-Octreotide single photon emission tomography
(SPECT) in characterization of lung masses which appeared
ambiguous on computerized tomography (CT). Also incre-
mental value of fusion of SPECT images on CT slices were
assessed prior to lung biopsy. Materials and Methods: Twenty
five consecutive patients (15 men and 10 women; mean age
59.2±13 years) with lung mass on CT scan were referred for
nuclear imaging for characterization of pulmonary mass, prior
to performing trans-thoracic CT guided lung biopsy. They
were prospectively allocated to undergo whole-body scintig-
raphy (WBS) and SPECT using Tc99m-Thyrosine-Octreotide
imaging. Then fusion of reconstructed SPECT images on CT
scan slices was performed using dedicated Siemens E-Cam
gamma camera software. Anatomic landmarks were used for
co-registration of images. Histologic findings after tissue bi-
opsy and also one year follow-up results served as gold stan-
dard for determining diagnostic accuracy of somatostatin re-
ceptor imaging in characterization of lung masses. Qualitative
visual assessment was complemented by semiquantitative
analysis based on target to background count ratio on opposite
side. Results: Among the 25 pulmonary lesions scanned with
Tc99m-Thyrosine-Octreotide, focal uptake was increased in
17 of 19 malignancies, whereas no uptake was found in 5 of
6 benign lesions (89.5% sensitivity, 83.3% specificity, 94.5%
PPV, 71.4% NPV) on SPECT. Planar scan had lower sensitiv-
ity than SPECT images (76.6% versus 89.5%, respectively),
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which is more considerable in small sized lesions with diam-
eter less than 1 centimeter. In semiquantitative study malignant
lesions showed higher target to background ratios comparison
to benign lesions (1.39±0.28 vs. 1.04±0.13 with p<0.01 in
planar and 2.39±1.04 vs. 1.33±0.58 with p=0.01 in SPECT,
respectively). Considering co-registered SPECT on CT, lung
biopsy was delayed in 5 and site of biopsy was changed in 2
from 25 patients. Conclusion: This study demonstrates that
Tc99m-Thyrosine-Octreotide have diagnostic value for char-
acterizing pulmonary lesions that appear ambiguous on CT.
Also co-registration of SPECT images on CT scan slices has
incremental value in management of about 28% of patients
with lung masses, which are candidate for lung biopsy. Key
Words: Tc-99m-Thyrosine-Octreotide, SPECT/CT, lung mass,
biopsy
P625
Self-pleural in culture of autologous tumor cells
from human lung adenocarcinoma by 18F-FDG imaging
and chemotherapy drug sensitivity
L. Chen, C. Liu, J. Cao, J. Lou, J. Jiang, W. Xie, S. Yang;
Shanghai Chest Hospital, Shanghai, CHINA.
Aim: Trying to set up a new method for individualized cancer
therapy. Methods: From April 2010 to July 2013, a total of 28
patients with pleural metastases diagnosed with adenocarcino-
ma originating in lung by 18F-FDG imaging. The pleural ef-
fusion were sterile piercing collection (250-500mL) contain-
ing 10U/mL heparin, 100U/mL Penicillin, 100μg/mL Strepto-
mycin and 0.2% Gentamicin after blending incubated in a
37°C humidified atmosphere with 5% CO2. The effusion cells
were collected by centrifugation on discontinuous Ficoll-
Hypaque as Lymphocyte separation medium density gradients
settings 1000g for 25 minute. Cells were inhaled to cell culture
flasks with 8 mL fresh pleural per flask. After incubation,
changed pleural as medium every day to remove non-
adherent cells. The immunocytochemical analysis comprised
of cell adhesion molecule CK7, TTF-1. Adherent cells were
harvested from the flask when cells were estimated at a total
amount of 3-5 × 105 cells. 3000-5000 / 0.1 mL autologous,
control group cells and blank were distributed in 75, 18, 3 of
96-well plates, respectively. After incubation 24 h, preparation
of drug concentration (high, middle, lower) to choose eight
kinds of chemotherapy drugs commonly used lung cancer,
Vinorelbine, Paclitaxel, Docetaxel, Gemcitabine, Pemetrexed,
Cisplatin, Carboplatin, Ifosfamide, then added the drugs to 96-
well plates respectively. Incubation 72h, CCK-8 (Dojindo, Ja-
pan) 10μL/ well was added and optical density (OD) was
measured at 450 nm by a microplate reader (Bio-rad, USA)
at 2 h. Results: The laboratory report showed Vinorelbine,
Paclitaxel and Gemcitabine are listed in the top three preferred
drugs besides Cisplatin, Carboplatin. Clinical data showed
partial response (PR) NP/NC 63.15%, DP/DC 15.8%, AP
15.8%, GP 5.3%, respectively. Stable disease (SD) NP/NC
19.2%, DP/DC 42.3%, GP 15.4%, AP 15.4%, TC 7.7%, re-
spectively. Progressive disease (PD) NP/NC 17.4%, GP/GC
34.8%, DP/DC 13%, TP/TC 13%, AP 21.7%. Time to prog-
ress (TTP) NP/NC 6-24mo, GP 0-19mo, DC/DP 6-14mo, AP
2-7mo, respectively. Overall survival (OS) NP/NC 45.57mo,
GP 28.4mo, DP/DC 24mo, AP 20.2mo, respectively. Conclu-
sion: 18F-FDG identifying imaging, self-medium and xeno-
free in cell culture, short-time obtained autologous cells, ap-
propriate drugs, good communication between laboratory and
clinical is key of individualized cancer therapy. Note: NP,
vinorelbine, cisplatin; NC, vinorelbine, carboplatin; DP, doce-
taxel, cisplatin; DC, docetaxel, carboplatin; TP, paclitaxel, cis-
platin; TC, paclitaxel, carboplatin; GP, gemcitabine, cisplatin;
AP, pemetrexed, cisplatin.
P626
Which factors are affecting development of the axillary
metastasis in lung cancer?
F. USTUN, G. Durmuş Altun; Trakya University Medical
Faculty, Edirne, TURKEY.
Aim: In lung cancer, axillary lymph nodemetastasis is rare and
is classified as a distant lymph nodemetastasis. In the presence
of axillary lymph node metastasis in lung cancer, are consid-
ered as the N3 in the staging system. We performed a retro-
spective study. The aim is this study to evaluate (i) the pres-
ence of axillary lymph node metastasis, and (ii) the effect of
the primary tumours characteristics to development the metas-
tasis of axillaries lymph node. Materials and Methods: We
retrospectively reviewed F-18 FDG PET/CT images with pri-
mary lung cancer performed at our institution from October
2009 to December 2014 to identify axillary’s lymph node
FDG uptake. 35 patients were identified. We re-evaluated pa-
tients PET/CT parameters, medical records and pathological
reports. Results: Among 35 patients with increased axillary
lymph node uptake on PET/CT, 5 patients were identified by
histopathologically benign. The mean age was 58.6 years
(range, 32-84). In 30 patients, lymphatic metastasis to medi-
astinum was evident, and supraclavicular and cervical lymph
nodes were involved in twenty-one. Twelve patients had direct
chest wall invasion. Sixteen patients had distant metastasis
other than axillary lymph node (sixteen bone, ten adrenal
gland, five liver, and four soft tissue). The mean primary tu-
mour size was 68.25 mm (range 17 to 149 mm). The mean
primary tumour SUVmax was 12.46 (range 2.1 to 24.6), and
axillary lymph node SUVmax was 5.77 (range 1.9 to 12.7).
There was a positive correlation between primary tumour size
and axillary lymph node SUVmax (R= 0.48, p=0.009), and
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primary tumour SUVmax and axial lymph node SUVmax
value’ (R= 0.44, p=0.010). Conclusion: The different mecha-
nisms in axillary lymph node involvement for lung cancer
have been identified. According to our results, large tumours
can spread by local invasion route. These tumours invaded
chest wall, and then extended to the axilla. Another reason
for these spread that the increased tumour SUVmax values’
leads to increased tumour aggressiveness. In large lung tu-
mours exhibiting pleural invasion and advanced lymph node
involvement, should be carefully examined axillary lymph
node involvement.
P627
Impact of Optimal Respiratory Gated Positron Emission
Tomography on Characterisation of Intra-Tumour
Heterogeneity in Lung Cancer Patients
W. Grootjans1, F. Tixier2, C. S. van der Vos1, D. Vriens3, C.
Cheze-le Rest2, J. Bussink1, W. J. G. Oyen1, L. F. de Geus-
Oei3, D. Visvikis4, E. P. Visser1; 1Radboud university medi-
cal center, Nijmegen, NETHERLANDS, 2University Hospital
Poitiers, Poitiers, FRANCE, 3Leiden UniversityMedical Cen-
ter, Leiden, NETHERLANDS, 4INSERM, UMR1101,
LaTIM, University of Brest, Brest, FRANCE.
Aim: Analysis of radiotracer uptake patterns in positron
emission tomography (PET) through computation of tex-
tural features is increasingly being proposed to improve
characterization of lung cancer lesions for the purpose of
disease prognostication and response monitoring. How-
ever, respiratory motion artefacts cause lesion blurring
that could result in loss of intra-tumour heterogeneity.
In this work we have investigated the effect of respira-
tory gating on the recovery of intra-tumour heterogene-
ity. Materials and Methods: Whole body [18F]-
fluorodeoxyglucose (FDG) PET/CT imaging was per-
formed in 70 lung cancer patients from our fast-track
outpatient diagnostic program. Amplitude-based optimal
respiratory gating (ORG) was performed on bed posi-
tions covering the thorax. The duty cycle (percentage
of the total PET data) used for image reconstruction of
the ORG images was 35%. Non-gated images were re-
constructed using 126 seconds of PET data, yielding
similar noise characteristics as their ORG equivalents.
Lesion segmentation was performed using the fuzzy lo-
cally adaptive Bayesian (FLAB) algorithm. Four hetero-
geneity parameters (entropy, dissimilarity, zone percent-
age (ZP), and high energy emphasis (HIE)), which have
previously shown to be robust and associated with sur-
vival in lung cancer patients, were calculated in non-
gated and ORG images. Statistical analysis was per-
formed using the Wilcoxon signed rank test, and
statistical significance was defined for p<0.05. Results:
Considering all lung lesions, respiratory gating did not
result in statistically significant differences in the hetero-
geneity parameters. The mean increase for entropy, dis-
similarity, ZP and HIE between the non-gated and ORG
images was 0.3±2.7% (p=0.5), 3.6±14.3% (p=0.2), 0.5
±3.3% (p=0.3), 4.2±21.4% (p=0.3). Sub-group analysis
revealed a significant effect of ORG on the heterogene-
ity parameters of lesions in the lower lung lobes. The
mean increase for entropy, dissimilarity, ZP and HIE,
considering lesions in the lower lobes was 1.3±1.5%
(p=0.02), 11.6±11.8% (p=0.006) 2.3±2.2% (p=0.002),
and 16.8%±17.2% (p=0.006) respectively. For the cen-
trally located lesions, the mean increase for entropy, dis-
similarity, ZP and HIE was 0.58±3.7% (p=0.6), 5.0
±19.0% (p=0.4) 0.59±4.0% (p=0.9), and 4.4±27.8%
(p=0.4), respectively. Lesions in the upper lobes showed
a mean increase of -0.35±1.8 (p=0.3), -1.0±7.7%
(p=0.3), -0.4±2.7% (p=0.5), -1.7±13.2% (p=0.4), for en-
tropy dissimilarity, ZP and HIE, respectively. There was
no significant correlation between lesion volume and the
change in parameters between non-gated and ORG im-
ages. Conclusion: Results from this study indicate that
ORG significantly impacts characterisation of intra-
tumour heterogeneity, particularly for lesions in the low-
er lung lobes. This suggests that adequate management
of respiratory motion artefacts is important for improv-
ing characterisation of intra-tumour heterogeneity in
PET.
P628
The Diagnostic Accuracy of PET/CT in the Evaluation
of Pulmonary Mass Lesions in a Tuberculosis-Endemic
Area
R. du Toit, E. M. Irusen, J. A. Shaw, F. von Groote-
Bidlingmaier, J. M. Warwick, C. F. N. Koegelenberg; Stel-
lenbosch University, Cape Town, SOUTH AFRICA.
Background: Integrated Positron Emission Tomography/
Computed Tomography (PET-CT) is a well-validated modali-
ty for assessing pulmonary mass lesions and specifically for
estimating the risk of malignant aetiology. Tuberculosis (TB)
is known to cause false positive PET-CT findings.We aimed to
investigate the modality of PET-CT in the evaluation of pul-
monary mass lesions and nodules in a high TB prevalence
setting.Methods: All patients referred for the evaluation of an
apparent solitary pulmonary nodule or mass and who
underwent PET-CTscanning over a 3-year period were includ-
ed. The PET-CT findings, including maximum standardized
uptake value (SUVmax), were compared to the gold standard
(confirmed histological or microbiological diagnosis) The
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sensitivity, specificity, positive and negative predictive values
for malignant disease were calculated according the SUVmax
cut-off of 2.5 and according to a proposed cut-off value ob-
tained from a ROC curve.Results: Forty-nine patients (60.1+/-
10.2 years, 29 males) were included, of which 30 had malig-
nant disease. Using an SUVmax cut-off of 2.5, PET-CT had a
sensitivity, specificity, positive predictive value and negative
predictive value for malignancy of 93.3%, 36.8%, 70.0%,
77.8% respectively. After a ROC curve analysis, a suggested
SUVmax cut-off of 5.0 improved the specificity to 78.9%with
only a small reduction in sensitivity to 90.0%.Conclusion: The
diagnostic accuracy of PET-CT in the evaluation of pulmonary
mass lesions using the conventional SUVmax cut-off of 2.5
was reduced in a TB endemic area. An SUVmax cut-off of 5.0
has a significantly higher specificity and comparable sensitiv-
ity for malignancy compared to a cut-off of 2.5.
P629
Estimating the probability of malignancy in patients
with solitary pulmonary nodules
R. Tian, C. Jiang, N. Hou, M. Su, F. Li; West China Hospital,
Sichuan University, Chengdu, CHINA.
Objective 18F-FDG PET/CT has been shown to be help-
ful in the detection and differentiation of solitary pulmo-
nary nodules (SPNs), however some benign lesions ex-
hibit high uptake of 18F-FDG. The important step in the
management of patients with lung nodules is to estimate
the probability of malignancy. In this study, a clinical
prediction model is developed using independent clinical
predictors of malignancy to estimate the probability of
malignancy in patients with SPN.Methods Data on age,
gender, smoking , cancer history, nodule size, location,
morphologic characteristics of nodules and SUV
(standard uptake value of 18F-FDG) were collected ret-
rospectively from the medical records of 251 patients
with an SPN measuring 7-30 mm and a final diagnosis
established by histopathology or 2-year follow-up. Mul-
tiple logistic regression analysis was used to identify
independent predictors of malignancy and to develop a
prediction model to estimate the probability of malig-
nancy in patients with SPN. The accuracy of the model
was assessed by calculating area under the receiver op-
erating characteristic (ROC) curve and the model was
calibrated by comparing predicted and observed rates
of malignancy.Results The logistic regression analysis
indicated that independent predictors of malignant SPN
included being male, having a positive smoking history,
older age, larger nodule diameter, and nodules exhibiting
specula or high SUV. The prediction model is described
by the following equation: Logit (P) = -18.408+ 2.354
(gender) + 3.581 (smoking) + 0.087 (age) + 0.101 (di-
ameter ) + 3.381 (spicula) + 0.743 (SUV). Model accu-
racy was very good (AUC was 0.901).ConclusionOur
prediction model provided helpful information in
predicting the malignant probability of SPN in Chinese
patients..
P630
Is There Any Correlation Between Serum Osteopontin,
CEA Levels, and FDG Uptake in BoneMetastasis in Lung
Cancer?
A. K. AYAN1, B. ERDEMCI2, E. ORSAL3, Z.
BAYRAKTUTAN4, E. AKPINAR5, A. TOPCU5, M.
TURKELI6, B. SEVEN7; 1Ataturk University School of
Medicine Department of Nuclear Medicine, Erzurum, TUR-
KEY, 2Ataturk University School of Medicine Department of
Radiation Oncology, Erzurum, TURKEY, 3Istanbul
Medeniyet University School of Medicine Department of Nu-
clear Medicine, Istanbul, TURKEY, 4Erzurum Regional
Training and Research Hospital, Department of Biochemistry,
Erzurum, TURKEY, 5Ataturk University School of Medicine
Department of Pharmacology, Erzurum, TURKEY, 6Ataturk
University School of Medicine Department of Internal Medi-
cine, Erzurum, TURKEY, 7Mevlana University School of
Medicine Department of Nuclear Medicine, Konya,
TURKEY.
Aim: Reliable blood tests for the early detection and
monitoring of progression are crucial in lung cancer pa-
tients. It has been suggested that high osteopontin
(OPN) and carcinoembryonic antigen (CEA) levels are
significantly correlated with metastasis. This study eval-
uated that the serum levels of carcinoembryonic antigen
(CEA) and osteopontin (OPN) levels were related to
semiquantitative parameters of 18F-FDG-PET/CT or not
in lung cancer patients with bone metastasis.Materials
and Methods: Fourty-two non-small cell lung cancer
(NSCLC) and 31 small cell lung cancer (SCLC) patients
who were referred to our institution for staging by 18F-
FDG PET/CT were included. The maximum standard-
ized uptake value (SUVmax) was calculated for primary
lesion. The biochemical parameters including CEA
(Beckman Coulter UniCel) and OPN (Platinum ELISA
kit) serum levels were measured.Results: The mean OPN
levels in NSCLC patients with and without bone metas-
tasis were 21.20±4.97 ng/ml and 13.33±4.53 ng/ml, re-
spectively (p<0.05). The mean OPN levels in SCLC
patients with and without bone metastasis were 23.95
±4.78 ng/ml and 17.30±3.09 ng/ml, respectively
(p<0.05). The mean CEA levels in NSCLC patients with
and without bone metastasis were 33.79±6.49 ng/ml and
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11.74±2.96 ng/ml, respectively (p<0.05). The mean CEA
levels in SCLC patients with and without bone metasta-
sis were 28.93±4.59 ng/ml and 13.88±4.47 ng/ml,
respectively(p>0.05).Conclusion: Bone metastasis can
be detected in patients with lung cancer by measuring
CEA and OPN levels. Routine PET/CT monitoring is
advised when these biomarkers increased.
P631
Lung cancer versus chronic inflammation: can we
differentiate the two on F-18 FDG PET/CT?
H. Kim1, I. Yoo1, H. Park1, Y. Lee1, S. Park1, H. Sohn2, S.
Kim1, Y. Park3; 1Seoul St Mary’s Hospital, College of Med-
icine, The Catholic University of Korea, Seoul, KOREA, RE-
PUBLIC OF, 2Yeouido St. Mary’s Hospital, College of Med-
icine, The Catholic University of Korea, Seoul, KOREA, RE-
PUBLIC OF, 3St. Vincent’s Hospital, College of Medicine,
The Catholic University of Korea, Suwon, KOREA, REPUB-
LIC OF.
Purpose: The aim of this study is to find differentiation
points between chronic inflammation and lung cancer of
similar findings on F-18 FDG PET/CT. Method: FDG
PET/CT images from January 2010 to October 2014,
performed for evaluation of pulmonary nodule in 180
patients (mean age 62±10 years) who had irregular
consolidative nodule/mass greater than 1cm in diameter
with low to moderate FDG avidity were retrospectively
reviewed. 174 patients (96.7%) had pathologic confirma-
tion. 6 patients (3.3%) had what were clinically consid-
ered benign nodules as they showed decrease in size
without treatment. Lesions were analyzed by component
(part solid, predominantly solid, and solid only), margin
(smooth, partly irregular, and irregular), location (lung
lobe), other lung lesion presence, axial diameter and
metabol ic parameters (SUVmean, SUVmax and
SUVpeak). The Student t test and Pearson’s Chi-square
test were used to compare continuous variables and cat-
egorical variables, respectively. Results: There were 35
(19%) benign and 155 (81%) malignant cases. The most
common type of component in malignant group was part
solid (80 cases, 55%) and in benign group was solid
only (19 cases, 54%). There was a tendency that malig-
nancy group had more part solid tumors than benign
group (80 cases, 55% vs. 11 cases, 31%) with statisti-
cally significance (p=0.038). The other parameters
showed no significant value in differentiating between
chronic inflammation and lung cancer. Conclusion: The
component of nodule provided differentiation value in
differentiating chronic inflammation and lung cancer on
F-18 FDG PET/CT. The pulmonary nodules with part
solid feature showed higher possibility of malignancy
than nodules with other component features. However,
other parameters including metabolic parameters had no
significant value in interpreting ambiguous pulmonary
lesions.
P632
Cost-Effectiveness of 18F-FDG PET-CT for preoperative
restaging in patients with non-small cells lung cancer IIIA
after neoadjuvant therapy
W. Valdés, A. Ramírez, E. Morillo, T. Aroui, N. Testart, E.
Triviño, A. Rodriguez-Fernandez, J. Llamas-Elvira;
H.VIRGEN DE LAS NIEVES, GRANADA, SPAIN.
Purpose: To determine the most efficient diagnostic
method, from the perspective of the Spanish National
Health System, for preoperative restaging in patients
with non-small cells lungs cancer IIIA after neoadju-
vant therapy. Materials and methods: Three possible
strategies were studied, from the perspective of the
Spanish National Health System, for management of
preoperative staging of patients with non-small cell
lung cancer IIIA after neoadjuvant therapy. These strat-
egies differ in the diagnostic imaging method used.
The first strategy use only CT+ c (CT + contrast
agent). The second one use only PET/CT. And the
last one use CT+c and PET/CT. The medical literature
was reviewed to obtain values of diagnostic validity of
differents techniques. Costs of these were obtained
from public prices of Spanish National Health System.
Quality-Adjusted Life Years (QALYs) produced in each
strategy were calculated, so total cost and incremental
cost-effectiveness ratio (ICER). Additionally, a sensitiv-
ity analysis was performed by changing the values
assigned cost both as to the factors affecting effective-
ness to check the robustness of the results obtained.
Results: Comparing with the strategy use only CT+c,
the other two presented a higher effectiveness, al-
though the one that use PET/CT had a higher cost.
The PET/CT and CT+c strategy obtained a lower cost
derivate for the reduction of almost 60% unnecessary
surgeries. ICER for only PET/CT strategy was 1122.73
€/QALY and -105078.95 €/QALY for CT+c and PET/
CT strategy, showing these one clearly dominant. Sen-
sibility analysis confirmed the robustness of these
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results. Discussion: The use of PET/CT for preopera-
tive staging for patients wiht non-small cells lung can-
cer IIIA after neoadjuvant therapy is clearly efficient
for the Spanish National Health System, further com-
bined with CT+c.
P633
The Value of the quantitative volumetric metabolic
measurements withF-18 FDG PET-CT in patients
with solitary pulmonary nodules.
D. Yüksel1, T. Şengöz1, O. Yaylalı1, H. Aslan1, F. Bir2;
1Pamukkale University, Medical Faculty, Dept. of Nuclear
Medicine, Denizli, TURKEY, 2Pamukkale University, Medi-
cal Faculty, Dept. of Pathology, Denizli, TURKEY.
Aim: We evaluated the effect of quantitative volumetric
metabolic measurements to distinguish benign from ma-
lignant in solitary pulmonary nodules(SPN). Materials
and methods: We retrospectively reviewed 78 patients
with diagnosis of SPN who underwent F-18 FDG PET-
CT. The patients were classified as benign/malignant le-
sions according to the results of pathology. Additionally,
malign lesions were classified as primary and metastatic
lung cancer. Volumetric areas of interest (VAI) were
drawn with the threshold of 40% by the way that to
comply with the limits of lesions on CT in PET/CT
images. Metabolic volume(MV), SUVmax, SUVmean,
maximum metabolic index (MImax=SUVmax X MV)
and mean metabolic index(MImean=SUVmean X MV)
were measured from VAI. Mean,median values and stan-
dard error of the parameters in each group were calcu-
lated. Because of the abnormal distribution, nonparamet-
ric tests were used for the comparison of each group.
The p<0.05 was accepted statistically significant. Partial
correlation analysis was used for the relation of the pa-
rameters. For all parameters, cut-off values were obtain-
ed with receiver operating characteristic (ROC) analysis
for basal and 2 hr respiratory gating PET-CT images
separately. Results: Of 78 lesions, 10 were benign
(12.8%), 38 were primary lung carcinoma (48.7%) and
30 were metastatic lung nodules (38.5%). The SUVmax,
MImax, SUVmean and MImean of the three groups
were presented as mean and standard Error (SE) in Ta-
ble 1. There was significant difference among the three
groups for SUVmax, MImax, SUVmean and MImean
parameters (p<0.05). There were significant difference
between benign lesions and primary lung cancer, be-
tween primary cancer and metastatic groups in all
parameters. There was significant difference between be-
nign and metastatic lung lesions in SUV mean and
SUVmax parameters (p<0.05). We determined highly
significant positive correlation between SUVmax and
MImax (r=0.73;p<0.05); moderate positive correlation
between SUVmean and MImean (r=0.56;p<0.05). In
ROC analysis, basal SUVmax and basal SUVmean were
found to be most sensitive and specific methods for
benign/malign discriminate. In the cut-off value=2.59,
the sensitivity and specificity for SUVmax were %98.0
and %91.7,respectively. In the cut-off value=1.65, the
sensitivity and spesificity for SUVmean were %94 and
%91.7, respectively. The sensitivity and specificity
values of respiratory gating PET-CT images was lower
than basal study. Conclusion: Basal SUVmax and basal
SUVmean were found to be most sensitive and specific
methods for benign/malign discriminate. In addition, all
of metabolic measurements may discriminate to primary
lung cancer from metastatic lung cancer.
P634
FDG-PET/CT in thymic epithelial tumors: correlation
with the WHO classification and the tumor stage
M. Ishibashi, Y. Tanabe, S. Fujii, Y. Ohta, T. Ogawa; Division
of Radiology, Department of Pathophysiological and Thera-
peutic Science, Faculty of Medicine, Tottori University,
Yonago, JAPAN.
The aim: The purpose of this studywas to assess the usefulness of
FDG-PET/CT for predicting the histological type based on the
World Health Organization classification and Masaoka tumor
stage of thymic epithelial tumors. Materials and Methods:
Thirty-three patients (9 males and 24 females; age range, 31-95
years old) with histologically verified thymic epithelial tumors,
who underwent integrated FDG-PET/CT before treatment, were
enrolled in this study. The maximum standardized uptake value
(SUVmax) of each tumor was measured, and the relationship
between the histological types based on the World Health Orga-
nization classification and the SUVmax of the tumor was inves-
tigated. We also analyzed the relationship between the Masaoka
tumor stage and the SUVmax of the tumor. Results: Tumors
included low-risk thymic tumors (type A in 1, type AB in 8,
and type B1 in 7) and high-risk thymic tumors (type B2 in 3,
type B3 in 4 and carcinoma in 11). The SUVmax of high-risk
tumors (6.43±3.45) was significantly higher than that of low-risk
tumors (3.07±0.87) (P<0.01). The SUVmax of 3.73 emerged as
the cut-off value for differentiating between low-risk and high-
risk tumors with area under the curve of 0.809. The Masaoka
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tumor stage was as follows: stage I in 13, stage II in 8, stage III in
10 and stage IV in 3 patients. The SUVmax of the stage III/IV
(7.49±5.08) was significantly higher than that of the stage I/II
(3.21±1.11) (P<0.01). Conclusions: FDG-PET/CT is a useful
modality for predicting the histological type and tumor stage of
thymic epithelial tumors.
P635
Solitary Pulmonary Nodule (SPN) investigation
with FDG-PET/CT
F. Vlachou1, V. Filippi1, A. Nikaki1, D. Savvidou1, P.
Kosmidis2, K. Iliadis3, T. Pipikos1, K. Gogos4, K. Dalianis4,
I. Andreou1, R. Efthymiadou1, V. Prassopoulos1; 1PET/CT
Department ,Hygeia S.A., Athens, Marousi, GREECE, 22nd
Internal Medicine - Oncology Clinic Hygeia SA, Athens,
Marousi, GREECE, 3Thoracic Surgery Clinic Hygeia SA,
Athens, Marousi, GREECE, 4Medical Physics Department ,
Hygeia S.A., Athens, Marousi, GREECE.
Aim: to evaluate the role of FDG-PET/CT in discrimination of
malignant/benign solitary pulmonary nodules (SPN), by co-
estimating nodule’s size and FDG uptake (SUVmax).
Material- Method: In total, 71 patients (31 female, 40 male)
who underwent FDG-PET/CT examination for investigation
of SPN at a Siemens Biograph LSO 16 sections system were
enrolled in the study. Nodule’s size and SUVmax were co-
evaluated. Statistical analysis using un-paired t-test was used
for discrimination of lung adenocarcinoma from benign for-
mations such as hamartomas and inflammation, as well as
from well-differentiated malignant formations, such as carci-
noids. Histologic confirmation was available for all included
patients. Results: SUVmax values were statistically signifi-
cantly higher (p 0.1). In a subgroup analysis, results are re-
corded depending on the size of SPN: a)In 20 cases, the size of
the nodule was ≤1cm. 11 were lung adenocarcinomas, 1 met-
astatic adenocarcinoma, 7 inflammations, 1 hamartoma. The
average SUVmax of adenocarcinomas was 2.6, while for in-
flammation was accordingly 2. There was no statistical signif-
icance in SUVmax for differentiation benign from malignant
lesions (p >0.05). b)In 36 cases, the size of the nodule was >1 -
≤2cm. 23 were lung adenocarcinomas (average SUVmax 6.2),
5 metastatic carcinomas, 3 were inflammations (average
SUVmax 2.1), 4 carcinoids (average SUVmax 2.3), 1
hamartoma. There was statistical significance in SUVmax
values for differentiation adenocarcinomas from benign/well
differentiated carcinoid lesions (p=0.003, 2 - ≤3. 9 were lung
adenocarcinomas (average SUVmax 8.1), 3 hamartomas (av-
erage SUVmax 2), 2 carcinoids, 1 inflammation. There was
statistical significance in SUVmax values for differentiation
adenocarcinomas from benign/well differentiated carcinoid le-
sions (p=0.0053, <0.05) Conclusion: PET is a very useful
imaging procedure in differentiation of malignant vs benign/
well-differentiated carcinoid pulmonary lesions of size >1cm.
For smaller SPNs, although there is tendency for higher
SUVmax values in adenocarcinomas, perhaps morphologic
characteristics of the nodules or complementary delayed PET
acquisition could be more helpful.
P636
The evaluation of clinical usefulness of continuous bed
motion scanning in positron emission tomography
in diagnosis of patients with subsolid pulmonary nodule
M. Endo, K. Asakura, T. Aramaki, E. Bekku, R. Sato, K.
Yoza; Shizuoka cancer center, Shizuoka, JAPAN.
Background and purpose: Recently, continuous bed mo-
tion (CBM) technology has been introduced to PET
scanning in routine clinical practice, but the evaluation
and/or benefits of this technique are unclear in abnormal
pulmonary opacity. The purpose of this study was to
access the clinical usefulness using CBM scanning of
18F-FDG PET/CT compared to conventional step and
shoot (SAS) scanning in diagnosis of patients with
subsolid pulmonary nodule. Materials and methods: We
were retrospectively enrolled patients with abnormal pul-
monary lesions smaller than 30 mm in diameter for di-
agnosing and/or staging lung cancer between May and
August 2014 in this study approved by our institutional
review board. 18F-FDG PET/CT scans were obtained
with an integrated PET/CT system (Biograph mCT Flow
64-4R, Siemens, Germany). All the patients were fasted
for at least 6 hour, then administered 200-210 MBq of
18F-FDG. CBM scanning was 0.4mm/sec speed w/o re-
spiratory gating, and SAS scanning was 600 sec/frame
acquisition w/o respiratory and cardiac gating at an axial
sampling thickness of 4 mm/slice. Amplitude-based op-
timal respiratory images reconstructed with 35% of ac-
quired PET data. Lesion localization, size and character-
istics, and final diagnosis were summarized. Image qual-
ity and calculated SUV max/peak of each reconstructed
images were evaluated corresponding with those of non-
gated SAS image. For the evaluation of image quality of
each scanning, we used 5 visual scales with consensus
compared to 3 point as the score of non-gated SAS
image. Kai square test and paired t-test were used for
the statistical analysis. Statistical significance was as-
sumed at a p-value <0.05. Results: 116 patients (41 fe-
males and 75 males) with 128 abnormal pulmonary le-
sions were enrolled. Pulmonary locations of abnormal
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lesions were 28 cases in RUL, 7 in RML, 29 in RLL,
35 in LUL and 29 in LLL. There were 86 solid and 42
subsolid nodules, and mean lesion size was 16.4mm and
16.5mm, respectively. Seventy-eight patients with lung
cancer, 11 in suspicious lung cancer, 22 metastatic nod-
ules, and the rest were inflammatory lesions. Image
quality and SUV max/peak values of four PET images
was higher evaluated than non-gated SAS image in solid
and subsolid nodules. Furthermore, SUV max/peak value
of CBM with respiratory gating was significantly highest
compared to the rest scanning methods in both. Conclu-
sion: Clinical PET scanning using CBM with respiratory
gating could demonstrate more accurate metabolic char-
acteristics and high image quality even in subsolid pul-
monary nodules same as solid in routine clinical setting.
P637
Efficacy of SUVmax and SUVpeak to predict distant
metastasis of non-small cell lung cancer before treatment
S. Toubaru1, S. Ohashi1, Y. Tachibana1, M. Hasebe1, K.
Tanimoto1, M. Zhang1, N. Yamamoto1, M. Nakajima1, M.
Karube1, T. Obata1, T. Saga1, Y. Ando1, K. Yoshikawa2, T.
Kamada1; 1National Institute of Radiological Sciences, Chi-
ba, JAPAN, 2Tokyo Bay Advanced Imaging & Radiation On-
cology Clinic MAKUHARI, Chiba, JAPAN.
[Introduction & purpose]SUVpeak index is now gradually be-
ing used to assess the efficacy of treatments for malignant
tumors. However, its advantage over classical SUVmax is still
not well discussed in various aspects of oncology. The purpose
of this study is to compare the significance of SUVmax and
SUVpeak regarding the prediction of future distant metastasis
before treatment in non-small cell lung cancer.[Materials and
methods]74 patients were selected as subjects from our local
database for this retrospective study. The patients were all
diagnosed as non-small cell lung cancer and were scanned
by FDG-PET/CT scanner before they finally underwent
charged particle radiation therapy. None of them had distant
metastasis before treatment. Their outcomes were followed up
for more than one year after treatment. Distant metastatic le-
sion appeared in 15 patients among the 74 patients in the
meanwhile.For the assessment, first, SUVmax as well as
SUVpeak6, SUVpeak10, and SUVpeak15 (numbers after
SUVpeak indicate the diameters of VOI in mm) were obtained
for each patient from their pre-treatment FDG-PET/CT. Sec-
ond, cut-off value was defined for each parameter (SUVmax
and SUVpeaks) by ROC analysis, respectively: the value
which made the sensitivity + specificity largest for each pa-
rameter regarding the later appearance of metastasis was de-
fined as its cut-off value. Third, the patients were divided into
two groups, over and under the cut-off value for each param-
eter, respectively. Finally, the ratio of metastasis-appearance
was compared between the groups by applying Kaplan-
Meier method. The deference was analyzed by log-rank test.
(P<0.05 was regarded significant.)[Result]Number of patients
categorized to the larger SUV group and the number of pa-
tients who had metastasis later in that group were 17 and
7(SUVmax), 20 and 6 (SUVpeak6), 13 and 5 (SUVpeak10),
and 5 and 3 (SUVpeak15), respectively. The ratio of metastasis
was higher in the larger SUV group in all assessed parameters.
Difference with significance was found in SUVmax (P=0.017)
and SUVpeak15 (P=0.007). The differences in SUVpeak6
(close to the most widely used SUVpeak, P=0.223) and
SUVpeak10 (P=0.078) was not significant.[Conclusion]The
significant differences of SUVmax and SUVpeak15 to predict
distant metastasis after charged particle radiation therapy were
obtained. Considering only 3 metastases were picked up in
SUBpeak15, SUVmax may be superior to any SUVpeak
evaluation.
P638
Role of 18FDG-PET/CT semiquantitative parameters
in the evaluation of therapy response in patients affected
by recurrent pleural mesothelioma
A. Di Palo, A. Niccoli Asabella, C. Altini, A. Notaristefano,
C. Ferrari, G. Rubini; Nuclear Medicine Unit, D.I.M., Univer-
sity of Bari, ITALY, Bari, ITALY.
Aim: To investigate the role of 18FDG-PET/CT semiquantita-
tive parameters compared with mRECIST criteria for therapy
response evaluation in patients (pts) with recurrent pleural
mesothelioma.Materials and methods: 35 pts with recurrent
pleural mesothelioma were enrolled and underwent 18F-
FDG PET/CT scans twice (baseline to confirm the recurrent
mesothelioma and 4-5 weeks post-therapy to evaluate the re-
sponse). Volume of interest (VOIs) were drawn on both the
18F-FDG PET/CT and SUVmax, SUVav, MTV, TLG were
collected. We also calculated ΔSUVmax (as difference be-
tween SUVmax1-SUVmax2), ΔSUVav (as difference be-
tween SUVav1-SUVav2), ΔMTV (MTV1-MTV2), ΔTLG
(TLG1-TLG2). Response indexes (RImax% and RIav%) were
also calculated as RI=[(SUV1−SUV2)/SUV1]x100). Radio-
logic response to therapy was evaluated using the modified
RECIST criteria for mesothelioma. Responders’ PET/CT pa-
tients were defined as patients with the disappearance of all
lesions or as at least a 30% reduction in RImax%. No re-
sponders patients were defined as patients with stable disease,
or with an increase of at least 30% in RImax%. T-student test
for unpaired groups was applied. The diagnostic capability of
18F-FDG PET/CT was calculated by ROC analysis and
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expressed as area under curve (AUC).Results: Based on mod-
ified RECIST criteria: responders were 12/35 (34.3%) while
23/35 (65.7%) were no responders; based on PET/CT evalua-
tion: 11/35 (31.5%) were responders and 24/35 (68.5%) pa-
tients were no responders. According RECIST, statistical dif-
ferences between responders and no-responders were signifi-
cant in the analysis of MTV1 (t=-3.725, p=0.003), TLG1 (t= -
3.259, p= 0.006) SUVmax2 (t=-3.994, p=0), SUVav2 (t=4.21,
p=0), MTV2 (t=4.186, p=0), TLG2 (t=3.463, p=0.002),
RImax% (t=-2.594, p=0.014) and RIav% (t==-2.385,
p=0.023), ΔMTV (t=-5.04, p=0) ΔTLG (t=-4.783, p=0). Ac-
cording modified RECIST criteria, all parameters defined a
good AUC but the better AUCs resulted for ΔMTV (cut-off
≤ 11.3, sensitivity 91.3%, specificity 91.7%) and ΔTLG (cut-
off ≤ 59.1, sensitivity 82.6%, specificity 100%).Conclusions:
It has been demonstrated that 18F-FDG PET/CT can be useful
to predict treatment response in MPM patients. Among the
semiquantitative parameters collectable, ΔMTV and ΔTLG
resulted the best predictive value according RECIST criteria.
P639
Assessment of the infuence of several clinical, surgical
and pathologic variables in bronchogenic carcinoma
increasing stage from diagnostic PET/CT to reparative
surgery.
E. Rodríguez Pelayo, E. Castillo Gallo, J. García Satué, B. De
Olaiz Navarro, J. Aramburu González, M. Balsa Bretón, C.
Paniagua Correa, M. Castillejos Rodríguez, F. Penín
González; Hospital Universitario de Getafe, Madrid, SPAIN.
AIM: Assess several clinical, surgical and pathologic variables
influence in bronchogenic carcinoma staging increase from
18FDG-PET/CT (cTNM) to reparative surgery (pTNM). MA-
TERIAL AND METHOD: We retrospectively reviewed 104
patients with bronchogenic carcinoma from may/09 to
june/2014, which showed a positive PET/CT for malignancy
and who were surgery’s candidates without neoadjuvant treat-
ment. PET/CT staging and pathologic postoperative staging
were recorded according to the 7th edition of the TNM classi-
fication. We also recorded demographic variables, pack-year,
reason for consultation, mediastinoscopy (yes/no), type of sur-
gery, tumour pathology/differentiation and the days between
diagnostic PET/CT and surgery. Univariate logistic regression
was performed to test for significant associations between any
of variables studied with staging increase. RESULTS: In 51 of
the 104 reviewed patients the diagnosis was adenocarcinoma
and 27 showed final staging increase. Remaining 53 patients
were diagnosed of squamous cell carcinoma, of which 22
showed staging increase. Statistical analysis showed that the
only variable significantly related to staging increase in the
time interval studied was smoking at diagnosis in squamous
cell carcinoma (p<0.039). Remaining variables analyzed, in-
cluding elapsed time, do not seem to correlate with the degree
of staging increase in bronchogenic carcinoma. CONCLU-
SION: Statistical analysis showed that the only variable which
significantly increased the final disease staging between diag-
nostic PET/CT and surgery was smoking at diagnosis in squa-
mous cell carcinoma (p < 0.039).
P640
Is Molecular Remission as Detected by 18F-FDG PET/CT
and Regression Grade After Neoadjuvant Treatment
in the Primary Tumor and the Involved Mediastinal
Lymph Nodes a Prognostic Factor in Patients With
NSCLC Stage III?
M. Schmuecking1, R. P. Baum2, N. D. Klass3, E. Fritz3, S.
C. Schaefer4, N. Presselt5, B. Hoksch6, K. M. Mueller7, T. G.
Wendt8, B. Klaeser9, R. Bonnet10; 1Strahlenzentrum
Hamburg/CyberKnife Center Hamburg, Hamburg, GERMA-
NY, 2Zentralklinik Bad Berka, Theranostics Center for Molec-
ular Radiotherapy and Molecular Imaging, Bad Berka, GER-
MANY, 3Inselspital Bern, Dept. of Radiation Oncology, Bern,
SWITZERLAND, 4University of Bern, Institute of Pathology,
Bern, SWITZERLAND, 5Zentralklinik Bad Berka, Dept. of
Thoracic Surgery, Bad Berka, GERMANY, 6Inselspital Bern,
Dept. of Thoracic Surgery, Bern, SWITZERLAND, 7Univer-
sity of Münster, Institute of Pathology, Münster, GERMANY,
8University of Jena, Dept. of Radiation Oncology, Jena, GER-
MANY, 9Inselspital Bern, Dept. of Nuclear Medicine, Bern,
SWITZERLAND, 10Zentralklinik Bad Berka, Dept. of
Pneumology, Bad Berka, GERMANY.
Aim: To evaluate the role of molecular remission as detected
by 18F-FDG-PET/CT and regression grade after neoadjuvant
treatment followed by surgical resection of pts with NSCLC
stage III. Materials andMethods: For 76pts with NSCLC stage
IIIA (44%) / IIIB (56%) neoadjuvant treatment consisted of 3
cycles of chemotherapy followed by concomitant chemoradi-
ation. 15/28pts with NSCLC stage IIIA (81%) / IIIB (19%)
received 3 cycles of chemotherapy followed by radiation ther-
apy, 13/28pts only 3 cycles of chemotherapy as a sole neoad-
juvant treatment. Documentation of involved lymph node sta-
tions as detected by 18F-FDG-PET/CT and lymph node sam-
pling during surgery according to the IASLC lymph node
mapping (2009). Evaluation of histological regression grade
(RG) according to Junker et al. (2001) and correlation with
18F-FDG-PET/CT for primary tumor and each lymph node
station. Calculation of disease free survival (Kaplan-Meier es-
timates, log-rank test). Results: Actuarial tumor specific sur-
vival for the 76pts with concomitant chemoradiation plus che-
motherapy: complete vs incomplete metabolic remission prior
to surgery after 60 months: 40% vs 24% (p = .018), RGIII/IIb
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(no/less than 10% of vital tumor cells) vs RGIIa/I (more than
10% vital tumor cells) after 60 months: 46% vs 15% (p <
.006). 42/76pts had RGIII/IIb, 20/76pts had regression grade
III. In 32/76pts 18F-FDG-PET/CT was correlated with the
regression grade: 1/8pts with RGIII were in the 18F-FDG-
PET/CT false positive, 10pts with RGIIb (i.e. all pts with
RGIIb) were in the 18F-FDG PET/CT false negative, 1pt with
RGIIa was in the 18F-FDG-PET/CT false negative: Hence, the
cut-off level in detecting vital tumor cells by 18F-FDG-PET/
CT after neoadjuvant chemoradiation for NSCLC is about
10%. Actuarial tumor specific survival for the 28pts with se-
quential chemoradiation or chemotherapy as a sole neoadju-
vant treatment: RGIII vs RGIIb/IIa/I after 60 months: 50% vs
16%. 05/28 pts had RGIII. Assuming a pts number of 540, the
treatment regimen consisting of concomitant chemoradiation
plus chemotherapy might be superior to the other neoadjuvant
treatment regimens. Conclusion: Molecular remission in me-
diastinal lymph nodes as detected by 18F-FDG-PETcorrelates
well with regression grade and both may predict (long-term)
therapeutic outcome in pts with stage III NSCLC. The cut-off
level in detecting vital tumor cells by 18F-FDG-PET after
neoadjuvant chemoradiation for NSCLC is about 10%. Our
preliminary data of 104pts suggest that intensification of neo-
adjuvant treatment may lead to a higher amount of complete
remission resulting in an increased survival. However this hy-
pothesis has to be tested in prospective trials.
P641
Study of FDG PET/CT in detecting mediastinal
and hilar/interlobar lymph nodes metastases of non-small
cell lung cancer
q. xue, z. yao; Beijing Hospital, Beijing, CHINA.
Aim: Precise mediastinal lymph nodes staging for non-small
cell lung cancer(NSCLC) patients without distant metastases
decides if surgery is advisable. The staging of hilar/interlobar
lymph nodes affects the operational styles. The value of max-
imum standard uptake value (SUVmax) in mediastinal lymph
nodes staging has been proven , while the value of SUVmax in
hilar/interlobar lymph nodes staging has not been studied. To
evaluate the value of 18F-FDG PET/CT in detecting medias-
tinal and hilar/interlobar lymph nodes metastases by SUVmax
for NSCLC patients. To analyse the characteristics of medias-
tinal and hilar/intralobar lymph nodes metastases separatly.
Materials and methods: 69 NSCLC patients with 18F-FDG
PET/CTexamination and surgery were analyzed. Preoperative
18F-FDG PET/CT was done and the lymph nodes were har-
vested during surgery. The SUVmax of lymph nodes were
compared to histology results. The sensitivity, specificity and
accuracy of SUVmax in detecting lymph nodes metastases
were calculated .The optimal SUVmax cutoff value in
detecting lymph nodes metastases was calculated by ROC
curve. The comparison about sensitivity, specificity and accu-
racy in detecting lymph nodes metastases for mediastinal and
hilar/intralobar lymph nodes between different cutoff values
was done. The optimal SUVmax cutoff value in detecting
mediastinal and hilar/intralobar lymph nodes metastases were
calculated by ROC curve separately. Results: 1. The value of
different SUVmax in diagnosing lymph nodes metastases: The
sensitivity, specificity and accuracy of SUVmax≥2.5 in diag-
nosing lymph nodes metastases were 83.6%,61.9%,65.8%.
The optimal cutoff value of SUVmax in diagnosing lymph
nodes metastases was 3.55 got by ROC curve ,with sensitivity
75.4%,specificity 79.5% and accuracy 78.8%. Compared with
SUVmax≥2.50 as standards in detecting lymph nodes metas-
tases ,there were statistical significance in specificity and
accuracy(P=0.000),with no statistical significance in sensitiv-
ity (P=0.262). 2. Lymph nodes’SUVmax in different regions:
The SUVmax of hilar/intralobar lymph nodes(4.87±2.7)was
significantly higher than that of mediastinal lymph
nodes(2.49±2.1),P=0.000.Both SUVmax≥3.55 and
SUVmax≥2.50 as standards in detecting lymph nodes metas-
tases, The sensitivity for mediastinal lymph nodes was low and
the specificity and accuracy for hilar/intralobar lymph nodes
were low. 3. The cutoff value of SUVmax in different regions
for detecting lymph nodes metastases: The cutoff value of
SUVmax inmediastinal and hilar/intralobar lymph nodes were
2.78,4.93 separatly. The sensitivity ,specificity and accuracy
were 71%, 87.1%, 84.9% for mediastinal lymph nodes by
SUVmax≥2.78 and 73.3%, 77.9%, 76.6% for hilar/intralobar
lymph nodes by SUVmax≥ 4.93. Conclusion: For getting bet-
ter diagnostic value, different SUVmax cutoff values should
be used in detecting mediastinal and hilar/intralobar lymph
nodes metastases.
P642
Is there a role for 18F-FDG PET/CT to differentiate
benign from malignant form of solitary fibrous tumors
of the pleura?
D. Familiari1, M. Migliore2, A. Missiato3, S. Russo1, A.
Ruggeri1, E. Potenza3, M. C. Fornito1; 1Nuclear Medicine
Department/PET-CT center - A.R.N.A.S. Garibaldi, Catania,
ITALY, 2Thoracic Sugery Department - Azienda Ospedaliera
Universitaria “Policlinico- Vittorio Emanuele”, Catania, ITA-
LY, 3Thoracic Sugery Department - A.R.N.A.S. Garibaldi,
Catania, ITALY.
AIM Solitary fibrous tumours of the pleura (SFTPs) is a rare
neoplasm that represent less than 5% of all pleural tumors and
it can occur in other extrathoracic areas. Although the majority
are benign forms and STPs is discovered incidentally on chest
radiographs, a 15-20% of all cases can show a malignant
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behavior characterized by a less favorable outcome. Some
benign form SFTP may transform into malignant after several
years. A preoperative role of 18F-FDGPET/TCwas suggested
to indicate or exclude malignancy and, eventually reveal local
recurrence or distant metastases. A SUVmax of 2.5 was gen-
erally considered as indicative of non aggressive process. The
aim of this study was to evaluate the role of 18F-FDG PET/TC
and to confirm if there is a real SUVmax cut-off value able to
discrimi-nate benign from malignant form. MATERIALS
AND METHODS Four patients (2 male and 2 female)
underwent a 18F-FDG PET/TC for metabolic evaluation of
an expansive process on the hemithorax suspected for SFTPs.
One of this patients was already submitted to lung superior
lobectomy and a local relapse was suspected. PET/TC scan
was obtained an hour after intravenous injec-tion of18FDG.
18F-FDG PET and unenhanced CT images were acquired by
Gemini PET/CT system (GXL Philips) with a time of acquisi-
tion of twominutes for bed. RESULTS In all the patients, PET/
CT images showed the presence of voluminous, smoothly
margined,lobulated extrapulmonary solid mass abutting the
wall of the in-volved hemithorax without invasion of the ad-
jacent structures. No pathologic uptake in mediastinal lymph
nodes or distant metastasis were shown. On average, a value of
SU-Vmax=3.5 (range 3.3-3.7) was found. Based on the liter-
ature, this uptake was interpreted as pathologic and therefore
suspected for malignant form of SFTPs. After PET/CT results
a thoracotomy was performed in order to remove the neo-
plasm. Histological examination reveal the benignant nature
of the mass that was finally interpreted as benignant form of
SFTPs in 3 of 4 case and as a relapse in the other one. CON-
CLUSIONSThis study demonstrate that PET/CT is not able to
differentiated be-tween malignant and benign form of SFTPs
and cannot substitute histology. A SUVmax of 2.5, as reported
in literature so far, is not indicative only of non aggressive
forms and therefore there is not a useful FDG uptake correlated
to malignant evolution.
P643
Positron Emission Tomography CT to differentiate
tumour recurrence and radiation-induced pulmonary
fibrosis after stereotactic body radiation therapy
G. Capriotti1, S. Di Traglia1, A. Covello1, P. Pizzichini1, D.
Prosperi1, M. Tuccimei1, R. Maurizi Enrici2, M. Osti2, F.
Scopinaro1; 1Sapienza University of Rome, NuclearMedicine
Unit, Sant’Andrea Hospital, ROME, ITALY, 2Sapienza Uni-
versity of Rome, Sant’Andrea Hospital, ROME, ITALY.
Aim: Changes in lung density on computed tomography CT
are common after stereotactic ablative radiotherapy (SABR)
and can confound to early detection of recurrence. The aim of
this study was to evaluate the role of Contrast Enhanced (CT)
and 18F-fluorodeoxiglucose positron emission tomography
(FDG-PET/CT) in differentiating tumour recurrence from ra-
diation fibrosis after SABR. Primary tumour maximum stan-
dardized uptake value (SUV max) on FDG-PET/CT before
and after therapy has been studied as potential prognostic fac-
tor for NSCLC patients receiving SABR.Methods: 24 patients
(Mean Age: 70 years; 14 male and 10 female) received SABR
for stage I non-small cell lung cancer or metastatic lung cancer.
Both FDG-PET/CT and CT were performed before and after
treatment in different time point (<6 months, 6-12 months, 12-
24 months). The FDG uptake in the lung region was assessed
qualitatively using a 3-point scale (0, none or faint; 1, mild; 2
moderate to intense) ad the shape was evaluated (mass-like or
non mass-like). For semi-quantitative analysis, SUVmean and
SUV max were calculated and compared them to the pre-
therapeutic values. Results: 7 patients had local relapse. In
recurrent tumours, the combination of intensity grade 2 and
mass-like shape was most common (90%). In contrast, the
combination of intensity grade 0 or 1 and no-mass like shape
was most common in radiation fibrosis (80%). The SUVmax
of tumour relapse after 12 months was higher than of radiation
fibrosis (p<0.01) and all tumour recurrence showed the
SUVmax> 4 at diagnosis of local failure. At ≥ 12 months after
SABR, the combination of intensity 2 and mass-like FDG
uptake or SUVmax ≥ 4 had a high predictive value of local
recurrence. Pre-RT and post-RT primary SUV can predict the
outcome of patients with NSCLC treated with SABR. We
observed the following pattern of changes in lung parenchyma
on CT post-SABR: acute (within 6 months, corresponding to
pneumonitis) and late (after 6 months, corresponding to fibro-
sis). Conclusion: The combination of FDG patterns and
SUVmax was a useful to discern tumour relapse from radia-
tion fibrosis. CT density changes are common post-SABR and
PET scan is more sensitive than CT in detecting recurrences.
P644
Predictive value of early dynamic and static FDG PET /
CT findings in evaluation of primary lung lesions
B. Vatankulu1, S. Bakan2, O. E. Şahin1, S. Sağer1, M.
Halaç1, H. B. Sayman3, K. Sönmezoğlu1; 1İstanbul Univer-
sity Cerrahpaşa Medical Faculty Department of Nuclear Med-
icine, İstanbul, TURKEY, 2İstanbul University Cerrahpaşa
Medical Faculty Department of Radiology, İstanbul, TUR-
KEY, 3İstanbul University Cerrahpaşa Medical Faculty De-
partment of Nuclear Medicineepartment of Nuclear Medicine,
İstanbul, TURKEY.
Aim: Although differentiation of benign and malignant lesions
of primary lung is performed with FDG PET / CT imaging,
FDG which is a glucose analogue is not a specific cancer
agent. To make differentiation of benign or malignant lesions
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is not easy in granulomatous processes , active inflammation
and infection.We aimed to find the value of dynamic and static
FDG PET / CT findings in detection of malignant and benign
lung lesions.Materials and method: A total of 17 patients de-
tected primary lung lesions with histopathological results were
prospectively evaluated. All patients in the study after FDG
injection series displays the first 15 minutes early to receive
dynamic imaging and after the injection 55-65. min in static
display was made to wholebody. 50% ofmaximum pixel value
threshold was used for VOI (volume of interest)which placed
on assessment of pulmonary lesion. Arterial blood flow were
evaluated with VOI’s which were placed in the same size on
the left ventricle and thoracic aorta. FDG phosphorylation rate
( Ki) and glucose metabolic rate (MRGlu) was calculated with
PATLAK analysis for each lesion. In addition to the increased
activity of the lesions time activity curve (TAC slope ) values
were recorded . The mean and maximum standardized uptake
values ( SUVmax , SUVmean ), total lesion glycolysis ( TLG )
values were calculated with static PET / CT images.Results:
Malignancy were detected in 12 of 17 patients in histopatho-
logical examination. 5 patients had normal histopathology. Ki,
MRGlu , the TAC slope , SUVmax , SUVmean and TLG
values in evaluating for benign and malignant lung lesions
were shown to be beneficial in ensuring the benign and ma-
lignant lesions with McNemar test (p<0.05). The sensitivity
and specificity for malignant lesions of the Ki and MRGlu
values obtained from dynamic studies were 92 % and 79%
respectively. Although static PET / CT parameters detected
malignancy, dynamic data showed benign lesions in one of
the five lesions.Conclusions: The differential diagnosis of be-
nign and malignant lung lesions may be performed with a high
accuracy with the values of Ki and MRGlu obtained from
dynamic FDG PET / CT imaging. The accuracy of FDG -
PET / CT imaging may be increased with dynamic images in
patients unable to distinguish malignant or granulomatous
lung lesions.
P645
Correlation of F-18 FDG PET-CT based on metabolic
volumetric parameters with survival in patients
with non-small cell lung carcinoma
M. Kula1, E. Kocaagaoglu1, U. Abdulrezzak1, H. Karaca2,
Ö. Onal3, A. Tutus1, Y. Kose Kurt1; 1Erciyes University,
School of Medicine, Department of Nuclear Medicine, Kay-
seri, TURKEY, 2Erciyes University, School of Medicine, De-
partment of Clinical Oncology, Kayseri, TURKEY, 3Erciyes
University, School of Medicine, Department of Cardiovascu-
lar Surgery, Kayseri, TURKEY.
Aim: To determine the relationship between metabolic-
volumetric parameters (PET-MVP) based on F-18 FDG PET-
CT with survival and prognostic factors in patients with non-
small cell lung carcinoma (NSCLC). Patients and Methods:
Total of 215 patients with NSCLC who underwent PET-CT
before any therapy between September 2009 and January
2012 were evaluated retrospectively. Univariate and multivar-
iate analyses were performed to assess the relation of survival
and PET-MVP, and the other prognostic factors. We compared
ROC curves obtained by thresholds segmentation method
(using thresholds of 50%/ 38% of the maximal SUV within
the lesion). Results: The mean follow up time was 22 months
and the estimated overall survival for cohort was 13±1, 4
months. Univariate analyses showed that age (p: 0.006), stage
(p< 0.0001), mediastinoscopy results (p: 0.001), PMD (p:
0.004), SUVmax values of mediastinal lymph nodes
(p:<0.0001), all of the PET-MVP (SUVmax p:0,02, others p:
0,0001) were significant prognostic factor for overall survival.
On multivariate analysis, independent prognostic factors asso-
ciated with overall survival were age (p:0,015, HR:1,5), stage
(p:<0,0001) and MTV (metabolic tumour volume) %38 (p:0,
009, HR:1,58). There was no significant difference between
ROC curves obtained by thresholds segmentation method.
Conclusion: PET-MVP based on F-18 FDG PET-CT, especial-
ly MTV 38% are important independent prognostic factors for
survival. It may be a promising tool for stratifying patients
with NSCLC for risk-adapted therapies.
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P646
Value of 18F-FDG PET/CT in the Staging of Gastric
Carcinoma
L.Mena Bares, V. Gónzalez Cosano, E. Carmona Asenjo, M.
Pleguezuelo Navarro, F. Maza Muret, V. Guiote Moreno, E.
Moreno Ortega, J. Vallejo Casas; Hospital Universitario Reina
Sofía, Córdoba, SPAIN.
Aim: The study’s objetive is to analize the utility of 18F-FDG
PET/CT in the gastric cancer staging comparing with the CT,
the ultrasound endoscopic results and the utility in the clinical
management of patients. Material and Methods: We analized
retrospectively 29 patients with gastric adenocarcinoma that
were diagnosed with upper endoscopy during the period be-
tween May 2012-November 2014. All patients underwent a
thorax and abdomen CT study with intravenous contrast and
PET/CT study with 18F-FDG from the skull base to proximal
third of legs after 26 days on average compared to CT scan.
With 13 patients an ultrasound endoscopic study was per-
formed during the same study period. Results: The study
consisted of 19 men and 10 women with middle ages of 67
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years old. The most frequent histological subtype was de ad-
enocarcinoma (68,2% of cases).The sensitivity values for the
detection of the primary tumour were 93,1% for PET/CT, 79,
3% for CT and 100% for ultrasound endoscopic. The PET/CT
study compared with CT changed the tumour stage and the
clinical management in 13 patients (44, 8%). For the patients
who performed CT and ultrasound endoscopic, the PET/CT
changed the tumour stage in 61,5% of the cases and the clinical
management in 38,5%. In the lymph stage all changes were to
reduce the stage, the results were: 2 patients went from N1 to
N0, 2 patients from N2 to N1 and one of them from N2 to N0.
In the other side, the changes in detection of distant metastases
were: one patient went fromM0 toM1 and 5 patients fromM1
to M0. The changes in the clinical management were: a) in
patients without surgery options before performed the PET/
CT: 3 patients received neoadjuvant treatment before the sur-
gery and 2 patients surgery. b) in patients with surgery options
before PET/CT: one patient became inoperable by the exis-
tence of distant metastases undetected with CT; 6 patient
underwent surgery without neoadjuvant treatment and one pa-
tient surgery after neoadjuvant treatment. Conclusions: The
18F-FDG PET/CT is an useful procedure for staging of gastric
carcinoma, showing higher sensitivity than CT in detecting
primary tumour. The PET/CT can lead to a modification of
tumour stage and therefore the clinical management of patients
in up to 45% of cases.
P647
Delayed FDG image obtained 90 min after injection gives
incremental information which correlates
histopathological data; Analysis with surgically resected
pancreatic cancer
T. Kudo1, R. Ideguchi1, M. Uetani1, A. Nanashima2, T.
Nagayasu1; 1Nagasaki University, Nagasaki, JAPAN, 2Uni-
versity of Miyazaki, Miyazaki, JAPAN.
Purpose: Histopathological-Nuclear Medicine correlation is
important issue to predict prognosis after surgical resection.
Histopathogical findings of surgically resected pancreatic can-
cer and preoperative FDG PET parameters are correlated.
Method: 16 consecutive patient who underwent surgical resec-
tion in division of surgical oncology, Nagasaki University
Hospital were analyzed. FDG images were obtained 60min
and 90 min after injection. SUVmax of main tumor at each
time point (SUVmax-60, SUVmax-90), SUVmax normalized
to normal liver average (TBR-60, TBR-90), difference be-
tween SUVmax-90min SUVmax-60 (SUVmax-diff), differ-
ence between TBR-90 and TBR-60 were calculated in each
patients. Histopathological parameters such as lymphatic(ly),
perineural(ne) and vascular(v) invasion were determined on
resected surgical specimen. Each parameter of invasion was
classified into 4 grading system (0=no invasion, 3=severe in-
vasion). Those histopathological parameters were correlated
with FDG PET parameters. Results: TBR-diff showed signif-
icant correlation between vascular invasions. “v3” showed
significantly higher TBR-diff (132%) compared to all other
v-grade (v0=16.9, v1=29.0, v2=34.5). TBR-90 also showed
similar pattern with vascular invasion (v0=2.5, v1=2.5,
v2=2.7, v3=5.3; p<0.05 between v3 and other 3 grades).
SUVmax-90 showed similar tendency but did not reach statis-
tical significance. TBR-60 and SUVmax-60 showed no rela-
tionship between vascular invasion grades. For perineural in-
vasion TBR-90, SUVmax-90, TBR-diff and SUVmax-diff
showed similar tendency like vascular invasion but also does
not reach statistical significance. Any FDG parameters
showed no correlation and tendency with lymphatic invasion.
Conclusion: FDG PET image obtained 90min after injection
may give us incremental information over image obtained af-
ter 60 min which was conventionally performed. However,
lymphatic invasion is hard to predict.
P648
The diagnostic performance of FDG-PET/CT versus
conventional imaging modalities in the evaluation
of treatment response following ablation therapy
for colorectal liver metastases: a meta-analysis
M. Samim1, Q. I. Molenaar1, M. F. J. Seesing1, M. A. A. J.
van den Bosch1, T. J. M. Ruers2, I. H. M. Borel Rinkes1, R.
van Hillegersberg1, M. G. E. H. Lam1, H. M. Verkooijen1;
1University Medical Center Utrecht, Utrecht, NETHER-
LANDS, 2Dutch Cancer Institute - Antoni van Leeuwenhoek,
Amsterdam, NETHERLANDS.
Background: Thermal ablation therapy is increasingly applied
for treatment of patients with unresectable colorectal liver me-
tastases (CLM). Uncertainty exists on the optimal imaging
modality for timely detection of local tumour progression.
This systematic review and meta-analysis evaluates the diag-
nostic accuracy of CT, MRI and FDG-PET for detection of
local tumour progression following thermal ablation
therapy.Methods: A comprehensive systematic review of the
literature published from inception to January 2015 was per-
formed. Included were all English written studies that reported
the diagnostic accuracy of at least FDG-PETor FDG-PET/CT
for postoperative evaluation of patients with liver malignan-
cies treated by means of ablation therapy. Studies had to report
either data on the true positive, false positive, true negative and
false negative results of the index test or the sensitivity and
specificity. The reference standard had to be specified and was
defined as histology results or clinical follow-up. Excluded
from the meta-analysis were studies that reported small case
series (n<10). The methodological quality of the studies was
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assessed using a modified version of the quality assessment of
diagnostic accuracy studies (QUADAS) tool. For meta-analy-
sis, the pooled sensitivity and specificity was calculated for
each imaging modality. A random effect model was chosen
in case of I2 >30%.Results: The literature search resulted in
4670 hits, 13 of which were included in the systematic review.
The critical appraisal showed that in the selected studies there
was a risk of bias regarding the use of the reference standard
and the blinding of the index tests. Based on the critical ap-
praisal, three studies were excluded from the meta-analysis.
Seven studies reported data on diagnostic performance of
FDG-PET (n=328), five studies for FDG-PET/CT (n=354),
eight studies for CT imaging (n=333) and three studies for
MRI (n=124). Pooled sensitivity estimates were 85% (78-
91%) for FDG-PET, 86% (80-91%) for FDG-PET/CT, 73%
(63-81%) for CT and 69% (54-81%) for MRI. The pooled
specificity estimates were 96% (91-98%) for FDG-PET, 89%
(84-98%) for FDG-PET/CT, 96% (92-98%) for CT and 99%
(93-100%) for MRI.Conclusion: Although the current avail-
able literature provides limited high-quality research evidence
upon which to base any firm decisions, the results of this meta-
analysis suggest that FDG-PET and FDG-PET/CT have the
highest diagnostic accuracy for detection of incomplete abla-
tion or local tumour progression in patients with CLM.
P649
Respiratory gated 18F-FDG-PET/CT improves
quantification of metabolic parameters and their
correlation with overall survival in patients
with pancreatic ductal adenocarcinoma
D. Withaar, W. Grootjans, J. Hermans, K. Van Laarhoven, L.
De Geus-Oei, M. Gotthardt, E. Aarntzen; Radboudumc, Nij-
megen, NETHERLANDS.
Aim: Metabolic parameters, especially SUVmax, are increas-
ingly being used to characterize tumors. Movement artifacts
during respiration introduce an error in quantification of met-
abolic parameters, especially around the diaphragm. Previous
studies in lung cancer showed that amplitude base optimal
respiratory-gated (ORG) 18F-FDG-PET/CT scanning results
in significant increase in metabolic parameters, except the
MTV (40% threshold), which decreased [Grootjans et al. Eur
Radiol 2014]. The present study investigates the additional
value of ORG scanning on quantification of metabolic param-
eters in patients with pancreatic ductal adenocarcinoma
(PDAC) in correlation with overall survival (OS). Material
andMethods: A cohort of 40 patients with histologically prov-
en PDAC underwent standard 18F-FDG-PET/CT scan and a
contrast-enhanced CT (ceCT). All 18F-FDG-PET images
were reconstructed according to the EANM guidelines for
quantitative oncology imaging. Additionally, the ORG images
were reconstructed with a duty cycle (the percentage of PET
data used for image reconstruction) of 35%. Tumor lesions
were identified on ceCT and two readers drew VOIs in con-
sensus. The paired t-test was performed to compare ORG
scans to their corresponding non-gated scans. The Cox propor-
tional hazard model was performed for univariate analysis for
correlation with OS. p<0.05 was considered significant. Re-
sults: Using non-gated reconstruction, tumor SUVmean (cut-
off 3.0; HR 0.31 (95%-CI 0.10-0.94), p=0.039), metabolic
tumor volume (MTV) determined at 70% SUVmax threshold
(cut-off 2500; HR 0.29 (95%-CI 0.12-0.68), p=0.004) and
TLG at 70% SUVmax threshold (cut-off 10000; HR 0.34
(95%-CI 0.15-0.78), p=0.011) are significantly associated
with OS. However, tumor SUVmax is not. Using
respiratory-gated reconstruction, these metabolic parameters
changed significantly. Interestingly, SUVmean (p=0.039) and
TLG (p=0.021) maintained their significant association with
OS, whereas SUVmax was still not associated. In contrast to
the EANM reconstructed scans, a 2.5 points difference be-
tween SUVmean in tumor lesion and normal pancreas showed
significant association with OS (HR 0.34 (95%-CI 0.14-0.85),
p=0.031). Conclusion: Respiratory-gated reconstruction sig-
nificantly impacts the quantification of metabolic parameters
in the characterization of PDAC. Particularly SUVmax does
not associate with OS, irrespective of respiratory motion.
SUVmean proves to be a more robust measure, and might
therefore be used for prognostication. Furthermore, illustrating
the improved visual discrimination of lesions on ORG scans, a
difference of 2.5 points or more between SUVmean in tumor
and normal pancreas is significantly associatedwith worse OS.
P650
18F-FDG PET/CT findings in a patient with Cowden’s
syndrome
K. Öksüzoğlu1, T. Öneş1, H. T. İlçe2, F. Dede1, H. T.
Turoğlu1, S. İnanır1, T. Y. Erdil1; 1S.B. Marmara Universitesi
Pendik Egitim ve Arastirma Hastanesi, Nükleer Tıp AD, Is-
tanbul, TURKEY, 2Sakarya Üniversitesi Eğitim ve Araştırma
Hastanesi, Nükleer Tıp AD, Sakarya, TURKEY.
Introduction: Cowden’s Syndrome (CS) is a rare autosomal
dominant inherited disorder (1/200.000) associated with mu-
tations in a tumour suppressor gene called PTEN (Phosphatase
and Tensin Homolog gene). CS is characterized by multiple
noncancerous tumorlike growths called hamartomas and in-
creased risk of developing cancers (breast, thyroid, uterus,
kidney, colorectal mostly). CS is also often associated with
macrocephaly, hamartomatous polyps (skin andmucousmem-
branes, 60-90 % located in the gastrointestinal tract), benign
skin lesions (trisilemmoma, acral keratoses) and dysplastic
gangliositoma of the cerebellum etc. Purpose: In this case
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report, the value of the FDG PET/CT findings evaluated in a
patient who had considered CS. Case report: A 35 years-old
male underwent partial small bowel resection and total gas-
trectomy with the diagnosis of malignant mesencymal tumour
on the background of small bowel hamartomatous polyps.
Postoperative histopathological examination revealed multiple
benign hamartomatous polyps in the stomach too. Cowden’s
Syndrome was considered. The patient was referred to FDG
PET/CT scan for staging. Focus of increased FDG uptake
(SUVmax: 4.8 and 5.8) as compatible with postoperative
changes was seen on FDG PET/CT. In addition, polypoid
masses that forming filling defects on the ileocolonic segments
showed intense (SUVmax: 8.9) FDG uptake and there were
multiple lytic / sclerotic / destructive metastatic lesions with
increased FDG uptake (SUVmax: 10.3) in the proximal part of
the right humerus and the pelvic bones of the skeletal system
prominently. Conclusion: Hamartamatous polyps usually have
low malignancy potential and malignant transformation of ad-
enomatous polyps in patients with CS has been reported in the
literature. The distinction between adenocarcinoma and be-
nign hamartomatous polyps in the gastrointestinal tract has
not been reported in the literature yet. Intense hypermetabolic
polyps in the gastrointestinal tract in patients with CS on FDG
PET/CT can also be caused by benign polyps.
P651
Better accuracy of SPECT/CT in determination of liver
hemangioma in patients with malignant tumor
M. PRPIC1, Z. KUSIC2; 1University Hospital Centre “Sestre
Milosrdnice”, ZAGREB, CROATIA, 2University Hospital
Centre “Sestre Milosednice”, ZAGREB, CROATIA.
AIM: to compare of Tc-99m labeled red blood cell
(RBC) SPECT study combined with “low dose“ CT
(SPECT/CT) and contrast- enhanced CT (ceCT)
concerning diagnostic accuracy in evaluation of liver
lesions. METHODS:41 pts (mean age 54,9 years, range
16-76 years) with suspected liver lesions was performed
RBC SPECT/CT for confirmation or exclusion of hem-
angioma diagnosed by ceCT in three occasions, as fol-
lows: metastasis from various primaries (endometrium,
breast,colon,renis, lung,cervicis uteri, prostate); suspected
liver tumors, atypical haemangioma. All pts underwent
RBC SPECT at 10 min (early) and SPECT/CT at
180 min (late scan) after injection of 740 MBq
(20 mCi )Tc-99m and performed within SPECT/CT sys-
tem (Siemens Simbia T2). In vivo technique was used
for RBC labeling. RESULTS:Overall 82 haemangiomas
were detected on RBC SPECT/CT study (38 ceCT pos-
i t ive, 44 ceCT negat ive) and 10 suspected on
haemangioma liver lesions (ceCT positive but RBC
negative). In total, on RBC/SPECT/CT study lesions
were better delineated and determined than on ceCT
only, especially in case of small lesion (diameter
<2cm). CONCLUSION: In our opinion, SPECT/CT al-
low better diagnostic confidence comparing to ceCT in
characterisation of liver lesion whether it is benign or
malignant.
P652
Metabolic FDG superscan in a patient with gastric
adenocarcinoma: A rare finding in PET/CT imaging
B. E. Akkas, S. Demirtas, B. Demirel, G. Ucmak; Ankara
Oncology Research and Training Hospital Department of Nu-
clear Medicine, Ankara, TURKEY.
The term “superscan” on bone scan is a well recognized phe-
nomenon which describes increased skeletal radiotracer up-
take relative to soft tissues and absent or faint genitourinary
tract activity. However, the superscan on 18FDG PET/CTwith
increased skeletal radiotracer uptake is an uncommon finding,
limited to only few case reports in the literature. In these cases,
physiological FDG distribution throughout the body was rela-
tively preserved where skeletal FDG uptake was significantly
increased. The aim of this report is to present the unusual
findings of a “metabolic FDG superscan “with severely altered
biodistrubution of FDG throughout the whole body. There is
only slight uptake in brain and significantly increased hetero-
geneous FDG uptake in the skeleton is seen due to widespread
metastases from the primary gastric carcinoma which also
demonstrates intense FDG uptake. Case Presentation: A 42
year old male patient with gastric adenocarcinoma
underwent FDG PET/CT initial staging of primary gas-
tric cancer following total gastrectomy. He had no his-
tory of bone marrow stimulating factor or corticosteroid
use. On PET/CT scan, altered biodistribution of FDG
was seen with significantly increased FDG uptake
throughout the bones and bone marrow. In addition,
multiple lytic bone lesions were detected on the corre-
sponding CT slices. Hypermetabolic lymph nodes sug-
gestive of metastasis were also noted in the mediasti-
num, supraclavicular fossa and in the abdomen. The
patient had pancytopenia (white blood cell count: 3170/
μl, Hemoglobin:8.8 g/dl, platelet:30000/ μl). He died
due to complications due to severe bone marrow in-
volvement. Discussion and Conclusion: Gastric cancer
is among the commonest cancers that cause superscan
appearance in bone scan. However, the”metabolic
superscan” is a very rare finding in the oncology prac-
tice. In this report, the altered distribution of FDG
throughout the whole body caused by the gross tumoral
involvement of the skeleton is presented demonstrating a
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“metabolic superscan”. The physiological FDG uptake is
completely altered without the use of bone marrow stim-
ulating agents.
P653
Efficacy of 18F-FDG-PET/CT for detection of suspected
recurrence in post treatment follow-up of patients
with carcinoma gall bladder, in a North Indian
population-a pilot study.
M. Ravina, S. Gambhir, A. Prashanth, S. Barai, N. Kumar, D.
Singh; Sanjay Gandhi Post Graduate Institute of Medical Sci-
ences, Lucknow, Uttar Pradesh, INDIA.
Aims and Objectives: Carcinoma gall bladder is among
the common causes of cancer related mortality in North
India and Chile. Recurrent carcinoma of the gall bladder
has a poor prognosis. Conventional imaging (CI) and
tumour markers have limited accuracy for detecting re-
currence in these patients. The aim of this study was to
evaluate the efficacy of 18F-FDG-PET/CT for follow-up
of patients with suspected recurrence of carcinoma of
the gall bladder in a north Indian population. Methods:
A total of 22 patients were evaluated with 18F-FDG-
PET/CT for suspected recurrence in a north Indian pop-
ulation. All patients had undergone surgery with or
without adjuvant therapy (chemotherapy, radiotherapy,
or both) for histologically proven carcinoma of the gall
bladder. Comparable CI (ultrasound or contrast-enhanced
CT) was available for 14 patients. Final confirmation of
recurrence was confirmed with clinical and/or imaging
follow-up. Results: Patient’s mean age was 53.9±9.78
years. 18F-FDG-PET/CT was positive for recurrence in
15 patients (68.1%) and negative in 7 (31.9%). Loco-
regional disease was observed in 5 patients, metastatic
disease was observed in 5, and 5 showed both loco-
regional and metastatic disease. Compared to CI, 18F-
FDG-PET/CT upstaged six patients, correctly character-
ized five patients suspected of recurrence as true nega-
tive, and concordant findings were noted in three pa-
tients. 4 of 15 recurrence positive patients detected with
FDG died during follow-up period of 3.0 months and 11
are undergoing palliative radiotherapy/chemotherapy. The
sensitivity, specificity, positive and negative predictive
values, and accuracy of 18F-FDG PET/CT were 93.5
%, 100%, 100%, 85.7%, and 95.4%, respectively. Con-
clusions: Accurate detection of recurrent carcinoma of
the gall bladder after intended curative surgery, radio-
therapy and/or chemotherapy is imperative to select the
most appropriate therapeutic strategy. 18F-FDG-PET/CT
appears to be a highly specific and sensitive modality
for detecting recurrence in post-therapy patients.
P654
Hepatic Epithelioid Hemangioendothelioma on FDG
PET/CT
K. Oksuzoglu, R. Maleki, S. Inanir; Marmara University
School of Medicine, Department of Nuclear Medicine, Istan-
bul, TURKEY.
Introduction: Hepatic Epithelioid Hemangioendothelioma
(HEH) is an uncommon (1/1,000,000 per year) low-middle
grade tumour, originating vascular endothelial cells. HEH
can be multicentric and metastatic. Multifocal HEH mimics
metastases radiologically and is most often confused with
cholangiocarcinoma pathologically or radiologically. The
prognosis of HEH is better than hepatocellular cancer and
cholangiocarcinoma even at metastatic stage.Purpose: We
want to report F-18 FDG PET/CT findings in a patient with
a r a r e hepa t i c t umor o f ma l ignan t ep i t h e l i o i d
hemangioendothelioma.Case Report: A 49 years-old male
with right upper quadrant pain and fullness complaints was
referred to USG and MR which revealed multiple lesions in
the liver parenchyma. Histopathological examination con-
firmed the diagnosis of HEH. The patient was admitted to
FDGPET/CT for staging. FDG PET/CTshowedmultiple nod-
ular hypodense lesions in the liver, the majority located sub-
capsular, causing the capsule retractions in both lobes and
showed intense FDG uptake (SUV max:6.6). Also, at the
lower-lobe of left lung, there was a mild hypermetabolic
(SUV max:1.9) nodule with spiculated border. The patient
treated with chemotherapy.Conclusion: In this case, FDG
PET/CT detected HEH and showed the extent of the tumor.
The diagnosis of HEH is difficult and the FDG avidity of
lesions is variable. Knowing characteristic imaging findings
of this rare tumor (Subcapsular localization, capsular
retraction/flattening and target-like appearance on MR and
CT images) helps us in differential diagnosis of hepatic multi-
focal lesions.
P655
Metabolic response assessment on 18F-FDG PET/CT
with delta SUVmax, and its utility in predicting
histological response following neoadjuvant
chemoradiotherapy in patients with oesophageal cancer.
N. Ahmed, G. Avery, A. Razack, T. Goldstone, R. Roy, M.
Hingorani, J. Cooke; Hull and East Yorkshire Hospitals NHS
Trust, Hull, UNITED KINGDOM.
Aim: To assess whether metabolic response on 18F-FDGPET/
CT can predict histological response in patients treated with
neoadjuvant chemoradiotherapy (CRT) for oesophageal can-
cer (OC).Material and Methods:A retrospective audit was
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conducted of 30 consecutive patients with OC. 5 patients were
excluded (2 patients had no significant FDG uptake on base-
line PET, whilst 3 did not undergo resection and could not be
histologically graded). All patients received CRT regimen
comprising of 1 cycle of induction Cisplatinum & Capecita-
bine followed by concurrent chemoradiation with 2 further
cycles of same chemotherapy with 45 Gy of Radiotherapy
over 5 weeks. A baseline 18F-FDG PET/CT was done in all
patients, followed by a post-treatment study 3-5 weeks after
finishing therapy. The SUVmax of the primary tumour site
was recorded for both PET examinations. Resection samples
were assessed and classified as per the Mandard criteria into
five tumour regression grades (TRG 1-5).Results:Twenty five
patients were included, mean age 62 years, of which 14 were
males. They were grouped into histological responders (HR,
TRG 1/2/3, n=15) and non-responders (HNR, TRG 4/5,
n=10). Using median percentage reduction in SUVmax (delta
SUVmax 52.2%) as threshold, metabolic response (MR) was
seen in 11/15 of HR, whilst 8/10 patients in the HNR group did
not show significant MR on PET (p= 0.0127, Sensitivity 73.3
%, Specificity 80%, Positive predictive value 84.6
%).Conclusion:Results of this relatively small series, suggests
strong association between metabolic and histological re-
sponse in this patient group. Larger studies are required to
validate these results. Furthermore, correlation of metabolic
response with long term survival will also help assess whether
post-chemoradiotherapy PET examination is of prognostic
benefit and contribute to patient selection for curative radical
surgery.
P39 - Tuesday, October 13, 2015, 4:00 PM - 4:30 PM, Hall 3 –
Poster Exhibition
Clinical Oncology: Neuroendocrine Tumours
P656
Additional value of the quantitative measurements
of the therapeutic effect in patients with somatostatin
expressing tumors using 99mTc-Tectrotyde
I. Kostadinova1, A. Demirev1, J. Mihailova2, V. Hadjiiska1;
1Clinic of nuclear medicine, Sofia, BULGARIA, 2Clinic of
medical oncology, Sofia, BULGARIA.
The scintigraphy for the diagnosis of somatostatin receptor
expressing (SR) neuroendocrine tumors, their staging,
restaging and monitoring therapy, is known to be highly sen-
sitive. Sometimes it is difficult to estimate visually minimal
changes during therapy. The aim of our study was to introduce
quantitative measurements in addition to the usual qualitative
criteria for a precise evaluation of the response to the applied
therapy in patients with SR-expressing tumors. During the
period 2012-2014, we have performed in total 54 examina-
tions on 22 patients (15 of them were examined twice, 7 of
them triple ) after 3-12 cycles of sandostatine therapy, using
the somatostatin analog 99mTc-HYNIC-TOC (Tektrotyd,PL)
in activity between 370-550 MBq. Whole body and hybrid
imaging investigation - SPECT-CT were performed 2- 4h p.i.
At presentation the average level of chromogranin was 234ng/
ml and dropped during therapy to 161ng/ml and the number of
pathological changes before and after therapy was respectively
65 and 60. For a quantitative measurement of the degree of
activity of the radiopharmaceutical in them / compared to
background /, an index of activity /IA/ was introduced, calcu-
lated in 1-5 target lesions / the number depended on the extend
of the tumor /. In 19/22 of the investigated patients, it was
difficult to evaluate therapeutic response, relying only on qual-
itative criteria, especially in those with multiple pathological
lesions. In 9 of all patients, there was a partial therapeutic
response with an average decrease of IA with 35.6% ( calcu-
lated as a sum of IA of the all affected structures) ; in 3-
complete response (without any pathological uptake); in 6 -
stable disease with IA change between -12% and + 11%; in 4
of the patients -progressive disease with IA increase with
34.5%. The last group of the patients and 2 of the patients with
a stable disease / all of them with Ki 67 index above 5/ were
referred to PET-CT exam for eventual visualization of undif-
ferentiated part of the tumor and further application of a com-
mon chemotherapy or surgery. In summary, we suggest that
applying additional quantitative criteria to the routine qualita-
tive one in patients SR expressing tumors, using 99mTc-
HYNIC-TOC, helps in many cases for a more precise evalua-
tion of the therapeutic effect, especially in those with an ad-
vanced disease. The therapeutic strategy could be optimized
additionally applying 18F-FDG PET-CT in some of the
patients.
P657
A retrospective comparison between 68Ga-DOTA-TOC
and 18F-DOPA PET/CT in metastatic extra-adrenal
paraganglioma
A. Kroiss1, B. L. Shulkin2, C. Uprimny1, T. Jazbec1, A.
Frech1, G. M. Sprinzl3, G. Gastl1, C. Thomé1, G. Fraedrich1,
I. J. Virgolini1; 1Medical University Innsbruck, Innsbruck,
AUSTRIA, 2Radiological Sciences, St. Jude Children’s Re-
search Hospital, Memphis, TN, UNITED STATES, 3State
Clinic St. Poelten, St. Poelten, AUSTRIA.
Purpose 18F-Fluoro-L-dihydroxyphenylalanine (18F-DOPA)
PET offers high sensitivity and specificity in the imaging of
nonmetastatic extraadrenal paragangliomas (PGLs) but lower
sensitivity in metastatic or multifocal disease. These tumors
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are of neuroendocrine origin and can be detected by 68Ga-
DOTA-Tyr3-octreotide (68Ga-DOTA-TOC) PET. Therefore,
we compared 68Ga-DOTA-TOC and 18F-DOPA as radiola-
bels for PET/CT imaging for the diagnosis and staging of
malignant extraadrenal PGL. Combined crosssectional imag-
ing was the reference standard.Methods A total of 2 men and 4
women (age range 22 to 60 years) with anatomical and/or
histologically proven malignant extraadrenal PGL were in-
cluded in this study. Of these patients, 2 female patients suf-
fered from metastatic head and neck PGL disease, while the
remaining 4 patients were diagnosed as extraadrenal multifo-
cal PGL disease. Comparative evaluation included morpho-
logical imaging with CT and functional imaging with 68Ga-
DOTA-TOC PET and 18F-DOPA PET. The imaging results
were analyzed on a per-patient and a per-lesion basis. The
maximum standardized uptake value (SUVmax) of each func-
tional imaging modality in concordant tumor lesions was mea-
sured. Results Compared with anatomical imaging, 68Ga-
DOTATOC PET and 18F-DOPA PET each had a per-patient
detection rate of 100 % in metastatic extraadrenal PGLs. How-
ever, the per-lesion detection rate of 68GaDOTATOCwas 100
% (McNemar, P<1.0), and that of 18FDOPA PETwas 59.3 %
(McNemar, P<0.001) in metastatic extraadrenal PGLs. Over-
all, 68GaDOTATOC PET identified 28 lesions; anatomical
imaging identified 27 lesions, and 18FDOPA PET identified
16 lesions. The SUVmax (mean +/- SD) of all concordant le-
sions was 31.4 +/- 22.3 for 68GaDOTATOC PET and 9.2 +/
9.0 for 18F-DOPA PET (MannWhitney U test, P<0.001).
Conclusion 68Ga-DOTA-TOC PET may be superior to
18FDOPA PET and even to diagnostic CT in providing valu-
able information for pretherapeutic staging of metastatic
paraganglioma disease.
P658
Oncogenic osteomalacia: Role of 68Ga DOTA-NOC
PET/CT scan in identifying the culprit lesion and its
management
S. Gambhir, D. Singh, M. Ravina, S. Barai, A. Prashanth, N.
Kumar; Sanjay Gandhi Post Graduate Institute of Medical Sci-
ences, Lucknow, Uttar Pradesh, INDIA.
Objective: Surgical removal of culprit lesion is the de-
finitive treatment for tumor induced Osteomalacia
(TIO). These patients showed multiple lesions due to
fractures and other bony changes and it is confusing
to identify culprit lesion. The aim of this study was
to evaluate role of 68Ga-DOTA-NOC PET/CT in the
detection of culprit lesion for biopsy and required in-
tervention (surgical/ radiofrequency ablation). Methods:
15 patients (6 male & 9 female) underwent 68Ga
DOTA-NOC PET/CT. The patients referred with clinical
symptoms of pain, multiple fractures and biochemical
evidence of hypo-phosphatemia & raised Fibroblast
Growth factor-23 (FGF-23). Qualitative & semi-
quantitative parameters like SUV-max and CT/MRI
findings were used to identify the culprit lesions. Re-
sults: Scan revealed 41 lesions in 15 patients, 31/41
lesions were tracer avid lesions and 10/41 lesions were
non tracer avid fractures. Among these 31 tracer avid
lesions, 23/41 lesions were focal tracer avid (SUV max
range 0.55-4.35) skeletal lesions (fracture and/or no as-
sociated CT abnormality). The 8/41 tracer avid skeletal
lesions present in 6 patients (3 lesions in one patient &
1 each in rest of the 5 patients) were highly suspicious
for culprit lesions in view of high SUV-max, size and
associated soft tissue involvement with SUV-max (range
1.5-13.4) and size (0.9 to 5.0 cm). 2 patients were
biopsied in view of suspicious lesion and both turned
out to be positive phosphaturic mesenchymal tumors
with SUV-max 2.2 and 8.0. 1 of the biopsy proven
patient improved biochemically & symptomatically fol-
lowing surgical resection. The other patient underwent
radiofrequency ablation (RFA) with near complete res-
olution of the culprit lesion. The SUV-max of lesion
decreased from SUV-max 8.0 to SUV-max 3.0 with
near normalization of S.FGF 23 (12000RU/ml to
180RU/ml). 1 patient with 3 lesions underwent further
imaging, 02 lesions showed discordant results and 1
lesion with soft tissue component showed concordant re-
sults on MRI is planned for surgery. Two other patients
with concordant results are planned for definitive treat-
ment The patient with discordant findings (lesion SUV
max- 13.4) is under further evaluation. Conclusion: There
is some overlap in the SUV-max between fractures/bone
associated lesions and the culprit lesion with tendency of
most non-culprit lesions to have lower SUV-max. In such
scenario tracer avid larger non fracture lesion with soft
tissue component may lead to culprit lesion amongst mul-
tiple lesions. Following detection of culprit lesion, surgical
removal or RFA (in cases of osteopenia and poor bone
health) is the best treatment
P659
Utility of Ga-68 DOTANOC PET CT in evaluation
of unusual or rare neuroendocrine tumors: Single
institutional experience
A. Pruthi, P. Pankaj, R. Verma, A. Jain, E. S. Belho, H.
Mahajan; Sir Ganga Ram Hospital and Research Centre,
New Delhi, INDIA.
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Ga-68 DOTANOC PET CT is an established modality for
imaging gastro-entero-pancreatic neuroendocrine tumours
(NETs). However, experience in evaluating unusual NETs
remains limited. Purpose: To retrospectively evaluate the
utility of Ga-68 DOTANOC PET CT scan in analyzing rare
or unusual neuro-endocrine tumors (NETs). Methods: A
total of 19 patients (10 males, 09 females; mean age 47.7
+/- 14.3 years, range 27-68 years) presenting with histo-
pathologically proven unusual / rare neuroendocrine tumors
(other than gastro-entero-pancreatic NETs & bronchial
NETs), who underwent Ga-68 DOTANOC PET CT scan
at our department were included for analysis. These patients
were investigated retrospectively and various parameters
like age, sex, sites of primary and metastatic neuroendocrine
lesions, and quantitative estimation of SSTR expression in
the form of maximal standardized uptake value (SUVmax)
in metastatic as well as primary sites were noted. The find-
ings were correlated with available anatomical imaging re-
sults. Results: Primary NET lesions were located in kidneys
(3 patients), esophagus (3 patients) and one each in pros-
tate, gall bladder and breast. In addition, 5 cases of
paragangliomas (1 mediastinal and 4 abdominal), 2 cases
of medullary thyroid carcinomas, one case each of adrenal
phaeochromocytoma, thymoma and merkel cell carcinoma
were also included. DOTANOC avid lesions were noted in
17 out of total 19 patients. Renal NETs showed an intense
DOTANOC uptake in the primary lesion (mean SUVmax
34.3 +/- 17.9) as well as metastatic lesions in liver (mean
SUVmax 23.8 +/- 8.08), lymph nodes and bones. Esopha-
geal NETs demonstrated moderate intensity DOTANOC up-
take in primary lesion (mean SUVmax 12.5 +/- 12.8) and
lymph nodal metastasis (mean SUVmax 7.6 +/- 4.1). In 5
cases of paragangliomas, Ga-68 DOTANOC PET CT scans
showed intense uptake in primary site (mean SUVmax 27.9
+/- 4.1) and metastatic sites (detected in 3/5 patients).
DOTANOC avid local recurrence was detected in two
post-operative cases of paragangliomas with raised serum
chromogranin levels. In one case of merkel cell carcinoma,
DOTANOC avid additional metastatic sites were detected in
soft tissue, lymph nodes, bones and pancreas, which were
undiagnosed before on anatomical imaging. In one case,
presenting with para-rectal lymph nodes, DOTANOC avid
primary site was identified in prostate gland along with
additional hepatic, skeletal and lymph nodal metastasis.
Conclusion: Our preliminary experience suggests that Ga-
68 DOTANOC PET/CT scan is a sensitive modality for
evaluation of unusual and rare neuroendocrine tumours
and provides quantitative estimate of somatostatin-receptor
expression, thereby guiding their overall clinical
management.
P660
Comparison between 18FDG-PET/CT scan
and Tc-99mHYNIC-[D-Phe1,Tyr3-Octreotide (Tektrotyd)
scintigraphy in patients with neuroendocrine tumor (NET)
.
I. NavalesMateu, M. Simó Perdigó, M. Salcedo Pujantell, M.
Barios Profitos, A. Garcia Burillo, J. Capdevila Castillón, J.
Monturiol Duran, M. Velasco Nuño, J. Castell Conesa; Hos-
pital Universitari Vall d’Hebron, Barcelona, SPAIN.
AIM: To analyze the behavior of both techniques in patients
with NET, in order to correlate the image profile with tumoral
grade (G1, G2 or G3) and the eventual impact on the thera-
peutic decision management of the patient. MATERIAL AND
METHODS: 26 patients (60median age, 11 w) with suspected/
diagnosed NET were studied with Tektrotyd and FDG as part
of the initial staging or in cases of recurrence. Tektrotyd scin-
tigraphy included planar and thoraco abdominal SPECT/CT
images. PET/CT scans were acquired according to EANM
tumour PET procedure guideline. RESULTS: 1. -FDG- PET/
CT was positive in 19 patients (73%) whereas Tektrotyd was
positive in 14 cases (54%). Fifty percent of negative Tektrotyd
patients (12 patients) showed a positive FDG-PET/CT study.
Only one FDG-PET/CT negative patient was Tektrotyd posi-
tive. 2.- In a subgroup of 14 patients with confirmed but
unresected NET tumor, FDG-PET/CT successfully localized
the primary tumor in 11 cases (78%), 5 of them showed neg-
ative Tektrotyd scans (3pG2, 1pG3, 1 paraganglioma).
Tektrotyd localized the primary tumor in 7 patients (50%),
having only one of them a negative FDG-PET/CT (G1). 3.-
Complete global agreement between both techniques was pos-
itive in 3 (16%) patients (2pG2, 1 pheocromocytoma) and
negative in 6 (32%). 10 patients (53%)showed positive find-
ings with partial concordance of both techniques (2pG1,
4pG2, 2pG3, 2pOthers). Region based analysis showed a bet-
ter agreement in supradiafragmatic regions and bones, where-
as higher discordance in the liver and abdomen. 4. -Regarding
histologic subgroups of gastreoenteropancreatic-NET (GEP-
NET): In 5 G1-NET patients, Tektrotyd detected 3 patients
and FDG-PET/CT 2. The other 2 patients were negative for
both tecniques. In 13 G2-G3-NET patients, FDG-PETshowed
a higher number of positive studies (7G2, 5G3) than Tektrotyd
(6G2, 2G3). Not a single Tektrotyd positive patient was FDG-
PET negative. 5.-Regading the eventual impact on the thera-
peutic decision , we found 13 patients with simultaneous
heterogenic profile lesions (hypermetabolic and/or differenti-
ated), identifying six of them as unexpected behavior. These
includes one G1-NET patient with avid FDG lesions and one
G3-NET patient with a predominantly trektrotyd positive
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lesions. CONCLUSION: The combined use of FDG-
PET/CT scan and Tektrotyd for the assessment of
NET revealed a high rate of heterogenic profile lesions,
some of them unexpected. FDG-PET/CT was better
than tektrotyd in detecting the NET primary site. Our
study suggests that the evaluation of NET patients with
both techniques can improve lesion characterization
allowing a better personalized therapeutic decision.
P661
Impact of SPECT/CT 99mTc-EDDA/ HYNIC-TOC
in the diagnosis and the extension of neuroendocrine
tumors
S. E. Bouyoucef, M. Habbeche, S. Rahabi, A. Talbi, B. Abdi,
S. Bellabas, A. Amimour; Department of Nuclear Medicine
CHU Bab El Oued, Algiers, ALGERIA.
Introduction : Incidence of neuro-endocrine tumors
(NET) is increasing due to the development of diagnos-
tic tools including nuclear medicine techniques, conven-
tional and TEP imaging. SPECT/CT 99mTc-EDDA/
HYNIC-TOC could be available everywhere and have
a great potential in the management of NET. Objective
: Assess the role of SPECT/CT 99mTc-EDDA/ HYNIC-
TOC in the management of NET. Methods and patients
A retrospective study of 110 patients with suspected or
confirmed NET had been done from 2010 to 2014 in
the department of nuclear medicine. Clinical indications
were, search of the primary (35%), contribution to the
strategy and assessment of therapy (48%), location of
the primary site (13%) and search for relapse after sur-
gery (4%). SPECT/CT used was a dual heads gamma
camera with a diagnostic CT. Double reading of
reporting was done systematically for all patients. Re-
sults: In the suspected NET, SPECT/CT 99mTc-EDDA/
HYNIC-TOC has permitted to find the primary in 14/
37 (37%) and has confirmed the diagnostic in 12 of 15
patients. All paragangliomas and pancreatic tumors
were positive on SPECT/CT 99mTc-EDDA/ HYNIC-
TOC. For therapy assessment, SPECT/CT 99mTc-
EDDA/ HYNIC-TOC has contributed to the therapeutic
strategy in 80% of patients and showed a poor re-
sponse to targeted therapy in 3 patients. Conclusion:
Despite the lack of Gallium peptide PET, SPECT/CT
99mTc-EDDA/ HYNIC-TOC was determinant with a
great clinical impact in the management of neuro endo-
crine tumors.
P662
Comparison of Early and Late SUVmax Values
of Somatostatin Reseptor Positive Lesions in Ga-68
DOTATATE PET/CT Images
J. Nematyazar, S. Sager, O. Erdem Sahin, B. Razavi, R.
Akyel, B. Vatankulu, E. Kaymak, M. Halac, H. Sayman, I.
Uslu, K. Sonmezoglu; 1Department of Nuclear Medicine,
Cerrahpasa Medical Faculty, Istanbul University, istanbul,
TURKEY.
Objective and Aim: Neuroendocrine tumors (NETs) are
rare but have been more common over the past decade.
PET/CT with Ga-68 DOTATATE achieved high sensitivity
and good specificity for determining the somatostatin
reseptor positive neuroendocrine tumors. The aim of the
our study is to compare early and late suvmax values of
lesions in Ga-68 DOTATATE PET/CT. Subjects and
Method: Ten patients with age range of 52±12.9 years,
and male to female ratio of 4to6 were referred for Ga-68
DOTATATE PET/CT scan for localisation of somatostain
positive lesions. Seven patients were known NETs, 3 pa-
tients were carsinoid tumor, 2 patients were thyroid can-
cer. A mean dose of 200.54±53.28 MBq 68Ga-
DOTATATE injected. Early imaging time was meanly
38.8±14.8 minutes after injection and late imaging time
was meanly 101.2±6.28 minutes after injection. Positive
findings were defined as areas of increased uptake other
than the organs of normal distribution and were correlated
with other imaging methods. Also early and late SUVmax
values of normal tissue uptakes were calculated. Results:
A total of 22 lesions were analysed. The early mean
SUVmax values of tatol lesion were 34.94±18.16 g/ml
and late mean SUVmax values were 29.87±26.02 g/ml
There is no difference between early and late image qual-
ity of Ga-68 DOTATATE imaging. Also late imaging did
not provide additional information according to lesion
number and localisation. There is no significant difference
between early and late SUVmax values of somatostatin
positive lesions and early and late SUVmax values of
normal liver tissue (the early mean SUVmax values were
2.89±2.19 g/ml and late mean SUVmax values were 3.16
±3.68 g/ml). Conclusion: Ga-68 DOTATATE PET/CT is
an effective tool for localising somatostatin positive le-
sions. There is no statistical difference between early
and late SUVmax values in malign lesions in Ga-68
DOTATATE PET/CT imaging. Ga68-Dotatate PET/CT
can be permormed in the diagnosis and follow-up of
somatostatin positive tumors after 60-90 min injection of
radiopeptides.
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P663
Analysis of carbidopa premedication in patients
with neuroendocrine tumors before a 18F-DOPA PET-CT
study
A. Ramírez, E. Morillo, W. Valdés, N. Testart, E. Triviño, T.
Aroui, A. Rodriguez-Fernandez, J. Llamas-Elvira;
H.VIRGEN DE LAS NIEVES, GRANADA, SPAIN.
Purpose: Test out if carbidopa premedication before a 18F-
DOPA PET/CT study in patients with neuroendocrine tumors
decline the turn of the tracer in to dopamine in peripheral
tissues, increasing the uptake in tumorals tissues. Patients
and methods: We carry out an observational retrospective
study divided in two females patient groups, that were includes
in a 18F-DOPA PET/CT study. The first group was composed
of 13 women in which was not indicated a previously admin-
istration of carbidopa. The second group was composed of 7
women who themeselves where given a dose of carbidopa
between 100 and 150mg one hour before of radiopharmaceu-
tical administration. The results were expressed as arithmetic
mean, standard deviation and student t was calculated, com-
paring SUV max means in different organs in both groups.
Discussion: Administrate a dose of carbidopa between 100-
150mg before a 18F-DOPA study decline the uptake of the
tracer in all pancreatic areas .However in other organs studied
we didn’t find differences in the uptake, unlike the results
observed in the literature that point at greater liver a lungs
uptake in those patients who were given carbidopa. This could
be due to a small number of patients included in our study with
carbidopa administration.
P664
Comparative evaluation of somatostatin receptor
scintigraphy using Tc-99m and In-111 labelled
somatostatin analogues
I. Szilvási1, Z. Varga2, R. Jóba1, K. Buga1, K. Bús2, E.
Takács2, G. Dabasi2; 1Hungarian Defense Forces Medical
Centre, Budapest, HUNGARY, 2Semmelweis University, Bu-
dapest, HUNGARY.
AimIn a prospective study we compared the diagnostic value
of In-111-pentetreotide(OC) and Tc-99m-EDDA/HYNIC-
TOC(TC) somatostatin receptor scintigraphy(SRS) in patients
with neuroendocrine tumours(NET).Pat ients and
MethodsTwo SRSs using OC and TC were performed within
four weeks in 30 patients with histologically confirmed NET.
Indication was staging in 15 patients and follow-up in 15 pa-
tients with suspected recidivism. The second SRS was per-
formed, if the first results were equivocal or contradicting to
clinical-data. The first radiopharmaceutical was OC in 20 and
TC in 10 patients. The two scintigraphic results were com-
pared in these selected 30 patients, mean age:47(35-80)years.
Both methods were performed according to procedure guide-
lines. Imaging (planar and SPECT study) was performed at 4
and 24 hours (6 cases: 48 hours as well) using OC, and at 1 and
4 hours (2 cases: 24 hours as well) using TC. Images were
evaluated qualitatively by two physiscians. Number of abnor-
mal lesions were compared by regions as well. Lesions were
validated by repeated SRS and/or radiological examinations
during at least one year of follow-up.Results27 out of 30 pa-
tients had abnormal, 3 patients had negative SRS by both
radiopharmaceuticals. 11 out of 25 patients had solitary lesion,
in the other 14 patients 34 lesions were seen by at least one of
the two SRS studies. Based on the follow-up examinations two
of the lesions seen on TCscan and one lesion seen on OCscan
proved to be false-positive, but in different regions. TcSRS had
one false negative finding in the abdomen, seen by OC only.
OCSRS had seven false-negative lesions: one in the thorax and
six in the abdominal-pelvic region. In 26 out of 30 patients (27
with, 3 without NET) both examinations had concordant find-
ings regarding to number of involved regions. Findings of TC
and OC were partly discordant in 4 patients, because number
of abnormal regions were more in 3 patients but less in 1
patient by TC.ConclusionsBased on our study, OC and TC
have similar diagnostic value. Image quality of TC is better,
interpretation is more reliable, sensitivity is higher. Duration of
scintigraphy is shorter, however to avoid false-positive find-
ings in the abdomen imaging at 24 hours are needed in about
1/3 of the patients. Our preliminary experience showed that
this number can be reduced by SPECT/CT. Further studies are
needed to define possible differences between TC and OC in
SRS of tumours with various histological types.
P665
Ga-68 DOTANOCPET/CT for Neuroendocrine Tumours:
Experience at Western Cape Academic PET/CT Centre
A. G. G. Doruyter, A. Ellmann, S. M. Rubow; Stellenbosch
University, Cape Town, SOUTH AFRICA.
Aim: In September 2013 theWestern Cape Academic PET/CT
Centre began performing Ga-68 DOTANOC PET/CT for neu-
roendocrine tumour patients. We report our clinical experience
with these scans thus far, including referral patterns; scan re-
sults and relevant clinical outcomes. Materials and methods:
Referral patterns, imaging results, and laboratory and clinical
data were collated for patients referred for Ga-68 DOTANOC
PET/CT since September 2013. Normal biodistribution of Ga-
68 DOTANOC was compared to experience with SPECT
agents. Clinical follow-up allowed us to identify any
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interpretative pitfalls in initial reporting. Results: Scans of 60
patients were reviewed. The majority of patients (46.7%) were
referred for staging procedures. Several differences between
the normal biodistribution of Ga-68 DOTANOC and SPECT
agents were identified. Correlative clinical information was
available in 56 of the patients, which allowed us to identify 8
false negative and 2 false positive studies. Two of the false
negative studies were due to tumour dedifferentiation, and in
one case the recurrent lesions were smaller than the resolution
limit of the camera. In one patient an insulinoma was not
detected. The reasons for the false negativity were not clear
in the other 4 cases. The two false positive studies were iden-
tified after clinical follow-up and subsequent literature review,
which identified an important pitfall in interpretation, namely
physiological DOTANOC uptake in the uncinate process of
the pancreas. Conclusion: Ga-68 DOTANOC PET/CT offers
several advantages over traditional somatostatin receptor im-
aging methods, including improved sensitivity and shorter to-
tal scan duration. While both methods image predominantly
SS2R, several notable differences exist in biodistribution. It is
important that nuclear physicians be mindful of these differ-
ences as well as potential pitfalls in the interpretation of these
studies. Interpreter knowledge of normal variants is important
for accurate reporting. Ga-68 DOTANOC PET offers signifi-
cant benefit in terms of directing clinical intervention and sub-
sequent follow-up.
P666
GLP-1 receptor scintigraphy as a potential tool
in the detection of neuroendocrine malignancies.
A. Sowa-Staszczak, A. Stefańska, M. Buziak-Bereza, M.
Trofimiuk-Muldner, M. Kołodziej, A. Hubalewska-
Dydejczyk; Nuclear Medicine Unit, Endocrinology Depart-
ment, University Hospital Krakow, Krakow, POLAND.
It is known that a very high expression of GLP-1 receptor is
seen in benign insulinoma, and scintigraphy with [Lys40(Ahx-
HYNIC-99mTc/EDDA)NH2]-exendin-4 and [Lys40(Ahx-
DTPA-111In)NH2]exendin-4 can be helpful in insulinoma
not detected by other methods. Moreover GLP-1 receptor ex-
pression can be also found in other neoplasms e.g.
gastrinomas, pulmonary NETs, paragangliomas, meningio-
mas, astrocytomasw, MTCs. Aim: The aim of our study was
to assess the diagnostic efficiency of [Lys40(Ahx-HYNIC-
99mTc/EDDA)NH2]exendin4 scintigraphy in the diagnosis
the recurrence of medullary thyroid carcinoma (MTC) not de-
tected by other available imaging methods, as well as locali-
zation of pheochromocytoma and gastrinoma. Material and
methods: 15 patients were enrolled in this study: 9 with recur-
rent MTC with negative standard imaging results, 5 with
pheochromocytoma, 1 with gastrinoma. All patients with
MTC underwent a total thyroidectomy with neck lymph nodes
resection, two of them - PRRT. MTC recurrence was diag-
nosed based on increasing values postoperative calcitonin
levels. Whole-body and SPECT/CT scans with a low dose
CT protocol were performed at 2 time points, between 3 -
4 h and 5 - 6 h after the injection of the 99mTc -GLP-1 ana-
logue. Volumetric analysis was performed to assess the tumor
to non-tumor ratio (T/nT ratio). Results: In 4 patients with
MTC with higher level of calcitonin (median value of 631
pg/ml) and/or abnormal results of pentagastrin test an accumu-
lation of the tracer in the location of the primary tumor or in
liver metastasis was described. In 5 cases radiolabelled GLP-1
did not localize the MTC recurrence. In 3 of 5 patients with
pheochromocytoma an accumulation of the tracer in adrenal
tumor was found. The lesions were removed surgically and
diagnosis of pheochromocytoma was confirmed histopatho-
logically. In the case of a patient with malignant pheochromo-
cytoma multiple foci of [Lys40(Ahx-HYNIC-99mTc/
EDDA)NH2]exendin-4 accumulation in bone and soft tissues
metastases was observed. In 1 patient with suspicion of recur-
rent gastrinoma, scintigraphy revealed focal lesions in liver
and in pancreas. Conclusion: 99mTc-GLP-1 receptor imaging
could be considered as a useful tool in cases of MTC, pheo-
chromocytoma and gastrinoma, especially when other diag-
nostic methods are equivocal or fail.
P667
Focally increased activity in the pancreas on In-111
Octreotide scan - can it be a physiologic variant?
Z. Kováčová1, D. Zogala1, A. Pudlač2, J. Kubinyi1; 1Insti-
tute of Nuclear Medicine, First Faculty of Medicine, Charles
University in Prague, Prague, CZECH REPUBLIC, 2Depart-
ment of Radiology, First Faculty of Medicine, Charles Univer-
sity in Prague, Prague, CZECH REPUBLIC.
AIM:The aim of the study was to find out whether there could
be a physiological uptake of 111-In Octreotide in the uncinate
process of the pancreas. By using retrospective analysis we
determined the percentage of cases where there was no expla-
nation for the phenomenon of focal increased activity within
the head of the pancreas on 111- In Oct reo t ide
scans.METHODS:We evaluated 306 111-In Octreotide scans
of 287 consecutive patients examined in the 2011-2014 period.
11 scans were excluded due to incomplete data. By analyzing
295 111-In Octreotide scans and all available clinical data we
determined the exact percentage of the phenomenon of focal
increased activity in the head of the pancreas for which there
was no explanation. The scoring system of the visual uptake
on a five point scale was used (0 - no uptake, 1 - very low
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uptake, 2 - clear, but faint uptake, 3 - moderate uptake, 4 -
intense uptake).RESULTS:Out of 295 111-In Octreotide scans
there were 69 cases (23%) with the focal increased activity
within the pancreatic region. 40 cases (13.5%) were located
within the head of the pancreas. For 29 cases (9.8%) there was
no explanation found for the high uptake in the head of the
pancreas even after the clinical research. By using our scoring
system those uptakes were usually in the category 1 - very low
uptake or 2 - clear, but faint uptake.CONCLUSION:The focal
increased activity in the pancreatic region on 111-In Octreotide
scan was interpreted as idiopathic in 29 cases (9.8%). None of
those idiopathic uptakes scored higher than 2 on our five point
scale scoring system. The results of the study indicated that
there was a physiological uptake of 111-In Octreotide within
the uncinate process of the pancreas due to higher concentra-
tion of somatostatin receptors. Therefore, nuclear medicine
specialists should be careful when interpreting faint uptake
within the epigastric region.
P668
Effect of I-131 MIBG Thyroid Uptake on Thyroid
Function Tests
A. Hassanzadeh-Rad, S. Katal, D. Beiki, A. Fard-Esfahani,
A. Emami-Ardekani, B. Fallahi, M. Eftekhari; Research Cen-
ter for Nuclear Medicine, Shariati Hospital, Tehran, IRAN,
ISLAMIC REPUBLIC OF.
Aim: I-131 MetaIodoBenzylGuanidine (MIBG) is used for
diagnosis and treatment of neural crest tumors and in particular
p h e o c h r o m o c y t o m a , n e u r o b l a s t o m a a n d
ganglioneuroblastoma. Various mechanisms are responsible
for thyroidal uptake of I-131 MIBG. I-131 can damage
thyrocytes by beta emission, leading to decrease in thyroid
hormone synthesis. Although all patients receive Lugol’s so-
lution to prevent thyroidal uptake, various amounts of 131I-
MIBG are taken up by thyroid. In this study, we wanted to
correlate thyroidal uptake of 131I- MIBG ( both qualitatively
and quantitatively) with changes in thyroid function tests by
comparison between baseline and follow-up Serum levels of
FT3, FT4 and TSH. Materials and Methods:34 euthyroid pa-
tients (20 males, 14 females with mean age of 11.4 years old)
with documented neural crest tumors who were referred to our
center for I-131 MIBG diagnostic or post therapy scans en-
rolled in the study. They were asked to orally take 1 drop/kg of
2 % Lugol’s solution, from 2 days before to 2 weeks after \I-
131 MIBG injection. 24 and 72 hours post injection of 1 mCi
(for diagnostic purposes) and 5 days post injection of 100-
300 mCi I-13 MIBG (for treatment purposes) whole body
scans were performed with (Siemens, Biograph, T2 Series)
Gamma camera. 5- minute anterior spot views from cervical
region were also obtained for visualization and quantification
of thyroidal uptake. Regions Of Interest (ROIs) were drawn
over thyroid bed and background and background-corrected
average counts were calculated for all patients. Blood samples
were obtained from patients prior to and 3 months after injec-
tion of I-131 MIBG for assessment of thyroid function. Re-
sults: No significant changes in thyroid function tests were
observed in the subgroup of patients without thyroid uptake
of I-131 MIBG. In the subgroup with visualized thyroid up-
take, mean TSH level increased significantly from baseline
level of 2.59 mIU/L to follow-up level of 8.42 mIU/L (P-value
<0.01). In this subgroup, mean FT3 and FT4 levels did not
change significantly; however, change from euthyroid state to
subclinical and clinical hypothyroidism occurred in 37.5 %
and 12.5 % of these patients, respectively. Mean ROI average
counts in patients converted to subclinical or clinical hypothy-
roidism were significantly higher than patients who remained
euthyroid in follow-up tests. Conclusion: Thyroidal uptake of
I-131 MIBG can result in TSH elevation and subclinical or
clinical hypothyroidism. Therefore, visualization and quantifi-
cation of thyroid uptake in I-131 MIBG scans are clinically
informative.
P669
Contribution of Ki67 proliferation index
and 111In-Pentetreotide somatostatin receptor
scintigraphy in Neuroendocrine Tumors
G.Muñiz Garcia1, J. Muñoz Iglesias1, C. Penín Corderi2, R.
Guitián Iglesias1; 1Nuclear Medicine Department. Complejo
Hospitalario Universitario de Ourense, Ourense, SPAIN, 2Pa-
thology Department. Complejo Hospitalario Universitario de
Ourense, Ourense, SPAIN.
Aim: The aim of this study was to asses the utility of 111In-
Pentetreotide somatostatin receptor scintigraphy (SSRS) and
the values of Ki67 proliferation index in patients with Neuro-
endocrine Tumors (NETs) in the selection of candidates with
somatostatin analogues therapy. Material and Methods:
Twenty-seven patients with histological diagnosis of NETs
were retrospectively studied with our usual protocol. SSRS
and Ki67 proliferation index were performed in all patients.
Ki67 proliferation index was classified according to World
Health Organization (WHO). All patient with positive SSRS
who had liver metastases or unresectable tumors, were treated
with somatostatin analogues. Clinical, laboratory and radio-
logical follow-up was performed (mean 12 months). Results:
SSRS was positive in 17/27 patients (63%) and showed low
Ki67/G1 index in 9 patients (53%), intermediate/G2 in 5 (29,
4%) and high/ G3 in 3 (17,6%). All patients with a positive
SSRS received somatostatin analogues therapy. Fifteen pa-
tients showed stable disease (88,20%) and only two of them
got worse (11,80%), showing a high/G3 Ki67 index. In ten
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patients, SSRS was negative: two showed low/G1 Ki67 index,
intermediate/G2 in 1 and high/G3 in 7. They did not receive
treatment with somatostatin analogues and in the follow-up,
six patients are stable, 3 have died (unresectable undifferenti-
ated tumors with distant metastasis) and one of them had pro-
gression of local and metastatic disease (unresectable and met-
astatic poorly differentiated tumor). Conclusions: In our expe-
rience, SSRS is necessary for patients diagnosed with NETs, in
order to select those who are candidates for treatment with
somatostatin analogues for both local control of unresectable
tumors and their metastases. Regardless Ki67 proliferation in-
dex, patients with positive SSRS should be included in therapy
with somatostatin analogues. Patients with negative SSRS and
low or intermediate Ki67 proliferation index should be indi-
vidually valued the use of somatostatin analogues.
P670
The diagnostic use of a 2 day protocol in Somatostatin
Receptor Scintigraphy using 99mTc-HYNIC-TOC.
Preliminary Results
P. Z. Stavrou, C. Giannopoulou, E. Persakis, K. Kouvelis, M.
Papachristou, E. Vlontzou, I. Datseris; Evaggelismos Hospital,
Athens, GREECE.
Introduction: 99mTc-HYNIC-TOC (Tektrotyde) represents a
valid Tc99m labelled compound alternative to In-111 labelled
radiopharmaceuticals in the detection of lesions overexpress-
ing somatostatin receptors. Images can be acquired up to 24
hours post injection, although the recommended time frame is
between 2 and 4 hours after the radiotracer administration. The
purpose of this study is to investigate the benefit of an addi-
tional delayed acquisition at 24 hours post injection. Patients
and Methods: This is a retrospective study of prospectively
collected data of patients with suspected or known neuroendo-
crine disease. All patients underwent an iv injection of 925-
1110 MBq (25-30 mCi) of Tektrotyde and images were col-
lected at 2, 4 and 24 hours post injection. Images were then
processed using Segami Mirage Workstation. All studies were
assessed by 2 experienced Nuclear Medicine physicians. Re-
sults: 17 studies in 16 patients, 5 females and 11males, age 30-
75 (mean 55) were assessed. Nine patients presented with
known neuroendocrine disease, mainly GEP-NETs, 5 of
which have been operated on the primary lesion. In 9 studies
of 8 patients. foci of increased Tektrotyde uptake were ob-
served (positive exams). Inmost cases the 2 and 4-hour images
were adequate to perform diagnosis. In only 1 case the 24-hour
acquisition was useful in excluding an ambiguous site of
slightly increased uptake. In both the 2 and 4-hour acquisitions
high gallbladder activity was seen, while in the 24-hour acqui-
sitions little to no gallbladder activity was observed in all pa-
tients. Conclusion: Although in the standard 2 and 4-hour
acquisitions foci of increased Tektrotyde uptake can accurately
be localized, an additional 24-hour acquisition could improve
specificity in ambiguous cases. This delayed acquisition can
also contribute in identifying gallbladder activity that could be
mistaken as a liver lesion in departments without a hybrid
SPECT/CT camera.
P671
Correlation between Tumor Volume Defined
by 68Ga-DOTANOC PET/CT scan and Maximum
Standardized Uptake Value Variation (ΔSUVmax)
after Peptide Receptor Radionuclide Therapy (PRRNT)
L. Sobral Violante1, I. Sampaio1, J. Teixeira1, A. Santos1, A.
Duarte2, F. Lopes1, L. Costa1, O. Soares1, I. Paula1, H.
Duarte1; 1Instituto Português de Oncologia, Porto, PORTU-
GAL, 2Instituto Politécnico de Bragança, Bragança,
PORTUGAL.
Aim: PRRNT is a promising treatment for patients with neu-
roendocrine tumours (NETs) giving rise to improved survival.
Literature refers that PRRT of NETs using DOTATATE la-
beled with beta-emitting 177Lu may be preferable for smaller
tumours. The aim of this study was to evaluate the correlation
between tumor volume defined by 68Ga-DOTANOC PET/CT
scan andΔSUVmax in patients who underwent PRRNTwith
177Lu-DOTATATE.Material and Methods: Twelve patients
with advanced well-differentiated NETs (5 women, 7 men,
mean age 54 ± 9) were included: 5 pancreatic (3 non-secreting,
1 glucagonoma and 1 insulinoma), 4 small intestine (secret-
ing), 2 pulmonary (non-secreting) and 1 rectum (secreting).
Clinical evaluation (symptoms and tumour markers) and
68Ga-DOTANOC PET/CT images were reviewed at baseline
and 3 to 12 months after completion of 3 cycles of PRRNT
(mean activity of 5,5 GBq/cycle). A fixed threshold of 30%
was used to calculate the volume of the lesions which present-
ed highest SUVmax value in 68Ga-DOTANOCPET/CT base-
line scan and a comparison of 68Ga-DOTANOC PET/CT
studies was performed based on visual analysis of uptake
and number of lesions and ΔSUVmax. Results were
interpreted as: a) response (qualitative: visual decrease of in-
tensity and/or number of lesions; semi-quantitative:
ΔSUVmax decrease ≤ 25%), b) stable disease (qualitative:
similar visual intensity and number of lesions; semi-quantita-
tive: -25% < ΔSUVmax < + 25%) and c) progressive disease
(qualitative: visual increase of intensity and/or number of le-
sions; semi-quantitative: ΔSUVmax increase ≥ 25%). Com-
parison between tumor volume and ΔSUVmax was per-
formed using linear regression model.Results: Tumor volume
of 27 lesions: 0.94 to 2113.4 cm3; average: 160.7 cm3; medi-
an: 12.13 cm3. Clinical evolution after PRRNT: improvement
in 10 patients (83.3%) and stabilization in 2 patients (16.7%).
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Qualitative 68Ga-DOTANOC evaluation: response in 8 pa-
tients (66.7%) and stable disease in 4 patients (33.3%).
Semi-quantitative (ΔSUVmax) 68Ga-DOTANOC evaluation:
response in 11 patients (91.7%) and progressive disease in 1
patient (8.3%). Qualitative and semi-quantitative (ΔSUVmax)
68Ga-DOTANOC evaluations were concordant in 8 patients
(66.7%). No correlation was found between tumor volume and
ΔSUVmax (R-squared= 0.01225).Conclusion: This study
shows that the majority of patients responded to treatment
and suggests that tumor volume in the 68Ga-DOTANOC
PET/CT baseline scan has no correlation with SUVmax re-
sponse to PRRNT using 177Lu-DOTATATE. A larger sample
is needed to further validate this statement.
P672
[68Ga]DOTANOC PET: sex specific differences
and influence of diabetes and usage of proton pump
inhibitors
A. Leisser, W. Wadsak, M. Mayerhoefer, M. Mitterhauser, G.
Karanikas, M. Hacker, A. R. Haug; Medical University of
Vienna, Vienna, AUSTRIA.
Aims: Imaging with [68Ga]DOTANOC PET has become an
important modality in patients with neuroendocrine tumors
(NETs). Physiological uptake has been found to vary strongly
in these patients. Some of them tend to develop type 2 diabetes
or take proton pump inhibitors, which could affect the physi-
ological uptake pattern, especially in regard to the pancreas
and the stomach respectively. The objective of this study was
to investigate these influencing aspects and also the signifi-
cance of gender on the [68Ga]DOTANOC-uptake
pattern.Methods: In 51 consecutive patients, who were exam-
ined with [68Ga]DOTANOC PET, SUVmax and SUVmean
of the pancreas - subdivided into caput, corpus, and cauda -,
the stomach, liver, spleen, kidneys and adrenal glands was
measured. Corresponding personal data such as sex, age, his-
tory of diabetes, usage of proton pump inhibitors or oral anti-
diabetics and capillary blood glucose levels, were collected.
For statistical analysis student’s T-test was used, to determine
significant differences.Results: In a study population of 51
patients, 26 were male and 25 female. Neither diabetes nor
the usage of proton pump inhibitors could be proven to signif-
icantly alter the physiological uptake, in particular in the pan-
creas and the stomach. However, significant gender-specific
(male vs female) differences were found regarding SUVmax
(16.9 vs 21.4) and SUVmean (8.4 vs 11.3) of the kidneys and
SUVmean (17.3 vs 21.7) of the spleen. Also, a gender-specific
non-significant trend was observed, concerning SUVmax of
the spleen (28.2 vs 31.9) and the liver (8.5 vs 7.5).Conclusion:
Gender has a significant impact on the physiological
[68Ga]DOTANOC-uptake pattern, whereas type 2 diabetes
and the usage of proton pump inhibitors demonstrated no such
effect.
P673
Predictors of FDG-F18 PET Positivity in Neuroendocrine
Tumours
R. Silva1, L. Pires1, R. Ferreira1, A. Moreira1, P. Lapa1, G.
Costa1, J. Pedroso de Lima2; 1Serviço de Medicina Nuclear
do Centro Hospitalar e Universitário de Coimbra, Coimbra,
PORTUGAL, 2Instituto de Ciências Nucleares Aplicadas à
Saúde, Coimbra, PORTUGAL.
AIM: PET/CT with DOTANOC-Ga68 and FDG-F18 exploit
different tumour characteristics of Neuroendocrine Neoplasms
(NETs) for imaging. The 2 tracers may be complementary for
tumour staging and response assessment, and several studies
confer a strong prognostic value to FDG-F18 PET/CT. In this
study we tried to predict PET/CT FDG-F18 positivity based
on several tumour and DOTANOC-Ga68 PET/CT
variables.MATERIAL AND METHODS: We retrospectively
reviewed the findings in 18 patients (13 males, 5 females,
aged:41-82 years, 1Q:53/median:62/3:70) with confirmed
NETs (6 pulmonary/10 GEP/1 MEN-1 and 1 metastatic NET
with unknown primary) who underwent both DOTANOC-
Ga68 and FDG-F18 PET/CT imaging (time window:0-12
months, 1°Q:0/median:2/3°Q:5).Patients were scanned for ini-
tial staging (5), staging after excision of the primary tumour (5)
and response assessment (8). All NETs were classified accord-
i ng t o m i t o t i c and K i67 i ndexe s (G1 : 2 /G2 : 8 /
G3:8).Chromogranin A (CrA) and Neuron-specific Enolase
(NSE) measurements were available for the majority of
patients.PET/CT with DOTANOC-Ga68 and FDG-F18 stud-
ies were classified as positive or negative, and the SUVmax,
SUVmean, SUVsd (Standard deviation of SUV) and SUVcv
(Coefficient of variation of SUV) values of the most heteroge-
neous DOTANOC-68Ga avid lesion were recorded.The statis-
tical analysis was performed using SPSSv20®. A p<0.05 was
considered significant for all statistical tests. The Mann-
Whitney test was used to test for statistically significant differ-
ences in continuous variables. A binary logistic analysis was
performed to evaluate the impact of several tumour and PET/
CT DOTANOC-Ga68 variables in the positivity of FDG-F18
PET/CT.RESULTS: DOTANOC-Ga68 PET/CT revealed tu-
mour uptake in 15 of 18 patients. FDG-F18 PET/CTwas pos-
itive in 11 of 18 patients. A statistical significant difference in
Ki67 values was found between positive and negative FDG-
F18 PET/CT patients. No statistical significant differences in
CrA and NSE values between positive and negative FDG-F18
PET/CT patients were found.The SUVmax, SUVmean and
SUVsd values of the most heterogeneous DOTANOC-Ga68
avid lesions were not statistically different between FDG-F18
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PET/CT positive and negative patients. A statistical significant
difference in SUVcv values was found between positive and
negative FDG-F18 PET/CT patients.In the multivariable anal-
ysis only the SUVcv value remained as a statistically signifi-
c a n t p r e d i c t o r f o r F D G - F 1 8 P E T / C T
positivity.CONCLUSION: In this study the Ki67 and the
SUVcv of the most heterogeneous DOTANOC-Ga68 avid le-
sions achieved a statistically significant difference between
FDG-F18 PET/CT positive and negative patients. However,
in the multivariable analysis, only the SUVcv value remained
as a statistically significant predictor of FDG-F18 PET/CT
positivity.
P674
Characterizing 68Ga-DOTA-peptide uptake in uncinate
process of pancreas: normality versus Pathology
A. Kasat, C. Goh, H. Li, X. Yan; Singapore general Hospital,
Singapore, SINGAPORE.
Objective: 68Ga-DOTA-peptides are somatostatin analogue
tracers used for imaging neuroendocrine tumours (NET). A
number of organs demonstrate normal physiological uptake
of which the uncinate process of pancreas is of particular con-
cern not only because pancreas itself is a common site for NET
but also the great variability of the tracer uptake at this location
that may make the interpretation difficult. Thus aim of the
study is to define the characteristics of 68Ga-DOTA-peptides
distribution in uncinate process of pancreas and its usefulness
in distinguishing pathology from normality. Material and
methods: 24 patients (each with multiple scans) with a total
of 81 (68Ga-DOTATATE 68, 68Ga-DOTATOC 13) PET/CT
scans performed between May 2009 and Oct. 2014 were
reviewed retrospectively. 66 scans from 20 patients without
tumor involvement and 15 scans from 4 patients with tumor
involvement of the uncinate process were determined based on
histological, clinical and radiological evaluation including at
least 1 year follow-up. Visual inspection is used to determine
the pattern of tracer distribution in the uncinate process by two
nuclear medicine physicians. The reconstructed axial PET im-
ages were used to determine the SUV in uncinated process,
body of the pancreas, spleen, pituitary and aorta. Statistical
analyses including univariable Generalized Estimating Equa-
tions (GEE) was conducted. Results: There are 3 types of
normal distribution in the uncinate process, diffuse (most com-
mon), focal and multifocal. The distribution pattern has noth-
ing to do with uptake intensity. There is dramatic intrapatient
and interpatients variability of the normal uptake: Average
SUVmax for uncinate process is 5.88 +/- 3.34, range 1.29-
14.88. There is strong positive correlation between the normal
uptake intensity in uncinate process and in pituitary and spleen
(both P< 0.0001). The uptake SUV is also negatively affected
by dose of 68Ga-DOTA-peptide (p=0.0002). In diseased un-
cinate processes, NET tumor demonstrated significantly
higher uptake with SUVmax of 82.49 +/- 46.32, with no cor-
relation to uptake in any other organs. However there are only
4 patients enrolled in this study and 3 of them the histology
features unknown. Conclusion: The distribution pattern and
intensity of uptake in uncinate process of pancreas varies
greatly between patients and between scans. Calling tumor
involvement in uncinate process of the pancreas must be very
cautious and cannot be made only on PET scan presentation
but also correlating with other imaging and /or biopsy results.
Pituitary and spleen uptake may be useful as reference in judg-
ing the nature of uncinate process uptake.
P675
The role of 68Ga-DOTA-NOC PET/CT as first step
examination in cases with suspected Neuroendocrine
Tumors (NET) based on clinical, biochemical
and radiologic data
L. M. P. Pires, R. Silva, J. Álban, M. Silva, A. Moreira, G.
Costa, J. P. Lima; Centro Hospitalário e Universitário de Co-
imbra, Coimbra, PORTUGAL.
Aim: Neuroendocrine tumors (NET) comprise a wide and het-
erogeneous group of neoplasms, historically considered rare
and whose diagnosis is often challenging. 68Ga-DOTA-
somatostatin analogs PET/CT is becoming the new gold stan-
dard for somatostatin receptor (SSTR) imaging of NETs. In the
past few years, several studies reported the higher accuracy of
this image modality for detection compared to morphological
imaging procedures. The aim of this work was to assess the
added value of 68Ga-DOTA-NOC PET/CT in patients with no
histopathological evidence of NET, referred to our department
when the presence of NET was suspected based on clinical,
biochemical or radiologic data.Material and Methods: We
reviewed the 298 PET/CT scans with 68Ga-DOTA-NOC per-
formed in our department, between 2012 and 2015. Suspected
NET cases (before histopathological studies) were selected,
based on the presence of either clinical signs/symptoms (S),
increased biomarkers (IBM) or imaging features findings (IF)
suggestive of NET, as well as a combination of these condi-
tions. PET/CT results were compared with the final diagnosis,
concerning the presence of NET.Results: Fifty two patients (25
females; 27 males; 62.9±16.1 years-old) underwent 68Ga-
DOTA-NOC PET/CT scans when the presence of NET was
suspected on the basis of IF (12/52; 23.1%), S (6/52; 11.5%),
IBM (2/52; 3.8%) or a combination of two or more of these
conditions (32/52; 61.6%). The most common condition con-
sidered, was the combination of IBM plus S (13/52; 25%),
followed by IF and IF plus IBM (both 12/52; 23.1%). Overall
68Ga-DOTA-NOC PET/CT was true-positive in 12 cases,
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true-negative in 37, false-negative in 1 and false-positive in 2
(sensitivity=92.3%, specificity=94.8%, VPP=85.7%,
VPN=97.4%, Accuracy=94.2%). The incidence of NET in
the studied population was 25% (13/52) and the primary tumor
was correctly identified in 12/12 cases. IBM plus IF were
associated with the highest frequency of true-positive findings
(7/12; 58.3%), with statistical significance regarding this pa-
rameter (chi square test, p<0.05), followed by IF alone (4/12;
33%). A statistical significant difference in Cromogranine-A
values was found between positive and negative 68Ga-DOTA-
NOC PET/CT (Mann-Whitney U test, p<0.05).Conclusions:
Our data suggest that diagnostic accuracy of 68Ga-DOTA-
NOC PET/CT is high (94.2%) even in cases wherein NET is
only suspected. The association of IBM plus IF findings and IF
alone are associated with a higher probability of true-positive
findings.
P676
Interest of 68Ga DOTATOC-PET-CT compared
to 111In-DTPA-octreotide scintigraphy to detect pancreas
and duodenum neuroendocrine tumors in patients
with MEN-1: preliminary results.
C. Morgat1,2,3, F. Vélayoudom-Céphise4, P. Schwartz1, M.
Nunes4, J. Schulz2,3, J. Mazère1,2,3, M. Guyot1, D. Gaye4,
E. Hindié1,2,3, A. Tabarin4, P. Fernandez1,2,3; 1Service de
Médecine Nucléaire, CHU de Bordeaux, Pessac, FRANCE,
2Univ Bordeaux, INCIA UMR-CNRS 5287, F-33400
Talence, FRANCE, 3CNRS, INCIA UMR 5287, F-33400
Talence, FRANCE, 4Service d’Endocrinologie, CHU de Bor-
deaux, Pessac, FRANCE.
Introduction: Overexpression of subtypes of somatostatine re-
ceptors by neuroendocrine tumors (NET) allows imaging with
111In-DTPA-octreotide scintigraphy. However, the use of this
technique to identify neuroendocrine tumors in pancreas and
duodenum in patients with Multiple Endocrine Neoplasia type
1 (MEN-1) is not well defined. The somatostatin analog,
68Ga-DOTATOC, improves the detection of NET. The aim
of our study was to compare PET with 68Ga-DOTATOC to
111In-DTPA-octreotide in screening pancreas or duodenal lo-
calization in MEN-1. Patients and Methods : 19 patients with
MEN-1 (12 females, age: 47 ± 12 years) were included con-
secutively over 6 months, in the Endocrinology department
and underwent a 68Ga-DOTATOC-PET-CT in addition to
their annual tests. PET was performed 1 hour after injection
of 68Ga-DOTATOC (97.1 ± 13.3 MBq). Metallation of the
active pharmaceutical ingredient DOTATOC (Anaspec, Inc.
or ABX GmbH) was performed with 68Ga obtained from a
68Ge/68Ga generator (IASON®). The gold standard was
based on histology or morphological imaging (Contrast-en-
hanced CT or MRI). Results : 68Ga-DOTATOC and 111In-
DTPA-octreotide have both detected at least one lesion in re-
spectively 95% and 74% of patients. PET visualized 58 duo-
denal and pancreatic lesions in 19 patients, vs 17 lesions by
111In-DTPA-octreotide. The sensitivity of PET and 111In-
DTPA-octreotide was 83% and 23% respectively for the de-
tection of pancreas or duodenal NET. Compare to 111In-
DTPA-octreotide, PET detected 41 additional lesions (pancre-
as, duodenum and extra-duodeno-pancreatic lesions such as
lung carcinoid tumor, thymic tumor, meningioma⋯). Conclu-
sion: Compare to 111In-DTPA-octreotide, sensitivity of 68Ga-
DOTATOC-PET-CT is better in detecting pancreas or duode-
nal NET in patients with MEN-1. PETwas also able to detect
extra-pancreatic lesions. It could be recommended in the initial
staging or monitoring of patients with MEN-1.
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Added value of dual time point 18F-FDG PET/CT
scanning in detection of local recurrence in rectal cancer
H. R. Farghaly1,2, H. A. Nasr1,3, A. Al Qarni1; 1Radiology
Department, Prince Sultan Military Medical City, Riyadh,
SAUDI ARABIA, 2Nuclear Medicine Unit, Assiut Universi-
ty, Assiut, EGYPT, 3Nuclear Medicine Unit, Cairo University,
Cairo, EGYPT.
Objectives : To assess the added value of dual time point FDG
PET/CT (DTP) and its associated quantitative parameters in
detection of local recurrence (LR) in patients with rectal cancer
(RC) Methods : Patients (n=28, 20 males and 8 females, mean
age 56.43±16.68 years). All patients underwent resection ±
chemotherapy and/or radiotherapy. All patients underwent
whole body FDG-PET/CT scan as well as 2 hours delayed
pelvic PET/CT images. To differentiate benign frommalignant
lesions an SUVmax cutoff of >4.0 for early images, >4.5 for
delayed images and an increase in delayed SUVmax
(ΔSUVmax>15%) based on ROC analysis, were used. Suspi-
cious pelvic lesions were correlated with biopsies in 13 pa-
tients (46%) and with clinical and/or imaging follow-up
(FDG-PET/CT, CT or MRI) in 15 patients (54%). Sensitivity,
specificity, positive and negative predictive values, and accu-
racy in detection of LR using different PET/CT parameters
were calculated. Results : Four patients had confirmed LR
(14%). Early SUVmax, delayed SUVmax and ΔSUVmax
were significantly higher in all patients with confirmed LR.
The specificity, PPV and accuracy to detect LR were highest
for ΔSUVmax>15% as a single parameter (83.3%, 50.0% &
85.7%) while combination of early SUVmax>4.0 or delayed
SUVmax>4.5 with ΔSUVmax>15% SUVmax revealed
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further improvement (87.5%, 57.1% & 89.3%) compared to
single parameters. Conclusions : PET/CT has an excellent
sensitivity but modest specificity and PPV for detection of
local rectal cancer recurrence. Delayed PET/CT when per-
formed is capable of improving the specificity and overall
accuracy of the PET/CT.
P678
Evaluation of recurrent disease in the re-staging
of colorectal cancer by 18F FDG PET/CT: can CEA
and CA 19.9 help in patient selection?
A. Chiaravalloti, A. Fiorentini, D. Rinino, L. Travascio, R.
Danieli, A. Lacanfora, E. Palombo, D. Di Biagio, O. Schillaci;
Department of Biomedicine and Prevention, University Tor
Vergata, Rome, ITALY.
Objective: The aim of our study was to evaluate the accuracy
of 18F FDG positron emission tomography/computed tomog-
raphy (PET/CT) in assessing the presence of recurrent colo-
rectal cancer, in relation to carcinoembryonic antigen (CEA)
and Carboidrate antigen 19.9 (CA 19.9).Methods: 18F FDG
PET/CT was performed in 72 patients for re-staging colon
cancer. Therapy has been discontinued at least three months
before the examination. The mean CEAvalue (measured in 64
patients prior PET/CT examination) was 31.15 (±128.3)
whereas the CA 19.9 (measured in 64 patients prior PET/CT
examination) were 67.5 (±173.3). Differences in CEA and CA
19.9 values in patients with a positive and negative scans were
analysed by means of ROC curve. ROC curve has been used
for the calculation of sensitivity and specificity of 18F FDG
PET/CT for CEA and CA 19.9 levels.Results: Results of 18F
FDG PET/CT were related to CEA levels and CA19.9. PET/
CTwas positive for recurrence in 45/74 patients (60.8%, mean
CEA and CA 19.9 were, respectively 40.97 ± 159.7 and 81.81
± 212.3); PET/CT was negative for recurrence in 29/74 pa-
tients (39.2%, mean CEA and CA 19.9 were, ,respectively,
14.79 ± 37.29 and 43.99 ± 73.46). As expected, CEA values
were higher in patients with a positive scan as compared to
negative scans (p=0.027). A CEAvalue lower than or equal to
3.8 ng/ml was associated with a positive scan in 7/27 subjects
while 31/39 subjects with a CEA cut-off value greater than or
equal to 3.8 ng/ml were positive for recurrence at PET/CT (p=
0.029; sensitivity 70%; specificity 70.9%). We did not find
statistically significant differences when comparing CA19.9
levels in patients with a positive or negative scan
respectively.Conclusions: The possibility of detecting recur-
rence in patients treated for colorectal cancer with 18F FDG
PET/CT is related to CEA and not to CA 19.9 serum levels. In
particular, during follow up, 18F FDG PET/CT should be rec-
ommended in patients with a CEAvalue of at least 3.8 ng/ml.
P679
Value of FDG PET/CT in the assessment of patients
with colon cancer comparing to stand-alone CT
K. Akbari1, S. Haim2, K. Emmanuel3, W. Zaglmair3, C.
Pirich4, F. Fellner1, W. Langsteger2,M. Beheshti2; 1Radiol-
ogy, General Hospital Linz, Linz, AUSTRIA, 2PET-CT Cen-
ter Linz, St. Vincent’s Hospital, Linz, AUSTRIA, 3GI-Cancer
Center, St. Vincent’s Hospital, Linz, AUSTRIA, 4Nuclear
Medicine & Endocrinology, Paracelsus Medical University,
Salzburg, AUSTRIA.
Purpose: To evaluate the potential of FDG PET/CT vs.
contrast-enhanced CT alone in the assessment of distant
metastases in primary staging, re-staging and follow up
of colon cancer patients. Material & Methods: Eighty-one
patients (46 men, 35 women, mean age: 70.4 ± 11.1) were
included in this retrospective study: 29 (35.8%) were pre-
operatively (primary staging) and 52 (64.2%) postopera-
tively. Sixty-nine (85.2%) patients had a primary tumor
stage of ≥ T3. Diagnostic contrast - enhanced CT was
performed in all patients either together with FDG PET
or in a separate setting (with a diagnostic protocol). Pa-
tients with a known second carcinoma, as well as patients
with mucinous carcinoma of colon were excluded. All
pathologic findings in both imaging modalities had to be
verified with histological findings or imaging and/or clini-
cal follow-up studies. All data were assessed based on the
FDG PET/CT and ce-CT reports. In 12 patients with dis-
cordant findings between two imaging modalities, the im-
ages were reviewed again by corresponding specialists.
Results: In the primary staging of pre-operative patients,
FDG PET changed tumor staging and consequently the
treatment approach in 10 (10/29) patients (34.5%). Nine
patients were down-staged: 5 of them with suspicious or-
gan metastases, 3 patients with suspicious lymph node
(LN) metastases and 1 patient with both suspicious organ
metastases and lymph nodes metastases on CT. In addition,
1 (1/29) patient (3.4%) was upstaged after FDG PET/CT.
In the postoperative setting, only 2 (2/52) patients (3.8%)
were down-staged. No additional findings were detected in
the FDG PET comparing CT studies. In almost 25 % of
follow - up patients and approx. 40 % of preoperative
patients FDG PETCT was performed in addition to stand
alone CT- Conclusion: The results of this study showed
that in staging of colon cancer patients FDG PET/CT
was able to better specify unclear lesions detected on
stand-alone CT thus changing the therapy approach in
34.5% (10/29) of patients in preoperative setting. Eight
of 10 patients (80%) had an advanced primary tumor
(i.e. > T3). In postoperative setting FDG PET/CT may
be useful in few special cases with unclear lesions on
CT. Further randomized prospective studies are warranted.
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18F-FDG PET/CT in rectal cancer preoperative staging:
improved detection of metastases and 2° unsuspected
tumour
N. TESTART, A. RODRÍGUEZ-FERNÁNDEZ, T. AROUI-
LUQUIN, R. SÁNCHEZ-SÁNCHEZ, M. GÓMEZ-RÍO, E.
TRIVIÑO-IBÁÑEZ, A. MEDINA-BENÍTEZ, R. CONDE-
MU IÑO , J . L LAMAS - ELV IRA ; COMPLE JO
HOSPITALARIO UNIVERSITARIO DE GRANADA,
GRANADA, SPAIN.
Aim: The objective of this study is to assess the value
of 18F-FDG PET/CT in the preoperative staging of rec-
tal cancer. Methods: We analyzed a retrospective cohort
including 300 patients (from January 2007 to December
2013) with pathologically confirmed rectal cancer. Pre-
operative staging was performed with conventional im-
aging techniques (colonoscopy, transrectal ultrasonogra-
phy, pelvic MRi or CT), and 18F-FDG-PET/CT. All
findings in 18F-FDG-PET/CT were confirmed histologi-
cally and/or by specific imaging tests and/or by clinical
follow up > 1 year. Results: Following this study proto-
col we included 300 patients (187 males and 113 fe-
males; mean age: 67,3 ± 12,46 years), all with rectal
adenocarcinoma (31 well, 258 moderately and 11 poor
differentiation grade). In 66/300 patients (22%) 18F-
FDG-PET/CT showed metastatic disease (M1): with a
single lesion in 19 (8 pulmonary, 7 liver, 1 bone, 2
retroperitoneal lymph node and 1 mesenteric implant)
and multiple location involvement in 47 patients (a total
of 74 regions involved in these patients: 19 pulmonary,
33 liver, 3 bone, 16 retroperitoneal lymph node and 3
mesenteric implants). In 45/300 patients (15% of total
patients, 68,2 % of metastatic patients) the 18F-FDG-
PET/CT results raised the initial staging by revealing
unsuspected metastases. In 23/300 patients (7,7%),
18F-FDG-PET/CT showed a second previously unsus-
pected malignant tumor: 16 synchronic colorectal, 2
lung, 1 prostatic, 1 thyroid, 1 endometrial, 1 gastric
and 1 maxillofacial). There were 5 false negatives
(FN): 3 lymph nodes, 1 mesenteric implant and 1 liver
lesion, all detected by CT and confirmed after surgery
by histopathological analysis; and 5 false positives (FP):
3 lymph nodes, 1 pulmonary and 1 mesenteric implant.
In our study 18F-FDG-PET/CT in M1 staging showed a
sensitivity of 92,4% [83,5-96,7; CI95%] and a specific-
ity of 97,9% [95,1-99,1; CI95%], (TP: 61, TN: 229, FP:
5, FN: 5). The Global Accuracy was 96,7% [94-98,2;
CI95%]. Conclusions: According to our results, the
18F-FDG-PET/CT was useful in the correct M1 preop-
erative staging of rectal cancer patients, mainly due to
its ability to detect metastatic disease that was
unsuspected by other imaging procedures. It also
allowed the detection of other unsuspected tumors, lead-
ing to a better therapeutic approach in these patients.
P681
18F-FDG PET-CT Predicting Pathological Response
to Neoadjuvant Therapy in Locally Advanced Rectal
Cancer
D. SANCHEZ FUENTES, S. PEDRAZA FERNANDEZ, S.
RUIZ SOLIS, A. HERNANDEZ MARTINEZ, P.
SARANDESES FERNANDEZ, A. GOMEZ GRANDE, M.
PEREZ-ESCUTIA, J. ESTENOZ ALFARO; HOSPITAL
UNIVERSITARIO 12 DE OCTUBRE, MADRID, SPAIN.
PURPOSE: To assess the utility of 18F-FDG PET-CT in
predicting pathological response to preoperative chemo-
radiotherapy (CRT) in patients with locally advanced
rectal cancer. MATERIALS AND METHODS: Thirty-
nine patients, 23(59%) men and 16(41%) women, mean
age: 62 (range 40-83) with locally advanced rectal can-
cer from September 2009 to May 2014 were retrospec-
tively included. All patients were staged with a thoracic-
abdominal-pelvic CT and pelvic MRI. 18F-FDG PET-CT
for staging and radiation therapy planning was also per-
formed. Tumor locat ion: 17(43.85%) super ior,
14(35.89%) middle, 8(20.51%) inferior rectum. Histolo-
gy: 37(94.87%) adenocarcinoma and 2(5.13%) mucinous
adenocarcinoma. Clinical stage according to AJCC 7th:
7(17.95%) II, 31(79.48%) III and 1(2.56%) IV (liver
metastases). Neoadjuvant treatment included radiotherapy
(4500- 5040 cGy) over 5 weeks and concomitant che-
motherapy (Capecitabine). Surgery was performed fol-
lowing CRT; low anterior resection was performed in
32(82.05%) and abdominoperineal resect ion in
7(17.95%) patients. The pathological treatment response
was evaluated by the determination of the tumor regres-
sion grade (TRG) according to the Mandard criteria.
Patients were divided into two groups, responders TRG
1-2 and non-responders TRG 3-5. The TRG was corre-
lated with 18F-FDG PET-CT findings (tumor size, tumor
SUVmax and nodal SUVmax). RESULTS: 7(17.94%)
patients had a complete pathological response (CPR) in
the resected specimens. According to the Mandard tumor
regression grade (TRG), 14(35.9%) patients were re-
sponders and 25(64.10%) non-responders. Statistically
significant differences between both groups were not
seen when correlating metabolic findings (tumor size,
tumor SUVmax and nodal SUVmax). However, were
found slightly higher tumor sizes (range 2 - 15 cm,
mean: 6,24) in non-responders versus tumor sizes (range
2.2 - 13.6 cm, mean: 5,84) in responders group and
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slightly higher levels of tumor SUVmax (range 6.64 -
37.21, mean:21,95) in responders in comparison with
non-responders (range 10.10 - 40.55, mean: 20,73).
The mucinous adenocarcinomas 2(5.13%) had high
levels of SUVmax (15.47 and 33.81), similar to other
adenocarcinomas. There was a significant correlation be-
tween the tumor size measured by MRI and 18F-FDG
PET-CT (Rho=0.49 p=0.003). Furthermore, pathological
responders had better overall survival (1,6 year) com-
pared to non-responders (0,7 year). However, this was
not statistically significant (p=0.37). CONCLUSIONS:
In our cohort, 18FDG PET-CT findings (tumor size, tu-
mor SUVmax and nodal SUVmax) before neoadjuvant
treatment (CRT) cannot predict the pathological re-
sponse. More series are required to establish a stronger
conclusion on this topic. There was a significant corre-
lation between the tumor size measured by MRI and
18F-FDG PET-CT.
P682
Correlation Between Carcinoembryonic Antigen,
Standard Uptake Value and Metabolic Volume in F-18
FDG PET/CT Positive Patients With Proven Recurrent
Colorectal Carcinoma
E. G. Matovina, J. Mihailovic, D. Srbovan; Oncology insti-
tute of Vojvodina, Novi Sad, SERBIA.
Objective: To evaluate correlation between level of
carcinoembryonic antigene (CEA), metabolic volume and
standard uptake value (SUVmax) of the true positive lesions
detected by PET/CT in patients with recurrent colorectal car-
cinoma. Methods: 50 18F-FDG PET/CT studies between Jan-
uary 2011. and January 2014 of 45 patients (14 women, 31
men; mean age: 62.93 years) with elevated CEA levels were
evaluated. Measurements of serum levels of CEA were per-
formed within 3 months of PET/CT examination. Final diag-
nosis of recurrence was made by histopathological findings,
radiology studies or clinical follow-up. Results: Among posi-
tive scans, we chose 20 operated patients with histologically
confirmed colorectal carcinoma in all lesions detected by PET/
CT. In this group of patients, levels of CEA, SUVmax and
summarized metabolic volume of all lesions in one patient
were correlated. There was no correlation between CEA level
and SUVmax in positive scans. Also there was not correlation
between SUVmax and volumes of the lesions. However we
have found strong positive correlation between CEA level and
metabolic volume of the lesions (r=0,59).Conclusion: Our re-
sults suggest that in CRC patient with higher level of CEAwe
can expect higher metabolic volume of lesions, however
higher level of CEA does not suggest and higher level of
FDG uptake.
P683
Incidentally detected increased 11C-Choline uptake
in bowel and hystopathological correlation.
E. Tabacchi, P. Ghedini, P. Castellucci, I. Grassi, S. Cambioli,
S. Fanti; S. Orsola-Malpighi Hospital - University of Bologna,
Bologna, ITALY.
Aim: The aim of this study is to investigate areas of unexpect-
ed increased uptake in bowel, detected during PET/CT with
11Choline in patients studied for prostate cancer. Materials and
Methods: Among 2796 consecutive patients performed from
January 2012 to February 2015 who underwent 11Choline-
PET/CT for stage or restage prostate cancer we included in
our study.21 patients in which an incidental focal Choline
uptake in the bowel have been found and in which a subse-
quent colonoscopy and biopsy were available. We have
analysed SUVmax, SUVmean and the v¬¬¬olume of the le-
sion and investigated relationship with biopsy results. Results:
Seven-teen of 21 areas of intense focal uptake were associated
with endoscopic pathological findings (positive predictive val-
ue, 81%), 4 patients resulted negative at endoscopy. Regarding
endoscopic positive findings 3/17 lesions were malignant (co-
lorectal cancer); 6/17 were pre-malignant (6 tubovillous ade-
noma); 8/17 lesions were benign (3 inflammatory, 2 inflamed
diverticula, 1 lesion was associated with Intestinal Bowel Dis-
ease and 2 were abscess). The Mean values of SUVmax ans
SUVmean were 6.4 and of 3.4 respectively in the 17 positive
PET findings.Mean SUVmax of malignant lesions was 7.2
and mean value of SUVmean was 4.2. Mean Volume of the
21 lesions was 24.6 cm3. No significant difference in the SUV
values was found between malignant or benign lesions
(P=0.6). Volume analysis didn’t show difference between ma-
lignant or benign lesion. Conclusions :Main limitation of our
study is the limited number of patients enrolled. According to
our retrospective study, the presence of any focal Choline up-
take in the bowel justifies a subsequent endoscopic investiga-
tion. Since Pet may detect malignant e premalignant lesion in
more than half of total findings. These could lead to a prompt
instauration of the correct therapy and may prevent degenera-
tion of the pre malignant lesions. Keywords: C11-Choline,
PET/CT, Incidental Findings, Bowel, Colorectal Cancer
P684
Contribution of FDG PET/CT for re-staging in patients
with colorectal cancer having suspicious radiological
findings and/or elevated serum tm marker levels.
M. YÜKSEL, M. T. Yanmaz, H. Akyol, M. A. Aydın, E.
Ziylan, T. Ipek, E. Eyüpoglu; Kemerburgaz University, Med-
ical Faculty, ISTANBUL, TURKEY.
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Aim: In patients with colorectal cancer (CRC-pts), confir-
mation of suspicious findings by radiological examinations
and/or elevated tm markers is important to decide for patient
management. Therefore, we aimed to evaluate the role of FDG
PET/CT in re-staging of CRC-pts having suspicious findings
by radiological examination and/or elevated serum tmmarkers
in follow-up period. Material and Methods: A total of 189
patients with colorectal cancer having suspicious findings in
radiologic examination and/or elevated serum tumour marker
levels in follow-up period were evaluated with FDG PET/CT
for re-staging. Medical records of the total patients were eval-
uated retrospectively. Results of the radiological examination
and serum tumour marker levels (CEA and/or CA.19.9) were
compared with FDG PET/CT findings. Results: FDG PET/CT
was positive in 69/125 (55%), 43/49 (8%), and 15/17 (88%) in
CRC-pts with suspicious radiological examination, elevated
Tm marker (CEA and/or CA.19.9), and radiological examina-
tion+elevated Tm marker, respectively. In 23 of 189 patients
(12%) with suspicious findings in radiological examination
additional unknown metastatic foci were detected. Conclu-
sion: FDG PET/CT has important contribution in evaluation
of re-staging CRC-pts with suspicious findings in radiological
examinations and/or elevated serum Tm marker levels. Ac-
cording to our findings, FDG PET/CT results were more com-
patible with elevated serum Tm marker levels or suspicious
radiological examination+elevated Tm marker levels. Since
approximately half of our CRC-pts with suspicious radiologi-
cal findings were negative for recurrence and/or metastasis of
the primary malignancy by FDG PET/CT, we suggest that the
results of the radiological findings should be correlated with
serum tm marker levels and FDG PET/CT. Further investiga-
tions with larger number of CRC-pts are needed to confirm out
findings.
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11С-Choline PET/CT in Prostate Cancer Patients
with Biochemical Recurrence
D.M. Pursanova1, I. P. Aslanidis1, O. V. Mukhortova1, A. S.
Rumyantsev1, O. B. Karyakin2, V. A. Biryukov2, V. I.
Shirokorad3; 1Bakoulev Scientific Center for Cardiovascular
Surgery, Moscow, RUSSIAN FEDERATION, 2A.Tsyb Med-
ical Radiological Research Centre – branch of the National
Medical Research Radiological Centre, Obninsk, RUSSIAN
FEDERATION, 3Moscow City Oncology Hospital №62,
Moscow, RUSSIAN FEDERATION.
Purpose: To evaluate the diagnostic impact of 11C-Choline
PET/CT in the detection of recurrent prostate cancer (PCa) in
patients with biochemical relapse and to assess the correlation
between PET/CT diagnostic accuracy and PSA levels.
Methods and materials: 11C-Choline PET/CT was performed
in 83 patients (age range 50-79) with biochemical relapse after
radical treatment for PCa. Imaging was performed on PET/CT
scanner (Biograph-64, Siemens) 10 min after injection of 11C-
Choline (700-950Mbq). The mean PSAvalue was 3.73 ± 4.25
(0.22-17.80) ng/ml. Patients were divided into three groups
according to PSA level: ≤ 2 ng/ml, 2 to 9 ng/ml and ≥ 9 ng/
ml. Results: Overall, 11C-Choline PET/CT detected PCa re-
lapse in 38 of 83 patients (46%). The mean PSAvalue in PET-
positive patients was 5.99 ± 5.10 (0.22-17.80) ng/ml, while in
negative patients PSA value was 1.82 ± 1.82 (0.27-8.89) ng/
ml. The majority - 69% (31/45) patients with PET-negative
scan had low PSA levels (<2 ng/ml). Although the median
PSA value was significantly higher in PET-positive than in
PET-negative patients (4.34 ng/ml vs 1.2 ng/ml, p < 0.001),
PET/CT confirmed its ability to detect relapse in patients with
low PSA levels (from 0.22 ng/ml). PET/CT was positive in 8
of 39 patients (21%) with PSA of ≤ 2 ng/ml, in 21 of 35
patients (60%) with PSA of 2 to 9 ng/ml, and in 9 of 9 patients
(100%) with PSA of ≥ 9 ng/ml. Local relapse was detected in
53% (20/38) patients. Both local and distant metastases were
diagnosed in 29% (11/38) cases: bone lesions (7), lymph
nodes (3), lymph nodes and adrenal gland (1). Distant relapse
was identified in 18% (7/38) cases: bone (4), lymph nodes (2)
and lungs (1). PET/CT allowed to assess the efficacy of treat-
ment in 27% (12/45) PET-negative patients under hormone
therapy at the scan time. However, PET/CT wasn’t able to
localize the site of PCa recurrence in these hormone-
sensitive patients what might have affected the overall detec-
tion rate. Conclusion: 1) 11C-Choline PET/CT was able to
detect and correctly identify the site of PCa relapse in 46%
cases and therefore was useful in determining the further ther-
apeutic approach. 2) Our data confirmed the strong correlation
between the 11C-Choline PET/CT detection rate and PSA
levels at restaging of PCa (r = 0.8). 3) 11C-Choline PET/CT
might have limited utility in localizing the site of PCa recur-
rence in some patients under hormone therapy.
P686
Diuretic FDG PET/CT and diffusion weighted MR
imaging for urothelial carcinoma: capability for prediction
of pathological characteristics and prognosis
M. Nogami1, H. Iwasa2, K. Miyatake2, S. Kohsaki2, K.
Ohgi2, M. Nishimori2, T. Yamagami2, D. Takenaka1, S.
Adachi1; 1Hyogo Cancer Center, Akashi, JAPAN, 2Kochi
Medical School, Kochi University, Nankoku, JAPAN.
PURPOSE: Diuretics yield rapid evacuation of urinary
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excretion of administrated FDG and enable evaluation of
urothelial carcinoma on FDG PET/CT. The purpose was to
determine the association between glucose metabolism and
pathological characteristics or short-term prognosis of high
grade urothelial carcinoma on FDG PET/CT after diuretic (di-
uretic PET/CT), and to compare those with diffusion weighted
(DWI) MR imaging.MATERIALS AND METHODS:
Twenty-six pathologically confirmed high grade urothelial
carcinomas (renal pelvis cancer, n=10; ureteral cancer, n=8;
and bladder cancer, n=8) were examined by diuretic PET/CT
and DWI MRI within one week before therapy. Diuretic PET/
CTwas performed 180 min after administration of F-18 FDG
and 60min after furosemide injection. DWIMRI was acquired
at 3.0T with b-values of 0 and 1000 sec/mm2. Maximum and
peak standardized uptake value (SUV max and SUV peak,
respectively) and minimum and average apparent diffusion
coefficient (ADC min and ADC mean, respectively) were
measured. Pathological results including tumor size, depth,
lymphatic and venous invasion were acquired by operations
and biopsies. The prevalence of short-term recurrence and/ or
metastasis after therapy was determined by follow-up studies
and recorded at six months after initial treatment. To determine
the relationship between glucose metabolism and restricted
diffusion of the tumors, SUVs were statistically compared
with ADCs by the Spearman’s rank correlation coefficient.
To evaluate the correlation of pathological characteristics and
short-term prognosis with glucose metabolism and restricted
diffusion, SUVs and ADCs were also statistically compared
with pathological and prognostic status by the Mann-Whitney
test.RESULTS: The histopathological results showed 21 inva-
sive and 5 non-invasive urothelial carcinomas. Significant in-
verse correlation was found between SUV max and ADC min
(r= -0.46, p= 0.019) and between SUVpeak and ADCmean (r=
-0.44, p= 0.019), respectively. Tumor size was significantly
correlated with SUVmax and SUVpeak (r= 0.74 and 0.75,
p= <0.0001 and <0.0001, respectively). There was no signif-
icant correlation of the other pathological characteristics and
short-term prognosis with SUVs andADCs.CONCLUSIONS:
Significant inverse correlation between SUV and ADC is
found in high-grade urothelial carcinomas similar to the other
cancers. SUVof high-grade urothelial carcinoma shows strong
correlation with its size; however, the other histopathological
characteristics and prognosis of the high-grade urothelial car-
cinoma are not predicted by SUVs and ADCs.
P687
68Ga-PSMA-11 dynamic PET/CT in the diagnostics
of primary prostate cancer
C. Sachpekidis1, M. Eder2, K. Kopka2, W. Mier3, B. A.
Hadaschik4, U. Haberkorn3, A. Dimitrakopoulou-Strauss1;
1Clinical Cooperation Unit Nuclear Medicine, German
Cancer Research Center, Heidelberg, GERMANY, 2Division
of Radiopharmaceutical Chemistry, German Cancer Research
Center, Heidelberg, GERMANY, 3Division of Nuclear Medi-
cine, University of Heidelberg, Heidelberg, GERMANY,
4Urology Clinic, University of Heidelberg, Heidelberg,
GERMANY.
Objectives: 68Ga-PSMA-11 PET/CT is a novel imaging
modality for the detection of prostate cancer (PC). Aims
of the present study are to analyze the pharmacokinetics
and biodistribution of the recently clinically introduced
radioligand 68Ga-PSMA-11, and to study the potential
correlation between tracer parameters and plasma PSA
levels in patients suffering from primary PC. Methods:
The study includes 22 patients with biopsy-confirmed,
not previously treated PC (mean age 67.5 yrs). Their
median PSA value was 54.0 ng/mL. All patients
underwent dynamic PET/CT (dPET/CT) scanning (60
min) of the pelvis as well as whole body PET/CT stud-
ies with 68Ga-PSMA-11. dPET/CT assessment was
based on qualitative evaluation, SUV calculation, and
quantitative analysis based on a 2-tissue compartment
model and a non-compartmental approach based on frac-
tal dimension. Statistical evaluation was based on de-
scriptive statistics and Spearman correlation analysis
(p<0.05). Results: In 21 patients at least one lesion
was detected. One patient demonstrated no tracer uptake
neither in tumor nor in tissues, where physiological up-
take is expected (salivary glands, lacrimal glands, liver,
spleen, bowel). A total of 66 lesions were detected (21
primary PCs, 45 metastatic lesions in lymph nodes, soft
tissue and bones). One patient demonstrated a diffuse
metastatic disease with innumerable focal lesions.
Semi-quantitative evaluations revealed the following
va l u e s f o r t h e PC - a s s o c i a t e d l e s i o n s : me an
SUVav e r a g e = 1 4 . 8 (m ed i a n = 1 2 . 0 ) a n d me a n
SUVmax=24.3 (median=20.9). Dynamic PET/CT studies
of the pelvis revealed the following absolute 68Ga-
PSMA-11 quantitative values: K1=0.26 (median=0.18),
k3=0.32 (median=0.28), influx=0.16 (median=0.10) and
fractal dimension (FD)=1.27 (median=1.31). Correlation
analysis revealed a strong, significant correlation be-
tween PSA plasma levels and the number of lesions
detected on 68Ga-PSMA-11 PET/CT (r=0.83). More-
over, PSA levels correlated significantly with the follow-
ing 68Ga-PSMA-11 parameters: SUVaverage (r=0.59),
SUVmax (r=0.57), K1 (r=0.31), k3 (r=0.42), influx
(p=0.53) and FD (r=0.56). Conclusions: 68Ga-PSMA-
11 PET/CT revealed at least one lesion per patient in
21/22 (95.0%) patients. PSA plasma levels correlated
significantly with the number of 68Ga-PSMA-11 posi-
tive lesions detected on PET/CT as well as with all
dynamic 68Ga-PSMA-11 PET parameters.
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68Ga-PSMA-11 dynamic PET/CT in biochemical relapse
of prostate cancer
C. Sachpekidis1, M. Eder2, K. Kopka2, W. Mier3, B. A.
Hadaschik4, A. Dimitrakopoulou-Strauss1; 1Clinical Cooper-
ation Unit Nuclear Medicine, German Cancer Research Cen-
ter, Heidelberg, GREECE, 2Division of Radiopharmaceutical
Chemistry, German Cancer Research Center, Heidelberg,
GREECE, 3Division of Nuclear Medicine, University of Hei-
delberg, Heidelberg, GREECE, 4Urology Clinic, University
of Heidelberg, Heidelberg, GREECE.
Objectives: The introduction of 68Ga-PSMA-11 PET/CT
is considered a promising step towards the improvement
of prostate cancer (PC) diagnostics. We aim to study the
pharmacokinetics and distribution of the recently clini-
cally introduced radioligand 68Ga-PSMA-11 in recurrent
PC by means of dynamic and whole body PET/CT.
Methods: 32 patients with biochemical recurrence of
pretreated PC (mean age 69.0 yrs) were enrolled in the
study. The median PSA value was 4.8 ng/mL and the
median Gleason score was 7. All patients underwent
dynamic PET/CT (dPET/CT) scanning (60 min) of the
pelvis as well as whole body PET/CT studies with
68Ga-PSMA-11. dPET/CT assessment was based on
qualitative evaluation, SUV calculation, and quantitative
analysis based on a 2-tissue compartment model and a
non-compartmental approach based on fractal dimension.
Results: In 25 patients at least one lesion was detected,
while 7 patients were 68Ga-PSMA-negative. A total of
71 lesions were detected (7 recurrent PCs, 64 metastatic
lesions in lymph nodes, soft tissue and bones). In one
patient the extent of disease was very large, rendering
the exact calculation of metastatic lesions practically im-
possible (innumerable focal lesions). Semi-quantitative
evaluations revealed the following values for the PC-
associated lesions: mean SUVaverage =10.9 (median
=8.5) and mean SUVmax =17.0 (median =13.7). Dy-
namic PET/CT studies of the pelvis revealed the follow-
ing absolute 68Ga-PSMA-11 quantitative values for the
suspicious recurrent or metastatic lesions: K1=0.23 (me-
dian=0.18), k3=0.33 (median=0.27), influx=0.12 (medi-
an=0.11) and fractal dimension (FD)=1.25 (medi-
an=1.28). Patients with lesions on 68Ga-PSMA-11
PET/CT had a median PSA of 9.3 ng/mL and a median
Gleason score of 7, while patients negative on 68Ga-
PSMA-11 PET/CT had a median PSA of 0.4 ng/mL
and a median Gleason score of 7. Correlation analysis
revealed a significant correlation (r=0.53) between PSA
levels and the number of lesions detected on 68Ga-
PSMA-11PET/CT (p<0.01). Conclusions: 68Ga-PSMA-
11 PET/CT revealed at least one lesion per patient in
25/32 (78.1%) patients. Patients positive on 68Ga-
PSMA-11 PET/CT had higher PSA values than those
who were 68Ga-PSMA-11 negative (p<0.01). PSA plas-
ma levels correlated significantly with the number of
68Ga-PSMA-11 positive lesions on PET/CT.
P689
Radiolabeled somatostatin analogs for diagnosis
and treatment of patients with advanced urothelial
carcinoma
M. Rodrigues1, L. Scarpa1, D. Kendler1, C. Uprimny1, B.
Nilica1, S. Buxbaum1, G. Gastl2, I. Virgolini1; 1Department
of Nuclear Medicine, Medical University, Innsbruck, AUS-
TRIA, 2Department of Internal Medicine, Division of
Haematology and Oncology, Medical University, Innsbruck,
AUSTRIA.
Somatostatin receptors (SSTR) can be overexpressed in a va-
riety of neoplasms, including neuroendocrine tumors, menin-
gioma, mesenchymal tumors, lymphoma, and, with a low in-
cidence and density, in renal cell carcinoma as well. Aim: to
evaluate the value of radiolabeled somatostatin analogs for the
diagnosis and treatment of patients with advanced urothelial
carcinoma. Material and Methods: a series of six patients (3
male, 3 female; age: 57-70 years) with urothelial carcinoma
(previous nephrectomy, 5 patients) was investigated with
radiolabeled somatostatin analogs (68Ga-DOTA-TOC-, 3 pa-
tients; 68Ga-DOTA-lanreotide-PET/CT, 2 patients; both ex-
aminations, 1 patient) and 18F-FDG-PET/CT for staging and
therapy decision-making. The time interval between PETwith
somatostatin analogs and 18F-FDG ranged 1-31 days. Peptide
receptor radionuclide therapy (PRRT) was applied in 3 pa-
tients (cumulative activity: 177Lu-DOTA-TATE 14.4 GBq
and 28.35 GBq, 90Y-DOTA-lanreotide 37.38 GBq). Follow-
up (range: 3-10 years) included 68Ga-DOTA-TOC/lanreotide-
PET, 18F-FDG-PET and diagnostic CT and/or MR. Results:
68Ga-DOTA-TOC/lanreotide-PET detected metastatic disease
in 6 patients (liver,3; lymph nodes,3; pancreas,2; bone,1; lung,
1; stomach,1 patient). 68Ga-DOTA-TOC-PET was false neg-
ative in 1 patient. 18F-FDG-PET showed metastases in only 4
patients (liver,2; lymph nodes,2; pancreas,1; bone,1; lung,1;
stomach,1 patient). Based on PET results, PRRTwas indicated
in 4 patients, surgery in 1 patient and chemotherapy in 1 pa-
tient. PRRT was well tolerated in all patients. Follow-up after
PRRT showed stable disease in 2 patients (3 and 6 years
follow-up) and complete remission in 1 patient (10 years fol-
low-up). Conclusions: 68Ga-DOTA-TOC and 68Ga-DOTA-
lanreotide-PET are valuable tools in the work-up and manage-
ment of patients with urothelial carcinoma. Furthermore, our
results illustrate that PRRT is a well tolerated treatment option
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that can be highly effective in controlling advanced urothelial
carcinoma.
P690
Correlation of serum PSA levels with 68Ga-PSMA tumor
SUV in patients with primary and metastatic prostate
cancer
S. Lütje1, B. Gomez1, S. Heskamp2, R. Reichel1, A.
Bockisch1, O. C. Boerman2, A. Wetter3, T. D. Poeppel1;
1Clinic for Nuclear Medicine, University Hospital Essen, Es-
sen, GERMANY, 2Department of Radiology and Nuclear
Medicine, Radboud university medical center, Nijmegen,
NETHERLANDS, 3Department of Diagnostic and Interven-
tional Radiology and Neuroradiology, University Hospital Es-
sen, Essen, GERMANY.
Aim: Prostate cancer (PCa) is the most commonmalignancy in
men worldwide, leading to substantial morbidity and mortali-
ty. The 68Ga-labeled HBED-CC-PSMA ligand is a highly
promising new tracer for imaging of PCa. The aim of this
study was to evaluate the correlation between 68Ga-PSMA-
PET/CT standardized uptake values (SUV) in primary and
metastatic PCa lesions and serum levels of prostate-specific
antigen (PSA). Materials and methods: Twenty-five patients
with primary or metastatic PCa received 112 ± 30 MBq of the
68Ga-HBED-CC-PSMA ligand intravenously and underwent
PET/CT (Siemens mCT) at 1 h after injection. Data were an-
alyzed regarding the detection rate of primary tumor lesions as
well as of bone and lymph node metastases, and regarding
radiotracer uptake in tumor lesions. The SUVmax, SUVmean
(average SUV within a 3D isocontour thresholded at 50% of
the SUVmax) and SUVpeak of 68Ga-PSMA were determined
within a spheroidal volume of interest (VOI) to evaluate the
correlation between SUVand serum PSA levels by calculating
the Pearson correlation coefficient. As reference standard a
characterization for malignancy was made in consensus taking
into account the available histopathological data, and existing
prior examinations. Results: In the 25 patients (mean PSA 6.8
ng/ml, range 0.1 - 16.0 ng/ml; mean SUVmax 10.6, range 3.3 -
27.5), a linear correlation between serum PSA levels and
SUVmax, SUVmean, and SUVpeak for 68Ga-PSMA-PET/CT
uptake in the tumor lesions was found (r=0.53, r=0.50, and
r=0.50, respectively). Strongest correlation between PSA and
SUVmax, SUVmean, and SUVpeak was observed for bone me-
tastases (n=5, r=0.97, r=0.96, and r=0.98, respectively) and for
metastatic lymph nodes (n=6, r=0.66, r=0.63, and r=0.59, re-
spectively). In addition, a moderate correlation was found be-
tween the number of tumor lesions detected with 68Ga-
PSMA-PET/CT and PSA serum levels in these 25 patients
(r=0.45). Conclusion: Serum PSA levels of patients with
PCa linearly correlate with uptake of the 68Ga-PSMA ligand
in terms of SUVmax, SUVmean, and SUVpeak. Strongest corre-
lation was observed for bone metastases. In addition, the se-
rum PSA level correlated with the number of tumor lesions
detected with 68Ga-PSMA-PET/CT. In future, the observed
correlation might facilitate the selection of patients for 68Ga-
PSMA-PET/CT imaging.
P691
Renal cell carcinoma: clinical and prognostic value
of FDG-PET/CT after surgery
P. Alongi1, M. Picchio1, M. Spallino2, L. Gianolli1, G.
Saladini3, L. Evangelista3; 1IRCCS San Raffaele Scientific
Institute, Milano, ITALY, 2University of Milano-Bicocca, Mi-
lano, ITALY, 3Veneto Institute of Oncology, Padova, ITALY.
AIM: Several studies, often with small cohort and divergent
results, have discussed the role and possible limitations of
FDG-PET/CT at staging and restaging for patients with renal
cell carcinoma (RCC). However, the possible prognostic role
remain still undefined. The aim of this retrospective study,
through a collaboration between San Raffaele Hospital(OSR)
and Veneto Institute of Oncology (IOV), was to evaluate the
clinical and prognostic impact of FDG PET in the restaging
process of renal cell cancer after surgery. Materials and
Methods: FromOSR and IOV database we reviewed restaging
FDG-PET/CT scans performed in 104 patients after surgery
for RCC. Diagnostic accuracy of visually interpreted FDG-
PET/CT was evaluated based on final diagnoses obtained by
histology, other diagnostic imaging (eCT, MRI, Bone scan)
and by clinical follow-up (mean 37 months). Additional infor-
mation such as, influence on treatment decisions, and impact
of FDG-PET/CT findings on survival were assessed.
Progression-free survival (PFS), overall survival (OS) using
Kaplan-Meier method, and relative risk of progression (RRP)
with Cox regression analysis were calculated in all cohort and
in a second step combining PET results with TNM staging
(available in 52 patients). RESULTS: Suspicious recurrence
of RCC was histologically (n = 24) or by other diagnostic
imaging and follow-up (n = 36) confirmed in 60/104 FDG-
PET/CT scans. Overall, the sensitivity, specificity, positive
predictive value, negative predictive value and diagnostic ac-
curacy using FDG-PET/CTwere 80%, 87%, 94%, 65%, 83%
respectively. FDG-PET/CT findings influenced therapeutic
management in 32 cases (30,7%). Cumulative survival rates
over 5 years in the PET-positive vs. the PET-negative group
were 19% vs. 69% respectively (p <0.005). PFS rates over 3
years in the PET positive vs. the PET-negative group were
20% vs. 67% (p <0.005). Cox regression analysis showed an
high RRP for PET-positive compared to PET-negative patients
(HR: 3.8; Chi-sq: 6.4; p<0,005). Conversely PET negative in
comparison to PET positive patients presents a lower RRP
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(HR: 0.6; Chi-sq: 1,8; p<0,005). In addition, FDG PET
showed an incremental prognostic value, in terms of relative
risk of progression, by comparing TNM Stage 3-4 alone (HR:
1,8; p:0.072 ) vs. FDG PET positivity associated with Stage 3-
4 (HR: 4.3; p:0,012). Conclusion: FDG-PET/CT demonstrated
to be a valuable tool in the treatment decision making and to
predict the survival and risk of progression of patients affected
by renal cancer, despite a possible false negativity in some
subtypes. Furthermore, FDG-PET in combination with TNM
staging system allowed incremental risk stratification.
P692
Optimising 18F-Choline PET-CT acquisition protocol
in prostate cancer
L. Mohamed Salem, Sr.1, M. Ibañez Ibañez1, L. Álvarez
Nieto1, V. Godoy Bravo1, R. Reyes Marles1, L. Frutos
Esteban1, J. Navarro Fernandez1, M. Castellón Sanchez1, P.
Nicolas Ruiz1, M. Claver Valderas1, B. Miñana López2, A.
Rosino Sánchez2, P. López Cubillana1, A. Montellano
Fenoy1, M. Roldan Rubio1; 1Hospital Clínico Universitario
Virgen de la Arrixaca, Murcia, SPAIN, 2Hospital
Universitario Morales Meseguer, Murcia, SPAIN.
Aim:In absence of an official standardised 18F-Choline PET-
CT acquisition protocol, we evaluate the utility and the results
of our acquisition protocols to propose an optimal acquisition
protocol.Materials and methods:We study retrospectively 75
patients, 64 patients with prostate cancer (PCa) with biochem-
ical relapse after treatment with curative intent (prostatectomy
or radiotherapy), 8 patients with histological diagnosis of high
risk PCa and negative conventional imaging techniques for
staging, and 3 patients with Castration-refractory PCa with
no previous curative intent, all patients underwent a bone scan
and a new determination of PSA level (if they had not one the
last month), if bone scan is positive, then PET-CT in not indi-
cated, all patients underwent PET-CT scan (4 MBq / Kg) ac-
cording to two different protocols; 55 patients had a dynamic
acquisition of 8 frames (image / minute), one minute after
injection, a pelvic bed at 15 and 60 minutes, and a whole body
PET-CT at 30 minutes, and 20 patients dual-phase protocol, a
pelvic bed one minute after injection and a whole body PET-
CTat 60 minutes.In 51 of 75 patients, who had a positive PET-
CT scan (68%), we analyse the mean SUVmax to assess both
acquisition protocols, and the relation between the SUVmax,
PSA level and the detection rate.Results:The SUVmax de-
creases slightly over the time in the consecutive acquisitions
in all the patients with soft tissue lesions.There is a clear de-
creasing tendency in 8 patients with 12 soft tissue lesions with
histological confirmation and an increasing tendency in 5 pa-
tients with bone lesions11 patients had positive bone scan (5
patients had PET-CT with similar findings), 19,23% PET-CT
studies could be avoided with positive bone scan.The higher is
the PSA level, the higher is the probability of a positive study
and the higher is SUVmax.Dual-phase is more comfortable for
the patient, easier to interpret, visualization of the pelvis before
the arrival of radioactive urine and better management of ad-
ministered activityConclusion:There is no correlation between
the SUVmax at different times, the tendency is clearly decreas-
ing in patients with histological diagnosis of high risk prostate
cancer.It has a decreasing tendency in soft tissue lesions and an
increasing one in bone lesions.Dual-phase protocol is more
accurate, comfortable and easier.The PSA level correlates with
the detection rate and the SUVmax.Practicing bone scan first
can avoid PET-CT in 19,23% of the patients.
P693
Clinical efficacy of PET/CT using 68Ga-DOTATOC
for restaging in renal cell carcinoma
Y. Nakamoto, K. Sano, T. Ishimori, K. Togashi; Kyoto Uni-
versity Graduate School of Medicine, Kyoto, JAPAN.
Objectives: Positron emission tomography / computed tomog-
r a phy (PET /CT ) w i t h 68Ga - l a b e l e d 1 , 4 , 7 , 1 0 -
tetraazacyclododecane-N,N’,N”,N”’-tetraacetic acid-D-Phe1-
Tyr3-octreotide (DOTATOC) has been accepted as a diagnos-
tic imaging tool especially for detecting neuroendocrine tu-
mors, but its clinical value for restaging in renal cell carcinoma
(RCC) remains unknown. The purpose of this study was to
evaluate the clinical efficacy of DOTATOC-PET/CT in pa-
tients with suspected recurrent RCC after surgery. Patients
and methods: A total of seven consecutive patients
(M:F=5:2) who had surgery for histologically-proven renal
cell carcinoma were analyzed. All patients who had been
suspected of having recurrence underwent DOTATOC-PET/
CT scan for restaging purpose during the follow-up period.
PET/CT findings were reviewed and sensitivity was calculated
in a patient-basis and lesion-basis. When patients had PET/CT
with fluorodeoxyglucose (FDG), PET findings were com-
pared. As a reference standard, histopathological findings
and/or clinical data including radiological findings were used.
Results: There were a total of 18 recurrent or metastatic lesions
(one local recurrence, 9 lesions in bone, 2 in pancreas, 2 in soft
tissue, 1 in liver, 1 in lung, 1 in parathyroid, 1 in lymph node)
in seven patients. Of 18 lesions, 13 lesions in 6 patients with
clear cell carcinoma were clearly depicted in DOTATOC-PET/
CT, the maximal standardized uptake values of which were
ranging from 2.8 to 23.3, with the average of 9.7. Excluding
2 of 13 lesions that were not assessed by FDG-PET/CT, only 3
lesions were positive in FDG-PET/CT. 4 of 18 lesions were
negative in DOTATOC-PET/CT, but positive in FDG-PET/
CT. Interestingly, these 4 lesions were papillary carcinomas.
The remaining one lesion was a metastatic liver tumor, which
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was not identified by both PET/CT. Overall, the sensitivities of
DOTATOC-PET/CT and FDG-PET/CT were 86% and 67%,
respectively, in patient-basis, and 72% and 56%, respectively,
in lesion-basis. Conclusion: Our preliminary data indicate that
DOTATOC-PET/CT could be useful for restaging in RCC. In
addition, there might be differences of diagnostic performance
according to histopathological types.
P694
[68Ga]PSMA-HBED uptake in sympathetic ganglia - A
potential pitfall in scan interpretation
G. Kanthan, E. Hsiao, D. Chan, J. Drummond, G. Schembri;
Royal North Shore Hospital, St Leonards, AUSTRALIA.
Aim: [68Ga]PSMA-HBED PET/CT imaging is a relatively
new technique used to evaluate the extent of disease in patients
with prostate carcinoma. A recent report suggests that PSMA
uptake in coeliac ganglia is common and likely physiological.
We have noted uptake in the lower neck region as a common
finding. Stellate ganglia are a potential site for this physiolog-
ical uptake of PSMA. In this study, we aim to determine the
frequency and intensity of positive uptake in the region of
coeliac and stellate ganglia on [68Ga] PSMA PET/CT imag-
ing. Materials and Methods: The study included 50 consecu-
tive patients with a history prostate carcinoma referred for
[68Ga] PSMA-HBED PET/CT imaging to assess the extent
of disease. The scans were evaluated for the presence of
PSMA uptake in the region of the coeliac and stellate ganglia.
Uptake was noted as either present or absent, and if present,
standardized uptake values (SUV max) were recorded. SUV
max:background uptake (gluteal muscle SUV mean) ratios
were calculated for PSMA positive ganglia. Results: Of the
50 patients, 27 (54%) had uptake in the region of right stellate
ganglion and 38 (76%) had uptake in the region of left stellate
ganglion. 41 (82%) patients had positive uptake in the region
of at least one stellate ganglion and 24 (50%) had uptake in the
region of both stellate ganglia. The SUVmax values ranged
from 1.41 to 3.61. SUVmax exceeded 3.00 in only 1 right
stellate ganglia (2%) and 5 left stellate ganglia (10%). The
mean SUV was 2.28 and mean SUV max:background SUV
ratio was 6.24. Of the 50 patients, 13 (26%) had positive up-
take in right celiac ganglion and 35 (70%) had positive uptake
in left celiac ganglion. 37 (74%) had uptake in at least one
celiac ganglion and 11 (22%) had uptake in both celiac gan-
glia. The SUVmax values ranged from 1.68 to 6.46. SUVmax
exceeded 3.00 in 5 right coeliac ganglia (10%) and 9 left coe-
liac ganglia (18%). For PSMA positive coeliac ganglia, the
mean SUV was 2.79 and mean SUV max to background
SUV was 7.26. Uptake in at least one of the four ganglia is
seen on 90% of patients. Conclusion: PSMA uptake in sym-
pathetic ganglia is a common finding in PSMA PET/CT
imaging. If not recognised, this can lead to false positive in-
terpretation of the scan and incorrect staging of prostate
carcinoma.
P695
Impact of 18F-choline PET-CTonmanagement of patients
with biochemical recurrence of prostate cancer
A. R. Teagle, A. Robinson, A. Nikapota, F. McKinna, S.
Dizdarevic; Brighton and Sussex University Hospitals NHS
Trust, Brighton, UNITED KINGDOM.
Introduction: Adenocarcinoma of the prostate is the most com-
mon cancer in men in the UK, accounting for 25% of all male
cancers. Around 35% of patients will have a biochemical re-
currence within 10 years after initial treatment. Detection of
disseminated disease is important in order to determine the
patient’s suitability for local salvage versus palliative therapy.
In many cases standard imaging methods such asMRI, CTand
nuclear medicine bone scanning are insensitive, PSA levels
needing to be over 20ng/ml in order to reliably detect disease.
18F-Choline positron-emission tomography-computed to-
mography (CH-PET-CT) has greater sensitivity in early detec-
tion of recurrence, even at PSA levels below 5ng/ml. The
purpose of this study was to determine the impact of CH-
PET-CT performed at our institution on management of pa-
tients with prostate cancer. Methods: This was a retrospective
analysis of patients treated for prostate cancer who underwent
CH-PET-CT at our institution between January 2014 and Oc-
tober 2014. Patient records, imaging and pathology results
were collected. Questionnaires were sent to referring clinicians
regarding the clinical indication for CH-PET-CT and its effect
on subsequent management and outcome. ResultsTwenty-four
CH-PET-CT scans were identified in 22 patients. After exclu-
sions, 21 scans in 21 patients were included. Questionnaires
were returned by referring clinicians in 90.5%. Fifteen scans
(71.4%) were done to investigate possible recurrence in pa-
tients with rising PSA post-treatment. Four (19.0%) were done
for clarification following equivocal or inconclusive conven-
tional imaging; two (9.5%) were done for re-staging in patients
with known nodal or other metastases. Positive findings of
CH-PET-CTwere reported in 15 patients (71.4%). In 11 cases
(52.4%), CH-PET-CT confirmed findings of previous conven-
tional imaging, and management plan was unaltered. In 10
cases (47.6%), management was altered, including beginning
antihormonal therapy or chemotherapy for disseminated dis-
ease, radical radiotherapy or brachytherapy for localised dis-
ease, or observation in cases of negative CH-PET-CT. In 7
cases (33.3%), treatment intent was also changed due to CH-
PET-CT result: palliative intent in 3 cases (14.3%), radical
local therapy in 2 cases (9.5%), and active surveillance in 2
cases (9.5%). Conclusion: Choline-PET-CT has a significant
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impact on management of patients with recurrent prostate can-
cer, leading to a change in therapy in almost half of our patient
population. In future this may lead to more targeted treatment
of such patients, with improvement in outcomes. Large pro-
spective trials are needed to fully assess the impact of CH-
PET-CT on management and subsequent patient outcomes.
P696
Preoperative Staging of Urinary Bladder Carcinoma
by F-18 FDG PET/CT Using a Novel Protocol- A
Prospective Study
Y. C. Lin, S. C. Tsai, J. Y. Li, W. Y. Lin; Taichung Veterans
Hospital, Taichung, TAIWAN.
Aim: The use of 18F FDG PET imaging in bladder carcinoma
has not been fully explored, mainly because the urinary excre-
tion of 18F FDG interferes with visualization of the primary
bladder tumor and regional lymph nodes. In this study, we
established a patient-friendly 18F FDG PET/CT (PET) proto-
col and evaluated the diagnostic accuracy of 18F FDG PET/
CT images in patients with urinary bladder carcinoma. Mate-
rials and methods: Twenty-three patients with newly diag-
nosed bladder cancer were enrolled in this study. PET scan
was performed before operation. The PETscan was performed
40-60 minutes after the injection of 3.7 MBq/kg of 18F FDG.
Immediately after the PET scanning, 10 mg of furosemide was
given intravenously and the patients were encouraged to drink
as much water as they can (but not compulsory) and urinate
frequently after the 18F FDG injection. A delayed pelvic PET
imaging was taken 3 hours after the 18F FDG injection and the
patients were asked to void about 30 minutes before the end of
the delayed imaging so the bladder could be refilled. Histo-
pathologic results from the surgery were used as the gold stan-
dard. Results: Of the 23 patients, 3 patients received systemic
chemotherapy instead of surgery because the PET images de-
tected multiple metastases. 2 patients received TURBt only
due to tumor in situ. 18 patients received radical cystectomy
and regional lymph nodes dissection after PET images. The
accuracy of PET images for primary bladder tumor and the N-
stage were 100% and 83% respectively. The M-stage was cor-
rectly determined in 22/23 patients (95%) except 1 patient
suspected of lung metastasis based on PET images was path-
ologically proved synchronous secondary lung adenocarcino-
ma. Overall, PET altered the TNM score in 9/23 patients
(39%), the AJCC stage in 5/23 patients (22%), and treatment
planning in 3/23 patients (13%).With our patient-friendly pro-
tocol, there’s no patient felt urinary urgency during delayed
images. Conclusion: PET/CT images proved to be more accu-
rate in assessing the TNM-stage compared with conventional
images and altered treatment planning in urinary bladder car-
cinoma. Our patient-friendly protocol, with drink at patients’
will, low dose furosemide, and short bladder refilling time, is a
feasible method of adequate urinary FDG clearance without
adverse effect.
P697
First Clinical Experience Using a Cold Kit Based
68Ga-PSMA PET/CT for Recurrence Detection
of Prostate Cancer
C. ARTIGAS , Z . WIMANA, G. GHANEM, B.
VANDERLINDEN, P. FLAMEN; Institut Jules Bordet, Brus-
sels, BELGIUM.
Introduction: Conventional imaging techniques are not accu-
rate enough in order to detect prostate cancer recurrences in
patients with biochemical relapse after radical treatment.
68Ga-PSMA-ligand PET/CTseems to be an excellent imaging
technique to detect prostate cancer lesions in patients with
biochemical relapse after radical treatment. However its use
is still limited due to expensive equipment and lengthy proce-
dures. To overcome these limitations, we used an original
radiosynthesis method consisting in a kit prefilled with GMP
lyophilized PSMA-ligand and additives able to chelate
68Ga3+ cathion at room temperature (ANMI S.A., Belgium).
Material and methods: We present the preliminary results of
the first clinical experience using a one-step cold
radiosynthesis of 68Ga-PSMA-ligand. As part of an ongoing
analysis, six patients with prostate cancer biochemical relapse
after radical treatment and negative state of the art imaging
techniques have been retrospectively analyzed [mean age 69
years (range (66-77)]. Mean PSA value was 5.1ng/ml (range
0.05-20). All patients received 68Ga- DKFZ-PSMA-11 pro-
duced using a one-step cold radiosynthesis. PET/CT images
were performed under the same conditions in all patients:
2.5min/bed at 60min post-injection of 2MBq/Kg of 68Ga-
PSMA-ligand. Physiological uptake was assessed by measur-
ing SUVmean of the liver, spleen, salivary glands, parotid
glands, kidneys and background activity (muscle and fatty
tissue). Tumor-to-background ratios were also measured. Re-
sults: All patients showed pathological uptake in at least one
lesion even with PSA values of 0.05ng/ml (100% detection
rate). Two patients presented pathologic PSMA uptake in
infracentimetric pelvic lymph nodes, two patients in the pros-
tatic bed and two other patients in bone tissue. Mean tumor-to-
background ratio was 24 (range 9-55.5). 68Ga-PSMA-ligand
biodistribution was comparable to what has been published so
far with intense uptake in kidneys and salivary glands and
moderate uptake in liver, spleen, lacrimal glands and proximal
small bowel. Physiological mean uptake in different organs
were: liver SUVmean 4.2 (range 2.9-5.1); spleen SUVmean
6.1 (range 4.5-8.2); sub-maxillary gland SUVmean 12.2
(range 10.7-15.2); parotid gland SUVmean 11.5 (range 9-
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12.5); kidney SUVmean 33 (range 27.9-41.7) and background
SUVmean 0.26 (range 0.20-0.40).Conclusion:Preliminary da-
ta of the first clinical experience using a one-step
radiosynthesis at room temperature of 68Ga-PSMA-ligand
PET/CT in prostate cancer recurrence detection show promis-
ing results with very good detection rates and high tumor-to-
background ratios. Biodistribution and physiological uptake
are comparable to what has been published so far.
P698
11C-Methionine PET-CT for imaging of prostate cancer:
preliminary results.
B. Padovano1, A. Lorenzoni1, A. Alessi1, N. Bedini2, S.
Morlino2, C. Pascali1, C. Cucchi1, G. Serafini1, R. Valdagni2,
F. Crippa1; 1Nuclear Medicine - PET Unit - Fondazione
IRCSS Istituto Nazionale Tumori, Milan, ITALY, 2Radiother-
apy Unit - Fondazione IRCSS Istituto Nazionale Tumori, Mi-
lan, ITALY.
Aim: 11C-Methionine (MET) PET-CT can be used for imag-
ing of tumors with increased amino acid utilization. MET is
manly used in neuro-oncology. Less frequently, other types of
malignancy has been studied with this tracer and very few
reports concern its utility in prostate cancer (Toth et al 2005
and Nunez et al. 2002). In this study, we present our prelimi-
nary results with MET PET/CT in patients (pts) with Prostate
Cancer (Pca), most of them with radiological and/or biochem-
ical diagnosis of cancer relapse. Materials and Methods: 24
consecutive Pca pts with Gleason score >7 (4+3), have been
evaluated: 17 (71%) with biochemical recurrence (PSA mean
value 7.2ng/ml), 5 (21%) with radiological diagnosis of local
and/or distant metastases and 2 (8%) for staging of locally
advanced disease. In fasting status, patients underwent a whole
body PET/CTexamination (from inguinal region to skull base;
4 min/bed), performed 30 minutes post-injections of a mean
dose of 750-800MBq of 11C-Methionine.MET PET-CT find-
ings were correlated with other imaging modalities (CT and/or
MRI), histological results of biopsied suspected lesions and/or
mean clinical follow-up of 48 months. Results:MET PET-CT
correctly identified the presence of disease in 16/24 pts (67%)
(PSA mean value 13.3 ng/ml; range 0.74-73), detecting local
recurrence in 9/16 (56%), local recurrence and distant meta-
static disease in 3/16 (19%) and distant bone metastases in the
remaining 4 pts (25%). MET PET-CT was negative in 7/24
(29%) pts. In 5 of them with PSA mean value of 1.1 ng/ml
(range 0.6-1.8) also the other imaging tests (CT, bone scan and
RM) were negative. In the other 2 pts positive biopsy of cancer
relapse was obtained (PSA value 1.88 and 2.2 ng/ml).In one
patient treated with radiotherapy (PSA value of 6.2 ng/ml),
MET PET-CT showed an abnormal focal uptake in prostate
lodge without confirmation of abnormal findings by other
imaging modalities and during a follow-up of 60
months.Conclusions:According to our preliminary data,
MET PET-CT might be used for imaging of prostatic cancer,
as possible alternative to 11C or 18F Choline. This preliminary
data have to be confirmed in a larger patient population.
P699
Cu-64 PSMA PET in Prostate Cancer
S. Mirzaei1, B. Grubmueller2, E. Capasso3, P. Knoll1, A.
Floth4, C. Meleddu3, S. Shariat2, H. Klingler4; 1Institute of
Nuclear Medicine with PET-Center, Wilhelminenspital, Vien-
na, AUSTRIA, 2Department of Urology, Medical University
of Vienna, Vienna, AUSTRIA, 3U.O.C. Nuclear Medicine,
Regional Oncological Hospital, Cagliari, AUSTRIA, 4Depart-
ment of Urology, Wilhelminenspital, Vienna, AUSTRIA.
Aim: Prostate specific membrane antigen (PSMA) is
overexpressed in most cases of prostate cancer. The aim of this
study is to evaluate the possible role of Cu-64 PSMA PET in
patients with prostate cancer.Patients and Methods: One pa-
tient with progressive local disease and fourteen patients
(mean age 70 y, age range 51-91 y) with suspected recurrent
disease were referred for PET imaging. PET images of the
whole body were performed 1 and additional images of the
pelvis 2 hours p.i. of mean 250 MBq Cu-64 DKFZ-PSMA-
617 on a PET-scanner (Siemens, Exact, Knoxville).Results: In
all, but three patient there was at least one focally enhanced
Tracer accumulation suspicious for recurrent disease. Themet-
abolic suspicious lesions were already visible in the one hour
images. The patient with locally progressive disease showed
only enhanced uptake in the prostate lobes and no nodal
involvement.Conclusion: The preliminary results of this study
demonstrate the potential of Cu-64 PSMA PET in patients
with recurrent disease and in primary staging of selected pa-
tients with progressive local disease.
P700
Role of PET/CTwith 18F-FDG in the staging of patients
with localized or locally advanced bladder and urinary
tract cancer
J. Duch, A.Montes, A. Domenech, C. Achury, G. Alfonso, G.
Anguera, P. Maroto, I. Carrió; Hospital de la Santa Creu i Sant
Pau, Barcelona, Barcelona, SPAIN.
Aim: Neoplasms of the urinary tract and bladder have a high
rate of recurrence. Nodal and distant metastases are important
prognostic factors, and abdominal CT is the standard tech-
nique for radiologic staging. The role of 18F-FDG PET/CT
in these neoplasms as well as its role in the therapeutic
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management are not well defined. Materials and methods: Be-
tween november 2010 and april 2015, patients with urothelial
carcinoma potentially candidates for surgical treatment were
retrospectively studied. All of them underwent abdominal CT
as well as perioperative 18F-FDG PET/CT (before or after
surgery). Staging was compared by both methods. We exclud-
ed patients with visceral metastatic involvement by CT,
allowing patients in stage IV due to lymph node involvement.
In our center, stage IV patients by lymph node involvement are
treated with salvage surgery in case of good response to che-
motherapy. Results: 48 patients were included. Median age
was 68 years, 87,5% men. Location was bladder, urinary tract
and urethra in 88%, 10% and 2%, respectively. Histology was
transitional cell in 92%. Median follow-up was 9 months (1-
30), mortality rate was 35% and median overall survival 20
months (15-25). 32 patients were operated (67%), being in
these pathological stages: II (25%), III (25%) and IV (50%).
Median time between abdominal CT and 18F-FDG PET/CT
was 1,7 months (0,3-5,8). 3 18F-FDG PET/CT were per-
formed after 1 cycle of chemotherapy. We found differences
in staging between the 18F-FDG PET/CT and CT in 56% of
cases (26). These changes implied a different strategy in 18
patients (37,5%): 10 patients (22%) considered candidates for
pre-surgical chemotherapy (neoadjuvant or induction), re-
ceived palliative chemotherapy because of detection of metas-
tases in 18F-FDG PET/CT , avoiding in these cases a
cystectomy which would have been indicated by the CT find-
ings. In addition, in 8 patients who had been operated, PET
detected persistent disease (3 loco-regional and 5 distance in-
volvement). Thus, cystectomy could have been avoided in 5
cases if 18F-FDG PET/CT had been made prior to the surgery
(10,4%). Conclusion: 18F-FDG PET/CT seems to provide ad-
ditional information to abdominal CT, not only regarding the
staging of tumors, but in terms of their prognostic and with
therapeutic implications.
P701
18F-Fluorocholine PET/CT acquisition protocol
in prostate cancer: the role of early acquisition of the pelvis
in lesion detection rate
S. Capitanio, A. Gerali, G. Virotta, R. Rota, L. Madaschi, A.
Bruno; Nuclear medicine Dept., A.O. Papa Giovanni XXIII,
Bergamo, ITALY.
Aim: 18F-Fluorocholine (FCH) PET/CT is a widely used im-
aging technique in the evaluation of patients with prostatic
cancer. However consensus concerning the best acquisition
protocol has not been reached yet. Most authors propose the
acquisition of early pelvic images before the standard whole
body scan to better evaluate local disease. Our aim was to
revise FCH PET/CT acquisition methodology, verifying
whether early scan could provide additional information in
staging of prostate carcinoma. Materials and Methods: We
retrospectively evaluated 150 prostatic cancer patients who
underwent FCH PET/CT in our centre and, among them, we
selected 33 patients (mean age=70±7; mean PSA 15,72±11
ng/dl) with a biopsy proved but untreated carcinoma (mean
Gleason score 7), within two months before the scan. All pa-
tients underwent a FCH PET/CT study according to the fol-
lowing protocol: early scan of the pelvis within two minutes
after tracer injection (220±31MBq - 2 bed position of 2 min
each) followed by a whole body scan 1 hour later, after bladder
voiding. Early and late images were then compared in terms of
detection rate of pathological findings. Semiquantitative anal-
ysis of lesions was performed by using the maximum stan-
dardized uptake value (SUV max). Results: Urinary activity
appeared very quickly and was already present, at least par-
tially, in all early images. A focal uptake within prostatic gland
compatible with the presence of primary tumour was detect-
able in 23/33 (70%) patients at early and in 25/33 (75%) at late
images. Actually, in two cases the presence of urinary activity
prevented the evaluation of prostate at early scan, on the con-
trary the late acquisition showed a positivity. In 3 patients (9%)
early scan showed an heterogeneous increased prostatic up-
take in absence of an evident focus attributable to tumour site;
the same pattern was confirmed at late scan.In the 23 subjects
positive at both imaging, SUV didn’t significantly change
from early to late images (average SUV max 5.4±3.37 vs
5.08±2.43 respectively, ns).Among these 23 patients, both
scans showed pathological pelvic lymph nodal uptake in 2
patients and skeletal pelvic metastasis in other two subjects,
with slightly higher uptake values in delayed scans .Conclu-
sion: These preliminary results do not support the need of early
FCH scan of the pelvis in staging prostatic cancer. To this
purpose, a delayed whole body imaging with an adequate
bladder voiding could be sufficient and could limit radiation
exposure.
P702
"Interpretation of 11C-choline PET/TC for the diagnosis
of local relapse (LR) in radically treated prostate cancer
(PCa)"
A. Matti1, G. M. Lima1, L. Zanoni1, C. Pultrone2, R.
Schiavina2, F. Lodi1, S. Fanti1, C. Nanni1; 1S.Orsola-Malpi-
ghi Hospital, Nuclear Medicine Department, Bologna, ITALY,
2S.Orsola-Malpighi Hospital, Urology Department, Bologna,
ITALY.
AIM: 11C-choline PET/CT is a widely-used tool for the diag-
nostic of PCa. In literature, a great variability of LR detection
rate is reported. The aim of this study is to provide a positivity
criteria for 11C-choline PET/CT detection of LR in patients
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who had surgery for PCa and presented PSA failure.
METHODS: 60 patients radically treated for PCa (radical
prostatectomy ± RT ± HT after surgery) and presenting PSA
failure (PSA levels at the time of the scan 0.2-16ng/ml, mean
8.1ng/ml) were retrospectively enrolled. Two of them were
under HT at the time of the exam. In these patients 11C-
choline PET/CT was used as the first imaging examination at
the time of the detection of the PSA failure. Two Nuclear
Medicine Doctors revised the 11C-choline PET/CT scans
and defined by consensus if even mild focal uptake was pres-
ent in the prostatic bed (PB) and bladder-urethral junction
(BUJ), regardless the previous report results. The results were
subsequently correlated with a clinical and radiological follow
up (FU) of one to two year. TNM staging, Gleason score, PSA
level at the time of the execution of the exam, RT and HTafter
surgery were considered as possible predictive variables. RE-
SULTS: Overall, there have been described focal uptakes
(from very low to mild) in the PB and BUJ in 22/60 patients
(36,7 %). 11 of them were true positive (18.3 %), 11 false
positive and 4 false negative (5.7 %) for LR, with a sensitivity
of 73.3 % and a specificity of 75.6 %. Analysing the variables
previously mentioned, it had been discovered a tight connec-
tion between the serum PSA level at the time of the exam and
the positivity/negativity of the findings reported. In fact, most
of true positive cases (10/11 patients) were associated with a
PSA ≥ 1 ng/ml, while approximatly half of the false positive
cases (5/11 patients) presented a lower serum level of PSA. In
this evaluation the sensitivity is 66.7 % and the specificity is
86.7 %. The other variables (TNM staging, Gleason score, RT
and HT after surgery) showed no influences on LR sensitivity.
CONCLUSIONS: This study shows that if there is an even
mild focal uptake in the PB and BUJ of patients who had
surgery for PCa and presented PSArelapse ≥ 1 ng/ml, this
finding must be reported, because there is a high possibility
of an inital LR.
P703
The predictive value of 18F-Methilcholine PET/CT
in metastatic castration-resistant prostate cancer patients
treated with abiraterone acetate
P. Caroli, U. De Giorgi, L. Fantini, A. Moretti, R. Galassi, V.
Conteduca, C. Lolli, G. Schepisi, E. Scarpi, D. Amadori, G.
Paganelli, F. Matteucci; IRCCS IRST, Meldola, ITALY.
Aim: The role of 18F-Methilcholine positron emission
tomography/computed tomography (18F-FCH-PET/CT) in
patients with metastatic castration-resistant prostate cancer
(mCRPC) has been demonstrated in recent years. In this study
we analyzed the predictive value of functional parameters as
Standard Volume Uptake (SUVmax) and total lesion activity
(TLA) estimated with FCH-PET/CT in mCRPC patients
treated with abiraterone therapy after chemotherapy. Methods:
We prospectically studied 53 patients (mean age 73yrs;
Gleason score &lt7 in 18 pts and >7 in 35 pts) with mCRPC.
All patients, previously treated with docetaxel, were submitted
to abiraterone acetate therapy (1,000 mg daily with prednisone
5 mg twice daily in continuous 28-day cycles). Before
abiraterone treatment, 18F-FCH-PET/CT was performed in
basal condition, 45 minutes after intravenous injection of
18F-Methilcholine (3,7 MBq/Kg of body weight, AAA-
Advanced Application Accellerator, Ivrea, Italy). All patients
were evaluated monthly for serological PSA response. For
each lesion, we measured maximum standardized uptake val-
ue (SUVmax), metabolic volume activity (MV, i.e. volume of
interest consisting of all spatially connected voxels within a
fixed threshold of 40% of the SUVmax) and total lesion activ-
ity (TLA as the product of MVand mean standardized uptake
value). We analyzed the sum of SUVmax (SSUVmax) and
TLA (STLA) values up to a max of 10 lesions and, by univar-
iate analysis, these data were correlated to PFS and OS. Re-
sults: The median value of PSA resulted 32 ng/ml ( 0,35-1812
ng/ml). 18F-FCH-PET/CT was positive in all pts: 29 patients
with only bone lesions, 20 pts with both prostate, bone and
lymphnodes, in 3 pts only lymphnodes metastasis and only 1
patients with visceral disease. The median value of SSUVmax
was 68 g/ml (3,4-140,7 g/ml), while median value of STLA
was 438400 (26159,4-757670,6). At univariate analysis, the
median value of PSA and the absolute value of STLA showed
a statistically significant correlation for both PFS and OS,
while regarding to SSUVmax we found a statistically signifi-
cant correlation only for PFS, considering either absolute
values than median values (p<0.013). The analysis related to
the median value of the TLA resulted statistically significant
only for OS (p<0.018). Conclusions: Our data seemed to con-
firm the possible role of semiquantitative parameters of 18F-
FCH-PET/CT as a prognostic tool in mCRCP pts.
P704
Incidental findings in 18F-choline PET/CT scans (FC) :
an update on our series of 759 patients studied for prostate
cancer (PC)
M. Rensi, F. Giacomuzzi, D. Capobianco, F. Di Gregorio, G.
Ferretti, M. Povolato, O. Geatti; University Hospital SMM,
Udine, ITALY.
Our aim is to present an overview of abnormal, unexpected
sites of FC uptake, unrelated to PC, that are not rare and con-
sequently must be kept in mind for correct scan interpretation.
Methods: we analyzed 759 consecutive FC scans, done in pts
with prostate cancer, in the large majority for restaging follow-
ing a biochemical relapse and in few cases for staging of ad-
vanced disease. Results: we found 220 abnormal PET findings
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(29 %) not corresponding to PC localizations, which were
related to:1. inflammation in 165 cases and were located in:•
mediastinal, cervical and inguinal lymph nodes (127 cases), of
which 1 was due to sarcoidosis• pulmonary thickening (35
cases), highly suspicious for pneumonia• muscular abscesses
(3 cases)2. benign nodular diseases in 32 cases, of which:• 31
adenomas (16 of the thyroid, 13 of the adrenal and 2 of the
parathyroid glands)• 1 liver haemangioma3. malignant disease
in 13 cases, of which:• 4 located in the lungs (3 adenocarci-
nomas and 1 bronchioloalveolar carcinoma),• 6 in the liver, all
were HCC,• 2 were colorectal cancers,• 1 was a lymphoma4.
Paget disease (4 cases), all had high bone uptake, and was
correctly interpreted owing to the corresponding CTabnormal-
ities which were not suggestive of metastases; histology con-
firmed later5. SNC diseases (4 cases), 3 were meningiomas
and 1 had a recent cortical stroke6. miscellaneous (2 cases), 1
was a hyperplastic bone marrow in chronic myeloid leukemia
and 1 had a head injury. Conclusion: FC is largely used to
study PC patients, as it is more sensitive than 18F-FDG, but
we must emphasize that this does not mean that the radiophar-
maceutical is specific for such a neoplasm.This must be kept in
mind, as in fact in almost 30% of patients, fluorocholine can
concentrate in different kinds of diseases as well, which in the
majority of cases are related to inflammations and benign nod-
ular diseases, although malignant ones cannot be excluded.
P705
Correlation Between GRP Receptor Expression
and Pathological and Clinical Characteristics in Radical
Prostatectomy Specimens
I. L. Bakker, G. J. L. H. van Leenders, E. de Blois, M.
Busstra, A. C. Fröberg, W. M. van Weerden, M. de Jong;
Erasmus MC, Rotterdam, NETHERLANDS.
AIM: Prostate cancer (PC) is diagnosed by pathological eval-
uation of biopsy samples. Transrectal ultrasound (TRUS)-
guided biopsies have disadvantages, as around 30% of the
time PC is missed at the first biopsy procedure, and they pro-
vide little information about the extent of disease, a crucial
parameter for patient management. MRI of PC enhances biop-
sy sensitivity, but only when a multi-parameter MRI is evalu-
ated by a trained prostate MRI-expert. An alternative imaging
technique to optimise the detection of PC including lymph
node status, thereby supporting the selection of those patients
who would benefit most of biopsy, is strongly desired. We
have recently initiated a trial using Gastrin releasing peptide
receptor (GRPr) targeting to detect primary PC, and the first
data look very promising. GRPr is highly expressed in PC, and
has low expression in benign prostate hyperplasia (BPH) and
prostatic intra-epithelial neoplasia (PIN). Since detailed infor-
mation on GRPr expression and its correlation to tumour
localisation and volume, stage of disease, Gleason score and
prostate specific antigen (PSA) levels is scarce, we initiated a
site study using retrospective radical prostatectomy specimen
to investigate this in more detail.MATERIALS AND
METHODS: Frozen samples of 33 patients with different
Gleason scores and PSA levels were selected from the Eras-
mus MC biobank. Iodine-125-Tyr4-bombesin autoradiogra-
phy was performed on frozen prostatectomy slices. HE stain-
ing, AMACR and 34betaE12 immunostaining were per-
formed on adjoining sections to evaluate tumour localisation
and volume. AMACR is a sensitive and relatively specific
staining for PC. Staining with 34betaE12 detects prostatic bas-
al cells that are absent in PC. A pathologist evaluated all
stainings. Autoradiography images were classified as high,
intermediate, low or no GRPr expression compared to a stan-
dard of a cytospin of 150,000 PC3 cells with high GRPr
expression.RESULTS: To date, we have obtained and evalu-
ated full datasets of three patients, the study is still on going.
PC tissue sections showed high or intermediate expression of
GRPr, normal prostate and BPH showed low or no GRPr
expression. Autoradiography showed good correlation with
tumour demarcation as determined by classic histological
staining. A clear relationship between autoradiographic classi-
fication, tumour localisation and tumour volume, could be
observed.CONCLUSION: GRPr imaging is only observed in
PC with no detection in BPH, PIN or normal prostate tissue.
This observation suggest that GRPr imagingmay be a valuable
asset to detect low Gleason PC tumours, which resemble nor-
mal tissue, that might be missed on MRI or TRUS imaging.
P706
Correlation between detectability with 18F-Choline
PET/CT in biochemical relapse after therapy and the risk
parameters at initial diagnosis with prostate cancer
J. J. Robles-Barba1, C. Gámez-Cenzano1, J. L. Vercher-
Conejero1, A. Sabaté-Llobera1, M. Cortés-Romera1, L.
Rodríguez-Bel1, L. M. Gràcia-Sánchez1, I. Romero-Zayas2,
M. Roca-Engronyat3, E. M. Merino-Serra4, A. M. Ferrer-
Artola5, A. Ferrer-González6, J. Pera-Fábregas7, A.
Arellano-Tolívar8, J. F. Suárez-Novo6; 1PET-CT Unit, Institut
de Diagnòstic per la Imatge (IDI). Bellvitge Hospital., L'Hos-
pitalet de Llobregat, SPAIN, 2Radiofarmacia, Institut de Di-
agnòstic per la Imatge (IDI). Bellvitge Hospital., L'Hospitalet
de Llobregat, SPAIN, 3Radiofarmacia. Bellvitge Hospital.,
L'Hospitalet de Llobregat, SPAIN, 4Servicio de Radiología.
Institut de Diagnòstic per la Imatge (IDI). Bellvitge Hospital.,
L'Hospitalet de Llobregat, SPAIN, 5Farnacia. Bellvitge Hos-
pital., L'Hospitalet de Llobregat, SPAIN, 6Unidad Funcional
de Próstata. Bellvitge Hospital., L'Hospitalet de Llobregat,
SPAIN, 7Braquiterapia. Institut Català d’Oncología.,
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L'Hospitalet de Llobregat, SPAIN, 8Oncología Radioterápica.
Institut Català d’Oncología., Badalona, SPAIN.
AIM: To assess the detection rate and recurrence loca-
tion with 18F-Choline PET/CT in biochemical relapse of
prostate cancer, in correlation to risk parameters at ini-
tial diagnosis (TNM staging, initial PSA and D’Amico
classification). MATERIAL AND METHODS: Retro-
spective study of 75 patients (age range 47 - 82 y.o.),
previously treated of prostate adenocarcinoma with cura-
tive intention that presented biochemical relapse (PSA
range: 2’5 250 ng/mL). The PET/CT protocol included
one early dynamic acquisition (1min x 8) of the pelvis
immediately after the e.v. administration of 370MBq of
18F-Choline, and one late whole body static acquisition.
PET resu l t s were c la s s i f i ed as “nega t ive” or
“positive”with 3 patterns of recurrence: 1) local (exclu-
sively prostatic bed), 2) pelvic nodes and 3) distant me-
tastasis. The positive results were correlated with TNM
staging, PSA and D’Amico classification at the moment
of initial diagnosis. RESULTS: The global detection rate
was 79% (59/75). In positive studies the patterns of
recurrence were local in 24 patients (41%), nodal in
the pelvis in 22 (37%) and metastatic in 13 (22%), pre-
dominantly in retroperitoneal nodes and bones. Patients
that presented metastases showed a higher incidence of
T ≥3 in TNM (7/13, 54%), Gleason ≥8 (6/13, 46%) and
high risk in D’Amico classification (10/13, 77%). Most
patients with negative PET (75%) showed initial PSA <
10. CONCLUSIONS: The detection rate of recurrence of
prostate cancer with 18F-Choline PET/CT in patients
with biochemical relapse seems to correlate with the
initial risk classification: a higher risk in initial parame-
ters such as TNM staging, Gleason or D’Amico classi-
fication seems to be associated with more detection of
distant metastasis.
P707
The diagnostic value of PET/CT imaging
with the 68Ga-labelled PSMA ligand HBED-CC
in the diagnosis of prostate cancer
E. Akdemir1, M. Tuncel1, M. Ç. Tuncalı1, C. Y. Bilen2, F.
Akyol3, D. Baydar4, H. Özen2; 1Hacettepe University, De-
partment of Nuclear Medicine, ANKARA, TURKEY,
2Hacettepe University, Department of Urology, ANKARA,
TURKEY, 3Hacettepe University, Department of Radiation
Oncology, ANKARA, TURKEY, 4Hacettepe University, De-
partment of Pathology, ANKARA, TURKEY.
Aim: PET-CT imaging with 68Ga-PSMA-HBED-CC,
has become the radiotracer of choice for detection of
prostate cancer(PCa). However the diagnostic value of
this method is yet to be determined in different patient
populations. The aim of this study was to analyse the
diagnostic value of 68Ga-PSMA-ligand PET-CT in
comparison with conventional imaging(CI)& clinical
dataMaterials and Methods: Thirty-two consecutive pa-
tients (age median:72±14) suffering from PCa were re-
ferred to 68Ga-PSMA-ligand PET-CT for staging(6) and
restaging(26) purposes. Among these patients 6/32(19%)
had no therapy prior to PETscan wheras 4/32(12%) had
PSA relapse after radical prostatectomy, 5/32(16%) had
hormonotherapy, 5(16%) had chemotherapy plus
hormonotherapy and 12 (37%) had radiation therapy
plus hormonotherapy. All patients underwent whole
body 68Ga-PSMA-ligand PET/CT 1 hour after i.v in-
jection of 129 MBq 68Ga-PSMA-HBED-CC. Delayed
images were also taken from the site of involvement
after 2 hours. The results of PET-CT were compared
with CI(7 MRI and 25 contast enhanced CT) and cor-
relation with clinical factors like prostate-specific
antigen(PSA) level at the time of PET scan(PET-PSA),
PSA doubling time(DT),PSAvelocity, PSAslope and
Gleason score(GSC) were investigated. Tumor index(TI,
SUV meanx volume of malign lesions) that represents
whole body tumor burden was also calculated for each
patient.Results In 82% of the patients at least one le-
sion indicative of PCa was detected. Tumor detection
showed moderate positive correlation with PSAslope
and moderate negative correlation with DT(Spearman’s
rho correlation coefficient(SCC): 0,409,p:0,019 and -0,
402 p:0,017 respectively) whereas there was no statis-
tically significant correlation with PSAvelocity, GSC
and PET-PSA (p:0,7 and 0,2 and 0,27 respectively).
Altough not statistically significant there is a slight de-
crease in the meanSUVmax of malign lesions in the
delayed phase 23±31 vs 15,9±19(p:0,18). 68Ga-PSMA-
ligand PET-CT detected more malign lesions than CI.
Among the 78 malign lesions (prostate: 16/78 (20%),
bone metastases: 5/78 (6%) and lymph node 57/78
(73%)) not detected by CI lymph node metastases were
prominent with median SUVmax of 10±22 (range:2-96)
and median size of 8±2,5 (range:3-14). TI was positive-
ly correlated with detection rate of PET-CT, PET-PSA
and GSC (SCC: 0,643, 0,47 and 0,48 p:0,005 respec-
tively) but not correlated with DT, PSAvelocity and
PSAslope (p>0.05)Conclusion: 68Ga-PSMA-ligand
PET/CT can detect recurrent PCa in high number of
patients. Tumour detection was positively correlated
with PSAslope wheras negative with DT. Detection of
lymph node metastases was the most prominent superi-
ority of 68Ga-PSMA-ligand PET-CT over CI. TI is a
good representative of tumor burden and better corre-
lated with PET-PSA.
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Lung uptake of Fluorine-18 Fluoroethyl-Choline PET-CT
in patients with recurrent prostate cancer: a first
retrospective analysis.
D. A. Pizzuto1, C. Caldarella1, S. Annunziata1, F. P. Ieria1,
M. A. Isgrò2, A. Del Ciello3, V. Rufini1, A. Giordano1; 1In-
stitute of Nuclear Medicine, Department of Radiological Sci-
ences. Catholic University of Sacred Heart, Rome, ITALY,
2Institute of General Pathology. Catholic University of Sacred
Heart, Rome, ITALY, 3Institute of Radiology, Department of
Radiological Sciences. Catholic University of Sacred Heart,
Rome, ITALY.
Background/aim: Presence ofmetastatic spreading to the lungs
is a well known negative prognostic factor in patients with
prostate cancer (PC). Fluorine-18 Fluoroethyl-Choline (18F-
FeCh) PET-CT is a reliable diagnostic tool in restaging PC
patients with biochemical failure ongoing androgenic depriva-
tion therapy (ADT). Aim of the study is to assess the role of
18F-FeCh PET-CT in the evaluation of lung lesions occurring
in patients with recurrent PC and to explore the role of
Gleason-Score (GS) and common biochemical markers in
predicting metastatic spreading to the lungs. Materials and
Methods: We retrospectively evaluated the scans of 963 pa-
tients ongoing 18F-FeCh PET-CT for PC between May 2010
and July 2014. Inclusion criteria were: histologically con-
firmed diagnosis of PC; finding of lung lesion with 18F-
FeCh uptake. Data concerning GS at diagnosis, “trigger”
PSA (PSAtr), PSA doubling time (PSAdt), PSA velocity
(PSAvel) and ongoing ADT were collected when available.
PET-CT findings were confirmed by histology or follow-up
(FU) and classified as follows: inflammation, primary lung
cancer or metastases from tumour other than PC, and metas-
tases from PC. Results: The retrospective evaluation identified
28 patients with lung lesion with 18F-FeCh uptake; histology
or FU data were available in 22/28 patients (78.5%). Inflam-
mation, primary lung cancer or metastases from tumour other
than PC, and metastases from PC were found in 4 (18.2%), 4
(18.2%) and 14 (63.6%) patients, respectively. PSAdt was
found to be significantly (p=0.029) shorter in patients with
lung metastases from PC (median PSAdt 1.7 months, inter-
quartile range [IQR] 1.5 - 4.1 months) than in patients without
lung PC relapse (median PSAdt 6.7 months, IQR 3.9 - 7.8);
PSAvel was found to be significantly (p=0.019) higher in pa-
tients with lung metastases from PC (median PSAvel 3.2 ng/
ml/month, IQR 0.65 - 6.65 ng/ml/month) than in patients with-
out lung PC relapse (median PSAvel 0.3 ng/ml/month, IQR
0.2 - 0.5 ng/ml/month). Patients with evidence of lung metas-
tases from PC had significantly (p=0.008) higher GS at diag-
nosis than patients with primary lung cancer or metastases
from tumour other than PC, and inflammation. No significant
differences were found in PSAtr between the three groups of
patients. Conclusion: As far as we know this is the first evi-
dence that 18F-FECh PET-CT is a useful tool in detection of
lung metastases in patients with PC. GS at diagnosis and bio-
chemical markers are good predictive factors of metastatic
spreading to the lungs.
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18F-FACBC PET/CT for the detection of recurrence
in patients radically treated for prostate cancer
with biochemical relapse: preliminary accuracy data.
L. Zanoni1, R. Schiavina2, C. Pultrone2, C. Pettinato1, C.
Fonti1, S. Semini1, S. Boschi1, M. Ferrari3, P. Rigatti3, E.
Brunocilla2, G. Martorana2, S. Fanti1, C. Nanni1; 1Nuclear
Medicine, University Hospital Sant’Orsola-Malpighi, Bolo-
gna, ITALY, 2Urology, University Hospital Sant’Orsola-Mal-
pighi, Bologna, ITALY, 3Urology, Italian Institute for
auxology, Capitanio Hospital, Milan, ITALY.
AIM: To compare the accuracy of 18F-FACBC and 11C-
Choline PET/CT in patients (pts) radically treated for prostate
cancer (PCa) presenting with biochemical relapse (BR). MA-
TERIALS AND METHODS: 100 pts, radically treated for
PCa and presenting with rising PSA, were consecutively and
prospectively enrolled. 11 pts dropped-out. 89 pts were includ-
ed in the analysis: all pts with BR after radical-prostatectomy
(RP) (at least 3 months before), 11C-Choline and 18F-FACBC
PET/CT performed within one week, out of hormonal therapy
at the moment of the scans. SUV max and Target to Back-
ground Ratio (TBR), were used to aid the visual analysis. TBR
≥1,5 was considered significant. Sensitivity, specificity,
positive-predictive-value (PPV), negative-predictive-value
(NPV), accuracy were calculated for both tracers; urological
follow-up of at least 1 year (PSATrend, imaging, and when
possible, histo-pathology) was considered as standard of ref-
erence. RESULTS: Pts characteristics (89 pts).Age: mean 69 y,
range: 55-83. PSATrigger: mean 2,95;median 1,48;range 0,20-
20,72;sd 3,9. PSAdoubling-time (months): 74/89 pts;mean 8,
5;median 3,9;range 0,4-120,2;sd 16,2;PSAVelocity (ng/ml/
yr):mean 5;median 2;range 0-49,2;sd 8,1 (available in 74/89
pts).Treatment after RP: 23 only HT; 12 only RT; 28 RT+HT.
GleasonScore: 12 pts ≤6; 33 pts 7; 32 pts 8-10; 12 pts not
available (n/a). TNM: 1 T1c, 17 T2, 59 T3, 27 N0, 39 N1,
11 Nx (12 n/a). Patient-based analysis.51 pts resulted negative
and 25 positive with both tracers, 8 positive with FACBC but
negative with Choline, 5 positive with Choline but negative
with FACBC. Overall 49 pts turned out false negative(FN), 2
true-negative(TN), 24 true-positive(TP) and none false-
positive(FP) with both tracer; 1 FN Choline but FP FACBC
(lymph-node, LN); 7 FN Choline but TP FACBC (5 LN; 1
BONE; 1 local relapse-LR); 1 FP Choline (LN) but TP
FACBC (LR); 2 FP Choline (1 LN; 1 LR) but FN FACBC; 3
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TP Choline (2 LN; 1 BONE) but FN FACBC. The sensitivity
resulted 32% with Choline versus (vs) 37% with FACBC,
specificity 40 vs 37, accuracy 33 vs 38, VPP 90 vs 97, VPN
3 vs 4. Psa-analysis. When pts were divided by PSA level, TP
(%) were generally superior with FACBC compared to Cho-
line: 28 pts <1 (ng/ml): 21% vs 14%; 28 pts 1≤x<2: 29% with
both tracers; 11 pts 2≤x<3: 45% vs 36%; 22 pts ≥3: 59% vs
50%. CONCLUSION: FACBC can be considered an alterna-
tive tracer of Choline in the setting of pts with BR after RP.
Further subgroup/region/semi-quantitative analyses are ongo-
ing to confirm these preliminary results.
P710
18F-Choline PET/CT and prostatic gland/fossae
recurrence: what can help to identify the local recurrence
of disease?
L. Evangelista1, M. Cimitan2, M. Hodolic3, T. Baseric2, A.
Cervino1, J. Fettich3, G. Saladini1, E. Borsatti2; 1Istituto
Oncologico Veneto I.R.C.C.S., PADOVA, ITALY, 2IRCCS
National Cancer Institute (CRO), Aviano, ITALY, 3University
Medical Center Ljubljana, Ljubljana, SLOVENIA.
Purpose. We aimed to determine when 18F-Choline
PET/CT can truly identify the presence of local prostate
recurrence of disease.Materials and methods. From a
multicenter collection of 1030 patients who underwent
PET/CT with 18F-Choline for the recurrence of disease,
we selected only with a positive 18F-Choline uptake in
prostatic gland or prostatic fossae. One-hundred thirty-
one patients (12.7%) had a positive uptake of 18F-
Choline in the prostatic gland/fossae. Median age was
72 years (range: 48-87 years) and the median PSA level
at the time of PET/CT scan was 4.41 ng/mL (0.22-18.13
ng/mL). Moreover, 45 patients (34.4%) had a gleason
score (GS) >7 and the residual subjects had a GS≤7.
The assessment of true or false positive findings was
verified by magnetic resonance imaging and/or biopsy.
A chi-square test and a Z Kolmogorov-Smirnov test
were used to assess the correlation between clinical var-
iables and PET/CT findings.Results. Positive findings at
PET/CT were confirmed by MRI and/or biopsy in 75
cases (57%). In particular, PET/CT resulted truly posi-
tive (TP) in 59 patients (79%) and falsely positive (FP)
in 16 subjects (21%). The median value of PSA at the
time of PET/CT scan was higher in TP as compared to
FP, although not statistically significant (4.76 vs. 3.04
ng/mL, p= 0.852). Similarly, median age, GS categories
and the type of therapy was similar between two groups
(p= 0.688, 0.689 and 0.427, respectively). However,
matching GS categories and PSA values, we found that
the rates of TP were higher in patients with a PSA>2
ng/mL independently from the GS (ranged between 74
and 92%). Conversely, the rates of FP were ranged be-
tween 50 and 65% in patients with a PSA≤2 ng/mL,
especially in case of GS≤7, but it was around 25% in
those with a GS>7 and PSA>2ng/mL.Conclusion. PET/
CT with 18F-Choline has some limitation for the evalu-
ation of prostatic gland/fossae, due to the physiological
biodistribution of the radiopharmaceutical agent. Howev-
er, in in 70-90% of patients with a PSA level>2 ng/mL,
independently from the GS, a focal 18F-Choline uptake
could be compatible with a local recurrence.
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Sentinel Node in Endometrial Cancer. Our Experience
C. Escabias del Pozo, I. Santos Gomez, M. Diestro Tejeda, S.
Rodado Marina, M. Coronado Poggio, M. Orduña Diez, M.
Marin Ferrer; Hospital Universitario La Paz, Madrid, SPAIN.
AIM: Detection and validation of sentinel lymph node (SLN)
in patients with early stage endometrial cancer in our hospital.
MATERIALS AND METHODS: Prospective study from
February 2012 to October 2014, 58 patients (p) with mean
age 66 (40-87), diagnosed of endometrial cáncer (50p
endometrioid, 2p clear cell, 3p serous, 3p carcinosarcoma)
FIGO (Federation of Gynecology and Obstetrics) stage I - II.
Four cervical injections of 1 ml technetium colloid (37 MBq
each) at 3 and 9 o´clock positions (superficial and deep) were
given the day before surgery. Scintigraphic images were ob-
tained 30 min and 2 hours after the injections and SPECT-CT
was obtained after scintigraphic images. Patent blue was
injected intracervically after induction of anesthesia and before
surgery. SLN were analysed by OSNA (One Step Nucleic
Acid Amplification). False negative was defined as positive
non-SLN with negative SLN. RESULTS: No complications
ocurred after injection of technetium colloid. The total numer
of SLN visualised was 100. SLN scintigraphic detection rate
was 98%. Paraortic SLN were detected in 1p (2%). The SLN
was bilateral in 34p (59%). No anaphylactic reactions were
noted after patient blue injection. SLN were removed
laparoscopically in all patients. SLN was positive in 7p
(12%). There were 3 falses negatives (5%), 2p in paraortic área
and 1p in pelvic área. CONCLUSION: The cervical injection
is associated with a high SLN detection rate and low detection
in paraortic área. Larger prospective series are needed before
considering its incorporation in the standard management of
endometrial cáncer.
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Dual-time FDG-PET/CT imaging in suspected ovarian
cancer
M. H. Vilstrup1, G. Neumann2, J. T. Asmussen3, O. Gerke1,
A. Alavi4, P. Høilund-Carlsen1; 1Department of Nuclear
Medicine, Odense University Hospital, Odense C, DEN-
MARK, 2Department of Obstetrics and Gynecology, Odense
University Hospital, Odense C, DENMARK, 3Department of
Radiology, Odense University Hospital, Odense C, DEN-
MARK, 4Division of Nuclear Medicine, Department of Radi-
ology, University of Pennsylvania, Philadelphia, PA, UNITED
STATES.
Aims: The clinical value of 18F-fluorodeoxyglycose (FDG)
positron emission tomography (PET)/computed tomography
(CT) in ovarian cancer diagnosis and/or staging has not yet
been established. PET/CT has shown improved staging accu-
racy but also significant overlap in standardized uptake value
(SUVmax) in benign and malignant lesions. We wanted to
investigate if dual-time PET/CT imaging could increase the
diagnostic accuracy of ovarian cancer FDG-PET/CT. Mate-
rials and methods: Thirty-four patients with suspected ovarian
cancer underwent preoperative 1h and 3h 18F-FDG-PET/CT
including diagnostic CT with contrast (immediately after the
3h PET). The maximum standardized uptake value (SUVmax)
for both time points (SUVmax1 and SUVmax3) was deter-
mined, and the retention index (RI) was calculated as
(SUVmax3 - SUVmax1)/SUVmax1. Histopathology was
used as reference. Results: Fourteen had ovarian cancer (9
serous, 1 mucinous, 1 endometrioid and 3 clear cell carcino-
ma). Five patient cases were borderline (3 serous, 2 mucin-
ous). Fourteen had benign lesions (fibroma, cystadenoma and
endometriosis) or other non-ovarian malignancies (1 colon
cancer, 1 endometrial cancer, 1 uterine sarcoma, and 1 mar-
ginal zone lymphoma). One patient was diagnosed with both
ovarian cancer and a synchronous colon cancer. PET/CTclear-
ly differentiated betweenmalignant and benign ovarian lesions
in both 1h and 3h PET. Thus, the median SUVmax1 in malig-
nancy was 13.3 (range 4.6-22.8; [95 % CI 11.5-16.6]), the
median SUVmax3 was 21.4 (5.5-29.7; [17.5-24.3]), and the
median RI was 0.46 (0.15-1.16; [0.35-0.66]) compared to the
following median values in benign lesions: SUVmax1 3.2
(range 1.6-8.7; [2.6-4.9]), SUVmax3 4.7 (1.3-9.3; [3.2-5.9]),
and RI 0.11 (-0.48-1.00; [0.00-0.51]). The mucinous carcino-
ma had the lowest SUVmax1/SUVmax3/RI values (4.6/5.5/
0.2) among the cancers. Borderline lesions had still lower me-
dian values: SUVmax1 3.1 (range:1.3-6.1; [1.6-4.9]),
SUVmax3 4.2 (1.5-7.8; [1.6-4.9]), and RI 0.28 (0.15-1.2;
[0.03-0.81]) overlapping the (above listed) values in benign
lesions. Conclusion: SUVmax1, SUVmax3 and RI values ob-
tained by 18F-FDG PET/CT in our material of suspected ovar-
ian cancers clearly differentiated malignant from benign
ovarian lesions at both 1h and 3h imaging. Though, for RI to
a lesser degree than SUV measurements. However, SUVmax
and RI values could not differentiate borderline from benign
lesions. Adding a 3h PET/CT did not seem to add further
diagnostic information in our small group of patients.
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Neoadjuvant treatment in advanced cervical cancer: can
18F-FDG PET/CT be predictive of response?
P. Mapelli1, F. Fallanca1, A. Bergamini2, A. Dell'Acqua2, G.
Mangili2, E. Rabaiotti2, E. Incerti1, M. Candiani2, L.
Gianolli1, M. Picchio1; 1Nuclear Medicine Unit, IRCCS
San Raffaele Scientific Institute, Milano, ITALY, 2Gynecolo-
gy Department, San Raffaele Scientific Institute, Milano,
ITALY.
Aim. The aim of the present study was to evaluate the possible
predictive role of 18F-FDG PET/CT in predicting response to
neoadjuvant treatment in patients with advanced cervical can-
cer (CC). Materials and Methods. This study included 9 pa-
tients with advanced cervical cancer who underwent to 18F-
FDG PET/CT before and after neoadjuvant treatment (chemo-
therapy: n=5; chemoradiotherapy: n=4). Semiquantitative and
quantitative measurements have been performed to assess
treatment response; specifically, maximum standardized up-
take value (SUVmax) and metabolic tumour volume with a
threshold of 60 (MTV60) of the primary tumours were mea-
sured on baseline and post-treatment scan, to investigate their
possible predictive role regarding therapy response. Results.
The median age at baseline PET/CT was 47 years (range: 35-
68) and the median time interval between baseline and post
neoadjuvant treatment scans was 2.7 months (range: 1.7-8).
Comparing the baseline and the post treatment scans, 6/9 pa-
tients showed response to therapy, while 4/9 patients showed
stable disease or progression after neoadjuvant treatment. The
mean and median SUVmax of the primary tumour were 15.6
and 12.2 (range 3.7-35.5) and 7.9 and 11.3 (range 2.8-4.1) for
the baseline and post-treatment scan, respectively. Considering
all patients, the average percentage change in SUV max be-
tween baseline and post treatment scan was 21.9 (range: -
102.7 - 79.4). Interestingly, baseline mean and median
SUVmax of the primary tumour were higher (19.3 and
19.15; range: 3.7-35.5) in patients that experienced no re-
sponse or progression after neoadjuvant treatment compared
to those patients who showed response to treatment (13.1 and
11.3; range: 8.3-25.3). The mean and median MTV60 (mm3)
of the primary tumour were 14 and 10.2 (range 3.1-56.4) and
7.6 and 4.7 (range 0.7-34.8) for the baseline and post-
treatment scan, respectively. Considering all patients, the av-
erage percentage change inMTV60 between baseline and post
treatment scan was 22.2 (range: -454.4 - 98.6). Strikingly,
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baseline mean and median MTV60 of the primary tumour
were lower (9.05 and 8.95; range: 3.1-15.2) in patients that
experienced no response or progression after neoadjuvant
treatment compared to those patients who showed response
to treatment (17.3 and 10.2; range: 5.8-56.4). Conclusion. Al-
though not reaching statistical significance, probably due to
the low number of patients included in the present cohort,
the reported results of this preliminary study should be taken
into account because the strong difference of SUVmax values
and MTV60 between responders and non-responders patients
which may be relevant for patients’ treatment decision-mak-
ing, if confirmed in larger populations.
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Is multimodality, multiparametric MRI complementary
or superfluous to PET-CT in the management of Pelvic
malignancies?
S. Raja1,2, M. S. Qureshi2, S. George3, A. S. Aldosary2;
1Baylor College of Medicine, Bellaire, TX, UNITED
STATES, 2KFMC, Riyadh, SAUDI ARABIA, 3Johns Hop-
kins Aramco Healthcare, Dhahran, SAUDI ARABIA.
Contemporary management of common pelvic malignancies
(pelMalig) demands a multimodality (CT, MR, US) imaging
approach to document tumor grade, stage and metastatic
spread. However, conventional MR [(cMR): T1-W, T2-W
etc.] is limited in grade prediction, evaluation of loco-
regional and distant metastasis. PET is recommended for post
therapeutic evaluation and restaging. Recently, advanced MR
(aMR) especially Diffusion Weighted Imaging (DWI) and
ADC mapping is being utilized as a complementary tool to
cMR. We explored the complementary roles of multimodality
FDG-PET and multiparametric MR in the workup of
pelMalig.Methods: On retrospective chart review, we identi-
fied 20 pts with suspected pelMalig having concurrent (+/3
months) FDG-PET and aMR. The pt. demographics were
[male=5, female=15; mean age=51 (range=27-80 yrs)]. All
PETand MRwere acquired with routinely accepted protocols.
PET and MR images were qualitatively reviewed by experi-
enced physicians. SUVand ADC were obtained by ROI anal-
ysis of coregistered FDG-PETand ADC maps.Results: All le-
sions but one, were concordantly pos. (18/20) or neg. (2/20) on
PET and MR, in 1 pt. both were indeterminate. MR was pos.
for pelvic lymph nodes in 14/20 pts, while only 7/14 were pos.
by PET; in 6 pts. both were concordantly neg. While MR was
suggestive of lympho-vascular space (mesorectal fat and
parametrium) involvement in 7/20 pts., only 1/20 was pos.
on PET. PET and MR were helpful in confirming suspicious
lesions on MR (2) and PET (2). In 2 pts. MR was helpful in
precise localization of hypermetabolic foci noted on PET-CT,
while PET demonstrated more extensive lymphadenopathy
outside the MR FOV in 4 pts. Correlation of lesional SUVmax
and minADC revealed a modest negative correlation (higher
the SUV lower the ADC) , bu t no t s t a t i s t i ca l ly
significant.Discussion: Our study is limited by a small sample
size, and includes a mixture of pelvic malignancies. FDG-PET
as compared to aMR was not helpful in evaluating the
lymphovascular space. MR was superior to PET for pelvic
lateral wall lymphadenopathy while PET detected more exten-
sive metastatic lymphadenopathy. Though not strong, a neg.
trend of higher the SUVon PET lower the ADC on MR was
observed.Conclusion: Concurrent aMR and PETappears to be
complementary and not superfluous, providing incremental
value. Prospective analysis in a larger series is warranted.
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Impact of PET-CT on the follow-up of patients
with cervical and ovarian cancers
S. Carrilho Vaz, Â. Silva, R. Sousa, T. C. Ferreira, P. Ratão,
A. Daniel, I. P. Carvalho, F. Brandão, L. Salgado; Portuguese
Institute of Oncology – Lisbon Center, Lisbon, PORTUGAL.
AIM: To evaluate the usefulness of PET-CT in re-staging and
follow-up of patients (pts) with cervical and ovarian cancers
after primary treatment.MATERIALS AND METHODS: A
single-center retrospective study was performed. All the pts
with cervical (n=17) or ovarian (n=19) cancer who performed
18F-FDG PET-CT in our department between January-
December 2014 were included. The mean age was 59 years
(22-81).The histology of cervical cancers was: squamous cell
carcinomas 12/17 (71%); adenocarcinoma 4/17 (23%) and
glassy cell 1/17 (6%). According to FIGO (7th edition), pts
staging was: stage I - 4; II - 10 and III - 3. Considering ovarian
cancer (n=19), the histology was serous 15/19 (79%) and bor-
derline tumor 4/19 (21%) and the FIGO staging was I - 3; II -
6; III - 5 and IV - 5.The mean follow-up was 8 months.We
p r e s e n t t h e p r e l im i n a r y r e s u l t s o f o n e y e a r
study.RESULTSThe reasons for asking a PET-CT in pts with
cervical cancer was suspicion of loco-regional recurrence -
9/17 or distant metastasis - 8/17. In pts with ovarian cancer
the reasons were increased tumor markers - 8/19, suspicion of
metastases - 10/19 or chemotherapy response evaluation -
1/19.Considering PET-CT results of pts with cervical cancer
we verified that it changed staging in 6/17 (35%): 12%
upstaging and 23% downstaging, with consequent treatment
modification. In pts with ovarian cancer, we found that PET-
CT changed staging in 6/19 (32%): 11% upstaging and 21%
downstaging, therefore, it had impact on therapeutic decision.
Furthermore, PET-CT confirmed suspected distant metastases
in 1 pt with cervical cancer and in 3 pts with ovarian cancer,
confirming stage IV disease.PET-CT identified polimetastatic
unknown disease in 2 pts with cervical cancer (included in
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upstaged pts) and in 7 pts with ovarian cancer (not changing
stage in 3 pts, upstaging in 2 pts and confirming suspected
metastases in other 2 pts).In 2 pts with ovarian cancer, PET-
CT identified focal breast uptake that was confirmed as breast
carcinoma.The false positive rate was 6% in the examinations
of pts with cervical cancer and 11% in pts with ovarian
cancer.CONCLUSION: Although the analyzed group is small,
this preliminary results show that PET-CT is useful in re-
staging and follow-up of pts with cervical and ovarian cancers.
It changed staging and had impact on therapeutic decision in
32-35% of cases.PET-CT has an important role when loco-
regional disease recurrence or distant metastases are
suspected.
P717
18F-FDG PET-CT in Ovarian Cancer: Can We Identify
the More Aggressive Histologies?
B. González García1, M. E. Bellón Guardia2, M. P. Talavera
Rubio2, A. M. Palomar Muñoz2, A. M. García Vicente2, G.
A. Jiménez Londoño2, J. M. Cordero García2, V. M. Poblete
García2, A. M. Soriano Castrejón2; 1HOSPITAL GENERAL
UNIVERSITARIO CIUDAD REAL, Ciudad Real, SPAIN,
2SESCAM, Ciudad Real, SPAIN.
OBJECTIVE: Determine the relationship between SUVmax
and the histological type, as well as with main clinico-
pathologic and biochemical prognostic factors in ovarian
cancer.MATERIALS AND METHODS:This is a retrospec-
tive study that included patients with epithelial ovarian cancer,
who underwent pre-treatment 18F-FDG PET-CT study for
staging, according to standard protocol.In all of them, the
SUVmax of the primary lesion was determined.Ovarian carci-
nomas were classified according to the hypothesised mode of
carcinogenesis and molecular characteristics into histopatho-
logical type I (indolent) or II (aggressive), and depending on
the final stage as early (I-II) or advanced (III-IV)
disease.Finally, we investigated the relationship between
SUVmax and the histopathological type, the final stage, and
the level of CA125 at diagnosis.RESULTS:Finally, 31 patients
with epithelial ovarian cancer were included, with a mean age
of 63,1 years (range: 33-85).The mean SUVmax of the prima-
ry lesion was 9.08 (range: 2.4-23.7).With respect to histopath-
ological type, 12 patients (38.7%) had type I neoplasms, and
the rest (19 patients) had type II ovarian cancer. The high-
grade serous carcinoma was the most prevalent histology
(45.2%), followed by endometrioid and clear cell carcinoma
carcinoma (19.4% and16.1%, respectively).The average
SUVmax in type I tumours was lower than in type II (6.66
and 10.77, respectively, p = 0.035). The value of SUVmax
with the best statistical parameters to detect type II neoplasms
was 7.65 (sensitivity 73.7%, specificity 75%; AUC 0.768, p =
0.013). Regarding the final stage, 9 patients had early stages,
while the majority (22/31: 71%) were in advanced stages. The
mean SUVmax in patients with early disease was lower than in
advanced (7.99 vs 9.52), although without statistical
significance.CA125 was abnormal in 26/31 patients (83.9%),
with an average of 345.7. The average was slightly higher in
advanced stages. No correlation between SUVmax and the
level of CA125 was found. CONCLUSION: Pre-treatment
18F-FDG PET-CT identify the more aggressive ovarian cancer
histologies (type II), which could have important implications
for prognosis and treatment of patients with epithelial ovarian
cancer.
P718
Accuracy of 18F-FDG-PET/CT in the Assessment
of Incidental Suspicious Ovarian Masses. Advantages
and Limitations of a Powerful Imaging Technique.
A. Marí-Hualde1, D. Zamudio1, P. Pilkinton1, T.
Castellanos2, S. Alonso2, L. Chiva2, J. Alonso1; 1ITSS.
MD ANDERSON CANCER CENTER MADRID, Madrid,
SPAIN, 2MD ANDERSON CANCER CENTER MADRID,
Madrid, SPAIN.
BACKGROUND: ovarian cancer (OC) is the second most
common malignancy of the female genital system, being the
leading cause of gynaecologic cancer mortality due to delay in
the diagnosis.AIM: To evaluate the accuracy of 18F-FDG-
PET / CT (PET/CT) in the preoperative characterization of
undetermined ovarian masses.PATIENTS AND METHODS:
From January 2012 to February 2014, 29 consecutive patients
with non simple cystic incidentally discovered ovarian masses
in other imaging techniques were recluted. A PET/CT was
done to characterize them and/or to perform a possible initial
staging in the cases of malignancy. A single reader classified
all the lesions as malignant of benign. The results of PET/CT
were compared with the histologic specimens obtained after
surgery in the cases where the PET/CTwas abnormal and / or
follow up with serial imaging techniques (at least 1 year) . In
the cases were the results were consistent with OC, FIGO
staging was also performed. Sensitivity (S), Specificity (SP),
Positive predictive value and (PPV) and Negative predictive
Value (NPV) of PET/CTwere calculated using Diagnosis test
calculator. RESULTS: 22/29 cases PET / CTwere classified as
malignant (75.86%), presenting 2 False Positive (mature tera-
toma and endometriosic cyst). 7/29p were classified as benign
(29.14%), with 1 false negative lesion (a borderline clear cell
carcinoma). The accuracy of PET/CT was S: 95.2% (IC
95%77.3-99.2%), SP: 75% (IC 95% 40.9-92.9%), PPV:
89.4% (IC 95% 71.8-96.6%) and NPV: 87.6% (IC 95%
50.1-98%).In 21/29 cases (72.41%) (mean age: 51.9 years)
tumour pathology was confirmed after surgery: 1 intestinal
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GIST, 2 fallopian tube carcinomas and 18 ovarian carcinomas.
PET/CT classified gynaecologic tumours according to FIGO
as: 8p(40%) stage I (SUVmáx:6.4), 2p(10%) stage II
(SUVmáx:5.9), 3p(15%) stage III (SUVmáx: 15.9 ) and
7p(35%) stage IV(SUVmáx:12.2) . These findings were histo-
logically confirmed: 16 serous adenocarcinomas (80%), 2
clear cell carcinomas (10%), 1 mucinous carcinoma and
1endometrioid carcinoma. In 8/29p (mean age: 40.9 years
and SUVmáx:3.2) malignancy was ruled out by surgery or
follow up: 4 cystic endometriosis, 2 mature teratomas and 2
simple cysts. CONCLUSION: PET/CT has an excellent sen-
sitivity and a moderate specificity for characterization of ovar-
ian lesions, being also a useful tool for initial OC staging.
P719
F-18 FDG PET-CT in restaging of patients with cervical
cancer: - experience at a tertiary care hospital
T. K. Jain, R. K. Basher, B. R. Mittal, J. Shukla, A.
Bhattacharya, V. Suri, N. Kumar, S. Kumar; PGIMER, Chan-
digarh, INDIA, Chandigarh, INDIA, INDIA.
Objectives: To evaluate the diagnostic performance of contract
enhanced F-18 FDG PET/CT in restaging of cervical carcino-
ma. Methods: A retrospective analysis of histopathological
proven female patients of carcinoma cervix (age range 32 -
82 years; mean age 51.7 years) was done. All the patients
had been treated previously (surgery, radiotherapy or chemo-
therapy) and referred for F-18 FDG PET/CT to rule out resid-
ual or recurrent disease. On FDG PET any abnormal tracer
uptake with corresponding CECT lesion were taken as posi-
tive. Histopathological examination and clinical or imaging
follow up were taken as gold standard. Results: Of the 140
patients, F-18 FDGPET/CT detected abnormal FDG uptake in
95 patients. Uptake at the primary site was detected in 45
(32%) patients and only metastatic lesions in 50(35.7%) pa-
tients. Out of 45 patients with primary lesions, 6 had only
regional lymph nodes ,7 only had distant lesions, 17 had both
regional and distant lesions and remaining had only primary
lesion. On lesion based analyses in 64 patients with distant
metastases, lymph nodes and peritoneal deposits, lung, liver,
skeleton, adrenal and muscle metastases were noted in 41, 20,
7, 38, 2 and 1 patients respectively. Additionally we also de-
tected metachronous primaries in 8 patients and confirmed on
histopathology (lung-4, Rectum-2,breast,lymphoma -one
each). We found F-18 FDG PET/CT sensitivity, specificity ,
PPV and NPV 96.4%, 67.3%, 81.6% and 92.5% respectively
for residual/recurrence detection (P <0.05). There was no cor-
relation between SUV max and patient survival (Spearman's
coefficient rank correlation). Conclusions: We concluded that
F-18 FDGPET/CT had high diagnostic accuracy for suspected
residual/recurrent disease in cervical cancer patients and also
useful in detection of additional metachronous second
primary.
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ΔSUV Reduction versus Deauville Visual criteria
in Follicular Lymphoma evaluated with 18F-FGD
PET/CT
M. COZAR SANTIAGO1, J. GARCIA GARZON2, R.
SANZ LLORENS1, M. MORAGAS SOLANES2, C.
VILLEGAS CARDOS3, M. SANCHEZ DELGADO3, J.
AGUILAR BARRIOS1, R. SANCHEZ JURADO1, J.
FERRER REBOLLEDA1 ; 1ERESA-GENERAL
UNIVERSITARY HOSPITAL, VALENCIA, SPAIN,
2CETIR-ESPLUGUES PET/CT UNIT, BARCELONA,
SPAIN, 3HEMATOLOGY GENERAL UNIVERSITARY
HOSPITAL, VALENCIA, SPAIN.
AIM: in order to improve disease characterization and out-
comes in Hodgkin and diffuse large cell B Lymphoma, a
five-point scale to grade response is being revising recently
in different workshops; at this point the objective of our work
was to assess different methods (visual and semi quantitative)
to evaluate response and prognosis in patients with follicular
lymphomaMATERIAL ANDMETHODS: we have evaluated
retrospectively 35 patients (18 men and 17 women with an
average age of 63 years) with follicular lymphoma (bcl-2 pos-
itive; Ki67>20%).All patients underwent a baseline PET/CT
(bPET) and an interim PET/CT (iPET) after first two-three
cycles of chemotherapy. We used two methods of evaluation
for both PET/CT: a visual method, using the Deauville criteria
(5 score scale from 1 to 5; PET/CT positivity for score for
score >4; liver treshhold) and a semiquantitative method (mea-
suring SUV max in the most metabolic lesion of bPET and
IPET).We calculated the concordance between these two eval-
uation methods according to the Kappa statistic and ROC
analysis to asses the value with the semiquantitative
method.We performed a follow up during fourteen months
and evaluated survival curves in ΔSUV REDUCTION and
Deauville score these the two valuation methods in using
Kaplan‐Meier plots comparing them with the log‐rank
test.RESULTS: with the visual analysis we found a ≥65%
SUV max reduction (ΔSUVmax = baseline SUVmax ‐ inter-
im SUVmax/baseline SUVmax) in patients with favourable
outcome with an area under the curve (AUC) of 0.875 (NPV:
83.30%).In case of Deauville criteria the area under de curve
was not statistically significant and showed no potential role in
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the discrimination of patients with favourable outcome.Our
kappa index (K: 0.273 p <0.05) showed a low concordance
between the two methods of evaluation.Log‐rank test in the
Kaplan‐Meier plots showed statistically significant in
predicting outcome only with the semiquantitative analysis
(X2 : 8 . 0 4 , p : 0 . 0 0 5 ) b u t n o t w i t h De auv i l l e
criteria.CONCLUSIONS: The use of iPET/CT in patients with
follicular lymphoma with a semiquantitative analysis (ΔSUV
REDUCTION) seems to be superior to visual analysis (Deau-
ville criteria) to identify patients with favourable outcome and
seems to have more predictive value in the follow up
P721
Could the ratio between lesion and liver SUVmax (rPET)
be a prognostic factor in patients with Hodgkin
Lymphoma undergoing interim FDG-PET/CT? A
retrospective study
S. ANNUNZIATA1, A. Cuccaro2, M. Calcagni1, L.
Indovina3, S. Hohaus2, A. Giordano1, V. Rufini1; 1Institute
of Nuclear Medicine - Università Cattolica del Sacro Cuore,
Rome, ITALY, 2Institute of Hematology - Università Cattolica
del Sacro Cuore, Rome, ITALY, 3Institute of Medical Physics
- Università Cattolica del Sacro Cuore, Rome, ITALY.
Aim. Interim FDG-PET/CT after first-line ABVD is a strong
prognostic factor in patients with Hodgkin Lymphoma (HL).
Recent studies demonstrated that interim target lesion
SUVmax has a prognostic significance in these patients. Re-
cently, the ratio between target lesion and liver SUV has been
proposed, to convert visual qualitative scale as 5-point Deau-
ville Score (5p-DS) in a continuous semi-quantitative scale.
This ratio allows to evaluate interim FDG-PET/CT through a
well-determined semi-quantitative based cut-point, and it is
not dependent from administered activity and body weight.
Aim of this study is to evaluate the prognostic role of the ratio
between target lesion and liver SUVmax (rPET) in patients
with HL undergoing interim FDG-PET/CT. Methods. Sixty-
seven patients with HL undergoing interim FDG-PET/CTafter
two courses of ABVD were evaluated. Interim FDG-PET/CT
visual interpretation was based on 5p-DS (score 4 and 5 con-
sidered as positive); we considered as semi-quantitative pa-
rameters interim target lesion SUVmax, liver SUVmax and
rPET. We defined rPET as the ratio between target lesion
SUVmax and liver SUVmax in each interim FDG-PET/CT
exam. Primary endpoint was event-free survival (EFS). We
analyzed 5p-DS, target lesion SUVmax and rPET as prognos-
tic factors. The receiver operating characteristic (ROC) ap-
proach was applied to identify the optimal cut-point of rPET
with respect to outcome, to calculate accuracy values and to
define the area under the curve (AUC). Results. Interim FDG-
PET/CTwas positive by using 5p-DS in 11/67 patients (16%).
Median target lesion SUVmax was 1.9 (range 0-15.7), median
liver SUVmax 2.7 (range 1.4-4.2), median rPET 0.66 (range 0-
6.54). To predict EFS, interim 5p-DS FDG-PET/CTwas stron-
ger than rPET and target lesion SUVmax as prognostic factor,
with an HR of 9.3 (SE 4.87, 95% CI 3.3-26.0, p<0.001), 4.9
(SE 2.09, 95% CI 2.1-11.3, p<0.001) and 1.5 (SE 0.17, 95%
CI 1.2-1.9, p<0.001), respectively. ROC analysis for rPET as
prognostic factor showed an AUC of 0.81, with an optimal
rPET cut-point of 1.14 (specificity 94.6%, sensitivity 53.3%).
At 2 years, patients with positive 5p-DS FDG-PET/CT had an
EFS of 27.3%, patients with rPET>1.14 of 15.3%. Conclu-
sion. rPET is a prognostic factor in patients with HL undergo-
ing interim FDG-PET/CT. 5p-DS FDG-PET/CT has con-
firmed to be the strongest prognostic factor. Nevertheless, pa-
tients with rPET>1.14 have a worse prognosis than patients
with positive 5p-DS. Therefore, rPET could be useful to avoid
unnecessary treatment intensification in patients with HL un-
dergoing interim FDG-PET/CT.
P722
Utility of 18F-FDG-PET/CT for bone assessment
in the initial staging of patients diagnosed of Hodgkin’s
lymphoma.
M. Fernández Rodríguez, E. Rodríguez Pelayo, M. L.
Castillejos Rodríguez, C. Sandoval Moreno, M. A. Balsa Bret-
ón, M. P. García Alonso, C. Paniagua Correa, A. Ortega Valle,
F. J. Penín González; Hospital Universitario de Getafe, Getafe,
SPAIN.
Aim: To confirm if 18-F-FDG-PET/CT in the staging of pa-
tients with Hodgkin’s lymphoma (HL) is useful for bone eval-
uation in order to avoid unnecessary bone marrow biopsies
(BMB). Materials and methods: We have retrospectively
reviewed newly diagnosed patients with Hodgkin’s lymphoma
from may/09 to feb/15. A total of 19 patients with 18F-FDG-
PET/CT and BMB at diagnosis. They had a mean age of 48 +
29 years (10 men and 9 women).We have reviewed clinical (B
symptoms at diagnosis) and analytical factors (presence of
anemia and/or increased levels of LDH). We classified PET/
CT results: 1) negative-N (no bone uptake), 2) focal positive-
FP (focal bone uptake) and 3) diffuse positive-DP (diffuse
bone uptake). BMB were performed on left iliac crest and in
2 cases it was repeated in other locations referred in the PET/
CT. It was considered to be positive when there was tumoral
involvement and negative if there was not. Results: 8/19 pa-
tients (42%) had negative PET/CT and negative BMB (NPV
100%). One of them had B symptoms, anemia and increased
LDH; two patients had B symptoms and another one had ane-
mia. 4/19 patients (21%) had FP uptake, two of them had
positive BMB and two, negative one. In these last 2 cases
the BMB was repeated on the bone locations referred in the
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PET/CT, and the result was positive. PPV was 100%. 7/19
patients (37%) had DP uptake: 6 negative BMB and another
one, positive BMB. Conclusion: Although our sample is
small, the results are similar to the published literature: BMB
can be avoided in patients with negative PET/CTor if it shows
focal bone uptake. Its utility could be questioned in those pa-
tients with diffuse bone uptake. PET/CT helps to locate lesions
for biopsy sampling.
P723
FDG-PET/CT in intravascular large B-cell lymphoma:
evaluation of diffuse splenic and bone marrow uptake
as predictive factors of hemophagocytic syndrome
T. Kinjo, K. Nakatani, K. Yoshino, K. Kitaguchi, T. Koyama;
Kurashiki Central Hospital, Kurashiki, JAPAN.
Aim: Intravascular large B-cell lymphoma (IVBCL) is a rare
subtype of extranodal lymphoma characterized by the specific
proliferation of lymphoma cells within the lumina of micro-
vasculature. Classical IVLBCL (Western form) usually has
several neurologic and skin symptoms, whereas Asian variant
of IVLBCL often lacks these signs and is rather associated
with hemophagocytic syndrome (HPS). The aim of this study
was to investigate the role of FDG-PET/CT as a predictor for
HPS in patients with IVLBCL. Materials and methods: 10
patients with histologically proven IVLBCL who underwent
FDG-PET/CT between 2009 and 2014 were analyzed. Their
histological specimens were obtained by biopsy prior to che-
motherapy from bone marrow, skin, lung, liver, stomach, or
adrenal gland. One patient was excluded since he had already
started chemotherapy before this study. Based upon the
hemophagocytic lymphohistiocytosis diagnostic criteria
2009, the patients were divided into HPS and non-HPS group
by their physical examination and laboratory tests. FDG up-
take in the following organs: brain, spleen, liver, bone marrow,
and ascending aorta, of each group was compared by measur-
ing SUVmax. For spleen and bone marrow, visual assessment
in comparison with liver uptake was also made. Mann-
Whitney's U test and Fisher's exact test were used for the
statistical analyses. Results: Among the 9 IVLBCL patients,
5 patients had HPS. HPS group showed significantly higher
splenic SUVmax than non-HPS group (8.33 ± 5.86 vs. 2.89 ±
0.51; p=0.032). The difference in SUVmax between each
group was not significant for brain (5.48 ± 2.41 vs. 6.79 ±
2.37; p=0.91), liver (4.00 ± 1.39 vs. 2.45 ± 0.63; p=0.063),
bone marrow (3.46 ± 0.53 vs. 2.88 ± 0.77; p=0.19), and as-
cending aorta (1.76 ± 0.31 vs. 1.40 ± 0.20; p=0.19). For the
visual assessment, diffuse increased splenic uptake relative to
liver was seen in 4 of 5 HPS patients and in 3 of 4 non-HPS
patients (p=1.00), and diffuse increased bone marrow uptake
was seen in 2 of 5 HPS patients and in 4 of 4 non-HPS patients
(p=0.17); neither were statistically significant difference. Con-
clusion: Increased splenic FDG uptake would be helpful as a
predictor of HPS in IVLBCL patients. Increased hepatic FDG
uptake might also be helpful, though not significant.
P724
[18F]FDG-PET/CT in extranodal lymphoma
M. Sollini, B. Zangheri, L. Calabrese, M. Gasparini; IRCCS
MultiMedica, Sesto San Giovanni, ITALY.
Aim: Although lymphoma generally originates from lymph
nodes, in up to 40% of HD/NHL (especially NHL), arises at
extranodal sites along the gastrointestinal tract, head and neck,
orbit, central/peripheral nervous system, thorax, bone, skin,
breast, testis, thyroid, and genitourinary tract. We aim to eval-
uate the role of [18F]FDG-PET/CT in extranodal manifesta-
tions of lymphoma. Materials and methods: we retrospectively
evaluate 28 patients (M=14; F=14) who performed from 04/
2011 to 03/2015 a [18F]FDG-PET/CT for a total of 63 exam-
inations. Lymphoma originated from gastrointestinal tract in
10 cases (stomach=7; bowel=3), head and neck in 5 cases
(orbit=1; pharynx=1; parotid=1; cheek=1; tongue=1), breast
in 6 cases, skin in 4 cases, heart in 2 cases and brain in 1 case.
PET/CTwas acquired 1 hour after [18F]FDG injection (medi-
an activity=304 MBq; range 245-644 MBq). [18F]FDG-PET/
CT was performed to stage (n=17), to evaluate treatment re-
sponse (n=5) or during follow-up (n=41) patients. [18F]FDG-
PET/CT results were compared to final diagnosis obtained by
follow-up (clinical-radiological, [18F]FDG-PET/CT or histol-
ogy). We excluded from the present analysis 3 patients affect-
ed by cardiac, ileum and orbital NHL respectively (for a total
of 4 scans), due to the lack of final diagnosis. Results: Out of
the 59 scans performed (staging=17, treatment response eval-
uation=5, follow-up=37), [18F]FDG-PET/CT resulted posi-
tive in 26 cases and negative in 33 cases. Based on final diag-
nosis was classified as true positive (TP), true negative (TN),
false positive (FP) and false negative (FN) in 23, 32, 3, and 1
cases, respectively. FP results were observed during the
follow-up period of a gastric and a rectum NHL patients in
which focal [18F]FDG uptake (SUVmax > 3.0) was present in
stomach (2 scans) and rectum (1 case). The only case resulted
FN was a patient with gastric NHL in which biopsy performed
after PET/CTconfirmed microscopic residual disease. Consid-
ering the clinical purpose, sensitivity and specificity of PET/
CT were 93% and 100% in the staging setting and 100% and
90% in the follow-up. Seven patients who performed PET/CT
to stage disease performed additional PET/CT during follow-
up which diagnosed disease recurrence in 2/7 and residual
disease in 1/7 case. In the only 5 scans performed to evaluate
treatment response PET/CT was TP in 1 case and TN in the
remaining 4 patients. PET/CT revealed additional site(s) of
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disease in 14 cases (lymph nodes=13, bone=1, spleen=1, ad-
renal=1, pharynx=1). Conclusion: as for nodal lymphoma,
[18F]FDG-PET/CT presents high diagnostic performances al-
so in extranodal lymphoma (sensitivity=96%, specifici-
ty=91%, accuracy=93%).
P725
FDG PET/CT Can Reliably Determine Bone Marrow
Involvement in Diffuse Large B Cell Lymphoma but not
in Follicular Lymphoma
A. R. Teagle1, H. Barton1, E. Charles-Edwards1, S.
Dizdarevic1, T. Chevassut2,1; 1Brighton and Sussex Univer-
sity Hospitals NHS Trust, Brighton, East Sussex, UNITED
KINGDOM, 2Brighton and SussexMedical School, Brighton,
East Sussex, UNITED KINGDOM.
Non-Hodgkins lymphoma (NHL) is a common malignancy,
accounting for an estimated 4% of all new cancer cases annu-
ally. It is important to identify bone marrow involvement as it
affects staging and management. Bone marrow biopsy (BMB)
is considered the gold standard for detecting marrow involve-
ment in NHL but the use of FDG PET/CT to provide addition-
al information for staging is becoming increasingly wide-
spread. BMB has a non-negligible complication rate and it is
unpleasant for patients to undergo. This study compares deter-
mination of bone marrow involvement by FDG PET/CT
against BMB in Diffuse Large B-cell Lymphoma (DLBCL)
and Follicular Lymphoma (FL).Methods: This was a retro-
spective study of patients with histologically confirmed NHL
treated at a single UK Cancer Centre, who had had a baseline
(pre-treatment/staging) FDG PET/CT and baseline BMB in
the period from June 2010 to February 2013. Information
was collected from patient notes and the local cancer register,
plus histological and imaging reports. All FDG PET/CT scans
were dual-reported by consultants in Nuclear Medicine and
Radionuclide Imaging. Results were compared between
BMB and FDG PET/CT to determine diagnostic accuracy of
FDG PET/CT using BMB as the reference standard. Results:
In total, 24 patients with DLBCL and 12 patients with FLwere
included in the study. 5 patients with DLBCL had bone mar-
row involvement on FDG PET/CT, whichwas confirmed in all
cases on BMB. 3 patients with FL had bone marrow involve-
ment on FDG PET/CT but not on BMB; 1 patient with FL had
bone marrow involvement on BMB but not on FDG PET/CT.
Using BMB as the reference standard, the sensitivity and spec-
ificity of FDG PET/CT in detecting bone marrow involvement
were 100% and 100%, respectively, in DLBCL, and 0% and
72.7% in FL, respectively. Conclusion: When compared to
BMB, FDG PET/CT is highly accurate for detection of bone
marrow involvement in our group of patients with newly di-
agnosed Diffuse Large B-cell Lymphoma, but not in those
with Follicular Lymphoma. This study adds to the literature
suggesting that FDG PET/CT may be able to safely rule out
bone marrow involvement in DLBCL without the need for
confirmatory BMB.
P726
The Liver as Reference Organ for Quantification
of 18F-FDG Uptake in Lymphoma
C. N. Strandholdt1, O. Gerke1, J. T. Friis1, T. S. Larsen2, K.
J. Mylam3, P. F. Høilund-Carlsen1; 1Dept. of Nuclear Medi-
cine, Odense University Hospital, Odense C, DENMARK,
2Dept. of Haematology, Odense University Hospital, Odense
C, DENMARK, 3Dept. of Medicine, Vejle Hospital, Vejle,
DENMARK.
Aim: It is widely accepted to use a reference organ when
quantitative PET methods are applied in the evaluation of var-
ious diseases. This study examined the applicability of the
liver as a reference organ in disease assessment in lymphoma
patients using 18F-FDG PET/CT and dedicated software. Ma-
terials and methods: Partial volume corrected standard uptake
values (cSUVmean) were obtained in the liver of ten patients,
aged 61-71 years, with diffuse large B-cell lymphoma, at base-
line and at interim PET/CT scans. Two interim scans were
excluded due to technical artefacts in the liver. 18F-FDG
PET/CT scans performed at 2-year follow-up in 10 survivors
of upper GI-cancer, aged 56-68 years, served as reference. All
patients in the latter group were still alive and recurrence free.
The FDG uptake was measured in three different regions (Reg
1,2,3) in the liver, using for each of them a small volume ROI
of about 25-35 cm3 and at a large volume ROI of approxi-
mately 95-115 cm3. A dedicated software, ROVER (ABX,
Radeberg, Germany), providing segmentation by a voxel
based adaptive threshold method and correction for partial
volume effect was used for the analysis. Mixed-effects regres-
sion was applied to test for differences between regions, small
and large volume sizes, time points, and patient groups. Re-
sults: For the 60 ROIs in lymphoma patients at baseline, the
mean cSUVmean was 2.53, range 2.0-3.4. For the 48 ROIs in
lymphoma patients at interim, the mean cSUVmean was 2.69,
range 2.1-3.3. For the 60 ROIs in the reference group, the
mean cSUVmean was 2.17, range 1.7-2.7. cSUVmean was
statistically significantly higher in lymphoma patients versus
reference (p<0.0001), whereas cSUVmean increase over time
was not. The mean difference in cSUVmean between Reg 1
ROI and Reg 2 ROI was -0.05 (95% CI: -0.07 to -0.02;
p<0.0001). The mean difference in cSUVmean between Reg
1 ROI and Reg 3 ROI was 0.01 (95% CI: -0.04 to 0.06;
p=0.71).The mean difference in cSUVmean in small volume
ROIs versus large volume ROIs was 0.01 (95% CI: 0.004 to
0.02; p=0.003).Conclusion: The differences between
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measured cSUVmean values were small and clinically insig-
nificant independent of ROI size and the location in the liver
demonstrating that in these categories of patients the liver up-
take of FDG is in fact very homogeneous. Therefore, it may be
feasible to use just a part of the liver as a reference, when
assessing disease activity in patients with diffuse large B-cell
lymphoma.
P727
The Utility Of 18F-FDG PET/CT In Evaluation Of Bone
Marrow Involvement In Non-Hodgkin’s Lymphoma
Patients
D. Vassileva1, B. Spassov1, I. Kostadinova2, M. Guenova1;
1Specialized Hospital for Active Treatment of Hematological
Diseases, Sofia, BULGARIA, 2University Hospital
Alexandrovska, Sofia, BULGARIA.
Background: Bone marrow biopsy (BMB) is a standard
method for the evaluation of bone marrow infiltration in
non-Hodgkin’s lymphoma (NHL) patients although it is
an invasive and painful procedure. Since BMB allows
analysis of very limited area, false negative results can
be observed. FDG-PET/CT has been used for follow-up
examinations in patients with aggressive NHL. However
few data are available regarding utility of FDG-PET/CT
in NHL patients with bone marrow involvement in com-
parison with BMB. Aims: To evaluate the value of 18-F
FDG PET/CT and its concordance with BMB in deter-
mining post-treatment bone marrow involvement (BMI)
in NHL patients. Methods: Data from 70 NHL patients
(39 men and 31 women), aged 21-69 years, were ana-
lyzed retrospectively. All patients were examined by
FDG PET-CT and iliac crest bone marrow biopsy.
BMB results were used as reference standard. FDG-
PET/CT results were compared with the BMB results
in order to evaluate BMI. Results: Both FDG-PET/CT
and BMB were negative in 52 (74.3%) patients after the
cytotoxic therapy. Eighteen patients (25.7%) were con-
sidered positive lymphomatous infiltration by FDG-PET/
CT (PET-CT/BM+). Focal and diffuse bone marrow 18
F-FDG uptake were detected in 10 and 8 patients, re-
spectively, and bone marrow SUV max values ranged 2,
8-9,6. Five patients (7.1%) were identified positive by
BMB (BMB/BM+). There was a discordant result in
thirteen patients (72.2%) who were PET-CT/BM+ but
BMB/BM- due to focal pattern of BMI. Conclusion:
FDG-PET/CT findings can complementally detect posi-
tive BMI patients missed by BMB due to focal pattern
of infiltration in NHL patients at follow-ups. Additional
clinical trials are needed to define the prognostic value
of positive BMI detected by FDG-PET/CT.
P728
Recognition of Graft-Versus-Host-Disease
by Semi-Quantitative Analysis of Lung Parenchyma
at FDG PET/CT images.
F. Fiz1, F. Bongioanni1, M. Pennone2, I. Calamia1, A.
Bacigalupo3, C. Marini4, S. Morbelli2, G. Sambuceti1; 1Nu-
clear Medicine Unit, Department of Health Sciences, Univer-
sity of Genoa, Genoa, ITALY, 2Nuclear Medicine Unit,
IRCCS San Martino - IST, Genoa, ITALY, 3Hematology and
Bone Marrow Transplantation Unit, IRCCS San Martino -
IST, Genoa, ITALY, 4CNR-IBFM, Milano, ITALY.
Background and Aims: Graft-Versus-Host-Disease (GVHD) is
a frequent complication of Heterologous Hematopoietic Stem
Cell Transplantation (HSCT), in which donor T-Lymphocytes
recognize the foreign antigens and mount an inflammatory
reaction towards the donor’s tissues. It can be acute or chronic,
it generally affects multiple organs, including the liver, the gut,
the skin and the lungs and can severely impact short-term
survival or long-term quality of life. Recongnizing GVHD at
its early stages is important for treatment planning and subse-
quent clinical outcome. In this study, we retrospectively ana-
lyzed the FDG PET/CT images of patients submitted to HSCT
to assess differences in tracer distribution within the lung pa-
renchyma. This tissue was chosen because the very low base-
line uptake might allow detecting even subtle changes in glu-
cose metabolism. Patients and methods: 30 patients (11 wom-
en, mean age 32 years), with relapsed Hodgkin Lymphoma,
underwent FDG PET/CT for response assessment 30 days
after Heterologous HSCT between 2009 and 2013. Vol-
umes of Interest (VOI) were manually drawn bilaterally
on the whole lung parenchyma, carefully excluding the
mediastinal structures and pleura. SUVmax and SUVmean
were then normalized for blood-pool, obtained from a 10-
slice thick VOI in the inferior vena cava. Any evidence of
pulmonary infection was a criterion of exclusion. 30 sex-
and age-matched controls from a published normalcy data-
base were used as reference. Results: Average SUVmean
was increased in the patients’ group when compared to
controls (0.6±0.32 vs 0.39±0.1, p<0.01); SUVmax was
similarly increased (p<0.05). This difference can be largely
attributed to immune mechanisms, as patients who subse-
quently had a Grade-2 or greater GVHD (7/30, 23%) had
a greatly increased SUVmean with respect to the remain-
ing ones (0.87±0.33 vs 0.47±0.18, p<0.001), as well as a
marked increase in SUVmax (p<0.01). Conversely, patients
with no subsequent acute or chronic GVHD didn’t show a
definite increase in metabolic indexes when compared to
controls. Conclusions: Semi-quantitative analysis of FDG
PET/CT is a sensitive modality, able to grasp minimal
metabolic changes that are associated with an ongoing
GVHD.
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Revised Criteria for 18F-FDG-PET Bone-marrow
Evaluation in Lymphoma-staging: High Diagnostic
Accuracy in selected patients
E. Orunesu1, M. Longo2, L. Florimonte1, M. Castellani1, F.
Zito1, C. Canzi1, F. Voltini1, M. Goldaniga3, R. Benti1, A.
Cortelezzi1; 1Department of Nuclear Medicine, Fondazione
IRCCS Cà Granda Ospedale Maggiore Policlinico, MILAN,
ITALY, 2Nuclear Medicine Residency, University of Milan,
Unit of Nuclear Medicine, San Paolo Hospital, MILAN, ITA-
LY, 3Oncohaematology Division, Fondazione IRCCS Cà
Granda Ospedale Maggiore Policlinico, MILAN, ITALY.
Background:For evaluation of bone-marrow-involvement in
staging of Hodgkin (HL) and Non-Hodgkin Lymphoma
(NHL), international recommendations (Lugano Classifica-
tion) state that bone-marrow-biopsy (BMB) is no longer man-
datory in all HL and high-grade-NHL, based on superior sen-
sitivity of 18F-FDG-PET/CT versus bone-marrow-biopsy
(BMB) in this setting. However, the lack of well-established
criteria for grading FDG bone-marrow-uptake, renders diffi-
cult a proper assessment of the bone-marrow-infiltration in
clinical practice. The aforementioned recommendations rely
on studies in which the presence of focal FDG-bone-uptake,
was considered as a proof of bone-marrow-involvement, ig-
noring the possibility of concomitant absent bone-marrow tu-
mor-spread. To improve our understanding of the effective
accuracy of PET in the evaluation of bone-marrow, we per-
formed a separate evaluation of bone marrow-involvement in
patients with focal bone-lesions. After evaluating our patients
with this method and with the previously adopted, we com-
pared the results, using BMB as gold-standard.Methods:We
evalutated 18F-FDG-PET/CT studies, performed for staging
of 51 NHL-patients (aggressive N=27; indolent N=24; M:F
ratio= 1.5:1; median age= 61). For evaluation of bone-
marrow uptake we adopted a 5-point scale, consisting in: 1=
no uptake; 2= uptake ≤mediastinum; 3= uptake >mediastinum
but < than liver; 4= uptake moderately higher than liver; 5=
uptake markedly higher than liver.Results:Overall accuracy
was best when setting the threshold for positivity, above or
equal to 3. When comparing results using our criteria with
previous criteria, the specificity for bone-marrow involvement
in high-grade NHL increased from 53% to 75% (for all NHL:
from 66% to 80%).Nevertheless the overall accuracy of 18F-
FDG-PET/CT with our criteria was 70% versus 61% for ag-
gressive NHL (and 70% vs. 68% for all NHL), showing equal-
ly low values for low- and high-grade NHL. Furthermore, we
observed that by setting a cut-off at level 4, the specificity of
bone-marrow-uptake reached a value of 93%, meaning that
most cases of high bone-marrow-uptake are BMB positive.
In patients with evidence of bone-lesions (N=9), the positive-
predictive-value for bone-marrow involvement was 100% for
all NHL, but further data is needed to confirm this
observation.Conclusion:Based on our results, despite the high
accuracy of FDG-PET in staging of NHL, the diagnostic per-
formance in detecting bone-marrow involvement seems poor
and in most cases we think that BMB would bring additional
value. Despite this, our preliminary data show high accuracy
of FDG-PET-bone-marrow evaluation in patients with con-
comitant FDG-avid bone-lesions. Further data will establish
if BMB might be reliably avoided in this subset of patients.
P730
18F-FDG-PET/CT in the evaluation of patients
with follicular lymphoma
R. Fonti1, B. Salvatore1, A. De Renzo2, S. Pellegrino3, C.
Cerchione2, M. Monti2, C. Cimmino2, F. Pane2, L. Pace4, S.
Del Vecchio3; 1Institute of Biostructures and Bioimages-
CNR, NAPLES, ITALY, 2Haematology Division, University
"Federico II", NAPLES, ITALY, 3Department of Advanced
Biomedical Sciences, University "Federico II", NAPLES, IT-
ALY, 4Department of Medicine and Surgery, University of
Salerno, SALERNO, ITALY.
Follicular lymphoma is characterized by slowly progressive
adenopathy showing variable FDG avidity. Recent studies
support the use of functional imaging by 18F-FDG-PET/CT
at diagnosis in order to identify patients with indolent or more
aggressive disease according to tumor metabolic behavior.
Aim. The aim of our study was to evaluate lymph node in-
volvement in patients with follicular lymphoma by 18F-FDG-
PET/CT and to correlate the imaging parameters derived by
this methodology with standardized clinical, biochemical and
haematological variables used in the staging and prognosis of
this lymphoproliferative disease. Methods. We evaluated ret-
rospectively 24 patients (9 males, 15 females; mean age±SD,
57±8.7 years) with follicular lymphoma who had undergone
whole-body 18F-FDG-PET/CT and contrast-enhanced CT
alone or as part of 18F-FDG-PET/CT examination at the time
of diagnosis. Patients were staged according to standard
criteria including the evaluation of parameters belonging to
the Follicular Lymphoma International Prognostic Index
(FLIPI) 1 such as age, stage, lactate dehydrogenase (LDH),
haemoglobin and number of pathological nodal sites or FLIPI
2 such as the diameter of the largest lymph node involved.
Results. In the 24 patients studied, the number of pathological
lymph node basins at 18F-FDG-PET/CT ranged between 1
and 33 and the SUVmax of the lymph node with the highest
metabolic rate varied from 2.9 to 14.6 while at CT the number
of pathological lymph node basins ranged between 1 and 28
and the maximum diameter of the largest involved lymph node
varied from 17 to 75 mm. The number of pathological lymph
nodes at 18F-FDG-PET/CT was significantly correlated with
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stage and FLIPI1 score (Spearman rank correlation coefficient
r=0.76, P=0.0002 and r=0.56, P=0.0068, respectively). Like-
wise, the number of pathological lymph nodes at CTwas sig-
nificantly correlated with stage and FLIPI1 score (Spearman
rank correlation coefficient r=0.65, P=0.0016 and r=0.64,
P=0.0022, respectively). Moreover, a statistically significant
direct correlation was found between the maximum diameter
of the largest pathological lymph node at CTand the SUVmax
of the lymph node with the highest tracer uptake (r=0.55
P=0.0075). The largest lymph node size showed a significant
correlation with stage (Spearman rank correlation coefficient
r=0.48, P=0.0252) while the highest SUVmax value was di-
rectly correlated with LDH levels (r=0.42 P=0.0464). Conclu-
sion. In patients with follicular lymphoma 18F-FDG-PET/CT
provides a useful contribution in evaluating lymph node in-
volvement and therefore can be of aid in the prognostic assess-
ment of these patients.
P731
Staging and Indices measured with 18F-FDG PET/CT
as a predictor of survival in Non-hodgkin’s lymphoma
B. DIRLIK SERIM1, E. UMIT2, F. USTUN3, B. TOKUÇ4,
M. DEMIR2, G. DURMUS ALTUN3; 1Istanbul Medicine
Faculty, Nuclear Nedicine Department, Istanbul, TURKEY,
2Trakya Universty Medicine Faculty, Hematology Depart-
ment, Edirne, TURKEY, 3Trakya UniverstyMedicine Faculty,
Nuclear Medicine Department, Edirne, TURKEY, 4Trakya
Universty Medicine Faculty, Department of Public Health,
Edirne, TURKEY.
Purpose: We aimed to evaluate the value of initial [18F]2-
fluoro-2-deoxyglucose (FDG)-positron emission tomography
(PET) scan for prediction of survival in patients with Non-
hodgkin’s lymphoma (NHL). We also aimed to assess the role
of other quantitative parameters such as mediastinum,liver and
brain indices measured at baseline and interim PET/CT for
prediction of survival.Methods: Data from 18F-FDG PET/
CT scans of 31 patients with NHL at the initial, after two
cycles and after the completion of treatment were evaluated
in a retrospective review (2015-2009). The ratio of SUVmax
value of primary lesion to SUVmean values of mediastinum,
liver and brain obtained from PET/CT scan were defined as
mediastinum, liver and brain indices. Indices were determined
at baseline and interim PET/CT. Treatment outcomes were
compared between groups according to metabolic parameters
and the International Prognostic Index (IPI). Relation between
quantitative parameters and overall survival (OS) was
analyzed.Results: After a median follow-up of 54 months
(range, 30-72 months) of 31 patients (F/M: 18/13, range: 58
±13 years), seven patients developed recurrence after chemo-
therapy while three patients never reached a remission.
Relation between quantitative parameters and OS was statisti-
cally analyzed using MannWhitney U test, Fischer Exact Test
and Kaplan Meier survival analyis. Among quantitative meta-
bolic parameters, there was a statistically significant relation
between initial mediastinum (p=0.008), liver (p=0.02), brain
(p=0.022) indices and pre-treatment staging. Additionally in-
terim PET/CT indices was negatively associated with treat-
ment outcomes. (mediastinum index r= -,642, p=0.00, liver
index r= -,641, p=0.00, brain index r=-,652, p=0.00) Further-
more initial PET staging was significantly associated with OS.
Advanced stages in initial PET/CT significantly reduced OS
(stage 1 versus stage 0 , 8.1 times reduces, 95%CI 1.82 - 36.85
and stage 2 versus stage 0 , 8.3 times reduces 95% CI 1.36 -
51.06)Conclusion: The significant relation of initial PET/CT
staging with OS improves the importance of PET scan in
NHL. Likewise, interim PET/CT indices give direction to the
decision about tailoring the treatment according to individual
response. Interim PET/CT indices may be useful to identify
patients with NHL who are at increased risk for relapse after
conventional therapy. Multicentral further studies with larger
patients groups are needed to identify quantitative parameters
contributing prognosis prediction in NHL.
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Delayed-time-point [18F]-FDG-PET inMALT lymphoma:
is [18F]-FDG-PET better than its reputation?
M. Mayerhoefer, C. Giraudo, D. Senn, M. Hartenbach, M.
Raderer; Medical University of Vienna, Vienna, AUSTRIA.
AIM: Current guidelines do not recommend [18F]-FDG-PET
for imaging of MALT lymphoma, because this lymphoma
subtype has shown a variable FDG avidity in previous studies.
It was thus the aim of this prospective study to determine
whether, in patients with MALT lymphoma, delayed-time-
point 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission to-
mography ([18F]-FDG-PET) performs better than standard-
time-point [18F]-FDG-PET. METHODS: Patients with un-
treated, histologically verified MALT lymphoma, who were
undergoing pre-therapeutic [18F]-FDG-PET/CT (computed
tomography) and consecutive [18F]-FDG-PET/MR (magnetic
resonance imaging), using integrated hybrid PET/CT and
PET/MR systems, and using a single [18F]-FDG injection
(250-300Mbq), were included in this prospective, Institutional
Review Board-approved study. Region-based and patient-
based rates of agreement of the respective [18F]-FDG-PET
scans at time points 1 (45-60 min after tracer injection, TP1)
and 2 (100-150 min after tracer injection, TP2) with the
histology-based reference standard were calculated, and
lesion-to-liver and lesion-to-blood SUVmax and SUVmean
(maximum and mean standardized uptake values) ratios were
assessed. Paired t-tests were used for group comparisons.
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RESULTS: Ten patients (six females and four males; mean
age, 65.4±16.1 years) with 5 nodal and 15 extranodal lympho-
ma manifestations met our criteria for participation in the
study. [18F]-FDG-PET at TP1 agreed with the reference stan-
dard in 14/20 involved regions, and 6/10 patients. [18F]-FDG-
PET at TP2 agreed with the reference standard in 18/20 in-
volved regions, and 8/10 patients. Lesion-to-liver and lesion-
to-blood SUVmax ratios were significantly lower at TP1 (ra-
tios, 1.12±0.42 and 1.67±0.63) than at TP2 (ratios, 1.85±0.76
and 2.82±1.11) (P=.006 and P=.003). Similarly, lesion-to-liver
and lesion-to-blood SUVmean ratios differed significantly be-
tween [18F]-FDG-PET at TP1 (ratios, 1.23±0.38 and 1.53
±0.52) and [18F]-FDG-PET at TP2 (ratios, 1.99±1.32 and
2.58±1.33) (P=.06 and P=.017). CONCLUSION: Delayed-
time-point imaging may improve the performance of [18F]-
FDG-PET in MALT lymphoma. Thus, [18F]-FDG-PET may,
after all, have a role in the clinical workup of MALT lympho-
ma patients.
P733
FDG-PET in aggressive non Hodgkin lymphoma:
the prognostic value of interim evaluation
L. Aloj1, F. Frigeri2, C. Caracò1, S. Crisci2, R. Farese3, F.
Ibello1, A. Morisco3, G. Capobianco2, F. Volzone2, A. Pin-
to2, S. Lastoria1; 1SC Medicina Nucleare, Istituto Nazionale
Tumori Fondazione G. Pascale - IRCCS, Napoli, ITALY, 2SC
Ematologia, Istituto Nazionale Tumori Fondazione G. Pascale
- IRCCS, Napoli, ITALY, 3Centro Ricerche Oncologiche
Mercogliano, Istituto Nazionale Tumori Fondazione G.
Pascale - IRCCS, Mercogliano (AV), ITALY.
Aim FDG-PET is growingly recognized as a very important
tool to assess early response to therapy in patients with lym-
phoma.We are evaluating the prognostic value of interim PET
in patients with aggressive non Hodgkin lymphoma (NHL)
treated at our institution. Materials and Methods We have
reviewed the charts of 125 patients (pts) undergoing first line
treatment for aggressive NHL between January 2006 and Sep-
tember 2013 (41% DLBCL, 33% DLBCL-ABC, 12% BCLU,
10% PMBCL, 4% other). Patients included in the analysis had
performed PET at baseline, interim (median of 4 cycles, range
2-5 from start of treatment) and at least 35 days following the
end of therapy (EOT). Deauville criteria were utilized to assess
the interim PET (iPET) studies. A score ≥ 3 was considered
positive. Findings were correlated with event free and overall
survival (EFS and OS). Results Forty of the 125 patients
(32%) had a positive iPET, the remaining 85 were negative
(iPET-). A complete response (CR) at EOT based on PET and
CT was obtained in 21 iPET+ pts (53%) and 77 iPET- pts
(91%). Relapses were observed in 5/21 (27%) of iPET+ pts
but only in 11/77 (14%) of iPET- patients. Of note in this latter
group 7/11 patients had a diagnosis of very aggressive NHL (6
DLBCL-ABC and 1 BCLU). With a median follow-up of 30
months, EFS was 68% vs 35% for iPET- vs iPET+ pts
(p<0.0001) and OS 71% vs 57% (p=0.006). EFS and OS rates
in pts who were CR at EOT were not statistically different in
the iPET- and iPET+ groups (EFS 75% vs 66%, OS 78% vs
74%, respectively p=ns). Conclusions Our data confirm that a
negative iPET is an important predictor of prolonged response
and overall survival in aggressive NHL. iPET may be utilized
to select patients requiring treatment intensification with the
aim of increasing the EOT CR rates and consequently long
term outcome.
P734
Prolonged effect of chemotherapy on FDG uptake
of the noraml bone marrow in patients with malignant
lymphoma
G. S. Alobthani1, T. Morita1, K. Isohashi1, H. Kato1, M.
Tatsumi1, E. Shimosegawa2, J. Hatazawa1; 1Department of
Nuclear Medicine and Tracer kinetic ,Graduate School of
Medicine, Osaka University, Osaka, JAPAN, 2Department of
Molcular Imaging in Medicine,Graduate School of Medicine,
Osaka University, Osaka, JAPAN.
Aim : 1-To evaluate the prolonged effect of chemotherapy on
FDG uptake in the normal bone marrow. 2- The possibility of
using PET-CT as good , quantitative and noninvasive tech-
nique for the evaluation of the condition of bone marrow.
Methods : 56 lymphoma patients without proven bonemarrow
involvement , the median age was 58.5 +/- 13.5 years . 26
patients were treated with CHOP regimen , 15 patients with
THP-COP regimen , 10 patients with Rituximab , 5 patients
with ABVD. Granulocytes colony stimulating (GCS ) factor
was not given to any case. The mean time interval between the
end of chemotherapy and scanning by PET-CT was 94 +/- 79
days . The bone marrow uptake of FDG was calculated by
measuring the maximum standardized uptake value (SUV
max) with setting of the region of interest (ROI) over the
lumbar vertebrae 1-5 . The sagittal , coronal and transaxial
planes of FDG PET- CT scan were used. We use SUV max
rather than SUV mean , to avoid the calculation of the FDG
uptake of intervertebral discs and cortical bone of the vertebral
bodies during the process of calculation of the bone marrow
FDG uptake. P value set as significant if less than 0.05. Results
: There was a statistically significant difference ( P value
0.0001 ) between Pre and Post chemotherapy bone marrow
FDG uptake , the mean of pre chemotherapy SUVmax was
1.97 +/- 0.45 and the mean of post chemotherapy SUVmax
was 1.67 +/- 0.37 , So There was 15 % reduction in post
chemotherapy bone marrow FDG uptake This study gives us
good idea about the normal FDG uptake of bone marrow ( pre
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chemotherapy ) which was about 1.97 +/- 0.45. Conclusion :
94 days, a relatively long period to see the effect of chemo-
therapy in the bone marrow by an imaging method but a sta-
tistically significant difference between pre and post chemo-
therapy bone marrow FDG uptake can be still found, so PET-
CT may be a good noninvasive method to quantify and visu-
alize the activity of bonemarrow. Bonemarrow FDG uptake at
about 3 months post chemotherapy still less than the pre che-
motherapy level , so any case at 3 months post chemotherapy
with SUVmax level same as pre chemotherapy level, bone
marrow infiltration may be considered , although this post
chemotherapy SUV max level is still within normal range.
P735
Predictive value of F-18 FDG PET/CT quantification
parameters for progression-free survival in patients
with B-cell lymphoma
W. He, W. Zhai, W. Yu; Huadong Hospital, Shanghai,
CHINA.
Purpose: To evaluate the predictive significance of F-18 FDG
PET/CT quantification parameters for progression-free surviv-
al in patients with B-cell lymphoma before chemotherapy.
Methods: We conducted a retrospective study including 54
patients with B-cell lymphoma between January 2010 and
July 2014 and underwent FDG PET/CT prior to first-line treat-
ment. Mean liver SUVwas measured by placing a 14 ml cubic
volume of interest in the liver,a smoothing filter to segmented
bones from CT to create a bone mask was applied. For each
patient,all lesions were segmented by using an Tumor Finder
Application with automatic 3D region-growing algorithmwith
a defined minimum SUV threshold [LiverSUVmean+
SD*2.00]. This computation, after removal of physiologic ac-
tivity above the measured threshold, defined the metabolic
tumor volume (MTV),and the total lesion glycolysis (TLG)
was then calculated as [TLG=SUVmean*MTV]. Results: At
Spearman analysis, the values of cumulative MTV and TLG
were positively related to Ann Arbor Stage, IPI Score and
LDH level. The number of enlarged lymph nodes was only
positively related to LDH level. There were no relationship
between the value of SUVmax and clinical characteristics.
At univariate Cox regression analysis, the values of total
MTV, cumulative TLG and number of enlarged lymph nodes
were predictive (HR=1.027, 1.059, 1.098 respectively;
P=0.001, 0.006, 0.046 respectively). The value of SUVmax
was not suitable for predicting PFS. According to cut-off of
ROC analysis, the lower values of total MTVand cumulative
TLG were highly predictive of favorable outcomes in PFS.
Conclusion: The quantitative method is a friendly-user inde-
pendent ,much faster repeatable and reliable . The F-18 FDG
PET/CT scan has great value for predicting the prognosis.
TotalMTVand cumulative TLGmay be significant prognostic
markers for PFS in B-cell lymphoma, in contrast to SUVmax.
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Is there any complomentary role of F-18 NaF PET/CT
in detecting of osseous involvement ofMultipleMyeloma?:
A comperative study for F-18 FDGPET/CTand F-18 FDG
NaF PET/CT
I. AK SIVRIKOZ1, H. ONNER1, O. AKAY2; 1ESOGU
SCHOOL OF MEDICINE, DEPARTMENT OF NUCLEAR
MEDICINE, ESKISEHIR, TURKEY, 2ESOGU SCHOOL
OF MEDICINE, DEPARTMENT OFHEMATOLOGY, ES-
KISEHIR, TURKEY.
Multiple myeloma (MM) is a disease characterized by amono-
clonal plasma cell population in the bone marrow whereby
osseous involvement is a predominant feature. F-18 FDG
PET/CT is an accurate and dependable technique in detecting
MM osteolytic lesions in a higher number of patients. There is
limited information in the literature regarding the diagnostic
utility of F-18 NaF PET/CT in the assessment of bone involve-
ment in MM. The aim of this prospective study was to inves-
tigate the combined use of F-18 FDG and F-18 NaF PET/CT
in the skeletal assessment of patients withMM and to compare
the efficacy of these two PET tracers regarding detection of
myeloma-indicative osseous lesions. A total of 26 patients (14
females and 12 males, mean age 61.8±1.8 years (range 40-81
years) with MM diagnosed according to standard criteria. All
patients underwent both F-18 FDG PET/CT and F-18 NaF
PET/CT scans within one week after the completion of the
usual staging workup for MM. In total, approximately 128
focal F-18 FDG avid skeletal lesions were detected; the stage
I (n=5) pts had 10 bone lesions, the stage II (n=11) pts had 43
lesions, and the stage III (n=10) pts demonstrated 75 focal
bone lesions. F-18 NaF PET/CTs demonstrated fewer myelo-
ma indicative lesions than F-18 FDG PET/CTs. Totally, 57
focal bone lesions were detected with whole body F-18 NaF
PET/CT (mean 2.19±0.34, between 1-9 lesions); the five stage
I pts had 6 bone lesions, the eleven stage II pts had 18 lesions,
and the ten stage III pts demonstrated 33 focal bone lesions.
On the other hand, F-18 NaF PET/CT demonstrated additionl
135 bone lesions defined as rib fractures, and other findings
due to degenerative changes. In conclusion, our study implies
that F-18 NaF PET/CT scan didn’t actually aid for assessing
the myelomatous bone lesions in patients with MM. There-
fore, F-18 NaF PET/CT can contribute to the detection of
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minor and unexpected fractures and give a general view of the
bone remodelling of the whole skeleton in a single exam.
P737
Bone marrow plasma cell infiltration rate is higher
in multiple myeloma patients with pathological 18F-FDG
PET/CT than in patients with normal scans
C. Sachpekidis1, E. K. Mai2, J. Hillengass2, H.
Goldschmidt2, U. Haberkorn3, A. Dimitrakopoulou-
Strauss1; 1Clinical Cooperation Unit Nuclear Medicine, Ger-
man Cancer Research Center, Heidelberg, GERMANY,
2Medical Clinic V, University of Heidelberg, Heidelberg,
GERMANY, 33Division of Nuclear Medicine, University of
Heidelberg, Heidelberg, GERMANY.
Purpose: We aim to compare the degree of bone marrow ma-
lignant plasma cell infiltration in patients suffering from pri-
mary multiple myeloma (MM) according to their 18F-FDG
PET/CT distribution pattern. Procedures: The study included
67 patients with primary, previously untreatedMM (mean age:
59.5 years; 43 male, 24 female). Whole body PET/CT studies
from the skull to the knees were performed. PET/CT evalua-
tions were based on visual/qualitative analysis and patients
were initially classified in two groups: those with normal tracer
distribution (negative) and those with pathological findings
(positive). Furthermore, the 18F-FDG PET/CT positive pa-
tients were classified in three groups: patients with foci of
increased tracer uptake (focal), patients with intense, diffuse
bone marrow 18F-FDG accumulation (diffuse) and patients
with a mixed pattern (diffuse bone marrow uptake with focal
osseous lesions). Bone marrow aspirates/biopsies were per-
formed within four weeks around the 18F-FDG PET/CT ex-
aminations. Percentage of bone marrow infiltration was
assessed via light microscope from Giemsa-stained bone-mar-
row smears. Wilcoxon rank-sum test was performed in order
to assess potential significant differences in terms of bone
marrow infiltration rate between the different groups of tracer
uptake (p<0.01). Results: PET/CT negative patients demon-
strated a mean infiltration rate of 21.2% (median 12%, n=15
patients), while PET/CT positive patients had a mean infiltra-
tion of 38.9% (median 35%, n=52 patients) (p<0.01). Among
PET/CT positive patients, those who presented with a focal
pattern had a 31.1% mean infiltration rate (median 20%, n=19
patients), those with diffuse 18F-FDG bone marrow uptake
had a 36.5% mean bone marrow plasma cell infiltration rate
(median 38%, n=12 patients) and, finally, patients with a
mixed pattern of tracer uptake demonstrated the highest mean
infiltration rate of 47.3% (median 50%, n=21 patients). Con-
clusions: MMpatients with pathological findings on 18F-FDG
PET/CT demonstrated higher bone marrow infiltration by ma-
lignant plasma cells than patients with negative PET/CTs.
Patients with a mixed pattern of tracer uptake had the highest
infiltration rate.
P738
Correlation of 18F-FDG SUVs derived from reference
bone marrow with recognized prognostic laboratory
parameters in multiple myeloma
C. Sachpekidis1, E. K. Mai2, J. Hillengass2, H.
Goldschmidt2, U. Haberkorn3, A. Dimitrakopoulou-
Strauss1; 1Clinical Cooperation Unit Nuclear Medicine, Ger-
man Cancer Research Center, Heidelberg, GERMANY,
2Medical Clinic V, University of Heidelberg, Heidelberg,
GERMANY, 3Division of Nuclear Medicine, University of
Heidelberg, Heidelberg, GERMANY.
Purpose: Our aim was to study 18F-FDG uptake derived from
reference bonemarrow of the os ilium in correlation with some
standard laboratory variables of recognized prognostic signif-
icance in multiple myeloma (MM). Procedures: 67 patients
with primary, previously untreatedMM (mean age: 59.5 years;
43 male, 24 female) were enrolled in the study. All patients
underwent dynamic PET/CT studies of the pelvis and lower
lumbar spine. SUVs evaluation was based on volumes of in-
terest (VOIs), drawn with a 50% isocontour, placed over the
bone marrow of os ilium that didn’t demonstrate any focal
tracer enhancement. 18F-FDG SUVs were studied in correla-
tion with the following laboratory recognized prognostic MM
factors parameters: β2-microglobulin, thrombocytes, serum
albumin, Hb, LDH, CRP and κ/λ ratio. The statistical evalua-
tion was based on Wilcoxon rank-sum test and Spearman´s
rank correlation analysis. The results were considered signifi-
cant for p less than 0.05 (p<0.05). Results: SUVaverage cor-
related positively with the levels ofβ2-microglobulin (r=0.22)
and negatively with the levels of thrombocytes (r=-0.18), al-
bumin (r=-0.21) and Hb (r=-0.45). SUVmax also correlated
significantly with β2-microglobulin (r=0.22), albumin (r=-
0.25) and Hb (r=-0.47). Patients with hypoalbuminemia had
a higher SUVmax than patients with normal albumin levels.
Anaemic patients had higher SUVaverage and SUVmax than
patients with normal haemoglobin levels. Furthermore, pa-
tients with pathologically elevated CRP and pathological κ/λ
ratio demonstrated higher values of both SUVaverage and
SUVmax than those with normal values of these indices. Con-
clusions: Correlation analysis revealed significant but weak -
moderate correlations between 18F-FDG SUV derived from
the bone marrow of the os ilium, and levels of the established
prognostic MM factors β2-microglobulin, thrombocytes, al-
bumin and Hb. SUVs were higher in patients with hypoalbu-
minemia, anemia, pathologically elevated CRP and patholog-
ical κ/λ ratio.
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Italian Interpretation Criteria for FDG PET/CT
in Multiple Myeloma(MM)
C. NANNI1, A. VERSARI2, A. BIANCHI3, M. RENSI4, M.
BELLO'5, S. CHAUVIE3, E. ZAMAGNI1, M. CAVO1, S.
FANTI1; 1AOU S.ORSOLA-MALPIGHI, BOLOGNA, ITA-
LY, 2S.MARIA NUOVA IRCCS, REGGIO EMILIA, ITALY,
3ASO S. CROCE E CARLE, CUNEO, ITALY, 4AOU
S.MARIA DELLA MISERICORDIA, UDINE, ITALY, 5AO
CITTA' DELLA SALUTE E DELLA SCIENZA, TORINO,
ITALY.
FDG PET/CT is able to detect active disease in MM
pts.An Italian group of physicians defined new visual in-
terpretation criteria to standardize FDG PET/CT evaluation
in MM and tested their reproducibility. This Italian multi-
center protocol is a sub-protocol of EMN02, an interna-
tional prospective multicenter trial of the European Myelo-
ma Network.The criteria were written in multidisciplinary
consensus meetings. They include the description of: bone
marrow metabolic state(BM), nr and site of focal PET
positive lesions(Fx), osteolysis(Lx), extramedullary
disease(EM), paramedullary disease(PM), fractures(Fr).
The uptake is defined for the target lesion and EM lesions
according to modified Deauville Criteria.MM pts who had
performed an FDG PET/CT at baseline(PET0), after
induction(PET-AI) and the end of treatment(PET-EoT)
were enrolled. The PET scans were interpreted in a
blinded independent central review process managed by
WIDEN®. 4 expert nuclear medicine reviewers scored
the scans according to the new criteria. Concordances on
different metrics were calculated using alpha Krippendorf’s
coefficient.17 consecutive pts were enrolled. PET0: Alpha
for BM score(BMs) and F score(Fs) was 0.33 and 0.47,
respectively. Alpha for Fx and Lx was 0.40 and 0.32.
Skull, spine and extra-spinal involvements were demon-
strated in 2, 14 and 12 pts with a mean concordance of
37%, 78% and 71%. 4 pts had a fracture for 1 reviewer
and 1 pt had fractures for two. 2 pts had a PM lesion for
1 reviewer and 2 had PM lesions for all. 4 pts had EM-
nodal and EM-extranodal lesions. PET-AI: Alpha for BMs
and Fs was 0.09 and 0.43. Alpha for Fx and Lx were 0.22
and 0.21. Skull, spine and extra-spinal involvements were
demonstrated in 1, 13 and 5 pts with a mean concordance
of 25%, 67% and 79%. 4 pts had a fracture for 1 reviewer
and 1 pt had fractures for all. 4 pts had a PM lesion for 1
reviewer and 2 had PM lesions for all. No pts had EM
disease. PET-EoT: Alpha for BMs and Fs was 0.07 and
0.28. Alpha for Fx and Lx was 0.25 and 0.21. Skull, spine
and extra-spinal involvements were demonstrated in 1, 9
and 5 patients with a mean concordance of 25%, 47% and
70%. 5 pts had a fracture for 1 reviewer. Agreement on
focal lesions’ score turned out to be good, as well as the
number of focal lesions.New visual interpretation criteria in
MM pts are therefore feasible in the clinical practice.
P740
Application of PET-CT for Evaluation of the Therapeutic
Effect in Patients with Multiple Myeloma
M. B. Garcheva-Tsacheva1, B. Spassov2, D. Vassileva3;
1Medical University, Sofia, BULGARIA, 2Department of
Clinical Hematology, Specialized Hospital for Active Therapy
of Haematological diseases, Sofia, BULGARIA, 3Department
of Nuclear Medicine, Specialized Hospital for Active Therapy
of Haematological diseases, Sofia, BULGARIA.
The aim of the study is to assess utility of PET/CT findings and
serum β2M levels and correlate them with therapeutic re-
sponse in multiple myeloma patients (MM) treated with che-
motherapy with or without autologous stem cell transplanta-
tion (ASCT). Material and methods: Thirteen MM patients
were evaluated. Eleven patients were assessed after chemora-
diotherapy and two - after chemoradiotherapy and ASCT. Two
of them had vertebroplasty, and other 2 - endoprostheses of the
fractured bones. PET/CTwas performed according to standard
pro tocol . Serum β2M leve ls were measured by
radioimmunoassay.Results: Complete remission (CR) was de-
tected in 53.8% (7/13) of the patients - no residual metabolic
focuses was registered in five patients, whereas in two patients
with vertebroplasty, areas around surgery were detected with
moderate metabolic activity, which was attributed to the pro-
cedure and to some hardening effect due to the used material.
The serum β2M levels of these MM patients were near to the
normal range of 1.2 - 2.4 mg/l. In one patient with multiple
lesions according to the baseline scan, only one of the previous
lesions had metabolic activity and new fracture was detected
on the follow-up. The serum β2M level was 3.28 and the
therapeutic effect was evaluated as a partial response (PR).
The remaining 38.5% (5/13) of the patients were evaluated
to have significant residual disease activity detected by PET/
CT. One of these patients had metabolic active lesion in just
one bone, whereas four patients had multibone infiltration.
The median serum β2M level was 8.58 mg/l and all of these
patients need to continue the treatment due to the active met-
abolic disease. The correlation with serum β2M levels in these
patients was very important for the confidence in the therapeu-
tic response evaluation. Conclusion. PET/CT was very useful
for the evaluation of MM patients after treatment by determin-
ing those with CR, PR or lack of response. It was also valuable
for planning further consolidation chemo- and/or radiotherapy.
The serum β2M level determination correlated well with PET/
CT evaluation of the therapeutic effect.
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FDG PET/CT correlates better than the percent bone
marrow infiltration with the status of active disease
in patients with Multiple Myeloma
G. Ucmak, B. E. Akkas, B. B. Demirel, S. Demirtas; Ankara
Oncology Research and Training Hospital Department of Nu-
clear Medicine, Ankara, TURKEY.
The aim of this study was to compare FDG PET/CT
findings with the percentage of atypical plasma cell infil-
tration in bone marrow and to evaluate the importance of
PET/CT results on follow-up of patients with multiple
myeloma (MM) . Method: 17 patients (10M, 7 F, mean
age:56.5± 12.3) with multiple myeloma underwent FDG
PET/CT imaging for staging and re staging. The percent-
age of plasma cell infiltration (CD38 /CD138) in bone
marrow on initial staging and after therapy were correlated
with FDG uptake in bone and soft tissue/plasmocytoma
lesions on staging and follow-up PET/CT studies. The
results of PET/CT and bone marrow biopsy were evaluat-
ed for correlated with the activation of disease prognosis
and on follow-up. Results: PET/CT showed hypermetabol-
ic bone lesions in all patients. PET/CT detected
extramedullary disease in addition to bone/bone marrow
disease in 9 patients. All patients had standard therapy
according to NCCN guidelines. On follow up (11-72
months;mean 30 months), 9 patients had remission, 2 pa-
tients had stable disease and 6 patients had progressive
disease. In 9 patients with remission, the percentages of
atypical plasma cell infiltration on bone marrow as well
as FDG uptake of lesions were significantly decreased and
patients had no evidence of disease clinically. In 6 pa-
tients with progressive disease, despite a significant de-
crease in the percentage of atypical plasma cell infiltration
in bone marrow, FDG uptake of lesions were significantly
elevated compared to initial study and/or new FDG-
positive lesions were detected. These patients had bio-
chemical signs of disease (eg. high M-protein production
rates, increased β2microglobulin levels). Patients with sta-
ble disease still had FDG-positive lesions. Conclusion:
The preliminary findings of this study showed that PET/
CT findings correlates better with active disease in pa-
tients with MM than the percentage of atypical plasma
cell infiltration in bone marrow. PET/CT offers the perfect
advantage to detect extramedullary disease and to scan
whole-body at one session as well. PET/CT may provide
important prognostic information regarding metabolically
active disease even if bone marrow biopsy may fail to
demonstrate the existence of disease in patients with
MM. In conclusion, we considered that further prospective
studies with larger patient population are needed to sup-
port the findings of this study.
P742
Combined Use Of PET/CTAnd Serum
Beta-2-Microglobulin In Patients With Multiple Myeloma
D. Vassileva1, B. Spassov1, M. Garcheva2; 1Specialized
Hospital for Active Treatment of Hematological Diseases, So-
fia, BULGARIA, 2University Hospital Alexandrovska, Sofia,
BULGARIA.
Background: Multiple myeloma (MM) is a malignant
haematologic disorder characterized by bone marrow in-
filtration with neoplastic plasma cells, paraproteinemia
and osteolytic bone destruction. Standard diagnostic im-
aging methods, such as radiography and bone scan, have
certain limitations for the early evaluation of bone and
bone marrow lesions in MM patients (pts). PET/CT is a
metabolic imaging technique useful to detect lesions in
malignant diseases. Serum beta-2-microglobulin (β2M)
levels had been used to detect tumour burden in MM
pts. However data regarding correlations between PET/
CT findings with serum β2M levels in MM pts are
limited.The aim of the study was to correlate PET/CT
findings with serum β2M levels in MM patients.Material
and methods: Twenty-two MM pts were evaluated (14
males and 8 females; a median age of 56.8 years (range
31-76). 18F-FDG-PET/CT scan was performed according
to the standard protocol. Serum β2M levels were mea-
sured by radioimmunoassay.Results: Different patterns of
18F-FDG-PET/CT uptake were described in 22 MM pts.
Diffuse 18F-FDG-PET/CT uptake was detected in the
bone marrow before other visual methods in 2 patients
without bone lesions. The metabolic activity correlated
with the percentage of bone marrow plasmocytes. The
median serum β2M levels was 4,3 mg/l.In one patient
bone lesions showed focally increased FDG uptake.
Nineteen pts had a multifocal pattern of FDG-PET/CT
uptake. A total of 76 bone lesions were detected in the
calvaria, spine, ribs, pelvis and long bones. The pts with
advanced disease had median serum β2M levels of 9,2
mg/l.The extramedullary lesion in the soft tissues was
detected in 18.2% (4/22) pts. The potential of PET/CT
to detect medullary and extramedullary lesions in a sin-
gle examination is important advantage over other visu-
alization methods.18 F-FDG PET revealed 3 previously
unknown additional lesions in two patients. The diagno-
sis was confirmed by bone and bone marrow biopsy.
The median SUV max value of PET/CT scans of the
pathological foci was 5.8.Conclusion: The results
showed the effectiveness of the PET/CT in detection of
skeletal involvement and bone marrow infiltration in pa-
tients with MM. Our data showed that 18 F-FDG PET
uptake correlated significantly with increased serum
β2M levels.
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Diagnostics of multiple myeloma using FET PET/CT -
fesibility study
B. Malkowski1, A. Jurczyszyn2, R. Lopatto1, M. Wrobel1,
M. Olejniczak1, J. Czyz3; 1Oncology Centre, Bydgoszcz, PO-
LAND, 2Hematology Clinic, JU, Krakow, POLAND, 3Uni-
versity Hospital, Bydgoszcz, POLAND.
Aim: Precision of FDG PET/CT scans in diagnostics of mye-
loma is not certain, but is better than conventional methods of
imaging. Publications give us conflicting results. Due to reac-
tions in bone marrow and post-terapeutic changes, assessment
and adequate conclusions using FDG could be difficult. There
are some reports about possibility of using amino-acid tracers
in this type of cancer. Positive experiences with 11C-
methionine confirm possibility of apply this group of
radiopharmaceutics in myeloma. Because the methionine's
transport and metabolism is similar to another aminoacid like
thyrosine, we are trying to use 18-fluoro-ethyl-thyrosine (FET)
to diagnose myeloma level of advance. Materials: 31 patients
from 34 to 72 years old (mean 59,6) with myeloma. They were
referred from Hematology Clinic to differentiate changes
which were detected with different methods like CT, X-ray
or MRI, in which there were doubts of possibility of the active
disease or the place of disease was unknown. Methods: FET
PET/CT were performed before start of treatment. FET were
produced in our Laboratory in Oncology Centre in Bydgoszcz
using module Syncrom R&D (Raytest). The acquisition was
made 60 minutes after injection of 350±10 MBq FET. The
acquisition were performed on BiographmCT128 or Biograph
mCT20 scanners. Foci of higher metabolism FET than back-
ground with coexistence or not myeloma changes in CT scans
was stated as pathological. The background activity in
the brain, spleen, gluteus muscle, Th10 and L4 and was
assessed. Results of PET were compared with clinical
stage and background activity. Results:23 patients had
active disease and 8 were in remission( not active)
FET-PET was negative in 8 patients in remission , pos-
itive in 23 patients with active disease. FET PET/CT
results were in the agreement with clinical state of the
patients. In FET-PET/CT scans SUV values in the path-
ological foci (103) were 1,850-6,02 (average 3,57).
There were lesions characteristic for myeloma in CT
scans without metabolic activity in FET . We found five
FET foci, which haven't been discovered by other ex-
aminations in four from the group of FET-PET positive
patients. Mean background activity ( SUV max) was :
brain - 1,1, spleen - 2,3, muscle - 1,74, Th10 - 2,14, L4
- 1,82. In individual patients background activity ( apart
from spleen) was clearly lower than in pathological foci.
Conclusion: FET could be the tracer used in diagnostics
of multiple myeloma.
P744
Possibility of the early assessment of treatment
effectiveness in multiple myeloma by FET PET/CT- initial
results
B. Małkowski1, R. Lopatto1, M. Wróbel1, M. Olejniczak1,
A. Jurczyszyn2, J. Czyz3; 1Oncology Centre Bydgoszcz,
Bydgoszcz, POLAND, 2Haematology Clinic Jagiellonian
University, Kraków, POLAND, 3Haematology Clinic CM
NC University, Bydgoszcz, POLAND.
Aim: There are experiences with 18-fluoro-ethyl-
thyrosine (FET) to diagnose activity of disease multiple
myeloma. The aim of the study was to use this amino-
acid tracer to assess early treatment efficacy in this
disease.Materials: 6 patients from 56 to 65 years old
(mean 62) with newly diagnosed of multiple myeloma.
They were referred from Hematology and Clinical Oncol-
ogy Clinics to treatment efficacy.Methods: First FET
PET/CT were performed before start of treatment. Second
FET PET/CT were performed after the second course of
chemotherapy just before the third course. FET were pro-
duced in our Laboratory in Oncology Centre in Byd-
goszcz using module Syncrom R&D (Raytest). The ac-
quisitions were made 60 minutes after injection of 350
±10 MBq FET. The acquisition were performed on
Biograph mCT128 or Biograph mCT20 scanners. Foci
of higher uptake of FET than background with coexis-
tence or not myeloma changes in CT scans were stated as
pathological. We compared individual uptake in all patholog-
ical foci (SUVmax) in these two examinations.Results: All 6
patients had active disease in first examination FET-PET. In
first FET-PET/CT scans SUVmax values in the pathological
foci were 3,85-8,2 (average 5,24). In second examination, after
second course of chemotherapy, SUVmax values in the path-
ological foci were 1,5-2,7 (average 2,31). In second FET PET/
CT scans SUV values were clearly lower than in the first
examination.We were noticed significant decline of SUVmax
in average 53% (from 34% to 74%).Conclusion: FETcould be
the tracer used in diagnostics and assessment of treatment ef-
fectiveness in multiple myeloma.
P745
Diagnostic value of F-18 FDGPET-CT imaging inmultiple
myeloma
F. CANBAZ1, Y. USTA1, O. YAPICI1, M. TURGUT2;
1Ondokuz Mayis University Hospital, Faculty of Medicine,
Nuclear Medicine Dept., KURUPELIT / SAMSUN, TUR-
KEY, 2Ondokuz Mayis University Hospital, Faculty of Med-
icine, Hematology Dept., KURUPELIT / SAMSUN,
TURKEY.
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Aim:Multiple myeloma(MM) is a malignant neoplasm of plasma
cells producing a monoclonal immunoglobulin that ac-
cumulate in bone marrow(BM) leading to bone destruc-
tion and marrow failure.According to The IMWG, di-
agnosis of MM requires the fulfillment of the following
criteria:Clonal bone marrow plasma cells ≥10% or
biopsy-proven bony/soft tissue plasmacytoma PLUS
one of related organ/tissue impairment(Anemia,Hyper-
calcemia,Renal insufficiency and bone lesions).The skel-
eton is involved in more than 80% of patients at the
time of initial diagnosis.Conventional imaging may miss
bone lesions related to the disease.The value of F18-
FDG PET in the diagnostic approach of MM remains
incompletely elicited.The aim of this study was to eval-
uate the diagnostic value of FDG-PET CT imaging in
MM. Material and Methods:Thirty patients, clinically
suspected of MM and who underwent FDG PET-CT
imaging were retrospectively analyzed.According to the
diagnostic criteria, findings of bone BM biopsy, pres-
ence of plasmasitoma with monoclonal gammopathy
and tissue impairment parameters were examined.
Results:The mean age of the patients was 60.51
±11.43(20 Male;10 Females).Considering the diagnostic
criteria of MM, 18/30 patients were fulfilled the diag-
nostic MM criteria and of these, 7/18 patients showed
multiple hypo-hypermetabolic lytic lessons, 5/18 pa-
tients showed increased heterogenic BM activity.In 2
patients with biopsy-proven skeletal plasmacytoma,
multiple hypermetabolic lesions were detected;in 4/18
patient, no abnormality could be found on PET/CT
imaging.PET/CT scan provided the diagnosis of MM
in three patients with >10% plasma cells (without any
other organ impairment parameters) by showing hyper-
metabolic lytic lesions.Patients with <10 % plasma cells
in BM, had negative findings or increased minimal
heterogen BM metabolic activity.Of 10 patients with
%10-60 plasma cells in BM, 4 had negative findings,
2 had heterogenic metabolic activity in BM and 4 had
multiple lytic lesions on FDG PET/CT scan.All of the
3 patients with >60% plasma cells in BM, had multiple
lytic lesions FDG PET/CT scan. Conclusion:It is impor-
tant to distinguish MM from other causes of the clini-
cal presentations for prognosis and treatment.To dis-
criminate MM patients in a timely fashion is also cru-
cial since a major delay in diagnosis leads to a nega-
tive impact on the disease course.Patients with negative
PET/CT demonstrated the lowest bone BM plasma cell
infiltration, whereas those with multiple lytic lesions in
different metabolic activity showed the highest BM in-
filtration rate.Our results supported that FDG PET CT
imaging is useful in the diagnostic workup of MM and
it can provide to make correct diagnosis or help to
exclude other clinical presentations mimicking MM.
P746
Discrepancies in detection of Myeloma's bone lesions
between PET and CT components in 18F-FDG PET/CT
studies.
L. F. León Ramírez, C. González Roiz, A. Ortega Candil, C.
Rodriguez Rey, A. Serrano Palacio, C. Riola Parada, R. Couto
Caro, J. L. Carreras Delgado; Hospital Clinico San Carlos,
Madrid, SPAIN.
AIM: To detect bone lesions by using PET/CT technique in pa-
tients with diagnosis of Multiple Myeloma (MM). Material and
Methods: We retrospectively reviewed 29 studies performed in
our Nuclear Medicine Department from November 2008 to Jan-
uary 2015 and we correlated these findings with MR results.
Lesions detected with CT were independently evaluated from
FDG uptakes suggestive of malignancy in PET. We established
a scale to evaluate CT findings according to the number of lytic/
sclerotic bone lesions, considering as an independent lesion the
presence of diffuse bone involvement, in the form of osteopenia or
myelomatosis. To evaluate PET results, the number of focal path-
ological FDG uptakes was considered and diffuse bone marrow
involvement was also considered an independent lesion. Results:
29 studies were analyzed. There were 14 women and 15 men
(mean age 62.9 years old) with diagnosis of MM. 55% of them
were heavy chains (45% IgG, 10% IgA). The remaining (45%)
wereBence Jones or not secreting (46%Kappa, 17%Lambda and
the remaining non-secretory). In 9/29 studies the same number of
lesions were detected with both techniques. In 16/29 studies the
CT detected more lesions than PET and in 4/29 the PET detected
no visible lesions in CT, with a moderate index of agreement
(kappa 0.46). From the total number of lesions detected with the
CTcomponent, PET detected 67% of them (Rho Spearman Index
0.66). It was taken into account if the patient received systemic
therapy at the time of the test, and no statistically significant dif-
ferences in the detection of lesions were found. Conclusions: PET
has a lower detection rate of bone lesions in multiple myeloma,
possibly because it is unable to detect low-grade lesions, which
makes imperative the combined use with CT.
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Bone scintigraphy as a new imaging biomarker:
the relationship between bone scan index and PSA
in prostate cancer patients receiving radium-223
dichloride therapy.
Y. Nakagami, D. Kano, M. Kusumoto; National Cancer Cen-
ter, Chiba, JAPAN.
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Aim: A computer-aided diagnosis system for bone scintigraphy
with a semiquantitative index from the Bone Scan Index (BSI)
has been used to quantify the spread of bone metastases. How-
ever, few papers have made clear associations among BSI, bone
metabolic markers, and prostate-specific antigen (PSA). And the
estrangement between the progression of cancer and a value of
the PSA may become for the castration-resistant prostate cancer.
On the other hand, radium-223 dichloride, a targeted α-emitter,
improved overall survival and was well tolerated in patients with
castration-resistant prostate cancer and symptomatic bonemetas-
tases. The objective of this study was to explore the prognostic
value of the Bone Scan Index (BSI) obtained at the time of
diagnosis in a group of high-risk prostate cancer patients receiv-
ing radium-223 dichloride therapy. Materials and Methods: This
was a retrospective study based on consecutive prostate cancer
patients at high risk, based on clinical stage (T2c/T3/T4),
Gleason score (8 to 10) and prostate-specific antigen (PSA)
(>20 ng/mL), who had undergone whole-body bone scans < 3
months after diagnosis and who received radium-223 dichloride
therapy. The intervals between bone scans and blood examina-
tions were 0-16 days (median 0 day). The serummarkers of PSA
were examined. Subjects were divided into 4 groups according
to BSI; Group A: 0 to <2, Group B: 2 to <4, Group C: 4 to <8,
and Group D: over 8. BSI was calculated using an automated
method. BSI, which corresponded to the amount of metastatic
lesion, was automatically calculated by BONENAVI software
(FUJIFILM RI Pharma, Co. Ltd., Tokyo, Japan; Exini
Bone, Exini Diagnostics, Sweden). Results and Conclu-
sions: In a multivariate analysis, Gleason score and BSI
were associated with survival, but clinical stage and
PSA were not prognostic. The 5-year probability of sur-
vival was 52% for patients without metastases, 41% for
patients with BSI < 1, 30% for patients with BSI = 1 to
5, and 0% for patients with BSI > 5. All bone scans
showed high uptake with bone metastases. BSI did not
correlate significantly with the serum PSA. The changes
in BSI did not show a close relationship with the serum
PSA. The BSI can be used as a complement to PSA to
risk-stratify high-risk prostate cancer patients at the time
of diagnosis. This imaging biomarker, reflecting the ex-
tent of metastatic disease, can be of value in patient
management when deciding on radium-223 dichloride
therapy.
P748
Automatic bone scan index for therapy response
assessment of radium-223-dichloride (Ra-223) therapy
in advanced prostate cancer
M. Sakretz, J. Kurth, S. M. Schwarzenböck, B. J. Krause, M.
Heuschkel; Rostock University Medical Center, Department
of Nuclear Medicine, Rostock, GERMANY.
Aim: Evaluation of progression and therapy response is needed to
improve and optimize individualized therapy management of pa-
tients suffering frommetastatic castration resistant prostate cancer
(mCRPC). However, there is a lack of consistent data for therapy
response assessment to optimize treatment. Treatment decisions
based on PSA-value alone are inadequate, therefore other clinical
and radiologic criteria indicating disease progression should be
taken into account. Therefore we evaluated the utility of an auto-
matic bone scan index (aBSI) to assess response to Ra-223-
therapy in patients with mCRPS with bone metastases, in com-
parison to established responsemarkers, e.g. number of lesions or
PSA.Materials andMethods: Nine patients with clinical progress
of bone metastases from mCRPC, who underwent 6 cycles of
Ra-223-therapy were retrospectively included in this pilot study.
Whole-body bone scans with Tc-99m-DPD were performed and
blood samples were taken approximately four weeks before and
after 6 cylces of Ra-223-therapy. The aBSI was calculated using
EXINIboneBSI (EXINI Diagnostics AB, Sweden). Changes of
aBSI, number of lesions, levels of PSA and alkaline phosphatase
(AP) were compared pre- and post-therapy. Correlation between
aBSI and PSA as well as AP was evaluated by calculation of
Pearson’s correlation coefficient. Results: Therapy response /
progress was defined as decreasing / increasing aBSI, less / more
than two new lesions in whole-body bone scan and lower / higher
PSA level compared to baseline. Response was found in 2/9 (22
%), stable disease in 1/9 (11%) and progress in 6/9 (67%) of the
patients. The median aBSI was 2,67±2,62 at baseline scan and 2,
71±2,73 at control scan after 6 cycles of therapy. The median
number of lesions was 18±40 and 22±42, respectively. The me-
dian PSA level was 38,5±339,19 and 46,7±364,63, respectively.
Median alkaline phosphatase level was 1,28±1,87 and 1,23±2,18,
respectively. The ΔaBSI (mean 0,04±0,86) showed a statistically
significant correlation withΔPSA (mean 60,79±117,2; r = 0,76, p
= 0,014) and weaker one with ΔAP (mean -0,28±1,86; r=0,59, p
= 0,093). Limitations are the small patient sample-size, the retro-
spective analysis and high inter-individual variability. Conclu-
sions: The aBSI might be a useful and promising data analysis
tool for the assessment of therapy response to Ra-223. Studies in
larger cohorts are needed.
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Benefits of performing ultrasound and US-guided FNAC
in melanoma patient scheduled for sentinel lymph node
biopsy
G. Horvatic Herceg1, I. Bracic1, M. Kralik2, D. Herceg3, S.
Kusacic-Kuna1, J. Antulov4; 1Clinical department of nuclear
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medicine and radiation protection, University Hospital Center
Zagreb, Zagreb, CROATIA, 2Department of radiology, Uni-
versity Hospital Center Zagreb, Zagreb, CROATIA, 3Depart-
ment of Medical Oncology, University Hospital Center Za-
greb,, Zagreb, CROATIA, 4Clinical department of histopa-
thology, University Hospital Center Zagreb, Zagreb,
CROATIA.
Lymph node status is the most meaningful prognostic
indicator for overall survival of patients with stage I/II
melanoma. Sentinel lymph node biopsy (SLNB) has be-
come a common procedure in melanoma and it is con-
sidered to be a highly accurate procedure that allows
appropriate regional nodal staging and identification of
patients without nodal metastases. However, this method
brings also some disadvantages: certain degree of inva-
siveness, possible risk of unnecessary surgery and the
high cost of the procedure. Therefore, high-frequency ul-
trasonography (US), with fine needle aspiration cytology
(FNAC) of suspicious lymph nodes, was investigated as a
tool to identify or exclude nodal disease in melanoma
patients. Methods: 136 consecutive patients with cutane-
ous melanoma (75 females and 61 males; mean age 59
years, range: 19-81 years) planned for SLNB between
August 2008 and April 2015 were included in the study.
The preoperative US of the regional lymph node basins
was carried out in 136 SNB candidates with FNAC of
suspicious lymph nodes (LN). In cases of malignant find-
ings, patients were submitted to complete lymph node
dissection (CLND). The findings were correlated with
histopathology after CLND. Results: In 23 SNB candi-
dates, the US-guided FNAB was positive for metastases
and they proceeded directly to CLND. All FNAC find-
ings were confirmed by histopathology, with no false
positive results. There were 9 false negative results out
of 113 patients with negative echographic findings. In
those patients histopathology revealed metastases, mostly
in form of small foci of tumor cells or individual atypical
cells. The sensitivity, specificity, positive predictive val-
ue, and negative predictive value of US combined with
FNAC were 71.87%, 100%, 100% and 92.04%. Conclu-
sion: Patients with US suspicious regional lymphadenop-
athy confirmed to be of metastatic nature by preoperative
FNAC, should undergo a therapeutic LND. However, in
such patients, especially those with primary melanoma of
the trunk or head and neck, lymphoscintigraphy should
be considered to identify other nodal basins at risk, and
SLNB in these areas may be performed in conjunction
with therapeutic lymphadenectomy of the clinically in-
volved nodal basin. More advanced US probes should
allow better spatial resolution and assessment of lymph
node vascularization, enabling diagnosis of metastasis
measuring less than 2 mm in diameter.
P750
Sentinel Lymph Node Biopsy for Melanoma: our
Experience
E. M. Triviño-Ibáñez, N. Testart, J. M. Ruiz-López, R.
Sánchez-Sánchez, J. M. Llamas-Elvira; Virgen de las Nieves
University Hospital, Granada, SPAIN.
Objective: to analyze our experience in the use of SLNB in
melanoma and identify the predictive factors of positive SLNB
and poor prognosis. Patients andmethods: Retrospective study
of 109 patients who underwent SLNB for melanoma between
December 1999 and November 2013. Demographic, topo-
graphic characteristics of MM were collected, histologic fea-
tures of the tumor (Breslow thickness, presence of ulceration,
mitotic index, regression), distribution and drainage of the
sentinel node (SN), result histogycal, development of distant
metastasis and survival time. Results: 109 patients (mean age
of 51.69 ± 15.05 years, women 56%). The most common
tumor location was the trunk with 50 cases (45.9%), followed
by the lower limbs with 36 (33%), upper limbs 20 (18.3%) and
head and neck in 3 cases (2.8%). The median Breslow thick-
ness was 2.43 ± 1.92 mm, with the presence of tumor ulcera-
tion in 23 (21.1%) cases. SN number of isolates was between 1
and 4, being in 80 cases (73.4%) of single location. The de-
finitive study of the SN was positive in 26 (23.9%) patients.
Related factors statistically significant, with a positive
result of SN were: age at diagnosis (49.10±14.79 vs
59.96±12.93 years, p= 0.01), Breslow thickness (1.98
±1.57 vs 3.82±2.22 mm; p <0.01), male sex (32/83 vs
16/26, p= 0.039, OR: 2.55) and tumor ulceration (12/44
vs 11/19, p= 0.021). The average follow-up was 60.08
±47.47 months. 10 patients have died (9.2%) and 21
(19.3%) developed metastases. Of the 21 patients who
developed distant metastases, 12 (57.1%) had a positive
result in the SLNB, while it was negative in 9/21
(42.8%). The comparative analysis between patients
who developed metastases and those without, showed
statistically significant differences in age at diagnosis
(50.16±14.61 vs 57.71±15.95 years, p= 0.042), Breslow
thickness (2.20±1.85 vs 3.6±1.94 mm; p< 0.01), presence
of ulceration (13/50 vs 10/13 cases; p<0.01) and positive
SN (14/87 vs 12/21 cases; p<0.01). Survival analysis
shows statistically significant differences in age at diag-
nosis (50.8±15.1 vs 60.5±12.3 years, p= 0.039), Breslow
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thickness (2.28±1.89 vs 3.93±1.83 mm, p= 0.009), tumor
ulceration (18/57 vs 5/6 patients; p= 0.012), positive SN
(20/99 vs 6/10 patients, p<0.01) and development of me-
tastases (12/98 vs 9/10 patients, p<0.01). Conclusions: In
our study, age at diagnosis, Breslow thickness, ulceration
of the tumor and the positive outcome of the SN are the
main factors related to the development of metastases in
the MM determining decreased survival.
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“SPECTacles” for surgeons: SECT-CT visualization
of axillary sentinel lymph nodes in patients with breast
cancer - obligatory step of surgery planning
P. Krzhivitskiy, S. Kanaev, S. N. Novikov, P. Krivorotko, L.
Jukova; N.N. Petrov Institute Oncology, St Petersburg, RUS-
SIAN FEDERATION.
Purpose: to determine individual variability of axillary
sentinel lymph nodes (SLN) localization in patient with
breast cancer (BC) and to evaluate clinical value of
SPECT-CT for surgery planning in patients with breast
cancer. Material and methods: Individual topography of
axillary SLN was determined in 127 patients with early
BC. All women were candidates for breast conserving
surgery with SLN biopsy. SPECT-CT visualization of
SLN started 120-240 min after intratumoral injection of
74-150MBq of 99mTc-macrocolloids (200-1000nm). Tak-
ing into account large particle size all visualized LN were
considered as sentinel. Distribution of SLN in axillary
region was allocated to following subregions: central
(C), anterior pectoral (AP), sub-(SP) intrapectoral (IP),
lateral (L), subscapular (SSc), LN “lying on the ribs”
(Th). According to routine practice in our surgical depart-
ments surgeons take for evaluation SLN localized in C
and AP subregions. In patients with positive SLN axillary
dissection obligatory cover IP and SP nodes. Results:
SPECT-CT visualization of SLN demonstrated large vari-
ability in their localization. In most cases they were de-
tected in C (64 observations, 50.5%) and AP (34 women,
26.8%) subregions. In 19 (14.9%) cases SLN were re-
vealed in Th and in another 10 (7.8%) patients -in L or
SSc subregions. In 17 (13.4%) women SLN were local-
ized both on I and II (IP, SP) levels. Analysis of surgery
practice demonstrated that SLN “lying on the ribs” were
effectively biopsied only after introduction of SPECT-CT
technology. Biopsy of SLN localized in IP, SP, L and
SSc regions become more accurate. Finally we find that
in 14.9%-22.7% cases SPECT-CT visualization of SLN
can improve accuracy of this surgical procedure. Con-
clusion: SPECT-CT localization of SLN is an important
part of surgery planning because in 14%-23% patients
SPECT-CT data can improve accuracy of SLN biopsy
P752
Sentinel node biopsy in head and neck tumors. Validation
results
M. Bellón Guardia1, M. Talavera Rubio1, A. Palomar
Muñoz1, R. Galan Hernandez2, L. Gonzalez Lopez3, B.
González García1, V. Poblete Garcia1, F. Pena Pardo1, A.
Soriano Castrejon1; 1Servicio de Medicina Nuclear. Hospital
General Universitario, Ciudad Real, SPAIN, 2Servicio de
Cirugía maxilofacial. Hospital General Universitario, Ciudad
Real, SPAIN, 3Servicio de Anatomia Patológica. Hospital
General Universitario, Ciudad Real, SPAIN.
OBJECTIVE. Compare selective sentinel node biopsy
(SLNB) with conventional lymphadenectomy in patients with
head and neck tumor (HNT) and evaluate parameters of clin-
ical applicability. MATERIALWe have included patients with
HNT prospectively (PI 2010/63), clinical and radiological T1-
2N0 stage, diagnosed by FNA and scheduled for elective re-
section and uni or bilateral lymphadenectomy between 2010
and 2014. METHOD Preoperative lymphoscintigraphy was
performed 2-3 hours before surgery. Four doses of 9MBq of
radiocolloid were injected perilesionary. Planar and tomo-
graphic images were obtained, identifying the number and
anatomical location of the sentinel nodes (SN). The SN was
studied by staining H/E. RESULTS 29 patients were recruited
(22males) with HNT. The most common location was floor of
the mouth (10p) and tongue (10p). In all patients evidenced at
least 1 SN. In 11 patients bilateral lymphadenectomy was the
optimal treatment, analyzing a total of 40 procedures. We
found positive lymphadenectomy in 9 patients. We obtained
two false negative results, both in patients with floor of mouth
tumor. Regarding the 40 procedures, the detection rate of SN
in lymphoscintigraphy was 92.5%. In our series SLNB
showed a sensitivity of 80%, specificity of 100% and NPV
of 93.1% for the detection of disease. CONCLUSION To date,
these results allow the validation process of SLNB technique
in patients with HNT and implementation in our environment,
taking special care in floor of mouth tumors.
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The clinical impact of selective axillary dissection
after lymphoscintigraphy axillary reverse mapping
to reduce breast-cancer related lymphedema : long term
results of a preliminary study
M. Maccauro1, M. Gennaro2, A. Lorenzoni1, G. Aliberti1,
C. Sigari3, L. Bedodi3, M. Castellani1, E. Seregni1, R.
Agresti2, A. Caraceni3, M. Greco2, F. Crippa1; 1Nuclear
Medicine Unit, Department of Diagnostic Imaging and
Radioterapy, Fondazione IRCCS Istituto Nazionale dei
Tumori, Milan, Italy, Milan, ITALY, 2Breast Unit, Department
of Oncological Surgery, Fondazione IRCCS Istituto Nazionale
dei Tumori, Milan, Italy, Milan, ITALY, 3Department of Re-
habilitation and Palliative Care, Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy, Milan, ITALY.
Aim: Axillary reverse mapping (ARM) is a technique to dis-
tinguish the lymphatic pathway of the arm from that of the
breast allowing the sparing of the draining nodes and/or lym-
phatic ducts from the arm during axillary dissection. The use
of ARM may preserve upper extremity drainage preventing
breast-cancer-related lymphedema (BCRL) in patient with in-
dication for axillary lymph node dissection (ALND). The aim
of this study was to assess the feasibility of selective axillary
dissection (SAD) after ARM and to evaluate the rate of related
lymphedema. Materials and methods: From 06-2009 to 02-
2012 sixty patients (pts) stage with II-III breast cancer and
positive sentinel lymph node (SLNB) were enrolled in the
study. ARM procedure included lymphoscintigraphy that
was performed 4-6 hours prior SAD by three subcutaneous
injection of 99mTc-nanocolloid (15 MBq, 0.3 ml) into the
dorsum of hand. SAD was performed up to Berg’s level III
with the gamma probe to identify and preserve the arm’s lym-
phatic hot spot. Breast-cancer-related lymphedema was eval-
uated by physiatric assessment (increase > 2 cm of the arm
circumference) and lymphoscintigraphy of the upper extremi-
ties during follow-up. Results: SAD was performed in all pts
patients who underwent to ARM (60/60). The draining lymph
nodes were located medially to where the thoracodorsal
merged with the axillary vein in 40/60 pts or laterally to the
thoracodorsal vein in 5/60 pts. In 15/60 (25%) patients hot
nodes were removed during surgery because located below
the second intercostobrachial nerve, where metastatic spread
from breast carcinoma is most likely to occur. At a mean
follow-up of 39 months (range 19-59) 5/15 pts (33%) in who
hot node was removed developed BRCL. Only 2/45 pts in
who the draining nodes from the arm during were spared de-
veloped BRCL (4%). One of these 2 pts was previously treated
with the extend mantle field radiation therapy for Hodgkin's
Disease. None of the patients had nodal relapses during con-
sidered follow-up. Conclusion: Selective axillary dissection
using axillary reverse mapping is a feasible and safe procedure
to markedly reduce BCRL (33% pts with ALND vs 4% pts
with SAD).
P754
Contribution of SPECT/CT imaging to radioguided
sentinel lymph node biopsy in melanoma
J. Villanueva Curto, A. Cobo Rodriguez, A. Sainz-Esteban,
C. Gamazo Laherrán, M. González Selma, M. Ruíz Gómez,
M. Alonso Rodríguez, R. Olmos García; HOSPITAL
CLÍNICO UNIVERSITARIO DE VALLADOLID, Vallado-
lid, SPAIN.
Aim: To assess the contribution of SPECT/CT to planar
images in radioguided sentinel lymph node biopsy
(SNLB) in patients with melanoma in terms of diagnos-
tic accuracy and anatomic localization of sentinel node
(SN). Methods: We include 40 patients (21 women,
mean age: 57) with melanoma located in head and neck
(6), trunk (13) and limbs (21). Acquisition of dynamic
and static planar images was performed after the intra-
dermal administration (peritumoral/pericitricial) of
148 MBq of 99mTc-nanocoloidal albumin the day be-
fore surgery. A SPECT/CT was performed in all pa-
tients. Detection of SN was marked on skin. During
the surgical procedure a hand-held gammaprobe was
used to identify hot nodes. When SN showed metastasic
disease, lymph node dissection was performed. Results:
Seventy three SN were detected in planar images in our
40 patients (detection index: 100%). SN were located in
head and neck (15), truck (53) and limbs (4). SPECT/
CT did not detected additional SN, but prevented mis-
interpretation of false positive no-nodal site of uptake
(in 3 patients) that corresponded to contamination (3)
and a canalicule (1). SPECT/CT detected the exact ana-
tomical localization of all the SN but was specially use-
ful in 15 patients (37.5% of patients) in which the SN
were located in auricular (5) and cervical region (4),
face (5) and thorax (1). Besides, SPECT/CT changed
the anatomical localization of 5 SN in 4 patients (10%
of patients), which were located in axilar region on pla-
nar images and were correctly located in periscapular
region on SPECT/CT. Finally, in one patient SPECT/
CT confirm one suspicious uptake detected in the planar
study that resulted a SN in the inguinal region. Conclu-
sion: SPECT/CT detected the exact anatomical localiza-
tion of all the SN and improved the anatomical locali-
zation of SN already visualized on planar images in
almost a third of the patients. Besides, it improved the
characterization of no-nodal site of uptakes, dismissing
false positives findings and confirmed a suspicious
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uptake detected on planar images. However, SPECT/CT
did not detect additional SN.
P755
Review of breast cancer sentinel node scintigraphy
at Hospital da Luz - 2009-2013
V. Sousa, T. Cunha, C. Loewenthal, M. Vieira; Hospital da
Luz, 1500-650, PORTUGAL.
Aim- The aim of this study was to review our popula-
tion of breast cancer scintigraphy patients (pts) and de-
termine if there is any predictive factor in our cohort of
patients related to: a positive sentinel lymph node biop-
sy (SLNB), a positive axillary lymph node clearance
(ALNC) and recurrence rate after treatment. Materials
and methods- A retrospective analysis of 317 breast can-
cer sentinel node scintigraphies performed between Jan-
uary 2009 and May 2013 was undertaken. It included a
cohort of 313 patients (4 patients were bilateral tumours)
with clinical follow-up in our breast cancer unit (average
38 months). Statistical data analysis was processed with
SPSS. Results- All the patients were females with a
median age of 56 years (range 27-88y). The histological
types most often seen were invasive ductal carcinoma
(82%), in situ ductal carcinoma (8%) and invasive lob-
ular carcinoma (5%). Seventy-three percent of carcino-
mas were G2 Elston-Ellis, 25% G1 and 2% G3. The
average size was 15mm (median 13mm) (pT1 size fre-
quency of 76%). Of 317 SLNB performed, 47 (15%)
h a d m e t a s t a s e s o f w h i c h 4 0 ( 8 2% ) w e r e
macrometastases and 9 (18%) micrometastases. Of 47
positive SLNB, 44 patients underwent axillary dissection
(average 16 nodes excised) and 18 (41%) had additional
lymph node disease. The rate of sentinel node identifi-
cation by lymph node scintigraphy was 98% (310/317).
Of 7 lymph node scintigraphies in which the sentinel
node was not identified, due to non-drainage, 6 (86%)
underwent ALNC. Of these 6 ALNC performed, 3
(50%) had axillary metastatic disease. One of 7 pts
(14%) later presented with disease recurrence. The
disease-free survival rate was 97.5%, with a recurrence
rate of 2.5%. The median time to recurrence was 24
months. Using statistical analysis, lymphovascular inva-
sion (p~0,000) and size (p=0,002) were significant pre-
dictors for positive sentinel node, whereas non-drainage
(p=0,044) was a significant predictor for recurrence. In
this population we were not able to demonstrate a cor-
relation between positive sentinel lymph node and dis-
ease recurrence. Conclusion- Our study confirms a high
breast cancer sentinel node identification rate with
lymphoscintigraphy and suggests not only a correlation
between lymphovascular invasion, size and a positive
sentinel node, but also, a correlation between non-
drainage on scintigraphy and recurrence.
P756
Utility of sentinel lymph node biopsy in vulvar cancer.
A. SAINZ-ESTEBAN, A. Cobo Rodríguez, J. Villanueva
Curto, C. Gamazo Laherrán, M. González Selma, M. Ruiz
Gómez, M. Alonso Rodríguez, R. Olmos García; Hospital
Clínico Universitario de Valladolid, VALLADOLID, SPAIN.
Aim: the aim of the study was to determine the detec-
tion rate and negative predictive value (NPV) of sentinel
lymph node biopsy (SLNB) in vulvar cancer (VC). Ma-
terial y methods: A retrospective study from 2007 and
2014 has been performed in women with VC who
underwent SLNB in our service. A total of 8 women
were studied: one with melanoma, one with adenocarci-
noma of the bartholino gland, 5 with epidermoid carci-
noma and one with sebaceous carcinoma. Seven patients
presented a stage I and the patient with the melanoma
presented a stage IIb. Three patients had tumours in the
midline. None of the patients had clinically suspicious
inguinofemoral lymph nodes or previous treatment with
surgery, chemotherapy or radiotherapy. Acquisition of
dynamic and static planar images was performed after
the intradermal administration of 37-148 MBq of
99mTc-nanocoloidal albumin. A SPECT/CT was per-
formed in 6 the patients. In 5 patients excision of sen-
t inel lymph nodes (SLN) was fol lowed by an
inguinofemoral lymphadenectomy (IFL) (bilateral or uni-
lateral depending on tumour localization) because the
SLNB in this centre was under the validation period.
All patients were observed with follow-up for at least
9 months. Results: Eleven were identified in planar im-
ages detected 11 SLN in the 8 patients (detection rate:
100%). SPECT/TC did not detect additional SLN but
improved the anatomical localization of all the SLN.
Unilateral drainage was obtained in 7 patients and one
patient with a midline tumour presented bilateral drain-
age. SLN was positive for metastasis in 2 patients and
negative in 6. Of the 6 patients with negative SLN, the
IFL was negative in three and the follow-up in 2. The
last patient with a midline tumour presented a SLN in
the right groin that was negative for metastasis and did
not show other lymph node affected. However, the left
IFL showed several metastatic lymph nodes (false posi-
tive) (NPV: 5/6). Conclusion: SLNB seems to be a use-
ful technique for the detection of nodal involvement in
early stages vulvar malignancies.
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Comparative evaluation of 99mТс-Аl2O3 and 99mТс-fitat
nanocolloids for sentinel lymph nodes visualization
in patients with cervical cancer
I. Sinilkin1,2, V. Chernov1,2, A. Chernyshova1, L.
Kolomiets1, A. Titskaya1,2, R. Zeltchan1,2, O. Bragina2, A.
Lyapunov1, V. Skuridin2; 1Tomsk Cancer Research Institute,
Tomsk, RUSSIAN FEDERATION, 2Tomsk Polytechnic Uni-
versity, Tomsk, RUSSIAN FEDERATION.
Purpose: To study the feasibility of using of 99mТс-Аl2O3
and 99mТс-fitat nanocolloids for sentinel lymph nodes
(SLN) visualization in patients with cervical cancer. Materials
and methods: Nanocolloid 99mТс-Аl2O3 with size of nano-
particles 80-100 nm coated with organic covering was studied.
During passage through the lymphatic way nanoparticles lose
organic coating and strongly accumulate in the sentinel lymph
nodes without redistribution. Nanocolloid 99mТс-fitat has size
of nanoparticles 50-100 nm. The study included 35 patients
with cervical cancer of stage I. To identify sentinel lymph
nodes a 99mTc-Al2O3 was administered to 15 patients (first
group) and 99mТс-fitat was injected to 20 patients (second
group). Nanocolloid was injected peritumoral in four points
to 40 MBq one day prior to the planned operation. SPECT
study was performed at 18 hours after injection, intraoperative
detection was executed by gamma probe at 20 hours after
injection. Results: In the first group in all patients 19 SLNwere
identified in by SPECT and 24 SLN by gamma probe. Accu-
mulation of 99mТс-Аl2O3 in SLN was 7-11% by SPECTand
17-31% by gamma probe (in compare to spot of injection). In
the second group by SPECT in 17 patients 23 SLN were iden-
tified and by gamma probe in 19 patients 27 SLN were visu-
alized. Accumulation of 99mТс-fitat in SLN was 1,5-2% by
SPECT and 3-7% by gamma probe (in compare to spot of
injection). Conclusion: The clinical study of 99mТс-Аl2O3,
a new radiopharmaceutical agent, have shown that the studied
nanocolloid has high uptake level in SLN and can be success-
fully used for visualization of SLN in patients with cervical
cancer.
P758
Comparative evaluation of 99mТс-Аl2O3 and 99mТс-fitat
nanocolloids for sentinel lymph nodes visualization
in patients with cancer of larynx and hypopharynx
V. Chernov1,2, I. Sinilkin1,2, E. Choynzonov1,2, S.
Chijevskaya1, A. Titskaya1,2, R. Zeltchan1,2, O. Bragina2,
A. Lyapunov1, V. Skuridin2; 1Tomsk Cancer Research Insti-
tute, Tomsk, RUSSIAN FEDERATION, 2Tomsk Polytechnic
University, Tomsk, RUSSIAN FEDERATION.
Purpose: To study the feasibility of using of 99mТс-Аl2O3
and 99mТс-fitat nanocolloids for sentinel lymph nodes
(SLN) visualization in patients with cancer of larynx and
hypopharynx.Materials and methods: Nanocolloid
99mТс-Аl2O3 with size of nanoparticles 80-100 nm coated
with organic covering was studied. During passage through
the lymphatic way nanoparticles lose organic coating and
strongly accumulate in the sentinel lymph nodes without re-
distribution. Nanocolloid 99mТс-fitat has size of nanoparticles
50-100 nm. The study included 28 patients with cancer of
larynx and hypopharynx (T1-3NxM0). To identify sentinel
lymph nodes a 99mTc-Al2O3 was administered to 10 patients
(first group) and 99mТс-fitat was injected to 18 patients (sec-
ond group). Nanocolloid was injected peritumoral submucous
in four points to 40 MBq one day prior to the planned opera-
tion. SPECT study was performed at 18 hours after injection,
intraoperative detection was executed by gamma probe at 20
hours after injection.Results: In the first group in all patients 12
SLN were identified in by SPECT and 14 SLN by gamma
probe. Accumulation of 99mТс-Аl2O3 in SLN was 5-10%
by SPECT and 18-33% by gamma probe (in compare to spot
of injection). In the second group by SPECT in 16 patients 18
SLN were identified and by gamma probe in 17 patients 23
SLN were visualized. Accumulation of 99mТс-fitat in SLN
was 1,2-1,9% by SPECT and 3-6% by gamma probe (in com-
pare to spot of injection).Conclusion: the clinical study of
99mТс-Аl2O3, a new radiopharmaceutical agent, have shown
that the studied nanocolloid has high uptake level in SLN and
can be successfully used for visualization of SLN in patients
with cancer of larynx and hypopharynx.
P759
Axillary lymph node biopsy: standard radioisotopic
technique with 99mTc-nanocolloid versus new magnetic
tracers.
C. Castillo-Berrio, M. Castrillón, F. Zelaya, D. Ruiz, F. Loira,
J. M. Nogueiras, A. Lopéz, A. Serena, L. Campos; Meixoeiro
University Hospital., Vigo, SPAIN.
Objective: Asses radioisotopic SLNB versus with magnetic
tracer, in patients with breast cancer. Material and methods:
Prospective descriptive study (March-April / 2014): 22 pa-
tients, mean age 57.7 (41-78 years), axilla clinically and radio-
logical negative.Lymphoscintigraphy (24 hours before sur-
gery): peritumoral /subareolar injection, 4 doses of 37MBq/
0.5ml of 99mTc-nanocolloid. Images: 30 min and 2 hours;
SPECT-CT. Skin label in hot spots site.Surgery: post-anesthe-
sia, subareolar injection of magnetic tracer (2ml-Sienna + in
3ml /SSN). Breast massage for 5 minutes. Verification
counting on skin marks and after incision, alternatively with
radioactive and magnetic detector probes. Removing lymph
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activity (threshold 10% maximum, for both) and / or palpable.
Detection rate and number of sentinel lymph node extracted by
both techniques were compared. Results: Overall removed 58
(sentinel lymph nodes) in 22 Patient (2.64 nodes per
patient).Detection rate: 100% isotopic technique; 95.4% (21 /
22Patients) magnetic technique.Number of nodes identified:
39 (67.2%) radioactive, 45 (77.5%) magnetic, 11 (18.9%) ex-
clusively palpation.-Same Number of nodes with both tech-
niques (15 patients):• 11 Patients: negative.1 Patient: 2 nodes
excised both positive (macrometastasis andmicrometastasis).1
Patient: 2 nodes excised 1 positive (micrometastasis).1 Patient:
4 nodes excised 1 positive (micrometastasis).1 Patient: 2 nodes
excised, 2 positive (micrometastasis).-Different Number of
nodes (7 patients):• 5 patients, negative sentinel: magnetic
technique detected one or two additional nodes per patient,
compared to radioisotopic technique.• 1 Patient with 4 nodes
excised: two palpables (macrometastasis) not detected by any
method. Two sentinel nodes negatives (localized by magnet-
ic), only 1 by isotopic.• 1 Patient with the excision of 2 nodes:
the first (macrometastasis) detected with both, the second
(negative) only bymagnetic. Conclusions: Although the radio-
isotope technique was slightly more sensitive in our series,
both methods were equivalent in identifying sentinel location,
however magnetic tracer showed more lymph nodes number.
The diagnostic accuracy was similar with both tracers. When
radioisotopic technique is used, the possibility of
lymphoscintigraphy for infrequent drains detection, the num-
ber of sentinel nodes displayed, its economy and minimal risk,
supports the isotopic technique as the method of choice in
Centers with Nuclear Medicine Services availables.
P760
Clinical Impact of the Implementation of Radioguided
Localization of Non-Palpable Breast Tumors
C. SANDOVAL MORENO, M. A. BALSA BRETON, P.
GARCIA ALONSO, E. RODRIGUEZ PELAYO, M.
FERNANDEZ RODRIGUEZ, L. CASTILLEJOS
RODRIGUEZ, A. ORTEGA VALLE, C. PANIAGUA
CORREA, F. J. PENIN GONZALEZ; HOSPITAL
UNIVERSITARIO DE GETAFE, MADRID, SPAIN.
Aim: To evaluate our experience after implementation of
ROLL and SNOLL techniques in our hospital, comparing
the results between radioguide surgery and wire localization
in non- palpable breast tumours. Material and methods: We
have reviewed 31 cases of non-palpable breast tumours
marked with ROLL or SNOLL (ultrasound guide) and 29
cases with wire localization (ultrasound guide too), performed
in our hospital along a year. A single 11-148 MBq dose of a
99mTc -colloid radiopharmaceutical in 0.3-0.4 mlwas injected
for both, radioguided localization and sentinel lymph node
biopsy. Imaging guidance was achieved with sonography.
Inmediately, the patients were submitted frontal and lateral
view planar scintigraphic images and localization of the area
of highest radioactivity was performed with a hand-held gam-
ma probe on the breast. In the SNOL group more scintigraphic
images were performed at least 2 hours after the injection to
localize sentinel nodes. The next day the handheld gamma
probe was used to remove the non-palpable breast tumours
and sentinel nodes. We collected information about surgical
margins and reexcision performed the same day or in a second
procedure (depending on pathology results). Results: - 21/31
patients (67.7%) in the radioguided surgery and 24/29 (82.7%)
in the wire localization of non-palpable of non-palpable le-
sions needed intraoperative extending edges. - Reexcision
was performed in a second procedure only on 1 of the 31
patients undergoing radioguided surgery (3.22%). By contrast
it was necessary on 7 of the 29 undergoing wire localization
(24.14%). Conclusion: According to our experience, we can
conclude that radioguided surgery reduces the number of in-
traoperative extending edges and reexcision in a second pro-
cedure which benefits patients and decreased costs.
P761
Validation of selective sentinel node biopsy in patients
with adenocarcinoma of the prostate
with high-intermediate and high-risk
V. Vera Pinto, P. Bello Arques, C. Igua Sáenz, P. Borrelli, P.
Olivan Sasot, J. Vercher Conejero, J. Loaiza Góngora, P.
Sopena Novales, C. Ruiz-Llorca; Hospital Universitario y
Politécnico La Fe, Valencia, SPAIN.
OBJECTIVE: To determine the effectiveness of Selective Sen-
tinel Node Biopsy (SLNB) in patients with adenocarcinoma of
the prostate with high-intermediate and high-risk. MATERI-
ALANDMETHODS: Descriptive study of 27 patients (50-73
years old) in which SLNB was performed between August
2012 to March 2015 after ruling out distant metastases. All
patients were diagnosed with prostate adenocarcinoma in
high-intermediate or high-risk stages. Prior to surgery day,
10 mCi (370 MBq) of nanocolloids labelled with 99mTc were
injected within the prostate guided by transrectal ultrasound.
Simultaneously, abdominopelvic acquisitions were made with
portable gamma camera to ensure intraprostatic deposit of the
tracer. 2 hours later, planar abdominopelvic acquisitions were
performed, followed by SPECT / CT. In all cases, laparoscopic
technique was done, using portable gamma camera and scin-
tigraphic probe to identify radioactive lymph nodes and lym-
phatic drainage chains involved. Systematically, pelvic lymph-
adenectomy was performed, which will become extended in
cases where migration of the tracer reaches unusual lymphatic
territories. Abdominopelvic acquisitions with portable gamma
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S705
camera pre and post lymphadenectomy were also done. All
sentinel lymph nodes (SLNs) were removed and examined
with haematoxylin and eosin staining and immunohistochem-
ical techniques. RESULTS: In 100% of cases there was mi-
gration of the radiotracer with positive scintigraphy. 26%
(7/27) of patients presented metastatic SLN infiltration. 74%
of patients (20/27) were true negatives, obtaining negative
predictive value of 100%. In 48% (13/27) of patients there
was migration of the radiopharmaceutical to paraaortic chain,
and 40% (11/27) to presacral chains. CONCLUSIONS: SLNB
in prostate cancer is a reliable and useful tool, capable to iden-
tify first landing lymphatic chains of the prostate, therefore
allowing properly assessing lymph node involvement in pros-
tate cancer. It is also useful and able to detect patients with
atypical prostate lymphatic drainage, in which extended
lymphadenectomy should be indicated.
P762
Sentinel lymph node biopsy after neoadjuvant
chemotherapy in breast cancer patients with initial
axillary node metastasis
N. Testart, A. C. Rebollo-Aguirre, R. Sánchez-Sánchez, T.
Aroui, E. M. Triviño-Ibáñez, J. García-García, S. Menjón-
Beltrán, J. M. Llamas-Elvira; Hospital Universitario Virgen
de las Nieves, Granada, SPAIN.
Aim: To analyze our experience in sentinel lymph node biopsy
(SLNB) in patients with operable breast cancer treated with
neoadjuvant chemotherapy (NAC) with axillary involvement
at diagnosis. Materials and methods. Prospective study (2008-
2014) including 77 patients with infiltrating breast carcinoma
T1-3/N1 treated with epirubicin/cyclophosphamide, docetaxel
and trastuzumab in Her2/neu positive patients, in which was
performed SLNB. Axillary status at diagnosis was evaluated
by physical examination, MRi and/or mammary ultrasound,
with guided core needle biopsy and histopathological confir-
mation of lymph nodes involvement (n=69, 89.6%). After
NAC, reevaluation of axillary status was performed by MRi
(n=64) and ultrasound (n=41). Sensitivity and specificity of
both imaging techniques was calculated. After the NAC, the
day before surgery, an experienced nuclear medicine physician
performed the SLN identification and radiolabelling following
the periareolar administration of 99mTc-albumin nanocolloid
(4 intradermical/subdermical injections, total dose: 74-
111MBq), acquiring static imaging (minimum 2 projections)
and marking the skin guided by a gamma probe. In the surgery
room, patients underwent SLNB performed by an experienced
radiosurgery team and subsequently axillary lymph node dis-
section (ALND). SLN were examined by hematoxylin-eosin
staining and immunohistochemical analysis or OSNA (one-
step nucleic acid amplification). Identification rate (IR),
false-negative rates (FNR) and global accuracy (GA) were
determined. Histopathological analysis of both, breast tumor
and axillary status was set down at diagnosis and after the
NAC to determine the cases with pathologically complete re-
sponse (pCR). Results. The SLNB IR was 83.1% (95%CI:
73.2-89.8%) with a FNR of 8.3% (95%CI: 2.9-21.8) and a
GA of 95.3% (95%CI: 87.1-98.4%). In the axillary status after
the NAC, the ultrasound showed sensitivity: 55.6% (95%CI:
33.7-75.4%), specificity: 91.7% (95%CI: 74.2-97.7%), GA:
76.2% (95%CI: 61.5-86.5%) and MRi showed sensitivity:
60.0% (95%CI: 44.6-73.7%), specificity: 75.0% (95%CI:
55.1-88.0%), GA: 65.6% (95%CI: 53.4-76.1%). The molecu-
lar subtypes: Luminal-A (n=12, 15.6%) showed pCR in breast
(n=2), axilla (n=0), breast-axilla (n=3); Luminal-B/HER2-
(n=28, 36.4%) had pCR in: breast (n=2), axilla (n=1), breast-
axilla (n=6); Luminal-B/HER2+ (n=15, 19.5%) exhibited
pCR in breast (n=1), axilla (n=1), breast-axilla (n=7);
HER2+ (n=8, 10.4%) revealed pCR in: breast (n=1), axilla
(n=5), breast-axilla (n=2); and Triple negative (n=14, 18.2%)
showed pCR in: breast (n=3), axilla (n=2), breast-axilla
(n=7).Conclusions. SLN biopsy after NAC is a feasible and
accurate staging tool in patients with operable breast cancer
T1-3,N1 and clinically node-negative after therapy. Patients
with HER2+ and triple negative subtypes are potential candi-
dates for avoiding unnecessary ALND due to its higher axil-
lary node negative status after NAC.
P763
Sentinel lymph node biopsy in vulvar cancer. Our
experience after five years
J. Muñoz Iglesias1, G. Muñiz García1, B. Couso Cambeiro2,
J. Doval Conde2, R. Guitián Iglesias1; 1Nuclear Medicine
Department. Complejo Hospitalario Universitario de Ourense,
Ourense, SPAIN, 2Gynecology and Obstetrics Department.
Complejo Hospitalario Universitario de Ourense, Ourense,
SPAIN.
Purpose: To assess the reliability of sentinel lymph node biop-
sy (SLNB) in the inguinal lymph node staging of vulvar cancer
and describe the technique and the results obtained after the
validation stage. Material and Methods: A retrospective study
from November 2009 to Febrary 2015 was performed in
thirty-one patients with vulvar cancer (94% squamous cancer,
mean age 71.24 years), who underwent SNLB. In all cases,
local anesthetic cream was applied 90-120 minutes before the
lymphscintigraphy (perilesional/pericicatricial injections,
0.1 ml of 99mTc-nanocolloidal albumin per injection; total
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activity was 74 MBq). Dinamic study and static planar images
were acquired sixty minutes post-injection (256x256 matrix,
zoom 1 and cobalt source). It was regarded as SLN any in-
creased focal uptake with drainage path and / or near the in-
jection site. The SLNs detected were marked on skin.SLNs
were removed during surgery guided by a gamma probe, with
or without dye. Histological analysis with hematoxylin / eosin
was made.Clinical and imaging follow-up was performed. Re-
sults: Fifty-four SLNs were identified in planar images in the
31 patients (detection rate 94%; 29/31), mean 1,75 nodes/pa-
tient: unilateral lymphatic drainage was obtained in 21/31
(72%) and bilateral drainage in 28%. The radiotracer did not
migrate in two patients but in one of them, the dye did
it.Histological grades: G1 19 (61.3%), G2 11 (35.5%) and
G3 1 (3.2%). Eighteen patients had lesions ≤ 2 cm and 13
patients had lesions> 2 cm.FIGO staging: IA 6 patients
(19.3%), IB 16 patients (51.6%), IIIA 7 patients (22.6%) IIIB
1 patient (3.2%) and IV 1 patient (3.2%).The SLN was nega-
tive in 22 patients (71%), 91% of them showed no recurrence
at follow-up.The most common postoperative complication
was wound dehiscence (22%). Conclusion: In our experience,
SLNB in patients with vulvar carcinoma is safe and accurate,
achieves suitable nodal staging and avoids lymphadenectomy
in patients with negative sentinel node.
P764
Sentinel lymph node biopsy and neoadjuvant
chemotherapy in breast cancer patients: a single
institution experience.
A. C. Rebollo-Aguirre, N. Testart, R. Sánchez-Sánchez, T.
Aroui, E. Triviño-Ibáñez, J. García-García, S.Menjón-Beltrán,
J. M. Llamas-Elvira; Hospital Universitario Virgen de las
Nieves, Granada, SPAIN.
Aim: To analyze our experience in sentinel lymph node biopsy
(SLNB) in patients with operable breast cancer treated with
neoadjuvant chemotherapy (NAC). Materials and methods.
Prospective study, from january 2008 to december 2014, in-
cluding 235 SLNB in patients with infiltrating breast carcino-
ma T1-3/N0-1 treated with epirubicin/cyclophosphamide, do-
cetaxel and trastuzumab in Her2/neu positive patients, in
which was performed SLNB. Exclusion criteria: inflammatory
carcinoma, previous breast treatment with surgery or radio-
therapy, multicentric tumors, metastatic disease, 2nd malig-
nancy, progression of disease during NAC, pregnancy or
breastfeeding and age <18y. Axillary status at diagnosis was
evaluated by physical examination, MRi and/or mammary ul-
trasound, with guided core needle biopsy of any suspicious
lymph node and histopathological analysis. After NAC,
reevaluation of axillary status was performed by the same
imaging procedures. The day before surgery, an experienced
nuclear medicine physician performed the SLN identification
and radiolabelling following the periareolar administration of
99mTc-albumin nanocolloid (4 intradermical/subdermical in-
jections, total dose: 74-111MBq), acquiring static imaging (at
least 2 projections) and marking the skin guided by a gamma
probe. In the surgery room, patients underwent SLNB per-
formed by an experienced team of surgeons and a nuclear
medicine physician, guided by a gamma probe and subse-
quently axillary lymph node dissection (ALND). SLN were
examined performing hematoxylin-eosin staining and immu-
nohistochemical analysis (n=92) or OSNA, one-step nucleic
acid amplification (n=114). Identification rate (IR), false-
negative rates (FNR) and global accuracy (GA) were deter-
mined. Results. Patients were divided into 4 groups according
to their clinical and pathological caracteristics and the intended
management: i) Group I-SLNB-preNAC in patients cN0 at
diagnosis: n=73, IR: 97.2% (95%CI: 90.5-99.2%); ii) Group
II-2thSLNB-posNAC in patients pN1(sn) at diagnosis: n=31,
IR: 61.3% (95%CI: 43.8-76.3%), FNR: 18.2% (95%CI: 5.1-
47.7%), GA: 89.5% (95%CI: 68.6-97.1%); iii) Group III-
SLNB-posNAC in patients cN0 at diagnosis: n=54, IR:
96.3% (95%CI: 87.5-99.0%), FNR: 9.5% (95%CI: 2.7-
28.9%), GA: 96.2% (95%CI: 87.0-98.9%); and iv) Group
IV-SLNB-posNAC in patients cN1 at diagnosis and ycN0
postreatment: n=77, IR: 83.1% (95%CI: 73.2-89.8%), FNR:
8.3% (95%CI: 2.9-21.8%), GA: 95.3% (95%CI: 87.1-98.4%).
Conclusions. The detection rate for the SLNB is excellent
prior NAC. A second SLNB after NAC in women with a
positive SLN at diagnosis is not a useful option. SLNB after
NAC is feasible in cN0 and cN1 patients at diagnosis, clini-
cally axillary node-negative after therapy (ycN0), with poste-
rior ALND if positive SLNB or not migration, when it is
performed by an experimented multidisciplinary team.
P765
Cervix Cancer: our Experience Using Lymphatic
Mapping and Sentinel Node Biopsy
P. Olivan Sasot, P. Borrelli, C. Igua Sáenz, V. Vera Pinto, P.
Bello Argués, J. Loaiza Góngora, C. Ruiz Llorca, A. Repetto;
Hospital La Fe, Valencia, SPAIN.
AIM: To correlate the images obtained using lymphatic mapping
and sentinel node biopsy (SLNB)with anatomopathologic results
from pelvic lymph node dissection in patients with cervix cancer
refered to nuclear medicine department prior to surgery interven-
tion. MATERIALS AND METHODS: 25 patients were includ-
ed, with an average age 51,2 years (31-80), fromNovember/2009
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to January/2015. Three injections were performed peritumorally
using 6mCi of 99mTc-albumin nanocolloid in a volume of 0.4ml
x 3 injections. After injection static pelvic imaging was obtained
using Philips BrightView XCT gamma camera, to visualize
radiofarmaceutical migration. In 16 patients, SPECT/CT was
added to improve lymph node anatomical location. RESULTS:
Location rate was 88% (22 patients), in the remaining 12% no
migration was detected and in lymph node dissection, lymph
node metastasis was found. Para-aortic sentinel lymph node
was found in 2 of our patients. Surgery average lymph node
was 2,27 per patient. 4 patients had SLNBpositive for metastasis.
The remaining 18 were negative, and pelvic lymph node dissec-
tion didn't shown any metastatic infiltration. Later monitoring,
one patient presented tumoral relapse with-in 4mesenteric lymph
nodes metastatic, and colonic infiltration. Another one, presented
tumoral relapse in suture stitches. After global evaluation of these
results, 100% negative predictive value was established to the
technic for pelvic lymphatic node affection in this patient series.
CONCLUSION:A negative result in the anatomopathologic sen-
tinel node biopsy, would be reasonable motive to limit pelvic
lymph node ressection extension to the sentinel node, and it
would avoid associated comorbidity. Rare lymph node chain
drainage like para-aortic was found.
P766
Feasibility of 3D-image guided resection
of neuroendocrine tumours
C. Bluemel, M. Gasser, M. Fassnacht, R. A. Werner, A. K.
Buck, K. Herrmann; Universitätsklinikum Würzburg,
Würzburg, GERMANY.
Aim: The aim of this study was to evaluate the feasibility and
advantages of 3-D image guided resection of gastro-entero-
pancreatic neuroendocrine tumours (GEP-NET) and their me-
tastases. Methods:4 patients with initial diagnosis of a GEP-
NET and scheduled for tumour resection were included in this
prospective study. All patients underwent somatostatin-
receptor (SSTR) scintigraphy (111-In-octreotide; mean,
114 MBq (98-148 MBq)) on the day prior to surgery to local-
ize the primary tumour and metastases. On the following day
intraoperative tumour localization was guided by palpation,
ultrasound and radioguided procedure with freehand SPECT
allowing for intraoperative imaging SSTR-positive tumour le-
sions and dedicated 3-D navigation to tumour lesions. Results:
2 patients had a pancreatic NET (insulinoma) and 2 patients
suffered from a metastasized (both lymph node metastases,
one patient additional liver metastases) ileum NET. In all pa-
tients localization and visualization of tumour lesions using
freehand SPECTwas feasible. However, also with convention-
al localization techniques (preoperative imaging as road map,
palpation and ultrasound) all lesions could be successfully
localized. Conclusions: These preliminary data show for the
first time that 3-D image guided intraoperative localization of
GEP-NETs using freehand SPECT is feasible; however, ad-
vantages over conventional localization techniques could not
be demonstrated.
P767
Sentinel lymph node biopsy in patients with locally
advanced breast cancer with negative axilla
after chemotherapy
P. Olivan Sasot, P. Borrelli, C. Igua Sáenz, V. Vera Pinto, P.
Bello Arqués, J. Loaiza Góngora, C. Ruiz Llorca, P. Sopena;
Hospital La Fe, Valencia, SPAIN.
Aim: To demonstrate (sentinel lymph node biopsy)
SLNB validity in patients with locally advanced breast
cancer after neoadjuvant chemotherapy in negative axilla
pre-chemotherapy and cases that became negative after
chemotherapy. Materials and methods: SLNB was per-
formed after chemotherapy to 88 women (March 2007-
March 2015), aged from 27-73 years , with mean age
47,36 years . At 68 first patients, axillary lymphadenec-
tomy was made to validate SLNB technique, after that,
20 routine SLNB was made and LN was studied by
OSNA technic and exclusively in SLNB positive cases
or in those cases without radiopharmaceutical axillary
migration, lymphadenectomy was performed. Axillary
staging was made by fine-needle aspiration biopsy and/
or ultrasound, 45 patients had negative axilla and 43 had
positive axilla previous chemotherapy. Histology types
were infiltrating ductal carcinoma in 93,2% cases, and
infiltrating lobular carcinoma in 6,8%. Results: Lymph
node (LN) location rate was 74% (65/88). Medium LN
removed per procedure was 1,52. In the 45 patients with
negative axilla before chemotherapy: 29 patients had
negative SLNB, 6 positive and 10 had no migration.
In the 43 patients with positive axilla before chemother-
apy: 13 patients had negative SLNB, 17 positive and 13
had no migration. No radiopharmaceutical migration was
found in 23 patients (26%): anatomopathology results
were positive in 14 cases and were negative in 9. Con-
clusion: In women with locally advanced breast tumor is
safe to use SLNB after chemotherapy, also in cases of
negative axilla clinically and radiologically before che-
motherapy and in women who converted positive axilla
before chemotherapy to negative after treatment. Unnec-
essary lymphadenectomy its morbidity could be avoided
using this technic. High no radiopharmaceutical migra-
tion rate could be attributed to: metastasis in 61% of
cases (14/23) and fibrosis produced by chemotherapy
39% of cases (9/23).
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Differences in clinical-biological characteristics and SLN
detectability in different age-groups of breast cancer
patients
S. M. Nieves Maldonado, S. Argibay Vazquez, M. Garrido
Pumar, V. Pubul Nuñez, J. Cortes Hernandez, A. Ruibal
Morell; Hospital Clínico Universitario de Santiago de
Compostela, Santiago de Compostela, SPAIN.
AIMS: Our goal is to evaluate the differences in clinical-
biological characteristics and sentinel node detectability in dif-
ferent age- groups of patients diagnosed with breast
cancer.MATERIALS AND METHODS: Our study Involved
828 consecutive breast cancer patients who underwent isoto-
pic detection of SLN in our department, without known pal-
pable or ecographic lymph node invasion. lymphoscintigraphy
images were acquired after the injection of 111 MBq of tc99m
nanocolloid for SLN mapping. SLN localization at surgery
was performed using a hand-held gamma probe. Conventional
Histopathological study was used in 439 patients for SLN
analysis, and molecular examination (OSNA) was performed
in 387 patients. Axillary lymphadenectomy was indicated in
SLN positive cases. Mean age of patients was 58 (range 28-
88), and they were divided into four age groups: <40 years old
(n = 56), 40-54 (n = 272), 55-69 (n = 326), and > 70 (n =
174).RESULTS: The most frequent type of tumor was the
ductal infiltrating carcinoma (84%), the most common tumor
site was the upper outer quadrant (35%), and the left breast
was the most commonly affected (53%) for all groups. The
molecular diagnosis was predominantly negative Her2 Lu-
minal B (36%) in the younger group, and for the other age
groups it was the Luminal A type (40%). The group of
patients between 40 and 54 years had a higher proportion
of tumor multifocality (6%) than other groups. Most groups
p r e s en t ed an ave r age o f 2 f oca l d epo s i t s i n
lymphoscintigraphy, and in the older than 70 years group
a higher proportion of patients showed absence of migration
of the tracer (19.5%) compared to younger groups. Patients
under 40 presented with increased detectability of intraop-
erative sentinel lymph nodes (94.6%), this group of patients
showed a greater positivity of the SLN (52%), and the same
age group had fewer positive nodes at the lymphadenecto-
my (mean 1, range 0-13).CONCLUSIONS: In our popula-
tion there are no differences between age groups respect to
histological type, or location, however with regard to mo-
lecular type there is a tendency towards Luminal A type at
older ages. Mamography screening in middle-age groups
helps the detection of non-palpable lesions in this age
group; this is not the case for younger and older women.
As expected the higher prevalence of absence of scinti-
graphic visualization of SNL was found in the population
older than 70 years.
P769
ROLL technique application for Minimally-Invasive
Radioguided Parathyroidectomy (MIRP)
in Hyperparathyroidism (HPT)
I. Santi1, P. Carcoforo2, G. Trasforini3, S. Panareo1, C.
Cittanti1, C. Peterle1, V. de Cristofaro1, E. Degli Uberti3, L.
Feggi1; 1Sant'Anna University Hospital, Nuclear Medicine
Unit, Department of Diagnostic Imaging and LaboratoryMed-
icine, Ferrara, ITALY, 2Sant'Anna University Hospital, Breast
and Radioguided Surgery Unit, Surgical Department, Ferrara,
ITALY, 3Sant'Anna University Hospital, Endocrinology Unit,
Department of Medical Sciences, Ferrara, ITALY.
Aim: In HPT patients (pts) requiring surgery, MIRP is usually
associated to MIBI imaging for preoperative parathyroid lo-
calization and intraoperative guidance.Aim of our study was to
evaluate the feasibility and reliability of MIRP performed
through ROLL technique for enlarged parathyroid gland
(epg) localization, likewise the established method in non-
palpable breast lesions.Materials and Methods: HPT pts ad-
dressed to parathyroidectomy for at least 1epg detected by
ultrasound and confirmed by dual-tracer parathyroid scintigra-
phy (PS) and/or FNA, were considered eligible.All pts
underwent ultrasound-guided injection of 99mTc-
nanocolloid inside the epg for scintigraphic localization on
the day before surgery (not MAA because colloid was already
prepared for scheduled breast cancer procedures).MIRPs were
performed using a gamma-probe to identify the pge and verify
complete excision that was further assessed through intraoper-
ative quick PTH assay (ioPTH). Histologic examination of
surgical specimens was carried out.Results: 28pts were studied
(21F, 7M, median age 56.5±21.5y), 27 had a single epg and
one had 2epg.Sintigraphy at 75±45' median time from injec-
tion (median activity 60±23MBq in 0.2ml) depicted 1active
spot in the anterior neck region in 27pts and 2spots in 1 (up-
take was also found in 1laterocervical lymph node in 3pts).The
same surgeon performed all MIRPs: 1active pge was identified
and removed in 27pts and 2glands in 1case, without residual
activity in the surgical field (no interference with MIRP oc-
curred in the 3pts with concurrent laterocervical lymph node
uptake); ioPTH confirmed complete removal (level reduc-
tion>50%) in all pts.Histology demonstrated pge in all speci-
mens: adenoma in 18pts (64%), hyperplasia in 10 (36%) -
single gland in 9 and 2glands in 1case.Prior to enrollment
26/28pts underwent PS: 5negative (19.2% - 4small adenoma
cases and the 2-gland hyperplasia case), 21positive
(80.8%).Conclusions: Despite our limited series, ROLL pro-
cedure for MIRP resulted feasible, reliable and reproducible
with 100% surgical success rate in HTP pts.Advantages are:
no background activity that makes it easier for surgeons to
identify the active pge and check its complete removal without
looking for >20% greater counts then background established
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for MIBI-based guidance; low activity of 37-74MBq injected
the day before surgery vs. 37-740MBq injected 1-3hours prior
to surgery, tying surgical timing, reported in literature for
MIBI; preoperative localization even in cases of negative
PS.However, highly skilled operators are needed to ensure
valid injection and thorough surgical removal.Further studies
are needed to better define pts that may benefit from this
approach.
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Improving the sensitivity of sentinel node biopsies
in malignant melanoma of the head and neck using
a handheld gamma camera
S . S chn e i d e r -Burru s , A . Pok r ywka ; Ch a r i t é
Universitätsmedizin, Berlin, GERMANY.
Objective: Sentinel lymph node biopsy (SLNB) is a very im-
portant tool for precise staging of patients with malignant mel-
anoma. Identification of sentinel lymph nodes (SLN) can be
difficult, especially when they are located in proximity to high
radiotracer activity or in challenging anatomic regions. This is
particularly true in tumors of the head and neck. The purpose
of this study was to evaluate the sensitivity of a handheld
gamma camera when used in combination with a conventional
gamma probe in SLNB in melanoma of the head and neck.
Methods: From October 2014 to April 2015, we conducted
SLNB in 15 patients with malignant melanoma of the head
and neck. Lymphoscintigraphy with 99mTc-nanocolloid was
done with a conventional fixed gamma camera (FGC). The
following day, SLNBwas performed using a handheld gamma
camera (HGC, CrystalCam, Crystal Photonics) in combination
with a gamma probe (GP, Navigator, Auto Suture). Results:
Before surgery, a total of 26 SLN were identified in 19
lymph node basins in 14 out of 15 patients by FGC
imaging. In one case, due to the proximity of the injec-
t i on s i t e t o the d r a in ing lymph node bas in ,
lymphoscintigraphy did not reveal any SLN. During sur-
gery, a total of 44 SLN were removed in 26 lymph node
basins. SLNB was successfully performed in all 15 pa-
tients. In 6 lymph node basins, the detection of the SLN
was only possible by HGC. Sensitivity for detecting
SLN basins was 82% for FGC and 100% for intraoper-
ative use of HGC. The histology report revealed in 4
out of 15 patients lymph node metastases, one of the
metastatic SLN was only detected using the HGC. Con-
clusions: Intraoperative HGC imaging in combination
with a gamma probe has a high sensitivity for detection
of SLN in the head and neck. Especially for SLNB in
challenging locations like the head and neck, the use of
a HGC can improve the detection rate for SLN in ma-
lignant melanoma.
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An Automatic Method for PET Delineation of Cervical
Tumors
A. Stefano1,2, S. Vitabile3, G. Russo1, F. Marletta4, C.
D'Arrigo4, D. D'Urso1, O. Gambino2, R. Pirrone2, E.
Ardizzone2, M. C. Gilardi1, M. Ippolito4; 1IBFM-CNR,
Cefalù, ITALY, 2DICGIM, University of Palermo, Palermo,
ITALY, 3DIBIMED, Palermo, ITALY, 4Cannizzaro Hospital,
Catania, ITALY.
Aim: PET imaging is increasingly utilized for radiation treat-
ment planning. Nevertheless, accurate segmentation of PET
images is a complex and unresolved problem. Aim of this
work is the development of an automatic segmentationmethod
of Biological Target Volume (BTV) in patients with cervical
cancer. Materials and methods: Random walks (RW) is a
graph-based method that represents a DICOM (Digital Imag-
ing and COmmunications in Medicine) image as a graph. The
voxels are its nodes and the edges are defined by a cost func-
tion which maps a change in image intensity to edge weights.
Then, RW partitions the nodes into target and background
subsets. To create an automatic method starting from previous
work (A. Stefano, et al. A Graph-Based Method for PET Im-
age Segmentation in Radiotherapy Planning: A Pilot Study, in
A. Petrosino, ed., Image Analysis and Processing - ICIAP
2013: LNCS, v. 8157, Springer Berlin Heidelberg, p. 711-
720), we propose an automated RW seed localization ap-
proach. The algorithm identifies the PET slice with the highest
SUVmax and a maximum of 10 target and 8 background seeds
for each volume slice. The voxels with a SUV>95% of
SUVmax are marked as target seeds. Then, the method ex-
plores the hottest voxel neighborhood through searching in 8
directions to identify the background voxels with a SUV<30%
of the average SUVof target seeds. Once the target and back-
ground seeds are localized, RW performs a 3D lesion delinea-
tion. BTV is manually defined by two nuclear medicine phy-
sicians in 18 patients with cervical metastases undergoing a
11C-labeled Methionine PET/CT examinations before the ra-
diotherapy treatment. The accuracy of the proposed method is
evaluated making a comparison with manual delineation by
the dice similarity coefficient (DSC) and median Hausdorff
distance (HD). Results: The BTV delineation is not subject
to both intra and inter-operator variability. An analysis of the
time performance shows that the segmentation time for single
slice is around 0.3 seconds. The DSC range of PET delineation
is found to be from 81.7% up to 92.6% with a mean of 88.57
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±3.22%. The HD range is found to be from 1.00mm up to
3.67mm with a mean of 1.96±0.62mm. Conclusion: A slice-
by-slice manual PETsegmentation is a time expensive method
because dozens of slices must be delineated. Results show that
our algorithm is automatic and fast, satisfying critical require-
ments in a clinical environment. In addition, high DSC and
low HD values confirm the accuracy of delineation method.
P772
The usefulness of intratumoral metabolic heterogeneity
in selecting patients for radiotherapy dose-escalation
S. Kang1, H. Kim1, K. Park2, G. Jeong1, H. Park1, J. Kim2,
J. Min1, H. Song2, H. Bom1, S. Kwon1; 1Chonnam National
Unuversity Hwasun Hospital, Hwasun-Gun, KOREA, RE-
PUBLIC OF, 2Chonnam National Unuversity Hospital,
Gwang-ju, KOREA, REPUBLIC OF.
Purpose:We evaluated the value of intratumoral metabolic het-
erogeneity assessed using area under curve of cumulative
SUV-volume histogram (AUC-CSH) in FDG PET/CT to se-
lect patients for radiotherapy dose-escalation in patients with
stage III non-small cell lung cancer.Materials and
methods:Fifty-nine patients with stage III non-small cell lung
cancer, who underwent pretreatment FDG PET/CT before
starting concurrent chemoradiotherapy (CCRT) were retro-
spectively reviewed (60 Gy: 27; 66 or 70 Gy: 32). For the
classification of metabolic heterogeneity of primary tumor,
median value of AUC-CSH calculated using P-mode software
was used. Progression-free survival (PFS), locoregional
recurrence-free survival (LRFS), and distant metastasis-free
survival (DMFS) curves were produced using Kaplan-Meier
methods and survival difference between groups was assessed
by Wilcoxon test.Results:Twenty-seven patients had metabol-
ic homogeneous primary tumor (AUC-CSH>4489) and 32
patients had heterogeneous tumor (AUC-CSH≤4489). In
Kaplan-Meier analysis, high-dose RT (66 or 70 Gy) was asso-
ciated with improved PFS (p=0.032), but not in LRFS
(p=0.112) and DMFS (p=0.183). In metabolic homogeneous
group, high-dose radiotherapy was strongly associated with
improved PFS (p=0.003) and LRFS (p=0.026). However, in
metabolic heterogeneous group, high-dose RTwas not associ-
a t ed w i t h imp roved PFS (p=0 .952 ) and LRFS
(p=0.949).Conclusion:This preliminary study suggests that ra-
diotherapy dose-escalation can improve progression-free sur-
vival (PFS) and locoregional failure survival (LRFS) not in
patients with metabolically heterogeneous stage III lung can-
cer but in patients with homogeneous lung cancer.
P49 - Tuesday, October 13, 2015, 4:00 PM - 4:30 PM, Hall 3 –
Poster Exhibition
Clinical Oncology: Therapy Response Assessment
P773
Tumor FDG-Metabolic Values to Predict Pathological
Response After Neoadjuvant Chemoradiotherapy
in Patients with Resectable Locally Advanced Esophageal
Cancer
K. Itoh1, T. Kitsukawa2, H. Takahashi3, M. Myoujin4, T.
Oishi5, T. Takenouchi5, S. Watanabe1, K. Kanegae1, M.
Hosokawa2; 1Keiyukai Sapporo Hospital, Radiological Imag-
ing Center, Sapporo, JAPAN, 2Keiyukai Sapporo Hospital,
Department of Digestive Surgery, Sapporo, JAPAN,
3Keiyukai Sapporo 2nd Hospital, Department of Internal
Medicine, Sapporo, JAPAN, 4Keiyukai Sapporo Hospital,
Deparrtment of Radiotherapy, Sapporo, JAPAN, 5Keiyukai
Sapporo Hospital, Department of Clinical Pathology, Sapporo,
JAPAN.
[Background and Objectives] Neoadjuvant chemoradiothera-
py (NACRT) followed by esophagectomy is a widely accepted
treatment options for patients with resectable locally advanced
esophageal cancer (LAEC). The value of [F-18] FDG PET/CT
(PET/CT) to predict response of LAEC to NACRT and to aid
in subsequent treatment decisions is still controversial. We
sought to clarify the role of PET/CT in these tumors. [Mate-
rials and Methods] We reviewed the cases of 52 patients (44
male, median age: 64 years) with LAEC (clinically staged T3
−4, N0−3 andM0). Prior to NACRT, patients were stagedwith
different modalities, including endoscopic ultrasonography,
CT,MRI, barium swallow, and PET/CT. PET/CTwas repeated
2−4 weeks after the completion of NACRT. The complete
treatment plan included NACRT (cisplatin + 5-FU, two
courses)/50.4 Gy (28 fractions of 1.8Gy) followed 3 to 6
weeks later by transthoracic en bloc esophagectomy. For
PET/CT (Gemini GXL®, Philips Medical Systems Inc. Eind-
hoven, the Netherlands), whole body images were obtained 1
hour after IV administration of 185 MBq to fasting patients.
The maximum standardized uptake value (SUVmax), meta-
bolic tumor volume (MTV), and total lesion glycolysis
(TLG) were calculated using a workstation (Syngo.via®, Sie-
mens Healthcare. Erlangen, Germany). The pre- and post-
NACRT SUVmax were compared in order to calculate the
response rate (RR). [Results] There were 50 patients with
squamous cell carcinoma and two patients with adenocarcino-
ma. Most resected specimens showed down-staging compared
with pre-treatment stage. The pre-treatment SUVmax values
(mean 16.85, 95%CI 14.30−18.13) were significantly higher
than the post-treatment values (mean 4.81, 95%CI 4.29−5.23)
(p<0.0001). A metabolically complete response (CR) (post-
treatment SUVmax < 3.0) was observed in 13 patients. How-
ever, there was no correlation between metabolic and patho-
logic responses (p=0.842). Pre- and post-treatment SUVmax,
MTV, TLG, and RR were not significantly different between
18 patients (35%) with a pathologic CR and 34 patients with
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pathologic partial response. ROC curve analysis also did not
reveal sufficiently high AUC values. [Conclusions] Metabolic
and morphologic changes in esophageal carcinoma on PET/
CT 2−4 weeks after NACRT did not correlate with patholog-
ical response, and cannot be used to guide decisions regarding
surgery.
P774
PET/CT Reconstruction and Its Impact on Quantitative
Image Analysis
G. Kuhnert1, R. Boellaard2, D. Kahramann1, M. Scheffler1,
J. Wolf1, M. Dietlein1, A. Drzezga1, C. Kobe1; 1University
Hospital of Cologne, Cologne, GERMANY, 2VU University
Medical Centre, Amsterdam, NETHERLANDS.
Background: In oncological imaging using PET/CT the
standardized uptake value (SUV) has become the most
common parameter used to measure tracer accumulation.
The aim of this analysis was to evaluate Ultra High
Definition (UHD) and Ordered Subset Expectation Max-
imization (OSEM) PET/CT reconstructions for their po-
tential impact on quantification. Patients and Methods:
We analyzed 10 PET/CT scans of lung cancer patients
who had undergone PET/CT. The maximal SUV
(SUVmax) and the peak SUV (SUVpeak) were deter-
mined in the single hottest lesion in the lung and nor-
malized to a reference region for UHD and OSEM re-
construction. SUVmax, SUVpeak and their normalized
ratios for the two reconstruction settings were compared
using the paired sample t-test. The distribution of
SUVmax and SUVratio in relation to the reconstruction
method was demonstrated in the form of histograms,
box-plots and frequency distribution curves. Assessment
of the agreement between OSEM and UHD reconstruc-
tions was performed with Bland-Altman analysis. Re-
sults: A significant difference was observed after OSEM
and UHD reconstruction for SUVmax (8.6 vs. 12.9,
p=0.000) and for SUVpeak (6.8 vs. 8.5, p=0.000). The
mean values of the ratios after OSEM and UHD recon-
struction showed equally significant differences for
SUVmax (4.0 vs. 6.1, p=0.001) and SUVpeak (4.0 vs.
6.1, p=0.003). Bland-Altman analysis showed that
SUVmax and its ratio were about 55% higher while
SUVpeak and its ratio were about 33% and 31% higher
after UHD reconstruction as compared to OSEM recon-
struction. Conclusion: OSEM and HD reconstruction
brought a significant difference of over 30 % for
SUVmax, SUVpeak, and their normalized ratios, indicat-
ing that standardization of reconstruction and the use of
comparable SUV measurements are crucial when using
PET/CT for response evaluation.
P775
Texture analysis for tumor hypoxia visualized by FMISO
PET/CT during radiation therapy
M. Hosono, I. Tachibana, Y. NIshimura, K. Hanaoka, S.
Kanamori, K. Nakamatsu, K. Ishikawa, K. Sakaguchi; Kinki
University Faculty of Medicine, Osaka-Sayama, JAPAN.
Aim: F-18-fluoromisonidazole (FMISO) PET/CT is one of the
useful tools that have been investigated to visualize hypoxic
status in tumors. The aim of this study was to clarify the fea-
sibility of texture analysis of tumor hypoxia as well as absolute
levels of FMISO uptake on FMISO PET/CT in association
with local control by radiation therapy (RT). Materials and
methods: This study involved 18 patients (pts) with neoplasms
(head and neck 8, esophagus 5, anus 2, lung 2, uterus 1) who
underwent RT and FMISO PET/CT. FMISO PET/CT scans
were conducted at the baseline and at 20 Gy of RT; each
patient received iv injection of FMISO (7.4 MBq/kg) and
underwent PET/CT at 180 min. Regions of interest were
placed on tumors to measure SUVs of FMISO. Additionally,
texture analyses dealt with the heterogeneity indices of skew-
ness, kurtosis, and another heterogeneity index of area under
curve of cumulative SUV histogram (AUC-CSH). And a larg-
er skewness, a larger kurtosis, and a smaller AUC-CSH were
considered to indicate a higher heterogeneity. Pts were catego-
rized into CR and non-CR (PR+NC+PD) groups, and the pa-
rameters were compared between the two groups by Mann-
Whitney’s U test. Results: Pts received chemoradiation thera-
py (n=17, 42-70 Gy) or RT alone (n=1, 64 Gy). Nine pts
reached CR, while 9 did not. Reduced FMISO SUVs were
observed at 20Gy as compared to before RT, which might
correspond to reoxygenation. CR group showed statistically
significant lower SUVmax and kurtosis and a tendency of
lower skewness and higher AUC-CSH. Conclusion: Texture
analysis of intratumoral FMISO distribution was feasible. Cor-
relation of heterogeneity and therapeutic response should be
clarified in further studies. A lower absolute level of FMISO
accumulation before RT might be predictive of a better thera-
peutic response.
P776
PERCIST versus RECIST versus Visual PET assessment
for the evaluation of response by PET/c.e.CT
to chemoradiation neoadjuvant therapy in patients
with locally advanced esophageal cancer
A. Cervino1, L. Evangelista1, E. Scagliori1, R. Alfieri1, V.
Sileni Chiarion1, S. Galuppo1, A. Ruol2, F. Pomerri3, G.
Saladini1; 1Istituto Oncologico Veneto I.R.C.C.S., PADOVA,
ITALY, 2Hospital of Padua, PADOVA, ITALY, 3University of
Padua, PADOVA, ITALY.
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Purpose. The aims of the present study were 1) to assess
the utility of PET/CT scan before and after neoadjuvant
therapy and 2) to evaluate the therapeutic response in
locally advanced esophageal cancer with comparing
PET response criteria (PERCIST), to visual PET/CT
analysis and to response evaluation criteria in solid tu-
mours (RECIST 1.1).Materials and methods. 38 patients
with locally advanced esophageal cancer receiving neo-
adjuvant chemoradiation therapy (NCRT) were prospec-
tively enrolled. Chemo-radiation responses were evaluat-
ed by using FDG PET/CT and c.e.CT performed in a
single-session, according to visual PET assessment,
RECIST 1.1. and PERCIST 1.0. PET/c.e.CT was per-
formed after at least 4-5 weeks from the end of NCRT.
In accordance with PERCIST and RECIST, the response
to therapy was categorized in four levels: CR (CMR)=1;
PR (PMR)=2; SD (SMD)=3; PD (PMD)=4. For visual
PET analysis, the readers identified three different cate-
gories on PET/CT scan on the basis of FDG-uptake [no
evidence, residual (near or superior to surrounding tis-
sue) and increase or new appearance]. Surgery or histo-
pathology was used for the final definition of the re-
sponse to therapy. Person chi-square was used to com-
pare the proportion of four levels in RECIST/PERCIST
and of three subsets in the visual PET analysis.Results.
The body weight of patients resulted significantly lower
after NCRT (75 vs. 71 kg, respectively before and after
therapy; p=0.025). Semiquantitative PET data (such as
SUVmax, SULpeak, metabolic tumour volume-MTV
and tumour lesion glycolysis-TLG) were significantly
higher before than after therapy (all p<0.05), indepen-
dently from the final response. After NCRT, SUVmax
of primary tumor, MTV and TLG resulted significantly
lower in responder patients as the counterpart (all
p<0.05). Moreover, the change in SUVmax and in
TLG were significantly higher in responder than non-
responder patients. The difference of evaluation results
between RECIST and PERCIST and between RECIST
and visual PET analysis were not significant (p=0.863
and p=0.527, respectively). Conversely, a significant dif-
ference for the evaluation of response to NAC between
the visual PET analysis and PERCIST was found
(p=0.001). A complete and partial response to therapy
was better discriminate by visual PET analysis and by
PERCIST as compared to RECIST.Conclusions. The
change in SUVmax and in TLG can be helpful to dis-
tinguish between responder and non-responder subjects.
Both visual PET assessment and PERCIST are more
sensitive than RECIST in detecting complete and partial
remission of esophageal cancer after NAC.
P777
Heterogeneity of Metabolic Parameters and Impact
on Early Response Evaluation with FDG PET/CT
in Patients with Metastatic Colorectal Cancer treated
with Cetuximab Monotherapy
E. J. van Helden, O. S. Hoekstra, R. Boellaard, H. M. W.
Verheul, C. W. Menke-van der Houven van Oordt; VU Med-
ical Center, Amsterdam, NETHERLANDS.
Aim.The aim of this study was to explore the level of
intrapatient heterogeneity in metabolic responses as de-
fined with 18F-FDG-based quantitative metrics, in pa-
tients with metastasized KRAS wild-type colorectal ade-
nocarcinoma (mCRC), treated with third line cetuximab
monotherapy.Methods.We performed 18F-FDG PET at
baseline and after four weeks (2 cycles) of cetuximab
in 10 patients with mCRC. Quantitative analysis of tar-
get lesions (≥2 cm and above background determined in
liver or aorta) was done for all lesions, ≤ 5 lesions (≤2
per organ) and for the metabolically most active lesion
per PET (cf. PERCIST guidelines). In addition, the ef-
fects of different quantification units (SULmax,
SULpeak and Total Lesion Glycolysis (TLG)) on re-
sponse prediction were evaluated. Metabolic response
was categorised with a threshold of 30% for SUL and
45% for TLG. Quantitative data were correlated with
clinical benefit, defined as SD, PR or CR according to
Response Evaluation Criteria In Solid Tumors version
1.1 (RECIST) after two months of treatment. Intrapatient
differences with respect to metabolic response between
lesions were analysed.Results.In nine evaluable patients
the total number of target lesions was 36 (1 - 8 per
patient). Evaluating individual lesions using SULpeak,
two patients had a mixed metabolic response (metaboli-
cally progressive, stable or responding lesions). Using
SULmax and TLG, mixed metabolic response was ob-
served in three patients. The overall concordance be-
tween dichotomised metabolic data of the metabolically
most active lesion (i.e. progressive and stable metabolic
disease versus metabolic response) and clinical benefit
was 89% for all three quantification units. Evaluating
metabolic response using SULmax or SULpeak summed
over maximally five or all target lesions, demonstrated
no improved concordance with clinical benefit. Howev-
er, using TLG (summed over the lesions) concordance
was 100%.Conclusion.Mixed metabolic response was
observed in 38% of all patients with multiple lesions
treated with cetuximab. However, using PERCIST
guidelines only one patient was miscategorised. A
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100% correlation with clinical benefit was observed if
response prediction was done using TLG summed over
multiple lesions. Validation of these promising prelimi-
nary results in a larger patient cohort is currently
ongoing.
P778
Therapeutic response assessment of bone metastatic
prostate carcinoma treated by abiraterone using x-SPECT
QUANT® : a feasibility study.
R. de Laroche, P. Robin, P. Le Roux, J. Malhaire, D. Bourhis,
P. Salaun, R. Abgral; University Hospital of Brest, Brest,
FRANCE.
Aim: The therapeutic response assessment is a major chal-
lenge in patients with bone metastatic prostate carcinoma
(BMPC). BMPC progression criteria (PCWG 2, 2007) take
into account serum PSA level changes or appearance of 2 or
more new bone scan lesions. Interpretation of SPECT-CTwith
a visual analysis limits its performance, making difficult an
objective response evaluation. The aim of this prospective
study is to assess the feasibility to use a SPECT-CT quantifi-
cation method for BMPC response evaluation. Materials and
Methods: Patients with castrate-resistant BMPC treated by
abiraterone (Zytiga®) were included. All patients underwent
3 SPECT-CT (Symbia, Intevo, Siemens®): baseline (M0), at 3
(M3) and 6months of treatment (M6). SUVmax and SUVpeak
quantification were performed using the xSPECT-QUANT®
tool on the highest uptake target lesions (maximum of 5).
Criteria used for response evaluation were arbitrarily the same
used in PET-CT for solid cancers (EORTC99 and
PERCIST1.0). Results were compared with serum PSA level
changes. Results: Eight patients aged of 73.4 +/- 8.5 years
were included from April 2014 to March 2015. Two patients
died before M6. The mean delay between M0 and M6 was 6.6
+/- 0.8 months. The mean SUVmax and SUVpeak on target
lesions were respectively 30.7 and 25.6 on M0 and 16.1 and
14.0 on M6. Two, 2 and 2 patients were respectively in partial
response (PR), stable disease (SD) and progressive disease
(PD) according to EORTC99. Two, 2 and 2 patients were
respectively in PR, SD and PD according to PERCIST1.0.
Four and 4 response evaluations according to EORTC99 and
PERCIST1.0 respectively matched with serum PSA level
changes. Conclusion: These preliminary results show the fea-
sibility to use the xSPECT QUANT® tool in bone scan for the
response assessment of BMPC treated by Zytiga®. To the best
of our knowledge, it is the first study evaluating this first
marked SPECT-CT quantification tool in a clinical series.
P779
Evaluation of Platinum-based Therapy Response
in Non-Small Cell Lung Cancer
M. Ippolito1, A. Stefano2,3, G. Russo2, S. Gieri2, S.
Cosentino1, G. Murè1, S. Baldari1, M. G. Sabini1, F.
Fraggetta1, S. Vitabile4, M. C. Gilardi2, G. Banna1;
1Cannizzaro Hospital, CATANIA, ITALY, 2IBFM CNR -
LATO, Cefalù, ITALY, 3DICGIM, University of Palermo, Pa-
lermo, ITALY, 4DIBIMED, Palermo, ITALY.
Aim: To evaluate the clinical value of PET imaging for an
early prediction of tumor response to platinum-based therapy
in patients with non-small cell lung cancer (NSCLC). In order
to avoid unnecessary toxicity of ineffective chemotherapy
treatment, an early identification of NSCLC patients who ben-
efit from this therapy is mandatory.Materials and methods:
Seventeen patients are enrolled prospectively: 18F-FDG-PET
examinations are carried out before treatment and after the first
course. The lesions with the highest uptake in each patient are
evaluated according to EORTC, PERCIST and RECIST clas-
sifications to discriminate between patients who respond
(complete and partial response) from those who do not re-
spond (stable and progressive disease) to treatment. Metabolic
Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) are
also used to evaluate therapeutic response. MTV indicates the
volume of metabolically active tumors; TLG is the product
between SUV mean and MTV. In literature, there are no cut-
off points for therapy evaluation based on TLG or MTV var-
iations (Δ) in sequential scans. In order to estimate cut-off
values for these parameters, receiver operating characteristic
(ROC) curves are used. RECIST classification is used as the
outcome for the ROC analysis. Kaplan-Meier test is used to
calculate Overall Survival (OS) time. OS is compared between
responders and non-responders using a log-rank test. The level
of statistical significance is defined as a p-value (p) of less than
0.05.Results: The ROC analysis indicates a cut-off point of -
36% forΔTLG, and -8% forΔMTV. The Kaplan-Meier anal-
ysis shows that RECIST, ΔTLG, and ΔMTV prove to be a
significant prognostic factor for predicting OS. For RECIST
responder patients median OS is 595 days whereas for non-
responder patients median OS is 238 days. ΔTLG shows a
median OS of 492 days for responders and 238 days for
non-responders. ΔMTV shows a median of 423 days for re-
sponders versus 188 days for non-responders. Conversely,
EORTC and PERCIST classifications are inadequate to dis-
criminate between responder and non-responder patients
(p>0.13). For this reason, we use ROC analysis to propose
an alternative PERCIST threshold of 17% for an early therapy
monitoring.Conclusion: PET examinations provide an early
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identification of patients who benefit from platinum-based
treatment. Results confirm that TLG proves a strong early
prognostic factor in patients with NSCLC and could play a
significant role in the field of personalized medicine, avoiding
the unnecessary administration of non-curative and toxic drugs
to preserve the patient’s quality of life.
P780
18F-FLT PET/CTas a surrogate biomarker for synergy
quantification in EGFR targeted combination therapy
of NSCLC
F. Iommelli1, V. De Rosa1, M. Monti2, M. Panico1, R.
Fonti1, S. Del Vecchio2; 1Institute of Biostructures and
Bioimages, National Research Council, Naples, ITALY, 2De-
partment of Advanced Biomedical Sciences, University
“Federico II”, Naples, ITALY.
Aim: A poor clinical response of non-small cell lung cancer
(NSCLC) to treatment with EGFR tyrosine kinase inhibitors is
often the results of concurrent mechanisms of resistance and
combination therapy is an emerging strategy to improve the
outcome of NSCLC patients treated with these agents. Previ-
ous studies indicated that the combined treatment with EGFR
and MET inhibitors of tumors bearing MET amplification and
mutant or wild type EGFR is more effective than single agent
alone in reducing the rate of proliferation. Here we tested
whether 18F-FLT uptake can be used as a surrogate biomarker
for synergy quantification in EGFR targeted combination ther-
apy of NSCLC. Materials and Methods: NSCLC H1993 cells
with METamplification and wild type EGFR, H820 cells with
MET amplification and EGFR T790M and H1975 cells with
EGFR T790M and MET expression, were selected and tested
for the effects of EGFR and MET inhibitors, alone or in com-
bination (at 1:1 constant ratio) on cell viability, proliferation
and levels of signaling mediators. Then, tumor-bearing mice
underwent 18F-FLT PET/CT scan before and after treatment
with EGFR and MET inhibitors alone or in combination and
post-treatment changes of 18F-FLT uptake in tumors were
determined on images. Dose-effect curves were generated for
each set of in vitro and in vivo data using the Chou and Talalay
method and CompuSyn software. The combination index (CI)
was then calculated for each effect level and total doses of
combined drugs. A CI <1, CI =1 or CI >1 indicates synergism,
additivity or antagonism, respectively. Results: In the selected
cell lines, data analysis of cell viability assays showed that the
CI at the total dose causing 50% of the effect ranged between
0.3 and 0.7 for H1993 cells, between 0.1 and 0.3 for H820
cells and between 0.7 and 0.85 for H1975 cells indicating
synergism, strong synergism and moderate synergism, respec-
tively. Similar results were obtained from cell cycle and sig-
naling mediators analysis. In agreement with in vitro data, the
CI corresponding to the mean reduction of 18F-FLT uptake in
response to escalating doses of combined inhibitors in H1993
xenografts varied between 0.5 and 0.7 indicating in vivo syn-
ergism. Finally, the analysis of cell proliferation in tumor sec-
tions confirmed the imaging results. Conclusion: Our findings
indicate that 18F-FLT uptake may be used as a surrogate bio-
marker for synergy quantification in combination therapy of
refractory NSCLC patients.
P781
The role of 18F-FDG PET-CT for evaluation
of radiotherapy response in lumbar and sacrococcygeal
spine chordoma
S. Cambioli1, C. Nanni1, P. Ghedini1, L. Zanoni1, E.
Tabacchi1, A. Svirydenka1, S. Diodato1, S. Bandiera2, S.
Fanti1; 1Nuclear Medicine Department, University Hospital
S.Orsola-Malpighi,, Bologna, ITALY, 2Department of Onco-
logical and Degenerative Spine Surgery, Rizzoli Orthopedic
Institute, Bologna, ITALY.
Aim: Chordoma is an uncommon primary bone tumour char-
acterized by a slow growth, often localized at the
sacrococcygeal level. The standard treatment consists in an
en-bloc excision with wide margins. In case of unresectable
chordoma, carbon-ion therapy is also considered as a new
experimental option. Current standard diagnosis are performed
by means of magnetic resonance and biopsy. In this context,
the scientific literature lack of a comprehensive study of pos-
itron emission tomography (PET) for the detection of primary
lesions and for the post therapy response. To this aim, the
present work reports a first attempt of using 18FDG-PET/CT
in the study of chordoma.Materials and Method: Nine patients
(4 female; mean-age 56) were enrolled in this study with a
diagnosis of primary chordoma of the lumbar (2 patients)
and sacrococcygeal (7 patients) spine. All patients underwent
a 18FDG-PET/CT at baseline and a second scan 5-12 months
(8 months average) after carbon-ion radiation therapy (one
patient underwent also surgery). The diagnostic results of the
subsequent 18FDG-PET/CTwere validated through compari-
son with post-therapy histological reports.The SUV of both
scans (SUV1,SUV2) and its variations (SUV1-SUV2/SUV1)
were analyzed. The volume of the lesion, named "metabolic
tumor volume" (MTV), of both scans (MTV1,MTV2) was
also evaluated. A threshold of 42% of the lesion SUV for the
definition of MTV was used. The variations of MTV (MTV1-
MTV2 /MTV1) we r e t h en compa r ed w i t h SUV
changes.Results: Baseline PET/CT scans resulted positive for
8 of 9 patients. The measured SUV1 at diagnosis was moder-
ately low and equals to 5.2 in average (from 2.2 to 10.4). After
the radiotherapy, 18FDG-PET/CT scan was still positive for
the same 8 of 9 patients while the biopsy was positive for all
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the 9 patients. The mean of SUV2 was 3.7 (from 2 to 5.5) and
the corresponding variation with the baseline scan was found
to be around 30%. The mean MTVat diagnosis was 39.7 cm3
while after therapy is 23.9 cm3 leading to a mean variation
around 40% roughly in agreement with the variation of
SUV.Conclusions: This study, based on 18FDG-PET/CT re-
sult, shows that carbon-ion therapy does not completely dump
the glucidic metabolic activity of the lesions. In fact, the post-
therapy 18FDG-PET/CTscans here reported show a minimum
residual FDG-uptake which is explained by a persistence of
disease confirmed by histological exams. These results high-
light the need of an extended follow-up in order to evaluate the
stability of disease.
P782
The response of metastatic lesions in renal cell carcinoma
to tyrosine kinase inhibitors evaluated by F-18 FDG
PET/CT
O. Yaylali, D. Yuksel, G. G. Dogu, T. Sengoz, A. Yaren;
Pamukkale University, Denizli, TURKEY.
BACKGROUND / AIM: Tyrosine kinase inhibitors (TKIs)
have been used quite a while for advanced renal cell carcinoma
(RCC), but it is not known exactly whether the antitumor
effect of TKIs depends on various areas of metastasis. In this
study we retrospectively investigated the metabolic F[18]-2-
fluoro-2-deoxyglucose (FDG) response of various metastatic
lesions to tyrosine kinase inhibitors (TKIs) treatment as
assessed by positron emission tomography/ computed tomog-
raphy (PET/CT) in renal cell carcinoma (RCC) patients.
METHODS: A total of 18 patients with advanced RCC treated
with a TKI and no prior anti-VEGF exposure were evaluated
by FDG PET/CT before and and at 3 to 12 months after the
onset of TKI treatment initiation. The maximum standardized
uptake value (SUVmax) of all metastatic RCC lesions were
measured and analyzed. RESULTS: Eightteen patients with
mRCCwere retrospectively enrolled in this study. The primary
lesions were surgically removed in all patients before TKI
treatment. We evaluated 55 RCC metastatic lesions. The met-
abolic response was evaluated from the PET/CT images. The
pretreatment and after treatment SUVmax values (mean ± SD)
were as follows: in the 9 lung metastases, 3.88 ± 1.37 and 2.10
± 1.38 (p = 0.004); in the 12 bone metastases, 3.60 ± 2.05 and
3.76 ± 1.42 (p = 0.853); in the 17 lymph node metastases, 2.98
± 2.26 and 1.86 ± 1.47 (p = 0.179); in the 17 abdominal
parenchymal organ/ other soft tissue metastases, 4.75 ± 1.67
and 3.21 ± 1.87 (p = 0.01), respectively. The SUVmax values
of the metastatic lesions after treatment were significantly de-
creased in the lung and abdominal parenchymal organ / other
soft tissuemetastases. There was no significant difference after
treatment in bone lesions and lymph nodes (p > 0.05). The
SUVmax change ratios after TKI treatment (mean ± SE) were
-11.6±47.8 % in the lung metastases, 30.5±48.4 % in the bone
metastases, 31.8±19.2 % in the lymph node metastases, -8.3
±31.7 % in the abdominal parenchymal organ metastases.
CONCLUSIONS: In patients with mRCC, the significant de-
crease of FDG SUVmax value of lung and abdominal paren-
chymal organ / other soft tissue metastases evaluated by PET/
CT at 3-12 months after TKI treatment initiation. However,
significant changes were not observed in bone and lymph node
metastases after TKI treatment. The degree of reduction in
18F-FDG uptake after TKI treatment in patients with aggres-
sive mRCC, may provide valuable prognostic information.
Larger studies are needed to confirm these findings.
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The clinical value of FDG-PET/CT in common cancers:
Actual use compared with literature-based
recommendations
P. F. Høilund-Carlsen1, H. Petersen1, P. C. Holdgaard2, P. H.
Madsen3, L. M. Knudsen4, D. Gad5, A. E. Gravergaard5, M.
Rohde6, B. Engelmann7, D. Theilmann-Jørgensen8, J. B.
Christensen9, A. Johansen1; 1Dept. of Nuclear Medicine,
Odense University Hospital, Odense C, DENMARK, 2Dept.
of Nuclear Medicine, Vejle Hospital, Vejle, DENMARK,
3Dept. of Medicine, Vejle Hospital, Vejle, DENMARK,
4Dept. of Haematology, Odense University Hospital, Odense
C, DENMARK, 5Dept. of Plastic Surgery, Odense University
Hospital, Odense C, DENMARK, 6Dept. of ORL Head &
Neck Surgery, Odense University Hospital, Odense C, DEN-
MARK, 7Dept. of Internal Medicine, Næstved Hospital,
Næstved, DENMARK, 8Dept. of Gynaecology and Obstet-
rics, Aabenraa Hospital, Aabenraa, DENMARK, 9Dept. of
Quality and Research, Odense University Hospital, Odense
C, DENMARK.
Aim: The Region of Southern Denmark (RSD), one of
Denmark’s five administrative regions holding about 1/5 of
the country’s population of about 6 million inhabitants,
appointed a task force to (1) search evidence in the literature
for the clinical usefulness of PET/CT, (2) establish consequent
recommendations for the use of PET/CT, (3) compare the ac-
tual use with established recommendations, and (4) identify
areas of future development and growth. Material and
methods: A professional Subgroup should coordinate and
present the results. It made six Clinician Groups conduct liter-
ature reviews on six selected cancers responsible for 61% out
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of 9,213 PET/CT scans in the RSD in 2012. Applying the
method of Rapid Evidence Assessment which uses the meth-
odology of systematic reviews with predefined limitations, a
structured search of relevant literature was conducted in
PubMed, EMBASE, and the Cochrane Library. Included were
only articles published in English/ Danish/ Swedish/ Norwe-
gian after 2002. PICO questions were defined (where P stands
for patients/problem; I for intervention; C for comparison; O
for outcome), and data were recorded, quality checked and
rated with regard to strength and evidence level. Following
that, the Subgroup compared the actual 2012 use of PET/CT
with the literature-based recommendations and suggested
areas of future development and growth of PET/CT. Results:
Out of 11,729 citations, 1,729 were eligible for review, and
204 were included. The retrieved evidence suggested that
PET/CT was a useful method in lung, lymphoma, melanoma,
head-and-neck, and colorectal cancers, whereas results were
less clear-cut and sparser in gynaecologic cancers. There was a
good agreement between the actual use of PET/CT in the first
five of the aforementioned cancers in that 96.2% of scans
performed in these were made for ‘established’ or ‘useful’
indications, while 0.6% were made for ‘potentially useful' in-
dications, 1.4% for non-recommendable indications and 1.8%
for indications lacking literature documentation. In
gynaecologic cancers, 22.2% of scans were made for
‘established’, none for ‘useful’, 77.2% for ‘potentially useful’
indications, and 0.6% for indications not addressed in this
literature review. Development and growth were foreseen in
cancer, inflammatory/infectious conditions, heart and neuro-
logic diseases. Conclusion: This task force found evidence for
the clinical usefulness of PET/CT in five of the six selected
cancer types, and sparse documentation in the sixth type,
gynaecologic cancers. The actual clinical use of PET/CT
agreedwell with the evidence-based recommendations. Devel-
opment and growth was foreseen in many cancers and in other
major types of disease.
P784
Diagnostic value of 18F-FDG PET/CT in whole body
cancer screening
Y. Sone1, M. Abe1, C. Arakawa1, I. Kato2, A. Sobajima2, T.
Kawachi2, I. Takeda3, T. Kumada3; 1Department of Radiol-
ogy, Ogaki Municipal Hospital, Ogaki, JAPAN, 2Department
of Radiological Technology, Ogaki Municipal Hospital,
Ogaki, JAPAN, 3Health Management Center, Ogaki Munici-
pal Hospital, Ogaki, JAPAN.
Aim: One remarkable advantage of whole-body 18F-FDG
PET/CT is the ability to detect cancer from healthy population.
This prospective study determined the prevalence and clinical
features of pathologically confirmed cancer detected by PET/
CT for cancer screening. Materials and Methods: Between
June 2008 and March 2015, a total of 318 participants (male
201, female 117, mean age: 60.6 years) underwent whole-
body 18F-FDG PET/CT for cancer screening. PET/CT find-
ings were interpreted, and divided among 4 groups as de-
scribed below, A: no abnormal findings, B: minor abnormal
findings (follow-up unnecessary), C: abnormal findings (fol-
low-up necessary), D: abnormal findings suspicious for malig-
nancy (further examination necessary). Medical records of
participants were reviewed to clarify pathological or clinical
diagnoses and the clinical courses. Results: The participants
were classified into group A: 148 (46.5%) , B: 86 (27.0%) , C:
36 (11.3%), D: 48 (15.1%). The major sites of abnormal find-
ings in group D were colorectum 11, genitourinary 11, head
and neck 10, chest 6, hepatobiliary and pancreas 6. Among 48
participants, 38 (79.2%) received further examination. Cancer
was pathologically confirmed in 6 participants (sigmoid colon
2, rectum 1, pancreas 1, thymus 1, thyroid 1). Positive rate was
15.1% (48/318), and detection rate was 1.89% (6/318). Cura-
tive resection was performed at 5, chemotherapy at 1 (pancre-
atic cancer with liver metastases). Follow-up records were
available in 166 participants. During follow-up period, uro-
genital cancers (kidney 1, bladder 1, prostate 1) were revealed.
The interval from PET/CT to pathological diagnosis was 2, 14,
42 months, respectively. Conclusion: PET/CT is a valuable
tool for detecting a wide variety of curable cancers, but
showed poor detectability of urogenital cancer.
P785
Cost-Utility Analysis for Improved Decision Making
in Method Comparison PET Studies: an Example
in Lymph Node Staging of Prostate Cancer
O. Gerke, M. H. Poulsen, P. Høilund-Carlsen; Odense Uni-
versity Hospital, Odense C, DENMARK.
Aim: To examine to which extent paired diagnostic studies of
accuracy can be also used to estimate economic implications
of introducing a new diagnostic test. Cost-effectiveness and
cost-utility analyses are commonly done directly in connection
with randomized controlled trials (RCTs) or indirectly by sto-
chastic modeling based on RCTs. However, in our rapidly
developing environment, RCTs are difficult to conduct and
their use in PET/CT imaging is sparse. We propose a simple
decision tree model-based cost-utility analysis comparing a
new test and its chosen reference standard and exemplify this
with local data from lymph node staging of prostate cancer.
Materials and Methods: Average procedure costs were taken
from the Danish Diagnosis Related 2013 Groups Tariff, and
life expectancy was estimated for an ideal 60-year old patient
based on prostate cancer stage and curative versus palliative
treatment. Quality-adjusted life-years (QALYs) were deduced
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from the literature, and the incremental cost-effectiveness ratio
( ICER) was used to compa re s t ag ing by 18F-
fluoromethylcholine PET/CT (FCH-PET/CT) with lymph
node dissection and histopathological examination as refer-
ence standard. Sensitivity and specificity of FCH-PET/CT
for the detection of lymph node metastases were estimated
previously to be 0.73 (95% CI: 0.58-0.84) and 0.88 (95%
CI: 0.82-0.92), respectively. Results: The ICER was -1,444 €
per QALY as FCH-PET/CT was both more costly (1,495 €)
and less effective in terms of QALYs than the reference stan-
dard (-1.0351 QALYs). However, lower bounds of sensitivity
and specificity of FCH-PET/CTwere established at which the
replacement of the reference standard by FCH-PET/CT came
with a trade-off between worse effectiveness and lower costs
(e.g. 0.78 and 0.92, respectively, resulting in an ICER of 11 €
per QALY). Conclusion: Compared to a true reference stan-
dard, any imperfections in accuracy means that replacing the
reference standard by the new test generates a loss in effective-
ness. So, a trade-off between (lower) cost and (decreased)
effectiveness is the best outcome in this situation. In the chosen
example, there was no benefit of FCH-PET/CT, which, how-
ever, is not the point. It is that similar assessments will prove
especially fruitful when comparing several imaging modalities
or the same PET modality using different tracers with a com-
mon independent reference standard. This will provide useful
additional information by ranking the different imaging tech-
niques by their economic benefit (or lack thereof).
P786
18-F-FDG-PET/CT Value in the Therapeutic
Management of Unknown Primary
M. B. Garcheva-Tsacheva, Sr.1, V. Hadzhiyska1, Z.
Mihaylova2; 1Medical University, Sofia, BULGARIA, 2Mil-
itary Medical Academy, Sofia, BULGARIA.
The aim of the study is to evaluate the place of 18F-FDG-PET/
CT in the diagnostic algorithm of unknown primary for short-
en ing the dec i s i on fo r fu r t he r managemen t o f
patients.Мatherial and methods. Forty three patients (aged
from 33 to 79 years) were evaluated and followed up during
a two years period by FDG-PET/CT on GE Discovery 16T,
using the weight adjusted activity, 60 minutes delay between
injection and registration, hydration of patients with diuretic
stimulation by furоsemide and oral contrast intake. The inclu-
sion criteria were patients with proved malignant histology by
lymph node biopsy (gr. LN, n= 23), patients with histological
proof of malignancy from brain surgery (gr.BS, n=7), patients
with imaging proofs of malignancy by other imaging methods
(gr. Im, n= 13). Results. Fifty eight percents (25/43 patients)
had positive PET results. Five patients from gr. LN with
proved by PET advanced disease were directed for
chemotherapy, 2 patients with proved lung and ovarian carci-
noma needed operation, and 2 - with head and neck tumors
were sent for radiotherapy. From gr. BS all 5 positive cases
were with lung carcinoma. Three of them were sent for
fibrobronchoscopy (FBS) and radiotherapy planning, 2- with
advanced disease - for chemotherapy. From gr. Im: 3 (
cholangio- and pancreatic carcinoma) without dissemination
were sent for surgery, and 2 - to SRS ( somatostatin receptor
scintigraphy) , because of suspicion for NET (neuroendocrine
tumors). Five patients with data of advanced disease were sent
for chemotherapy. As a whole PET/CT directed for treatment 9
patients from gr. LN, 2 from BS, 8 from gr.Im. Three pts were
sent for FBS, 2 patients needed additional imaging examina-
tions, besides the group with PET negative studies (2+18 pa-
tients, 46%). Conclusion. PET/CTwas positive in the majority
of patients (58%) sent for the detection of unknown primary. It
reduced the need of additional imaging examinations in 54%
of patients and directed to therapy 19 (44%) of patients (un-
fortunately the majority of themwith advanced disease). In 4.5
% (H&N tumors with regional spread) PET/CT examination
seems able to improve the patients’ prognosis and survival.
FDG-PET/CT may contribute to the management of patients
with CUP tumors and especially those with cervical
adenopathies and single metastases ( IV,B)
P787
Barriers and Facilitators to Doctors’ Engagement
with the National PET CT Clinical Audit Programme
P. Ross1, J. Hubert2, M. Saunders3,W. L.Wong4; 1Birkbeck
University of London, London, UNITED KINGDOM, 2NHS
SouthWest Commissioning Group Englang, Bristol, UNITED
KINGDOM, 3Alliance Medical Molecular Imaging, London,
UNITED KINGDOM, 4Mount Vernon Hospital, Northwood,
UNITED KINGDOM.
Aim: The NHS England PET-CT Clinical Audit Programme
[Audit Programme] represents a significant change initiative
and is one of the major national clinical audit programmes in
the NHS. To implement change effectively healthcare profes-
sionals need to be fully engaged. The purpose of the study was
to 1] identify the barriers and facilitators of doctors’ engage-
ment and 2] explore how and why levels of engagement varied
between doctors reporting on the Audit Programme. Materials
and Methods: A single embedded case study centred on the
Audit Programme. A mixed methods approach was adopted
using qualitative and quantitative data to investigate the factors
which influence medical engagement. A pilot study of 13 pur-
posefully selected in-depth semi-structured interviews with
consultant doctors was undertaken over a six month period
and informed an on-line survey to all 59 doctors reporting on
the Audit Programme. 58/59 doctors responded to the survey.
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The interview data and free text was coded and analysed using
directed thematic content analysis with the themes compared
against the study’s propositions. The numeric survey data was
transferred to an excel spread sheet and statistical tests were
run to produce descriptive charts and graphs to summarise the
factors to affect the medical engagement of doctors. Data tri-
angulation techniques were used to corroborate and validate
the findings across the different methodological techniques.
Results: The main barriers to engagement with the Audit Pro-
gramme were lack of a common vision, poor communication
and poor inter-professional relationships. The factors to facil-
itate engagement centred on the adoption of a collaborative
non-judgemental culture within which audit was re-framed
as a process of learning and professional validation. Survey
responses showed: doctors initially found audit threatening
76%; doctors nevertheless found audit reassuring 85%; audit
helped validate professional competence 92%; participation in
audit improved reporting skills 76%. The factors which influ-
enced doctors’ engagement most were: perception of audit’s
usefulness; trust and the dissemination of clinical performance
data. Conclusion: The studymakes use of a unique data set and
to the best of our knowledge is one of the first studies to
document how the dissemination of doctors’ performance data
positively influences engagement with clinical audit. The
study also shows that a supportive audit environment is asso-
ciated with increased levels of engagement and learning, re-
duced levels of professional anxiety and can provide a frame-
work for the validation of professional competence.
P788
Does 18F-FDG PET-CT field of view that includes vertex
have an impact on oncological patients management
Y. E. Ramirez, I. Santos, A. Martinez, S. Rodado, I.
Hernandez, C. Escabias, M. Coronado; Hospital Universitario
La Paz, Madrid, SPAIN.
The field of view (FOV) in oncological PET/CT is not stan-
dardized therefore many centers perform limited scans (base of
skull to thigh) but often do not performed other image studies
(CT/MR) to detect brain/skull metastases. To determine
whether performing 18F-FDG-PET/CT FOV from the vertex
of skull to mid thigh is clinically useful. This is a retrospective
review of 566 consecutive patients (from January to Au-
gust2013) who had performed 18F-FDGPET/CT for oncolog-
ical purpose: hemathologic 112 (98lymphoma), lung cancer
100 (6 small cell and 80 non small cell), breast 55, head-
neck 54, colorectal 48, gynaecological 35, esophagus-gastric
21, tumor unknown origin 14, melanoma 16, and other 117.
Patients (250 female; mean-age 60; 11pediatric) fasted at least
6h, blood glucose test was obtained (≤180mG/dL) and after
60min 18F-FDG injected underwent PET/CT without
intravenous contrast on same scanner (DiscoveryLS,
GEMedical Systems). FOV included acquisition from vertex
to mid thigh with patient’s head locked. Head abnormalities
(PET and/or CT) were classified by location (brain, skull or
soft tissue) and whether known or not based on previous (im-
age studies or medical record) available data. Findings were
correlated with imaging studies, pathology and/or clinical fol-
low-up. Twenty six of the 566 (4.6%) scans showed head
abnormalities (30lesions were found: 23CT, 12PET uptake)
that were unknown in 15 cases. Lesions were localized: brain
(19/26), bone (5/26), both (1/26) and soft tissue (1/26). In 13/
26 patients were metastases (9brain and 4skull), one patient
soft tissue inflammatory lesion, 8vascular lesions (1/8 un-
known), 1trauma and 3other lesions (arachnoid cyst,
meningiom). According to primary tumors, brain-skull metas-
tases: (1/98) lymphoma, (1/55) breast, (1/48) colorectal, (1/35)
gynaecological, (2/54)3.7%head-neck (6/86) 6.9% lung can-
cer (6.25% of non small cell lung cancer) and (1/14) 7.14%
unknown primary tumor. Despite these new metastases were
detected stage only changed in 7/13 patients and modified
management/treatment in 8/13head metastases patients. Eight
patients (1.4%,8/556) changed their clinical management.
Altought FOV (vertex to thigh) 18F-FDG-PET/CT has shown
little benefit to detect additional metastases in oncological pa-
tients these metastases have an outstanding potential to signif-
icantly impact clinical management. Out of these data and
within the constrains we had evaluated a small number of
patients use limited FOV in order to reduce scanning time it
is not cost-effectiveness, especially with new PET/CT equip-
ments (considering scan time and exposure radiations) and in
some tumors (unknown primary tumor, head and neck and
lung cancer) with higher incidence of head metastases.
P789
The Evaluation of Dual-time-point F-18 FDG PET/CT
and chest CT for the prediction of the WHO grade
in thymic epithelial neoplasms
T. Shinya1, Y. Otomi1, T. Tanaka2, R. Inai2, S. Kanazawa2,
M. Harada1; 1Tokushima university graduate school,
Tokushima-city, JAPAN, 2Okayama university hospital, Oka-
yama-city, JAPAN.
Objectives: The purposes of the present study were to assess
dual-time-point (DTP) 18-fluorine fluorodeoxyglucose (F-18
FDG) positron emission tomography/ computed tomography
(PET/CT) findings of thymic epithelial neoplasms (TEN) and
to investigate the diagnostic capacity of PET/CT comparing
chest computed tomography (CT) features for differentiating
thymic carcinoma from thymoma with receiver operating
characteristic (ROC) analyses.Methods: We performed a ret-
rospective study of data fromAugust 2006 to September 2014,
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on 56 patients with pathologically proven TEN. The patients
were categorized into three groups according to World Health
Organization classification (low-risk: 9 A, 7 AB, 11 B1; high-
risk: 9 B2, 5 B3; 15 C). For semiquantitative analyses of FDG
uptake, we calculated the ratio between standardized uptake
value of the tumour and aortic arch (T/M ratio) on both 90-min
early and 2-h delayed scans. Multivariate logistic regression
analysis was used to estimate the CT features of thymic carci-
noma. We compared the diagnostic capacities between PET/
CT and chest CT using ROC analyses.Results: T/M ratio of
thymic carcinomas was significantly higher than thymoma on
both early and delayed scans (p=0.002 for early scan; p=0.003
for delayed scan). No significant difference were found in T/M
ratio between early and delayed scans between three groups.
The ROC curve for diagnosing thymic carcinoma revealed
that the appropriate cut-off value of T/M ratio for the highest
accuracy was 2.39, with a sensitivity of 86.7%, specificity of
73.2%, and accuracy of 75.0%. The area under the curve
(AUC) was 0.855. The statistical analyses for DTP scans with
35 TEN demonstrated the accuracy and AUC were the accu-
racy of 74.3% and AUC of 0.838 for early scan and the accu-
racy of 82.9% and AUC of 0.825 for delayed scan. The mul-
tivariate logistic regression indicated increased pericardial ef-
fusion (p=0.018) and mediastinal fat infiltration (p=0.026)
were the predictors of thymic carcinoma. Obtained ROC curve
for the model showed that AUC 0.899.Conclusions: Delayed
scans with T/M ratio calculation may have the potential to
improve the diagnostic capacity for thymic carcinoma. For
chest CT features, increased pericardial effusion and medias-
tinal fat infiltration were the predictors of thymic carcinoma
with moderate diagnostic capacity.
P790
Physiological joint pitfall and misinterpration of PET/CT
DOPA Scan
A. Cervino, L. Evangelista, M. Burei, P. Reccia, G. Saladini;
Istituto Oncologico Veneto I.R.C.C.S., PADOVA, ITALY.
Introduction. 18F-DOPA PET/CT is increasingly being used
in the evaluation of neuroendocrine tumors, although the stan-
dardization of protocol acquisition is still missed. The aim of
this study was to retrospectively determine the rate of false
positive DOPA uptake at bone level, in a cohort of 148 pa-
tients. Materials and methods. Between December 2012 and
July 2014, we retrospectively re-viewed 148 18F-DOPA PET/
CT scan in patients with known or suspected neuroendocrine
tumors. PET/CT was performed after the injection of 3 MBq/
Kg of 18F-DOPA, and the acquisition was started 60 minutes
later. All images were interpreted by an expert nuclear medi-
cine physician and later re-analyzed by a second physician.
Co-registrated CT images were used for assessing the presence
of a malignant or a benign bone lesion. Results. Out of 148
PET/CT scans, 67 were negative while the residual 81 resulted
positive (45.2% and 54.7%, respectively). In 31 patients
(21%), PET/CT showed an abnormal uptake in the joints.
Eleven out of 67 (16.4%) patients with a negative scan had a
significant uptake in the joints versus 20/81 (24.7%) subjects
with a positive scan. In 10/31 cases (32.3%), DOPA-uptake
was reported in acromion-clavicular joints; whereas in 26/31
(83.4%), it was seen in the vertebral joints, mostly at cervical
and thoracic levels (n=12; 46%). In the selected patients, the
c l i n i c a l i nd i c a t i on s we r e known o r su spec t ed
pheocromocytoma (n=5; 16.1%), medullary thyroid cancer
(n=13; 41.9%), multi-endocrine familiar syndromes (n=5;
16.1%) and known or suspected neuroendocrine neoplasia
(n=8; 25.8%). Finally, in these 31 patients, a malignant bone
involvement was depicted in only 5 cases. Conclusions. The
interpretation of 18F-DOPA PET/CT appears extremely im-
portant, because the rate of false positive findings can be high,
both in negative and in positive scans, ranging between 15%
and 25%. A misinterpretation can be avoided by a careful
lecture of co-registrated CT images.
P791
FDGPET/CT for Pseudomyxoma Peritonei (PMP)
and other peritoneal malignancies: Diagnostic features
and prognostic consideration
K. Kubota, M. Morooka, M. Okasaki, M. Kameyama, Y.
Miyata, R. Minamimoto, Y. Goda, H. Yano; National Center
for Global Health and Medicine, TOKYO, JAPAN.
PMP is a rare pathology characterized by mucinous peritoneal
effusion mostly associated with appendiceal adenocarcinoma,
and some with ovarian cancer or others. Previously FDG-PET
had been said not useful because of low FDG uptake by PMP.
Recent advances in combined therapy of radical surgery and
intra-operative hyper-thermic chemotherapy dramatically im-
proved survival. It prompted us to re-evaluate the possible role
of FDGPET/CT for the diagnosis of PMP in comparing to
other peritoneal malignancy.Purpose: To find diagnostic char-
acteristics and prognostic potential of FDGPET/CT for
PMP.Method: From Jan. 2013 to Dec.2014, 64 FDG-PET/
CT studies ( 48 PMP, 8 peritoneal mesothelioma and 8 perito-
neal dissemination of colon cancer patients ) were analyzed
retrospectively. PMP patients were divided into two groups
based on the amount of ascites.Results:22 patients (group A)
having larger amount of peritoneal effusion including both
mutinous and serous tended to have moderate FDG uptake
in the disseminated nodular foci of abdominal and pelvic wall,
also have larger swollen ometum with moderate FDG uptake,
26 patients (group B) having smaller amount of ascites, little
nodules on abdominal wall and low FDG uptake by
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omentum.Definite mass lesions with high FDG uptake
(SUV>3.0) in the appendix or peritoneum were observed in
13/22 of Goup A and in 12/26 of Goup B. The incidences were
similar in both groups despite the differences of the
ascites.Mesothelioma and colon cancer tended to have definite
mass lesion with higher FDG uptake in peritoneum with
higher incidence, little effusion and lower omentum FDG up-
take than PMP.Conclusion: Large amount of ascites and mod-
erate FDG uptake by swollen omentum and peritoneal wall are
characteristic findings of PMP, however, incidence of high
FDG uptake by definite mass lesion (known prognostic factor)
may not directory correlated to such characteristics. These
findings can be derived only by FDGPET/CT not by CT. Ap-
propriate evaluation of FDGPET/CT of PMP may help to
search best therapeutic strategy.
P792
The utility of 18F-FDG PET/CT in patients
with carcinoma of unknown primary.
A. Sowa-Staszczak, M. Kołodziej, M. Buziak-Bereza, M.
Trofimiuk-Muldner, A. Stefańska, A. Hubalewska-
Dydejczyk; Nuclear Medicine Unit, Endocrinology Depart-
ment, University Hospital Krakow, Krakow, POLAND.
INTRODUCTION: Patients with carcinoma of unknown pri-
mary (CUP) are a diverse and heterogenous group. There are
various clinical manifestations and some of the patients could
be asymptomatic and diagnosed incidentally. An adequate di-
agnostic and primary focus finding seem to be essential for the
proper treatment of the patient. Among numerous imagining
techniques, PET/CT seems to be the most suitable for localiz-
ing the primary tumor. The sensitivity of PET/CT in detecting
primary tumor is 29%-69% according different authors and it
is higher comparing to contrast enhanced CT. AIM: The aim of
our study was to evaluate the utility of 18F-FDG PET/CT for
localizing the primary tumor. METHODS: We analyzed 144
patients (73 males, 71 females, the median age 64y) in whom
18F-FDG PET/CT imaging was performed in a standard pro-
tocol in Nuclear Medicine Department University Hospital
Krakow, Poland between October 2012 and September 2014.
All of the patients were diagnosed with metastases and other
diagnostic methods hadn’t revealed a primary tumor. RE-
SULTS: FDG PET/CT suggested a primary tumor in 105
cases. Among them, the most common site of primary tumor
detected was gastrointestinal tract, including pancreas (n = 25),
which was followed by lung (n = 14), liver (n = 14), head and
neck including thyroid (n=11), lymphoproliferation (n = 9),
prostate (n = 2) and others (n=30) e.g. ovary, kidney, uterus,
bladder. In 14 cases the result of PET/CTconfirmedmetastases
but the primary tumor remained unidentified. In 25 patients
PET/CT didn’t confirm the presence of metastases and
allowed to exclude previously suspected malignancywith high
glucose metabolism. CONLUSION: Our study suggests that
18F-FDG PET/CT may be an effective diagnostic tool in pa-
tients with carcinoma of unknown primary.
P793
(18) F-FDG PET-TC imaging in the detection of primary
tumors in patients with metastatic carcinoma of unknown
primary origin: a multicentric study
M. Rossi1, A. Romeo2, M. Della Porta1, F. Malvaldi1, D.
Bacciardi1, S. Stefanini1, R. Pratali1, N. Mazzuca1; 1U.O.
medicina nucleare, USL 6 di Livorno, Livorno, ITALY,
2U.O. medicina nucleare, Ospedale Maggiore, Bologna,
ITALY.
Aim: to assess the value of 2-[fluorine-18]-fluoro-2-deoxy-D-
glucose (18F-FDG) positron emission tomography/computed
tomography (PET/CT) in the detecting of cancer of unknown
primary (CUP) in patients with histologically proven tumor
metastasis and/or with a high clinical suspicion of metastatic
diffusion.Methods: 172 patients with cancer of unknown pri-
mary, unsuccessfully investigated with extensive conventional
diagnostic procedures (including CT/MRI/endoscopy) and
laboratory investigation, were enrolled for 18 F-FDG PET-
CT whole body imaging. Patients received 370 MBq FDG
(10 mCi) intravenously, and whole-body images were ac-
quired at 60 min after injection. The images obtained were
analyzed with visual and semi-quantitative methods. Histopa-
thology and/or cytology were used to evaluate the PET/CT
results.Results: the primary tumor site was correctly identified
by 18 F-FDG PET/CT in 25 patients (56/172; 32.5%): lung
(n=11), rino/oro-pharynx (n=9), lymphatic system (n=6), co-
lon (n=6), ovary (n=4) liver (n=4), pancreas (n=3), mammary
gland (n=3) muscles-endothelium (n=2), stomach (n=2), testi-
cle (n=1), mesothelium (n=1), prostate gland (n=1), thyroid
(n=1), parotid gland (n=1) and kidney (n=1). 18 F-FDG
PET/TC results were proved false positive in 17/172 patients
(19.8%), in which 18 F-FDG focal uptake were located in the
lung (n= 10), the rino/oro-pharynx (n=6) and ileocolonic junc-
tional region (n=1). In 77 patients 18 F-FDG PET/CT scans
were negative (77/172; 44.7%) and in 12 of them histopathol-
ogy revealed a primary localization (false negative 15.5%). In
95 patients (95/172; 55.2%), the primary tumor was not local-
ized, although in 21 of them (21/95; 22.1%), 18 F-FDG-PET/
CT detected newly unexpectedmetastases. And globally, in 48
patients of the whole enrolled population (48/172; 27,9%), 18
F-FDG-PET/CT depicted new metastatic sites modifying the
s t a g e o f t h e d i s e a s e a n d t h e s u b s e q u e n t
management.Conclusion: our results showed that 18F-FDG
PET/CT correctly revealed the primary tumor site in 32.5%
of patients and in 27.9% of subjects detected further
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localization of metastasis providing a relevant value in the
clinical and therapeutic management of patients with cancer
of unknown primary.
P794
Time-dependent reduction of liver 18 FDG activity
in the dual-phase 18 FDG PET/CT study.
O. Kupik, M. Tuncel, P. Kiratli, B. Erbas; Hacettepe Univer-
sity, Ankara, TURKEY.
AIM: Liver SUVmean value corrected for lean body mass has
been used as a quality measure in the PERCIST. There is
visual interpretation scales comparing tumoral tissue 18FDG
uptake with liver 18FDG activity which have been used in the
response assessment. However, time-dependent reduction of
liver 18FDG activity has been reported, and because of time-
differences between pre and post-therapy studies might result
in discrepancies. Therefore, the change of liver SUVmean
values were studied in a dual-phase 18 FDG PET/CT
study.MATERIALS AND METHODS: Early and late 18
FDG PET/CT studies were performed in 37 patients who had
normal liver functions. 118 FDG PET/CT images were obtain-
ed before the therapy and after 2. cycles of chemoterapy.
SUVmean values were measured using volumetric region of
interests drawn on the right lobe of the liver and corrected for
lean body mass values. Early and late SULmean values were
compared with wilcoxon analysis. Percentage change was
calculated.RESULTS: At baseline study, late SULmean values
were significantly lower than early values [ 1.01 (0.57-1.5) vs
1.29 ( 0.82-2.04), p=0.0001]. At interim period, similar differ-
ence between late and early images was observed [ 1.18 (64-
1.39) vs 1.39 (0.91-1.97)]. SULmean values were not different
between baseline and interim studies.Median value of the time
difference between early and late studies for baseline and in-
terim period were 70 min (39-114) and 79 min (43-157), re-
spectively. Median percentage change of SULmean was -29%
for baseline and -16% for interim period. Percentage changes
were correlated with elapsed time ( r= 0.57, p=0.0001).CON-
CLUSION: Liver 18 FDG activity is dependent on the elapsed
time. Time-dependent reduction of liver 18 FDG activity
should be kept in mind in the interpretation of dual-phase
stuies and response assesment, especially in the studies in
which liver activity has been used as reference point.
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Peptide Receptor Radionuclide Therapy with Lu-177
DOTATATE in patients with somatostatin receptor
positive tumours
K. Kamaleshwaran, n. sudhakar, s. paulvannan, m. vysakh,
A. shinto; Kovai medical center and hospital limited, Coimba-
tore, INDIA.
Aim: Aim is to assess the therapeutic efficacy of 177Lu-
DOTATATE in therapy of Neuroendocrine tumours. Methods:
30 patients (age 45±15 years) with Neuroendocrine tumors were
included The study was approved by institutional ethics
committee.Pre-treatment 99mTc-HYNICTOC SPECT/CT study
was performed to confirm the presence of somatostatin receptors.
Transfusion of reno-protective amino-acids and anti-emeticswere
done before and during the treatment. 100-150 mCi of 177-Lu-
DOTATATE was administered over 30 minutes and cycles were
repeated at intervals of 3 months. Response assessment was done
by comparing serum biochemical markers and 99mTc-
HYNICTOC SPECT/CT. Results: 20 patients each of medullary
carcinoma thyroid (MTC), pancreatic NET (PNET), and gastro-
intestinal NET (GI-NET), 1 of mediastinal teratoma with NET
component, 3 paragangliomas and 6 NETwith unknown prima-
ry. There was history of prior surgery in 15, sandostatin treatment
in 18, chemotherapy in 17 and radiotherapy in 2 cases. There
were lymph node metastases in 19 patients, liver metastasis in
10 , primary in 15, skeletal mets in 7 and pulmonary lesions in 4
cases.10 patients have been administered more than two thera-
peutic administrations and assessed for treatment efficacy. Bio-
chemical response measured using tumour markers and serum
Chromogranin A demonstrated a significant decrease of >50%
in 20 (66%) patients and stabilization of the same in 10 (33%)
cases. Partial remission, stable disease and progressive disease
was observed in 20 (66%), 5 (17%) and 5 (17%) patients, respec-
tively using RECIST criteria. There was a significant improve-
ment in quality of life in 24 (80%) and moderate improvement in
6 (20%) cases. The median overall survival of the patients was
found to be 18months. Conclusions:177Lu-DOTATATE inNeu-
roendocrine tumours is a safe treatment with significant clinical
response and reduction tumour size and biochemical markers.
P796
Early side effects of radio ligand therapy
with 177-Lutetium-PSMA of metastatic castrate-resistant
prostate cancer
H. Ahmadzadehfar1, A. Yordanova1, S. Kürpig1, E.
Eppard1, F. Gärtner1, S. Rogenhofer2, M. Essler1; 1Universi-
ty Hospital Bonn, Department of Nuclear Medicine, Bonn,
GERMANY, 2University Hospital Bonn, Department of Urol-
ogy, Bonn, GERMANY.
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Objectives: Peptide radionuclide ligand therapy (PRLT) with
177Lu-PSMA-DKFZ 617 (LU-PSMA) (prostate-specific
membrane antigen) is a novel targeted therapy of metastatic
prostate cancer. We present the first clinical experiences
assessing early possible side effects of this therapy. Methods:
25 PRLTwere performed in 16 hormone and/or chemo refrac-
tory patients with distant metastases and progressive disease
(mean age: 74 y/o). 68Ga-PSMA PET/CT was performed in
all patients 1-2 weeks prior to and 7 weeks after PRLT.Median
PSAwas 376 ng/ml (range: 20-1650). We tried to protect the
salivary glands with ice packs during therapy. All patients
received CBC, renal and liver function tests on the day before
and two days after application (median administered activity
6.2 GBq, range 4.1 - 7.2 GBq), followed by further tests every
two weeks. All patients were contacted by telephone every
week regarding side effects or any positive and negative
changes. Results: All patients showed in Ga-PSMA-PET bone
and lymph node metastases, of whom six patients also had
residual/locally recurrent tumor. All lesions detected by PET/
CT exhibited high Lu-PSMA uptake on post-therapy planar
and SPECT/CT scan performed two days after application.
Although the treatment was well tolerated by all patients with-
out any significant adverse effects, four patients complained 6-
9 hours after the application of mild nausea. A mild dry mouth
and fatigue in the first 4 weeks after the application in 3 and 4
patients, respectively, were the most important complaints of
the patients. Majority of patients experienced no
hematotoxicity and nephrotoxicity. A PSA response were ob-
served in about 70 % of patients. Conclusions: Our initial
results indicate that PRLT with Lu-PSMA is safe and seems
to have low early side effects profile. A significant PSA de-
cline was observed in the majority of patients.
P797
The clinical efficacy and effectiveness of the Lu-177
DOTATATE therapy
E. Acar, H. Durak, G. Çapa Kaya; Dokuz Eylül University,
School of Medicine, Department of Nuclear Medicine, İzmir,
TURKEY.
Aim: The purpose of this study was to compare disease state
before-and-after Lu-177 DOTATATE therapy in patients with
metastatic well-differentiated neuroendocrine tumor/
carcinoma.Material and Method: We retrospectively evaluated
the total of 15 patients who received 50 courses of (1-6
courses/patient) Lu-177 DOTATATE therapy in the Depart-
ment of Nuclear Medicine between October 2013-January
2015. There were 10 women and 5 men (mean age: 50, range:
36-78); 3 with pancreatic, 1 with stomach, 1 with bowel, 10
with unknown primary neuroendocrine tumor/carcinoma. CT
and Ga-68 DOTANOC PET/CTwere performed to all patients
before-and-after treatment. Therapy responses were deter-
mined based on RECIST (Response Evaluation Criteria In
Solid Tumors) and PERCIST (PET Response Criteria In Solid
Tumors) criteria.Results: 4 patients were excluded from study
due to recent therapy administration which was too early to
assess response to treatment. Among the 11 patients evaluated;
6 patients had regression (54.5%), 3 patients had progression
(27,5%), 1 patient had regression after first-two treatments but
after the following two treatment courses; the patient had re-
gression with RECIST criteria, progression with PERCIST
criteria (9%) and 1 patient had progression with RECIST
criteria, stable disease with PERCIST criteria (9%). 1 patient
died 7 months after the second treatment. She had poorly dif-
ferentiated pancreatic neuroendocrine tumor (Ki-67 >30%,
grade 3), she received Lu-177 DOTATATE therapy because
of negative F-18 FDG PET/CT but positive Ga-68
DOTANOC PET/CT. She had regression after two treatment
courses, so the treatment was discontinued. Other 2 patients
with progression and 1 patient with progression with RECIST
criteria, stable disease with PERCISTcriteria, did not have Ki-
67 indices reported by pathology.Conclusion: Approximately
in 50% of patients with well-differentiated neuroendocrine tu-
mors, regression/stable disease was observed after Lu-177
DOTATATE therapy have. Ki-67/mitotic index has a prognos-
tic value.Key words: neuroendocrine carcinoma, metastasis,
Lu 177 DOTATATE therapy
P798
Peptide Receptor Radionuclide Therapy
with 177Lu-dotatate is an active treatment in advanced
bronchial carcinoids: prognostic role of TTF1
and FDG-PET.
A. Ianniello, M. Sansovini, S. Severi, S. Nicolini, V. Lanzetta,
K. Massri, F. Matteucci, P. Caroli, A. Bongiovanni, M. Monti,
V. D' Errico, G. Paganelli; IRCCS IRST of Meldola, Meldola,
ITALY.
Aim: Bronchial carcinoids, Typical carcinoids (TCs) and
Atypical carcinoids (ACs), represent 20-25% of all neuroen-
docrine tumors. Their incidence is increasing and in advanced
disease new therapeutic options are still needed. We prospec-
tively investigated the efficacy and safety profile of Peptide
Receptor Radionuclide Therapy with 177Lu-dotatate (Lu-
PRRT) in advanced TCs and ACs patients (pts) treated at
two different dosages. We also investigated the role of TTF-
1 and FDG-PET as prognostic factors for pts treated with Lu-
PRRT. Methods: Thirty-four consecutive pts with documented
radiological progression were treated with Lu-PRRT at two
different therapeutic cumulative activity (CA) of 18.5 GBq
or 27.8 GBq in four or five cycles. CAwas choosen according
to the patient’s kidney function and bone marrow reserve
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(IRST protocol n°100.01). TTF-1 was available in all pts.
FDG-PET was available in 29/34 pts at baseline. Results: All
patients received at least 4 cycles of Lu PRRT with a median
cumulative dosage of 21.5 GBq (12.9-27.8).Median follow up
was 29 months (range 7-69). Regardless the CA received, pts
with TCs showed a Disease Control Rate (DCR) equal to 80%
with 6% of CR, 27% of PR and 47% of SD. Median
progression-free survival (PFS) was 20.1 months (range
11.8-26.8). In ACs pts we obtained SD in 47% whereas 53%
continued PD. PFS was 15.7 months (range 10.6-25.9). Re-
markably, none of the pts had major acute or delayed toxicity,
including pts with reduced kidney’s function and bonemarrow
reserve. Of note, PFS in TCs TTF1 negative showed a median
value of 26.3 months (range 12.9-45.2), while in TCs TTF1
positive the PFS was 7.2 months (4.2-14.0); p=0.0009. FDG-
PETwas negative 13 pts: 10 in TCs and 3 in ACs. FDG-PET
was positive in 16 pts: 4 in TCs and 12 in ACs. The median
PFS in negative FDG-PET pts was 26.4 months (range 14.2-
48.9) and it was 15.3 months (range 11.7-31.1) in pts with
increased glucose metabolism at baseline FDG-PET; p
0.201. Conclusion: Lu-PRRT has an antitumor activity in
bronchial carcinoids in terms of DCR and PFS. According to
the IRST protocol, Lu-PRRT is safe in all patients including
those at higher risk of side effect. TTF1 seems to be an impor-
tant prognostic factor in bronchial carcinoids. As for GEP-
NET, FDG-PET positivity is a hallmark of more aggressive
tumors and is more frequent in ACs compared to TCs.
P799
The clinical efficacy and effectiveness of the Y-90
radioembolization therapy for the treatment of liver
malignancies
E. Acar1, G. Çapa Kaya1, A. Gülcü2, H. Durak1; 1Dokuz
Eylül University, School of Medicine, Department of Nuclear
Medicine, İzmir, TURKEY, 2Dokuz Eylül University, School
of Medicine, Department of Radiology, İzmir, TURKEY.
Aim: The purpose of this study was to compare disease state
before-and-after Y-90 radioembolization therapy in patients
with primary or metastatic liver carcinomas. Material and
Method: We retrospectively evaluated the total of 32 patients
who received 43 courses of (1-3 courses/patient) Y-90
radioembolization therapy in the Department of Nuclear Med-
icine between April 2009-December 2014. There were 15
women and 17 men (mean age: 56, range: 40-77); 12 with
colorectal cancer, 8 with HCC, 7 with neuroendocrine tumor/
carcinoma, 2 with gastric cancer, 1 with breast cancer, 1 with
pancreas cancer, 1 with unknown primary/metastatic liver can-
cer. CT, MR and F-18 FDG/Ga-68 DOTATATE PET/CTwere
performed to all patients before-and-after treatment. Therapy
responses were determined based on RECIST (Response
Evaluation Criteria In Solid Tumors) and PERCIST (PET Re-
sponse Criteria In Solid Tumors) criteria. Results: 6 patients
were excluded from study, 4 of them had a recent therapy
administration which was too early to assess response to treat-
ment and 2 patients with very poor general condition so they
were unable to undergo therapy response imaging. Among the
26 patients evaluated; 7 patients had regression (27%), 1 pa-
tient had regression with RECIST criteria, stable disease with
PERCIST criteria (3.8%), 2 patients had regression in therapy
field but had progression in the other part of the body (7.7%), 5
patients had initial regression but had progression after 5.2 (1-
11) months (19.2%), 2 patients had regression in some liver
lesions and progression in other liver lesions (7.7%), and 9
patients had progression (34.6%). 12 patients died in an aver-
age of 9 (2-22) months after the therapy. There was no signif-
icant difference compared to disease progression or regression
with localizations of primary disease. Conclusion: Approxi-
mately in 1/4 of patients with primary/metastatic liver cancer,
regression was observed after Y-90 radioembolization therapy.
62% of patients are still alive. This suggests that the treatment
is partially successful. Key words: liver, metastasis,
radioembolization, Y-90
P800
Assessment of Response with Evaluation of Renal Toxicity
in Patients Receiving 177Lu-DOTA-(Tyr3)-octreotate
Therapy in a Tertiary Care Centre in Mumbai, India
T. BHARADWAJ1, H. Rathore1, H. Shah1, P. Aland1, B.
Jois KS1, S. Ghosh1, P. Singh2, P. Chandrak3, P. Chaudhuri1,
L. Reddy1, P. Kumar1, S. Patro1, V. Lele1; 1Jaslok Hospital
and Research Centre, Mumbai, INDIA, 2K.E.M Hospital,
Mumbai, INDIA, 3Tata Memorial Hospital, Mumbai, INDIA.
Introduction: Peptide receptor radionuclide therapy is an
established modality of treatment for metastatic or inoperable
somatostatin receptor expressing tumours. Indigenously syn-
thesised 177Lutetium Chloride in BARC, India has added to
both its cost effectiveness and easy availability. However,liter-
ature pertaining to clinical and radiological response assess-
ment, and related toxicities in Indian scenario is sparse. Aim:
The primary objective is to assess the clinicaland radiological
response following repeated cycles of therapy in patients,
among those primarily failed to respond conventional modal-
ities. Studying the effect on findings of serial renograms was a
secondary objective. Materials and Methods: A cohort of 23
patients who had 1. Received cumulative dose of 29.6 GBq (+/
-10%) 177Lu-DOTA-(Tyr3)-octreotate (four cycles of 200mci
each at 6-8 weeks interval) 2. Baseline and post therapy So-
matostatin receptor PET-CTscan.3. Baseline and post therapy
clinical status recorded through subjective interview and
Karnofsky's Performance Score. Radiologic response was
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evaluated through RECIST 1.1 criteria. Patients were grouped
i n t o s u bg r o up s a c c o r d i n g t o s i t e o f p r ima r y
(Gastroenteropncreatic, thyroid, paraganglioma or others),
sites of metastases (liver, bones or lymphnodes). Clinical and
radiological response was assessed for each subgroup individ-
ually and in combination with site of primary. Mean percent-
age reduction in clearances was calculated. Results: Out of 23
patients 15 had gastroenteropancreatic (GEP), 2- thyroid, 2-
paraganglioma ,4- others. Most of them were failures to con-
ventional therapy(16). Subgroups (based on site of metasta-
sis): A- 6/23 (liver+ bone + lymphnodes), B-5/23 (bone +
lymphnodes), C- 4/23( liver + lymphnodes), D- 5/23 (liver),
E- 2/23(lymphnodes), F- 1/23 (bone). Symptoms subsided in
56.5%, unchanged in 26.1% and new symptoms in 17.4% of
which 2 died. KPS improved by 10% in 65%, unchanged in
26.1% and decreased by >= 10% in 8.7% who died. Radio-
logically, 26.1% showed response, 34.8% stable disease,
39.1% progression. Poor response was seen with patients hav-
ing liver metastasis(r=-0.44) and good response with bone
metastasis(r=0.93). Mean percentage reduction in 99mTc-EC
clearance was 16.1%(+/-12.2%), more so in patients with prior
chemotherapy. Conclusion: 177Lu-DOTA-(Tyr3)-octreotate
can be used as a viable treatment option in inoperable cases
of somatostatin receptor expressing tumours with good re-
sponse and tolerable renal side effects.
P801
Peptide receptor radionuclide therapy of neuroendocrine
tumours with 177Lu-octreotate: first experience
in a French Canadian centre
M. Del Prete, F. A. Buteau, J. M. Beauregard; Université
Laval, Quebec City, QC, CANADA.
Aim: Peptide receptor radionuclide therapy (PRRT) with
radiolabeled somatostatin analogues is currently a promising
targeted palliative treatment against advanced/metastatic
gastroenteropancreatic neuroendocrine tumours (NETs). We
report initial data of a retrospective study in metastatic NET
patients treated with PRRT at CHU de Québec.Materials and
methods: Files of patients with NET treated with 177Lu-
octreotate between November 2012 and March 2015 were
reviewed. Four induction cycles of approximately 7.4 GBq
(lowered to 5.5 GBq in cases of impaired renal function or
widespread bone metastasis) were administered at 8-10 week
intervals, with concurrent amino acids infusion. Maintenance
cycles were administered to responders. Overall response was
assessed at 3 months following 4th cycle. Radiological re-
sponse was evaluated according to RECIST 1.1 and SWOG
criteria, while biochemical response was evaluated by the
analysis of chromogranin-A (CgA). Haematological, hepatic
and renal function tests were performed before, and at 2 and 4
weeks after each cycle, and 3 months after the 4th cycle. Treat-
ment toxicity was evaluated according to the National Cancer
Institute Common Toxicity Criteria (CTCAE) version 4.0.Re-
sults: Twenty-two patients (median age 61; range: 43-82) were
treated and 79 treatments (75 induction and 4 maintenance
cycles) were given. Nine patients were assessable 3 months
after the 4th induction cycle. According to RECISTcriteria, all
patients (100%) had stable disease (SD), while according to
SWOG criteria, 8 (88.9%) patients had SD and 1 (11.1%) had
minor response. Six patients were evaluable for biochemical
response at 3 months, with a stabilization of CgA levels in 4
(66.7%) and a biochemical progression in the other 2 (33.3%).
Symptomatic response was observed in 6 (66.7%) patients, 1
(11.1%) patient had stabilization of symptoms and 2 (22.2%)
patients had aggravation of symptoms (pain, fatigue, flushing
and diarrhea).Most common toxicities were haematological or
renal, of grade 1 or 2 (20% of all cycles). No patients experi-
enced any grade 4 toxicity, while subacute grade 3 haemato-
logical toxicity occurred in 2 (2.7%) cycles and in 2 (9.1%)
patients. No patient experienced chronic toxicity grade 3 or 4
or death due to PRRT.Conclusion: Our preliminary results
indicate that 177Lu-octreotate PRRT appears to be a safe and
effective palliative treatment for metastatic NET patients. The
low rate of minor or partial radiological responses we observed
may be due to an initial referral bias towards patients with
more advanced disease.
P802
Peptide Receptor Radionuclide Therapy (PRRT)
in Patients with Metastatic Neuroendocrine Tumors: How
Effective and Safe Are They?
T. Liotsou, A. P. Stefanoyiannis, S. N. Chatziioannou; 2nd
Department of Radiology, Nuclear Medicine Section, National
and Kapodistrian University of Athen, Athens, GREECE.
Aim: Neuroendocrine tumors (NETs) are well-differentiated
tumors, the majority of which express peptide receptors in
the surface of their cells. Peptide receptor radionuclide therapy
(PRRT) is based on the systemic administration of a synthetic
peptide, labeled with β-emitting radionuclides 90Yor 177Lu.
This study aimed to evaluate the efficacy and safety of this
therapy. Material and Methods: Twenty (20) patients were
treated with 90Y-DOTATOC (total dose of 13.3 GBq) or
177Lu-DOTATATE (total dose of 29.6GBq). These patients
were presented with histologically proven well-differentiated,
metastatic or unresectable NETs (15 patients with
gastroenteropangreatic tumors, GEP-NETs, 3 patients with
lung carcinoid and 2 patients with medullary thyroid carcino-
ma). In all patients, somatostatin receptor scintigraphy was
positive before treatment and the burden of their disease was
determined via CTorMRI imaging. Patients were followed up
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for 3-36 months after the end of the PRRT. Co-administration
of amino acid solution was carried out in all patients in order to
avoid nephrotoxicity. RECIST criteria were used to evaluate
radiological response, WHO criteria for biochemical response
evaluation, whereas clinical response was based on the reduc-
tion of the symptoms’ frequency. Toxicity was estimated using
Common Toxicity Criteria version 4.0. Results: Radiological
partial response was observed in 40%, biochemical partial re-
sponse in 35% and clinical partial response in 60%.
Concerning toxicity, it appeared only in some patients who
received 90Y-DOTATOC treatment (1 patient with transient
liver toxicity grade II and 3 patients with renal toxicity of grade
I). Other side effects during therapy were nausea, vomiting and
headache due to administration of amino acids, with complete
remission few hours after therapy. Conclusion: The efficacy of
this treatment is very important based on tumor response rates.
On the other hand, the few side effects and the clinical im-
provement makes this treatment a important tool for the ther-
apy of NETs.
P803
Efficacy and and long-term tolerability
of 177Lu-DOTATATE treatment
J. Svensson1, A. Elf2, R. Rossi Norrlund3, V. Johansson2, B.
Wängberg2, P. Bernhardt4; 1Department of Oncology, The
Sahlgrenska Academy, Sahlgrenska University Hospital,
Göteborg, SWEDEN, 2Department of Surgery, The
Sahlgrenska Academy, Sahlgrenska University Hospital,
Göteborg, SWEDEN, 3Department of Radiology, The
Sahlgrenska Academy, Sahlgrenska University Hospital,
Göteborg, SWEDEN, 4Department of Radiation Physics,
The Sahlgrenska Academy, Sahlgrenska University Hospital,
Göteborg, SWEDEN.
Aim: Peptide receptor radionuclide therapy is a valuable op-
tion for patients with neuroendocrine tumours overexpressing
somatostatin receptors. Durable disease control is reported,
though randomised data is still lacking. Tolerability is gener-
ally reported as very good, though renal and hematologic tox-
icity exist. More recent reports on this therapy have focused on
potential prognostic factors for effect and toxicity, to improve
the selection of patients. Both toxicity during treatment and
long term tolerability is relevant for these patients who have a
relatively long life expectancy and later often are candidates
for further therapy. The aim of this study was to evaluate renal
and bone marrow function at late follow up.Material &
Methods: 51 patients were treated with in average 24.6 GBq
(range 8.0-44.8) 177Lu-DOTATATE on 1 to 6 occasions dur-
ing 2006-2011 at Sahlgrenska University Hospital, Gothen-
burg. Kidney protecting amino acids were co-infused at treat-
ment. Responses were monitored radiologically with RECIST
criteria, and biochemically. To evaluate treatment tolerance,
hemoglobine, leucocytes, platelets, serum creatinine and glo-
merular filtration rate (GFR) was monitored during treatment
and follow up. Results: 40 patients were radiologically
evaluable according to RECIST 1.1. Of these patients 6 had
PR, 32 SD and 2 PD, with a mean time to progression of 37
months. Of 40 patients biochemically followed, 31 had elevat-
ed Chromogranin A in serum or tU-5HIIA in urine. 21 of these
patients responded with a reduction to less than 75 % of base
line values after treatment. Mean values for leukocytes, plate-
lets, serum creatinine (n=49) and GFR (n=36) did not differ
significantly from baseline values after a mean follow up time
of 45 months (36 months for GFR). Hemoglobine values had
decreased from 129 to 117 g/L (p<0.01). 23 patients are still
alive, with a mean follow up time of 74 months. Conclusion:
Disease control rate (PR+SD) was 95 % for radiologically
evaluable patients with a response time comparable to what
has been reported by other groups. Renal and bone marrow
function seems preserved at long term follow up.
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Effect of application of prophylactic central compartment
lymph node dissection to radioiodine ablation doses
in patients with papillary thyroid carcinoma.
C. Soydal, E. Ozkan, N. O. Kucuk, K. M. Kir; Tip Fakultesi,
Ankara, TURKEY.
Aim: We aimed to document the effect of application of pro-
phylactic central compartment dissection to radioiodine abla-
tion doses for papillary thyroid carcinoma. Material and Meth-
od: 452 (382F, 69M, mean age: 46.69, min-max: 13-71) pa-
tients who received ablative doses of radioiodine between
April 2010 and December 2014 were included retrospectively.
Histopathological reports of thyroidectomy and given
radioiodine doses were evaluated. Frequencies of prophylactic
central compartment dissection according to T stage of prima-
ry tumor, detection rate of lymph nodemetastases and its effect
to given radioiodine ablation dose were calculated. Results:
Totally 252 (56%) of patients had undergone prophylactic
central compartment dissection. T stages of these patients were
T1a, T1b, T2 and T3 in 85 (34%), 106 (42%), 41(16%) and 20
(8%). Given radioiodine ablation doses was affected from cen-
tral compartment lymph node metastases 112 (44%) patients.
Whi le 32 (29%) of these pat ients had papi l la ry
microcarcinoma (T1a), 48 (43%), 20 (18%) and 12 (11%) of
them had T1b, T2 and T3 tumors. Conclusion: Application of
prophylactic central compartment dissection affects
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radioiodine ablation dose in approximately half of patients.
This effect comes forward in T1 stage tumors.
P805
Radioiodine therapy outcome in older patients
with thyreotoxicosis caused by Graves’ disease : our
experience
M. Yaneva; UMBAL St.George Plovdiv, PLOVDIV,
BULGARIA.
Older patients have fear or some contraindications for opera-
tive treatment. In the last years the endocrinologists try, some-
times for a very long time and unsuccessfully, to treat them
with antithyroid drugs. Some of these collegues discovered
that in practice radionuclide treatment with 131-I still exists.
Aim:We wanted to evaluate the effectiveness of 131-I therapy
in older patients with thyreotoxicosis caused by Grave’s dis-
ease in 10 years time. Material and method: We made a retro-
spective assessment of 187 patients with thyreotoxicosis, 151
women and 36 men at median age 67 ± 7,5. All of them were
treated with thyreostatics for 3-5 years with data of relapse.
The hormonal tests showed higher values than normal, they
did not accept operative treatment and their possibility for
treatment remained 131-I.The applied doses of 131-I were 5-
6 mCi .The patients were treated as outpatients for the clinic.
Results: After a follow up on the sixth month 57% (107 pts)
did not need treatment, 19 % (36 pts) still accepted
Laevothyroxin, but in a lower dosage and only 1 patient had
no effect after the application of 131-I. Patients that did not
respond to the first dosage of 5 mCi got another 5 mCi on the
next year. Then the response was good and they had no need of
thyrostatics. Our results show favourable influence of 131-
treatment on hyperthyroidism. Patients felt much better after
the iodine treatment and they remember the radionuclide treat-
ment with131-I with satisfaction.No side effects were ob-
served in all patients. Conclusion: We strongly suggest that
131-I therapy should be applied to patients who had under-
gone unsuccessful treatment with thyreostatics, those that have
relapse after operation and contraindications or unwillingness
for operative treatment.
P806
99mTc-HYNIC Octreotide and F-18 FDG PET -CT
in differentiated thyroid cancer patients with raised
thyroglobulin levels and negative 131I whole-body scans
K.Kamaleshwaran, n. sudhakar, m. vysakh, A. shinto; Kovai
medical center and hospital limited, Coimbatore, INDIA.
Objectives: Thyroid cancer is the most common endocrine
tumor and its incidence is increasing. Nuclear medicine plays
an important role in the clinical management of the disease. It
has been described the use of 99mTc labeled somatostatin
analogues for thyroid cancer patient evaluation after surgery
and iodine treatment in those who persist with high thyroglob-
ulin levels and a negative iodine whole body scan. The aim of
our work was to perform an intrapatient comparison of F-18
FDG PET-CT with 99mTc HYNIC Octreotide scans in 20
patients of thyroid cancer and follow up them for one year.
Methods: FDG PET/CT examinations were performed to 20
patients bearing differentiated thyroid cancer (15 papillary and
5 follicular) post-thyroidectomized with raised thyroglobulins
(21 to 67 ng-ml; mean 35 ng-ml), negative antithyroglobulins
and negative I 131whole body scans (15 women, age 29-55 yr,
5 men, age 45-75) that already had a positive 99mTc HYNIC
Octreotide scintigraphy. Studies were performed after
obtaining informed consent and our Ethics Committee approv-
al. Results: 99mTc HYNIC Octreotide scintigraphy showed
focal thyroid bed (n=10), node (n=3) and lung (n=7) uptake .
F-18 FDG PET-CT studies showed discordant matches with
99mTc HYNIC Octreotide scans in most of the patients. The
patients with somatostatin receptor uptake does not show glu-
cose uptake.those patients which showed HYNICTOC posi-
tivity underwent LU-177 DOTATATE therapy and with FDG
uptake underwent retinoic acid redifferentiation therapy. Con-
clusions: These results may reflect the different somatostatin
receptor and glucose receptor expression in thyroid cancer
associated to different affinities of these two radiolabeled an-
alogues . This information may path the way to new insights to
in vivo molecular understanding of somatostatin receptor ex-
pression in thyroid cancer and used in peptide receptor
therapy..
P807
Thymic involution after radioiodine therapy for Graves’
disease
M. Jinguji1, M. Nakajo1, M. Nakajo1, Y. Nakabeppu1, C.
Koriyama2, T. Yoshiura1; 1Department of Radiology, Kago-
shima University Graduate School of Medical and Dental Sci-
ences, Kagoshima, JAPAN, 2Department of Epidemiology
and Preventive Medicine, Kagoshima University Graduate
School of Medical and Dental Sciences, Kagoshima, JAPAN.
Aim: Graves’ disease is an autoimmune condition character-
ized by the presence of circulating thyroid stimulating hor-
mone receptor antibody (TRAb). Thymic hyperplasia in pa-
tients with Graves’ disease is well documented. However, the
underlying mechanism of thymic hyperplasia in patients with
Graves’ disease is not understood. The aims of this study were
to examine whether the volume and CT attenuation of the
thymus in patients with Graves’ disease will change after
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radioiodine therapy, and to elucidate factors that affect these
changes. Materials and Methods: The subjects were 40 con-
secutive patients with Graves’ disease (7 males and 33 fe-
males; mean age, 49.6 years; age range, 20-73 years) who
underwent neck and chest CT before and 6 months after
radioiodine I-131 therapy. Thymic and thyroid volumes were
measured on CT, and thymic CT attenuation value (thymic
density) was measured at the level where the thymus appeared
most prominently. We examined the associations between thy-
mic volume or density and the following factors: age, serum
triiodothyronine (T3), thyroxin (T4) and TRAb levels and thy-
roid volume before radioiodine therapy using the Spearman
rank correlation test. Thymic volume, density and TRAb were
compared between before and after the therapy using the
Wilcoxon signed-rank test. Furthermore, we examined the as-
sociations between thymic volume reduction ratio and the fol-
lowing factors: age, serum T3, T4 and TRAb decline and
thyroid volume reduction ratios using the Spearman rank cor-
relation test. Results: A significant correlation was observed
only between thymic density and age (ρ=-0.650, P<0.001)
before radioiodine therapy. Thymic volume and density were
significantly decreased after radioiodine therapy (P <0.001 for
both). There were significant correlations between thymic and
thyroid volume reduction ratios (ρ=0.422, P=0.007), and thy-
mic volume reduction and T3 decline ratios (ρ=0.345,
P=0.029), respectively. Six months after radioiodine therapy,
serum TRAb levels were significantly increased (P =0.003).
No significant correlation was found between thymic volume
reduction and TRAb decline ratio (ρ=0.052, P=0.772). Con-
clusion: Significant thymic involution occurs after radioiodine
therapy in patients with Graves’ disease. Serum T3, but not
TRAb may be related to thymic hyperplasia and involution
following radioiodine therapy.
P808
First experience of treatment of thyroid cancer
with high-ablative dose of I-131
R. Alimanovic-Alagic1, A. Skopljak-Beganovic2, E. Elma
Kucukalic-Selimovic1; 1University Clinical Centre Sarajevo,
Clinic of Nuclear Medicine, Sarajevo, BOSNIA AND HER-
ZEGOVINA, 2University Clinical Centre Sarajevo, Depart-
ment of Medical Physics and Radiation Safety, Sarajevo,
BOSNIA AND HERZEGOVINA.
Introduction: Radioactive iodine treatment is a type of internal
radiotherapy and has been used for over 60 years in the treat-
ment of patients. After total thyroidectomy, a patient is treated
with I-131 targeted treatment. Main types of cancer for I-131
treatment are follicular and papillary thyroid cancer. This study
represents our own experiences with ablation therapy at thy-
roid cancer over a period of 12 months. Materials and
methods: The study included 91 patients after total thyroidec-
tomy. We have analyzed 67 patients with papillary thyroid
carcinoma iand 24 patients with follicular thyroid carcinoma.
All subjects were assessed prior to treatment: personal history
and physical status, laboratories, appropriate blood tests, EKG
exam, internal medicine specialist examination, ultrasound ex-
amination residual part of the thyroid gland. There was a TSH
hormone, Titer Antibodies: Tg and ATGL. Then certain abla-
tive dose doses of 1,85 GBq to 7,4 GBq (50 to 200 mCi) of
I-131 in the form of a capsule is administered to the patient. 72
hours after the treatment of the patient, the whole body scin-
tigraphy is performed. 2-3 months after discharge from the
hospital, the patient is ordered to come back and check the
hormone status. Results of Investigation: After total thyroid-
ectomy and without therapy levotiroxine all patients has high
TSH. A total of 91 patients with papillary and follicular carci-
noma were treated with I-131 for ablation of a postoperative
thyroid remnant. In the both therapeutic groups blood test
showed decreased TSH values (from 46,5 to >100 mIU/ml),
Tg (from < 0,1 to > 500 ng/ml), and elevated ATGL (from 1,3
to 2509 IU/ml). With this study we demonstrated that the dose
(specific activity of I-131 administered) required to achieve
ablation is a high dose of approximately 100 mCi, and, in
terms of successful remnant ablation, lower doses are not as
beneficial as the conventional doses of 1,85 GBq to 7,4 GBq
(50 to 200 mCi). Conclusion: In the both therapeutic groups
there was normalization of the hormonal status, subjective and
objectives parameters, at the control examinations, already af-
ter three months and sixmonths follow-up. The side effects did
not appear in the any of therapeutic groups, what demonstrates
safe application. We conclude that after increasingly meticu-
lous near-total surgery and careful patient selection, the avail-
able data continue to favor higher doses of radioiodine ( 1,
85 GBq to 7,4 GBq (50 to 200 mCi) for remnant ablation,
especially after near-total thyroidectomy.
P809
Radioioeine Retreatment or Wait for a Limited Time
in Patients with Differentiated Thyroid Carcinoma
with Negative Thyroglobulin and Antithyroglobulin,
but Remained Thyroid Residue after Post-Surgery
Radioiodine Ablative Therapy?
A. Fard-Esfahani, B. Fallahi, A. Emami-Ardekani, S. Sahari,
D. Beiki, M. Abedi, A. Hassanzadeh-Rad, M. Eftekhari; Teh-
ran University of Medical Sciences, Research Center for Nu-
clear Medicine, Tehran, IRAN, ISLAMIC REPUBLIC OF.
Thyroid cancer follow-up after total thyroidectomy and
radioiodine ablation therapy is performed mainly by assess-
ment of radioiodine whole body scan (131I-WBS), thyroglob-
ulin (Tg), anti-thyroglobulin antibody (Anti-TgAb) levels and
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sonography. Considering there are a number of patients with
negative Tg, Anti-TgAb and sonography, but with a remained
thyroid residue, and there is a concern about prolonged thera-
peutic effect of radioiodine, the best therapeutic approach as to
give another therapeutic I-131 dose, or wait for a limited time
to get more I-131 therapeutic effect from the first dose, is
evaluated in this paper. Materials and Methods: In this study,
we enrolled the DTC patients with only thyroid remnant in
131I-WBS six months after first ablative therapy. Patients with
detectable Tg, high Anti-TgAb, evidence of neck mass in so-
nography and evidence of local or distant metastasis were
excluded. The patients were randomly placed in two groups:
A group who received I-131 retreatment and those who did not
(follow-up group). Then after six months, the clinical results of
these two groups were compared by evaluating 131I-WBS,
Tg, Anti-TgAb and sonography. Results: From 94 enrolled
patients, 36 patients were in retreatment group and 58 patients
were in follow-up group without retreatment. Both groups
matched by the variables including age, sex, pathology, tumor
size, capsular, vascular and lymphatic invasion. In 47.2% of
the retreatment group 131I-WBS still showed thyroid remnant,
while in 52.8% 131I-WBS became negative. These values for
the follow-up group without retreatment were 65.5% and
34.5%, respectively (p=0.08). In retreatment group, six
months after retreatment, 97.2% of patients still had Tg<1ng/
ml and 2.8% showed Tg elevation (Tg>1ng/ml). In the follow-
up group, after six months 96.6% of patients still had Tg<1ng/
ml and 3.4% showed Tg elevation (Tg>1ng/ml) (p=0.857). In
94.4% of retreatment and 98.3% of follow-up group Anti-
TgAb six months after retreatment was <100mIU/ml
(p=0.304). Sonography results were also insignificant (p=
0.403). Conclusion: In patients with undetectable Tg/Anti-
TgAb and only thyroid remnant in the six- month post-
ablation 131I-WBS, delay in prompt radioiodine retreatment
may be considered, as due to continued ablative effect of
radioiodine, about one-third of these patients may have a neg-
ative 131I-WBS in the next six-month study, consequently less
patient and society radiation burden and less economical loss,
with same clinical results will be achieved.
P810
Risk Factors for Persistent Disease in Papillary Thyroid
Carcinoma with Lymph Node Metastasis
A. Oral1, B. Yazici1, A. Akgun1, H. Hassoy2, Z. Ozcan1;
1Ege University, Faculty of Medicine, Department of Nuclear
Medicine, Izmir, TURKEY, 2Ege University, Faculty of Med-
icine, Department of Public Health, Izmir, TURKEY.
Aim: It is known that the presence of neck lymph node (LN)
metastasis is correlated with persistent and recurrent disease in
papillary thyroid carcinoma (PTC) patients. Cervical LN
metastasis in PTC is present in an average of 60 % of the
patients. After surgery and radioiodine treatment most of the
patients become disease-free. But some of the patients have
persistent disease. In the present study it was aimed to deter-
mine the factors affecting persistent disease in PTC patients
with histopathologically confirmed LN metastasis. Materials
and Methods: In this study, patients with non-papillary thyroid
carcinoma, without LN metastasis, having less than 2 years of
follow-up or initial distant metastasis and patients with high
serum thyroglobulin antibodies were excluded. We analyzed
130 (F/M: 93/37, median age: 40.5 years) consecutive PTC
patients with histopathologically proven LN metastasis. In 94
of the patients LN metastasis were detected on histologic ex-
amination of initial surgical material. In 36 patients LN metas-
tasis were surgically removed during the follow-up after
radioiodine therapy. Clinicopathological characteristics and
persistent disease after treatment were examined. Univariate
and multivariate analysis were performed to identify risk fac-
tors for persistent disease. Results: At the end of a median
follow-up of 84 months, 90 (69 %) of the patients became
disease free, and 40 (31 %) patients had persistent disease.
Univariate analysis showed that male gender, older age at ini-
tial diagnose (≥45 years), larger tumor size (>4 cm), presence
of lateral cervical LN metastasis, extrathyroidal invasion and
higher number of metastatic LN (≥10) were significant predic-
tors for persistent disease. Multivariate analysis showed that
extrathyroidal involvement, presence of lateral cervical LN
metastasis and older age at initial diagnose (≥45 years) were
independent predictors for persistent disease. Conclusion: De-
spite the presence of LN involvement, most of patients may
become disease free with therapy. Patients with extrathyroidal
invasion, presence of lateral cervical LN metastasis and older
age at initial diagnose (≥45 years) are more likely to have
persistent disease. However disease control can be achieved
with close follow-up and therapy.
P811
Clinical impact of circulating anti-thyroglobulin
autoantibodies on the prediction of recurrence in patients
with differentiated thyroid cancer after first remnant
ablation
G. Shen, S. Hu, A. Kuang; West China Hospital of Sichuan
University, Chengdu, CHINA.
Aim: The aim of the study was to evaluate the clinical impact
of circulating anti-thyroglobulin antibody (TgAb) titers after
remnant ablation on the prediction and management of differ-
entiated thyroid carcinoma patients who had undetectable thy-
roglobulin (Tg) values. Materials and methods: Patients with
differentiated thyroid carcinoma who underwent total thyroid-
ectomy followed by 131I remnant ablation between 2007 and
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2011 were enrolled. Of these, three hundred and seventeen
consecutive DTC patients with undetectable Tg were the sub-
jects of this study, which consisted of positive-TgAb and
negative-TgAb patients. All the patients had been followed
for 2 years. Recurrence was assessed by 131I scan, 18F-
fluorodeoxyglucose positron emission tomography, sonogra-
phy, computed tomography, or by surgical operation. The tu-
mor characteristics and final outcomes were compared be-
tween these two groups. In addition, the mean ablation courses
of each group were also counted. Results: Ninety-seven pa-
tients (30.6%) of the Tg-undetectable patients showed positive
TgAb, and the prevalence rate of high-risk patients in TgAb-
positive patients was significantly higher than that of TgAb-
negative controls (12.2% vs. 3.1%, p<0.05). Forty eight of
these TgAb-positive patients were confirmed with recurrence,
and the recurrence rate of TgAb-positive patients was signifi-
cantly higher than that of TgAb-negative patients (49.4% vs.
11.7%, p<0.001). During the two-year follow-up, 64.7% of the
disease-free patients showed spontaneously decreased TgAb
levels. A total of 59.4% of patients with recurrent cancer, who
showed responses to surgical operation or radio-iodine treat-
ment, also showed a decreased TgAb level. In addition, the
TgAb-positive cohort had more 131I therapy courses than
TgAb-negative group (mean 2.7 vs. 1.0, p<0.05). Conclu-
sions: Positive serum TgAb titer after first thyroid remnant
ablation appears to be a useful marker for recurrence in DTC
patients with undetectable serum Tg results.
P812
J - 131 Therapy of Autonomously Functioning Thyroid
Adenoma: the Outcome of Our 20 Years Experience
Z. PETROVSKI; DEPARTMENT OF NUCLEAR MEDI-
CINE CLINICAL HOSPITAL - BITOLA, BITOLA, MACE-
DONIA, THE FORMER YUGOSLAV REPUBLIC OF.
Objective: To investigate the results of J - 131 treatments in
patients (pts) with autonomous thyroid adenomas in long pe-
riod of follow up. Material and Methods: We enrolled 68 con-
secutive pts with Plummer’s disease ( 50 females, 18 males,
mean age 54,7 yrs, range 21 - 79 yrs) for period 1994 - 2014.
87%(59/68) pts had a unifocal nodule, while 13% (9/68) pts
had multifocal toxic autonomous nodules.Pts stopped antithy-
roid drugs for at least one month prior to the radioiodine ther-
apy and than we administered a J- 131 activity of 740 -+
180 MBq (range 550 - 1150 MBq), based of size and weight
of “hot” nodules and the value of radiiodine uptake.Volumetry
was done by ultrasound.The mean duration of follow up was
7,84 yrs.Results: In 65/68 (95%) pts was administered a single
dose, while 3/68(5%) pts needed two doses. 62/68 (91,3%) pts
who received a single dose were euthyroid with scintigraphic
normalization.The percentage of euthyroid did not
significantly change in long term of 20 yrs observation.The
recurrent hyperthyroidism was 2,9% (2/68) pts.The cumula-
tive incidence of hypothyroidism was 11,8% (8/68) pts
withing 1 - 6,2 yrs.The nodular volume was statistically higher
in pts who had recurrent hyperthyroidism over hypothyroid-
ism (p<0,01) and euthyroidism (p<0,02).The development of
hypothyroidism was higher in pts who showed extranodular
uptake and after TSH suppression.No differences were ob-
served in the results between unifocal and multifocal
nodules.Conclusion:J - 131 therapy is a simple, safe and
97% effective treatment of autonomous functioning thyroid
adenoma after one or more radioiodine doses.
P813
Evaluation of ablation of thyroid remnants with 1850MBq
iodine-131 in patients with thyroid cancer
J. Kawabe, S. Higashiyama, K. Kotani, A. Yoshida, S.
Shiomi; Graduate School of Medicine, Osaka City University,
Osaka City, JAPAN.
Aim: Radioiodine remnant ablation (RRA) with I-131 is rec-
ommended for differentiated thyroid cancer patients without
residual macroscopic metastases post-thyroidectomy. The ad-
ministered iodine activity necessary for ablation is controver-
sial. We have been performing RRA with 1850 MBq at our
facility since 2011, and evaluated the outcome retrospectively.
Materials and methods: Of the postoperative thyroid papillary
carcinoma patients without macroscopic metastases, 61 pa-
tients who underwent ablation at our facility from November
2011 to December 2014 (17 men, 44 women; mean age, 59.5
years) were evaluated. TSH, thyroglobulin (Tg), and anti-Tg
antibody levels were measured in pretereatment status, just
before RRA after a 2-week low iodine diet combined either
with thyroxine withdrawal (THW) (n=16) or recombinant hu-
man TSH (rhTSH) stimulation (n=45). All patients received
I-131 (1850MBq) treatment, followed by I-131 scintigraphy
after 10 days. Three months later, 2-week low iodine diet com-
bined with either THW (n=51) or rhTSH stimulation (n=10)
was restarted, followed by measurement of TSH, Tg and anti-
Tg antibody levels and I-131 scintigraphy. Successful RRA
was defined as follows: visually negative thyroid bed uptake
(TBU) and a Tg level 3 months after RRA < 2 ng/mL. Results:
Visually, negative TBU shown in 55 patients (90.16%) of 61
patients. Quantitatively, the averages of pretreatment Tg
levels, just before RRA and 3 months after RRA of 53 patients
excluding 8 patients with anti-Tg antibody was 2.87 +/- 5.80
ng/mL, 27.92 +/- 70.88 ng/mL and 21.50 +/- 41.27 ng/mL,
respectively. In 50 patients excluding 11 patients both with
positive anti-Tg antibody and positive TBU from all 61 pa-
tients, patients with the Tg levels below 2 ng/mL 3 moths after
RRA were 28 patients (56%). In five characteristics such as:
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Body weight (p=0.0016), BMI (p=0.0035), body surface area
(p=0.0031), Pretreatment Tg levels (p<0.0001) and Tg levels
just before RRA (p<0.0001) of 14 characteristics, significant
differences were shown. Of them, Pretreatment Tg levels (p =
0.0065) and Tg levels just before RRA (p = 0.03) were signif-
icant predictive factors for success of RRA with univariate
logistic regression analysis. Conclusion: Ablation with
1850MBq I-131 effectively destroyed the thyroid bed. Mea-
surements of pretreatment Tg levels and Tg levels just before
RRA are useful for prognoses of success of RRA.
P814
Radioiodine scan feature [multifocal versus unifocal
pattern] as the determinant for radioiodine ablative
treatment dose in patients of Differentiated Thyroid
Carcinoma
P. Singh1,2, S. Basu2, R. Asopa2, M. Rajan2; 1Seth G.S. and
K.E.M. Hospital, Mumbai, INDIA, 2RadiationMedicine Cen-
tre, BARC, Mumbai, INDIA.
Aim: To evaluate and compare the appropriate effective
dose of 131I therapy for successful ablation in differen-
tiated thyroid cancer patients demonstrating multifocal
radioiodine uptake/uptake outside thyroid bed and thus
proposing this factor as an important determinant in jus-
tifying higher dose for successful radioiodine ablation in
neck as compared to that administered for standard
unifocal radioiodine uptake in neck after total
thyroidectomyMaterials and Methods: Patients of differ-
entiated carcinoma of thyroid (post-thyroidectomy and
considered for radioiodine remnant ablative therapy) in-
cluding aggressive histological variants were included in
the study (n=125). A preablative scan with 3.7 MBq
131I, post-treatment scan before discharge and follow-
up scan after 6 months of therapy with 0.111-
0.136 GBq 131I were part of regular protocol. Scans
were done on gamma camera and interpreted by two
independent Nuclear Medicine Physicians. In case of
discordance, opinion of a third Nuclear Medicine Physi-
cian was taken. Patients with multifocal uptake in
neck/uptake outside thyroid bed in preablative and/or
post ablative scintigraphy were included in the study
group (84/125). Unifocal uptake in neck in both
preablative and postablative scintigraphy comprised the
control group (41/125). Patients with distant metastasis
were excluded. 49/84 patients with multifocal neck up-
take received low ablative dose (1.85GBq) and 35/84
received high dose 3.7-7.4 GBq. 7/84 patient’s scan
had discordant findings and were dropped in favor of
multifocality restricted to thyroid bed. 20/41 patients
with unifocal neck uptake in scintigraphy received low
ablative dose (1.85GBq) and 21 received high ablative
dose (3.7-7.4 GBq). The objective ablation parameters
were Scintigraphy, biochemical markers (Thyroglobulin),
relevant radiological investigations and SPECT-CT when
available.Results: 44.44 % (20/45) of patients demon-
strating multifocal uptake outside thyroid bed in pre/
post-treatment dose scan treated with initial low dose
(1.85 GBq) required a second higher dose of radioiodine
(total 3.7-7.4 GBq). 95% (19/20) had either papillary or
its follicular variant as histopathology. 5% (1/20) had
follicular carcinoma of thyroid. 100% (32/32) curative
rate was noted in patients with multifocal uptake in
and outside thyroid bed treated with initial higher
radioiodine ablative dose. 2/32 patients had aggressive
histopathology. 31.25% (10/32) of patients with multifo-
cal uptake outside thyroid bed were missed on 3.7 MBq
preablative scan.Conclusion: Multifocality outside thy-
roid bed in pre / post-ablative scans required second
high dose treatment in significant number of patients
who were treated with low ablative radioiodine dose.
The preablative diagnostic scan can play a major role
in the risk stratification and dose determination.
P815
Radioiodine treatment of Grave's disease despite history
of iodine allergy
i. G. E. el bez, n. bechir, I. MEDDEB, I. YEDDES, k. trabelsi,
h. boutruigua, l. zaabar, D. BEN SELLEM, B. letaief, I. SLIM,
A. MHIRI, M. BEN SLIMENE, M. BEN SLIMENE; institut
salah azaiez, tunis, TUNISIA.
Graves's disease is the most common cause of hyperthyroid-
ism. There are three current therapeutic options: anti-thyroid
medication, surgery, and radioactive iodine (I 131). There are
few data in the literature regarding the effects of radioiodine
therapy.We describe a 47-year-old patient who had Grave's
disease and has a history of an anaphylactic reaction to com-
puted tomography (CT) contrast agent. She came to our insti-
tute for further management of her hyperthyroidism.We con-
sidered her normal salt-containing diet and advised ra-
dioactive iodine treatment, which did not carry any re-
action in the patient. It makes us question whether
radioiodine treatment is harmful for patients with a his-
tory not only of ‘iodine allergy’ but also of the exis-
tence of an allergy to iodine itself.The patient agreed
with this analysis and successfully underwent treatment
with 12 mCi (444 MBq) radioactive iodine.The patient
was followed up for 2 weeks after radioactive iodine
treatment. The patient reported no problems during or
after the treatment.
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S731
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Evaluation of the expression of ADAMTS-3, -4 and -15
genes in parotid and submandibular salivary glands
after RAI therapy
M. SADIC1, H. I. ATILGAN2, S. O. HALACLI3, K.
DEMIRCAN4,M.KORKMAZ1; 1Ministry of Health Ankara
Training and Research Hospital, ANKARA, TURKEY, 2Di-
vis ion of Nuclear Medic ine ,Minis t ry of Heal th ,
Kahramanmaras Necip Fazıl City Hospital, Kahramanmaras,
TURKEY, 3Hacettepe University, School of Medicine, De-
partment of Molecular Biology, ANKARA, TURKEY,
4Turgut Ozal University, School of Medicine, Department of
Molecular Biology, ANKARA, TURKEY.
Aim: The genetic changes of salivary glands are not well de-
scribed in the literature after radioactive iodine (RAI) admin-
istration. A disintegrin-like and metalloproteinase with
thrombospondin type-1 motif (ADAMTS) proteases might
play role in damage of salivary glands after high dose RAI
administration as well as their critical roles in matrix degrada-
tion and repair. The aim of this study which is the first in this
area is to investigate the expression of ADAMTS-3, -4, and -
15 genes in acute and subacute salivary gland damage after
high dose RAI. Materials andMethods: Sixty four male Wistar
albino rats were divided into six groups. Group 1 was the
unexposed control group (n=20), group 2 (n=6) four hours
after RAI administration, group 3 (n=20) 24 hours after RAI
administration, group 4 (n=6) 48 hours after RAI administra-
tion, group 5 (n=6) 7 days after RAI administration, group 6
(n=6) 30 days after RAI administration. RAI was administered
100 MBq (~3 mCi, 12 mCi/kg) via orogastric route. We eval-
uated the mRNA expression of ADAMTS genes with quanti-
tative real time PCR. In addition, histopathological evaluation
(sialadenitis, interstitial, cellular and nuclear changes) was per-
formed with the samples obtained from right parotid and sub-
mandibular salivary glands according to the designated time
courses. Results: There was not statistically significant in-
crease in the expression of ADAMTS-3, -4 and -15 with quan-
titative real time PCR after high dose RAI administration at the
designated time courses defined as group 2, 3, 4, 5 and 6
compared to unexposed control group. Histologic exam-
inations of salivary glands in the RAI administered
groups showed the extensive nuclear coarsening,
binucleolization and focal subnuclear vacuolization while
normal nuclear properties have been demonstrated in the
control group. Other histopathologic parameters were not
different between RAI and control groups in acute and
subacute periods. Conclusion: We could not generate a
convincing data supporting our hypothesis that
ADAMTS-3, -4 and -15 genes are substantial proteases
for radiation-damaged rat salivary glands as no gene
expression was evaluated.
P817
Treatment of hyperthyroidism with iodine-131:
Experience of nuclear medicine department at the salah
azaiez Institute in Tunis
i. G. E. el bez, n. bechir, k. trabelsi, h. boutruigua, I. SLIM, I.
YEDDES, l. zaabar, I. MEDDEB, D. BEN SELLEM, B.
LTAIEF, A. MHIRI, M. BEN SLIMENE; institut salah azaiez,
tunis, TUNISIA.
Aim : We report through this work the experience of nuclear
medicine department at Salah Azaiez Institute, in the treatment
of hyperthyroidism with iodine-131. Materiel and methods :
We retrospectively studied a cohort of 300 patients with hy-
perthyroidism, from several regions of tunisia between Janu-
ary 2006 and december 2012. A clinical examination and a
serum assessment of TSHus, FT4 and anti thyroid antibodies,
have been made at baseline and at 3, 6 and 12 months after
radioiodine therapy. Results : The activity of iodine-131 ad-
ministered ranged from 444 to 925 MBq and depended on the
pathology being treated, age, thyroid volume, intensity of clin-
ical and biological hyperthyroidism and socioeconomic situa-
tion. Radioiodine therapy has often been proposed as a treat-
ment for second intention, after failure of medical treatment.
Graves’ disease was the most common etiology (80%),
followed by toxic adenoma (15%), and multinodular toxic
goiter (5%). The therapeutic efficacy of a fixed single dose
of radioiodine evaluated after a 6-months follow-up was
95% in Graves’ disease, 98% in toxic adenomas and 96% in
toxic multinodular goiter. No acute complication was ob-
served. Conclusion : Taking into account our socioeconomic
context, radioiodine therapy remains the preferred treatment of
hyperthyroidism in our country with good value vs price and
excellent tolerance.
P818
Comparison between low and high radioactive iodine
(131I) ablation dose in patients with low risk of papillary
thyroid cancer
i. G. E. el bez, I. SLIM, T. BEN GHACHEM, I. YEDDES, I.
MEDDEB, l. zaabar, D. BEN SELLEM, B. LTAIEF, A.
MHIRI, M. BEN SLIMENE; institut salah azaiez, tunis,
TUNISIA.
AIM:The aim of this study was to compare the ablation rate
after low and high ablation doses of iodine-131 dose in pa-
tients with low risk of papillary thyroid cancer.PATIENTS
AND METHODS:The study included 50 patients with low
risk of papillary thyroid cancer. The patients received an abla-
tion dose, which was low (1110 MBq) in 25 patients and high
in the remaining 25 patients (3700 MBq ). Awhole-body scan
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and Tg level assessment were carried out. The criteria for
complete ablation included absence of residual functioning
thyroid tissue and a Tg level lower than 1 ng/ml.RESULTS:
The overall successful complete ablation was achieved in 18
of 25 patients who received a low ablation dose and in 19 of 25
patients who received a high reablation dose; no statistically
significant difference was found between the two groups
(P>0.05).CONCLUSION: The overall complete ablation rate
after both a low and a high dose was no statistically significant
difference. An activity of 30 mCi 131I is effective in patients
with a low risk of papillary thyroid.
P819
Hürthle cell Carcinoma of the thyroid gland presenting
a favorable outcome (about 2 cases)
S. TALEB, G. CHERKAOUI SALHI, S. CHOUKRY, M.
AIT IDIR, A. GUENSI; Nuclear medicine department, CA-
SABLANCA, MOROCCO.
Hürthle cell Carcinoma (HCC) is a rare and aggressive thyroid
cancer histotype. It is considered by the World Health Organi-
sation as a variant of the conventional follicular derived neo-
plastic subtypes. Local invasion and distant metastasis are fre-
quent making its treatment difficult and worsening its progno-
sis. The aim of this study was to report the clinical and histo-
logical features and outcome of HCC patients treated at a nu-
clear medicine institution in Morocco. Among 1239 thyroid
carcinoma treated at Nuclear Medicine Department - Ibn
Rochd University Hospital - Morocco between January 2011
and December 2013, two patients were diagnosed HCC. Treat-
ed by total thyroidectomy and radioiodine, these two cases had
a favorable outcome with undetectable stimulated serum Thy-
roglobulin and negative Whole Body Scan. These two cases
will exemplify an unusual outcome of HCC.
P820
Effectiveness of total remnant ablation with single
therapeutic dose of radioiodine in patients with thyroid
cancer after initial surgery
E. Takacsova, R. Králik, J. Kausitz; St. Elisabeth Cancer In-
stitute, BRATISLAVA, SLOVAKIA.
AIM: The aim of our study was to evaluate the effectiveness of
total remnant ablation with therapeutic dose of radioiodine (>
than 30 mCi) in patients with differentiated thyroid cancer
after initial surgery and thyreoelimination radioiodine dose.
METHODS: We analysed 108 patients after total thyroidecto-
my for papillary or follicular thyroid cancer who were treated
with radioiodine (131I) in our hospital from January2012 to
December 2012. There were 50 (46%) low risk and 58 (54%)
high risk patients. We investigated the effectiveness of total
remnant ablation after initial surgery and thyreoelimination
131I dose (activity 42 - 120 mCi, average 78 mCi) with the
use of therapeutic dose (activity 36 - 200 mCi, average 114
mCi) administered 6 months after the thyreoelimination dose,
aside from the level of corresponding serumthyroglobulin.
Persistence of remnant thyroid tissue was evaluated using scin-
tigraphy after therapeutic 131I dose. Included were also pa-
tients with active disease, but investigated was only scinti-
graphic persistence of remnant thyroid tissue. Patients with
pre-thyreoelimination radioiodine uptake in the thyroid bed
higher than 10% were excluded from the study. RESULTS:
We achieved complete ablation ofremnant thyroid tissue with
the use of therapeutic 131I dose only in 49 (45%) of 108
patients - in 24 (48%) of 50 low risk patients and in 25
(43%) of 58 high risk patients. Neck ultrasonography before
the second dose of radioiodine showed persistent remnant tis-
sue in 14 (13%) of 108 patients - in 8 (16%) of 50 low risk
patients and in 6 (10%) of 58 high risk patients. CONCLU-
SION: We found complete ablation of remnant thyroid tissue
after thyreoelimination 131I dose only in 45% of all patients.
Persistence of remnant thyroid tissue was evaluated using scin-
t igraphy af ter therapeut ic 131I dose (> than 30
mCi)administered 6 months after thyreoelimination dose.
Neck ultrasonography was not useful method for detecting
persistent remnant thyroid tissue after thyreoelimination dose
of radioiodine.
P821
Patients (Pts) with Differentiated Cancer Thyroid (DTC):
prognostic value of Serum Thyroglobulin (Tg0) at the time
of the first Ablative Radioiodine Treatment (RAI)
and follow up with 131I Whole Body Scan (WBS)
L. Bertolazzi, V. Barbetti, L. Di Ciolo, C. Cananzi, M.
Gaffuri, G. Agnese, C. Motta, E. Piccardo, P. Moresco;
Azienda Ospedaliera Santa Corona, PIETRA LIGURE (SV),
ITALY.
Aim. The purpose of this review is twofold. To assess retro-
spectively the initial prognostic factors for treatment efficacy
and the relevant cut off of Tg0 in a large cohort of consecutive
patients (Pts) submitted to RAI. To evaluate, in the follow up,
which is the best factor to detect functioning recurrence: diag-
nostic thyroglobuline (Tgl) or WBS. Materials and Methods.
The study included 278 Pts who had had total thyroidectomy
and RAI between 2007 and march 2015. Tg0 was measured
off L-T4 and just before RAI (131I mean dose 2,5 GBq, range
2,2-3,0 GBq). Tg values were the result of duplicate measure-
ments done with RIA in our laboratories (Thyroglobuline
IRMA Radim, detection limit <0,5 ng/ml). 15 Pts were
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excluded for positive anti-Tg antibodies. The 263 Pts enrolled
(192 females and 71 males, age 18-84, mean age 47) were
affected by papillary cancer (221 Pts = 84%) and by follicular
cancer (42 Pts = 16%). 108 Pts (AGroup)) had Tg0 <1,5 ng/ml
and 155 Pts >1,5 ng/ml (B Group): we have considered only
Pts of A Group (41% of all Pts). After 6-12 months A Group,
which followed a low iodine diet and off L-T4 (TSH > 40 uU/
ml), underwent diagnostic assessment withWBS (185MBq of
131I) and Tg1. Results. WBS after RAI in 90/108 Pts 83 % (C
Group) was positive for thyroid remnants (R); in the remaining
18 Pts 17% (DGroup)WBSwas positive for R and for lymph
nodes metastases (N). In 61/90 Pts of C Group Tg0 was un-
detectable (<0,5 ng/ml), while in D Group 9 Pts Tg0 was >0,6
ng/ml. At diagnostic assessment after 6-12 months from RAI
in C Group (90 Pts)WBS and TG1 were negative for R and N.
In D Group 9 Pts had WBS and Tg1 negative for R and N
while 9 Pts had WBS positive for lymph nodes and Tg1 was
detectable between 0,6 and 1,5 ng/ml. Conclusion. In 90/108
Pts (83 %) with Tg0 undetectable is not necessary to perform a
second RAI. In 18/108 Pts (17 %)WBS diagnostic assessment
allowed the identification of positive lymph nodes while Tg0
and Tg1 are < 1,5 ng/ml. In 9/18 Pts (50 %) with Tg0 unde-
tectable and with positive lymph nodes only first ablative ther-
apy was sufficient. On the basis of these findings we recom-
mend the complementary diagnostic use of 131I WBS.
P822
Assessment of prognosis in differentiated thyroid
carcinoma patients showing detectable thyroglobulin level
6 months after therapy based on radioactive iodine whole
body scan results (A preliminary report)
B. Fallahi, A. Fard-Esfahani, N. Ahmadpour, D. Beiki, A.
Emami-Ardekani, M. Eftekhari, S. Farzanefar, S. Izadyar; Re-
search Center for Nuclear Medicine, Tehran University of
Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.
Aim: Differentiated thyroid carcinoma is a highly treatable and
usually curable cancer with excellent survival rate; however,
as to the possibility of recurrence, the management of this
cancer is a lifelong process. Furthermore, the prognosis may
be variable from case to case and the disease-free survival may
be affected by many factors. The effectiveness of the first
radioactive iodine (RAI) therapy, as defined by off-T4 thyro-
globulin (TG) level and the results of RAI whole body scan
(WBS) following a 6-month post-treatment interval, may play
an important role in the enduring prognosis of these patients.
The aim of this study was to compare the patient’ prognosis in
four subgroups of cases showing detectable TG levels 6-
months following RAI therapy, defined by serum off-T4 TG
levels, i.e. 10>TG>2ng/dl vs. TG≥10ng/dl combined with
WBS results, i.e. negative vs. positive.Materials andMethods:
Totally 450 patients were enrolled in our retrospective study.
These patients had TG more than 2 ng/dl, 6 months after the
first RAI therapy. On the basis of the first 6-month follow-up
evaluations, the patients were divided in 4 subgroups, G1 were
consisted of cases with TG<10 and negative WBS, G2
consisted of patients with TG=10 and negative WBS and fi-
nally the patients with TG >=10 and positive WBS were in-
cluded in G4 subgroup. All patients were followed for at least
5 years (up to 15 years) and lab data, clinical examinations and
the results of WBS were reviewed. Results: Median follow-up
duration was 99 months. Number of repeated surgeries, the
rate of recurrences based on histopathological findings, the
frequency and cumulative doses of repeated RAI therapies as
well as the frequency of disease progression defined by the
new findings on WBS images were different between sub-
groups (p<0.001). The risk of recurrence or disease progres-
sion was estimated as 0% for G1, 29% for G2, 8% for G3 and
33% for G4 (p=0.10). Conclusion: We concluded that patients
with higher TG level (>=10) 6 months after the first RAI
therapy reveal higher rate of hospital admissions, higher fre-
quency of repeated neck surgeries, higher cumulative RAI
dosage and higher rate of disease progression. Positive whole
body RAI scan 6 months after the first RAI therapy also show
additive prognostic value for these patients.
P823
Epidemiological analysis of patients referred to nuclear
medicine consultation for therapeutic evaluation
M. J. Ibáñez Ibáñez, M. V. Godoy Bravo, L. F. Álvarez
Nieto, R. Reyes Marlés, M. I. Castellón Sánchez, F. Nicolás
Ruiz, L. Mohamed Salem, L. Frutos Esteban, J. L. Navarro
Fernández, M. A. Claver Valderas; Servicio de Medicina Nu-
clear. Hospital Clínico Universitario Virgen de la Arrixaca,
Murcia, SPAIN.
AIM: Perform a descriptive epidemiological analysis of pa-
tients referred to Nuclear Medicine department in 2014. MA-
TERIAL AND METHOD: We study 526 patients retrospec-
tively analyzing the following variables: age, sex, pathology,
pathology results, scintigraphic findings and metabolic treat-
ment given to each of them. With all this, we build a database
that would allow us to group patients by diseases and analyze
the different variables. RESULTS: Of the total of 526 patients
(77% women, aged between 15 and 94 years), 329 patients
(62.5%) were referred for differentiated thyroid carcinoma
(DTC), 194 patients (36.9%) for hyperthyroidism, 2 for eval-
uation pre-adrenocortical scintigraphy and 1 for previous as-
sessment to treatment with Samarium-153. Among the 329
patients seen by DTC (77% women; mean age 50 years;
61.4% with over 45 years of age), 44.1% are post-
thyroidectomy ablation of thyroid remnants (of which 80.7%
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were papillary carcinomas, 22.7% folicular carcinomas and
4.5% micropapillary carcinomas, and 28.3% had lymph node
involvement), 47.4% are diagnostics whole body scans, 6.7%
therapeutic doses and 1.8% empirical I-131 doses. Of the 194
patients with hyperthyroidism (78% women; mean age 58
years), 20.1% is due to Graves' disease and the patterns ob-
served in thyroid scintigraphy are: diffuse pattern in 17.5%,
plurimicronodular in 23.2%, plurinodular in 43.8% and toxic
adenoma in 15.5%. CONCLUSION: In the Region of Murcia,
with a high incidence and prevalence of thyroid disease in both
malignant and benign, we emphasize the importance in treat-
ment and monitoring of these patients by Nuclear Medicine,
and the high workload it generates in our service.
P824
Revaluation of risk of recurrence in patients
with differentiated thyroid cancer depending on their
initial response to treatment
L. F. Cáncer Garza, M. Delgado, A. Andrés, L. Tardin, S.
Ayala, P. Razola, M. López, V. Cardona, E. Prats; Hospital
Clínico Universitario Lozano Blesa, Zaragoza, SPAIN.
AIM: To analyze the usefulness of revaluation risk
criteria based on response to initial treatment (RIT), total
thyroidectomy and radioactive iodine remnant ablation,
in pat ients with Different iated Thyroid Cancer
(DTC).MATERIAL AND METHODS: We retrospective-
ly reviewed 108 patients diagnosed of DTC, 94 (87%)
papillary and 14 (13%) follicular, after total thyroidecto-
my and radioactive iodine remnant ablation. 78.7% were
women and 21.3% men, 17 - 77 years old (mean age
46.8 y.o.) with a median follow-up period of 7'5 years.
According to modified Tuttle criteria, we revaluated the
patients depending on their initial response to treatment
based on stimulated thyroglobulin, antithyroglobulin an-
tibodies levels and structural imaging into three groups:
Excellent, Acceptable and Incomplete Response. Each
patient was also stratified using European Thyroid As-
sociation (ETA) and American Thyroid Association
(ATA) criteria. Then, we have correlated the three risk
criteria systems with the status at final follow-up: no
e v i d e n c e o f d i s e a s e o r p e r s i s t e n t / r e c u r r e n t
disease.RESULTS: Following ATA criteria, 8 patients
(7.4%) were considered as high risk, 44 (40.7%) inter-
mediate and 56 (51.9%) low risk. According to ETA
criteria, 46 (42.6%) were of high risk and 62 (57.4%)
low risk. When we use the modified RIT system, 18
(16'7%) patients presented incomplete response, 12
(11'1%) acceptable and 78 (72.2%) excellent. At the
end of the follow-up 96 patients (88.9%) had no evi-
dence of disease and 12 (11.1%) had persistent or
recurrent disease. With the proposed RIT criteria, 100%
of patients with excellent response had no evidence of
disease at final follow-up, while this rate decreased to
75% with acceptable and 50% with an incomplete re-
sponse. With the modified RIT criteria the NPV was
100%. Comparing to ATA and ETA risk stratification
systems: 53.8% of patients with high/intermediate risk
(ATA) and 52'17% of high risk criteria (ETA) were con-
sidered as excellent response using modified RIT
criteria. All of them were free of disease at the end of
follow-up.CONCLUSIONS: The modified risk stratifica-
tion criteria based on the response to initial therapy in
patients with DTC predicts the long-term follow-up, es-
pecially in patients with an excellent response to initial
treatment.
P825
Follicular thyroid carcinoma in Morocco : predictive
factors of distant metastasis
S. TALEB, G. CHERKAOUI SALHI, S. CHOUKRY, M.
AIT IDIR, A. GUENSI; Nuclear medicine department, CA-
SABLANCA, MOROCCO.
The aim of this study was to determine predictive fac-
tors of distant metastasis in patients with FTC in a ter-
tiary medical center in Morocco.METHODS: This is a
retrospective study. It included all patients with a histo-
logical diagnosis of FTC treated in Nuclear Medicine
Department in IBN ROCHD University Hospital in Ca-
sablanca between January 2005 and December 2013.
Patient’s files were reviewed for clinico-pathological
characteristics, treatment and outcome compared with a
papillary carcinoma sample treated during the same
study period. Univariate analysis of patients’ features
was performed using IBM SPSS Software.RESULTS:
Among 3400 patients treated during the study period
for a thyroid malignancy, 82 patients (2.4%) were in-
cluded. Mean age was 51 years old (+/- 14), sex ratio
(M/F) was 0,17. Bone metastases at presentation were
noted in 10% of cases. More than half patients lived
in non coastal regions, known for their iodine deficien-
cy. On univariate analysis, age > 45 years (p = 0.003),
tumor multifocality (p = 0.01), capsular invasion (p =
0.07), vascular emboli (p=0.03) and serum thyroglobulin
concentration over 300 ng/ml (p<0,001) were indepen-
dent predictors of distant metastasis.Compared to a pap-
illary carcinoma, FTC histotype correlates with higher
risk of metastasis (p <0.001).All patients underwent a
total thyroidectomy followed by radioiodine therapy. Ex-
ternal beam radiation therapy and metastasis surgery was
indicated in 7% and 11% of cases respectively,
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depending on each subject. Mean follow-up period was
6 years. It showed a persistent disease in 27 % of cases,
a progressive disease in 5% of cases, a complete remis-
sion in 60% of cases whereas one patient died of the
disease (1.1%)CONCLUSION: Older age, multifocality,
capsular invasion, vascular emboli and high thyroglobu-
lin concentration seem to be independent risk factors for
predicting distant metastases in patients with FTC. Pro-
spective study with more patients is needed to confirm
these results.
P826
Influence of coexistence of Hashimoto’s disease
on the prognosis of patients with differentiated thyroid
cancer. A retrospective study
D. PAPADOULI, L. Iordanidou, E. Doika, C. Petropoulos, E.
Matselas, E. Trivizaki; METAXA CANCER HOSPITAL, PI-
RAEUS, GREECE.
Aim: The association between Hashimoto’s thyroiditis
(HT) and differentiated thyroid carcinoma (DTC) re-
mains controversial. The aim of this study is to investi-
gate the difference of the prognostic outcome between
patients with DTC with and without HT. Methods: We
studied the records of 87 patients (72 females and 15
males) who were treated for DTC (all with papillary
carcinoma) in the department of Nuclear Medicine at
Metaxa’s Hospital. The mean follow-up was 40 months
(range 12 to 50 months). The patients were classified
into 2 groups according to the existence or not of HT.
All patients were analyzed according to the stage of the
disease and the radioiodine treatments. Complete/partial
response or persistent disease, was assessed within 1
year from ablative dose. Results: This preliminary study
included 87 pts, 55 /87 had DTC without HT (control
group) and 31/87 (35.6%) had DTC with HT (DTC-HT
group). There were 63 pts with stage I disease, 41
(65%) from the control group and 22 (35%) from the
DTC- HT group, 4 pts with stage II, 3 pts from control
group and 1 from DTC- H, 16pts with stage III, 7 from
the control group and 3 from the DTC-HT group and 4
pts with stage IV, 3 from control group and 1 from the
DTC-HT group. From the total number of pts, 54 (62%)
had complete response with one ablative dose. In the
stage I, 19/41pts (46%) from the control group and
6/22 pts (27%) from DTC- HT group received additional
I131 therapies and in the stage II, 1/3 pts from the
control group. In the stage III, 3/10 pts from the control
group and 3/6 from the DTC-HT group had additional
treatments and in the stage IV 1/2 pts from the DTC-HT
group. Conclusion: According to our preliminary results
although there is no significant difference in the prog-
nostic outcome between the two groups, it seems that
the DTC-HT patients need less radioiodine treatments to
achieve remission, indicating a less aggressive behavior.
P827
Iodine 131 uptake in lactating breasts
P. Martineau, W. Zeng; The Ottawa Hospital, Ottawa, ON,
CANADA.
Iodine accumulation in the lactating breast has been rec-
ognized for 60 years. Radioiodine in lactating breast and
milk results in increased radiation to the mother’s
breasts and damage to the nursing baby’s thyroid gland.
Patients are routinely instructed on discontinuation of
breastfeeding prior to high dose radioiodine therapy;
however, failure to communicate this effectively to pa-
tients occasionally occurs, as illustrated in the case.A 39
year old female status post total thyroidectomy was
treated with 3700 MBq (100 mCi) I-131 sodium iodine
for T3N0M0 papillary thyroid carcinoma. The patient
had given birth to a daughter two years prior and was
diagnosed with thyroid cancer shortly after the birth. A
nuclear medicine consultation took place 14 months af-
ter the birth of her daughter. Instructions on radiation
safety precaution were provided to the patient. However,
the instruction to discontinue breastfeeding was not doc-
umented, and presumably not reinforced by the referring
physician. The patient unfortunately delayed the treat-
ment due to personal reasons. Consequently her
radioiodine ablation therapy was given approximately
10 months after the initial consultation. At the time of
therapy only radiation exposure precaution to her 2 year
old daughter and other family members was discussed
and the issue of breastfeeding had never been raised
with the treating physician.On the post therapy whole
body scan, significantly increased activity was noted in
the anterior chest. The findings of bilateral breast uptake
were confirmed on SPECT/CT images. On questioning
the patient it became clear that she only stopped
breastfeeding on the day of radioiodine therapy. The
patient was instructed to continue pumping her breast
milk frequently to reduce radiation exposure to her
breasts.It is critical to emphasize the importance of com-
munication to thyroid cancer patients. The problems
leading to breast uptake in this patient will be reviewed.
Steps to ensure that lactating patients be well informed
on breastfeeding issue and changes to improve our ser-
vice will be discussed. The current guidelines by SNM
and American Thyroid Association on discontinuing
breastfeeding prior to treatment will be reviewed. The
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absorbed dose to the breasts and the probability for in-
duction of fatal breast cancer will be estimated based on
the available literature.
P828
Feasibility of Blood Dosimetry Estimation
by Remote-Measurement System in DTC Patients
with High Dose Radioiodine Therapy.
Y. Chen, Y. Lai, Q. Chang, M. Chung, P. Hsiao, H. Chen, F.
Chiang; Kaohsiung Medical University Hospital; Kaohsiung
Medical University, Kaohsiung, TAIWAN.
Practically individual blood dosimetry assessment of DTC pa-
tients with high dose radioiodine therapy is an important issue
in clinic. Herein, we introduce remote- measurement method
to estimate blood dosimetry during hospitalization. Patients
and Methods: Among our hospital data, we collect forty-two
and seventeen DTC patients (female to male ratio as 3:1; age
over 45 y/o as 59.3%) with 100 mCi and 200 mCi radioiodine
therapy, respectively after bilateral total thyroidectomy or re-
currence. Patient after high dose radioiodine intake are allowed
to release based on 70 uSv/ hr/ M (by regulation) when ad-
ministration in radiation protection ward. Serial time-
dependant dose measurements are acquired as one-meter away
by remote- monitor system (GM counter). Blood dosimetry
calculation is based on formulation as rad/ mCi by ERC
2009. The weighting clearance time of radioiodine is com-
pared between patients with rh TSH preparation or thyroxin-
withdraw method. Results: The estimated rad/mCi is 0.92 in
the patient with 100 mCi and 200 mCi radioiodine intake,
respectively. The calculated blood dosimetry is 0.92 Sv and
1.97 Sv in patient with 100mCi and 200m Ci radioiodine in-
take, respectively. In 100mCi radioiodine intake group, the
weighting clearance time of radioiodine is faster (14.4 3.4 hr)
in patient with rh TSH preparation. However, there is no sig-
nificant difference of weighting clearance time (around sixteen
to eighteen hr) by meaning of rh TSH preparation or thyroxin-
withdraw method in patient with 200 mCi radioiodine intake.
Conclusion: The average of rad/ mCi among 59 patients with
100mCi and 200 mCi radioiodine intakes is around 0.96. The
practically individual blood dosimetry assessment is feasible
and convenient by means of remote measurement system.
P829
Advantages of thyroidal therapy uptake calculation
with 2D-diagnostic imaging
R. Ringler, M. Stich, K. Schuller; Technische Hochschule
Amberg-Weiden, Weiden, GERMANY.
Introduction:For the determination of thyriodal uptake is
usually either a thyroid uptake counter (TUC) or a gamma
camera (GC) to choose from. The recommendations of the
guidelines of the German Society of Nuclear Medicine
(DGN) are to use a TUC-device. The aim of the study was to
compare the two methods with the use of phantoms either with
Tc-99m or I-131.Methods:The study was performed using a
TCU-ISOMED 2162 and two gamma cameras - e.cam and
Multicam 1000. The I-131 (3-5MBq) uptake was simulated
with a cylindrical neck phantom which was used at the two
GC and TCU. The evaluation of the count rates was carried out
under different intervals and distances. The evaluation of the
count rates was carried out under different distances of phan-
tom to the detector surface to determine the optimal patient-
gamma camera distance. The influence of the deviations from
the center line in the thyroid uptake counter was also
tested.Results:The results support the recommendation of the
minimum distance of 25cm to the guideline of DGN. Taking
into account the optimized distance, the ROI analysis in the
2D-diagnostics improves the uptake calculation and the
resulting dose for therapy. The ROI in the 2D image reduces
the scattered radiation from neck and salivary glands by a
mean of 28% (24.9% to 33.54%). The uptake calculation de-
pends on the depth of the I-131 test activity inserted in the neck
phantom - differences of about 17% (compared with / without
ROI) were determinde.Conclusion:The results show that a
ROI technique in 2D imaging with a gamma camera for de-
termining the thyroidal uptake is superior to TUC devices. The
correct depth of the hot node in the thyroid is important for a
optimized I-131 uptake calculation. By using a TUC device
the correct placement along the center line of the system is
important.
P830
Thyroidal diagnostics need optimized collimation
and segmentation within 2D-imaging
R. Ringler, J. Vogt, S. Seemann, M. Stich; Technische
Hochschule Amberg-Weiden, Weiden, GERMANY.
Introduction:Two setups of gamma cameras for thyroidal im-
aging are used. The user can either choose from a thyroid
collimator or a high resolution collimator. The aim of our study
was to characterize the resolution and detectability of cold and
hot nodes in a thyroidal phantom with a high resolution of a
gamma camera. A correct segmentation of the thyroid lobule is
essential for the uptake value in the diagnostic. To evaluate the
influence on the uptake different algorithms for segmentation
were tested by Tc-99m and I-131.MethodsThe study was per-
formed using a gamma camera - Mult icam 1000
(Intermedical) with a Low Energy High Resolution collimator
(LEHR) and a thyroidal collimator (TC) for Tc99m (5 - 15
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MBq). The Multicam 1000 was used with a High Energy
collimator (HEC) for the I-131 (3 - 37 MBq). The optimized
collimation with Tc-99m was evaluated with a standard 2D
thyroid phantom. The measurements to determine the resolu-
tion and detectability of cold and hot nodes in a thyroidal
phantom a variable background activity was used (0-5 MBq.
To validate the Uptake in the thyroid different algorithm were
tested (Canny, LOG, Prewitt, Sobel, Roberts and an intensity
filter).ResultsThe comparisons of the thyroid collimator to the
LEHR collimator show significant differences in favor of the
resolution to TC collimator but a much better sensitivity in
LEHR collimator. The results support also the recommenda-
tion of the guideline of DGN. The automated segmentation of
the thyroid lobes with Canny and LOG detect the outlines of
the thyroid in a closed outer contour. Using the modified 1/e-
intensity filter the two lobes are automatically segmented. The
ROI’s for I-131 in a thyroid phantom can outline the contours
of the thyroid with the above mentioned segmentation
algorithm.ConclusionThe results of the studies show that a
automated ROI-segmentation-technique in 2D imaging with
a gamma camera for determining the thyroidal uptake is pos-
sible. The choice of the collimator shows that with a LEHR
collimator even at low signal-to-background a good contrasts
and results can be achieved. The uptake by using a thyroid
phantom with I-131 can be calculated whereas the resolution
of the nodes is to be considered using a HEC-collimator.
P831
Exposition Rates of Thyroid Cancer Patients Treated
with Radioiodine. Differences Between Endogenous
and Exogenous Stimulation
J. Rodríguez-Rubio Corona1, E. Noriega Álvarez1, O.
Puig1, G. Martinez Pimienta1, J. Rojas Camacho1, M.
Boya-Román1, P. Saldaña Gutiérrez2, I. Romero-Zayas3, A.
Rodríguez-Gasén1; 1Hospital Universitari de Bellvitge, Bar-
celona, SPAIN, 2Medical Physiscs and Radiation Protection
Department, Instituto Catalán de Oncología, L'Hospitalet de
Llobregat, SPAIN, 3IDI-PET Unit, Hospital Universitari de
Bellvitge-IDIBELL, Barcelona, SPAIN.
AIM: To compare exposure rates (ER) after administration of
3700 MBq of 131I in thyroid cancer patients stimulated with
recombinant human thyrotropin (rhTSH) or levothyroxine
withdrawal during 4 weeks (T4W). MATERIAL AND
METHODS: 80 thyroid cancer patients who underwent total
thyroidectomy and who received a remnant ablation dose of
3700 MBq of 131I were studied and divided in two groups
according to their TSH stimulation method (rhTSH group: 40p
and T4W group: 40p), with similar age and gender features
(average age: rhTSH group: 53.5 years old and T4W: 50 years
old; and gender: rhTSH: 27 women and T4W: 30 women).
None of the patients had renal failure. They were measured
immediately after the dose administration (ERi), and after 2h,
4h, 24h and 48h, with an ionization camera (Nardeux,
Babyline 81) focusing 1m away on the cervicothoracic region
of the patient. We analyzed the data with the t-Student test.
RESULTS: The mean values obtained at each time of mea-
surement (ERi, 2h, 4h, 24h, 48h), expressed in mRad/h (with a
confidence interval at 95% for each average value) were those
shown below: A. rhTSH group: ERi=28,6(25,9-31,2),
ER2h=20,5(19,3-21,8), ER4h=16,8(15,6-17,9), ER24h=5,
1(4,2-6,1), ER48h=1,7(1,2-2,1) B. T4W group: ERi=23,
5(22,1-24,9), ER2h=19,9(19-20,8), ER4h=17,2(15,8-18,5),
ER24h=6,4(5,6-7,1), ER48h=2,2(1,9-2,6) The means values
showed the following p for comparisons between each group
at each measurement time: o ERi: significant (95%, p=0.001)
o ER 2h: not significant (95%, p=0.43) o ER 4h: not signifi-
cant (95%, p=0.64) o ER 24h: inconclusive (95%, p=0.04) o
ER 48h: inconclusive (95%, p=0.05) CONCLUSIONS: These
data show that the ERi is greater with rhTSH stimulation than
with T4W, being this statistically different (p=0.001). The de-
crease of the ER along time seems to be faster with rhTSH than
with T4W, but the differences between both groups are not
statistically significant, probably due to the wide variability
of the values of the measurements
P53 - Tuesday, October 13, 2015, 4:00 PM - 4:30 PM, Hall 3 –
Poster Exhibition
Radionuclide Therapy & Dosimetry: Bone Metastases -
Pain Palliation
P832
Hematotoxicityand non-hematological adverse events
of Ra-223 dichloride (Ra-223) in patients
with castration-resistant prostate cancer (CRPC) and bone
metastases
H. Ahmadzadehfar1, K. Azgomi1, S. Rogenhofer2, R.
Bundschuh1, S. Kürpig1, L. Thomas1, M. Essler1; 1Univer-
sity Hospital Bonn, Department of Nuclear Medicine, Bonn,
GERMANY, 2University Hospital Bonn, Department of Urol-
ogy, Bonn, GERMANY.
Objectives:Ra-223 is a first-in-class alpha-emitting pharma-
ceutical recently Food and Drug Administration approved for
treatment of CRPC patients with bone metastases.The aim of
this study was to investigate the incidence and severity of
hematotoxicity and other non-hematological adverse events
(AE) of this therapy. Methods: Eligible patients had progres-
sive hormone and/or chemo refractory PC with bone
metastasesand no known visceral involvement. Bone scintig-
raphy was performed in all patients 1-2 weeks prior to Ra-223
Therapy. All patients received CBC and renal tests as well as
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measurements of PSA and alkaline phosphatase (ALP) on the
therapy days and at least 4 weeks after the last therapy. Results:
a total of 140 treatments (range: 1-6 (median: 4)) were per-
formed for 35 patients (mean age: 74 (range: 56-86)) with a
mean PSA-Value of 545 ng/ml (0.5-4710) and a mean ALP of
203 U/l (43-517). 17 patients had a history of chemotherapy.
No hematological toxicity more than grade 2 was observed
until 8 weeks after the last cycle. There was not any significant
correlation between the cumulative activity and the level of
hematotoxicity in this time period. 67 treatments were not
associated with any subjective side effects. The most impor-
tant non-hematological AE were mild diarrhea for 2-3 days in
about 7-10 days after 13 therapies and severer generalized pain
in 2 patients began3 h after application, which lasted 1day.No
renal toxicity was observed. Conclusions: Ra-223 is a well-
tolerated tx for CRPC with bone metastases.
P833
Therapeutic response of Sm-153 EDTMP treatment
in breast cancer with painful bone metastases
M. Elzahry1, H. Sinzinger2, B. Palumbo3; 1Faculty of
Medicine-Department of Clinical Oncology and NuclearMed-
icine, South Valley University, EGYPT, 2Faculty of Medicine,
ISOTOPIX- Institute for Nuclear Medicine, Vienna, AUS-
TRIA, 33Department of Surgical, Radiological and
Odontostomatological Sciences, Nuclear Medicine Section,
University of Perugia, ITALY.
Bone metastases from breast cancer are associated with signif-
icant morbidity including immobility and the development of
pathological fractures, spinal cord compression and the need
for surgery and radiotherapy to bone. An improved under-
standing of the pathophysiology of bone metastases from
breast cancer has encourged the development and clinical
use of bone-targeted agents in this area. Systemic therapy with
radionuclides as Sm-153 EDTMP is used in patients with pain-
ful skeletal metastases owing to its efficacy, low cost and low
toxicity. Aim of this study was to assess if there is a difference
in uptake and therapeutic response of Sm-153 EDTMP in 164
female patients suffering from recurrent breast cancer who
received single dose of therapy for painful metastatic bone
lesions (osteoblastic(BL), osteolytic(LY) or mixed(MI). Pa-
tients &methods, 164 female patients suffering from breast
cancer were included in this study. Their age ranged from
35-77 years. Their tumor histology was the following: 116
(70.03%) ductal, 37(22.56%) lobular, 10 (6.09%) mixed and
1(0.61%) medullar. All the patients had metastatic bone pain
and lesions number varied from 1 up to ≤ 5 judged intially by
sequential x-ray and/or MRI to be verified later by bone scin-
tigraphy. Results, among the different types of bone recur-
rences, there was no significant difference in uptake (mean:
55.2%, 53.6% and 54.9%) respectively. While there was a
decline in pain response rate with time (91.8% vs 77.9% and
96.3% vs 81.5%, with more pronounced decline at mixed type
87.5% vs 66.7%), respectively at 7 and 12 weeks. Number and
extent of bone lesions had no influence on the findings. Fe-
males on long-term statin therapy (n=61) showed a significant-
ly more pronounced decrease in adhesion molecules (p<0.05)
being comparable for all histological types of breast cancer. In
conclusion, there was no significant difference of bone uptake
and pain response rate between the different types of bone
recurrences either BL, LY or MI in breast cancer patients on
single dose of 153Sm-EDTMP. Therefore, Sm-153 EDTMP
can be used as the most effective palliative treatment in painful
metastatic skeletal lesions irrespective of the type of bone re-
currences on scintigraphy. Wherever, the effect of statins on
adhesion molecules is a direct drug effect or reflect an antitu-
moral action as well as, the influence on the extent of recur-
rences should be examined in prospective studies.
P834
Radium-223 therapy in metastatic castration resistant
prostate cancer: South Central England single centre early
experience
h. chorfi, F. sundram; Southampton general hospital, south-
ampton, UNITED KINGDOM.
Aim:Majority of metastatic castration resistant prostate cancer
(mCRPC) patients experience painful bone metastases,
resulting in death, disability and decreased quality of life.
Radium-223 is a novel bone-targeted α-emitter associated
with a survival benefit. We present our early experience and
outcomes in mCRPC patients undergoing Ra-223
treatment.Material and methods: Retrospective study over 1
year (March 2014 - February 2015) of mCRPC patients re-
ferred for Ra-223 treatment. Information obtained included
age, prior treatments, bone symptoms, analgesic requirements,
imaging and blood results. Ra-223 (50 kBq/kg) was adminis-
tered every 4 weeks, up to the recommended 6 therapy cycles.
Endpoints assessed included pain patterns, side effects, skele-
tal related events (SREs), disease biomarkers (PSA & ALP
levels) and haematological parameters. Results: 32 patients
were referred. Median age was 74 yr (range 54-91 yr). Median
follow-up was 5.3 months (range 1-11 months). All patients
received on average, three previous lines of treatment. All
bone scans showed foci of abnormal uptake. CT scans re-
vealedmalignant lymphadenopathy in 7 patients, with absence
of visceral involvement. 22 commenced Ra-223 therapy. 10
were unable to commence treatment for the following rea-
sons:• 5 were affected by radiopharmaceutical unavailability•
4 deceased before treatment commencement• 1 unsuitable due
to liver metastases22 patients had Ra-223 therapy:• 18 (82%)
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were symptomatic, 17 (94%) required analgesics (9 opioids, 8
non-opioids)• 4 (18%) had no bony pain• 7 completed the
recommended 6 cycles, of whom: 3 had bony pain reduction
1 had worsening 3 had absence of bony pain, remaining sta-
ble, not requiring analgesia• 10 are currently undergoing treat-
ment• 5 discontinued treatment : 3 developed extra skeletal
disease 1 deteriorated clinically 1 experienced significant side
effectsOf 7 patients who completed 6 therapy cycles, side ef-
fects were mostly mild gastrointestinal symptoms. No patients
developed SREs during follow-up. A marked decrease in me-
dian blood count parameters was noted after cycle 1, remain-
ing broadly stable after cycle 3. There was a significant post
treatment reduction in ALP levels, however, mean PSA levels
increased from baseline. Conclusion: Ra-223 improves bony
symptoms , wi th mi ld s ide e ffec t s encounte red .
Myelosuppression is significant after the first cycle. Ra-223
has a major impact on serumALP levels, with negligible effect
on PSA levels. Therefore ALP appears to be a useful biomark-
er of therapy response.
P835
Radiopharmaceutical therapy for palliation of bone pain
from osseous Metastases: what about beta Therapy
in prostate cancer?
T. Ben Ghachem1, A. Mhiri1, I. Slim1, I. Yeddes1, I. Elbez1,
I. Meddeb1, A. Sellem2, H. Hammami2, M. F. Ben Slimène1;
1Nuclear Medicine department; Salah Azaiez Institute, Tunis,
TUNISIA, 2Nuclear Medicine department; Military Hospital,
Tunis, TUNISIA.
Introduction: Bone pain from metastatic prostate cancer is the
most common symptom and the most difficult to support. Its
treatment aims to improve the quality of life of patients. It has
been treated historically by palliative external beam radiation
therapy and pharmacological analgesics. Bone-seeking
targeting radiopharmaceuticals have entered the therapeutic
armamentarium for the treatment of multiple painful osseous
lesions: Beta-emitting agents, such as Strontium-89 and
Samarium-153 and recently Alpha-emitting radiopharmaceu-
tical Radium-223. Our study will focus on metabolic
r a d i o t h e r a p y w i t h S a m a r i u m 1 5 3 -
ethylenediaminetetramethylenephosphonic acid (153Sm-
EDTMP; Quadramet) which is a beta-particles emitter that
concentrates in the areas of enhanced osteoblastic activity.
Purpose: Our aim was to evaluate the value of this therapy in
prostate cancer. Methods: A retrospective, descriptive longitu-
dinal and multicentric study was carried about 15 years on 74
patients with prostate adenocarcinoma with bone metastases,
in the nuclear medicine department of Salah Azaiez Institute
(ISA) and Military Hospital. All these patients were treated
with at least one cure 153Samarium-EDTMP (37 MBq/kg).
All patients had painful bone metastases to more than one
anatomical region. For assessment of therapy effectiveness,
three parameters were evaluated before and after treatment:
motor activity, pain relief and reduction in analgesic require-
ments with a receding of 35 months. Toxicity of
153Samarium-EDTMP was also estimated. Results: Treat-
ment response was positive in 86.1% of cases: complete in
33.78% and partial in 52.32%. The administration of succes-
sive cures of 153Samarium-EDTMP, with 3 months interval
between treatments showed that the cures could be repeated
with similar response as in the first cure. Neither status of the
patients before treatment nor treatment previously received
had influence on this metabolic radiotherapy response. The
therapeutic effectiveness was at least equivalent to those of
other therapeutic modalities, with almost no side effects. The
only observed toxicity was hematologic; usually mild and re-
versible. Besides, the effect on the pain came with an improve-
ment of the quality of life of the patients treaties. Conclusion:
Due to its half-life of 46 hours and its beta emissions, a high
dose rate of 153Samarium-EDTMP can be delivered to re-
gions adjacent to enhanced osteoblastic activity over a short
period of time with little residual long term activity being left
in the bone marrow. It should no longer be a solution of last
resort thanks to its efficiency and low toxicity. Its early intro-
duction in the management of patients with prostate cancer
and painful bone metastases could greatly improve their qual-
ity of life.
P836
Bone metastases in patients with differentiated thyroid
carcinoma: clinical features and outcome (medullary
carcinoma excluded)
G. CHERKAOUI SALHI1, S. TALEB1, S. CHOUKRY1,
M. AITIDIR2, A. GUENSI1; 1IBN ROCHD UNIVERSITY
HOSPITAL, CASABLANCA, MOROCCO, 2MOHAMED
IV UNIVERSITY HOSPITAL , MARRAKECH,
MOROCCO.
Bone metastases are the second most common metastasis site
in differentiated thyroid carcinoma (DTC). Its occurrence
makes the treatment difficult and worsens the prognosis. The
aim of this study was to report the clinical features and out-
come of patients with bone metastases of DTC treated in a
Nuclear Medicine department in Morocco. Patients and
Methods: Retrospective study selecting all patients with bone
metastases of DTC treated in Nuclear Medicine Department in
Ibn Rochd University Hospital in Casablanca between January
2005 and December 2013. Patient’s files were reviewed for
background data, clinico-pathological characteristics, treat-
ment and outcome. Results: Among 3077 patients treated for
DTC during the study period, 32 were included in the study
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(1%). Patient’s average age was 59 years old [29-75], sex ratio
(M/F) was 0.14. Bonemetastasis was recorded as the revealing
sign of the disease in 34 % of cases. All patients underwent a
total thyroidectomy, it was completed by cervical lymph node
dissection in 12% of cases. Half of cases had a follicular car-
cinoma. Mean primary tumour size was 4cm [1 - 11cm]. Pa-
tients were staged pT3 and pT4 respectively in 48% and 10%
of cases. Lymph node extension was noted in 9% of cases and
lung metastasis in 34% of cases. Bone metastases were often
multiple and located at the axial skeleton. All tumours showed
radioiodine avidity. Repeated radioiodine therapy was com-
pleted by external beam therapy in 28% of cases and metasta-
ses surgery in 31% of cases. Median follow-up period was 6
years. It showed a complete remission in 15% of cases, per-
sistent disease in 55% of cases and a progressive disease in 9%
of cases with a local recurrence. To date, the survival rate is
84%. Bone metastases are synonym of pejorative prognosis in
DTC. However, a multidisciplinary care adapted to each case
remains the best way to insure an optimal treatment and hence,
a better outcome.
P837
Roll of different XCAT phantom BMIs in dosimetery
for 153Sm-EDTMP bone pain palliation
M. Fallahpoor, S. Farzanefar, S. Heydarinejad, M. Abbasi;
Department of Nuclear Medicine , Vali-e-asr Hospital, Tehran
University of Medical Sciences, Tehran, IRAN, ISLAMIC
REPUBLIC OF.
For internal dosimetry either patient’s CT scan or the attenua-
tion maps of available phantoms are used. The most accurate
way is to use patient CTscanwhich needs organ segmentation.
XCAT is one of the most flexible data bases which may elim-
inate the need for time consuming and operator dependent
organ segmentation procedures. Nevertheless the phantom is
different in the body shape and composition including the BMI
from the patient’s reality. Recently different BMIs for the
XCAT phantom were generated which may solve this obsta-
cle. In this study we examine the effect of different BMIs on
the dosimetry for a bone pain palliation agent, 153Sm
EDTMP.The simulation was done by the GATE Monte Carlo
code. S-factor (mGy/MBq-s) and SAFs (kg-1) were calculated
for the dosimetry of the radiation from the spine as source
organ into the whole body. Female XCAT phantoms with the
following different BMIs were employed: 18.6, 20.8,22.1,
26.8, 30.3 and 34.7. The difference of the whole body dosim-
etry from the phantom with BMI 26.8 were calculated for both
gamma and beta radiations.The differences of the SAFs of the
dosimetry in phantoms with lowest to highest BMI from the
referral phantom (i.e. BMI=26.8) were 16.4%, 8.2%, 4.1%, -
9.5% and -1.4%. All these difference fit well within the 10%
acceptable dosimetry calculation error. The differences of the
S-factor for the phantoms from the BMIs equal to 18.6, 20.8,
22.1, 30.3 and 34.7 from the phantom with BMI of 26.8 were
40.2%, 20.1%, 9.0%, -7.9% and -4.9%.The dosimetry of the
gamma photons do not change with the use of phantoms with
unfitted BMI but the dosimetry of the beta particle which
results in the therapeutic effect of 153Sm-EDTMP and is im-
portant for dose calculation changes remarkably with
employing the phantom with wrong BMI.
P838
Role of EDTMP-Samarium in the management of Bone
metastasis:
S. E. Bouyoucef, B. Abdi, R. Drahmoune, A. Talbi, S. Rahabi,
M. Habbeche; Department of Nuclear Medicine CHU Bab El
Oued, Algiers, ALGERIA.
Introduction: Radionuclide therapy is an important tool in the
management of painful bone metastasis. The strategy of its use
depdends on a certain parameters including local medical pro-
tocols of chemotherapy. Objective: To determine the best re-
sponse to radionuclide therapy according the stage and the
extension to the bone of cancer disease Patients and Methods
70 patients with prostate and breast cancer and bone metasta-
ses have been referred to the department of nuclear medicine
for radionuclide therapy of painful bone metastasis from 2009
to 2012. All patients have had multiple lesions on bone scan
and normal blood and kidney tests. Incontinent patients, pa-
tients with medullar compression and fractures have been ex-
cluded from the study. Average activity of 153Sm-EDTMP
used was 37MBq/kg for all patients and injection was done
slowly during 3 minutes with glucose line. Assessment of
response was done each 6 weeks according clinical symptoms,
dose of morphine and Eva and Karnofsky score. Results: Clin-
ical Improvement was observed in 85% of patients including
decrease of the dose of morphine or drugs. The drugs and
morphine were totally stopped in 13% after 3months of radio-
nuclide therapy. The response to treatment was much better
when the number of lesions is limited and widespread. The
rate of response was little bit higher in patients with prostate
cancer. Only one case had had bone marrow suppression after
6 months. 15% of patients relapsed and needed a second or a
third cycle of radionuclide therapy. Most patients (89%) sur-
vived at 3 months and 13% at 2 years. Conclusion: Radionu-
clide therapy of painful bone metastasis of Prostate and breast
is efficient in most cases. However, selection of patients is
absolutely required to avoid bone marrow complications and
better efficiency of treatment. Despite the new Alpha thera-
peutic agent (Radium 223), 153Sm-EDTMP will remain an
excellent alternative for controlling pain in metastatic cancer
patients.
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S741
P839
223Ra Therapy: A Successful Patient Outcome
K. Gannon, R. Cornhill, R. Gunasekera, K. Tarver; Barking,
Havering and Redbridge University Hospitals Trust, Romford,
UNITED KINGDOM.
Introduction: 223Ra dichloride (Xofigo®) has been avail-
able in the UK for the treatment of advanced castration-
resistant prostate cancer since Jan 2014. Its success fol-
lows the positive outcome of the ALSYMPCA phase III
clinical study[1] which generated results for 921 patients
(614 study drug patients, 307 placebo patients), with an
overall survival improvement of 3.6 months in the study
drug group. Queen’s Hospital has provided a therapy ser-
vice for patients since Sept 2014 and recently completed
a full treatment cycle for the first patients recruited. Ma-
terials and Methods: Patients DS (77yr male) was identi-
fied as a candidate for treatment in September 2014 after
meeting a strict set of recruitment criteria. The patient
began 6 cycles of injection spaced approximately 28 days
apart, with a treatment interruption after the first admin-
istration due to drug availability. Patient weight was ob-
tained prior to each administration and the activity of
each injection was determined using a 50kBq /kg calcu-
lation. Prior to commencing treatment the patient
underwent a 99mTc Whole Body Bone scan to determine
the extent of skeletal metasteses. Upon completion of the
treatment the patient underwent a follow up bone scan to
determine disease progression. Throughout the course of
treatment the patient underwent regular blood testing to
check Hb, PLT, ALP and PSA levels. Results: Initially
the patient’s PSA (409.1 μg/L) and ALP (554 iu/L)
values were very high and the patient complained of
poorly controlled bone pain in the left hip. A 99mTc
whole body bone scan was obtained 3 months prior to
treatment following a course of chemotherapy. This re-
vealed multiple skeletal lesions and prominent activity in
the spine and pelvis, potentially due to disease progres-
sion. By the end of the 6 cycles of treatment, the pa-
tient’s PSA (363.5 μg/L) and ALP (233 iu/L) had im-
proved and the subsequent bone scan revealed improve-
ment in previously suppressed activity in the ribs, pelvis
and long bones. Previously noted focal abnormal activity
in the skull was no longer visible. Stable Hb and PLT
levels throughout treatment also suggest it was well tol-
erated. Conclusions: In patients with castration resistant
prostate cancer and multiple bone metasteses, the use of
223Ra therapy can provide marked improvement in PSA
and ALP, whilst reducing the number and intensity of
existing bone lesions. References: 1. Parker C et al “Al-
pha Emitter Radium-223 and Survival in Metastatic Pros-
tate Cancer” N Engl J Med. 2013; 369: 213-223
P840
Early experience with 223Ra-dichloride treatment
of prostate cancer patients with multiple bone metastases
O. Sántha, J. Szegedi, I. Garai; Scanomed Ltd., Debrecen,
HUNGARY.
Aim: Presenting our experience in the alpha-radiating 223Ra-
dichloride treatment of prostate cancer patients with multiple
bone metastases by the overview of the medical history of the
patient and relevant literature.Method:Castration resistent
prostate cancer patients with symptomatic multiple bone me-
tastases without the involvement of any other organ can be
treated with 223Ra-dichloride. So far 15 patients have been
under treatment at our institute. The treatment consists of 6
intravenous injections, 4 weeks between each. Every time 50
kBq/kg of activity is administered. A known side effect of the
radiopharmaceutical is bone marrow suppression, so a week
before each treatment the hematological status of the patient is
checked to insure patient safety. On the day of the treatment a
pain scale is used to determine the level of pain the patient
suffers from. The radiopharmaceutical is administered by
using an intravenous cannula. Approximately 30 minutes after
the injection the patients can go home. The medical history
and the examination results of these patients were
reviewed.Results:At our institute, 2 of the 15 patients complet-
ed the whole 6 cycle treatment. By the end of the treatment
their bone pain decreased significantly according to the pain
scale data. The treatment had to be aborted in 5 cases: 2 pa-
tients had increased risk of pathological fracture, 3 patients had
severe hematological blood test anomalies. At present 8 pa-
tients are under treatment, 4 of them have received 4 injections
so far, their bone pain has been reduced according to the pain
scale.Discussion:According to our results the 223Ra-
dichloride treatment reduces patients’ bone pain. We are plan-
ning to compare the AP, PSA and bone scintigraphy results
before and after treatment.
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Biological Therapy and Radiosynoviorthesis in Patients
with Rheumatoid Arthritis
M. Szentesi, Z. Nagy, P. Géher, I. Nagy; Budai Irgalmasrendi
Kórház, BUDAPEST, HUNGARY.
The treatment of patients with rheumatoid arthritis (RA) has
been spectaculary changed since the 1950’s. Introduction of
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the steroid compounds and their local application, the chemi-
cal and radionuclide synovectomy, surgical synovectomy, use
of non steroid drugs, the basic treatment and the spread of
biological therapy are the most important steps. Introduction
of the biological therapy has changed the quality of life for
these patients. Objectives: During biological therapy some-
times 1 or 2 joints could be affected by inflammation. In this
cases always the question is how to solve the problem. Change
of the biological or basic therapy, use surgical synovectomy or
radiosynovectomy (RSO)? Patients and Methods: In our
reumatological department 1500 patients with RAwere treated
with biological therapy between 2002 and 2014. In 100 pa-
tients we applied RSO because of the inflammation of the knee
joint during biological therapy. We made a long term follow-
up in 62 patient. All participants provided written in-
formed consent. In all participants inflammatory knee
joint disease was diagnosed on the basis of the Ameri-
can College of Rheumatology. 55 of 62 patients with
rheumatoid arthritis were seropositive, 7 seronegative.
Mean age of 8 male and 56 female patients was 51.4
years (range 24-79) years. In 32 patients the right knee,
in 30 the left knee was treated by radiosynovectomy.
Steinbrocker functional stadium II was observed in 52,
stadium III in 10. Mean duration of disease was 7.3
years (range 0.5-25), of synovitis (6.3month (range 3-
8) Mean number of punctions of the treated joint prior
to radiosynovectomy was 4,2 per patient and of steroid
administrations prior to radiosynovectomy 3,0. In 12 pa-
tients a systemic steroid therapy has been performed.
Results: During the study period, inflammation de-
creased. In the first two years excellent and good results
w e r e r e c o r d e d i n 8 2 , 2% . Two y e a r s a f t e r
radiosynoviorthesis 83.3% of patients did not need an-
other punction. Before the knee inflammation patients
were in complete remission which status has been
achieved after RSO as well. DAS: 2,4+-0,4. Conclu-
sions: 1. RSO is an effective method to treat the inflam-
mation of the knes. 2. The RSO performed during bio-
logical tehrapy is as effective as in the case of patients
without biological therapy.
P842
Trans Arterial Radio Embolization (TARE) In
The Management Of Intractable Hypoglycemia In
Malignant Insulinoma
M. Menga1, M. Zotta2, A. Codegone1, E. Richetta1, A.
Piovesan3, E. Arvat3, R. E. Pellerito1; 1Nuclear Medicine -
A.O. Ordine Mauriziano, Turin, ITALY, 2Nuclear Medicine -
A.O.U. Città della Salute e della Scienza, Turin, ITALY, 3On-
cological Endocrinology - A.O.U. Città della Salute e della
Scienza, Turin, ITALY.
Insulinoma is a rare islet cell tumor with an incidence of
4 cases per million per year, presenting usually with re-
current episodes of symptomatic hypoglycemia. Recently
has been reported efficacy of selective hepatic artery
radioembolization with radioisotope Yttrium-90 (Y-90)
in patients with malignant neuroendocrine tumors. Mate-
rials and methods: Male patient 37 years-old presented in
2 0 1 1 w i t h e p i s o d e s o f h y p o g l y c e m i a a n d
hyperinsulinemia. Imaging demonstrated a lesion of the
pancreatic body, multiple hepatic metastasis and a small
nodule in the right lung. Patient began therapy with
Diazoxide (up to 600 mg/die) and Octreotide (0,6 mg/
die). Fine needle agobiopsy of the dominant hepatic le-
sion was performed highlighting neuroendocrine origin
(Ki67 30%). January 2012 spleno-distal pancreasectomy
and enucleoresection of hepatic lesions followed by
Thermoablation on several hepatic lesions (S6, S7 e S8).
March 2012 PET-CT with 68Ga DOTATATE uptake only
on a hepatic lesion, no indication to the Peptide Radio
Receptor Therapy. May 2012 hepatic progression of dis-
ease (PD), persistence of hypoglycemia and aggravation
of the general conditions; initiated therapy with Everoli-
mus 10 mg/die. July 2013 recurrence of disease, multiple
Trans Arterial Chemo Embolization (TACE) with DC-
Beads, treating both right and left liver. February 2014
evidence of PD (increase of the well known hepatic le-
sions, new hepatic lesion in S5 and left adrenal node
suggestive for secondary localization). September 2014
further PD (increase of the adrenal node and hepatic le-
sion in S4; enlargement of abdominal lymph nodes). In
consideration of failure of conventional standard
m u l t i a g e n t m e d i c a l t r e a t m e n t a n d h e p a t i c
chemoembolization, it has been proposed TARE with
90-Y resin-based microspheres as palliative treatment.
R e s u l t s a n d con c l u s i o n s : P a t i e n t u nd e rwen t
radioembolization after scintigraphic assessment of the
presence of pulmonary and gastrointestinal shunts and
dosimetric evaluation of the optimal therapeutic activity.
On 5 November 2014 patient underwent preliminary scin-
tigraphy with 99mTc-MAA and TARE at the confluence
of right and left hepatic artery (1.4 GBq) experiencing
only mild pain. Post-procedural imaging (bremsstrahlung
and PET-CT) confirmed the correct localization of the
microspheres in the hepatic tumoral lesions. Clinical im-
provement was seen in the subsequent days after the pro-
cedure indeed dextrose infusion was rapidly discontinued
and patient was discharged from hospital. Despite few
studies on the use of TARE in hepatic metastases of neu-
roendocrine tumors and experience with malignant
insulinoma is even more limited because of the very
low incidence, nevertheless, as demonstrated by our case,
management of malignant hypoglycemia seems safe and
feasible by means of 90-Y microspheres TARE.
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P843
Radioembolization with Y-90 resin microspheres
for intrahepatic cholangiocellular carcinoma: Prognostic
factors
C. Soydal, N. O. Kucuk, S. Bilgic, E. Ibis; Tip Fakultesi,
Ankara, TURKEY.
Aim: We have investigated prognostic factors to predict over-
all survival after radioembolization in patients with
cholangiocellular carcinoma. Material and Method: 16 pa-
tients who received radioembolization with Y-90 resin micro-
spheres for cholangiocarcinoma were included to the study.
Statistical relationship between overall survival after
radioembolization and age, serum AST, ALT, total bilirubin
levels, presence of extrahepatic metastases, number, dimen-
sion and FDG avidity of liver lesions have been analyzed.
Results: Mean 1.7± 0.1 GBq Y-90 microspheres were admin-
istered total 16 patients (mean age: 55.37±17.7; 8 Male, 8
Female). Mean AST, ALT, total bilirubin levels were calculat-
ed as 35±15 IU/L, 40±37 IU/L and 0.77±0.37 mG/dl patients
had extrahepatic metastases before treatment. Number of liver
lesions was 1, equal or less than 5 and multiple in 6, 2 and 8
patients and their dimensions varied between 12-120 mm.
Liver lesions of 13 patients were FDG avid (mean SUVmax:
7.4±2.2). Extrahepatic metastases were demonstrated in 5 pa-
tients. 12 patients were died during 243±229 days follow-up
period. In Cox-regression analysis, serum AST (p=0.035) and
ALT (p=0.020) levels, FDG avidity (p=0.018) and dimension
(p=0.019) of liver lesions have been found statistically signif-
icant parameters to predict overall survival after
radioembolization (p=0.007). Conclusion: Serum AST and
ALT level, FDG avidity and dimension of liver lesion are
prognostic factors in patients who received radioembolization
for cholangiocellular carcinoma. Patients with good liver re-
serve, FDG negative and smaller tumors seem to survive lon-
ger after radioembolization.
P844
177Lu-labeled hydroxyapatite (Lu-177 HA)
in Radiosynovectomy of knee joints due to Rheumatoid
arthritis.
K. Kamaleshwaran, S. Thirumalaisamy, V. Rajamani, E.
Radhakrishnan, A. shinto; Kovai medical center and hospital
limited, Coimbatore, INDIA.
Aim: To evaluate the use of radiosynovectomy (RS) using Lu-
177 labeled hydroxyapatite (Lu-177 HA) in the treatment of
knee joints in rheumatoid arthritis(RA). Methods: 22 patients,
diagnosed with RA and suffering from synovitis of the knee
joints were referred for RS and were followed up for period of
1 year.The duration of the disease was 11.2± 10 months.15/22
knees had pain during the night and 10/22 had abnormal flex-
ibility. Three-phase bone scintigraphy(BS3) of knee joint was
performed to confirm active synovitis and RS was performed
according to the EANM guidelines.All were treated with 333
± 46 MBq of Lu-177 HA administered intra-articularly. Mon-
itoring of activity distribution was performed by static imaging
of knee joint. They were evaluated clinically at 1 year after the
treatment by considering the pain improvement from baseline
values in terms of 100-point visual analogue scale(VAS), the
improvement of knee flexibility and the pain remission during
the night.RS response was classified as poor (VAS < 25), fair
(≥25 - 50), good (≥50 - 75) and excellent ( ≥75),with excellent
and good results considered as success,while fair and poor as
failure.BS3 was repeated after 1 year and Changes in the 2nd
phase of BS3 were assessed visually,using a 4-degree scale
and in the 3rd phase, semiquantitatively with J/B ratio to see
the response. Results: 1 year after treatment, the VAS% im-
provement from baseline was 90% ± 5.2% and found to be
significantly related to patients age (P = 0.01), duration of the
disease(P = 0.03).The overall success rate (VAS ≥ 50) was
90%.Remission of pain during the night achieved in 100%
and knee flexibility improved in 80%.The changes in blood
pool phase before RSV were 3.8 ± 0.5 and after 0.8 ± 0.4 (P <
0.001).The J/B ratio was: before RSV 2.8 ± 0.5; after treatment
1.0 ± 0.3 (P < 0.05).RS side effects were minor and not sig-
nificant. Conclusion:RSV with Lu-177 HA was safe and ef-
fective in patients with knee joint synovitis of rheumatoid
origin. They show significant therapeutic effect after 1 year
follow- up period with no significant side effects.Controlled
clinical trials are necessary to evaluate therapeutic efficacy and
safety compared to treatment with other radionuclides and
steroids.
P846
Evaluation of the delivered activity of yttrium-90 resin
microspheres with sterile water and 5% dextrose (D5W)
as application agents
H. Ahmadzadehfar1, C. Meyer2, C. Pieper2, R.
Bundschuh3, M. Muckle3, F. Gärtner3, H. Schild2, M.
Essler3; 1University Hospital Bonn, BONN, GERMANY,
2University Hospital Bonn Department of Radiology, BONN,
GERMANY, 3University Hospital Bonn Department of Nu-
clear Medicine, BONN, GERMANY.
Purpose: To evaluate impact of switching from sterile water to
5% dextrose (D5W) as the application agent for yttrium-90
(90Y)-resin microspheres on: total activity of 90Y adminis-
tered (expressed as a proportion of the prescribed/calculated
activity), as well as the number of cases of stasis and the
reported incidence of discomfort during the Selective Internal
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Radiation Therapy (SIRT) procedure. Methods: In December
2013, we switched from sterile water to D5W for the applica-
tion of SIRT in all patients. This retrospective observational
single-center case series describes our experience in the
months preceding and after the switch. Apart from the change
in application agent, the protocol for SIRTwas otherwise iden-
tical. Results: One hundred and four SIRT procedures were
performed on 78 patients (45 male, mean age: 63 years, range:
31-87 years) with either unresectable hepatocellular carcino-
ma, cholangiocarcinoma or chemorefractory liver-dominant
metastatic cancer. Compared with sterile water, the whole pre-
scribed activity was administered in significantly more proce-
dures with D5W: 85% vs. 22%; p<0.0001. A significantly
higher proportion of the calculated activity was administered
with D5W: 96.1% ± 11.0 vs. 77.4% ± 24.3 (p<0.0001). D5W
procedures were also associated with a lower incidence of
stasis or flow reduction (20% vs. 56 % procedures;
p<0.0001) and mild-to-moderate upper abdominal pain during
the procedure (1.8% vs. 44% procedures; p<0.0001). Conclu-
sions: Replacing sterile water with isotonic D5Was the appli-
cation agent favorably impacts on the safety of SIRT, elimi-
nates and/or minimizes flow reductions/reflux during admin-
istration of 90Y-resin microspheres and improves percentage
activity delivered and ease of delivery.
P847
First ever use of Peptide Receptor Radionuclide Therapy
(PRRT) with the Radiolabeled Somatostatin Analog
(177Lu-DOTATATE) in metastasized neuroendocrine
tumors (NETs) in a Spanish Public Hospital. Our
experience in the first year.
I. Plaza de las Heras, C. Field Galán, R. de Teresa Herrera, A.
Prieto Soriano, B. Rodriguez Alfonso, J. Cardona Arboniés, J.
Aller Pardo, M. Mitjavila Casanovas; University Hospital
Puerta de Hierro, Majadahonda, SPAIN.
Aim: Describe the first ever use of metabolic treatment with
177Lu-DOTATATE in metastasized NETs in progress in our
hospital in the first year. Materials and methods: Treatment
approval is needed as “individualized use” by the Spanish
Agency for Medicines and Health Products (AEMPS). From
February 2014 until May 2015, 12 treatments with 177Lu-
DOTATATE were given to 7 patients (4 men and 3 women)
with metastasized NETs in progress, 6 of themwere diagnosed
with gastroenteropancreatic tumours (2 insulinomas, 1
vipoma, 3 small mid intestine) and 1 of them a bronchial car-
cinoid. All patients had a positive OctreoScan preceding the
treatment and they had previously received another alternative
treatment modalities whithout response. 6 of the 7 patients met
the inclusion criteria according to the guideline of the EANM.
They had received 1-4 cycles of 200 mCi (7.4 GBq of 177Lu-
DOTATATE) with intervals of 6 to 12 weeks. In one case, the
treatment was terminated before because of the poor physical
condition of the patient. All patients received premedication
against nausea and steroids. The treatment started with a dual
infusion of a solution containing amino-acids (VAMIN®)
through an intravenous three-step cannula (to protect the kid-
neys from radiation) from 30 minutes before and during 6
hours. The infusion of radioactive premedication was given
30 minutes after the start of the amino-acids and took 30
min. Finally we washed the cannula and the drip was removed.
It was well tolerated in all cases. Images were acquired after 24
hours (wholebody scintigraphy and thoracoabdominal
SPECT/CT) to determine whether the radioactivity had been
well absorbed by the tumors. To asses response we monitorize
renal, hepatic and hematologic function with blood samples
and imaging (ECO, CT-scan or MRI).Results: All patients
showed stable disease on the Octreoscan and improvement
in quality of life. They have not submitted short term renal,
hepatic or hematologic toxicity. Six of them are still alive and 1
deseaced. Conclusion: The literature shows very promising
results with treatment with 177Lu-DOTATATE in metasta-
sized NETs which supports it’s general approval for individual
use by AEMPS. In our Hospital with a long experience in
metabolic treatment and a multidisciplinary team it’s easily
administered, well tolerated, has few adverse short term effects
and requires a 24 hour hospitalization. Our results show dis-
ease stability in all the patients and improved quality of life.
P848
Radioembolization of primary and / or metastatic hepatic
tumors with 90-yttrium microspheres: our experience.
R. DE TERESA HERRERA, I. PLAZA DE LAS HERAS,
C. FIELD GALAN, M. BERESOVA, J. CARDONA
ARBORIES, A. PRIETO SORIANO, S. MENDEZ
ALONSO, S. MENDEZ ALONSO, M. MITJAVILA CASA-
NOVAS; HOSPITAL UNIVERSITARIO PUERTA DE
HIERRO, MAJADAHONDA, MADRID, SPAIN.
Objective: To analize the results after radioembolization (RE)
with 90Y microspheres in our hospital. Material and methods:
From 10/2012 to 02/2015 we evaluated 35 patients, of which
we treated 27 (11 women, 17 men, mean age 63.1 years) ,11
hepatocellular carcinoma, 1 cholangiocarcinoma and 15 liver
metastatic tumors (13 colorectal 1 neuroendocrine tumor, 1
adenoid cystic tumor). In 22 we used resin radiolabelled mi-
crospheres and in 5 of them we used glass microspheres. All
patients had previously received at least two lines of treatment.
Before radioembolization treatment, hepatic arteriography and
scintigraphy 99mTc-MAAwere performed. According to the
results obtained in these tests it was decided which patients
were candidates for therapy with 90-Y (four patients were
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excluded, one because of vascularization problems, one due to
> 20% hepatic-pulmonary shunt, one because of difficult he-
patic surgery access, and the last one because of extensive
infiltration of the rigth hepatic lobe with extense thrombosis
of the rigth portal vein). The 90Y activity was calculated ac-
cording to the instructions of use of the microspheres. In the
patients treated with resins we used the body surface method.
To assess response to treatment we used modified RECIST
criteria, tumor viability (EASL) and liver tests. Results: Of
the 27 patients treated, 10 are still alive, with an overall aver-
age survival after RE of 10.5 months and progression-free
survival average of 4 months. Eight of the 27 patients present-
ed secondary complications of RE (3 liver radiotoxicity, 2
ulcers due to radiation, 1 intrahepatic hemorrhage, 1 febrile
syndrome, 1 hydropic decompensation), six of those eight
had a metastatic liver disease. Conclusions: in our experience
, we found similar results to those reported in the literature ,
with particular emphasis on liver toxicity in the treatment of
metastatic disease , which forces to reconsider the hepatic re-
serve in these patients.
P849
Resin-Based 90 Yttrium Radioembolization Of Liver
Tumors: The Three First Cases Performed In Lebanon.
F. CHEHADE, J. DAHER, F. KAMAR, C. TAYAR, M.
GHOSN, B. MOURANI, K. YAMMINE; CLEMENCEAU
MEDICAL CENTER, BEIRUT, LEBANON.
I N TRODUCT ION : R e s i n - b a s e d 9 0 Y t t r i u m
radioembolization (RYRE) is a complex procedure that re-
quires multidisciplinary management for safety and success.
The published literature suggests that there is sufficient evi-
dence to support the safety and effectiveness of RYRE in se-
lected patients with non-resectable primary or secondary liver
tumors. MATERIAL AND METHODS: Three patients with
non-resectable liver tumors were hospitalized in our institution
within a period of 24 hours and underwent RYRE for their
liver tumors. A 65 years-old and a 68 years-old female patients
have cholangiocarcinoma and recurrent cholangiocarcinoma
respectively, and an 88 years-old male has hepato-cellular
carcionoma. The patients received 0.65 MBq, 1.4 MBq and
1.2 MBq of the radiopharmaceutical respectively. The pre-
treatment work up included: 1) whole body 18FDG PETC;
2) catheterization to delineate arteries irrigating tumors selec-
tively according to the individual anatomy of each patient; 3)
instillation in the selected artery of 148MBq of 99mTc-human
albumin aggregates in order to assess by planar and tomo-
graphic scintigraphy the lungs shunt, the tumor to non-tumor
activity ratio, and the possibility of inadvertent spread of the
microspheres to non-target organs such as stomach and small
bowels; 4) measurement of the tumor volume using 3-
dimensional CT Scan reconstruction; 5) calculation of the ther-
apeutic activity dose according to tumors volume, BSA, per-
centage of lung shunts, and liver laboratory tests. RYRE was
monitored by cross sectional and metabolic imaging modali-
ties including 18F-FDG PET CT. RESULTS: RYRE was tol-
erated in all patients, there were no major post therapeutics
complications and 90Y Bremsstrahlung scintigraphy revealed
preferential tracer accumulation in diseased liver parenchyma.
This treatment was efficient since two months later,
radioembolized tumor masses showed decrease in number,
size and activity. Moreover, the female patient with recurrent
cholangiocarcinoma had no active liver tumor after RYRE.
Liver tumors that are still active or newly appeared, are
programed for a second session of RYRE at 4 months interval.
CONCLUSION: Our initial clinical experiences with RYRE
has led to encouraging response of the liver tumors with sur-
vival potential.
P850
Clinical efficacy of radiosynoviorthesis in finger joint
systemic arthritis.
I. Iakovou, K. Badiavas, A. Doumas, V. Mpalaris, S.
Tosounoglou, D. Kotrotsios, V. Athanasiou, D. Katsaboukas,
S. Georga, D. Lo Presti, G. Arsos; Academic Nuclear Medi-
cine dpt, Papageorgiou hsp, THESSALONIKI, GREECE.
PURPOSE:To retrospectively evaluate the long-term effi-
cacy of radiosyniviorthesis (RS) in patients with systemic
arthritis (rheumatoid or psoriatic arthritis) of the finger
joints.METHODS:Thirty-six painful despite pharmacother-
apy finger joints of 29 patients (28 females, 67.4 ±
7years ) were treated by intra-articular injection of
169Er citrate. All joints presented a positive blood pool
pattern in a pretherapeutic bone scan, suggestive for local
synovitis. Success rate was determined by a change com-
posite index (CCI, from 1-> total disability to 10 -> lack
of any impairment, with CCI≥6 -> success) calculated
taking into account functional disability, a ten-step visual
analog scale (VAS) for pain, joint tenderness and swell-
ing, patients and physician’s total assessment prior to and
after treatment, with a mean follow-up of 12
months.RESULTS:Twenty-nine (83.4%) joints reported a
pronounced improvement (19 good and 10 moderate re-
sponse) proved by a CCI≥6 at the end of the year’s
follow up vs. 72.3% at 6 months, p<0.05 (18 good and
7 moderate response). Interphalangeal joints were more
frequently resistant to therapy whereas best results were
obtained in the thumb base joints.CONCLUSION:RS is
highly effective in finger joint systemic arthritis with con-
comitant local synovitis.
S746 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
P851
The impact of isotope intra-articular distribution
and extra-articular leakage on the clinical outcome
of radiosynoviorthesis (RS) of the knee.
I. Iakovou, A. Doumas, K. Badiavas, V. Mpalaris, S.
Tosounoglou, D. Kotrotsios, V. Athanasiou, D. Katsaboukas,
S. Georga, D. Lo Presti, G. Arsos; Academic Nuclear Medi-
cine dpt, Papageorgiou hsp, THESSALONIKI, GREECE.
AIM: To assess the impact of extra-articular leakage and the
intra-articular distribution of 90Y on the clinical outcome of
RS in patients with knee activated osteoarthritis (aOA) and
rheumatoid arthritis (RA) in a 18 months follow-up period.
METHODS: We prospectively evaluated 52 patients, 26 with
aOA resistant to conventional therapy and 26 with RA referred
for RSO due to synovial inflammation, as demonstrated by
early-phase bone scintigraphy, for a 18months’ period of time.
They were all treated with 185 MBq 90Y combined with a
glucocorticoid intra-articular injection. Success rate was deter-
mined by a change composite index (CCI, from 1-> total dis-
ability to 10 -> lack of any impairment, with CCI≥6 -> suc-
cess) calculated taking into account functional disability, a ten-
step visual analog scale (VAS) for pain, joint tenderness and
swelling, patients and physician’s total assessment prior to and
after treatment. Yttrium-90’s intra-articular distribution (IAD)
was assessed by planar imaging 20minutes after RS (scored as
mainly diffuse or mainly focal). Leakage to regional lymph
nodes, the liver and spleen was assessed with a dual-head
gamma-camera after 24 hours. RESULTS: The overall re-
sponse rate (RR) for all treated joints was 65% at 6 months
and 60% at 18 months (P = ns). The mean improvement rate
for the treated joints in RAwas higher than aOA in total. IAD
was mainly diffuse in 84% with RR of 67% versus 65% in
cases with focal distribution, p> 0.05. 90Y leakage was found
only to the liver and the spleen (0.3% vs. 1%, respectively)
being significantly less in case of diffuse IAD. Neither IAD
nor 90Y leakage were correlated with CCI. CONCLUSION:
Yttrium-90 radiation synovectomy exerts a beneficial thera-
peutic effect in patients suffering of knee synovial inflamma-
tion, providing better results in rheumatoid arthritis than in
osteoarthritis. Isotope IAD and leakage do not influence its
clinical effect
P852
Radioisotope synoviorthesis in paediatric and adolescent
patients with haemophilia
A. Martínez-Esteve, R. Álvarez-Pérez, J. Tirado-Hospital, R.
García-Jiménez, R. Núñez-Vázquez, I. Borrego-Dorado;
Virgen del Rocío Universitary Hospital, Seville, SPAIN.
Objective: To assess the outcome and adverse-effects of the
radioisotope synoviorthesis in paediatric and adolescent pa-
tients with haemophilia.Methods: Prospective study of histor-
ical cohort was conducted in our department between
June 2005 and July 2014. A total of 21 consecutive
haemophiliac boys with a mean age of 12.42 years (range 4-
17) were included. The diagnosis of synovitis was established
on the basis of clinical follow-up including radiological im-
ages (radiography and / or MRI). For evaluation, the classifi-
cation proposed by Fernandez-Palazzi was used. Inclusion
criteria: patients aged less than 18 years old with hemophilia
and more than one haemarthrosis in less than three months
remaining a chronic synovitis despite prophylactic therapy in-
tensification. All the patients underwent 28 radioisotope
synoviorthesis with 90Y-citrate-colloid and/or 186Re-sul-
phide-colloid. The effectiveness of the procedure was assessed
through pre and post treatment clinical comparison at 6
months after radioisotope synoviorthesis. The mean follow-
up was 66.05 months (range 18-109).Results: Twenty-seven
of the 28 synoviorthesis (96.4%) had a good response (13
procedures) or excellent response (14 procedures), and only
1 (3.5%) had partial response. No patient had no response to
the procedure. It was necessary to repeat the procedure in 3
joints of 3 different patients, due to haemarthrosis at 6 months
after treatment and at a late stage at 20 and 23 months,
obtaining in all cases a good or excellent response with disap-
pearance of haemarthrosis, and subsequent recovery of the
joint range of motion. We appreciated inflammatory reaction
after procedure in 4 cases (14.3%), which improved with an-
algesics and nonsteroidal anti-inflamatory drugs. None of the
patients presented malignant or premalignant lesions during
the follow-up.Conclusion: The radionuclide synoviorthesis is
a very effective procedure in paediatric and adolescent patients
with hemophilia, being a minimally invasive procedure, easy
to perform, safe and with minimal side effects.
P853
Safety and efficacy of transarterial Y-90 radioembolisation
for liver metastases of neuroendocrine tumours
G. Boni1, I. Bargellini2, M. Tredici3, s. mazzarri3, A.
Farnesi4, S. Chiacchio3, A. C. Traino5, G. Manca1, F.
Guidoccio3, R. Cioni2, C. Bartolozzi2, S. Ricci6, D.
Volterrani3; 1Regional Center Of Nuclear Medicine,Universi-
ty Hospital Of Pisa, pisa, ITALY, 2Department of Radiology,
Vascular and Interventional Radiology,University Hospital Of
Pisa, pisa, ITALY, 3Regional Center Of Nuclear Medicine,
University Hospital Of Pisa, pisa, ITALY, 4Division of Oncol-
ogy, Hospital of Pisa, pisa, ITALY, 5Health Physics Unit,
Section of Medical Physics, University Hospital, Pisa, Italy,
pisa, ITALY, 6Division of Oncology, University Hospital of
Pisa, pisa, ITALY.
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AIMTo present the preliminary data about transarterial
radioembolisation (TARE) with Y-90 microspheres in patients
(pts) with liver metastases of neuroendocrine tumors (NETs).
METHOD: Since 2012 up to now 11 patients (3 male and 8
female) with a mean age of 62±11.7 yrs (range 40-77) affected
by unresectable liver neuroendocrine metastases underwent
Y-90 TARE with resin microspheres (Sirtex). Primary site of
the NETs was ileum (3 pts), lung (3 pts) and pancreas (5 pts).
We didn't treat with TARE those pts with high bilirubin level
(>1.8 mg/dl). Pts with minor extrahepatic metastases were
included, because it didn't affect the prognosis. All pts previ-
ously selected by MRI or CT scans had pre-TARE planning
angiography and Tc-99m-MAA SPECT/CT in order to detect
possible shunting into gastrointestinal vasculature, to assess
the lung shunt and to simulate the distribution of the micro-
spheres within the tumoral and the non-tumoral liver.Y-90
TARE was performed 7-14 days later followed by PET/CT
imaging within 24 hrs. The estimated activity was determined
using the standard BSA method. Response to TARE was eval-
uated with morphological criteria measured at 4-6 weeks and
then every 3 months on CT or MRI scan. RESULTS: We
totally perform 17 treatments for 11 pts, because 6 patients
were submitted to the TARE twice (bi-lobar treatment), and
14 diagnostic SPECT/CT with 99Tc-MAA, because 3 of the
“double treatment”were performed within a month by the first
diagnostic scan. The mean injected activity of resin micro-
spheres was 0.96±0.33 GBq and the mean target volume was
326±321 mL (range 5-1180 mL).In 10/11 evaluable pts at a
mean follow-up of 9±5.5 months, we obtained after the first
TARE a partial response in 3/10 pts (33%) and a stable disease
in the remaining 7 pts. In 4/6 evaluable pts ,who were submit-
ted to second TARE, we observed a partial response in 3 pts,
and a stable disease in 1 pt. No significant side effects and
TARE related complications were observed in our series. He-
patic toxicity occurred at grade G1 in 3 pts and at grade G2 in 1
pt. CONCLUSIONS: Y-90 TARE is a feasible and safe meth-
od to treat liver metastases of NETs with an acceptable level of
complications, a low percentage of toxicity, a good response
rate and high clinical benefit.
P854
Safety and efficacy of selective internal radiotherapy
with Y-90 glass-microspheres in patients with progressive
hepatocellular carcinoma (HCC) after failure
of transarterial chemoembolization (TACE)
A. P. Bellendorf1, S. P. Müller1, A. Bockisch1, S. Ezziddin2,
J. Nagarajah3, J. Best4, J. Schelhorn5, T. D. Poeppel1, A.
Sabet1; 1University Hospital Essen, Germany, Department
of Nuclear Medicine, Essen, GERMANY, 2Saarland
University Homburg, Germany, Department of Nuclear Med-
icine, Homburg, GERMANY, 3Memorial Sloan Kettering
Cancer Center, New York, NY, UNITED STATES, 4Univer-
sity Hospital Essen, Germany, Department of Internal Medi-
cine and Gastroenterology, Essen, GERMANY, 5University
Hospital Essen, Germany, Institute for Diagnostic and Inter-
ventional Radiology and Neuroradiology, Essen, GERMANY.
Aim: Transarterial chemoembolization (TACE) is currently
the standard of care in patients with non-resectable, locally
advanced hepatocellular carcinoma (HCC). Selective internal
radiotherapy (SIRT) is mostly used as an alternative modality
in patients considered poor candidates for TACE. Data on
SIRT in TACE-refractory patients are sparse. This study aims
to evaluate the safety and efficacy of SIRT with glass micro-
spheres in patients with progressive HCC after failure of
TACE.Methods:47 patients with progressive HCC after a me-
dian of 2 (range 1-13) TACE sessions received SIRTwith Y-90
microspheres (3.5±1.5 GBq; liver target dose 110-120 Gy).
Toxicity was recorded 4 and 12 weeks after the treatment
and reported according to Common Terminology Criteria for
Adverse Events v.4. Treatment response was assessed 1 and 3
mo after treatment using modified response criteria in solid
tumors (mRECIST) and survival analyses were performed
with the Kaplan-Meier method (log-rank test, P < 0.05). Re-
sults: Reversible hepatotoxicity (≥ grade 3) occurred in 15 of
47 patients (32%). Treatment response consisted of partial re-
sponse in 26 (55%), stable disease in 12 (26%), and progres-
sive disease in 9 (19%) patients. Median overall survival (OS)
was 14 months (95%CI: 12-16) and objective response to
SIRT was associated with longer OS (p=0.006) .
Conclusion:Selective internal radiotherapy is a safe and effec-
tive salvage treatment option in HCC patients refractory to
TACE.
P855
Radiosynovectomy application after arthroscopic surgery
on the hip joint
H. I. ATILGAN1,M. SADIC2, H. OZSOY3, G. KOCA2, A.
OZSOY4, M. KORKMAZ2; 1Kahramanmaras Necip Fazıl
City Hospital , Department of Nuclear Medicine,
Kahramanmaras, TURKEY, 2Ministry of Health Ankara
Training and Research Hospital, ANKARA, TURKEY, 3Me-
morial Ankara Hospital, Department of Orthopedics and
Traumatology, ANKARA, TURKEY, 4Ministry of Health
Ankara Numune Training and Research Hospital, Clinic of
Radiology, ANKARA, TURKEY.
Aim: Pigmented villonodular synovitis (PVNS) is
S748 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
characterized as the proliferation of synovial tissue of the joint,
tendon sheath and bursa. It is usually seen in middle-aged
women and the most common joints are knee, hip and ankle.
Recurrence is common and recurrent tumors cause more de-
struction and invasion. Besides wide surgical excision,
radiosynovectomy (RS) increases local control. In the litera-
ture, RS performed after open surgery to the hip joint in almost
all of the cases. In this case, we present the efficacy of RS after
arthroscopic surgery of the hip joint with PVNS. Case Presen-
tation: Synovial hypertrophy and effusion compatible with
PVNS was observed in contrast enhanced magnetic resonance
imaging (MRI) of a 32-year-old patient that had administered
to orthopedic clinic with right hip pain. The patient underwent
arthroscopic synovectomy for the lesion in the hip joint. Six
weeks after surgery, RS was performed with yttrium-90 (Y-90)
colloid (CIS Bio International, France) to the hip joint. Three
phase bone scintigraphy was taken before RS. Minimal in-
creased perfusion in blood flow phase, minimal hyperemia in
blood pool phase and relatively increased activity accumula-
tion in late images were seen in right hip joint. 3 mCi (111
MBq) Y-90 colloid was applied to right hip joint under fluo-
roscopy. Bremsstrahlung imaging was made for the evaluation
of distribution of Y-90 colloid in fourth hour after RS with
gamma camera (Siemens, ECAM, Hoffman Estates, IL,
USA) equipped with low energy general purpose collimator.
Distribution of Y-90 colloid was normal with no extraarticular
leakage (Figure). Hip joint was stabilized for 72 hours after
RS. Patient did not have any complaints in sixth and ninth
month controls. MRI and three phase bone scintigrapy were
taken in ninth month control. There was no pathological ac-
tivity accumulation in bone scintigraphy and no residual or
recurrent tumour was detected in MRI. Conclusion: As an
alternative to RS applied to the hip joint after open surgery,
RS application after arthoscopic surgery is effective in achiev-
ing local control. Key words: radiosynovectomy, yttrium-90
(Y-90), pigmented villonodular synovitis (PVNS). Figure:
Good intraarticular distribution is seen in anterior whole body
(a) and static (b) images four hours after Y-90 colloid injection
to right hip joint. There was no extraarticular leakage.
P856
Phase I Clinical Experience of Post-Radioembolization
Yttrium-90 Imaging Using Next Generation Digital
PET/CT
C. L. Wright1, J. Zhang1, K. Binzel1, E. J. Wuthrick1, P.
Maniawski2, M. V. Knopp1; 1The Ohio State University, Co-
lumbus, OH, UNITED STATES, 2Philips Healthcare, Cleve-
land, OH, UNITED STATES.
AIM: Targeted intraarterial delivery of Yttrium-90 (90Y)
microspheres into unresectable hepatic malignancies and
metastases allows for embolization of the tumor-
associated neovascularity and local deposition of high
therapeutic doses of radioactivity. Bremsstrahlung scin-
tigraphy of 90Y radioactivity using planar and SPECT/
CT approaches is the current imaging standard for im-
mediate post-therapy assessment. Alternatively, there is a
small fraction of 90Y internal pair production which can
be readily imaged using conventional photomultiplier-
based PET systems but its clinical use is limited due
to long image acquisition times which can disrupt rou-
tine clinical workflows. The solid-state digital photon
counting PET detector (i.e., digital PET or dPET) is
the fundamental innovation to advance clinical PET im-
aging of 90Y. The purpose of this ongoing Phase I clin-
ical trial is to assess the feasibility and clinical capabil-
ity of next-generation dPET/CT to accurately and more
efficiently image post-therapy 90Y biodistribution. MA-
TERIALS AND METHODS: A next-generat ion
dPET/CT system (Philips Vereos 64 ToF) was used to
image patients following 90Y radioembolization for
malignant/metastatic liver lesions in an ongoing Phase
I clinical trial. Qualitative and volumetric dPET/CT as-
sessment of 90Y activity within the liver was compared
with standard bremsstrahlung SPECT/CT images (Sie-
mens Symbia T16). In order to determine minimum ac-
quisition times per bed position, segmented reconstruc-
tion of list mode acquired data was obtained from 1 to 7
min. Matched pair comparison of dPET/CT image char-
acteristics with standard bremsstrahlung SPECT/CT im-
aging were also performed and assessed by multi-reader
review. RESULTS: 90Y dPET imaging is clinically fea-
sible and produces evaluable images with improved
quality when compared with standard bremsstrahlung
SPECT/CT. Digital PET images demonstrate markedly
improved 90Y-to-background contrast and enable more
accurate volumetric assessment of 90Y activity. Faster
image acquisition times are attainable with dPET/CT
which appears to be become robust around 5 min per
bed position. CONCLUSION: At present, there is an
unmet clinical need to more accurately and efficiently
assess 90Y biodistribution in post-radioembolization pa-
tients. The current results demonstrate that dPET/CT
technology is capable of imaging 90Y with improved
image quality and volumetric assessment. Faster acquisi-
tion times are also attainable with dPET/CT without sig-
nificant impact on image quality. Continued refinement
of 90Y dPET image acquisition strategies and image
reconstruction will enable more accurate and even faster
evaluation of 90Y patients.
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S749
P55 - Tuesday, October 13, 2015, 4:00 PM - 4:30 PM, Hall 3 –
Poster Exhibition
Radionuclide Therapy & Dosimetry: Data Collection
Methods & Pharmacokinetics
P857
Image Quality Parameters and Quantification Issues
with Y-90 Bremsstrahlung SPECT/CT
S. Beykan, M. Lassmann, S. Schlögl; Department of Nuclear
Medicine, University of Würzburg, Würzburg, GERMANY.
OBJECTIVES: The aim is to investigate the influence of
various parameters on the reliability of quantitative
bremsstrahlung SPECT/CT. A phantom study was per-
formed for studying the influence of collimators, energy
windows and reconstruction-settings on image-contrast,
image-noise, contrast-recovery-coefficient, coefficient of
variation, visibility and calibration. METHODS: For
measuring the image-quality a torso-based-phantom con-
taining 6 spheres (diameters: 10-37mm) was used. Each
sphere was filled with 1.59MBq/ml Y-90. A 50ml bottle
(~80MBq) was used for calibration in air. SPECT/CT
data were acquired (SIEMENS Symbia T2) by using
several acquisition-parameters, two reconstruction proto-
cols (2D-OSEM and 3D-FLASH), collimator-sets
(‘HEGP’ and ‘MEGP’) and CT-based attenuation correc-
tion. As image quality parameters; the results of contrast
(C [%]), contrast-recovery-coefficient (QH), coefficient
of variation (CV), visibility (VH) and signal-noise-ratio
(SNR) of the spheres and the bottle in Y-90 SPECT-CT
images were calculated and compared for both collima-
tors and reconstruction-algorithms in each energy win-
dows setting. >For 11 different energy window ranges,
collimators and reconstruction algorithms, the total and
specific number of counts-to-activity concentration ratios
(CA-Ratio) were calculated for each sphere and the bot-
tle. Moreover, the difference between a calibration in air
and water was investigated. RESULTS: The best energy
window for CV was determined as 50-195keV while the
best energy window for C [%], QH, VH and SNR was
established as 86-106keV. The measurements based on
2D-OSEM with HEGP showed better results. The best
results of CA-Ratios per spheres (which also show the
lowest partial volume effect) were observed in the
energy-window 86-106keV for the HEGP-collimator.
Changing the order of processing for the combined
energy-windows has no influence on the image quality
parameters. Higher count rates per MBq were observed
in MEGP-collimator. The calibration factors obtained in
air as compared to those in water were inconsistent most
l i ke ly caused by mate r i a l -dependen t va r i ab l e
bremsstrahlung yields. CONCLUSIONS: Collimation,
applied energy window range and reconstruction algo-
rithm have substantial effects on Y-90 bremsstrahlung
image quality. For the best image quality based on de-
termined parameters, the 86-106keV energy window in
conjunction-with the 2D-OSEM reconstruction algorithm
using a HEGP collimator is recommended.
P858
Radiation dose estimate from patients undergoing
18F-FDG scanning: implications for the general public
and nuclear medicine technicians
B. Liu, R. Tian; Department of Nuclear Medicine, West China
Hospital, Sichuan University, Chengdu, CHINA.
As 18F-FDG PET/CT is increasingly applied in clinical prac-
tice and patients will contact with the general public after
completing the scanning. It is necessary to consider the poten-
tial exposure burden to the general public and nuclear staff.
This study was to estimate the exposure dose to the general
public and nuclear medicine technicians from patients under-
going 18F-FDG PET/CT scanning. Methods Fifty-seven pa-
tients (38 males,19 females; age range: 19-72 years, average
age: 43±16 years) with different malignancies undergoing
18F-FDG PET/CT scanning were randomly and prospectively
recruited. Approximately at 5 minutes after intravenous injec-
tion of 18F-FDG , whole-body initial dose rate was measured
with a radiation-survey meter at 0.3 and 1.0 m from the pa-
tients. On the basis of human 18F-FDG metabolic rate pro-
posed by the International Commission of Radiological Pro-
tection and human social contact model proposed by the Na-
tional Council on Radiation Protection and Measurements, the
total effective dose equivalent (TEDE) to the general public
from exposure to patients who have completed 18F-FDG
PET/CT scanning and left nuclear medicine department were
calculated. On the assumption that a nuclear medicine techni-
cian typically spends 5 minutes at a distance of 0.3m for posi-
tioning the patient, the technician’s TEDE was also estimated.
Results The whole-body initial dose rates at 0.3m and 1.0 m
were 100.5-156.4 μSv/h and 16.8-46.8 μSv/h, respectively.
The TEDE to a family member sleeping with the patient at
night was predicted to be 32.49-58.01 μSv, to a family mem-
ber contacting the patient at daytime 4.59-13.48 μSv, to a
colleague 6.06-17.79 μSv and to a passenger 98.43-175.77
μSv. The TEDE to a technician per 18F-FDG PET/CT scan-
ning procedure was predicted to be 4.05-7.24 μSv. Conclusion
The predicted doses to the general public and nuclear medicine
technicians from exposure to patients undergoing 18F-FDG
PET/CT scanning are significantly lower than the regulatory
dose limits. The general public should not be afraid of
contacting with the patients who have undergone 18F-FDG
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PET/CT scanning. This work was supported by the National
Natural Science Fund of China Grant No. 81401445,
81471693.
P859
The Importance of Treatment Planning
in Radiopharmaceutical Therapy According to Human
Data of 153Sm-EDTMP
M. Meftahi1,2, A. Bahrami Samani2, I. Jabbari1, T.
Hoseinnejad3; 1University of Isfahan, Isfahan, IRAN, IS-
LAMIC REPUBLIC OF, 2Nuclear Science and Technology
Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF,
3Mashhad University of Medical Science, Mashhad, IRAN,
ISLAMIC REPUBLIC OF.
Aim: to Show that different patients have various
physiologic responses in treatment by 153Sm-EDTMP
as a therapeutic agent by means of comparing of
patient by patient data obtained from the routine
method of fixed value injection.Material and method:
7 patients (6 males and 1 female) were injected with
t h e r a d i o p h a rm a c e u t i c a l (m a n u f a c t u r e d b y
PARSISOTOPE Company) and each one received a
dose of 1mCi/kg and was scanned at intervals of
15min, 3, and 24h post injection. Planar imaging
was performed at anterior posterior direction. Then
total counts of whole body were calculated as geo-
metric mean of counts in anterior and posterior states.
Results were analyzed in order to evaluation of ab-
sorption and excretion of the agent for each patient.
Regarding that the first image was performed before
urinary excretion of the patients, it was considered to
b e a r e f e r e n c e o f t o t a l a c t i v i t y f o r e a c h
patient.Results: the results indicated obvious variation
in physiologic behavior among patients. The minimum,
maximum, and mean values of excretion were 57%,
12%, and 30%, respectively at 3h post injection.
More than 50% of administered total activity remained
in bone in 5 patients at 24h post injection. The max-
imum, minimum, and mean values of absorption were
60%, 25%, and 47% at this time interval.Conclusion:
Consideration of the results demonstrates an egregious
fluctuation in physiologic response among the patients.
It can be problematic in many cases. Because some
patients may be overdosed and suffer from the com-
mon side effects or vice versa may receive ineffective
dose and not have suitable response to the therapy.
Therefore the fixed value injection cannot be suitable
for all cases and optimization and treatment planning
for each patient is a matter of great concern.
P860
Absolute SPECT/CT calibration for dosimetry in 177Lu
targeted radionuclide therapy
F. Fioroni, E. Grassi, V. Ferri, S. Marco Antonio, F. Angelina,
A. Versari, M. Iori; IRCCS-ASMN, Reggio Emilia, ITALY.
Purpose: Peptide Radionuclide Radiation Therapy (PRRT)
with somatostatin analogues labelled with 90Y and 177Lu is
increasingly used for the treatment of NETs. An accurate eval-
uation of tumour and organs at risk doses is mandatory for a
personalized therapy. The purpose of this study is to develop a
SPECT/CT quantitative protocol to generate an accurate
177Lu activity quantification for dosimetry assessment.
Methods: First of all, the calibration factor (CF) for the abso-
lute quantification was obtained by a cylindrical uniform
phantom filled with 177Lu (0.187 MBq/ml; volume 5640
ml), unaffected by partial volume effect. In order to evaluate
the count rate effect, several acquisitions of the phantom were
performed in about one month. Images were obtained with a
SPECT-CT system (Symbia T2, Siemens) with a clinical ac-
quisition protocol and reconstructed using a commercial
3DOSEM algorithm (Flash3D) with CT-based attenuation cor-
rection, energy window-based scatter correction and full
collimator-detector response compensation.In order to validate
the calculated CF, we acquired a cylindrical phantom with hot
inserts and an antropomorphic torso phantom with organs and
added lesion inserts [2.5÷1200 ml], filled with known activity
concentration of 177Lu [0.07÷2.25 MBq/ml]. Volumes and
concentrations were chosen as close as possible to the clinical
data, thus mainly simulating the volume of tumours and or-
gans at risk. Recovery coefficients and noise dependence as
function of OSEM iterations and subsets for different volumes
were evaluated. Results: We obtained a CF (15.8cps/MBq)
with a coefficient of variation of 5%; the CF doesn’t depend
on count-rate in the evaluated activity range. The system is
capable of recovering the activity in a 280 ml sphere by an
accuracy of ±4%. The linear dependence of noise on the num-
ber of subsets and iterations is visible as for fixing the number
of subsets, varying the number of iterations and viceversa.
This dependence is also confirmed by the ANOVA two factor
factorial model (<10-7).SPECT-CTwas been calibrated in sen-
sitivity taking into account the insert volume to consider Par-
tial Volume Effect, for body and brain protocols. We found out
the optimum combination of the iterations and subsets
employed in our commercial algorithm (10 iter-8 subsets), in
order to establish the quantitative accuracy of our clinical
SPECT patient imaging studies. Conclusions: The 177Lu
SPECT/CT reconstruction algorithm settings for dosimetry
purpose were evaluated. Clinical absolute quantification for
SPECT/CT dosimetry is feasible, though further efforts to im-
prove physics modelling are wished to enhance accuracy and
reproducibility.
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Comparison of Geant4 andMCNPXMonte Carlo systems
in the calculation of voxel S values for the therapeutic
radionuclides 90Y, 111In, 177Lu and 131I
L. Auditore1, E. Amato1, A. Italiano2, F. Minutoli1, A.
Campennì1, S. Baldari1; 1University of Messina, MESSINA,
ITALY, 2Istituto Nazionale di Fisica Nucleare, MESSINA,
ITALY.
This work was aimed to compare the differences in voxel S
values in soft tissue calculated through twoMonte Carlo codes
for four radionuclides commonly used in nuclear medicine
therapies.We developed two Monte Carlo simulations, in
Geant4 and in MCNPX, of tissue regions divided into
11x11x11 cubic voxels of 3 mm side. The different physics
models available for low-energy electromagnetic processes
were tested.The decay of each radionuclide (90Y, 111In,
177Lu, 131I) was simulated as homogeneously distributed
within the central voxel (0,0,0), and the energy deposited in
it and in the surrounding voxels was properly scored.The re-
sults obtained with the twoMonte Carlo codes were compared
each others and with the ones calculated by means of a previ-
ously published analytical method. Voxel S factors were rep-
resented as a function of the “normalized radius”, defined as
the ratio between the source-target voxel distance and the vox-
el side. MC simulations show a good agreement each other
and with the analytical calculation method. Main differences
are probably due to the different implementation of the decay
spectra for the considered nuclides. The analytical model pro-
vides results which differ up to 50% fromMCNPXdata. These
differences can be explained by the approximations introduced
by the analytical approach which, however, do not influence
significantly the accuracy of the dosimetric calculation.
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Pre-therapy Initial Dosimetry Results of Lu-177
-DOTA-617-PSMA In Castration Resistant Prostate
Cancer
M. M. Abuqbeitah, N. Yeyin, A. Aygün, E. Demirci, M.
Ocak, M. Demir, L. Kabasakal; Istanbul University, İstanbul,
TURKEY.
Aim: Targeted radionuclide therapy (TRT) is an increasingly
used in treatment of wide Types of cancer. Presently dosimetry
is highly required either to plan treatment or to estimate the
absorbed dose delivered to critical organs during treatment.
Methods and materials : The study comprised 7 patients suf-
fered from prostat cancer with progressive disease and
candidated to undergo Lu-177-DOTA-617 therapy following
to Ga-68-PSMA PET/CT imaging for all patients. 192.4±11.1
Mbq (5.2±0.3 mCi) was intravenously injected and to evaluate
bone marrow absorbed dose 2 cc blood samples were with-
drawn in short variable times ( 3, 15, 30, 60, 180. Minutes and
24, 48, 120. hours) after injection .further more whole body
scans were performed using scintillation gama camera in 4, 24,
48 and 120 hour after injection and in order to quantify the
activity taken up in the body, kidneys, liver, right parotid and
left parotid, the geometric mean of anterior and posterior
counts were determined through ROI analysis, after that back-
ground subtraction and attenuation correction were applied
using patients Ga-68-PSMA PET/CT images taking in a con-
sideration; organ thickness ,body thickness and Hounsfield
unites from Computed Tomography scan. OLINDA/EXM do-
simetry program was used for curve fitting, residence time
calculation and absorbed dose calculations. Results: Calculat-
ed absorbed dose of bone marrow, left kidney, right kidney,
liver, left parotid, right parotid and total body. 1.28±0.52,
32.36±16. 36,32.7±13.68, 10.35±3.45, 38.67±21.29, 37.55
±19.77, 2.25±0.95 (mGy/mCi) respectively. Conclusions :
Our first results clarify that Lu-177-DOTA-617 is safe and
reliable therapy as there was no complications seen.İn the oth-
er hand the observable variation in the absorbed dose of the
critical organs among the patients necessitate patient- specific
dosimetry approach to save body organs and particularly high-
ly exposed kidneys and parotid gland.
P863
Influence of syringe residual activity (SRA) on effective
dose (ED) estimates from myocardial perfusion imaging
(MPI) exams
F. A. A. de Jonge, S. Valente, T. C. Ferreira; Hospital Lusíadas
Lisboa, Lisbon, PORTUGAL.
Aim: To estimate the effect of syringe residual activity on ED
from MPI exams. Methods: MPI was done with a one-day
low-dose stress, high-dose rest protocol with 99m-Tc-
tetrofosmin. Stress (S) and rest (R) dose activity (DA in
MBq) was measured in a dose calibrator (Veenstra); for S a
1 ml syringe was used; for R a 2,5 or 3ml syringe was used
(with occasional use of 5ml syringe); measured residual activ-
ity (RA) after injection was available for three different co-
horts: C1= 148 MPI consecutive exams, period FEB-MAR
2014, RA for all S, only for 16 R exams. C2= 27 MPI consec-
utive exams APR 2015, RA for 27 S and 26 R exams. C3= 88
MPI non-consecutive exams, executed in 2014, for which RA
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for S and R exams were available (not included in C1). All
data processing was done in R: A Language and Environment
for Statistical Computing (http://www.R-project.org). Data are
presented as median (minimum - maximum). ED was calcu-
lated with the ICRU voxel phantom / ICRP 103 values, as
cited for tetrofosmin S and R exams in Andersson et al
(EJNMMI Physics 2014), using either the uncorrected dose
activity DA or the DA, corrected for RA (CDA). Results:
Stress RA for the three cohorts (263 exams) was 21.2 MBq
(8 - 67); as a percentage of DA: 5.9 % (2.3% - 17.8%) at a
median S DA of 364 MBq. Rest RA, availbale for 130 exams,
was 35MBq (5 - 65); as a percentage of DA: 3.8% (0.58% - 7.
0%) at a median R DA of 900 MBq. ED for S exams (263
exams) was 2.1 mSv (1.7 - 2.7) and using S CDA, 1.97 mSv
(1.6 - 2.6). ED corrected as percent of non-corrected was 94.1
% (82.3% - 97.7%), mean 93.6% ED for R exams (130 exams)
, was 5.6 mSv (4.7 - 6.3) and, using R CDA, 5.4 mSv (4.5 - 6.
3). ED corrected as percent of non-corrected was 96.2 % (93%
- 99.4%), mean 96.1%. For 130 S+R exams, ED corrected for
RA as percent of non-corrected was 95.2 % (92.6% - 98.3%),
mean 95.2%. Conclusion: Taking into account syringe residual
activity, lower ED estimates will be obtained, both for stress
(by median 94.1%) and rest exams (by median 96.2%). For a
combined stress and rest exam, on average a 95.2% lower ED
estimate is obtained.
P864
Revised dose calculations for 99mTc-pertechnetate used
for diagnostic nuclear medicine procedures in adults
M. ANDERSSON1, L. JOHANSSON2, D. MINARIK1, S.
MATTSSON1, S. LEIDE SVEGBORN1; 1Medical Radiation
Physics, Malmö, SWEDEN, 2Department of Radiation Sci-
ences, Umeå, SWEDEN.
Aim and background: Technetium-99m is the most commonly
used radionuclide at nuclear medicine investigations. The ra-
dionuclide is eluted as 99mTc-sodium pertechnetate from a
99Mo/99mTc generator and is then used for labelling a variety
of pharmaceuticals. There are also some examinations where
99mTc-pertechnetate is used directly. Moreover for substances
labelled with 99mTc there is always a risk that 99mTc get loss
from the specific molecules and therefore dosimetrically has to
be treated as free pertechnetate. Recently a detailed review of
the biokinetics of pertechnetate in adult humans was published
(Legget and Giussani, 2015). In 2009, ICRP/ICRU published
new adult reference computational voxel phantoms. These two
updates have created a possibility to perform new risk estima-
tions for intravenously and orally administered 99mTc-
pertechnetate. Materials and methods: Absorbed dose and ef-
fective dose estimation were performed with the internal dose
computer program IDAC 2.0 and based on the new biokinetic
model referred to above. IDAC 2.0 uses the ICRP/ICRU ref-
erence adult voxel phantom and the tissue weighting factors
from ICRP publication 103 to calculate the effective dose.
Nuclear data were gathered from the ICRP publication 107.
Dose calculations were performed for both intravenous and
oral administrations. In both calculations the urinary bladder
was assumed to have a voiding time of 3.5 h. Results and
conclusion: The effective dose for intravenously and orally
administered 99mTc-pertechnetate was estimated to 0.027
and 0.024 mSv/MBq, respectively. For intravenous adminis-
tration the effective dose is a factor of 0.6 of that obtained with
calculations based on the biokinetic model given in ICRP pub-
lication 53 with the adult reference voxel phantom and the
ICRP publication 103 organ weighting factors. For orally ad-
ministered activity the effective dose was a factor of 2.6 higher
using the new biokinetic model than the ICRP Publication 53
biokinetic data. In conclusion, new biokinetic data have in-
creased the accuracy for new estimations of patient doses at
diagnostic examinations with 99mTc-pertechnetat, or with Tc-
labelled substances from which technetium is released.
P865
Partial volume effect restoration in dose volume
histograms for Y-90 dosimetry: a proof of concept
M. Sanchez-Garcia1, P. Buyssens2, I. Gardin3, R. Lebtahi1,
A. Dieudonné1; 1Department of Nuclear Medicine, Beaujon
Hospital, Assistance Publique-Hôpitaux de Paris (APHP) &
INSERM U1149, Clichy, FRANCE, 2QuantIF – LITIS [EA
4108], Rouen, FRANCE, 3Department of Nuclear Medicine,
Henri Becquerel Cancer Center and Rouen University Hospi-
tal, & QuantIF – LITIS [EA 4108], Rouen, FRANCE.
Objective: 3D dosimetry of Y-90-radioembolization is based
on Dose Volume Histograms (DVH) which are degraded by
partial volume effect (PVE). A PVE correction has been de-
velop to improve 3D dosimetry, using a semi-automated seg-
mentation of sub-regions and the geometric transfer matrix
(GTM) method. Material and Methods: A phantom consisting
of an ellipsoid with radii 4x4x5 cm and a 2 cm radius sphere
close to its center was analytically modeled to simulate an
heterogeneous distribution. The sphere-to-background ratio
took values of 1.1, 1.2, 1.3, 1.5 and 2.0. Projections were
generated using the STIR software (stir.sourceforge.net) with
a 3D modeling of the system PSF with depth dependent
FWHM tuned to simulate a Symbia T2 camera. Poisson noise
was added to projections. The reconstruction was done with
STIR using the OSMAPOSL algorithmwith 3D PSF. For each
data set, the ellipsoid was subdivided into uniform sub-regions
using an eikonal-based region growing algorithm (Buyssens
et al. Image Vision Comput 2014). Then, partial volume cor-
rection was performed using the GTM algorithm. The DVHs
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were calculated on the ideal, measured and corrected distribu-
tions using dose-point kernel convolution. The number of sub-
regions was chosen by the user to reproduce the degraded
DVH. The absorbed doses values covering 95%, 50% and
5% of the tumor where calculated for the simulated and
corrected activity distributions and the results compared to
the ideal one. The corresponding relative deviations were not-
ed ΔD95, ΔD50 and ΔD5 respectively. Results: For 1.1 and
1.2 datasets, the segmentation algorithm failed to find the het-
erogeneity with the worst results found for a ratio of 1.2 where
ΔD95,ΔD50 andΔD5 were -10.8%, 0.8% and -2.4% for the
simulated distribution and 2.0%, 2.1% and -14.7% for the
corrected one. For ratios 1.3, 1.5 and 2.0 the segmentation
algorithm identified the heterogeneity. Maximum deviation
in D95, D50 and D5 were -10.7%, 0.6% and -5.7% for the
simulated distributions and below 1% for the corrected ones.
Conclusion: A PVE correction based on sub-region segmen-
tation with a region growing algorithm and GTM method has
been developed. This method showed promising results on an
analytical phantom in the cases where the concentration ratio
is higher than 1.3.
P866
Automatic image segmentation for 3D dosimetry
in Lu177-DOTATATE PRRTusing a robust cluster
algorithm on dynamic SPECT data
L. Vomacka, A. Delker, A. Gosewisch, E. Mille, H. Ilhan, F.
J. Gildehaus, P. Bartenstein, G. Böning; Ludwig-Maximilian-
University of Munich, Munich, GERMANY.
Aim: In Lu-177-DOTATATE PRRT the estimation of dosimet-
ric values for tumours and radiation sensitive organs such as
the kidneys supports individualized therapies. For this purpose
a volume-of-interest (VOI) for each entity has to be defined in
image data, acquired at days 1, 2 and 3 p.i.. We have studied a
method to automatically segment tumour and kidney VOIs in
4D SPECT data compared tomanually defined VOIs.Material
and methods: Three patients (mean 70.7y) with neuroendo-
crine tumours who received 7.4GBq of Lu-177 DOTATATE
were imaged with a Dual-head SPECT/CT (Siemens Symbia
T2) with 20s/step in 64 steps/head. The CT image taken at day
1 was coregistered to each SPECT dataset and utilized for
attenuation correction in penalized OSEM reconstruction
employing compensation for distance dependent detector blur
and photon scatter. The three SPECT volumes were synthe-
sized to form a 4D SPECT study. A robust k-means cluster
algorithm was used to automatically detect eight clusters in
these dynamic image data, followed by a labeller to segment
each individual connected VOI. For comparison, three to five
tumours and two kidney VOIs were manually defined for each
patient and an auto contour at the 40% of maximum value was
applied. Based on the mean time-activity curves of each se-
lected VOI a 3D dose map was calculated using S-value con-
volution kernels (Monte Carlo simulation in soft tissue). Re-
sults: The automatic segmentation successfully found 11 out
of 12 tumour VOIs and three out of six kidney cortex VOIs.
The missed entities can be addressed to overlapping with sur-
rounding high-activity VOIs, mainly tumours and spleen. The
mean dose values of the 11 tumours were 17.2±9.1Gy with the
automatic and 16.5±9.1Gy with the manual method. The esti-
mated dose to the cortex of the three successfully segmented
kidneys was 9.7±1.7Gy with the automatic and 8.7±1.1Gy
with the manual method. We found a strong correlation
(ρ=0.8) and no significant difference (paired t-test) between
the dose estimates of both methods. Conclusion: The automat-
ic segmentation is a promising approach to reduce the effort to
generate dose estimates in PRRT. Nevertheless we observed
that the position of kidneys can significantly change between
measurement days, hindering an accurate coregistration on the
voxel or organ boundary level. These misregistered bound-
aries can result in false segmentation and dosimetric results.
Furthermore the inclusion of structural information such as the
CT image into the automatic segmentation algorithm could be
a promising improvement.
P867
Estimation of local photon dose to active bone marrow
in Lu-177 PSMA PRRT therapy using patient-specific
Monte Carlo simulations
A. Gosewisch1, A. Delker1, L. Vomacka1, W. P. Fendler1, A.
Brunegraf1, F. J. Gildehaus1, A. Mairani2, K. Parodi3, P. A.
Bartenstein1, G. Böning1; 1University Hospital Munich, Mu-
nich, GERMANY, 2National Centre for Oncological Treat-
ment, Pavia, ITALY, 3Ludwig-Maximilians University Mu-
nich, Munich, GERMANY.
Aim: Active bone marrow is a main critical organ in targeted
radionuclide therapy. Particularly in Lu-177 DKFZ-PSMA-
617 for treatment of metastasizing prostate cancer high radio-
activity accumulations are observed close to active marrow
bearing regions due to a high activity uptake in the bone me-
tastasis. Further for dosimetry especially the long-range pho-
ton dose contribution cannot be predicted by simple standard
models accurately. Thus the aim of our work was to determine
the photon absorbed dose to regions which contain a high
amount of active marrow (thoracic and lumbar vertebrae, pel-
vis) and show bone metastasis at the same time by means of
patient-specific Monte Carlo (MC) simulations.Material and
methods: Accumulated activity maps for three source regions
(bone metastasis, kidneys, rest of body (ROB)) were generated
for 2 patients using quantitative SPECT images acquired ap-
proximately 1h, 24h, 48h and 72h after administration of
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3.7 GBq Lu-177 DKFZ-PSMA-617 on a Siemens Symbia
SPECT/CT. Thereby the fitting of the activity-time points
was done with a combination of a linear and an exponential
fit. For dose calculation 200 million photons were simulated
using the FLUKAMC code in combination with the accumu-
lated activity maps and the patient CT data as patient-specific
simulation input. To generate weighting factors for the energy
deposition specifically in active marrow during simulation for
each interaction in an active marrow region of interest the
ratios of the mass energy absorption coefficients for active
marrow and total bone were scored according to the energy
of the interacting photon and the site-specific total bone
composition.Results: The averaged active marrow doses to
the lumbar, thoracic and pelvis regions are, respectively,
21.3, 23.0 and 20.0 mGy. Thereby the tumour doses make
up 26.4, 36.8 and 42.4 % of the lumbar, thoracic and pelvis
mean active marrow doses while the largest dose contribution
comes from the ROB with 62.2, 54.7 and 55.7 %. The relative
uncertainty of all MC simulations was below 6.5 % (mean 3.2
± 1.3 %).Conclusions: In this study we developed a simple
model to study the local photon dose to bone marrow in se-
lected regions bearing a high amount of active marrow and
activity using patient-specific MC simulations. Preliminary
results show that bone metastasis contribute notably to the
marrow dose although the magnitude of the estimated dose
values in general is below commonly applied dose constraints.
P868
Partition model for accurate radiation therapy
with yttrium-90 Glass microspheres in hepatocellular
carcinoma.
S. Adib, M. Monteiro, S. Gnesin, P. Bize, A. Denys, J. Prior,
A. Boubaker; CHUV, Lausanne, SWITZERLAND.
Aim: To evaluate the impact of individualized dosimetry using
partition model for radioembolisation of hepatocellular carci-
noma with yttrium-90 glass microspheres. Materials and
methods: We performed a selective internal radiation therapy
with yttrium-90 glass microspheres for patients with hepato-
cellular carcinoma, between February 2013 and July 2014,
using a partition model analysis for accurate dose prescription
to tumoral and non tumoral liver. The child score was A5 in 9
cases, A6 in 4 cases and B6 in 2 cases. Results: In total, 15
patients (aged 67±8y) were followed for an average of 10±15
[range 1-20] months. They were treated with 254±135 [110-
548] Gy in the tumoral volume. Progression was observed in
6/15 patients (40%). Progression-free survival at 6, 12 and 18
months was 87%, 49% and 49%, while overall survival was
92%, 69% and 69%, respectively. Median progression-free
survival time was 11.7m and not reached for overall survival.
No unexpected events were recorded and all desired activity
could be injected to the patient. These numbers compare ad-
vantageously with historical survival in published cohorts
(Hepatology 2010;52:1741-1749; OS@6/12m=75%/59%
with a 16.4m median survival rate and PFS=10m). Conclu-
sions: Using partition model to compute dosimetry using Tc-
99m-MAA is feasible and safe. Overall survival and
progression-free survival seems to be comparable to historical
cohorts.
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Radiation Protection Challenges When Treating Dialysis
Patients With I-131
S. Gould, R. Fernandez, J. Robinson, P. Geraghty, C.Mills, H.
Mohan; Guy's and St Thomas' NHS Foundation Trust, Lon-
don, UNITED KINGDOM.
Aim: Three patients in renal failure undergoing haemodialysis
have been treated with radioiodine (I-131) at our centre recent-
ly. For such patients, removal of radioactivity following ad-
ministration occurs only with dialysis. Patient management
therefore requires careful consideration of various issues relat-
ed to radiation protection of the patient, their family and
healthcare staff. Materials and Methods: The three
haemodialysis patients were administered with 3849 MBq
(thyroid ablation), 818 MBq and 770 MBq (thyrotoxicosis).
All patients underwent dialysis immediately prior to
radioiodine administration and were then admitted to a dedi-
cated therapy isolation suite. Subsequently, each patient
underwent at least two dialysis sessions in a side room (desig-
nated a radiation controlled area) in a dialysis unit within the
hospital. Staff members caring for the patients in the dialysis
unit were issued with electronic personal dosimeters (EPDs) to
measure whole body doses. EPDs and dose rate meters were
used to measure radiation dose to patients undergoing dialysis
in adjacent rooms. Disposable tubing and clinical waste gen-
erated during each dialysis session was collected and disposed
of via the usual hospital radioactive waste stream. Patients
were permitted to resume their usual arrangements for dialysis
when the activity in the solid waste collected from a dialysis
session was below the 40 kBq threshold for very low level
waste. The patients presented challenging radiation protection
issues upon hospital discharge. One patient required a carer to
assist her at home whilst another patient was blind. For the
latter, her husband was designated a ‘comforter and carer’ and
was issued with a whole body dosimeter which was worn for
one month following hospital discharge. Results: All radiation
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doses received by staff were well below permitted limits. A
maximum of 66 μSv and 30 μSv were received by nurses
caring for the thyroid cancer and thyrotoxic patients respec-
tively. Over a four hour dialysis session, a maximum of 19μSv
was recorded by an EPD placed in an adjacent room. Solid
waste collected from the dialysis procedure contained low
levels of radioactivity (maximum 10 MBq). There was no
evidence of radioactive contamination of the dialysis machine.
The comforter and carer radiation dose recorded was not sig-
nificant. Conclusion: Treatment of haemodialysis patients with
radioiodine is complex and challenging but not impossible.
Control of radioactive contamination, staff doses and appro-
priate waste disposal can all be effectively managed with hos-
pital admission and appropriate input from the dedicated mul-
tidisciplinary team members before discharge back into the
community.
P871
Single-cell dosimetry: effect of cell geometry on cellular
S-values
N. Falzone1,2, J. M. Fernández-Varea3, G. Flux4, K. A.
Vallis1; 1University of Oxford, Oxford, UNITED KING-
DOM, 2Tshwane University of Technology, Department of
Biomedical Science, Pretoria, SOUTH AFRICA, 3Universitat
de Barcelona, Facultat de Física (ECM and ICC), Barcelona,
SPAIN, 4RoyalMarsden NHSFT, Physics Department, UNIT-
ED KINGDOM.
Aim: Several radionuclides used in medical imaging emit a
significant number of Auger electrons (AE) which, depending
on the targeting strategy, could either be exploited for thera-
peutic purposes or may contribute to an unintentional mean
absorbed dose. The virtues of twelve AE emitting radionu-
clides are evaluated in terms of cellular S-values in concentric
and eccentric cell/nucleus arrangements and by comparing
their dose point kernels (DPKs). Materials and Methods: The
Monte Carlo code PENELOPE was used to transport the full
particulate spectrum of 67Ga, 80mBr, 89Zr, 90Nb, 99mTc,
111In, 117mSn, 119Sb, 123I, 125I, 195mPt and 201Tl by
means of event-by-event simulations. Cellular S-values were
calculated for varying cell and nucleus radii and the effects of
cell eccentricity on S-values were evaluated. DPKs were de-
termined up to 30 μm. Energy deposition at DNA scales are
also compared to an emitter, 223Ra. Results: PENELOPE de-
termined S-values were generally within 10% of MIRD values
when the source and target regions strongly overlap, i.e. S(NN)
configurations, but greater differences were noted for S(NCy)
and S(NCS) configurations. Cell eccentricity has the greatest
effect when the nucleus is small compared with the cell size
and for cases where the radiation sources are located on the
cell surface. DPKs taken together with the energy spectra of
the radionuclides can account for some of the differences not-
ed in energy-deposition patterns between the radionuclides.
The relative dose of 119Sb, 125I, 195mPt and 201Tl are
higher compared to 223Ra over dimensions 2 nm. Conclusion:
A single-cell dosimetric approach is required to evaluate the
efficacy of individual radionuclides for theragnostic purposes,
taking cell geometry into account with internalizing and non-
internalizing targeting strategies.
P872
A 3D Printed Anthropomorphic Phantom for Validating
Quantitative SIRT Imaging in Multicentre Trials
J. Gear1, C. Cummings2, M. Tapner3, G. Flux1; 1Royal
Marsden NHSFT, Sutton, UNITED KINGDOM, 2Institute
of Cancer Research, Sutton, UNITEDKINGDOM, 3SIRTEX,
North Sydney, AUSTRALIA.
The use of selective internal radiation therapy (SIRT) is rapidly
increasing and dosimetry for SIRT is very appealing with a
number of large scale clinical trials currently underway. The
aim of this project was to develop an anthropomorphic phan-
tom that can be used for validating SIRT imaging in
multicentre clinical trials. Anatomical data was obtained from
a 24 second T1 weighted volume interpolated breath hold
examination (VIBE) on a Siemens Aera 1.5 T MRI scanner,
giving an in-plane pixel size of 0.7 mm and 2.8 mm contigu-
ous slices. The liver, lungs and abdominal trunk were segment-
ed using the Hermes image processing workstation. Organ
volumes were then uploaded to the Delft Visualization and
Image processing Development Environment for smoothing
and surface rendering. Triangular meshes defining the iso-
surfaces were saved as STL files and imported into the
Autodesk® meshmixer software, The organ volumes were
subtracted from the abdomen and a removable base designed
to allow access into the liver cavity. Connection points for
placing lesion inserts and filling holes were also added in the
design stage. A 50% scale model of the phantom was printed
using an Objet EDEN 300V 3D printer. The printer uses
stereolithography technology combined with ink jet printing.
A 16micron layer of liquid ultraviolet curable photopolymer is
printed and cured using an ultraviolet laser. This process is
repeated printing each layer of photopolymer on to the last
and curing with the laser. Final print material is an opaque
solid acrylic plastic, with reasonable tensile strength, low wa-
ter absorption and density similar to water (1.09g/cm3). Total
print time for the phantom was dependant on size, with the
scale model taking 27 hours and the full size torso estimated at
76 hours. Smaller tumour inserts, for placement inside the liver
cavity are printed with a transparent photopolymer and take
under 2 hours to print. Initial scans of the phantom have been
performed with Tc99m SPECT/CT, the organ shape showed
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good correspondence with anatomical references. After these
initial tests with the scale model a full size phantom will be
printed shortly.
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Application of a dual nuclear medicine protocol in patients
with urolithiasis.
V. Hadzhiyska1, T. Petrov1, I. Kostadinova1, V.
Marianovski2, B. Mladenov2, Y. Asenov3; 1University Hos-
pital Alexandrovska, Sofia, BULGARIA, 2University
Multiprofile Hospital for Active Treatment and Emergency
Medicine “N.I.Pirogov”, Sofia, BULGARIA, 3University
Hospital "Tsaritsa Yoanna", Sofia, BULGARIA.
The aim of this study was to apply a dual nuclear medicine
protocol, using dynamic renal scintigraphy (DRS) and single
photon emission tomography/computed tomography
(SPET/CT) and to determine its additional value in patients
with known or suspected urolithiasis. Subjects and methods:
We have examined 50 patients by dual nuclear medicine pro-
tocol, including dynamic renal scintigraphy (DRS) and single
photon emission tomography/computed tomography
(SPET/CT). Thirty of the patients had known urolithiasis,
while twenty were suspected for urolithiasis in the emergency
department. Results: By our dual protocol we detected patho-
logical findings in 78 (78%) of 100 investigated kidneys, while
by DRS alone in 53 (53%) and by SPET/CTalone in 36 (36%)
of them. The proposed dual imaging protocol have better re-
sults in the diagnosis of obstructive uropathy and in the eval-
uation of its functional impact on the renal parenchyma. The
estimated accuracy for the diagnosis of urolithiasis and the
obstructive uropathy was 96% and 92%, respectively. When
interpreting the obstructive uropathy we found a significant
correlation (R=0.612, p<0.00010) between the results, obtain-
ed by the DRS (drainage impairments) and those, obtained by
the CT-part of the imaging protocol (secondary signs of ob-
struction). However, the use of the combined imaging protocol
gave 35% change in the final interpretation (respectively in 27
out of 78 kidneys with detected pathological changes), com-
pared to DRS (27 %, in 21 kidneys) or to the low dose CT
alone (8%, in 6 kidneys).The most frequently encountered
functional and morphological findings in the kidneys with
calculous pyelonephrits were inhomogeneous and/or dimin-
ished fixation of the tracer (18 out of 26 kidneys - 69%),
reduced parenchymal thickness (8 out of 26 kidneys - 31%),
and irregular renal contours (9 out of 26 kidneys - 34%).
Impaired drainage function was detected by scintigraphy in
17 (85%) out of 20 patients with suspected renal colic. Sec-
ondary CT signs of obstruction in this patient group were re-
ported in 6 (60%) of the cases with total obstruction by scin-
tigraphy and in 2 (40%) of those with partial obstruction.
SPET procedure alone could be helpful for better visualization
and identification of a late accumulation of the tracer in the
collecting system and in some cases for recognizing the level
of the obstruction. Conclusion: The proposed dual nuclear
medicine protocol can be applied not only for establishing
the diagnosis of urolithiasis but also for determining its com-
plications even in patients from the emergency department.
P874
Extracellular volume (ECV) assessment by Cr-51-EDTA
plasma clearance and bioimpedance spectrometry (BIS) :
a comparison study
G. Arsos1, D. Katsampoukas1, C. Sachpekidis2, E. Manou3,
K. Lazaridis1, E. Mitsopoulos3; 13rd Dept of Nuclear Medi-
cine, Aristotle University of Thessaloniki Medical School,
Papageorgiou Hospital, Thessaloniki, GREECE, 2Clinical
Cooperation Unit Nuclear Medicine, German Cancer Re-
search Center, Heidelberg, GERMANY, 3Dept of Nephrology,
Papageorgiou Hospital, Thessaloniki, GREECE.
Aim : ECV measurement by exogenous tracer plasma clear-
ance kinetics during the bolus injection-multiple sample tech-
nique of glomerular filtration rate (GFR) measurement has
been recently reported. ECVmay be useful for both body fluid
balance assessment in a variety of clinical situations and for a
physiologically meaningful GFR indexation. Although ECV
values in health and disease have been reported using Cr-51-
EDTA as the tracer (ECV-Cr), validation against an
established ECV assessment method like bromide dilution is
lacking. Moreover, ECV-tracer values are influenced by the
molecular size of the tracer, the duration of the procedure
and the magnitude of the ECV itself. BIS, based on Hanai
mixture theory, is a simple, non-invasive, higly reproducible
method for ECVassessment (ECV-BIS), extensively validated
against and showing negligible bias and excellent precision
compared to bromide dilution. Hence, we aim to evaluate
ECV-Cr using ECV-BIS as the reference in a number of indi-
viduals submitted to GFR measurement for clinical purposes.
Subjects and methods : A total of 156 Caucasian adult patients
(33.3% F), aged 55.6±16.8 years, including 142 patients with
chronic kidney disease and 14 prospective kidney donors were
evaluated. GFR and ECVwere measured by bolus injection of
3.7MBq Cr-51-EDTA, 10 plasma samples at 5, 10, 15, 30, 45,
60, 90, 120, 180 and 240 min p.i. and tracer plasma kinetics
data analysis. ECV-Cr was expressed in l and GFR, after nor-
malization by body surface area (GFRn), in ml/min/1.73 m2.
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ECV-BIS (in l) was also assessed by four-electrode
multifreequency impedance measurement using a Body Com-
position Monitor (Fresenius Medical Care). Proper statistics
were applied for the between-variable differences and correla-
tions assessment. Agreement between ECV-Cr and ECV-BIS
was assessed by Blant-Altman statistics. Results : ECV-BIS
and ECV-Cr were (mean±SD, 17.7±3.2 vs 15.7±3.2 l respec-
tively, p<0.05), significantly different and their correlation was
moderate (r = 0.737, p<0.001). The difference ECV-BIS -
ECV-Cr (DECV) was 2.0±2.3 l with a 95% confidence inter-
val of -2.6 - 6.6 l. DECV was correlated positively with ECV-
BIS (r=0.366, p<0.001) and negatively with ECV-Cr (r=-
0.359, p<0.001). DECV was not correlated with GFRn
(r=0.06, p=0.481). Conclusions : ECV determined by Cr-51-
EDTA plasma kinetic analysis during radionuclide GFR mea-
surement does not reliably represents true ECV because it
significantly underestimates the later. Predictably, the under-
estimation is higher as true ECV increases. The present find-
ings question the validity of ECV-Cr for both the clinical as-
sessment of the body fluid balance and the GFR indexing.
P875
Extracellular volume (ECV) may not represent a major
improvement in glomerular filtration rate (GFR)
normalization compared to body surface area (BSA)
G. Arsos1, C. Sachpekidis2, D. Katsampoukas1, E. Manou3,
K. Lazaridis1, E. Mitsopoulos3; 13rd Dept of Nuclear Medi-
cine, Aristotle University of Thessaloniki Medical School,
Papageorgiou Hospital, THESSALONIKI, GREECE, 2Clini-
cal Cooperation Unit Nuclear Medicine, German Cancer Re-
search Center, Heidelberg, GERMANY, 3Dept of Nephrology,
Papageorgiou Hospital, THESSALONIKI, GREECE.
Aim : GFR normalisation remains an open issue with consid-
erable criticism exerted on the traditional but unreasonable
GFR indexation by BSA (GFR/BSA). Given the central role
of kidneys in body fluid balance, ECV and total body water
(TBW) have been proposed as more suitable “physiological”
indexes for GFR normalisation compared to BSA, lacking
substantial supporting evidence however. ECV derivation
from exogenous tracer plasma clearance kinetics (PCK) during
bolus injection-multiple sample techniques of GFR measure-
ment (ECV-Cr) has been recently shown but not validated
against bromide dilution, the established reference.
Bioimpedance spectroscopy (BIS), a convenient, non-
invasive method for both ECV (ECV-BIS) and TBW (TBW-
BIS) assessment, is successfully validated against bromide and
deuterised water dilution methods respectively. In order to test
for additional value of GFR indexing by parameters beyond
BSA, we first explored the correlations between BSA and
TBW-BIS, ECV-Cr and ECV-BIS and then between GFR/
BSA and GFR normalized by TBW-BIS, ECV-Cr and ECV-
BIS (GFR/TBW-BIS, GFR/ECV-Cr and GFR/ECV-BIS re-
spectively) in a number of individuals submitted to GFR mea-
surement for clinical purposes. Subjects and methods : One
hundred fifty-six Caucasian adult individuals (33.3% F), aged
55.6±16.8 years including 142 patients with chronic kidney
disease and 14 prospective kidney donors were evaluated.
GFR and ECV were measured by bolus injection of
3.7 MBq Cr-51-EDTA, 10 plasma samples at 5, 10, 15, 30,
45, 60, 90, 120, 180 and 240 min p.i. and PCK analysis. BSA
was calculated according to Haycock formula. ECV-Cr was
expressed in l and GFR, after normalization by BSA (GFRn),
in ml/min/1.73 m2. ECV-BIS and TBW-BIS (both in l) were
also assessed by four-electrode multifreequency impedance
measurement using a Body Composition Monitor (Fresenius
Medical Care). Between-variable correlations were assessed
by linear regression analysis. Results : TBW-BIS, ECV-Cr,
ECV-BIS were (mean±SD) 38.1±7.9, 15.7±3.2, 17.7±3.2 l re-
spectively. BSA was moderately correlated with ECV-Cr (r
0.617, p<0.001) and well with TBW-BIS and ECW-BIS (r
0.824 and 0.879 respectively, p<0.0001 for both). GFR/BSA
was strongly correlated with all of the GFR/ECV-Cr, GFR/
TBW-BIS and GFR/ECV-BIS (r 0.930, 0,917 and 0.977 re-
spectively, p<0.0001 for all). Conclusions : GFR normalised
by body fluid volumes derived either during GFR measure-
ment (ECV-Cr) or by BIS (TBW-BIS, ECV-BIS) are closely
correlated with BSA normalised GFR values, body size being
the probable link connecting BSA and body fluid volumes.
Our findings question the additional utility of ECV or TBW
as GFR indexing parameters in a clinical setting.
P876
Diuretic Renography in Seated Position F+10(sp)
for Post-Emergency Clinical Management
in PerCutaneous Nephrostomy.
G. Tartaglione1, M. Vittori2, A. Cina3, M. Pagan1, A.
D'Addessi2, P. F. Bassi2; 1Nuclear Medicine, Cristo Re Hos-
pital, Rome, ITALY, 2Urology, Catholic University of the Sa-
cred Heart, Rome, ITALY, 3Radiology, Catholic University of
the Sacred Heart, Rome, ITALY.
Aim: PerCutaneous Nephrostomy (PCN) is an emergency pro-
cedure to relieve an obstructed or infected collecting renal
system. A catheter perforates the skin and terminates in the
renal pelvis providing a temporary drainage. Before planning
surgery, it is recommended to evaluate renal function and
drainage. In order to test function and drainage, we performed
a diuresis renography, with PCN clamped, in a seated position
using the procedure F+10(sp). Material and Methods: We en-
rolled 51 consecutive Patients (26 m, 25 f. with a PCN. 7 pts
had a bilateral PCN. A total of 58 renal units with PCN were
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studied. The test was deferred for 3-4 weeks after positioning
PCN, to enable the urinary system to decompress. Renograms
were performed in posterior view, using a dual detector system
with rectangular large view (Infinia II-Xeleris, GE), with a
single-head flexibility allowing scan in seated position. After
consulting with a urologist the PCN was clamped during the
study. A dose of 99mTc-MAG3, 150 MBq was injected using
a 22G peripheral IV catheter with injection port. A 20-min
dynamic phase was acquired, 60 frames x 2” and 108 frames
x10”, ,128x128 matrix, zoom 1. At 5th min after tracer injec-
tion, the pt drank 400-500 mL of water. A dose of 20 mg of
Furosemide was injected IV at 10th min, during dynamic ac-
quisition, using procedure F+10(sp). Later images at 20’-60’
were acquired post voiding. The clamp was removed at end of
study, or during the test in the event of obstruction signs or
symptoms. The serum Creatinine levels were ranging from
0.68 to 4.12 mg/dL. Results: 28 kidneys with PCN clamped
had a complete obstruction, 7 kidneys had a partial obstruction
(ratio 20min/peak >0.25), 10 kidneys had a normal drainage
(Tmax< 6mins; ratio 20min/peak <0.25), 12 kidneys showed a
poorly function (split renal function <10%), 1 kidney had a
complete failure. Conclusion: Due to the gravity effect, the test
F+10(sp) in seated position may allow a better discrimination
between obstruction and a normal drainage, reducing equivo-
cal results. Diuretic renography is well tolerated also in pts
with Creatinine level >2 mg/dL.This test may be an useful
alternative to antegrade or retrograde pyelography before plan-
ning surgery in PCN kidney, especially in patients at risk of
infection or contrast allergy.
P877
A new quantitative index for baseline renal transplant
scintigraphy with Tc-99m DTPA in evaluation of delayed
graft function and prediction of 1-year graft function
B. Yazici1, A. Oral1, C. Gokalp2, A. Akgün1, H. Toz2; 1Ege
University Medical Faculty Department of Nuclear Medicine,
Izmir, TURKEY, 2Ege University Medical Faculty Depart-
ment of Internal Medicine Division of Nephrology, Izmir,
TURKEY.
Aim: The aim of this study was to assess the value of a single
renal transplant scintigraphy (RTS) with Tc-99m DTPA per-
formed in the first two days after transplantation for evaluation
of delayed graft function (DGF) and prediction of 1-year graft
function. Quantitative indices were compared between each
other and a new index for baseline RTS was described.Mate-
rials andMethods: A total of 165 patients to whom RTS with
Tc-99m DTPAwas performed within 2-days after transplanta-
tion were analyzed retrospectively. Hilson’s perfusion index
(HI), time between peak perfusion of graft and iliac artery
(ΔP), peak-to-plateau ratio (P:Pl), ratio of peak graft perfusion
to peak iliac artery (P:A), T½ of perfusion curve downslope
(GW½), peak perfusion to peak uptake ratio (P:U), ratio of
peak perfusion to uptake at 3 minutes (P:U3) and ratio of up-
take at 20 to 3 minutes (R20/3) were obtained. In addition, we
first described the following formula called as Graft Index (GI)
or Yazici’s index (YI) for assessment of graft function:
GI=(ΔPxAxPl)/(PxU3). A sCr of >1.5 mg/dl at 1-year fol-
low-up was considered to be abnormal. Mann-Whitney U,
Spearman’s coefficient of correlation tests and receiver-
operating characteristic (ROC) curve analysis were used for
statistical analysis. P<0.05 was accepted significant. Sensitiv-
ity, specificity and predictive values of the tests were calculat-
ed. Results: Mean values of the all indices were significant
between the patients with and without needing dialysis and the
patients with 1-year sCr of >1.5 and ≤1.5 mg/dl. Among the all
indices, GI had the strongest correlation (r=0.67) with 1-week
sCr and only GI and P:A had a correlation coefficient of ≥0.40
or ≤-0.40 (r=0.40 for GI, r=-0.42 for P:A) with 1-year sCr.
Using the ROC curve analysis, the most accurate index for
both evaluation of DGF and prediction of 1-year graft function
was GI. Area under the curve (AUC) for GI was 0.94 in eval-
uating DGF and 0.79 in predicting 1-year graft function. Ad-
ditionally, the most sensitive and specific index was also GI
not only for DGF (sensitivity of 86.1%, specificity of 86.2%)
but also for prediction of 1-year graft function (sensitivity of
74.1%, specificity of 76.0%).Conclusion: Several methods of
quantifying RTS have been suggested. The question is which
index is the best indicator. This study demonstrated that the
parameters of baseline RTS should be assessed together by the
formula of GI which provides more accurate information to
diagnose DGF and predict 1-year graft function.
P878
Correction of Differential Renal Function for Asymmetric
Renal Area Ratio in Unilateral Hydronephrosis
G. Ege Aktas, A. Sarikaya; Trakya University Medical Fac-
ulty Department of Nuclear Medicine, Edirne, TURKEY.
Objective: Children with unilateral hydronephrosis are follow-
ed up with anterior posterior pelvic diameter (APD),
hydronephrosis grade, MAG-3 drainage pattern and differen-
tial renal function (DRF). İndeterminate drainage, preserved
DRF in higher grade of hydroneprosis, in some situations
complicates the decision making proses. False negative DRF
estimations, due to asymmetric renal area ratio, can cause
missing optimal surgery timing. This study was designed to
assess whether correcting the DRF estimation according to
kidney area could reflect the clinical situation of
hydronephrotic kidney better than classical DRF calculation;
concurrently with hydronephrosis grade, APD and MAG-3
drainage pattern. Material & methods: We reviewed MAG-3,
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DMSA scans and ultrasonography (US) of 23 children (6 girls,
17 boys, mean age: 29±50 months) with unilateral
hydronephrosis. MAG-3 and DMSA scans were performed
within 3 months (mean 25.4±30.7 days). Closest US (mean
41.5±28.2 days) findings were used in evaluation. DMSA
DRF estimations were obtained using geometric mean meth-
od. Second calculation was done correcting the counts (total
counts divided by the number of pixels in ROI) according to
kidney area. Renogram patterns of patients were evaluated
retrospectively and separated into four subgroups. Visual as-
sessment of DMSA scan was also noted and the
hydronephrotic kidney was classified (compared to the normal
contralateral kidney’s uptake) as normal, slightly decreased
and decreased. Correlations of DRF values of classical and
area corrected methods withMAG-3 renogram patterns, visual
classification of DMSA scan, hydronephrosis grade and APD
were assessed. Results: DRF estimations of two methods were
statistically different (p: 0.001). 11 hydronephrotic kidney
changed category. There were no correlations between classi-
cal DRF estimations and hydronephrosis grade, APD, MAG-3
drainage patterns, visual DMSA uptake evaluation. DRF esti-
mations with corrected method correlated with all: With the
increasing hydronephrosis grade and APD, DRF estimations
were decreasing, MAG-3 drainage patterns were worsening (c:
-.649, -.675, -.745, -.873, p: 0.001, 0.001, 0.001, 0.001 respec-
tively). Decrease in DRF (<45%) was determined when APD
was ≥10 mm. When APD was ≥26 mm, reduction of DRF
below 40% was determined. Conclussion: We found a good
correlation between area corrected DRF estimations and wide-
ly accepted clinical parameters that are taken into consider-
ation in follow up of persistent hydronephrosis. Our results
suggest that, correcting DRF estimation for asymmetric renal
area ratio in unilateral hydronephrosis can be more robust than
classical DRF estimations, in defining the clinical situation of
the kidney; especially in higher grades of hydronephrotic kid-
neys, under equivocal circumstances
P879
The evaluation of inter- and intraobserver variability
of 99mTc-Dimercaptosuccinic acid SPECT renal
scintigraphy
U. Can, G. DURMUS ALTUN; Trakya University Medical
Faculty, Edirne, TURKEY.
99mTc-Dimercaptosuccinic acid (DMSA) scintigraphy is a
frequently used diagnostic test to assess the presence and se-
verity of cortical damage. The aim of this study is to investi-
gate the variability in the interpretation of 99mTc-DMSA
SPECT scans by using of the standart criterions. The study
consisted 106 patients amog 4-81 years old (the mean age:
30±21 years). After 2-6 hours later from the injection of
99mTc-DMSA, in addition to the standart planar projection
posterior 180 degrees SPECT imaging were obtained simulta-
neously using a dual head camera. Two experienced nuclear
medicine physicians independently interpreted 106 DMSA
scans (206 kidneys). While first observer was evaluating the
only SPECT images,during his fist and second readings, and
evaluating SPECT and planar images together in his third
reading, the second observer evaluated only the SPECT im-
ages. In the calculation of the agreement rates, the analysis of
kappa statistics (к), Spearmann correlation (rs) and Kendall
corrrelation (rk tau-b) and total agreement rates (%) were used.
In the localization of the kidneys, the place of the prevalent
lesions with the contour disorder and the evaluation of the
defect severity, it was found that there are agreements among
all three agreements highly and about excellent. Highly agree-
ment rates in the spheric lesions place and in the evaluation of
defect severity were obtained. In the evaluation of the 54
agreement in the normal, scar, inflammation in commentary/
interpretation, in the variability of intra-oberserver, highly
agreement (right rs=0.767, 72,7%; left rs=0.664, 55,6%) was
found. As a result, the SPECT imaging can be used alonly and
trustly in the finding of the place of the kidneys, in the exis-
tence of the contour disorder, in the place of the prevalent
lesions and in the evaluation of the defect severity. Each ob-
server, as general impression, states that only SPECT images
can not be enough for certain diagnosis in the evalution of the
kidneys as normal, scar/inflammation/scar+inflammation and
states that they should be evluated with their planar images.
P880
Clinical Value of Cystatin C and Beta-trace Protein
in Glomerular Filtration Rate in Chronic Renal Disease
Adult Cases With Different Degree Renal Function
Disorder: Comparison by The 99mTc-DTPA Plasma
Sample Method
F. AYDIN, E. Surer BUDAK, S. DEMIRELLI, A. ONER, G.
SULEYMANLAR, H. AKBAS, F. DAVRAN, S. BOZKURT,
F. GUNGOR; Akdeniz University, Antalya, TURKEY.
Glomerular filtration rate (GFR) is the best indicator of the
renal function. Gold standard for GFR measurement is inulin
clearance (Cin). However, its measurement is inconvenient,
time-consuming, and non-economic. Thus, in both scientific
studies and routine clinical practice Nuclear Medicine
methods (99mTc DTPA, 51Cr EDTA) are preferred, which
are highly correlated with Cin. In addition, recently cystatin
C (Cys) and beta trace protein (BTP) are also used for this
purpose. In literature, however, data are limited about the clin-
ical value of Cys and BTP in GFRmeasurement in CKD cases
and the results have been inconclusive. In this study, we aimed
to determine the efficiency of Cys and BTP in determination of
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GFR in CKD patients. A total of 84 (59 males, 25 females)
CKD patients aged 21 to 88 years (mean 61 years) were in-
cluded criteria. GFR was calculated with three different
methods: 1) using the gold standard DTPA two plasma sample
method (TPSM); 2) using formula containing Cys to calculate
GFR ; 3) using formula containing BTP. Correlation of GFR
values calculated with Cys and BTP with that obtained with
DTPA TPSM was assessed. GFRs calculated with both
methods were significantly correlated with that calculated with
gold standard method. However, GFR values obtained with
Cys had a better correlation com-pared to those of BTP. Using
Bland Altman analysis, scatter graphics of the differences be-
tween GFR values calculated using DTPA TPSM and those
calculated with Cys, BTP at a confidence interval of 95%
(mean ± 1.96SD). The GFR values obtained with Cys and
BTP did not have reliable consistency. As a conclusion, we
showed that GFR values calculatedwith Cys and BTP failed to
show GFR of the CKD. Based on these results, our study
demonstrated that Cys and BTP is not sufficient in reflecting
GFR.
P881
“Hot Kidney” Artifact on Bone Scan: Incidence
and Approach to Quantification
A. K. Kondakov1, D. S. Kharina1,2, E. A. Servuli1,2, I. A.
Znamenskiy2,1; 1Pirogov RNRMU, Moscow, RUSSIAN
FEDERATION, 2CCH RAS, Moscow, RUSSIAN
FEDERATION.
Aim. It is well known that intense renal hyperfixation, or “hot
kidney” artifact, appears in 0.5 - 2% of bone scintigraphy,
though cause of this phenomenon is not clear. Hypercalcemia,
acute kidney injury and chemotherapy are main predisposing
factors of this condition. Aim of this study is to analyze inci-
dence of the “hot kidney” artifact and propose the method of
its quantification. Materials and methods. 1080 bone scans of
adult patients (1 : 1.02 male-to female ratio) were retrospec-
tively analyzed. All patients underwent whole-body bone scin-
tigraphy in 2.5 - 3 hours after intravenous injection of 99mTc-
pyrophosphate (53%), 99mTc-EDTMP (42%) or 99mTc-
zoledronic acid (5%). In order to quantify severity of artifact,
kidney-to-lumbar index (KLI) was determined as ratio be-
tween counts in equal regions of interest (ROIs) above kidney
and lumbar spine on posterior views. There were three degrees
of “hot kidney” severity: mild (1<=KLI<1.5), moderate
(1.5<=KLI<=2) and severe (KLI more then 2), while KLI<1
was treated as absence of artifact. Results. Analysis revealed
15 cases of “hot kidney” artifact that corresponds to incidence
about 1.4%. Most of cases (11 cases, 73%) were mild, two
cases were moderate (13.5%) and two cases were severe
(13.5%). In cases of severe “hot kidney” artifact, there was
virtually no bone uptake of bone-seeking radiopharmaceutical.
Both cases were performed with 99mTc-pyrophosphate. Re-
peated bone scans with 99mTc-zoledronic acid 5 days later
showed increase in bone accumulation (KLI<1 in first case,
KLI=1.6 in second). In first case (male, 58 years old), medical
history was unremarkable, except prostatectomy for a prostate
cancer. In the second case (male, 69 years old, prostate cancer)
there was found that patient underwent MDCT with intrave-
nous contrast a day before first scan, so it was suggested, that
contrast-induced nephropathy (a form of acute kidney injury)
was primary cause of artifact. Conclusion. “Hot kidney” ap-
pearance is relatively common artifact that affects about 1.4%
of bone scans. Mild and moderate forms, defined by kidney-
to-lumbar index, are prevalent and usually have little influence
on interpretation. Severe form of artifact complicates the inter-
pretation of bone scan results and it may be necessary to repeat
bone scan few days later. If possible, contrast radiographic
studies should be avoided before bone scintigraphy in order
to prevent contrast-induced nephropathy. Radioactive tracer
distribution should be studied for all forms of increased renal
parenchymal uptake for correct effective dose estimation in
patients.
P883
Diagnostic and Prediction Accuracy of GFR Prediction
Equations in Comparison with 51Cr-EDTA
V. Ptacnik, J. Kubinyi, H. Jiskrova, D. Skibova, R. Rysava, V.
Tesar, M. Samal; Charles University Prague, Prague, CZECH
REPUBLIC.
Prediction of glomerular filtration rate (GFR) by regression
equations from the patient serum creatinine and anthropomet-
ric data is simple, cheap but inaccurate. Measurement of GFR
by 51Cr-EDTA, 99mTc-DTPA, or iohexol is accurate but
more costly and not readilly available. The aim of our study
was to compare diagnostic and prediction accuracy of GFR
prediction equations and 51Cr-EDTA. Methods: In 49 adult
patients with creatinine clearance (CC) 3 - 153 ml/min/
1.73m2, serum creatinine level (SC) and EDTA clearance
were measured with 1 day median interval between laboratory
and radionuclide examinations. Reference EDTA GFR was
calculated from 2 blood samples obtained 2 and 4 hrs post-
injection. Mean absolute (MAE) and relative (MRE) errors of
predicting reference GFR were calculated for single-sample
EDTA (4 hrs), reciprocal SC, CC, and several prediction equa-
tions (Cockcroft-Gault, MDRD, CKD-EPI, Lund-Malmö,
Mayo). Diagnostic accuracy of identifying the patients with
GFR<30 and GFR<60 ml/min was assessed by ROC curves.
Results: In the range of GFR<30 ml/min, MAE (~3.6 ml/min)
andMRE (~23%) of prediction equations were similar to those
of CC and reciprocal SC while the error of single-sample
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EDTAwas greater (5 ml/min, 34%). In the range of GFR≥30ml,
the lowest error was found with single-sample EDTA (2.4 ml/
min, 5%); CC reflected reference GFR with error 9 ml/min or
16%, prediction equations 14-17 ml/min or 23-28%, and recip-
rocal SC 19 ml/min or 31%. In population with high prevalence,
prediction equations identified the patients with GFR<30ml/min
with diagnostic accuracy 93-95%, in comparison with 95%
using CC, 92% using reciprocal SC, and 99% using single-
sample EDTA. Patients with GFR<60 ml/min were identified
with diagnostic accuracy 97-100% by all methods. Conclusion:
In agreement with previous reports, prediction equations per-
formed best in the range of lower GFR values (but not better
than CC and only slightly better than reciprocal SC). Despite
large prediction errors in the range of GFR≥30 ml/min, predic-
tion equations identified the patients with GFR<30 and GFR<60
ml/min with good diagnostic accuracy comparable with that of
CC and EDTA. Except Mayo-clinic equation with lower accu-
racy, no significant differences were found between respective
prediction equations. Diagnostic accuracy of prediction equa-
tions is sufficient to identify the patients with GFR below certain
level. However, they should not be used to assess quantitative
changes in GFR and wherever accurate GFR value is required to
assess true renal function. In the latter applications, measurement
with radionuclides or iohexol remains standard.
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Recombinant Human Thyrotropin Stimulation
Before 131I Therapy in Toxic Multinodular Goiter
with Low Radioactive Iodine Uptake
M. Azorín-Belda, A. Martínez-Caballero, G. C. Figueroa-
Ardila, C. A. Gómez-Jaramillo, J. Verdú-Rico, J. I. Dolado-
Ardid, M. Antón-Leal, M. Martínez-Ramírez; Hospital
Universitario San Juan de Alicante, Alicante, SPAIN.
AIM: To evaluate the efficacy of recombinant human thyro-
tropin (rhTSH) stimulation prior to 131I therapy in patients
with a large toxic multinodular goiter and low radioiodine
uptake. We have studied its effect on hyperthyroidism and
thyroid volume reduction. MATERIALS AND METHODS:
In a prospective trial from March-2012 through July-2014, 32
patients (26 women) with a goiter bigger than 50 g, radioactive
iodine uptake (RAIU) at 24 hours <18% and surgery excluded,
were treated with 800 MBq of 131I. 16 patients received a
single 0,3 mg dose of rhTSH 24 hours before (Group I), and
16 patients were treated without stimulation (Group II). The
follow-up period was 9 months and included evaluation of
thyroid size reduction by scintigraphy, clinical assessment of
compression complaints and serum TSH and FT4 levels.
Complete response was considered when there was compres-
sive clinical improvement and cure of hyperthyroidism, partial
response if only improved one of the two factors and null if no
response was observed. RESULTS: There were no statistically
significant differences between the 2 groups for age, sex, goi-
ter volume, RAIU at 24 hours and estimated absorbed dose. At
9 month, size reduction in group I was 36,6 ± 13,2% vs 28,3 ±
20,6% in group II (p<0,05). In group I 92,3% of patients
showed compressive clinical improvement vs 63,6% in group
II (p<0,05). Regarding hyperthyroidism, a cure of 93,8% and
68,8% was observed respectively in groups I and II (p<0,
05).Full response was observed in 14/16 patients (87,5%) in
group I and 9/16 (56,3%) in group II, partial response in 2/16
(12,5%) in group I and 4/16 (25%) in group II and null re-
sponse 3/16 (18,8%) in group II (p<0,05). CONCLUSION: In
patients with toxic multinodular goiter and low RAIU, rhTSH
stimulation prior to radioiodine therapy achieved functional
and clinical improvement, representing a treatment option in
patients who previously would have been discarded.
P885
Correlation between auotimmunthyroid diseases
and Vitamin D deficiency in a German population
C. Körber, N. Körber-Hafner; Nuclear Medicine Fulda, Ful-
da, GERMANY.
AIM OF STUDY: Vitamin D deficiency is considered to be a
predictor for chronic diseases (1). Here the correlation to thy-
roid autoimmune disorders should be evaluated.METHOD: In
blood samples of 880 patients with autoimmune thyroid dis-
eases we measured TSH-level (BRAHMS Hennigsdorf, TSH
1), parathyroid hormone levels (IBL, parathyroid hormone
total intact IRMA) and 25-hydroxyvitamin-D (IBL, 25 OH-
Vit D3-RIA CT). These data were correlated to gender, age,
thyroid volume diagnosed by ultrasound (ESAOTE my lab
seven), thyroid hormone, thyroid medication and the influence
of these parameters according to the level of D3 was statisti-
cally analysed. Also TPO-levels (each BRAHMS, anti TPOn
), TRAK (TRAK human ) and fT4-levels (FT4 RIA ) were
correlated. Patients under Vitamin D medication werde ex-
cluded. Statistical analyses were conducted with Statistica
10.0 (StatSoft). Two-tailed P values of less than 0,05 were
considered to indicate statistical significance using student t-
test and multiple regression analysis. Hashimoto thyreoiditis
(H) andGraves disease (GD)were analysed as different patient
groups. RESULTS: 790 females and 90 males each younger
than 35 years participated in the study. The age of the patients
was 31,5±4,2 (mean ±SE) years, TSH-level (H) 2,1±3,5 (GD
under antithyroid medication) 1,3±2,5, parathyroid hormone
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concentration 27,1±16,7 pg/ml (normal range 10-57), 25-
hydroxyvitamin- D 17,8±11,8 ng per ml (normal range 8 -
60). The statistical analysis revealed a very high significane
for the study population between vitamin D and parathyroid
hormone level (p<0,001) in the student t-test, often seen in
vitamin D deficiency. The table shows the significance levels
of the parameters in the multiple regression analysis, the tests
itself reached the significance level with H p< 0,03 and GD
p<0,0059. DISCUSSION: In both diseases the Vitamin D con-
centration was influenced significantly by only few parameter.
Thus a significant influence of Viatmin D deficiency on the
disease development and progession can be excluded. Litera-
ture: Table of Contents (1) Bioavailability of Vitamin D and Its
Metabolites in Black and White Adults (1) Bioavailability of
Vitamin D and Its Metabolites in Black and White Adults
Michael F. Holick, M.D., Ph.D. N Engl J Med 2013;
369:2047-2048November 21, 2013DOI: 10.1056/
NEJMe1312291
P886
Comparison of planar and tomographic methods
for calculating thyroid volumes in cats and dogs
R. P. Jóba1, G. Dabasi1, A. Polyák2, Z. Pöstényi2, J.
Thuroczy3, K. Bús1, L. Jorgov1, L. Balogh2; 1Dept. of Nu-
clear Medicine, Semmelweis University, Budapest, HUNGA-
RY, 2National “F.J.C.” Research Institute for Radiobiology
and Radiohygiene (NRIRR), Budapest, HUNGARY, 3Veteri-
nary Faculty, Szent Istvan University, Budapest, HUNGARY.
Aim: Our aim was to compare several well established planar,
and three dimensional SPECT methods for calculating thyroid
volumes in cats and dogs. In addition we goaled to adopt the
human volumetric procedures to be more accurate in
therapeutc 131-iodine dose applications for feline and canine
thyroid patients. Materials And Methods: More than twenty
animals, referred feline and canine thyroid patients were sent
for SPECT/CT examination from the early of december 2011.
The suspected cases were uni- and bilateral hyperthyroidisms,
benign and malignant thyroid tumors (adenomas and carcino-
mas). The intravenously applied radiopharmaceuticals were
99mTc-pertechnetate and 131I-iodine both 15 MBq/bwkgs.
Data collection was carried-out in intravenous anaesthesia
within 8-14 minutes per case in planar images, we calculated
the thyroid volumen using some different standard methods
from the human diagnostic: A: [(π/6) × L × H × W], B: [(π /
2)× L ×W2], C: [0.33 × (area cm2)3/2], D: [1.08 × (π /6) × L ×
W2], E: (area × H), F: (0.27 × area × L), G: (π × L × W2) and
H: [π × (4/3) ×W3]. In SPECT images we selected the thyroid
volumens with the help of automatic isocount VOIs.We used
diagnostic dose CT images as a gold standard. CT measure-
ments were made by selecting the thyroid VOI manually on
each slices. Results: Compared to the golden standard CT
volumetric data the only SPECTmethod proved to be the most
similar. Planar method ”D” resulted also non-significant alter-
ations from the golden standard and SPECT method while
data from planar methods ”A” and ”B” slightly differ and
methods ”C, E, F, G and H” provide significatly differing data
from CT volumes.Conclusion: Based on our preliminary data
SPECT/CT thyroid calculations seems to be the most accurate
volumetric estimation however planar method ”D” might be
also applicable especially when hybrid instrumentation is not
available. Authors believe that SPECT/CT thyroid imaging
and volumetric estimation methods will be also applied into
veterinary diagnostics within soon.
P887
Detection of papillary carcinoma in patients with chronic
nodular autoimmunothyroiditis
K. Zaplatnikov1, V. Soukhov2; 1MAZ Clinic for Nuclear
Medicine, Nürnberg, GERMANY, 2Military Medical Acade-
my, ST. PETERSBURG, RUSSIAN FEDERATION.
OBJECTIVE: Multinodulary goiter as a consequence of auto-
immune immunothyroiditis (AIT) Hashimoto type (HT) often
associated with autonomous thyroid nodules (ATNs). Unfor-
tunately it is not fully examined at a time and we have no even
background understanding. Increased thyroid dysfunction in
regions with low iodine supply and additional radiation expo-
sure (eg., North Kazahstan Nuclear-weapon-tests region) led
to increased incidence of AIT, papillary carcinoma (PC) and
ATNs. This study exploited multimodal approach as combina-
tion of nuclear medicine data and laboratory characteristics of
AITand ATNs. MATERIALS ANDMETHODS: 411 patients
- immigrants from North Kazakhstan that were lived in Ger-
many between 2005 and 2013, with US-diagnosed goiter and
thyroid nodules, and RIA-evidenced AIT, underwent full in-
vitro examination, US with Doppler and scintigraphy. AIT
patients with coexisting suspicious hypo functional nodes goi-
ter was evaluated by FAB or histologically and verified (39 pts
- Gr. A), pts with ATN and AIT (Gr. B, 23 pts) were compared
with patients with group ATNs alone (group C, n=112) and
typical AITonly (Gr. D - 237 pts). RESULTS: From the whole
cohort of 411 patients 17 (11/6 F:M ratio; age 43±15 yrs) had
multifocal papillary carcinoma (PC) and coexisting AIT HT,
remaining in euthyreo/hypothyreosis state wiyh levels of TSH
1,0-12,00EU and TU 0,3-3,2%. There were only 6 PC patients
in Gr. B with suppressed TSH (<0.01 mU/L) and typical
scintgraphic signs of AIT. Hyperthyroidism/or subclinical hy-
perthyroidism signs not considered as AIT evidence were no-
ticed in 37 pts of Gr. C. There were no histological confirma-
tion of PC in any pts in Grs C and D. In group A there was shift
to subclinical hyperthyroidism (76 vs. 24%), opposite to group
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B (56 vs. 44%) ( P=0.005). Maximal diameter of the ATNs
was down to 8% smaller in group A as compared with group
B. A positive correlation between nodule size and age was
found only in group B (P=0.015). RESUME: Besides of very
small difference in the size of nodules (non-statistic
significance between groups A and B) chronic thyroid lym-
phocytic infiltration in presence of HT AIT may decrease the
growth tendency of ATNs and reduce their functionality.
P888
Factors Influencing the Length of Remission Period
in Patients with Graves' Disease
D. Šfiligoj1, S. Gaberšček1, P. Jaki Mekjavič2, K. Zaletel1, E.
Pirnat1; 1University Medical Centre Ljubljana, Department of
Nuclear Medicine, Ljubljana, SLOVENIA, 2University Med-
ical Centre Ljubljana, Eye Hospital, Ljubljana, SLOVENIA.
AIM. Most patients with Graves' disease (GD) are initially
treated with antithyroid drugs (ATD). In case of prolonged or
recurrent disease, a definite treatment with radioiodine (RAI)
usually follows. The reported relapse rate after the cessation of
treatment with ATD is 51-68%. The aim of our study was to
evaluate factors influencing the length of remission period in
patients with GD, previously treated with ATD. MATERIALS
AND METHODS. We reviewed medical records of 724 pa-
tients, first diagnosed with GD between 2005 and 2009, and
later on treated with RAI. Patients failing to achieve remission
during treatment with ATD were not included in the analysis.
Patients with a period of GD remission after the cessation of
ATD were empirically divided into two groups. Group 1 in-
cluded patients in whom remission period lasted for 6 months
or less and Group 2 included patients in whom remission pe-
riod lasted for more than 6 months. RESULTS. We included
261 patients, 212 females and 49 males. In Group 1 we
established 147/261 patients (56.3%) and in Group 2 114/
261 patients (43.7%). With respect to age, patients in Group
1 were significantly older than in Group 2 (46.1±15.1 years,
range 18-85 years and 41.0±13.1 years, range 18-75 years,
respectively, p=0.003). Patients in Group 1 were initially treat-
ed with ATD for a significantly longer period of time than
patients in Group 2 (12.0±3.7 months and 11.1±2.9 months,
respectively, p=0.021), and had a larger thyroid volume at the
onset of GD (20.5±11.9 mL and 17.2±9.6 mL, respectively,
p=0.036). Regarding the level of thyroid hormones at the onset
of GD, patients in Group 1 had significantly higher levels of
free thyroxine (fT4) (57.0±26.6 pmol/L and 49.8±23.2
pmol/L, respectively, p=0.029) and free triiodothyronine
(fT3) (22.0±8.0 pmol/L and 19.4±8.1 pmol/L, respectively,
p=0.011), while the initial fT4/fT3 ratio did not differ between
the two groups (p=0.430). Patients in Group 1 also had signif-
icantly higher levels of TSH receptor antibodies than patients
in Group 2 (13.9±11.3 U/L and 9.5±7.0 U/L, respectively,
p=0.005). CONCLUSION. Patients with the shorter remission
period after the cessation of treatment with ATD were older,
they have been initially treated with ATD for a longer period of
time, had a larger thyroid volume, they were more severly
hyperthyroid, and had higher levels of TSH receptor antibod-
ies at the onset of GD as compared to patients with the longer
remission period.
P889
Late single uptake measurement for accurate absorbed
dose calculations in I-131 treatments of hyperthyroidism
K. S. Andreasson1, J. Svensson2,3, F. Henriksson2,3, P.
Bernhardt4,3; 1Sahlgrenska University Hospital, Departments
of Medical Physics & Biomedical Engineering, Gothenburg,
SWEDEN, 2Sahlgrenska University Hospital, Department of
Oncology, Gothenburg, SWEDEN, 3The Sahlgrenska Acade-
my, University of Gothenburg, Gothenburg, SWEDEN,
4Sahlgrenska University Hospital, Department of Radiation
Physics, Gothenburg, SWEDEN.
The administrated activity in I-131 treatment of hyperthyroid-
ism is often based on individual dosimetry, where the estimat-
ed biologic half-life is calculated from two or more uptake
measurements of a given test activity. However, from patient
data a relationship between the measurement time (t) and the
product of initial uptake and effective half times could be used
for determine a linear coefficient (kt), sufficient for estimation
of the absorbed dose by a single uptake measurement (Jönsson
and Mattsson, 2003). This method seems to be reliable for one
late uptake measurement, but more data are needed to confirm
this statement. The aim of this study was to evaluate the pre-
cision of the single uptake measurement method. Method:
This retrospective study is based on 300 patients with Graves’
disease (n=100), multinodular goiter (n=100), and autono-
mous noduli (n=100). The percentage of women in all three
groups is equivalent to the ratio of women with hyperthyroid-
ism in the population (80 %). The treatment of these patients
was based on individual dosimetry with two uptake measure-
ments at 24h (n=300) and 4 days (n=156) or 6 days (n=144)
after administration of 0.3 MBq I-131. For these measurement
times the kt factor was estimated by linear regression. Results:
The value and precision of the linear coefficient increased with
measurement time points; k(24h)= 6.27 (r2=0.58), k(4d)=6.92
(r2=0.88), and k(6d)=7.38 (r2=0.97). No statistical significant
difference in kt between sex and diagnosis was observed. Con-
clusion: We confirm the earlier statement that a late single
uptake measurement is sufficient for accurate dosimetry, and
preferably the uptake measurement should be performed as
late as 6 days after the injection of the test activity. A single
late uptake measurement can simplify the I-131 treatment for
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patients and reducing the cost for the health care insurances,
and could therefore be considered as an alternative approach
for I-131 dosimetry.
P890
Patients with Different Types of Hypothyroidism have
Different Biochemical Characteristics in Spite of Normal
Thyrotropin Levels and Similar Weekly Dose
of L-Thyroxine
S. Gaberscek1,2, B. Samec2, G. Setnikar2, E. Pirnat1, K.
Zaletel1; 1Department of Nuclear Medicine, University Med-
ical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of
Medicine, University of Ljubljana, Ljubljana, SLOVENIA.
AIM. Most frequent causes of hypothyroidism are
Hashimoto’s thyroiditis (HT), treatment with radioactive io-
dine 131 (I-131), and thyroidectomy. For decades, monother-
apy with L-thyroxine (L-T4) has represented the mainstay of
treatment of hypothyroidism. However, little is known about
the effectiveness and characteristics of this treatment in differ-
ent types of hypothyroidism. MATERIALS AND
METHODS. We reviewed records of all patients with most
frequent causes of hypothyroidism treated with L-T4 between
2011 and 2013. In this study we only included patients with
thyrotropin (TSH) levels inside the reference range (0.35-5.5
mU/L). Cumulative weekly dose of L-T4, levels of TSH, free
thyroxine (fT4), and free triiodothyronine (fT3) were evaluat-
ed. The fT4/fT3 ratio was calculated. RESULTS. We included
498 patients with HT (Group 1), 24 patients after I-131 treat-
ment (Group 2) and 34 patients after thyroidectomy (Group 3).
According to ANOVA analysis, patients in the three groups
significantly differed with respect to age (median (range), 53
(16-91), 48 (20-77), and 65 (38-87) years, respectively,
p=019). However, they did not differ with respect to weekly
dose of L-T4 (median (range), 350 (125-1050), 700 (175-
1400) and 750 (175-1275) mcg, respectively, p=0.053). Pa-
tients in the three groups had significantly different TSH levels
(median (range), 2.06 (0.35-5.48), 2.17 (0.36-5.44), and 1.61
(0.45-5.21) mU/L, respectively, p<0.001). Levels of fT4 were
not significantly different (median (range), 16.2 (11-24.8),
19.1 (14.4-28.8), and 18.7 (13.8-25.5) pmol/L, respectively,
p=0.597). Patients in the three groups had different levels of
fT3 (median (range), 4.6 (2.1-6.5), 4.3 (3.5-4.8), 4.4 (2.9-5.5)
pmol/L, respectively, p<0.001). Accordingly, patients in the
three groups had different fT4/fT3 ratio (median (range), 3.5
(2.5-8.1), 4.5 (3.2-7.6), and 4.4 (2.5-6.1), respectively,
p=0.011). Patients after I-131 treatment and patients after thy-
roidectomy had similar levels of fT4 and fT3 as well as similar
fT4/fT3 ratio (p=0.658, p=0.137, p=0.775, respectively). Pa-
tients with HTand patients after I-131 had similar levels of fT4
(p=0.797), different levels of fT3 (p<0.001), and different fT4/
fT3 ratio (p=0.037). Patients with HT and patients after thy-
roidectomy had similar levels of fT4 (p=0.497), different
levels of fT3 (p<0.001), and different fT4/fT3 ratio
(p<0.001). CONCLUSION. Patients with HT have different
TSH and fT3 levels as well as different fT4/fT3 ratio in spite of
TSH level within the reference range and similar weekly dose
of L-T4 as compared to patients after I-131 treatment and
patients after thyroidectomy. The difference is probably
caused by the remaining thyroid function in HT patients.
P891
Patients Treated for Central Hypothyroidism have
Different Biochemical Characteristics than Patients
Adequately Treated for Hypothyroid Hashimoto's
Thyroiditis
S. Gaberscek1,2, G. Setnikar2, B. Samec2, T. Kocjan3,2, E.
Pirnat1, K. Zaletel1; 1Department of Nuclear Medicine, Uni-
versity Medical Centre Ljubljana, Ljubljana, SLOVENIA,
2Faculty of Medicine, University of Ljubljana, Ljubljana,
SLOVENIA, 3Department of Endocrinology, Diabetes and
Metabolic Diseases, University Medical Centre Ljubljana,
Ljubljana, SLOVENIA.
AIM. In contrast to the widespread Hashimoto’s thyroiditis
(HT), central hypothyroidism (CH) is a rare condition. Patients
with CH have otherwise normal thyroid gland, which is not
sufficiently stimulated by thyrotropin (TSH. Unlike in patients
with HT, in those having CH treatment with L-thyroxine (L-
T4) cannot rely on TSH levels. Therefore, treatment of CH still
represents a challenge. Our aim was to establish the adequacy
of L-T4 treatment in CH.MATERIALS AND METHODS. In
this retrospective study we included age-matched groups of
consecutive patients treated with L-T4 because of HT or CT
and compared them with healthy subjects (HS). Patients with
HTand HS had TSH within the reference range (0.35-5.5 mU/
L). Cumulative weekly dose of L-T4, levels of free thyroxine
(fT4), and free triiodothyronine (fT3) were evaluated. The fT4/
fT3 ratio was calculated.RESULTS. We included 40 patients
with HT (Group 1), 40 patients with CH (Group 2) and 40 HS
(Group 3). According to ANOVA analysis, subjects in the
three groups did not differ with respect to age (median (range),
64 (26-86), 64 (26-87), and 65 (26-86) years, respectively,
p=0.883). Subjects in the three groups had significantly differ-
ent levels of fT4 (median (range), 18.1 (12.4-22.0), 15.6 (12.7-
21.3), and 14.2 (11.0-18.9), respectively, p<0.001). Levels of
fT3 were also different (median (range), 4.8 (2.1-5.7), 4.5 (2.7-
5.9), and 4.9 (3.5-6.7), respectively, p=0.004). Subjects in the
three groups had significantly different fT4/fT3 ratio (median
(range), 3.7 (2.5-8.1), 3.7 (2.5-5.2), and 2.9 (2.0-5.2), respec-
tively, p<0.001). In patients with HT, the weekly dose of L-T4
was significantly lower than in patients with CH (median
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(range), 525 (175-1050) and 700 (350-1252), respectively,
p=0.002). In spite of that, patients with HT had higher levels
of fT4 (p=0.002), higher levels of fT3 (p=0.007), while the
fT4/FT3 ratio was similar (p=0.747). In both treated groups
of patients, levels of fT4 were significantly higher than in HS
(p=0.003 and p<0.001, respectively). In CH but not in HT,
levels of fT3 were lower than in HS (p=0.001 and p=0.245,
respectively). In both treated groups of patients, the fT4/fT3
ratio was significantly higher than in HS (p<0.001 for
both).CONCLUSION. Patients with CH have lower fT4 and
fT3 levels in spite of higher weekly dose of L-T4 as compared
to adequately treated patients with HT. The difference is prob-
ably caused by the remaining thyroid function in HT patients
and by the inability to rely on TSH levels in patients with CH.
P892
The Role of Colour Flow Doppler Sonography
in the Evaluation of Autonomous Thyroid Nodule Activity
K. Zaletel1, M. Jakič2, M. Jager2, E. Pirnat1, S. Gaberšček1,
2; 1University Medical Centre Ljubljana, Ljubljana, SLOVE-
NIA, 2University of Ljubljana, Ljubljana, SLOVENIA.
AIM. Colour flow Doppler sonography (CFDS) provides use-
ful information on thyroid vascularity and activity in different
thyroid diseases. The data in the literature on autonomous
thyroid nodule vascularity before and after the treatment with
radioactive iodine 131 (I-131) are scarce. Therefore, our aim
was to evaluate the role of CFDS in the evaluation of autono-
mous nodule activity. MATERIALS ANDMETHODS. In our
prospective clinical study, which was performed between Oc-
tober 2013 and April 2014, we enrolled 37 consecutive newly
diagnosed hyperthyroid patients with autonomous thyroid
nodule (29 females and 8 males), aged between 17 and 90
years (mean, 60.8±18.6 years). They were treated with activity
between 737 and 979 MBq of I-131 (median, 920 MBq) with-
out any concomitant treatment with antithyroid drugs. A day
before I-131 treatment, we measured thyroid uptake of I-123.
One day before and 3 months after I-131 treatment, we deter-
mined thyroid function and we ultrasonographically measured
the volume of autonomous nodule. Additionally, we estimated
the CFDS pattern value and measured the peak systolic veloc-
ity (PSV) of autonomous nodule and paranodular tissue at the
level of intrathyroid arteries. We compared the measurements
before and after I-131 treatment and determined associations
between variables. RESULTS. Autonomous thyroid nodule
had higher CFDS pattern value (p<0.001) and higher PSV
(14.44±4.87 cm/s and 9.24±2.53 cm/s, respectively,
p<0.001) than paranodular tissue. A correlation between au-
tonomous nodule PSV and paranodular tissue PSV was posi-
tive (R=0.779, p<0.001). Thyroid uptake of I-123 varied be-
tween 9.37 and 46.85% (mean, 23.63±9.59%). PSV of
autonomous nodule was positively associated with I-123 up-
take (Beta=0.651, p=0.007), but not with age, thyroid hor-
mones or nodule volume. After I-131 treatment, thyroid func-
tion significantly improved (TSH 1.66 mU/L compared with
0.045 mU/L before treatment, p<0.001), and nodule volume
significantly reduced (4.82±5.81 mL compared with 10.35
±9.95 mL before treatment, p=0.003). A significant decrease
in both CFDS pattern (p<0.001) and PSV (9.38±3.29 cm/s
compared with 14.44±4.87 cm/s before treatment, p<0.001)
of autonomous nodule was observed. In paranodular tissue,
we found a significant increase in both CFDS pattern
(p<0.001) and PSV (11.13±2.67 cm/s compared with 9.24
±2.53 cm/s before treatment, p=0.003). We determined a neg-
ative correlation between PSVand the applied activity of I-131
(R=-0.496, p=0.003). CONCLUSION. On the basis of our
findings we may assume that CFDS provides additional useful
information in the evaluation of autonomous nodule activity
and effectiveness of I-131 therapy.
P893
Predictors of outcome in radioiodine treatment of Graves’
disease
M. Silva1, L. Cardoso2, R. Silva1, L. Pires1, F. Rodríguez1,
N. Vicente2, P. Lapa1, G. Costa1, F. Carrilho2, J. Pedroso de
Lima1; 1Serviço de Medicina Nuclear do Centro Hospitalar e
Universitário de Coimbra, Coimbra, PORTUGAL, 2Serviço
de Endocrinologia, Diabetes e Metabolismo do Centro
Hospitalar e Universitário de Coimbra, Coimbra,
PORTUGAL.
Aim: Graves’ disease (GD) is a common thyroid disorder.
Radioiodine is a reliable and cost-effective therapy choice.
However, there are several factors that can influence the clin-
ical outcome. The aim of this study is to identify predictors of
therapeutic outcomes.Material and methods: Patients with
GD, submitted to radioiodine therapy between October/2002
and April/2014 and with a follow-up longer than 12 months
were selected. We found 143 patients (116 females, 27 males;
age: mean 42.5±15.3yr, range 13-81yr). All patients were
assessed before (laboratorial and ultrassonographic thyroid
status), and at 3, 6 and 12 months after radioiodine treatment
(laboratorial thyroid status). Antithyroid drugs (ATD) were
routinely discontinued at least 1 week before radioiodine and
therapeutic activity was calculated based on 24h radioiodine
uptake (24h-RIU) and thyroid mass (TM). Several variables
were recorded: age, gender, type of ATD used, anti-
thyrotrophin-receptor antibody (TRAb), nodules larger than
10mm, 24h-RIU, functioning TM, heterogeneity in
radioiodine distribution and administered therapeutic activity.
Therapy success was defined as a euthyroid or hypothyroid
status without the need for additional radioiodine or ATD.
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Variables were analyzed to identify the potential predictive
factors for therapeutic failure. Influence of those variables on
the rate of hypothyroidism at 3, 6 and 12month after treatment
was also evaluated. All statistical analyses were carried out
using SPSS-version-22. A p<0.05 was considered significant
for all statistical tests. A multivariable analysis, including all
p r ev iou s s t a t i s t i c a l s i gn i f i c an t v a r i ab l e s , was
performed.Results: Overall success rate (euthyroidism or hy-
pothyroidism) was 80.4 % (115/143). Herein, 43.2% (48/115)
developed hypothyroidism at 3 months, 72.4% (84/115) at 6
months and 87.0% (100/115) at 12 months. The 19.6% (28/
143) unsuccessful cases showed a significantly higher TRAb
values, TM and radioiodine activity than successful ones (re-
spectively: 48.2U/L vs. 20.0U/L; 77.8g vs. 48.1g; 517MBq vs.
398MBq). Age, gender, type of ATD, nodules >10mm, 24h-
RIU, radioiodine heterogeneity distribution and therapeutic
activity were not statistically significant. We found a statistical
significant relationship between age and hypothyroidism de-
velopment at 3 months. The rate of hypothyroidism in the first
3 months after radioiodine therapy was significantly higher in
younger patients (p=0.018). In the multivariable analysis only
TM remained as statistically significant.Conclusions:
Radioiodine is very effective in GD, even in patients previous-
ly submitted to ATD. Patients with higher TRAb titres and
larger thyroid glands have a lower probability of remission
with just one radioiodine course. On the other hand, hypothy-
roidism shortly after treatment often develops in the youngest.
P894
Prevalence of normal TSH levels in patients with thyroid
autonomy detected by thyroid scintigraphy.
G. Treglia1, P. Trimboli2, F. Verburg3, M. Luster4, L.
Giovanella1,2; 1Department of Nuclear Medicine, Oncology
Institute of Southern Switzerland, Bellinzona and Lugano,
SWITZERLAND, 2Thyroid Center, Ente Ospedaliero
Cantonale, Bellinzona and Lugano, SWITZERLAND, 3De-
partment of Nuclear Medicine, University Hospital of Aachen,
Aachen, GERMANY, 4Department of Nuclear Medicine,
University Hospital of Marburg, Marburg, GERMANY.
Background: International guidelines diverge significantly
about the usefulness of thyroid scintigraphy (TS) in patients
with nodular goiter. Particularly its role in detecting/excluding
autonomously functioning thyroid nodules (AFTN) in patients
with normal serum thyrotropin (TSH) is widely debated.
Therefore we assessed the prevalence of normal TSH values
among patients with AFTN detected by TS performed in our
Center. Furthermore we carried out a meta-analysis of the lit-
erature to evaluate the usefulness of TS in European patients
with AFTN and normal TSH values. Methods: We included
patients with AFTN detected by TS and enrolled at the
Thyroid Center of Southern Switzerland. Prevalence of AFTN
with normal TSH values was calculated. Furthermore a com-
prehensive literature search of European studies published un-
til 2014 on AFTN detected by TS was performed and a meta-
analysis on the prevalence of patients with AFTN and normal
TSH values was carried out. Results: 110 patients with AFTN
enrolled at our Center and 2662 European patients with AFTN
described by six articles were selected for the meta-analysis.
Prevalence of patients with AFTN and normal TSH was 35%
in our Center. Pooled prevalence of AFTN detected by TSwith
normal TSHwas 45% (95% confidence interval: 27-64%) on a
per patient-based analysis. Conclusions: Serum TSHmeasure-
ment is not an effective screening test to diagnose AFTN, at
least in Europe, as a significant proportion of patients with
AFTN detected by TS had a normal TSH value. TS remains
the only technique that permits the diagnosis of thyroid auton-
omy which does not require invasive procedures.
P895
The role of combined single-isotope dual-phase
scintigraphy with 99mTc -tetrofosmin with SPECT
technique in minimal invasive parathyreoidecomy
M. Yaneva, A. Botushanowa; UMBAL St.George Plovdiv,
PLOVDIV, BULGARIA.
Preoperative parathyroid scintigraphy is highly beneficial for
reduction of the duration and extent of surgery in the common-
ly used nowadays minimal invasive parathyroidectomy. Aim:
To evaluate the diagnostic value of combining single isotope
dual-phase scintigraphy with 99mTc -tetrofosmin with SPECT
technique in preoperative evaluation of patients with
hyperparathyreodism. Materials and methods: 26 patients
from 38 to 62 years of age were included in the study. Of these
22 were women and 4 men. Elevated levels of serum calcium
and parathyroid hormone were registered in all of them. The
examination was conducted on a dual-headed SPECT gamma
camera SIMBIA using protocol for single-isotope dual-phase
technique with 99mTc -tetrofosmin. Patients were injected
with 740 MBq 99mTc -tetrofosmin, after which planar images
were taken at an early phase / 20min / and late phase / 120 min
/. SPECT registration of the neck and upper thorax was per-
formed after the early phase. Results: Hyperfunctioning para-
thyroid glands were registered in 14 patients in both phases
and on the SPECT images as well. Areas suspicious for abnor-
mal parathyroid glands were visualized in the early SPECT
images in 5 patients, which were not registered in the late
phase. This may be due to ear ly washout of the
radionucleotide.All 19 patients undergone surgical explora-
tion. In 18 of them a parathyroid adenoma was found. Con-
clusions: Combining both techniques provides complementa-
ry information for the localization of abnormal parathyroid
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glands, does not expose the patients with additional radiation
and is easy to perform technically and increase sensitivity.
P896
Subacute ThyroiditisManagement and Follow-upwith use
dual scintigraphy modality
V. Soukhov1, K. Zaplatnikov2; 1Military Medical Academy,
ST. PETERSBURG, RUSSIAN FEDERATION, 2MAZ Clin-
ic for Nuclear Medicine, Nürnberg, GERMANY.
Aim: This study was the next step evaluation of relationship
between accumulation of Technetium-99m (Tc-99m)
tetrofosmin (TF) in thyroid gland for staging of subacute thy-
roiditis (SAT) as well as assessment of response to therapy.
Material and methods: We performed 747 studies in 266 pa-
tients with SAT using 99mTc-pertechnetate scintigraphy and
99mTc-tetrofosmin imaging before prescribing of therapy,
during treatment and follow-up. Tc-99m-TF scans were
interpreted both visually and quantitatively before treatment,
within therapy course (2-6 weeks) and in early and delayed
follow-up. Results: Clinical signs of thyrotoxicosis: fever,
tremor of extremities, unexplainable fears and painful goitre
- were seen in all cases. That first stage of SATwas concordant
with significantly poorer uptake of 99mTc-pertechnetate in
thyroid (close to background). At the same time 99mTc-TF
thyroid images showed diffuse increased uptake at 10 min
and 1,5-2 hours p.i. The thyroid-to-background uptake ratio
of tetrofosmin was associated with the stage of SAT: slope of
clearance curves in the acute stage and in the recovery differed
appr. twice. The uptake ratio assessed as thyroid-to-
background uptake correlated with the serum concentrations
of biochemical substances and immunological data. Resume:
Use of Tc-99m-TF thyroid scan procedures in patients with
SAT is significantly diagnostically and prognostically helpful
for staging and treatment of inflammatory process in a glabd.
99mTc-TF uptake may serve as an indicator of SAT’s activity
and help to manipulate with therapy strategy according to
states severity of the inflammation process.
P897
Clinical Value of I-131 SPECT/CT over planar imaging
in Detecting Metastases in Patients with Differentiated
Thyroid Carcinoma
W. Yao, Y. Wang, N. Chiu, C. Hung; College of Medicine,
National Cheng Kung University, TAINAN, TAIWAN.
Aim: I-131 planar whole body scan (WBS) is routinely used
for detecting metastases of differentiated thyroid carcinoma
(DTC). However, the WBS is limited by lacking anatomic
landmark and characteristic findings. We investigated whether
a hybrid SPECT/CT may have additional value over planar
imaging in detecting metastases in DTC patients. Materials
and methods: In a two-year period, 319 thyroidectomized
DTC patients (65 men and 254 Women, aged 20-83 years)
received I-131 WBS a week after an ablative or therapeutic
dose of I-131. Patients with focal uptakes on WBS had addi-
tional focal SPECT/CT. The final diagnosis was proved by
pathology and diagnostic images. Results: Among 319WBSs,
104 foci of uptake were detected in 60 patients. All 104 focal
uptake and additional 21 uptakes were localized by SPECT/
CT. Eighteen uptakes were regarded as physiological uptake: 7
in GI tract, 2 in urinary bladder, 3 in endometrium, 1 in lacri-
mal gland and 5 contaminations. Thirty-three uptakes repre-
sented benign lesions, including: 17 uterine cervix, 3 renal
cysts, 3 thymus, 2 sinusitis, 2 myomas, 1 parotid sialoadenitis,
1 bronchiectasia, 1 prostate, 1 cystic teratoma, 1 ovarian cyst,
and 1 benign bone lesion. The remaining 74 uptakes were
characterized as metastases, including: 57 in lung, 15 in bone,
and 2 in abdominal wall. In addition, patients with metastases
had higher serum TG levels than with physiologic uptake and
benign lesions (117.8 vs. 4.6 and 2.2 ng/mL, p<0.001). Con-
clusion: SPECT/CT may correctly localize and characterize
focal uptake on I-131 WBS, detect more lesions, help to dif-
ferentiating between physiologic uptake, benign lesions and
metastases, and permits appropriate therapeutic approach for
DTC patients.
P898
Evaluation of Radioiodine Therapy with an Adapted
Dosimetric Approach in Patients with Hyperthyroidism
A. Fernandes1, T. Faria1, P. Coelho1, J. Casalta-Lopes2,3, A.
Oliveira1, V. Alves1, A. Pinto1, M. Pérez1, T. Vieira1, J.
Pereira1; 1Centro Hospitalar São João, Porto, PORTUGAL,
2Centro Hospitalar e Universitário de Coimbra, Coimbra,
PORTUGAL, 3Faculdade de Medicina da Universidade de
Coimbra, Coimbra, PORTUGAL.
Aim: The recommended activities for the treatment of hyper-
thyroidism associated with benign thyroid disorders are sub-
ject to discussion, as is the use of a fixed approach over a
dosimetric one. We aim to evaluate the 1-year-treatment suc-
cess rate at our department using a dosimetric approach that
considers 24-hour radioiodine uptake, and thyroid mass esti-
mation, as well as 2 and 4h radioiodine uptake, diagnosis,
gender, age, and clinical history. We also evaluated success
rates differences between lower and higher activities. Mate-
rials and Methods: We reviewed data from all patients
(n=133) treated with radioiodine therapy (RIT) for hyperthy-
roidism at our department, from January 2008 to March 2014,
including 74 patients with Graves Disease (62.2%), 23 with
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toxic multinodular goiter (19.3%), 15 with solitary hyperfunc-
tioning thyroid nodules (12.6%), 5 with toxic adenomas
(4.2%) and 2 with toxic diffuse goiter (1.7%). Patients without
follow-up in our institution (n=18) were excluded. RIT was
considered successful if euthyroidism or hypothyroidism were
achieved. All statistical analyses were carried out using IBM
SPSS version 20.0 for Mac. A type I error 0.05 was consid-
ered. Results: 115 patients were included. 102 (87.4%) were
submitted to only one therapy, and 13 (12.6%) to two. From
the latter, only two remained with hyperthyroidism. Regarding
treatment response, 91 (79.1%) succeeded, while 24 (20.9%)
remained hyperthyroid after one RIT. The activities used var-
ied between 148 MBq and 703 MBq, (388.5 ± 135.1 MBq).
There were no significant differences between the lower and
higher activities used (p=0.879). Conclusion: Our results con-
firm RITeffectiveness in hyperthyroidism treatment, with suc-
cess rates of 79.1% with only one treatment. Mean activities
used in our department were inferior to those generally pre-
scribed, irrespective of the method used (200-800 MBq, with
the majority of patients receiving 400-600 MBq). Though we
used inferior activities, we achieved high success rates one
year after treatment, comparable to the best in literature. There
were no significant outcome differences between the lower
and the higher activities used. These results suggest we should
take into careful consideration each patient singularities to
warrant the best therapeutic outcome, avoiding unnecessary
exposure.
P899
Middle-TermOutcome and safety of hyperthyroid patients
treated with calculated activity of radioiodine
A. Campenni'1, E. Amato1, M. Murè1, F. Di Mauro1, M.
Stipo1, G. Cabbanè1, V. Gangemi1, M. Bertia1, M.
Cucinotta1, M. Ruggeri2, S. Baldari1; 1Nuclear Medicine
Unit of Messina, Messina, ITALY, 2Department of Clinical
and Experimental Medicine, Endocrinology Section, Univer-
sity of Messina, Italy, Messina, ITALY.
Aim: Radio-iodine-treatment (RaIT) is a well-established
method for treatment of hyperthyroidism due to Graves' dis-
ease (GD), toxic adenoma (TA), toxic multinodular goiter
(TMG).The optimal 131-Iodine (131I) activity to be adminis-
tered is still debated.We report our experience with calculated
activity of 131I.Materials andMethods: Sixty-nine (16 GD, 39
TA, 14 TMG) patients [44 females and 25men; mean age 64.2
±12.6 years] were enrolled. All but 17 patients (24.6%) were
overtly hyperthyroid and 41 (59.4%) had received anti-thyroid
drugs, withdrawn 5-10 days before RaIT. Twenty patients
were anti-thyroid antibody positive. All patients underwent:
a) Thyroid Scintigraphy (TS) and Radioiodine-Thyroid-
Uptake (RTU) measurements from 3 to 168 hours after 131I
administration (1.8MBq); b) thyroid ultrasonography (TU), to
calculate the volume of “hot” thyroid nodule(s) or of the whole
gland. In TMG and TA patients, the “effective” volume of the
hot nodule(s) was calculated subtracting the volume of invo-
lution area(s).Mean RTU was 49.1±13.8%. Therapeutic activ-
ity was calculated by Snyder formula modified according to
“effective” volume. In 11 patients with TMG the activity was
calculated for all “hot” nodules. Mean administrated activity
was 303±135.4 MBq and mean adsorbed dose was 223±48.6
Gy. Mean follow-up was 47.4±16.9 months.Results: Fifty pa-
tients became euthyroid within a mean of 3.2±2 months after
RaIT. Fourteen patients developed overt hypothyroidismwith-
in a mean of 5.6±5.0 months. Two women (TMG and GD)
developed sub-clinical hypothyroidism respectively 12 and 16
months after RaIT. Other 3 patients with GD showed recur-
rence of hyperthyroidism after 2 months and underwent a sec-
ond RaIT (with standard activity). TS was performed in 34
TMG or TA patients about 3 months after RaIT, demonstrating
partial (22 patients) or total (12 patients) ablation of the “hot”
area(s). In 15 patients with TA, the TU performed 4 months
after RaIT showed a significant reduction of the nodule vol-
ume (p 0.03). No side effects were observed during follow-
up.Conclusions: Calculated activity of 131I permitted to ob-
tain euthyroidism in 50/69 (72.5%) patients [in 48/53 (90.6%)
patients considering only TA and TMG cases]. The cure-rate
was higher (95.6%) if we consider hypothyroidism as a suc-
cessful outcome. In an our previous experience with standard
activity of 131I we found a lower cure-rate, despite a signifi-
cantly higher administered activity (mean 541 MBq vs 303
MBq; p<0,05). It follows that calculated activity will corre-
spondingly reduce both the dose absorbed by “critical organs”
(stomach, bladder) and the radiation exposure to other people.
P900
Predictive value of pyramidal lobe, % thyroid uptake
and age for ablation outcome after 15mCi fixed dose
of radioiodine-131 in Graves’ disease
M. u. Zaman1, N. Fatima2, U. Zaman3, Z. Sajjad1, A.
Zaman3, R. Tahseen3; 1AKUH, Karachi, PAKISTAN, 2Dr
Ziauddin Hospital, Karachi, PAKISTAN, 3Dow University
of Health Sciences (DUHS), Karachi, PAKISTAN.
Objective: Aim was to find out efficacy of a fixed 15 mCi
radioactive iodine-131 (RAI) dose and predictive values of
various factors for inducing hypothyroidism in patients with
Graves’ disease (GD). Methods: This was a retrospective
study conducted from January 2012 till August 2014. Records
of all patients with GD treated with RAI were evaluated. Pa-
tients who had a Tc-99m thyroid scan, thyroid antibodies,
received fixed 15 mCi RAI and did follow endocrine clinics
for at least 6 months were selected. Patients with GD who did
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not meet these criteria were excluded. RAI was considered
successful if within 06 months of RAI therapy patients devel-
oped hypothyroidism. Results: Out of 370 patients with GD
who had RAI during study period, 210 (57%) qualified study
criteria. Mean age of patients was 48 ± 15 years with female:
male ratio of 69:31, positive thyroid antibodies in 61%, means
thyroid uptake of 15.09 ± 11.23% and presence of pyramidal
lobe in 40% of total population. Within 06 months after RAI
therapy, 161 (77%) patients developed hypothyroidism while
49 (23%) patients failed to achieve it (remained hyperthyroid
or euthyroid on antithyroid medication). Patients who became
hypothyroid were significantly younger with higher propor-
tion of presence of thyroid antibodies and pyramidal lobe
and lower % thyroid uptake on thyroid scan than those who
failed. Multiple logistic regression analysis revealed that age
(odd ratio; OR= 2.074), pyramidal lobe (OR = 3.317), thyroid
antibodies (OR = 8.198) and % thyroid uptake (OR = 3.043)
were found to be significant prognostic risk factors for post-
RAI hypothyroidism within 06 month. Gender was not found
to have any significant association with the development of
post-RAI hypothyroidism. Receiver operating characteristic
(ROC) analysis revealed age <42 years and thyroid uptake
<15% as threshold values for the development of post-RAI
hypothyroidism. Conclusion: We conclude that fixed (15
mCi) RAI dose is highly effective in rendering hypothyroid-
ism in patients with GD. Age (≤42 years), thyroid uptake
(≤15%) and presence of pyramidal lobe are strong predictors
of hypothyroidism and must be considered for selecting opti-
mal RAI dose.
P901
99mTc-MIBI SPECT/CT in patients
with hyperparathyroidism and the relationship
between uptake ratio and serum PTH, calcium as well
as volume of lesion
Z. Cheng, S. Zou,X. Zhu; Department of NuclearMedicine&
PET, Tongji Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, CHINA.
Objectives: This study aimed to compare the diagnostic effi-
ciency among of ultrasound, 99mTc-MIBI scintigraphy and
SPECT/CT for hyperparathyroidism, investigate the relation-
ship between 99mTc-MIBI uptake and biochemical features,
including preoperative serum PTH, calcium levels as well as
volume of lesion in patients with hyperparathyroidism. Pa-
tients and Methods: 60 patients with hyperparathyroidism
were retrospectively enrolled. A Dual-phase 99mTc-MIBI pla-
nar scintigraphy and delayed SPECT/CT, ultrasonography
were performed after calcitonin treatment. The pathologic vol-
ume (Vp) of the lesion was measured after parathyroidectomy.
Then 34 primary hyperparathyroidism patients were selected
with scintigraphy positive but ultrasonography showing no
sign of thyroid nodule. Mean uptakes of surgery confirmed
parathyroid lesion and mean uptakes of contralateral thyroid
tissue were measured to calculate the parathyroid lesion-to-
background ratio (T/NT) on dual-phase 99mTc-MIBI planar
scintigraphy and SPECT/CT images. The biochemical fea-
tures, including preoperative serum PTH and calcium levels
before and after calcitonin treatment were also evaluated. Re-
sults: Surgery confirmed 63 lesions of 58 patients including
87.30%(55/63) parathyroid adenoma, 11.11%(7/63) parathy-
roid hyperplasia and 1 parathyroid carcinoma, 2 patients with
nodular goiter and normal parathyroid tissue. All 3 ectopia
parathyroid adenomas were displayed by parathyroid scintig-
raphy, but only one of them was detected by ultrasonography.
The sensitivity and positive predictive value of the ultrasonog-
raphy, dual-phase 99mTc-MIBI planar scintigraphy and de-
layed SPECT/CT for preoperative localization of hyperpara-
thyroidism lesion were 68.97%(40/58), 79.31%(46/58),
86.21%(50/58) and 95.24%(40/42), 97.87%(46/47),
96.15%(50/52), respectively. Serum calcium significantly de-
creased after calcitonin treatment (p<0.01). T/NT in delayed
phase was significantly higher than that of early phase
(p<0.01). T/NT in both early and delayed phase and SPECT/
CT significantly correlated with Vp, serum PTH and initial
calcium (p<0.05), but not correlated with the calcium after
calcitonin treatment. Vp significantly correlated with serum
PTH and initial calcium (p<0.05). Conclusions: The sensitiv-
ity of dual-phase 99mTc-MIBI planar scintigraphy and de-
layed SPECT/CT for preoperative localization of hyperpara-
thyroidism lesion are higher than ultrasonography, especially
in the cases of ectopia parathyroid adenoma. Uptake ratio of
hyperparathyroidism lesion significantly correlated with vol-
ume of lesion, serum PTH and calcium so that preoperative
99mTc-MIBI SPECT/CT can be a good image modality to
evaluate disease severity quantitatively. Calcitonin treatment
may not affect the uptake ratio of hyperparathyroidism lesion.
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Contribution of diuretic renal scintigraphy
with 99mTc-MAG-2 to surgical indication in infants
with antenatal hydronephrosis.
C. Gamazo Laherrán, J. Villanueva Curto, A. Cobo
Rodriguez, A. Sainz-Esteban, M. González Selma, M. Ruiz
Gómez, R. Olmos García; HOSPITAL CLINICO
UNIVERSITARIO DE VALLADOLID, VALLADOLID,
SPAIN.
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AIM: To assess the contribution of diuretic renal scintigra-
phy with 99mTc -MAG-2 to surgical indication for treatment
in infants with antenatal hydronephrosis. METHODS: We in-
clude 36 infants referred to our department (24 male and 12
female, mean age: 4,4 months) who had been diagnosed by
ultrasound of antenatal hydronephrosis (unilateral in 25 and
bilateral in 11, a total of 47 pathological kidneys). All patients
underwent a 40 minutes diuretic renal scintigraphy after the
intravenous administration of 3,7 MBq/kg of 99mTc -MAG-2
and the later diuretic furosemide stimulation. Prenatal and
postnatal ultrasound were indicated in all cases, characterizing
as causes of hydronephrosis ureteropelvic junction stenosis in
20 cases, megaureter in 8, ureterocele in 4 and 15 from other
causes. Renographic curve pattern was classified after images
evaluation in obstructive, partially obstructive and non-ob-
structive. RESULTS: Twenty-three out of 47 hydronephrotic
kidneys confirmed by postnatal ultrasound in different degrees
according to renal pelvis dilatation, presented in the scintigra-
phy an obstructive pattern, 9 a partially obstructive and a 15
non-obstructive pattern. Three kidneys presented duplex
collecting system associated (2 of them within the obstructive
group and the other one within the non-obstructive group).
Eighteen out of 23 obstructive kidneys, underwent surgery
(78%) and 5 are currently pending intervention. Of the 9 kid-
neys with partial obstructive pattern, 5 had surgery. Only one
out of 15 kidneys with non-obstructive pattern had a surgical
treatment due to severe renal hypofunction and 4 resolved
spontaneously. The surgical technique used in the 24 kidneys
depended on the etiology of hydronephrosis in each case,
p e r f o rm ing 15 pye l op l a s t i e s , 3 expan s i on s , 3
heminephrectomies (corresponding to duplex collecting sys-
tem) and 3 interventions by other techniques. CONCLUSION:
Diuretic renal scintigraphy is a simple protocol that provides
both functional and anatomic information with relatively low
radiation dose to the patient. When combined with ultrasound
study, diuretic renal scintigraphy can be used to determine the
need for surgery especially in patients with an obstructive pat-
tern due to an ureteropelvic junction stenosis.
P903
Preliminary Validation of Blood-Pool Compensation
Method for Assessment of Relative Renal Uptake
in Children
M. Samal1, A. Brink2, M. J. Wesolowski3, C. A.
Wesolowski3; 1Charles University Prague, Prague, CZECH
REPUBLIC, 2Red Cross War Memorial Children's Hospital,
Cape Town, SOUTH AFRICA, 3University of Saskatchewan,
Saskatoon, SK, CANADA.
In dynamic renal scintigraphy, relative renal uptake is mea-
sured by several techniques with recent dominance of integral
and Patlak-Rutland (PR) methods. In 2013, Wesolowski et al
introduced the newmethod for determining split renal function
based on a simple plot of the renal curve against the curve
measured over blood-pooling organs such as the heart, liver,
or spleen. During uptake interval, the plot demonstrates a lin-
ear segment that is back extrapolated to zero counts in the
blood-pooling organ (intercept with vertical axis). The inter-
cept is proportional to single-kidney function and is used to
calculate split renal uptake. Compensation for vascular back-
ground is intrinsic to the method. The method was recently
validated in adults with good results. The aim of our study was
to test performance of the method in children. Methods: 172
dynamic renal studies (128x128 images recorded in 15s inter-
vals for 40 minutes) with 99mTc-MAG3 in children of various
age and renal function collected for inclusion into the database
www.dynamicrenalstudy.org were analyzed. Relative renal
function was measured by PR as a reference. Blood-pool com-
pensation (BPC) method was applied with the heart (BPC-H)
and the liver (BPC-L) ROI curves. No background was
subtracted prior to analysis. The results of all three methods
(PR, BPC-H, BPC-L) were highly correlated (0.9986 - 0.
9995). Mean absolute difference between PR and BPC-H
was 0.5 ± 0.6 % (p > 0.05) and between PR and BPC-L 1.0
± 1.0 % (p > 0.05). Mean absolute difference between BPC-H
and BPC-L was 0.9 ± 1.1 % (p > 0.05). Maximum absolute
difference between PR and BPC-H was 3.9 %, between PR
and BPC-L 4.7 % and between BPC-H and BPC-L 7.2 % (all
in the patients with poor unilateral or total renal function).
Conclusion: Preliminary results in children confirm previous
good results in adults. The new, technically simple method
provides the values of relative renal function that are practical-
ly identical to those provided by Patlak-Rutland plot. One of
the advantages of the new method is freedom of choice of
blood pooling organ in case the heart is outside the field of
view while preserving intrinsic subtraction of vascular back-
ground. It can be also used in parallel with other techniques as
simple but efficient quality control tool.
P904
Importance of Vesicoureteral Reflux Detected
During Routine 99mTc-MAG3 Renal Scintigraphy
in Pediatric Patients
N. C.M.Gulaldi, N. Altun Yologlu, S. Ozyurt; Department of
Nuclear Medicine, Dr. Sami Ulus Maternity and Children's
Health and Diseases Training and Research Hospital, ANKA-
RA, TURKEY.
Aim: The aim of the study is to investigate the importance of
vesicoureteral reflux (VUR) detected on routine 99mTc-
MAG3 renal scintigraphy compared to VCUG (voiding
cystourethrography) in pediatric patients. Methods: Eighteen
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S771
patients (5 female, 13 male) in whom VUR episodes were
detected on routine renal scintigraphy were included into the
study (1-113 months, mean=16,5±31 months) Dynamic
99mTc-MAG3 renal scintigraphies were performed in all pa-
tients to reveal any obstruction at collecting systems or to
measure renal functions because of antenatally detected
hydronephrosis. All patients had VCUG within 3 months of
renal scan. Indirect VUR episodes were detected on scintigra-
phy from cine display and from ROI's drawn over ureter and
pelvicalyceal systems. Spontaneous micturation during the
study into the diaper was used as a triggering event for detect-
ing VUR with cine display or quantitative approach. Results:
Ten patients withVUR detected on dynamic renal scintigraphy
were also diagnosed as VUR on VCUG. While 9 of these
patients had Gr III-IV reflux, only 1 patient had Gr I-II reflux
on VCUG. Lateralization of the VUR was exactly the same in
concordant patients (3 left side, 2 right side and 2 bilateral)
(positive predictive value is 100%), while VCUG also re-
vealed VUR in contraletal side in 3 patients. 2 patients didn’t
make micturation during the study and showed VUR during
the filling phase of bladder. Rest of 8 patients with VUR epi-
sodes detected on scintigraphy did not reveal any reflux sign in
VCUG. These patients were between 1-6 months old and all
VCUG examinations were done after the renal scintigraphy.
This situation gave rise the suspicion of naturally resolving
reflux between the exams which are predicted within this age
group especially in low-grade reflux. Conclusions: Our study
suggested that careful examination of late part of 99mTc-
MAG3 renal scintigraphy can give complimentary and valu-
able information to the refering physician if it reveals any
unknown high-grade VUR in patients with hydronephrosis.
If there is backward activity to ureters and to renal collecting
systems, it should be included into the scintigraphy report to
alert physician for the possibility of VUR to prevent further
renal function deterioration. VCUG is the gold standard for the
first diagnosis and indirect and direct radionuclide
cystography should be used for the follow-up of patients.
VUR detected on routine renal scintigraphy should only be
regarded as a varrant for the further evaluation.
P905
Invalidity of Gates method to assess renal function
in children
V.Markovic1,2,D. Eterovic1,2, A. Punda1,2, Z. Antunovic3;
1University Hospital Split, Split, CROATIA, 2School ofMed-
icine, University of Split, Split, CROATIA, 3Department of
Physics, Faculty of Science, University of Split, Split,
CROATIA.
AIM: The gamma camera early kidney uptake of Tc-99m-
DTPA- the Gates method of measuring glomerular filtration
rate (GFR) demonstrated limited value in majority of evalua-
tion reports. Still, owing to its simplicity, the method is offered
in many commercial gamma camera software packages. We
noticed that the problems with the method may be especially
exacerbated in children and addressed the issue systematically.
MATERIALS ANDMETHODS: In the consecutive group of
102 patients (51 were females) with wide range of age (2
months-87 years) and renal function (14-155 ml/min/1.73
m2) GFR was concurrently assessed by the Gates method
(GFRG) and the single sample Tc-99m-DTPA plasma clear-
ancemethod (GFRss; reference method). The primary descrip-
tors were systematic error-bias (mean percentage difference
between GFRG and GFRss) and random error-precision (stan-
dard deviation of those percentage differences). The percent-
ages were used to account for proportional error (errors in
GFRG increased with increasing GFR). The secondary de-
scriptors were the outputs of the regression analyses, both
linear (correlation coefficient (r) and root-mean squared error
(RMSE)) and non-linear. RESULTS AND CONCLUSION:
With respect to age the error of the Gates method sharply
increased for children aged 13 years or less. In the older group
the Gates method underestimated GFR (bias = -29.4%) with
substantial variability (precision = 18.2%). In this group the
relation between GFRss and GFRG was apparently bilinear
(the percentage underestimation error increased at the cut-off
point of 60 ml/min; overall r = 0.83, p<10-6 ). Therefore,
slightly better than linear, was the following regression equa-
tion: GFRss = -96.9 + 106 x log (GFRG). This rescaling re-
duces the bias, but not the random error (RMSE = 15.4%). In
case of children younger than 13 years the Gates GFR esti-
mates were both large and variable overestimations (bias =
77%, precision = 87%) in poor correlation with the reference
standard (r = 0.15, p=0.29). Thus, for patients over 13 years of
age the Gates method has some, but limited validity (compa-
rable performances were reported for serum creatinine-based
GFR estimations) and is completely unreliable for younger
children.
P906
Impact of 99mTc-DMSA scan during acute phase
of pyelonephritis
S. E. Bouyoucef, M. Habbeche, S. Benadda, A. Bellabes, B.
Abdi, K. Chentli, A. Khelifa; Department of Nuclear Medicine
CHU Bab El Oued, Algiers, ALGERIA.
Objectives: To evaluate the role of 99mTc-DMSA scan vs
Ultrasonography during the acute phase of pyelonephritis. Pa-
tients and methods: 197 children aged from 1 month to 14
years underwent 99mTc-DMSA scan for assessment of an
acute pyelonephritis (PNA). 68% were under 5 years and
60% were girls. Diagnostic of PNA has been made on clinical
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signs, biological parameters and positive urine bacterias. Re-
sults: In 91 children (46%), 99mTc-DMSA scan was positive
showing kidney scars meanwhile US was totally normal. Both
99mTc-DMSA scan and US were negative in 53 children
(26%). US was positive in 55 children by showing parenchy-
ma reduction patterns of hydronephrosis, uretero-
hydronephrosis, horse kidner or kidney duplicity. In those chil-
dren, 99mTc-DMSA scan showed scars only in 33 children. In
a sub group of 21 children with a vesico-ureteral reflux,
99mTc-DMSA scan showed evidence of kidney infection in
18 of them meanwhile US was positive only in 7. During the
follow up of 45 patients with positive 99mTc-DMSA scan, a
new 99mTc-DMSA scan showed a critical improvement in 22,
slight improvement or stabilization in 23. In this group of
children, US showed no changes. Discussion: 99mTc-DMSA
scan is more performed during the assessment of the initial
stage of PNA. The role of US is to assess the morphological
features of the urinary tract but has a little impact in the man-
agement of PNA.
P907
The Four Year Experience of Congenital Hydronephrosis
in the Single Centre of Nuclear Medicine
from the North-Eastern Region of Romania
I. C. Grierosu, Sr.1,2, M. Starcea3,2, M. Munteanu3, R.
Russu3, A. Rotaru3, A. Statescu1, R. Gherasim1, S.
Atudosie2, V. Ghizdovat1,2, I. Miron3,2, C. Stefanescu1,2;
1Emergency Clinical Hospital Sf. Spiridon, Iasi, ROMANIA,
2Faculty ofMedicine, Iasi, ROMANIA, 3Emergency Hospital
for Children Sf. Maria, Iasi, ROMANIA.
Aim: We wish to share our experience and results of the col-
laboration between two departments (Nuclear Medicine and
Pediatric Nephrology Department), from two major Public
Hospitals of North-Eastern region of Romania, Moldavia re-
gion, regarding congenital hydronephrosis. Materials and
methods: The study is a retrospective one and was realized
on a four year period of time (2011 - 2014), meaning 158 cases
of congenital hydronephrosis at children (under 18). From
these, we counted only 137 cases for which there was maxi-
mum two days between the creatinine dosage and the DTPA
scintigraphy. The patients were classified according with age,
sex and urban/rural provenience. 99mTc DTPA dynamic scin-
tigraphy with diuretic administration (according to EANM
guidelines) at 20th minute was performed to determine the
type of obstruction and to calculate the GFR. There were prac-
ticed two methods to estimate the GFR: the scintigraphic ac-
quired images processing through a standard Siemens protocol
and Schwartz equation. We calculated both formulas and we
compared them ussing statistical correlations. Results: Related
to the age, we found: group 1 (1 to 12 months old) = 24 cases
(17.5%), group 2 (1-3 years) = 31 cases (22.6%), group 3 (3-7
years) = 35 cases (25.5%), group 4 (7-18 years) = 47 cases
(34.3%). In the first group, 83.33%were diagnosed antenatally
by ultrasonography. The main diagnostics were: congenital
ureteropelvic junction obstruction (51.82%), vesicoureteral re-
flux (25.55%), megaureter uni- or bilaterally (9.49%) and
reno-ureteral duplication (13,14%). 99mTc DTPA renal dy-
namic scintigraphy parameters were correlated to Schwartz
equation. We found a medium correlation (r = Pearson corre-
lation) in group 2, children aged 1 to 3 years (r2 = 0.3291, with
p value = 0.07064), and low correlation in other groups: r1 =
0.1683, r3 = 0.1758, r4 = 0.1760. Conclusion: Our experience,
certified by this retrospective study, recommend the use of
GFR value results from radioisotopic investigations for the
management of congenital hydronephrosis and for follow up
after conservative or surgery treatment.
P908
Study of association of lesion and ambulation level
with kidney dysfunction in spina bifida
E. Ozgonenel1, L. Ozgonenel2, I. Karalok3; 1Istanbul Bilim
University Department of Nuclear Medicine, Istanbul, TUR-
KEY, 2Istanbul Bilim University Department of Physical
Theraphy and Rehabilitation, Istanbul, TURKEY, 3Istanbul
Bilim University Department of Radiology, Istanbul,
TURKEY.
Introduction:This is a pilot study to investigate the as-
sociation of lesion and ambulation level with kidney
dysfunction in children with spina bifida.Functional Mo-
bility Scale(FMS)is a simple assessment tool used for
measuring ambulation abilities in children with cerebral
palsy.Tc-99m-DMSA(Tc-99m dimercaptosuccinic acid
)scintigraphy was performed to evaluate kidney function.
Methods-results:In this study 42 children(25boys,17
g i r l s ) w i t h m y e l om e n i n g o c e l e (MMC ) w e r e
enrolled.Mean age of the patients was 5.1±2.6(2-14)
years.31 patients had thoracic and upper lumbar le-
sion(73.8%),11 had mid-lumbar(26.1%) .Functional Mo-
bility Scale(FMS)was used for measuring ambulation
abilities in children with spina bifida.Total sum of
FMS score was calculated for each patient.Mean score
of FMS was 7(5-26).Significant loss of renal function
was scored if there was >10% functional difference be-
tween two kidneys in Tc-99m-DMSA scintigraphy.There
was not a statistically significant difference in FMS
scores between patients with kidney dysfunction and pa-
t i e n t s w i t h o u t k i d n e y d y s f u n c t i o n ( p= 0 . 2 3 ) .
Conclusion:Children with spina bifida should be evalu-
ated for kidney function even they have low FMS score
and ambulation level.
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Diagnostic Accuracy of Tc-99m DMSA Scintigraphy
and Renal Ultrasonography in Children with Spina Bifida
During Long Term Follow up
E. Ozgonenel1, I. Karalok2, &. Alatas3, E. Ceylan Günay1,
L. Özgönenel4, P. Gün Atak5, B. Yazıcı6, K. Özel7; 1Istanbul
Bilim University Department of Nuclear Medicine, Istanbul,
TURKEY, 2Istanbul Bilim University Department of Radiol-
ogy, Istanbul, TURKEY, 3Istanbul Bilim University Depart-
ment of Neurosurgery, Istanbul, TURKEY, 4Istanbul Bilim
University Department of Physical Theraphy and Rehabilita-
tion, Istanbul, TURKEY, 5Istanbul Bilim University Depart-
ment of Biochemistry, Istanbul, TURKEY, 6Istanbul Bilim
University Department of Peadiatrics, Istanbul, TURKEY, 7Is-
tanbul Bilim University Department of Peadiatric Surgery, Is-
tanbul, TURKEY.
Introduction:As part of the follow up of children with Spina
Bifida(SB) we compared Tc-99m dimercaptosuccinic acid(Tc-
99m-DMSA)scintigraphy with renal ultrasonography in iden-
tification of renal scarring. Methods:We reviewed data on all
children with SB referred to our specialized outpatient clinic
between April 2014 and April 2015.DMSA scan and renal
ultrasonography have been performed to check for the status
of the upper urinary tract and due to complications such as
febrile urinary tract infection and chronic renal failure. Data
of 100 children of 135 could be evaluated by the end of the
study.Outcomes of both modalities were compared with focus
on renal scarring. Results: In total 100 patients with 198 renal
units underwent both scintigraphy and ultrasonography.
More scars were seen on DMSA scintigraphy than on
ultrasonography:5% vs. 1,5% of renal units; p<0,
05.Conclusion:In children with SB,renal ultrasonography
is used to demonstrate dilatation,presumed function and
renal scarring but renal scars are often missed, especially
when the interpretation of ultrasound is impaired by
body shape(e.g. scoliosis,obesity).
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Title: Does the Differences in Hydration Influence
the Image Quality in 99mTc-MDP Bone Scintigraphy?
N. Hosseinifar1, M. Hosntalab1,M. Eftekhari2, F. Babapour
Mofrad1, P. Geramifar2; 1Islamic Azad University Science
and Research Branch, Faculty of Engineering, Tehran, Iran,
Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Research Center
For Nuclear Medcine, Tehran University of Medical Sciences,
Tehran, IRAN, ISLAMIC REPUBLIC OF.
Aim: Drinking large volume of water is cumbersome specially
in patients suffering from renal disease, GI cancer or heart
failure. In this study we evaluated the effects of different levels
of hydration on quality of images as evidenced by the bone-to-
soft tissue ratio (B: ST), contrast-to-noise ratio (CNR) and
overall image quality following 99mTc-MDP skeletal scintig-
raphy.Materials andMethods: Forty patients were divided into
four groups with various levels of hydration (water intake) in
liters equal to 0.5, 1, 1.5 and 2.5 liters respectively. Qualitative
and quantitative methods were applied for evaluation of image
quality. For qualitative measurements, three nuclear medicine
physicians without knowledge of the hydration history of the
patients were asked to visually rate and characterize the fol-
lowing indices: bone-to-soft tissue contrast, differentiation of
single ribs in anterior and posterior projections, lateral process-
es of vertebrae, visibility of bony details of the pelvis and
filling of the bladder. For quantitative evaluation, we calculat-
ed bone-to-soft tissue and contrast-to-noise ratios. For B: ST,
we drew equal regions of interest over the femoral diaphysis
and the contralateral adductor area. The total number of counts
from bone region of interest (ROI) and soft tissue ROI was
expressed as a ratio and mean values were calculated in ante-
rior and posterior projections. Pelvic CNR was measured by
drawing ROIs over the hip region to determine the number of
counts in the bone as well as the soft tissue and background
noise. We also investigated possible relation of image quality
score to patient’s age, body mass index (BMI), and/or post
injection time interval. Results: No statistically significant dif-
ference was found between the mean B: ST ratios [P=1] and
the semi quantitative scores [P =0.98] or CNR [P= 0.58] in our
four groups of patients. Conclusion: In conclusion the effect of
hydration on bone-to-soft tissue ratio and image quality is
negligible. Instead other factors namely age, BMI and post
injection time interval play important role in overall bone im-
age quality. Post injection time interval being the most impor-
tant direct factor while age and BMI inversely affect the image
quality.
P911
Improved therapy response assessment in patients
with bone metastases of prostate cancer using an expert
system for bone scan interpretation
F. Päsler1, G. Berding1, A. Namazian1, F. Wilke2, A.
Böker3, L. Geworski2, M. Kuczyk3, F. Bengel1, I. Peters3;
1Dpt. for Nuclear Medicine, MHH, Hannover, GERMANY,
2Dpt. of Medical Physics and Radiation Protection, MHH,
Hannover, GERMANY, 3Dpt. for Urology, MHH, Hannover,
GERMANY.
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Aim: For the evaluation of treatment response in bone metas-
tases of prostate cancer, biomarkers like prostate specific anti-
gen (PSA) and visually interpreted bone scans have limitations
in early and accurate assessment of the further course of dis-
ease. Hence we investigated if a semi-quantitative parameter
of systemic bone involvement - the bone scan index (BSI) -
enables an improved response assessment. Methods: In 43 pa-
tients with prostate cancer (73±6yrs; median Gleason score: 8,
range 5-10) 157 bone scan pairs with a median interval of 3
months were performed for the assessment of response to che-
motherapy. Whole body bone scanning was acquired 2-3 hours
after injection of 7MBqTc-99m-MDPper kg bodyweightwith a
large field dual-head gamma-camera. Scans were evaluated (i)
visually by an experienced nuclear medicine specialist and (ii)
by the artificial neural network based determination of the BSI
using the expert system EXINI bone (EXINI, Lund, Sweden).
Progression of metastatic bone involvement was defined by (i)
occurrence of two new lesions in the visual interpretation (VI) by
a nuclear medicine specialist and (ii) different thresholds for the
relative increase of the BSI by 5, 10 or 25% (BSI-5%, BSI-10%;
BSI-25%) between two scans. Finally, assessments according to
bone scanning were compared to changes of prostate specific
antigen (PSA) in serum. Results: Based on VI and BSI-25%
progression was detected in a similar magnitude (28 vs. 27%,
p=0.7440). Though, PSA increases suggested progression signif-
icantly more frequently (50%, p<0.0001). Using BSI-5% and
BSI-10% significantly higher rates of progression compared to
VI (49 and 43 vs. 27%, p<0.0001) were detected - not signifi-
cantly different to the rate of PSA increase. However, assessment
of progression diverged between PSA and BSI changes in 38%
of the cases (for BSI-5%) and 39% (for BSI10%), respectively.
Conclusion: A relative increase of 5 - 10% in the BSI - in a
frequency comparable to PSA - is superior to the visual interpre-
tation of scintigraphy in the assessment of bone metastatic pro-
gression. Thus bone scintigraphy in conjunction with expert sys-
tem evaluation holds potential for more accurate response mon-
itoring in these patients. Nevertheless, results have to be correlat-
ed to longer follow up, in order to explain differences in progres-
sion assessment between BSI and PSA in a considerable number
of cases.
P912
Validation of the Imaging Biomarker Bone Scan Index -
Influence of Image Quality on Reproducibility
R. Kaboteh1, A. Anand2, L. Bath1, A. Bjartell2, L.
Edenbrandt1; 1Sahlgrenska University Hospital, Gothenburg,
SWEDEN, 2Division of Urological Cancer, Lund University,
Malmo, SWEDEN.
Objective: Bone Scan Index (BSI) represents the tumor burden
as percentage of total skeletal mass. In several studies, BSI has
shown to be associated with survival in prostate cancer pa-
tients. To clinically qualify BSI as an imaging biomarker a
comprehensive analytical validation is required. In this study,
we assessed the reproducibility of BSI in assessing bone scans
with varying image quality, measured as total number of
Counts. Method: Two repeat whole-body bone scans were
obtained from each of 48 patients with prostate cancer. Both
bone scans were done within four hours after a single intrave-
nous injection of 600 MBq 99mTc MDP. In 21 patients the
same scan speed was used in both scans, adjusted so that
routine bone scans were in accordance with the EANM pro-
cedure guidelines (anterior and posterior images each contain
>1.5 million counts). In 27 patients, the second scan was ac-
quired with double scan speed, resulting in a reduction of
counts in the images by 50%. The BSI values were generated
automatically using the software EXINI boneBSI. A reproduc-
ibility threshold of automated BSI for consistent measurement
of change in bone scan was defined as 95th percentile of the
absolute difference. Result: The mean BSI was 2.29 in the
“same scan speed” group and the mean absolute difference
between the two BSI values was 0.16 (SD 0.28), the reproduc-
ibility threshold was observed at 0.37. In the group with one
double speed scan the mean BSI was 1.98. The mean differ-
ences between the low counts scan and standard counts scan
were 0.08 (SD 0.29) (p=0.17). Five of the 27 patients (19%)
showed differences greater than the reproducibility threshold
of 0.37. Conclusion: Bone scans with low counts are less re-
producible and it is important that EANM procedure guide-
lines are followed for this type of quantitative analysis. Within
reproducibility threshold of 0.37, BSI can be used to produce a
consistent quantitative analysis of bone scans in patients with
prostate cancer.
P913
Feasibility of bone scan index for the diagnosis
and follow-up of medication-related osteonecrosis
of the jaw
S. Watanabe, K. Nakajima, H. Yaegashi, A. Mizokami, N.
Noguchi, S. Kawashiri, M. Inokuchi, S. Kinuya; Kanazawa
University Hospital, Kanazawa-city, JAPAN.
Aim: A computer-aided diagnosis using a bone scan index
(BSI) has been shown to enhance diagnostic accuracy of bone
metastases. However, no study has applied BSI to the detec-
tion and quantification of osteonecrosis of the jaw. Bisphos-
phonate (BP)-related osteonecrosis of the jaw was recently
renamed to medication-related osteonecrosis of the jaw
(MRONJ). The aim of this study was to determine optimal
methodology for detecting MRONJ and validate the useful-
ness of BSI. Methods: A total of 26 patients (32 lesions) diag-
nosed with MRONJ were selected. Median age was 68 years
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(range 45-82 years). The primary disease was prostate cancer
(69%), breast cancer (12%), renal cancer (12%), lung cancer
(4%), and osteoporosis (4%). Regarding the treatment, 89% of
the patients had BP, 4% denosumab, and both in 8%. The
median duration of medication was 36.5 months (range 7-82
months) by the time of MRONJ diagnosis. All patients
underwent Tc-99m methylene diphosphonate bone scintigra-
phy. Bone uptake in the jaw was analyzed using BSI, which
was calculated by BONENAVI (FUJIFILMRI Pharma, Japan;
EXINIbone, EXINI Diagnostics, Sweden). Significant hot
spots were manually selected according to both serial scinti-
graphic images and dental records, and the fraction of them to
the entire skeleton was referred as BSI of the jaw (BSIJ). The
BSIJ was compared with conventional semiquantitative
methods, uptake ratios (URs), which were determined as
lesion-to-opposite jaw or forehead count ratios. Relationship
between BSIJ and URs was evaluated in comparison with
various clinical parameters. Results: The median BSIJ of le-
sions was 0.14% (range 0.0-0.47) at the time of MRONJ di-
agnosis. When patients were classified according to their clin-
ical stages of MRONJ, BSIJ was significantly higher in the
higher stage. Correlation with the clinical stage was better
evaluated by BSIJ than URs. The reproducibility of BSIJ
was superior to URs. Of 4 inflammatory clinical parameters
including pus discharge, pain, swelling and C-reactive protein
(CRP), patients with ≥2 parameters showed the significantly
higher BSIJ (p < 0.01). The median CRP was 1.3 (range 0.0-
9.5), and BSIJ was significantly correlated with CRP (r = 0.62,
p = 0.0015). Conclusion: To detect the inflammatory reaction
due to MRONJ, this study indicated that BSIJ approach was
promising. BSIJ is highly reproducible and well correlated
with the clinical stage and the inflammatory reaction of
MRONJ. Therefore, BSIJ could be a good parameter to eval-
uate the occurrence and follow up of MRONJ.
P914
Are the patients who observed as definitely benign
in planar bone scintigraphy actually benign? The value
of SPECT/CT
P. Arıcan, B. Okudan Tekin, R. Şefizade, S. Naldöken; An-
kara Numune Education and Research Hospital, Ankara,
TURKEY.
Aim: Bone scintigraphy is higher sensitivity for the diagnosis
of bone metastasis in patients with known malignancies. But it
can be difficult to distinguish between metastasis and other
conditions such as postoperative, degenerative and traumatic
changes, especially in compact bone structures. The aim of our
study was evaluated the role of SPECT/CT for the diagnosis of
bone metastasis in patients with known malignancies who
were interpreted as definitely benign by planar bone
scintigraphy. Methods ve Materials: One thousand patients
who known cancer and referred to our department for
performing planar bone scintigraphy and SPECT/CT between
2010 and 2014 were analysed retrospectively. Five hundred
ten patients (250 women, 260 men; mean age 50 years) who
had definitely benign lesions on planar bone scintigraphy were
included in this study. Whole body and static images were
performed at 3 hours after 740 MBq Tc-99m methylene
diphosphonate (MDP) injection. After the planar bone scan,
SPECT/CT was performed to the region of equivocal lesions
in all patients. First planar bone scan was separately assessed
by two nuclear medicine physicians. Second fusion images
were evaluated. The results of planar bone scan and SPECT/
CT were compared. Follow up clinical information, radiolog-
ical studies and/or PET/CT were used as a gold standard. Re-
sults: SPECT/CTwas determined bone metastasis in 24 of 510
patients (4.7%). The final diagnosis was malign in these pa-
tients. There were breast cancer in 8 patients, unknown prima-
ry in 3 patients, nasopharynx cancer in 2 patients, malign mel-
anoma in 2 patients, primer bone cancer in 2 patients, and
others in 7 patients (bladder cancer, soft tissue tumour, hepa-
tocellular cancer, over cancer, gastric cancer, prostate cancer,
spinal mass). The localisation of bone metastasis was vertebral
column (n=18), pelvis (n=7), sternum (n=4), rib (n=1), and
femur (n=1). These metastatic lesions were lytic (n=14), scle-
rotic (n=4), and lytic-sclerotic (n=6). Conclusion: SPECT/CT
is better than planar bone scan for the diagnosis of bone me-
tastasis in patients with known malignancies, by providing
accurate anatomic localization and morphologic characteristic,
especially in compact bone structures as cranium, vertebral
column, and pelvis. Even though bone sintigraphy is
interpreted as definitely benign, SPECT/CT should be per-
formed in the patients who suspected bone metastasis with
clinic and radiological findings.
P915
Sacral Insufficiency Fractures in Oncologic Patients
Revealed by Bone Scan and SPECT/CT
O. Lapina, S. Tiskecivius, M. Stalnionis; National Cacner
Institute, Vilnius, LITHUANIA.
Aim: Sacral insufficiency fracture (SIF) is a type of fracture
which occurs within normal stress on weakened bone matrix
due to conditions such as osteoporosis, previous radiotherapy
or chemotherapy. Although, relatively common in the
elderly and patients with structurally weakened bones
and low back pain, SIF often remains underdiagnosed.
SIF can also get misinterpreted as bone metastases in
oncologic patients. In this case series we aim to empha-
size the awareness of this condition and to demonstrate
the importance of SPECT/CT imaging in patients with
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SIF seeking to avoid misinterpretation in the setting of
concomitant oncologic disease.
Materials and Methods: From July 2013 to January
2015, 14 oncologic patients (12 female and 2 male;
mean age 67.5) diagnosed with SIF after the 99mTc-
MDP bone scan were retrospectively reviewed. Those
patients were referred to the NM department after the
initial radiological assessment due to onset low back
pain and suspected bone metastases. Patient data and
NM images were analyzed and evaluated for SIF fea-
tures, localization of fracture lines and associated pelvic
fractures.
Results: Bone scans revealed increased osteoblastic ac-
tivity in lateral parts of sacrum which makes typical
“Honda” sign in 71.4% of the cases. SPECT/CT images
showed obvious fracture lines with mottled sclerosis in
92.9%, cortical break in 85.7% of the cases. Bilateral
SIF occurred in 71.4%, whereas unilateral in 28.6% of
the cases. In 85.7% of the cases the fracture lines were
located in zone 1, according to Denis classification,
whereas in 14.3% in zone 2 and 3. Associated pelvic
fractures were found in 46.1% of the cases. 50% of
these fractures were located in pubis, 25% in acetabu-
lum, 12.5% in ischium and 12.5% in transverse process
of L5 vertebra. 64.3% of the patients underwent previ-
ous pelvic radiotherapy and 42.9% had previous chemo-
therapy.
Conclusion: “Honda” sign on the bone scan, fracture
lines with adjacent bone sclerosis and cortical break on
the CT images are considered diagnostic features for SIF
and occurred in up to 93% of the cases. In most cases
fracture lines occurred in zone 1. SIFs were more com-
mon in elderly women. Precise review of the whole
pelvic ring is advisable due to high incidence of associ-
ated fractures. SPECT/CT proved to be the determining
modality in SIF diagnosis.
P916
Role of bone scintigraphy in the early detection of fatigue
fractures
H. Boudriga, I. Yeddes, I. Meddeb, I. El Bez, A. Mhiri, M.
Ben Slimène; Salah Azaiez Institut, Tunis, TUNISIA.
Introduction :Fatigue fractures (FF) or stress fractures (SF)
occur on healthy bone when subjected to constant loading,
which the normal carrying range capacity is exceeded. With
high load-bearing activities, active people tend to be more
prone to such bone lesions. Bone scintigraphy facilitates the
early detection of abnormalities in bone prior to the develop-
ment of cortical disruption, thereby preventing increased mor-
bidity and possible disabling sequelae.The aim of our study is
to demonstrate the role of bone scintigraphy in the early de-
tection of fatigue fractures.Materials and methods :We retro-
spectively reviewed a series of 10 patients (7 women and 3
men ) with a mean age of 42 years ( 75-20 years) from 1999 to
2015, all suspected to have had a fatigue fracture. They all
presented with bone pain while all having negative standard
X-rays.They were submitted to technetium-99m-hydroxy
methylene diphosphonate (99mTc-HMDP) intravenous injec-
tion. Two hours later a whole body scan was performed along
with selected planar spot views.Results :Of 10 patients, frac-
tures were demonstrated within three. Whereas in the rest they
were excluded. Three of which were normal, while osteitis
was confirmed in one patient, periostitis was found in one
patient, and algodystrophy was confirmed in two
patients.Positive planar scintigraphies showed an increased
uptake fractures in the second left metatarsal bone in one pa-
tient, in the first right metatarsal bone in the second patient and
in the lower third of the left t ibia with the third
patient.Conclusion :Scintigraphy with a bone-seeking radio-
pharmaceutical is suitable for the early detection of stress le-
sions and its follow up It may lead to an early and a timely
management of the fracture especially with athletes.
P917
A new area for F-18 NaF PET/CT: Avascular Necrosis
of the Femoral Head as a benign disease
I. AK SIVRIKOZ1, H. ONNER1, N. KOSE2; 1ESOGU
SCHOOL OF MEDICINE DEPARTMENT OF NUCLEAR
MEDICINE, ESKISEHIR, TURKEY, 2ESOGU SCHOOL
OF MEDICINE DEPARTMENT OF ORTHOPEDIC SUR-
GERY, ESKISEHIR, TURKEY.
Avascular necrosis (AVN) of the femoral head is an increas-
ingly common cause ofmusculoskeletal disability, and it poses
a major diagnostic and therapeutic challenge. Although pa-
tients are initially asymptomatic, AVN of the femoral head
usually progresses to joint destruction, requiring total hip re-
placement. The widespread availability of positron emission
tomography (PET) and PET/computed tomography (PET/CT)
cameras has led to renewed interest in F-18 Na Fluoride (NaF)
bone scanning. It provides highly sensitive, 3-dimensional im-
aging of the skeleton, with demonstrable utility in a growing
range of benign and malignant bone disorders.The authors
present an interesting image of bilateral AVN of the femoral
heads diagnosed on F-18 NaF positron emission tomography/
computed tomography. An 45-year-old female patient with a
history of long termed steroid use presented with pain in both
hips (more on the left side) for 1 year. PET/CT images were
acquired in 3D mode 60 minutes after intravenous injection of
370MBq of F-18 NaF. Photopenic areas were detected in both
femoral heads, with surrounding margins of increased tracer
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uptake in the axial, sagittal and coronal MIP PET images.
Intense F-18 NaF uptake was also noted in both acetabular
margins. The photopenic areas in the femoral heads
corresponded to sclerotic changes on the CT (bone window)
image and likely represent microvascular occlusion. A diag-
nosis of bilateral avascular necrosis of the femoral heads was
made.While magnetic resonance imaging (MRI) is considered
the most sensitive and specific technique in the early diagnosis
of AVN, 3-phase bone scan with single photon emission com-
puted tomography/computed tomography (SPECT/CT) has
also shown comparable diagnostic accuracy. F-18 Fluoride
uptake depends on regional blood flow and osteoblastic activ-
ity similar to Tc-99m Methylene Diphosphonate. However,
the better spatial resolution of PET and the favorable pharma-
cokinetic characteristics of F-18 Fluoride make this a more
sensitive modality. The present case suggests that F-18 NaF
PET has the advantages of high spatial resolution, attenuation
correction, 3-dimensional tomographic images, and hybrid
PET/CT imaging. In addition, it may be an effective alternative
for the diagnosis of femoral head AVN in patients with con-
traindications to MRI like cardiac pacemakers, intracranial
clips, or claustrophobia.
P918
Evaluation of sternoclavicular hyperosteosis in 20
patients: preliminary study
B. Celik1, F. Canbaz2, Y. Bilgin Büyükkarabacak1, A. Taslak
Sengul1, Z. Pelin Sürücü1, A. Başoğlu1; 1Ondokuz Mayis
University Hospital, Faculty of Medicine, Thoracic Surgery
Dept., KURUPELIT / SAMSUN, TURKEY, 2Ondokuz
Mayis University Hospital, Faculty of Medicine, Nuclear
Medicine Dept., KURUPELIT / SAMSUN, TURKEY.
Aim: Sternocostoclavicular hyperostosis(SCCH) is a chronic
inflammatory disorder, characterized by erythema, swelling
and pain of the sternoclavicular joint. Palmoplantaris
pustulosis may develop at any stage of the disease in approx-
imately 50% of patients. Trauma, degenerative or infections
should be considered in the differential diagnosis. Bullhorn
sign is a characteristic, highly sensitive pattern on bone scan.
The diagnosis of SCCH is confirmed radiologically by hyper-
ostosis and sclerosis of the sternum with involvement of the
first rib on computed tomography (CT). In this study we aimed
to evaluate clinical and imaging characteristics of patients di-
agnosed with SCCH. Methods: Twenty patients presented
with swelling of sternoclavicular junction (SCJ) with or with-
out pain and diagnosed with SCCH scintigraphically were
retrospectively studied. Their clinical, laboratory and scinti-
graphic findings were analyzed. Results: Of twenty patients,
sixteen were female and four were men. The mean age was 51
±13 (21-68). Eight patients had only swelling and eight had
swellingwith pain on SCJ. Four patients had only pain on SCJ.
The mean duration of complaints was 6 (2-18 ) months. None
of our patients had skin manifestations of the disease. All
patients were advised anti-inflammatory medicine in the be-
ginning of the diagnosis. Laboratory findings including
hemogram, sedimentation rate and C-reactive protein were
all normal. Eight / 20 patients had bilateral and 12/20 patients
had unilateral increased osteoblastic activity on bone scan
which was typical for SCCH. 11/20 patients showed increased
sclerosis of SCJ on computed tomography 5/ 20 patients had
arthritis in other joints. Three patients were biopsied because
of the detriment of complaints and the suspicious of malignan-
cy. All of the histopathological results were benign. On follow
up, of 14 patients whomwe could be informed, seven had near
to completely remission and seven had persistent swelling in
the sternoclavicular joint. Conclusion: Sternocostoclavicular
hyperostosis is a chronic sterile osteomyelitis of the sternum,
the medial end of the clavicle, and the upper ribs. Restricted
mobility of the adjacent shoulder joint may also be the sole
presenting symptom. Patients often undergo multiple serolog-
ic, imaging and also unnecessary invasive examinations before
a correct diagnosis is made. Greater awareness of SCCH
among nuclear medicine physicians as well as rheumatologists
and other clinicians needed to prevent irreversible physical,
psychological impairment associated with the delay in the di-
agnosis and the treatment of the disease.
P919
Semiquantitative analysis of bone SPECT studies
in the detection of active sacroiliitis
A. Kokkini, G. Koniaris, A. Zafirakis, K. Athanasiou, D.
Kassimos, J. Koutsikos; 401 General Military Hospital, ATH-
ENS, GREECE.
INTRODUCTION: Bone SPECT has progressively become
an excellent diagnostic imaging modality in the detection of
active sacroilitis in patients with spondyloarthropathies. Al-
though visual evaluation appears to be quite efficient in most
nuclear medicine studies, semi-quantitative (SQ) analysis is
also applied in order to standardise the quality of the proce-
dures. Our aim was to assess accuracy and inter-operator re-
producibi l i ty of bone SPECT, analyzed by a SQ
method.MATERIALS AND METHODS: Bone SPECT stud-
ies of 45 patients suffering from spondyloarthropathies, were
retrospectively analyzed for detecting active sacroilitis. Two
experienced nuclear medicine physicians were asked to eval-
uate each SPECT study, using the same default processing
procedure. The algorithm consisted of the following steps:1.
Review of projection data in cine mode for an initial determi-
nation of scan quality, patient motion, and artifacts2. Use of
ReSPECT iterative reconstruction software.3. Reconstruction
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of images into slices in 3 axes (frontal, vertical and sagittal)4.
Reorientation of images5. Selection of 5 images of interest
using the frontal axis reconstructed data, in order to create
one summed static image6. SQ analysis of sacroiliac joints
(SIJ), applying ROIs to both SIJ and L4.SQ data were ana-
lyzed by Receiver Operating Characteristic (ROC) analysis to
establish the accuracy; the inter-class correlation coefficient
(ICC) was used to evaluate the inter-observer reproducibility.
The later was evaluated also for the visual assessment; focally
increased radiotracer uptake at the base of the SIJ was evalu-
ated as positive. The diagnosis of sacroilitis was established
according to ASAS criteria.RESULTS: Area under the curve,
estimated by ROC analysis, regarding SQ method was 0.266
(p=ns) and ICC demonstrated no significant correlation among
the operators (p=ns). On the contrary, regarding the visual
analysis, inter-observer reproducibility was very good, with
correlation coefficient 0.89-0.96 (p<0.0001).CONCLUSION:
Estimation of SIJ ratios in bone SPECT studies by a semi-
quantitative analysis shows neither accuracy, nor significant
reproducibility among different operators, and can therefore
not be used as a solid method. These results were mainly
attributed to the subjective selection of static image sequence.
The qualitative assessment of radiopharmaceutical uptake in
the SIJ of the reconstructed tomographic images is highly ac-
curate and reliable.
P920
Bone scintigraphy, DAS 28 score and biochemical
parameters in patients with Rheumatoid Arthritis
S. Karacavus1, M. Ucar2, M. F. Gecer3, O. Balbaloglu2, O.
Nas4, U. Sarp4; 1Bozok University, School of Medicine, De-
partment of Nuclear Medicine, Yozgat, TURKEY, 2Bozok
University, School of Medicine, Department of Physical Med-
icine and Rehabilitation, Yozgat, TURKEY, 3Yozgat State
Hospital, Department of Nuclear Medicine, Yozgat, TUR-
KEY, 4Yozgat State Hospital, Department of Physical Medi-
cine and Rehabilitation, Yozgat, TURKEY.
Aim: Rheumatoid arthritis (RA) is a chronic inflammatory and
autoimmune disease characterized by progressive damage of
joints. In this study, we investigated the relationship between
the disease activity scores and bone scan findings and bio-
chemical parameters in patients with RA. Material and Meth-
od: Sixty two patients (F/M: 44/8, age 51,8±11,1; range 31-77)
diagnosed with RA according to the American College of
Rheumatology (ACR) criteria were included in the study. All
patients were divided to two groups regarding their DAS28
score; Group 1 was DAS28 score≥3,2 and Group 1 was
DAS28 score<3,2. The whole body bone scintigraphy with
Tc99m-MDP (TVKS) was performed all subject. A increased
uptake on any joint in blood pool phase and late static phase of
bone scan was evaluated as a positive result. Laboratory data
including the erythrocyte sedimentation rate and C-reactive
protein were recorded. The clinical parameters were assessed
by the Health Assessment Questionnaire (HAQ) and Ritchie
articular index (RAİ). Results: The mean number of peripheral
joint involvement was higher in Group 1 than in Group 2 (11/
8; p<0.05). Number of joint involvement (r=0.5,p=0.019) and
biochemical parameters (r=0.7,p<0.001) were increased with
clinical score in Higher disease activity score group. In 6 of 13
patients of lower DAS28 group, number of peripheral joint
involvement were similar to high DAS28 group. Conclusion:
Whole body bone scintigraphy is a cheap and easy method,
that contributes a lot to the clinical approach in patients with
rheumatoid arthritis, in the evaluation of peripheral joints in a
single session and determining the joints those not expressing
significant clinical findings yet.
P921
Interest of SPECT/CT hybrid imaging in the management
of McCune-Albright syndrome
A. Matrane, M. Bsiss, S. Hiroual, S. Bennani Doubli; Mo-
hammed VI University Hospital, Marrakech, MOROCCO.
Introduction. McCune-Albright syndrome is a genetical dis-
ease with a mosaïc distribution. It is characterized by skin
pigmentations, fibrous dysplasia and sexual precosity but can
also include others endocrinopathies (hyperthyroidism,
Cushing's syndrome and acromegaly). Fibrous dysplasia may
involve one or more skeletal sites and it is manifested by lame-
ness, pain and sometimes by a pathological fracture. The aim
of our work is to elucidate the contribution of SPECT/CT in
the diagnosis and management of osteo-articular complica-
tions of McCune-Albright syndrome about a clinical case.
Case report. A 41 years-old patient, with McCune-Albright
syndrome, presents a painful limp progressively worsening.
Clinical examination shows skin pigmentations with facial
dysmorphia combining prognathism, hypertelorism and fron-
tal bossing. The standard radiological assessment shows fi-
brous dysplasia interesting long bones, skull, maxilla and the
mandible. The SPECT / CTshowed a Polyostotic achievement
of fibrous dysplasia. The lesions involve all the bones of the
axial and peripheral skeleton. Discussion. McCune-Albright
syndrome is a genetical disease characterized by skin pigmen-
tations, fibrous dysplasia and sexual precosity. Fibrous dyspla-
sia is classified among benign bone tumors. It can be
monostotic or polyostotic. The craniofacial localization occurs
in 10%-25% of cases in monostotic forms and in 50% of cases
in polyostotic forms. Fibrous dysplasia essentially affects chil-
dren and young adults, with no sex preference. Its diagnosis is
not always straightforward because the functional
symptomology is often absent or not specific. Medical
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imagery is necessary and in difficult cases a bone biopsy. The
major complication of the illness remains sarcomatous degen-
eration. The SPECT/CT can increase the sensitivity and spec-
ificity of planar bone scintigraphy. It confirms the location of
Fibrous dysplasia and defines its anatomical relationships in
order to optimize surgical management. Conclusion. The
SPECT/CT has an important role in the management of pa-
tients with McCune-Albright syndrome. It provides better an-
atomical localization and improves the diagnosis value in the
assessment of Fibrous dysplasia.
P922
Value of quantitative 3 - phase bone scintigraphy
in the assessment of hip and knee endoprosthesis
C. C. Schiller, F. Fitz, S. Haim, H. Söser, J. Hochreiter, W.
Langsteger, M. Beheshti; Nuclear Medicine & Endocrinology,
St. Vincent’s Hospital, LINZ, AUSTRIA.
Aim: This study evaluates the impact of quantitative 3-phase
bone scintigraphy in patients with clinically suspicious knee-
or hip- prosthesis loosening and equivocal findings on the
visual assessment of bone scanning. Methods: A total of 196
patients with knee - and / or hip- total endoprosthesis (TEP)
[70 H-TEP (hip) and 126 K-TEP (knee)] with equivocal find-
ings in the visual assessment who underwent quantitative 3-
phase scintigraphy and 6 months follow-up study were includ-
ed in this study. A region of interest (ROI) was defined over
the pathologic peri-prosthetic uptake as well as normal ipsilat-
eral and/or contralateral bone. Counts per ROI were measured
and the ratio of pathologic to normal bone was calculated in
various segments of prosthesis. All patients have been follow-
ed - up with quantitative 3-phase bone scintigraphy. Increasing
pattern of uptake was considered as prosthesis loosening. The
imaging findings have been correlated with clinical follow-up
and/or surgical results within 2 years as standard of truth. Re-
sults: Quantitative analysis improves the predictive value for
the diagnosis of prosthesis loosening in the Tibia plateau. A
cut-off ratio of 1.26 was suggestive of loosening with a sensi-
tivity of 100% and specificity of 33% (AUC = 0.614, p = n.s.).
Increasing target to normal bone ratio in the 6 months follow-
up quantitative scans improves the predictive value for loos-
ening process with a cut-off of 3.45% on the Tibia plateau
(sensitivity 71%, specificity 73%, AUC = 0.692, p = 0.056)
and 16.5% on the Femoral condyle (sensitivity 67%, specific-
ity 90%, AUC = 0.733, p = 0.129).No meaningful data could
be extracted in the H-TEP region. Conclusion: Quantitative 3-
phase bone scintigraphy seems to improve the diagnostic ac-
curacy of the knee - TEP loosening. However, it providess no
additional value to visual assessment of the Hip - TEP. Further
research with a homogeneous patient’s population and a
higher number of cases are needed to draw an accurate
conclusion.
P923
Scintigraphy studies for the evaluation of painful hip
and knee prosthetic joints
J. A. Sequeira1, J. G. Santos1, A. Prata1, S. Carmona1, J.
Salreta2, M. Tapadinhas2, A. I. Santos1; 1Hospital Garcia de
Orta - Serviço de Medicina Nuclear, Almada, PORTUGAL,
2Hospital Garcia de Orta - Serviço de Ortopedia, Almada,
PORTUGAL.
Aim: To retrospectively evaluate the triple scintigraphic ap-
proach - three-phase 99mTc-HMDP bone scintigraphy (BS)
in conjunction with 99mTc-antigranulocyte monoclonal anti-
body BW 250/183 scintigraphy (AGS) and 99mTc-albumine-
colloid bonemarrow scintigraphy (BMS) - for the diagnosis of
infected hip and knee prosthetic joints. Materials andMethods:
56 patients with painful hip and knee prostheses and suspected
prosthetic joints infection (20 prosthetic hips and 36 prosthetic
knees) who underwent BS, AGS and BMS, were selected.
AGS images were acquired 2 and 4-6 hours post radiophar-
maceutical administration in all studies; in 11 studies an addi-
tional image at 24 hours was also performed. Images were
interpreted in conjunction with the ones obtained through BS
and BMS, according to the following criteria considered pos-
itive for infection: a) Increased periprosthetic AGS uptake
with congruent pattern with BS. b) AGS increased uptake or
extension over time. c) Incongruent AGS/BMS images. In
addition to visual interpretation of the images, semiquantita-
tive analysis was also employed, calculating early and late
ratios between uptake on the area of suspected infection and
a contralateral area. Final diagnosis was based on surgical,
histological and bacteriological data (33 patients submitted to
surgery) or clinical follow-up at 12 months as proof of absence
of infection (the remaining 23 patients). Results: Among the
56 hip and knee prostheses investigated, the final diagnoses
were: infection in 20; non-infection in 33; and inconclusive in
3. The overall sensitivity, specificity and accuracy of com-
bined BS, AGS and BMS for the diagnosis of periprosthetic
infection were 83%, 86% and 85%, respectively. Positive and
negative predictive values were 75% and 91%, respectively.
All five infected hip prostheses and 10 of the 13 infected knee
prostheses were correctly diagnosed with this triple scinti-
graphic evaluation. There were 5 false positive findings (3
with massive loosening without infection, 1 with allergic reac-
tion and 1 with arthrofibrosis) and 3 false negative (in one of
these the studies were performed on antibiotic therapy). Neg-
ative studies (33/56 cases) were very helpful for the exclusion
of infection. In 18/20 patients with positive studies reoperation
was performed, motivated by the scintigraphic results.
S780 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
Conclusions: Our results suggest that the conjunction of
bone scintigraphy with antigranulocyte and bone marrow
scintigraphies has a role on the diagnostic workup of
infected hip and knee prostheses, its greatest strength
being a high negative predictive value. Further analysis
should be performed to evaluate the additional value of
bone marrow scintigraphy over bone and granulocyte
scintigraphies.
P924
Does bone scintigraphy keeps a place in para-articular
osteoma?
D. BEN SELLEM, L. ZAABAR, B. DHAOUADI, B.
LETAIEF, M. F. BEN SLIMENE; Nuclear Medicine Depart-
ment, Salah AZAIEZ Institute, TUNIS, TUNISIA.
Aim: Para-articular osteomas (PAO) are ossifications occur-
ring around articulations and muscles limiting their functions.
They occur in situations like hemophilia, cerebral vascular
accidents but especially on cranial traumatized patients and
those with medullary injuries. They occur early during inten-
sive care hospitalization. The removal of these PAO permits at
least the recuperation of functional articular amplitudes. The
risk of recurrence with then the possibility of deterioration is
possible after this surgery, especially if it is done early on
osteoma still evolving. The purpose is to evaluate the indica-
tion and usefulness of bone scintigraphy in PAO. Materials
and methods: 32 patients confined to bed for a long period
(24 males and 8 females mean age 33.45 years) were referred
to our department for suspicion of PAO. Thirty seven bone
scintigraphies with 99mTc-HMDP were performed (32 for
initial evaluation and 5 for follow up). Results: We evaluated
60 articulations with suspicion of PAO to the hip in 28 patients
(44%), to elbow in 16 cases (27%), to knees in 14 cases (23%)
and to the hip shoulder in 2 cases (3%). Bilateral localization
was diagnosed in 20 articulations among 12 patients (12 for
the hips, 6 to knees and 2 for elbows). The bone scintigraphy
was positive in 61 times, with the following respective results,
27 (44%), 17 (28%), 14 (23%) and 2 (3%) for hip, elbow,
knees and shoulder. An anterior tarsal infra clinical and radio-
logical localization was diagnosed (2%). In fact bone scintig-
raphy confirmed the 57 suspected articulations 26 (46%) for
hip, 15 (26%) for elbow, 14 (25%) for knees and 2 (3%) for
shoulders, infirmed 3 localizations and revealed 4 unknown
localizations. Bilateral localization occurred in 13 cases.
Among PAO diagnosed, 55 were immature. During follow
up, 3 immature PAO passed to maturation, the first one at 5
months, the second at 7 months and the third, 13 months later.
Conclusion: Three phase bone scintigraphy with HMDP tech-
netium 99m remains the exam of choice for the diagnosis,
cartography and especially the evaluation of maturation of
PAO to indicate the adequate moment for surgical remove of
theses PAO.
P925
FDG-PET/CT of bone lesions
Y. Otomi1, H. Otsuka2, T. Shinya1, K. Terazawa1,M. Kubo1,
M. Harada1; 1Tokushima University Hospital, Tokushima,
JAPAN, 2Tokushima University, Tokushima, JAPAN.
Objectives: The aim of this study was to evaluate the
usefulness of 18F -2-fluoro-2-deoxyglucose positron
emission tomography/computed tomography (FDG-PET/
CT) in detecting malignancy arising from a variety of
bone lesions. Methods: Data were retrospectively ana-
lyzed for 25 consecutive patients (13 men, 12 women;
mean age: 57.4 years, range: 16-86 years) with bone
lesions examined using FDG-PET/CT prior to therapy
between May 2008 and July 2014. Twenty-four cases
were pathologically proven to involve bone lesions and
one case was diagnosed during follow-up. We performed
a semi-quantitative analysis to assess the FDG uptake of
the lesions by measuring the maximum standardized up-
take value (SUVmax). There were 16 malignant lesions
(5 plasmacytomas, 4 diffuse large B cell lymphomas, 2
chondrosarcomas, 2 metastatic bone tumors, 1 bone sar-
coma, 1 fibrosarcoma, 1 spindle cell sarcoma) and nine
benign lesions (3 cases of osteomyelitis, 2 cases of
Langerhans cell histiocytosis, 1 hemangioma, 1 simple
bone cyst, 1 chordoma, 1 case of pyogenic spondylitis).
The cutoff value for balancing the sensitivity and spec-
ificity was obtained according to a ROC analysis. The
sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV) and accuracy of FDG-
PET/CT in detecting malignant lesions of the bone were
evaluated. Results: The results of the semi-quantitative
analysis were as follows. The SUVmax of the malignant
lesions was 8.9 ± 7.3 and that of the benign lesions was
6.6 ± 3.4; the difference between the SUVmax values of
the malignant and benign lesions was not statistically
significant. The cutoff value for the SUVmax obtained
using the ROC analysis was 10. The sensitivity, speci-
ficity, PPV, NPV and accuracy of FDG-PET/CT were
31.3%, 88.9%, 83.3%, 42.1% and 48.0%, respectively.
Conclusions: The average SUVmax of malignant lesions
is higher than that of benign lesions, although the range
for malignant and benign lesions overlaps. Differentiat-
ing between malignant and benign bone lesions is diffi-
cult. In particular, the possibility of malignancy is con-
siderably high for bone lesions showing high accumula-
tion with a SUVmax of more than 10.
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P926
Role of F18 Bone Scan in metastatic workup of Primary
Bone tumors
H. B, Sr., V. Pawar, S. C H; BGS Global Hospital, Bangalore,
INDIA.
Primary bone tumours constitute less than 1% of all
cancers. They mainly metastasize by haematogenous
route. Lungs and bones form most common areas of
metastases. During metastasis workup we require to
do MDP bone scan and CT chest to rule out metastases
to bone and lung respectively. However since F18 bone
scan produced cross sectional images we will have
better anatomical correlation for bone lesions and in
addition due to presence of whole body CT scan, lung
evaluation is also done together. Lung metastases in
primary bone tumors are in the form of soft tissue
density/calcified nodules which are usually less than
6 mm. FDG PET CT will not show uptake in these
nodules due to partial volume effect. Since F18 bone
scan provide both information about metastases to
lungs and bone, we tried to assess impact of bone scan
in management of primary bone tumors. AIM : To
evaluate role of F18 bone scan in metastatic workup
o f p r im a r y b o n e t umo r s . MATER IAL AND
METHODS: It is an observational study done in Dept
of Nuclear medicine in collaboration with Dept of
Orthoonco at BGS Global Hospital, Bangalore between
June 2013 to Feb 2015. 48 consecutive patients with
biopsy proven primary bone tumors (osteosarcoma -34,
Ewing’s sarcoma- 8, Condrosarcoma-5 and fibrosarco-
ma-1) were enroled. Male: female ratio is 1. Age
ranged between 6 -60 years. Out of 48 patients 16
patient had lung nodules (4 had solitary and rest had
multiple) and 19 patient had F18 avid skeletal lesions
of which 1 was histological proven osteochondroma
and other was osteoid osteoma . Rest 17 were metas-
tases. CONCLUSIONS: F18 bone scan plays an impor-
tant role in the evaluation of primary bone tumors. It
is more specific for extra primary skeletal lesions as it
has anatomical correlation with CT scan. Attenuation
correction of PET images by CT images can be used
for assessing lung metastases. Since bone tumors me-
tastases predominantly to lungs and bones, F18 bone
scan can be cost effective one stop shop for metastatic
workup from primary bone tumors. LIMITATIONS:
Pure marrow metastases can be picked up by FDG
PET CT and may be missed by F18 bone scan. This
can happen in Ewing’s Sarcoma than in other primary
bone tumors. Hence it is advantageous to do metastatic
workup by FDG PET CT for Ewing’s Sarcoma and
F18 bone scan for others.
P927
SPECT-CTwith 99mTc-MIBI in patients with recurrent
malignant soft tissue sarcomas: is it important
for radiotherapy planning and monitoring of its efficacy.
S. Kanaev, S. N. Novikov, P. Krzhivitskiy, G. Gafton; N.N.
Petrov Institute Oncology, St Petersburg, RUSSIAN
FEDERATION.
Purpose: to evaluate clinical value of SPECT-CTwith 99mTc-
MIBI in radiotherapy planning and monitoring of treatment
efficacy. Material and methods: the study group consisted of
9 patients with recurrent malignant soft tissue sarcomas
(RMSTS) that were inoperable (2 patients with pelvic tu-
mours) or considered as candidates for amputation (7 patients
with RMSTS of extremities). High dose rate (HDR) brachy-
therapy was performed in order to reduce tumor volume and to
decrease invasive potential of RMSTS during non-
compartmental surgery. After CT guided insertion of plastic
needles and HDR therapy planning 3 fractions of 7 Gy (with at
least 4-6 hours of interfractional interval) were delivered in
first 4 patients and 3 fractions of 8Gy - in last 5 cases.
SPECT-CT with 99mTc-MIBI was performed before treat-
ment in order to visualize viable tumour subregions and areas
with reduced tracer uptake. Posttreatment SPECT-CTwas per-
formed 3-4 and 6-8 weeks after the end of brachytherapy for
monitoring of its efficacy and in order to determine optimal
time for surgical intervention. Results: SPECT-CT with
99mTc-MIBI effectively visualized viable and hypoxic-
necrotic subregions of RMSTS. This helps us to perform dose
painting with obligatory irradiation of all viable tumor regions
and if possible to increase radiation dose to areas with de-
creased tracer uptake. After treatment SPECT-CT correctly
determine tumour regression in all 2 patients with
pathomorphological complete or nearly complete (>90%) re-
sponse, all 2 cases with partial pathologic response and 3 ob-
servation with stabilization or tumour progression. All 4 pa-
tients with complete or partial SPECT-CT response underwent
limb saving surgery and are in remission. Conclusion: SPECT-
CT with 99mTc-MIBI can accurately determine response of
RMSTS to HDR brachytherapy and can be considered as a
promising tool for monitoring of radiotherapy efficacy in this
patient group.
P928
Follow-up in patients with Ewing sarcoma: value of an
imaging protocol including FDG-PET(-CT) and MRI
for recurrence detection
M. Heinemann1, A. Ranft1, H. Jürgens1, T. Langer2, V.
Vieth1, M. Schäfers1, M. Weckesser1, L. Stegger1, U. Dirk-
sen1; 1University Hospital Münster, Münster, GERMANY,
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2University Hospital Schleswig-Holstein, Campus Lübeck,
Lübeck, GERMANY.
Aim: To evaluate a prospectively defined imaging protocol
with regular FDG-PET(-CT), MRI, bone scintigraphy, thorac-
ic CT/-x-ray and x-ray at the site of primary tumour for the
detection of recurrence in patients with Ewing sarcoma and to
compare detection rates with those for recurrence detection by
clinical symptoms. To additionally assess the influence of de-
tection mode on survival.Methods:After achieving complete
remission, eighty patients with Ewing sarcoma treated at one
institution underwent regular follow-up examinations with to-
mographic and conventional imaging methods according to a
prospectively defined protocol over a duration of 5 years. In
case of clinical symptoms additional non-protocol imaging
was performed. The number of recurrences and the modes of
recurrence detection (imaging method, clinical symptom)
were determined from the imaging reports and patient files.
Additionally, the influence of the mode of recurrence detection
on 3-year survival was investigated.Results:From the eighty
patients included in this study thirty had tumour recurrence
within the first five years of follow-up; 14 (47%) relapsed
during the first year. Recurrent tumour was detected by proto-
col imaging studies in 19 patients (63%) and by clinical symp-
toms in 11 patients (37%). Detection rate of protocol imaging
was: 8/164 investigations for FDG-PET(-CT), 1/309 for MRI,
2/151 for thoracic CT, 2/318 for bone scan, 6/1052 for X-
ray.FDG-PET-CT and thoracic CT detected significantly more
frequently pulmonary metastases <1cm than chest X-ray
(P=0.002). Most frequent clinical symptom of recurrence
was pain (n=9), followed by sensomotor dysfunction,
swelling/oedema and dyspnoea. Osseous metastases were sig-
nificantly more frequently symptomatic than pulmonary me-
tastases (P=0.036).Nine patients achieved 3-year survival (2
additional patients still alive <3 years after recurrence detec-
tion), all of them after relapse detection by protocol imaging
(P=0.026).Conclusion:Most recurrences of Ewing sarcoma
were detected by protocol imaging studies, among these many
with FDG-PET(-CT). Diagnosis of recurrence by protocol
seems to be associated with advantage for survival.
P929
Disappearing Bone Disease (Gorham’s Disease)
demonstrated on SPECT/CT imaging
A. Atabaki1,2, R. Mansberg2; 1Westmead Hospital, Sydney,
NSW, AUSTRALIA, 2Concord Hospital, Sydney, NSW,
AUSTRALIA.
BACKGROUND: Gorham's disease (vanishing bone disease)
is a very rare skeletal condition of uncertain aetiology,
characterised by the uncontrolled proliferation of distended,
thin walled vascular or lymphatic channels within bone, which
leads to resorption and replacement of bone with angiomas
and/or fibrosis. AIMS: To assess the patient case study of a
lytic bone lesion due to a rare diagnosis of "vanishing bone
disease" (Gorham’s disease). METHODS: A 55-year-old male
with nonspecific headache was referred for a CT scan, which
demonstrated a lytic lesion in the left parietal skull. A bone
scan with SPECT/CT and MRI were performed to further
evaluate the lesion and assess for the presence of occult lesions
elsewhere in the skeleton for malignancy. RESULTS: The im-
aging investigations revealed a large solitary lytic lesion in the
left parietal bone with pseudo-herniation of the brain into the
defect. No other occult lesion was demonstrated elsewhere in
the skeleton. The patient subsequently underwent left parietal
craniectomy, reduction of encephalocoele and reconstructive
duraplasty/cranioplasty. The histopathology showed
osteolysis and thin walled blood vessels (occasionally cyst-
like) without evidence of malignancy consistent with
Gorham’s disease. CONCLUSION: The evaluation of a lytic
lesion is a common indication for performing skeletal scintig-
raphy, in order to assess for the presence of primary or meta-
static neoplasm. Due to the rarity of this condition, it is impor-
tant for imaging doctors to consider Gorham’s disease in the
differential diagnosis of a lytic lesion as demonstrated in this
case with multi-modality imaging and histological
confirmation.
P930
Prominent thallium-201 uptake of giant cell tumor
of bone : comparison with osteosarcoma
R. Inai1, S. Takayoshi2, T. Tanaka1, Y. Tsuboi1, S.
Norikane1, K. Kojima1, A. Tada1, T. Kunisada1, S. Sato1,
T. Ozaki1, S. Kanazawa1; 1Okayama university hospital,
Okayama, JAPAN, 2Tokushima university hospital,
Tokushima, JAPAN.
Aim: Giant cell tumor of bone (GCT) is a local aggressive
benign tumor. This tumor shows the lytic lesion without scle-
rosis around it on radiography and low signal intensity on T2-
weighted MRI. These findings are often similar to osteosarco-
ma, especially in the case of osteoblastic calcification’s ab-
sence. GCT has also been reported to show the prominent
uptake in thallium-201 (201-Tl) scintigraphy. We hypothe-
sized GCT showed higher 201-Tl uptake than osteosarcoma.
This study aims to compare with 201-Tl uptake between GCT
and osteosarcoma. Materials and Methods: Between January
2006 and December 2012, 19 patients with GCT and 24 pa-
tients with osteosarcoma underwent 201-Tl scintigraphy be-
fore treatment. We used the tumor-to-background contrast
(TBC) and washout rate (WR) to evaluate the 201-Tl uptake.
The differences of TBC on the early and delayed imaging and
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WR were estimated by the Mann-Whitney U test. Results:
This retrospective study included 19 patients with GCT (12
men, 7 women; mean age, 38.5 years; range, 20-61 years) and
24 patients with osteosarcomas (12 men, 12 women; mean
age, 32.4 years; range, 9-69 years). The median TBC of
GCTwas higher than that of osteosarcoma on delayed imaging
(236 vs. 119, p < 0.05) in 201-Tl scintigraphy. However, there
were not statistically significant differences in the median
TBC on early imaging (331 vs. 230, NS) and WR (0.49%
vs. 0.46%, NS). Conclusion: Giant cell tumor of bone showed
higher uptake than osteosarcoma only on the delayed imaging
in 201-Tl scintigraphy.
P931
Inclusion of Trabecular Bone Score (TBS) in Risk
Assement of Fragility Fracture in PostmenopausalWomen
B. PEREZ LOPEZ, R. RUANO PEREZ, L. G. DIAZ
GONZALEZ, M. E. MARTIN GOMEZ, E. MARTIN
GOMEZ, M. P. TAMAYO ALONSO, F. GOMEZ
CAMINERO LOPEZ, P. GARCIA-TALAVERA SAN
MIGUEL, J. DEL PINO MONTES, T. CARRANCO; HOS-
PITAL UNIVERSITARIO CLINICO DE SALAMANCA,
SALAMANCA, SPAIN.
TBS is a measure of gray-level texture used to evaluate pixel
measurements from a two-dimensional DXA image of the
lumbar spine. TBS provides information about bone
microarchitecture and has the potential to discern differences
betweenDXA scans that show similar BMDmeasurements, in
such a way an elevated TBS value correlates with better skel-
etal microstructure.OBJECTIVEEvaluate if TBS provides
complementary information to T-scores of lumbar spine from
DXA scans.PATIENTS ANDMETHODS174 postmenopaus-
al womenwere included, the mean age was 66 years old (range
50-89), without previous fragility fracture or medical treatment
for osteoporosis. 55 of them had normal BMI (<25), 85 over-
weight (BMI 25-30) and 34 obesity (BMI >30). According to
bone mineral density were classified in: normal (T > -1.0),
osteopenia (-2.5<T< -1.0) and osteopososis (T<- 2.5). Bone
structure was classified in: normal (TBS<1.300), partially
degradated (1.200<TBS<1.300), degradated (TBS< 1.200).
Mayor fragility fracture risk using both parameters was de-
fined as: low (<5/1000/year), moderated (5-10/1000/year)
and high (>10/1000/year).RESULTSIn the whole sample 68
women (39.1%) showed normal T-score, 81 (46.6%)
osteopenia, and 25 (14.4%) osteoporosis. Osteoporosis detec-
tion was 18.2% if normal BMI, 16.5% if overweight, and only
2.9% if obesity was associated. This difference was statistical-
ly significant (x2, p<0.05).When combining T-score and TBS,
mayor fracture risk was low in 75 women (43.1%), moderated
in 65 (37.4%) and high in 34 (19.5%). TBS rised up 27/81
(33.3%) osteopenic women to high risk. Biggest modification
was found in obesity group, 56% women were re-classified as
high risk, liable to treatment.CONCLUSIONInclusion of TBS
in DXA scans of lumbar spine allows to classify osteopenic
women in a higher fracture risk. Obesity underestimates oste-
oporosis detection that can be solved by evaluating bone struc-
ture with TBS.
P932
Bone Mineral Density in Patients Treated
with Antipsychotics
A. Cengiz1, V. Altınyazar2, B. G. Manoğlu2, F. Vahapoğlu2,
O. Kocabaş2, I. Kurt Ömürlü3, Y. Yürekli1; 1Adnan Mende-
res University, Medical School, Department of Nuclear Med-
icine, Aydin, TURKEY, 2Adnan Menderes University, Medi-
cal School, Department of Psychiatry, Aydin, TURKEY,
3Adnan Menderes University, Medical School, Department
of Biostatistics, Aydin, TURKEY.
Purpose: Antipsychotic drugs may reduce the bone mineral
density (BMD). In this study we investigated the effect of
prolactin levels, duration of disease, metabolic syndrome,
use of mood stabilizer drug, smoking and exercise on BMD
in schizophrenia and bipolar disorder patients treated with an-
tipsychotics. Methods: 130 patients (54 females and 76 males,
mean 40±12 years old) were included in the study. All patiens
with diagnosis of bipolar affective disorder (30 patients) and
schizophrenia (100 patients) were being treated with antipsy-
chotic drugs. BMD was measured at the lumbar spine L1-L4,
the femoral neck, the trochanteric regions of the left hip using
dual energy x-ray absorptiometry (DEXA). Blood sampling
was performed for prolactin levels. Arterial blood pressure,
waist circumference, fasting glucose, HDL cholesterol, tri-
glyceride levels of the patients were measured for diagnosis
of metabolic syndrome. Age, weight, height, smoking habit,
regular physical exercise (with a minimum duration of 30 mi-
nutes a day, three days per week) and additional mood stabi-
lizer drugs administered were recorded. Results: In lomber
region, 57 patient’s BMD were normal, osteopenia was found
in 45 patient and osteoporosis was found in 28 patient in terms
of T score derivation. Prolactin level was high in 60 patients
(normal range: 2.58-18.12). In patients evaluated for metabolic
syndrome, 49 of 113 (%43) were suffering from metabolic
syndrome. There was no statistically significant relationship
between BMD and plasma prolactin level, using additional
mood stabilizer drug, dose of antipsychotic drug and metabol-
ic syndrome (p>0.05). Negative correlations between duration
of illness, duration of antipsychotic drug use and BMD of
femoral neck were found (r=-0.248 ve -0.232). Lomber
BMD was significantly higher in patients who don’t smoke
and make exercise regularly than those of patients who smoke
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and don’t make regular physical exercise (p<0.05). Conclu-
sion: Due to sedantary lifestyle, prolonged use of antipsychotic
drugs and smoking, risk of osteoporosis can increase in pa-
tients with schizophrenia and bipolar affective disorder. BMD
measurement should be performed before starting treatment
with antipsychotics and BMD of these patients should be
followed-up with regular intervals.
P933
Knowledge Challange: Garlet Sign on DXA Scan
N. Fatima1, M. u. Zaman2; 1Department of Nuclear Medi-
cine, Dr Ziauddin Medical University, Karachi, PAKISTAN,
2AKUH, Karachi, PAKISTAN.
This is a 55 years old postmenopausal lady, being worked
up for left sided breast cancer. On first to Radiology de-
partment she had a contrast enhanced abdomen chest CT
studies and then had a Dual Energy X-ray Absorptiometry
(DXA) scan (Figure 1). However, after reviewing the scan,
the nuclear physician requested a repeat study after 3 days.
Figure 1: DXA scan of lumbar spine on first visit. Ques-
tion 1: Why a repeat study was suggested? Answer: a.
Patient was not positioned properly b. Error in energy
window of X-ray c. Computer error in calculating T and
Z-scores d. Optimal study but with abnormally high T and
Z scores Figure 2: DXA scan of lumbar spine on subse-
quent visit. After 3 days a repeat DXA scan done and this
time exam was found satisfactory. Q2: Why abnormally
high T and Z-scores got normalized? Answer a. Patient
was positioned properly b. Technical error in DXA ma-
chine was rectified c. Oral contrast has been washed out
d. Patient has received some treatment to bring her T and
Z score into normal limits.
Comment: Correct answers are 1d and 2 c. One her first
visit she had a contrast enhanced CT study which was
followed by a DXA scan. Due to presence of oral
gastrografin in transverse colon (visible in Figure 1 as
a “Garlet Sign”) this has resulted in higher photon at-
tenuation over the lumbar spine. This attributes to false-
ly elevated bone mineral density (BMD), T and Z-scores
for her age. Repeat scan after 3 days shows absent
“Garlet Sign” due to clearance of gastrografin and cor-
rect measurement of BMD and other scores over lumbar
spine. It is important to defer a DXA scan for at least 2
weeks after an intravenous contrast, 3-7 days after an
oral contrast and 1-2 days after a nuclear medicine pro-
cedure performed with Tc-99m to avoid falsely high
BMD, T and Z-score values.
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FDG PET/CT in left ventricular assist device infection
D. Grigolato, M. Zuffante, E. Carmagnani, M. Cucca, E.
Concia, M. Ferdeghini; Azienda Ospedaliera di Verona, VE-
RONA, ITALY.
Aim: To evaluate the utility of FDG PET/CT in confirming or
excluding the presence of left ventricular assist device infec-
tion (LVADI), defining the extent of the involvement and guid-
ing the most appropriate therapy. Methods: Between 2013 and
2014 ten consecutive patients, all males (age 51-69, mean
60.8), with Heartmate II and infections of the skin at the exit
of the driveline, underwent 16 FDG PET/CT. A whole body
scan (head to feet) was performed after 1 hour from FDG
injection in fasting condition. Four sites of increased FDG
uptake in LVADI were recognized: of the driveline (DL), of
the prosthetic device (PD), of the inflow valve housing (IV)
and outflow valve housing (OV); the tracer uptake was de-
scribed as focal or extensive, the grade of involvement with
SUV max values and SUV ratio between infection site and
liver (mild, moderate and severe) was depicted. Every site of
increased uptake of FDG was checked in non-attenuation
corrected images (NAC). Results: Microbiology cultures from
percutaneous DL and blood mainly isolated Staphylococcus
Aureus in 5 patients, coagulase-negative Staphylococci in
three men and Burkholderia Cepacia in one case. Fourteen
PET were positive and infectious sites were attributed to the
DL in 13, IV in 8, PD in 4, OV in 7. The grade of infection was
mild in 9 PET, moderate in 2 and severe in 3 scans. All patients
were treated with the most suitable antibiotics according to the
pathogens and the extension of the LVADI. Two patients with
severe and one patient with moderate but extensive involve-
ment at PET, who did not respond to antibiotic treatment,
underwent transplantation with confirmation of the sites of
infection. All patients with mild grade and focal uptake of
LVADI had their personalized antibiotic treatments and they
are in good life conditions at follow-up. One patient died for
non-infectious reasons. In our study we did not see any chang-
es in the OV tracer uptake during different antibiotic treat-
ments, the SUV values and the extension of the uptake were
always mild and focal respectively, suggesting a chronic in-
flammatory response to the prosthetic graft material rather than
a site of infection. None of these patients revealed the presence
of septic embolism at PET imaging. Conclusion: In this small
sample of patients, FDG PET/CTwas helpful to the clinicians
in recognizing the sites, the extension and grade of LVADI,
which had important implications on patient management.
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Diagnosis value of 18F-FDG PET/CTwith myocardial
suppression in the deteccion of cardiovascular implantable
electronic device infections
U. Granados, D. Fuster, J. Pericas, S. Ninot, J. Tolosana, A.
Moreno, C. Falces, J. Miro, F. Lomeña; Hospital Clínic, Bar-
celona, SPAIN.
Aim: To asses the usefulness of 18F-Flurodeoxyglucose pos-
itron emission tomography/computed tomography (18F-FDG
PET/CT) with myocardial suppression in patients with
suspected infection of cardiovascular implantable electronic
device (CIED). Material and Methods: A total of 19 consecu-
tive patients (mean age 68±18.0 years) with suspected CIED
infection (11 pacemakers and 8 implantable cardiac defibrilla-
tors) were prospectively included. All patients underwent
whole-body 18F-FDG PET/CT with myocardial suppression
protocol (Heparin 50 UI/Kg). The results were interpreted by
two experienced nuclear medicine physicians. All of the pa-
tients were subjected to clinical, microbiological, and echocar-
diographic evaluation. Diagnosis of infection was made by
microbiological documentation of explanted devices or clini-
cal follow-up for 12months. Results: 7/19 patients (37%) were
diagnosed of CIED infection (4 implantable cardiac defibrilla-
tors and 3 pacemakers). Sensitivity, specificity, NPVand PPV
of 18F-FDG PET/CTwere 84%, 92%, 91% and 83%, respec-
tively. The overall accuracy of 18F-FDG PET/CT in the de-
tection of CEID infection was 84%. In two patients 18F-FDG
PET/CT was the only technique to identify infection. As and
additional contribution 18F-FDG PET/CT imaging revealed 5
unexpected extracardiac findings in 4 patients diagnosed of
pulmonary embolism (n=2), splenic embolism (n=1),
spondylodiscitis (n=1) and high grade villous colon adenoma
(n=1). Conclusions: This study suggests that 18F-FDG PET/
CT may be relevant in the evaluation of patients with a
suspected CIED infection. 18F-FDG PET/CT can detect un-
expected embolic infection which influence in the therapeutic
management of the patients.
P936
Diagnostic value of 18FDG PET imaging patients
with clinical suspicion of vasculitis
E. Piekarski, F. Hyafil, N. Mikail, B. Mahida, J. Slama, E.
Blanchet, J. Calais, H. Regaieg, R. De Paola Chequer, F.
Rouzet, D. Le Guludec, K. BenAli; Bichat's hospital, Paris,
FRANCE.
Introduction: The diagnosis of large vessel vasculitis relies on
the association of clinical, biological and histological criteria
but can sometimes be difficult. In this study, we evaluated the
diagnostic performances of 18FDG-PET imaging in a large
monocentric cohort of patients with a clinical suspicion of
active vasculitis. Material and methods: A total of 152 patients
with a clinical suspicion of vasculitis were sent in our depart-
ment for 18FDG-PET imaging. Patients were imaged with
PET 90 minutes after injection of 4 MBq/kg. 18FDG-PET
imaging was found positive (1) for active vasculitis in pres-
ence of high 18FDGuptake in the aorta and supra-aortic trunks
wall using a semi-quantitative visual scale; (2) for polymyalgia
rheumatic (PR) in presence of high 18FDG uptake in proximal
joints (pelvic and scapular girdle) and in spinous processes of
cervical and lumbar spine. Clinical outcome of all patients was
collected one year after 18FDG-PET imaging. Patients were
considered as presenting active vasculitis and/or PR based on
validated clinical criteria either at time of the scanning or dur-
ing FU. Results: From the 152 patients imaged with 18FDG-
PET imaging, 34 patients (22,4%) were considered as present-
ing an active vasculitis or PR. Twenty patients (13,1%) pre-
sented isolated giant cell arteritis (GCA), 4 combined GCA
and PR (2,6%), 1 patient Takayasu arteritis (0,6%), 9 patients
isolated PR (5,9%). From the 34 patients, active vasculitis or
PR was confirmed in 25 patients. In the remaining 9 patients
with positive 18FDG-PET, diagnosis of active vasculitis or PR
was not clinically confirmed (atheromatous disease was consid-
ered in 4, 1 had CADASIL associated with atheromatous dis-
ease, 2 had ankylosing spondylitis and psoriatic arthritis). In the
118 patients with negative 18FDG-PET imaging, only three
patients had a confirmed GCA on histology. These 3 patients
had all been treated by corticotherapy before the imaging. The
remaining 115 patients did not present any sign of vasculitis
during a 1-year follow-up. 18FDG-PET imaging demonstrated
sensitivity of 89,2%, specificity of 92,7%, predictive positive
and negative value of 73,5% and 97,4% for the diagnostic of
active vasculitis or PR. Conclusions: In this monocentric cohort
of 152 patients with a clinical suspicion of active vasculitis,
18FDG-PET imaging demonstrated good diagnostic perfor-
mances for the detection for active vasculitis and PR. This con-
firms that 18FDG-PET imaging has an incremental role over
usual criteria for the early identification of active vasculitis.
P937
FDG-PET in suspected infection versus loosening
of Orthopedic Fixation Device (rods, plates, screws,
and wire loops) - correlation with cultures.
S. Raja1,2, N. Alnakshabandi2, S. George3, M. AlHarbi2, R.
Sergey2; 1Baylor College of Medicine, Bellaire, TX, UNIT-
ED STATES, 2KFMC, Riyadh, SAUDI ARABIA, 3Johns
Hopkins Aramco Healthcare, Dhaharan, SAUDI ARABIA.
Objectives: Orthopedic devices (ODev) including rods, plates,
screws, chains, and wire loops etc. (RO, PL, SC, CH, WL) are
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increasingly used for fracture fixation. Despite the deployment
of conventional multimodality imaging, the diagnosis of in-
fected ODev/ underlying osteomyelitis (Uost) in traumatized
bone continues to be challenging. Recently, FDG-PET has
been found to be encouraging in the evaluation of MSK infec-
tions. We explored the utility of PET in evaluating suspected
ODev infections/Uost - post hardware placement. Methods:
Retrospective review of all PET scans from 2012 to current
revealed 15 pts (male=9, female=6, mean age=41.5 yrs)
scanned for suspected infected ODev/Uost post hardware
placement. The PET-CT fusion images were reviewed interac-
tively on a dedicated workstation, findings on PET were cor-
related with cultures (when available), and clinical follow-up.
Results: Out of total 160 ODev, 7 (6/128 SC, and 1/9 WL)
were infected in 6/21 pts. The remaining 8/8 RO, 12/12 PL and
3/3 CH were not infected. In all 6 pts with infected ODev,
concurrent 3-Phase Bone Scan (3PhBS) was +ve on blood
pool and delayed phases. In discordant 3-PhBS +ve on de-
layed phase only and -ve on PET, cultures/followup were -ve
for infection/Uost. In 1 pt. two SC were +ve for infection by
concurrent PET and 3PhBS, however, repeated biopsies
showed nonspecific granulating tissue. Correlative
multimodality imaging i.e. plain films, MRI, diagnostic CT,
routine 3PhBS and Ga-67 were complementary to PET. Not
documented observations suggest that concurrently negative
PET and bone scans essentially rule out infected ODev and/or
Uost in traumatized bone, while increasing the confidence in
interpretation of PET. MRI was not efficacious in evaluating
ODev, and was falsely suspicious for Uost in 2 cases. In 4/5
cultures from extracted Odev PET was true positive. Conclu-
sions: Findings in our series suggest that FDGmay be superior
to contemporary multimodality imaging for evaluating
suspected infections complicating orthopedic fixation devices.
Literature search suggests that our group is the 1st to present
comprehensive utility of PET-CT in infected hardware.
P938
FDG PET/CT and WBC scan in vascular graft infection
M. Pacilio, C. Lauri, F. Trapasso, I. Baldazzi, D. Prosperi, A.
Lenza, C. Tirotti, M. Taurino, F. Scopinaro, A. Signore;
Università Sapienza Roma, Rome, ITALY.
Introduction: there are few studies comparing [18F]FDG-PET/
CT and scintigraphy with 99mTc-HMPAO-WBC in the diag-
nosis of vascular prostheses infections. Moreover, the distri-
bution patterns of FDG and of radiobelled-WBC in patients
with endoprosthesis, in relation to the type of stent and time
from surgery, is not know. Aim: to compare [18F]FDG and
99mTc-HMPAO-WBC in patients operated with vascular
endoprosthesis Endurant® and to define the patterns of nor-
mality and abnormality for both radiopharmaceuticals.
Materials & Methods: 16 patients, that underwent an
endovascular exclusion of abdominal aneurysm with
Endurant® endoprostheses, were retrospectively enrolled in
the study. Half of patients had suspicion of infection (based
on CT, ESR, GB, PCR, fever), half were clinically and bio-
chemically infection free and were operated 8-41 months be-
fore. Each patient performed both scans. For WBC: dynamic
images were acquired on the abdomen in the anterior-posterior
from time 0 to 2.5 minutes (one frame every 4 seconds for 40
frames). Planar images were acquired on the abdomen in
antero-posterior and oblique front left and right. The first set
of images was acquired 10 minutes after administration of
WBC (100 seconds acquisition time), the second set at 3h
(141 seconds acquisition), the third set at 20h (1040 seconds
acquisition). For PET: images were acquired 1h after admin-
istration of 185 MBq [18F]FDG. All images were examined
by 2 independent physicians. Qualitative analysis was per-
formed for WBC scans and both qualitative and semi-
quantitative analysis (SUVmax and SUVmaxT/SUVmeanBKG)
was performed for PET scans. Final diagnosis was made by
clinical-surgical follow-up. Results: no patients of first group
had an infection but 5 of second group were infected. All
patients but 1 were correctly identified using the following
interpretation criteria: for WBC scan, positivity for infection
is represented by the accumulation of radioactivity with time
in the peri-prosthetic tissue; negativity for infection was con-
sistent with no uptake in peri-prosthetic tissues; for FDG-PET/
CT, positivity was characterized by an inhomogeneous intra-
and extra-vascular uptake with a SUVmax≥3.6 and a SUVmaxT/
SUVmeanBKG>3.0; negativity was considered an homogeneous
up t a k e w i t h a n SUVm a x<3 . 6 and a SUVma x T /
SUVmeanBKG≤2.0. The only discordant case (FDG positive
and WBC negative) had no infection. Conclusions: PET/CT
with FDG seems to be equally sensitive than WBC but less
specific using the above mentioned interpretation criteria. Pa-
tients with an Endurant® type of endoprostheses and no infec-
tion, have a negative FDG andWBC scan from 8 months after
surgery.
P939
Assessment of the Diagnostic Performance of Quantitative
FDG-PET/CT Parameters in the Detection of Vascular
Graft Infection
S. Houshmand1, A. Salavati1, M. Sadic2, K. T. Pedersen3, A.
Alavi1, P. F. Høilund-Carlsen3, S. Hess3; 1University of
Pennsylvania, Philadelphia, PA, UNITED STATES, 2Ankara
Training and Research Hospital, Ankara, TURKEY, 3Odense
University Hospital, Odense, DENMARK.
AIM: Vascular graft infections are associated with significant
morbidity and mortality. The diagnosis may be difficult and
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accurate and precise diagnostic tools are pivotal to improve pa-
tient management and outcome. Visually assessed FDG-PET/CT
has been suggested as a reliable modality in this setting, albeit
with relatively poor specificity especially infections early after
surgery. In this study, we explored the potential of novel quanti-
tative parameters derived from FDG-PET/CT in suspected vas-
cular graft infections. MATERIAL AND METHODS: Thirty-
one patients with suspected vascular graft infections were retro-
spectively included in this study. Comprehensive data on all di-
agnostic procedures, results of cultures, events during follow-up,
and treatment regimens were obtained through reviews of the
patients’medical charts. Final diagnoses were based on all avail-
able clinical information including results of surgical revisions,
cultures, and/or follow-up. Quantitative analyses were obtained
by dedicated software using an adaptive contrast-oriented
thresholding algorithm. Three-dimensional regions of interest
were placed around the sites of suspected infection by an experi-
enced physician and metabolically active volume (MAV; i.e. a
volume with an uptake above a specified threshold), maximum
standard uptake values (SUVmax), mean SUV (SUVmean), total
lesion glycolysis (TLG=MAV*SUVmean), and SUVpeak (i.e.
the average SUV within a 1 cubic cm volume of the lesion with
the highest uptake) were calculated. Receiver operating curve
(ROC) was performed for assessment of diagnostic performance
of the volumetric FDG-PET/CT parameters. RESULTS: Eleven
female and 20 male patients aged 37-82 years old (median age
70) were included.Median graft age was 11months (range 1-144
months). Several graft types were represented, i.e. aorto-
bifemoral (n=16), aortic (n=7), femoro-femoral (n=5), axillo-
bifemoral (n=2), femoro-popliteal bypass (n=1). Infection was
the final diagnosis in 19 patients (61%). The areas under the
ROC curves were 0.883 for TLG, 0.876 for SUVpeak, 0.849
for SUVmax and 0.823 for MAV and SUVmean (p<0.001).
TLG > 54.6, SUVmax > 4.5, and SUVmean > 2.6 all yielded
94.7% sensitivity, 72.7% specificity with positive predictive
values (PPV) of 84%, and negative predictive values (NPV) of
89%. SUVpeak > 3.6 had a sensitivity of 94.7% and a specificity
of 81.8% with PPV and NPV of 89% and 90%, respectively.
MTV > 18.6 was 84% sensitive and 72.7% specific with
PPV=82% and NPV=74%. CONCLUSION: In suspected vas-
cular graft infection, quantitative parameters obtained from FDG-
PET/CTseem feasible with relatively high sensitivity, specificity,
and predictive values. However, larger scale prospective studies
are needed to conclude further on the potential of this technique.
P940
Usefulness of (18)F-FDG PET/CT in the infections
of peritoneal catheter
S. SANFILIPPO, A. Svirydenka, P. Ghedini, P. Castellucci, R.
Bonfiglioli, S. Diodato, S. Cambioli, S. Fanti; Azienda
ospedaliero-universitaria S.Orsola-Malpighi, Bologna, ITALY.
Aim: The aim of our study was to evaluate the diagnostic role
of (18)F-FDGPET/CT in the detection of the site of infection
in patients with peritoneal catheter during peritoneal dialysis
(PD). Material and Methods: we enrolled 20 patients (10
women; 10 men; mean age 61y; range 31-87y) between Oc-
tober 2010 and January 2015, with the clinical suspicious of
infection in the peritoneal catheter. All the enrolled patients
were treated with peritoneal dialysis due to chronic kidney fail-
ure. All patients underwent (18)F-FDGPET/CT scan, per-
formed according to standard procedure. We evaluated 18F-
FDG uptake in the soft tissue contouring the peritoneal catheter.
Any uptake higher than the liver has been considered positive.
(18)F-FDG PET/CT findings were validated by clinical and/or
cytological and biochemical findings during follow up. Thirteen
out of 20 enrolled patients were symptomatic (fever of un-
known origin (FUO), asthenia, clinical observation like heat
and redness of the skin); 5/20 patients had positive laboratory
findings; 2/20 had suspicious US findings. Results: (18)F-FDG
PET/CT resulted positive in 12/20 patients. Among these: 8 pts
were confirmed to be positive by cytological analysis (Staphy-
lococcus Aureus and Pseudomonas Aeruginosa). The remain-
ing 4 pts were referred to (18)F-FDG PET/CT for FUO and/or
positive laboratory tests. In these patients cytological analysis
performed in the site of peritoneal catheter resulted to be nega-
tive. Among the 8/20 negative (18)F-FDG PET/CT, one was
false-negative, as shown by the result of cytological analysis
(Staphilococcus). The remaining 7 patients were (18)F-FDG
PET/CT true negatives, according to normalization of inflam-
matory markers in subsequent clinical and laboratory follow-up
without any kind of therapy. According to our results (18)F-
FDG PET/CT showed: Sensitivity: 88%, Specificity: 64%.
and Accuracy 75%. Conclusions: main limitations of our study
is the small number of patients enrolled. According to our pre-
liminary data however, (18)F-FDG PET/CT could have an ef-
fective role in establishing the presence and the extent of the
infections of peritoneal catheter. Keywords: (18)F-FDG PET/
CT; infection; peritoneal catheter; FUO.
P941
Fever of Unknown Origin (FUO). Utility of 18F-FDG
PET-CT.
C. Riola-Parada1, M. N. Cabrera-Martín2, O. Salsidua-Ar-
royo1, M. Pedrera-Canal1, M. Martínez-de-Bourio1, E. Cala-
Zuluaga1, L. Lapeña-Gutierrez2, R. Couto-Caro1, J. L.
Carreras-Delgado2; 1Nuclear Medicine Department. Hospital
Clínico San Carlos, Madrid, SPAIN, 2Nuclear Medicine De-
partment. Hospital Clínico San Carlos. Universidad
Complutense, Madrid, SPAIN.
Objectives: The aim of this study was to evaluate the utility of
18F-FDG PET-CT in the identification of the causes of
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FUO.Material and methods:A retrospective study was per-
formed in 51 consecutive patients with FUO (34 men and 17
women, mean age 61years, range 21-89) who received 18F-
FDG PET-CTexamination from December 2008 to December
2014.All patients met the Durack and Street criteria for FUO
and signed informed consent form.Final diagnosis was obtain-
ed through microbiological and histopathological examination
and clinico- radiological follow-up.Mean follow-up was 7,02
months (range 0,17-23,30).Results:30 of 51 studies (59%)
showed abnormal findings.Among the true positive studies
(29), the cause of fever was infection in 17 patients, inflam-
matory process in 7, malignancy in 4 and miscellanea (ische-
mic colitis) in one patient.The only one false positive case
showed increased FDG uptake in bone marrow suspicious
for lymphoproliferative syndrome. Bone marrow biopsy was
negative, and final diagnosis was mesenteric panniculitis and
febrile neutropenia, without evidence of localized infection.8
studies were considered true negative because etiology was
not identified despite diagnostic procedures and clinico-
radiological follow-up (mean 6.74 months).Among the false
negative studies (13), the cause of fever was infection in 7
patients, inflammatory process in 5 and miscellanea
(dysautonomia in the setting of degenerative neurologic dis-
ease) in one patient.Accuracy was 72%, sensitivity 69%, spec-
ificity 89%, positive predictive value 97% and negative pre-
dictive value 38%.Conclusion:18F-FDG PET-CT contributes
significantly in the etiologic diagnosis of FUO. 18F-FDG
PET-CT should be included in diagnostic protocols of FUO.
P942
The Clinical Value of FDG-PET/CT in Bacteraemia
of Unknown Origin: A Retrospective Study
M. B. Brøndserud1, S. Hess1, A. H. D. Johansen1, C. Peder-
sen2, P. F. Høilund-Carlsen1; 1Dept. of Nuclear Medicine,
Odense University Hospital, Odense, DENMARK, 2Dept. of
Infectious Diseases, Odense University Hospital, Odense,
DENMARK.
AIM: Gram-positive bacteraemia without a known focus of
infection (i.e. bacteraemia of unknown origin; BUO) is a seri-
ous condition associated with high morbidity and high mortal-
ity. A fast and reliable diagnosis is imperative to institute
targeted treatment at an early stage and avoid delay in diag-
nosing clinically “silent” foci of infection, which may other-
wise give rise to complicated and prolonged disease courses.
The diagnostic process relies traditionally on extensive clini-
cal, microbiological, and serological testing, and a variety of
sometimes futile diagnostic and imaging procedures, including
invasive ones. We investigated the clinical value of FDG-PET/
CT in BUO. MATERIAL ANDMETHOD: Our retrospective
study population comprised patients admitted to Odense
University Hospital in 2013 with gram-positive BUO who
subsequently underwent FDG-PET/CT. Patients were exclud-
ed if they had active cancer and no baseline FDG-PET/CT
scan. Clinical data was collected from the patients’ medical
records. A final decision about the origin of bacteraemia was
based on the entire patient course and included all available
data. This served as a composite reference standard for com-
parison with the result of the FDG-PET/CT scan. FDG-PET/
CT was considered of high clinical impact if it correctly re-
vealed sites of bacteraemia (in agreement with the composite
reference standard) in areas not assessed by other imaging
modalities, or if other imaging modalities where negative or
equivocal in these areas, if it established a new diagnosis, and/
or changed the antimicrobial treatment. All other results were
considered of low clinical impact. RESULTS: A total of 67
patients were evaluated, 4 were excluded. The remaining 63
patients were 29 females and 34males with a mean age of 69.3
years (range 23-94). The median time span from BUO was
suspected to FDG-PET/CT was performed was 6 days (range
2-21). FDG-PET/CT located the source of bacteraemia in 62%
(95% CI: 49-74) of patients, and had a high clinical impact in
56% (95% CI: 43-68). Patients underwent in median 5 (range
2-19) examinations prior to FDG-PET/CT, and 2 (range 0-19)
examinations afterwards. CONCLUSION: FDG-PET/CT ap-
pears to be a reasonable first-line modality in BUO with high
clinical impact in more than half of the patients and a potential
to obviate a substantial number of futile examinations. Our
results were limited by their retrospective nature, but highlight
the need for prospective studies of FDG-PET/CT in BUO.
P943
Comparison of 18F-FDG-PET/CT
and 99mTc-HMPAO-labelled-leukocyte SPECT/CT
in the evaluation of patients with fever
G. Cusato1, P. Ferro1, S. Fiorino1, M. Spallino1, C. E.
Popescu2, R. Sara2, M. Milella2, G. Cabrini2, C. Rossetti2;
1Università Milano-Bicocca, Milano, ITALY, 2Ospedale
Niguarda, Milano, ITALY.
Aim: Inflammatory and infectious processes are a
heterogeneuos class of diseases with a wide setting of presen-
tation, including fever. Early diagnosis is crucial and involve
CT, blood cultures, serological tests and Nuclear Medicine
tecniques such as PET/CT with 18-F-FDG and SPECT/CT
with 99mTC-HMPAO labelled leukocyte. The aim of our pre-
liminary study was to compare the clinical value of the two
techniques in localizing infection loci in patients with fever.
Methods: we retrospectively analysed 24 consecutive patients
(10 women and 14 men, age range 5-85 years) with fever and
no other significative symptoms undergoing both 18F-FDG-
PET/CT and 99mTc-HMPAO-SPECT/CT for precise
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anatomical mapping . Patients were under investigations for:
fever of unknown origin (FUO) (9), endocarditis (4), vascular
prosthetis infection (3), heart device infection (1), identifica-
tion of unknown septical foci (3), evaluation of surgical
wounds (3), cerebral aracnoiditis(1). Both methods were con-
sidered "positive" or "negative" on agreement of 3 indepen-
dent observers on qualitative analysis of the images. Final
diagnosis was based on biopsy/microbiological findings,
and/or clinical/serological/imaging follow up. Results: In
FUO, concordance was observed in 5/9 patients : 4 both neg-
ative ( in 3/4 no cause of FUO was found on further investi-
gations, 1/4 had a hodontegenous sepsis) and 1 both positive
(pace-maker). There was discordance in 4/9 patients, with pos-
itive 18F-FDG-PET/CT and negative 99mTc-HMPAO-
SPECT/CT. In these 4 patients the diagnosis of inflammation
was confirmed by further investigations, in particular the final
diagnosis were pericarditis, aortititis, inflammation of hepatic
cysti and inflammatory paravertebral expance. In suspected
endocarditis, SPECT/CT and PET/CT showed concordance
in 2/4 patients: 1 positive (increasing levels of PCR and no
antibiotic therapy), 1 negative (diagnosis of endocarditis later
rejected). In 2/4 patients there was discordance: both positive
on PET/CT and negative on SPECT/CT (endocarditis con-
firmed by further follow up). Discordance was found also in
identification of unknown septical foci (1/3), evaluation of
surgical wounds (3/3). PET/CT showed an overall higher le-
sion detection rate (22vs5). Conclusion: PET/CT detected
more lesions, whereas SPECT/CT added value was to exclude
an ongoing infection mainly in FUO. Even in this limited
group of patients, PET/CT seems to be a better tool in the
evaluation of suspected endocarditis. Hybrid imaging allows
better anatomical correlation and may improve the
inflammatory/infection disease management. Signs of acute
infection (especially PCR levels and fever) should be consid-
ered in choosing 99mTC-HMPAO-SPECT/CT over 18F-
FDG-PET/CT, even if influenced by the ongoing antibiotic
therapy.
P944
Complementary roles of retrospectively co-registered PET
and MR in evaluation of suspected osteomyelitis of foot.
S. Raja1,2, N. Alnakshabandi2, S. George3, M. AlHarbi2, S.
Rumyantsev2; 1Baylor College of Medicine, Bellaire, TX,
UNITED STATES, 2KFMC, Riyadh, SAUDI ARABIA,
3Johns Hopkins Aramco Healthcare, Dhahran, SAUDI
ARABIA.
Accurate diagnosis of Osteomyelitis (Osteo) often necessitates
multimodality imaging including MR and scintigraphy.
Though MR is very sensitive, it is limited in its specificity;
especially in post-surgical settings, post hardware placement,
and in violated bone. FDG-PET is emerging as an important
tool in MSK infections. We exhibit difficult/complicated cases
of Osteo, wherein PET has been helpful. Furthermore the com-
plementary roles of PET and multiparametric MR in compar-
ison with conventional imaging (plain films, CT and scintig-
raphy) will be illustrated. Materials: Retrospective review of
radiology archives revealed 12 pts. (Male = 9, Female = 3;
mean age= 38.3 yrs). All PET and MR scans were acquired
per accepted protocols. The case mix was as follows:
suspected Osteo in foot 6, pelvis 2, skull base 2, chest 1, and
spine 1. Teaching points: 1. Unique findings on both MR and
PET in Madura Foot. 2. Utility of 3D rendered PET, and PET-
CT/MR fused images to track the sinuous sinus tracts in 2 pts
(1 pt. with infected cardiac pacemaker wire sinus formation
tunneling parallel to the sternum from pericardium to subcu-
taneous tissue, and draining pus. 3. Superior efficacy of PETas
compared to MR in complicated Osteo, such as infected hard-
ware. 4. Utility of functional MR (DWI-ADC) and PET-SUV
in quantitating response to antibiotic therapy utilizing
maxSUV and ADC estimates derived from PET and MR.
5.Resolving indeterminate findings on either MR or PETwith
the help of its coadjutor PET or MR respectively. 6. Use of
Novel coregistration algorithm (MIMsoft, Cleveland Ohio,
USA) in accurately co-registering often technically difficult
to coregister and fuse feet and ankle 3D PETandMR datasets.
Conclusion: Our unique series will illustrate the need for
coregistering PET and MR images, and interactively review
the fused datasets for an accurate diagnosis. Findings in our
series concur that PETandMR are complementary in pts. with
complicated Osteo.
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SPECT/CT value in the diagnosis of diabetic foot
infections by 99mTc-HMPAO-labeled leucocyte scan
S. Georga1, C. Manes2, D. Lo-Presti1, V. Mpalaris1, I.
Tsavdaridis2, I. Iakovou1, D. Katsaboukas1, V. Athanasiou1,
K. Badiavas1, A. Doumas1, G. Arsos1; 13rd Dept of Nuclear
Medicine, Aristotle University Medical School, Papageorgiou
Hospital, THESSALONIKI, GREECE, 2Diabetes Center,
Papageorgiou Hospital, THESSALONIKI, GREECE.
Introduction-Aim: Scintigraphy with in vitro labeled
leucocytes is a well established method for diagnosing diabetic
foot osteomyelitis (DFO). However, poor spatial resolution
and lack of anatomic landmarks often limit the ability of la-
beled leucocyte scan to discriminate bone from soft tissue
infection, especially in areas with small bone structures as in
the foot. The aim of the study was to evaluate the contribution
of SPECT/CT as an adjunct to planar images of 99mTc-
HMPAO-labeled leucocyte scan (LS) for diagnosing and lo-
calizing infection in the diabetic foot. Patients and methods:
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Thirty-one consecutive patients with clinical suspicion of DFO
or under antibiotic treatment for proven DFO were included in
the study. Totally 40 pedal sites suspected for DFO were in-
vestigated. Planar images were acquired 1 and 4 hours post
injection of in vitro labeled autologous leucocytes followed by
a SPECT/CT scan at the end of the study. LS images were
interpreted alone and in conjunction with SPECT/CT scans
and were considered to be positive for DFO when focally
increased persistent leucocyte bone uptake was observed. Fi-
nal diagnosis was based on clinical and radiological follow-up
or surgical findings. Results: Among the 40 pedal sites inves-
tigated, 7 cases of DFO, 5 cases with Charcot arthropathy
without osteomyelitis, 14 sites with simple soft tissue infection
and 14 sites of cured DFO were finally diagnosed. LS planar
images showed increased leucocyte accumulation compatible
with active infection in 26 of 40 sites, and were negative for
active infection in 14 of 40 sites. In patients with positive
scans, the addition of SPECT/CT correctly localized infection
to bone in 7/7 sites with DFO and to soft tissues in 32 sites,
changing the interpretation of planar images in 12 of 26 pa-
tients (46%) with positive scans. On the contrary, the addition
of SPECT/CT did not significantly altered the evaluation of
patients with negative LS planar scans as it changed the inter-
pretation of planar images in only 1 patient. Totally, the addi-
tion of SPECT/CT improved the diagnostic accuracy of LS for
DFO from 85.0% to 97.5%. Conclusion: SPECT/CTenhances
the diagnostic performance of 99mTc-HMPAO-labelled leu-
cocyte scan for diabetic foot infections. The CT component of
SPECT/CT provides accurate anatomical localization of in-
creased leucocyte uptake, enabling discrimination of bone
from soft tissue infection and better assessment of the extent
of infection.
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99mTc-HMPAO white blood cell labelled scintigraphy
in patient with osteosynthesis material and inter-observer
reproducibility
E. Noriega, M. Bajén Lázaro, A. Benítez Segura, A.
Rodríguez-Gasén, P. Saldaña, O. Puig Calvo, G. Martínez
Pimienta, M. Boya Román, J. Mora Salvadó; Hospital
Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat
(BARCELONA), SPAIN.
Aim: Scintigraphies with 99mTc-HMPAO labelled white
blood cells (SWBC) in patients with osteosynthesis material
and suspected bone infection are not easy to interpret and,
because of this, often inter-observer discrepancies exist. The
aim of this study is to evaluate the inter-observer reproducibil-
ity when interpreting the SWBC planar images in patients with
osteosynthesis material and suspicion of bone infection. Ma-
terials and methods: Prospective study of 41 patients (29
women, age between 40 and 86 years old) with osteosynthesis
material and suspected bone infection (25 patients had a knee
prosthesis, 11 had a hip prosthesis, one had a shoulder pros-
thesis and 4 had other osteosynthesis material). Planar images
with 99mTc-HMPAO labelled white blood cells were acquired
at 30 minutes, 4, 8 and 24 hours with acquisition times of 5, 8,
12 and 20 minutes respectively (acquisition time corrected for
decay). The unprocessed images were reviewed by 4 nuclear
medicine specialists (with more than 10 years of experience)
independently and blinded to other diagnostic tests and/or clin-
ical course. The scintigraphy was considered negative when
there was no leukocyte accumulation, and positive, when there
was leukocyte accumulation that increased over time (in ex-
tension or intensity). The definitive diagnostic was obtained by
culture/biopsy or after six months of follow up. Statistical cal-
culation was done using the kappa coefficient (κ), the inter-
pretation of which is done by correlating its value with a qual-
itative scale that includes six levels of strength agreement: 0
(Poor); from 0.01 to 0.20 (Mild); from 0.21 to 0.40
(Acceptable); from 0.41 to 0.60 (Moderate); from 0.61 to
0.80 (Considerable) and from 0.81 to 1.00 (Almost perfect).
Results: The overall inter-observer κ value was κ = 0.739,
indicating a considerable agreement between the observers.
The agreement in the studies that were considered negatives
was considerable (κ = 0,758), but in those considered positive
it was just acceptable (κ = 0,444). Conclusion: This study has
demonstrated considerable inter-observer agreement in the in-
terpretation of the planar images of SWBC in patients with
osteosynthesis material and suspicion of bone infection. The
agreement in negative studies is higher than in positive studies.
P947
Contribution of labelled leukocytes scintigraphy
with decay correction at 8 or 24 hours in the diagnosis
of osteoarticular infection
J. Rodríguez-Rubio Corona1, E. Noriega Álvarez1, I. Gil
Viciano1, A. Rodríguez-Gasén1, A. Benítez-Segura1, I.
Romero-Zayas2, G. Martínez-Pimienta1, M. Boya-Román1,
M. Roca Engronyat1; 1Nuclear Medicine Department, Hospi-
tal Universitari de Bellvitge-IDIBELL, L'Hospitalet de
Llobregat (Barcelona), SPAIN, 2IDI-PET Unit, Hospital
Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat
(Barcelona), SPAIN.
AIM: In bone infection diagnosis by labelled leukocyte scin-
tigraphy (LLS) it is important to perform delayed images, at 8
or 24h, although in clinical guidelines they are optional regis-
trations. The objective of this study is to demonstrate that
delayed images are essentials in bone infection diagnosis.MA-
TERIAL AND METHODS: - 70 patients were studied (43
women, 22-83 years old) with suspected osteoarticular
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infection. - The labelling of leukocytes with 99mTc-HMPAO
was based on EANM guideline (2010). - Planar images with
99mTc-HMPAO labelled with white blood cells (WBC) were
acquired (with high resolution and low energy collimator) at
30 minutes, 3, 8 and 24 hours after reinjection of labelled
WBCwith acquisition times of 5, 8, 12 and 20minutes respec-
tively (acquisition time corrected for decay). - Three groups of
images have been evaluated by two expert nuclear physicians:
A: 30 minutes and 3 hours images; B: 30 minutes, 3 hours and
8 hours images; and C: 30 minutes, 3 hours and 24 hours
images. - The scintigraphy was considered negative when
there was no leukocyte accumulation, and positive, when there
was WBC accumulation that increased over time (in extension
or intensivity). The definitive diagnostic was obtained by
culture/biopsy or after six months of follow up. - Sensitivity
(SE), specificity (SP), positive predictive value (PPV), nega-
tive predictive value (NPV) and accuracy (ACC) have been
analysed. RESULTS: - Definitive clinical diagnosis: 19 pa-
tients with bone infection and 51 patients without bone infec-
tion. - Scintigraphy diagnosis: A. (30 min-3h): 45 patients with
scintigraphy suggestive of infection (LLS +) and 25 with neg-
ative scintigraphy (LLS-) (29 false positives). B. (30 min-3h-
8h): 20 with LLS+ and 50 with LLS- (4 false positives). C. (30
min-3h-24h): 16 with LLS + and 54 with LLS- (2 falses pos-
itives). The values of SE, SP, PPV, NPV and ACC were the
following for the different groups: A. SE=84.2%, SP=43.1%,
PPV=35.6%, NPV=88%, ACC=54.3%. B. SE=84.2%,
SP=92.2%, PPV=80%, NPV=94%, ACC=90%. C.
SE=73.7%, SP=96.1%, PPV=87.5%, NPV=90.7%,
ACC=90%. CONCLUSION: The implementation of delayed
images with 99mTc-HMPAO labelled WBC in bone infection
diagnosis is essential because it decreases significantly the rate
of false positives and, therefore, increases the specificity and
positive predictive value.
P948
Effectiveness of 18F-FDG PET/CT in patients
with suspected residual spinal infection, with or
without surgical device : a prospective 30 case study.
A. DUTERTRE; CHU Bordeaux, BORDEAUX, FRANCE.
Aim of the study : Evaluate the predictive value of 18F-
fluorodeoxyglucose Positron Emission Computed Tomogra-
phy (18F-FDG PET/CT) in patients with suspected residual
spinal infection (SI), after antibiotic treatment, compared to
magnetic resonance imaging (MRI).Materials & Methods :
From March 2010 to June 2013, 30 patients with suspected
residual SI were involved in a prospective monocentric study
after well conducted treatment. They all underwent a 18F-
FDG PET/CT and an MRI. Each modality was blindly
interpretated by 2 physicians in a qualitative way. For 18F-
FDG PET/CT, we added a combined “qualitative-quantita-
tive” analysis with a ratio of maximum standard uptake value
(SUV) (SUVmax) compared to reference (healthy vertebral
b o d y ) . A 1 - y e a r f o l l ow - u p e x am i n a t i o n wa s
performed.Results : Among the thirty patients, only 7 present-
ed a residual SI at the 1-year follow-up examination : 1 patient
underwent a biopsy and 6 patients presented a clinical or bio-
logical unfavorable outcome. For qualitative and combined
“qualitative-quantitative” (with a threshold of SUVmax ratio
= 2,3), the sensitivity, specificity, positive (VPP) and negative
(VPN) predictive values were respectively 85,7%, 73,9%,
50%, 94,4% and 85,7%, 82,6%, 60%, 95%. Out of 27 MRI,
the values were respectively of 66,6%, 61,9%, 33,3% and 86,
6%. Diagnosis performances of 18F-FDG PET/CT were
higher than those of MRI but non significantly (p=0.295).
FDG uptake patterns were determined to differenciate infected
from non-infected patients.Conclusion : Our results suggest
that 18F-FDG PET/CT may be useful for evaluating patients
with suspected residual SI after treatment, moreover in post-
operative cases where F-18 FDG PET/CT seems to be more
effective than MRI with a high VPN.
P949
The role of 18F-FDG PET / CT in HIV positive patients.
R. BONFIGLIOLI, T. Graziani, F. Ceci, S. Sanfilippo, L.
Zanoni, C. Pettinato, M. Bartoletti, P. Viale, C. Nanni, P.
Castellucci, S. Fanti; Azienda ospedaliero-universitaria
S.Orsola-Malpighi, BOLOGNA, ITALY.
AIM: to investigate the role of 18F-FDG-PET/CT in detecting
eventual co-morbidity in patients with HIV positive serology
and to evaluate the added value of 18F-FDG-PET/CT to
change the therapeutic approach.MATERIALS AND
METHODS:Inclusion criteria were: a) HIV positive serology;
b) suspected or already known tumors (lymphoma or other
tumors HIV-related) or suspected infections; c) 18F-FDG-
PET/CT performed for clinical/diagnostic suspicious of co-
morbidity d) histological validation of 18F-FDG-PET/CT
positive findings.We retrospectively analyzed 79 HIV patients
studied with PET/CT from 2008 to 2013. Twenty seven out of
79 fulfilled the inclusion criteria of a full clinical profile and
histological diagnosis of the 18F-FDG-PET/CT positive
findings.RESULTS:In 4/27 of patients 18F-FDG-PET/CT re-
vealed 2 progressions (lymphoma ) and 2 relapse (Kaposi
Sarcoma of the face and hepatocellular carcinoma ) of the
knownmalignant disease. These findings were later confirmed
by biopsy and the management was changed according to
18F-FDG-PET/CT results. In 4/27 patients 18F-FDG-PET/
CTshowed new malignancy not previously diagnosed (2 lym-
phoma:1 hepatic,1 diffused with bone involvement; 2 cancer-
HIV related: 1 Bartolini gland cancer, 1 mesenchymal
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sarcoma) and confirmed to be as true positive by biopsy on
18F-FDG PET/CT findings.In 7/27 18F-FDG-PET/CT result-
ed negative, but in one patient autopsy revealed the presence
of a malignancy (penis cancer). Two out of 7 patients, had
inflammation described by 18F-FDG PET/CT and not
suspected before in which 18F-FDG PET/CT has been able
to guided biopsy and the subsequent therapy (1 was consistent
with RCU, 1 was an infected ascitis).In 3/27 patients unex-
pected lung infections have been diagnosed by 18F-FDG-
PET/CT, and later confirmed by bronchoscopy.Finally in 13/
27 (48%) 18F-FDG PET/CTchanged the clinical management
and in 14/27 patients no significant changes of the therapeutic
approach have been performed on the basis of 18F-FDG PET
results.CONCLUSIONS:Main limitation of our study is the
small number of patients investigated. In our series 18F-
FDG-PET/CT proved to be a useful imaging technique to in-
vestigate HIV patients proving an added value to change the
therapeutic strategy in almost the half of the patients.
P950
FDG PET/CT in pulmonary aspergillosis
D. Grigolato, M. Zuffante, M. Cucca, E. Carmagnani, E.
Concia, M. Ferdeghini; Azienda Ospedaliera di Verona, VE-
RONA, ITALY.
Aim: to evaluate if functional metabolic image findings with
FDG PET/CT in the patients with suspected pulmonary asper-
gillosis (PA) or during their antifungal treatment may help the
clinicians in their work-flow.Methods: We retrospectively
evaluated 20 consecutive patients from our Nuclear Medicine
database who underwent 18F-FDG PET/CT for suspected PA
(number 12) or during their treatment between March 2011
and February 2015 (11 men, 9 women, mean age 52 years).
Half of them had underlying predisposing condition or co-
morbidity (in transplantation, previous chemotherapy or radio-
therapy, previous TBC, diabetes mellitus). Chest radiography
and CT were performed in all patients. We analysed the pat-
terns of FDG uptake, both visually and with maximum stan-
dardized uptake value (SUVmax) of the pulmonary lesions on
PET/CT, together with the number and shape of the
lesions.Results: the diagnosis of PA was confirmed with the
histological identification of Aspergilus spp in biopsies or pos-
itive sputum cultures or positive galactomannan assay of bron-
choalveolar lavage specimens. All patients had positive results
on Chest radiography and CT with excavated pulmonary
thickening in 17 patients and fibrosis with bronchiectasis in
3 cases. Twentyfive FDG-PET/CT were performed in 20 pa-
tients. Twelve patients underwent FDG-PET/CT for suspected
PA and in 7/12 (58.3%) were positive and PAwas confirmed.
In this group of patients the SUVmax values were 1.5-8.4 The
remaining 3/5 patients had other features with increased
uptake in PET which guided further biopsies and a definitive
diagnosis (sarcoidosis and lymphoma). Among the nine pa-
tients who performed 12 FDG PET for the control of therapy
or for the follow-up we registered 8 positive PET/CT in 4
patients (44%), they had higher FDG values in the lesions
and in three of them the antifungal therapy was not
discontinued. Five patients were considered negative at PET/
CT with very low FDG uptake (<1.5) and they are in follow-
up.Conclusions: FDG PET/CT could help to determine suit-
able treatment plans, particularly in immunocompromised pa-
tients to guide the timing for the antifungeal treatment and in
the follow-up
P951
FDG-PET/CT in ANCA Associated Vasculitis: An
Exploratory Pilot Study
S. Hess1,2, M. J. Velander3, P. F. Høilund-Carlsen1,2, H.
Laustrup4; 1Dept. of Nuclear Medicine, Odense University
Hospital, Odense, DENMARK, 2Institute of Clinical Re-
search, University of Southern Denmark, Odense, DEN-
MARK, 3Department of Internal Medicine, Section of Rheu-
matology, Odense University Hospital - Svendborg Hospital,
Odense, DENMARK, 4Dept. of Rheumatology, Odense Uni-
versity Hospital, Odense, DENMARK.
INTRODUCTION: FDG-PET/CT is useful in large vessel
vasculitis, but virtually unexplored in ANCA associated vas-
culitides (AAV), i.e., a heterogeneous group of small-medium
vessel vasculitides. Initial diagnosis is difficult, especially in
early and clinically quiescent lesions. Furthermore, during the
course of disease, flares, indistinguishable from infection and
cancer, may occur. We aimed to explore the potential of FDG-
PET/CT in prevalent and incident AAV. METHODS: FDG-
PET/CTwas performed in 35 patients in 2009-2012. Eighteen
patients had known AVV (prevalent cases) with suspected
cancer or infection versus flare of disease, while 17 turned
out to have AAV following FDG-PET/CT (incident cases).
Clinical data was collected from patient records. FDG-PET/
CT data were obtained from routine scan interpretations (prev-
alent cases) or after re-interpretation (incident cases). RE-
SULTS: In prevalent cases, FDG-PET/CT was undertaken
for suspected cancer (10/18; 56%) or infection (8/18; 44%).
In the former subgroup, 4/10 had areas of increased FDG
uptake; biopsy confirmed novel malignancies in 3 of these,
AAV-flare in 1. The remaining 6 did not develop cancer during
38-65 months of follow-up. In the latter subgroup, 5/8 had
areas of increased FDG-uptake. Four had pneumonia (verified
clinically or by diagnostic imaging) and one had clinically
verified flare. One of the remaining three recovered spontane-
ously, while two had clinical AAV-flare. Recurrence of infec-
tion did not occur during follow up. In incident cases, FDG-
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PET/CT was originally performed on the suspicion of cancer
(9/17; 53%), infection (3/17; 29%), vasculitis (2/17; 12%), or
other (1/17; 6%). In total, 15/17 (88%) had areas of increased
FDG uptake. Six received glucocorticoids at the time of scan,
including the two with negative FDG-PET/CTs. Compared to
the clinically established organ involvement, FDG uptake was
present in the lungs in 10/11, kidneys in 6/7, upper respiratory
tract in 2/4, eyes in 1/4, and joints in 2/5. Seven patients had
possible occult organ involvement (aorta, pericardium, lung,
shoulder, or kidneys). There was no correlation between
SUVmax and clinical disease score. CONCLUSIONS: In
prevalent AAV, FDG-PET/CT is a promising modality in pa-
tients with suspected malignancy or infections as the site of
malignancy or infection was correctly identified in all cases
and reliably ruled out in the remainder. The clinical value of
FDG-PET/CT in incident AAV is debatable, although PET
may have a role in identifying sites of occult inflammation
allowing tailored treatment. There was no association between
disease activity and SUVmax suggesting that there is need of
novel quantitative PET approaches.
P952
The role of 18F-FDG PET/CT combined with MRI
in the diagnosis and follow-up of the retroperitoneal
fibrosis and vasculitis in a 14year-old girl
D. Chroustova1, J. Jahoda1, M. Kyncl2, J. Trnka1, P.
Dolezalova1, J. Kubinyi1; 1General University Hospital and
1st Faculty of Medicine Charles University, PRAGUE 2,
CZECH REPUBLIC, 2Hospital Motol and 2nd Faculty of
Medicine Charles University, PRAGUE 5, CZECH
REPUBLIC.
Aim: Retroperitoneal fibrosis (RPF) is characterized by the
development of extensive fibrosis throughout the
retroperitoneum, which results in entrapment retroperitoneal
structures. We present a case of an adolescent girl with RPF,
where severe fibro-inflammatory process involved right kid-
ney, abdominal aorta and other arteries. 18F-FDGPET/CTand
MRI determined accurately the extent of pathological changes
and served as the main follow-up tool. Patient and methods:
Retrospective case analysis of a 14 year-old girl is presented
with clinical and laboratory assessments and serial imaging
using FDG-PET/CT and MRI/MRA. Both PET/CT whole
body scans were started 70 minutes after i.v. administration
of 155 MBq 18F-FDG on PET/CT GE Discovery 690 imme-
diately after injection of 55 ml Iomeron 400 with the following
acquisition parameters 3min/bed, and CT parameters: Helical,
80kV, 100mA, Pitch 0,948:1.The PET images were recon-
structed using CT transmission data for attenuation correction
including TOF and PSF reconstruction options. Within year
2014 abdomen MRI and MRA angiography were repeatedly
performed to patient follow -up during therapy. The examina-
tion was done in the basal plane T1W, T2W, DW after i.v.
10ml Gd-DTPA application. Results: The first signs of disease
started at the age of 13 years with fever, high inflammatory
parameters and back pain. Abdominal ultrasound showed ret-
roperitoneal mass. Initial PET/CTscan confirmed the presence
of extensive inflammatory lymphadenopathy. The biopsy of
cervical lymph node did not confirm the presence of malig-
nancy In August 2013 her back pain returned with hyperten-
sion. The follow-up PET/CT imaging showed the high 18F-
FDG accumulation in abdominal aorta and renal arteries with
amputation of the right renal artery. After hypertensive crisis
due to ischaemic and nonfunctional right kidney the patient
underwent nephrectomy. Histopathological findings from
retroperitoneum confirmed the presence of granulomatous in-
flammation and vessel vasculitis affecting the spectrum of
blood vessels. The girl was treated with corticosteroids and a
course of pulse intravenous cyclophosphamide with no signif-
icant effect on MRI imaging. B-cell depleting therapy with
rituximab was then commenced and the next follow-up PET/
CT scan demonstrated complete metabolic and partial mor-
phologic regression of the retroperitoneal lymphadenopathy.
However there was found aortitis progression with new vas-
culitis changes on both iliac and pulmonary arteries, which
were confirmed on MRA Methotrexate has been added. Con-
clusion: Our case report demonstrates the essential role of both
18F-FDG PET/CT and MRI imaging not only in the diagnosis
of RPF and vasculitis, but more importantly in the patient
follow-up during therapy.
P953
Long fasting withHNF is effective in inhibitingmyocardial
18FDG uptake for evaluating cardiac sarcoidosis
or endocarditis
P. VIAU, G. Nivaggioni, R. Capet, M. Razzouk-Cadet; Uni-
versity Hospital Archet, Nice, FRANCE.
Aim: To evaluate the effectiveness in inhibiting physiological
myocardial 18FDG uptake of a complete preparation (CP)
including long fasting over than 15 hours, carbohydrate re-
striction regimen the previous day and non-fractioned heparin
loading 15 minutes before 18FDG injection to study cardiac
sarcoidosis or endocarditis in Mediterranean population. Ma-
terial and method: We analysed 32 ptts (15 male; mean age
52y±18; BMI 25±5 kg/m2; fasting period 16,9h ±1,1,
glycaemia 0,97±0,35 g/L) suspected of cardiac sarcoidosis
(25) or endocarditis (7) had a CP before 18FDG injection
When cardiac sarcoidosis was confirmed, the lower 18FDG
uptake was evaluated. A visual four-point scale was used to
assess myocardial 18FDG uptake in comparison with hepatic
uptake (1 no uptake, 2 lower, 3 moderate heterogeneous, 4
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higher diffuse). Most of them (28) had serum free fatty acid
and glycaemia blood test before heparin. CP's patients were
compared to 34 ptts control (20 male; mean age 62±14; BMI
26±4 kg/m2; fasting period 15±4,4h; glyc 1,05±0,24 g/L) with
only a long fasting over 12h (LF) before 18FDG injection.
Results: Myocardial 18FDG uptake was 1,44 ± 0,84 in CP
with heparin and 2,68 ± 1,07 in LF (p < 0,05). In CP, free fatty
acid immediately before heparin load was above the normal
threshold in 25/28 ptts. Myocardiac analysis was considered as
interpretable in 27/32 ptts (84,4%) with no (75%) or low phys-
iological uptake (9,4%). In LF, myocardiac analysis was con-
fident in 12/34 ptts (35,3%) with no uptake (20,6%) or low
uptake (14,7%). Conclusion: In our study we found that a
complete preparation before myocardiac analysis (carbohy-
drate restriction, long fasting >15h and non-fractioned hepa-
rin) was better than long fasting alone for inhibiting physio-
logical myocardial 18FDG uptake.
P954
The role of 18F-FDG PET/CT in clinical management
of patient with spondylodiscitis
N. Prandini1, L. Massi1, A. Bedini2, S. Taralli1, A.
Franceschetto1, A. Casolo1, S. Zona2, C. Mussini2; 1Nuclear
Medicine University Hospital, Modena, ITALY, 2Infectious
Disease Clinic, University, Modena, ITALY.
Introduction: Diskitis is an inflammatory process that involve
vertebral column. The most common way is the
haematogenous spread but direct contamination of the inter-
vertebral disc or vertebral body can occur during surgery or
after surgical procedures. 18F-FDG PET/CT is being used to
examine and manage patients with infectious disorders. Aim
of our study was to evaluate the potential role of 18F-FDG
PET/CT in clinical management of spondylodiscitis. Methods:
We retrospectively evaluated 88 18F-FDG PET/CT scans per-
formed in 33 patients (21 males; mean age 63.6±17.5 years)
with histopathological, laboratoristic and/or clinical diagnosis
of spondylodiscitis. For each patient a visual and semiquanti-
tative image analysis (SUVmax) were performed after a base-
line PET/CT (PET/CT1). A second PET/CT (PET/CT2) was
performed for therapy response assessment (median after 30
days). Nineteen patients underwent to a third PET/CT and
three patients to a fourth PET/CT because of clinical compli-
cations. The final diagnosis about the status of the patients at
the end of therapy was assessed by clinical/radiological
follow-up of more than 4 months. Results: A single vertebral
body was involved in 26/33 cases: cervical (n=1), dorsal
(n=5), lumbar (n=16), sacral (n=4); 7/33 patients presented a
multifocal spondylodiscitis. A causative microorganism was
identified in 24/33 patients: S. aureus (n=6), M. tuberculosis
(n=5), E. coli (n=3), Streptococcus (n=3), Candida albicans
(n=2), Aspergillus (n=1), Pseudomonas aeruginosa (n=1),
Klebsiella pneumoniae (n=1), Proteus mirabilis (n=1), Entero-
coccus (n=1). Histopathology or microbiological test resulted
not-diagnostic in the remaining 9 cases. In most cases
etiopathogenesis was hematogenous (n=31), contiguous tissue
(n=1) or post-spinal surgical (n=1) spread. At initial evalution
(PET/CT1), 24/33 patients (72.7%) presented with adjacent
tissue involvement and a mean SUVmax of 7.2±3.3, and
9/33 showed only vertebral involvement and a lower SUVmax
of 5.5±0.8. According to final disease status, 29/33 patients
(87.9%) were classified as responders and 4/33 (12.1%) as no
responders. Responder patients showed a decreased uptake at
early therapy response evaluation (PET/CT2). No responder
patients showed a mean SUVmax of 6.2±3 at PET/CT1, sim-
ilarly to responders, and an increased uptake at PET/CT2
(mean SUVmax: 7.3±3.1), conversely to responder ones.
Moreover, all no responder patients had multifocal disease
and 3/4 showed adjacent tissue involvement. Conclusions:
The highest metabolic activity ad baseline PET/TC, the mul-
tifocal disease, the adjacent tissue involvement are different
metabolic findings observed in no responder patients. A
post-therapy 18F-FDG PET/CT assessment is able to predict
the prognosis of patients with spondylodiscitis and suggest a
potential impact on therapeutic strategy planning.
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Comparison of Prognostic Value Between NP-59 Adrenal
Scintigraphy and Adrenal Venous Sampling in Primary
Aldosteronism Patients After Adrenalectomy
C. Lu, V. Wu, C. Chang, K. Wu, TAIPAI Study Group, R.
Yen; National Taiwan University Hospital, Taipei, TAIWAN.
Purpose: Adrenal venous sampling (AVS) is the gold standard
for lateralization in primary aldosteronism (PA). NP-59 single
photon emission tomography/computed tomography (NP-59
SPECT/CT) is an alternative method for lateralization with
good prognostic value of post-surgical outcome. This study
is aimed to compare the prognostic ability according to the
post-surgical outcome between AVS and NP-59 SPECT/CT.
Methods: From March 2010 to April 2014, 22 PA patients
were included with AVS and NP-59 adrenal scintigraphy re-
sults before adrenalectomy. Four-point blood pressure (BP)
scale (0-3), serum aldosterone to renin ratio (ARR, 0 or 1)
and a 5-point score (0-4) combining BP and ARR were used
to evaluate the prognostic ability after adrenalectomy. Serum
potassium is normalized in all patients and is not included for
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outcome assessment. Lateralization results of AVS and NP-59
SPECT/CTwere compared according to two outcome param-
eters, BP scale of 2 and 5-point score of 3, to evaluate the
prognostic value after adrenalectomy. Results: Taking BP
scale of 2 as the outcome parameter, NP-59 SPECT/CT
showed slightly better sensitivity (92%) than AVS (69%) with
p value of 0.08, while both of them had similar specificity
(78% and 33%, respectively, p=0.10). Considering 5-point
score of 3 as the outcome parameter, NP-59 SPECT/CT also
had better sensitivity (100%) than AVS (70%) with p value of
0.08, and both of them had similar specificity (67% and 33%,
respectively, p=0.10). The concordance rate between AVS and
NP-59 SPECT/CT was 59% (13/22). Conclusion: As a non-
invasive procedure, NP-59 SPECT/CT has slightly better sen-
sitivity and equal specificity compared to AVS in post-surgical
outcome prediction, mainly on significant outcome improve-
ment such as large scale of BP improvement and overall nor-
malization. NP-59 SPECT/CT may stand for a trustable study
as AVS to predict clinical outcome after adrenalectomy.
P956
Transport capacity of lymphatic system of lower
extremities in patients with diabetes
O. Lang1,2, V. Prymkova2, I. Kunikova1, H. Krizova1, H.
Balon1; 1Charles Univ, Prague 10, CZECH REPUBLIC,
2District Hosp, Pribram, CZECH REPUBLIC.
Introduction: Lymphatic system can play an important role in
the development of some pathological processes in diabetic
foot syndrome. It is associated with neurological abnormalities
and various degree of peripheral vascular disease in the lower
limbs which can increase the amount of interstitial fluid. We,
therefore, tested function of lymphatic system of lower ex-
tremities in diabetic patients. Material and methods: We eval-
uated 13 diabetic patients (4 male, 9 female, average age 64
years) with undefined feeling in lower limbs. We selected con-
trol group (13 paired patients without diabetes) from our his-
torical database. Lymphoscintigraphy was performed after
subcutaneous injection of radio-colloid in the web spaces of
the feet. Static images were performed immediately post injec-
tion, 30 minutes post injection at rest and after 30 minutes of
walking. The transport capacity (percentage of the injected
dose accumulated in the regional lymph nodes) was then cal-
culated. Paired t-test was used for comparison. Results: Mean
transport capacity in diabetic and non-diabetic pts on the right
and left side at rest and after stress was 4.4%, 18.6%, 4.8%,
19.5%, 0.4%, 4.8%, 0.3%, and 2.9%, respectively (p=0.000-
0.007). Rest transport capacity in diabetics was at the level of
stress transport capacity in non-diabetics while transport ca-
pacity reserve in non-diabetic pts was twice as higher as in
diabetics - see table. Conclusion: Transport capacity of
lymphatic system of both lower extremities at rest is much
higher in diabetic patients comparing to patients without dia-
betes while their transport capacity reserve is much lower. We
believe this is a sign of overload of lymphatics due to increased
amount of interstitial fluid which can contribute to develop-
ment of diabetic foot syndrome.
P957
The effect of age on indices of quantitative
lymphoscintigraphy (LS)
G. Arsos1, D. Dionyssiou2, C. Sachpekidis3, K. Michailos1,
E. Demiri2; 13rd Dept of Nuclear Medicine, Aristotle Univer-
sity of Thessaloniki Medical School, Papageorgiou Hospital,
THESSALONIKI, GREECE, 2Plastic Surgery Clinic, Aristot-
le University of Thessaloniki Medical School, Papageorgiou
Hospital, THESSALONIKI, GREECE, 3Clinical Cooperation
Unit Nuclear Medicine, German Cancer Research Center, Hei-
delberg, GERMANY.
Aim : LS quantitation has been shown to enhance diagnostic
sensitivity in lymphedema investigation. However, lymph
flow dynamics may be altered by body habitus or age thus
rendering the derivation of normal ranges of the quantitative
LS indices complicate. In order to test the hypothesis that age-
related relative lymphatics dysfunction can be reflected in the
“normal” quantitative LS indices, we examined the relation-
ship between age and some LS indices in lower limbs (LL)
with clinically intact lymph drainage. Subjects and methods :
All of the 31 adult patients (5 men) enrolled in the study were
submitted to LL quantitative LS. By the age cut off value of 45
years patients were allocated in two age groups, A1 (10) and
A2 (21 patients). Sixteen of them, without signs of LL oede-
ma, were examined in the context of donor area evaluation
before vascularised inguinal lymph nodes transplants harvest-
ing for the treatment of secondary upper limb lymphedema
and contributed one randomly selected LL per patient for anal-
ysis. The rest 15 of the patients were investigated for contra-
lateral LL oedema. Body mass index (BMI) and body surface
area (BSA) were calculated according to Quetelet and Hay-
cock formulas respectively. For quantitative LS, 55 MBq of
Tc-99m-nanocolloid were subcutaneously injected in the first
interdigital web of both foot. Spot images over the injection
sites at 0, 45 and 180 min p.i. and over inguinal-pelvic area at
45 and 180 min p.i. were obtained. Tracer clearance from the
injection site (CIS) and uptake by the inguinal lymph nodes
(INU) at 180 min p.i., both in % of injected dose (%ID), were
calculated. Differences between A1 and A2 groups were
assessed by the Mann-Whitney U test and correlation between
age and CIS and INU by linear regression analysis. Results :
Age significantly differed between A1 and A2 groups (34.1
±8.6 vs 62.0±10.0 years, p<0.05). BSA and BMI did not
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significantly differ between the groups. CIS and INU signifi-
cantly differed between the groups (30.5±16.9 vs 20.8±11.1
%ID and 15.8±6.6 vs 9.0±5.0 %ID respectively, p<0.05 for
both). Significant negative correlations were found between
CIS and age and INU and age (r = -0.351 and r =-0.461 re-
spectively, p<0.05 for both). Conclusions : Normal lymph
drainage deteriorates with advancing age and indices of quan-
titative LS are similarly affected . This fact should be taken
into consideration when normal values of quantitative LS in-
dices are to be determined.
P958
Accuracy of 99mTc-Sestamibi Molecular Breast Imaging
Guided Needle Biopsy Using a Stereotactic Lesion
Localisation System
A. Collarino1,2,3, L. M. Pereira Arias-Bouda2,3, F. Smit2, P.
Neijenhuis4, L. M. H. Wijers5, A. F. Van der Hoeven3, K.
Hofkes-Fillekes5, A. Zeillemaker4, R. A. Valdés Olmos2; 1In-
stitute of Nuclear Medicine, Università Cattolica del Sacro
Cuore, Roma, ITALY, 2Department of Nuclear Medicine, Lei-
den University Medical Center, Leiden, NETHERLANDS,
3Department of Nuclear Medicine, Alrijne Hospital,
Leiderdorp, NETHERLANDS, 4Department of Surgery,
Alrijne Hospital, Leiderdorp, NETHERLANDS, 5Department
o f R a d i o l o g y, A l r i j n e Ho s p i t a l , L e i d e r d o r p ,
NETHERLANDS.
Aim: Molecular Breast Imaging (MBI), also called BSGI, is
useful to detect radiologically occult lesions suspicious of can-
cer. Using slant-hole collimation, the device is able to deter-
mine lesion depth enabling radio-guided biopsy. The present
study evaluates both workability and accuracy of this novel
biopsy modality in patients with non-palpable breast lesions in
whom radiological image-guided biopsy was not possible.
Materials and Methods: In 27 patients (mean age 60, range
41-77y) with breast lesions occult on second-look ultrasound
or in whom radiological image-guided biopsy failed, an aver-
age of 600 MBq 99mTc-Sestamibi was administered and two
stereotactic images were performed with a breast-dedicated
gamma camera (Dilon 6800®, Dilon Technologies, USA)
equipped with slant-hole collimators to determine X, Y, Z
coordinates of the lesion. After lesion localisation using an
MBI-based system (GammaLōc®, Dilon Technologies,
USA) equippedwith a vacuum-assisted device (VAD), a trocar
needle was placed into the lesion followed by verification
using a radioactive Cerium source to ensure correct position.
Subsequently, biopsies were taken and a radiological marker
was left behind at the biopsy site to enable further lesion ex-
cision or follow-up. Tissue sample activity was measured ex-
vivo, followed by histopathological analysis. Finally, mam-
mography was performed to verify marker position. Results:
The mean procedure duration was 75 minutes. In all patients,
samples were found to be radioactive and contained enough
tissue for histopathological analysis. In 16/27 patients, histo-
pathology revealedmalignancy. In 11/27 patients, lesions were
benign, histopathology revealed fibrocystic mastopathy or
adenosis; four of these patients were followed for at least one
year and nomalignancy was found.Mammography confirmed
correct marker position in 25 patients, in two patients the
marker had migrated directly after placement. Conclusion:
MBI-guided breast lesion needle biopsy using 99mTc-
Sestamibi and a stereotactic lesion localisation device appears
to be highly accurate with good patient acceptability. The mo-
dality appears to be a helpful alternative in patients with occult
breast lesions not possible to be sampled by conventional ra-
diological image-guided biopsy.
P959
The hidden sentinel node in breast cancer: reevaluating
the role of SPECT/CT and tracer reinjection
B. Pouw, D. Hellingman, M. Kieft, W. V. Vogel, E. J. T.
Rutgers, M. P. M. Stokkel, R. A. Valdés Olmos; Netherlands
Cancer Institute, Amsterdam, NETHERLANDS.
Introduction: Lymphoscintigraphy with planar imaging is con-
sidered a helpful tool to depict lymph node drainage in patients
with invasive breast cancer. Single Photon Emission Comput-
ed Tomography with integrated CT (SPECT/CT) is usually
performed to detect sentinel nodes (SN) in breast cancer pa-
tients showing non-visualisation on planar images. In our in-
stitution, the incorporation of new SN indications (N0 patients
with previous breast surgery and/or radiotherapy, neo-adjuvant
chemotherapy) has led to an increase of non-visualisation on
lymphoscintigraphy. The present study (re)evaluates the over-
all contribution of SPECT/CTand tracer reinjection in patients
showing no drainage on planar lymphoscintigraphy in terms of
SN visualisation and surgical identification rate. Materials and
Methods: Between 1st of July 2008 and 6th of November
2014 in total 1982 breast cancer patients underwent a SN pro-
cedure after intra-tumoural tracer administration. SPECT/CT
was performed in 298 patients (15%) who showed non-
visualisation on planar lymphoscintigraphy. Ninety-one
(30.5%) of these patients had previous surgery or radiation
therapy at the same breast prior to the SN procedure and 40
(13.4%) were scheduled for neo-adjuvant chemotherapy. If SN
non-visualisation persisted on the SPECT/CT images, a sec-
ond radiotracer injection with repeated scintigraphy was per-
formed when logistics allowed this. Univariate analysis was
performed to examine if specific subgroups, such as age, BMI,
T-stage or previous treatment, have influence on visualisation
rates of SPECT/CT. Results: SPECT/CT visualised one or
more SN in 22.8% (68/298) of the patients with no drainage
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on planar images. Univariate analysis of subgroups revealed
no significant factors influencing SPECT/CT visualisation. In
patients with persistent non-visualisation on SPECT/CT and
having a reinjection, the SN visualisation rate reached 60.3%
(38/63). The overall visualisation rate including planar imag-
ing, SPECT/CTand reinjection was 90.3% (1790/1982). In the
operating room the combination of gamma-probe detection
and blue dye led to identify SN in 87.1% (175/201) of the
patients with a primary tumour after non-visualisation on pla-
nar imaging. Conclusion: The visualisation rate of SPECT/CT
after non-visualisation on planar imaging was lower than the
SN visualisation after reinjection, in an evaluation including
all new breast cancer SN indications. Therefore, our institu-
t iona l pro tocol fo r non-v i sua l i sa t ion on p lanar
lymphoscintigraphy has been adjusted reserving SPECT/CT
imaging only for patients with persistent absence of drainage
after reinjection.
P960
SPECT/CT Imaging: Clinical Utility
in Lymphoscintigraphy for Sentinel Node Mapping
in Patients with Melanoma .
J. RODRIGUEZ ALBAN, A. ALBUQUERQUE, M. SIL-
VA, L. PIRES, P. LAPA, A. MOREIRA, R. VIEIRA, A. FI-
GUEIREDO, G. COSTA, J. PEDROSO DE LIMA; CHUC,
Coimbra, PORTUGAL.
Introduction: To evaluate the added value of an integrated
SPECT /CT sy s t em , ov e r c onv en t i o n a l p l a n a r
lymphoscintigraphy, for anatomic mapping of the sentinel
lymph nodes (SLN) in patients with operable melanomas. Ma-
terials and Methods: Between April 2009 and April 2015, one
hundred fifty four patients (80 male and 74 female, age range
29-82 years, mean 65.4 years) with malignant melanomas of
the skin were evaluated for detection and localization of SLN,
by using both planar lymphoscintigraphy and SPECT/CT. Pla-
nar and SPECT/CT images were interpreted in separate and
later compared to surgical information for a correct anatomic
localization. Results: Melanoma was located on the head (25
patients), trunk (70), upper extremities (18) and lower extrem-
ities (41). Eighteen melanomas of the head drained to post-
mandibular nodes, two to occipital nodes and five to parotid
gland, all localized by SPECT/CT. Of the trunk melanomas
SPECT/CT localized the SLN as superficial or deep in the
nodal basin; 1 patient with melanoma of abdominal wall
showed a subcutaneous sentinel node underneath the injection
site that is not visible on the conventional images and only
visualized by SPECT/CT; 4 patients showed also drainage to
SLN in the iliac-obturator region, 2 to the para-aortic and in-
tercostal nodes, anatomical information only provided by
SPECT/CT. Of the 18 upper extremity lesions, SPECT/CT
showed anatomical information not restricted to axilla and in
2 recognized the precise location of interval nodes in middle
humeral level. In the lower extremity melanoma, SPECT/CT
helped the surgical approach, with enhanced superiority in
overweight patients. Conclusions: On a patient basis,
SPECT/CT had an overall added value in addition to conven-
tional dynamic and static lymphoscintigraphy in 90% of the
cases. SPECT/CT is a useful imaging tool in melanoma pa-
tients, with an added value over planar lymphoscintigraphy for
the detection of SLN and the anatomical mapping of lymph
drainage. It provides more precise information to the surgeon
about the anatomic location and depth of SLN and shows the
relationship between sentinel nodes and other anatomic struc-
tures facilitating sentinel node biopsy.
P961
Potential role of Lymphangioscintigraphy in anticipating
results of Lymphatic-Venous Anastomoses: Clinical
and Imaging Patterns
E. Cracco1, A. Busetto2, A. Bonazza1, F. Dei Rossi1, M.
Gallan1, R. Mameli1, M. Rizzo2, M. Sicolo2; 1Division of
NuclearMedicine, Ospedale dell'Angelo,Mestre, ITALY, 2Di-
vision of Surgery, Ospedale dell'Angelo, Mestre, ITALY.
Aim:Modified radical mastectomy, performed in patients with
clinically detected axillary lymphadenopathy, bears a signifi-
cantly high risk of upper limb lymphedema, because of region-
al lymph drainage impairment, with an estimated frequency of
5-30%.Microsurgical Multiple Lymphatic-Venous Anastomo-
ses (MLVA) can correct lymph drainage and prevent or cure
upper limb lymphedema when performed before or after sur-
g e r y , r e s p e c t i v e l y . We u s e d i n t e r s t i t i a l
lymphangioscintigraphy to assess regional lymph drainage
changes induced by clinical axillary lymphadenopathies and
to evaluate if lymphoscintigraphic pattern may anticipate the
result of micro-surgical MLVA. Materials and methods: Ten
consecutive patients underwent lymphoscintigraphy: 4 before
radical mastectomy, 6 after surgery and before MLVA. In two
cases lymphoscintigraphy was performed after MLVA. For all
patients a transport kinetics score was designed (Transport
Index, TI) based on: radionuclide temporal and spatial distri-
bution, lymph nodes appearance time, intensitv of lymph
nodes and vessels uptake, ranging from 0 to 9. Thus, the
resulting TI ranged from 0 (normal) to 36 (pathological).
MLVAwas performed by injecting a blue dye in the skin and
subcutaneus tissue of the medial region of the arm to trace
regional lymphatic vessels and inserting the “blue lymphatics”
coming from the upper limb into one of the small collateral
branches of the axillary vein (telescopic end-to-end anastomo-
sis). Results: Lymphatic-venous anastomoses allowed an ef-
fective lymphatic drainage of the affected areas in 9 cases.
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Only 1 patient had a lymphangitis during radiotherapy.
Lymphangioscintigraphic results showed a total mean trans-
port index of 39.5 and 4.5 (n.v. < 9) before and after MLVA,
respectively, showing the patency of microvascular
anastomoses.None of the patients had nodal relapses during
the follow-up time. Clinical outcomes were measured by pre-
and post- microsurgical MLVA volumetry. Conclusions:
MLVA has been shown to be a safe procedure for patients in
order to prevent or cure the upper limb breast-cancer related
lymphedema. Microsurgical lymphatic derivative and recon-
structive techniques can yield positive results in the treatment
of peripheral lymphedema, mostly in early stages, when there
are only slight tissular changes and a complete restore of lym-
phatic drainage is feasible. Lymphangioscintigraphy appears
to be a promising technique in identifying upper arm lymphat-
ic pattern before and after modified radical mastectomy proce-
dure. Transport index is a simple, operator-independent semi-
quantitative parameter, which allows a correct assessment of
limphatic drainage and of the patency of microvascular
anastomoses.
P963
Scintigraphy is a Validated Method for in vivo Evaluation
of Drug Delivery to Gastrointestinal System
B. E. Akkas1, L. Guner2, A. Celkan3, F. Acarturk3, F. Tugcu
Demiroz3, N. Gokcora4; 1Ankara Oncology Research and
Training Hospital Department of Nuclear Medicine, Ankara,
TURKEY, 2Acibadem Hospital Department of Nuclear Med-
icine, Istanbul, TURKEY, 3Gazi University Faculty of Phar-
macy, Department of Pharmaceutical Technology, Ankara,
TURKEY, 4Gazi University Faculty of Medicine, Department
of Nuclear Medicine, Ankara, TURKEY.
PURPOSE: The purpose of the present study was the devel-
opment and in vitro/in vivo evaluation of the guar gum-based
colon-specific compression-coated tablet formulation of the-
ophylline which can be used for the treatment of nocturnal
asthma. METHODS: The core tablets containing 100 mg of
theophylline were compression coated with various amount of
guar gum. The physical properties of tablets were tested and
in vitro release studies were performed by a USPApparatus I
in simulated gastric juice at a pH of 1.2 followed by simulated
intest inal juice at a pH of 6.8 with and without
galactomannanase enzyme. Samarium oxide (152-Sm) was
added to the core tablet as the tracer. After the conversion of
non-radioactive 152-Sm to 153-Sm via neutron bombardment,
scintigraphy was used to monitor the tablet’s movement and
distribution throughout the GI system on 6 healthy volunteers.
Comparative dissolution test of tablets containing samarium
oxide was also carried out in the same conditions. RESULTS:
The drug release from these tablets was found to be 0.318-
3.29% for the first 2 hours, 27-54% during the 12 hours and
82-104% at 24 hours. Addition of the galactomannase enzyme
increased the teophylline release. The physicopharmaceutical
properties of the tablets which were used in in vivo studies met
the compendial requirements. Addition of samarium oxide to
the core tablets (Formulation T2-S) did not affect the release of
the drug. In vivo scintigraphy studies showed that the gastric
emptying time for the tablets varied between 1-2 hours. The
tablets reached the colon at 5, 6 and 8 hours in three of the six
subjects. CONCLUSION: Theophylline delivery to terminal
ileum or colon could be achieved and theophylline-guar gum
compression coated tablet formulation may be a promising
system for the treatment nocturnal asthma. Scintigraphy is a
validated method to monitor the passage and behaviour of
drug delivery to gastrointestinal system.
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Scintigraphic evaluation of pyloroplasty role in Ivor-Lewis
esofagectomy
M. Zuffante, L. Gobbi, L. Pavanello, S. Giacopuzzi, J.
Weindelmayer, F. Longo, E. Carmagnani, M. Cucca, D.
Grigolato, G. de Manzoni, M. Ferdeghini; AOUI, Verona,
ITALY.
BACKGROUND-AIM: The neoadjuvant treatment has in-
creased patients (pts) survival with esophageal cancer. In our
recently published experience (155 pts) we have achieved an
overall survival of 43%. After surgery quality of life become
our main goal. Routinely, pyloroplasty (PP) is used to improve
gastric emptying and to reduce ab-ingestis pneumonia and
anastomotic leakage. We analyzed the importance of the scin-
tigraphic data for the decision making of a routinely
performing PP during Ivor-Lewis esophagectomy in a bigger
study on a group of pts underwent to a complete functional
analysis for liquid and solid emptying, acid reflux and quality
of life. METHODS: The whole study includes 63 pts.with
locally advanced carcinoma, R0 resections, at least 6 months
of follow-up, no recurrence or anastomotic stricture. Pts en-
rolled to scintigraphic study were 26: in 15 PP was performed,
in 11 was not done (NPP). A semisolid balanced meal labeled
with 40 MBq of 99mTc-nanocolloid was given to pts seated
close to gamma-camera. To study gastric emptying first we
acquired dynamic images of 60 sec/frame for 30 minutes, then
we acquired static images of 60 sec/frame every 10 min until
120 min. RESULTS: The study evidences that the mean per-
centage of radioactivity in the gastric conduit at 30 and 120
minutes were 43±30.19 and 10.63±9.08 in PP group and 41.09
±29.5 and 16.08±17.7 in NPP group (p-value>0.05). Mean
half-life (T1/2) was lower in PP group (29.03±22.32 minutes)
than in NPP group (40.64±51.48 minutes), but the difference
was not statistically relevant (p-value=0.5). Nevertheless
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analyzing the T1/2 box and whisker plot of the 11 NPP pts is
notable a great dispersion with a large 25-75 percentile box.
This was due to 3 pts that had a mean T1/2 of 106 min com-
pared to a mean T1/2 of 6.5 min for the other 8. CONCLU-
SIONS: Scintigraphyc study has discriminated between a
good or a delayed emptying of gastric conduit and demonstrat-
ed a non-inferiority of the NPP group compared to the PP.
There wasn’t a statistically relevant difference between the
two groups. Nevertheless 3 NPP pts had a longer T1/2. They
could be defined as a potentially “high risk pneumonia” in the
early post-operative period. Our interpretation of this study is
that, in the majority of pts, PP is an overtreatment with possi-
ble post-operative morbility and increasing of biliary reflux
and dumping syndrome. Even if we would like to identify
the “high risk group” treatable.with PP.
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Gastric Motility SPECT/CTwith Tc99m labelled standard
quality food (SQF)
I. Garai1, A. Forgács1, K. Kukuts1, S. Barna1, G. Opposits2,
S. A. Kiss2, M. Emri2, Z. Csiki3; 1ScanoMed Ltd,, Debrecen,
HUNGARY, 2Institute of Nuclear Medicine, University of
Debrecen, Debrecen, HUNGARY, 3Institute of Internal Med-
icine, University of Debrecen, Debrecen, HUNGARY.
Dyspepsia is a common disease in all ages. In about 50-70% of
patients with dyspepsia, no definite organic changes can be
revelaed. This functional dyspepsia is estimated to affect about
15% of the general population in developed countries causing
severe discomfort for the patients. Aim of our study was to
assess the changes of the volume of gas and solid food after
comsuption of radiolabelled standard quality food (SQF) and
emptying dinamics using SPECT/CT. Method: We investigat-
ed 6 patients suffering from dyspepsia. All was undergone on
prior gastroscopy to exclude organic disorders of the stomach.
The examination was performed in fasting state. 22 g standard
quality food (Gastroscint, Mediradiopharma) was labelled
with 70MBq Tc99m and we provided 4.8 g extruded bread
(Abonett) and 200 ml nutritional supplements(Nutri-Drink.,
Nutricia) with known contents. QC of radiolabelled food was
also made to check in vitro radiochemical stability. The exam-
inations were performed with 3 head SPECT/CT ( Anyscan,
Mediso) with LEHR collimator. The acquisition was the fol-
lowing: Early and late SPECT: 128x128 matrix, 20sec/frame,
32 view, Total SPECTacquisition was 10 min 40 sec. Dynam-
ic images: 60x1min. Low dose CT (20mAs,120kV) was made
of the abdominal region before the early and after the late
SPECT. The total time of collimation was 90 min. Evaluation:
Low-dose CT images were segmented by an in-house devel-
oped automatic classification software using mathematical
morphology and dedicated clustering algorithms. Using
reconstructed SPECT data the volume of Tc99m SQF were
calculated by a threshold-based (20% of maximum value) seg-
mentation procedure. The speed of digestion was estimated
from the dynamic gamma-camera scan by nonlinear weighted
least-squares estimation algorithms implemented in R soft-
ware. A complex image processing pipeline was developed
to integrate the analysis of repeated measurements of CT,
SPECT and the dynamic planar data. Results: Increased vol-
ume of total gas calculated from CTwas revealed 5 cases from
6. Decrease of solid volume calculated from SPECTwas pre-
sented 4 cases from 6. The rate of gastric emptying was sig-
nificantly low only in one patient, (emptying fraction: 17%
versus 30-41% in other cases) The emptying fraction of stom-
ach calculated from dynamic images showed correlation with
the emptying rate. However the correlation was weaker with
changes in volume of total abdominal gas. Conclusion:This
newly developed method seems promising in investigation
of functional dyspepsia providing additional sensitive param-
eters of gastric motility. However further studies are needed to
define population based normal values.
P966
Diagnostic accuracy of 123I-MIBG SPECT-CT using
semi-quantitative analysis in patients with adrenal
pheochromocytoma
Y. Sugihara, Y. Fukushima, S. Kumita; Nippon Medical
School Hospital, Tokyo, JAPAN.
Background: 123I-metaiodobenzylguanidine (MIBG)
SPECT-CT plays an important role in the diagnosis of pheo-
chromocytoma. However, the diagnostic accuracy of MIBG
SPECT-CT is reported to be insufficient up to now (both sen-
sitivity and specificity are 82%). Increased physiological up-
take in adrenal glands may be mistaken for pheochromocyto-
ma and impair its diagnostic accuracy. The purpose of this
study was to examine the diagnostic accuracy of MIBG
SPECT-CT using semi-quantitative analysis in patients with
adrenal pheochromocytoma. Materials and methods: Nineteen
consecutive patients from January 2011 with adrenal tumors,
suspected as pheochromocytoma, were included in this study.
All patients underwent MIBG SPECT-CT, and a total of 38
adrenal glands were examined. In the visual analysis of MIBG
SPECT-CT, the diagnosis of adrenal tumor type was con-
firmed with the consensus of two experienced nuclear medi-
cine specialists. By contrast, in the semi-quantitative analysis
ofMIBG SPECT-CT, adrenal-gland-to-blood ratio (AAR) was
calculated to estimate the amount of MIBG accumulation in
adrenal glands. Two-dimensional regions of interest were
drawn on both affected and unaffected adrenal glands, and also
placed in the lower portion of abdominal aorta. AAR was
calculated by dividing adrenal maximal counts by mean blood
S800 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
pool counts in the abdominal aorta. In all participants, defini-
tive diagnosis was confirmed according to the pathological
findings after surgical resection or various clinical examina-
tions, including hormone tests. The cut-off value of AAR be-
tween pheochromocytoma and normal adrenal gland or other
kinds of tumor was determined using an receiver-operating-
curve (ROC) analysis. Furthermore, diagnostic accuracy of
MIBG SPECT-CT using semi-quantitative analysis was eval-
uated and compared with visual analysis alone. Results: In all
38 examined adrenal glands, definitive diagnoses were 9 pheo-
chromocytomas, 17 normal adrenal glands, 10 adenomas and
2 metastatic tumors. In the visual analysis of MIBG SPECT-
CT, the sensitivity, specificity and accuracy were 80%, 73%
and 82% respectively. In the semi-quantitative analysis, AAR
were 24.1 (16.4-48.8) in pheochromocytomas and 6.5 (4.6-
8.3) in non-pheochromocytoma sites (p<0.001). As a result
of ROC analysis, the cut-off value of AAR for the diagnosis
of pheochromocytomawas calculated as 14.00. Using this cut-
off value, its sensitivity, specificity and accuracy were 89%,
100% and 97% respectively. Namely, the true negative rate
was 100%, and adrenal physiological uptake was completely
differentiated from pheochromocytoma.Conclusions: The di-
agnostic performance of MIBG SPECT-CT for pheochromo-
cytoma can improve under semi-quantitative analysis and
avoid its pseudo positive results.
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The value of parathyroid hormon determination in fine
needle aspiration washout fluid in patients with negative
or equivocal scintigraphic findings
S. INCE, H. SAN, M. O. EMER, E. ALAGOZ, A. AYAN, K.
OKUYUCU, B. GUNALP, A. O. KARACALIOGLU, N.
ARSLAN; GÜLHANEMILITARYMEDICAL ACADEMY,
ANKARA, TURKEY.
Aim: Tc-99m MIBI parathyroid scintigraphy (PS) could be
negative or equivocal in some cases with highly suspicious
clinical and biochemical results for parathyroid adenoma
(PA). Some of the patients referred for PS have concomitant
diseases such as nodular guatr or Hashimato thyroiditis with
perithyroidal lymph nodes which may cause difficulty in
differantial diagnosis with ultrasound (US). The aim of this
study was to evaluate the role of parathyroid hormon (PTH)
determination in the fine needle aspiration (FNA) washout
fluid in order to distinguish PA from other concomitant lesions
in patients with negative or equivocal scintigraphic findings.
Materials and Methods: One hundred-eight patients with pri-
mary hyperparathyroidismwere referred to our clinic for PS. A
detailed neck US was performed to all patients in order to
document any intra or extrathyroidal lesion. 24 (22.2%) of
them had scintigraphic and ultrasonographic findings
concordant with PA. 45 (41.6%) of them had no finding both
in PS and US. The remaining 39 (36.1%) patients (10 male, 29
female, mean age±SD: 53±15) were included in the study. In
all 39 cases, there were hypoechoic lesions, adjacent or outside
the thyroid capsule, suspected to be PA in US, although their
PS was negative or equivocal. PTH assay in FNA washout
fluid was performed in these patients. PTH washout levels at
least two times higher than blood PTH levels were considered
as concordant with PA. Results: The mean serum PTH and
calcium levels were 204.4±237.7 pg/ml and 10.8±1.04 mg/
dl, respectively in the study group. The values of PTH in the
aspirates ranged from 4.0 to 23604 pg/ml. 35 patients (89.7%)
had elevated PTH concentrations in FNAwashout fluid and 15
(42.8%) of them underwent surgery. Final histopathologic ex-
amination showed PA in these 15 patients with a positive pre-
dictive value of %100. The postoperative serum PTH (55.5
±36.2 pg/ml) and calcium (9.3±0.8 mg/dl) levels decreased
significantly. 4 patients (10.3%) had low levels of PTH in
the aspirate (<10 pg/m) and FNA biopsy revealed 2 nodular
goiters and 2 benign lymph nodes. The sensitivity and speci-
ficity of the PTH assay in FNAwashout fluid were both found
%100 in the group of patients underwent surgery. Conclusion:
Our results showed that elevated PTH concentration in FNA
washout fluid has high accuracy in differential diagnosis of PA
from thyroid nodules and lymph nodes before surgery, espe-
cially in patients with negative or equivocal scintigraphic
findings.
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PSYCHIATRIC SYMPTOMS IN A PATIENT WITH
PARATHYROID ADENOMA: diagnostic role
of sestamibi scintigraphy.
M. FINESSI1, A. Pia2, V. Podio1, A. Barberi3, P. Moretto4,
V. Marci5, T. Angusti1; 1Nuclear Medicine, San Luigi Hospi-
tal, University of Turin, Orbassano, ITALY, 2Internal Medi-
cine, San Luigi Hospital, University of Turin, Orbassano, IT-
ALY, 3Psychiatry, San Luigi Hospital, University of Turin,
Orbassano, ITALY, 4Radiology, San Luigi Hospital, Universi-
ty of Turin, Orbassano, ITALY, 5Division of Pathology, San
Luigi Hospital, University of Turin, Orbassano, ITALY.
AIM. Primary hyperparathyroidism (PHPT) is the most com-
mon cause of hypercalcemia in patients over 50y with a
female:male ratio 4:1. PHPT is diagnosed by laboratory test;
afterwards, patients undergo cervical ultrasound (US) and
scintigraphy in order to localize the affected gland/s, sestamibi
parathyroid scintigraphy is the most accurate approach for
detection of enlarged parathyroid glands. Psychic manifesta-
tions of PHPT are usually understimated, however often we
can observe a large number of patients report symptoms like
depression, fatigue, sleep disturbance, personality changes,
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anxiety and, in advanced cases, psychosis. Our report describes
a case of PHPTwith dominant psychiatric symptoms where the
scintigraphy had a diagnostic rather than localizing role, and
resulted crucial also in the therapeutic workup of the patient.
MATERIAL AND METHODS. A 63y male, with depression,
fatigue, personality changes and psychosis was referred to our
institution for an episode of attempted suicide. Laboratory tests
did not show a typical PHPT biohumoral pattern: hypercalce-
mia (calcium 2.84 mmol/L, normal value 2.10-2.55 mmol/L)
was associated with normal range PTH value; in order to reduce
hypercalcemia and to verify if PTH value was “inappropriately
low”, hydratation and medical therapy with diuretic, glucocor-
ticoids and bisphosphonates was administered. It provided an
increase of PTH value to highly abnormal levels and a reduction
of hypercalcemia (2.47 mmol/L), suggesting hyperparathyroid-
ism. The patient was referred to sestamibi scintigrahy which
detected an “hot spot” in left cervical region and ultrasound
confirmed the presence of an enlarged gland posterior to thy-
roid. The patient underwent minimally invasive parathyroidec-
tomy (MIP): at surgery a parathyroid adenoma was found. One
month later the patient was free from both psychiatric symp-
toms and biohumural sign of HPT. CONCLUSION. 1) Al-
though the association between PHPT and psychiatric symp-
toms is reported in the literature, psychiatric specialists rarely
refer to endocrinologists these patients; serum calcium screen-
ing test appears to be very important not only in the monitoring
lithium-treated patients, but also in patients with severe psychot-
ic episodes to verify a possible PHPT. 2) Usually parathyroid
scintigraphy is used for lesion(s) localization, according to
EANM guidelines; in this case, scintigraphy led to diagnosis
in spite of equivocal laboratory test: sestamibi scintigraphy
seems indicated in cases of inappropriately normal iPTH in
relation to the calcium value. This case supports other evidences
that suggest a possible extended use of parathyroid scintigraphy
for diagnostic purposes, at least in selected clinical situations.
P970
99mTc-MIBI dual phase planar and SPECT CT
scanning in diagnosis of hyperparathyroidism
in patients with MEN 1
M. Castellon Sanchez, M. Godoy Bravo, M. Balsalobre
Salmeron, L. Alvarez Nieto, M. Ibáñez Ibáñez, J. Rodriguez
Gonzalez, F. Nicolás Ruiz, L. Mohamed Salem, R. Reyes
Marlés, M. Claver Valderas; Nuclear Medicine department,
Hospital universitario clínico Virgen de la Arrixaca, Murcia,
SPAIN.
AIM: The aim is to evaluate the performance and to discuss
the value of preoperative 99mTc-MIBI parathyroid dual phase
planar, PinHole and SPECTCTscanning in hyperparathyroidism
diagnosis in patients with MEN1 and in recurrent
hyperparathyroidism after surgery. MATERIAL AND
METHODS: A retrospective study of 82 patients with MEN 1,
of which 57 (74%) had hyperparathyroidism, we studied 54 (29
women and 25 men, aged between 17-70, mean age 38.3 years).
32 (59.2%) were asymptomatic and 22 (40.8%) had hyperpara-
thyroidism symptoms. Calcium, phosphorus and PTHi levels
were measured and genotype and mutations in the MEN1 gene
were studied. 50 patients underwent a preoperative 99mTc-MIBI
parathyroid dual phase planar, PinHole and SPECT CTscanning
to detect and localize parathyroid glands. After surgery, a 65.2
months (6-180) follow up, we found 86.3% cure rate and 10
(18.5%) patients (7 women and 3 men, mean age 36.4 years)
presented recurrent hyperparathyroidism. The recurrent hyper-
parathyroidismmean time after surgerywas 85.8 (6-124)months.
All patients underwent 99mTc-MIBI parathyroid dual phase pla-
nar, PinHole and SPECT CT scanning. RESULTS: Preoperative
99mTc-MIBI parathyroid dual phase planar, PinHole and SPECT
CTscanning found 1 gland in 18 patients, 2 glands in 21 patients,
3 glands in 2 patients and 4 glands in 3 patients andwas negative/
uncertain in 6 patients. 2 ectopic glands were found. In 100% of
patients with recurrent hyperparathyroidism the localization diag-
nosis wasmadewith 99mTc-MIBI parathyroid dual phase planar,
PinHole and SPECTCTscanning, finding 1 gland in 8 patients, 2
glands in 2 patients and 4 ectopic glands. No genotype was
associated with higher hyperparathyroidism incidence. Calcium,
phosphorus and PTHi levels were 11.6mg/dl (10.2-14), 2.6mg/dl
(1.1-4) and 146.1(23-610) respectively. Mean age of asymptom-
atic patients was lower than symptomatic ones (33.2 vs 45.9
years) p<0.001 and the mutation in MEN 1 gene presented in
80% of recurrent hyperparathyroidism was 1650delC-
ter558exon10. CONCLUSIONS: Although surgical bilateral
neck exploration is required in patients with MEN 1 and hyper-
parathyroidism, preoperative 99mTc-MIBI parathyroid dual
phase planar, PinHole and SPECTCTscanning detected 2 ectop-
ic glands before surgery improving the success of the
procedure.In recurrent hyperparathyroidism, 99mTc-MIBI para-
thyroid dual phase planar, PinHole and SPECT CT scanning is
the first line imaging technique for detection and localizing para-
thyroid glands and SPECT CT allows a better anatomical corre-
lation which is especially useful in ectopic glands.We didn’t
found correlation between PTHi, calcium and phosphorus levels
and scintigraphics findings.
P971
Lung Ventilation/Perfusion SPECT feasibility
and interobserver concordance in patients with suspected
pulmonary embolism
D. Balaguer, L. Marbello, H. Rodríguez, P. Abreu, D. Reyes,
T. Mut, C. Plancha, E. Caballero; Dr. Peset Hospital, Valencia,
SPAIN.
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Aim: Several studies have assessed the feasibility of the
Ventilation/Perfusion SPECT (V/P SPECT) and its improve-
ment in diagnosis compared to Ventilation/Perfusion planar
scintigraphy (V/P PLANAR). After implementing this tech-
nique as a clinical routine in Dr.Peset Hospital, this study aims
to: 1. Assess the feasibility of the process. 2. Assess the inter-
observer concordance (κ value) of the V/P PLANAR and V/P
SPECT in patients where both tests were performed. 3. Eval-
uate when the V/P PLANAR diagnosis was changed by the
V/P SPECT. Materials and methods: Sixty-three consecutive
patients with suspected pulmonary embolism (PE) were in-
cluded between May 14th 2014 and January 31st 2015. The
V/P test was performed using Technegas (20mCi) for ventila-
tion and 99mTc-MAA (6mCi) for perfusion. The exploration
was done in the sequence: V-PLANAR, V-SPECT, P-PLA-
NAR, P-SPECT, without moving the patient. A minimum
1:4 ratio for V:P was sought. The study was processed with
subtraction software to avoid false negative diagnoses. The
ventilation and the subtracted perfusion images were merged.
The image evaluation was done separately by two observers
and the diagnosis was reached using trinary interpretation (PE
present / PE absent / Non-diagnostic) as EANM recommends.
The feasibility was then calculated, as well as the interobserver
concordance and the percentage of cases where the V/P
SPECT changed the diagnosis. Results: 1. V/P SPECT test
was done to 25 patients. The other 38 patients did not undergo
the complete exploration. Thus the feasibility is of 39.7%.
Analysing the causes of non-performance of the V/P SPECT,
more than half of the cases were due to logistic problems
(mainly the long duration of the exploration). To a lesser de-
gree it was due to the patient’s clinical status. 2. The interob-
server concordance (κ) for the 25 patients was of 0.82 for the
V/P PLANAR and 0.80 for the V/P SPECT, indicating a very
good concordance in both tests. 3. The main advantage of the
V/P SPECTover the V/P PLANAR was the reduction of non-
diagnostic explorations (0% versus 8%). Conclusions: The
feasibility of V/P SPECT in our department is low. It is limited
by logistical problems and to a lesser degree by the clinical
status of the patient. Given that V/P SPECT has a high degree
of interobserver concordance and fewer non-diagnostic cases
than V/P PLANAR, we propose V/P SPECT as the standard
technique, and the option of not performing the V/P PLANAR
test.
P972
Body fat changes in HIV patients on highly active
antiretroviral therapy (HAART): a longitudinal DEXA
study.
G. Madeddu1, A. Spanu2, P. Solinas2, G. M. Calia1, C.
Lovigu1, M. Mannazzu1, P. Bagella1, S. Nuvoli2, M. S. Mu-
ra1, G. Madeddu2; 1Unit of Infection Disease, University of
Sassari, Sassari, ITALY, 2Unit of Nuclear Medicine, Univer-
sity of Sassari, Sassari, ITALY.
AIM.HIV patients receiving HAART may develop metabolic
and morphologic abnormalities including body fat changes de-
spite virologic control and pathogenetic mechanism is still un-
clear. In a long follow-up we monitored quantitative body fat
composition inHIV patients treated with HAART to also identify
possible therapeutic and host related associated risk factors.
METHODS.We studied 180 HIV patients on HAART, of whom
in 72 CDC stage A, 60 stage B, 48 stage C; 86 had protease
inhibitors (PI) + non nucleoside reverse transcriptase inhibitors
(NRTI) and 94 non nucleoside reverse transcriptase inhibitors
(NNRTI) + NRTI in their therapeutic protocol. Fat changes were
clinically present in 78 patients (Group 1) and absent in 102
patients (Group 2). In each patient, in basal conditions and during
follow up, we measured by DEXA fat mass (FM) in whole body
(WBF), trunk (TF) and peripheral (PF) regions such as arms (A)
and legs (L), calculating trunk/peripheral (T/P) ratio, total weight
(TW) and BMI. CD4 count by cytometry and HIV viral load by
Nuclisens NASBAwere also determined. RESULTS. At the first
observation, WBF, FP, L values were significantly lower in
Group 1 than in Group 2 (p<0.01, p<0.001, p<0.001, respective-
ly), while Awere lower in Group 1, but not significantly. Group 1
patients had higher TF and FT/FP ratio than in Group 2, but
significantly only for the latter parameter. No TW and BMI dif-
ference was present between the two patient groups. CD4 count
and CD4 rise from nadir were significant higher in Group 1 than
Group 2. WBF, PF and L negatively correlated, while FT/TP
positively, with PI and NRTI therapy duration, but not with
NNRTI. At 5 year follow up, we could monitor 84 (39 receiving
PI and 45 NNRTI) patients who continued the same therapy
remaining with stable disease. In these patients, TF further in-
creased and A and L further decreased, especially in patients
receiving PI.CONCLUSIONS. Fat changes can occur in HIV
patients on HAARTwith fat loss higher in the cases with clinical
signs, mainly involving peripheral regions, with central fat accu-
mulation tendency and with significantly higher rise in CD4 cell
count from nadir, thus suggesting proinflammatory cytokine me-
diated role of immune recovery and peripherical fat loss dysfunc-
tion. These changes seem to worsen over time and should be
considered in HIV patient in order to optimize treatment manage-
ment in clinical practice and a DEXA study is suggested during
follow up.
P973
Extravasation of Radiopharmaceuticals: Which Action Is
Required? A Systematic Review
J. A. J. van der Pol, F. M. Mottaghy, S. Vöö; Maastricht
University Medical Center, Maastricht, NETHERLANDS.
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Background and aim: Extravasation of radiopharmaceuticals is
rare, but can potentially have serious consequences, such as tissue
necrosis. Nevertheless, little is known about preventive measures
that can be taken to limit its complications and, to our knowledge,
no specific recommendations are being proposed to date.The aim
of the current study is to determine the incidence of radiophar-
maceutical extravasation, subsequent clinical consequences, clin-
ical management, and efficacy of appliedmedical treatments sug-
gested in the available literature.Materials and methods: A com-
prehensive computer literature search of studies and cases pub-
lished in Pubmed/MEDLINE and Embase databases through
April 2015 was carried out. Inclusion criteria was extravasation
of a diagnostic radiopharmaceutical (EDR) and/or a therapeutic
radiopharmaceutical (ETR) in patients (search keywords included
‘misadministration’, ‘extravasation’, ‘paravascular infiltration’,
combined with ‘tracer’, ‘radionuclide’, ‘radiopharmaceutical’,
and a list of keywords referring to clinically used tracers (i.e.
‘Technetium 99m’, ‘Yttrium 90’)). The search included also
guidelines on diagnostic and therapeutic radiopharmaceutical
procedures of EANM, SNM, and the Dutch Society of Nuclear
Medicine (NVNG). Included publications were systematically
reviewed, data was pooled and a per patient analysis was
performed.Results: Twenty-one articles comprising of in total
68 patients with radiopharmaceutical extravasation were found.
Despite low incidence of ETR (4/68), all cases resulted in severe
radiotoxic lesions such as wet desquamation and tissue necrosis
within 7 weeks following the extravasation event. In contrast, the
majority of EDR cases (61/64) described no or only limited and
short-lasting skin lesions (i.e. erythema) with spontaneous recov-
ery within days after the extravasation event. However, wet des-
quamation and tissue necrosis were reported in three EDR cases
(3/64), involving Thallium 201 and Iodine 131 radionuclides.
Only 4 out of 13 EANM/SNM/NVNG guidelines on therapeutic
radiopharmaceuticals refer to the risk of extravasation but give no
clear indications on its clinical management. In addition, specific
measures taking into account the radiotoxicity of the radionuclide
and the type of radiopharmaceutical were summarized from lit-
erature. Advised clinical management included immediate cessa-
tion of injection, fluid aspiration, and local tissue
drainage.Conclusion: Cases of radionuclide extravasation are
scarcely reported in the literature and are insufficiently taken in
consideration in current guidelines. Reported events did result in
severe skin lesions in all reported therapeutic cases, as well as in a
minority of diagnostic cases. An advice on standard medical
procedures is provided, based on experience in existing literature.
P974
Nuclear medicine in veterinary practice: preliminary
experiences at Az. Polo Veterinario di Lodi
D. De Zani1, C. Pettinato2, M. Longo1, G. Ravasio1,
M. Di Giancamillo1, D. Zani1; 1DIVET, University of
Milano, Milano, ITALY, 2Medical Physics Unit, Bolo-
gna, ITALY.
Introduction and aimThe aim of this report was to describe the
preliminary clinical and experimental experience in our veteri-
nary nuclear medicine department in oncology, internal medicine
and orthopaedics applications.Material and methodsIn our centre
we study primarly horses but also small animals (dogs and cats)
as clinical subjects, as well as pigs and rabbits for experimental
protocols.In our Nuclear Medicine facility we have a single head
gammacamera, performing SPECT and planar scintigraphy, and
a stand alone gammacamera head, mounted on a pensile, to in-
vestigate big animals like horses.Equine scintigraphic scans were
performed using 99mTc-labelled methylene diphosphonate, (
99mTc-MDP 1 Gbq/100 kg) and both pool and bone phase have
been acquired with the horse standing.Bone scan were also ac-
quired in dogs in order to investigate lameness localized to the
elbow (planar acquisition) and shoulder regions (planar acquisi-
tion and SPECT).Thyroid scans (both planar and SPECT) were
performed in dogs injecting 99mTc-Pertecnetate.Feline injection-
site sarcoma (FISS) has been investigated using 99mTc-
sestaMIBI.For experimental purposes gated myocardial perfu-
sion SPECT with 99mTc-sestaMIBI was performed in piglets
affected by induced myocardial infarction.ResultsA total of 26
horses underwent bone scintigraphy. In 24 lame horses bone scan
allowed to recognize the site of injuries while in 2 cases, referred
for poor performance, no lesions were detected.In two lame dogs
a focal and intense uptake of the radiotracer was observed in
planar or SPECT images at level of elbow or shoulder.Thyroid
scintigraphy allowed identification of a mass in two dogs. In one
case, the mass showed a focal and severe IRU while in the other
case, no IRU was observed.In the cat with a diagnosis of FISS a
very intense and well-defined uptake was observed in the mass
localized on the back. No uptake was visible in other sites
suspected of metastases as lung or satellite lymph nodes. Gated
myocardial perfusion SPECT allowed the exact localization of
myocardial lesions in 2 piglets.ConclusionNuclear medicine has
high potentiality in veterinary medicine.In our preliminary expe-
rience we can assert that, in both equine and small animal prac-
tice, nuclear medicine could be a very useful diagnostic tool,
especially in association with other diagnostic techniques as CT
or MRI. Furthermore, experimental studies could be helpful in
veterinary like human medicine not only for research purposes
but also as pre-clinical experiences for future development of new
clinical approaches.
P975
18F-FDG PET/CT Contribution in Characterization
of Malignancy of Brain Tumors
L. F. León Ramírez, M. Martinez de Bourio, M. N. Cabrera
Martin, C. Gonzalez Roiz, A. Ortega Candil, M. J. Pérez
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Castejón, E. Cala Zuluaga, M. Pedrera Canal, A. Jiménez
Ballvé, J. L. Carreras Delgado; Hospital Clinico San Carlos,
Madrid, SPAIN.
AIM: To determine the utility of 18F-FDG PET-CT in the
differentiation of low-grade from high-grade cerebral tumors
and to correlate with hystopathological analysis (HA). Mate-
rial andMethods:We retrospectively evaluated 56 consecutive
18F-FDG PET-TC studies performed in our department from
December 2008 to January 2015 (27 women, 29 men, mean
age 63.7 years) in order to characterize and stage brain lesions.
All lesion were corregistered with MRI studies. We use cutoff
levels of FDG uptake ratios described by Delbeke in the dif-
ferentiation of high-grade from low-grade tumors: 1.5 for
tumor-to-white matter (T/WM) ratios and 0.6 for tumor-to-
cortex (T/C) ratios.RESULTS37/56 studies were compared
with histopathological analysis. 32 PET-CT studies suggested
high grade malignancy (true positive results) and 3 were sug-
gestive of benign lesions (true negative results). We had two
false positive results, who corresponded to Erdheim-Chester
Disease and tuberculosis. CONCLUSION: 18F-FDG PET-TC
is a useful diagnostic tool in metabolic characterization of
brain tumors, and could be helpful to guide the best area for
biopsy.
P976
Added value of SPECT/CT to Technetium 99m-labeled
red blood cells scintigraphy in small bowel bleeding
W. Amouri, F. Hamza, I. Jardak, H. Charfi, M. Maaloul, F.
Kallel, S. Charfeddine, F. Guermazi; Habib Bourguiba Hospi-
tal, Sfax, TUNISIA.
AIM: to underline the role of Tc-99m-labeled red blood cells
(RBC) spect/ct in localizing and guiding management of small
bowel bleeding. MATERIALS ANDMETHODS: We present
two cases of intestinal bleeding in whom planar dynamic im-
ages were performed after injection of 20 mci in vivo Tc-99m-
labeled RBC, followed by serial static abdominal images. A
fused image composed of those from Tc-99m-labeled RBC
SPECT and from x-ray CT revealed small intestinal bleeding
with specific anatomic information. RESULTS: The two pa-
tients were hospitalized with anaemia from recurrent gastroin-
testinal bleeding. Endoscopic explorations have failed to lo-
cate the bleeding. Planar 99mTc-tagged RBC bleeding scan
suggested an active site of bleeding in the lower abdomen,
but it could not conclusively define the bleeding as originating
in small versus large bowel. The SPECT / CT allowed speci-
fying the exact site of bleeding at the small intestine. Surgical
resection of the bleeding site was performed successfully and
the pathological examination showed angiodysplasia. CON-
CLUSION: RBC scintigraphy is an effective imaging
modality in localizing lower gastrointestinal bleeding in pa-
tients for whom other diagnostic tests have failed to locate
the bleeding. We conclude that spect/ct is useful for anatomic
localization of bleeding sites in the small intestine and helpful
for surgical intervention.
P977
Lung perfusion scintigraphy with SPECT-CT
for diagnosis of pulmonary embolism.
A. Tzonevska1, M. Shindov1, M. Yaneva2; 1National Center
of Oncology, SOFIA, BULGARIA, 2University Hospital
"St.Geori", PLOVDIV, BULGARIA.
The aim of the study is to compare the results of planar lung
perfusion scintigraphy and SPECT-CT in patients with suspected
pulmonary embolism(PE) and to assess the impact of SPECT-CT
in the diagnosis. Material and methods: We included 39 patients
in the study. All patients passed clinical assessment, planar lung
perfusion scintigraphy combined with SPECT-CT. PISA-PED
criteria for interpretationwere applied. Results: All of the included
patients were with pretest clinical probability of PE (Wells
score>4). All of the patients had abnormal perfusion scan. In
24(62%) patients the results confirmed PE with abnormal (PE+)
scan: 59 segmental and subsegmental defects were registered,
SPECT-CT identified 17(29%) defects additionally. In 9(23%)
patients with perfusion defects in planar scintigraphy, but incon-
clusive for PE, SPECT-CT identified abnormal (PE-) results with
nonsegmental hypoperfusion defects and assessed the concomi-
tant disease (COPD, emphysema, CHD), in 6(15%) patients
SPECT-CT identified abnormal (PE+) results with subsegmental
hypoperfusion defects. Conclusion: The study results show that
using SPECT-CT in patients with suspected PE, it is possible to
precise localization of perfusion defects, the false negative results
decrease, the diagnostic accuracy increases. The PE diagnosis
should be performed by team including pulmologist and nuclear
medicine specialist who interpret clinical and nuclear medicine
results all together. Key wards: PE, planar lung perfusion scintig-
raphy, SPECT-CT
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Impact of Fluorodeoxyglucose-PET scan in characterizing
pleural effusions (massive/submassive) in non-oncologic
patients
M. SIMO, J. MONTURIOL, M. VELASCO, I. NAVALES,
M. BARIOS, J. CASTELL; HOSPITAL UNIVERSITARIO
VALL HEBRON BARCELONA, BARCELONA, SPAIN.
AIM: Determined the ability of 18F-fluorodeoxyglucose
(FDG) positron emission tomography (PET) to differentiate
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S805
benign and malignant pleural effusions (massive/submassive)
in non-oncologic patients. MATERIALS AND METHODS:
We included 38 consecutive patients (29men/8 women, medi-
an age: 67 years old) with massive/submassive pleural effu-
sion. None of them had history of cancer and showed non-
diagnostic paracentesis. The diagnostic approach in our insti-
tution included a diagnostic Chest computed tomography
(CT), a PET-scan and talc pleurodesis. CT findings which
were suggestive of malignancy was pleural nodularity, pleural
rind, mediastinal pleural involvement, and pleural thickening.
FDG PET revealed positive findings if pleural activity was
greater than background mediastinal activity; FDG PET re-
vealed negative findings if pleural activity was the same as
or less than background mediastinal activity. All the results
of PET-scan and Chest CT were correlated with pathologic
diagnosis determined with thoracentesis. RESULTS: FDG
PET revealed positive findings in 19 patients (1 False posi-
tive), negative findings in 17 (1 False negative) and indeter-
minate result in 2 patients (1 was true positive). The mean
SUV value in PET positive patients was 9.6 compared to
SUV max of 2.3 in the PET negative group. The definitive
histological examination showed benign condition in 18 pa-
tients (acute, chronic or fibrous pleuritis), malignant in 19
(mesothelioma n=8 or pulmonary adenocarcinoma, intestinal
adenocarcinoma, unknown primary site n=11) and non diag-
nostic in one patient. Sensitivity, specificity, PPV, NPV values
for PET were 95%, 94%, 95% and 94% respectively, with a
unique false negative result. The PET-scan located the primary
en 5 patients (4 lung cancers and 1 gastric cancer). CONCLU-
SION: This study suggests that FDG PETmay be useful in this
group of non-oncologic patients with massive/submassive
pleural effusions. PET scan showed high sensitivity and PPV
to detect malignancy. The inclusion of this technique in the
work-up of pleural effusions help to select patients to aggres-
sive therapeutic approach.
P979
Determining prognosis using lower limb perfusion
SPECT-CT in patients with arteriosclerosis obliterans
H. Hashimoto; Department of Radiology, Nippon Medical
School, Tokyo, JAPAN.
Aims: Patients with arteriosclerosis obliterans (ASO), espe-
cially with critical limb ischemia, have high morbidity of car-
diovascular disease and mortality. Whereas the diagnostic ac-
curacy of lower-limb perfusion scintigraphy was previously
reported, the prognostic value of lower-limb perfusion
SPECT-CT using quantitative analysis has not been demon-
strated up to now. The purpose of this study was to estimate
lower-limb-muscle-perfusion abnormality using lower-limb
perfusion SPECT-CT, and to determine the prognostic value
of lower-limb perfusion SPECT-CT in patients with ASO.
Materials and methods: A total of 29 patients, who were clin-
ically diagnosed with arteriosclerosis obliterans, were included
in this study (23 men and 6 women, 71 ± 13 years). The
clinical diagnosis was based on clinical symptoms, a treadmill
exercise test, ankle-brachial indices, and lower-extremity an-
giography findings. Patients with collagen disease, Behçet dis-
ease, Buerger disease, diabetic foot and other types of vascu-
litis were excluded from this study. All enrolled patients
underwent lower-limb perfusion SPECT-CT using SPECT-
CT combined system, Symbia T2. SPECT acquisition was
started from 15 min following the administration of 99mTc-
tetrofosmin 740 MBq. In all images, 3D volumes of interest
were drawn on each lower-extremity muscle, and lower-limb-
muscle-to-blood ratio (LMBR) was calculated by dividing
lower-limb-muscular mean counts/volume by blood-pool
mean counts/volume in unaffected distal-femur bone marrow.
In order to estimate the clinical importance of LMBR, all par-
ticipants were divided into two groups based on their LMBR
value. All patients were followed up over one year from the
initial test and observed for the occurrence of major adverse
events; defined as amputations of ischemic leg, cardiovascular
events, cerebrovascular events, or all-cause mortality. The re-
lationships between the occurrence of major adverse events
and various clinical parameters including LMBR were also
analyzed. Results: High and low LMBR groups included 23
and 6 patients respectively. LMBR in the high group was 8.43
± 3.23 and was 3.68 ± 0.27 in the low LMBR group. The
proportion of patients that adverse events occurred was signif-
icantly higher in the low LMBR group than in the high LMBR
group (5 of 6 versus 1 of 23, p < 0.001). Conclusions: The
amount of lower-limb-muscle perfusion was estimated by cal-
culating LMBR using lower-limb perfusion SPECT-CT.
LMBR was proved to have a high prognostic value for the
occurrence of major adverse events in patients with ASO.
P980
Is diffuse increased FDG uptake in renal parenchyma
associated with impaired renal disfunction?
N. Hayakawa, Y. Nakamoto, T. Ishimori, K. Togashi; Kyoto
University Graduate School of Medicine, Kyoto, JAPAN.
Aim: The aim of this study was to evaluate the association
between diffuse increased FDG uptake in renal parenchyma
and impaired renal function. Materials and Methods: 25 pa-
tients who showed diffuse increased renal uptake (higher than
liver) pattern in FDG PET/CT (DRU group) was compared
with age- and gender-matched 25 patients with normal renal
uptake (control group), regarding parameters related to renal
function as follows: (i) estimated glomerular filtration rate
(eGFR), (ii) Cr ratio = serum creatinine level within two days
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before or after the PET/CT scan / the lowest creatinine level in
one month before or after the PET/CT scan (minimal Cr), and
(iii) maximal Cr ratio = the highest serum creatinine level
during the past one month before PET/CT scan / minimal Cr.
In DRU group, we also assessed the correlation between these
parameters and the SUVmax in renal parenchyma. Results:
Underlying disease in DRU group is malignant tumor (n =
16), collagen disease (n = 4), and other diseases (n = 5). No
significant difference was observed between DRU group and
control group in eGFR (83.5 ± 50.4 vs. 92.0 ± 40.8, p = 0.23)
and Cr ratio (1.52 ± 0.76 vs. 1.21 ± 0.19, p = 0.30). On the
other hand, maximal Cr ratio in DRU group was significantly
higher than that in control group (1.81 ± 0.78 vs. 1.39 ± 0.45, p
= 0.04). The ratio of patients whose maximal Cr ratio equal to
or greater than 1.5 is 56% (14/25) in DRU group and 20%
(5/25) in control group (p = 0.01). In DRU group, no apparent
correlation was observed between SUVmax in renal parenchy-
ma and each parameter. Conclusion: Diffuse FDG uptake in
renal parenchyma may indicate recent impaired renal function
even when renal function is normal at PET/CT scan.
P981
Evaluation of preventive effect of dexpanthenol
in radiation injury by lung perfusion scintigraphy
Z. Koç1, E. In1, Ö. Üçer1, I. Karslıoğlu2, S. Canpolat3; 1Fırat
University Hospital, Elazig, TURKEY, 2Medical Park Hospi-
tal, Elazig, TURKEY, 3Fırat University, Elazig, TURKEY.
Aim: The aim of this study was to demonstrate the preventive
effect of dexpanthenol from radiation injury caused by radio-
therapy using lung perfusion scintigraphy in preradiotherapy
and postradiotherapy period. Materials and Methods: Six male
New Zaelland rabbits (5-6 month old, approximately 2,5-3 kg
in weight) were subjects of this study. The animals were sub-
jected to Tc-99m MAA lung perfusion scintgraphy in the
preradiotherapy and postradiotherapy (after two weeks peri-
od). The scintigraphies were performed by the same dose
and methodology by the same acquisition parameters and by
same staff. The rabbits were divided into two groups; Group 1
(only administering RT) and Group 2 (administering Im
500mg dexpanthenol injections for consecutive 14 days after
RT). Quantification was performed in order to compare groups
and quantification variables were compared using Paired Sam-
ples T Test, p<0,05 considered statistically significant. Addi-
tional pathological analysis was performed to all rabbit’s
lungs. Results: The postradiotherapy scintigraphies contained
demonstrative decrease in counts in both lungs indicating early
postradiotherapy injury. The difference between counts ob-
tained from both lungs in Group 1 and 2 was significantly
different favoring the Group 2. Pathological analysis showed
findings of severe injury in the lungs of rabbits in Group 1 and
milder injury in Group 2. Conclusion: It is possible to estimate
postradiotherapy changes in early period (in contrary to previ-
ous data) by lung perfusion scintgraphy. Dexpanthenol may
prevent the effects of RT in a degree. Although this is the first
study indicating preventive effect of Dexpanthenol from RT
injury, further studies are warranted in this area.
P982
Application of combined nuclear medicine protocol
including Whole Body Bone Scintigraphy and Single
Photon Emission Computed Tomography/Computed
Tomography (SPECT/CT) of the pelvis for the initial
staging of prostate cancer
V. Hadzhiyska1, T. Petrov1, I. Kostadinova1, V.
Mariyanovski2, D. Zlatareva1, M. Garcheva-Tsacheva1;
1University Hospital Alexandrovska, Sofia, BULGARIA,
2Pirogov Hospital, Sofia, BULGARIA.
The aim of the study was to apply a combined nuclear medi-
cine protocol, including Whole Body Bone Scintigraphy and
Single Photon Emission Computed Tomography/Computed
Tomography (SPECT/CT) for the initial staging of patients
with prostate cancer. Material and Methods: We have exam-
ined 23 patients with newly diagnosed prostate cancer by
using a combined nuclear medicine protocol including Whole
Body Bone Scintigraphy (WBS) and Single Photon Emission
Computed Tomography/Computed Tomography (SPECT/CT)
of the pelvis. According to the NCCN Guidelines (version
2.2014) the patients were divided in to three risk groups, re-
spectively low risk group (5 patients, 22%), intermediate risk
group (6 patients, 26%) and high risk group ( 12 patients,
52%). Results: Pathological findings detected by WBS were
reported in 16 (67%) of the patients. In 7 (30%) of them they
were suspicious for metastases.After the SPECT /CT of the
pelvis all suspicious foci from the WBS were confirmed to
be osteosclerotic metastatic leasons. In addition, the CT scan
visualized enlarged regional lymph nodes in 7 patients (30%),
respectively presacral lymph nodes (N=5) and parailiac lymph
nodes (N=9). Additional findings from the CTwere also sem-
inal vesicles with altered morphology suspected for infiltration
in 5 patients ( 22%) and unexpected extracapsular extension of
the primary in 2 patients (9%). In four out of 7 patients with
enlareged lymph nodes we found simultaneous bone metasta-
ses, while in the rest of them the lymphadenopathy was an
isolated finding. As a result from the application of the com-
bined nuclear medicine protocol in one of the patients from the
low risk group and in one of those with intermediate risk, as
well as in six high-risk patients the opportunity for surgery was
rejected because of bone metastases and/or regional lymph-
adenopathy. In the remaining 15 patients, including also those
with high risk, decision for radical prostatectomy was made.
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Conclusion: Our first experience with the application of the
combined nuclear medicine protocol, including WBS and
SPECT/CT of the pelvis demonstrated that the procedure al-
lows for right initial staging of patients with prostate cancer as
well as for choosing an appropriate treatment by performing a
one-stop complex imaging examination.
P984
Tc99m tagged RBCs venography with additional
abdominal/pelvic SPECTCT in diagnosis of Iliac venous
compression (May-Thurner syndrome).
Y. Chen, C. Lin, D.Wu, C. Chiu; KaohsiungMedical Univer-
sity Hospital, Kaohsiung, TAIWAN.
May Thurner syndrome is status of iliac venous compression,
due to small space between bifurcation and the 5th lumbar
spine. Tc99m tagged RBCs venography (CNM, 2001) is a
highly sensitive routine method to evaluate lower leg swelling
and differentiate deep venous thrombosis. Among those leg
swelling patients with susp deep venous thrombosis, high-
level venous flow deficiency, as iliac/ femoral portion is com-
mon findings on Tc99m RBCs venography. In this article, we
introduce additional abdominal/pelvic SPECTCT during
Tc99m RBCs venography to elucidate pathophysiology of po-
tential May-Thurner syndrome. Patients andMethods:We col-
lect leg-swelling patients with high-level venous flow defi-
ciency in Tc99m RBCs venography and applying additional
abdominal/ pelvic SPECTCT process, retrospectively. There
are thirty two patients (male to female ratio as 19:13; age range
34-82 y/o as 63.2±13.1 y/o) during one year. All of them have
bilateral or unilateral leg swelling in clinic. In vivo RBCs
tagged technique is applied. Then, each 8 mCi pertechnetate
is subcutaneous injection around digital- space of feet. Two
phase half-body imagings are acquired with/ without tourni-
quet compression applied, consequently. The additional ab-
dominal SPECTCT (Philips Bright-views X CT) is needed
when patients with asymmetrical reduction of iliac/ femoral
venous radioactivity. Results: Based on imaging interpreta-
tion, twenty-one patients (66%) are suspicion of iliac venous
compression, mostly involved left iliac vessel. The average
age in this group is 54.9 y/o. The other eleven (34%) cases,
with high-level venous flow deficiency are not identified as
iliac venous compression on SPECTCT imaging. However,
several findings are still seen on SPECTCT imaging, as large
osteophyte formation, psoas abscess and abdominal aneurysm
adjacent abdominal bifurcation , also have risk of venous he-
modynamic disturbance and potential thrombosis formation.
The average age is 72.3 y/o in the non iliac venous compres-
sion group. We have two patients with malignant history as
rectal and breast cancer. Conclusion: Tc99m RBCs
venoscintigraphy is a convenient and high sensitive method
for evaluate status of deep venous flow from calf to iliac por-
tion and diagnosis of deep venous thrombosis. Additional
abdominal/ pelvic SPECTCT provides function and anatomy
to elucidate risk of iliac venous compression in subgroup
patients.
P985
Prognostic impact of deep-inspiratory breath-hold
pulmonary perfusion SPECT-CT in patients
with pulmonary thromboembolism
Y. Fukushima, S. Kumita, H. Hashimoto, Y. Sugihara; Nip-
pon Medical School Hospital, Tokyo, JAPAN.
Introduction: Pulmonary perfusion SPECT is commonly used
for the assessment of pulmonary perfusion abnormality in pa-
tients with pulmonary thromboembolism (PTE). However, in
conventional non-breath-hold SPECT, respiratory lungmotion
during image acquisition deteriorates its image quality and
smears perfusion defects. Conversely, pulmonary perfusion
SPECT-CT, using deep-inspiration breath-hold (DIBH) acqui-
sition, can obtain each static image and estimate the severity of
pulmonary perfusion defect with a high degree of accuracy.
The aims of this study were to calculate the percentage of
pulmonary perfusion defect (%PPD) using DIBH pulmonary
perfusion SPECT-CT, and to evaluate its prognostic value in
patients with PTE.Materials and methods: A total of 97 pa-
tients (47 men and 50 women, 67 ± 15 y) with respiratory
failure and suspected PTE were included in this study. All
patients underwent DIBH pulmonary perfusion SPECT-CT.
Clinical diagnosis of PTE was confirmed based on the combi-
nation of CT pulmonary angiography, DIBH pulmonary per-
fusion SPECT-CT and serum D-dimer level. The DIBH meth-
od required patients to hold their breath for 10 seconds during
each continuous 360 degrees image acquisition. It was per-
formed 12 times with 10 second intervals between each acqui-
sition. These data were combined to create SPECT images.
SPECT data were reconstructed using CT attenuation correc-
tion, and SPECT-CT images were built by hardware fusion. In
pulmonary perfusion SPECT-CT images, %PPD was calculat-
ed by dividing perfusion defect volume in SPECT image by
lung volume in CT image. In order to evaluate the clinical
importance of %PPD, all patients were divided into two
groups based on the value of %PPD using receiver-
operating-curve analysis. All patients were followed up over
two years from the onset of PTE and observed for the occur-
rence of major adverse events, defined as all-cause mortality,
non-fatal symptomatic recurrent PTE, hospitalization due to
deterioration of respiratory failure and hospitalization due to
deterioration of heart failure.Results: This study contained 38
PTE patients, with low and high %PPD groups consisting of
17 and 21 participants respectively. Median %PPD in the low
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%PPD group was 19 (15-28) and 63 (50-81) in the high%PPD
group. The proportion of patients that occurred major adverse
events was significantly higher in the high %PPD group than
in the low %PPD group (p = 0.022).Conclusions: The severity
of pulmonary perfusion defect was estimated by calculating
%PPD using DIBH pulmonary perfusion SPECT-CT. %PPD
was proved to have a high prognostic value for the occurrence
of major adverse events.
P986
Physiological uptake of the uncinate process
of the pancreas: incidence of this potential pitfall
in a retrospective study fo 220 patients.
J. Pinaquy, Sr., P. Schwartz, L. Bordenave; CHU BOR-
DEAUX, Bordeaux, FRANCE.
Whereas the ability to tag somatostatin analogs with Gallium-68
has significantly improved the diagnosis and staging of patients
with neuroendocrine tumors (NETs), the gold standard and most
used for detection and staging of most of the NETs is always
111Indium-DTPA-octreotide (SRS). Most of the pitfalls are well
known but some remains few described. The aim of our study
was to retrospectively evaluate the incidence and the intensity of
physiological uncinate process of the pancreas. Materials and
methods : 246 patients (124 women, mean age 57 years [15-
92]) who underwent SRS were retrospectivelyincluded from
June 2012 to March 2015. 229 abdominal SPECT-CTwere per-
formed. 9 patients with a prooved uncinate process tumor were
excluded. The intensity of the uptake uncal was evaluated based
on Rotterdam visual scale. The clinical, radiological, or surgical
follow-up was used as gold standard. Results: 42.3% (93/220) of
the patients had an uncinate process uptake. Of these 93 patients,
39.8% (37/93) had an uptake greater than or equal to the liver. No
significant lesion were highlighted. Conclusion : These study
shows that significant uncinate process uptake is not uncommon
and must be known. Mistaking exaggerated physiologic pancre-
atic uptake for pancreatic tumor can result in harmful conse-
quences for the patient, especially if a whipple procedure is per-
formed on the basis of these findings. Close correlation with
findings at MRI imaging and thin-section multiphase CT can be
helpful in further assessing equivocal findings.
P987
IMP and MIBG scintigraphy as an index comparable
to the core symptoms for a diagnosis of dementia
with Lewy bodies?
F. Sakamoto1, S. Shiraishi1, N. Tsuda1, H. Yuki1, T.
Namimoto1, M. Kitajima1, M. Hashimoto2, S. Tomiguchi3,
M. Ikeda2, Y. Yamashita4; 1Diagnostic Radiology Graduate
School of Life Sciences Kumamoto University, kumamoto,
JAPAN, 2Department of Neuropsychiatry, Graduate School
of Life Sciences, Kumamoto University, Kumamoto, Japan,
kumamoto, JAPAN, 3Department of Diagnostic Medical Im-
aging, School of Health Faculty of Life Sciences, Kumamoto
University, Kumamoto, Japan, kumamoto, JAPAN, 4Depart-
ment of Diagnostic Radiology, Graduate School of Life Sci-
ences, Kumamoto University, kumamoto, JAPAN.
Aim: As the clinical symptoms of different types of dementia
overlap, it is difficult to distinguish dementia with Lewy bod-
ies (DLB) from other neurodegenerative dementias based on
clinical manifestations alone. Nuclear medicine may yield a
high-value index for the objective evaluation and diagnosis of
DLB. We attempted to develop a nuclear medicine index that
used factors other than clinical core symptoms for the diagno-
sis of DLB. Materials and Methods: We enrolled 332 patients
with suspected DLB; all underwent 123I-MIBG myocardial
scintigraphy. The diagnosis was probable DLB in 92patients
(39 males, 52 females; mean age ± SD, 78.0 ± 8.9 years; range,
56 - 89 years), and no DLB in 240 (98 males, 142 females;
mean age, 75.2 ± 4.8 years; range, 70 - 87 years). The clinical
evaluation index was primarily based on fluctuating cognition,
visual hallucinations, and Parkinsonism. The nuclear medicine
index used the cerebral blood flow on IMP scintigraphs of the
posterior cingulate, precuneus, and occipital lobe, the MIBG
washout rate, and the early and delayed heart to mediastinum
(H/M) ratio. Results: Univariate and multivariate analysis of
fluctuating cognition, visual hallucinations, Parkinsonism, and
the early H/M ratio in patients with probable and without DLB
revealed significant differences. The area under the curve
(AUC) in receiver operating characteristic (ROC) analysis
was 0.693, 0.760, 0.611, and 0.918. The diagnostic value of
the highest 123I-MIBG uptake on the AUC was 82.4% for
sensitivity, 96.3% for specificity, and 92.5% for accuracy.
Conclusion: 123I-MIBG myocardial scintigraphy can serve
as a diagnostic index equal to the core clinical features of
DLB. The diagnostic value of the objective nuclear medicine
index is high. We expect that 123I-MIBG scinitigraphy will be
valuable for the early diagnosis and early treatment of DLB.
P988
Assessment of vascular reserve state with brain SPECT
in asymptomatic patients with steno-occlusive lesion
in Brain MRA
S. OH1, J. Han2, M. Cha3, S. Pyun3, J. Lee1; 1Department of
Nuclear Medicine, National Police Hospital, Seoul, KOREA,
REPUBLIC OF, 2Department of Nuclear Medicine, National
Police HospitalGapyeong Public Health Center, Gapyeong,
KOREA, REPUBLIC OF, 3Department of Neurology, Na-
tional Police Hospital, Seoul, KOREA, REPUBLIC OF.
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Objectives : This study is to assess the vascular reserve state
with Brain SPECT in asymptomatic patients with
stenoocclusive lesion on Brain MRA. Methods : Fourteen
asymptomatic patients who were identified as steno-
occlusive lesion on their MRA performed for general medical
examination underwent brain SPECT. On MRA, the lesion
was classified into 4 grades (mild, moderate, severe, total oc-
clusion). Brain SPECT was visually analyzed by two nuclear
medicine physician. Location, severity of the lesions were
compared between two modalities. Statistical analysis using
Chi-square test was performed to compare the frequency of
perfusion or vascular reserve decrease between the subgroups
by the severity of stenosis. Results : On MRA, 6, 4, 2, 2,
patients had the lesion in MCA, ICA, carotid bulb and ACA,
respectively. Five patients were identified as total occlusion, 4,
2, 3 patients were severe, moderate and mild stenosis. On
SPECT, 5 cases were normal, otherwise, 9 showed perfusion
or reserve decrease. No patients with mild stenosis on MRA
showed abnormal finding on SPECT. Four Of 5 cases with
total occlusion showed perfusion and reserve decrease on
SPECT. All of 4 patients with severe stenosis showed concor-
dant perfusion and reserve decrease. One of 2 moderate steno-
sis cases was normal on SPECT. By location of lesions, 1 of 2
ACA lesion, 1 of 2 carotid bulb, all of 4 ICA lesion, 3 of 6
MCA lesion showed concordant perfusion or reserve decrease.
In group with severe stenosis or total occlusion on MRA,
reserve decrease was more frequent as compared with the
group with mild to moderate stenosis (p<0.05) Conclusions :
Even in asymptomatic patients with steno-occlusive lesion on
MRA, vascular reserve might be decreased. Brain SPECT
could give additional valuable information in asymptomatic
patients with steno-occlusive lesion on Brain MRA.
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Radiosynovectomy as a Primary Modality of Treatment
for Diffuse Pigmented Villonodular Synovitis of Elbow
joint treated with Rhenium-188 labelled Tin-Colloid.
K. Kamaleshwaran, L. Babu, b. krishnan, m. mallia, A. shin-
to; Kovai medical center and hospital limited, Coimbatore,
INDIA.
Aim: Diffuse Pigmented villonodular synovitis (DPVNS) is a
rare, relatively benign, intra-articular lesion characterized by a
slowly progressive proliferation of synovial tissue. The knee is
the most frequently involved joint, but elbow joint can be also
involved. There are previous reports which used Re-188 tin
colloid in knee joint synovitis but use of Re- 188 tin colloid in
elbow joint DPVNS is not yet reported. We describe the use of
Re-188 tin colloid in a 30 year old male who presented with
DPVNS of left elbow joint. Methods: A 30 year-old male
patient presented with left elbow joint swelling and pain for
duration of 4 months.X ray of elbow was done which showed
soft tissue swelling with no bone involvement. Magnetic res-
onance imaging(MRI )of elbow joint was done which showed
synovial thickening and enhancement with mild joint effusion
noted ,suggesting DPVNS .He was referred for RSV due to
high rate recurrence with surgery.Three phase bone scintigra-
phy showed increased blood pooling in left elbow joint con-
sistent with synovitis.Whole body image showed increased
uptake in left elbow joint Results: RSV was performed with
precise intra-articular injection under sterile conditions and
fluroscopic guidance.Before joint puncture, local anesthesia
was administered with 2% lidocaine- hydrochloride.Prior to
the injection of Re 188 tin colloid , Depomedrol (10 mg in
0.2 mL) was injected into the joint in order to reduce the risk of
acute radiation induced synovitis and to avoid skin radiation
necrosis.Subsequently, 370 MBq dispersed in 0.5 mL of ster-
ile, apyrogenic normal saline was administered intra-
articularly into left elbow joint and then the needle was flushed
with 0.3 ml of normal saline.An orthopedic bandage was ap-
plied as a semi rigid splint was immobilised for 48 hours.
Images were acquired in an dual head gamma camera in high
energy general purpose collimator with 155±20 Kev window.
Re-188 tin colloid SPECT/CT images showed good distribu-
tion of tracer in the left elbow joint inside the synovium. On
follow up after 3 months,there was significant decrease in pain
and swelling of elbow joint. Conclusion: In our case, RSVwas
useful as primary modality of treatment with DPVNS of elbow
joint . We suggest that Re- 186 tin colloid can be used safely
for the elbow involvement of DPVNS.
TP002
Comparison Between Left Ventricular Function
Parameters as Measured on 8- Versus 16-Frame
ECG-Gated 13NH3 Myocardial Perfusion PET Studies
N. J. Hoogvorst; Medical Center Alkmaar, Alkmaar,
NETHERLANDS.
Aim: The purpose of the present study was to validate the
accuracy of the 8-frame gated reconstruction for assessing
left ventricular ejection fraction (LVEF), end diastolic vol-
ume (EDV) and end systolic volume (ESV) from gated
13NH3 PET using 16-frame reconstruction as a reference.
By implementing the 8-frame gated reconstruction it would
be possible to reduce the reconstruction time and eventual-
ly decrease injected dose. Methods: 35 patiënts underwent
rest and stress myocardial perfusion PET using a Siemens
Biograph 16 TruePoint PET/CT scanner in listmode format
after the intravenous injection of 300 and 400 MBq 13NH3,
respectively. Datasets were reconstructed in a 168x168 ma-
trix and ECG-gated in either 8 or 16 intervals per cardiac
cycle. Left ventricular ejection fraction (LVEF), end dia-
stolic volume (EDV) and end systolic volume (ESV) were
determined using the QGS software package (2012 Cedars
Sinai Medical Center) for all datasets, and differences were
tested for significance and correlation between both
groups, for rest and stress studies. Results: A significantly
lower LVEF was obtained from the 8-frame reconstructed
rest 13NH3 PET dataset as compared to the 16-frame re-
constructed data (60.7%±13.2% vs 64.3%±13.5%, respec-
tively, P<0.001), but measurements correlated strongly (r
=0.996). The 8-frame reconstruction of the rest study pro-
duced a significantly higher ESV (48.9±38.7 ml vs 44.7
±38.6 ml for 16 frames, P<0.001 and r=0.999) and EDV
was not significantly different (113.1±42.3 ml vs 113.7
±42.4 ml, P=0.133 and r=0.998). The stress data also re-
vealed a significantly lower LVEF in the 8-frame vs the 16-
frame gated study (60.3%±12.6% vs 64.2%±12.9%,
P<0.001 and r =0.993), a higher ESV (53.0±39.6 ml vs
48.6±4.3 ml, P<0.001 and r=0.997) and not significantly
different EDV (123.3±43.0 ml vs 123.7±44.1 ml, P=0.485
and r=0.997). Conclusions: Reconstruction of 13NH3 gated
PET studies using 8 frames per cardiac cycle leads to sig-
nificantly lower LVEF, significantly higher ESV and not
significantly different EDV as compared to those obtained
from 16-frame gated studies, but correlation is very strong
for all values.
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TP003
Renal Parenchymal Analysis: 99mTc-MAG3 ‘v’
99mTc-DMSA
T. De Sousa, D. Bailey; Guy's and St. Thomas' NHS Founda-
tion Trust, London, UNITED KINGDOM.
Background: 99mTc-DMSA scan is currently used for the
analysis of renal parenchymal defects, particularly in paediat-
ric patients. Diuretic 99mTc-MAG3 dynamic scintigraphy has
been used in the evaluation of kidney function and to exclude
obstruction. However, 99mTc-MAG3 provides visualisation
of parenchyma with high object/background ratio at 2-4 min
post injection and can be considered in the analysis of paren-
chymal disorders. Aim: To evaluate the reliability of the pa-
renchymal analysis using 99mTc-MAG3 instead of 99mTc-
DMSA for paediatrics patients, allowing simultaneous infor-
mation on parenchymal evaluation, split kidney function and
drainage. Method:Paediatric patients referred for both scans
were considered for the study. Patients had 99mTc-MAG3
scan done first followed by 99mTc-DMSA 3 hours later as
per local protocol. Administrated activities were consistent
for EANM paediatric recommendations. Data Analysis: Im-
ages from three different patients were displayed on the same
grey scale and blinded with respect to radiopharmaceutical
used. Images analysed by 3 observers for evidence of renal
parenchymal defects. Confidence level when reporting scored
on a 1 to 5 scale.Results:Confidence level is higher when
reporting 99mTc-DMSA than 99mTc-Mag3 images: 4.5 vs.
2.9, on a scale from 1 to 5.88.9% concordance was achieved
between both reports.No false negatives reported on 99mTc-
Mag3 images.One false positive for focal parenchymal lesion
was reported by one observer on a 99mTc-Mag3 image.
Conclusion:99mTc-MAG3 could be used as a stand alone
study for the assessment of suspected renal damage and would
offer the following advantages of providing simultaneous ad-
ditional information on renal drainage, reduce the total atten-
dance time for patients and their carer and reduce radiation
exposure in the paediatric population;The use of LEHR colli-
mators may improve resolution and increase reporting
confidence.
TP004
Influence of attenuation correction in the MPI image
reconstructed by the Evolution for Cardiac™ software
D. F. F. Ribeiro1, J. Vilaça1, C. Nunes1, L. Freire1, M.
Pinheiro1, G. Cantinho2, E. Carolino1, E. Sousa1; 1Escola
Superior de Tecnologia da Saúde de Lisboa, Lisbon, PORTU-
GAL, 2Atomedical, Laboratório deMedicina Nuclear, Lisbon,
PORTUGAL.
Introduction - The acquisition of a Myocardial Perfusion im-
age (MPI) has great importance for the diagnosis of coronary
artery disease, since it allows evaluating which areas of the
heart are not being properly perfused, in rest and stress situa-
tions. This exam is greatly influenced by photon attenuation
which creates image artifacts and affects quantification. Aim -
To evaluate the influence of incorporating an attenuation cor-
rection map in the analysis of MPI and the outcome in perfu-
sion quantification and imaging quality. Methods - The popu-
lation comprised two sets of individuals (ten male and ten
female, with a body mass index (BMI) above 30Kg/m2). A
MPI study was acquired after the Computed Tomography
(CT), using EANMguidelines and reconstructed with the Evo-
lution for Cardiac software. Studies were reconstructed twice,
the first time relying uniquely on the MPI and the second time
relying on the MPI and on the attenuation correction map
given by the CT image. For perfusion quantification purposes,
images were segmented by vascular territories. For imaging
quality, the location of each wall in the short axis was identi-
fied. Each study was processed three times by the same oper-
ator, and average values were computed and compared be-
tween studies with and without attenuation correction . Results
- The level of significance for all comparisons was 1%. Sig-
nificant differences were found in female rest studies for the
right coronary (p=0.004) and the circumflex artery (p=0.0),
and in stress for the right coronary (p=0.0). For the male rest
set these were found for the right coronary (p=0.0) and the
circumflex artery (p=0.002), and in stress for the right coro-
nary (p=0.0) and the circumflex artery (p=0.002). The data
acquired for noise in female rest studies revealed, significant
differences for the inferior (p=0.003) and septum (p=0.0) walls
and in stress for the inferior wall (p=0.005). In the male rest set
these were found for the inferior (p=0.001) and septum (p=0.0)
walls, in stress for the lateral (p=0.007) and inferior (p=0.005)
walls. When evaluating the contrast, significant differences
were found in all walls for both sets, except for the inferior
wall in male stress studies (p=0.049). Conclusion - Results
show that performing attenuation correction with CT attenua-
tion maps, produces differences in perfusion and image qual-
ity. The study showed that contrast is greatly influenced by
attenuation correction. Differences between the male and fe-
male sets, correlate with the ones described in literature.
TP005
Influence of geometry on the measurement of an alpha
emitter radionuclide, Ra-233.
K. Thongklam, P. Charoenphun; Division of Nuclear Medi-
cine, Ramathibodi hospital, Mahidol University, Bangkok,
THAILAND.
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Aim: Alpha-emitting radionuclide therapy has been used for
treating cancer with metastasis such as Radium-223 dichloride
for the recent years. Alpha particles are highly efficient to kill
the target tumour cells with minimum damage to surrounding
normal cells. Regarding the dose calibrator measurement, ge-
ometry is very important to measure activity accurately. Aim
of this work is to evaluate the influence of geometry and obtain
an appropriate dial factor for Ra-223. Materials and Methods:
The dial setting for Ra-223 was initially applied in dose cali-
brator according to manufacturer recommendation using Ra-
223 dichloride solution in a vial. Decay correction was applied
for activity readings at the time of measurements. Radium-223
solution was exactly dispensed 1.0 ml into 5.0 ml syringe.
Actual activity of 1.0 ml Ra-223 solution was calculated. First,
radioactivity was measured with the initial factor. Consequent-
ly, dial setting was adjusted until activity reading of Ra-223
was the same as calculated activity before repeating measure-
ments. Ra-223 solution was additionally withdrawn to get the
final volume of 2.0, 3.0, 4.0 and 5.0 ml in the same syringe.
The measurements were sequentially performed in the same
manner for each volume (using either initial factor or adjusted
factors corresponding to each volume). Measurements with
initial factor were compared to those measurements with ad-
justed factors to get the percentage of differences. Statistical
significances between reading activities from initial factor and
adjusted factors were analysed using pair T-test. Results and
conclusions: Initial dial factor of Ra-223 in the vial was 16.9
while dial factors for 1.0, 2.0, 3.0, 4.0 and 5.0 ml were respec-
tively 13.5, 15.6, 15.7, 16.1 and 17.0. Differences between
measured activities of Ra-223 solutions (with initial factor
and adjusted factors) ranging between 1.0 and 4.0 ml were
respectively 25.23% and 4.87%. On the other hand whenmea-
suring 5.0 ml Ra-223 in syringe, the difference was only -
0.33% (p= 0.01). In conclusion measurement of Ra-223 is
increasingly influenced with geometry at lower volumes. In-
accurate measurements of Ra-223 activity was obtained when
initial factor is used to measure less than 5.0 ml Ra-223 in
syringe. We suggest that appropriate dial factor should be ap-
plied in order to administer accurate doses to patients.
TP006
Patient satisfaction in The Department of Nuclear
Medicine and PET-Centre, Aarhus University Hospital,
Denmark
A. Dysterdich , V. Larsen, L. Pedersen; Aarhus
Universitetshospital, Aarhus, DENMARK.
Aim: This study was preformed to evaluate patient satisfaction
with The Department of Nuclear Medicine and PET-Centre.
Our main aims were to examine the quality of the information
to be given prior to the examination and the patients’ satisfac-
tion and experience on the day of examination.Materials and
methods: Validated patients feedback questionnaires were col-
lected prospectively from 454 patients who attended NUK-
PET over a period of 2 weeks (December 8 to December 19
2014)This study was conducted at one of the largest depart-
ments in Denmark with 140 employees and an average survey
data of 16000 per year.The study questionnaire included 17
questions based on an ordinal scale. Descriptive and analytical
statistics were preformed in SurveyXact.Results527 patients
was handed the questionnaire and a collection of 454 question-
naires gave a response rate of 86%. The information to be
given prior to the survey was oral (66%) and written (77%).
Almost all of the patients (>95%) felt they had received all the
necessary information and were satisfied with the content and
quality. Only 8% of patients had visited the department
website.98% of patients thought that the number of staff they
met was adequate. 100% of the patients thought that the staff
was friendly and had the necessary time fore them.15% of the
patient experienced waiting time but 86% were informed ac-
cordingly. In deepening their answers the maximum of waiting
time were 35 minutes. Half of the patients were not aware of
the complaints system or that they could report unintended
events. 5% of patients did not think that there were possibili-
ties to exchange confidential information. The patients’ com-
ments have been prepared in a prioritization diagram divided
into major / minor and low satisfaction / high satisfaction.
Conclusion: The study findings indicated that there is great
satisfaction with the information patients receive before they
show up for examination. The number of patients who receive
both written and verbal information prior to examination can
be improved. Not many have visited the department's website.
The study findings indicated that there is great satisfaction
with the examination and with the number of staff they meet.
The study also shows that the staff are welcoming and accom-
modating. Patient awareness of reporting unintended events
and complaints can be improved. Efforts should focus on the
patients' comments and improving patients' experiences during
waiting.
TP007
Technologist radiation exposure performing PET/CT
using F18-FDG automatic dispenser
M. I. Larg, C. Pestean, M. Crisan, E. Barbus, D. Piciu; Ion
Chiricuta Institute of Oncology, Cluj-Napoca, ROMANIA.
AIM. PET/CTusing F18-FDG needs specific radiation protec-
tion due to the high energy photons produced by positron
annihilation: strong shielding devices, appropriate working
conditions and strict rules. The aim of this study is to evaluate
the efficiency of radiation protection devices from the
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department such as FDG automatic dispenser, and also the
efficiency ofthe procedures performed by the nuclear medicine
technologist. MATERIAL AND METHODS. The study was
conducted over a period of one month on 50 patients (10
patients/day), an average daily activity of 187mCi
(6919MBq) was manipulated, with a mean+/-SD of 187+/-
12.79mCi (6919+/-473.23MBq). The administrated activity/
patient had mean+/-SD of 7.85+/-1.24mCi (290,45+/-45,
88MBq). The dose rate measurements were taken during the
F18-FDG loadingin the dispenser (5 minutes/procedure) and
syringe dispensing procedures (4 minutes/procedure). The
dose rate has been measured with a Radiagem 2000 Portable
Dose Rate Meter.For the F18-FDG loading and dispensing
was used a Karl 100 system where the lead pot containing
the multi dose vial with F18-FDG is automatically uncapped
by the system. Automated infusions were performed using the
tungsten shielded infusion device. RESULTS. The average
dose rate at a distance of 30cm from the loading system was
70.1μSv/h with a mean+/-SD of 69.8+/-3.93μSv/h, which
means an exposure dose of 29.2μSv. Using aWi-Fi remote
control system the average dose decreased at 0.034μSv/h with
a mean+/-SD of 0.04+/-0.0089μSv/h which means an expo-
sure dose of 0.014μSv/month resulting from this procedure.
During the dispensing syringes procedures in the automated
injector for F18-FDG the average dose rate at a distance of
30cm was 7.008μSv/h with a mean+/-SD of 7+/-1.17μSv/h
which means an exposure dose of 23.36μSv. By increasing the
distance using the Wi-Fi remote control system the average
dose rate decreased at 0.035μSv/h with a mean+/-SD of
0.04+/- 0.01μSv/h, which means an exposure dose of 0,
11μSv/month/procedure.CONCLUSIONS. Besides shielding
devices the increasing of the distance by using an F18-FDG
autodispenser could be the most useful method to optimize
radiation protection in PET/CT practice. Extrapolation of these
results from these procedures to an annual dose revealed that
the annual extrapolated exposure values remained under the
authorized limits for workers classified to work in a
radioactivity-controlled area.
TP008
Studies on measurement of thyroid uptake rate on I-131
scintigraphy images
Y. Koshiba1, S. Abe2, S. Tsuchiya1, N. Fujita2, T.
Odagawa1, K. Kato1; 1Nagoya University Graduate School
of Medicine, Nagoya-shi, JAPAN, 2Nagoya University Hos-
pital, Nagoya-shi, JAPAN.
Aim: Measurement of I-131 thyroid uptake rate (TUR) is usu-
ally performed before the internal I-131 therapy for patients
with Graves’ disease, and the dose of I-131 to be administered
is determined from the data of TUR. TUR values before and
after I-131 therapy are not necessarily the same. In the previ-
ous study using a thyroid phantom, we found that TUR could
be measured on the planar and SPECT/CT images with less
than 5% of errors. In this study, we compared TUR values
before and after I-131 therapy using clinical data. Materials
andMethods: Thirty-seven patients with Graves’ disease treat-
ed with I-131 therapy between August 2013 and March 2015
in Nagoya University Hospital, 13 patients of whom
underwent SPECT/CTscans, were enrolled in this study. First,
using the planar and SPECT/CT images acquired with the
I-131 capsule, the equation for indicating the relationship be-
tween the I-131 radioactivity and the counts on the planar and
SPECT/CT images was established. Using the equation, the
counts on the planar and SPECT/CT images corresponding to
the I-131 dose administered were determined. TUR values
were calculated with the clinical data acquired from the planar
and SPECT/CT images and compared with those measured by
the TUR measurement system (AZ-800, Anzai Medical) be-
fore I-131 therapy. Results and Conclusion: TUR values mea-
sured on the planar and SPECT/CT images after I-131 therapy
closely correlated with those measured by the TUR measure-
ment system before I-131 therapy. The difference between
TUR values measured on the planar images and those before
the therapy were about 25%, whereas the difference between
those measured on the SPECT/CT images after the therapy
and those before the therapy was less than 20%. Results sug-
gest that TUR values measured on SPECT/CT images after the
therapy more closely approximate those measured before the
therapy than those measured on the planar images.
TP009
Semi-quantitative 18F-NaF PET/CT in the assessment
of bone mineral density (BMD): Comparison
with dual-energy X-Ray Absorptiometry (DXA)
S. Haim1, F. Fitzal2, B. Saboury3, A. Alavi3, C. Schiller1, W.
Langsteger1, M. Beheshti1; 1Nuclear Medicine & Endocri-
nology, St. Vincent's Hospital, Linz, AUSTRIA, 2Breast Can-
cer Center, St. Vincent's Hospital, Linz, AUSTRIA, 3Division
of Nuclear Medicine, University of Pennsylvania, Philadel-
phia, PA, UNITED STATES.
Aim: To examine the value of semi-quantitative 18F-NaF
PET/CT by means of standardized uptake value (SUV) in
the assessment of bone mineral density (BMD) correlating
with DXA BMD scanning, aging and various therapies. Ma-
terial & Methods: Seventy patients (mean age of 56.6±12.3
years) in the context of initial staging of breast cancer (64
pts) and prostatic cancer (6 pts) without known bone metasta-
ses were included. The maximum time interval between 18F-
NaF PET/CT and DXA scan was 9 months. Patients with
recent chemo- and/or radiotherapy (less than 3 months) were
S814 Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924
excluded. Semi-quantitative analysis was performed using
volume of interest (VOI) which was manually drawn on the
medullary part of L1, L2, and L3 as well as left femoral neck
excluding the vertebral cortex. DXA measurements in the
same regions were used for comparative analysis. Results:
SUVmean showed a significant correlation with T and Z score
in L1 and L2 (P = 0.01). However, there was no significant
correlation between SUVmean and BMD (g/cm2) in L1 and
L3. Using linear regression, the possibility for prediction of
bone mineral deficit by means of SUVmean was very low. No
significant differences were noted in the bone density of pa-
t ients with or without calcium supplementat ion,
bisphosphonates, hormonal and chemotherapy. However, pa-
tients with bisphosphonates therapy had significantly lower
SUV in lumbar spine compared to patients without bisphos-
phonate treatment. In addition, there was no significant corre-
lation between age and SUVmean (p > 0.6), while statistically
significant negative correlation was seen between age and
DXA BMD. Conclusion: In osteoporotic patients a significant
correlation was found between semi-quantitative 18F-NaF
PET/CTanalysis and DXA BMD Tand Z scores in the lumbar
spine. However, its potential for prediction of bone mineral
deficit should be evaluated in future prospective studies focus-
ing on volume-based apparent bone mineral density assess-
ment an approximation of the volumetric density of bone cal-
culated on different sites.
TP010
Implementation of new Hidex automatic gamma counter
S. M. Virtaniemi, J. Laine, K. Bergström; Helsinki University
Central Hospital, HUS, FINLAND.
Aim: A new Hidex automatic gamma counter was acquired to
measure Cr-51, Ge-68 and Ga-68 for GFR-studies, Ge-68 break-
through from Ge-68/Ga-68 generator and Ga-68 tracers’ quality
control, respectively, in our Nuclear medicine unit. The Hidex
gamma counter has a 3 inch NaI crystal, and optimized 55-
80mm lead shielding to minimize the background and interfer-
ence from samples on the conveyor. Hidex gamma counter is
equippedwith amultichannel analyzer for gamma spectrum anal-
ysis and software which will enable automatic reporting of re-
sults. The implementation of the new gamma counter conforms
to the requirements of the Finnish Radiation and Nuclear Safety
Authority (STUK). Materials and methods: The linearity, sensi-
tivity, stability, repeatability and background of the Hidex gamma
counter was tested with Cr-51 and Ge-68 samples. Suitability of
the gamma counter for PET tracer application was tested by
analyzing the distribution of the Ga-68 on the TLC plate. These
results were used to determine the radiochemical purity of theGa-
68-Dotanoc. All the results were cross-checked with the results
achieved with the Wallac/Perkin Elmer Wizard 3” 1480
Automatic gamma counter. Results and conclusion: The linearity
was measured with a Ge-68 standard solution series of 8 tripli-
cated samples with count rates between 1 900 and 244 000 CPM.
The achieved calibration line was linear (R2=0,9997) and the
relative standard deviation between triplicated samples was ≤1,
3%. Stability of the gamma counter was studied weekly with two
Ge-68 standard solution samples activities approx. 10000 and
30000 CPM. Measured activity differed always less than 1%
from the calculated activity. Dilution series of Cr-51-EDTA stan-
dard solution gave linear (R2=0,9999) results from triplicated
samples measured four times. The shift of the sample takes about
33 sec. Therefore, half-life correction should be done especially
for PET-radioisotopes with a short half-life. The linearity, sensi-
tivity, stability and repeatability of the Hidex gamma counter was
shown to be comparable with the Perkin Elmer Wizard gamma
counter. The user friendly software interface with a touch screen
made the Hidex gamma counter pleasant to use.
TP011
Enhanced Myocardial Glucose Uptake During Viability
Assessment Using Modified Niacin Induced Protocol
2-[18F] Fluoro-2-Deoxy-D-Glucose (18F-FDG) Positron
Emission Tomography/Computed Tomography (PET/CT)
M. Che Nordin1, A. Nordin1, F. Ahmad Saad1, H. Abdul
Razak2; 1Universiti Putra Malaysia (UPM), Serdang, MA-
LAYSIA, 2Universiti Teknologi Mara (UiTM), Puncak Alam,
MALAYSIA.
There are several established protocols available in the clinical
assessment of myocardial viability using 18F-FDG PET/CT.
This study was aimed to assess the intensity of 18F-FDG up-
take in the wall of left ventricle (LV) using a modified protocol
in a total of 33 subjects who had been equally divided into
three groups; Group A for normal volunteers, Group B for
oncology patients, and Group C for ischemic heart disease
patients. The 18F-FDG uptake in the wall of LV was qualita-
tively and quantitatively evaluated. The mean age for group A,
B and C were 35.00 ± 11.91, 45.91 ± 14.58 and 51.36 ± 9.97
respectively. The results showed that there was an increment
on 18F-FDG uptake in LVof group A subjects, in which sig-
nificant differences of mean SUVmax had been noticed at mid
(5.32 ± 3.48 vs 3.71 ± 2.16 vs 4.92 ± 3.99, p=0.04), basal (8.28
± 3.88 vs 3.79 ± 2.92 vs 6.94 ± 3.63, p=0.015) and apex (7.39
± 3.57 vs 3.84 ± 2.82 vs 6.17 ± 3.48, p=0.023) regions. The
mean normalized 18F-FDG distribution in 20-segment polar
map expressed in percentage for group B was the lowest in
comparison with the other two groups; A and C (61.02% vs
72.28% vs 61.64%, p=0.04). The outcome of this study may
postulate that niacin can be utilized together with modified
glucose loading protocol to enhance 18F-FDG uptake in rou-
tine clinical assessment of myocardial viability study using
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glucose uptake
TP012
Possible sources of artificial focal 18F-FDG accumulations
in the lung tissue without corresponding morphological
CT changes
T. K. Lehnskov, T. A. Roholm, U. Talleruphuus; Bispebjerg
and Frederiksberg Hospital, Copenhagen, DENMARK.
Aim: To investigate the source and possible physiological rea-
son for a number of lung foci in whole body 18F-FDG PET
scans not visible as co-existing lesions on the simultaneously
performed CTscans. Materials &Methods:In eleven patients a
whole body 18F-FDG PET/CT scan revealed focal FDG ac-
cumulations in the lung tissue without corresponding morpho-
logical changes in the concomitant diagnostic CT scan. All
artefacts occurred within a three month period. Details
concerning dispensing and administration of 18F-FDG, study
acquisition were noted, and the technologists involved in the
examinations were interviewed.We registered time of dispens-
ing, weekday of examination, external supplier of tracer, order
of patients, total tracer activity, volume administered to the
patient, residual activity in syringe and administering technol-
ogist. Finally we noted the volume of x-ray contrast and flush-
ing saline administered. Results: The 18F-FDG was adminis-
tered between 8:55 AM and 11:36 AM. Six patients received
FDG tracer from one external supplier and five from another
external supplier. Three patients received the first dose of the
day, while the remaining patients received doses ranging from
number three to eight. Mean injected dose was 202 MBq
±1.84 (SD), residual activity was 2.55 MBq ±1.05 (SD). All
CTscans were diagnostic and intravenously contrast-enhanced
(iohexol) . The volume of contrast was weight-adjusted (1 mg/
kg) and varied from 70 to 128 ml. The subsequent volume of
saline was 50ml for all patients. The artefacts were seen at least
once on any given weekday, but only when the 18F-FDG was
administered by one of the same two technologists. The inter-
views revealed that these 2 out of 11 technologists didn’t fol-
low proper guidelines by not flushing the catheter with 10 ml
saline after administration of tracer. The two technologists
were retrained and re-certified. After this intervention we have
not seen additional foci for three months.Conclusion:Since the
18F-FDG PET foci only appeared in patients where the cath-
eter was not flushed immediately after administration of tracer,
and because they received contrast in conjunction with the
scan, we speculate that not properly flushing the catheter
allowed small clots to form in the presence of 18F-FDG,
which were subsequently flushed into the lungs of the patients
while administering contrast intravenously at high flow rate.
TP013
Evaluation of therapeutic response to 131I in the treatment
of hyperthyroidism
A. C. C. Caetano1, A. P. S. Leite1, J. I. R. Madrid2, J. S.
Vicente2, E. Carolino1, L. Vieira1; 1Escola Superior de
Tecnologia da Saúde de Lisboa, IPL, Lisboa, PORTUGAL,
2Hospital Infanta Cristina, Badajoz, SPAIN.
Introduction: Thyroid disorders are the most common form of
endocrine disorders, and Nuclear Medicine has contributed sig-
nificantly to the handling thereof, binding together the 131I
therapy, which aims to reach a normal state of hormonal levels.
Hyperthyroidism is mainly caused by Graves' disease, Toxic
Adenoma (TA), Multi Nodular Goiter (MNG) and Toxic Nod-
ular Goiter (TNG). Objective: To evaluate the therapeutic re-
sponse to 131I in the treatment of benign hyperthyroidism
caused by different etiologies, taking into consideration the
age and 131I administered dose. Methodology: Retrospective
study, using non-probability convenience sample of 90 female
patients with benign etiology of hyperthyroidism, submitted by
clinical indication to therapy with 131I at the Nuclear Medicine
Service of Infanta Cristina Hospital, from 2005 to 2009, with
activities between 370MBq and 740MBq. After treatment, the
sample was divided by three categories - Hypothyroidism, Nor-
mal, and Hyperthyroidism - depending on the outcome of ther-
apy for each patient. To determine the presence of statistically
significant differences in age and dose depending on the out-
come of therapy, and depending on the initial type of hyperthy-
roidism, we used the non-parametric Kruskal-Wallis Test. To
study the association of the outcome of therapy with the initial
type of hyperthyroidism, we used the Chi-Square Test for the
Monte Carlo Simulation. Results: From the sample of 90 pa-
tients with an average age of 51 years, 43 had hyperthyroidism
caused by Graves' disease (42 years ± 13) 25 byMNG (64 years
± 8), 10 by TNG (56 years ± 14) and 12 by TA (53 years ± 20).
It was determined that 4% (4) of patients continued to have
hyperthyroidism, 30% (27) reached a normal hormonal levels
and 66% (59) acquired post-therapeutic hypothyroidism. It was
also found that the patients with hyperthyroidism derived from
Graves' disease had a higher incidence of hypothyroidism post-
therapy. In contrast, patients with hyperthyroidism derived from
NMR reached a state of normal hormonal levels after therapy.
Conclusions: In this sample, treatment with 131I was found
effective at treating hyperthyroidism. It was in hyperthyroidism
associated with NMR that the therapy with 131I showed higher
efficacy, since the patients had hormonal values within normal
limits. Patients with hyperthyroidism primarily associated with
Graves' disease responded well to therapy with 131I, but had
major side effects such as post-therapeutic hypothyroidism. In
hyperthyroidism associated with NBTand TAA, the final result
of the therapy was shown partitioned between post-therapy hy-
perthyroidism and normal state.
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TP014
Standardization analysis protocol proposal for isotopic
ventriculography
P. Borrelli1, J. Loaiza Góngora1, J. Vercher-Conejero1, C.
Ruiz Llorca1, C. Igua Sáenz1, D. Hervás Marín2, C. Olivas
Arroyo1, V. Vera Pinto1, P. Olivan Sasot1, P. Bello Arqués1;
1Hospital Universitario y Politecnico La Fe, Valencia, SPAIN,
2Instituto Investigación del Hospital Universitario y
Politecnico La Fe, Valencia, SPAIN.
Aim: To establish the post-processed analysis method for de-
termining left ventricular ejection fraction (LVEF) in isotopic
ventriculography, that presents the minimum interobserver
variability and a consistent reproducibility. Material and
methods: During 2014, 50 isotopic ventriculographies were
aleatorized and anonymized and then selected to analysis. Five
nuclear specialists then performed 4 different analysis
methods, totalizing 1000 studies performed. After
aleatorization patients selected were, 32 female and 18 males,
mean age 59 years. Referring clinical departments were oncol-
ogy in 96%, neurology 2% and neurology 2%. All studies
were performed at the Philips Extended Brilliance Worksta-
tion. The first three analysis were performed using manual left
ventricular multi unit gated analysis (LV-MUGA), with the
following color schemes: method A (inversegray), method B
(gray) and method C (smart). The forth and last anaylisis,
method D, was performed using semi-automatic LV-MUGA.
Patients were injected with 296 MBq (8mCi) of 99mTc- au-
tologous erythrocytes. Images were acquired using a double-
headed gamma camera (BrightView XCT, Philips Healthcare)
using standard acquisition parameters. Interobsever variability
was estimated among the different methods, calculating
intraclass correlation coefficient (ICC) for each of them. Com-
parison P-values between distinct ICC was estimated using
bootstrapping analysis. Statistical analysis was made using R
software (3.1.2 version). Results: ICC for method A
(inversegray manual MUGA) was 0,58, 95% confidence in-
terval (CI) 0,45 - 0,70, for method B (gray manual MUGA)
ICC was 0,53, CI 0,40 - 0,66, method C (smart manual
MUGA) the ICC was 0,58, 95% CI 0,45 - 0,71. For method
D (semi-automatic muga) ICCwas 0,84, with 95%CI 0,77 - 0,
90. Due to the high ICC presented by method D, all other
methods were compared with it. P-values for the comparison
among the three with method D were < 0,001 for all of them.
Conclusion: Semi-automatic LV MUGA was proven to have
the best intraclass correlation coefficient at the Philips Extend-
ed Brilliance Worstation, and it is safe to recommend its use in
the routine daily practice for the Philips Brighview XCT gam-
ma-camera, due to its reproducibility among observers. Fur-
ther studies among different gamma-camera brands would be
necessary to establish which analysis protocol could present
the best ICC for the different analysis software.
TP015
Surface contamination from 99mTc -Technegas aerosols
in the SPECT/CT room after lung ventilation.
S. D. Lind, R. S. Olsen, I. L. Rasmussen, M. Lonsdale; De-
partment of Clinical Physiology & Nuclear Medicine,
Bispebjerg and Frederiksberg University Hospital, København
NV, DENMARK.
Aim: We want to examine the surface contamination from
99mTc -Technegas aerosols on different sites of interest in
the SPECT/CT room when used in lung aerosol ventila-
tion studies. Airborne 99mTc-Technegas is known to ad-
here to surfaces, due to the chemical and physical charac-
ter of the aerosol particles. This may lead to an unknown
contamination of the room. Materials and methods: Seven
sites, specifically marked in the SPECT/CT room, were
wiped down with alcoholic swaps (82% ethanol, 0.5%
chlorhexidine). The swaps were put in different test tubes,
immediately after the ventilation but before the initiation
of image acquisition, and measured in a gamma counter to
estimate the 99mTc surface contamination. The chosen
areas were located on top of the TechnegasPlus Generator
(Cyclomedica), on the front of the generator, on the back-
side of the generator acrylic lead shield, on one detector
arm, on the measuring detector head, on the non-
measuring detector and on the door for patient entry. Prior
to any isotope handling, a background measurement was
obtained for all seven sites. All measurements, found in
counts per minute (CPM) by the gamma counter, were
corrected for decay and background and reported as activ-
ity per area (Bq/cm2). Results: A total of 14 day series
(with 1 – 3 patients/day) were studied, in which we ob-
serve a clear overall increase in the surface contamination
after each patient scanning. Initially, we measure an aver-
age background level of 0.22 (between 0.1 and 0.4) Bq/
cm2 from all seven sites in the room. This level increases
up to an average of 0.34 (between 0.1 - 0.7) Bq/cm2 after
the initial patients of the day and further to an average of
0.60 (range 0.2 - 1) Bq/cm2 after the second patients.
Finally, an average of 0.62 (range 0.2 - 1.2) Bq/cm2 is
detected after the third patients. The seven different sites
studied also show different levels of contamination with a
clear tendency of the generator sites being in the low end
(around 0.2 Bq/cm2) of the measurement scale and the
detector sites in the high end of the scale, i.e. between
0.4 and 1.0 Bq/cm2.ConclusionWe do measure a room
surface contamination, but with values below safety
threshold. In general, we observe an increase in the sur-
face contamination level during the day – after each pa-
tient scanning. Also, the different sites show different con-
tamination levels naturally due to the nature of the sites
studied in the room.
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TP016
Clinical classification versus semiquantification
with adapted reference values for 123I-FP-CIT SPECT
in a Nuclear Medicine Department
D. Silva1, M. Queiroga1, M. Elias1, J. Serrano2, J. Madrid2,
E. Carolino1, E. Sousa1; 1Escola Superior de Tecnologia da
Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon,
PORTUGAL, 2NuclearMedicine Department, Hospital Infan-
ta Cristina, Badajoz, Spain, Badajoz, SPAIN.
Introduction: Although semiquantification in 123I-FP-CIT
SPECT (DaTScanTM) is used in clinic daily basis, sometimes
there is a suspicious about discriminative capability and con-
cordance with the diagnostic classification for Parkinson Syn-
dromes performed by a physician.Aim: The aim of this study
is to test the capability of reference values obtaind from an
adapted database of healthy controls - named DBRV. This
Database was previously created and validated for 60 to 75
years old population of Hospital Infanta Cristina, located in
Badajoz.Methods: In previously studies the DBRV was creat-
ed and validated. For creation proposes, a group of 30 healthy
controls (GI) was submitted to semiquantification used semi-
automatic method of segmentation. Average and standard de-
viation (x ̅ ± δ) values were calculated for the following ratios:
left and right Caudate nucleus/ Occipital respectively (A) and
(B); left and right Putamen/Occipital respectively (C) and (D);
striatum/Occipital (E); left striatum/occipital (F), right
striatum/occipital (G), Putamen/ nucleus caudate (H). ). These
values were calculated and stablished DBRV. For validation
process DBRV was compared with two different groups of 30
patients each, of same age group: database of healthy controls
(DBVGIIH), and database of subjects with diagnosed Parkin-
sonian Syndromes (DBVGIIIP). Control Chards and ROC
(Receiver operating characteristic) Curves were calculated.In
this segment of study, for test de capability of DBRV in
Parkinson Syndromes diagnostics, a random Group of 30 pa-
tients was also submitted to semiquantification by the same
method and calculi of Rations A to H. Ratios C to H are the
ones with higher sensibility for early stages of Parkinson Syn-
dromes. The values obtained for these ratios were compared
with DBRV. If one of the Ratios was below of the respective
reference value (x -̅ δ) the exam was considered Pathological.
The physician reports based on visual assessment were com-
pared with diagnostics based on DBRV. Specificity, Sensibil-
ity, Positive (PPV) and Negative (NPV) predictive values were
calculated.Results: For comparison between DBRV and phy-
sician confirmation for Parkinson Syndromes it was obtained
P P V = 0 . 4 6 6 ; N P V = 1 ; S e n s i b i l i t y = 1 a n d
Specificity=0.65.Discussion/Conclusion: From these concor-
dance results is possible to confirm that DBRV have high
sensibility and consequently high NPV in diagnostic of
Parkinson Syndromes, so has high capability to predict heathy
studies. From the value of Specificity and PPV is possible to
conclude that sometimes, obtained values below of the respec-
tive reference value, essentially in early stages of Parkinson
Syndromes, cannot match Pathological studies.
TP017
Elution features of sorptive generators technetium-99m.
A. Rogov, V. Sкuridin, E. Stasyuk, N. Varlamova, E.
Nestwrov, V. Sadkin, L. Larionova, E. Ilina; National Re-
search Tomsk Polytechnic University, Tomsk, RUSSIAN
FEDERATION.
Short lived isotopes technetium-99m is widely used for diag-
nostic studies in medicine. To date, up to 83% all radionuclide
procedures performed using radiopharmaceuticals based
99mTc. For obtaining isotope technetium-99m is used gener-
ator technetium. Greatest distribution has received sorption
generators. World production of sorption technetium-99m
generators based on using highly active 99Mo. Its production
is based on the fission products of uranium-235. The technol-
ogy of obtaining poses risks to the environment. Alternative
possibility for production of 99Mo is its getting by radiation
capture reaction (n, γ) by irradiating the of molybdenum-98
with neutrons nuclear reactor. This technology has virtually no
of waste, but the resulting product has a low specific activity of
99Mo at a level 6-10 Ci/g. Use of such materials for the pro-
duction of generators requires the use of oversized columns.
This leads to a decrease in the volume of activity of the
resulting preparation of technetium-99m. The aim of the work
was to study the factors influencing the elution features gen-
erators of technetium-99m, made of neutron irradiation of
enriched molybdenum-98. The objectives of the research
was to determine elution profiles generators with different
adsorbed mass of molybdenum. The objectives of the research
was to determine elution profiles generators with different
adsorbed mass of molybdenum. Subsequent study of the na-
ture of the distribution of molybdenum over the length of the
sorption columns. The experiments show that with increasing
mass of the adsorbed molybdenum elution profile generators
narrowed. Reaching a minimum at certain limiting mass cor-
responding to the maximum sorption capabilities of the select-
ed sorbent. When studying the distribution in columns of the
generator is set that the value of maximum adsorption of mo-
lybdenum (maximum concentration) immediately upstream of
entrance columns depends on the total mass of molybdenum
introduced. Indicating that the initial decomposition of com-
plex polyanions and subsequent redistribution of the tracks on
the free active centers oxide. The degree of polymerization n
within the mass of molybdenum changes from 180 to 70mg in
a 0.6 times decrease, which leads to a nonlinear change of the
degree of filling columns molybdenum. Based on this
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suggested that the active centers of the vacant sorbent present
in the outlet portion columns hinders elution of 99mTc gener-
ator. Their number to achieve the desired output 99mTc should
be strictly regulated conditions predsorbtsionnoy training ox-
ides Al2O3. This work was financially supported by Ministry
of Education and Science of the Russian Federation
(RFMEFI57514Х0034).
TP018
The Evaluation of External Dose Measurements
in Children and Adolescent Patients Receiving
Radioiodine Therapy for Well-Differentiated Thyroid
Cancer
N. Edis, A. Ogretici, M. O. Tamam, M. Mulazimoglu;
Okmeydanı Training and Research Hospital, Istanbul,
TURKEY.
Background: In Turkey, the dose rate of discharge limits for
the patients treated with 131I at the end of hospitalization is,
under 30 μSv/h (3mR/h) at 1meter (m) or the activity in the
body is under 600 MBq. The aim of this study was to evaluate
the changes in external dose measurements (EDM) according
to patient age, administrated dose and hospitalization time in
children and adolescent well-differentiated thyroid cancer pa-
tients during the discharge. Materials and Methods: Between
3-19ages (16 ± 3.5 years), 67 patients’ (15M, 52F) 87 EDM
were evaluated retrospectively. Patients were divided into two
groups according to their ages: under the age of 10 (4 patients)
and above 10 (63 patients). Radioactive 131I doses were eval-
uated in 4 groups as follows: (a) Less than 3700 MBq, (b)
3700 MBq, (c) 5550 MBq and (d) 7400 MBq. Hospitalization
time comparisons were done in 3 groups as 2 days, 3 days and
4 days. EDM were done at 1m distance from the patient in
abdominal level using a portable Geiger-Müller survey meter
in μSv/h units. Results: All the EDMwere below the threshold
of 30 μSv/h. EDM of patients under the age of 10 and above
10 were 1-25μSv /h (mean 9.71 ± 9.52 μSv/h), and 1-30 μSv/
h (mean 8.87 ± 7.89 μSv/h), respectively. External dose mea-
surements according to the dose for groups a, b, c, d were
measured as; 2 -18 μSv/h (mean 10.38 ± 9.35 μSv/h), 1-30
μSv/h (mean 9.17 ± 7.68 μSv/h), 1 -20 μSv/h (mean 7.93 ±
5.70 μSv/h) and 1 - 25 μSv/h (mean 9.00 ± 8.99 μSv/h),
respectively. External dose measurements according to hospi-
talization time groups were measured as; 1 -30 μSv/h (mean
10 ± 9,53 μSv/h) for 2 days group,1 -27 μSv/h (mean 11.15 ±
7.47 μSv/h) for 3 days group, 1 -20 μSv/h (mean 5.61 ± 4.39
μSv/h) for 4 days group. Conclusion: The external dose mea-
surements are reduced as the day of hospitalization is in-
creased. Dose measurement average value is considered to
be within the permissible limits when evaluated according to
given doses. In particular, parents of children under the age of
10, receive more radiation due to staying closer to the children
for a longer period. The results of this study will provide more
information about radiation exposure, thus children with thy-
roid cancer treated with radioactive 131I and their family
members will benefit in terms of radiation protection.
TP019
Radiotherapy Planning in PET/CT: The Process
and Challenges
S. A. Summers, A. Ribeiro; The Royal Marsden NHS Hospi-
tal, Sutton, UNITED KINGDOM.
Aims: Accurate imaging is vital for treatment planning process
for most malignancies managed with curative intent. Positron
Emission Tomography scanning has brought about a revolu-
tion in the imaging of many common cancers and has it be-
comes widely available in developed countries, is increasingly
being incorporated into routine radiation therapy planning.
Materials and Methods: Radiotherapy planning is a multistep
process which requires the appropriate selection and delinea-
tion of target volumes (TV) and Organs at Risk (OAR) is of
paramount importance. It requires the proper use of both ex-
tremely sensitive and specific imaging modalities. PET/CT
offers Radiotherapy Planning numerous advantages, however
it does present us with a few limitations and challenges which
need to be addressed before the service is installed. The most
important precondition for successful integration of functional
imaging in Radiotherapy treatment planning is the goal orien-
tated as well as close and thorough communication between
PET/CTand Radiotherapy/Oncology departments on all levels
of interaction; careful planning is required. All roles from re-
ceiving requests and booking patients to scanning and
reporting of the images need to be established at the outset
of the process. The essential resources need to be in place to
run the service, including appropriate training of all staff and
important quality control procedures and protocols
established. Resources include: PET/CT Camera, Carbon Fi-
bre table top, Laser lights, Immobilisation devices, contrast
media, computer network and trained staff. Last but not least
the patient needs to be considered; this will include a decision
as to which patients would be appropriate for PET/CT Radio-
therapy planning and what is required to ensure the patient
receives optimal patient care. Results: The challenges a depart-
ment will face setting up this service will vary. These could
depend on the timing of the PET/CT scan, camera availability
and increased radiation dose to staff and other practical instal-
lation issues. Conclusion:With the successful planning and set
up, the inclusion of PET allows functional imaging to be in-
corporated in the localization and planning process giving a
further level of accuracy to the definition of the tumour volume
and the individualisation of treatment.
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S819
TP020
Comparative study on recovery coefficients of SPECT-CT
S. Tsuchiya1, S. Abe2, N. Fujita2, Y. Sakuragi2, Y. Koshiba1,
T. Odagawa1, K. Kato1; 1Nagoya University Graduate School
of Medicine, Nagoya, JAPAN, 2Nagoya University Hospital,
Nagoya, JAPAN.
Aim: Calculation of the recovery coefficients (RCs) are usually
conducted for assessment of the quantitativity of nuclear med-
icine imaging. RCs of hot spots change due to the difference in
shapes and reconstruction methods even if their volumes are the
same. In this study, we compared RCs of hot spots having the
same volume but different shapes. Materials and Methods: A
solution of Tc-99m was enclosed into the spherical phantom
including 6 spheres and the irregularly shaped phantom includ-
ing 5 containers having the same volume but different shapes.
SPECT-CT data of the phantomswere acquired and reconstruct-
ed using 3D-OSEM.Varied conditions on the subsets×iterations
(SI) and FWHM of the Gaussian filter were used for the recon-
struction of images. ROIs were drawn on the reconstructed
images, average counts per pixel were measured, and the radio-
activity of the Tc-99m solution was calculated. RCs were
aquired using the calculated values and the actually measured
activities. RCs of the spherical and the irregularly shaped phan-
tom were compared and the differences in the RCs (D values)
were obtained. Results: Slopes of the recovery curves were
increased at the range of SI≦120 and fixed at the range of
SI>120. The quantitativity of images became worse with an
increase of the FWHM of the Gaussian filter. RCs of each
container of the irregularly shaped phantom did not depend on
SI, but became lower with an increase of FWHM of the Gauss-
ian filter. D values were high at the range of SI≦60 and fixed at a
relatively low value at the range of SI>60. D values could be
lowered when FWHMof the Gaussian filter≦4mm or non-filter.
Conclusions: The reconstruction parameters capable of improv-
ing the quantitativity of SPECT-CT images and lowering their D
values are as follows: the SI>60 and FWHM of the Gaussian
filter≦4mm or non-filter. Further studies will be needed to im-
prove physical and visual qualities of SPECT-CT images.
TP021
Practical consequences of new indications for sentinel node
procedures in breast cancer: evaluating the role
of SPECT/CTand tracer reinjection
M. Kieft, B. Pouw, D. Hellingman, W. V. Vogel, M. P. M.
Stokkel; NKI-AVL, Amsterdam, NETHERLANDS.
Introduction: Sentinel Node (SN) procedures for breast cancer
is now common practice in many countries. Planar
lymphoscintigraphic imaging with Single Photon Emission
Computed Tomography with integrated CT (SPECT/CT) for
particular indications can be used for preoperative imaging.
However, together with the incorporation of SPECT/CT, indi-
cations for the SN procedure were extended to patients with
more locally advanced breast cancer receiving neo-adjuvant
chemotherapy, multicentric/multifocal breast cancer, and pa-
tients with local breast cancer recurrence after surgery and/or
radiotherapy. In our institution, we experienced increasing
numbers of non-visualisation on planar imaging since the in-
troduction of these new breast cancer SN indications. The
present study evaluates the practical consequences in terms
of the additional workload at the nuclear medicine department
required for patients with non-visualisation on planar imaging
scheduled for a breast cancer SN procedure. Materials and
Methods: Between 1st of July 2008 and 6th of November
2014 in total 1982 breast cancer patients underwent a SN pro-
cedure after intra-tumoural tracer administration. SPECT/CT
was performed in 298 patients (15%) who showed non-
visualisation on planar lymphoscintigraphy. Ninety-one
(30.5%) of these patients had previous surgery or radiation
therapy at the same breast prior to the SN procedure and 40
(13.4%) were scheduled for neo-adjuvant chemotherapy. If SN
non-visualisation persisted on the SPECT/CT images, a sec-
ond radiotracer injection with repeated lymphoscintigraphy
was performed when logistics allowed this. All information
about additional time on the SPECT/CT scanner and the addi-
tional time required to perform a reinjection was collected.
Results: SPECT/CT and reinjection visualised respectively in
22.8% (68/298) and 60.3% (38/63) of the patients SNs on the
preoperative imaging. All 298 SPECT/CT scans took approx-
imately 30-40 minutes including examination of the images by
the nuclear physician. The 63 reinjections of the Tc-99m tracer
took approximately 5-30 minutes preparation and 10 minutes
administration with 15 minutes additional scanning after a
resting period of an hour. This all required considerable flex-
ibility and rescheduling for technologist, nuclear physicians,
and the surgical department. Conclusion: The new breast can-
cer SN indications caused an increase in the non-visualisation
rate and therefore demands more time for the preoperative SN
imaging at the nuclear medicine department. Flexibility is re-
quired to allow additional SPECT/CT scans and tracer
reinjections in case of non-visualisation and should be consid-
ered for these new indications in breast cancer SN procedures.
TP022
Non-invasive quantification of the regional cerebral blood
flow using I-123 IMP SPECT and phase contrast MRA;
preliminary study of combination and revisit
of the matured technologies.
S. Mano, M. Tadokoro, S. Shirakawa, M. Ishiguro, H. Toya-
ma; Fujita Health University, Toyoake City, JAPAN.
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Background: SPECT is now widely used for the patients who
need regional cerebral blood flow evaluation. But most of the
cerebral blood flow (CBF) SPECTare performed without quan-
tification, because of the difficulties in quantification technique
and the invasiveness. Phase contrast (PC)MRA can stably mea-
sure the velocity and amount of blood flow at cervical vessels;
internal carotid arteries, vertebral arteries and basilar artery. The
flowmeasurements of these arteries give accurate quantification
of whole brain blood flow without invasiveness. Combined use
of both techniques could non-invasively make quantitative re-
gional CBF images, theoretically. This idea was already pro-
posed by several investigators, almost twenty years ago. But,
we have never seen this technique in clinical practice of CBF
evaluation. Aim: In this paper, we would like to present prelim-
inary study of non-invasive quantification of regional CBF with
combination of SPECT and PC-MRA in a few subjects, and
discuss on the possibility of this method in daily clinical
practice.Methods: Two patients who were ordered both CBF-
SPECT and MRI on the same day for the evaluation of mild
memory impairment were hired. The CBF-SPECT were per-
formed after injection of 167 MBq of I-123-N-isopropyl
iodoamphetamine (IMP). MR studies were performed by 1.5T
MR scanner. PC-MRAwere performed at the level of just above
the carotid bifurcation, and the velocity and flowweremeasured
in bilateral internal carotid and vertebral arteries. ImageJ (NIH)
was used for image calculations. Results: Quantitative CBF-
SPECT images were easily produced by simple calculation.
Total brain CBF measured by PC-MRA were just divided by
whole brain counts of the CBF-SPECT to produce pixel-by-
pixel images of quantitative CBF. Measured CBF of the gray
matter were within the range of 35 to 55ml/min/100g.Discus-
sion: Preliminary study of the combined use of SPECTand PC-
MRA showed the possibility of easy and non-invasive quanti-
fication of regional CBF, which can be used in daily clinical
practice of cerebral diseases. But this study only showed the
possibility. Comparative assessments with other methods of
CBF quantification are essential for the validation.
TP023
Dynamic F18-FDG studies with a dedicated breast-PET:
Preliminary results.
R. Sanchez Jurado1, J. Ferrer Rebolleda1, B. Kundu2, S.
Majewski2, X. Zhang3, Y. Li3, A. González4, M. Garcia1;
1ERESA, VALENCIA, SPAIN, 2Radiology and Medical Im-
aging, University of Virginia, Virginia, VA, UNITED
STATES, 3Beijing Institute of Technology, Beijing, CHINA,
4Institute for Instrumentation in Molecular Imaging, VALEN-
CIA, SPAIN.
PURPOSE: To develope an image segmentation method for
dynamic F18-FDG MAMMI-PET. METHOD AND
MATERIALS: Prone dynamic F18-FDG PET studies were
performed on five patients covering affected breast region
(40 mm only). Training database was established with some
typical pixels to different features (tumor and non-tumor re-
gion) using back-propagation (BP) Artificial Neural Network
(ANN) combined with time activity curves (TAC) features of
18F-FDG uptake of breast in vivo using a dedicated breast-
PET (MAMMI-PET; Oncovision). Results were correlated
with biopsy and histology. RESULTS: The TAC and uptake
rate of tumor and non-tumor region were clearly distinguished.
The TACs of tumor region had higher value of FDG uptake as
time passes and the curves had steep slopes. However in non-
tumor región TACs had a gentle slope and a downward trend.
We stablished a clear differentiation between tumor and non-
tumor region around 12-15 minutes after injection. CONCLU-
SION: An innovative approach for image segmentation of
breast cancer has been proposed. ANN with BP algorithm in
F18-FDG breast PET images had a good performance in the
segmentation of breast tumor and background. Here we shown
preliminary data that, despite being very encouraging, further
studies are needed to validate them.
TP024
A Case Report: Suitability of Measuring Kidney Depth
with Assessment of GFR Using 99mTc-DTPA in Ectopic
Kidney and Pediatric Patients.
J. CHOI; Asan Medical Center, SEOUL, KOREA, REPUB-
LIC OF.
Aim: This case report is to share three specific cases regarding
glomerular filtration rate(GFR) study. Furthermore, this report
verifies significant differences among five different methods
for kidney depth measurement. Case 1: 49-y-old woman had a
GFR study for kidney donation. Due to the misplacement of
her kidney, depth correction was conducted. For depth correc-
tion, CT images were evaluated.Depth was determined by av-
eraging the anterior and posterior depth at the CT images.The
two CT images that show the most superficial anterior kidney
surface and the deepest posterior kidney surface were chosen.
There was a gap more than twice between Tonnesen and man-
ual method. Case 2: 69-y-old man had a GFR study for kidney
donation. The patient had GFR studies twice at intervals since
right kidney’s GFR was below normal. GFR slightly fell short
of the normal value while other pathologic results indicated
normal. Similar to the first case, the two CT images were
selected. It showed a remarkable difference between the kid-
ney depth and GFR. Case 3: 3-y-old toddler had a GFR study.
GFR slightly fell short of the normal value while other patho-
logic results indicated normal. The problem here was that we
applied the Tonnesen in a young patient. Tonnesen’s method
was quiet underestimated while others stay in normal. How
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serious are these differences especially in young patients? Ma-
terials and methods: Along with this case report, we made
comparison between kidney depth of 57 adults kidney donors
( 26 male and 31 female; mean age, 42.6 y) who took GFR
study. One way anova test was performed with SPSS 13.0 to
analyze and compare kidney depth, GFR and normalized GFR
derived from 5 methods including Tonnesen, Taylor, Itoh, T-
Itho and manual method. Results: It showed significant differ-
ences between Tonnesen and other 4 methods in kidney depth,
GFR and normalized GFR(p< 0.05). Otherwise, there was no
significant differences among Taylor, Itoh, T-itoh and manual
method. Conclusion: It is essential for technologists to mea-
sure exact kidney depth. In case of a follow up study, consis-
tency of the method must be observed. The importance of
measuring for skin to kidney distance has been well recog-
nized in adults. However, similar corrections have not gener-
ally been incorporated into algorithms which evaluate renal
function in children. As one of the study performers, we
should contemplate what the best option for pediatric patients
would be.
TP025
Planar Scintigraphy vs SPECT/CT in The Visualisation
of Sentinel Node(s) for Patients with Vulvar Carcinoma
M. Brom-Attard, E. Mijnheere, M. Janssen; Radboud Uni-
v e r s i t y N i jmeg en Med i c a l Cen t r e , N i jmegen ,
NETHERLANDS.
Aim: Vulvar carcinoma is a demoralising disease involving
older women. Women diagnosed with primary cancer of the
vulva go through complicated surgery to remove the tumour
with the possibility of distressing complications, in addition to
the removal of lymph nodes. The removal of lymph nodes
adds to the complications of the surgery. Sentinel node imag-
ing has been developed to remove the affected lymph nodes
that receive drainage from the tumour thereby keeping the
removal of lymph nodes to a minimum and reduces the pos-
sibility of developing complications from having a total lymph
node dissection. Planar scintigraphy is the routine procedure
performed but might introduce some problems, such as non-
visualisation of sentinel nodes, contamination, and a mislead-
ing location of sentinel nodes. This pilot study has been carried
out to determine whether SPECT/CT is better than planar scin-
tigraphy in the detection of sentinel nodes. Materials and
Methods: In this pilot study, ten patients were included, who
underwent the routine sentinel node procedure with the addi-
tion of the SPECT/CT four hours post-injection of 99mTc-
labelled Nanocolloid. Four nuclear medicine physicians and
five nuclear medicine practitioners were asked to document
the number of sentinel nodes seen on planar scintigraphy and
SPECT/CT. The inter-observer agreement was determined by
Cohen’s Kappa agreement. Results: The results of the study
showed that there was no significant difference in the detection
of sentinel nodes by SPECT/CT when compared to planar
scintigraphy. SPECT/CT was useful in determining the exact
depth and location of the sentinel node(s), especially if found
in an unexpected location, and in incidents of contamination.
The inter-observer agreement was higher between nuclear
medicine practitioners (K=0.468) when compared to that of
physicians (K=0.256). Conclusion: In this pilot study,
SPECT/CT is only better than planar scintigraphy in
the visualisation of depth of the sentinel node(s) and
displaying their exact location. SPECT/CT has shown
the same number of sentinel node(s) as planar scintigra-
phy and will only be performed adjacent to the routine
procedure if needed.
TP026
Evaluation of a rhodamine-angiotensin conjugate
as a potential breast cancer imaging agent
S. Okarvi, I. Jammaz; King Faisal Specialist Hospital & Re-
search Centre, Riyadh, SAUDI ARABIA.
Aim: Rhodamine (Rh) is a positively charged lipophilic fluo-
rescent dye that accumulates specifically in mitochondria of
living cells. Rh dyes are known to accumulate in the heart and
share several properties with 99mTc-sestamibi. Additionally
mitochondrial-specific Rh dye has been evaluated as a poten-
tial anticancer agent because of its high uptake and prolonged
retention in most cancer cells and rapid release from normal
cells. Change in mitochondrial potential is an important fea-
ture in tumor cells. It is believed that cancerous cells as com-
pared to normal epithelial cells may have higher mitochondrial
or plasma trans membrane potential and Rh crosses these bar-
riers because of net positive charge on the molecule. The high
specificity for mitochondria and low toxicity to normal cells
coupled with selective accumulation in carcinoma cells sug-
gest that 99mTc-Rh-AngII may prove to be an effective tumor
imaging agent. It is therefore of great interest to evaluate the
potential of 99mTc-Rh-AngII as breast cancer targeting agent.
Materials and Methods: Rh-angiotensin (Rh-AngII) Rh-Lys-
Gly-Gly-Cys-βAla-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-NH2
was synthesized by Fmoc/HBTU based solid-phase peptide
synthesis. Carboxytetramethylrhodamine (TAMRA) was
linked to AngII peptide via the free amino group of Lys residue
by manual synthesis. Rh-AngII was radiolabeled with 99mTc
via GGC chelating moiety by tartrate ligand exchangemethod.
In vitro cell binding was determined on MDA-MB-231 and
MCF7 breast cancer cell lines and in vivo biokinetics was
studied in balb/c mice at 1 and 4 h p.i. Results: Rh-AngII
conjugate was prepared conveniently by solid-phase synthesis
and its structure was confirmed by mass spectrometry and
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purity by HPLC. The conjugate was radiolabeled efficiently
with 99mTc. In vitro tumor cell-binding demonstrated high
affinity and specificity of 99mTc-Rh-AngII towards human
breast cancer cells (binding affinities below 20 nM). The tumor
cells binding characteristics of 99mTc-Rh-AngII was found to
be comparable with 99mTc-sestamibi. In vivo biodistribution
and clearance kinetics in mice displayed a rapid clearance from
the blood and other tissues and organs both at 1 and 4 h p.i.
99mTc-Rh-AngII was excreted mainly by the renal pathway
with some elimination via the hepatobiliary system.Conclusion:
The results of this initial study towards the development of a
breast cancer imaging agent indicate some similarities of
99mTc-Rh-AngII with 99mTc-MIBI highlighting the potential
of hybrid conjugate for targeting of breast cancer. The use of
hybrid conjugate appears to hold a great promise as a new and
attractive approach for tumor targeting. More tumor targeting
studies are in progress and will be reported.
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TP027
A new amyloid imaging probe 125I-EISB in PET/SPECT
imaging of amyloid was developed for both brain
and whole body for clinical use
S. Tsukimoto; Kumamoto University, Kumamoto, JAPAN.
[purpose] We developed a new radio-compound 125I-EISB
(1-(2-125I-ethoxy)-2,5bis (styryl) benzene) which is amyloid
imaging probe to detect β-amyloid plaques both in human
brain and the whole body using PET/SPECT. The aim of this
study is to evaluate in vivo bio-distribution of 125I-EISB and
accumulation to amyloid in mice. We performed bio-
distribution studies in mice to examine in vivo distribution of
125I-EISB and find an affinity of the compound to amyloid
plaques in amyloid deposition. [method] In bio-distribution
studies, 0.3 ml of 125I-EISB was injected by tail vein to nor-
mal and amyloid deposition mice. After 1, 3, 15, 30 and 60
minutes, brain, heart, spleen, liver, stomach, the small intes-
tine, large intestine, kidney and muscle were taken out and the
weight and radioactivity of the organs are measured and ob-
tained %Dose/ g. Following bio-distribution studies, autora-
diographs of mouse brain and SPECT/CT imagings of whole
body were measured. [result] In bio-distribution studies of the
normal mice, 125I-EISB was accumulated mainly to liver
(40.1±3.6%) and kidney (15.1±2.2%). With the amyloid de-
position mice, 125I-EISB was accumulated mainly to liver
(40.1±4.8%) and spleen (15.1±1.6%). The images of the brain
were obtained using imaging plate (IP) detector and 125I-
EISB of the amyloid mouse was observed a high brain uptake
in IP. In SPECT imaging of normal mouse, 125I-EISB was
accumulated mainly to liver and kidney as obtained in bio-
distribution. On the other hand, 125I-EISB was accumulated
mainly to liver and spleen in amyloid mice. [conclusion] In
bio-distribution and SPECT imaging, it was found that 125I-
EISB were accumulated to β-amyloid. 125I-EISB was prom-
ising for the detection of the amyloid plaques for clinical use.
TP028
Influence of Nuclear Medicine Technologists’ professional
experience and visual function in the Myocardial
Perfusion Gated-SPECT semi-automatic processing
A. S. Reimão1, F. Nascimento2, E. Carolino3, J. Pereira4, M.
Nobre2, I. Poças2, L. Vieira5; 1Nuclear Medicine Scientific
Area, Lisbon School of Health Technology – Lisbon Polytech-
nic Institute (ESTeSL-IPL), Lisbon, PORTUGAL & Brighton
and Sussex University Hospitals NHS Trust, Brighton, UNIT-
ED KINGDOM, 2Orthoptics Scientific Area, ESTeSL-IPL,
Lisbon, PORTUGAL, 3Mathematics Scientific Area,
ESTeSL-IPL, Lisbon, PORTUGAL, 4Nuclear Medicine Sci-
entific Area, ESTeSL-IPL, Lisbon, PORTUGAL, 5Nu-
clear Medicine Scientific Area, ESTeSL-IPL & Instituto
de Biofísica e Engenharia Biomédica, Faculdade de
Ciênc ias da Univers idade de Lisboa , L i sbon ,
PORTUGAL.
Aim: Myocardial Perfusion Gated-SPECT (MPS) plays an
important role in the diagnosis, evaluation and follow-up
of patients with Coronary Artery Disease. Its processing
can be performed manually, semi-automatically or auto-
matically, however the semi-automatic is the most widely
used for routine clinical practice. Since the Nuclear Med-
icine Technologists (NMT) performance might be affected
by individual and environmental factors, the aim of this
study was to evaluate the influence of NMT professional
experience and visual function on the MPS semi-
automatic processing, and therefore in the determination
of function and perfusion quantitative parameters (QP)
measured. Materials and Methods: 20 NMT were selected
and categorized into two groups according to their expe-
rience on the Quantitative Gated SPECTTM software:
Group A (GA) - NMT ≥ 600 h and Group B (GB) -
NMT without experience. All NMT underwent an
orthoptic evaluation for assessment of visual function
and processed 21 MPS five times in a non-consecutive
way. It was assumed to be an altered vision when at least
one visual function parameter was found abnormal.
Friedman’s and Wilcoxon Tests were applied to compare
the QP between operators and to analyse GA and GB
performance respectively. To compare the NMT with nor-
mal vs. altered vision, the Mann-Whitney Test was used
and the ETA association coefficient was performed to
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evaluate the visual function influence in each QP. Statisti-
cally significant differences at a significance level of 5%
were assumed. Results: A greater discrepancy in GB was
noted when compared with GA, and the Septal Wall (SW)
was the only statistical difference (zw=-2,051, P=0.040).
Regarding the influence of visual function, significant sta-
tistical differences in Left Ventricle Ejection Fraction
(LVEF) (U=11.5, P=0.012) were observed, contributing
the vision 33.99% for its variation. It was denoted more
differences between NMT that have a greater incidence
of ocular symptomology and a diminished Binocular Vi-
sion. Conclusion: On MPS semi-automatic processing, it
was verified that professional experience and visual
function influence the SW and LVEF QP respectively.
This work was supported in part by Fundação para a
Ciência e a Tecnologia - Portugal (UID/BIO/00645/
2013).
TP029
I131 Effective Half-Life in Well Differentiated Thyroid
Cancer Patients
S. Saengsuda; Rajavithi hospital, Bangkok, THAILAND.
Background: Oral administration of radioiodine (131I) has
been used in treatment of well differentiated thyroid cancer
(DTC) after surgery to decrease recurrence and mortality. Pa-
tients with high dose 131I administration (>2.96 GBq) re-
quires hospitalization with isolation ward for radiation precau-
tion to limit the radiation dose to family members and member
of the public. The advised precautions are generally based on
radiation dose rate and effective half-life for clearance of ra-
dioactive body burden. Objective: To assess the effective half-
life of 131I in DTC patients who had been administered high-
dose 131I (>2.96 GBq). Material and method: From January
2009 to Febuary 2012, a retrospective review of total 200 DTC
patients with age range 8-80 years, mean age 41.98±15.57
years, 173 women and 27 men treated postoperatively with
high dose 131I administration were collected for this study.
The range of 131I administered activity was 3.18-8.51 GBq
with the mean activity was 4.82±1.0GBq. Two measurements
of exposure at t time (1-3 days later, Et) were used for calcu-
lation of effective half-life of clearance of administered activ-
ity. Result: The range of 131I administered activity was 3.18-
8.51 GBq with the mean activity was 4.82±1.0GBq. The mean
initial exposure rates of total patients 81.65±32.36 (E0) and
17.55±15.94 (Et) μSv/h were shown with the mean duration
time between E0 and Et 61.68±24.48 h. The mean effective
half-life of 131I clearance was 13.2±12.96 h and the median
effective half-life was 9.60 h. Conclusion: In DTC patients
receiving 131I administration after surgery, the value of effec-
tive half-life is in accordance with the previous reports in
literature. Patient release planning should be differentiated on
the basis of individual measurements of exposure rate and
calculation of effective half-life.
TP030
Optimizing the azeotropic drying of 18F- way to improve
18F-Fluorocholine radiochemical yields!
H. Hassan1, S. Abu Bakar2, K. Che A. Halim2, J. Idris2, A.
Nordin1; 1Universiti Putra Malaysia, Serdang, Selangor, MA-
LAYSIA, 2National Cancer Institute, Putrajaya, MALAYSIA.
Aim: 18F-Fluorocholine has been suggested as one of the
reputable imaging agents for detection of prostate cancer in
Positron Emission Tomography / Computed Tomography
(PET/CT) modality. Nevertheless, it has never been synthe-
sized in Malaysia. Thus, there was no available data on 18F-
Fluorocholine synthesis was reported. We acknowledged the
major problem with 18F-Fluorocholine is due to its relatively
low radiochemical yield at the end of synthesis. Therefore, we
reported improved 18F-Fluorocholine radiochemical yields
before and after we had optimized the azeotropic drying of
18F-Fluorine. Materials and methods: Syntheses were per-
formed using a modified GE TracerLab MXFDG module (n =
6). 18F-Fluorocholine was synthesized via N-alkylation of
d i m e t h y l e t h a n o l a m i n e ( DMEA ) w i t h 1 8 F -
fluorobromomethane (BrCH2F), followed by purification on
the CM cartridge with ethanol and water. Prior to addition of
dibromomethane (100 ul) in acetonitrile (3 ml) to reactor vial,
an aqueous 18F-Fluorine solution (25 - 75 GBq) delivered
from cyclotron was subjected to azeotropic drying (with ace-
tonitrile in the reactor vial). We investigated the effect of du-
ration time during azeotropic drying phase and pressure inside
the reactor vial on the radiochemical yield. Radiochemical
yield of 18F-Fluorocholine synthesized in shorter duration
time of azeotropic drying at atmospheric pressure (0 atm)
(Condition 1; n = 3) was compared to radiochemical yield of
18F-Fluorocholine synthesized in longer duration time of
azeotropic drying at high vacuum pressure (-0.65 to - 0.85
bar) (Condition 2; n = 3). In the end, the mean radiochemical
yield was statistically compared between two azeotropic dry-
ing conditions to observe whether the improvement made was
significant to the radiochemical yield. Results: After six con-
secutive runs, the 18F-Fluorocholine was obtained in 9 - 25%
radiochemical yields (decay not corrected), with more than
95% radiochemical purity. In Condition 1, the 18F-
Fluorocholine mean radiochemical yield obtained was 10.4 ±
0.8% (decay not corrected) whereas in Condition 2 was 21.3 ±
2.6% (decay not corrected). We observed 18F-Fluorocholine
radiochemical yield increased at one fold, when the duration
time of azeotropic drying was made longer at high vacuum
pressure inside the reactor vial, regardless on the initial amount
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of 18F-Fluorine activity. Conclusion: An improved 18F-
Fluorocholine radiochemical yields were obtained after we
had optimized the azeotropic drying of 18F-Fluorine. From
the paired sample t-test analysis, it reveals that the improve-
ment made was statistically significant difference in the mean
of 18F-Fluorocholine radiochemical yield (p < 0.05).
TP031
The Radiation Dose Received by the Staff Responsible
for the Collection and Transport of the Radioactive Waste
N. Edis, A. Ogretici, M. O. Tamam, M. Mulazimoglu;
Okmeydanı Training and Research Hospital, Istanbul,
TURKEY.
Objective: Radioactive waste arising after the imaging and
treatment in nuclear medicine clinic are considered to be
low-level. However, according to intensity of the work in the
clinic and variety of imaging modalities effect the amount and
the variety of the radioactive waste. The aim of current study
was to assess the radiation dose received by the staff respon-
sible for the collection and transport of the radioactive waste.
Material and Method: In our clinic, the radioactivity used
monthly are approximately 296 GBq activity of Tc-99m,
249GBq of I-131, 166GBq of FDG. We evaluated the 3 years
thermoluminescent dosimeter data (TLD) whole body dose of
4 staff responsible for the collection and transport of the radio-
active waste. One staff was responsible of I-131 and Tc-99m
waste, 2 staff were responsible of FDG waste and one staff for
removing the waste from waste processing center. The staff
responsible of I-131 and Tc-99m waste was also followed up
daily for 1-month with a digital dosimeter. These data were
analyzed according to monthly activity amount, daily external
dose measurement, and the variety of radioactivity. For the
measurements Chest type thermoluminescent dosimeter is
(TLD) and ÇNAEM NEB-236-C brand digital dosimeter
was used and reading of TLDs is a two-month period. Surface
dose measurements of waste were performed with the device
ÇNAEM brands NEB211 Geiger Müller. Results:The annual
measurement of the staff collecting I-131 ve Tc-99m wastes
showed a sum of 0,49mSv/year. The Daily measurement of
this staff with digital dosimetry showed a mean value of 4,79
±0,36 μSv at the day collecting I-131 and a mean value of 3,95
± 0,06 μSv/h at the day collecting Tc-99m wastes. Digital
dosimeter recorded daily average operating time was found
to be 425minutes. I-131 surface dosemeasurements of month-
ly average of 13.5±24.6 μSv/h waste, whereas the Tc-99m
waste 28.9±38.8 μSv/h was calculated. The other 3 personnel
have been found under the average annual dose of 0.1 mSv.
Discussion: The measured annual dose was far below than the
dose limit, which is 20 mSv / year, permitted for workers
responsible of collection and transport of radioactive waste.
Maximum exposure dose measurements of the staff observed,
was even 1/40 of the allowed annual dose limit. The reason
lower dosimetry measurement of the staff responsible for the
of FDG waste than other staff is that FDG has very short half-
life and the FDG waste is collected the next day.
TP032
Additional findings above skull base on 18F-FDGPETCT:
the usefulness of imaging from vertex
N. Gulliver, A. Almeida, N. Mulholland, G. Vivian, A.
Eccles; King's College Hospital, London, UNITED
KINGDOM.
Background: Recently updated EANM guidelines for 18F-
FDG PETCT in tumour imaging (2015) state that for most
oncology indications covering the range from the base of the
skull to the mid-thigh (half-body) is sufficient. In patients with
tumours with a high risk of head and brain metastasis but not
metastasis in the lower extremities (e.g. lung cancer), it may be
appropriate to perform an extended half-body scan from vertex
to include the brain. Imaging from vertex on FDG PETCT has
been demonstrated to be of use in assessment of patients with
myeloma or melanoma, and in investigating paraneoplastic
syndrome and pyrexia of unknown origin. Standardisation of
image acquisition technique can be difficult to maintain with a
rotating technologist workforce with varying experience of
interpreting clinical indications. Methods: We conducted a ret-
rospective audit of all half-body FDG PETCTs carried out in
our department March 2014-March 2015. In our centre, con-
flicting methodology over the length of scan required clear &
concise streamlining. PET and low dose CT for attenuation
correction and localisation were performed with a GE Discov-
ery 710 PETCT. In order to simplify departmental protocol we
introduced vertex to mid-thigh scan length for all FDGPETCT
scan indications that previously started at skull-base. Discus-
sion: Instances where abnormal clinically-significant intra-cra-
nial FDG uptake was demonstrated coincidental to the primary
indication were recorded (<5% of cases) and four cases are
presented here: (i) a staging scan for lung cancer revealing a
photopenic parietal brain lesion alongside avid lung primary
and bone metastases; (ii) a staging scan for lung cancer show-
ing a recent extensive hypometabolism through the right tem-
poral lobe, a likely recent ischaemic event; (iii) a staging scan
for Hodgkin ’s lymphoma pat ien t demonst ra t ing
paraneoplastic cerebrallitis; (iv) a scan for assessing extent of
metastases prior to local resection on a patient with breast
cancer which demonstrated posterior parietal hypometabolism
consistent with a dementia diagnosis. CTacquisition from ver-
tex instead of skull-base increased average effective dose by
~0.15mSv. Conclusion: Although additional intra-cranial find-
ings were relatively uncommon, retrospective review of cases
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has underlined the usefulness of imaging from vertex. All
FDG PETCT patients in our department are now scanned from
vertex with an extra 3 minute PET bed position acquired com-
pared to imaging from skull-base. This has had no impact on
the smooth running of patient worklists withminimal addition-
al CT dose.
TP033
Technologist Radiation Exposure in Routine Clinical
Practice with I-131 Administration for Ablation
of Thyroid Cancer
A. Ergulen, F. Ustun, O. N. Yigitbası, G. Durmus-Altun;
Trakya University Medical Faculty, EDIRNE, TURKEY.
Objective: In many countries, patients treated with therapeutic
amounts of radioactive iodine (I-131) is hospitalized because
of radiation safety considerations. The use of radioactive io-
dine for clinical thyroid cancer ablation therapy increases tech-
nologist radiation dose exposure because of the higher γ-
radiation energy of this isotope than of other conventional
medical γ-radiation-emitting isotopes. Therefore, I-131 thera-
py necessitates stronger radiation protection requirements. The
aims of this study were to assess technologist whole-body
exposure in our radionuclide department and to evaluate the
efficiency of our radiation protection devices. Methods: In 119
patients with DTC, I-131 ablation of thyroid cancer was mon-
itored for technologist radiation exposure in routine clinical
practice. Radiation dose assessment was performed for single
as well as for multidose application with both LiF thermolu-
minescence dosimeters (TLD) and electronic personal dosim-
eters (ED). Results: The mean dose of I-131 treatment was 122
±28 mCi (range 75-200 mCi). The mean ± SD total effective
doses received by technologists (n=119) during all of the
working steps were 1.12 ± 2.38 μSv and dose rate 31.2 ±
22.8 μSv/hr, respectively, as measured with ED. These values
were confirmed by daily TLD technologist whole-body dose
measurements. There was a faint correlation between
I-131 dose and technologist radiation dose rate (r=0.21,
p: 0.01). In our department four technologists were
working routine clinical practice. The mean ± SD total
effective doses received by each technologist were 0.68
±0.55, 1.65±3.62, 0.54±0.57, 1.61±2.99, respectively;
p>0.05). Conclusion: These results showed that technol-
ogist radiation doses in our radionuclide therapy depart-
ment were lower than those reported in the literature.
Extrapolation of these results to an annual dose (2 pa-
tients per day per technologist) revealed that the annual
extrapolated exposure values remained under the autho-
rized limits for workers classified to work in a
radioactivity-controlled area
TP034
Comparison of capability of diagnosis supporting system
between two deifferent gamma cameras for bone
scintigraphic images in diagnosing bone metastasis
of cancer
K. Shimizu1, M. Hino1, K. Matsumoto2, S. Yamamoto3;
1Kobe City Medical Center General Hospital, Kobe, JAPAN,
2Kyoto College of Medical Science, Nantan, JAPAN, 3Na-
goya University Graduate School of Medicine, Nagoya, JA-
PAN.
Aim: BONENAVI, a diagnosis supporting system for
evaluating bone scintigraphic images with a computer,
was developed and less variance among interpreters
and improved diagnostic accuracy have been reported.
Clinical trials with diagnosis supporting systems have
been carried out and it is important to compare capabil-
ity of diagnosing bone metastasis with different gamma
cameras in a multi-center study. However, capability of
diagnosing the bone scintigraphic images obtained with
different gamma cameras remains unclear. This study
aimed to investigate the difference in diagnostic capabil-
ity of bone metastasis between different gamma cameras
for bone scintigraphic images. Materials and Methods:
The subjects comprised 181 cases examined by bone
scintigraphy with 99mTc-MDP. They were cancer cases
with a pathologically confirmed primary lesion, in which
presence or absence of bone metastasis had been clini-
cally diagnosed. Exclusion criteria were patients that
could not be analyzed due to abnormal body posture
and extraskeletal accumulation and contraindications for
the employed drugs. Bone scintigraphic images obtained
with two different gamma cameras, GE SPECT/CT Dis-
covery 670NM and Infinia Hawkeye, were subjected to
analysis with diagnosis supporting system software
BONEVAVI. According to the obtained results (ANN
values) and the results of interpreters, sensitivity, speci-
ficity, positive predictive value, negative predictive val-
ue, and AUC by ROC analysis were calculated to com-
pare capability of diagnosing bone metastasis. Results:
Discovery 670NM and Infinia Hawkeye provided sensi-
tivity at 83% and 85%, specificity at 85% and 92%,
positive predictive value at 86% and 65%, negative pre-
dictive value at 82% and 97%, and AUC at 0.893 and
0.948 (p = 0.175), respectively. Conclusion: There was
no significant difference in diagnostic capability with
bone scintigraphic images obtained with two different
gamma cameras. It was elucidated that different diagno-
sis supporting systems could be used in a multi-center
study as long as accuracy of the systems had been con-
firmed in advance.
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TP035
Dosimetric analysis of Lu-177-DOTA-Rituximab
in patients of relapsed/refractory Non-Hodgkin’s
Lymphoma
M. P. Yadav, S. Singla, P. Thakral, S. Ballal, S. K. Gupta, C.
Bal, A. Malhotra; All India Institute ofMedical Sciences, New
Delhi, INDIA.
Aim: Radioimmunotherapy (RIT) targeting CD20 receptors in
lymphoma using radiolabelled chimeric antibodies may dem-
onstrate better therapeutic responses than radiolabeled chime-
ric antibodies or cold anti-CD20 antibodies. The study was
designed to assess the biodistribution and give reasonable es-
timates of normal organ doses, including red marrow using
177Lu-DOTA-Rituximab.Materials &Methods: Patients with
relapsed/ refractory CD20+ B-cell NHL were recruited in the
prospective study. In house labeling of 177Lu-DOTA-
Rituximab was performed and administered after quality as-
surance. Rituximab (375 mg/m2) followed by 50 mCi (1850
MBq) of 177Lu-DOTA-Rituximab was administered as slow
intravenous infusion and emission images were acquired. Re-
gion of interest (ROI) were drawn for kidney, liver, heart,
bladder, spleen and tumor lesions on both anterior and poste-
rior images. Internal dose estimation was made using
OLINDA v1.0 software. Results: The mean age of the ten
patients (8 males and 2 females) was 52 ± 1 years. The uptake
of radiolabeled antibody was visualized within 30 minutes of
administration in liver, kidneys, heart, spleen and bladder. The
coefficient of determination (R2) was greater than 0.95 for
organs and whole body in all patients. The effective half-life
of radioimmunoconjugate was 100 ± 28 hours (42 - 126 hrs).
The critical organ in our study was the red marrow. Conclu-
sion: There may be considerable inter-individual differences in
absorbed doses of organs and generalization or extrapolation
of doses in clinical setting at present does not seem feasible
with 177Lu-DOTA-Rituximab in NHL patients.
TP036
Validation of an in-house media-fill
on radiopharmaceuticals compared to ready-to-use kits:
a cost-effective procedure fitted on each nuclear medicine
needs
M. Di Franco1, S. Valfre2, T. Scotognella3, T. Angusti1, D.
Ielo1, V. Podio1; 1Ospedale San Luigi Gonzaga, Orbassano
(TO), ITALY, 2Università degli Studi, Torino, ITALY,
3Policlinico Agostino Gemelli, Roma, ITALY.
AIM: Most radiopharmaceuticals are designed for parenteral
admninistration and for this reason must be produced by asepting
processing; asepsys has to be continuously assessed in order to
guarantee drug safety.Media-fill tests (recommended by Pharma-
copoeias) are designed to simulate normal labeling procedures
but with microbiological growth medium in place of drug solu-
tions. Many producers make available expensive ready-to-use
kits (vacuum vials, colture medium or vials containing colture
medium, labels) that do not always fit specific nuclear medicine
needs. In our institution, we aimed to develop and test media-fill
from raw materials to final data analysis. MATERIALS AND
METHODS: All materials are certified as sterile and apyrogenic;
tryptic soy broth (TSB) is certified by producer also for fertility.
Vial types and sizes were chosen to properly match the single
procedure, avoiding large vials (not fitting shields or labeling
devices). Operating in a class A laminar flow cell, TSB was
transferred into vials (fitted with bromobutyl rubber closures
and aluminium cap seals) by 0.22 μm syringe filters; sterility
and apyrogenicity were checked after filling. Vacuum and TSB-
filled vials were used to simulate the different steps of routine
procedures. Similarly to ready-to-use kit procedures, also in our
laboratory four main steps were identified: elution (if appropri-
ate), labeling, fractioning and dispensing. In addition, samples
subjected to heating, cooling under cold water and mixing were
analyzed as single-steps using fresh culture medium for every
elementary procedure. All TSB samples were incubated for 7+7
days (25 °C and 35 °C respectively) in a stove formicrobiological
studies and visually assessed each day; all results were recorded
on appropriate worksheet. RESULTS: All materials were already
in use in our hospital or readily available on the market. In-house
media-fill achieved a perfect match with all elements of standard
procedures of radiopharmaceutical synthesis and manipulation;
this match was not possible with ready-to-use kits. Moreover,
despite the larger number of steps involved (with 33 vs 21 vials
to be tested), the total expense was much lower than costs of
commercially available kits. CONCLUSIONS: Despite various
operating procedures and different radiopharmaceuticals, in-
house media-fill could match each single nuclear medicine de-
partment needs; it is versatile, easily designed by the quality
assurance supervisor and prepared in any hospital with available
vials and TSB. In our experience, no test was positive, but a
positive test would exactly identify the single step involved: no
uncertainty would be possible.
TP037
Myocardial Perfusion Radiopharmaceuticals and Imaging
in SPECT and PET
R. Adães1, E. Pereira2, M. Fernandes2, E. Sousa1; 1Escola
Superior de Tecnologia da Saúde de Lisboa, Instituto
Politécnico de Lisboa, Lisbon, PORTUGAL, 2Nuclearmed -
Instituto de Medicina Nuclear, Lisbon, PORTUGAL.
Purpose/Introduction: Myocardial perfusion imaging (MPI)
has an effective role and are well implemented in detecting
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disorders of left ventricle myocardial perfusion and function,
yet it is a major subject of research. The development of new
radiopharmaceuticals in this field allows increasingly more
sensitive and specific for the diagnosis and monitoring of heart
diseases along with the development of more specific radio-
pharmaceuticals. This work aims to conduct a review of the
inherent examinations that use radiopharmaceuticals in clini-
cal practice in studies of myocardial perfusion tomography by
single photon emission tomography (SPECT) and Positron
Emission Tomography (PET). Is also intended to focus radio-
pharmaceuticals that are under investigation or in clinical trials
with great potential for cardiac imaging in conventional Nu-
clear Medicine and PET, proceeding to a comparative analysis
of both techniques. Subjects/Methods: Literature search was
undertaken through the portal b-on and in scientific journals,
where the search words SPECT, myocardial perfusion imag-
ing, PET radiopharmaceuticals and SPECT radiopharmaceuti-
cals, which were subsequently revised. Results/Discussion: In
clinical use for SPECTapplications technetium labelled agents
are the ones now available and in clinic utilization: 99mTc-
Tetrafosmine and 99mTc-Sestamibi, the most used. 99mTc-
Teboroxime is approved and in clinic use in United States,
and 99mTc-N-NOET has good characteristics for MPI but at
this point is still not approved in USA. 201Talium Chloride it
was a popular myocardial perfusion agent but is now of very
little importance and use in clinical practice. In clinical use for
MPI PET applications the semi-disintegration time is one of
the major concerns, it can be used 13N-Amonia, Rubidium-82
( 8 2 R b ) , O x i g e n i um - 1 5 ( H 2 1 5O ) , 1 8 F - FDG
(Fluordesoxiglucose). Rubídium-82 (82Rb), is the mostly
used radiopharmaceutical for its availability due to the gener-
ator of 82Stroncium/82 Rubidium. Conclusion: MPI by PET
has great advantages of imaging resolution and several radio-
pharmaceuticals available. SPECTMPI are still very used due
to their financial cost and availability in most of countries.
TP038
Evaluation of the quality of neuroimaging features
as Alzheimer’s Disease biomarkers
F. Lucena1, T. F. Vaz1, J. Pé-Leve2, A. S. Ribeiro3, L.
Lacerda4, N. Silva5, D. Nutt3, J. McGonigle3, H. A.
Ferreira2; 1Institute of Biophysics and Biomedical Engineer-
ing of the Faculty of Sciences of the University of Lisbon /
Lisbon School of Health Technology of the Polytechnic Insti-
tute of Lisbon, Lisbon, PORTUGAL, 2Institute of Biophysics
and Biomedical Engineering of the Faculty of Sciences of the
University of Lisbon, Lisbon, PORTUGAL, 3Centre for
Neuropsychopharmacology, Division of Brain Sciences, De-
partment of Medicine, Imperial College London, London,
UNITED KINGDOM, 4Centre for Neuroimaging Sciences,
Institute of Psychiatry, King’s College London, London,
UNITED KINGDOM, 5Institute of Neuroscience and Medi-
cine 4, Forschungszentrum Jülich GmbH, Jülich, GERMANY.
The main challenges in Alzheimer’s Disease (AD) are earlier
diagnosis and classification of different stages, being neuroim-
aging an important tool. This work aims to evaluate the quality
of neuroimaging features as AD biomarkers.T1-weighted
magnetic resonance imaging (MRI), diffusion tensor imaging
(DTI) and 18F-AV-45 positron emission tomography (PET)
data were processed and analyzed using the Multimodal Im-
aging Brain Connectivity Analysis (MIBCA) toolbox. Data
from 45 individuals, obtained from the Alzheimer’s Disease
Neuroimaging Initiative database, were divided in: 12 healthy
controls (CTRL); and 11 early mild cognitive impairment
(EMCI), 11 late mild cognitive impairment (LMCI), and 11
AD patients.The metrics evaluated were: gray-matter-volume
(GMV); cortical thickness (CThk); mean diffusivity (MD);
fractional anisotropy (FA); fiber count (FiberConn), structural
connectivity node degree (Deg) and clustering coefficient
(ClusC); and relative standard-uptake-values (rSUV). Receiv-
er operating characteristic curves were used to evaluate and
compare the diagnostic accuracy of the most significant neu-
roimaging metrics and brain regions, expressed as the area
under the curve (AUC). Comparisons were performed be-
tween CTRL-EMCI, CTRL-LMCI and CTRL-AD, based on
biomarkers showing AUC>70% and intervals of confidence
>0.5.Our results suggest that cortical atrophy begins in con-
fined areas of the temporal region and mainly in the left hemi-
sphere. The atrophy gradually involves other parts of the ce-
rebral cortex from both hemispheres at later stages ofMCI and
AD, indicating an increased spread of cortical atrophy charac-
teristic of AD progression, which can be the result of the ac-
cumulation of neurofibrillary tangles.Regarding CTRL-EMCI
comparison, several brain regions act as potential biomarkers
when assessed by PET and DTI, supporting the evidence that
metabolic and microstructural alterations, respectively, might
precede atrophy. The elevated MD and decreased FA in tem-
poral regions are consistently found in MCI stages, and are
thought to reflect progressive loss of the barriers
restricting the motion of water molecules in tissue com-
partments associated with the neuronal loss and disruption
of myelin sheaths in AD.Temporal lobe regions were
highlighted in CTRL-LMCI, being more related with
structural changes and connectivity metrics due to pro-
gression to AD. Other regions from the parietal and frontal
lobes were identified as having high AUC regarding rSUV
(AUC=99%), corroborating the literature.In this study,
several potential biomarkers (brain regions/neuroimaging
metrics) were studied and the best candidates for differen-
tiating between healthy controls and patients groups iden-
tified. Nonetheless, results must be taken with caution as
the study sample was small and consequently further stud-
ies are warranted with larger samples.
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Qualitative and quantitative analysis of 123I-DaTSCAN
SPECT in the diagnosis of Parkinson’s diseases:
body-contouring versus circular orbit acquisition
A. PALMIERI1, A. ZOCCO2; 1SANTA MARIA NUOVA
HOSPITAL, REGGIO EMILIA, ITALY, 2UNIVERSITA' DI
MODENA E REGGIO EMILIA, MODENA, ITALY.
BACKGROUND: SPECT (single photon emission computed
tomography) with N-u-fluoropropyl-2a-carbomethoxy-3a-(4-
iodophenyl) nortropane, also called FP-CIT, labelled with
123Iodine (commercially known as DaTSCAN) has been
proven to be useful in the diagnosis of Parkinson’s diseases.
DaTSCAN-SPECT provides qualitative and quantitative in-
formation to confirm dopaminergic degeneration in patients
with parkinsonism. AIM: SPECT data acquisition can be per-
formed using a circular orbit or a body-contouring system. The
aim of this study is to investigate whether circular orbit offers
different information about qualitative and quantitative analy-
sis than body-contouring orbit in cerebral SPECT with 123I-
DaTSCAN. MATERIALS ANDMETHODS: To acquire data
we used a Symbia T2 SPECT-CT scanner (Siemens Medical
Solutions). Acquisitions were performed on three patients, 3
hours after receiving 185 MBq of 123I-DaTSCAN. Each
study was acquired using the same standard acquisition’s pa-
rameters provided for a cerebral SPECT. Scans were per-
formed using LEHR parallel hole collimators, over 360 de-
grees at 120 angles, 30 seconds/angle, 128x128 matrix, zoom
1.23. Every patient was scanned twice: for the first study we
used a body-contouring orbit and patient’s head was placed at
the center of FOV; for the second we selected a circular orbit
with fixed radius and patient’s head was decentralized. Images
were processed using data management system “Syngo”.
SPECT projections were reconstructed with filtered
backprojection algorithm, butterworh filter (cutoff: 0.45, or-
der: 8). We analyzed qualitative transaxial images and we per-
formed ROI on basal ganglia and background for quantitative
analysis. RESULTS Qualitative analysis: Images obtained
using circular orbit have a worse quality, lower resolution
and they appear more smoothed and noisy than images ac-
quired with body-contouring. Quantitative analysis revealed
a decrease of absolute counts in SPECT data acquired with
circular orbit SPECT, because distance between detector and
patient was more than in the acquisition with body-contouring
orbit. On the other hand, relative counts (ratio: basal ganglia-
background/background) were very similar in both acquisi-
tions. CONCLUSION This study demonstrates that using
body-contouring in SPECT we can obtain better results from
a qualitative point of view, because the image’s resolution
worsens with increasing distance to the camera. Instead,
semi-quantitative analysis doesn’t reveal important differences
between two acquisitions.
TP040
Influence of disposable materials in 99mTc-MAG3
radiolabelling
M. Menzaghi, R. Lucianini; Ospedale di Circolo, VARESE,
ITALY.
AIM: The evidence of the reduction of MAG3 Radio-
chemical Purity during routine workload has led a sys-
tematic analysis of the whole “in situ” product process.
Our evaluation has revealed a correlation between the
loss in product quality and medical devices recently in-
troduced such as disposable syringes. MATHERIAL
AND METHOD: The MAG3 compound is radiolabelled
with dual-step process, the first one introduces a known
99mTcO4- saline radioactivity volume in the lyophilized
vial and the second step is the boiling phase which gets
the metal complex 99mTc-MAG3 binding reaction.
Traceabi l i ty int roduced by the Rules of Good
Manufactoring Practice in radiopharmaceuticals (NBP-
RF) highlighted a significant loss of the radiochemical
purity in a two-month period, by relating the syringe
used in the process with Radiochemical Purity and pH
value of the RF MAG3. The entire process systematic
analysis has suggested the likely lossy factor the use of
new 10 ml syringes during labelling. The comparative
analysis of the disposable material data-sheets (Artsana,
Farmac-Zabban, BD) and the available literature
prompted the conclusion that the only factor responsible
is the oil lubricant of the three parts syringe plunger
(body, piston, elastomer). The amount of silicone oil
used in the syringe can determine interference in the
labeling reaction of 99mTc-MAG3. RESULTS: The
comparative analysis showed that all manufacturers use
the same medical lubricant and the specific oil amounts
refer to the Rule limits therefore they don't indicate the
exact quantity. This assumption suggests that the prob-
lem is pretty quantitative: the silicone material released
from the syringe to the lyophilized kit defines alterations
in the Red-Ox reactions during the complex formation.
A gold standard analytical method, such as mass spec-
trometry, is desiderable to measure the amount of sili-
cone oil in the suspension. This method could indicate
new reference limits for lubricants used in disposable
devices for the 99mTc-MAG3 labelling. CONCLU-
SIONS: The quality of Radiopharmaceuticals prepared
in the Radiopharmacy Laboratory must be guaranteed
by the careful choice of used disposable materials. The
continuous check of the more significant qualitative in-
dicators for 99mTcMAG3, such as RadioChemical Purity
and pH values, can help a Nuclear Medicine Department
to guarantee the necessary product quality and help to
define a quality improvement strategy.
Eur J Nucl Med Mol Imaging (2015) 42 (Suppl 1):S1–S924 S829
TP041
Intraobserver and interobserver variation of myocardial
perfusion SPECT results related to repeated
reconsructions
M. Kraft, T. Koivumäki, M. Hakulinen, M. Kokkonen, A.
Leinonen, T. Laitinen; Kuopio University Hospital, Kuopio,
FINLAND.
Aim: The myocardial perfusion SPECT is used to detect and
assess obstructive coronary artery desease. During image re-
construction process maching the attenuation map and
SPECT-image, orientation of myocardium and exclusion of
extracardiac activity is done manually by the technologists,
which can potentially lead to variation in results. The aim of
this work was to study intra- and interobserver variation in
myocardial perfusion results from reconstruction point of
view. Material and methods: Data of eleven patients (7 male,
4 female, age 50-86 years) were collected. Images were ac-
quired with Siemens Symbia SPECT-CT camera (Tc99m-
tetrofosmin, matrix 128*128, 64 angles, time per view 25-
30s, 16 ECG frames). Images were reconstructed iteratively
(OSEM, 5 iteration, 16 subsets, 3D Gaussian 14mm FWHM).
Perfusion parameters, that are Summed stress score (SSS),
Summed rest score (SRS), Summed difference score (SDS),
Stress Extent%, Rest Extent% and Ischemia%, were calculated
using Quantitative Perfusion SPECT 2012 software (QPS,
Cedars-Sinai Medical Center, Los Angeles, CA). If the QPS
program told about mask failure, experienced doctor verified
the contours. The reconstructions and analyses were per-
formed three times with four weeks separation by three tech-
nologists. Intra- and interobserver variations were evaluated
by calculating intraclass correlation (ICC), Cronbach's alpha
and coefficient of variation (CV%, root mean square). Results:
The reproducibility results were practically similar in intra-
and interobserver variations. Intraobserver ICC was lowest in
SDS 0,268 and highest in SRS 0,986. Mean CV% varied be-
tween 24,4 (Ischemia) and 76,1 (Rest Extent). Lowest
Cronbach's alpha was 0,51 (SDS) and highest 1,0 (SRS). In-
terobserver reproducibility (ICC) was lowest in SDS 0,290
and highest in SRS 0,98. Mean CV% varied between 33
(Ischkemia) and 80,8 (SRS). Lowest Cronbach's alpha was
0,51 (SDS) and highest 0,99 (extent stress and extent rest).
In cases with disagreement between analyses of different re-
constructions, slight changes in contour detection had signifi-
cant impact on results. Conclusions: The intra- and interob-
server reproducibility (ICC) was good in SSS, SRS, stress
extent and rest extent.The rebroducibility of SDS was poor
in both, intra- and interobserver variation. Ischemia had mod-
erate reproducibility, in intra- and interobserver variation. In
addition to effect of variation in reconstructions, also variation
in contour detection is responsible for poor reproducibility in
SDS.
TP042
Influence of Reconstruction Parameters for FBP
in Semiquantif ication of Brain Studies
with 123I-FPCIT
F. Alves1, R. Adães2, C. Fortes2, E. V. Sousa2; 1Alliance
Medical, London, UNITED KINGDOM, 2Escola Superior
de Tecnologia da Saúde de Lisboa, Instituto Politécnico de
Lisboa, Lisbon, PORTUGAL.
Aim: Brain dopamine transporters imaging by Single
Photon Emission Tomography (SPECT) with 123I-FP-
CIT has become an important tool in the diagnosis
and evaluation of parkinsonian syndromes. However,
Ordered Subset Expectation Maximization (OSEM) is
the method recommended in the literature for imaging
reconstruction Filtered Back Projection (FBP) and is
still used due to its fast processing. The aim of this
work is to investigate the Influence of reconstruction
parameters for FBP in semiquantification of Brain
Studies with 123I-FPCIT compared with those obtained
with OSEM recommended reconstruction. Material and
methods: 16 exams of Brain Studies with 123I-FPCIT
were processed by using Butterworth filter in FBP,
with the cutoff frequencies (Cf) 0.4, 0 .5, and 0.6
cycles per pixel combined with the orders of 6 , 8,
10 and 15. For OSEM reconstruction it was used 3
iterations with 8 subsets. Chang’s attenuation correc-
tion (μ=0.11cm-1) was applied for both reconstruction
methods, and each exam was reconstructed three times.
The outcome measure was the specific binding ratio
(SBR). For statistical analysis it was used the
Friedman’s test, a non-parametric approach for paired
samples. Results: OSEM and FBP methods were com-
pared, and for the last one with the orders 8 and 10
with 0.5Cf it wasn’t found out any significant differ-
ences (pvalue=0.16). Those combinations of orders and
cutoff frequencies produce an image with a compro-
mise between resolution and noise reduction similar,
This led to conclude that both methods of reconstruc-
tion allow to identify the regions in study in a reliable
way, permitting the identification of the SBR of the
pathology independently of the reconstruction method.
However FBP Cf 0.6 and order 6 are the parameters
where FBP rates more differently from OSEM; Cf 0.5
and order 8 are the ones that rates closest. A signif-
icance level of 5% was used. Conclusion: Both recon-
struction methods can identify the regions to study,
allowing identifying and classifying in similar way
the SBR. FBP method with Cf 0.5 and order 8 shows
closer values to the ones from OSEM, and it can be
used as a reliable alternative in clinical practice for
the SBR calculation
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TP043
Half-time oncologic bone scintigraphy imaging in patients
with prostate and breast cancer
S. J. C. Serém1, M. I. Gomes1, W. Grootjans2, W. J. M. van
den Broek2, E. P. Mijnheere2, B. F. Bulten2, L. Heijmen2, R.
Hermsen2; 1Coimbra Health School, Polytechnic Institute of
Coimbra, Coimbra, PORTUGAL, 2Radboud University Med-
ical Center, Nijmegen, NETHERLANDS.
Aim: Bone scintigraphy has an established role in the manage-
ment of patients diagnosed with breast and prostate cancer.
However, the noisy character of the images either requires a
sufficient amount of radiotracer to be administered or suffi-
ciently long image acquisition times, resulting in considerable
radiation exposure or reduced patient comfort. In this study,
the performance of a Pixon enhanced planar processing (EPP)
algorithmwas investigated with the purpose of reducing image
acquisition time in bone scintigraphy of breast and prostate
cancer patients. Materials and Methods: Standardized phan-
tom experiments were conducted to access the performance
of the EPP software. For this purpose, the sphere insert of
the National Electrical Manufacturers Association (NEMA)
phantom was placed in the cylindrical casing of the Jaszczak
phantom. Images were acquired with different sphere-to-
background ratios (4:1, 8:1, 17:1, 22:1, 32:1 and 71:1) and
scan speeds (8, 12, 16 and 20 cm/min). Image quality was
determined by calculation of signal-to-noise ratio (SNR) and
contrast-to-noise ratio (CNR) of the spheres, and coefficient of
variation of the background ROIs. Furthermore, 51 patients
diagnosed with breast and prostate carcinomas were included
for clinical investigation. Each patient was scanned using a
standard protocol, in concordance with the EANM guidelines
for bone scintigraphy, and a shortened acquisition protocol.
Three nuclear medicine physicians performed independent
reading of standard, half-time, and half-time processed (EPP)
images, scoring image quality, and providing a final diagnosis.
Results: Image noise, as reflected by the coefficient of varia-
tion, was considerably reduced in EPP images. Based on the
phantom experiments, it was determined that EPP images ac-
quired with half-time protocol (16 cm/min) had similar image
quality as standard images (8 cm/min). Subjective and objec-
tive image quality in the clinical EPP images improved, being
comparable to the standard images. There was substantial
agreement with respect to diagnosis and diagnostic confidence
based on all three image types between observers. Moreover,
the number of lesions or affected anatomical areas was not
considerably different based on all three image types. Conclu-
sion: It was shown in this study that half-time imaging in
oncologic bone scintigraphy is feasible with the current clini-
cal protocol. Although EPP improved image quality, the diag-
nosis providedwas not different in all three image types. These
results emphasize that there may be the possibility to further
reduce image acquisition time, certainly with the availability
of EPP tools, eventually contributing to improving clinical
workflow and patient comfort.
TP044
Albumin macroagregates (MAA) kit fractionation
for labeling with 99mTc: temperature and storage time
influence in quality parameters
S. F. C. Mendes, B. F. Oliveira, A. G. F. Ramos, F. Lucena;
Escola Superior de Tecnologias da Saúde, IPL, Lisboa,
PORTUGAL.
Albumin macroagregates (MAA) kit-fractionation for 99mTc-
labeling is a procedure that can be used as strategy to maximize
resources and reduce costs. Therefore, quality parameters [per-
centage of 99mTcO4- (%99mTcO4-), pH and size of particles]
should be accurately controlled. It is necessary to optimize the
procedures assuring the quality of the radiopharmaceutical and
not compromising the diagnostic procedure. The aim of this
work is to evaluate the influence of fractionation, temperature
and storage time on the quality parameters of 99mTc-
MAA.Two fractions were obtained from eachMAA-kit provid-
ed by the manufacturer which were evaluated immediately after
fractioning (G1) and after 1 week in the freezer (G2). Each
fraction was radiolabelled with 99mTc (740MBq / 6mL) and
the variables pH (10 min), size of the particles (2h) and
%99mTcO4- (10 min and hourly from 1-6h) were determined.
Also residual activity in the syringe wasmeasured with different
incubation times (0, 10 and 20 min), with (Sh) and without
shaking (n-Sh). Descriptive and inferential statistics were ap-
plied (IBM-SPSS software, version22). Significance was con-
sidered for p-value<0.05.Preliminary results: there were no sig-
nificant differences in %99mTcO4, pH and size of particles
between groups; significant differences in % 99mTcO4- over
time were found for G1 (p-value=0.000) and G2 (p-val-
ue=0.001) with a decreasing pattern from 1-4h (G1) and 1-5h
(G2); freezing produced %99mTcO4- (1h) above the 10% limit
of themanufacturer; there were differences in residual activity at
0 min (p-value = 0,000) and 20 min (p-value = 0,000) of incu-
bation, with syringe shake between groups; residual activity
ranged between 11% (0 min-Sh) and 85% (20 min-n-Sh) for
G1 and between 12% (10 min-Sh) and 88% (20 min-n-Sh) for
G2; in each group, differences related with residual activity
were found between 0, 10 and 20 minutes of incubation, except
in the Sh-syringes of G2; significant differences were found in
G1 and G2 between Sh vs n-Sh syringes, except in G2 syringes
with 0minutes of incubation.Based on our results, fractioning of
MAA should be used carefully and further research should be
developed. Incubation time and shaking of syringe affect con-
siderably the residual activity and procedures should be man-
aged accordingly while handling 99mTc-MAA.
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TP045
The Study on Effect of the Image Applying to Breast
Implants in Breast Specific Gamma Imaging
J. Lee1, H. Lee2, J. Kim3, H. Park4; 1Graduate school of
Public Health, Yonsei University, Seoul, KOREA, REPUB-
LIC OF, 2Department of Nuclear Medicine, Konkuk Univer-
sity Medical Center,, Seoul, KOREA, REPUBLIC OF, 3De-
partment of Nuclear Medicine, Seoul Medical Center, Seoul,
KOREA, REPUBLIC OF, 4Shingu College, Seongnam, KO-
REA, REPUBLIC OF.
There are limits to check the lesion as inserting a breast implant
patients. So the application of BSGI based on Nuclear Medicine
examination has increased. In this study, therefore we confirmed
the effect of the image applying to breast implants in Breast
Specific Gamma Imaging.We utilizedDilon 6800BSGI scanner
and developed the phantom. The self-development phantomwas
a rectangular shape of 230 × 190 × 80mm size and had 5 spheres
which consisted of diameters of 10, 13, 17, 22, 28 mm in central
part. We injected 99mTcO4 into the self-development phantom
in the proportion of four to one and made each additional phan-
tom filled with 0.9% sodium chloride, silicon and paraffin. Each
additional phantom was placed between detector and self-
development phantom. Each image was acquired five times de-
pending on the type and thickness of the additional phantom.
Statistical analysis with SPSS ver.18 was applied. In the test of
variation according to the thickness of all additional phantoms,
as the phantoms which 0.9% sodium chloride, silicon and par-
affin increased, the attenuation variation was higher(P<0.005).
The attenuation variation was not significant difference for each
material of additional phantom. The attenuation variation was
similar in 10, 20 and 30 mm of the variation according to each
additional phantom(P<0.005). In the study, as the thickness in-
creased, the attenuation variation got higher, and the quality of
image declined. Therefore, if the effect of the image applying to
breast implants in Breast Specific Gamma Imaging is confirmed,
the higher diagnostic value can be achieved.
TP046
Biodistribution Assessment of Sodium Pamidronate
andMethylene Diphosphonate for Rats Bone Scintigraphy
Images
T. S. C. Camozzato, Sr.1, A. Z. P. De Souza2, M. Tizon1, S. J.
Garcia1, V. F. Dutra1, T. G. Costa1; 1Instituto Federal de
Educação, Ciência e Tecnologia de Santa Catarina,
Florianópolis, BRAZIL, 2Universidade Federal de Santa
Catarina, Florianópolis, BRAZIL.
Once there are more studies on radiopharmaceuticals interaction
in nuclear medicine (NM) examinations with standard
pharmaceuticals, it will be possible to trace strategies in order to
enable the least possible interactions between them during clinical
NM testing on patients. This study aims to develop a research to
assessment drugs biodistribution and interaction with radiophar-
maceuticals used in NM protocols. Sixteen Wistar rats were ran-
domly divided into 2 groups, weighing between 200 and 250
grams. Group #1 was injected with 1 mCi (99m)Tc-methylene
diphosphonate (MDP) intravenously. Group #2 was administered
0.1 ml Sodium pamidronate intravenously and after 10 minutes
was administered 1 mCi (99m)Tc-MDP intravenously. Each rat
syringes was imaged and activities were recorded prior and post
injection. After 60 minutes, scintigraphic images were acquired
using a Philips SPECTgamma camerawithmultiplane formatting
and a 60 seconds acquisition time, with unleaded shield on rat`s
tail. We acquired images during 10 minutes with rat's tail lead
shielded. Image acquisition were similar for both groups. The
images analysis of Group 1 showed a normal bone structure, with
increased osteoblastic activity similar on both sides joints, and
face. Four out of 8 rats in group #1 had radiopharmaceutical renal
retention.Most animals presented detailed bone definition. the rats
on group #1 no showed increased uptake in soft tissues. On group
#2, all images showed a normal appearance bone structurewith an
increase in osteoblast activity similar on both sides joints, and face.
Three of 8 rats in group #1 showed a radiopharmaceutical kidney
retention. The majority of rats showed little detail in bone defini-
tion, and 2 animals showed soft tissue uptake. The study showed
that in group #1 there were no cases of soft tissue uptake, except
for renal retention, which is common for (99m)Tc-MDP is mainly
excreted by urinary tract. On the other hand, group #2 showed 2
cases of soft tissues uptake. Another fact is bone definition: in
group #2 they presented very detailed bone definition, while in
group #2, they presented few details in bone definition. One can
concluded that both groups had common outcomes such as renal
retention and bony structures, but also showed different results.
Difference in bone definition and the uptake occurred in group #2
are examples of this, establishing the idea that Pamidronate Sodi-
um can alter normal biodistribution of (99m)Tc-MDP.
TP047
Implementation of a New Reference values's Database
for Semiquantification in 123I-FP-CIT Brain Single
Photon Emission Tomography
M. Queiroga1, D. Silva1, M. Elias1, J. Serrano2, J. Madrid2,
E. Carolino1, E. Sousa1; 1Escola Superior de Tecnologia da
Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon,
PORTUGAL, 2NuclearMedicine Department, Hospital Infan-
ta Cristina, Badajoz, Spain, Badajoz, SPAIN.
Purpose/Introduction: Brain dopamine transporters imaging by
Single Photon Emission Tomography with 123I-FP-CIT has be-
come an important tool in the diagnosis and evaluation of
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parkinsonian syndromes, in this exam semiquantification can im-
prove the diagnosis and is useful to have adapted reference values
for a specific protocol and clinic’s population. Aim: To create and
validate a database of healthy controls for the Dopamine trans-
porters (DAT) with 123I - FP-CIT named DBRV. The created
database is adapted to Nuclear Medicine Department’s protocol
and population of Infanta Cristina’s Hospital located in Badajoz.
Subjects/Methods: It was used a semiautomatic method for seg-
mentation and posterior calculi of binding potential in dopamine
transporters (DAT) in striatum structures and in a nonspecific
binding region, of the 30 healthy controls of the DBRV. All
exams where acquired by EANM’s Guidelines protocol, and
processed three times for one operator, average values were used.
Average and standard deviation (x ̅± δ) valueswere calculated for
the following ratios: left and right Caudate nucleus/ Occipital
respectively (A) and (B); left and right Putamen/Occipital respec-
tively (C) and (D); striatum/Occipital (E); left striatum/occipital
(F), right striatum/occipital (G), Putamen/ nucleus caudate (H).
These values where calculated and stablished new reference
values for this hospital’s population between 60 and 75 years.
For validation purposes two database of thirty patients each: da-
tabase of healthy controls (DBVGIIH), and database of subjects
with diagnosed Parkinsonian Syndromes (DBVGIIIP), where
processed using the same protocol, and its results where com-
pared with the ones of DBRV. Assessment control charts where
calculated. Results: The reference values (x ̅ ± δ) obtained were
for the following ratios: A (2.60 ± 0.40); B (2.57±0.36); C (2.29±
0.36); D (2.31±0.35); E (2.44±0.35); F (4.89±0.74); G (4.88
±0.68); H (0.89±0.07). The DBVGIIH results were within the
new reference values for healthy subjects; the DBVGIIIP results
were below the new reference values for healthy subjects. Dis-
cussion: It was considered that all values for all ratios that were
above negative value of stand deviation (-δ) were healthy, it was
considered that all values for all ratios that were below negative
value of stand deviation (-δ) were classified as pathological pos-
itive for Parkinson syndromes. Conclusion: The new created da-
tabase and reference values for of Infanta Cristina’s Hospital lo-
cated in Badajoz agreedwith the external classification of patients
as healthy and as pathological for Parkinson Syndromes classifi-
cation. The new database is an adapted and improved tool for
clinical use assessment.
TP048
ASTRIM® Software Implementation - Complying
with the Italian Current Regulations -
for the Radiolabelling of Therapeutic
Radiopharmaceuticals: the Role of Nuclear Medicine
Technicians
N. Bartolini, G. Di Guilmi, G. Marchi, M. Casi, F. De Lauro,
M. Bartolomei; Nuclear Medicine Unit M.Bufalini Hospital,
Cesena, ITALY.
INTRODUCTION AND PURPOSE: Since the beginning of
2013 a novel software ASTRIM® has being employed in the
Nuclear Medicine Unit of M. Bufalini Hospital in Cesena. This
computer tool was created by the computing company - and cur-
rently used in many Nuclear Medicine Centers - to manage, con-
trol and register all the phases regarding the diagnostic use of
radioparmaceuticals. This modality of work is required by Italian
Current Regulations, which include also specific issues and rec-
ommendations regarding the therapeutic use of radiopharmaceu-
ticals. Unfortunately, the basic version of the software ASTRIM®
was not able to manage the therapeutic activities, which were
carried on using an ordinary approach, not computerized and
based on hand-written papers. The Nuclear Medicine Technicians
(NMTs) of our Unit have an important role in the organization of
therapeutic procedures: in particular, NMTs take part in the
radiolabelling of somatostatin analogues with the high energy
beta-emitting isotope Yttrium-90 for PRRT. After a formal agree-
ment with the ASTRIM® Company, the NMTs began collaborat-
ing with the Application Technologists of ASTRIM® in order to
develop the software, making it suitable for therapeutic applica-
tions. METHODS: The specific procedure regarding the
radiolabelling of 90Y-DOTATOC was taken into account and
splitted in seven subsequent phases, as follows: 1) storage and
registration of devices, peptide, isotope and any other reagent for
radiolabelling; 2) preparations of devices for radiolabelling; 3)
preparations of peptide, isotope and other reagents for
radiolabelling; 4) radiolabelling of 90Y-DOTATOC; 5) quality
control of 90Y-DOTATOC; 6) dilution and ultrafiltration of
90Y-DOTATOC; 7) fractionation of 90Y-DOTATATE into single
rates for patients. Therefore, new modules were included in the
software. In particular, for each of the seven above listed phases,
new pages and specific schemes were created and then integrated
with the other software parts, as well. RESULTS: In particular, the
NMTs and the other operators are guided in any single phase of
thework process, and all themain data and parameters concerning
the procedure (radiopharmaceuticals’ total activity and expiration
time, efficacy of radiolabelling assessed by a specific control qual-
ity test, amount of activity injected in any patient) are registered in
the software archive. CONCLUSIONS: The specific role and
knowledge of theNuclearMedicine Technicianswas fundamental
for improving theASTRIM® software. Thesemodificationsmade
the software able to manage, control and register all the diagnostic
and therapeutic activities in our Nuclear Medicine Unit, saving
time and lowing the risk of mistakes.
TP049
5-HT1A agonist and antagonist PET
radiopharmaceuticals bind differently to receptors
in Alzheimer ’s disease: a postmortem study
B. VIDAL1, J. SEBTI1, M. VERDURAND1, S. FIEUX1, N.
STREICHENBERGER1, T. BILLARD2, A. NEWMAN-
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TANCREDI3, L. ZIMMER1; 1Université Claude Bernard
Lyon 1, Lyon, FRANCE, 2CNRS, Lyon, FRANCE,
3Neurolixis, Dana Point, CA, UNITED STATES.
Aim: PET studies revealed a decreased density of 5-HT1A
receptors in hippocampi of Alzheimer’s disease (AD) patients
at advanced stages. A limitation of this approach is that PET 5-
HT1A radiopharmaceuticals are antagonists, thought to bind
to the high-affinity state of 5-HT1A receptors (functional) and
to the low-affinity state of these receptors (decoupled from G
proteins and non-functional). Comparing the PET images ob-
tained using a new agonist radiopharmaceutical, which binds
selectively to functional receptors, with the PET imaging ob-
tained using an antagonist radiopharmaceutical would there-
fore provide original information on 5-HT1A receptor impair-
ment during AD. Materials and Methods: Quantitative autora-
diography using [18F]F13640 or [18F]MPPF, a 5-HT1A ago-
nist and antagonist, respectively, was performed in hippocam-
pi of AD patients (n=25, at different Braak’s stages) and con-
trol subjects (n=10). The coronal sections were incubated in a
saline buffer containing 37 kBq/mL of [18F]F13640 or
[18F]MPPF. Hippocampal subregions were drawn according
to a brain atlas and binding quantification was performed with
extemporaneous fluorine-18 scales. The specific binding of
both radiotracers was determined by addition of WAY-
100635 and the agonist binding of [18F]F13640 was revealed
by addition of Gpp(NH)p. The neuronal density in ROIs was
quantified in adjacent brain sections by NeuN immunohisto-
chemistry. Results: The highest binding density of both 5-
HT1A PET radiotracers was in the pyramidal layer of CA1.
The incubation with Gpp(NH)p reduced significantly
[18F]F13640 binding, confirming its specific binding to G-
coupled receptors. In the same conditions, no significant mod-
ification of [18F]MPPF binding was measured after
decoupling of receptors. Whereas total 5-HT1A receptor sites
measured by the antagonist, [18F]MPPF, were unchanged in
CA1 area at all AD stages (except for the more advanced
stage), there was a significant decrease in the density of bind-
ing sites labeled by the 5-HT1A agonist, [18F]F13640, at the
early and advanced Braak’s stages (from I to VI). There
was a significant correlation between the neuronal density
(NeuN) and the [18F]F13640 agonist binding sites, but
not with the [18F]MPPF antagonist binding sites, sug-
gesting that 5-HT1A non-functional receptors could have
a non-neuronal overexpression at AD advanced stages.
Conclusion: The present results support a new concept
consisting in comparing the binding profiles of a PET
agonist and antagonist in patients to determine the extent
of G-protein coupling of 5-HT1A receptors and to follow
their functional modifications during the neurodegenera-
tive process. A first-in-man study of [18F]F13640 is
therefore scheduled to prepare the transposition of this
paradigm to in vivo PET neuroimaging.
TP050
Introduction of a new Gallium-68 (Ga-68) DOTATATE
synthesis module: a retrospective evaluation of GMP
qualification and validation, radiation hygiene
and organizational planning.
S. Baank, L. de Wit-van Veen, M. Jonker, E. Aalbersberg;
Antoni van Leeuwenhoek Hospi ta l , Amsterdam,
NETHERLANDS.
Introduction: Since 2012 the department of Nuclear Medicine
of the Antoni van Leeuwenhoek hospital (AVL) has started
with the production of Gallium-68 (Ga-68) DOTATATE for
the localization of Neuroendocrine Tumors (NET). Although
initially a semi-automatic module was used, the continuity of
the synthesis could not be assured resulting in unacceptable
waiting periods for patients. These issues have led to the pur-
chase of a commercially available automatic production mod-
ule (Scintomics GmbH, Germany). With the purchase of this
module the following issues needed to be addressed: qualifi-
cation and validation according to good manufacturing prac-
tice (GMP), radiation hygiene, organizational planning and
personnel. Aim: To enumerate the advantages and disadvan-
tages of the implementation process, which can be used as
future starting point for the production of other radiopharma-
ceuticals in a clinical setting with this module. Methods and
materials: A retrospective evaluation of the implementation
and initial production of Ga-68 DOTATATEwithin the depart-
ment nuclear medicine was performed. This included a quali-
tative and retrospective review of all the used documents, in-
terviews with the personnel involved with the implementation
and/or production and assessment of the first clinical usage of
the Ga-68 DOTATATE radiotracer within the department of
nuclear medicine of the AVL. Results: The validation and
qualification by GMP standards was successful and the pro-
duction of Ga-68 DOTATATE using the commercial module
for clinical use is nowadays a fact. The findings of this study
indicate a learning curve when using the system. Furthermore,
future improvements can be made in education of personnel,
organizational planning and logistics regarding both patients
and personnel. Conclusion: Based on the results of this retro-
spective study, a generalized checklist and a thorough imple-
mentation and evaluation plan were constructed, which in-
cludes factors from GMP qualification of the product to orga-
nizational planning.
TP051
Nuclear Medicine/PET/CT Research: The role
of a technologist/radiographer
A. S. F. Ribeiro, S. Summers; Royal Marsden Hospital, Sut-
ton, UNITED KINGDOM.
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Aims: Nuclear Medicine/PET/CT is an area of constant evolu-
tion. New tracers combined with equipment and software devel-
opment have seen the role of Nuclear Medicine (NM) technolo-
gists and radiographers evolve over the past years. Research has
become one of the “new roles” for technologists/radiographers.
Materials and Methods: The role of a research NM technologist/
radiographer however is not standardized across the board. Dif-
ferent countries, different areas in the same country and just dif-
ferent hospitals have very different practices. We are seeing more
jobs advertised for “research NM technologists/radiographers”,
mainly in centres who have strong foundations in research. In
our centre we have a dedicated team to research; composed of
consultants, trial coordinators, research fellows, physicists and
NM research technologists/radiographers, who all work as a team
and oversee all aspects of researchwithin the department. Results:
The input a research NM technologist/radiographer can have in
research is as fundamental as it is diverse. In our experience there
are clear advantages; setting up scanning protocols for different
studies; dealing with data queries from sponsors, being a point of
contact; relieving other members of staff from having to perform
extra tasks that are purely research such as dynamic scans and/or
blood tests; reviewing protocols and having a direct input in
setting up imaging studies. But there are some disadvantages,
which can arise from sparsely clinical exposurewhere some skills
can become rudimental. Conclusion: Nuclear Medicine/PET/CT
can perhaps be defined as unstable as its isotopes. Particularly
with the availability and widespread of PET/CT scanners who
have urged for new and improved tracers and with that comes
research. The role of technologists/radiographers in research is
crucial and should be deep-rooted, starting in universities, post
graduate programmes and by managers and nuclear medicine
consultants. However a balance between research and clinical is
fundamental for achieving excellence.
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TP052
The use of non-attenuation corrected PET images
in the assessment of cardiac implantable electronic device
infections
C. Abreu1, J. O'Doherty1, A. Corrigan2, S. Barrington1, J.
John1; 1PET Imaging Centre, King's College London, King’s
Health Partners, St Thomas’ Hospital, London, UNITED
KINGDOM, 2Department of Radiology, Maidstone Hospital,
Maidstone and Tunbridge Wells NHS Trust, Kent, UNITED
KINGDOM.
Aim: This study assessed the need for interrogation of the non-
attenuation corrected images (non-AC) in patients with clinical
suspicion of cardiovascular implantable electronic devices
(CIED) infect ion invest igated with 18FDG-PET/
CT.Introduction: 18FDG-PET/CT has a role in the assessment
of potential CIED infection. CT artefacts induced by metallic
components of CIEDs may cause inappropriate CT-based at-
tenuation correction (CTAC) maps. This can result in overes-
timation of local tracer accumulation on attenuation corrected
(AC) images.Method: We retrospectively reviewed AC and
non-AC images of 43 patients referred for assessment of po-
tential CIED infection with 18F-FDG PET/CT. An experi-
enced clinician scored as ‘positive’ or ‘negative’, uptake at
both the lead and at the CIED.Results: Difference in uptake
occurred between AC and non-AC images in 7/43 (16.2%)
cases; 7 positive scores were observed in AC images when
the non-AC did not show uptake. From the 7 devices with
different uptake, 4 were pacemakers, 2 implantable
cardioverter defibrillator and one Cardiac Resynchronization
Therapy Defibrillator. This supports the suggestion that
artefactual CTAC occurs in AC images, which potentially
overestimate the level of 18F-FDG uptake around the
CIED.Conclusion: Positive uptake at CIED or lead raises con-
cern for local infection. We have shown that significant uptake
may be related to CTAC artefact and that the non-AC images
should routinely be used in conjunction with the AC images in
the clinical reporting of suspected CIED infection to avoid
false-positive results.
TP053
Performance of image evaluation due to the difference
in the acquisition time using multifocal collimator
with 99mTc myocardial SPECT: Evidence
from a phantom study
Y. Banno1, M. Onoguchi1, K. Nakajima2, S. Matsuo2; 1De-
partment of QuantumMedical Technology, KanazawaUniver-
sity Graduate School of Medical Sciences, Kanazawa, JA-
PAN, 2Department of Nuclear Medicine, Kanazawa Universi-
ty Hospital, Kanazawa, JAPAN.
The goal of this study was to compare image quality and de-
tectability of defects due to difference in the acquisition time
using a myocardial phantom with normal or defects. Method:
SPECT/CT (Symbia T6, Siemens) equipped with
SMARTZOOM collimator (SZC) and torso phantom (Data
Spectrum) were used to simulate a normal myocardium and
a inferior wall defect. The radioactive concentration of Tc-99m
in the normal myocardium (120mL) was 4.17μCi/mL, SPECT
was performed with an acquisition time of 3, 6, 9 and 15 sec/
view. Acquisition parameters were set as 4.8 mm/pixel, 1282
matrix, 34 views over 208°arc. Reconstruction was performed
with no correction (NoAC), attenuation correction (AC) and
both attenuation and scatter corrections (ACSC). Visual
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evaluation (with 5 grade scores,1=poor to 5=excellent)
and quantitative evaluations (%count) were done. Re-
sults: Acquisition time of 3, 6, 9 and 15 sec resulted in
8, 16, 24 and 40 counts/pixel respectively. Percent count
of the normal myocardium did not depend on acquisition
time and was approximately 90% in the anterior wall
after each correction. The uniformity score showed a
low score (3.0) with < 6-sec acquisition before correc-
tion. The acquisition time of > 9-sec improved uniformity
scores (≥4) in each condition. A false defect was seen in
four o’clock direction with NoAC regardless of acquisi-
tion time, which was improved after correction. Defect
detectability score was high (4.0) independent of the ac-
quisition time. Improvement of uniformity was not ob-
served with a 3-sec acquisition even after each correc-
tion. Conclusion: The image qualities and defect detect-
ability of ≥6-sec was nearly equivalent to a 9-sec acqui-
sition. Image quality, however, was not improved even
with 15-sec acquisition. We therefore suggest that ≥16
counts/pixel for average counts were needed for stable
image evaluation.
TP054
64Cu-ATSM PET studies: Are radiation protection
restrictions required for patients after scan?
S. Pereira, E.Woods, J. John, A. Jacob, C. Abreu, L. Alves, L.
Pike; PET Imaging Centre, St Thomas' Hospital, King's Col-
lege London, London, UNITED KINGDOM.
Aims: 64Cu-ATSM is used in our department as a marker for
hypoxic tissue for head and neck cancers. The long half-life of
64Cu (T1/2 =12.7 hours), in comparison with other PET
tracers, means that restrictions on patients following discharge
may be required. No data currently exists on measured dose-
rates from 64Cu patients. The aim of the study was to estimate
the radiation doses to family members, ward staff and the
general public deriving from patients undergoing 64Cu-
ATSM PET studies. Materials and Methods: Radiation dose-
rates were measured from 15 patients who were administered
with 64Cu-ATSM (activity = 546 ± 51 MBq). Measurements
were performed at 0.1, 0.5, 1.0 and 2.0m from patient
prior to discharge. Patient contact with critical groups
was modelled and combined with the 95th percentile
measured dose-rates. The biological half-life was not
taken into account to provide the worst-case estimates.
The total doses received were calculated for approxi-
mately four half-lives of 64Cu. Results: The mean
dose-rate coefficient for 64Cu at 1m was (0.020 ±
0.008) μSv/MBq/hr, with the highest dose rate measure-
ments from the right torso, corresponding to location of
liver. Calculated doses to all groups for different contact
scenarios were less than the recommended dose limit of
1mSv. The maximum calculated dose was 0.9mSv for
contact with partner and children <2 years old. Conclu-
sion: The dose-rates at discharge do not result in any
legal dose limits being breached. However as best prac-
tice, radiation protection advice may be prudent regard-
ing contact with partner, especially if pregnant, and chil-
dren under 5 years old.
TP055
The Comparison of Lesion LocalizationMethods in Breast
Lymphoscintigraphy
Y. Joonho, H. Gunchul; SamsungMedical Center, Seoul, KO-
REA, REPUBLIC OF.
Purpose: Breast lymphoscintigraphy is an important technique
to present for body surface precisely. In this study, we evalu-
ated several methods of body outline imaging to present exact
location of lesions, as well as compared respective exposure
doses. Methods: RANDO phantom and SYMBIA T-16 were
used. A lesion and an injection site were created by inserting a
point source of 0.33 MBq on the axillary sentinel lymph node
and 37MBq on the right breast. The first method for acquiring
the image was used by drawing the body surface of phantom
for 30 sec using Na99mTcO4 as a point source. The second,
the image was acquired with Co-57 flood source for 30 sec on
the rear and left side of the phantom, the image as the third
method was obtained using a syringe filled with 37 MBq of
Na99mTcO4 in 10 mL of saline, and as the fourth, we used a
photon and scatter energy of Technesium emitting from phan-
tom. Finally, the image was fused the scout image and the
basal image of SPECT/CT using MATLAB® program. We
measured radiation exposure and conducted preference of 10
images from nuclear medicine doctors by the survey. Results:
TBR values of anterior and right image in the first to fifth
method were 334.9 and 117.2 (1st), 266.1 and 124.4 (2nd),
117.4 and 99.6 (3rd), 3.2 and 7.6 (4th), and 565.6 and 141.8
(5th) respectively. And also exposure doses of these method
were 2, 2, 2, 0, and 30 μSv. Among five methods, the fifth
method showed the highest TBR value as well as exposure
dose, whereas the fourth method showed the lowest TBR val-
ue and exposure dose. And the fifth method showed the
highest score in the survey result. Conclusion: Scout method
of SPECT/CT can be useful that provides the best values of
TBR and the best score of survey result. Even though personal
exposure dose when patients take scout of SPECT/CT was
higher than another scan, it was slight level comparison
to 1 mSv as the dose limit to non-radiation workers. If
the scout is possible to less than 80 kV, exposure dose
can be reduced, and also useful lesion localization
provided.
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TP056
Clinical application of breath-hold PET/CT to improve
quantitation of the NSCLC
W. Huang1, S. Tasi1, T. Pan2, J. Tseng1, K. Lin1, T. Yen1;
1Molecular Imaging Center and Department of Nuclear Med-
icine, Chang Gung Memorial Hospital, Taoyuan, TAIWAN,
2Department of Imaging Physics, The University of Texas
M.D. Anderson Cancer Center, Houston, TX, UNITED
STATES.
Aim: Impact of respiratory motion to quantitation of the NSCLC
has been reported. However,most studies proposed a 30 to 40 sec
deep-inspiration breath-hold (DIBH), difficult for patients to
comply. Some suggested a single DIBH of 20 sec, which lacked
the statistics for quality PET images. In this study, we designed a
clinically practical protocol of breath-hold PET/CT to improve
quantitation of the NSCLC based onmultiple 15-sec DIBHs, and
compared the quantitation results with the baseline free-breathing
data.Materials andMethods:We recruited a cohort of 16NSCLC
patients in this study. Each patient was injected with 370 MBq
18F-FDG and whole-body PET/CT scanned with free-breathing
(FB)1 hour post-injection. The same patient was scanned follow-
ing the whole-body PET/CT for a series of three DIBH of 15-sec
to reduce the impact of tumor motion. The three DIBH scan data
were summed to increase the statistics of the study. All scans
were conducted on the Siemens Biography mCT scanner. The
respiratorymonitoring device was theAZ-733V (AnzaiMedical)
to ensure the breath-hold position was maintained during the
DIBH scan by the patient. Comparison of the SUVmax from
breath-hold with the baseline free-breathing PETwas made. Re-
sults: The study included 17 lesions from 16 patients.There were
mis-alignments between the CT and the PET images on nine
lesions for the FB PET, and one lesion for the DIBH PET. The
SUVmax values of the DIBH images were significantly higher
than the SUVmax values of the FB whole-body PET/CT scans
(4.72 vs. 3.33, P=0.043) Conclusions: Using a series of three 15-
second DIBH PET scans can improve the quantitation of
NSCLC. The average SUVmax increase was 50.8%.
TP057
The Correlation of PSA and PSA kinetics to 11C-Choline
Positron Emission Tomography/Computerized
Tomography for recurrent Prostate Cancer after Radical
Prostatectomy
L. G. Jordan, III, G. Dimonte, M. L. Burton, R. Haloi, L. J.
Rangel, J. C. Hung, B. J. Davis,M. A. Nathan, E. D. Kwon, R.
J. Karnes; Mayo Clinic, Rochester, MN, UNITED STATES.
Purpose: We examined the correlation of PSA and PSA kinet-
ics with serial 11C-Choline positron emission tomography/
computerized tomography (PET/CT) to detect recurrent pros-
tate cancer (PC) after radical prostatectomy (RP). Methods:
Sequential PSA records were analyzed for Mayo Clinic pa-
tients (N = 54) who underwent salvage lymph node dissection
(sLND) for PC detected by 11C-Choline PET/CT scans (N =
124). Some patients had 2 or more scans (maximum of 7 serial
scans). In patients that had serial scans, the scan just prior to
(sLND) surgery was used for analysis. The probability of a
positive PET/CT scan was ascertained as a function of PSA
and PSA velocity (PSAV). For positive lesions, the standard-
ized uptake value (SUV) and tumor volume (TV), as measured
on the PET image, were used to calculate a total uptake activity
(TUA) as their aggregated product and was then compared
with PSA and PSAV. In addition, PET/CT TV was compared
to TVas seen on sLND Results: The probability of a positive
PET/CT (P+PET/CT) scan was found to increase with PSA to
100% for PSA > 3 ng/mL. For PSA ≤ 3 ng/mL, P+PET/CT
increased from 0 to 62% to > 90% for PSAV < 0.5, 0.5-1 and >
1 ng/mL/Yr, respectively. The TUA of the PC lesions was
found to increase linearly with PSAV with a correlation coef-
ficient of R = 0.68. Furthermore, the TV’s from the PET/CT
and the subsequent sLND correlated well (R = 0.68). Conclu-
sion: In this small select group of patients, the five-year expe-
rience at the Mayo Clinic showed 11C-Choline PET/CT scans
with a 100% detection rate for patients with PSA > 3 ng/mL.
The PC detection rate increases with increasing PSAV to P+
PET/CT > 90% for PSAV ≥ 1 ng/mL/Yr. These results suggest
that PSA and PSAV are useful correlative markers for tumor
size and disease progression as seen on 11C-Choline PET/CT
scans. TVas predicted by 11C-Choline PET/CTcorrelates well
with sLND TV measurements. Performing this analysis in the
future using a larger number of 11C-Choline PET/CT scans
will help to decrease statistical variation and possibly substan-
tiate these findings.
TP058
FCH for detection of parathyroid adenomas
in Tc-99m-sestamibi negative patients
B.M. de Jong, M. Postma, S. J. Eelkman Rooda, J. P. Esser, J.
M. H. de Klerk; Meander Medisch Centrum, Amersfoort,
NETHERLANDS.
Introduction: Preoperative ultrasonography and 123I-
sodiumiodide/Tc-99m-sestamibi dual phase subtraction scin-
tigraphy and SPECT/CT are commonly used to localize para-
thyroid adenomas in patients with hyperparathyroidism
(HPT). In some patients both of these imaging techniques turn
out to be a false negative. 18F-fluoromethylcholine (FCH)
PET/CT is used for the detection of metastases of prostate
cancer. Thus far few studies report the use of FCH for detect-
ing parathyroid adenomas. We report six cases showing a
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negative (ultrasound and) dual phase subtraction scintigraphy
and SPECT/CT with positive FCH PET/CT. Methods: FCH-
PET/CT was performed in six patients, five females and one
male with a mean age of 64 (range, 54-68 years), clinically
presenting with hyperparathyroidism were retrospectively
evaluated, with histopathologic examination as the golden
standard. All patients underwent ultrasound and dual phase
subtraction scintigraphy and SPECT/CT prior to FCH-PET/
CT. In patients where dual phase scintigraphy and SPECT/
CT were negative patients were referred for FCH-PET/CT.
First phase of dual phase subtraction scintigraphy consisted
of a dynamic series acquired directly post 750 MBq Tc-99m-
sestamibi injection. 35 MBq I-123-sodiumiodide was admin-
istered directly after the dynamic series. Second phase started
60 minutes post I-123-sodiumiodide injection with a dual-
isotope static series. SPECT/CT was acquired adjacent to the
second phase in dual-head 180° configuration, 25 seconds per
frame for 64 frames. Patients are scanned up from medulla
auris externa (MAE) down to and including the heart, posi-
tioned feet-first supine arms down. PET/CT acquisition was
performed 30 minutes after the administration of 150 to
300 MBq FCH. Two bed positions of 5 minutes each were
made, up from MAE down to and including the liver. Patients
are positioned headfirst supine arms down. Results: All six
patients showed marked FCH uptake in parathyroid adeno-
mas. Patients were referred for surgery. Five out of six patients
have had surgery. Post-surgery histopathologic examination
confirmed parathyroid adenoma in these five patients. Conclu-
sion: This study shows that FCH is both highly sensitive and
specific for the detection of parathyroid adenomas and can be
recommended for patients presenting with a HPT while ultra-
sound and dual phase subtraction scintigraphy including
SPECT/CT are negative.
TP059
Positioning of the arms is essential in reducing artefacts
in PET/CT-scans
B. Christensen, P. C. Holdgaard, MD; Vejle Hospital, part of
Lillebaelt Hospital, Vejle, DENMARK.
AIM: Investigate the implications of scanning patients who are
unable to hold their arms above the head during a PET/CT-
scan and to determine which arm position gives least artefacts.
Materials and Methods: Retrospective study of all patients
PET/CT-scanned with arms down in a recent 2 month period
in our department. Arm position was recorded: Alongside of
the patient or in front of the patient, and if there were a pillow
or blanket in between for comfort. A physician in Nuclear
medicine evaluated the studies and scored PET attenuation
artefacts and CT-streak-artefacts on a scale from 0 to 5 and
location was determined to be in the abdomen or in the spine.
Patients were scanned on Philips Gemini 16/64 PET/CT scan-
ners with mainly(89%) a dose modulated low-dose CT
(Doseright ACS-Z-dom, 120kV, 50mAs). CT-doses were re-
corded and compared with arms up. Results: 9% of patients
were scanned with their arms down(=55 scans). 24(44%) with
the arms alongside, 31(56%) in front and 24(77%) of these had
a pillow/blanket in between. Artefacts were visible on 53
scans(96%). Arms alongside the body showed 17 scans(71%)
with moderate to severe CT-artefacts compared to 13(42%)
with the arms in front(p=0,055). The localisation of the arte-
facts depended on the position of the arms(p<0,001). Arms
alongside: 18(75%) showed artefacts in the spine. Arms in
front: 5(16%) showed artefacts in the spine, instead artefacts
were shown in the abdomen. Only the 4 patients(7%) with
elbows outside CT field of view had PET-artefacts(p<0,001)
and arm misalignment alone had no influence. CT-artefacts
increased with patient weight(p<0,01). Men had more CT-
artefacts(p=0.017) compared to women. Patient CT-
doses(DLP) increased 34 percent(p<0,001) with arms down
(from 280 to 376 mGy*cm on average in sex matched group)
Conclusion: It is important to try and position arms over the
head whenever possible to reduce artefacts and patient CT-
dose. If arms are kept down CT-artefacts are unavoidable no
matter how arms are positioned when using only a low-dose
CT. PET attenuation artefacts will always appear if elbows are
not in CT field of view and is not dependent on misalignment
of arms. It is advisable to take notice of the positioning of the
arms if there is a special region of interest e.g. above the thighs
on a blanket if the vertebral column is of special interest.
TP060
Fast or Food: a Study on Cardiac FDG Preparation
Effectiveness
A. Almeida, N. Gulliver, G. Vivian, A. Eccles, N.Mulholland,
B. Corcoran; King's College Hospital NHS Foundation Trust,
London, UNITED KINGDOM.
Background and Aim: We recently started cardiac sarcoidosis
PET-CT imaging service, and decided to apply the prolonged
fasting preparation method to reduce the normal physiological
myocardial 18F-FDG uptake, as suggested in the EANM
guidelines. We initiated this service evaluation with the aim
to assess the effectiveness of the method and patient compli-
ance. Materials and Methods: Eighteen patients referred for a
standard PET-CTscan, within an age range from 24 to 79 years
old, were included in the study and divided in three groups.
The selection occurred from November 2014 to April 2015,
with exclusion criteria of diabetes mellitus, known cardiac
conditions, dementia, and concurrent steroid medication. The
first 10 patients were asked to follow the standard 6h fasting
preparation. From these, 5 patients fasted for less than 10h and
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were included in the first group. The other 5 patients fasted for
between 10 and 15h and were included in the second group.
The last 8 patients were asked to follow the prolonged 18h
fasting preparation. These patients were included in the third
group if they fasted for over 15hours. All patients were admin-
istered 4.5MBq/kg ±10% 18F-FDG (max 400MBq), with an
average uptake period of 67.5min. A low dose CT and a stan-
dard half-body PET acquisition were performed using the GE
Discovery 710TOF PET-CT scanner. A quantitative assess-
ment of the SUVmax of background mediastinal blood pool
(MBP), background liver and myocardium was carried out
using Hermes Hybrid Viewer. We compared the myocardial
activity against liver and MBP for each of the three groups of
patients, using a method we based using Deauville philosophy
(D-score).Results:The average value of the BGLwas lowest in
the longest fasting group, but there is no statistically significant
difference between the groups (P>0.05).The mean SUVmax
of the three areas was higher in the 3rd group, although it also
is not statistically significant (P>0.05).Observing the D-score
values, 4/5 patients with the shortest fast and 4/8 patients with
the longest fasting period scored 5 (myocardium uptake much
higher than liver). However, 3/8 patients that fasted longer
scored 1 (no cardiac uptake), which averages as the lowest
D-score, although not statistically significant (P>0.05). Con-
clusion: The novel D-scores are proposed to measure cardiac
FDG uptake.Prolonged fasting as a method of eliminating car-
diac activity for dedicated cardiac PET/CT studies is insuffi-
cient for reliable imaging.
TP061
Evaluation on Artifacts by Bone Cement of PVP
Performed Patients and Usefulness of CT Correction
in SPECT/CT Examinations
J. Kim1, H. Park2, J. Lee3, H. Son1, S. Park1; 1Seoul Med-
ical Center, Seoul, KOREA, REPUBLIC OF, 2Shingu Col-
lege, Seongnam-si, KOREA, REPUBLIC OF, 3Graduate
School of Public Health, Yonsei University, Seoul, KOREA,
REPUBLIC OF.
Aim: The most commonly performed percutaneous
vertebroplasty(PVP) to treat compression fracture is in the
increasing trend. But, the bone cement material used in the
PVP influences the image quality by forming an artifact in
the CT image. Therefore, the objective of the research lies on
evaluating the effect the bone cement gives to SPECT/CT
image. Materials and methods: The images were acquired by
inserting model cement to each cylinder, after setting the back-
ground, hot cylinder and cold cylinder to the NEMA-1994
phantom. Non-attenuation correction(NAC), attenuation
co r r ec t i on (AC+SC- ) and a t t enua t ion & sca t t e r
correction(AC+SC+) were used for the CTcorrection method.
The mean count by each correction method and the count
change ratio by the existence of the cement material were
compared and the contrast recovery coefficient(CRC) was ob-
tained. Additionally, the bone/soft tissue(B/S) ratio was ob-
tained by 20 patients who had the PVP. Results : AC+SC-
for the quantitative count and AC+SC+ for the contrast ratio
were analyzed to be the highest. The rate of mean count increase
of NAC, AC+SC- and AC+SC+ when cement existed showed
12.4%, 6.5%, 1.5% at the hot cylinder, 75.2%, 85.4%, 102.9%
at the cold cylinder about phantom and 33.1%, 41.4%, 63.5% at
the fracture region, 53.1%, 61.6%, 67.7% at the normal region
about clinical image. CRC and B/S ratio implying the contrast
ratio were improved in the order of NAC, AC+SC-, AC+SC+
when cement existed showed 6.4, 6.8, 8.0 at the hot cylinder,
0.9, 0.8, 0.9 at cold cylinder, 20.5, 38.0, 70.0 at the fracture
region and 6.6, 13.3, 21.2 at the normal region. Conclusions :
The use of AC+SC- in the spine SPECT/CT examination of
PVP performed patients drastically increases the image count
and enables a high density image of the lesion. But it also in-
creases the noise count of the soft tissue and the scatter area as
well along with the effect of the bone cement. Therefore, it is
considered to be useful in a clinical diagnosis if the application
of AC+SC+ that improves the contrast ratio is combined.
TP062
Whole body bone SPECT: aspects of methodology
K. Kukuts, I. Fordzyun, A. Forgács, S. Barna, I. Garai;
Scanomed Ltd., Debrecen, HUNGARY.
Aim: The basic limitations of diagnostic imaging with radionu-
clides are the amount of radioactivity administered to the patient,
the physical and biological half time of the radionuclide and the
duration of the examination. With these conditions the primary
aim is to maximize the information content and to increase the
diagnostic value. As a large number of bone scintigraphies are
performed, the duration of the examination and the availability
of the radionuclide are both critical points of the management of
these examinations. Routinely a bone scintigraphy has a 15min-
ute acquisition time, followed by one or multiple regions multi-
FOV SPECT/CT if necessary for the exact localisation with a 16
minute additional acquisition time. Making decision to require
further SPECT/CT takes at least 5-10 minutes additionally, de-
pending on the availability of the specialist. Our aim is to define
a whole body bone SPECT acquisition protocol on a 3-headed
SPECT/CT camera to reduce the total acquisition time and the
radionuclide demand compared to conventional bone scintigra-
phy. Method: In case of 30 patients after the conventional bone
scintigraphy we performed a whole body SPECTacquisition on
a 3-headed Mediso AnyScan SC camera. Usually the examina-
tion contains 5-6 FOVs depending on the height of the patient, 5
minute acquisiton time per bed position, so the total examination
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time is 25-30 minutes, which is the same as the acquisiton time
of a whole body bone scintigraphy and a SPECT/CT of one
region. The iterative image reconstruction was performed by
using the Interview XP software. A nuclear medicine specialist
identified the lesions on both the anonimized bone scintigraphy
and the 3Dwhole body SPECT images. Results: The acquisition
time on a 3-headed camera is comparable to the acquisition time
of a common conventional bone scintigraphy, with increased
diagnostic value. After the optimalization of the reconstruction
there was no significant difference between the two methods
regarding the number of the bone lesions identified. There is
the possibility of performing an additional low-dose CT to gain
more diagnostic information in equivocal cases. Discussion:
Whole body SPECT examination can be a good alternative of
whole body bone scintigraphy. At nuclear medicine departments
with a large number of patients this examination method is able
to reduce the daily total acquisition time and radionuclide
demand.
TP063
Evaluation of 68Ge-68Ga Generator and Synthesis
Module efficiency in the procedure of 68Ga-DOTATOC
labelling
L. Pavanello, F. Sciume', M. Zuffante, D. Grigolato, E.
Carmagnani, M. Ferdeghini; Nuclear Medicine AOUI, Vero-
na, ITALY.
AIM: To evaluate efficiency of 68Ge-68Ga Generator and
Synthesis Module in the procedure of peptide DOTATOC la-
belling. The evaluation was carried by comparing the radiation
activity between expecteds and obtained values in 38 synthe-
sis. MATERIALS AND METHODS: 68Ge-68Ga Generator
calibrated 1110MBq to 4 April 2014 (IDBHolland), Synthesis
Module (Scintomics GRP), cassettes for peptide labelling
(ABX) and peptide DOTATOC (ABX) are used. It was con-
sidered the time from 1 April 2014 and 30 March 2015. The
comparison of radiation activity between expected and obtain-
ed values considering that synthesis procedure has a duration
of 36 min, elution is performed 6 min after the start of the
procedure, the measurement of 68Ga radiation activity is per-
formed 34 min after the elution. Comparative tables are creat-
ed considering that the radiation activity at the time calibration
of the 68Ge-68Ga Generator (with half-life of 288 days for
68Ge) has a linear decay and radiation activity in the Synthesis
procedure has a loss to 25% compared to the expected value
because it is measured 34 min after the elution of the Genera-
tor. Synthesis procedure was performed every seven days for
two consecutive days. 68Ge-68Ga Generator has not eluted
daily and only one elution was made 24 hours before the first
procedure of the week. The activity was measured using al-
ways the same calibrator and vials size. In 37 cases the
synthesis performed 24 hours after the first procedure. RE-
SULTS: Activity obtained in the synthesis procedure showed
gradually decreased than expected during the 52 weeks.
Values decreased of 95% after the 2nd week reaching 65%
of values in 52th weeks. 68Ge-68Ga Generator inactivity for
periods over than seven days, resulted in a loss of radiation
activity in synthesis (10-15% greater than expected). In the 37
cases of second synthesis, was measured a higher radiation
activity of 3-5% compared to the value of the first synthesis
obtained the day before. CONCLUSION: Due to non-elution
daily of 68Ge-68Ga Generator showed that the decrease of
radiation activity obtained was higher than expected. This
work demonstrated the importance of a periodic and constant
elution of the Generator independently of the number of syn-
thesis. It was also showed the importance of synthesis execu-
tion every 24 hours to increase the quantity of radio-labeled
product.
TP064
The devil is in the details⋯. Radioactive Waste disposal
changes
C. Vroonland, M. Sonneborn, L. Janssen-Pinkse; Antonie
van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.
Aim: Two years ago several of our waste bins were returned to us
by the Waste Disposal Facility as they were “still radioactive”.
The facility had upgraded their radiation detectors and nowmain-
tained a zero tolerance limit instead of the National exemption
limit. Our departmentmaintains an even lower exemption limit of
< 2x background.Wewere thus required to review and adjust our
radioactive waste procedures or be forced to dispose of these (and
future) bins as radioactive waste at a much higher cost. Our aim
was to clarify and optimise our radioactive waste procedures to
ensure that ourwastewill not be returned to us again.Method and
Materials: Our Radiation Safety officers determined that the
returned waste bins were indeed very mildly radioactive and
below the National exemption limit. Radiation measurements
within our hospital’s radioactive waste storage area revealed that
the background measurements were not above normal. The only
abnormality was the fact that the waste bins were still radioactive
despite having been sealed more than 6 months previously. It
became clear that a long-lived isotope was present. Additional
examination (spectrometry) showed that the bins were emitting
radiation consistent with 154Europium which is now known to
be a manufacturing impurity in the production of 153Sm-
EDTMP. Results: A separate disposal procedure was set up for
153Sm-EDTMP vials, injection waste and possible contaminated
items. To ensure no other impurities are discovered this way, all
new radiopharmaceuticals are now left to decay separately. These
are then measured at periodic intervals for radioactive impurities.
This led to a complete overhaul of our radioactive waste
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management procedures, including periodic wipe testing within
the department to check for contamination in unexpected area’s
(such as keyboards, light- and door switches, dictaphones etc).
Also a new radioactive waste procedure has been implemented
for long lived radiopharmaceuticals (154Eu and now also 68Ge)
in the form of COVRAwaste bins. This company collects, pro-
cesses and stores radioactive waste with a long half-life. Conclu-
sion: The waste procedures within our department have been
mapped and altered to ensure that even mildly radioactive waste
is no longer sent to the Waste disposal facility.
TP065
Static Myocardial Perfusion Imaging using denoised
dynamic Rb-82 PET/CT scans
M. N. M. Petersen , C. M. Hoff, H. J. Harms, K.
Bouchelouche, J. Sørensen, L. P. Tolbod; Dept. Nuclear Med-
icine & PET-Centre, Aarhus University Hospital, Aarhus N,
DENMARK.
Introduction: Relative and absolute measures of myocardial
perfusion are derived from a single 82Rb PET/CT scan. How-
ever, images are inherently noising due to the short half-life of
82Rb. We have previously shown that denoising techniques
can be applied to dynamic 82Rb series with excellent quanti-
tative accuracy. In this study, we examine static images created
by summing late frames of denoised dynamic series. Method:
47 random clinical 82Rb stress and rest scans (27 male, age
68+/- 12 y., BMI 27.9 +/- 5.5 kg/m2) performed on a GE
Discovery 690 PET/CT scanner were included in the study.
Administered 82Rb dose was 1110 MBq. Denoising using
HYPR-LR or Hotelling 3D algorithms was performed as
post-processing on the dynamic images series. Static series
were created by summing frames from 2.5-5 min. The image
data was analysed in QPET (Cedars-Sinai). Relative segmen-
tal perfusion (normalized to the hottest pixel) was compared in
order to assess whether a correlation between original image
data and denoised image data could be found. In addition to
this, correlations for TPD, Extent of defect and summed defect
scores (SSS, SRS and SDS) were investigated. The data was
analysed using linear regression and Bland-Altman analysis.
Results: For HYPR-LR, a good correlation was found for rel-
ative segmental perfusion for both stress (y=1.007x+0.313,
R2=0.98) and rest (y=1.007x+ 0.421, R2=0.96) scans with
negative bias of -0.79±1.44 and -0.90±1.63, respectively. Cor-
relations for SSS (R2=0.94), SRS (R2=0.92), SDS (R2=0.89),
TPD (stress, R2=0.99; rest, R2=0.97) and Extent (stress,
R2=0.99; rest, R2=0.96) were likewise excellent. For
Hotelling 3D, correlations were slightly lower than for
HYPR-LR: relative perfusion (rest, y=1.016x-0.131,
R2=0.95; stress, y=0.982x+3.165, R2=0.87), SSS (R2=0.90),
SRS (R2=0.88), SDS (R2=0.75), TPD (stress, R2=0.98; rest,
R2=0.93) and Extent (stress, R2=0.97; rest, R2=0.90).Conclu-
sion: Static 82Rb series for quantifying relative myocardial
perfusion can be created by summing denoised late frames of
dynamic 82Rb series. Excellent quantitative accuracy was
found for both HYPR-LR and Hotelling 3D algorithms. This
enables either an improvement in image quality or a reduction
in administered dose. Further studies are required to define the
optimal tradeoff between administered dose and image quality.
TP066
RubiShort: Reducing scan time in 82Rb heart scans
to minimize movements artifacts
J. Madsen, K. J. Vraa, H. J. Harms, K. Bouchelouche, J.
Frøkiær, J. Sørensen, L. P. Tolbod; Dept. Nuclear Medicine
& PET-Centre, Aarhus University Hospital, Aarhus N,
DENMARK.
Aim: Relative and absolute myocardial blood flow (MBF) can
derived from a single 82Rb PET/CT scan using list mode data
to extract both static and dynamic PET series. However, pa-
tient movement and changes in breathing pattern, especially
during pharmacological stress, reduce the quality of the scans
and are known to introduce artifacts in 10-15% of all scans. By
reducing scan time from 7 min. to 5 min, we expect to reduce
the frequency of motion artifacts. This is, however, at the cost
of information used for MBF calculation and count statistics in
the relative blood flow images. We set out to examine if a
reduction of scan time would affect the accuracy of the
examination. Method: Both stress and rest 82Rb scans
from 11 random clinical patients without motion artifacts
were selected. Using list mode data, dynamic series from
0-7 min (standard) and 0-5 min (short) after 82Rb infu-
sion as well as static series from 2.5-7 min (standard) and
2.5-5 min (short) after 82Rb infusion were reconstructed.
Data was analyzed using QPET (Cedar Sinai). Absolute
(MBF, 17-segment AHA-model) and relative (%Extend,
%Reversible and Total Perfusion Deficit (TPD), 5 seg-
ments) parameters were compared by using scatter plots
and linear regression. Results: Excellent correlation be-
tween the 7 min. and 5 min. data was found for absolute
MBF (y=1.014x, R2=0.98). For all relative parameters
obtained from the static reconstructions, excellent corre-
lation was likewise observed between 7 min. and 5 min.
reconstructions (%Extent: y=1.013x, R2=0.98; %Revers-
ible: y=1.008x, R2=0.95; TPD: y=1.000x, R2=0.99).
Conclusion:, Scan time of myocardial perfusion scans
using 82Rb can be reduced from 7 min. to 5 min. with-
out loss of quantitative accuracy. Since patient motion is
frequent in the last minutes of the scans, scan time re-
duction is likely to reduce motion artifacts.
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TP067
Comparison of absolute myocardial blood flow
with 13N-NH3 cardiac PET determined by different
compartmental models and softwares
B. Olsson1, S. Akil1, F. Hedeer1, H. Engblom1, C. Hindorf2;
1Clinical Physiology and Nuclear medicine, LUND, SWE-
DEN, 2Radiation Physics, LUND, SWEDEN.
Aim: The absolute myocardial blood flow (MBF) can be
determined from a dynamic acquisition that starts simulta-
neously with the injection of 13N-NH3. Activity in blood
and in the myocardium as a function of time after injection
serve as input functions to the compartmental model ap-
plied for the calculation of the MBF. Several softwares and
compartmental models have previously been developed for
the calculation. The aim of this study was to compare the
MBFs from different softwares and compartmental models.
The intraobserver variability was also evaluated. Methods:
Five patients diagnosed with coronary artery disease were
examined with 13N-NH3 at rest and in stress (10 cardiac
PET studies). A listmode acquisition was performed after
injection of 555 MBq 13N-NH3. A dynamic study with a
duration of 10 minutes (12 images for 10s, 6 images for
30s, 2 images for 60s and 1 image for 180s) were recon-
structed with OSEM from the listmode acquisition. The
global MBF was determined by the deGrado, Hutchins
and Krikovapich compartmental models in the Carimas
software (Turku, Finland) and with the Hutchins compart-
mental model in the syngoMBF software (Siemens). Each
evaluation was performed three times to assess the
intraobserver variability (determined as (max-min)/mean
for each cardiac PET study). Results: The mean value for
the first of three evaluations of all patient studies was
MBFdeGrado,Carimas=1.8ml/min-g, MBFHutchins,
Carimas=1.9 ml/ml-g, MBFKrivokapich,Carimas= 2.3
ml/min-g and MBFHutchins,syngo =1.7ml/min-g. The
intraobserver variability, reported as the mean of the
percentual deviation, was 9% for deGrado,Carimas; 15%
for Hutchins,Carimas; 7% for Krivokapich,Carimas and
8% for Hutchins,syngo.ConclusionsThe mean of the global
myocardial blood flow varied between 1.7 and 2.3 ml/min-
g for the compartmental models and softwares that were
evaluated. The Krivokapich compartmental model in
Carimas showed the smallest intraobserver variability but
the mean myocardial blood flow deviated from the results
from the other methods. The Hutchins compartmental
model in syngo showed a smaller intraobserver variability
than the same model in Carimas, whichmight be explained
by a more automatic image processing in the syngo
software.
TP068
Assessing left ventricular dysfunction by the use of three
distinct molecular imaging techniques
J. Reis1, L. Cunha1, P. Costa1, D. Neves2, T. Oliveira2, A.
Ferrer-Antunes2, M. Faria Joao2, L. Metello1; 1Nuclear Med-
icine Department, ESTSP.IPP, Porto, PORTUGAL, 2Nuclear
Medicine Department, DIATON SA, Leiria, PORTUGAL.
AIMS: Left ventricular dysfunction might be assessed
using distinct molecular imaging modalities. The most
relevant are first pass radionuclide ventriculography
(FPRV), multigated radionuclide angiography (MUGA)
and gated blood-pool SPECT (GBPS) and are very often
used for monitoring chemotherapy-related cardiomyopa-
thy. This work aims to correlate these three molecular
imaging techniques. METHODS: 400mg of potassium
perchlorate and 20 μg/kg of stannous agent were admin-
istered to a group of 30 patients (35-65 years old) 20
minutes before the iv bolus injection of 740-925 MBq
of 99mTc. First pass images were acquired in anterior
projection immediately after 99mTc injection, in a total
of 1.500 frames with 25 msec/frame each. Fifteen mi-
nutes later, MUGA images were acquired in left anterior
oblique projection for a minimum of 600 cardiac cycles
using 24 bins/cycle. Finally, GBPS images were obtain-
ed using 24 bins/cycle and 20 cycles/projection in a
total of 60 projections acquired over 180° in step-and-
shoot mode. All images were acquired with a double-
headed gamma camera, equipped with LEHR collimator.
Left and right ventricular ejection fraction (LVEF and
RVEF) as well as ventricular volumes were calculated.
RESULTS: The first subgroup of 14 patients were ana-
lyzed. Global LVEF assessed by GBPS showed a good
correlation with conventional planar methods (correlation
coefficient = 0.87). The average LVEF obtained by pla-
nar techniques was 59.7 ± 9.7%, whereas for GBPS was
66.2 ± 10.4%. The correlation coefficient between
MUGA and FPRV was 0.92. The average LVEF obtain-
ed by FPRV was 56.3 ± 7.5%. The correlation coeffi-
cient between FPRV and GBPS was 0.81. CONCLU-
SION: Results obtained so far suggest a better correla-
tion for LVEF between FPRV and MUGA techniques in
comparison to GBPS. Moreover, GBPS provides addi-
tional information, since it allows the assessment of
RVEF and wall motion, which can be of value in pa-
tients with congestive heart failure. The work is still
ongoing and the final subjects will be evaluated shortly,
with their contribution for the results being added sub-
sequently. Final results will be presented and discussed
using the adequate statistical tools.
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Strategies to reduce Radiation Dose from Myocardial
Perfusion Imaging:
A. Ghilardi, G. Medolago, L. Pozzi, M. Caloiero, C. Bianchi,
E. Iampietro, A. Bruno; Papa Giovanni XXIII, BERGAMO,
ITALY.
Aim: Nuclear Cardiology plays an essential role in the evalu-
ation, management in coronary artery disease[CAD]. Indeed it
demands ongoing re-evaluation of myocardial perfusion
imaging[MPI] to improve patient care: accurate definition of
candidates [appropriateness], optimization of MPI protocol
and upgraded technologies to give the lowest possible radia-
tion dose upholding high accuracy. Great challenge is to
choose the proper radiotracer, acquisition-processing proce-
dures for each patient to provide accurate and clinically mean-
ingful information to physician. Methods: Patient selection is
the primary and most relevant issue of handling radiation ex-
posure from MPI and needs appropriate use criteria[AUC].
When MPI is clinically appropriate the benefits in terms of
advance clinical decision making and care are greater than
any potential risk from radiation exposure. Once MPI is con-
sidered the best diagnostic procedure next step is choosing the
best protocol-stressor test to be used. Tc99m-perfusion tracers
are preferable for availability, imaging quality, lower radiation
dose: anyway injected dose must be adjusted for patient
weight. Normal Stress imaging as first step allows to avoid
rest perfusion: the accuracy of single stress protocol is un-
equivocally high. IQSPECT, using cardiac-focusing collima-
tor, offers increased sensitivity with similar resolution, com-
pared to LEHR collimator, resulting in reduced administered
dose, shorter acquisition time. With CZT detectors, having the
greatest sensitivity, energetic and spatial resolution, dosimetry
is further reduced: dynamic studies can also be acquired to
obtain quantification of blood-flow and coronary reserve. Iter-
ative reconstruction filtering [with resolution recovery] allows
to obtain very good quality images also with lower count den-
sity, demonstrating to be a valid tool to use low-dose protocol.
Current-generation PET 3D-scanners are equipped with ad-
vanced ha rdware - so f tware capab i l i t i e s o f h igh
resolution[2mm], low dose imaging [time-of-flight, high-
definition iterative reconstruction and motion-frozen imag-
ing]. Single-Stress PET MPI [NH13, Rb82] with myocar-
dial blood flow and coronary reserve assessment can be
performed with less than a 1-mSv radiation dose. With
the availability of F18 perfusion agents PET is going to
be MPI procedure of choice. In our laboratory of Nu-
clear Cardiology since July-2012 we’ve been using
IQSPECT with excellent results, obtaining significant re-
duction of radiation dose to patient, acquisition time,
maintaining very good quality images and not least ap-
propriate selection of patients to be studied. Conclu-
sions: MPI studies should be performed in appropriate
patients using short-lived perfusion tracers and using all
possible and available measures to minimize radiation
exposure, so that the benefits of the diagnostic and
prognostic information outweigh the risk of radiation
exposure.
TP070
Impact of attenuation and scatter corrections
in the quantification of SPECT brain images
S. Chaves1, T. S. Vieira1, J. G. Pereira1, F. Caramelo2, N. C.
Ferreira2; 1Centro Hospitalar S. João, Porto, PORTUGAL,
2Instituto Biomédico de Investigação de Luz e Imagem (IBILI
– FMUC), Coimbra, PORTUGAL.
Aim: One of the most challenging tasks in Nuclear Medicine
(NM) is to quantify the activity concentration of a radiopharma-
ceutical in acquired images. The emergence of multi-modal
equipment combined with the evolution of fully 3D image recon-
struction algorithms, that demand correction techniques of differ-
ent physical phenomena, have been contributing to derive better
solutions for the quantification problem.Our purpose is to evalu-
ate the effect of attenuation correction (AC) and scatter correction
(SC) in SPECT quantification of brain images. Materials and
Methods: We determined the system calibration factor using a
cylindrical phantom filled with a uniform concentration of activ-
ity, for two isotopes: 123I and 99mTc.To quantify the activity
concentration, two phantom experiments were performed. The
first trial was carried out using a Jaszczak phantom with six
spheres of different diameters (4.2 - 47mm) filled with the same
activity (0.5 MBq/cm3 for 123I and 0.8 MBq/cm3 for 99mTc).
The second test was performed using an anthropomorphic striatal
brain phantom filled with water: the striatal nuclei with a concen-
tration of 0.2 MBq/cm3 for the two isotopes and without back-
ground. For the SPECT/CT (Infinia-Hawkeye 4,GE®)were used
LEHR collimators; rotation of 360°; 120 projections, 40 seconds/
projection; 128x128 matrix; 20% energy window centred on the
isotope photopeak. OSEM reconstruction method was adopted
and all images were submitted to CT-based AC and SC by dual
energy window (defining a second window - 130 keV +/- 10%
for 123I, 120 keV +/- 5% for 99mTc). After image reconstruc-
tion, VOI’s were drawn around spheres and basal nuclei (AM-
IDE®), guided byCT, to obtain the total counts (decay corrected).
The concentration of the corresponding activity was calculated
using the calibration factor. It was determined the relative error
between real concentration and calculated activity. Results and
Conclusion: The activity was underestimated by at least 65% if
no correction was applied, in both phantom experiments.In the
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brain phantom, when applying AC and SC, the mean relative
error in quantifying radioactivity concentration in absolute terms
was 45% for 123I and 35% for 99mTc. Otherwise, for the
Jaszczak phantom, the mean relative error of estimated spheres
activity was 4% for 123I and 1% for 99mTc, for spheres with
higher volumes. For both isotopes, we observed an increase in the
quantification error with decreasing sphere volumes. Attenuation
and scatter corrections are important to SPECT absolute quanti-
fication, and for small structures other additional corrections
might be needed to achieve better results.
TP071
Validation of a New Reference Values's Database
for Semiquantification of 123I-FP-CIT SPECT scans
in one Nuclear Medicine Department
M. Elias1, M. Queiroga1, D. Silva1, J. Serrano2, J. Madrid2,
E. Carolino1, E. Sousa1; 1Escola Superior de Tecnologia da
Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon,
PORTUGAL, 2NuclearMedicine Department, Hospital Infan-
ta Cristina, Badajoz, Spain, Badajoz, SPAIN.
Introduction: Reference adaptaded values of healthy and patho-
logical controls for quantification the Dopamine Transporters
(DAT) with 123I - FP-CIT have become an important tool in
the diagnosis and evaluation of parkinsonian syndromes. Aim:
The aim of this studywas evaluate the discriminate capability of a
department’s adapted database reference’s values of healthy con-
trols for DATwith 123I - FP-CIT, this database is named DBRV.
The reference values are adapted to Nuclear Medicine Depart-
ment’s protocol and population of Infanta Cristina’s Hospital lo-
cated in Badajoz. Subjects/Methods: It was used a semiautomatic
method for segmentation and posterior calculi of binding poten-
tial in dopamine transporters (DAT) in striatum structures and in a
nonspecific binding region, of the 30 healthy controls of the
DBRV. All exams were acquired by EANM’s Guidelines proto-
col, and processed three times for one operator, average values
were used. Average and standard deviation (x ̅ ± δ) values were
calculated for the following ratios: left and right Caudate nucleus/
Occipital respectively (A) and (B); left and right Putamen/
Occipital respectively (C) and (D); striatum/Occipital (E); left
striatum/occipital (F), right striatum/occipital (G), Putamen/ nu-
cleus caudate (H). These values where calculated and stablished
new reference values for infanta Cristina's Hospital population
between 60 and 75 years. For validation purposes two database
of thirty patients each: database of healthy controls (DBVGIIH),
and database of subjectswith diagnosed Parkinsonian Syndromes
(DBVGIIIP), were processed using the same protocol, and its
results where compared with the ones of DBRV. Assessment
Control Charts and Receiver Operating Characteristic Curves
(ROCC) were calculated.Results: The DBVGIIH results were
within the new reference values for healthy subjects; the
DBVGIIIP results were below the new reference values for
healthy subjects. By the ROCC assessment for each ratio the
values of area under the curve (AUC) it was obtained the follow-
ing values: A (AUC= 0.81); B (AUC= 0.79); C (AUC= 0.91); D
(AUC= 0.93); E (AUC= 0.88); F (AUC= 0.86); G (AUC= 0.87);
H (AUC= 0.87), the ROCC curve discriminate well, AUC sig-
nificantly different from 0.5, p<0.0001. Discussion/Conclusion:
From the ROCC analysis it’s possible to conclude that the DBRV
and its reference values newly created have good discriminative
capability between healthy controls and subjects with Parkinso-
nian Syndromes. The new database is an adapted and improved
tool for clinical use assessment.
TP072
PET- CT Determinants of Achievement Experience
C. D. R. Oliveira1, C. Pacheco1, A. Grilo1, L. Vieira1, L.
Vieira2, D. Faria3, D. Faria4, J. C. A. Farto5,M. C. Vázquez5;
1Escola Superior de Tecnologia da Saúde de Lisboa, Lisboa,
PORTUGAL, 2Faculdade de Ciências da Universidade de Lis-
boa, Lisboa, PORTUGAL, 3Hospital Lusíadas do Porto, Porto,
PORTUGAL, 4Faculdade de Engenharia da Universidade do
Porto, Porto, PORTUGAL, 5Instituto Tecnológico de Serviços
Sanitários, MD Anderson Cancer Center, Madrid, SPAIN.
An inadequate provision of information on diagnostic tests in
daily practice of a Nuclear Medicine Service, can generate the
feeling of fear of the unknown on the patient, and thereby increase
the anxiety level of the same. Nuclear Medicine Technologist has
to develop the gift of perceiving when a patient is anxious in his
daily life, if anxiety is inherent to his medical situation, or if it's
related to a pathologic diagnosis.Many factors can induce anxiety
on the patient, e.g. contact with radiation.Injection of the radio-
pharmaceutical is one of the main causes of anxiety because of
everything that is involved, as the patient has to be kept away
within a certain distance fromhis family and peoplewho surround
him during the day, especially pregnancy women and
children.High levels of anxiety can also result in a low image
quality as a result of patient motion during acquisition or as a
result ofmuscular uptake of the radiopharmaceutical. On the other
hand, it can decrease the global comfort of the patient as he may
feel dissatisfied with the health care which he received during his
exam.The aims of this study are to evaluate the subjective percep-
tion of patients about the exam, understand if the information
given to the patient was adequate and identify the factors that
decrease or increase the anxiety state.Material and methods: 60
patients of both genders, grouped by age groups 18-39, 40-59 and
60-79 and 80+. The study will exclude patients with significant
communication impairments that would affect their ability to re-
spond to the interviewer’s questions, patients with a history of
psychiatric illness , patients in poor condition who were unable
to cooperate, patients who were illiterate and had neurological
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problems. Evaluation of the state of anxiety before and after the
examination, based on the results of a questionnaire and STAI
forms [State Anxiety Inventory (STAI-S): evaluating how the
patient feels in that particular situation or moment, and Trait Anx-
iety Inventory (STAI-T): evaluating how the patient feels inde-
pendently of the situation or condition at that moment].Results/
Conclusions: An appropriated communication between the Nu-
clear Medicine Technologist and the patient helps to decrease
anxiety levels on the patient. Informed patients on the procedures
related to the exam itself are quiet and are more cooperative.Note:
This work was supported in part by Fundação para a Ciência e a
Tecnologia - Portugal (project UID/BIO/00645/2013)
TP073
Comparison of GFR estimation methods in chemotherapy
Monitoring
V. Rangarajan, V. Kumar, N. Purandare, S. Shah, A.
Agrawal, J. Bajpai; Tata Memorial centre, Mumbai, INDIA.
INTRODUCTION: Simple and accurate determination of the
Glomerular filtration rate (GFR) in chemotherapy monitoring
still poses a challenge. Our goal was to compare various
methods and find out a simple, cost effective, precise and
accurate method for GFR estimation. OBJECTIVES OF
STUDY: Primary objective: Comparison of standard two sam-
ple plasma sampling method (PS2) to gamma camera Gates
method (GT) by retrospective analysis of data of patients re-
ceiving chemotherapy. Secondary objective: - Comparison of
other serum creatinine based formulae methods with PS2
method for estimation of GFR. METHODS: GFR estimation
was done in patients diagnosed of Osteogenic sarcoma at base-
line (prechemotherapy) and post 4 cycles of Cisplatin based
chemotherapy using PS2, GT (with 99mTC DTPA) and other
serum creatinine based methods like Cockcroft-Gault (CCG),
MDRD, Schwartz (SHW), and Counahan-Barrat (CB). Gold
standard PS2 was compared with all the other methods using
paired T test, linear regression and coefficient of correlation.
RESULTS: 37 patients had pre and post 4 cycle chemotherapy
GFR data, which met all the inclusion and exclusion criteria
with a median age of 18 years. There was statistically no sig-
nificant change in the mean difference between the PRE (PR)
and POST (PO) 4 cycles of GFR values either by standard PS2
or by test GT method. The mean difference and p values are
PR PS2 - PO PS2 = 1.438, (p= 0.819), and PR GT - PO GT=-
2.13, (p= 0.575). Whereas the other test methods based on
serum creatinine, body weight and height, (CCG, MDRD,
SHW, and CB) showed significant change (increase) in
GFR. The mean difference and p values are - PR CG - PO
CG = -17.7, (p=0.00), PR MDRD - PO MDRD= -33.54,
(p=0.00) PR SHW - PO SHW= -23.14, (p=0.00), PR CB -
PO CB= -19.94, (p=0.00). Similar results were also observed
in individual pediatric and adult groups. CONCLUSION: GT
can be used as a reliable substitute for PS2 in estimating the
change in GFR as its results are similar to that of PS2 in adults
as well as in pediatric age group. The formula methods based
on serum creatinine are not as reliable as PS2 in accurately
estimating the change in GFR.
TP074
Therapy planning and dose prescription
in radioiodine-131 therapy for hyperthyroidism using
radioiodine-123 SPECT/CT imaging
K. Hanaoka, M. Hosono, M. Otsuka, Y. Asai, M. Okumura,
K. Ishii, T. Murakami; Kinki University, Osaka Sakai-city,
JAPAN.
Objectives: Functional thyroid weight is one of the most im-
portant factors for prescribing radioiodine doses in iodine-131
(I-131) therapy for hyperthyroidism. Thyroid weights are usu-
ally determined with planar scintigraphic methods such as
Allen’s method, which may include statistical deviations espe-
cially in case of atypical thyroid morphology. In this study, we
assessed the usefulness of SPECT/CT in the measurement of
functional thyroid weight for radioiodine therapy. Methods:
Forty patients with Graves’ disease who underwent I-131 ther-
apy along with preceding radioiodine-123 (I-123) planar scin-
tigraphy and SPECT/CT scan between February 2010 and
November 2014 were enrolled in this retrospective study. On
planar images, thyroid weight was measured using Okubo’s
(2D) method, a modified Allen's method for Japanese popula-
tion. On SPECT/CT images, volumetric regions of interest
(VOI) were placed over the thyroid on SPECT images by
referring to CT images. These measurements were performed
by 4 operators. Thyroid weights estimated by these methods
were analyzed and compared by regression analysis and
Bland-Altman Plot. Results: Variations among 4 operators
were 4.50% and 11.22% for the SPECT/CT and 2D methods,
respectively. In the patients, a good correlation was observed
between the twomethods (r=0.98, p<0.01) with a difference of
4.69±16.1%. Bland-Altman Plot revealed no systematic errors
between the SPECT/CTand 2Dmethods. However, 7 patients
showed differences of over 20% in the estimated thyroid
weights between the two methods, and peculiar findings such
as a heterogeneous uptake, an ectopic uptake and a non-
functional mass were identified on SPECT/CT fusion images
and were thought to be one of the causes of the discrepancy. In
terms of change in dose prescription, the prescribed I-131 dose
in capsules was increased in 6 patients and was decreased in 4
using the SPECT/CT method. Conclusions: Our method using
SPECT/CT is one of the optimal ways to determine functional
thyroid weight. This method navigates an operator-
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reproducible measurement by adding morphological informa-
tion to functional images.
TP075
Emerging role of Bremsstrahlung SPECT/CT imaging
in yttrium-90 radiosynovectomy
A. Atabaki, R. Mansberg, R. Russo, S. Gunaratne; Concord
Hospital, Sydney, NSW, AUSTRALIA.
BackgroundYttrium-90 radiosynovectomy has been a thera-
peutic option in the management of monoarticular prolifera-
tive arthropathy for decades. Post therapy imaging has been
used to confirm successful administration of tracer to the af-
fected joint and to image extravasation at the joint, draining
lymph nodes and the liver, however the benefit has been lim-
ited by the poor imaging characteristics of yttrium-90AimsTo
evaluate the role of Bremsstrahlung SPECT/CT imaging in
yttrium-90 radiosynovectomy in confirming successful thera-
p e u t i c a d m i n i s t r a t i o n a n d a s s e s s m e n t o f
extravasation.MethodsPatients referred for radiosynovectomy
were assessed and treated in the conventional manner. Follow-
ing intra-articular in administration of yttrium-90 patients were
arrested in the supine position for 72 hours. Regular planar
images were performed of the treated joint, draining lymph
nodes and the liver. In addition Bremsstrahlung SPECT/CT
of the treated joint was performed and the images were com-
pared with the planar images.ConclusionBremsstrahlung
SPECT/CT imaging in yttrium-90 radiosynovectomy may
benefit patients undergoing this therapy by more accurate im-
aging of treated joints. This may result in better and more
specific localisation of extravasation which could benefit pa-
tients by instituting earlier and more specific therapy.
TP076
Nuclear Medicine therapies applied to small animals
D. F. F. Ribeiro, F. Lucena; Escola Superior de Tecnologia da
Saúde de Lisboa, Lisbon, PORTUGAL.
Introduction - Nuclear Medicine (NM) procedures have been
used in the field of Veterinary Medicine (VM) for some years,
with a recent increasing interest in Radionuclide Therapy
(RNT), especially in hyperthyroidism and bone metastasis.
Aims - Describe RNT applications in VM, with focus on well
established procedures for small animals. A new therapeutic
approach with 177Lu-DOTMPwill also be included. Methods
- A systematic review was conducted based on key-words,
“Radioactive iodine therapy”, “Iodine 131 therapy”,
“Radioiodine treatment”, “hyperthyroidism", "therapies with
radiopharmaceuticals", "Palliation treatment with
radiopharmaceuticals", "radionuclide therapy”, “veterinary”,
“153Sm-EDTMP”, “dogs”, "177Lu-DOTMP”, “animals”
and “small animals", and relevance of the content. Twenty
articles were included and the analysis was focused on precau-
tions prior and post therapy, therapeutic procedures and ad-
verse effects of therapies with 131I, 153Sm-EDTMP and
177Lu-DOTMP. Results - The research included review arti-
cles (N=2; 15.38%), experimental articles (N=6; 46.15%), of-
ficial documents (N=3; 23.08%) and official webpages (N=2;
15.38%). 131I therapy represents the most common treatment
in VM due to its effectiveness and less disadvantages. Prior to
the therapy it is advisable to determine thyroxine blood con-
centration, blood pressure and renal and cardiac function. An-
imals should by isolated no less then 7 days, in a quiet envi-
ronment with shielded cages. The administered activity may
be determined by: fixed activity; based on a scoring system; or
by kinetic models. After the therapy renal function should be
monitored. Regarding bone metastasis, 153Sm-EDTMP and
177Lu-DOTMP are being used as they represent attractive
therapies although 177Lu-DOTMP seems to be more effective
since it doesn’t deteriorate the urinary tract. Prior to the thera-
py, erythrocytes, leucocytes and platelets levels should be
evaluated and a bone scintigraphy is also advisable. The activ-
ities for each radiopharmaceutical should be determined based
on the animal’s weight, and motorization should be provided
until 14 days post therapy. Although none of these two thera-
pies are considered for the first therapeutic approach, they are
often used as palliative treatment and might potentiate the
effects of radiotherapy. Conclusion - RNT allied with simple
therapeutic procedures provides an effective therapeutic ap-
proach in VM, giving the animals better chances of survival,
with low incidence of adverse effects. Although 131I is the
better established RNT, both the 153Sm-EDTMP and 177Lu-
DOTMP appear promising and are slowly gaining their way
into the VM community.
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Comparative retrospective study of peptide receptor
radionuclide therapy (PRRT) with Y-90-DOTATOC
and Y-90-DOTATATE in neuroendocrine tumours (NET)
M. Marx, H. Plagge, C. Winkler, Y. Zhao, U. Lützen, M.
Zuhayra; Universitätsklinikum Schleswig-Holstein, KIEL,
GERMANY.
Aim: Peptide receptor radionuclide therapy (PRRT) for treat-
ment of metastasized neuroendocrine tumours (NET) can be
performed with Y-90- or Lu-177-labelled DOTA-peptides.
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Usually DOTATOC is used for labelling Y-90, while
DOTATATE is used for labelling with Lu-177. In this study
we compared the outcome and side effects of Y-90-
DOTATATE compared with Y-90-DOTATOC in patients with
NET. Materials and Methods: 83 consecutive patients with
NETwere treated with Y-90-DOTATOC (27 patients, 6 wom-
en, 21 men, aged median 68 years (47-81 years); 10 CUP, 8
foregut , 7 midgut und 2 hindgut tumours; median 7,0 GBq) or
Y-90-DOTATATE (56 patients, 21 women, 35 men; aged me-
dian 69 years (41-81 years); 18 CUP, 24 foregut, 10 midgut, 4
hindgut tumours; median 6,8 GBq). We compared response
rates (clinical and morphological), progressive free survival
(PFS), overall survival (OS), as well as side effects to bone
marrow (blood cells) and kidney function. Results: Response
rates showed no significant differences in both groups
(DOTATOC: remission 34,8%, stable disease 43,5%, progres-
sive disease 21,7%, DOTATATE: remission 22,4%, stable dis-
ease 57,1%, progressive disease 20,4%). Furthermore, no sig-
nificant differences were seen concerning PFS: DOTATOC 5
months (KI95 % 3,5-6,5), DOTATATE 6 months (KI95% 4,2-
7,7) and OS: DOTATOC median 23 months (KI95% 0-50,5),
DOTATATEmedian 32months (KI95% 22,8-51,2). Effects on
blood cells were pronounced in the DOTATATE group for red
blood cells (p=0,011), white blood cells (p=0,012) and plate-
lets (p=0,04). Severe side effects (infections, bleeding, blood
transfusion necessary) were more seen in the DOTATOC
group (p=0,018). No significant differences were shown be-
tween the pre- and post therapeutic creatinine concentrations
in plasma in both groups, whereas (until now) renal failure
occurred only in 4 patients(14,8%) following Y-90-
DOTATOC therapy after a period of mean 35,5 months (14 -
59 months). Conclusions: Peptide receptor radionuclide ther-
apy with Y-90-DOTATOC and Y-90-DOTATATE lead to sim-
ilar results concerning response rates, progressive free survival
and overall survival. Severe side effects were more often seen
after Y-90-DOTATOC.
TP078
Development of a new quantification method of dopamine
transporter density with 123I-ioflupane
S. Okumiya, A. Ofuji, S. Ito; Kumamoto University, Kuma-
moto, JAPAN.
[Objective]123I-ioflupane has a high affinity for dopamine
transporters (DAT) in the corpus striatum, and the single pho-
ton emission tomography (SPECT) imaging provides distribu-
tion density of DAT in brain. Quantifying specific binding
ratio (SBR) of 123I-ioflupane's signal at the striatal region is
a common brain imaging method to confirm the diagnosis of
the Parkinson's disease. Generally, SBRs are calculated by
comparing the activity in the structure of interest with the
activity in a reference region (with a very low DAT concentra-
tion) by the semi-quantification method. However, the SBR by
the semi-quantification method depends on the system perfor-
mance of the SPECT camera.Therefore, quantification is im-
portant for research and for completion of a diagnostic
evaluation.The purpose of this study is to develop a new quan-
tification method for obtaining the true-SBR.[Materials and
methods]A striatal phantom filled with 123I solution
(1.4~123 kBq/ml) using striatal to background (BG) ratios
between 4:1 (left side: BG) of and 8:1 (right side : BG) was
imaged on two different SPECT systems with two different
collimators (low-energy high resolution (LEHR) and low and
medium energy general purpose(LMEGP)). Data from each
systemwere reconstructed using 2-dimensional ordered subset
expectation maximization method (subsets:10, iterations:10).
Attenuation and scatter corrections were performed. After fu-
sion of SPECT and CT data, left and right side region of in-
terest (ROI) of striatum were obtained by tracing the striatal
outline of the CT images. These ROIs and a rectangular ROI of
the BG were set on the SPECT images. The activity in each
ROI was obtained by using a count-activity conversion coef-
ficient (CC). The CC was obtained by analyzing the count-
activity curve of each ROI. The activity in each ROI was
calculated by multiplying the SPECT counts by the CC. The
true-SBR was determined by using these activities.
[Result]Linear regression equations of the count-activity
curves were obtained for the phantom study in all SPECT
systems. The CC of the left side striatum was approximately
equal to that of the right side. The true-SBRs of the four
SPECT systems were approximately equal to the theoretical
values. The lower detection limit of the striatum was 7.2 kBq/
ml.[Conclusion]A new quantification method was developed
using the individual CC of the striatum and BG. Clinical study
is necessary to confirm the feasibility of this method.
TP079
To Manual Handle, or to NOT Manual Handle?
C. Vroonland, S. Baank, M. Stokkel; Antonie van Leeuwen-
hoek Hospital, Amsterdam, NETHERLANDS.
Aim It is widely known that nursing staff has one of the
highest incidences of musculoskeletal pain and injuries, which
has resulted in the development of Patient and Manual Han-
dling strategies and equipment. Employees in other depart-
ments can also benefi t from these strategies and
equipment.Our aim is to raise awareness of the necessity and
to stimulate the implementation of patient/manual handling
techniques and equipment within Nuclear Medicine depart-
ments, not only due to heavier patients but also especially
due to the lead shielding we are required to work with.Method
and MaterialsI n the Netherlands there are currently only
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guidelines, no legal legislation requiring the use of Patient/
Manual Handling techniques and equipment. As a result, such
equipment is often only scarcely available within imaging de-
partments. Several years ago a Risk Analysis was performed in
our department in which the staff indicated which areas of their
activities were physically demanding. These activities includ-
ed patient handling (transfer of the patient from chair-bed or
bed-bed), collimator exchanging, and Hotlab activities mainly
due to the use of lead shielding.With the help of a Nuclear
Medicine Technologist experienced in Manual Handling, a
newly appointed Health and Safety advisor and the Risk Anal-
ysis, we were able to pinpoint specific areas where Manual
Handling strategies and equipment could be implemented
and training provided at a relatively low cost.Results Simple
and low cost equipment has been installed benefitting both
staff and patients. Manual Handling coaches have been
appointed and trained through the Health & Safety depart-
ment. These coaches are able to train their own colleagues
and oversee the use of Manual Handling techniques and
equipment.The Risk Analysis was a key tool in the decision
making process for a ceiling mounted patient hoist during the
purchase of the new big bore PET camera.Conclusion Despite
the lack of legal legislation we have been able to implement
several improvements, the results of which we hope will be
reflected in the Risk Analysis due to take place later this
year.Possible new improvements and/or strategies are often
evaluated and implemented as the raised awareness stimulates
staff to think of new solutions to Manual Handling problems.
TP080
Evaluation of CZT-SPECT system for nuclear cardiology:
comparison with conventional Anger SPECT
T. Niimi1, M. Sugimoto1, M. Nanasato1, H. Maeda2; 1Na-
goya Daini Red Cross Hospital, NAGOYA, JAPAN, 2Nagoya
University, NAGOYA, JAPAN.
Purpose: Recently, the D-SPECT (D-SPECT; Spectrum
Dynamics, Israel) system, based on cadmium-zinc-telluride
(CZT) detectors, has been commercialized for myocardial
single-photon emission computerized tomography (SPECT).
However, the most of the differences in the performance of the
CZTcamera or collimation systems remain unclear, except for
evaluations by some research organizations. We evaluated the
performance of the D-SPECT system to understand the differ-
ences in the performance of the CZT camera or collimation
systems in comparison with a conventional Anger SPECT (A-
SPECT).Materials and Methods: We evaluated the perfor-
mance of the D-SPECT system in terms of its energy resolu-
tion, detector sensitivity, uniformity, spatial resolution, and
collimator resolution compared with an A-SPECT
(BrightView; Philips, Japan). The energy resolution was
measured for Co-57, Tc-99m, I-123, and Tl-201 using line
sources placed at the same locations in each system. Corre-
sponding measurements were also done on an A-SPECT. The
full width at half maximum (FWHM), which is an index of
energy resolution and spatial resolution, was separately esti-
mated for each pixel by fitting the sum of a Gaussian function,
reporting the Gaussian FWHM. The detector sensitivity and
uniformity were also determined using the same phantom data
as the energy resolution. The spatial resolution was evaluated
using a NEMA phantom and the reported FWHM. The colli-
mator resolution was calculated based on the material and
geometry (the collimator of A-SPECT was LEGP.).Results:
The energy resolution (FWHM) values of the D-SPECT sys-
tem for Co-57, Tc-99m, I-123, and Tl-201 were 5.8%, 5.5%,
5.2%, and 10.9%, respectively; the corresponding values in A-
SPECT for Tc-99m and I-123 were 9.1% and 9.3%, respec-
tively. The D-SPECT system with Tc-99m and I-123 had an
energy resolution that was twice that of the A-SPECT. Tc-99m
and Tl-201 had detector sensitivities that were respectively 6.4
and 11.7 times higher than that of the A-SPECT. The unifor-
mity was equal, and the spatial resolution was twice that of the
A-SPECT. The collimator resolution (FWHM at a distance of
10 cm) of the D-SPECTsystemwas 13.3 mm, where as that of
A-SPECT was 7.6 mm, which was superior to that of the D-
SPECT.Conclusion: The energy resolution and detector sensi-
tivity of the D-SPECTwere superior to those of a conventional
A-SPECTsystem, with similar uniformity. However, the qual-
ity of the D-SPECT image is still unclear because the collima-
tor resolution, which is an index of image quality, showed a
value that was 1.75 times lower than that of the A-SPECT.
TP081
Post therapeutic 131I Scan Total Body after a successive
therapy (WBS) in Patients (Pts) affected by metastases
of thyroid cancer (DTC) and 18F-FDG PET/CT (PET):
usefulness of PET for staging and evolution recurrence
in Pts with elevated Thyroglobulin (Tg)
L. Bertolazzi, L. Di Ciolo, V. Barbetti, C. Cananzi, M.
Gaffuri, E. Piccardo, C. Motta, G. Agnese, P. Moresco;
Azienda Ospedaliera Santa Corona, PIETRA LIGURE (SV),
ITALY.
Aim. The purpose of this study is to investigate the possible
role of PET in Pts with DTC and positive WBS in which was
planned a successive 131I-radiomethabolic therapy (RAI) for
metastases. Meanwhile the study tries to evaluate PET’s pos-
sible utility and helpful for staging and evolution recurrence
and maybe skip a successive diagnostic 131I-scan (TB). Ma-
terials and Methods. This retrospective review comprised 113
Pts that, after total thyroidectomy andmore RAI between 2007
and march 2015 (80 females and 33 males, age 34 - 83 years,
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mean age 48 years), were affected by papillary cancer (83
Pts=73% ) and by follicular cancer (30 Pts=27%) undergoing
in already a second RAI in off L-T4 (TSH > 40 uU/ml). All
133 Pts had elevated Tg (range 5 - 600 ng/ml, mean range 133
ng/ml) and performed PET and Tg just before RAI and after 5
days post therapeutic WBS. Results. WBS after a second RAI
in all 113 Pts showed lymph nodes and-or lung or bones me-
tastases. In 44 Pts (39%) PETwas positive (A group). In 69 Pts
(61%) PET was negative (B group). PET in A group has
showed in 24 Pts more metastases than WBS. Tg values in
A group (44 Pts) were very elevated (mean range 255 ng/ml).
In B group (69 Pts) Tg values were lower (mean range 56 ng/
ml). Conclusion. PET is a well-established method in the fol-
low up of Pts with DTC with elevated Tg and negative WBS:
high FDG uptake in large tumor masses may have an unfavor-
able prognostic significance. In our research, PET detected all
or more metastases in about 1/3 of Pts who had positive WBS
with most elevated Tg (range 143 - 600 ng/ml). In these clin-
ical cases PET is a valuable tool in investigating Pts and it
seems reasonable to omit a successive TB to evaluate outcome
after RAI, achieving real clinical managerial vs in off LT4 Pts
and valuable economic advantages vs recombinant human
thyrotropin (rhTSH) method. TB with 185MBq of 131I de-
creases thyroid uptake for several weeks and can impair im-
mediate subsequent RAI (stunning effect). 44 Pts of A group
with the most elevated Tg levels (over 143 ng/ml) have posi-
tive PET and follow up may be with PET; in B group Pts with
lower levels of Tg could leave out to perform PET.
TP082
One pot synthesis of [18F]labelled benzyl chloride
for asymmetric nucleophilic synthesis of 6-[18F]
fluoro-L-DOPA
V. Orlovskaja1, O. Fedorova1, E. Studentsov2, A.
Golovina2, R. Krasikova1; 1N.P.Bechtereva Institute of Hu-
man Brain Russian Academy of Science, St.-Petersburg, RUS-
SIAN FEDERATION, 2Saint-Petersburg State Institute of
Technology, St.-Petersburg, RUSSIAN FEDERATION.
Aim: In the past two decades many efforts were directed to
develop or optimize nucleophilic production methods for
6-[18F]fluoro-L-DOPA starting from easy available aqueous
[18F]fluoride. Suggested approaches were based on multi-
stage “built-up” procedures and asymmetric synthesis strate-
gies (Lemaire et al, 2004; Krasikova et al., 2004), affording
6-[18F]fluoro-L-DOPA in a high enantiomeric purity.
Substituted [18F]fluorobenzyl halides employed at the key
chiral alkylation step were usually prepared in a three steps
synthesis. It comprised nucleophilic displacement of the leav-
ing group in a labeling precursor (substituted benzaldehyde
(BZ)); reduction of 18F-labelled BZ into alcohol and
halogenation. This procedure involved intermediate purifica-
tions and associated with the radioactivity losses and longer
synthesis time. Here we report simple one-pot three steps syn-
thesis procedure for a substituted [18F]fluorobenzyl chloride
using novel label ing precursor, 4 ,5-dibutoxy-2-
nitrobenzaldehyde (I). Methods: 18F-fluorination of (I) was
performed in DMF at 150°C for 5-10 min in the presence of
kryptofix/K2CO3. After cooling reaction mixture, the solution
of NaBH4 (0.8 mg in 0.2 mL of DMF) was added, the reduc-
tion was carried out at r.t. for 3 min. The following halogena-
tion step was accomplished by adding SOCl2/DMF (12 μL in
0.3 mL) and keeping reaction mixture at r.t. for 3 min. All the
three synthesis steps were performed in a standard closed 5mL
conic reaction vial. The courses of radiofluorination, reduction
and halogenation steps were monitored by radio TLC with
minimal amounts of reagents. Results: 18F-incorporation rate
into (I) was 83±5%, n=15. Extremely high (up to 100%) con-
version rates were observed at the following reduction and
halogenation steps. The synthesis lasts 11 min and avoids in-
termediate purifications. Noteworthy, the protecting 4,5-
dibutoxy groups in a new labeling precursor (I) can be cleaved
under mild reaction conditions that facilitates final hydrolysis/
deprotection step in the synthesis of 6-[18F]fluoro-L-DOPA.
Conclusions: One pot three step synthesis has been developed
for the preparation of 4,5-dibutoxy-2-[18F]fluoro
benzylchloride, a useful radiolabeled alkylating agent for
asymmetric synthesis of 6-[18F]fluoro-L-DOPA or other ap-
plications. The feasibility of this approach was confirmed in
the test experiments for asymmetric synthesis of
6-[18F]fluoro-L-DOPA using NiII Schiff base complex of gly-
cine as a chiral inductor. This study was supported by RFBR
grant 14-03-31492.
TP083
Comparison of 2 Methods for Reduction of Infra-Cardiac
Activity in Myocardial Perfusion Imaging
M. Schalken1, I. Rutten - Vermeltfoort1, J. de Jong1, M.
Brink-Wieringa2; 1Institute Verbeeten, Tilburg, NETHER-
LANDS, 2Elisabeth-TweeSteden Ziekenhuis, Tilburg,
NETHERLANDS.
Aim: In technetium (Tc)-99m myocardial perfusion imaging
(MPI), abdominal activity often interferes with the evaluation
of the perfusion of the inferior wall. Because of a reduction of
the diagnostic accuracy in these cases, repetition of the imag-
ing is often necessary. The aim of the study was to compare the
efficacy of 2 different types of patient preparation in reducing
infra-cardiac activity. In order to improve the image quality of
MPI studies we also examined the effect of other risk factors
for infra-cardiac activity. Methods: Data of 454 consecutive
MPI studies in Institute Verbeeten Tilburg (NL) were
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prospectively collected. This includes all studies with exercise,
pharmacological stress (adenosine and regadenoson) and rest.
Patients were randomized to receive either conventional prep-
aration (water, fatty meal and exercise) or conventional prep-
aration with the addition of chocolate milk prior to myocardial
SPECT imaging. The frequency of intestinal activity adjacent
to the inferior myocardial wall resulting in the need for a re-
peated scan, was evaluated by observers on SPECT images.
Results: For all rest studies, the need for rescan due to abdom-
inal activity was 16% (35/219) in the conventional group ver-
sus 12% (28/235) in the chocolate milk group, (p=0.21); in
pharmacological stress these were resp. 14% (22/158) versus
11% (19/173), (p=0.42). There was no significant difference
between the groups. Univariate-analysis for gender, diabetes
mellitus, age, gastrointestinal medication and bodymass index
showed no significant difference except age in the pharmaco-
logical stress group (p=0.04). A multivariate-analysis logistic
regression model using above mentioned risk factors also
showed no significant difference. Conclusion: This study
shows no significant improvement in the reduction of infra-
cardiac activity in MPI using chocolate milk in addition to our
conventional preparation. With the exception of age, no other
risk factors were found to have a significant impact on the risk
of repeated scan.During exercise abdominal activity is a far
less frequent problem and is in this respect the preferred
modality.
TP084
DMSA scintigraphy: Do we really need to perform
geometric mean assessment?
i. G. E. el bez, h. boutruigua, n. bechir, k. trabelsi, l. zaabar, I.
YEDDES, I. MEDDEB, D. BEN SELLEM, B. LTAIEF, I.
SLIM, A. MHIRI, M. BEN SLIMENE; institut salah azaiez,
tunis, TUNISIA.
The aim of this study is to validate the use of Geometric mean
(GM) method, in the calculation of relative renal function
(RRF) in paediatric patients with various renal problems com-
pared to aritmethical mean (AM) method. Material and
Methods: one hundred Tc99m DMSA scans were studied ret-
rospectively. The patients were divided into five age groups:
group I : patients aged under 10 years; group II, patients aged
betewen 10 and18 years; and group III : patients ageded upper
18 years. The RRF of the right and left kidney was calculated
using the posterior images for AM and anterior and posterior
images for GM. The differences between AM and GM were
calculated for all patients according to age groups and renal
pathologies. A difference more than 5% was accepted signif-
icant. Results: Out of 100 patients, 60 had normal kidneys, 40
had abnormal findings on the DMSA scans as parenchymal
damages, cortical scarring and atrophy due to urinary tract
infection while 6 of them had malrotated or malpositioned
kidneys. The AM of the kidneys were calculated as 0.49 for
the right kidney and 0.51 for the left kidney, while the GMwas
0.50 for both kidneys, respectively (p>0.05). When the pa-
tients were analysed according to the age groups, the difference
was not significant (p>0.05), except group III. Interestingly, no
statistical difference was observed between the patients when
they were evaluated according to their renal pathologies. How-
ever in the 6 malrotated or malpositioned kidneys the RRF
change 15% for right and 12% for left kidney when GM meth-
od is used. Conclusions: The calculation of RRF using the GM
method revealed no significant difference from that using pos-
terior images except in group III. Therefore, it is unnecessary to
performanterior imaging in young patients unless they have
malrotated or malpositioned kidneys for RRF.
TP085
The technologist role in 177Lu dosimetry for PRRT
(Peptide Receptor Radionuclide Therapy )
E. Leoni, A. Filice, A. Palmieri, G. Ghiraldini, F. Fioroni, E.
Grassi, S. Cola, A. Versari; ASMN, Reggio Emilia, ITALY.
Background: Neuroendocrine cancers are neoplasms that gen-
erate from the diffuse neuroendocrine system (DNES). This
kind of neoplasms can express somatostatin receptors (SSTR2,
SSTR3, SSTR5). Treatment consists in using the specific high
affinity of receptor-peptide interactions in order to convey ra-
dioactivity to tissues that show this kind of receptors through a
specific radionuclide (68Ga, 90Y, 177Lu).Aim: The dosimetric
analysis allows evaluating the patient’s radiopharmaceutical dis-
tribution in order to calculate the dose absorbed by the cancer
and healthy tissues. The aim is to prescribe the maximum ra-
diopharmaceutical quantity, establish a dose-response relation
for toxicity to healthy organs and evaluate treatment’s effective-
ness.Matherials andMethods: Patients are injected with 177Lu-
DOTATOC (equivalent to somatostatin). The activity is specif-
ically calculated on single patients (depending on weight, age,
kidney and marrow dosimetry, risk factors, lesions size). After
therapeutical administration, the dosimetry protocol requires: 5
SPECT/CT image acquisitions of abdomen to be executed 1, 4,
20, 40 and 70 hours after administrating 177Lu-DOTATOC, in
order to evaluate the dose absorbed by the kidney, liver, spleen
and cancer lesions of the abdomen zone. Whether there should
be cancer lesions in other zones than abdomen, more SPECT/
CT image acquisitions must be carried out in the second zone of
interest (e.g. cranium or thorax) 4, 40 and 70 hours after admin-
istration. Every SPECT/CT image acquisition is carried out by
following the same image acquisition protocol. The dose assess-
ment for organs and lesions will not be affected by any change
due to a patient’s different set-up or different acquisition param-
eters. The equipment consists of a SPECT/CT hybrid machine
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with variable geometry double-headed gamma ray demodulator
and a spiral CT (Siemens Symbia T). Dose re-elaborations and
assessments are carried out through the OLINDA software (Or-
gan Level International Dose Assessment).Conclusion: After
the first treatment session, the dosimetric analysis allows estab-
lishing the toxicity degree of undamaged organs and the correct
dose for the lesion, in order to prescribe an effective and
personalised treatment cycle.
TP086
18F-Fluoride PET for quantification of axial
and peripheral lesions in adjuvant-induced arthritis
in Lewis rats.
R. OUICHKA1, A. DERRIEN1, C. HENRIONNET1, F.
MASKALI2, G. KARCHER2, P. GILLET1, D. LOEUILLE3,
A. PINZANO1; 1University of lorraine, VANDOEUVRE-
L E S - NANCY, FRANCE , 2NANCYCLOTEP,
VA N D O E U V R E - L E S - N A N C Y, F R A N C E ,
3DEPARTEMENT OF RHEUMATOLOGY, HOSPITAL
OF BRABOIS, VANDOEUVRE-LES-NANCY, FRANCE.
Aim: Evaluation of disease severity in experimental arthritis is
inevitably associated with assessment of structural bone dam-
age. A non-invasive imaging technology allowing objective
quantification of pathophysiological alterations of bone struc-
ture in rodents could substantially extend the methods used to
date in preclinical arthritis research, for staging of autoimmune
disease severity or efficacy of therapeutical intervention. 18F-
fluoride (18F-FNa) is a bone-seeking tracer well suited for mo-
lecular imaging. Therefore, we examined the use of 18FNa
positron emission tomography (PET) in Lewis rats with
adjuvant-induced arthritis for cross-sectional quantification of
pathological bone metabolism. Methods: 18F-FNa was injected
in rats before disease onset and at various time points of
progressing experimental arthritis (Days 4, 12, 21, 30, 60, 90).
Naive age-matched rats were used as controls. Radioisotope
accumulation in joints of hind paws and proximal tail was ana-
lyzed by PET measurements. For validation of bone metabo-
lism quantified by 18F-FNa PET, high-resolution radiographs
scoring and clinical parameters were used. Results: Before clin-
ical arthritis onset, no distinct accumulation of 18FNa was de-
tectable in hind limbs of rats immunized with complete adju-
vant. In the course of experimental autoimmune disease, 18FNa
bone uptake was increased at sites of enhanced bone metabo-
lism caused by arthritic process and cicatricial bone remodeling
at both peripheral and axial (tail) locations. Moreover, 18F-FNa
uptake at different stages of adjuvant arthritis was significantly
correlated with the degree of radiological bone sdestruction/re-
modeling, rather than inflammatory parameters. Conclusions:
The results from this study suggest that small animal PET using
18F-FNa as tracer is a feasible method for quantitative
assessment of pathophysiological bone metabolism in rat
adjuvant-induced arthritis. Furthermore, the possibility to per-
form repeated non-invasive measurements in vivo should allow
longitudinal studies monitoring therapeutical intervention.
TP087
Our experiences with reinjections for non-visualisation
in sentinel lymph node procedures for penile cancer
G. A. Ebbens, B. Pouw, D. Hellingman, M. L. Donswijk, M.
P. M. Stokkel; Antoni van Leeuwenhoek, Amsterdam,
NETHERLANDS.
Aim: Currently there are several methods to visualise and iden-
tify sentinel lymph nodes (SLN) in penile cancer preoperatively
or during surgery. Unfortunately in a subgroup of patients non-
visualisation on preoperative imaging is observed. In such
cases, we perform a reinjection of the radioactive tracer and
repeat additional lymphoscintigraphy to improve the visualisa-
tion rate. The aim of this study is to assess the value of a pre-
operative reinjection for SLN imaging in penile cancer. Method
and materials: In total, 193 patients were scheduled for a penile
SLN procedure within a period of 3 years (02-03-2012 till 05-
03-2015). Preoperative imaging, lymphoscintigraphy and Sin-
gle Photon Emission Computed Tomography with integrated
CT (SPECT/CT), was performed after 99mTc-nanocolloid or
Indocyanine green (ICG)-99mTc-nanocolloid injection. During
surgery, SLN were initially approached using a gamma probe,
followed by patentblue dye and/or fluorescence imaging. A
portable gamma camera was used to confirm excision of all
SLN. In this group, 22/193 patients had unilateral visualisation
of SLN. We assessed if a reinjection was performed and if
bilateral drainage was visualised. Furthermore, we searched
for all relevant parameters about the preoperative visualisation,
surgical identification, and pathological outcomes of SLN and
non-SLN. Results: In 171/193 patients (88.6%) bilateral SLN
were visualised and in 22/193 patients (11.4%) unilateral SLN
on preoperative imaging. A reinjection was performed in 19/22
patients, and in 3/22 patients a reinjection was not possible due
to logistics. After reinjection, bilateral SLN were visualised in
7/19 patients, unilateral SLN were visualised in 10/19 patients,
and no further imaging was performed in 2/19 patients. Intraop-
eratively, bilateral SLNs were found in 7/15 (46.7%) patients
who did not show bilateral lymphatic drainage on preoperative
imaging. Pathologic analyses of all excised non-SLN and SLN
revealed metastases in 3/22 patients (13.6%), of which 1 patient
had metastases in a groin without lymphatic drainage on preop-
erative imaging and during surgery. Conclusion: In penile car-
cinoma patients, preoperative lymphoscintigraphy visualises bi-
lateral SLN in 88.6% and after reinjection in 92.2% (178/193
patients). Combined with the intraoperative results bilateral
SLN identification rises up to 95.9% (185/193 patients).
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TP088
Prone versus supine breast F18-FDG PETacquisition
in breast cancer
R. SANCHEZ-JURADO1, J. Ferrer Rebolleda1, M. Cózar
Santiago1, R. Sanz Llorens1, J. Aguilar Barrios1, E. Blanco
Pérez1, C. Fuster Diana2; 1ERESA, VALENCIA, SPAIN,
2UNIVERSITY GENERAL HOSPITAL, VALENCIA,
SPAIN.
PURPOSE: Retrospective evaluation of positioning in patients
with breast cancer who underwent a 18FDG-PET. Benefits of
prone position for locorregional diagnosis.METHOD AND
MATERIALSIn an internal data review we selected 50 female
patients (55 ± 15 years-old) histologically confirmed breast
cancer who were performed a FDG PET-CT in prone and
supine position at the same or not scanning session. All pa-
tients were scanned with PET-CT system (Gemini TF16;
Philips) and with a dedicated breast-PET (MAMMI-PET;
Oncovision) 60-80 min and 90-120 min after injection,
respectively.Locorregional staging, maximal tumor diameter
and affected breast quadrants were evaluated in prone versus
supine breast-PET positioning and compared to previous re-
ports of mammography, ultrasound and breast-MRI studies
that had been performed previously.RESULTSTotally 68 af-
fected breasts were scanned. The sensitivity was 96,8% for
lesions located within the scanning range of dedicated breast-
PET (prone position); 87,3% for supine breast PET-CTand 92,
8% for prone breast PET-CT. Similar maximal tumor diameter
were registered between PET-positioning but a clear correla-
tion was shown in the register of the affected breast quadrants
comparing with previous studies: 99,3% db-PET, 78% prone
PET-CT and 56% supine PET-CT.CONCLUSIONThe imple-
mentation of prone position for the locoregional PET imaging
results provides amore correct definition of Tand N-stage than
standard supine PET-positioning. Also, affected breast quad-
rants can’t be evaluated clearly by supine method and there-
fore it demonstrated that prone positioning was more accurate
for tumor localization. Finally T-stage and affected breast
quadrants were better diagnosed (rinsed) by MAMMI-PET
than Whole Body prone PET-CT.
TP089
The effectiveness of dopamine transporter volume
estimated by C-11 PE-2I PET in diagnosing
Parkinsonism-Novel parameter for quantifying the total
amount of dopamine transporter-
S. Nagamachi1, R. Nishii1, Y. Mizutani1, Y. Umemura2, R.
Ohkubo2, H. Takashima3, T. Hirai1; 1MIyazaki University,
Miyazaki, JAPAN, 2Fujimoto Hayasuzu Hospital,
Miyakonojou, JAPAN, 3Kagoshima University, Kagoshima,
JAPAN.
(Objective) In the diagnosis of Parkinsonism, C-11 PE2I (N- (3-
iodoprop -2E-enyl)-2β-carbomethoxy-3β-(4-methyl-phenyl)
nortropane) is useful radiopharmaceutical for its high binding
selectivity and specificity to dopamine transporter (DAT) . The
current study was done to evaluate the effectiveness of novel
parameter, dopamine transporter volume (DTV) that was calcu-
lated with C-11 PE-2I PET/CT, in diagnosing Parkinsonism.
(Materials and Methods) Twenty-three patients with Parkinson-
ism, 16 idiopathic Parkinson diseases (PD) and 7 Parkinsonism
of other cause (PS) were evaluated. All patients were done two
kinds of examination, C-11 PE-2I PET/CT, I-123-
metaiodobenzylguanidine (123I-MIBG) myocardial scintigra-
phy and I-123 DAT SPECT. Three dimensional VOI (volume
of interest) was automatically drawn around striatum respective-
ly on C-11 PE-2I PET/CT images using workstation (syngo.via,
Siemens). Both sided maximum standardized uptake value
(SUVmax) and dopamine transporter volume (DTV) were ob-
tained. The threshold value for calculating DTV was 40% of
SUVmax. On MIBG scintigraphy, Heart to mediastinum ratio
(H/M) and washout ratio (WR) were calculated from early (E)
and delayed (D) chest planar images. On I-123 DAT SPECT,
Specific binding ratio (SBR) was calculated. Correlation analy-
sis among all C-11 PE-2I PET/CT parameters, MIBG parame-
ters and SBR on I-123 DAT SPECTwere done. In addition, all
parameters were compared between PD and PS. (Results) Both
sides DTV showedweak positive correlation with both the early
and delayed H/M (correlation coefficients were from 0.29 to
0.39). In addition, mean value of both sided DTV in PD were
significantly lower compared with those of PS (Right DTV:
7.81ml vs. 10.28ml, Left DTV: 7.26ml vs. 9.85ml). However,
SUVmax showed no statistical significance. (Conclusion) Nov-
el parameter, dopamine transporter volume (DTV), calculated
from C-11 PE-2I PET/CTwas useful for quantifying conditions
of dopamine transporters in Parkinsonism. In addition, it was
also useful parameter in differentiating PD from PS.
TP090
Simplified and reliable quality control analysis method
of 18F-Fluorocholine for a small scale hot lab
H. Hassan1, S. Abu Bakar2, K. Che A. Halim2, J. Idris2, A.
Nordin1; 1Universiti Putra Malaysia, Serdang, Selangor, MA-
LAYSIA, 2National Cancer Institute, Putrajaya, MALAYSIA.
Aim: 18F-Fluorocholine has never been synthesized inMalay-
sia. Thus, there was no available data or guideline for quality
control analysis of 18F-Fluorocholine was documented. The
study aims to present simplified and reliable method of quality
control analysis for 18F-Fluorocholine in order to assist small
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scale hot laboratory and local authority in Malaysia.Materials
and methods: 18F-Fluorocholine was synthesized via N-
alkylation of dimethylethanolamine (DMEA) with 18F-
fluorobromomethane (BrCH2F), followed by purification on
the CM cartridge with ethanol and water. Prior to synthesis,
quality control analysis method for 18F-Fluorocholine was
developed and validated, by adapting the equipment set-up
used in 18F-Fluorodeoxyglucose (18F-FDG) routine produc-
tion. Quality control on the 18F-Fluorocholine was performed
by means of pH, radionuclidic identity, radio-high perfor-
mance liquid chromatography equipped with ultraviolet,
radio-thin layer chromatography and gas chromatography. Re-
sults: Post-synthesis; the pH of 18F-Fluorocholine was 6.42 ±
0.04, with half-life of 109.5 minutes (n y 12). This affirmed the
labelling of Fluorocholine tracer with radioisotope Fluorine-18
was successful. The radiochemical purity was consistently
higher than 99%, both in radio-high performance liquid chro-
matography equipped with ultraviolet (r-HPLC; SCX column,
0.25 M NaH2PO4: acetonitrile) and radio-thin layer chroma-
tography method (r-TLC). The calculated relative retention
time (RRT) in r-HPLC was 1.02, whereas the retention factor
(Rf) in r-TLC was 0.64. Potential impurities from 18F-
Fluorocholine synthesis such as ethanol, acetonitrile,
dimethylethanolamine and dibromomethane were determined
in gas chromatography. Using our parameters, (capillary col-
umn: DB-200, 30 m x 0.53 mm x 1 um) and oven temperature
of 35°C (isothermal), all compounds were well resolved and
eluted within 3 minutes. Level of ethanol and acetonitrile in
18F-Fluorocholine were detected below threshold limit; less
than 5 mg/ml and 0.41 mg/ml respectively. Meanwhile,
dimethylethanolamine and dibromomethane were undetect-
able. Conclusion: A simplified and reliable quality control
analysis method for 18F-Fluorocholine has been developed
and validated for a small scale hot laboratory, which in com-
pliance to release criteria. This simplified method may provide
a guideline to local GMP radiopharmaceuticals laboratory and
local authority in Malaysia.
TP091
Histopathological correlation of 123-I
Metaiodobenzylguanidine (MIBG) scintigraphy findings
in pediatric patiens with suspected neuroblastoma
S.M.NievesMaldonado, J. Lopez Urdaneta, P. Fierro Alanis,
S. Argibay Vazquez, I. Dominguez Prado, M. C. Pombo
Passin, A. Ruibal Morell; Hospital Clínico Universitario de
Santiago de Compostela, Santiago de Compostela, SPAIN.
AIM: Our purpose was to determine the diagnostic value of
the study with 123-I MIBG and evaluate the correlation of the
scintigraphic findings with pathology results in pediatric pa-
tients with suspected diagnosis of neuroblastoma.
MATERIALS ANDMETHODS: We have evaluated 58 pedi-
atric patients with suspected diagnosis of neuroblastoma, not
receiving medication that could block radiotracer uptake
mechanism, which underwent a 123-I MIBG scintigraphy in
our department between 1997 and 2013. The imaging findings
were assessed taking into account the 123-I MIBG tumor up-
take and histopathology results (incisional or escisional biop-
sy), and other parameters as age at diagnosis, sex, location of
the mass, and tumor dissemination. RESULTS: The evaluated
population was 55% male, with an average age of 2 years
(range 0-13 years). The location of 48% of the masses was
on the right side (n = 20/58), and 50% were located at the
abdomen. 52% (n = 30/58) of the scintigraphic studies showed
abnormal uptake, histopathological results were compatible
with neuroblastoma in 77% (n = 23/30) of cases. Metastases
were found in 40% (n = 12/30) of patients with positive im-
aging, bone metastases represented a 42% (n: 12.5) of these
findings. There were 7 positive studies with different patho-
logic results from clinical suspicion, they were listed as
nephroblastoma, sarcoma and bleeding. Studies without patho-
logical uptake, 82% (23/28) presented results corresponding to
other tumor histopathological groups, and 17% (n = 5/28) was
compatible with poorly differentiated / undifferentiated neuro-
blastoma (n = 4) and well differentiated witha high degree of
necrosis neuroblastoma (n = 1). CONCLUSIONS: The 123-I
MIBG scintigraphy is still an useful tool in the diagnosis and
staging of neuroblastomas. The correlation of the scintigraphic
findings with the degree of tumor differentiation in pathology is
possible. Some undifferentiated neuroblastomas and other well
differentiated with necrosis may show and absence of uptake.
TP092
Nodal Visualisation in Sentinel Node Imaging
A. Vaz; St Barts Hospital, London, UNITED KINGDOM.
Histological evaluation of the first draining lymph node (sen-
tinel node) in the axilla of patients with breast cancer has
dramatically altered the surgical approach to these patients,
with sparing of the axilla if no tumour cells are identified. In
a fraction of patients imaged after injection of radiocolloids,
there is no visualisation of the sentinel node. A retrospective
study including patients with successful and unsuccessful nod-
al identification was performed to assess the variables associ-
ated with failure to identify a node. 1023 patients were imaged
following subcutaneuos injection of 99mTc-Nanocolloid, im-
mediately and up to 5.5h post injection. The scintigraphic data
were analysed with reference to patient’s age, tumour location,
volume injected and radiopharmaceutical’s labelling concen-
tration, using univariate analysis and a logistic regression
model. A sentinel node was visualised in 990 of 1023 patients
(97.2%). Comparison of patients with non-visualised sentinel
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nodes disclosed no statistically significant relation to tumour
location (quadrant, p=0.338 and side, p=0.581). Age
(p=0.032), radioactive labelling concentration (p=0.002), vol-
ume of injection (p=0.023) and concentration of particles
(p=0.010) were statistically significant at interfering with nod-
al visualisation. The results show that increasing age, high
labelling concentration, low particle concentration and small
volume of injection decrease nodal visualisation. Key-words:
Breast Cancer, Sentinel lymph node, lymphoscintigraphy,
nodal non-visualisation.
TP093
Preliminary Study of Multicenter Nuclear Medicine
Imaging Quality Assurance by ACR Phantom in Taiwan
C. Lo, Esq., P. Kao; Chnug-Shan University Hospital, Tai-
chung, TAIWAN.
Introduction: To improve nuclear medicine practice and to ad-
vance scientific initiatives as well as clinical research projects, a
phantom study is to subjectively evaluate image quality of routine
SPECT/CT and PET/CT acquisition with Jaszczak Deluxe
Flangeless ECT (ACR) phantom at 4 different nuclear medicine
sites in Taiwan. Materials and Methods: Phantom preparation for
this study at 4 different sites were done by a teammembers for the
research. Radioactivity concentrations in different parts of the
phantom were predetermined by the team. Imaging acquisition
parameters were standardized for each brand name of the imaging
modalities simulating routine clinical practice. These imaging
were centralized for interpretation by 7 experienced nuclear med-
icine physicians. Five items of the phantom studies were to assess,
including PET-CT and SPECT-CT alignment, hot spheres resolu-
tion and deformity, and overall satisfaction. All level for five parts:
5=excellent, 4=good, 3=acceptable, 2=poor, 1=non-diagnostic.
Result: The results of SPECT-CT and PET-CT alignment were
2.8±0.8 and 3.8±0.6 respectively; hot spheres resolution level
were 2.2±1.1 and 3.4±0.8; deformity rate represent 2.6±0.9 and
3.8±1.2; overall satisfaction were 2.7±1.2 and 3.5±1.3. Conclu-
sion: The results of this preliminary studymake us feel confidence
for a future study as a standardized procedure for accreditation in
nuclear medicine practice. The study is still in progress, we will
conduct 4 more nuclear medicine sites in the next 3 months to
conclude the standards for accreditation in the future.
TP094
Influence of the application of post-filter, variation
of the number of iterations and attenuation correction
in the tomographic image quality.
A. A. Santos1, A. F. Fernandes2, H. R. Martins1, E. Pereira3,
L. Vieira4; 1Escola Superior de Tecnologia da Saúde de
Lisboa - IPL, Lisboa, PORTUGAL, 2Escola Superior de
Tecnologia da Saúde de Lisboa- IPL, Lisboa, PORTUGAL,
3Hospital Particular de Almada / Escola Superior De
Tecnologia Da Saúde de Lisboa - Instituto Politécnico de Lis-
boa, Lisboa, PORTUGAL, 4Área Científica de Medicina Nu-
clear, Escola Superior de Tecnologia da Saúde de Lisbo-IPL/
Instituto de Biofísica e Engenharia Biomédica, Faculdade de
Ciências da Universidade de Lisboa, Lisboa, PORTUGAL.
Abstract: Tomographic image reconstruction can be done with
analytic and iterative algorithms. The iterative reconstruction
methods appeared as a solution to the limitations of the ana-
lytic methods and its application in Nuclear Medicine Center
has been growing. The purpose of this study consist in evalu-
ating the effects of the application of post-filter (Butterworth),
the variation of the number of iterations (2 and 4) and the
application of attenuation correction (Chang’s uniform meth-
od) in Single Photon Emission Computed Tomography
(SPECT) image quality. Methods: Experimental study using
a GE™ Healthcare Discovery NM630 and a Jaszczak phan-
tom filled with 740MBq of Sodium Pertechnetate
(99mTcO4-). A tomographic study was obtained with a low
energy high resolution collimator, with an acquisition angle of
360.°, in step-and-shoot mode, with a matrix of
128x128pixels, zoom of 1.33, 120 projections, and 30 seconds
per projection. The image was reconstructed with FBP and
OSEM with and without the application of attenuation correc-
tion with Chang’s method and the application of post-filter
Butterworth and ranging the number of iterations, 2 to 4, dur-
ing reconstruction. Results: The study is still ongoing however
it is already possible, through the statistical analysis of the
results so far, verify that as the number of iterations increases
so does the contrast and special resolution as well as image
noise. The application of a post-filter is useful to diminish
image noise and this effect is more significant than the increase
of the number of iterations. The attenuation correction has
effect on noise, diminishing it, and improves qualitatively spe-
cial resolution. However, attenuation correction does not have
a significant influence on contrast. Conclusions: It is envis-
aged that the application of the post-filter and the application
of 4 iterations in OSEM has a positive contribute to the global
image quality, even though the reconstruction time is longer
TP095
Reference Range in Blood-Pool and Liver SUV
for 18F-FDG PET/CT
Y. Parlak, D. Goksoy, G. Gumuser, E. Bilgin; Celal Bayar
University, MANISA, TURKEY.
Aim: The aim of this study was to document the normal range
in blood-pool SUV and liver SUV for 18F-FDG PET/CT.
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Material and Methods: Five hundred oncology patients (mean
age: 60±5 years; 255 female, 245 male ) had PET/CT scans
using a Philips True Flight Select 16 PET/CT scanner. Patient
preparation, acquisition parameters and reconstruction proto-
cols for all patients were standardized. All patients were divid-
ed into ten cancer groups, including 50 patients (esophagus,
stomach, colon, rectum, larynx, lung, breast, endometrial,
ovarian and lymphoma cancer) in each group. Mean SUV
values were obtained from 2-dimensional regions of interest
in the aortic arch blood pool and in the right lobe of the liver.
Results: The group’s mean serum glucose level was 6.0
mmol/L. The variation in blood-pool and liver SUVs had
gaussian distributions. The group’s mean blood-pool and liver
SUV were 1.57, with an SD of 0.14; 2.34, with an SD of 0.16,
respectively. The variation in blood-pool SUV had a mean of
0.12 and SD of 0.35. The variation in liver SUV had a mean of
0.18 and SD of 0.43. Conclusion: These ranges are applicable
in clinical practice as they indicate a practical limitation on
qualitative tumor response assessment or tumor to background
ratios in comparisions using 18F-FDG PET/CT.
TP096
Appropriate time interval of dynamic 201Tl SPECT-MPI
data acquisition for quantitative myocardial blood flow
analysis on cardiac dedicated ultrafast SPECT camera
G. Ogushi, S. Kudo, R. Matsuda, S. Tomiguchi, S. Shiraishi,
Y. Yamashita; Kumamoto University, Kumamoto, JAPAN.
[Aim/Purpose] Single photon emission computed tomography
myocardial perfusion imaging (SPECT-MPI) is useful and im-
portant to evaluate coronary artery disease (CAD). Recently,
cardiac dedicated ultrafast SPECT camera is has been devel-
oped and enables to shorten the SPECT data acquisition time.
Thus, dynamic SPECT-MPI for the quantitative assessment of
myocardial blood flow (MBF) and flow reserve (MFR) is
available in clinical use. It is important to obtain an accurate
input function for the quantitative MBF analysis. The input
function is defined by analyzing the time-activity curve
(TAC) made to set a ROI on the left ventricular cavity. Time
interval of dynamic SPECT-MPI data acquisition affects to the
shape of TAC. The aim of this study is to clarify the optimal
time interval for making the accurate input function from the
TAC by phantom study. [Material and Methods] An anthropo-
morphic torso phantom with cardiac insert filled with 201Tl
water solution in the myocardial part was used. 201Tl radio-
activity concentration in the myocardium was regulated to the
equivalent radioactive concentration to 111MBq injection (full
dose). List-mode SPECT data acquisition (list-mode SPECT)
was performed in the phantom for 30 minutes with dedicated
ultrafast SPECTcamera (Discovery NM 530c:GE). List-mode
SPECT was also performed in the phantom with 201Tl
radioactivity concentration(RC) corresponding to 1/2, 1/4
and 1/8 injection dose. Five set of images with 5 different time
intervals ( 1,2,3,4 and 5 second) for making the TAC were
reconstructed by using Maximum a Posteriori Expectation
maximization (MAP-EM) algorithm. The appropriate time in-
terval was assessed by linearity between RC in the myocardi-
um and the calculated SPECT counts (SC) in each time inter-
val. Area under the curve (AUC) value of TAC made every
time interval was defined As AC. [Result] Linear corre-
lation with high correlation coefficients from 0.986 to
0.988 was observed between RC and SC in time interval
of more than 3 second on full dose phantom study.
Good liner correlation between RC and SC was also
demonstrated on 1/2 dose phantom in time interval of
more than 3 second. [Conclusion] Appropriate time in-
terval of dynamic SPECT data acquisition is considered
to be more than 3 second in case of both full dose and
half dose 201Tl injection. Therefore, 201Tl dynamic
SPECT-MPI with half-dose injection is considered an
useful method for the quantitative analysis of MBF
and MFR.
TP097
Analysis and discussion of CT attenuation correction
on apical muscular of in myocardial perfusion imaging
Y. Wang; Nuclear Medicine, Huashan Hospital, Fudan Uni-
versity, Shanghai, CHINA.
Objective: To study the influence of CT attenuation cor-
rection on cardiac apex in SPECT myocardial perfusion
imaging. Methods: All the patients did SPECT resting
myocardial perfusion imaging in my hospital from Sep-
tember to November 2014. Coronary angiography was
carried out before and after SPECT examination, and
the results of DSA showed that all the plunger of three
major blood vessels were less than 10%. Do a compar-
ison of the apex changes before and after CT attenuation
correction at a non-gated condition. A 17 - segment
model were used to divde the myocardium. 13 to 17
area represented respectively apical segments, apical an-
terior, apical septal, apical inferior, apical lateral apex.
Results: There were 7 cases of data for discussion. Nor-
malized Map statistics data were analyzed by using soft-
ware Corridor4DM. T test results of 13 to 17 areas for:
(t=-2.485, p=0.047; t=-0.117 p=0.911; t=-2.848 p=0.029;
t=0.915, p=0.395; t=-5.365, p=0.002). The blood perfu-
sion of the apical segments, apical anterior, apical septal
were reduced after CT attenuation correction. Conclu-
sion: CT attenuation correction will reduce the blood
perfusion of apical segments, apical septal, apical lateral
apex area in SPECT resting myocardial perfusion.
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TP098
Investigation of Methods to Reduce Staff Whole Body
Radiation Exposure in a PET-CT Department
L. Alves, E. Woods, A. Jacob, C. Abreu, S. Pereira, R. Cabral,
J. John; King's College London and Guy's and St Thomas'
NHS Fundation Trust, London, UNITED KINGDOM.
Aim: Due to the risk of high radiation exposure in a PET-CT
facility, department design and working procedures should be
optimised to ensure staff radiation doses are as low as reason-
ably practicable. The purpose of this study was to evaluate the
dose-saving efficiency of various simple dose reduction tech-
niques currently used in the PET Centre. Materials and
Methods: Four dose reduction methods were analysed: expla-
nation of the procedure to patient pre-injection, use of an in-
tercom to communicate with patient post-injection, use of
colour-coded system to assist with patient navigation, and
use of whole-body shields when positioning the patient on
the scanner. Radiation doses received by staff at each stage
of the patient pathway were measured using calibrated dosim-
eters, and doses estimated with and without use of the above
dose reduction techniques. Only patients referred for half body
scans with 18F-FDG were considered. Results: Assuming a
single technologist deals with 5 patients per day, the tech-
niques investigated can result in a daily dose-saving of 5.2
μSv. The highest dose reduction was recorded for full expla-
nation of procedure pre-injection (62% of the measured dose-
saving). The use of whole body shielding reduced dose during
patient set-up by 47%. Conclusion: Use of simple radiation
protection methods in a PET-CT department can result in a
decrease in technologist mean daily dose of 47%. This corre-
sponds to a potential whole body dose saving of 1.3 mSv per
year.
TP099
Occupational radiation exposure of nursing staff in PET
facility in association with performance status of patients
M. Hosono, N. Takahara, Y. Yakushiji, K. Sakaguchi, Y.
Yamada, C. Hosokawa, K. Ishii; Kinki University Faculty of
Medicine, Osaka-Sayama, JAPAN.
Aim: Radiation protection is an important issue for nurses who
take care of patients in PET facilities. Radiation exposure of
nurses may be increased when patients have problems in ac-
tivities of daily living (ADL) and need intensive nursing care.
We measured individual dose of nurses in consideration of
performance status of patients. Materials and methods: Indi-
vidual dose of nurses was measured during PET examination
through injection of FDG, nursing care, to patients’ discharge
from the facility. Each nurse wore 2 individual dosimeters
(MYDOSE PDM-111, Hitachi Aloka Medical, Ltd.) on the
chest and abdomen. Performance status of patients was record-
ed using Katz index of independence in ADL (Katz S et al. N
Engl J Med 1983;309:1218), which is a standard method to
assess ADL by categorizing into 7 grades from Index 6 (good
ADL, needs no special care) to Index 0 (poor ADL, needs
extensive care). Radiation doses and contact time were record-
ed and analyzed. Results: Nurses cared overall 902 consecu-
tive patients, who were grouped into Index 6 of 825 patients
(91.5%), Index 5 of 41 (4.5%), Index 4 of 13 (1.4%), Index 3
of 7 (0.8%), Index 2 of 6 (0.7%), Index 1 of 3 (0.3%), and
Index 0 of 7 (0.8%). Mean contact time of nurses to patients
was 1 min to 10 min for Indices 6 to 0. Radiation doses of
nurses were correlated with ADL of patients. The difference in
radiation doses between the chest and abdomen of nurses may
be attributable to the geometry of shielding materials. On the
basis of these results, the weighted average of exposure of a
nurse was 0.25 μSv/patient. Conclusion: This approach of
considering ADL of patients for dose evaluation of nursing
staff was useful to optimize radiation protection countermea-
sures. In our facility, patients with poor ADL account for a
small fraction of patients, then, how to reduce radiation expo-
sure from good ADL patients is an important issue for reduc-
ing overall radiation exposure.
TP100
Obtaining medical isotope 99mTc by extracting
and chromatography.
A. Rogov1, V. Sкuridin1, E. Stasyuk1, E. Nestwrov1, E.
Ilina1, V. Sadkin1, V. Chernov2, R. Zelchan3, L. Larionova1;
1National Research Tomsk Polytechnic University, Tomsk,
RUSSIAN FEDERATION, 2FSBI "RI Cardiology" SB
RAMS, Tomsk, Tomsk, RUSSIAN FEDERATION, 3Cancer
Research Institute of SiberianВranch of the Russian Academy
of Medical Sciences , Tomsk, Tomsk, RUSSIAN
FEDERATION.
Radiopharmaceuticals based on the radionuclide (99mTc) are
used for diagnostic studies in oncology, cardiology, endocri-
nology, and other areas of medicine. They can spend more
than 80% of the total number of radiodiagnostic procedures.
Technetium-99m has a half-life of 6.02 hours, and is a daugh-
ter product β-decay of the isotope 99Mo. To separate it from
the isotope 99Mo in a medical laboratory use devices called
99Mo/99mTc generators. The basis is the chromatographic
column filled with aluminum oxide adsorbed thereon 99Mo.
In contrast, sorption, extraction method for separating a pair of
99Mo/99mTc is concentrated and produces highly active prep-
aration of 99mTc low-level (5-8 Ci/g) 99Mo produced by
waste-free nuclear reaction of radiative capture (n,γ) of mo-
lybdenum (trioxide) natural composition or enriched in the
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isotope 98Mo. Such materials are prepared by srednepotochnyh
nuclear reactors, which are widespread in Russia and in the
world. The aim of this work was to study the method of sepa-
ration of 99mTc from the extractant express method using a
sorbent. As such sorbent investigated in gamma alumina. The
objectives of the research was to study the effect of pH form of
aluminum oxide on the value of their sorption capacity of
99mTc in static and dynamic modes of adsorption, as well as
the determination of the distribution coefficients of 99mTc-ethyl
ketone in the 99mTc-alumina. In this work a studywas conduct-
ed adsorption extracted with methyl ethyl ketone 99mTc on
gamma-alumina with different pH in the form of static and
dynamic conditions of the process. The coefficients of distribu-
tion of 99mTc in the methyl ethyl ketone - 99mTc - alumina.
The parameters of pH at which the maximum adsorption capac-
ity of an oxide of radionuclides, and the highest yield of 99mTc
(over 98%) for its subsequent allocation in the form of sodium
pertechnetate 99mTc. The total duration of the separation of
99mTc from the extractant, 20 minutes, which is comparable
with the time of receipt of 99mTc eluate from traditional sorp-
tion generators, and, ultimately, provides the ability to create
resource-efficient environmentally friendly production of radio-
pharmaceuticals 99mTc. This work was financially supported
byMinistry of Education and Science of the Russian Federation
(RFMEFI57514Х0034).
TP101
New system for production of reactor medical
radionuclides tested with Lu-176
D. Seifert, M. Kropáček, M. Tomeš, J. Kučera, O. Lebeda;
Nuclear Physics Institute of the CAS, v. v. i., Řež, CZECH
REPUBLIC.
Aim: Development and testing of a new system for irradiation
and subsequent processing of Lu-176 target. Material and
Methods: A new type of an irradiation vessel consisting of
external aluminum alloy cover and inner quartz tube for sam-
ple placement was designed and tested. The system is water-
proof. The ampoule was designed as disposable and has been
tested for He leak - achieved leakage level was in order of 2E-
09 mbar.l/s and in a real irradiation conditions.Results: Exper-
iments performed under the highest available neutron flux
density have shown reproducible behaviour of the systems
regarding leakage, target processing and activity
recovery.Conclusion: The designed system demonstrated suit-
ability for high-level activities production of reactor medical
radionuclides, in particular of Lu-177.
TP102
First Danish experiences of Radium-223 treatment
to patients with prostate cancer and bone metastases. Is it
safe for the staff?
A. K. Cortsen, A. K. Cortsen; Rigshospitalet, Copenhagen,
DENMARK.
Introduction: Ra-223 dicloride is an alfa-emitting radionuclide
therapy approved for treatment of patients with castration-
resistant prostate cancer and symptomatic bone metastases.
In a large randomised placebo-controlled study, prolonged sur-
vival and time to bone-related complications and improved
quality-of-life was demonstrated. As a calcium mimick Ra-
223 binds into newly formed bone tissue, and accumulates in
bone metastases. Ra-223 emits alpha-radiation with a high
linear energy transfer.This radiation, which accounts for
95% of the emitted energy, kills the cells of the bone
metastases, with relatively little damage to the surround-
ing tissues. Less than 5% of the radiation is in the form of
X-ray and gamma radiation. Method: It is essential during
the staffs´ handling of the Ra-223, that there is no internal
contamination either from inhalation, ingestion, injection
or adsorption. Therefore, we apply special safety precau-
tions when handling the Ra-223. The staff, which partici-
pate in the direct handling of Ra-223, are measured in our
whole-body-counter in the morning before, and in the af-
ternoon immediately after handling (dispensing, adminis-
tration, clean up) the Ra-223 to the patients, so we can
demonstrate, that any internal contamination has been
avoided. To avoid this a special protective dress is used
and control measurement of gloves/hands are performed
after each handling of the therapy dose. The treatment
itself is simple. A dose based on the patient's weight is
injected slowly over 1 minute via an intravenous cannula.
After 15 minutes of observation the patient can go home.
Results: As yet, Rigshospitalet is the only center in Den-
mark approved for the Ra-223 treatment. From May 2014
to May 2015, we have administered a total of 200 Ra-223
treatments to 60 patients on 25 different days (1-15 pa-
tients at each treatment day). The WBC measurements
have demonstrated no internal contamination to any staff
member. Table of Contents. Conclusion: When special ra-
diation safety precausions are used Ra-223 is a safe treat-
ment both for the staff and the patients. In the majority of
the prostate cancer patients with symptomatic bone metas-
tases Ra-223 reduces pain without serious side effects.
On-going studies may show whether Ra-223 treatment al-
so will be beneficial in other types of bone metastases e.g.
from breast cancer.
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